<SEC-DOCUMENT>0000078003-22-000027.txt : 20220224
<SEC-HEADER>0000078003-22-000027.hdr.sgml : 20220224
<ACCEPTANCE-DATETIME>20220224142501
ACCESSION NUMBER:		0000078003-22-000027
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		160
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220224
DATE AS OF CHANGE:		20220224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		22669771

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pfe-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:ad91efd1-2241-49cf-a17f-7cbe86f9ba4a,g:feca3a10-f613-46f2-b813-b8f4d7d48955,d:4bff405b2205487eb835dd4cd589f5c6--><html xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:pfe="http://www.pfizer.com/20211231" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>pfe-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl8yLTEtMS0xLTE1NTYzOA_de7247f2-19f5-4b9c-8988-4ceb434883b4">0000078003</ix:nonNumeric><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl80LTEtMS0xLTE1NTYzOA_94f096af-e06a-434b-8735-938d98ddbb89">2021</ix:nonNumeric><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl81LTEtMS0xLTE1NTYzOA_1aa8bbba-07a7-4a60-8155-10731f29a432">FY</ix:nonNumeric><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl82LTEtMS0xLTE1NTYzOA_7f910169-c75c-48bb-b0ac-7cabae2ad569">false</ix:nonNumeric><ix:nonNumeric contextRef="i574afde0d29749d9a45d3066b313f102_D20210101-20211231" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcwNjc_b11edfc2-cb4f-4099-b138-98c6766b88f5">P4Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ifa1343d51f60440184a9f78f1c9375fa_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yLTItMS0xLTI3MTM3Ng_b4c6f3b9-8438-420f-9ac0-6d540cd6e739">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ibcba539f4ba046dd8c2d86a34034ea81_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yLTMtMS0xLTI3MTM4Mw_2dc430e3-09d0-442a-9b2e-2a095bd3215d">10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="if3cacc2f9fbf423f91cee329fa9e42d5_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zLTItMS0xLTI3MTM3Ng_8b03453a-f25c-425d-ab34-d278c1dbbb5c">20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="idb7e4de941cd41a68b47d69317c51b21_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zLTMtMS0xLTI3MTM4Mw_a974c308-9010-4419-8fcc-4c8d44dd24d8">40</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iecfedf0b60464ee4ad5a115a4e7bb74a_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF82LTItMS0xLTI3MTM3Ng_0dacf702-43b3-4892-bbeb-4577d639a5d6">45</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7e1c0d0059f0445cbd0935e842d98ee3_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF82LTMtMS0xLTI3MTM4Mw_c78e26c5-e92b-46a5-b914-ebf670bc636a">75</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i4eecfc1306b84ab281bd797e77e015f4_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xMC0yLTEtMS0yNzEzNzY_9c0e5109-34cd-4c1d-8c3b-5d1d95a672d4">5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic0b8c791011a4a579e971f6153d22ff8_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xMC0zLTEtMS0yNzEzODM_9a8f2202-d8cb-4925-953f-c1ee8f7810d6">20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i847e93c8a82e46f1802cb25b6ad0f2a7_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNi0yLTEtMS0yNzEzNzY_8fe86dfd-2890-418d-9c93-99b230adf99e">0%</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i622723f52e094267ad1f1a6f20f16021_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNi0zLTEtMS0yNzEzODM_2b024c0e-04b8-4441-8a70-e307e5d19725">10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i813308e909ae4e17a701ee9b75f8371f_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNy0yLTEtMS0yNzEzNzY_80e705ef-7e0c-4b34-99e3-3e4c97467eec">10</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iadc214917ea744b79b2b73e6471dbf01_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNy0zLTEtMS0yNzEzODM_f41bd812-97d6-4986-8a13-757288f6c799">20</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iebcfd4c10a4142fb88a316179c35e0a0_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xOS0yLTEtMS0yNzEzNzY_8d69df82-7cc2-483a-a9e4-8d2f36fe6a11">45</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ica401af8d1ff43afb5c3de05ed7396cc_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xOS0zLTEtMS0yNzEzODM_e1b8f010-ef94-4e70-9e1a-adb55b5e19e8">70</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i27ea04bb8c1e41a9bdd1d1dc8714d350_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yMy0yLTEtMS0yNzEzNzY_3d9592bf-406c-4347-acf9-efdc8ff0c771">15</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i51d675d40b3748ea9f8d5ed88c985153_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yMy0zLTEtMS0yNzEzODM_80031335-1fcd-43cc-9f1e-ccf5839be307">35</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ia1825332913b4ce7b251fe06cd990eb4_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yOS0yLTEtMS0yNzEzNzY_90a33cb2-8e6b-4d0e-8a5e-e0d559bebb09">0</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib14b680e409142e6ac7c80709cd5e4eb_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yOS0zLTEtMS0yNzEzODM_05ba382c-8662-400f-b68a-2004b73685b2">5</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i13785fc5583c485a8b9868f58464c651_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zMC0yLTEtMS0yNzEzNzY_c4ec9488-3601-4581-92d8-c20e3b98a940">95</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i2a668a32aa7b440ba577921b46eb3b30_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zMC0zLTEtMS0yNzEzODM_f584170c-5e52-4188-85b4-36777c423c7c">100</ix:nonFraction><ix:nonNumeric contextRef="i79ebdb6315104090a143c1f852c2ca78_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i867dddfc2367440eab83840a05865495_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="i04e1e8887418409c8efc97bcddd13100_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfMTA5OTUxMTYyODQ4MQ_0da09f05-3e8c-4080-bb4d-fc5dd48fbbca">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i9b45cc72fe144a41a027fcc9d82be277_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNDQz_4d00d2e4-77a0-4861-9e03-9cd48bf4e5b8">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg5_e6c42dac-714f-4f5e-996c-4d0353676184">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNDg1_fcbb828a-fc1b-45e8-92d8-b04179945bfd">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDk_1531252f-ed7d-4bb0-98f0-50eaa78bb5c6">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_408086e2-3444-4b88-b89b-d101186f774f">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_46ee31d6-1f28-4ba5-b2be-d5c564d17665">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_74739711-6874-4a56-93f6-73a0506beaac">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_8b4b2c6e-76ae-4492-a995-73bb701632ff">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b27ac467-c383-4750-82e2-f39d2460df2f">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b50ecd3f-01e3-4abd-991d-dc5d329b8f81">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i52bc922f23d94809b6348416f7d67f89_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODk5L2ZyYWc6NGI3YzJkZDVmY2I1NDczZTg4NDcxN2JiOTk4MzEyZTUvdGFibGU6MDE2NGNjODZhYTIzNGJjNThiZGE3YjE1MzBkOTgzMmIvdGFibGVyYW5nZTowMTY0Y2M4NmFhMjM0YmM1OGJkYTdiMTUzMGQ5ODMyYl8yLTEtMS0xLTI1Mzg5NA_17afd8e8-e3ad-4d00-81d9-1d2cad4fb14b">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ic1efb123775446d4afb050c15a9de3c2_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODk5L2ZyYWc6NGI3YzJkZDVmY2I1NDczZTg4NDcxN2JiOTk4MzEyZTUvdGFibGU6MDE2NGNjODZhYTIzNGJjNThiZGE3YjE1MzBkOTgzMmIvdGFibGVyYW5nZTowMTY0Y2M4NmFhMjM0YmM1OGJkYTdiMTUzMGQ5ODMyYl8zLTEtMS0xLTI1Mzg5NA_7e6bcf1a-6bdd-4816-b2af-fe2e5dd891e5">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ifd473cbb8e244c0baf184d66619e9bab_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODk5L2ZyYWc6NGI3YzJkZDVmY2I1NDczZTg4NDcxN2JiOTk4MzEyZTUvdGFibGU6MDE2NGNjODZhYTIzNGJjNThiZGE3YjE1MzBkOTgzMmIvdGFibGVyYW5nZTowMTY0Y2M4NmFhMjM0YmM1OGJkYTdiMTUzMGQ5ODMyYl80LTEtMS0xLTI3MDA4Mg_7343cdd6-da43-43c4-8107-39ad262930d6">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="pfe-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia364c08bab1f4be7a0489033e72f9182_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7b0a597b277c43419d1b9be3ccd9b0bd_I20220222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a79fdd21944aa89c066de9cbbfee5d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8bb2c5291c4b5c9a5015f9815e4ee3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a2a3761e1b1438383b3a8eb28300997_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70369ec902474685b7ee35afae6111aa_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e769fcaccc349d5b816b47154d226a6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa41a976be144ff95f4427e340cfcab_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595cd5191b614c5896a444e2f5f45def_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f468b487cc540788a176ec913956dca_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e10b1e1c1f846769573d84f9a61fc72_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e366b426034c2d8e2255483179463e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57063444ae6416ea155fe3b461c2ed1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6ae9c7231104451b51d26af9103a373_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia99d4818adb64cf09382dd79ab3ff911_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a4e3937ea1429897d5a87a331d97a4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9258b1a52e41f7b182a2eb16acdb9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id51cff7fa3b2450293ac21547637f902_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5931a8435e8847bbb43008b48c1d8f71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd94794713d841c39b811cf2ccdd0e5b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c15300160eb40199b2470fd99513c75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3ccccf6fbe4566816a85a5ac4c621a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc359e016414e0fb3f5cdc5fc783e30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i140dd48fd747453ba5305db06d75f19f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a777038d48408c84c682c9db5a1598_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e60bc72e4ba4235bf53b47acbec77c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id949a0db74974d919ea4ea4b3db15ae6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6632dff49814e8badeff7ff58c71158_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf786bbc81494d359b7cda3127ee3152_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07fc9de38c8c4c7e9d03753b2fca1f74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7422d124677a4ff7b2f8d8076c12acca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5835359a69d471cbf36ab74d0cbe6a8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9a1f0a2c3f454aa866582d5102b28a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8080b824a5384f898232ba254171a741_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibedd8e5bdd3547a59b222ebb89139a56_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4091403708c44027bed1ab29ab967de7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ab09e3a09e941018ddf6f7cc1e0fd05_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib478cdce593043b4a6f3edef11be42c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93c09cc9d0f940729939d72e229af012_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67081b13ebb6408d9bfb81829f457cbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffea6a63f21448c2a42fb089c227bdf1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba64542fbbc240b2b05039d5b8e8bf4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa81ae38e1ae496d93643844df0b8455_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa9bac0ccad24d18a5d2306fb3b1e0f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6af06169f58446f8067cc5be10a39e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d6aaf11901b4bceaf30103029c6a00d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19da914ba5ba4066bf3d29d7d1eeb9c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie607d29116be4fa5babac488462d4080_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic3380b060ff04a11833194263e6f152c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34dd2e3fa1c248e29e1d6758b3059e2d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="operatingsegment"><xbrli:measure>pfe:operatingSegment</xbrli:measure></xbrli:unit><xbrli:context id="ifcf32e48dba146a8a8302424e15199af_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081d264148eb46f1afc0ba411e33410f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68bc59daf06d4c87a9c731683260774d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9edb7a944ede457bb2ca3502417492fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfadeff2c1f5480394b1866913a3183a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopNineProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f0ae3d8acd41fa96131bb2d2405985_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopSevenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if173d80ef8d44c438cb34092fab6cadf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopSixProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f7cb8f0966747fd9a171cc0fd9a0c50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d45585212a4650a36d5467a52c00b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c659cb958e94f909ae64de8887c53e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0e5d69b58349a58289b22b8b683cd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aaf677ffe1c461b92474fb66fe48c68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3eaee674151468f8779787aca2fbdd8_I20211117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TrilliumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TrilliumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-17</xbrli:startDate><xbrli:endDate>2021-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a5967cba7c42799e4a32e326df03fd_D20210101-20211116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:TrilliumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i863e4743e2d145be857ddf010856d1d2_I20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5adbe40672074cb28e27345d594c6111_D20190730-20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-30</xbrli:startDate><xbrli:endDate>2019-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i763f14d53a0f47d2bb88afb5100aeece_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef40e33d0e245579352ff0b15309b81_I20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00cc3ffe8b74509b0746823ba987ea5_D20190730-20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-30</xbrli:startDate><xbrli:endDate>2019-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee11b1723a234cdfad038a7b6b8d6698_I20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e43a0fe85848159c571b3aee53daf1_I20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8f7c06b3f04a218265c1e05e918490_I20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsTechnologyInDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f466f58bbb14f0c960799ddb7db2885_I20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbc5264b1b924484a590099fbbf18894_D20190730-20190730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-30</xbrli:startDate><xbrli:endDate>2019-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b3ec61b4cf4015ab587fac323995eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314f8d3de1434b56bb2fdf8061d7a953_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b44d95032624046bce69d6abe17288c_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i888e24f18a1748c6b73bcfc6bda4a9b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PurchaserOfMeridianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f02e49d15574798a17efff00d83ccb9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PurchaserOfMeridianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaffca7f3bf5b4256aed31e1ad5ab0cce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PurchaserOfMeridianMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i389169f22b244d9c8c2e87bfedee54c2_D20201113-20201113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-13</xbrli:startDate><xbrli:endDate>2020-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93ea4a3a591476aab3a080ee5c9429b_D20201113-20201113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:MylanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-13</xbrli:startDate><xbrli:endDate>2020-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ff88c8caf540d29f9a1a2759e9218f_I20201113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18320fc2b9594ddea18b362bf4514a69_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23323cf2700144a6b84393ffab357354_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:MylanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031df9beab9042be9970f64529890934_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bf57b2d36c745beb81e1b7026d3c318_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i0a559b470d334b43b79260c8d2f79c2d_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncAndUpjohnFinanceBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia69d0ecee9684b1386c94a8b435e6cd7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncAndUpjohnFinanceBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5994c3e02a45da952846df4b47bfbc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8dbebb0e9d49428a97f4323e05244a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e71e04bd5f14e7e934d2585e74e3b2b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i146ddcb53ba74d66b6cd862e76bc22d2_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d984e1a55d04f109e2f4777e30a7cef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa8744bbf8a04e279bfe049ce4a864ba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574afde0d29749d9a45d3066b313f102_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a3ba48023e426a88cc41e754f240ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e17ee2ad705475da2fd98425c5438a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb26d7550d34c4fa8277bc4dd130b09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83182589a2cf40518e59a55a207f4a48_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74dbcccac2f4425289e1e6696c212de4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25df7ea17ef54fb9b9166956b884cb0b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife130b27142a4922bf44614565f191c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncAndUpjohnFinanceBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181dc4bf05244a10b3b37faa99909cbf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnFinanceBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if072dc370d29444380b25f1c9000934b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i252c5ea241a04813985449d2cebbba79_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e3dc812e321400f96f18d4c30fd6ac5_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e80f25bd480402595d2aea33e91039a_D20190701-20190929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icface7a1ee2b4ff28ac480b07f52e93f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8959c4c50fb407583ed92f9c3322282_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i545389717f154954b7abb4cddabeb1cf_D20190930-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-30</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43de6de86aee4f1981210b2cfbd70d8b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c41e610d4514bd2960d85db52a70189_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21520495e93a4b6f82c194548d489020_D20190101-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie644969c98bc4ecd8d8103171f4b1758_I20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-04</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0336041406e84b0dbc587db051c08162_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5259b031a6bd4f3eacca9ff85942926b_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a3cfa0088ba4234af8b08e75e132786_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9db49261fe34983839218bcd3832009_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0027658381944a395727958a68002bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80aa0ad3eddf4f7391796743da2c7d4a_D20200330-20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-30</xbrli:startDate><xbrli:endDate>2020-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib167df84d3de4e098cfb61db76e453f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fbdbdf768e24f2a8c5d0a5b25a12f65_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:AkceaAndIonisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc0e4c459d54fad8d446a48587269e9_D20211224-20211224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-24</xbrli:startDate><xbrli:endDate>2021-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b61ff9024b46bb9e45f08915a7f41e_D20211224-20211224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-24</xbrli:startDate><xbrli:endDate>2021-12-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a2ae55438c4493a657b96e948feffb_D20211004-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea2eb9e0f80d46748855049032762b62_I20211224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if407180f055943a98b83de59f2cd5a1f_D20210721-20210721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-21</xbrli:startDate><xbrli:endDate>2021-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812cbbdf3b1245069237af890fdcecae_I20210721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d66cd919bde400083d7783f18057f72_D20210705-20211003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-05</xbrli:startDate><xbrli:endDate>2021-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375a1296a03d4608aa7dadc39a4081b0_D20210721-20210721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-21</xbrli:startDate><xbrli:endDate>2021-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095915c17bba4c2681c503f9e07eb593_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bdb38bc93ee4bdca889f98c7227ecd3_I20201226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-26</xbrli:startDate><xbrli:endDate>2020-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe998e9fae8489392c54ceb8b6c3cfc_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie99ef111b6e645c6a56cc65ad07091e8_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33e0253955c412683af05e909d4151f_I20201226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5a99e4814b4f128ec2c686a1ec35d1_I20200929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CStoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d62ac5456af448bbff21978df756208_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CStoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b21456e1b1e45de977384ffe2104b0d_D20211230-20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:ShinglesVaccineProgramMRNABasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f00f7ed3e2c4bebad99f1f2c882a39e_D20211230-20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:ShinglesVaccineProgramMRNABasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i603a6eec721f4ae6823ed9ad58021e0a_I20211230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:ShinglesVaccineProgramMRNABasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a30949432804cb2a16f9d87c25227db_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f76f6dc48f4d43b42b0c3a2fd099ea_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ebf471468de402693afa6538be7c48a_D20200330-20200628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-30</xbrli:startDate><xbrli:endDate>2020-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa219a8d864348459268e3b1408b148a_I20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0797c37dfa45c7a80ce32bac03a312_D20200409-20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-09</xbrli:startDate><xbrli:endDate>2020-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c579c9b9f224be594bcabbfa663f822_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea93613082a4762abffed23b2ec080b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b05b7dcaa61407aba318478b7c59025_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae539c60336f4a0c94b5a022dcf96c0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a2adb8ca784b4ea94e14866c48cc70_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib015687530a043e399f09540ca86222d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1967572353a4cf69f29aa1e5a12c183_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i778d084ed9064541a22124cd2f5453c5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f7200b60394988b20633966561bd86_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b71faadf0d40afaad23404443a875b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98027c8fc6b44691900fa8e4048b8871_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CorporateEnablingFunctionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied12c12ed32548d6a549bafb56e60cd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:GoToMarketModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b210be8e114d32a572f0bd0df9088a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bc539f8d9004dc099e25a88c5b43895_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i925e41f449714bd2bf405763d6debabb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40868579307a4b29940d0afd5af8d703_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e76156347742d59ab87928f0b59b21_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626b2657ceb64b34b2c9c95e2661d1fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee83e2bae3b7490d9df5cb5de4b214ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3b3ff3fbc764236bcf7f1991593041b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f963471072a434bbb65ec9314d42418_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da04c0815ec4b519aab9003bbf9e69b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63611b219ac54cf69a70430c5ef474f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia831fe68ea464a7696d368c0b964d933_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99d15499afc94f0f88944990ff7e08fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5dd3ecfac844087a740d27d7e403e89_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a03d9e689ec4fae8e3c0b59a2584fa3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2daa7c6ae294186bbe568931b7486c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8edaec2b4f8a4f18b37022f2160559cb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f5a6ab0d6bb475ea4b794272ee41557_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92e3b0b44374006b6d45a2bf6b453ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bff8c57bb424ff78fbf4a3f0ebccedf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie05f357a90bb455c808448dd5bdb82b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0f6d5d21e848678b8da48c334034bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i877d264408a04f79a16737d91ace0ab4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1c9f4206be4156af7e5bbf360b0c50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ea5bfd40cc43e0b0057cd2055809db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a552f33566495aa5aad8a8ce07ffee_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia829878673b04d45a644a83794ea47f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id19560e1e9e846f1917dd34fe6665c2f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c9c1d9cd337481ea21924d113ae20f0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc28c341b16f4257858e79aa91bfbb0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e69ebbcd7843c09dba286f7a84a32e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85ea9a17643b4ba993c0d7767b7df734_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c5139d761040739c960494538b4e36_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8de8376bf36443928b6f33affb450d42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib978af64a1074124af383834e607186e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia26d7da2bf204ad39d1d01e1c8c71720_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d619ef872034dfea120fc28f055f6a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08555d6e17894c0ebe9ccf5b8c4a0767_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c69c8a8bbc74fa887cd2c9dc0ed4c80_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20f99441233647049f94a89b177f28e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2de81f39d0e4b198f2516dade160b06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if94a5fe65bae431b99f55fff931ebea4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421339ba223042529cc05db65a67a1fc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndSpringWorksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18931406f81e4214af8bdf650ea9a501_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CortexymeIncAndSpringWorksTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5017fc8db5942798d4a4ab792e69007_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6feb23a7d7ad4d25b3ff9db357c2d2b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64fb7f03591425caf0f8ec0bc10107b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:CK1AssetsSoldToBiogenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cd393823f0a466cb163341642a080ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PumaTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2547961512514f6a99fc62e7d1581590_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a8a5bae1304da28157e10b33ab0a5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia825faa5b2044c4d9d91b62b8f59c653_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MylanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd3d48c945234584a9a562a3e928cd52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56031b6c3a9542fd9a53b737a162f549_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied002bca63d9483da7deb14447eca722_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d4c757c4044ceab2e6cbc41cab4a64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f422da6aefa4071bc05f672d391dba2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic20790f22ade4cf6b4a0533bf036316c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id442e3abd12b4a22a3b95e39aae09ed2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ac48141e3840ebb5504bd97d592bec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77c1de86a8744d5f9ef90c3fe81d1656_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafeac22251414180abb3e88565bac3e0_D20190701-20190929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb74e76f421148d08f33e3b64b0f55a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i361e612fd47344f486642a0505329347_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15795fd91413493f98813b66ab28bc23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20860e5e0d834bd0a887924f23c1ddeb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ea397ae7d44969805ee21fb8ef3cc5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i841ae3241c284442a2a9ed328bb982f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredTaxLiabilitiesNetNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21b2ee9ddfcb4ba59cfcd0e1406e7519_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7054cf3b6aaa45ed9aab6e96ec09198c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id25117217bb84d749d33874e62b57092_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b847e7890394d15be5612bf0c10a5ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d1928a49a1c409b9412c1399a30a560_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb4c669061b481d96c1121c6720d70d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcbad3af6ffb42d3a5323f694e0b67e4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd2b1aa38ce4c06af821df843b89ce4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2feb25a701eb4da483a23b858699b65e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if58e15d3f4084fffb7602c9eb76f8bc9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e3cd7c442ae43b9bfd024d7dd0d36b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4281959bef4c1493773621b7096825_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b2c92e98294f13b4dbf574dc8305f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0393c39513f4c3eac3873a1cd6c7164_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7547ea8333dc473b9f7ac1c8f733c20d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c35fcf0cfc44fd48d3257adee8a9f7c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e18b8241eb4dca8f8c5339c218af0e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11c6dc78bf6441e287c9ac69448c1f36_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab5367055954f1ab2c49e8bb7ad206d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a66120c91484bf482696981e59cfd8c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a5e9e7d598442bb2845131112f1a27_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2dcb1cb0b18446282f631ef686d469e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia43c881a511349ed8186adf0171213b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61f3046c6f3740088aecf1f8ab49180c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80d286ba9a84220b133795a7fe5879e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic24d6578cd564b11b05d748a5940c8cc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i511ba9110aec4c1ebb32704e802fdfcf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1ca16d7938490db0ffebf5bafa0e71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa37587879b40bf9f95c485b7bc8caa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13cd8db58f3548899c2ef209a3207f51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e841c53a84a4c519f13fc764830af27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b0f53b05386403bb5d5091940b9f1f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b19f0bbfb7432a8e12a91e563366db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa85376258a44a4ae685454ee4b4522_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3418a2b3afcb431cb8d6bb202f7c9e6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64912c49208a4823a52b20d54f71c167_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1832b894d034229bf17f14653fff53a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbfbfd55f6844d2d82e7590378589389_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ccb03a8326a4f5d815ce199580340b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58d8b7dd831245b68c651101e4deb9ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i145d0984ee1244d0b37449d0c40e9475_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e2191840f24816b76892c14e08c0a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786207e27ed54f20957d50f7249fc8f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fb95d9dac1143469cff7c05c1e9b8ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e34c85175c24f12a4b000731b5e3f27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30d4ea08901f40f8ae26a54cf87605c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d9b25ab1bf48c4a7eb2a2fab5ba59b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08b8d363fe87400582215a448d41b61e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d34428a8a7a4c3a9834e0ab26aac210_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie423b51a2f17446f883f1e3d141a5644_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27e86737f524429b9f6404bf63655dcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dadd6168e384b76b96623c95ede9e40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0f6509e6a7745c6b86b58623ec0a3da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3db2d0cd435749399fb50288da8b36ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7b7712fc3d46dc8c9ab62732f132e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f878726ed649d3b72ab3c31f1e3bbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2890488b7754499db8478c21b1fced49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cadeec4d4b465ca3663ef815d82155_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5925981dea3b42b6b80c80390ff93ce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dbee34efeb54f89b1cf37526e026635_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d63549fe7b43a793936e93998114f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4730f5e3a64488fa803d7863caba436_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83ae4366de7949d1b80d0154a8d14014_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93817b4a8c5f47a784df62085b5ef330_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ac7b2f72a949818e50952dcb98d810_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i253d96f29fcc4271be1786978a7085bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia483bb7e1f8c43579b9a40f336b26091_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51bffa6b2c284c08942e4b334c1d5704_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id721d4b7291d43418158c108dc4def27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb1556a00d4f48a98b1c9c8bdeb762d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id530a91ad1454541a5602cb3294a21df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac39c0dad404d8d8153c80ebdcf66dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0561e1ebce474b1eb9d143fd298c0a82_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ac2146872344a5aa5941ed2d0c3cd9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic697c580bd3e4b12adcbe2d6812a9bbf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e262b7b10634d05983458087d0d704a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i855416e6b6cc4e2bbbe94916d33fb451_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32bef417f19d46c69b2db7cca231ae59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i348aaa35951d4227a378574421582221_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7724991aa49b4c29813095ac7d7118c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a6657a1ee6049f2939f90c46a8b565e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70512a720d8249c6a447f770e98bf667_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9410a99ac78b49fea836856840cfa817_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16561960de5b416bb80606e87a745433_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcddc652bbad488ab1ee0afa359aebde_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07737ad4fa9241c6a7af7bedb530cec2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice49e3789be5439c9f19101663f83790_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb7a0fce89244b7852f6f7fb2718f88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d8e1febfc94acb9d1eb950557e11ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cf180ee19904407b6436c68eeb033d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a1a4330d80747c7ae68476b979046c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35ef7c64d623476b9744d8d1d932a8ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fae9b56ccbf497790ea241830626958_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica452679157c46e0baa897976e18621f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d5ee66c1ff843b58eb05f3777b56b8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22cbf7ef28864700b19759fa6f01b5b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i699fae78a900497eaac754517d1030c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa71df5a7c754df9b330874d5b7d0aa0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1cd464351ee4fdbb492774c72b7f0ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61199b2ae71d4a119d9701e06a107a16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c3c53af69848b88bfbc37caf07b4f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i035dd6d3c0a642048d88fe63f7a78ef4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c04c36693542238bff2f892e06e98f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c1489c0b2445858572277f4815c6fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i266d5bf8ac8d461eb1d35c89e5cbf036_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53680812f8648f0b2a86cf92d5a834c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3401d442aa0e49cc9ca695e109e88114_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaacf9e2737204b3fb0fc33abd7e63fa4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e8e9e1c789345cebe1a2feb0a026d46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044a5eb77497431eb9a60b053d4b39b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb044a8108646f5b407e315c13bc306_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8394064421940caaa44168cccf97ba7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef434e9c591416e9cd79efc4e0aa93c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64f9f7b7805469997412f2d21b49cff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1030e92ca546ef841323d8c13bf48e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f41b9fb6664114ba8990752669ce62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4039c10bfb794c72a6cdf0439f64ad94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47b0fd0f68794d0dbf248bb676c8872d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad0dd09085d4434922268dce88a5be1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9bf003cb624560a24158c89f5b413c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5495ffcbab4b708606247546b1099b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64af4f01f854deba8682c77d92bad2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d5b2cbf5877457a84627eb0b3ef18bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if727b53b9c13428d8682f12d2a2a91a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b344a25e0974083bfd701101c5fa14c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b605fdab274710a7049bf3271f2010_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4661b56a33040d39e0288c81b250b79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74421933bb0140d9aef90e0ba650d3ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52caa45e571f49c4a4927dc80ab53ddc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i059b59eb77974214a452371c05d01877_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b28fcf96cfe404bad85bce40692dab2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i391f0428ef3846feba697cee554a7311_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971392f8a1ed4acabefb0363b735d97c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedacf36cb97e40da88831c92a1a13dab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1de3fb51d6144fd87ad3b271bddef08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ea277d746d44a1f85486e2e86259f6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66bc55df7fa54d8eb2c01252174f998d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02ed3353738f4d0bbc5f8a1517448c88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d7f920dd98641c9922cd5f40499d770_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7730012552f84e97b24d81ea22e392e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic33e861c80224332a9e4e4a2669d4e87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b128fac9ff5430ba36b5956d34c25e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib17ddb927ae6489e842698e9bbfc563f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e722d345f9a4cb1959d4880f98fb229_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b117048a90e4162b3f01f76bd79817e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i660aa25f8def4a02a2ee5ff867c78198_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33a943429e8d4b39919d0b4271200bc6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95769ff280e143bbbf58c6acb40fc937_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5211751f163f4b0f91dd14ccc368ad60_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c71733d54f40a39764458c5aa47582_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a15e9f4278a4ea88fac685bd5263002_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf5508327199483d8b8486b1d9a35897_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i687b62defe464388a420482db5f02ab4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9963f3c49e9547c8bd245f5a63f96465_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b38f67d770f409b806366759e0b2089_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa108cbd7564f07a6abba1a44e49cc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe045779c301429da73c967dc0c4fef3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8d95576ec143738ffeac1cac97942a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:CreditFacilityExpiring2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib87e561cb5e04d748723b1e3acc726a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e7c524a0cf45b6a07e42355b143830_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cb403f6b8f742a98ca63fc690188314_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bae6de665ed403789bfbe721f25e08b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3147b1fbc1bd43a2a4e14a4f08917b76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if62b572a74364f54934ae9592882c5ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib981a715bfdd4b488f432d8966a210fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie795359bbbc64f42b3251279ad6b39c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cf98b9fedf540bc805e6e4573df80ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c8b6ecab3d40c483eb2e43be3fb7a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie28c7ac7e9a14c6793a223d8dc99e719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib90c748be7c2480295ad0c48f90c8398_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc5564b52b29440f930fbe373023198e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91d3d8e7604d481c8c76134979113fe2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20282032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i245fc7da45bc4ff69d0b71a3f9034fcd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20282032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b85141bb6247309c0b1758b23b1d09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20332037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8cbda9015c407c87c364cc6e12a77d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20332037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb5bd2da85b845cfa033f3fccf9badef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20382042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9525871ed73f44d6aa391c6a1148f943_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20382042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21459a6d65ad49e68898cea099e9eefe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fc4b12027964c209dd3f92de86d4757_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if76ee4034a204733a425e8616536a46d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20482050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3c3f8d66c14cbc8ae2209a47f7b04f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20482050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002328e67ca24b3c928fb4df0a88e15a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife593b88c8974bd987809c90a29a6b72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c6cb1e41494eb09f678d0edb941748_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7b65d44132448f82b9c8c9f19d2196_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b576060fcf349178ba58a38684ce7d4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819cd9fe271b4f23b98c4aa8123518f4_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i764ea60e3c5843d187463c0e16bc3a31_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44be768342d5410a8bc44e78dbfd764a_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibffce84ee6544fab8b3ff9dad69b30c5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2047Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02409e3cf3f84191a57923a7a02a3573_I20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd2fabc2dd040398c9f16166684d63e_D20190101-20190131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2c27ab7b79c44eb8dc5cacfdfc2c180_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe6795e8aaa24dacb586776b212b0467_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5642d601e9b4575855e7055a2179740_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5da43009894cfcbe030a782ed8ab5c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f629b69199e405fba72ae99793d09db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e05b819b13428c8901fb90ffc12e0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb95eee963804a9da724fc0b9a933126_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80221d1eb71049dd901d6934d2a813dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50751deda7b94646b1c4601f55800d04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09f964de2c74f4480c86cb376df89cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256d1411f2e24c3dbb0fff716df03a28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51958a6058fb4561962481a91445c919_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dfe78c0227242da8d1e000875a849f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b659aec1f844db2a05972343ce9b28e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf57de0273184de19e0ad20b261a65ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b39b578b49438883023557a0dafa81_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a733f3976f84308acb3ea5484b8f248_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d6c69496dfc4b09a0f1e641b148beb4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491b1222430d4a789c206cbc43deb5e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07fb7c4b4ddb4737a9d1ce7c1eef3b72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i072201acff8f4a2a8a8840f832ffafad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc6ccc570ab144e78a6500343885c124_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe7be2f9ab543b2823384dc71197c46_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be3ad34af1447dd989b5ed287902d69_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f72bb2019c143ebb3750784176bb259_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73fd8308cd7540aab95e1803c2e1110a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e28876e1ad94a04ba445e3810de2781_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16480fd269184b4aa44edd9f8afb1421_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a9736e786f4e32b7b3bb0b15bf0fb6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie224dcd349da476b855b2421bb0a0132_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice3bec2ad3a649d58890db5c58d3e893_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53b2599306346b5a4ab30f2665dab82_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17f9a88a6c804b04a3204e7b05960707_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7df24c7dea094c21834367203566accb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifabc11d015734342b4ec641fcb91a048_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81cf4819818d418f86a5c4e9f3aa0dd2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd276ef364814442a7a5f98817403b1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b05567ffb6747f98016146f80cbafbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a02ec9594b94a0fa152afb9f34199d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fe163dc007411b888238de88875679_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7faad75e5b2e4283af9e7fd2a1138431_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6929b7c58269479390aaeda0ef2a64ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib28e1bec91174c29b172af677b8adb54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862ba5d064f0443ea496670357f0e14d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c3ddbbd35b4a9c93f095e97b3679ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a96e38f1c5942afbd2a39144f01eea9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id891db98fa4a41bd8a834b3d854a897f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1196e921cab43bc8fcebc72a5b56c82_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f9b0f72c81473eaed6b48b9824aa65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5473f4c065384253983909169cb3535b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i533cb430fd184762a6597353269cb90c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id841cfa6c6904f82aef7fd3fa2b9d2f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c5c5b1d3ad49599584c64b0869f298_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292ecffd1f5943b892a2111a12ad7ce2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16152f7453824ee58ba88fc30ea238bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i392594e0d42141e994ae16e92832c84a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38fbf9bf0a244c6846d8ca1b19c3cb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a6cc9cf7be4281b01b2de3a7c6a65e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i877c3de4913144ab97a4f7a18ca1272e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7dfda91c8274099a7be0f74bfe932e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d01fcc1ead34ff9ad40afc6bbf19695_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3062c07484944e3cba9f2336f472c327_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6ebee0abdc945fb9926a62c16c68fbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c28b6acb28f4060af3af8398ee4be76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bf1a42539e54965958a728a93c1e756_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc5354914a145cc8d158da2eb6e9aed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7f4f4115a4440391144e3b67630665_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b140461d860414c8311ca9c9a1bcc99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i041d9d29860b421d98fc6a57f3ec5050_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e809c5ad84543eba6828d3d0602e30e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210ff70401cd4760bb6335c8c08e0015_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d8008250614fd8b057a37d793a0b06_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d89dabae4f640e895f7324d6d8a39ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab33eff7f5d845e9a17bebbe4e745ebb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678256d1b0484d0391cb0e64324ad0d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7941373e994dfa8bce5cfe572bc7e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc33aaaa074a4869814243060c036a4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae113685f9d84078877817f16330ae5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib52bc8201e914daf823fa750d650a1f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c471c4205474e1e97c8885b423a5556_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i630b3dfbbd09454388a5a6976f3655c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idec3f3c060644f67803ed29adf181171_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5710bf2055845c2bb0af48ab186abf3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60429211f00e4543a9d87883c1802d3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c7b4506a324d4bbcbab70e430c8662_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283602e4cefb4da5950be8e7d92e7b33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49bdb977a6c048ed8147d55a219d65bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64901c28b3e4435fb58c625d1c7cf873_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e82614b28e43cda6969e8c6d06b101_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if89fbc914ea0495c84a57e279acd25e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba84ca9e34e4da6acddd4a5dca78acb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eee230e2ad24b56a95a98c396863239_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b1e9bd443e4b9dacb7b420ea97a93a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f847d9790b41829a5de2c58516e44b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36aad9909fb14c9e88dc6e895d2ae970_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88fc1d8b0293450faef44d3939baa104_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee309d4671204beb982620ca87935160_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a840d48179840c58c095b54740189e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43adc45933224ebb81d095ee790ac1f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee6805ceeab9416ab34598f009a9a3dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd31c166a8342b1ab79aa126ec89e2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia386fe05870a4d00bf574703282f8e14_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ecf8cfa85c844e994e95ff8a0b018cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e867961a86c46988276f2a8e0b5563b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1eee291364c41d79df9b38be936c743_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f82686b88b4e99b6d4c1a1a66cb7e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia951c8cab72446a18ae9742d230213ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83f95cfd93704f94897bc57033b1b31e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6fb94fe8a7447b0b43f4729bc6367ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib998445075734dc0859b69f2f70d7eae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cdce9769d51453485e9ffd8c6432ac9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efb9b34ff354aa695d0ce5519469de9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de93f17bb5246deaf177cd4c179c2d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd08d03a6f8444e8e25322e621edaea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fea9359eb542c88235d0e94cc3e253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7baf2c21a80d4f38986f54d8c0033701_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2702036ed2fc41b8bd3ca11952dd39fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123f921d862b428288283381a090761f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ccdaa1a811a44b99f3c0c1ca7eb44bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a51613c60584714a3ec9b2ab496acce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09a618c301e845ed90388735dad7841b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9316f5dab24cc588e8c9e879cd9341_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id568702500f6432588ff76e3c3f36577_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib38fc00053aa4c199b39dece7cad7cd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20c6d20908b4daaa553daa64deaf5f2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc201aae7f2142fa93d6f1984cee3475_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08bf866f12c4207b983f1e7a10c0e8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5407c5de8f4429b9e4f43939bf305b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf1f6db9b9894f909a5796169e3fa818_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57fea877a08c4296bf2ba0c929fae62a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bcc6044a5d34518a267a09836a28a8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i742813cbab044d04a09ecf0ff835c7f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d5003d9185448588413661fda71f1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6960f5ec76174cb5a4931498467bfc1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c51183fe29945a1bc46769c25b05d2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a2177b163f24101a81bc962d77be4de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9254bb662ee04eb7851f6a0b2686c6a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia249cd5c4d3a4607ad781d7a08f45a32_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id179af66abf14a9fa7b1bba32e3acde8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0614fc26162d4735ab928995a4525919_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57504ba4b31c4e419514d3d822decba5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76b3e3473a8474aacfe913ead06f99c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecd486b3bd864997bc5dc92f53919f6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f7ba90f110d40e2805438dda627ba7e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73e7d40fad2b40cab376ebfc9484a1fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic97e4ef4dedc4cd4b036e878ea92ff23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if24ee12e5a364e699f1ccff806b6610a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24262e3bc3d74c4f9d4ebcd94821b450_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91370cf282454c17b017708814f29a5f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i589b9c0f0529485b88483ec95805a113_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id792c4fa30b54b0f86d3a756dec19969_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557b046786b54cf5a7fd128f940aa558_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d5e155c28ce45949b23ef1c2aa7bdcb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib89426b5421f48bda2e841651169370a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0eeba8032f54437b2332b040493be10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa59de110c24310a8a3947fd9bf785c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01e99ad5a3624b79beda47b0277cfc08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9178dd6228bb49e6ac59b6bc450f5f0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde04c3fab9a4225922b968a4ae389ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447a8db12c9c4335a9e7ce727e1c6c75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27f1331fac0a44ab8ab767c27460f01c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8df318e157488ebba552305374f247_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a6859a81d948b1b05d1524a2329d05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5be279af8994b7baf6fe7f41d4659d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a28d95791fd48349d327616387cf43e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3fdb174e64745cbb589727b895dff68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8ad87158d744cb98b1afcde979e2e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3acdd3ac8bd749d6bf766df1d252e13b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4cadda8ddf40c0865e66aa16db1fb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd30853b5aeb4360a8572bbff63519e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b913c838f444389b2b5e72727c9ead7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbcbfb8ada844189c00d8838d1d06df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb2a8f3e3f5140a6bbf5b850dd9df831_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61b5f086df574c9692cfb7bc457ede83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b1262aee15447893f4283772570e1c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2204111742ee4465b254c1d8def302f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5054f1ba961b478e81844b3970edd709_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407c2c84a6fa46d19c024b335e5207de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4789a2744a994126861e99bbaa61a091_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib632f9766b1b4f088ee3c17033d9b730_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b14ebd35ab942468b155850a50635d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b022b7da864f55abf40a8814adcc45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57736d5c9bd045889e3e70f907687568_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d396dc1a9fc4ebc987eb95b09e2dc46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2fe0961b7445768068020c53ad927d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie575e7d2482f4c67ae9b25248a9ad0a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7d8a3434554d0399db965a1f07c58c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be90fe1c0944a43b096201649b0b9c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8da59af46f4f0386aa576b69074f33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22075a2e3ef34cbf995ac7e82012dce0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0863c82bbc51409b8efa496f8db9fdeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib30b271d8b274f408f4ec6c14285b00c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0445954f919744a9887083dd3819fb37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf9c3b10b55044c49138dc630a759469_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee038f714c2946bcbbebc2ca551337d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62bb9a408ac64e97878a6c8ad73e05e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecc0a667f1e24e80a1d4b531f082b57d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b85b80107be4fb8965249fc26340ed0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b0a5ac77175482aad6b61c53e7c43e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6f712dd8c0447aa8f70d3d13ad1e6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i329e2ccb8f4547afa328cdbd5609b4be_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5836472a076b460991d1eebeaa047f8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d752324547a45d8b253e8c8bcdc884f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if86170cd6f9d428380420d95b35931fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17a849b4291f46ee8770bfb32d9b35e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9982822ef54206a5a46c76586d2f84_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a347ca6972c4ccf8546cf5025e6876f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd4a43b1598443a7ab6eca61208eba5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c25f3b4c7ec40969b854e0ac925ba55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c46658794be4817aac85595e3b4fbc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c11b3f4356845d6aadac688a6d24730_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i692794301332409594d055d1c7f8e64f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5326e53aef0646728ea9fa61b1a7a0ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1e59e825ee4981a7d38ce2c03e80f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic93ff27c78464387b5ed9bc21e35646c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb581ffa12d14ff2a9a1844bbaab94cf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c36130da21474a97558823d72cc9c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b2e88175ff4f378684f8507ae69794_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758430987c524ca79a1aaea82cb98356_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b995529e4646e5b6becab80303e6e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f16642eeded411e90331536700f0546_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i379e7c46cec74ebd955ac7a7e03511cc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2eeca61f3244ee5af945c85a0919a57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c237700488c4cb8b091e549169f189d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d125dfcb4a417187130ddbb9460600_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53a90980f6dd46818498f9ee7d139756_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce607f8a3a94cb29fe8250722ea7383_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632d5976180f4e41b0ae66ce2781ec7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c72066d02e480a8fcbf60f3979e383_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i671b1638704a44c290bc349298d71e48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17829ca318b1498cbfae61d52d4675a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a7fdc62e800449d92622b90c9db4ffd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dfdef0347e94d1498a69a86deaa56d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9b0fa1fef2342d79c4cb9415d79ffd1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f84fb522f6f458e920f395b641bc9ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1120f4dcad384a9abe38b1b29af1c6a6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i015c2dd1d8224aaba8f11e2779372636_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674db30e4e6e4a1d9f25a2bfb6a2ca07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732d0c54d73849b69f3d917bd43daa7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2238ba918384e999cc84aed3dcd385d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i866e56c0277b4bc9a25f19ec84f3fb26_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24949bc17dc543c08cedcde9b2f3d7e8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie133e397deff441e98308ae589756218_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bdc708391174865b782df989e1ce518_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574f79e048bb417ca2f0db77a714f150_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77d6d46b530f43febb88f895a185afb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifea2ce2cd7f74f449218e9ebc7dcf7c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba350294128c42bc87995ecc8e035456_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i532f4bd22c5c45d4af63afa5a4f2453f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9306a220094a4ee4851877329040ec09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98efc316265f4aeba589a5cdcdb2ba3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i255f65b9224f4081b95ec6f405a1952b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59707801ebc544c4aef8569d05013809_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f9185b14e74414b6142cd14b78487b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca53c720af3408083112ad16a8d242f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13d65917ea214718aabb6241059fbb61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab50e3974e214326979f7b8957262eec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fc429f107fb4881b04687f32fc0685e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2413d9a6104540883ae20a14dee735_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic18418a4253841c684ea8af6ccec0aa6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3151aa7ee6ab4f8398bd9a46d307ae04_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie891101977024301955e23a929e1b4bf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17489845f01240d096281d798554cdc7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i778bcf63d499487093fcd6b390c2334b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3987296f1084db39f1525b58cd1a718_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i495275bffa674b0f800ed1decb890131_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624dc668a9d84bf4918f26033ef6b532_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5289bfcfe10644b0945be402d243ebfe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife9e20479d3c4f3a82eec65d7edb2fec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9af20ea2173648718c35eddadc26f4d7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16cae3cccb9b437482e0606550ca5f7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e4072641bf848fd9a69cde4746de8af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4895c42f91a3449d9e4a69e220f8567d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie49724b7bcd8476597210f4014ed8c5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e9d20521f84171a18296ea65d842c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaafcfb726811461e84845b5dba189707_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a77fde9c8d47a0b5a6ce8b6f44b599_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388802b089ce4803af64b6ab3e8a745d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if48068ea782f42749ec61f3378bf81b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib94cc14b225548bca7b6f25c551f7130_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60ffdd0bae334efa9bc4cc9090bf826b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bc6edc92b8c4f049c4a39984706caa1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f245cfadb84797965a899a8eeb520c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i793b789e8a0242258ea94c9fd8c9f383_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf0f90452504d429ae0f90828d23cc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8be255951e4b8481ed15370c61e701_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib471922b03524068902766bc0fa91108_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1343d51f60440184a9f78f1c9375fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcba539f4ba046dd8c2d86a34034ea81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3cacc2f9fbf423f91cee329fa9e42d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7e4de941cd41a68b47d69317c51b21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecfedf0b60464ee4ad5a115a4e7bb74a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e1c0d0059f0445cbd0935e842d98ee3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eecfc1306b84ab281bd797e77e015f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b8c791011a4a579e971f6153d22ff8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847e93c8a82e46f1802cb25b6ad0f2a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i622723f52e094267ad1f1a6f20f16021_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i813308e909ae4e17a701ee9b75f8371f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadc214917ea744b79b2b73e6471dbf01_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebcfd4c10a4142fb88a316179c35e0a0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica401af8d1ff43afb5c3de05ed7396cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ea04bb8c1e41a9bdd1d1dc8714d350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d675d40b3748ea9f8d5ed88c985153_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1825332913b4ce7b251fe06cd990eb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14b680e409142e6ac7c80709cd5e4eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13785fc5583c485a8b9868f58464c651_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a668a32aa7b440ba577921b46eb3b30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i367c45882da94e7f95af6582e7a69196_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2017StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44e280570da48ac9f0565d31167fa82_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2018StockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cbd61ea7e074c3cb9b549fc73f7ea50_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31c50772d7a4726a1a5529a7fef8da5_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i952c34b232a94d2d8ad00e03c4de2d9e_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e39a223d384b35843e9b8e7445832b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:OpenMarketPurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56eda332625c487ca483e8359eb0f33a_D20200504-20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-04</xbrli:startDate><xbrli:endDate>2020-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152722889eb34e0db6ad2e1dfaeb0eed_I20200504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employeestockownershipplan"><xbrli:measure>pfe:employeeStockOwnershipPlan</xbrli:measure></xbrli:unit><xbrli:context id="i7ee44a1fecca4b32be7705bc2cf810b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd44478503164fd8a8e14462b5e7a729_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i917415daad0a4424b8d7a97c2d07bb8f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805079d974574ff6a2d5f8b886169231_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2151f3e772140029f5252c02f68b75b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44cb9f5305946c5afb2c81a69675dff_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic17568d2b6964d96a3edee3790b0ffae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7be31568a945ebb1201de1758225e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79ebdb6315104090a143c1f852c2ca78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i867dddfc2367440eab83840a05865495_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tradingday"><xbrli:measure>pfe:tradingDay</xbrli:measure></xbrli:unit><xbrli:context id="i04e1e8887418409c8efc97bcddd13100_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b45cc72fe144a41a027fcc9d82be277_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="measure"><xbrli:measure>pfe:measure</xbrli:measure></xbrli:unit><xbrli:unit id="period"><xbrli:measure>pfe:period</xbrli:measure></xbrli:unit><xbrli:context id="i6748c5eccf3f46b1be9064d93a0b8af6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a49ac6e8d614f469106f20db9f45fd0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28be20f732ea48069576d8342f25116e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie383f1f76d1640bb8be8220be13b0054_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7ecda840fd43338a51a3f00ae86688_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia083e623ee674e548622522766f25245_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9593b3f58b76448e920aee74df7e93c9_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f80dcb721524320b19d3c6b3d3391e6_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pfe:GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443cb80c5f964703aaecddf09596d6a4_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie346598571a44f5e9df70a558c1951da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i025b64a058c74145a3d20c83e55e303f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2473beb495894534a4c23085d71539f7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f0385272bd4aac882c487c230d065c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief795c9787db4b308dde841b75ab39f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30bd7895983642db9bf813a473267120_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i220423650ddd4f2190621f8d4fc9821b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41e5d4716e04e498cba46b05595ab61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc53e6e2a9e49298a3cfd288203afd2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84a9df877b7a4600aec68656dac6703a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f0f1f3fa304519914914cfa722b7a5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97f983501e904503babee369fc4f690c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9d4654dee8466e88457fed9824652f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibabdd67705e148c3827e146d45375317_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94325d0fdc4e459f931d66a9b73fffa3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb707d364c664f20a32ea1127fd4286b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a24c56d22cc4eb1ba8bcbaa319b4761_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9cb70c93197414db93c20b578e77936_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38cd1de7c7d4dbd86cd29bd60031120_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57785a499e164f5bacbcf350c3fb80f3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i983864cac72f40e9a85d8421bcaebe0f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c06c854564f400a90dbefc01376069e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1f62383330418da8e053b9b9db9ba8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d1bc977a4bf4a8d8dd29d3800b05abf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bbea5f2ec0948fb967b4a1b64621b58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34e871fd1d44e8ab3ff53c514b55b51_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>pfe:patent</xbrli:measure></xbrli:unit><xbrli:context id="id0ad5620c98c434fba738a4d9c4cf398_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd76542ed8b4ec69bc988447f8ffb86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:OtherPatentInfringementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>pfe:defendant</xbrli:measure></xbrli:unit><xbrli:context id="ib18ea7fb4e2b467092e7d8b1a4245c1c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>pfe:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="if309e75442d740928d61d06aba360a99_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lagoon"><xbrli:measure>pfe:lagoon</xbrli:measure></xbrli:unit><xbrli:context id="ib6e95e1dcabd4e7d8e7e9244ff512b69_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4cc2245228440d2887171a58dc8189f_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7fbd03fa994fe7aec0e5f20e5005af_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9655062295ea4eb786880d4953a18367_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic74107e930484043af252b70ef86b1c3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsPurchaseAccountingAdjustmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46149707465a45269f0a4d9663481faf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsPurchaseAccountingAdjustmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4388992791af4d329ee32af6b701ed74_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsPurchaseAccountingAdjustmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea96d19d201f43f78403ae7000de580e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3331360a352a4974b87a0863eff1cb2b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TrilliumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01706a25eaf44000861f8a5988b1cfd7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b14f941e6742209cf14aecbed2dcc2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66820026161242ecb7114f5badd98288_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61f3df5393924c84a4d3bd1ee41d293c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1faeba83c004ae2b29779566eb052c7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee440d1ba7794b8ab3cfc128d24b19b1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib12fb6fa02754813a733da0d0a3c5217_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2bf364c90ee403f905cf44b76b83795_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5545fe7ef044230b942499024d73124_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07534c0ef5da443f9d23bb709f1f887a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e4f467b53b54c268aaf5ebd5d255312_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b50c81dd41c4b93866757262314077f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic62778dbebe74ea5854c11429ef857e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>pfe:country</xbrli:measure></xbrli:unit><xbrli:context id="i99f0e6a9eab54ae4a8ed112ae8d226a7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d0a8aaa82ec487cbe6efb57bd4d09ae_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b31b69d78a84395930b25d3a0a78c1b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d67ec1ac5234c0d9f621dcbbb4183bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c607e23c364498a9220f891e27bfcb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76154b8bae914f14a3264e5b5345009a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86eb9d30e32741049330f056b435d474_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70843c611e141548bd971cd5410e88d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02e740ce254147a096ae80d08c9094f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice936d0c8940458e99b8cd6b72505a29_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1412106f3b64e9190b955c58956f7ea_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fee695ccc6d4951bceaa4452197ada8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2057fb4eee634619a81384ca8181d059_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b05c103030344159abe87626ef3fc58_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c71dca498146b98b69c59745867f99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if47ab8b761c145ba8c1e38b804fff672_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08d75cc0ddf8452ca93b381cb375ed5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec439aa05d4f4752ba182e07bea798ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b1ecddc539948bfb8fb4cf369085020_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9e53394f559452ca83fffb3a7e16401_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdaa8f31455343a4a4b78e91aea00e81_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67454cc77ab148d1a8042c793aab9a02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba39cae55e2432688515ca3a47f62e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4ab42ea69a04305a2fa6db983f61342_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3fcc1684c04124ad431600c3ae2310_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie683f91cae7e4f439a204f20f28ecdd3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790164b8b500487995993a2e01eb13c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i010d3fafcc354cc784caf06fb723ade2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff979b3974154ad0803e20ebd7c32f30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78e81b138394cc1884da57948dee8e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a4239b3555a4e418c8a9a5e9d67c2e6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5d56e1790d4d3298629659396a640a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ed595eccea49ffb73f0798a75a1773_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76fcd41f92da44e289e82affd418e306_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84925602fa144f3ba3a71b13029588f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a69e52cd15347808dffa431d34044db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf42e0f52a3e45b59df985db36745f16_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieff4fe2fbc324b449cb56e68fdcd1a9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2238b79faba4effaac005b81ff23304_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf497a35e6494fad8698744787351909_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f72c5f82d75415ba597df7de74760b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0750214c46a64ab6b39e459f0d49daba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e64081e3f0434b872e5a4506e536de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb6a72bdf8141cf863b344e751661ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eda9019748445348870a74c3bd3ab6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5790195bd954466ba793840f2495ee93_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a6b539896c45d79c389bacbc2f4743_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie427a740ab1c443d87ea004b5125ac8d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa09786cae24e62ad36d600ee535ad2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92db76fc792d40ad86670b655627f383_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95c0ae9140eb4237841af25b9edac128_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3efd621f0e0d4d2a8760e00099eb67a5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c93ecc7240f4fa3ad8ec0c4c64303bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3a6827b38a41d7a516870ab707a086_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55b91f673fc04f73a3ae024b9a41752d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1f7d47181e475bb3aa38336cc6209a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5858407930714ddc909e6bd243e24efc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcfc0ac3a4bb41e6b2470eb7d7c0ed54_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic828b8310b6d4b5bb05dea1dfee3affc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c1116b8782479b9a95ddf926b9e0b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28052556477d473b8c21d8bafb9cead1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b1304b5f82e4e58a1c55dc33b956260_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bad590cb383439c9110aca0d945cd2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22e5406f5f364c5eb193983737f6387f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6acf78ac097b422b88e179ee9b747007_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67bcc609ff5d4139b0a6a18177feb882_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef0fffb95fb47da8f0bdd6c91925689_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7590755364db416f9e17b48ea64413d0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e7d6b26d7d4a74b5f922d708d9a413_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2460aa2b09c74030b8381ba12fb645fd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b6c834fb1c4292b59fda40ade5b9d1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ae2a7d71d9425d8152e464a315bf21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975049da60424e96b8b532025ae69caa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7484561be64aeb9ac7738d08ab387f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4de75bb8b77440d0bf45934e1ba87237_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83d8b4737c1840a0b89442498290ca65_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0fb8d22c1645438cba3e8ce25ca48c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67382282eea44a6a957d3764ba308d11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b122ab8ca744c749dc432ff78c16ea0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36583488c824eb4892877ea211dbad5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc957ad3d68e45c5ae1a74b135305349_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b391f47cfe48fe93bdb715d0951829_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23070ab492904e61a59b2297b56b0953_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7733f5b2e9345d9a1e642d4c79139f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1933184cd1e5441e87193869a01461e8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb7b7f56fda4c10a3da08d150f67fc4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i625be7e17cbc4e3cb80799060c42b8a4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e621ffd98b54fd29f2e02643a70ad30_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9007e1cc1b42109548c43dc4c66fae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7d9fcaa44eb493cb0d96f6c81f2a2ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28dd61ade4364d5a90e0a17c4f83e822_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60a9e485dc774f3ba6d70e30217f15f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e987f25dd8b46eca97df2eca4a9c075_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736cfbcbd4874cd1bb2dfded6deaeeb8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b56db0f447c437197c532ee8f7047fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3eeb0ff7cc45b8b0e9b9da65bac12e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id911443b1d0c48de95a2929266a7582c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c019e4bb9043ffaab47e93d8c852aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a302d7f90c3424fab750ed285db9b29_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a027609db240a7866905b49f8d682d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb26436d0a1448cb81ceb46110a4f3eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bfb7acabb24a67a1151e63cc4fce68_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8c89535e85f4038a7ec373e8a3123cf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea9873a8979b4508be42cfcfe7747f50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabcd20f9c06a43dabd464c0015ff8930_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cdd55ff3b5d4c52861b121e66ab3ac7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36bb0606d8cc44ddbf05cfe5192a51de_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4ecb4c49ac45c096a8e6606e325b90_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33477546f42a4341949e28a3012fca3d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55ac74fef9494583b8e81681775bc2b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc1f43e55c834e949f22669758cc7ee7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f598e5471364ba699cade3d65d16c2c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b97da5e9af14fe396e47b0d71d869f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7e0cc1b139d40adbb8d7340de280263_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3e974364904421b9ba3879babbf5f1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb84bd57d736452e8091760a4451bf32_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i789c240c68ac4def920f05c29c59b9ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc19ff52f7843b19250144e07c70512_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28339e568e9484e962b70b87aa216f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47352f77aa394099a094f2eb6b3aee0e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c315b990d4b4ef4b6f4fe096b1108fe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93eaf75f91e64395917e59ebf57f6d3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb67eb0248104e43bdd406f377b6ff52_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5951a6d7c24aabbf638e2cfc5d9fad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1efecefa4ebc419689066fe6e6521f2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie86f9d77d3ac4df098fa6d23ca3fd9c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0eb57c151e4a51b244e35e9ceb3409_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864f375b8a0b4cb9ac443ab41aef9bc3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib48b9e43f20748079898c888a0319e4d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23cf6ca73857476c8ff2bdba66164ed9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fcee28088674808b29e46b75901de61_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26c6c1402924d3389d90318d7b7a05d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed935509397465ebdcfc54a917081b4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic429688b0a95432ca599be902169635c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7715e12d4d640cab70794a4955462a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3657cbe2097d49f09bc5c7ace046f357_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea0f38aa0b8344479ee03e3bf63754ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556e45078d274acaae78248df82d7516_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa5c08d894ca47fcb948a6643738b465_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11b6e37093449bb86170837f29de961_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cacfa22e3f24fba9a769d3980dee98d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92765a1b79944c1c9064745303c5bb8f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9c00b6c0fe43929b5baaef97fd98df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f1bb2ae72c408dbdd9691315c5ceed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i976152f132e54933961ff0eb781c15eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5573eebca954b888eb53c05194e1cb1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec61b9fd42f4e11b22c341a2f524130_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icecd0bd3f5d64be6b655bd11f2dec987_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac09b89e5bbc4d37ad7c15e4b948b194_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15803142604d40aaba5216963466084d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if479f5e8c2794e9e90a2742677f13fa3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1505f771b019477290eb9cd549444c29_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e4fd49f5a94424933d7ef2c6829721_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b70715abc94491a9f13b0b6351cfa47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie735373e16a54b109a6ca3eef912bee6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf401509c5154ce99e7c8858bbbacba4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c1ea9c9b504497db6d2486610d3f9be_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08011c6d22d84826921f15b42efbd425_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0d8215e037429fa7a23c4023f0d1e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb660a81d4c4eab803661bac2510826_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5eab6ea9c344750a8cbb61f815ce93d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a69b57be5b4ffb9798f0dd614f0c40_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6571d00942e43b7978e3b7b74f6edd6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8053c4ee14d4eb98043aa3562d93dc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa0004eb00541dd973b2f4b93c282c5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713a733530404ed18373bae05f6b3cb6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d0dfa4a22a74f91abffb964783f5b3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47bcf7ce353c44f5bcfdcdee0877890b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4f1c35594c544dab5b1dfa223ee4637_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c6cef914b94f1d9ad5c0270ad54b42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5563b77001b44cb1904e2c79fdf3e92a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc98ac45c09142c7bd8010806f4ab103_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8922522ea93a4f3daa0785e1fc05776a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05428f6e4c154ff7b4054980d1d8cb46_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350105d44425447281d31cd6eb39f7c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47901365d3d4bc0bb6d60c486ef4e67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6baae032a571408ca95cda7430a3f436_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71f59e7bda3142f187e0612cca60056e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34bb0e10a3254deb9c9b88fa560808c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie013202cd4c84b0ca180ef2bac1c2fd6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f99cd213cd422f98453a77ea72f411_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d18c120b6c467ab4451263aebe5da0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62b3761d83784fc7a895b99aab8312b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfcbdb031a3e4014a0cbb064217500aa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62bf6fb9bf9145e6badc4cd8e5f71064_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4105a4588d4e35915a905b52f68c56_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff6d7e329bd24eb4a5a437d5f214dc41_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03db65ef941c451aa8dda7f330bc59a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4ea528937245a980a0cd68ff2881a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib70adb8ce46e49d0b66f7c5db2e887d0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cc90c9a8c6548658c7c62c694f4b1b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc908d4ea1448b3be3181f507e32499_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71abae4333e54c548a4315c66f1b397f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3287158066bd486e8eb1277ac8bd7a2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i378275fdf5c241309e4fc13c042fb25d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i484dba9ec8d0445bb323aed6db364c28_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d6d788ad4143ccb88dbf6bae7eeafc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd236c60a6694d4cb50a6a582663bb1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503af1f1138c4021a803c193d30090a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i623d184c533f47bc94f2a7ad9168813f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ecd1a0cd424241b3ef5a26c2f58f23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c4ac602963e4692bf2396276e8987c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629787cb4c6e49829464bc26f89c64cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff57629495074f9eba67dffa28d6db32_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9b3c1fffde345738b432a24553ace13_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc38387d7e3642be97acbeb8bf6bdcb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ef775a73de440e793ff799dbf7b5fa7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e851a6e197444cb8fc69f8308332f99_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d39854eb2b4573a531d5ba9f61e8f7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7d6064a3a64aa6ad422f45888299a0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39801c36e4b84ce8b6d398e7fc12447b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c3b4b2ebc94e5697c6ff08a35994e8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec324211aedf4500bf27dd971b841288_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4868147c644c12aa0f667d7f6e8057_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1631e191e764640a3ad6ad0db704edb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2fae2aac94946139c72a9f5a683a557_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027e0fdd3ba440ae86709e0f6c28fbf2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8abd4017e8f04c56a2d4cf46f2d31c44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c32373d4dac49c19122e22f70bfe22e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic21b6b2a9bc64c5cb347be77855ca1be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52bc922f23d94809b6348416f7d67f89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1efb123775446d4afb050c15a9de3c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd473cbb8e244c0baf184d66619e9bab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894356ab8eef44b399b55416273a7ef0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id502e86301f6476e98c1e91bd227d64b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTAw_78fef901-ac4d-4640-a287-c2584eb06359" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc2_0d9c7877-627d-44ed-bc12-b660cce44b18" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTAw_78fef901-ac4d-4640-a287-c2584eb06359" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="3"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="3"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="3"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzI_ed1f660f-a339-423e-a681-4ee8c16fd64b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzI_ed1f660f-a339-423e-a681-4ee8c16fd64b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzE_c6c9f186-f975-4b2f-9a61-23664fe96dfa" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc2_0d9c7877-627d-44ed-bc12-b660cce44b18" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="3"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="2"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzMtMi0xLTEtMTU1NjM4_7daeca07-7fb5-4238-8e5a-f50d6b2124ea" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjE_cb8ad76c-af7b-4cb3-9b21-56b340a790e5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNC0xLTEtMTU1NjM4_3bdff635-14c6-4f72-8238-0b7e0362e571 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTItMS0xLTE1NTYzOA_a38ccb42-7b44-4153-978f-eee616f1d02c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNi0xLTEtMTU1NjM4_c523199d-997d-4a19-8355-cea3d890630e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEyLTEtMS0xNTU2Mzg_5f1e6ae2-9ee1-4d55-bae9-cab3ac64546b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNC0xLTEtMTU1NjM4_fd95f5fe-9788-42b7-98a7-2ebcfd5e321f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTItMS0xLTE1NTYzOA_d0cd48f4-f91e-4631-babd-45ea614f93a3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTItMS0xLTE1NTYzOA_9136e4e7-dd83-4a34-a2bf-5479fca27462 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEwLTEtMS0xNTU2Mzg_9d601fd9-6e60-4673-a18a-9c8efc23f039 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNC0xLTEtMTU1NjM4_df59b808-c19a-458d-9a08-fcc08454107a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTItMS0xLTE1NTYzOA_9a80eaa2-1cc5-46e9-84d5-2982df1449c7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTQtMS0xLTE1NTYzOA_081dcc47-cdde-4218-b274-fb74672a032a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMi0xLTEtMTU1NjM4_98785a01-befa-4c10-b041-8f84db3b9aa2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMi0xLTEtMTU1NjM4_e61f106a-42e6-4cf2-bf52-aac6d39c699d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNi0xLTEtMTU1NjM4_de0b7543-ea69-4805-8352-777920c516c7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTAtMS0xLTE1NTYzOA_4a2275a9-7705-4579-8874-1206874376a9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNi0xLTEtMTU1NjM4_d8130e94-33e2-41d9-bd5f-dc35bca090cb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTAtMS0xLTE1NTYzOA_123ca141-8291-470b-b0dd-6eda82b33426 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTAtMS0xLTE1NTYzOA_80cc64e5-d4bf-4658-b77e-6608ae105363 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTYtMS0xLTE1NTYzOA_d3edc723-36cf-4444-b015-fbeec8e2ee52 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMi0xLTEtMTU1NjM4_0df94e6e-dd72-4a26-9d13-48322b242766" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTItMS0xLTE1NTYzOA_934964c5-66e2-498b-96c7-e1e11097f2bf id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktNi0xLTEtMTU1NjM4_7a8c75d3-6197-43c1-a9e3-3b11f55e48bb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNi0xLTEtMTU1NjM4_00ebe2e3-fffa-4d43-8cf2-d10877fccc59 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTgtMS0xLTE1NTYzOA_95c4277e-6053-4020-b8f5-b5eb8adf6ae2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTQtMS0xLTE1NTYzOA_5f72f016-f854-4d35-b32e-a1523936cf71 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtNi0xLTEtMTU1NjM4_8da22a9a-074d-4f15-8ef1-49ba93ed5ef6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTQtMS0xLTE1NTYzOA_83cb9115-e0fb-4619-aef9-ab67c7d44420 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTgtMS0xLTE1NTYzOA_2f1f2081-7178-4eff-980a-f932885400d6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtMi0xLTEtMTU1NjM4_889185dd-849f-404a-85bb-92422714cc9e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTItMS0xLTE1NTYzOA_dc770b75-d0bb-4cad-9696-a02e91952b4f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTYtMS0xLTE1NTYzOA_c4fe5a30-44ae-4d42-b16c-dfad5d473ec6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTgtMS0xLTE1NTYzOA_37f18589-53d6-4dd8-aebf-aa5edae64b03 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTQtMS0xLTE1NTYzOA_07797e84-f31d-440f-8696-0e022691ac42 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTItMS0xLTE1NTYzOA_b19cafe6-5af3-425b-a11f-746e7e40d664 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTYtMS0xLTE1NTYzOA_1be889d8-f1cd-4d88-aae6-0e47f2e407eb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTQtMS0xLTE1NTYzOA_5c85bd6b-451b-400e-81ad-73936f0d12c8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktMi0xLTEtMTU1NjM4_b8c25820-33a9-41ca-963b-17e84c50bf38 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTItMS0xLTE1NTYzOA_18ea3c1a-9447-45a7-a412-95630ed61f83 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtMi0xLTEtMTU1NjM4_3cb674c8-26ff-4296-a3e2-d27455fd0b41 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTgtMS0xLTE1NTYzOA_a16f7605-4987-4a6a-b6db-1bace5af0ee5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtOC0xLTEtMTU1NjM4_cffbe9e3-2f79-455d-8521-2b76def7f868 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTItMS0xLTE1NTYzOA_08096b56-06d2-44ca-bf3c-0c1d5ce92617 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTYtMS0xLTE1NTYzOA_a9060b32-109c-4e94-9c63-a2e31f16ea3b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNC0xLTEtMTU1NjM4_0c488731-aa77-4405-9d8b-f1278437dba0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTYtMS0xLTE1NTYzOA_9aa0edcb-ec53-4eff-9523-c670836ea3d4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTYtMS0xLTE1NTYzOA_dd1abc95-de40-47a7-8e31-ae4082c6ba2f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTItMS0xLTE1NTYzOA_1e898dab-8f93-4ef8-94ae-b8e82db17466 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTQtMS0xLTE1NTYzOA_b2fe21d4-54c8-40ac-ab41-f210c214bc66 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTYtMS0xLTE1NTYzOA_f6e6827d-16c5-473d-b9a4-970beab322dd" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyNQ_31721eb0-f80c-45c8-9db8-a5fd7509ba21" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNi0xLTEtMTU1NjM4_c2a32bf3-b01a-4af5-8c9f-0d092ab35f6c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNC0xLTEtMTU1NjM4_17d32bc8-693e-49b2-9755-f0c64e3067e0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtMi0xLTEtMTU1NjM4_31b5dfa2-8634-409b-8b1b-5241f26bdbf0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ1_5f3d2047-e309-46f8-a0d2-9b42e2fe3713" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTQtMS0xLTE1NTYzOA_4228acb7-0a7e-45cd-bc41-1d26c3fad96a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTYtMS0xLTE1NTYzOA_3722d7d6-c8c4-4e6e-8d19-e418b391b627 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTItMS0xLTE1NTYzOA_70150eaf-49c1-40c8-a5b3-4c2dc5a3e763" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk2_8ecaa1ee-28f5-4418-b11d-5f6b7758233b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtOC0xLTEtMTU1NjM4_6ba80a00-e040-44ed-9659-681083a3a33a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtMTAtMS0xLTE1NTYzOA_881afe32-f53d-401e-a9d9-f395a68c9bb7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtNi0xLTEtMTU1NjM4_315394a9-0040-4ea2-bb7c-aa5eb50c4ae2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIz_b47b6a34-d867-43a4-a71a-0856e26745d2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1OTYwNQ_4b55c588-fcbb-46e2-b19a-c1eca06a2fc3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1OTYwNQ_522f8a54-1dd9-44eb-97f7-44c711e37e6b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTk2MDU_f2d9c413-bb86-4b22-92e4-ff5805dbf0ea id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1OTYwNQ_6cd5bbd6-d390-47be-b4d1-7c6fb8217b14 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTk2MDU_ca00c7b3-bb10-422e-8c22-eefaeaf2ba59 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTk2MDU_12f5cf08-b296-4d3d-8e58-d4edd5422f7c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTk2MDU_243c4254-90bb-4790-a9b0-be9c0a8e38ad id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1OTYwNQ_111bd224-a3dd-4f82-bb71-0880092a2fdc id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTk2MDU_55f4db3e-a874-4ef3-bfc6-ff9a9d08c0ce" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE3NjQyNg_1d1a6952-df5d-4cd6-8d55-4c84f4196f29 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIwLTEtMS0xNzY2NTE_bbefd3e9-b4f2-4678-9562-3af5bffe61e1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNzY2NDI_59c98ae1-8711-4d60-8f1f-664796bfed11 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE1NTYzOA_d8aeab8c-3274-41ea-b63d-f760575f61ae id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNTU2Mzg_2bc90cbe-8d40-409b-ba58-60ba596ba1d2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE3NjUxNg_e6bd7c83-d3d0-47a5-a1f2-aee47f3caf86 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE3NjQ3MQ_64cb9db0-2dcb-4e78-ad63-f53d8e5e81d1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTItMS0xLTE3NjM3NQ_d05385c1-a4e4-4f26-9a73-12054be9aa08 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE4LTEtMS0xNzY2NDI_66f395c5-8823-4e54-99d7-da791aa1f371 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTgtMS0xLTE3NjUxNg_0a72140e-bfc6-45fc-a6db-b16e3475ccc4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNTU2Mzg_602cce56-20e0-4ce1-94c3-e47dc1b24772 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE0LTEtMS0xNzY2MjE_4082ca8f-abbf-473f-91bd-db8e8256cad1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTQtMS0xLTE3NjQyNg_357498f3-eae3-47e6-a717-100ee9859b9a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNTU2Mzg_44eb4742-6f2b-478c-8d05-cfec32546ac0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE1NTYzOA_79452b9b-8bc1-4b93-b873-62597a118422 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNzY2MjE_c61eac8c-1ade-4f37-90c2-b80ac6d9c38c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTYtMS0xLTE3NjQ3MQ_b1de6f06-71ed-4e13-9dcd-7988706f68ea id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNzY2NTE_a5997f8e-98cf-4081-9f7e-e019e7d6edd2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE1NTYzOA_7b5921d0-3be3-4e5f-a29d-b19cfb7ba075" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtMi0xLTEtMTU1NjM4_4852e44b-060b-4524-8cde-acdd45c8d69f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNC0xLTEtMTU1NjM4_bd5d325b-76f5-4dd4-a23f-b3930e7dc4ec id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNi0xLTEtMTU1NjM4_812d0cf5-bd12-44dd-a0d9-31b83dc34171" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA1_58f624c6-ad90-43de-8026-7a18986026d8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNi0xLTEtMTU1NjM4_8c950b8b-ad69-4ccf-983e-ea64d5755d84 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktMi0xLTEtMTU1NjM4_b45deda5-c9eb-4249-973c-69e48319db9e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNC0xLTEtMTU1NjM4_29e6b7ac-2fe7-4877-a124-b300cdd5a22f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU2_5902b619-e434-4c25-9870-f93ab88b0fb6" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtMi0xLTEtMTU1NjM4_eac59ed0-b395-4f44-91ec-98b484b8f4b4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtNC0xLTEtMTU1NjM4_5e0bc421-d01b-4490-af80-b7bf03c05d79" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwMA_40ce384d-31be-4b40-aaa6-9b94f7f3d188" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTYtMS0xLTE1NTYzOA_b173fb43-0d28-4160-8fd4-5c4b99367cb5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTQtMS0xLTE1NTYzOA_1e6a6321-5b59-4629-a177-6e2866459aee id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjYtMS0xLTE1NTYzOA_e3208f64-720b-4f0f-8801-e090f70792e1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNi0xLTEtMTU1NjM4_75b7d650-b93e-46a1-87ad-f8b8375f99cd id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTgtMS0xLTE1NTYzOA_72fd28a5-d393-4635-8f84-5f5b000a4bc4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtOC0xLTEtMTU1NjM4_3ddbadfe-2c7e-469b-8b74-ac53c8330c60 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjgtMS0xLTE1NTYzOA_b49a6e3c-efe7-4be4-92f6-272d3b6a1aa8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMzAtMS0xLTE1NTYzOA_eaafc4ca-df82-4841-949c-5e448cee1d0c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMi0xLTEtMTU1NjM4_0030d148-ccdb-493d-9ef6-9c6e5e073b5c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjAtMS0xLTE1NTYzOA_3a83e750-3f49-46d0-a35a-4b9f84e9a9e4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjQtMS0xLTE1NTYzOA_dffb3ed7-9572-487e-ad9c-3dc22c16c91a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNC0xLTEtMTU1NjM4_466fd797-58fa-45d5-848d-734df1c99bde id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTAtMS0xLTE1NTYzOA_5ce6a7c9-5907-47d5-a423-c9b0057bbc7d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjItMS0xLTE1NTYzOA_de7e819a-94c2-4908-b137-6debfd7edbc1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTItMS0xLTE1NTYzOA_9f88f9b8-9153-4eae-9b34-60c2f6485b91" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTYtMS0xLTE1NTYzOA_16ed3388-ebc3-4c1b-af6e-ee2db9e45355 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTQtMS0xLTE1NTYzOA_b84fbe8e-6a3f-4099-9eac-641d1f1b18dd id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTItMS0xLTE1NTYzOA_ed6860e8-6cef-4092-85bd-14b0db566a9f" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTM_1eed2719-76dd-4177-b92f-3f667b7d5c40" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTItMS0xLTE1NTYzOA_1d5c60d8-aa15-4f85-b15a-567ac23fc306 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTYtMS0xLTE1NTYzOA_fb7a05db-3539-44fd-85eb-fce98e4a8eec id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTQtMS0xLTE1NTYzOA_19a96083-6c93-4b19-9643-21dfc7e6a33e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc0_74c907cb-0fd0-422c-9947-ca1d7ea7c38a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTgtMS0xLTE1NTYzOA_d6a323fc-7cb7-4834-ac37-0568992d3f35 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE4LTEtMS0xNTU2Mzg_00b437d0-18c0-450b-9dd6-1bfd8657d584 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIwLTEtMS0xNTU2Mzg_bfef0997-7812-4779-a11e-800743cd3459 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIwLTEtMS0xNTU2Mzg_eb54842d-f09d-4c97-9447-596ba9c828e9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE0LTEtMS0xNTU2Mzg_7633de53-4390-47ba-baf3-1655f72106d6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTgtMS0xLTE1NTYzOA_7e1703d0-e7a0-4115-b0b2-9ff77b3df847 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE2LTEtMS0xNTU2Mzg_26d5df97-f0ad-4152-8dee-55f18443891e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEwLTEtMS0xNTU2Mzg_9c49a9e0-a9b6-45a3-bda0-99fa573d9310 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE4LTEtMS0xNTU2Mzg_f3c443bf-eba7-44c5-a8dd-89017a09bda3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTQtMS0xLTE1NTYzOA_59235c5e-1fcd-4074-9c0d-c21db292ee70 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTQtMS0xLTE1NTYzOA_3f59ffed-384c-4297-9043-94b52041efad id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE2LTEtMS0xNTU2Mzg_1fc74320-cc41-4d0c-9bc9-8f4d0f01bd77 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTYtMS0xLTE1NTYzOA_1e4d1b6c-f5a4-40d2-844a-3ab0a45b0bef id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE0LTEtMS0xNTU2Mzg_2f220032-7e9b-4c18-b46b-94a7e5cade71 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEwLTEtMS0xNTU2Mzg_67b09b8f-e216-4d69-9e74-d98f90ff3ac8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTYtMS0xLTE1NTYzOA_9e395521-4d55-4496-bfba-db44fa808527" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTQtMS0xLTE1NTYzOA_14faf7c2-7a01-4302-b4ef-c4f8cd899ae8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTQtMS0xLTE1NTYzOA_64af5ac8-922a-4e1d-a5a2-766e1fd5157d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE0LTEtMS0xNTU2Mzg_6c6bceb0-130d-49af-862b-de96ffd1fba6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTItMS0xLTE1NTYzOA_2f464006-2cdb-4183-b0fd-f41fe79230da id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEyLTEtMS0xNTU2Mzg_30a08688-abc7-4fc1-a6dc-6a6a58197d10 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTItMS0xLTE1NTYzOA_cd0713ce-a174-401d-a6cf-b7a389c052b5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTQtMS0xLTE1NTYzOA_465e3f25-0b56-4f09-812f-8698f3314174 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTItMS0xLTE1NTYzOA_4211c29b-37c3-4166-8a7b-994500cacb41 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTItMS0xLTE1NTYzOA_532a46be-433a-42ba-8ed4-9fbf1cd26e71 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTQtMS0xLTE1NTYzOA_3af3c0e7-b52e-4fe4-a24f-8ddc2ed8a412" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTItMS0xLTE1NTYzOA_a7bec050-b698-4726-bd56-085e3fa47cb8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTQtMS0xLTE1NTYzOA_a037f3fe-76de-4e3a-b45e-df594d2e8044" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Mw_b1b8ff7f-ad8d-468c-af41-2061ee702628" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNC0xLTEtMTU1NjM4_006cdb55-7f81-45c9-9480-57256a9c9967 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNi0xLTEtMTU1NjM4_a4dd9cc9-d0a1-4d4b-87f1-abb2ee502128 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMi0xLTEtMTU1NjM4_1db96457-241e-4457-bb5d-70a065db8f45 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtOC0xLTEtMTU1NjM4_a6383107-a58a-4a33-969c-54b74cd56a82 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTAtMS0xLTE1NTYzOA_86e86249-8876-4e05-ace4-6b91dc0302da id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTItMS0xLTE1NTYzOA_91798efa-c2a4-4afb-b009-5535e620a515" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTYtMS0xLTE1NTYzOA_d40c85f6-ad5d-486b-95fb-11dc5f86ce26 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTYtMS0xLTE1NTYzOA_8d165f23-be85-4dc1-adc5-76c248b7d5f6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTEwLTEtMS0xNTU2Mzg_1e28e996-4c45-4799-b7ef-7dc4e5449fdd id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTgtMS0xLTE1NTYzOA_83acb8fa-0dbe-484f-b7a3-7b391952efb2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTYtMS0xLTE1NTYzOA_5cd58def-c2a2-44d2-afeb-aba885aa2fc8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTgtMS0xLTE1NTYzOA_dc88088c-58ae-4f64-b4b7-52c9484035eb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTEwLTEtMS0xNTU2Mzg_f22d3ac4-76d9-4abe-b144-2724bdadf6a6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTEwLTEtMS0xNTU2Mzg_daf6262b-ed94-4815-aa85-d2b76b855eae id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTgtMS0xLTE1NTYzOA_d075da76-8e37-4fb0-92e5-e64957caf8ad id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTEwLTEtMS0xNTU2Mzg_12244f3f-27df-420a-9f0b-1652ddbc6248 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTgtMS0xLTE1NTYzOA_d09cd04e-2282-4eee-b696-e9040247d88d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTYtMS0xLTE1NTYzOA_a1fe41aa-bf30-4747-9aea-81360d159eb5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtMi0xLTEtMTU1NjM4_2f7f6c8a-d1ea-4776-b3bf-f600ef3cb02e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtOC0xLTEtMTU1NjM4_af969f26-65f5-42e4-84a6-c2edff83475d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNC0xLTEtMTU1NjM4_8725e295-9631-41e9-964a-1c35d13d3069 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNi0xLTEtMTU1NjM4_9dc8b5f6-80fe-4a13-bf28-33b00373b705" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTgtMS0xLTE1NTYzOA_dc3ec28d-15f6-4bc6-ac30-354a3d100de1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEwLTEtMS0xNTU2Mzg_78ddf880-771b-4688-96e0-3cb5279fd390 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEyLTEtMS0yNzAxNDE_0357e9db-9c5e-4779-b022-c590a5995791" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzU1ODA_bdebfab6-bd01-4f6b-bc21-f6fe009452ff" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTItMS0xLTE1NTYzOA_061e55c1-6b6a-46e3-b613-1c3fa13abb1e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTYtMS0xLTE1NTYzOA_154dbc6d-b981-40d8-abc4-8299b6b7a746 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTQtMS0xLTE1NTYzOA_b5dd47cb-0404-4dcb-8afb-8ac782a5f655" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNQ_deb48efb-7fb2-48e3-9a1a-db0fc4767348" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtOS0xLTEtMTU1NjM4_71b8000c-8a67-476f-86aa-688705b47476 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNy0xLTEtMTU1NjM4_c50c3076-23b9-4810-8ae0-51e5cafd05d0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNS0xLTEtMTU1NjM4_7ab61130-3ef5-44a9-b13a-d58d1b2ac9ed id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNy0xLTEtMTU1NjM4_82fdb0a5-c8c5-471d-9db1-f99ad35bface id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtOS0xLTEtMTU1NjM4_d0fdaa6b-4fdb-4251-9f23-b2d4a66f8c2a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNS0xLTEtMTU1NjM4_3a5b51d9-038d-4f73-bddf-66ec154f7f42 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtOS0xLTEtMTU1NjM4_37504520-2fa3-4477-a8d2-80fd135923e2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNS0xLTEtMTU1NjM4_c68ccd3e-9a44-46de-b86e-808d367c30de id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNy0xLTEtMTU1NjM4_83da3ba5-9e6d-46f0-bb6d-5f51c1771b0d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMi0xLTEtMTU1NjM4_ae4ec295-92df-44ec-931c-f072f3457cad id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtOC0xLTEtMTU1NjM4_eebcdce6-a625-447a-a666-c34372d924ab" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4Mjc_73f8b4d4-3c0f-4f3a-a283-8ce485fdaac1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctNC0xLTEtMTU1NjM4_5e8f8213-8684-4d59-b1e8-3a41c24da7e9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctMi0xLTEtMTU1NjM4_13d9c7d2-fd2e-4a7e-b9bb-60309e878951" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU0Mg_c50654f8-e8b0-4416-af9a-f39ecf1625c9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTYtMS0xLTE1NTYzOA_a86bd816-10b9-4f9b-912a-4d22b7e4fec4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTgtMS0xLTE1NTYzOA_05bf4b6b-a861-4cb5-8cc3-aff476c0dce8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTQtMS0xLTE1NTYzOA_9378fa2a-a4bc-47fc-a652-1bec85705217" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTM_2e9bea88-c690-449e-914e-399b541e82de" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtMi0xLTEtMTU1NjM4_fc48ed28-a2ed-4f89-931a-25408f08f1f5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNi0xLTEtMTU1NjM4_69712d4d-8f49-4a68-a2fd-58aefe02d4df id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNC0xLTEtMTU1NjM4_ffec8e3d-06b3-47b3-8031-20a54e5ae1b2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MDU_7baae9c8-1263-4e3d-8ee5-851cb7fc1bec" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE2LTEtMS0xNzc0NDY_00320b28-4117-40ba-9719-fa9dddf0ac7e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTYtMS0xLTE3NzQ0Ng_c78f2480-6e0a-4812-b437-d0f3b88908f9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE2LTEtMS0xNzc0NDY_50095a15-4d77-4d87-8ded-edd7b8c37440 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE0LTEtMS0xNzc0NDY_26e77d3c-7ba5-43c0-9206-33f175077456 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE4LTEtMS0xNzc0NDY_6a4bc1bb-7dd3-49d7-8cc0-6412bf9dbb14 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTQtMS0xLTE3NzQ0Ng_d5714a79-a33f-4049-ad78-b4ab062cf73d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE4LTEtMS0xNzc0NDY_4eeae3f4-c6c2-4bd3-b9ec-88e7109b6ce4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE4LTEtMS0xNzc0NDY_bfcd77b6-37cf-47da-a023-ed1e44db59f5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE0LTEtMS0xNzc0NDY_763275c5-6edd-4d3b-af4f-eca2881128a4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTgtMS0xLTE3NzQ0Ng_3a0c44fa-4538-4105-b1d4-477ae7b6d295 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE0LTEtMS0xNzc0NDY_55e56b9a-2c34-47c6-b317-0ec27b23f0d5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE2LTEtMS0xNzc0NDY_7c74cf89-4939-4846-a03a-8d93ceceec86" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTItMS0xLTE1NTYzOA_61571985-418a-446b-bc96-93bdab6232b4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTQtMS0xLTE1NTYzOA_36f289d7-f860-4248-ae43-2a845a2fb3a8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTYtMS0xLTE1NTYzOA_037968a6-be5e-4506-93f4-cb98e0757bd3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTItMS0xLTE1NTYzOA_27302940-e95f-4411-87f2-0004674e6fa8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTQtMS0xLTE1NTYzOA_06f71829-0412-4c42-b7fe-8a9facdb36c2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTItMS0xLTE1NTYzOA_10fe7932-e01c-454e-8302-def516f99899 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTYtMS0xLTE1NTYzOA_460a0367-95db-4b42-8410-22d206dd026d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTYtMS0xLTE1NTYzOA_2014424e-8adc-4a3b-9815-9c81bcd3344a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTQtMS0xLTE1NTYzOA_19c6fa4b-dbf0-4efd-8ff8-0b7287c1ac97" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktNC0xLTEtMTU1NjM4_c41e5f42-b905-4960-9834-889541822283 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246Y2IyMGJkMzcyODA4NGEwMmJmZTljMDUyMTRiMWZjNmNfMTUzOTMxNjI3ODg4ODA_775c18f7-b166-4b7f-9eb2-d8e4c8d70788" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjk_7317c2e6-d737-4f5f-88f6-e7ca9d4c840d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNC0xLTEtMTU1NjM4_a6ee1f90-c8ba-493a-8df1-90679ee7be35 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNi0xLTEtMTU1NjM4_430e3341-aa36-4836-80f2-03307cb6e72a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctMi0xLTEtMTU1NjM4_b93c897e-d113-4fca-af85-ca8fdbfac426" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDY3_1b44c33c-7fa4-431f-b8a2-bc19239b1199" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtOC0xLTEtMTU1NjM4_aa6a1288-623f-45a0-aa24-c0b1f7307d3a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNC0xLTEtMTU1NjM4_256f11b6-83b4-4563-84bd-ca2eb2bc8d16 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtMi0xLTEtMTU1NjM4_37eb2fce-9891-4368-9c58-5e41f032a21d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNC0xLTEtMTU1NjM4_2e4c1c81-5d34-4e61-8316-477276aa7c19 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctOC0xLTEtMTU1NjM4_7480d3a8-bcd9-4499-9bb2-09960d855b59 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNi0xLTEtMTU1NjM4_48aa033e-20be-49e8-8390-4b9e5a393d82 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNi0xLTEtMTU1NjM4_4072a90f-f140-48e6-8f8d-0cfc44b9f2ef id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctMi0xLTEtMTU1NjM4_594ea094-3524-4937-806c-5adc4fdae564" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtMi0xLTEtMTc3Nzcz_1412e961-c1d0-4724-998b-2b5f26860881 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNC0xLTEtMTU1NjM4_704706b6-4bd6-4188-ab0c-928c0e14cea6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNC0xLTEtMTU1NjM4_f5357124-e200-4036-888f-25abdac4d3e3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTQtMS0xLTE1NTYzOA_e223faad-d99d-4053-b5f6-cf210bcfee95 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTQtMS0xLTE1NTYzOA_a7b0aba4-6383-4a13-b9e3-48c7a459c533 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNC0xLTEtMTU1NjM4_f37f9bc2-c292-4db8-be47-b29936878c30 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTYtMS0xLTIwMTgxOA_07f27bea-6a9c-40c6-a2d6-ea80214973a8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNi0xLTEtMTU1NjM4_674641be-b310-442e-9649-04d23ac403da id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNi0xLTEtMTU1NjM4_152f7f45-ad94-4198-8e30-d82dea1a7243 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTgtMS0xLTIwMTgyNA_d6f5724b-f6f8-41ea-863c-9951d0e46489 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTYtMS0xLTE1NTYzOA_8f186694-3022-48ef-a96b-b90b416e0172 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTYtMS0xLTE1NTYzOA_792dcf23-7855-4ba8-be67-f2f2b8a93e38 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTE1NTYzOA_b8c5bf77-08f1-454f-8409-0583dba8d4d9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNC0xLTEtMTU1NjM4_1ea56822-d50c-454c-ac25-324f18d696a2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTIwMTgxNg_245ea242-174d-4d97-8181-86a8c6c5246d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTgtMS0xLTIwMTgxOA_9afe2f6a-295d-4a12-9d6c-1feeef937d00 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNi0xLTEtMTU1NjM4_9d188531-33a5-407c-acf6-cd88c74e75be id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTgtMS0xLTE1NTYzOA_1f9cb0cd-0fa5-4116-b603-cb6776f180dc id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctOC0xLTEtMTU1NjM4_831490eb-418d-4b0f-8395-f8cd4a584883 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNi0xLTEtMTU1NjM4_74eecd18-698c-4b18-bed9-423ee0f2b18f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNC0xLTEtMTU1NjM4_12370406-3121-4fd4-9452-791c6fa14d56 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTgtMS0xLTIwMTgyNg_6bd6df99-dd55-4fbf-baa8-aa34cf0a89fc id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTE1NTYzOA_d4777b69-bca4-4da9-8bee-c95607807af1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTQtMS0xLTIwMTgyNg_02fe2472-92fb-4536-8323-8b8e4f134181 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtOC0xLTEtMTU1NjM4_c8a95008-1738-44b6-8266-dfaf053446f7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtOC0xLTEtMTU1NjM4_771a964a-8c6d-4951-9757-362ce504769c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktOC0xLTEtMTU1NjM4_19067ebf-2420-4493-9559-b40f806bb59c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTIwMTgxNg_bb899a3f-9057-4c42-b88a-a0484d40b99a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNi0xLTEtMTU1NjM4_5f400010-0c6d-4c36-8261-5a6d490d4a94 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTE1NTYzOA_173beaaa-761b-48ed-9f25-caabbf15d941 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtOC0xLTEtMTU1NjM4_55c6aa5f-d0e6-4069-a4cc-b50d9f74cfe7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNC0xLTEtMTU1NjM4_0c5983f5-742e-4c31-9456-0a86eb67f31b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTYtMS0xLTIwMTgyNA_26d4a734-0b52-4e5d-81b1-025ded81faa6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTQtMS0xLTE1NTYzOA_ad3a56fe-b25c-47fa-883e-2628687e528e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNi0xLTEtMTU1NjM4_5cf15bee-1f6f-4f92-96c0-441dcdc3b93d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtOC0xLTEtMTU1NjM4_3bdde6d7-1ca3-471f-837a-552086df7002 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTgtMS0xLTE1NTYzOA_b2209aa3-59c1-4278-bffe-dbda51926033 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTYtMS0xLTIwMTgyNg_485a912c-0f9e-4947-8e28-5ea90d0b44d3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNC0xLTEtMTU1NjM4_a6c1e828-1373-4fbc-98bb-0c166c24987f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTIwMTgxNg_4d3d9288-bb84-4f45-bb13-a4f8ec4ec044 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTYtMS0xLTE1NTYzOA_21f1e072-7210-4f67-920f-95f886cd5e7f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTgtMS0xLTE1NTYzOA_8a0c1ae2-b59a-4ab8-a792-11ae10dc864c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTQtMS0xLTIwMTgyNA_79efd58c-9573-475f-92b1-25eb9339724b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTQtMS0xLTIwMTgxOA_5a215c3a-de6d-4316-a287-c5044c461f1d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtMi0xLTEtMTU1NjM4_54059ecd-aa69-44bb-b887-d96f99d57bae id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtNC0xLTEtMTU1NjM4_762c2983-3a02-42e0-8d59-df56b7f5c031" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU1NQ_8fe7f8af-5095-4cd6-9f9d-0efa59c2547b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtMTAtMS0xLTE1NTYzOA_69cb70ec-f0d5-43fd-a42b-cdb0a66d8fd3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtNi0xLTEtMTU1NjM4_e39da51d-aeec-4e8d-a1e7-561787656116 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtOC0xLTEtMTU1NjM4_eb84dd73-f48f-4386-91cc-70803e7c166b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzUw_1275eb2f-488b-4d6e-b5cf-9069ca46c946" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTItMS0xLTE1NTYzOA_19a2a01e-f627-4122-9470-6414cdd9c8c2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktNC0xLTEtMTU1NjM4_b271c359-33bf-4a28-9b00-fa0f9401e3ab id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM5NDY_756947b2-ff01-4e85-9822-5130790587b6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTItMS0xLTE1NTYzOA_28876c1f-28e3-452b-93e2-c007e4934d1f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTgtMS0xLTE1NTYzOA_6e799da1-2a95-45a6-b1fb-6b0cdd11fcd7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTYtMS0xLTE1NTYzOA_4faca393-6869-4ebe-8b22-d8cb925c1d64 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTItMS0xLTE1NTYzOA_d1ade32c-1b05-4905-aa93-36e64fc6a13b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTEwLTEtMS0xNTU2Mzg_e1c3d9bb-c8bb-401f-85f1-4325c3b51baa id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTYtMS0xLTE1NTYzOA_7c714191-b0a7-4358-88cb-92054d43fc7f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTYtMS0xLTE1NTYzOA_c68c8ee5-011e-4dc7-86e5-aad7661b831f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTgtMS0xLTE1NTYzOA_ecbe1641-b29d-48d0-9ddf-cbd51d19a42b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTEwLTEtMS0xNTU2Mzg_b9cf7014-7622-4266-bc4f-c827c6e37cb2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEyLTEtMS0xNTU2Mzg_5564e357-a498-4e15-bcdf-ee4d239a8744 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktMi0xLTEtMTU1NjM4_405037fa-97c4-4b99-97b5-1572a2575232 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTQtMS0xLTE1NTYzOA_28d7ee0d-cb9f-4b69-8080-ff9068ce947e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTQtMS0xLTE1NTYzOA_aa828aee-7b1e-4248-910d-fe1d51c6c6af id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTgtMS0xLTE1NTYzOA_3651a24b-22e2-46d0-868b-1ae4481d2de0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTQtMS0xLTE1NTYzOA_0211c1c4-f749-4f17-adca-203d6d94039d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEwLTEtMS0xNTU2Mzg_1935d6fe-b15b-4323-8d03-7cb189a21e32" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTYtMS0xLTE1NTYzOA_65c2fd73-d37f-4010-8461-ed242702667b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEyLTEtMS0xNTU2Mzg_047edc6c-e2d8-4c5f-bb4c-a50070519254 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEwLTEtMS0xNTU2Mzg_072775e8-2b98-4b98-8a60-50ca224f222b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTQtMS0xLTE1NTYzOA_37ea546b-438a-45e2-8bf8-c5daef1deea9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTE0LTEtMS0xNTU2Mzg_c9cf5bc8-d558-48e8-89d0-a7d284348289 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTItMS0xLTE1NTYzOA_5fd2c1e6-9de7-40c1-ae80-d3392b8c0703" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctMi0xLTEtMTU1NjM4_4a4349dc-9933-450e-a8f0-cd01ed05abc3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNi0xLTEtMTU1NjM4_f03523c1-3500-433c-a25c-7a51aa58bc66 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNC0xLTEtMTU1NjM4_265b3940-4872-4dde-a89e-85ff8265bd36" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDYw_9c5cb05a-2ebe-49e7-baaa-1924b1949864" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTQtMS0xLTE1NTYzOA_a7fee7c6-d026-4ef8-b904-5d6d5e67d18a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEyLTEtMS0xNTU2Mzg_fa9adc0d-8d18-4bf5-b697-f1f1be9f4967 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEwLTEtMS0xNTU2Mzg_5dad725e-549b-4223-aac9-3f2d9059f3a0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTIwLTEtMS0xNTU2Mzg_c1666a68-f1a5-4f68-bec4-836e47f2d352 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTItMS0xLTE1NTYzOA_dba37449-e851-4f87-b74b-3133af112ca0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTI0LTEtMS0xNTU2Mzg_31952f84-68a5-48a4-a73b-e4df2294aaff id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTE0LTEtMS0xNTU2Mzg_b372f346-0ed7-48aa-8a70-f15d24733d34" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNi0xLTEtMTU1NjM4_5e3e9775-1f4c-4a1a-81a9-ac9d3fc427d8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNC0xLTEtMTU1NjM4_4735257f-9e5d-4241-a813-229562d69690 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtMi0xLTEtMTU1NjM4_f570d567-250b-4be3-a646-a17475e0f375" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE2_c92105d3-98d3-434a-b36a-0127835a98d8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxODk5_277205d7-51d1-41dc-9ba5-25bbc37331e1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxODk5_616bc566-ed61-48d2-a689-843292929258 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxODk5_017fe27d-e80f-421b-8f33-cf6e30a994cf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzE_c89bfeea-0241-4819-96f1-38baefbea46b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTItMS0xLTE1NTYzOA_776c7a5d-e044-4ec7-96e2-4308574f3e72 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTQtMS0xLTE1NTYzOA_ed86179d-92be-4657-b47f-3d6a84617613 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTYtMS0xLTE1NTYzOA_2942a965-a598-4acd-bff1-0c02e059da86" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjE_26f1389f-55c0-455d-bee3-4c13d585abc3" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNi0xLTEtMTc3NDQ2_7cda6e54-0181-4805-8205-7bbf2c4abc48 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNC0xLTEtMTc3NDQ2_48faa6f0-3a30-4022-b30b-caa0a4b7f684 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMi0xLTEtMTc3NDQ2_d98a92f6-45bd-4e4c-a439-374f7de87b82" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctMTAtMS0xLTE1NTYzOA_a73c9239-ead4-4169-9fcc-f5c747a69fc4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctNi0xLTEtMTU1NjM4_7593f700-33a1-4b98-91bf-879b34110428 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctOC0xLTEtMTU1NjM4_2d6c1a68-5552-4be1-a010-836b6862e20b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI0_d66425c4-36ea-42ca-9afe-89f26f33ded1" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTYtMS0xLTE1NTYzOA_a23043da-80f6-4944-b8c8-a7314fbae96c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTItMS0xLTE1NTYzOA_1d63a504-43b3-4e6e-b318-390daf304a54 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTQtMS0xLTE1NTYzOA_23f0c89d-0e2d-4917-8d88-8815bb9cb5cf" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODY_8f0897b6-0412-434f-8608-7a97cbafee5e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTQtMS0xLTE1NTYzOA_709a14a0-1fa2-48ec-9db7-e7fe83b24faf id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTYtMS0xLTE1NTYzOA_a46f22eb-ae36-4c35-a84e-cd3183e01176 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTYtMS0xLTE1NTYzOA_e617887c-3da5-43a0-8050-ff8df10abdf9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTQtMS0xLTE1NTYzOA_f1eb3203-bad7-4a37-b9ba-d995e4c010f3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTYtMS0xLTE1NTYzOA_d083c457-1d57-4eff-b8ba-5cda20c59421 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTQtMS0xLTE1NTYzOA_dffafcd0-1e07-4cc5-bef0-d88fb845c696 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTQtMS0xLTE1NTYzOA_1807f3e3-32c3-4436-8597-9a8d224768f0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTQtMS0xLTE1NTYzOA_0ec087d1-5d2f-45e8-af0a-963acbdc9c35 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTQtMS0xLTE1NTYzOA_022b7343-cc02-4d0b-bd17-9219c56120d2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTYtMS0xLTE1NTYzOA_cea60af2-8c6c-44ce-9379-0c9408a7edd9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNC0xLTEtMTU1NjM4_4f4c89e4-6db7-40f7-88d6-39114c8aa258 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTYtMS0xLTE1NTYzOA_5890084d-8e26-4833-a562-8c7fbb06d03e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNi0xLTEtMTU1NjM4_9e892a40-9f6c-426f-a55e-95264845f896 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTYtMS0xLTE1NTYzOA_c4a54d97-7d11-4bc4-b781-3dfecf9a8d4a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtNC0xLTEtMTU1NjM4_fcff6e04-cf91-4aab-a1bf-9b6b771c59d2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMi0xLTEtMTU1NjM4_d0719a5a-8f70-4d72-8488-4163b8e663c2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjg_2bdbd7b3-002f-414d-9e23-4b1958cb6998" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtNC0xLTEtMTU1NjM4_5b191432-aea1-4255-a33b-3456f30d377f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtMi0xLTEtMTU1NjM4_421fa183-684f-4276-acad-fc30922c2cca id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNi0xLTEtMTU1NjM4_9f9d95f4-c3d5-4ad4-b5ad-2f3a60e9eb08 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNC0xLTEtMTU1NjM4_f8c79b07-3f6a-4a33-92bb-3a6e9e257dd3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNi0xLTEtMTU1NjM4_70764fa8-bcdf-4adc-b1d0-98a361ff980a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtMi0xLTEtMTU1NjM4_ca2f17af-403d-45d2-a722-b3ea169f5d62 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNC0xLTEtMTU1NjM4_748e2b39-345f-44a8-b39b-41e92c60ab82 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNi0xLTEtMTU1NjM4_809ed143-c113-4f6a-81ff-ddef984737d1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtMi0xLTEtMTU1NjM4_cb603cf5-b5a6-4654-b0c4-e4fd67fa97ac id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNC0xLTEtMTU1NjM4_03bc2458-9954-4213-81e3-95026eb68409 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctMi0xLTEtMTU1NjM4_2adf412a-914a-4578-a230-cd3632fc59e5" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTEwLTEtMS0xNTU2Mzg_c5e3b7b3-ad7b-4372-8fc9-743761958514 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTYtMS0xLTE1NTYzOA_26b576fd-e42f-47a6-aeab-565869399e1b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTgtMS0xLTE1NTYzOA_c72ce72f-d017-48b5-aa58-e2a94bf428d9" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDk_1533b714-7a5d-4d55-8c40-da98cfed12f5" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTItMS0xLTE1NTYzOA_4fe324c3-d960-439a-ae02-e73b759a4327 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTItMS0xLTE1NTYzOA_44292426-f74c-4292-8893-599c22df01ba id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTYtMS0xLTE1NTYzOA_6effaeb9-5185-45a2-a184-6f978e917747 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTQtMS0xLTE1NTYzOA_b0a85b84-e2ba-46b4-9a58-11d5cf85d31b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEwLTEtMS0xNTU2Mzg_5100b054-8edb-48f5-9e21-212ef96b39ab id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEyLTEtMS0xNTU2Mzg_bee459d5-4eee-40cc-a39f-9ff08d6aa4c7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTQtMS0xLTE1NTYzOA_021028ad-3fe7-4eb7-b9b1-d290f1ea062b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTgtMS0xLTE1NTYzOA_eca4bfad-a0a2-4fa0-b7fe-396339e3ace6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTgtMS0xLTE1NTYzOA_7214571e-28c5-4a59-a95b-1a80823e8a1a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEwLTEtMS0xNTU2Mzg_e06cdaea-af2d-4e26-b6e8-ad3f73f77f00 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEyLTEtMS0xNTU2Mzg_ff0dd3dd-2896-4174-8239-5da3b6b44a34 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTYtMS0xLTE1NTYzOA_5575fd5a-00b6-47b7-89f6-01bc979677c8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNi0xLTEtMTU1NjM4_de2f933a-4fc4-4b54-9f85-3b4de5212a79 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNC0xLTEtMTU1NjM4_e8bbbce6-fc9b-431c-8278-af06ccb82a49 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE1NTYzOA_84d1e18f-fce3-4724-a67d-9e622d48d437 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTItMS0xLTE1NTYzOA_f79fd294-b4a8-4bf1-b851-ba56ed959b3c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtOC0xLTEtMTU1NjM4_f79fd294-b4a8-4bf1-b851-ba56ed959b3c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE1NTYzOA_bb7ecbef-0b64-4b85-8cef-019466b07d02 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE1NTYzOA_e127b306-d2c4-4e38-b370-f5ab9071a5f2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjYtMS0xLTE1NTYzOA_229afef2-6bb7-4825-b021-99094d2266fa id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctOC0xLTEtMTU1NjM4_87c54e86-a569-4df7-b8e6-04951fcb6787 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMzAtMS0xLTE1NTYzOA_38732335-d53e-4f06-84e2-85dd1154c1a0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjQtMS0xLTE1NTYzOA_fcb4ae62-0c3e-4fac-a30c-235ab34d77a1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNC0xLTEtMTU1NjM4_992fa98a-bf2f-4f41-a787-082f6d3b2a31 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNi0xLTEtMTU1NjM4_07778de6-12fc-43bd-ade7-053555389107 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTgtMS0xLTE1NTYzOA_7bfc61f9-ca76-4c82-a926-959e839402ce id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTItMS0xLTE1NTYzOA_e6579469-97e3-4adb-8f01-c8be1876bf76 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjAtMS0xLTE1NTYzOA_4b62f3d1-5853-4f73-8a18-d81f343f0906 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjItMS0xLTE1NTYzOA_fa3d1f38-ed77-4ad5-ac7d-a22f0e7a7326 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTYtMS0xLTE1NTYzOA_ca3030ec-ef12-4e8d-bc08-dda9ca807e2a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTAtMS0xLTE1NTYzOA_5806a747-3c80-4200-947d-3b5d951b4251 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMi0xLTEtMTU1NjM4_1a94ef26-c091-4e7d-9c52-3172fbaf29df id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjgtMS0xLTE1NTYzOA_d579c4af-57c0-45ef-981f-37cabba91840 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTQtMS0xLTE1NTYzOA_d4d12f82-0c20-47ed-9fbe-8e0227117c6d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTItMS0xLTE1NTYzOA_91ad9a52-8b73-4986-a4f4-2d66d93c84da id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTYtMS0xLTE1NTYzOA_d35f7b7b-d5e5-4e97-970d-198f3a89ac4c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTQtMS0xLTE1NTYzOA_ec5b8174-b3c0-42d6-9907-197f66ed9e22" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcz_15ee60a1-e236-41ba-9ba0-faa094ee830e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTYtMS0xLTE1NTYzOA_6d5a2b60-1371-418d-92ac-a68824feb0eb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTItMS0xLTE1NTYzOA_2c13d92c-9eb8-49ba-a2d9-4ff8ede9d098 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTQtMS0xLTE1NTYzOA_eff9c8b3-b659-4e27-b655-f84aa2e38f10" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODU_a0039e7b-b917-408b-9d6a-752d7c16fb64" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTQtMS0xLTE1NTYzOA_3786047f-58ec-42ac-aabe-4be56f21b571 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTYtMS0xLTE1NTYzOA_c47971c5-0f64-4f2e-a645-0124bc609cc0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTgtMS0xLTE1NTYzOA_57875fd3-c720-43ff-aa35-5b92292df7bb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEwLTEtMS0xNTU2Mzg_6c7828d5-2f33-49d9-99b3-17ae37984b5a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEyLTEtMS0xNTU2Mzg_6d74d7a6-e6f5-4721-a6da-f3c1fd721422 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTItMS0xLTE1NTYzOA_11f37d67-9f26-40c9-8a93-23dd3aae225c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEyLTEtMS0xNTU2Mzg_891932bd-4a2f-4cb7-9c32-7626400194a1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEyLTEtMS0xNTU2Mzg_b13354c5-fdff-4035-bb77-b00434096449 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEyLTEtMS0xNTU2Mzg_888ab502-03a6-4cb7-b620-959b81a348e6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIyLTEtMS0xNTU2Mzg_206b5f3d-e5de-48a7-8d90-972f83316239 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIyLTEtMS0xNTU2Mzg_90374e62-0e6f-46ef-9c7f-4640ff4d6c2e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIyLTEtMS0xNTU2Mzg_12545fb2-9126-41b2-8856-19f2b608c590 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjItMS0xLTE1NTYzOA_942e2c6f-bd14-48d6-938e-405a246cdb45 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIyLTEtMS0xNTU2Mzg_49e38d60-4156-420c-b0d3-559b21653490 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIyLTEtMS0xNTU2Mzg_8adc4b9f-29fa-4003-9600-58615581fd36 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEyLTEtMS0xNTU2Mzg_de7d172e-e54a-4dfb-9374-e22f89b1b318 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjItMS0xLTE1NTYzOA_fedba956-ea2f-4539-b3f9-abf2ae69c37b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEyLTEtMS0xNTU2Mzg_b9283d4a-b481-499c-84cc-ab9add6e6bd0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEyLTEtMS0xNTU2Mzg_7fda2a9e-7697-4cfa-86e9-0fefaeb05694 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEyLTEtMS0xNTU2Mzg_93a56760-b80a-4d6b-8987-359570948f94 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTItMS0xLTE1NTYzOA_9116dce1-29a6-400a-b560-bf236c4d1e10 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEyLTEtMS0xNTU2Mzg_b95480d8-ffdc-448c-bc49-6676b68b2698 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEyLTEtMS0xNTU2Mzg_ea1505b5-7690-4876-bb95-cfe8a69dd83f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIyLTEtMS0xNTU2Mzg_31a8ad27-20a2-4a38-a7b3-82a1801e8339 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIyLTEtMS0xNTU2Mzg_91fb8c8a-dfd0-46c4-afe4-83080ad0c295 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIyLTEtMS0xNTU2Mzg_a214d9db-3c4a-4696-8ebd-fa3ec28ff00e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTItMS0xLTE1NTYzOA_242ba833-456a-4cfd-b898-3a48906babf6 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIyLTEtMS0xNTU2Mzg_b0a663b2-9770-4574-9771-931cbd79c542 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEyLTEtMS0xNTU2Mzg_2071fbd6-afae-4a6e-950d-29a48f960b3e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTItMS0xLTE1NTYzOA_285610aa-5b55-40aa-8047-ddd3c15916b4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjItMS0xLTE1NTYzOA_2db1f194-c5bb-4342-8607-e1df12dcbf12" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTQtMS0xLTE1NTYzOA_493e864e-9e6e-490a-a7d1-a8f30874fddb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTYtMS0xLTE1NTYzOA_db43a12b-305c-43f3-b08d-6ea28ca0bb34 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIwLTEtMS0xNTU2Mzg_2dc36c80-8978-4b78-a6b4-e9cf97ed1694 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEwLTEtMS0xNTU2Mzg_960e3182-0ff8-451e-94e9-0bad467aa196 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE2LTEtMS0xNTU2Mzg_7e00f49e-413c-41cd-ade6-d6f7386418df id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE4LTEtMS0xNTU2Mzg_d7965b05-3ae7-452b-aa1c-9dfd16d067a9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEwLTEtMS0xNTU2Mzg_728ee219-374d-437b-9420-1dcc85581038 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE0LTEtMS0xNTU2Mzg_581ab145-e28c-46d0-ab7b-4a546efa180c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTYtMS0xLTE1NTYzOA_504edd22-f235-41c2-beb8-c3f5ea16078f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTQtMS0xLTE1NTYzOA_58fd0a00-0fde-4880-a602-5212e1070940 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE4LTEtMS0xNTU2Mzg_5bfaf30c-da33-4555-91d7-1f74139286eb id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE2LTEtMS0xNTU2Mzg_a112cd8f-66f3-4c2f-abe3-05cb919427ff id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE0LTEtMS0xNTU2Mzg_2f8d3eaa-a853-434b-829f-7ea3e7269a84 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIwLTEtMS0xNTU2Mzg_dc51b3f5-f461-44e1-a6f5-5f96e785f863 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTgtMS0xLTE1NTYzOA_bb9dd044-d788-44d7-96d0-4a99a18f204a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTYtMS0xLTE1NTYzOA_00bd7ddf-3c27-4b55-a7de-7a4be52f9b58 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTQtMS0xLTE1NTYzOA_e26ed09a-7f53-4a55-b695-a525fb799f8f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTItMS0xLTE1NTYzOA_20517041-af91-4389-8aae-99fcc9ce939c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjQ_d2b8d63a-76b5-4c71-adec-7930b09e22e4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE2NDYwMg_75ce4bd5-1146-426e-a42c-516b04aa5a41 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE2NDk3NQ_f1946444-2e33-45ab-9b79-73f3bb433ed8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE2NDYwMA_8bc8c2da-2d5b-4c39-bae1-d91078e9f19b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTI_8e54b3d4-6b69-441d-8368-d4e6af77c9fd" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEwLTEtMS0xNTU2Mzg_b786aead-0eb3-4880-bb46-0174ca150730 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTQtMS0xLTE1NTYzOA_47101ccf-cf07-4de7-bb9b-28d921f5d23a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEyLTEtMS0xNTU2Mzg_d747b835-40c4-4736-9e1a-06a05ad61374 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTYtMS0xLTE1NTYzOA_2dad020e-49dc-4f46-9166-52fd70e40e4d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTItMS0xLTE1NTYzOA_8560e1e6-113f-49a9-a5db-00c29f18a662 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTE0LTEtMS0xNTU2Mzg_820b8eec-4175-4e49-b47a-d53cf5c61a03" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtMi0xLTEtMTU1NjM4_94dbdfbe-5859-4c23-9d8d-2d3e183bbfd0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtNC0xLTEtMTU1NjM4_dd146452-18dc-4d23-a080-83e4f78e3d3b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzc0NQ_18d5f6d7-e265-405d-b5ef-606a4d9ca43e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNi0xLTEtMTU1NjM4_49615fd2-0a4b-44b8-a14d-ea8b0be890e2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNC0xLTEtMTU1NjM4_e4128565-3c24-48a5-b18f-612d542f6555 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtMi0xLTEtMTU1NjM4_f68267a4-1cac-41fe-9805-9dee9acc44b0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDIx_9a567361-c846-4e20-a07b-8e6b3bf9e974" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtMi0xLTEtMTU1NjM4_d31e2e96-23db-4582-8a3b-1875408a08a9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNC0xLTEtMTU1NjM4_2946e08a-d232-4528-a2f0-63419668fd07 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNi0xLTEtMTU1NjM4_732ab48d-d360-432a-bd11-178fbd622007" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNA_9830691d-ff66-4fc3-a498-0043a67eab32" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNi0xLTEtMTU1NjM4_0f6f6780-b698-4e7e-9a46-e03c9a909569 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktMi0xLTEtMTU1NjM4_b189be12-71d4-4059-9bf6-009e6706aa64 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNC0xLTEtMTU1NjM4_e5bdff91-87d3-4fcc-b133-d858a5c2b28b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTQtMS0xLTE5MjY0Mg_973de251-1059-4bc4-8eb8-a7ca4fcc9007 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTYtMS0xLTE5MjY0Mg_df1f1f1e-4008-4cda-ac0a-e639d27cec71 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTgtMS0xLTE5MjY0Mg_225a7c3f-25ee-4409-844a-ca7bb3aca5e2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNi0xLTEtMTU1NjM4_8b8f1901-f635-44ee-9d4a-eb7fdb7e5051 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtMi0xLTEtMTU1NjM4_0f5fe7b6-5c36-460b-897e-812a74d93bfa id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNC0xLTEtMTU1NjM4_e704333c-12e8-4a4c-b863-0e3dcb069f41" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY4_42c85971-5021-482d-b383-51e54647f6a4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTYtMS0xLTE1NTYzOA_f9e63e0c-4405-44e8-a587-74d7b2a3a01b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEwLTEtMS0xNTU2Mzg_256ac849-9771-4c25-922b-dee9ffa34d45 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTItMS0xLTE1NTYzOA_ec8ed15c-853f-4f9d-9077-d757457c043f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTQtMS0xLTE1NTYzOA_25a2f8eb-5da8-4020-ba2c-8e014a264ad9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTgtMS0xLTE1NTYzOA_fc3931a6-a25a-4777-b4ba-3e187909c117 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEyLTEtMS0xNTU2Mzg_501583b2-b019-46e5-97c6-28b9baafb81e" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTYtMS0xLTE1NTYzOA_c697291f-04b7-45d2-b1f2-649da30c1f4f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTItMS0xLTE1NTYzOA_18721505-f445-4d7f-8156-359aab0e6695 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTQtMS0xLTE1NTYzOA_8855cfec-668e-4aaf-b7b2-4e8a81025858" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTk_eb112cb9-f220-4b30-8aac-7377f127f4a0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTQtMS0xLTE1NTYzOA_ce663fcc-934b-4f97-bc38-6a9f03ef0645 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTQtMS0xLTE1NTYzOA_6d723252-e0db-426d-9f98-c3ba2727adce id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTgtMS0xLTE1NTYzOA_dcd76900-b494-4bb3-ae58-5e24f2f31d15 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTItMS0xLTE1NTYzOA_1d521dba-67e6-4774-ad3e-263f21d6ba2d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTgtMS0xLTE1NTYzOA_011302af-b5f5-4dac-8819-02eafbbd14d4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTItMS0xLTE1NTYzOA_da4468a1-5047-41ec-9622-d82ce1b6ca86 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTYtMS0xLTE1NTYzOA_52f6660e-780d-4444-9d2b-959ce46860ac id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTItMS0xLTE1NTYzOA_e478804d-42ac-4204-89c1-1eb3b3c4d922 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTYtMS0xLTE1NTYzOA_1359244d-9ca7-42ec-af97-2d6bf9cb686b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTgtMS0xLTE1NTYzOA_7be9e936-f8d0-4072-9eb0-3e7538b8a30d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTQtMS0xLTE1NTYzOA_8ee7ad89-2b40-4fc9-986d-77b006d108ea id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTgtMS0xLTE1NTYzOA_eef6cb3b-6941-4582-bc48-cf1dc25da512 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTYtMS0xLTE1NTYzOA_087da3aa-6d1a-444e-99cb-fb3ba334d61b id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTYtMS0xLTE1NTYzOA_63fc9557-bdc2-4b91-a304-6bfa8d2f3a68 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTQtMS0xLTE1NTYzOA_25fdaedb-fcea-4223-915c-2953a3bd0c5d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTItMS0xLTE1NTYzOA_f59a388e-1923-46fe-946e-8ddcbb26213c" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTQtMS0xLTE1NTYzOA_e2fa2de8-d998-4b80-bebc-4cd7c402c0c8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTgtMS0xLTE1NTYzOA_4a4fd6f2-6e82-4b8a-b870-339dfe8edb35 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTYtMS0xLTE1NTYzOA_625152f8-e200-4048-8ec7-2928d62faf56" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzI_70d446fc-6d87-4eaa-9bc7-53cbba59b771" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNi0xLTEtMTU1NjM4_3213929f-51ad-4505-8713-b09ae07ab6ff id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtMi0xLTEtMTU1NjM4_5a7da2e0-b310-4992-9ead-53d778086a59 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNC0xLTEtMTU1NjM4_7610cbaa-8fc4-4815-b1d5-99eac4d0bbb0" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Nw_399e05ff-d281-48cc-9c48-a9128c75a260" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE2LTEtMS0xNTU2Mzg_55d6612b-509e-4e4e-9e3f-38aeafd8d90f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTYtMS0xLTE1NTYzOA_d78cb2b6-5dc0-4f55-8ec1-99c8a25c3a7a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE4LTEtMS0xNTU2Mzg_d6752f22-093b-4587-8387-81799384a918 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEwLTEtMS0xNTU2Mzg_94f58f7c-725d-4068-95d6-a5d42c4fec72 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTQtMS0xLTE1NTYzOA_253e4e25-a98a-4cf5-8749-395c9dedcd3d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIwLTEtMS0xNTU2Mzg_aaddd5c9-00c9-410b-ae32-5c465dfd74f4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEwLTEtMS0xNTU2Mzg_69a9ad1c-52a1-4930-bd2e-8e9bbc9e8e46 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIwLTEtMS0xNTU2Mzg_dab840e9-9bf7-41cd-937b-b650f194bbdf id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTgtMS0xLTE1NTYzOA_858c9006-32b2-48a8-8d60-39f2cd0e9d08 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTgtMS0xLTE1NTYzOA_68e027e6-af0e-4ef0-afae-8b7bf7ff0d27 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE0LTEtMS0xNTU2Mzg_a07d3655-9ba7-4a78-ac67-692db249b25f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE0LTEtMS0xNTU2Mzg_b7b49a6c-8ac0-40dd-900c-08b8b9b128ff id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE2LTEtMS0xNTU2Mzg_298650ef-6ab3-4cb3-81f1-a735e51a7f90 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE4LTEtMS0xNTU2Mzg_e89a0ca5-4065-4544-9e31-f514a259a70d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTQtMS0xLTE1NTYzOA_70aac13a-baf8-4171-84d1-f83e89dc4d6f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTYtMS0xLTE1NTYzOA_b93deecb-4ab1-4c04-bb4f-c3884d271f31" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNC0xLTEtMTU1NjM4_ed5826a8-7da8-49e4-8756-b5185b33aa9d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtMi0xLTEtMTU1NjM4_aa2deccf-47ae-41ab-967e-42c0d0e0faea id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNi0xLTEtMTU1NjM4_71f74a89-7dbf-4577-a87e-55fadd19a618 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNC0xLTEtMTU1NjM4_c2438de5-3204-47f9-9685-f2d214131cd7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNi0xLTEtMTU1NjM4_b77dc72b-c8f9-4d74-adcf-0cc74961cc96 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtMi0xLTEtMTU1NjM4_db22426c-6c10-4c2a-a824-e4c66d87abec" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzYtMTAtMS0xLTE1NTYzOA_2ffcb87d-156e-488c-ab55-3b76d0184eaa id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTQtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTItMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzItMTAtMS0xLTE1NTYzOA_495466a8-c79e-4cc0-969b-e8a7379b21b8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzUtMTAtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzgtMTAtMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTI0LTEtMS0xNzc0NDY_ed46c745-7e0a-44cb-a4eb-bd65a5789eac id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjItMS0xLTE3NzQ0Ng_7f261ace-5a86-4ffd-a6e4-932d53aefa61 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTI0LTEtMS0xNzc0NDY_0b14d794-f57a-4276-ba3f-c9f69d425ee7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIwLTEtMS0xNzc0NDY_67bd40ae-61e5-4b13-b748-ff051595a96f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIwLTEtMS0xNzc0NDY_f1fc0f33-3394-49b5-938e-49c96d2b3d65 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjAtMS0xLTE3NzQ0Ng_ced6d2cc-140c-4c29-904f-0f866c56c86e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTI0LTEtMS0xNzc0NDY_f6c3282a-ce85-437a-9714-ec11e7f051f1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIyLTEtMS0xNzc0NDY_905c3a81-05ac-4ad2-b380-1cf7f60f4219 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIyLTEtMS0xNzc0NDY_8faca64c-3b06-4ec4-b420-0e3155170551 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjQtMS0xLTE3NzQ0Ng_272ec279-d27e-4efd-83ad-a0d2b248698e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIwLTEtMS0xNzc0NDY_8c2ed33c-a0b1-422d-bae1-3dc5d98f8602 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIyLTEtMS0xNzc0NDY_54c2cdd6-b12d-4c75-ac60-2812a95fe9c4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTgtMS0xLTE1NTYzOA_f45c3b5f-a7dd-48d8-9864-4df1b90c966f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtOC0xLTEtMTU1NjM4_a8ea7123-02b9-4280-a4ee-558383a13da3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtOC0xLTEtMTU1NjM4_03c5052c-0e84-48f7-9edf-6b33ec73e5b5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtMi0xLTEtMTU1NjM4_2a363825-77ea-4727-b774-2d27000e61c9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNC0xLTEtMTU1NjM4_bc3cca5e-42f5-463e-8b51-f54d4eb4fc38 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNi0xLTEtMTU1NjM4_8e7b2b15-4b8a-49c5-90e8-18a0750addb7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjA3NA_29abafd8-1987-4b69-8d7b-7b36e729d14d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjA3NA_898220b7-d9bd-4658-9116-f1f7647bfbf0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTYtMS0xLTE1NTYzOA_95ca3f57-7179-4721-b012-2d1c1e26855e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjAxMA_d5f94ded-8f05-494f-867a-3ada9c6f4618 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTQtMS0xLTE1NTYzOA_b5a3ef71-2dba-41da-9044-3e1f336183ad id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTYtMS0xLTE2MjA4NQ_0c5c6baa-55e5-4560-8e48-d75e567c277c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjAxMA_6cb5c6c4-f805-4d7c-a4d5-2d9f7e295dd8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTIwNDQ1Ng_873b90bc-fe83-4098-a714-9762073a68b3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjAxMA_b01f1c97-93f1-46a1-99e8-af9042092584 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTgtMS0xLTE1NTYzOA_22e67cb7-a692-4f22-b211-654b1e63675f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE1NTYzOA_492c7816-9dbc-458f-9896-5645ccb7be3a id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE1NTYzOA_b156dc16-529f-44d0-ac01-d31d1d7d5ba1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTIwNDQ1MQ_9a68c631-ef4a-4008-9ad5-f858dec514b7 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTQtMS0xLTE2MjA4NQ_862ece23-b22d-41fb-b445-a8fb8400869e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTIwNDQ1OA_a7dd1abd-ef00-4aab-b4b3-aa247e5e03e9 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTgtMS0xLTE2MjA4NQ_83c25b6b-7635-4a3f-b803-2b579fac20a1 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE1NTYzOA_ef2210fc-2af3-4987-9ee4-e4fabe090c27 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjA3NA_9fafef35-c537-48a3-9506-c3d44e8130fb" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNC0xLTEtMTU1NjM4_ed4904c4-f0ad-4598-afb5-a7e4c97cb911 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtMi0xLTEtMTU1NjM4_dd00f2ae-15ce-4545-aac3-21a8dfd1b54a" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTItMS0xLTE1NTYzOA_53166da9-0d32-42c1-976b-015a7a580e30 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNC0xLTEtMTU1NjM4_6296c906-9226-4ec4-aca1-227c25bb96ef id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTYtMS0xLTE1NTYzOA_c1445037-0154-4a97-810f-8753322de790 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTgtMS0xLTE1NTYzOA_5a142064-c9bd-4118-8f10-6076f944cba2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctOC0xLTEtMTU1NjM4_cbc1dcb8-9d88-4907-86d3-176196e23a1c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNi0xLTEtMTU1NjM4_e619fedf-b7de-4035-8db4-50b4796cc9e8 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEyLTEtMS0xNTU2Mzg_28c1b928-0392-404d-b275-6cd17bae9db5 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMi0xLTEtMTU1NjM4_0da5e0e3-0810-4a16-a80c-2f4b195000fd id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTItMS0xLTE1NTYzOA_58c9c685-66d0-4b27-8fd8-86a99f375625 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEwLTEtMS0xNTU2Mzg_01d5126a-6e40-4228-a15d-40bed1fa2985 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTQtMS0xLTE1NTYzOA_f60350e2-50aa-4469-a082-b854a2607d33 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTAtMS0xLTE1NTYzOA_874ff190-7970-4199-9c5a-cb06a3757dac" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktOC0xLTEtMTU1NjM4_87a0a4bb-c12e-4cc9-a43b-925eafd0e253 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktNi0xLTEtMTU1NjM4_524c8e42-409b-4ca5-b64b-d98bdfb311bc id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktMTAtMS0xLTE1NTYzOA_1282a7c8-801c-4056-b485-27f13357c051" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIw_d222fed4-a927-447d-8d82-a2d2c986c588" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTEwLTEtMS0xNTU2Mzg_016183c2-2cbd-4ead-8585-43ac37496738 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTgtMS0xLTE1NTYzOA_b66de0ca-ed0f-46b4-966e-453127eb66ca id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTgtMS0xLTE1NTYzOA_e0c6ceaf-a4e8-47bf-849b-5a80428433a3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTgtMS0xLTE1NTYzOA_2b0e9445-59e0-4280-b6cc-187607b67d79 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTgtMS0xLTE1NTYzOA_2dc67f00-13b1-40b3-996a-b5a90fc6ab6f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTEwLTEtMS0xNTU2Mzg_9b4bc5aa-1531-4ea6-816c-1d6a55260e53 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTYtMS0xLTE1NTYzOA_14c75760-4acd-4558-9ca3-a81fa2c1c265 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTYtMS0xLTE1NTYzOA_33ad584f-aedf-448a-a767-6e77c5498e33 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTYtMS0xLTE1NTYzOA_facc63c8-eaf3-4e01-9322-54be6880643c id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTYtMS0xLTE1NTYzOA_098c4e4a-148e-47f7-be0d-6ed93e8aef4e id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTEwLTEtMS0xNTU2Mzg_3eddf7f0-e898-4039-abae-9b3e4026d40d id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTEwLTEtMS0xNTU2Mzg_8ab28955-fc79-44d8-8a32-662618a1141b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE4LTEtMS0xNjM1Mzk_47af01b1-de4e-4a07-a969-19224cfd7f0f id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNjM2MDQ_d0d9da6e-b77b-4841-b3b0-a87f3981f083 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNjM2NDI_cbc5aa61-24ae-48c8-8216-7aefb1f5b7fe id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE2LTEtMS0xNjM1MDc_f12fa9f4-f2af-418c-9f50-a45b98820fb3 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIwLTEtMS0xNjM1NzU_7ce6965c-8867-47ca-9836-5f1b997950d3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNi0xLTEtMTU1NjM4_f86e5b8a-d846-49f5-82e8-3bfb2f963c41 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNi0xLTEtMTU1NjM4_e3085a62-dc56-4860-80fe-177014844a33" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTc_c297e4fb-ce0c-4b32-bf03-e6b83d4cb4fc" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMi0xLTEtMTU1NjM4_8dd5e7fe-af80-4f7e-8aae-6bcbf03bcbba id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNi0xLTEtMTU1NjM4_23f14970-65b7-4f45-b3d0-015d907672b2 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtOC0xLTEtMTU1NjM4_535dfa3d-1e8c-4ba6-b772-d7a9d3638050 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTAtMS0xLTE1NTYzOA_d6e3fb05-0b79-4e60-b252-30ba3f67fce4 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTItMS0xLTE1NTYzOA_26719813-b100-4a9c-ad1e-f487528d7291 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNC0xLTEtMTU1NjM4_d2ea657c-d7cb-4f42-b560-3a7013368f69" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTYtMS0xLTE1NTYzOA_8cbdacb9-5fe2-4b95-940c-37cd2b822cbf id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTQtMS0xLTE1NTYzOA_46ec01a2-0164-49be-80a9-759dd72302e0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTItMS0xLTE1NTYzOA_d587cb35-245e-4884-bf51-680732bfade2" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MzA_1c246f72-a3f7-480c-b93d-85c62a4ffdb7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTQtMS0xLTE3NzQ0Ng_dfdde423-a842-42c0-bafc-1efbed3dd6e0 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTItMS0xLTE3NzQ0Ng_b13619e0-1809-4023-9173-70819e782a56 id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTYtMS0xLTE3NzQ0Ng_43752d49-1ae0-4846-8821-0cdf421ce9dc" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i4bff405b2205487eb835dd4cd589f5c6_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:399.75pt"><tr><td style="width:1.0pt"></td><td style="width:397.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xMg_9e4926d3-49eb-4951-9776-e77ed607ed48">10-K</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:399.75pt"><tr><td style="width:1.0pt"></td><td style="width:397.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:531.00pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:478.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6NGI4MGE3YTU3MTczNGJlNGI0OTVjYzQ0YjU3YmJjZmEvdGFibGVyYW5nZTo0YjgwYTdhNTcxNzM0YmU0YjQ5NWNjNDRiNTdiYmNmYV8xLTAtMS0xLTE1NTYzOA_c81af558-c45b-4c4f-b052-3f7ad72af68c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF80Ng_fff77130-116a-4a59-9613-20a0ca1f854d"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF80Ng_1c01cf7f-06c2-425d-b5b0-3ef8eb140a74">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:531.00pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:478.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6NzA1ZTc0ZDc3YzVlNDA3NTk5Mzg5YWJhYmYwODUyOWQvdGFibGVyYW5nZTo3MDVlNzRkNzdjNWU0MDc1OTkzODlhYmFiZjA4NTI5ZF8wLTAtMS0xLTE1NTYzOA_2aad131e-247f-4907-8d1c-246428f99cd2">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">             </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">to           </span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;text-decoration:underline">Commission file number <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xMzI_fc95e0f7-a4a0-4b6d-9cb4-d2e925ab8a6a">1-3619</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><img src="pfe-20211231_g1.jpg" alt="pfe-20211231_g1.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"/></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xMzg_ba610356-024a-447d-9265-c93db4a82db2">PFIZER INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.548%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ODBhYmRjODJhMGRiNGViOGI5MzNmYzNmOWFkYTBiNWMvdGFibGVyYW5nZTo4MGFiZGM4MmEwZGI0ZWI4YjkzM2ZjM2Y5YWRhMGI1Y18wLTAtMS0xLTE1NTYzOA_4500c05c-b4fb-4588-88d3-159ce7970599">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ODBhYmRjODJhMGRiNGViOGI5MzNmYzNmOWFkYTBiNWMvdGFibGVyYW5nZTo4MGFiZGM4MmEwZGI0ZWI4YjkzM2ZjM2Y5YWRhMGI1Y18wLTEtMS0xLTE1NTYzOA_d9cdf8f1-73e4-4732-9cb8-9a050497bfe7">13-5315170</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xOTk_319083a1-a2ae-4b01-8018-e4b5f296e835">235 East 42nd Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yMDM_05fb14a5-bf92-4cc6-8690-cecebe12804b">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yMDc_7b248e0e-791c-47a9-8145-bda0d5beac87">New York</ix:nonNumeric>  <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yMTE_54911415-02cb-4e63-9c32-0fd411f85a6d">10017</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices)  (zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yNjk_05f64656-d7b1-4032-bb9f-28a4bacc9ce1">212</ix:nonNumeric>) <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yNzM_102c8447-9047-40f2-8c5c-5b4f47fd0597">733-2323</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.548%"><tr><td style="width:1.0%"></td><td style="width:34.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.677%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-top:1pt solid #acacac;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Name&#160;of&#160;each&#160;exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8yLTAtMS0xLTE1NTYzOA_62c489d2-7f84-491f-ac5a-dac1adcc877a">Common Stock, $.05 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8yLTEtMS0xLTE1NTYzOA_77bf467c-c0e3-493e-981c-328e14c7946c">PFE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8yLTItMS0xLTE1NTYzOA_e6d0a87f-e617-4f01-adf5-7986ae553cf8">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8zLTAtMS0xLTE1NTYzOA_4cadcdb7-246a-4193-be01-c35a6d0a694b">0.250% Notes due 2022</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8zLTEtMS0xLTE1NTYzOA_4844b559-06da-44bc-a862-d95a149b2aba">PFE22</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8zLTItMS0xLTE1NTYzOA_e830e780-3da5-4523-9761-667a42b73d2a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV80LTAtMS0xLTE1NTYzOA_a5effaa3-9f9a-4194-bf28-0afe03598372">1.000% Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV80LTEtMS0xLTE1NTYzOA_ea2f0023-eccf-461e-be57-2b1686773603">PFE27</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV80LTItMS0xLTE1NTYzOA_829b5cf9-262f-4cb4-93e5-51b9ce478a19">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:276.00pt"><tr><td style="width:1.0pt"></td><td style="width:274.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #acacac;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">None</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;&#160;&#160;<ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzcy_f8ab659b-8a64-487f-9dfd-b1ea48e29a55">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;<ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc3_c4d2360e-77c1-4cfa-a5a9-052da9c337fc">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzcz_93b9698b-d58c-461e-bcf0-4c1b4465e7d5">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc0_40ae870f-35d1-4d03-881d-e735794c2750">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc4_bce0a4f7-e709-4613-b7df-b0af30e43a64">Large Accelerated filer</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Accelerated filer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc5_5902a06c-b215-400d-99e2-b43a5f686057">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">      </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzgw_46c88530-7c13-4b30-9a1c-880328b715f6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;   &#9744;</span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#8239;  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc1_c7c24c25-5032-459f-aef9-7935733f77c6">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc2_9d5675a3-8d60-413b-9d95-84ac47808a94">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, July&#160;4, 2021, was approximately $<ix:nonFraction unitRef="usd" contextRef="ia364c08bab1f4be7a0489033e72f9182_I20210704" decimals="-9" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yODAy_6b285ed0-5473-4d2a-b435-51f508a112b8">223</ix:nonFraction> billion. This excludes shares of common stock held by directors and executive officers at July&#160;4, 2021. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has no non-voting common stock. </span></div><div style="margin-bottom:1pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant&#8217;s common stock as of February&#160;22, 2022 was <ix:nonFraction unitRef="shares" contextRef="i7b0a597b277c43419d1b9be3ccd9b0bd_I20220222" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzI1_994b5511-f18f-4480-9856-dbf86ec73421">5,623,346,471</ix:nonFraction> shares of common stock, all of one class.</span></div><div style="margin-top:5pt;text-align:center"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzcx_26a6c8e4-6210-4b07-8852-d564b94a5c9d" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.75pt"><tr><td style="width:1.0pt"></td><td style="width:397.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:9pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">DOCUMENTS INCORPORATED BY REFERENCE</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Portions of the Proxy Statement for the 2022 Annual Meeting of Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Part III</span></td></tr></table></ix:nonNumeric></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TABLE OF CONTENTS</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:93.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_13">Defined Terms</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_13">i</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_1754">Available Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_1754">iii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_16">Forward-Looking Information and Factors that May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_19">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">ITEM&#160;1. BUSINESS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_25">About Pfizer</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_28">Commercial Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_31">Collaboration and Co-Promotion Agreements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_34">Research and Development</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_37">International Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_37">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_40">Sales and Marketing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_40">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_43">Patents and Other Intellectual Property Rights</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_43">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_46">Competition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_46">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_49">Pricing Pressures and Managed Care Organizations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_49">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_52">Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_52">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_55">Government Regulation and Price Constraints</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_55">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_58">Environmental Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_58">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_61">Human Capital</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_61">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_67">ITEM&#160;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_67">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0a0bff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_70">ITEM&#160;2. PROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_70">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_73">ITEM&#160;3. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_73">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0a0bff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_76">INFORMATION ABOUT OUR EXECUTIVE OFFICERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_76">23</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_79">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_79">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_82">ITEM&#160; 5. MARKET FOR THE COMPANY&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_82">24</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0a0bff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0a0bff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_88">ITEM&#160;6. </a>[RESERVED]</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_88">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_91">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_91">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_139">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_139">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_142">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_142">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_247">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_247">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_250">ITEM&#160;9A. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_250">107</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0a0bff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">ITEM&#160;9B. OTHER INFORMATION</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0a0bff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">ITEM&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_259">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_259">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_262">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_262">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_265">ITEM&#160;11. EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_265">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_268">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_268">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_271">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_271">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_274">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_274">110</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_277">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_277">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_280">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_280">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_283">15(a)(1) Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_283">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_286">15(a)(2) Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_286">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_289">15(a)(3) Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_289">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_292">ITEM 16. FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_292">114</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N/A = Not Applicable</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">DEFINED TERMS</span></td></tr></table></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this Form 10-K (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer&#8217;s fiscal year-end for subsidiaries operating outside the U.S. is as of and for the year ended November&#160;30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. References to &#8220;Notes&#8221; in this Form 10-K are to the Notes to the consolidated financial statements in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in this Form 10-K. We also have used several other terms in this Form 10-K, most of which are explained or defined below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Form 10-K</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K for the fiscal year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Proxy Statement</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proxy Statement for the 2022 Annual Meeting of Shareholders, which will be filed no later than 120 days after December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AbbVie Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated benefit obligation represents the present value of the benefit obligation earned through the end of the year but does not factor in future compensation increases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ACA (also referred to as U.S. Healthcare Legislation)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ACIP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Advisory Committee on Immunization Practices</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Akcea</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Akcea Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ALK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">anaplastic lymphoma kinase</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Alliance revenues</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Anacor</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Anacor Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ASR</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">accelerated share repurchase agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Arena</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Arena Pharmaceuticals, Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Array</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Array BioPharma Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Arvinas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Arvinas, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Astellas</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ATTR-CM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">transthyretin amyloid cardiomyopathy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Beam</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beam Therapeutics Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Biogen</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Biogen Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Biohaven</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Biohaven Pharmaceutical Holding Company Ltd., Biohaven Pharmaceutical Ireland DAC and BioShin Limited. (collectively, Biohaven)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">BioNTech</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BioNTech SE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Biopharmaceuticals Group</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Biologics License Application</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">BMS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Bristol-Myers Squibb Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">BNT162b2*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer-BioNTech COVID-19 Vaccine, also known as Comirnaty</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">BOD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Board of Directors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">BRCA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BReast CAncer susceptibility gene</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">CDC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Centers for Disease Control and Prevention</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">cGMPs</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">current Good Manufacturing Practices </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Comirnaty*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer-BioNTech COVID-19 Vaccine, also known as BNT162b2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Consumer Healthcare JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">GSK Consumer Healthcare JV</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">COVID-19</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">novel coronavirus disease of 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">CMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">conditional marketing authorisation</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">CStone</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CStone Pharmaceuticals</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">DEA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Drug Enforcement Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes the following markets: Western Europe, Scandinavian countries and Finland</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Developed Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes the following markets: U.S., Developed Europe, Japan, Canada, South Korea, Australia and New Zealand</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes the following markets: Japan, Canada, South Korea, Australia and New Zealand</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">European Commission</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Central Europe, Eastern Europe, the Middle East, Africa and Turkey</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EPS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">earnings per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ESOP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">employee stock ownership plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EUA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">emergency use authorization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Exchange Act</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Foreign Corrupt Practices Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">FFDCA</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Federal Food, Drug and Cosmetic Act</span></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">i</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Generally Accepted Accounting Principles</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">GDFV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">grant-date fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">GIST</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">gastrointestinal stromal tumors</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">GPD</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Global Product Development organization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">GlaxoSmithKline plc</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Hospira</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Hospira, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Ionis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Ionis Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in-process research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">IRC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal Revenue Code</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Internal Revenue Service</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">JAK</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt;padding-left:6.75pt;padding-right:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Janus kinase</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">JV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">joint venture</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">King</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">LIBOR</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">London Interbank Offered Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Lilly</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Eli Lilly and Company</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">LOE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">loss of exclusivity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">MCO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">managed care organization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">mCRC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">metastatic colorectal cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">mCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">metastatic castration-resistant prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">mCSPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">metastatic castration-sensitive prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">mRNA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">messenger ribonucleic acid</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Medivation</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Medivation LLC (formerly Medivation, Inc.)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Meridian</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Meridian Medical Technologies, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Moody&#8217;s</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Moody&#8217;s Investors Service</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">MTM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">mark-to-market</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Mylan</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Mylan N.V.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Mylan-Japan collaboration</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Myovant</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Myovant Sciences Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NAV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">net asset value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">new drug application</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">nmCRPC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">non-metastatic castration-resistant prostate cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NMPA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">National Medical Product Administration in China</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NSCLC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">non-small cell lung cancer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">NYSE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">New York Stock Exchange</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OPKO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">OPKO Health, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">OTC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">over-the-counter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Paxlovid*</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">PBM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">pharmacy benefit manager</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Projected benefit obligation; represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">PC1</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer CentreOne</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">PGS</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Global Supply</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pharmacia</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pharmacia Corporation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">PMDA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pharmaceuticals and Medical Device Agency in Japan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">PRAC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pharmacovigilance Risk Assessment Committee</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">PsA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">psoriatic arthritis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">QCE</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">quality consistency evaluation</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">RA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">rheumatoid arthritis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">RCC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">renal cell carcinoma</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ROU</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">right of use</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Sandoz</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sandoz, Inc., a division of Novartis AG</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">S&amp;P</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Standard &amp; Poor&#8217;s</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax Cuts and Jobs Act or TCJA</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Therachon</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Therachon Holding AG</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Trillium</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trillium Therapeutics Inc.</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">TSAs</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">transition service arrangements</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">UC</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ulcerative colitis</span></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ii</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United Kingdom</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Upjohn Business</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer&#8217;s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">United States</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Valneva</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Valneva SE</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">VBP</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">volume-based procurement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Viatris</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Viatris Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">ViiV</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ViiV Healthcare Limited</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">WHO</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">World Health Organization</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">WRDM</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Worldwide Research, Development and Medical</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">WTO</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">World Trade Organization</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.28pt">This Form 10-K includes discussion of the COVID-19 vaccine that Pfizer has co-developed with BioNTech (BNT162b2) and our oral COVID-19 treatment (Paxlovid). This Form 10-K may refer to the vaccine by its brand name, Comirnaty (approved under a BLA), or as BNT162b2 (authorized under EUA). The vaccine is FDA-approved to prevent COVID-19 in individuals 16 years of age and older. The vaccine is authorized by the FDA to prevent COVID-19 in individuals 5 years of age and older. In addition, Comirnaty/BNT162b2 is authorized by the FDA for a third dose in certain immunocompromised individuals 5 years of age and older and as a booster dose in individuals 12 years of age and older. Paxlovid has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. The FDA has issued EUAs to certain other companies for products intended for the prevention or treatment of COVID-19 and may continue to do so during the duration of the Declaration. Please see the EUA Fact Sheets at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">www.cvdvaccine-us.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">www.covid19oralrx.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Form 10-K includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Some amounts in this Form 10-K may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_1754"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#i4bff405b2205487eb835dd4cd589f5c6_1754">AVAILABLE INFORMATION</a></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our website is located at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">www.pfizer.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. This Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and our proxy statements, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are, or will be, available (free of charge) on our website, in text format and, where applicable, in interactive data file format</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as soon as reasonably practicable after we electronically file this material with, or furnish it to, the SEC.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Throughout this Form 10-K, we &#8220;incorporate by reference&#8221; certain information from other documents filed or to be filed with the SEC, including our Proxy Statement. Please refer to this information. This Form 10-K will be available on our website on or about February 24, 2022. Our Proxy Statement will be available on our website on or about March 17, 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our 2021 Environmental, Social and Governance (ESG) report, which provides enhanced ESG disclosures, will be available on our website on or about March 17, 2022. We also have a Pfizer Investor Insights website, which includes articles on the company, its products and its pipeline, located at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">insights.pfizer.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Information in our ESG Report and on the Pfizer Investor Insights website are not incorporated by reference into this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">We may use our website as a means of disclosing material information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures are included on our website in the &#8220;About</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Investors&#8221; or &#8220;News&#8221; sections. Accordingly, investors should monitor these portions of our website, in addition to following our press releases, SEC filings, public conference calls and webcasts, as well as our social media channels (our Facebook, YouTube and LinkedIn pages and Twitter accounts (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">@Pfizer </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">@Pfizer_News</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">)). The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Information relating to corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Pfizer Policies on Business Conduct (for all of our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of Business Conduct and Ethics for Members of the Board of Directors; information concerning our Directors; ways to communicate by e-mail with our Directors; information concerning our Board Committees; Committee Charters; Charter of the Lead Independent Director; and transactions in Pfizer securities by Directors and Officers are available on our website. We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New York, NY 10017. We will disclose any future amendments to, or waivers from, provisions of the Pfizer Policies on Business Conduct affecting our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer on our website as promptly as practicable, as may be required under applicable SEC and NYSE rules. Information relating to shareholder services, including the Computershare Investment Program, book-entry share ownership and direct deposit of dividends, is also available on our website.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">iii</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">This Form 10-K contains forward-looking statements. We also provide forward-looking statements in other materials we release to the public, as well as public oral statements. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;potential&#8221; and other words and terms of similar meaning or by using future dates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We include forward-looking information in our discussion of the following, among other topics:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data, revenue contribution, growth, performance, timing of exclusivity and potential benefits;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">strategic reviews, capital allocation objectives, dividends and share repurchases;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">sales, expenses, interest rates, foreign exchange rates and the outcome of contingencies, such as legal proceedings;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">expectations for impact of or changes to existing or new government regulations or laws;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our ability to anticipate and respond to macroeconomic, geopolitical, health and industry trends, pandemics, acts of war and other large-scale crises; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">manufacturing and product supply. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In particular, forward-looking information in this Form 10-K includes statements relating to specific future actions and effects, including, among others, our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 and an oral COVID-19 treatment, the forecasted revenue contribution of Comirnaty and the potential number of doses that we and BioNTech believe can be manufactured and/or delivered; the forecasted revenue contribution of Paxlovid and the potential number of treatment courses that we believe can be manufactured; our expectations regarding the impact of COVID-19 on our business; the expected patent term for Comirnaty and Paxlovid; the expectations for ongoing revenue streams from Comirnaty and Paxlovid; the expected impact of patent expiries and competition from generic manufacturers; the expected pricing pressures on our products and the anticipated impact to our business; the availability of raw materials for 2022; the expected charges and/or costs in connection with the spin-off of the Upjohn Business and its combination with Mylan; the benefits expected from our business development transactions; our anticipated liquidity position; the anticipated costs and savings from certain of our initiatives, including our Transforming to a More Focused Company program; our planned capital spending; and the expected benefit payments and employer contributions for our benefit plans.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. Actual outcomes may vary materially from past results and those anticipated, estimated, implied or projected. These forward-looking statements may be affected by underlying assumptions that may prove inaccurate or incomplete, or by known or unknown risks and uncertainties, including those described in this section and in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Therefore, you are cautioned not to unduly rely on forward-looking statements, which speak only as of the date of this Form 10-K. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Some of the factors that could cause actual results to differ are identified below, as well as those discussed in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K and within MD&amp;A. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. The occurrence of any of the risks identified below or in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K, or other risks currently unknown, could have a material adverse effect on our business, financial condition or results of operations, or we may be required to increase our accruals for contingencies. It is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations, and Business Development:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the outcome of R&amp;D activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; and whether and when additional data from our pipeline programs will be published in scientific journal publications, and if so, when and with what modifications and interpretations;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; the impact of recommendations by technical or advisory committees; and the timing of pricing approvals and product launches;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential, including uncertainties regarding the commercial or other impact of the results of the Xeljanz ORAL Surveillance (A3921133) study or actions by regulatory authorities based on analysis of ORAL Surveillance or other data, including on other JAK inhibitors in our portfolio;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the success and impact of external business development activities, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired products; significant transaction costs; and unknown liabilities;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the ability to successfully market both new and existing products, including biosimilars;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of public health outbreaks, epidemics or pandemics (such as the COVID-19 pandemic), including the impact of vaccine mandates where applicable, on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&amp;D and clinical trials;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">risks and uncertainties related to our efforts to develop a vaccine to help prevent COVID-19 and an oral COVID-19 treatment, as well as challenges related to their manufacturing, supply and distribution;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of the increased presence of counterfeit medicines or vaccines in the pharmaceutical supply chain;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any significant issues related to the outsourcing of certain operational and staff functions to third parties; and any significant issues related to our JVs and other third-party business arrangements;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any changes in business, political and economic conditions due to actual or threatened terrorist activity, civil unrest or military action;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">trade buying patterns;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of any U.S. healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">legislation or regulatory action in markets outside of the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">legal defense costs, insurance expenses, settlement costs and contingencies, including those related to actual or alleged environmental contamination;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk and impact of an adverse decision or settlement and the adequacy of reserves related to legal proceedings;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk and impact of tax related litigation;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">governmental laws and regulations affecting our operations, including, without limitation, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., including, among others, potential adoption of global minimum taxation requirements and potential changes to existing tax law by the current U.S. Presidential administration and Congress;</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Intellectual Property, Technology and Security:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">any business disruption, theft of confidential or proprietary information, extortion or integrity compromise resulting from a cyber-attack;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:9pt;padding-right:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">our ability to protect our patents and other intellectual property, including against claims of invalidity that could result in LOE, unasserted intellectual property claims and in response to any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products, including our vaccine to help prevent COVID-19 and our oral COVID-19 treatment.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_19"></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART I</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_22"></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BUSINESS</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_25"></div><div><img src="pfe-20211231_g1.jpg" alt="pfe-20211231_g1.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:75px"/></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ABOUT PFIZER</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. is a research-based, global biopharmaceutical company. We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The Company was incorporated under the laws of the State of Delaware on June 2, 1942. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Most of our revenues come from the manufacture and sale of biopharmaceutical products. We believe that our medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. We seek to enhance the value of our medicines and vaccines and actively engage in dialogues about how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We seek to maximize patient access and evaluate our pricing arrangements and contracting methods with payers to minimize adverse impact on our revenues within the current legal and pricing structures. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to fulfilling our purpose: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Breakthroughs that change patients&#8217; lives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Our purpose fuels everything we do and reflects both our passion for science and our commitment to patients. Pfizer&#8217;s growth strategy is driven by five &#8220;Bold Moves&#8221; that help us deliver breakthroughs for patients and create value for shareholders and other stakeholders:</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Unleash the power of our people</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Deliver first-in-class science</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Transform our go-to-market model</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Win the digital race in pharma</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:11.34pt">Lead the conversation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, Pfizer continues to enhance its ESG strategy, which is focused on six areas where we see opportunities to create a meaningful impact over the next decade: product innovation; equitable access and pricing; product quality and safety; diversity, equity and inclusion; climate change; and business ethics.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our significant recent business development activities in 2021 include, among others: (i) the July 2021 global collaboration with Arvinas to develop and commercialize ARV-471, an investigational oral PROTAC&#174; (PROteolysis TArgeting Chimera) estrogen receptor protein degrader (the estrogen receptor is a well-known disease driver in most breast cancers); (ii) the November 2021 collaboration and license agreement with Biohaven to acquire rights to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S. upon approval; (iii) the November 2021 acquisition of Trillium, a clinical stage immuno-oncology company developing innovative potential therapies for the treatment of cancer; and (iv) the December 2021 research collaboration with Beam to utilize Beam&#8217;s in vivo base editing programs, which use mRNA and lipid nanoparticles, for three targets for rare genetic diseases of the liver, muscle and central nervous system. In addition, in December 2021, we entered into a definitive agreement to acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. On February 2, 2022, Arena shareholders voted to approve the proposed acquisition, which is targeted to close in the first half of 2022, subject to review under antitrust laws and other customary closing conditions. For a further discussion of our strategy and our business development initiatives, see the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Overview of Our Performance, Operating Environment, Strategy and Outlook </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2020 and 2021, our business, operations and financial condition and results were impacted by the COVID-19 pandemic. To confront the public health challenge posed by the pandemic, we have made some important advances, including, the development of a vaccine to help prevent </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">COVID-19 and an oral COVID-19 treatment. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;COVID-19 Pandemic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A and the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_28"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMERCIAL OPERATIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Following (i) the spin-off and combination of the Upjohn Business (which was our global, primarily off-patent branded and generics business) with Mylan in 2020, which created a new global pharmaceutical company, Viatris, and (ii) the formation of the Consumer Healthcare JV with GSK in 2019, we saw the culmination of Pfizer&#8217;s transformation into a more focused, global leader in science-based innovative medicines and vaccines, and beginning in the fourth quarter of 2020, we operated as a single operating segment engaged in the discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products worldwide. At the beginning of our fiscal fourth quarter 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our Biopharma business includes the following therapeutic areas and key products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.25pt dotted #80c9ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Key Products</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:9pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Vaccines</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Includes innovative vaccines across all ages&#8212;infants, adolescents and adults&#8212;in pneumococcal disease, meningococcal disease, tick-borne encephalitis and COVID-19, with a pipeline focus on infectious diseases with significant unmet medical need.</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comirnaty/BNT162b2*, the Prevnar family*, Nimenrix, FSME/IMMUN-TicoVac and Trumenba</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:9pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Oncology</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes innovative oncology brands of biologics, small molecules, immunotherapies and biosimilars across a wide range of cancers. </span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ibrance*, Xtandi*, Inlyta*, Sutent, Retacrit, Lorbrena and Braftovi</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:9pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Internal Medicine</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes innovative brands in cardiovascular metabolic and women&#8217;s health, as well as regional brands.</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eliquis* and the Premarin family</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:9pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Hospital**</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Includes our global portfolio of sterile injectable and anti-infective medicines, as well as an oral COVID-19 treatment.</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:9pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Inflammation &amp; Immunology</span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Includes innovative brands and biosimilars for chronic immune and inflammatory diseases. </span></div></td><td colspan="3" style="border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xeljanz*, Enbrel (outside the U.S. and Canada)*, Inflectra, Eucrisa/Staquis and Cibinqo</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:6pt;padding-right:9pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Rare Disease</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Includes innovative brands for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases.</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;border-left:0.25pt dotted #80c9ff;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vyndaqel/Vyndamax*, BeneFIX and Genotropin</span></div></td></tr></table></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:10.39pt">Each of Prevnar 13/Prevenar 13, Ibrance, Eliquis, Xeljanz and Enbrel recorded direct product and/or Alliance revenues of more than $1 billion in 2021, 2020 and 2019. Each of Comirnaty/BNT162b2 and Inlyta recorded direct product and/or Alliance revenues of more than $1 billion in 2021. Each of Xtandi and Vyndaqel/Vyndamax recorded direct product and/or Alliance revenues of more than $1 billion in 2021 and 2020. Comirnaty/BNT162b2, Eliquis and Xtandi include Alliance revenues and direct sales. Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult).</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prior to the fourth quarter of 2021, PC1 had been managed within the Hospital therapeutic area. Also, on December 31, 2021, we completed the sale of our Meridian subsidiary, which was part of the Hospital therapeutic area prior to its sale. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for additional information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on our operating segments and products, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and for additional information on the key operational revenue drivers of our business, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A. For a discussion of the risks associated with our dependence on certain of our major products, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Concentration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_31"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COLLABORATION AND CO-PROMOTION </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We use collaboration and/or co-promotion arrangements to enhance our development, R&amp;D, sales and distribution of certain biopharmaceutical products, which include, among others, the following: </span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Comirnaty/BNT162b2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> is an mRNA-based coronavirus vaccine to help prevent COVID-19, which is being jointly developed and commercialized with BioNTech. Pfizer and BioNTech equally share the costs of development for the Comirnaty program. Comirnaty/BNT162b2 has been granted an approval or an authorization in many countries around the world in populations varying by country. We also share gross profits equally from commercialization of Comirnaty/BNT162b2 and are working jointly with BioNTech in our respective territories to commercialize the vaccine worldwide (excluding China, Hong Kong, Macau and Taiwan), subject to regulatory authorizations or approvals market by market. For discussion on Comirnaty/BNT162b2, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;COVID-19 Pandemic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Eliquis </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(apixaban) is part of the Novel Oral Anticoagulant market and was jointly developed and commercialized with BMS as an alternative treatment option to warfarin in appropriate patients. We fund between 50% and 60% of all development costs depending on the study, and profits and losses are shared equally except in certain countries where we commercialize Eliquis and pay a percentage of net sales to BMS. In certain smaller markets we have full commercialization rights and BMS supplies the product to us at cost plus a percentage of the net sales to end-customers.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Xtandi </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(enzalutamide) is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells that is being developed and commercialized in collaboration with Astellas. We share equally in the gross profits and losses related to U.S. net sales and also share equally all Xtandi commercialization costs attributable to the U.S. market, subject to certain exceptions. In addition, we share certain development and other collaboration expenses. For international net sales we receive royalties based on a tiered percentage.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Bavencio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(avelumab) is a human anti-programmed death ligand-1 (PD-L1) antibody that is being developed and commercialized in collaboration with Merck KGaA. We jointly fund the majority of development and commercialization costs and split profits equally related to net sales generated from any products containing avelumab. </span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Orgovyx </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer that is being developed and commercialized with Myovant. The companies are also collaborating on</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> Myfembree</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (relugolix 40 </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for heavy menstrual bleeding associated with uterine fibroids in premenopausal women and the management of moderate to severe pain associated with endometriosis. The companies will equally share profits and allowable expenses in the U.S. and Canada for Orgovyx and Myfembree, with Myovant bearing our share of allowable expenses up to a maximum of $50 million in 2022. Myovant will remain responsible for regulatory interactions and drug supply and continue to lead clinical development for the relugolix combination tablet.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues associated with these arrangements are included in Alliance revenues (except in certain markets where we have direct sales and except for the majority of revenues for Comirnaty/BNT162b2, which are included as direct product revenues). In addition, we have collaboration arrangements for the development and commercialization of certain pipeline products that are in development stage, including, among others, (i) with BioNTech to develop a modified mRNA-based vaccine for the prevention of varicella zoster (Shingles), and (ii) with Valneva to co-develop and commercialize Valneva&#8217;s Lyme disease vaccine candidate, VLA15. For further discussion of collaboration and co-promotion agreements, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Collaborations and Other Relationships with Third Parties </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section in this Form 10-K and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_34"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RESEARCH AND DEVELOPMENT</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients&#8217; lives as we work to translate advanced science and technologies into the therapies that may be the most impactful for patients. The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. In addition to discovering and developing new products, our R&amp;D efforts seek to add value to our existing products by improving their effectiveness and ease of dosing and by discovering potential new indications.</span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our R&amp;D Priorities and Strategy. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our R&amp;D priorities include:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">delivering a pipeline of highly differentiated medicines and vaccines where we have a unique opportunity to bring the most important new therapies to patients in need;</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">advancing our capabilities that can position us for long-term R&amp;D leadership; and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">To that end, our R&amp;D primarily focuses on our main therapeutic areas.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">While a significant portion of our R&amp;D is internal, we also seek promising chemical and biological lead molecules and innovative technologies developed by others to incorporate into our discovery and development processes or projects, as well as our product lines. We do so by entering into collaboration, alliance and license agreements with universities, biotechnology companies and other firms as well as through acquisitions and investments. These collaboration, alliance and license agreements and investments allow us to share knowledge, risk and cost. They also enable us to access external scientific and technological expertise, as well as provide us the opportunity to advance our own products and in-licensed or acquired products. For information on certain of these collaborations, alliances and license arrangements and investments, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our R&amp;D Operations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2021, we continued to strengthen our global R&amp;D operations and pursue strategies to improve R&amp;D productivity to achieve a sustainable pipeline that is positioned to deliver value in the near term and over time</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our R&amp;D activity is conducted through various platform functions that operate in parallel within our global operations, including the following:</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">WRDM. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Research units within WRDM are generally responsible for research and early-stage development assets for our business (assets that have not yet achieved proof-of-concept) and are organized by therapeutic area to enhance flexibility, cohesiveness and focus. We can rapidly redeploy resources within a research unit and between various projects to leverage, as necessary, common skills, expertise or focus.</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">GPD. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">GPD organization is a unified center for clinical development and regulatory activities that is generally responsible for the clinical development strategy and operational execution of clinical trials for late-stage clinical assets in Pfizer&#8217;s pipeline.</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%;padding-left:6.2pt">Science-based platform-services organizations within WRDM.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> These organizations provide technical expertise and other services to various R&amp;D projects, and are organized into science-based functions. These organizations allow us to react more quickly and effectively to evolving needs by sharing resources among projects, candidates and targets across therapeutic areas and phases of development. Examples of these platform organizations include Pharmaceutical Sciences and Medicine Design, and Worldwide Medical and Safety.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage R&amp;D operations on a total-company basis through our platform functions described above. Specifically, the Portfolio Strategy &amp; Investment committee, composed of senior executives, is accountable for aligning resources among all of our WRDM, GPD and R&amp;D projects and for seeking to ensure optimal capital allocation across the innovative R&amp;D portfolio. We believe that this approach also serves to maximize accountability and flexibility.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We do not disaggregate total R&amp;D expense by development phase or by therapeutic area since, as described above, we do not manage our R&amp;D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, we believe that any prior-period information about R&amp;D expense by development phase or by therapeutic area would not necessarily be representative of future spending.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Costs and Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and Development (R&amp;D) Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our R&amp;D Pipeline. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The process of drug and biological product discovery from initiation through development and to potential regulatory approval is lengthy and can take more than ten years. As of February&#160;8, 2022, we had the following number of projects in various stages of R&amp;D: </span></div><div style="margin-top:8pt;text-align:center"><img src="pfe-20211231_g2.jpg" alt="pfe-20211231_g2.jpg" style="height:130px;margin-bottom:5pt;vertical-align:text-bottom;width:520px"/></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Development of a single compound is often pursued as part of multiple programs. While our drug candidates may or may not receive regulatory approval, new candidates entering clinical development phases are the foundation for future products. Information concerning several of our drug candidates in development, as well as supplemental filings for existing products, is set forth in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product Developments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A. For information on the risks associated with R&amp;D, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Research and Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section of this Form 10-K. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_37"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INTERNATIONAL OPERATIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our operations are conducted globally, and we sell our products in over 125 countries. Emerging markets are an important component of our strategy for global leadership, and our commercial structure recognizes that the demographics and rising economic power of the fastest-growing emerging markets are becoming more closely aligned with the profile found within developed markets. Urbanization and the rise of the middle class in emerging markets provide potential growth opportunities for our products. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Revenues from operations outside the U.S. of $51.5 billion accounted for 63% of our total revenues in 2021. Revenues exceeded $500 million in each of 21, 8 and 10 countries outside the U.S. in 2021, 2020 and 2019, respectively, with the increase in the number of countries in 2021 primarily driven by Comirnaty/BNT162b2. By total revenues, Japan was our largest national market outside the U.S. in 2021. For a geographic breakdown of revenues, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Analysis of the Consolidated Statements of Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Revenues by Geography</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> section within MD&amp;A and the table captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Geographic Information</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Note 17B</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:2pt;text-align:center;text-indent:24.75pt"><img src="pfe-20211231_g3.jpg" alt="pfe-20211231_g3.jpg" style="height:225px;margin-bottom:5pt;vertical-align:text-bottom;width:529px"/></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our international operations are subject to risks inherent in carrying on business in other countries. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Global Operations </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections in this Form 10-K.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_40"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SALES AND MARKETING</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our prescription biopharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Certain of these government contracts may be renegotiated or terminated at the discretion of a government entity. In addition, our contracts with government and supranational organizations for the sales of Comirnaty/BNT162b2 and Paxlovid, which are on a committed basis, represented a significant amount of revenues in 2021. We also seek to gain access for our products on formularies, which are lists of approved medicines available to members of healthcare programs or PBMs. PBMs use various benefit designs, such as tiered co-pays for formulary products, to drive utilization of products in preferred formulary positions. We may also work with payers on disease management programs that help to develop tools and materials to educate patients and physicians on key disease areas. For information on our significant customers, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We promote our products to healthcare providers and patients. Through our marketing organizations, we explain the approved uses, benefits and risks of our products to healthcare providers and patients; MCOs that provide insurance coverage, such as hospitals, integrated delivery systems, PBMs and health plans; and employers and government agencies who hire MCOs to provide health benefits to their employees. In the U.S., we market directly to consumers through direct-to-consumer advertising that seeks to communicate the approved uses, benefits and risks of our products while motivating people to have meaningful conversations with their doctors. In addition, we sponsor general advertising to educate the public on disease awareness, prevention and wellness, important public health issues and our patient assistance programs.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PATENTS AND OTHER INTELLECTUAL PROPERTY RIGHTS</span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Patents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. We own or license a number of patents covering pharmaceutical and other products, their uses, formulations, and product manufacturing processes.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Patents for individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The scope of protection afforded by a patent can vary from country to country and depends on the patent type, the scope of its patent claims and the availability of legal remedies. Patent term extensions (PTE) may be available in some countries to compensate for a loss of patent term due to delay in a product&#8217;s approval due to the regulatory requirements. One of the primary considerations in limiting our operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products, although international and U.S. free trade agreements have included some improved global protection of intellectual property rights. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In various markets, a period of regulatory exclusivity may be provided for drugs or vaccines upon approval. The scope and term of such exclusivity will vary but, in general, the period will run concurrently with the term of any existing patent rights associated with the drug at the time of approval.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Based on current sales, and considering the competition with products sold by our competitors, the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires, are as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Major Europe Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #929292;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Japan Basic Product Patent Expiration Year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chantix/Champix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sutent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inlyta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xeljanz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prevnar 13/Prevenar 13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eliquis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ibrance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xtandi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vyndaqel/Vyndamax/Vynmac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024<br/>(2028 pending PTE)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026/2029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xalkori</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Braftovi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031<br/>(2031 pending PTE)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mektovi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2031</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(9)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bavencio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2032</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prevnar 20/Apexxnar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033 <br/>(2035 pending PTE) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2033</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(12)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cibinqo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(13)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2034 <br/>(2038 pending PTE) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comirnaty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(14), (15)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(14)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt dotted #828282;border-top:1pt dotted #828282;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Paxlovid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt dotted #929292;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt dotted #929292;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(16)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt dotted #929292;border-top:1pt dotted #929292;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(16)</span></div></td></tr></table></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">Unless otherwise indicated, the years pertain to the basic product patent expiration, including granted PTEs, supplementary protection certificates (SPC) or pediatric exclusivity periods. SPCs are included when granted in three out of five major European markets (France, Germany, Italy, Spain and the U.K.). Noted in parentheses is the projected year of expiry of the earliest pending patent term extension in the U.S. or Japan and/or SPC application in Europe, the term of which, if granted, may be shorter than originally requested due to a number of factors. In some instances, there are later-expiring patents relating to our products which may or may not protect our product from generic or biosimilar competition after the expiration of the basic patent.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">The basic product patent for Chantix expired in the U.S. in November 2020 and in Europe in September 2021.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">The basic product patent for Sutent expired in the U.S. in August 2021 and in Europe in January 2022.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">Expiry is provided by regulatory exclusivity in this market.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">The Europe patent that covers the combination of the 13 serotype conjugates of Prevenar</span><span style="color:#1f497d;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13 was revoked following an opposition and has now been withdrawn. There are other Europe patents and pending applications covering the formulation, various aspects of the manufacturing process, and the combination of serotype conjugates of Prevenar</span><span style="color:#1f497d;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">13 that remain in force.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">Eliquis was developed and is being commercialized in collaboration with BMS. For Eliquis in the U.S., two patents listed in the FDA Orange Book, the composition of matter patent claiming apixaban specifically and a formulation patent, were challenged by numerous generic companies and were the subject of patent infringement litigation. Prior to the resolution of the litigation in our favor on both challenged patents, we and BMS settled with a number of these generic companies (settled generic companies) while continuing to litigate against three remaining generic companies (remaining generic companies). As a result of the litigation, the remaining generic companies are not permitted to launch their products until the 2031 expiration date of the formulation patent. Under the terms of the settlement agreements, the permitted date of launch for the settled generic companies under these patents is April 1, 2028.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Both patents may be subject to subsequent challenges. While we cannot predict the outcome of any potential future litigation, these are the alternatives that might occur: (a) if both patents are upheld in future litigation, through appeal, the permitted date of launch for the settled generic companies under these patents would remain April 1, 2028; (b) if the formulation patent is held invalid or not infringed in future litigation, through appeal, the settled generic companies and any successful future litigant would be permitted to launch on November 21, 2026; or (c) if both patents are held invalid or not infringed in future litigation, through appeal, the settled generic companies and any successful future litigant could launch products immediately upon such an adverse decision.  </span></div><div style="margin-bottom:3pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Refer to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Note 16A1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> for more information.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">Xtandi is being developed and commercialized in collaboration with Astellas, which has exclusive commercialization rights for Xtandi outside the U.S. Pfizer receives tiered royalties as a percentage of international Xtandi net sales.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">Vyndaqel (tafamidis meglumine) basic patent expiry in Japan is August 2026 for treatment of polyneuropathy. Vynmac (tafamidis) was approved in Japan for treatment of cardiomyopathy with regulatory exclusivity expiring March 2029.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.95pt">We have exclusive rights to Braftovi and Mektovi in the U.S. The Pierre Fabre Group has exclusive rights to commercialize both products in Europe and Ono Pharmaceutical Co., Ltd. has exclusive rights to commercialize both products in Japan. We receive royalties from The Pierre Fabre Group and Ono Pharmaceutical Co., Ltd. on sales of Braftovi and Mektovi outside the U.S.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(10)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.42pt">Mektovi U.S. expiry is provided by a method of use patent.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(11)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.42pt">Bavencio is being developed and commercialized in collaboration with Merck KGaA. </span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(12)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.42pt">Product not yet approved or authorized in this market.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(13)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.42pt">An SPC has been filed for Cibinqo in the U.K. with expected expiry in 2036 based on the September 2021 approval. Cibinqo was approved in other major European markets in December 2021.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(14)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.42pt">The basic product patent application for Comirnaty has been filed in these markets. If granted, a full term is expected in these markets. Comirnaty is being developed and commercialized in collaboration with BioNTech</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(15)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.42pt">Pfizer does not have co-promotion rights for Comirnaty in Germany.</span></div><div style="margin-bottom:3pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(16)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.42pt">The basic product patent application for Paxlovid has been filed in these markets. If granted, a full term is expected in these markets.</span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Loss of Intellectual Property Rights. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we typically lose exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price. The date at which generic or biosimilar competition commences may be different from the date that the patent or regulatory exclusivity expires. However, when generic or biosimilar competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short period of time. Also, if one of our product-related patents is found to be invalid by judicial, court or regulatory or administrative proceedings, generic or biosimilar products could be introduced, resulting in the erosion of sales of our existing products. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Competitive Products, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property Protection </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Third-Party Intellectual Property Claims </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections in this Form 10-K and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16A1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. For additional information on the impact of LOEs on our revenues, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trademarks</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Our products are sold under brand-name and logo trademarks and trade dress. Registrations generally are for fixed, but renewable, terms and protection is provided in some countries for as long as the mark is used while in others, for as long as it is registered. Protecting our trademarks is of material importance to Pfizer.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_46"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business is conducted in intensely competitive and often highly regulated markets. Many of our products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications. The principal forms of competition include efficacy, safety, ease of use and cost. Though the means of competition vary among our products, demonstrating the value of our products is a critical factor for success.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We compete with other companies that manufacture and sell products that treat or prevent diseases or indications similar to those treated or prevented by our major products. These competitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus and generic drug and biosimilar manufacturers. Our competitors also may devote substantial funds and resources to R&amp;D and their successful R&amp;D could result in erosion of the sales of our existing products and potential sales of products in development, as well as unanticipated product obsolescence. In addition, several of our competitors operate without large R&amp;D expenses and make a regular practice of challenging our product patents before their expiration.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">To address competitive trends we continually emphasize innovation, which is underscored by our multi-billion-dollar investment in R&amp;D, as well as our business development transactions, both designed to result in a strong product pipeline. Our investment in research continues even after drug or vaccine approval as we seek to further demonstrate the value of our products for the conditions they treat or prevent, as well as potential new applications. We educate patients, physicians, payers and global health authorities on the benefits and risks of our medicines and vaccines, and seek to continually enhance the organizational effectiveness of our biopharmaceutical functions, including to accurately and ethically launch and market our products to our customers.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating conditions have also shifted as a result of increased global competitive pressures, industry regulation and cost containment. We continue to evaluate, adapt and improve our organization and business practices in an effort to better meet customer and public needs. We believe that we have taken an industry-leading role in evolving our approaches to U.S. direct-to-consumer advertising, interactions with, and payments to, healthcare professionals and medical education grants. We also continue to sponsor programs to address patient affordability and access barriers, as we strive to advance fundamental health system change through our support for better healthcare solutions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our vaccines may face competition, including from the introduction of alternative vaccines or &#8220;next-generation&#8221; vaccines prior to or after the expiration of their patents, which may adversely affect our future results.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our biosimilars, which include biosimilars of certain inflammation &amp; immunology and oncology biologic medicines, compete with branded products from competitors, as well as other generics and biosimilars manufacturers. We seek to maximize the opportunity to establish a &#8220;first-to-</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">market&#8221; or early market position for our biosimilars to provide customers a lower-cost alternative immediately when available and also to potentially provide us with higher levels of sales and profitability until other competitors enter the market. </span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Generic Products</span><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent and often charge much less. Several competitors regularly challenge our product patents before their expiration. Generic competitors often operate without large R&amp;D expenses, as well as without costs of conveying medical information about products to the medical community. In addition, the FDA approval process exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy data of the innovator product. In China, for example, we expect to continue to face intensified competition by certain generic manufacturers in 2022 and beyond, which may result in price cuts and volume loss of some of our products. In addition, generic versions of competitors&#8217; branded products may also compete with our products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MCOs that focus primarily on the immediate cost of drugs often favor generics over brand-name drugs. Many governments also encourage the use of generics as alternatives to brand-name drugs in their healthcare programs, including Medicaid in the U.S., and U.S. laws generally allow, and in some cases require, pharmacists to substitute generic drugs for brand-name drugs. In a small subset of states, prescribing physicians are able to expressly prevent such substitution. </span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of our biologic products, including Enbrel (we market Enbrel outside the U.S. and Canada), already face, or may face in the future, competition from biosimilars (also referred to as follow-on biologics). Biosimilars are versions of biologic medicines that have been developed and proven to be highly similar to the original biologic in terms of safety and efficacy and that have no clinically meaningful differences in safety, purity or potency. Biosimilars have the potential to offer high-quality, lower-cost alternatives to innovative biologic medicines. In the U.S.,  biosimilars referencing innovative biologic products are approved under the U.S. Public Health Service Act. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_49"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PRICING PRESSURES AND MANAGED CARE ORGANIZATIONS</span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Commercial Pricing Pressures. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pricing and access pressures in the commercial sector continue to be significant. Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Many employers have adopted high deductible health plans, which can increase out-of-pocket costs for medicines. This trend is likely to continue. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and a reduction in demand for our products. Pricing pressures also may occur as a result of highly competitive insurance markets. Healthcare provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Longer term, we foresee a shift in focus away from fee-for-service payments towards outcomes-based payments and risk-sharing arrangements that reward providers for cost reductions and improved patient outcomes. These new payment models can, at times, lead to lower prices for, and restricted access to, new medicines. At the same time, these models can also promote utilization of drugs by encouraging physicians to screen and diagnose and consider drugs as a means of forestalling more costly medical interventions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In light of the COVID-19 pandemic and related large-scale healthcare disruptions, we expect value-based payment models may have reduced participation if the incentives to participate are reduced or eliminated. Financially weakened hospitals may weigh their ability to take on the financial risk of downside models. In contrast, providers in more advanced value-based models, such as full capitation, a fixed amount paid in advance per patient per unit of time-period, generally found their revenues remained steady during the pandemic, which may ultimately encourage the growth of such models.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We believe medicines and vaccines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We work with law makers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and help ensure access to medicines and vaccines within an efficient and affordable healthcare system. This includes assessing our go-to market model to address patient affordability challenges. We have engaged with major payors and the U.S. government to explore opportunities to improve access and reimbursement in an effort to drive pro-patient policies. In addition, in response to the evolving U.S. and global healthcare spending landscape, we work with health authorities, health technology assessment and quality measurement bodies and major U.S. payers throughout the product-development process to better understand how these entities value our compounds and products. Further, we are developing stronger internal capabilities focused on demonstrating the value of the medicines and vaccines that we discover or develop, register and manufacture, by recognizing patterns of usage of our medicines and vaccines and competitor medicines and vaccines along with patterns of healthcare costs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on government pricing pressures, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pricing and Reimbursement </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections in this Form 10-K. </span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Managed Care Organizations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The evolution of managed care in the U.S. has been a major factor in the competitiveness of the healthcare marketplace. Approximately 302 million people in the U.S. now have some form of health insurance coverage, and the marketing of prescription drugs and vaccines to both consumers and the entities that manage coverage in the U.S. continues to grow in importance. In particular, the influence of MCOs has increased in recent years due to the growing number of patients receiving coverage through MCOs. At the same time, consolidation in the MCO industry has resulted in fewer, even larger MCOs, which enhances those MCOs&#8217; ability to negotiate pricing and increases their importance to our business. Since MCOs seek to contain and reduce healthcare expenditures, their growing influence has increased pressure on drug prices as well as revenues.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">MCOs typically negotiate prices with pharmaceutical providers by using formularies (which are lists of approved medicines available to MCO members), clinical protocols (which require prior authorization for a branded product if a generic product is available or require the patient to first fail on one or more generic products before permitting access to a branded medicine), volume purchasing, long-term contracts and their ability to influence volume and market share of prescription drugs. In addition, by placing branded medicines on higher-tier or non-preferred status in their formularies, MCOs transfer a portion of the cost to the patient, resulting in significant patient out-of-pocket expenses. This financial disincentive is a tool for MCOs to manage drug costs and channel patients to medicines preferred by the MCOs. The ACA has accelerated payment reform by distributing risk across MCOs and other stakeholders in care delivery with the intent of improving quality while reducing costs, which creates </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">pressure on MCOs to tie reimbursement to defined outcomes. We are closely monitoring these newer approaches and developing appropriate strategies to respond to them.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The breadth of the products covered by formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular medical problems. MCOs also emphasize primary and preventive care, out-patient treatment and procedures performed at doctors&#8217; offices and clinics as ways to manage costs. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed, and drugs that can reduce the need for hospitalization, professional therapy or surgery may become favored first-line treatments for certain diseases.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exclusion of a product from a formulary or other MCO-implemented restrictions can significantly impact drug usage in the MCO patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products, typically on the basis of unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, as well as the overall cost of the therapy. We have been generally, although not universally, successful in having our major products included on MCO formularies. However, increasingly our branded products are being placed on the higher tiers or in a non-preferred status. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Managed Care Trends</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_52"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">RAW MATERIALS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We procure raw materials essential to our business from numerous suppliers worldwide. In general, these materials have been available in sufficient quantities to support our demand and in many cases are available from multiple suppliers. No significant impact to our operations due to the availability of raw materials is currently anticipated in 2022. However, we are seeing an increase in overall demand in the industry for certain components and raw materials with the potential to constrain available supply, which could have a future impact on our business. We are continuing to monitor and implement mitigation strategies in an effort to reduce any potential risk or impact, including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_55"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION AND PRICE CONSTRAINTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government authorities in the countries in which we do business. This includes laws and regulations governing the operations of biopharmaceutical companies, such as the approval, manufacturing and marketing of products, pricing (including discounts and rebates) and health information privacy, among others. These laws and regulations may require administrative guidance for implementation, and a failure to comply could subject us to legal and/or administrative actions. Enforcement measures may include substantial fines and/or penalties, orders to stop non-compliant activities, criminal charges, warning letters, product recalls or seizures, delays in product approvals, exclusion from participation in government programs or contracts as well as limitations on conducting business in applicable jurisdictions, and could result in harm to our reputation and business. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16A. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Compliance with these laws and regulations may be costly, and may require significant technical expertise and capital investment to ensure compliance. While capital expenditures or operating costs for compliance with government regulations cannot be predicted with certainty, we do not currently anticipate they will have a material effect on our capital expenditures or competitive position. </span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">In the United States</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Drug and Biologic Regulation</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The FDA, pursuant to the FFDCA, the Public Health Service Act and other federal statutes and regulations, extensively regulates pre- and post-marketing activities related to our biopharmaceutical products. The regulations govern areas such as the safety and efficacy of medicines and vaccines, clinical trials, advertising and promotion, quality control, manufacturing, labeling, distribution, post-marketing safety surveillance and reporting, and record keeping. Other U.S. federal agencies, including the DEA, also regulate certain of our products and activities. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a biopharmaceutical company to market a drug or a biologic product, including vaccines, in the U.S., the FDA must evaluate whether the product is safe and effective for its intended use. If the FDA determines that the drug or biologic is safe and effective, the FDA will approve the product&#8217;s NDA or BLA (or supplemental NDA or supplemental BLA), as appropriate.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A drug or biologic may be subject to postmarketing commitments, which are studies or clinical trials that the product sponsor agrees to conduct, or postmarketing requirements, which are studies or clinical trials that are required as a condition of approval. In addition, we are also required to report adverse events and comply with cGMPs (the FDA regulations that govern all aspects of manufacturing quality for pharmaceuticals) and the Drug Supply Chain Security Act (the law that, among other things, sets forth requirements related to product tracing, product identifiers and verification for manufacturers, wholesale distributors, repackagers and dispensers to facilitate the tracing of product through the pharmaceutical distribution supply chain), as well as advertising and promotion regulations. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Development, Regulatory Approval and Marketing of Products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Post-Authorization/Approval Data </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the context of public health emergencies, like the COVID-19 pandemic, we may apply to the FDA for an EUA, which if granted, allows for the distribution and use of our products during the declared emergency, in accordance with the conditions set forth in the EUA, unless the EUA is otherwise terminated by the government. Although the criteria for an EUA differ from the criteria for approval of an NDA or BLA, EUAs nevertheless require the development and submission of data to satisfy the relevant FDA standards, and a number of ongoing obligations. The FDA generally expects EUA holders to work toward submission of full applications, such as a BLA or an NDA, as soon as possible. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Biosimilar Regulation.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The FDA is responsible for approval of biosimilars. Innovator biologics are entitled to 12 years of market exclusivity by statute, and biosimilars applications may not be submitted until four years after the approval of the reference innovator biologic. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Sales and Marketing Regulations</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our marketing practices are subject to state laws, as well as federal laws, such as the Anti-Kickback Statute and False Claims Act, intended to prevent fraud and abuse in the healthcare industry. The Anti-Kickback Statute generally prohibits corruptly soliciting, offering, receiving, or paying anything of value to generate business. The False Claims Act generally prohibits anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods or services, including to government payers, such as Medicare and Medicaid, that are false or fraudulent and generally treat claims generated through kickbacks as false or fraudulent. The federal government and states also regulate sales and marketing activities and financial interactions between manufacturers and healthcare providers, requiring disclosure to government authorities and the public of such interactions, and the adoption of compliance standards or programs. State </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">attorneys general have also taken action to regulate the marketing of prescription drugs under state consumer protection and false advertising laws. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pricing, Reimbursement and Access Regulations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pricing and reimbursement for our products depend in part on government regulation. Any significant efforts at the federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded or more directly impose controls on drug pricing, government reimbursement, and access to medicines and vaccines on public and private insurance plans could have a material impact on us. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, in order to have our products covered by Medicaid, we must offer discounts or rebates on purchases of pharmaceutical products under various federal and state programs. We also must report specific prices to government agencies. The calculations necessary to determine the prices reported are complex and the failure to do so accurately may expose us to enforcement measures. See the discussion regarding rebates in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues by Geography </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1H.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government and private payers routinely seek to manage utilization and control the costs of our products, and there is considerable public and government scrutiny of pharmaceutical pricing. Efforts by states and the federal government to regulate prices or payment for pharmaceutical products, including proposed actions to facilitate drug importation, limit reimbursement to lower international reference prices, require deep discounts, and require manufacturers to report and make public price increases and sometimes a written justification for the increase, could adversely affect our business if implemented. We expect to see continued focus by Congress and the Biden Administration on regulating pricing which could result in legislative and regulatory changes designed to control costs. For example, there is proposed legislation that, if enacted, would allow Medicare to negotiate prices for certain prescription drugs, as well as require that penalties be paid by manufacturers who raise drug prices faster than inflation. In addition, changes to the Medicaid program or the federal 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities, could have a material impact on our business. For example, certain changes issued in a final rule by the Centers for Medicare &amp; Medicaid Services (CMS) in December 2020 to the Medicaid Drug Rebate Program could increase our Medicaid rebate obligations and increase the discounts we extend to 340B covered entities. Additional changes to the 340B program are undergoing review and their status is unclear. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pricing and Reimbursement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A majority of states use preferred drug lists to manage access to pharmaceutical products under Medicaid, including some of our products. For example, access to our products under the Medicaid managed care programs typically is determined by the health plans with which state Medicaid agencies contract to provide services to beneficiaries. States seek to control healthcare costs related to Medicaid and other state healthcare programs, including the implementation of supplemental rebate agreements under the Medicaid drug rebate program tied to patient outcomes. States&#8217; budgets were impacted less by the COVID-19 pandemic than expected and are generally growing. We expect states to seek cost cutting within Medicaid, which may focus on managed care capitation payments and/or formulary management. States may also advance drug-pricing initiatives with a focus on affordability review boards, financial penalties related to pricing practices, manufacturer pricing and reporting requirements, as well as regulation of prescription drug assistance or copay accumulator programs in the commercial market. Payers may promote generic drugs and biosimilars more aggressively to generate savings and attempt to stimulate additional price competition. In addition, we expect that consolidation and integration among pharmacy chains, wholesalers and PBMs will increase pricing pressures in the industry. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Managed Care Trends</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Anti-Corruption. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data Privacy. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The collection and use of personal data by us is increasingly important to our business and is subject to various federal and state privacy and data security laws and regulations, including oversight by various regulatory and other governmental bodies. Such laws and regulations continue to evolve and are increasingly being enforced vigorously.</span></div><div style="margin-top:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Outside the United States</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">New Drug Approvals.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In the EU, the EMA conducts the scientific evaluation, supervision and safety monitoring of our innovative medicinal products, and employs a centralized procedure for approval for the EU and the European Economic Area (EEA) countries. In the U.K., the Medicines and Healthcare products Regulatory Agency is the sole regulatory authority. In Japan, the PMDA is involved in a wide range of regulatory activities, including clinical studies, approvals, post-marketing reviews and pharmaceutical safety. In China, the NMPA is the primary regulatory authority for approving and supervising medicines. Health authorities in many middle- and lower-income countries require marketing approval by a recognized regulatory authority (e.g., the FDA or EMA) before they begin to conduct their application review process and/or issue their final approval. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pharmacovigilance.</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the EU, the EMA&#8217;s PRAC is responsible for reviewing and making recommendations on product safety issues. Outside developed markets, pharmacovigilance requirements vary and are generally not as extensive, but there is a trend toward increasing regulation.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pricing and Reimbursement</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain governments, including in the different EU member states, the U.K., Japan, China, Canada and South Korea, provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global financing pressures. Governments globally may use a variety of measures to control costs, including proposing price reform or legislation, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), QCE processes and VBP. In addition, the international patchwork of price regulation, differing economic conditions and incomplete value assessments across countries has led to varying access to quality medicines in many markets and some third-party trade in our products between countries. Several important multilateral organizations such as the WHO are increasing scrutiny of international pharmaceutical pricing through policy recommendations and sponsorship of programs, such as &#8220;The Oslo Medicines Initiative&#8221; which is planning a high-level meeting in 2022 to agree on WHO Europe Member States&#8217; commitments to ensure &#8220;affordability for high-priced medicines&#8221;. In November 2020, the EC published its new Pharmaceutical Strategy for Europe which envisions a broad range of new initiatives and legislation including a significant focus on affordability and access to medicines.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In China, pricing pressures have increased in recent years because of an overall focus on healthcare cost containment with government officials emphasizing improved health outcomes, healthcare reform and decreased drug prices as key indicators of progress towards reform. For patented products, drug prices have decreased dramatically as a result of adding innovative drugs (including oncology medicines) to the National Reimbursement Drug List (NRDL). In the off-patent space, numerous local generics have been officially deemed bioequivalent under a QCE process that required domestically-manufactured generic drugs to pass a test to assess their bioequivalence to a qualified reference drug (typically the originator drug). A centralized VBP program, a tender process where a certain portion of included molecule volumes are guaranteed to tender winners and is intended to contain healthcare costs by driving utilization of generics that have passed QCE, has resulted in dramatic price cuts for off-patent medicines. Furthermore, the Chinese government has discussed moving toward efforts to unify the reimbursement price between QCE-approved generic medicines and the applicable original medicines, which the government currently plans to implement within the next few years. We and most off-patent originators have mostly not been successful in the VBP bidding process. The government has indicated that additional post-LOE drugs could be subjected to VBP qualification in future rounds. While certain details of future QCE expansion have been made available, we are unable to determine the impact on our business and financial condition until the initiation of these future rounds. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Provider Transparency and Disclosures.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Several countries have implemented laws requiring (or industry trade associations have recommended) disclosure of transfers of value made by pharmaceutical companies to healthcare providers and/or healthcare organizations, such as academic teaching hospitals. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Intellectual Property</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reliable patent protection and enforcement around the world are among the key factors we consider for continued business and R&amp;D investment. The WTO Agreement on Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) requires participant countries to provide patent and other intellectual property-related protection for pharmaceutical products by law, with an exemption provided for least-developed countries until 2033. While some countries have made improvements, we still face patent grant, enforcement and other intellectual property challenges in many countries. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">While the global intellectual property policy environment has generally improved following WTO-TRIPS and bilateral/multilateral trade agreements, our growth and ability to bring new product innovation to patients depends on further progress in intellectual property protection. In certain developed international markets, governments maintain relatively effective intellectual property policies. However, in the EU, pursuant to the ongoing review of pharmaceutical intellectual property and regulatory incentives, legislative change may result in the reduction of certain protections. In several emerging market countries, governments have used intellectual property policies as a tool to force innovators to accept less than fair value for medicines, as well as to advance industrial policy and localization goals. Discussions are ongoing at the WTO that seek to limit intellectual property protections within the context of the COVID-19 pandemic response.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Considerable political and economic pressure has weakened current intellectual property protection in some countries and has led to policies such as more restrictive standards for obtaining patents and more difficult procedures for patenting biopharmaceutical inventions, restrictions on patenting certain types of inventions, revocation of patents, laws or regulations that promote or provide broad discretion to issue a compulsory license, weak intellectual property enforcement and failure to implement effective regulatory data protection. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our industry advocacy efforts focus on seeking a fair and transparent business environment for foreign manufacturers, underscoring the importance of strong intellectual property systems for local innovative industries and helping improve patients&#8217; access to innovative medicines and vaccines. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Data Privacy. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Outside of the U.S., many countries have privacy and data security laws and regulations concerning the collection and use of personal data, including but not limited to, the EU&#8217;s General Data Protection Regulations and China&#8217;s Personal Information Protection Law. The legislative and regulatory framework for privacy and data protection issues worldwide is also rapidly evolving as countries continue to adopt new and updated privacy and data security laws. The interpretation and application of such laws and regulations remain uncertain and continue to evolve. In addition, enforcement of such laws and regulations is increasing.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_58"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ENVIRONMENTAL MATTERS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our operations are affected by national, state and/or local environmental laws. We have made, and intend to continue to make, the expenditures necessary for compliance with applicable laws. We also are cleaning up environmental contamination from past industrial activity at certain sites. We incurred capital and operational expenditures in 2021 for environmental compliance purposes and for the clean-up of certain past industrial activity as follows: $55 million in environment-related capital expenditures and $152 million in other environment-related expenses.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">While capital expenditures or operating costs for environmental compliance cannot be predicted with certainty, we do not currently anticipate they will have a material effect on our capital expenditures or competitive position. See also </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16A3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Climate change presents risks to our operations, including the potential for additional regulatory requirements and associated costs, the potential for more frequent and severe weather events, and water availability challenges that may impact our facilities and those of our suppliers. We cannot provide assurance that physical risks to our facilities or supply chain due to climate change will not occur in the future. We periodically review our vulnerability to potential weather-related risks and other natural disasters and update our assessments accordingly. Based on our reviews, we do not believe these potential risks are material to our operations at this time. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_61"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HUMAN CAPITAL</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our purpose is: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Breakthroughs that change patients&#8217; lives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. These breakthroughs are delivered through the relentless collaboration of our talented workforce. As of December 31, 2021, we employed approximately 79,000 people worldwide, with approximately 29,000 based in the U.S. Women compose approximately 49% of our global workforce, and approximately 34% of our U.S.-based employees are individuals with ethnically diverse backgrounds.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our continued success links directly to the commitment, engagement and performance of our employees. It is important that we not only attract and retain the best and brightest diverse talent, but also ensure they remain engaged and can thrive in an environment that is committed to helping them grow, succeed and contribute directly to achieving our purpose. As part of these efforts, we strive for an inclusive and empowering work environment, adopting practices to simplify processes and remove needless complexity, rewarding both performance and leadership skills, </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">fostering career growth and internal mobility and offering competitive compensation and benefits programs that encourage mental and physical well being.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Core Values.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">To fully realize Pfizer&#8217;s purpose we have established a clear set of goals regarding what we need to achieve for patients and how we will go about achieving them. The &#8220;how&#8221; is represented by four simple, powerful company values &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Courage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Excellence</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Joy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Each value defines our company and our culture:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Courage</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Breakthroughs start by challenging convention &#8211; especially in the face of uncertainty or adversity. This happens when we think big, speak up and are decisive.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Excellence</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We can only change patients&#8217; lives when we perform at our best together. This happens when we focus on what matters, agree who does what and measure outcomes.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: Every person deserves to be seen, heard and cared for. This happens when we are inclusive, act with integrity and reduce health care disparities.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Joy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">: We give ourselves to our work, and it also gives to us. We find joy when we take pride, recognize one another and have fun.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Equity and Inclusion.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> At Pfizer, every person deserves to be seen, heard and cared for, and we work to further this goal by bringing together people with different backgrounds, perspectives and experiences. Our commitments to equity consist of specific actions to help foster a more inclusive environment within Pfizer, including, among others: (i) building a more inclusive colleague experience through representation and meaningful connections; (ii) advancing equitable health outcomes by evaluating our work through the lens of the communities we serve, (iii) providing resources on allyship and the science behind inclusion to support all colleagues in having courageous conversations about equity, race and the avoidance of bias; (iv) working to help transform society with external diversity, equity and inclusion partnerships, including deploying capital, engaging diverse suppliers and amplifying equity initiatives; and (v) working to help ensure demographics of clinical trials correlate to those of the countries where trials are taking place.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Colleague Engagement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. To attract, develop and inspire the brightest talent, we aim to support our colleagues by engaging and partnering with them to help ensure they feel they are part of a community. We understand the importance of continuously listening and responding to colleague feedback and our annual engagement survey, Pfizer Pulse, provides a forum for our colleagues to give structured feedback about their colleague experience. Through this survey, we measure and track key areas of the overall colleague experience and equip leaders with actionable insights for discussion and follow up. Regular topics in the survey include: (i) employee engagement, such as colleagues&#8217; commitment to and advocacy for Pfizer; (ii) purpose, including how colleagues&#8217; work connects with our purpose; (iii) inclusion, such as having a climate in which diverse perspectives are valued; and (iv) growth, including the ability for colleagues to gain new experiences that align with their individual career goals. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2021, we continued to maintain low turnover rates relative to the pharmaceutical industry and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> our 2021 Pfizer Pulse survey,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on average</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 90% of colleagues reported feeling engaged, as measured by pride in working at Pfizer, willingness to recommend Pfizer as a great place to work and intent to stay. In addition, 92% of the colleagues agreed </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">that </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">their daily work contributes to our purpose. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">While we are slightly behind in our Bold Moves goal to create room for meaningful work, we continue to make progress on simplifying processes and removing needless complexity. We have committed to tangible actions and principles that incorporate the similar behaviors and mindset we used to develop a COVID-19 vaccine in an accelerated timeline. These behaviors include working with urgency and overcoming bureaucracy, as well as believing in our purpose, trusting in one another and being transparent.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Performance, Leadership and Growth.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to helping our colleagues reach their full potential by rewarding both their performance and leadership skills and by providing opportunities for growth and development. Our performance management approach&#8212;called Performance and Leadership Insights&#8212;is based on six-month semesters during which our colleagues and their managers set goals, receive feedback and meet to discuss performance. These conversations are meant to help colleagues grow and develop by evaluating performance (what the colleague achieved, measured by outcomes), leadership (how they achieved it, taking into account Pfizer&#8217;s values of courage, excellence, equity and joy), and identifying areas of growth that help move colleagues towards fulfilling their career goals and their potential. Our commitments to colleague development consist of specific actions to encourage non-linear career growth paths for all colleagues, including (i) a common language around growth&#8212;along with a guiding framework&#8212;to help colleagues identify their next best growth experience, (ii) tools and resources to encourage growth conversations and offer transparency on the sources of growth available, and (iii) a variety of programs including mentoring, job rotations, experiential project roles, skill-based volunteering and learning resources focused on various topics, including leadership and management skills and industry- and job-specific learning, as well as general business, manufacturing, finance and technology skills.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Well-Being</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Protecting the health, safety and well-being of colleagues and contingent workers, all of whom are essential to delivering our business objectives, is an integral part of how we operate. Our Global Environment, Health &amp; Safety (EHS) Policy and supporting standards outline our approach to assessment, evaluation, elimination, and mitigation of EHS risks across our operations. COVID-19 pandemic preparedness and response continues to be a key focus to help ensure on-site workers at our commercial, manufacturing and research sites remain safe and healthy while continuing to support work from home arrangements for colleagues who can work remotely. As part of these efforts, we (i) implemented a vaccination program for colleagues and their families in the U.S. and 23 other countries where employer vaccination programs were possible, (ii) partnered with and launched Thrive Global, a wellness and organizational change initiative with a primary focus on colleague mental health and wellness, and (iii) hosted educational webinars and information sessions on mental health and well-being, nutrition and work life balance through our employee assistance program provider.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pay Equity.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our commitment to pay equity for all colleagues is based in our value of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and our intention to continue to build a diverse and inclusive workforce.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to equitable pay practices at Pfizer for employees based on role, education, experience, performance, and location and we conduct and report publicly on pay equity on an annual basis.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional information regarding our human capital programs and initiatives is available in the &#8220;About</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Careers&#8221; section of Pfizer&#8217;s website and our ESG Report. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_67"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">This section describes the material risks to our business, which should be considered carefully in addition to the other information in this report and our other filings with the SEC. Investors should be aware that it is not possible to predict or identify all such factors and that the following is </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">not meant to be a complete discussion of all potential risks or uncertainties. Additionally, our business is subject to general risks applicable to any company, such as economic conditions, geopolitical events, extreme weather and natural disasters. If known or unknown risks or uncertainties materialize, our business operations, financial condition, operating results (including components of our financial results), cash flows, prospects, reputation or credit ratings could be adversely affected now and in the future, potentially in a material way. The following discussion of risk factors contains forward-looking statements, as discussed in the Forward-Looking Information and Factors that May Affect Future Results section in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MANAGED CARE TRENDS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Private payers, such as health plans, and other managed care entities, such as PBMs, continue to take action to manage the utilization and costs of drugs. The negotiating power of MCOs and other private third-party payers has increased due to consolidation, and they, along with governments, increasingly employ formularies to control costs and encourage utilization of certain drugs, including through the use of formulary inclusion or favorable formulary placement. These initiatives have increased consumers&#8217; interest and input in medication choices, as they pay for a larger portion of their prescription costs and may cause them to favor lower-cost generic alternatives. We may fail to obtain or maintain timely or adequate pricing or formulary placement of our products, or fail to obtain such formulary placement at favorable pricing.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The growing availability and use of innovative specialty pharmaceutical medicines that treat rare or life-threatening conditions, which typically have smaller patient populations, combined with their relative higher cost as compared to other types of pharmaceutical products, also has generated increased payer interest in developing cost-containment strategies targeted to this sector.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Third-party payers also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing and value-based pricing/contracting to improve their cost containment efforts. Such payers are also increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product if a generic product is available or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. As the U.S. private third-party payer market consolidates further and as more drugs become available in generic form, we may face greater pricing pressure from private third-party payers as they continue to drive more of their patients to use lower cost generic alternatives.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Also, business arrangements in this area are subject to a high degree of government scrutiny, and available safe harbors under applicable federal and state fraud and abuse laws are subject to change through legislative and regulatory action, as well as evolving judicial interpretations. Our approach to these arrangements may also be informed by such government and industry guidance.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMPETITIVE PRODUCTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Competitive product launches may erode future sales of our products, including our existing products and those currently under development, or result in unanticipated product obsolescence. Such launches continue to occur, and potentially competitive products are in various stages of development. We cannot predict with accuracy the timing or impact of the introduction of competitive products that treat diseases and conditions like those treated by our in-line products and product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, competition from manufacturers of generic drugs, including from generic versions of competitors&#8217; branded products that lose their market exclusivity, is a major challenge for our branded products. Certain of our products have experienced significant generic competition over the last few years. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8212;Patents and Other Intellectual Property Rights </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section in this Form 10-K. In China, we expect to continue to face intense competition by certain generic manufacturers, which may result in price cuts and volume loss of some of our products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, our patented products may face generic competition before patent exclusivity expires, including upon the &#8220;at-risk&#8221; launch (despite pending patent infringement litigation against the generic product) by a manufacturer of a generic version of one of our patented products. Generic manufacturers have filed applications with the FDA seeking approval of product candidates that they claim do not infringe our patents or claim that our patents are not valid; these include candidates that would compete with, among other products, Ibrance and Xeljanz. Our licensing and collaboration partners also face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may become subject to competition from biosimilars referencing our biologic products if competitors are able to obtain marketing approval for such biosimilars.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also commercialize biosimilar products that compete with products of others, including other biosimilar products. The entry to the market of competing biosimilars is expected to increase pricing pressures on our biosimilar products. Uptake of our biosimilars may be lower due to various factors, such as anti-competitive practices, access challenges where our product may not receive appropriate coverage/reimbursement access or remains in a disadvantaged position relative to an innovator product, physician reluctance to prescribe biosimilars for existing patients taking the innovative product, or misaligned financial incentives. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on competition our products face, see the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Competition </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONCENTRATION</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recorded direct product and/or Alliance revenues of more than $1 billion for each of nine products that collectively accounted for 75% of our total revenues in 2021. In particular, Comirnaty/BNT162b2 accounted for 45% of our total revenues in 2021. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If these products or any of our other major products were to experience loss of patent protection (if applicable), changes in prescription or vaccination growth rates, material product liability litigation, unexpected side effects or safety concerns, regulatory proceedings, negative publicity affecting doctor or patient confidence, pressure from existing competitive products, changes in labeling, pricing and access pressures or supply shortages or if a new, more effective product should be introduced, the adverse impact on our revenues could be significant. In particular, certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and patents covering a number of our best-selling products are, or have been, the subject of pending legal challenges. For additional information on our patents, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K. For Comirnaty/BNT162b2 and </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Paxlovid, while we believe that these products have the potential to provide ongoing revenue streams for Pfizer for the foreseeable future, revenues of these products following the COVID-19 pandemic may not be at the similar levels as those being generated during the pandemic. For information on additional risks associated with Comirnaty/BNT162b2 and Paxlovid, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Pandemic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section below.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, we sell our prescription pharmaceutical products principally through wholesalers in the U.S. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. If one of our significant biopharmaceutical wholesalers should encounter financial or other difficulties, it might decrease the amount of business the wholesaler does with us and/or we might be unable to timely collect all the amounts that the wholesaler owes us or at all, which could negatively impact our results of operations. In addition, we expect that consolidation and integration of pharmacy chains and wholesalers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RESEARCH AND DEVELOPMENT </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The discovery and development of new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our business. Our product lines must be replenished over time to offset revenue losses when products lose exclusivity or market share, as well as to provide for earnings growth, primarily through internal R&amp;D or through collaborations, acquisitions, JVs, licensing or other arrangements. Growth depends in large part on our ability to identify and develop new products or new indications for existing products that address unmet medical needs and receive reimbursement from payers. However, balancing current growth, investment for future growth and the delivery of shareholder return remains a major challenge. The costs of product development continue to be high, as are regulatory requirements in many therapeutic areas, which may affect the number of candidates we are able to fund as well as the sustainability of the R&amp;D portfolio. Decisions made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketing strategy and payer reimbursement possibilities if the candidate receives regulatory approval. We try to plan clinical trials prudently and to reasonably anticipate and address challenges, but there is no assurance that an optimal balance between trial conduct, speed and desired outcome will be achieved.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, our product candidates can fail at any stage of the R&amp;D process, and may not receive regulatory approval even after many years of R&amp;D. We may fail to correctly identify indications for which our science is promising or allocate R&amp;D investment resources efficiently, and failure to invest in the right technology platforms, therapeutic areas, product classes, geographic markets and/or licensing opportunities could adversely impact the productivity of our pipeline. Further, even if we identify areas with the greatest commercial potential, the scientific approach may not succeed despite the significant investment required for R&amp;D, and the product may not be as competitive as expected because of the highly dynamic market environment and the hurdles in terms of access and reimbursement. For example, our gene therapy product candidates are based on a novel technology with only a few gene therapies approved to date, which makes it difficult to predict the time and cost of development and the ability to obtain regulatory approval. Further, gene therapy may face difficulties in gaining the acceptance of patients or the medical community. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GLOBAL OPERATIONS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We operate on a global scale and could be affected by currency fluctuations, capital and exchange controls, global economic conditions including inflation, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, trade regulations, tax laws and regulations and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the current conflict between Russia and Ukraine, terrorist activity, unstable governments and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Some emerging market countries may be particularly vulnerable to periods of financial or political instability or significant currency fluctuations or may have limited resources for healthcare spending. As a result of these and other factors, our strategy to grow in emerging markets may not be successful, and growth rates in these markets may not be sustainable.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government financing and economic pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through health technology assessments) or other means of cost control. For additional information on government pricing pressures, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8212;Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We continue to monitor the global trade environment and potential trade conflicts and impediments that could impact our business. If trade restrictions or tariffs reduce global economic activity, potential impacts could include declining sales; increased costs; volatility in foreign exchange rates; a decline in the value of our financial assets and pension plan investments; required increases of our pension funding obligations; increased government cost control efforts; delays or failures in the performance of customers, suppliers and other third parties on whom we may depend for the performance of our business; and the risk that our allowance for doubtful accounts may not be adequate.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We operate in many countries and transact in over 100 different currencies. Changes in the value of those currencies relative to the U.S. dollar, or high inflation in these countries, can impact our revenues, costs and expenses and our financial guidance. Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to exchange rate changes. 63% of our total 2021 revenues were derived from international operations, including 29% from Europe and 19% from China, Japan and the rest of Asia. Future changes in exchange rates or economic conditions and the impact they may have on our results of operations, financial condition or business are difficult to predict. For additional information about our exposure to foreign currency risk, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, our borrowing, pension benefit and postretirement benefit obligations and interest-bearing investments, are subject to risk from changes in interest and exchange rates. The risks related to interest-bearing investments and borrowings and the measures we have taken to help contain them are discussed in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For additional details on critical accounting estimates and assumptions for our benefit plans, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions&#8212;Benefit Plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">From time to time, we issued variable rate debt based on LIBOR, or undertook interest rate swaps that contain a variable element based on LIBOR. The U.K. Financial Conduct Authority announced in 2017 that it will no longer compel banks to submit rates used to calculate LIBOR after 2021. This deadline was extended until June 2023 for a number of key U.S. dollar benchmark maturities (including the 1-month and 3-month </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">LIBOR rates). The U.S. Federal Reserve has selected the Secured Overnight Funding Rate (SOFR) as the preferred alternate rate and the transition away from LIBOR will continue despite the extended timeline. We are planning for this transition and will amend any contracts to accommodate the SOFR rate where required. We do not expect the transition to have significant impact on our business or financial condition.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PRODUCT MANUFACTURING, SALES AND MARKETING RISKS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We could encounter difficulties or delays in our supply chain, product manufacturing and distribution networks, as well as sales or marketing, due to regulatory actions, shut-downs, work stoppages or strikes, approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on, reputational harm, the impact to our facilities due to health pandemics or natural or man-made disasters, including as a result of climate change, product liability or unanticipated costs. Examples of such difficulties or delays include the inability to increase production capacity commensurate with demand; challenges related to component materials to maintain supply and/or appropriate quality standards throughout our supply network and/or comply with applicable regulations; inability to supply certain products due to voluntary product recalls (as is the case with Chantix); and supply chain disruptions at our facilities or at a supplier or vendor. In addition, we engage contract manufacturers, and, from time to time, our contract manufacturers may face difficulties or are unable to manufacture our products at the necessary quantity or quality levels.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Regulatory agencies periodically inspect our manufacturing facilities, as well as third-party facilities that we rely on, to evaluate compliance with cGMP or other applicable requirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, product recalls, delays or denials of product approvals, import bans or denials of import certifications. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In July and August 2021, Pfizer recalled 16 lots of Chantix in the U.S. due to the presence of a nitrosamine, N-nitroso-varenicline, at or above the FDA interim acceptable intake limit. In September 2021, Pfizer expanded its voluntary recall in the U.S. to include all lots of Chantix. We currently also have a voluntary recall across multiple markets and a global pause in shipments of Chantix. Technical solutions are being pursued to reduce nitrosamine levels in Chantix to enable return to market. Nitrosamines are impurities common in water and foods and everyone is exposed to some level of nitrosamines. In response to requests from various regulatory authorities, manufacturers across the pharmaceutical industry, including Pfizer, are evaluating their product portfolios for the potential for the presence or formation of nitrosamines. This may lead to additional recalls or other market actions for Pfizer products.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We depend on third-party collaborators, service providers, and others in the research, development, manufacturing and commercialization of our products and product candidates and also enter into JVs and other business development transactions. To achieve expected longer-term benefits, we may make substantial upfront payments as part of these transactions, which may negatively impact our reported earnings or cash flows. We rely heavily on these parties for multiple aspects of our drug development, manufacturing and commercialization activities, but we do not control many aspects of those activities. We also outsource certain services, including activities related to transaction processing, accounting, information technology, manufacturing, clinical trial recruitment and execution, clinical lab services, non-clinical research, safety services, integrated facilities management and other areas. Failure by one or more of the third-party collaborators, service providers and others to complete activities on schedule or in accordance with our expectations or to meet their contractual or other obligations to us; failure of one or more of these parties to comply with applicable laws or regulations; or any disruption in the relationships between us and these parties, could delay or prevent the development, approval, manufacturing or commercialization of our products and product candidates, expose us to suboptimal quality of service delivery or deliverables, result in repercussions such as missed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry standards or subject us to reputational harm, all with potential negative implications for our product pipeline and business. Further, our Alliance revenues will be adversely affected by the termination or expiration of collaboration and co-promotion agreements that we have entered into and that we may enter into from time to time. For information on additional risks specific to our Consumer Healthcare JV, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consumer Healthcare JV with GSK </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">below.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COUNTERFEIT PRODUCTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our reputation and promising pipeline render our medicines and vaccines prime targets for counterfeiters. Counterfeit medicines and vaccines pose a significant risk to patient health and safety because of the conditions under which they are manufactured&#8212;often in unregulated, unlicensed, uninspected and unsanitary sites&#8212;as well as the lack of regulation of their contents. Failure to mitigate this threat could adversely impact Pfizer&#8217;s patients, potentially causing them harm. This, in turn, may result in the loss of patient confidence in the Pfizer name and in the integrity of our medicines and vaccines, and potentially impact our business through lost sales, product recalls, and possible litigation. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The prevalence of counterfeit medicines is an industry-wide issue due to a variety of factors, including the adoption of e-commerce, which increased during the COVID-19 pandemic, greatly enhancing consumers&#8217; ability to obtain prescriptions and other medical treatments via the internet in lieu of traditional brick and mortar pharmacies or authorized full-service internet pharmacies. The internet exposes patients to greater risk as it is a preferred vehicle for dangerous counterfeit offers and scams because of consumers&#8217; misplaced trust with certain e-commerce retailers coupled with the anonymity the internet affords counterfeiters. While counterfeiters generally target any medicine or vaccine boasting strong demand, we have observed heightened counterfeit and fraud attempts to our COVID-19 vaccine, as well as other products potentially utilized in the treatment of COVID-19.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We consistently invest in an enterprise-wide strategy to aggressively combat counterfeit threats by educating patients and health care providers about the risks, investing in innovative technologies to detect and disrupt sophisticated internet offers and scams, proactively monitoring and interdicting supply with the help of law enforcement; and advising legislators and regulators. However, our efforts and those of others may not be entirely successful, and the presence of counterfeit medicines may continue to increase.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PRICING AND REIMBURSEMENT</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">U.S. and international governmental regulations that mandate price controls or limitations on patient access to our products or establish prices paid by government entities or programs for our products impact our business, and our future results could be adversely affected by changes in such regulations or policies. The adoption of restrictive price controls in new jurisdictions, more restrictive controls in existing jurisdictions or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue. We expect pricing pressures will continue globally.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the U.S., pharmaceutical product pricing is subject to government and public scrutiny and calls for reform, and many of our products are subject to increasing pricing pressures as a result. We expect to see continued focus by the Federal government on regulating pricing which could result in legislative and regulatory changes designed to control costs. Some states have implemented, and others are considering, patient access constraints or cost cutting under the Medicaid program, and some are considering measures that would apply to broader segments of their populations that are not Medicaid-eligible. State legislatures also have continued to focus on addressing drug costs, generally by increasing price transparency or limiting drug price increases. Measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation, could adversely affect our business. For additional information on U.S. pricing and reimbursement, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in this Form 10-K. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We encounter similar regulatory and legislative issues in most other countries in which we operate. In certain markets, such as in EU member states, the U.K., Japan, China, Canada and South Korea, governments have significant power as large single payers to regulate prices, access criteria, or impose other means of cost control, particularly as a result of recent global financing pressures. For example, the QCE and VBP tender process in China has resulted in dramatic price cuts for off-patent medicines. For additional information regarding these government initiatives, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K. We anticipate that these and similar initiatives will continue to increase pricing pressures in China and elsewhere in the future. In addition, in many countries, with respect to our vaccines, we participate in a tender process for selection in national immunization programs. Failure to secure participation in national immunization programs or to obtain acceptable pricing in the tender process could adversely affect our business. We also anticipate pricing pressures will be amplified by COVID-19 induced budget deficits and focus on pricing for COVID-19 treatments and vaccines.  </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. HEALTHCARE REGULATION</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. Any significant efforts at the U.S. federal or state levels to reform the healthcare system by changing the way healthcare is provided or funded could have a material impact on us. For additional information on U.S. healthcare regulation, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs to the U.S. at prices that are regulated by foreign governments, revisions to reimbursement of biopharmaceuticals under government programs that could reference international prices or require new discounts, limitations on interactions with healthcare professionals and other industry stakeholders, or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A reduction of U.S. federal spending on entitlement programs, including Medicare and Medicaid, may affect payment for our products or services provided using our products. Any other significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented could have an adverse impact on our results of operations.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The discovery and development of drugs, vaccines and biological products are time consuming, costly and unpredictable. The outcome is inherently uncertain and involves a high degree of risk due to the following factors, among others: </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">The process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Product candidates can and do fail at any stage of the process, including as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data, including results that may not support further clinical development of the product candidate or indication. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We may need to amend our clinical trial protocols or conduct additional clinical trials under certain circumstances, for example, to further assess appropriate dosage or collect additional safety data.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We may not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We may not be able to successfully address all the comments received from regulatory authorities such as the FDA and the EMA, or be able to obtain approval for new products and indications from regulators. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Regulatory approvals of our products depend on myriad factors, including regulatory determinations as to the product&#8217;s safety and efficacy. In the context of public health emergencies like the COVID-19 pandemic, regulators evaluate various factors and criteria to potentially allow for marketing authorization on an emergency or conditional basis. Additionally, clinical trial and other product data are subject to differing interpretations and assessments by regulatory authorities. As a result of regulatory interpretations and assessments or other developments that occur during the review process, and even after a product is authorized or approved for marketing, a product&#8217;s commercial potential could be adversely affected by potential emerging concerns or regulatory decisions regarding or impacting labeling or marketing, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may not be able to receive or maintain favorable recommendations by technical or advisory committees, such as the ACIP or any FDA Advisory Committee that may be convened to review our applications such as EUAs, NDAs or BLAs, which may impact the potential marketing and use of our products. Further, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates can negatively impact product sales, and potentially lead to product recalls or withdrawals, including regulator-directed risk evaluations and </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">assessments, and/or consumer fraud, product liability and other litigation and claims. Further regulatory agency requirements may result in a more challenging, expensive and lengthy regulatory approval process than anticipated due to requests for, among other things, additional or more extensive clinical trials prior to granting approval, or increased post-approval requirements. For these and other reasons discussed in this Risk Factors section, we may not obtain the approvals we expect within the timeframe we anticipate, or at all. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">POST-AUTHORIZATION/APPROVAL DATA</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As a condition to granting marketing authorization or approval of a product, the FDA may require additional clinical trials or other studies. The results generated in these trials could result in the loss of marketing approval, changes in labeling, and/or new or increased concerns about the side effects, efficacy or safety. Regulatory agencies in countries outside the U.S. often have similar regulations and may impose comparable requirements. Post-marketing studies and clinical trials, whether conducted by us or by others, whether mandated by regulatory agencies or conducted voluntarily, and other emerging data about products, such as adverse event reports, may also adversely affect the availability or commercial potential of our products. Further, if safety or efficacy concerns are raised about a product in the same class as one of our products, those concerns could implicate the entire class; and this, in turn, could have an adverse impact on the availability or commercial viability of our product(s) as well as other products in the class. The potential regulatory and commercial implications of post-marketing study results typically cannot immediately be determined. For example, in December 2021, in light of the results from the completed required postmarketing safety study of Xeljanz, ORAL Surveillance (A3921133), the U.S. label for Xeljanz was revised. Updates include a new boxed warning for major adverse cardiovascular events (MACE) and updated boxed warnings regarding mortality, malignancies and thrombosis (with corresponding updates to applicable warnings and precautions). In addition, indications for the treatment of adults with moderately to severely active RA or active PsA, and patients who are two years of age and older with active polyarticular course juvenile idiopathic arthritis have been revised; Xeljanz is now indicated in patients who have had inadequate response or intolerance to one or more tumor necrosis factor blockers. In addition, at the request of the EC, the PRAC of the EMA has adopted a referral procedure under Article 20 of Regulation (EC) No 726/2004 to assess safety information relating to oral JAK inhibitors authorized for inflammatory diseases, including Xeljanz and Cibinqo, which is ongoing. We continue to work with regulatory agencies to review the full results and analyses of ORAL Surveillance and their impact on product labeling.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The terms of our EUA for Comirnaty require that we conduct post-authorization observational studies in patients at least 5 years of age or older who received a booster dose, or other populations of interest including healthcare workers, pregnant women, immunocompromised individuals, and subpopulations with specific comorbidities. Additionally, in relation to the FDA approval for Comirnaty, we are required to complete certain postmarketing study requirements and commitments by 2024 as identified in the August 2021 approval letter. The terms of our EUA for Paxlovid require monitoring for convergence of global viral variants of SARS-CoV-2 and potential assessment of Paxlovid activity against identified global variants of interest. Additionally, in relation to the potential FDA approval for Paxlovid, we are required to complete certain other analyses and studies as identified in the December 2021 authorization letter.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">LEGAL MATTERS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are and may be involved in various legal proceedings, including patent litigation, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial and other asserted and unasserted matters, environmental, government investigations, employment, tax litigation and other legal proceedings that arise from time to time in the ordinary course of our business. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe that our claims and defenses in matters in which we are a defendant are substantial, we could in the future incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Claims against our patents include challenges to the coverage and/or validity of our patents on various products or processes. There can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and could materially affect future results of operations.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Government investigations and actions could result in substantial fines and/or criminal charges and civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements and other disciplinary actions, as well as reputational harm, including as a result of increased public interest in the matter. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our sales and marketing activities and the pricing of our products are subject to extensive regulation under the FFDCA, the Medicaid Drug Rebate Program, the FCPA and other federal and state statutes, including those discussed elsewhere in this Form 10-K, as well as the Anti-Kickback Statute, anti-bribery laws, the False Claims Act, and similar laws in international jurisdictions. In addition to the potential for changes to relevant laws, the compliance and enforcement landscape is informed by government litigation, settlement precedent, advisory opinions, and special fraud alerts. Our approach to certain practices may evolve over time in light of these types of developments. Requirements or industry standards in the U.S. and certain jurisdictions abroad require pharmaceutical manufacturers to track and disclose financial interactions with healthcare professionals and healthcare providers and can increase government and public scrutiny of such financial interactions. If an interaction is found to be improper, government enforcement actions and penalties could result. Like many companies in our industry, we have from time-to-time received, and may receive in the future, inquiries and subpoenas and other types of information demands from government authorities. In addition, we have been subject to claims and other actions related to our business activities, brought by governmental authorities, as well as consumers and private payers. In some instances, we have incurred significant expense, civil payments, fines and other adverse consequences as a result of these claims, actions and inquiries. Such claims, actions and inquiries may relate to alleged non-compliance with laws and regulations associated with the dissemination of product (approved and unapproved) information, potentially resulting in government enforcement action and reputational damage. This risk may be heightened by digital marketing, including social media, mobile applications and blogger outreach.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the resolution of a U.S. government investigation concerning independent copay assistance organizations that provide financial assistance to Medicare patients, in 2018, we entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the U.S. Department of Health and Human Services, which is effective for a period of five years. In the CIA, we agreed to implement and/or maintain certain compliance program elements to promote compliance with federal healthcare program requirements. Breaches of the CIA could result in severe sanctions against us.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are also subject to numerous contingencies arising in the ordinary course of business relating to legal claims and proceedings, including environmental contingencies. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. While we have accrued for worldwide legal liabilities, no guarantee exists that additional costs will not be incurred beyond the amounts accrued. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, including information regarding certain legal proceedings in which we are involved in, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATED TO INTELLECTUAL PROPERTY, TECHNOLOGY AND SECURITY:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY PROTECTION</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from launching generic or biosimilar versions of our branded products, from using our proprietary technologies or from marketing products that are very similar or identical to ours. Our currently pending or future patent applications may not result in issued patents or be granted on a timely basis. Similarly, any term extensions that we seek may not be granted on a timely basis, if at all. For example, in May 2021, the Brazilian Supreme Court voted to invalidate Article 40 of Brazil&#8217;s Patent Law, which guaranteed a minimum 10-year patent term from patent grant, and to give retroactive effect to such decision. In addition, our issued patents may not contain claims sufficiently broad to protect us against claims regarding validity, enforceability, scope and effective term made by parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particular product area. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Further, legal or regulatory action by various stakeholders or governments could potentially result in us not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our products. Discussions are ongoing at the WTO regarding the role of intellectual property in the context of the COVID-19 pandemic response. This includes a proposal that would release WTO members from their obligation under WTO-TRIPS to grant and enforce various types of intellectual property protection on health products and technology in relation to the prevention, containment or treatment of COVID-19. In May 2021 and again in November 2021, the Biden Administration called on countries to waive intellectual property protections on COVID-19 vaccines.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The scope of our patent claims also may vary between countries, as individual countries have distinct patent laws, and our ability to enforce our patents depends on the laws of each country, its enforcement practices, and the extent to which certain countries engage in policies or practices that weaken a country&#8217;s intellectual property framework (e.g., laws or regulations that promote or provide broad discretion to issue a compulsory license). In countries that provide some form of regulatory exclusivity, mechanisms exist permitting some form of challenge to our patents by competitors or generic drug marketers prior to or immediately following the expiration of such regulatory exclusivity, and generic companies are employing aggressive strategies, such as &#8220;at risk&#8221; launches that challenge our patent rights. Most of the suits involve claims by generic drug manufacturers that patents covering our products, uses, processes or dosage forms are invalid and/or do not cover the product of the generic or biosimilar drug manufacturer. Independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. Such claims may also be brought as counterclaims to actions we bring to enforce our patents. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents or a competitors&#8217; patents is found to be invalid in such proceedings, generic or biosimilar products could be introduced into the market resulting in the erosion of sales of our existing products. For additional information, including information regarding certain legal proceedings in which we are involved, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16A1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Further, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties grant us rights to intellectual property, our operating results and financial condition could be adversely affected. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We currently hold trademark registrations and have trademark applications pending in many jurisdictions, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors increases and, as a result, our business could be adversely affected if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our rights. We seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their relationship with us. Despite these efforts and precautions, we may be unable to prevent a third-party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization, and legal remedies may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">THIRD-PARTY INTELLECTUAL PROPERTY CLAIMS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A properly functioning intellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights of other companies, but the patent granting process is imperfect. Accordingly, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by others that we believe were improperly granted, including challenges through negotiation and litigation, and such challenges may not always be successful.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Part of our business depends upon identifying biosimilar opportunities and launching products to take advantage of those opportunities, which may involve litigation, associated costs and time delays, and may ultimately not be successful. These opportunities may arise in situations where patent protection of equivalent branded products has expired or been declared invalid, or where products do not infringe the patents of others. In some circumstances we may take action, such as litigation, asserting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable in order to achieve a &#8220;first-to-market&#8221; or early market position for our products.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Third parties may claim that our products infringe one or more patents owned or controlled by them. Claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant royalty payments or damages. </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For example, our R&amp;D in a therapeutic area may not be first and another company or entity may have obtained relevant patents before us. We are involved in patent-related disputes with third parties over our attempts to market pharmaceutical products. Once we have final regulatory approval of the related products, we may decide to commercially market these products even though associated legal proceedings (including any appeals) have not been resolved (i.e., &#8220;at-risk&#8221; launch). If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">INFORMATION TECHNOLOGY AND SECURITY </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Significant disruptions of information technology systems or breaches of information security could adversely affect our business. We extensively rely upon sophisticated information technology systems (including cloud services) to operate our business. We produce, collect, process, store and transmit large amounts of confidential information (including personal information and intellectual property), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality, integrity and availability of such confidential information. We have outsourced significant elements of our operations, including significant elements of our information technology infrastructure and, as a result, we manage relationships with many third-party providers who may or could have access to our confidential information. We rely on technology developed, supplied and/or maintained by third-parties that may make us vulnerable to &#8220;supply chain&#8221; style cyber-attacks. Further, technology and security vulnerabilities of acquisitions, business partners or third-party providers may not be identified during due diligence or soon enough to mitigate exploitation. The size and complexity of our information technology and information security systems, and those of our third-party providers (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or contingent workers, providers, or malicious attackers. As a global pharmaceutical company, our systems and assets are the target of frequent cyber-attacks. Such cyber-attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. Due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. While we have invested in the protection of data and information technology, our efforts may not prevent service interruptions, extortion, theft of confidential or proprietary information, compromise of data integrity or unauthorized information disclosure. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">RISKS RELATED TO BUSINESS DEVELOPMENT:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">BUSINESS DEVELOPMENT ACTIVITIES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We expect to enhance our in-line products and product pipeline through various forms of business development, which can include alliances, licenses, JVs, collaborations, equity- or debt-based investments, dispositions, divestments, mergers and acquisitions. The success of these activities is dependent on the availability and accurate cost/benefit evaluation of appropriate opportunities, competition from others that are seeking similar opportunities and our ability to successfully identify, structure and execute transactions, including the ability to satisfy closing conditions in the anticipated timeframes or at all, and successfully integrate acquisitions. Pursuing these opportunities may require us to obtain additional equity or debt financing, which could result in increased leverage and/or a downgrade of our credit ratings. Where we acquire debt or equity securities as all or part of the consideration for business development activities, the value of those securities will fluctuate, and may depreciate. We may not control a company in which we invest, and, as a result, we will have limited ability to determine its management, operational decisions and policies. Further, while we seek to mitigate risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such efforts fail to discover, that are not disclosed to us, or that we inadequately assess. The success of any of our acquisitions will depend, when applicable, on our ability to realize anticipated benefits from integrating these businesses with us. We, for example, may fail to achieve cost savings anticipated with certain of these acquisitions, or such cost savings within the expected time frame. Similarly, the accretive impact anticipated from certain of these acquisitions may not be realized or may be delayed. Integration of these businesses may result in the loss of key employees, the disruption of ongoing business, including third-party relationships, or inconsistencies in standards, controls, procedures and policies. We also may fail to generate the expected revenue growth for the acquired business. Expected revenue from acquired products and product candidates also may be constrained by developments outside of our control. Unsuccessful clinical trials, regulatory hurdles and commercialization challenges may adversely impact revenue and income contribution from products and product candidates, including those acquired in these acquisitions. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SPIN-OFF AND COMBINATION OF UPJOHN WITH MYLAN</span></div><div style="margin-top:8pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may not realize some or all of the expected benefits of the spin-off and combination (the Transactions) of the Upjohn Business with Mylan, which resulted in the creation of Viatris in November 2020, due to many factors, including, among others, strategic adjustments required to reflect the nature of our business following the Transactions, increased risks resulting from us becoming a company that is a more focused, innovative science-based biopharmaceutical products business and the possibility that we may not achieve our strategic objectives. In addition, we have agreed to provide certain transition services to Viatris, generally for an initial period of 24 months following the completion of the Transactions (with certain possibilities for extension). These obligations under the transition services agreements may divert our focus and resources that would otherwise be invested into maintaining or growing our business. </span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CONSUMER HEALTHCARE JV WITH GSK</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, we and GSK combined our respective consumer healthcare businesses into a JV that operates globally under the GSK Consumer Healthcare name. Although we have certain consent, board representation and other governance rights, we are a minority owner of the JV and do not control the JV, its management or its policies. As a result, our ability to realize the anticipated benefits of the transaction depend upon GSK&#8217;s operation and management of the JV. In addition, the JV is subject to risks that are different than the risks associated with our business. Many of these risks are outside GSK&#8217;s or the JV&#8217;s control and could materially impact the business, financial condition and results of operations of the JV.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2021, GSK announced that it intends to demerge at least 80% of its 68% ownership interest in the JV in mid-2022, subject to GSK shareholder approval. Following the demerger, the JV is expected to be an independent, listed company on the London Stock Exchange with American Depositary Receipts to be listed in the U.S., in which Pfizer would initially hold a 32% ownership interest and GSK may hold up to a 13.6% ownership interest. Notwithstanding GSK&#8217;s announcement, the demerger may not be completed within expected time periods or at all, and both the timing and success of the demerger (or any other separation and public listing transaction), will be subject to prevailing market conditions and other factors at the time of such transaction. Any future distribution or sale of our stake in the JV will similarly be subject to prevailing market conditions and other factors at the time of such transaction. Our ability to complete any such future distribution or sale may also be impacted by the size of our retained stake at the time. The uncertainty relating to any separation and public listing transactions (including the announced demerger), their implementation, their timing and their yet to be determined effects on the JV&#8217;s business may subject us and the JV to risks and uncertainties that may adversely affect our business and financial results.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL RISKS:</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COVID-19 PANDEMIC</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business, operations and financial condition and results have been and may continue to be impacted by the COVID-19 pandemic to varying degrees. The pandemic has presented a number of risks and challenges for our business, including, among others: impacts due to travel limitations and mobility restrictions; manufacturing disruptions and delays; supply chain disruptions and shortages, including challenges related to reliance on third-party suppliers resulting in reduced availability of materials or components used in the development, manufacturing, distribution or administration of our products; disruptions to pipeline development and clinical trials, including difficulties or delays in enrolling certain clinical trials, retaining clinical trial participants, accessing needed supplies, and accruing a sufficient number of cases in certain clinical trials; decreased product demand, due to reduced numbers of in-person meetings with prescribers, patient visits with physicians, vaccinations and elective surgeries, resulting in fewer new prescriptions or refills of existing prescriptions and reduced demand for products used in procedures; reduced product demand as a result of unemployment or increased focus on COVID-19 vaccination; challenges presented by reallocating personnel and R&amp;D, manufacturing and other resources to assist in responding to the pandemic; costs associated with the COVID-19 pandemic, including practices intended to reduce the risk of transmission, increased supply chain costs and additional R&amp;D costs incurred in our efforts to develop a vaccine to help prevent COVID-19 and an oral COVID-19 treatment; challenges related to our business development initiatives, including potential delays or disruptions related to regulatory approvals; interruptions or delays in the operations of regulatory authorities, which may delay potential approval of new products we are developing, potential label expansions for existing products and the launch of newly-approved products; challenges operating in a virtual work environment; increased cyber incidents such as phishing, social engineering and malware attacks; challenges related to our intellectual property, both domestically and internationally, including in response to any pressure or legal or regulatory action that could potentially result in us not seeking intellectual property protection for, licensing, or agreeing not to enforce or being restricted from enforcing, intellectual property rights related to our products, including our vaccine to help prevent COVID-19 and an oral COVID-19 treatment; challenges related to conducting oversight and monitoring of regulated activities in a remote or virtual environment; challenges related to our human capital and talent development, including challenges in attracting, hiring and retaining highly skilled and diverse workforce; challenges related to vaccine mandates; and other challenges presented by disruptions to our normal operations in response to the pandemic, as well as uncertainties regarding the duration and severity of the pandemic and its impacts, and government or regulatory actions to contain the virus or control the supply of medicines and vaccines.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also face risks and uncertainties related to our efforts to develop and commercialize a vaccine to help prevent COVID-19 and an oral COVID-19 treatment, as well as challenges related to their manufacturing, supply and distribution, including, among others: </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">uncertainties inherent in R&amp;D, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with pre-clinical and clinical data (including the Phase 1/2/3 or Phase 4 data for BNT162b2 or any other vaccine candidate in the BNT162 program or Paxlovid or any other future COVID-19 treatment) in any of our studies in pediatrics, adolescents or adults or real world evidence, including the possibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the ability to produce comparable clinical or other results for BNT162b2 or Paxlovid, including the rate of effectiveness and/or efficacy, safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial for BNT162b2 or Paxlovid and additional studies, in real-world data studies or in larger, more diverse populations following commercialization; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the ability of BNT162b2 or any future vaccine to prevent, or Paxlovid or any other future COVID-19 treatment to be effective against, COVID-19 caused by emerging virus variants; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that more widespread use of the vaccine or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of which may be serious; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">whether and when additional data from the BNT162 mRNA vaccine program, Paxlovid or other programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">whether regulatory authorities will be satisfied with the design of and results from these and any future pre-clinical and clinical studies; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">whether and when submissions to request emergency use or conditional marketing authorizations for BNT162b2 or any potential future vaccines in additional populations, for a booster dose for BNT162b2 or any potential future vaccines (including potential future annual boosters or re-vaccinations), and/or biologics license and/or EUA applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines, and if obtained, whether or when such EUA or licenses will expire or terminate; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">whether and when submissions to request emergency use or conditional marketing authorizations for Paxlovid or any other future COVID-19 treatment and/or any drug applications for any indication for Paxlovid or any other future COVID-19 treatment may be filed in any jurisdiction, and if obtained, whether or when such EUA or licenses will expire or terminate; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">whether and when any application that may be pending or filed for BNT162b2 or other vaccines that may result from the BNT162 program, Paxlovid or any other future COVID-19 treatment or any other COVID-19 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine&#8217;s or drug&#8217;s benefits outweigh its known risks and determination of the vaccine&#8217;s or drug&#8217;s efficacy and, if approved, whether it will be commercially successful; </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine or drug, including development of products or therapies by other companies;</span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including our relationship with BioNTech; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that other companies may produce superior or competitive products; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that demand for any products may be reduced or no longer exist; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the possibility that COVID-19 will diminish in severity or prevalence, or disappear entirely; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">risks related to the availability of raw materials to manufacture or test any such products; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">challenges related to our vaccine&#8217;s formulation, dosing schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by us; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that we may not be able to successfully develop other vaccine formulations, booster doses or potential future annual boosters or re-vaccinations or new variant-specific vaccines; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that we may not be able to recoup costs associated with our R&amp;D and manufacturing efforts; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">risks associated with any changes in the way we approach or provide research funding for the BNT162 program, Paxlovid or any other COVID-19 program; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">challenges and risks associated with the pace of our development programs; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the risk that we may not be able to maintain or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine or any treatment for COVID-19, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine or treatment courses of Paxlovid within the projected time periods; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">whether and when additional supply or purchase agreements will be reached; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">uncertainties regarding the ability to obtain recommendations from vaccine or treatment advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">pricing and access challenges for such products; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">challenges related to public confidence or awareness of our COVID-19 vaccine or Paxlovid, including challenges driven by misinformation, access, concerns about clinical data integrity and prescriber and pharmacy education; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">trade restrictions; </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">potential third-party royalties or other claims related to our COVID-19 vaccine or Paxlovid; and</span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">competitive developments.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Further, the COVID-19 pandemic, and the volatile global economic conditions stemming from the pandemic, could precipitate or amplify the other risks that we identify in this Risk Factors section, which could adversely affect our business, operations and financial condition and results.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are continuing to monitor the latest developments regarding the COVID-19 pandemic and its effects on our business, operations and financial condition and results, and have made certain assumptions regarding the COVID-19 pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration, severity and the global macroeconomic impact of the pandemic, as well as COVID-19 vaccine and oral COVID-19 treatment supply and contracts, which remain dynamic. Despite careful tracking and planning, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. In particular, we believe the ultimate impact on our business, operations and financial condition and results will be affected by the speed and extent of the continued spread of the coronavirus globally, the emergence of additional virus variants, the duration of the pandemic, new information regarding the severity and incidence of COVID-19, the safety, efficacy and availability of vaccines and treatments for COVID-19, the rate at which the population becomes vaccinated against COVID-19, the global macroeconomic impact of the pandemic and governmental or regulatory actions to contain the virus or control supply of medicines and vaccines. The pandemic may also affect our business, operations or financial condition and results in a manner that is not presently known to us or that we currently do not consider as presenting significant risks.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">MARKET FLUCTUATIONS IN OUR EQUITY AND OTHER INVESTMENTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in fair value of certain equity investments need to be recognized in net income that may result in increased volatility of our income. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our pension benefit obligations and postretirement benefit obligations are subject to volatility from changes in fair value of equity investments and other investment risk in the assets funding these plans. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Benefit Plans </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 11.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COST AND EXPENSE CONTROL AND NONORDINARY EVENTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Growth in costs and expenses, changes in product and geographic mix and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product withdrawals, recalls and other unusual events that could result from evolving business strategies, evaluation of asset realization and organizational restructuring could adversely affect future results. Such risks and uncertainties include, in particular, our ability to realize the projected benefits of our cost-reduction and productivity initiatives, other corporate strategic initiatives and any acquisitions, divestitures or other initiatives, as well as potential disruption of ongoing business.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our consolidated balance sheet contains significant amounts of intangible assets, including IPR&amp;D and goodwill. For IPR&amp;D assets, the risk of failure is significant, and there can be no certainty that these assets ultimately will yield successful products. Our ability to realize value on these significant investments is often contingent upon, among other things, regulatory approvals and market acceptance. As such, we expect that many of these IPR&amp;D assets will become impaired and/or be written off at some time in the future if the associated R&amp;D effort is abandoned or is curtailed. For goodwill, all reporting units can confront events and circumstances that can lead to a goodwill impairment charge such as, among other things, unanticipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in the </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">business climate and/or a failure to replace the contributions of products that lose exclusivity. Our other intangible assets, including developed technology rights and brands, face similar risks for impairment. Our equity-method investments may also be subject to impairment charges that may result from the occurrence of unexpected adverse events or management decisions that impact our estimates of expected cash flows to be generated from these investments. We may recognize impairment charges as a result of a weak economic environment, events related to particular customers or asset types, challenging market conditions or decisions by management. Any such impairment charge of our intangible assets, goodwill and equity-method investments may be significant. For additional details, see the S</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">ignificant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CHANGES IN LAWS AND ACCOUNTING STANDARDS</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our future results could be adversely affected by changes in laws and regulations or their interpretation, including, among others, changes in accounting standards, tax laws and regulations internationally and in the U.S. (including, among other things, any potential adoption of global minimum taxation requirements and any potential changes to existing tax law and regulations by the Biden Administration and Congress), competition laws, privacy laws and environmental laws in the U.S. and other countries. For additional information on changes in tax laws or rates or accounting standards, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(Benefit) for Taxes on Income </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> New Accounting Standards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_70"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTIES</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We own and lease space globally for sales and marketing, customer service, regulatory compliance, R&amp;D, manufacturing and distribution and corporate enabling functions. In many locations, our business and operations are co-located to achieve synergy and operational efficiencies. Our global headquarters are located in New York City. We continue to advance our global workplace strategy to provide workplaces that enable collaboration and foster innovation. As of December 31, 2021, we had 327 owned and leased properties, amounting to approximately 41 million square feet.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We expect to relocate our global headquarters to the Spiral, an office building in the Hudson Yards neighborhood of New York City, with occupancy expected beginning in the second half of 2022. In April 2018, we entered into an agreement to lease space at this property. In July 2018, we completed the sale of our current headquarters in New York City. We remain in a lease-back arrangement with the buyer while we complete our relocation. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our PGS platform function is headquartered in various locations, with leadership teams primarily in New York City and in Peapack, New Jersey. As of December 31, 2021, PGS had responsibility for 39 plants around the world, including in Belgium, Germany, India, Ireland, Italy, Japan, Singapore and the U.S., which manufacture products for our business. PGS expects to exit three of these sites over the next several years. PGS also operates multiple distribution facilities around the world.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In general, we believe that our properties, including the principal properties described above, are well-maintained, adequate and suitable for their current requirements and for our operations in the foreseeable future. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 9 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for amounts invested in land, buildings and equipment. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_73"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LEGAL PROCEEDINGS</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain legal proceedings in which we are involved are discussed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_76"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">INFORMATION ABOUT OUR EXECUTIVE OFFICERS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The executive officers of the Company are set forth in this table. Each holds the office or offices indicated until his or her successor is chosen and qualified at the regular meeting of the BOD to be held on the date of the 2022 Annual Meeting of Shareholders, or until his or her earlier death, resignation or removal. Each of the executive officers is a member of the Pfizer Executive Leadership Team.</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Albert Bourla</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018. Group President, Pfizer Innovative Health from June 2016 until December 2017. Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Our Director since February 2018. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">William Carapezzi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Executive Vice President, Global Business Services and Transformation since June 2020. Senior Vice President of Global Business Operations from June 2013 until June 2020. Senior Vice President of Global Tax from 2008 until June 2013.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Frank A. D&#8217;Amelio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Financial Officer, Executive Vice President since January 2022. Chief Financial Officer and Executive Vice President, Global Supply from June 2020 until December 2021. Chief Financial Officer, Executive Vice President, Business Operations and Global Supply from November 2018 until June 2020. Executive Vice President, Business Operations and Chief Financial Officer from December 2010 until October 2018. Senior Vice President and Chief Financial Officer from September 2007 until December 2010. Director of Zoetis Inc. and Humana Inc. and Chair of the Humana Inc. Board of Directors&#8217; Audit Committee. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mikael Dolsten</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Scientific Officer, President, Worldwide Research, Development and Medical since January 2019. President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research &amp; Development Group from October 2009 until May 2010. Director of Agilent Technologies, Inc, and Vimian Group AB.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:14.681%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lidia Fonseca</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of Laboratory Corporation of America Holdings from 2008 until March 2013. Director of Tegna, Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Angela Hwang</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Group President, Pfizer Biopharmaceuticals Group since January 2019. Group President, Pfizer Essential Health from January 2018 until December 2018. Global President, Pfizer Inflammation and Immunology from January 2016 until December 2017. Regional Head, U.S. Vaccines from January 2014 until December 2015. Vice President, Emerging Markets for the Primary Care therapeutic area from September 2011 until December 2013. Director of United Parcel Service, Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rady A. Johnson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Compliance, Quality and Risk Officer, Executive Vice President since January 2019. Executive Vice President, Chief Compliance and Risk Officer from December 2013 until December 2018. Senior Vice President and Associate General Counsel from October 2006 until December 2013.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Douglas M. Lankler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">General Counsel, Executive Vice President since December 2013. Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013. Executive Vice President, Chief Compliance Officer from December 2010 until February 2011. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aamir Malik</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Business Innovation Officer, Executive Vice President since August 2021. Various U.S. geographic leadership roles with McKinsey &amp; Company from 2019 to 2021; previously co-led McKinsey &amp; Company&#8217;s Global Pharmaceuticals &amp; Medical Products practice from 2015 to 2018. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michael McDermott</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Global Supply Officer, Executive Vice President since January 2022. President of Pfizer Global Supply from 2018 until 2021. Vice President of Pfizer Global Supply from 2014 until 2018. Vice President of the Biotechnology Unit from 2012 until 2014. </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payal Sahni</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief People Experience Officer, Executive Vice President since January 2022. Chief Human Resources Officer, Executive Vice President from June 2020 to December 2021. From May 2016 until June 2020 served as Senior Vice President of Human Resources for multiple operating units. Vice President of Human Resources, Vaccines, Oncology &amp; Consumer from 2015 until 2016. Ms. Sahni has served in a number of positions in the Human Resources organization with increasing responsibility since joining Pfizer in 1997.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sally Susman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Chief Corporate Affairs Officer, Executive Vice President since January 2019. Executive Vice President, Corporate Affairs (formerly Policy, External Affairs and Communications) from December 2010 until December 2018. Senior Vice President, Policy, External Affairs and Communications from December 2009 until December 2010. Director of WPP plc.</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_79"></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.111%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART II</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_82"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MARKET FOR THE COMPANY&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The principal market for our common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol &#8220;PFE&#8221;. As of February&#160;22, 2022, there were 133,758 holders of record of our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following summarizes purchases of our common stock during the fourth quarter of 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:36.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.227%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid&#160;per</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased&#160;as<br/>Part of Publicly<br/>&#160;&#160;&#160;&#160;Announced&#160;Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Value of Shares</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">that May Yet Be Purchased</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Under&#160;the&#160;Plan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 4 through October 31, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,817</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.74&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,292,881,709&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 1 through November 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,687</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,292,881,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 1 through December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,186</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,292,881,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,690&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.27&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents (i) 44,604 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 2,086 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">24</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PEER GROUP PERFORMANCE GRAPH</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following graph assumes a $100 investment on December 31, 2016, and reinvestment of all dividends, in each of the Company&#8217;s Common Stock, the S&amp;P 500 Index, and a composite peer group of the major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson &amp; Johnson, Merck &amp; Co., Inc., Novartis AG, Roche Holding AG and Sanofi SA.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="pfe-20211231_g4.jpg" alt="pfe-20211231_g4.jpg" style="height:450px;margin-bottom:5pt;vertical-align:text-bottom;width:609px"/></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Five Year Performance</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.795%"><tr><td style="width:1.0%"></td><td style="width:14.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.662%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PFIZER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$115.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$144.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$134.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$139.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$232.0</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PEER GROUP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$117.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$126.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$154.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$160.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$186.9</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P&#160;500&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.0</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$121.8</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$116.5</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$153.1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$181.3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$233.3</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_88"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">[RESERVED]</span></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span><br/></span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_91"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:7.184%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_94"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial Highlights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following is a summary of certain financial performance metrics (in billions, except per share data):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Total Revenues&#8211;&#8211;$81.3 billion</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Net Cash Flow from Operations&#8211;&#8211;$32.6 billion</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">An increase of 95% compared to 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">An increase of 126% compared to 2020</span></td></tr></table></div><div style="text-align:center"><img src="pfe-20211231_g5.jpg" alt="pfe-20211231_g5.jpg" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/><img src="pfe-20211231_g6.jpg" alt="pfe-20211231_g6.jpg" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:250.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Reported Diluted EPS&#8211;&#8211;$3.85</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Adjusted Diluted EPS (Non-GAAP)&#8211;&#8211;$4.42*</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">An increase of 137% compared to 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">An increase of 96% compared to 2020</span></td></tr></table></div><div style="text-align:center"><img src="pfe-20211231_g7.jpg" alt="pfe-20211231_g7.jpg" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/><img src="pfe-20211231_g8.jpg" alt="pfe-20211231_g8.jpg" style="height:138px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.28pt">For additional information regarding Adjusted diluted EPS (which is a non-GAAP financial measure), including reconciliations of certain GAAP reported to non-GAAP adjusted information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> section within MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of our business, they are not within our control and since they can mask positive or negative trends in the business, we believe presenting operational variances excluding these foreign exchange changes provides useful information to evaluate our results.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our Business and Strategy</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Most of our revenues come from the manufacture and sale of biopharmaceutical products. With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our former Upjohn Business in the fourth quarter of 2020, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines and beginning in the fourth quarter of 2020 operated as a single operating segment engaged in the discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products worldwide. At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments: Biopharma and PC1. Biopharma is the only reportable segment. On December 31, 2021, we completed the sale of our Meridian subsidiary, and beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and the Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organizational structure. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Item 1. Business&#8211;&#8211;Commercial Operations </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of this Form 10-K for additional information. We expect to incur costs of approximately $700 million in connection with separating Upjohn, of which, approximately 75% has been incurred since inception and through December 31, 2021. These charges include costs and expenses related to separation of legal entities and transaction costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transforming to a More Focused Company: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have undertaken efforts to ensure our cost base and support model align appropriately with our new operating structure. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;D and PGS platform functions. In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section of this MD&amp;A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">R&amp;D:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> We believe we have a strong pipeline and are well-positioned for future growth. R&amp;D is at the heart of fulfilling our purpose to deliver breakthroughs that change patients&#8217; lives as we work to translate advanced science and technologies into the therapies that may be the most impactful for patients. Innovation, drug discovery and development are critical to our success. In addition to discovering and developing new </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">products, our R&amp;D efforts seek to add value to our existing products by improving their effectiveness and ease of dosing and by discovering potential new indications. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and Development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">section</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">of this Form 10-K for our R&amp;D priorities and strategy. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We seek to leverage a strong pipeline, organize around expected operational growth drivers and capitalize on trends creating long-term growth opportunities, including:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an aging global population that is generating increased demand for innovative medicines and vaccines that address patients&#8217; unmet needs;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">advances in both biological science and digital technology that are enhancing the delivery of breakthrough new medicines and vaccines; and</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the increasingly significant role of hospitals in healthcare systems.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our Business Development Initiatives</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are committed to strategically capitalizing on growth opportunities, primarily by advancing our own product pipeline and maximizing the value of our existing products, but also through various business development activities. We view our business development activity as an enabler of our strategies and seek to generate growth by pursuing opportunities and transactions that have the potential to strengthen our business and our capabilities. We assess our business, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will help advance our business strategy.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our significant recent business development activities that closed or are targeted to close in 2022 include:</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Arena</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In December 2021, we and Arena announced that the companies entered into a definitive agreement under which we will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, we will acquire all outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7 billion. On February 2, 2022, Arena shareholders voted to approve the proposed acquisition, which is targeted to close in the first half of 2022, subject to review under antitrust laws and other customary closing conditions.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration with Biohaven</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2021, we entered into a collaboration and license agreement and related sublicense agreement with Biohaven Pharmaceutical Holding Company Ltd., Biohaven Pharmaceutical Ireland DAC and BioShin Limited (collectively, Biohaven) pursuant to which we acquired rights to commercialize rimegepant and zavegepant for the treatment and prevention of migraines outside of the U.S., subject to regulatory approval. Rimegepant is currently commercialized in the U.S., Israel, and the U.A.E. under the brand name Nurtec</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ODT, with certain additional applications pending outside of the U.S. Biohaven will continue to lead R&amp;D globally and we have the exclusive right to commercialization globally, outside of the U.S. Upon the closing of the transaction, which occurred on January&#160;4, 2022, we paid Biohaven $500 million, including an upfront payment of $150 million and an equity investment of $350 million. Biohaven is also eligible to receive up to $740 million in non-U.S. commercialization milestone payments, in addition to tiered double-digit royalties on net sales outside of the U.S. In addition to the milestone payments and royalties above, we will also reimburse Biohaven for the portion of certain additional milestone payments and royalties due to third parties in accordance with preexisting Biohaven agreements, which are attributed to ex-U.S. sales.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, including discussion of recent significant business development activities, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our 2021 Performance</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increased $39.6 billion, or 95%, to $81.3 billion in 2021 from $41.7 billion in 2020, reflecting an operational increase of $38.4 billion, or 92%, as well as a favorable impact of foreign exchange of $1.2 billion, or 3%. Excluding direct sales and alliance revenues of Comirnaty and sales of Paxlovid, revenues increased 6% operationally, reflecting strong growth in Eliquis, Biosimilars, PC1, Vyndaqel/Vyndamax, the Hospital therapeutic area, Inlyta and Xtandi, partially offset by declines in the Prevnar family, Chantix/Champix, Enbrel and Sutent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines the components of the net change in revenues:</span></div><div style="margin-top:3pt;text-align:center"><img src="pfe-20211231_g9.jpg" alt="pfe-20211231_g9.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues by Geography</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues&#8211;&#8211;Selected Product Discussion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections within MD&amp;A for more information, including a discussion of key drivers of our revenue performance. For information regarding the primary indications or class of certain products, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17C.</span></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of $17.3 billion in 2021, compared to 2020, was primarily attributable to: (i) higher revenues, (ii) net periodic benefit credits in 2021 versus net periodic benefit costs in 2020, (iii) lower asset impairment charges, and (iv) higher net gains on equity securities, partially offset by (v) increases in: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Selling, informational and administrative expenses.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Analysis of the Consolidated Statements of Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on our tax provision and effective tax rate, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(Benefit) for Taxes on Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Our Operating Environment</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We, like other businesses in our industry, are subject to certain industry-specific challenges. These include, among others, the topics listed below. See also the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">sections of this Form 10-K.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment&#8211;&#8211;Pipeline Productivity</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our product lines must be replenished to offset revenue losses when products lose exclusivity or market share or to respond to healthcare and innovation trends, as well as to provide for earnings growth. As a result, we devote considerable resources to our R&amp;D activities which, while essential to our growth, incorporate a high degree of risk and cost, including whether a particular product candidate or new indication for an in-line product will achieve the desired clinical endpoint or safety profile, will be approved by regulators or will be successful commercially. We conduct clinical trials to provide data on safety and efficacy to support the evaluation of a product&#8217;s overall benefit-risk profile for a particular patient population. In addition, after a product has been approved or authorized and launched, we continue to monitor its safety as long as it is available to patients. This includes postmarketing trials that may be conducted voluntarily or pursuant to a regulatory request to gain additional medical knowledge. For the entire life of the product, we collect safety data and report safety information to the FDA and other regulatory authorities. Regulatory authorities may evaluate potential safety concerns and take regulatory actions in response, such as updating a product&#8217;s labeling, restricting its use, communicating new safety information to the public, or, in rare cases, requiring us to suspend or remove a product from the market. The commercial potential of in-line products may be negatively impacted by post-marketing developments.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Intellectual Property Rights and Collaboration/Licensing Rights</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues. Certain of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face increased generic competition over the next few years. While additional patent expiries will continue, we expect a moderate impact of reduced revenues due to patent expiries from 2022 through 2025. We continue to vigorously defend our patent rights against infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to help ensure appropriate patient access.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on patent rights we consider most significant to our business as a whole, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8211;&#8211;Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K. For a discussion of recent developments with respect to patent litigation, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16A1.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Environment/Pricing and Access&#8211;&#8211;Government and Other Payer Group Pressures</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The pricing of medicines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, medical services and hospital services, continues to be important to payers, governments, patients, and other stakeholders. Federal and state governments and private third-party payers in the U.S. continue to take action to manage the utilization of drugs and cost of drugs, including increasingly employing formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. We consider a number of factors impacting the pricing of our medicines and vaccines. Within the U.S., we often engage with patients, doctors and healthcare plans. We also often provide significant discounts from the list price to insurers, including PBMs and MCOs. The price that patients pay in the U.S. for prescribed medicines and vaccines is ultimately set by healthcare providers and insurers. Governments globally may use a variety of measures to control costs, including proposing pricing reform or legislation, cross country collaboration and procurement, price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), QCE processes and VBP. In the U.S., we expect to see continued focus by Congress and the Biden Administration on regulating pricing which could result in legislative and regulatory changes designed to control costs. For example, there is proposed legislation that, if enacted, would allow Medicare to negotiate prices for certain prescription drugs, as well as require that penalties be paid by manufacturers who raise drug prices faster than inflation. Also, certain changes proposed by the CMS in December 2020 to the Medicaid program and 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities, could increase our Medicaid rebate obligations and increase the discounts we extend to 340B covered entities if they go into effect. Additional changes to the 340B program are undergoing review and their status is unclear. We anticipate that these and similar initiatives will continue to increase pricing pressures globally. For additional information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Pricing Pressures and Managed Care Organizations </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">and &#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Government Regulation and Price Constraints</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> sections in this Form 10-K.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Product Supply</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We periodically encounter supply delays, disruptions or shortages, including due to voluntary product recalls such as our recent Chantix recall. For information on our recent Chantix recall and risks related to product manufacturing, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8211;&#8211;Product Manufacturing, Sales and Marketing Risks</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">The Global Economic Environment</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition to the industry-specific factors discussed above, we, like other businesses of our size and global extent of activities, are exposed to economic cycles. Certain factors in the global economic environment that may impact our global operations include, among other things, currency fluctuations, capital and exchange controls, global economic conditions including inflation, restrictive government actions, changes in intellectual property, legal protections and remedies, trade regulations, tax laws and regulations and procedures and actions affecting approval, </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">production, pricing, and marketing of, reimbursement for and access to our products, as well as impacts of political or civil unrest or military action, including the current conflict between Russia and Ukraine, terrorist activity, unstable governments and legal systems, inter-governmental disputes, public health outbreaks, epidemics, pandemics, natural disasters or disruptions related to climate change. Government pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria or other means of cost control.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The COVID-19 pandemic has impacted our business, operations and financial condition and results.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Our Response to COVID-19</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer has helped lead the global effort to confront the COVID-19 pandemic by advancing a vision for industry-wide collaboration while making significant investments in breakthrough science and global manufacturing.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Comirnaty/BNT162b2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">We have collaborated with BioNTech to jointly develop Comirnaty/BNT162b2, a mRNA-based coronavirus vaccine to help prevent COVID-19. The FDA has approved Comirnaty in the U.S. to prevent COVID-19 in individuals 16 years of age and older as a two-dose primary series (30 &#181;g per dose). Comirnaty is the first COVID-19 vaccine to be granted approval by the FDA and had previously been available to this patient population in the U.S. under an EUA since December 2020. The vaccine is also available to individuals 5 to 15 years old under an EUA granted by the FDA in 2021 (10 &#181;g per dose for children 5 through 11 years of age (October 2021) and 30 &#181;g per dose for individuals 12 years of age and older (May 2021)). The FDA has also authorized for emergency use: (i) a third dose of Comirnaty/BNT162b2 in certain immunocompromised individuals 5 years of age and older and (ii) Comirnaty/BNT162b2 as a booster dose in individuals 12 years of age and older. Comirnaty/BNT162b2 has also been granted an approval or an authorization in many other countries around the world in populations varying by country. We continue to evaluate our vaccine, including for additional pediatric indications, and the short- and long-term efficacy of Comirnaty. We are also studying vaccine candidates to potentially prevent COVID-19 caused by new and emerging variants, such as the Omicron variant, or an updated vaccine as needed.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">In 2021, we manufactured more than three billion doses and, in fiscal 2021, delivered 2.2 billion doses around the world. Pfizer and BioNTech expect we can manufacture up to four billion doses in total by the end of 2022. The companies have entered into agreements to supply pre-specified doses of Comirnaty in 2022 with multiple developed and emerging countries around the world and are continuing to deliver doses of Comirnaty to governments under such agreements. We also signed agreements with multiple countries to supply Comirnaty doses in 2023 and are currently negotiating similar potential agreements with multiple other countries. We anticipate delivering at least two billion doses to low- and middle-income countries by the end of 2022&#8212;one billion that was delivered in 2021 and one billion expected to be delivered in 2022, with the possibility to increase those deliveries if more orders are placed by these countries for 2022. One billion of the aforementioned doses to low- and middle-income countries are being supplied to the U.S. government at a not-for-profit price to be donated to the world&#8217;s poorest nations at no charge to those countries.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">As of February 8, 2022, we forecasted approximately $32&#160;billion in revenues for Comirnaty in 2022, with gross profit to be split evenly with BioNTech, which includes doses expected to be delivered in fiscal 2022 under contracts signed as of late-January 2022. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Paxlovid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">In December 2021, the FDA authorized the emergency use of Paxlovid, a novel oral COVID-19 treatment, which is a SARS-CoV2-3CL protease inhibitor and is co-administered with a low dose of ritonavir, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The FDA based its decision on clinical data from the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients), which enrolled non-hospitalized adults aged 18 and older with confirmed COVID-19 who are at increased risk of progressing to severe illness. Paxlovid has been granted an authorization or approval in many other countries.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">We continue to evaluate Paxlovid in other populations, including in patients with a confirmed diagnosis of SARS-CoV-2 infection who are at standard risk (i.e., low risk of hospitalization or death) (Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard Risk Patients)) and in adults living in the same household as someone with a confirmed COVID-19 infection (Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis)). </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">We have entered into agreements with multiple countries to supply pre-specified courses of Paxlovid, such as the U.S. and U.K., and have initiated bilateral outreach to approximately 100 countries around the world. Additionally, we have signed a voluntary non-exclusive license agreement with the Medicines Patent Pool (MPP) for Paxlovid. Under the terms of the agreement, MPP can grant sublicenses to qualified generic medicine manufacturers worldwide to manufacture and supply Paxlovid to 95 low- and middle-income countries, covering up to approximately 53% of the world&#8217;s population.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">Pfizer plans to manufacture up to 120 million treatment courses by the end of 2022, depending on the global need, which will be driven by advance purchase agreements, with 30 million courses expected to be produced in the first half of 2022 and the remaining 90 million courses expected to be produced in the second half of 2022.</span></div><div style="margin-bottom:5pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">As of February 8, 2022, we forecasted approximately $22&#160;billion of revenues for Paxlovid in 2022, which includes treatment courses expected to be delivered in fiscal 2022, primarily relating to supply contracts signed or committed as of late-January 2022.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">IV Protease Inhibitor:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">In February 2022, we discontinued the global clinical development program for PF-07304814, an intravenously administered SARS-CoV-2 main protease inhibitor being evaluated in adults hospitalized with severe COVID-19. This decision was made based on a totality of information, including a careful review of early data and a thorough assessment of the candidate&#8217;s potential to successfully fulfill patient needs. Dosing of PF-07304814 in the National Institutes of Health&#8217;s ongoing Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-3 study has ceased.</span></div><div style="margin-bottom:5pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Impact of COVID-19 on Our Business and Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As part of our on-going monitoring and assessment, we have made certain assumptions regarding the pandemic for purposes of our operational planning and financial projections, including assumptions regarding the duration, severity and the global macroeconomic impact of the pandemic, </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as well as COVID-19 vaccine and oral COVID-19 treatment supply and contracts, which remain dynamic. Despite careful tracking and planning, we are unable to accurately predict the extent of the impact of the pandemic on our business, operations and financial condition and results due to the uncertainty of future developments. We are focused on all aspects of our business and are implementing measures aimed at mitigating issues where possible, including by using digital technology to assist in operations for our commercial, manufacturing, R&amp;D and corporate enabling functions globally.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Apart from our introduction of Comirnaty/BNT162b2 and Paxlovid, our business and operations have been impacted by the pandemic in various ways. Our portfolio of products experienced varying impacts from the pandemic in 2021. For example, certain of our vaccines such as the Prevnar family were impacted by disruptions to healthcare activity related to COVID-19, including the prioritization of primary and booster vaccination campaigns for COVID-19. For some products such as Vyndaqel/Vyndamax, we continued to see postponement of elective and diagnostic procedures in 2021 due to COVID-19, which may subside in 2022 as COVID-19 vaccination and booster rates continue to increase and/or if COVID-19 cases subside. On the other hand, some products such as Ibrance saw accelerating demand in 2021 as the delays in diagnosis and treatment initiations caused by the COVID-19 pandemic show signs of recovery across several international markets. For detail on the impact of the COVID-19 pandemic on certain of our products, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income&#8212;Revenues by Geography </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Revenues&#8212;Selected Product Discussion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections within this MD&amp;A. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2021, engagement with healthcare professionals started to return to pre-pandemic levels and we continue to review and assess epidemiological data to inform in-person engagements with healthcare professionals and to help ensure the safety of our colleagues, customers and communities. As part of our commitment to engaging our customers in the manner they prefer, we are also taking a hybrid approach of virtual and in person engagements and saw customer response to both approaches. During the pandemic, we adapted our promotional platform by amplifying our digital capabilities to reach healthcare professionals and customers to provide critical education and information, including increasing the scale of our remote engagement. Most of our colleagues who are able to perform their job functions outside of our facilities continue to temporarily work remotely, while certain colleagues in the PGS and WRDM organizations continue to work onsite and are subject to strict protocols intended to reduce the risk of transmission. As of December 31, 2021, more than 96% of our U.S. employee population had been fully vaccinated or received an approved exception. Also, in 2021 and to date, we have not seen a significant disruption to our supply chain, and all of our manufacturing sites globally have continued to operate at or near normal levels. However, we are seeing an increase in overall demand in the industry for certain components and raw materials potentially constraining available supply, which could have a future impact on our business. We are continuing to monitor and implement mitigation strategies in an effort to reduce any potential risk or impact including active supplier management, qualification of additional suppliers and advanced purchasing to the extent possible. Certain of our clinical trials were impacted by the COVID-19 pandemic in 2021, which included, in some cases, challenges related to recruiting clinical trial participants and accruing cases in certain studies. Our clinical trials also progressed in this challenging environment through innovation, such as decentralized visits (e.g., telemedicine and home visits) to accommodate participants&#8217; ability to maintain scheduled visits, as well as working with suppliers to manage the shortage of certain clinical supplies. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We will continue to pursue efforts to maintain the continuity of our operations while monitoring for new developments related to the pandemic. Future developments could result in additional favorable or unfavorable impacts on our business, operations or financial condition and results. If we experience significant disruption in our manufacturing or supply chains or significant disruptions in clinical trials or other operations, or if demand for our products is significantly reduced as a result of the COVID-19 pandemic, we could experience a material adverse impact on our business, operations and financial condition and results. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, please see the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Item 1A. Risk Factors&#8212;COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section of this Form 10-K.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_100"></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Following is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. Also, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our significant accounting policies, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&#160;Fair Value (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1F</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">); Revenues (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&#160;Asset Impairments (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1M</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&#160;Tax Assets and Liabilities and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income Tax Contingencies (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">);&#160;Pension and Postretirement Benefit Plans (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">); and Legal and Environmental Contingencies (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1S</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a discussion of a recently adopted accounting standard and a change in accounting principle related to our pension and postretirement plans, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1B </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> 1C.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair value as of the acquisition date. For further detail on acquisition accounting, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Historically, intangible assets have been the most significant fair values within our business combinations. For further information on our process to estimate the fair value of intangible assets, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Asset Impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. The potential of our estimates to vary (sensitivity) differs by program, product, type of customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material adjustment because of the extensive time delay </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this lag, our recording of adjustments to reflect actual amounts can incorporate revisions of several prior quarters. Rebate accruals are product specific and, therefore for any period, are impacted by the mix of products sold as well as the forecasted channel mix for each individual product. For further information, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenue Deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Asset Impairments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1M.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Examples of events or circumstances that may be indicative of impairment include:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">A significant adverse change in the extent or manner in which an asset is used such as a restriction imposed by the FDA or other regulatory authorities that could affect our ability to manufacture or sell a product.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">An expectation of losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor&#8217;s product that impacts projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payers. For IPR&amp;D projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable Intangible Assets</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We use an income approach, specifically the discounted cash flow method to determine the fair value of intangible assets, other than goodwill. We start with a forecast of all the expected net cash flows associated with the asset, which incorporates the consideration of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions that impact our fair value estimates include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological advancements and risk associated with IPR&amp;D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic origin of the projected cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, those that are most at risk of impairment include IPR&amp;D assets (approximately $3.1 billion as of December 31, 2021) and newly acquired or recently impaired indefinite-lived brand assets. IPR&amp;D assets are high-risk assets, given the uncertain nature of R&amp;D. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment charge.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our goodwill impairment review work as of December 31, 2021 concluded that none of our goodwill was impaired and we do not believe the risk of impairment is significant at this time.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In our review, we first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors that we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">When we are required to determine the fair value of a reporting unit, we typically use the income approach. The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, we use the discounted cash flow method. We start with a forecast of all the expected net cash flows for the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent goodwill impairment testing. For a list of these factors, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Forward-Looking Information and Factors That May Affect Future Result</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">s and the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> sections in this Form 10-K.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our different benefit plans, see</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in determining the costs of our benefit plans can materially impact our results of operations.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:57.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides (i) at the end of each year, the expected annual rate of return on plan assets for the following year, (ii) the actual annual rate of return on plan assets achieved in each year, and (iii) the weighted-average discount rate used to measure the benefit obligations at the end of each year for our U.S. pension plans and our international pension plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">U.S. Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate used to measure the plan obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">International Pension Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual annual rate of return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate used to measure the plan obligations</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For detailed assumptions associated with our benefit plans, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 11B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Expected Annual Rate of Return on Plan Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The assumptions for the expected annual rate of return on all of our plan assets reflect our actual historical return experience and our long-term assessment of forward-looking return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our targeted asset allocation in our respective plans. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The expected annual rate of return on plan assets for our U.S. plans and the majority of our international plans is applied to the fair value of plan assets at each year-end and the resulting amount is reflected in our net periodic benefit costs in the following year.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:61.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following illustrates the sensitivity of net periodic benefit costs to a 50 basis point decline in our assumption for the expected annual rate of return on plan assets, holding all other assumptions constant (in millions, pre-tax):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Assumption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in 2022 </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Periodic</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit Costs</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected annual rate of return on plan assets</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 basis point decline</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$133</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The actual return on plan assets was approximately $2.6 billion during 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discount Rate Used to Measure Plan Obligations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at least annually and evaluated and modified, as required, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better, that reflect the rates at which the pension benefits could be effectively settled. The discount rate used to measure the plan obligations for our international plans is determined at least annually by reference to investment grade corporate bonds, rated AA/Aa or better, including, when there is sufficient data, a yield-curve approach. These discount rate determinations are made in consideration of local requirements. The measurement of the plan obligations at the end of the year will affect the amount of service cost, interest cost and amortization expense reflected in our net periodic benefit costs in the following year. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:49.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following illustrates the sensitivity of net periodic benefit costs and benefit obligations to a 10 basis point decline in our assumption for the discount rate, holding all other assumptions constant (in millions, pre-tax):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Assumption</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease in 2022 Net Periodic Benefit Costs</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase to 2021 Benefit Obligations</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 basis point decline</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$16</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$442</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The change in the discount rates used in measuring our plan obligations as of December 31, 2021 resulted in a decrease in the measurement of our aggregate plan obligations by approximately $786 million.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Tax Assets and Liabilities</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income tax assets and liabilities include income tax valuation allowances and accruals for uncertain tax positions. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1Q </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">5, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as well as the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section within MD&amp;A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Contingencies</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax, legal contingencies and guarantees and indemnifications. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> 1S</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> 5D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_103"></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONSOLIDATED STATEMENTS OF INCOME</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_106"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues by Geography</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="93" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents worldwide revenues by geography:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="51" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21/20</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21/20</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21/20</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20/19</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating segments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Biopharma</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79,557</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29,221</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,055&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,901&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">50,336</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">156</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Pfizer CentreOne</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,206</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">31</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Consumer Healthcare</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,082&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(100)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,288</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,651&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40,905&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">29,746</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,455&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,326&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51,542</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,196&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,579&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:700;line-height:100%">155</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:64.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides an analysis of the change in worldwide revenues by geographic areas in 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Growth from Comirnaty, Eliquis, Biosimilars, Vyndaqel/Vyndamax, the Hospital therapeutic area, Inlyta and Xtandi, partially offset by a decline from the Prevnar family, while Xeljanz and Ibrance were flat. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> within MD&amp;A for additional analysis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,802</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,744</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Growth from PC1 primarily reflecting manufacturing of legacy Upjohn products for Viatris under manufacturing and supply agreements and certain Comirnaty-related manufacturing activities performed on behalf of BioNTech. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> within MD&amp;A for additional analysis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">124</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">656</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Lower revenues for Chantix/Champix, Enbrel and Sutent:  </span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">The decrease for Chantix/Champix was driven by the voluntary recall across multiple markets in the second half of 2021 and the ongoing global pause in shipments of Chantix due to the presence of N-nitroso-varenicline above an acceptable level of intake set by various global regulators, the ultimate timing for resolution of which may vary by country, and the negative impact of the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventive health purposes</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">The decrease for Enbrel internationally primarily reflects continued biosimilar competition, which is expected to continue</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">The decrease for Sutent primarily reflects lower volume demand in the U.S. resulting from its loss of exclusivity in August 2021, as well as continued erosion as a result of increased competition in certain international developed markets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operational growth, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,429</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Favorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,208</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,208</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,637</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging markets revenues increased $12.3 billion, or 147%, in 2021 to $20.7 billion from $8.4 billion in 2020, reflecting an operational increase of $12.2 billion, or 145%, and a favorable impact from foreign exchange of approximately 2%. The operational increase in emerging markets was primarily driven by revenues from Comirnaty and growth from certain products in the Hospital therapeutic area, Eliquis and PC1, partially offset by a decline from the Prevnar family.</span></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:64.920%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides an analysis of the change in worldwide revenues by geographic areas in 2020:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Operational growth/(decline):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Growth from Vyndaqel/Vyndamax, Eliquis, Biosimilars, Ibrance, Inlyta, Xeljanz, Xtandi, the Hospital therapeutic area and the Prevnar family</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Growth from PC1 in international markets driven by growth of certain key accounts as well new contract manufacturing activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impact of completion of the Consumer Healthcare JV transaction. Revenues in 2019 reflect seven months of Consumer Healthcare business domestic operations and eight months of  international operations, and none in 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,082)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(988)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,094)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lower revenues for Enbrel internationally, primarily reflecting continued biosimilar competition in most developed Europe markets, as well as in Japan and Brazil, all of which is expected to continue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decline from Chantix/Champix reflecting the negative impact of the COVID-19 pandemic resulting in a decline in patient visits to doctors for preventive health purposes as well as the loss of patent protection in the U.S. in November 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other operational factors, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(214)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operational growth/(decline), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unfavorable impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(331)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> increase/(decrease)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues for 2020 included an estimated unfavorable impact of approximately $700 million, or 2%, due to COVID-19, primarily reflecting lower demand for certain products in China and unfavorable disruptions to wellness visits for patients in the U.S., which negatively impacted prescribing patterns for certain products, partially offset by increased U.S. demand for certain sterile injectable products and increased adult uptake for the Prevnar family in certain international markets, resulting from greater vaccine awareness for respiratory illnesses, and U.S. revenues for Comirnaty.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging markets revenues decreased $456 million, or 5%, in 2020 to $8.4 billion, from $8.8 billion in 2019, and were relatively flat operationally, reflecting an unfavorable impact of foreign exchange of 5% on emerging markets revenues. The relatively flat operational performance was primarily driven by growth from Eliquis, the Prevnar family, Ibrance and Zavicefta, offset by lower revenues for Consumer Healthcare, reflecting the July 31, 2019 completion of the Consumer Healthcare JV transaction.</span></div><div style="margin-top:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenue Deductions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. These deductions represent estimates of related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, adjustments to these estimates to reflect actual results or updated expectations, have not been material to our overall business and generally have been less than 1% of revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product revenue growth trends.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:55.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents information about revenue deductions:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicare rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">726</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medicaid and related state program rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance-based contract rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,122</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,531&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,809</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales returns and cash discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,054</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,178</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,733&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,284&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenue deductions are primarily a function of product sales volume, mix of products sold, contractual or legislative discounts and rebates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on our accruals for revenue deductions, including the balance sheet classification of these accruals, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenues&#8212;Selected Product Discussion</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Biopharma</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year Ended Dec. 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Comirnaty</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$36,781</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">*</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7,809</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Driven by global uptake, following a growing number of regulatory approvals and temporary authorizations.</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">28,972</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">36,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliquis</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$5,970</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 19%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,688&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Global growth driven primarily by continued increased adoption in non-valvular atrial fibrillation and oral anti-coagulant market share gains, as well as a favorable adjustment related to the Medicare &#8220;coverage gap&#8221; provision resulting from lower than previously expected discounts in prior periods.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,810</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,970</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,949&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ibrance</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$5,437</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Flat </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,418</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">3,634&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Flat performance driven primarily by accelerating demand internationally as the delays in diagnosis and treatment initiations caused by the COVID-19 pandemic show signs of recovery across several international markets, offset by a decline in the U.S., primarily driven by an increase in the proportion of patients accessing Ibrance through our Patient Assistance Program.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,437</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,392&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:123pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prevnar family</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$5,272</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Down 11% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(8)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Decline primarily resulting from:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">the normalization of demand in Germany and certain other developed markets following significantly increased adult demand in 2020 resulting from greater vaccine awareness for respiratory illnesses due to the COVID-19 pandemic;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">the adult indication due to disruptions to healthcare activity related to COVID-19, including the prioritization of primary and booster vaccination campaigns for COVID-19 in the U.S.;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">the continued impact of the lower remaining unvaccinated eligible adult population in the U.S. and the June 2019 change to the ACIP recommendation for the Prevnar 13 adult indication to shared clinical decision-making; and</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">a decline in the pediatric indication internationally due to disruptions to healthcare activity related to COVID-19. </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">This decline was partially offset by:</span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">U.S. growth in the pediatric indication, driven by government purchasing patterns, which was partially offset by disruptions to healthcare activity related to COVID-19.</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,571</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,272</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(10)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:68pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xeljanz</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$2,455</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Flat  </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Flat performance as a decline in the U.S. was offset by operational growth internationally. The decline in the U.S. was primarily driven by:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">the negative impact of data from a long-term safety study, which resulted in JAK class labeling issued by the FDA in December 2021;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">an unfavorable change in channel mix toward lower-priced channels, despite a 2% increase in underlying demand, driven by growth in our UC and PsA indications; and </span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">continued investments to improve formulary positioning and unlock access to additional patient lives. </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">The decline in the U.S. was offset by: </span></div><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;padding-left:6.73pt">operational growth internationally mainly driven by continued uptake in the UC indication in certain developed markets.</span></div></td></tr><tr style="height:36pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vyndaqel/ <br/>Vyndamax</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$2,015</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 55%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">909</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Growth primarily driven by continued strong uptake of the ATTR-CM indication in the U.S., developed Europe and Japan.</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Xtandi</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,185</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 16% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Growth primarily driven by strong demand across the mCRPC, nmCRPC and mCSPC indications.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inlyta</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,002</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 26% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">599</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Growth primarily reflects continued adoption in developed Europe and the U.S. of combinations of certain immune checkpoint inhibitors and Inlyta for the first-line treatment of patients with advanced RCC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">403</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year Ended Dec. 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biosimilars</span></td><td colspan="3" rowspan="3" style="border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$2,343</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 51% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,561</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Growth primarily driven by recent oncology monoclonal antibody biosimilar launches and growth from Retacrit in the U.S.</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">782</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">628&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospital</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$7,301</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 5% </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,688</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,705&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Growth primarily driven by the anti-infectives portfolio in international markets, primarily as a result of recent launches of Zavicefta and Cresemba.</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,613</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7,301</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,777&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer CentreOne</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year Ended Dec. 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Segment</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global<br/>Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Region</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Oper.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operational Results Commentary</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PC1</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-right:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000000;border-left:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$1,731</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Up 84%</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(operationally)</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Growth primarily reflects manufacturing of legacy Upjohn products for Viatris under manufacturing and supply agreements and certain Comirnaty-related manufacturing activities performed on behalf of BioNTech.</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Worldwide</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Comirnaty includes direct sales and alliance revenues related to sales of the Pfizer-BioNTech COVID-19 vaccine, which are recorded within our Vaccines therapeutic area. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. Revenues related to these manufacturing activities totaled $320 million for 2021 and $0 million in 2020.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">Calculation is not meaningful or results are equal to or greater than 100%.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Patents and Other Intellectual Property Rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K for information regarding the expiration of various patent rights, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17C </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information regarding the primary indications or class of the selected products discussed above.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_115"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Costs and Expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:39.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs and expenses follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21/20</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20/19</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30,821</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,484&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,054&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percentage of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">37.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,703</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,597&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,829</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,385&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">47</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related </span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">802</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8212;net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,878)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="border-top:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:107%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:107%;padding-left:5.89pt">Calculation is not meaningful or results are equal to or greater than 100%.</span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Cost of Sales</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increased $22.3 billion, primarily due to:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the impact of Comirnaty, which includes a charge for the 50% gross profit split with BioNTech and applicable royalty expenses;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">increased sales volumes of other products, driven mostly by PC1; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the unfavorable impact of foreign exchange and hedging activity on intercompany inventory.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as a percentage of revenues was primarily due to all of the factors discussed above, partially offset by an increase in alliance revenues, which have no associated cost of sales.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> increased $431 million, primarily due to:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">increased sales volumes;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase in royalty expenses, due to an increase in sales of related products; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an unfavorable impact of incremental costs incurred in response to the COVID-19 pandemic; and</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an unfavorable impact of foreign exchange and hedging activity on intercompany inventory,</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare JV transaction.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as a percentage of revenues was primarily due to all of the factors discussed above, partially offset by an increase in alliance revenues, which have no associated cost of sales.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Selling, Informational and Administrative (SI&amp;A) Expenses</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SI&amp;A expenses increased $1.1 billion, mostly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">increased product-related spending across multiple therapeutic areas; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">costs related to Comirnaty, driven by a higher provision for healthcare reform fees based on sales; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase in costs related to implementing our cost-reduction/productivity initiatives,</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower spending on Chantix following the loss of patent protection in the U.S. in November 2020.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">SI&amp;A expenses decreased $1.1 billion, mostly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare JV transaction;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower spending for corporate enabling functions;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower spending on sales and marketing activities due to the impact of the COVID-19 pandemic; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower investments across the Internal Medicine and Inflammation &amp; Immunology portfolios,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase in costs related to implementing our cost-reduction/productivity initiatives; and</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">an increase in business and legal entity alignment costs.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Research and Development (R&amp;D) Expenses</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D expenses increased $4.4 billion, primarily due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a charge for acquired IPR&amp;D related to our acquisition of Trillium;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net increase in charges for upfront and milestone payments on collaboration and licensing arrangements, driven by payments to Arvinas and Beam; and </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">increased investments across multiple therapeutic areas, including additional spending related to the development of the oral COVID-19 treatment program.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D expenses increased $1.0 billion, mainly due to: </span></div><div style="margin-bottom:3pt;margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">costs related to our collaboration agreement with BioNTech to co-develop a COVID-19 vaccine, including an upfront payment to BioNTech and a premium paid on our equity investment in BioNTech;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net increase in upfront payments, mainly related to Myovant and Valneva; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">increased investments towards building new capabilities and driving automation,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">a net reduction of upfront and milestone payments associated with the acquisition of Therachon and Akcea in 2019.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets increased $353 million, primarily due to amortization of capitalized Comirnaty sales milestones to BioNTech.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets decreased $1.1 billion, mainly due the non-recurrence of amortization of fully amortized assets and the impairment of Eucrisa in the fourth quarter of 2019, partially offset by the increase in amortization of intangible assets from our acquisition of Array.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 2A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">10A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Transforming to a More Focused Company Program</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our program, as well as the anticipated and actual costs, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The program savings discussed below may be rounded and represent approximations. In connection with restructuring our corporate enabling functions, we expect gross cost savings of $1.0 billion, or net cost savings, excluding merit and inflation growth and certain real estate cost increases, of $700 million, to be achieved primarily from 2021 through 2022. In connection with transforming our marketing strategy, we expect net cost savings of $1.3&#160;billion, to be achieved primarily from </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022 through 2024. In connection with manufacturing network optimization, we expect net cost savings of $550 million to be achieved primarily from 2020 through 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain qualifying costs for this program were recorded in 2021 and 2020, and in the fourth quarter of 2019, and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measure: Adjusted Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section of this MD&amp;A.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition to this program, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Other (Income)/Deductions&#8211;&#8211;Net</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other income&#8212;net increased $6.1&#160;billion, mainly due to:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">net periodic benefit credits recorded in 2021 versus net periodic benefit costs recorded in 2020;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower asset impairment charges;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">higher net gains on equity securities; and</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">net gains on asset disposals in 2021 versus net losses in 2020.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other deductions&#8212;net decreased $2.3 billion, mainly due to:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower asset impairment charges;</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower business and legal entity alignment costs;</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">higher Consumer Healthcare JV equity method income;</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower charges for certain legal matters; and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">higher income from collaborations, out-licensing arrangements and sales of compound/product rights, </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">higher net losses on asset disposals.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_118"></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Provision/(Benefit) for Taxes on Income</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:39.376%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21/20</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20/19</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate on continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_121"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information about our discontinued operations, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_112"></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENTS </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A comprehensive update of Pfizer&#8217;s development pipeline was published as of February&#160;8, 2022 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides information about significant marketing application-related regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The table below includes only approvals for products that have occurred in the last twelve months and does not include approvals that may have occurred prior to that time. The table includes filings with regulatory decisions pending (even if the filing occurred outside of the last twelve-month period).</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">38</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.231%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.526%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT</span></td><td colspan="3" rowspan="2" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">DISEASE AREA</span></td><td colspan="9" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">APPROVED/FILED*</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">U.S.</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EU</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">JAPAN</span></td></tr><tr style="height:27pt"><td colspan="3" rowspan="4" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comirnaty/BNT162b2</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(PF-07302048)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (16 years of age and older)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">BLA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Aug. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dec. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2021</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (12-15 years of age)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#160;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#160;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2021</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (booster)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#160;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CMA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr style="height:26pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (5-11 years of age)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">EUA</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Oct.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">CMA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">&#160;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bavencio </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(avelumab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line maintenance urothelial cancer</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Xtandi</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(enzalutamide)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%"> </span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">mCSPC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">April </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Cibinqo<br/>(abrocitinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Atopic dermatitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Xeljanz <br/>(tofacitinib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ankylosing spondylitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Myfembree</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(relugolix fixed dose combination)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Uterine fibroids (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Endometriosis (combination with estradiol and norethindrone acetate)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sep.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Lorbrena/Lorviqua </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(lorlatinib)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line ALK-positive NSCLC</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mar. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nov.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Ngenla</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(somatrogon)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Pediatric growth hormone deficiency</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Prevnar 20/Apexxnar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(Vaccine)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent invasive and non-invasive pneumococcal infections (adults)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">June</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">TicoVac<br/>(Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent tick-borne encephalitis</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;Aug. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:107%">Paxlovid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:107%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:107%">(nirmatrelvir [PF-07321332]; ritonavir)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">COVID-19 infection (high risk population)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">EUA </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dec.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CMA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Jan.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;2022</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Approved </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></div></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:107%">Rimegepant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:107%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Acute migraine</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Migraine prevention</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Feb. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">For the U.S., the filing date is the date on which the FDA accepted our submission. For the EU, the filing date is the date on which the EMA validated our submission. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with BioNTech. Prior to BLA, Comirnaty/BNT162b2 for ages 16 and up was available in the U.S. pursuant to an EUA from the FDA on December 11, 2020. In December 2021, a supplemental BLA was submitted to the FDA requesting to expand the approval of Comirnaty to include individuals ages 12 through 15 years. In February 2022, following a request from the FDA, a rolling submission seeking to amend the EUA to include children 6 months through 4 years of age (6 months to &lt;5 years of age) was initiated as we wait for data evaluating a third 3 &#181;g dose given at least two months after the second dose of the two-dose series in this age group. A booster dose received EUA from the FDA on September 22, 2021 for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2. In addition, in October 2021, the FDA authorized for emergency use a booster dose to eligible individuals who have completed primary vaccination with a different authorized COVID-19 vaccine. Subsequently, the FDA expanded the booster EUA: (i) in November 2021 to include individuals 18 years of age and older, (ii) in December 2021 to include individuals 16 years of age and older and (iii) in January 2022 to include individuals 12 years of age and older as well as individuals 5 through 11 years of age who have been determined to have certain kinds of immunocompromise. A booster dose received conditional marketing authorization from the EMA in October 2021 for individuals 18 years of age and older and may be given to individuals 5 years and older with a severely weakened immune system, at least 28 days after their second dose. A booster dose received approval in Japan in November 2021 for 18 years of age and older.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with Merck KGaA, Germany.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%;padding-left:2.94pt">Being developed in collaboration with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with OPKO. In January 2022, Pfizer and OPKO received a Complete Response Letter (CRL) from the FDA for the BLA for somatrogon. Pfizer is evaluating the CRL and will work with the FDA to determine an appropriate path forward in the U.S.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In October 2021, the CDC&#8217;s ACIP voted to recommend Prevnar 20 for routine use in adults. Specifically, the ACIP voted to recommend the following: (i) adults 65 years of age or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either pneumococcal 20-valent conjugate vaccine (PCV20) or pneumococcal 15-valent conjugate vaccine (PCV15)). If PCV15 is used, this should be followed by a dose of pneumococcal polysaccharide vaccine (PPSV23); and (ii) adults aged 19 years of age or older with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23. The </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recommendations were published in the Morbidity and Mortality Weekly Report on January 28, 2022. The publication also notes &#8220;for adults who have received pneumococcal conjugate vaccine (PCV13) but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of Prevnar 20 may be used if PPSV23 is not available.&#8221;</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In December 2021, the FDA authorized the emergency use of Paxlovid for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. In January 2022, the EMA approved the CMA of Paxlovid for treating COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of the disease becoming severe.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Under a commercialization arrangement with Biohaven.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In September 2021, the FDA issued a Drug Safety Communication (DSC) related to Xeljanz/Xeljanz XR and two competitors&#8217; arthritis medicines in the same drug class, based on its completed review of the ORAL Surveillance trial. The DSC stated that the FDA will require revisions to the Boxed Warnings for each of these medicines to include information about the risks of serious heart-related events, cancer, blood clots, and death. In addition, the DSC indicated the FDA&#8217;s intention to limit approved uses of these products to certain patients who have not responded or cannot tolerate one or more tumor necrosis factor (TNF) blockers. In December 2021, in light of the results from the completed required postmarketing safety study of Xeljanz, ORAL Surveillance (A3921133), the U.S. label for Xeljanz was revised. In addition, at the request of the EC, the PRAC of the EMA has adopted a referral procedure under Article 20 of Regulation (EC) No 726/2004 to assess safety information relating to oral JAK inhibitors authorized for inflammatory diseases, including Xeljanz and Cibinqo, which is ongoing. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Post-Authorization/Approval Data</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">In China, the following products received regulatory approvals in the last twelve months: Cresemba for fungal infection and Besponsa for second line acute lymphoblastic leukemia, both in December 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%">The following provides information about additional indications and new drug candidates in late-stage development:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:12.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PRODUCT/CANDIDATE</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">PROPOSED DISEASE AREA</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="11" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.25pt solid #000;padding:2px 1pt;text-align:center;text-indent:7.2pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Ibrance (palbociclib)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">ER+/HER2+ metastatic breast cancer</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Xtandi (enzalutamide)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Non-metastatic high-risk castration sensitive prostate cancer</span></div></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Talzenna (talazoparib)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for first-line mCRPC</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with Xtandi (enzalutamide) for DNA Damage Repair (DDR)-deficient mCSPC</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06482077 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunization to prevent invasive and non-invasive pneumococcal infections (pediatric)</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">somatrogon (PF-06836922)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Adult growth hormone deficiency</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (cetuximab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">First-line BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant mCRC</span></div></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Myfembree</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(relugolix fixed dose combination)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with estradiol and norethindrone acetate for contraceptive efficacy</span></td></tr><tr style="height:27pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Braftovi (encorafenib) and Mektovi (binimetinib) and Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> (pembrolizumab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">v600E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">-mutant metastatic or unresectable locally advanced melanoma</span></div></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Comirnaty</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">/</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">BNT162b2</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(PF-07302048)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (children 2 to &lt;5&#8239;years of age)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent COVID-19 (infants 6 months to &lt;24 months)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Paxlovid (nirmatrelvir [PF-07321332]; ritonavir)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">COVID-19 Infection (standard</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%"> risk population)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">COVID-19 Infection (</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">post exposure prophylaxis)</span></div></td></tr><tr style="height:18pt"><td colspan="3" rowspan="14" style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:center;text-indent:5.65pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">aztreonam-avibactam<br/>(PF-06947387)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Treatment of infections caused by Gram-negative bacteria</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">fidanacogene elaparvovec (PF-06838435)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia B</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">giroctocogene fitelparvovec </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">(PF-07055480)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia A</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06425090 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent primary clostridioides difficile infection</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06886992 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent serogroups meningococcal infection (adolescent and young adults)</span></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-06928316 (Vaccine)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent respiratory syncytial virus infection (maternal)</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Immunization to prevent respiratory syncytial virus infection (older adults)</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">PF-07265803</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Dilated cardiomyopathy due to Lamin A/C gene mutation</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ritlecitinib (PF-06651600)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Alopecia areata</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">sasanlimab (PF-06801591)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Combination with Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">fordadistrogene movaparvovec (PF-06939926)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Duchenne muscular dystrophy</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">marstacimab (PF-06741086)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Hemophilia</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">elranatamab (PF-06863135)</span></td><td colspan="3" style="border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Multiple myeloma, double-class exposed </span></td></tr><tr style="height:18pt"><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Omicron-based mRNA vaccine</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.25pt solid #000;border-right:0.5pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Immunization to prevent COVID-19 (adults)</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with The Alliance Foundation Trials, LLC.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with Astellas.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Being developed in collaboration with OPKO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of ImClone LLC. In the EU, we are developing in collaboration with the Pierre Fabre Group. In Japan, we are developing in collaboration with Ono Pharmaceutical Co., Ltd. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with Myovant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &amp; Dohme Corp.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with BioNTech.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">40</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Being developed in collaboration with Spark Therapeutics, Inc.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt">Being developed in collaboration with Sangamo Therapeutics, Inc.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2022, Pfizer and Merck KGaA, Darmstadt, Germany (Merck KGaA) provided an update on the Phase 3 JAVELIN Lung 100 trial, which assessed the safety and efficacy of two dosing regimens of avelumab monotherapy compared with platinum-based doublet chemotherapy as first-line treatment in patients with metastatic NSCLC whose tumors express PD-L1. While avelumab showed clinical activity in this population, the study did not meet the primary endpoints of overall survival and progression-free survival in the high PD-L1+population for either of the avelumab dosing regimens evaluated. The safety profile for avelumab in this trial was consistent with that observed in the overall JAVELIN clinical development program. Avelumab is not approved for the treatment of any patients with NSCLC. The outcome of the JAVELIN Lung 100 trial has no bearing on any of avelumab&#8217;s currently-approved indications. Full results of the study will be shared at a future date.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, enrollment was stopped in C4591015 Study (a Phase 2/3 placebo controlled randomized observer-blind study to evaluate the safety, tolerability, and immunogenicity of BNT162b2 against COVID-19 in healthy pregnant women 18 years of age and older). This study was developed prior to availability or recommendation for COVID-19 vaccination in pregnant women. The environment changed during 2021 and by September 2021, COVID-19 vaccines were recommended by applicable recommending bodies (e.g., ACIP in the U.S.) for pregnant women in all participating/planned countries, and as a result the enrollment rate declined significantly. With the declining enrollment, the study had insufficient sample size to assess the primary immunogenicity objective and continuation of this placebo controlled study could no longer be justified due to global recommendations. This proposal was shared with and agreed to by FDA and EMA.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information about our R&amp;D organization, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section of this Form 10-K.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_124"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income is an alternative measure of performance used by management to evaluate our overall performance in conjunction with other performance measures. As such, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide&#8211;&#8211;prior to considering certain income statement elements as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.879%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Measure</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Definition</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Relevance of Metrics to Our Business Performance</span></td></tr><tr style="height:83pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%">before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provides investors useful information to:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.17pt">assist in modeling expected future performance on a normalized basis</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td></tr><tr style="height:68pt"><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses, Adjusted amortization of intangible assets and Adjusted other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> an</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">d Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"> (a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, each before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted diluted EPS</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> before the impact of purchase accounting for acquisitions, acquisition-related items, discontinued operations and certain significant items</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Most directly comparable GAAP measure.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The short-term incentive plans for substantially all non-sales-force employees worldwide are funded from a pool based on our performance, measured in significant part by three metrics, one of which is Adjusted diluted EPS, which is derived from Adjusted income and accounts for 40% of the bonus pool funding tied to financial performance. Additionally, the payout for performance share awards is determined in part by Adjusted net income, which is derived from Adjusted income. The bonus pool funding, which is largely based on financial performance, may be modified by our R&amp;D performance as measured by four metrics relating to our pipeline and may be further modified by our Compensation Committee&#8217;s assessment of other factors.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their directly comparable GAAP measures of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">EPS attributable to Pfizer Inc. common shareholders&#8212;diluted</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, respectively. See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information&#8212;certain line items for 2021, 2020 and 2019 below. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Purchase Accounting Adjustments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The exclusion of amortization attributable to acquired intangible assets provides management and investors an alternative view of our results by providing a degree of parity to internally developed intangible assets for which R&amp;D costs have been expensed. However, we have not factored in the impacts of any other differences that might have occurred if we had discovered and developed those intangible assets on our own, such as different R&amp;D costs, timelines or resulting sales; accordingly, this approach does not intend to be representative of the results that would have occurred if we had discovered and developed the acquired intangible assets internally.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Acquisition-Related Items</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes acquisition-related items, which are comprised of transaction, integration, restructuring charges and additional depreciation costs for business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate businesses as a result of an acquisition. We have made no adjustments for resulting synergies.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The significant costs incurred in connection with a business combination result primarily from the need to eliminate duplicate assets, activities or employees&#8211;&#8211;a natural result of acquiring a fully integrated set of activities. For this reason, we believe that such costs incurred can be viewed differently in the context of an acquisition from those costs incurred in other, more normal, business contexts. The integration and restructuring costs for a business combination may occur over several years, with the more significant impacts typically ending within three years of the relevant transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Discontinued Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes the results of discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our therapeutic areas and product lines for strategic fit with our operations, we do not build or run our business with the intent to discontinue parts of our business. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Certain Significant Items</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted income excludes certain significant items representing substantive and/or unusual items that are evaluated individually on a quantitative and qualitative basis. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, although major non-acquisition-related cost-reduction programs are specific to an event or goal with a defined term, we may have subsequent programs based on reorganizations of the business, cost productivity or in response to LOE or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Gains and losses on equity securities have a very high degree of inherent market volatility, which we do not control and cannot predict with any level of certainty and because we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. Unusual items represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">below for a non-inclusive list of certain significant items.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2021, we exclude pension and postretirement actuarial remeasurement gains and losses from our measure of Adjusted income because of their inherent market volatility, which we do not control and cannot predict with any level of certainty and because we do not believe including these gains and losses assists investors in understanding our business or is reflective of our core operations and business.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">42</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Reconciliations of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="42" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:40pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">30,821</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">12,703</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">13,829</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">3,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(4,878)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">21,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">3.85</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchase accounting adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(450)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Upfront and milestone payments on collaborative and licensing arrangements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Asset acquisitions of IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(141)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Income tax provision&#8212;Non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,848)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">30,685&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12,110&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">10,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,473)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">25,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4.42&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-right:0.25pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="45" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:40pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">8,484</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">11,597</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">9,393</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">3,348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1,219</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">9,159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">1.63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchase accounting adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(3,064)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(75)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(197)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">791&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,691)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Upfront and milestone payments on collaborative and licensing arrangements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(454)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(557)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,092)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,092&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Asset acquisitions of IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(50)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(292)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(j)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Income tax provision&#8212;Non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,299)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">8,386&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">11,106&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">8,872&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">284&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,779)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12,727&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2.26&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.499%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.357%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="42" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:40pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Data presented will not (in all cases) aggregate to totals.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="6" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income attributable to Pfizer Inc. common shareholders</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Earnings per common share attributable to Pfizer Inc. common shareholders&#8211;&#8211;diluted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">GAAP reported</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">8,054</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">12,726</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">8,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">4,429</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">3,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">16,026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">2.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td style="border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchase accounting adjustments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(4,158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">4,153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Acquisition-related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(6,056)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain significant items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(89)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(73)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">611&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(2,757)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Upfront and milestone payments on collaborative and licensing arrangements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(279)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(Gains)/losses on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(415)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Actuarial valuation and other pension and postretirement plan (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(750)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(8,107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Asset acquisitions of IPR&amp;D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(337)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(190)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(18)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1,007)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1,333&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Income tax provision&#8212;Non-GAAP items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-left:0.25pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(797)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:0.25pt solid #000000;border-right:0.25pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Non-GAAP adjusted</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">7,865&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12,463&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">7,726&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">271&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(623)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">11,056&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-left:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1.95&#160;</span></td><td style="border-bottom:3pt double #000;border-right:0.25pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">Items that reconcile GAAP Reported to Non-GAAP Adjusted balances are shown pre-tax and include discontinued operations. Our effective tax rates for GAAP reported income from continuing operations were: 7.6% in 2021, 5.3% in 2020 and 5.2% in 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. Our effective tax rates on Non-GAAP adjusted income were: 15.3% in 2021, 13.7% in 2020 and 16.0% in 2019.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">Purchase accounting adjustments include items such as the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, depreciation related to the increase/decrease in fair value of the acquired fixed assets, amortization related to the increase in fair value of acquired debt, and the fair value changes for contingent consideration. For all years presented, primarily consists of amortization of intangible assets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.71pt">Relates primarily to the spin-off of our Upjohn Business, and our sale of Meridian. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">See Note 2B.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 3.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes intangible asset impairment charges. For 2020, $900 million is related to IPR&amp;D assets acquired from Array and $528 million is related to Eucrisa. For 2019, $2.6 billion is related to Eucrisa. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Primarily includes the following charges: (i) for 2021, an upfront payment to Arvinas and a premium paid on our equity investment</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in Arvinas totaling $706 million, a $300 million upfront payment to Beam and a $50 million net upfront payment to BioNTech; (ii) for 2020, a payment of $151 million representing the expense portion of an upfront payment to Myovant, an upfront payment to Valneva of $130 million, an upfront payment to BioNTech and a premium paid on our equity investment in BioNTech totaling $98 million, as well as a $75 million milestone payment to Akcea; and (iii) for 2019, an upfront license fee payment of $250&#160;million to Akcea.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">(Gains)/losses on equity securities, and actuarial valuation and other pension and postretirement plan (gains)/losses are removed from adjusted earnings due to their inherent market volatility.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(h)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.45pt">Primarily includes payments for acquired IPR&amp;D. For 2021, includes a $2.1 billion charge related to our acquisition of Trillium, which was accounted for as an asset acquisition, and a $177 million charge related to an asset acquisition completed in the second quarter of 2021. For 2019, included a $337 million charge related to our acquisition of Therachon, which was accounted for as an asset acquisition.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.97pt">For 2021, the total of $334 million primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">includes: (i) charges representing our equity-method accounting pro rata share of restructuring charges and costs of preparing for separation from GSK of $185 million recorded by the Consumer Healthcare JV and (ii) charges for certain legal matters of $162&#160;million. For 2020, the total of $697 million primarily included: (i) charges of $367 million, which represent our equity-method accounting pro rata share of transaction-specific restructuring and business combination accounting charges recorded by the Consumer Healthcare JV, and (ii) losses on asset disposals of $238 million. For 2019, the total of $1.0 billion primarily included: (i) $300&#160;million of business and legal entity alignment costs for consulting, legal, tax and advisory services associated with the design, planning and implementation of our then new business structure, effective in the beginning of 2019, (ii) charges for certain legal matters of $291 million, (iii) charges of $152&#160;million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the Consumer Healthcare JV, (iv) net losses on early retirement of debt of $138&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(v)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">charges of $112&#160;million representing our equity-method accounting pro rata share of restructuring and business combination accounting charges recorded by the Consumer Healthcare JV. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(j)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.97pt">For 2020, amounts in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> of $292 million primarily include costs for consulting, legal, tax and advisory services associated with a non-recurring internal reorganization of legal entities.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">44</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Continuing Operations</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Drivers of change</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash provided by/(used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">32,922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,540&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,015&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven primarily by higher net income adjusted for non-cash items, the payment for the acquisition of Trillium, a decrease in contributions to pension plans, and the impact of timing of receipts and payments in the ordinary course of business, mostly from an increase in cash flows from Other current liabilities driven by: (i) a $9.7&#160;billion accrual for the gross profit split due to BioNTech, (ii) an increase in royalties payable, as well as (iii) an increase in deferred revenues for advance payments in 2021 for Comirnaty. </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other Adjustments, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">, is mostly due to an increase in unrealized gains on equity securities.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven mainly by higher net income adjusted for non-cash items, advanced payments in 2020 for Comirnaty recorded in deferred revenue, the upfront cash payment associated with our acquisition of Therachon in 2019, and the upfront cash payment associated with our licensing agreement with Akcea in 2019, partially offset by an increase in benefit plan contributions.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change also reflects the impact of timing of receipts and payments in the ordinary course of business.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other adjustments, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">was driven primarily by an increase in equity method dividends received, partially offset by an increase in equity income and increases in net unrealized gains on equity securities.</span></div></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(22,534)</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,162)</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,825)</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven mainly by a $24.7&#160;billion increase in purchases of short-term investments with original maturities of greater than three months and a $9.0&#160;billion increase in net purchases of short-term investments with original maturities of three months or less, partially offset by a $16.4&#160;billion increase in redemptions of short-term investments with original maturities of greater than three months.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven mostly by a $6.0 billion decrease in net proceeds from short-term investments with original maturities of three months or less and $2.7 billion in net purchases of short-term investments with original maturities of greater than three months in 2020 (compared to $2.3 billion net proceeds from short-term investments with original maturities of greater than three months in 2019), partially offset by the cash used to acquire Array, net of cash acquired, of $10.9 billion in 2019. </span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financing activities from continuing operations</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(9,816)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,640)</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,485)</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven mostly by a $9.8&#160;billion net reduction in repayments of short-term borrowings with maturities of greater than three months, a $4.0&#160;billion decrease in net payments on short-term borrowings with maturities of three months or less and a $2.0&#160;billion reduction in repayments of long-term debt, partially offset by a $4.2&#160;billion decrease in proceeds from issuances of long-term debt.  </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The change was driven mostly by $14.0 billion net payments of short-term borrowings in 2020 (compared to $10.6 billion net proceeds raised from short-term borrowings in 2019) and an increase in cash dividends paid of $397 million, partially offset by a decrease in purchases of common stock of $8.9 billion, lower repayments on long-term debt of $2.8 billion, and an increase in issuances of long-term debt of $280 million.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cash Flows from Discontinued Operations</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from discontinued operations primarily relate to our former Meridian subsidiary, Upjohn Business and the Mylan-Japan collaboration (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2020, net cash provided by financing activities from discontinued operations primarily reflects issuances of long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_133"></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY, CAPITAL RESOURCES AND MARKET RISK</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Due to our significant operating cash flows, which is a key strength of our liquidity and capital resources and our primary funding source, as well as our financial assets, access to capital markets, revolving credit agreements, and available lines of credit, we believe that we have, and will maintain, the ability to meet our liquidity needs to support ongoing operations, our capital allocation objectives, and our contractual and other obligations for the foreseeable future.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We focus efforts to optimize operating cash flows through achieving working capital efficiencies that target accounts receivable, inventories, accounts payable, and other working capital. Excess cash from operating cash flows is invested in money market funds and available-for-sale debt securities which consist of primarily high-quality, highly liquid, well-diversified debt securities. We have taken, and will continue to take, a conservative approach to our financial investments and monitoring of our liquidity position in response to market changes. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, we may obtain funding through short-term or long-term sources from our access to the capital markets, banking relationships and relationships with other financial intermediaries to meet our liquidity needs.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Diverse sources of funds:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Related disclosure presented in this Form 10-K</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Internal sources:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Operating cash flows</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows &#8211; Operating Activities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Analysis of the Consolidated Statements of Cash Flows </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">within MD&amp;A</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Money market funds</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7A, 7B</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">External sources:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Short-term funding:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Commercial paper</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7C</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Revolving credit facilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7C</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Lines of credit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7C</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Long-term funding:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Long-term debt</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Consolidated Statements of Equity </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 12</span></div></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information about the sources and uses of our funds and capital resources for the years ended December 31, 2021 and 2020, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of the Consolidated Statements of Cash Flows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in this MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In August 2021, we completed a public offering of $1 billion aggregate principal amount of senior unsecured sustainability notes. We are using the net proceeds to finance or refinance, in whole or in part as follows: R&amp;D expenses related to our COVID-19 vaccines, capital expenditures in connection with the manufacture and distribution of COVID-19 vaccines and our other projects that have environmental and/or social benefits. For additional information, see</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Note 7D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Credit Ratings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The cost and availability of financing are influenced by credit ratings, and increases or decreases in our credit rating could have a beneficial or adverse effect on financing. Our long-term debt is rated high-quality by both S&amp;P and Moody&#8217;s. In November 2020, upon the completion of the Upjohn separation, both Moody&#8217;s and S&amp;P lowered our long-term debt rating one notch to &#8216;A2&#8217; and &#8216;A+&#8217;, respectively, and our short-term rating remained unchanged. S&amp;P continues to rate our long-term debt rating outlook as Stable since November 2020, while Moody&#8217;s recently upgraded our long-term debt rating outlook to Positive in December 2021.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The current ratings assigned to our commercial paper and senior unsecured long-term debt:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NAME OF RATING AGENCY</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer Short-Term Rating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer Long-Term Rating</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outlook/Watch</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Moody&#8217;s</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">P-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Positive</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A-1+</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A+</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stable</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Capital Allocation Framework</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our capital allocation framework is devised to facilitate (i) the achievement of medical breakthroughs through R&amp;D investments and business development activities and (ii) returning capital to shareholders through dividends and share repurchases. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our Business and Strategy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section of this MD&amp;A.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our business. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer&#8217;s BOD and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. In December 2021, our BOD declared a first-quarter dividend of $0.40 per share, payable on March 4, 2022, to shareholders of record at the close of business on January 28, 2022. The first-quarter 2022 cash dividend will be our 333rd consecutive quarterly dividend.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for information on the shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including our accelerated share repurchase agreements. At December 31, 2021, our remaining share-purchase authorization was approximately $5.3 billion.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Off-Balance Sheet Arrangements, Contractual, and Other Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the ordinary course of business, (i) we enter into off-balance sheet arrangements that may result in contractual and other obligations and (ii) in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">46</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">may arise in connection with the transaction or that are related to events and activities. For more information on guarantees and indemnifications, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products. Furthermore, collaboration, licensing or other R&amp;D arrangements may give rise to potential milestone payments. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization milestones, which may span several years and which may never occur.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our significant contractual and other obligations as of December 31, 2021 consisted of:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Long-term debt, including current portion (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) and related interest payments;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Estimated cash payments related to the TCJA repatriation estimated tax liability (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Estimated future payments related to the TCJA repatriation tax liability that will occur after December 31, 2021 total $8.3 billion, of which an estimated $750 million is to be paid in the next twelve months and an estimated $7.6 billion is to be paid in periods thereafter;</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Certain commitments totaling $5.2 billion, of which an estimated $1.5&#160;billion is to be paid in the next twelve months, and $3.7 billion in periods thereafter (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">see Note 16C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">);</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Purchases of property plant and equipment (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">see Note 9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). In 2022, we expect to spend approximately $3.3 billion on property, plant and equipment; and</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Future minimum rental commitments under non-cancelable operating leases (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Gl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">o</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">bal Economic Conditions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our Venezuela and Argentina operations function in hyperinflationary economies. The impact to Pfizer is not considered material. For additional information on the global economic environment, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8211;&#8211;Global Operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Market Risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are subject to foreign exchange risk, interest rate risk, and equity price risk. The objective of our financial risk management program is to minimize the impact of foreign exchange rate and interest rate movements on our earnings. We address such exposures through a combination of operational means and financial instruments. For more information on how we manage our foreign exchange and interest rate risks, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Notes 1G</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">7E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as well as the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8212;Global Operations </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section in this Form 10-K for key currencies in which we operate. Our sensitivity analyses of such risks are discussed below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this analysis, holding all other assumptions constant and assuming that a change in one currency&#8217;s rate relative to the U.S. dollar would not have any effect on another currency&#8217;s rates relative to the U.S. dollar, if the dollar were to appreciate against all other currencies by 10%, as of December 31, 2021, the expected adverse impact on our net income would not be significant.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this analysis, holding all other assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point decrease in interest rates as of December 31, 2021, the expected adverse impact on our net income would not be significant.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Price Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;We hold equity securities with readily determinable fair values in life science companies as a result of certain business development transactions. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. From time to time, we will sell such equity securities based on our business considerations, which may include limiting our price risk. Our equity securities with readily determinable fair values are analyzed at year-end to determine their sensitivity to equity price rate changes. In this sensitivity analysis, the expected adverse impact on our net income would not be significant.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">LIBOR</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For information on interest rate risk and LIBOR, see the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8211;&#8211;Global Operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> section in this Form 10-K. We do not expect the transition to an alternative rate to have a material impact on our liquidity or financial resources.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Recently Adopted Accounting Standard</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1B.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Recently Issued Accounting Standards, Not Adopted as of December 31, 2021</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard/Description</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the Financial Statements</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Reference rate reform</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> provides temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued after 2021 because of reference rate reform.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The new guidance provides the following optional expedients: </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.34pt">Simplify accounting analyses under current U.S. GAAP for contract modifications.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.34pt">Simplify the assessment of hedge effectiveness and allow hedging relationships affected by reference rate reform to continue.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.34pt">Allow a one-time election to sell or transfer debt securities classified as held to maturity that reference a rate affected by reference rate reform.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Elections can be adopted prospectively at any time through December 31, 2022. </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are assessing the impact, but currently, we do not expect this new guidance to have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accounting for contract assets and contract liabilities from contracts with customers </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606. This new guidance will generally result in the acquirer recognizing contract assets and contract liabilities at the same amounts that were recorded by the acquiree. Previously, these amounts were recognized by the acquirer at fair value as of the acquisition date.</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">January 1, 2023. Early adoption is permitted.</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We do not expect this new guidance to have a material impact on our consolidated financial statements.</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_139"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the discussion in the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Analysis of Financial Condition, Liquidity, Capital Resources and Market Risk </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">section within MD&amp;A.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_142"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="margin-top:5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></td></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div><span><br/></span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_145"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">To the Board of Directors and Shareholders</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies (the Company) as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Internal Control </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Integrated Framework (2013) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February&#160;24, 2022 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="padding-right:15.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Change in Accounting Principle</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">As discussed in Note 1C to the consolidated financial statements, the Company has elected to change its method of accounting for pension and postretirement plans in 2021 to immediately recognize actuarial gains and losses in the consolidated statements of income.</span></div><div><span><br/></span></div><div style="padding-right:15.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="padding-right:15.75pt"><span><br/></span></div><div style="padding-right:15.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matters</span></div><div style="padding-right:15.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of the U.S. Medicare, Medicaid, and performance-based contract rebates accrual</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in Note 1H to the consolidated financial statements, the Company records estimated deductions for Medicare, Medicaid, and performance-based contract rebates (collectively, U.S. rebates) as a reduction to gross product revenues. The accrual for U.S. rebates is recorded in the same period that the corresponding revenues are recognized. The length of time between when a sale is made and when the U.S. rebate is paid by the Company can be as long as one year, which increases the need for significant management judgment and knowledge of market conditions and practices in estimating the accrual. </span></div><div style="margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We identified the evaluation of the U.S. rebates accrual as a critical audit matter because the evaluation of the product-specific experience ratio assumption involved especially challenging auditor judgment. The product-specific experience ratio assumption relates to estimating which of the Company&#8217;s revenue transactions will ultimately be subject to a related rebate.</span></div><div style="margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s U.S. rebates accrual process related to the development of the product-specific experience ratio assumptions. We estimated the U.S. rebates accrual using internal information and historical data and compared the result to the Company&#8217;s estimated U.S. rebates accrual. We evaluated the Company&#8217;s ability to accurately estimate the accrual for U.S. rebates by comparing historically recorded accruals to the actual amount that was ultimately paid by the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of gross unrecognized tax benefits</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in Notes 5D and 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, the Company&#8217;s tax positions are subject to audit by local taxing authorities in each respective tax jurisdiction, and the resolution of such audits may span multiple years. Since tax law is complex and often subject to varied interpretations and judgments, it is uncertain whether some of the Company&#8217;s tax positions will be sustained upon audit. As of December 31, 2021, the Company has recorded gross unrecognized tax benefits, excluding associated interest, of $6.1 billion. </span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div style="margin-bottom:5pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We identified the evaluation of the Company&#8217;s gross unrecognized tax benefits as a critical audit matter because a high degree of audit effort, including specialized skills and knowledge, and complex auditor judgment was required in evaluating the Company&#8217;s interpretation of tax law and its estimate of the ultimate resolution of its tax positions.</span></div><div style="margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of an internal control over the Company&#8217;s liability for unrecognized tax position process related to (1) interpretation of tax law, (2) evaluation of which of the Company&#8217;s tax positions may not be sustained upon audit, and (3) estimation and recording of the gross unrecognized tax benefits. We involved tax and valuation professionals with specialized skills and knowledge who assisted in evaluating the Company&#8217;s interpretation of tax laws, including the assessment of transfer pricing practices in accordance with applicable tax laws and regulations. We inspected settlements with applicable taxing authorities, including assessing the expiration of statutes of limitations. We tested the calculation of the liability for uncertain tax positions, including an evaluation of the Company&#8217;s assessment of the technical merits of tax positions and estimates of the amount of tax benefits expected to be sustained.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of product and other product-related litigation</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in Notes 1S and 16 to the consolidated financial statements, the Company is involved in product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others. Certain of these pending product and other product-related legal proceedings could result in losses that could be substantial. The accrued liability and/or disclosure for the pending product and other product-related legal proceedings requires a complex series of judgments by the Company about future events, which involves a number of uncertainties.</span></div><div style="margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We identified the evaluation of product and other product-related litigation as a critical audit matter. Challenging auditor judgment was required to evaluate the Company&#8217;s judgments about future events and uncertainties.</span></div><div style="margin-top:8pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company&#8217;s product liability and other product-related litigation processes, including controls related to (1) the evaluation of information from external and internal legal counsel, (2) forward-looking expectations, and (3) new legal proceedings, or other legal proceedings not currently reserved or disclosed. We read letters received directly from the Company&#8217;s external and internal legal counsel that described the Company&#8217;s probable or reasonably possible legal contingency to pending product and other product-related legal proceedings. We inspected the Company&#8217;s minutes from meetings of the Audit Committee, which included the status of key litigation matters. We evaluated the Company&#8217;s ability to estimate its monetary exposure to pending product and other product-related legal proceedings by comparing historically recorded liabilities to actual monetary amounts incurred upon resolution of prior legal matters. We analyzed relevant publicly available information about the Company, its competitors, and the industry.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><img src="pfe-20211231_g10.jpg" alt="pfe-20211231_g10.jpg" style="height:49px;margin-bottom:5pt;vertical-align:text-bottom;width:141px"/></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">We have not been able to determine the specific year that we or our predecessor firms began serving as the Company&#8217;s auditor, however, we are aware that we or our predecessor firms have served as the Company&#8217;s auditor since at least 1942.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New York, New York</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">February 24, 2022</span></td></tr></table></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_148"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:65.973%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzItNS0xLTEtMTU1NjM4_483684ae-d3a9-4f4e-a1d4-8e4c43732120">81,288</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzItNy0xLTEtMTU1NjM4_a613a535-5035-4806-9718-d8b2254855b9">41,651</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzItOS0xLTEtMTU1NjM4_2f539057-26c6-4c9f-a099-8c917a3ed8ee">40,905</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNS0xLTEtMTU1NjM4_3a5b51d9-038d-4f73-bddf-66ec154f7f42">30,821</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNy0xLTEtMTU1NjM4_82fdb0a5-c8c5-471d-9db1-f99ad35bface">8,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtOS0xLTEtMTU1NjM4_37504520-2fa3-4477-a8d2-80fd135923e2">8,054</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNS0xLTEtMTU1NjM4_7ab61130-3ef5-44a9-b13a-d58d1b2ac9ed">12,703</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNy0xLTEtMTU1NjM4_83da3ba5-9e6d-46f0-bb6d-5f51c1771b0d">11,597</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtOS0xLTEtMTU1NjM4_71b8000c-8a67-476f-86aa-688705b47476">12,726</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNS0xLTEtMTU1NjM4_c68ccd3e-9a44-46de-b86e-808d367c30de">13,829</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNy0xLTEtMTU1NjM4_c50c3076-23b9-4810-8ae0-51e5cafd05d0">9,393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtOS0xLTEtMTU1NjM4_d0fdaa6b-4fdb-4251-9f23-b2d4a66f8c2a">8,385</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzctNS0xLTEtMTU1NjM4_f806b26c-3f6b-470f-8f1c-2cc99d226980">3,700</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzctNy0xLTEtMTU1NjM4_71b3ebd7-7244-4068-b3f8-37f61e1c0527">3,348</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzctOS0xLTEtMTU1NjM4_ee0cf2dc-65c4-420a-8ebf-412b2c69eb6c">4,429</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzgtNS0xLTEtMTU1NjM4_80ffaa79-fcd8-4a59-89d2-3381af224bd9">802</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzgtNy0xLTEtMTU1NjM4_e341c4a1-fc93-4aba-a0c6-11313a940986">579</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzgtOS0xLTEtMTU1NjM4_9b959c76-bddb-4ddf-ac94-be4872444ce6">601</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) on completion of Consumer Healthcare JV transaction</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzktNS0xLTEtMTU1NjM4_e4c6377a-8a3d-4e68-a21c-68db41c2ed11">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzktNy0xLTEtMTU1NjM4_d97f7061-da2a-4d3d-b3e5-f92bd6bc6e8f">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzktOS0xLTEtMTU1NjM4_5ef1ee20-71b0-4fe9-bba9-a2d5b9f3a3f4">8,107</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEwLTUtMS0xLTE1NTYzOA_b4e851e8-dada-4e99-9f60-7ca607ffbc0e">4,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEwLTctMS0xLTE1NTYzOA_c1d512b1-f464-41ab-972b-e99bc10ae4bf">1,219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEwLTktMS0xLTE1NTYzOA_00f627ae-495c-440d-90c5-9ea23af6d8f1">3,497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3">24,311</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663">7,036</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2">11,321</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEyLTUtMS0xLTE1NTYzOA_1ce2ac83-55f8-45b7-a1ca-82e48cb7f220">1,852</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEyLTctMS0xLTE1NTYzOA_46648b7b-1536-456a-a925-29ed449f699a">370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEyLTktMS0xLTE1NTYzOA_b679645e-b9b8-4443-9007-e145851af4e6">583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEzLTUtMS0xLTE1NTYzOA_04ace51c-d6d2-4d50-a11e-63f47dfac56e">22,459</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEzLTctMS0xLTE1NTYzOA_b0eb3f9a-686b-4197-aae3-802a2a804af6">6,666</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEzLTktMS0xLTE1NTYzOA_99460422-1d0c-4616-87e0-be7bbedfe2fd">10,738</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE1LTUtMS0xLTE1NTYzOA_e5d7c609-0b4b-4142-9fc2-2a3e85192096">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE1LTctMS0xLTE1NTYzOA_bb74f6bb-682b-45eb-88da-72fedd1a54bd">2,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE1LTktMS0xLTE1NTYzOA_45508b8f-b29f-458b-bd37-34a303e8ea87">5,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE4LTUtMS0xLTE1NTYzOA_63381e29-0a2c-496d-b4c6-68a394474885">22,025</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE4LTctMS0xLTE1NTYzOA_af50c122-aeea-46a2-8596-4a51c83c4ee2">9,195</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE4LTktMS0xLTE1NTYzOA_8fa47364-c204-4959-bd6f-cbdf0d676305">16,056</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE5LTUtMS0xLTE1NTYzOA_57edee31-ae84-4725-82df-9433375f7967">45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE5LTctMS0xLTE1NTYzOA_37cb86df-be74-46a3-875e-611d5bfbb13b">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE5LTktMS0xLTE1NTYzOA_16d0978e-95a3-497b-9467-cfe9d8227c44">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIwLTUtMS0xLTE1NTYzOA_77a1a59a-c3ab-4127-9754-8818e2a6c7d5">21,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIwLTctMS0xLTE1NTYzOA_0df638b6-48e0-4e58-9cac-8993692d6dda">9,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIwLTktMS0xLTE1NTYzOA_1f7da7ae-37c9-4e2a-847b-68e42674ea1a">16,026</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIzLTUtMS0xLTE1NTYzOA_0e545ecc-37de-49d0-9333-adbb95aa1e66">4.00</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIzLTctMS0xLTE1NTYzOA_9266c59a-72d5-4d5f-b9d4-bd97404d6dd3">1.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIzLTktMS0xLTE1NTYzOA_99164c61-c68d-4acd-bb6b-985f75ae5e88">1.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI0LTUtMS0xLTE1NTYzOA_4f1c724c-81bf-4225-845a-3345c65cdc0b">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI0LTctMS0xLTE1NTYzOA_5e4fb396-35eb-4d8b-822a-67cafb2bad27">0.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI0LTktMS0xLTE1NTYzOA_65987aba-5b6e-44bd-a2b9-e6ffc251497e">0.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI1LTUtMS0xLTE1NTYzOA_91dcc62c-eae1-41fe-a34e-d84b4ce79239">3.92</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI1LTctMS0xLTE1NTYzOA_f44cc108-aac9-4178-a98e-881274d828dd">1.65</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI1LTktMS0xLTE1NTYzOA_1fc0bc1d-9832-4e66-80ee-c8b637bc7a9d">2.88</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI3LTUtMS0xLTE1NTYzOA_1e36cbb6-6a9a-4002-9173-dc548d96b324">3.93</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI3LTctMS0xLTE1NTYzOA_cc501ebd-4849-406b-adaa-8e1ae22ca36f">1.18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI3LTktMS0xLTE1NTYzOA_5e4c41dd-ce98-4775-bf52-4a90c65db349">1.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI4LTUtMS0xLTE1NTYzOA_08ad40bd-f385-476d-91e3-a03c3399eb91">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI4LTctMS0xLTE1NTYzOA_9b64b50c-6b5e-4517-985c-3ef44b44465d">0.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI4LTktMS0xLTE1NTYzOA_6eeb9e52-b337-4eec-9983-dce9a12cb031">0.94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI5LTUtMS0xLTE1NTYzOA_bbc14571-6dc0-4efb-a9e4-087a1b831e5e">3.85</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI5LTctMS0xLTE1NTYzOA_2ab136c1-d27e-40b8-9734-a64365a4aec6">1.63</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI5LTktMS0xLTE1NTYzOA_63fb6b34-d608-4eaf-a67a-5950f882d07c">2.82</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMxLTUtMS0xLTE1NTYzOA_b81f7d02-b490-4236-859f-b314719489a3">5,601</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMxLTctMS0xLTE1NTYzOA_800efef4-3464-486b-9d73-1adb195d92a9">5,555</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMxLTktMS0xLTE1NTYzOA_fc5dd36c-dab4-40db-ac14-34cb7e933318">5,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average shares&#8211;&#8211;diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMyLTUtMS0xLTE1NTYzOA_2e6162b1-f05d-4337-b157-9aade0cc0169">5,708</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMyLTctMS0xLTE1NTYzOA_152e60bb-7a54-4e8e-b3c3-b5f1610ce051">5,632</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMyLTktMS0xLTE1NTYzOA_1da896c1-6e2b-4800-8d69-e25b3a2b44cc">5,675</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:285pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1M.</span></ix:footnote></div><div style="padding-right:-13.5pt;text-align:center;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">51</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_151"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:72.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzItMi0xLTEtMTU1NjM4_63381e29-0a2c-496d-b4c6-68a394474885">22,025</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzItNC0xLTEtMTU1NjM4_af50c122-aeea-46a2-8596-4a51c83c4ee2">9,195</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzItNi0xLTEtMTU1NjM4_8fa47364-c204-4959-bd6f-cbdf0d676305">16,056</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzQtMi0xLTEtMTU1NjM4_e3873478-26ae-4b41-a0b0-65677f23bda8">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzQtNC0xLTEtMTU1NjM4_b09e94b1-53f8-4315-ae78-7c93bba2b749">772</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzQtNi0xLTEtMTU1NjM4_fb93be5f-2162-4f8a-aeae-79face3b46e9">675</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzUtMi0xLTEtMTU1NjM4_32d994d4-b1da-48d7-a29a-37ae415432d1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzUtNC0xLTEtMTU1NjM4_03080745-536e-465c-8c34-e2912b2e41ed">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzUtNi0xLTEtMTU1NjM4_78180590-276f-4e78-8f21-f62bc089dcf6">288</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzYtMi0xLTEtMTU1NjM4_639072ee-e612-4388-97b5-6d2dcb0b30e1">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzYtNC0xLTEtMTU1NjM4_6fa117ff-fbaf-44d7-8895-31467355e81b">755</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzYtNi0xLTEtMTU1NjM4_835c12e1-7986-4142-b02a-eb1350cff8fb">387</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzctMi0xLTEtMTU1NjM4_24b20650-6c06-4a7d-b3be-84372d41bb0e">526</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzctNC0xLTEtMTU1NjM4_fddce784-4db8-4693-ba42-78dc07e68a2f">582</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzctNi0xLTEtMTU1NjM4_b4af388f-45c1-4b94-a6db-4dcbe2cb5480">476</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtMi0xLTEtMTU1NjM4_d31e2e96-23db-4582-8a3b-1875408a08a9">134</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNC0xLTEtMTU1NjM4_2946e08a-d232-4528-a2f0-63419668fd07">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNi0xLTEtMTU1NjM4_732ab48d-d360-432a-bd11-178fbd622007">664</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzktMi0xLTEtMTU1NjM4_2870a8c1-6fdc-40e5-8728-d03337339475">660</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzktNC0xLTEtMTU1NjM4_2fafceaf-d492-4b13-8526-5f6fdfda0f1a">561</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzktNi0xLTEtMTU1NjM4_eca88248-5de7-46c4-a411-1590c98179d0">188</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEwLTItMS0xLTE1NTYzOA_545d28a7-7a04-487a-bc08-12414c055b27">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEwLTQtMS0xLTE1NTYzOA_951ac434-5788-49eb-8caf-f3478adbc2dd">361</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEwLTYtMS0xLTE1NTYzOA_ecb20ed4-3522-4112-ae29-20499f9f7889">1</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTItMS0xLTE1NTYzOA_061e55c1-6b6a-46e3-b613-1c3fa13abb1e">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTQtMS0xLTE1NTYzOA_b5dd47cb-0404-4dcb-8afb-8ac782a5f655">188</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTYtMS0xLTE1NTYzOA_154dbc6d-b981-40d8-abc4-8299b6b7a746">39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEzLTItMS0xLTE1NTYzOA_3e0ca31a-3b7c-4c27-bed1-2bd4b4ec3be7">384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEzLTQtMS0xLTE1NTYzOA_64f79834-ae5b-42cf-a147-27e3b7444265">173</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEzLTYtMS0xLTE1NTYzOA_6ce4d7b7-da63-4460-9dbe-4613f2fe8368">38</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit plans: prior service (costs)/credits and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzE5LTItMS0xLTE1NTYzOA_e8f9ecbb-3333-4fa6-9693-c764f60b8350">116</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzE5LTQtMS0xLTE1NTYzOA_9261c8c6-0a01-414c-9b05-deac29a5320a">52</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzE5LTYtMS0xLTE1NTYzOA_e4b06e5b-75cf-4862-a676-f74cd0083aad">7</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIwLTItMS0xLTE1NTYzOA_8e9227ee-0951-4b67-b6e2-bf4feb1831f6">154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIwLTQtMS0xLTE1NTYzOA_a93b0275-6ee2-48a8-9009-3b67e669d27f">176</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIwLTYtMS0xLTE1NTYzOA_b388c0ba-6113-43ce-93e2-2a8d0c9586b6">181</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIxLTItMS0xLTE1NTYzOA_f725ba91-6df6-4888-a45c-59fd55ba9f27">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIxLTQtMS0xLTE1NTYzOA_1fa4e5c7-01ea-43bb-aa99-32bfe3ddb65f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIxLTYtMS0xLTE1NTYzOA_566f530b-2b6d-4f4f-8a6d-518b5eed83b2">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIyLTItMS0xLTE1NTYzOA_89a12c56-e943-429f-a732-603f68bc9afe">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIyLTQtMS0xLTE1NTYzOA_489504d6-db28-4379-a967-c32868d2b9bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIyLTYtMS0xLTE1NTYzOA_708680c8-8be9-4fc9-bcbc-f2f11d236500">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIzLTItMS0xLTE1NTYzOA_ea1d39ee-a810-4964-9e05-d7a36061210b">113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIzLTQtMS0xLTE1NTYzOA_3acdc66e-129d-4f97-a5f5-e302e685ede5">124</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIzLTYtMS0xLTE1NTYzOA_36b24dae-caf3-4b6c-9b63-83c9e3a6db46">189</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss), before tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI0LTItMS0xLTE1NTYzOA_ace33eaa-df32-468a-9f8d-67ea411f67e1">519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI0LTQtMS0xLTE1NTYzOA_da7c2513-eae5-4249-8fd8-2e34cba6916f">243</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI0LTYtMS0xLTE1NTYzOA_d1708934-cd97-4d54-baeb-dd99c65332d6">48</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI1LTItMS0xLTE1NTYzOA_7b95a10f-077d-46ac-8b68-58e892e35acd">71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI1LTQtMS0xLTE1NTYzOA_3cda1fc7-d2ed-4956-aadb-f3dac3657d13">227</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI1LTYtMS0xLTE1NTYzOA_74cc3428-e932-42df-88fb-ec011206b016">178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI2LTItMS0xLTE1NTYzOA_eeae9349-18b5-4415-9c52-40956ac3e1fb">589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI2LTQtMS0xLTE1NTYzOA_fded3238-d0bf-49d3-8f94-c817fc303279">471</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI2LTYtMS0xLTE1NTYzOA_9c7a4c54-7314-4176-8a99-adf87004f203">130</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI4LTItMS0xLTE1NTYzOA_23c74318-8cf9-4daf-b163-ed9cb7aaa9cc">21,435</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI4LTQtMS0xLTE1NTYzOA_dfae4ae4-8342-4406-9e83-489940f989b3">9,666</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI4LTYtMS0xLTE1NTYzOA_565e670e-39eb-4d87-96ea-3889855ebf27">15,926</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Comprehensive income/(loss) attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI5LTItMS0xLTE1NTYzOA_b8cc0873-0cf5-46ec-83a7-62955e25549b">43</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI5LTQtMS0xLTE1NTYzOA_18c5fcd1-3964-4635-8afa-b1e3af7bc5ee">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI5LTYtMS0xLTE1NTYzOA_b36e0503-01f4-4c7a-a7af-bdb673ec629f">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income/(loss) attributable to Pfizer Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzMwLTItMS0xLTE1NTYzOA_0a338497-d933-4d75-beea-99aabd0437b2">21,393</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzMwLTQtMS0xLTE1NTYzOA_b2686617-6f3f-4f0a-8bc3-72253dc1b289">9,639</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzMwLTYtMS0xLTE1NTYzOA_21b14619-66b9-4358-98cd-d4afc6bc9625">15,908</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNA_9830691d-ff66-4fc3-a498-0043a67eab32" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></ix:footnote></div><div style="margin-bottom:315pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNQ_deb48efb-7fb2-48e3-9a1a-db0fc4767348" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">52</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_154"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br/></span></div></div><div style="margin-bottom:70pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:73.266%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT  PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQtMi0xLTEtMTU1NjM4_01af50bf-f259-4642-8f5e-6c51e58dcc9b">1,944</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQtNC0xLTEtMTU1NjM4_6139d87e-823b-43d4-bd4d-3089d8211448">1,786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUtMi0xLTEtMTU1NjM4_f9e13b2a-f1a7-4f23-95bf-ff6a6e6ab519">29,125</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUtNC0xLTEtMTU1NjM4_46eee88a-511a-4d3d-b0a2-59bde6f3954a">10,437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade accounts receivable, less allowance for doubtful accounts: 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246NGQ4YzU0NTA0NGM1NGFlMDg4ZWZmOGUwYWMyMzFiZTdfNzQ_6ed16d0c-890d-4382-87ae-ff285dee1c21">492</ix:nonFraction>; 2020&#8212;$<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246NGQ4YzU0NTA0NGM1NGFlMDg4ZWZmOGUwYWMyMzFiZTdfODM_ed4ed753-5a3a-42c5-9913-acb6b71fe85f">508</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtMi0xLTEtMTU1NjM4_990d4f9e-b815-4a84-9743-4e8154659187">11,479</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtNC0xLTEtMTU1NjM4_c841b661-b351-4089-aa18-d63d2791d21c">7,913</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzctMi0xLTEtMTU1NjM4_0bfa1acc-0879-4700-83cd-9ac4d0af7445">9,059</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzctNC0xLTEtMTU1NjM4_dc820441-f2d8-4da4-b1d0-9bbc4f88e000">8,020</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Current tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzgtMi0xLTEtMTU1NjM4_88f2d2d1-ab88-45e8-81d4-55aec1626994">4,266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:OtherTaxAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzgtNC0xLTEtMTU1NjM4_20d3c57b-1bd3-4dcb-a629-d4830681d616">3,264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzktMi0xLTEtMTU1NjM4_412efa00-35ce-4d19-8ae0-a4cd22317a92">3,820</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzktNC0xLTEtMTU1NjM4_8e086121-677c-4d60-8137-101e20c4efe1">3,646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzExLTItMS0xLTE1NTYzOA_4149bdf7-fda3-4719-9396-833b8190899d">59,693</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzExLTQtMS0xLTE1NTYzOA_c37fa48a-6902-4cd9-b82c-be5d3e0d5a40">35,067</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEyLTItMS0xLTE1NTYzOA_e92117e2-65e3-4f39-84f8-806cf6c260a2">16,472</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEyLTQtMS0xLTE1NTYzOA_73c0072f-c22c-4afc-abc3-bb67ee46ae41">16,856</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEzLTItMS0xLTE1NTYzOA_fdba4ba5-40ac-4519-ba1f-970d6e1ff1cd">5,054</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEzLTQtMS0xLTE1NTYzOA_7292e5d4-645a-469a-b3fe-5abd3a51f1fe">3,406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE0LTItMS0xLTE1NTYzOA_7b1530b8-38b3-4302-8fee-2c3004c7e4cf">14,882</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE0LTQtMS0xLTE1NTYzOA_06f41800-440b-4105-93d3-95f318698cf8">13,745</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identifiable intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE1LTItMS0xLTE1NTYzOA_f9ed2ee3-a376-4f00-b5d7-40e663523c4f">25,146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE1LTQtMS0xLTE1NTYzOA_bbb5c74b-68ed-4c93-9363-1a4a45c5f213">28,337</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTItMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7">49,208</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTQtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614">49,556</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE3LTItMS0xLTE1NTYzOA_704923cc-f82f-4f0e-8aea-52fe36121004">3,341</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE3LTQtMS0xLTE1NTYzOA_afdeb93a-ba5b-44e8-af2b-5643be60584c">2,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE4LTItMS0xLTE1NTYzOA_7329abef-62ff-4d1f-8727-b0e241585826">7,679</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE4LTQtMS0xLTE1NTYzOA_7818e897-b369-473e-9c31-655472745e0e">4,879</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIwLTItMS0xLTE1NTYzOA_36b993a2-a144-4b31-ab64-0ed8b612253b">181,476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIwLTQtMS0xLTE1NTYzOA_f58df7bc-f422-4437-8a72-2fec6d2308fd">154,229</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Liabilities and Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Short-term borrowings, including current portion of long-term debt: 2021&#8212;$<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjkwYTc5MzdhM2RhNDQzYzFhNjQwZDFiMmI4OThiOTljXzc3_b3a5efec-5dfe-4bce-845a-dad8959f75f9">1,636</ix:nonFraction>; 2020&#8212;$<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjkwYTc5MzdhM2RhNDQzYzFhNjQwZDFiMmI4OThiOTljXzg2_d4ad19c0-0377-4034-9ee6-885cdef9df67">2,002</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTItMS0xLTE1NTYzOA_bdf2a27b-e46c-40e6-b386-bc59126752fe">2,241</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTQtMS0xLTE1NTYzOA_1db9a4d1-f0c7-414a-a24f-276e6ca72db0">2,703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI0LTItMS0xLTE1NTYzOA_e47ad4e4-ca8d-4919-b47e-3c782e0dc6d0">5,578</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI0LTQtMS0xLTE1NTYzOA_d77546ba-8ff6-4848-aa5c-2a27c28d1f9c">4,283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Dividends payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI1LTItMS0xLTE1NTYzOA_a9cbfe93-9fdd-4e6b-abbd-7bdf5b8ca48f">2,249</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI1LTQtMS0xLTE1NTYzOA_8ba94e6e-7841-4588-8519-90d2d8a34846">2,162</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI2LTItMS0xLTE1NTYzOA_4e925446-c952-474f-996f-29b5ff5b644e">1,266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI2LTQtMS0xLTE1NTYzOA_51dd99de-0d9f-4690-b05a-515c74178ecf">1,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued compensation and related items</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI3LTItMS0xLTE1NTYzOA_90a9ad95-3669-4bcf-9b4c-4e35adbede49">3,332</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI3LTQtMS0xLTE1NTYzOA_278e39ea-5305-405f-8481-4821e00a5326">3,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI4LTItMS0xLTE1NTYzOA_d82d3488-46f5-451e-9784-d585a0dcb693">3,067</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI4LTQtMS0xLTE1NTYzOA_b460d8a4-ae4b-4195-8f41-b57dbd86f9df">1,113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI5LTItMS0xLTE1NTYzOA_5c2b3079-cd44-4a9e-bb8d-b35d333c093e">24,939</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI5LTQtMS0xLTE1NTYzOA_57d11a0f-51c6-473f-bb87-4b00705346e6">11,561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMxLTItMS0xLTE1NTYzOA_b7304963-b4c1-4633-93c5-0ba5e4814c67">42,671</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMxLTQtMS0xLTE1NTYzOA_6a775158-ef9e-4a77-9c0c-3cb2c4d96e84">25,920</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMzLTItMS0xLTE1NTYzOA_3e03b5b5-e6c2-4a2c-8b2c-000773b8fea4">36,195</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMzLTQtMS0xLTE1NTYzOA_a7b0e4eb-0911-406e-9147-3725e3385453">37,133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM0LTItMS0xLTE1NTYzOA_47d27fa0-dfc4-4fe0-82de-e94d1246690c">3,489</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM0LTQtMS0xLTE1NTYzOA_930bb524-2019-472c-8b9a-19deb059cc40">4,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Postretirement benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM1LTItMS0xLTE1NTYzOA_59e77402-8abb-4ce1-ae86-94e25b8a7554">235</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM1LTQtMS0xLTE1NTYzOA_418eb048-a467-44e0-9a66-ed0f710e5b5f">645</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM2LTItMS0xLTE1NTYzOA_927c1b51-2039-4d18-ac37-4b21c088fbea">349</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM2LTQtMS0xLTE1NTYzOA_218442bd-a092-40ab-b19a-24663d37ba48">4,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other taxes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM3LTItMS0xLTE1NTYzOA_2fdcdbdb-f250-4b0d-9257-4f3fc53778d1">11,331</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM3LTQtMS0xLTE1NTYzOA_3a4d4e4b-c26e-4c9e-90a8-02cdcea3f347">11,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM4LTItMS0xLTE1NTYzOA_75d9d52b-c88d-45b1-b4d5-0525c78cc907">9,743</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM4LTQtMS0xLTE1NTYzOA_4bc38830-56fe-4c4b-b738-3e3994992141">6,669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM5LTItMS0xLTE1NTYzOA_897c04b9-6231-4ed2-9b69-b84af5291d0d">104,013</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM5LTQtMS0xLTE1NTYzOA_ab1d4bb0-d1d2-4f4d-a596-537aff26be2e">90,756</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Commitments and Contingencies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQxLTItMS0xLTE1NTYzOA_d5cdced0-71f5-462c-a235-1fff562dfa4d"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQxLTQtMS0xLTE1NTYzOA_7d187368-ef70-461f-aa31-ad762496b9e4"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Preferred stock, no par value, at stated value; <ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzUy_00829a47-59ef-4d65-84eb-0a3f082af5da"><ix:nonFraction unitRef="shares" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzUy_8409c7b6-6ce1-4f1b-8115-1019bca7a856">27</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_04bb5f48-f18c-4748-bcf5-86dad6026414"><ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_15f3478d-2f25-424f-8a19-60f4df32b54f"><ix:nonFraction unitRef="shares" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_5ca81dc3-7bec-4383-8f51-10293e7890e5"><ix:nonFraction unitRef="shares" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_f3826e12-4c17-40b5-824b-029962b505a8">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December 31, 2021 and December 31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTItMS0xLTE1NTYzOA_dcf6230e-9090-4aa4-9af6-77db4147ce06">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTQtMS0xLTE1NTYzOA_59fdc4c5-3e9d-42b2-9c61-f88abf8c4be1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE4_7571583a-fa3f-4fb8-a031-370a0280d97a"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE4_a9cd47ef-0f4c-43af-8a76-5c702534f396">0.05</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzMy_6a979e66-67b7-4d01-94e5-b7388f3b28c3"><ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzMy_abd53949-bf1c-4e25-ad4d-3185756cd9ae">12,000</ix:nonFraction></ix:nonFraction> shares authorized; issued: 2021&#8212;<ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE2NDkyNjc0NDE3Njc_ed78cb9a-16c3-48c5-a6fc-a60384736450">9,471</ix:nonFraction>; 2020&#8212;<ix:nonFraction unitRef="shares" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE2NDkyNjc0NDE3NzI_ab6b5fad-b6a2-49be-b222-83d4d0c63e9a">9,407</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTItMS0xLTE1NTYzOA_a284eaea-1d97-4bbe-8bb3-4dc2b020e069">473</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTQtMS0xLTE1NTYzOA_8865f245-c316-403c-ab90-904758b480e0">470</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ1LTItMS0xLTE1NTYzOA_7fb6a44f-5ca4-47ae-a2a9-d04571072afa">90,591</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ1LTQtMS0xLTE1NTYzOA_df791389-1768-44c1-a5e5-443791147cab">88,674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Treasury stock, shares at cost: 2021&#8212;<ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjVkZTYzZmQ5ZDJlNjQ4NWI5ZDU2ODFjZDkxMGE2MGE4XzE2NDkyNjc0NDE3NDE_786842a7-43cc-4e6a-ae85-9551742c7df3">3,851</ix:nonFraction>; 2020&#8212;<ix:nonFraction unitRef="shares" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjVkZTYzZmQ5ZDJlNjQ4NWI5ZDU2ODFjZDkxMGE2MGE4XzE2NDkyNjc0NDE3NDg_bb7f10f6-6ace-4cb5-a67d-b3915e11921a">3,840</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTItMS0xLTE1NTYzOA_4927892f-96c1-49d6-a6af-9526e643c400">111,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTQtMS0xLTE1NTYzOA_e2fb437a-325b-444b-a93f-4cec2020c4de">110,988</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ4LTItMS0xLTE1NTYzOA_bcdecde8-fd24-493d-85a1-d37f586ed1a5">103,394</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ4LTQtMS0xLTE1NTYzOA_e0b9e02a-3686-4034-8c34-6adf65ce0d34">90,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ5LTItMS0xLTE1NTYzOA_fa91a244-e48c-4371-9239-c5ea6ec5caa7">5,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ5LTQtMS0xLTE1NTYzOA_2599286e-c17d-4a8c-abff-919150586d2d">5,310</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Pfizer Inc. shareholders&#8217; equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUwLTItMS0xLTE1NTYzOA_fd7594a7-207b-4f0f-9471-74b8f7f175eb">77,201</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUwLTQtMS0xLTE1NTYzOA_a19d2f2a-a0ec-4fa0-bfb9-4909ef40a96a">63,238</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUxLTItMS0xLTE1NTYzOA_d7591a0f-ca53-47a4-b8c6-a3a9705d387b">262</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUxLTQtMS0xLTE1NTYzOA_83e00d46-532f-4d0c-bc6a-9779097d0214">235</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUyLTItMS0xLTE1NTYzOA_54ce2ca1-d139-4e68-9e5a-bd9c8f0ba003">77,462</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUyLTQtMS0xLTE1NTYzOA_67509819-fa05-42c8-a0b5-3071bebf9a68">63,473</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total liabilities and equity</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUzLTItMS0xLTE1NTYzOA_5d4db4ab-1875-464d-a53d-03c2fb2b7a01">181,476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUzLTQtMS0xLTE1NTYzOA_8c4f322b-3cdc-47de-a106-c2a602408cd1">154,229</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_157"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Equity</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.381%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="57" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">PFIZER INC. SHAREHOLDERS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:11pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Preferred Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS,&#160;EXCEPT PREFERRED SHARES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Stated Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Add&#8217;l<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Accum.<br/>Other<br/>Comp. Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Share -<br/>holders&#8217;<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Non-controlling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Total<br/>Equity</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Balance, January&#160;1, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21a79fdd21944aa89c066de9cbbfee5d_I20181231" decimals="0" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMi0xLTEtMTU1NjM4_35016769-62d4-407f-a841-b834140874c8">478</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a79fdd21944aa89c066de9cbbfee5d_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtNC0xLTEtMTU1NjM4_789f08e2-5bb2-40bd-a18f-56dc68a22d34">19</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief8bb2c5291c4b5c9a5015f9815e4ee3_I20181231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtNi0xLTEtMTU1NjM4_6b6e7e2c-79fe-4a69-a2b0-c64a88accb59">9,332</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8bb2c5291c4b5c9a5015f9815e4ee3_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtOC0xLTEtMTU1NjM4_9c6bea80-aa46-4393-ab99-1718dd95527a">467</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a2a3761e1b1438383b3a8eb28300997_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTAtMS0xLTE1NTYzOA_b533bee1-fe7c-4c77-9ce8-eb221e392b93">86,253</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i70369ec902474685b7ee35afae6111aa_I20181231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTItMS0xLTE1NTYzOA_950199de-3beb-47bc-a97c-864979108920">3,615</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70369ec902474685b7ee35afae6111aa_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTQtMS0xLTE1NTYzOA_908ba995-70b4-42ee-918c-94d2c5b52d46">101,610</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e769fcaccc349d5b816b47154d226a6_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTYtMS0xLTE1NTYzOA_91abdcbb-83a1-4642-927b-0142cf3d0171">83,527</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fa41a976be144ff95f4427e340cfcab_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTgtMS0xLTE1NTYzOA_c71d54e7-945b-47a5-85cc-a86621eaf03b">5,249</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i595cd5191b614c5896a444e2f5f45def_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMjAtMS0xLTE1NTYzOA_d9ea415e-63c8-413a-adcf-f64cff8236fd">63,407</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f468b487cc540788a176ec913956dca_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMjItMS0xLTE1NTYzOA_2b9db380-e5fe-42fb-b276-7c9e2a6623f2">351</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e10b1e1c1f846769573d84f9a61fc72_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMjQtMS0xLTE1NTYzOA_73c3178c-79df-4b73-ad96-1cec23f0bdae">63,758</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMTYtMS0xLTE1NTYzOA_64adc5d5-49d5-41f4-b4c6-bcbc2f473865">16,026</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMjAtMS0xLTE1NTYzOA_7adc3ed5-016c-45d2-8d4b-bfc4b443a1af">16,026</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMjItMS0xLTE1NTYzOA_e71557e0-dbdf-4e95-93c4-25c15c5a733c">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMjQtMS0xLTE1NTYzOA_0b602244-37de-48a8-b73f-cb11d19241fc">16,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57063444ae6416ea155fe3b461c2ed1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMTgtMS0xLTE1NTYzOA_16978a62-b40f-4d30-bc9a-e59aa0a2835b">118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMjAtMS0xLTE1NTYzOA_9f35e96d-97ff-447f-b33b-d2df66fdbf0b">118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMjItMS0xLTE1NTYzOA_2b646c56-d904-42d6-9a28-e10aa99d7f90">11</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMjQtMS0xLTE1NTYzOA_ffb8d2ee-b8cd-4187-955c-89e0870cfc1b">130</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MTM0MTEwNWNhZmUyNDUzMWI0M2Y1NTVlMWE5YTQzZTRfMTY0OTI2NzQ0MTcwNw_b5992faf-1a4e-4553-a0eb-a44348c626c8">1.46</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzctMTYtMS0xLTE1NTYzOA_cdac24c3-a52a-46ab-b3c7-2bf7b5a23014">8,174</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzctMjAtMS0xLTE1NTYzOA_90d30b7f-abd0-4ebb-9770-c1d84af0b9bc">8,174</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzctMjQtMS0xLTE1NTYzOA_f764f8bc-4b84-4ab4-aca6-402de5dc3109">8,174</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Preferred stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231" decimals="-6" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzgtMTYtMS0xLTE1NTYzOA_a7d8f145-c31a-4406-b440-fd498a2f2fc2">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzgtMjAtMS0xLTE1NTYzOA_e1042e26-41e4-4359-a13e-c30d33bf61da">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DividendsPreferredStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzgtMjQtMS0xLTE1NTYzOA_ebdcfc0e-7a76-4602-926f-e7bf9bda4ccd">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzktMjItMS0xLTE1NTYzOA_954413e5-d57a-4f0e-9d9d-cb0c4450a2ce">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzktMjQtMS0xLTE1NTYzOA_6d9d06ea-afb5-4592-bfad-78ce72db38d1">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Share-based payment transactions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6ae9c7231104451b51d26af9103a373_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTYtMS0xLTE1NTYzOA_cdce96a3-dc7a-463b-b085-ffa0c88c0f3f">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6ae9c7231104451b51d26af9103a373_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTgtMS0xLTE1NTYzOA_bc989c75-a598-4f65-acef-7f5973cea35b">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTEwLTEtMS0xNTU2Mzg_233a12c1-d08e-489f-8843-3c8b3ca7215a">1,219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTEyLTEtMS0xNTU2Mzg_02d44a33-2a88-4a5d-b2e5-e00c7228416b">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTE0LTEtMS0xNTU2Mzg_65f68417-7444-4eff-adcc-377e10543308">326</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTIwLTEtMS0xNTU2Mzg_e1da76bf-b845-44ba-82fe-76f598b111a4">894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTI0LTEtMS0xNTU2Mzg_36465679-aee7-460e-b4fe-415df15a5dd4">894</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Purchases of common stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTEyLTEtMS0xNTU2Mzg_103671cb-d24d-47ab-b1e4-cca517d108ef">213</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTE0LTEtMS0xNTU2Mzg_a373a04e-880a-4ff6-ac83-f184cdfa2023">8,865</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTIwLTEtMS0xNTU2Mzg_dc98a30d-a5f4-4c1c-87a9-2e8534978fc8">8,865</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTI0LTEtMS0xNTU2Mzg_13a064a6-95f2-4cdf-9632-0633a9d8ace0">8,865</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Preferred stock conversions and redemptions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia99d4818adb64cf09382dd79ab3ff911_D20190101-20191231" decimals="0" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTItMS0xLTE1NTYzOA_5cec47fc-9d60-45a4-8a16-4ec8eba884d1">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia99d4818adb64cf09382dd79ab3ff911_D20190101-20191231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTQtMS0xLTE1NTYzOA_b363b7cb-c5b4-4eea-b0ed-6cfff8a8abd4">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTEwLTEtMS0xNTU2Mzg_cf9c2d3c-2acd-4d32-86d3-a3658d75dc6c">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231" decimals="-6" sign="-" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTE0LTEtMS0xNTU2Mzg_2c24bef5-dede-40ba-89bb-8de0e658b6f2">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTIwLTEtMS0xNTU2Mzg_6aa6a1d8-356a-4b72-86d5-283b2a20a8ba">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTI0LTEtMS0xNTU2Mzg_54d410b6-33a4-45d2-bf2c-3e6359bd38b7">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTEwLTEtMS0xNTU2Mzg_65aa3215-1817-4efd-987e-e06af1a23721">40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTE2LTEtMS0xNTU2Mzg_86c00528-560a-4601-97b0-87ad26497379">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTIwLTEtMS0xNTU2Mzg_50a119bd-b681-4e27-80e5-6da8f9c8aea2">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTIyLTEtMS0xNTU2Mzg_e96fdd6f-546e-4ac4-8512-58ef1bcacb6c">60</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTI0LTEtMS0xNTU2Mzg_639d3e36-c1ca-44d6-9a24-5a254b80e366">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a4e3937ea1429897d5a87a331d97a4_I20191231" decimals="0" name="us-gaap:SharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTItMS0xLTE1NTYzOA_07657776-30a9-4b73-856d-c62a728d48f6">431</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a4e3937ea1429897d5a87a331d97a4_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTQtMS0xLTE1NTYzOA_fbd20766-9988-4259-a6dc-5fc644155706">17</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf9258b1a52e41f7b182a2eb16acdb9c_I20191231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTYtMS0xLTE1NTYzOA_22f14ae7-f5b6-47a9-96fe-aea2f91b3a87">9,369</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf9258b1a52e41f7b182a2eb16acdb9c_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTgtMS0xLTE1NTYzOA_953b0dba-6a02-4712-9e28-778aa19cafb7">468</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id51cff7fa3b2450293ac21547637f902_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTEwLTEtMS0xNTU2Mzg_a6bfd0d9-54bd-48fe-9253-02558a9d0f31">87,428</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5931a8435e8847bbb43008b48c1d8f71_I20191231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTEyLTEtMS0xNTU2Mzg_ce0010ab-96ed-4d96-8001-408a5d7afb11">3,835</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5931a8435e8847bbb43008b48c1d8f71_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTE0LTEtMS0xNTU2Mzg_9bfc3a00-4122-40f1-a727-31447513840d">110,801</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd94794713d841c39b811cf2ccdd0e5b_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTE2LTEtMS0xNTU2Mzg_01a5fd6f-453e-4848-b666-3b6999adb528">91,397</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c15300160eb40199b2470fd99513c75_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTE4LTEtMS0xNTU2Mzg_0e0b472e-f98c-4de0-b242-2fdb768b1f9a">5,367</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3ccccf6fbe4566816a85a5ac4c621a_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTIwLTEtMS0xNTU2Mzg_38653531-2737-425b-bb3a-ecab87de1c5e">63,143</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc359e016414e0fb3f5cdc5fc783e30_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTIyLTEtMS0xNTU2Mzg_ff6ecf19-94d3-41e0-9bf3-72314f0fb9bf">303</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTI0LTEtMS0xNTU2Mzg_7f602d52-c8c1-440e-834a-e3e093c2b0ff">63,447</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTE2LTEtMS0xNTU2Mzg_f532e4c0-3667-4019-89ca-d9a63418e445">9,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTIwLTEtMS0xNTU2Mzg_d80d6c24-6e62-410d-b368-6a42ad4d1668">9,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTIyLTEtMS0xNTU2Mzg_366ca9d8-193b-4333-b370-97b302f1068f">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTI0LTEtMS0xNTU2Mzg_36b25251-a42e-46f1-bf6d-261e6e3ddde8">9,195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTE4LTEtMS0xNTU2Mzg_67968595-15dc-4e60-a75c-e6b9500facd3">480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTIwLTEtMS0xNTU2Mzg_59d3c311-afd2-4702-93d8-fa0dc91dffbd">480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTIyLTEtMS0xNTU2Mzg_67203a57-f04c-4ab2-8b09-8dc1ef8900c3">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTI0LTEtMS0xNTU2Mzg_74fb7479-20aa-4b3c-894d-0cf548712ac4">471</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE3LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmNmYzI3NGU5MzZkZTQ0NDNhYzZkZThjMmIxM2Y3ODI4XzE2NDkyNjc0NDE3MDc_cfa62d64-f04b-4442-a2bb-411b7cc3e6f9">1.53</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE4LTE2LTEtMS0xNTU2Mzg_226b6c4b-3dcf-45f1-b050-1dd3ac10575b">8,571</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE4LTIwLTEtMS0xNTU2Mzg_d88aff73-e8fe-4027-8149-ab3c66a2ab22">8,571</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE4LTI0LTEtMS0xNTU2Mzg_c48edd6e-81e9-4504-b0d9-65e63e580af7">8,571</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Preferred stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIwLTIyLTEtMS0xNTU2Mzg_d998ebe1-58cc-4528-a559-8ee48e79c8db">91</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIwLTI0LTEtMS0xNTU2Mzg_fb8c1718-ddb4-43dd-a4c7-27802c4cf1d3">91</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1a777038d48408c84c682c9db5a1598_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTYtMS0xLTE1NTYzOA_e4223c1f-f97f-46bc-a3d1-729aecc42059">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1a777038d48408c84c682c9db5a1598_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTgtMS0xLTE1NTYzOA_ef4e76ca-9e65-44d8-857a-f41c1ee7cb2c">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e60bc72e4ba4235bf53b47acbec77c9_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTEwLTEtMS0xNTU2Mzg_d42a99a0-4e68-41df-9744-343191ae74ce">1,261</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTEyLTEtMS0xNTU2Mzg_d05788fd-a03d-41ef-9d48-3d3e546d86ce">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTE0LTEtMS0xNTU2Mzg_f3436f82-7fc8-4d61-b733-1427663776f1">218</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTIwLTEtMS0xNTU2Mzg_e493dfba-38c8-4cd7-8b47-4f342db5066d">1,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTI0LTEtMS0xNTU2Mzg_8ef9c145-9595-45da-9820-3de2fed4882b">1,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Preferred stock conversions and redemptions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id949a0db74974d919ea4ea4b3db15ae6_D20200101-20201231" decimals="0" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTItMS0xLTE1NTYzOA_dba37449-e851-4f87-b74b-3133af112ca0">431</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id949a0db74974d919ea4ea4b3db15ae6_D20200101-20201231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTQtMS0xLTE1NTYzOA_a7fee7c6-d026-4ef8-b904-5d6d5e67d18a">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e60bc72e4ba4235bf53b47acbec77c9_D20200101-20201231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEwLTEtMS0xNTU2Mzg_5dad725e-549b-4223-aac9-3f2d9059f3a0">15</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231" decimals="-6" sign="-" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEyLTEtMS0xNTU2Mzg_fa9adc0d-8d18-4bf5-b697-f1f1be9f4967">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231" decimals="-6" sign="-" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTE0LTEtMS0xNTU2Mzg_b372f346-0ed7-48aa-8a70-f15d24733d34">31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTIwLTEtMS0xNTU2Mzg_c1666a68-f1a5-4f68-bec4-836e47f2d352">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTI0LTEtMS0xNTU2Mzg_31952f84-68a5-48a4-a73b-e4df2294aaff">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Distribution of Upjohn Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE2LTEtMS0xNjM1MDc_f12fa9f4-f2af-418c-9f50-a45b98820fb3">1,592</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE4LTEtMS0xNjM1Mzk_47af01b1-de4e-4a07-a969-19224cfd7f0f">423</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIwLTEtMS0xNjM1NzU_7ce6965c-8867-47ca-9836-5f1b997950d3">2,015</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNjM2MDQ_d0d9da6e-b77b-4841-b3b0-a87f3981f083">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNjM2NDI_cbc5aa61-24ae-48c8-8216-7aefb1f5b7fe">2,018</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNTU2Mzg_9c12f538-bb60-4840-bd14-e468314fc6c3">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNTU2Mzg_6b835bf5-04b6-4105-949c-ed7a550982db">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6632dff49814e8badeff7ff58c71158_I20201231" decimals="0" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTItMS0xLTE1NTYzOA_c458716e-24f2-4b4c-b8e3-96cbd41d0f7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6632dff49814e8badeff7ff58c71158_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTQtMS0xLTE1NTYzOA_562181ba-3b24-4a03-85bf-da89cf6323d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf786bbc81494d359b7cda3127ee3152_I20201231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTYtMS0xLTE1NTYzOA_7e7e17db-ac07-4c7d-8539-a191224a114c">9,407</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf786bbc81494d359b7cda3127ee3152_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTgtMS0xLTE1NTYzOA_ee9d7c17-56fd-4693-94ca-322b447c8ab5">470</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07fc9de38c8c4c7e9d03753b2fca1f74_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTEwLTEtMS0xNTU2Mzg_3ecaacaa-2d13-4cd3-a926-ee536c8e3197">88,674</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7422d124677a4ff7b2f8d8076c12acca_I20201231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTEyLTEtMS0xNTU2Mzg_e0d0c644-bfae-4624-9694-b0f76b23a172">3,840</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7422d124677a4ff7b2f8d8076c12acca_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTE0LTEtMS0xNTU2Mzg_2c7365e3-b6a9-40f0-b354-f63a40365ded">110,988</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5835359a69d471cbf36ab74d0cbe6a8_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTE2LTEtMS0xNTU2Mzg_34102309-ff8e-4240-a48c-22346d815a00">90,392</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica9a1f0a2c3f454aa866582d5102b28a_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTE4LTEtMS0xNTU2Mzg_1c02910e-18ce-440f-a164-73e9b956e2af">5,310</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8080b824a5384f898232ba254171a741_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTIwLTEtMS0xNTU2Mzg_09c58043-024b-4769-9718-a26a1953c020">63,238</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedd8e5bdd3547a59b222ebb89139a56_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTIyLTEtMS0xNTU2Mzg_2f181023-8b52-4f6d-bd4e-2273b73fd23b">235</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTI0LTEtMS0xNTU2Mzg_b2c82206-d31b-40ce-8757-8879b771b6cb">63,473</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTE2LTEtMS0xNTU2Mzg_5f6b419a-62ec-4d57-b024-6b7bf8ce646f">21,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTIwLTEtMS0xNTU2Mzg_f9bfaf8d-58c1-4783-9b14-ae796cb694e0">21,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTIyLTEtMS0xNTU2Mzg_79426e0e-63cc-4faf-b627-5355eabc1365">45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTI0LTEtMS0xNTU2Mzg_fb4a85d6-04d4-4bf9-a323-bad18b99060b">22,025</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4091403708c44027bed1ab29ab967de7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTE4LTEtMS0xNTU2Mzg_4da9313a-76f9-4326-b48a-2831566916a7">587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTIwLTEtMS0xNTU2Mzg_0def2d48-8182-4096-b2ee-5bb6d2e29f7c">587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTIyLTEtMS0xNTU2Mzg_8215351b-48c5-41ab-8897-70fab98045f7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTI0LTEtMS0xNTU2Mzg_bfeca38c-4d8a-4261-97a4-77ae1de9c2e2">589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Cash dividends declared, per share: $<ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI4LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjg2YzFmZThhYzk1ODRjOWFhZTUxMDk4ZThiZDY2MzNkXzE2NDkyNjc0NDE3MDc_647a2b5a-2335-4e6a-abeb-c029bccd2346">1.57</ix:nonFraction></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common stock </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI5LTE2LTEtMS0xNTU2Mzg_53138950-d3ef-406f-a3b7-4b23ea135449">8,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI5LTIwLTEtMS0xNTU2Mzg_1fd0fb00-6894-4f76-8187-516e4d52fc2c">8,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI5LTI0LTEtMS0xNTU2Mzg_86ee0243-8789-452b-bff2-e1f1dda76485">8,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Preferred stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling interests</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMxLTIyLTEtMS0xNTU2Mzg_d4ad385d-1153-4986-9fc3-951d77c9a829">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMxLTI0LTEtMS0xNTU2Mzg_ee767e2b-ae39-48ae-b6ee-f4d05410b346">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Share-based payment transactions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ab09e3a09e941018ddf6f7cc1e0fd05_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTYtMS0xLTE1NTYzOA_a4d7ef6a-46c3-4a52-852b-2df253ef5fb3">64</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab09e3a09e941018ddf6f7cc1e0fd05_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTgtMS0xLTE1NTYzOA_114bbef1-d025-410c-809e-b0e79d841297">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib478cdce593043b4a6f3edef11be42c0_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTEwLTEtMS0xNTU2Mzg_f08c04c1-c59d-4b52-bd0d-f53a90c5328f">1,917</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i93c09cc9d0f940729939d72e229af012_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTEyLTEtMS0xNTU2Mzg_a8ae4a0e-457d-47e4-97d7-310303430799">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93c09cc9d0f940729939d72e229af012_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTE0LTEtMS0xNTU2Mzg_2984553e-91a3-4f85-a5fb-3056c87e8dc9">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMzLTE2LTEtMS0xNjM4ODI_f7ef22ac-12b0-44cf-b1bb-3b5e87e66785">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTIwLTEtMS0xNTU2Mzg_3e4dd48c-7776-4445-b5c4-8f59f06fdf0c">1,470</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTI0LTEtMS0xNTU2Mzg_5e66a17b-c6f9-48b2-a8cd-f29b1b111580">1,470</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTE2LTEtMS0xNTU2Mzg_deca069e-998a-40e7-b9ce-9848360056e7">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTIwLTEtMS0xNTU2Mzg_c4a9a7f7-e93c-46bd-8bff-31efbe041d65">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTIyLTEtMS0xNTU2Mzg_e5fd5894-2f21-4fdb-a210-ca140f25194b">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTI0LTEtMS0xNTU2Mzg_fd3ede3a-ccf6-4639-9688-068bf66ef399">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67081b13ebb6408d9bfb81829f457cbb_I20211231" decimals="0" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTItMS0xLTE1NTYzOA_cf3172f0-4874-49c5-aa9c-2db226b78e92">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67081b13ebb6408d9bfb81829f457cbb_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTQtMS0xLTE1NTYzOA_ac51f218-6d4a-4b02-9485-3c3d3b57fd1b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffea6a63f21448c2a42fb089c227bdf1_I20211231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTYtMS0xLTE1NTYzOA_fd0374ef-8749-412e-a2ee-b1f418bb49a2">9,471</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffea6a63f21448c2a42fb089c227bdf1_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTgtMS0xLTE1NTYzOA_ec1c165b-f8a9-4ee7-aba5-420d8a22c7b3">473</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba64542fbbc240b2b05039d5b8e8bf4e_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTEwLTEtMS0xNTU2Mzg_3400f129-9f4c-448e-929a-a749cae28284">90,591</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifa81ae38e1ae496d93643844df0b8455_I20211231" decimals="-6" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTEyLTEtMS0xNTU2Mzg_9e856544-13c0-4929-b15d-72ef10dd17a6">3,851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa81ae38e1ae496d93643844df0b8455_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTE0LTEtMS0xNTU2Mzg_df1efb84-adf9-414d-b344-f8426baffdac">111,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9bac0ccad24d18a5d2306fb3b1e0f8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTE2LTEtMS0xNTU2Mzg_20b522a0-9d79-4d6a-9f8f-2072f20699a4">103,394</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6af06169f58446f8067cc5be10a39e9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTE4LTEtMS0xNTU2Mzg_cdf8811f-0b6c-474d-95a4-7fd9e189ea36">5,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6aaf11901b4bceaf30103029c6a00d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTIwLTEtMS0xNTU2Mzg_e8a758fc-e177-4b11-a2e9-dc396d1bfff7">77,201</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19da914ba5ba4066bf3d29d7d1eeb9c2_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTIyLTEtMS0xNTU2Mzg_8af85c22-95cf-475f-a4b8-9aeb97e03122">262</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTI0LTEtMS0xNTU2Mzg_f4d75ce5-75c0-4373-8906-51544d691ab6">77,462</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:209pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></ix:footnote></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_160"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Operating Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQtMi0xLTEtMTU1NjM4_63381e29-0a2c-496d-b4c6-68a394474885">22,025</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQtNC0xLTEtMTU1NjM4_af50c122-aeea-46a2-8596-4a51c83c4ee2">9,195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQtNi0xLTEtMTU1NjM4_8fa47364-c204-4959-bd6f-cbdf0d676305">16,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Discontinued operations&#8212;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUtMi0xLTEtMTU1NjM4_b4a57dfd-5d28-4f0a-be43-3d176038a3ed">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUtNC0xLTEtMTU1NjM4_9f34713f-42c2-490b-b977-8081cdae8bc8">2,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUtNi0xLTEtMTU1NjM4_5dd6c81f-5fc6-44a2-8bda-c91dcbbd8708">5,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income from continuing operations before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzYtMi0xLTEtMTU1NjM4_023feeab-f978-4d2b-8b6b-e65a7d063c2e">22,459</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzYtNC0xLTEtMTU1NjM4_c7f3cd5e-3a3b-47bd-b448-a54cc44fa663">6,666</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzYtNi0xLTEtMTU1NjM4_a8236d90-802f-4539-b6ff-c72c31264dde">10,738</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzgtMi0xLTEtMTU1NjM4_011359dc-c779-4363-9044-c7654c84e3a8">5,191</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzgtNC0xLTEtMTU1NjM4_5ae7cc81-c073-43c7-9f69-4a606922147f">4,681</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzgtNi0xLTEtMTU1NjM4_1f7a0c8a-60fe-46b4-8b14-6d5012fcca94">5,755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset write-offs and impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzktMi0xLTEtMTU1NjM4_1ff380b5-274e-40e9-b0a9-2c324efb369c">276</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzktNC0xLTEtMTU1NjM4_c51ec24a-138a-4eff-a168-5a9284ce3d9b">2,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzktNi0xLTEtMTU1NjM4_d379e196-a5d2-45c0-a707-08a5bf0daf3a">2,889</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">TCJA impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEwLTItMS0xLTE1NTYzOA_5bcacf0d-aca6-4138-8524-38db1a498e8a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEwLTQtMS0xLTE1NTYzOA_3a368134-bf83-458a-9f92-97d2317fe66e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEwLTYtMS0xLTE1NTYzOA_9e8a9568-334a-4d3a-85fa-3f050fb20354">323</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTItMS0xLTE1NTYzOA_61571985-418a-446b-bc96-93bdab6232b4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTQtMS0xLTE1NTYzOA_36f289d7-f860-4248-ae43-2a845a2fb3a8">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTYtMS0xLTE1NTYzOA_460a0367-95db-4b42-8410-22d206dd026d">8,254</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEyLTItMS0xLTE1NTYzOA_60a6de51-0c19-4c56-a0c2-1854579e0752">4,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEyLTQtMS0xLTE1NTYzOA_8e51493f-7b20-43d9-8a88-f621958e33b0">1,575</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEyLTYtMS0xLTE1NTYzOA_b9380118-4864-4253-bcc2-52db9c11f32b">561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE0LTItMS0xLTE1NTYzOA_60035cc9-3106-4d30-ac8c-c91c33f04e7c">1,182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE0LTQtMS0xLTE1NTYzOA_5dbfee39-9402-4b4d-8070-192b0c1f430f">755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE0LTYtMS0xLTE1NTYzOA_37d314b2-e2de-43be-93a9-041cf88cff67">687</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE1LTItMS0xLTE1NTYzOA_ef7d36f0-d22f-4e16-9ab0-58f14ff1f26b">3,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE1LTQtMS0xLTE1NTYzOA_93afbcb3-1e89-4229-ba7f-625e65d2459d">1,242</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE1LTYtMS0xLTE1NTYzOA_b5837c87-63af-4c6b-9d92-c0edea583f99">55</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE3LTItMS0xLTE1NTYzOA_7210b006-9b1e-4048-8f1c-f40b87a2de97">1,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE3LTQtMS0xLTE1NTYzOA_a3c9d7c8-991c-4cb8-808f-a24808e3cc14">479</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE3LTYtMS0xLTE1NTYzOA_31acbe9a-e47b-41fa-990a-01b51d57ee4c">1,080</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other changes in assets and liabilities, net of acquisitions and divestitures:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Trade accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE5LTItMS0xLTE3MDM1OQ_619d79a0-d818-44e8-9025-b4fe0c59fd08">3,811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE5LTQtMS0xLTE3MDM2OQ_10882e03-89bf-4ce4-8ddc-8466c2a46265">1,275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE5LTYtMS0xLTE3MDM4Mw_dc9f4947-0101-4a0f-9432-01571b73f3ee">1,124</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIwLTItMS0xLTE3MDM1OQ_34b08c68-4bed-4672-9a05-241223a05dd1">1,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIwLTQtMS0xLTE3MDM2OQ_7234760c-6bba-4b3d-a2db-0bc30855a9f7">778</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIwLTYtMS0xLTE3MDM4Mw_f3b978e9-43b9-4f5a-8a17-a77466e87ae7">1,071</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIxLTItMS0xLTE3MDM1OQ_8a81d4d9-3602-4d4c-90d9-62a53e71d590">1,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIxLTQtMS0xLTE3MDM2OQ_4a85f0c8-d400-4e3b-94ac-acee360c9a35">137</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIxLTYtMS0xLTE3MDM4Mw_5dc1be9a-0948-46e3-8203-89decaeaf60f">847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIyLTItMS0xLTE3MDM1OQ_aac66853-7539-464b-ad42-75fe1425d8f5">1,242</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIyLTQtMS0xLTE3MDM2OQ_06962c6d-cc05-40b1-b588-f6e3b6ca8e32">355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIyLTYtMS0xLTE3MDM4Mw_02c29a4b-057c-48d1-b6d4-48394dc23e67">341</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIzLTItMS0xLTE3MDM1OQ_7319b9f0-6b6c-4ab0-a60e-371d79dcbdc9">18,721</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIzLTQtMS0xLTE3MDM2OQ_87cfb2d9-931e-43bb-a601-864ccdd0de2b">2,768</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIzLTYtMS0xLTE3MDM4Mw_e7e6cf82-1415-4ed8-8f49-448eaa76ae60">861</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other tax accounts, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI0LTItMS0xLTE3MDM1OQ_7bb7cb4c-40c0-45fb-9a34-f878c36845fa">1,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI0LTQtMS0xLTE3MDM2OQ_d3a3ef2b-a78e-4b86-b093-be6594e7a303">1,240</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI0LTYtMS0xLTE3MDM4Mw_3d72489f-3d63-4e82-b02a-d589d4865e97">3,074</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI1LTItMS0xLTE1NTYzOA_aef2e792-2124-4082-9ca4-96b3deff3380">32,922</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI1LTQtMS0xLTE1NTYzOA_63e6dc77-b145-4610-b23b-5aeb2175da4e">10,540</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI1LTYtMS0xLTE1NTYzOA_c871ed45-c89e-4ad1-9c24-7a649dd37c20">7,015</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) operating activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI2LTItMS0xLTE1NTYzOA_e126175e-c9eb-4989-bc47-de0498352283">343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI2LTQtMS0xLTE1NTYzOA_7bb88fbd-8b4e-4489-9acf-3f29f309cd0f">3,863</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI2LTYtMS0xLTE1NTYzOA_129d737f-a82a-41a3-bb43-4d450e72035a">5,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI3LTItMS0xLTE1NTYzOA_56740753-9d7e-4025-8e7d-4673c84e7c43">32,580</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI3LTQtMS0xLTE1NTYzOA_689df0da-fb90-4af0-83a4-401efb16d17e">14,403</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI3LTYtMS0xLTE1NTYzOA_8653b656-c5ac-4d4b-9eea-89eeaa09715a">12,588</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Investing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMwLTItMS0xLTE1NTYzOA_28842b17-15e7-4597-9bdb-30041d5cdb5c">2,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMwLTQtMS0xLTE1NTYzOA_28f480aa-99b3-458f-83f0-dc52c322d262">2,226</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMwLTYtMS0xLTE1NTYzOA_caba672c-6e1d-44bf-9eeb-4bdbaf3e0bf2">2,046</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMxLTItMS0xLTE1NTYzOA_cc4d68ee-b60c-44b6-a122-a04c55a2d909">38,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMxLTQtMS0xLTE1NTYzOA_c31f6df8-a569-46e6-8756-07a5e916fa04">13,805</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMxLTYtMS0xLTE1NTYzOA_5f485f61-2688-4163-ab1a-2a5a3b3fcf54">6,835</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMyLTItMS0xLTE1NTYzOA_551b190e-6d38-49a3-b907-e30f980b8422">27,447</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMyLTQtMS0xLTE1NTYzOA_18474f7f-9ad5-49d3-8234-a80baca00f93">11,087</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMyLTYtMS0xLTE1NTYzOA_80dd7182-739c-4dcc-8796-1486c2d05f21">9,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMzLTItMS0xLTE1NTYzOA_8d7d984a-c113-47ed-89c6-c7006562dfce">8,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMzLTQtMS0xLTE1NTYzOA_d3a0ef05-8252-46c9-9c91-b2232dba2b7f">920</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMzLTYtMS0xLTE1NTYzOA_2c5a4554-190f-4b16-8c53-c397f8bab760">6,925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM0LTItMS0xLTE1NTYzOA_d4b9ca1c-6cc5-438b-b2a0-e4eb2b08e623">1,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM0LTQtMS0xLTE1NTYzOA_9fe01b4c-f3b1-4d5b-a6f8-44e8d77bdc6c">597</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM0LTYtMS0xLTE1NTYzOA_02ed1ab7-e0d9-4f0d-9829-537234e58c42">201</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from redemptions/sales of long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM1LTItMS0xLTE1NTYzOA_5588e8ce-53f8-4eec-969a-e1b663feec7a">649</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM1LTQtMS0xLTE1NTYzOA_e3984a30-560e-4745-8cbb-d68c7c5b3754">723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM1LTYtMS0xLTE1NTYzOA_7e35b505-6b56-43f6-9de4-0e1c2cd040c0">232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM2LTItMS0xLTE1NTYzOA_d4649de4-a3eb-46a5-88bc-4e04b5f20485">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM2LTQtMS0xLTE1NTYzOA_f2d93f0b-5692-413f-b01a-af207a1b09e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM2LTYtMS0xLTE1NTYzOA_749c4286-3a45-4f8a-b603-75f992b323e5">10,861</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other investing activities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTItMS0xLTE1NTYzOA_27302940-e95f-4411-87f2-0004674e6fa8">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTQtMS0xLTE1NTYzOA_06f71829-0412-4c42-b7fe-8a9facdb36c2">265</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTYtMS0xLTE1NTYzOA_037968a6-be5e-4506-93f4-cb98e0757bd3">223</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM4LTItMS0xLTE1NTYzOA_9d500b03-1e32-47bd-83a3-e371e795727b">22,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM4LTQtMS0xLTE1NTYzOA_c400c835-bd7e-41c5-80e6-7afd44b888bc">4,162</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM4LTYtMS0xLTE1NTYzOA_25133874-1cda-4ecf-91e1-eaa401553a7e">3,825</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM5LTItMS0xLTE1NTYzOA_9769831c-3cc5-4408-8760-8e4e1731da48">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM5LTQtMS0xLTE1NTYzOA_7d464530-628a-44a3-ba82-e8fda491d5f3">109</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM5LTYtMS0xLTE1NTYzOA_01c480e6-32bd-4177-88d5-1c1dc4c7a6f7">120</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) investing activities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQwLTItMS0xLTE1NTYzOA_b0650607-23df-42f8-a0ef-1ebad1c6fd98">22,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQwLTQtMS0xLTE1NTYzOA_8e5393ad-3ada-447d-9e2f-9566343d0ee3">4,271</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQwLTYtMS0xLTE1NTYzOA_2d440c40-1cbd-4804-8d68-4997ec152765">3,945</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Financing Activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQzLTItMS0xLTE1NTYzOA_b66b646e-ff86-4b45-be05-934febe83982">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQzLTQtMS0xLTE1NTYzOA_6d6835cd-202d-4d15-9c3c-e4e6328d2e10">12,352</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQzLTYtMS0xLTE1NTYzOA_92e7485c-f752-42da-88a1-20cd153bcecc">16,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Principal payments on short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ0LTItMS0xLTE1NTYzOA_246a182f-511d-41ad-989b-c1f538f447b5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ0LTQtMS0xLTE1NTYzOA_cfef50c9-7c08-405e-851d-f56e5b9bd178">22,197</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ0LTYtMS0xLTE1NTYzOA_2376f7c5-2cef-48e7-a15c-6293d31aafc4">8,378</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ1LTItMS0xLTE1NTYzOA_a9b9145a-492b-4d50-9fb6-a0d4d7d53af3">96</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ1LTQtMS0xLTE1NTYzOA_816f0bff-6826-4750-930e-f72e6aa0fe1e">4,129</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ1LTYtMS0xLTE1NTYzOA_200bc92b-b0c6-45ee-b0d1-fbccfb43640a">2,551</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ2LTItMS0xLTE1NTYzOA_b34fb6e6-01c0-4707-8a67-07496c229e78">997</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ2LTQtMS0xLTE1NTYzOA_072161fc-09fd-42c1-b6ed-8d3b12266886">5,222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ2LTYtMS0xLTE1NTYzOA_9d40601f-6340-4c2b-8185-9cd2978e7329">4,942</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Principal payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ3LTItMS0xLTE1NTYzOA_0d5ca583-2728-4738-a32c-7f5912ffb588">2,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ3LTQtMS0xLTE1NTYzOA_5619fe7a-b58c-40c7-9eed-d8dcb3479194">4,003</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ3LTYtMS0xLTE1NTYzOA_7fea1396-833f-44a3-8d2c-82edab7c80bc">6,806</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ4LTItMS0xLTE1NTYzOA_5d131b34-0a3b-4778-9e9f-fb03f397947d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ4LTQtMS0xLTE1NTYzOA_f7b1b341-2876-4b62-9c1a-be0659282006">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ4LTYtMS0xLTE1NTYzOA_4a23e553-d1de-4483-a671-af8655bd90ac">8,865</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash dividends paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ5LTItMS0xLTE1NTYzOA_262de7e1-9bb8-4c10-84a2-2d6e7f4f339d">8,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ5LTQtMS0xLTE1NTYzOA_b899cd88-389d-4c1c-8418-373975834c70">8,440</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ5LTYtMS0xLTE1NTYzOA_f24ac3bf-1d65-4e73-8341-3595c5feddfe">8,043</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other financing activities, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUwLTItMS0xLTE1NTYzOA_db87ea62-b783-48b2-a829-01d7ccf5e691">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUwLTQtMS0xLTE1NTYzOA_3a57de83-20be-41bf-bb10-124b4b008db9">444</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUwLTYtMS0xLTE1NTYzOA_93dc82f7-827c-4979-a87f-662ea0608387">342</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUxLTItMS0xLTE1NTYzOA_4f2a5708-6d2d-4c87-9d57-6b453d619872">9,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUxLTQtMS0xLTE1NTYzOA_3df325c9-48ab-47e2-aa30-8517aa38b695">21,640</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUxLTYtMS0xLTE1NTYzOA_72a141e4-518b-41f9-8407-abb348042bf0">8,485</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities from discontinued operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUyLTItMS0xLTE1NTYzOA_f2aa6a66-4989-419b-bcf5-b52f43417fea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUyLTQtMS0xLTE1NTYzOA_72af45d5-ce1f-4c5e-8d17-56f7e0bbe48b">11,991</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUyLTYtMS0xLTE1NTYzOA_75bd2568-8c7c-46ea-bdc8-b45cdfe9e596">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by/(used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUzLTItMS0xLTE1NTYzOA_11062f68-e98a-44a2-b2d2-d32e7b955627">9,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUzLTQtMS0xLTE1NTYzOA_92a2ed35-d4c8-4593-855d-4c5bdbfd46fd">9,649</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUzLTYtMS0xLTE1NTYzOA_8c4fbcba-4306-4623-8d90-ad8822c05776">8,485</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU0LTItMS0xLTE1NTYzOA_56f66306-71ef-44ae-a4e9-dd860638916b">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU0LTQtMS0xLTE1NTYzOA_395cc03b-0653-44f0-96cb-78ad834e448c">8</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU0LTYtMS0xLTE1NTYzOA_97b86904-7654-4c78-a692-f0fc87245453">32</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU1LTItMS0xLTE1NTYzOA_d747e8d1-6f16-48d6-a9b3-b04f48edba6d">159</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU1LTQtMS0xLTE1NTYzOA_5f6bafd6-5971-43b7-bc20-7dd4bb1d279c">475</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU1LTYtMS0xLTE1NTYzOA_e715240e-5cd6-4cb1-95c7-65edd00d4787">125</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU2LTItMS0xLTE1NTYzOA_9741f2df-f347-412d-a2f7-0b7e2165325c">1,825</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU2LTQtMS0xLTE1NTYzOA_56eacea0-e09f-4f98-b07d-e9ad7f1a555a">1,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e10b1e1c1f846769573d84f9a61fc72_I20181231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU2LTYtMS0xLTE1NTYzOA_588143ad-b767-40d1-bcfe-72de3aacf886">1,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU3LTItMS0xLTE1NTYzOA_f554d633-5dd1-4eac-8b0e-f4494c906c7e">1,983</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU3LTQtMS0xLTE1NTYzOA_0eb5ae8b-2d8b-4374-9d80-9ae0a7ebe617">1,825</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU3LTYtMS0xLTE1NTYzOA_a080876f-cadc-408d-a50d-6dfb37ed2265">1,350</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">- Continued -</span></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.688%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="21" style="border-bottom:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline">Supplemental Cash Flow Information</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash paid/(received) during the period for:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTItMS0xLTE1NTYzOA_43cc687a-b803-4547-80bd-f9aaecabf732">7,427</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTQtMS0xLTE1NTYzOA_4efd385e-9055-4fa2-89fe-c6c912de203a">3,153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTYtMS0xLTE1NTYzOA_e4a7f37b-8bbe-4694-8acd-b9d0c668bf5b">3,664</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY2LTItMS0xLTE1NTYzOA_c0d4f2b4-73d3-4a92-8baf-8bef55e1a5ec">1,467</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY2LTQtMS0xLTE1NTYzOA_d0382e56-fa25-419f-b08d-d1ce06e3de31">1,641</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY2LTYtMS0xLTE1NTYzOA_f3701413-1731-4e58-9b15-562d5a024e3a">1,587</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:InterestReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY3LTItMS0xLTE1NTYzOA_b9e60793-e1a2-4356-827f-6914e0286a08">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:InterestReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY3LTQtMS0xLTE1NTYzOA_6635a979-62cc-46b8-a82b-94dfeb4039e1">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:InterestReceivedInterestRateHedges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY3LTYtMS0xLTE1NTYzOA_84ad179b-f77e-47a2-997c-7c6fccd8a928">42</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Non-cash transactions:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTItMS0xLTE2NzQ1Nw_35007f70-2d5e-4042-9cc8-e2cc6de505c8">1,943</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTQtMS0xLTE2NzQ2Mw_dc4bdc7f-d2c0-40ad-9fd3-342e96ad0f41">410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTYtMS0xLTE2NzQ3MA_fca6ed56-cc50-4400-9307-eecc0ed00cfa">314</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie607d29116be4fa5babac488462d4080_I20191231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjU1OTRhNTkxNWE1ZDRhNjI5NDYwMWU1N2M3YTNjNDIwXzU_1241243c-7336-42f0-aa02-91ef3754845b">32</ix:nonFraction>%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> equity-method investment in the Consumer Healthcare JV received in exchange for contributing Pfizer&#8217;s Consumer Healthcare business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231" decimals="-6" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTItMS0xLTE1NTYzOA_10fe7932-e01c-454e-8302-def516f99899">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34dd2e3fa1c248e29e1d6758b3059e2d_D20200101-20201231" decimals="-6" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTQtMS0xLTE1NTYzOA_19c6fa4b-dbf0-4efd-8ff8-0b7287c1ac97">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231" decimals="-6" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTYtMS0xLTE1NTYzOA_2014424e-8adc-4a3b-9815-9c81bcd3344a">15,711</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:480pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The $<ix:nonFraction unitRef="usd" contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231" decimals="-8" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzEy_6b5403a6-b53d-4f87-99ec-d68bedcb184f">8.3</ix:nonFraction> billion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> reflects the receipt of a <ix:nonFraction unitRef="number" contextRef="ie607d29116be4fa5babac488462d4080_I20191231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzEyMA_1241243c-7336-42f0-aa02-91ef3754845b">32</ix:nonFraction>% equity-method investment in the new company initially valued at $<ix:nonFraction unitRef="usd" contextRef="ie607d29116be4fa5babac488462d4080_I20191231" decimals="-8" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzE4Nw_462fe8ce-f277-4f04-ae3f-878ceac3f0a7">15.7</ix:nonFraction> billion in exchange for net assets contributed of $<ix:nonFraction unitRef="usd" contextRef="ie607d29116be4fa5babac488462d4080_I20191231" decimals="-8" name="pfe:DeconsolidationNetAssetsContributed" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzIzMg_ccd90f96-1f85-42ec-8718-fa2a86308cd8">7.6</ix:nonFraction> billion and is presented in operating activities net of $<ix:nonFraction unitRef="usd" contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231" decimals="-6" name="pfe:DeconsolidationGainLossAmountCashConveyed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzI4Mw_d14606d4-ad03-456e-a7c2-9f8a701ae6d2">146</ix:nonFraction> million cash conveyed that is reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other investing activities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C.</span></ix:footnote></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See Accompanying Notes.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_163"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div><span><br/></span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_166"></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDM2_c6b3fa4f-ea37-4c83-808b-075e900f600e" continuedAt="ieb3241c5f3074c5993edc0867558a1c4" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ieb3241c5f3074c5993edc0867558a1c4" continuedAt="i47805001149049a1a55662d18d041bd3"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDE3_e58a8c78-56a1-45d2-9382-7037054d1506" escape="true">The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP.</ix:nonNumeric> <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTY1_50da091a-be31-455f-a0ef-48f230491fc8" escape="true">The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our subsidiaries have been eliminated.</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQxMjMxNjg2MTQxMjU4_07d9dfbb-05f8-4e94-9dc5-8120a487780b" escape="true">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of <ix:nonFraction unitRef="operatingsegment" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzEwOTk1MTE3MzEyODI_36183524-29d9-404f-84cc-f1c9c73c36ea">two</ix:nonFraction> operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.</ix:nonNumeric> See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">. On December 31, 2021, we completed the sale of our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products. Prior to its sale, Meridian was managed within the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. On December 21, 2020, Pfizer and Viatris completed the termination of a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (the Mylan-Japan collaboration) pursuant to an agreement dated November 13, 2020, and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and the Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. The assets and liabilities associated with Meridian and the Mylan-Japan collaboration are classified as assets and liabilities of discontinued operations as of December 31, 2020. Upon completion of the spin-off of the Upjohn Business on November&#160;16, 2020, the Upjohn assets and liabilities were derecognized from our consolidated balance sheet and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Retained Earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Distribution of Upjohn Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> in the consolidated statement of equity. Prior to the spin-off of the Upjohn Business in November 2020, the Upjohn Business, the Mylan-Japan collaboration and Meridian were managed as part of our former Upjohn operating segment. With the separation of the Upjohn Business, the Mylan-Japan collaboration and Meridian, as well as the formation of the Consumer Healthcare JV in 2019, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines. Certain prior year amounts have been reclassified to conform with the current year presentation. In addition, other acquisitions and business development activities completed in 2021, 2020 and 2019 impacted financial results in the periods presented. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Note 2.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. </span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDI1_a1d2fa7a-fb5a-41da-aad7-292dd66015af" continuedAt="i0a0ae2651d904233b5ff4cb8da4b2d9b" escape="true">New Accounting Standard Adopted in 2021</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i0a0ae2651d904233b5ff4cb8da4b2d9b">On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.</ix:continuation></span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Change in Accounting Principle</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (MTM Accounting).</span><span style="color:#000000;font-family:'Georgia',serif;font-size:8pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Under the prior policy, we deferred recognition of these gains and losses in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. The accumulated actuarial gains/losses outside of a &#8220;corridor&#8221; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> of $<ix:nonFraction unitRef="usd" contextRef="ifcf32e48dba146a8a8302424e15199af_I20200101" decimals="-8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzkwOTM_a19d9eea-6aac-4921-ad28-ac24a58efec1"><ix:nonFraction unitRef="usd" contextRef="ifcf32e48dba146a8a8302424e15199af_I20200101" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzkwOTM_f8553265-d7fb-423d-a4a8-9705b516cd6a">6.0</ix:nonFraction></ix:nonFraction> billion, with a corresponding offset to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i47805001149049a1a55662d18d041bd3" continuedAt="i36307b3c055848148cac7da7baf2a99f"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQzOTgwNDY1NzkwMjk_61d8fda1-1d49-43f3-bf0b-db8556c906da" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.745%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The impacts of the adjustments on our consolidated financial statements are summarized as follows:</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(Gain) on completion of Consumer Healthcare JV transaction</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMi0xLTEtMTk1OTA2_bc7c3cf1-825d-47f8-8aa8-0ce61e8ac02d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNC0xLTEtMTk1OTA2_1806779c-9b0a-40d7-8b88-e326ec7197b2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTk1ODcy_e4c6377a-8a3d-4e68-a21c-68db41c2ed11">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtOC0xLTEtMTk1OTE2_7d44f143-1322-4aaa-a53c-ed88ed3874c4">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTAtMS0xLTE5NTkxNg_83e058c7-c0c2-4292-9dae-6c3b90836b85">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE5NTg4MA_d97f7061-da2a-4d3d-b3e5-f92bd6bc6e8f">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTQtMS0xLTE5NTkyNQ_0528c310-2d7d-4b18-95b7-1377501a2266">8,086</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTYtMS0xLTE5NTkyNQ_ee649ed2-6db5-4709-a8c9-d075e26ca808">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE5NTg5MQ_5ef1ee20-71b0-4fe9-bba9-a2d5b9f3a3f4">8,107</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMi0xLTEtMTU1NjM4_a8c24596-c4e8-4aaa-a1f8-59635457c3ab">2,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtNC0xLTEtMTU1NjM4_eb7b2a56-0ca4-4ca3-950f-58e39c2f471a">2,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtNi0xLTEtMTU1NjM4_b4e851e8-dada-4e99-9f60-7ca607ffbc0e">4,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtOC0xLTEtMTU1NjM4_60871837-4ddf-4f02-9913-ec586b1f58cd">672</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTAtMS0xLTE1NTYzOA_3b558b40-826c-4112-85ef-2541e53fe68d">547</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTItMS0xLTE1NTYzOA_c1d512b1-f464-41ab-972b-e99bc10ae4bf">1,219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTQtMS0xLTE1NTYzOA_b8d83cf9-64e6-4063-8bc3-a37621e851df">3,264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTYtMS0xLTE1NTYzOA_2d4c0b1f-3a03-442f-ab5c-c69db2df5f3c">233</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTgtMS0xLTE1NTYzOA_00f627ae-495c-440d-90c5-9ea23af6d8f1">3,497</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMi0xLTEtMTU1NjM4_0614c209-9dc5-4b67-9b3c-c6804d6690ac">22,253</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNC0xLTEtMTU1NjM4_d81f917c-575c-4c63-b8bd-93a45c0c27ac">2,058</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3">24,311</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtOC0xLTEtMTU1NjM4_b90945b7-2595-47c1-8c61-e56abdc77117">7,584</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTAtMS0xLTE1NTYzOA_fac85c0f-cbd0-4c06-ac4a-c35c45377dfe">547</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663">7,036</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTQtMS0xLTE1NTYzOA_d351653b-ba46-4985-ad18-5b8319b71d48">11,533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTYtMS0xLTE1NTYzOA_55563f9c-9f04-4dd9-9cd6-19dbe4af74d7">212</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2">11,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMi0xLTEtMTU1NjM4_d81915bb-b2a3-4b5b-b767-e32b0e45b403">1,399</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtNC0xLTEtMTU1NjM4_fb9f9ae6-a699-4dc6-8f86-53524f5c5d67">453</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtNi0xLTEtMTU1NjM4_1ce2ac83-55f8-45b7-a1ca-82e48cb7f220">1,852</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtOC0xLTEtMTU1NjM4_a93c4b48-f261-4c9c-a6ab-09fd8aafe16c">496</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTAtMS0xLTE1NTYzOA_9165618c-02cb-4bfe-9c07-3e0069bd7165">125</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTItMS0xLTE1NTYzOA_46648b7b-1536-456a-a925-29ed449f699a">370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTQtMS0xLTE1NTYzOA_99de404e-3ecc-4ca4-96e6-8cc2ca69a79a">631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTYtMS0xLTE1NTYzOA_2da45aaf-ac09-410a-bc2b-7a9ad56a2df0">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTgtMS0xLTE1NTYzOA_b679645e-b9b8-4443-9007-e145851af4e6">583</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMi0xLTEtMTU1NjM4_d3c4eb6c-0166-4174-bed6-57bfbe0c9cd4">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctNC0xLTEtMTU1NjM4_f600d9c3-dbca-4042-baed-b00196412af8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctNi0xLTEtMTU1NjM4_e5d7c609-0b4b-4142-9fc2-2a3e85192096">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctOC0xLTEtMTU1NjM4_47e1dac8-7637-4978-a66a-5da2859019e8">2,564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTAtMS0xLTE1NTYzOA_7472d9ad-f441-45e2-bb72-642a4f921538">35</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTItMS0xLTE1NTYzOA_4d9fd474-da17-46bd-9955-e2c453350084">2,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTQtMS0xLTE1NTYzOA_bbfe93da-6381-4ce2-b8f3-ee5968afe7bd">5,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTYtMS0xLTE1NTYzOA_3793095d-3cfe-4f81-8508-ce7f1cc278d3">82</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTgtMS0xLTE1NTYzOA_45508b8f-b29f-458b-bd37-34a303e8ea87">5,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMi0xLTEtMTU1NjM4_e5a25800-bf7c-4319-8db0-1357be5bdf2e">20,420</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtNC0xLTEtMTU1NjM4_c80bc3b5-a258-4f06-9490-a4ce348c0cad">1,605</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtNi0xLTEtMTU1NjM4_63381e29-0a2c-496d-b4c6-68a394474885">22,025</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtOC0xLTEtMTU1NjM4_a09d3430-2065-430d-8ef0-3854ea32568d">9,652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTAtMS0xLTE1NTYzOA_26ef6320-debf-42a6-8063-6cb0b37715ff">457</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTItMS0xLTE1NTYzOA_af50c122-aeea-46a2-8596-4a51c83c4ee2">9,195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTQtMS0xLTE1NTYzOA_e5d1f133-628b-42f3-9b7f-7541dfa84356">16,302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTYtMS0xLTE1NTYzOA_af9c842a-a8f8-4f1c-9522-30f530818287">246</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTgtMS0xLTE1NTYzOA_8fa47364-c204-4959-bd6f-cbdf0d676305">16,056</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMi0xLTEtMTU1NjM4_2fd5a10c-9938-43b0-9077-b9cb03064bca">20,374</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktNC0xLTEtMTU1NjM4_9a66ccb1-e731-49a3-8aa6-b60e0fc2d4d5">1,605</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktNi0xLTEtMTU1NjM4_77a1a59a-c3ab-4127-9754-8818e2a6c7d5">21,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktOC0xLTEtMTU1NjM4_d961285d-b46d-4f25-a1a1-bf5ed0efd339">9,616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTAtMS0xLTE1NTYzOA_ceb9104d-f067-4da6-ba0e-60c1700d7181">457</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTItMS0xLTE1NTYzOA_0df638b6-48e0-4e58-9cac-8993692d6dda">9,159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTQtMS0xLTE1NTYzOA_2c5bc2df-4f05-4b6a-adb0-6812440e17ba">16,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTYtMS0xLTE1NTYzOA_41e1db16-ca3d-4d55-aae4-52f4bb00a6e6">246</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTgtMS0xLTE1NTYzOA_1f7da7ae-37c9-4e2a-847b-68e42674ea1a">16,026</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTItMS0xLTE1NTYzOA_669465e3-848a-4eca-ab96-61699fba03d7">3.71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTQtMS0xLTE1NTYzOA_9f29c43e-5bdc-4760-a884-080091ee4cf3">0.29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTYtMS0xLTE1NTYzOA_0e545ecc-37de-49d0-9333-adbb95aa1e66">4.00</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTgtMS0xLTE1NTYzOA_9898ecf4-a278-4ec3-af59-f98418914f5c">1.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTEwLTEtMS0xNTU2Mzg_2ba7a659-28d5-4a12-a469-4b3b3c3410fc">0.08</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTEyLTEtMS0xNTU2Mzg_9266c59a-72d5-4d5f-b9d4-bd97404d6dd3">1.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTE0LTEtMS0xNTU2Mzg_f5870ad3-7f70-4e3e-aa54-830b6d7d2453">1.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTE2LTEtMS0xNTU2Mzg_38e9e708-3d64-46e7-8c0f-b4df9bd15217">0.03</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTE4LTEtMS0xNTU2Mzg_99164c61-c68d-4acd-bb6b-985f75ae5e88">1.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTItMS0xLTE1NTYzOA_05d09569-4258-4332-a6f2-3cfb1d11e38f">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTQtMS0xLTE1NTYzOA_4be499b4-eb98-41a5-9c13-b98f37bb16c9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTYtMS0xLTE1NTYzOA_4f1c724c-81bf-4225-845a-3345c65cdc0b">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTgtMS0xLTE1NTYzOA_4c3e707b-525b-454f-a72a-5e82777a7a30">0.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTEwLTEtMS0xNTU2Mzg_824774bd-9528-44db-81c0-5752510c803c">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTEyLTEtMS0xNTU2Mzg_5e4fb396-35eb-4d8b-822a-67cafb2bad27">0.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTE0LTEtMS0xNTU2Mzg_4afd8b53-b939-4448-931d-944f770cdff8">0.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTE2LTEtMS0xNTU2Mzg_222c857a-f5df-4910-b7a6-e5645738f4c4">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTE4LTEtMS0xNTU2Mzg_65987aba-5b6e-44bd-a2b9-e6ffc251497e">0.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTItMS0xLTE1NTYzOA_79a34e7e-98a1-445b-a6ed-60587e9f3840">3.63</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTQtMS0xLTE1NTYzOA_1495cf92-9a24-45c2-bc8d-d49daf8da1a4">0.29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTYtMS0xLTE1NTYzOA_91dcc62c-eae1-41fe-a34e-d84b4ce79239">3.92</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTgtMS0xLTE1NTYzOA_d7bc6a99-4f19-4e86-b2ec-26d9a83142cb">1.73</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTEwLTEtMS0xNTU2Mzg_ced91ae8-93df-4a06-b881-9b17672874cc">0.08</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTEyLTEtMS0xNTU2Mzg_f44cc108-aac9-4178-a98e-881274d828dd">1.65</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTE0LTEtMS0xNTU2Mzg_ee5830e6-e0df-4b2d-a55e-6aae657126e4">2.92</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTE2LTEtMS0xNTU2Mzg_eefba0bb-2ec6-4b41-8707-c8d766e14fa2">0.04</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTE4LTEtMS0xNTU2Mzg_1fc0bc1d-9832-4e66-80ee-c8b637bc7a9d">2.88</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTItMS0xLTE1NTYzOA_9e379d60-0036-4208-9325-63b47a71f655">3.65</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTQtMS0xLTE1NTYzOA_aa6ccca0-aaab-4173-ba66-490e0c91074c">0.28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTYtMS0xLTE1NTYzOA_1e36cbb6-6a9a-4002-9173-dc548d96b324">3.93</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTgtMS0xLTE1NTYzOA_b93effd7-8060-43c2-92c3-25cc5621bd6b">1.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTEwLTEtMS0xNTU2Mzg_06c8dfd8-43f7-46d3-95d2-02a28b5c0d42">0.07</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTEyLTEtMS0xNTU2Mzg_cc501ebd-4849-406b-adaa-8e1ae22ca36f">1.18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTE0LTEtMS0xNTU2Mzg_12480bac-cff2-4468-8158-045c1a7b5741">1.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTE2LTEtMS0xNTU2Mzg_cd65351a-55cf-4bd4-a7a3-5f4436d1b608">0.03</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTE4LTEtMS0xNTU2Mzg_5e4c41dd-ce98-4775-bf52-4a90c65db349">1.89</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTItMS0xLTE1NTYzOA_668aca76-5e0f-4746-8643-ab5107a769d4">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTQtMS0xLTE1NTYzOA_7c34ec79-ec72-4e98-850e-9385ccbfe593">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTYtMS0xLTE1NTYzOA_08ad40bd-f385-476d-91e3-a03c3399eb91">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTgtMS0xLTE1NTYzOA_4e3cfee4-80e6-44ee-abd6-2f0348fd876e">0.46</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTEwLTEtMS0xNTU2Mzg_815b8af5-39f0-425a-b207-fdd97e397eff">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTEyLTEtMS0xNTU2Mzg_9b64b50c-6b5e-4517-985c-3ef44b44465d">0.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTE0LTEtMS0xNTU2Mzg_7a9075c6-3725-4293-9cd3-d02a34bdb213">0.95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTE2LTEtMS0xNTU2Mzg_c74ffde6-de29-4247-ac10-bc80aa85afbf">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTE4LTEtMS0xNTU2Mzg_6eeb9e52-b337-4eec-9983-dce9a12cb031">0.94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTItMS0xLTE1NTYzOA_7fc62245-d082-428a-839a-93e43ec0749c">3.57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTQtMS0xLTE1NTYzOA_5dcab71a-c92c-4a09-95ef-f27c9fb4aa6d">0.28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTYtMS0xLTE1NTYzOA_bbc14571-6dc0-4efb-a9e4-087a1b831e5e">3.85</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTgtMS0xLTE1NTYzOA_a14fa987-48db-406d-9164-d7b77175c723">1.71</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTEwLTEtMS0xNTU2Mzg_541db502-a558-45aa-971c-7a200c72a2f6">0.08</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTEyLTEtMS0xNTU2Mzg_2ab136c1-d27e-40b8-9734-a64365a4aec6">1.63</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTE0LTEtMS0xNTU2Mzg_49ad20b0-9599-4129-a6b3-f43604b8daf9">2.87</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTE2LTEtMS0xNTU2Mzg_15f3c967-e339-4649-b312-85bab861cdca">0.04</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTE4LTEtMS0xNTU2Mzg_63fb6b34-d608-4eaf-a67a-5950f882d07c">2.82</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="57" style="border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Comprehensive Income:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTItMS0xLTE1NTYzOA_d92b2f2b-910e-4947-8f32-e430b429e941">731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTQtMS0xLTE1NTYzOA_ad5d8dc0-75c3-4070-9fb6-300340269976">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTYtMS0xLTE1NTYzOA_e3873478-26ae-4b41-a0b0-65677f23bda8">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTgtMS0xLTE1NTYzOA_0e0c880e-a2de-4f67-86a8-06fc51664281">957</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTEwLTEtMS0xNTU2Mzg_1ee6aa44-67cd-4a90-a376-a71d2391fb43">185</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTEyLTEtMS0xNTU2Mzg_fd104b1a-5f82-4cc7-ae89-4540e09f591f">772</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTE0LTEtMS0xNTU2Mzg_680f150a-a33d-44de-8647-618292e58a2f">654</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTE2LTEtMS0xNTU2Mzg_dd505de7-56fc-4054-87ab-9446ad581f4b">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTE4LTEtMS0xNTU2Mzg_fb93be5f-2162-4f8a-aeae-79face3b46e9">675</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Benefit plans: actuarial gains/(losses), net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTItMS0xLTE1NTYzOA_f22c4d42-3b66-4a76-8a76-e5fb12eb9011">1,565</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTQtMS0xLTE1NTYzOA_0804acee-cc07-4424-879e-b7c8c7cf6c64">1,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTYtMS0xLTE1NTYzOA_c4308bcc-36be-4bba-b75b-548f53e442a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTgtMS0xLTE1NTYzOA_37f07d74-01fc-48ce-9e66-b5911de86cb0">1,128</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTEwLTEtMS0xNTU2Mzg_1ba954d4-ff0a-4851-b7b8-2959371b4cf9">1,128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTEyLTEtMS0xNTU2Mzg_bbb5d531-6310-478c-9f7a-a54effc804f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTE0LTEtMS0xNTU2Mzg_fd18d875-9ae1-4e6f-9fb7-e0439d3ed105">826</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTE2LTEtMS0xNTU2Mzg_3995947b-81c5-493a-98d4-344923e0b894">826</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTE4LTEtMS0xNTU2Mzg_79029474-2269-44c7-9bb7-98e060af0ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTItMS0xLTE1NTYzOA_cd6749a8-5bf0-4d37-aa0e-dff2ca18c982">285</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTQtMS0xLTE1NTYzOA_32afd02c-1385-4231-85ef-b73d7f933e9f">285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTYtMS0xLTE1NTYzOA_7a700efd-5828-46c1-98c8-dbb598cae622">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTgtMS0xLTE1NTYzOA_fb6a24d4-4361-4e31-830c-ce98c5b08f11">276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTEwLTEtMS0xNTU2Mzg_23249273-a296-4fca-93c7-02bcdd4bb52a">276</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTEyLTEtMS0xNTU2Mzg_4af11490-885d-43f5-b095-3080b366eda8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTE0LTEtMS0xNTU2Mzg_37ec162b-a3a6-40b7-8514-0b6d284ec4d2">241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTE2LTEtMS0xNTU2Mzg_5e9c4cad-c229-47fc-a22b-61f3f2329212">241</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTE4LTEtMS0xNTU2Mzg_de3c3234-ec42-4a32-88c4-ccd18aecb840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to settlements, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTItMS0xLTE1NTYzOA_ddc6cb2d-d0cd-43bd-a298-91c87b0629f9">209</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTQtMS0xLTE1NTYzOA_3939d77f-3605-47f9-8614-27ae6d786b16">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTYtMS0xLTE1NTYzOA_12f6fdf0-2f83-485e-8c90-808227e14cea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTgtMS0xLTE1NTYzOA_c7cbbc4e-7da4-4669-b54a-06c97cec19ef">278</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTEwLTEtMS0xNTU2Mzg_29e7d3e7-ee39-479b-84f7-8ad28f3d627f">278</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTEyLTEtMS0xNTU2Mzg_6502563c-6b0e-4783-b1a2-003b8f9adf57">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTE0LTEtMS0xNTU2Mzg_208f6eab-a973-4847-be10-1ebd3c2ba861">274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTE2LTEtMS0xNTU2Mzg_69a35cf1-e9b0-4751-aafb-3ac28471c4ab">274</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTE4LTEtMS0xNTU2Mzg_662ea075-be99-4cdc-8af5-96af91817292">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTItMS0xLTE1NTYzOA_fbdd68ae-d90f-4840-8f88-0bf511d93a16">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTQtMS0xLTE1NTYzOA_fbb6ac25-d422-4dc0-8460-8b937ab3562e">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTYtMS0xLTE1NTYzOA_4b5b063a-5ce8-4da6-b10d-c87a29b6d802">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTgtMS0xLTE1NTYzOA_bd18e024-bf54-4e38-b5ed-c94bf1bcae46">189</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTEwLTEtMS0xNTU2Mzg_837dc8b2-4098-42d1-8fb7-93c30cfdb916">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTEyLTEtMS0xNTU2Mzg_b0166fb6-4358-422d-8a17-8c0d733ee543">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTE0LTEtMS0xNTU2Mzg_45cd3e4b-5a1e-4b93-93be-d883e206c20e">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTE2LTEtMS0xNTU2Mzg_8743df37-d6f5-45b2-bc1e-6cca169594ba">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTE4LTEtMS0xNTU2Mzg_03f92fad-3294-4707-889f-de6c5efaaeab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTItMS0xLTE1NTYzOA_784dab3c-60e8-4760-aa83-e87bd7eff391">545</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTQtMS0xLTE1NTYzOA_f27c32ba-9f66-4dde-acd9-4bae8e82c2d5">475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTYtMS0xLTE1NTYzOA_7b95a10f-077d-46ac-8b68-58e892e35acd">71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTgtMS0xLTE1NTYzOA_ba27ab4a-6ab2-4cb3-ba40-5f1c249efee5">349</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTEwLTEtMS0xNTU2Mzg_42f94024-310b-4b15-9b04-012646fac1c4">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTEyLTEtMS0xNTU2Mzg_681bdf19-13fc-4c95-806f-ff080bde94ae">227</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTE0LTEtMS0xNTU2Mzg_e4b8790e-a28f-43c7-805d-942c45c0b920">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTE2LTEtMS0xNTU2Mzg_04a3d318-ba6a-4b28-9596-32c0b45df905">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTE4LTEtMS0xNTU2Mzg_74cc3428-e932-42df-88fb-ec011206b016">178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTItMS0xLTE1NTYzOA_a2dcf71a-e43c-4c3d-b044-07ccca0b39a0">4,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTQtMS0xLTE1NTYzOA_ba5d5374-c355-4171-99ee-925956d5e912">453</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTYtMS0xLTE1NTYzOA_60a6de51-0c19-4c56-a0c2-1854579e0752">4,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTgtMS0xLTE1NTYzOA_bdb2111d-cbbe-43e9-8673-b2114b3b902a">1,449</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTEwLTEtMS0xNTU2Mzg_42511a08-e885-46df-8c33-7e5e7524448f">125</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTEyLTEtMS0xNTU2Mzg_8e51493f-7b20-43d9-8a88-f621958e33b0">1,575</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTE0LTEtMS0xNTU2Mzg_77bc4414-871b-45aa-87b9-a56b9fc270fa">609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTE2LTEtMS0xNTU2Mzg_11709f31-d336-4b9f-baaa-f1d4a7d3615c">48</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTE4LTEtMS0xNTU2Mzg_b9380118-4864-4253-bcc2-52db9c11f32b">561</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTItMS0xLTE1NTYzOA_c131e031-435f-4052-9ebc-5835fc582e40">1,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTQtMS0xLTE1NTYzOA_9da38216-dd57-456c-aac5-39e7a78bec85">2,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTYtMS0xLTE1NTYzOA_ef7d36f0-d22f-4e16-9ab0-58f14ff1f26b">3,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTgtMS0xLTE1NTYzOA_960f67be-5151-4bd0-b279-62b58dcafdbe">1,790</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231" decimals="-6" sign="-" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTEwLTEtMS0xNTU2Mzg_7c4b01ab-2a4e-45c2-a087-99d086c78777">547</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTEyLTEtMS0xNTU2Mzg_93afbcb3-1e89-4229-ba7f-625e65d2459d">1,242</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTE0LTEtMS0xNTU2Mzg_d86245c7-4b06-4b26-8016-8c9cdb099af5">288</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231" decimals="-6" sign="-" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTE2LTEtMS0xNTU2Mzg_ef33bebc-fd5f-4f04-8313-49c8cdacec03">233</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTE4LTEtMS0xNTU2Mzg_b5837c87-63af-4c6b-9d92-c0edea583f99">55</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtMi0xLTEtMTU1NjM4_20149a80-2e86-46d9-993e-88a0117bd79d">3,320</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtNC0xLTEtMTU1NjM4_6ae46f50-e4e5-49f4-83e6-5a5543217130">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtNi0xLTEtMTU1NjM4_704923cc-f82f-4f0e-8aea-52fe36121004">3,341</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtOC0xLTEtMTU1NjM4_6f0ed9da-5ab0-4752-8ce0-4c3d2114927c">2,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtMTAtMS0xLTE1NTYzOA_108c43df-e1d5-4871-b825-72f8a7f7d4e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtMTItMS0xLTE1NTYzOA_afdeb93a-ba5b-44e8-af2b-5643be60584c">2,383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtMi0xLTEtMTU1NjM4_c42f2155-73c4-416b-8073-af3728e869ab">7,679</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtNC0xLTEtMTU1NjM4_875564d9-890e-4072-bb9e-0af590c6603a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtNi0xLTEtMTU1NjM4_7329abef-62ff-4d1f-8727-b0e241585826">7,679</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtOC0xLTEtMTU1NjM4_1c759361-1112-40a9-af4e-ebcbba821bd0">4,879</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtMTAtMS0xLTE1NTYzOA_12f8c2f7-33a6-479d-9a2f-77719a0be979">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtMTItMS0xLTE1NTYzOA_7818e897-b369-473e-9c31-655472745e0e">4,879</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtMi0xLTEtMTU1NjM4_9f403cf9-3dd0-428e-8670-7ce72455095a">3,489</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtNC0xLTEtMTU1NjM4_28c7fe29-6363-47ca-94c3-d8f91f6ea981">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtNi0xLTEtMTU1NjM4_47d27fa0-dfc4-4fe0-82de-e94d1246690c">3,489</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtOC0xLTEtMTU1NjM4_3db7627c-2589-4c9d-a227-0c93b0c53a0c">4,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtMTAtMS0xLTE1NTYzOA_eef5fe3a-e0f3-4216-9716-c241223adefc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtMTItMS0xLTE1NTYzOA_930bb524-2019-472c-8b9a-19deb059cc40">4,766</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtMi0xLTEtMTU1NjM4_269ad8e3-de06-4c1f-a32c-08eb6c6b9756">101,789</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtNC0xLTEtMTU1NjM4_81b587bc-9816-42d6-bdbc-d43ed6b71ad9">1,605</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtNi0xLTEtMTU1NjM4_bcdecde8-fd24-493d-85a1-d37f586ed1a5">103,394</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtOC0xLTEtMTU1NjM4_cf62923e-e936-4047-b546-7343725b0536">96,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtMTAtMS0xLTE1NTYzOA_88eace87-1817-4150-b031-ec9feeb1ce16">6,378</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtMTItMS0xLTE1NTYzOA_e0b9e02a-3686-4034-8c34-6adf65ce0d34">90,392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctMi0xLTEtMTU1NjM4_89a2b295-64c7-4661-b88e-7091e2bc045e">4,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctNC0xLTEtMTU1NjM4_86beeeea-1d1c-4ae6-8491-89b4fa4965a2">1,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctNi0xLTEtMTU1NjM4_fa91a244-e48c-4371-9239-c5ea6ec5caa7">5,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctOC0xLTEtMTU1NjM4_30afaedd-dfd9-473d-9f52-4fbeccbcc1b8">11,688</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctMTAtMS0xLTE1NTYzOA_64e68ee0-15bb-4b67-a896-76ba901ac39a">6,378</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctMTItMS0xLTE1NTYzOA_2599286e-c17d-4a8c-abff-919150586d2d">5,310</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">58</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i36307b3c055848148cac7da7baf2a99f" continuedAt="i94b163abf633465d968b538066bcabff"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1MzY5_c9b4ca6b-9847-4af8-953e-67fe86c3086c" continuedAt="id22825b936ef4960889ee075ea8372d4" escape="true">Estimates and Assumptions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="id22825b936ef4960889ee075ea8372d4"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of income. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDc0_279471f5-787b-4967-a48a-c61c6c143e28" continuedAt="i978f1cb545f94664a073f99e8e977775" escape="true">Acquisitions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i978f1cb545f94664a073f99e8e977775"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTU5_8cd544c1-70a4-405f-81f0-d278406bd615" continuedAt="ic84dae8f388c45cca870dea3cf221108" escape="true">Fair Value</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic84dae8f388c45cca870dea3cf221108"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities&#8212;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities with readily determinable fair values&#8212;quoted market prices and observable NAV prices.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Derivative assets and liabilities&#8212;third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Money market funds&#8212;observable NAV prices.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.</span></div></ix:continuation></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i94b163abf633465d968b538066bcabff" continuedAt="i2d1051d228894cc4888ccb027aa737c7"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">G. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTUw_9d805957-c911-4198-82df-78044bc367db" continuedAt="i4a82226ad67f42d0a921e46d75a4b874" escape="true">Foreign Currency Translation</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i4a82226ad67f42d0a921e46d75a4b874"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and we translate non-monetary items at historical rates.</span></ix:continuation></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">H. Revenues and Trade Accounts Receivable</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDk5_d2f8cafc-caa4-4138-8b1e-d4c577da273b" continuedAt="i3f557b597c1b4e8eb28289bdb75a1528" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our Sales Contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to LOE, product recalls or a changing competitive environment.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provisions for pharmaceutical sales returns&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as LOE, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines our common sales arrangements:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#008080;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies, and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period&#8217;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#8220;coverage gap,&#8221; also known as the &#8220;doughnut hole,&#8221; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#8217;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recorded direct product sales and/or Alliance revenues of more than $<ix:nonFraction unitRef="usd" contextRef="ibfadeff2c1f5480394b1866913a3183a_D20210101-20211231" decimals="-9" name="pfe:ConcentrationRiskAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNTk3_060498e7-ab9b-4ad9-8c54-9eebe0f5be6c"><ix:nonFraction unitRef="usd" contextRef="i11f0ae3d8acd41fa96131bb2d2405985_D20200101-20201231" decimals="-9" name="pfe:ConcentrationRiskAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNTk3_3f7f24df-4e36-4e56-b0b9-03263c67ee7e"><ix:nonFraction unitRef="usd" contextRef="if173d80ef8d44c438cb34092fab6cadf_D20190101-20191231" decimals="-9" name="pfe:ConcentrationRiskAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNTk3_bbfe0c16-e942-44d2-b038-67e88ab8b2e7">1</ix:nonFraction></ix:nonFraction></ix:nonFraction> billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented <ix:nonFraction unitRef="number" contextRef="ibfadeff2c1f5480394b1866913a3183a_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNzg1_780afbbb-01f2-487b-9f6c-d38459cf9137">75</ix:nonFraction>% of our revenues in 2021, <ix:nonFraction unitRef="number" contextRef="i11f0ae3d8acd41fa96131bb2d2405985_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyODEx_462bb10b-45f0-406e-a363-80bc616c35c0">54</ix:nonFraction>% of our revenues in 2020 and <ix:nonFraction unitRef="number" contextRef="if173d80ef8d44c438cb34092fab6cadf_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyODQw_03da4573-855b-42ee-9a99-a2bd40e947d9">49</ix:nonFraction>%</span><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of our revenues in 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17B </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.</span></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">60</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2d1051d228894cc4888ccb027aa737c7" continuedAt="ibfa9e56277824120922a3fb25dc325a7"><div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDE2_ca6eb23d-3e09-4859-893e-865bb8927024" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:70.392%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.631%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f7cb8f0966747fd9a171cc0fd9a0c50_I20211231" decimals="-6" name="pfe:RebatesAndOtherSalesRelatedAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzMtMi0xLTEtMTU1NjM4_a7fb6a6a-5f5b-4e40-9f98-3e1e4eeb71d3">1,077</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d45585212a4650a36d5467a52c00b1_I20201231" decimals="-6" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzMtNC0xLTEtMTU1NjM4_3cdb3a7b-06c7-47f7-8b31-8d0b800e68c8">861</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c659cb958e94f909ae64de8887c53e5_I20211231" decimals="-6" name="pfe:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzYtMi0xLTEtMTU1NjM4_060ab353-5dd2-496c-80e0-72f1719b406c">3,811</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231" decimals="-6" name="pfe:AccruedRebates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzYtNC0xLTEtMTU1NjM4_d1cba3d9-1199-4cb6-b3f9-0d0911e8a138">3,017</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c659cb958e94f909ae64de8887c53e5_I20211231" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzctMi0xLTEtMTU1NjM4_d17ccc14-d510-4a46-82ce-722b14d1ecae">528</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231" decimals="-6" name="pfe:OtherAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzctNC0xLTEtMTU1NjM4_dbba5c1e-c509-47a9-9f07-39e59263973a">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0e5d69b58349a58289b22b8b683cd0_I20211231" decimals="-6" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzktMi0xLTEtMTU1NjM4_a4cb7bf8-4f7b-44af-854d-896a95a6cf52">433</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aaf677ffe1c461b92474fb66fe48c68_I20201231" decimals="-6" name="pfe:RebatesAndOtherSalesRelatedAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzktNC0xLTEtMTU1NjM4_b95d3b18-68a8-4514-a867-9a8fae836bbc">399</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:RebatesAndOtherSalesRelatedAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzEwLTItMS0xLTE1NTYzOA_56802fc6-4ac1-45ac-b616-ec028c0fbd22">5,850</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:RebatesAndOtherSalesRelatedAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzEwLTQtMS0xLTE1NTYzOA_fe23ed8b-49a8-40cd-830c-4f6fbd15ea03">4,708</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:3pt"><ix:continuation id="i3f557b597c1b4e8eb28289bdb75a1528" continuedAt="i4c920d8d44764bd38f0377bb5a87b886"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTUz_7220f432-1d84-4ed1-825d-6b6024e5d682" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During 2021 and 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">I. <ix:continuation id="i4c920d8d44764bd38f0377bb5a87b886" continuedAt="i9ca9a1cddbf64e39b46fcb562739f228">Collaborative Arrangements</ix:continuation></span></div><div><span><br/></span></div><ix:continuation id="i9ca9a1cddbf64e39b46fcb562739f228"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received for our share of gross profits from our collaboration partners as alliance revenues, a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Royalty payments received from collaboration partners are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reimbursements to or from our collaboration partners for development costs are typically recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets&#8212;Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> over the development period for the products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">J. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTU0_94c7f175-b960-4594-893f-1dcee6cb6860" continuedAt="i8dcc943ca4ff4e2c894408dd5addceb2" escape="true">Cost of Sales and Inventories</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i8dcc943ca4ff4e2c894408dd5addceb2">Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">K. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1MzYy_d80d8b25-8111-402c-b2ec-a2f7b350cdf5" continuedAt="i6cfd7f1c9def40bb8963dcb5f25ff6dd" escape="true">Selling, Informational and Administrative Expenses</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i6cfd7f1c9def40bb8963dcb5f25ff6dd">Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.</ix:continuation> Advertising expenses totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzI4OTQz_59f9436c-111b-4bf9-aa4c-8e909ace7854">2.0</ix:nonFraction> billion in 2021, $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzI4OTUz_afcbea84-5dd7-417a-8412-86d267565200">1.8</ix:nonFraction> billion in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzI4OTY2_9cdd54ad-71b4-46d8-bde1-0c72cdda47e4">2.3</ix:nonFraction> billion in 2019. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ibfa9e56277824120922a3fb25dc325a7" continuedAt="i60e510a87137494bb9cfeeaeec12f5e8"><div style="margin-top:7pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">L. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTQx_390b4779-9b0e-4ef8-91cc-58921c0d943d" continuedAt="i688afd2527434bdf846bfa0b1e864781" escape="true">Research and Development Expenses</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i688afd2527434bdf846bfa0b1e864781"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.</span></ix:continuation></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">M. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets include:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTE0_603b5bb0-6002-4a83-b3ca-21bdfca33139" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, less accumulated depreciation&#8212;These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span></ix:nonNumeric></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDcw_c046b5a9-6c74-4020-8054-961aab5786de" continuedAt="iad051f5d6fa64ab1b46f1cab34b7b722" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;These assets are recorded at fair value at acquisition. Intangible assets with finite lives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.</span></ix:nonNumeric></div><ix:continuation id="iad051f5d6fa64ab1b46f1cab34b7b722" continuedAt="i7c72b7642b964f35ae05d86209b4c4cf"><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as these intangible assets benefit multiple business functions. Amortization of intangible assets that are for a single function and depreciation of property, plant and equipment are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as appropriate.</span></div></ix:continuation><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDYz_74b173ae-def5-4760-815c-00d54aa51fab" escape="true">We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i7c72b7642b964f35ae05d86209b4c4cf"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For indefinite-lived intangible assets, such as brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">N. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTcy_fc01f6c6-f0d8-490e-94cc-0a793bb8a78e" continuedAt="idafd8e78a4ed46ecbe5b8c3883b61be7" escape="true">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idafd8e78a4ed46ecbe5b8c3883b61be7"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business and platform functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as our corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement).</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">O. Cash Equivalents and Statement of Cash Flows</span></div><div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDEy_42f67dd8-4402-4941-b27b-358a4a1fb58a" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:nonNumeric></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">62</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i60e510a87137494bb9cfeeaeec12f5e8" continuedAt="i5148b9c2b4a947d985fd7202defb8e3f"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:DerivativesReportingOfDerivativeActivity" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDU1_66cb7d95-25c8-4558-adf5-3065ba63e4cc" escape="true">Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">P. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDcy_ec04b923-0b34-4d4b-a97d-28fb7de29504" continuedAt="i28a59a1a127d4436b2d19ed61d88358e" escape="true">Investments and Derivative Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i28a59a1a127d4436b2d19ed61d88358e"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">until realized.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Held-to-maturity debt securities, which are carried at amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#8217;s income and expenses in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.</span></div></ix:continuation><div><span><br/></span></div><div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTY4_aa70e101-706f-4308-ae27-367cbdd1ce74" continuedAt="i51e372be863740b2bbaf882557143cfe" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative financial instruments are carried at fair value in various balance sheet categories (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> or, for derivative financial instruments in certain qualifying hedging relationships, in </span></ix:nonNumeric><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i51e372be863740b2bbaf882557143cfe">Other comprehensive income/(loss)</ix:continuation> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Q. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDU5_c48cb181-c100-41e0-82a0-22896b24f19e" continuedAt="i8c2ba3f84652421eb887b3b8895b4737" escape="true">Tax Assets and Liabilities and Income Tax Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8c2ba3f84652421eb887b3b8895b4737" continuedAt="i445bcf8d7b0a45d3a0b987827e5b0d17"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Assets and Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Current tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Global Intangible Low-Taxed Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as of December 31, 2021 and 2020 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for uncertain tax positions and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Income Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.</span></div></ix:continuation></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i5148b9c2b4a947d985fd7202defb8e3f"><ix:continuation id="i445bcf8d7b0a45d3a0b987827e5b0d17"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#8220;more likely than not&#8221;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTQ1_1560cd2e-5e4e-4839-ae96-1ed18d75c366" continuedAt="i210dcae9bae041b28d8d739b670ccf10" escape="true">Pension and Postretirement Benefit Plans</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i210dcae9bae041b28d8d739b670ccf10"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">S. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTYy_9b0c030a-e289-4499-9c28-fad61ac6d835" continuedAt="ie716d121ac04492dbe0fb9eb66f36298" escape="true">Legal and Environmental Contingencies</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:continuation id="ie716d121ac04492dbe0fb9eb66f36298">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</ix:continuation></span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">T. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDM5_9cc713ab-cf44-4ce1-9b72-6093f12beef3" continuedAt="i5c9a5dc730404bbe8125fb8c83cfae91" escape="true">Share-Based Payments</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:continuation id="i5c9a5dc730404bbe8125fb8c83cfae91"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms with the related costs recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate.</span></ix:continuation></div></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_169"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA2_c24d438d-0c84-481a-8755-4d6637273e93" continuedAt="iae1da38af6954e719fef8ea9ac3ead52" escape="true">Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iae1da38af6954e719fef8ea9ac3ead52" continuedAt="i99ff23c3fa6340debeb1f62de224c416"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisitions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Trillium</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno-oncology company developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id3eaee674151468f8779787aca2fbdd8_I20211117" decimals="2" name="pfe:AssetAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2OTE1NjQ_c40d1c9a-a205-4c26-92bf-2207f6cf27ef">18.50</ix:nonFraction> per share in cash, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NDk2_7a98c0df-8f2c-4ed7-a8e8-f5a231260948">2.0</ix:nonFraction> billion, net of cash acquired. As a result, Trillium became our wholly owned subsidiary. We previously held a <ix:nonFraction unitRef="number" contextRef="i40a5967cba7c42799e4a32e326df03fd_D20210101-20211116" decimals="2" name="pfe:InvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2OTE1NDA_0455f2bc-ac28-47e4-b799-b7ca05e264b7">2</ix:nonFraction>% ownership investment in Trillium. Trillium&#8217;s lead program, TTI-622, is an investigational fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">We accounted for the transaction as an asset acquisition since the lead asset, TTI-622, represented substantially all of the fair value of the gross assets acquired, which exclude cash acquired. At the acquisition date, we recorded a $<ix:nonFraction unitRef="usd" contextRef="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117" decimals="-8" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NTEz_4a847d13-6615-4db3-85f9-8f9db3283813">2.1</ix:nonFraction> billion charge representing an acquired IPR&amp;D asset with no alternative future use in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">, of which the $<ix:nonFraction unitRef="usd" contextRef="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117" decimals="-8" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzQ1ODc_7a98c0df-8f2c-4ed7-a8e8-f5a231260948">2.0</ix:nonFraction> billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $<ix:nonFraction unitRef="usd" contextRef="id3eaee674151468f8779787aca2fbdd8_I20211117" decimals="-6" name="pfe:AssetAcquisitionAssetsAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NTMy_094d8ea3-66d2-4671-bbe1-e0d69c4195fd">256</ix:nonFraction> million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $<ix:nonFraction unitRef="usd" contextRef="id3eaee674151468f8779787aca2fbdd8_I20211117" decimals="-6" name="pfe:AssetAcquisitionLiabilitiesAssumed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NTM4_e64b1cfd-de94-4bf3-bee6-67b7836b34ab">81</ix:nonFraction> million.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Array</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On July&#160;30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $<ix:nonFraction unitRef="usdPerShare" contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI2Mw_efce6f9b-38e5-428d-81e8-8b5127f7f14e">48</ix:nonFraction> per share in cash. The total fair value of the consideration transferred was $<ix:nonFraction unitRef="usd" contextRef="i5adbe40672074cb28e27345d594c6111_D20190730-20190730" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM0Mw_0da11ef9-8cd1-4675-b008-42f1d773ecab">11.2</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i5adbe40672074cb28e27345d594c6111_D20190730-20190730" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM0Nw_354decf4-ec43-4e0f-8f72-fd44de2289aa">10.9</ix:nonFraction> billion, net of cash acquired). In addition, $<ix:nonFraction unitRef="usd" contextRef="i763f14d53a0f47d2bb88afb5100aeece_D20190101-20191231" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM4Nw_e2482a99-6d2d-463b-8a3f-444be93f641d">157</ix:nonFraction> million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). We financed the majority of the transaction with debt and the balance with existing cash. </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">64</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i99ff23c3fa6340debeb1f62de224c416" continuedAt="if55d0a0f61c7486d9a2454ecd444d287"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Array&#8217;s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib), a broad pipeline of targeted cancer medicines in different stages of R&amp;D, as well as a portfolio of out-licensed medicines, which may generate milestones and royalties over time.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $<ix:nonFraction unitRef="usd" contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzExNDg_221a3e3c-2b52-49ac-b266-c954bee12fe5">6.3</ix:nonFraction> billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, consisting of $<ix:nonFraction unitRef="usd" contextRef="i6ef40e33d0e245579352ff0b15309b81_I20190730" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyMDA_171f3160-5e44-42ab-aa51-0855f199465e">2.0</ix:nonFraction> billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> with a useful life of <ix:nonNumeric contextRef="if00cc3ffe8b74509b0746823ba987ea5_D20190730-20190730" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNTY_d05dd152-5932-4d33-8df0-e38ec564b46b">16</ix:nonNumeric> years</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="iee11b1723a234cdfad038a7b6b8d6698_I20190730" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjA_4ce98fe2-d266-4d64-874e-da5c4ce4c75c">2.8</ix:nonFraction> billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i60e43a0fe85848159c571b3aee53daf1_I20190730" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNzY_b123434c-9d4e-4f7a-bb50-0e2fe8165704">1.5</ix:nonFraction> billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Licensing agreements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="i8c8f7c06b3f04a218265c1e05e918490_I20190730" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzMDQ_e67fca75-c764-4502-80b7-18cf53f1a718">1.2</ix:nonFraction> billion for technology in development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">indefinite-lived licensing agreements and $<ix:nonFraction unitRef="usd" contextRef="i1f466f58bbb14f0c960799ddb7db2885_I20190730" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzODA_d9e83d6c-b4cc-4e93-a448-abe0842f5517">360</ix:nonFraction> million for developed technology</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">finite-lived licensing agreements with a useful life of <ix:nonNumeric contextRef="ibbc5264b1b924484a590099fbbf18894_D20190730-20190730" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE0NjU_7b49a19a-880e-4528-9d01-7a1024e56826">10</ix:nonNumeric> years), (ii) $<ix:nonFraction unitRef="usd" contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE0NzU_93edb67b-0005-41fe-b4f4-6b4097b5004c">6.1</ix:nonFraction> billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, (iii) $<ix:nonFraction unitRef="usd" contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE0OTc_b452e6ba-acfd-4320-be8f-481618eb46cc">1.1</ix:nonFraction> billion of net deferred tax liabilities and (iv) $<ix:nonFraction unitRef="usd" contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE1NDE_e97e7925-29cd-445b-b10e-c6ceed71b792">451</ix:nonFraction> million of assumed long-term debt, which was paid in full in 2019.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">In 2020, we recorded measurement period adjustments to the estimated fair values initially recorded in 2019, which resulted in a reduction in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> of approximately $<ix:nonFraction unitRef="usd" contextRef="i40b3ec61b4cf4015ab587fac323995eb_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NTc5NDg_fe4631ab-1ade-4bae-83c8-f278d56bec63">900</ix:nonFraction> million with a corresponding change to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and net deferred tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date and did not have a material impact on our consolidated statement of income for the year ended December 31, 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Therachon</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for $<ix:nonFraction unitRef="usd" contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701" decimals="-6" name="pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI0NTI_5a0ba9db-4480-43ea-911f-0246cc18e016">340</ix:nonFraction> million upfront, plus potential milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701" decimals="-6" name="pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MDc_0333e5e2-6255-4fe0-8270-cafc0fb4e217">470</ix:nonFraction> million contingent on the achievement of key milestones in the development and commercialization of the lead asset. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was $<ix:nonFraction unitRef="usd" contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI5MjM_e0ec8ef9-cb85-4a11-8ab5-063497e4b874">322</ix:nonFraction> million, which consisted of $<ix:nonFraction unitRef="usd" contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI5NDY_88dc5720-ed17-44ea-92b3-79afb6e40fd7">317</ix:nonFraction> million of cash and our previous $<ix:nonFraction unitRef="usd" contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI5NzQ_856c2cc9-7647-41f7-965b-67c14463305a">5</ix:nonFraction> million investment in Therachon. In connection with this asset acquisition, we recorded a charge of $<ix:nonFraction unitRef="usd" contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwNjk_20394849-4c99-48fb-bf23-b768fb57692e">337</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Divestitures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Meridian</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On December 31, 2021, we completed the sale of our Meridian subsidiary for approximately $<ix:nonFraction unitRef="usd" contextRef="i314f8d3de1434b56bb2fdf8061d7a953_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA3MDk5_a7497050-1f8d-4595-8a77-0af05c8347f2">51</ix:nonFraction> million in cash and recognized a loss of approximately $<ix:nonFraction unitRef="usd" contextRef="i4b44d95032624046bce69d6abe17288c_D20211231-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3NzM_bb07d65c-b3e8-4106-bd6f-69e86ae5b547">167</ix:nonFraction>&#160;million, net of tax, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">. In connection with the sale, Pfizer and the purchaser of Meridian entered into various agreements to provide a framework for our relationship after the sale, including interim TSAs and a manufacturing supply agreement (MSA). The TSAs primarily involve Pfizer providing services related to information technology, among other activities, and are generally expected to be for terms of no more than <ix:nonNumeric contextRef="i888e24f18a1748c6b73bcfc6bda4a9b9_D20210101-20211231" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MzY4MDg_3d02ea01-f374-45ce-83a1-55042b308237">12</ix:nonNumeric> to <ix:nonNumeric contextRef="i0f02e49d15574798a17efff00d83ccb9_D20210101-20211231" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3NzY_6408bced-52d8-40f2-b1fa-c4a90edc76d0">18</ix:nonNumeric> months post sale. The MSA is for a term of <ix:nonNumeric contextRef="iaffca7f3bf5b4256aed31e1ad5ab0cce_D20210101-20211231" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3Nzc_40e9c95c-56ac-4c47-b4f9-2dddf3ece556">three years</ix:nonNumeric> post sale with a <ix:nonNumeric contextRef="iaffca7f3bf5b4256aed31e1ad5ab0cce_D20210101-20211231" name="pfe:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3Nzg_b9eb604b-2205-4771-809c-94387010a809">two year</ix:nonNumeric> extension period. No amounts were recorded under the above arrangements in 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Upjohn Separation and Combination with Mylan</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan (the Transactions) to form Viatris. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">The Transactions were structured as an all-stock, Reverse Morris Trust transaction. Specifically, (i) we contributed the Upjohn Business to a wholly owned subsidiary, which was renamed Viatris, so that the Upjohn Business was separated from the remainder of our business (the Separation), (ii) following the Separation, we distributed, on a pro rata basis, all of the shares of Viatris common stock held by Pfizer to Pfizer stockholders as of the November&#160;13, 2020 record date, such that each Pfizer stockholder as of the record date received approximately <ix:nonFraction unitRef="number" contextRef="i389169f22b244d9c8c2e87bfedee54c2_D20201113-20201113" decimals="INF" name="pfe:DiscontinuedOperationRatioSharesReceivedForEachShareOwned" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM4Mzg_6f60f160-6cfd-4f81-9f01-27c7fc48f0ce">0.124079</ix:nonFraction> shares of Viatris common stock per share of Pfizer common stock (the Distribution); and (iii) immediately after the Distribution, the Upjohn Business combined with Mylan in a series of transactions in which Mylan shareholders received <ix:nonFraction unitRef="number" contextRef="id93ea4a3a591476aab3a080ee5c9429b_D20201113-20201113" decimals="INF" name="pfe:DiscontinuedOperationRatioSharesReceivedForEachShareOwned" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQwNzY_e1ac9f16-d327-4d2a-96d2-5f86589eba44">one</ix:nonFraction> share of Viatris common stock for each Mylan ordinary share held by such shareholder, subject to any applicable withholding taxes (the Combination). Prior to the Distribution, Viatris made a cash payment to Pfizer equal to $<ix:nonFraction unitRef="usd" contextRef="i10ff88c8caf540d29f9a1a2759e9218f_I20201113" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzMDI_66edeab1-5ee1-4a5f-b9d3-d5222a42f158">12.0</ix:nonFraction> billion as partial consideration for the contribution of the Upjohn Business to Viatris. As of the closing of the Combination, Pfizer stockholders owned approximately <ix:nonFraction unitRef="number" contextRef="i18320fc2b9594ddea18b362bf4514a69_I20201116" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQ0NjQ_fa2031d7-f255-4874-96ef-1401be04e719">57</ix:nonFraction>% of the outstanding shares of Viatris common stock, and Mylan shareholders owned approximately <ix:nonFraction unitRef="number" contextRef="i23323cf2700144a6b84393ffab357354_I20201116" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQ1NjE_fdde0048-00b1-45b2-9725-7b497c4284f6">43</ix:nonFraction>% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis. The Transactions are generally expected to be tax free to Pfizer and Pfizer stockholders for U.S. tax purposes. Beginning November&#160;16, 2020, Viatris operates both the Upjohn Business and Mylan as an independent publicly traded company, which is traded under the symbol &#8220;VTRS&#8221; on the NASDAQ.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the Transactions, in June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings of $<ix:nonFraction unitRef="usd" contextRef="i031df9beab9042be9970f64529890934_I20200630" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUwOTM_5b98e76c-8f9d-4b6f-a7e5-8b37226e4ffb">7.45</ix:nonFraction> billion and &#8364;<ix:nonFraction unitRef="eur" contextRef="i5bf57b2d36c745beb81e1b7026d3c318_I20200630" decimals="-7" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUxMDA_5eb44bd8-cc7b-4fa7-9da2-85adb933a860">3.60</ix:nonFraction> billion aggregate principal amounts, respectively, (approximately $<ix:nonFraction unitRef="usd" contextRef="i0a559b470d334b43b79260c8d2f79c2d_D20200601-20200630" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUxNjE_0969cc85-0519-47a1-989b-91cc4c38cc0f">11.4</ix:nonFraction> billion) of senior unsecured notes and entered into other financing arrangements, including a $<ix:nonFraction unitRef="usd" contextRef="ia69d0ecee9684b1386c94a8b435e6cd7_I20200630" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUyNTA_ae94d0b2-d74d-4470-a919-8e1c08966eb9">600</ix:nonFraction> million delayed draw term loan agreement and a revolving credit facility agreement for up to $<ix:nonFraction unitRef="usd" contextRef="idc5994c3e02a45da952846df4b47bfbc_I20200630" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUzMzg_7cadaaa2-733f-4e38-80d8-ea932aee9758">4.0</ix:nonFraction> billion. Proceeds from the debt offerings and other financing arrangements were used to fund the $<ix:nonFraction unitRef="usd" contextRef="i10ff88c8caf540d29f9a1a2759e9218f_I20201113" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU0MzA_66edeab1-5ee1-4a5f-b9d3-d5222a42f158">12.0</ix:nonFraction> billion cash distribution Viatris made to Pfizer prior to the Distribution. We used the cash distribution proceeds to pay down commercial paper borrowings and redeem the $<ix:nonFraction unitRef="usd" contextRef="ifc8dbebb0e9d49428a97f4323e05244a_I20200630" decimals="-7" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU1OTU_02e047f3-983a-4938-8616-909f3fd9b981">1.15</ix:nonFraction> billion aggregate principal amount outstanding of our <ix:nonFraction unitRef="number" contextRef="ifc8dbebb0e9d49428a97f4323e05244a_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU2NDQ_78313074-1ea0-47be-8345-c5b1098ba069">1.95</ix:nonFraction>% senior unsecured notes that were due in June 2021 and $<ix:nonFraction unitRef="usd" contextRef="i1e71e04bd5f14e7e934d2585e74e3b2b_I20200630" decimals="-6" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU2OTQ_07ead6ce-c690-4d3d-a700-64eb0d860ab4">342</ix:nonFraction> million aggregate principal amount outstanding of our <ix:nonFraction unitRef="number" contextRef="i1e71e04bd5f14e7e934d2585e74e3b2b_I20200630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU3NDM_f250b2f2-669e-414e-a10a-b873d397aa77">5.80</ix:nonFraction>% senior unsecured notes that were due in August 2023, before the maturity date. Interest expense for the $<ix:nonFraction unitRef="usd" contextRef="i0a559b470d334b43b79260c8d2f79c2d_D20200601-20200630" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU4NDE_0969cc85-0519-47a1-989b-91cc4c38cc0f">11.4</ix:nonFraction> billion in debt securities incurred during 2020 is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Following the Separation and Combination of the Upjohn Business with Mylan, we are no longer the obligor or guarantor of any Upjohn debt or Upjohn financing arrangements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As a result of the spin-off of the Upjohn Business, we distributed net assets of $<ix:nonFraction unitRef="usd" contextRef="i146ddcb53ba74d66b6cd862e76bc22d2_I20201116" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxOTkwMjMyNjYyMDg4_d184f630-5352-4fa4-ba7b-e04a48b995ab">1.6</ix:nonFraction> billion as of November&#160;16, 2020, which was reflected as a reduction to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Retained earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and reflects the change in accounting principle in the first quarter of 2021 to MTM Accounting. See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Note 1C.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Of this amount, $<ix:nonFraction unitRef="usd" contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116" decimals="-6" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxOTkwMjMyNjYyMTgx_7ab240db-e30d-4d5c-8062-8c4e15601b3a">412</ix:nonFraction> million represents cash transferred to the Upjohn Business, with the remainder considered a non-cash activity in the consolidated statement of cash flows for the year ended December 31, 2020. The spin-off also resulted in a net increase to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> of $<ix:nonFraction unitRef="usd" contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDkyNjc1ODE3NTU_7c8b000d-5d7d-403d-b1e1-3846edf5282f">423</ix:nonFraction> million for the derecognition of net gains on foreign currency translation adjustments of $<ix:nonFraction unitRef="usd" contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDkyNjc1ODE3Njk_ed70f013-9d6d-4044-aefe-2ea25deb205f">397</ix:nonFraction> million and prior service net credits associated with benefit plans of $<ix:nonFraction unitRef="usd" contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDkyNjc1ODE3NjI_b60ed05f-31aa-4b6c-95df-88bc77263ebb">26</ix:nonFraction> million, which were reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:115%">. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As a result of the separation of Upjohn, we incurred separation-related costs of $<ix:nonFraction unitRef="usd" contextRef="i4d984e1a55d04f109e2f4777e30a7cef_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzYyMTQ_63f8dee6-3375-4179-af7f-c4cebac6d93d">434</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="iaa8744bbf8a04e279bfe049ce4a864ba_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2OTE1NzU_45fd10ea-7e56-4b9b-a6a3-5e4dfa11d452">83</ix:nonFraction> million in 2019, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. These costs primarily relate to professional fees for regulatory filings and separation activities within finance, tax, legal and information system functions as well as investment banking fees.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if55d0a0f61c7486d9a2454ecd444d287" continuedAt="i228ffc35402f4fe2ad793c4f5b99f81f"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">In connection with the Transactions, Pfizer and Viatris entered into various agreements to effect the Separation and Combination to provide a framework for our relationship after the Combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. The terms of the MSAs range in initial duration from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcwNjc_b11edfc2-cb4f-4099-b138-98c6766b88f5">four</span> to <ix:nonNumeric contextRef="i05a3ba48023e426a88cc41e754f240ac_D20210101-20211231" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcwNzM_85401c59-cb14-4e7f-b669-af654483778d">seven years</ix:nonNumeric> post-Separation. The TSAs primarily involve Pfizer providing services to Viatris related to finance, information technology and human resource infrastructure and are generally expected to be for terms of no more than <ix:nonNumeric contextRef="i2e17ee2ad705475da2fd98425c5438a5_D20210101-20211231" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcyOTM_6c015bec-67e8-401b-84c8-2dfbc748d3d5">three years</ix:nonNumeric> post-Separation. The amounts recorded under the above agreements were not material to our consolidated results of operations in 2021 and 2020. In addition, Pfizer and Mylan had a pre-existing arms-length commercial agreement, which is continuing with Viatris and is not material to Pfizer&#8217;s consolidated financial statements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net amounts due from Viatris under the above agreements were $<ix:nonFraction unitRef="usd" contextRef="i8bb26d7550d34c4fa8277bc4dd130b09_I20211231" decimals="-6" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzgwNzk_e7a3ad1b-939b-4a39-be3c-b4ead09e3a3c">53</ix:nonFraction> million as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i83182589a2cf40518e59a55a207f4a48_I20201231" decimals="-6" name="us-gaap:NontradeReceivablesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjI4Njc_bef9b23f-9484-433a-80f7-7955ddcf251b">401</ix:nonFraction> million as of December 31, 2020. The cash flows associated with the above agreements are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">except for</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">a $<ix:nonFraction unitRef="usd" contextRef="i74dbcccac2f4425289e1e6696c212de4_D20210101-20211231" decimals="-6" name="pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjU2MDc_7b55140f-7590-4245-b02b-11cfb15013e4">277</ix:nonFraction> million payment to Viatris made in 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Other financing activities, net, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and was recorded as a payable to Viatris in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> as of December 31, 2020. </span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ5_0b3a72ca-0347-47c6-b874-cb50840c59b4" continuedAt="i553118f02a6f47aa8b26e30b4fd33213" escape="true"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> Discontinued operations&#8211;&#8211;net of tax: </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNC0xLTEtMTU1NjM4_12370406-3121-4fd4-9452-791c6fa14d56">277</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNi0xLTEtMTU1NjM4_9d188531-33a5-407c-acf6-cd88c74e75be">7,572</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtOC0xLTEtMTU1NjM4_3bdde6d7-1ca3-471f-837a-552086df7002">10,845</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNC0xLTEtMTU1NjM4_1ea56822-d50c-454c-ac25-324f18d696a2">204</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNi0xLTEtMTU1NjM4_74eecd18-698c-4b18-bed9-423ee0f2b18f">2,106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtOC0xLTEtMTU1NjM4_771a964a-8c6d-4951-9757-362ce504769c">2,173</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNC0xLTEtMTU1NjM4_f5357124-e200-4036-888f-25abdac4d3e3">26</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNi0xLTEtMTU1NjM4_5f400010-0c6d-4c36-8261-5a6d490d4a94">1,682</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtOC0xLTEtMTU1NjM4_c8a95008-1738-44b6-8266-dfaf053446f7">1,624</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNC0xLTEtMTU1NjM4_a6c1e828-1373-4fbc-98bb-0c166c24987f">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNi0xLTEtMTU1NjM4_5cf15bee-1f6f-4f92-96c0-441dcdc3b93d">224</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctOC0xLTEtMTU1NjM4_831490eb-418d-4b0f-8395-f8cd4a584883">265</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNC0xLTEtMTU1NjM4_0c5983f5-742e-4c31-9456-0a86eb67f31b">45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNi0xLTEtMTU1NjM4_152f7f45-ad94-4198-8e30-d82dea1a7243">224</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtOC0xLTEtMTU1NjM4_55c6aa5f-d0e6-4069-a4cc-b50d9f74cfe7">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNC0xLTEtMTU1NjM4_f37f9bc2-c292-4db8-be47-b29936878c30">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNi0xLTEtMTU1NjM4_674641be-b310-442e-9649-04d23ac403da">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktOC0xLTEtMTU1NjM4_19067ebf-2420-4493-9559-b40f806bb59c">146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTQtMS0xLTE1NTYzOA_a7b0aba4-6383-4a13-b9e3-48c7a459c533">365</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTYtMS0xLTE1NTYzOA_792dcf23-7855-4ba8-be67-f2f2b8a93e38">428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTgtMS0xLTE1NTYzOA_8a0c1ae2-b59a-4ab8-a792-11ae10dc864c">401</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax income/(loss) from discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTQtMS0xLTE1NTYzOA_ad3a56fe-b25c-47fa-883e-2628687e528e">375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTYtMS0xLTE1NTYzOA_8f186694-3022-48ef-a96b-b90b416e0172">2,879</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTgtMS0xLTE1NTYzOA_b2209aa3-59c1-4278-bffe-dbda51926033">6,056</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTQtMS0xLTE1NTYzOA_e223faad-d99d-4053-b5f6-cf210bcfee95">107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTYtMS0xLTE1NTYzOA_21f1e072-7210-4f67-920f-95f886cd5e7f">349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTgtMS0xLTE1NTYzOA_1f9cb0cd-0fa5-4116-b603-cb6776f180dc">738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTIwMTgxNg_bb899a3f-9057-4c42-b88a-a0484d40b99a">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTIwMTgxNg_4d3d9288-bb84-4f45-bb13-a4f8ec4ec044">2,529</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTIwMTgxNg_245ea242-174d-4d97-8181-86a8c6c5246d">5,318</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax loss on sale of discontinued operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTQtMS0xLTIwMTgxOA_5a215c3a-de6d-4316-a287-c5044c461f1d">211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTYtMS0xLTIwMTgxOA_07f27bea-6a9c-40c6-a2d6-ea80214973a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTgtMS0xLTIwMTgxOA_9afe2f6a-295d-4a12-9d6c-1feeef937d00">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit for taxes on income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTQtMS0xLTIwMTgyNA_79efd58c-9573-475f-92b1-25eb9339724b">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTYtMS0xLTIwMTgyNA_26d4a734-0b52-4e5d-81b1-025ded81faa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTgtMS0xLTIwMTgyNA_d6f5724b-f6f8-41ea-863c-9951d0e46489">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTQtMS0xLTIwMTgyNg_02fe2472-92fb-4536-8323-8b8e4f134181">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTYtMS0xLTIwMTgyNg_485a912c-0f9e-4947-8e28-5ea90d0b44d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTgtMS0xLTIwMTgyNg_6bd6df99-dd55-4fbf-baa8-aa34cf0a89fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTE1NTYzOA_d4777b69-bca4-4da9-8bee-c95607807af1">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTE1NTYzOA_b8c5bf77-08f1-454f-8409-0583dba8d4d9">2,529</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTE1NTYzOA_173beaaa-761b-48ed-9f25-caabbf15d941">5,318</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations&#8212;net of tax, which includes a pre-tax amount for a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $<ix:nonFraction unitRef="usd" contextRef="i25df7ea17ef54fb9b9166956b884cb0b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzM3ODE_c3d1efa0-3bef-4a9d-b708-bb0bf3d2a66f">345</ix:nonFraction>&#160;million; and (ii) the after tax loss of $<ix:nonFraction unitRef="usd" contextRef="i4b44d95032624046bce69d6abe17288c_D20211231-20211231" decimals="-6" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MzY4NTM_bb07d65c-b3e8-4106-bd6f-69e86ae5b547">167</ix:nonFraction>&#160;million related to the sale of Meridian recognized in Loss on sale of discontinued operations&#8211;&#8211;net of tax. To a much lesser extent, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-closing adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations&#8212;net of tax. In 2020 and 2019, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">includes pre-tax interest expense of $<ix:nonFraction unitRef="usd" contextRef="ife130b27142a4922bf44614565f191c9_D20200101-20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjQxMjA_63996794-518d-4eb3-a8bc-468b6a6dd838">116</ix:nonFraction> million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="i181dc4bf05244a10b3b37faa99909cbf_D20200101-20201231" decimals="-6" sign="-" name="pfe:DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjQyOTE_cc6830f9-e003-481d-ac7e-6a3ce3901b88">223</ix:nonFraction> million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.</span></ix:footnote></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of assets and liabilities of discontinued operations and other assets held for sale:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" rowspan="22" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets of discontinued operations and other assets held for sale&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNC0xLTEtMTU1NjM4_4f4c89e4-6db7-40f7-88d6-39114c8aa258">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072dc370d29444380b25f1c9000934b_I20201231" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNi0xLTEtMTU1NjM4_9e892a40-9f6c-426f-a55e-95264845f896">215</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTQtMS0xLTE1NTYzOA_1807f3e3-32c3-4436-8597-9a8d224768f0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072dc370d29444380b25f1c9000934b_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTYtMS0xLTE1NTYzOA_a46f22eb-ae36-4c35-a84e-cd3183e01176">155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTQtMS0xLTE1NTYzOA_dffafcd0-1e07-4cc5-bef0-d88fb845c696">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072dc370d29444380b25f1c9000934b_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTYtMS0xLTE1NTYzOA_5890084d-8e26-4833-a562-8c7fbb06d03e">134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTQtMS0xLTE1NTYzOA_022b7343-cc02-4d0b-bd17-9219c56120d2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072dc370d29444380b25f1c9000934b_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTYtMS0xLTE1NTYzOA_c4a54d97-7d11-4bc4-b781-3dfecf9a8d4a">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTQtMS0xLTE1NTYzOA_f1eb3203-bad7-4a37-b9ba-d995e4c010f3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072dc370d29444380b25f1c9000934b_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTYtMS0xLTE1NTYzOA_d083c457-1d57-4eff-b8ba-5cda20c59421">319</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTQtMS0xLTE1NTYzOA_0ec087d1-5d2f-45e8-af0a-963acbdc9c35">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072dc370d29444380b25f1c9000934b_I20201231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTYtMS0xLTE1NTYzOA_e617887c-3da5-43a0-8050-ff8df10abdf9">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTQtMS0xLTE1NTYzOA_709a14a0-1fa2-48ec-9db7-e7fe83b24faf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if072dc370d29444380b25f1c9000934b_I20201231" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTYtMS0xLTE1NTYzOA_cea60af2-8c6c-44ce-9379-0c9408a7edd9">16</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i553118f02a6f47aa8b26e30b4fd33213" continuedAt="i63b947e663cd44abbf1b2e542d8f0d96">(a)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8" footnoteRole="http://www.xbrl.org/2003/role/footnote"><ix:continuation id="i63b947e663cd44abbf1b2e542d8f0d96">Amounts as of December 31, 2021 represent property, plant and equipment held for sale. Amounts as of December 31, 2020 primarily relate to discontinued operations of our former Meridian subsidiary and the Mylan-Japan collaboration.</ix:continuation> </ix:footnote> </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">66</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i228ffc35402f4fe2ad793c4f5b99f81f" continuedAt="i42a0c02309df49a28bce19de076ae105"><div style="margin-top:8pt;padding-right:9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Equity-Method Investments</span></div><div style="margin-top:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Formation of Consumer Healthcare JV</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a <ix:nonFraction unitRef="number" contextRef="i252c5ea241a04813985449d2cebbba79_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzNzM2_5a137e0d-1c98-4bce-b543-a1926307a9e9">32</ix:nonFraction>% equity stake in the new company and GSK owns the remaining <ix:nonFraction unitRef="number" contextRef="i7e3dc812e321400f96f18d4c30fd6ac5_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzNzk4_9ae1393f-a33a-4cfd-b560-d90a4a274c37">68</ix:nonFraction>%. Upon closing, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="i6e80f25bd480402595d2aea33e91039a_D20190701-20190929" decimals="-8" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzOTAw_c5e79e30-44f9-4e23-b214-aad73f65c94c">8.1</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i6e80f25bd480402595d2aea33e91039a_D20190701-20190929" decimals="-8" name="pfe:DeconsolidationGainLossAmountNetOfTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzOTA0_fd1e7bfd-cb2d-4b61-85d6-59010110dd45">5.4</ix:nonFraction> billion, net of tax) in the third quarter of 2019 in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the difference in the fair value of our <ix:nonFraction unitRef="number" contextRef="i252c5ea241a04813985449d2cebbba79_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzOTk5_2586f691-8f05-408f-97e8-a3620b31ac6f">32</ix:nonFraction>% equity stake and the carrying value of our Consumer Healthcare business. Our financial results and our Consumer Healthcare segment&#8217;s operating results for</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The financial results for 2021 and 2020 do not reflect any contribution from the Consumer Healthcare business.</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In valuing our investment in the Consumer Healthcare JV, we used discounted cash flow techniques. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long term; the discount rate, which seeks to reflect our best estimate of the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. </span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our investment in the Consumer Healthcare JV is $<ix:nonFraction unitRef="usd" contextRef="icface7a1ee2b4ff28ac480b07f52e93f_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE1MDg2_29dbebcc-13d4-403a-978b-e33fd8f0b464">16.3</ix:nonFraction> billion as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="if8959c4c50fb407583ed92f9c3322282_I20201231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE1MTAy_1cf0658b-1581-4e98-9aed-8348aaf907ee">16.7</ix:nonFraction> billion as of December 31, 2020 and is reported as a private equity investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as of December 31, 2021 and 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 to December 31, 2021 is primarily due to dividends totaling $<ix:nonFraction unitRef="usd" contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231" decimals="-6" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MzY5MDI_e7000332-50f7-46ad-988e-0e27bcc76c26">499</ix:nonFraction> million, as well as $<ix:nonFraction unitRef="usd" contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231" decimals="-6" name="pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2Njc2NDQ_629d6562-8733-44b6-8a66-40c3850546ad">384</ix:nonFraction> million in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), partially offset by our share of the JV&#8217;s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> commencing from August 1, 2019. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2020 and the first nine months of 2021, which we recorded in our operating results in 2021, was $<ix:nonFraction unitRef="usd" contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjgwNjc_bcec21a0-261c-4a7d-a5a9-1521d4703917">495</ix:nonFraction> million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2019 and the first nine months of 2020, which we recorded in our operating results in 2020, was $<ix:nonFraction unitRef="usd" contextRef="i34dd2e3fa1c248e29e1d6758b3059e2d_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2MTc0_8201f977-f8c4-4bf6-8041-d40743d6c120">417</ix:nonFraction> million. Our total share of two months of the JV&#8217;s earnings generated in the third quarter of 2019, which we recorded in our operating results in the fourth quarter of 2019, was $<ix:nonFraction unitRef="usd" contextRef="i545389717f154954b7abb4cddabeb1cf_D20190930-20191231" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2MzQ3_4c39b6f2-32a9-4652-88db-06895b8a2201">47</ix:nonFraction> million. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in the Consumer Healthcare JV was $<ix:nonFraction unitRef="usd" contextRef="i252c5ea241a04813985449d2cebbba79_I20190731" decimals="-8" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDc0_05eaf4f5-0f38-4144-86a6-c513217fa80a">15.7</ix:nonFraction> billion and that <ix:nonFraction unitRef="number" contextRef="i252c5ea241a04813985449d2cebbba79_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDg2_5a137e0d-1c98-4bce-b543-a1926307a9e9">32</ix:nonFraction>% of the underlying equity in the carrying value of the net assets of the Consumer Healthcare JV was $<ix:nonFraction unitRef="usd" contextRef="i252c5ea241a04813985449d2cebbba79_I20190731" decimals="-8" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NTg4_a3cba238-4988-4436-8695-44b8609eb96d">11.2</ix:nonFraction> billion, resulting in an initial basis difference of approximately $<ix:nonFraction unitRef="usd" contextRef="i252c5ea241a04813985449d2cebbba79_I20190731" decimals="-8" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NjUw_e920e2bc-82c2-4b08-a3f0-02b0cb6c52ad">4.5</ix:nonFraction> billion. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. During the fourth quarter of 2019, the Consumer Healthcare JV revised the initial carrying value of the net assets of the JV and our <ix:nonFraction unitRef="number" contextRef="i252c5ea241a04813985449d2cebbba79_I20190731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE3MjIz_5a137e0d-1c98-4bce-b543-a1926307a9e9">32</ix:nonFraction>% share of the underlying equity in the carrying value of the net assets of the Consumer Healthcare JV was reduced to $<ix:nonFraction unitRef="usd" contextRef="ie607d29116be4fa5babac488462d4080_I20191231" decimals="-8" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE3MzQy_b371c4cc-1886-4f1b-9433-83388ff1bd36">11.0</ix:nonFraction> billion and our initial basis difference was increased to $<ix:nonFraction unitRef="usd" contextRef="ie607d29116be4fa5babac488462d4080_I20191231" decimals="-8" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE3Mzk1_a1483520-a77b-4360-849e-fbdbe6677283">4.8</ix:nonFraction> billion. The adjustment was allocated to equity method goodwill within the investment account. We began recording the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> commencing August 1, 2019. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and was not material to our results of operations in the periods presented. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of basis differences on inventory and related deferred tax liabilities was completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from <ix:nonNumeric contextRef="i43de6de86aee4f1981210b2cfbd70d8b_D20210101-20211231" name="pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE4NzE5_be15b83f-a86e-4a91-9b1f-2d4a918a6709">8</ix:nonNumeric> to <ix:nonNumeric contextRef="i7c41e610d4514bd2960d85db52a70189_D20210101-20211231" name="pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE4NzI1_3430a8b8-d835-4a2f-9711-64d4229ae4a6">20</ix:nonNumeric> years.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As a part of Pfizer in 2019, pre-tax income on a management basis for the Consumer Healthcare business was $<ix:nonFraction unitRef="usd" contextRef="i21520495e93a4b6f82c194548d489020_D20190101-20190731" decimals="-6" name="pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIwMjE5_27e1edcf-3e78-4ac5-940b-6e5080b3ffbe">654</ix:nonFraction> million through July&#160;31, 2019.</span></div><div style="margin-bottom:3pt;padding-right:9pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU3_7d7853be-0e60-44d7-ad69-c48aab16b90d" continuedAt="i6cf04c6791b54433830dc870769b2282" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.661%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, as of September 30, 2021, the most recent period available, and as of September 30, 2020 and for the periods ending September 30, 2021, 2020, and 2019 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzItNC0xLTEtMTU1NjM4_103aaf22-ff1b-4b75-8ebb-1d9247f528d6">6,890</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzItNi0xLTEtMTU1NjM4_e716bdd0-1bb3-4934-8eff-9333a2fc9fb3">6,614</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzMtNC0xLTEtMTU1NjM4_af0c56da-ebec-49cc-8e1b-f782f54489e1">39,445</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzMtNi0xLTEtMTU1NjM4_5badf77b-22a4-4a2a-8f6b-ab3ea6074f4d">38,361</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzQtNC0xLTEtMTU1NjM4_17208a61-bf07-4ca4-b184-92287f8db77e">46,335</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzQtNi0xLTEtMTU1NjM4_41dc8449-f5bf-49bb-8116-272d340cb4b4">44,975</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzYtNC0xLTEtMTU1NjM4_0257cee9-e17e-45f4-bc58-8810d68d3545">5,133</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzYtNi0xLTEtMTU1NjM4_ff01a3ef-a4a2-49ce-829d-2d2ef54d4931">5,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzctNC0xLTEtMTU1NjM4_07f2e9c8-d6a7-4dc6-9c30-b466fbd0679e">5,218</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzctNi0xLTEtMTU1NjM4_abec386e-598c-4922-a667-c823fa9b6f34">5,330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzgtNC0xLTEtMTU1NjM4_8f67bc43-04e9-4c0b-9b85-c10df01ff997">10,351</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzgtNi0xLTEtMTU1NjM4_79112438-e388-4b83-bd39-476c0afdd67b">10,576</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEwLTQtMS0xLTE1NTYzOA_e7e9be79-1643-44aa-b623-06ae01696b70">35,705</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEwLTYtMS0xLTE1NTYzOA_3502a88d-c22a-420e-88ec-249192f6ebc9">34,154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzExLTQtMS0xLTE1NTYzOA_8289999d-c811-495a-b530-5c0452531e36">279</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzExLTYtMS0xLTE1NTYzOA_6efe0fb0-a551-4b3c-aebf-541f7f4a1892">245</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net equity</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEyLTQtMS0xLTE1NTYzOA_30c10d13-342a-4c7d-a1c8-7a37df2637a0">35,984</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEyLTYtMS0xLTE1NTYzOA_67223f82-1456-40d3-b3e3-8c53dd4f21e6">34,400</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i42a0c02309df49a28bce19de076ae105" continuedAt="i9f8d7eec0e1a4d35ba4be6a0d0b37452"><div style="margin-bottom:8pt;padding-right:9pt"><ix:continuation id="i6cf04c6791b54433830dc870769b2282" continuedAt="if3ccba9ba9d849eeb07ddb8f780b2c36"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.596%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Twelve Months Ending</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Two Months Ending</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzItNC0xLTEtMTYxMzMw_01ae9e51-02bf-4a07-be03-5bfc8ac9c5ef">12,836</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzItNC0xLTEtMTU1NjM4_49c43407-1282-4c33-b18b-29ad92a01087">12,720</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzItNi0xLTEtMTU1NjM4_222ca5e8-0bf5-4d8e-9749-7e69622d73ca">2,161</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzMtNC0xLTEtMTYxMzMw_4e4cae15-d4f6-45e0-a80a-1a9bd01d7c91">4,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927" decimals="-6" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzMtNC0xLTEtMTU1NjM4_e18a127b-656e-4c90-9f9c-711b6cd6e3e6">5,439</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929" decimals="-6" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzMtNi0xLTEtMTU1NjM4_79f9ed61-c286-41dc-aa84-f1eb30ca96f2">803</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzQtNC0xLTEtMTYxMzMw_fcb5d0f5-714c-4a21-900b-7dd76ca94d92">8,081</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzQtNC0xLTEtMTU1NjM4_57f14a86-3889-41c5-ab71-3c83d132f527">7,281</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzQtNi0xLTEtMTU1NjM4_69b63ab5-c72d-4de1-83c1-ab04fc6c7d02">1,358</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzUtNC0xLTEtMTYxMzMw_fc4f37c0-ab1f-412b-b8b4-5f93eb0f83a3">1,614</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzUtNC0xLTEtMTU1NjM4_f8222a1d-4997-47b0-adce-d8e3922bb477">1,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzUtNi0xLTEtMTU1NjM4_9c32c1ad-3cc3-4f20-8736-dab797908ca8">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzYtNC0xLTEtMTYxMzMw_d984decb-ce84-4576-87d7-f7a1c9e4efe1">1,614</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzYtNC0xLTEtMTU1NjM4_d8fff60d-4df9-490c-8f8d-73dd9ba3e447">1,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzYtNi0xLTEtMTU1NjM4_62f7f464-18be-496a-9220-78aa928f58f3">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzctNC0xLTEtMTYxMzMw_abd58b1c-5aa4-40dd-9b41-615a3a4b490e">1,547</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzctNC0xLTEtMTU1NjM4_e6bbb99e-586e-430d-b34c-156632dd61ab">1,307</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzctNi0xLTEtMTU1NjM4_110cd900-8545-4e4e-a16f-04b7a42f25fc">148</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Investment in ViiV</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately <ix:nonFraction unitRef="number" contextRef="i0336041406e84b0dbc587db051c08162_I20211231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIwNDQy_cc6f2c77-d8b7-42da-8e68-6a3f3420f421">11.7</ix:nonFraction>% of ViiV, and prior to 2016 we accounted for our investment under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to <ix:nonFraction unitRef="usd" contextRef="i5259b031a6bd4f3eacca9ff85942926b_I20161231" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIwNzk4_963844c8-7860-45a8-a63d-e996f683a19a">zero</ix:nonFraction> due to the recognition of cumulative equity method losses and dividends. Since 2016, we have recognized dividends from ViiV as income in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when earned, including dividends of $<ix:nonFraction unitRef="usd" contextRef="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxMDA1_3fac75bf-2035-498f-8636-6b21f0455bf7">166</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxMDE1_8fa17084-bdac-4acb-942a-85af47d4e831">278</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxMDI4_40498035-3118-4ccc-846e-27e398432227">220</ix:nonFraction> million in 2019 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><ix:continuation id="if3ccba9ba9d849eeb07ddb8f780b2c36" continuedAt="i2a4edae8f00541acb519fd8343baad57"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.968%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.971%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.271%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, ViiV, as of December 31, 2021 and 2020 and for the years ending December 31, 2021, 2020, and 2019 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzMtNC0xLTEtMTU1NjM4_7a1cf1b9-d392-4552-b9f7-3cb462ef0070">3,608</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzMtNi0xLTEtMTU1NjM4_8ec4d6e6-b312-489a-9038-2512852dc7ed">3,283</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzQtNC0xLTEtMTU1NjM4_c792c5a1-9e50-456e-8a65-514d012c5723">3,563</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzQtNi0xLTEtMTU1NjM4_8b9ec2ce-cffc-4254-8fc0-a37292d63db8">3,381</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzUtNC0xLTEtMTU1NjM4_13f8114c-f3bc-4a93-bfd0-d82942e9c5d7">7,171</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzUtNi0xLTEtMTU1NjM4_b27f10d2-4d68-49fa-aa3e-bc63abb8f82d">6,664</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzctNC0xLTEtMTU1NjM4_fba72730-65b0-4f23-bf5e-0c5e01bb5067">3,497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzctNi0xLTEtMTU1NjM4_693c80a5-4fb6-4356-a798-2b794e1d4f18">3,028</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzgtNC0xLTEtMTU1NjM4_0b049853-ca23-4cbb-b8c0-387b1d0e7c7d">6,536</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzgtNi0xLTEtMTU1NjM4_037881b4-361f-45d8-a4d3-e326049321a3">6,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzktNC0xLTEtMTU1NjM4_988c3585-c5b4-4324-9208-5a0e43f5f65b">10,033</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzktNi0xLTEtMTU1NjM4_1f0535cd-8f66-426b-84be-0db8d8226a91">9,398</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net equity/(deficit) attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzExLTQtMS0xLTE1NTYzOA_d232f8b4-08a4-4c35-a491-602b5c29d045">2,862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzExLTYtMS0xLTE1NTYzOA_79972d57-bd1e-48ab-b6d9-5c8d7fb2c76c">2,734</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt"><ix:continuation id="i2a4edae8f00541acb519fd8343baad57"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzItNC0xLTEtMTU1NjM4_09d206c2-596e-40ac-9cb1-0c5e2ab833c7">6,380</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0027658381944a395727958a68002bb_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzItNi0xLTEtMTU1NjM4_0ceda6b5-56e6-4958-af97-c9497ab81343">6,224</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzItOC0xLTEtMTU1NjM4_4f71dde2-626a-498a-9c21-0dd4e7597552">6,139</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231" decimals="-6" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzMtNC0xLTEtMTU1NjM4_5f324ea6-dcfd-4b9c-bdc2-a3c8515c46e6">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0027658381944a395727958a68002bb_D20200101-20201231" decimals="-6" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzMtNi0xLTEtMTU1NjM4_620834dc-2406-48b6-9412-40f5099cec46">574</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231" decimals="-6" name="us-gaap:CostOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzMtOC0xLTEtMTU1NjM4_e49f0962-515e-4a71-92fe-7e3f718d3246">516</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzQtNC0xLTEtMTU1NjM4_8172aa8a-1a82-4b81-b4e0-2b13359102ae">5,698</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0027658381944a395727958a68002bb_D20200101-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzQtNi0xLTEtMTU1NjM4_9c5c2fd0-c21c-4df0-a783-103d6d18d14a">5,650</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzQtOC0xLTEtMTU1NjM4_9de0c307-64ff-43fd-80ce-1465e2d005b2">5,623</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzUtNC0xLTEtMTU1NjM4_1b55a5d0-af34-40ed-9cab-133f7a8309e9">2,040</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0027658381944a395727958a68002bb_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzUtNi0xLTEtMTU1NjM4_35e22918-633b-4155-82de-b6d87fae21b3">2,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzUtOC0xLTEtMTU1NjM4_bffc17b9-fc13-4e66-bce5-5b176653874f">3,398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzYtNC0xLTEtMTU1NjM4_4ebe5dd9-cfd9-4e02-9e42-573953d4a14a">2,040</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0027658381944a395727958a68002bb_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzYtNi0xLTEtMTU1NjM4_477acfec-5a46-40da-a8fa-766a3802c803">2,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzYtOC0xLTEtMTU1NjM4_0cd38e5f-8766-46d6-abcf-3a741537b1be">3,398</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzctNC0xLTEtMTU1NjM4_389f95ec-6eee-4d11-98b0-815697c19550">2,040</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0027658381944a395727958a68002bb_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzctNi0xLTEtMTU1NjM4_9430472d-8989-4a44-aba6-a8353f023150">2,012</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzctOC0xLTEtMTU1NjM4_ca44730c-734f-4071-ba75-fbd2fbc6e3aa">3,398</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">      </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-right:9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Licensing Arrangements</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Agreement with Valneva</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">On April&#160;30, 2020, we signed an agreement to co-develop and commercialize Valneva&#8217;s Lyme disease vaccine candidate, VLA15, which covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of up to $<ix:nonFraction unitRef="usd" contextRef="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430" decimals="-6" name="pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNDIy_5ddfcf35-a313-4dcb-b8ce-c1ee1d91472f">308</ix:nonFraction> million in cash payments from us consisting of a $<ix:nonFraction unitRef="usd" contextRef="i80aa0ad3eddf4f7391796743da2c7d4a_D20200330-20200628" decimals="-6" name="pfe:PaymentForLicensingArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNDY2_019a815f-5b61-4849-9c8b-7a7d045c37fc">130</ix:nonFraction> million upfront payment, which was paid and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our second quarter of 2020, as well as $<ix:nonFraction unitRef="usd" contextRef="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430" decimals="-6" name="pfe:ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNTkz_01976b81-bc2e-4bd0-ae7b-c80feb5e45f4">35</ix:nonFraction> million in development milestones and $<ix:nonFraction unitRef="usd" contextRef="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430" decimals="-6" name="pfe:ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNjI2_d10ea93c-7e5c-4745-9663-4a7bdb677e55">143</ix:nonFraction> million in early commercialization milestones. Under the terms of the agreement, Valneva will fund <ix:nonFraction unitRef="number" contextRef="ib167df84d3de4e098cfb61db76e453f9_D20210101-20211231" decimals="2" name="pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNzIw_47627210-7c9c-492d-af8d-8d421c76eee6">30</ix:nonFraction>% of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement with Akcea</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On October&#160;4, 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a wholly-owned subsidiary of Ionis. The transaction closed in November 2019 and we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i0fbdbdf768e24f2a8c5d0a5b25a12f65_D20191101-20191130" decimals="-6" name="pfe:PaymentForLicensingArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIyODgy_4bbd0427-0ac5-427c-8fb1-41044742dcca">250</ix:nonFraction> million to Akcea, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our fourth quarter of 2019. On January 31, 2022, we and Ionis announced the discontinuation of the Pfizer-led clinical development program for the licensed product and that we would be returning the rights to the licensed product to Ionis.</span></div></ix:continuation><div style="padding-right:9pt"><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">68</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i9f8d7eec0e1a4d35ba4be6a0d0b37452" continuedAt="i4c248eaaf0c64d0a88bce440e40419c4"><div style="margin-bottom:8pt;padding-right:9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Collaborative Arrangements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration with Beam</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December&#160;24, 2021, we entered into a multi-year research collaboration with Beam to utilize Beam&#8217;s in vivo base editing programs, which use mRNA and lipid nanoparticles, for three targets for rare genetic diseases of the liver, muscle and central nervous system. Under the terms of the agreement, Beam conducts all research activities through development candidate selection for three undisclosed targets, which are not included in Beam&#8217;s existing programs, and we may opt in to obtain exclusive licenses to each development candidate. Beam has a right to opt in, at the end of phase 1/2 studies, upon the payment by Beam of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which we and Beam would share net profits as well as development and commercialization costs in a <ix:nonFraction unitRef="number" contextRef="i5cc0e4c459d54fad8d446a48587269e9_D20211224-20211224" decimals="2" name="pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExMTI_b0a1e87a-d5cb-4658-8708-88371618467d">65</ix:nonFraction>%/<ix:nonFraction unitRef="number" contextRef="ia6b61ff9024b46bb9e45f08915a7f41e_D20211224-20211224" decimals="2" name="pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExMTg_5374638b-1d82-4ff0-b2f0-7e664005c21e">35</ix:nonFraction>% ratio (Pfizer/Beam). Upon entering into the agreement, we recorded $<ix:nonFraction unitRef="usd" contextRef="i69a2ae55438c4493a657b96e948feffb_D20211004-20211231" decimals="-6" name="pfe:PrepaymentsandPaymentstoCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExMjQ_93e2da4e-5923-46a4-8ebf-2bfe316a5398">300</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the fourth quarter of 2021 for an upfront payment due to Beam, and if we exercise our opt in to licenses for all three targets, Beam would be eligible for up to an additional $<ix:nonFraction unitRef="usd" contextRef="iea2eb9e0f80d46748855049032762b62_I20211224" decimals="-7" name="pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExNDI_ee2439cf-c771-4dcf-a7fe-6d60a46224aa">1.05</ix:nonFraction> billion in development, regulatory and commercial milestone payments for a potential total deal consideration of up to $<ix:nonFraction unitRef="usd" contextRef="iea2eb9e0f80d46748855049032762b62_I20211224" decimals="-7" name="pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExNjM_b006cb56-cff9-4e4f-a0e3-107433790793">1.35</ix:nonFraction> billion. Beam is also eligible to receive royalties on global net sales for each licensed program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration with Arvinas</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On July&#160;21, 2021, we entered into a global collaboration with Arvinas to develop and commercialize ARV-471, an investigational oral PROTAC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. In connection with the agreement, we made an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="if407180f055943a98b83de59f2cd5a1f_D20210721-20210721" decimals="-6" name="pfe:PrepaymentsAndPaymentsToCollaboratorsCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5MDY_930ea738-ef0e-42ee-9ead-0d1a5aa295b7">650</ix:nonFraction> million to Arvinas and we made a $<ix:nonFraction unitRef="usd" contextRef="i812cbbdf3b1245069237af890fdcecae_I20210721" decimals="-6" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5MjM_9d58d881-a13e-43b7-aa76-6f0700831fe4">350</ix:nonFraction> million equity investment in the common stock of Arvinas. We recognized $<ix:nonFraction unitRef="usd" contextRef="i6d66cd919bde400083d7783f18057f72_D20210705-20211003" decimals="-6" name="pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcxNDY4MjU3MTcyMzk_9d1bf800-7931-418d-950f-42e2d2db51e1">706</ix:nonFraction> million for the upfront payment and a premium paid on our equity investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">in our third quarter of 2021. Arvinas is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i375a1296a03d4608aa7dadc39a4081b0_D20210721-20210721" decimals="-6" name="pfe:CollaborativeArrangementMilestonePaymentUponApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NzA1NTk_3290fa32-6636-447d-b7ed-6ccb992c7b01">400</ix:nonFraction> million in approval milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i375a1296a03d4608aa7dadc39a4081b0_D20210721-20210721" decimals="-9" name="pfe:CollaborativeArrangementMilestonePaymentUponCommercializing" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NzA1OTY_ae83ad9e-ccc5-4cee-bec5-7b4c5788b017">1</ix:nonFraction> billion in commercial milestones. The companies will equally share worldwide development costs, commercialization expenses and profits. As of December 31, 2021, we held a <ix:nonFraction unitRef="number" contextRef="i095915c17bba4c2681c503f9e07eb593_D20211231-20211231" decimals="3" name="pfe:InvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODI4MDg3_b78c9dd4-aa3e-40bf-96da-91277a41d89f">6.5</ix:nonFraction>% equity stake of Arvinas.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration with Myovant</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December&#160;26, 2020, we entered into a collaboration with Myovant to jointly develop and commercialize Orgovyx (relugolix) in advanced prostate cancer and Myfembree (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women&#8217;s health in the U.S. and Canada. We also received an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries, which we declined to exercise. Under the terms of the agreement, the companies will equally share profits and allowable expenses for Orgovyx and Myfembree in the U.S. and Canada, with Myovant bearing our share of allowable expenses up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i5bdb38bc93ee4bdca889f98c7227ecd3_I20201226" decimals="-6" name="pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI0Nzc5_0d62720a-2ab6-4eb9-83d8-e93c868a9c04">100</ix:nonFraction> million in 2021 and up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i5bdb38bc93ee4bdca889f98c7227ecd3_I20201226" decimals="-6" name="pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI0ODEz_e046b2df-cf05-4922-b5b4-8f32c0989470">50</ix:nonFraction> million in 2022. We record our share of gross profits as Alliance revenue. Myovant remains responsible for regulatory interactions and drug supply and continues to lead clinical development for Myfembree. Myovant is entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226" decimals="INF" name="pfe:CollaborativeArrangementContingentPaymentsMaximumExposure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MDg2_6f047d1c-d23a-412f-a1c5-632844fdc8b2">4.35</ix:nonFraction> billion, including an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="iffe998e9fae8489392c54ceb8b6c3cfc_D20201201-20201231" decimals="-6" name="pfe:PrepaymentsandPaymentstoCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MTIy_917d3adb-f6d8-4814-86f0-fabda95e7ae2">650</ix:nonFraction> million, which was made in December 2020, $<ix:nonFraction unitRef="usd" contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226" decimals="-6" name="pfe:CollaborativeArrangementUpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MTU5_a2c74eb7-0136-4f1b-a5c1-b3c17be85813">200</ix:nonFraction> million in potential regulatory milestones for FDA approvals for Myfembree in women&#8217;s health, of which $<ix:nonFraction unitRef="usd" contextRef="ie99ef111b6e645c6a56cc65ad07091e8_D20210701-20210731" decimals="-6" name="pfe:PrepaymentsandPaymentstoCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODI4MTk1_3d8362e5-4255-4bdf-93ac-624f0b8f48ac">100</ix:nonFraction> million was paid to Myovant in July 2021 and recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets&#8212;Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and tiered sales milestones of up to $<ix:nonFraction unitRef="usd" contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226" decimals="-8" name="pfe:CollaborativeArrangementTieredSalesMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MzA0_50751ed6-8157-4474-8fa4-0e68aae97c35">3.5</ix:nonFraction> billion in total for prostate cancer and for the combined women&#8217;s health indications. In connection with this transaction, in 2020 we recognized $<ix:nonFraction unitRef="usd" contextRef="if33e0253955c412683af05e909d4151f_I20201226" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1NjQ4_ccd100ad-a046-4949-b8b7-5658ab57cac6">499</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets&#8211;&#8211;Developed technology</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1NzE4_20588121-c118-4334-852e-8746312852a4">151</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">representing the relative fair value of the portion of the upfront payment allocated to the approved indication and unapproved indications of the product, respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Collaboration with CStone</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On September&#160;29, 2020, we entered into a strategic collaboration with CStone to address oncological needs in China. The collaboration encompasses our $<ix:nonFraction unitRef="usd" contextRef="i0e5a99e4814b4f128ec2c686a1ec35d1_I20200929" decimals="-6" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NzkxMjE_a9885f5d-a901-48f3-8fbc-f2b773414dea">200</ix:nonFraction> million upfront equity investment in CStone, the development and commercialization of CStone&#8217;s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between the companies to bring additional oncology assets to the Greater China market. The transaction closed on October&#160;9, 2020. As of December 31, 2021, we held a <ix:nonFraction unitRef="number" contextRef="i2d62ac5456af448bbff21978df756208_D20210101-20211231" decimals="3" name="pfe:InvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI2NDI0_8b891783-6d05-4a73-a9e6-807fabcf8050">9.8</ix:nonFraction>% equity stake of CStone.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Collaborations with BioNTech</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">On December 30, 2021, we entered into a new research, development and commercialization agreement to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus) based on BioNTech&#8217;s proprietary mRNA technology and our antigen technology. Under the terms of the agreement, we agreed to pay BioNTech $<ix:nonFraction unitRef="usd" contextRef="i4b21456e1b1e45de977384ffe2104b0d_D20211230-20211230" decimals="-6" name="pfe:PrepaymentsandPaymentstoCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyNDE_aeeee9a8-c840-4dfa-82df-96629e922319">225</ix:nonFraction> million, including an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i5f00f7ed3e2c4bebad99f1f2c882a39e_D20211230-20211230" decimals="-6" name="pfe:PrepaymentsAndPaymentsToCollaboratorsCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyNTg_cc24550c-f6fe-48e4-a1fd-8568f39c671f">75</ix:nonFraction> million and an equity investment of $<ix:nonFraction unitRef="usd" contextRef="i603a6eec721f4ae6823ed9ad58021e0a_I20211230" decimals="-6" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyNzc_2806ed69-c170-4059-91fb-f4982bd1b4c3">150</ix:nonFraction> million. BioNTech is eligible to receive future regulatory and sales milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i603a6eec721f4ae6823ed9ad58021e0a_I20211230" decimals="-6" name="pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyOTQ_8bdc85ef-2c1e-400b-b885-5d9e23a6e912">200</ix:nonFraction> million. In return, BioNTech agreed to pay us $<ix:nonFraction unitRef="usd" contextRef="i5f00f7ed3e2c4bebad99f1f2c882a39e_D20211230-20211230" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIzMTE_b20c3171-445e-433f-b999-eb3b80709625">25</ix:nonFraction> million for our proprietary antigen technology. The net upfront payment to BioNTech was recorded to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our fourth quarter of 2021. We and BioNTech will share development costs. We will have commercialization rights to the potential vaccine worldwide, excluding Germany, Turkey and certain developing countries where BioNTech will have commercialization rights. We and BioNTech will share gross profits from commercialization of any product. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On April&#160;9, 2020, we signed a global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program, BNT162b2, aimed at preventing COVID-19 infection. In connection with the April 2020 agreement, we made an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i4a30949432804cb2a16f9d87c25227db_D20200401-20200430" decimals="-6" name="pfe:PrepaymentsAndPaymentsToCollaboratorsCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5NDA_1ff68dc6-ac27-4288-8e91-d2c18e0facd8">72</ix:nonFraction> million and an equity investment in the common stock of BioNTech of $<ix:nonFraction unitRef="usd" contextRef="i29f76f6dc48f4d43b42b0c3a2fd099ea_I20200430" decimals="-6" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5NTY_34735300-eb6a-43e5-bccd-e38adf4044ce">113</ix:nonFraction> million. We recognized $<ix:nonFraction unitRef="usd" contextRef="i1ebf471468de402693afa6538be7c48a_D20200330-20200628" decimals="-6" name="pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcxNDY4MjU3MTcyNjE_7cfee7f2-6712-4b37-b77b-7958117e24a1">98</ix:nonFraction> million for the upfront payment and a premium paid on the equity investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our second quarter of 2020. BioNTech became eligible to receive potential milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="iaa219a8d864348459268e3b1408b148a_I20200409" decimals="-6" name="pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI3NDM2_e3f53f7e-050b-4cbb-8807-5d823b6ba4b9">563</ix:nonFraction> million for a total consideration of $<ix:nonFraction unitRef="usd" contextRef="iaa219a8d864348459268e3b1408b148a_I20200409" decimals="-6" name="pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI3NDY4_d88f1f2a-150f-43f0-9e87-d480086d3c1a">748</ix:nonFraction> million. Under the terms of this agreement, we and BioNTech share gross profits and development costs equally after approval and successful commercialization of the vaccine, and we were responsible for all of </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i4c248eaaf0c64d0a88bce440e40419c4"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the development costs until commercialization of the vaccine. Thereafter, BioNTech was to repay us its <ix:nonFraction unitRef="number" contextRef="i6f0797c37dfa45c7a80ce32bac03a312_D20200409-20200409" decimals="2" name="pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI3Nzc5_4f928860-f0f6-4dc4-8c6a-ade8288b30b3">50</ix:nonFraction> percent share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. On January 29, 2021, we and BioNTech signed an amended version of the April 2020 agreement. Under the January 2021 agreement, BioNTech paid us their <ix:nonFraction unitRef="number" contextRef="i6f0797c37dfa45c7a80ce32bac03a312_D20200409-20200409" decimals="2" name="pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI4MDU3_4f928860-f0f6-4dc4-8c6a-ade8288b30b3">50</ix:nonFraction> percent share of prior development costs in a lump sum payment during the first quarter of 2021. Further R&amp;D costs are being shared equally. We have commercialization rights to the vaccine worldwide, excluding Germany and Turkey where BioNTech markets and distributes the vaccine under the agreement with us, and excluding China, Hong Kong, Macau and Taiwan, which are subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. We recognize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on a gross basis in markets where we are commercializing the vaccine and we record our share of gross profits related to sales of the vaccine by BioNTech in Germany and Turkey in Alliance revenues. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We made an additional investment of $<ix:nonFraction unitRef="usd" contextRef="i0c579c9b9f224be594bcabbfa663f822_I20200731" decimals="-6" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI4ODA4_2119dd8c-4023-4aa8-8ea8-0e32e04ad557">50</ix:nonFraction> million in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020. As of December 31, 2021, we held an equity stake of <ix:nonFraction unitRef="number" contextRef="i9ea93613082a4762abffed23b2ec080b_D20210101-20211231" decimals="3" name="pfe:InvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI4OTU5_7cff3189-5bd1-4bdf-b47f-15222b65de77">2.5</ix:nonFraction>% of BioNTech.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Summarized Financial Information for Collaborative Arrangements</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE5_7c5819b1-c378-4970-a17a-654775287107" continuedAt="ia71040c7ec4e421ab5dbbf86d2d15c2f" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b05b7dcaa61407aba318478b7c59025_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtMi0xLTEtMTU1NjM4_4852e44b-060b-4524-8cde-acdd45c8d69f">590</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae539c60336f4a0c94b5a022dcf96c0a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNC0xLTEtMTU1NjM4_bd5d325b-76f5-4dd4-a23f-b3930e7dc4ec">284</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a2adb8ca784b4ea94e14866c48cc70_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNi0xLTEtMTU1NjM4_812d0cf5-bd12-44dd-a0d9-31b83dc34171">305</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">s&#8212;Alliance revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib015687530a043e399f09540ca86222d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtMi0xLTEtMTU1NjM4_0f5fe7b6-5c36-460b-897e-812a74d93bfa">7,652</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1967572353a4cf69f29aa1e5a12c183_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNC0xLTEtMTU1NjM4_e704333c-12e8-4a4c-b863-0e3dcb069f41">5,418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778d084ed9064541a22124cd2f5453c5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNi0xLTEtMTU1NjM4_8b8f1901-f635-44ee-9d4a-eb7fdb7e5051">4,648</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from collaborative arrangements</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzUtMi0xLTEtMTU1NjM4_bd5a6e7b-8a2f-40a3-895e-500791e3aa61">8,241</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzUtNC0xLTEtMTU1NjM4_6c5f938f-65b0-4221-8fdc-4bee24fcdb95">5,703</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzUtNi0xLTEtMTU1NjM4_50e83aeb-ef19-41e5-a76b-749d819dc3c1">4,953</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtMi0xLTEtMTU1NjM4_f570d567-250b-4be3-a646-a17475e0f375">16,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNC0xLTEtMTU1NjM4_4735257f-9e5d-4241-a813-229562d69690">61</ix:nonFraction>)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNi0xLTEtMTU1NjM4_5e3e9775-1f4c-4a1a-81a9-ac9d3fc427d8">52</ix:nonFraction>)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctMi0xLTEtMTU1NjM4_4a4349dc-9933-450e-a8f0-cd01ed05abc3">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNC0xLTEtMTU1NjM4_265b3940-4872-4dde-a89e-85ff8265bd36">194</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNi0xLTEtMTU1NjM4_f03523c1-3500-433c-a25c-7a51aa58bc66">176</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtMi0xLTEtMTU1NjM4_31b5dfa2-8634-409b-8b1b-5241f26bdbf0">742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNC0xLTEtMTU1NjM4_17d32bc8-693e-49b2-9755-f0c64e3067e0">192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNi0xLTEtMTU1NjM4_c2a32bf3-b01a-4af5-8c9f-0d092ab35f6c">104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other income/(deductions)&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktMi0xLTEtMTU1NjM4_b45deda5-c9eb-4249-973c-69e48319db9e">820</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNC0xLTEtMTU1NjM4_29e6b7ac-2fe7-4877-a124-b300cdd5a22f">567</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNi0xLTEtMTU1NjM4_8c950b8b-ad69-4ccf-983e-ea64d5755d84">362</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA1_58f624c6-ad90-43de-8026-7a18986026d8" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents sales to our partners of products manufactured by us.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY4_42c85971-5021-482d-b383-51e54647f6a4" footnoteRole="http://www.xbrl.org/2003/role/footnote">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2021 reflects increases in alliance revenues from Comirnaty, Eliquis and Xtandi, while the increase in 2020 reflects increases in alliance revenues from Eliquis and Xtandi.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE2_c92105d3-98d3-434a-b36a-0127835a98d8" footnoteRole="http://www.xbrl.org/2003/role/footnote">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The increase in 2021 is primarily related to Comirnaty.</ix:footnote></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDYw_9c5cb05a-2ebe-49e7-baaa-1924b1949864" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</ix:footnote></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ1_5f3d2047-e309-46f8-a0d2-9b42e2fe3713" footnoteRole="http://www.xbrl.org/2003/role/footnote">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. </ix:footnote></span></div></ix:nonNumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="ia71040c7ec4e421ab5dbbf86d2d15c2f" continuedAt="ia86fbf4bb9c24b69b57d01cfb69470a0">(f)</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU2_5902b619-e434-4c25-9870-f93ab88b0fb6" footnoteRole="http://www.xbrl.org/2003/role/footnote"><ix:continuation id="ia86fbf4bb9c24b69b57d01cfb69470a0">Primarily relates to royalties from our collaboration partners.</ix:continuation> </ix:footnote></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The amounts outlined in the above table do not include transactions with third parties other than our collaboration partners, or other costs for the products under the collaborative arrangements.</span></div></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_172"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">. </span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NzY_0510ea55-f664-4147-93c1-77e603af957a" continuedAt="i23b5ea9f114948cd8a3838ec8ef0edc8" escape="true">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ix:nonNumeric></span></div><ix:continuation id="i23b5ea9f114948cd8a3838ec8ef0edc8" continuedAt="ice45afe332b1491092c61b9c386affbc"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, we substantially completed several multi-year initiatives focused on positioning us for future growth and creating a simpler, more efficient operating structure within each business.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a more focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base and support model align appropriately with our new operating structure. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, to total $<ix:nonFraction unitRef="usd" contextRef="i98027c8fc6b44691900fa8e4048b8871_I20211231" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDgyODU_636efc7e-bb41-449e-a85b-9c5c0ef567a5">1.6</ix:nonFraction> billion, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We expect costs of $<ix:nonFraction unitRef="usd" contextRef="ied12c12ed32548d6a549bafb56e60cd7_I20211231" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDg4Mjg_ff5a0523-059c-4e8b-a10a-a6b23be7fcdc">1.1</ix:nonFraction>&#160;billion, with substantially all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $<ix:nonFraction unitRef="usd" contextRef="i86b210be8e114d32a572f0bd0df9088a_I20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDkyNjA_8028a159-da43-4622-8b36-2ad1b5115783">800</ix:nonFraction> million, with approximately <ix:nonFraction unitRef="number" contextRef="i9bc539f8d9004dc099e25a88c5b43895_D20210101-20211231" decimals="2" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDkyODQ_979868a7-5fa2-4807-bc50-b3c641e783c2">25</ix:nonFraction>% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The program costs discussed above are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">From the start of this program in the fourth quarter of 2019 through December 31, 2021, we incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i925e41f449714bd2bf405763d6debabb_I20211231" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE3ODc_d523d85d-a476-4ea2-8e05-f6f881d9b8b9">2.2</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="i40868579307a4b29940d0afd5af8d703_I20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU2OTE_4b65f0b6-67b9-4b4e-b1c9-b7633e810ac0">856</ix:nonFraction> million is associated with Biopharma ($<ix:nonFraction unitRef="usd" contextRef="ic6e76156347742d59ab87928f0b59b21_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU3MDk_ae828c23-0a0a-4936-baa4-410c873432ea">712</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i626b2657ceb64b34b2c9c95e2661d1fd_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU3Mjc_3d39e5b7-f287-4eb5-a67c-7c276865e963">79</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="iee83e2bae3b7490d9df5cb5de4b214ac_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU3NDQ_bede9eda-7c91-45a8-bed4-8548bfb9f3cb">64</ix:nonFraction> million in 2019).</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ice45afe332b1491092c61b9c386affbc"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2021 and 2020, we incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NjcxNjM_4a320f49-c6d4-40c4-92bb-f72bdf307ff5">1.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NjcxODg_82d2fcd7-d49e-46bf-9325-445898c50dc0">838</ix:nonFraction>&#160;million, respectively, composed primarily of the Transforming to a More Focused Company program. In 2019, we incurred costs of $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTYxNjU_556bd094-953e-4dcd-8719-2a4fb43eeef2">820</ix:nonFraction> million composed of $<ix:nonFraction unitRef="usd" contextRef="ia3b3ff3fbc764236bcf7f1991593041b_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE5NTU_dc5bb0fd-a5a4-4e02-8507-23422f77394a">548</ix:nonFraction> million for the 2017-2019 and Organizing for Growth initiatives, $<ix:nonFraction unitRef="usd" contextRef="i9f963471072a434bbb65ec9314d42418_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIwMTU_e8000505-abf7-4e7d-9b02-c6506f5a2b19">288</ix:nonFraction> million for the integration of Array, $<ix:nonFraction unitRef="usd" contextRef="i4da04c0815ec4b519aab9003bbf9e69b_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIwNDg_c313c64e-0cfa-410e-889c-49a26bd093bb">94</ix:nonFraction> million for the integration of Hospira, and $<ix:nonFraction unitRef="usd" contextRef="i63611b219ac54cf69a70430c5ef474f3_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIwODc_a97fa5a8-429d-466d-ad58-9e80f23a9d4c">87</ix:nonFraction> million for the Transforming to a More Focused Company program, partially offset by income of $<ix:nonFraction unitRef="usd" contextRef="ia831fe68ea464a7696d368c0b964d933_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIxNzY_bf616fe3-d9fe-4d25-b983-4fee2d0bfaad">197</ix:nonFraction> million, primarily due to the reversal of certain accruals upon the effective favorable settlement of an IRS audit for multiple tax years and other acquisition-related initiatives.</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDY_b7d14ef0-35b5-45ae-ab22-e96635981016" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzQtNi0xLTEtMTU1NjM4_99180e59-1d15-4041-99a7-015f26d36da9">680</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzQtOC0xLTEtMTU1NjM4_ce7d8665-b85b-47da-b064-1af3c169f6c4">474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzQtMTAtMS0xLTE1NTYzOA_7fa21ceb-1d4c-420e-9c51-340cd76e362f">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzUtNi0xLTEtMTU1NjM4_2456c9b6-f073-4f1b-915b-be85249099c9">53</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzUtOC0xLTEtMTU1NjM4_0189d48d-9fb4-42ca-8185-ab2749a77413">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:RestructuringAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzUtMTAtMS0xLTE1NTYzOA_d09a59e8-5c92-4258-9340-079608315bfd">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzYtNi0xLTEtMTU1NjM4_d8704cd5-47f0-4efa-818a-6cb50fb0cef3">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzYtOC0xLTEtMTU1NjM4_2236a15c-faac-40cf-9197-9ce7e00954d6">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzYtMTAtMS0xLTE1NTYzOA_ce5c94bb-6acd-4c56-a524-282f0a987828">50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctNi0xLTEtMTU1NjM4_7593f700-33a1-4b98-91bf-879b34110428">741</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctOC0xLTEtMTU1NjM4_2d6c1a68-5552-4be1-a010-836b6862e20b">535</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctMTAtMS0xLTE1NTYzOA_a73c9239-ead4-4169-9fcc-f5c747a69fc4">227</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtNi0xLTEtMTU1NjM4_315394a9-0040-4ea2-bb7c-aa5eb50c4ae2">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtOC0xLTEtMTU1NjM4_6ba80a00-e040-44ed-9659-681083a3a33a">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtMTAtMS0xLTE1NTYzOA_881afe32-f53d-401e-a9d9-f395a68c9bb7">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktNi0xLTEtMTU1NjM4_524c8e42-409b-4ca5-b64b-d98bdfb311bc">41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktOC0xLTEtMTU1NjM4_87a0a4bb-c12e-4cc9-a43b-925eafd0e253">34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktMTAtMS0xLTE1NTYzOA_1282a7c8-801c-4056-b485-27f13357c051">311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEwLTYtMS0xLTE1NTYzOA_31ef0c63-2fc2-4573-8442-55604d8b61ed">802</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEwLTgtMS0xLTE1NTYzOA_4680639e-1a65-4b0b-a797-21e746cd4611">579</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEwLTEwLTEtMS0xNTU2Mzg_0168edb4-cb22-47ce-a969-ec69aab7905f">601</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99d15499afc94f0f88944990ff7e08fa_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTYtMS0xLTE1NTYzOA_26b576fd-e42f-47a6-aeab-565869399e1b">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dd3ecfac844087a740d27d7e403e89_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTgtMS0xLTE1NTYzOA_c72ce72f-d017-48b5-aa58-e2a94bf428d9">3</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a03d9e689ec4fae8e3c0b59a2584fa3_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTEwLTEtMS0xNTU2Mzg_c5e3b7b3-ad7b-4372-8fc9-743761958514">23</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">recorded in our consolidated statements of income as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2daa7c6ae294186bbe568931b7486c0_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTYtMS0xLTE1NTYzOA_5cd58def-c2a2-44d2-afeb-aba885aa2fc8">63</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8edaec2b4f8a4f18b37022f2160559cb_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTgtMS0xLTE1NTYzOA_dc88088c-58ae-4f64-b4b7-52c9484035eb">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f5a6ab0d6bb475ea4b794272ee41557_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTEwLTEtMS0xNTU2Mzg_12244f3f-27df-420a-9f0b-1652ddbc6248">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTYtMS0xLTE1NTYzOA_8d165f23-be85-4dc1-adc5-76c248b7d5f6">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTgtMS0xLTE1NTYzOA_d09cd04e-2282-4eee-b696-e9040247d88d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92e3b0b44374006b6d45a2bf6b453ae_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTEwLTEtMS0xNTU2Mzg_daf6262b-ed94-4815-aa85-d2b76b855eae">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTYtMS0xLTE1NTYzOA_a1fe41aa-bf30-4747-9aea-81360d159eb5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bff8c57bb424ff78fbf4a3f0ebccedf_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTgtMS0xLTE1NTYzOA_d075da76-8e37-4fb0-92e5-e64957caf8ad">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f357a90bb455c808448dd5bdb82b9_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTEwLTEtMS0xNTU2Mzg_f22d3ac4-76d9-4abe-b144-2724bdadf6a6">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTYtMS0xLTE1NTYzOA_d40c85f6-ad5d-486b-95fb-11dc5f86ce26">87</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTgtMS0xLTE1NTYzOA_83acb8fa-0dbe-484f-b7a3-7b391952efb2">17</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringReserveAcceleratedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTEwLTEtMS0xNTU2Mzg_1e28e996-4c45-4799-b7ef-7dc4e5449fdd">40</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Implementation costs recorded in our consolidated statements of income as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2daa7c6ae294186bbe568931b7486c0_D20210101-20211231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTYtMS0xLTE1NTYzOA_14c75760-4acd-4558-9ca3-a81fa2c1c265">45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8edaec2b4f8a4f18b37022f2160559cb_D20200101-20201231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTgtMS0xLTE1NTYzOA_b66de0ca-ed0f-46b4-966e-453127eb66ca">40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f5a6ab0d6bb475ea4b794272ee41557_D20190101-20191231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTEwLTEtMS0xNTU2Mzg_9b4bc5aa-1531-4ea6-816c-1d6a55260e53">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTYtMS0xLTE1NTYzOA_098c4e4a-148e-47f7-be0d-6ed93e8aef4e">426</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTgtMS0xLTE1NTYzOA_2b0e9445-59e0-4280-b6cc-187607b67d79">197</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92e3b0b44374006b6d45a2bf6b453ae_D20190101-20191231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTEwLTEtMS0xNTU2Mzg_016183c2-2cbd-4ead-8585-43ac37496738">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTYtMS0xLTE1NTYzOA_33ad584f-aedf-448a-a767-6e77c5498e33">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bff8c57bb424ff78fbf4a3f0ebccedf_D20200101-20201231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTgtMS0xLTE1NTYzOA_2dc67f00-13b1-40b3-996a-b5a90fc6ab6f">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie05f357a90bb455c808448dd5bdb82b9_D20190101-20191231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTEwLTEtMS0xNTU2Mzg_3eddf7f0-e898-4039-abae-9b3e4026d40d">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTYtMS0xLTE1NTYzOA_facc63c8-eaf3-4e01-9322-54be6880643c">472</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTgtMS0xLTE1NTYzOA_e0c6ceaf-a4e8-47bf-849b-5a80428433a3">238</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:ImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTEwLTEtMS0xNTU2Mzg_8ab28955-fc79-44d8-8a32-662618a1141b">156</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzI0LTYtMS0xLTE1NTYzOA_6068f09f-bf24-43bc-8c5b-d3756ee9fe37">1,298</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzI0LTgtMS0xLTE1NTYzOA_d6399b89-ee36-432b-b7a2-83fda306bdc1">838</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzI0LTEwLTEtMS0xNTU2Mzg_556bd094-953e-4dcd-8719-2a4fb43eeef2">820</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI0_d66425c4-36ea-42ca-9afe-89f26f33ded1" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents acquisition-related costs ($<ix:nonFraction unitRef="usd" contextRef="iaa0f6d5d21e848678b8da48c334034bc_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NjYxMzg_d3b181e6-a770-416a-9a24-4c114290e10a">9</ix:nonFraction>&#160;million credit in 2021 and $<ix:nonFraction unitRef="usd" contextRef="i877d264408a04f79a16737d91ace0ab4_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI0NDA_1bfcb2e7-86b0-4cc4-b865-2525b13fb5b3">192</ix:nonFraction> million credit in 2019) and cost reduction initiatives ($<ix:nonFraction unitRef="usd" contextRef="i9a1c9f4206be4156af7e5bbf360b0c50_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI0OTE_fb5fb760-62f4-4c44-983a-f70b58bae0c1">750</ix:nonFraction> million charge in 2021, $<ix:nonFraction unitRef="usd" contextRef="ie7ea5bfd40cc43e0b0057cd2055809db_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI1MTA_ee22f552-4598-41d2-82e7-db2a7860e3d2">535</ix:nonFraction> million charge in 2020, and $<ix:nonFraction unitRef="usd" contextRef="i17a552f33566495aa5aad8a8ce07ffee_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI1MzM_53ba4cbd-d178-41ba-b9ce-be344ba411a5">418</ix:nonFraction> million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIz_b47b6a34-d867-43a4-a71a-0856e26745d2" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents external costs for banking, legal, accounting and other similar services.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIw_d222fed4-a927-447d-8d82-a2d2c986c588" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2021 costs primarily related to our acquisition of Trillium. 2020 costs primarily related to our acquisition of Array. 2019 costs mainly related to our acquisitions of Array, including $<ix:nonFraction unitRef="usd" contextRef="i763f14d53a0f47d2bb88afb5100aeece_D20190101-20191231" decimals="-6" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTQ3NTE_e2482a99-6d2d-463b-8a3f-444be93f641d">157</ix:nonFraction> million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and Hospira.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDk_1533b714-7a5d-4d55-8c40-da98cfed12f5" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDE_a1b3b72c-ce04-43f0-ba32-3e58ee90cbe9" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:52.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.795%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2020 </span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia829878673b04d45a644a83794ea47f3_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItMi0xLTEtMTU1NjM4_ee75f122-6d06-4682-87fa-2483c1e4eebc">770</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19560e1e9e846f1917dd34fe6665c2f_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItNC0xLTEtMTU1NjM4_80c7ded3-3904-4420-938e-905ab247cc03">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c9c1d9cd337481ea21924d113ae20f0_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItNi0xLTEtMTU1NjM4_e0598e81-8d6f-41f2-bce1-8c89690855df">46</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItOC0xLTEtMTU1NjM4_0b7d4ee1-d9ef-46d6-8e2a-dacb8797c6f7">816</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc28c341b16f4257858e79aa91bfbb0f_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtMi0xLTEtMTU1NjM4_99b773c7-6f74-4fa8-ad0a-3d9872f2cd47">474</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8e69ebbcd7843c09dba286f7a84a32e_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtNC0xLTEtMTU1NjM4_9835c9a3-ad89-4662-9ef7-1d7406b91ed6">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85ea9a17643b4ba993c0d7767b7df734_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtNi0xLTEtMTU1NjM4_f78a7fc4-2bbd-4c7f-afa7-9759c59b03fa">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtOC0xLTEtMTU1NjM4_3e757d02-5244-4cff-90fc-078785117e84">535</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc28c341b16f4257858e79aa91bfbb0f_D20200101-20201231" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtMi0xLTEtMTU1NjM4_37eb2fce-9891-4368-9c58-5e41f032a21d">462</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8e69ebbcd7843c09dba286f7a84a32e_D20200101-20201231" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNC0xLTEtMTU1NjM4_2e4c1c81-5d34-4e61-8316-477276aa7c19">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85ea9a17643b4ba993c0d7767b7df734_D20200101-20201231" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNi0xLTEtMTU1NjM4_48aa033e-20be-49e8-8390-4b9e5a393d82">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtOC0xLTEtMTU1NjM4_aa6a1288-623f-45a0-aa24-c0b1f7307d3a">554</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c5139d761040739c960494538b4e36_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtMi0xLTEtMTU1NjM4_2f7f6c8a-d1ea-4776-b3bf-f600ef3cb02e">782</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8de8376bf36443928b6f33affb450d42_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNC0xLTEtMTU1NjM4_8725e295-9631-41e9-964a-1c35d13d3069">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib978af64a1074124af383834e607186e_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNi0xLTEtMTU1NjM4_9dc8b5f6-80fe-4a13-bf28-33b00373b705">15</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtOC0xLTEtMTU1NjM4_af969f26-65f5-42e4-84a6-c2edff83475d">798</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26d7da2bf204ad39d1d01e1c8c71720_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtMi0xLTEtMTU1NjM4_8cef56f3-a45b-4fa7-8917-7a8578627b7d">680</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d619ef872034dfea120fc28f055f6a7_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtNC0xLTEtMTU1NjM4_8b6df9d6-f083-4f23-b00f-77ee8a297534">53</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08555d6e17894c0ebe9ccf5b8c4a0767_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtNi0xLTEtMTU1NjM4_22c9103f-bb44-4ace-a379-561776a03aad">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtOC0xLTEtMTU1NjM4_789b435b-1162-4b99-9c0d-e22fc7121bdb">741</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia26d7da2bf204ad39d1d01e1c8c71720_D20210101-20211231" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctMi0xLTEtMTU1NjM4_594ea094-3524-4937-806c-5adc4fdae564">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d619ef872034dfea120fc28f055f6a7_D20210101-20211231" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNC0xLTEtMTU1NjM4_256f11b6-83b4-4563-84bd-ca2eb2bc8d16">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08555d6e17894c0ebe9ccf5b8c4a0767_D20210101-20211231" decimals="-6" sign="-" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNi0xLTEtMTU1NjM4_4072a90f-f140-48e6-8f8d-0cfc44b9f2ef">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctOC0xLTEtMTU1NjM4_7480d3a8-bcd9-4499-9bb2-09960d855b59">468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c69c8a8bbc74fa887cd2c9dc0ed4c80_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtMi0xLTEtMTU1NjM4_2a363825-77ea-4727-b774-2d27000e61c9">1,014</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f99441233647049f94a89b177f28e1_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNC0xLTEtMTU1NjM4_bc3cca5e-42f5-463e-8b51-f54d4eb4fc38">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2de81f39d0e4b198f2516dade160b06_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNi0xLTEtMTU1NjM4_8e7b2b15-4b8a-49c5-90e8-18a0750addb7">57</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtOC0xLTEtMTU1NjM4_03c5052c-0e84-48f7-9edf-6b33ec73e5b5">1,071</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes adjustments for foreign currency translation.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTcyMTc_ef850c66-5871-4846-a83b-04621d330ec1">628</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i0aaf677ffe1c461b92474fb66fe48c68_I20201231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTcyNTY_76ae62e6-3cfa-4577-8002-191fc6497ab3">169</ix:nonFraction> million).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="i5c659cb958e94f909ae64de8887c53e5_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTczMDA_27c269bd-4b3d-430a-bbed-5b85917405cc">816</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="ibe0e5d69b58349a58289b22b8b683cd0_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTczMzk_ad8bf4b0-4094-40aa-8710-6bd129cd14a2">255</ix:nonFraction> million).</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_175"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTY_3dde7173-1f4e-4acd-a824-38950d000d73" continuedAt="i7b1f7cc95842439eb5447810886ffede" escape="true">Other (Income)/Deductions&#8212;Net</ix:nonNumeric></span></div><ix:continuation id="i7b1f7cc95842439eb5447810886ffede"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczNjY_cb1c7789-8e79-451e-b039-dc5a8c4b8e88" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:63.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzMtMi0xLTEtMTU1NjM4_9101db9c-d02a-45ea-b7ed-ef5493f67d42">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzMtNC0xLTEtMTU1NjM4_d06c1a31-2b50-4f47-a7da-14fdcd72ff7f">73</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzMtNi0xLTEtMTU1NjM4_653248af-702a-4606-ad44-081c7bf552c2">225</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtMi0xLTEtMTU1NjM4_fc48ed28-a2ed-4f89-931a-25408f08f1f5">1,291</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNC0xLTEtMTU1NjM4_ffec8e3d-06b3-47b3-8031-20a54e5ae1b2">1,449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNi0xLTEtMTU1NjM4_69712d4d-8f49-4a68-a2fd-58aefe02d4df">1,573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net interest expense</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzUtMi0xLTEtMTU1NjM4_4e01d22d-76b4-4b9e-962d-b0a6dd19d665">1,255</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzUtNC0xLTEtMTU1NjM4_b56938a9-cdad-41f3-a291-20bd4169d463">1,376</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:InterestRevenueExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzUtNi0xLTEtMTU1NjM4_343ebccb-dd8c-43fa-bd89-fa9cc80ed529">1,348</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzYtMi0xLTEtMTU1NjM4_716bd02d-edea-470b-b2ac-099bd2527724">857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzYtNC0xLTEtMTU1NjM4_d6fc7258-a493-4d6a-bb34-a04bbea26661">770</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzYtNi0xLTEtMTU1NjM4_b906d8c2-f73b-4537-ad32-1822c276722e">646</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzctMi0xLTEtMTU1NjM4_a57bee86-72df-4640-a5df-2661a5548028">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzctNC0xLTEtMTU1NjM4_4196ef42-fba5-4809-9bbc-f01237a735d5">237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzctNi0xLTEtMTU1NjM4_65ffe075-3f5e-4bae-92f7-6fd12f750c3b">32</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtMi0xLTEtMTU1NjM4_dd00f2ae-15ce-4545-aac3-21a8dfd1b54a">1,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNC0xLTEtMTU1NjM4_ed4904c4-f0ad-4598-afb5-a7e4c97cb911">540</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974">454</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTItMS0xLTE1NTYzOA_776c7a5d-e044-4ec7-96e2-4308574f3e72">396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTQtMS0xLTE1NTYzOA_ed86179d-92be-4657-b47f-3d6a84617613">326</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTYtMS0xLTE1NTYzOA_2942a965-a598-4acd-bff1-0c02e059da86">168</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTItMS0xLTE1NTYzOA_d587cb35-245e-4884-bf51-680732bfade2">2,547</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTQtMS0xLTE1NTYzOA_46ec01a2-0164-49be-80a9-759dd72302e0">311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTYtMS0xLTE1NTYzOA_8cbdacb9-5fe2-4b95-940c-37cd2b822cbf">305</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain legal matters, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTItMS0xLTE1NTYzOA_2c13d92c-9eb8-49ba-a2d9-4ff8ede9d098">182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTQtMS0xLTE1NTYzOA_eff9c8b3-b659-4e27-b655-f84aa2e38f10">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTYtMS0xLTE1NTYzOA_6d5a2b60-1371-418d-92ac-a68824feb0eb">292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTItMS0xLTE1NTYzOA_20517041-af91-4389-8aae-99fcc9ce939c">86</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTQtMS0xLTE1NTYzOA_e26ed09a-7f53-4a55-b695-a525fb799f8f">1,691</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTYtMS0xLTE1NTYzOA_00bd7ddf-3c27-4b55-a7de-7a4be52f9b58">2,792</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business and legal entity alignment costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:BusinessAlignmentCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTItMS0xLTE1NTYzOA_1d63a504-43b3-4e6e-b318-390daf304a54">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:BusinessAlignmentCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTQtMS0xLTE1NTYzOA_23f0c89d-0e2d-4917-8d88-8815bb9cb5cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:BusinessAlignmentCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTYtMS0xLTE1NTYzOA_a23043da-80f6-4944-b8c8-a7314fbae96c">300</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTItMS0xLTE1NTYzOA_18721505-f445-4d7f-8156-359aab0e6695">471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTQtMS0xLTE1NTYzOA_8855cfec-668e-4aaf-b7b2-4e8a81025858">298</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTYtMS0xLTE1NTYzOA_c697291f-04b7-45d2-b1f2-649da30c1f4f">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTItMS0xLTE1NTYzOA_ed6860e8-6cef-4092-85bd-14b0db566a9f">687</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTQtMS0xLTE1NTYzOA_b84fbe8e-6a3f-4099-9eac-641d1f1b18dd">491</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTYtMS0xLTE1NTYzOA_16ed3388-ebc3-4c1b-af6e-ee2db9e45355">224</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE3LTItMS0xLTE1NTYzOA_b4e851e8-dada-4e99-9f60-7ca607ffbc0e">4,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE3LTQtMS0xLTE1NTYzOA_c1d512b1-f464-41ab-972b-e99bc10ae4bf">1,219</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE3LTYtMS0xLTE1NTYzOA_00f627ae-495c-440d-90c5-9ea23af6d8f1">3,497</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MDU_7baae9c8-1263-4e3d-8ee5-851cb7fc1bec" footnoteRole="http://www.xbrl.org/2003/role/footnote">Capitalized interest totaled $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc1_d83049ac-56fa-4f69-9d8c-4e999f47178d">108</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzg2_5c8f4106-08e9-4dcd-880d-6f10794a6e4b">96</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEwMA_9268bd0c-96ec-4b39-ad56-2471a31f8117">88</ix:nonFraction> million in 2019.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 gains include, among other things, unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="if94a5fe65bae431b99f55fff931ebea4_D20210101-20211231" decimals="-8" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTI3MDU4_ae778893-5bfe-4523-aea3-27e170104fd9">1.6</ix:nonFraction> billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i421339ba223042529cc05db65a67a1fc_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1MzkzMTYyODA0MTEx_22993120-4fd2-4817-a096-aa28c5d70e12">405</ix:nonFraction>&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i18931406f81e4214af8bdf650ea9a501_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzMxOQ_f51cbd57-bc3b-4dad-aad6-d64c6ec3ef06">295</ix:nonFraction>&#160;million related to investments in Cortexyme, Inc. and SpringWorks.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjE_26f1389f-55c0-455d-bee3-4c13d585abc3" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2021 includes, among other things, $<ix:nonFraction unitRef="usd" contextRef="ie5017fc8db5942798d4a4ab792e69007_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1MzkzMTYyODA0MDgx_dd19d562-50c7-4c99-a406-c9008c0b198b">188</ix:nonFraction>&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine and $<ix:nonFraction unitRef="usd" contextRef="i6feb23a7d7ad4d25b3ff9db357c2d2b0_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1OTQyOTE4NjI3Njky_eb7cb85f-1d8b-487e-b002-8697130d7291">97</ix:nonFraction> million of milestone income from multiple licensees. 2020 included, among other things, (i) a $<ix:nonFraction unitRef="usd" contextRef="ib64fb7f03591425caf0f8ec0bc10107b_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzExMTE_29bacd83-2b03-4393-ae1f-50561affc2d2">75</ix:nonFraction> million upfront payment received from our sale of our CK1 assets to Biogen, (ii) $<ix:nonFraction unitRef="usd" contextRef="i5cd393823f0a466cb163341642a080ad_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzExNjI_d751fe12-bc93-4d69-9751-fb8fcbbb6d5b">40</ix:nonFraction> million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, (iii) $<ix:nonFraction unitRef="usd" contextRef="i2547961512514f6a99fc62e7d1581590_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyNzQ_172f67ce-2d3a-4f86-912e-7f41589bf4d4">30</ix:nonFraction> million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC and (iv) $<ix:nonFraction unitRef="usd" contextRef="i60a8a5bae1304da28157e10b33ab0a5a_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE0MjU_4a31cdb8-d34a-470e-b87f-d98d4bc848b7">108</ix:nonFraction> million in milestone income from multiple licensees. 2019 included, among other things, $<ix:nonFraction unitRef="usd" contextRef="ia825faa5b2044c4d9d91b62b8f59c653_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1MDY_9b78fa7b-9b61-4f71-a175-6a8c5e9377e3">78</ix:nonFraction> million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, a generic of Advair Diskus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(fluticasone propionate and salmeterol inhalation powder) and $<ix:nonFraction unitRef="usd" contextRef="ibd3d48c945234584a9a562a3e928cd52_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE3MDk_9b93357a-ae66-465b-89e6-15779e151fb8">52</ix:nonFraction> million in milestone income from multiple licensees.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MzA_1c246f72-a3f7-480c-b93d-85c62a4ffdb7" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2019, other non-service cost components&#8217; activity related to the Consumer Healthcare JV transaction, such as gain on settlements, were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODU_a0039e7b-b917-408b-9d6a-752d7c16fb64" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes legal reserves for certain pending legal matters.</ix:footnote> </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjQ_d2b8d63a-76b5-4c71-adec-7930b09e22e4" continuedAt="ia2301aed99c14dc0a9df9cdce9ddeb7b" footnoteRole="http://www.xbrl.org/2003/role/footnote">2020 represents intangible asset impairment charges associated with our Biopharma segment: (i) $<ix:nonFraction unitRef="usd" contextRef="i56031b6c3a9542fd9a53b737a162f549_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzI5Nzk_73f570cc-0ee9-415d-ab9f-7130049e3e19">900</ix:nonFraction> million related to IPR&amp;D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts; (ii) $<ix:nonFraction unitRef="usd" contextRef="ied002bca63d9483da7deb14447eca722_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzMxNjU_72381706-5d93-4e5f-9402-b5212f2efdcf">528</ix:nonFraction> million related to Eucrisa, a finite-lived developed technology right acquired in our Anacor acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures; and (iii) $<ix:nonFraction unitRef="usd" contextRef="i42d4c757c4044ceab2e6cbc41cab4a64_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzMzNTk_8cc5f3bf-cc0f-4766-af1b-fba89c89dc64">263</ix:nonFraction>&#160;million related to finite-lived developed technology rights for certain generic sterile injectables acquired in our Hospira acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures.</ix:footnote></span></div><div style="margin-top:1pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:continuation id="ia2301aed99c14dc0a9df9cdce9ddeb7b">2019 primarily included intangible asset impairment charges of $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzM2MzU_318fcc9e-ba98-48c8-8eef-d4aec609f6b8">2.8</ix:nonFraction> billion, mainly composed of $<ix:nonFraction unitRef="usd" contextRef="i4f422da6aefa4071bc05f672d391dba2_D20190101-20191231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzM2NTg_471e19d6-f38e-482e-9ada-81f7424426a2">2.6</ix:nonFraction> billion, related to Eucrisa, and reflected updated commercial forecasts mainly reflecting competitive pressures.</ix:continuation></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODY_8f0897b6-0412-434f-8608-7a97cbafee5e" footnoteRole="http://www.xbrl.org/2003/role/footnote">Mainly represents incremental costs for the design, planning and implementation of our then new business structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and other advisory services.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTk_eb112cb9-f220-4b30-8aac-7377f127f4a0" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTM_1eed2719-76dd-4177-b92f-3f667b7d5c40" footnoteRole="http://www.xbrl.org/2003/role/footnote">2021 includes, among other things, (i) income net of costs associated with TSAs of $<ix:nonFraction unitRef="usd" contextRef="ic20790f22ade4cf6b4a0533bf036316c_D20210101-20211231" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTMxMDE1_85f2a516-54fd-4d14-9d7a-ee49dd45aaf8">288</ix:nonFraction> million; (ii) dividend income of $<ix:nonFraction unitRef="usd" contextRef="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTI3MDEw_3fac75bf-2035-498f-8636-6b21f0455bf7">166</ix:nonFraction> million from our investment in ViiV and (iii) charges of $<ix:nonFraction unitRef="usd" contextRef="id442e3abd12b4a22a3b95e39aae09ed2_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTI2ODU3_5802328e-4c6d-4f99-962e-73a891d0b5af">142</ix:nonFraction> million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $<ix:nonFraction unitRef="usd" contextRef="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE2NDkyNjc0NjEzODI_8fa17084-bdac-4acb-942a-85af47d4e831">278</ix:nonFraction> million from our investment in ViiV; (ii) income net of costs associated with TSAs of $<ix:nonFraction unitRef="usd" contextRef="i26ac48141e3840ebb5504bd97d592bec_D20200101-20201231" decimals="-6" name="pfe:OtherNonoperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTMxMDgw_8e8e8efe-c094-481a-852e-6d238918752d">114</ix:nonFraction> million and (iii) charges of $<ix:nonFraction unitRef="usd" contextRef="i77c1de86a8744d5f9ef90c3fe81d1656_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE2NDkyNjc0NjEzNjI_e89f8473-bea6-4139-b0d0-871a8485b3a0">105</ix:nonFraction> million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $<ix:nonFraction unitRef="usd" contextRef="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE2NDkyNjc0NjE0MjI_40498035-3118-4ccc-846e-27e398432227">220</ix:nonFraction>&#160;million from our investment in ViiV; (ii) charges of $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:DeconsolidationExternalIncrementalCostsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzUxODU_53ab0f3d-2004-44f1-804a-c2e680da980b">152</ix:nonFraction> million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzU0NDQ_85abf751-9c6b-4ae1-af64-e44ed70cb918">138</ix:nonFraction>&#160;million.</ix:footnote></span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The asset impairment charges included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are based on estimates of fair value.</span></div></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_178"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg4_554274db-284a-4003-a137-5c07ecb04933" continuedAt="i579ee0a2f7b64abebf5c608c0dcda1fd" escape="true">Tax Matters</ix:nonNumeric></span></div><ix:continuation id="i579ee0a2f7b64abebf5c608c0dcda1fd" continuedAt="i66d3abf81d0743eda20bce7e26dcab7b"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk3_c38bc7b1-54e4-4358-95d6-95773068553e" continuedAt="ief9f60b473fa4c4895130c90b3cd115f" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:67.305%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzMtMi0xLTEtMTU1NjM4_15eb2b09-957e-4bf1-84ed-5e5bc5723175">6,064</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzMtNC0xLTEtMTU1NjM4_1c063a9f-5884-46fd-8101-0f7337f27449">2,887</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzMtNi0xLTEtMTU1NjM4_f278db2c-1a9c-4a6a-a42d-600796fb5ed6">7,332</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzQtMi0xLTEtMTU1NjM4_45709ff4-c072-4116-95c4-ed5f7a61556d">18,247</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzQtNC0xLTEtMTU1NjM4_d14ce17a-f634-4f10-91c7-b27dd1d7c85f">9,924</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzQtNi0xLTEtMTU1NjM4_d458b7ec-898c-4f99-9b22-988f026fa2cc">3,988</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3">24,311</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663">7,036</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2">11,321</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">72</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i66d3abf81d0743eda20bce7e26dcab7b" continuedAt="ifab922bf8b16439b8a9a82b1660b9acb"><ix:continuation id="ief9f60b473fa4c4895130c90b3cd115f"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</span></ix:footnote></div></ix:continuation><div style="margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzY0_eec0a405-fe12-49e8-8c5c-d2d460169f77" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> based on the location of the taxing authorities include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzUtMi0xLTEtMTU1NjM4_36782f2e-148e-4134-91d3-35266c79df93">3,342</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzUtNC0xLTEtMTU1NjM4_0b85ee0a-0721-4ac1-a03c-b3aedf7e7bb2">372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzUtNi0xLTEtMTU1NjM4_9831361b-d7e2-4bbb-b3fe-baa8fcf14983">1,887</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzYtMi0xLTEtMTU1NjM4_2f2095a4-5fb3-46e1-ade2-ce0748ccae0a">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzYtNC0xLTEtMTU1NjM4_d3d77bf0-a643-4d0a-a336-e89504edb4ec">56</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzYtNi0xLTEtMTU1NjM4_c064f5e0-207a-4c65-8204-decc5f4339ed">186</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzgtMi0xLTEtMTU1NjM4_3d14877f-2784-4d4e-844d-38f1897ff07d">3,850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzgtNC0xLTEtMTU1NjM4_9f0c5455-5f79-42ad-a5ea-9fd596d90af2">1,164</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzgtNi0xLTEtMTU1NjM4_5c3238d9-4d5a-400e-a3ed-f577c0637b7e">1,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzktMi0xLTEtMTU1NjM4_36c5598f-9e64-48c8-a4b7-59d812a42bc5">491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzktNC0xLTEtMTU1NjM4_10ec84ec-3a0d-4be0-b0ea-6d6d0e3d30bd">131</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzktNi0xLTEtMTU1NjM4_d358e074-5cc2-48b8-9a53-6ce7400c09cc">276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total U.S. tax benefit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEwLTItMS0xLTE1NTYzOA_1ef3deea-76a6-4bb9-b10b-98f2bdcbfd0a">964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEwLTQtMS0xLTE1NTYzOA_50708395-8c05-4b15-8dd1-e079c529afee">867</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEwLTYtMS0xLTE1NTYzOA_2956ac84-1b9a-45ab-a472-5703ba602e94">543</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">TCJA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEyLTItMS0xLTE1NTYzOA_30ab224e-84ac-4a51-ba6c-2e02c871374e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEyLTQtMS0xLTE1NTYzOA_2868b591-ad86-4112-9cf7-6c742963dec8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEyLTYtMS0xLTE1NTYzOA_f58ff270-4309-4b28-a942-61fc814d8aca">135</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEzLTItMS0xLTE1NTYzOA_eae7aa55-314d-411f-8c57-52aeda3f9d49">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEzLTQtMS0xLTE1NTYzOA_6dd9e479-252d-4145-b031-a4b4e4b38956">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEzLTYtMS0xLTE1NTYzOA_39da479b-e09a-449c-9a16-adfc3d9657c9">187</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total TCJA tax benefit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE0LTItMS0xLTE1NTYzOA_0c9d4876-1838-4cbf-9faa-b731ac728376">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE0LTQtMS0xLTE1NTYzOA_7580a0db-62a7-4645-8b5b-41ffa1e2ef89">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE0LTYtMS0xLTE1NTYzOA_80115918-d012-4957-9f24-33d28537c64d">323</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE2LTItMS0xLTE1NTYzOA_29eb4786-2113-4959-a42b-9d4885bbf7d3">2,769</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE2LTQtMS0xLTE1NTYzOA_c727d74e-0999-495d-ab5d-babd0eb3c518">1,517</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE2LTYtMS0xLTE1NTYzOA_dbc88e5d-f149-4f04-a5c9-83556fae84d8">2,418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE3LTItMS0xLTE1NTYzOA_c485f665-ce3d-4f85-9bac-085e8ae57194">48</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE3LTQtMS0xLTE1NTYzOA_a742a737-ca33-414b-99be-902262e1e694">279</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE3LTYtMS0xLTE1NTYzOA_c09fcb75-17ed-472b-8b6d-f57df9ebded0">969</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total international tax provision</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE4LTItMS0xLTE1NTYzOA_d2dd06e5-4719-4c90-8965-3b8ce871ae18">2,816</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE4LTQtMS0xLTE1NTYzOA_200303b6-2f58-490f-9f83-7d209226ba35">1,237</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE4LTYtMS0xLTE1NTYzOA_a1b29fdc-46c5-4846-b171-9801eda849f0">1,449</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE5LTItMS0xLTE1NTYzOA_82df1f87-fe7b-4338-809e-5ab383556210">1,852</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE5LTQtMS0xLTE1NTYzOA_75cf28d6-699a-4374-a382-538381e0c8d8">370</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE5LTYtMS0xLTE1NTYzOA_48d139aa-8c42-4cb1-a4cf-461b0810763b">583</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts discussed below are rounded to the nearest hundred million and represent approximations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-9" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE4NDI_e1829130-a225-4b69-a484-d294aa657d0b">15</ix:nonFraction> billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date. The fourth annual installment is due April 18, 2022 and is reported in current </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as of December 31, 2021. The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The changes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> impacting the effective tax rate year-over-year are summarized below:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The higher effective tax rate in 2021 was mainly the result of:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the change in the jurisdictional mix of earnings primarily related to Comirnaty; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower tax benefits related to the impairment of intangible assets,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK based on estimates and assumptions that we believe to be reasonable.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The higher effective tax rate in 2020 was mainly the result of:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-8" sign="-" name="us-gaap:IncomeTaxReconciliationTaxSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjE0Mzc_96882155-c281-44be-8356-3a23b6ca3bc3">1.4</ix:nonFraction> billion tax benefits, representing taxes and interest, recorded in 2019 due to the favorable settlement of an IRS audit for multiple tax years; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the tax benefits related to certain tax initiatives associated with the implementation of our then new business structure; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the tax benefits recorded in 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA, as well as:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower tax benefits related to the impairment of intangible assets,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the tax expense of $<ix:nonFraction unitRef="usd" contextRef="iafeac22251414180abb3e88565bac3e0_D20190701-20190929" decimals="-8" name="pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjMyMzE_0373aa24-c556-41bd-9892-6d455f69f208">2.7</ix:nonFraction> billion recorded in the third quarter of 2019 associated with the gain on the completion of the Consumer Healthcare JV transaction; and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ifab922bf8b16439b8a9a82b1660b9acb" continuedAt="i2bcf4ef402344ba18d5b2abb5742ebb1"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Rate Reconciliation</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDA0_ebd86811-b39b-469a-9dfb-94c18f45f2e1" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.483%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. statutory income tax rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzMtMi0xLTEtMTU1NjM4_1f35bad7-de19-4321-90d5-ddc1f225fc3c">21.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzMtNC0xLTEtMTU1NjM4_8092bc0b-bf1f-424c-aceb-55e38c2fcced">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzMtNi0xLTEtMTU1NjM4_13137ce1-8a91-4963-8287-88f28ff47640">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TCJA impact</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtMi0xLTEtMTU1NjM4_421fa183-684f-4276-acad-fc30922c2cca">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNC0xLTEtMTU1NjM4_03bc2458-9954-4213-81e3-95026eb68409">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNi0xLTEtMTU1NjM4_9f9d95f4-c3d5-4ad4-b5ad-2f3a60e9eb08">2.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxation of non-U.S. operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b">4.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf">9.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b">4.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax settlements and resolution of certain tax positions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtMi0xLTEtMTU1NjM4_cb603cf5-b5a6-4654-b0c4-e4fd67fa97ac">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNC0xLTEtMTU1NjM4_f8c79b07-3f6a-4a33-92bb-3a6e9e257dd3">2.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNi0xLTEtMTU1NjM4_70764fa8-bcdf-4adc-b1d0-98a361ff980a">14.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctMi0xLTEtMTU1NjM4_2adf412a-914a-4578-a230-cd3632fc59e5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNC0xLTEtMTU1NjM4_748e2b39-345f-44a8-b39b-41e92c60ab82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNi0xLTEtMTU1NjM4_809ed143-c113-4f6a-81ff-ddef984737d1">8.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain Consumer Healthcare JV initiatives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtMi0xLTEtMTU1NjM4_ca2f17af-403d-45d2-a722-b3ea169f5d62">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtNC0xLTEtMTU1NjM4_5b191432-aea1-4255-a33b-3456f30d377f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. R&amp;D tax credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzktMi0xLTEtMTU1NjM4_ee7ff9c9-e32b-43cc-b120-f2be8c0c55a2">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzktNC0xLTEtMTU1NjM4_674b927d-2f8f-469d-bedf-426037e8e0bb">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzktNi0xLTEtMTU1NjM4_b8d1333b-9c0b-494a-a0b5-ca4733c89186">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" sign="-" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTItMS0xLTE1NTYzOA_91ad9a52-8b73-4986-a4f4-2d66d93c84da">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" sign="-" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTQtMS0xLTE1NTYzOA_ec5b8174-b3c0-42d6-9907-197f66ed9e22">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" sign="-" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTYtMS0xLTE1NTYzOA_d35f7b7b-d5e5-4e97-970d-198f3a89ac4c">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTItMS0xLTE1NTYzOA_1d5c60d8-aa15-4f85-b15a-567ac23fc306">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTQtMS0xLTE1NTYzOA_19a96083-6c93-4b19-9643-21dfc7e6a33e">2.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTYtMS0xLTE1NTYzOA_fb7a05db-3539-44fd-85eb-fce98e4a8eec">2.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate for income from continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEzLTItMS0xLTE1NTYzOA_3854ac8e-aa49-4175-9773-79ce7f31ed1c">7.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEzLTQtMS0xLTE1NTYzOA_918c7dc0-c7e0-4295-a4a5-2071a35e60b7">5.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEzLTYtMS0xLTE1NTYzOA_c6e2260a-845c-4d04-8f3a-bd8a469dee4a">5.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></ix:footnote></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions,&#8221; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for the components of pre-tax income and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></ix:footnote></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c" footnoteRole="http://www.xbrl.org/2003/role/footnote">In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2029. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2047 on income from manufacturing and other operations.</ix:footnote></span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcz_15ee60a1-e236-41ba-9ba0-faa094ee830e" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes changes in interest related to our uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221;.</ix:footnote></span></div><div style="margin-bottom:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc0_74c907cb-0fd0-422c-9947-ca1d7ea7c38a" footnoteRole="http://www.xbrl.org/2003/role/footnote">All other, net is primarily due to routine business operations.</ix:footnote></span></div></ix:nonNumeric><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Deferred Taxes</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTE1_fb31486f-539b-43be-be41-3454962025d3" continuedAt="ibc0878cfe624478a8e9cad288b46035b" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:50.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Deferred Tax*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 Deferred Tax*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Liabilities)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Liabilities)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid/deferred items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70">4,086</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54">456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f">3,114</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142">336</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtMi0xLTEtMTU1NjM4_889185dd-849f-404a-85bb-92422714cc9e">408</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNC0xLTEtMTU1NjM4_0c488731-aa77-4405-9d8b-f1278437dba0">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNi0xLTEtMTU1NjM4_00ebe2e3-fffa-4d43-8cf2-d10877fccc59">276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtOC0xLTEtMTU1NjM4_cffbe9e3-2f79-455d-8521-2b76def7f868">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a">1,778</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45">4,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36">793</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a">5,355</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7">117</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387">1,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5">211</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92">1,220</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee benefits</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261">1,594</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad">178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b">1,981</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae">124</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructurings and other charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtMi0xLTEtMTU1NjM4_3cb674c8-26ff-4296-a3e2-d27455fd0b41">303</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtNi0xLTEtMTU1NjM4_8da22a9a-074d-4f15-8ef1-49ba93ed5ef6">291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal and product liability reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktMi0xLTEtMTU1NjM4_b8c25820-33a9-41ca-963b-17e84c50bf38">373</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktNi0xLTEtMTU1NjM4_7a8c75d3-6197-43c1-a9e3-3b11f55e48bb">382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss/tax credit carryforwards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1">1,431</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8">1,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unremitted earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTQtMS0xLTE1NTYzOA_07797e84-f31d-440f-8696-0e022691ac42">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTgtMS0xLTE1NTYzOA_37f18589-53d6-4dd8-aebf-aa5edae64b03">46</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local tax adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTItMS0xLTE1NTYzOA_b19cafe6-5af3-425b-a11f-746e7e40d664">197</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTYtMS0xLTE1NTYzOA_9aa0edcb-ec53-4eff-9523-c670836ea3d4">171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f">70</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc">689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3">130</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2">3,545</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTItMS0xLTE1NTYzOA_934964c5-66e2-498b-96c7-e1e11097f2bf">89</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTQtMS0xLTE1NTYzOA_5c85bd6b-451b-400e-81ad-73936f0d12c8">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTYtMS0xLTE1NTYzOA_a9060b32-109c-4e94-9c63-a2e31f16ea3b">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTgtMS0xLTE1NTYzOA_95c4277e-6053-4020-b8f5-b5eb8adf6ae2">76</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTItMS0xLTE1NTYzOA_dc770b75-d0bb-4cad-9696-a02e91952b4f">10,446</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTQtMS0xLTE1NTYzOA_5f72f016-f854-4d35-b32e-a1523936cf71">7,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTYtMS0xLTE1NTYzOA_1be889d8-f1cd-4d88-aae6-0e47f2e407eb">9,190</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTgtMS0xLTE1NTYzOA_2f1f2081-7178-4eff-980a-f932885400d6">10,726</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTItMS0xLTE1NTYzOA_08096b56-06d2-44ca-bf3c-0c1d5ce92617">1,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTYtMS0xLTE1NTYzOA_dd1abc95-de40-47a7-8e31-ae4082c6ba2f">1,586</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTItMS0xLTE1NTYzOA_18ea3c1a-9447-45a7-a412-95630ed61f83">8,983</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTQtMS0xLTE1NTYzOA_83cb9115-e0fb-4619-aef9-ab67c7d44420">7,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTYtMS0xLTE1NTYzOA_c4fe5a30-44ae-4d42-b16c-dfad5d473ec6">7,604</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTgtMS0xLTE1NTYzOA_a16f7605-4987-4a6a-b6db-1bace5af0ee5">10,726</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset/(liability)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d">1,269</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1">3,123</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></ix:footnote></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690" footnoteRole="http://www.xbrl.org/2003/role/footnote">The increase in net deferred tax assets in 2021 is primarily related to temporary differences associated with Comirnaty royalty accruals and the result of operating lease ROU liabilities recognized during the period.</ix:footnote></span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04" footnoteRole="http://www.xbrl.org/2003/role/footnote">The increase in the deferred tax assets is primarily due to the acquisition of intangible assets relating to Trillium and the decrease in the 2021 deferred tax liabilities is primarily the result of amortization of intangible assets.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">74</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2bcf4ef402344ba18d5b2abb5742ebb1" continuedAt="ibe652e1ef2414ee9a32667d5beababc6"><ix:continuation id="ibc0878cfe624478a8e9cad288b46035b"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase in net deferred tax liabilities in 2021 is primarily the result of operating lease ROU assets recognized during the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease in net deferred tax assets in 2021 is primarily the result of favorable pension plan asset performance reported in the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 11A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc2_0d9c7877-627d-44ed-bc12-b660cce44b18" footnoteRole="http://www.xbrl.org/2003/role/footnote">The amounts in 2021 and 2020 are reduced for unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3Xzk1MjY_9ecce49c-afb8-4d82-8caf-4e5381b98dc1">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-8" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3Xzk1MzM_3c1d1069-fe05-45da-9297-082aaca4fa06">3.0</ix:nonFraction> billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.</ix:footnote></span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6" footnoteRole="http://www.xbrl.org/2003/role/footnote">The decrease in net deferred tax liabilities in 2021 is primarily due to certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV.</ix:footnote></span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTAw_78fef901-ac4d-4640-a287-c2584eb06359" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="ibb74e76f421148d08f33e3b64b0f55a7_I20211231" decimals="-8" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3Xzk5ODM_88730be9-f480-411a-b50b-a063444e0aaf">1.6</ix:nonFraction> billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i361e612fd47344f486642a0505329347_I20211231" decimals="-8" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwMDI5_2e5faebf-4863-4d8e-a1e5-b25117c53140">0.3</ix:nonFraction> billion). In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i15795fd91413493f98813b66ab28bc23_I20201231" decimals="-8" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwMTA1_dc55bb08-1755-4bc0-bd09-ced0c215c19a">0.9</ix:nonFraction> billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i20860e5e0d834bd0a887924f23c1ddeb_I20201231" decimals="-8" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwMTUx_88b71f61-4346-483a-a0e2-2580d4b76168">4.1</ix:nonFraction> billion).</span></ix:footnote></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have carryforwards, primarily related to net operating and capital losses, general business credits, foreign tax credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2022 to 2041. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section&#160;382.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2021, we have not made a U.S. tax provision on $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-8" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwNjcz_295c41e0-56ff-40c3-87be-97d9a2666b86">55.0</ix:nonFraction> billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2021 is not practicable. The amount of indefinitely reinvested earnings is based on estimates and assumptions and subject to management evaluation, and is subject to change in the normal course of business based on operational cash flow, completion of local statutory financial statements and the finalization of tax returns and audits, among other things. Accordingly, we regularly update our earnings and profits analysis for such events.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our accounting policies associated with accounting for income tax contingencies, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Uncertain Tax Positions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-8" name="pfe:UnrecognizedTaxBenefitsExcludingInterest" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzExNjUw_cbbfcbfa-4540-4736-bf85-bab66ff8edd8">4.5</ix:nonFraction> billion and as of December 31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-8" name="pfe:UnrecognizedTaxBenefitsExcludingInterest" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzExNjc0_fd6f089c-371c-4505-987a-f20eb746ea71">4.3</ix:nonFraction> billion in net unrecognized tax benefits, excluding associated interest.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Tax assets for uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-8" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNDA5_55aeb3cf-0efd-497f-bfe9-99c4507aaa83">1.5</ix:nonFraction> billion in assets associated with uncertain tax positions. These amounts were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="ibb74e76f421148d08f33e3b64b0f55a7_I20211231" decimals="-8" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNTU4_785da9aa-932d-4fb4-9f47-5e3b5c56f471">1.4</ix:nonFraction> billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i33ea397ae7d44969805ee21fb8ef3cc5_I20211231" decimals="-6" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNjI5_0928d93c-1244-42fc-823d-f2bd05304aeb">105</ix:nonFraction> million). As of December 31, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-8" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNjUx_39023125-e48b-4fbd-9ff9-5f736b8be685">1.3</ix:nonFraction> billion in assets associated with uncertain tax positions. These amounts were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i15795fd91413493f98813b66ab28bc23_I20201231" decimals="-8" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyODAw_ea36cd15-5f87-474a-b6e0-550aa184358a">1.1</ix:nonFraction> billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="i841ae3241c284442a2a9ed328bb982f0_I20201231" decimals="-6" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyODQ1_d84785b2-1bc1-4db3-8cd9-5db7c608356d">122</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($<ix:nonFraction unitRef="usd" contextRef="i21b2ee9ddfcb4ba59cfcd0e1406e7519_I20201231" decimals="-6" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjgxOTI_d18f886c-0a9b-4ca0-8d55-535549dad4d0">46</ix:nonFraction>&#160;million).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. </span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTM1_01f8db05-bf9c-447c-8fd1-bbcd38e7ae33" escape="true"><div style="margin-top:5pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"></td><td style="width:65.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzItMi0xLTEtMTU1NjM4_ae5216be-41d4-496d-bb94-71122bb1d472">5,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzItNC0xLTEtMTU1NjM4_cfc69dc9-e217-45e8-bde5-9e8fb3346f9c">5,381</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e10b1e1c1f846769573d84f9a61fc72_I20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzItNi0xLTEtMTU1NjM4_97239417-d74f-4d3f-b6c2-658ad6534d9b">6,259</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzMtMi0xLTEtMTU1NjM4_69128509-98d6-4882-b9f9-63563ae584e6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzMtNC0xLTEtMTU1NjM4_e6b51f26-a062-4297-85b5-c9cc367870b3">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzMtNi0xLTEtMTU1NjM4_d28966a1-8962-44d0-900f-e480feaecefa">44</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divestitures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtMi0xLTEtMTU1NjM4_f68267a4-1cac-41fe-9805-9dee9acc44b0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNC0xLTEtMTU1NjM4_e4128565-3c24-48a5-b18f-612d542f6555">265</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNi0xLTEtMTU1NjM4_49615fd2-0a4b-44b8-a14d-ea8b0be890e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtMi0xLTEtMTU1NjM4_db22426c-6c10-4c2a-a824-e4c66d87abec">111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNC0xLTEtMTU1NjM4_c2438de5-3204-47f9-9685-f2d214131cd7">232</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNi0xLTEtMTU1NjM4_71f74a89-7dbf-4577-a87e-55fadd19a618">36</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5">103</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f">1,109</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases based on settlements for a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctMi0xLTEtMTU1NjM4_b93c897e-d113-4fca-af85-ca8fdbfac426">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNC0xLTEtMTU1NjM4_a6ee1f90-c8ba-493a-8df1-90679ee7be35">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNi0xLTEtMTU1NjM4_430e3341-aa36-4836-80f2-03307cb6e72a">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases based on tax positions taken during the current period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtMi0xLTEtMTU1NjM4_aa2deccf-47ae-41ab-967e-42c0d0e0faea">550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNC0xLTEtMTU1NjM4_ed5826a8-7da8-49e4-8756-b5185b33aa9d">411</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNi0xLTEtMTU1NjM4_b77dc72b-c8f9-4d74-adcf-0cc74961cc96">383</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzktMi0xLTEtMTU1NjM4_9d3b3b43-5e87-4853-97ed-16b172d898a0">22</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzktNC0xLTEtMTU1NjM4_02662971-0841-4247-a175-4363378746e7">72</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzktNi0xLTEtMTU1NjM4_d62d3510-ec04-4bb0-aa2f-b0f1d16f38fb">25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba">40</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84">107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTItMS0xLTE1NTYzOA_70150eaf-49c1-40c8-a5b3-4c2dc5a3e763">6,068</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTQtMS0xLTE1NTYzOA_4228acb7-0a7e-45cd-bc41-1d26c3fad96a">5,595</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTYtMS0xLTE1NTYzOA_3722d7d6-c8c4-4e6e-8d19-e418b391b627">5,381</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDIx_9a567361-c846-4e20-a07b-8e6b3bf9e974" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2020, related to the separation of Upjohn. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income.</span></ix:footnote></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></ix:footnote></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDY3_1b44c33c-7fa4-431f-b8a2-bc19239b1199" footnoteRole="http://www.xbrl.org/2003/role/footnote">Primarily related to cash payments and reductions of tax attributes.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d" footnoteRole="http://www.xbrl.org/2003/role/footnote">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk2_8ecaa1ee-28f5-4418-b11d-5f6b7758233b" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2021, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i7054cf3b6aaa45ed9aab6e96ec09198c_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNTM3_b12714cb-d0ad-4c07-bf8c-49aa445b9161">19</ix:nonFraction> million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="id25117217bb84d749d33874e62b57092_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0OTgzMDQ_5f4aa614-d3b5-48fe-ace6-ea176b55a7d5">42</ix:nonFraction>&#160;million) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="ibb74e76f421148d08f33e3b64b0f55a7_I20211231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNjA2_ea37b927-b4f5-42d4-a896-357abf51b73f">3.0</ix:nonFraction> billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i361e612fd47344f486642a0505329347_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNjQ4_5cd22f52-ba44-4ccd-9f8b-8f0adc7cee3b">5</ix:nonFraction> million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i33ea397ae7d44969805ee21fb8ef3cc5_I20211231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNjc3_b61f248f-66b9-4241-85e2-d1ac43731fb8">3.0</ix:nonFraction> billion). In 2020, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i7b847e7890394d15be5612bf0c10a5ef_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNzIz_e0ce0f5c-38a3-4d10-8345-3b7f831ae2b9">34</ix:nonFraction> million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i15795fd91413493f98813b66ab28bc23_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzODE3_c39b570c-18ee-4f25-9f8b-dbf91adba6b5">18</ix:nonFraction> million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i20860e5e0d834bd0a887924f23c1ddeb_I20201231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzODU5_35c482fe-6c59-41f7-82c9-ea97fddfd6af">3.0</ix:nonFraction> billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($<ix:nonFraction unitRef="usd" contextRef="i21b2ee9ddfcb4ba59cfcd0e1406e7519_I20201231" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzODg4_37973408-f110-4c97-8cb4-62234ab7c6d3">2.5</ix:nonFraction> billion).</span></ix:footnote></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In 2021 and 2020, we recorded net increases in interest of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0MTI1_dab4ca32-10c7-487d-b20c-038729916daf">108</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzYwNDczMTQwMjMxNDQ_47183b07-c823-4a52-8406-9de796672333">89</ix:nonFraction> million, respectively. In 2019, we recorded a net decrease in interest of $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0Mjg3_4135d46e-0bca-4a80-823f-2817b4bbbebf">564</ix:nonFraction> million, resulting primarily from a settlement with the IRS. Gross accrued interest totaled $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0MzIy_a91525f3-3392-441a-a5b6-3151271bd576">601</ix:nonFraction> million as of December 31, 2021 (reflecting a decrease of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0MzYw_7e40aab7-1787-4c59-802e-cff9bf61b8b7">1</ix:nonFraction> million as a result of cash payments) and gross </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ibe652e1ef2414ee9a32667d5beababc6"><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">accrued interest totaled $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0NDg2_7ee2eb01-dc34-49cf-821d-7caad7c9ee54">493</ix:nonFraction> million as of December 31, 2020 (reflecting a decrease of $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0NTI0_0dbce7bf-4571-483c-9ebc-f865c5803f78">5</ix:nonFraction> million as a result of cash payments and a decrease of $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjkxNTc_159259c9-4fbb-4514-a90e-19339f1df035">75</ix:nonFraction>&#160;million relating to the separation of Upjohn). In 2021 and 2020, these amounts were substantially all included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued penalties are not significant. See also </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent&#8217;s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions such as Canada (2013-2021), Europe (2011-2021, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (2011-2021, primarily reflecting China, Japan and Singapore) and Latin America (1998-2021, primarily reflecting Brazil). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE1OTEy_e1b90b0c-637d-475a-9439-33f88cd944aa">75</ix:nonFraction> million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.</span></div><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDEw_60b86d5c-4e6e-4fa8-b4a2-075bf4857336" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:68.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtNi0xLTEtMTU1NjM4_e39da51d-aeec-4e8d-a1e7-561787656116">43</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtOC0xLTEtMTU1NjM4_eb84dd73-f48f-4386-91cc-70803e7c166b">119</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtMTAtMS0xLTE1NTYzOA_69cb70ec-f0d5-43fd-a42b-cdb0a66d8fd3">260</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzUtNi0xLTEtMTU1NjM4_0296fd60-8941-4c50-a08d-dd1d63fffeed">84</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzUtOC0xLTEtMTU1NjM4_f8b358aa-1d8d-441a-a3fd-15af3f198180">88</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzUtMTAtMS0xLTE1NTYzOA_4a67f947-164f-4e83-baca-f650606bfa29">83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzYtNi0xLTEtMTU1NjM4_7f9809ea-6c05-48a9-9dcb-b6f2f14ded7c">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzYtOC0xLTEtMTU1NjM4_70428691-287a-4a41-9905-51d8e2ce48fa">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzYtMTAtMS0xLTE1NTYzOA_8101598c-8aaf-425c-9ab9-4b52fe6dcf3b">125</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzgtNi0xLTEtMTU1NjM4_9c6ec356-3559-44c2-b74b-0b93a7c5df23">114</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzgtOC0xLTEtMTU1NjM4_e35dc1e2-ed53-4ac3-adbe-e4efd92f85e0">113</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzgtMTAtMS0xLTE1NTYzOA_319a6f0d-a4ae-45f2-a642-cc4807ae3122">42</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzktNi0xLTEtMTU1NjM4_2d04bfde-09ff-44c4-8128-e03587b248a1">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzktOC0xLTEtMTU1NjM4_3010c6a2-5d3f-48d2-8b55-760f56f67849">45</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEwLTYtMS0xLTE1NTYzOA_ea62ddf7-7b7f-4c39-959c-1e309f50bd35">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEwLTgtMS0xLTE1NTYzOA_af5853fa-90f8-4f17-a5d2-a8af2bbc2065">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEwLTEwLTEtMS0xNTU2Mzg_ad6a7f3c-1974-4b23-9940-b0497203f96a">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEyLTYtMS0xLTE1NTYzOA_6be97b48-de09-49dd-bd7d-094cc4126181">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEyLTgtMS0xLTE1NTYzOA_6831c346-301e-477e-8f2d-6ee7507f9b0a">22</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEyLTEwLTEtMS0xNTU2Mzg_1c1c55a7-f647-4b7b-975e-ec7b885240e8">5</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit plans: prior service (costs)/credits and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzE5LTYtMS0xLTE1NTYzOA_16225be0-292b-44e4-9b56-37d3406ea061">27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzE5LTgtMS0xLTE1NTYzOA_b008cd54-cfe3-4f30-8096-1ad84a26704a">12</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzE5LTEwLTEtMS0xNTU2Mzg_bcfa992d-9650-4199-8b5a-e6df006a5cf3">1</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIwLTYtMS0xLTE1NTYzOA_4fb6841d-3613-4b4a-ab6e-d34d5dc48f7e">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIwLTgtMS0xLTE1NTYzOA_fdea3a86-d56d-4d61-8404-a4fde76ca370">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIwLTEwLTEtMS0xNTU2Mzg_c84a52ac-105a-445c-b2b6-f0e350fd575b">43</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIxLTYtMS0xLTE1NTYzOA_c2297656-4d20-407e-a5b5-273d55b5f009">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIxLTgtMS0xLTE1NTYzOA_275fbf3f-1f44-4d35-9185-4b35d454f657">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIxLTEwLTEtMS0xNTU2Mzg_2b69f825-363e-40e1-bc58-d97a183b2d4f">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIzLTYtMS0xLTE1NTYzOA_718539f0-d987-4562-a344-ac4ff726b04f">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIzLTgtMS0xLTE1NTYzOA_9270c685-977a-4946-936e-538af6cf90fe">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIzLTEwLTEtMS0xNTU2Mzg_bab09426-91fd-4e7a-9741-38f65fa936da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI0LTYtMS0xLTE1NTYzOA_7c829053-d934-4703-9ab0-7f9583255f77">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI0LTgtMS0xLTE1NTYzOA_16af20ab-c768-4f03-87de-43df2011c3d3">17</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI0LTEwLTEtMS0xNTU2Mzg_c1ac2535-e9ac-402e-945c-878768732aeb">45</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI1LTYtMS0xLTE1NTYzOA_30a8da0c-76ab-4650-8bf5-40d98bcac4b5">71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI1LTgtMS0xLTE1NTYzOA_1e175cd3-0e13-477e-bf6e-feca9033b8e9">227</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI1LTEwLTEtMS0xNTU2Mzg_b38a9536-a3ed-4928-8095-ec6afdf7cda3">178</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzUw_1275eb2f-488b-4d6e-b5cf-9069ca46c946" footnoteRole="http://www.xbrl.org/2003/role/footnote">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_181"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0Nzk_0e495520-f857-48ae-a8e4-1d9fbaecc968" continuedAt="i7022bae6eeff495a8a507eb1b530d32e" escape="true">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ix:nonNumeric></span></div><ix:continuation id="i7022bae6eeff495a8a507eb1b530d32e"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODE_50e3460c-1015-44b5-aee0-23743fe98e39" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Prior Service (Costs)/ Credits and Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d1928a49a1c409b9412c1399a30a560_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMi0xLTEtMTU1NjM4_e61f106a-42e6-4cf2-bf52-aac6d39c699d">6,075</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb4c669061b481d96c1121c6720d70d_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNC0xLTEtMTU1NjM4_df59b808-c19a-458d-9a08-fcc08454107a">167</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcbad3af6ffb42d3a5323f694e0b67e4_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNi0xLTEtMTU1NjM4_de0b7543-ea69-4805-8352-777920c516c7">68</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fd2b1aa38ce4c06af821df843b89ce4_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTAtMS0xLTE1NTYzOA_80cc64e5-d4bf-4658-b77e-6608ae105363">728</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fa41a976be144ff95f4427e340cfcab_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTItMS0xLTE1NTYzOA_a38ccb42-7b44-4153-978f-eee616f1d02c">5,249</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2feb25a701eb4da483a23b858699b65e_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def">139</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if58e15d3f4084fffb7602c9eb76f8bc9_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b">146</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3cd7c442ae43b9bfd024d7dd0d36b9_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc4281959bef4c1493773621b7096825_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6">144</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib57063444ae6416ea155fe3b461c2ed1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40">118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40b2c92e98294f13b4dbf574dc8305f3_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMi0xLTEtMTU1NjM4_98785a01-befa-4c10-b041-8f84db3b9aa2">5,936</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0393c39513f4c3eac3873a1cd6c7164_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNC0xLTEtMTU1NjM4_fd95f5fe-9788-42b7-98a7-2ebcfd5e321f">20</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7547ea8333dc473b9f7ac1c8f733c20d_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNi0xLTEtMTU1NjM4_d8130e94-33e2-41d9-bd5f-dc35bca090cb">35</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c35fcf0cfc44fd48d3257adee8a9f7c_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTAtMS0xLTE1NTYzOA_123ca141-8291-470b-b0dd-6eda82b33426">584</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c15300160eb40199b2470fd99513c75_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTItMS0xLTE1NTYzOA_9136e4e7-dd83-4a34-a2bf-5479fca27462">5,367</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e18b8241eb4dca8f8c5339c218af0e_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a">883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11c6dc78bf6441e287c9ac69448c1f36_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046">448</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab5367055954f1ab2c49e8bb7ad206d_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5">151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a66120c91484bf482696981e59cfd8c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987">106</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc">480</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distribution of Upjohn Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24e18b8241eb4dca8f8c5339c218af0e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480">397</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c6dc78bf6441e287c9ac69448c1f36_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab5367055954f1ab2c49e8bb7ad206d_D20200101-20201231" decimals="-6" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a66120c91484bf482696981e59cfd8c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd">423</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53a5e9e7d598442bb2845131112f1a27_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMi0xLTEtMTU1NjM4_0df94e6e-dd72-4a26-9d13-48322b242766">5,450</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2dcb1cb0b18446282f631ef686d469e_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNC0xLTEtMTU1NjM4_3bdff635-14c6-4f72-8238-0b7e0362e571">428</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia43c881a511349ed8186adf0171213b4_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNi0xLTEtMTU1NjM4_c523199d-997d-4a19-8355-cea3d890630e">116</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f3046c6f3740088aecf1f8ab49180c_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTAtMS0xLTE1NTYzOA_4a2275a9-7705-4579-8874-1206874376a9">452</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica9a1f0a2c3f454aa866582d5102b28a_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTItMS0xLTE1NTYzOA_9a80eaa2-1cc5-46e9-84d5-2982df1449c7">5,310</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if80d286ba9a84220b133795a7fe5879e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582">722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic24d6578cd564b11b05d748a5940c8cc_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb">547</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i511ba9110aec4c1ebb32704e802fdfcf_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa1ca16d7938490db0ffebf5bafa0e71_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4091403708c44027bed1ab29ab967de7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c">587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9aa37587879b40bf9f95c485b7bc8caa_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTItMS0xLTE1NTYzOA_d0cd48f4-f91e-4631-babd-45ea614f93a3">6,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cd8db58f3548899c2ef209a3207f51_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTQtMS0xLTE1NTYzOA_081dcc47-cdde-4218-b274-fb74672a032a">119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e841c53a84a4c519f13fc764830af27_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTYtMS0xLTE1NTYzOA_d3edc723-36cf-4444-b015-fbeec8e2ee52">220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0f53b05386403bb5d5091940b9f1f0_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEwLTEtMS0xNTU2Mzg_9d601fd9-6e60-4673-a18a-9c8efc23f039">377</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6af06169f58446f8067cc5be10a39e9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEyLTEtMS0xNTU2Mzg_5f1e6ae2-9ee1-4d55-bae9-cab3ac64546b">5,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and the impact of our net investment hedging program.</span></ix:footnote></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></ix:footnote></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">76</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_184"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyMzY_0f7f58e8-1a6f-4fdd-9529-c22d8401ae15" continuedAt="i470cbc1b0e2b4b1b897a8a1ab46f8f4a" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i470cbc1b0e2b4b1b897a8a1ab46f8f4a" continuedAt="i7005e5988a8346a489883aaf66a7c485"><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyMzM_436c3bc7-5687-45ac-b85e-2bfbdfd3be40" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b19f0bbfb7432a8e12a91e563366db_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMi0xLTEtMTU1NjM4_444d150b-efaf-41d4-9ef4-da4ef2155309">5,365</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa85376258a44a4ae685454ee4b4522_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtNC0xLTEtMTU1NjM4_a68426e3-4d16-44e7-bf87-763cd51f7148">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3418a2b3afcb431cb8d6bb202f7c9e6e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtNi0xLTEtMTU1NjM4_dfbe7e14-7e1c-4351-9680-a0600daaa2bb">5,365</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64912c49208a4823a52b20d54f71c167_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMTAtMS0xLTE1NTYzOA_578237a9-808b-49b1-bf09-0551f05a71c7">567</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1832b894d034229bf17f14653fff53a_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMTItMS0xLTE1NTYzOA_777525a4-6b16-4ae6-aed4-2376e409096a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfbfd55f6844d2d82e7590378589389_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMTQtMS0xLTE1NTYzOA_27078cde-4b6a-49bb-b84a-7a02bd447a1c">567</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ccb03a8326a4f5d815ce199580340b0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMi0xLTEtMTU1NjM4_3cfd30fa-8ab7-43ad-b45a-7c3e3cca641f">17,318</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58d8b7dd831245b68c651101e4deb9ea_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtNC0xLTEtMTU1NjM4_6cd40697-7cfb-4fdf-a2aa-740b7207febd">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i145d0984ee1244d0b37449d0c40e9475_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtNi0xLTEtMTU1NjM4_5ed0076a-ef3a-40ac-b0d0-41549ef0c829">17,318</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54e2191840f24816b76892c14e08c0a5_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMTAtMS0xLTE1NTYzOA_b8ea55b1-008e-42a2-afda-a8a9945b3508">7,719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i786207e27ed54f20957d50f7249fc8f8_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMTItMS0xLTE1NTYzOA_f7d038a8-0414-4ef1-b074-abaebb723d79">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fb95d9dac1143469cff7c05c1e9b8ec_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMTQtMS0xLTE1NTYzOA_51232922-857f-4487-a225-1db2d6897f51">7,719</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e34c85175c24f12a4b000731b5e3f27_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMi0xLTEtMTU1NjM4_8c53015d-26e6-449d-a7ca-f67a8b380479">4,050</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30d4ea08901f40f8ae26a54cf87605c1_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktNC0xLTEtMTU1NjM4_db7d5bc9-1d86-48a8-b528-895c68c383cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d9b25ab1bf48c4a7eb2a2fab5ba59b_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktNi0xLTEtMTU1NjM4_5882fc88-2785-4566-87e0-c08aec837b9b">4,050</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b8d363fe87400582215a448d41b61e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMTAtMS0xLTE1NTYzOA_70825b9f-84c9-4f87-a6b7-7f3fd00e82bc">982</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d34428a8a7a4c3a9834e0ab26aac210_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMTItMS0xLTE1NTYzOA_b8805c3e-9207-4281-ae12-53aaeda98957">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie423b51a2f17446f883f1e3d141a5644_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMTQtMS0xLTE1NTYzOA_29df739a-fabb-410e-8c65-bac54f8ff53c">982</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27e86737f524429b9f6404bf63655dcb_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTItMS0xLTE1NTYzOA_e48d8103-721b-40b3-a6cd-7a304ee7eeb3">647</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dadd6168e384b76b96623c95ede9e40_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTQtMS0xLTE1NTYzOA_e3792084-95db-41e5-9b6c-01443caa0a5f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f6509e6a7745c6b86b58623ec0a3da_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTYtMS0xLTE1NTYzOA_9b63a0de-117c-4649-8226-20db56c54896">647</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3db2d0cd435749399fb50288da8b36ca_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTEwLTEtMS0xNTU2Mzg_39ff8345-8dc9-474f-9939-5168acca3540">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a7b7712fc3d46dc8c9ab62732f132e3_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTEyLTEtMS0xNTU2Mzg_619978ea-1e5e-4694-bb41-cec85fd6ff96">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f878726ed649d3b72ab3c31f1e3bbd_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTE0LTEtMS0xNTU2Mzg_e419ae1f-892b-4e2a-bdc0-d5474b87ccdf">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2890488b7754499db8478c21b1fced49_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTItMS0xLTE1NTYzOA_127e4c85-6eeb-47d6-a6bd-16233fb0f68f">22,014</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cadeec4d4b465ca3663ef815d82155_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTQtMS0xLTE1NTYzOA_5c270e66-5819-470c-9de3-0421c9c679e7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5925981dea3b42b6b80c80390ff93ce3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTYtMS0xLTE1NTYzOA_0716db17-e10d-4ea1-bf33-842045a93475">22,014</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbee34efeb54f89b1cf37526e026635_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTEwLTEtMS0xNTU2Mzg_47958a9c-5440-4c70-bee0-bb2c283fd9c9">9,709</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d63549fe7b43a793936e93998114f0_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTEyLTEtMS0xNTU2Mzg_42c8de7e-e485-40d1-9dd0-0ae568e0cc4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4730f5e3a64488fa803d7863caba436_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTE0LTEtMS0xNTU2Mzg_c2d109f3-1906-4190-97fa-819c4e38ffc8">9,709</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2890488b7754499db8478c21b1fced49_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTItMS0xLTE1NTYzOA_7f3886d4-329b-4c5d-9766-a0be44c2a0b6">27,379</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cadeec4d4b465ca3663ef815d82155_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTQtMS0xLTE1NTYzOA_9994c6be-156b-40a3-a23e-952cb20e8780">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5925981dea3b42b6b80c80390ff93ce3_I20211231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTYtMS0xLTE1NTYzOA_39753e9f-0ec2-4380-9081-492caab90689">27,379</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbee34efeb54f89b1cf37526e026635_I20201231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTEwLTEtMS0xNTU2Mzg_3a017a3e-e737-40a0-8a40-9eb6907e0de3">10,276</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d63549fe7b43a793936e93998114f0_I20201231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTEyLTEtMS0xNTU2Mzg_e45613d3-047f-404f-bda7-f35141c10bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4730f5e3a64488fa803d7863caba436_I20201231" decimals="-6" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTE0LTEtMS0xNTU2Mzg_153614d1-c0e7-40ba-835f-05af6964c28f">10,276</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83ae4366de7949d1b80d0154a8d14014_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTItMS0xLTE1NTYzOA_cf739142-774c-4492-a8c1-4f64c9804261">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93817b4a8c5f47a784df62085b5ef330_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTQtMS0xLTE1NTYzOA_e5a51fd5-3a44-4943-b59c-b8c49cb0ea77">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ac7b2f72a949818e50952dcb98d810_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTYtMS0xLTE1NTYzOA_31a9f683-229e-483e-bb55-d18599f9f74c">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i253d96f29fcc4271be1786978a7085bd_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTEwLTEtMS0xNTU2Mzg_ec76d7ee-b7a5-4b8c-a4dc-1fa1e54199fe">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia483bb7e1f8c43579b9a40f336b26091_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTEyLTEtMS0xNTU2Mzg_ae5addb7-7fd0-48cc-b4a1-ce80888de3cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51bffa6b2c284c08942e4b334c1d5704_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTE0LTEtMS0xNTU2Mzg_2b79719d-b8ae-4dca-937b-e8a0004353a5">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id721d4b7291d43418158c108dc4def27_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTItMS0xLTE1NTYzOA_eff310ac-4a1e-44ec-a515-37f2db39c0b1">704</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1556a00d4f48a98b1c9c8bdeb762d3_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTQtMS0xLTE1NTYzOA_f1f49a35-fb84-4227-acd5-2abdf5d41209">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id530a91ad1454541a5602cb3294a21df_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTYtMS0xLTE1NTYzOA_4c9aadeb-a514-4278-a426-9254fddc6c83">704</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac39c0dad404d8d8153c80ebdcf66dc_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTEwLTEtMS0xNTU2Mzg_606277de-d1b8-4c07-afd8-b107b497ce89">234</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0561e1ebce474b1eb9d143fd298c0a82_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTEyLTEtMS0xNTU2Mzg_7a862cdf-821f-4039-9a23-5a8be8f22c5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ac2146872344a5aa5941ed2d0c3cd9_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTE0LTEtMS0xNTU2Mzg_522ce0b7-a572-45ec-80ee-015927f2e6f9">234</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic697c580bd3e4b12adcbe2d6812a9bbf_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTItMS0xLTE1NTYzOA_9ffb740d-9008-4933-b70f-291a17716c7c">709</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e262b7b10634d05983458087d0d704a_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTQtMS0xLTE1NTYzOA_45481eeb-9e55-4361-939a-7e996bce9a50">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855416e6b6cc4e2bbbe94916d33fb451_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTYtMS0xLTE1NTYzOA_c973034c-a5e0-48f9-b135-946ccea26554">709</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bef417f19d46c69b2db7cca231ae59_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTEwLTEtMS0xNTU2Mzg_e4fdbc8c-357c-4950-9b80-5e362e9c5772">251</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348aaa35951d4227a378574421582221_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTEyLTEtMS0xNTU2Mzg_d83671f7-db4c-4a40-b2a5-cf41e624b5ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7724991aa49b4c29813095ac7d7118c5_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTE0LTEtMS0xNTU2Mzg_6c20ffda-e346-4b4a-bd8f-7e0ecd56cb3c">251</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTItMS0xLTE1NTYzOA_5fd2c1e6-9de7-40c1-ae80-d3392b8c0703">3,876</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6657a1ee6049f2939f90c46a8b565e_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTQtMS0xLTE1NTYzOA_37ea546b-438a-45e2-8bf8-c5daef1deea9">3,849</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTYtMS0xLTE1NTYzOA_65c2fd73-d37f-4010-8461-ed242702667b">27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70512a720d8249c6a447f770e98bf667_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEwLTEtMS0xNTU2Mzg_072775e8-2b98-4b98-8a60-50ca224f222b">2,809</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9410a99ac78b49fea836856840cfa817_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEyLTEtMS0xNTU2Mzg_047edc6c-e2d8-4c5f-bb4c-a50070519254">2,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16561960de5b416bb80606e87a745433_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTE0LTEtMS0xNTU2Mzg_c9cf5bc8-d558-48e8-89d0-a7d284348289">32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcddc652bbad488ab1ee0afa359aebde_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTItMS0xLTE1NTYzOA_04252906-382c-4a74-b5ba-eb3c5e6209e1">465</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07737ad4fa9241c6a7af7bedb530cec2_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTQtMS0xLTE1NTYzOA_99d2bfe4-3aae-4db8-ad27-4434b6cd6e6a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice49e3789be5439c9f19101663f83790_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTYtMS0xLTE1NTYzOA_bbe8ad14-b4a5-4804-920f-a7aea1240325">465</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb7a0fce89244b7852f6f7fb2718f88_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTEwLTEtMS0xNTU2Mzg_1c0b36e0-bc23-4f91-b3e9-d60e7e0e5801">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d8e1febfc94acb9d1eb950557e11ff_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTEyLTEtMS0xNTU2Mzg_1c560993-73d5-473f-a2f4-899a56dc89f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf180ee19904407b6436c68eeb033d2_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTE0LTEtMS0xNTU2Mzg_23a36466-e146-4b91-a3d6-e5e4f480dbbe">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a1a4330d80747c7ae68476b979046c3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTItMS0xLTE1NTYzOA_8673e3ee-5eb5-4558-bb1b-1d831da901ec">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35ef7c64d623476b9744d8d1d932a8ac_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTQtMS0xLTE1NTYzOA_8daf23a9-6758-40b3-891f-e62ff19d1fed">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fae9b56ccbf497790ea241830626958_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTYtMS0xLTE1NTYzOA_cf5992e0-af1b-41f6-b544-be6f2844d9a3">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica452679157c46e0baa897976e18621f_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTEwLTEtMS0xNTU2Mzg_538c1a26-7b61-4f2d-8e6e-dd442952a0b6">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d5ee66c1ff843b58eb05f3777b56b8e_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTEyLTEtMS0xNTU2Mzg_a78c8f4a-67ed-4010-94dc-367d5f121ddb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cbf7ef28864700b19759fa6f01b5b9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTE0LTEtMS0xNTU2Mzg_1713b036-694c-40eb-87db-dc8b3bace86d">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i699fae78a900497eaac754517d1030c4_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTItMS0xLTE1NTYzOA_6b1d1459-bb30-4313-8c24-56b090ea6f91">50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa71df5a7c754df9b330874d5b7d0aa0_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTQtMS0xLTE1NTYzOA_cc35f474-bdad-45ed-8c06-a8899e1fcca9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1cd464351ee4fdbb492774c72b7f0ea_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTYtMS0xLTE1NTYzOA_6813a88d-71ed-4d8a-893d-a8bb2dc88b03">50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61199b2ae71d4a119d9701e06a107a16_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTEwLTEtMS0xNTU2Mzg_e5810af7-c8ee-49f0-b868-529a3c8270ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c3c53af69848b88bfbc37caf07b4f7_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTEyLTEtMS0xNTU2Mzg_2fa137ad-52c9-460e-ace5-aeccc800b6a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035dd6d3c0a642048d88fe63f7a78ef4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTE0LTEtMS0xNTU2Mzg_964bd196-f34b-49d5-ac68-8ff78fb93266">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTItMS0xLTE1NTYzOA_3eeebdb3-28c9-437c-9487-189b801dc027">521</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6657a1ee6049f2939f90c46a8b565e_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTQtMS0xLTE1NTYzOA_8391baa0-851d-4156-93a6-6a07dcf63a71">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTYtMS0xLTE1NTYzOA_79a22b30-c5db-4ace-a791-254c23986cf7">521</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70512a720d8249c6a447f770e98bf667_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTEwLTEtMS0xNTU2Mzg_c65c039e-ed82-4ad8-ad2b-a538862489ec">128</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9410a99ac78b49fea836856840cfa817_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTEyLTEtMS0xNTU2Mzg_e77c4220-54ec-48d5-accb-70a04f1c2bcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16561960de5b416bb80606e87a745433_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTE0LTEtMS0xNTU2Mzg_a7e8f666-390b-4219-b2e4-c3896943d5ff">128</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTItMS0xLTE1NTYzOA_dc9f0a9f-912d-4c5a-8ff1-3ec399376339">4,397</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a6657a1ee6049f2939f90c46a8b565e_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTQtMS0xLTE1NTYzOA_a7a326b6-ca83-49f0-b0e7-787733fb192a">3,849</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTYtMS0xLTE1NTYzOA_8b496dc6-d2bf-43b1-a9d0-524264dddaa3">548</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70512a720d8249c6a447f770e98bf667_I20201231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTEwLTEtMS0xNTU2Mzg_48573c59-50d6-463e-8362-b6183c38d0e1">2,936</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9410a99ac78b49fea836856840cfa817_I20201231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTEyLTEtMS0xNTU2Mzg_d46619fc-9b3d-49c3-bea7-abb41d167ed6">2,776</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16561960de5b416bb80606e87a745433_I20201231" decimals="-6" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTE0LTEtMS0xNTU2Mzg_6fade632-3fda-43ac-b7bc-de4fd1758c2c">160</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c04c36693542238bff2f892e06e98f_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTItMS0xLTE1NTYzOA_441e2b30-58f9-491f-99ea-27b4d9922a4d">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6c1489c0b2445858572277f4815c6fb_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTQtMS0xLTE1NTYzOA_81a4c8a6-afaf-45dd-a0a1-89eb85b77cfc">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266d5bf8ac8d461eb1d35c89e5cbf036_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTYtMS0xLTE1NTYzOA_1a6242d5-2cd4-4bc7-a601-64577593b96f">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53680812f8648f0b2a86cf92d5a834c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTEwLTEtMS0xNTU2Mzg_01d1e49c-84d0-4d40-b2f2-65afcda248d7">117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3401d442aa0e49cc9ca695e109e88114_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTEyLTEtMS0xNTU2Mzg_c51232b3-737f-4051-b963-59f4d164f8e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacf9e2737204b3fb0fc33abd7e63fa4_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTE0LTEtMS0xNTU2Mzg_e4a489a5-c179-48c4-b35c-2e10d318d82c">117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e8e9e1c789345cebe1a2feb0a026d46_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTItMS0xLTE1NTYzOA_3174a526-f3ce-48d9-8d23-910a3d82e2bd">242</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044a5eb77497431eb9a60b053d4b39b8_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTQtMS0xLTE1NTYzOA_f3033467-bfc8-4721-8edf-4fafd99aedf4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb044a8108646f5b407e315c13bc306_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTYtMS0xLTE1NTYzOA_10749c1f-f06c-4a75-84fb-d7bcb1beb09c">242</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8394064421940caaa44168cccf97ba7_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTEwLTEtMS0xNTU2Mzg_114ef4a0-8a2a-49dd-b7a1-55daf834e7a6">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef434e9c591416e9cd79efc4e0aa93c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTEyLTEtMS0xNTU2Mzg_b1beb010-5067-4b38-98cc-ea91d702a7ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic64f9f7b7805469997412f2d21b49cff_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTE0LTEtMS0xNTU2Mzg_bfa7f137-f295-4741-91df-7b83c6fb232b">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1030e92ca546ef841323d8c13bf48e_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTItMS0xLTE1NTYzOA_276d609f-a26f-4f6a-a761-6b801694ce9f">259</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f41b9fb6664114ba8990752669ce62_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTQtMS0xLTE1NTYzOA_6c7aa4a8-51c6-49be-9045-d038f329d1ea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4039c10bfb794c72a6cdf0439f64ad94_I20211231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTYtMS0xLTE1NTYzOA_36d8788d-3593-407a-a8b1-fba04ea607ec">259</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b0fd0f68794d0dbf248bb676c8872d_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTEwLTEtMS0xNTU2Mzg_80a4479b-dafc-48c5-86ac-dc529bc917f7">122</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad0dd09085d4434922268dce88a5be1_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTEyLTEtMS0xNTU2Mzg_4ba9dd58-8787-43e8-ad95-289b7edd4f92">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9bf003cb624560a24158c89f5b413c_I20201231" decimals="-6" name="us-gaap:DerivativeAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTE0LTEtMS0xNTU2Mzg_42eea0d2-27ae-4537-a9d5-fd74e87372fc">122</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1030e92ca546ef841323d8c13bf48e_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTItMS0xLTE1NTYzOA_8560e1e6-113f-49a9-a5db-00c29f18a662">808</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f41b9fb6664114ba8990752669ce62_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTQtMS0xLTE1NTYzOA_47101ccf-cf07-4de7-bb9b-28d921f5d23a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4039c10bfb794c72a6cdf0439f64ad94_I20211231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTYtMS0xLTE1NTYzOA_2dad020e-49dc-4f46-9166-52fd70e40e4d">808</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b0fd0f68794d0dbf248bb676c8872d_I20201231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEwLTEtMS0xNTU2Mzg_b786aead-0eb3-4880-bb46-0174ca150730">693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad0dd09085d4434922268dce88a5be1_I20201231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEyLTEtMS0xNTU2Mzg_d747b835-40c4-4736-9e1a-06a05ad61374">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9bf003cb624560a24158c89f5b413c_I20201231" decimals="-6" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTE0LTEtMS0xNTU2Mzg_820b8eec-4175-4e49-b47a-d53cf5c61a03">693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1030e92ca546ef841323d8c13bf48e_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTItMS0xLTE1NTYzOA_c6841798-ece2-4ad4-a6cf-93c7ecd7d48c">1,067</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f41b9fb6664114ba8990752669ce62_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTQtMS0xLTE1NTYzOA_bb2dc4ba-2857-42ff-95f1-94d504ef7eea">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4039c10bfb794c72a6cdf0439f64ad94_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTYtMS0xLTE1NTYzOA_fff3a9a3-c527-4a3e-adf4-fea98c862326">1,067</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47b0fd0f68794d0dbf248bb676c8872d_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTEwLTEtMS0xNTU2Mzg_a3d3653d-45d7-4a38-8a86-d2cf17d4ac05">814</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad0dd09085d4434922268dce88a5be1_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTEyLTEtMS0xNTU2Mzg_54d8868e-16c1-46a1-98cd-f73878c8f000">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9bf003cb624560a24158c89f5b413c_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTE0LTEtMS0xNTU2Mzg_e941cd7a-e34b-4cd2-802e-cf6b23ba0987">814</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5495ffcbab4b708606247546b1099b_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTItMS0xLTE1NTYzOA_f8e7fd79-8fb9-4995-b028-0aeaeb946812">33,552</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64af4f01f854deba8682c77d92bad2c_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTQtMS0xLTE1NTYzOA_c74d4d20-eaf7-42ce-a87e-eb619a9c4217">3,849</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d5b2cbf5877457a84627eb0b3ef18bc_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTYtMS0xLTE1NTYzOA_d937d1be-923d-48ee-bfd3-95c89588e411">29,703</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if727b53b9c13428d8682f12d2a2a91a2_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTEwLTEtMS0xNTU2Mzg_e3249881-3bc2-4e9c-8b25-2ab27ad7d312">14,278</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b344a25e0974083bfd701101c5fa14c_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTEyLTEtMS0xNTU2Mzg_640c62ca-7ee4-4bb3-b86c-cd3383bf8429">2,776</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b605fdab274710a7049bf3271f2010_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTE0LTEtMS0xNTU2Mzg_ef315302-2615-48cc-8265-ed478d78bfd6">11,501</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4661b56a33040d39e0288c81b250b79_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTItMS0xLTE1NTYzOA_0659e79d-602f-4b2a-9cf8-a9c7750e7b9b">476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74421933bb0140d9aef90e0ba650d3ae_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTQtMS0xLTE1NTYzOA_7e03e4e7-5b0f-452e-bb61-6e234788d525">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52caa45e571f49c4a4927dc80ab53ddc_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTYtMS0xLTE1NTYzOA_16432840-1196-44c6-9531-a5143a737d65">476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i059b59eb77974214a452371c05d01877_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTEwLTEtMS0xNTU2Mzg_c67a8ec8-a46a-4a96-9f66-65c6d2d2540b">501</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b28fcf96cfe404bad85bce40692dab2_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTEyLTEtMS0xNTU2Mzg_484b5897-30b0-4e32-8cef-7e1eb5fc9b1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i391f0428ef3846feba697cee554a7311_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTE0LTEtMS0xNTU2Mzg_5aecaa5f-543e-4c51-9eac-7a51b885b83b">501</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i971392f8a1ed4acabefb0363b735d97c_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTItMS0xLTE1NTYzOA_fcfc51e0-f07f-4914-b2cf-38c0cd133d96">476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedacf36cb97e40da88831c92a1a13dab_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTQtMS0xLTE1NTYzOA_fa7c5f99-3819-48bd-a06e-f0ad4639ef53">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1de3fb51d6144fd87ad3b271bddef08_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTYtMS0xLTE1NTYzOA_f6cfa852-ba51-4732-9e79-2c63601230d0">476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea277d746d44a1f85486e2e86259f6b_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTEwLTEtMS0xNTU2Mzg_228848ec-5cc1-4562-9fdb-9cb211ad7def">501</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66bc55df7fa54d8eb2c01252174f998d_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTEyLTEtMS0xNTU2Mzg_1dcceb4e-dab2-4e59-8bf5-44de4bb6c795">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ed3353738f4d0bbc5f8a1517448c88_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTE0LTEtMS0xNTU2Mzg_d3b80ed6-fb79-4fc8-aa8f-0ef7f207739d">501</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7f920dd98641c9922cd5f40499d770_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTItMS0xLTE1NTYzOA_bf1a2766-1dfa-4200-8ccf-baa687ddec93">405</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7730012552f84e97b24d81ea22e392e1_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTQtMS0xLTE1NTYzOA_20e3e12e-a3a6-4248-a702-91416f894af2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic33e861c80224332a9e4e4a2669d4e87_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTYtMS0xLTE1NTYzOA_2c0ec8ce-d199-4a19-b840-472f3f49bb93">405</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b128fac9ff5430ba36b5956d34c25e6_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTEwLTEtMS0xNTU2Mzg_21476965-d560-47d9-9045-4784f7e434db">599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17ddb927ae6489e842698e9bbfc563f_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTEyLTEtMS0xNTU2Mzg_419ca879-0170-40dd-8c23-859e8ce24527">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e722d345f9a4cb1959d4880f98fb229_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTE0LTEtMS0xNTU2Mzg_8e0c0a02-fdff-4a8f-9fea-7560aa083878">599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b117048a90e4162b3f01f76bd79817e_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTItMS0xLTE1NTYzOA_563dc102-944c-440e-bcc7-6ce36d69ed6c">405</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660aa25f8def4a02a2ee5ff867c78198_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTQtMS0xLTE1NTYzOA_568cdd85-cd83-44e9-95fa-2b3c3989753d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a943429e8d4b39919d0b4271200bc6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTYtMS0xLTE1NTYzOA_a1aca99a-d2bc-431c-bc31-dbcee9564052">405</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95769ff280e143bbbf58c6acb40fc937_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTEwLTEtMS0xNTU2Mzg_ccb189ec-556b-4d31-8956-a247012152bc">599</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5211751f163f4b0f91dd14ccc368ad60_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTEyLTEtMS0xNTU2Mzg_c6993b13-0097-4c66-85c5-69fe19142cf7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c71733d54f40a39764458c5aa47582_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTE0LTEtMS0xNTU2Mzg_b0a82844-20d3-4b73-813c-24549d4c8ac6">599</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660aa25f8def4a02a2ee5ff867c78198_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTQtMS0xLTE1NTYzOA_07c1b247-14db-41ec-b5c4-efc3e2ccf61c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a943429e8d4b39919d0b4271200bc6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTYtMS0xLTE1NTYzOA_6bbeb90b-d7f8-4e33-bae4-28c2d1d4cfac">881</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95769ff280e143bbbf58c6acb40fc937_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTEwLTEtMS0xNTU2Mzg_c83af4f1-51e0-4758-85c4-925ffbcf0a76">1,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5211751f163f4b0f91dd14ccc368ad60_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTEyLTEtMS0xNTU2Mzg_d38f112d-f669-4a9e-b186-34a683f8fa23">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c71733d54f40a39764458c5aa47582_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTE0LTEtMS0xNTU2Mzg_e1023e6f-b141-42d5-a6df-c3505ad09b66">1,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41" footnoteRole="http://www.xbrl.org/2003/role/footnote">Long-term equity securities of $<ix:nonFraction unitRef="usd" contextRef="i6a5495ffcbab4b708606247546b1099b_I20211231" decimals="-6" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzIyNA_eb1f4a56-45dc-4b66-8ac6-3d0559d8c013">194</ix:nonFraction> million as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="if727b53b9c13428d8682f12d2a2a91a2_I20201231" decimals="-6" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzI0MA_6753646b-f55d-4c61-8d5f-8f88dd758b2f">190</ix:nonFraction> million as of December 31, 2020 were held in restricted trusts for U.S. non-qualified employee benefit plans.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The carrying value of Long-term debt, excluding the current portion was $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-9" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDYwNzU_d9f8859f-046b-4f91-95ba-7624fe32206a">36</ix:nonFraction>&#160;billion as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-9" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDYwODI_d47be7b7-42b6-4234-81d1-e30f6850f6f5">37</ix:nonFraction>&#160;billion as of December 31, 2020. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $<ix:nonFraction unitRef="usd" contextRef="i9a15e9f4278a4ea88fac685bd5263002_I20211231" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDU0OTE_045ad6ab-fed6-4d84-bf53-31076cc669e1">42</ix:nonFraction>&#160;billion as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="iaf5508327199483d8b8486b1d9a35897_I20201231" decimals="-9" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDU1MTA_519dae90-50e4-41a8-b160-5154e9ba6c8c">46</ix:nonFraction> billion as of December 31, 2020.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i7005e5988a8346a489883aaf66a7c485" continuedAt="id5b2c9ae41a24c73ab766b9a8d3c74af">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2021 and 2020. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.</ix:continuation></span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_187"></div><ix:continuation id="id5b2c9ae41a24c73ab766b9a8d3c74af" continuedAt="i8dcb8275e19e48d481b261df637baed4"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Total Short-Term, Long-Term and Equity-Method Investments</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg4MQ_083dfa8c-6b68-4606-a849-e8621e31ab17" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtMi0xLTEtMTU1NjM4_eac59ed0-b395-4f44-91ec-98b484b8f4b4">5,365</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtNC0xLTEtMTU1NjM4_5e0bc421-d01b-4490-af80-b7bf03c05d79">567</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzUtMi0xLTEtMTU1NjM4_7f6dfefd-26ed-4f49-99cd-9f093e801983">22,014</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzUtNC0xLTEtMTU1NjM4_c0e6aeb9-aed0-4eed-8a7e-3bbbab139d61">9,709</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzYtMi0xLTEtMTU1NjM4_2ff3046c-f92a-4611-9d05-428d46afe2a3">1,746</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzYtNC0xLTEtMTU1NjM4_bf8899a4-9f22-448d-8d9f-fa752c706ef8">161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzctMi0xLTEtMTU1NjM4_f9e13b2a-f1a7-4f23-95bf-ff6a6e6ab519">29,125</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzctNC0xLTEtMTU1NjM4_086e9ad3-a135-4df0-ad62-f8d2dd91a472">10,437</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEwLTItMS0xLTE1NTYzOA_4612ee98-aa8e-47ea-9ed3-88eee03a60be">3,876</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEwLTQtMS0xLTE1NTYzOA_2b2c8cfd-1d35-4b4e-bba8-9e6028719705">2,809</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzExLTItMS0xLTE1NTYzOA_395cea86-d322-4642-922d-7e1756fc2766">521</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzExLTQtMS0xLTE1NTYzOA_2e611b16-7f64-41a9-bc0c-9e449446af70">128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEyLTItMS0xLTE1NTYzOA_9f48646c-4eff-4264-9a89-ab729425a24e">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEyLTQtMS0xLTE1NTYzOA_d9bdd317-656a-455e-bbb7-12902dcad813">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTItMS0xLTE1NTYzOA_a7bec050-b698-4726-bd56-085e3fa47cb8">623</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:PrivateEquityInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTQtMS0xLTE1NTYzOA_a037f3fe-76de-4e3a-b45e-df594d2e8044">432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE0LTItMS0xLTE1NTYzOA_fdba4ba5-40ac-4519-ba1f-970d6e1ff1cd">5,054</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE0LTQtMS0xLTE1NTYzOA_0b1d02ff-b7ae-4a66-a5a4-ba8265fc7555">3,406</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE1LTItMS0xLTE1NTYzOA_e92117e2-65e3-4f39-84f8-806cf6c260a2">16,472</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE1LTQtMS0xLTE1NTYzOA_ddb656d3-819d-4cb0-909e-51aef1d4e357">16,856</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE2LTItMS0xLTE1NTYzOA_456f4f6e-57ea-431d-9117-b6b00a8a0624">21,526</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE2LTQtMS0xLTE1NTYzOA_291aa6a5-bb88-4ce4-9c06-ea6e3f71fa23">20,262</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE3LTItMS0xLTE1NTYzOA_fa68f9d1-13ce-4b04-80df-60822d32524f">268</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:HeldToMaturityCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE3LTQtMS0xLTE1NTYzOA_cceb43b9-59c0-4b2a-98cd-c66408afde9b">89</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwMA_40ce384d-31be-4b40-aaa6-9b94f7f3d188" footnoteRole="http://www.xbrl.org/2003/role/footnote">As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Mw_b1b8ff7f-ad8d-468c-af41-2061ee702628" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represent investments in the life sciences sector.</ix:footnote></span></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg4Mg_80856edf-9864-486a-ab7f-95514daf2541" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwNA_2df1a97f-d0a1-4779-b422-6eaee3de855f" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkxMg_d7989c1a-1d4f-42f9-bb7c-c68d34244514" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:21.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.684%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMi0xLTEtMTU1NjM4_92b1a056-d0eb-4c53-8113-1a74b68b9504">18,032</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtNC0xLTEtMTU1NjM4_c8ae0638-27f8-4919-a147-4a8e615ba391">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtNi0xLTEtMTU1NjM4_3d671f58-5ed6-4ba3-9f30-30dcbab947df">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtOC0xLTEtMTU1NjM4_f7357671-942d-486d-8c27-75922ab9dc95">17,783</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTAtMS0xLTE1NTYzOA_55ca12fa-66a6-435e-8517-c19a9779bd22">17,318</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTItMS0xLTE1NTYzOA_d5eeb6cc-d833-4772-bc79-3b3ae70a44d7">465</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTQtMS0xLTE1NTYzOA_349494c0-3977-46d8-8699-5f7708d672cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTYtMS0xLTE1NTYzOA_9e98073d-bcee-4468-8901-baeb16ad6ef6">7,593</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTgtMS0xLTE1NTYzOA_fa32a791-aca2-421c-83ae-9ca8088cfb83">136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMjAtMS0xLTE1NTYzOA_f7bd4f3a-8927-4098-8864-c4d01bdd9b36">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMjItMS0xLTE1NTYzOA_a97cd337-3aba-415f-a755-4aed724c6603">7,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMi0xLTEtMTU1NjM4_b1c426f2-7069-41fc-b774-335ea603adc8">4,056</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtNC0xLTEtMTU1NjM4_a0350c50-060f-4352-ba6e-0d2752409c46">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtNi0xLTEtMTU1NjM4_d35ecb1d-3b75-4adb-ba87-487b00d06b36">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtOC0xLTEtMTU1NjM4_3c88b5df-508f-479a-b6ed-f8152e9175b4">4,055</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTAtMS0xLTE1NTYzOA_b552cf2d-2d33-4798-883d-c15d460a2e6f">4,050</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTItMS0xLTE1NTYzOA_e3b7c8c0-2f59-47ab-9ee4-5384f6718760">6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTQtMS0xLTE1NTYzOA_15c28168-8f05-4b90-9b30-3cda018fc402">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTYtMS0xLTE1NTYzOA_03784a85-02fe-4a91-bff5-9584f95c28a5">1,104</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTgtMS0xLTE1NTYzOA_c327c002-e943-40ba-bdd5-90e0a68c8f58">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMjAtMS0xLTE1NTYzOA_7c369d8c-7ce4-4ceb-8c30-4de3d2bf2458">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMjItMS0xLTE1NTYzOA_4078a91e-7435-47eb-a9e7-be6c0616ade3">1,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMi0xLTEtMTU1NjM4_2c136b2e-c6a9-4d0f-9892-05a26d8d7323">698</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctNC0xLTEtMTU1NjM4_89ab55aa-e486-4d56-8d2b-66f90620add7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctNi0xLTEtMTU1NjM4_883708d4-b23b-4c93-8dd1-5ebfb9b3a9f4">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctOC0xLTEtMTU1NjM4_af9d1192-2218-46a4-b9b1-8929be91f868">697</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTAtMS0xLTE1NTYzOA_94284635-8e10-4ee1-bd30-506a0cd57bbd">647</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTItMS0xLTE1NTYzOA_77bb7a2e-99e3-4716-a836-cb826446dc97">50</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231" decimals="-6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTQtMS0xLTE1NTYzOA_fde94977-0e76-43bd-8a70-3e6fd47a60b8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTYtMS0xLTE1NTYzOA_f3988a45-b3c6-42d1-aca2-c994b47773fc">1,006</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTgtMS0xLTE1NTYzOA_2e977ddd-1030-41eb-a6e0-42af1ec14082">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMjAtMS0xLTE1NTYzOA_181cb716-b35f-4697-ae35-549df5e0b01d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMjItMS0xLTE1NTYzOA_b39e99b2-1900-40b4-ad0c-f6fc24dccf05">1,008</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b38f67d770f409b806366759e0b2089_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMi0xLTEtMTU1NjM4_011f2e31-f3eb-4225-b209-ccf9d5bcfda1">947</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b38f67d770f409b806366759e0b2089_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktNC0xLTEtMTU1NjM4_0462df6e-55ee-4d95-a507-991c16b0174d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b38f67d770f409b806366759e0b2089_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktNi0xLTEtMTU1NjM4_3a31a32e-2054-4cfd-8474-a37ea2377442">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b38f67d770f409b806366759e0b2089_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktOC0xLTEtMTU1NjM4_8afbdaba-ab6e-4af8-a243-a3bcb33a0181">947</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b38f67d770f409b806366759e0b2089_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTAtMS0xLTE1NTYzOA_636260cb-3d2f-4afe-b41a-edd22352c7bc">917</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b38f67d770f409b806366759e0b2089_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTItMS0xLTE1NTYzOA_445c3664-628e-49f3-b01d-5a6170b3849b">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b38f67d770f409b806366759e0b2089_I20211231" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTQtMS0xLTE1NTYzOA_49f94f4d-925d-42f7-8b8f-e98d42db5cfb">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTYtMS0xLTE1NTYzOA_ea933433-798d-4205-aa6b-a16a8bfbced8">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTgtMS0xLTE1NTYzOA_5eebab0e-fba3-4159-8f20-7e723fa595e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMjAtMS0xLTE1NTYzOA_df503ae1-bd19-4c70-af7d-ea26a188a0fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMjItMS0xLTE1NTYzOA_2184c78e-d7c8-41e2-b4dc-30c0ee08f592">283</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTItMS0xLTE1NTYzOA_9f17995a-3f17-4cbb-8f48-bdcad11b0ee7">1,102</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTQtMS0xLTE1NTYzOA_e95b769f-79c8-4b42-af8d-8c296ace86e4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTYtMS0xLTE1NTYzOA_fc18df76-fbaa-4fe1-8bd2-8ab7606307c1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTgtMS0xLTE1NTYzOA_40f80324-9dbb-4f91-8994-044f89aad2b6">1,102</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTEwLTEtMS0xNTU2Mzg_709107bb-3da1-4e5f-aee8-bef0a573f15b">1,097</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTEyLTEtMS0xNTU2Mzg_ab03b990-c916-42c5-8749-793b3cade05a">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231" decimals="-6" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTE0LTEtMS0xNTU2Mzg_94ddb736-0a04-4c26-bab6-c686f464a60c">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTE2LTEtMS0xNTU2Mzg_0fcce6d8-139d-48a6-8c53-be2d6d351f1b">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTE4LTEtMS0xNTU2Mzg_24ff06dc-e638-497f-af59-1afaac68cfce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTIwLTEtMS0xNTU2Mzg_db4000e3-0380-494f-bf46-56ef516f8729">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687b62defe464388a420482db5f02ab4_I20201231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTIyLTEtMS0xNTU2Mzg_240e4817-4c47-4b5d-a209-aaf6bcdd3aa7">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTItMS0xLTE1NTYzOA_7a1fca54-ba83-4296-9aea-ffa8a9e26709">24,835</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTQtMS0xLTE1NTYzOA_e8b4ef09-d971-4165-b9cf-4d84814372f0">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTYtMS0xLTE1NTYzOA_d463bfe2-04b6-4fd5-a49b-8601bb45348c">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTgtMS0xLTE1NTYzOA_975b6273-7178-4f33-99c4-7c286065a5aa">24,584</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTEwLTEtMS0xNTU2Mzg_3aa2716b-b3f5-4492-8f41-7183f953b32d">24,029</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTEyLTEtMS0xNTU2Mzg_d8f1214e-83f3-47af-b8e9-f998b0b666e9">543</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTE0LTEtMS0xNTU2Mzg_962b2150-4e18-4a9a-8e7b-fc33803286bc">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTE2LTEtMS0xNTU2Mzg_f47c9161-fc38-4c21-a3d0-cb618afedee9">9,991</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTE4LTEtMS0xNTU2Mzg_9166548a-e3bd-4d2c-9c9a-e9f3a9580618">138</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTIwLTEtMS0xNTU2Mzg_25453e19-11c9-45c0-96e4-4774cfd73b8b">5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTIyLTEtMS0xNTU2Mzg_1325d903-7fd7-44db-8dfe-230bcd896d50">10,124</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Securities</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5MQ_fbd89d64-1b6b-4748-bc95-a2d6a35f3bbc" escape="true"><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.013%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtMi0xLTEtMTc3Nzcz_1412e961-c1d0-4724-998b-2b5f26860881">1,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNC0xLTEtMTU1NjM4_704706b6-4bd6-4188-ab0c-928c0e14cea6">540</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974">454</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzQtMi0xLTEtMTU1NjM4_6066ba3a-f027-44f7-8111-51321a3c9818">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzQtNC0xLTEtMTU1NjM4_83c96879-57d9-44a7-b57d-eb3c17203450">24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzQtNi0xLTEtMTU1NjM4_031a6ec7-2ed6-4b5c-b168-997830e99b30">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtMi0xLTEtMTU1NjM4_5a7da2e0-b310-4992-9ead-53d778086a59">1,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNC0xLTEtMTU1NjM4_7610cbaa-8fc4-4815-b1d5-99eac4d0bbb0">515</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNi0xLTEtMTU1NjM4_3213929f-51ad-4505-8713-b09ae07ab6ff">429</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Nw_399e05ff-d281-48cc-9c48-a9128c75a260" footnoteRole="http://www.xbrl.org/2003/role/footnote">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzc2Mw_7a40c052-d00a-4d75-af04-723920066f1e">97</ix:nonFraction> million and upward adjustments of $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzc5Mg_010492f4-b192-4078-a78d-44937014c7e0">156</ix:nonFraction> million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019</ix:footnote>.</span></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_190"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8dcb8275e19e48d481b261df637baed4" continuedAt="i8f4a8f3008a54b4789bb7dfbdd66cfcd"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzczOQ_6f609302-2dbf-4d59-a452-f36bd5684b06" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:73.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.842%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:CommercialPaper" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzMtMi0xLTEtMTU1NjM4_c68e4e66-9e15-4661-94de-43d3c293c71a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:CommercialPaper" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzMtNC0xLTEtMTU1NjM4_2938a3e4-12c9-4084-9f65-1b8196126544">556</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzQtMi0xLTEtMTU1NjM4_ab9592b6-d6eb-4a50-9e4a-8ebf8fd3acc1">1,636</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzQtNC0xLTEtMTU1NjM4_73f21de6-0bcc-4b37-9db5-860429fda96c">2,004</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtMi0xLTEtMTU1NjM4_94dbdfbe-5859-4c23-9d8d-2d3e183bbfd0">605</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OtherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtNC0xLTEtMTU1NjM4_dd146452-18dc-4d23-a080-83e4f78e3d3b">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:ShorttermDebtGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzYtMi0xLTEtMTU1NjM4_5234f086-0deb-4eb7-a281-902ab5c2ca19">2,241</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="pfe:ShorttermDebtGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzYtNC0xLTEtMTU1NjM4_1333ca5f-ffae-4f64-a68f-0cda7d65b967">2,705</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzgtMi0xLTEtMTU1NjM4_09dd6443-07dc-495b-9920-830609a5b819">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzgtNC0xLTEtMTU1NjM4_4f36ead3-6d2b-4e9b-b17c-c77730a94a81">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzktMi0xLTEtMTU1NjM4_c393ed62-e401-4edc-bed6-b0bfbb1e451e">2,241</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzktNC0xLTEtMTU1NjM4_fd1c67f1-5c2e-4f1a-8e74-7bcd6c050fca">2,703</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzc0NQ_18d5f6d7-e265-405d-b5ef-606a4d9ca43e" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes cash collateral. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average effective interest rate on commercial paper outstanding was approximately <ix:nonFraction unitRef="number" contextRef="ibe045779c301429da73c967dc0c4fef3_I20201231" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzIxOQ_5764537c-d817-4ff5-9567-19d71150477b">0.13</ix:nonFraction>% as of December 31, 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2021, we had access to a $<ix:nonFraction unitRef="usd" contextRef="i7b8d95576ec143738ffeac1cac97942a_I20211231" decimals="-9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzI3MA_130f3b0c-50f5-4d94-b5af-313ffa7263d2">7</ix:nonFraction> billion committed U.S. revolving credit facility expiring in 2026, which may be used for general corporate purposes including to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have provided us an additional $<ix:nonFraction unitRef="usd" contextRef="ib87e561cb5e04d748723b1e3acc726a0_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzYyMg_c4993439-fcc6-432b-b478-ed83eaf0f15f">360</ix:nonFraction> million in lines of credit, of which $<ix:nonFraction unitRef="usd" contextRef="ib87e561cb5e04d748723b1e3acc726a0_I20211231" decimals="-6" name="pfe:LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzY1NA_486f505c-9288-4eb4-bb3d-3e84cae34aaa">322</ix:nonFraction> million expire within one year. Essentially all lines of credit were unused as of December 31, 2021.</span></div></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_193"></div><ix:continuation id="i8f4a8f3008a54b4789bb7dfbdd66cfcd" continuedAt="i725ea94a55f54a2589452a8ffb80e515"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mzc_4774dfa0-3621-4bfc-8921-7d595718e039" escape="true"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following outlines our senior unsecured long-term debt and the weighted-average stated interest rate by maturity:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2022 (<ix:nonFraction unitRef="number" contextRef="ic5e7c524a0cf45b6a07e42355b143830_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246YzM0MDEzMDZlNWU3NDcxNDk3ODlmYTMwYzIxOGFiNzJfMTIwOTQ2Mjc5MDU2Mjc_00de34fa-8fc3-4cfa-92e4-794ddef2a04f">1.0</ix:nonFraction>% for 2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cb403f6b8f742a98ca63fc690188314_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMi0xLTEtMTU1NjM4_d0719a5a-8f70-4d72-8488-4163b8e663c2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e7c524a0cf45b6a07e42355b143830_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtNC0xLTEtMTU1NjM4_fcff6e04-cf91-4aab-a1bf-9b6b771c59d2">1,728</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2023 (<ix:nonFraction unitRef="number" contextRef="i3bae6de665ed403789bfbe721f25e08b_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MGNlMzFkNjcyYjkwNDI3NThkMjJiMThjMDRhNTRmMTBfMjA_54f192ed-e3a9-45c4-98ec-d9ddcce323c2"><ix:nonFraction unitRef="number" contextRef="i3147b1fbc1bd43a2a4e14a4f08917b76_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MGNlMzFkNjcyYjkwNDI3NThkMjJiMThjMDRhNTRmMTBfMjA_669a822a-a73e-46c2-b475-6a586219ece0">3.2</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bae6de665ed403789bfbe721f25e08b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtMi0xLTEtMTU1NjM4_ff18272b-935a-41cd-a603-1af12a0c59d2">2,550</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3147b1fbc1bd43a2a4e14a4f08917b76_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtNC0xLTEtMTU1NjM4_acb69870-5b71-40a7-8bea-98705a18510e">2,550</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2024 (<ix:nonFraction unitRef="number" contextRef="if62b572a74364f54934ae9592882c5ff_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MDM3NTM3NmY3YzBkNGM0MTk5MWU1YmJlNmY5MzQ1NjVfMjA_1d9e0e92-70cd-49ef-82c3-80808fe93f51"><ix:nonFraction unitRef="number" contextRef="ib981a715bfdd4b488f432d8966a210fe_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MDM3NTM3NmY3YzBkNGM0MTk5MWU1YmJlNmY5MzQ1NjVfMjA_e212f962-4fa3-4e88-9cf8-9bced6c2f589">3.9</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib981a715bfdd4b488f432d8966a210fe_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtMi0xLTEtMTU1NjM4_5cde5dec-f4b6-444a-896f-af8b9c6c7cfa">2,250</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62b572a74364f54934ae9592882c5ff_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtNC0xLTEtMTU1NjM4_cb9983e4-0603-4fa3-924a-7ad4a2942264">2,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2025 (<ix:nonFraction unitRef="number" contextRef="ie795359bbbc64f42b3251279ad6b39c1_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctMC0xLTEtMTU1NjM4L3RleHRyZWdpb246YTI1MzUwOTU1OGUxNDViNmIyZjI5OTk1NDg0ZTE3NDNfMjA_60f7b7aa-7295-4294-9218-8d4bcaaec7f6"><ix:nonFraction unitRef="number" contextRef="i2cf98b9fedf540bc805e6e4573df80ae_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctMC0xLTEtMTU1NjM4L3RleHRyZWdpb246YTI1MzUwOTU1OGUxNDViNmIyZjI5OTk1NDg0ZTE3NDNfMjA_f46c39b2-87b3-44aa-9877-3335d3946025">0.8</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cf98b9fedf540bc805e6e4573df80ae_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctMi0xLTEtMTU1NjM4_433a8eb6-a9bb-4e32-8356-992faf74b447">750</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie795359bbbc64f42b3251279ad6b39c1_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctNC0xLTEtMTU1NjM4_975c7f47-109c-472b-b265-6cc67ae2e715">750</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2026 (<ix:nonFraction unitRef="number" contextRef="i66c8b6ecab3d40c483eb2e43be3fb7a3_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYxZTVkY2ExNGE2NDM0Zjk3ZjQxYWUwYWE2MDU5MDdfMjA_c19cfd7b-8054-48e0-9c8e-c4c4f27521a7"><ix:nonFraction unitRef="number" contextRef="ie28c7ac7e9a14c6793a223d8dc99e719_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYxZTVkY2ExNGE2NDM0Zjk3ZjQxYWUwYWE2MDU5MDdfMjA_f8fbe43f-1bc9-4b03-8a5f-76c78ca6e191">2.9</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie28c7ac7e9a14c6793a223d8dc99e719_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtMi0xLTEtMTU1NjM4_16742f28-b3c6-4386-a3a6-f221f6597b7e">3,000</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c8b6ecab3d40c483eb2e43be3fb7a3_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtNC0xLTEtMTU1NjM4_9b81b2ac-b807-4b91-8ccb-377b37eeff5f">3,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2027 (<ix:nonFraction unitRef="number" contextRef="ib90c748be7c2480295ad0c48f90c8398_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246ZTM3ZjFkN2I5ZDYzNGEyYzkyNTlmZmE2YTA0OGM0NTRfMjU_5bc5acbb-09c6-413f-b1c6-199a755e003f">2.1</ix:nonFraction>% for 2021 and <ix:nonFraction unitRef="number" contextRef="ifc5564b52b29440f930fbe373023198e_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246ZTM3ZjFkN2I5ZDYzNGEyYzkyNTlmZmE2YTA0OGM0NTRfNDE_e1fb36c8-16b3-485e-b755-3f0c819f05fb">2.0</ix:nonFraction>% for 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib90c748be7c2480295ad0c48f90c8398_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktMi0xLTEtMTU1NjM4_1640f868-7f39-4ca5-9977-4d90b495d986">1,051</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc5564b52b29440f930fbe373023198e_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktNC0xLTEtMTU1NjM4_90f3c8fe-4edf-4f31-a50f-bf35b94f4cc2">1,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2028-2032 (<ix:nonFraction unitRef="number" contextRef="i91d3d8e7604d481c8c76134979113fe2_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNmOGI2YjkxMmJhNjQwOTI4Nzg0OWQzZjAwZWY4NmQ3XzI1_645cd45c-4933-401d-a097-c37b43753d07">3.1</ix:nonFraction>% for 2021 and <ix:nonFraction unitRef="number" contextRef="i245fc7da45bc4ff69d0b71a3f9034fcd_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNmOGI2YjkxMmJhNjQwOTI4Nzg0OWQzZjAwZWY4NmQ3XzE1OTQyOTE4NjAyODI4_d3c3faa4-8b9e-405e-9807-5a2dcc004061">3.4</ix:nonFraction>% for 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91d3d8e7604d481c8c76134979113fe2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTItMS0xLTE1NTYzOA_6fca44e4-b736-4987-9c3f-e893b305702a">6,660</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245fc7da45bc4ff69d0b71a3f9034fcd_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTQtMS0xLTE1NTYzOA_46b00bbe-4e01-4c87-9349-3a379faccfac">5,660</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2033-2037 (<ix:nonFraction unitRef="number" contextRef="i15b85141bb6247309c0b1758b23b1d09_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjFmMjAwN2Q5NWIyNzQzOGU5NjMwNjRhOTQyMzExMTM3XzI1_b6c851e0-7c83-4dde-8b8b-321402a471d4"><ix:nonFraction unitRef="number" contextRef="iaf8cbda9015c407c87c364cc6e12a77d_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjFmMjAwN2Q5NWIyNzQzOGU5NjMwNjRhOTQyMzExMTM3XzI1_e75b8177-077a-4cbe-99bc-0697e91da370">5.6</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8cbda9015c407c87c364cc6e12a77d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTItMS0xLTE1NTYzOA_3392dd72-76cf-4346-a4cd-9e251247e3a7">4,250</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b85141bb6247309c0b1758b23b1d09_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTQtMS0xLTE1NTYzOA_d74a31c6-18cc-4961-a384-eb07aee3deba">4,250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2038-2042 (<ix:nonFraction unitRef="number" contextRef="icb5bd2da85b845cfa033f3fccf9badef_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNkMGMwMjViODQxNjQ1ZWRhZDQ1M2EzZTk5MDE3NjAxXzI1_cff89260-8877-4fbf-a986-a75ad2d0f274"><ix:nonFraction unitRef="number" contextRef="i9525871ed73f44d6aa391c6a1148f943_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNkMGMwMjViODQxNjQ1ZWRhZDQ1M2EzZTk5MDE3NjAxXzI1_de86f4f5-4191-4d96-b380-28c05c008163">5.5</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9525871ed73f44d6aa391c6a1148f943_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTItMS0xLTE1NTYzOA_b25db178-d4c2-4ac8-9cac-d1a55d301b7e">6,079</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5bd2da85b845cfa033f3fccf9badef_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTQtMS0xLTE1NTYzOA_ff99bbe6-7c9a-4b4c-8bc2-f3728199cded">6,086</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2043-2047 (<ix:nonFraction unitRef="number" contextRef="i21459a6d65ad49e68898cea099e9eefe_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmZiZDAyYmU2ZGQ2ODRlNTNiNGZjMTNiM2I5NTkzMWYwXzI1_64ab3ffb-09bb-47ef-bd56-cb7bb5ddda7e"><ix:nonFraction unitRef="number" contextRef="i6fc4b12027964c209dd3f92de86d4757_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmZiZDAyYmU2ZGQ2ODRlNTNiNGZjMTNiM2I5NTkzMWYwXzI1_7f2710f4-7f2f-4ebb-a01e-d77504c175c9">3.7</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc4b12027964c209dd3f92de86d4757_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTItMS0xLTE1NTYzOA_3d4bdd3c-b945-42b3-b90d-4cfaa664fc6b">4,858</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21459a6d65ad49e68898cea099e9eefe_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTQtMS0xLTE1NTYzOA_d35c410f-2d27-42d9-8423-3b7309cd6101">4,878</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2048-2050 (<ix:nonFraction unitRef="number" contextRef="if76ee4034a204733a425e8616536a46d_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTIzNjk4Mi90ZXh0cmVnaW9uOmYzN2E1ZTViNzFhOTQ0NDBiNTI1OTFmODhjYWVjYjFjXzEyMDk0NjI3OTA1NTY2_6563e6ae-df5b-476c-a07b-cbf636aadca2"><ix:nonFraction unitRef="number" contextRef="i4b3c3f8d66c14cbc8ae2209a47f7b04f_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTIzNjk4Mi90ZXh0cmVnaW9uOmYzN2E1ZTViNzFhOTQ0NDBiNTI1OTFmODhjYWVjYjFjXzEyMDk0NjI3OTA1NTY2_7f8c62fe-5eef-49b6-af2d-eb5f5e15e7a1">3.6</ix:nonFraction></ix:nonFraction>% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3c3f8d66c14cbc8ae2209a47f7b04f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTItMS0xLTIzNzA5Mw_aa2c053a-6975-4f1b-aaee-fb28d2dd91aa">3,500</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if76ee4034a204733a425e8616536a46d_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTQtMS0xLTIzNzYyMw_3eb73003-d726-4ef6-aaae-823e33346740">3,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE0LTItMS0xLTE1NTYzOA_95383b03-1cc5-4c52-bb0a-4f9bffaa43a6">34,948</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE0LTQtMS0xLTE1NTYzOA_08dd2c52-ee4d-475e-adf4-7017031bf4c5">35,774</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE1LTItMS0xLTE1NTYzOA_2f2e27e2-798f-4868-bb36-1669fbffb815">1,438</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231" decimals="-6" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE1LTQtMS0xLTE1NTYzOA_6bc84e75-1548-44ad-b5f9-5671485eb369">1,562</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE2LTItMS0xLTE1NTYzOA_b030497a-0441-45c2-87e7-81e7bfb9d223">195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE2LTQtMS0xLTE1NTYzOA_4b5ea304-4217-4cf8-97d9-2df27314d56b">207</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE3LTItMS0xLTE1NTYzOA_fd341ed1-22de-443d-93ed-eefcd9d3db19">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231" decimals="-6" name="us-gaap:OtherLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE3LTQtMS0xLTE1NTYzOA_25cbe2af-6246-4bb8-ab9a-c5459102df1f">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE4LTItMS0xLTE1NTYzOA_ecbf7fd9-65f9-4dac-be8f-c1068ac85142">36,195</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE4LTQtMS0xLTE1NTYzOA_0491606f-db1c-4db1-ae54-c4185dc3bf68">37,133</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (<ix:nonFraction unitRef="number" contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmRmMGQyNDkzZGVlZDQ0NzQ4NTc4Y2ExODAyOTQxMTY3XzEwNA_8953588b-5a17-463d-b98a-f6809cf31ea0">1.0</ix:nonFraction>% for 2021 and <ix:nonFraction unitRef="number" contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231" decimals="3" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmRmMGQyNDkzZGVlZDQ0NzQ4NTc4Y2ExODAyOTQxMTY3XzExMQ_bac68bde-7d76-4f00-825b-2a8834a35879">2.6</ix:nonFraction>% for 2020))</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTItMS0xLTE1NTYzOA_0ead3812-90db-4268-9681-e8d5f95c3317">1,636</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTQtMS0xLTE1NTYzOA_5e8d987f-bbf5-4a3b-ab1b-12e28dcc823c">2,002</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjg_2bdbd7b3-002f-414d-9e23-4b1958cb6998" footnoteRole="http://www.xbrl.org/2003/role/footnote">Reclassified to the current portion of long-term debt.</ix:footnote></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our long-term debt outlined in the above table is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Issuances</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.615%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In August 2021, we issued the following senior unsecured notes at an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzAtMC0xLTEtMTcyNTAyL3RleHRyZWdpb246NmM2MTAyM2E5NzBmNGI5YWI4MTIyZWU0NjlhZGM4NzdfMTE0_f41761c6-511a-489b-a2c4-d80f35398370">1.79</ix:nonFraction>%:</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246Y2IyMGJkMzcyODA4NGEwMmJmZTljMDUyMTRiMWZjNmNfMTUzOTMxNjI3ODg4ODA_775c18f7-b166-4b7f-9eb2-d8e4c8d70788">1.750</ix:nonFraction>%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August&#160;18, 2031</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktNC0xLTEtMTU1NjM4_c41e5f42-b905-4960-9834-889541822283">1,000</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjk_7317c2e6-d737-4f5f-88f6-e7ca9d4c840d" footnoteRole="http://www.xbrl.org/2003/role/footnote">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</ix:footnote></span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In May 2020, we completed a public offering of $<ix:nonFraction unitRef="usd" contextRef="ie5c6cb1e41494eb09f678d0edb941748_I20200531" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3NDk_27caf779-76c6-46fe-a665-925a0ed3328c">4.0</ix:nonFraction> billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of <ix:nonFraction unitRef="number" contextRef="ie5c6cb1e41494eb09f678d0edb941748_I20200531" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzY1OTcwNjk3NzAyMTQ_4e569f24-27d0-4ece-a29d-74396502d91a">2.11</ix:nonFraction>% and in March 2020, we completed a public offering of $<ix:nonFraction unitRef="usd" contextRef="i9d7b65d44132448f82b9c8c9f19d2196_I20200331" decimals="-7" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3Njc_19936d0f-4749-4490-af2a-4767afae1dec">1.25</ix:nonFraction> billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of <ix:nonFraction unitRef="number" contextRef="i9d7b65d44132448f82b9c8c9f19d2196_I20200331" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3ODY_c3ee08fb-68f2-40a1-9e23-44acb31e56f8">2.67</ix:nonFraction>%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">In March 2019, we completed a public offering of $<ix:nonFraction unitRef="usd" contextRef="i7b576060fcf349178ba58a38684ce7d4_I20190331" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3OTQ_00f77a93-d52b-401a-859c-a7b63e781603">5.0</ix:nonFraction>&#160;billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of <ix:nonFraction unitRef="number" contextRef="i7b576060fcf349178ba58a38684ce7d4_I20190331" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU4MjA_c27881a8-f2b5-4e69-9b30-73d0526701a0">3.57</ix:nonFraction>%.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i725ea94a55f54a2589452a8ffb80e515" continuedAt="i7d08860cde864ed890ebbcdbea6c5f50"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Retirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2020, we repurchased all $<ix:nonFraction unitRef="usd" contextRef="i819cd9fe271b4f23b98c4aa8123518f4_I20201130" decimals="-7" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEwMTM_40cf44c3-8912-43d0-bbdd-fba3132755b6">1.15</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i764ea60e3c5843d187463c0e16bc3a31_I20201130" decimals="-6" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEwMjA_0cc7260d-112f-4e32-bd31-983315722431">342</ix:nonFraction> million principal amount outstanding of the <ix:nonFraction unitRef="number" contextRef="i819cd9fe271b4f23b98c4aa8123518f4_I20201130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEwNTk_7a88895b-f224-4166-8d0d-50de6f3b1af8">1.95</ix:nonFraction>% senior unsecured notes due June 2021 and <ix:nonFraction unitRef="number" contextRef="i764ea60e3c5843d187463c0e16bc3a31_I20201130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzExMDM_17d59131-de28-493e-aa3b-8f9122da050e">5.80</ix:nonFraction>% senior unsecured notes due August 2023 and recorded a total net loss of $<ix:nonFraction unitRef="usd" contextRef="i44be768342d5410a8bc44e78dbfd764a_D20201101-20201130" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzExNzg_a1a0d450-cdde-4a6d-bc7e-b9619bef4c94">36</ix:nonFraction>&#160;million, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In March 2020, we repurchased at par all $<ix:nonFraction unitRef="usd" contextRef="ibffce84ee6544fab8b3ff9dad69b30c5_I20200331" decimals="-6" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEyNzE_260c3f8a-941a-466c-8875-53a6f44490c9">1.065</ix:nonFraction> billion principal amount outstanding of our senior unsecured notes due in 2047.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In January 2019, we repurchased all &#8364;<ix:nonFraction unitRef="eur" contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131" decimals="-8" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEzODI_aa7ec76b-a26d-449f-b356-fbf64c0f0c09">1.1</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131" decimals="-8" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEzODY_0d1dbf69-5ae9-4c84-88a4-2ad559fb7514">1.3</ix:nonFraction> billion) principal amount outstanding of the <ix:nonFraction unitRef="number" contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE0MjY_948a17f8-66dd-4695-800a-ae02a1c38b04">5.75</ix:nonFraction>% euro-denominated debt due June 2021 at a redemption value of &#8364;<ix:nonFraction unitRef="eur" contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE0OTA_89c5cc7b-9878-4ec6-b7d7-3f19caaff171">1.3</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131" decimals="-8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE0OTQ_5d4554ce-3149-4916-b266-33df8d3a5609">1.5</ix:nonFraction> billion). We recorded a net loss of $<ix:nonFraction unitRef="usd" contextRef="i8dd2fabc2dd040398c9f16166684d63e_D20190101-20190131" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE1MjU_b28ffa13-43c2-4f0d-8841-fdf54db8cca9">138</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which included the related termination of cross currency swaps</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_196"></div><ix:continuation id="i7d08860cde864ed890ebbcdbea6c5f50" continuedAt="ia3770d96c0cb4ab99dc0b66a40811aa7"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen and Canadian dollar. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We hedge a portion of our forecasted intercompany inventory sales denominated in euro, Japanese yen, Canadian dollar, Chinese renminbi, U.K. pound and Australian dollar for up to <ix:nonNumeric contextRef="ie2c27ab7b79c44eb8dc5cacfdfc2c180_D20210101-20211231" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0Xzc3OA_45b1afc6-ae47-4b74-820e-0e04769a33cb">two years</ix:nonNumeric>.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Under certain market conditions, we may seek to protect against possible declines in the reported net investments of our foreign business entities.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in fair value are reported in earnings or in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, depending on the nature and purpose of the financial instrument (hedge or offset relationship). For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an amortization approach in earnings. The hedge relationships are as follows: </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged item. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Generally, we record in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts into earnings in the same period or periods during which the hedged transaction affects earnings. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We record in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;Foreign currency translation adjustments, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses immediately into earnings along with the earnings impact of the items they generally offset. These contracts take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognize the change in fair value on interest rate contracts that are designated as fair value hedges in earnings, as well as the offsetting earnings impact of the hedged risk attributable to the hedged item.</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MjA_9f2334c4-592e-4835-9602-159897de168a" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MjE_6ab3c43d-1ddd-41dd-a3c4-df0a5490153a" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NDA_d23618ef-4e01-4643-a818-5f8150461a1d" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:40.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.855%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.858%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6795e8aaa24dacb586776b212b0467_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMi0xLTEtMTU1NjM4_8dd5e7fe-af80-4f7e-8aae-6bcbf03bcbba">29,576</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6795e8aaa24dacb586776b212b0467_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNC0xLTEtMTU1NjM4_d2ea657c-d7cb-4f42-b560-3a7013368f69">787</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe6795e8aaa24dacb586776b212b0467_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNi0xLTEtMTU1NjM4_23f14970-65b7-4f45-b3d0-015d907672b2">717</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5642d601e9b4575855e7055a2179740_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtOC0xLTEtMTU1NjM4_535dfa3d-1e8c-4ba6-b772-d7a9d3638050">24,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5642d601e9b4575855e7055a2179740_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTAtMS0xLTE1NTYzOA_d6e3fb05-0b79-4e60-b252-30ba3f67fce4">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5642d601e9b4575855e7055a2179740_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTItMS0xLTE1NTYzOA_26719813-b100-4a9c-ad1e-f487528d7291">1,005</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5da43009894cfcbe030a782ed8ab5c_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtMi0xLTEtMTU1NjM4_b4e82fbb-768a-47e6-a64f-4a0681a2ed7a">2,250</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5da43009894cfcbe030a782ed8ab5c_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtNC0xLTEtMTU1NjM4_d3e4c685-6e04-441c-961b-f6ad46fe72b1">21</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb5da43009894cfcbe030a782ed8ab5c_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtNi0xLTEtMTU1NjM4_528119e3-4d66-4c49-845f-71d10c2b7d61">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f629b69199e405fba72ae99793d09db_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtOC0xLTEtMTU1NjM4_dd23ce44-4734-4589-98b9-add943de0a9c">1,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f629b69199e405fba72ae99793d09db_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtMTAtMS0xLTE1NTYzOA_cf968d56-aca5-4d93-a025-227011734cb6">135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f629b69199e405fba72ae99793d09db_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtMTItMS0xLTE1NTYzOA_acb49c74-3641-4d05-b179-7bc720fc8774">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e05b819b13428c8901fb90ffc12e0d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctNC0xLTEtMTU1NjM4_50a8677e-88a4-47e7-95fa-90a3f369d076">808</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e05b819b13428c8901fb90ffc12e0d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctNi0xLTEtMTU1NjM4_83c5c93f-ab8a-4dff-8d8b-0ac6796f69fb">717</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb95eee963804a9da724fc0b9a933126_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctMTAtMS0xLTE1NTYzOA_b2ca0144-80b2-4062-8c6f-26cbc70042f9">280</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb95eee963804a9da724fc0b9a933126_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctMTItMS0xLTE1NTYzOA_f549fc65-d5df-461a-9222-3b43a3597a60">1,005</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80221d1eb71049dd901d6934d2a813dc_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTItMS0xLTE1NTYzOA_79078ed1-0ab7-477c-9e6a-d444434b945a">21,419</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80221d1eb71049dd901d6934d2a813dc_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTQtMS0xLTE1NTYzOA_13c92ca5-d2e6-4a5d-af84-f6cb7976526e">160</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80221d1eb71049dd901d6934d2a813dc_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTYtMS0xLTE1NTYzOA_945f829a-a77a-4f6a-88c9-5305bcfd6d34">164</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50751deda7b94646b1c4601f55800d04_I20201231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTgtMS0xLTE1NTYzOA_03001d41-44e1-4080-a2ab-aa7af1d510e6">15,063</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50751deda7b94646b1c4601f55800d04_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTEwLTEtMS0xNTU2Mzg_0c88de47-271d-4372-9cc0-daa73a34e621">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50751deda7b94646b1c4601f55800d04_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTEyLTEtMS0xNTU2Mzg_d08e1020-d1fd-4502-bdc1-6e3b4d6ce810">95</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTQtMS0xLTE1NTYzOA_fb0ca067-97ba-45b3-bd82-7730caa86577">968</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTYtMS0xLTE1NTYzOA_39cf4dbc-e7bd-44e7-a05a-db37521a6298">881</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTEwLTEtMS0xNTU2Mzg_ba5856d9-d299-45e7-bcfa-75cef78df917">373</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTEyLTEtMS0xNTU2Mzg_80fe4a72-b604-41b7-9758-967fbb0467fb">1,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d" footnoteRole="http://www.xbrl.org/2003/role/footnote">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $<ix:nonFraction unitRef="usd" contextRef="ia09f964de2c74f4480c86cb376df89cc_I20211231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM1MjE_5acd3e1c-f89d-46cd-91e7-ba983acc914e">4.8</ix:nonFraction> billion as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i256d1411f2e24c3dbb0fff716df03a28_I20201231" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM1Mzc_02c1b343-657f-4111-81a7-1d26c914232c">5.0</ix:nonFraction> billion as of December 31, 2020.</ix:footnote></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia3770d96c0cb4ab99dc0b66a40811aa7" continuedAt="i29f6a50bd5624e978d21e3c90dd7e868"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NDI_988337c8-9372-4570-b0f2-2a453d3cfe1c" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br/>Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94">488</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0">649</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51958a6058fb4561962481a91445c919_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf">173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dfe78c0227242da8d1e000875a849f9_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432">77</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b659aec1f844db2a05972343ce9b28e_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375">38</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf57de0273184de19e0ad20b261a65ce_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca">55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b39b578b49438883023557a0dafa81_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8">38</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a733f3976f84308acb3ea5484b8f248_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d6c69496dfc4b09a0f1e641b148beb4_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktMi0xLTEtMTU1NjM4_405037fa-97c4-4b99-97b5-1572a2575232">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491b1222430d4a789c206cbc43deb5e5_D20200101-20201231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktNC0xLTEtMTU1NjM4_b271c359-33bf-4a28-9b00-fa0f9401e3ab">369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6c69496dfc4b09a0f1e641b148beb4_D20210101-20211231" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTItMS0xLTE1NTYzOA_28876c1f-28e3-452b-93e2-c007e4934d1f">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i491b1222430d4a789c206cbc43deb5e5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTQtMS0xLTE1NTYzOA_aa828aee-7b1e-4248-910d-fe1d51c6c6af">369</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTYtMS0xLTE1NTYzOA_c68c8ee5-011e-4dc7-86e5-aad7661b831f">468</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTgtMS0xLTE1NTYzOA_6e799da1-2a95-45a6-b1fb-6b0cdd11fcd7">501</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51958a6058fb4561962481a91445c919_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTEwLTEtMS0xNTU2Mzg_b9cf7014-7622-4266-bc4f-c827c6e37cb2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07fb7c4b4ddb4737a9d1ce7c1eef3b72_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774">52</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i072201acff8f4a2a8a8840f832ffafad_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6ccc570ab144e78a6500343885c124_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2">109</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabe7be2f9ab543b2823384dc71197c46_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be3ad34af1447dd989b5ed287902d69_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTYtMS0xLTE1NTYzOA_7c714191-b0a7-4358-88cb-92054d43fc7f">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f72bb2019c143ebb3750784176bb259_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTgtMS0xLTE1NTYzOA_ecbe1641-b29d-48d0-9ddf-cbd51d19a42b">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73fd8308cd7540aab95e1803c2e1110a_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTEwLTEtMS0xNTU2Mzg_e1c3d9bb-c8bb-401f-85f1-4325c3b51baa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e28876e1ad94a04ba445e3810de2781_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a">86</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16480fd269184b4aa44edd9f8afb1421_D20200101-20201231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3">183</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a9736e786f4e32b7b3bb0b15bf0fb6_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie224dcd349da476b855b2421bb0a0132_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTItMS0xLTE1NTYzOA_d1ade32c-1b05-4905-aa93-36e64fc6a13b">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice3bec2ad3a649d58890db5c58d3e893_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTQtMS0xLTE1NTYzOA_28d7ee0d-cb9f-4b69-8080-ff9068ce947e">178</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a">12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53b2599306346b5a4ab30f2665dab82_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17f9a88a6c804b04a3204e7b05960707_D20200101-20201231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99d15499afc94f0f88944990ff7e08fa_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTItMS0xLTE1NTYzOA_19a2a01e-f627-4122-9470-6414cdd9c8c2">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dd3ecfac844087a740d27d7e403e89_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTQtMS0xLTE1NTYzOA_0211c1c4-f749-4f17-adca-203d6d94039d">178</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTYtMS0xLTE1NTYzOA_4faca393-6869-4ebe-8b22-d8cb925c1d64">1,210</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTgtMS0xLTE1NTYzOA_3651a24b-22e2-46d0-868b-1ae4481d2de0">1,077</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib53b2599306346b5a4ab30f2665dab82_D20210101-20211231" decimals="-6" sign="-" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEwLTEtMS0xNTU2Mzg_1935d6fe-b15b-4323-8d03-7cb189a21e32">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17f9a88a6c804b04a3204e7b05960707_D20200101-20201231" decimals="-6" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEyLTEtMS0xNTU2Mzg_5564e357-a498-4e15-bcdf-ee4d239a8744">133</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions&#8212;net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710" continuedAt="i94fe309fc7da4b9493d61b675ca73fb3" footnoteRole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI into COS were:</ix:footnote></span></div><ix:continuation id="i94fe309fc7da4b9493d61b675ca73fb3"><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net loss of $<ix:nonFraction unitRef="usd" contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM5NDY_756947b2-ff01-4e85-9822-5130790587b6">89</ix:nonFraction> million in 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net gain of $<ix:nonFraction unitRef="usd" contextRef="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQwNTY_791d08fe-20d0-4e18-baa7-0d642f352005">172</ix:nonFraction> million in 2020 (including a gain of $<ix:nonFraction unitRef="usd" contextRef="i7df24c7dea094c21834367203566accb_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQwODQ_57ded72b-dff8-4e3e-8925-3813cf7ba2c5">22</ix:nonFraction>&#160;million reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQzMTc_a7549a57-e51a-40f0-ba09-da36da4652b3">362</ix:nonFraction> million within the next 12 months into income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately <ix:nonNumeric contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MzU_39acac43-0466-4c5e-a404-9e8e2fd9381d">21</ix:nonNumeric> years and relates to foreign currency debt.</span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" footnoteRole="http://www.xbrl.org/2003/role/footnote">The amounts reclassified from OCI were reclassified into OID.</ix:footnote></span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce" footnoteRole="http://www.xbrl.org/2003/role/footnote">Short-term borrowings and long-term debt include foreign currency borrowings which are used as net investment hedges. The short-term borrowings carrying value as of December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ifabc11d015734342b4ec641fcb91a048_I20211231" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MTk_fc1259e5-e547-477d-9b4f-c27a7b71382c">1.1</ix:nonFraction> billion. The long-term debt carrying values as of December 31, 2021 and December 31, 2020 were $<ix:nonFraction unitRef="usd" contextRef="ifabc11d015734342b4ec641fcb91a048_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MDQ_a96e55fe-4b47-4ad9-802b-86197b55d6a2">844</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81cf4819818d418f86a5c4e9f3aa0dd2_I20201231" decimals="-8" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MDE_cb9a7a82-c469-4b05-b6b4-06fecb2a0e0d">2.1</ix:nonFraction> billion, respectively.</ix:footnote></span></div></ix:nonNumeric><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MjY_b59afd0e-06ff-4a1c-9742-a1ed046e86ca" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTI_f3216551-17ac-4bf2-91dd-54a51e342511" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:24.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair<br/>Value Hedging Adjustment<br/>Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair <br/>Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active<br/>Hedging<br/>Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd276ef364814442a7a5f98817403b1b_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMi0xLTEtMTU1NjM4_ae4ec295-92df-44ec-931c-f072f3457cad">2,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd276ef364814442a7a5f98817403b1b_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtNC0xLTEtMTU1NjM4_4ed5ccb5-f4e6-4137-82de-8a1a4cc601ba">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd276ef364814442a7a5f98817403b1b_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtNi0xLTEtMTU1NjM4_a949026c-49f6-45ad-8d13-b2af62af1b52">1,154</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b05567ffb6747f98016146f80cbafbe_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtOC0xLTEtMTU1NjM4_eebcdce6-a625-447a-a666-c34372d924ab">2,016</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b05567ffb6747f98016146f80cbafbe_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMTAtMS0xLTE1NTYzOA_949d4adb-f694-4459-b52a-2c9c579fa46e">117</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b05567ffb6747f98016146f80cbafbe_I20201231" decimals="-6" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMTItMS0xLTE1NTYzOA_768449e4-bd9e-425d-9688-cd07b05f371d">1,149</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4Mjc_73f8b4d4-3c0f-4f3a-a283-8ce485fdaac1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</ix:footnote></span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_199"></div><ix:continuation id="i29f6a50bd5624e978d21e3c90dd7e868" continuedAt="i9832214a9b954502b7560ba364f31536"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">.</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On an ongoing basis, we monitor and review the credit risk of our customers, financial institutions and exposures in our investment portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our trade accounts receivable, we monitor the creditworthiness of our customers to which we grant credit in the normal course of business. In general, there is no requirement for collateral from customers. For additional information on our trade accounts receivable and </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i9832214a9b954502b7560ba364f31536"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">allowance for credit losses, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our investments, we monitor concentrations of credit risk associated with government, government agency, and corporate issuers of securities. Investments are placed in instruments that are investment grade and are primarily short in duration. Exposure limits are established to limit a concentration with any single credit counterparty. As of December 31, 2021, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by the U.S., Canada, Japan, U.K., Germany, France, Australia, and Switzerland.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association (ISDA) master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of December 31, 2021, the aggregate fair value of these derivative financial instruments that are in a net payable position was $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzE4ODI_623323a4-efe9-4798-8b8c-2176d13bf386">372</ix:nonFraction> million, for which we have posted collateral of $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzE5MjU_c2c75dcb-3938-4080-ba32-f79da31092df">382</ix:nonFraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As of December 31, 2021, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:DerivativeNetReceivablePositionAggregateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzEyMDk0NjI3OTA4MjM5_25a09e34-c6dc-499d-bef9-3e2fcaa2ae56">477</ix:nonFraction> million, for which we have received collateral of $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:SecuritiesReceivedAsCollateral" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzIxNjk_d894deff-e3dd-4be5-87d8-598e56336b9d">581</ix:nonFraction> million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></div></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_202"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 8. </span><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzQzOTgwNDY1MTIzODk_8b96f075-cbf9-4984-9eb3-505b9bf9f625" continuedAt="i14b6cc8e5d514beca9957a9286cd4b97" escape="true">Other Financial Information</ix:nonNumeric></span></div><ix:continuation id="i14b6cc8e5d514beca9957a9286cd4b97" continuedAt="idd56bf539df24fbd9f8b6b07cdc5a6ef"><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.45pt;text-decoration:underline"> Inventories</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzUyNw_954b4c18-b0f4-48eb-a89a-a9491e0ba1cb" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzUyOQ_0c94fd0e-9e34-43dc-82cc-b6cd1d5f0d5f" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzMtMi0xLTEtMTU1NjM4_e3a24aee-d342-475b-89db-f7088898af81">3,641</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzMtNC0xLTEtMTU1NjM4_31cbdca8-81aa-4d6f-a6df-eee6a04cb52e">2,867</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzQtMi0xLTEtMTU1NjM4_7adb8ea4-85a8-4cf9-8a95-1b54be6b3af4">4,424</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzQtNC0xLTEtMTU1NjM4_ec03208b-2247-43af-8db0-0f3a6facffe9">4,436</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzUtMi0xLTEtMTU1NjM4_6abfa5d7-7e42-4630-a0ae-6cc09c80fd5e">994</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzUtNC0xLTEtMTU1NjM4_0e334bfe-90da-4ff3-9677-800d1fcb2f2f">716</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtMi0xLTEtMTU1NjM4_54059ecd-aa69-44bb-b887-d96f99d57bae">9,059</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtNC0xLTEtMTU1NjM4_762c2983-3a02-42e0-8d59-df56b7f5c031">8,020</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctMi0xLTEtMTU1NjM4_13d9c7d2-fd2e-4a7e-b9bb-60309e878951">939</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctNC0xLTEtMTU1NjM4_5e8f8213-8684-4d59-b1e8-3a41c24da7e9">890</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU1NQ_8fe7f8af-5095-4cd6-9f9d-0efa59c2547b" footnoteRole="http://www.xbrl.org/2003/role/footnote">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU0Mg_c50654f8-e8b0-4416-af9a-f39ecf1625c9" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></ix:footnote></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="idd56bf539df24fbd9f8b6b07cdc5a6ef" continuedAt="id1faf0dc7e8c48b2b53f2d5cac8e7968">Other current liabilities</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="id1faf0dc7e8c48b2b53f2d5cac8e7968"> includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $<ix:nonFraction unitRef="usd" contextRef="i9a02ec9594b94a0fa152afb9f34199d4_I20211231" decimals="-8" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzQ3OQ_9500e936-48c5-4d55-ab71-eb76a1caec69">9.7</ix:nonFraction>&#160;billion as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie0fe163dc007411b888238de88875679_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzQ5NQ_9d3cedfb-dcc9-4271-8b9c-f596059a964e">25</ix:nonFraction>&#160;million as of December 31, 2020.</ix:continuation> </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_205"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90ZXh0cmVnaW9uOmZiZGQ3MTlhMGI3YTQwMmVhMTZlY2E1ZGJiYWQ1MWZmXzYz_cea605d3-e890-460b-b635-b9280168fc72" continuedAt="i5fb46967c9d84ae4a55a0eb7c627a9e1" escape="true">Property, Plant and Equipment (PP&amp;E)</ix:nonNumeric></span></div><ix:continuation id="i5fb46967c9d84ae4a55a0eb7c627a9e1"><div style="margin-bottom:3pt;margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90ZXh0cmVnaW9uOmZiZGQ3MTlhMGI3YTQwMmVhMTZlY2E1ZGJiYWQ1MWZmXzQ5_44f829b4-23d8-41da-a31e-64b3c5b636ff" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:62.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.587%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Useful Lives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Years)&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7faad75e5b2e4283af9e7fd2a1138431_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzMtNC0xLTEtMTU1NjM4_d25c9bab-13b1-4199-ae43-a0e04c5a0c2d">423</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6929b7c58269479390aaeda0ef2a64ef_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzMtNi0xLTEtMTU1NjM4_b72e6ef0-7e6a-4751-a54f-2d012d4d0cf9">443</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib28e1bec91174c29b172af677b8adb54_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246ZjdhNGYwNWUxNGY5NGZiZGFkZGVmMTBkZmI0YjRhNmJfNA_8ab1f844-a9df-4bc4-ae7f-04b1ed99748e">33</ix:nonNumeric>-<ix:nonNumeric contextRef="i862ba5d064f0443ea496670357f0e14d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246ZjdhNGYwNWUxNGY5NGZiZGFkZGVmMTBkZmI0YjRhNmJfNw_31ad4268-381c-404d-890e-9b4c949a4a8f">50</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4c3ddbbd35b4a9c93f095e97b3679ae_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtNC0xLTEtMTU1NjM4_3595c07e-aa09-458f-b37e-6c3ba146d973">9,001</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a96e38f1c5942afbd2a39144f01eea9_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtNi0xLTEtMTU1NjM4_9a5242d2-12ff-4f9b-afa5-3a2ad38e5c40">8,998</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id891db98fa4a41bd8a834b3d854a897f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246NGRmN2NjMTRkMzBjNDI5Nzk1OTVkNjZiMzUyY2JiM2JfNA_38e19acd-8823-462f-a9bd-f639b48db917">8</ix:nonNumeric>-<ix:nonNumeric contextRef="ib1196e921cab43bc8fcebc72a5b56c82_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246NGRmN2NjMTRkMzBjNDI5Nzk1OTVkNjZiMzUyY2JiM2JfNw_78f84baf-4ef1-4758-8d99-997673f62b92">20</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0f9b0f72c81473eaed6b48b9824aa65_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtNC0xLTEtMTU1NjM4_70aa99f7-1031-4703-974a-f6bf6d55e9e0">12,252</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5473f4c065384253983909169cb3535b_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtNi0xLTEtMTU1NjM4_3dcd99d1-b7e6-4a39-b466-c380916a4110">11,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i533cb430fd184762a6597353269cb90c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246MDU2YjhiZmQ3Zjg2NDM3MWJiYmMyNThmNzA4ZmM1MTRfNA_035a38f3-7ff0-4e9b-85a0-166d7d4e6412">3</ix:nonNumeric>-<ix:nonNumeric contextRef="id841cfa6c6904f82aef7fd3fa2b9d2f5_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246MDU2YjhiZmQ3Zjg2NDM3MWJiYmMyNThmNzA4ZmM1MTRfNw_6dc98eaf-fbf1-4330-9a6e-4a55794ca353">12.5</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c5c5b1d3ad49599584c64b0869f298_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtNC0xLTEtMTU1NjM4_18b58f0e-1e9a-4fa9-8b90-e4cbc81c1c23">4,457</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i292ecffd1f5943b892a2111a12ad7ce2_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtNi0xLTEtMTU1NjM4_2a4cd8ea-acab-4844-910c-7bf17f1e0d09">4,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16152f7453824ee58ba88fc30ea238bd_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzctNC0xLTEtMTU1NjM4_ac92be53-05b0-4663-b44b-e255b4741b01">3,822</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i392594e0d42141e994ae16e92832c84a_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzctNi0xLTEtMTU1NjM4_d0839a16-5b0a-44c8-bede-ca48cea5914b">3,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzgtNC0xLTEtMTU1NjM4_58b14bae-89de-4d3e-a9a1-4e3ff029ff48">29,955</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzgtNi0xLTEtMTU1NjM4_b90389a7-db12-4789-a1ee-32b307d5b8d9">28,406</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzktNC0xLTEtMTU1NjM4_051bb250-3e3a-4265-a476-d59fe091df33">15,074</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzktNi0xLTEtMTU1NjM4_628ae782-3728-41ce-9714-30ebafcad0aa">14,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzEwLTQtMS0xLTE1NTYzOA_2b7ef0c9-fbbe-4d27-9d06-ae562924003e">14,882</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzEwLTYtMS0xLTE1NTYzOA_a9c2be17-0ca6-4f07-8b96-baf5faa14cc4">13,745</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90ZXh0cmVnaW9uOmZiZGQ3MTlhMGI3YTQwMmVhMTZlY2E1ZGJiYWQ1MWZmXzQ1_fc67596c-7fef-484f-8f74-dbaa4014bf5e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides long-lived assets by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38fbf9bf0a244c6846d8ca1b19c3cb9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzQtMi0xLTEtMTU1NjM4_65603bc6-06ac-4632-9597-884cdda6ebe7">8,385</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0a6cc9cf7be4281b01b2de3a7c6a65e_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzQtNC0xLTEtMTU1NjM4_46a6198d-a4c8-4dd4-a6aa-94c439ced94c">7,666</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877c3de4913144ab97a4f7a18ca1272e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzUtMi0xLTEtMTU1NjM4_eab4604a-e7e3-429b-816a-7af3b43787da">5,094</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7dfda91c8274099a7be0f74bfe932e6_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzUtNC0xLTEtMTU1NjM4_cec3b8ce-de97-424d-a361-03227c9dfa77">4,775</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d01fcc1ead34ff9ad40afc6bbf19695_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzYtMi0xLTEtMTU1NjM4_6863421b-5e02-41b6-8b36-6e9ad2c062bf">347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3062c07484944e3cba9f2336f472c327_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzYtNC0xLTEtMTU1NjM4_b9c9c11e-66df-42e8-881f-65717bdb4509">413</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ebee0abdc945fb9926a62c16c68fbc_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzctMi0xLTEtMTU1NjM4_b8eaa808-37bb-45b3-9763-a29e0eef846c">1,056</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c28b6acb28f4060af3af8398ee4be76_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzctNC0xLTEtMTU1NjM4_9e2ab058-272f-49f2-9e16-56dc13973f53">890</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzgtMi0xLTEtMTU1NjM4_8a9ff77d-13c7-4144-9849-64dc2589e90e">14,882</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzgtNC0xLTEtMTU1NjM4_22070ac9-09b1-4500-9dd1-64f4dd384446">13,745</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">82</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_208"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczODQ_dcc640fe-e48f-4a17-9f86-3f9c3d045f9d" continuedAt="ibe6516ead3bb4c40876ea92a8e059a32" escape="true">Identifiable Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="ibe6516ead3bb4c40876ea92a8e059a32" continuedAt="id26bd0ab658d48a98ab90e46830c1a3f"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Identifiable Intangible Assets</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczOTQ_94abbc71-f050-44f0-9e6f-25c4e2bdbec9" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1Xzc0MDg_5fff6c83-fcbc-409e-8f3d-dccbb8d3d186" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.213%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf1a42539e54965958a728a93c1e756_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMi0xLTEtMTU1NjM4_1db96457-241e-4457-bb5d-70a065db8f45">73,346</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bf1a42539e54965958a728a93c1e756_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNC0xLTEtMTU1NjM4_006cdb55-7f81-45c9-9480-57256a9c9967">53,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bf1a42539e54965958a728a93c1e756_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNi0xLTEtMTU1NjM4_a4dd9cc9-d0a1-4d4b-87f1-abb2ee502128">19,614</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc5354914a145cc8d158da2eb6e9aed_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtOC0xLTEtMTU1NjM4_a6383107-a58a-4a33-969c-54b74cd56a82">73,040</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfc5354914a145cc8d158da2eb6e9aed_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTAtMS0xLTE1NTYzOA_86e86249-8876-4e05-ace4-6b91dc0302da">50,532</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfc5354914a145cc8d158da2eb6e9aed_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTItMS0xLTE1NTYzOA_91798efa-c2a4-4afb-b009-5535e620a515">22,508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtMi0xLTEtMTU1NjM4_cba4d999-d117-4302-a757-1cbefacd97b6">922</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtNC0xLTEtMTU1NjM4_25821d04-b3f1-4115-92e2-f70b222a579b">807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtNi0xLTEtMTU1NjM4_802c0116-0323-4c86-af9c-ac58d6bf7027">115</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7f4f4115a4440391144e3b67630665_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtOC0xLTEtMTU1NjM4_0c59fcd5-38ef-4c63-ad0b-6aa15730f405">922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c7f4f4115a4440391144e3b67630665_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtMTAtMS0xLTE1NTYzOA_0851137a-80eb-48f0-8453-6f4fa6f672a8">774</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7f4f4115a4440391144e3b67630665_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtMTItMS0xLTE1NTYzOA_c4cc2b75-2f1b-4e97-bbe5-68df4a7b2092">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b140461d860414c8311ca9c9a1bcc99_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtMi0xLTEtMTU1NjM4_2327bb71-ae85-4397-bfb5-ec5b5ab439eb">2,284</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b140461d860414c8311ca9c9a1bcc99_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtNC0xLTEtMTU1NjM4_9b9389cf-d3af-4f6c-a7fb-37283347ae79">1,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b140461d860414c8311ca9c9a1bcc99_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtNi0xLTEtMTU1NjM4_a552659d-be55-415b-bc32-2b0fcf8bdf97">985</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041d9d29860b421d98fc6a57f3ec5050_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtOC0xLTEtMTU1NjM4_a20b3e89-7cd6-4174-a439-8adf9de1ff41">2,292</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i041d9d29860b421d98fc6a57f3ec5050_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtMTAtMS0xLTE1NTYzOA_a13ded9b-d1ad-4bdf-94b7-9f688b87ed26">1,187</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041d9d29860b421d98fc6a57f3ec5050_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtMTItMS0xLTE1NTYzOA_42f7cae2-7dfe-4a95-96db-54072798a2b5">1,106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctMi0xLTEtMTU1NjM4_23223cad-a82f-40c2-99a2-229611b54023">76,552</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctNC0xLTEtMTU1NjM4_2d4d2f82-6a72-452c-83e3-ca326c649393">55,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctNi0xLTEtMTU1NjM4_5046e14f-be5f-4e0b-b04c-5fe852a2428f">20,714</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctOC0xLTEtMTU1NjM4_0fc05bca-2cc1-4c24-966e-035a22f5a611">76,255</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctMTAtMS0xLTE1NTYzOA_26e955bc-1f0a-46c4-927c-0ffd5698c91f">52,493</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctMTItMS0xLTE1NTYzOA_2bd00522-0525-4ce0-9012-03374fe9343c">23,762</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e809c5ad84543eba6828d3d0602e30e_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktMi0xLTEtMTU1NjM4_8c73d8c2-50c8-40cf-8eab-6cc1d97d76a8">827</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e809c5ad84543eba6828d3d0602e30e_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktNi0xLTEtMTU1NjM4_756c4e74-0ba1-4ac2-8cbd-e71d510160fa">827</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210ff70401cd4760bb6335c8c08e0015_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktOC0xLTEtMTU1NjM4_33498752-ea9b-447a-902e-58cd7534e49f">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i210ff70401cd4760bb6335c8c08e0015_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktMTItMS0xLTE1NTYzOA_b1ab9b23-ca05-4540-ba7d-36247a64fd77">827</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d8008250614fd8b057a37d793a0b06_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTItMS0xLTE1NTYzOA_64aa0cd8-acfd-4166-88a8-87ef84d54e26">3,092</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d8008250614fd8b057a37d793a0b06_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTYtMS0xLTE1NTYzOA_2f13c263-f24e-4f40-ada1-c269e2fa3dc2">3,092</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d89dabae4f640e895f7324d6d8a39ad_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTgtMS0xLTE1NTYzOA_7808cdf0-f184-430d-b09d-447082a6d9c9">3,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d89dabae4f640e895f7324d6d8a39ad_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTEyLTEtMS0xNTU2Mzg_c6a4693d-9bb1-4812-aa58-a3778fa1e96e">3,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab33eff7f5d845e9a17bebbe4e745ebb_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTItMS0xLTE1NTYzOA_38493c6e-bc33-4f8e-b0e4-0b019dfc3d85">513</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab33eff7f5d845e9a17bebbe4e745ebb_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTYtMS0xLTE1NTYzOA_33b29443-c12b-4544-a4d7-5179cb4ed1d4">513</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678256d1b0484d0391cb0e64324ad0d4_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTgtMS0xLTE1NTYzOA_6d63aab0-3d6b-4b2c-8476-712a80adc931">573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678256d1b0484d0391cb0e64324ad0d4_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTEyLTEtMS0xNTU2Mzg_e23cfe04-802a-4723-b855-6152b0dd17da">573</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTItMS0xLTE1NTYzOA_45cf656c-ce26-4454-9cc9-3304c00081f6">4,432</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTYtMS0xLTE1NTYzOA_1de8e741-dfe2-4a4c-9fdc-a34fbcbf94bb">4,432</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTgtMS0xLTE1NTYzOA_f68df439-8f40-40dd-b7b4-7f26d0287496">4,575</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTEyLTEtMS0xNTU2Mzg_4a33ea88-7d66-4668-9bfb-aebd231ab821">4,575</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTItMS0xLTE1NTYzOA_ec8ed15c-853f-4f9d-9077-d757457c043f">80,984</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTQtMS0xLTE1NTYzOA_25a2f8eb-5da8-4020-ba2c-8e014a264ad9">55,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTYtMS0xLTE1NTYzOA_f9e63e0c-4405-44e8-a587-74d7b2a3a01b">25,146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTgtMS0xLTE1NTYzOA_fc3931a6-a25a-4777-b4ba-3e187909c117">80,830</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEwLTEtMS0xNTU2Mzg_256ac849-9771-4c25-922b-dee9ffa34d45">52,493</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEyLTEtMS0xNTU2Mzg_501583b2-b019-46e5-97c6-28b9baafb81e">28,337</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.24pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751" footnoteRole="http://www.xbrl.org/2003/role/footnote">The increase in the gross carrying amount primarily reflects $<ix:nonFraction unitRef="usd" contextRef="i1c7941373e994dfa8bce5cfe572bc7e4_D20210101-20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzE2NDkyNjc0NDk3NDM_f1304669-b13e-43c7-aa20-5536459254a4">500</ix:nonFraction> million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a" footnoteRole="http://www.xbrl.org/2003/role/footnote">The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.</ix:footnote></span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Developed Technology Rights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed technology rights represent the cost for developed technology acquired from third parties and can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing our commercialized products. The significant components of developed technology rights are the following: Xtandi, Prevnar 13/Prevenar 13 Infant, Braftovi/Mektovi, Premarin, Prevnar 13/Prevenar 13 Adult, Eucrisa, Orgovyx, Zavicefta, Tygacil, Bavencio, Merrem/Meronem and Comirnaty. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain prescription pharmaceutical products.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Brands</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands represent the cost for tradenames and know-how, as the products themselves do not receive patent protection. Indefinite-lived brands include Medrol and Depo-Medrol, while finite-lived brands include Zavedos and Depo-Provera.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D assets represent R&amp;D assets that have not yet received regulatory approval in a major market. The significant components of IPR&amp;D are the following: the program for the oral poly adenosine diphosphate (ADP) ribose polymerase inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part of the Medivation acquisition and assets acquired in connection with the Array acquisition. IPR&amp;D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&amp;D effort. Accordingly, during the development period after the date of acquisition, these assets are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify it out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is abandoned, the related IPR&amp;D assets will likely be written-off, and we will record an impairment charge.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D assets are high-risk assets, given the uncertain nature of R&amp;D. Accordingly, we expect that many of these IPR&amp;D assets will become impaired and be written-off at some time in the future.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Licensing Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements for developed technology and for technology in development primarily relate to out-licensing arrangements acquired from third parties, including the Array acquisition. These assets represent the cost for the license, where we acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partner. A significant component of the licensing arrangements are for out-licensing arrangements with a number of partners for oncology technology in varying stages of development that have not yet received regulatory approval in a major market. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will likely be written-off, and we will record an impairment charge.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id26bd0ab658d48a98ab90e46830c1a3f"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average life for each of our total finite-lived intangible assets is approximately <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzE2NDkyNjc0NjkwNzQ_c94b14d1-6db0-42ec-bad4-64d1490c1491">8</ix:nonNumeric> years, and for the largest component, developed technology rights, is approximately <ix:nonNumeric contextRef="icc33aaaa074a4869814243060c036a4f_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczODc_6e6de56f-3d33-4956-b9cb-734aa085825f">7</ix:nonNumeric> years. Total amortization expense for finite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzU3NjY_92638339-9cbc-4c2e-8b5f-e35e374ae20e">3.7</ix:nonFraction> billion in 2021, $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzU3NzY_7bca7a95-0889-430d-a926-2411250fa67e">3.4</ix:nonFraction> billion in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzU3ODk_928d0edc-dec4-4b68-aa48-97b090d267b0">4.5</ix:nonFraction> billion in 2019.</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczOTg_1ce8d4de-c8c2-4ef6-8848-1e1e55f8f9ab" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:40.604%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the expected annual amortization expense:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItMi0xLTEtMTU1NjM4_cf34a2db-4816-4a2e-8ea6-214ed9c950ae">3,279</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItNC0xLTEtMTU1NjM4_7899adca-747f-4fea-8d5f-9e772108d762">2,936</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItNi0xLTEtMTU1NjM4_844d3997-ca46-4d29-bec1-9d173b46a055">2,686</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItOC0xLTEtMTU1NjM4_32913ddc-d61c-456b-949d-6725abc73e0e">2,500</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItMTAtMS0xLTE1NTYzOA_f69587e0-86f4-4b21-921c-23f82a0452cf">2,449</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:3pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Goodwill</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczOTk_d8eccc8d-2423-4762-adaf-3335dfb34eaf" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components and changes in the carrying amount of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzItMTAtMS0xLTE1NTYzOA_495466a8-c79e-4cc0-969b-e8a7379b21b8">48,181</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40">727</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca">648</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzUtMTAtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614">49,556</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzYtMTAtMS0xLTE1NTYzOA_2ffcb87d-156e-488c-ab55-3b76d0184eaa">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzgtMTAtMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7">49,208</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzE_c6c9f186-f975-4b2f-9a61-23664fe96dfa" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzI_ed1f660f-a339-423e-a681-4ee8c16fd64b" footnoteRole="http://www.xbrl.org/2003/role/footnote">Other represents the impact of foreign exchange</ix:footnote>.</span></div></ix:nonNumeric></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_214"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">.</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTkz_7f59e0ab-850d-410c-a34d-c0f63374913b" continuedAt="i0b0cdddab12044008cc92ae12b0b3e60" escape="true">Pension and Postretirement Benefit Plans and Defined Contribution Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i0b0cdddab12044008cc92ae12b0b3e60" continuedAt="i78f22de967d249a69f3a2c58f160465b"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of pension and postretirement plans. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY1_9e0160e5-8c62-4dfc-b7a4-c20f49bfaa9d" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit), including those reported as part of discontinued operations for 2020 and 2019, and the changes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">for our benefit plans:</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMi0xLTEtMTU1NjM4_6c1daf5d-8267-4b8a-ab2f-21fff91102fb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtNC0xLTEtMTU1NjM4_65a99a87-bc17-4248-b5fb-3bec3bf5507f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtNi0xLTEtMTU1NjM4_11a98b2f-ec79-4b0d-ab13-fcd4cbe586c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtOC0xLTEtMTU1NjM4_082bff1b-da17-42d6-b7ae-a559e90c70f1">130</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTAtMS0xLTE1NTYzOA_34f22271-9dc8-42f9-a874-17200b9a6d16">146</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTItMS0xLTE1NTYzOA_6f51870c-acd1-4845-b650-29abb524fdbe">125</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTQtMS0xLTE1NTYzOA_e580cf7a-3e7e-47e5-aa8f-b72f0d07659f">36</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTYtMS0xLTE1NTYzOA_d0354659-f9ad-4d15-9d77-d2f7f1627ee1">38</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTgtMS0xLTE1NTYzOA_1b58234f-453b-422e-9972-e1e39fd81ce0">37</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMi0xLTEtMTU1NjM4_de3be480-f1a4-48ef-a49e-289a92854f5a">455</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctNC0xLTEtMTU1NjM4_3bb5a2fe-e5c9-445c-93ee-b377e67f8b16">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctNi0xLTEtMTU1NjM4_88831db4-58fd-44ae-ba7b-56e6288704c7">676</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctOC0xLTEtMTU1NjM4_affad6ed-70d0-4f10-b4d4-b802df1525ec">146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTAtMS0xLTE1NTYzOA_a514ced1-fa9f-4438-9d60-5ccdaccdce2a">164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTItMS0xLTE1NTYzOA_cc10349e-09bd-4ba8-8fbd-4d649707f357">215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTQtMS0xLTE1NTYzOA_ddd2ec8a-6742-429e-a95e-20b61214e5bf">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTYtMS0xLTE1NTYzOA_936eba50-f2cb-4579-8d56-4edb2b197fd6">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTgtMS0xLTE1NTYzOA_d5a68479-d496-41e9-8902-b795b2e92352">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMi0xLTEtMTU1NjM4_31794087-880d-4187-a73d-33c9a5cb4543">1,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtNC0xLTEtMTU1NjM4_2d82003e-f6a5-46c8-80bc-1c4a5c3bebe8">1,015</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtNi0xLTEtMTU1NjM4_00ff6316-7482-4e1e-852c-8b39186d15bc">890</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtOC0xLTEtMTU1NjM4_79e6a701-7e70-49da-a88e-ef0d5dd8e8f1">327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTAtMS0xLTE1NTYzOA_760b7e06-900a-46b3-b26f-2d1a7c61c1e8">314</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTItMS0xLTE1NTYzOA_1c4970b9-0d1c-41e8-8b44-cc77bcbf59ce">318</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTQtMS0xLTE1NTYzOA_b7cf010d-3d1e-4219-82be-ce41129669cc">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTYtMS0xLTE1NTYzOA_1b2fd7a2-bcab-43f0-9060-5420993652ff">36</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTgtMS0xLTE1NTYzOA_14e37f98-045d-445d-881d-890f4d6dd0e8">33</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMi0xLTEtMTU1NjM4_a1cd854f-5f4d-4893-988c-8d75b5dc1091">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktNC0xLTEtMTU1NjM4_17d63f6f-920e-418e-9671-3674872cb11a">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktNi0xLTEtMTU1NjM4_f19392f3-4eff-498c-a88d-f9ef89ed8015">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktOC0xLTEtMTU1NjM4_43535e71-a702-4f86-a074-006fb13e9376">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTAtMS0xLTE1NTYzOA_e705ce7c-bf42-4da6-b2f0-8b5f004a8e1d">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTItMS0xLTE1NTYzOA_2d0c3000-7ddb-40f4-924a-f8bd975115c8">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTQtMS0xLTE1NTYzOA_f21a7fa9-7a85-4acf-bf83-db6d673f6bfe">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTYtMS0xLTE1NTYzOA_f445bd6e-882c-4a73-aac8-862f4fc7d770">170</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTgtMS0xLTE1NTYzOA_fc819e50-430d-4b3a-93d6-d580b04a6c83">173</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1OTYwNQ_4b55c588-fcbb-46e2-b19a-c1eca06a2fc3">684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1OTYwNQ_6cd5bbd6-d390-47be-b4d1-7c6fb8217b14">1,152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1OTYwNQ_111bd224-a3dd-4f82-bb71-0880092a2fdc">284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1OTYwNQ_522f8a54-1dd9-44eb-97f7-44c711e37e6b">690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTk2MDU_243c4254-90bb-4790-a9b0-be9c0a8e38ad">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTk2MDU_ca00c7b3-bb10-422e-8c22-eefaeaf2ba59">669</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTk2MDU_12f5cf08-b296-4d3d-8e58-d4edd5422f7c">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTk2MDU_f2d9c413-bb86-4b22-92e4-ff5805dbf0ea">165</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTk2MDU_55f4db3e-a874-4ef3-bfc6-ff9a9d08c0ce">118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1NTYzOA_adbf45c2-ad70-4f58-834d-465ae27a2995">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1NTYzOA_afb0f5e0-ba51-4e40-9992-bd5721f4d64e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1NTYzOA_752392a0-57cf-4ba7-83a9-c2d9e7bced5b">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1NTYzOA_249c72c3-28f0-4d20-bdda-64853bc97152">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTU2Mzg_e3f9eae7-fd47-401c-b505-100bb2634a80">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTU2Mzg_20590064-aaf2-4fde-bde5-df117d3fafa6">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTU2Mzg_e877984d-f911-43c8-9f25-79257bbff51c">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTU2Mzg_150066e3-857b-4391-a37e-7541db480583">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTU2Mzg_562c3e5a-70a1-4b1a-aad0-fbc08d34d9e4">62</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTItMS0xLTE1NTYzOA_c0137553-8fab-4393-ad90-5d81b79957d6">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTQtMS0xLTE1NTYzOA_d9a6316f-8821-4fdd-8761-120424d5f890">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTYtMS0xLTE1NTYzOA_0c92ff0e-b99c-4116-8298-77a730d1c3ee">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTgtMS0xLTE1NTYzOA_a4226001-61d5-4891-b634-eadd543fabe9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTEwLTEtMS0xNTU2Mzg_81f3b49a-75f3-4752-99c8-0b99a77d2dd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTEyLTEtMS0xNTU2Mzg_a0c41b71-0695-4785-a6b2-75f7bbf9fd83">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTE0LTEtMS0xNTU2Mzg_df2f87b9-0eae-4eb2-bd6c-cd2b9a50b882">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTE2LTEtMS0xNTU2Mzg_84d54169-15ee-41fa-ba9e-d0eba9bb3929">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTE4LTEtMS0xNTU2Mzg_360911dc-736e-4482-897e-295cc721773b">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTItMS0xLTE1NTYzOA_e05ac771-319a-4690-bf31-86c65bf2a238">1,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTQtMS0xLTE1NTYzOA_78be34d1-cf35-4f2a-abdb-bafc33a3920d">668</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTYtMS0xLTE1NTYzOA_0691ccf6-9103-4489-8ff6-0769b22871ab">82</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTgtMS0xLTE1NTYzOA_f8d460b7-3066-474c-bc19-2ec3e0d82426">746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTEwLTEtMS0xNTU2Mzg_452d2606-f7df-4676-b742-803ddaa238d8">141</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTEyLTEtMS0xNTU2Mzg_e55d5c78-5b35-4482-a00e-637953e94731">686</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTE0LTEtMS0xNTU2Mzg_cf93e3d1-6ec2-4969-bf6d-8593a5dd9c02">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTE2LTEtMS0xNTU2Mzg_01c47758-eb97-4b0a-b963-d0bd2d47f683">282</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTE4LTEtMS0xNTU2Mzg_b6c4b24a-9811-480f-8511-ac57778563f2">271</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost/(credit) reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTItMS0xLTE1NTYzOA_137238f1-c3d9-46cf-8457-ee44e3f68bfe">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTQtMS0xLTE1NTYzOA_b0ea5b7a-04af-4b77-a374-2f988fa5d26b">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTYtMS0xLTE1NTYzOA_d972cdf7-a8e6-4b4e-a3cd-2737a78b4598">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTgtMS0xLTE1NTYzOA_e540e962-0465-46c8-a635-42cfa94a6ae9">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTEwLTEtMS0xNTU2Mzg_4ae9bcb3-9180-4b16-9a99-7cdb6c8cdec3">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTEyLTEtMS0xNTU2Mzg_ea222b8d-fee4-472c-930d-b9935951842f">21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTE0LTEtMS0xNTU2Mzg_fd01931a-7fc0-43c5-9eea-f2b66fe9ff17">107</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTE2LTEtMS0xNTU2Mzg_5a7fd774-44d3-4ed4-a31a-a9a1ce749bbc">114</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTE4LTEtMS0xNTU2Mzg_d3fdf70e-858b-497d-90fd-82b03a82672e">164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost/(credit) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Comprehensive income</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTItMS0xLTE1NTYzOA_d819088f-a4d5-4d7f-b430-c950137a0138">1,264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTQtMS0xLTE1NTYzOA_1ec0cfda-868a-4777-843b-72e4eb0ad399">674</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTYtMS0xLTE1NTYzOA_06fd46b2-e2c5-4cc4-a955-afec785876fb">86</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTgtMS0xLTE1NTYzOA_8aba6b9a-e3d5-44d1-9f1a-3e1be7401d58">742</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTEwLTEtMS0xNTU2Mzg_3b0e3274-602a-4a99-8d09-ca3389a41f96">145</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTEyLTEtMS0xNTU2Mzg_a9af0e71-d07f-442c-8a22-9ef3757b3eb4">707</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTE0LTEtMS0xNTU2Mzg_1f3c80e2-bfe7-46fa-aece-f43e7bab56e7">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTE2LTEtMS0xNTU2Mzg_3d665274-c835-4d4d-aa89-466a14968fc6">168</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTE4LTEtMS0xNTU2Mzg_475cdeb1-306a-4665-8736-2d1d2dc76294">107</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e" footnoteRole="http://www.xbrl.org/2003/role/footnote">Reflects actuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates, and actuarial remeasurement losses in 2020 and 2019, primarily due to decreases in discount rates partially offset by favorable plan asset performance.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">84</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i78f22de967d249a69f3a2c58f160465b" continuedAt="ie69905f78cb043418b1178c55cb518fe"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Actuarial Assumptions</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTQ_1280fd2f-0c78-4c1e-a95e-6e8adfca758a" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(PERCENTAGES)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions used to determine net periodic benefit cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension plans/postretirement plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMi0xLTEtMTU1NjM4_00c2e2f7-e0a5-49d1-b5e3-825a3797effb">2.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtNC0xLTEtMTU1NjM4_78a8a5fa-9f32-415e-803e-198aefa7ec49">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtNi0xLTEtMTU1NjM4_cc6a61eb-03da-42f8-9c00-8923265b5ba0">4.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMTQtMS0xLTE1NTYzOA_22decf87-07ee-4106-96f3-5e369bfa1dd6">2.5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMTYtMS0xLTE1NTYzOA_33924467-58d1-4f11-bd08-5e33128ad4f6">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMTgtMS0xLTE1NTYzOA_bb5bf43e-3167-4a5f-9c32-3a3719286a47">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="3" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzctOC0xLTEtMTU1NjM4_769ad733-4f06-41c5-8dff-ea939d870880">1.2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="3" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzctMTAtMS0xLTE1NTYzOA_5d69e0cf-2f6d-41d2-a214-ac67b77e0585">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="3" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzctMTItMS0xLTE1NTYzOA_373b6a56-39ed-4d0c-a4ac-5aa11d4ee672">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="3" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzgtOC0xLTEtMTU1NjM4_b72b484a-d731-4064-95f0-1b2775093589">1.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="3" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzgtMTAtMS0xLTE1NTYzOA_dcb80005-7231-4767-8901-9b6df224c5ed">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="3" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzgtMTItMS0xLTE1NTYzOA_74918878-16d2-4f96-a3eb-631c573d3a4b">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMi0xLTEtMTU1NjM4_0470de32-2168-4cf1-a233-95ec5bf9baf4">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktNC0xLTEtMTU1NjM4_a8ec351e-593a-4dc1-96c5-2d8a5812c878">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktNi0xLTEtMTU1NjM4_f6568181-e8be-49bc-ae58-b2f4ce45ba3a">7.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktOC0xLTEtMTU1NjM4_f518e0b7-7c33-4b62-958b-2d4eee8b9d6d">3.4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTAtMS0xLTE1NTYzOA_a54b2c0f-d454-45c0-9da3-c443a252cc29">3.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTItMS0xLTE1NTYzOA_18004f25-4d14-45ac-b664-ab8f9f254998">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTQtMS0xLTE1NTYzOA_6440d193-2d6a-4a00-8ffa-d5146807963c">6.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTYtMS0xLTE1NTYzOA_36f3bd92-a029-4eb4-a2d9-9189d3b12479">7.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTgtMS0xLTE1NTYzOA_e7744716-ba94-4c47-bb5e-e1e1db4940fa">7.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEwLTgtMS0xLTE1NTYzOA_dc8c9941-a1bb-4111-a68e-d263dc192856">2.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEwLTEwLTEtMS0xNTU2Mzg_90dd473c-0d4d-4f71-bfaf-9af2fb6b0d39">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEwLTEyLTEtMS0xNTU2Mzg_40132255-35fc-4ce9-ac93-160dae4b6398">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTItMS0xLTE1NTYzOA_413e9c5c-d029-4902-bfb1-8ccbca946baf">2.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTQtMS0xLTE1NTYzOA_406c56e0-0068-4b00-992f-b1424d15fa36">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTYtMS0xLTI3MDA2OA_26ce669e-86f8-4b7d-b964-e3d0817a1381">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTgtMS0xLTE1NTYzOA_86ad21cd-ec4e-4193-aa46-8ba3f7c1cc31">1.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTEwLTEtMS0xNTU2Mzg_bb9fc44f-289b-448e-a9b5-001821ad3616">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTEyLTEtMS0yNzAxNDE_010078b2-4248-4de3-b0f1-e9d22cbbd493">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTE0LTEtMS0xNTU2Mzg_43c138db-aeab-4922-840c-16168b2bf8aa">2.9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTE2LTEtMS0xNTU2Mzg_312b9688-9498-451f-87e9-30027170fb93">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idec3f3c060644f67803ed29adf181171_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTE4LTEtMS0xNzQwNjM_9170ffee-f6fd-40cd-816a-c234648bf3c0">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTgtMS0xLTE1NTYzOA_dc3ec28d-15f6-4bc6-ac30-354a3d100de1">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEwLTEtMS0xNTU2Mzg_78ddf880-771b-4688-96e0-3cb5279fd390">2.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231" decimals="3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEyLTEtMS0yNzAxNDE_0357e9db-9c5e-4779-b022-c590a5995791">1.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzU1ODA_bdebfab6-bd01-4f6b-bc21-f6fe009452ff" footnoteRole="http://www.xbrl.org/2003/role/footnote">The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.</ix:footnote></span></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All of the assumptions are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends as well as market conditions that may have an impact on the cost of providing retirement benefits.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2021 resulted in higher discount rates as compared to the prior year.</span></div><div style="margin-bottom:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY4_2b783d0c-73fe-4f56-8aab-03843a247e9d" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:75.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.780%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzQtMi0xLTEtMTU1NjM4_9b9c4bf8-cf6f-401d-8cc5-016fa1fdeffb">6.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzQtNC0xLTEtMTU1NjM4_2e45c0fc-7385-4742-875f-1877056e4648">5.6</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzYtMi0xLTEtMTU1NjM4_4849af4c-9663-445a-baa9-b3b6d3261b17">4.0</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="3" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzYtNC0xLTEtMTU1NjM4_d7019b22-51de-4500-a4be-55e8c25c1d45">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year that the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2045</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2037&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ie69905f78cb043418b1178c55cb518fe" continuedAt="i14fe206530ee4c248df1a49843a133d2"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Obligations and Funded Status</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_0cf91b43-af10-412f-8b77-55e04b051558" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_189155e9-6bda-4d95-bef9-e5db370d1ea6" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_83df9955-6922-4a8c-8222-e9da30791825" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_a257b1b4-3a78-4412-bd9c-34a6eb74bc4a" escape="true"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_c8608efd-7ccf-426b-b5db-4b7ddee571ce" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMi0xLTEtMTU1NjM4_0da5e0e3-0810-4a16-a80c-2f4b195000fd">18,306</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNC0xLTEtMTU1NjM4_6296c906-9226-4ec4-aca1-227c25bb96ef">17,886</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNi0xLTEtMTU1NjM4_e619fedf-b7de-4035-8db4-50b4796cc9e8">12,001</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctOC0xLTEtMTU1NjM4_cbc1dcb8-9d88-4907-86d3-176196e23a1c">11,059</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTAtMS0xLTE1NTYzOA_874ff190-7970-4199-9c5a-cb06a3757dac">1,238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec3f3c060644f67803ed29adf181171_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTItMS0xLTE1NTYzOA_53166da9-0d32-42c1-976b-015a7a580e30">1,667</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtMi0xLTEtMTU1NjM4_5566c3a7-0646-4c2a-b7fd-00e85eb582c2">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtNC0xLTEtMTU1NjM4_b3a062d1-de9d-476d-a64c-58ced3850e04">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtNi0xLTEtMTU1NjM4_0027fc31-9d28-4160-9878-8e6d6a95b92d">130</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtOC0xLTEtMTU1NjM4_1921735d-5f6f-49a8-8b6a-7da084fc456d">146</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtMTAtMS0xLTE1NTYzOA_bcf4771e-51f6-4e08-b43f-2cf472ce15bc">36</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtMTItMS0xLTE1NTYzOA_c081957a-94a9-4d35-954e-836b35dc006b">38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktMi0xLTEtMTU1NjM4_a7bb493d-12f4-4296-8d1c-8ff8f9b70762">455</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktNC0xLTEtMTU1NjM4_0d94c174-7b85-4652-bfe3-ece730d743bf">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktNi0xLTEtMTU1NjM4_31637ead-c36f-4169-8d1b-ce03d1f46884">146</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktOC0xLTEtMTU1NjM4_4d51fdf4-bdce-49ae-aeee-55d5f49a1673">164</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktMTAtMS0xLTE1NTYzOA_2cfaea76-515e-45c1-9ce3-7c651770980a">29</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktMTItMS0xLTE1NTYzOA_67284ef6-cbeb-497a-bf17-9abd38971439">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTItMS0xLTE1NTYzOA_9741639d-0337-4afc-9db0-e9f3fcb450cf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTQtMS0xLTE1NTYzOA_fafd7397-89e6-4b33-8f2f-e9a396336003">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTYtMS0xLTE1NTYzOA_cc972c06-9d3d-4748-a4b7-f80d1f86f598">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTgtMS0xLTE1NTYzOA_6cff64c9-ce22-4211-9fc4-8ed827b8d8a7">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTEwLTEtMS0xNTU2Mzg_e6783b35-4312-4dc1-9396-b1efc3a56f4e">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTEyLTEtMS0xNTU2Mzg_b0afe461-9dab-4bec-ab95-81adc32434bf">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTItMS0xLTE1NTYzOA_297b04a5-d3c9-4608-a535-6698ac308af9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTQtMS0xLTE1NTYzOA_e2ee2ea2-7118-40d3-a579-ec962432162f">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTYtMS0xLTE1NTYzOA_0cc671a5-5312-4b4a-a81e-fc5a707f5a20">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTgtMS0xLTE1NTYzOA_dbbac8eb-3e20-498d-a2af-ac22b9e2a947">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTEwLTEtMS0xNTU2Mzg_b337ef38-b1da-4d51-b3c8-c6cc6e6513fa">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTEyLTEtMS0xNTU2Mzg_c9cea09d-2757-412f-af52-76ce4fc8860b">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTItMS0xLTE1NTYzOA_11f37d67-9f26-40c9-8a93-23dd3aae225c">331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTQtMS0xLTE1NTYzOA_3786047f-58ec-42ac-aabe-4be56f21b571">2,112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTYtMS0xLTE1NTYzOA_c47971c5-0f64-4f2e-a645-0124bc609cc0">89</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTgtMS0xLTE1NTYzOA_57875fd3-c720-43ff-aa35-5b92292df7bb">702</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEwLTEtMS0xNTU2Mzg_6c7828d5-2f33-49d9-99b3-17ae37984b5a">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEyLTEtMS0xNTU2Mzg_6d74d7a6-e6f5-4721-a6da-f3c1fd721422">132</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTItMS0xLTE1NTYzOA_87485582-96d2-47a5-a9d8-a3c8d85d19e6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTQtMS0xLTE1NTYzOA_f1f2c3bd-d02a-409a-99f5-5bca3b8b67aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTYtMS0xLTE1NTYzOA_27519abf-a1a4-4500-bd13-4ddbb5407eeb">298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTgtMS0xLTE1NTYzOA_72b50253-2e1b-46f3-87e6-a73cc3bef965">646</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTEwLTEtMS0xNTU2Mzg_22f28013-4282-4aea-ad2d-00602d64cc81">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTEyLTEtMS0xNTU2Mzg_d5697fea-c538-42e6-a426-4e32098f17b7">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTItMS0xLTE1NTYzOA_44292426-f74c-4292-8893-599c22df01ba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTQtMS0xLTE1NTYzOA_b0a85b84-e2ba-46b4-9a58-11d5cf85d31b">1,016</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTYtMS0xLTE1NTYzOA_6effaeb9-5185-45a2-a184-6f978e917747">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTgtMS0xLTE1NTYzOA_7214571e-28c5-4a59-a95b-1a80823e8a1a">320</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEwLTEtMS0xNTU2Mzg_e06cdaea-af2d-4e26-b6e8-ad3f73f77f00">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEyLTEtMS0xNTU2Mzg_bee459d5-4eee-40cc-a39f-9ff08d6aa4c7">218</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures/other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTItMS0xLTE1NTYzOA_175a8beb-69d8-4afb-a85d-4455c3ac7d7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTQtMS0xLTE1NTYzOA_4c084078-8f44-414a-84ae-4e3b4e711752">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTYtMS0xLTE1NTYzOA_c6fce690-6c88-422a-98a8-5613176c5d7d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTgtMS0xLTE1NTYzOA_8615d9ca-ecb2-4c17-acb7-17d29480da05">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTEwLTEtMS0xNTU2Mzg_3895843b-ac78-4fae-9208-f8f9d28f1299">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTItMS0xLTE1NTYzOA_b21735ad-d966-4a81-ac1f-b07afdb44628">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTQtMS0xLTE1NTYzOA_c9b3b1fb-0e9e-4236-9ab0-f679c542a64d">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTYtMS0xLTE1NTYzOA_384461e2-bf59-4314-8ada-ff8450eb18d0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTgtMS0xLTE1NTYzOA_2ae40eba-347a-4b87-82b9-1a464945d994">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" sign="-" name="pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTEwLTEtMS0xNTU2Mzg_69f7b18e-b6fb-4f45-ac3c-04c4d575eb28">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTEyLTEtMS0xNTU2Mzg_c86fedec-7c7e-4476-a2e2-8a93aae2edfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTItMS0xLTE1NTYzOA_3e7eb8b4-eb87-4df6-9274-5d002fec072d">785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTQtMS0xLTE1NTYzOA_6b113e88-0880-45a7-9906-97894b7739aa">767</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTYtMS0xLTE1NTYzOA_00c37f90-4aa1-4cf5-a5c7-3d69ef084462">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTgtMS0xLTE1NTYzOA_364fb638-b2dc-4acb-8454-7d84d9d2044c">34</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTEwLTEtMS0xNTU2Mzg_320097bb-fd8d-4010-bc74-5de663310bc6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTEyLTEtMS0xNTU2Mzg_0eeec7c5-6c87-436f-85fd-61ebd20fa826">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTItMS0xLTE1NTYzOA_9594358b-ab5b-4cc3-b28d-29ff7d1c942d">512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTQtMS0xLTE1NTYzOA_85c72d03-e5d1-4f22-a3f4-191098087c72">445</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTYtMS0xLTE1NTYzOA_813d6cad-544b-4f0b-95a3-51b307f5820a">374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTgtMS0xLTE1NTYzOA_2f128b89-b1ed-43e0-bb6b-32a01fb0e9e1">372</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTEwLTEtMS0xNTU2Mzg_763bca9a-ebd9-4221-bd67-91f38c823c3a">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTEyLTEtMS0xNTU2Mzg_efb0f95b-d2e0-4e1e-8110-55ffadb44345">201</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTItMS0xLTE1NTYzOA_58c9c685-66d0-4b27-8fd8-86a99f375625">17,150</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTQtMS0xLTE1NTYzOA_f60350e2-50aa-4469-a082-b854a2607d33">18,306</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTYtMS0xLTE1NTYzOA_c1445037-0154-4a97-810f-8753322de790">11,657</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTgtMS0xLTE1NTYzOA_5a142064-c9bd-4118-8f10-6076f944cba2">12,001</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEwLTEtMS0xNTU2Mzg_01d5126a-6e40-4228-a15d-40bed1fa2985">995</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEyLTEtMS0xNTU2Mzg_28c1b928-0392-404d-b275-6cd17bae9db5">1,238</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTItMS0xLTE1NTYzOA_f1a20b1f-0a25-4629-811f-ad2948ffa27d">16,094</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTQtMS0xLTE1NTYzOA_030f776d-4afd-44c7-b48b-88dc2d1008fa">14,586</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTYtMS0xLTE1NTYzOA_4900e28a-e7d3-43b4-b380-d69fd97f8dea">9,811</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTgtMS0xLTE1NTYzOA_07658a0f-4f7b-4b83-9d61-fc0ca78de52a">8,956</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTEwLTEtMS0xNTU2Mzg_9b5aaa2c-3311-4eb8-85f2-691955996709">588</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec3f3c060644f67803ed29adf181171_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTEyLTEtMS0xNTU2Mzg_e9f59bcf-a07d-4284-bb45-08c5bff14bda">519</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTItMS0xLTE1NTYzOA_0bfeebf1-2943-4869-8e27-a8ef20bda75f">1,405</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTQtMS0xLTE1NTYzOA_d361d81e-0b62-499d-94cb-4c101159803c">1,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTYtMS0xLTE1NTYzOA_f71c30b8-cf78-4e89-8a4d-9c26e068f3c3">1,106</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTgtMS0xLTE1NTYzOA_191ce6ba-fdb3-4ece-b6b9-a7e10cb922bc">868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTEwLTEtMS0xNTU2Mzg_cfd1ea74-ecce-4211-93d4-4f90554d2be0">89</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTEyLTEtMS0xNTU2Mzg_e6c319b1-0bdf-4f93-ae65-4bb5cf83e910">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTItMS0xLTE1NTYzOA_e290273a-ef4b-4349-b8dd-bc9303e88dd3">143</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTQtMS0xLTE1NTYzOA_832ae95a-e912-4973-a414-c3c7c1a67087">1,433</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTYtMS0xLTE1NTYzOA_698c06e6-0e2c-4515-836f-dc7014d72398">451</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTgtMS0xLTE1NTYzOA_fd14b0a4-e8cb-4d3e-bf42-1ca82d1e76ac">197</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTEwLTEtMS0xNTU2Mzg_f16f03c2-7393-41dc-a6de-e7852c5b9673">145</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTEyLTEtMS0xNTU2Mzg_14db6f02-d11e-43ba-b708-fa6d831190a7">113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTItMS0xLTE1NTYzOA_23f33517-32e6-4fae-8333-ad6cae95f348">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTQtMS0xLTE1NTYzOA_9aa94532-f73a-4eba-bc23-674ee4fe8fbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTYtMS0xLTE1NTYzOA_ed8df1e8-6c59-4b13-bf4c-990db7c31c77">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTgtMS0xLTE1NTYzOA_869cf102-dede-4113-a8dd-7d523e313997">8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTEwLTEtMS0xNTU2Mzg_25819382-55fd-4ee9-a3ef-649a4349149a">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTEyLTEtMS0xNTU2Mzg_4787028e-90f0-4130-87f1-0e2e1832b0b9">88</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTItMS0xLTE1NTYzOA_8b985f30-2e4a-4ed1-90d1-492bdb71b25b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTQtMS0xLTE1NTYzOA_cf0d70ea-3635-4890-9fed-b1a695d7a8c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTYtMS0xLTE1NTYzOA_92ffeeb8-4670-4f87-bb1a-b18b3dde5cd3">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTgtMS0xLTE1NTYzOA_766fc894-bc82-4092-a946-8ed1afbe489a">462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTEwLTEtMS0xNTU2Mzg_b97f1940-b8a8-4c62-9757-49709df5c675">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTEyLTEtMS0xNTU2Mzg_2c4c337f-fd50-455b-8dd1-00e20852f7d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTItMS0xLTE1NTYzOA_4fe324c3-d960-439a-ae02-e73b759a4327">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTQtMS0xLTE1NTYzOA_021028ad-3fe7-4eb7-b9b1-d290f1ea062b">687</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTYtMS0xLTE1NTYzOA_5575fd5a-00b6-47b7-89f6-01bc979677c8">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTgtMS0xLTE1NTYzOA_eca4bfad-a0a2-4fa0-b7fe-396339e3ace6">270</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEwLTEtMS0xNTU2Mzg_5100b054-8edb-48f5-9e21-212ef96b39ab">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEyLTEtMS0xNTU2Mzg_ff0dd3dd-2896-4174-8239-5da3b6b44a34">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" sign="-" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI5LTgtMS0xLTE1NTYzOA_1f68ee4a-7dff-4bce-968f-2422aba1eee6">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI5LTEwLTEtMS0xNTU2Mzg_a7c91c57-338e-4f4b-8410-51a4957d3f90">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI5LTEyLTEtMS0xNTU2Mzg_9368920f-5d70-486a-8a5e-573986bfe1bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTItMS0xLTE1NTYzOA_daf77705-c9e2-42c5-8e8e-42367f5d93ce">785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTQtMS0xLTE1NTYzOA_e9278fbb-623d-429f-8146-df2274e32897">767</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTYtMS0xLTE1NTYzOA_30d6a588-af08-4b03-aed9-3036f1ccb79a">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTgtMS0xLTE1NTYzOA_94cd222b-0add-4439-b5f5-7e628e8ac03e">34</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTEwLTEtMS0xNTU2Mzg_df9f2ed4-aab7-4bc9-873b-f60987f40ae9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTEyLTEtMS0xNTU2Mzg_5148b05b-dc73-4519-8f80-296c0b22f830">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTItMS0xLTE1NTYzOA_de2d91ae-8601-48de-8c38-99daa8352fb3">512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTQtMS0xLTE1NTYzOA_d0b99f71-7f22-4584-b7f1-e458e06edc63">445</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTYtMS0xLTE1NTYzOA_73c74d8c-f195-488e-9d4b-eac762ee4b0a">374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTgtMS0xLTE1NTYzOA_06473701-4c29-478f-8d4d-27901e8c8ba1">372</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTEwLTEtMS0xNTU2Mzg_6b7a3620-ca69-4496-919d-a2c446687f22">147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTEyLTEtMS0xNTU2Mzg_a9895693-8cfd-4e1d-ae35-bdeda7be0ce1">201</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTItMS0xLTE1NTYzOA_e644bc41-75ce-4ed9-b176-4e53cdc7b10a">16,346</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTQtMS0xLTE1NTYzOA_18268926-acae-4323-ad0a-209890e46d39">16,094</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTYtMS0xLTE1NTYzOA_c9276e20-d089-4adf-890b-f13aba341147">10,729</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTgtMS0xLTE1NTYzOA_91be3edf-d81d-402c-86af-f6e8af129641">9,811</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTEwLTEtMS0xNTU2Mzg_53560837-7125-4f8f-92b5-9aabf9351bfb">753</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTEyLTEtMS0xNTU2Mzg_a21109ed-3a27-4704-9788-b86f84b6c533">588</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTItMS0xLTE1NTYzOA_38ec37f9-9fb6-4d8e-bb50-fd1e881e7fb4">805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTQtMS0xLTE1NTYzOA_eea5a9cc-5be7-46c6-a419-816f223c9540">2,211</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTYtMS0xLTE1NTYzOA_d0054f61-190a-48df-ad53-571a3578e058">928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTgtMS0xLTE1NTYzOA_b877fcf2-d912-4608-9e2b-9333772cd88b">2,191</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTEwLTEtMS0xNTU2Mzg_b2b58f3c-b0e0-4067-886b-f3320a9c87fe">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTEyLTEtMS0xNTU2Mzg_7fb405f2-3171-4721-9787-771885f46e13">651</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Amounts recorded in our consolidated balance sheet: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTItMS0xLTE1NTYzOA_8f14a053-55e7-484d-9d25-e93960c20688">447</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTQtMS0xLTE1NTYzOA_351fd1df-8e80-47ba-a9ee-219e6be9505d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTYtMS0xLTE1NTYzOA_92b4f368-2e3d-464b-aa06-c4c2372a872e">1,480</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTgtMS0xLTE1NTYzOA_be38023a-71ab-4da7-842f-dd4121ae0da4">522</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTEwLTEtMS0xNTU2Mzg_54f27304-e29c-4766-9016-22e6fa3b7271">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTEyLTEtMS0xNTU2Mzg_4b9ea827-8840-46fc-b61a-b697820016a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTItMS0xLTE1NTYzOA_7cefd068-b073-413d-befe-e157755425b4">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTQtMS0xLTE1NTYzOA_39247317-5359-43ae-b18d-0e90b83ee380">127</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTYtMS0xLTE1NTYzOA_4253484c-9880-47b7-9424-fe55cea7b304">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTgtMS0xLTE1NTYzOA_41b35c9e-a9c8-4d1b-bfbb-8936f3106a6d">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTEwLTEtMS0xNTU2Mzg_76df07bb-034d-4c2d-affb-9f0a8dff5937">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTEyLTEtMS0xNTU2Mzg_b3871978-c341-4f4b-ac24-10ac664a7b4d">6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTItMS0xLTE1NTYzOA_db209ec7-4b72-45f0-b031-2d168860f28b">1,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTQtMS0xLTE1NTYzOA_111b48fb-152c-4db4-81ca-befb73834da7">2,084</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTYtMS0xLTE1NTYzOA_b8916270-62cf-4d36-ae18-f747ad175ac7">2,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTgtMS0xLTE1NTYzOA_9284fefc-ca64-47bf-9672-2cde1791b0d9">2,681</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTEwLTEtMS0xNTU2Mzg_2f4aa8b2-2a6d-4d6f-911e-ab0196fb4b85">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTEyLTEtMS0xNTU2Mzg_66079cd5-6005-4a84-ae04-ba676a98cdc1">645</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTItMS0xLTE1NTYzOA_3f733dc7-ec77-42fe-aca9-5e44efa17b16">805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTQtMS0xLTE1NTYzOA_13f750da-25a1-44e5-a6c9-2d4ac778e5c9">2,211</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTYtMS0xLTE1NTYzOA_8e17a516-a8e0-44d0-8f27-85c5d38d0d17">928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTgtMS0xLTE1NTYzOA_bbefc452-ad22-403b-9340-3e790560dcb3">2,191</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTEwLTEtMS0xNTU2Mzg_dc9028b8-e92b-4743-bac0-ba7d109d966b">241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTEyLTEtMS0xNTU2Mzg_efb55c83-466e-4298-9275-14629b542918">651</ix:nonFraction>)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTItMS0xLTE1NTYzOA_532f9124-3712-47e0-860e-bd6e2b7c2af4">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTQtMS0xLTE1NTYzOA_fea2ee19-ca53-4e0b-b0fb-ad2b6bf94b25">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTYtMS0xLTE1NTYzOA_a640325a-10ae-4f8b-b812-9182606793fb">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTgtMS0xLTE1NTYzOA_1ec6cacf-0d34-4785-9687-09a653a3ef73">31</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTEwLTEtMS0xNTU2Mzg_2508554a-9534-43cb-9578-9129e92fcbab">581</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTEyLTEtMS0xNTU2Mzg_6eea9dcc-dfa2-4b17-92ba-93386a04ea33">688</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTItMS0xLTE1NTYzOA_e478804d-42ac-4204-89c1-1eb3b3c4d922">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTQtMS0xLTE1NTYzOA_6d723252-e0db-426d-9f98-c3ba2727adce">16,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTYtMS0xLTE1NTYzOA_1359244d-9ca7-42ec-af97-2d6bf9cb686b">1,304</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTgtMS0xLTE1NTYzOA_7be9e936-f8d0-4072-9eb0-3e7538b8a30d">6,674</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTItMS0xLTE1NTYzOA_f59a388e-1923-46fe-946e-8ddcbb26213c">1,371</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTQtMS0xLTE1NTYzOA_25fdaedb-fcea-4223-915c-2953a3bd0c5d">18,306</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTYtMS0xLTE1NTYzOA_087da3aa-6d1a-444e-99cb-fb3ba334d61b">3,344</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTgtMS0xLTE1NTYzOA_011302af-b5f5-4dac-8819-02eafbbd14d4">8,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTItMS0xLTE1NTYzOA_da4468a1-5047-41ec-9622-d82ce1b6ca86">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTQtMS0xLTE1NTYzOA_ce663fcc-934b-4f97-bc38-6a9f03ef0645">16,094</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTYtMS0xLTE1NTYzOA_63fc9557-bdc2-4b91-a304-6bfa8d2f3a68">1,381</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTgtMS0xLTE1NTYzOA_eef6cb3b-6941-4582-bc48-cf1dc25da512">6,735</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTItMS0xLTE1NTYzOA_1d521dba-67e6-4774-ad3e-263f21d6ba2d">1,371</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTQtMS0xLTE1NTYzOA_8ee7ad89-2b40-4fc9-986d-77b006d108ea">18,306</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTYtMS0xLTE1NTYzOA_52f6660e-780d-4444-9d2b-959ce46860ac">3,789</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTgtMS0xLTE1NTYzOA_dcd76900-b494-4bb3-ae58-5e24f2f31d15">9,447</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8" footnoteRole="http://www.xbrl.org/2003/role/footnote">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $<ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM3MDk_2d57a360-3185-454e-bd3f-e7ebbe59ad41">11.2</ix:nonFraction>&#160;billion in 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-8" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM3Mjk_090b58c3-f655-4bc1-b65a-570b111746b0">11.5</ix:nonFraction>&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c" footnoteRole="http://www.xbrl.org/2003/role/footnote">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</ix:footnote></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">86</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i14fe206530ee4c248df1a49843a133d2" continuedAt="i85e50cd542bb4dd99e8316f07b9ae7da"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Plan Assets</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMx_5570607b-7baa-4ce9-b3f0-e8678658df39" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.072%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">The following provides the components of plan assets, including those reported as part of discontinued operations for 2020:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Target Allocation Percentage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level <br/>2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level<br/>&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. pension plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5710bf2055845c2bb0af48ab186abf3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtNC0xLTEtMTU1NjM4_8f8a4545-3ee6-4b76-acc4-eb8102dd23c7">1,326</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60429211f00e4543a9d87883c1802d3a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtNi0xLTEtMTU1NjM4_5d7a8d0c-5e71-4e5a-ae01-b2647c3880e0">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c7b4506a324d4bbcbab70e430c8662_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtOC0xLTEtMTU1NjM4_7ac08ad7-4819-4499-ab91-2fdd6bbae30d">1,248</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283602e4cefb4da5950be8e7d92e7b33_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTAtMS0xLTE1NTYzOA_08c87c27-3ef7-4d3e-8c58-13979a6ba514">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49bdb977a6c048ed8147d55a219d65bb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTItMS0xLTE1NTYzOA_9116dce1-29a6-400a-b560-bf236c4d1e10">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64901c28b3e4435fb58c625d1c7cf873_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTQtMS0xLTE1NTYzOA_49662ad2-7b5e-4f3e-9686-6c17312e512e">781</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74e82614b28e43cda6969e8c6d06b101_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTYtMS0xLTE1NTYzOA_c0b9ac50-fcc0-40ae-9772-c22055149830">70</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if89fbc914ea0495c84a57e279acd25e7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTgtMS0xLTE1NTYzOA_8a91deca-f4a3-4d27-b2bb-e4cdda935523">711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba84ca9e34e4da6acddd4a5dca78acb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjAtMS0xLTE1NTYzOA_689c1cd2-33c8-4056-9e7c-d7357db82ace">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eee230e2ad24b56a95a98c396863239_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjItMS0xLTE1NTYzOA_2db1f194-c5bb-4342-8607-e1df12dcbf12">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20-40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Global equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b1e9bd443e4b9dacb7b420ea97a93a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctNC0xLTEtMTU1NjM4_8c626707-10cd-4aa6-a6fd-d7fd48b3f542">2,273</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f847d9790b41829a5de2c58516e44b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctNi0xLTEtMTU1NjM4_44b94996-c908-47d1-b168-24331f7ae8aa">2,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36aad9909fb14c9e88dc6e895d2ae970_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctOC0xLTEtMTU1NjM4_2e58f3e2-e34e-4ea9-928f-3d44e4cd0676">38</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fc1d8b0293450faef44d3939baa104_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTAtMS0xLTE1NTYzOA_6629be45-9242-4a4e-bd24-60453f52de6c">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee309d4671204beb982620ca87935160_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTItMS0xLTE1NTYzOA_242ba833-456a-4cfd-b898-3a48906babf6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a840d48179840c58c095b54740189e3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTQtMS0xLTE1NTYzOA_ff76f35c-e32b-4677-81a1-411a85f2ede7">3,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43adc45933224ebb81d095ee790ac1f7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTYtMS0xLTE1NTYzOA_9a827cd6-5f39-4cc1-b4a8-e996cb47d63a">3,213</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6805ceeab9416ab34598f009a9a3dc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTgtMS0xLTE1NTYzOA_d5be236e-b757-4d5f-8496-f94ced4a9688">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd31c166a8342b1ab79aa126ec89e2b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjAtMS0xLTE1NTYzOA_c4292b6e-cfd8-4205-aec4-d505cd915fcb">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia386fe05870a4d00bf574703282f8e14_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjItMS0xLTE1NTYzOA_942e2c6f-bd14-48d6-938e-405a246cdb45">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecf8cfa85c844e994e95ff8a0b018cb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtNC0xLTEtMTU1NjM4_f3438b85-1ba4-4056-a05d-a9136b6abfc6">1,352</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e867961a86c46988276f2a8e0b5563b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtNi0xLTEtMTU1NjM4_210ffc95-fb23-45a9-81c7-ee2040fb22f9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1eee291364c41d79df9b38be936c743_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtOC0xLTEtMTU1NjM4_d114910a-6e4d-4687-aa07-dcc368bcd9de">1,152</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f82686b88b4e99b6d4c1a1a66cb7e8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTAtMS0xLTE1NTYzOA_a2ec5dbf-d608-44a3-9b94-a40808eb128f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia951c8cab72446a18ae9742d230213ad_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTItMS0xLTE1NTYzOA_285610aa-5b55-40aa-8047-ddd3c15916b4">200</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f95cfd93704f94897bc57033b1b31e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTQtMS0xLTE1NTYzOA_3227f37e-9281-4da3-87a0-f36f2c4c6d5b">1,325</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6fb94fe8a7447b0b43f4729bc6367ef_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTYtMS0xLTE1NTYzOA_2023f9b9-d4cb-4d4d-9441-ff016c24e52d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib998445075734dc0859b69f2f70d7eae_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTgtMS0xLTE1NTYzOA_ce9f5431-0b37-480d-997d-1736110b18b1">1,110</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdce9769d51453485e9ffd8c6432ac9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjAtMS0xLTE1NTYzOA_765f6c9a-803e-45c0-8160-e5e714fe7690">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5efb9b34ff354aa695d0ce5519469de9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjItMS0xLTE1NTYzOA_fedba956-ea2f-4539-b3f9-abf2ae69c37b">215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45-75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de93f17bb5246deaf177cd4c179c2d8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTQtMS0xLTE1NTYzOA_399eb3ce-9773-4de8-8d3c-dff2d82b5679">5,566</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedd08d03a6f8444e8e25322e621edaea_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTYtMS0xLTE1NTYzOA_0bc4e969-6ddb-41f5-9c0e-cdbf1f973b76">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2fea9359eb542c88235d0e94cc3e253_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTgtMS0xLTE1NTYzOA_ee1c77d5-8e91-408d-b072-76df6e0532a7">5,548</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7baf2c21a80d4f38986f54d8c0033701_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEwLTEtMS0xNTU2Mzg_f44b1d19-47cb-4e38-9f21-cb3531be557b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2702036ed2fc41b8bd3ca11952dd39fd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEyLTEtMS0xNTU2Mzg_b95480d8-ffdc-448c-bc49-6676b68b2698">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i123f921d862b428288283381a090761f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTE0LTEtMS0xNTU2Mzg_14a4bcc5-3983-476f-9c44-7783117ecdb4">6,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ccdaa1a811a44b99f3c0c1ca7eb44bd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTE2LTEtMS0xNTU2Mzg_cc67cbce-9be1-4a26-bd34-7d483f55836d">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a51613c60584714a3ec9b2ab496acce_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTE4LTEtMS0xNTU2Mzg_1ac3230b-27aa-463a-b72d-f156f47fb637">6,476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09a618c301e845ed90388735dad7841b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTQtMS0xLTE1NTYzOA_3f59ffed-384c-4297-9043-94b52041efad">2,533</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9316f5dab24cc588e8c9e879cd9341_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTYtMS0xLTE1NTYzOA_1e4d1b6c-f5a4-40d2-844a-3ab0a45b0bef">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id568702500f6432588ff76e3c3f36577_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTgtMS0xLTE1NTYzOA_7e1703d0-e7a0-4115-b0b2-9ff77b3df847">2,533</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38fc00053aa4c199b39dece7cad7cd1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEwLTEtMS0xNTU2Mzg_67b09b8f-e216-4d69-9e74-d98f90ff3ac8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id20c6d20908b4daaa553daa64deaf5f2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc201aae7f2142fa93d6f1984cee3475_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE0LTEtMS0xNTU2Mzg_2f220032-7e9b-4c18-b46b-94a7e5cade71">1,555</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08bf866f12c4207b983f1e7a10c0e8e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE2LTEtMS0xNTU2Mzg_26d5df97-f0ad-4152-8dee-55f18443891e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5407c5de8f4429b9e4f43939bf305b8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE4LTEtMS0xNTU2Mzg_00b437d0-18c0-450b-9dd6-1bfd8657d584">1,555</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1f6db9b9894f909a5796169e3fa818_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIwLTEtMS0xNTU2Mzg_bfef0997-7812-4779-a11e-800743cd3459">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57fea877a08c4296bf2ba0c929fae62a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcc6044a5d34518a267a09836a28a8b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTQtMS0xLTE1NTYzOA_63589cea-c837-4db8-8fca-c1f3063afff9">38</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742813cbab044d04a09ecf0ff835c7f3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTgtMS0xLTE1NTYzOA_4edec239-3aed-46e7-aa51-3419f0287a1b">38</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d5003d9185448588413661fda71f1d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEwLTEtMS0xNTU2Mzg_15170d7e-8a48-4c9d-903b-1429344b469d">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6960f5ec76174cb5a4931498467bfc1a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEyLTEtMS0xNTU2Mzg_891932bd-4a2f-4cb7-9c32-7626400194a1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c51183fe29945a1bc46769c25b05d2c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTE0LTEtMS0xNTU2Mzg_a891e0f8-83b9-4225-aca1-859e732cd9b8">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a2177b163f24101a81bc962d77be4de_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTE2LTEtMS0xNTU2Mzg_ea02d588-c380-43a2-b9a8-875f573b1842">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9254bb662ee04eb7851f6a0b2686c6a4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTE4LTEtMS0xNTU2Mzg_a9b53299-52e3-4815-9fe2-10b6ec500b15">23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia249cd5c4d3a4607ad781d7a08f45a32_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIwLTEtMS0xNTU2Mzg_740d8a61-f06f-4ce0-aead-2435e33fd773">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id179af66abf14a9fa7b1bba32e3acde8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIyLTEtMS0xNTU2Mzg_91fb8c8a-dfd0-46c4-afe4-83080ad0c295">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0614fc26162d4735ab928995a4525919_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTQtMS0xLTE1NTYzOA_58fd0a00-0fde-4880-a602-5212e1070940">2,079</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57504ba4b31c4e419514d3d822decba5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTYtMS0xLTE1NTYzOA_504edd22-f235-41c2-beb8-c3f5ea16078f">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id76b3e3473a8474aacfe913ead06f99c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEwLTEtMS0xNTU2Mzg_960e3182-0ff8-451e-94e9-0bad467aa196">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd486b3bd864997bc5dc92f53919f6f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016">2,076</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7ba90f110d40e2805438dda627ba7e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE0LTEtMS0xNTU2Mzg_2f8d3eaa-a853-434b-829f-7ea3e7269a84">1,431</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73e7d40fad2b40cab376ebfc9484a1fa_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE2LTEtMS0xNTU2Mzg_a112cd8f-66f3-4c2f-abe3-05cb919427ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic97e4ef4dedc4cd4b036e878ea92ff23_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE4LTEtMS0xNTU2Mzg_5bfaf30c-da33-4555-91d7-1f74139286eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if24ee12e5a364e699f1ccff806b6610a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIwLTEtMS0xNTU2Mzg_dc51b3f5-f461-44e1-a6f5-5f96e785f863">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24262e3bc3d74c4f9d4ebcd94821b450_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e">1,431</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91370cf282454c17b017708814f29a5f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTQtMS0xLTE1NTYzOA_362e43a1-d549-4a76-8375-b398929a3029">158</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i589b9c0f0529485b88483ec95805a113_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTYtMS0xLTE1NTYzOA_906925e8-cc91-4aa1-9fc5-2d02dfbb10f9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id792c4fa30b54b0f86d3a756dec19969_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTgtMS0xLTE1NTYzOA_aa641efa-7340-4b49-8c6d-43b07497c6b0">158</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557b046786b54cf5a7fd128f940aa558_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEwLTEtMS0xNTU2Mzg_b5fdbd7b-51af-411e-bff9-b62ade9ac9ec">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5e155c28ce45949b23ef1c2aa7bdcb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEyLTEtMS0xNTU2Mzg_7fda2a9e-7697-4cfa-86e9-0fefaeb05694">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib89426b5421f48bda2e841651169370a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTE0LTEtMS0xNTU2Mzg_cf008acb-b18f-4a2c-9774-ee7a24a8d3c6">190</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0eeba8032f54437b2332b040493be10_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTE2LTEtMS0xNTU2Mzg_9316293d-741f-4994-bf4d-d170c80f50ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa59de110c24310a8a3947fd9bf785c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTE4LTEtMS0xNTU2Mzg_a3ff76ee-8b86-485b-a961-f3c1964ed3ce">190</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01e99ad5a3624b79beda47b0277cfc08_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIwLTEtMS0xNTU2Mzg_e11393f9-cc5e-4e3a-a9fc-1fde9d25d812">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9178dd6228bb49e6ac59b6bc450f5f0b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIyLTEtMS0xNTU2Mzg_31a8ad27-20a2-4a38-a7b3-82a1801e8339">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other commingled funds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde04c3fab9a4225922b968a4ae389ac_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTQtMS0xLTE1NTYzOA_253e4e25-a98a-4cf5-8749-395c9dedcd3d">1,019</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i447a8db12c9c4335a9e7ce727e1c6c75_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTYtMS0xLTE1NTYzOA_b93deecb-4ab1-4c04-bb4f-c3884d271f31">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f1331fac0a44ab8ab767c27460f01c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTgtMS0xLTE1NTYzOA_68e027e6-af0e-4ef0-afae-8b7bf7ff0d27">10</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8df318e157488ebba552305374f247_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEwLTEtMS0xNTU2Mzg_69a9ad1c-52a1-4930-bd2e-8e9bbc9e8e46">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a6859a81d948b1b05d1524a2329d05_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182">1,009</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5be279af8994b7baf6fe7f41d4659d5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE0LTEtMS0xNTU2Mzg_a07d3655-9ba7-4a78-ac67-692db249b25f">1,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a28d95791fd48349d327616387cf43e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE2LTEtMS0xNTU2Mzg_55d6612b-509e-4e4e-9e3f-38aeafd8d90f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3fdb174e64745cbb589727b895dff68_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE4LTEtMS0xNTU2Mzg_e89a0ca5-4065-4544-9e31-f514a259a70d">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8ad87158d744cb98b1afcde979e2e3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIwLTEtMS0xNTU2Mzg_aaddd5c9-00c9-410b-ae32-5c465dfd74f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3acdd3ac8bd749d6bf766df1d252e13b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4">1,038</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTItMS0xLTE3NDk0Mw_cec51836-bac9-4439-822b-4efcaa1e537c">100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTQtMS0xLTE1NTYzOA_f0a90553-88b7-426a-8764-8d8fba17b76a">16,346</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4cadda8ddf40c0865e66aa16db1fb9_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTYtMS0xLTE1NTYzOA_0f35b385-52db-4f18-b2b7-ab9f58e646c8">2,332</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd30853b5aeb4360a8572bbff63519e1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTgtMS0xLTE1NTYzOA_a00b2a6c-ba53-4fd6-86ab-f59d41755b56">10,726</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b913c838f444389b2b5e72727c9ead7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEwLTEtMS0xNTU2Mzg_56164a78-868b-4aca-9640-d285dd3056dc">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfbcbfb8ada844189c00d8838d1d06df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEyLTEtMS0xNTU2Mzg_b9283d4a-b481-499c-84cc-ab9add6e6bd0">3,286</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTE0LTEtMS0xNTU2Mzg_732cca42-2573-4efb-98c8-ed72ebc54bb9">16,094</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb2a8f3e3f5140a6bbf5b850dd9df831_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTE2LTEtMS0xNTU2Mzg_d8802859-0279-4229-a81e-c51cbecda373">3,306</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61b5f086df574c9692cfb7bc457ede83_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTE4LTEtMS0xNTU2Mzg_37fb29e1-e1a2-454c-b2c1-bfc8671a3d1f">10,103</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5b1262aee15447893f4283772570e1c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIwLTEtMS0xNTU2Mzg_c511edfd-94ac-402e-bc12-0c3d00bf6c04">1</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2204111742ee4465b254c1d8def302f8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIyLTEtMS0xNTU2Mzg_206b5f3d-e5de-48a7-8d90-972f83316239">2,684</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">International pension plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5054f1ba961b478e81844b3970edd709_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTQtMS0xLTE1NTYzOA_7bac0546-8cd1-43dd-a2d3-afa47b156d81">541</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407c2c84a6fa46d19c024b335e5207de_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTYtMS0xLTE1NTYzOA_210e7d84-f59b-472d-849c-37e41ea5531d">191</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4789a2744a994126861e99bbaa61a091_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTgtMS0xLTE1NTYzOA_1abc2d0d-a28a-4975-bd50-c6fb79b2c63c">346</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib632f9766b1b4f088ee3c17033d9b730_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEwLTEtMS0xNTU2Mzg_c29db45a-5c87-4414-9856-cd6a397ed11a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b14ebd35ab942468b155850a50635d1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEyLTEtMS0xNTU2Mzg_2071fbd6-afae-4a6e-950d-29a48f960b3e">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b022b7da864f55abf40a8814adcc45_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTE0LTEtMS0xNTU2Mzg_02cb0167-3c82-40dd-b2d4-9c5723d31323">407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57736d5c9bd045889e3e70f907687568_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTE2LTEtMS0xNTU2Mzg_867a5ac1-93fd-48c4-a874-1360d2d22595">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d396dc1a9fc4ebc987eb95b09e2dc46_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTE4LTEtMS0xNTU2Mzg_13640567-b84d-4b81-b176-23241efeed6f">346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e2fe0961b7445768068020c53ad927d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIwLTEtMS0xNTU2Mzg_d4ca7211-fe54-46d0-825b-b7e1a35e1934">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie575e7d2482f4c67ae9b25248a9ad0a6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIyLTEtMS0xNTU2Mzg_a214d9db-3c4a-4696-8ebd-fa3ec28ff00e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7d8a3434554d0399db965a1f07c58c_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTQtMS0xLTE1NTYzOA_c3baf82d-f2d0-4984-9470-3b4e9955f8d6">1,453</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be90fe1c0944a43b096201649b0b9c6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTYtMS0xLTE1NTYzOA_a12a2ae1-970f-46ef-8c3c-e8fa2165ed8b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8da59af46f4f0386aa576b69074f33_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTgtMS0xLTE1NTYzOA_c492aef3-7806-4537-930a-a736903a16f6">1,386</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22075a2e3ef34cbf995ac7e82012dce0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEwLTEtMS0xNTU2Mzg_3608e02b-dc3d-474e-b8c7-7201468f9fd4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0863c82bbc51409b8efa496f8db9fdeb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEyLTEtMS0xNTU2Mzg_b13354c5-fdff-4035-bb77-b00434096449">67</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30b271d8b274f408f4ec6c14285b00c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTE0LTEtMS0xNTU2Mzg_a3ef8297-da62-45d2-9e44-fac88b0500bb">2,051</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0445954f919744a9887083dd3819fb37_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTE2LTEtMS0xNTU2Mzg_d2db1ca3-b68f-4161-8687-58c1bfefa9e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf9c3b10b55044c49138dc630a759469_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTE4LTEtMS0xNTU2Mzg_cbc65931-edcd-46c2-99c0-ba9ac87ef322">1,681</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee038f714c2946bcbbebc2ca551337d2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIwLTEtMS0xNTU2Mzg_4af73134-292f-4086-b231-63fdf6681b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bb9a408ac64e97878a6c8ad73e05e5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIyLTEtMS0xNTU2Mzg_12545fb2-9126-41b2-8856-19f2b608c590">370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45-70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc0a667f1e24e80a1d4b531f082b57d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTQtMS0xLTE1NTYzOA_fd059b24-1180-40c7-8648-9f97add7526c">1,187</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b85b80107be4fb8965249fc26340ed0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTYtMS0xLTE1NTYzOA_97dc468f-aeef-47b0-9e0b-29bea8a23f86">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b0a5ac77175482aad6b61c53e7c43e8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTgtMS0xLTE1NTYzOA_cf04dcc9-614e-4ffd-8de2-3df5420a7c04">1,187</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6f712dd8c0447aa8f70d3d13ad1e6e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEwLTEtMS0xNTU2Mzg_c78878ae-c8a1-41ed-9082-af6e682cfd20">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i329e2ccb8f4547afa328cdbd5609b4be_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEyLTEtMS0xNTU2Mzg_93a56760-b80a-4d6b-8987-359570948f94">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5836472a076b460991d1eebeaa047f8e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTE0LTEtMS0xNTU2Mzg_9ade59bd-0cb5-4fde-a1b1-e2e8b69a9b77">925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d752324547a45d8b253e8c8bcdc884f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTE2LTEtMS0xNTU2Mzg_bb562f69-9d4c-4389-b7f2-ec7b81b19d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86170cd6f9d428380420d95b35931fe_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTE4LTEtMS0xNTU2Mzg_cb407699-09c1-41eb-81de-f3cfa01e90cc">925</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17a849b4291f46ee8770bfb32d9b35e7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIwLTEtMS0xNTU2Mzg_c59c32b5-d2bd-4919-bc5a-4ba6337f0559">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9982822ef54206a5a46c76586d2f84_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIyLTEtMS0xNTU2Mzg_90374e62-0e6f-46ef-9c7f-4640ff4d6c2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a347ca6972c4ccf8546cf5025e6876f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTQtMS0xLTE1NTYzOA_59235c5e-1fcd-4074-9c0d-c21db292ee70">2,415</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4a43b1598443a7ab6eca61208eba5d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTYtMS0xLTE1NTYzOA_9e395521-4d55-4496-bfba-db44fa808527">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c25f3b4c7ec40969b854e0ac925ba55_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTgtMS0xLTE1NTYzOA_d6a323fc-7cb7-4834-ac37-0568992d3f35">2,415</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c46658794be4817aac85595e3b4fbc7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEwLTEtMS0xNTU2Mzg_9c49a9e0-a9b6-45a3-bda0-99fa573d9310">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c11b3f4356845d6aadac688a6d24730_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i692794301332409594d055d1c7f8e64f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE0LTEtMS0xNTU2Mzg_7633de53-4390-47ba-baf3-1655f72106d6">1,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5326e53aef0646728ea9fa61b1a7a0ce_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE2LTEtMS0xNTU2Mzg_1fc74320-cc41-4d0c-9bc9-8f4d0f01bd77">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1e59e825ee4981a7d38ce2c03e80f8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE4LTEtMS0xNTU2Mzg_f3c443bf-eba7-44c5-a8dd-89017a09bda3">1,334</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93ff27c78464387b5ed9bc21e35646c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIwLTEtMS0xNTU2Mzg_eb54842d-f09d-4c97-9447-596ba9c828e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb581ffa12d14ff2a9a1844bbaab94cf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c36130da21474a97558823d72cc9c3_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTQtMS0xLTE1NTYzOA_0a3ab404-913a-42ec-a9ec-f4f2016f231d">2,266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82b2e88175ff4f378684f8507ae69794_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTYtMS0xLTE1NTYzOA_bd7dbf8c-59e4-4953-a0d7-ece7afb92361">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758430987c524ca79a1aaea82cb98356_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTgtMS0xLTE1NTYzOA_67e5b5cc-f51d-4888-85d9-64f5b5965244">1,138</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b995529e4646e5b6becab80303e6e7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEwLTEtMS0xNTU2Mzg_4f61b8b4-fdb3-43a3-a595-fe75896e5164">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f16642eeded411e90331536700f0546_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEyLTEtMS0xNTU2Mzg_888ab502-03a6-4cb7-b620-959b81a348e6">1,128</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379e7c46cec74ebd955ac7a7e03511cc_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTE0LTEtMS0xNTU2Mzg_e93e20f7-5972-4da4-b816-d751cab4ae0f">2,484</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2eeca61f3244ee5af945c85a0919a57_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTE2LTEtMS0xNTU2Mzg_e5f983d9-b615-4e61-9604-d60fc8cfe908">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c237700488c4cb8b091e549169f189d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTE4LTEtMS0xNTU2Mzg_8d778465-08dd-4dee-ae29-7c1fa5e93d16">1,217</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03d125dfcb4a417187130ddbb9460600_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIwLTEtMS0xNTU2Mzg_c89926df-0341-4216-9d5a-a829afba5b1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a90980f6dd46818498f9ee7d139756_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIyLTEtMS0xNTU2Mzg_b0a663b2-9770-4574-9771-931cbd79c542">1,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15-35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce607f8a3a94cb29fe8250722ea7383_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTQtMS0xLTE1NTYzOA_493e864e-9e6e-490a-a7d1-a8f30874fddb">107</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632d5976180f4e41b0ae66ce2781ec7b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTYtMS0xLTE1NTYzOA_db43a12b-305c-43f3-b08d-6ea28ca0bb34">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c72066d02e480a8fcbf60f3979e383_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTgtMS0xLTE1NTYzOA_bb9dd044-d788-44d7-96d0-4a99a18f204a">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i671b1638704a44c290bc349298d71e48_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEwLTEtMS0xNTU2Mzg_728ee219-374d-437b-9420-1dcc85581038">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17829ca318b1498cbfae61d52d4675a1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6">106</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a7fdc62e800449d92622b90c9db4ffd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE0LTEtMS0xNTU2Mzg_581ab145-e28c-46d0-ab7b-4a546efa180c">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dfdef0347e94d1498a69a86deaa56d7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE2LTEtMS0xNTU2Mzg_7e00f49e-413c-41cd-ade6-d6f7386418df">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b0fa1fef2342d79c4cb9415d79ffd1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE4LTEtMS0xNTU2Mzg_d7965b05-3ae7-452b-aa1c-9dfd16d067a9">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f84fb522f6f458e920f395b641bc9ab_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIwLTEtMS0xNTU2Mzg_2dc36c80-8978-4b78-a6b4-e9cf97ed1694">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1120f4dcad384a9abe38b1b29af1c6a6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015c2dd1d8224aaba8f11e2779372636_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTQtMS0xLTE1NTYzOA_dec758d7-245e-4ce0-bb37-bab214ec28c1">1,329</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i674db30e4e6e4a1d9f25a2bfb6a2ca07_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTYtMS0xLTE1NTYzOA_c1c3936d-0653-46e9-a3e2-14c7d47c719f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i732d0c54d73849b69f3d917bd43daa7f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTgtMS0xLTE1NTYzOA_1efe439c-3d60-43e5-a8ef-ea4151612c7f">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2238ba918384e999cc84aed3dcd385d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEwLTEtMS0xNTU2Mzg_add6197d-a74d-4d5b-aab2-266dd4844309">1,273</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i866e56c0277b4bc9a25f19ec84f3fb26_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEyLTEtMS0xNTU2Mzg_ea1505b5-7690-4876-bb95-cfe8a69dd83f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24949bc17dc543c08cedcde9b2f3d7e8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTE0LTEtMS0xNTU2Mzg_adbc75e9-5416-4689-a64f-404a70a92a06">1,027</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie133e397deff441e98308ae589756218_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTE2LTEtMS0xNTU2Mzg_1a6fcd86-b127-438d-a7e1-cafe318a0b30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bdc708391174865b782df989e1ce518_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTE4LTEtMS0xNTU2Mzg_c84c7acf-b4f5-4bd0-8aa1-c2ed6bae64c3">57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574f79e048bb417ca2f0db77a714f150_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIwLTEtMS0xNTU2Mzg_e9f0abc8-e514-4b00-8284-bea112d70346">969</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d6d46b530f43febb88f895a185afb9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIyLTEtMS0xNTU2Mzg_8adc4b9f-29fa-4003-9600-58615581fd36">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea2ce2cd7f74f449218e9ebc7dcf7c4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTQtMS0xLTE1NTYzOA_70aac13a-baf8-4171-84d1-f83e89dc4d6f">1,431</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba350294128c42bc87995ecc8e035456_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTYtMS0xLTE1NTYzOA_d78cb2b6-5dc0-4f55-8ec1-99c8a25c3a7a">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i532f4bd22c5c45d4af63afa5a4f2453f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTgtMS0xLTE1NTYzOA_858c9006-32b2-48a8-8d60-39f2cd0e9d08">141</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9306a220094a4ee4851877329040ec09_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEwLTEtMS0xNTU2Mzg_94f58f7c-725d-4068-95d6-a5d42c4fec72">404</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98efc316265f4aeba589a5cdcdb2ba3a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61">886</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i255f65b9224f4081b95ec6f405a1952b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE0LTEtMS0xNTU2Mzg_b7b49a6c-8ac0-40dd-900c-08b8b9b128ff">1,514</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59707801ebc544c4aef8569d05013809_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE2LTEtMS0xNTU2Mzg_298650ef-6ab3-4cb3-81f1-a735e51a7f90">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f9185b14e74414b6142cd14b78487b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE4LTEtMS0xNTU2Mzg_d6752f22-093b-4587-8387-81799384a918">117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca53c720af3408083112ad16a8d242f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIwLTEtMS0xNTU2Mzg_dab840e9-9bf7-41cd-937b-b650f194bbdf">393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13d65917ea214718aabb6241059fbb61_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13">1,003</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTItMS0xLTE3NjM2Ng_425f57a6-607d-4ebb-af52-19699ffd0302">100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTQtMS0xLTE1NTYzOA_20f456d2-56b6-46eb-a3bf-23473aef2796">10,729</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab50e3974e214326979f7b8957262eec_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTYtMS0xLTE1NTYzOA_8a1d0f7f-bc88-434a-bb61-8529134021dd">191</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fc429f107fb4881b04687f32fc0685e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTgtMS0xLTE1NTYzOA_daade72a-2367-4bff-8f44-48258c42c8bd">6,672</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2413d9a6104540883ae20a14dee735_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEwLTEtMS0xNTU2Mzg_e75df7df-9d4e-4ccf-9eee-b3c012270a4d">1,677</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18418a4253841c684ea8af6ccec0aa6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEyLTEtMS0xNTU2Mzg_de7d172e-e54a-4dfb-9374-e22f89b1b318">2,189</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTE0LTEtMS0xNTU2Mzg_2986f19a-466d-4240-8d5b-922e76669fbc">9,811</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3151aa7ee6ab4f8398bd9a46d307ae04_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTE2LTEtMS0xNTU2Mzg_255763de-a751-4ff6-a8b2-9a9484643116">61</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie891101977024301955e23a929e1b4bf_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTE4LTEtMS0xNTU2Mzg_0c2caa2f-b81f-4fff-bda9-4528a7b0691d">5,681</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17489845f01240d096281d798554cdc7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIwLTEtMS0xNTU2Mzg_5c2089f9-8056-4ba5-92d3-dd8caa08ffa5">1,362</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778bcf63d499487093fcd6b390c2334b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIyLTEtMS0xNTU2Mzg_49e38d60-4156-420c-b0d3-559b21653490">2,707</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. postretirement plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3987296f1084db39f1525b58cd1a718_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTQtMS0xLTE3NjQyNg_357498f3-eae3-47e6-a717-100ee9859b9a">85</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495275bffa674b0f800ed1decb890131_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTYtMS0xLTE3NjQ3MQ_b1de6f06-71ed-4e13-9dcd-7988706f68ea">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624dc668a9d84bf4918f26033ef6b532_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTgtMS0xLTE3NjUxNg_0a72140e-bfc6-45fc-a6db-b16e3475ccc4">82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5289bfcfe10644b0945be402d243ebfe_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE0LTEtMS0xNzY2MjE_4082ca8f-abbf-473f-91bd-db8e8256cad1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9e20479d3c4f3a82eec65d7edb2fec_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE4LTEtMS0xNzY2NDI_66f395c5-8823-4e54-99d7-da791aa1f371">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9af20ea2173648718c35eddadc26f4d7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIwLTEtMS0xNzY2NTE_bbefd3e9-b4f2-4678-9562-3af5bffe61e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16cae3cccb9b437482e0606550ca5f7c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95-100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4072641bf848fd9a69cde4746de8af_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE1NTYzOA_79452b9b-8bc1-4b93-b873-62597a118422">669</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4895c42f91a3449d9e4a69e220f8567d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE1NTYzOA_7b5921d0-3be3-4e5f-a29d-b19cfb7ba075">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49724b7bcd8476597210f4014ed8c5a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE1NTYzOA_d8aeab8c-3274-41ea-b63d-f760575f61ae">669</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e9d20521f84171a18296ea65d842c4_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNTU2Mzg_2bc90cbe-8d40-409b-ba58-60ba596ba1d2">588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafcfb726811461e84845b5dba189707_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNTU2Mzg_602cce56-20e0-4ce1-94c3-e47dc1b24772">588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a77fde9c8d47a0b5a6ce8b6f44b599_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNTU2Mzg_44eb4742-6f2b-478c-8d05-cfec32546ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388802b089ce4803af64b6ab3e8a745d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if48068ea782f42749ec61f3378bf81b4_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTItMS0xLTE3NjM3NQ_d05385c1-a4e4-4f26-9a73-12054be9aa08">100</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if48068ea782f42749ec61f3378bf81b4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE3NjQyNg_1d1a6952-df5d-4cd6-8d55-4c84f4196f29">753</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib94cc14b225548bca7b6f25c551f7130_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE3NjQ3MQ_64cb9db0-2dcb-4e78-ad63-f53d8e5e81d1">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60ffdd0bae334efa9bc4cc9090bf826b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE3NjUxNg_e6bd7c83-d3d0-47a5-a1f2-aee47f3caf86">750</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bc6edc92b8c4f049c4a39984706caa1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNzY2MjE_c61eac8c-1ade-4f37-90c2-b80ac6d9c38c">588</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f245cfadb84797965a899a8eeb520c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNzY2NDI_59c98ae1-8711-4d60-8f1f-664796bfed11">588</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i793b789e8a0242258ea94c9fd8c9f383_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNzY2NTE_a5997f8e-98cf-4081-9f7e-e019e7d6edd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf0f90452504d429ae0f90828d23cc3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" footnoteRole="http://www.xbrl.org/2003/role/footnote">Government and agency obligations are inclusive of repurchase agreements</ix:footnote>.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" footnoteRole="http://www.xbrl.org/2003/role/footnote">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" footnoteRole="http://www.xbrl.org/2003/role/footnote">Mostly includes investments in hedge funds and real estate.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1" footnoteRole="http://www.xbrl.org/2003/role/footnote">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</ix:footnote></span></div></ix:nonNumeric><div style="margin-top:3pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY0_f5700cd7-79df-42ca-865c-51fd94401e8d" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.876%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs, including those reported as part of discontinued operations for 2020:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17489845f01240d096281d798554cdc7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzUtMTAtMS0xLTE1NTYzOA_20297c66-b2e1-4cf7-aa7c-9781fb7cea49">1,362</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice8be255951e4b8481ed15370c61e701_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzUtMTItMS0xLTE1NTYzOA_95893552-9d0a-4d85-9e03-81471e7bba62">1,342</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held, ending</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzctMTAtMS0xLTE1NTYzOA_6f054186-1403-4c67-81dd-e739121bab15">23</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzctMTItMS0xLTE1NTYzOA_e16a6735-310d-43f8-a72d-692effa643cb">22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases, sales, and settlements, net</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzktMTAtMS0xLTE1NTYzOA_9f6ffc76-4dc0-4763-b147-f95928e5bd7b">52</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzktMTItMS0xLTE1NTYzOA_6ce47a35-4c66-4993-8ef3-092a5eeb4a8d">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer into/(out&#160;of) Level 3</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEwLTEwLTEtMS0xNTU2Mzg_4a44274b-ea82-4bcf-b1dc-16db65f758e8">265</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEwLTEyLTEtMS0xNTU2Mzg_d0095aad-3663-402d-8825-5de9495e9552">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange rate changes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzExLTEwLTEtMS0xNTU2Mzg_80aad849-fc3a-49bd-9b87-b4d0052dd66e">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzExLTEyLTEtMS0xNTU2Mzg_32204547-20af-4e9c-b57c-84955c2c2fe5">58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, ending</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2413d9a6104540883ae20a14dee735_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEyLTEwLTEtMS0xNTU2Mzg_d33e8e1f-3097-418c-bc85-5add2283feb3">1,677</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17489845f01240d096281d798554cdc7_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEyLTEyLTEtMS0xNTU2Mzg_093525fa-ac94-4c66-89d0-e68473bdb72d">1,362</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i85e50cd542bb4dd99e8316f07b9ae7da"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans&#8217; assets:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Level 3 investments may include securities or insurance contracts that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans&#8217; invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDA0_6e5e45c2-ba37-4756-aa27-3a79fe9d9490" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the expected future cash flow information related to our benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected employer contributions:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzQtMi0xLTEtMTU1NjM4_6b0a4dc6-8d89-464e-8a14-e691438da250">138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzQtNC0xLTEtMTU1NjM4_cb037f61-8e11-4537-822c-8185f636adfd">177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzQtNi0xLTEtMTU1NjM4_45b1acc2-0975-41ad-a6b8-6a42a9eb393c">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected benefit payments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzYtMi0xLTEtMTU1NjM4_755aa90b-3264-4897-97f3-93e60dce8c29">1,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzYtNC0xLTEtMTU1NjM4_ad9342c4-0bb2-43c7-9f12-7d96acd9c64b">384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzYtNi0xLTEtMTU1NjM4_614c3340-e33f-42cb-a3e9-5d0ddb12940b">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzctMi0xLTEtMTU1NjM4_d65b5e31-5a65-4c0c-9fd4-fae0610cac2d">1,155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzctNC0xLTEtMTU1NjM4_6f38ec66-30fe-4ae0-878f-fa54185979dd">372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzctNi0xLTEtMTU1NjM4_3552b48e-e9ce-4918-9888-42fb16c5181f">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzgtMi0xLTEtMTU1NjM4_55fda206-8c5d-4898-abae-fbdc73f78571">1,140</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzgtNC0xLTEtMTU1NjM4_0bc7f4f5-dbc2-47e8-9484-03dac5a8ccc6">383</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzgtNi0xLTEtMTU1NjM4_42783a02-2c1e-4ddb-a6cb-32bebd371e08">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzktMi0xLTEtMTU1NjM4_c03fcaae-b41c-4164-bc50-4613722f9dec">1,089</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzktNC0xLTEtMTU1NjM4_ff8a19a2-73b8-4f62-ab07-5fdbaef467ff">392</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzktNi0xLTEtMTU1NjM4_0f37266a-1cdd-4d09-a8ad-a3696b819b10">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzEwLTItMS0xLTE1NTYzOA_c3d3574c-9c21-4929-83a4-be44391a42be">1,058</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzEwLTQtMS0xLTE1NTYzOA_1a70d239-9b0c-469b-9174-ade98d0a43e3">397</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzEwLTYtMS0xLTE1NTYzOA_0a4660bb-0092-4305-8878-b4acb33cbe09">68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027&#8211;2031</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzExLTItMS0xLTE1NTYzOA_3f043be4-7ede-49b7-9129-87d276026a0a">4,908</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzExLTQtMS0xLTE1NTYzOA_9e065847-bb07-439a-979d-2fa7e3d77d42">2,124</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzExLTYtMS0xLTE1NTYzOA_4a8dc67d-32b6-4b60-afe7-bf9353c15824">359</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Defined Contribution Plans</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have defined contribution plans in the U.S. and other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. We also offer a Retirement Savings Contribution (RSC) which is an annual non-contributory employer contribution in the U.S. and Puerto Rico. We recorded charges related to the employer contributions to global defined contribution plans of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM2NjU_b30059d9-5f23-4cd4-99d1-78d1d2a22e8a">732</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM2NTc_bfad13f3-477f-4f37-8d6c-33c23e9059f0">685</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM2NDk_01c3bce7-a488-4924-88e2-424b9b2ea2b5">659</ix:nonFraction> million in 2019.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_220"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NzQ_95f6a7ae-7125-46be-a804-7718211c55b1" continuedAt="id49bab6577354c3f928cf9ab3a9373ea" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="id49bab6577354c3f928cf9ab3a9373ea"><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Common Stock Purchases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We purchase our common stock through privately negotiated transactions or in the open market as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our BOD, are available for general corporate purposes. In December 2017, the BOD authorized a $<ix:nonFraction unitRef="usd" contextRef="i367c45882da94e7f95af6582e7a69196_I20171231" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzQ4NA_07e01513-c86f-494c-b929-261bdf279581">10</ix:nonFraction> billion share repurchase program, which was exhausted in the first quarter of 2019. In December 2018, the BOD authorized another $<ix:nonFraction unitRef="usd" contextRef="ie44e280570da48ac9f0565d31167fa82_I20181231" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzYwOA_1aaebf71-cbfd-40e5-878b-c429c5e75d8c">10</ix:nonFraction> billion share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2019, we entered into an ASR with Goldman Sachs &amp; Co. LLC to repurchase $<ix:nonFraction unitRef="usd" contextRef="i5cbd61ea7e074c3cb9b549fc73f7ea50_I20190228" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE0MTA_317d33b4-e003-43c8-9056-3380f06a0f0b">6.8</ix:nonFraction> billion of our common stock pursuant to our previously announced share repurchase authorization. We paid $<ix:nonFraction unitRef="usd" contextRef="i5cbd61ea7e074c3cb9b549fc73f7ea50_I20190228" decimals="-8" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE1MTA_4c2cf730-c3b8-4a7a-8379-a65270df14fe">6.8</ix:nonFraction> billion and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="if31c50772d7a4726a1a5529a7fef8da5_D20190201-20190228" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE1NDk_730424dc-4a09-4a62-9c42-322efcb55740">130</ix:nonFraction> million shares of common stock, which represented approximately <ix:nonFraction unitRef="number" contextRef="if31c50772d7a4726a1a5529a7fef8da5_D20190201-20190228" decimals="2" name="pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE2MDg_551a9bec-da3b-41b8-9d4d-afd82aad4f1e">80</ix:nonFraction>% of the notional amount of the ASR. In August 2019, the ASR with Goldman Sachs &amp; Co. LLC was completed resulting in Goldman Sachs &amp; Co. LLC owing us an additional <ix:nonFraction unitRef="shares" contextRef="i952c34b232a94d2d8ad00e03c4de2d9e_D20190801-20190831" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE3MjI_6987d4af-9b80-46a6-afbf-d3e8a0b88b1c">33.5</ix:nonFraction> million shares of our common stock. The average price paid for all of the shares delivered under the ASR was $<ix:nonFraction unitRef="usdPerShare" contextRef="i952c34b232a94d2d8ad00e03c4de2d9e_D20190801-20190831" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE4MjY_ac88dce9-a341-49c0-9b7f-a34317a68dac">41.42</ix:nonFraction> per share. The common stock received is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Treasury stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTU_9a0e5954-b8a7-4665-b660-4b992451c070" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:46.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.616%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.768%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our ASR:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of common stock purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtMi0xLTEtMTU1NjM4_5ddd7032-2734-4e63-b8ef-bd1e472a69bf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNC0xLTEtMTU1NjM4_bf8d12fe-c187-4087-9b79-67cfe4477e03">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNi0xLTEtMTU1NjM4_f86e5b8a-d846-49f5-82e8-3bfb2f963c41">213</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of purchase</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtMi0xLTEtMTU1NjM4_d8495ded-2d5d-4a4f-9d8d-7cb3d75f1172">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNC0xLTEtMTU1NjM4_5eaa3323-053f-49a2-8a83-24c5cd9be3ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNi0xLTEtMTU1NjM4_e3085a62-dc56-4860-80fe-177014844a33">8.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTc_c297e4fb-ce0c-4b32-bf03-e6b83d4cb4fc" footnoteRole="http://www.xbrl.org/2003/role/footnote">Represents shares purchased pursuant to the ASR with Goldman Sachs &amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $<ix:nonFraction unitRef="usd" contextRef="i81e39a223d384b35843e9b8e7445832b_D20190101-20191231" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzIwMjA_4a0adf2e-3681-4e8d-ae9f-190f50e6b017">2.1</ix:nonFraction> billion</ix:footnote>.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our remaining share-purchase authorization was approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzIyMTU_16baaacd-f520-4c49-a09f-0385a40b08a8">5.3</ix:nonFraction> billion at December 31, 2021.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Preferred Stock and Employee Stock Ownership Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior to May 4, 2020, we had outstanding Series A convertible perpetual preferred stock (the Series A Preferred Stock) that was held by an ESOP trust (the Trust). All outstanding shares of Series A Preferred Stock were converted, at the direction of the independent fiduciary under the Trust and in accordance with the certificate of designations for the Series A Preferred Stock, into shares of our common stock on May 4, 2020. The Trust received an aggregate of <ix:nonFraction unitRef="shares" contextRef="i56eda332625c487ca483e8359eb0f33a_D20200504-20200504" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE2NDkyNjc0NDkxOTE_2b4dc8be-8215-45a5-8596-206cc7ce6e13">1,070,369</ix:nonFraction> shares of our common stock upon conversion, with <ix:nonFraction unitRef="shares" contextRef="i152722889eb34e0db6ad2e1dfaeb0eed_I20200504" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDgy_b37f7fdd-dad7-4643-af32-c5300f96d1f5">zero</ix:nonFraction> shares of Series A Preferred Stock remaining outstanding as a result of the conversion. In December 2020, we filed a certificate of elimination and a restated certificate of incorporation with the Delaware Secretary of State, which eliminated the Series A Preferred Stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Since May 4, 2020, we have <ix:nonFraction unitRef="employeestockownershipplan" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="INF" name="pfe:NumberofEmployeeStockOwnershipPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzMwODk_7b75b074-dab9-4153-a3de-f5709ebae997">one</ix:nonFraction> ESOP that holds common stock of the Company (Common ESOP). As of December 31, 2021, all shares of common stock held by the Common ESOP have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $<ix:nonFraction unitRef="usd" contextRef="i7ee44a1fecca4b32be7705bc2cf810b0_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDAy_6a889194-0fa7-4cae-b05e-724cedd4fba7">19</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="ifd44478503164fd8a8e14462b5e7a729_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDA2_2e0363cc-4370-4b71-9da0-b8ce9459f470">19</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i917415daad0a4424b8d7a97c2d07bb8f_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDE2_e9779538-8bfd-4118-b8c8-504236152707">20</ix:nonFraction> million in 2019.</span></div></ix:continuation><div id="i4bff405b2205487eb835dd4cd589f5c6_223"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDg_408c783b-271d-45c9-9410-57e7b358c01b" continuedAt="i8fa711fce48e4c1b980769742be76b13" escape="true">Share-Based Payments</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i8fa711fce48e4c1b980769742be76b13" continuedAt="id76d155017a54b78bfeba755ac648673"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Our compensation programs can include share-based payment awards with value that is determined by reference to the fair value of our shares and that provide for the grant of shares or options to acquire shares or similar arrangements. Our share-based awards are designed based on competitive survey data or industry peer groups used for compensation purposes, and are allocated between different long-term incentive awards, generally in the form of Total Shareholder Return Units (TSRUs), Restricted Stock Units (RSUs), Portfolio Performance Shares (PPSs), Performance Share Awards (PSAs), Breakthrough Performance Awards (BPAs) and Stock Options, as determined by the Compensation Committee.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The 2019 Stock Plan (2019 Plan) replaced and superseded the 2014 Plan. It provides for <ix:nonFraction unitRef="shares" contextRef="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2Xzc3Nw_dc61253b-ae81-48dc-b975-427d174693c8">400</ix:nonFraction> million shares, in addition to shares remaining under the 2014 Plan, to be authorized for grants. The 2019 Plan provides that the number of stock options, TSRUs, RSUs, or performance-based awards that may be granted to any one individual during any <ix:nonNumeric contextRef="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQzOTgwNDY1MTk0NjE_daa779b1-9279-4b8d-b767-c9b98ac45870">36-month</ix:nonNumeric> period is limited to <ix:nonFraction unitRef="shares" contextRef="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231" decimals="INF" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzEwNTE_c4b1eadb-537e-4b1b-b7a7-792047c27c73">20</ix:nonFraction> million shares, and that RSUs count as three shares, PPSs, PSAs and BPAs count as <ix:nonFraction unitRef="shares" contextRef="i805079d974574ff6a2d5f8b886169231_D20210101-20211231" decimals="INF" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExMDA_5038a510-9459-4a05-94c6-9a79a5befb66"><ix:nonFraction unitRef="shares" contextRef="ic2151f3e772140029f5252c02f68b75b_D20210101-20211231" decimals="INF" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExMDA_8334ada6-4860-429c-bd63-a7715d22a15d"><ix:nonFraction unitRef="shares" contextRef="ic44cb9f5305946c5afb2c81a69675dff_D20210101-20211231" decimals="INF" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExMDA_8bd087c9-5bcf-4311-a7dc-20215c3b0247">three</ix:nonFraction></ix:nonFraction></ix:nonFraction> shares times the maximum potential payout, while TSRUs and stock options count as <ix:nonFraction unitRef="shares" contextRef="ic17568d2b6964d96a3edee3790b0ffae_D20210101-20211231" decimals="INF" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExNTA_3d1a7d3b-791e-4101-804e-425faac704d1"><ix:nonFraction unitRef="shares" contextRef="idc7be31568a945ebb1201de1758225e9_D20210101-20211231" decimals="INF" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExNTA_a208dd86-148c-4ad0-b03e-b40a26678619">one</ix:nonFraction></ix:nonFraction> share, toward the maximum shares available under the 2019 Plan. As of December 31, 2021, <ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzEyMjc_5b0cc664-6e5e-4776-aec0-24ed69891e07">315</ix:nonFraction> million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">89</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="id76d155017a54b78bfeba755ac648673" continuedAt="ia2cd75f9cfef4b46be323b2abaffcf88"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTM_22da06f8-775a-4f70-bdfb-a9a9844e06ff" continuedAt="id019b6b3c19e458eb69dd89d2a88ea97" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A summary of the awards and valuation details:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total Shareholder Return Units (TSRUs)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a), (b)</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management and select  employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107">five</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03">seven</span>-year term, if and to the extent the total value is positive.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Settlement price is the average closing price of our common stock during the <ix:nonFraction unitRef="tradingday" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f">20</ix:nonFraction> trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using a Monte Carlo simulation model</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Units (RSUs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For RSUs granted, in virtually all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portfolio Performance Shares (PPSs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#8217;s long-term product portfolio during a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfMTA5OTUxMTYyODQ4MQ_0da09f05-3e8c-4080-bb4d-fc5dd48fbbca">three</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNDQz_4d00d2e4-77a0-4861-9e03-9cd48bf4e5b8">five</span>-year performance period from the year of the grant date, as applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The number of shares that may be earned ranges from <ix:nonFraction unitRef="number" contextRef="i04e1e8887418409c8efc97bcddd13100_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNTU1_ea826cc7-d654-49ff-822b-867a89ad94f9">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9b45cc72fe144a41a027fcc9d82be277_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNTYx_938610a8-9551-4292-90a7-caf419284548">200</ix:nonFraction>% of the initial award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance Share Awards (PSAs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to <ix:nonFraction unitRef="measure" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMjI5_6df88edb-9105-474c-aa2b-f8fc0fafb579">two</ix:nonFraction> measures:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">Adjusted net income over <ix:nonFraction unitRef="period" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg2_ff1df9d3-99bf-4f89-858f-7dc326b3ffb5">three</ix:nonFraction> <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg5_e6c42dac-714f-4f5e-996c-4d0353676184">one</span>-year periods; and</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNDg1_fcbb828a-fc1b-45e8-92d8-b04179945bfd">three</span>-year performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The award that may be earned ranges from <ix:nonFraction unitRef="number" contextRef="i6748c5eccf3f46b1be9064d93a0b8af6_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNjM0_2a3aaf0d-96e4-4459-bd78-231a46d87734">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i0a49ac6e8d614f469106f20db9f45fd0_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNjQw_186566ae-e432-4a07-988b-d1d508acd3d6">200</ix:nonFraction>% of the target award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Breakthrough Performance Awards (BPAs)</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDk_1531252f-ed7d-4bb0-98f0-50eaa78bb5c6">one</span>-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer&#8217;s product pipeline during the performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">The number of shares that may be earned ranges from <ix:nonFraction unitRef="number" contextRef="i28be20f732ea48069576d8342f25116e_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDE_889cf845-9507-4253-bca6-12ff137683bc">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie383f1f76d1640bb8be8220be13b0054_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2MjkzOTQ_718ad5ea-cbd9-4669-b3a7-1a334b36a6f9">600</ix:nonFraction>% of the target award depending on the level and timing of goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the probable vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#8217;s assessment of the probability that the specified performance criteria will be achieved and/or management&#8217;s assessment of the probable vesting term.</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">90</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia2cd75f9cfef4b46be323b2abaffcf88" continuedAt="ia10d59beaffb4c938568de16331e3b6b"><ix:continuation id="id019b6b3c19e458eb69dd89d2a88ea97"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.979%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Since 2016, only a limited set of non-U.S. employees received stock option grants. <ix:nonFraction unitRef="shares" contextRef="ifd7ecda840fd43338a51a3f00ae86688_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI1YzI5YzlkZjQ0ZDRlNWU4NmJjODZkNmUwZjNmZTAxXzI3NQ_5288758e-d983-4718-bbb9-309b130eabaa">No</ix:nonFraction> stock options were awarded to senior and other key management in any period presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of <ix:nonNumeric contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI1YzI5YzlkZjQ0ZDRlNWU4NmJjODZkNmUwZjNmZTAxXzQ2Ng_3f140c97-e4fd-42f5-b17c-b6499c8a16b8">10</ix:nonNumeric> years. </span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the Black-Scholes-Merton option-pricing model</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418" footnoteRole="http://www.xbrl.org/2003/role/footnote">Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#8217; original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d" footnoteRole="http://www.xbrl.org/2003/role/footnote">In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (<ix:nonFraction unitRef="shares" contextRef="i9593b3f58b76448e920aee74df7e93c9_D20170101-20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIwODg_203953c5-7182-48c9-93e4-7cbfec99bc78">1,444,395</ix:nonFraction> PTSRUs) and <ix:nonFraction unitRef="shares" contextRef="i2f80dcb721524320b19d3c6b3d3391e6_D20170101-20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIxMDM_9edc92d1-99bf-44af-beb4-d540d84fc058">361,099</ix:nonFraction> PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i443cb80c5f964703aaecddf09596d6a4_D20170101-20171231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIyNDg_4a078a9e-685e-4bad-8ada-cad81ce3881a">30.31</ix:nonFraction> and at a GDFV of $<ix:nonFraction unitRef="usdPerShare" contextRef="i443cb80c5f964703aaecddf09596d6a4_D20170101-20171231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIyNjg_f0c9ae70-d792-4a54-b349-a9a134fd5b8b">5.54</ix:nonFraction> per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions</ix:footnote>.</span></div></ix:continuation><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDk_0012b297-30ea-422c-877a-adca8d8ceef1" continuedAt="i72c002a02de5418d92f136ec06453156" escape="true"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="93" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PPSs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total fair value of shares vested</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMi0xLTEtMTU1NjM4_0030d148-ccdb-493d-9ef6-9c6e5e073b5c">7.26</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNC0xLTEtMTU1NjM4_466fd797-58fa-45d5-848d-734df1c99bde">6.22</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNi0xLTEtMTU1NjM4_75b7d650-b93e-46a1-87ad-f8b8375f99cd">8.52</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtOC0xLTEtMTU1NjM4_3ddbadfe-2c7e-469b-8b74-ac53c8330c60">304</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTAtMS0xLTE1NTYzOA_5ce6a7c9-5907-47d5-a423-c9b0057bbc7d">334</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie346598571a44f5e9df70a558c1951da_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTItMS0xLTE1NTYzOA_9f88f9b8-9153-4eae-9b34-60c2f6485b91">454</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTQtMS0xLTE1NTYzOA_1e6a6321-5b59-4629-a177-6e2866459aee">181</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTYtMS0xLTE1NTYzOA_b173fb43-0d28-4160-8fd4-5c4b99367cb5">119</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTgtMS0xLTE1NTYzOA_72fd28a5-d393-4635-8f84-5f5b000a4bc4">136</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjAtMS0xLTE1NTYzOA_3a83e750-3f49-46d0-a35a-4b9f84e9a9e4">33</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjItMS0xLTE1NTYzOA_de7e819a-94c2-4908-b137-6debfd7edbc1">25</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjQtMS0xLTE1NTYzOA_dffb3ed7-9572-487e-ad9c-3dc22c16c91a">64</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjYtMS0xLTE1NTYzOA_e3208f64-720b-4f0f-8801-e090f70792e1">4.86</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjgtMS0xLTE1NTYzOA_b49a6e3c-efe7-4be4-92f6-272d3b6a1aa8">3.56</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMzAtMS0xLTE1NTYzOA_eaafc4ca-df82-4841-949c-5e448cee1d0c">5.98</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised or share units converted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="-6" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMi0xLTEtMTU1NjM4_03dc70e4-91e3-43fc-be3b-f6553da659d7">594</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" decimals="-6" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtNC0xLTEtMTU1NjM4_422ccd07-400b-458b-80e3-ac06caaaaa98">84</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" decimals="-6" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtNi0xLTEtMTU1NjM4_eccd41c1-2ce8-47a1-a047-3044812539ef">175</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="-6" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMTQtMS0xLTE1NTYzOA_75ccbad2-9a98-4785-b55c-920b87ac2366">228</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231" decimals="-6" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMTYtMS0xLTE1NTYzOA_3be03cca-754d-482b-a237-3265c88f9803">224</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231" decimals="-6" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMTgtMS0xLTE1NTYzOA_33b8cb4d-733f-4430-8eeb-36c72e21b783">245</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMjYtMS0xLTE1NTYzOA_bb9c9394-f9a0-412f-be17-717ad59b0770">584</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMjgtMS0xLTE1NTYzOA_f1937fed-cfe0-41a5-b14d-9e41185ca6e7">293</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMzAtMS0xLTE1NTYzOA_514b2111-a888-43a6-9ac7-6de6d5366e4b">261</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash received upon exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzUtMjYtMS0xLTE1NTYzOA_a716dd4e-23c3-4b1c-8e5e-4e71018d62c2">795</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzUtMjgtMS0xLTE1NTYzOA_05766779-6f44-44c3-b6a4-0f547a0a03c0">425</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzUtMzAtMS0xLTE1NTYzOA_5dcef52b-0450-49c1-8668-ef8382abe056">394</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax benefits realized from exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzYtMjYtMS0xLTE1NTYzOA_55485b73-6c6e-4ca1-937b-9aa80922a7fe">106</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzYtMjgtMS0xLTE1NTYzOA_10d051ca-097e-4661-ac55-1bbb7678bde5">55</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzYtMzAtMS0xLTE1NTYzOA_f8864890-eb52-47d7-b37e-e8f2b0d5afd1">47</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation cost recognized, pre-tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMi0xLTEtMTU1NjM4_1a94ef26-c091-4e7d-9c52-3172fbaf29df">259</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNC0xLTEtMTU1NjM4_992fa98a-bf2f-4f41-a787-082f6d3b2a31">287</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNi0xLTEtMTU1NjM4_07778de6-12fc-43bd-ade7-053555389107">294</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctOC0xLTEtMTU1NjM4_87c54e86-a569-4df7-b8e6-04951fcb6787">281</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTAtMS0xLTE1NTYzOA_5806a747-3c80-4200-947d-3b5d951b4251">272</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie346598571a44f5e9df70a558c1951da_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTItMS0xLTE1NTYzOA_e6579469-97e3-4adb-8f01-c8be1876bf76">275</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTQtMS0xLTE1NTYzOA_d4d12f82-0c20-47ed-9fbe-8e0227117c6d">535</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTYtMS0xLTE1NTYzOA_ca3030ec-ef12-4e8d-bc08-dda9ca807e2a">180</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTgtMS0xLTE1NTYzOA_7bfc61f9-ca76-4c82-a926-959e839402ce">114</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjAtMS0xLTE1NTYzOA_4b62f3d1-5853-4f73-8a18-d81f343f0906">76</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjItMS0xLTE1NTYzOA_fa3d1f38-ed77-4ad5-ac7d-a22f0e7a7326">31</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjQtMS0xLTE1NTYzOA_fcb4ae62-0c3e-4fac-a30c-235ab34d77a1">28</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjYtMS0xLTE1NTYzOA_229afef2-6bb7-4825-b021-99094d2266fa">5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjgtMS0xLTE1NTYzOA_d579c4af-57c0-45ef-981f-37cabba91840">6</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMzAtMS0xLTE1NTYzOA_38732335-d53e-4f06-84e2-85dd1154c1a0">7</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total compensation cost related to nonvested awards not yet recognized, pre-tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMi0xLTEtMTU1NjM4_6f4a9d0c-9981-4015-8d28-347ef86a4bcd">187</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtNC0xLTEtMTU1NjM4_917c700f-f374-4d9c-8ada-cbeaacf86df8">224</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i2473beb495894534a4c23085d71539f7_I20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtNi0xLTEtMTU1NjM4_ee814931-ee55-46db-a91f-95c6e92ba6af">229</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i32f0385272bd4aac882c487c230d065c_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtOC0xLTEtMTU1NjM4_e4b89f4a-6278-43da-8e10-b891c0fdbb32">271</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ief795c9787db4b308dde841b75ab39f2_I20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTAtMS0xLTE1NTYzOA_8a50fc82-45f4-4066-a171-61d249fb1000">228</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i30bd7895983642db9bf813a473267120_I20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTItMS0xLTE1NTYzOA_fcc52ab4-8046-4261-9e29-b80cabd048c6">241</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTQtMS0xLTE1NTYzOA_60be4c9e-6411-45f0-b9f5-683657d3f996">175</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="if41e5d4716e04e498cba46b05595ab61_I20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTYtMS0xLTE1NTYzOA_740e5470-772f-4cbb-a59f-34f05f0eef03">104</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i4fc53e6e2a9e49298a3cfd288203afd2_I20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTgtMS0xLTE1NTYzOA_6c72f42a-d0b9-4a16-8456-9b688b4a3c8a">87</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjAtMS0xLTE1NTYzOA_0d9e2f33-02bc-489c-bd68-f2f6b515018f">54</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i84a9df877b7a4600aec68656dac6703a_I20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjItMS0xLTE1NTYzOA_1a51cd48-1a7f-4437-93ec-4ebeac3d5194">32</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ic7f0f1f3fa304519914914cfa722b7a5_I20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjQtMS0xLTE1NTYzOA_3bc06075-c243-48a3-9283-026e537ae368">34</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i97f983501e904503babee369fc4f690c_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjYtMS0xLTE1NTYzOA_f9c7003c-50b3-489c-a090-91495fe7e44c">3</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i1b9d4654dee8466e88457fed9824652f_I20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjgtMS0xLTE1NTYzOA_76c28f3d-63b8-4e5e-942d-a455f8251902">4</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ibabdd67705e148c3827e146d45375317_I20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMzAtMS0xLTE1NTYzOA_0988425e-c6db-41bc-aeba-fa82296cc9e7">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted-average period over which cost is expected to be recognized (years)</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMi0xLTEtMTU1NjM4_c8360efa-797b-4b3a-9039-865604d3b4ce">1.6</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktNC0xLTEtMTU1NjM4_930117f1-c0e6-46c2-826d-18b8452dfe6b">1.6</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktNi0xLTEtMTU1NjM4_f413bcf3-4913-4b10-8b9c-0915588e8ab7">1.6</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktOC0xLTEtMTU1NjM4_3c5ac71e-6c33-47ab-8198-b909ebe49cf4">1.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTAtMS0xLTE1NTYzOA_30334fdd-8da3-44e1-995d-3d2f46d9d1a1">1.7</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie346598571a44f5e9df70a558c1951da_D20190101-20191231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTItMS0xLTE1NTYzOA_c6fb925a-9a8b-4bd9-8f5a-2b998664da9e">1.7</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTQtMS0xLTE1NTYzOA_1e4489a1-28c5-4ee7-ad3c-017eaa9f51d8">1.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTYtMS0xLTE1NTYzOA_181c257d-d8e6-4fa7-9a65-bf7aeb3e5606">1.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTgtMS0xLTE1NTYzOA_012b6bc7-d1d3-45ec-88bc-f5298e103a3d">1.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjAtMS0xLTE1NTYzOA_65aa1b79-61f1-4632-be43-7503d5bd5644">1.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjItMS0xLTE1NTYzOA_46f5a6ca-ca1a-419a-808e-f53be303b1e6">1.9</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjQtMS0xLTE1NTYzOA_b82b3c1a-1489-4f42-9af8-ef0f218705d8">1.8</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjYtMS0xLTE1NTYzOA_0c850efe-9c3b-48ee-b50a-003d4858dae3">1.6</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjgtMS0xLTE1NTYzOA_ea77eda9-ebde-438b-9c41-0f054211cc69">1.7</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMzAtMS0xLTE1NTYzOA_26981495-84d9-46ea-8536-41988ec87380">1.6</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39" footnoteRole="http://www.xbrl.org/2003/role/footnote">Weighted-average GDFV per TSRUs and stock options.</ix:footnote></span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81" footnoteRole="http://www.xbrl.org/2003/role/footnote">TSRU includes expense for PTSRUs, which is not significant for all years presented</ix:footnote>.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total share-based payment expense was $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI2ODk_32511e7b-e063-47a9-a520-d4ea20491a09">1.2</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI2OTM_912dcb5d-c7dc-4a10-80b1-68fa85f384e9">780</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI3MDA_bc34ce82-9fe4-49e8-999a-de7bfd06cb58">718</ix:nonFraction> million in 2021, 2020 and 2019, respectively, which includes pre-tax share-based payment expense included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="i94325d0fdc4e459f931d66a9b73fffa3_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI4NDk_c2e618d0-82be-4df1-8206-2364765da6fc">2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="icb707d364c664f20a32ea1127fd4286b_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI4NTM_88bcd10f-ddcd-48de-8332-79fbc0912059">25</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5a24c56d22cc4eb1ba8bcbaa319b4761_D20190101-20191231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI4NjA_42620df8-d558-47b5-bb4a-a78c2dba3f4b">32</ix:nonFraction> million in 2021, 2020 and 2019, respectively. Tax benefit for share-based compensation expense was $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI5NDg_db5a9385-4cc9-4b37-9221-e58892125587">227</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI5NTI_890a2a1a-260f-41e0-93e9-3c9bdd072bda">141</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI5NTk_be003806-b1ec-408c-b04d-98a8cdee4c8c">137</ix:nonFraction> million in 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all years presented and is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Amounts capitalized as part of inventory cost were not significant for any period presented.</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="pfe:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTQ_6d22720a-4112-4746-a75c-17f520620402" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected dividend yield </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(based on a constant dividend yield during the expected term)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtMi0xLTEtMTU1NjM4_6a08fc3b-40b7-46bb-9dea-d70b7c01263e">4.51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtNC0xLTEtMTU1NjM4_ed38c7c4-3c4e-44d3-81d3-55a3a1776e32">4.36</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtNi0xLTEtMTU1NjM4_30016952-2366-4757-ac9d-bd07b8a49c7b">3.27</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtOC0xLTEtMTU1NjM4_80ee0b2f-9df0-49b2-b7af-a969aebd209a">4.51</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtMTAtMS0xLTE1NTYzOA_27be2afb-dc0e-4547-bfcc-44cf66bcffb8">4.36</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtMTItMS0xLTE1NTYzOA_0ded1a9b-4392-4de8-846e-0001dd8252e4">3.27</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on interpolated yield on U.S. Treasury zero-coupon issues)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtMi0xLTEtMTU1NjM4_1fafb186-ce2c-40a4-8e98-5ce1e03cdd64">0.93</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtNC0xLTEtMTU1NjM4_9c370a45-6f90-4edb-b52d-ff9d7040d4b4">1.15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtNi0xLTEtMTU1NjM4_6e210d60-b51f-4021-8d37-f1f179e09b15">2.55</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtOC0xLTEtMTU1NjM4_23ef547e-c772-487b-8097-28f9c35eec22">1.27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtMTAtMS0xLTE1NTYzOA_651c0767-76b2-498c-8a56-f389a241d29d">1.25</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtMTItMS0xLTE1NTYzOA_9da39f07-b2d4-4e40-a8a9-89980eb480d7">2.66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on implied volatility, after consideration of historical volatility)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtMi0xLTEtMTU1NjM4_3f640f34-706a-497b-9630-c8748b0b3cd5">26.53</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtNC0xLTEtMTU1NjM4_067189c5-a926-4f17-8009-747d41ba888e">20.99</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtNi0xLTEtMTU1NjM4_8764f3a3-e1f3-46ef-a637-f4a019ea838c">18.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtOC0xLTEtMTU1NjM4_6e687cac-10c7-4214-ad51-46a99b1b0e71">26.54</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtMTAtMS0xLTE1NTYzOA_ff7b2806-d844-4a79-a4cc-af79a0313c24">20.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtMTItMS0xLTE1NTYzOA_1980a517-df81-495d-abe6-fa53784c78a7">18.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TSRUs contractual/stock options expected term, years</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on historical exercise and post-vesting termination patterns for stock options) </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtMi0xLTEtMTU1NjM4_ca3ba93f-485d-4140-b43b-1e1ae783e675">5.15</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtNC0xLTEtMTU1NjM4_4a1bb09a-b387-49d2-8a9e-08d59cba11a6">5.12</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtNi0xLTEtMTU1NjM4_b2b51fb3-e1e6-464c-b7b8-eedd3469960a">5.13</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtOC0xLTEtMTU1NjM4_c20c8475-8fc8-43a2-a7df-a07dc4046ab5">6.75</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtMTAtMS0xLTE1NTYzOA_b19ee2d4-8e18-4990-a12e-579ca992c092">6.75</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtMTItMS0xLTE1NTYzOA_6c4b5c82-f265-48ed-90aa-44e223222d15">6.75</ix:nonNumeric></span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia10d59beaffb4c938568de16331e3b6b"><ix:continuation id="i72c002a02de5418d92f136ec06453156"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="69" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of all TSRU, RSU, PPS, PSA and BPA activity during 2021 (with the shares granted representing the maximum award that could be achieved for PPSs, PSAs and BPAs):</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PPSs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BPAs</span></td></tr><tr style="height:5pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">TSRUs&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="9" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Per TSRU, Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;Weighted Avg. GDFV per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">GDFV</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Grant Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nonvested, </span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMi0xLTEtMTU1NjM4_2fdc7757-f649-4996-b091-ba89eab6285a">129,844</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtNC0xLTEtMTU1NjM4_f1b7ff23-d2ed-4b57-aea1-b5d7de3a886f">6.90</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtNi0xLTEtMTU1NjM4_c8c0ad08-1204-4bc1-9d98-7b1df4d10648">32.94</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief795c9787db4b308dde841b75ab39f2_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtOC0xLTEtMTU1NjM4_b6c4fd24-8c3b-4daf-b1f0-5ee9465975c0">23,692</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief795c9787db4b308dde841b75ab39f2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTAtMS0xLTE1NTYzOA_d49a869a-6853-4802-8229-a4c3736d3500">35.50</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if41e5d4716e04e498cba46b05595ab61_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTItMS0xLTE1NTYzOA_cd0713ce-a174-401d-a6cf-b7a389c052b5">20,077</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if41e5d4716e04e498cba46b05595ab61_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTQtMS0xLTE1NTYzOA_64af5ac8-922a-4e1d-a5a2-766e1fd5157d">36.81</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i84a9df877b7a4600aec68656dac6703a_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTYtMS0xLTE1NTYzOA_29872a2d-0656-44d6-ab7a-1ef42e1f6e56">5,264</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i84a9df877b7a4600aec68656dac6703a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTgtMS0xLTE1NTYzOA_c05aa8ae-781c-4a13-8369-247bf8229f5a">36.81</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9cb70c93197414db93c20b578e77936_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMjAtMS0xLTE5NjQ0Mw_45930ec5-a1c4-43b4-954c-24ea8a282911">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9cb70c93197414db93c20b578e77936_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMjItMS0xLTE5NjQ5NA_20983ce8-7e2b-4b93-8bab-64ca9a9ddc0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMi0xLTEtMTU1NjM4_265f0150-c839-4fb9-8bc4-7fa060fddd6f">34,522</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtNC0xLTEtMTU1NjM4_752478fa-b051-4b20-9bd6-ec11127faf62">7.26</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtNi0xLTEtMTU1NjM4_3f4f55a2-cc3b-4afa-9bc7-99c1935e660d">33.83</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtOC0xLTEtMTU1NjM4_82e477ba-1cd3-48c1-bfb9-dc1b64547bdc">10,893</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTAtMS0xLTE1NTYzOA_57b94018-d7d4-4ce2-a596-894cd954f6e4">34.31</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTItMS0xLTE1NTYzOA_4211c29b-37c3-4166-8a7b-994500cacb41">8,632</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTQtMS0xLTE1NTYzOA_14faf7c2-7a01-4302-b4ef-c4f8cd899ae8">33.82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTYtMS0xLTE1NTYzOA_ebbde6c8-9cf9-4c75-a299-9c373c1e2f24">1,798</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTgtMS0xLTE1NTYzOA_c9b81a6f-5cdd-4f35-817f-d753d6aaf746">33.82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMjAtMS0xLTE5NjQ0Mw_31d8f060-2290-477d-a885-6bbf64728de3">1,165</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMjItMS0xLTE5NjQ5NA_219f7804-b5b6-4527-93a0-3338fc9eaab9">38.73</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMi0xLTEtMTU1NjM4_d9b91d49-65bc-4a91-9a09-743e7f544dda">44,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctNC0xLTEtMTU1NjM4_42612d0e-2b90-467f-82c3-b67fbf6b6ea1">7.21</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctNi0xLTEtMTU1NjM4_a8f9e630-441f-42a5-b28e-9cd41ba0836d">30.54</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctOC0xLTEtMTU1NjM4_645dd690-6164-4e4f-8079-c01458fc8fbc">8,747</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTAtMS0xLTE1NTYzOA_fe00f3e0-dcd9-4bdb-85dc-aed9ba13cb8c">34.66</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTItMS0xLTE1NTYzOA_2f464006-2cdb-4183-b0fd-f41fe79230da">6,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTQtMS0xLTE1NTYzOA_465e3f25-0b56-4f09-812f-8698f3314174">33.88</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTYtMS0xLTE1NTYzOA_b037bb9b-5bfb-49fa-b311-da514d3bc40f">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTgtMS0xLTE1NTYzOA_909f7ac2-138e-457a-9b20-cf9010878726">33.85</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMjAtMS0xLTE5NjQ0Mw_faa430f3-a986-4858-b025-a1d146fde154">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMjItMS0xLTE5NjQ5NA_ce77e5d6-a822-452f-bafc-879fb2707589">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reinvested dividend equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="-3" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzgtOC0xLTEtMTU1NjM4_07165532-992c-4d21-9566-6438231b115b">956</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzgtMTAtMS0xLTE1NTYzOA_9eb0160d-40b4-4db0-a925-5dbffeea30d0">41.33</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMi0xLTEtMTU1NjM4_e7a7c0cb-9a52-4af6-8ad3-101561a59bdc">4,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktNC0xLTEtMTU1NjM4_ee1317c7-af38-4a4b-a928-b24dfb176e6e">6.77</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktNi0xLTEtMTU1NjM4_cd2900aa-4f3c-48ef-b13c-7377166fd875">33.78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktOC0xLTEtMTU1NjM4_123fef7a-6d37-4e73-8912-0489cfed0e39">1,255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTAtMS0xLTE1NTYzOA_ac4627a7-6f1c-41a0-82c2-7de38d4fba79">35.17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTItMS0xLTE1NTYzOA_532a46be-433a-42ba-8ed4-9fbf1cd26e71">1,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTQtMS0xLTE1NTYzOA_3af3c0e7-b52e-4fe4-a24f-8ddc2ed8a412">41.45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTYtMS0xLTE1NTYzOA_6438e57b-a5f0-412e-b96f-e188eac5534a">924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTgtMS0xLTE1NTYzOA_e0225c8c-626b-4bf9-b0ad-c2c8d0b97ef3">34.43</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMjAtMS0xLTE5NjQ0Mw_522af3ee-0da4-4d02-8652-7eb79e75703f">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMjItMS0xLTE5NjQ5NA_e84f71c1-eee3-4e93-ab19-bc2ae28463ff">47.47</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nonvested, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTItMS0xLTE1NTYzOA_ab792de6-3c8c-41e0-b7ee-3e6b6b406a08">114,599</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTQtMS0xLTE1NTYzOA_ca20ae79-66c2-45bf-8702-dd72771b636a">6.90</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTYtMS0xLTE1NTYzOA_00449635-98f0-41e9-85fe-1dda1c419612">34.12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32f0385272bd4aac882c487c230d065c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTgtMS0xLTE1NTYzOA_89e88527-d7d5-4755-b238-998ae8db9bdb">25,540</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i32f0385272bd4aac882c487c230d065c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEwLTEtMS0xNTU2Mzg_65c775aa-eea8-430b-91ee-c9953c3125fe">35.52</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEyLTEtMS0xNTU2Mzg_30a08688-abc7-4fc1-a6dc-6a6a58197d10">21,480</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE0LTEtMS0xNTU2Mzg_6c6bceb0-130d-49af-862b-de96ffd1fba6">59.05</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE2LTEtMS0xNTU2Mzg_59fb6a1d-60bb-467d-ac41-15e9e31e03bc">5,154</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE4LTEtMS0xNTU2Mzg_462f283c-5741-4ea9-b2e5-abf6b80ca956">59.05</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia38cd1de7c7d4dbd86cd29bd60031120_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzEwLTIwLTEtMS0xOTY0NDM_4d24e5c6-ae53-4c07-afa8-43618dde3225">859</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia38cd1de7c7d4dbd86cd29bd60031120_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzEwLTIyLTEtMS0xOTY1MDQ_81e3181b-fd99-46c7-bd65-de89bec6ebab">59.05</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406" footnoteRole="http://www.xbrl.org/2003/role/footnote">Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were <ix:nonFraction unitRef="shares" contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzM0NTQ_1faff4f5-8a46-4959-a73b-ffa14d778b4c">34.1</ix:nonFraction>&#160;million.</ix:footnote></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of TSRU and PTU information as of December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TSRUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PTUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average<br/>Grant&#160;Price<br/>Per TSRU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Contractual Term </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca">206,996</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe">31.71</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d">5,969</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="-3" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9">92,398</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945">28.72</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617">0.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc">2,946</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Expected to vest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="-3" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7">110,476</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9">34.16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051">3.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231" decimals="-6" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182">2,910</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs exercised and converted to PTUs</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57785a499e164f5bacbcf350c3fb80f3_I20211231" decimals="-3" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44">3,074</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i983864cac72f40e9a85d8421bcaebe0f_D20210101-20211231" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765">0.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57785a499e164f5bacbcf350c3fb80f3_I20211231" decimals="-6" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981">182</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" footnoteRole="http://www.xbrl.org/2003/role/footnote">In 2021, we settled <ix:nonFraction unitRef="shares" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQzNjM_bc802032-9dbe-4d6a-973d-8e9b3dc6da76">46,060,346</ix:nonFraction> TSRUs with a weighted-average grant price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ0MTE_c8956feb-b099-4545-b7ef-9bdb256e349b">23.04</ix:nonFraction> per unit.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" footnoteRole="http://www.xbrl.org/2003/role/footnote">In 2021, <ix:nonFraction unitRef="shares" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ0MzE_07d61c9a-af73-4de2-b314-bd591f98bc45">7,093,787</ix:nonFraction> TSRUs with a weighted-average grant price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231" decimals="2" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ0Nzk_004bef92-e359-4e28-96a4-86bbaaebaa3b">27.41</ix:nonFraction> per unit were converted into <ix:nonFraction unitRef="shares" contextRef="i983864cac72f40e9a85d8421bcaebe0f_D20210101-20211231" decimals="INF" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ1MTE_c5948704-62c8-46af-8db8-e423edcbf86c">2,943,737</ix:nonFraction> PTUs.</ix:footnote></span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a" footnoteRole="http://www.xbrl.org/2003/role/footnote">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</ix:footnote></span></div></ix:continuation><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDY_cd63a67a-281e-4836-a199-ec2bc2789481" escape="true"><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of all stock option activity during 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzItMi0xLTEtMTU1NjM4_72d83504-38f4-4131-8ffe-c542310c1690">75,402</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzItNC0xLTEtMTU1NjM4_5a13851f-f257-4ae1-b4ea-074be5a2e77b">28.31</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzMtMi0xLTEtMTU1NjM4_574ae24e-6cb4-4c89-825f-d533213af7a5">779</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzMtNC0xLTEtMTU1NjM4_aa6913cc-f989-437e-bf6c-9a1b1c3667a8">33.82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzQtMi0xLTEtMTU1NjM4_928dbe48-61c4-4902-860d-29b325656569">31,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzQtNC0xLTEtMTU1NjM4_b34032fe-1e65-46d4-8a46-738c20f2c52e">25.75</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzUtMi0xLTEtMTU1NjM4_3091ff2b-7c39-406f-a9de-f601284bc2b8">89</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzUtNC0xLTEtMTU1NjM4_988e62ce-f24c-47b7-a195-49e4c1f96100">34.39</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzYtMi0xLTEtMTU1NjM4_1fc5d47f-cbfe-480a-847f-b77096979a46">181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzYtNC0xLTEtMTU1NjM4_9c5dfa77-d737-4590-81e0-f4c70bd437ef">20.27</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding, December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtMi0xLTEtMTU1NjM4_71f440f8-5ad5-40eb-a48c-cc92cae9946d">44,874</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtNC0xLTEtMTU1NjM4_da9dd5b2-c275-45e2-9660-bb1ac6b49edd">30.20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtNi0xLTEtMTU1NjM4_44242e42-da66-4011-be23-097e6ede38cd">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtOC0xLTEtMTU1NjM4_a8ea7123-02b9-4280-a4ee-558383a13da3">1,295</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vested and expected to vest, December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktMi0xLTEtMTU1NjM4_b189be12-71d4-4059-9bf6-009e6706aa64">44,747</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNC0xLTEtMTU1NjM4_e5bdff91-87d3-4fcc-b133-d858a5c2b28b">30.19</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNi0xLTEtMTU1NjM4_0f6f6780-b698-4e7e-9a46-e03c9a909569">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599">1,291</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable, December 31, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTItMS0xLTE1NTYzOA_f12e986f-c581-4568-83de-2eaf5cd2d78a">41,583</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTQtMS0xLTE1NTYzOA_2d557ee2-214d-414b-af01-65a333acaae9">29.81</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTYtMS0xLTE1NTYzOA_359659c6-5e7b-440b-8b27-5b2f9441c9f0">2.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTgtMS0xLTE1NTYzOA_f45c3b5f-a7dd-48d8-9864-4df1b90c966f">1,216</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759" footnoteRole="http://www.xbrl.org/2003/role/footnote">Market price of our underlying common stock less exercise price.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8" footnoteRole="http://www.xbrl.org/2003/role/footnote">The number of options expected to vest takes into account an estimate of expected forfeitures.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_226"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> Note 14. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyOA_50d3e618-606d-4a41-bc43-41946d437c88" continuedAt="i628e8a36a10e4f2f87600f250b04bfbf" escape="true">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ix:nonNumeric></span></div><ix:continuation id="i628e8a36a10e4f2f87600f250b04bfbf" continuedAt="ifded73cb500d4358844fc177f2875607"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYzMA_dbfe8d8a-7cc8-4396-85d2-466f51386d44" escape="true"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:66.411%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EPS:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(IN MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzQtMi0xLTEtMTU1NjM4_f7d8e03b-88de-4a98-885c-c76d25b1b796">22,414</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzQtNC0xLTEtMTU1NjM4_7623259f-d14e-4443-8f1d-e984fcff2e19">6,630</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzQtNi0xLTEtMTU1NjM4_3773e9d6-2762-46ac-80ae-45a9514ae7d1">10,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzUtMi0xLTEtMTU1NjM4_672d96d9-529c-44df-b10a-7744ef3b4c31">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzUtNC0xLTEtMTU1NjM4_32034bac-5078-4403-b938-65108a99cd94">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzUtNi0xLTEtMTU1NjM4_2a1c7935-7798-4d92-91dd-b8374af47f35">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzYtMi0xLTEtMTU1NjM4_58371438-6ab1-4623-b71c-d522d4462cba">22,414</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzYtNC0xLTEtMTU1NjM4_ea3e7d80-d8d2-4804-b169-75f386cd2f6a">6,630</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzYtNi0xLTEtMTU1NjM4_d6100fb5-b1d9-40e4-abd9-c5ca08e4336b">10,708</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzktMi0xLTEtMTU1NjM4_d532bc1a-03f4-4c8e-acd6-192c9d6498f8">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzktNC0xLTEtMTU1NjM4_2bd6d72a-7f4a-4b67-ba5b-c026cfaa9594">2,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzktNi0xLTEtMTU1NjM4_7d2be479-0166-4f15-9d90-aceb90724017">5,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEwLTItMS0xLTE1NTYzOA_631baeca-5590-49e0-937a-01d7c254387a">21,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEwLTQtMS0xLTE1NTYzOA_b85607fe-e9b5-4af0-ae2d-bba75260c851">9,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEwLTYtMS0xLTE1NTYzOA_a4602888-f233-4e62-a041-0edbb1028caf">16,025</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEyLTItMS0xLTE1NTYzOA_c95414c0-124b-42e6-b70c-be9bfe803c9f">22,414</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEyLTQtMS0xLTE1NTYzOA_80e1b7f7-e1a3-460a-826c-64e03243a6d7">6,630</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEyLTYtMS0xLTE1NTYzOA_97c65b1c-1dc8-4f9e-8d90-de85810722df">10,708</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEzLTItMS0xLTE1NTYzOA_b9473729-4e52-4c25-90d4-7e5bb7570102">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEzLTQtMS0xLTE1NTYzOA_0b82e2dc-7840-4407-b44a-ab2955f345d4">2,529</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEzLTYtMS0xLTE1NTYzOA_2a232e00-7201-4b76-918d-91f12522fe90">5,318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE0LTItMS0xLTE1NTYzOA_c3e86a89-7d92-459a-ac3d-ee85b68e878a">21,979</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE0LTQtMS0xLTE1NTYzOA_995c75d7-27cb-4d53-b6c3-7fd14e48c7d5">9,159</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE0LTYtMS0xLTE1NTYzOA_aea1c8b7-3be7-4005-a898-84dbb47c6d65">16,026</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE2LTItMS0xLTE1NTYzOA_b81f7d02-b490-4236-859f-b314719489a3">5,601</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE2LTQtMS0xLTE1NTYzOA_2677238c-3cb5-42b0-8e9c-cc9bbf7f8fdb">5,555</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE2LTYtMS0xLTE1NTYzOA_9b6bf15c-0575-44f1-94a4-b25b124acea7">5,569</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE3LTItMS0xLTE1NTYzOA_719a15c0-a8bc-450c-9ada-44a5f94084aa">107</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE3LTQtMS0xLTE1NTYzOA_3dc1d107-36ca-442a-a012-370aab59a5da">77</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE3LTYtMS0xLTE1NTYzOA_5a0fbe7b-8a9d-4ad4-b470-5ebbbdd3f69d">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE4LTItMS0xLTE1NTYzOA_2e6162b1-f05d-4337-b157-9aade0cc0169">5,708</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE4LTQtMS0xLTE1NTYzOA_139029e1-6948-4748-8b53-ae3e69a75bd4">5,632</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE4LTYtMS0xLTE1NTYzOA_724575f9-164d-4370-a0da-5643b3f412b0">5,675</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTItMS0xLTE1NTYzOA_1e898dab-8f93-4ef8-94ae-b8e82db17466">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTQtMS0xLTE1NTYzOA_b2fe21d4-54c8-40ac-ab41-f210c214bc66">4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTYtMS0xLTE1NTYzOA_f6e6827d-16c5-473d-b9a4-970beab322dd">2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyNQ_31721eb0-f80c-45c8-9db8-a5fd7509ba21" footnoteRole="http://www.xbrl.org/2003/role/footnote">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</ix:footnote></span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><ix:continuation id="ifded73cb500d4358844fc177f2875607" continuedAt="if57854add55045b7893863e9094407a4"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP was assumed in the diluted EPS calculation until the conversion date, which occurred in May 2020. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="if57854add55045b7893863e9094407a4">.</ix:continuation> </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_229"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 15. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjM_668c9f50-c32c-4854-94b9-d020cd84d01a" continuedAt="i753a894082634c909306d9cfbfba319d" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i753a894082634c909306d9cfbfba319d" continuedAt="i8c35af4c02c243b3bec47cbff9fa616f"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMzA_8a7c3be4-f6ae-4ead-be9e-83c8a7e150ea" escape="true"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of <ix:nonNumeric contextRef="i3c06c854564f400a90dbefc01376069e_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzEzMw_1a82e224-574f-427c-9beb-33b34d97a4e4">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i3f1f62383330418da8e053b9b9db9ba8_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzEzOQ_7f6c76c0-fcd2-4f4d-a447-6db6d8f3b67e">30</ix:nonNumeric> years, some of which include options to terminate or extend leases for up to <ix:nonNumeric contextRef="i1d1bc977a4bf4a8d8dd29d3800b05abf_D20210101-20211231" name="pfe:LesseeOperatingLeaseOptionToExtendTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIxMw_485e8958-5f15-4781-8291-420f2b9b5beb">5</ix:nonNumeric> to <ix:nonNumeric contextRef="i0bbea5f2ec0948fb967b4a1b64621b58_D20210101-20211231" name="pfe:LesseeOperatingLeaseOptionToExtendTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIxOQ_b9c406a8-bbbb-4709-8329-287cd43ac44d">10</ix:nonNumeric> years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzkwOQ_09fe62d0-ac6a-4d30-9386-8a96b76843ce">381</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzkyMg_e8c23781-9d1b-4369-bc5d-2a583198d00c">380</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzE2NDkyNjc0NDQzNzI_cb95e54a-d72a-4eb1-a91f-695d27b6533d">326</ix:nonFraction> million in 2019. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div></ix:nonNumeric><div style="margin-top:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjY_97cc8ba9-96da-4212-a3e6-c66f29811122" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_408086e2-3444-4b88-b89b-d101186f774f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_46ee31d6-1f28-4ba5-b2be-d5c564d17665">Other noncurrent assets</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtNC0xLTEtMTU1NjM4_590e7fdd-20fd-4dc2-9247-5b1f8277ef78">2,839</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtNi0xLTEtMTU1NjM4_66a12a57-eb90-4171-81d6-3104ff730906">1,386</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liabilities (short-term)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_74739711-6874-4a56-93f6-73a0506beaac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_8b4b2c6e-76ae-4492-a995-73bb701632ff">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtNC0xLTEtMTU1NjM4_aed593e7-b95b-4c4d-a7ce-a4a922e75d24">449</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtNi0xLTEtMTU1NjM4_5f9f8bbc-6321-4d37-9592-09c425c56eea">320</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liabilities (long-term)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b27ac467-c383-4750-82e2-f39d2460df2f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b50ecd3f-01e3-4abd-991d-dc5d329b8f81">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtNC0xLTEtMTU1NjM4_304141dd-b91b-4b0d-8a2b-6984f3c633e0">2,510</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtNi0xLTEtMTU1NjM4_f4b634b4-9814-4892-8e1e-efe08f17c77b">1,108</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjQ_5be33e70-e3ff-4c1a-a02b-07e75ccc4f81" continuedAt="i0f92629c028849faa0b0a5eb9db05e13" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:52.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of total lease cost includes:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzMtMi0xLTEtMTk0MTIw_25339440-1004-4451-ba4d-d82498093b83">548</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzMtMi0xLTEtMTU1NjM4_50f49e76-b84a-4968-8dd3-f60a6818f0f1">432</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzMtNC0xLTEtMTU1NjM4_feabb24a-4a39-4111-a380-7ba1b8dd4d71">421</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzctMi0xLTEtMTk0MTIw_cf7cbdaa-3d31-4568-9a45-3e04932d8981">381</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzctMi0xLTEtMTU1NjM4_a63eac93-bf3f-4d99-b625-eb1bc946f2fd">380</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzctNC0xLTEtMTU1NjM4_ea877075-507f-49fb-96f8-9b09a077f673">326</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzgtMi0xLTEtMTk0MTIw_27b01393-0957-4e21-bc0f-c31efd519006">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzgtMi0xLTEtMTU1NjM4_eefc3a91-98dc-4a65-8a52-4777c6fd4259">40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzgtNC0xLTEtMTU1NjM4_80f54a9e-1856-44d6-adbe-8f31bdd8443b">45</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzktMi0xLTEtMTk0MTIw_cb010f70-0cb4-4214-b780-8637418535b9">888</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzktMi0xLTEtMTU1NjM4_15c1de8e-0527-4453-88f5-aaa1b8ed97ec">772</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzktNC0xLTEtMTU1NjM4_be4c67d1-d541-4400-a383-0739bb0dd7be">702</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8c35af4c02c243b3bec47cbff9fa616f" continuedAt="i8dc5cabd028c4ff9bef2ef1f69d0a42d"><ix:continuation id="i0f92629c028849faa0b0a5eb9db05e13"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other supplemental information follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Remaining Contractual Lease Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzQtMi0xLTEtMTU1NjM4_c6a472a5-26f1-440d-9881-6355678fa67d">12</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzQtNC0xLTEtMTkzOTk0_6762d00c-837b-422e-a11a-b39faf6a7c7b">6.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzUtMi0xLTEtMTkzOTcw_32db8bf0-0623-4a62-9adc-da572f17867b">2.8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzUtNC0xLTEtMTkzOTk4_d955d51d-6cb4-48e8-be05-f098b3e41e28">2.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.932%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="21" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzktMi0xLTEtMTk0MDYx_53ba338f-8644-4bad-ac1a-c92a9d398549">387</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzktNC0xLTEtMTk0MDY4_4027d31a-1b49-416a-b661-e360816ed0ee">333</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzktNi0xLTEtMTU1NjM4_b6adbea7-fdaa-410f-852e-1310098f082f">338</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains)/losses on sale and leaseback transactions, net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzExLTItMS0xLTE5NDA2NA_d35becf4-6f48-4995-9ed5-ed55b96fa800">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzExLTQtMS0xLTE5NDA2OA_d1442bba-041d-4cee-bb86-b2bff8e8a065">3</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzExLTYtMS0xLTE1NTYzOA_190dd628-45a0-414c-ab1d-bfa9fdb04c57">29</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjU_0266b5ba-8f06-4d60-bdca-c5058c7f1d48" continuedAt="i202653fb711041d5b4763bbff4a2e5e3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating Lease Liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Next one year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzMtMi0xLTEtMTU1NjM4_7daeca07-7fb5-4238-8e5a-f50d6b2124ea">520</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzQtMi0xLTEtMTU1NjM4_7fcc7880-94d2-4739-98b0-8e550b10be77">417</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzUtMi0xLTEtMTU1NjM4_8ca77d14-64c0-41ff-aa17-59ba42d268e9">322</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3-4 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzYtMi0xLTEtMTU1NjM4_5ded3493-c39c-4361-a4f1-196e0a576231">279</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzctMi0xLTEtMTU1NjM4_bfb29190-b59a-4aaa-853d-ec2cfa071356">217</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzgtMi0xLTEtMTU1NjM4_3dbbcb76-655c-4017-be11-7df1aa87071f">1,865</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzktMi0xLTEtMTU1NjM4_40765424-75f2-4053-b972-c1fff617e04c">3,621</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Imputed interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzEwLTItMS0xLTE1NTYzOA_0d55ca11-3e2a-4268-9841-37eacddb6cca">661</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzExLTItMS0xLTE1NTYzOA_2abca1e4-79dc-40b2-b42b-24e08d2caa45">2,960</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzEyLTItMS0xLTE1NTYzOA_c5d6b5f2-b3d9-4545-bd98-e6cf4cda7f74">449</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzEzLTItMS0xLTE1NTYzOA_108c0775-c6b6-4830-a76b-92ddf979e05c">2,510</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i8dc5cabd028c4ff9bef2ef1f69d0a42d" continuedAt="ibd120ac4aaad47a78cc6d32025f36944"><ix:continuation id="i202653fb711041d5b4763bbff4a2e5e3" continuedAt="i56afddd6757b4c3f96f914b57214e694">(a)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:continuation id="ibd120ac4aaad47a78cc6d32025f36944"><ix:continuation id="i56afddd6757b4c3f96f914b57214e694"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjE_cb8ad76c-af7b-4cb3-9b21-56b340a790e5" footnoteRole="http://www.xbrl.org/2003/role/footnote">Reflects lease payments due within 12 months subsequent to the balance sheet date.</ix:footnote></ix:continuation></ix:continuation> </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_235"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 16. <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUyNzk3_ef6235eb-91d4-4665-8868-692193cf2a1a" continuedAt="icfe51efb881e4375ae49d0501baa776b" escape="true">Contingencies and Certain Commitments</ix:nonNumeric></span></div><ix:continuation id="icfe51efb881e4375ae49d0501baa776b" continuedAt="i23f8bfe4c153403c821003731f69d0dd"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from that product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i23f8bfe4c153403c821003731f69d0dd" continuedAt="i9f8b7210a6014a389cd40c0e89788b06"><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzM1NTA_ed6ceb59-158d-47cf-b572-c74243185747">1</ix:nonFraction> million in potential or actual governmental monetary sanctions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. For example, some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings with respect to <ix:nonFraction unitRef="patent" contextRef="ia34e871fd1d44e8ab3ff53c514b55b51_D20170101-20171231" decimals="INF" name="pfe:GainContingencyPatentsWithoutCourtProceedingsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzcwMjk_6551df84-3376-41f5-8fc8-484f8b68fb8a">two</ix:nonFraction> of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those <ix:nonFraction unitRef="patent" contextRef="id0ad5620c98c434fba738a4d9c4cf398_D20210101-20211231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkxNDk1NTA_46e78d3e-ac05-4524-892c-3049acde40f2">two</ix:nonFraction> patents, and <ix:nonFraction unitRef="patent" contextRef="ifdd76542ed8b4ec69bc988447f8ffb86_D20210101-20211231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkxNDk1NTY_cf7c6e5b-48e0-4ed2-9f3f-589495717c72">one</ix:nonFraction> other patent, were challenged in federal court in Delaware. In September 2021, Pfizer and a challenger entered into a settlement and license agreement, resolving all worldwide legal proceedings involving that challenger, related to our pneumococcal vaccine patents. Other challenges to pneumococcal vaccine patents remain pending at the PTAB and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines into the marketplace. In the event that any of the patents are found valid and infringed, a competitor&#8217;s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the patent covering the active ingredient expiring in December 2025 and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">In February 2022, we brought a separate patent-infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets.</span></div></ix:continuation><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i9f8b7210a6014a389cd40c0e89788b06" continuedAt="i2f9ebfdb8213498ea9324ae22d52f1d2"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2022, we brought a separate patent-infringement action against Slayback Pharma LLC (Slayback) asserting the infringement and validity of our compound patent covering the active ingredient that was challenged by Slayback in its ANDA seeking approval to market a generic version of tofacitinib oral solution 1 mg/mL.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance capsules. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent. We have settled with one of these generic companies on terms not material to the company. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Eucrisa</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Eliquis</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2017, <ix:nonFraction unitRef="defendant" contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231" decimals="INF" name="pfe:GainContingencyNumberofDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE3NTYz_89d87952-bc6b-4416-a32d-ff12499b6248">twenty-five</ix:nonFraction> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the <ix:nonFraction unitRef="patent" contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE3Nzgx_389662c0-c92e-40fa-8b83-8c622f99a316">three</ix:nonFraction> patents listed in the Orange Book for Eliquis. <ix:nonFraction unitRef="patent" contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231" decimals="INF" name="pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE3ODMx_dd21cdde-5ccc-4ae8-923b-33d33384e0ca">One</ix:nonFraction> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all <ix:nonFraction unitRef="patent" contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE4NTE0_d8974931-e936-490b-ae6b-b4de6c0962e8">three</ix:nonFraction> patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision. </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">96</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i2f9ebfdb8213498ea9324ae22d52f1d2" continuedAt="i5adf3b66be2a46708728d1acd29ce6a0"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lipitor</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EpiPen (Direct Purchaser)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants&#8217; motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Personal Injury Actions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and <ix:nonFraction unitRef="manufacturer" contextRef="ib18ea7fb4e2b467092e7d8b1a4245c1c_D20180101-20181231" decimals="INF" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkyMjk2ODk_e6c9d452-88a3-48a2-a561-c89e76b6109c">eight</ix:nonFraction> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Zantac</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">97</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i5adf3b66be2a46708728d1acd29ce6a0" continuedAt="i50cbc99b2ec1434eb40077c9b575c0fa"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. Plaintiffs previously had filed a consolidated third-party payor class action complaint alleging violation of the federal Racketeer Influenced and Corrupt Organizations Act (RICO) statute and seeking reimbursement for payments made for the prescription version of Zantac, but the Multi-District Litigation court dismissed that complaint; Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eleventh Circuit. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state court, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Chantix</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer&#8217;s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2009, we submitted a revised site-wide feasibility study with regard to the Wyeth Holdings Corporation (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the U.S. Environmental Protection Agency (EPA) with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy. In 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for <ix:nonFraction unitRef="lagoon" contextRef="if309e75442d740928d61d06aba360a99_D20130101-20131231" decimals="INF" name="pfe:FeasibilityStudyNumberOfLagoons" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzM5NTky_0a4b86c5-9ec0-44de-8d8e-d4aa2a7924cb">two</ix:nonFraction> adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the <ix:nonFraction unitRef="lagoon" contextRef="ib6e95e1dcabd4e7d8e7e9244ff512b69_D20180101-20181231" decimals="INF" name="pfe:FeasibilityStudyNumberOfLagoons" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzQwMDcz_b78b5806-ec30-4d84-b513-f7caab014b49">two</ix:nonFraction> adjacent lagoons. In 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. In September 2021, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey, which the court approved in November 2021, that will allow Wyeth Holdings LLC to complete the design and implement the remedy for the <ix:nonFraction unitRef="lagoon" contextRef="ib4cc2245228440d2887171a58dc8189f_D20210901-20210930" decimals="INF" name="pfe:FeasibilityStudyNumberOfLagoons" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkyNzc0MTQ_e4aa2e92-60f7-43a0-a897-66e56338f30b">two</ix:nonFraction> adjacent lagoons. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have accrued for the estimated costs of the site remedies for the Bound Brook facility.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. In January 2022, the Court of Appeals reversed the District Court&#8217;s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals&#8217; decision.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">98</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i50cbc99b2ec1434eb40077c9b575c0fa" continuedAt="i8f662764953249918b35cc51cd173960"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Breach of Contract&#8211;&#8211;Xalkori/Lorbrena</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The action was originally filed in 2013. In 2015, the Supreme Court dismissed the action and, in 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2020, NYU filed a separate breach of contract action against Pfizer alleging that it is entitled to royalties on sales of Lorbrena under the terms of the same NYU-Sugen, Inc. Research and Licensing Agreement. In February 2022, the parties reached an agreement to settle both breach of contract actions on terms not material to Pfizer.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Viatris Securities Litigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company&#8217;s current and former officers, directors and employees are named as defendants. The complaint alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">State Attorneys General and Multi-District Generics Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020. The Multi-District Litigation also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Subpoena relating to Manufacturing of Quillivant XR</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the  U.S. Department of Justice&#8217;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8f662764953249918b35cc51cd173960" continuedAt="i9207d7504fdb40b2a2091262c00466ee"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#8217;s FCPA Unit. We are producing records pursuant to these requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Zantac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">State of New Mexico and Mayor and City Council of Baltimore Civil Actions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A5. Legal Proceedings&#8211;&#8211;Matters Resolved During 2021</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During 2021, certain matters, including the matter discussed below, were resolved or became the subject of definitive settlement agreements or settlement agreements-in-principle.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EpiPen</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its current and former affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan former Chief Executive Officer, Heather Bresch. The plaintiffs in these actions represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal and various state antitrust laws. At least one lawsuit also alleges that Pfizer and/or Mylan violated RICO. Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In 2017, all of these indirect purchase actions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In July 2021, Pfizer and plaintiffs filed a stipulation of settlement to resolve the Multi-District Litigation for $<ix:nonFraction unitRef="usd" contextRef="i0d7fbd03fa994fe7aec0e5f20e5005af_D20210701-20210731" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkzMDcwMTM_7983850d-9976-49f5-81cb-8976300949a7">345</ix:nonFraction>&#160;million. The District Court approved the settlement in November 2021, and the payment was made in accordance with the terms of the settlement agreement.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2021, the estimated fair value of these indemnification obligations has been included in our financial statements and is not material to Pfizer. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may agree to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, Viatris has agreed to assume, and to indemnify Pfizer for, liabilities arising out of certain matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Certain Commitments</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2021, we had commitments totaling $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxMDE1_89d8ebc7-85f4-49b3-86f1-0ddaf29abd19">5.2</ix:nonFraction> billion that are legally binding and enforceable. These commitments include payments relating to potential milestone payments deemed reasonably likely to occur, and purchase obligations for goods and services.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for information on the TCJA repatriation tax liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The estimated fair value of contingent consideration as of December 31, 2021 is $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE2NDkyNjc2OTc0MTQ_8a43f9f1-26c8-4a91-82e1-258171c2dce4">697</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE2NDkyNjc2OTc0MjI_d7d87a46-4fc4-410d-883d-a990fbf42b35">135</ix:nonFraction>&#160;million is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE2NDkyNjc2OTc0MzA_dd0d56f7-9794-42c8-9e25-0bbdd460a07f">563</ix:nonFraction>&#160;million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and as of December 31, 2020 is $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxNzEw_e2d678ac-f8d0-4753-a824-16e145bc6ca6">689</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxNzIz_3340239b-91e6-4a30-b82e-f2693dd2ee2e">123</ix:nonFraction> million is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxNzcx_c67d813e-ef01-4b51-a4de-3450c57994f2">566</ix:nonFraction> million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase in the contingent consideration balance from December 31, 2020 is primarily due to fair value adjustments, partially offset by payments made upon the achievement of certain sales-based milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Insurance</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability.</span><span style="color:#1f497d;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">100</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i9207d7504fdb40b2a2091262c00466ee">coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued.</ix:continuation></span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_238"></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQyOTY_9cf4dd96-82c3-4e28-9b6a-3867699b6caf" continuedAt="i066418cab3d94e15b8c0a713bb113c79" escape="true">Segment, Geographic and Other Revenue Information</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i066418cab3d94e15b8c0a713bb113c79" continuedAt="ia647b6831ffb444385fcc8b9efa268e0"><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Segment Information</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources. With the formation of the Consumer Healthcare JV in 2019 and the completion of the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines and beginning in the fourth quarter of 2020 operated as a single operating segment engaged in the discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products worldwide. At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of <ix:nonFraction unitRef="operatingsegment" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzE2NDkyNjc1MzAyNDE_601f28d2-8bd9-4e1f-a3b0-7fef1db7f239">two</ix:nonFraction> operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is a science-based medicines business that includes six therapeutic areas &#8211; Oncology, Inflammation &amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital therapeutic area commercializes our global portfolio of sterile injectable and anti-infective medicines. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;D services from GPD and WRDM. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma is the only reportable segment. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Other Costs and Business Activities</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">WRDM&#8211;&#8211;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">GPD&#8211;&#8211;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late-stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Corporate and Other Unallocated&#8211;&#8211;the costs associated with (i) corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others), all strategy, business development, portfolio management and valuation capabilities, patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments; (ii) overhead expenses primarily associated with our manufacturing (which include manufacturing variances associated with production) operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs; and (iii) our share of earnings from the Consumer Healthcare JV.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related items, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as pension and postretirement actuarial remeasurement gains and losses, gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The operating results of PC1, our global contract development and manufacturing organization, and through July 31, 2019 our former Consumer Healthcare business are included in Other business activities.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Segment Assets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-9" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMzMzI_36b2bd0b-4909-43f8-9ba0-261d5a1b0e9b">181</ix:nonFraction> billion as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231" decimals="-9" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMzMzk_ce8e4830-fad1-4c1b-a88f-af2e1c6cb6d1">154</ix:nonFraction> billion as of December 31, 2020.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia647b6831ffb444385fcc8b9efa268e0" continuedAt="i6e3a833ad9d5465da1c3541cad4d8a93"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Income Statement Information</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1MzA1NDY_e6dee14f-5d7f-48bc-87bb-ab4a0494af74" continuedAt="i58f2acfa5ba147e08c6d6541698b59de" escape="true"><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"></td><td style="width:27.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following table provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9655062295ea4eb786880d4953a18367_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMi0xLTEtMTc3NDQ2_7907a335-b6e5-4e89-9327-3369993fcb70">79,557</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtNC0xLTEtMTc3NDQ2_5773ff19-5977-407f-9857-866f5abd9758">40,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtNi0xLTEtMTc3NDQ2_822d2be2-4e30-49b1-b0fa-1c5f12d8be68">38,013</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9655062295ea4eb786880d4953a18367_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTQtMS0xLTE3NzQ0Ng_d5714a79-a33f-4049-ad78-b4ab062cf73d">40,226</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTYtMS0xLTE3NzQ0Ng_c78f2480-6e0a-4812-b437-d0f3b88908f9">27,089</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTgtMS0xLTE3NzQ0Ng_3a0c44fa-4538-4105-b1d4-477ae7b6d295">24,419</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9655062295ea4eb786880d4953a18367_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjAtMS0xLTE3NzQ0Ng_ced6d2cc-140c-4c29-904f-0f866c56c86e">1,439</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjItMS0xLTE3NzQ0Ng_7f261ace-5a86-4ffd-a6e4-932d53aefa61">1,013</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjQtMS0xLTE3NzQ0Ng_272ec279-d27e-4efd-83ad-a0d2b248698e">978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMi0xLTEtMTc3NDQ2_d98a92f6-45bd-4e4c-a439-374f7de87b82">1,731</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNC0xLTEtMTc3NDQ2_48faa6f0-3a30-4022-b30b-caa0a4b7f684">926</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNi0xLTEtMTc3NDQ2_7cda6e54-0181-4805-8205-7bbf2c4abc48">2,892</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd">10,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2">12,308</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379">11,216</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f">598</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023">603</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922">592</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74107e930484043af252b70ef86b1c3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTItMS0xLTE3NzQ0Ng_b6b2c880-962a-4299-bed4-13df367d28ad">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46149707465a45269f0a4d9663481faf_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTQtMS0xLTE3NzQ0Ng_ca302969-0199-4f74-931f-1860caf7feb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4388992791af4d329ee32af6b701ed74_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTYtMS0xLTE3NzQ0Ng_decaabbb-d51f-4e80-8c6e-a1aa03573408">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic74107e930484043af252b70ef86b1c3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE0LTEtMS0xNzc0NDY_55e56b9a-2c34-47c6-b317-0ec27b23f0d5">3,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46149707465a45269f0a4d9663481faf_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE2LTEtMS0xNzc0NDY_50095a15-4d77-4d87-8ded-edd7b8c37440">3,117</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4388992791af4d329ee32af6b701ed74_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE4LTEtMS0xNzc0NDY_bfcd77b6-37cf-47da-a023-ed1e44db59f5">4,153</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic74107e930484043af252b70ef86b1c3_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIwLTEtMS0xNzc0NDY_8c2ed33c-a0b1-422d-bae1-3dc5d98f8602">3,067</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46149707465a45269f0a4d9663481faf_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIyLTEtMS0xNzc0NDY_8faca64c-3b06-4ec4-b420-0e3155170551">3,047</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4388992791af4d329ee32af6b701ed74_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTI0LTEtMS0xNzc0NDY_0b14d794-f57a-4276-ba3f-c9f69d425ee7">4,145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea96d19d201f43f78403ae7000de580e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTItMS0xLTE3NzQ0Ng_6f9a1a93-440c-46bb-b62b-5c9257b61c6c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTQtMS0xLTE3NzQ0Ng_c18da5b6-d003-460c-8f9d-6834203d50ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTYtMS0xLTE3NzQ0Ng_0ba3cce1-23f3-44da-935b-1582558339db">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea96d19d201f43f78403ae7000de580e_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE0LTEtMS0xNzc0NDY_26e77d3c-7ba5-43c0-9206-33f175077456">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE2LTEtMS0xNzc0NDY_7c74cf89-4939-4846-a03a-8d93ceceec86">44</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE4LTEtMS0xNzc0NDY_4eeae3f4-c6c2-4bd3-b9ec-88e7109b6ce4">185</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea96d19d201f43f78403ae7000de580e_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIwLTEtMS0xNzc0NDY_f1fc0f33-3394-49b5-938e-49c96d2b3d65">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIyLTEtMS0xNzc0NDY_54c2cdd6-b12d-4c75-ac60-2812a95fe9c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTI0LTEtMS0xNzc0NDY_f6c3282a-ce85-437a-9714-ec11e7f051f1">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTItMS0xLTE3NzQ0Ng_b13619e0-1809-4023-9173-70819e782a56">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTQtMS0xLTE3NzQ0Ng_dfdde423-a842-42c0-bafc-1efbed3dd6e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTYtMS0xLTE3NzQ0Ng_43752d49-1ae0-4846-8821-0cdf421ce9dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b">2,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88">4,584</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4">2,456</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39">87</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f">37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTItMS0xLTE3NzQ0Ng_4e00268c-4a50-41e9-ad17-c1c9904256cf">81,288</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTQtMS0xLTE3NzQ0Ng_3d67b997-73af-44b9-9488-9ff83e4d60c5">41,651</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTYtMS0xLTE3NzQ0Ng_b3285840-8bf6-415d-a35e-3c1330c64557">40,905</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE0LTEtMS0xNzc0NDY_763275c5-6edd-4d3b-af4f-eca2881128a4">24,311</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE2LTEtMS0xNzc0NDY_00320b28-4117-40ba-9719-fa9dddf0ac7e">7,036</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE4LTEtMS0xNzc0NDY_6a4bc1bb-7dd3-49d7-8cc0-6412bf9dbb14">11,321</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIwLTEtMS0xNzc0NDY_67bd40ae-61e5-4b13-b748-ff051595a96f">5,191</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIyLTEtMS0xNzc0NDY_905c3a81-05ac-4ad2-b380-1cf7f60f4219">4,681</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTI0LTEtMS0xNzc0NDY_ed46c745-7e0a-44cb-a4eb-bd65a5789eac">5,755</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $<ix:nonFraction unitRef="usd" contextRef="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMxOTc_f4da4664-1937-473d-b347-80bf213616a9">166</ix:nonFraction> million in 2021, $<ix:nonFraction unitRef="usd" contextRef="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMyMjQ_9640921c-dc74-478a-8d0c-a5f56fa9af01">278</ix:nonFraction> million in 2020 and $<ix:nonFraction unitRef="usd" contextRef="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeDividend" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMyNTA_cefe860a-5ebf-4444-904b-c9998ab596e5">220</ix:nonFraction> million in 2019.</span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" footnoteRole="http://www.xbrl.org/2003/role/footnote">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></ix:footnote></div></ix:nonNumeric><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="i58f2acfa5ba147e08c6d6541698b59de" continuedAt="iffc99ca2a5134fa3a56ba5611e29d192"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" continuedAt="i8fb6f744d6904a4f8c78efa69ee5bc06" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $<ix:nonFraction unitRef="usd" contextRef="i3331360a352a4974b87a0863eff1cb2b_D20210101-20211231" decimals="-8" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzg3OTYwOTMwMzA3Njg4_35653fa5-9e6f-4380-8436-b5a91e7ecd0a">2.1</ix:nonFraction> billion charge for IPR&amp;D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzODA3MjAx_4e91c20c-c4f5-4e3f-8bde-a101d0ab4220">1.3</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg3MTU4_3a534934-86d2-43a2-b077-1a330cb3884a">450</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and (iii) upfront and milestone payments on collaborative and licensing arrangements of $<ix:nonFraction unitRef="usd" contextRef="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231" decimals="-8" name="pfe:PaymentForCollaborativeAndLicensingArrangements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg3Mzc1_3f20ec19-5c65-47f9-8dc1-dfd9d9404367">1.1</ix:nonFraction> billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMzExOTgw_bfc27195-4b56-424d-93d4-90a6f2aee4db">1.6</ix:nonFraction> billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (v) gains on equity securities of $<ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-8" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzkyNzI2_d4f2e67b-5f99-4836-9400-d020de949def">1.3</ix:nonFraction> billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. For Earnings in 2020, includes, among other items; (i) charges of $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg3NTMz_619a0d9f-de24-4a50-a1bf-1b9e2c560965">1.7</ix:nonFraction> billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) actuarial valuation and other pension and postretirement plan losses of $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-8" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4NjMz_762e9298-7632-464f-b720-096026a57a41">1.1</ix:nonFraction> billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $<ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4Njk1_a0c02af1-15c6-4e93-b7e2-6f1acc3cb3bc">791</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231" decimals="-6" name="pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4NzIw_a6fb3d12-ed86-4b59-8f30-4e2b05c508a4">197</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231" decimals="-8" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzkyNzQ1_b037ea58-3415-47e4-a7ae-a6fe76bf06fb">8.1</ix:nonFraction> billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4ODY5_de43c566-573f-495a-ac60-461ffce8d81d">2.8</ix:nonFraction> billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) actuarial valuation and other pension and postretirement plan losses of $<ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzODAyNDA5_58838d8a-0c35-4cff-add4-e21f4e1201c1">750</ix:nonFraction> million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 2A, 2C, 3 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span></ix:footnote></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="iffc99ca2a5134fa3a56ba5611e29d192"><ix:continuation id="i8fb6f744d6904a4f8c78efa69ee5bc06">4</ix:continuation>.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Geographic Information</span></div><div style="margin-bottom:3pt;margin-top:3pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzk_278ae39a-7efe-4dc0-8021-c20bc1f4b079" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01706a25eaf44000861f8a5988b1cfd7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzMtOC0xLTEtMTU1NjM4_b74ed92b-ea3c-4ff8-8cc5-1dc89acd1eff">29,746</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b14f941e6742209cf14aecbed2dcc2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzMtMTAtMS0xLTE1NTYzOA_76116342-b96a-4eaf-8c3c-aa68aae9c4de">21,455</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66820026161242ecb7114f5badd98288_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzMtMTItMS0xLTE1NTYzOA_ca61a9da-68a2-4e48-9e38-8f75c12124e4">20,326</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61f3df5393924c84a4d3bd1ee41d293c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzQtOC0xLTEtMTU1NjM4_6c740ada-27d2-4228-821d-3828b524878f">18,336</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1faeba83c004ae2b29779566eb052c7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzQtMTAtMS0xLTE1NTYzOA_627dc2a3-4131-451f-b8e6-1ff65d9c6305">7,788</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee440d1ba7794b8ab3cfc128d24b19b1_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzQtMTItMS0xLTE1NTYzOA_43b0a4ee-4f72-49bb-ac06-21e71a347a54">7,729</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12fb6fa02754813a733da0d0a3c5217_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzUtOC0xLTEtMTU1NjM4_1b9c9771-bfa9-40a3-a022-a37b8fb8d764">12,506</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2bf364c90ee403f905cf44b76b83795_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzUtMTAtMS0xLTE1NTYzOA_d76e1a76-7229-4b47-8d7d-2c8c52b05da6">4,036</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5545fe7ef044230b942499024d73124_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzUtMTItMS0xLTE1NTYzOA_7b358f48-fc22-42b2-8721-7e2793a31f87">4,022</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07534c0ef5da443f9d23bb709f1f887a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzYtOC0xLTEtMTU1NjM4_719ae8b3-139d-4e4c-855f-ae75a6cb955e">20,701</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e4f467b53b54c268aaf5ebd5d255312_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzYtMTAtMS0xLTE1NTYzOA_eeeb0bda-8bb9-4163-8e1e-293fc0434de8">8,372</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b50c81dd41c4b93866757262314077f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzYtMTItMS0xLTE1NTYzOA_f3e825c4-b53d-4cab-82f2-ed11745bb984">8,828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctOC0xLTEtMTU1NjM4_483684ae-d3a9-4f4e-a1d4-8e4c43732120">81,288</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTAtMS0xLTE1NTYzOA_a613a535-5035-4806-9718-d8b2254855b9">41,651</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTItMS0xLTE1NTYzOA_f79fd294-b4a8-4bf1-b851-ba56ed959b3c">40,905</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues exceeded $500 million in each of <ix:nonFraction unitRef="country" contextRef="ic62778dbebe74ea5854c11429ef857e7_I20211231" decimals="INF" name="pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNQ_f1583119-7954-492a-a5f0-96dbf1567ca2">21</ix:nonFraction>, <ix:nonFraction unitRef="country" contextRef="i99f0e6a9eab54ae4a8ed112ae8d226a7_I20201231" decimals="INF" name="pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyOQ_7626b3ca-a090-4c2a-9304-855a0db0ddab">8</ix:nonFraction> and <ix:nonFraction unitRef="country" contextRef="i4d0a8aaa82ec487cbe6efb57bd4d09ae_I20191231" decimals="INF" name="pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEzNg_3a62a8c4-34a8-4252-beec-a2831b29e657">10</ix:nonFraction> countries outside the U.S. in 2021, 2020 and 2019, respectively. The U.S. is the only country to contribute more than <ix:nonFraction unitRef="number" contextRef="i6b31b69d78a84395930b25d3a0a78c1b_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzI1MQ_afa6b299-0744-44f8-85a4-afbbf9e29c4c"><ix:nonFraction unitRef="number" contextRef="i6d67ec1ac5234c0d9f621dcbbb4183bc_D20210101-20211231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzI1MQ_b5cd0b2b-ab79-4843-ac76-485968659045"><ix:nonFraction unitRef="number" contextRef="ia9c607e23c364498a9220f891e27bfcb_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzI1MQ_bdcaad2b-2a61-486c-ada3-deffa891a5b7">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of total revenue in 2021, 2020 and 2019. As a percentage of revenues, our largest national market outside the U.S. was Japan, which contributed <ix:nonFraction unitRef="number" contextRef="i76154b8bae914f14a3264e5b5345009a_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQ3Mw_0ca4c54d-6454-4612-8775-4e8bc58cff9a">9</ix:nonFraction>% of total revenue in 2021 and <ix:nonFraction unitRef="number" contextRef="i86eb9d30e32741049330f056b435d474_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzUwMw_0876bb99-f9d5-489d-bff9-9833a73cc7d4"><ix:nonFraction unitRef="number" contextRef="ie70843c611e141548bd971cd5410e88d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzUwMw_a1bfab0b-fa9f-45a9-8225-03cf7dcb68d6">6</ix:nonFraction></ix:nonFraction>% in each of 2020 and 2019.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty with multiple developed and emerging nations around the world and are continuing to deliver doses of Comirnaty under such agreements. We currently sell the Comirnaty vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February and May 2021 with the EC on behalf of the different EU member states and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Other Revenue Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Customers</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">102</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i6e3a833ad9d5465da1c3541cad4d8a93" continuedAt="ia00ccd08720943a2908ec7e7ae9236ac"><div style="margin-bottom:5pt"><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzE_194b6a44-385b-4da7-89ef-8c65dcf1e648" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">McKesson, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02e740ce254147a096ae80d08c9094f0_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzMtMi0xLTEtMTU1NjM4_e25dce8d-c420-457d-8a41-df292b741cc6">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice936d0c8940458e99b8cd6b72505a29_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzMtNC0xLTEtMTU1NjM4_263aaa07-f1f4-4f84-a72a-d1cd3423b5ca">16</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1412106f3b64e9190b955c58956f7ea_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzMtNi0xLTEtMTU1NjM4_99dbfb78-e7a1-4c73-bec0-eeac13a35ef5">15</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9fee695ccc6d4951bceaa4452197ada8_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzQtMi0xLTEtMTU1NjM4_c4ee7d65-9e47-47b5-93f7-7e7fd10ae99e">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2057fb4eee634619a81384ca8181d059_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzQtNC0xLTEtMTU1NjM4_760329a0-dd96-4249-abe3-03ed4718eadc">14</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b05c103030344159abe87626ef3fc58_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzQtNi0xLTEtMTU1NjM4_f5780f4d-0b08-4db7-97d3-5e75db6da49f">11</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12c71dca498146b98b69c59745867f99_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzUtMi0xLTEtMTU1NjM4_07844136-ea7c-4ff2-9c94-49400dff19e8">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if47ab8b761c145ba8c1e38b804fff672_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzUtNC0xLTEtMTU1NjM4_249e2ce5-ffb6-405f-9dac-5d20fedbd195">10</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08d75cc0ddf8452ca93b381cb375ed5d_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzUtNi0xLTEtMTU1NjM4_6cdad8ad-b347-4e65-bc47-c64821ce4524">9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collectively, our three largest U.S. wholesaler customers represented <ix:nonFraction unitRef="number" contextRef="iec439aa05d4f4752ba182e07bea798ee_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzc0Mw_43e622da-5bc3-47b9-9ae2-f2d4f7234904">24</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i1b1ecddc539948bfb8fb4cf369085020_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzc0Nw_9c628183-11b7-49c4-ac92-5b51dfa2859a">30</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia9e53394f559452ca83fffb3a7e16401_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzc1NA_6117e083-b8d8-4ab5-a75a-1bc89819cfaa">25</ix:nonFraction>% of total trade accounts receivable as of December 31, 2021, 2020 and 2019.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, revenues from the U.S. government represented <ix:nonFraction unitRef="number" contextRef="ibdaa8f31455343a4a4b78e91aea00e81_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzcxNDY4MjU1ODU3Mjg_fd340d49-e315-4bac-960c-af8b9d22da15">13</ix:nonFraction>% of total revenues for 2021, and primarily represent sales of Comirnaty. Accounts receivable from the U.S. government represented <ix:nonFraction unitRef="number" contextRef="i67454cc77ab148d1a8042c793aab9a02_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzcxNDY4MjU1ODU4ODg_2ead479b-67a5-4ea6-a440-e22e61818b3d">12</ix:nonFraction>% of total trade accounts receivable as of December 31, 2021, and primarily relate to sales of Comirnaty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njg_5ea53535-3f61-4bd7-a999-08818d5ba70b" continuedAt="i67ecda6552564f0d8a121be732f9fd17" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:20.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNC0xLTEtMTU1NjM4_e8bbbce6-fc9b-431c-8278-af06ccb82a49">81,288</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNi0xLTEtMTU1NjM4_de2f933a-4fc4-4b54-9f85-3b4de5212a79">41,651</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtOC0xLTEtMTU1NjM4_f79fd294-b4a8-4bf1-b851-ba56ed959b3c">40,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba39cae55e2432688515ca3a47f62e2_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae">79,557</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4ab42ea69a04305a2fa6db983f61342_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e">40,724</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3fcc1684c04124ad431600c3ae2310_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c">38,013</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie683f91cae7e4f439a204f20f28ecdd3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTYxODk5_ec2694c1-0583-459e-a31c-55e2675ae948">42,625</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790164b8b500487995993a2e01eb13c0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTYxODk5_b98834ea-224d-4322-91b5-25b2baa7ac69">6,575</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i010d3fafcc354cc784caf06fb723ade2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTYxODk5_e6fa7690-0e67-4c7e-aec8-da1876f01c9e">6,504</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Comirnaty direct sales and alliance revenues</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent COVID-19</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff979b3974154ad0803e20ebd7c32f30_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxOTE5_a1e7d7a4-34af-4346-8bd3-6ef912f76d62">36,781</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if78e81b138394cc1884da57948dee8e5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxOTE5_51361f70-4b00-4000-a701-186d811cf7d4">154</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4239b3555a4e418c8a9a5e9d67c2e6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxOTE5_56260df1-0a6a-415b-a1d8-01d57283b351">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Prevnar family</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5d56e1790d4d3298629659396a640a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxODk5_616bc566-ed61-48d2-a689-843292929258">5,272</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ed595eccea49ffb73f0798a75a1773_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxODk5_277205d7-51d1-41dc-9ba5-25bbc37331e1">5,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76fcd41f92da44e289e82affd418e306_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxODk5_017fe27d-e80f-421b-8f33-cf6e30a994cf">5,847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nimenrix</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84925602fa144f3ba3a71b13029588f0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNC0xLTEtMTk4MjQ1_9d386c72-04d9-459d-8b6d-3ecb3918d3d7">193</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a69e52cd15347808dffa431d34044db_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNi0xLTEtMTk4MjQ1_d4de6f1c-922c-4de9-8398-0ebdc1eff27d">221</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf42e0f52a3e45b59df985db36745f16_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtOC0xLTEtMTk4MjQ1_42502b14-4d0a-4568-a60e-ffc8eb925132">230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieff4fe2fbc324b449cb56e68fdcd1a9c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNC0xLTEtMTYxOTM3_08b020c0-a780-4fa4-bff5-6c8cb0c51168">185</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2238b79faba4effaac005b81ff23304_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNi0xLTEtMTYxOTM3_fbb0c85f-65ec-452a-b163-34fa49cb20c6">196</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf497a35e6494fad8698744787351909_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctOC0xLTEtMTYxOTM3_b636d60a-56be-4475-b1c8-10003d086c7a">220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Trumenba</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Meningococcal B disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f72c5f82d75415ba597df7de74760b1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNC0xLTEtMTYxODk5_5a4c69f6-2d75-48e4-9813-1b1ffc534f5e">118</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0750214c46a64ab6b39e459f0d49daba_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNi0xLTEtMTYxODk5_ac796295-bccb-4581-992a-24bd1e60b4f1">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e64081e3f0434b872e5a4506e536de_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctOC0xLTEtMTYxODk5_357edd99-842c-4a85-8d74-5f54cd693b09">135</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Vaccines</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb6a72bdf8141cf863b344e751661ae_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNC0xLTEtMTYxODk5_6386c56d-61f2-4662-8a23-af5d4e4e5578">74</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eda9019748445348870a74c3bd3ab6f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNi0xLTEtMTYxODk5_7e90db37-12d7-44c5-92be-8d933e4fd391">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5790195bd954466ba793840f2495ee93_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktOC0xLTEtMTYxODk5_14599c6d-b935-4103-bd53-3661d87bc8c1">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a6b539896c45d79c389bacbc2f4743_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzExLTQtMS0xLTE2MjAxMA_a9b87b37-3c42-4ab2-b490-e518c5ebc377">12,333</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie427a740ab1c443d87ea004b5125ac8d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzExLTYtMS0xLTE2MjAxMA_b6825040-6ac8-4480-82d0-cbc9e6e5507d">10,867</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa09786cae24e62ad36d600ee535ad2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzExLTgtMS0xLTE2MjAxMA_5439acc4-bdc3-4693-9f65-55a0a8f0b4ae">9,014</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Ibrance</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92db76fc792d40ad86670b655627f383_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEyLTQtMS0xLTE2MjAxMA_d88cd670-836d-472c-9c28-6ab57949f74e">5,437</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c0ae9140eb4237841af25b9edac128_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEyLTYtMS0xLTE2MjAxMA_895d22d6-e9e7-47f6-b21e-a760983bb291">5,392</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3efd621f0e0d4d2a8760e00099eb67a5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEyLTgtMS0xLTE2MjAxMA_2db541a6-8c64-48af-99ba-eb97e65be903">4,961</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c93ecc7240f4fa3ad8ec0c4c64303bf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEzLTQtMS0xLTE2MjAxMA_3efa1eac-47ce-423c-9ca8-8024c578acb4">1,185</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3a6827b38a41d7a516870ab707a086_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEzLTYtMS0xLTE2MjAxMA_e29a858a-bb4e-4c0b-a494-5743390d8d76">1,024</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55b91f673fc04f73a3ae024b9a41752d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEzLTgtMS0xLTE2MjAxMA_1788c5c7-30b0-403d-8211-0c5dacebfe7d">838</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inlyta</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1f7d47181e475bb3aa38336cc6209a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTQtMS0xLTE2MjA1NQ_300e637a-1731-476c-b4ca-313514ed544e">1,002</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5858407930714ddc909e6bd243e24efc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTYtMS0xLTE2MjA1NQ_d2fec52b-af5f-46ef-9e71-9f45e6824d5a">787</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcfc0ac3a4bb41e6b2470eb7d7c0ed54_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTgtMS0xLTE2MjA1NQ_fe8f9412-096c-44bc-97a6-8583eb99db21">477</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sutent</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic828b8310b6d4b5bb05dea1dfee3affc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTQtMS0xLTE2MjAxMA_8846e87b-14c5-4536-baa5-35496a16d605">673</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c1116b8782479b9a95ddf926b9e0b5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTYtMS0xLTE2MjAxMA_25534abe-026c-4413-970d-3de1c971e09b">819</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28052556477d473b8c21d8bafb9cead1_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTgtMS0xLTE2MjAxMA_0ab32ae5-2a2d-4759-8b49-891d89e29a41">936</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bosulif</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b1304b5f82e4e58a1c55dc33b956260_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE1LTQtMS0xLTE2MjAxMA_764233d1-56f7-4dd0-a5ff-7b9ccd09a31d">540</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bad590cb383439c9110aca0d945cd2a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE1LTYtMS0xLTE2MjAxMA_a3198963-77cf-4149-aec0-ead494df16e2">450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e5406f5f364c5eb193983737f6387f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE1LTgtMS0xLTE2MjAxMA_a33c1b99-20b1-42f5-8145-698b2582b2c3">365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xalkori</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6acf78ac097b422b88e179ee9b747007_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE2LTQtMS0xLTE2MjAxMA_1a77ae72-ca64-47ef-8497-29690a87acac">493</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bcc609ff5d4139b0a6a18177feb882_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE2LTYtMS0xLTE2MjAxMA_16c95711-dd87-44df-b772-6731608386be">544</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibef0fffb95fb47da8f0bdd6c91925689_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE2LTgtMS0xLTE2MjAxMA_0f0cd947-a91d-4571-b76c-48f88be08f2b">530</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Ruxience</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7590755364db416f9e17b48ea64413d0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjA3NA_9fafef35-c537-48a3-9506-c3d44e8130fb">491</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e7d6b26d7d4a74b5f922d708d9a413_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjA3NA_898220b7-d9bd-4658-9116-f1f7647bfbf0">170</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2460aa2b09c74030b8381ba12fb645fd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjA3NA_29abafd8-1987-4b69-8d7b-7b36e729d14d">1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retacrit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b6c834fb1c4292b59fda40ade5b9d1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjAxMA_b01f1c97-93f1-46a1-99e8-af9042092584">444</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6ae2a7d71d9425d8152e464a315bf21_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjAxMA_6cb5c6c4-f805-4d7c-a4d5-2d9f7e295dd8">386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i975049da60424e96b8b532025ae69caa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjAxMA_d5f94ded-8f05-494f-867a-3ada9c6f4618">225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zirabev</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7484561be64aeb9ac7738d08ab387f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTQtMS0xLTE2MjA4NQ_862ece23-b22d-41fb-b445-a8fb8400869e">444</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de75bb8b77440d0bf45934e1ba87237_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTYtMS0xLTE2MjA4NQ_0c5c6baa-55e5-4560-8e48-d75e567c277c">143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d8b4737c1840a0b89442498290ca65_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTgtMS0xLTE2MjA4NQ_83c25b6b-7635-4a3f-b803-2b579fac20a1">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0fb8d22c1645438cba3e8ce25ca48c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTQtMS0xLTE2MjExNQ_77a4e38e-b3a9-4b8e-a365-75748ccd98d8">266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67382282eea44a6a957d3764ba308d11_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTYtMS0xLTE2MjExNQ_53885455-62cc-48a7-892f-3515d25275f8">204</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b122ab8ca744c749dc432ff78c16ea0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTgtMS0xLTE2MjExNQ_5d969c0f-f2c0-4878-9e8d-364bbb1b5b20">115</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36583488c824eb4892877ea211dbad5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTQtMS0xLTE2MjA5OA_dd01c4d6-8d66-4e66-9b2a-022ed2b3537e">211</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc957ad3d68e45c5ae1a74b135305349_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTYtMS0xLTE2MjEwMQ_01382730-5417-4952-8642-6037e49b0300">148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b391f47cfe48fe93bdb715d0951829_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIyLTgtMS0xLTE2NDg1Ng_f4c5dd7d-52b0-4e67-8631-60fbbfc7dc9e">136</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Trazimera</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%">HER-positive breast cancer and metastatic stomach cancers</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23070ab492904e61a59b2297b56b0953_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTIwNDQ1MQ_9a68c631-ef4a-4008-9ad5-f858dec514b7">197</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7733f5b2e9345d9a1e642d4c79139f3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTIwNDQ1Ng_873b90bc-fe83-4098-a714-9762073a68b3">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1933184cd1e5441e87193869a01461e8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTIwNDQ1OA_a7dd1abd-ef00-4aab-b4b3-aa247e5e03e9">6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb7b7f56fda4c10a3da08d150f67fc4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIyLTQtMS0xLTE2MjEwOA_cebd0eb5-3fa9-4e90-a1e6-5e066362b78c">192</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i625be7e17cbc4e3cb80799060c42b8a4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIyLTYtMS0xLTE2MjExMQ_1d4df047-23a6-4164-9fc9-845267247d89">182</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e621ffd98b54fd29f2e02643a70ad30_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTgtMS0xLTE2NDg2Mw_a985d820-a747-4d95-8961-ff2f09823906">157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Braftovi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9007e1cc1b42109548c43dc4c66fae_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTQtMS0xLTE2MjAxMA_e83125ad-5d69-46da-aaae-9e693bde8351">187</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d9fcaa44eb493cb0d96f6c81f2a2ea_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTYtMS0xLTE2MjAxMA_6353ebf5-6892-4a9e-858b-6c952702ac3e">160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dd61ade4364d5a90e0a17c4f83e822_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTgtMS0xLTE2MjAxMA_12f69580-1319-437d-9110-c6d0b67e635f">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60a9e485dc774f3ba6d70e30217f15f8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE2MjEzMQ_ea4508ec-2a66-4db7-946d-b3e41699159b">178</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e987f25dd8b46eca97df2eca4a9c075_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE2MjEzMw_791c2ff8-36f4-4819-b94b-70ac7502d574">80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736cfbcbd4874cd1bb2dfded6deaeeb8_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE2NDg2OQ_f30a8c1b-f1ed-46db-aa8d-03a59830e579">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mektovi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Braftovi for metastatic melanoma in patients  with a BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E/K</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> mutation</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b56db0f447c437197c532ee8f7047fc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTQtMS0xLTE2MjAxMA_9935fb69-86dd-4e24-8ff1-880c1943313b">155</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3eeb0ff7cc45b8b0e9b9da65bac12e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTYtMS0xLTE2MjAxMA_d39b9ae4-f1ab-48aa-826d-9a9208664af3">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id911443b1d0c48de95a2929266a7582c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTgtMS0xLTE2MjAxMA_e505c568-6476-4879-b757-c2f872a81936">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Oncology</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c019e4bb9043ffaab47e93d8c852aa_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTE2MjAzMg_2b9cc75f-c32a-4a16-ba9f-28158fa8bde7">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a302d7f90c3424fab750ed285db9b29_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTE2MjAzMg_04cc689d-6353-4b66-afbc-c479b1895a86">137</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a027609db240a7866905b49f8d682d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTE2MjAzMg_9bffbc3d-7d28-4e88-9406-c6f2fbe32483">122</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb26436d0a1448cb81ceb46110a4f3eb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTU1NjM4_5e625bc4-4ef6-4a37-a7b8-8b366f3dd43d">9,329</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4bfb7acabb24a67a1151e63cc4fce68_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTU1NjM4_ec6361fc-0439-4de2-b387-fbda57bb50ee">9,003</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c89535e85f4038a7ec373e8a3123cf_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTU1NjM4_5006991a-a52b-4b7e-8d89-c8f253f13bf9">8,790</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Eliquis alliance revenues and direct sales</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea9873a8979b4508be42cfcfe7747f50_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTU1NjM4_47179b3b-840a-41ed-9ca9-1e2e7a95c19d">5,970</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabcd20f9c06a43dabd464c0015ff8930_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTU1NjM4_c20b2237-6e57-449c-96cc-7564cc651ed6">4,949</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdd55ff3b5d4c52861b121e66ab3ac7_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTU1NjM4_bb4bb18f-271c-48b8-abb0-223e07cb71cf">4,220</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Premarin family</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36bb0606d8cc44ddbf05cfe5192a51de_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMwLTQtMS0xLTE2NDUzNg_63b52829-faa6-4c88-aa66-621bf0a698de">563</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b4ecb4c49ac45c096a8e6606e325b90_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMwLTYtMS0xLTE2NDUzNg_6e70f635-5398-4843-96ac-0f02eb479684">680</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33477546f42a4341949e28a3012fca3d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMwLTgtMS0xLTE2NDUzNg_1cdb4772-34c5-417b-a5ee-1765c13b5f66">734</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Chantix/Champix</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ac74fef9494583b8e81681775bc2b7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYtNC0xLTEtMTU1NjM4_2c2fb541-942b-43ce-8d8f-470bcbb41bfe">398</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc1f43e55c834e949f22669758cc7ee7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYtNi0xLTEtMTU1NjM4_cb4fd6ee-a829-4275-9650-3607a3f5c6a4">919</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f598e5471364ba699cade3d65d16c2c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYtOC0xLTEtMTU1NjM4_86e43375-5676-4c87-8de7-d988709eb494">1,107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">BMP2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b97da5e9af14fe396e47b0d71d869f3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNC0xLTEtMTU1NjM4_9711e40a-36ec-454b-bcdc-1d2521466a59">266</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e0cc1b139d40adbb8d7340de280263_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNi0xLTEtMTU1NjM4_955db1cf-7e39-4ef4-bbd3-8f59e52e87e9">274</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3e974364904421b9ba3879babbf5f1_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtOC0xLTEtMTU1NjM4_0cf1ca36-fd87-4df4-800e-b834e7d2a696">287</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Toviaz</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb84bd57d736452e8091760a4451bf32_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNC0xLTEtMTU1NjM4_621630f6-c0ed-4aba-afb5-9c95381060a4">238</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i789c240c68ac4def920f05c29c59b9ba_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNi0xLTEtMTU1NjM4_25842b9a-729f-4f6e-ad5e-d96226ce0162">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc19ff52f7843b19250144e07c70512_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktOC0xLTEtMTU1NjM4_138dc191-39dd-404a-b2ec-1c36a2d8f187">250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pristiq</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Depression</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28339e568e9484e962b70b87aa216f5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM0LTQtMS0xLTE2NDU0OA_9c21423a-a0f9-4d04-89e6-0f9b2942d1c9">187</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47352f77aa394099a094f2eb6b3aee0e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM0LTYtMS0xLTE2NDU1MA_9f48fa76-31b9-47a4-a596-628633771442">171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c315b990d4b4ef4b6f4fe096b1108fe_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM0LTgtMS0xLTE2NDkxMQ_6fef23f8-2db1-4574-89b3-06b73c5aaa47">176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Internal Medicine</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93eaf75f91e64395917e59ebf57f6d3b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEwLTQtMS0xLTE1NTYzOA_8ac9d042-b4aa-439b-972c-a92851b8d83a">1,706</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb67eb0248104e43bdd406f377b6ff52_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEwLTYtMS0xLTE1NTYzOA_d535c716-cf3e-48be-b5aa-340a2ce7eb09">1,758</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5951a6d7c24aabbf638e2cfc5d9fad_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEwLTgtMS0xLTE1NTYzOA_c4565262-ead6-48e8-b9ae-edf40915855e">2,016</ix:nonFraction>&#160;</span></td><td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ia00ccd08720943a2908ec7e7ae9236ac" continuedAt="if78ab6f63ed048b4866ddc0bc2ad4578"><ix:continuation id="i67ecda6552564f0d8a121be732f9fd17"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:20.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.460%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hospital</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efecefa4ebc419689066fe6e6521f2a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE1NTYzOA_84d1e18f-fce3-4724-a67d-9e622d48d437">7,301</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie86f9d77d3ac4df098fa6d23ca3fd9c3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE1NTYzOA_e127b306-d2c4-4e38-b370-f5ab9071a5f2">6,777</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0eb57c151e4a51b244e35e9ceb3409_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE1NTYzOA_bb7ecbef-0b64-4b85-8cef-019466b07d02">6,695</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sulperazon</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i864f375b8a0b4cb9ac443ab41aef9bc3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI2LTQtMS0xLTE1NTYzOA_545eb026-c85a-4bee-ada1-b278ea00b6ab">683</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib48b9e43f20748079898c888a0319e4d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI2LTYtMS0xLTE1NTYzOA_a01fa71e-8e3c-4ff5-aa15-db1bead5ffd4">618</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23cf6ca73857476c8ff2bdba66164ed9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI2LTgtMS0xLTE1NTYzOA_fe8eb5cd-5aa9-4e26-b7a8-fdad41de423c">684</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Medrol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fcee28088674808b29e46b75901de61_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI3LTQtMS0xLTE1NTYzOA_340c1407-a32d-4b2b-a7d8-b3039b055bb3">432</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26c6c1402924d3389d90318d7b7a05d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI3LTYtMS0xLTE1NTYzOA_8b493168-0eb1-464f-b821-dff381d3df7f">402</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed935509397465ebdcfc54a917081b4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI3LTgtMS0xLTE1NTYzOA_f776c90e-f262-4936-a9c7-07132e8af9aa">469</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic429688b0a95432ca599be902169635c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM5LTQtMS0xLTE2NDU1Ng_03e0dbf8-17ca-4356-9499-58dd82ca25ec">413</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7715e12d4d640cab70794a4955462a2_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM5LTYtMS0xLTE2NDU1Ng_77b7caec-3b75-477f-8ff0-acb13a29e227">212</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3657cbe2097d49f09bc5c7ace046f357_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM5LTgtMS0xLTE2NDU1Ng_3fc2a782-5aec-4efd-ac6d-30304210824d">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fragmin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0f38aa0b8344479ee03e3bf63754ad_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTQtMS0xLTE5ODQ1Ng_52f2b34f-f870-4c68-9a5f-2b3b10a2806b">305</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556e45078d274acaae78248df82d7516_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTYtMS0xLTE5ODQ1Ng_9bf9cfef-e516-468d-aa18-d80960960916">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa5c08d894ca47fcb948a6643738b465_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTgtMS0xLTE5ODQ1Ng_c9548c8c-e0fb-4724-8819-de2ecad1e072">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11b6e37093449bb86170837f29de961_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTQtMS0xLTE2NDU2NQ_12447790-7d7d-4432-9d55-44b84b4a9d5a">278</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cacfa22e3f24fba9a769d3980dee98d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTYtMS0xLTE2NDU2NQ_f02afd30-fc35-470b-9dee-bf1c775e78e9">276</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92765a1b79944c1c9064745303c5bb8f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTgtMS0xLTE2NDU2NQ_2ee14edc-adf0-4ca6-89eb-c4dc4d362ce7">336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vfend</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d9c00b6c0fe43929b5baaef97fd98df_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQyLTQtMS0xLTE2NDU3Mg_46f02be5-3f8c-4962-a770-84d28163122a">267</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48f1bb2ae72c408dbdd9691315c5ceed_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQyLTYtMS0xLTE2NDU3Mg_773da79a-1315-43b0-8da8-21f5397798c2">270</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i976152f132e54933961ff0eb781c15eb_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQyLTgtMS0xLTE2NDU3Mg_fae20f86-2c80-4f28-8b57-2c930e344feb">346</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tygacil</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5573eebca954b888eb53c05194e1cb1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ0LTQtMS0xLTE2NDU4NQ_927339bf-bce9-4c30-86d2-5cd314a5d6c6">200</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ec61b9fd42f4e11b22c341a2f524130_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ0LTYtMS0xLTE2NDU4Nw_2d147988-0176-4ba9-9d05-6fe202f04276">160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icecd0bd3f5d64be6b655bd11f2dec987_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ0LTgtMS0xLTE2NDkzNQ_97e70aca-edf7-4656-91e3-33f196b2ea62">197</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Precedex</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sedation agent in surgery or intensive care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac09b89e5bbc4d37ad7c15e4b948b194_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTQtMS0xLTE2NDU5MQ_82a1fbf4-be81-4aa2-82bd-4f11f102deeb">177</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15803142604d40aaba5216963466084d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTYtMS0xLTE2NDU5MQ_3c602997-85d5-4a43-8139-ee491c9e726a">260</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if479f5e8c2794e9e90a2742677f13fa3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTgtMS0xLTE2NDU5MQ_9afbe674-31cc-488f-be01-d9eb86014efd">155</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zyvox</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1505f771b019477290eb9cd549444c29_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTQtMS0xLTE2NDU5MQ_67d992b5-a7b1-4f03-b6a9-f07c3fdc081d">173</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e4fd49f5a94424933d7ef2c6829721_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTYtMS0xLTE2NDU5MQ_7d396500-9546-48db-8ac4-5a888c8e1b26">222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b70715abc94491a9f13b0b6351cfa47_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTgtMS0xLTE2NDU5MQ_f9092839-15ea-4e50-8845-358ff10582f2">251</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Paxlovid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">COVID-19 Infection (</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">high risk population)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie735373e16a54b109a6ca3eef912bee6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE5Nzk2Nw_aa0ca3ce-697e-4a68-ae98-277d627422e7">76</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf401509c5154ce99e7c8858bbbacba4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE5Nzk3MA_035bfa5e-5b80-4006-85bb-06e7eb49148d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c1ea9c9b504497db6d2486610d3f9be_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE5Nzk4NQ_dea0fdf4-fa5a-4a84-b661-c3f92cdd325a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">IVIg Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08011c6d22d84826921f15b42efbd425_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE2NDYwMA_8bc8c2da-2d5b-4c39-bae1-d91078e9f19b">430</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0d8215e037429fa7a23c4023f0d1e4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE2NDYwMg_75ce4bd5-1146-426e-a42c-516b04aa5a41">376</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb660a81d4c4eab803661bac2510826_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE2NDk3NQ_f1946444-2e33-45ab-9b79-73f3bb433ed8">275</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Anti-infectives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5eab6ea9c344750a8cbb61f815ce93d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM3LTQtMS0xLTE1NTYzOA_abd7b0b7-dba1-40c5-8cc6-49ddc6c6e7ce">1,453</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a69b57be5b4ffb9798f0dd614f0c40_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM3LTYtMS0xLTE1NTYzOA_bbd3d804-c4df-43c2-8666-37c58169f34b">1,294</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6571d00942e43b7978e3b7b74f6edd6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM3LTgtMS0xLTE1NTYzOA_ae04e05b-a4ec-4291-8394-6843d98acc6e">1,396</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Hospital</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8053c4ee14d4eb98043aa3562d93dc6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM4LTQtMS0xLTE1NTYzOA_72d209ba-2afc-416c-ae46-5d27be497e91">2,412</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaa0004eb00541dd973b2f4b93c282c5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM4LTYtMS0xLTE1NTYzOA_0d671c6f-cb59-45de-a261-fcac99b0f072">2,435</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i713a733530404ed18373bae05f6b3cb6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM4LTgtMS0xLTE1NTYzOA_4da9eca7-255d-47ae-b452-4232471717c3">2,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d0dfa4a22a74f91abffb964783f5b3a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTQtMS0xLTE1NTYzOA_57a9c96b-24da-41a7-9148-0b6057723413">4,431</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47bcf7ce353c44f5bcfdcdee0877890b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTYtMS0xLTE1NTYzOA_a7e89de7-ca32-4095-a0eb-0c4646d670d3">4,567</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4f1c35594c544dab5b1dfa223ee4637_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTgtMS0xLTE1NTYzOA_b803ba39-d9f5-4238-800d-3424cf75acac">4,733</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xeljanz</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c6cef914b94f1d9ad5c0270ad54b42_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTQtMS0xLTE1NTYzOA_a4893523-c398-4d64-9e53-1c1600735e5e">2,455</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5563b77001b44cb1904e2c79fdf3e92a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTYtMS0xLTE1NTYzOA_d763b952-6725-4d8c-9103-e92fc8f608cc">2,437</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc98ac45c09142c7bd8010806f4ab103_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTgtMS0xLTE1NTYzOA_26e2c666-8347-4ada-83e7-94b755e7034e">2,242</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Enbrel (Outside the U.S. and Canada)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8922522ea93a4f3daa0785e1fc05776a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE1NTYzOA_4c23db60-a64e-4132-908f-8691821d414b">1,185</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05428f6e4c154ff7b4054980d1d8cb46_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE1NTYzOA_81cabc4e-28a5-4f06-b880-dcd11b948e5b">1,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350105d44425447281d31cd6eb39f7c9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE1NTYzOA_46df3ae9-52ed-4b3b-829a-455af7ffc166">1,699</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inflectra/Remsima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47901365d3d4bc0bb6d60c486ef4e67_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE1NTYzOA_ef2210fc-2af3-4987-9ee4-e4fabe090c27">657</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6baae032a571408ca95cda7430a3f436_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE1NTYzOA_b156dc16-529f-44d0-ac01-d31d1d7d5ba1">659</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71f59e7bda3142f187e0612cca60056e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE1NTYzOA_492c7816-9dbc-458f-9896-5645ccb7be3a">625</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other I&amp;I</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bb0e10a3254deb9c9b88fa560808c6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ5LTQtMS0xLTE1NTYzOA_aeb05748-49ad-4425-af79-a740b7afbdc0">134</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie013202cd4c84b0ca180ef2bac1c2fd6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ5LTYtMS0xLTE1NTYzOA_fdaa91d6-cdfd-4bdc-a8e9-1fec847da873">121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49f99cd213cd422f98453a77ea72f411_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ5LTgtMS0xLTE1NTYzOA_f9d4b1f6-3ab4-4b5f-8a86-e405246a1488">167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare Disease</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d18c120b6c467ab4451263aebe5da0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUwLTQtMS0xLTE1NTYzOA_f74d2f1d-0f76-4973-93d2-e911bb2a499c">3,538</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62b3761d83784fc7a895b99aab8312b3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUwLTYtMS0xLTE1NTYzOA_f07ce368-0afb-4c29-a617-b80e2292c6b5">2,936</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcbdb031a3e4014a0cbb064217500aa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUwLTgtMS0xLTE1NTYzOA_07e21691-c471-47cd-83a3-822bdc5d22b0">2,278</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bf6fb9bf9145e6badc4cd8e5f71064_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUxLTQtMS0xLTE1NTYzOA_adc120dc-26c7-49cc-9012-cdefdecbae12">2,015</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4105a4588d4e35915a905b52f68c56_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUxLTYtMS0xLTE1NTYzOA_2d4bd790-b635-4bac-8902-dca5ed1fd229">1,288</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6d7e329bd24eb4a5a437d5f214dc41_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUxLTgtMS0xLTE1NTYzOA_b2e7e1b1-de2c-4f72-88b5-c56e4211fe8b">473</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03db65ef941c451aa8dda7f330bc59a4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUyLTQtMS0xLTE1NTYzOA_c68008b9-ea46-47be-82f6-be98e7030112">438</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d4ea528937245a980a0cd68ff2881a0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUyLTYtMS0xLTE1NTYzOA_66f4625a-058e-471a-96b4-f11f2c27fd50">454</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib70adb8ce46e49d0b66f7c5db2e887d0_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUyLTgtMS0xLTE1NTYzOA_f766ceb0-12b4-4bd1-a37f-5c10adea742e">488</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Genotropin</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cc90c9a8c6548658c7c62c694f4b1b0_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUzLTQtMS0xLTE1NTYzOA_29bafd57-3117-4150-9d0a-a25a414d10b9">389</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfc908d4ea1448b3be3181f507e32499_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUzLTYtMS0xLTE1NTYzOA_76fc21b3-1ad2-415f-9868-6d7a4c2721e4">427</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71abae4333e54c548a4315c66f1b397f_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUzLTgtMS0xLTE1NTYzOA_91df1b65-49ba-4064-956c-b334b4121d25">498</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Refacto AF/Xyntha</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3287158066bd486e8eb1277ac8bd7a2f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU0LTQtMS0xLTE1NTYzOA_5775949a-a34a-45c3-b1d9-ddc8177cb2dc">304</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378275fdf5c241309e4fc13c042fb25d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU0LTYtMS0xLTE1NTYzOA_9897d63c-1f13-49ce-8e00-3b7073da917b">370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i484dba9ec8d0445bb323aed6db364c28_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU0LTgtMS0xLTE1NTYzOA_0e8cb7b7-0eb1-4cb9-a45b-b3ef71970934">426</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Somavert</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0d6d788ad4143ccb88dbf6bae7eeafc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU1LTQtMS0xLTE1NTYzOA_e19c7858-e5be-4160-b282-c81d0dfa6d76">277</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd236c60a6694d4cb50a6a582663bb1d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU1LTYtMS0xLTE1NTYzOA_00a593f3-0ae3-416b-b2fe-d08ab62bb748">277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i503af1f1138c4021a803c193d30090a6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU1LTgtMS0xLTE1NTYzOA_68e8d502-9ae8-4bb2-ac18-e558ad0608b1">264</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Rare Disease</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i623d184c533f47bc94f2a7ad9168813f_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU2LTQtMS0xLTE1NTYzOA_923fd574-c718-4857-afab-3e47ea34b4f3">115</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ecd1a0cd424241b3ef5a26c2f58f23_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU2LTYtMS0xLTE1NTYzOA_141da2c5-f52c-42ee-9321-585b2aa49431">120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c4ac602963e4692bf2396276e8987c4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU2LTgtMS0xLTE1NTYzOA_7c936533-1664-4f0a-885f-c30bae188022">129</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629787cb4c6e49829464bc26f89c64cf_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTQtMS0xLTE5MjY0Mg_973de251-1059-4bc4-8eb8-a7ca4fcc9007">1,731</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff57629495074f9eba67dffa28d6db32_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTYtMS0xLTE5MjY0Mg_df1f1f1e-4008-4cda-ac0a-e639d27cec71">926</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9b3c1fffde345738b432a24553ace13_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTgtMS0xLTE5MjY0Mg_225a7c3f-25ee-4409-844a-ca7bb3aca5e2">810</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CONSUMER HEALTHCARE BUSINESS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc38387d7e3642be97acbeb8bf6bdcb8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTQtMS0xLTE1NTYzOA_e2fa2de8-d998-4b80-bebc-4cd7c402c0c8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ef775a73de440e793ff799dbf7b5fa7_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTYtMS0xLTE1NTYzOA_625152f8-e200-4048-8ec7-2928d62faf56">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e851a6e197444cb8fc69f8308332f99_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTgtMS0xLTE1NTYzOA_4a4fd6f2-6e82-4b8a-b870-339dfe8edb35">2,082</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d39854eb2b4573a531d5ba9f61e8f7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU5LTQtMS0xLTE1NTYzOA_14dfe05a-c342-446a-980a-fc7a95642740">7,652</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7d6064a3a64aa6ad422f45888299a0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU5LTYtMS0xLTE1NTYzOA_c993556c-1ae4-4f68-a6f2-63cfd83b3cf6">5,418</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39801c36e4b84ce8b6d398e7fc12447b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU5LTgtMS0xLTE1NTYzOA_19d1622f-fff1-4295-944e-e11d0b33158b">4,648</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c3b4b2ebc94e5697c6ff08a35994e8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTQtMS0xLTE1NTYzOA_b5a3ef71-2dba-41da-9044-3e1f336183ad">2,343</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec324211aedf4500bf27dd971b841288_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTYtMS0xLTE1NTYzOA_95ca3f57-7179-4721-b012-2d1c1e26855e">1,527</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4868147c644c12aa0f667d7f6e8057_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTgtMS0xLTE1NTYzOA_22e67cb7-a692-4f22-b211-654b1e63675f">911</ix:nonFraction>&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1631e191e764640a3ad6ad0db704edb_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTQtMS0xLTE1NTYzOA_9378fa2a-a4bc-47fc-a652-1bec85705217">5,746</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fae2aac94946139c72a9f5a683a557_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTYtMS0xLTE1NTYzOA_a86bd816-10b9-4f9b-912a-4d22b7e4fec4">5,315</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027e0fdd3ba440ae86709e0f6c28fbf2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTgtMS0xLTE1NTYzOA_05bf4b6b-a861-4cb5-8cc3-aff476c0dce8">5,013</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></ix:footnote></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519" footnoteRole="http://www.xbrl.org/2003/role/footnote">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($<ix:nonFraction unitRef="usd" contextRef="i8abd4017e8f04c56a2d4cf46f2d31c44_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2NTk1NTE_6816d3be-b6f0-4f15-9d63-bbad2cdc2780">320</ix:nonFraction> million for 2021 and $<ix:nonFraction unitRef="usd" contextRef="i5c32373d4dac49c19122e22f70bfe22e_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2NjIyODA_069baf12-cd25-4337-8195-b90e4497310f"><ix:nonFraction unitRef="usd" contextRef="ic21b6b2a9bc64c5cb347be77855ca1be_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2NjIyODA_f9e66a03-94c6-4487-b814-c80b3c3d93b3">0 million</ix:nonFraction></ix:nonFraction> for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzE_c89bfeea-0241-4819-96f1-38baefbea46b" footnoteRole="http://www.xbrl.org/2003/role/footnote">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). </ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21" footnoteRole="http://www.xbrl.org/2003/role/footnote">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTI_8e54b3d4-6b69-441d-8368-d4e6af77c9fd" footnoteRole="http://www.xbrl.org/2003/role/footnote">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.</ix:footnote></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzI_70d446fc-6d87-4eaa-9bc7-53cbba59b771" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">On July&#160;31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare JV. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></ix:footnote></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTM_2e9bea88-c690-449e-914e-399b541e82de" footnoteRole="http://www.xbrl.org/2003/role/footnote">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</ix:footnote></span></div></ix:continuation><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Remaining Performance Obligations</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totals $<ix:nonFraction unitRef="usd" contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231" decimals="-8" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMjk0NzYw_89ade013-8341-431c-a287-b73ef10545f9">34.4</ix:nonFraction> billion as of December 31, 2021, which includes amounts received in advance and deferred and amounts that will be invoiced as we deliver the product to our customers in future periods. Of this amount, we expect to recognize revenue of </span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">104</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if78ab6f63ed048b4866ddc0bc2ad4578"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i52bc922f23d94809b6348416f7d67f89_I20211231" decimals="-8" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMjk0Nzcx_67c3db4c-fe82-4af9-85d4-bc6bf56e57b5">22.3</ix:nonFraction> billion in 2022, $<ix:nonFraction unitRef="usd" contextRef="ic1efb123775446d4afb050c15a9de3c2_I20211231" decimals="-8" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMjk0Nzgx_cf73cd04-d6b2-4713-b18e-3d58769fa217">11.8</ix:nonFraction> billion in 2023 and $<ix:nonFraction unitRef="usd" contextRef="ifd473cbb8e244c0baf184d66619e9bab_I20211231" decimals="-6" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzcxNDY4MjU2NjgwODI_8254e16c-1b01-4dc0-a210-3a63a5e7eb0b">265</ix:nonFraction> million in 2024. Remaining performance obligations exclude arrangements with an original expected contract duration of less than one year.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenues</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of Comirnaty. The deferred revenues associated with the advance payments related to Comirnaty total $<ix:nonFraction unitRef="usd" contextRef="i894356ab8eef44b399b55416273a7ef0_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzM4Nzg_e951c0b2-adb5-49ac-8ed8-ef864ea198b9">3.3</ix:nonFraction> billion as of December 31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="id502e86301f6476e98c1e91bd227d64b_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkxNzE_f70208cc-065d-4859-83cf-588d41f31536">957</ix:nonFraction> million as of December 31, 2020, with $<ix:nonFraction unitRef="usd" contextRef="i894356ab8eef44b399b55416273a7ef0_I20211231" decimals="-8" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkyMjM_d89f1072-8c10-4ad7-9211-614b08974e12">3.0</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i894356ab8eef44b399b55416273a7ef0_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkyMzE_d2008ae4-5fb7-4e36-9643-d3c64d044242">249</ix:nonFraction> million recorded in current liabilities and noncurrent liabilities, respectively as of December 31, 2021, and $<ix:nonFraction unitRef="usd" contextRef="id502e86301f6476e98c1e91bd227d64b_I20201231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkzMjM_7e89508e-aecf-4110-afe0-f4179d0ff357">957</ix:nonFraction> million recorded in current liabilities as of December 31, 2020. The increase in the Comirnaty deferred revenues during 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries less amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> as we delivered doses to our customers. During 2021, we recognized in revenue substantially all of the balance of Comirnaty deferred revenues as of December 31, 2020. The Comirnaty deferred revenues as of December 31, 2021 will be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> in 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of December 31, 2021 or 2020.</span></div></ix:continuation><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">105</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_244"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selected Quarterly Financial Data (Unaudited)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarter</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,516</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,899</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24,035</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,838</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs and expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,802</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,951</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,546</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">646</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,692</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,949</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,843</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,827</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(328)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,885</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,825</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,171</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,578</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(236)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,886</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,589</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,159</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,391</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,393</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) per common share&#8212;basic:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.04</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.64</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.99</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) per common share&#8212;diluted:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.02</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.04)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.42</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Business development activities impacted our results of operations in 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 1A.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The fourth quarter historically reflects higher costs in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Research and development expenses. Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for all quarters reflects higher costs for Comirnaty.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The fourth quarter includes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">a $2.1&#160;billion charge for IPR&amp;D expense associated with the acquisition of Trillium, as well as other upfront and milestone payments on collaboration and licensing arrangements. See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Notes 2A, D </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> E.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The third and fourth quarters of 2021 primarily include employee termination costs associated with our Transforming to a More Focused Company program. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 3.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">All periods reflect a change in the jurisdictional mix of earnings primarily related to Comirnaty. The third quarter of 2021 reflects benefits resulting from certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">All periods include the operating results of Meridian prior to its sale on December 31, 2021 and to a lesser extent post-closing adjustments directly related to prior discontinued businesses. The second quarter of 2021 includes a pre-tax charge of $345&#160;million to resolve a legal matter related to Meridian and the fourth quarter of 2021 includes an after tax loss of $167&#160;million related to the sale of Meridian. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Selected Quarterly Financial Data (Unaudited)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc. and Subsidiary Companies</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quarter</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">First</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Second</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Third</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fourth</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,007&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,795&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,634&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs and expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,389&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,917&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) on completion of Consumer Healthcare JV transaction</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income/(loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(334)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,621&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,489&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) per common share&#8212;basic:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) per common share&#8212;diluted:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.47&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Business development activities impacted our results of operations in 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 1A.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The fourth quarter historically reflects higher costs in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Research and development expenses. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Certain asset impairments totaled $900&#160;million in the third quarter of 2020 and $791&#160;million in the fourth quarter of 2020 recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Operating results of the Upjohn Business through November 16, 2020, the date of the spin-off and combination with Mylan, the Mylan-Japan collaboration and Meridian are presented as discontinued operations in all periods presented. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_247"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">None.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_250"></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of the end of the period covered by this Form 10-K, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During our most recent fiscal quarter, there has not been any change in the Company&#8217;s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">107</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_253"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">To the Board of Directors and Shareholders</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pfizer Inc.:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have audited Pfizer Inc. and Subsidiary Companies&#8217; (the Company) internal control over financial reporting as of December&#160;31, 2021, based on criteria established in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Internal Control</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Integrated Framework </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. </span></div><div style="margin-top:6pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements), and our report dated February&#160;24, 2022 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span><img src="pfe-20211231_g10.jpg" alt="pfe-20211231_g10.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"/></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New York, New York</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">February 24, 2022</span></td></tr></table></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_256"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Report</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We prepared and are responsible for the financial statements that appear in this Form 10-K. These financial statements are in conformity with accounting principles generally accepted in the United States of America and, therefore, include amounts based on informed judgments and estimates. We also accept responsibility for the preparation of other financial information that is included in this document.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. The Company&#8217;s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Based on our assessment and those criteria, management believes that the Company maintained effective internal control over financial reporting as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company&#8217;s independent auditors have issued their auditors&#8217; report on the Company&#8217;s internal control over financial reporting. That report appears above in this Form 10-K</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.714%"></td><td style="width:0.1%"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"><div><img src="pfe-20211231_g11.jpg" alt="pfe-20211231_g11.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:164px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Albert Bourla</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:60.954%"></td><td style="width:0.1%"></td></tr><tr style="height:63pt"><td colspan="3" style="padding:0 1pt"><div><img src="pfe-20211231_g12.jpg" alt="pfe-20211231_g12.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:217px"/></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><img src="pfe-20211231_g13.jpg" alt="pfe-20211231_g13.jpg" style="height:65px;margin-bottom:5pt;vertical-align:text-bottom;width:198px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Frank D&#8217;Amelio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jennifer B. Damico</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Financial Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal Accounting Officer</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">February 24, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">109</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_259"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.755%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART III</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_262"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Information about our Directors is incorporated by reference from the discussion under the heading </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Election of Directors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. Information about the Pfizer Policies on Business Conduct governing our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, and the Code of Business Conduct and Ethics for Members of the Board of Directors, is incorporated by reference from the discussions under the headings </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Policies on Business Conduct </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Code of Conduct for Directors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. Information regarding the procedures by which our shareholders may recommend nominees to our Board of Directors is incorporated by reference from the discussion under the headings </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Election of Directors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Criteria for Board Membership</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Annual Meeting Information&#8212;Submitting Proxy Proposals and Director Nominations for the 2023 Annual Meeting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our Proxy Statement. Information about our Audit Committee, including the members of the Committee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the heading </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Board and Committee Information</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Board Committees&#8212;The Audit Committee</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. The balance of the information required by this item is contained in the discussion entitled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Information about Our Executive Officers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in this Form 10-K. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_265"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXECUTIVE COMPENSATION</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Information about Director and executive compensation is incorporated by reference from the discussion under the headings </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Non-Employee Director Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Executive Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Governance&#8212;Board and Committee Information&#8212;Board Committees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The Compensation Committee</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Compensation Committee Interlocks and Insider Participation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_268"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Information required by this item is incorporated by reference from the discussion under the headings </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Compensation Tables&#8212;Equity Compensation Plan Information</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Securities Ownership</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_271"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Information about certain relationships and transactions with related parties is incorporated by reference from the discussion under the headings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Governance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other Governance Practices and Policies&#8212;Related Person Transactions and Indemnification </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Transactions with Related Persons</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. Information about director independence is incorporated by reference from the discussion under the heading </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Election of Directors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Director Independence</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. </span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_274"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yNzQvZnJhZzoyYjc3NmE1MTUzYzQ0MTk5OWNjM2FjODRlNWYwYTY2My90ZXh0cmVnaW9uOjJiNzc2YTUxNTNjNDQxOTk5Y2MzYWM4NGU1ZjBhNjYzXzQxMjMxNjg2MDQyNzA5_c4e235c6-6016-4c64-8fdc-ab1e8e8e5700">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yNzQvZnJhZzoyYjc3NmE1MTUzYzQ0MTk5OWNjM2FjODRlNWYwYTY2My90ZXh0cmVnaW9uOjJiNzc2YTUxNTNjNDQxOTk5Y2MzYWM4NGU1ZjBhNjYzXzQxMjMxNjg2MDQyNzEw_50319a69-66db-4685-b90e-9a417b173bc9">New York, NY</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yNzQvZnJhZzoyYjc3NmE1MTUzYzQ0MTk5OWNjM2FjODRlNWYwYTY2My90ZXh0cmVnaW9uOjJiNzc2YTUxNTNjNDQxOTk5Y2MzYWM4NGU1ZjBhNjYzXzQxMjMxNjg2MDQyNzEx_52b5bc54-7c0b-4e22-a7ef-87ca32919cf6">185</ix:nonNumeric>. Information about the fees for professional services rendered by our independent registered public accounting firm in 2021 and 2020 is incorporated by reference from the discussion under the heading </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Ratification of Selection of Independent Registered Public Accounting Firm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Audit and Non-Audit Fees</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Proxy Statement. Our Audit Committee&#8217;s policy on pre-approval of audit and permissible non-audit services of our independent registered public accounting firm is incorporated by reference from the discussion under the heading </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Ratification of Selection of Independent Registered Public Accounting Firm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our Proxy Statement. </span></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">110</span></div></td></tr></table></div></div></div><div id="i4bff405b2205487eb835dd4cd589f5c6_277"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:36.755%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt dotted #006ebf;border-top:1pt dotted #006ebf;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PART IV</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_280"></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_283"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15(a)(1) Financial Statements.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The following consolidated financial statements, related notes, report of independent registered public accounting firm and supplementary data are set forth in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in this Form 10-K:</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Report of Independent Registered Public Accounting Firm on the Consolidated Financial Statements</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Consolidated Statements of Income</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Consolidated Statements of Comprehensive Income</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Consolidated Balance Sheets</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Consolidated Statements of Equity</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Consolidated Statements of Cash Flows</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Notes to Consolidated Financial Statements</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Selected Quarterly Financial Data (Unaudited)</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_286"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15(a)(2) Financial Statement Schedules.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Schedules are omitted because they are not required or because the information is provided elsewhere in the financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_289"></div><div style="-sec-extract:summary;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">15(a)(3) Exhibits.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> These exhibits are available upon request. Requests should be directed to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New York, New York 10017. The exhibit numbers preceded by an asterisk (*) indicate exhibits filed with this Form 10-K. All other exhibit numbers indicate exhibits filed by incorporation by reference. Exhibit numbers 10.1 through 10.44 are management contracts or compensatory plans or arrangements.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.823%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit22x12312018x10k.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Stock and Asset Purchase Agreement, dated December 19, 2018, by and among us, GlaxoSmithKline plc and GlaxoSmithKline Consumer Healthcare Holdings Limited is incorporated by reference from our 2018 Annual Report on Form 10-K. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Stock and Asset Purchase Agreement.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312519204818/d769805dex21.htm">2.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Business Combination Agreement, dated as of July 29, 2019, by and among us, Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V. and Mylan II B.V. is incorporated by reference from our Current Report on Form 8-K filed on July 29, 2019. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Business Combination Agreement.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312520157434/d904465dex21.htm">2.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 1 to the Business Combination Agreement, dated as of May 29, 2020, by and among us, Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V. and Mylan II B.V. is incorporated by reference from our Current Report on Form 8-K filed on June 1, 2020. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Amendment No. 1 to the Business Combination Agreement.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312519204818/d769805dex22.htm">2.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Separation and Distribution Agreement, dated as of July 29, 2019, by and between us and Upjohn Inc. is incorporated by reference from our Current Report on Form 8-K filed on July 29, 2019. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Separation and Distribution Agreement.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000014/pfe-exhibit24x12312019.htm">2.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 1 to the Separation and Distribution Agreement, dated as of February 18, 2020, by and between us and Upjohn Inc. is incorporated by reference from our 2019 Annual Report on Form 10-K. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Amendment No. 1 to the Separation and Distribution Agreement.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312520157434/d904465dex22.htm">2.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 2 to the Separation and Distribution Agreement, dated as of May 29, 2020, by and between us and Upjohn Inc. is incorporated by reference from our Current Report on Form 8-K filed on June 1, 2020. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Amendment No. 2 to the Separation and Distribution Agreement.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000070/pfe-exh21x927202010q.htm">2.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 3 to the Separation and Distribution Agreement, dated as of September 18, 2020, by and between us and Upjohn Inc. is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 27, 2020. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Amendment No. 3 to the Separation and Distribution Agreement.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh28x12312020x10k.htm">2.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 4 to the Separation and Distribution Agreement, dated as of November 15, 2020, by and between us and Upjohn Inc. is incorporated by reference from our 2020 Annual Report on Form 10-K. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Amendment No. 4 to the Separation and Distribution Agreement.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312520317074/d36307dex32.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Our Restated Certificate of Incorporation dated December 14, 2020, is incorporated by reference from our Current Report on Form 8-K filed on December 14, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800317000057/exh31_by-laws20171.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Our By-laws, as amended December 18, 2017, are incorporated by reference from our Current Report on Form 8-K filed on<br/>December 21, 2017.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000091412101000106/0000914121-01-000106-0002.txt">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Indenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is incorporated by reference from our Current Report on Form 8-K filed on January 30, 2001.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000115752309005774/a6022539ex4-1.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">First Supplemental Indenture, dated as of March 24, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 28, 2009.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800309000122/ex0603x.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Second Supplemental Indenture, dated as of June 2, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2009.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312513245261/d547019dex42.htm">4.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Third Supplemental Indenture, dated as of June 3, 2013, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2013.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312514201187/d727538dex42.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fourth Supplemental Indenture, dated as of May 15, 2014, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on May 15, 2014.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312515338599/d37576dex42.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fifth Supplemental Indenture, dated as of October 5, 2015, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on October 6, 2015.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312516612635/d193755dex43.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sixth Supplemental Indenture, dated as of June 3, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on June 3, 2016.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000110465916158373/a16-21499_7ex4d2.htm">4.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Seventh Supplemental Indenture, dated as of November 21, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on November 21, 2016.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312517087159/d347858dex42.htm">4.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eighth Supplemental Indenture, dated as of March 17, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (successor to the Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on March 17, 2017.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312517071809/d335900dex42.htm">4.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ninth Supplemental Indenture, dated as of March 6, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent and calculation agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on March 6, 2017.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312517373738/d476089dex42.htm">4.11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Tenth Supplemental Indenture, dated as of December 19, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on December 19, 2017.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/5187/0000950112-95-000091.txt">4.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Indenture, dated as of April 10, 1992, between Wyeth (formerly American Home Products Corporation) and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Registration Statement on Form&#160;S-3, filed on January 18, 1995.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/5187/0000950112-95-000091.txt">4.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Supplemental Indenture, dated as of October 13, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Registration Statement on Form&#160;S-3, filed on January 18, 1995.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/5187/000000518704000048/indent5.txt">4.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fifth Supplemental Indenture, dated as of December 16, 2003, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s 2003 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/5187/000000518705000060/y14795.htm">4.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Sixth Supplemental Indenture, dated as of November 14, 2005, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Current Report on Form 8-K filed on November 15, 2005.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/5187/000119312507067406/dex41.htm">4.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Seventh Supplemental Indenture, dated as of March 27, 2007, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Current Report on Form 8-K filed on March 28, 2007.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/5187/000091412109001203/pf17591951-ex4_1.htm">4.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Eighth Supplemental Indenture, dated as of October 30, 2009, between Wyeth, us and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, formerly The Chase Manhattan Bank), as trustee, to Indenture dated as of April 10, 1992 (as amended on October 13, 1992), is incorporated by reference from our Current Report on Form 8-K filed on November 3, 2009.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312518269276/d618110dex41.htm">4.18</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on September 7, 2018. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312518269276/d618110dex42.htm">4.19</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">First Supplemental Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on September 7, 2018. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312519070967/d720336dex42.htm">4.20</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Second Supplemental Indenture, dated as of March 11, 2019, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on March 11, 2019.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000093041320000918/c95505_ex4-2.htm">4.21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Third Supplemental Indenture, dated as of March 27, 2020, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on March 27, 2020.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">112</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312520154311/d916063dex42.htm">4.22</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fourth Supplemental Indenture, dated as of May 28, 2020, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on May 28, 2020.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312521250347/d340659dex42.htm">4.23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Fifth Supplemental Indenture, dated as of August 18, 2021 between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on August 18, 2021.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh424x12312021x10k.htm">4.24</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Description of Pfizer&#8217;s Securities. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Except as set forth in Exhibits 4.1-24 above, the instruments defining the rights of holders of long-term debt securities of the Company and its subsidiaries have been omitted.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000093041301500008/c19779-def14a.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001 Annual Meeting of Shareholders.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312512085703/d278590dex102.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Inc. 2004 Stock Plan, as Amended and Restated is incorporated by reference from our 2011 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh103x12312020x10k.htm">10.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 1 to Pfizer 2004 Stock Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000093041314001277/c76328_def14a.htm">10.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Inc. 2014 Stock Plan is incorporated by reference from our Proxy Statement for the 2014 Annual Meeting of Shareholders.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh105x12312020x10k.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 1 to Pfizer Inc. 2014 Stock Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000037/pfe-exh101x0329202010q.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Form of Acknowledgment and Consent and Summary of Key Terms for Grants of RSUs, TSRUs, PPSs and PSAs is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended March 29, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800316000077/pfe-12312015x10kexhibit105.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Form of Executive Grant Letter is incorporated by reference from our 2015 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit106x1231201.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2017 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit107x12312018x10k.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 1 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2018 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1010x123120x10k.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 2 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800316000096/pfe-4032016x10qexhibit101.htm">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2016.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800317000049/pfe-10012017x10qexhibit101.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 1 to the Pfizer Supplemental Savings Plan (Amended and Restated as of January 1, 2016), is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1, 2017.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit109x1231201.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 2 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2017 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000091/pfe-930201810qxexhibit101.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 3 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 30, 2018.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1012x12312018x1.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 4 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1013x12312018x1.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 5 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000064/pfe-630201910qxexh101.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 6 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 30, 2019.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000014/pfe-ex1015x12312019xk.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 7 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2019 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1019x123120x10k.htm">10.19</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 8 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1020x12312020x10k.htm">10.20</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 9 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1021x123120x10k.htm">10.21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amended and Restated Pfizer Inc. Global Performance Plan </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">is incorporated by reference from our 2020 Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800313000006/pfe-12312012xex109.htm">10.22</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2012 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000018/pfe-12312013xex1011.htm">10.23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment to Amended and Restated Deferred Compensation Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800316000105/pfe-07032016x10qexhibit101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800316000105/pfe-07032016x10qexhibit101.htm">4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 2 to Amended and Restated Deferred Compensation Plan, dated April 27, 2016, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended July 3, 2016.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1025x123120x10k.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1025x123120x10k.htm">5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 3 to Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000018/pfe-12312013xex1014.htm">10.26</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Wyeth 2005 (409A) Deferred Compensation Plan (frozen as of January 2012), together with certain Amendments, is incorporated by reference from our 2013 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1027x123120x10k.htm">10.27</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 2 to Wyeth 2005 (409A) Deferred Compensation Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312512085703/d278590dex1011.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312512085703/d278590dex1011.htm">8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amended and Restated Wyeth Supplemental Employee Savings Plan (effective as of January 1, 2005 and frozen as of January 2012), together with all material Amendments is incorporated by reference from our 2011 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000018/pfe-12312013xex1016.htm">10.29</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment to Amended and Restated Wyeth Supplemental Employee Savings Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/0000950116-97-000605.txt">10.30</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The form of Indemnification Agreement with each of our non-employee Directors is incorporated by reference from our 1996 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">113</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/0000940180-98-000332.txt">10.31</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">The form of Indemnification Agreement with each of the Named Executive Officers identified in our Proxy Statement for the 2021 Annual Meeting of Shareholders is incorporated by reference from our 1997 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0a0bff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0a0bff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800307000213/ex101822.htm">10.32</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Letter to Frank A. D&#8217;Amelio regarding replacement pension benefit dated August 22, 2007 is incorporated by reference from our Current Report on Form 8-K filed on August 22, 2007.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800309000024/exhf09.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800309000024/exhf09.htm">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Inc. Executive Severance Plan is incorporated by referenced from our Current Report on Form 8-K filed on February 20, 2009.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1026x12312018x1.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1026x12312018x1.htm">4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 1 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2018 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000014/pfe-exh1029x12312019x1.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000014/pfe-exh1029x12312019x1.htm">5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 2 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2019 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1036x123120x10k.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-exh1036x123120x10k.htm">6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Amendment No. 3 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2020 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312509040568/dex1022.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000119312509040568/dex1022.htm">7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference from our 2008 Annual Report on Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000046/pfe-9282014x10qexhibit102.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000046/pfe-9282014x10qexhibit102.htm">8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 28, 2014.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800309000235/ex1009.htm">10.39</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Form of Special Award Letter Agreement is incorporated by reference from our Current Report on Form 8-K filed on October 28, 2009.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000115752311003088/a6715256ex10-1.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000115752311003088/a6715256ex10-1.htm">0</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Offer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2011.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit1026x123120.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit1026x123120.htm">1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Form of Special Performance-Based Incentive Award Letter is incorporated by reference from our 2017 Annual Report on<br/>Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit1027x123120.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit1027x123120.htm">2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Form of Special Performance-Based Incentive Grant Letter is incorporated by reference from our 2017 Annual Report on <br/>Form 10-K.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000093041319000953/c93082_def14a.htm#x2_c93082a060">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000093041319000953/c93082_def14a.htm#x2_c93082a060">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pfizer Inc. 2019 Stock Plan is incorporated by reference from our Proxy Statement for the 2019 Annual Meeting of Shareholders.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000060/pfe-exhibit101x6282020.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800320000060/pfe-exhibit101x6282020.htm">4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Time Sharing Agreement, dated July 9, 2020, between Pfizer Inc. and Albert Bourla is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 28, 2020.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh21x12312021x10k.htm">21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Subsidiaries of the Company.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/78003/000007800321000065/pfe-exh22x0404202110q.htm">22</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Subsidiary Issuers of Guaranteed Securities is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 4, 2021.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh23x12312021x10k.htm">23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Consent of Independent Registered Public Accounting Firm.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4bff405b2205487eb835dd4cd589f5c6_295">24</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Power of Attorney (included as part of signature page).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh311x12312021x10k.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh312x12312021x10k.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh321x12312021x10k.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="pfe-exh322x12312021x10k.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">*101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div id="i4bff405b2205487eb835dd4cd589f5c6_292"></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM 10-K SUMMARY</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">None.</span></div><div id="i4bff405b2205487eb835dd4cd589f5c6_295"></div><div><span><br/></span></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">114</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dated: February&#160;24, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;MARGARET M. MADDEN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Margaret M. Madden<br/>Senior Vice&#160;President&#160;and&#160;Corporate&#160;Secretary<br/>Chief Governance Counsel</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date indicated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.146%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.884%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" rowspan="29" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" rowspan="29" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">/S/&#160;&#160;&#160;&#160;ALBERT BOURLA</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Albert Bourla</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">/S/&#160;&#160;&#160;&#160;FRANK A. D&#8217;AMELIO</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Frank A. D&#8217;Amelio</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Financial Officer, Executive Vice President (Principal Financial Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">/S/&#160;&#160;&#160;&#160;JENNIFER B. DAMICO</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Jennifer B. Damico</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Vice President and Controller<br/>(Principal Accounting Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;RONALD E. BLAYLOCK<br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ronald E. Blaylock</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;SUSAN DESMOND-HELLMANN</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Susan Desmond-Hellmann</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;JOSEPH J. ECHEVARRIA</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Joseph J. Echevarria</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;SCOTT GOTTLIEB</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Scott Gottlieb</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;HELEN H. HOBBS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Helen H. Hobbs</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;SUSAN HOCKFIELD</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Susan Hockfield</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;DAN R. LITTMAN</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dan R. Littman</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;SHANTANU NARAYEN</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shantanu Narayen</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;SUZANNE NORA JOHNSON</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Suzanne Nora Johnson</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;JAMES QUINCEY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">James Quincey</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">/S/&#160;&#160;&#160;&#160;JAMES C. SMITH</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">James C. Smith</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 22, 2022</span></td></tr></table></div><div style="height:51.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pfizer Inc.</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 Form 10-K</span></td><td colspan="3" style="border-left:1pt dotted #0093d0;border-top:1pt dotted #0093d0;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">115</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.24
<SEQUENCE>2
<FILENAME>pfe-exh424x12312021x10k.htm
<DESCRIPTION>EX-4.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i450e09a299cd413c9654689566c87416_1"></div><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 4.24</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February 24, 2022 Pfizer Inc. has common stock, the 0.250% Notes due 2022 (the 2022 notes) and the 1.000% Notes due 2027 (the 2027 notes and together with the 2022 notes, the notes) registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following descriptions of our common stock and the notes are summaries and do not purport to be complete. The description of our common stock is subject to and qualified in its entirety by reference to our restated certificate of incorporation (the Certificate of Incorporation), and our bylaws, as amended (the Bylaws), and the description of the notes is subject to and qualified in its entirety by reference to the base indenture (as defined below) and the ninth supplemental indenture (as defined below), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.24 is a part. We encourage you to read our Certificate of Incorporation, our Bylaws, the applicable provisions of the Delaware General Corporation Law (the DGCL), the base indenture and the ninth supplemental indenture for additional information. References in this section to &#8220;Pfizer,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; are to Pfizer Inc., unless otherwise stated or the context so requires.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Certificate of Incorporation, we are authorized to issue up to 12&#160;billion shares of common stock, par value $0.05 per share. The common stock is not redeemable, does not have any conversion rights and is not subject to call. Holders of shares of common stock have no preemptive rights to maintain their percentage of ownership in future offerings or sales of our stock. Holders of shares of common stock have one vote per share in all elections of Directors and on all other matters submitted to a vote of our stockholders. The holders of common stock are entitled to receive dividends, if any, as and when may be declared from time to time by our Board of Directors, out of funds legally available therefor. Upon liquidation, dissolution or winding up of our affairs, the holders of common stock will be entitled to participate equally and ratably, in proportion to the number of shares held, in our net assets available for distribution to holders of common stock. The shares of common stock currently outstanding are fully paid and nonassessable. The common stock is traded on the New York Stock Exchange under the trading symbol &#8220;PFE.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the Certificate of Incorporation, we are authorized to issue up to 27&#160;million shares of preferred stock, without par value. The preferred stock may be issued in one or more series, and the Board of Directors of Pfizer is expressly authorized (i)&#160;to fix the descriptions, powers, preferences, rights, qualifications, limitations, and restrictions with respect to any series of preferred stock and (ii)&#160;to specify the number of shares of any series of preferred stock. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Anti-takeover Effects of the Certificate of Incorporation,&#160;By-laws&#160;and Delaware Law</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Certificate of Incorporation and&#160;Bylaws</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Various provisions contained in the Certificate of Incorporation and the&#160;Bylaws&#160;could delay or discourage some transactions involving an actual or potential change in control of us or a change in our management and may limit the ability of our stockholders to remove current management or approve transactions that our stockholders may deem to be in their best interests. Among other things, these provisions&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">limit the right of stockholders to call special meetings of stockholders to holders of at least 10% of the total number of shares of stock entitled to vote on the matter to be brought before the proposed special meeting&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">authorize our Board of Directors to establish one or more series of preferred stock without stockholder approval&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">authorize the Board to issue dividends in the form of stock purchase or similar rights, including rights that would have the effect of making an attempt to acquire us more costly&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">grant to the Board of Directors, and not to the stockholders, the sole power to set the number of Directors&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">require that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">subject to the rights of the holders of any one or more series of preferred stock then outstanding, allow our Directors, and not our stockholders, to fill vacancies on our Board of Directors, including vacancies resulting from the removal of one or more Directors or an increase in the number of Directors constituting the whole Board of Directors.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Delaware Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. We are a Delaware corporation and consequently are also subject to certain anti-takeover provisions of the DGCL. Subject to certain exceptions, Section&#160;203 of the DGCL prevents a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for three years following the date that the person became an interested stockholder, unless (a)&#160;the interested stockholder attained such status with the approval of the corporation&#8217;s board of directors, (b)&#160;upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, exclusive of shares owned by directors who are also officers and by certain employee stock plans or (c)&#160;at or subsequent to such time, the business combination is approved by the board of directors and authorized by the affirmative vote at a stockholders&#8217; meeting, and not by written consent, of at least 66-2&#47;3% of the outstanding voting stock which is not owned by the interested stockholder. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving the corporation and the &#8220;interested stockholder&#8221; and the sale of more than 10% of the corporation&#8217;s assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of the corporation&#8217;s outstanding voting stock, and any entity or person affiliated with or controlling or controlled by such entity or person. Section&#160;203 makes it more difficult for an interested stockholder to effect various business combinations with a corporation for a three-year period. This statute could prohibit or delay mergers or other takeover or change in control attempts not approved in advance by our Board of Directors, and, as a result, could discourage attempts to acquire us, which could depress the market price of our common stock.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DESCRIPTION OF DEBT SECURITIES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reference should be made to the indenture dated as of January 30, 2001, between Pfizer and The Bank of New York Mellon (formerly known as The Bank of New York), as successor to JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank), as trustee, which we refer to as the &#8220;base indenture,&#8221; as supplemented by the ninth supplemental indenture dated as of March 6, 2017, among Pfizer Inc., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent, which we refer to as the &#8220;ninth supplemental indenture.&#8221; When we refer to the &#8220;indenture,&#8221; we mean the base indenture, as supplemented by the ninth supplemental indenture. The following description is a summary of selected portions of the base indenture and the ninth supplemental indenture. It does not restate the base indenture or the ninth supplemental indenture, and those documents, not this description, define the rights of a holder of the notes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Principal, Maturity and Interest</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2022 notes were limited to &#8364;1,000,000,000 aggregate principal amount and the 2027 notes were limited to &#8364;750,000,000 aggregate principal amount. The 2022 notes will mature on March 6, 2022 and the 2027 notes will mature on March 6, 2027. We issued the notes in denominations of &#8364;100,000 and in integral multiples of &#8364;1,000 in excess thereof.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest on the 2022 notes accrues at the annual rate of 0.250% and interest on the 2027 notes accrues at the annual rate of 1.000%. Interest on the notes is payable on March 6 of each year. Interest on the notes is computed on the basis of the actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes to, but excluding, the next scheduled interest payment date. This payment convention is referred to as ACTUAL&#47;ACTUAL (ICMA) (as defined in the rulebook of the International Capital Market Association).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We make each interest payment to the holders of record of the notes at the close of business on the 15th calendar day (whether or not a business day) preceding the relevant interest payment date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Bank of New York Mellon, London Branch, acts as our paying agent with respect to the notes. Upon notice to the trustee, we may change any paying agent. Payments of principal, interest and premium, if any, will be made by us through the paying agent to Euroclear Bank S.A.&#47;N.V. (the &#8220;Euroclear Operator&#8221;), as operator of the Euroclear System (&#8220;Euroclear&#8221;) and&#47;or Clearstream Banking, Soci&#233;t&#233; Anonyme, Luxembourg (&#8220;Clearstream&#8221;) as described under &#8220;&#8212;Book-Entry.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Issuance in Euros</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal, premium, if any, and interest payments and additional amounts, if any, in respect of the notes are payable in euros.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or the euro is no longer used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount payable on any date in euros will be converted to U.S. dollars on the basis of the most recently available market exchange rate for euros, as determined by us in our sole discretion. Any payment in respect of the notes so made in U.S. dollars does not constitute an event of default under the indenture or the notes. Neither the trustee nor the paying agent is responsible for obtaining exchange rates, effecting conversions or otherwise handling redenominations.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Payment of Additional Amounts</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All payments in respect of the notes are made by or on behalf of us without withholding or deduction for, or on account of, any present or future taxes, duties, assessments or governmental charges of whatever nature, imposed or levied by the United States or any taxing authority thereof or therein, unless such withholding or deduction is required by law. If such withholding or deduction is required by law, we pay to a beneficial owner who is not a United States person such additional amounts on the notes as are necessary in order that the net payment of the principal of, and premium or redemption price, if any, and interest on, such notes to such beneficial owner, after such withholding or deduction (including any withholding or deduction on such additional amounts), will not be less than the amount provided in such notes to be then due and payable&#59; provided, however, that the foregoing obligation to pay additional amounts will not apply&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.01pt">to any tax, assessment or other governmental charge that would not have been imposed but for the beneficial owner, or a fiduciary, settlor, beneficiary, member or shareholder of the beneficial owner if the beneficial owner is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as (i) having a current or former connection with the United States (other than a connection arising solely as a result of the ownership of such notes, the receipt of any payment or the enforcement of any rights thereunder), including being or having been a citizen or resident of the United States, or being or having been engaged in a trade or business in the United States or having or having had a permanent establishment in the United States&#59; (ii) being a controlled foreign corporation related to Pfizer directly, indirectly or constructively through stock ownership for U.S. federal income tax purposes&#59; (iii) being an owner of a 10% or greater interest in voting stock of Pfizer within the meaning of Section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) or any successor provision&#59; or (iv) being a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.01pt">to any holder that is not the sole beneficial owner of such notes, or a portion of such notes, or that is a fiduciary, partnership or limited liability company, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial owner or a member of the partnership or limited liability company would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly from Pfizer its beneficial or distributive share of the payment&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.51pt">to any tax, assessment or other governmental charge imposed by reason of the holder&#8217;s or beneficial owner&#8217;s past or present status as a passive foreign investment company, a controlled foreign corporation, a foreign tax exempt organization or a personal holding company with respect to the United States or as a corporation that accumulates earnings to avoid U.S. federal income tax&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.01pt">to any tax, assessment or other governmental charge that would not have been imposed but for the failure of the holder or beneficial owner of the applicable notes to comply with any applicable certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of such notes, if compliance is timely requested by Pfizer and required by statute, by regulation of the United States or any taxing authority therein or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.01pt">to any tax, assessment or other governmental charge that is imposed otherwise than by withholding or deducting from the payment&#59;</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:12.51pt">to any estate, inheritance, gift, sales, transfer, wealth, capital gains or personal property tax or similar tax, assessment or other governmental charge&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.01pt">to any tax, assessment or other governmental charge required to be withheld by any paying agent from any payment of principal of or interest on any such note, if such payment can be made without such withholding by at least one other paying agent in a Member State of the European Union&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">h)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.01pt">to any tax, assessment or other governmental charge that is imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.02pt">to any tax, assessment or other governmental charge that would not have been imposed but for the presentation by the holder of any note, where presentation is required, for payment on a date more than 30 days after the date on which payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later, except to the extent that the holder or beneficial owner thereof would have been entitled to additional amounts had the note been presented for payment on the last day of such 30 day period&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">j)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.02pt">to any withholding or deduction that is imposed on a payment pursuant to Sections 1471 through 1474 of the Code and related Treasury regulations and pronouncements or any successor provisions thereto (that are substantively comparable and not materially more onerous to comply with) and any regulations or official law, agreement or interpretations thereof in any jurisdiction implementing an intergovernmental approach thereto&#59; or</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">k)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.51pt">in the case of any combination of the above listed items.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as specifically provided under this heading &#8220;&#8212;Payment of Additional Amounts,&#8221; we are not required to make any payment for any tax, duty, assessment or governmental charge of whatever nature imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As used under this heading &#8220;&#8212;Payment of Additional Amounts&#8221; and under the heading &#8220;&#8212;Optional Redemption of 2022 Notes and 2027 Notes&#59; Redemption for Tax Reasons&#59; No Sinking Fund,&#8221; the term &#8220;United States&#8221; means the United States of America, any state thereof, and the District of Columbia, and the term &#8220;United States person&#8221; means (i) any individual who is a citizen or resident of the United States for U.S. federal income tax purposes, (ii) a corporation, partnership or other entity created or organized in or under the laws of the United States, any state thereof or the District of Columbia (other than a partnership that is not treated as a United States person for U.S. federal income tax purposes), (iii) any estate the income of which is subject to U.S. federal income taxation regardless of its source, or (iv) any trust if a U.S. court can exercise primary supervision over the administration of the trust and one or more United States persons can control all substantial trust decisions, or if a valid election is in place to treat the trust as a United States person.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ranking</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes are unsecured general obligations of Pfizer and rank equally with all other unsecured and unsubordinated indebtedness of Pfizer from time to time outstanding.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Listing</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes are listed on the NYSE. We have no obligation to maintain such listing, and we may delist the notes at any time.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Covenants</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The indenture contains a provision that restricts our ability to consolidate with or merge into any other person or convey or transfer our properties and assets as an entirety or substantially as an entirety to any other person. The indenture does not restrict our ability to convey or transfer our properties and assets other than as an entirety or substantially as an entirety to any other person. See &#8220;Article VIII - Consolidation, Merger, Conveyance or Transfer&#8221; in the base indenture. The indenture contains no other restrictive covenants, including those that would afford holders of the notes protection in the event of a highly-leveraged transaction involving Pfizer or any of its affiliates or other events involving us that may adversely affect our creditworthiness or the value of the notes. The indenture also does not contain any covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">dividends and distributions to shareholders, current ratios or acquisitions and divestitures. The notes do not have the benefit of covenants that relate to subsidiary guarantees, liens and sale leaseback transactions that apply to other of our existing unsecured and unsubordinated notes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer may, without the consent of the holders of notes of any series, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of any series (except for the issue date and the public offering price). Any additional notes having such similar terms, together with the notes of the applicable series, will constitute a single series of debt securities under the indenture. No additional notes of any series may be issued if an event of default has occurred with respect to the notes of that series. Pfizer will not issue any additional notes intended to form a single series with the notes of any series, unless such further notes will be fungible with all notes of the same series for U.S. federal income tax purposes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Optional Redemption of 2022 Notes and 2027 Notes&#59; Redemption for Tax Reasons&#59; No Sinking Fund</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At our option, we may redeem the 2022 notes or the 2027 notes (together, the redemption notes), in whole, at any time, or in part, from time to time, prior to February 6, 2022 (one month prior to the maturity date) with respect to the 2022 notes and December 6, 2026 (three months prior to the maturity date) with respect to the 2027 notes. The redemption price will be equal to the greater of the following amounts&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">100% of the principal amount of the redemption notes being redeemed on the redemption date&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the sum of the present values of the remaining scheduled payments of principal and interest on the redemption notes being redeemed on that redemption date (not including the amount, if any, of accrued and unpaid interest to, but excluding, the redemption date) discounted to the redemption date on an annual basis at a rate equal to the sum of the Comparable Government Bond Rate plus (a) 15 basis points in the case of the 2022 notes and (b) 15 basis points in the case of the 2027 notes&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">plus, in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the redemption date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At any time on or after February 6, 2022 (one month prior to the maturity date) with respect to the 2022 notes and December 6, 2026 (three months prior to the maturity date) with respect to the 2027 notes, we may redeem such series of redemption notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the redemption notes to be redeemed, plus in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the redemption date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, installments of interest on the applicable redemption notes that are due and payable on interest payment dates falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the applicable redemption notes and the indenture. The redemption prices for the redemption notes will be calculated on the basis of a 365-day year or a 366-day year, as applicable, and the actual number of days elapsed.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We will mail notice of any redemption at least 10 days, but not more than 60 days, before the redemption date to each registered holder of the redemption notes to be redeemed. Once notice of redemption is mailed, the redemption notes called for redemption will become due and payable on the redemption date at the applicable redemption price, plus accrued and unpaid interest applicable to such redemption notes to, but excluding, the redemption date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond&#8221; means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an Independent Investment Banker, a German government bond whose maturity is closest to the maturity of the redemption notes to be redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such Independent Investment Banker may, with the advice of three brokers of, and&#47;or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8220;Comparable Government Bond Rate&#8221; means the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the fixed rate notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond on the basis of the middle market price of the Comparable Government Bond prevailing at 11&#58;00 a.m. (London time) on such business day as determined by an Independent Investment Banker.</font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8220;Independent Investment Banker&#8221; means one of the Reference Treasury Dealers appointed by us to act as the &#8220;Independent Investment Banker.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8220;Reference Treasury Dealer&#8221; means each of Barclays Bank PLC, BNP Paribas, Goldman, Sachs &#38; Co. and J.P. Morgan Securities plc (or their respective affiliates that are Primary Treasury Dealers), and their respective successors&#59; provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and&#47;or market maker in, German government bonds (a &#8220;Primary Treasury Dealer&#8221;), we will substitute therefor another Primary Treasury Dealer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On and after the redemption date, interest will cease to accrue on the redemption notes or any portion of the redemption notes called for redemption (unless we default in the payment of the redemption price and accrued and unpaid interest). On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the redemption price of and accrued and unpaid interest on the redemption notes to be redeemed on that date. If fewer than all of the redemption notes of any series are to be redeemed, the redemption notes to be redeemed shall be selected by Euroclear and&#47;or Clearstream, in the case of redemption notes represented by a global security, or by the trustee by a method the trustee deems to be fair and appropriate, in the case of redemption notes that are not represented by a global security.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes are not entitled to the benefit of a sinking fund.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Redemption for Tax Reasons</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If, as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United States (or any taxing authority thereof or therein), or any change in, or amendments to, an official position regarding the application or interpretation of such laws, regulations or rulings, which change or amendment is announced or becomes effective on or after February 28, 2017, we become or, based upon a written opinion of independent tax counsel of recognized standing selected by us, will become obligated to pay additional amounts as described herein under the heading &#8220;&#8212;Payment of Additional Amounts&#8221; with respect to any series of the notes, then we may at our option, having given not less than 10 nor more than 60 days prior notice to holders, redeem, in whole, but not in part, the applicable series of notes at a redemption price equal to 100% of the principal amount, together with accrued and unpaid interest (including any additional amounts) on such notes to, but excluding, the redemption date. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Book-Entry</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Global Clearance and Settlement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The notes of each series were issued in the form of one or more global notes in fully registered form, without coupons, and are deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. Except as described herein, certificates will not be issued in exchange for beneficial interests in the global notes representing the notes.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as set forth below, the global notes representing the notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beneficial interests in the global notes representing the notes are represented, and transfers of such beneficial interests are effected, through accounts of financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests are in denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof. Investors may hold the notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are participants in such systems.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For so long as any series of the notes is represented by a global note deposited with, and registered in the name of a nominee for, a common depositary for Euroclear and&#47;or Clearstream, each person (other than Euroclear or Clearstream) who is for the time being shown in the records of Euroclear or of Clearstream as the holder of a particular nominal amount of the notes (in which regard any certificate or other document issued by Euroclear or Clearstream as to the nominal amount of the notes standing to the account of any person shall be conclusive and binding for all purposes save in the case of manifest error) shall upon their receipt of a certificate or other document be treated by Pfizer and the trustee as the holder of such nominal amount of the notes and the registered holder of the global note representing such notes shall be deemed not to be the holder for all purposes other than with respect to the payment of principal or interest on such nominal amount of the notes, for which purpose the registered holder of the relevant global note shall be treated by Pfizer and the trustee as the holder of such nominal amount of notes in </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">accordance with and subject to the terms of the global note representing the notes, and the expressions &#8220;noteholder&#8221; and &#8220;holder of notes&#8221; and related expressions shall be construed accordingly.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information in this section concerning Euroclear and Clearstream Banking and their book-entry systems and procedures has been obtained from sources that we believe to be reliable. We are not responsible for the accuracy or completeness of this information.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We have been advised by Clearstream and Euroclear, respectively, as follows&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clearstream has advised that&#58;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">It is incorporated under the laws of Luxembourg and licensed as a bank and professional depositary. Clearstream holds securities for its participating organizations and facilitates the clearance and settlement of securities transactions among its participants through electronic book-entry changes in accounts of its participants, thereby eliminating the need for physical movement of certificates.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Clearstream provides to its participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic markets in several countries.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Clearstream has established an electronic bridge with the Euroclear Operator to facilitate the settlement of trades between the nominees of Clearstream and Euroclear.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">As a registered bank in Luxembourg, Clearstream is subject to regulation by the Luxembourg Commission for the Supervision of the Financial Sector.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Clearstream customers are recognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations and may include the underwriters. Indirect access to Clearstream is also available to others, such as banks, brokers, dealers and trust companies that clear through, or maintain a custodial relationship with, a Clearstream participant, either directly or indirectly.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Distributions with respect to the notes held beneficially through Clearstream will be credited to cash accounts of Clearstream participants in accordance with its rules and procedures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Euroclear has advised that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">It was created in 1968 to hold securities for its participants and to clear and settle transactions between Euroclear participants through simultaneous electronic book-entry delivery against payment, thereby eliminating the need for physical movement of certificates and any risk from lack of simultaneous transfers of securities and cash.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Euroclear includes various other services, including securities lending and borrowing and interfaces with domestic markets in several countries.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Euroclear is operated by the Euroclear Operator. All operations are conducted by the Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear cash accounts are accounts with the Euroclear Operator.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Securities clearance accounts and cash accounts with the Euroclear Operator are governed by the Terms and Conditions Governing Use of Euroclear and the related operating procedures of Euroclear, and applicable Belgian law (collectively, the &#8220;Terms and Conditions&#8221;). The Terms and Conditions govern transfers of securities and cash within Euroclear, withdrawals of securities and cash from Euroclear, and receipts of payments with respect to securities in Euroclear. All securities in Euroclear are held on a fungible basis without attribution of specific certificates to specific securities clearance accounts. The Euroclear Operator acts under the Terms and Conditions only on behalf of Euroclear participants, and has no records of or relationship with persons holding through Euroclear participants.</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Euroclear participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries and may include the underwriters. Indirect access to Euroclear is also </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">available to other firms that clear through or maintain a custodial relationship with a Euroclear participant, either directly or indirectly.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Distributions with respect to the notes held beneficially through Euroclear will be credited to the cash accounts of Euroclear participants in accordance with the Terms and Conditions.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Euroclear and Clearstream Arrangements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">So long as Euroclear or Clearstream or their nominee or their common depositary is the registered holder of the global notes representing the notes, Euroclear, Clearstream or such nominee, as the case may be, will be considered the sole owner or holder of the notes represented by such global notes for all purposes under the indenture and the notes. Payments of principal, interest and additional amounts, if any, in respect of the global notes representing the notes are made to Euroclear, Clearstream, such nominee or such common depositary, as the case may be, as registered holder thereof. Neither Pfizer nor the trustee, or any affiliate of any of the above or any person by whom any of the above is controlled (as such term is defined in the Securities Act) has any responsibility or liability for any records relating to or payments made on account of beneficial ownership interests in the global notes representing the notes or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Distributions of principal, premium, if any, and interest with respect to the global notes representing the notes are credited in euros to the extent received by Euroclear or Clearstream from the paying agent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant system&#8217;s rules and procedures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because Euroclear and Clearstream can only act on behalf of participants, who in turn act on behalf of indirect participants, the ability of a person having an interest in the global notes representing the notes to pledge such interest to persons or entities which do not participate in the relevant clearing system, or otherwise take actions in respect of such interest, may be affected by the lack of a physical certificate in respect of such interest.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Secondary Market Trading</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Because the purchaser determines the place of delivery, it is important to establish at the time of trading of any notes where both the purchaser&#8217;s and seller&#8217;s accounts are located to ensure that settlement can be made on the desired value date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We understand that secondary market trading between Clearstream and&#47;or Euroclear participants occurs in the ordinary way following the applicable rules and operating procedures of Clearstream and Euroclear. Secondary market trading is settled using procedures applicable to conventional eurobonds in global registered form.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The holder of the notes should be aware that investors are only able to make and receive deliveries, payments and other communications involving the notes through Clearstream and Euroclear on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United States.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, because of time-zone differences, there may be problems with completing transactions involving Clearstream and Euroclear on the same business day as in the United States. U.S. investors who wish to transfer their interests in the notes, or to make or receive a payment or delivery of the notes, on a particular day, may find that the transactions are not performed until the next business day in Luxembourg or Brussels, depending on whether Clearstream or Euroclear is used.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clearstream or Euroclear credits payments to the cash accounts of Clearstream customers or Euroclear participants, as applicable, in accordance with the relevant system&#8217;s rules and procedures, to the extent received by its depositary. Clearstream or the Euroclear Operator, as the case may be, takes any other action permitted to be taken by a holder under the indenture on behalf of a Clearstream customer or Euroclear participant only in accordance with its relevant rules and procedures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of the notes among participants of Clearstream and Euroclear. However, they are under no obligation to perform or continue to perform those procedures, and they may discontinue those procedures at any time.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Exchange of Global Notes for Certificated Notes</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Subject to certain conditions, the notes represented by the global notes are exchangeable for certificated notes in definitive form of like tenor in minimum denominations of &#8364;100,000 principal amount and multiples of &#8364;1,000 in excess thereof if&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the common depositary notifies us that it is no longer willing or able to act as a depositary for such global notes or ceases to be a clearing agency registered under the Exchange Act and we fail to appoint a successor common depositary within 90 days&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">an event of default has occurred and is continuing and the common depositary requests the issuance of certificated notes&#59; or</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we determine not to have the notes represented by a global note.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In all cases, certificated notes delivered in exchange for any global note or beneficial interest therein will be registered in the names, and issued in any approved denominations, requested by or on behalf of the common depositary (in accordance with its customary procedures).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payments (including principal, premium and interest) and transfers with respect to the notes in certificated form may be executed at the office or agency maintained for such purpose in London (initially the corporate trust office of the paying agent) or, at our option, by check mailed to the holders thereof at the respective addresses set forth in the register of holders of the notes (maintained by the registrar), provided that all payments (including principal, premium and interest) on the notes in certificated form, for which the holders thereof have given wire transfer instructions, are required to be made by wire transfer of immediately available funds to the accounts specified by the holders thereof. No service charge is made for any registration of transfer, but payment of a sum sufficient to cover any tax or governmental charge payable in connection with such registration may be required.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Modification of Indenture</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the indenture, the rights of the holders of the notes may be modified through a supplemental indenture if the holders of a majority in aggregate principal amount of the outstanding notes of all series affected by the modification (voting as one class) consent to it. No modification of the maturity date or principal or interest payment terms, no modification of the currency for payment, no impairment of the right to sue for the enforcement of payment at the maturity of the debt security, no modification of any conversion rights, no modification reducing the percentage required for any such supplemental indenture or the percentage required for the waiver of certain defaults, and no modification of the foregoing provisions or any other provisions relating to the waiver of past defaults or the waiver of certain covenants, is effective against any holder without its consent.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Events of Default</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Each of the following will constitute an Event of Default under the indenture with respect to the notes of the applicable series&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we fail to make the principal or any premium payment on any note of such series when due&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we fail to make any sinking fund payment for 60 days after payment was due by the terms of any note of such series&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we fail to pay interest on any note of such series for 60 days after payment was due&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we fail to perform any other covenant in the indenture and this failure continues for 90 days after we receive written notice of it&#59; or</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we, or a court, take certain actions relating to the bankruptcy, insolvency or reorganization of our company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A default under our other indebtedness will not be a default under the indenture for the notes, and a default under one series of the notes will not necessarily be a default under another series. The trustee may withhold notice to the holders of notes of the applicable series of any default (except for defaults that involve our failure to pay principal or interest) if it considers such withholding of notice to be in the best interests of the holders.</font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an Event of Default with respect to outstanding notes of any series occurs and is continuing, then the trustee or the holders of at least 33% in principal amount of outstanding notes of that series may declare, in a written notice, the principal amount (or, if any of the notes of that series are original issue discount securities, such portion of the principal amount of such notes) plus accrued and unpaid interest on all notes of that series to be immediately due and payable. At any time after a declaration of acceleration with respect to notes of any series has been made, the holders of a majority in principal amount of the outstanding notes of such series may rescind and annul the acceleration if&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">the holders act before the trustee has obtained a judgment or decree for payment of the money due&#59;</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we have paid or deposited with the trustee a sum sufficient to pay overdue interest and overdue principal other than the accelerated interest and principal&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we have cured or the holders have waived all Events of Default, other than the non-payment of accelerated principal and interest with respect to notes of that series, as provided in the indenture.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If a default in the performance or breach of the indenture shall have occurred and be continuing, the holders of not less than a majority in principal amount of the outstanding notes of all series affected thereby, by notice to the trustee, may waive any past Event of Default or its consequences under the indenture. However, an Event of Default cannot be waived with respect to any series of notes in the following two circumstances&#58; &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a failure to pay the principal of, and premium, if any, or interest on any security or in the payment of any sinking fund installment&#59; or</font></div><div style="padding-left:18pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a covenant or provision that cannot be modified or amended without the consent of each holder of outstanding notes of that series.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other than its duties in case of a default, the trustee is not obligated to exercise any of its rights or powers under the indenture at the request, order or direction of any holders, unless the holders offer the trustee reasonable indemnity. Holders of a majority in principal amount outstanding of any series of notes may, subject to certain limitations, direct the time, method and place of conducting any proceeding or any remedy available to the trustee, or exercising any power conferred upon the trustee, for such applicable series of notes.</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">We are required to deliver an annual officers&#8217; certificate to the trustee, stating whether we are in default in the performance and observance of any of the terms, provisions and conditions of the indenture, and, if we are in default, specifying all such defaults and the nature and status thereof.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defeasance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">When we use the term defeasance, we mean discharge from some or all of our obligations under the indenture. Subject to certain additional conditions, if we irrevocably deposit with the trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums due to the stated maturity date or a redemption date of the notes of a particular series, then at our option&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we will be discharged from our obligations with respect to the notes of such series&#59; or</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">we will no longer be under any obligation to comply with certain restrictive covenants under the indenture, and certain events of default will no longer apply to us.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">To exercise our defeasance option, we must deliver to the trustee an officer&#8217;s certificate and an opinion of counsel, each stating that all conditions precedent related to the defeasance have been complied with.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>pfe-exh21x12312021x10k.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i56564b512ff14739aaef232665e3ca7f_1"></div><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:8pt;padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 21</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a list of subsidiaries of the Company as of December 31, 2021 omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary. </font></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.126%"><tr><td style="width:1.0%"></td><td style="width:60.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d6dce4;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Company Name</font></td><td colspan="3" style="background-color:#d6dce4;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Where Incorporated or Organized</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Agouron Pharmaceuticals, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">California</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AH Robins LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AHP Manufacturing B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Alpharma Pharmaceuticals LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">American Food Industries LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amplyx Pharmaceuticals, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Anacor Pharmaceuticals, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Array BioPharma Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bamboo Therapeutics, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Blue Whale Re Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vermont</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">C.P. Pharmaceuticals International C.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CICL Corporation</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">COC I Corporation</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Coley Pharmaceutical GmbH</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Coley Pharmaceutical Group, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cyanamid de Argentina, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cyanamid de Colombia, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Distribuidora Mercantil Centro Americana, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encysive Pharmaceuticals Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Farminova Produtos Farmaceuticos de Inovacao, Lda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">FoldRx Pharmaceuticals, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fort Dodge Manufatura Ltda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brazil</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">G. D. Searle &#38; Co. Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">G. D. Searle International Capital LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Genetics Institute, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">GenTrac, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wisconsin</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">GI Europe, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">GI Japan, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Adelaide Pty Ltd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Australia Pty Ltd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Benelux BVBA</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Belgium</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Holdings (S.A.) Pty Ltd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hong Kong</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Philippines, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Philippines</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Pte. Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Singapore</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Puerto Rico, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira UK Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Worldwide, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira Zagreb d.o.o.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Croatia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hospira, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">InnoPharma, Inc.</font></td><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.126%"><tr><td style="width:1.0%"></td><td style="width:60.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">International Affiliated Corporation LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">John Wyeth &#38; Brother Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">King Pharmaceuticals Holdings LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">King Pharmaceuticals LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">King Pharmaceuticals Research and Development, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Laboratoires Pfizer, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Morocco</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Laboratorios Pfizer Ltda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brazil</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Laborat&#243;rios Pfizer, Lda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Laboratorios Wyeth LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennsylvania</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Laboratorios Wyeth S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Venezuela</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mayne Pharma IP Holdings (Euro) Pty Ltd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Medivation Field Solutions LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Medivation LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Medivation Neurology LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Medivation Prostate Therapeutics LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Medivation Services LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Medivation Technologies LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Monarch Pharmaceuticals, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tennessee</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MTG Divestitures LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Neusentis Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PAH USA IN8 LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Parke Davis Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hong Kong</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Parke, Davis &#38; Company LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Michigan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Parkedale Pharmaceuticals, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Michigan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PBG Puerto Rico LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Puerto Rico</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">P-D Co., LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Peak Enterprises LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF Argentum Acquisition ULC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Canada</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF Consumer Healthcare Holdings LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF Consumer Healthcare Holdings US Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF Czech Republic Holdings B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF Finland Holdings B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF OFG Ireland 2 B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF OFG South Korea 1 B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF OFG South Korea 2 B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF PR Holdings C.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF PRISM C.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF PRISM Holdings B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PF PRISM IMB B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PFE Wyeth-Ayerst (Asia) LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">France</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer (China) Research and Development Co. Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">People's Republic China</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer (Malaysia) Sdn Bhd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Malaysia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer (Perth) Pty Ltd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer (Thailand) Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thailand</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PFIZER (VIETNAM) LIMITED COMPANY</font></td><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vietnam</font></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.126%"><tr><td style="width:1.0%"></td><td style="width:60.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer (Wuhan) Research and Development Co. Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">People's Republic China</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer AB</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sweden</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Afrique de L'Ouest</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Senegal</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer AG</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Anti-Infectives AB</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sweden</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer ApS</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Denmark</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer AS</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Norway</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Asia Manufacturing Pte. Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Singapore</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Australia Holdings B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Australia Holdings Pty Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Australia Investments Pty Ltd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Australia Pty Ltd</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Australia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Biopharma Egypt LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Egypt</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Biopharmaceuticals Egypt LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Egypt</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Bolivia S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bolivia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Canada ULC &#47; Pfizer Canada SRI</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Canada</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Chile S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chile</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Cia. Ltda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ecuador</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Colombia Spinco I LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennsylvania</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Consumer Healthcare</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Cork Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Corporation Austria Gesellschaft m.b.H.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Austria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Corporation Hong Kong Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hong Kong</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Corporation S. de R.L.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Panama</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Croatia d.o.o.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Croatia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Deutschland GmbH</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Development B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Development LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Development LP</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Development Services (UK) Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer East India B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Eastern Investments B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Export B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Europe MA EEIG</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Belgium</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Export Company</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Finance Share Service (Dalian) Co., Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">People's Republic China</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer France International Investments</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">France</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Free Zone Panama, S. de R.L.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Panama</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Global Holdings B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Global Supply Japan Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Japan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Global Trading</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Gulf FZ-LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer H.C.P. Corporation</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New York</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Health AB</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sweden</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Health Solutions Inc.</font></td><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.126%"><tr><td style="width:1.0%"></td><td style="width:60.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Healthcare India Private Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">India</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Healthcare Ireland</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Hellas, A.E.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Greece</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Himalaya Holdings Co&#246;peratief U.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Holding France</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">France</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Holdings Corporation</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Holdings International Corporation</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Holdings International Luxembourg (PHIL) SARL</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Innovations AB</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sweden</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Innovations LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Russia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer International LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New York</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer International Operations</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">France</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Investment Capital Unlimited Company</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Investment Co. Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">People's Republic China</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Ireland PFE Holding 1 LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Ireland PFE Holding 2 LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Ireland Pharmaceuticals</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Ireland Ventures Unlimited Company</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Italia S.r.l.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Italy</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Japan Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Japan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Laboratories (Pty) Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">South Africa</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Laboratories Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kenya</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Leasing Ireland Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Leasing UK Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">India</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Taiwan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Luxco Holdings SARL</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Luxembourg Global Holdings S.&#224; r.l.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Luxembourg SARL</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing Austria G.m.b.H.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Austria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing Belgium N.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Belgium</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing Deutschland GmbH</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing Deutschland Grundbesitz GmbH &#38; Co. KG</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing Holdings LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing Ireland Unlimited Company</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Manufacturing Services</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer MAP Holding, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Medicamentos Genericos e Participacoes Ltda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brazil</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Mexico Holding B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer New Zealand Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New Zealand</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer North America Services LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer OTC B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Overseas LLC</font></td><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.126%"><tr><td style="width:1.0%"></td><td style="width:60.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Oy</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Finland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pakistan Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pakistan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE AsiaPac Holding B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE CIA. Ltda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ecuador</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE Eastern Investments B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE Global Holdings B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE &#304;la&#231;lar&#305; Anonim &#350;irketi</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Turkey</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE Pharmaceuticals Israel Holding LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE Pharmaceuticals Israel Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Israel</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE Service Company Holding B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE Spain B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer PFE UK Holding 4 LP</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharm Algerie</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Algeria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharma GmbH</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharma PFE GmbH</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Germany</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharmaceutical (Wuxi) Co., Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">People's Republic China</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharmaceutical Trading Limited Liability Company (a&#47;k&#47;a Pfizer Kft. or Pfizer LLC)</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hungary</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharmaceuticals Global B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharmaceuticals Israel Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Israel</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharmaceuticals Korea Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Republic of Korea</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pharmaceuticals Science and Technology Co., Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">People's Republic China</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Pigments Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Polska Sp. z.o.o.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Poland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Private Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Singapore</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Production LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Products Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Connecticut</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Products India Private Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">India</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer R&#38;D Holding B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer R&#38;D Japan G.K.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Japan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer R&#38;D UK Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Research (NC), Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Romania SRL</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Romania</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Peru</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer S.A.S.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Colombia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer S.G.P.S. Lda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer S.R.L.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Argentina</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer S.r.l.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Italy</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer SA (Belgium)</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Belgium</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Saudi Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Service Company BVBA</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Belgium</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Service Company Ireland Unlimited Company</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Shared Services Unlimited Company</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Shareholdings Intermediate SARL</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Singapore Holding Pte. Ltd.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Singapore</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Specialties Limited</font></td><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nigeria</font></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.126%"><tr><td style="width:1.0%"></td><td style="width:60.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer SRB d.o.o.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Serbia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Trading Polska sp.z.o.o.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Poland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Transactions LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Tunisie SA</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tunisia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Vaccines LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Venezuela, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Venezuela</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Ventures (US) LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Ventures LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Worldwide Services Unlimited Company</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ireland</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer Zona Franca, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Costa Rica</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer, Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Philippines</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Costa Rica</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer, S.A. de C.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mexico</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer, S.L.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Spain</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pfizer, spol. s r.o.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Czech Republic</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia &#38; Upjohn Company LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia &#38; Upjohn LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia Brasil Ltda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brazil</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia Hepar LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia Inter-American LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennsylvania</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia International B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Kingdom</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pharmacia LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PHIVCO Corp.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PHIVCO Holdco S.&#224; r.l.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PIMB OFG Spain Holding, S.L.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Spain</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PRISM Holdings B.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Netherlands</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PT. Pfizer Indonesia</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Indonesia</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Purepac Pharmaceutical Holdings LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Renrall LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyoming</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rinat Neuroscience Corp.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Roerig S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chile</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Searle Laboratorios, Lda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Servicios P&#38;U, S. de R.L. de C.V.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mexico</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shiley LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">California</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sinergis Farma-Produtos Farmaceuticos, Lda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Solinor LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sugen LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tabor LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Trillium Therapeutics ULC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Canada</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Trillium Therapeutics USA, LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Upjohn Laboratorios Lda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portugal</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vicuron Holdings LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warner Lambert del Uruguay S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Uruguay</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warner-Lambert Company GmbH</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Switzerland</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warner-Lambert Company LLC</font></td><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div><div style="margin-bottom:0.1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.126%"><tr><td style="width:1.0%"></td><td style="width:60.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">W-L LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Ayerst Inc.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Ayerst S.&#224; r.l.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Luxembourg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Farma, S.A.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Spain</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Holdings LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Maine</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Industria Farmaceutica Ltda.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brazil</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Lederle S.r.l.</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Italy</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Pakistan Limited</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pakistan</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Pharmaceuticals FZ-LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Pharmaceuticals LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Subsidiary Illinois Corporation</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Illinois</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth Whitehall Export GmbH</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Austria</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth-Ayerst (Asia) LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth-Ayerst International LLC</font></td><td colspan="3" style="border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 2.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wyeth-Ayerst Promotions Limited</font></td><td colspan="3" style="border-bottom:1pt solid #c0c0c0;border-top:1pt solid #c0c0c0;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>pfe-exh23x12312021x10k.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i76d6ed34c8c94eeda1bab2a89a5aa95a_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23</font></div><div><font><br></font></div><div style="margin-top:4pt;padding-left:6.75pt;text-indent:128.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:6pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">To the Board of Directors</font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pfizer Inc.&#58;</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the registration statements listed below of Pfizer Inc. and Subsidiary Companies (Pfizer Inc.) of our reports dated February&#160;24, 2022, with respect to the consolidated balance sheets of Pfizer Inc. as of December 31, 2021 and 2020, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2021, which reports appear in the 2021 Annual Report on Form 10-K of Pfizer Inc.</font></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated October 27, 1983 (File No. 2-87473),</font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated March 22, 1990 (File No. 33-34139),</font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated January 24, 1991 (File No. 33-38708),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated November 18, 1991 (File No. 33-44053),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated May 27, 1993 (File No. 33-49631),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated May 19, 1994 (File No. 33-53713),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated October 5, 1994 (File No. 33-55771),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated December 20, 1994 (File No. 33-56979),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated March 29, 1996 (File No. 333-02061),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated September 25, 1997 (File No. 333-36371),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated June 19, 2000 (File No. 333-39606),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated April 27, 2001 (File No. 333-59660),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated April 16, 2003 (File No. 333-104582),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated November 18, 2003 (File No. 333-110571),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated December 18, 2003 (File No. 333-111333),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated April 26, 2004 (File No. 333-114852),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated March 1, 2007 (File No. 333-140987),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-4 dated March 27, 2009 (File No. 333-158237),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated October 16, 2009 (File No. 333-162519),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated October 16, 2009 (File No. 333-162520),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated October 16, 2009 (File No. 333-162521),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated March 1, 2010 (File No. 333-165121),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated March 2, 2015 (File No. 333-202437), </font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-4 dated September 3, 2015 (File No. 333-206758),</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-8 dated August 8, 2019 (File No. 333-233166), and </font></div><div style="margin-top:1pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-Form S-3 ASR dated February 26, 2021 (File No. 333-253605)</font></div><div style="margin-top:1pt;padding-left:4.5pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#47;s&#47; KPMG LLP</font></div><div style="margin-top:2pt;padding-left:4.5pt;padding-right:416.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:151%">New York, New York February&#160;24, 2022</font></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>pfe-exh311x12312021x10k.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i41f2e7a7bb224e618a5dfb048f0dcd2c_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certification by the Chief Executive Officer Pursuant to </font></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Albert Bourla, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Pfizer Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;&#160;February&#160;24, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; ALBERT BOURLA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Albert Bourla</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>pfe-exh312x12312021x10k.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i07ac6bd558f545b599a7122a771126bf_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:8pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certification by the Chief Financial Officer Pursuant to </font></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">I, Frank A. D'Amelio, certify that&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Pfizer Inc.&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date&#58;&#160;February&#160;24, 2022 </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.473%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; FRANK A. D'AMELIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Frank A. D'Amelio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Financial Officer, Executive Vice President</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>pfe-exh321x12312021x10k.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i72703bba88874ce2ba574efdccfd5804_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; ALBERT BOURLA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Albert Bourla</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>pfe-exh322x12312021x10k.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i283cff538c2f44dfb862995e1b7cfb56_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:5pt;margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to 18 U.S.C. Section 1350, I, Frank A. D'Amelio, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#47;s&#47; FRANK A. D'AMELIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Frank A. D'Amelio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Financial Officer, Executive Vice President</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>pfe-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ad91efd1-2241-49cf-a17f-7cbe86f9ba4a,g:feca3a10-f613-46f2-b813-b8f4d7d48955-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pfe="http://www.pfizer.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>000010001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.pfizer.com/role/AuditInformation">
        <link:definition>000020002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofIncome">
        <link:definition>100010003 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>100020004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheets">
        <link:definition>100030005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofEquity">
        <link:definition>100050007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>100060008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>100070009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>100080010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>210011001 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>220022001 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTables" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables">
        <link:definition>230033001 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>240044001 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails">
        <link:definition>240054002 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails">
        <link:definition>240064003 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements">
        <link:definition>210071002 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables">
        <link:definition>230083002 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails">
        <link:definition>240094004 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails">
        <link:definition>240104005 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails">
        <link:definition>240114006 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails">
        <link:definition>240124007 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails">
        <link:definition>240134008 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails">
        <link:definition>240144009 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Licensing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail">
        <link:definition>240154010 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Collaborative Arrangements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails">
        <link:definition>240164011 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives">
        <link:definition>210171003 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables">
        <link:definition>230183003 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail">
        <link:definition>240194012 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail">
        <link:definition>240204013 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail">
        <link:definition>240214014 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail">
        <link:definition>240224015 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail">
        <link:definition>240234016 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNet" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet">
        <link:definition>210241004 - Disclosure - Other (Income)/Deductions - Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetTables" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables">
        <link:definition>230253004 - Disclosure - Other (Income)/Deductions - Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails">
        <link:definition>240264017 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails">
        <link:definition>240274018 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMatters" roleURI="http://www.pfizer.com/role/TaxMatters">
        <link:definition>210281005 - Disclosure - Tax Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTables" roleURI="http://www.pfizer.com/role/TaxMattersTables">
        <link:definition>230293005 - Disclosure - Tax Matters (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" roleURI="http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails">
        <link:definition>240304019 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersProvisionforTaxesonIncomeDetails" roleURI="http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails">
        <link:definition>240314020 - Disclosure - Tax Matters - Provision for Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersNarrativeDetails" roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetails">
        <link:definition>240324021 - Disclosure - Tax Matters - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTaxRateReconciliationDetails" roleURI="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails">
        <link:definition>240334022 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersDeferredTaxesDetails" roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails">
        <link:definition>240344023 - Disclosure - Tax Matters - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersDeferredTaxesFootnotesDetails" roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails">
        <link:definition>240354024 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>240364025 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" roleURI="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails">
        <link:definition>240374026 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" roleURI="http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails">
        <link:definition>240384027 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests">
        <link:definition>210391006 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables">
        <link:definition>230403006 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails">
        <link:definition>240414028 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pfizer.com/role/FinancialInstruments">
        <link:definition>210421007 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables">
        <link:definition>230433007 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>240444029 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails">
        <link:definition>240454030 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>240464031 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails">
        <link:definition>240474032 - Disclosure - Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsDebtSecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails">
        <link:definition>240484033 - Disclosure - Financial Instruments - Investments - Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails">
        <link:definition>240494034 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails">
        <link:definition>240504035 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsShortTermBorrowingsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails">
        <link:definition>240514036 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails">
        <link:definition>240524037 - Disclosure - Financial Instruments - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtNewIssuancesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails">
        <link:definition>240534038 - Disclosure - Financial Instruments - Long-Term Debt, New Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails">
        <link:definition>240544039 - Disclosure - Financial Instruments - Long-Term Debt, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails">
        <link:definition>240554040 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails">
        <link:definition>240564041 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails">
        <link:definition>240574042 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails">
        <link:definition>240584043 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails">
        <link:definition>240594044 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCreditRiskDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails">
        <link:definition>240604045 - Disclosure - Financial Instruments - Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformation" roleURI="http://www.pfizer.com/role/OtherFinancialInformation">
        <link:definition>210611008 - Disclosure - Other Financial Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationTables" roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables">
        <link:definition>230623008 - Disclosure - Other Financial Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationInventoriesDetails" roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails">
        <link:definition>240634046 - Disclosure - Other Financial Information - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialInformationOtherCurrentLiabilitiesDetails" roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails">
        <link:definition>240644047 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPPE" roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPE">
        <link:definition>210651009 - Disclosure - Property, Plant and Equipment (PP&amp;E)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPPETables" roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables">
        <link:definition>230663009 - Disclosure - Property, Plant and Equipment (PP&amp;E) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails" roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails">
        <link:definition>240674048 - Disclosure - Property, Plant and Equipment (PP&amp;E) - Components of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails" roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails">
        <link:definition>240684049 - Disclosure - Property, Plant, and Equipment (PP&amp;E) - Long-lived Assets by Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsandGoodwill" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwill">
        <link:definition>210691010 - Disclosure - Identifiable Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsandGoodwillTables" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables">
        <link:definition>230703010 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails">
        <link:definition>240714050 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>240724051 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails">
        <link:definition>240734052 - Disclosure - Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsandGoodwillGoodwillDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails">
        <link:definition>240744053 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlans" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans">
        <link:definition>210751011 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables">
        <link:definition>230763011 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails">
        <link:definition>240774054 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails">
        <link:definition>240784055 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails">
        <link:definition>240794056 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails">
        <link:definition>240804057 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails">
        <link:definition>240814058 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails">
        <link:definition>240824059 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails">
        <link:definition>240834060 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails" roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails">
        <link:definition>240844061 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.pfizer.com/role/Equity">
        <link:definition>210851012 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.pfizer.com/role/EquityTables">
        <link:definition>230863012 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.pfizer.com/role/EquityNarrativeDetails">
        <link:definition>240874062 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofCommonStockPurchasesDetails" roleURI="http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails">
        <link:definition>240884063 - Disclosure - Equity - Summary of Common Stock Purchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.pfizer.com/role/ShareBasedPayments">
        <link:definition>210891013 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTables">
        <link:definition>230903013 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsNarrativeDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail">
        <link:definition>240914064 - Disclosure - Share-Based Payments - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails">
        <link:definition>240924065 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails">
        <link:definition>240934066 - Disclosure - Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofValuationAssumptionsDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail">
        <link:definition>240944067 - Disclosure - Share-Based Payments - Schedule of Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail">
        <link:definition>240954068 - Disclosure - Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails">
        <link:definition>240964069 - Disclosure - Share-Based Payments - Summary of TSRU and PTU Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail">
        <link:definition>240974070 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders">
        <link:definition>210981014 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables">
        <link:definition>230993014 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails">
        <link:definition>241004071 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.pfizer.com/role/Leases">
        <link:definition>211011015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.pfizer.com/role/LeasesTables">
        <link:definition>231023015 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.pfizer.com/role/LeasesNarrativeDetails">
        <link:definition>241034072 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails">
        <link:definition>241044073 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" roleURI="http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails">
        <link:definition>241054074 - Disclosure - Leases - Schedule of Lease Costs and Other Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" roleURI="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail">
        <link:definition>241064075 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1" roleURI="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1">
        <link:definition>241064075 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitments" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments">
        <link:definition>211071016 - Disclosure - Contingencies and Certain Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitmentsPatentLitigationDetails" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails">
        <link:definition>241084076 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails">
        <link:definition>241094077 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails" roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails">
        <link:definition>241104078 - Disclosure - Contingencies and Certain Commitments (Certain Commitments and Contingent Consideration for Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformation" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation">
        <link:definition>211111017 - Disclosure - Segment, Geographic and Other Revenue Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationTables" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables">
        <link:definition>231123016 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationNarrativeDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail">
        <link:definition>241134079 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1">
        <link:definition>241134079 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>241144080 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail">
        <link:definition>241154081 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails">
        <link:definition>241164082 - Disclosure - Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail">
        <link:definition>241174083 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="pfe_PumaTechnologiesMember" abstract="true" name="PumaTechnologiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ProfitUnitsMember" abstract="true" name="ProfitUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CollaborativeArrangementMilestonePaymentUponCommercializing" abstract="false" name="CollaborativeArrangementMilestonePaymentUponCommercializing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherNonoperatingIncomeExpenseNet" abstract="false" name="OtherNonoperatingIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BiopharmaSegmentMember" abstract="true" name="BiopharmaSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AgreementAxis" abstract="true" name="AgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pfe_AssetAcquisitionSharePrice" abstract="false" name="AssetAcquisitionSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_PatentInfringementMember" abstract="true" name="PatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PfizerCentreOneMember" abstract="true" name="PfizerCentreOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeTaxesPayableMember" abstract="true" name="IncomeTaxesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_MektoviMember" abstract="true" name="MektoviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" abstract="false" name="AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_TransitionServiceAgreementMember" abstract="true" name="TransitionServiceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_HeldToMaturityCashEquivalents" abstract="false" name="HeldToMaturityCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CollaborativeArrangementTieredSalesMilestonePayments" abstract="false" name="CollaborativeArrangementTieredSalesMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" abstract="true" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" abstract="false" name="UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherVaccinesProductsMember" abstract="true" name="OtherVaccinesProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_December2018StockPurchasePlanMember" abstract="true" name="December2018StockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ShinglesVaccineProgramMRNABasedMember" abstract="true" name="ShinglesVaccineProgramMRNABasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" abstract="false" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_LesseeOperatingLeaseOptionToExtendTerm" abstract="false" name="LesseeOperatingLeaseOptionToExtendTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pfe_LicensingAgreementsDevelopedTechnologyMember" abstract="true" name="LicensingAgreementsDevelopedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" abstract="false" name="DeferredTaxAssetsStateandLocalTaxesAdjustments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RetacritMember" abstract="true" name="RetacritMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue20332037Member" abstract="true" name="SeniorUnsecuredDebtDue20332037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeconsolidationGainLossAmountNetOfCashConveyed" abstract="false" name="DeconsolidationGainLossAmountNetOfCashConveyed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherFinancialInformationAbstract" abstract="true" name="OtherFinancialInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" abstract="true" name="DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ReconcilingItemsOtherMember" abstract="true" name="ReconcilingItemsOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" abstract="false" name="PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherPatentInfringementMember" abstract="true" name="OtherPatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pfe_VyndaqelMember" abstract="true" name="VyndaqelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" abstract="false" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_DeconsolidationGainLossAmountCashConveyed" abstract="false" name="DeconsolidationGainLossAmountCashConveyed" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CollaborativeArrangementUpfrontAndMilestonePayments" abstract="false" name="CollaborativeArrangementUpfrontAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PaxlovidMember" abstract="true" name="PaxlovidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TrilliumMember" abstract="true" name="TrilliumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TygacilMember" abstract="true" name="TygacilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ComirnatyMember" abstract="true" name="ComirnatyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DomesticIncomeTaxesAbstract" abstract="true" name="DomesticIncomeTaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OtherIncomeDeductionsAndCostOfSalesMember" abstract="true" name="OtherIncomeDeductionsAndCostOfSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BusinessIntegrationCostsMember" abstract="true" name="BusinessIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_HospiraMember" abstract="true" name="HospiraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TopNineProductsMember" abstract="true" name="TopNineProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_ToviazMember" abstract="true" name="ToviazMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DerivativeNetReceivablePositionAggregateFairValue" abstract="false" name="DerivativeNetReceivablePositionAggregateFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" abstract="false" name="DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_TotalShareholderReturnUnitsTSRUsMember" abstract="true" name="TotalShareholderReturnUnitsTSRUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_NotesDue20271.000Member" abstract="true" name="NotesDue20271.000Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanOtherInvestmentsMember" abstract="true" name="DefinedBenefitPlanOtherInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" abstract="true" name="PfizerandBMSVersusSeveralGenericManufacturersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ArrayMember" abstract="true" name="ArrayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" abstract="false" name="ShorttermInvestmentsExcludingHeldToMaturitySecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" abstract="false" name="BusinessCombinationAcquisitionRelatedCostsTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_PrepaymentsandPaymentstoCollaborators" abstract="false" name="PrepaymentsandPaymentstoCollaborators" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_AllOtherRareDiseaseProductsMember" abstract="true" name="AllOtherRareDiseaseProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ScenarioPreviousAccountingPrincipleMember" abstract="true" name="ScenarioPreviousAccountingPrincipleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" abstract="true" name="NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" abstract="false" name="DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_MedrolMember" abstract="true" name="MedrolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue20482050Member" abstract="true" name="SeniorUnsecuredDebtDue20482050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CopromotionMember" abstract="true" name="CopromotionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" abstract="false" name="AssetAcquisitionConsiderationTransferredUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" abstract="false" name="DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_ForeignCurrencyShortTermBorrowingsMember" abstract="true" name="ForeignCurrencyShortTermBorrowingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EquitySecuritiesFVNIRestrictedNoncurrent" abstract="false" name="EquitySecuritiesFVNIRestrictedNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ImplementationCostAbstract" abstract="true" name="ImplementationCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_UpjohnFinanceB.V.Member" abstract="true" name="UpjohnFinanceB.V.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AromasinMember" abstract="true" name="AromasinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" abstract="false" name="DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_NimenrixMember" abstract="true" name="NimenrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BraftoviMember" abstract="true" name="BraftoviMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ChantixChampixMember" abstract="true" name="ChantixChampixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_EliquisMember" abstract="true" name="EliquisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GenotropinMember" abstract="true" name="GenotropinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" abstract="false" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" abstract="true" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" abstract="false" name="DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" abstract="true" name="TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_XtandiAllianceRevenuesMember" abstract="true" name="XtandiAllianceRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CommonESOPPlanMember" abstract="true" name="CommonESOPPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CreditFacilityExpiring2025Member" abstract="true" name="CreditFacilityExpiring2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="LeaseAssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_ViiVMember" abstract="true" name="ViiVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" abstract="false" name="DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_MeridianMember" abstract="true" name="MeridianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ArvinasIncMember" abstract="true" name="ArvinasIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" abstract="false" name="PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" abstract="false" name="PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" abstract="true" name="ScenarioChangeInAccountingPrincipleAdjustmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AssetAcquisitionLiabilitiesAssumed" abstract="false" name="AssetAcquisitionLiabilitiesAssumed" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ZyvoxMember" abstract="true" name="ZyvoxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AgreementDomain" abstract="true" name="AgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_InvestmentOwnershipPercentage" abstract="false" name="InvestmentOwnershipPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_LicensingAgreementsTechnologyInDevelopmentMember" abstract="true" name="LicensingAgreementsTechnologyInDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherTaxesPayableMember" abstract="true" name="OtherTaxesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" abstract="false" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" abstract="false" name="ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_IbranceMember" abstract="true" name="IbranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" abstract="true" name="SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" abstract="false" name="ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" abstract="false" name="DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ViatrisMember" abstract="true" name="ViatrisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" abstract="true" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" abstract="true" name="SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" abstract="false" name="ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AccruedRebates" abstract="false" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue2027Member" abstract="true" name="SeniorUnsecuredDebtDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" abstract="false" name="LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ForeignCurrencyLongTermDebtMember" abstract="true" name="ForeignCurrencyLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" abstract="false" name="DebtSecuritiesAccumulatedGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue2025Member" abstract="true" name="SeniorUnsecuredDebtDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_InsuranceContractsMember" abstract="true" name="InsuranceContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ViivHealthcareLimitedMember" abstract="true" name="ViivHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AssetWriteOffsAndAssetImpairmentCharges" abstract="false" name="AssetWriteOffsAndAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ReconcilingItemsAcquisitionRelatedCostsMember" abstract="true" name="ReconcilingItemsAcquisitionRelatedCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EpiPenMember" abstract="true" name="EpiPenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_MyovantMember" abstract="true" name="MyovantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" abstract="false" name="DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" abstract="false" name="DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_VaccinesMember" abstract="true" name="VaccinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_NoncurrentDeferredTaxLiabilitiesMember" abstract="true" name="NoncurrentDeferredTaxLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SutentMember" abstract="true" name="SutentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ManufacturingAndSupplyAgreementMember" abstract="true" name="ManufacturingAndSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" abstract="true" name="ConsolidatedStatementsOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_InternationalIncomeTaxesAbstract" abstract="true" name="InternationalIncomeTaxesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue2024Member" abstract="true" name="SeniorUnsecuredDebtDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_HedgedItemDomain" abstract="true" name="HedgedItemDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_FragminMember" abstract="true" name="FragminMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_TherachonAssetAcquisitionMember" abstract="true" name="TherachonAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" abstract="false" name="DebtSecuritiesMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" abstract="false" name="NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_LongtermInvestmentsMember" abstract="true" name="LongtermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ZithromaxZmaxMember" abstract="true" name="ZithromaxZmaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" abstract="false" name="LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_NumberofEmployeeStockOwnershipPlans" abstract="false" name="NumberofEmployeeStockOwnershipPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_McKessonInc.Member" abstract="true" name="McKessonInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PrevnarPrevenarFamilyMember" abstract="true" name="PrevnarPrevenarFamilyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_FocusedCompanyPlanMember" abstract="true" name="FocusedCompanyPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TrumenbaMember" abstract="true" name="TrumenbaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RebatesAndOtherSalesRelatedAccruals" abstract="false" name="RebatesAndOtherSalesRelatedAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" abstract="false" name="CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherAccruals" abstract="false" name="OtherAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" abstract="false" name="RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BeneFIXMember" abstract="true" name="BeneFIXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherHospitalProductsMember" abstract="true" name="OtherHospitalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" abstract="false" name="ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_XeljanzMember" abstract="true" name="XeljanzMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" abstract="false" name="IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" abstract="true" name="SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ZirabevMember" abstract="true" name="ZirabevMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DevelopedEuropeMember" abstract="true" name="DevelopedEuropeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" abstract="false" name="LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" abstract="false" name="EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" abstract="false" name="HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" abstract="false" name="EquityMethodInvestmentExcessBasisAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" abstract="false" name="CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PortfolioPerformanceSharesMember" abstract="true" name="PortfolioPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TopSixProductsMember" abstract="true" name="TopSixProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" abstract="false" name="GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_BMP2Member" abstract="true" name="BMP2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_HospitalMember" abstract="true" name="HospitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue2026Member" abstract="true" name="SeniorUnsecuredDebtDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_InlytaMember" abstract="true" name="InlytaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CK1AssetsSoldToBiogenIncMember" abstract="true" name="CK1AssetsSoldToBiogenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AllOtherInflammationandImmunologyProductsMember" abstract="true" name="AllOtherInflammationandImmunologyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AssetAcquisitionAssetsAcquired" abstract="false" name="AssetAcquisitionAssetsAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_ScheduleOfAccruedLiabilitiesLineItems" abstract="true" name="ScheduleOfAccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pfe_LorbrenaMember" abstract="true" name="LorbrenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentForLicensingArrangement" abstract="false" name="PaymentForLicensingArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" abstract="false" name="CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" abstract="false" name="UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RuxienceMember" abstract="true" name="RuxienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" abstract="false" name="ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" abstract="false" name="RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RareDiseaseMember" abstract="true" name="RareDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentForCollaborativeAndLicensingArrangements" abstract="false" name="PaymentForCollaborativeAndLicensingArrangements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AkceaAndIonisMember" abstract="true" name="AkceaAndIonisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" abstract="false" name="DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned" abstract="false" name="DiscontinuedOperationRatioSharesReceivedForEachShareOwned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="pfe_AnacorMember" abstract="true" name="AnacorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BesponsaMember" abstract="true" name="BesponsaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_RestructuringChargesAndAcquisitionRelatedCosts" abstract="false" name="RestructuringChargesAndAcquisitionRelatedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_NonUnitedStatesMember" abstract="true" name="NonUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue2023Member" abstract="true" name="SeniorUnsecuredDebtDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeconsolidationGainLossAmountNetOfTax" abstract="false" name="DeconsolidationGainLossAmountNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" abstract="true" name="PerformanceTotalShareholderReturnUnitPTSRUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CoronavirusVaccineProgramMRNABasedMember" abstract="true" name="CoronavirusVaccineProgramMRNABasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_December2017StockPurchasePlanMember" abstract="true" name="December2017StockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_UnrecognizedTaxBenefitsExcludingInterest" abstract="false" name="UnrecognizedTaxBenefitsExcludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" abstract="false" name="TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" abstract="false" name="AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember" abstract="true" name="CortexymeIncAndSpringWorksTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" abstract="true" name="DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TopSevenProductsMember" abstract="true" name="TopSevenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_XalkoriMember" abstract="true" name="XalkoriMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" abstract="false" name="LossContingencyNumberOfDefendantsOtherThanMainDefendant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue20432047Member" abstract="true" name="SeniorUnsecuredDebtDue20432047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PristiqMember" abstract="true" name="PristiqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" abstract="false" name="UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_InternalMedicineMember" abstract="true" name="InternalMedicineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EucrisaMember" abstract="true" name="EucrisaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" abstract="false" name="DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_BavencioAllianceRevenuesMember" abstract="true" name="BavencioAllianceRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TotalSterileInjectablePharmaceuticalsMember" abstract="true" name="TotalSterileInjectablePharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" abstract="false" name="DomesticIncomeTaxExpenseBenefitContinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" abstract="false" name="ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="pfe_DevelopedRestOfWorldMember" abstract="true" name="DevelopedRestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" abstract="false" name="StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_CardinalHealthInc.Member" abstract="true" name="CardinalHealthInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TotalBiosimilarsMember" abstract="true" name="TotalBiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" abstract="false" name="DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" abstract="true" name="PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" abstract="false" name="TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_InflammationandImmunologyMember" abstract="true" name="InflammationandImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ScheduleOfAccruedLiabilitiesTable" abstract="true" name="ScheduleOfAccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_BeamMember" abstract="true" name="BeamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorNotesDue2047Member" abstract="true" name="SeniorNotesDue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" abstract="false" name="DebtSecuritiesAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ImplementationCosts" abstract="false" name="ImplementationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ManufacturingOptimizationMember" abstract="true" name="ManufacturingOptimizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SomavertMember" abstract="true" name="SomavertMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" abstract="false" name="DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EnvironmentalRemediationLitigationMember" abstract="true" name="EnvironmentalRemediationLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_TotalAllianceBiopharmaceuticalsMember" abstract="true" name="TotalAllianceBiopharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" abstract="false" name="StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="pfe_InflectraRemsimaMember" abstract="true" name="InflectraRemsimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AllOtherInternalMedicineMember" abstract="true" name="AllOtherInternalMedicineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EffectofTaxCutsandJobsActAbstract" abstract="true" name="EffectofTaxCutsandJobsActAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OpenMarketPurchasesMember" abstract="true" name="OpenMarketPurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RestructuringAssetImpairmentCharges" abstract="false" name="RestructuringAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BioNTechAndCerevelTherapeuticsLLCMember" abstract="true" name="BioNTechAndCerevelTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" abstract="false" name="ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_UpjohnFinanceBVMember" abstract="true" name="UpjohnFinanceBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GSKConsumerHealthcareMember" abstract="true" name="GSKConsumerHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PrepaymentsAndPaymentsToCollaboratorsCash" abstract="false" name="PrepaymentsAndPaymentsToCollaboratorsCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" abstract="true" name="EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" abstract="true" name="BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OtherAntiinfectivesMember" abstract="true" name="OtherAntiinfectivesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" abstract="true" name="GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeferredTaxLiabilitiesNetNoncurrentMember" abstract="true" name="DeferredTaxLiabilitiesNetNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BioNTechMember" abstract="true" name="BioNTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorNotesDue2023Member" abstract="true" name="SeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BosulifMember" abstract="true" name="BosulifMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_FinancialInstrumentsAbstract" abstract="true" name="FinancialInstrumentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_OtherOncologyProductsMember" abstract="true" name="OtherOncologyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_BreakthroughPerformanceAwardsMember" abstract="true" name="BreakthroughPerformanceAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_RestructuringandRelatedCostNoncashChargesPercentage" abstract="false" name="RestructuringandRelatedCostNoncashChargesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue2022Member" abstract="true" name="SeniorUnsecuredDebtDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_SeniorNotesDue2021Member" abstract="true" name="SeniorNotesDue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" abstract="false" name="SiteContingencyRegulatoryProceedingsDisclosureThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" abstract="false" name="GainContingencyPatentsWithoutCourtProceedingsNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_TrazimeraMember" abstract="true" name="TrazimeraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BusinessAlignmentCosts" abstract="false" name="BusinessAlignmentCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CollaborativeArrangementMilestonePaymentUponApproval" abstract="false" name="CollaborativeArrangementMilestonePaymentUponApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ConsolidatedStatementsOfCashFlowsAbstract" abstract="true" name="ConsolidatedStatementsOfCashFlowsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_SulperazonMember" abstract="true" name="SulperazonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CorporateEnablingFunctionsMember" abstract="true" name="CorporateEnablingFunctionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EliLillyCompanyMember" abstract="true" name="EliLillyCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ConcentrationRiskAmount" abstract="false" name="ConcentrationRiskAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_FSMEIMMUNTicoVacMember" abstract="true" name="FSMEIMMUNTicoVacMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GSKMember" abstract="true" name="GSKMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_ReFactoAfXynthaMember" abstract="true" name="ReFactoAfXynthaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" abstract="false" name="CollaborativeArrangementContingentPaymentsMaximumExposure" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CStoneMember" abstract="true" name="CStoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" abstract="false" name="DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" abstract="true" name="RestructuringChargesAndAcquisitionRelatedCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_CurrentTaxAssetsMember" abstract="true" name="CurrentTaxAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_ConsolidatedStatementsOfIncomeAbstract" abstract="true" name="ConsolidatedStatementsOfIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="pfe_GainContingencyNumberofDefendants" abstract="false" name="GainContingencyNumberofDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue20282032Member" abstract="true" name="SeniorUnsecuredDebtDue20282032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" abstract="false" name="PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" abstract="false" name="UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_PrecedexMember" abstract="true" name="PrecedexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_IVIgProductsMember" abstract="true" name="IVIgProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GoToMarketModelMember" abstract="true" name="GoToMarketModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherTaxAssetsCurrent" abstract="false" name="OtherTaxAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" abstract="false" name="AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ShorttermDebtGross" abstract="false" name="ShorttermDebtGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember" abstract="true" name="ReconcilingItemsPurchaseAccountingAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ZaviceftaMember" abstract="true" name="ZaviceftaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_UpjohnIncAndUpjohnFinanceBVMember" abstract="true" name="UpjohnIncAndUpjohnFinanceBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_A2019StockPlanMember" abstract="true" name="A2019StockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_GovernmentAndGovernmentSponsoredMember" abstract="true" name="GovernmentAndGovernmentSponsoredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_UpjohnIncMember" abstract="true" name="UpjohnIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PurchaserOfMeridianMember" abstract="true" name="PurchaserOfMeridianMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" abstract="false" name="DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_FeasibilityStudyNumberOfLagoons" abstract="false" name="FeasibilityStudyNumberOfLagoons" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_HedgedItemAxis" abstract="true" name="HedgedItemAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="pfe_PremarinFamilyMember" abstract="true" name="PremarinFamilyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" abstract="true" name="SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PneumococcalVaccinePatentInfringementMember" abstract="true" name="PneumococcalVaccinePatentInfringementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ThreeLargestUSWholesaleCustomersMember" abstract="true" name="ThreeLargestUSWholesaleCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeconsolidationNetAssetsContributed" abstract="false" name="DeconsolidationNetAssetsContributed" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" abstract="false" name="AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_CostReductionInitiativesMember" abstract="true" name="CostReductionInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_NotesDue20220.250Member" abstract="true" name="NotesDue20220.250Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SeniorUnsecuredDebtDue20382042Member" abstract="true" name="SeniorUnsecuredDebtDue20382042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" abstract="false" name="ConcentrationRiskRevenues500000000orMoreNumberofCountries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="pfe_OtherCommingledFundsMember" abstract="true" name="OtherCommingledFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ShareRepurchaseAgreementwithGSCoMember" abstract="true" name="ShareRepurchaseAgreementwithGSCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_InterestReceivedInterestRateHedges" abstract="false" name="InterestReceivedInterestRateHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_BioNTechAndSpringWorksMember" abstract="true" name="BioNTechAndSpringWorksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PrivateEquityInvestments" abstract="false" name="PrivateEquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="pfe_ForeignCurrencyDebtMember" abstract="true" name="ForeignCurrencyDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" abstract="false" name="OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" abstract="false" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_DebtSecuritiesAmortizedCostBasis" abstract="false" name="DebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_ConsumerHealthcareReportingUnitMember" abstract="true" name="ConsumerHealthcareReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DeconsolidationExternalIncrementalCostsAmount" abstract="false" name="DeconsolidationExternalIncrementalCostsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="pfe_GenericSterileInjectableProductMember" abstract="true" name="GenericSterileInjectableProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_LicensingAgreementsAndOtherMember" abstract="true" name="LicensingAgreementsAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_MylanMember" abstract="true" name="MylanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_DocetaxelMember" abstract="true" name="DocetaxelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EnbrelMember" abstract="true" name="EnbrelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_ValnevaSEMember" abstract="true" name="ValnevaSEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_AssetImpairmentsMember" abstract="true" name="AssetImpairmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_VfendMember" abstract="true" name="VfendMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_EmergingMarketsMember" abstract="true" name="EmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" abstract="false" name="PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>pfe-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ad91efd1-2241-49cf-a17f-7cbe86f9ba4a,g:feca3a10-f613-46f2-b813-b8f4d7d48955-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c1d316c5-014a-4944-9c85-f91dfd75e5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f93d12e7-de7c-4862-a209-793fd069ca2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c1d316c5-014a-4944-9c85-f91dfd75e5a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f93d12e7-de7c-4862-a209-793fd069ca2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3c6a8231-8dca-4ffc-a74d-72143e8d3e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c1d316c5-014a-4944-9c85-f91dfd75e5a7" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3c6a8231-8dca-4ffc-a74d-72143e8d3e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5923035d-4b8a-48d7-837c-9ead736ca585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f867798c-73f5-4d17-ad6e-93ca33902893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5923035d-4b8a-48d7-837c-9ead736ca585" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_f867798c-73f5-4d17-ad6e-93ca33902893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d690ad17-6fcc-43b2-a0e7-399704b06056" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_5923035d-4b8a-48d7-837c-9ead736ca585" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d690ad17-6fcc-43b2-a0e7-399704b06056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d5e5a1ee-90bd-467b-8c83-d991f04660ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d5e5a1ee-90bd-467b-8c83-d991f04660ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_606aa71a-c38b-4131-b0ec-3643cd4ebdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_606aa71a-c38b-4131-b0ec-3643cd4ebdbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4a7fc38b-a484-44ab-9b99-b41fa4c8dd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4a7fc38b-a484-44ab-9b99-b41fa4c8dd1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5c87ddb3-d251-462f-8406-ecad21f5195d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5c87ddb3-d251-462f-8406-ecad21f5195d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_159dcb4b-54f9-4afd-8c83-c917352eae78" xlink:href="pfe-20211231.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_159dcb4b-54f9-4afd-8c83-c917352eae78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_84a7de8f-4edb-4031-ad10-0aaca507d3dd" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_84a7de8f-4edb-4031-ad10-0aaca507d3dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_75cb1fe9-dd36-4ffc-87bf-cba11cbde1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_75cb1fe9-dd36-4ffc-87bf-cba11cbde1f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_37c14d2c-33e1-491c-80a3-4abbcf393a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd627f6e-d0e2-4754-9dc8-09330753a5a9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_37c14d2c-33e1-491c-80a3-4abbcf393a71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_eb4f3925-d725-42c8-9364-329c40371c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e451443a-ea87-4082-81a3-8944d59771b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_eb4f3925-d725-42c8-9364-329c40371c1e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e451443a-ea87-4082-81a3-8944d59771b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2385cb63-0d93-471e-a0e5-2b5f4dbd6565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_eb4f3925-d725-42c8-9364-329c40371c1e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2385cb63-0d93-471e-a0e5-2b5f4dbd6565" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_371109b7-7f38-4131-9f0c-ff891d3b6b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb4e2c40-ae5d-40d9-82ac-f23e2d87bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_371109b7-7f38-4131-9f0c-ff891d3b6b30" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fb4e2c40-ae5d-40d9-82ac-f23e2d87bc23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_55c2a17d-03c2-4e16-aaab-71b93cbc0547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_371109b7-7f38-4131-9f0c-ff891d3b6b30" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_55c2a17d-03c2-4e16-aaab-71b93cbc0547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff36ecb1-bf5f-4944-909e-77136137bc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0b2f4ce0-61a4-480e-b623-cf6f7196f1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ff36ecb1-bf5f-4944-909e-77136137bc86" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0b2f4ce0-61a4-480e-b623-cf6f7196f1c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4fbd4b86-1012-45c2-b0d3-490266251d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ff36ecb1-bf5f-4944-909e-77136137bc86" xlink:to="loc_us-gaap_ProfitLoss_4fbd4b86-1012-45c2-b0d3-490266251d3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_063208e4-d5af-4c4e-a204-0c6d67750a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_61300789-200b-4eeb-80ee-fef284f2b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_063208e4-d5af-4c4e-a204-0c6d67750a2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_61300789-200b-4eeb-80ee-fef284f2b98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_2e29f4b9-7749-4fec-aa07-08337c3a196a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_063208e4-d5af-4c4e-a204-0c6d67750a2c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_2e29f4b9-7749-4fec-aa07-08337c3a196a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_15f4ad0d-69d7-4629-887a-e80efd61e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_1743ab1b-9bcc-4937-913c-984ff9150209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_15f4ad0d-69d7-4629-887a-e80efd61e4b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_1743ab1b-9bcc-4937-913c-984ff9150209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d6e3aa72-c92a-4f70-ac34-6e4a4c06d7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_15f4ad0d-69d7-4629-887a-e80efd61e4b9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d6e3aa72-c92a-4f70-ac34-6e4a4c06d7b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d4d09f81-a95c-4068-97e8-53575c6cd31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_544b3c88-8f44-4da8-8ff8-3b07c7bb6aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d4d09f81-a95c-4068-97e8-53575c6cd31a" xlink:to="loc_us-gaap_ProfitLoss_544b3c88-8f44-4da8-8ff8-3b07c7bb6aee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f42589cb-509d-4d1a-aeff-7df1deeec3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d4d09f81-a95c-4068-97e8-53575c6cd31a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f42589cb-509d-4d1a-aeff-7df1deeec3ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_00038d78-ccc3-4487-a560-f0c79d1f061f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d33051f8-a095-4cab-b7d7-60ae3d186a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_00038d78-ccc3-4487-a560-f0c79d1f061f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d33051f8-a095-4cab-b7d7-60ae3d186a5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_57f3509e-397d-4165-b10e-a6f806cb5292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_00038d78-ccc3-4487-a560-f0c79d1f061f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_57f3509e-397d-4165-b10e-a6f806cb5292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_df4bf90f-f551-4a61-ae0d-f449568ccffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_df9da488-7366-46fc-92d7-e43b8ce649aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_df4bf90f-f551-4a61-ae0d-f449568ccffd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_df9da488-7366-46fc-92d7-e43b8ce649aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_8640b1f8-7807-4c2a-a185-468bb28e45b4" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_df4bf90f-f551-4a61-ae0d-f449568ccffd" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_8640b1f8-7807-4c2a-a185-468bb28e45b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_35af5706-9866-424b-8f25-e6eecc2b5724" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_df4bf90f-f551-4a61-ae0d-f449568ccffd" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_35af5706-9866-424b-8f25-e6eecc2b5724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_073a88fc-1677-4bd9-b041-4f594aef1022" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_df4bf90f-f551-4a61-ae0d-f449568ccffd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_073a88fc-1677-4bd9-b041-4f594aef1022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_a709cd78-8124-4764-b742-307b25738a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_aee91a5c-2fbb-4351-bfdd-ff5c658b3339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_a709cd78-8124-4764-b742-307b25738a41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_aee91a5c-2fbb-4351-bfdd-ff5c658b3339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_ebcdbfaa-6cf8-47b7-bbc5-61776d6a828a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_a709cd78-8124-4764-b742-307b25738a41" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_ebcdbfaa-6cf8-47b7-bbc5-61776d6a828a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6eac82cd-706e-4e91-bc70-125e6d8087b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_a709cd78-8124-4764-b742-307b25738a41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6eac82cd-706e-4e91-bc70-125e6d8087b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_3a59ad62-c0b6-4e19-987f-1d5863511aab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_a709cd78-8124-4764-b742-307b25738a41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_3a59ad62-c0b6-4e19-987f-1d5863511aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_7fc6075c-9ca4-4341-85a5-7f925d11023a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_3cf07a87-7ed1-4c9e-815e-011702cb6762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_7fc6075c-9ca4-4341-85a5-7f925d11023a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_3cf07a87-7ed1-4c9e-815e-011702cb6762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_a47054f2-afa3-4d14-b71c-22a8510985cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_7fc6075c-9ca4-4341-85a5-7f925d11023a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_a47054f2-afa3-4d14-b71c-22a8510985cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cdeab9d7-5003-4774-aed8-bd831bb1439f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_1969c28e-898e-4c6b-b00b-eb3690395f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cdeab9d7-5003-4774-aed8-bd831bb1439f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_1969c28e-898e-4c6b-b00b-eb3690395f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_f8214d5a-e5a1-4ee1-917b-97a9454c026c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cdeab9d7-5003-4774-aed8-bd831bb1439f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_f8214d5a-e5a1-4ee1-917b-97a9454c026c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f423c6e3-050a-4339-b1e2-8dd223dd41de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5729096f-c3f8-4680-9666-f7ee53793eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f423c6e3-050a-4339-b1e2-8dd223dd41de" xlink:to="loc_us-gaap_InventoryNet_5729096f-c3f8-4680-9666-f7ee53793eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_d464bc93-0ad8-48ff-9b54-3a6c44697d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f423c6e3-050a-4339-b1e2-8dd223dd41de" xlink:to="loc_us-gaap_OtherShortTermInvestments_d464bc93-0ad8-48ff-9b54-3a6c44697d2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent_8fd4e773-7a36-4b9f-9760-5fbf783db3da" xlink:href="pfe-20211231.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f423c6e3-050a-4339-b1e2-8dd223dd41de" xlink:to="loc_pfe_OtherTaxAssetsCurrent_8fd4e773-7a36-4b9f-9760-5fbf783db3da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_ab347794-0e84-4ab1-9de2-303dede7ab4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f423c6e3-050a-4339-b1e2-8dd223dd41de" xlink:to="loc_us-gaap_OtherAssetsCurrent_ab347794-0e84-4ab1-9de2-303dede7ab4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8f85d8f-9e77-4d79-889c-d8f77b64163d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f423c6e3-050a-4339-b1e2-8dd223dd41de" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8f85d8f-9e77-4d79-889c-d8f77b64163d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_77e20c6c-7e45-48b4-aba7-4ad54c29d119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f423c6e3-050a-4339-b1e2-8dd223dd41de" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_77e20c6c-7e45-48b4-aba7-4ad54c29d119" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f55bf6ac-8544-48b4-b07e-ca7c212f5ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bfb4525b-db54-4f02-a01a-5bd7090ce72d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f55bf6ac-8544-48b4-b07e-ca7c212f5ed5" xlink:to="loc_us-gaap_Liabilities_bfb4525b-db54-4f02-a01a-5bd7090ce72d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_55b3d568-d1e0-4a98-9263-251f09547122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f55bf6ac-8544-48b4-b07e-ca7c212f5ed5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_55b3d568-d1e0-4a98-9263-251f09547122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_afc9988e-d583-43cd-bfd9-9b68dc7c720e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f55bf6ac-8544-48b4-b07e-ca7c212f5ed5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_afc9988e-d583-43cd-bfd9-9b68dc7c720e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2355f3b2-f5a2-4dda-beb0-aa7971763926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:to="loc_us-gaap_LiabilitiesCurrent_2355f3b2-f5a2-4dda-beb0-aa7971763926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_27beadd2-1c24-46cc-84c4-e8989240f188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_27beadd2-1c24-46cc-84c4-e8989240f188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_30bebe3e-d2f5-43de-b4fa-f154eee56fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_30bebe3e-d2f5-43de-b4fa-f154eee56fbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f21c2814-14af-4e23-afea-4b479ab1df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f21c2814-14af-4e23-afea-4b479ab1df8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e49925eb-04b5-4879-bffd-ecaa1b197c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e49925eb-04b5-4879-bffd-ecaa1b197c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_21a92cde-55b0-44fe-a345-dc13851f2135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_21a92cde-55b0-44fe-a345-dc13851f2135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_01927eb8-0940-49be-b6e4-1ea42974912e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_76610db7-17e5-4282-9b76-e5ebd9c39fb0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_01927eb8-0940-49be-b6e4-1ea42974912e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f37f6aac-b207-4aed-b455-4371948dbe9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_31fa6359-d27a-4bff-8f58-20e3c0abb2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37f6aac-b207-4aed-b455-4371948dbe9c" xlink:to="loc_us-gaap_PreferredStockValue_31fa6359-d27a-4bff-8f58-20e3c0abb2c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8b0c5b47-e52d-4786-a1bf-170fff95fd71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37f6aac-b207-4aed-b455-4371948dbe9c" xlink:to="loc_us-gaap_CommonStockValue_8b0c5b47-e52d-4786-a1bf-170fff95fd71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_5a3a71d4-700f-4727-bbe5-2f358284efd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37f6aac-b207-4aed-b455-4371948dbe9c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_5a3a71d4-700f-4727-bbe5-2f358284efd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_661d0c7a-2e3f-480a-b949-b28cf3bec924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37f6aac-b207-4aed-b455-4371948dbe9c" xlink:to="loc_us-gaap_TreasuryStockValue_661d0c7a-2e3f-480a-b949-b28cf3bec924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac605840-2cd6-4808-a1af-16997bfa4f05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37f6aac-b207-4aed-b455-4371948dbe9c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ac605840-2cd6-4808-a1af-16997bfa4f05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b5a58fb-20af-4816-9819-f9bfb546315d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f37f6aac-b207-4aed-b455-4371948dbe9c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b5a58fb-20af-4816-9819-f9bfb546315d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_a15545d3-e941-4733-949b-6c023bc40bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:to="loc_us-gaap_TaxesPayableCurrent_a15545d3-e941-4733-949b-6c023bc40bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9d482f7-47c3-44e9-94df-4913a497efff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9d482f7-47c3-44e9-94df-4913a497efff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_39e9c139-d28b-4f67-8ab1-63ebb3de480e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:to="loc_us-gaap_DividendsPayableCurrent_39e9c139-d28b-4f67-8ab1-63ebb3de480e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_08731aba-034d-407e-a449-098c57b0ca7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:to="loc_us-gaap_AccountsPayableCurrent_08731aba-034d-407e-a449-098c57b0ca7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_b3458022-f293-4daf-8c9d-7ecdee77ba79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:to="loc_us-gaap_DebtCurrent_b3458022-f293-4daf-8c9d-7ecdee77ba79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_975cdaed-83c0-4eae-99b3-3d8ec99e60bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_975cdaed-83c0-4eae-99b3-3d8ec99e60bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a33e825e-c396-4341-bf1c-1a56ec0ba939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_cf3b14bc-364a-4540-a6bf-2a323eac344c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a33e825e-c396-4341-bf1c-1a56ec0ba939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75992a61-cf71-494b-9488-f1386a9d3810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_474d9e93-d9b0-4aad-85b1-12757d52aa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75992a61-cf71-494b-9488-f1386a9d3810" xlink:to="loc_us-gaap_StockholdersEquity_474d9e93-d9b0-4aad-85b1-12757d52aa9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_5cead019-f212-4a07-beae-8fccf641c6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_75992a61-cf71-494b-9488-f1386a9d3810" xlink:to="loc_us-gaap_MinorityInterest_5cead019-f212-4a07-beae-8fccf641c6c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af571462-5734-44a1-913b-4a49d26c3229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af571462-5734-44a1-913b-4a49d26c3229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_2c6b9b1f-226e-4595-b5d6-2b84ce8d8a7d" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_2c6b9b1f-226e-4595-b5d6-2b84ce8d8a7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e403f71d-9b17-41fd-80b4-c0f60097f103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e403f71d-9b17-41fd-80b4-c0f60097f103" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_365c3349-6b67-4b2e-9825-36f6995b1000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_365c3349-6b67-4b2e-9825-36f6995b1000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6c9f8d4a-12d1-41d9-8c9e-1a114f30cd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_us-gaap_Goodwill_6c9f8d4a-12d1-41d9-8c9e-1a114f30cd9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bb601555-666f-4759-a920-b33f1fca2014" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_us-gaap_AssetsCurrent_bb601555-666f-4759-a920-b33f1fca2014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_607532ea-4e10-4584-b3aa-d7ef70c2e817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_us-gaap_OtherLongTermInvestments_607532ea-4e10-4584-b3aa-d7ef70c2e817" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_817be5b2-5621-42a2-8273-6e922bf97210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_42e18ac7-665d-478c-b22b-f8ca455e8f1d" xlink:to="loc_us-gaap_EquityMethodInvestments_817be5b2-5621-42a2-8273-6e922bf97210" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_954286e5-3712-483c-a327-1e1781d9ae3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2c51c396-7466-4920-8cc6-8cef0cfc3fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_954286e5-3712-483c-a327-1e1781d9ae3b" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_2c51c396-7466-4920-8cc6-8cef0cfc3fcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d7917270-f014-4041-8e05-8aa90ba1b480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_954286e5-3712-483c-a327-1e1781d9ae3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_d7917270-f014-4041-8e05-8aa90ba1b480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59e83b76-5716-4a84-8eb8-5e697d0d8ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0baf5a33-3249-4edc-93b5-af51329af8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59e83b76-5716-4a84-8eb8-5e697d0d8ccb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0baf5a33-3249-4edc-93b5-af51329af8a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cb90b95-7021-4574-be13-9c976f6a45a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59e83b76-5716-4a84-8eb8-5e697d0d8ccb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0cb90b95-7021-4574-be13-9c976f6a45a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82f41866-5584-409f-9966-bd4c93cff394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59e83b76-5716-4a84-8eb8-5e697d0d8ccb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82f41866-5584-409f-9966-bd4c93cff394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a777a6c7-322b-491c-8dd4-989bdb4751b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_59e83b76-5716-4a84-8eb8-5e697d0d8ccb" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a777a6c7-322b-491c-8dd4-989bdb4751b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de58499d-52bd-43ec-91c1-898dedab20bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_39c2f27e-1c22-41d4-84bc-5f75937fec32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de58499d-52bd-43ec-91c1-898dedab20bc" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_39c2f27e-1c22-41d4-84bc-5f75937fec32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_a14f1e16-5c32-454d-9a64-4014a7bb5efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_de58499d-52bd-43ec-91c1-898dedab20bc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_a14f1e16-5c32-454d-9a64-4014a7bb5efc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_89142352-2e02-440e-a90f-2ab7a75cb0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_89142352-2e02-440e-a90f-2ab7a75cb0dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2b9d3d94-3ac7-42e7-86bc-3bfa828a4d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2b9d3d94-3ac7-42e7-86bc-3bfa828a4d33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_0892ee93-907b-45ac-ae7b-5ac563a3f154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_0892ee93-907b-45ac-ae7b-5ac563a3f154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a6e0029-3480-4e1e-93f6-a37cd073e7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9a6e0029-3480-4e1e-93f6-a37cd073e7ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_d2b984f4-5a5a-4ced-b7d4-b12ba2ff8e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_d2b984f4-5a5a-4ced-b7d4-b12ba2ff8e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_854e5914-6ac8-4b43-84e7-242546b40f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_854e5914-6ac8-4b43-84e7-242546b40f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_6670a81b-b440-40e9-b95b-a099e24b807d" xlink:href="pfe-20211231.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_6670a81b-b440-40e9-b95b-a099e24b807d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6b3196eb-67d3-4ade-bb32-428324f9d208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_d567d190-a61a-44af-9be6-18df6ccb7eff" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6b3196eb-67d3-4ade-bb32-428324f9d208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ffcfde6a-8b87-4621-a365-7523ead903ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ffcfde6a-8b87-4621-a365-7523ead903ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_45c0ad0c-80ab-4061-94c8-b9b41a91d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_45c0ad0c-80ab-4061-94c8-b9b41a91d2eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_7d88ebaf-e203-4dca-8ba2-657b78f2afbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_7d88ebaf-e203-4dca-8ba2-657b78f2afbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ba36e572-40b5-4a60-b1d1-69b697066940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ba36e572-40b5-4a60-b1d1-69b697066940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9b850773-e6dc-4f8b-9261-5db90a0238be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9b850773-e6dc-4f8b-9261-5db90a0238be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_e40b2c0b-3ac2-41a7-b1e6-559475f58b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_e40b2c0b-3ac2-41a7-b1e6-559475f58b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_96af785a-1020-456d-b674-51a2c4c27601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_96af785a-1020-456d-b674-51a2c4c27601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_adef8fc1-c280-40d4-84bd-4f70309b4fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_115334a6-4946-41dd-8be6-0347c0c6158c" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_adef8fc1-c280-40d4-84bd-4f70309b4fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb6e472-518a-4b14-a44e-ac72bf040588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_fd634444-3157-4771-b1d8-37ccddf0af49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb6e472-518a-4b14-a44e-ac72bf040588" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_fd634444-3157-4771-b1d8-37ccddf0af49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_42125008-3013-4f36-8026-fb9ad93daac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_edb6e472-518a-4b14-a44e-ac72bf040588" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_42125008-3013-4f36-8026-fb9ad93daac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_248c6997-4e7f-41dc-a419-a4ddb88a6f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_248c6997-4e7f-41dc-a419-a4ddb88a6f94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_e0f55967-6682-440d-b820-f365a3907ac6" xlink:href="pfe-20211231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_e0f55967-6682-440d-b820-f365a3907ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_344e0f00-23ab-4409-84f7-2dced96c0270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_344e0f00-23ab-4409-84f7-2dced96c0270" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_db84139b-3d44-4971-91f1-e4d77d7357dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_db84139b-3d44-4971-91f1-e4d77d7357dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3341ea62-e138-4d91-a034-c6b2eeb2c879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3341ea62-e138-4d91-a034-c6b2eeb2c879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0dd3e49f-389c-40b5-8058-64bb8f711fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_ShareBasedCompensation_0dd3e49f-389c-40b5-8058-64bb8f711fe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_41460b6d-8ab0-4517-8a46-00bf81e0f56c" xlink:href="pfe-20211231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_41460b6d-8ab0-4517-8a46-00bf81e0f56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0fdabb23-3b56-4672-994a-dcd3b465ba69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0fdabb23-3b56-4672-994a-dcd3b465ba69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ced2b642-b8a9-496b-bbe9-deff1d7924a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ced2b642-b8a9-496b-bbe9-deff1d7924a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_5ee28787-a534-4e32-bafa-eab39ea41af7" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_5ee28787-a534-4e32-bafa-eab39ea41af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_f11d6afb-9e4a-4cfb-8ce4-954194e5aaed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_f11d6afb-9e4a-4cfb-8ce4-954194e5aaed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_03175011-caf1-4cab-a4d6-d9b91f105493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_03175011-caf1-4cab-a4d6-d9b91f105493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63ee89d7-b078-4e54-96e0-aeca224d7628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_63ee89d7-b078-4e54-96e0-aeca224d7628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_aee30bb0-067e-4a75-9450-e5a7835410d2" xlink:href="pfe-20211231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_aee30bb0-067e-4a75-9450-e5a7835410d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_96ef8b67-80f5-4502-9680-70d67621812b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_fde19d37-7388-4dee-9321-2301ead4047f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_96ef8b67-80f5-4502-9680-70d67621812b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9e2b27fd-11e9-4582-a9a9-65ff90a0fcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_11b11c2e-6a86-47a3-b6b6-ef7fc4c798c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9e2b27fd-11e9-4582-a9a9-65ff90a0fcb8" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_11b11c2e-6a86-47a3-b6b6-ef7fc4c798c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_296b3ac4-cf65-4d86-afdf-d55c8799af3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9e2b27fd-11e9-4582-a9a9-65ff90a0fcb8" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_296b3ac4-cf65-4d86-afdf-d55c8799af3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc7f78bc-658d-403b-84f5-916dfbdfe25e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_7125cfb3-0ade-42e7-b7a8-ec879811305c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc7f78bc-658d-403b-84f5-916dfbdfe25e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_7125cfb3-0ade-42e7-b7a8-ec879811305c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_3955d143-3700-4085-824f-4cf8d706482d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc7f78bc-658d-403b-84f5-916dfbdfe25e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_3955d143-3700-4085-824f-4cf8d706482d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_6ecea391-3864-4060-8dcc-79299fb327fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc7f78bc-658d-403b-84f5-916dfbdfe25e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_6ecea391-3864-4060-8dcc-79299fb327fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_05b84231-cfea-4e32-b45d-80b609fdc121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_30872be8-6394-48a8-8dfb-a463c4e6668c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_05b84231-cfea-4e32-b45d-80b609fdc121" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_30872be8-6394-48a8-8dfb-a463c4e6668c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_4117bd04-78b2-4ead-ad65-145d2ef14b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_05b84231-cfea-4e32-b45d-80b609fdc121" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_4117bd04-78b2-4ead-ad65-145d2ef14b8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_9e62b6f1-7c29-4769-b7aa-ce4081c4327c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_ff675e26-237a-4b2d-a8cf-06ba52ffecd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_9e62b6f1-7c29-4769-b7aa-ce4081c4327c" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_ff675e26-237a-4b2d-a8cf-06ba52ffecd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_b5ea7066-1fca-4d42-a266-c0f4b28f1949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_9e62b6f1-7c29-4769-b7aa-ce4081c4327c" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_b5ea7066-1fca-4d42-a266-c0f4b28f1949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_bf3460af-5dbb-438a-9be9-d27f60dd4db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_bf3460af-5dbb-438a-9be9-d27f60dd4db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_173ce4f7-fae6-4cce-af0a-ee1d73cfcc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_173ce4f7-fae6-4cce-af0a-ee1d73cfcc8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_de89c6d2-de2e-435a-8539-0c58ede21ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_de89c6d2-de2e-435a-8539-0c58ede21ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_cfd96152-bcc1-4dd3-bc52-44d97059aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_cfd96152-bcc1-4dd3-bc52-44d97059aee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_af3ea118-08c8-458d-b120-30765379c70a" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_af3ea118-08c8-458d-b120-30765379c70a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_e9ab819f-ec88-45fe-bad0-45f0001acdef" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_e9ab819f-ec88-45fe-bad0-45f0001acdef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_80d50a3f-959b-4206-a3a8-c3cf9ba2707d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_769e902e-54c0-43db-8bdf-508f1f5b6691" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_80d50a3f-959b-4206-a3a8-c3cf9ba2707d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_83b4bf3e-9eaa-47ff-ba90-b94572110e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_68c3ec6d-ebe0-4660-a68e-31ac8d672ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_83b4bf3e-9eaa-47ff-ba90-b94572110e03" xlink:to="loc_us-gaap_Revenues_68c3ec6d-ebe0-4660-a68e-31ac8d672ca3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_06ee4cf7-a2b7-4a5a-bffd-fb712fcdf8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_83b4bf3e-9eaa-47ff-ba90-b94572110e03" xlink:to="loc_us-gaap_CostOfRevenue_06ee4cf7-a2b7-4a5a-bffd-fb712fcdf8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_26c2e306-c90b-47ce-a84d-d8093746ec82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_dedcd9b3-32b3-4f84-a384-90c01f2d786d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26c2e306-c90b-47ce-a84d-d8093746ec82" xlink:to="loc_us-gaap_AssetsNoncurrent_dedcd9b3-32b3-4f84-a384-90c01f2d786d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a844c1af-18d0-428c-a127-29b31d0f119f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_26c2e306-c90b-47ce-a84d-d8093746ec82" xlink:to="loc_us-gaap_AssetsCurrent_a844c1af-18d0-428c-a127-29b31d0f119f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cfbcec46-a7db-48ea-81c1-eb9b7d4cab42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_32810e3d-d714-4873-8850-51902f129c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cfbcec46-a7db-48ea-81c1-eb9b7d4cab42" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_32810e3d-d714-4873-8850-51902f129c15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f85f5902-cd04-4210-9f1b-faed0e44c65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cfbcec46-a7db-48ea-81c1-eb9b7d4cab42" xlink:to="loc_us-gaap_LiabilitiesCurrent_f85f5902-cd04-4210-9f1b-faed0e44c65c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_bdde5003-0fef-42e1-9b0d-33ae9f5c8094" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_e6f14d7b-6a90-4f02-97b5-6229cb98801b" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_bdde5003-0fef-42e1-9b0d-33ae9f5c8094" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_e6f14d7b-6a90-4f02-97b5-6229cb98801b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2f176985-1330-4365-9f57-b3225fabb726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_bdde5003-0fef-42e1-9b0d-33ae9f5c8094" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_2f176985-1330-4365-9f57-b3225fabb726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_aae75941-49ee-4ced-b643-1de8252292d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_bdde5003-0fef-42e1-9b0d-33ae9f5c8094" xlink:to="loc_us-gaap_RestructuringCharges_aae75941-49ee-4ced-b643-1de8252292d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_513f8908-833c-4af2-a12e-35ad4b1e4553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_ed011a1c-6605-449f-a3fa-d12cac831786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_513f8908-833c-4af2-a12e-35ad4b1e4553" xlink:to="loc_us-gaap_BusinessExitCosts1_ed011a1c-6605-449f-a3fa-d12cac831786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_77bc520f-c3cd-49da-a8f1-5bba74aef628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_513f8908-833c-4af2-a12e-35ad4b1e4553" xlink:to="loc_us-gaap_SeveranceCosts1_77bc520f-c3cd-49da-a8f1-5bba74aef628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_182b4168-ed06-43b1-a50b-60b0e8f095c5" xlink:href="pfe-20211231.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_513f8908-833c-4af2-a12e-35ad4b1e4553" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_182b4168-ed06-43b1-a50b-60b0e8f095c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0ff5c15d-37cd-4d8e-8600-68d9d5de6b7c" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_6e22c03a-9ad4-4e1c-86e9-3adbc3490b25" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0ff5c15d-37cd-4d8e-8600-68d9d5de6b7c" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_6e22c03a-9ad4-4e1c-86e9-3adbc3490b25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_717b202c-80ff-48d6-83a0-13a6cdc852f9" xlink:href="pfe-20211231.xsd#pfe_ImplementationCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0ff5c15d-37cd-4d8e-8600-68d9d5de6b7c" xlink:to="loc_pfe_ImplementationCosts_717b202c-80ff-48d6-83a0-13a6cdc852f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_893c59ee-36d9-41dc-a931-3f668055e9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0ff5c15d-37cd-4d8e-8600-68d9d5de6b7c" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_893c59ee-36d9-41dc-a931-3f668055e9c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c5e32d98-68fc-4aac-9234-15162f424201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_0ff5c15d-37cd-4d8e-8600-68d9d5de6b7c" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c5e32d98-68fc-4aac-9234-15162f424201" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_01384ef7-8b40-4a58-8d68-58f1129ea2d6" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_01384ef7-8b40-4a58-8d68-58f1129ea2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_274bb255-d57f-44c9-b883-d8deca28f67b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_274bb255-d57f-44c9-b883-d8deca28f67b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2cd53390-05b8-453f-b736-277fd8982ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_2cd53390-05b8-453f-b736-277fd8982ee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_06fa94fd-0a06-4432-8b52-fe654a33f006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_06fa94fd-0a06-4432-8b52-fe654a33f006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessAlignmentCosts_bb42b3e4-eeee-484d-950e-a036ce797485" xlink:href="pfe-20211231.xsd#pfe_BusinessAlignmentCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_pfe_BusinessAlignmentCosts_bb42b3e4-eeee-484d-950e-a036ce797485" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_cdbcac2e-8690-470b-9fde-c5601a5a195d" xlink:href="pfe-20211231.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_cdbcac2e-8690-470b-9fde-c5601a5a195d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_c8b47bef-f43a-4e01-b564-1708765f4980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_c8b47bef-f43a-4e01-b564-1708765f4980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6f1204ca-491a-451c-aef9-fe351eb6c146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_us-gaap_AssetImpairmentCharges_6f1204ca-491a-451c-aef9-fe351eb6c146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_fc98a010-0e2b-409b-a8fd-898aacee31e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_fc98a010-0e2b-409b-a8fd-898aacee31e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_83439470-80d7-45d0-9643-e5c54eda62f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_83439470-80d7-45d0-9643-e5c54eda62f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_95fe475e-8031-4b76-97ad-be1b3d98e6e5" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_15f342a5-07f0-465c-9c05-b0173dac06ff" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_95fe475e-8031-4b76-97ad-be1b3d98e6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_bb74e84c-de78-48d6-ab84-166b38af9664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b019aa7f-7892-414a-920c-5f6d0c354c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_bb74e84c-de78-48d6-ab84-166b38af9664" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b019aa7f-7892-414a-920c-5f6d0c354c26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3a7abb87-10c2-4861-af56-21837a9f8736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_bb74e84c-de78-48d6-ab84-166b38af9664" xlink:to="loc_us-gaap_InterestExpense_3a7abb87-10c2-4861-af56-21837a9f8736" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4b0b5b2-f9cf-4cc0-ba5a-b3f09fd7137d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4bf1aba5-56d1-4873-bed7-d85ee9a4312f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4b0b5b2-f9cf-4cc0-ba5a-b3f09fd7137d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_4bf1aba5-56d1-4873-bed7-d85ee9a4312f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_eb21d159-d3ab-4eeb-a540-1e6cb203c253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4b0b5b2-f9cf-4cc0-ba5a-b3f09fd7137d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_eb21d159-d3ab-4eeb-a540-1e6cb203c253" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersProvisionforTaxesonIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_99c05d06-eb94-4c01-8778-199e1ec9b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_22ada8e3-46d6-4ff1-ab52-26339fbab59b" xlink:href="pfe-20211231.xsd#pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_99c05d06-eb94-4c01-8778-199e1ec9b58a" xlink:to="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_22ada8e3-46d6-4ff1-ab52-26339fbab59b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_0e0d3c62-8f01-47a3-a6a6-90ce8827d46d" xlink:href="pfe-20211231.xsd#pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_99c05d06-eb94-4c01-8778-199e1ec9b58a" xlink:to="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_0e0d3c62-8f01-47a3-a6a6-90ce8827d46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_02c782a6-39c9-49c1-9926-0e9e1c4142f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_21bb18ec-6dd5-41de-8d23-c304dbc1e0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_02c782a6-39c9-49c1-9926-0e9e1c4142f1" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_21bb18ec-6dd5-41de-8d23-c304dbc1e0fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_6896ed97-5d89-428e-8b4d-8f2d6efaa7f7" xlink:href="pfe-20211231.xsd#pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_02c782a6-39c9-49c1-9926-0e9e1c4142f1" xlink:to="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_6896ed97-5d89-428e-8b4d-8f2d6efaa7f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_5587f97c-96e0-4899-bf05-ba233a39377a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_02c782a6-39c9-49c1-9926-0e9e1c4142f1" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_5587f97c-96e0-4899-bf05-ba233a39377a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_a3185be5-b182-4d44-93f3-48c2c04aab48" xlink:href="pfe-20211231.xsd#pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0fdf9947-8e46-4dc4-8f07-dce60d69be8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_a3185be5-b182-4d44-93f3-48c2c04aab48" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0fdf9947-8e46-4dc4-8f07-dce60d69be8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_005c7e1c-e184-4c38-93d3-32a1b345165c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_a3185be5-b182-4d44-93f3-48c2c04aab48" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_005c7e1c-e184-4c38-93d3-32a1b345165c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0d4b7ee3-0de1-4555-9b36-02b3f55d6f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_a3185be5-b182-4d44-93f3-48c2c04aab48" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0d4b7ee3-0de1-4555-9b36-02b3f55d6f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f3bb2df5-9c81-43c9-ab73-91ec1c01ea57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_a3185be5-b182-4d44-93f3-48c2c04aab48" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f3bb2df5-9c81-43c9-ab73-91ec1c01ea57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8771ef5a-403a-41b2-ad6b-8c6afd335ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e6d64d79-be52-4c19-bbc9-99e19033a0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8771ef5a-403a-41b2-ad6b-8c6afd335ec8" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_e6d64d79-be52-4c19-bbc9-99e19033a0ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1b2392aa-46ef-43fa-9952-10f27ee147dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8771ef5a-403a-41b2-ad6b-8c6afd335ec8" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_1b2392aa-46ef-43fa-9952-10f27ee147dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e82c6512-9704-42dc-aec5-6088224eb6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e82c6512-9704-42dc-aec5-6088224eb6b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_5778eaf8-1ea4-468c-82b6-d9c982b9f662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_5778eaf8-1ea4-468c-82b6-d9c982b9f662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4358e65f-2348-4254-9377-35057feafb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_4358e65f-2348-4254-9377-35057feafb0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_bb0f5a9b-3ff7-422d-9a38-7af43cc37ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_bb0f5a9b-3ff7-422d-9a38-7af43cc37ffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent_52122105-d2b2-477d-b8ac-58c0fca3b6b3" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent_52122105-d2b2-477d-b8ac-58c0fca3b6b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_d32f2cef-a3b1-4c77-8738-bfb762b95dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_d32f2cef-a3b1-4c77-8738-bfb762b95dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent_623f38c7-6173-448a-8f23-e9a9bdacb928" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent_623f38c7-6173-448a-8f23-e9a9bdacb928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9ad33e0f-268e-4752-b6c6-489bfcda2006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9ad33e0f-268e-4752-b6c6-489bfcda2006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_0b61d598-7c3d-4517-877a-fb1423fd15d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0d8b2be6-378d-4b11-b086-eb474e87d2f1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_0b61d598-7c3d-4517-877a-fb1423fd15d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1ca75268-c2f9-4e56-8215-98dc33df453f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_73621ebe-0b28-40dd-942b-60948da0fdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1ca75268-c2f9-4e56-8215-98dc33df453f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_73621ebe-0b28-40dd-942b-60948da0fdc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d4c12c63-ac0f-44c0-9d34-709cf0b10e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1ca75268-c2f9-4e56-8215-98dc33df453f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d4c12c63-ac0f-44c0-9d34-709cf0b10e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5cbaa62b-f47d-41ea-a337-ce6b33dfda79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_17a8bbaa-0e5c-48b3-982a-2731e347477f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5cbaa62b-f47d-41ea-a337-ce6b33dfda79" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_17a8bbaa-0e5c-48b3-982a-2731e347477f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_560a1ab2-2a57-4cb9-859f-3ed6be3f1a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5cbaa62b-f47d-41ea-a337-ce6b33dfda79" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_560a1ab2-2a57-4cb9-859f-3ed6be3f1a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_29714d48-6acf-4a91-8ff1-94639b5021b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_29714d48-6acf-4a91-8ff1-94639b5021b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_4e5bdc1b-ff46-424f-b9c7-d1c1800feb03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_4e5bdc1b-ff46-424f-b9c7-d1c1800feb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_423c146c-d7c7-4553-8d75-9677f56a030d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_423c146c-d7c7-4553-8d75-9677f56a030d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_870ce264-25cf-422f-b947-1dbbdde0b6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_870ce264-25cf-422f-b947-1dbbdde0b6b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_0ac34136-8e8f-41b1-a22e-6b1b2be5ab21" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_0ac34136-8e8f-41b1-a22e-6b1b2be5ab21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_20d8f5d3-1351-4e6e-9c84-c3809e9f1c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_20d8f5d3-1351-4e6e-9c84-c3809e9f1c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_8d72b160-6934-480c-a82a-a46545686ea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_8d72b160-6934-480c-a82a-a46545686ea2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_0ec4f573-395c-406c-90bf-c9f91f0d5f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_03c5def1-f800-4f44-aa13-0639e2f3c70a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_0ec4f573-395c-406c-90bf-c9f91f0d5f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_954c86bb-ca3b-4bf2-ad7c-828aa0f612f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9fd95d2f-6645-4efc-adb3-4cf9e9161501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_954c86bb-ca3b-4bf2-ad7c-828aa0f612f1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9fd95d2f-6645-4efc-adb3-4cf9e9161501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2b14c348-09fb-46ad-85f2-240b8b75d915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_954c86bb-ca3b-4bf2-ad7c-828aa0f612f1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2b14c348-09fb-46ad-85f2-240b8b75d915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_1a91f98a-4124-4a00-b43e-822e74590a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_1a91f98a-4124-4a00-b43e-822e74590a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_80e4f930-c858-40d1-883c-134bb0d586e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_80e4f930-c858-40d1-883c-134bb0d586e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_957f805d-0434-4046-8cee-29578c6094c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_957f805d-0434-4046-8cee-29578c6094c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_55f0b672-a34c-4e0c-94da-3d69f9e2fc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_55f0b672-a34c-4e0c-94da-3d69f9e2fc4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_d4e5bae0-92d5-4f5d-89e4-88fc4e9a8e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_d4e5bae0-92d5-4f5d-89e4-88fc4e9a8e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_65e4df6d-8d19-45c7-93e6-ed69d542ee58" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_65e4df6d-8d19-45c7-93e6-ed69d542ee58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_0a5d5141-50a7-456f-acdc-86c7323b73af" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_0a5d5141-50a7-456f-acdc-86c7323b73af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_b4dcd272-2315-4403-833c-4a3a1dd0f127" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_b4dcd272-2315-4403-833c-4a3a1dd0f127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f55b1033-eae4-48b0-a9a3-12376895aad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f55b1033-eae4-48b0-a9a3-12376895aad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_ba5afaeb-7489-4817-98ff-5b7c508a971c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_ba5afaeb-7489-4817-98ff-5b7c508a971c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_39c77230-acca-4f7d-ba74-d0c889a44579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_85d30d2a-fd13-4c45-926d-63cfcdc99076" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_39c77230-acca-4f7d-ba74-d0c889a44579" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_40e1e1b3-7c1d-49dd-b296-505b57240bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_31ae3187-073a-4e53-8114-ca9ded52b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_40e1e1b3-7c1d-49dd-b296-505b57240bc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_31ae3187-073a-4e53-8114-ca9ded52b4f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ee857179-1c30-43fa-a4ab-d95a5a6248f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_40e1e1b3-7c1d-49dd-b296-505b57240bc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ee857179-1c30-43fa-a4ab-d95a5a6248f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_ebee0fbe-88c2-42f1-a26f-016c3cc4b52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_40e1e1b3-7c1d-49dd-b296-505b57240bc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_ebee0fbe-88c2-42f1-a26f-016c3cc4b52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_922735e1-d83c-4e54-ba9b-a2fd0ba17bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_40e1e1b3-7c1d-49dd-b296-505b57240bc1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_922735e1-d83c-4e54-ba9b-a2fd0ba17bf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_a089d480-de96-42a8-b7f0-a9c41a27864d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_04a791b9-e84f-409d-bc28-883cf0747cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_a089d480-de96-42a8-b7f0-a9c41a27864d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_04a791b9-e84f-409d-bc28-883cf0747cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_dedc7c39-d745-4308-b524-0a12c1d0c889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_a089d480-de96-42a8-b7f0-a9c41a27864d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_dedc7c39-d745-4308-b524-0a12c1d0c889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_95754b5a-9066-4a6f-8290-c4957fa92967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_63daf762-03f0-4784-8c31-85b3cb1cdda7" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_95754b5a-9066-4a6f-8290-c4957fa92967" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_63daf762-03f0-4784-8c31-85b3cb1cdda7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_5ad81d09-0447-4b67-9660-f1c6ebcfa585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_95754b5a-9066-4a6f-8290-c4957fa92967" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_5ad81d09-0447-4b67-9660-f1c6ebcfa585" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_6dccf7f5-4917-41a6-be3a-cb2f25b0d7d8" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_95754b5a-9066-4a6f-8290-c4957fa92967" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_6dccf7f5-4917-41a6-be3a-cb2f25b0d7d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1c562e39-1111-4541-9ace-57310618979a" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_95754b5a-9066-4a6f-8290-c4957fa92967" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1c562e39-1111-4541-9ace-57310618979a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ad2bf96d-fe0c-4723-b354-ef87d51d469b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_86f7efa4-66ee-457a-8edc-cbecaa36ded3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ad2bf96d-fe0c-4723-b354-ef87d51d469b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_86f7efa4-66ee-457a-8edc-cbecaa36ded3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_d38ffb8a-a087-4eb7-9228-c2cee554d2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_ad2bf96d-fe0c-4723-b354-ef87d51d469b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_d38ffb8a-a087-4eb7-9228-c2cee554d2a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_5de519a1-1560-45fd-8c3a-0bb99a525181" xlink:href="pfe-20211231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f0af1a50-d138-4f7d-861a-0ff3ab79056b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_5de519a1-1560-45fd-8c3a-0bb99a525181" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f0af1a50-d138-4f7d-861a-0ff3ab79056b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_db4d6b2d-3e4b-4004-b899-ce8e4992f059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_5de519a1-1560-45fd-8c3a-0bb99a525181" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_db4d6b2d-3e4b-4004-b899-ce8e4992f059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_4161451e-dc79-4f92-85cb-f86582f5e468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_a33b618e-374c-4e35-99e4-b590fbcb6721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_4161451e-dc79-4f92-85cb-f86582f5e468" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_a33b618e-374c-4e35-99e4-b590fbcb6721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_95e53f4f-48a4-4ecf-8a1c-423e341b0166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_4161451e-dc79-4f92-85cb-f86582f5e468" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_95e53f4f-48a4-4ecf-8a1c-423e341b0166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_7e873365-5d19-441e-9e1e-e070d2637496" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e1cdbbec-b130-4813-a327-2516cb82a27c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_7e873365-5d19-441e-9e1e-e070d2637496" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e1cdbbec-b130-4813-a327-2516cb82a27c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6ae2e8dd-8125-482e-852e-3570b2d6ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_7e873365-5d19-441e-9e1e-e070d2637496" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6ae2e8dd-8125-482e-852e-3570b2d6ef6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f7dbcb3c-7171-4108-af4c-3d37d0291655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_1b2a99aa-3577-49e8-ab64-c9fe6bec9931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f7dbcb3c-7171-4108-af4c-3d37d0291655" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_1b2a99aa-3577-49e8-ab64-c9fe6bec9931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_6aef86ad-80e7-49bf-91b1-9e1cb2b4d4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_f7dbcb3c-7171-4108-af4c-3d37d0291655" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_6aef86ad-80e7-49bf-91b1-9e1cb2b4d4c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_fcc9abb2-4606-4084-a5a4-0a22ab426803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_7bb1a164-8fd2-4477-87e4-dc208eea60c1" xlink:href="pfe-20211231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fcc9abb2-4606-4084-a5a4-0a22ab426803" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_7bb1a164-8fd2-4477-87e4-dc208eea60c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_79ad787d-066a-4688-ba06-367c7ebf7038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fcc9abb2-4606-4084-a5a4-0a22ab426803" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_79ad787d-066a-4688-ba06-367c7ebf7038" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_c4b6865f-cc0f-47f8-9712-8f8b825ba25e" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fcc9abb2-4606-4084-a5a4-0a22ab426803" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_c4b6865f-cc0f-47f8-9712-8f8b825ba25e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_13e68a31-e1fd-4853-817f-db412ea0151a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_fcc9abb2-4606-4084-a5a4-0a22ab426803" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_13e68a31-e1fd-4853-817f-db412ea0151a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_0d9b7411-5751-45ae-beda-8d4fa0c5cbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e71f86e7-5e2d-4f71-8ec7-c058a7668f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_0d9b7411-5751-45ae-beda-8d4fa0c5cbf6" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e71f86e7-5e2d-4f71-8ec7-c058a7668f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1900ca4f-2fb3-4bb2-b13d-2a67cb1ea7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_0d9b7411-5751-45ae-beda-8d4fa0c5cbf6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1900ca4f-2fb3-4bb2-b13d-2a67cb1ea7a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_f27a1820-87f7-4fdd-863e-1ff6768b207d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_0d9b7411-5751-45ae-beda-8d4fa0c5cbf6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_f27a1820-87f7-4fdd-863e-1ff6768b207d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments_c4194d1e-bce5-489b-a5b1-4f53fb4e74d5" xlink:href="pfe-20211231.xsd#pfe_PrivateEquityInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLongTermInvestments_0d9b7411-5751-45ae-beda-8d4fa0c5cbf6" xlink:to="loc_pfe_PrivateEquityInvestments_c4194d1e-bce5-489b-a5b1-4f53fb4e74d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_f46a2a52-a07b-4392-ae2b-8ecd30f4121b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_5399be0b-588c-4c3b-b844-b17224534450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_f46a2a52-a07b-4392-ae2b-8ecd30f4121b" xlink:to="loc_us-gaap_OtherLongTermInvestments_5399be0b-588c-4c3b-b844-b17224534450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_38b1ab5f-a889-4be5-afd0-bd6c760c58ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_f46a2a52-a07b-4392-ae2b-8ecd30f4121b" xlink:to="loc_us-gaap_EquityMethodInvestments_38b1ab5f-a889-4be5-afd0-bd6c760c58ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_82185045-e604-4518-8e01-595d62940752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_beab8612-a6e3-4cc9-a2b1-e7026440c134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherShortTermInvestments_82185045-e604-4518-8e01-595d62940752" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_beab8612-a6e3-4cc9-a2b1-e7026440c134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e440b3b7-93ce-442f-9b89-c3bc51e0da78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherShortTermInvestments_82185045-e604-4518-8e01-595d62940752" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e440b3b7-93ce-442f-9b89-c3bc51e0da78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_6ba8e6b1-d6f9-4128-8e14-e27406263ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherShortTermInvestments_82185045-e604-4518-8e01-595d62940752" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_6ba8e6b1-d6f9-4128-8e14-e27406263ed6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsDebtSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_4850d5fc-2695-4237-9674-8b4d7562b032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_6dc63120-60f1-4d39-ba50-cb6b4625a99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_4850d5fc-2695-4237-9674-8b4d7562b032" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_6dc63120-60f1-4d39-ba50-cb6b4625a99d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7d50a8cf-6ee4-42bf-b3c4-581b0c74946c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_4850d5fc-2695-4237-9674-8b4d7562b032" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7d50a8cf-6ee4-42bf-b3c4-581b0c74946c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_6ccec245-53c3-4d80-a04b-09d779595b79" xlink:href="pfe-20211231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_4850d5fc-2695-4237-9674-8b4d7562b032" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_6ccec245-53c3-4d80-a04b-09d779595b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_4514ba2a-42ba-4569-8e3b-2ffc41fed7d1" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_0278e071-c5f5-447b-bd98-3a60a5624e66" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_4514ba2a-42ba-4569-8e3b-2ffc41fed7d1" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_0278e071-c5f5-447b-bd98-3a60a5624e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_559db87c-9ceb-42e9-aa0d-00195a7553f3" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_4514ba2a-42ba-4569-8e3b-2ffc41fed7d1" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_559db87c-9ceb-42e9-aa0d-00195a7553f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_caf003c2-13b8-4f7a-bfd1-84755eb5180c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_4514ba2a-42ba-4569-8e3b-2ffc41fed7d1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_caf003c2-13b8-4f7a-bfd1-84755eb5180c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76fdf60e-c9f1-4354-9d48-a2f2cf3f42e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cfa692fa-4b51-4274-87fe-b609df841bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76fdf60e-c9f1-4354-9d48-a2f2cf3f42e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_cfa692fa-4b51-4274-87fe-b609df841bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_13333a7e-7380-4556-b53c-791915047cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76fdf60e-c9f1-4354-9d48-a2f2cf3f42e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_13333a7e-7380-4556-b53c-791915047cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_4cb597d7-2806-4346-be34-8761386a7c6b" xlink:href="pfe-20211231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76fdf60e-c9f1-4354-9d48-a2f2cf3f42e8" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_4cb597d7-2806-4346-be34-8761386a7c6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f4d75a-bf7f-4ecd-abb5-976ce8af6d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2609a94c-8489-4b22-8273-ae61bc64bc10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f4d75a-bf7f-4ecd-abb5-976ce8af6d7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2609a94c-8489-4b22-8273-ae61bc64bc10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f69606d-dddb-425f-abd7-bd76cf5e1183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f4d75a-bf7f-4ecd-abb5-976ce8af6d7a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6f69606d-dddb-425f-abd7-bd76cf5e1183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d107bb33-634e-4181-b3fd-1fc57df0c6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f3f4d75a-bf7f-4ecd-abb5-976ce8af6d7a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d107bb33-634e-4181-b3fd-1fc57df0c6f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_5185409b-7003-45ab-906b-868c12f4dd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_c1c0ac04-39ec-449e-92cc-e5dbff9f1139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_5185409b-7003-45ab-906b-868c12f4dd7e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_c1c0ac04-39ec-449e-92cc-e5dbff9f1139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e3b062c1-5578-4e08-a77b-27cd68533163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_5185409b-7003-45ab-906b-868c12f4dd7e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e3b062c1-5578-4e08-a77b-27cd68533163" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsShortTermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_8eeac845-3397-4fc7-bbf3-5a21d039475b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_001359a8-961e-4952-a308-14516bcbd041" xlink:href="pfe-20211231.xsd#pfe_ShorttermDebtGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_8eeac845-3397-4fc7-bbf3-5a21d039475b" xlink:to="loc_pfe_ShorttermDebtGross_001359a8-961e-4952-a308-14516bcbd041" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b25fdd21-c52b-4730-aa17-d9338c550d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_8eeac845-3397-4fc7-bbf3-5a21d039475b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b25fdd21-c52b-4730-aa17-d9338c550d0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_eeddbcbb-c162-4c18-944d-c8d9dd175365" xlink:href="pfe-20211231.xsd#pfe_ShorttermDebtGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_b9002dd0-8eb6-463d-9c0a-526fe87fffcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_eeddbcbb-c162-4c18-944d-c8d9dd175365" xlink:to="loc_us-gaap_CommercialPaper_b9002dd0-8eb6-463d-9c0a-526fe87fffcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0a1ff288-8687-46c0-a8e4-35084b2ef801" xlink:href="pfe-20211231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_eeddbcbb-c162-4c18-944d-c8d9dd175365" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0a1ff288-8687-46c0-a8e4-35084b2ef801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_4fc958b1-7709-44a0-bd36-f6571f9381b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_eeddbcbb-c162-4c18-944d-c8d9dd175365" xlink:to="loc_us-gaap_OtherShortTermBorrowings_4fc958b1-7709-44a0-bd36-f6571f9381b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0f302136-349e-40e1-bca9-38f2ca60bb48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_3675f217-13a8-456b-b1bd-8728834a1b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_0f302136-349e-40e1-bca9-38f2ca60bb48" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_3675f217-13a8-456b-b1bd-8728834a1b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_eb134997-7c43-439a-936e-11c36a74978d" xlink:href="pfe-20211231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_0f302136-349e-40e1-bca9-38f2ca60bb48" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_eb134997-7c43-439a-936e-11c36a74978d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d68679b5-c2ac-4b54-9bf0-cfc9299d93fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_0f302136-349e-40e1-bca9-38f2ca60bb48" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d68679b5-c2ac-4b54-9bf0-cfc9299d93fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_46629504-9459-4dec-a226-af67af31845a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_0f302136-349e-40e1-bca9-38f2ca60bb48" xlink:to="loc_us-gaap_OtherLongTermDebt_46629504-9459-4dec-a226-af67af31845a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_176560bc-7af7-4a56-af46-5734080fae3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_87191e00-3d39-40fb-be6a-3471c71abdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_176560bc-7af7-4a56-af46-5734080fae3c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_87191e00-3d39-40fb-be6a-3471c71abdfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_914e7874-b3e4-4dc1-a3ce-b83093b544d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_176560bc-7af7-4a56-af46-5734080fae3c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_914e7874-b3e4-4dc1-a3ce-b83093b544d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_755a4be9-01d8-4f02-84a0-2886e5a665f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_176560bc-7af7-4a56-af46-5734080fae3c" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_755a4be9-01d8-4f02-84a0-2886e5a665f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_585ad208-bc3b-47ea-b11f-ab4d9bd36054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fa94fffa-89cd-471c-91eb-8af4a6d892a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_585ad208-bc3b-47ea-b11f-ab4d9bd36054" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fa94fffa-89cd-471c-91eb-8af4a6d892a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d0024771-7b89-400c-be4f-0c4f3bbc4ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_585ad208-bc3b-47ea-b11f-ab4d9bd36054" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d0024771-7b89-400c-be4f-0c4f3bbc4ead" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d189f9d1-4fb1-476e-b64b-602d7c8a89f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ed92257f-074c-4bdf-87b9-bea19bd54f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d189f9d1-4fb1-476e-b64b-602d7c8a89f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ed92257f-074c-4bdf-87b9-bea19bd54f20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c7513406-bfc1-42a6-8f99-b26b3bc33fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d189f9d1-4fb1-476e-b64b-602d7c8a89f2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c7513406-bfc1-42a6-8f99-b26b3bc33fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_682aa76c-55bb-48e0-8662-c7abe310037c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_984e40e8-3129-4356-a318-d50b4522a098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_682aa76c-55bb-48e0-8662-c7abe310037c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_984e40e8-3129-4356-a318-d50b4522a098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_755f7b92-2d6f-4d1f-b133-1b7004ca83a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_682aa76c-55bb-48e0-8662-c7abe310037c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_755f7b92-2d6f-4d1f-b133-1b7004ca83a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_156a59e0-8345-4e0b-b1e7-6f2d21af01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4091b4c5-35b4-4409-a870-43cae7f31e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_156a59e0-8345-4e0b-b1e7-6f2d21af01e2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4091b4c5-35b4-4409-a870-43cae7f31e54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_923060e0-9202-4c8f-bc68-81aafaeb988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_156a59e0-8345-4e0b-b1e7-6f2d21af01e2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_923060e0-9202-4c8f-bc68-81aafaeb988a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_8ebb367a-fbae-400a-b2b5-b117466e2117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_8ebb367a-fbae-400a-b2b5-b117466e2117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f0cda40f-8277-4bf4-9e29-53993a289dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f0cda40f-8277-4bf4-9e29-53993a289dea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_b347dfe7-a970-4e53-9379-49c66096a33b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_b347dfe7-a970-4e53-9379-49c66096a33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_cc5b16db-a962-438b-ac3d-f6aef4677494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_cc5b16db-a962-438b-ac3d-f6aef4677494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_2715069a-0c6c-4b09-a48f-67245c0658f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_2715069a-0c6c-4b09-a48f-67245c0658f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ecdd8d4c-e0e6-47af-9b1a-f8ec4e960d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_ecdd8d4c-e0e6-47af-9b1a-f8ec4e960d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_9ace4712-487c-49a3-9f05-f804af5e7091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_edaa447f-06e0-4a36-9247-55c46d374b87" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_9ace4712-487c-49a3-9f05-f804af5e7091" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_64e8977a-342a-41c7-9720-98f489305464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9b319e8b-d82a-48a9-9b5c-b5fa4f6ce1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_64e8977a-342a-41c7-9720-98f489305464" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9b319e8b-d82a-48a9-9b5c-b5fa4f6ce1b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_e3f11a49-adce-40a6-a364-333482be2dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_64e8977a-342a-41c7-9720-98f489305464" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_e3f11a49-adce-40a6-a364-333482be2dab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7d58f94a-5cb6-40cd-9735-9753c4a01fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_873b7ecb-3742-48b1-a2a5-279af5e7e7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7d58f94a-5cb6-40cd-9735-9753c4a01fe5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_873b7ecb-3742-48b1-a2a5-279af5e7e7ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bd034411-c836-4abf-b564-62b0f8809328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7d58f94a-5cb6-40cd-9735-9753c4a01fe5" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bd034411-c836-4abf-b564-62b0f8809328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0ae87969-66e3-4a64-ac83-874123329354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7d58f94a-5cb6-40cd-9735-9753c4a01fe5" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_0ae87969-66e3-4a64-ac83-874123329354" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_f4188496-2fe0-45a3-a473-dbfa2d766bd5" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_be8fa170-e9d8-4359-85b4-6691596a9dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_f4188496-2fe0-45a3-a473-dbfa2d766bd5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_be8fa170-e9d8-4359-85b4-6691596a9dfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_70e96dcc-c05b-4660-b1fe-bacffa34c12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_f4188496-2fe0-45a3-a473-dbfa2d766bd5" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_70e96dcc-c05b-4660-b1fe-bacffa34c12d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d3ebd18-02eb-4e05-ab19-4902d8a06af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87467f1a-a91a-4f4d-8d21-176aa69a39ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d3ebd18-02eb-4e05-ab19-4902d8a06af6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_87467f1a-a91a-4f4d-8d21-176aa69a39ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_c69c5abf-4973-4f1a-b477-140bc31272e8" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d3ebd18-02eb-4e05-ab19-4902d8a06af6" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_c69c5abf-4973-4f1a-b477-140bc31272e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e685f3d4-ca46-4485-8164-d16392fbaa16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8aad4ea5-c64c-4766-9a4e-0772f2ae8c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e685f3d4-ca46-4485-8164-d16392fbaa16" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8aad4ea5-c64c-4766-9a4e-0772f2ae8c5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_4f7d92e7-8327-4c4b-b428-9e7638b2c2da" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e685f3d4-ca46-4485-8164-d16392fbaa16" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_4f7d92e7-8327-4c4b-b428-9e7638b2c2da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9f5a1ce-4573-41c4-ae98-72bd64c494c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2da65aa-f987-4898-9b03-19335cb4d530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9f5a1ce-4573-41c4-ae98-72bd64c494c9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2da65aa-f987-4898-9b03-19335cb4d530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c415ec87-60c1-47e1-99ef-d21444f012d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9f5a1ce-4573-41c4-ae98-72bd64c494c9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c415ec87-60c1-47e1-99ef-d21444f012d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b7ea42fc-433e-41e1-8333-ceafb7d091c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_46132898-dcbc-4d33-9f4a-94ab0e81899c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b7ea42fc-433e-41e1-8333-ceafb7d091c2" xlink:to="loc_us-gaap_SubleaseIncome_46132898-dcbc-4d33-9f4a-94ab0e81899c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d4735a00-2dd3-4daf-98cc-4d8f5a213c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b7ea42fc-433e-41e1-8333-ceafb7d091c2" xlink:to="loc_us-gaap_OperatingLeaseCost_d4735a00-2dd3-4daf-98cc-4d8f5a213c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e8a5d31a-5b9b-4ce9-935a-b360e6ede85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b7ea42fc-433e-41e1-8333-ceafb7d091c2" xlink:to="loc_us-gaap_VariableLeaseCost_e8a5d31a-5b9b-4ce9-935a-b360e6ede85d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b10ed010-b1e3-47db-9d1f-bfd06dc20af9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f6778feb-0c4e-498c-b5ce-ce1ae2ab5c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b10ed010-b1e3-47db-9d1f-bfd06dc20af9" xlink:to="loc_us-gaap_OperatingLeaseLiability_f6778feb-0c4e-498c-b5ce-ce1ae2ab5c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bfa63e4b-64ab-4a11-8b16-4727a33471d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b10ed010-b1e3-47db-9d1f-bfd06dc20af9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bfa63e4b-64ab-4a11-8b16-4727a33471d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e466a27d-b8ee-460b-adae-f424b697ffea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b21dc35-c26d-4aa3-8a7b-9cf2c770ba79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e466a27d-b8ee-460b-adae-f424b697ffea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b21dc35-c26d-4aa3-8a7b-9cf2c770ba79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c4454de-b9ca-45d1-8c2a-f788264225e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_e466a27d-b8ee-460b-adae-f424b697ffea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c4454de-b9ca-45d1-8c2a-f788264225e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1"/>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc3e54be-71aa-4b4a-8b61-006f5d99e80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_240da603-bc94-4d0c-b623-b1336fe23d64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc3e54be-71aa-4b4a-8b61-006f5d99e80e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_240da603-bc94-4d0c-b623-b1336fe23d64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_69e51c83-d179-4721-82ca-44111134729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc3e54be-71aa-4b4a-8b61-006f5d99e80e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_69e51c83-d179-4721-82ca-44111134729f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_69debe25-7fce-4729-81c0-c9c946baa2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc3e54be-71aa-4b4a-8b61-006f5d99e80e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_69debe25-7fce-4729-81c0-c9c946baa2d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_ceb99794-dd4f-4cc3-b526-4b915b65e8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc3e54be-71aa-4b4a-8b61-006f5d99e80e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_ceb99794-dd4f-4cc3-b526-4b915b65e8ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_c5552460-cf8e-4fac-8f4a-ff68fa9aaa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc3e54be-71aa-4b4a-8b61-006f5d99e80e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_c5552460-cf8e-4fac-8f4a-ff68fa9aaa4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_ecc938bf-07cd-4203-8a7e-60450223b3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc3e54be-71aa-4b4a-8b61-006f5d99e80e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_ecc938bf-07cd-4203-8a7e-60450223b3b4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>pfe-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ad91efd1-2241-49cf-a17f-7cbe86f9ba4a,g:feca3a10-f613-46f2-b813-b8f4d7d48955-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20211231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended" id="ibf699b28a04549128609a87e7a231d45_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1291cd99-dfc0-4de9-a33e-9faece9c6465" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentType_1291cd99-dfc0-4de9-a33e-9faece9c6465" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3dcf012b-22f7-43e5-8294-df288921e6ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentAnnualReport_3dcf012b-22f7-43e5-8294-df288921e6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f96cbfe9-1c67-4832-af92-94b9391980da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentPeriodEndDate_f96cbfe9-1c67-4832-af92-94b9391980da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dd3cd6c0-271b-446c-87db-f503a95bfe8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_CurrentFiscalYearEndDate_dd3cd6c0-271b-446c-87db-f503a95bfe8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b88be423-0369-4b51-8a93-4374426b251c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentTransitionReport_b88be423-0369-4b51-8a93-4374426b251c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3e7c1922-3f8e-4a62-8f63-5889e299bf35" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityFileNumber_3e7c1922-3f8e-4a62-8f63-5889e299bf35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0e7502c3-efe0-4ac0-949f-cbce97a65302" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityRegistrantName_0e7502c3-efe0-4ac0-949f-cbce97a65302" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_364420a4-e7b8-4a61-a05a-e91bd1f1d55f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_364420a4-e7b8-4a61-a05a-e91bd1f1d55f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_79ae18a5-2a12-426b-9816-ff1cc4c50d93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityTaxIdentificationNumber_79ae18a5-2a12-426b-9816-ff1cc4c50d93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3f5bc0e7-6c28-42a4-a0b6-9f0d29d8add8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressAddressLine1_3f5bc0e7-6c28-42a4-a0b6-9f0d29d8add8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8393a282-f9ee-46b3-a05e-2ece59474c93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressCityOrTown_8393a282-f9ee-46b3-a05e-2ece59474c93" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_630c29b0-165f-4ce9-afe1-aef95fdccb8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressStateOrProvince_630c29b0-165f-4ce9-afe1-aef95fdccb8e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e5e2d110-6265-4b66-bdef-a2cb85ab2eb0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressPostalZipCode_e5e2d110-6265-4b66-bdef-a2cb85ab2eb0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_76c1ffe9-00e9-4f74-ba32-a93b5ef74bd7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_CityAreaCode_76c1ffe9-00e9-4f74-ba32-a93b5ef74bd7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a5c6af46-46dc-488a-a38b-f4be8aa873c1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_LocalPhoneNumber_a5c6af46-46dc-488a-a38b-f4be8aa873c1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_de66f243-0d20-4910-9fef-c6b3acf25daf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_Security12bTitle_de66f243-0d20-4910-9fef-c6b3acf25daf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3f1b7472-c860-4201-99c6-5a4b4230e835" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_TradingSymbol_3f1b7472-c860-4201-99c6-5a4b4230e835" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_75b1abe7-bd6c-4873-ace9-3e522a35ccfb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_SecurityExchangeName_75b1abe7-bd6c-4873-ace9-3e522a35ccfb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b2e16696-a095-4f87-8900-bc8c4fae358f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b2e16696-a095-4f87-8900-bc8c4fae358f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c3af93da-ea75-4319-8c23-6357da807c2a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityVoluntaryFilers_c3af93da-ea75-4319-8c23-6357da807c2a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9cbf882d-89b0-4d82-a0e7-5fecfe6674e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityCurrentReportingStatus_9cbf882d-89b0-4d82-a0e7-5fecfe6674e1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2eee3b98-4025-4a50-bbe6-54522c0966a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityInteractiveDataCurrent_2eee3b98-4025-4a50-bbe6-54522c0966a7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dc291f06-c103-48ac-b600-6f01f7b558a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityFilerCategory_dc291f06-c103-48ac-b600-6f01f7b558a3" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e602bbe1-f5d8-4a60-9bcb-8bdaf84285f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntitySmallBusiness_e602bbe1-f5d8-4a60-9bcb-8bdaf84285f5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cd813f51-4150-40ed-8c9d-a222cb2e87af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityEmergingGrowthCompany_cd813f51-4150-40ed-8c9d-a222cb2e87af" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9014d4eb-185a-4570-9243-b58baa56f960" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9014d4eb-185a-4570-9243-b58baa56f960" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b4da111e-7ca5-4998-a5bf-bed15b0b046c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityShellCompany_b4da111e-7ca5-4998-a5bf-bed15b0b046c" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7202c1f9-b506-4793-8634-5c4a4c0094b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityPublicFloat_7202c1f9-b506-4793-8634-5c4a4c0094b5" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_38b784de-9066-47c7-9a01-af3ce06e9b05" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_38b784de-9066-47c7-9a01-af3ce06e9b05" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ab7bb1cd-99d9-4c80-a0d7-31939ec8018b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityCentralIndexKey_ab7bb1cd-99d9-4c80-a0d7-31939ec8018b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_76d5daab-865c-4a4d-9035-39b34a0400ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentFiscalYearFocus_76d5daab-865c-4a4d-9035-39b34a0400ac" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2efdc7f3-d18e-4a6b-83a2-51feb2d3c9f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2efdc7f3-d18e-4a6b-83a2-51feb2d3c9f6" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_508ef0d2-4cfc-4360-ad2a-4dcd814821c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_AmendmentFlag_508ef0d2-4cfc-4360-ad2a-4dcd814821c0" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_19da37b7-3df5-4f1a-981d-e62440129c7e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_19da37b7-3df5-4f1a-981d-e62440129c7e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_49df7ea4-e8e1-4112-8b3d-0cfe8241be80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntitiesTable_49df7ea4-e8e1-4112-8b3d-0cfe8241be80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c0be931b-fd31-4e54-8a4d-604431a3bd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_49df7ea4-e8e1-4112-8b3d-0cfe8241be80" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c0be931b-fd31-4e54-8a4d-604431a3bd6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c0be931b-fd31-4e54-8a4d-604431a3bd6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c0be931b-fd31-4e54-8a4d-604431a3bd6f" xlink:to="loc_us-gaap_ClassOfStockDomain_c0be931b-fd31-4e54-8a4d-604431a3bd6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c0be931b-fd31-4e54-8a4d-604431a3bd6f" xlink:to="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e06232f7-7dd5-4402-a3e7-b4a2cbaa92a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:to="loc_us-gaap_CommonStockMember_e06232f7-7dd5-4402-a3e7-b4a2cbaa92a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20220.250Member_40207e4a-496b-4d02-8021-a1a5b5adb53f" xlink:href="pfe-20211231.xsd#pfe_NotesDue20220.250Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:to="loc_pfe_NotesDue20220.250Member_40207e4a-496b-4d02-8021-a1a5b5adb53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_3f39ed15-e60c-4f78-a16f-63c23f1b2254" xlink:href="pfe-20211231.xsd#pfe_NotesDue20271.000Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:to="loc_pfe_NotesDue20271.000Member_3f39ed15-e60c-4f78-a16f-63c23f1b2254" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="idd50c1e255654011b177907ba4352967_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_255f6d1e-a7e4-4ed9-80a7-789e41aab548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_255f6d1e-a7e4-4ed9-80a7-789e41aab548" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1b24ed92-ba79-44cc-a4f3-99068b332c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_SharesIssued_1b24ed92-ba79-44cc-a4f3-99068b332c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53fa248c-151f-4dd3-b7ea-cc867c9f8981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53fa248c-151f-4dd3-b7ea-cc867c9f8981" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e63751f-3d33-4d83-84a2-612828fa337e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_ProfitLoss_7e63751f-3d33-4d83-84a2-612828fa337e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ac642bf-0445-4e50-b068-df103f3e4cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ac642bf-0445-4e50-b068-df103f3e4cdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_c0ca481f-b45f-4c10-8b65-97261adc9751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:to="loc_us-gaap_DividendsCommonStockCash_c0ca481f-b45f-4c10-8b65-97261adc9751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_9cbfbf71-442e-4388-9ceb-89a4cf7232d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:to="loc_us-gaap_DividendsPreferredStockCash_9cbfbf71-442e-4388-9ceb-89a4cf7232d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_98e047b9-5cc3-4ea2-bf6f-986a28900fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_98e047b9-5cc3-4ea2-bf6f-986a28900fea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f61dcd57-b947-49b3-ac74-9c1d658c2613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f61dcd57-b947-49b3-ac74-9c1d658c2613" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f921f03c-3e91-40bc-8657-f817673a5300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f921f03c-3e91-40bc-8657-f817673a5300" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a0b23ec7-b5bc-4f70-b3f1-39d0e8d70d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a0b23ec7-b5bc-4f70-b3f1-39d0e8d70d32" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8f3cca7a-ec24-4876-98a1-7ccc28421811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8f3cca7a-ec24-4876-98a1-7ccc28421811" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_039f5201-7504-4e2b-a280-a3192461507b" xlink:href="pfe-20211231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_039f5201-7504-4e2b-a280-a3192461507b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_88a5a51f-1edf-45d3-bb9a-2ffe0aa0beed" xlink:href="pfe-20211231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_88a5a51f-1edf-45d3-bb9a-2ffe0aa0beed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a44682e4-cb87-4e3e-812f-7f6832825348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a44682e4-cb87-4e3e-812f-7f6832825348" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_38c4928b-2df0-4c92-a6de-e82080ebbf42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockholdersEquityOther_38c4928b-2df0-4c92-a6de-e82080ebbf42" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b354eedb-a405-4fcc-a470-901a1f13afa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c820b074-9d25-4d84-94d8-17bad043b489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7694b10-de56-40ad-8d07-0cb3712a4219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_255f6d1e-a7e4-4ed9-80a7-789e41aab548" xlink:to="loc_us-gaap_StatementTable_a7694b10-de56-40ad-8d07-0cb3712a4219" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68dfb6d4-62e6-43d5-be27-926bae0c53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a7694b10-de56-40ad-8d07-0cb3712a4219" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68dfb6d4-62e6-43d5-be27-926bae0c53f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_68dfb6d4-62e6-43d5-be27-926bae0c53f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68dfb6d4-62e6-43d5-be27-926bae0c53f9" xlink:to="loc_us-gaap_EquityComponentDomain_68dfb6d4-62e6-43d5-be27-926bae0c53f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68dfb6d4-62e6-43d5-be27-926bae0c53f9" xlink:to="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:to="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_74c2db50-7c50-4ae4-8eed-7f22bad1ec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_PreferredStockMember_74c2db50-7c50-4ae4-8eed-7f22bad1ec3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a1032562-f488-40b4-9571-d3477791b691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_CommonStockMember_a1032562-f488-40b4-9571-d3477791b691" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fcbfb7f5-2c16-47d6-8c6a-49fc207d5744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fcbfb7f5-2c16-47d6-8c6a-49fc207d5744" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_24abc618-c33a-4a96-88b3-a847b2980bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_TreasuryStockMember_24abc618-c33a-4a96-88b3-a847b2980bdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9459ef4a-2cc3-4b59-8961-2fc01bc6d73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_RetainedEarningsMember_9459ef4a-2cc3-4b59-8961-2fc01bc6d73d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_38ab94d4-c0ca-4b62-82b8-45dfc71d31da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_38ab94d4-c0ca-4b62-82b8-45dfc71d31da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d6d2711f-6511-43aa-8485-2ed45d9cbc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d6d2711f-6511-43aa-8485-2ed45d9cbc36" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="ic27501829cda42ee9345da59d3d7aa3d_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ea1516c7-4289-42ba-9d57-ac91a74ec61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_ProfitLoss_ea1516c7-4289-42ba-9d57-ac91a74ec61f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e15b5bc5-701d-4363-9b90-2a94b29f086c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e15b5bc5-701d-4363-9b90-2a94b29f086c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8afbdb19-7426-4565-b986-e45c75b05d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8afbdb19-7426-4565-b986-e45c75b05d89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_22ad97a4-8642-4ea8-a516-b6b965cca7f5" xlink:href="pfe-20211231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_22ad97a4-8642-4ea8-a516-b6b965cca7f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_ce75941b-60d7-40ca-8c55-db1d715af1f8" xlink:href="pfe-20211231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_ce75941b-60d7-40ca-8c55-db1d715af1f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_b9142b63-102f-4f1d-b29d-30d4445c2ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_b9142b63-102f-4f1d-b29d-30d4445c2ca9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_bbc2df25-bbf3-46ea-a74b-6e0464b56419" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_bbc2df25-bbf3-46ea-a74b-6e0464b56419" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06f51ca0-f25d-4496-9022-3ff1642fa751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06f51ca0-f25d-4496-9022-3ff1642fa751" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f29770ce-9e76-4736-84df-df819066cbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_ShareBasedCompensation_f29770ce-9e76-4736-84df-df819066cbf8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_ee35acc0-8409-46cb-a75c-2ffad7fc73c4" xlink:href="pfe-20211231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_ee35acc0-8409-46cb-a75c-2ffad7fc73c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fa065ea6-66f7-4066-bc04-c97cb65b5a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fa065ea6-66f7-4066-bc04-c97cb65b5a9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c77e98b4-e32e-4e0e-8e77-8599c2d683c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c77e98b4-e32e-4e0e-8e77-8599c2d683c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9c564473-404d-4c83-9687-dc3a02fe8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9c564473-404d-4c83-9687-dc3a02fe8fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3c388244-e674-4c19-989b-1bc0dde8570c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3c388244-e674-4c19-989b-1bc0dde8570c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_00a74f36-c25d-4ec2-8fa9-28b478361bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_00a74f36-c25d-4ec2-8fa9-28b478361bc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a2663d3d-d9a5-4564-81d8-695e2b867731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a2663d3d-d9a5-4564-81d8-695e2b867731" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_dfbcab28-23b8-451a-890e-7ffa8b142477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_dfbcab28-23b8-451a-890e-7ffa8b142477" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bf2e65f-b116-42c1-8ed7-5e60a321c777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bf2e65f-b116-42c1-8ed7-5e60a321c777" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_224ddb64-caf3-4a7b-baea-07cdc1198a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_224ddb64-caf3-4a7b-baea-07cdc1198a2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754978af-d795-4aa5-bcf0-453d70732cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754978af-d795-4aa5-bcf0-453d70732cd2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1bd87924-2a8f-4424-9627-3814326a0679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1bd87924-2a8f-4424-9627-3814326a0679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4203fcb0-1c73-4d86-97af-4b07852e3b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4203fcb0-1c73-4d86-97af-4b07852e3b3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_0b7375e4-886d-4e56-8395-f881719173bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_0b7375e4-886d-4e56-8395-f881719173bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_679e0a31-92a7-4de9-9d6f-bf8f6b9f0e18" xlink:href="pfe-20211231.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_679e0a31-92a7-4de9-9d6f-bf8f6b9f0e18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e993818c-1964-452b-b05e-dab74d2fe68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e993818c-1964-452b-b05e-dab74d2fe68a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_8657ccdf-81d3-4cf7-b2cb-5157fc02c87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_8657ccdf-81d3-4cf7-b2cb-5157fc02c87f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e7623f3-0ed5-48b1-82b4-f2250d5817a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e7623f3-0ed5-48b1-82b4-f2250d5817a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b7a9002a-2f27-4976-9e0c-42b591d38dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b7a9002a-2f27-4976-9e0c-42b591d38dbe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_568c9342-21fb-4b9f-8a9e-170769db23cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_568c9342-21fb-4b9f-8a9e-170769db23cd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_72d8980a-9817-42c6-a328-82e532091d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_72d8980a-9817-42c6-a328-82e532091d4a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_650ab175-5f8d-40b2-9266-3d539a27cd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_650ab175-5f8d-40b2-9266-3d539a27cd8b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_cf56f407-10d4-4e97-8911-f306dec88ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_cf56f407-10d4-4e97-8911-f306dec88ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_e32099cc-658d-49d5-b965-fa262e221500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_e32099cc-658d-49d5-b965-fa262e221500" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_1b758fad-dbc0-4167-bf41-5c6265c82918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_1b758fad-dbc0-4167-bf41-5c6265c82918" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_511528e3-ff75-4975-8b93-9ec1c29acc57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_511528e3-ff75-4975-8b93-9ec1c29acc57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_14701b26-a650-4367-bbb3-3746625bb40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_14701b26-a650-4367-bbb3-3746625bb40c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af993242-a335-491d-a047-e26519c68093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af993242-a335-491d-a047-e26519c68093" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_714bfe33-add3-4a2c-b1b7-358c08647017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_714bfe33-add3-4a2c-b1b7-358c08647017" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7a06d0ad-7aa1-4702-a526-2efb90e215e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7a06d0ad-7aa1-4702-a526-2efb90e215e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_d8a6a588-7a66-447a-90b5-f56290ca27b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_d8a6a588-7a66-447a-90b5-f56290ca27b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_49da7111-40d4-483b-9e07-2092fde6099a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_49da7111-40d4-483b-9e07-2092fde6099a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f0f2e5e-7b3c-41c3-961d-653927db4814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f0f2e5e-7b3c-41c3-961d-653927db4814" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cee0561-de96-437b-9ffe-8aa402a7fe05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cee0561-de96-437b-9ffe-8aa402a7fe05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c57ca421-3796-4560-8c3c-343414f2d7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c57ca421-3796-4560-8c3c-343414f2d7df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6442637-489a-4bad-9bf2-b6a8256ff404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6442637-489a-4bad-9bf2-b6a8256ff404" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03c952d9-4e87-429e-af08-8bd7d2865430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3f46b40e-ea95-48bc-81a4-dc254708594b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3f46b40e-ea95-48bc-81a4-dc254708594b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b3ef9aa4-c589-43ad-94c9-c47284818cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:to="loc_us-gaap_InterestPaidNet_b3ef9aa4-c589-43ad-94c9-c47284818cef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InterestReceivedInterestRateHedges_3378c47b-05fe-4e39-b350-7bb320a807a2" xlink:href="pfe-20211231.xsd#pfe_InterestReceivedInterestRateHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:to="loc_pfe_InterestReceivedInterestRateHedges_3378c47b-05fe-4e39-b350-7bb320a807a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3ad0586a-f4c6-44bb-988e-fa59b6851587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3ad0586a-f4c6-44bb-988e-fa59b6851587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_611bf4f1-cc10-439a-ae5f-5a5d4fa094db" xlink:href="pfe-20211231.xsd#pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_611bf4f1-cc10-439a-ae5f-5a5d4fa094db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_15f7b57d-93b8-45cd-a095-a63926f8a9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_StatementTable_15f7b57d-93b8-45cd-a095-a63926f8a9a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a7670b3-0af4-4b31-ae85-d7778d363875" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_15f7b57d-93b8-45cd-a095-a63926f8a9a4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a7670b3-0af4-4b31-ae85-d7778d363875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6a7670b3-0af4-4b31-ae85-d7778d363875_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a7670b3-0af4-4b31-ae85-d7778d363875" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6a7670b3-0af4-4b31-ae85-d7778d363875_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cd387ac7-c458-4274-b590-2c8a4effff57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a7670b3-0af4-4b31-ae85-d7778d363875" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cd387ac7-c458-4274-b590-2c8a4effff57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_a096f46f-0e69-44f3-901c-a66dda65769f" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cd387ac7-c458-4274-b590-2c8a4effff57" xlink:to="loc_pfe_GSKConsumerHealthcareMember_a096f46f-0e69-44f3-901c-a66dda65769f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="i4de0492a574a4f1696b92a97fa0ad9b1_ConsolidatedStatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_071ff29d-b73b-4a8a-8058-5e0c9c993a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_071ff29d-b73b-4a8a-8058-5e0c9c993a12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_a9f94836-c8d0-4a4c-8349-7d50f8179420" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_a9f94836-c8d0-4a4c-8349-7d50f8179420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_1855c44f-241a-4f08-b1bf-d892b42dab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_1855c44f-241a-4f08-b1bf-d892b42dab5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationNetAssetsContributed_01d549dc-6e11-4735-b828-ccc1f4be8a75" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationNetAssetsContributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_pfe_DeconsolidationNetAssetsContributed_01d549dc-6e11-4735-b828-ccc1f4be8a75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountCashConveyed_597e98d1-f271-4fec-bfe2-89a5fb670ffe" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountCashConveyed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_pfe_DeconsolidationGainLossAmountCashConveyed_597e98d1-f271-4fec-bfe2-89a5fb670ffe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_73143956-365e-489a-bfb2-caac40325b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_us-gaap_StatementTable_73143956-365e-489a-bfb2-caac40325b52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7e152858-3e01-4aa6-bbc8-15162ab51403" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_73143956-365e-489a-bfb2-caac40325b52" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7e152858-3e01-4aa6-bbc8-15162ab51403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7e152858-3e01-4aa6-bbc8-15162ab51403_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7e152858-3e01-4aa6-bbc8-15162ab51403" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7e152858-3e01-4aa6-bbc8-15162ab51403_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2514f3a6-cd42-43de-9754-263ef3822418" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7e152858-3e01-4aa6-bbc8-15162ab51403" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2514f3a6-cd42-43de-9754-263ef3822418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_a8c92de2-f17c-438f-9a90-f2c55200eec3" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2514f3a6-cd42-43de-9754-263ef3822418" xlink:to="loc_pfe_GSKConsumerHealthcareMember_a8c92de2-f17c-438f-9a90-f2c55200eec3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i4f789448a7424cb3a4b9d4376ca702a0_BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6f73b27c-a91e-486b-ad4c-e0b2cf02681b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6f73b27c-a91e-486b-ad4c-e0b2cf02681b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71b785cc-2d9a-48a2-b920-6f9f5d97a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71b785cc-2d9a-48a2-b920-6f9f5d97a4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b7a201e-e69e-4739-b796-28a456519e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b7a201e-e69e-4739-b796-28a456519e14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConcentrationRiskAmount_f342c857-e46e-48d8-b161-bd66b2bfdb95" xlink:href="pfe-20211231.xsd#pfe_ConcentrationRiskAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_pfe_ConcentrationRiskAmount_f342c857-e46e-48d8-b161-bd66b2bfdb95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8e22cf24-55bd-414e-90fe-39a1c4a6c1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8e22cf24-55bd-414e-90fe-39a1c4a6c1cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_dffe6130-6206-4937-9092-71ebe95f1b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_AdvertisingExpense_dffe6130-6206-4937-9092-71ebe95f1b37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_92390aa3-60c1-49d1-9cdf-0374cea81ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_92390aa3-60c1-49d1-9cdf-0374cea81ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92390aa3-60c1-49d1-9cdf-0374cea81ca3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_92390aa3-60c1-49d1-9cdf-0374cea81ca3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92390aa3-60c1-49d1-9cdf-0374cea81ca3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4658231-b97c-46f2-983c-670c00408568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_92390aa3-60c1-49d1-9cdf-0374cea81ca3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4658231-b97c-46f2-983c-670c00408568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_1d4c89a3-070b-48b9-b81e-a9f34af3a806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4658231-b97c-46f2-983c-670c00408568" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_1d4c89a3-070b-48b9-b81e-a9f34af3a806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73a20070-0bcb-49fb-bc16-568d13a70cc7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_srt_ProductOrServiceAxis_73a20070-0bcb-49fb-bc16-568d13a70cc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73a20070-0bcb-49fb-bc16-568d13a70cc7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73a20070-0bcb-49fb-bc16-568d13a70cc7" xlink:to="loc_srt_ProductsAndServicesDomain_73a20070-0bcb-49fb-bc16-568d13a70cc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73a20070-0bcb-49fb-bc16-568d13a70cc7" xlink:to="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopNineProductsMember_0e03011c-240a-46bf-abf1-65409ce72d07" xlink:href="pfe-20211231.xsd#pfe_TopNineProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:to="loc_pfe_TopNineProductsMember_0e03011c-240a-46bf-abf1-65409ce72d07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopSevenProductsMember_bc31ec75-4fc2-4ba4-845d-a36fd75d11bd" xlink:href="pfe-20211231.xsd#pfe_TopSevenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:to="loc_pfe_TopSevenProductsMember_bc31ec75-4fc2-4ba4-845d-a36fd75d11bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopSixProductsMember_89b0e95e-336a-4027-98c4-e579fc783990" xlink:href="pfe-20211231.xsd#pfe_TopSixProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:to="loc_pfe_TopSixProductsMember_89b0e95e-336a-4027-98c4-e579fc783990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_967afb53-a2cf-47f2-ae93-6545842326aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_967afb53-a2cf-47f2-ae93-6545842326aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_967afb53-a2cf-47f2-ae93-6545842326aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_967afb53-a2cf-47f2-ae93-6545842326aa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_967afb53-a2cf-47f2-ae93-6545842326aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_13d5208d-6ef6-4b7d-b406-01442584d0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_967afb53-a2cf-47f2-ae93-6545842326aa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_13d5208d-6ef6-4b7d-b406-01442584d0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_28200758-e420-4d16-b2af-d6880c7292bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_13d5208d-6ef6-4b7d-b406-01442584d0a7" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_28200758-e420-4d16-b2af-d6880c7292bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_987b18db-faed-4638-81c4-614354fed7b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_srt_RestatementAxis_987b18db-faed-4638-81c4-614354fed7b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_987b18db-faed-4638-81c4-614354fed7b8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_987b18db-faed-4638-81c4-614354fed7b8" xlink:to="loc_srt_RestatementDomain_987b18db-faed-4638-81c4-614354fed7b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_fb43258e-3577-40a8-9ae2-ddd9823a941b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_987b18db-faed-4638-81c4-614354fed7b8" xlink:to="loc_srt_RestatementDomain_fb43258e-3577-40a8-9ae2-ddd9823a941b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_48282cdd-5c32-4335-88c3-7b441d7c4654" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_fb43258e-3577-40a8-9ae2-ddd9823a941b" xlink:to="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_48282cdd-5c32-4335-88c3-7b441d7c4654" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="extended" id="i4c7879c6ba44429098e2d50a780028a1_BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_7d47a9fb-cfd2-4a66-b05a-9565f0da4284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_7d47a9fb-cfd2-4a66-b05a-9565f0da4284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3640803c-c342-4407-8ea8-459d2df5b06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3640803c-c342-4407-8ea8-459d2df5b06a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_01c04edb-33a0-4c91-8330-861a0b341acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_01c04edb-33a0-4c91-8330-861a0b341acf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_18aee5dc-f6c5-4bda-9699-12be5d4473b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_18aee5dc-f6c5-4bda-9699-12be5d4473b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_af24fb47-5bd9-4c19-9851-905034772d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_af24fb47-5bd9-4c19-9851-905034772d04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98f54563-bae4-4831-9dd9-cc4ca48042a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_ProfitLoss_98f54563-bae4-4831-9dd9-cc4ca48042a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_885270b2-03a9-4777-bc26-c8e8adbbdcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_NetIncomeLoss_885270b2-03a9-4777-bc26-c8e8adbbdcf0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c863161e-c065-463b-847b-c2df3449be63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c863161e-c065-463b-847b-c2df3449be63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_08e86b86-ee36-44b5-a09f-663c9c2784cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_08e86b86-ee36-44b5-a09f-663c9c2784cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c7919858-ef0c-49a0-90c0-e8dab5153eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:to="loc_us-gaap_EarningsPerShareBasic_c7919858-ef0c-49a0-90c0-e8dab5153eb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_529f147b-5d4f-4f43-a0f1-f982118e9a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_529f147b-5d4f-4f43-a0f1-f982118e9a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8d32a398-71a0-4264-bb70-6742f85c4a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8d32a398-71a0-4264-bb70-6742f85c4a28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0eae4fe2-69f5-40c1-ba03-9e083fd659e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0eae4fe2-69f5-40c1-ba03-9e083fd659e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_72bff63f-38ae-4ab6-9fc7-c340564b02a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_72bff63f-38ae-4ab6-9fc7-c340564b02a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_30990b64-09f1-4292-8d9f-927c3d185aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_30990b64-09f1-4292-8d9f-927c3d185aac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_b3070516-61d3-4376-9079-fa9870d98630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_b3070516-61d3-4376-9079-fa9870d98630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_6a2417fb-99cf-41e8-b290-e38d56b7aa10" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_6a2417fb-99cf-41e8-b290-e38d56b7aa10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_c938e181-d5a2-4b19-acaa-1d1c89e2b7b1" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_c938e181-d5a2-4b19-acaa-1d1c89e2b7b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_d9596745-2d3c-47f8-9c0b-e0b9bb1cea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_d9596745-2d3c-47f8-9c0b-e0b9bb1cea02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4e9d3f5b-da89-4653-a588-bd03f4be094e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4e9d3f5b-da89-4653-a588-bd03f4be094e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_7a73c511-c457-43e1-b036-f486d9005347" xlink:href="pfe-20211231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_7a73c511-c457-43e1-b036-f486d9005347" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedBalanceSheetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_537b69ac-bedd-4ebb-ad88-65551ea44f96" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_537b69ac-bedd-4ebb-ad88-65551ea44f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a71b00f8-10f6-4d23-b4af-0ddb016d4e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a71b00f8-10f6-4d23-b4af-0ddb016d4e80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_97089aee-5d8b-4ab1-a379-65d699760c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_97089aee-5d8b-4ab1-a379-65d699760c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66269991-b0bb-4f72-aef6-60ed6d617b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66269991-b0bb-4f72-aef6-60ed6d617b33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d0bb718-d94f-431a-8551-d5a5173ce2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d0bb718-d94f-431a-8551-d5a5173ce2b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_479439de-1102-45f0-8834-816c16aa7745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_479439de-1102-45f0-8834-816c16aa7745" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_fd3666a2-5998-492a-8aae-08999b263473" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_479439de-1102-45f0-8834-816c16aa7745" xlink:to="loc_srt_RestatementAxis_fd3666a2-5998-492a-8aae-08999b263473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_fd3666a2-5998-492a-8aae-08999b263473_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_fd3666a2-5998-492a-8aae-08999b263473" xlink:to="loc_srt_RestatementDomain_fd3666a2-5998-492a-8aae-08999b263473_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_fd3666a2-5998-492a-8aae-08999b263473" xlink:to="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioPreviousAccountingPrincipleMember_baf0ec0c-4a1b-4eeb-a3dd-e6545fe45bf1" xlink:href="pfe-20211231.xsd#pfe_ScenarioPreviousAccountingPrincipleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:to="loc_pfe_ScenarioPreviousAccountingPrincipleMember_baf0ec0c-4a1b-4eeb-a3dd-e6545fe45bf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_96b8aa2a-e275-4c53-b03a-2bfba91e8993" xlink:href="pfe-20211231.xsd#pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:to="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_96b8aa2a-e275-4c53-b03a-2bfba91e8993" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" xlink:type="extended" id="i2302ed391e6341dfaf1704bd155de483_BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndOtherSalesRelatedAccruals_2f3438df-40cd-4149-a2c8-86ec4ceb411a" xlink:href="pfe-20211231.xsd#pfe_RebatesAndOtherSalesRelatedAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:to="loc_pfe_RebatesAndOtherSalesRelatedAccruals_2f3438df-40cd-4149-a2c8-86ec4ceb411a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates_b848cbf6-a6fb-4b4d-ad7c-2ef1c4d4c453" xlink:href="pfe-20211231.xsd#pfe_AccruedRebates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:to="loc_pfe_AccruedRebates_b848cbf6-a6fb-4b4d-ad7c-2ef1c4d4c453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals_bf30b812-453f-4f60-928e-9677261237d4" xlink:href="pfe-20211231.xsd#pfe_OtherAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:to="loc_pfe_OtherAccruals_bf30b812-453f-4f60-928e-9677261237d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_1a034fbc-f20a-4696-b47c-a2218c3f5ef6" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_1a034fbc-f20a-4696-b47c-a2218c3f5ef6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_513b4e6d-c653-4495-8d3b-dac20adbec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_1a034fbc-f20a-4696-b47c-a2218c3f5ef6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_513b4e6d-c653-4495-8d3b-dac20adbec85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_513b4e6d-c653-4495-8d3b-dac20adbec85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_513b4e6d-c653-4495-8d3b-dac20adbec85" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_513b4e6d-c653-4495-8d3b-dac20adbec85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_513b4e6d-c653-4495-8d3b-dac20adbec85" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_77e71210-cc85-4c7c-9e5e-a4615baadf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:to="loc_us-gaap_AccountsReceivableMember_77e71210-cc85-4c7c-9e5e-a4615baadf82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6900002c-556b-472f-9414-eb2874eab09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6900002c-556b-472f-9414-eb2874eab09f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7f8891f4-ce50-41d1-9d12-8147cb1c9963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7f8891f4-ce50-41d1-9d12-8147cb1c9963" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails" xlink:type="extended" id="ie00b9ef1ffc34296b88bbe32efb4dd96_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionSharePrice_1649278d-87f9-409a-972e-bcddfa63f526" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionSharePrice_1649278d-87f9-409a-972e-bcddfa63f526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_7faad7b5-4888-490f-8b84-ee6f527c0491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_7faad7b5-4888-490f-8b84-ee6f527c0491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InvestmentOwnershipPercentage_e9475c10-9e36-416f-9dff-60d1253ea9f4" xlink:href="pfe-20211231.xsd#pfe_InvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_InvestmentOwnershipPercentage_e9475c10-9e36-416f-9dff-60d1253ea9f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_6018f29a-5162-4d57-981a-3ab3a288f504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_6018f29a-5162-4d57-981a-3ab3a288f504" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionAssetsAcquired_3b8e4f2d-1a0b-4fdf-bb4a-d92be6853ba3" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionAssetsAcquired_3b8e4f2d-1a0b-4fdf-bb4a-d92be6853ba3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionLiabilitiesAssumed_c429f6d6-e893-4a8d-a4b5-795756caaa79" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionLiabilitiesAssumed_c429f6d6-e893-4a8d-a4b5-795756caaa79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_b499765a-0b36-43c4-9c79-28c48840650e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_b499765a-0b36-43c4-9c79-28c48840650e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0238c40-d8b1-4e68-819e-f5d29dd5092c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0238c40-d8b1-4e68-819e-f5d29dd5092c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d59ba53-5cd6-4ded-afa8-3a17a7c73078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d59ba53-5cd6-4ded-afa8-3a17a7c73078" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_db42d550-f74b-4731-af59-994212b8c0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_db42d550-f74b-4731-af59-994212b8c0bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ce3bc29c-64d7-4e29-bf3d-dd3320ad9f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ce3bc29c-64d7-4e29-bf3d-dd3320ad9f17" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8505f3d0-b672-48fc-b93d-85917cf576fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8505f3d0-b672-48fc-b93d-85917cf576fe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f8d747da-e7f5-463c-9a57-2a0c252e9786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f8d747da-e7f5-463c-9a57-2a0c252e9786" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_68bd45d4-dd55-4c1e-92f8-d5af75abe078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_68bd45d4-dd55-4c1e-92f8-d5af75abe078" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fc45f930-4c4d-45a4-a3c5-ac6cda1a7b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_Goodwill_fc45f930-4c4d-45a4-a3c5-ac6cda1a7b8c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_85a2a5ff-2608-45fd-921d-aa4cd9b1eace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_85a2a5ff-2608-45fd-921d-aa4cd9b1eace" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_565122fc-8b48-44f5-8c54-7a4504df03c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_565122fc-8b48-44f5-8c54-7a4504df03c7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_7dd2f675-87e1-4912-8df9-5d920d5ac8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_7dd2f675-87e1-4912-8df9-5d920d5ac8c6" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_239bfe10-1400-43d5-8e13-3ba52d81d99e" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_239bfe10-1400-43d5-8e13-3ba52d81d99e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_0ea21493-71ab-4804-b18a-3eb384e07687" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_0ea21493-71ab-4804-b18a-3eb384e07687" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_b0627ca0-873f-4ac0-8f24-72d013fb8eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_b0627ca0-873f-4ac0-8f24-72d013fb8eca" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_bf07552b-ab65-4fee-a9ea-dc443734eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_bf07552b-ab65-4fee-a9ea-dc443734eb3c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1bad3981-5a84-4a96-b28f-44edc42f602f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1bad3981-5a84-4a96-b28f-44edc42f602f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3c9c4b6d-5b7f-4000-bf2f-2f34a16acb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_us-gaap_LicensingAgreementsMember_3c9c4b6d-5b7f-4000-bf2f-2f34a16acb27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_c4179f58-88aa-4fa0-8710-5b72451511b3" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_c4179f58-88aa-4fa0-8710-5b72451511b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_36e15886-bda2-49cc-8bff-9d59a50ce0f6" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_36e15886-bda2-49cc-8bff-9d59a50ce0f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf685605-002a-43b6-8e24-a14243690634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf685605-002a-43b6-8e24-a14243690634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf685605-002a-43b6-8e24-a14243690634_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf685605-002a-43b6-8e24-a14243690634" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bf685605-002a-43b6-8e24-a14243690634_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bf1f73f-efad-41d3-a6ad-8a0dcf233f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf685605-002a-43b6-8e24-a14243690634" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bf1f73f-efad-41d3-a6ad-8a0dcf233f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3c121dfa-1a3c-4b3b-bebd-1ee4065f248f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bf1f73f-efad-41d3-a6ad-8a0dcf233f2e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3c121dfa-1a3c-4b3b-bebd-1ee4065f248f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4b17465-c40b-4ffe-ab11-86a8e0f9d625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4b17465-c40b-4ffe-ab11-86a8e0f9d625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4b17465-c40b-4ffe-ab11-86a8e0f9d625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4b17465-c40b-4ffe-ab11-86a8e0f9d625" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4b17465-c40b-4ffe-ab11-86a8e0f9d625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_793eaa52-eec6-4aed-85da-992d92bbd381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4b17465-c40b-4ffe-ab11-86a8e0f9d625" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_793eaa52-eec6-4aed-85da-992d92bbd381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_bf238719-5a3f-49ad-8034-fddc6e1d3f19" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_793eaa52-eec6-4aed-85da-992d92bbd381" xlink:to="loc_pfe_ArrayMember_bf238719-5a3f-49ad-8034-fddc6e1d3f19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_331bef18-fc10-4253-8864-111a2461bcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_331bef18-fc10-4253-8864-111a2461bcde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_331bef18-fc10-4253-8864-111a2461bcde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_331bef18-fc10-4253-8864-111a2461bcde" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_331bef18-fc10-4253-8864-111a2461bcde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1019580d-151e-4ede-8b92-e3145ee554e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_331bef18-fc10-4253-8864-111a2461bcde" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1019580d-151e-4ede-8b92-e3145ee554e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_1009a8f9-14b2-4915-a04e-a63ac551367b" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1019580d-151e-4ede-8b92-e3145ee554e3" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_1009a8f9-14b2-4915-a04e-a63ac551367b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_4abfd578-8402-4807-acc5-6d74b2dc0ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_AssetAcquisitionAxis_4abfd578-8402-4807-acc5-6d74b2dc0ca7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_4abfd578-8402-4807-acc5-6d74b2dc0ca7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_4abfd578-8402-4807-acc5-6d74b2dc0ca7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_4abfd578-8402-4807-acc5-6d74b2dc0ca7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_4abfd578-8402-4807-acc5-6d74b2dc0ca7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrilliumMember_2b93fe7e-b32b-4e86-a65a-d34a9e646e8e" xlink:href="pfe-20211231.xsd#pfe_TrilliumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:to="loc_pfe_TrilliumMember_2b93fe7e-b32b-4e86-a65a-d34a9e646e8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_d45d9891-fca4-4725-931e-9fa834cfd968" xlink:href="pfe-20211231.xsd#pfe_TherachonAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_d45d9891-fca4-4725-931e-9fa834cfd968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21cb7ad9-853d-46da-be0b-8ce957a90109" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21cb7ad9-853d-46da-be0b-8ce957a90109" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_21cb7ad9-853d-46da-be0b-8ce957a90109_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21cb7ad9-853d-46da-be0b-8ce957a90109" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_21cb7ad9-853d-46da-be0b-8ce957a90109_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_98024e7e-8826-4545-92d4-e7d532f1565c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21cb7ad9-853d-46da-be0b-8ce957a90109" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_98024e7e-8826-4545-92d4-e7d532f1565c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrilliumMember_4ed6935a-8e0a-4c3c-af75-e3413f66351c" xlink:href="pfe-20211231.xsd#pfe_TrilliumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98024e7e-8826-4545-92d4-e7d532f1565c" xlink:to="loc_pfe_TrilliumMember_4ed6935a-8e0a-4c3c-af75-e3413f66351c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails" xlink:type="extended" id="i96608f4bb4c944578e624e6c0286f897_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_da364757-2360-49ba-932f-1e7d4eafb3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_da364757-2360-49ba-932f-1e7d4eafb3a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_613affce-145d-4ec2-b2c1-6a6fcdc0480d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_613affce-145d-4ec2-b2c1-6a6fcdc0480d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_22e6b9a4-9baf-4cc9-93de-974efedc227f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_22e6b9a4-9baf-4cc9-93de-974efedc227f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod_c8e0c6c0-1d0d-45c0-87b3-ebebbea30c46" xlink:href="pfe-20211231.xsd#pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod_c8e0c6c0-1d0d-45c0-87b3-ebebbea30c46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned_2b141f40-dfe8-4af8-90de-0bca72af6292" xlink:href="pfe-20211231.xsd#pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned_2b141f40-dfe8-4af8-90de-0bca72af6292" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0efe0ee7-0811-428b-9e25-97110abccdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0efe0ee7-0811-428b-9e25-97110abccdf5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4512414d-ae96-4462-8e22-1b2b1094eced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4512414d-ae96-4462-8e22-1b2b1094eced" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0e95f5ec-7b6d-4ded-84a7-9b8a88e9955e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_LongTermDebt_0e95f5ec-7b6d-4ded-84a7-9b8a88e9955e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_be711528-8d7f-4611-9eb4-f6bc901132b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_be711528-8d7f-4611-9eb4-f6bc901132b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2253a330-70b4-41b3-9212-b9ae08ddbd31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2253a330-70b4-41b3-9212-b9ae08ddbd31" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dc782f-6fb6-44b8-accf-b00dd54541c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dc782f-6fb6-44b8-accf-b00dd54541c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_cac889a4-1cfe-4686-8522-72d1121612e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_cac889a4-1cfe-4686-8522-72d1121612e6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_651684d5-4c34-433c-a9c2-85bfa50db1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_651684d5-4c34-433c-a9c2-85bfa50db1fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ed5a49f-8b1e-4aca-86c6-3a41d6a10dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ed5a49f-8b1e-4aca-86c6-3a41d6a10dca" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_bf0244ed-bf53-4b33-abf0-147ad3b0a13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_bf0244ed-bf53-4b33-abf0-147ad3b0a13a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax_15cd1374-6e88-4bdc-97a1-07943f891e62" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax_15cd1374-6e88-4bdc-97a1-07943f891e62" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_e1e35209-8a7b-446f-847e-858fa79b42a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_e1e35209-8a7b-446f-847e-858fa79b42a0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_82799e7a-b74d-499e-9125-fc23ff093ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_82799e7a-b74d-499e-9125-fc23ff093ca1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_a9c5b26c-439f-42ee-9a2e-6e4bc56a3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_a9c5b26c-439f-42ee-9a2e-6e4bc56a3bd8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_ea2785a3-d8f4-4c7a-849e-0d83b2747415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_ea2785a3-d8f4-4c7a-849e-0d83b2747415" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_1d049de5-eb39-41dc-b984-9e840c51ca82" xlink:href="pfe-20211231.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_1d049de5-eb39-41dc-b984-9e840c51ca82" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_24179861-dab3-4377-9ffd-33e19a3c23ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_srt_OwnershipAxis_24179861-dab3-4377-9ffd-33e19a3c23ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_24179861-dab3-4377-9ffd-33e19a3c23ca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_24179861-dab3-4377-9ffd-33e19a3c23ca" xlink:to="loc_srt_OwnershipDomain_24179861-dab3-4377-9ffd-33e19a3c23ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1425188d-9a11-4cec-8327-b09b2a1a3bea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_24179861-dab3-4377-9ffd-33e19a3c23ca" xlink:to="loc_srt_OwnershipDomain_1425188d-9a11-4cec-8327-b09b2a1a3bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_9776b7d4-f15d-4ae5-8754-b5958a533b6b" xlink:href="pfe-20211231.xsd#pfe_ViatrisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_1425188d-9a11-4cec-8327-b09b2a1a3bea" xlink:to="loc_pfe_ViatrisMember_9776b7d4-f15d-4ae5-8754-b5958a533b6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8fb3027c-bdc2-4640-8f54-681ad0ac54fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8fb3027c-bdc2-4640-8f54-681ad0ac54fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8fb3027c-bdc2-4640-8f54-681ad0ac54fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8fb3027c-bdc2-4640-8f54-681ad0ac54fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8fb3027c-bdc2-4640-8f54-681ad0ac54fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca68c2f5-4ece-45b7-b19a-6ecd391f013a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8fb3027c-bdc2-4640-8f54-681ad0ac54fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca68c2f5-4ece-45b7-b19a-6ecd391f013a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eb8953b1-d4d9-4ae1-96dd-cd0fb427ecd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca68c2f5-4ece-45b7-b19a-6ecd391f013a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eb8953b1-d4d9-4ae1-96dd-cd0fb427ecd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d354450c-2efc-4fcc-a23e-f3cf736a38b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_dei_LegalEntityAxis_d354450c-2efc-4fcc-a23e-f3cf736a38b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d354450c-2efc-4fcc-a23e-f3cf736a38b0_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d354450c-2efc-4fcc-a23e-f3cf736a38b0" xlink:to="loc_dei_EntityDomain_d354450c-2efc-4fcc-a23e-f3cf736a38b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d354450c-2efc-4fcc-a23e-f3cf736a38b0" xlink:to="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MylanMember_efea1723-40a3-4a5b-a790-39d33272381c" xlink:href="pfe-20211231.xsd#pfe_MylanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:to="loc_pfe_MylanMember_efea1723-40a3-4a5b-a790-39d33272381c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncAndUpjohnFinanceBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:to="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncMember_9bb9f90a-bf49-4abc-8fc4-6d3314148f27" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:to="loc_pfe_UpjohnIncMember_9bb9f90a-bf49-4abc-8fc4-6d3314148f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnFinanceB.V.Member_dcc7a631-9ddd-4a68-9962-d0c24d95db14" xlink:href="pfe-20211231.xsd#pfe_UpjohnFinanceB.V.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:to="loc_pfe_UpjohnFinanceB.V.Member_dcc7a631-9ddd-4a68-9962-d0c24d95db14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ee67afc5-44dd-4324-94f9-aa7773604c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ee67afc5-44dd-4324-94f9-aa7773604c36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ee67afc5-44dd-4324-94f9-aa7773604c36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ee67afc5-44dd-4324-94f9-aa7773604c36" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ee67afc5-44dd-4324-94f9-aa7773604c36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c81bd6ca-e812-4f16-ae6e-6782791a84b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ee67afc5-44dd-4324-94f9-aa7773604c36" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c81bd6ca-e812-4f16-ae6e-6782791a84b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_deaa7cdc-b4f8-473a-afd4-fbb195d37b47" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c81bd6ca-e812-4f16-ae6e-6782791a84b6" xlink:to="loc_pfe_LongtermInvestmentsMember_deaa7cdc-b4f8-473a-afd4-fbb195d37b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27be2e0d-3a10-4628-acdb-8f69fb97b184" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_srt_CounterpartyNameAxis_27be2e0d-3a10-4628-acdb-8f69fb97b184" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27be2e0d-3a10-4628-acdb-8f69fb97b184_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_27be2e0d-3a10-4628-acdb-8f69fb97b184" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27be2e0d-3a10-4628-acdb-8f69fb97b184_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_27be2e0d-3a10-4628-acdb-8f69fb97b184" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PurchaserOfMeridianMember_9c7fc627-1dee-4947-8f81-f93602057a5e" xlink:href="pfe-20211231.xsd#pfe_PurchaserOfMeridianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:to="loc_pfe_PurchaserOfMeridianMember_9c7fc627-1dee-4947-8f81-f93602057a5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_ea6a63b3-01e1-464b-a846-1907570420c7" xlink:href="pfe-20211231.xsd#pfe_ViatrisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:to="loc_pfe_ViatrisMember_ea6a63b3-01e1-464b-a846-1907570420c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fac5eeb9-39bc-4582-a8d6-221279864d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fac5eeb9-39bc-4582-a8d6-221279864d49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_7c07d7ef-8546-4f90-97d7-671c93fa069c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_7c07d7ef-8546-4f90-97d7-671c93fa069c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e845305-7197-4722-8565-dc89bfe8314c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e845305-7197-4722-8565-dc89bfe8314c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e845305-7197-4722-8565-dc89bfe8314c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e845305-7197-4722-8565-dc89bfe8314c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3e845305-7197-4722-8565-dc89bfe8314c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e845305-7197-4722-8565-dc89bfe8314c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_bbcd60d3-957f-4267-b019-696bdfb11707" xlink:href="pfe-20211231.xsd#pfe_MeridianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:to="loc_pfe_MeridianMember_bbcd60d3-957f-4267-b019-696bdfb11707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncMember_cc4aedef-c1fa-4388-90de-c60d5ecedc52" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:to="loc_pfe_UpjohnIncMember_cc4aedef-c1fa-4388-90de-c60d5ecedc52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d63241a-86a3-44d3-a9cb-111b38c15b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d63241a-86a3-44d3-a9cb-111b38c15b92" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5d63241a-86a3-44d3-a9cb-111b38c15b92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d63241a-86a3-44d3-a9cb-111b38c15b92" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5d63241a-86a3-44d3-a9cb-111b38c15b92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d63241a-86a3-44d3-a9cb-111b38c15b92" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_16e214be-0250-422a-8634-b7091432fed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:to="loc_us-gaap_SeniorNotesMember_16e214be-0250-422a-8634-b7091432fed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_35c7075f-ccd6-47c6-a4e9-a622348787c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:to="loc_us-gaap_UnsecuredDebtMember_35c7075f-ccd6-47c6-a4e9-a622348787c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba670180-23d2-41ed-88f9-3eb776a60750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba670180-23d2-41ed-88f9-3eb776a60750" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ba670180-23d2-41ed-88f9-3eb776a60750_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba670180-23d2-41ed-88f9-3eb776a60750" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ba670180-23d2-41ed-88f9-3eb776a60750_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba670180-23d2-41ed-88f9-3eb776a60750" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2021Member_974cafd8-d871-4a60-9b48-567c297e21f5" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:to="loc_pfe_SeniorNotesDue2021Member_974cafd8-d871-4a60-9b48-567c297e21f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2023Member_522c2d01-894b-459b-88e2-05e3ccded946" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:to="loc_pfe_SeniorNotesDue2023Member_522c2d01-894b-459b-88e2-05e3ccded946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6bd1278-0f9b-465f-a68e-a9b0334fb554" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_srt_RangeAxis_a6bd1278-0f9b-465f-a68e-a9b0334fb554" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6bd1278-0f9b-465f-a68e-a9b0334fb554_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a6bd1278-0f9b-465f-a68e-a9b0334fb554" xlink:to="loc_srt_RangeMember_a6bd1278-0f9b-465f-a68e-a9b0334fb554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a6bd1278-0f9b-465f-a68e-a9b0334fb554" xlink:to="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c20930bf-e5e4-483e-9180-2ae41cd53d54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:to="loc_srt_MinimumMember_c20930bf-e5e4-483e-9180-2ae41cd53d54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fe56509f-7e55-4a6b-8b53-b6b0690eb509" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:to="loc_srt_MaximumMember_fe56509f-7e55-4a6b-8b53-b6b0690eb509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_CreditFacilityAxis_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb" xlink:to="loc_us-gaap_CreditFacilityDomain_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_079eabb2-b901-44a0-b9ae-dbfc6a8af967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb" xlink:to="loc_us-gaap_CreditFacilityDomain_079eabb2-b901-44a0-b9ae-dbfc6a8af967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6321992a-1b9a-4e22-b227-faaa72137c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_079eabb2-b901-44a0-b9ae-dbfc6a8af967" xlink:to="loc_us-gaap_LineOfCreditMember_6321992a-1b9a-4e22-b227-faaa72137c00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b3748a90-5d3e-4e92-953c-5c4c94e40928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b3748a90-5d3e-4e92-953c-5c4c94e40928" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b3748a90-5d3e-4e92-953c-5c4c94e40928_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b3748a90-5d3e-4e92-953c-5c4c94e40928" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b3748a90-5d3e-4e92-953c-5c4c94e40928_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_a9471b3c-7502-4f5a-8db7-7925d7f3868b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b3748a90-5d3e-4e92-953c-5c4c94e40928" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_a9471b3c-7502-4f5a-8db7-7925d7f3868b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_eb43b204-886a-4bd6-87d7-32c068ef39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_a9471b3c-7502-4f5a-8db7-7925d7f3868b" xlink:to="loc_us-gaap_CommercialPaperMember_eb43b204-886a-4bd6-87d7-32c068ef39a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementAxis_a25b3288-6cf4-493c-944c-a469f31cd2a9" xlink:href="pfe-20211231.xsd#pfe_AgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_pfe_AgreementAxis_a25b3288-6cf4-493c-944c-a469f31cd2a9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementDomain_a25b3288-6cf4-493c-944c-a469f31cd2a9_default" xlink:href="pfe-20211231.xsd#pfe_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_AgreementAxis_a25b3288-6cf4-493c-944c-a469f31cd2a9" xlink:to="loc_pfe_AgreementDomain_a25b3288-6cf4-493c-944c-a469f31cd2a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:href="pfe-20211231.xsd#pfe_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_AgreementAxis_a25b3288-6cf4-493c-944c-a469f31cd2a9" xlink:to="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TransitionServiceAgreementMember_f632d108-09ee-4c7a-8082-12f7ea5998b6" xlink:href="pfe-20211231.xsd#pfe_TransitionServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:to="loc_pfe_TransitionServiceAgreementMember_f632d108-09ee-4c7a-8082-12f7ea5998b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingAndSupplyAgreementMember_5f8cf2ef-edef-468c-b974-370b1a3e8f47" xlink:href="pfe-20211231.xsd#pfe_ManufacturingAndSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:to="loc_pfe_ManufacturingAndSupplyAgreementMember_5f8cf2ef-edef-468c-b974-370b1a3e8f47" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="extended" id="i5991b1fe586c49d8a5ee1a7ea46bb0c6_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5be9fece-6e76-44f0-8f15-146a979449b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5be9fece-6e76-44f0-8f15-146a979449b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c7dab54a-9b09-42a4-ae05-8d9485420cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c7dab54a-9b09-42a4-ae05-8d9485420cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_54809113-0fdd-4ea0-8a7e-d1e2dcad9c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_54809113-0fdd-4ea0-8a7e-d1e2dcad9c1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_c7dfc7a6-dffe-4c63-8082-b2b35dff203d" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_c7dfc7a6-dffe-4c63-8082-b2b35dff203d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1543dcaf-bf65-4c5d-aa62-f7bda396b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1543dcaf-bf65-4c5d-aa62-f7bda396b3ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_a2f21607-0c31-4d6b-862e-87e078a55767" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_a2f21607-0c31-4d6b-862e-87e078a55767" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1bbec8d4-94e9-411f-b627-db1401243ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1bbec8d4-94e9-411f-b627-db1401243ed1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_e2c79570-2647-4b71-a133-1f5297ea608e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_e2c79570-2647-4b71-a133-1f5297ea608e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_f4070731-b09d-405c-8186-53af91a44273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_f4070731-b09d-405c-8186-53af91a44273" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_fa4b3526-e4df-4bd0-bc44-74a42c314c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_fa4b3526-e4df-4bd0-bc44-74a42c314c55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d7ad4d4e-af26-407c-885c-7001b1d8e974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d7ad4d4e-af26-407c-885c-7001b1d8e974" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_7605de41-59c3-4d83-b539-19de7c63a1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_7605de41-59c3-4d83-b539-19de7c63a1ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e40985fe-a451-4184-a621-794c09503087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e40985fe-a451-4184-a621-794c09503087" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_81564efb-cd91-4647-9c80-cc9965d9630d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_81564efb-cd91-4647-9c80-cc9965d9630d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_7f2a1720-01cb-4c2c-b868-7555edb3b117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_7f2a1720-01cb-4c2c-b868-7555edb3b117" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e238460d-ef9e-4a8b-8347-c97d2b99a361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e238460d-ef9e-4a8b-8347-c97d2b99a361" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses_373aa0d4-d0f1-4938-a25e-660f1e117f14" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses_373aa0d4-d0f1-4938-a25e-660f1e117f14" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_982f8272-3293-41b7-bf03-c5e223b11b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_982f8272-3293-41b7-bf03-c5e223b11b40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_057971f2-e958-4211-b5e8-cf4f77989481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_057971f2-e958-4211-b5e8-cf4f77989481" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_712ea01f-453e-4589-8b4a-e109a68321a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_712ea01f-453e-4589-8b4a-e109a68321a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fdfbc2a0-1058-46e5-933a-e796978b6e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fdfbc2a0-1058-46e5-933a-e796978b6e47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc078847-7e20-4ca7-b6fa-2f7869d0bd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc078847-7e20-4ca7-b6fa-2f7869d0bd25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9ee34d53-cfc1-4037-911f-d7c06f72dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9ee34d53-cfc1-4037-911f-d7c06f72dc69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_650afc84-438c-4979-8c2b-0bb5d2bfc8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_650afc84-438c-4979-8c2b-0bb5d2bfc8b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_9da30510-faaa-4eba-91a9-e809a912eb52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_9da30510-faaa-4eba-91a9-e809a912eb52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dcf55991-c715-45fb-ba07-f16fbd82db4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dcf55991-c715-45fb-ba07-f16fbd82db4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_92384a7e-6d4f-4443-a2c5-13169bbc710e" xlink:href="pfe-20211231.xsd#pfe_MeridianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:to="loc_pfe_MeridianMember_92384a7e-6d4f-4443-a2c5-13169bbc710e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_ab36b966-4cf0-4061-8bdb-a622a4a02317" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncAndUpjohnFinanceBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:to="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_ab36b966-4cf0-4061-8bdb-a622a4a02317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnFinanceBVMember_7924d539-04d5-45a4-bf66-3cd43568688e" xlink:href="pfe-20211231.xsd#pfe_UpjohnFinanceBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:to="loc_pfe_UpjohnFinanceBVMember_7924d539-04d5-45a4-bf66-3cd43568688e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17a083bc-fb50-4240-8973-69cc2326dcca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:to="loc_srt_ProductOrServiceAxis_17a083bc-fb50-4240-8973-69cc2326dcca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17a083bc-fb50-4240-8973-69cc2326dcca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_17a083bc-fb50-4240-8973-69cc2326dcca" xlink:to="loc_srt_ProductsAndServicesDomain_17a083bc-fb50-4240-8973-69cc2326dcca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f38e0356-6aca-4fa9-b16b-eb4390d8984b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_17a083bc-fb50-4240-8973-69cc2326dcca" xlink:to="loc_srt_ProductsAndServicesDomain_f38e0356-6aca-4fa9-b16b-eb4390d8984b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_7ddb9e11-ad18-4aaa-b004-c585b24b6ff4" xlink:href="pfe-20211231.xsd#pfe_EpiPenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f38e0356-6aca-4fa9-b16b-eb4390d8984b" xlink:to="loc_pfe_EpiPenMember_7ddb9e11-ad18-4aaa-b004-c585b24b6ff4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails" xlink:type="extended" id="ib03d5e54b2624778a583a8efa36239b5_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0ee4115a-2ceb-4cc9-a3fb-3aeb1ec630ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0ee4115a-2ceb-4cc9-a3fb-3aeb1ec630ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_8831cd9a-d17c-429d-9dd1-7727766dc7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_8831cd9a-d17c-429d-9dd1-7727766dc7df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_f34ba90d-c392-4365-860f-7a1b3305e9f6" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfTax_f34ba90d-c392-4365-860f-7a1b3305e9f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8dcece58-43bd-4a1e-a0c5-04ed03c54654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestments_8dcece58-43bd-4a1e-a0c5-04ed03c54654" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_ddd288bb-25d3-42bc-8442-afe2fda7d397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_ddd288bb-25d3-42bc-8442-afe2fda7d397" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_2e214581-856e-45b2-bc95-d1089119e2e0" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_2e214581-856e-45b2-bc95-d1089119e2e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3520adf6-41af-42a3-b38e-c1173dfc696e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3520adf6-41af-42a3-b38e-c1173dfc696e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c11d77b1-2299-48d4-adbb-6908ebcc235f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c11d77b1-2299-48d4-adbb-6908ebcc235f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_ae8f5a3c-fc0e-452f-8eea-49b7d9d1b92a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_ae8f5a3c-fc0e-452f-8eea-49b7d9d1b92a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_0626d2bb-47bc-41da-a47d-94e8fb0fbdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_0626d2bb-47bc-41da-a47d-94e8fb0fbdfb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_593599fd-ceb8-4113-969d-10d38a40fad8" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_593599fd-ceb8-4113-969d-10d38a40fad8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_f96ff80c-71c7-4d00-b912-de3d938a052d" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_f96ff80c-71c7-4d00-b912-de3d938a052d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_1576440d-af88-4a8e-aae2-cdabbfddd241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_InvestmentIncomeDividend_1576440d-af88-4a8e-aae2-cdabbfddd241" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_62e8daf6-5625-4796-a027-079f1b92ba2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_srt_RangeAxis_62e8daf6-5625-4796-a027-079f1b92ba2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_62e8daf6-5625-4796-a027-079f1b92ba2f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_62e8daf6-5625-4796-a027-079f1b92ba2f" xlink:to="loc_srt_RangeMember_62e8daf6-5625-4796-a027-079f1b92ba2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_62e8daf6-5625-4796-a027-079f1b92ba2f" xlink:to="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2b65d20c-a77e-4d6a-83e7-a84306395206" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:to="loc_srt_MinimumMember_2b65d20c-a77e-4d6a-83e7-a84306395206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89f17041-c6d0-4258-a5c0-1fcd59f06103" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:to="loc_srt_MaximumMember_89f17041-c6d0-4258-a5c0-1fcd59f06103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1bdb99a0-377c-4400-80dc-e707bfd3505e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1bdb99a0-377c-4400-80dc-e707bfd3505e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1bdb99a0-377c-4400-80dc-e707bfd3505e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1bdb99a0-377c-4400-80dc-e707bfd3505e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1bdb99a0-377c-4400-80dc-e707bfd3505e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fac4ce3c-2f03-4207-a0b8-6bd31377e0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1bdb99a0-377c-4400-80dc-e707bfd3505e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fac4ce3c-2f03-4207-a0b8-6bd31377e0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_2ca2117c-8238-4fc0-a52c-32b08721fdff" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fac4ce3c-2f03-4207-a0b8-6bd31377e0ab" xlink:to="loc_pfe_GSKConsumerHealthcareMember_2ca2117c-8238-4fc0-a52c-32b08721fdff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_22309c12-17e5-46d6-ae2c-1ff11801dce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_22309c12-17e5-46d6-ae2c-1ff11801dce0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_22309c12-17e5-46d6-ae2c-1ff11801dce0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22309c12-17e5-46d6-ae2c-1ff11801dce0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_22309c12-17e5-46d6-ae2c-1ff11801dce0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_82676133-1513-4ff1-8148-32bdbf3081aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22309c12-17e5-46d6-ae2c-1ff11801dce0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_82676133-1513-4ff1-8148-32bdbf3081aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_024ec797-1419-41e7-980e-ba589e4df13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_82676133-1513-4ff1-8148-32bdbf3081aa" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_024ec797-1419-41e7-980e-ba589e4df13a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_31bc7261-7c80-4382-b600-5d5f3bef5aef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_dei_LegalEntityAxis_31bc7261-7c80-4382-b600-5d5f3bef5aef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_31bc7261-7c80-4382-b600-5d5f3bef5aef_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_31bc7261-7c80-4382-b600-5d5f3bef5aef" xlink:to="loc_dei_EntityDomain_31bc7261-7c80-4382-b600-5d5f3bef5aef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6a8147c4-cdac-433c-ba59-47dd676eaf1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_31bc7261-7c80-4382-b600-5d5f3bef5aef" xlink:to="loc_dei_EntityDomain_6a8147c4-cdac-433c-ba59-47dd676eaf1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember_c12e2c62-5282-4c30-8584-04798e1840ff" xlink:href="pfe-20211231.xsd#pfe_GSKMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6a8147c4-cdac-433c-ba59-47dd676eaf1a" xlink:to="loc_pfe_GSKMember_c12e2c62-5282-4c30-8584-04798e1840ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebfa9f4c-496f-4b45-9e17-d1b926677165" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebfa9f4c-496f-4b45-9e17-d1b926677165" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ebfa9f4c-496f-4b45-9e17-d1b926677165_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebfa9f4c-496f-4b45-9e17-d1b926677165" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ebfa9f4c-496f-4b45-9e17-d1b926677165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebfa9f4c-496f-4b45-9e17-d1b926677165" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_2953ddb7-63b1-49de-a4e5-1fbc275da373" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:to="loc_pfe_GSKConsumerHealthcareMember_2953ddb7-63b1-49de-a4e5-1fbc275da373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_b80f823f-efc4-4182-aa21-2e7d6a54f2c1" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:to="loc_pfe_ViivHealthcareLimitedMember_b80f823f-efc4-4182-aa21-2e7d6a54f2c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails" xlink:type="extended" id="i3546514239dd4f6ebfa65f69b66f3b00_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:to="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32765799-ffd9-4b1b-ba1c-3e7eef3cecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_AssetsCurrent_32765799-ffd9-4b1b-ba1c-3e7eef3cecd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_cfc256a9-b85c-4caf-ae0d-48cf46c7a8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_AssetsNoncurrent_cfc256a9-b85c-4caf-ae0d-48cf46c7a8ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_827c3d7e-f576-43d0-8ad0-a4437c44cb10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_Assets_827c3d7e-f576-43d0-8ad0-a4437c44cb10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e11c243-1a1b-426f-85f4-d6de5165ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e11c243-1a1b-426f-85f4-d6de5165ef54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2d98fc93-8fb8-4ad4-a9d4-1552c9a87d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_2d98fc93-8fb8-4ad4-a9d4-1552c9a87d4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ab8e8f5d-7222-40da-b63b-bbb58cad8415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_Liabilities_ab8e8f5d-7222-40da-b63b-bbb58cad8415" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2f548da-c33d-446f-b14d-8a9166c32566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_StockholdersEquity_e2f548da-c33d-446f-b14d-8a9166c32566" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_eb207c5e-60b0-427f-9c82-2b2c7999775c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_MinorityInterest_eb207c5e-60b0-427f-9c82-2b2c7999775c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6c952427-9692-457a-a9ba-23fe274de20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6c952427-9692-457a-a9ba-23fe274de20e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_89ed405c-a83c-4057-8c0d-563b10ea7730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_Revenues_89ed405c-a83c-4057-8c0d-563b10ea7730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1b7a9b96-70a7-4373-b5f9-e2bb9742a891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_CostOfRevenue_1b7a9b96-70a7-4373-b5f9-e2bb9742a891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_88f1b057-8e3a-4a09-822e-5f23ccb87063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_GrossProfit_88f1b057-8e3a-4a09-822e-5f23ccb87063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b33b61d7-9024-4cc8-91b8-9300a242dc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b33b61d7-9024-4cc8-91b8-9300a242dc42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_221d154e-5a47-4ec8-a6bd-0c73ee1e20c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_ProfitLoss_221d154e-5a47-4ec8-a6bd-0c73ee1e20c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8356d65c-22c7-4492-8214-f761c7ac057d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_NetIncomeLoss_8356d65c-22c7-4492-8214-f761c7ac057d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b19208ed-7a47-41f5-939c-91449ef3b315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b19208ed-7a47-41f5-939c-91449ef3b315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b19208ed-7a47-41f5-939c-91449ef3b315_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b19208ed-7a47-41f5-939c-91449ef3b315" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b19208ed-7a47-41f5-939c-91449ef3b315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b19208ed-7a47-41f5-939c-91449ef3b315" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_5802688c-5d03-479a-9a66-77c59a7f56b5" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:to="loc_pfe_GSKConsumerHealthcareMember_5802688c-5d03-479a-9a66-77c59a7f56b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_3c4220fa-be5f-4322-b826-f833e5ae836c" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:to="loc_pfe_ViivHealthcareLimitedMember_3c4220fa-be5f-4322-b826-f833e5ae836c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5537f9e3-cd38-462b-a5e0-43d6f28f60f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5537f9e3-cd38-462b-a5e0-43d6f28f60f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5537f9e3-cd38-462b-a5e0-43d6f28f60f5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5537f9e3-cd38-462b-a5e0-43d6f28f60f5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5537f9e3-cd38-462b-a5e0-43d6f28f60f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2adb44bb-f1eb-4526-be88-d293ea03a795" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5537f9e3-cd38-462b-a5e0-43d6f28f60f5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2adb44bb-f1eb-4526-be88-d293ea03a795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_b5017f1f-4f52-41de-87c7-3f5aaaf00e09" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2adb44bb-f1eb-4526-be88-d293ea03a795" xlink:to="loc_pfe_ViivHealthcareLimitedMember_b5017f1f-4f52-41de-87c7-3f5aaaf00e09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="extended" id="i364075e171b14c84b9f2ba7309069e4d_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_13ef532e-486b-43c7-af9a-93ab8c8c5640" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_13ef532e-486b-43c7-af9a-93ab8c8c5640" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentForLicensingArrangement_006521f8-f8ae-426b-9819-757e79ca2edb" xlink:href="pfe-20211231.xsd#pfe_PaymentForLicensingArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_PaymentForLicensingArrangement_006521f8-f8ae-426b-9819-757e79ca2edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_ea5cd4cf-0d05-4331-af6b-67e876a0522f" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_ea5cd4cf-0d05-4331-af6b-67e876a0522f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_bd8547ab-ec81-4b66-86c1-329213ab1a75" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_bd8547ab-ec81-4b66-86c1-329213ab1a75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_c4ca6149-c4e1-4926-b795-44f14a560b33" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_c4ca6149-c4e1-4926-b795-44f14a560b33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50dc1cf0-f414-478e-a443-9a35c6fbdb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50dc1cf0-f414-478e-a443-9a35c6fbdb1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50dc1cf0-f414-478e-a443-9a35c6fbdb1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50dc1cf0-f414-478e-a443-9a35c6fbdb1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_50dc1cf0-f414-478e-a443-9a35c6fbdb1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_136a140d-9b44-498d-8e23-638cc1a9943b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50dc1cf0-f414-478e-a443-9a35c6fbdb1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_136a140d-9b44-498d-8e23-638cc1a9943b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_d09113b6-3aeb-49d6-9bee-342d27f4ec88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_136a140d-9b44-498d-8e23-638cc1a9943b" xlink:to="loc_us-gaap_LicensingAgreementsMember_d09113b6-3aeb-49d6-9bee-342d27f4ec88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_srt_CounterpartyNameAxis_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ValnevaSEMember_50c049fe-8732-4f29-bf7e-8eb6a5c42ae5" xlink:href="pfe-20211231.xsd#pfe_ValnevaSEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:to="loc_pfe_ValnevaSEMember_50c049fe-8732-4f29-bf7e-8eb6a5c42ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AkceaAndIonisMember_9ec93a87-5b93-4bc9-a809-63c74a65eb44" xlink:href="pfe-20211231.xsd#pfe_AkceaAndIonisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:to="loc_pfe_AkceaAndIonisMember_9ec93a87-5b93-4bc9-a809-63c74a65eb44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a211dcf9-115b-40dc-ae5d-9427e3097f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a211dcf9-115b-40dc-ae5d-9427e3097f50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a211dcf9-115b-40dc-ae5d-9427e3097f50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a211dcf9-115b-40dc-ae5d-9427e3097f50" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a211dcf9-115b-40dc-ae5d-9427e3097f50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a0b1a9e8-8157-40c2-a350-8bc3e8f4cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a211dcf9-115b-40dc-ae5d-9427e3097f50" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a0b1a9e8-8157-40c2-a350-8bc3e8f4cadc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d817efb1-f284-4f0a-b7fe-aceb1db6e0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0b1a9e8-8157-40c2-a350-8bc3e8f4cadc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d817efb1-f284-4f0a-b7fe-aceb1db6e0b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_75fefbfe-365a-4e9e-a00a-d27358ef6a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_75fefbfe-365a-4e9e-a00a-d27358ef6a1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75fefbfe-365a-4e9e-a00a-d27358ef6a1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_75fefbfe-365a-4e9e-a00a-d27358ef6a1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_75fefbfe-365a-4e9e-a00a-d27358ef6a1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_709c77f4-c1ac-47fc-90df-1913ebec0883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_75fefbfe-365a-4e9e-a00a-d27358ef6a1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_709c77f4-c1ac-47fc-90df-1913ebec0883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_935daa8a-7238-405d-87b4-6fa7d8ebfa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_709c77f4-c1ac-47fc-90df-1913ebec0883" xlink:to="loc_us-gaap_LicensingAgreementsMember_935daa8a-7238-405d-87b4-6fa7d8ebfa71" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail" xlink:type="extended" id="i4eb30a1a6f3b40b4934f00368c393409_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_52181d48-2be3-47d5-8a33-b87bd37e38c0" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_52181d48-2be3-47d5-8a33-b87bd37e38c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsandPaymentstoCollaborators_4b93cb58-fc7c-4bf6-90f1-16903f86cdbe" xlink:href="pfe-20211231.xsd#pfe_PrepaymentsandPaymentstoCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_PrepaymentsandPaymentstoCollaborators_4b93cb58-fc7c-4bf6-90f1-16903f86cdbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_54fb2b4d-b143-45fe-a59a-0519ea4415fa" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_54fb2b4d-b143-45fe-a59a-0519ea4415fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_168ddd8a-4fa0-464c-b026-d011d9a4629b" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_168ddd8a-4fa0-464c-b026-d011d9a4629b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_ad1be270-99a7-47e7-ad61-02304701aef7" xlink:href="pfe-20211231.xsd#pfe_PrepaymentsAndPaymentsToCollaboratorsCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_ad1be270-99a7-47e7-ad61-02304701aef7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_d607a85c-90d2-4e04-a9bd-69db7421b845" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_d607a85c-90d2-4e04-a9bd-69db7421b845" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_bf31cf95-50bd-4cb4-8484-396d53fbddcf" xlink:href="pfe-20211231.xsd#pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_bf31cf95-50bd-4cb4-8484-396d53fbddcf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentUponApproval_978983f8-13b8-4fee-955d-94b508535804" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMilestonePaymentUponApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMilestonePaymentUponApproval_978983f8-13b8-4fee-955d-94b508535804" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing_0a45b885-3c10-46e7-a4a1-a50189a09ae7" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMilestonePaymentUponCommercializing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing_0a45b885-3c10-46e7-a4a1-a50189a09ae7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InvestmentOwnershipPercentage_38118eae-9dee-4e44-895e-033f33f30150" xlink:href="pfe-20211231.xsd#pfe_InvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_InvestmentOwnershipPercentage_38118eae-9dee-4e44-895e-033f33f30150" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne_30995ffe-1ddb-4be1-badf-663b65258117" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne_30995ffe-1ddb-4be1-badf-663b65258117" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo_377330c4-2706-427f-8e0b-b5c735490cab" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo_377330c4-2706-427f-8e0b-b5c735490cab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_658e2a22-cdfc-48d5-99dd-041fb351bc9b" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementContingentPaymentsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_658e2a22-cdfc-48d5-99dd-041fb351bc9b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_041c82cd-ed55-406d-931e-fbce8d7a5777" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementUpfrontAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_041c82cd-ed55-406d-931e-fbce8d7a5777" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementTieredSalesMilestonePayments_c5d6633b-c5d3-4254-b174-55d1265fa88d" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementTieredSalesMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementTieredSalesMilestonePayments_c5d6633b-c5d3-4254-b174-55d1265fa88d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7d08628f-8093-486b-b115-509ccb9d8de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7d08628f-8093-486b-b115-509ccb9d8de5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_63f904c7-01f9-41c2-a39a-8ea584a196d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_63f904c7-01f9-41c2-a39a-8ea584a196d6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_06b28c2b-a16a-4c51-994e-6445cebb3383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_us-gaap_ProceedsFromCollaborators_06b28c2b-a16a-4c51-994e-6445cebb3383" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_4e6feca6-611c-4bb3-aa86-f4b3483976f9" xlink:href="pfe-20211231.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_4e6feca6-611c-4bb3-aa86-f4b3483976f9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4cbf327-cb32-46bf-bdef-afa4cddbc4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4cbf327-cb32-46bf-bdef-afa4cddbc4f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5e3feacc-e7a5-434d-9c70-aa40da3a0af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4cbf327-cb32-46bf-bdef-afa4cddbc4f2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5e3feacc-e7a5-434d-9c70-aa40da3a0af2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_srt_CounterpartyNameAxis_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeamMember_4ae5448b-de67-47be-9558-da654999fecd" xlink:href="pfe-20211231.xsd#pfe_BeamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_BeamMember_4ae5448b-de67-47be-9558-da654999fecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember_6d0b63a6-819a-405b-90a0-fcb0f8dd9248" xlink:href="pfe-20211231.xsd#pfe_ArvinasIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_ArvinasIncMember_6d0b63a6-819a-405b-90a0-fcb0f8dd9248" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MyovantMember_0d059a4f-8ae4-4605-ada8-91781a1a8bc3" xlink:href="pfe-20211231.xsd#pfe_MyovantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_MyovantMember_0d059a4f-8ae4-4605-ada8-91781a1a8bc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_1385e823-c6e6-4106-a0a1-619ad123b858" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_BioNTechMember_1385e823-c6e6-4106-a0a1-619ad123b858" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember_10bcd52e-8b1e-4bce-a86d-57ec0f8f0147" xlink:href="pfe-20211231.xsd#pfe_ArvinasIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:to="loc_pfe_ArvinasIncMember_10bcd52e-8b1e-4bce-a86d-57ec0f8f0147" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CStoneMember_70fc3aab-1fd1-44f1-9c5e-5d52eab069b3" xlink:href="pfe-20211231.xsd#pfe_CStoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:to="loc_pfe_CStoneMember_70fc3aab-1fd1-44f1-9c5e-5d52eab069b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_4168c8e3-cf89-4ab6-a01a-a423ce94fd1a" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:to="loc_pfe_BioNTechMember_4168c8e3-cf89-4ab6-a01a-a423ce94fd1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a30b15c-172a-4114-87e1-640c82016400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a30b15c-172a-4114-87e1-640c82016400" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a30b15c-172a-4114-87e1-640c82016400_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a30b15c-172a-4114-87e1-640c82016400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5a30b15c-172a-4114-87e1-640c82016400_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7073e322-22e2-47c6-87b3-c85779166f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a30b15c-172a-4114-87e1-640c82016400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7073e322-22e2-47c6-87b3-c85779166f28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_27c60cb5-475d-4d35-a4fc-2a8048828c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7073e322-22e2-47c6-87b3-c85779166f28" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_27c60cb5-475d-4d35-a4fc-2a8048828c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d86ea47e-d734-445f-9ccb-106ebb65304a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_dei_LegalEntityAxis_d86ea47e-d734-445f-9ccb-106ebb65304a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d86ea47e-d734-445f-9ccb-106ebb65304a_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d86ea47e-d734-445f-9ccb-106ebb65304a" xlink:to="loc_dei_EntityDomain_d86ea47e-d734-445f-9ccb-106ebb65304a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_31dc2647-42dd-4a17-b3ff-64f63a69c1d5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d86ea47e-d734-445f-9ccb-106ebb65304a" xlink:to="loc_dei_EntityDomain_31dc2647-42dd-4a17-b3ff-64f63a69c1d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeamMember_3a583ced-b22a-4529-9d69-3ba926954cd1" xlink:href="pfe-20211231.xsd#pfe_BeamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_31dc2647-42dd-4a17-b3ff-64f63a69c1d5" xlink:to="loc_pfe_BeamMember_3a583ced-b22a-4529-9d69-3ba926954cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22a8fcd7-61df-43b6-87af-a6112fe18b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22a8fcd7-61df-43b6-87af-a6112fe18b31" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_22a8fcd7-61df-43b6-87af-a6112fe18b31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22a8fcd7-61df-43b6-87af-a6112fe18b31" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_22a8fcd7-61df-43b6-87af-a6112fe18b31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22a8fcd7-61df-43b6-87af-a6112fe18b31" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShinglesVaccineProgramMRNABasedMember_7ad72f62-4f64-40d8-9465-72ef1848cedc" xlink:href="pfe-20211231.xsd#pfe_ShinglesVaccineProgramMRNABasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:to="loc_pfe_ShinglesVaccineProgramMRNABasedMember_7ad72f62-4f64-40d8-9465-72ef1848cedc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CoronavirusVaccineProgramMRNABasedMember_cbfce302-647f-47f1-8069-550216b6c607" xlink:href="pfe-20211231.xsd#pfe_CoronavirusVaccineProgramMRNABasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:to="loc_pfe_CoronavirusVaccineProgramMRNABasedMember_cbfce302-647f-47f1-8069-550216b6c607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9370aa7f-30c2-486e-95ee-1c7f255ed33f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9370aa7f-30c2-486e-95ee-1c7f255ed33f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9370aa7f-30c2-486e-95ee-1c7f255ed33f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9370aa7f-30c2-486e-95ee-1c7f255ed33f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9370aa7f-30c2-486e-95ee-1c7f255ed33f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b21a3f8b-6d4b-4b69-a6be-4e1aa5d09629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9370aa7f-30c2-486e-95ee-1c7f255ed33f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b21a3f8b-6d4b-4b69-a6be-4e1aa5d09629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4248a8b0-58be-400d-879e-ed6a9a8557bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b21a3f8b-6d4b-4b69-a6be-4e1aa5d09629" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4248a8b0-58be-400d-879e-ed6a9a8557bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" xlink:type="extended" id="i4779c3576c9f465cbf31f21db6df69d2_AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5876546-1725-40d8-bdab-e7e6488f834c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5876546-1725-40d8-bdab-e7e6488f834c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_961d2ddb-d7f3-4280-96de-9423f532eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_961d2ddb-d7f3-4280-96de-9423f532eb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f77b6008-5fa2-41f9-8e02-8fe205fa1f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f77b6008-5fa2-41f9-8e02-8fe205fa1f92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77a302c5-8d87-488d-863d-9eaf65be070e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77a302c5-8d87-488d-863d-9eaf65be070e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9c7e1a04-1998-47c1-bedc-4eca22d095b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9c7e1a04-1998-47c1-bedc-4eca22d095b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21ccf00c-e11c-4909-a811-fff8e49e4f0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:to="loc_srt_ProductOrServiceAxis_21ccf00c-e11c-4909-a811-fff8e49e4f0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21ccf00c-e11c-4909-a811-fff8e49e4f0e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_21ccf00c-e11c-4909-a811-fff8e49e4f0e" xlink:to="loc_srt_ProductsAndServicesDomain_21ccf00c-e11c-4909-a811-fff8e49e4f0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_21ccf00c-e11c-4909-a811-fff8e49e4f0e" xlink:to="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8f7ad8b0-fe81-4dc6-a609-e36736c2e592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:to="loc_us-gaap_ProductMember_8f7ad8b0-fe81-4dc6-a609-e36736c2e592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CopromotionMember_e030c6d8-347d-4eb7-86fe-f0fa3921d328" xlink:href="pfe-20211231.xsd#pfe_CopromotionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:to="loc_pfe_CopromotionMember_e030c6d8-347d-4eb7-86fe-f0fa3921d328" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0ee67883-38c6-45a3-a697-2cf9592a112f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0ee67883-38c6-45a3-a697-2cf9592a112f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ee67883-38c6-45a3-a697-2cf9592a112f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0ee67883-38c6-45a3-a697-2cf9592a112f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ee67883-38c6-45a3-a697-2cf9592a112f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2980fcf-9710-4863-97d4-7304d344ed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0ee67883-38c6-45a3-a697-2cf9592a112f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2980fcf-9710-4863-97d4-7304d344ed9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8e4b6efc-10eb-4808-b0a8-4233872b2647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2980fcf-9710-4863-97d4-7304d344ed9f" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8e4b6efc-10eb-4808-b0a8-4233872b2647" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" xlink:type="extended" id="ia4e4ef6a7fee47aa8eb70a127599171c_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d4aa1a6a-22d2-41f2-918e-32098c7b1388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d4aa1a6a-22d2-41f2-918e-32098c7b1388" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_115c9d75-6c2d-460d-9ec5-9aa1a86d8874" xlink:href="pfe-20211231.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_115c9d75-6c2d-460d-9ec5-9aa1a86d8874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_a530e018-ada6-4ef2-a651-39fba0004e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_a530e018-ada6-4ef2-a651-39fba0004e75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4abd28c7-12ea-4fff-9e34-f32f5ad243c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4abd28c7-12ea-4fff-9e34-f32f5ad243c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_d38c5880-daab-4816-b688-a1846a345217" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_d38c5880-daab-4816-b688-a1846a345217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8194aac9-80db-4295-8b94-43fa47c66eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8194aac9-80db-4295-8b94-43fa47c66eb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8194aac9-80db-4295-8b94-43fa47c66eb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8194aac9-80db-4295-8b94-43fa47c66eb6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8194aac9-80db-4295-8b94-43fa47c66eb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8194aac9-80db-4295-8b94-43fa47c66eb6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_e14be0aa-556b-4c09-839d-15c307f94a81" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:to="loc_pfe_ArrayMember_e14be0aa-556b-4c09-839d-15c307f94a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospiraMember_513953d1-9c30-46ae-8cce-45a06bd4d0d6" xlink:href="pfe-20211231.xsd#pfe_HospiraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:to="loc_pfe_HospiraMember_513953d1-9c30-46ae-8cce-45a06bd4d0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_81946f10-df55-4380-8709-88a3e7f438a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_RestructuringPlanAxis_81946f10-df55-4380-8709-88a3e7f438a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_81946f10-df55-4380-8709-88a3e7f438a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_81946f10-df55-4380-8709-88a3e7f438a4" xlink:to="loc_us-gaap_RestructuringPlanDomain_81946f10-df55-4380-8709-88a3e7f438a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_81946f10-df55-4380-8709-88a3e7f438a4" xlink:to="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember_570b549b-e95f-4836-98b2-54e6e397a718" xlink:href="pfe-20211231.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:to="loc_pfe_FocusedCompanyPlanMember_570b549b-e95f-4836-98b2-54e6e397a718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_b1aea8b7-bdcb-4a31-83f1-e06a045fc05e" xlink:href="pfe-20211231.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:to="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_b1aea8b7-bdcb-4a31-83f1-e06a045fc05e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CorporateEnablingFunctionsMember_fdb51cd9-8031-4c6d-979b-73f6e1c29257" xlink:href="pfe-20211231.xsd#pfe_CorporateEnablingFunctionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_CorporateEnablingFunctionsMember_fdb51cd9-8031-4c6d-979b-73f6e1c29257" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GoToMarketModelMember_e35479f8-6f72-43a6-95de-c832183624c1" xlink:href="pfe-20211231.xsd#pfe_GoToMarketModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_GoToMarketModelMember_e35479f8-6f72-43a6-95de-c832183624c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember_1e850a1f-2a35-4db2-92e0-fe7b0ab39174" xlink:href="pfe-20211231.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_ManufacturingOptimizationMember_1e850a1f-2a35-4db2-92e0-fe7b0ab39174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessIntegrationCostsMember_4e5ccd74-864b-49a0-9b6e-eb2c425ddbf8" xlink:href="pfe-20211231.xsd#pfe_BusinessIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_BusinessIntegrationCostsMember_4e5ccd74-864b-49a0-9b6e-eb2c425ddbf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e" xlink:to="loc_us-gaap_SegmentDomain_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33d0baf1-5757-4fd6-8947-a43d939454a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e" xlink:to="loc_us-gaap_SegmentDomain_33d0baf1-5757-4fd6-8947-a43d939454a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_70d007bd-eb30-480e-be45-9b0a252275a8" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33d0baf1-5757-4fd6-8947-a43d939454a6" xlink:to="loc_pfe_BiopharmaSegmentMember_70d007bd-eb30-480e-be45-9b0a252275a8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" xlink:type="extended" id="ic7ad9dfced31454ba31084839dd3cdb3_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7e175eae-e002-4362-af5b-efde19138cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_us-gaap_SeveranceCosts1_7e175eae-e002-4362-af5b-efde19138cd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_3a4d5e7b-3058-44a2-8a1e-3b94d8a31efb" xlink:href="pfe-20211231.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_3a4d5e7b-3058-44a2-8a1e-3b94d8a31efb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_10f74461-d57c-4892-85fa-efd9e5232352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_us-gaap_BusinessExitCosts1_10f74461-d57c-4892-85fa-efd9e5232352" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3e95d91a-7c2c-4aef-9a16-10820ae25f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_us-gaap_RestructuringCharges_3e95d91a-7c2c-4aef-9a16-10820ae25f54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_422377e2-f201-4c82-8370-457fb958f7b7" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_422377e2-f201-4c82-8370-457fb958f7b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e8e6c49e-e3ba-4a8e-9543-7a9fd32c9ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e8e6c49e-e3ba-4a8e-9543-7a9fd32c9ff3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_d9a14d10-ee24-483e-abe3-8c1e53f38184" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_d9a14d10-ee24-483e-abe3-8c1e53f38184" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44ce8cab-a66e-48b6-a1c2-c78ab65cceab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44ce8cab-a66e-48b6-a1c2-c78ab65cceab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8a87242f-d6c0-41d8-8b7d-7cb93cb16f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8a87242f-d6c0-41d8-8b7d-7cb93cb16f9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCostAbstract_8c7231c2-e18e-4d5a-a5b4-f161c6493a82" xlink:href="pfe-20211231.xsd#pfe_ImplementationCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_ImplementationCostAbstract_8c7231c2-e18e-4d5a-a5b4-f161c6493a82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_5102ad84-43e6-4068-ada5-9d25a15a3f4b" xlink:href="pfe-20211231.xsd#pfe_ImplementationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ImplementationCostAbstract_8c7231c2-e18e-4d5a-a5b4-f161c6493a82" xlink:to="loc_pfe_ImplementationCosts_5102ad84-43e6-4068-ada5-9d25a15a3f4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e1f6bafd-8c41-463e-87f7-61993a859c0b" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e1f6bafd-8c41-463e-87f7-61993a859c0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77d18d77-486e-4717-8744-ed2bb71d51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77d18d77-486e-4717-8744-ed2bb71d51fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f35bd048-70d1-47c8-9d4b-8993716a6357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77d18d77-486e-4717-8744-ed2bb71d51fa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f35bd048-70d1-47c8-9d4b-8993716a6357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f35bd048-70d1-47c8-9d4b-8993716a6357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f35bd048-70d1-47c8-9d4b-8993716a6357" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f35bd048-70d1-47c8-9d4b-8993716a6357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f35bd048-70d1-47c8-9d4b-8993716a6357" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6cff7146-fba8-4eb4-9654-00755c40f18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6cff7146-fba8-4eb4-9654-00755c40f18b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8bac1e43-0031-4a54-9283-0d0ff43c23b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_CostOfSalesMember_8bac1e43-0031-4a54-9283-0d0ff43c23b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d43aaf50-15b1-4b81-94b3-7e2e23565613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d43aaf50-15b1-4b81-94b3-7e2e23565613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_629635f0-2659-4590-9744-de896e22c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_629635f0-2659-4590-9744-de896e22c1ab" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="extended" id="ia6526afec79c44d19594bf47a832e397_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3a1b2755-ecfe-41de-87d9-897dbadf3606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:to="loc_us-gaap_RestructuringCharges_3a1b2755-ecfe-41de-87d9-897dbadf3606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_f31583ac-ea05-481a-b223-364fca6a19ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_f31583ac-ea05-481a-b223-364fca6a19ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43d4388b-3fd4-4ba5-bf61-05fc9243b43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43d4388b-3fd4-4ba5-bf61-05fc9243b43b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43d4388b-3fd4-4ba5-bf61-05fc9243b43b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43d4388b-3fd4-4ba5-bf61-05fc9243b43b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43d4388b-3fd4-4ba5-bf61-05fc9243b43b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d385a3a-c242-449a-98ed-852308bf1141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43d4388b-3fd4-4ba5-bf61-05fc9243b43b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d385a3a-c242-449a-98ed-852308bf1141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5fd9d22b-8a9c-4378-b0be-cb6c28366ff7" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d385a3a-c242-449a-98ed-852308bf1141" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5fd9d22b-8a9c-4378-b0be-cb6c28366ff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4630c39b-0e37-4d13-b62a-501ea7b56d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4630c39b-0e37-4d13-b62a-501ea7b56d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4630c39b-0e37-4d13-b62a-501ea7b56d60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4630c39b-0e37-4d13-b62a-501ea7b56d60" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4630c39b-0e37-4d13-b62a-501ea7b56d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20795e96-ec1f-4cb7-8d76-65a248559805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4630c39b-0e37-4d13-b62a-501ea7b56d60" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20795e96-ec1f-4cb7-8d76-65a248559805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_a964963e-bdf2-4c4c-ad43-fc0064e5e97c" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20795e96-ec1f-4cb7-8d76-65a248559805" xlink:to="loc_pfe_ArrayMember_a964963e-bdf2-4c4c-ad43-fc0064e5e97c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_41147dab-8b81-494f-8334-46997bd0b283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_41147dab-8b81-494f-8334-46997bd0b283" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_41147dab-8b81-494f-8334-46997bd0b283_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_41147dab-8b81-494f-8334-46997bd0b283" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_41147dab-8b81-494f-8334-46997bd0b283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_41147dab-8b81-494f-8334-46997bd0b283" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_6ec4ddf8-3f5e-46dc-bee6-f3a5c77906c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_6ec4ddf8-3f5e-46dc-bee6-f3a5c77906c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CostReductionInitiativesMember_f5bb40cd-f928-4d61-8413-e03ee82d77b3" xlink:href="pfe-20211231.xsd#pfe_CostReductionInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:to="loc_pfe_CostReductionInitiativesMember_f5bb40cd-f928-4d61-8413-e03ee82d77b3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended" id="i552d823524ce48b7bfefd1049ddf675f_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0c062e67-2409-4d6b-a828-570a462f4c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0c062e67-2409-4d6b-a828-570a462f4c46" xlink:to="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3914988f-54ed-4508-958d-fc655c45c9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:to="loc_us-gaap_RestructuringReserve_3914988f-54ed-4508-958d-fc655c45c9d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e9e52b2c-cd5d-49a9-a6c2-db88d96c372b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:to="loc_us-gaap_RestructuringCharges_e9e52b2c-cd5d-49a9-a6c2-db88d96c372b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_c46af10f-f1be-497a-92fc-4e42c75095ea" xlink:href="pfe-20211231.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_c46af10f-f1be-497a-92fc-4e42c75095ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6bef1d06-7767-470e-a72d-ff7c9e19f059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bf8ebb5f-7e19-408d-bd3b-d8cce1dfcbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0c062e67-2409-4d6b-a828-570a462f4c46" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bf8ebb5f-7e19-408d-bd3b-d8cce1dfcbc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d3411f64-f291-4220-9188-c7afd4011f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bf8ebb5f-7e19-408d-bd3b-d8cce1dfcbc8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d3411f64-f291-4220-9188-c7afd4011f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d3411f64-f291-4220-9188-c7afd4011f76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d3411f64-f291-4220-9188-c7afd4011f76" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d3411f64-f291-4220-9188-c7afd4011f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d3411f64-f291-4220-9188-c7afd4011f76" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_290ee186-8d1c-43e3-a0f2-78aa70e8049c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_290ee186-8d1c-43e3-a0f2-78aa70e8049c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember_cedd91b8-b01f-4ea0-aecc-886a40381f40" xlink:href="pfe-20211231.xsd#pfe_AssetImpairmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:to="loc_pfe_AssetImpairmentsMember_cedd91b8-b01f-4ea0-aecc-886a40381f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_7c3376e7-a031-4ece-9838-d5eeb7336601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:to="loc_us-gaap_OtherRestructuringMember_7c3376e7-a031-4ece-9838-d5eeb7336601" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended" id="i6242b8b31bf14462bd7fa1b6ad69951a_RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_555b4d7d-6aa6-4ac4-8886-55084108bca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f3edede5-3254-48eb-884a-164d3e5986f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_555b4d7d-6aa6-4ac4-8886-55084108bca1" xlink:to="loc_us-gaap_RestructuringReserve_f3edede5-3254-48eb-884a-164d3e5986f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1bf1714b-3acf-4efa-b4ee-9dc9a0ee05f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_555b4d7d-6aa6-4ac4-8886-55084108bca1" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1bf1714b-3acf-4efa-b4ee-9dc9a0ee05f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1bf1714b-3acf-4efa-b4ee-9dc9a0ee05f9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9056182f-4228-46e2-a09e-8d4622b94be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9056182f-4228-46e2-a09e-8d4622b94be0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ebafe373-37ab-4dae-bc47-5511b99dde80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ebafe373-37ab-4dae-bc47-5511b99dde80" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" xlink:type="extended" id="ie6f93a8ee7134ae1b08c44d3a2313055_OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_7520e611-9ea4-4f4b-a808-18bc431e489d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_InterestCostsCapitalized_7520e611-9ea4-4f4b-a808-18bc431e489d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d203b270-c059-45a2-9d27-e7c3da7ab439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d203b270-c059-45a2-9d27-e7c3da7ab439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_03b8aa63-a2ed-4af1-8268-3d049c065718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_ProceedsFromCollaborators_03b8aa63-a2ed-4af1-8268-3d049c065718" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_805cc78e-d43c-4072-aa82-2d6ae84ebf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_805cc78e-d43c-4072-aa82-2d6ae84ebf6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58cf3579-9fbe-4429-94aa-34883eae8061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58cf3579-9fbe-4429-94aa-34883eae8061" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_366a85ce-ef67-49a2-9a98-f005c3151201" xlink:href="pfe-20211231.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_366a85ce-ef67-49a2-9a98-f005c3151201" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_24f48639-e54b-4de5-acf7-adb363031d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_InvestmentIncomeDividend_24f48639-e54b-4de5-acf7-adb363031d88" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_30545c0b-5b14-4ed5-b84c-8a2d8b53913c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_30545c0b-5b14-4ed5-b84c-8a2d8b53913c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_04f1b17b-2223-4392-b2ae-691a85cbdf9f" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_04f1b17b-2223-4392-b2ae-691a85cbdf9f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c3474800-9029-4141-a953-0388d7e5b346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c3474800-9029-4141-a953-0388d7e5b346" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fa9b8198-b195-44bd-b295-2b17f0d205ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fa9b8198-b195-44bd-b295-2b17f0d205ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa9b8198-b195-44bd-b295-2b17f0d205ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa9b8198-b195-44bd-b295-2b17f0d205ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa9b8198-b195-44bd-b295-2b17f0d205ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa9b8198-b195-44bd-b295-2b17f0d205ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_3d3838e1-40ad-48a0-a34b-d982982ad344" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_ArrayMember_3d3838e1-40ad-48a0-a34b-d982982ad344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AnacorMember_156742a7-e2f8-4b4f-be02-15adee73a20b" xlink:href="pfe-20211231.xsd#pfe_AnacorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_AnacorMember_156742a7-e2f8-4b4f-be02-15adee73a20b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospiraMember_f91d8ac0-ecc4-447b-a8d8-77abbdee64bc" xlink:href="pfe-20211231.xsd#pfe_HospiraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_HospiraMember_f91d8ac0-ecc4-447b-a8d8-77abbdee64bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViiVMember_eac039c2-f43e-490e-92d9-b39707085c7e" xlink:href="pfe-20211231.xsd#pfe_ViiVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_ViiVMember_eac039c2-f43e-490e-92d9-b39707085c7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4dca719-de8f-4a3a-8d11-f58a8a797528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4dca719-de8f-4a3a-8d11-f58a8a797528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4dca719-de8f-4a3a-8d11-f58a8a797528_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4dca719-de8f-4a3a-8d11-f58a8a797528" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f4dca719-de8f-4a3a-8d11-f58a8a797528_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_305603df-9c1f-4902-98f8-7455c672a4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4dca719-de8f-4a3a-8d11-f58a8a797528" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_305603df-9c1f-4902-98f8-7455c672a4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_daa1fbbe-8193-42c1-b5ee-7807f7a9c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_305603df-9c1f-4902-98f8-7455c672a4d4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_daa1fbbe-8193-42c1-b5ee-7807f7a9c2d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_036c75d9-b954-4c35-89eb-ca293a6d9bb6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_036c75d9-b954-4c35-89eb-ca293a6d9bb6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_036c75d9-b954-4c35-89eb-ca293a6d9bb6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_036c75d9-b954-4c35-89eb-ca293a6d9bb6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_036c75d9-b954-4c35-89eb-ca293a6d9bb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_036c75d9-b954-4c35-89eb-ca293a6d9bb6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_f9a2c65e-b39d-47f9-8f83-eda1ea9faad8" xlink:href="pfe-20211231.xsd#pfe_BioNTechAndCerevelTherapeuticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_f9a2c65e-b39d-47f9-8f83-eda1ea9faad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndSpringWorksMember_d1ea5cf5-d8ae-4242-98ef-d65e4e155626" xlink:href="pfe-20211231.xsd#pfe_BioNTechAndSpringWorksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_BioNTechAndSpringWorksMember_d1ea5cf5-d8ae-4242-98ef-d65e4e155626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember_5a77b052-efe4-4252-b689-fa413f026c39" xlink:href="pfe-20211231.xsd#pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember_5a77b052-efe4-4252-b689-fa413f026c39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_a6e3d59e-dd8b-44c4-9947-d7942ab1b02d" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_BioNTechMember_a6e3d59e-dd8b-44c4-9947-d7942ab1b02d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_d4add2e8-5d45-4bf3-bb68-3dfb12051d8b" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_ViivHealthcareLimitedMember_d4add2e8-5d45-4bf3-bb68-3dfb12051d8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ac45789f-ad94-46b4-9c73-fa3a8555f352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ac45789f-ad94-46b4-9c73-fa3a8555f352" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ac45789f-ad94-46b4-9c73-fa3a8555f352_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ac45789f-ad94-46b4-9c73-fa3a8555f352" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ac45789f-ad94-46b4-9c73-fa3a8555f352_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cdf49b8e-9918-4bae-9e4c-a05eb4d7c8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ac45789f-ad94-46b4-9c73-fa3a8555f352" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cdf49b8e-9918-4bae-9e4c-a05eb4d7c8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b0f168ef-8471-47bf-a74c-538a7ad39dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cdf49b8e-9918-4bae-9e4c-a05eb4d7c8ba" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b0f168ef-8471-47bf-a74c-538a7ad39dcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bbe404b2-52b5-483f-b685-5d0e743a9dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bbe404b2-52b5-483f-b685-5d0e743a9dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember_d66da0cd-4165-4d79-bf08-dbafca2e9cac" xlink:href="pfe-20211231.xsd#pfe_CK1AssetsSoldToBiogenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bbe404b2-52b5-483f-b685-5d0e743a9dca" xlink:to="loc_pfe_CK1AssetsSoldToBiogenIncMember_d66da0cd-4165-4d79-bf08-dbafca2e9cac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_335029bb-bf08-46a5-a445-e19db2215a73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_srt_CounterpartyNameAxis_335029bb-bf08-46a5-a445-e19db2215a73" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_335029bb-bf08-46a5-a445-e19db2215a73_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_335029bb-bf08-46a5-a445-e19db2215a73" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_335029bb-bf08-46a5-a445-e19db2215a73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_335029bb-bf08-46a5-a445-e19db2215a73" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_63652194-99b1-43c0-a5fd-8bd16f0e0d59" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_BioNTechMember_63652194-99b1-43c0-a5fd-8bd16f0e0d59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PumaTechnologiesMember_4592a0fb-79c1-4ad5-a11a-c2d5a11fea12" xlink:href="pfe-20211231.xsd#pfe_PumaTechnologiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_PumaTechnologiesMember_4592a0fb-79c1-4ad5-a11a-c2d5a11fea12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliLillyCompanyMember_171b1550-f240-41da-ae06-e9779a7fdb56" xlink:href="pfe-20211231.xsd#pfe_EliLillyCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_EliLillyCompanyMember_171b1550-f240-41da-ae06-e9779a7fdb56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MylanMember_c4824375-856e-4864-aa97-e1f588ff5944" xlink:href="pfe-20211231.xsd#pfe_MylanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_MylanMember_c4824375-856e-4864-aa97-e1f588ff5944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d2d4d32-d2a5-433f-8be7-273dff436733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d2d4d32-d2a5-433f-8be7-273dff436733" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d2d4d32-d2a5-433f-8be7-273dff436733_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d2d4d32-d2a5-433f-8be7-273dff436733" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d2d4d32-d2a5-433f-8be7-273dff436733_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d2d4d32-d2a5-433f-8be7-273dff436733" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_59ec6199-35da-4993-8e38-8318a6cc20b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:to="loc_us-gaap_CollaborativeArrangementMember_59ec6199-35da-4993-8e38-8318a6cc20b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a8e4889b-7b72-49cb-b8ea-e7cd5506fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:to="loc_us-gaap_LicensingAgreementsMember_a8e4889b-7b72-49cb-b8ea-e7cd5506fb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_55428f58-62bd-4886-a3bc-431bc3b21a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_55428f58-62bd-4886-a3bc-431bc3b21a0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_55428f58-62bd-4886-a3bc-431bc3b21a0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_55428f58-62bd-4886-a3bc-431bc3b21a0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_55428f58-62bd-4886-a3bc-431bc3b21a0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73386242-75bd-4d64-aa67-a35a0785099e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_55428f58-62bd-4886-a3bc-431bc3b21a0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73386242-75bd-4d64-aa67-a35a0785099e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed89c828-accf-4d68-b765-a49984a41729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73386242-75bd-4d64-aa67-a35a0785099e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed89c828-accf-4d68-b765-a49984a41729" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db753c16-2f08-497f-8f3b-87a7e3296d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db753c16-2f08-497f-8f3b-87a7e3296d0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5bd519fa-ff8d-49a3-9643-d4cb24f78038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db753c16-2f08-497f-8f3b-87a7e3296d0b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5bd519fa-ff8d-49a3-9643-d4cb24f78038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2b8fbde9-2744-43b0-8400-6c0753cafa19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_srt_ProductOrServiceAxis_2b8fbde9-2744-43b0-8400-6c0753cafa19" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b8fbde9-2744-43b0-8400-6c0753cafa19_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2b8fbde9-2744-43b0-8400-6c0753cafa19" xlink:to="loc_srt_ProductsAndServicesDomain_2b8fbde9-2744-43b0-8400-6c0753cafa19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2b8fbde9-2744-43b0-8400-6c0753cafa19" xlink:to="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_8d71d0da-d66c-408c-b3c9-ebe289cf558c" xlink:href="pfe-20211231.xsd#pfe_EpiPenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:to="loc_pfe_EpiPenMember_8d71d0da-d66c-408c-b3c9-ebe289cf558c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EucrisaMember_a8819fad-b832-44d4-89df-ceae49a418fb" xlink:href="pfe-20211231.xsd#pfe_EucrisaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:to="loc_pfe_EucrisaMember_a8819fad-b832-44d4-89df-ceae49a418fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenericSterileInjectableProductMember_e04b2b85-2cc9-4e10-bb88-2c49a122c6a9" xlink:href="pfe-20211231.xsd#pfe_GenericSterileInjectableProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:to="loc_pfe_GenericSterileInjectableProductMember_e04b2b85-2cc9-4e10-bb88-2c49a122c6a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementAxis_e463c169-284b-40e5-ae8f-a3ea6a48545f" xlink:href="pfe-20211231.xsd#pfe_AgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_pfe_AgreementAxis_e463c169-284b-40e5-ae8f-a3ea6a48545f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementDomain_e463c169-284b-40e5-ae8f-a3ea6a48545f_default" xlink:href="pfe-20211231.xsd#pfe_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_AgreementAxis_e463c169-284b-40e5-ae8f-a3ea6a48545f" xlink:to="loc_pfe_AgreementDomain_e463c169-284b-40e5-ae8f-a3ea6a48545f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementDomain_5c64dce7-cab8-4d37-b7f3-a04e2c8baa84" xlink:href="pfe-20211231.xsd#pfe_AgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_AgreementAxis_e463c169-284b-40e5-ae8f-a3ea6a48545f" xlink:to="loc_pfe_AgreementDomain_5c64dce7-cab8-4d37-b7f3-a04e2c8baa84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TransitionServiceAgreementMember_3e423042-6a3a-4d73-9caf-8798295cc91e" xlink:href="pfe-20211231.xsd#pfe_TransitionServiceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_AgreementDomain_5c64dce7-cab8-4d37-b7f3-a04e2c8baa84" xlink:to="loc_pfe_TransitionServiceAgreementMember_3e423042-6a3a-4d73-9caf-8798295cc91e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3882ee86-a90d-451e-b3c8-bcd9c2feccb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3882ee86-a90d-451e-b3c8-bcd9c2feccb8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3882ee86-a90d-451e-b3c8-bcd9c2feccb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3882ee86-a90d-451e-b3c8-bcd9c2feccb8" xlink:to="loc_us-gaap_SegmentDomain_3882ee86-a90d-451e-b3c8-bcd9c2feccb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a53c3e50-d4b3-43a9-b34f-03cdd176a803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3882ee86-a90d-451e-b3c8-bcd9c2feccb8" xlink:to="loc_us-gaap_SegmentDomain_a53c3e50-d4b3-43a9-b34f-03cdd176a803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_d5b53730-1e60-487a-9cf5-760a384f5836" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a53c3e50-d4b3-43a9-b34f-03cdd176a803" xlink:to="loc_pfe_BiopharmaSegmentMember_d5b53730-1e60-487a-9cf5-760a384f5836" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:type="extended" id="i54173ff59189474ea7b2fbc1b597bcbf_TaxMattersNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b41259e2-bf30-46cf-85c5-4e4dd89249c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b41259e2-bf30-46cf-85c5-4e4dd89249c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c6d15d94-d60f-4bf3-a92c-760a4346d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c6d15d94-d60f-4bf3-a92c-760a4346d44c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_68461758-a2a0-4c81-a5cc-7589ef247c09" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_68461758-a2a0-4c81-a5cc-7589ef247c09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_abe9ed6e-d476-4b9c-9fda-f74f44a85b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_abe9ed6e-d476-4b9c-9fda-f74f44a85b30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_c834882b-7e86-4897-8449-b4d6443422fe" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsExcludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_c834882b-7e86-4897-8449-b4d6443422fe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_85c77ae7-ad73-4330-b9c0-41d33e32b2e7" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_85c77ae7-ad73-4330-b9c0-41d33e32b2e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_900818c6-14ab-4c82-9c1f-b9306726ec7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_900818c6-14ab-4c82-9c1f-b9306726ec7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_5c284aa6-4688-4886-9618-8107b275de79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_5c284aa6-4688-4886-9618-8107b275de79" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_57144e57-4cb2-4a0c-b10e-7af6f2d0f642" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_57144e57-4cb2-4a0c-b10e-7af6f2d0f642" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures_aceca776-75ac-426a-8e1b-6a1784f3960d" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures_aceca776-75ac-426a-8e1b-6a1784f3960d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_697c5759-0b33-43dc-b9f3-efc25afb49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_697c5759-0b33-43dc-b9f3-efc25afb49e0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_f1545397-f904-4959-937b-69c29c2429a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_f1545397-f904-4959-937b-69c29c2429a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f896705d-a4e0-44eb-b58a-b6ad86484c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f1545397-f904-4959-937b-69c29c2429a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f896705d-a4e0-44eb-b58a-b6ad86484c59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f896705d-a4e0-44eb-b58a-b6ad86484c59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f896705d-a4e0-44eb-b58a-b6ad86484c59" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f896705d-a4e0-44eb-b58a-b6ad86484c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f896705d-a4e0-44eb-b58a-b6ad86484c59" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_58ff9da8-7c0c-4854-ad07-6c4da6aff513" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_58ff9da8-7c0c-4854-ad07-6c4da6aff513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxesPayableMember_0ea34cea-617e-4591-8942-d6fef0276a06" xlink:href="pfe-20211231.xsd#pfe_OtherTaxesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:to="loc_pfe_OtherTaxesPayableMember_0ea34cea-617e-4591-8942-d6fef0276a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_42e1d0eb-7230-404d-882e-c8ae056446b5" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxLiabilitiesNetNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:to="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_42e1d0eb-7230-404d-882e-c8ae056446b5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersDeferredTaxesFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:type="extended" id="ib381f44bb2d547299f1dd14b205bc873_TaxMattersDeferredTaxesFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_8cc445a7-bce5-4c3f-9d62-347fd53e9fe1" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_8cc445a7-bce5-4c3f-9d62-347fd53e9fe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0971729e-2bbb-41e1-8119-4ecb27279412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0971729e-2bbb-41e1-8119-4ecb27279412" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_5cebcfcf-2bac-40db-8a53-2258ea9685a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_5cebcfcf-2bac-40db-8a53-2258ea9685a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0e418e42-67da-4ee4-b3cc-10c3c31650d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_5cebcfcf-2bac-40db-8a53-2258ea9685a3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0e418e42-67da-4ee4-b3cc-10c3c31650d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0e418e42-67da-4ee4-b3cc-10c3c31650d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0e418e42-67da-4ee4-b3cc-10c3c31650d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0e418e42-67da-4ee4-b3cc-10c3c31650d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0e418e42-67da-4ee4-b3cc-10c3c31650d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_b4877856-c60f-449c-ab38-5aa937798d60" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_b4877856-c60f-449c-ab38-5aa937798d60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_01ba9a23-8ac0-4631-add9-7b2bd68e671a" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_01ba9a23-8ac0-4631-add9-7b2bd68e671a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="extended" id="i5d287c5ec4d64820af41941659c6fccf_TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_4962c40b-7f65-4720-8f02-e9843b217139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d21b06e8-386b-42ba-8240-7507315a7aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4962c40b-7f65-4720-8f02-e9843b217139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d21b06e8-386b-42ba-8240-7507315a7aa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1926cb51-bd56-48c9-b782-8f6e75a0e459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4962c40b-7f65-4720-8f02-e9843b217139" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1926cb51-bd56-48c9-b782-8f6e75a0e459" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a00490bc-bf79-4f27-ad15-e2a7e26e08ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1926cb51-bd56-48c9-b782-8f6e75a0e459" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a00490bc-bf79-4f27-ad15-e2a7e26e08ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a00490bc-bf79-4f27-ad15-e2a7e26e08ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a00490bc-bf79-4f27-ad15-e2a7e26e08ff" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a00490bc-bf79-4f27-ad15-e2a7e26e08ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a00490bc-bf79-4f27-ad15-e2a7e26e08ff" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeTaxesPayableMember_29696350-bc58-4e6e-bc97-833bcc079492" xlink:href="pfe-20211231.xsd#pfe_IncomeTaxesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_IncomeTaxesPayableMember_29696350-bc58-4e6e-bc97-833bcc079492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CurrentTaxAssetsMember_ff2d01be-fdd0-4a7a-a2b7-7a78ffd63867" xlink:href="pfe-20211231.xsd#pfe_CurrentTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_CurrentTaxAssetsMember_ff2d01be-fdd0-4a7a-a2b7-7a78ffd63867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_1ae12ccc-1ef5-424e-b7e1-f59f8de40140" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_1ae12ccc-1ef5-424e-b7e1-f59f8de40140" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_dd66f46b-722b-4b53-be9c-a6006ad2149f" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_dd66f46b-722b-4b53-be9c-a6006ad2149f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxesPayableMember_6bf499e3-3356-4daf-9829-b3807d3bf67b" xlink:href="pfe-20211231.xsd#pfe_OtherTaxesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_OtherTaxesPayableMember_6bf499e3-3356-4daf-9829-b3807d3bf67b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="extended" id="idb0e42db39a644f8810d4130247a4555_AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33b8301f-8f30-480c-bf14-38a4db79bd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33b8301f-8f30-480c-bf14-38a4db79bd07" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da5f041e-376f-48b3-908d-5fab485dc274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da5f041e-376f-48b3-908d-5fab485dc274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c1d9b868-451c-45c8-afac-9a840f72c15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c1d9b868-451c-45c8-afac-9a840f72c15c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_41b1e25b-dad9-422a-a7d3-72a875903a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_41b1e25b-dad9-422a-a7d3-72a875903a63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a85df586-9752-4a12-9c06-3a3b41c0b78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3c0995f-7bad-4a7d-a8d4-9ecf897ae85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33b8301f-8f30-480c-bf14-38a4db79bd07" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3c0995f-7bad-4a7d-a8d4-9ecf897ae85a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3c0995f-7bad-4a7d-a8d4-9ecf897ae85a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77" xlink:to="loc_us-gaap_EquityComponentDomain_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_739e5cca-b905-413e-9f40-fdbfde73bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77" xlink:to="loc_us-gaap_EquityComponentDomain_739e5cca-b905-413e-9f40-fdbfde73bbe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_739e5cca-b905-413e-9f40-fdbfde73bbe4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aa1e4844-94e5-479c-8d69-567402e1e4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aa1e4844-94e5-479c-8d69-567402e1e4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c4142e64-22c6-451d-bcd5-c7c36c8e801f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c4142e64-22c6-451d-bcd5-c7c36c8e801f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8522b3f8-c90e-42e4-abf9-1563bb21f18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8522b3f8-c90e-42e4-abf9-1563bb21f18a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8e66615f-cb8e-485a-bdb0-4203cbb2d422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8e66615f-cb8e-485a-bdb0-4203cbb2d422" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="id37d3700fc944cb29954f3662c9ec348_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_95acdaec-b3fe-403e-9029-e1b0e34fb67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_95acdaec-b3fe-403e-9029-e1b0e34fb67c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8d4e5d7b-c59c-4ff5-b267-96ed6c01a772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8d4e5d7b-c59c-4ff5-b267-96ed6c01a772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_b32e2c13-3043-4b68-b66e-7902c01ea041" xlink:href="pfe-20211231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_b32e2c13-3043-4b68-b66e-7902c01ea041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_ab914fd2-143d-46d8-ae51-5af7c7d3b096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_ab914fd2-143d-46d8-ae51-5af7c7d3b096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_47a44055-c6e4-465e-9071-7c7b24c3b297" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_47a44055-c6e4-465e-9071-7c7b24c3b297" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_33d946e6-fe62-4b5a-bf75-c4af4f94b9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_33d946e6-fe62-4b5a-bf75-c4af4f94b9ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_d41e937d-c56b-41ee-aa24-35996cf709b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_d41e937d-c56b-41ee-aa24-35996cf709b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_366f7551-48d0-4b7e-b2bb-8bc082400e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_366f7551-48d0-4b7e-b2bb-8bc082400e25" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0bae91e8-dab2-41a5-8026-e4d14758e4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_Assets_0bae91e8-dab2-41a5-8026-e4d14758e4b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_189f7cdb-6c1a-409f-a44f-848a4d7aaa54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_189f7cdb-6c1a-409f-a44f-848a4d7aaa54" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_12d1a6a9-f61c-4411-9abe-3a5e04672117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_12d1a6a9-f61c-4411-9abe-3a5e04672117" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f828ae38-f283-4df4-b063-3bf342cdac08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeLiabilities_f828ae38-f283-4df4-b063-3bf342cdac08" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3f333c70-4ae0-4304-bc63-809e30ef64dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3f333c70-4ae0-4304-bc63-809e30ef64dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3f333c70-4ae0-4304-bc63-809e30ef64dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f333c70-4ae0-4304-bc63-809e30ef64dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3f333c70-4ae0-4304-bc63-809e30ef64dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f333c70-4ae0-4304-bc63-809e30ef64dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_c17f3021-6347-4314-b34f-88991920be2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_c17f3021-6347-4314-b34f-88991920be2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f8c87a5d-71cd-4201-83f7-1d5be8e31264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f8c87a5d-71cd-4201-83f7-1d5be8e31264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_8c0e00c3-e3c1-4359-8d35-8fb2ec174a22" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_pfe_LongtermInvestmentsMember_8c0e00c3-e3c1-4359-8d35-8fb2ec174a22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_28b94050-10a7-4a3b-bada-8e981fc10fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_28b94050-10a7-4a3b-bada-8e981fc10fea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_140225d1-69b2-45b6-8a52-adeaaa46882b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_140225d1-69b2-45b6-8a52-adeaaa46882b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c8f2f0d7-7de9-4305-add2-8ebc209903da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c8f2f0d7-7de9-4305-add2-8ebc209903da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_576c9473-9064-4611-9d99-a36b82f54438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_576c9473-9064-4611-9d99-a36b82f54438" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_576c9473-9064-4611-9d99-a36b82f54438_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_576c9473-9064-4611-9d99-a36b82f54438" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_576c9473-9064-4611-9d99-a36b82f54438_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_576c9473-9064-4611-9d99-a36b82f54438" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3d54b6d8-1306-4355-abc6-f2e1c67aa1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3d54b6d8-1306-4355-abc6-f2e1c67aa1f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_efb9dad2-bd8b-4597-9bf7-71cf31d1f47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_efb9dad2-bd8b-4597-9bf7-71cf31d1f47b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f07c9a9-82c9-4db9-8c79-2c279e0388f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f07c9a9-82c9-4db9-8c79-2c279e0388f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f07c9a9-82c9-4db9-8c79-2c279e0388f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f07c9a9-82c9-4db9-8c79-2c279e0388f1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f07c9a9-82c9-4db9-8c79-2c279e0388f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f07c9a9-82c9-4db9-8c79-2c279e0388f1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_65034358-478b-48be-912b-c0af695fc2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_65034358-478b-48be-912b-c0af695fc2c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4e5b044d-72c6-48e6-9217-b7b958c7975c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4e5b044d-72c6-48e6-9217-b7b958c7975c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6ef22e8b-d4db-4a11-927d-b4f3e88e830e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6ef22e8b-d4db-4a11-927d-b4f3e88e830e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8123842d-2af1-440d-b28f-07edb70f927e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8123842d-2af1-440d-b28f-07edb70f927e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1ba6146f-6be5-4d37-9099-ca188626e248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1ba6146f-6be5-4d37-9099-ca188626e248" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ba6146f-6be5-4d37-9099-ca188626e248_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1ba6146f-6be5-4d37-9099-ca188626e248" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1ba6146f-6be5-4d37-9099-ca188626e248_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d253cb1e-d47f-426e-b516-a2a06db2171f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1ba6146f-6be5-4d37-9099-ca188626e248" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d253cb1e-d47f-426e-b516-a2a06db2171f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e909813f-87ed-4a2f-8748-29ad5b41657b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d253cb1e-d47f-426e-b516-a2a06db2171f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e909813f-87ed-4a2f-8748-29ad5b41657b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_53024de0-0d7c-458e-bdc9-f727cd63c74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_53024de0-0d7c-458e-bdc9-f727cd63c74a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_53024de0-0d7c-458e-bdc9-f727cd63c74a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_53024de0-0d7c-458e-bdc9-f727cd63c74a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_53024de0-0d7c-458e-bdc9-f727cd63c74a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_53024de0-0d7c-458e-bdc9-f727cd63c74a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_95af2d34-b62d-44b7-93a7-1062aee05db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:to="loc_us-gaap_InterestRateContractMember_95af2d34-b62d-44b7-93a7-1062aee05db1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_034f5b97-34db-4c00-8a77-41513dbbfebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:to="loc_us-gaap_ForeignExchangeContractMember_034f5b97-34db-4c00-8a77-41513dbbfebb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" xlink:type="extended" id="i8ecdf1ffbc0f42f59ac2e1d7512e7a3e_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f510774e-031b-4e23-b970-ccdf23a8c16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ea333bf0-9b08-47e4-93e8-f00e7a91349c" xlink:href="pfe-20211231.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f510774e-031b-4e23-b970-ccdf23a8c16c" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ea333bf0-9b08-47e4-93e8-f00e7a91349c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78279083-4f41-4006-a585-61a21624932f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f510774e-031b-4e23-b970-ccdf23a8c16c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78279083-4f41-4006-a585-61a21624932f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_243cb21b-1195-4af3-8ebf-4fdd22d8b33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78279083-4f41-4006-a585-61a21624932f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_243cb21b-1195-4af3-8ebf-4fdd22d8b33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_243cb21b-1195-4af3-8ebf-4fdd22d8b33e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_243cb21b-1195-4af3-8ebf-4fdd22d8b33e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_243cb21b-1195-4af3-8ebf-4fdd22d8b33e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25503260-3ed3-4d84-9be8-47316f5951e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_243cb21b-1195-4af3-8ebf-4fdd22d8b33e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25503260-3ed3-4d84-9be8-47316f5951e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0cff12-8097-4072-bac2-d66953624b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_25503260-3ed3-4d84-9be8-47316f5951e2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0cff12-8097-4072-bac2-d66953624b51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i428848cc3ce04a0d816d52dd15056e88_FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7b992823-1d8c-45d0-b8af-3a9ec645717e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7b992823-1d8c-45d0-b8af-3a9ec645717e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_466287c4-2143-45a1-a7a1-d4e9258c00f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:to="loc_us-gaap_LongTermDebtFairValue_466287c4-2143-45a1-a7a1-d4e9258c00f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2aeaca15-e4bb-470e-ba48-6c4f791282eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2aeaca15-e4bb-470e-ba48-6c4f791282eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2aeaca15-e4bb-470e-ba48-6c4f791282eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2aeaca15-e4bb-470e-ba48-6c4f791282eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2aeaca15-e4bb-470e-ba48-6c4f791282eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13a4f03d-9759-451a-b6db-12e654f66608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2aeaca15-e4bb-470e-ba48-6c4f791282eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13a4f03d-9759-451a-b6db-12e654f66608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ea55cf58-6b3e-4cf7-b611-ec4fa54865db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13a4f03d-9759-451a-b6db-12e654f66608" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ea55cf58-6b3e-4cf7-b611-ec4fa54865db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_be452e45-efaf-4b79-ac6b-8f61a503d56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_be452e45-efaf-4b79-ac6b-8f61a503d56c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be452e45-efaf-4b79-ac6b-8f61a503d56c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_be452e45-efaf-4b79-ac6b-8f61a503d56c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_be452e45-efaf-4b79-ac6b-8f61a503d56c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_be452e45-efaf-4b79-ac6b-8f61a503d56c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1e459cd6-9f3a-46fe-be6c-c67fde433b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1e459cd6-9f3a-46fe-be6c-c67fde433b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6be90e8d-fb62-4bbc-aa7a-db8bf8aa0218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6be90e8d-fb62-4bbc-aa7a-db8bf8aa0218" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsDebtSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" xlink:type="extended" id="idebc5b8e66134d27912150b86d615487_FinancialInstrumentsInvestmentsDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd0e7f02-0b63-44d9-83f2-34635193e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd0e7f02-0b63-44d9-83f2-34635193e5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9dc94171-cc53-4464-9c4b-4e008aa1f110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9dc94171-cc53-4464-9c4b-4e008aa1f110" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_504c8c05-eb69-42de-92c5-654a684cac52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_504c8c05-eb69-42de-92c5-654a684cac52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5735063b-2675-4493-8226-21c8d92f9bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5735063b-2675-4493-8226-21c8d92f9bf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_52e63c8e-d67b-4fc4-bac9-0e04c03562e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_52e63c8e-d67b-4fc4-bac9-0e04c03562e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c78b01bc-d67a-45f8-8e6a-2037b972db48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c78b01bc-d67a-45f8-8e6a-2037b972db48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_8ce861e3-efd6-4eee-957c-6694b37e9c2d" xlink:href="pfe-20211231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_8ce861e3-efd6-4eee-957c-6694b37e9c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf8506da-4c38-487f-b552-b938a229f532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_17ed03de-2c01-4d52-90c3-dba0ddb0cf25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecurities_17ed03de-2c01-4d52-90c3-dba0ddb0cf25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_3cd77058-199a-46c6-81f3-5e20e9451623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_3cd77058-199a-46c6-81f3-5e20e9451623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_423a0380-5cac-47a1-a07e-31ff57f598dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_423a0380-5cac-47a1-a07e-31ff57f598dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_8421a297-d2f7-4715-bb65-53e3e4ab1aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_8421a297-d2f7-4715-bb65-53e3e4ab1aa5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_06df3125-486e-4a2a-91c3-f8755019bfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_06df3125-486e-4a2a-91c3-f8755019bfa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb1d7bfe-c117-48c5-8696-979497ad3633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb1d7bfe-c117-48c5-8696-979497ad3633" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_4f132446-5226-4521-9647-c5f3a514d55e" xlink:href="pfe-20211231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_4f132446-5226-4521-9647-c5f3a514d55e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_bbd0ecb1-d0d7-4411-aca3-192d61e276d7" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_bbd0ecb1-d0d7-4411-aca3-192d61e276d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_c152444e-091c-4875-a234-e7c69a3f5803" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_c152444e-091c-4875-a234-e7c69a3f5803" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_188b9423-3054-45ff-a749-0b614a99ba87" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_188b9423-3054-45ff-a749-0b614a99ba87" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_db14c376-bdf5-4f77-b6ea-4314d92d50b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_db14c376-bdf5-4f77-b6ea-4314d92d50b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_81495125-339d-4a3a-b409-334f99589797" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_81495125-339d-4a3a-b409-334f99589797" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_c0562757-daa6-47c4-a780-f207e8f23783" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_c0562757-daa6-47c4-a780-f207e8f23783" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_6e48cd4d-af6e-4756-b259-4a407387b536" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_6e48cd4d-af6e-4756-b259-4a407387b536" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_bfe78fd8-34c3-494d-a9af-940f55e752f0" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_bfe78fd8-34c3-494d-a9af-940f55e752f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_23a82e94-4a53-4338-8351-0741856301c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_bfe78fd8-34c3-494d-a9af-940f55e752f0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_23a82e94-4a53-4338-8351-0741856301c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23a82e94-4a53-4338-8351-0741856301c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23a82e94-4a53-4338-8351-0741856301c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23a82e94-4a53-4338-8351-0741856301c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23a82e94-4a53-4338-8351-0741856301c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_32512497-f4ee-43af-8689-f8c975c740d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_32512497-f4ee-43af-8689-f8c975c740d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b6cc6d8d-a36a-4c7c-8222-88c150adbf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b6cc6d8d-a36a-4c7c-8222-88c150adbf2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_faeece48-d356-488a-b2a5-21c0713e03cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_faeece48-d356-488a-b2a5-21c0713e03cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_ae4d30f1-9f61-4a46-a5b9-831ffc43a7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_BankTimeDepositsMember_ae4d30f1-9f61-4a46-a5b9-831ffc43a7f7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended" id="i1e5dc092633441a197af64e26756bc04_FinancialInstrumentsShortTermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_24ea1b4e-9ed7-4722-841a-d1da00aa0e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_CommercialPaper_24ea1b4e-9ed7-4722-841a-d1da00aa0e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_6e4f2128-49d7-40f1-90a4-13a7bc44d3d6" xlink:href="pfe-20211231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_6e4f2128-49d7-40f1-90a4-13a7bc44d3d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_484e1693-a1ab-4c48-9c63-d28b0d617c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_OtherShortTermBorrowings_484e1693-a1ab-4c48-9c63-d28b0d617c53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_05e024fe-c126-4abd-bef5-9e44e0a32400" xlink:href="pfe-20211231.xsd#pfe_ShorttermDebtGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_pfe_ShorttermDebtGross_05e024fe-c126-4abd-bef5-9e44e0a32400" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_337bc63b-b5c6-4360-af7d-2e75b63405dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_337bc63b-b5c6-4360-af7d-2e75b63405dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_0b7987d5-e2ac-4a40-98cf-b637864ca704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_DebtCurrent_0b7987d5-e2ac-4a40-98cf-b637864ca704" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_97ade02a-0809-41f1-98b0-db087104ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_97ade02a-0809-41f1-98b0-db087104ac8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_66af32d9-5eeb-4747-8c9f-3f8adfb430bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_66af32d9-5eeb-4747-8c9f-3f8adfb430bb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_5629fa5b-2efa-4ad7-b4d0-daaaa129ad81" xlink:href="pfe-20211231.xsd#pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_5629fa5b-2efa-4ad7-b4d0-daaaa129ad81" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_917dbfa6-5ae5-4327-8ad1-e0ec809569b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:to="loc_us-gaap_DebtInstrumentAxis_917dbfa6-5ae5-4327-8ad1-e0ec809569b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_917dbfa6-5ae5-4327-8ad1-e0ec809569b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_917dbfa6-5ae5-4327-8ad1-e0ec809569b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_917dbfa6-5ae5-4327-8ad1-e0ec809569b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0974612b-de2c-497e-ab3a-82c8561fb727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_917dbfa6-5ae5-4327-8ad1-e0ec809569b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0974612b-de2c-497e-ab3a-82c8561fb727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CreditFacilityExpiring2025Member_8a8685ed-5948-46ce-8f97-f16b91534252" xlink:href="pfe-20211231.xsd#pfe_CreditFacilityExpiring2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0974612b-de2c-497e-ab3a-82c8561fb727" xlink:to="loc_pfe_CreditFacilityExpiring2025Member_8a8685ed-5948-46ce-8f97-f16b91534252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7e7e8d48-9592-4445-9faa-7bad1a35de05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:to="loc_us-gaap_CreditFacilityAxis_7e7e8d48-9592-4445-9faa-7bad1a35de05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7e7e8d48-9592-4445-9faa-7bad1a35de05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7e7e8d48-9592-4445-9faa-7bad1a35de05" xlink:to="loc_us-gaap_CreditFacilityDomain_7e7e8d48-9592-4445-9faa-7bad1a35de05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_81be2a7c-f363-4a3a-979a-56f51afee3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7e7e8d48-9592-4445-9faa-7bad1a35de05" xlink:to="loc_us-gaap_CreditFacilityDomain_81be2a7c-f363-4a3a-979a-56f51afee3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e261682f-ee6f-4282-94f2-15217c453e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_81be2a7c-f363-4a3a-979a-56f51afee3af" xlink:to="loc_us-gaap_LineOfCreditMember_e261682f-ee6f-4282-94f2-15217c453e2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_655d6008-c6e1-4b92-a51a-82b5e1a599de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_655d6008-c6e1-4b92-a51a-82b5e1a599de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_655d6008-c6e1-4b92-a51a-82b5e1a599de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_655d6008-c6e1-4b92-a51a-82b5e1a599de" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_655d6008-c6e1-4b92-a51a-82b5e1a599de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_82fa5b44-0ad0-4e60-9928-752061f7087f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_655d6008-c6e1-4b92-a51a-82b5e1a599de" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_82fa5b44-0ad0-4e60-9928-752061f7087f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_95673560-8cec-4e0d-9a90-ffe587648a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_82fa5b44-0ad0-4e60-9928-752061f7087f" xlink:to="loc_us-gaap_CommercialPaperMember_95673560-8cec-4e0d-9a90-ffe587648a99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended" id="i5611455cb3ed48aab0383874a34c440d_FinancialInstrumentsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_88bca960-ce40-4360-991d-b29773bec4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_88bca960-ce40-4360-991d-b29773bec4b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ba760f87-c8b2-481f-9148-b7bfb1bba965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ba760f87-c8b2-481f-9148-b7bfb1bba965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_fbb429dc-03e6-40d8-bc79-a9c43375c217" xlink:href="pfe-20211231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_fbb429dc-03e6-40d8-bc79-a9c43375c217" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_97d22fd8-6d1b-4b30-9bc6-e20dce22d353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_97d22fd8-6d1b-4b30-9bc6-e20dce22d353" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_f1145d51-8200-42dd-8420-86e2efc54e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_OtherLongTermDebt_f1145d51-8200-42dd-8420-86e2efc54e4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_43758325-c4bf-4f93-8e23-128b823cace9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_43758325-c4bf-4f93-8e23-128b823cace9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9653bf51-b242-4c25-b73a-ca6ec15de6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_LongTermDebtCurrent_9653bf51-b242-4c25-b73a-ca6ec15de6f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3d3f2eab-e05b-483b-ad97-b396a54fd4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3d3f2eab-e05b-483b-ad97-b396a54fd4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3d3f2eab-e05b-483b-ad97-b396a54fd4ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d3f2eab-e05b-483b-ad97-b396a54fd4ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3d3f2eab-e05b-483b-ad97-b396a54fd4ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_490d0d58-e32f-4d77-a6e8-eb28b22bf361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d3f2eab-e05b-483b-ad97-b396a54fd4ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_490d0d58-e32f-4d77-a6e8-eb28b22bf361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_86058669-0df3-4fd6-88a1-4f6fda121f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_490d0d58-e32f-4d77-a6e8-eb28b22bf361" xlink:to="loc_us-gaap_UnsecuredDebtMember_86058669-0df3-4fd6-88a1-4f6fda121f4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40c51644-396c-467a-96e3-af04f0358f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:to="loc_us-gaap_DebtInstrumentAxis_40c51644-396c-467a-96e3-af04f0358f49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_40c51644-396c-467a-96e3-af04f0358f49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_40c51644-396c-467a-96e3-af04f0358f49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_40c51644-396c-467a-96e3-af04f0358f49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_40c51644-396c-467a-96e3-af04f0358f49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2022Member_58b43fab-45e8-4976-912a-f82b486b22f9" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2022Member_58b43fab-45e8-4976-912a-f82b486b22f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2023Member_9e5da086-5dc4-4595-8903-3ef0cce082bd" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2023Member_9e5da086-5dc4-4595-8903-3ef0cce082bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2024Member_85c4e82e-9ed5-478d-ab7d-31dbffe0fa19" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2024Member_85c4e82e-9ed5-478d-ab7d-31dbffe0fa19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2025Member_3b4beaa6-327b-4772-8059-2f7c6f054cbf" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2025Member_3b4beaa6-327b-4772-8059-2f7c6f054cbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2026Member_e1445e27-ed95-464c-8e1d-11b1b9175cf2" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2026Member_e1445e27-ed95-464c-8e1d-11b1b9175cf2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2027Member_4d1c4e3c-a7e8-480d-a2e5-32f4ac50653c" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2027Member_4d1c4e3c-a7e8-480d-a2e5-32f4ac50653c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20282032Member_3630102d-b55a-415b-a80c-20d29049169f" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20282032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20282032Member_3630102d-b55a-415b-a80c-20d29049169f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20332037Member_e90cf308-a0d1-4758-9228-23c163912194" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20332037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20332037Member_e90cf308-a0d1-4758-9228-23c163912194" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20382042Member_58e88809-7e90-40f0-a0bf-6569ec473452" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20382042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20382042Member_58e88809-7e90-40f0-a0bf-6569ec473452" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20432047Member_3d0df5cd-2e20-4e83-8817-489ebd0ab1df" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20432047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20432047Member_3d0df5cd-2e20-4e83-8817-489ebd0ab1df" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20482050Member_cb5f8212-507e-45e8-a289-e5cf49c45519" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20482050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20482050Member_cb5f8212-507e-45e8-a289-e5cf49c45519" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended" id="i426800f87f144bbfa11c4f8e60a7dea7_FinancialInstrumentsLongTermDebtNewIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a6cf44da-bc62-4acb-902b-cfa970d1672e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a6cf44da-bc62-4acb-902b-cfa970d1672e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b555da87-9b40-42ac-a50a-e3059ee71b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b555da87-9b40-42ac-a50a-e3059ee71b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1714c1c6-3a46-4d80-9bc7-74316e70525c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:to="loc_us-gaap_LongTermDebt_1714c1c6-3a46-4d80-9bc7-74316e70525c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:to="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a8dd3ad-6963-4caf-9656-cee8d3268ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a8dd3ad-6963-4caf-9656-cee8d3268ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a8dd3ad-6963-4caf-9656-cee8d3268ce2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a8dd3ad-6963-4caf-9656-cee8d3268ce2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a8dd3ad-6963-4caf-9656-cee8d3268ce2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2380692b-dcd8-46b6-9a6a-51133f229996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a8dd3ad-6963-4caf-9656-cee8d3268ce2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2380692b-dcd8-46b6-9a6a-51133f229996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ebc3a460-bfd7-43fc-88e0-904772fbf24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2380692b-dcd8-46b6-9a6a-51133f229996" xlink:to="loc_us-gaap_SeniorNotesMember_ebc3a460-bfd7-43fc-88e0-904772fbf24a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_734309a5-b223-445e-b32e-8674e360e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:to="loc_us-gaap_DebtInstrumentAxis_734309a5-b223-445e-b32e-8674e360e45a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_734309a5-b223-445e-b32e-8674e360e45a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_734309a5-b223-445e-b32e-8674e360e45a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_734309a5-b223-445e-b32e-8674e360e45a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a15da4f0-88a0-4dec-9efb-08aeb495c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_734309a5-b223-445e-b32e-8674e360e45a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a15da4f0-88a0-4dec-9efb-08aeb495c57b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member_9c8ed546-e2e2-420c-8a18-36ffe477be04" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a15da4f0-88a0-4dec-9efb-08aeb495c57b" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member_9c8ed546-e2e2-420c-8a18-36ffe477be04" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended" id="i8d594aa99c92462eb65a1dda905eedf3_FinancialInstrumentsLongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_08257128-493a-4fbb-9cfc-ac4f7f048de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_08257128-493a-4fbb-9cfc-ac4f7f048de7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_e578c4bf-280e-4a26-aaa7-fa7576ae141f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_e578c4bf-280e-4a26-aaa7-fa7576ae141f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_783e4281-f1f4-47a8-870c-621168f5d088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_783e4281-f1f4-47a8-870c-621168f5d088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb27e929-e512-4eb6-a11d-ea5e47292627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb27e929-e512-4eb6-a11d-ea5e47292627" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cfd0e9e0-cca0-4211-86f5-f12532083a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cfd0e9e0-cca0-4211-86f5-f12532083a45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4330aba6-043a-4008-b45a-ecfbbf5cee04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4330aba6-043a-4008-b45a-ecfbbf5cee04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fe01e53-7d65-4421-9e7d-f157c165c79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fe01e53-7d65-4421-9e7d-f157c165c79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3fe01e53-7d65-4421-9e7d-f157c165c79a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fe01e53-7d65-4421-9e7d-f157c165c79a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3fe01e53-7d65-4421-9e7d-f157c165c79a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fe01e53-7d65-4421-9e7d-f157c165c79a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_12a2ad6c-5735-4cb7-8695-a88afd7a477e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:to="loc_us-gaap_SeniorNotesMember_12a2ad6c-5735-4cb7-8695-a88afd7a477e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_53599f5e-86ce-4eef-a1a4-2406a71d33ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:to="loc_us-gaap_UnsecuredDebtMember_53599f5e-86ce-4eef-a1a4-2406a71d33ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_365cc1cf-7813-47f3-9e96-a5d201ee65cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:to="loc_us-gaap_DebtInstrumentAxis_365cc1cf-7813-47f3-9e96-a5d201ee65cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_365cc1cf-7813-47f3-9e96-a5d201ee65cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_365cc1cf-7813-47f3-9e96-a5d201ee65cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_365cc1cf-7813-47f3-9e96-a5d201ee65cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_365cc1cf-7813-47f3-9e96-a5d201ee65cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member_6d745fd0-feec-41f2-93e9-0643a56c51aa" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member_6d745fd0-feec-41f2-93e9-0643a56c51aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member_dacadf2b-0d7f-43d1-a753-267d9db83e8c" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member_dacadf2b-0d7f-43d1-a753-267d9db83e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2047Member_4dfb4380-89bf-4d0e-a483-aef7c38a2b56" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorNotesDue2047Member_4dfb4380-89bf-4d0e-a483-aef7c38a2b56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_393c86f5-7782-4236-aeee-ee926ac1aadf" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_393c86f5-7782-4236-aeee-ee926ac1aadf" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="extended" id="i12087566f74c4f9daa5417222248ea80_FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_183d1724-4cc8-486c-a84e-5d84b666ed99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_0b58188b-f5de-42e7-96dc-4dcfe0f2c742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_183d1724-4cc8-486c-a84e-5d84b666ed99" xlink:to="loc_us-gaap_DerivativeTermOfContract_0b58188b-f5de-42e7-96dc-4dcfe0f2c742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_97d417d8-c2c4-4e09-83ef-b7e394e8a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_183d1724-4cc8-486c-a84e-5d84b666ed99" xlink:to="loc_us-gaap_DerivativeTable_97d417d8-c2c4-4e09-83ef-b7e394e8a7bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bf8813d3-9720-43a4-8786-52dec893b39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_97d417d8-c2c4-4e09-83ef-b7e394e8a7bb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bf8813d3-9720-43a4-8786-52dec893b39b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_bf8813d3-9720-43a4-8786-52dec893b39b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bf8813d3-9720-43a4-8786-52dec893b39b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_bf8813d3-9720-43a4-8786-52dec893b39b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c8ed9c89-d165-417c-8024-ba94227bc76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bf8813d3-9720-43a4-8786-52dec893b39b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c8ed9c89-d165-417c-8024-ba94227bc76e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_44520fde-7ea2-4b7c-b725-46f0847742e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ed9c89-d165-417c-8024-ba94227bc76e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_44520fde-7ea2-4b7c-b725-46f0847742e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="extended" id="iba1cbc0fab2c43feb86e4caac58766ac_FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b1dd41c9-d1ad-42d5-b4c0-cce7057c51df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b1dd41c9-d1ad-42d5-b4c0-cce7057c51df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_62ef5f65-3f8d-482c-90f6-c29572ac6470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:to="loc_us-gaap_DerivativeAssets_62ef5f65-3f8d-482c-90f6-c29572ac6470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_87ee52bb-3ad3-4c51-abc1-91b121a56699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:to="loc_us-gaap_DerivativeLiabilities_87ee52bb-3ad3-4c51-abc1-91b121a56699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:to="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis_2db1911a-d98b-45e7-865a-61fab769e678" xlink:href="pfe-20211231.xsd#pfe_HedgedItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:to="loc_pfe_HedgedItemAxis_2db1911a-d98b-45e7-865a-61fab769e678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_2db1911a-d98b-45e7-865a-61fab769e678_default" xlink:href="pfe-20211231.xsd#pfe_HedgedItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_HedgedItemAxis_2db1911a-d98b-45e7-865a-61fab769e678" xlink:to="loc_pfe_HedgedItemDomain_2db1911a-d98b-45e7-865a-61fab769e678_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_d32308a5-acc1-49f8-8691-6bbe4ea35ce2" xlink:href="pfe-20211231.xsd#pfe_HedgedItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_HedgedItemAxis_2db1911a-d98b-45e7-865a-61fab769e678" xlink:to="loc_pfe_HedgedItemDomain_d32308a5-acc1-49f8-8691-6bbe4ea35ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ebdce09d-5444-4a08-93dc-8ac220f3462f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_HedgedItemDomain_d32308a5-acc1-49f8-8691-6bbe4ea35ce2" xlink:to="loc_us-gaap_SalesMember_ebdce09d-5444-4a08-93dc-8ac220f3462f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0852316b-1ed5-40c6-b47f-68bec1f513a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0852316b-1ed5-40c6-b47f-68bec1f513a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0852316b-1ed5-40c6-b47f-68bec1f513a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0852316b-1ed5-40c6-b47f-68bec1f513a8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0852316b-1ed5-40c6-b47f-68bec1f513a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0852316b-1ed5-40c6-b47f-68bec1f513a8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c51f0242-1d68-4993-9c4d-f0457fe9e288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c51f0242-1d68-4993-9c4d-f0457fe9e288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_22e35398-d367-43ed-83ba-cf81e7b3afec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:to="loc_us-gaap_InterestRateContractMember_22e35398-d367-43ed-83ba-cf81e7b3afec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:to="loc_us-gaap_HedgingDesignationAxis_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c" xlink:to="loc_us-gaap_HedgingDesignationDomain_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c" xlink:to="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_719afe45-cb29-4714-8468-e2006077f874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_719afe45-cb29-4714-8468-e2006077f874" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0ece9326-8514-4c65-8413-e00372e0e198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:to="loc_us-gaap_NondesignatedMember_0ece9326-8514-4c65-8413-e00372e0e198" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="extended" id="i074d32af77c34ef694cac65225c7fa34_FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c371c616-218e-42e2-8c76-004ab3bf6291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c371c616-218e-42e2-8c76-004ab3bf6291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_00adc950-c2eb-4b19-9617-3c83f4416db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_00adc950-c2eb-4b19-9617-3c83f4416db7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_679e639c-7c50-4c05-b2f6-8a8cce28a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_679e639c-7c50-4c05-b2f6-8a8cce28a4e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_049b3751-91fa-43ee-8086-914f2fd570d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_049b3751-91fa-43ee-8086-914f2fd570d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ed734d6c-894b-49f3-9b14-824fa7cd2bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ed734d6c-894b-49f3-9b14-824fa7cd2bb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_1fce873b-7f4f-4d92-8711-1236ed49cb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_1fce873b-7f4f-4d92-8711-1236ed49cb46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8983a696-196d-4e1e-893c-6e580daebcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8983a696-196d-4e1e-893c-6e580daebcb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_050d3a05-1e6c-4ea8-b8cc-98ba3cc87ff3" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_050d3a05-1e6c-4ea8-b8cc-98ba3cc87ff3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_989c2a30-bb60-4464-8c01-41ced27bd91f" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_989c2a30-bb60-4464-8c01-41ced27bd91f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_77dc8ae8-fa23-4110-8369-b9fc016d4475" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_77dc8ae8-fa23-4110-8369-b9fc016d4475" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0590401d-2cef-442f-96d9-3c9900e8bb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0590401d-2cef-442f-96d9-3c9900e8bb1a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_c7ff8373-6bd0-404a-b5d2-5dfc676dfc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_c7ff8373-6bd0-404a-b5d2-5dfc676dfc33" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6600bf0d-b2d9-419f-b950-8a3edb9b86dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6600bf0d-b2d9-419f-b950-8a3edb9b86dd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_82c3c10b-1ebf-4a05-b140-606aa78a4508" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_82c3c10b-1ebf-4a05-b140-606aa78a4508" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_3b9a057d-e73f-4f23-b4c5-73c048b31d01" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_3b9a057d-e73f-4f23-b4c5-73c048b31d01" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_142aa153-8f6d-49b3-b9b8-4a9131cc40d3" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_142aa153-8f6d-49b3-b9b8-4a9131cc40d3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a03456b6-6fed-453a-a038-4f345ab44cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_HedgingDesignationAxis_a03456b6-6fed-453a-a038-4f345ab44cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a03456b6-6fed-453a-a038-4f345ab44cec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a03456b6-6fed-453a-a038-4f345ab44cec" xlink:to="loc_us-gaap_HedgingDesignationDomain_a03456b6-6fed-453a-a038-4f345ab44cec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a03456b6-6fed-453a-a038-4f345ab44cec" xlink:to="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cf25f02d-6706-4aa2-880c-b5f7d2f095e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cf25f02d-6706-4aa2-880c-b5f7d2f095e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_98ad7dcd-e254-4f1d-a331-ea1d0cf9dec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:to="loc_us-gaap_NondesignatedMember_98ad7dcd-e254-4f1d-a331-ea1d0cf9dec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_16aa1ff8-ff6b-419c-8932-43d0d7306815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_16aa1ff8-ff6b-419c-8932-43d0d7306815" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_16aa1ff8-ff6b-419c-8932-43d0d7306815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_16aa1ff8-ff6b-419c-8932-43d0d7306815" xlink:to="loc_us-gaap_HedgingRelationshipDomain_16aa1ff8-ff6b-419c-8932-43d0d7306815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_16aa1ff8-ff6b-419c-8932-43d0d7306815" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_dc2261af-cf56-4454-ba37-b7320440b43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:to="loc_us-gaap_CashFlowHedgingMember_dc2261af-cf56-4454-ba37-b7320440b43f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e54e92e6-3e1f-4327-827d-642e9983fac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e54e92e6-3e1f-4327-827d-642e9983fac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_38d16086-ff01-4a27-a2a1-006b5741869f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_38d16086-ff01-4a27-a2a1-006b5741869f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_38d16086-ff01-4a27-a2a1-006b5741869f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38d16086-ff01-4a27-a2a1-006b5741869f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_38d16086-ff01-4a27-a2a1-006b5741869f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38d16086-ff01-4a27-a2a1-006b5741869f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e875e81e-5fe1-48fd-9919-429eae2ad34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e875e81e-5fe1-48fd-9919-429eae2ad34a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_e3d5102f-2f41-4f5c-9db5-af1bcc230abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_us-gaap_InterestRateContractMember_e3d5102f-2f41-4f5c-9db5-af1bcc230abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_f7353849-b385-47d7-8ef3-bc15a4cf0819" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_f7353849-b385-47d7-8ef3-bc15a4cf0819" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_efc9822d-7e36-45fb-b9ff-bbb5095f4236" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_efc9822d-7e36-45fb-b9ff-bbb5095f4236" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_959cbf11-94b0-432b-8d26-91cecca7d999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_959cbf11-94b0-432b-8d26-91cecca7d999" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_959cbf11-94b0-432b-8d26-91cecca7d999_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_959cbf11-94b0-432b-8d26-91cecca7d999" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_959cbf11-94b0-432b-8d26-91cecca7d999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_959cbf11-94b0-432b-8d26-91cecca7d999" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f1c1891-79dc-4b81-b3e2-2bf45bb07609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f1c1891-79dc-4b81-b3e2-2bf45bb07609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_91389e2b-ce5b-4a68-91d2-880731dbb283" xlink:href="pfe-20211231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_91389e2b-ce5b-4a68-91d2-880731dbb283" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="extended" id="i2ff174988f024c24aa8ade53328f8998_FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9a2ab77-a730-474d-9c27-6a421b0d74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9a2ab77-a730-474d-9c27-6a421b0d74fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_5027f2d8-396b-46a3-a7b4-1355b2820d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_5027f2d8-396b-46a3-a7b4-1355b2820d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_17eb7e0a-7d54-4eee-a8f6-cfc180ad19f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_17eb7e0a-7d54-4eee-a8f6-cfc180ad19f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_31065499-b4d8-48f7-a8e6-9effc226061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_DebtCurrent_31065499-b4d8-48f7-a8e6-9effc226061c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_306cd422-9ca5-457f-a2b1-81cd2f968989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_LongTermDebt_306cd422-9ca5-457f-a2b1-81cd2f968989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1018ee81-0c84-4766-b740-a843c53b1680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_HedgingDesignationAxis_1018ee81-0c84-4766-b740-a843c53b1680" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_1018ee81-0c84-4766-b740-a843c53b1680_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_1018ee81-0c84-4766-b740-a843c53b1680" xlink:to="loc_us-gaap_HedgingDesignationDomain_1018ee81-0c84-4766-b740-a843c53b1680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7d6aa998-b50d-4f28-bc99-e71e6638c153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_1018ee81-0c84-4766-b740-a843c53b1680" xlink:to="loc_us-gaap_HedgingDesignationDomain_7d6aa998-b50d-4f28-bc99-e71e6638c153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fea99884-3a44-4062-9100-ecfcf74e2c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7d6aa998-b50d-4f28-bc99-e71e6638c153" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fea99884-3a44-4062-9100-ecfcf74e2c7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ac288bfb-dfc9-45ff-b257-42e00da78b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ac288bfb-dfc9-45ff-b257-42e00da78b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ac288bfb-dfc9-45ff-b257-42e00da78b06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac288bfb-dfc9-45ff-b257-42e00da78b06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ac288bfb-dfc9-45ff-b257-42e00da78b06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_66df56b9-7f21-4fd3-a352-9544258a5333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac288bfb-dfc9-45ff-b257-42e00da78b06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_66df56b9-7f21-4fd3-a352-9544258a5333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4444543e-0d3d-4ca9-90f3-2c2bf390fef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_66df56b9-7f21-4fd3-a352-9544258a5333" xlink:to="loc_us-gaap_UnsecuredDebtMember_4444543e-0d3d-4ca9-90f3-2c2bf390fef2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2d625c38-ad80-4af1-bf13-7ccb9561c8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2d625c38-ad80-4af1-bf13-7ccb9561c8a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2d625c38-ad80-4af1-bf13-7ccb9561c8a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d625c38-ad80-4af1-bf13-7ccb9561c8a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2d625c38-ad80-4af1-bf13-7ccb9561c8a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d625c38-ad80-4af1-bf13-7ccb9561c8a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_4cd76056-c82c-4a10-b9a6-042693246a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:to="loc_us-gaap_ForeignExchangeContractMember_4cd76056-c82c-4a10-b9a6-042693246a9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_6c7e486b-96ea-48e7-8a7d-e0652bb1fb16" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:to="loc_pfe_ForeignCurrencyDebtMember_6c7e486b-96ea-48e7-8a7d-e0652bb1fb16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_34309030-f313-493d-aa4d-22cc36f55ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_34309030-f313-493d-aa4d-22cc36f55ede" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_34309030-f313-493d-aa4d-22cc36f55ede_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_34309030-f313-493d-aa4d-22cc36f55ede" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_34309030-f313-493d-aa4d-22cc36f55ede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_1a549d36-6254-4524-b761-0a30973cb5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_34309030-f313-493d-aa4d-22cc36f55ede" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_1a549d36-6254-4524-b761-0a30973cb5dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_f83170a5-01ee-4b46-adeb-7f01d6815da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_1a549d36-6254-4524-b761-0a30973cb5dd" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_f83170a5-01ee-4b46-adeb-7f01d6815da6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="extended" id="idbb8777915d74fb3a016e94c250dff13_FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_8aabfcf2-978d-489c-8467-00a502537658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_8aabfcf2-978d-489c-8467-00a502537658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_d8049077-c68b-4544-a5ef-14e6a4ea99ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_d8049077-c68b-4544-a5ef-14e6a4ea99ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_c1776f57-947e-4682-9523-3ec47547072c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_c1776f57-947e-4682-9523-3ec47547072c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_6347fa51-da4c-4f2d-b062-29773cb2400f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:to="loc_us-gaap_DerivativeTable_6347fa51-da4c-4f2d-b062-29773cb2400f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_6347fa51-da4c-4f2d-b062-29773cb2400f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cae6f525-a02f-4585-93ed-30680484202c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cae6f525-a02f-4585-93ed-30680484202c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_e2388778-caf8-4bf3-a534-cd88bc5c1a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cae6f525-a02f-4585-93ed-30680484202c" xlink:to="loc_us-gaap_LongTermDebtMember_e2388778-caf8-4bf3-a534-cd88bc5c1a1f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended" id="i5efd083f03ef4d109079f31a966821af_OtherFinancialInformationOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f937fe38-6da0-43ef-a2ef-60876da4aa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f542687f-6797-45ba-8591-400c394119ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f937fe38-6da0-43ef-a2ef-60876da4aa94" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f542687f-6797-45ba-8591-400c394119ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f937fe38-6da0-43ef-a2ef-60876da4aa94" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c6abfdce-8543-4eb3-8a20-4e3ffdffc010" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:to="loc_srt_CounterpartyNameAxis_c6abfdce-8543-4eb3-8a20-4e3ffdffc010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6abfdce-8543-4eb3-8a20-4e3ffdffc010_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c6abfdce-8543-4eb3-8a20-4e3ffdffc010" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c6abfdce-8543-4eb3-8a20-4e3ffdffc010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b12bdc1-01f0-44d6-9bf6-422a7d45528d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c6abfdce-8543-4eb3-8a20-4e3ffdffc010" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b12bdc1-01f0-44d6-9bf6-422a7d45528d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_df1a402c-1b33-48a7-b759-cd3c0ade83a1" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b12bdc1-01f0-44d6-9bf6-422a7d45528d" xlink:to="loc_pfe_BioNTechMember_df1a402c-1b33-48a7-b759-cd3c0ade83a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee34914c-f394-48c4-96c5-0c9b5408c124" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:to="loc_srt_ProductOrServiceAxis_ee34914c-f394-48c4-96c5-0c9b5408c124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ee34914c-f394-48c4-96c5-0c9b5408c124_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ee34914c-f394-48c4-96c5-0c9b5408c124" xlink:to="loc_srt_ProductsAndServicesDomain_ee34914c-f394-48c4-96c5-0c9b5408c124_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a19e851f-4841-49a2-8118-5b0a00a5735a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ee34914c-f394-48c4-96c5-0c9b5408c124" xlink:to="loc_srt_ProductsAndServicesDomain_a19e851f-4841-49a2-8118-5b0a00a5735a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_dd867ca2-cdb6-42cb-9557-475366b41a33" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a19e851f-4841-49a2-8118-5b0a00a5735a" xlink:to="loc_pfe_ComirnatyMember_dd867ca2-cdb6-42cb-9557-475366b41a33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c415eb95-4434-473b-a81f-2ebcff19d335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c415eb95-4434-473b-a81f-2ebcff19d335" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c415eb95-4434-473b-a81f-2ebcff19d335_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c415eb95-4434-473b-a81f-2ebcff19d335" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c415eb95-4434-473b-a81f-2ebcff19d335_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e07d1e86-7e86-4482-aafd-655c1dec4fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c415eb95-4434-473b-a81f-2ebcff19d335" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e07d1e86-7e86-4482-aafd-655c1dec4fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f358489c-62dd-43be-95ea-e9e704b952cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e07d1e86-7e86-4482-aafd-655c1dec4fd8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f358489c-62dd-43be-95ea-e9e704b952cf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i285180f22e124d94a62a75e76a435914_PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48832ab7-d73d-4b8f-8b37-75d59eed3bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48832ab7-d73d-4b8f-8b37-75d59eed3bd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34c0da34-217a-4d16-ab61-ef9f574afc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34c0da34-217a-4d16-ab61-ef9f574afc12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bff7e489-7fd9-4be6-90fd-f921ae40c1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bff7e489-7fd9-4be6-90fd-f921ae40c1aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_db55804b-9e9c-47a9-a981-8e173a256785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_db55804b-9e9c-47a9-a981-8e173a256785" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5c005f4-5613-4509-aaf7-8607c8f61ae3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:to="loc_srt_RangeAxis_d5c005f4-5613-4509-aaf7-8607c8f61ae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5c005f4-5613-4509-aaf7-8607c8f61ae3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d5c005f4-5613-4509-aaf7-8607c8f61ae3" xlink:to="loc_srt_RangeMember_d5c005f4-5613-4509-aaf7-8607c8f61ae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d5c005f4-5613-4509-aaf7-8607c8f61ae3" xlink:to="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4223d205-7a99-4e14-a069-746b9fd12c31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:to="loc_srt_MinimumMember_4223d205-7a99-4e14-a069-746b9fd12c31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_255684ed-4fb8-4057-b45d-aab4bcf016eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:to="loc_srt_MaximumMember_255684ed-4fb8-4057-b45d-aab4bcf016eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_d49f49f8-9a9d-4c43-9389-ed0c4f78934f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_LandMember_d49f49f8-9a9d-4c43-9389-ed0c4f78934f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_0a621b5a-089e-4e05-aba3-33bd3e9ed81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_BuildingMember_0a621b5a-089e-4e05-aba3-33bd3e9ed81c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ccb5baef-8198-4822-b538-7f151787ed24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ccb5baef-8198-4822-b538-7f151787ed24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3657c2a2-da57-4eb8-8fe2-ea0c9ac9d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3657c2a2-da57-4eb8-8fe2-ea0c9ac9d7ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7a7c95d4-f04f-4b43-bd04-e74bb2de7143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_ConstructionInProgressMember_7a7c95d4-f04f-4b43-bd04-e74bb2de7143" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails" xlink:type="extended" id="i7c5928af34be4cbd85b9c3a347a036bd_PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5508e729-4b68-4104-a62b-aeb7dcf71edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_98c89bb5-4053-4833-a49b-202af4900976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5508e729-4b68-4104-a62b-aeb7dcf71edc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_98c89bb5-4053-4833-a49b-202af4900976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c71d49b4-c050-448d-904f-3545b907df18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5508e729-4b68-4104-a62b-aeb7dcf71edc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c71d49b4-c050-448d-904f-3545b907df18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c71d49b4-c050-448d-904f-3545b907df18" xlink:to="loc_srt_StatementGeographicalAxis_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54" xlink:to="loc_srt_SegmentGeographicalDomain_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54" xlink:to="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a1cf70b4-56a2-4322-9b3d-60b50583c4d2" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_country_US_a1cf70b4-56a2-4322-9b3d-60b50583c4d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_05233ffd-8e12-4426-a625-d34bd5d2fe26" xlink:href="pfe-20211231.xsd#pfe_DevelopedEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_pfe_DevelopedEuropeMember_05233ffd-8e12-4426-a625-d34bd5d2fe26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_cd489704-26f8-45ce-983a-fabd2fd35179" xlink:href="pfe-20211231.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_pfe_DevelopedRestOfWorldMember_cd489704-26f8-45ce-983a-fabd2fd35179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_11fa2dd1-645e-4caa-9284-a16506f6ba21" xlink:href="pfe-20211231.xsd#pfe_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_pfe_EmergingMarketsMember_11fa2dd1-645e-4caa-9284-a16506f6ba21" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" xlink:type="extended" id="i50e3d43780ab45cbab620e85f9766488_IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62577cd1-4c65-4a3a-92ff-875cf2f09a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62577cd1-4c65-4a3a-92ff-875cf2f09a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41f91f85-4e45-4bd0-ad12-3fdf02da8a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41f91f85-4e45-4bd0-ad12-3fdf02da8a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77f5a103-282c-4a2f-9429-a79d5864b65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77f5a103-282c-4a2f-9429-a79d5864b65a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_0b0f188d-a8a5-4043-a117-b46863dffa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_0b0f188d-a8a5-4043-a117-b46863dffa0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ded74b79-80aa-4699-a293-07acd135dad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ded74b79-80aa-4699-a293-07acd135dad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ded74b79-80aa-4699-a293-07acd135dad3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ded74b79-80aa-4699-a293-07acd135dad3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ded74b79-80aa-4699-a293-07acd135dad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ded74b79-80aa-4699-a293-07acd135dad3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5d4efe49-2b66-4079-9edb-e4eff04a9e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5d4efe49-2b66-4079-9edb-e4eff04a9e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9c9e386d-c993-4eeb-a456-4d46dbfe68ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:to="loc_us-gaap_TradeNamesMember_9c9e386d-c993-4eeb-a456-4d46dbfe68ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_1ad76e58-cdd8-45ac-83ce-e71e251f5986" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_1ad76e58-cdd8-45ac-83ce-e71e251f5986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d0eac59-2876-4e2f-a330-78f3149fd0cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:to="loc_srt_CounterpartyNameAxis_4d0eac59-2876-4e2f-a330-78f3149fd0cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d0eac59-2876-4e2f-a330-78f3149fd0cd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4d0eac59-2876-4e2f-a330-78f3149fd0cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d0eac59-2876-4e2f-a330-78f3149fd0cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b23f5918-293b-4dac-83a5-2d6bbb6d6258" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4d0eac59-2876-4e2f-a330-78f3149fd0cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b23f5918-293b-4dac-83a5-2d6bbb6d6258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_6c01ec28-5955-4d7d-a35a-78dd040fe382" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b23f5918-293b-4dac-83a5-2d6bbb6d6258" xlink:to="loc_pfe_BioNTechMember_6c01ec28-5955-4d7d-a35a-78dd040fe382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2bf569d-d2ef-4141-b97b-3a08e0a905d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:to="loc_srt_ProductOrServiceAxis_e2bf569d-d2ef-4141-b97b-3a08e0a905d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2bf569d-d2ef-4141-b97b-3a08e0a905d9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e2bf569d-d2ef-4141-b97b-3a08e0a905d9" xlink:to="loc_srt_ProductsAndServicesDomain_e2bf569d-d2ef-4141-b97b-3a08e0a905d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52f1747a-37db-4803-a892-13b8d7abf5c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e2bf569d-d2ef-4141-b97b-3a08e0a905d9" xlink:to="loc_srt_ProductsAndServicesDomain_52f1747a-37db-4803-a892-13b8d7abf5c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_ee1fa6c7-db57-4faa-999f-2618cbf1c7ab" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_52f1747a-37db-4803-a892-13b8d7abf5c2" xlink:to="loc_pfe_ComirnatyMember_ee1fa6c7-db57-4faa-999f-2618cbf1c7ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5e426ca0-e4ee-462f-b5d6-3d85d746c191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dc405d68-28d6-48e1-9c4f-0a2a40087754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5e426ca0-e4ee-462f-b5d6-3d85d746c191" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dc405d68-28d6-48e1-9c4f-0a2a40087754" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_46ab79d1-a215-47dd-81b1-58221d526876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5e426ca0-e4ee-462f-b5d6-3d85d746c191" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_46ab79d1-a215-47dd-81b1-58221d526876" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_871cc9d3-f954-4553-8502-1c2dc66cc4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_46ab79d1-a215-47dd-81b1-58221d526876" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_871cc9d3-f954-4553-8502-1c2dc66cc4d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_871cc9d3-f954-4553-8502-1c2dc66cc4d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_871cc9d3-f954-4553-8502-1c2dc66cc4d2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_871cc9d3-f954-4553-8502-1c2dc66cc4d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_871cc9d3-f954-4553-8502-1c2dc66cc4d2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b6049cdd-5a3a-4591-9a87-2a69a019d853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:to="loc_us-gaap_TradeNamesMember_b6049cdd-5a3a-4591-9a87-2a69a019d853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_059e33c9-6d73-497e-8a37-ae82987fd75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_059e33c9-6d73-497e-8a37-ae82987fd75d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_e6254d1e-48f8-47f6-8bc6-d71ed38ed2cf" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_e6254d1e-48f8-47f6-8bc6-d71ed38ed2cf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="if09fd53f46be426cb57f0fea8be5520f_IdentifiableIntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3ad15497-13d7-4ad0-ba29-883a3e882fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3ad15497-13d7-4ad0-ba29-883a3e882fc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6dd357f9-95bd-41d7-ade2-b3de5cb793f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6dd357f9-95bd-41d7-ade2-b3de5cb793f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6822c8e-ff32-4b9f-8184-b4785a10a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6822c8e-ff32-4b9f-8184-b4785a10a00a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e528ac1d-300f-4870-823f-18958dc17f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6822c8e-ff32-4b9f-8184-b4785a10a00a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e528ac1d-300f-4870-823f-18958dc17f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e528ac1d-300f-4870-823f-18958dc17f9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e528ac1d-300f-4870-823f-18958dc17f9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e528ac1d-300f-4870-823f-18958dc17f9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_017e036f-5272-4db6-932d-1a5a2a406723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e528ac1d-300f-4870-823f-18958dc17f9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_017e036f-5272-4db6-932d-1a5a2a406723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f4d77740-8425-421d-a297-c5a3603d4a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_017e036f-5272-4db6-932d-1a5a2a406723" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f4d77740-8425-421d-a297-c5a3603d4a1c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" xlink:type="extended" id="i348887e6f2ed4b06964c78b9cf6d3894_PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_2f5c9681-e5bc-4299-9f48-dae67c093c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_2f5c9681-e5bc-4299-9f48-dae67c093c4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_8b2d094b-ca2a-4662-b9a8-2ce10cf277b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_8b2d094b-ca2a-4662-b9a8-2ce10cf277b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f25638fc-8e13-47b3-bcd1-a32929c39127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f25638fc-8e13-47b3-bcd1-a32929c39127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_a16829d5-5403-4641-9431-18cb693acbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_a16829d5-5403-4641-9431-18cb693acbbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2ea586b0-b948-4615-b89c-ac1a9691e20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2ea586b0-b948-4615-b89c-ac1a9691e20f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_7528e8d1-d8a6-4fd3-93ef-f37c6a9a64d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_7528e8d1-d8a6-4fd3-93ef-f37c6a9a64d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_305fba6c-f0a7-422c-8735-d3bb5a6f02f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_305fba6c-f0a7-422c-8735-d3bb5a6f02f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d20ad997-2fd1-438a-a826-e3b3169caf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d20ad997-2fd1-438a-a826-e3b3169caf61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_cf07ca13-6ed4-4cf3-a039-c5e386b77e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_cf07ca13-6ed4-4cf3-a039-c5e386b77e4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_da572958-ecfd-4b5e-b8d4-8b374e4c3190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_da572958-ecfd-4b5e-b8d4-8b374e4c3190" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_51ccc823-a21f-4bef-a023-70925cf65e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_51ccc823-a21f-4bef-a023-70925cf65e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_51ccc823-a21f-4bef-a023-70925cf65e1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_51ccc823-a21f-4bef-a023-70925cf65e1b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_51ccc823-a21f-4bef-a023-70925cf65e1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_51ccc823-a21f-4bef-a023-70925cf65e1b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_a6a79cb1-db82-4345-92b9-49ec458887e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:to="loc_us-gaap_DomesticPlanMember_a6a79cb1-db82-4345-92b9-49ec458887e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_22e42019-726b-4728-ba0c-5422d39b64b8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_a6a79cb1-db82-4345-92b9-49ec458887e1" xlink:to="loc_country_US_22e42019-726b-4728-ba0c-5422d39b64b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_31c9a64f-ea6a-40a7-9875-416a22021317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:to="loc_us-gaap_ForeignPlanMember_31c9a64f-ea6a-40a7-9875-416a22021317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_722e4a48-5b46-4853-a494-234a1e43ba01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_722e4a48-5b46-4853-a494-234a1e43ba01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_51840cad-6b0c-4fd4-83c9-2fd91bf601c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_51840cad-6b0c-4fd4-83c9-2fd91bf601c9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="extended" id="i24fa96267a1b4b5cb24f4f0090826171_PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_37b41cb5-78a6-4e05-839c-c721f0905366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_37b41cb5-78a6-4e05-839c-c721f0905366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_58358e33-d3d5-49bf-8d88-921cf736ef42" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_58358e33-d3d5-49bf-8d88-921cf736ef42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_003be0a5-553d-4775-903c-560283111588" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_003be0a5-553d-4775-903c-560283111588" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_6a35b992-6645-41ea-96e0-1dc2517f8e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_6a35b992-6645-41ea-96e0-1dc2517f8e66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_291910ec-43ae-492c-8bf5-75d8c93623c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_291910ec-43ae-492c-8bf5-75d8c93623c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_4fb12d8e-0706-49a3-9cdf-9c5bf8549bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_4fb12d8e-0706-49a3-9cdf-9c5bf8549bc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_eb51f1f3-8e87-4589-baf3-269310555f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_eb51f1f3-8e87-4589-baf3-269310555f06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e367ceb8-c8e5-4ce8-a743-65288720deef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e367ceb8-c8e5-4ce8-a743-65288720deef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e367ceb8-c8e5-4ce8-a743-65288720deef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e367ceb8-c8e5-4ce8-a743-65288720deef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e367ceb8-c8e5-4ce8-a743-65288720deef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e367ceb8-c8e5-4ce8-a743-65288720deef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_54b6e2f2-f18c-495b-8da7-ffea6fc9e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:to="loc_us-gaap_DomesticPlanMember_54b6e2f2-f18c-495b-8da7-ffea6fc9e9a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ae2d1d5-191b-4b50-a1d5-a71abd04bbf8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_54b6e2f2-f18c-495b-8da7-ffea6fc9e9a6" xlink:to="loc_country_US_2ae2d1d5-191b-4b50-a1d5-a71abd04bbf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_b97b6806-611d-44c7-b742-d0d0ef00d624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:to="loc_us-gaap_ForeignPlanMember_b97b6806-611d-44c7-b742-d0d0ef00d624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_644540be-a138-4ad8-8c36-3a94d76853a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_644540be-a138-4ad8-8c36-3a94d76853a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_644540be-a138-4ad8-8c36-3a94d76853a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_644540be-a138-4ad8-8c36-3a94d76853a6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_644540be-a138-4ad8-8c36-3a94d76853a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_644540be-a138-4ad8-8c36-3a94d76853a6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e2ed56b6-2a09-4e11-88fb-fbf63fe1a52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e2ed56b6-2a09-4e11-88fb-fbf63fe1a52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_49ff5bf3-3ba6-4d93-b893-aff5d3dee0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_49ff5bf3-3ba6-4d93-b893-aff5d3dee0a9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="extended" id="ied196d2583d34d60b14d3dedbdeb2748_PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ff517208-851e-46f3-8ad7-83eaa6fcc085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ff517208-851e-46f3-8ad7-83eaa6fcc085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e898bcc9-0965-4b69-80e4-8522cc40f994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e898bcc9-0965-4b69-80e4-8522cc40f994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d17990-2478-4a57-8ed0-a45292a6fb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d17990-2478-4a57-8ed0-a45292a6fb7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_daeb672d-dbff-4bec-b2ae-f81a47510eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d17990-2478-4a57-8ed0-a45292a6fb7b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_daeb672d-dbff-4bec-b2ae-f81a47510eab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_daeb672d-dbff-4bec-b2ae-f81a47510eab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_daeb672d-dbff-4bec-b2ae-f81a47510eab" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_daeb672d-dbff-4bec-b2ae-f81a47510eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3298bed3-c55a-476d-9765-c843bf9a8047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_daeb672d-dbff-4bec-b2ae-f81a47510eab" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3298bed3-c55a-476d-9765-c843bf9a8047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_005b9c3f-3647-48bb-92cf-a002bdf320be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3298bed3-c55a-476d-9765-c843bf9a8047" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_005b9c3f-3647-48bb-92cf-a002bdf320be" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" xlink:type="extended" id="i86b780501dcf454b8c87edd135359670_PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_024b4c72-a682-4eec-be50-e4dfdd56bfee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_024b4c72-a682-4eec-be50-e4dfdd56bfee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_8cb43be3-e331-42f3-881a-7179f8f19bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_8cb43be3-e331-42f3-881a-7179f8f19bc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_abd7aea5-aa26-4fc6-a34e-e507e5fd174b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_abd7aea5-aa26-4fc6-a34e-e507e5fd174b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_7e15e44d-a761-4998-86c7-72adb57cadc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_7e15e44d-a761-4998-86c7-72adb57cadc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d11c7faa-751b-4a5f-b4dd-d944cbde184c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d11c7faa-751b-4a5f-b4dd-d944cbde184c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f46aba37-44bc-481b-8264-b566738867f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f46aba37-44bc-481b-8264-b566738867f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c329bfb4-8a65-4123-b4a5-cc35399997a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c329bfb4-8a65-4123-b4a5-cc35399997a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_2b3e9745-c08a-46a2-b9b9-2fad4a3c7784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_2b3e9745-c08a-46a2-b9b9-2fad4a3c7784" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_c28928e9-9c3a-4dfe-97f2-2607bf730816" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_c28928e9-9c3a-4dfe-97f2-2607bf730816" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits_79ff43ae-8664-49de-b6f4-55b6f5da7353" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits_79ff43ae-8664-49de-b6f4-55b6f5da7353" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_856e7694-d040-49e9-b2f0-0717ac7cba44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_856e7694-d040-49e9-b2f0-0717ac7cba44" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_ab5ccae4-d8c0-4de9-bcb0-9f191760e516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_ab5ccae4-d8c0-4de9-bcb0-9f191760e516" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_4d2a1ea2-b7d6-49a8-a6fb-0dc124b55ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2bf518ed-9383-4ce8-8d57-e29b4e6c0aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2bf518ed-9383-4ce8-8d57-e29b4e6c0aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9020d2c9-97b3-4578-9197-a019d5c4b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9020d2c9-97b3-4578-9197-a019d5c4b89d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_af4610d3-9ecf-4052-a80c-c05ca88d6984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_af4610d3-9ecf-4052-a80c-c05ca88d6984" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_53d3d517-4b4b-4528-8ea2-303127efad2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_53d3d517-4b4b-4528-8ea2-303127efad2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_ea71816f-84fc-4c9a-a79b-72a37c1a9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_ea71816f-84fc-4c9a-a79b-72a37c1a9f02" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_63b96b84-1879-4003-8624-76ee272769d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_63b96b84-1879-4003-8624-76ee272769d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_c9acff8f-f01f-465c-975d-a8199266709e" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_c9acff8f-f01f-465c-975d-a8199266709e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_86a7263b-f820-4c87-a2ba-bc1fbb088649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_86a7263b-f820-4c87-a2ba-bc1fbb088649" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6eb811df-92c4-4e3e-bfb6-81fb6f6b4b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6eb811df-92c4-4e3e-bfb6-81fb6f6b4b9d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_23b1c2a5-4ac9-457b-b869-5561e7cc16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_09e337e7-d6d3-4d22-bded-0f2e8752d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_09e337e7-d6d3-4d22-bded-0f2e8752d3ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1c1b1314-a17b-47fa-b64d-1b074570c117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1c1b1314-a17b-47fa-b64d-1b074570c117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e7476af-5bb4-40c6-8dcf-25c05530c4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e7476af-5bb4-40c6-8dcf-25c05530c4fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8a59a853-b983-430c-b2aa-4820276d78f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8a59a853-b983-430c-b2aa-4820276d78f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7cef5b8b-2312-4827-8556-43ec3d647a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7cef5b8b-2312-4827-8556-43ec3d647a96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_c44e75ef-d999-4b65-81b4-6a5b56f1aeab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_c44e75ef-d999-4b65-81b4-6a5b56f1aeab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_ee7c0a3e-3838-40ba-a256-125cea2b2025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_c44e75ef-d999-4b65-81b4-6a5b56f1aeab" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_ee7c0a3e-3838-40ba-a256-125cea2b2025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_090061b9-5f65-4d97-899e-d7007d13ab65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_090061b9-5f65-4d97-899e-d7007d13ab65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_cce63d9b-eb49-4b98-8211-ef9c6ff78f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_cce63d9b-eb49-4b98-8211-ef9c6ff78f86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_c9ccd7f9-b964-4319-9444-b7f640ace5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_c9ccd7f9-b964-4319-9444-b7f640ace5d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_c09abdc4-6cab-4304-ae2f-ccc03bbab72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_c09abdc4-6cab-4304-ae2f-ccc03bbab72e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6d6d16c9-e6ae-46ef-be81-9020d79e930f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6d6d16c9-e6ae-46ef-be81-9020d79e930f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_c8bb2130-5ab8-46ad-a8d9-d81eb0d80427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:to="loc_us-gaap_DomesticPlanMember_c8bb2130-5ab8-46ad-a8d9-d81eb0d80427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4a64386c-b7bb-43d9-ba45-f11574cbb793" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_c8bb2130-5ab8-46ad-a8d9-d81eb0d80427" xlink:to="loc_country_US_4a64386c-b7bb-43d9-ba45-f11574cbb793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_327dd6e9-a6fc-4fdc-ac0b-2177aa20d5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:to="loc_us-gaap_ForeignPlanMember_327dd6e9-a6fc-4fdc-ac0b-2177aa20d5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e90f392f-d917-4a85-91d4-967362289a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e90f392f-d917-4a85-91d4-967362289a7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e90f392f-d917-4a85-91d4-967362289a7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e90f392f-d917-4a85-91d4-967362289a7f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e90f392f-d917-4a85-91d4-967362289a7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e90f392f-d917-4a85-91d4-967362289a7f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_18f9408c-c550-4161-8a47-3357d9e2a592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_18f9408c-c550-4161-8a47-3357d9e2a592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aedac4d3-2e96-4e5e-8e1c-6c0351e81344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aedac4d3-2e96-4e5e-8e1c-6c0351e81344" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" xlink:type="extended" id="ie2148cb634394d1e8296aba1ab739895_PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ad4c38f-5011-4505-86d8-34ed64142375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ad4c38f-5011-4505-86d8-34ed64142375" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6ebdcca4-add6-472f-a94d-580e49c95ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6ebdcca4-add6-472f-a94d-580e49c95ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_a2a423db-a35e-4ef2-a066-c9d0a5063a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_a2a423db-a35e-4ef2-a066-c9d0a5063a6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_a2a423db-a35e-4ef2-a066-c9d0a5063a6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a2a423db-a35e-4ef2-a066-c9d0a5063a6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_a2a423db-a35e-4ef2-a066-c9d0a5063a6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a2a423db-a35e-4ef2-a066-c9d0a5063a6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_006f8825-ede5-4c0a-829c-d97343013e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:to="loc_us-gaap_DomesticPlanMember_006f8825-ede5-4c0a-829c-d97343013e86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ddbe79e0-c8d2-4a06-a5e1-4b645b73babe" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_006f8825-ede5-4c0a-829c-d97343013e86" xlink:to="loc_country_US_ddbe79e0-c8d2-4a06-a5e1-4b645b73babe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e01d1201-13bc-44a5-8ec5-02c6aee0741d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:to="loc_us-gaap_ForeignPlanMember_e01d1201-13bc-44a5-8ec5-02c6aee0741d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2f9334e1-3588-409e-afe8-7f6f1fb96d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2f9334e1-3588-409e-afe8-7f6f1fb96d54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2f9334e1-3588-409e-afe8-7f6f1fb96d54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2f9334e1-3588-409e-afe8-7f6f1fb96d54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2f9334e1-3588-409e-afe8-7f6f1fb96d54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2f9334e1-3588-409e-afe8-7f6f1fb96d54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b482a093-8b85-401f-98b4-b2857201eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b482a093-8b85-401f-98b4-b2857201eeb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f1816667-4f6d-468c-8f0a-f9ea10d901ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f1816667-4f6d-468c-8f0a-f9ea10d901ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d073975e-a8c3-4eb0-8947-0a709dabc680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d073975e-a8c3-4eb0-8947-0a709dabc680" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_d073975e-a8c3-4eb0-8947-0a709dabc680_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d073975e-a8c3-4eb0-8947-0a709dabc680" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_d073975e-a8c3-4eb0-8947-0a709dabc680_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d073975e-a8c3-4eb0-8947-0a709dabc680" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_ef7534d9-77b0-42c1-823a-680179fe1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_ef7534d9-77b0-42c1-823a-680179fe1a1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember_73536146-1f68-4962-b2ff-fb3b3f67e504" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember_73536146-1f68-4962-b2ff-fb3b3f67e504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_b127f305-5fa5-440e-8a29-0e17d925c6c6" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_b127f305-5fa5-440e-8a29-0e17d925c6c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_81aebb6a-bad9-46fb-a8cc-ac54fc22a0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_81aebb6a-bad9-46fb-a8cc-ac54fc22a0d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7e4c9047-5924-4dd4-86a8-3d8ccee460e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7e4c9047-5924-4dd4-86a8-3d8ccee460e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_3e4abe5e-3c36-4b19-8953-4fa04a5ce88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_3e4abe5e-3c36-4b19-8953-4fa04a5ce88e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanOtherInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_5af63db8-a2d7-48e7-b900-f5e259497622" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_srt_PartnershipInterestMember_5af63db8-a2d7-48e7-b900-f5e259497622" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InsuranceContractsMember_33cfffae-42e3-4a06-ae18-422a0831afab" xlink:href="pfe-20211231.xsd#pfe_InsuranceContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_pfe_InsuranceContractsMember_33cfffae-42e3-4a06-ae18-422a0831afab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherCommingledFundsMember_6df01c4b-94a5-476f-85b3-509832051883" xlink:href="pfe-20211231.xsd#pfe_OtherCommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_pfe_OtherCommingledFundsMember_6df01c4b-94a5-476f-85b3-509832051883" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_70e76567-ae17-4684-bec9-51a0f28da619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_70e76567-ae17-4684-bec9-51a0f28da619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_955323b8-643a-4564-b661-162096281445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_955323b8-643a-4564-b661-162096281445" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_955323b8-643a-4564-b661-162096281445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_955323b8-643a-4564-b661-162096281445" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_955323b8-643a-4564-b661-162096281445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_955323b8-643a-4564-b661-162096281445" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_86e90bda-641d-4c63-ad0f-f24ac18f9837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_86e90bda-641d-4c63-ad0f-f24ac18f9837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0e0c8df7-37c3-4978-a4d8-af22fb3f1f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0e0c8df7-37c3-4978-a4d8-af22fb3f1f67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94765807-0bcf-4b16-b499-faa569e47ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94765807-0bcf-4b16-b499-faa569e47ce9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_8424e3c6-116c-4d82-99c7-5073e9f000b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_8424e3c6-116c-4d82-99c7-5073e9f000b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_acf52724-10a9-4bc6-b990-1f4b8dcda7eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_srt_RangeAxis_acf52724-10a9-4bc6-b990-1f4b8dcda7eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_acf52724-10a9-4bc6-b990-1f4b8dcda7eb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_acf52724-10a9-4bc6-b990-1f4b8dcda7eb" xlink:to="loc_srt_RangeMember_acf52724-10a9-4bc6-b990-1f4b8dcda7eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_acf52724-10a9-4bc6-b990-1f4b8dcda7eb" xlink:to="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_02efb004-9a1c-43d6-97c9-8a8f5a524e2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:to="loc_srt_MinimumMember_02efb004-9a1c-43d6-97c9-8a8f5a524e2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a9d48c0-130c-43af-9eea-709af911bdc4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:to="loc_srt_MaximumMember_0a9d48c0-130c-43af-9eea-709af911bdc4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="extended" id="ifac7756ecca54f35bca6faaa625d7120_PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_149679d9-c0c5-4c7e-98ba-6fb0e8302af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_149679d9-c0c5-4c7e-98ba-6fb0e8302af0" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_22446737-2ff8-421b-b131-55ff7c892854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_22446737-2ff8-421b-b131-55ff7c892854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_fa44f1bb-79db-4089-8e50-4c6602f3fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_fa44f1bb-79db-4089-8e50-4c6602f3fabc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f0c4a845-af67-4f2b-911d-d69efae930e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_fa44f1bb-79db-4089-8e50-4c6602f3fabc" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f0c4a845-af67-4f2b-911d-d69efae930e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_1043be44-6c81-43af-b3cd-7ea11c2c5a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_1043be44-6c81-43af-b3cd-7ea11c2c5a0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_6dbe1e10-46a8-4a99-9b9c-dc501cd1fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_6dbe1e10-46a8-4a99-9b9c-dc501cd1fc0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_74e84b1a-c603-40ee-9038-62f3ad39e7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_74e84b1a-c603-40ee-9038-62f3ad39e7d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9ac1535f-11f6-42fc-861f-877719a304e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_149679d9-c0c5-4c7e-98ba-6fb0e8302af0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_912e28f1-1f0c-4088-84e0-43dbcfbf4558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_912e28f1-1f0c-4088-84e0-43dbcfbf4558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_912e28f1-1f0c-4088-84e0-43dbcfbf4558_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_912e28f1-1f0c-4088-84e0-43dbcfbf4558" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_912e28f1-1f0c-4088-84e0-43dbcfbf4558_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ca6a58f0-279f-445e-b3b1-0c4858f4fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_912e28f1-1f0c-4088-84e0-43dbcfbf4558" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ca6a58f0-279f-445e-b3b1-0c4858f4fe39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_589e35d8-9364-4042-8e66-e1cedc689885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ca6a58f0-279f-445e-b3b1-0c4858f4fe39" xlink:to="loc_us-gaap_ForeignPlanMember_589e35d8-9364-4042-8e66-e1cedc689885" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_66ee3f9d-91c1-4596-85ae-1e75db28a1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_66ee3f9d-91c1-4596-85ae-1e75db28a1be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_66ee3f9d-91c1-4596-85ae-1e75db28a1be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_66ee3f9d-91c1-4596-85ae-1e75db28a1be" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_66ee3f9d-91c1-4596-85ae-1e75db28a1be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_73aa9986-0647-42d8-bcdf-84d30b89787b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_66ee3f9d-91c1-4596-85ae-1e75db28a1be" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_73aa9986-0647-42d8-bcdf-84d30b89787b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_24f4d3b5-b40d-4019-a754-1ff6bdc46913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_73aa9986-0647-42d8-bcdf-84d30b89787b" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_24f4d3b5-b40d-4019-a754-1ff6bdc46913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199381bd-142c-460d-aa03-da4166e2059b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199381bd-142c-460d-aa03-da4166e2059b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_199381bd-142c-460d-aa03-da4166e2059b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199381bd-142c-460d-aa03-da4166e2059b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_199381bd-142c-460d-aa03-da4166e2059b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b46bc37-01b6-45d5-9d0f-77875bc4a601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199381bd-142c-460d-aa03-da4166e2059b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b46bc37-01b6-45d5-9d0f-77875bc4a601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_62919e71-64e7-4226-80e7-251b6cbbbf44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b46bc37-01b6-45d5-9d0f-77875bc4a601" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_62919e71-64e7-4226-80e7-251b6cbbbf44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="extended" id="ia22d402a776540879d2a583505c897ac_PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_57df5e95-5dbc-4f25-9708-1dd9d830391f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_57df5e95-5dbc-4f25-9708-1dd9d830391f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_95617858-1b09-4a85-849e-8a048db69f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_95617858-1b09-4a85-849e-8a048db69f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_a24605a0-4113-4515-9469-790df26aa077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_a24605a0-4113-4515-9469-790df26aa077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_80e15b84-4f98-4766-9852-9d5fbe04d8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_80e15b84-4f98-4766-9852-9d5fbe04d8e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_086c251a-7d1b-4c12-9c55-6ff69aeb92c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_086c251a-7d1b-4c12-9c55-6ff69aeb92c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_6dd65ce6-d1e2-4b54-b2f7-e54a4fcad7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_6dd65ce6-d1e2-4b54-b2f7-e54a4fcad7a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5449a0f0-86d3-43b6-b679-1f0c213e998c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5449a0f0-86d3-43b6-b679-1f0c213e998c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e5306d3b-b5bb-48b6-8904-48c80d0b526a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e5306d3b-b5bb-48b6-8904-48c80d0b526a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e5306d3b-b5bb-48b6-8904-48c80d0b526a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e5306d3b-b5bb-48b6-8904-48c80d0b526a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e5306d3b-b5bb-48b6-8904-48c80d0b526a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e5306d3b-b5bb-48b6-8904-48c80d0b526a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_063e5433-8b31-464a-b055-d00724483999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:to="loc_us-gaap_DomesticPlanMember_063e5433-8b31-464a-b055-d00724483999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e1fb8e6f-281b-4bac-808e-33fb7b19b3ab" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_063e5433-8b31-464a-b055-d00724483999" xlink:to="loc_country_US_e1fb8e6f-281b-4bac-808e-33fb7b19b3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_02427980-1398-4ae9-86bd-d9f4fe1c3eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:to="loc_us-gaap_ForeignPlanMember_02427980-1398-4ae9-86bd-d9f4fe1c3eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a820e4e1-5d31-465e-b415-f14bee073be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a820e4e1-5d31-465e-b415-f14bee073be2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_a820e4e1-5d31-465e-b415-f14bee073be2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a820e4e1-5d31-465e-b415-f14bee073be2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_a820e4e1-5d31-465e-b415-f14bee073be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a820e4e1-5d31-465e-b415-f14bee073be2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_812c143b-7e48-4fa4-a1c6-2934dfab9f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_812c143b-7e48-4fa4-a1c6-2934dfab9f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d35f76b7-a162-40e2-b312-00b3c62fca89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d35f76b7-a162-40e2-b312-00b3c62fca89" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:type="extended" id="ib83bb8811ee242a78bb593be71ab89ad_EquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d14be875-469a-4bf3-95b4-f5e66f3e5e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d14be875-469a-4bf3-95b4-f5e66f3e5e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6a941b8b-10ba-4e90-a057-36f9f6e500de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6a941b8b-10ba-4e90-a057-36f9f6e500de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_29c09c9b-cf43-47e6-adc1-bc3cdd67a80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_29c09c9b-cf43-47e6-adc1-bc3cdd67a80f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_e7068d84-eb9b-4ab0-a0a7-f71135ba03dd" xlink:href="pfe-20211231.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_e7068d84-eb9b-4ab0-a0a7-f71135ba03dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f098b250-f30c-4300-9aa6-a0da6742d9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f098b250-f30c-4300-9aa6-a0da6742d9f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_46a40166-1eea-470f-8d6e-7987dbf5f36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_46a40166-1eea-470f-8d6e-7987dbf5f36a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0b532c2d-869c-4d25-ac64-5a02d0b3af51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0b532c2d-869c-4d25-ac64-5a02d0b3af51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e8e8ce53-ba95-4e1b-8f28-b380738df2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e8e8ce53-ba95-4e1b-8f28-b380738df2b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NumberofEmployeeStockOwnershipPlans_87dc2ba4-ee3a-47b6-9e5c-a3cfd78e3b45" xlink:href="pfe-20211231.xsd#pfe_NumberofEmployeeStockOwnershipPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_pfe_NumberofEmployeeStockOwnershipPlans_87dc2ba4-ee3a-47b6-9e5c-a3cfd78e3b45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_db7e62bf-1769-40e4-b31c-c8c89dc108f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_db7e62bf-1769-40e4-b31c-c8c89dc108f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_627ecf15-083a-4273-963e-9210882efbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_627ecf15-083a-4273-963e-9210882efbbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_627ecf15-083a-4273-963e-9210882efbbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_627ecf15-083a-4273-963e-9210882efbbc" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_627ecf15-083a-4273-963e-9210882efbbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_627ecf15-083a-4273-963e-9210882efbbc" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_December2017StockPurchasePlanMember_1ac43785-1595-4666-97d6-f1227dcd185d" xlink:href="pfe-20211231.xsd#pfe_December2017StockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:to="loc_pfe_December2017StockPurchasePlanMember_1ac43785-1595-4666-97d6-f1227dcd185d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_December2018StockPurchasePlanMember_2339fa5e-43b4-4587-abdc-2b1b28bf4a51" xlink:href="pfe-20211231.xsd#pfe_December2018StockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:to="loc_pfe_December2018StockPurchasePlanMember_2339fa5e-43b4-4587-abdc-2b1b28bf4a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_b0bc853a-be8d-4d98-ad0d-6e1c749f0369" xlink:href="pfe-20211231.xsd#pfe_ShareRepurchaseAgreementwithGSCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:to="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_b0bc853a-be8d-4d98-ad0d-6e1c749f0369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_89300d1f-44f2-4269-9ae0-8eda2a694df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_89300d1f-44f2-4269-9ae0-8eda2a694df1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_89300d1f-44f2-4269-9ae0-8eda2a694df1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_89300d1f-44f2-4269-9ae0-8eda2a694df1" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_89300d1f-44f2-4269-9ae0-8eda2a694df1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_92ba8f2c-d10f-46f3-833f-ef57913e8532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_89300d1f-44f2-4269-9ae0-8eda2a694df1" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_92ba8f2c-d10f-46f3-833f-ef57913e8532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CommonESOPPlanMember_ec00ceec-f460-4ed5-bdde-8c14baf5eaef" xlink:href="pfe-20211231.xsd#pfe_CommonESOPPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_92ba8f2c-d10f-46f3-833f-ef57913e8532" xlink:to="loc_pfe_CommonESOPPlanMember_ec00ceec-f460-4ed5-bdde-8c14baf5eaef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d1c29a5e-41c3-4861-b473-3c025e8caecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d1c29a5e-41c3-4861-b473-3c025e8caecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d1c29a5e-41c3-4861-b473-3c025e8caecc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d1c29a5e-41c3-4861-b473-3c025e8caecc" xlink:to="loc_us-gaap_EquityComponentDomain_d1c29a5e-41c3-4861-b473-3c025e8caecc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e5acbc0-ad53-4578-9227-41735bbe7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d1c29a5e-41c3-4861-b473-3c025e8caecc" xlink:to="loc_us-gaap_EquityComponentDomain_2e5acbc0-ad53-4578-9227-41735bbe7de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36597a42-3089-4f4d-99e8-b4a92ec5ee2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e5acbc0-ad53-4578-9227-41735bbe7de9" xlink:to="loc_us-gaap_CommonStockMember_36597a42-3089-4f4d-99e8-b4a92ec5ee2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#EquitySummaryofCommonStockPurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails" xlink:type="extended" id="i59bc92a4b8f14930a4c378877c555130_EquitySummaryofCommonStockPurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4006f8d6-6358-4ed8-8580-4877187981bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4006f8d6-6358-4ed8-8580-4877187981bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_dafefabd-bf85-4d4f-948c-6495893ce9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_dafefabd-bf85-4d4f-948c-6495893ce9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_b0adff5a-0b02-44df-b192-04dbe2f15842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_b0adff5a-0b02-44df-b192-04dbe2f15842" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_39a912af-4fe0-46fd-882d-938c7b1658ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_b0adff5a-0b02-44df-b192-04dbe2f15842" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_39a912af-4fe0-46fd-882d-938c7b1658ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_39a912af-4fe0-46fd-882d-938c7b1658ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_39a912af-4fe0-46fd-882d-938c7b1658ea" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_39a912af-4fe0-46fd-882d-938c7b1658ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e8ad2247-41eb-495a-ad23-f3384efee06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_39a912af-4fe0-46fd-882d-938c7b1658ea" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e8ad2247-41eb-495a-ad23-f3384efee06d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OpenMarketPurchasesMember_0186400e-71cb-4f87-af9d-bf9a916f98ac" xlink:href="pfe-20211231.xsd#pfe_OpenMarketPurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_e8ad2247-41eb-495a-ad23-f3384efee06d" xlink:to="loc_pfe_OpenMarketPurchasesMember_0186400e-71cb-4f87-af9d-bf9a916f98ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:type="extended" id="ib61b8b28979c4102b9603d25cfe3e6c3_ShareBasedPaymentsNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ce16af83-ccea-42c4-b044-85bc10a7021d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ce16af83-ccea-42c4-b044-85bc10a7021d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c2470d5f-bef2-4e8d-bf4a-13bcc90af718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c2470d5f-bef2-4e8d-bf4a-13bcc90af718" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_283b3329-9e6b-452b-b7bd-078b9b45b479" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_283b3329-9e6b-452b-b7bd-078b9b45b479" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_2f359857-251c-4b39-ae76-22c9adf4ceda" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_2f359857-251c-4b39-ae76-22c9adf4ceda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_886cfe61-68b8-41c8-94ff-22d044bae4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_886cfe61-68b8-41c8-94ff-22d044bae4b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_00e5c880-41a8-499f-be17-d6df96907872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_00e5c880-41a8-499f-be17-d6df96907872" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_255c4637-c589-42cf-b758-73686668303c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_255c4637-c589-42cf-b758-73686668303c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca22a521-89d7-4ddd-8445-63d86b5ebd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:to="loc_us-gaap_AwardTypeAxis_ca22a521-89d7-4ddd-8445-63d86b5ebd8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca22a521-89d7-4ddd-8445-63d86b5ebd8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ca22a521-89d7-4ddd-8445-63d86b5ebd8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca22a521-89d7-4ddd-8445-63d86b5ebd8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ca22a521-89d7-4ddd-8445-63d86b5ebd8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0bf8303a-5222-43e5-b586-0c2326bdf127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0bf8303a-5222-43e5-b586-0c2326bdf127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_dce4d9b3-b66d-41ac-aa53-a5038e98d20f" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_dce4d9b3-b66d-41ac-aa53-a5038e98d20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_24df455e-1d13-47ec-8600-5a88b6cc2b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_us-gaap_PerformanceSharesMember_24df455e-1d13-47ec-8600-5a88b6cc2b75" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_ea4312f6-4ea6-495b-ab08-295ef46c0946" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_ea4312f6-4ea6-495b-ab08-295ef46c0946" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_85251e5d-2091-4316-b809-fd4aec46431e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_85251e5d-2091-4316-b809-fd4aec46431e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_624e673e-161b-46e3-bf52-c035523326fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:to="loc_us-gaap_PlanNameAxis_624e673e-161b-46e3-bf52-c035523326fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_624e673e-161b-46e3-bf52-c035523326fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_624e673e-161b-46e3-bf52-c035523326fd" xlink:to="loc_us-gaap_PlanNameDomain_624e673e-161b-46e3-bf52-c035523326fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_24d8f2a5-71a7-4e9e-b2e5-b51dfa977708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_624e673e-161b-46e3-bf52-c035523326fd" xlink:to="loc_us-gaap_PlanNameDomain_24d8f2a5-71a7-4e9e-b2e5-b51dfa977708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_A2019StockPlanMember_cae92ec7-74d4-4ca8-9934-d1366f531701" xlink:href="pfe-20211231.xsd#pfe_A2019StockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_24d8f2a5-71a7-4e9e-b2e5-b51dfa977708" xlink:to="loc_pfe_A2019StockPlanMember_cae92ec7-74d4-4ca8-9934-d1366f531701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_22b79a65-87b2-4e30-881a-8bbf873bb1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_22b79a65-87b2-4e30-881a-8bbf873bb1d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_22b79a65-87b2-4e30-881a-8bbf873bb1d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_22b79a65-87b2-4e30-881a-8bbf873bb1d3" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_22b79a65-87b2-4e30-881a-8bbf873bb1d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_576b7972-7e7f-4f4e-af7b-b47590c36aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_22b79a65-87b2-4e30-881a-8bbf873bb1d3" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_576b7972-7e7f-4f4e-af7b-b47590c36aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_6bbb59fc-e1d0-4b5c-b8e8-6f2da1338749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_576b7972-7e7f-4f4e-af7b-b47590c36aa9" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_6bbb59fc-e1d0-4b5c-b8e8-6f2da1338749" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" xlink:type="extended" id="i5246f3a042ab4ae19385a5565994d2b8_ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a27357f4-5fb0-461b-98c8-a09a5c73e3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a27357f4-5fb0-461b-98c8-a09a5c73e3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_84ad37be-ea20-498e-92e2-3c0ea152a77a" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_84ad37be-ea20-498e-92e2-3c0ea152a77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_41092e43-9573-4b6e-9748-97d8ede01277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_41092e43-9573-4b6e-9748-97d8ede01277" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_2a7c5307-e685-4550-8a2f-8708012b663a" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_2a7c5307-e685-4550-8a2f-8708012b663a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_a3c55636-88e2-4281-a6fe-60e9d0af02de" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_a3c55636-88e2-4281-a6fe-60e9d0af02de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_e2f1e5db-4bd5-4bc7-8789-12445859f519" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_e2f1e5db-4bd5-4bc7-8789-12445859f519" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod_2d1cda30-5fe4-485f-898d-2556dc41fd98" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod_2d1cda30-5fe4-485f-898d-2556dc41fd98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1fb764f4-c901-41e6-8ac7-f985a972c583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1fb764f4-c901-41e6-8ac7-f985a972c583" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0bb6820b-102b-4ebb-b0f1-7e2b7d15eaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0bb6820b-102b-4ebb-b0f1-7e2b7d15eaf3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_2b9a660d-f6af-44eb-83b7-156a19f74a87" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_2b9a660d-f6af-44eb-83b7-156a19f74a87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_70f36043-a06b-48a2-bb01-f055d770ffc8" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_70f36043-a06b-48a2-bb01-f055d770ffc8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:to="loc_us-gaap_AwardTypeAxis_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_12e50d89-2443-41f6-ae91-1513568c5e3d" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_12e50d89-2443-41f6-ae91-1513568c5e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_999e8b70-c644-40cd-b896-39e92c818d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_999e8b70-c644-40cd-b896-39e92c818d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_7ab2e160-499b-48d8-b0c9-2595b5a981ba" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_7ab2e160-499b-48d8-b0c9-2595b5a981ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b7e1e625-6eed-4d21-a735-81ab770d4d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_us-gaap_PerformanceSharesMember_b7e1e625-6eed-4d21-a735-81ab770d4d81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BreakthroughPerformanceAwardsMember_9bdc0540-8f87-48b4-8e9f-5f65a0da5816" xlink:href="pfe-20211231.xsd#pfe_BreakthroughPerformanceAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_BreakthroughPerformanceAwardsMember_9bdc0540-8f87-48b4-8e9f-5f65a0da5816" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b3120630-b60e-4220-a70c-ae9b970f602b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b3120630-b60e-4220-a70c-ae9b970f602b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6c7b996c-5a27-42b6-9c03-b09dc153dd9f" xlink:href="pfe-20211231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6c7b996c-5a27-42b6-9c03-b09dc153dd9f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:to="loc_srt_RangeAxis_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134" xlink:to="loc_srt_RangeMember_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134" xlink:to="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78d1fdf3-b4fa-4ac1-86cc-31df7947dc84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:to="loc_srt_MinimumMember_78d1fdf3-b4fa-4ac1-86cc-31df7947dc84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7249ef03-2a67-4010-b3f8-25e7e95ff46c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:to="loc_srt_MaximumMember_7249ef03-2a67-4010-b3f8-25e7e95ff46c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_358725b9-2ed1-45e2-9661-38ce05251d81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:to="loc_srt_TitleOfIndividualAxis_358725b9-2ed1-45e2-9661-38ce05251d81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_358725b9-2ed1-45e2-9661-38ce05251d81_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_358725b9-2ed1-45e2-9661-38ce05251d81" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_358725b9-2ed1-45e2-9661-38ce05251d81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_358725b9-2ed1-45e2-9661-38ce05251d81" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_22faa200-7398-49b9-9db2-7db4ca4d606f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:to="loc_srt_ManagementMember_22faa200-7398-49b9-9db2-7db4ca4d606f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_6cea97fc-97c4-4cef-9ac5-fada565e40af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_6cea97fc-97c4-4cef-9ac5-fada565e40af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_0b7096f5-19e1-4af8-8c27-664b368f9496" xlink:href="pfe-20211231.xsd#pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:to="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_0b7096f5-19e1-4af8-8c27-664b368f9496" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" xlink:type="extended" id="iac90c2fa0a1541c8bb06f39507fcf898_ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcfc3e00-6d8d-4f5a-ab60-5c6e780170b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcfc3e00-6d8d-4f5a-ab60-5c6e780170b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c6efc3de-bf6f-40ff-8a9d-22f62219f24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c6efc3de-bf6f-40ff-8a9d-22f62219f24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6758c89e-4da0-419a-92ac-926c053cfe46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6758c89e-4da0-419a-92ac-926c053cfe46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue_74025ea6-50c1-47ec-a659-1f41f1a8d56b" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue_74025ea6-50c1-47ec-a659-1f41f1a8d56b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39250ba8-3561-4951-940d-858ea0635a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39250ba8-3561-4951-940d-858ea0635a0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_68251a0a-8947-4f9e-bc9e-29527c42d6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_68251a0a-8947-4f9e-bc9e-29527c42d6d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_349785ee-f6d5-45ea-a69c-51f2fa375172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_349785ee-f6d5-45ea-a69c-51f2fa375172" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9de59c42-5744-4ba1-a2f3-8a22ec9e3ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9de59c42-5744-4ba1-a2f3-8a22ec9e3ac6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_93dcfe13-235f-4417-8a9a-4a0615866b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_93dcfe13-235f-4417-8a9a-4a0615866b1f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_297f087d-d9e2-4a68-865b-2b14a1ad2ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_297f087d-d9e2-4a68-865b-2b14a1ad2ad3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_957efbc1-5ab9-4618-9b67-4a7328246eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_957efbc1-5ab9-4618-9b67-4a7328246eb1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1879acbe-1ca0-4c38-8beb-c017959aa5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1879acbe-1ca0-4c38-8beb-c017959aa5a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7092fe56-9b12-48c5-bd3b-b4f55690d802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1879acbe-1ca0-4c38-8beb-c017959aa5a9" xlink:to="loc_us-gaap_AwardTypeAxis_7092fe56-9b12-48c5-bd3b-b4f55690d802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7092fe56-9b12-48c5-bd3b-b4f55690d802_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7092fe56-9b12-48c5-bd3b-b4f55690d802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7092fe56-9b12-48c5-bd3b-b4f55690d802_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7092fe56-9b12-48c5-bd3b-b4f55690d802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_a76c881f-1979-4be1-9059-14915cd2f2ef" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_a76c881f-1979-4be1-9059-14915cd2f2ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_82c01b6a-ab04-45b6-ae23-0888c8bf7416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_82c01b6a-ab04-45b6-ae23-0888c8bf7416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_36301091-2864-42cd-b26c-b8565bbc5474" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_36301091-2864-42cd-b26c-b8565bbc5474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_32d145a8-30cd-4d6a-8363-dad6328dbd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_us-gaap_PerformanceSharesMember_32d145a8-30cd-4d6a-8363-dad6328dbd18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a072d73-38e4-457b-87c9-c24c8e272ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a072d73-38e4-457b-87c9-c24c8e272ce3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsScheduleofValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" xlink:type="extended" id="ifbb797de931646aa802ebc98e6db4f57_ShareBasedPaymentsScheduleofValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bb0a6bdb-2871-4843-89b3-60a7d51823c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bb0a6bdb-2871-4843-89b3-60a7d51823c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d0c2ddf-ec65-4098-974a-82cd68e3fe38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d0c2ddf-ec65-4098-974a-82cd68e3fe38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6906956-937e-4105-886a-ec60cd1ba05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6906956-937e-4105-886a-ec60cd1ba05d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a08cca4c-ab8c-4f94-ab34-d8aced367da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a08cca4c-ab8c-4f94-ab34-d8aced367da0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c105809b-dfda-40bc-b8e8-395a14a67071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c105809b-dfda-40bc-b8e8-395a14a67071" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bebdce60-3463-470c-babe-1588d005a739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c105809b-dfda-40bc-b8e8-395a14a67071" xlink:to="loc_us-gaap_AwardTypeAxis_bebdce60-3463-470c-babe-1588d005a739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebdce60-3463-470c-babe-1588d005a739_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bebdce60-3463-470c-babe-1588d005a739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bebdce60-3463-470c-babe-1588d005a739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bebdce60-3463-470c-babe-1588d005a739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6c05a55f-9053-4eb9-90ff-e20ff8df5509" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6c05a55f-9053-4eb9-90ff-e20ff8df5509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6e4d9b89-8276-49eb-a168-771748172068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6e4d9b89-8276-49eb-a168-771748172068" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" xlink:type="extended" id="ic39d8a96867d403197a857bd104023b8_ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c51db7de-2d58-4016-b072-1084ca2bf513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c51db7de-2d58-4016-b072-1084ca2bf513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06175b42-74c5-4998-bbfa-948bcf86bd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06175b42-74c5-4998-bbfa-948bcf86bd2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0aa13d1a-9b06-4382-8391-7a2009981861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0aa13d1a-9b06-4382-8391-7a2009981861" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_5796eb1a-e20a-4761-a9fd-67b1678b0bcf" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_5796eb1a-e20a-4761-a9fd-67b1678b0bcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f96a70bf-aef6-4bda-a895-cfc325f81a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f96a70bf-aef6-4bda-a895-cfc325f81a5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17863249-d0d0-476b-8c91-1887673f5301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c34a1aa-c4c8-418c-856f-1b89972a61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c34a1aa-c4c8-418c-856f-1b89972a61cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ebeb92-08fd-4297-acdc-cf2c93bf005a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ebeb92-08fd-4297-acdc-cf2c93bf005a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_03415ffd-e015-4226-9c5e-43bd4095ee51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_03415ffd-e015-4226-9c5e-43bd4095ee51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_4c0aaf5a-3b28-4c5d-8960-bfa8bf98efb2" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_4c0aaf5a-3b28-4c5d-8960-bfa8bf98efb2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82154575-e133-4cba-b25a-55eee5089860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82154575-e133-4cba-b25a-55eee5089860" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82aeea5e-9240-4393-bb2f-e2cf73f81f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_eca6b61b-2d37-4973-ac64-05999598bd55" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_eca6b61b-2d37-4973-ac64-05999598bd55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_8305c218-8d6c-4900-9252-546075b8b67d" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_8305c218-8d6c-4900-9252-546075b8b67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_abfbcd74-172c-4c38-b410-65dfcc83664b" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_abfbcd74-172c-4c38-b410-65dfcc83664b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_dd15cc15-7d8f-4384-bb16-442335a80bd7" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_dd15cc15-7d8f-4384-bb16-442335a80bd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_fc007024-deae-463b-b8ea-437fdc82c3d5" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c63778e4-0b4e-41a5-a3bb-0364869162e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c63778e4-0b4e-41a5-a3bb-0364869162e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_4019349e-40fa-4230-8bc8-65d4f8420926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_4019349e-40fa-4230-8bc8-65d4f8420926" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_18046aa6-8886-45b7-816a-1ead41bcae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_18046aa6-8886-45b7-816a-1ead41bcae8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_b6d91d35-11aa-4e27-a6b3-1d8c9f894190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_b6d91d35-11aa-4e27-a6b3-1d8c9f894190" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_7a774729-096a-4642-9efa-969b1627fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0a53102e-6620-44dc-b484-bcb3b9c02a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0a53102e-6620-44dc-b484-bcb3b9c02a90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9cc808-70bf-4f4d-b020-1f3347143456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9cc808-70bf-4f4d-b020-1f3347143456" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ebf9395b-d56a-4701-9221-f3d846ce459b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9cc808-70bf-4f4d-b020-1f3347143456" xlink:to="loc_us-gaap_AwardTypeAxis_ebf9395b-d56a-4701-9221-f3d846ce459b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebf9395b-d56a-4701-9221-f3d846ce459b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ebf9395b-d56a-4701-9221-f3d846ce459b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebf9395b-d56a-4701-9221-f3d846ce459b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ebf9395b-d56a-4701-9221-f3d846ce459b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_aeaccd5d-c93d-4ee5-a394-85399884618f" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_aeaccd5d-c93d-4ee5-a394-85399884618f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_401fb77f-5b94-4129-8a93-c098ffc33ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_401fb77f-5b94-4129-8a93-c098ffc33ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_281597dd-b2fb-4fb9-a386-34690000ee05" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_281597dd-b2fb-4fb9-a386-34690000ee05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cfc40dee-f470-4b3f-acd9-cb0a0fd06dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_us-gaap_PerformanceSharesMember_cfc40dee-f470-4b3f-acd9-cb0a0fd06dcf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BreakthroughPerformanceAwardsMember_b6dd57fb-a778-478f-97fc-263000da2c70" xlink:href="pfe-20211231.xsd#pfe_BreakthroughPerformanceAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_pfe_BreakthroughPerformanceAwardsMember_b6dd57fb-a778-478f-97fc-263000da2c70" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails" xlink:type="extended" id="iac6803e9353f4cdb9d622641a34b31f4_ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b1bd6ecd-3800-4fd8-aa17-b7d9fc7ff2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b1bd6ecd-3800-4fd8-aa17-b7d9fc7ff2e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_8b267808-5151-46f9-bcf3-6776dad675bf" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_8b267808-5151-46f9-bcf3-6776dad675bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_a7b9c034-3982-420f-96d6-54a9805ff6a6" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_a7b9c034-3982-420f-96d6-54a9805ff6a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber_d39cf70e-baa3-456b-8193-28f1d3c8c4a3" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber_d39cf70e-baa3-456b-8193-28f1d3c8c4a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_2f053ce6-01f5-4060-b912-62c824353011" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_2f053ce6-01f5-4060-b912-62c824353011" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_6b3db183-0528-4047-b502-3fccf559c06c" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_6b3db183-0528-4047-b502-3fccf559c06c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_ccf8d635-229a-4d17-b4a5-6f0a9b9ae082" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_ccf8d635-229a-4d17-b4a5-6f0a9b9ae082" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e05dd181-d94e-47c3-9c63-b6d90ffe6243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e05dd181-d94e-47c3-9c63-b6d90ffe6243" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_899a6798-4e41-4097-88b5-f30d8bded23d" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_899a6798-4e41-4097-88b5-f30d8bded23d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_be3c4dcd-6d5f-41c3-8f42-b0cd84bec354" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_be3c4dcd-6d5f-41c3-8f42-b0cd84bec354" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm_9b94fc1c-f9f0-419c-b917-99c0fb2af9c3" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm_9b94fc1c-f9f0-419c-b917-99c0fb2af9c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_bc64230d-428d-4d40-9e12-1815fb172a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_bc64230d-428d-4d40-9e12-1815fb172a7f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_66dd7b59-62ba-48e0-90d4-f62d27ae3e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_66dd7b59-62ba-48e0-90d4-f62d27ae3e8a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_6eb57497-1e53-46bb-a0e8-ba9615c4a0a9" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_6eb57497-1e53-46bb-a0e8-ba9615c4a0a9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted_97a61af4-f7c0-4074-9da2-3e8bc02a21d2" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted_97a61af4-f7c0-4074-9da2-3e8bc02a21d2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_6975709c-3b43-4abd-9c8e-b8a7e7f0bbe6" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_6975709c-3b43-4abd-9c8e-b8a7e7f0bbe6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_5f18cf75-6953-4d8c-a186-ab14c2fc7a70" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_5f18cf75-6953-4d8c-a186-ab14c2fc7a70" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c8dd4f36-a293-4207-8533-517e7a8d7862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c8dd4f36-a293-4207-8533-517e7a8d7862" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_61b7752a-8642-4d1d-8a38-4020aeb8fe41" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_61b7752a-8642-4d1d-8a38-4020aeb8fe41" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_e08028ff-9934-4f05-9ace-ccffc3ad6448" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_e08028ff-9934-4f05-9ace-ccffc3ad6448" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4edd251-291a-4dbb-9581-0358d0412e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4edd251-291a-4dbb-9581-0358d0412e19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ab1e85d8-b667-42fb-a7d2-14d67256d9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4edd251-291a-4dbb-9581-0358d0412e19" xlink:to="loc_us-gaap_AwardTypeAxis_ab1e85d8-b667-42fb-a7d2-14d67256d9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab1e85d8-b667-42fb-a7d2-14d67256d9a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ab1e85d8-b667-42fb-a7d2-14d67256d9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ab1e85d8-b667-42fb-a7d2-14d67256d9a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ab1e85d8-b667-42fb-a7d2-14d67256d9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6bcc2a7a-7ef5-438d-be85-6a374da56690" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6bcc2a7a-7ef5-438d-be85-6a374da56690" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ProfitUnitsMember_6ea11d86-5894-462b-be32-99a82f90b524" xlink:href="pfe-20211231.xsd#pfe_ProfitUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:to="loc_pfe_ProfitUnitsMember_6ea11d86-5894-462b-be32-99a82f90b524" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ida7e109cab394890a9e2706995590010_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_64a7589d-e62b-41f0-befd-4e1097655b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_64a7589d-e62b-41f0-befd-4e1097655b90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_a04710da-c238-4324-b65c-1c7e7e25290f" xlink:href="pfe-20211231.xsd#pfe_LesseeOperatingLeaseOptionToExtendTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:to="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_a04710da-c238-4324-b65c-1c7e7e25290f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a9ccf320-d7df-4351-8b34-d805da594aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:to="loc_us-gaap_VariableLeaseCost_a9ccf320-d7df-4351-8b34-d805da594aed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_44b10b8d-7bff-455f-8558-61a2c70a02cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_44b10b8d-7bff-455f-8558-61a2c70a02cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44b10b8d-7bff-455f-8558-61a2c70a02cc" xlink:to="loc_srt_RangeAxis_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3" xlink:to="loc_srt_RangeMember_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3" xlink:to="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41085851-382c-4776-bcd1-57a05fefcac5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:to="loc_srt_MinimumMember_41085851-382c-4776-bcd1-57a05fefcac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b9b8bda-ef28-493b-a26d-a62f6b954b82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:to="loc_srt_MaximumMember_6b9b8bda-ef28-493b-a26d-a62f6b954b82" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ContingenciesandCertainCommitmentsPatentLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="extended" id="ie88f554efa7a469cb193a9387e1e595a_ContingenciesandCertainCommitmentsPatentLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_5e9d747b-048b-4c27-b291-36b6cacd6eb1" xlink:href="pfe-20211231.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_5e9d747b-048b-4c27-b291-36b6cacd6eb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_0ff40e33-b7d5-4907-a3cb-a7fb448e8399" xlink:href="pfe-20211231.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_0ff40e33-b7d5-4907-a3cb-a7fb448e8399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1cc2e3c7-6c85-4f1d-a5f5-6d0f97d27889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1cc2e3c7-6c85-4f1d-a5f5-6d0f97d27889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants_1e2aca12-18ea-4450-8191-2f24302bb251" xlink:href="pfe-20211231.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_GainContingencyNumberofDefendants_1e2aca12-18ea-4450-8191-2f24302bb251" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_01efb54d-0d7a-435a-9f5f-4bf271869ffd" xlink:href="pfe-20211231.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_01efb54d-0d7a-435a-9f5f-4bf271869ffd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_daa58ed5-973b-4550-b036-bf3560a04843" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_srt_ProductOrServiceAxis_daa58ed5-973b-4550-b036-bf3560a04843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_daa58ed5-973b-4550-b036-bf3560a04843_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_daa58ed5-973b-4550-b036-bf3560a04843" xlink:to="loc_srt_ProductsAndServicesDomain_daa58ed5-973b-4550-b036-bf3560a04843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_daa58ed5-973b-4550-b036-bf3560a04843" xlink:to="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_e51f338b-b42a-4a6c-aaac-29bf8c1d5743" xlink:href="pfe-20211231.xsd#pfe_XeljanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:to="loc_pfe_XeljanzMember_e51f338b-b42a-4a6c-aaac-29bf8c1d5743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_78e6a299-598f-4744-a9cf-f579fa25b756" xlink:href="pfe-20211231.xsd#pfe_EliquisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:to="loc_pfe_EliquisMember_78e6a299-598f-4744-a9cf-f579fa25b756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ad27dfab-95cb-470f-8345-968dd0b63d2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_srt_LitigationCaseAxis_ad27dfab-95cb-470f-8345-968dd0b63d2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ad27dfab-95cb-470f-8345-968dd0b63d2a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ad27dfab-95cb-470f-8345-968dd0b63d2a" xlink:to="loc_srt_LitigationCaseTypeDomain_ad27dfab-95cb-470f-8345-968dd0b63d2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cd108782-91d2-4e7e-9be0-ba9e37b68a89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ad27dfab-95cb-470f-8345-968dd0b63d2a" xlink:to="loc_srt_LitigationCaseTypeDomain_cd108782-91d2-4e7e-9be0-ba9e37b68a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_13701a7e-efd7-400c-9622-9c1b7d8cd28e" xlink:href="pfe-20211231.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_cd108782-91d2-4e7e-9be0-ba9e37b68a89" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_13701a7e-efd7-400c-9622-9c1b7d8cd28e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_2fc9970b-0fcb-4b23-929a-2f297a573d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_2fc9970b-0fcb-4b23-929a-2f297a573d51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_2fc9970b-0fcb-4b23-929a-2f297a573d51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_2fc9970b-0fcb-4b23-929a-2f297a573d51" xlink:to="loc_us-gaap_GainContingencyNatureDomain_2fc9970b-0fcb-4b23-929a-2f297a573d51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_2fc9970b-0fcb-4b23-929a-2f297a573d51" xlink:to="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_0cc48a92-acea-4ae4-90f2-235b7c54992d" xlink:href="pfe-20211231.xsd#pfe_PatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:to="loc_pfe_PatentInfringementMember_0cc48a92-acea-4ae4-90f2-235b7c54992d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PneumococcalVaccinePatentInfringementMember_29ea6d63-265f-4b0c-a86c-cdea92c8d3f0" xlink:href="pfe-20211231.xsd#pfe_PneumococcalVaccinePatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:to="loc_pfe_PneumococcalVaccinePatentInfringementMember_29ea6d63-265f-4b0c-a86c-cdea92c8d3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPatentInfringementMember_978acf1b-2186-4dc9-8ba8-06b1841b95a7" xlink:href="pfe-20211231.xsd#pfe_OtherPatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:to="loc_pfe_OtherPatentInfringementMember_978acf1b-2186-4dc9-8ba8-06b1841b95a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_us-gaap_LitigationStatusAxis_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd" xlink:to="loc_us-gaap_LitigationStatusDomain_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2cbbb588-3e5c-4c0f-9424-9553cbe50ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd" xlink:to="loc_us-gaap_LitigationStatusDomain_2cbbb588-3e5c-4c0f-9424-9553cbe50ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_b171420f-21c2-4653-b338-ef08b6cd0afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_2cbbb588-3e5c-4c0f-9424-9553cbe50ad2" xlink:to="loc_us-gaap_PendingLitigationMember_b171420f-21c2-4653-b338-ef08b6cd0afb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa81dc7d-e3e1-461d-9b57-07254ca550b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa81dc7d-e3e1-461d-9b57-07254ca550b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_aa81dc7d-e3e1-461d-9b57-07254ca550b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa81dc7d-e3e1-461d-9b57-07254ca550b5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_aa81dc7d-e3e1-461d-9b57-07254ca550b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_36223cdb-dbec-4cba-a842-26d7bf7bfb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa81dc7d-e3e1-461d-9b57-07254ca550b5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_36223cdb-dbec-4cba-a842-26d7bf7bfb1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_3586d350-fabb-4ee2-a523-35315c60676a" xlink:href="pfe-20211231.xsd#pfe_PatentInfringementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_36223cdb-dbec-4cba-a842-26d7bf7bfb1a" xlink:to="loc_pfe_PatentInfringementMember_3586d350-fabb-4ee2-a523-35315c60676a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="extended" id="ibc6d27d519a941e3b8767284cb7a7a1d_ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_7b8ab264-bfce-486a-bc41-1b08cdb85d0f" xlink:href="pfe-20211231.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_7b8ab264-bfce-486a-bc41-1b08cdb85d0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_9f9cc89e-0741-4f69-a1d1-b00cc615b4c2" xlink:href="pfe-20211231.xsd#pfe_FeasibilityStudyNumberOfLagoons"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_9f9cc89e-0741-4f69-a1d1-b00cc615b4c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f8e44f3a-016a-44fa-bb95-d3664b3d2f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f8e44f3a-016a-44fa-bb95-d3664b3d2f10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:to="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae6b83f0-8459-4663-9b63-4557878ae2d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_srt_RangeAxis_ae6b83f0-8459-4663-9b63-4557878ae2d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae6b83f0-8459-4663-9b63-4557878ae2d4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ae6b83f0-8459-4663-9b63-4557878ae2d4" xlink:to="loc_srt_RangeMember_ae6b83f0-8459-4663-9b63-4557878ae2d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_678bdbdf-adfb-4a3e-a0f0-b35d190e2418" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ae6b83f0-8459-4663-9b63-4557878ae2d4" xlink:to="loc_srt_RangeMember_678bdbdf-adfb-4a3e-a0f0-b35d190e2418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_55836d99-0ce6-46de-9571-7ef8e1a907bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_678bdbdf-adfb-4a3e-a0f0-b35d190e2418" xlink:to="loc_srt_MinimumMember_55836d99-0ce6-46de-9571-7ef8e1a907bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a" xlink:to="loc_us-gaap_LossContingencyNatureDomain_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_70e001e1-a495-472e-8e22-8b36d7c82be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a" xlink:to="loc_us-gaap_LossContingencyNatureDomain_70e001e1-a495-472e-8e22-8b36d7c82be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_e435f730-5b53-4f1b-93ca-92e293f76caf" xlink:href="pfe-20211231.xsd#pfe_EnvironmentalRemediationLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_70e001e1-a495-472e-8e22-8b36d7c82be0" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_e435f730-5b53-4f1b-93ca-92e293f76caf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_0edfe132-3d00-4d15-a6bc-047bbb4b530f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_srt_LitigationCaseAxis_0edfe132-3d00-4d15-a6bc-047bbb4b530f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0edfe132-3d00-4d15-a6bc-047bbb4b530f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_0edfe132-3d00-4d15-a6bc-047bbb4b530f" xlink:to="loc_srt_LitigationCaseTypeDomain_0edfe132-3d00-4d15-a6bc-047bbb4b530f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ea8a5ca1-6523-4b11-a2fc-6e6d88a62156" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_0edfe132-3d00-4d15-a6bc-047bbb4b530f" xlink:to="loc_srt_LitigationCaseTypeDomain_ea8a5ca1-6523-4b11-a2fc-6e6d88a62156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_b1270d7d-4f70-48a2-9a12-f58bfb2439a7" xlink:href="pfe-20211231.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ea8a5ca1-6523-4b11-a2fc-6e6d88a62156" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_b1270d7d-4f70-48a2-9a12-f58bfb2439a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2238d8c5-c065-4be1-8c5b-0d915d067663" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_srt_ProductOrServiceAxis_2238d8c5-c065-4be1-8c5b-0d915d067663" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2238d8c5-c065-4be1-8c5b-0d915d067663_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2238d8c5-c065-4be1-8c5b-0d915d067663" xlink:to="loc_srt_ProductsAndServicesDomain_2238d8c5-c065-4be1-8c5b-0d915d067663_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2238d8c5-c065-4be1-8c5b-0d915d067663" xlink:to="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_a07df938-a03b-47f4-82ff-2aa157092057" xlink:href="pfe-20211231.xsd#pfe_EpiPenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:to="loc_pfe_EpiPenMember_a07df938-a03b-47f4-82ff-2aa157092057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember_d26564cc-5312-4d38-bc95-bfa3b8014042" xlink:href="pfe-20211231.xsd#pfe_DocetaxelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:to="loc_pfe_DocetaxelMember_d26564cc-5312-4d38-bc95-bfa3b8014042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_LitigationStatusAxis_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9" xlink:to="loc_us-gaap_LitigationStatusDomain_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_387ef97b-5be1-4d65-a193-f68d6af5496f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9" xlink:to="loc_us-gaap_LitigationStatusDomain_387ef97b-5be1-4d65-a193-f68d6af5496f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_24ff41e0-8841-44f4-b8eb-b29ea35c48d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_387ef97b-5be1-4d65-a193-f68d6af5496f" xlink:to="loc_us-gaap_PendingLitigationMember_24ff41e0-8841-44f4-b8eb-b29ea35c48d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_449b35ee-0bd9-4cd6-9afd-872a16dcf03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_449b35ee-0bd9-4cd6-9afd-872a16dcf03b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_449b35ee-0bd9-4cd6-9afd-872a16dcf03b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_449b35ee-0bd9-4cd6-9afd-872a16dcf03b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_449b35ee-0bd9-4cd6-9afd-872a16dcf03b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bf2a4da0-ea1b-48bd-bf06-e1cdc91d6910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_449b35ee-0bd9-4cd6-9afd-872a16dcf03b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bf2a4da0-ea1b-48bd-bf06-e1cdc91d6910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0db2feb2-5eb0-40b7-b83b-4ed90ae816b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_bf2a4da0-ea1b-48bd-bf06-e1cdc91d6910" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0db2feb2-5eb0-40b7-b83b-4ed90ae816b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6eb6424a-1b93-48d9-88a4-18bd0cec36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6eb6424a-1b93-48d9-88a4-18bd0cec36eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6eb6424a-1b93-48d9-88a4-18bd0cec36eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6eb6424a-1b93-48d9-88a4-18bd0cec36eb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6eb6424a-1b93-48d9-88a4-18bd0cec36eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a7f530-eb3a-4990-8348-0db852c90f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6eb6424a-1b93-48d9-88a4-18bd0cec36eb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a7f530-eb3a-4990-8348-0db852c90f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_8662df78-ce9f-4232-ade3-435ca36e43e6" xlink:href="pfe-20211231.xsd#pfe_MeridianMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a7f530-eb3a-4990-8348-0db852c90f8e" xlink:to="loc_pfe_MeridianMember_8662df78-ce9f-4232-ade3-435ca36e43e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="extended" id="idda4079728d143769e9aefd2810d4776_SegmentGeographicandOtherRevenueInformationNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_acf48cb9-df8a-4f23-a83e-0ef4693c9dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_acf48cb9-df8a-4f23-a83e-0ef4693c9dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_efb75b25-94f8-43f8-9ba7-3ee6f976b0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_Assets_efb75b25-94f8-43f8-9ba7-3ee6f976b0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_95252902-342f-4698-a04e-a6ee443568f6" xlink:href="pfe-20211231.xsd#pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_95252902-342f-4698-a04e-a6ee443568f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e2bbfb7f-205e-4d27-b5f2-93856703fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e2bbfb7f-205e-4d27-b5f2-93856703fb69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ed5a503c-a0cb-4a2a-9473-73fb80eb04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ed5a503c-a0cb-4a2a-9473-73fb80eb04ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a7fb9786-0fcd-48d0-9740-fe603d3af17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a7fb9786-0fcd-48d0-9740-fe603d3af17b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43703ab0-fe9d-4f93-aa85-e19ccee005ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43703ab0-fe9d-4f93-aa85-e19ccee005ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3ab7e9a0-1d1f-4441-a37c-c38f94b2367c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3ab7e9a0-1d1f-4441-a37c-c38f94b2367c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_358ef141-70f7-4a50-8c0f-79844d0e79d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_358ef141-70f7-4a50-8c0f-79844d0e79d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c9cb083b-f84d-425f-acd2-d8eae472ecd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c9cb083b-f84d-425f-acd2-d8eae472ecd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_52bd81b5-8684-4739-a638-71c8eb4f208d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_52bd81b5-8684-4739-a638-71c8eb4f208d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_00f40ceb-c5ed-4506-9f36-960d9c411f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_00f40ceb-c5ed-4506-9f36-960d9c411f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_d0a0ebb9-632d-4b6c-8aec-50d13dced1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_d0a0ebb9-632d-4b6c-8aec-50d13dced1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b873b3af-8343-460f-b5c0-501f6f12d26c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b873b3af-8343-460f-b5c0-501f6f12d26c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8de0bfa5-05bc-401a-a62f-4f47dfc649f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8de0bfa5-05bc-401a-a62f-4f47dfc649f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ada52ef0-f6dd-4bd8-b4be-790ac4c4590f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:to="loc_us-gaap_AccountsReceivableMember_ada52ef0-f6dd-4bd8-b4be-790ac4c4590f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_16b0147c-691a-45a8-8ef7-2291075aff0e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:to="loc_srt_SegmentGeographicalDomain_16b0147c-691a-45a8-8ef7-2291075aff0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:to="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NonUnitedStatesMember_b3dc8374-46fe-44b6-815b-22cd1c87ab8f" xlink:href="pfe-20211231.xsd#pfe_NonUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_pfe_NonUnitedStatesMember_b3dc8374-46fe-44b6-815b-22cd1c87ab8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_51c9d3f1-9b74-4496-aa45-ab6851ce0b80" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_country_US_51c9d3f1-9b74-4496-aa45-ab6851ce0b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c4630686-323a-47fb-8610-30b161e45ae0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_country_JP_c4630686-323a-47fb-8610-30b161e45ae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_175484a7-5ea7-477f-8eb2-eb3d181dafc1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:to="loc_srt_NameOfMajorCustomerDomain_175484a7-5ea7-477f-8eb2-eb3d181dafc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:to="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ThreeLargestUSWholesaleCustomersMember_bae285a3-0e68-497a-84e3-f810eecae86e" xlink:href="pfe-20211231.xsd#pfe_ThreeLargestUSWholesaleCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:to="loc_pfe_ThreeLargestUSWholesaleCustomersMember_bae285a3-0e68-497a-84e3-f810eecae86e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_ab5898e4-09d6-4abf-9172-2f47eb3264e8" xlink:href="pfe-20211231.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_ab5898e4-09d6-4abf-9172-2f47eb3264e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_011f16bb-de30-496c-8c1e-0315eda75cd9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:to="loc_srt_ProductsAndServicesDomain_011f16bb-de30-496c-8c1e-0315eda75cd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:to="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_4bcaaea3-b2b2-4984-885b-90862dd738d0" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:to="loc_pfe_ComirnatyMember_4bcaaea3-b2b2-4984-885b-90862dd738d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_379bce3c-bc51-4b15-a5b2-f50b64b87b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_379bce3c-bc51-4b15-a5b2-f50b64b87b92" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail_1"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="extended" id="i82c51b2a6ee241dfa9b090341ea5bf9e_SegmentGeographicandOtherRevenueInformationNarrativeDetail_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_acf48cb9-df8a-4f23-a83e-0ef4693c9dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_acf48cb9-df8a-4f23-a83e-0ef4693c9dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_efb75b25-94f8-43f8-9ba7-3ee6f976b0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_Assets_efb75b25-94f8-43f8-9ba7-3ee6f976b0e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_95252902-342f-4698-a04e-a6ee443568f6" xlink:href="pfe-20211231.xsd#pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_95252902-342f-4698-a04e-a6ee443568f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e2bbfb7f-205e-4d27-b5f2-93856703fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e2bbfb7f-205e-4d27-b5f2-93856703fb69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ed5a503c-a0cb-4a2a-9473-73fb80eb04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ed5a503c-a0cb-4a2a-9473-73fb80eb04ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a7fb9786-0fcd-48d0-9740-fe603d3af17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a7fb9786-0fcd-48d0-9740-fe603d3af17b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43703ab0-fe9d-4f93-aa85-e19ccee005ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43703ab0-fe9d-4f93-aa85-e19ccee005ae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3ab7e9a0-1d1f-4441-a37c-c38f94b2367c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3ab7e9a0-1d1f-4441-a37c-c38f94b2367c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_358ef141-70f7-4a50-8c0f-79844d0e79d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_358ef141-70f7-4a50-8c0f-79844d0e79d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c9cb083b-f84d-425f-acd2-d8eae472ecd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c9cb083b-f84d-425f-acd2-d8eae472ecd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_52bd81b5-8684-4739-a638-71c8eb4f208d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_52bd81b5-8684-4739-a638-71c8eb4f208d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_00f40ceb-c5ed-4506-9f36-960d9c411f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_00f40ceb-c5ed-4506-9f36-960d9c411f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_d0a0ebb9-632d-4b6c-8aec-50d13dced1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_d0a0ebb9-632d-4b6c-8aec-50d13dced1b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b873b3af-8343-460f-b5c0-501f6f12d26c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b873b3af-8343-460f-b5c0-501f6f12d26c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8de0bfa5-05bc-401a-a62f-4f47dfc649f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8de0bfa5-05bc-401a-a62f-4f47dfc649f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ada52ef0-f6dd-4bd8-b4be-790ac4c4590f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:to="loc_us-gaap_AccountsReceivableMember_ada52ef0-f6dd-4bd8-b4be-790ac4c4590f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_16b0147c-691a-45a8-8ef7-2291075aff0e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:to="loc_srt_SegmentGeographicalDomain_16b0147c-691a-45a8-8ef7-2291075aff0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:to="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NonUnitedStatesMember_b3dc8374-46fe-44b6-815b-22cd1c87ab8f" xlink:href="pfe-20211231.xsd#pfe_NonUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_pfe_NonUnitedStatesMember_b3dc8374-46fe-44b6-815b-22cd1c87ab8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_51c9d3f1-9b74-4496-aa45-ab6851ce0b80" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_country_US_51c9d3f1-9b74-4496-aa45-ab6851ce0b80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c4630686-323a-47fb-8610-30b161e45ae0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_country_JP_c4630686-323a-47fb-8610-30b161e45ae0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_175484a7-5ea7-477f-8eb2-eb3d181dafc1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:to="loc_srt_NameOfMajorCustomerDomain_175484a7-5ea7-477f-8eb2-eb3d181dafc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:to="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ThreeLargestUSWholesaleCustomersMember_bae285a3-0e68-497a-84e3-f810eecae86e" xlink:href="pfe-20211231.xsd#pfe_ThreeLargestUSWholesaleCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:to="loc_pfe_ThreeLargestUSWholesaleCustomersMember_bae285a3-0e68-497a-84e3-f810eecae86e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_ab5898e4-09d6-4abf-9172-2f47eb3264e8" xlink:href="pfe-20211231.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_ab5898e4-09d6-4abf-9172-2f47eb3264e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_011f16bb-de30-496c-8c1e-0315eda75cd9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:to="loc_srt_ProductsAndServicesDomain_011f16bb-de30-496c-8c1e-0315eda75cd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:to="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_4bcaaea3-b2b2-4984-885b-90862dd738d0" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:to="loc_pfe_ComirnatyMember_4bcaaea3-b2b2-4984-885b-90862dd738d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended" id="ibf0544ff508d4712804ab28b404795ef_SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce04e5bf-81ff-4338-b2a8-c501384bd9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce04e5bf-81ff-4338-b2a8-c501384bd9d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61bf18a7-f0ef-4143-a549-51ea2e0ed9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61bf18a7-f0ef-4143-a549-51ea2e0ed9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_238452ec-b5e2-4918-bde1-4c78f363d171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_238452ec-b5e2-4918-bde1-4c78f363d171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_e96c2a81-38d1-42be-8054-f62405553be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_InvestmentIncomeDividend_e96c2a81-38d1-42be-8054-f62405553be0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8359e56e-d49f-4c0b-ae3a-eb01b67a002d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8359e56e-d49f-4c0b-ae3a-eb01b67a002d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_ebb688f8-955a-42d5-ad3d-c2c59f57659f" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_ebb688f8-955a-42d5-ad3d-c2c59f57659f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentForCollaborativeAndLicensingArrangements_e8906e8e-f980-4b2f-b1dc-4d0e1b08f5ad" xlink:href="pfe-20211231.xsd#pfe_PaymentForCollaborativeAndLicensingArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_pfe_PaymentForCollaborativeAndLicensingArrangements_e8906e8e-f980-4b2f-b1dc-4d0e1b08f5ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_b3f67ea1-3677-4014-b9e9-3e878fdb48fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_b3f67ea1-3677-4014-b9e9-3e878fdb48fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7fa08fb9-a2f8-4e6f-bf21-ee92c4e830f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7fa08fb9-a2f8-4e6f-bf21-ee92c4e830f4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e80c6d3-70bf-4fb3-9701-5396bd21625c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e80c6d3-70bf-4fb3-9701-5396bd21625c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_c5658f09-ef7d-44e2-a25e-f91dbcfbc374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_c5658f09-ef7d-44e2-a25e-f91dbcfbc374" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ea721c1c-4982-4253-87cb-b2f94a1d6633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ea721c1c-4982-4253-87cb-b2f94a1d6633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ea721c1c-4982-4253-87cb-b2f94a1d6633_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ea721c1c-4982-4253-87cb-b2f94a1d6633" xlink:to="loc_us-gaap_SegmentDomain_ea721c1c-4982-4253-87cb-b2f94a1d6633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7acf4f9-f233-436d-ab9e-7018fc31eccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ea721c1c-4982-4253-87cb-b2f94a1d6633" xlink:to="loc_us-gaap_SegmentDomain_c7acf4f9-f233-436d-ab9e-7018fc31eccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_1db10e78-8ba4-44c0-9296-0cba58d4ab65" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7acf4f9-f233-436d-ab9e-7018fc31eccd" xlink:to="loc_pfe_BiopharmaSegmentMember_1db10e78-8ba4-44c0-9296-0cba58d4ab65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e8c04e70-b365-4a3a-a5f0-c29991ccbe60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_srt_ConsolidationItemsAxis_e8c04e70-b365-4a3a-a5f0-c29991ccbe60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e8c04e70-b365-4a3a-a5f0-c29991ccbe60_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e8c04e70-b365-4a3a-a5f0-c29991ccbe60" xlink:to="loc_srt_ConsolidationItemsDomain_e8c04e70-b365-4a3a-a5f0-c29991ccbe60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e8c04e70-b365-4a3a-a5f0-c29991ccbe60" xlink:to="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c8a8e5f2-99af-4a7b-b995-2d7f88f9d135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:to="loc_us-gaap_OperatingSegmentsMember_c8a8e5f2-99af-4a7b-b995-2d7f88f9d135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_6dfc5756-161a-4e36-b8ad-c5c1d5d6b263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:to="loc_us-gaap_CorporateNonSegmentMember_6dfc5756-161a-4e36-b8ad-c5c1d5d6b263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_7cfe56a3-4c9a-442e-aff2-366f82b6a868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_7cfe56a3-4c9a-442e-aff2-366f82b6a868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_691bf559-956c-40f5-bdd7-8b1bcefc2de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_691bf559-956c-40f5-bdd7-8b1bcefc2de2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_691bf559-956c-40f5-bdd7-8b1bcefc2de2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_691bf559-956c-40f5-bdd7-8b1bcefc2de2" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_691bf559-956c-40f5-bdd7-8b1bcefc2de2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_691bf559-956c-40f5-bdd7-8b1bcefc2de2" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember_d4dfbb34-89c2-4662-a3f2-1b523495cf68" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:to="loc_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember_d4dfbb34-89c2-4662-a3f2-1b523495cf68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_cda04102-ff7c-4aab-9872-9cc32d9389b7" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsAcquisitionRelatedCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:to="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_cda04102-ff7c-4aab-9872-9cc32d9389b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsOtherMember_35be61c6-70d7-45d6-a31d-cbdcb16fb317" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:to="loc_pfe_ReconcilingItemsOtherMember_35be61c6-70d7-45d6-a31d-cbdcb16fb317" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1d48a72-97c6-4252-b48f-af2c96a7a619" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1d48a72-97c6-4252-b48f-af2c96a7a619" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a1d48a72-97c6-4252-b48f-af2c96a7a619_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1d48a72-97c6-4252-b48f-af2c96a7a619" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a1d48a72-97c6-4252-b48f-af2c96a7a619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1d48a72-97c6-4252-b48f-af2c96a7a619" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_6249ba88-e1e1-4c7e-a9fb-af2fbf3c3c14" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:to="loc_pfe_ViivHealthcareLimitedMember_6249ba88-e1e1-4c7e-a9fb-af2fbf3c3c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_a28e1187-b042-43af-a6b7-5fe2907a29f7" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:to="loc_pfe_GSKConsumerHealthcareMember_a28e1187-b042-43af-a6b7-5fe2907a29f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2de41a23-5fa6-452f-af2c-1fc7f15518db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2de41a23-5fa6-452f-af2c-1fc7f15518db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2de41a23-5fa6-452f-af2c-1fc7f15518db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2de41a23-5fa6-452f-af2c-1fc7f15518db" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2de41a23-5fa6-452f-af2c-1fc7f15518db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8fcf54fe-f3e5-49b5-96f4-519b082bf2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2de41a23-5fa6-452f-af2c-1fc7f15518db" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8fcf54fe-f3e5-49b5-96f4-519b082bf2fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrilliumMember_4fec9b4d-ad12-4cfa-8c2d-311768c6480a" xlink:href="pfe-20211231.xsd#pfe_TrilliumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_8fcf54fe-f3e5-49b5-96f4-519b082bf2fd" xlink:to="loc_pfe_TrilliumMember_4fec9b4d-ad12-4cfa-8c2d-311768c6480a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33003408-7648-4e34-93af-578aca70139f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33003408-7648-4e34-93af-578aca70139f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_33003408-7648-4e34-93af-578aca70139f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33003408-7648-4e34-93af-578aca70139f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_33003408-7648-4e34-93af-578aca70139f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33003408-7648-4e34-93af-578aca70139f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_04b5d3d6-b450-42c2-a8c2-f7404eb4b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_04b5d3d6-b450-42c2-a8c2-f7404eb4b7e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b09f1b35-8b9a-45f8-8b89-29a08f922901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b09f1b35-8b9a-45f8-8b89-29a08f922901" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended" id="i4ccf9d3b22b748f6ab85b5062e64a8bb_SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_415ef4a9-253d-4aa7-9512-645f670f6919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70d4d81a-4b65-4810-bb95-a13f84dfe12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_415ef4a9-253d-4aa7-9512-645f670f6919" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70d4d81a-4b65-4810-bb95-a13f84dfe12a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0db4b49a-5f69-48a6-870e-ca267d760f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_415ef4a9-253d-4aa7-9512-645f670f6919" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0db4b49a-5f69-48a6-870e-ca267d760f2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ba3f6485-f26c-4b6c-b940-7de4ea26cebc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0db4b49a-5f69-48a6-870e-ca267d760f2f" xlink:to="loc_srt_StatementGeographicalAxis_ba3f6485-f26c-4b6c-b940-7de4ea26cebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ba3f6485-f26c-4b6c-b940-7de4ea26cebc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ba3f6485-f26c-4b6c-b940-7de4ea26cebc" xlink:to="loc_srt_SegmentGeographicalDomain_ba3f6485-f26c-4b6c-b940-7de4ea26cebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ba3f6485-f26c-4b6c-b940-7de4ea26cebc" xlink:to="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fb8d7653-6cc9-4935-bec2-def231242eaa" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_country_US_fb8d7653-6cc9-4935-bec2-def231242eaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_a32a80fc-6c35-4f70-a947-5ca33c76210d" xlink:href="pfe-20211231.xsd#pfe_DevelopedEuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_pfe_DevelopedEuropeMember_a32a80fc-6c35-4f70-a947-5ca33c76210d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_4a91cdb0-ffa9-49f2-939e-1e15dd58e9ef" xlink:href="pfe-20211231.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_pfe_DevelopedRestOfWorldMember_4a91cdb0-ffa9-49f2-939e-1e15dd58e9ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_1cbc17fe-780c-445a-8e19-cb46c10f6cc0" xlink:href="pfe-20211231.xsd#pfe_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_pfe_EmergingMarketsMember_1cbc17fe-780c-445a-8e19-cb46c10f6cc0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" xlink:type="extended" id="if06c08386c944c128c624c240bbaf468_SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3c5f4afb-5597-4e08-91b1-6037e28d30e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1a1ca68b-b508-48bf-8fcf-16d7fbe70eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3c5f4afb-5597-4e08-91b1-6037e28d30e9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1a1ca68b-b508-48bf-8fcf-16d7fbe70eda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3c5f4afb-5597-4e08-91b1-6037e28d30e9" xlink:to="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ecd0ea37-b8e4-4254-8095-39921752186f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:to="loc_srt_MajorCustomersAxis_ecd0ea37-b8e4-4254-8095-39921752186f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ecd0ea37-b8e4-4254-8095-39921752186f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ecd0ea37-b8e4-4254-8095-39921752186f" xlink:to="loc_srt_NameOfMajorCustomerDomain_ecd0ea37-b8e4-4254-8095-39921752186f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ecd0ea37-b8e4-4254-8095-39921752186f" xlink:to="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_McKessonInc.Member_2e4cd017-c17d-49ad-9b57-8d50a1df09aa" xlink:href="pfe-20211231.xsd#pfe_McKessonInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:to="loc_pfe_McKessonInc.Member_2e4cd017-c17d-49ad-9b57-8d50a1df09aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmerisourceBergenCorporationMember_21b195cb-5765-4d29-9986-9e0cd13fc1a3" xlink:href="pfe-20211231.xsd#pfe_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:to="loc_pfe_AmerisourceBergenCorporationMember_21b195cb-5765-4d29-9986-9e0cd13fc1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CardinalHealthInc.Member_5fb63115-c9de-4f88-9506-813d16c76f19" xlink:href="pfe-20211231.xsd#pfe_CardinalHealthInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:to="loc_pfe_CardinalHealthInc.Member_5fb63115-c9de-4f88-9506-813d16c76f19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d7a703-7f0a-47e6-ab53-650361075b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d7a703-7f0a-47e6-ab53-650361075b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_db5adc0a-22a8-4993-94ba-f9719446f75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d7a703-7f0a-47e6-ab53-650361075b8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_db5adc0a-22a8-4993-94ba-f9719446f75d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_50f1f097-e089-433b-82c4-1937b4ae6f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_50f1f097-e089-433b-82c4-1937b4ae6f1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50f1f097-e089-433b-82c4-1937b4ae6f1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50f1f097-e089-433b-82c4-1937b4ae6f1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_50f1f097-e089-433b-82c4-1937b4ae6f1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_53b04c17-e054-4453-971f-e0fd65cacb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50f1f097-e089-433b-82c4-1937b4ae6f1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_53b04c17-e054-4453-971f-e0fd65cacb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8d388ebf-b9bd-47e6-aafe-370b8dd286bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_53b04c17-e054-4453-971f-e0fd65cacb79" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8d388ebf-b9bd-47e6-aafe-370b8dd286bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"/>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended" id="i6f884340f70d4f9388646da21dda0a39_SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_dcafd3fc-a399-43e4-a7f1-b5ffaad7f8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20f7ee24-a320-48c8-8778-54546490d112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_dcafd3fc-a399-43e4-a7f1-b5ffaad7f8f2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20f7ee24-a320-48c8-8778-54546490d112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_dcafd3fc-a399-43e4-a7f1-b5ffaad7f8f2" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_us-gaap_ReportingUnitAxis_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4" xlink:to="loc_us-gaap_ReportingUnitDomain_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4" xlink:to="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VaccinesMember_2d0078d7-309c-4ca6-a508-d57c2c992c1d" xlink:href="pfe-20211231.xsd#pfe_VaccinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_VaccinesMember_2d0078d7-309c-4ca6-a508-d57c2c992c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember_7ac66340-5c04-4bad-a012-be6513ecbb15" xlink:href="pfe-20211231.xsd#pfe_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_OncologyMember_7ac66340-5c04-4bad-a012-be6513ecbb15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternalMedicineMember_f7f31805-25b0-4231-8e58-4318fad022cb" xlink:href="pfe-20211231.xsd#pfe_InternalMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_InternalMedicineMember_f7f31805-25b0-4231-8e58-4318fad022cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospitalMember_e3f8a582-7517-49b3-98a5-2dfeeeae745b" xlink:href="pfe-20211231.xsd#pfe_HospitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_HospitalMember_e3f8a582-7517-49b3-98a5-2dfeeeae745b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflammationandImmunologyMember_426b0a70-7a65-49cd-bd9b-94d0a894c776" xlink:href="pfe-20211231.xsd#pfe_InflammationandImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_InflammationandImmunologyMember_426b0a70-7a65-49cd-bd9b-94d0a894c776" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RareDiseaseMember_52453523-3900-4534-a896-16b5cec9389e" xlink:href="pfe-20211231.xsd#pfe_RareDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_RareDiseaseMember_52453523-3900-4534-a896-16b5cec9389e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_faafee14-d57a-4bd2-a1af-435efed2a547" xlink:href="pfe-20211231.xsd#pfe_ConsumerHealthcareReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_ConsumerHealthcareReportingUnitMember_faafee14-d57a-4bd2-a1af-435efed2a547" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_srt_ProductOrServiceAxis_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03" xlink:to="loc_srt_ProductsAndServicesDomain_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03" xlink:to="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_a4ba74e8-af3a-48e8-9c33-57492e1f59f3" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ComirnatyMember_a4ba74e8-af3a-48e8-9c33-57492e1f59f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_0b463b37-664a-4c3c-b676-c7947d574c22" xlink:href="pfe-20211231.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_0b463b37-664a-4c3c-b676-c7947d574c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember_65a9c1bf-8afe-42e1-9d9f-8dcecfe413cb" xlink:href="pfe-20211231.xsd#pfe_NimenrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_NimenrixMember_65a9c1bf-8afe-42e1-9d9f-8dcecfe413cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_bb67d37b-2908-4d1e-8fb5-aef3dc4415e6" xlink:href="pfe-20211231.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_bb67d37b-2908-4d1e-8fb5-aef3dc4415e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrumenbaMember_9222b5dd-aaa9-4391-9e9f-8c42dd1e3b3c" xlink:href="pfe-20211231.xsd#pfe_TrumenbaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TrumenbaMember_9222b5dd-aaa9-4391-9e9f-8c42dd1e3b3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherVaccinesProductsMember_0e6c685f-fc9f-4335-853a-fc38262cf05b" xlink:href="pfe-20211231.xsd#pfe_OtherVaccinesProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherVaccinesProductsMember_0e6c685f-fc9f-4335-853a-fc38262cf05b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember_cfe2a7db-0e96-49ef-ad54-49c0e23d6880" xlink:href="pfe-20211231.xsd#pfe_IbranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_IbranceMember_cfe2a7db-0e96-49ef-ad54-49c0e23d6880" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_6eb6c475-2929-4838-be25-c875087592ce" xlink:href="pfe-20211231.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_6eb6c475-2929-4838-be25-c875087592ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember_ac0158be-5098-4399-a74c-3f4efa4be1ee" xlink:href="pfe-20211231.xsd#pfe_InlytaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_InlytaMember_ac0158be-5098-4399-a74c-3f4efa4be1ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember_b89ffd87-7400-4b58-af12-e994cbe2bba3" xlink:href="pfe-20211231.xsd#pfe_SutentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_SutentMember_b89ffd87-7400-4b58-af12-e994cbe2bba3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember_eb2461d7-9ae8-49f3-9d0a-98a45c7a6d61" xlink:href="pfe-20211231.xsd#pfe_BosulifMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BosulifMember_eb2461d7-9ae8-49f3-9d0a-98a45c7a6d61" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember_8db191c5-bb51-48b6-8206-6ff9ad840493" xlink:href="pfe-20211231.xsd#pfe_XalkoriMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_XalkoriMember_8db191c5-bb51-48b6-8206-6ff9ad840493" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember_cdcc19a9-68b7-4c29-9b09-54b4c7ca3731" xlink:href="pfe-20211231.xsd#pfe_RuxienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_RuxienceMember_cdcc19a9-68b7-4c29-9b09-54b4c7ca3731" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember_2df70e9d-a0bf-482f-9628-2c22d59df067" xlink:href="pfe-20211231.xsd#pfe_RetacritMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_RetacritMember_2df70e9d-a0bf-482f-9628-2c22d59df067" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember_e3434dbf-8402-4353-9e3a-5bc19d3a1d2b" xlink:href="pfe-20211231.xsd#pfe_ZirabevMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZirabevMember_e3434dbf-8402-4353-9e3a-5bc19d3a1d2b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember_e0da73e7-f1c6-428b-93c6-3d19170131e2" xlink:href="pfe-20211231.xsd#pfe_LorbrenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_LorbrenaMember_e0da73e7-f1c6-428b-93c6-3d19170131e2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember_ab032b99-60ba-4ce7-9809-43a21436706a" xlink:href="pfe-20211231.xsd#pfe_AromasinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AromasinMember_ab032b99-60ba-4ce7-9809-43a21436706a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrazimeraMember_cd63db85-0cbe-49aa-90e8-29c6fa343f06" xlink:href="pfe-20211231.xsd#pfe_TrazimeraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TrazimeraMember_cd63db85-0cbe-49aa-90e8-29c6fa343f06" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember_65225bc8-20b5-4df4-a0b5-e38cfd812ce7" xlink:href="pfe-20211231.xsd#pfe_BesponsaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BesponsaMember_65225bc8-20b5-4df4-a0b5-e38cfd812ce7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember_16fae200-9581-450d-9c6a-ac2e6792f9c0" xlink:href="pfe-20211231.xsd#pfe_BraftoviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BraftoviMember_16fae200-9581-450d-9c6a-ac2e6792f9c0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BavencioAllianceRevenuesMember_6a81e05a-852a-49df-a31d-caa5e79597de" xlink:href="pfe-20211231.xsd#pfe_BavencioAllianceRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BavencioAllianceRevenuesMember_6a81e05a-852a-49df-a31d-caa5e79597de" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_9403c952-6c06-4f89-8870-5be2fab45d87" xlink:href="pfe-20211231.xsd#pfe_MektoviMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_MektoviMember_9403c952-6c06-4f89-8870-5be2fab45d87" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember_d86982f6-cdf5-410b-a645-bc842d470690" xlink:href="pfe-20211231.xsd#pfe_OtherOncologyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherOncologyProductsMember_d86982f6-cdf5-410b-a645-bc842d470690" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_ec9c9d7d-6c3e-46cb-8ec4-db0255ecd20f" xlink:href="pfe-20211231.xsd#pfe_EliquisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_EliquisMember_ec9c9d7d-6c3e-46cb-8ec4-db0255ecd20f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember_b46b7652-8959-4368-a60e-a289b12d89ed" xlink:href="pfe-20211231.xsd#pfe_PremarinFamilyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PremarinFamilyMember_b46b7652-8959-4368-a60e-a289b12d89ed" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember_d6bfd26e-8f7a-43ff-a629-6fe22c1e6f45" xlink:href="pfe-20211231.xsd#pfe_ChantixChampixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ChantixChampixMember_d6bfd26e-8f7a-43ff-a629-6fe22c1e6f45" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BMP2Member_d8d60c93-9515-47d0-aadb-24278986d495" xlink:href="pfe-20211231.xsd#pfe_BMP2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BMP2Member_d8d60c93-9515-47d0-aadb-24278986d495" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember_245fa7cc-25ec-4b8e-b432-63a95f627534" xlink:href="pfe-20211231.xsd#pfe_ToviazMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ToviazMember_245fa7cc-25ec-4b8e-b432-63a95f627534" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PristiqMember_042119c2-9d6a-4423-8313-4755e5256067" xlink:href="pfe-20211231.xsd#pfe_PristiqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PristiqMember_042119c2-9d6a-4423-8313-4755e5256067" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInternalMedicineMember_975b3c78-9cd4-4e67-8139-41356aa9096c" xlink:href="pfe-20211231.xsd#pfe_AllOtherInternalMedicineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AllOtherInternalMedicineMember_975b3c78-9cd4-4e67-8139-41356aa9096c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember_bcb68fdc-a3f3-4250-9a5d-0ff6fec5925d" xlink:href="pfe-20211231.xsd#pfe_SulperazonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_SulperazonMember_bcb68fdc-a3f3-4250-9a5d-0ff6fec5925d" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember_898fe160-51a0-4bf3-acde-83064c6eb970" xlink:href="pfe-20211231.xsd#pfe_MedrolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_MedrolMember_898fe160-51a0-4bf3-acde-83064c6eb970" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember_ebdbaf5f-2553-45ae-bc5f-62bdabdbe217" xlink:href="pfe-20211231.xsd#pfe_ZaviceftaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZaviceftaMember_ebdbaf5f-2553-45ae-bc5f-62bdabdbe217" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember_cd25d16d-586b-45fa-9f3a-ec2e77210c9d" xlink:href="pfe-20211231.xsd#pfe_FragminMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_FragminMember_cd25d16d-586b-45fa-9f3a-ec2e77210c9d" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember_29ed40af-3770-4711-a32b-a0b1ccbe0c86" xlink:href="pfe-20211231.xsd#pfe_ZithromaxZmaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZithromaxZmaxMember_29ed40af-3770-4711-a32b-a0b1ccbe0c86" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember_225a7966-0606-4019-a410-c919fb590543" xlink:href="pfe-20211231.xsd#pfe_VfendMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_VfendMember_225a7966-0606-4019-a410-c919fb590543" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TygacilMember_c3a4a033-6e01-4663-85c6-5bcb3bcf6d64" xlink:href="pfe-20211231.xsd#pfe_TygacilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TygacilMember_c3a4a033-6e01-4663-85c6-5bcb3bcf6d64" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrecedexMember_924afd7a-2b54-45d1-90eb-b37bd52b747d" xlink:href="pfe-20211231.xsd#pfe_PrecedexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PrecedexMember_924afd7a-2b54-45d1-90eb-b37bd52b747d" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZyvoxMember_3a5bcceb-c116-4584-aab9-4ee4ad489d14" xlink:href="pfe-20211231.xsd#pfe_ZyvoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZyvoxMember_3a5bcceb-c116-4584-aab9-4ee4ad489d14" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_240e5c44-cb65-4562-acdd-b8816e653dc9" xlink:href="pfe-20211231.xsd#pfe_PaxlovidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PaxlovidMember_240e5c44-cb65-4562-acdd-b8816e653dc9" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IVIgProductsMember_99c3abc6-f367-4cc7-b29d-1f097156c232" xlink:href="pfe-20211231.xsd#pfe_IVIgProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_IVIgProductsMember_99c3abc6-f367-4cc7-b29d-1f097156c232" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember_23bce63d-69ec-4663-9bb3-45a1d7f5f1c4" xlink:href="pfe-20211231.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherAntiinfectivesMember_23bce63d-69ec-4663-9bb3-45a1d7f5f1c4" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherHospitalProductsMember_9e3bbd5f-946e-4be7-b451-13e1233e6d4b" xlink:href="pfe-20211231.xsd#pfe_OtherHospitalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherHospitalProductsMember_9e3bbd5f-946e-4be7-b451-13e1233e6d4b" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_c9f91022-c211-497c-a6c4-ab8d394e6812" xlink:href="pfe-20211231.xsd#pfe_XeljanzMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_XeljanzMember_c9f91022-c211-497c-a6c4-ab8d394e6812" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember_1c423c99-3072-453d-b973-3d4638c95e09" xlink:href="pfe-20211231.xsd#pfe_EnbrelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_EnbrelMember_1c423c99-3072-453d-b973-3d4638c95e09" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraRemsimaMember_9e090209-2015-4376-9d1e-17c62e58207e" xlink:href="pfe-20211231.xsd#pfe_InflectraRemsimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_InflectraRemsimaMember_9e090209-2015-4376-9d1e-17c62e58207e" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_06c68583-acd5-460f-9e59-f6da70f3a650" xlink:href="pfe-20211231.xsd#pfe_AllOtherInflammationandImmunologyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_06c68583-acd5-460f-9e59-f6da70f3a650" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember_218ccc51-afe9-482a-a8f3-84571eeb2e7d" xlink:href="pfe-20211231.xsd#pfe_VyndaqelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_VyndaqelMember_218ccc51-afe9-482a-a8f3-84571eeb2e7d" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember_7cbc3c91-3f13-4457-9253-65558607a402" xlink:href="pfe-20211231.xsd#pfe_BeneFIXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BeneFIXMember_7cbc3c91-3f13-4457-9253-65558607a402" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember_77acc3b8-9a86-47cc-8797-ea1062a75ee3" xlink:href="pfe-20211231.xsd#pfe_GenotropinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_GenotropinMember_77acc3b8-9a86-47cc-8797-ea1062a75ee3" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember_eaed3b5a-6787-4b43-8665-1b24a0df1aa5" xlink:href="pfe-20211231.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ReFactoAfXynthaMember_eaed3b5a-6787-4b43-8665-1b24a0df1aa5" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember_c1dbcdc7-6f06-4cdb-81e9-887ce02872eb" xlink:href="pfe-20211231.xsd#pfe_SomavertMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_SomavertMember_c1dbcdc7-6f06-4cdb-81e9-887ce02872eb" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_5e9b794a-b7bd-4b3b-a64a-0932a34d1c1b" xlink:href="pfe-20211231.xsd#pfe_AllOtherRareDiseaseProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_5e9b794a-b7bd-4b3b-a64a-0932a34d1c1b" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_2b57abcd-dcf8-4e4c-a81e-013d143858a3" xlink:href="pfe-20211231.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_2b57abcd-dcf8-4e4c-a81e-013d143858a3" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalBiosimilarsMember_7a904dec-8d72-47d6-bcd1-d6d6746b948b" xlink:href="pfe-20211231.xsd#pfe_TotalBiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TotalBiosimilarsMember_7a904dec-8d72-47d6-bcd1-d6d6746b948b" xlink:type="arc" order="54"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_9901766c-74be-4eb4-b22b-f9b6c544ca4f" xlink:href="pfe-20211231.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_9901766c-74be-4eb4-b22b-f9b6c544ca4f" xlink:type="arc" order="55"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_srt_CounterpartyNameAxis_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da828a59-1631-4bbd-82c1-2b82d5d8f516" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da828a59-1631-4bbd-82c1-2b82d5d8f516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_ae203fb1-e810-445d-9c56-bb51cdd5466c" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da828a59-1631-4bbd-82c1-2b82d5d8f516" xlink:to="loc_pfe_BioNTechMember_ae203fb1-e810-445d-9c56-bb51cdd5466c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ba054d8-54c0-4500-aad1-1f73e281e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ba054d8-54c0-4500-aad1-1f73e281e3b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ba054d8-54c0-4500-aad1-1f73e281e3b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ba054d8-54c0-4500-aad1-1f73e281e3b7" xlink:to="loc_us-gaap_SegmentDomain_2ba054d8-54c0-4500-aad1-1f73e281e3b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ba054d8-54c0-4500-aad1-1f73e281e3b7" xlink:to="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_b17aa54c-2452-4d79-b438-cab5673b5098" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:to="loc_pfe_BiopharmaSegmentMember_b17aa54c-2452-4d79-b438-cab5673b5098" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneMember_bb6947a0-2624-4388-9113-09de6c325225" xlink:href="pfe-20211231.xsd#pfe_PfizerCentreOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:to="loc_pfe_PfizerCentreOneMember_bb6947a0-2624-4388-9113-09de6c325225" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>pfe-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ad91efd1-2241-49cf-a17f-7cbe86f9ba4a,g:feca3a10-f613-46f2-b813-b8f4d7d48955-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_6e1ec5d5-c69d-4510-8f03-bfa94ecd7c30_terseLabel_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_label_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_documentation_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:href="pfe-20211231.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:to="lab_pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SomavertMember_d96798f3-dbc2-4a60-9ee4-bd57357f9404_terseLabel_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_label_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_documentation_en-US" xlink:label="lab_pfe_SomavertMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Somavert [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember" xlink:href="pfe-20211231.xsd#pfe_SomavertMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SomavertMember" xlink:to="lab_pfe_SomavertMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_5f80df8d-8859-4acc-aabd-811ae7b5c500_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid/(received) during the period for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8f5bddac-9a3f-4464-98dc-dd67e47737b6_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9c92f9bd-8e94-45fc-af3a-053848ab0113_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_c278f9a1-518e-4731-bda6-88ea08795444_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in actuarial assumptions and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0d4366e5-b027-487b-9c65-7fb1075d93ae_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_03c25913-7023-41ea-8f3d-a9b4e8b4462d_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_c45985ea-6158-47cd-a121-7233e78f348f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0043af15-691b-4df5-8a97-984008fd7932_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_f405d61b-c21d-47fd-9b67-e859795c7047_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_c24c9a29-2a13-4b9a-a01c-a994e2516aef_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_309fb89a-5450-470d-958f-830a35cc297a_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_a44cf9a1-b9a2-489d-b496-5c674fd13f28_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_114f60c0-ae54-4397-b862-bfd2d9c2462f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_289fb012-2985-4dd6-af4a-8e66862bb078_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_bf6bc8bd-50c6-4acb-bc81-e23875870198_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f9df626a-3f62-4e26-86fc-173279b690ac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3b6d99a8-8046-4157-98cd-74de5d8bac11_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_c094565f-970e-44cb-9dd1-d19c5c33f3ba_terseLabel_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_label_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_documentation_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember" xlink:href="pfe-20211231.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAntiinfectivesMember" xlink:to="lab_pfe_OtherAntiinfectivesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c14f5040-9557-437f-abcf-08116345a04e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DomesticIncomeTaxesAbstract_8debcbd8-d12c-4427-b84c-2015befe20a5_terseLabel_en-US" xlink:label="lab_pfe_DomesticIncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxesAbstract_label_en-US" xlink:label="lab_pfe_DomesticIncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Income Taxes [Abstract]</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxesAbstract_documentation_en-US" xlink:label="lab_pfe_DomesticIncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DomesticIncomeTaxesAbstract" xlink:href="pfe-20211231.xsd#pfe_DomesticIncomeTaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract" xlink:to="lab_pfe_DomesticIncomeTaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ArrayMember_ebc63905-48bf-4cf4-a6c8-ba3a55fc53c9_terseLabel_en-US" xlink:label="lab_pfe_ArrayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Array [Member]</link:label>
    <link:label id="lab_pfe_ArrayMember_label_en-US" xlink:label="lab_pfe_ArrayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Array [Member]</link:label>
    <link:label id="lab_pfe_ArrayMember_documentation_en-US" xlink:label="lab_pfe_ArrayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Array [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ArrayMember" xlink:to="lab_pfe_ArrayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_faf9bc11-7372-4332-bb0a-a460ff34efee_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_01e68e49-f455-4d6d-b301-404c0a570d24_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Lease Term (Years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_154a5183-b972-4248-a152-d1eb61f5586f_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ToviazMember_2cd7f8bf-63ff-46c0-9ec2-7c205c7b8b2c_terseLabel_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_label_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_documentation_en-US" xlink:label="lab_pfe_ToviazMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember" xlink:href="pfe-20211231.xsd#pfe_ToviazMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ToviazMember" xlink:to="lab_pfe_ToviazMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_77eed418-cb40-4d62-b249-72939fda7ef9_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_5beb32c6-d2b2-4607-a455-05ea090d2263_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation tax liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IVIgProductsMember_a80c0582-284e-422c-85bd-bc34e14f475e_terseLabel_en-US" xlink:label="lab_pfe_IVIgProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVIg Products [Member]</link:label>
    <link:label id="lab_pfe_IVIgProductsMember_label_en-US" xlink:label="lab_pfe_IVIgProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVIg Products [Member]</link:label>
    <link:label id="lab_pfe_IVIgProductsMember_documentation_en-US" xlink:label="lab_pfe_IVIgProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IVIg Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IVIgProductsMember" xlink:href="pfe-20211231.xsd#pfe_IVIgProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IVIgProductsMember" xlink:to="lab_pfe_IVIgProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6fc54af5-5817-493b-94ac-26f2c5721c3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2f7132b4-e7ca-4b78-bbf2-4447b2c315a7_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_24cb81e1-06a0-44f5-8c10-c63bd9ac45ab_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_2bcf4611-5933-4148-8766-cdb0725f6c36_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_fb62f750-71f3-4910-81a9-cec0f9c86008_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_5ffe435a-ed4e-4da8-a8d2-75acdeaad864_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4ae07963-c378-4866-9197-1d225fa78cc2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_ddb0457d-bf22-4b91-be81-b769d9a3c2e7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f499963a-0f5d-4174-95dc-18b331624962_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_0986563c-96e4-43d7-8a3a-ee6a0b2a9ddd_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EnbrelMember_d090e7f0-c02e-4665-80ca-99edae6ef579_terseLabel_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_label_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_documentation_en-US" xlink:label="lab_pfe_EnbrelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember" xlink:href="pfe-20211231.xsd#pfe_EnbrelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnbrelMember" xlink:to="lab_pfe_EnbrelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1d8cad65-b00f-494f-8575-85fa3af28a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value on exercise</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0eb056ec-a3fc-4906-a1e9-34dbad23b052_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gains and Losses on Investment Securities</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_label_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:to="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_d8d30984-157a-425d-9a4e-edf8263241ed_terseLabel_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_label_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_documentation_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:href="pfe-20211231.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:to="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BioNTechAndSpringWorksMember_9878949f-4552-4442-baf3-a4fad3f628d1_terseLabel_en-US" xlink:label="lab_pfe_BioNTechAndSpringWorksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and SpringWorks [Member]</link:label>
    <link:label id="lab_pfe_BioNTechAndSpringWorksMember_label_en-US" xlink:label="lab_pfe_BioNTechAndSpringWorksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and SpringWorks [Member]</link:label>
    <link:label id="lab_pfe_BioNTechAndSpringWorksMember_documentation_en-US" xlink:label="lab_pfe_BioNTechAndSpringWorksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and SpringWorks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndSpringWorksMember" xlink:href="pfe-20211231.xsd#pfe_BioNTechAndSpringWorksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechAndSpringWorksMember" xlink:to="lab_pfe_BioNTechAndSpringWorksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PortfolioPerformanceSharesMember_e3d22824-c924-4444-8226-1b104927aae4_terseLabel_en-US" xlink:label="lab_pfe_PortfolioPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portfolio Performance Shares [Member]</link:label>
    <link:label id="lab_pfe_PortfolioPerformanceSharesMember_label_en-US" xlink:label="lab_pfe_PortfolioPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portfolio Performance Shares [Member]</link:label>
    <link:label id="lab_pfe_PortfolioPerformanceSharesMember_documentation_en-US" xlink:label="lab_pfe_PortfolioPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portfolio Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PortfolioPerformanceSharesMember" xlink:to="lab_pfe_PortfolioPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_8d24ab86-8e52-42d8-96af-1ced8df2b6ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses on asset disposals</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CommonESOPPlanMember_b34734ee-52b9-4842-9839-838c61226723_terseLabel_en-US" xlink:label="lab_pfe_CommonESOPPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common ESOP Plan [Member]</link:label>
    <link:label id="lab_pfe_CommonESOPPlanMember_label_en-US" xlink:label="lab_pfe_CommonESOPPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common ESOP Plan [Member]</link:label>
    <link:label id="lab_pfe_CommonESOPPlanMember_documentation_en-US" xlink:label="lab_pfe_CommonESOPPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common ESOP Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CommonESOPPlanMember" xlink:href="pfe-20211231.xsd#pfe_CommonESOPPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CommonESOPPlanMember" xlink:to="lab_pfe_CommonESOPPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_4a6eb333-ac1d-4c01-bcbc-7abbd4ec724d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0777ea69-6880-4261-8473-8b9e5bdf9c06_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_af2e6d31-0d6d-4598-b311-522ae7de52a6_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_c239b9ec-aa05-4c78-a3d8-092b373aea76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_89cc740a-f960-47d7-b1b2-8132993ac61f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_62869679-6d46-4d0e-982a-fbb797ac579c_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_497f4280-b399-401d-8d48-26352330549b_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_364dc965-00cd-45d2-b15b-3c0124e4359b_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_label_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_documentation_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants" xlink:href="pfe-20211231.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyNumberofDefendants" xlink:to="lab_pfe_GainContingencyNumberofDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_514c7392-52ff-449e-9df1-25bb0df72b3e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of remaining shares authorized in stock purchase plan, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_e2437e6d-5d59-4660-b53f-c1094425e1b7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income securities [Member]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Debt Security [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:to="lab_us-gaap_DefinedBenefitPlanDebtSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e408edab-3e2c-40d4-b366-677c65e7789a_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases based on tax positions taken during a prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_10f65ca6-05b7-46e7-8c7c-600b1eb59cf7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_19049b35-8af8-4e31-8853-d9233149c88b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Discount Rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_fcba6ca5-8ee9-44ba-99bc-653015b45873_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive common stock equivalents (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ca19101c-8893-4816-a8a3-e4712df77ff6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Inventories, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_edf4c4be-33f8-499e-80e1-a2d2c4f79aef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5c8a9fcd-7692-404e-b3fe-5aa4d9b987ef_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_0200b0bf-0f66-4e90-b694-0505e96c1bf3_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember" xlink:href="pfe-20211231.xsd#pfe_ConsumerHealthcareReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareReportingUnitMember" xlink:to="lab_pfe_ConsumerHealthcareReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_a8dd59eb-ed74-45b8-8af2-470e5d6be73c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_d7e455a7-346e-4434-8cdc-237334e73808_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred taxes - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_aec81be2-5732-43be-a7c5-2260452d7b0e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Hedged Assets Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures_e3c96b6b-d46a-4b6b-a450-c3d2d29663ba_terseLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Divestitures</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:to="lab_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_880b37fd-6023-4e92-a411-efece28e4bba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f6a8bc15-6f62-42ae-97f4-a3de7b21db96_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_56fb150b-f3e7-42c5-8bd6-e7689254d2e4_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_14eda1f9-ea16-4ae9-9aec-17f2e5dd30a9_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency short-term borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_label_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Short Term Borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency short - term borrowings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:to="lab_pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_6516458a-4173-43d4-930f-ff10b038d19b_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_24d61be7-b73e-4011-8a57-32aca7e589f2_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units settled, shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_7efc97a5-e14b-439d-b2d0-33f84dc8fd7e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_295492e6-45b4-4f37-8a4d-9f52f91a63d5_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares earned as a percentage of initial award</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_83a096f0-feab-442f-94d5-9cac5245a46c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_9bd6edc2-37c6-4d23-a245-5e77970ba043_terseLabel_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_label_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_documentation_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:href="pfe-20211231.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:to="lab_pfe_TotalAllianceBiopharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_91c40b17-4d4d-476c-bad8-c0b22e3e3e41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_201b8540-a1c9-461a-bbe0-d7cde2949b29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_899ef962-40d0-476f-bde3-4b04c023e489_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local tax adjustments - Deferred tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, State and Local Taxes Adjustments</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, State and Local Taxes Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:to="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bd041d45-d1d3-4723-a2fa-5ca11be5b7b2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_59bf4210-9722-475b-80f7-3b1c413bfeeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_97a3da69-72f7-4fbe-b05a-1d16dc61b2e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_084190dd-20ef-4b45-802e-8f46cf94cb72_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains)/losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MyovantMember_4b6849ab-06b2-4118-b7eb-c655fba74061_terseLabel_en-US" xlink:label="lab_pfe_MyovantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myovant [Member]</link:label>
    <link:label id="lab_pfe_MyovantMember_label_en-US" xlink:label="lab_pfe_MyovantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myovant [Member]</link:label>
    <link:label id="lab_pfe_MyovantMember_documentation_en-US" xlink:label="lab_pfe_MyovantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Myovant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MyovantMember" xlink:href="pfe-20211231.xsd#pfe_MyovantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MyovantMember" xlink:to="lab_pfe_MyovantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_c5b3d11c-ed30-4d3d-8be6-88a83dcabf92_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency long-term debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_label_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Long Term Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency long - term debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyLongTermDebtMember" xlink:to="lab_pfe_ForeignCurrencyLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member_6d78449c-c56e-4f93-99c5-084079549da6_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, One Point Seven Five Zero Percent, Due August 2031</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, One Point Seven Five Zero Percent, Due August 2031 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, One Point Seven Five Zero Percent, Due August 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_45db9375-a915-4a41-a11c-36b0fd1a8aad_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_b150fc6f-1899-4bd2-bd0e-fcf26d822930_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available-for-sale and Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_7df28f84-2ffe-4adb-a84e-bf25b50ecf5a_verboseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures_3bf7cf58-e1b2-4819-a060-4084fb0ea04d_terseLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued, decrease resulting from divestiture</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Decrease Resulting From Divestitures</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Decrease Resulting From Divestitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" xlink:to="lab_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_ccbb9e54-af49-467f-8d9c-6bcde7a0a1e2_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_c852cc8b-80f3-47f1-90f8-5cafaa283fe8_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units granted upon conversion, shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_24dbed50-7634-4fe0-accb-8ce2336a1f1f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_34d01cea-6ac1-4985-8fdd-40453ea16e7e_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents without court proceedings</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:href="pfe-20211231.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:to="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_4e823445-2273-4783-a28f-45d25d14e467_terseLabel_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CK1 Assets Sold To Biogen, Inc [Member]</link:label>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_label_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CK1 Assets Sold To Biogen, Inc [Member]</link:label>
    <link:label id="lab_pfe_CK1AssetsSoldToBiogenIncMember_documentation_en-US" xlink:label="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CK1 Assets Sold To Biogen, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember" xlink:href="pfe-20211231.xsd#pfe_CK1AssetsSoldToBiogenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CK1AssetsSoldToBiogenIncMember" xlink:to="lab_pfe_CK1AssetsSoldToBiogenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_0961de54-1122-4854-b517-a22335502f81_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_446c0fb3-6c90-4011-9590-4d7dcf408d6b_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_428a4b89-e754-4d60-9b7c-e80ba33f2b76_negatedTerseLabel_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan contributions in excess of expense/income</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_label_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_documentation_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:href="pfe-20211231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:to="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_dda3b7c1-62d0-4a90-a7c2-814f2e5bb231_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_9529210c-45fe-46de-b056-4916694a19b1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post closing compensation expense</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_87742ed8-6cf5-41f3-b9bb-c93fff1ca0d5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit cost:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_ff7acda0-6f03-4e06-8351-a5205170e6db_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_f8a46128-12a3-458a-b8a6-6152460ac7f2_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units expected to vest, shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_ddd29aff-5757-46b8-bc32-49c31139f2ae_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TopSevenProductsMember_dc4e7f3b-392b-4d9d-8010-28405ca812a2_terseLabel_en-US" xlink:label="lab_pfe_TopSevenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Seven Products [Member]</link:label>
    <link:label id="lab_pfe_TopSevenProductsMember_label_en-US" xlink:label="lab_pfe_TopSevenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Seven Products [Member]</link:label>
    <link:label id="lab_pfe_TopSevenProductsMember_documentation_en-US" xlink:label="lab_pfe_TopSevenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Seven Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopSevenProductsMember" xlink:href="pfe-20211231.xsd#pfe_TopSevenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TopSevenProductsMember" xlink:to="lab_pfe_TopSevenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_346b3ebd-ab3b-4c3e-930b-0f03eb26756c_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_label_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:to="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RareDiseaseMember_a25a0c1e-8239-4f9d-9868-fbc1efa211ee_terseLabel_en-US" xlink:label="lab_pfe_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_label_en-US" xlink:label="lab_pfe_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_documentation_en-US" xlink:label="lab_pfe_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RareDiseaseMember" xlink:href="pfe-20211231.xsd#pfe_RareDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RareDiseaseMember" xlink:to="lab_pfe_RareDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_59cf5ae9-267d-4521-a6c0-913663a7bc44_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds received from upfront payments and milestone payments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_5de3fd24-5898-4526-a971-642d10d5aef2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend received</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_2e3000c4-5aa4-42c9-a451-24f31150e392_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_169c17a5-b5d5-4fdc-8dc3-c3b14e9b18bb_terseLabel_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored [Member]</link:label>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_label_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored [Member]</link:label>
    <link:label id="lab_pfe_GovernmentAndGovernmentSponsoredMember_documentation_en-US" xlink:label="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Government Sponsored</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember" xlink:href="pfe-20211231.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GovernmentAndGovernmentSponsoredMember" xlink:to="lab_pfe_GovernmentAndGovernmentSponsoredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0356f8b2-da4d-4975-b1fa-6f8a4ae18915_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_75f219b2-6efd-4a64-864e-b9b649736650_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_1539d55d-9f40-4af5-b353-578b3a3f3f11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) on completion of Consumer Healthcare JV transaction</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_249eea4c-e4af-4043-b167-e89dab24ad29_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on completion of transaction</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_d53500f4-58f8-40b7-817e-f33fafc78583_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_228001f8-a608-4103-95c5-63e8b55d5b66_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_6de31506-b5b3-4140-9528-f8c6ffa44eb7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6cd3a44f-8970-4e59-921b-828a3ff98ec9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_32c5f50e-0732-4ec8-abde-cb65025cc77b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_4274d61b-4a31-4ef3-ac70-1e687714557c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit from IRS settlement</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_30ae85d8-9a02-4b7d-9a5e-d80e35b47ead_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, percentage</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_4e5af825-21e0-4e44-bdf3-6a139debc97a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_998caff2-f0d1-4986-879f-1b843f59d439_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income/(loss) before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_bea3d822-55e6-44ef-8ec4-18a6a9debc04_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_c54b8c14-4a93-4571-b2e4-43ea15ac7d08_terseLabel_en-US" xlink:label="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries with revenue exceeding $500 million</link:label>
    <link:label id="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_label_en-US" xlink:label="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Revenues, $500,000,000 or More, Number of Countries</link:label>
    <link:label id="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_documentation_en-US" xlink:label="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Revenues, $500,000,000 or More, Number of Countries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:href="pfe-20211231.xsd#pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:to="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_2c29b341-9ce2-4410-a6c2-512d6034cd53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_ad71078a-6480-4064-a0e0-daa0f75bb089_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax assets</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_label_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_documentation_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent" xlink:href="pfe-20211231.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxAssetsCurrent" xlink:to="lab_pfe_OtherTaxAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FragminMember_f05326a4-4cbc-45ae-89e4-04537993b66a_terseLabel_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_label_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_documentation_en-US" xlink:label="lab_pfe_FragminMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember" xlink:href="pfe-20211231.xsd#pfe_FragminMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FragminMember" xlink:to="lab_pfe_FragminMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_1693e598-3553-4095-bc51-5ad07f2462d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f377db50-037a-40d1-8aaa-7fecea799123_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0a163865-b90c-42ad-a246-323b471abc2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrivateEquityInvestments_0d8c806b-6605-44ff-8726-28c6d056260c_terseLabel_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private equity securities at cost</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_label_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Investments</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_documentation_en-US" xlink:label="lab_pfe_PrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments" xlink:href="pfe-20211231.xsd#pfe_PrivateEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrivateEquityInvestments" xlink:to="lab_pfe_PrivateEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_ecb40c7b-eea0-4562-b913-05e707b2c8c8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_bc8b2236-9b12-4289-b1c6-e5330ccfc90c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_7e61404f-0b55-4235-a487-24387ae12a66_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend" xlink:to="lab_us-gaap_InvestmentIncomeDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_775b6a1e-7fc3-4fa5-8416-32f1f68069e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_22a96178-61ea-4de2-a9c7-6e44307a3282_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_da592c9a-15d0-43a4-aeb1-5f564c19acec_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs and Expenses [Abstract]</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_418f7116-af5b-42c7-850d-f0698d165f59_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_1b4bcd90-8c1c-481b-8641-aaaa3587eee5_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition_2a4a8242-160f-4e7d-b457-8880a22c78eb_negatedTerseLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" xlink:to="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_f66737bc-ac01-4ba3-bd6b-ed80928be0ab_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems" xlink:to="lab_us-gaap_GainContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_0dae0dbf-5f09-4e08-82b0-78867085c88a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_6556269c-93ce-487e-9dc0-68c3b41fac27_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share&#8211;&#8211;diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_35b67496-4ae2-468e-afc4-e5c81c4050da_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_62ce3e8a-1dea-4bd5-b1de-8fe1b711886a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefit obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_276f2dca-0463-4399-b3a7-212a9c9470d3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_c15e33cd-b0dd-4e7b-be94-7d84e8afc829_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment [Member]</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_fd1f0ec2-5973-4fd3-923a-35dda23780c5_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinvested dividend equivalents, shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_603a2068-1bae-46f6-be45-ed23bc98a0f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_1d0e0c6f-3f56-4f5a-b164-747df8a0b7c9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_9be53876-dbdb-49d7-8e90-39e92d3293c6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_8a3fddcd-2263-4974-a731-ca1f2e2ec053_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_911dbbbb-0304-45e8-8fac-bb60e283c9e4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_e11b56e6-a016-43a1-a9e6-edce27ecbfe1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_f03ed380-4b52-40b7-b975-0674336b1304_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_a19073b4-f8eb-4397-bba2-60e6d793843b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition of net gains on foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_db887833-ee84-47e0-a5c7-8824f33f4f25_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_822cb0e0-f449-4a3e-95dd-644079c5f270_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to curtailments of prior service costs and other, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7d1b6da4-8822-45ac-b773-d7a154968d69_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_8350f0b6-8532-41cc-8b6e-10a41ec60ce2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_ebcdc0d1-394e-4066-a7ac-3d37d00a6307_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit for taxes on income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_792d1d9b-2a8b-495f-af0a-d26a1c2e2cec_periodStartLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_f370336b-37fc-4e97-b15d-dc828ac4d334_periodEndLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_8273eb82-b9bd-4497-a6b8-c0a3325fb2c4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_7aff6835-f905-4499-b714-a35b5c4831df_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c7e155eb-5a57-431a-bd06-5063113154c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9d7cbb40-1615-4a71-a767-b546f63bfc64_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_5e2d2dee-8e71-412c-a6f8-89817dcc34fb_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_d35d0cfa-4cca-4ba7-b65d-0683a6e9b521_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7510b680-ac63-411d-a5b5-bd4bcdbed05a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_499f4eb3-d541-40a1-8a06-a688342edab1_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases based on tax positions taken during the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_cedee176-5ea6-4e85-98e0-da5a20ab16b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_08f43555-829c-48e6-aec7-f02ffcb08400_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_3f6a98c7-2ea6-478d-8ee1-867abba6945b_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_08aa095d-184b-4844-9598-d4e07ee92dbb_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares counted toward maximum</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_a418f687-3abc-40dc-97d0-9ae3f34793ea_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20282032Member_6ab1ed5f-c28c-4e54-ae6d-94a61fde57e3_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20282032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2028-2032 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20282032Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20282032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2028-2032 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20282032Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20282032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2028-2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20282032Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20282032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20282032Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20282032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7475f3f7-59fd-4376-80a5-9d80267aec24_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CreditFacilityExpiring2025Member_ad4dd19d-e209-4e7f-8da7-46cbdd4f6cf1_terseLabel_en-US" xlink:label="lab_pfe_CreditFacilityExpiring2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Expiring 2025 [Member]</link:label>
    <link:label id="lab_pfe_CreditFacilityExpiring2025Member_label_en-US" xlink:label="lab_pfe_CreditFacilityExpiring2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Expiring 2025 [Member]</link:label>
    <link:label id="lab_pfe_CreditFacilityExpiring2025Member_documentation_en-US" xlink:label="lab_pfe_CreditFacilityExpiring2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Expiring 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CreditFacilityExpiring2025Member" xlink:href="pfe-20211231.xsd#pfe_CreditFacilityExpiring2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CreditFacilityExpiring2025Member" xlink:to="lab_pfe_CreditFacilityExpiring2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_384b4ba3-eb1a-4f1e-99f2-5ec3b55c972d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_361d7fa2-82ae-4093-b4da-f2050103419a_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InterestReceivedInterestRateHedges_77312c3f-8f3e-4054-90ce-5822bae550ea_negatedTerseLabel_en-US" xlink:label="lab_pfe_InterestReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate hedges</link:label>
    <link:label id="lab_pfe_InterestReceivedInterestRateHedges_label_en-US" xlink:label="lab_pfe_InterestReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Received, Interest Rate Hedges</link:label>
    <link:label id="lab_pfe_InterestReceivedInterestRateHedges_documentation_en-US" xlink:label="lab_pfe_InterestReceivedInterestRateHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Received, Interest Rate Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InterestReceivedInterestRateHedges" xlink:href="pfe-20211231.xsd#pfe_InterestReceivedInterestRateHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InterestReceivedInterestRateHedges" xlink:to="lab_pfe_InterestReceivedInterestRateHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_af507ec4-2f19-449f-9e2b-aa2d8e834aba_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:to="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_7c6428ab-cb94-49c5-af01-3c7996f80a23_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_1306be00-263b-4aab-afa1-5e815eda2029_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_079abfd6-cf5d-4a7c-8220-9b657a2361d6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses recognized during the period on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_f4af3d71-7d35-4545-a3b5-cc138357905e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains)/losses recognized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fcd60f2c-24f0-4ea2-99ac-4f1023ecc3d1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_53024f38-0468-400d-b5fa-b37aea16bf36_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_03e2ac1c-ccd5-4721-896f-358b420e074f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_719128b0-e231-41b7-99cd-f4f4b5558d2b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_c9a1c49f-bf28-47b2-b4d2-d7103268d975_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_b5d0fecc-82ca-480a-a9f1-379727df8849_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases based on settlements for a prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZyvoxMember_0c05c841-924d-4f26-81cb-a3a659167f59_terseLabel_en-US" xlink:label="lab_pfe_ZyvoxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_label_en-US" xlink:label="lab_pfe_ZyvoxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_documentation_en-US" xlink:label="lab_pfe_ZyvoxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZyvoxMember" xlink:href="pfe-20211231.xsd#pfe_ZyvoxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZyvoxMember" xlink:to="lab_pfe_ZyvoxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VfendMember_70a376c1-96a5-4d26-b007-18233e7310ec_terseLabel_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_label_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_documentation_en-US" xlink:label="lab_pfe_VfendMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vfend [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember" xlink:href="pfe-20211231.xsd#pfe_VfendMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VfendMember" xlink:to="lab_pfe_VfendMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_85fa9cd3-2cb5-4dab-bcf2-186002e9405d_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent [Member]</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_label_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent [Member]</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_documentation_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxLiabilitiesNetNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:to="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_01c21472-e8cd-4e61-b8e2-2942f5e18613_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of fair value contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_e00605ea-e0e4-4a92-ab6d-84318292a31d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other taxes payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_4425f45b-b741-4a9c-862e-0b8e54881dcb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn spin-off</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_e84833e4-fcbd-4938-828f-ac44a51e9366_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_label_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:href="pfe-20211231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:to="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_7115f825-3be3-4575-a3c2-9507abe9a737_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a4f2d4a0-0b68-4683-ac42-e7e86d0418d8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Comprehensive income/(loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted_2a50fd8c-b80b-4f75-ab30-dbd71068b94b_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units exercised and converted, aggregate intrinsic value</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8b5a1a8e-7843-40ae-8846-9715764f54e8_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a9b9aaea-6cc4-4606-bf9a-e40f70fcc79a_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_ce2cd7a8-5aff-4260-8b14-dd6a87cb6688_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_bdd6d8dc-e896-4e66-a7ef-ad5d4427fdd6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_c538e6b1-60a4-433b-882b-246295b49e2c_terseLabel_en-US" xlink:label="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, due to expire within one year</link:label>
    <link:label id="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_label_en-US" xlink:label="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year</link:label>
    <link:label id="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_documentation_en-US" xlink:label="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:href="pfe-20211231.xsd#pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:to="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_ba63be62-cd13-40c1-a980-f2ef13ed1d65_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit costs/(credits) other than service costs</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5281e1e3-0925-4b5e-8379-dec425021548_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8df48edc-4fba-45c5-b8a6-cbcf196b2912_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, gross unrealized gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_91d3294d-5c0f-4c45-80f4-0be0b6eff458_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of pre-tax loss to be reclassified</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NumberofEmployeeStockOwnershipPlans_d27ba127-6076-42e7-a176-68bc8d8d38ce_terseLabel_en-US" xlink:label="lab_pfe_NumberofEmployeeStockOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employee stock ownership plans</link:label>
    <link:label id="lab_pfe_NumberofEmployeeStockOwnershipPlans_label_en-US" xlink:label="lab_pfe_NumberofEmployeeStockOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Employee Stock Ownership Plans</link:label>
    <link:label id="lab_pfe_NumberofEmployeeStockOwnershipPlans_documentation_en-US" xlink:label="lab_pfe_NumberofEmployeeStockOwnershipPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Employee Stock Ownership Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NumberofEmployeeStockOwnershipPlans" xlink:href="pfe-20211231.xsd#pfe_NumberofEmployeeStockOwnershipPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NumberofEmployeeStockOwnershipPlans" xlink:to="lab_pfe_NumberofEmployeeStockOwnershipPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_093bbe2c-180f-43bf-ae7c-5b968d7e4a9f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bae87378-22ef-4481-86ab-87b275a63223_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_c09d7643-bffa-4eaa-a2d4-a4d424ea906b_negatedTerseLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized accrued interest decrease as a result of cash payments</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:to="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_97cd4571-db8e-417a-b897-da89ab123d53_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_61e7f9e5-b84b-437f-8211-57b9b1a2b330_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ad8fed4f-1789-4747-badd-2493d6e037e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_9063a6f3-4cee-4ac0-ab8f-acdafd604ea0_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_0e20c156-6c60-409d-8c6e-eea4356315bc_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IbranceMember_68682207-c2d7-4392-92fa-f98b24b4f4fe_terseLabel_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_label_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_documentation_en-US" xlink:label="lab_pfe_IbranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember" xlink:href="pfe-20211231.xsd#pfe_IbranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IbranceMember" xlink:to="lab_pfe_IbranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_356ac74a-0df7-437b-8357-b5f59b848494_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GSKMember_e67f9c1c-c47c-49c0-8b79-caa7d88c5b66_terseLabel_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_label_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_documentation_en-US" xlink:label="lab_pfe_GSKMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember" xlink:href="pfe-20211231.xsd#pfe_GSKMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKMember" xlink:to="lab_pfe_GSKMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_bd312e7e-9adb-4647-9b08-7facdc416daf_terseLabel_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_label_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Of Intangible Assets Not Associated With Single Function</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_documentation_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:href="pfe-20211231.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:to="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_371cc014-6f92-4090-90aa-e8d5f968b4d0_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_4bec9a60-664f-4483-9499-624fbdb3bf50_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency debt - non-U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7e6c1011-406a-4f91-9f75-a02d1a47b202_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_d5192c97-d344-494b-ae31-703a8d3ced7b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_abbced1c-8ac9-496b-9e7e-f9736dd6c89d_terseLabel_en-US" xlink:label="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Change [Member]</link:label>
    <link:label id="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_label_en-US" xlink:label="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Change in Accounting Principle, Adjustment [Member]</link:label>
    <link:label id="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_documentation_en-US" xlink:label="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Change in Accounting Principle, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:href="pfe-20211231.xsd#pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:to="lab_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_8ee2c891-4f07-49dd-9ce8-cd60500cb60e_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_72a4f833-0a78-4d5e-85f6-31df044eac35_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_b0c530a5-cb10-4143-9dab-e5552e0bede2_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a8fa3654-f199-457b-8148-22e3d3cd8411_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_5e9adadc-d9e2-44ff-8029-ddfe280ca299_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2c6d3322-021c-42c0-9606-57213627cac9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021&#8212;9,471; 2020&#8212;9,407</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_edb2cfe7-5791-4be9-b3fd-1ad57db0bbea_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_a63c1926-d6aa-47ea-b5dd-66aaa6abc693_terseLabel_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment pursuant to terms of the separation agreement</link:label>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_label_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Pursuant to Terms of Separation Agreement, Financing Activities</link:label>
    <link:label id="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_documentation_en-US" xlink:label="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Pursuant to Terms of Separation Agreement, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:href="pfe-20211231.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:to="lab_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3d2d73d4-9ab9-49e0-9181-b18939da6062_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period over which cost is expected to be recognized (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_f0bcf12e-3dfe-4c41-b7f6-348b85245c10_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a53d7f90-e148-4e2b-936e-e63573757860_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c2f82953-481f-4b62-a1a8-d7f05135bb83_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7ccb6c97-eb04-4f08-ac88-6d71694b7c1f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetAcquisitionAssetsAcquired_35071569-386d-48a4-951b-5be1f88557cc_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, assets acquired</link:label>
    <link:label id="lab_pfe_AssetAcquisitionAssetsAcquired_label_en-US" xlink:label="lab_pfe_AssetAcquisitionAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Assets Acquired</link:label>
    <link:label id="lab_pfe_AssetAcquisitionAssetsAcquired_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionAssetsAcquired" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionAssetsAcquired" xlink:to="lab_pfe_AssetAcquisitionAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_09fba9f2-a0f9-4968-bd84-53179b76a23d_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_a0c18a4a-3724-4514-8b0b-f55534a66750_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status&#8212;Plan assets less than benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_51823fbd-5367-4a3b-90db-9a4fde28a31f_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Comprehensive Income:</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:to="lab_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1d204822-e39e-4411-9137-ea63199cd08e_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_00aab63c-78a9-44df-b8fd-8c4b2ce1ebd5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BreakthroughPerformanceAwardsMember_7a525d52-6a49-44f4-bb63-7d5232261bc5_terseLabel_en-US" xlink:label="lab_pfe_BreakthroughPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Breakthrough Performance Awards (BPAs) [Member]</link:label>
    <link:label id="lab_pfe_BreakthroughPerformanceAwardsMember_label_en-US" xlink:label="lab_pfe_BreakthroughPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Breakthrough Performance Awards [Member]</link:label>
    <link:label id="lab_pfe_BreakthroughPerformanceAwardsMember_documentation_en-US" xlink:label="lab_pfe_BreakthroughPerformanceAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Breakthrough Performance Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BreakthroughPerformanceAwardsMember" xlink:href="pfe-20211231.xsd#pfe_BreakthroughPerformanceAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BreakthroughPerformanceAwardsMember" xlink:to="lab_pfe_BreakthroughPerformanceAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_a74720d2-e2d9-4e88-b27d-f99740a43b7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Arrangement Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_22128619-380c-40fb-8fee-8101c1f2d904_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TrumenbaMember_cbf78c23-9d81-4122-ad71-66af61664cbe_terseLabel_en-US" xlink:label="lab_pfe_TrumenbaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trumenba [Member]</link:label>
    <link:label id="lab_pfe_TrumenbaMember_label_en-US" xlink:label="lab_pfe_TrumenbaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trumenba [Member]</link:label>
    <link:label id="lab_pfe_TrumenbaMember_documentation_en-US" xlink:label="lab_pfe_TrumenbaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trumenba</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrumenbaMember" xlink:href="pfe-20211231.xsd#pfe_TrumenbaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TrumenbaMember" xlink:to="lab_pfe_TrumenbaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_62b2f88a-28d0-4a19-9823-b395c7742277_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plans: prior service (costs)/credits and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_cff33557-159f-452d-b8e1-39d6a6d6699f_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_4feadb8c-8694-4b22-ad20-62a216f088d2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_b980a810-3a44-4f1e-86ce-5c25884e6e99_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_63b25816-93a3-4424-ad73-5c40b22fe2f2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_606ff7b2-8c49-43e1-b0a6-98f0ce876304_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_bb81ca9e-ab74-45c0-a6fb-9e746b013b43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derecognition of prior service credits associated with benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_745054a4-8d7c-4bcd-bcf3-19e7d705e867_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_5a48e9ce-220d-4721-96e8-a22bf6db2e9b_negatedTerseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions/divestitures/other, net</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:to="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_d737f34f-60e1-4f7d-b321-1c20fa2c0960_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related Costs [Member]</link:label>
    <link:label id="lab_us-gaap_AcquisitionRelatedCostsMember_label_en-US" xlink:label="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionRelatedCostsMember" xlink:to="lab_us-gaap_AcquisitionRelatedCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DevelopedEuropeMember_677e9d8d-7402-4174-96b3-264692f6f81e_terseLabel_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_label_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_documentation_en-US" xlink:label="lab_pfe_DevelopedEuropeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember" xlink:href="pfe-20211231.xsd#pfe_DevelopedEuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedEuropeMember" xlink:to="lab_pfe_DevelopedEuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_3c6c14c3-1b2f-4aaa-99c0-598b1d221893_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_4f0f01fb-97be-4e9e-af18-53b524cd5367_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedStatementsOfIncomeAbstract_dc480505-b664-454d-b71d-af1f0fe34330_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Income:</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfIncomeAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Income [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfIncomeAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:to="lab_pfe_ConsolidatedStatementsOfIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_f60f99aa-1d0c-415c-beeb-c719f4772fe4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member_1a791b64-44f2-4c8c-9653-28100365e14a_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Five Point Eight Zero Percent, Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Five Point Eight Zero Percent, Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Five Point Eight Zero Percent, Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" xlink:to="lab_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_c2388dea-3970-4b35-987c-0272e29ad842_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential early commercialization milestones</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Commercialization Milestones, Maximum Exposure</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Commercialization Milestones, Maximum Exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_382bcfa7-41ff-41db-93b5-9a4d6651e278_negatedLabel_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Utilization and other</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_label_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_documentation_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:href="pfe-20211231.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:to="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_1e780abf-d1b8-4d67-8a87-c3eb69837777_terseLabel_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-cash restructuring charges expected</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_label_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_documentation_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:href="pfe-20211231.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:to="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_7c45cff0-e39c-4f93-ab06-040fe90cb45d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TherachonAssetAcquisitionMember_4a9204cb-b5f5-4bb1-986c-533b1c423b78_terseLabel_en-US" xlink:label="lab_pfe_TherachonAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therachon Asset Acquisition [Member]</link:label>
    <link:label id="lab_pfe_TherachonAssetAcquisitionMember_label_en-US" xlink:label="lab_pfe_TherachonAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therachon Asset Acquisition [Member]</link:label>
    <link:label id="lab_pfe_TherachonAssetAcquisitionMember_documentation_en-US" xlink:label="lab_pfe_TherachonAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Therachon Asset Acquisition [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TherachonAssetAcquisitionMember" xlink:href="pfe-20211231.xsd#pfe_TherachonAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TherachonAssetAcquisitionMember" xlink:to="lab_pfe_TherachonAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_878edd28-2f9d-49e9-a299-103e026f27b7_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, Informational and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_db229e73-8bc0-4c9b-9a2a-45330ab28a5d_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_e672dd3b-f546-4114-b342-35aebac145bc_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_42bb7bea-b2c2-44be-8dd6-a2b7dca96c56_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_c6af824a-37f1-41ae-a4be-ac745a3da9bc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, consideration transferred, equity interest</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30af816b-fb65-468d-8191-42af3fcf2157_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_f710c9c9-2e89-4f49-9ef7-07dd64678ccb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue_678658d7-239d-4a7f-aebd-c9a38fdc50f7_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units converted, aggregate intrinsic value</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a2379d8d-c642-4c3b-82d2-303a83988c06_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_13c076b8-ca77-4f79-b1f1-08de6749fe4e_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to curtailments of prior service costs and other, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PumaTechnologiesMember_73178a45-96d1-46a0-87a0-a4e2a6c3c166_terseLabel_en-US" xlink:label="lab_pfe_PumaTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Puma Technologies [Member]</link:label>
    <link:label id="lab_pfe_PumaTechnologiesMember_label_en-US" xlink:label="lab_pfe_PumaTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Puma Technologies [Member]</link:label>
    <link:label id="lab_pfe_PumaTechnologiesMember_documentation_en-US" xlink:label="lab_pfe_PumaTechnologiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Puma Technologies [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PumaTechnologiesMember" xlink:href="pfe-20211231.xsd#pfe_PumaTechnologiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PumaTechnologiesMember" xlink:to="lab_pfe_PumaTechnologiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_f0368f0c-9013-40a5-a1e3-47b2bf2b1a0a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_3cac096a-56b6-4f25-862f-b039d842c251_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6550cf13-37ce-45d3-9e70-7fa4a478ddcb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Fair Value of Plan Assets by Measurement [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_24eb61a9-f8be-4c35-934c-ae02e35b3cf9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_f4ddfa56-6f45-42ee-bdc8-65ee38b08f35_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_82b37538-fd90-43f9-882a-7a6ce6818f6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. R&amp;D tax credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_7491fef8-c853-41b5-bee9-d4794cb6aa45_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherCommingledFundsMember_687ff596-7036-414b-bcd7-cbee4c939421_terseLabel_en-US" xlink:label="lab_pfe_OtherCommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commingled Funds [Member]</link:label>
    <link:label id="lab_pfe_OtherCommingledFundsMember_label_en-US" xlink:label="lab_pfe_OtherCommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commingled Funds [Member]</link:label>
    <link:label id="lab_pfe_OtherCommingledFundsMember_documentation_en-US" xlink:label="lab_pfe_OtherCommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commingled Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherCommingledFundsMember" xlink:href="pfe-20211231.xsd#pfe_OtherCommingledFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherCommingledFundsMember" xlink:to="lab_pfe_OtherCommingledFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_2c29b25d-68b4-4ca5-87ce-cd0d3fd4b230_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_86fb89b5-1f14-4391-9e73-b2d2b492c21c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographic and Other Revenue Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ArvinasIncMember_51080b68-e471-4d7f-8b39-6d996326c158_terseLabel_en-US" xlink:label="lab_pfe_ArvinasIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arvinas, Inc [Member]</link:label>
    <link:label id="lab_pfe_ArvinasIncMember_label_en-US" xlink:label="lab_pfe_ArvinasIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arvinas, Inc [Member]</link:label>
    <link:label id="lab_pfe_ArvinasIncMember_documentation_en-US" xlink:label="lab_pfe_ArvinasIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arvinas, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember" xlink:href="pfe-20211231.xsd#pfe_ArvinasIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ArvinasIncMember" xlink:to="lab_pfe_ArvinasIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c704f14e-ddac-4897-bfbe-638ab12ef388_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_c2d2108e-19ae-4c2c-b627-2ffc400c757b_terseLabel_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for disclosure of proceedings under environmental laws</link:label>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_label_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency, Regulatory Proceedings, Disclosure Threshold</link:label>
    <link:label id="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_documentation_en-US" xlink:label="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Site Contingency, Regulatory Proceedings, Disclosure Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:href="pfe-20211231.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:to="lab_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_587b26f9-4830-4fb5-8031-8afd74f10a65_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_de4150eb-4628-47f9-b303-829ca1576301_terseLabel_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_label_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_documentation_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:to="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_c1eab845-1eb8-49d1-bf86-a9a28939214a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3-4 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_880cafa0-5048-4b39-89ae-b44e65e48df3_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Principle, Adjustment [Member]</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Change in Accounting Principle, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c4f41980-f8c7-4524-9d67-30b50cbb20f4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_b5d90806-694c-48e8-8cba-0885929efeea_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7f243559-a8d2-4704-bd9e-fa26e145fd1a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentForCollaborativeAndLicensingArrangements_bbc2bb48-6358-4a54-8298-4ab72b283606_terseLabel_en-US" xlink:label="lab_pfe_PaymentForCollaborativeAndLicensingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for collaborative and licensing arrangements</link:label>
    <link:label id="lab_pfe_PaymentForCollaborativeAndLicensingArrangements_label_en-US" xlink:label="lab_pfe_PaymentForCollaborativeAndLicensingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Collaborative and Licensing Arrangements</link:label>
    <link:label id="lab_pfe_PaymentForCollaborativeAndLicensingArrangements_documentation_en-US" xlink:label="lab_pfe_PaymentForCollaborativeAndLicensingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Collaborative and Licensing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentForCollaborativeAndLicensingArrangements" xlink:href="pfe-20211231.xsd#pfe_PaymentForCollaborativeAndLicensingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentForCollaborativeAndLicensingArrangements" xlink:to="lab_pfe_PaymentForCollaborativeAndLicensingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ba6eec48-c908-4f30-bbd1-de579aed4048_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add&#8217;l Paid-In Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_a9527da8-370a-4c7a-a339-cf0f4bf994be_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027&#8211;2031</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3884678a-c1d6-401f-8093-c8dad4c2dadb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_05dc2784-98bf-435a-8a34-adb84b0baf8c_terseLabel_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20211231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_27bc8158-c9a6-4db3-aa22-332496e61988_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next one year</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ThreeLargestUSWholesaleCustomersMember_c9971032-9e42-459b-9ed0-d4f8fe851560_terseLabel_en-US" xlink:label="lab_pfe_ThreeLargestUSWholesaleCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest U.S. Wholesaler Customers [Member]</link:label>
    <link:label id="lab_pfe_ThreeLargestUSWholesaleCustomersMember_label_en-US" xlink:label="lab_pfe_ThreeLargestUSWholesaleCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest US Wholesale Customers [Member]</link:label>
    <link:label id="lab_pfe_ThreeLargestUSWholesaleCustomersMember_documentation_en-US" xlink:label="lab_pfe_ThreeLargestUSWholesaleCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest US Wholesale Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ThreeLargestUSWholesaleCustomersMember" xlink:href="pfe-20211231.xsd#pfe_ThreeLargestUSWholesaleCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ThreeLargestUSWholesaleCustomersMember" xlink:to="lab_pfe_ThreeLargestUSWholesaleCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d8621272-1b5a-42e2-ba67-3d29b6313e23_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_70e75d41-16fa-4139-b639-9bfb3de343d8_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate: Service cost</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:to="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_30cb3beb-8596-486e-9be1-058655bfdb01_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BesponsaMember_77eceb00-d49c-489f-bf89-5aecb21975cc_terseLabel_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_label_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_documentation_en-US" xlink:label="lab_pfe_BesponsaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember" xlink:href="pfe-20211231.xsd#pfe_BesponsaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BesponsaMember" xlink:to="lab_pfe_BesponsaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8132af22-442a-4f47-aeb0-d7a8874e4d08_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f3ab52f0-8fcc-46c1-a4ce-a0fd3bc9a29f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income/(deductions)&#8212;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_604bd1aa-121e-4b50-bd1b-e69223da4fed_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_dd66c8d4-3a6a-4964-a48b-63572e2cde4b_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, excluding the current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d1d53be5-037e-47b9-bad1-f3554b07d62e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_916c8eb3-17db-409f-bb60-20ea6d521db2_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units vested, shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_be34a389-97d9-42b4-85cc-06b357dcbe3f_terseLabel_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_label_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_documentation_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember" xlink:href="pfe-20211231.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FocusedCompanyPlanMember" xlink:to="lab_pfe_FocusedCompanyPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AgreementDomain_ac4f56cf-8268-4da3-9fca-be2fc07eab68_terseLabel_en-US" xlink:label="lab_pfe_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_pfe_AgreementDomain_label_en-US" xlink:label="lab_pfe_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Domain]</link:label>
    <link:label id="lab_pfe_AgreementDomain_documentation_en-US" xlink:label="lab_pfe_AgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementDomain" xlink:href="pfe-20211231.xsd#pfe_AgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AgreementDomain" xlink:to="lab_pfe_AgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f0f6c7bc-f476-4dbb-8898-0a24413ba7bc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f32d7fef-d98a-47b4-9aa0-f017bfe55675_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e20378c0-e33d-4ce2-b943-334dd33db020_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_fc1648bd-0ec1-4305-9bb4-41ee73ddeb9e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fd03996-c6e4-4eb4-9ba4-ecf9f5e2af12_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_be6a3221-a14e-4b5d-88ab-99cb272a6565_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4b0b4242-a8a6-4c98-b643-74e25243e833_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_5c491875-4d23-4860-989f-82971f9ec143_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_05af063e-3b5b-4dab-bfd2-6da710fc71bb_totalLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost/(credit) recognized in Comprehensive income</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_948c5e87-5010-4a30-826e-a65dcc919c42_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan [Member]</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f92e9e2e-bf22-467d-9200-1b0c90891f25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information About Balance Sheet Classification of Accruals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_779aa31e-7fef-4a21-a9d6-3318ff142252_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6cac9ba7-a501-4c62-9474-d8ac55a94b10_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_cca1c23f-4450-401d-b062-2a8e9fd9412d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_df6db2a2-52eb-451f-b8c6-ff9448385d6b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Pfizer Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1ce86c5a-35ce-48b7-9973-ea468dd9fd7c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net equity/(deficit) attributable to shareholders</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c3991c56-12c6-4c9e-9058-4733c7fddf81_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_1736e8d4-eac4-4fdc-87b6-01341d6e05bc_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon due to expire in December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:href="pfe-20211231.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_0632bca4-2a01-4f34-b443-804ee8bdb4c5_terseLabel_en-US" xlink:label="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</link:label>
    <link:label id="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_label_en-US" xlink:label="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</link:label>
    <link:label id="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_documentation_en-US" xlink:label="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:href="pfe-20211231.xsd#pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:to="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_e073a2cc-8de9-4341-878f-8e4b3c62ed12_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss/credit carryforwards - Deferred tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:to="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_bc57bdd3-4461-4d6a-9379-95ec144284ab_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_a11e32be-5a36-48c4-87b6-12a372931654_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a02a2ff7-1b7a-4ab8-88ec-3db5ff40ca3e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_8d069843-e638-4235-becf-7861e68ce396_verboseLabel_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, principal amount</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_label_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_documentation_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:href="pfe-20211231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:to="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5c1a49ac-c337-4dfd-8057-60a9dfcf2f3d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_e1751d7b-af67-41bb-beec-770db24527f3_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_775d75b9-65ca-4809-9450-edb707263baa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_7797280e-50bf-4e6a-8a80-55d3e37b7ada_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful lives (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_35eac37f-2c76-41c3-91ad-b88e5f855356_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, per share in cash (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MylanMember_52815f21-0742-4802-ab29-0b99d77109e9_terseLabel_en-US" xlink:label="lab_pfe_MylanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mylan [Member]</link:label>
    <link:label id="lab_pfe_MylanMember_label_en-US" xlink:label="lab_pfe_MylanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mylan [Member]</link:label>
    <link:label id="lab_pfe_MylanMember_documentation_en-US" xlink:label="lab_pfe_MylanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mylan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MylanMember" xlink:href="pfe-20211231.xsd#pfe_MylanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MylanMember" xlink:to="lab_pfe_MylanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InternationalIncomeTaxesAbstract_682133e3-8c4c-4a6f-8b6f-82bce0262bb2_terseLabel_en-US" xlink:label="lab_pfe_InternationalIncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_pfe_InternationalIncomeTaxesAbstract_label_en-US" xlink:label="lab_pfe_InternationalIncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Income Taxes [Abstract]</link:label>
    <link:label id="lab_pfe_InternationalIncomeTaxesAbstract_documentation_en-US" xlink:label="lab_pfe_InternationalIncomeTaxesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternationalIncomeTaxesAbstract" xlink:href="pfe-20211231.xsd#pfe_InternationalIncomeTaxesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract" xlink:to="lab_pfe_InternationalIncomeTaxesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_d30848b8-b5ff-4b94-b39d-606f64683f4c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_3276776f-5a3e-4200-9c9f-ffd7b74569ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefit obligations</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ff6ace7f-3ae5-4a3f-9cfd-372ccdae9646_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (long-term)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_608f933a-b495-41bc-a7da-27738068f6b4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_b69bcf4c-351d-4732-95d7-db38bcfa2ac0_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_label_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Upfront Payment</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:to="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0d0251bf-9187-4f40-8861-3175f0e5451e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20220.250Member_1a61110e-b50a-4b56-8aa8-e435231d7b22_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20220.250Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_label_en-US" xlink:label="lab_pfe_NotesDue20220.250Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20220.250Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20220.250Member" xlink:href="pfe-20211231.xsd#pfe_NotesDue20220.250Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20220.250Member" xlink:to="lab_pfe_NotesDue20220.250Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e4a606c3-6b68-4cd4-91ef-be741aa30838_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9d71cbf1-04c6-4409-89f8-37983111b244_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost/(credit) reported in income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_December2017StockPurchasePlanMember_a93771f2-5204-41ec-bc24-183c16a69304_terseLabel_en-US" xlink:label="lab_pfe_December2017StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2017 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2017StockPurchasePlanMember_label_en-US" xlink:label="lab_pfe_December2017StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2017 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2017StockPurchasePlanMember_documentation_en-US" xlink:label="lab_pfe_December2017StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2017 Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_December2017StockPurchasePlanMember" xlink:href="pfe-20211231.xsd#pfe_December2017StockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_December2017StockPurchasePlanMember" xlink:to="lab_pfe_December2017StockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_37494af4-727f-475f-81b9-2a673b8a2a23_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_eeba3df5-c20d-4e4d-9e03-978c7c050d90_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit for share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_694c993b-1c1d-4abb-830a-2d2bac0ba9b6_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units vested, weighted average grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_1297b802-2feb-4834-9366-d48c5e8e500c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4c00df6e-be3b-4fdb-96d6-bf88b1b89627_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_c4cda6ef-3f14-4b29-ab99-56d586755446_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VyndaqelMember_3b1e0fd9-160e-479a-9bc0-412a62966ed6_terseLabel_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel/Vyndamax [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_label_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_documentation_en-US" xlink:label="lab_pfe_VyndaqelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember" xlink:href="pfe-20211231.xsd#pfe_VyndaqelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VyndaqelMember" xlink:to="lab_pfe_VyndaqelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1e6275d0-3466-480c-bf8f-5d13a93f93e6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_583bbfa9-1bd0-49df-8183-cce4c32a04f1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_95812db7-52b7-4c90-a682-4bf86f80fbd1_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_96be3a70-94d1-4819-950c-ca105800a35a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, Informational and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_af268a98-8439-4b79-90b8-556b8277004a_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PurchaserOfMeridianMember_309fb0a0-1759-41b4-88ed-f5d0e5f119bf_terseLabel_en-US" xlink:label="lab_pfe_PurchaserOfMeridianMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser of Meridian [Member]</link:label>
    <link:label id="lab_pfe_PurchaserOfMeridianMember_label_en-US" xlink:label="lab_pfe_PurchaserOfMeridianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser of Meridian [Member]</link:label>
    <link:label id="lab_pfe_PurchaserOfMeridianMember_documentation_en-US" xlink:label="lab_pfe_PurchaserOfMeridianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser of Meridian</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PurchaserOfMeridianMember" xlink:href="pfe-20211231.xsd#pfe_PurchaserOfMeridianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PurchaserOfMeridianMember" xlink:to="lab_pfe_PurchaserOfMeridianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_0daccb88-12ac-4613-b98c-1fdce70aabbf_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_652a6d7c-63fc-42b7-a99e-99fa3ed79a60_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_67280f69-7d34-4e3e-bf1e-341dfbf8fc33_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_4bd78676-f8f1-4ede-9091-b7a2ebe3d5e2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities [Member]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_cc421bc3-6eb1-4d0e-85fd-66bfc1fa65ed_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_ba73aad5-bf82-429d-8920-61b196c75c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_217b216e-6402-41b0-af95-174cb42f033f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e89387e3-bf1f-461f-b684-5bff51493bf5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaxlovidMember_ef4f87ea-2f86-40e8-994e-d51e68437e43_terseLabel_en-US" xlink:label="lab_pfe_PaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paxlovid [Member]</link:label>
    <link:label id="lab_pfe_PaxlovidMember_label_en-US" xlink:label="lab_pfe_PaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paxlovid [Member]</link:label>
    <link:label id="lab_pfe_PaxlovidMember_documentation_en-US" xlink:label="lab_pfe_PaxlovidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paxlovid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember" xlink:href="pfe-20211231.xsd#pfe_PaxlovidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaxlovidMember" xlink:to="lab_pfe_PaxlovidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4d35f729-c667-480d-8b6c-68ac698b58b0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_7b628675-0e4f-4b56-94a9-fbbf842fc253_terseLabel_en-US" xlink:label="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term, option to extend</link:label>
    <link:label id="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_label_en-US" xlink:label="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Term</link:label>
    <link:label id="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_documentation_en-US" xlink:label="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:href="pfe-20211231.xsd#pfe_LesseeOperatingLeaseOptionToExtendTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:to="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EucrisaMember_a69add4a-67eb-4fd3-a1a3-2465edb75424_terseLabel_en-US" xlink:label="lab_pfe_EucrisaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:label id="lab_pfe_EucrisaMember_label_en-US" xlink:label="lab_pfe_EucrisaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:label id="lab_pfe_EucrisaMember_documentation_en-US" xlink:label="lab_pfe_EucrisaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EucrisaMember" xlink:href="pfe-20211231.xsd#pfe_EucrisaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EucrisaMember" xlink:to="lab_pfe_EucrisaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AmerisourceBergenCorporationMember_ccd307af-b068-4bb7-b0b0-5c7626fe153e_terseLabel_en-US" xlink:label="lab_pfe_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_pfe_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_pfe_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_pfe_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_pfe_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmerisourceBergenCorporationMember" xlink:href="pfe-20211231.xsd#pfe_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmerisourceBergenCorporationMember" xlink:to="lab_pfe_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_23cda284-8f42-4386-98a1-4b2389b3d04c_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Development Milestone, Maximum Exposure</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Development Milestone, Maximum Exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_b40927d0-39dd-4dad-9a24-6b11a6158aba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_9d29a7df-6563-4d36-8eeb-7f149d49294c_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs incurred</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_39156296-0872-46db-9aa5-cc5ff3abd88c_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs associated with acquisitions and cost-reduction/productivity initiatives</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_label_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:to="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0e9529b6-237f-42d1-ad5a-3f9e0237f45d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c5378473-7181-491f-a266-bcb9f758a703_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1f826b15-2ba1-4d74-b978-311cfe8f84eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a973c8d8-329a-4467-a6c5-56acefc2838d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UpjohnFinanceB.V.Member_d6a6f279-3364-4153-8b0b-54c376e10f30_terseLabel_en-US" xlink:label="lab_pfe_UpjohnFinanceB.V.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Finance B.V. [Member]</link:label>
    <link:label id="lab_pfe_UpjohnFinanceB.V.Member_label_en-US" xlink:label="lab_pfe_UpjohnFinanceB.V.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Finance B.V. [Member]</link:label>
    <link:label id="lab_pfe_UpjohnFinanceB.V.Member_documentation_en-US" xlink:label="lab_pfe_UpjohnFinanceB.V.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Finance B.V. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnFinanceB.V.Member" xlink:href="pfe-20211231.xsd#pfe_UpjohnFinanceB.V.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnFinanceB.V.Member" xlink:to="lab_pfe_UpjohnFinanceB.V.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_76df5b17-8eeb-4d3c-9bf9-b37eb2623a56_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ca20f42e-069b-4c7d-b141-a2f4f07e1a8b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts: 2021&#8212;$492; 2020&#8212;$508</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_35a763d0-cbc3-4b43-a9f5-6a543ae720ca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_72d3c519-1322-47e4-9fe4-6f25820c34bd_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f1116c47-46f4-45dc-a879-647865a9e15c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_bfb40cb0-7a0d-431c-83d6-1e5b846c15a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9600dc51-2180-4a67-9cd3-0f64c70ecc8e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_27115c54-4686-43b7-a748-9f0e43b97e19_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract_2e4da144-9a27-4a89-ba57-c9ba99df87aa_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows:</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="lab_pfe_ConsolidatedStatementsOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_f7ef17b4-cfa6-4984-9847-419537862643_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_714965b9-3c8e-4556-8d34-c6d837e46cf4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_aaa346ce-7696-470a-8736-bb88ced20331_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_dce51d92-a18f-4e3d-8c87-8cb8c9d9ad46_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cacea21-9c0b-4f7d-a0df-22de1a1a39a3_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_c31780c2-ad19-4e42-a4ab-45481845f735_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_e949abb0-4786-490c-9ea1-373c4efd0eed_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_273a468c-714f-4c7d-9060-7e806fdfef00_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_49ce64ca-e2d1-4315-ad3b-50ee5454d473_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5119237f-c75d-428c-992f-892e03a4a2d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1a4a25b6-8ecf-4507-97f0-af830860eb53_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_5df2a7cf-9d77-4fbe-bc65-317c11094c9d_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV equity method (income)/loss</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_label_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:to="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_7ac039ab-a182-4e11-9fdb-cfa101313e4c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESOP compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_37a13d58-e459-4c7e-8763-a6fbe2f863ce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_2be94fdb-ff86-4c79-9c48-33f874320ba1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_643c4ea3-07ea-4409-b339-3319a42140b2_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_44308daa-5da1-4143-b96f-47ee6e11e33f_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gain/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_528e8764-347f-4d7d-aa23-047881d79a62_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CopromotionMember_468b1152-9a31-438d-92bc-d4a05b511622_terseLabel_en-US" xlink:label="lab_pfe_CopromotionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion [Member]</link:label>
    <link:label id="lab_pfe_CopromotionMember_label_en-US" xlink:label="lab_pfe_CopromotionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion [Member]</link:label>
    <link:label id="lab_pfe_CopromotionMember_documentation_en-US" xlink:label="lab_pfe_CopromotionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-promotion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CopromotionMember" xlink:href="pfe-20211231.xsd#pfe_CopromotionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CopromotionMember" xlink:to="lab_pfe_CopromotionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_199bc1ad-f867-4770-ae03-b8bdb69b8ccd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_55422ef8-b5c5-401b-a5f3-a963ddabf7f1_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_c300bb3c-43d5-473f-81db-83a475f0f27e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_388f5920-d7f8-4d8f-9da5-15cb9864cd27_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_5a15e6b1-3481-4ce7-b8f4-9c9ad7ea198f_negatedLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of foreign exchange</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:to="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1e99125a-c37b-4b8a-a26b-c907d2b36e45_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost related to nonvested awards not yet recognized, pre-tax</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d9b0696d-aa62-4989-b7a2-d5990226406a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_532dc550-79c8-462f-876a-eb8f923c5f46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains)/losses on sale and leaseback transactions, net</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_label_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:to="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c00f1844-f632-481c-9918-18435fc57aa2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_bf8a4237-7982-44df-b7af-1e5c80f5113c_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid/deferred items - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_80c2be9c-531d-428f-be33-914e451fd73c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6073c772-3bc8-4b20-82c4-2545f77c34f5_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a3a6835a-a0b7-4cc0-8050-613a016ef12b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_d2380104-5e26-4bf7-8051-3c43badc82f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c2b867e7-bb0a-4e5c-9699-7581d7f5a9ef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_9d685c85-63ae-4faf-b334-b9189f138d20_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_f459f63c-6b07-47d9-b5d9-310be85ff00f_terseLabel_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_label_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherVaccinesProductsMember" xlink:href="pfe-20211231.xsd#pfe_OtherVaccinesProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherVaccinesProductsMember" xlink:to="lab_pfe_OtherVaccinesProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_7fa99e8c-95c8-4290-8480-0c22167675d1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other tax accounts, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_c73b6ad9-6ffa-42b7-a6ec-965329907791_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_1ec5ca72-f029-4182-b0dd-33b3c3a159bc_terseLabel_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ReFacto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_label_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_documentation_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember" xlink:href="pfe-20211231.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReFactoAfXynthaMember" xlink:to="lab_pfe_ReFactoAfXynthaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_f9fabbf1-9696-446c-9fea-bc732ac50c92_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaper_f2b0f502-3db2-48a8-b692-3b9791b8e906_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_label_en-US" xlink:label="lab_us-gaap_CommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper" xlink:to="lab_us-gaap_CommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_a824c4bb-d7ef-441f-8cc7-9e15da704b7c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c2838977-2cc2-4c0b-ac17-0993b37eff70_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RuxienceMember_85912e88-532b-4166-bfb3-725ac7785dfe_terseLabel_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience [Member]</link:label>
    <link:label id="lab_pfe_RuxienceMember_label_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience [Member]</link:label>
    <link:label id="lab_pfe_RuxienceMember_documentation_en-US" xlink:label="lab_pfe_RuxienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ruxience</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember" xlink:href="pfe-20211231.xsd#pfe_RuxienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RuxienceMember" xlink:to="lab_pfe_RuxienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_cafa6ee9-f7c1-4f8d-8360-8ee91ab36273_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income/(loss) from discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_38fa8be4-b5d9-49dd-9e57-2e886c71f717_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs (income)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7a1dca3f-a305-4ef3-96e6-502c37904d52_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_7c2c093c-fd4e-4ded-8c69-8c34420b99d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_1135a246-d314-4fc7-9116-e254605cb631_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer into/(out&#160;of) Level 3</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:to="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_4337b9cc-8f37-4d5b-a497-be82078e744c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_f9915041-f2db-4cf6-bdb3-5418fd571b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c8bfa5f2-493d-4e3b-8fb4-8b5ef18f0e5c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8203d7f7-fb85-4650-95d6-549cb53f25e7_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_a6361c49-3192-41aa-8c4e-3a6bc6670384_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3dfa913e-fd7d-4356-b80e-a8af3586186c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_338c0eb3-e2db-4a06-aba1-a99e52f09915_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c077937f-4a45-4592-99cf-185ef77f4916_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_12f14d72-011a-4e6c-b685-d76e72603e87_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_bbbcd7d4-7bbf-4b4f-b712-96a4db5dd10d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_6b8d2f65-0fa6-4e91-a7ba-9ea5e95d381a_terseLabel_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in a net receivable position</link:label>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_label_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Receivable Position, Aggregate Fair Value</link:label>
    <link:label id="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue_documentation_en-US" xlink:label="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Receivable Position, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:href="pfe-20211231.xsd#pfe_DerivativeNetReceivablePositionAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:to="lab_pfe_DerivativeNetReceivablePositionAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_817641fe-36f8-4e3f-80e7-97e5f731fd35_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_ba05e52f-4901-4097-884c-91e3ccf016de_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c3514159-6345-429c-9c64-7a6ac720c785_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_db0d6509-70d8-4f66-8e57-31a8d382fba3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1c07807d-5b1a-4ce7-a31a-2551fbe9ba92_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_ab8f2b24-d48e-4553-8583-092e55201e29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1a9b8393-69fe-476d-993a-ddb0b3cee88e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_dcbd2cb8-765f-4633-9edb-dc1fd62c72cb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_26166a7d-0e51-4eb4-8e8f-09baa0c43cac_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0bc6878c-be13-479c-a344-c4e12b703a0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherFinancialInformationAbstract_label_en-US" xlink:label="lab_pfe_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information [Abstract]</link:label>
    <link:label id="lab_pfe_OtherFinancialInformationAbstract_documentation_en-US" xlink:label="lab_pfe_OtherFinancialInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract" xlink:href="pfe-20211231.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherFinancialInformationAbstract" xlink:to="lab_pfe_OtherFinancialInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InflectraRemsimaMember_042111f1-a303-42a8-8a68-a65ceb8b1ed6_terseLabel_en-US" xlink:label="lab_pfe_InflectraRemsimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_label_en-US" xlink:label="lab_pfe_InflectraRemsimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_documentation_en-US" xlink:label="lab_pfe_InflectraRemsimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraRemsimaMember" xlink:href="pfe-20211231.xsd#pfe_InflectraRemsimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraRemsimaMember" xlink:to="lab_pfe_InflectraRemsimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermDebt_4cd7b9cc-f516-4a20-9e7a-e150833b563f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt" xlink:to="lab_us-gaap_OtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_888783de-6fd3-4f73-b0f8-50874101992c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_6c8b3361-5311-4262-a5bc-228080877fc0_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Increase (Decrease), Foreign Currency Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:to="lab_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_b077163a-50b0-47a7-8106-9b7396c3b9d4_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_4b41ddb8-5203-48cf-88f7-4ce52c4e9ab0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, weighted-average intrinsic value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ComirnatyMember_40619f2d-0af9-4e15-980f-0d7e425f9911_terseLabel_en-US" xlink:label="lab_pfe_ComirnatyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty direct sales and alliance revenues [Member]</link:label>
    <link:label id="lab_pfe_ComirnatyMember_label_en-US" xlink:label="lab_pfe_ComirnatyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty [Member]</link:label>
    <link:label id="lab_pfe_ComirnatyMember_documentation_en-US" xlink:label="lab_pfe_ComirnatyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comirnaty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ComirnatyMember" xlink:to="lab_pfe_ComirnatyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_19c20b7d-fb8c-42ca-8106-5969646d112d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_80c8d2f6-0173-4786-9578-9934d257b953_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_e2dcbe6e-5d16-4e6e-8561-2b59fb77d895_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_b05c9699-9184-47df-8464-378361d179a3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d9e41f71-3c64-48cd-a0a4-31326ec66748_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_7b0c9ee7-c372-41d2-811f-a934f690537e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax settlements and resolution of certain tax positions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_fd2d82d6-7f2a-4e7a-b791-7190f98c0a4a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f7259543-cde7-487d-a7ec-9b657d146a5c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_020b1783-50dc-4e77-9eb1-ad160426246c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_927bde9d-2646-45b0-98a3-86b4a6c92866_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_6c552b90-02d2-4b84-83bf-021043e7980e_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External incremental costs</link:label>
    <link:label id="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_label_en-US" xlink:label="lab_pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, External Incremental Costs, Amount</link:label>
    <link:label id="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_documentation_en-US" xlink:label="lab_pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, External Incremental Costs, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:to="lab_pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_83835474-1fac-4200-a0ec-c61a9b6bb04e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_5bcd4a4f-e369-490f-919f-980b704c80a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d0c24880-c56e-45b0-8c2f-cc1b2d5893d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_ded07c1d-30d6-4517-a3f8-19309e7e804c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_350592b8-befb-4c8c-988d-296ddbde3396_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_fde8f6e8-840a-4b0f-acc8-5e5633cb88ed_totalLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders Basic</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_b69c1802-baec-47b1-9c6b-b4c52323ebda_terseLabel_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20211231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UpjohnIncMember_ac6630a7-2dc3-4c1a-b850-33842694e061_terseLabel_en-US" xlink:label="lab_pfe_UpjohnIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Inc [Member]</link:label>
    <link:label id="lab_pfe_UpjohnIncMember_label_en-US" xlink:label="lab_pfe_UpjohnIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Inc [Member]</link:label>
    <link:label id="lab_pfe_UpjohnIncMember_documentation_en-US" xlink:label="lab_pfe_UpjohnIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncMember" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnIncMember" xlink:to="lab_pfe_UpjohnIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c16f306b-9c5a-4ede-8d7f-195bad48cd26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_87d83ba3-4bad-4789-8a2b-33e9bcc98bdf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm_c78948a8-22c2-4f84-8e90-dc32fcf7f623_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units exercised and converted, weighted average remaining contractual term</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_41183775-0066-44d3-b564-271f3d937013_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unremitted earnings - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_eabbc598-44da-453e-a1c4-57bb41290e75_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4542b80f-7773-4453-ac2f-82edd16ec9f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_bd8dc42b-8180-4287-8f15-46d2f5b10226_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Costs and Other Supplemental Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NotesDue20271.000Member_dc7cba75-e99c-4875-bb0d-3d2b471e6049_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member" xlink:href="pfe-20211231.xsd#pfe_NotesDue20271.000Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member" xlink:to="lab_pfe_NotesDue20271.000Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_96079802-b290-481f-8ec3-aef532408bf6_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member_26011c18-efdd-44b1-be9a-968e71eaaf53_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, One Point Nine Five Percent, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, One Point Nine Five Percent, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, One Point Nine Five Percent, Due 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" xlink:to="lab_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_5a9be019-a66a-4c31-9147-0266699b4736_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_34e199cb-7316-4431-bb45-2e31940b6e7c_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ef55cceb-a71c-4632-b369-e6086a409ac4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BosulifMember_1362cf07-e9ee-4ee7-9b4b-e480d7e060b5_terseLabel_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_label_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_documentation_en-US" xlink:label="lab_pfe_BosulifMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember" xlink:href="pfe-20211231.xsd#pfe_BosulifMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BosulifMember" xlink:to="lab_pfe_BosulifMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_4550cb13-b9b3-42d3-a2a1-ac96a30661ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MektoviMember_399a7af2-dfa0-48a3-b23d-7d38d9675952_terseLabel_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_label_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_documentation_en-US" xlink:label="lab_pfe_MektoviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember" xlink:href="pfe-20211231.xsd#pfe_MektoviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MektoviMember" xlink:to="lab_pfe_MektoviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_a6f7c3ff-6a77-4f65-aee6-ccce0b2721d1_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring</link:label>
    <link:label id="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_label_en-US" xlink:label="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring</link:label>
    <link:label id="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:to="lab_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_d1b3aae5-573d-4712-a15f-b0b36bacf6e5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA impact</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PristiqMember_31dd5d74-e05d-44d0-a0ac-0a72be2956da_terseLabel_en-US" xlink:label="lab_pfe_PristiqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pristiq [Member]</link:label>
    <link:label id="lab_pfe_PristiqMember_label_en-US" xlink:label="lab_pfe_PristiqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pristiq [Member]</link:label>
    <link:label id="lab_pfe_PristiqMember_documentation_en-US" xlink:label="lab_pfe_PristiqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pristiq</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PristiqMember" xlink:href="pfe-20211231.xsd#pfe_PristiqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PristiqMember" xlink:to="lab_pfe_PristiqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_075340e0-7538-48c5-ae4a-7c4bb841f779_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_08ce8c84-b196-4096-a404-60d3ae53bfde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_c108d19e-c123-4fab-b1f9-8e8c8794b253_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_de25f690-36b8-4b94-852a-496212858663_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_d905aa17-5ec3-4302-b5ae-a95953b2a921_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA impact</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_61443536-0085-4e52-a69e-d2afc2054a80_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total TCJA tax benefit</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_a28058d2-3c0d-4270-8574-481b79060b53_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Service (Costs)/Credits and Other [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e06d1d0d-fe1c-48b7-9ae3-1ce3bf0f7547_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_4f6b9203-1408-4d03-bd52-757cd9ce307e_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares at cost: 2021&#8212;3,851; 2020&#8212;3,840</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentForLicensingArrangement_39bfd935-277c-48f9-8f08-dd2453734229_terseLabel_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for licensing arrangement</link:label>
    <link:label id="lab_pfe_PaymentForLicensingArrangement_label_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Licensing Arrangement</link:label>
    <link:label id="lab_pfe_PaymentForLicensingArrangement_documentation_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Licensing Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentForLicensingArrangement" xlink:href="pfe-20211231.xsd#pfe_PaymentForLicensingArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentForLicensingArrangement" xlink:to="lab_pfe_PaymentForLicensingArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_58f3e0e6-47e2-48c3-9cbd-5b3cc7fdd5ac_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_8a9ae9f7-54df-442e-a28c-3b8987b44340_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate: Interest cost</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:to="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e7f5be7f-754e-4acb-a47a-290b689b021e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_33934078-8e44-4c74-b34c-877c0611b20d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OpenMarketPurchasesMember_8ce04b85-de85-46ae-8ead-95887a6003e9_terseLabel_en-US" xlink:label="lab_pfe_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:label id="lab_pfe_OpenMarketPurchasesMember_label_en-US" xlink:label="lab_pfe_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:label id="lab_pfe_OpenMarketPurchasesMember_documentation_en-US" xlink:label="lab_pfe_OpenMarketPurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OpenMarketPurchasesMember" xlink:href="pfe-20211231.xsd#pfe_OpenMarketPurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OpenMarketPurchasesMember" xlink:to="lab_pfe_OpenMarketPurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_14f96652-549d-42f2-b2a6-84156f1b8aae_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares available per individual during the plan period</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_8b2c9a9b-9a7b-4638-8e73-8cb711141564_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed investment from collaborator</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Investment From Collaborator, Amount</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Committed Investment From Collaborator, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:to="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ProfitUnitsMember_8e046300-41bc-4057-a0e5-ec6233c2c945_terseLabel_en-US" xlink:label="lab_pfe_ProfitUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Units [Member]</link:label>
    <link:label id="lab_pfe_ProfitUnitsMember_label_en-US" xlink:label="lab_pfe_ProfitUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Units [Member]</link:label>
    <link:label id="lab_pfe_ProfitUnitsMember_documentation_en-US" xlink:label="lab_pfe_ProfitUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ProfitUnitsMember" xlink:href="pfe-20211231.xsd#pfe_ProfitUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ProfitUnitsMember" xlink:to="lab_pfe_ProfitUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_03f6aebc-f79f-4370-ae52-2bd34d65e2b8_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring charges/(credits)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_95658bca-11c6-4c4b-b7b2-976710cf284e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge (credit)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_7ec1c8a4-6c33-44cd-8d56-a669bccfe99a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_027c2708-d26f-4c9e-a189-1742d6572da9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BeneFIXMember_fa851135-a0b5-4533-acdf-cac64c15b3b5_terseLabel_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BeneFIX [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_label_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_documentation_en-US" xlink:label="lab_pfe_BeneFIXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember" xlink:href="pfe-20211231.xsd#pfe_BeneFIXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BeneFIXMember" xlink:to="lab_pfe_BeneFIXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_7a5a6a20-951f-431d-8e61-27ed2e288e00_terseLabel_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_label_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Settlement Contracts, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:to="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_508d54a9-d7f4-46f0-b8ec-a8495cf33589_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_d0bd7a30-0a57-4007-b914-84b365b697ce_terseLabel_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_label_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_documentation_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember" xlink:href="pfe-20211231.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XtandiAllianceRevenuesMember" xlink:to="lab_pfe_XtandiAllianceRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrepaymentsandPaymentstoCollaborators_38e0d0c8-c096-4527-9d7a-ceaf225710a3_verboseLabel_en-US" xlink:label="lab_pfe_PrepaymentsandPaymentstoCollaborators" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to collaborators</link:label>
    <link:label id="lab_pfe_PrepaymentsandPaymentstoCollaborators_label_en-US" xlink:label="lab_pfe_PrepaymentsandPaymentstoCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments and Payments to Collaborators</link:label>
    <link:label id="lab_pfe_PrepaymentsandPaymentstoCollaborators_documentation_en-US" xlink:label="lab_pfe_PrepaymentsandPaymentstoCollaborators" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments and Payments to Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsandPaymentstoCollaborators" xlink:href="pfe-20211231.xsd#pfe_PrepaymentsandPaymentstoCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrepaymentsandPaymentstoCollaborators" xlink:to="lab_pfe_PrepaymentsandPaymentstoCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_a89eaa6e-4ac1-488f-a725-dc5b0e22e153_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_047061f3-057f-494e-98aa-56c22aadc508_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges:</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XeljanzMember_368f7c77-b16f-4afc-a884-47d75d2797c7_terseLabel_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_label_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_documentation_en-US" xlink:label="lab_pfe_XeljanzMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember" xlink:href="pfe-20211231.xsd#pfe_XeljanzMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XeljanzMember" xlink:to="lab_pfe_XeljanzMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_a5f50a3a-7d8c-4a53-888b-52d804eed7c0_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions/divestitures, net</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:to="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_47e3de45-93c4-43eb-b526-115059a1317a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_ab207436-735f-459b-80c3-7f4d838bd132_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_e8ad7fa7-c641-4162-ac68-5a9a759c8772_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_1ecd9564-71e7-4423-9871-c48263faa91e_terseLabel_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase, percentage of agreement</link:label>
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_label_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</link:label>
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_documentation_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:href="pfe-20211231.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:to="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_e620777e-f911-47c6-a3b4-a1bb73afb64e_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis" xlink:to="lab_pfe_DebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_65cf619d-826a-4f50-b94d-4af310e54e58_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_bf737fbd-b2b7-40f6-af56-b66a34d27096_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Future Milestone Payments, Maximum Exposure</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Future Milestone Payments, Maximum Exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9126ce3d-3312-4801-8061-1a67b7e46098_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_d3ed2ea3-ce1a-4fb1-830f-b7947141639d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_472583eb-bcbd-4ff3-a501-c06a898a2aa9_terseLabel_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-offs and impairments</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_documentation_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:href="pfe-20211231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:to="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_8f9ee63c-a0e3-44bb-b7ba-e0381e0b1364_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Commingled Funds [Member]</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:to="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_46428e76-acd5-4098-af34-8c3cfaf02592_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_387e3067-c202-4298-ba22-f1a68b5cfc26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (Thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c8e0edf8-e0e3-4408-b284-28c4507c3561_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_01bfde12-11be-4977-9abd-be30aa93045a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c84ee5ca-4d97-482d-b532-f20fb7432a3c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_9afa3f4b-a27e-494d-95ae-2eae0446fcb7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_f0713fba-58c2-4fff-8cae-7e14bd455b1d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash transactions:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e3f8d4cf-c08f-4b46-95ee-956721c51d63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_345b90bb-1cf6-4c45-9d4b-fc49f9a2002e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_6b49dfad-e151-46d3-aa93-ee7cadcf8445_negatedLabel_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_label_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:label id="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_documentation_en-US" xlink:label="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:href="pfe-20211231.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:to="lab_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RetacritMember_ff754bb1-12d5-4b25-98fd-d5b7d5e881d9_terseLabel_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_label_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_documentation_en-US" xlink:label="lab_pfe_RetacritMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember" xlink:href="pfe-20211231.xsd#pfe_RetacritMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RetacritMember" xlink:to="lab_pfe_RetacritMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ViiVMember_bc1246ec-1f49-483a-b43f-26dfa71e54c6_terseLabel_en-US" xlink:label="lab_pfe_ViiVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV [Member]</link:label>
    <link:label id="lab_pfe_ViiVMember_label_en-US" xlink:label="lab_pfe_ViiVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV [Member]</link:label>
    <link:label id="lab_pfe_ViiVMember_documentation_en-US" xlink:label="lab_pfe_ViiVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViiVMember" xlink:href="pfe-20211231.xsd#pfe_ViiVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViiVMember" xlink:to="lab_pfe_ViiVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ChantixChampixMember_3d798435-cdde-4a9d-bb7f-c8197c8e2594_terseLabel_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_label_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_documentation_en-US" xlink:label="lab_pfe_ChantixChampixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember" xlink:href="pfe-20211231.xsd#pfe_ChantixChampixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ChantixChampixMember" xlink:to="lab_pfe_ChantixChampixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1fc8eb29-08fa-44f8-83cd-26f18b018b1b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_12ddf8b2-a33c-46ae-a0dd-8d05a26ba9c2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6d46f1c8-4bad-434d-b469-10277f25e7f0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_165414c8-8dea-478c-86d9-8287744027d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted-average intrinsic value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_59c92ec2-5031-49a8-be73-ef695fac782f_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash" xlink:to="lab_us-gaap_DividendsPreferredStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f6b2b911-1b6d-4a80-afdb-c99176cc8b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20482050Member_09991204-1deb-4671-bb0a-744c3de9af22_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20482050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2048-2050 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20482050Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20482050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2048-2050 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20482050Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20482050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2048-2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20482050Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20482050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20482050Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20482050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_f5cf0dbe-6643-46fb-b063-4cd7e131ea18_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_592b495c-aaa9-43e8-afa4-b051d156df01_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_518ab1cb-2040-4335-8da1-4ab933e046cb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_3c218b9b-656b-49d0-ad3d-7454b6136ee2_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Developed Technology [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_label_en-US" xlink:label="lab_pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Developed Technology [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Developed Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:to="lab_pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorNotesDue2021Member_5ce03378-84cf-406a-8e56-2a767122ca07_terseLabel_en-US" xlink:label="lab_pfe_SeniorNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2021Member_label_en-US" xlink:label="lab_pfe_SeniorNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2021Member_documentation_en-US" xlink:label="lab_pfe_SeniorNotesDue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2021Member" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorNotesDue2021Member" xlink:to="lab_pfe_SeniorNotesDue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_cf68f951-3ea9-4104-a106-c46bb8f69067_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment before accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_50f4a0d5-ae5a-4160-8c55-16ae4f9a2a32_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Member]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_447fab6c-da5e-4cd2-919a-019d2cdaf2ef_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_59e0c470-0665-4735-8ea3-d4aec4e24a8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_c80732e0-3891-41f3-ac1e-9088822b3434_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_316c0f2d-663f-43e7-8575-ffbbdd1a6efb_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne_15988dd8-cfcd-4c74-9c9f-95599396ba35_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum reimbursement due from collaborators, 2021</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year One</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" xlink:to="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShinglesVaccineProgramMRNABasedMember_876898fb-9c3b-4e42-983f-1c0f0ac9eabe_terseLabel_en-US" xlink:label="lab_pfe_ShinglesVaccineProgramMRNABasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shingles Vaccine Program, mRNA-Based [Member]</link:label>
    <link:label id="lab_pfe_ShinglesVaccineProgramMRNABasedMember_label_en-US" xlink:label="lab_pfe_ShinglesVaccineProgramMRNABasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shingles Vaccine Program, mRNA-Based [Member]</link:label>
    <link:label id="lab_pfe_ShinglesVaccineProgramMRNABasedMember_documentation_en-US" xlink:label="lab_pfe_ShinglesVaccineProgramMRNABasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shingles Vaccine Program, mRNA-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShinglesVaccineProgramMRNABasedMember" xlink:href="pfe-20211231.xsd#pfe_ShinglesVaccineProgramMRNABasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShinglesVaccineProgramMRNABasedMember" xlink:to="lab_pfe_ShinglesVaccineProgramMRNABasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_3b8a44b4-6168-47fa-b99e-6127c9ada9d9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Impairment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_074e3353-5496-4705-b5f4-6462254e6176_totalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total international tax provision</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_18c9634f-d555-4638-ab5f-45dda244255a_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits and other [Member]</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeconsolidationNetAssetsContributed_4010b20e-68c5-499d-b821-d219efac2f2c_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationNetAssetsContributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation net assets contributed</link:label>
    <link:label id="lab_pfe_DeconsolidationNetAssetsContributed_label_en-US" xlink:label="lab_pfe_DeconsolidationNetAssetsContributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Net Assets Contributed</link:label>
    <link:label id="lab_pfe_DeconsolidationNetAssetsContributed_documentation_en-US" xlink:label="lab_pfe_DeconsolidationNetAssetsContributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Net Assets Contributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationNetAssetsContributed" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationNetAssetsContributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationNetAssetsContributed" xlink:to="lab_pfe_DeconsolidationNetAssetsContributed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_2d6a759a-432e-49d0-b858-296e06375fc7_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_ac2e9a15-6c7e-4aa2-bb6c-996ff2a8852a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DocetaxelMember_192d8f83-a55b-4357-8223-825dd7526fb7_terseLabel_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_label_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_documentation_en-US" xlink:label="lab_pfe_DocetaxelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember" xlink:href="pfe-20211231.xsd#pfe_DocetaxelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DocetaxelMember" xlink:to="lab_pfe_DocetaxelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_1ef5605d-4f2c-42ab-afbd-360c41febbe4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_e65cf9ff-de57-4144-bf64-3e002cac0a5a_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, within 1 year, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_a9ea1215-32e6-4763-aa72-e29e5a615440_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, consideration transferred</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_508dc7ef-6b4e-4c36-8f10-8bb477036511_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5f0aeb03-e723-45ab-9299-4f3416f805fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b633c278-35e7-4f74-aa58-e884c494b2f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (long-term), statement of financial position</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CurrentTaxAssetsMember_d15e63fe-e42a-4aba-8f6a-cbabe239af13_terseLabel_en-US" xlink:label="lab_pfe_CurrentTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_CurrentTaxAssetsMember_label_en-US" xlink:label="lab_pfe_CurrentTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_CurrentTaxAssetsMember_documentation_en-US" xlink:label="lab_pfe_CurrentTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Tax Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CurrentTaxAssetsMember" xlink:href="pfe-20211231.xsd#pfe_CurrentTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CurrentTaxAssetsMember" xlink:to="lab_pfe_CurrentTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_d1787951-4eec-4d39-a448-8d8fbfb0eaf0_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_8e6358d9-cf8b-437f-bae8-b55f1774a82d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_1fda1c6f-a09d-4ae8-8d63-a5fc0f32e35b_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_cbd3ca4f-ad17-4c3c-adaa-2126abc13688_totalLabel_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term investments</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_label_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_documentation_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:href="pfe-20211231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:to="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_61522f84-7699-4df7-8374-5d50c263caa8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_dea940f5-a0a7-4b10-8c47-0e1987d774a3_terseLabel_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_label_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_documentation_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:href="pfe-20211231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:to="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_f887db29-c9b0-4ae1-8160-95306d54e38b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TygacilMember_8336a5ad-5df4-41a2-b300-8b38efade613_terseLabel_en-US" xlink:label="lab_pfe_TygacilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:label id="lab_pfe_TygacilMember_label_en-US" xlink:label="lab_pfe_TygacilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:label id="lab_pfe_TygacilMember_documentation_en-US" xlink:label="lab_pfe_TygacilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tygacil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TygacilMember" xlink:href="pfe-20211231.xsd#pfe_TygacilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TygacilMember" xlink:to="lab_pfe_TygacilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_34688aa3-2cde-4387-a8cb-48ce22718d3f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d7791866-0f1e-4054-b5b0-a5f61f53cec2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Avg. GDFV per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9649d254-5cf0-4e18-88cc-66880552beae_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_46a35be3-3aa9-4c1b-82cc-c7b7c85b7c53_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, ending</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_41cba78e-0c04-4ed4-a889-0ee00b1a0b2f_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_30f417c1-0cb7-489c-b652-c7efa750424d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa7e77a0-d3b0-45f7-92c9-77ecedf5a7a1_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate for income from continuing operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_9b71f50a-db5e-4890-9be9-8b5e18dfea65_terseLabel_en-US" xlink:label="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Related Costs [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_label_en-US" xlink:label="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Acquisition Related Costs [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_documentation_en-US" xlink:label="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsAcquisitionRelatedCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:to="lab_pfe_ReconcilingItemsAcquisitionRelatedCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_773ce79c-b985-4110-b7a4-a40b01150e30_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected contributions in 2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TrilliumMember_4e4abcbf-5441-4389-87fb-6eda36def619_terseLabel_en-US" xlink:label="lab_pfe_TrilliumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trillium [Member]</link:label>
    <link:label id="lab_pfe_TrilliumMember_label_en-US" xlink:label="lab_pfe_TrilliumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trillium [Member]</link:label>
    <link:label id="lab_pfe_TrilliumMember_documentation_en-US" xlink:label="lab_pfe_TrilliumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trillium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrilliumMember" xlink:href="pfe-20211231.xsd#pfe_TrilliumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TrilliumMember" xlink:to="lab_pfe_TrilliumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_0255d508-f463-4866-bb2b-33c00d8980ee_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings, including current portion of long-term debt: 2021&#8212;$1,636; 2020&#8212;$2,002</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_8d48254e-e8d0-4e4d-9426-2a39c4e9b176_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_58a75716-3045-47df-904a-9bbe4c2846be_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of short-term borrowings</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_18669583-e98d-42a8-a3f6-a9c1af44e3f4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchases, cash paid</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_56bc3f50-63a3-4a19-aa06-9405245b643e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_03846fdb-bef2-4045-b726-5feac6d9b3a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AccruedRebates_34d38d01-86e7-498a-8679-a38803f01763_terseLabel_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_label_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_documentation_en-US" xlink:label="lab_pfe_AccruedRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates" xlink:href="pfe-20211231.xsd#pfe_AccruedRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AccruedRebates" xlink:to="lab_pfe_AccruedRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_28d1443f-5798-47a1-a14f-62be66efb62c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_82490308-5e1f-42b9-9ce0-0147de86c90f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_f8f2bb9e-ace2-4f4b-937d-789607c0a8a8_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US [Member]</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_3de98fd1-fb91-418c-a6a4-91e33ec5c8a3_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_3366c2c1-23b8-494e-b6d7-88363c21bda3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_ae253f06-32ee-423e-888a-e6620a94cfab_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_30c76c67-40ae-49e8-90f7-4ae40bd9d762_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity commingled funds [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:to="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_af1ba170-92c8-4035-b115-31549a3e879e_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_label_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyDebtMember_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency long - term debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyDebtMember" xlink:to="lab_pfe_ForeignCurrencyDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BioNTechMember_f9476185-db62-4abf-a605-8d937ca0b822_terseLabel_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech [Member]</link:label>
    <link:label id="lab_pfe_BioNTechMember_label_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech [Member]</link:label>
    <link:label id="lab_pfe_BioNTechMember_documentation_en-US" xlink:label="lab_pfe_BioNTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BionTech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechMember" xlink:to="lab_pfe_BioNTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9e2fd870-222e-402f-adae-25f08aec8b67_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Assets and Liabilities and Income Tax Contingencies</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_16bdfb46-2555-43d1-991c-7e5c9e60be08_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_82e3ea14-7127-4db9-aafa-c733e5b4d1dd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8a09495b-ba24-4caf-acba-74ac50874a4a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_a3d7e159-eb5e-4cee-bb87-70a1c173d938_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent inventories not included above</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f42bbef1-021b-471a-8d15-b8a9b6b719bd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b4340799-6011-4563-9414-732bfdacf00b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares&#8211;&#8211;diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5b9f90a-a5de-49f3-a7e5-c2115e37866c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_74540b67-548f-45e4-b836-3fb8e45eb231_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_a467e8ac-8276-4fb0-a1d9-d67b859551e7_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction for unrecognized tax benefit</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:to="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_4d8c4eb8-40aa-4995-9121-32785d37ff5b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d8741666-c7fa-4b8b-af44-8ce0a1d6f491_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_3c309d5b-46e1-4c52-91c6-53291578e871_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities of discontinued operations&#8211;&#8211;Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_f0ae874b-1d05-4e9b-941e-15a7137ca30f_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:href="pfe-20211231.xsd#pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:to="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6274791a-a466-48f7-9e01-e547ca2072de_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f94bb6aa-a0a1-4e7b-a293-a295cdbe8b64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherOncologyProductsMember_30cde485-90ca-401f-8875-30a14bca90bc_terseLabel_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_label_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember" xlink:href="pfe-20211231.xsd#pfe_OtherOncologyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherOncologyProductsMember" xlink:to="lab_pfe_OtherOncologyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TransitionServiceAgreementMember_eca41f8e-73b8-4b8c-9e82-3f8f96e9a3b9_terseLabel_en-US" xlink:label="lab_pfe_TransitionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Service Agreement [Member]</link:label>
    <link:label id="lab_pfe_TransitionServiceAgreementMember_label_en-US" xlink:label="lab_pfe_TransitionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Service Agreement [Member]</link:label>
    <link:label id="lab_pfe_TransitionServiceAgreementMember_documentation_en-US" xlink:label="lab_pfe_TransitionServiceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition Service Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TransitionServiceAgreementMember" xlink:href="pfe-20211231.xsd#pfe_TransitionServiceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TransitionServiceAgreementMember" xlink:to="lab_pfe_TransitionServiceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d1f72860-9313-440c-b93e-193834ec901f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_627e7029-c1bb-4358-b435-a3dd7b9f2893_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_b0de2ed9-b761-4dc8-be11-3d9bb7801788_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_4211021e-413f-4308-ab09-e19123cfca75_totalLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2f6ba2e1-f585-462d-bccf-88018eb41698_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_fef2fa2d-c36a-4316-869b-f95aa4559117_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_79699a32-9feb-4a10-ba96-59bf167d012d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_647700a2-2445-4d31-96ec-0291a72f7530_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a14c6dc9-ff51-4cf7-b97e-e0d7aba96c84_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_d36af25a-7b91-4714-99cf-6033feadd606_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7e37020b-e891-41a4-bc39-8de25c8fd465_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_9448e441-9bd3-4357-affd-5dbfea0f8613_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0e63fb37-d59b-4427-b3f4-64140d809004_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_6ad9fd6b-e7e6-4ff9-947f-c295b406907d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_8406353f-038e-429d-ba5b-72553e4e44cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_49f7f25f-4b87-4f01-86b5-e8c4b9b65280_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_1ac611b0-4da1-4756-b68c-9a9339bcf556_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_d6e3d6c7-8b65-4c53-a013-1a818e676745_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units vested, weighted average remaining contractual term</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11535ed4-ce03-43c2-b776-5259fbad9c21_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term/expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_1ccf1ac8-7b3e-454c-a743-ac42c1ef1bb5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a7876f51-c1d8-4397-8987-1588778adae8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cc50904c-1b1b-4597-97f8-0b5d5d4e5826_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerCentreOneMember_31cb8a95-6750-4b7e-a780-3d59b9cada25_terseLabel_en-US" xlink:label="lab_pfe_PfizerCentreOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_label_en-US" xlink:label="lab_pfe_PfizerCentreOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_documentation_en-US" xlink:label="lab_pfe_PfizerCentreOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneMember" xlink:href="pfe-20211231.xsd#pfe_PfizerCentreOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerCentreOneMember" xlink:to="lab_pfe_PfizerCentreOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_b30778e8-dca5-432f-891e-0c1ac57b98de_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_619f25ea-69a4-4f42-a06c-c08ba7aa98fa_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ImplementationCosts_71394f8e-374e-4632-976d-8e262d844a39_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_label_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation Costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_documentation_en-US" xlink:label="lab_pfe_ImplementationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts" xlink:href="pfe-20211231.xsd#pfe_ImplementationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCosts" xlink:to="lab_pfe_ImplementationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_58292c31-695a-40e8-931e-212ed3a94e5d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9fe34e27-c8c1-442a-af4b-253c9d709f00_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_3908d710-29b9-4db2-b5f6-4ec0f282b94f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_89bcf634-afd2-4b7f-9969-e296649186b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_0d39b717-a6f5-4a35-a4ea-b9d959383eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d6703de7-d151-4541-809b-6e94b58da544_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InternalMedicineMember_7564cb7b-1fc4-4f16-9018-3af571e7a696_terseLabel_en-US" xlink:label="lab_pfe_InternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_label_en-US" xlink:label="lab_pfe_InternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_documentation_en-US" xlink:label="lab_pfe_InternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternalMedicineMember" xlink:href="pfe-20211231.xsd#pfe_InternalMedicineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InternalMedicineMember" xlink:to="lab_pfe_InternalMedicineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_086e0714-8d59-423e-b8eb-90b5f0500212_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_XalkoriMember_ff2ed562-68ed-40b1-8544-c8b1933d2305_terseLabel_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_label_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_documentation_en-US" xlink:label="lab_pfe_XalkoriMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember" xlink:href="pfe-20211231.xsd#pfe_XalkoriMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalkoriMember" xlink:to="lab_pfe_XalkoriMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_05540e7b-5282-4fe4-8115-78ae2d5255a5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_84b81046-fe23-4147-98e5-4a7a05a5e8fd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_865878c7-8354-41c3-b178-d344d33b1e2a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_b7370035-55c4-457a-85f4-e59f41409c88_terseLabel_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_label_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_documentation_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:href="pfe-20211231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:to="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GenotropinMember_a62eeb6b-a32a-4749-9b28-d7fc6614afba_terseLabel_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_label_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_documentation_en-US" xlink:label="lab_pfe_GenotropinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember" xlink:href="pfe-20211231.xsd#pfe_GenotropinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenotropinMember" xlink:to="lab_pfe_GenotropinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fd346328-626d-44b4-b3ef-0b02ece5da2c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_15496766-72ac-4395-a02c-797feeab02df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_24156c5b-9ba8-4059-a301-3f44f13d9203_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ABO</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_1a3e6e37-41a4-4ff4-8cb9-61f415624ab2_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_label_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs, Transaction Costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:to="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8df7f142-7d95-417a-9383-642442b95f14_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standards Adopted in 2021</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_353271c2-6165-499b-8bac-c4be5bd0c1a9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax_18cd0ef1-a229-4ab2-881b-b2d0a5dc59ae_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase to accumulated other comprehensive loss</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Reclassification Adjustment from AOCI, After Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Reclassification Adjustment from AOCI, After Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_be59e0cb-916e-48c5-93a6-50a68a76d278_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_56de0d6b-d15c-471b-9ca8-5aa7f187fe66_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of costs to be reimbursed</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Percentage of Costs to be Reimbursed</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Percentage of Costs to be Reimbursed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:href="pfe-20211231.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:to="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorNotesDue2023Member_2305569c-1d77-40a6-a17f-e2c1bf63fbd9_terseLabel_en-US" xlink:label="lab_pfe_SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2023Member_label_en-US" xlink:label="lab_pfe_SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_pfe_SeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2023Member" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorNotesDue2023Member" xlink:to="lab_pfe_SeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned_dd923dc0-1cde-4cb8-9a40-02ac6b9f05d2_terseLabel_en-US" xlink:label="lab_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio, shares received for each share held</link:label>
    <link:label id="lab_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned_label_en-US" xlink:label="lab_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Ratio, Shares Received for Each Share Owned</link:label>
    <link:label id="lab_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned_documentation_en-US" xlink:label="lab_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Ratio, Shares Received for Each Share Owned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned" xlink:href="pfe-20211231.xsd#pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned" xlink:to="lab_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ed1ae2f2-6f9e-48c4-986a-c4ff69f9b0fd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost related to nonvested awards not yet recognized, pre-tax</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_4b88487b-105c-49d9-b03a-e79181897cda_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EliLillyCompanyMember_a2fd0b4a-5523-4e5d-9fc3-9538812a5030_terseLabel_en-US" xlink:label="lab_pfe_EliLillyCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:label id="lab_pfe_EliLillyCompanyMember_label_en-US" xlink:label="lab_pfe_EliLillyCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:label id="lab_pfe_EliLillyCompanyMember_documentation_en-US" xlink:label="lab_pfe_EliLillyCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliLillyCompanyMember" xlink:href="pfe-20211231.xsd#pfe_EliLillyCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliLillyCompanyMember" xlink:to="lab_pfe_EliLillyCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_158d141a-c542-4d90-934f-cf5163f9b4f3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e4202b10-ad60-4db1-9d26-3b78f6aa82b9_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_dec9e850-6878-47fd-a0a1-38c03e3a6a94_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_37d8e8ce-f1f5-45db-9c13-aa938bd30b4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_77cb3978-e043-4d02-a88d-56b14fc53cfa_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_da0440cc-c908-4c83-9c23-d8b4df725655_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets, statement of financial position</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_e7dcbf1c-84ab-42f8-b8dc-847ae8a60153_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents [Member]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c1a0199e-b400-493b-ade7-4799f20fe5e6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_f647beaf-578b-477e-b614-c38a625e4b3b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxation of non-U.S. operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrecedexMember_5c9182ce-a302-4644-9321-baa673720f7c_terseLabel_en-US" xlink:label="lab_pfe_PrecedexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_label_en-US" xlink:label="lab_pfe_PrecedexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precedex [Member]</link:label>
    <link:label id="lab_pfe_PrecedexMember_documentation_en-US" xlink:label="lab_pfe_PrecedexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Precedex [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrecedexMember" xlink:href="pfe-20211231.xsd#pfe_PrecedexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrecedexMember" xlink:to="lab_pfe_PrecedexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_a8808e07-1f91-4ab4-aff0-cad56428f76d_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod_39dd23f1-dc6b-477f-816d-843f1a4592e0_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share payout measures, adjusted net income, period</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_d0bb8d9a-cee3-4ea4-b0f4-f1a8cd9f8c54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Measured at NAV [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured at Net Asset Value Per Share [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:to="lab_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_7003b572-b880-4c34-ab24-7d3a80511ef8_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock conversions and redemptions (in shares)</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:href="pfe-20211231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f4fbd68c-741a-41f6-ae0c-58eeff569609_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_197601f3-3a91-4b3f-8cb7-4c81677c297c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UpjohnFinanceBVMember_cddde27b-a282-4b4b-a1ef-646ca1d5252c_terseLabel_en-US" xlink:label="lab_pfe_UpjohnFinanceBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Finance B. V.</link:label>
    <link:label id="lab_pfe_UpjohnFinanceBVMember_label_en-US" xlink:label="lab_pfe_UpjohnFinanceBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Finance B. V. [Member]</link:label>
    <link:label id="lab_pfe_UpjohnFinanceBVMember_documentation_en-US" xlink:label="lab_pfe_UpjohnFinanceBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Finance B. V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnFinanceBVMember" xlink:href="pfe-20211231.xsd#pfe_UpjohnFinanceBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnFinanceBVMember" xlink:to="lab_pfe_UpjohnFinanceBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_42224152-02c2-4b31-90b6-9555f1c954cd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_abd80551-ff8f-4b44-98c5-e43a05dd3e62_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upward price adjustments on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AgreementAxis_3a3d347d-3482-46f6-97cf-e6e430929c36_terseLabel_en-US" xlink:label="lab_pfe_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_pfe_AgreementAxis_label_en-US" xlink:label="lab_pfe_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement [Axis]</link:label>
    <link:label id="lab_pfe_AgreementAxis_documentation_en-US" xlink:label="lab_pfe_AgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementAxis" xlink:href="pfe-20211231.xsd#pfe_AgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AgreementAxis" xlink:to="lab_pfe_AgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_904700d6-2960-4145-80b0-09fb05c25c2d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives in a net liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Net Liability Position, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:to="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_648814c9-5db2-469a-b89c-0dc0a9a8c19a_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4fbcad97-6ee2-4ddd-a1e3-2e05b08a1e4e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes from continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e3eb8f97-b11e-483a-baa1-cb2156e0aabe_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes from continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c886a293-bc60-4d72-858d-5ce221c73594_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_6b1d30db-58e3-408f-9f59-14e3fe44e59f_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3a05326b-776c-4332-a62c-0419295191be_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares authorized in stock purchase plan, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_ffa74f19-a6ca-4427-8ffe-e0f21f0b6167_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_10a237dd-25b4-4ebe-81bf-d3ede51ddf69_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsAbstract_62bc5a7d-a9d7-483a-8abe-8ca6f2b8f44e_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared:</link:label>
    <link:label id="lab_us-gaap_DividendsAbstract_label_en-US" xlink:label="lab_us-gaap_DividendsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAbstract" xlink:to="lab_us-gaap_DividendsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_23d06a26-c7b9-4e7e-8701-cde12b175fdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock Purchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember_e0f6fe89-557e-4d3c-8574-7bba5ee64a63_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Equity Securities [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Global Equity Securities [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Global Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" xlink:to="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_72e3b603-d85f-4b6b-89e7-280c323b1ded_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_57b34e2d-dcb4-4562-8de2-5d6c5f02d951_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Integration costs and other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_57dec70e-a871-481f-b536-c09a4730224f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8a7fc47c-62e7-4b41-948e-720d9cfbd25a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a35b325-8220-4279-a938-9fac91b626ae_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Plan Asset Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5c5de983-0d24-4714-9c96-896848553c83_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f5f5400c-8132-4be2-a807-e8c11cd23d64_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_06c77ae7-db90-4d1c-9f23-be4cee21841f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income attributable to shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_51275935-0816-43b2-8c01-1b8d6d4da9dc_terseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation gain</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_966ce30f-b55f-4cfa-8cbd-7f7ca6a1d993_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_f8baa23d-78b7-457c-b8b3-3d3822b94844_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_769e9a82-a9e4-46b5-8f08-b1020cab1f1b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesReportingOfDerivativeActivity_967bdb55-b075-46a6-8898-8ba6627612fa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_DerivativesReportingOfDerivativeActivity_label_en-US" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Reporting of Derivative Activity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="lab_us-gaap_DerivativesReportingOfDerivativeActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_3c17e4f5-23e1-4fdb-90ce-19dd9d907a2f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_6eacdbd5-16b1-47ab-8e9d-2956542a96c7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_2bbc0037-1fe9-470f-9a04-1e8745326c3c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related items</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_7a960fa0-c270-4f4d-b788-afe42740f3d8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_e15f68ac-6329-4211-9d41-993e0a428d37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_953e938c-940e-4eb3-8094-169e3f56887a_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_515232fc-5c4e-42b2-a759-392f4017e8d7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_af590e60-a72a-4cb5-80be-b75a67171a9d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_8f56debc-5213-4074-8fe5-2776711a502c_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_1d22e6ae-699c-4396-ba39-753854060447_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_91e75504-e0ad-4aa6-befe-d4426ebf5741_terseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet" xlink:href="pfe-20211231.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeExpenseNet" xlink:to="lab_pfe_OtherNonoperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_b125388b-69b6-4697-bd0e-616381773fe0_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for disposition</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9659023a-7b47-4edd-87eb-4a2c07a83a95_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_fb560d30-f72f-483a-9d50-69caf4dc4343_terseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash divested</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TrazimeraMember_193fa0e5-5364-48c9-b7b7-911dfd259c34_terseLabel_en-US" xlink:label="lab_pfe_TrazimeraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trazimera [Member]</link:label>
    <link:label id="lab_pfe_TrazimeraMember_label_en-US" xlink:label="lab_pfe_TrazimeraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trazimera [Member]</link:label>
    <link:label id="lab_pfe_TrazimeraMember_documentation_en-US" xlink:label="lab_pfe_TrazimeraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trazimera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrazimeraMember" xlink:href="pfe-20211231.xsd#pfe_TrazimeraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TrazimeraMember" xlink:to="lab_pfe_TrazimeraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_cc43236a-c3a0-4237-af17-ceaec9113e51_terseLabel_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feasibility study, number of lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_label_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_documentation_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons" xlink:href="pfe-20211231.xsd#pfe_FeasibilityStudyNumberOfLagoons"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FeasibilityStudyNumberOfLagoons" xlink:to="lab_pfe_FeasibilityStudyNumberOfLagoons" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_db9c4918-9aaf-4d98-be85-610e18b85603_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairments</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_832ab1e0-bc6e-4fca-874a-5cc91a6b8b10_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7421c84f-5cd3-428d-b8ed-af18ab6496bc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1696e087-d5dd-494c-bec4-d5e6f2f1cf7d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_17f952f4-6834-46f4-ba09-81c20b1a65b7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_66ae52dd-a96a-4e44-9b7a-dcfcfbbcdded_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7f1406df-9e14-475a-91f6-76c2105074b5_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_97df55a1-ab7c-4dd1-b0e6-e048fb6bf7d6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4a30a609-14bf-4701-a449-d6bdc0c7bc95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_e8edd955-bf6c-4fa2-afcd-eddc96efd119_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_f96c8a64-c08f-46bb-84ea-6d7c196a41fd_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_8172ff79-b61f-4121-b0c1-b52023c2a7ff_terseLabel_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Agreement with Goldman, Sachs &amp; Co. LLC [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_label_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Agreement with GS&amp;Co [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_documentation_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Agreement with GS&amp;Co [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:href="pfe-20211231.xsd#pfe_ShareRepurchaseAgreementwithGSCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:to="lab_pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3fb62225-197d-4f7d-a84f-9a03ec3687a8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_8a65c061-eb2c-4367-9f0d-5d126599498c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_9df75227-2c32-4d69-9d97-a1670f942c14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit costs/(credits)</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReconcilingItemsOtherMember_72b10d62-3798-4d4b-8589-6039831c6522_terseLabel_en-US" xlink:label="lab_pfe_ReconcilingItemsOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Reconciling Items [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsOtherMember_label_en-US" xlink:label="lab_pfe_ReconcilingItemsOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Other [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsOtherMember_documentation_en-US" xlink:label="lab_pfe_ReconcilingItemsOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsOtherMember" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReconcilingItemsOtherMember" xlink:to="lab_pfe_ReconcilingItemsOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AromasinMember_21efa704-cdfb-41a9-b6bf-0e3b672e5e6b_terseLabel_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin [Member]</link:label>
    <link:label id="lab_pfe_AromasinMember_label_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin [Member]</link:label>
    <link:label id="lab_pfe_AromasinMember_documentation_en-US" xlink:label="lab_pfe_AromasinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aromasin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember" xlink:href="pfe-20211231.xsd#pfe_AromasinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AromasinMember" xlink:to="lab_pfe_AromasinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MedrolMember_c90d1ffb-24b9-42e3-92b3-8155c195aab9_terseLabel_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_label_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_documentation_en-US" xlink:label="lab_pfe_MedrolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medrol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember" xlink:href="pfe-20211231.xsd#pfe_MedrolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedrolMember" xlink:to="lab_pfe_MedrolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_ac18dc3d-b222-4b9f-a70c-2efab4159bd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_2b210803-324f-45e8-8c1f-d208dca1dbb0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_a4190256-fe0b-48e3-a9c3-a94b397a59ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Security Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAggregatedInvestmentsMember" xlink:to="lab_us-gaap_OtherAggregatedInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9eb7f149-1ec5-403d-be28-c35c49da39c0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_306ef53c-312d-44c3-bc2b-c557c461bfef_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_f61a509f-3b22-4ef0-98cf-bbb84f060d6c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b1183f73-76dd-45d9-9d9f-720ddc2d8933_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_d6647894-3f12-4019-a58b-9047b4e6eb5f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BeamMember_24aa9f25-9b97-4401-9609-9e6fae726970_terseLabel_en-US" xlink:label="lab_pfe_BeamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beam [Member]</link:label>
    <link:label id="lab_pfe_BeamMember_label_en-US" xlink:label="lab_pfe_BeamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beam [Member]</link:label>
    <link:label id="lab_pfe_BeamMember_documentation_en-US" xlink:label="lab_pfe_BeamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeamMember" xlink:href="pfe-20211231.xsd#pfe_BeamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BeamMember" xlink:to="lab_pfe_BeamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits_82564c0a-2e81-431c-867d-54288ae01d6a_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and special termination benefits</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" xlink:to="lab_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0ac29eb0-40ab-43ff-9a74-85b65aeab7b5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_PartnershipInterestMember_dfa691f6-0ecf-4908-936e-110589e7f601_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_label_en-US" xlink:label="lab_srt_PartnershipInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember" xlink:to="lab_srt_PartnershipInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_1b4effc5-3166-4448-8d61-897606ab5a40_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_3d4b2905-08b3-4b85-82ae-7b77e18477cc_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_390edb8c-fc74-4d5c-b6e1-215e182e6a2d_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_2b993457-c943-4b2c-bd02-28c55176783d_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_4a9d12b6-aacc-4d2f-ad9d-628d7fb7ee60_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development cost ownership percentage</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_302dc713-45d7-4b81-8c45-4379d4727734_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_28de0bf2-421c-4d68-9edd-c745b6a8b4ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted-average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_65398acd-ee64-4cfa-a8b0-b876f36e2174_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EffectofTaxCutsandJobsActAbstract_b46cc171-5485-499f-93e9-52082f24d3dd_terseLabel_en-US" xlink:label="lab_pfe_EffectofTaxCutsandJobsActAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA</link:label>
    <link:label id="lab_pfe_EffectofTaxCutsandJobsActAbstract_label_en-US" xlink:label="lab_pfe_EffectofTaxCutsandJobsActAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Tax Cuts and Jobs Act [Abstract]</link:label>
    <link:label id="lab_pfe_EffectofTaxCutsandJobsActAbstract_documentation_en-US" xlink:label="lab_pfe_EffectofTaxCutsandJobsActAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Tax Cuts and Jobs Act [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectofTaxCutsandJobsActAbstract" xlink:href="pfe-20211231.xsd#pfe_EffectofTaxCutsandJobsActAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract" xlink:to="lab_pfe_EffectofTaxCutsandJobsActAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_3fe7b7ff-073a-4128-8217-cc77fcc00001_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_d1ec83e0-f71d-40cf-b648-814b0e750533_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_8050679a-5665-4bae-9c07-326a2ed86373_terseLabel_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential consideration</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_label_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contingent Payments, Maximum Exposure1</link:label>
    <link:label id="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_documentation_en-US" xlink:label="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Contingent Payments, Maximum Exposure1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:to="lab_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_30354192-604e-448a-9dda-727b08f3933a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e51f385c-a843-42b4-805a-6b2740bc817f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9b1c864d-e7ae-465d-b7a4-c4e0ccc25988_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_47f514e3-eb60-418c-972e-30e584d818a0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_678727da-a04a-455e-aa68-016e361bbf42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted-average intrinsic value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_06135d6f-42bd-4580-9de5-df4255e3dcd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShorttermDebtGross_2bfd30d9-9816-49e2-85d9-00a98ea46cbe_totalLabel_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term borrowings, principal amount</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_label_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_documentation_en-US" xlink:label="lab_pfe_ShorttermDebtGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross" xlink:href="pfe-20211231.xsd#pfe_ShorttermDebtGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermDebtGross" xlink:to="lab_pfe_ShorttermDebtGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock_a334d00c-0f94-46b0-82a6-c1f1da5a5f18_terseLabel_en-US" xlink:label="lab_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities</link:label>
    <link:label id="lab_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="pfe-20211231.xsd#pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2afe269f-3615-42a2-87ca-2c9d7b237f5d_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_155b4e31-dd45-41ac-929a-db433e40460a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_af3108e1-c887-463e-b817-7c31f47b7686_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_818145b1-2763-4f7f-819f-96a9457c4aca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_3acd3c1b-20e4-40b0-8ec6-aa77ef0c54d1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with an ABO in excess of plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_770b8ad5-ee6d-4cda-b7d0-57b813d228ad_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items [Member]</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5027d75-5793-4291-9aa5-f354cc94a9d4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_65cf5477-bc68-41c7-a866-bfec78e35611_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_76b22d7d-c432-4ea8-bed7-f1a29ffb0fe9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9e05809b-3c09-4618-a2f9-95164f43b63a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_8fea4b79-b2c3-45f5-8c65-174ffa6c8374_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_79e5fe7f-d681-4875-82a5-bcf640685843_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_640c2618-c20a-4f94-8c1d-f5def3d6d023_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3d44a274-4605-4d80-b0d3-4f1e8fe7b1cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d691d5f1-5648-4cd2-9562-1e274eb7d083_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8bd248b-ba3e-4624-93ba-40f53b6e9d1c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a3265c78-2d4a-424b-9334-751df062edaf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1e376248-9e1b-4f5f-8993-f2d9fe786d18_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_954dca8c-e54e-469b-8bc3-a3c43fd8a6ea_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brands [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_f90925ce-cdb1-4e5a-af97-4b36f2602b13_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share payout measures, adjusted net income, number of periods</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_98b895f0-fa56-4240-8a76-211186408e83_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_cda6ecc7-272d-4098-8248-76141c104fd2_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess basis amortization period</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization, Period</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:to="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UpjohnIncAndUpjohnFinanceBVMember_964b4d72-8b32-4443-95ec-abbc8b161e4a_terseLabel_en-US" xlink:label="lab_pfe_UpjohnIncAndUpjohnFinanceBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Inc and Upjohn Finance B.V. [Member]</link:label>
    <link:label id="lab_pfe_UpjohnIncAndUpjohnFinanceBVMember_label_en-US" xlink:label="lab_pfe_UpjohnIncAndUpjohnFinanceBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Inc and Upjohn Finance B.V. [Member]</link:label>
    <link:label id="lab_pfe_UpjohnIncAndUpjohnFinanceBVMember_documentation_en-US" xlink:label="lab_pfe_UpjohnIncAndUpjohnFinanceBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn Inc and Upjohn Finance B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncAndUpjohnFinanceBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember" xlink:to="lab_pfe_UpjohnIncAndUpjohnFinanceBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8cd2f270-a51a-4567-95bc-60e33568e837_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Certain Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_4bd4c4d7-4d20-4e23-a930-56df2d9b74ec_verboseLabel_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income attributable to disposal group</link:label>
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_label_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</link:label>
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_documentation_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:to="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_5cb967b1-f650-43d7-977e-133aad71f243_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_6ebdfb34-bfc2-4b20-b845-a803fadaeddb_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units exercised, weighted average grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_ed316364-e0b4-4a0f-8a8b-cbf8c0e0febe_terseLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits excluding associated interest</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Excluding Interest</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Excluding Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsExcludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:to="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_94e15303-06dc-4c80-ba74-6aa6f5f501b3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) of interest on income taxes expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_2d904404-3835-4618-9306-ca1938912bbc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credits/(credits)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_63ac8596-fdb2-49ca-bf63-3b984baac5b3_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements and Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_label_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsAndOtherMember" xlink:to="lab_pfe_LicensingAgreementsAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_8bf990a4-2ca3-4adb-8c33-69462d878b51_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_89917e18-2876-40bd-bc32-517d02bdf1a5_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_145c71b8-cb46-4762-be34-746ae0804a58_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7d60f3e7-63f5-480e-a23a-b396cf8c6b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_e4c48f98-63a6-479a-9030-d06be0c18917_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units exercised, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_deba3c34-563b-4a95-80b2-68b5f7e30ddb_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock conversions and redemptions</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:href="pfe-20211231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e46f3812-ea12-4916-b225-cd645e270f49_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_a9ed078d-1fe4-4cdb-a67b-7b4950ea856d_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units expected to vest, weighted average grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_72b6f178-7fd3-4c30-bd96-9ff43b6f619f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and debt securities, target allocation percentage</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_9aa8c350-a079-4fa1-8933-79749a44e952_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plans: actuarial gains/(losses), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1a5d56c0-1244-4adb-9298-db6a14e45c32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_d76702f8-4d5d-4dfc-805f-71587316d96f_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessAlignmentCosts_662a1efd-8bc3-4bac-b3f8-081fd76faa1a_terseLabel_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business and legal entity alignment costs</link:label>
    <link:label id="lab_pfe_BusinessAlignmentCosts_label_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Alignment Costs</link:label>
    <link:label id="lab_pfe_BusinessAlignmentCosts_documentation_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Alignment Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessAlignmentCosts" xlink:href="pfe-20211231.xsd#pfe_BusinessAlignmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessAlignmentCosts" xlink:to="lab_pfe_BusinessAlignmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_McKessonInc.Member_a298e4e3-6a04-4c0c-b1dd-b3080d5655cb_terseLabel_en-US" xlink:label="lab_pfe_McKessonInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson, Inc. [Member]</link:label>
    <link:label id="lab_pfe_McKessonInc.Member_label_en-US" xlink:label="lab_pfe_McKessonInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson, Inc. [Member]</link:label>
    <link:label id="lab_pfe_McKessonInc.Member_documentation_en-US" xlink:label="lab_pfe_McKessonInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_McKessonInc.Member" xlink:href="pfe-20211231.xsd#pfe_McKessonInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_McKessonInc.Member" xlink:to="lab_pfe_McKessonInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_0e8a1623-7184-4cdd-af99-6ccdede966f9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss), before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4d91b4f2-b51f-41ad-be2d-e0a9ddf8da75_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2766bb50-cd7b-47b1-b95e-8fe2d0644b7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_da0f7bb3-986f-48e3-b35b-54dd29f4fd19_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetImpairmentsMember_af9d98dd-f61b-4abe-b945-a5baa4427a20_terseLabel_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_label_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairments [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_documentation_en-US" xlink:label="lab_pfe_AssetImpairmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember" xlink:href="pfe-20211231.xsd#pfe_AssetImpairmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetImpairmentsMember" xlink:to="lab_pfe_AssetImpairmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InsuranceContractsMember_85b2a621-16e0-459d-967c-25435694aa28_terseLabel_en-US" xlink:label="lab_pfe_InsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts [Member]</link:label>
    <link:label id="lab_pfe_InsuranceContractsMember_label_en-US" xlink:label="lab_pfe_InsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts [Member]</link:label>
    <link:label id="lab_pfe_InsuranceContractsMember_documentation_en-US" xlink:label="lab_pfe_InsuranceContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InsuranceContractsMember" xlink:href="pfe-20211231.xsd#pfe_InsuranceContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InsuranceContractsMember" xlink:to="lab_pfe_InsuranceContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_b5759603-8752-41ee-a780-5c6d7f70e052_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation-related costs</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_f57cfbf6-f057-4a67-b4db-c50dd2d0d46f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_43047c74-502d-4773-9df5-c713b2648a0e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and Environmental Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CardinalHealthInc.Member_fbbabbf6-4577-46a1-a768-c32e860a2e24_terseLabel_en-US" xlink:label="lab_pfe_CardinalHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CardinalHealthInc.Member_label_en-US" xlink:label="lab_pfe_CardinalHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CardinalHealthInc.Member_documentation_en-US" xlink:label="lab_pfe_CardinalHealthInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CardinalHealthInc.Member" xlink:href="pfe-20211231.xsd#pfe_CardinalHealthInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CardinalHealthInc.Member" xlink:to="lab_pfe_CardinalHealthInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_29fc9776-3d3a-4664-8871-6d6937f71f14_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, cost recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_34498399-9529-4d21-ad92-82067791f620_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_984ec61e-810d-4d65-8971-021f393c85f3_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_7e12e2db-81d9-427b-9879-34a903c3374f_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BiopharmaSegmentMember_1106f52a-6178-4295-83e4-eefc22fa904b_terseLabel_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_label_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_documentation_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiopharmaSegmentMember" xlink:to="lab_pfe_BiopharmaSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_12ff3f6a-7778-4978-a7e4-bdd6f8f1a07f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_34b8cad2-f2db-4a12-92c5-c22e3532869f_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_a41d9c76-ed54-4e3f-a874-ee5699e8f94e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AkceaAndIonisMember_513d1f7b-0c5e-4ae1-bb73-6a483f3c036a_terseLabel_en-US" xlink:label="lab_pfe_AkceaAndIonisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akcea And Ionis [Member]</link:label>
    <link:label id="lab_pfe_AkceaAndIonisMember_label_en-US" xlink:label="lab_pfe_AkceaAndIonisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akcea And Ionis [Member]</link:label>
    <link:label id="lab_pfe_AkceaAndIonisMember_documentation_en-US" xlink:label="lab_pfe_AkceaAndIonisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akcea And Ionis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AkceaAndIonisMember" xlink:href="pfe-20211231.xsd#pfe_AkceaAndIonisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AkceaAndIonisMember" xlink:to="lab_pfe_AkceaAndIonisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_40fefcd3-da28-4e4d-acc3-9d82ccb42115_terseLabel_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_label_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_documentation_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember" xlink:href="pfe-20211231.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FSMEIMMUNTicoVacMember" xlink:to="lab_pfe_FSMEIMMUNTicoVacMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_272597b5-6fa9-49b7-b5db-278f2665830c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_22a002dc-ce36-4bcd-b1e6-2585b54e4c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total principal amount of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScenarioPreviousAccountingPrincipleMember_4ac98d84-4391-40b6-80ec-1d2edd0b0519_terseLabel_en-US" xlink:label="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previous Accounting Principle [Member]</link:label>
    <link:label id="lab_pfe_ScenarioPreviousAccountingPrincipleMember_label_en-US" xlink:label="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Previous Accounting Principle [Member]</link:label>
    <link:label id="lab_pfe_ScenarioPreviousAccountingPrincipleMember_documentation_en-US" xlink:label="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Previous Accounting Principle</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:href="pfe-20211231.xsd#pfe_ScenarioPreviousAccountingPrincipleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:to="lab_pfe_ScenarioPreviousAccountingPrincipleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_ef62a084-0efe-4f8c-899f-4cab9eab1163_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_e85c6d78-eb8c-4b98-8ef6-f6ee5a240d5b_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term equity securities held in trust</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:href="pfe-20211231.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:to="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d3a47e2e-a695-4dea-a253-a3a6efd8b8d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_f440a5da-634e-4db5-806e-c5bf64ca5312_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of measures used to determine share payout</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0e470a49-35b1-496f-990b-3c3011b805ce_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_3bebedc9-6b3e-4d71-b851-689c853febc7_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income taxes</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:href="pfe-20211231.xsd#pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:to="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PremarinFamilyMember_a08d05e3-2d94-447c-929b-200947e07a4a_terseLabel_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_label_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_documentation_en-US" xlink:label="lab_pfe_PremarinFamilyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember" xlink:href="pfe-20211231.xsd#pfe_PremarinFamilyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PremarinFamilyMember" xlink:to="lab_pfe_PremarinFamilyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6df6e787-015a-46aa-af22-fad7352b8e24_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7f99eb4d-5457-4ca8-a7be-fa3e835adae9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3f154f8d-7949-4925-a948-7f12b7f53947_negatedLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease), Other</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease), Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:to="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZaviceftaMember_1088198f-1cf3-45d2-8642-ef04a8a3c23b_terseLabel_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta [Member]</link:label>
    <link:label id="lab_pfe_ZaviceftaMember_label_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta [Member]</link:label>
    <link:label id="lab_pfe_ZaviceftaMember_documentation_en-US" xlink:label="lab_pfe_ZaviceftaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zavicefta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember" xlink:href="pfe-20211231.xsd#pfe_ZaviceftaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZaviceftaMember" xlink:to="lab_pfe_ZaviceftaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_33e06f52-febe-46a6-90ce-7abbdd252a5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_7e57a658-e95a-4566-9503-6b4f83801a56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0e64aa95-278d-4d2e-91ed-05c11475c3e0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a14bb314-6404-4575-8eb1-be9048075b88_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_27c5c084-810f-4542-a6cc-8a3867d79a5a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected benefit payments:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_b5365c71-e9b9-4dcb-b97d-f13371b8cc96_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d76b758e-f9b7-4457-bfd0-94c5723fa065_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_7dcc0808-74f2-4843-8cdf-99395e179eb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_1b07ffef-504d-4c89-b282-594988ed766b_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency - U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_dbb3a5a7-39bc-44f0-a5c3-88d0db01f3fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HedgedItemDomain_da7c08e7-6ec3-4115-822c-cf69ff6faae2_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_label_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_documentation_en-US" xlink:label="lab_pfe_HedgedItemDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Hedged Item [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain" xlink:href="pfe-20211231.xsd#pfe_HedgedItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemDomain" xlink:to="lab_pfe_HedgedItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_65807315-8f83-4fad-b97e-d5117444764c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits realized from exercise</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_458d6ece-6773-44cb-9e07-e0a2d40e2429_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_f2d18407-9bf1-4bd1-9014-dce2b47fc2cd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases, sales, and settlements, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:to="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_bfaac366-0039-40d3-b474-b9bcb8a50c34_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_3c83a1f7-baa2-4ff5-a3a6-ce9d5ea833b3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_df8b4087-f4c4-4980-9de1-b4ca1cdf0099_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_61a48106-abfa-4558-ba84-a7c3d7f288ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZithromaxZmaxMember_132f7fdf-6de0-49eb-b039-7addc25731e2_terseLabel_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_label_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_documentation_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zithromax / Zmax [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember" xlink:href="pfe-20211231.xsd#pfe_ZithromaxZmaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZithromaxZmaxMember" xlink:to="lab_pfe_ZithromaxZmaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EpiPenMember_b32a71fa-15e9-4d91-920c-d994484920c0_terseLabel_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_label_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_documentation_en-US" xlink:label="lab_pfe_EpiPenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember" xlink:href="pfe-20211231.xsd#pfe_EpiPenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EpiPenMember" xlink:to="lab_pfe_EpiPenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7d0ba632-775b-491d-8611-f7640f90d580_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_732586a0-d02d-4b59-99f4-1dbf175b7be3_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_e07e0328-b463-4649-ab71-8aa2cd6f0a9d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of purchase</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_ec39fcf3-b163-4a5c-a49a-d46da6828e50_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_fbb38a5c-85d9-4502-b3a1-07e4935c62bc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_2ba1934b-51c9-452e-afe9-2e4ce3895406_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_af0d919a-3b1a-4a1c-aae5-b2509da8bd96_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetAcquisitionSharePrice_92d5646d-2fe2-44e5-9fec-f3e928cfcc8d_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_pfe_AssetAcquisitionSharePrice_label_en-US" xlink:label="lab_pfe_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Share Price</link:label>
    <link:label id="lab_pfe_AssetAcquisitionSharePrice_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionSharePrice" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionSharePrice" xlink:to="lab_pfe_AssetAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_61f1a08b-8fd1-4163-99cf-2b8a53b154c4_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_647f59e4-0a17-4524-874b-a43c022ec4c2_terseLabel_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment in exchange for Pfizer's assets</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_label_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_documentation_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:href="pfe-20211231.xsd#pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:to="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TotalBiosimilarsMember_c37482b2-0482-495b-9194-c644283a94bc_terseLabel_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_label_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_documentation_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalBiosimilarsMember" xlink:href="pfe-20211231.xsd#pfe_TotalBiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalBiosimilarsMember" xlink:to="lab_pfe_TotalBiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_c213e709-fa6d-48e9-92e1-1d0a84596ac2_negatedLabel_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits - Deferred tax liabilities</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_documentation_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:to="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_06133cf6-e917-4a5e-a61d-da48c94193b9_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TopSixProductsMember_70e62443-caf3-493d-966c-5d3257463e76_terseLabel_en-US" xlink:label="lab_pfe_TopSixProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Six Products [Member]</link:label>
    <link:label id="lab_pfe_TopSixProductsMember_label_en-US" xlink:label="lab_pfe_TopSixProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Six Products [Member]</link:label>
    <link:label id="lab_pfe_TopSixProductsMember_documentation_en-US" xlink:label="lab_pfe_TopSixProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Six Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopSixProductsMember" xlink:href="pfe-20211231.xsd#pfe_TopSixProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TopSixProductsMember" xlink:to="lab_pfe_TopSixProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dade865b-16d6-481a-ba58-dfa1cc94ac67_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_79c14b36-892e-4900-9e1e-f678f7e2e413_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_1e27c104-58fd-4d31-ba85-e82ba3681e2c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_cafa1c3f-f598-404f-941f-00a1c045287c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d060194e-2cdf-470a-a6e1-9abc7598f03c_negatedLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_a46fa221-d2bb-4870-864e-2347fa273cf2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RebatesAndOtherSalesRelatedAccruals_fe423aba-a4ee-4531-97da-c381ca203d8e_terseLabel_en-US" xlink:label="lab_pfe_RebatesAndOtherSalesRelatedAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued rebates and other sales-related accruals</link:label>
    <link:label id="lab_pfe_RebatesAndOtherSalesRelatedAccruals_label_en-US" xlink:label="lab_pfe_RebatesAndOtherSalesRelatedAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates And Other Sales-Related Accruals</link:label>
    <link:label id="lab_pfe_RebatesAndOtherSalesRelatedAccruals_documentation_en-US" xlink:label="lab_pfe_RebatesAndOtherSalesRelatedAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain accrued rebates and accrued sales returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndOtherSalesRelatedAccruals" xlink:href="pfe-20211231.xsd#pfe_RebatesAndOtherSalesRelatedAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RebatesAndOtherSalesRelatedAccruals" xlink:to="lab_pfe_RebatesAndOtherSalesRelatedAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3428054d-5ab5-43ea-835c-1815c825fa64_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HospiraMember_60bf2c02-e49c-4c02-8503-0c1be88cd2d8_terseLabel_en-US" xlink:label="lab_pfe_HospiraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_label_en-US" xlink:label="lab_pfe_HospiraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_documentation_en-US" xlink:label="lab_pfe_HospiraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospira [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospiraMember" xlink:href="pfe-20211231.xsd#pfe_HospiraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraMember" xlink:to="lab_pfe_HospiraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_63ad192a-2535-461e-b6ef-76ba283752b7_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets associated with unrecognized tax benefits</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:to="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorNotesDue2047Member_42a903ff-2c1a-4193-aabd-f8541657c76c_terseLabel_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2047Member_label_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2047Member_documentation_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2047Member" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorNotesDue2047Member" xlink:to="lab_pfe_SeniorNotesDue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanOtherInvestmentsMember_5233921e-d736-48cf-81cc-4b46add84c87_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanOtherInvestmentsMember_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Other Investments [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanOtherInvestmentsMember_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanOtherInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanOtherInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember" xlink:to="lab_pfe_DefinedBenefitPlanOtherInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_c3b767ef-d318-4b1f-b2d6-dc0a948ac635_terseLabel_en-US" xlink:label="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to collaborators</link:label>
    <link:label id="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_label_en-US" xlink:label="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments and Payments to Collaborators, Cash</link:label>
    <link:label id="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_documentation_en-US" xlink:label="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayments and Payments to Collaborators, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:href="pfe-20211231.xsd#pfe_PrepaymentsAndPaymentsToCollaboratorsCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:to="lab_pfe_PrepaymentsAndPaymentsToCollaboratorsCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2dc5e0b1-6e03-43ce-aa37-0476a1571662_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_805bf97e-865b-4e0c-b3d2-8e72e21b7cc4_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20382042Member_fcefc8bd-aa18-4e0e-b182-641d3ec9861a_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20382042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2038-2042 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20382042Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20382042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2038-2042 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20382042Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20382042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2038-2042</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20382042Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20382042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20382042Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20382042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_1dcacea5-6daa-47d2-9d0e-b682aa5cb63c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_52480b35-95f7-4bbc-ba4c-da19debfa78a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts recorded in our consolidated balance sheet:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7ab45eec-aa5b-4029-afe0-8efae483e45f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Taxes on Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_96dd022f-a644-445d-a8ab-6137b7b04d2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b94ccd40-1c86-4276-8f8b-afa0140173bd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_e73a3049-a2a3-43ca-91cb-6140a8d75282_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7bcb89d4-f5da-455c-bbe7-2873d84f813c_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock_6ef63bcf-8fce-4f18-bf06-ea800bb7150e_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" xlink:to="lab_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_1027751a-1663-47fa-959f-d47ff9b7f77e_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_df3d95fa-9066-4524-a87e-6669320b83a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_513a24b8-5175-4e3b-8510-70c96deefb13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_df72f4c0-fa72-4e01-81c2-2a660949a87b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between carrying amount and underlying equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_0d9eae14-114d-4a13-842e-2153e39a96ca_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on completion of transaction, after-tax</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Tax</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfTax" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_1a819f09-e689-447e-95d0-ca8adee400b9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructurings and other charges - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AnacorMember_b2fb7cf2-b25f-4725-9d9e-52ce2d0de993_terseLabel_en-US" xlink:label="lab_pfe_AnacorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_label_en-US" xlink:label="lab_pfe_AnacorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_documentation_en-US" xlink:label="lab_pfe_AnacorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anacor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AnacorMember" xlink:href="pfe-20211231.xsd#pfe_AnacorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AnacorMember" xlink:to="lab_pfe_AnacorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ab2d1ffe-734b-48f3-a062-04c8a46142c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_bdcfd0b8-b06d-410b-931f-7e8198bf15bc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e56cecc3-e087-4a32-b11e-2ada4d0104ee_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_10d842dd-cca3-414e-99e3-da28a70761de_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Awards [Member]</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_b3713acb-35d8-46b4-9594-7d0d9cdf0e05_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefits Plan [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9748b475-1b84-4180-8249-465437f8cfc7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_562f08de-219e-4cf9-b01d-41df189f5f98_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_49ce4f25-f5b2-4b0f-a4f1-e96cd93e6d04_terseLabel_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_label_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_documentation_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FinancialInstrumentsAbstract" xlink:to="lab_pfe_FinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6fbfc2cf-5c64-4e22-b40e-4866090ccf4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c1a32a48-4c62-46f6-bfc2-0091278a42b2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to AOCI</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_df1afb40-3767-4e13-b87c-851ebf6079aa_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b7c998af-fc2a-4e48-9e89-285dbb124d85_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20432047Member_38a3a9af-39a9-4807-ac0d-a4eb9a59a016_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20432047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2043-2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20432047Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20432047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2043-2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20432047Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20432047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2043-2047</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20432047Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20432047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20432047Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20432047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_20147fbe-a42d-462a-80e2-0fd508eddcb0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ff88d20e-f0a9-4998-93be-5e85d0912c8a_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_14ab7c3f-65ba-4bae-a900-481111102b9b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SulperazonMember_4424505c-5a55-4414-aa93-dd0f388a7f22_terseLabel_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_label_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_documentation_en-US" xlink:label="lab_pfe_SulperazonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember" xlink:href="pfe-20211231.xsd#pfe_SulperazonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SulperazonMember" xlink:to="lab_pfe_SulperazonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherAccruals_28de2213-a17c-4f16-8518-29be59424d96_terseLabel_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_label_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_documentation_en-US" xlink:label="lab_pfe_OtherAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals" xlink:href="pfe-20211231.xsd#pfe_OtherAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAccruals" xlink:to="lab_pfe_OtherAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses_e466c39d-3f01-4df6-8c3a-77d5e9863302_negatedTerseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax charges related to remeasurement of Euro debt</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Foreign Denominated Debt Remeasurement Gains (Losses)</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Foreign Denominated Debt Remeasurement Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BraftoviMember_49dcfc7e-4d35-47b9-a61e-2791ed34e5a9_terseLabel_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_label_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_documentation_en-US" xlink:label="lab_pfe_BraftoviMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember" xlink:href="pfe-20211231.xsd#pfe_BraftoviMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BraftoviMember" xlink:to="lab_pfe_BraftoviMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_623ae00f-a999-4457-ba56-4289bf5ef38f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_73e72c45-27be-4d7f-9118-e23830d10b7b_terseLabel_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontrade receivables</link:label>
    <link:label id="lab_us-gaap_NontradeReceivablesCurrent_label_en-US" xlink:label="lab_us-gaap_NontradeReceivablesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontrade Receivables, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontradeReceivablesCurrent" xlink:to="lab_us-gaap_NontradeReceivablesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_c7fdf411-618d-4ddd-af0a-f45abdcdb699_terseLabel_en-US" xlink:label="lab_pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Units (TSRUs) [Member]</link:label>
    <link:label id="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_label_en-US" xlink:label="lab_pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Units (TSRUs) [Member]</link:label>
    <link:label id="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_documentation_en-US" xlink:label="lab_pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Units (TSRUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:to="lab_pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_f9ba683a-cf58-4a30-9b7f-6f1f758a11ba_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cf1b2468-6cf7-41b6-98e9-a6d6849041a8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5fa488c4-fc8e-449f-8fe5-427e97cccf61_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_ad83975d-06b5-433c-873b-13d73f3d3118_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GoToMarketModelMember_01a7e99a-4226-4699-84b5-c4e6724b0762_terseLabel_en-US" xlink:label="lab_pfe_GoToMarketModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go-to Market Model [Member]</link:label>
    <link:label id="lab_pfe_GoToMarketModelMember_label_en-US" xlink:label="lab_pfe_GoToMarketModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go-to Market Model [Member]</link:label>
    <link:label id="lab_pfe_GoToMarketModelMember_documentation_en-US" xlink:label="lab_pfe_GoToMarketModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go-to Market Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GoToMarketModelMember" xlink:href="pfe-20211231.xsd#pfe_GoToMarketModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GoToMarketModelMember" xlink:to="lab_pfe_GoToMarketModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6442f75e-b6a1-4083-ba78-a67f39e0ac19_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_75cc92bb-dc19-4711-8005-46fa769c7e0c_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) operating activities from discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_a5e9ec2d-e369-4dd9-893f-7e86837f80ae_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:to="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_39625218-885e-4599-9e39-6f7b0297bae7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_586206f9-a289-4ca6-b7cb-fa84803802fe_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_2a6c2f3f-1576-4895-911f-ef53db8c4dec_negatedTerseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_84583f04-266f-491f-add6-617323c9c64f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_d140fdae-f817-4910-823a-77235a0d0224_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_f2737204-cf1b-4552-b717-e6dc4bfe403b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_3db6d14b-34e5-4abc-a6f6-43b150247079_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_c99b89a6-c1ad-4bd0-a4d7-d11bf9851321_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_943f2433-7870-4baa-ad75-73eda7182342_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber_13dfc0df-348e-4c9d-9689-fd5e6d942cef_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units exercised and converted, shares</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AssetAcquisitionLiabilitiesAssumed_2f34a201-e4b5-4ae4-8e18-d6550fe01bfa_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, liabilities assumed</link:label>
    <link:label id="lab_pfe_AssetAcquisitionLiabilitiesAssumed_label_en-US" xlink:label="lab_pfe_AssetAcquisitionLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Liabilities Assumed</link:label>
    <link:label id="lab_pfe_AssetAcquisitionLiabilitiesAssumed_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionLiabilitiesAssumed" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionLiabilitiesAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionLiabilitiesAssumed" xlink:to="lab_pfe_AssetAcquisitionLiabilitiesAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PatentInfringementMember_9cd1a88c-aa0a-4d24-bd75-ddafab9ee804_terseLabel_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_label_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_documentation_en-US" xlink:label="lab_pfe_PatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember" xlink:href="pfe-20211231.xsd#pfe_PatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentInfringementMember" xlink:to="lab_pfe_PatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TopNineProductsMember_2c9f7121-4ace-4eff-a85e-8a987478d931_terseLabel_en-US" xlink:label="lab_pfe_TopNineProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Nine Products [Member]</link:label>
    <link:label id="lab_pfe_TopNineProductsMember_label_en-US" xlink:label="lab_pfe_TopNineProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Nine Products [Member]</link:label>
    <link:label id="lab_pfe_TopNineProductsMember_documentation_en-US" xlink:label="lab_pfe_TopNineProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Top Nine Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopNineProductsMember" xlink:href="pfe-20211231.xsd#pfe_TopNineProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TopNineProductsMember" xlink:to="lab_pfe_TopNineProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_01e3ddc3-f6ed-40a3-924f-e904a8af5ca8_terseLabel_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_label_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_documentation_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:href="pfe-20211231.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:to="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_ba28cde5-d5cb-4125-9378-5896368780b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GenericSterileInjectableProductMember_cf4abd33-d8ee-441c-a537-495d6666bb5b_terseLabel_en-US" xlink:label="lab_pfe_GenericSterileInjectableProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Sterile Injectable Product [Member]</link:label>
    <link:label id="lab_pfe_GenericSterileInjectableProductMember_label_en-US" xlink:label="lab_pfe_GenericSterileInjectableProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Sterile Injectable Product [Member]</link:label>
    <link:label id="lab_pfe_GenericSterileInjectableProductMember_documentation_en-US" xlink:label="lab_pfe_GenericSterileInjectableProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generic Sterile Injectable Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenericSterileInjectableProductMember" xlink:href="pfe-20211231.xsd#pfe_GenericSterileInjectableProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenericSterileInjectableProductMember" xlink:to="lab_pfe_GenericSterileInjectableProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_09a81b71-a6fa-40a8-8391-d22bb6d8dcab_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_cfaf41e4-2d91-440e-8f4a-388b6fc79ffe_terseLabel_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Healthcare JV [Member]</link:label>
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_label_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_documentation_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKConsumerHealthcareMember" xlink:to="lab_pfe_GSKConsumerHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_64780d7f-1f2d-4f3d-aee0-746dc5d80bdb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_6663016a-3f67-4b87-9c51-266e44f071fc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_7736be19-641e-4a50-94d1-6676845dbb61_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_f032984c-163d-468a-a609-18283b4f5b57_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountCashConveyed_c3d97d28-d013-4945-956b-6055e0b664a6_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountCashConveyed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, cash conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountCashConveyed_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountCashConveyed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Cash Conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountCashConveyed_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountCashConveyed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Cash Conveyed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountCashConveyed" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountCashConveyed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountCashConveyed" xlink:to="lab_pfe_DeconsolidationGainLossAmountCashConveyed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a613895d-255f-4dfd-8c12-1ced8c3e1a8f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (short-term)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_af246dce-a013-4778-abef-f9b6b431b16e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_35c2022a-4485-466b-82e7-9574a7636fad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities, gross unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_24b8a8ef-038a-497b-9d15-1d0ee8b6c97c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_c56db72d-11f0-41a6-afc1-b77dacafc509_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HedgedItemAxis_11593b84-e700-40ac-963d-8bbbbc1c3f34_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_label_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_documentation_en-US" xlink:label="lab_pfe_HedgedItemAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis" xlink:href="pfe-20211231.xsd#pfe_HedgedItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemAxis" xlink:to="lab_pfe_HedgedItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_a4fa4f47-5cf9-4ca1-8064-290d8c88c31b_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income/(loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7492d407-f03a-4c90-ad36-d3b1a1ebc600_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_7f18fc47-9966-4146-9251-4bec9b3fcad4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_ebf29a93-abbc-4b8d-ab5f-a8277025bbbc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9f5ed6e8-3124-452c-9157-53b47a7421f8_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f24c830e-d209-4af0-afaf-f4b5caf25d88_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_f605bec2-79c5-4f9c-8aba-5abe91e42d65_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_label_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_documentation_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInternalMedicineMember" xlink:href="pfe-20211231.xsd#pfe_AllOtherInternalMedicineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInternalMedicineMember" xlink:to="lab_pfe_AllOtherInternalMedicineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_0f2bc5fa-6d4b-41a3-a028-65f707df4f8a_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:to="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_6cae6cb3-d807-4898-9b58-9ab6083a62fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_035909fc-f862-4455-ad68-fe2c8e3c7957_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_1fd2e735-0c93-4932-bed5-f18e8c314427_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_940038a8-ac59-4981-81c3-94f2bc2751c6_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0715c2f-449f-4023-a9ea-bd39ea2e8749_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_dae7812e-edd6-4812-8dc5-c7027edbfaf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Component of Inventories, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_8421c3b2-3b94-4533-8b26-ac15da321e7a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_077a7a1f-551a-480c-aa17-6a123c8f9ae5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Change in Accounting Principle</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_f67d5e61-c3a4-4c8a-8a47-126b5f0fb03e_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and product liability reserves - Deferred tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:to="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b37475bf-437d-4396-b1fc-6aa867260a76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities (short-term), statement of financial position</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_fb4fe2e4-e762-46c0-812e-d182fbab43fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_e4e57e4f-7d9e-4683-9fb9-e1ae868f6eb2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_751f4bb3-4552-4dfd-908e-ac88d75f2923_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_aa7fc1c6-9673-4ee0-a547-634693d9f5ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation arrangement, shares issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_7222f464-6318-4e9f-831c-db5fa1b4d6c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_38bf7a06-5110-4870-941f-a9f80c0a943b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge to research and development expenses in connection with asset acquisition</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_323d815d-14b1-46fc-bb05-30f9622c6120_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_24e03962-7085-42f0-9299-3066dbfc2cef_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange rate changes</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d182ab93-5043-4f2c-9139-f2411cbf45ce_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_96e9b74b-6b64-45cc-90bb-70a0b21e61ab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_60d1b361-092b-4eee-a8fa-ed12b37d1314_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_9ed65a85-f5c9-4a57-884e-27a7825f84fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Preferred stock dividends&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_9b1db45c-1093-4adc-8fa7-5a56eea9af2c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_c045e805-cac7-4af0-bfd2-4d2ef88c720b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_4b6ebccb-fba0-4e96-be73-23970f9d45a4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_15d1f63c-4b61-49cb-b9bb-44e3ebfa72ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c013be14-f8c0-4a6b-ad10-497ad9e0342b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherTaxesPayableMember_97da8aa0-aeb9-485f-b320-4a4115c7734e_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_OtherTaxesPayableMember_label_en-US" xlink:label="lab_pfe_OtherTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_OtherTaxesPayableMember_documentation_en-US" xlink:label="lab_pfe_OtherTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Taxes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxesPayableMember" xlink:href="pfe-20211231.xsd#pfe_OtherTaxesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxesPayableMember" xlink:to="lab_pfe_OtherTaxesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConsolidatedBalanceSheetsAbstract_85299b63-8e25-490a-932d-acdc9f8299ab_terseLabel_en-US" xlink:label="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets:</link:label>
    <link:label id="lab_pfe_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_pfe_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedBalanceSheetsAbstract" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_pfe_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_9c366e9a-3dbd-48d7-80fe-66ec8aa61632_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_01e5f1db-384c-4c5f-a34a-505923b1f7ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7578467a-9359-4261-8776-fc335238cd46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_a2b509b8-f614-408b-a957-6b3df2d0e455_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, end of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_29b5e1de-6c53-4ddc-b5ba-21605f577171_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_94848a08-07a7-40ba-ac76-c00c8b1dfb2a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod_e1836c4d-2c33-47bf-9859-de1d07bce0cb_terseLabel_en-US" xlink:label="lab_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of continuing involvement after disposal, extension period</link:label>
    <link:label id="lab_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod_label_en-US" xlink:label="lab_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Period of Continuing Involvement after Disposal, Extension Period</link:label>
    <link:label id="lab_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod_documentation_en-US" xlink:label="lab_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Period of Continuing Involvement after Disposal, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" xlink:href="pfe-20211231.xsd#pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" xlink:to="lab_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5046f67c-8d13-4464-bcb7-ab03635f2857_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9d5dc3fb-66a8-488a-8926-d039ea97dce1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_December2018StockPurchasePlanMember_6278944e-3a13-4564-ad57-b81d8cb17ebd_terseLabel_en-US" xlink:label="lab_pfe_December2018StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2018StockPurchasePlanMember_label_en-US" xlink:label="lab_pfe_December2018StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2018StockPurchasePlanMember_documentation_en-US" xlink:label="lab_pfe_December2018StockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2018 Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_December2018StockPurchasePlanMember" xlink:href="pfe-20211231.xsd#pfe_December2018StockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_December2018StockPurchasePlanMember" xlink:to="lab_pfe_December2018StockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_be40a027-9afc-41dc-9303-8411f153625e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost/(credit) reported in Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CostReductionInitiativesMember_cf159dd5-c82c-4df1-b0fd-662b26638117_terseLabel_en-US" xlink:label="lab_pfe_CostReductionInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reduction Initiatives [Member]</link:label>
    <link:label id="lab_pfe_CostReductionInitiativesMember_label_en-US" xlink:label="lab_pfe_CostReductionInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reduction Initiatives [Member]</link:label>
    <link:label id="lab_pfe_CostReductionInitiativesMember_documentation_en-US" xlink:label="lab_pfe_CostReductionInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Reduction Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CostReductionInitiativesMember" xlink:href="pfe-20211231.xsd#pfe_CostReductionInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CostReductionInitiativesMember" xlink:to="lab_pfe_CostReductionInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_5aced8be-6b52-4620-95f0-20152146be10_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet" xlink:to="lab_us-gaap_InterestRevenueExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_f94a8433-4aea-41e3-9a54-66d75091123a_terseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders diluted</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_b576460d-7492-468f-8772-36c0d37ee084_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1ace557c-a3b6-4f2c-9d91-85954dbf4268_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_e33b20af-4e64-481d-842e-1af797a1ad2e_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading day average</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f5c617cc-ab57-4175-949d-27ba717e5536_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net losses on early retirement of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_bcc342e9-047e-47ee-82ec-2481af2b4184_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early retirement of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_c280019c-c126-4704-bb3f-3021cc7ff84b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_2f89c306-52ec-4445-8508-57e9b84d2257_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest costs capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LorbrenaMember_b6fb216c-6107-46f2-a541-f533342287bd_terseLabel_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena [Member]</link:label>
    <link:label id="lab_pfe_LorbrenaMember_label_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena [Member]</link:label>
    <link:label id="lab_pfe_LorbrenaMember_documentation_en-US" xlink:label="lab_pfe_LorbrenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lorbrena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember" xlink:href="pfe-20211231.xsd#pfe_LorbrenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LorbrenaMember" xlink:to="lab_pfe_LorbrenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_9dcc05ef-e1ec-4889-bfce-80e30438c241_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_6036520b-c59c-4d16-8ee1-5e3597953cab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Future Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_947f4c61-3862-4a44-80b7-57d074666425_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_c3ace662-7ed2-415a-94a7-a8c2af31e76d_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_34319f80-8b48-4caf-9917-8c3e46d9c213_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_fd919070-7f60-409c-8a05-e4be47876f2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e3c96630-6499-447a-9eff-d62c8c7e52f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing_31e467ab-00f8-420a-9b70-4fa54fb8d2d7_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, milestone payment upon commercializing</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Upon Commercializing</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Upon Commercializing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMilestonePaymentUponCommercializing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing" xlink:to="lab_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1fcde03d-fdc0-465d-b24a-afbe8064b934_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_514896f0-5fd8-493e-a847-66e26b907d20_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsConsolidationItemsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:to="lab_us-gaap_SubsegmentsConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_4ba28b7b-3632-4c23-84fc-81755219ad8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_38dc03cf-e9e4-408e-8f73-922b0aa968aa_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_77368696-0914-40ea-968c-767f78335d47_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f16eeca5-a75f-4797-b42c-bcf49a2d5835_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CoronavirusVaccineProgramMRNABasedMember_2ff432dd-afa3-4e60-bbec-1b77ada52082_terseLabel_en-US" xlink:label="lab_pfe_CoronavirusVaccineProgramMRNABasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Vaccine Program, mRNA-Based [Member]</link:label>
    <link:label id="lab_pfe_CoronavirusVaccineProgramMRNABasedMember_label_en-US" xlink:label="lab_pfe_CoronavirusVaccineProgramMRNABasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Vaccine Program, mRNA-Based [Member]</link:label>
    <link:label id="lab_pfe_CoronavirusVaccineProgramMRNABasedMember_documentation_en-US" xlink:label="lab_pfe_CoronavirusVaccineProgramMRNABasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Vaccine Program, mRNA-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CoronavirusVaccineProgramMRNABasedMember" xlink:href="pfe-20211231.xsd#pfe_CoronavirusVaccineProgramMRNABasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CoronavirusVaccineProgramMRNABasedMember" xlink:to="lab_pfe_CoronavirusVaccineProgramMRNABasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0db954cf-fa49-4eb9-aef9-3d01d4824b2a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_481eab02-f921-4b69-a87e-7aaa114f7cab_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper, weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_0c362b66-c625-4b95-b03d-52af6a8a6d3b_terseLabel_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_label_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_documentation_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges" xlink:href="pfe-20211231.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringAssetImpairmentCharges" xlink:to="lab_pfe_RestructuringAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_a6ddefde-3739-4a8a-9a80-8a5604c4ab4f_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_b2d3dcdd-5a32-4eed-8b52-d905560ae617_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_af6a1b15-5e81-4efe-ba20-2b611ff9f94b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3ddd1cc5-47fa-49b6-b519-cde1ac5a343b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_f335ee47-1c08-4f4d-98df-553cba471f11_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative impairment losses and downward price adjustments on equity securities</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:label id="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:href="pfe-20211231.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_fec749f1-0402-4149-8bd1-1eebbbfe26d3_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_label_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_documentation_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:href="pfe-20211231.xsd#pfe_AllOtherInflammationandImmunologyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:to="lab_pfe_AllOtherInflammationandImmunologyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_e7f2f726-3ebe-4c38-a232-68f202ead514_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_a118dd50-45fa-43b1-bcfe-56d44ba07acb_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementTieredSalesMilestonePayments_9ed725b6-a19d-4fd5-9521-80a91dd93284_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementTieredSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, tiered sales milestone payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementTieredSalesMilestonePayments_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementTieredSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Tiered Sales Milestone Payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementTieredSalesMilestonePayments_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementTieredSalesMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Tiered Sales Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementTieredSalesMilestonePayments" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementTieredSalesMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementTieredSalesMilestonePayments" xlink:to="lab_pfe_CollaborativeArrangementTieredSalesMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_221b1c21-622c-409a-b9c4-2a1664476e43_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e2a85537-e74b-4a62-8ed7-796030822f7f_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b5f63d62-d2fc-472d-a965-9acea82673df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_aa7dff71-dd6f-4f72-8d99-30d100acdaf1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_317b60bb-f7b9-4bad-b6f5-978f62a6b51e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2ec32600-6d86-40f7-8c5b-3e78afe198b5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_d768343f-b024-444f-9a8b-3dd03a861597_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from collaborations, out-licensing arrangements and sales of compound/product rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_label_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:to="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5fdc856d-e2fe-4dcc-9770-432d663ffe81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_f9deeae4-f5af-48fa-b0be-8dc1a8a9bb4c_terseLabel_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment and premium paid in equity investment</link:label>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_label_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment</link:label>
    <link:label id="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_documentation_en-US" xlink:label="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:href="pfe-20211231.xsd#pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:to="lab_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_71adca34-6cde-4b84-bfff-77dd2e408899_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Financial Information of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_502df14d-7680-4504-9f13-93e6cea81032_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_791e52f4-ed92-4d07-9e55-b31f20c3e907_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_d975a18e-f3fb-4759-940e-f0d3f25ec64c_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Technology In Development [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_label_en-US" xlink:label="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Technology In Development [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements, Technology In Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:to="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_961b926c-25e3-4db8-a07d-1ff74aebdacb_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Price</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Roll Forward]</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f5e7b5ed-0413-4ea4-abc1-49b760d05f4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_bb8c8d5b-5742-4783-8442-b18be5aad6a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NimenrixMember_650ba9cf-9b60-4594-bcf0-3172d119ac99_terseLabel_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_label_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_documentation_en-US" xlink:label="lab_pfe_NimenrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember" xlink:href="pfe-20211231.xsd#pfe_NimenrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NimenrixMember" xlink:to="lab_pfe_NimenrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0feeb4bb-79b5-47f3-96e8-ca1bba3927ce_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and Agency Obligations [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EmergingMarketsMember_8a072d70-c562-404e-b948-6321c20c3514_terseLabel_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_label_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_documentation_en-US" xlink:label="lab_pfe_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember" xlink:href="pfe-20211231.xsd#pfe_EmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EmergingMarketsMember" xlink:to="lab_pfe_EmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_fe72c0ad-8463-4132-b6ba-b31d5349f684_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_e04d2a11-02f9-4f0e-8fba-bb5838e06c4a_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value [Member]</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_88781f3a-93fb-40c0-860f-a31b21c093e6_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_53292902-fe4e-4a41-ab75-e6481a9fc7c9_terseLabel_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity cash equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_label_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_documentation_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldToMaturityCashEquivalents" xlink:href="pfe-20211231.xsd#pfe_HeldToMaturityCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldToMaturityCashEquivalents" xlink:to="lab_pfe_HeldToMaturityCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_9dd8a41f-3d16-447b-9f58-9479d0217f83_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_4a2d6356-4560-4595-8a06-1be537466a90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_523ceb4e-59a1-4901-955f-4ecba08d766e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received upon exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c17b9813-0e1c-4ada-a807-349f7aebd157_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember_a8f34fcf-bd86-49f4-ae11-9def688a2edd_terseLabel_en-US" xlink:label="lab_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cortexyme, Inc. and SpringWorks [Member]</link:label>
    <link:label id="lab_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember_label_en-US" xlink:label="lab_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cortexyme, Inc. and SpringWorks Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember_documentation_en-US" xlink:label="lab_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cortexyme, Inc. and SpringWorks Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember" xlink:href="pfe-20211231.xsd#pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember" xlink:to="lab_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_65732f52-1e0a-49df-9cad-dfafee230ace_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Avg. Intrinsic Value per share</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_2b059daf-1f17-428e-af26-e9b13220b3ea_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_8b1a9d6d-8556-44f2-82ad-e892a6214af6_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Contingent Payments, Maximum Exposure</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Contingent Payments, Maximum Exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementContingentPaymentsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:to="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_677e6dcc-6799-4949-8754-092abab53994_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_95add5cf-e16d-4af3-96e7-2ab24101666e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ee57d813-eb41-43f7-8b35-f32bbbdb3400_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_950bf501-48c7-47bf-bdb1-b3ec3a7e81b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_029f64d1-3945-4312-b9d1-5fec05705d1b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9f03bd9a-59b2-4261-ba19-ee870a36f546_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InflammationandImmunologyMember_78e3ea3d-1cd9-4637-8653-9bf5e89a65e5_terseLabel_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_label_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_documentation_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflammationandImmunologyMember" xlink:href="pfe-20211231.xsd#pfe_InflammationandImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflammationandImmunologyMember" xlink:to="lab_pfe_InflammationandImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ca718c8e-cdc0-4ae4-bb93-f0c6693ba78c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_3d56cf97-dc54-425f-a649-9978067436de_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5484c503-b775-40e9-8a3a-66769e85fb9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_eec5abc4-944d-401b-9bc9-4036f9e048b3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_93536dfa-0251-43f0-be02-a37317b6c877_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a6d78a1a-7588-4a20-b176-771b432096d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_5593c8ca-2953-4627-a161-91ffd351b8af_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2916d1df-9bc5-4943-9151-f60d373acd60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f322bd40-1d12-41d8-947f-e2ff778833ab_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c8181f98-99ed-4e86-bd0e-d0d6d163ca74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c95ca36f-1325-437b-ab32-b03e5ccd6f4d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_fd109863-d389-4ca5-b3e6-d15249021dbc_terseLabel_en-US" xlink:label="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Total Shareholder Return Unit (PTSRUs) [Member]</link:label>
    <link:label id="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_label_en-US" xlink:label="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Total Shareholder Return Unit (PTSRUs) [Member]</link:label>
    <link:label id="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_documentation_en-US" xlink:label="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Total Shareholder Return Unit (PTSRUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:href="pfe-20211231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:to="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_24f78563-86e3-4c23-9e9d-cb581fe86a84_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74131ead-1e59-4858-b02b-2d97babbb78a_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_documentation_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:href="pfe-20211231.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_b977965a-1c50-4d51-afcb-7be9f21d7b15_terseLabel_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_label_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_documentation_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember" xlink:href="pfe-20211231.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedRestOfWorldMember" xlink:to="lab_pfe_DevelopedRestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_5223659d-4c1c-4271-ae38-b048f869d9fd_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ManufacturingAndSupplyAgreementMember_512116e8-51af-43fb-9aae-19b96cb589fa_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingAndSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingAndSupplyAgreementMember_label_en-US" xlink:label="lab_pfe_ManufacturingAndSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingAndSupplyAgreementMember_documentation_en-US" xlink:label="lab_pfe_ManufacturingAndSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingAndSupplyAgreementMember" xlink:href="pfe-20211231.xsd#pfe_ManufacturingAndSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingAndSupplyAgreementMember" xlink:to="lab_pfe_ManufacturingAndSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OncologyMember_c57ff4fe-59c6-479f-9fe5-de8f48a98edb_terseLabel_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_label_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_documentation_en-US" xlink:label="lab_pfe_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember" xlink:href="pfe-20211231.xsd#pfe_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OncologyMember" xlink:to="lab_pfe_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_6141a133-5702-4ab4-bddf-a2fcebcf2fad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember_91c17d27-eeaf-40c7-8c7b-00b05a8b2b5b_terseLabel_en-US" xlink:label="lab_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember_label_en-US" xlink:label="lab_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling Items, Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember_documentation_en-US" xlink:label="lab_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember" xlink:to="lab_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_fe0b79eb-2493-456b-8f8b-65b8a2dbb86c_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_30c3be25-008b-4116-a0ec-16cf45f9ba54_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_0e3a0992-c64e-45ea-b116-a7d4aeecd808_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_40d2de85-553b-4717-9999-0996ab18e568_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment transactions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0ab0e5b3-d539-47de-bb87-c4999bd72fa7_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_78a041d9-86bc-46ae-be7b-7fa96567bd8a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_dd3c02d8-c20b-4516-a30f-96c6c5aca11e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2814e7cc-3f39-47c0-bb54-2e55a943656b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_bf103bfb-0d82-4dc8-b089-ff0ec766b85b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_95778748-c340-4dea-8cf2-73168fec2971_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentUponApproval_97f3d1d5-6802-4c5c-9f31-36917874a70e_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentUponApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, milestone payment upon approval (up to)</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentUponApproval_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentUponApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Upon Approval</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentUponApproval_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentUponApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment Upon Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentUponApproval" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMilestonePaymentUponApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementMilestonePaymentUponApproval" xlink:to="lab_pfe_CollaborativeArrangementMilestonePaymentUponApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_d3a3ff2b-dbc4-4a61-b811-a3e6e8c0e1f8_terseLabel_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_label_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_documentation_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessIntegrationCostsMember" xlink:href="pfe-20211231.xsd#pfe_BusinessIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessIntegrationCostsMember" xlink:to="lab_pfe_BusinessIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_401a61da-73d9-4eea-8a6f-fcf047ef9a3e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment transactions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_4d3f41f8-b0aa-4955-97f0-98ee87d4e2cc_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_MeridianMember_80bcb2da-a388-410a-b19b-3763978cd6ce_terseLabel_en-US" xlink:label="lab_pfe_MeridianMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meridian [Member]</link:label>
    <link:label id="lab_pfe_MeridianMember_label_en-US" xlink:label="lab_pfe_MeridianMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meridian [Member]</link:label>
    <link:label id="lab_pfe_MeridianMember_documentation_en-US" xlink:label="lab_pfe_MeridianMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Meridian</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember" xlink:href="pfe-20211231.xsd#pfe_MeridianMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MeridianMember" xlink:to="lab_pfe_MeridianMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_65a35c17-101d-4318-8822-df556b1381f4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4cc1abc0-45e2-4ba1-9b32-6cac9a454f19_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b54a8d18-7082-4396-bc6e-eb6aae2cd919_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3f40b54b-1dac-4b26-b243-59c5708433ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_a89dd62f-e0be-4773-9945-aa26e369861e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Awards and Valuation Details</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_1852c7a6-7f88-4e5c-8b8c-ab35ade3ee9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fb70376-68f0-4af2-a392-8093028dcfbb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_26ba7aa4-a2b6-4afd-808d-8df3865f67cf_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f55c1bae-cc3b-4814-afd8-21da937b1d5c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations&#8211;&#8211;Other current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_ab5ea5ca-31d0-421e-8b21-98b473835628_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Business Activities [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_4c81154f-2fd6-457b-8ea1-cc023425a636_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PBO</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_414b0480-64b8-448a-9f8d-50530a495a79_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_060fe120-176b-4843-8e1b-dac4e0bde84f_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_8b3f17bd-76fc-42ad-aff5-daf0c25e5d8f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_540aeeb5-1c04-412e-a4e9-424262e0b5ef_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_792a124b-ae9f-4b0f-b706-ccb4fe8b65f8_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited, grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_da1e32e3-8ad5-4de1-b5a9-f2e4350bba97_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a185199b-ddce-46c9-8b91-abfa801655c1_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Postretirement Benefit Plans and Defined Contribution Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_7ea1104e-c470-4671-842a-336eff606c6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_faf7f8f6-62e4-4dec-9530-cdbf96010296_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CStoneMember_8f6b95e5-ca67-4eba-9e53-cf8b262f78ec_terseLabel_en-US" xlink:label="lab_pfe_CStoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStone [Member]</link:label>
    <link:label id="lab_pfe_CStoneMember_label_en-US" xlink:label="lab_pfe_CStoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStone [Member]</link:label>
    <link:label id="lab_pfe_CStoneMember_documentation_en-US" xlink:label="lab_pfe_CStoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CStone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CStoneMember" xlink:href="pfe-20211231.xsd#pfe_CStoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CStoneMember" xlink:to="lab_pfe_CStoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e5da51c1-947e-495a-843a-8a58c4143357_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_978f2ced-0b1c-4b6b-b50e-6405cfaa7737_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_6048a42d-8991-48da-a851-b039b586e3ca_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b60d1b8e-ef85-42f9-a706-1aa9c8d5a44e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c674f1b7-3dcf-477d-883b-e6f1f6755400_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_f01c84b5-c259-47c8-ad3c-5d724b510da7_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_2d70282f-7e2e-4bcc-95af-4da77b3c0f8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_2abbee78-5b13-4eaa-8236-4d4c32858a18_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_a1a9c860-2173-4f68-a23d-de8c2365e0f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain legal matters, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_d23af10a-a7d5-46f5-bf22-f511f5071c9f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_73ab651f-4d72-4c5d-8160-98d8b5dcb9d6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_bf44b2aa-2379-41aa-9337-e7e1e4e2e9e1_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_60119f7e-f110-426d-a31a-fd6b2d82b1a6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7a1d8cd8-6cb7-4798-a6e4-3e60ec01e09c_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_575b5ca3-c93a-4338-aa6c-de239ca6bedd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_128babe2-72ed-459e-902d-19bed82b669a_terseLabel_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Deferred Tax Liabilities [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_label_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Deferred Tax Liabilities [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_documentation_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent Deferred Tax Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:to="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_11088fc3-5461-407d-a887-534a5dcc9b7b_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units expected to vest, weighted average remaining contractual term</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherPatentInfringementMember_da7032be-a75c-412f-a9ea-8118c761b6b3_terseLabel_en-US" xlink:label="lab_pfe_OtherPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_OtherPatentInfringementMember_label_en-US" xlink:label="lab_pfe_OtherPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_OtherPatentInfringementMember_documentation_en-US" xlink:label="lab_pfe_OtherPatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Patent Infringement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPatentInfringementMember" xlink:href="pfe-20211231.xsd#pfe_OtherPatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherPatentInfringementMember" xlink:to="lab_pfe_OtherPatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent_eb58d5e7-0a95-4aec-96e2-4afca887ae4a_negatedTerseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Consumer Healthcare JV initiatives</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Joint Venture Initiatives, Percent</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Joint Venture Initiatives, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_84b2abe0-10f8-4692-8c97-a6a5991d579f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completion of Consumer Healthcare JV transaction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_63e55770-74a2-4e31-9bcf-123a107c56aa_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interests [Member]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_62ab564f-6c72-4183-96ec-82bafea6b627_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e88f39ca-0c59-4bae-b56a-f6f0293e4b59_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_37cbf635-856d-421e-81f9-b56625a3c833_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service (costs)/credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b12fd254-5c04-4821-8801-cbc0ecaa5b0e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_76e94af3-51b2-4db5-ac24-813f34c109c9_negatedLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty-related income</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_4b119e69-be77-47ee-82c2-0adff51a4c35_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unremitted earnings of international subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_0f56483c-56b1-4170-8eab-dd6d9e75fdc6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_66a8afb7-1d34-45f3-b5f4-2a923bfa1f1c_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants other than main defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:href="pfe-20211231.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:to="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_758b8232-3bb9-4012-b540-fe3541690b7c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, period of recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1ffe1d74-87d6-43f9-8905-27f3d0230688_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BMP2Member_2637de3c-d6ec-4570-ad39-93b4d65c00e6_terseLabel_en-US" xlink:label="lab_pfe_BMP2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_label_en-US" xlink:label="lab_pfe_BMP2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_documentation_en-US" xlink:label="lab_pfe_BMP2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BMP2Member" xlink:href="pfe-20211231.xsd#pfe_BMP2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BMP2Member" xlink:to="lab_pfe_BMP2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_8c651e79-ff38-4f90-bc26-e5db4d761a2a_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_label_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_documentation_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember" xlink:href="pfe-20211231.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingOptimizationMember" xlink:to="lab_pfe_ManufacturingOptimizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_fe63e549-91d4-4d20-a32d-6fad21c9d634_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_62a822ce-ae58-43b1-89b2-f9e44bae3ddf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_295ad935-99cf-4c0a-9350-f42e7dcfd356_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures and other [Member]</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8c96dc56-ec51-40e3-b375-da5ff08b8614_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_47e5a2e0-cc31-4252-86c2-632c7091381c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_4c79de3b-1811-4dea-a413-fe86a4240f9f_totalLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:to="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_84d23788-24e1-44a3-bbe2-609aa647a15b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2-3 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_e466179d-b90f-4852-a036-65fe556be20d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share&#8211;&#8211;basic:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a7dbd077-d5f9-415c-bbe3-5202c3daee73_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Numerator-Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fde0f303-0ba6-4a7e-aa13-ee8d6e6ddd5a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares&#8211;&#8211;basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ec6f184e-82ed-4b4c-b173-7d206e94d3b9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b729853a-dd21-4ddf-bc6b-e87323dbb8dd_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_ff2a1d60-5b3a-4ebf-a611-7e87b2e117ba_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_NonUnitedStatesMember_4ad17897-19e6-484c-a3c2-0dd89bbaf662_terseLabel_en-US" xlink:label="lab_pfe_NonUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside United States [Member]</link:label>
    <link:label id="lab_pfe_NonUnitedStatesMember_label_en-US" xlink:label="lab_pfe_NonUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-United States [Member]</link:label>
    <link:label id="lab_pfe_NonUnitedStatesMember_documentation_en-US" xlink:label="lab_pfe_NonUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-United States [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NonUnitedStatesMember" xlink:href="pfe-20211231.xsd#pfe_NonUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NonUnitedStatesMember" xlink:to="lab_pfe_NonUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ed4cc273-78c8-4821-8f04-79f1a33709eb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_0db526b3-4323-4d25-85f6-466a5616f9a8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_fa943e5a-7aea-43b8-8267-8717726ccebf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount excluded from effectiveness testing and amortized into earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_OtherHospitalProductsMember_4c4440d6-997e-449c-b934-00279fcb752f_terseLabel_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_label_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_documentation_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherHospitalProductsMember" xlink:href="pfe-20211231.xsd#pfe_OtherHospitalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherHospitalProductsMember" xlink:to="lab_pfe_OtherHospitalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_d1b4d697-fbad-49df-a290-3130ec052de8_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_098b181d-ec21-4e5e-b8dc-043751d8122e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_c39ab2ed-c867-48ce-bb84-24f2d4360965_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit, actuarial valuation and other pension and postretirement plan gains</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_8fba2c2c-5a56-40fe-8280-3e42a5274cf3_negatedLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plans: prior service (costs)/credits and other, net</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:to="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_c2397c86-801c-4a2c-96f4-9f6ff75fec3a_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_a52a71ba-30dd-40de-ac4f-9baed0c97d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Assets at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Assets at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9cef3bc2-efb7-4ecf-a899-b698483b9571_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_306e96d4-96a1-4113-8daa-4682e0748b2c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ecdc520a-7f3d-4ef1-88fb-6754ba0d099e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Intangible Assets, less Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d1599326-d03c-45b2-93c7-fe02b30f4ec8_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income/(loss) attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_2827b0eb-3042-45be-853d-df06929b0387_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Termination Costs [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9a3f4020-10c2-45c7-8329-344d899ce8d8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AuditInformationAbstract_label_en-US" xlink:label="lab_pfe_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_pfe_AuditInformationAbstract_documentation_en-US" xlink:label="lab_pfe_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AuditInformationAbstract" xlink:href="pfe-20211231.xsd#pfe_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AuditInformationAbstract" xlink:to="lab_pfe_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_8ca4220e-b153-4246-a7c6-4d8b39a3e930_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_57c276ad-aae5-4e87-a9b5-7f17a0c71621_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_30db053d-301e-4f7f-bbdc-f8f567418ba6_terseLabel_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017-2019 and Organizing for Growth [Member]</link:label>
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_label_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]</link:label>
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_documentation_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:href="pfe-20211231.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:to="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_1d8562a2-c8b5-4874-95ee-c7cd3dc89e1b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_00c711d2-cb2d-452e-9fdd-2f2f9342540b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3f9694a7-3acc-440e-98eb-5a67da2f7027_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_21e95446-621d-4b8a-8508-b0774ad229b0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_2047b8f3-ec24-4c10-bb97-3d5497b4234e_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral posted</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_e2bdce8c-e4d4-43c8-abf7-1a225f485055_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_34b15eac-07c6-441b-8396-4792b3ad0ad9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b72e06bc-314e-41d4-9de5-d0778f9a1dde_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_766cd5a7-e275-4f41-a278-9d603e3f551d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_17a916e8-add7-436e-abbc-efcf56b862d7_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and Other [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_dd7ed12d-bf6c-4743-8bc9-bd3bcb2a002e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_1f19b819-4c23-4b7d-947e-a2ad651942b9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension plans with a PBO in excess of plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_89ea10d1-4628-48f8-a260-2a4414a6d3cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7001ad75-6f2d-4a1d-9c95-a41961b3c008_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d3131509-b2f5-467b-b158-c56f7833fef2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_b813a337-a462-4ccf-b2f5-c2153e2aca1e_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; Equity [Member]</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_cf5a15ee-5a3b-426f-8e33-e79bf3473d88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in intangible assets due to measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_acdda941-e7d7-40c7-abe3-dc57db26f0d4_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase, final average price paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e30129c1-16c0-4a55-bdd0-729e439d4497_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_a7a71be6-a440-46a7-9717-58515352ed1e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held, ending</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_510ffb95-fe28-4623-b22c-263fda3597cb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accum. Other Comp. Loss [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_398245b8-7178-4ede-bce2-51c2e11eab36_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_cc9b5228-6dc6-4502-90d1-3fe82e889750_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_9f3cb8e5-4b72-473f-b021-e6fd166b0893_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_f437911a-402d-4632-8845-dda54cea2728_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term investments and equity-method investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92932a7c-d817-49ce-baed-e9570870538d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InlytaMember_a5e25131-a9ea-4ff1-97c5-4c39f01fff2d_terseLabel_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_label_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_documentation_en-US" xlink:label="lab_pfe_InlytaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember" xlink:href="pfe-20211231.xsd#pfe_InlytaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InlytaMember" xlink:to="lab_pfe_InlytaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_a3c41338-ad4e-4384-85a0-a08fd2b6f7a3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2dcd1af0-7f08-4ad2-837b-2ec4c29fd6fc_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_d2057931-9c9f-4f42-959c-548ab2b2d546_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3ca8636e-6ffc-472a-9b14-cf83074292c0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_07a93675-e470-4328-8635-d3047bef6858_terseLabel_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_label_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_documentation_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember" xlink:href="pfe-20211231.xsd#pfe_AllOtherRareDiseaseProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherRareDiseaseProductsMember" xlink:to="lab_pfe_AllOtherRareDiseaseProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2027Member_6b9f69de-d6dd-49c6-bfea-2fcd72ee82dd_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2027 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2027Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2027 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2027Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2027Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2027Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_68032c3f-4bb8-4311-a705-97e370c55f60_terseLabel_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevenar 13/Prevnar 13 [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_label_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar Prevenar Family [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_documentation_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevnar/Prevenar Family 13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember" xlink:href="pfe-20211231.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrevnarPrevenarFamilyMember" xlink:to="lab_pfe_PrevnarPrevenarFamilyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_fde1c895-63e1-401f-9d75-d0293de44ec0_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_47e325b1-903b-4e0e-a584-86cd445a562e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_18d4889e-9ac4-4974-94f5-39f0faa578a4_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ea8f0a23-55ff-4e6f-a65e-2beb6341cca1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_VaccinesMember_02f41288-d30f-4dcd-a10e-7a0dc49b53fb_terseLabel_en-US" xlink:label="lab_pfe_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_label_en-US" xlink:label="lab_pfe_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_documentation_en-US" xlink:label="lab_pfe_VaccinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VaccinesMember" xlink:href="pfe-20211231.xsd#pfe_VaccinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VaccinesMember" xlink:to="lab_pfe_VaccinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_4131a803-8e6b-41f4-9aae-ad8a904e7d6c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4-5 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_3a42de29-c38f-4232-889a-216905135092_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases based on tax positions taken during a prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_38fe8257-79b1-4b97-9547-8dec5eb9010a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_ade7f0ee-9351-4e38-ba7f-43051fe12ead_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_489b07f2-8d1a-4a01-87de-e80cfcd125f0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid/deferred items - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_38f377eb-5750-4c22-bcff-4d54a35443b0_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment (PP&amp;E)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_b975d830-6fcb-4937-aac6-a8fe71f486fd_totalLabel_en-US" xlink:label="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total U.S. tax benefit</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_label_en-US" xlink:label="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Income Tax Expense (Benefit), Continued Operations</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_documentation_en-US" xlink:label="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Income Tax Expense (Benefit), Continued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:href="pfe-20211231.xsd#pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:to="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_816795bf-15a7-4c41-9c44-f73bbd316794_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of continuing involvement after disposal</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Period of Continuing Involvement after Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:to="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_f7760376-153d-44ae-834b-56097ce0055f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed long-term debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a3851669-a9e6-4b63-8c40-19554cb5f252_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_IncomeTaxesPayableMember_0e9af5e2-0b6c-4cc1-81d6-c1665f059927_terseLabel_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_IncomeTaxesPayableMember_label_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_IncomeTaxesPayableMember_documentation_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeTaxesPayableMember" xlink:href="pfe-20211231.xsd#pfe_IncomeTaxesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeTaxesPayableMember" xlink:to="lab_pfe_IncomeTaxesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_3db60d0e-8237-4d6a-845d-fe3b2f5a0640_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_b86d3fac-a36b-42b4-8fcc-2afd89c69cc2_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_283f94d0-5029-4e4e-9e4b-64926bef01e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation, beginning</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_f2784a61-0327-49f7-af4c-1a4882031ae6_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit obligation, ending</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fe24f669-9118-49b3-b81b-7c78baa4e9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f7ed964a-7266-4ba9-8f08-22e01f513c0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_a57c954f-b8bf-4c47-868a-27c9b2d2caba_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2c114ecd-b0f1-4d46-a0a1-eade8bf8b93b_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5858ab5e-70c7-43e4-a912-b64023c4c629_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_42526717-a49f-44da-a36f-8dd2a0a3e5dc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_c35290c5-6f09-4592-b600-8cb84d7adb6b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CorporateEnablingFunctionsMember_ba986ff3-67a7-4179-8795-82c85390c3a7_terseLabel_en-US" xlink:label="lab_pfe_CorporateEnablingFunctionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Enabling Functions [Member]</link:label>
    <link:label id="lab_pfe_CorporateEnablingFunctionsMember_label_en-US" xlink:label="lab_pfe_CorporateEnablingFunctionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Enabling Functions [Member]</link:label>
    <link:label id="lab_pfe_CorporateEnablingFunctionsMember_documentation_en-US" xlink:label="lab_pfe_CorporateEnablingFunctionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Enabling Functions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CorporateEnablingFunctionsMember" xlink:href="pfe-20211231.xsd#pfe_CorporateEnablingFunctionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CorporateEnablingFunctionsMember" xlink:to="lab_pfe_CorporateEnablingFunctionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_d95bf96d-810d-4360-803c-a1167d7b1322_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_b4a70d67-c293-41f8-b6a0-a13576c2f00a_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_8130c46a-87d2-447c-a6e1-a7688f7bb87a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_033f38ef-9dd1-4f49-b29a-e16ab26122e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3d05a3d4-41af-4819-b610-4e568e0b67dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_de086eaa-5f3a-45cc-a5e5-05944d292e48_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax loss on sale of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_c9053847-14ef-41eb-9b82-59824163a1ea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_012f746f-2c4a-49ba-a745-58524ff03063_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_f38b5046-5dd0-4385-8b80-a27bd7625771_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee terminations</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_4a4e766f-e9fc-47b5-98e9-b3672621ef8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_b4d1165e-af01-4f75-be9a-2d6f3e62101d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_3fc4ad65-6933-4c6e-8a05-a0854611bb1a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ImplementationCostAbstract_7fbec480-6526-44d1-bec4-e014f94feafd_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation costs recorded in our consolidated statements of income as follows:</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_label_en-US" xlink:label="lab_pfe_ImplementationCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_documentation_en-US" xlink:label="lab_pfe_ImplementationCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCostAbstract" xlink:href="pfe-20211231.xsd#pfe_ImplementationCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCostAbstract" xlink:to="lab_pfe_ImplementationCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ViatrisMember_a401b0c0-b67b-4faf-82f6-9b18f34250fa_terseLabel_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris [Member]</link:label>
    <link:label id="lab_pfe_ViatrisMember_label_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris [Member]</link:label>
    <link:label id="lab_pfe_ViatrisMember_documentation_en-US" xlink:label="lab_pfe_ViatrisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viatris</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember" xlink:href="pfe-20211231.xsd#pfe_ViatrisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViatrisMember" xlink:to="lab_pfe_ViatrisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f696db36-1227-4465-b1de-95c27e0a3081_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_bc673202-7a2a-488c-99ac-1141b0897deb_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e8ba2ca9-b50c-445b-93b8-60b95d219bb2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost recognized, pre-tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_3861ffc9-7a18-4f16-9a6d-8f052dd59314_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember_a21092d9-1bd9-4a2e-bcd9-96d47144c70e_terseLabel_en-US" xlink:label="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and Cerevel Therapeutics, LLC [Member]</link:label>
    <link:label id="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember_label_en-US" xlink:label="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and Cerevel Therapeutics, LLC [Member]</link:label>
    <link:label id="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember_documentation_en-US" xlink:label="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioNTech and Cerevel Therapeutics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:href="pfe-20211231.xsd#pfe_BioNTechAndCerevelTherapeuticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:to="lab_pfe_BioNTechAndCerevelTherapeuticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_c9cf5eed-ed44-4b77-a2d4-b415587e7fdf_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_85f423c6-4e5a-4ed3-8f16-f50ee1ddf3bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution of Upjohn business</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_f48a27d1-3739-4af6-b03b-d91db5127f23_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution of Upjohn Business</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_2c36574d-b73b-4dab-955b-73304cada3f7_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_77baa7df-433c-4a1b-90e4-c45690e8837b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0875b1a1-e4bd-40a0-a2a0-ca0b09d9407d_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f6e82c27-0908-403b-b851-edd59a56bb6b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2022Member_2ca0fa92-84d2-468b-a2a2-4d4b9744a327_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2022Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2022Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2022Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2022Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo_a2c01894-91da-4181-ae8f-f4ae6569be8a_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum reimbursement due from collaborators, 2022</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year Two</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" xlink:to="lab_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_9da6afa1-7e70-4d95-b039-064f85bb573b_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received</link:label>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_label_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Received as Collateral</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesReceivedAsCollateral" xlink:to="lab_us-gaap_SecuritiesReceivedAsCollateral" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_19e1d9c8-46e4-4f29-b1b1-0c8ff00f8783_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_623140b1-f467-497a-abcf-58c679becd8c_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress [Member]</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32ad5dd0-d396-42f7-afbf-a2a4cc6406bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_88d56d3f-6bb9-4f2b-b313-34c962e45f35_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_e88930d1-a710-4189-a817-f69eb2cecc93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_9d1c87a1-e67d-4a2e-a052-af55091b71bc_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Upfront And Milestone Payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow to our partners for payments made upfront as part of a collaborative arrangement and the payments upon the achievement of milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementUpfrontAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:to="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20332037Member_01d6ba75-ad6f-4cd7-858d-6ca996d8fdb1_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20332037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2033-2037 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20332037Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20332037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2033-2037 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20332037Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20332037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2033-2037</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20332037Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20332037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20332037Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20332037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_InvestmentOwnershipPercentage_c59e11a6-3e6f-4319-b2a7-ba72bee58a0c_terseLabel_en-US" xlink:label="lab_pfe_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_pfe_InvestmentOwnershipPercentage_label_en-US" xlink:label="lab_pfe_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Ownership Percentage</link:label>
    <link:label id="lab_pfe_InvestmentOwnershipPercentage_documentation_en-US" xlink:label="lab_pfe_InvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InvestmentOwnershipPercentage" xlink:href="pfe-20211231.xsd#pfe_InvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InvestmentOwnershipPercentage" xlink:to="lab_pfe_InvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0eb1d105-6356-48d3-95ca-8acadccacd3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_5b6b73b4-c57e-4601-8e6b-db00ed29d464_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ValnevaSEMember_bd9af77f-d988-4b62-b0e0-fe743ba353b6_terseLabel_en-US" xlink:label="lab_pfe_ValnevaSEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valneva [Member]</link:label>
    <link:label id="lab_pfe_ValnevaSEMember_label_en-US" xlink:label="lab_pfe_ValnevaSEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valneva SE [Member]</link:label>
    <link:label id="lab_pfe_ValnevaSEMember_documentation_en-US" xlink:label="lab_pfe_ValnevaSEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valneva SE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ValnevaSEMember" xlink:href="pfe-20211231.xsd#pfe_ValnevaSEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ValnevaSEMember" xlink:to="lab_pfe_ValnevaSEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_HospitalMember_0a966da6-3989-476a-a8b5-ef9627c80918_terseLabel_en-US" xlink:label="lab_pfe_HospitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_label_en-US" xlink:label="lab_pfe_HospitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_documentation_en-US" xlink:label="lab_pfe_HospitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospitalMember" xlink:href="pfe-20211231.xsd#pfe_HospitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospitalMember" xlink:to="lab_pfe_HospitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_46457669-a58c-4d77-9483-20e37c5b9d09_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1-2 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6e3669b7-f813-4592-960c-a907e7213bd2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_229255c2-a170-4153-a09c-28d8615d7581_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_37e2fddb-2387-482e-887d-0031df58604a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_47467dec-a4cf-496d-b15b-72623b13633d_negatedTerseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_7674088e-5acc-4e30-aad5-b8f0c3ba1de3_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f05167ab-c418-4e9c-b3ad-88ffb2d8afcd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9c56b29b-120d-4584-8dfc-e026d0dd2d3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2023Member_767fe6b5-0a1b-45fa-bacf-5b0d40ec0182_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2023Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2023Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2023Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2023Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b8b897c4-565b-4734-8833-1a4d7a18de38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SutentMember_2390bc32-5d19-4bf1-9ed1-49c6398b2141_terseLabel_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_label_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_documentation_en-US" xlink:label="lab_pfe_SutentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sutent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember" xlink:href="pfe-20211231.xsd#pfe_SutentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SutentMember" xlink:to="lab_pfe_SutentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b50996e-cd38-44cf-9a5d-11b0dbe9dbd1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_866f8165-7348-40b0-8461-481bdff44d4a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units vested, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_b9fa2885-d932-4bfe-9dba-965562b0c0c9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemptions/sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b8c657e7-2af6-48c9-81f9-e02b98e587d6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_66052f57-0d99-4c70-9bc4-ce619b021575_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other&#160;comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c1a000de-2286-4c75-bd49-76e0e9a83606_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_25dc6aba-8512-41a6-aad2-10456585afc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_b4e62bb4-6f2e-4e30-bf12-0436419e267b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_0987765e-e581-457a-8434-95af6fd97c31_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_13f99a62-17c1-45ce-aec1-ea5fc0aaab79_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets of discontinued operations&#8211;&#8211;Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_PneumococcalVaccinePatentInfringementMember_05b8a619-dc0d-4d3a-9a69-004ecaef54d3_terseLabel_en-US" xlink:label="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumococcal Vaccine Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PneumococcalVaccinePatentInfringementMember_label_en-US" xlink:label="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumococcal Vaccine Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PneumococcalVaccinePatentInfringementMember_documentation_en-US" xlink:label="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumococcal Vaccine Patent Infringement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PneumococcalVaccinePatentInfringementMember" xlink:href="pfe-20211231.xsd#pfe_PneumococcalVaccinePatentInfringementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PneumococcalVaccinePatentInfringementMember" xlink:to="lab_pfe_PneumococcalVaccinePatentInfringementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EliquisMember_6869eb36-8bb9-4e12-ad00-3664ee73c8a3_terseLabel_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_label_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_documentation_en-US" xlink:label="lab_pfe_EliquisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember" xlink:href="pfe-20211231.xsd#pfe_EliquisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliquisMember" xlink:to="lab_pfe_EliquisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de0f92cd-0c9c-4d28-8cde-24615ec62d24_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_8a942e30-e03e-4e36-94c9-e2615cab9eae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Financial Information of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_70abc91d-d713-45b4-9f91-7fe70aade781_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_214d9c24-78f9-4cca-bc34-1b293b935d3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_de26ba93-6126-4b6b-aeab-73ab73da0be9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_27bc1cd5-8040-4d72-bf46-7549e0c273bb_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_61151f7e-eaba-4c6d-83c8-1844bd6b6e87_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:to="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d1e7248e-e487-4954-93ec-f4d2cf275241_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_f70d889e-c791-4ef1-8868-dfac2b5e9b7c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_8cf0b8d6-2d22-4c21-bfc0-c48c43b69ef7_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9591ff8d-da03-467a-906d-37c5fb6b7400_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_c0123f20-0319-4c48-b5d9-9a3f8405df6f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying equity in net assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_5d6a788d-e979-45ec-8753-b9cc3884974e_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e03d39f4-0380-484f-b08d-510efecbfa4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted-average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_5d854970-8d65-4494-b206-4f1fd8e14aae_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Disclosures</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_dbb6cde4-b01f-490a-95b0-560af3056bf9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2026Member_3a7db5e6-16d6-4a4e-86aa-2cf11dc10dc5_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2026 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2026Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2026 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2026Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2026Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2026Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_74261361-48f5-4764-bb04-97bf22389ae0_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses, cash portion</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_66f593c7-ce55-44af-bbb5-c2b03c24a0cb_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_0adcf8de-2720-4caf-97f6-bd58cd159c08_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_254e024c-7a83-4859-be8d-81fd66529396_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_fd1d99f6-df50-45d9-87d1-a4c9503a5b44_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_f19b860c-72ee-4bcc-97f2-05477b1722a5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_02d0952c-a405-4f93-bd4a-ec77d440a7a8_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_9fb5eaa2-9863-4425-9774-ccae12097e11_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_50956346-ba2f-4bbd-9a4c-d427ce1db06d_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Acquisition Related Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent_41a6346d-8e40-4736-9ec9-6eb298c9a939_negatedTerseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Interest on Litigation Settlement, Percent</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Interest on Litigation Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_BavencioAllianceRevenuesMember_0531f635-bbf7-4720-a2f7-130ac500cc7b_terseLabel_en-US" xlink:label="lab_pfe_BavencioAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bavencio Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_BavencioAllianceRevenuesMember_label_en-US" xlink:label="lab_pfe_BavencioAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bavencio Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_BavencioAllianceRevenuesMember_documentation_en-US" xlink:label="lab_pfe_BavencioAllianceRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bavencio Alliance Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BavencioAllianceRevenuesMember" xlink:href="pfe-20211231.xsd#pfe_BavencioAllianceRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BavencioAllianceRevenuesMember" xlink:to="lab_pfe_BavencioAllianceRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_6468ac5a-a217-497d-8e36-419459eeec97_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate: Pension plans/postretirement plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_d40b5baa-2443-4e1f-a0d6-e9b8ba1178be_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations and other assets held for sale&#8211;&#8211;Other current assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_47f2567a-dc43-4fd6-8818-297634cb36b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2025Member_e40d2111-8cdc-48bd-9ad2-6f0935ca5c01_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2025 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2025Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2025 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2025Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2025Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2025Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_69d98856-3650-4f13-8991-c32cc7a57995_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_f9fe6bf9-5225-426f-ac43-61ddb961afa8_terseLabel_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_label_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_documentation_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViivHealthcareLimitedMember" xlink:to="lab_pfe_ViivHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_bc27624f-dc1f-433b-9092-67d08eeef648_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent deferred tax assets and other noncurrent tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:to="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d5dfdbc4-b73b-40ef-9f38-eb4aceac5d12_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_45454461-2e28-421e-9352-4ac9115cb9d0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_f46e38e2-70cd-4ba1-9770-1a209329f0e1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_41ae97ed-0e06-40a2-9293-7cc37b5bf3fa_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_3b6baad0-d81b-4b43-8b29-102cfb021cbb_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ConcentrationRiskAmount_24835d60-d546-4266-963b-01d1ea218e1a_terseLabel_en-US" xlink:label="lab_pfe_ConcentrationRiskAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, amount</link:label>
    <link:label id="lab_pfe_ConcentrationRiskAmount_label_en-US" xlink:label="lab_pfe_ConcentrationRiskAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Amount</link:label>
    <link:label id="lab_pfe_ConcentrationRiskAmount_documentation_en-US" xlink:label="lab_pfe_ConcentrationRiskAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConcentrationRiskAmount" xlink:href="pfe-20211231.xsd#pfe_ConcentrationRiskAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConcentrationRiskAmount" xlink:to="lab_pfe_ConcentrationRiskAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_ZirabevMember_432ae5d7-b19c-46d2-8a86-7b3cb0de7f16_terseLabel_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev [Member]</link:label>
    <link:label id="lab_pfe_ZirabevMember_label_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev [Member]</link:label>
    <link:label id="lab_pfe_ZirabevMember_documentation_en-US" xlink:label="lab_pfe_ZirabevMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zirabev</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember" xlink:href="pfe-20211231.xsd#pfe_ZirabevMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZirabevMember" xlink:to="lab_pfe_ZirabevMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_8f891847-d0a3-4030-8d50-83fbb5400445_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS Numerator&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_e035b92b-cfeb-4c98-a9b6-739a2a340bd3_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units outstanding, weighted average grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_1e6e7921-ffb0-4026-84ec-8f8a6e2d271b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring cost incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_df9577d0-4811-431e-99f3-067335bb4879_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain" xlink:to="lab_us-gaap_GainContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_11c233e7-71bf-4558-b075-33707c187c0f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from redemptions/sales of long-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_12dd86df-b8c9-403a-9058-8c5ab2146ba9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining period of hedging exposure</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_d4f863ae-e6bc-4933-892b-659641687d06_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2024Member_985923a3-35bf-4421-977c-943879c1ad03_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2024 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2024Member_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2024 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2024Member_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Debt, Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2024Member" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2024Member" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_05a38db0-1ea2-46e0-a261-05a822e60148_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_LongtermInvestmentsMember_623c3185-45e1-4bf0-b5ac-69f1e58db7ed_terseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember" xlink:to="lab_pfe_LongtermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_a705fe96-94ea-4a19-984e-ad270bf596a8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4c02b034-e4ac-4f6d-a787-558668d92843_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_fa655e13-8c13-4beb-8ac8-09f8e9251007_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_A2019StockPlanMember_0b2aaa5c-75fe-4670-ae5c-836e55510fe8_terseLabel_en-US" xlink:label="lab_pfe_A2019StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Plan [Member]</link:label>
    <link:label id="lab_pfe_A2019StockPlanMember_label_en-US" xlink:label="lab_pfe_A2019StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Plan [Member]</link:label>
    <link:label id="lab_pfe_A2019StockPlanMember_documentation_en-US" xlink:label="lab_pfe_A2019StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Stock Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_A2019StockPlanMember" xlink:href="pfe-20211231.xsd#pfe_A2019StockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_A2019StockPlanMember" xlink:to="lab_pfe_A2019StockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_ba73a3db-66da-4247-a49e-9bda49c1a19c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_3c9f6b17-ab53-4700-9701-2a8468f28e3c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_110a9e48-4870-4a03-b337-c609a1864f6c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from continuing operations before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_bdf82b6d-aa5f-42a7-9f76-1d544ffe2d85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_362a646e-eee0-4668-9b69-2d95eeff5a7c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales and Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3b2fecb5-125f-4304-8cbf-37def732fd27_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_1ceed1d7-8063-40c9-9ea1-d95240f789dc_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_765afc63-f886-4609-b01d-d11e465d85fd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_99e7bff5-b518-47c7-b2a3-c14e5c1e5c0c_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_44ccccd8-a0c9-4735-8950-a3091d673805_terseLabel_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_label_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_documentation_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember" xlink:href="pfe-20211231.xsd#pfe_EnvironmentalRemediationLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnvironmentalRemediationLitigationMember" xlink:to="lab_pfe_EnvironmentalRemediationLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesTable_33731058-3c3c-47d7-8288-3fbf95d83255_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable" xlink:to="lab_us-gaap_GainContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_574d1554-0bca-4a18-9c6a-7dc3a7b862a1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_40047099-2188-4c77-9776-fcd4d7ed5ae2_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Units settled, weighted average grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bef80bf7-29ea-42e7-b98c-a379ed6f721e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_6415b0b8-c725-4d2a-8cb6-866715eba464_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upjohn spin-off</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanDivestituresPlanAssets" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>pfe-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:ad91efd1-2241-49cf-a17f-7cbe86f9ba4a,g:feca3a10-f613-46f2-b813-b8f4d7d48955-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:type="simple" xlink:href="pfe-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2133a358-e330-47a1-af83-973548dde817" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_49df7ea4-e8e1-4112-8b3d-0cfe8241be80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2133a358-e330-47a1-af83-973548dde817" xlink:to="loc_dei_EntitiesTable_49df7ea4-e8e1-4112-8b3d-0cfe8241be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c0be931b-fd31-4e54-8a4d-604431a3bd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_49df7ea4-e8e1-4112-8b3d-0cfe8241be80" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c0be931b-fd31-4e54-8a4d-604431a3bd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c0be931b-fd31-4e54-8a4d-604431a3bd6f" xlink:to="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e06232f7-7dd5-4402-a3e7-b4a2cbaa92a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:to="loc_us-gaap_CommonStockMember_e06232f7-7dd5-4402-a3e7-b4a2cbaa92a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20220.250Member_40207e4a-496b-4d02-8021-a1a5b5adb53f" xlink:href="pfe-20211231.xsd#pfe_NotesDue20220.250Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:to="loc_pfe_NotesDue20220.250Member_40207e4a-496b-4d02-8021-a1a5b5adb53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NotesDue20271.000Member_3f39ed15-e60c-4f78-a16f-63c23f1b2254" xlink:href="pfe-20211231.xsd#pfe_NotesDue20271.000Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_bac47500-1188-4844-aea7-e89e1a2795f3" xlink:to="loc_pfe_NotesDue20271.000Member_3f39ed15-e60c-4f78-a16f-63c23f1b2254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_49df7ea4-e8e1-4112-8b3d-0cfe8241be80" xlink:to="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1291cd99-dfc0-4de9-a33e-9faece9c6465" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentType_1291cd99-dfc0-4de9-a33e-9faece9c6465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3dcf012b-22f7-43e5-8294-df288921e6ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentAnnualReport_3dcf012b-22f7-43e5-8294-df288921e6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f96cbfe9-1c67-4832-af92-94b9391980da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentPeriodEndDate_f96cbfe9-1c67-4832-af92-94b9391980da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dd3cd6c0-271b-446c-87db-f503a95bfe8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_CurrentFiscalYearEndDate_dd3cd6c0-271b-446c-87db-f503a95bfe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b88be423-0369-4b51-8a93-4374426b251c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentTransitionReport_b88be423-0369-4b51-8a93-4374426b251c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3e7c1922-3f8e-4a62-8f63-5889e299bf35" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityFileNumber_3e7c1922-3f8e-4a62-8f63-5889e299bf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0e7502c3-efe0-4ac0-949f-cbce97a65302" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityRegistrantName_0e7502c3-efe0-4ac0-949f-cbce97a65302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_364420a4-e7b8-4a61-a05a-e91bd1f1d55f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_364420a4-e7b8-4a61-a05a-e91bd1f1d55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_79ae18a5-2a12-426b-9816-ff1cc4c50d93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityTaxIdentificationNumber_79ae18a5-2a12-426b-9816-ff1cc4c50d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3f5bc0e7-6c28-42a4-a0b6-9f0d29d8add8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressAddressLine1_3f5bc0e7-6c28-42a4-a0b6-9f0d29d8add8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8393a282-f9ee-46b3-a05e-2ece59474c93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressCityOrTown_8393a282-f9ee-46b3-a05e-2ece59474c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_630c29b0-165f-4ce9-afe1-aef95fdccb8e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressStateOrProvince_630c29b0-165f-4ce9-afe1-aef95fdccb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e5e2d110-6265-4b66-bdef-a2cb85ab2eb0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityAddressPostalZipCode_e5e2d110-6265-4b66-bdef-a2cb85ab2eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_76c1ffe9-00e9-4f74-ba32-a93b5ef74bd7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_CityAreaCode_76c1ffe9-00e9-4f74-ba32-a93b5ef74bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a5c6af46-46dc-488a-a38b-f4be8aa873c1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_LocalPhoneNumber_a5c6af46-46dc-488a-a38b-f4be8aa873c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_de66f243-0d20-4910-9fef-c6b3acf25daf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_Security12bTitle_de66f243-0d20-4910-9fef-c6b3acf25daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3f1b7472-c860-4201-99c6-5a4b4230e835" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_TradingSymbol_3f1b7472-c860-4201-99c6-5a4b4230e835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_75b1abe7-bd6c-4873-ace9-3e522a35ccfb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_SecurityExchangeName_75b1abe7-bd6c-4873-ace9-3e522a35ccfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b2e16696-a095-4f87-8900-bc8c4fae358f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b2e16696-a095-4f87-8900-bc8c4fae358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c3af93da-ea75-4319-8c23-6357da807c2a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityVoluntaryFilers_c3af93da-ea75-4319-8c23-6357da807c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9cbf882d-89b0-4d82-a0e7-5fecfe6674e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityCurrentReportingStatus_9cbf882d-89b0-4d82-a0e7-5fecfe6674e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2eee3b98-4025-4a50-bbe6-54522c0966a7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityInteractiveDataCurrent_2eee3b98-4025-4a50-bbe6-54522c0966a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dc291f06-c103-48ac-b600-6f01f7b558a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityFilerCategory_dc291f06-c103-48ac-b600-6f01f7b558a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e602bbe1-f5d8-4a60-9bcb-8bdaf84285f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntitySmallBusiness_e602bbe1-f5d8-4a60-9bcb-8bdaf84285f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cd813f51-4150-40ed-8c9d-a222cb2e87af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityEmergingGrowthCompany_cd813f51-4150-40ed-8c9d-a222cb2e87af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9014d4eb-185a-4570-9243-b58baa56f960" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9014d4eb-185a-4570-9243-b58baa56f960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b4da111e-7ca5-4998-a5bf-bed15b0b046c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityShellCompany_b4da111e-7ca5-4998-a5bf-bed15b0b046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7202c1f9-b506-4793-8634-5c4a4c0094b5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityPublicFloat_7202c1f9-b506-4793-8634-5c4a4c0094b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_38b784de-9066-47c7-9a01-af3ce06e9b05" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_38b784de-9066-47c7-9a01-af3ce06e9b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ab7bb1cd-99d9-4c80-a0d7-31939ec8018b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_EntityCentralIndexKey_ab7bb1cd-99d9-4c80-a0d7-31939ec8018b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_76d5daab-865c-4a4d-9035-39b34a0400ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentFiscalYearFocus_76d5daab-865c-4a4d-9035-39b34a0400ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_2efdc7f3-d18e-4a6b-83a2-51feb2d3c9f6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_2efdc7f3-d18e-4a6b-83a2-51feb2d3c9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_508ef0d2-4cfc-4360-ad2a-4dcd814821c0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_AmendmentFlag_508ef0d2-4cfc-4360-ad2a-4dcd814821c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_19da37b7-3df5-4f1a-981d-e62440129c7e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_479fb50a-f9a4-4c89-b29a-f8db1bcc34e6" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_19da37b7-3df5-4f1a-981d-e62440129c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AuditInformation" xlink:type="simple" xlink:href="pfe-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AuditInformationAbstract_8167391f-2ff4-43fa-b905-d896a6bb8585" xlink:href="pfe-20211231.xsd#pfe_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_b6ea4b9a-4659-46df-8833-1489f837f71f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AuditInformationAbstract_8167391f-2ff4-43fa-b905-d896a6bb8585" xlink:to="loc_dei_AuditorName_b6ea4b9a-4659-46df-8833-1489f837f71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d75c12a2-b380-476d-a472-975f53359bed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AuditInformationAbstract_8167391f-2ff4-43fa-b905-d896a6bb8585" xlink:to="loc_dei_AuditorLocation_d75c12a2-b380-476d-a472-975f53359bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_45026e3c-317e-4801-b4b3-7e1bcc991dc2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AuditInformationAbstract_8167391f-2ff4-43fa-b905-d896a6bb8585" xlink:to="loc_dei_AuditorFirmId_45026e3c-317e-4801-b4b3-7e1bcc991dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f26b6e04-917a-4a48-8523-b5e4a4c97390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f26b6e04-917a-4a48-8523-b5e4a4c97390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c477b715-dc93-426a-803c-c8b66e86877a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c477b715-dc93-426a-803c-c8b66e86877a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a3a9c0ef-781e-4478-80c2-4a15cfe26c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a3a9c0ef-781e-4478-80c2-4a15cfe26c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_164a05c4-1aae-49f5-9077-850eeae01417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_164a05c4-1aae-49f5-9077-850eeae01417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_5a244df7-cd87-4af2-b5d3-817cc47a9150" xlink:href="pfe-20211231.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_5a244df7-cd87-4af2-b5d3-817cc47a9150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_bd905d4d-a930-4ec0-af0a-fdc09543661b" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_bd905d4d-a930-4ec0-af0a-fdc09543661b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_fd7dc084-4cf7-4f6e-9b51-6dd9af77edf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_fd7dc084-4cf7-4f6e-9b51-6dd9af77edf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f8d5df1c-494d-4732-9e81-65122c028d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_e7f524a6-11e1-4875-8e22-fabeaa716ffe" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f8d5df1c-494d-4732-9e81-65122c028d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f122e456-645b-4a3d-8d60-f91fc75e9278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f122e456-645b-4a3d-8d60-f91fc75e9278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dc0ea928-37e7-454d-84f2-c031661149da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dc0ea928-37e7-454d-84f2-c031661149da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7d863154-b06f-4f77-a9a0-18f32ff18d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7d863154-b06f-4f77-a9a0-18f32ff18d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f564c1b0-eecf-40ee-881f-c131a004a977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f564c1b0-eecf-40ee-881f-c131a004a977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5be90090-022d-4048-b633-1d50d6602a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_ProfitLoss_5be90090-022d-4048-b633-1d50d6602a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8ec3cf3c-0552-4ea6-8eb9-c85fea5614d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8ec3cf3c-0552-4ea6-8eb9-c85fea5614d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d5df4f0-32a4-4992-bc1e-8216dd201093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_NetIncomeLoss_5d5df4f0-32a4-4992-bc1e-8216dd201093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_eb465b61-bfa1-4f49-b421-976bc8586559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_eb465b61-bfa1-4f49-b421-976bc8586559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bf5d806f-a52d-466a-8d82-732015271f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_eb465b61-bfa1-4f49-b421-976bc8586559" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bf5d806f-a52d-466a-8d82-732015271f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b9f93ec6-c600-4aa8-bc6b-f9bd33c3c678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_eb465b61-bfa1-4f49-b421-976bc8586559" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b9f93ec6-c600-4aa8-bc6b-f9bd33c3c678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fa160f54-8d8c-4ea2-9e66-8f5de1b65227" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_eb465b61-bfa1-4f49-b421-976bc8586559" xlink:to="loc_us-gaap_EarningsPerShareBasic_fa160f54-8d8c-4ea2-9e66-8f5de1b65227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_ea039016-fc9f-4490-80c9-bc9c1d4c8049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_ea039016-fc9f-4490-80c9-bc9c1d4c8049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1a00a26e-939f-491f-bb8a-dcc4d3a87322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_ea039016-fc9f-4490-80c9-bc9c1d4c8049" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_1a00a26e-939f-491f-bb8a-dcc4d3a87322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3c1a02c1-ecde-45ad-b643-30d545792a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_ea039016-fc9f-4490-80c9-bc9c1d4c8049" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3c1a02c1-ecde-45ad-b643-30d545792a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a183d0f8-5502-4a0b-aa92-c308b54e05a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_ea039016-fc9f-4490-80c9-bc9c1d4c8049" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a183d0f8-5502-4a0b-aa92-c308b54e05a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9d1b217-c8e7-4b07-a88c-e8db9d94a63a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f9d1b217-c8e7-4b07-a88c-e8db9d94a63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34203267-dc2e-4984-a8ca-74de0051c06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6fcf5123-7cc9-44cb-a548-45c01dc579e3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34203267-dc2e-4984-a8ca-74de0051c06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5d079324-a40e-4f3a-8f9f-03828843edb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_ProfitLoss_5d079324-a40e-4f3a-8f9f-03828843edb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_ee60fac9-56f1-4b4d-9a4d-333b4aa4f80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_ee60fac9-56f1-4b4d-9a4d-333b4aa4f80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_d4524155-4262-422b-84a5-1c2bcca6f311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_d4524155-4262-422b-84a5-1c2bcca6f311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_89da6757-251f-4cfe-8cd2-8decaeb96c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_89da6757-251f-4cfe-8cd2-8decaeb96c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_de6e1647-3ac8-4e97-b87d-cef0f9f8d080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_de6e1647-3ac8-4e97-b87d-cef0f9f8d080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_44966cfb-95fe-4f8f-932e-7798cdf0e6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_44966cfb-95fe-4f8f-932e-7798cdf0e6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_8cd62461-4cee-4efb-95be-cd563e5bffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_8cd62461-4cee-4efb-95be-cd563e5bffd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_c60fe982-864d-44ce-93ee-58ce66520fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_c60fe982-864d-44ce-93ee-58ce66520fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_8b153898-1d6f-48c7-8ac5-8f7537163d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_8b153898-1d6f-48c7-8ac5-8f7537163d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_408ee241-f63b-4472-a690-7f51b03cc9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_408ee241-f63b-4472-a690-7f51b03cc9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_a3e9b830-d100-4f5f-be0e-3d6f06e96dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_a3e9b830-d100-4f5f-be0e-3d6f06e96dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c0d53954-7fec-43d1-a860-cb8fbd961133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c0d53954-7fec-43d1-a860-cb8fbd961133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_5b255cc6-cfe4-487d-a2d8-03e47373d2e9" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_5b255cc6-cfe4-487d-a2d8-03e47373d2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_2a7ecf83-b4cf-4a37-a595-1e7b201c6e60" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_2a7ecf83-b4cf-4a37-a595-1e7b201c6e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_9db79436-34fb-429b-8231-1d9b8d71f216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_9db79436-34fb-429b-8231-1d9b8d71f216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c6e210f6-3218-4161-aec6-f7f42fec40e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_c6e210f6-3218-4161-aec6-f7f42fec40e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_2d2c627d-13bf-4464-adc9-bdc0c8203f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_2d2c627d-13bf-4464-adc9-bdc0c8203f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfe530f3-6077-445b-92a7-134da50d2dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cfe530f3-6077-445b-92a7-134da50d2dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_935299c8-1004-4d81-9302-f62de22486ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_935299c8-1004-4d81-9302-f62de22486ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0a7b13e7-9b3b-4eb6-8e91-35dbcc9d9e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_0a7b13e7-9b3b-4eb6-8e91-35dbcc9d9e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c15e0c4d-8cfd-40dd-bebb-0e334acfa759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_4cf53bf2-f8a1-4d0a-b1f6-af3e3a4226f7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c15e0c4d-8cfd-40dd-bebb-0e334acfa759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_36d6d4e2-4fa6-4b9f-8b0a-2d5585463141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36d6d4e2-4fa6-4b9f-8b0a-2d5585463141" xlink:to="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170e454c-a189-4cf2-a0af-69c9edb9c962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_170e454c-a189-4cf2-a0af-69c9edb9c962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_d8c9eaf8-39bb-459a-b6fe-61d473886285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_OtherShortTermInvestments_d8c9eaf8-39bb-459a-b6fe-61d473886285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_60dec8be-2c0b-4382-8b31-c7ba68195c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_60dec8be-2c0b-4382-8b31-c7ba68195c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_40cb0078-0696-4f29-b87d-28fd41844186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_InventoryNet_40cb0078-0696-4f29-b87d-28fd41844186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxAssetsCurrent_fbd1dc2d-2898-4e0d-9d63-a6f8ac5b6e02" xlink:href="pfe-20211231.xsd#pfe_OtherTaxAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_pfe_OtherTaxAssetsCurrent_fbd1dc2d-2898-4e0d-9d63-a6f8ac5b6e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_d725a651-3351-4b15-ab51-61afbe3bcd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_OtherAssetsCurrent_d725a651-3351-4b15-ab51-61afbe3bcd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_44c71c35-5f21-4183-a40b-4224ee97c694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_AssetsCurrent_44c71c35-5f21-4183-a40b-4224ee97c694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b5334ba0-a32b-40a6-ac71-a2e765c4a0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_EquityMethodInvestments_b5334ba0-a32b-40a6-ac71-a2e765c4a0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_63da029e-cf90-4f4e-9583-17759f92bec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_OtherLongTermInvestments_63da029e-cf90-4f4e-9583-17759f92bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f2dc866f-bc97-456f-a5d3-88cf22b9a298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f2dc866f-bc97-456f-a5d3-88cf22b9a298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2b392cd8-19b2-4761-8ac1-5f2d937ee416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2b392cd8-19b2-4761-8ac1-5f2d937ee416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_14cb578a-97a6-448b-942b-79187600c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_Goodwill_14cb578a-97a6-448b-942b-79187600c8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_fee1209b-3ea8-4584-8e5d-dfc174406cd1" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_fee1209b-3ea8-4584-8e5d-dfc174406cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5b3a82c5-6ad1-4c9e-aef2-25ed2258c508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5b3a82c5-6ad1-4c9e-aef2-25ed2258c508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9c81eaa2-942c-4093-876a-3edfccfaa6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1b6056a5-0f43-447d-8357-95dbf28aaf62" xlink:to="loc_us-gaap_Assets_9c81eaa2-942c-4093-876a-3edfccfaa6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36d6d4e2-4fa6-4b9f-8b0a-2d5585463141" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_0eec4b46-0dae-4ff8-bf68-d7b72598b084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_DebtCurrent_0eec4b46-0dae-4ff8-bf68-d7b72598b084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b554b8cc-052b-4643-a213-a8fe9b31a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_AccountsPayableCurrent_b554b8cc-052b-4643-a213-a8fe9b31a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_6d50a477-8f26-4d12-bcee-2284ccc0b65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_DividendsPayableCurrent_6d50a477-8f26-4d12-bcee-2284ccc0b65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_c5337bc6-a004-4c81-80ce-acce062a6125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_TaxesPayableCurrent_c5337bc6-a004-4c81-80ce-acce062a6125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_824bde16-16db-4fb5-8a52-f91722eb62e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_824bde16-16db-4fb5-8a52-f91722eb62e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_87c16361-421c-4227-abff-80335a62e2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_87c16361-421c-4227-abff-80335a62e2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_276d30ed-f7cd-4710-a588-35248042841d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_276d30ed-f7cd-4710-a588-35248042841d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b203f187-fef3-46cd-b52b-1f63d06fe8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_LiabilitiesCurrent_b203f187-fef3-46cd-b52b-1f63d06fe8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6290d43b-8060-414f-b531-581bc16424cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6290d43b-8060-414f-b531-581bc16424cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_03beeab6-4616-4ff7-b883-84b5339ccfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_03beeab6-4616-4ff7-b883-84b5339ccfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_eab44524-3d51-40a2-952f-0784c8cd80fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_eab44524-3d51-40a2-952f-0784c8cd80fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_934e7d97-6599-4474-8134-76f61bee5c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_934e7d97-6599-4474-8134-76f61bee5c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_11219d9c-19f7-4d5d-90f4-d97c780900c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_11219d9c-19f7-4d5d-90f4-d97c780900c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_24f5ed56-06be-4454-9743-95f77cd432fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_24f5ed56-06be-4454-9743-95f77cd432fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9c23af41-4145-46e9-b527-1b0a066870ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_Liabilities_9c23af41-4145-46e9-b527-1b0a066870ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_18c35ab9-b1a2-4bad-a3ec-3997f88fe303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_18c35ab9-b1a2-4bad-a3ec-3997f88fe303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_316d5041-3753-4ddb-92e7-d1d92dd3fab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_PreferredStockValue_316d5041-3753-4ddb-92e7-d1d92dd3fab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2eb598e7-5ca7-471d-82ce-16d41c4d8d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_CommonStockValue_2eb598e7-5ca7-471d-82ce-16d41c4d8d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_140a781e-0a61-42ae-940b-5e173a3884b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_140a781e-0a61-42ae-940b-5e173a3884b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_f5216e61-0b6a-4a13-8841-f0e005a86ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_TreasuryStockValue_f5216e61-0b6a-4a13-8841-f0e005a86ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1e01b03d-cf14-4ae2-b2b8-8295dcf37f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1e01b03d-cf14-4ae2-b2b8-8295dcf37f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90489ba6-82ce-4c73-a207-7521acad28c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_90489ba6-82ce-4c73-a207-7521acad28c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b5ca7e5-ff81-4bf7-9271-dd1925e5f9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_StockholdersEquity_5b5ca7e5-ff81-4bf7-9271-dd1925e5f9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3fb7f566-9ed0-436c-81f3-07055252a236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_MinorityInterest_3fb7f566-9ed0-436c-81f3-07055252a236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31af31ba-53cb-4a8e-b42b-619bde0b8d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31af31ba-53cb-4a8e-b42b-619bde0b8d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d53c98d6-ecf0-4dbd-a672-ea4eac096239" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_eaa45aea-bf02-4fad-806d-57dac7ee2fb3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d53c98d6-ecf0-4dbd-a672-ea4eac096239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aa0f499a-e9cd-47cd-a4ec-d666f196a73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_aa0f499a-e9cd-47cd-a4ec-d666f196a73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8ece4752-ce6c-4e13-ba06-08d290fb8173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_LongTermDebtCurrent_8ece4752-ce6c-4e13-ba06-08d290fb8173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a763438e-03a7-4449-92a5-f6b36adf8332" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a763438e-03a7-4449-92a5-f6b36adf8332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9263fd09-a635-43d6-b13c-d0dadf8bdccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9263fd09-a635-43d6-b13c-d0dadf8bdccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d8ffa028-4dfd-4c7f-99dd-f65d93c1c5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d8ffa028-4dfd-4c7f-99dd-f65d93c1c5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_139bfe3b-bc5a-4a8d-972e-c3d3e3353663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_139bfe3b-bc5a-4a8d-972e-c3d3e3353663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_35ab575a-4460-4b49-b13a-1ac6c52a6b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_35ab575a-4460-4b49-b13a-1ac6c52a6b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_df635f25-5787-49ff-8a01-d4f92a7a4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_CommonStockSharesIssued_df635f25-5787-49ff-8a01-d4f92a7a4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_db59e6ec-6620-449c-bb5d-79804b5b0219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_257702bc-db43-4c3e-a953-faa2a7d1315b" xlink:to="loc_us-gaap_TreasuryStockShares_db59e6ec-6620-449c-bb5d-79804b5b0219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd89885b-1259-4fda-a56a-3efe6e542b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7694b10-de56-40ad-8d07-0cb3712a4219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_dd89885b-1259-4fda-a56a-3efe6e542b3f" xlink:to="loc_us-gaap_StatementTable_a7694b10-de56-40ad-8d07-0cb3712a4219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68dfb6d4-62e6-43d5-be27-926bae0c53f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7694b10-de56-40ad-8d07-0cb3712a4219" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68dfb6d4-62e6-43d5-be27-926bae0c53f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68dfb6d4-62e6-43d5-be27-926bae0c53f9" xlink:to="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:to="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_74c2db50-7c50-4ae4-8eed-7f22bad1ec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_PreferredStockMember_74c2db50-7c50-4ae4-8eed-7f22bad1ec3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a1032562-f488-40b4-9571-d3477791b691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_CommonStockMember_a1032562-f488-40b4-9571-d3477791b691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fcbfb7f5-2c16-47d6-8c6a-49fc207d5744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fcbfb7f5-2c16-47d6-8c6a-49fc207d5744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_24abc618-c33a-4a96-88b3-a847b2980bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_TreasuryStockMember_24abc618-c33a-4a96-88b3-a847b2980bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9459ef4a-2cc3-4b59-8961-2fc01bc6d73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_RetainedEarningsMember_9459ef4a-2cc3-4b59-8961-2fc01bc6d73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_38ab94d4-c0ca-4b62-82b8-45dfc71d31da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_35078789-28f8-470d-99a7-8854e9083228" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_38ab94d4-c0ca-4b62-82b8-45dfc71d31da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d6d2711f-6511-43aa-8485-2ed45d9cbc36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b2a92a8-1d69-4f3f-910a-17100df86595" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d6d2711f-6511-43aa-8485-2ed45d9cbc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_255f6d1e-a7e4-4ed9-80a7-789e41aab548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7694b10-de56-40ad-8d07-0cb3712a4219" xlink:to="loc_us-gaap_StatementLineItems_255f6d1e-a7e4-4ed9-80a7-789e41aab548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_255f6d1e-a7e4-4ed9-80a7-789e41aab548" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_1b24ed92-ba79-44cc-a4f3-99068b332c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_SharesIssued_1b24ed92-ba79-44cc-a4f3-99068b332c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53fa248c-151f-4dd3-b7ea-cc867c9f8981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53fa248c-151f-4dd3-b7ea-cc867c9f8981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e63751f-3d33-4d83-84a2-612828fa337e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_ProfitLoss_7e63751f-3d33-4d83-84a2-612828fa337e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ac642bf-0445-4e50-b068-df103f3e4cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7ac642bf-0445-4e50-b068-df103f3e4cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_c0ca481f-b45f-4c10-8b65-97261adc9751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:to="loc_us-gaap_DividendsCommonStockCash_c0ca481f-b45f-4c10-8b65-97261adc9751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStockCash_9cbfbf71-442e-4388-9ceb-89a4cf7232d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:to="loc_us-gaap_DividendsPreferredStockCash_9cbfbf71-442e-4388-9ceb-89a4cf7232d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_98e047b9-5cc3-4ea2-bf6f-986a28900fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_d9766458-5b02-4096-a572-66bb28b33ec3" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_98e047b9-5cc3-4ea2-bf6f-986a28900fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f61dcd57-b947-49b3-ac74-9c1d658c2613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_f61dcd57-b947-49b3-ac74-9c1d658c2613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f921f03c-3e91-40bc-8657-f817673a5300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f921f03c-3e91-40bc-8657-f817673a5300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a0b23ec7-b5bc-4f70-b3f1-39d0e8d70d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a0b23ec7-b5bc-4f70-b3f1-39d0e8d70d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8f3cca7a-ec24-4876-98a1-7ccc28421811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_8f3cca7a-ec24-4876-98a1-7ccc28421811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_039f5201-7504-4e2b-a280-a3192461507b" xlink:href="pfe-20211231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_039f5201-7504-4e2b-a280-a3192461507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_88a5a51f-1edf-45d3-bb9a-2ffe0aa0beed" xlink:href="pfe-20211231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_88a5a51f-1edf-45d3-bb9a-2ffe0aa0beed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a44682e4-cb87-4e3e-812f-7f6832825348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_a44682e4-cb87-4e3e-812f-7f6832825348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_38c4928b-2df0-4c92-a6de-e82080ebbf42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockholdersEquityOther_38c4928b-2df0-4c92-a6de-e82080ebbf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_b354eedb-a405-4fcc-a470-901a1f13afa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_SharesIssued_b354eedb-a405-4fcc-a470-901a1f13afa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c820b074-9d25-4d84-94d8-17bad043b489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83febc13-f771-4577-9184-73f7461f6515" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c820b074-9d25-4d84-94d8-17bad043b489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b85d9482-e9ab-45d8-95e7-639ab5044959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_f6c1daf6-d725-4fa2-942b-d8957fd6dcbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b85d9482-e9ab-45d8-95e7-639ab5044959" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_f6c1daf6-d725-4fa2-942b-d8957fd6dcbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_44672c13-3aef-4f03-97c2-d2132bec4795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_15f7b57d-93b8-45cd-a095-a63926f8a9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_44672c13-3aef-4f03-97c2-d2132bec4795" xlink:to="loc_us-gaap_StatementTable_15f7b57d-93b8-45cd-a095-a63926f8a9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a7670b3-0af4-4b31-ae85-d7778d363875" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_15f7b57d-93b8-45cd-a095-a63926f8a9a4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a7670b3-0af4-4b31-ae85-d7778d363875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cd387ac7-c458-4274-b590-2c8a4effff57" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6a7670b3-0af4-4b31-ae85-d7778d363875" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cd387ac7-c458-4274-b590-2c8a4effff57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_a096f46f-0e69-44f3-901c-a66dda65769f" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_cd387ac7-c458-4274-b590-2c8a4effff57" xlink:to="loc_pfe_GSKConsumerHealthcareMember_a096f46f-0e69-44f3-901c-a66dda65769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_15f7b57d-93b8-45cd-a095-a63926f8a9a4" xlink:to="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ea1516c7-4289-42ba-9d57-ac91a74ec61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_ProfitLoss_ea1516c7-4289-42ba-9d57-ac91a74ec61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e15b5bc5-701d-4363-9b90-2a94b29f086c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e15b5bc5-701d-4363-9b90-2a94b29f086c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8afbdb19-7426-4565-b986-e45c75b05d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_8afbdb19-7426-4565-b986-e45c75b05d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_22ad97a4-8642-4ea8-a516-b6b965cca7f5" xlink:href="pfe-20211231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_22ad97a4-8642-4ea8-a516-b6b965cca7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_ce75941b-60d7-40ca-8c55-db1d715af1f8" xlink:href="pfe-20211231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_ce75941b-60d7-40ca-8c55-db1d715af1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_b9142b63-102f-4f1d-b29d-30d4445c2ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_b9142b63-102f-4f1d-b29d-30d4445c2ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_bbc2df25-bbf3-46ea-a74b-6e0464b56419" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_bbc2df25-bbf3-46ea-a74b-6e0464b56419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06f51ca0-f25d-4496-9022-3ff1642fa751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06f51ca0-f25d-4496-9022-3ff1642fa751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f29770ce-9e76-4736-84df-df819066cbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_ShareBasedCompensation_f29770ce-9e76-4736-84df-df819066cbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_ee35acc0-8409-46cb-a75c-2ffad7fc73c4" xlink:href="pfe-20211231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_ee35acc0-8409-46cb-a75c-2ffad7fc73c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_fa065ea6-66f7-4066-bc04-c97cb65b5a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_fa065ea6-66f7-4066-bc04-c97cb65b5a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_57905f88-e1e0-4d4f-979b-3a50535630ba" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c77e98b4-e32e-4e0e-8e77-8599c2d683c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c77e98b4-e32e-4e0e-8e77-8599c2d683c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9c564473-404d-4c83-9687-dc3a02fe8fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9c564473-404d-4c83-9687-dc3a02fe8fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3c388244-e674-4c19-989b-1bc0dde8570c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3c388244-e674-4c19-989b-1bc0dde8570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_00a74f36-c25d-4ec2-8fa9-28b478361bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_00a74f36-c25d-4ec2-8fa9-28b478361bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a2663d3d-d9a5-4564-81d8-695e2b867731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a2663d3d-d9a5-4564-81d8-695e2b867731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_dfbcab28-23b8-451a-890e-7ffa8b142477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_544de844-6fad-49ef-827c-23251749bf80" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_dfbcab28-23b8-451a-890e-7ffa8b142477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bf2e65f-b116-42c1-8ed7-5e60a321c777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4bf2e65f-b116-42c1-8ed7-5e60a321c777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_224ddb64-caf3-4a7b-baea-07cdc1198a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_224ddb64-caf3-4a7b-baea-07cdc1198a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754978af-d795-4aa5-bcf0-453d70732cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_444c70f6-c83e-42a2-8931-3cb71b4a7a8b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_754978af-d795-4aa5-bcf0-453d70732cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1bd87924-2a8f-4424-9627-3814326a0679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1bd87924-2a8f-4424-9627-3814326a0679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4203fcb0-1c73-4d86-97af-4b07852e3b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4203fcb0-1c73-4d86-97af-4b07852e3b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_0b7375e4-886d-4e56-8395-f881719173bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_0b7375e4-886d-4e56-8395-f881719173bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_679e0a31-92a7-4de9-9d6f-bf8f6b9f0e18" xlink:href="pfe-20211231.xsd#pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess_679e0a31-92a7-4de9-9d6f-bf8f6b9f0e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e993818c-1964-452b-b05e-dab74d2fe68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e993818c-1964-452b-b05e-dab74d2fe68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_8657ccdf-81d3-4cf7-b2cb-5157fc02c87f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_8657ccdf-81d3-4cf7-b2cb-5157fc02c87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e7623f3-0ed5-48b1-82b4-f2250d5817a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e7623f3-0ed5-48b1-82b4-f2250d5817a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b7a9002a-2f27-4976-9e0c-42b591d38dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b7a9002a-2f27-4976-9e0c-42b591d38dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_568c9342-21fb-4b9f-8a9e-170769db23cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_568c9342-21fb-4b9f-8a9e-170769db23cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_72d8980a-9817-42c6-a328-82e532091d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_72d8980a-9817-42c6-a328-82e532091d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_650ab175-5f8d-40b2-9266-3d539a27cd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fe885cd3-c48e-43fd-a95b-e3b5e8f8c267" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_650ab175-5f8d-40b2-9266-3d539a27cd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_cf56f407-10d4-4e97-8911-f306dec88ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_cf56f407-10d4-4e97-8911-f306dec88ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_e32099cc-658d-49d5-b965-fa262e221500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_e32099cc-658d-49d5-b965-fa262e221500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_1b758fad-dbc0-4167-bf41-5c6265c82918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_1b758fad-dbc0-4167-bf41-5c6265c82918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_511528e3-ff75-4975-8b93-9ec1c29acc57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_511528e3-ff75-4975-8b93-9ec1c29acc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_14701b26-a650-4367-bbb3-3746625bb40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_14701b26-a650-4367-bbb3-3746625bb40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af993242-a335-491d-a047-e26519c68093" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af993242-a335-491d-a047-e26519c68093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_714bfe33-add3-4a2c-b1b7-358c08647017" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_714bfe33-add3-4a2c-b1b7-358c08647017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7a06d0ad-7aa1-4702-a526-2efb90e215e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7a06d0ad-7aa1-4702-a526-2efb90e215e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_d8a6a588-7a66-447a-90b5-f56290ca27b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_d8a6a588-7a66-447a-90b5-f56290ca27b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_49da7111-40d4-483b-9e07-2092fde6099a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_49da7111-40d4-483b-9e07-2092fde6099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f0f2e5e-7b3c-41c3-961d-653927db4814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3aac9105-91be-4630-bc72-2d9f4bdd2786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f0f2e5e-7b3c-41c3-961d-653927db4814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cee0561-de96-437b-9ffe-8aa402a7fe05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cee0561-de96-437b-9ffe-8aa402a7fe05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c57ca421-3796-4560-8c3c-343414f2d7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c57ca421-3796-4560-8c3c-343414f2d7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6442637-489a-4bad-9bf2-b6a8256ff404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6442637-489a-4bad-9bf2-b6a8256ff404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03c952d9-4e87-429e-af08-8bd7d2865430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_03c952d9-4e87-429e-af08-8bd7d2865430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_618d3d16-40eb-4f22-834e-89df25c979ae" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3f46b40e-ea95-48bc-81a4-dc254708594b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3f46b40e-ea95-48bc-81a4-dc254708594b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b3ef9aa4-c589-43ad-94c9-c47284818cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:to="loc_us-gaap_InterestPaidNet_b3ef9aa4-c589-43ad-94c9-c47284818cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InterestReceivedInterestRateHedges_3378c47b-05fe-4e39-b350-7bb320a807a2" xlink:href="pfe-20211231.xsd#pfe_InterestReceivedInterestRateHedges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_877b587d-2142-405a-91d7-c70731d12a28" xlink:to="loc_pfe_InterestReceivedInterestRateHedges_3378c47b-05fe-4e39-b350-7bb320a807a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_862b9bd0-d9c9-4e2d-bda9-889e87712a83" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3ad0586a-f4c6-44bb-988e-fa59b6851587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3ad0586a-f4c6-44bb-988e-fa59b6851587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_611bf4f1-cc10-439a-ae5f-5a5d4fa094db" xlink:href="pfe-20211231.xsd#pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d537ff74-93c6-47a6-8e89-47946f419777" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_611bf4f1-cc10-439a-ae5f-5a5d4fa094db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="pfe-20211231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b109d1b7-6a5d-4b34-9f6e-9d76094f130c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_73143956-365e-489a-bfb2-caac40325b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b109d1b7-6a5d-4b34-9f6e-9d76094f130c" xlink:to="loc_us-gaap_StatementTable_73143956-365e-489a-bfb2-caac40325b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7e152858-3e01-4aa6-bbc8-15162ab51403" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73143956-365e-489a-bfb2-caac40325b52" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7e152858-3e01-4aa6-bbc8-15162ab51403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2514f3a6-cd42-43de-9754-263ef3822418" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7e152858-3e01-4aa6-bbc8-15162ab51403" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2514f3a6-cd42-43de-9754-263ef3822418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_a8c92de2-f17c-438f-9a90-f2c55200eec3" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2514f3a6-cd42-43de-9754-263ef3822418" xlink:to="loc_pfe_GSKConsumerHealthcareMember_a8c92de2-f17c-438f-9a90-f2c55200eec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_73143956-365e-489a-bfb2-caac40325b52" xlink:to="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_071ff29d-b73b-4a8a-8058-5e0c9c993a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_071ff29d-b73b-4a8a-8058-5e0c9c993a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_a9f94836-c8d0-4a4c-8349-7d50f8179420" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_a9f94836-c8d0-4a4c-8349-7d50f8179420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_1855c44f-241a-4f08-b1bf-d892b42dab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_1855c44f-241a-4f08-b1bf-d892b42dab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationNetAssetsContributed_01d549dc-6e11-4735-b828-ccc1f4be8a75" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationNetAssetsContributed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_pfe_DeconsolidationNetAssetsContributed_01d549dc-6e11-4735-b828-ccc1f4be8a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountCashConveyed_597e98d1-f271-4fec-bfe2-89a5fb670ffe" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountCashConveyed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ca606e78-8d4e-4ac3-aea5-d1979483fa87" xlink:to="loc_pfe_DeconsolidationGainLossAmountCashConveyed_597e98d1-f271-4fec-bfe2-89a5fb670ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee3658c3-5414-4e6b-8fd6-5e0ac9ee8a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8f37b9c6-858e-4085-92b1-8f4423984f11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee3658c3-5414-4e6b-8fd6-5e0ac9ee8a0e" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8f37b9c6-858e-4085-92b1-8f4423984f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f00c4b5e-818c-4d30-8ee3-80bb0cf5c9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f00c4b5e-818c-4d30-8ee3-80bb0cf5c9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f67fb0ee-0c4f-4d21-b336-0b4cff997245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f67fb0ee-0c4f-4d21-b336-0b4cff997245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_005a50b3-9619-4bd0-9537-d17950c4b469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_005a50b3-9619-4bd0-9537-d17950c4b469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a5c1e3e1-78f3-4f9e-8a63-22045f82505b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a5c1e3e1-78f3-4f9e-8a63-22045f82505b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bcccfe15-fce8-4ca9-829c-49de973492ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_UseOfEstimates_bcccfe15-fce8-4ca9-829c-49de973492ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_60e49194-25bc-4c02-98d1-7c445243dbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_60e49194-25bc-4c02-98d1-7c445243dbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_010c68b8-41cd-47d2-ba26-66d05ef0982a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_010c68b8-41cd-47d2-ba26-66d05ef0982a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d489d981-58a3-4bbd-be0e-0246db20ec34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d489d981-58a3-4bbd-be0e-0246db20ec34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_275ce2fe-981d-491d-be3e-18c56be9959d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_275ce2fe-981d-491d-be3e-18c56be9959d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_d6488db3-1da2-443d-95a7-34913007a3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_d6488db3-1da2-443d-95a7-34913007a3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_32e5d31f-f3e3-4613-a0d1-2e69acbf5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_32e5d31f-f3e3-4613-a0d1-2e69acbf5bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_faf56284-3775-44fe-b70f-8fcd9401d1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_faf56284-3775-44fe-b70f-8fcd9401d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ba3a124d-8a91-4a69-8c24-7486abfdc608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ba3a124d-8a91-4a69-8c24-7486abfdc608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_27f6a31b-01e4-455e-9a31-91a68c63f55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_27f6a31b-01e4-455e-9a31-91a68c63f55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9796bcfb-087b-498f-a5d8-5a5f23374d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9796bcfb-087b-498f-a5d8-5a5f23374d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_8cab8a38-e0d7-4831-bd37-70ba0b5ac729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_8cab8a38-e0d7-4831-bd37-70ba0b5ac729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_b4fc4f90-a4d1-477c-9858-d46b0f0f1817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_b4fc4f90-a4d1-477c-9858-d46b0f0f1817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_29f3ff96-329b-4c3c-b776-8e491e0bed74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_29f3ff96-329b-4c3c-b776-8e491e0bed74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity_62618dfc-1610-48ac-bb49-1dab4a23fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_DerivativesReportingOfDerivativeActivity_62618dfc-1610-48ac-bb49-1dab4a23fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_66dc0475-bdd9-4d1d-a944-f751b7d28e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_66dc0475-bdd9-4d1d-a944-f751b7d28e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_80f3b591-1032-484f-9155-65a503df28f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_80f3b591-1032-484f-9155-65a503df28f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_25b17edb-8218-415f-a335-8d8a19567c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_25b17edb-8218-415f-a335-8d8a19567c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_0ebc4b08-4e0f-445c-bb4b-5a6ef2e2d7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_0ebc4b08-4e0f-445c-bb4b-5a6ef2e2d7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b70ef3ef-d49a-4b43-a280-6b4903e8af7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b70ef3ef-d49a-4b43-a280-6b4903e8af7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_eeb642ea-a5a6-4f92-8536-08547e892dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_eeb642ea-a5a6-4f92-8536-08547e892dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_487d150e-955b-4786-80ac-dce3f78a0cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68659637-89e7-4f77-ba9c-946831f16a09" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_487d150e-955b-4786-80ac-dce3f78a0cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b367040-6678-4445-a4f7-17eb76684cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_246f4a2c-b8f8-49d5-a070-311729880c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b367040-6678-4445-a4f7-17eb76684cc7" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_246f4a2c-b8f8-49d5-a070-311729880c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_15e3e78d-f092-46c6-be62-efe65226b2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2b367040-6678-4445-a4f7-17eb76684cc7" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_15e3e78d-f092-46c6-be62-efe65226b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e1bbcd8-cfaa-48ec-b9de-de1a8321f385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0e1bbcd8-cfaa-48ec-b9de-de1a8321f385" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_92390aa3-60c1-49d1-9cdf-0374cea81ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_92390aa3-60c1-49d1-9cdf-0374cea81ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4658231-b97c-46f2-983c-670c00408568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_92390aa3-60c1-49d1-9cdf-0374cea81ca3" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4658231-b97c-46f2-983c-670c00408568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_1d4c89a3-070b-48b9-b81e-a9f34af3a806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e4658231-b97c-46f2-983c-670c00408568" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_1d4c89a3-070b-48b9-b81e-a9f34af3a806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73a20070-0bcb-49fb-bc16-568d13a70cc7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_srt_ProductOrServiceAxis_73a20070-0bcb-49fb-bc16-568d13a70cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73a20070-0bcb-49fb-bc16-568d13a70cc7" xlink:to="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopNineProductsMember_0e03011c-240a-46bf-abf1-65409ce72d07" xlink:href="pfe-20211231.xsd#pfe_TopNineProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:to="loc_pfe_TopNineProductsMember_0e03011c-240a-46bf-abf1-65409ce72d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopSevenProductsMember_bc31ec75-4fc2-4ba4-845d-a36fd75d11bd" xlink:href="pfe-20211231.xsd#pfe_TopSevenProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:to="loc_pfe_TopSevenProductsMember_bc31ec75-4fc2-4ba4-845d-a36fd75d11bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TopSixProductsMember_89b0e95e-336a-4027-98c4-e579fc783990" xlink:href="pfe-20211231.xsd#pfe_TopSixProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_51854f64-219d-426d-8902-a63cb2302070" xlink:to="loc_pfe_TopSixProductsMember_89b0e95e-336a-4027-98c4-e579fc783990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_967afb53-a2cf-47f2-ae93-6545842326aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_967afb53-a2cf-47f2-ae93-6545842326aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_13d5208d-6ef6-4b7d-b406-01442584d0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_967afb53-a2cf-47f2-ae93-6545842326aa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_13d5208d-6ef6-4b7d-b406-01442584d0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_28200758-e420-4d16-b2af-d6880c7292bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_13d5208d-6ef6-4b7d-b406-01442584d0a7" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_28200758-e420-4d16-b2af-d6880c7292bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_987b18db-faed-4638-81c4-614354fed7b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_srt_RestatementAxis_987b18db-faed-4638-81c4-614354fed7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_fb43258e-3577-40a8-9ae2-ddd9823a941b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_987b18db-faed-4638-81c4-614354fed7b8" xlink:to="loc_srt_RestatementDomain_fb43258e-3577-40a8-9ae2-ddd9823a941b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_48282cdd-5c32-4335-88c3-7b441d7c4654" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_fb43258e-3577-40a8-9ae2-ddd9823a941b" xlink:to="loc_srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember_48282cdd-5c32-4335-88c3-7b441d7c4654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_333d2a48-85dd-4353-8065-3f934728f17f" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6f73b27c-a91e-486b-ad4c-e0b2cf02681b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6f73b27c-a91e-486b-ad4c-e0b2cf02681b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71b785cc-2d9a-48a2-b920-6f9f5d97a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71b785cc-2d9a-48a2-b920-6f9f5d97a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b7a201e-e69e-4739-b796-28a456519e14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7b7a201e-e69e-4739-b796-28a456519e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConcentrationRiskAmount_f342c857-e46e-48d8-b161-bd66b2bfdb95" xlink:href="pfe-20211231.xsd#pfe_ConcentrationRiskAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_pfe_ConcentrationRiskAmount_f342c857-e46e-48d8-b161-bd66b2bfdb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_8e22cf24-55bd-414e-90fe-39a1c4a6c1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_8e22cf24-55bd-414e-90fe-39a1c4a6c1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_dffe6130-6206-4937-9092-71ebe95f1b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f2f40e4e-24e6-49a5-bb34-16c24a8373b7" xlink:to="loc_us-gaap_AdvertisingExpense_dffe6130-6206-4937-9092-71ebe95f1b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4b4218f-6993-4a3d-be49-b1484f3788f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_479439de-1102-45f0-8834-816c16aa7745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f4b4218f-6993-4a3d-be49-b1484f3788f9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_479439de-1102-45f0-8834-816c16aa7745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_fd3666a2-5998-492a-8aae-08999b263473" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_479439de-1102-45f0-8834-816c16aa7745" xlink:to="loc_srt_RestatementAxis_fd3666a2-5998-492a-8aae-08999b263473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_fd3666a2-5998-492a-8aae-08999b263473" xlink:to="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioPreviousAccountingPrincipleMember_baf0ec0c-4a1b-4eeb-a3dd-e6545fe45bf1" xlink:href="pfe-20211231.xsd#pfe_ScenarioPreviousAccountingPrincipleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:to="loc_pfe_ScenarioPreviousAccountingPrincipleMember_baf0ec0c-4a1b-4eeb-a3dd-e6545fe45bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_96b8aa2a-e275-4c53-b03a-2bfba91e8993" xlink:href="pfe-20211231.xsd#pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_cd0e6396-bf59-4603-ac9f-334a7318348e" xlink:to="loc_pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember_96b8aa2a-e275-4c53-b03a-2bfba91e8993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_479439de-1102-45f0-8834-816c16aa7745" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfIncomeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_7d47a9fb-cfd2-4a66-b05a-9565f0da4284" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_7d47a9fb-cfd2-4a66-b05a-9565f0da4284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3640803c-c342-4407-8ea8-459d2df5b06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3640803c-c342-4407-8ea8-459d2df5b06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_01c04edb-33a0-4c91-8330-861a0b341acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_01c04edb-33a0-4c91-8330-861a0b341acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_18aee5dc-f6c5-4bda-9699-12be5d4473b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_18aee5dc-f6c5-4bda-9699-12be5d4473b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_af24fb47-5bd9-4c19-9851-905034772d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_af24fb47-5bd9-4c19-9851-905034772d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98f54563-bae4-4831-9dd9-cc4ca48042a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_ProfitLoss_98f54563-bae4-4831-9dd9-cc4ca48042a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_885270b2-03a9-4777-bc26-c8e8adbbdcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_NetIncomeLoss_885270b2-03a9-4777-bc26-c8e8adbbdcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c863161e-c065-463b-847b-c2df3449be63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c863161e-c065-463b-847b-c2df3449be63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_08e86b86-ee36-44b5-a09f-663c9c2784cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_08e86b86-ee36-44b5-a09f-663c9c2784cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c7919858-ef0c-49a0-90c0-e8dab5153eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_fff15368-1a97-4ad3-982f-022b43e2b701" xlink:to="loc_us-gaap_EarningsPerShareBasic_c7919858-ef0c-49a0-90c0-e8dab5153eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfIncomeAbstract_a02898a1-b86c-4725-b64b-170c600ca181" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_529f147b-5d4f-4f43-a0f1-f982118e9a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_529f147b-5d4f-4f43-a0f1-f982118e9a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8d32a398-71a0-4264-bb70-6742f85c4a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_8d32a398-71a0-4264-bb70-6742f85c4a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0eae4fe2-69f5-40c1-ba03-9e083fd659e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_59f64dae-c114-40bb-97dd-4a11de6fb3ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0eae4fe2-69f5-40c1-ba03-9e083fd659e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_72bff63f-38ae-4ab6-9fc7-c340564b02a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_72bff63f-38ae-4ab6-9fc7-c340564b02a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_30990b64-09f1-4292-8d9f-927c3d185aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_30990b64-09f1-4292-8d9f-927c3d185aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_b3070516-61d3-4376-9079-fa9870d98630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_b3070516-61d3-4376-9079-fa9870d98630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_6a2417fb-99cf-41e8-b290-e38d56b7aa10" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_6a2417fb-99cf-41e8-b290-e38d56b7aa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_c938e181-d5a2-4b19-acaa-1d1c89e2b7b1" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_c938e181-d5a2-4b19-acaa-1d1c89e2b7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_d9596745-2d3c-47f8-9c0b-e0b9bb1cea02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract_a92688bc-89b4-4541-9a34-1304c171915d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_d9596745-2d3c-47f8-9c0b-e0b9bb1cea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4e9d3f5b-da89-4653-a588-bd03f4be094e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4e9d3f5b-da89-4653-a588-bd03f4be094e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_7a73c511-c457-43e1-b036-f486d9005347" xlink:href="pfe-20211231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedStatementsOfCashFlowsAbstract_ce5f62af-fe69-40fb-a466-87d6c897b712" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_7a73c511-c457-43e1-b036-f486d9005347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:href="pfe-20211231.xsd#pfe_ConsolidatedBalanceSheetsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_716a1152-4950-4154-9792-960932449fb8" xlink:to="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_537b69ac-bedd-4ebb-ad88-65551ea44f96" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_537b69ac-bedd-4ebb-ad88-65551ea44f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a71b00f8-10f6-4d23-b4af-0ddb016d4e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a71b00f8-10f6-4d23-b4af-0ddb016d4e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_97089aee-5d8b-4ab1-a379-65d699760c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_97089aee-5d8b-4ab1-a379-65d699760c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66269991-b0bb-4f72-aef6-60ed6d617b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_66269991-b0bb-4f72-aef6-60ed6d617b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d0bb718-d94f-431a-8551-d5a5173ce2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ConsolidatedBalanceSheetsAbstract_590b8a8c-950c-4034-a2fc-5b2718d0c84f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d0bb718-d94f-431a-8551-d5a5173ce2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9072983-2a47-4717-ab01-42b61f79cac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_1a034fbc-f20a-4696-b47c-a2218c3f5ef6" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d9072983-2a47-4717-ab01-42b61f79cac6" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_1a034fbc-f20a-4696-b47c-a2218c3f5ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_513b4e6d-c653-4495-8d3b-dac20adbec85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_1a034fbc-f20a-4696-b47c-a2218c3f5ef6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_513b4e6d-c653-4495-8d3b-dac20adbec85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_513b4e6d-c653-4495-8d3b-dac20adbec85" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_77e71210-cc85-4c7c-9e5e-a4615baadf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:to="loc_us-gaap_AccountsReceivableMember_77e71210-cc85-4c7c-9e5e-a4615baadf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6900002c-556b-472f-9414-eb2874eab09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6900002c-556b-472f-9414-eb2874eab09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7f8891f4-ce50-41d1-9d12-8147cb1c9963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a060c483-0a4f-42d6-a4a1-e317a228c59c" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_7f8891f4-ce50-41d1-9d12-8147cb1c9963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_1a034fbc-f20a-4696-b47c-a2218c3f5ef6" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RebatesAndOtherSalesRelatedAccruals_2f3438df-40cd-4149-a2c8-86ec4ceb411a" xlink:href="pfe-20211231.xsd#pfe_RebatesAndOtherSalesRelatedAccruals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:to="loc_pfe_RebatesAndOtherSalesRelatedAccruals_2f3438df-40cd-4149-a2c8-86ec4ceb411a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AccruedRebates_b848cbf6-a6fb-4b4d-ad7c-2ef1c4d4c453" xlink:href="pfe-20211231.xsd#pfe_AccruedRebates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:to="loc_pfe_AccruedRebates_b848cbf6-a6fb-4b4d-ad7c-2ef1c4d4c453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAccruals_bf30b812-453f-4f60-928e-9677261237d4" xlink:href="pfe-20211231.xsd#pfe_OtherAccruals"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_1d4f6630-dc4f-43a7-a29c-a9f8eae8171f" xlink:to="loc_pfe_OtherAccruals_bf30b812-453f-4f60-928e-9677261237d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_ba71e9e8-8508-4840-9d72-31a9307294bb" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_13c34492-c748-4677-9da5-ab264906d8c3" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_ba71e9e8-8508-4840-9d72-31a9307294bb" xlink:to="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_13c34492-c748-4677-9da5-ab264906d8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_b2e942a5-b941-41e9-a6bd-9b1c74905e00" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b7fd162e-8260-4cd8-97aa-7fc61d71d574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_b2e942a5-b941-41e9-a6bd-9b1c74905e00" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_b7fd162e-8260-4cd8-97aa-7fc61d71d574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_0b9fae44-8c82-4092-bb59-89119f1092f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_b2e942a5-b941-41e9-a6bd-9b1c74905e00" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_0b9fae44-8c82-4092-bb59-89119f1092f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_26805cd9-5f04-4b37-818c-8fe87f555545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_b2e942a5-b941-41e9-a6bd-9b1c74905e00" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_26805cd9-5f04-4b37-818c-8fe87f555545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_20909b2c-b8eb-491a-9954-72ae550e8e15" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_20909b2c-b8eb-491a-9954-72ae550e8e15" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e75e1e52-75c8-4a62-8fc1-2a0b26efb8e8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1bad3981-5a84-4a96-b28f-44edc42f602f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1bad3981-5a84-4a96-b28f-44edc42f602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_3c9c4b6d-5b7f-4000-bf2f-2f34a16acb27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_us-gaap_LicensingAgreementsMember_3c9c4b6d-5b7f-4000-bf2f-2f34a16acb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_c4179f58-88aa-4fa0-8710-5b72451511b3" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_c4179f58-88aa-4fa0-8710-5b72451511b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_36e15886-bda2-49cc-8bff-9d59a50ce0f6" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2f231384-5258-4538-b494-955cc3750681" xlink:to="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_36e15886-bda2-49cc-8bff-9d59a50ce0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf685605-002a-43b6-8e24-a14243690634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf685605-002a-43b6-8e24-a14243690634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bf1f73f-efad-41d3-a6ad-8a0dcf233f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bf685605-002a-43b6-8e24-a14243690634" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bf1f73f-efad-41d3-a6ad-8a0dcf233f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3c121dfa-1a3c-4b3b-bebd-1ee4065f248f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4bf1f73f-efad-41d3-a6ad-8a0dcf233f2e" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3c121dfa-1a3c-4b3b-bebd-1ee4065f248f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4b17465-c40b-4ffe-ab11-86a8e0f9d625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4b17465-c40b-4ffe-ab11-86a8e0f9d625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_793eaa52-eec6-4aed-85da-992d92bbd381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4b17465-c40b-4ffe-ab11-86a8e0f9d625" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_793eaa52-eec6-4aed-85da-992d92bbd381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_bf238719-5a3f-49ad-8034-fddc6e1d3f19" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_793eaa52-eec6-4aed-85da-992d92bbd381" xlink:to="loc_pfe_ArrayMember_bf238719-5a3f-49ad-8034-fddc6e1d3f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_331bef18-fc10-4253-8864-111a2461bcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_331bef18-fc10-4253-8864-111a2461bcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1019580d-151e-4ede-8b92-e3145ee554e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_331bef18-fc10-4253-8864-111a2461bcde" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1019580d-151e-4ede-8b92-e3145ee554e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_1009a8f9-14b2-4915-a04e-a63ac551367b" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1019580d-151e-4ede-8b92-e3145ee554e3" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_1009a8f9-14b2-4915-a04e-a63ac551367b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_4abfd578-8402-4807-acc5-6d74b2dc0ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_AssetAcquisitionAxis_4abfd578-8402-4807-acc5-6d74b2dc0ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_4abfd578-8402-4807-acc5-6d74b2dc0ca7" xlink:to="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrilliumMember_2b93fe7e-b32b-4e86-a65a-d34a9e646e8e" xlink:href="pfe-20211231.xsd#pfe_TrilliumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:to="loc_pfe_TrilliumMember_2b93fe7e-b32b-4e86-a65a-d34a9e646e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_d45d9891-fca4-4725-931e-9fa834cfd968" xlink:href="pfe-20211231.xsd#pfe_TherachonAssetAcquisitionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_5f2d4a94-0907-412e-b81c-268254abf26c" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_d45d9891-fca4-4725-931e-9fa834cfd968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21cb7ad9-853d-46da-be0b-8ce957a90109" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21cb7ad9-853d-46da-be0b-8ce957a90109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_98024e7e-8826-4545-92d4-e7d532f1565c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_21cb7ad9-853d-46da-be0b-8ce957a90109" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_98024e7e-8826-4545-92d4-e7d532f1565c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrilliumMember_4ed6935a-8e0a-4c3c-af75-e3413f66351c" xlink:href="pfe-20211231.xsd#pfe_TrilliumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98024e7e-8826-4545-92d4-e7d532f1565c" xlink:to="loc_pfe_TrilliumMember_4ed6935a-8e0a-4c3c-af75-e3413f66351c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_349ecb3e-c923-414f-a818-29f392fd6274" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionSharePrice_1649278d-87f9-409a-972e-bcddfa63f526" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionSharePrice_1649278d-87f9-409a-972e-bcddfa63f526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_7faad7b5-4888-490f-8b84-ee6f527c0491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_7faad7b5-4888-490f-8b84-ee6f527c0491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InvestmentOwnershipPercentage_e9475c10-9e36-416f-9dff-60d1253ea9f4" xlink:href="pfe-20211231.xsd#pfe_InvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_InvestmentOwnershipPercentage_e9475c10-9e36-416f-9dff-60d1253ea9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_6018f29a-5162-4d57-981a-3ab3a288f504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_6018f29a-5162-4d57-981a-3ab3a288f504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionAssetsAcquired_3b8e4f2d-1a0b-4fdf-bb4a-d92be6853ba3" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionAssetsAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionAssetsAcquired_3b8e4f2d-1a0b-4fdf-bb4a-d92be6853ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionLiabilitiesAssumed_c429f6d6-e893-4a8d-a4b5-795756caaa79" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionLiabilitiesAssumed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionLiabilitiesAssumed_c429f6d6-e893-4a8d-a4b5-795756caaa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_b499765a-0b36-43c4-9c79-28c48840650e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_b499765a-0b36-43c4-9c79-28c48840650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0238c40-d8b1-4e68-819e-f5d29dd5092c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0238c40-d8b1-4e68-819e-f5d29dd5092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d59ba53-5cd6-4ded-afa8-3a17a7c73078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8d59ba53-5cd6-4ded-afa8-3a17a7c73078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_db42d550-f74b-4731-af59-994212b8c0bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_db42d550-f74b-4731-af59-994212b8c0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ce3bc29c-64d7-4e29-bf3d-dd3320ad9f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ce3bc29c-64d7-4e29-bf3d-dd3320ad9f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8505f3d0-b672-48fc-b93d-85917cf576fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_8505f3d0-b672-48fc-b93d-85917cf576fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f8d747da-e7f5-463c-9a57-2a0c252e9786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f8d747da-e7f5-463c-9a57-2a0c252e9786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_68bd45d4-dd55-4c1e-92f8-d5af75abe078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_68bd45d4-dd55-4c1e-92f8-d5af75abe078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fc45f930-4c4d-45a4-a3c5-ac6cda1a7b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_Goodwill_fc45f930-4c4d-45a4-a3c5-ac6cda1a7b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_85a2a5ff-2608-45fd-921d-aa4cd9b1eace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_85a2a5ff-2608-45fd-921d-aa4cd9b1eace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_565122fc-8b48-44f5-8c54-7a4504df03c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_565122fc-8b48-44f5-8c54-7a4504df03c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_7dd2f675-87e1-4912-8df9-5d920d5ac8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_7dd2f675-87e1-4912-8df9-5d920d5ac8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_239bfe10-1400-43d5-8e13-3ba52d81d99e" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_239bfe10-1400-43d5-8e13-3ba52d81d99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_0ea21493-71ab-4804-b18a-3eb384e07687" xlink:href="pfe-20211231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_0ea21493-71ab-4804-b18a-3eb384e07687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_b0627ca0-873f-4ac0-8f24-72d013fb8eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_b0627ca0-873f-4ac0-8f24-72d013fb8eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_bf07552b-ab65-4fee-a9ea-dc443734eb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bb2efd51-e4b5-4d6e-b2ce-bc4e3e4d1f15" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_bf07552b-ab65-4fee-a9ea-dc443734eb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_58f20a36-9e12-444a-aec3-5cd7fcad7bfe" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_58f20a36-9e12-444a-aec3-5cd7fcad7bfe" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_24179861-dab3-4377-9ffd-33e19a3c23ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_srt_OwnershipAxis_24179861-dab3-4377-9ffd-33e19a3c23ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1425188d-9a11-4cec-8327-b09b2a1a3bea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_24179861-dab3-4377-9ffd-33e19a3c23ca" xlink:to="loc_srt_OwnershipDomain_1425188d-9a11-4cec-8327-b09b2a1a3bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_9776b7d4-f15d-4ae5-8754-b5958a533b6b" xlink:href="pfe-20211231.xsd#pfe_ViatrisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_1425188d-9a11-4cec-8327-b09b2a1a3bea" xlink:to="loc_pfe_ViatrisMember_9776b7d4-f15d-4ae5-8754-b5958a533b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8fb3027c-bdc2-4640-8f54-681ad0ac54fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8fb3027c-bdc2-4640-8f54-681ad0ac54fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ca68c2f5-4ece-45b7-b19a-6ecd391f013a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8fb3027c-bdc2-4640-8f54-681ad0ac54fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ca68c2f5-4ece-45b7-b19a-6ecd391f013a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eb8953b1-d4d9-4ae1-96dd-cd0fb427ecd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ca68c2f5-4ece-45b7-b19a-6ecd391f013a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_eb8953b1-d4d9-4ae1-96dd-cd0fb427ecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d354450c-2efc-4fcc-a23e-f3cf736a38b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_dei_LegalEntityAxis_d354450c-2efc-4fcc-a23e-f3cf736a38b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d354450c-2efc-4fcc-a23e-f3cf736a38b0" xlink:to="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MylanMember_efea1723-40a3-4a5b-a790-39d33272381c" xlink:href="pfe-20211231.xsd#pfe_MylanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:to="loc_pfe_MylanMember_efea1723-40a3-4a5b-a790-39d33272381c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncAndUpjohnFinanceBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e2e6c546-87db-4829-9d6f-93663ab9b8f2" xlink:to="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncMember_9bb9f90a-bf49-4abc-8fc4-6d3314148f27" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:to="loc_pfe_UpjohnIncMember_9bb9f90a-bf49-4abc-8fc4-6d3314148f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnFinanceB.V.Member_dcc7a631-9ddd-4a68-9962-d0c24d95db14" xlink:href="pfe-20211231.xsd#pfe_UpjohnFinanceB.V.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_d4ce6958-59a7-4541-a25a-753abdcccaa8" xlink:to="loc_pfe_UpjohnFinanceB.V.Member_dcc7a631-9ddd-4a68-9962-d0c24d95db14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ee67afc5-44dd-4324-94f9-aa7773604c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ee67afc5-44dd-4324-94f9-aa7773604c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c81bd6ca-e812-4f16-ae6e-6782791a84b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ee67afc5-44dd-4324-94f9-aa7773604c36" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c81bd6ca-e812-4f16-ae6e-6782791a84b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_deaa7cdc-b4f8-473a-afd4-fbb195d37b47" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_c81bd6ca-e812-4f16-ae6e-6782791a84b6" xlink:to="loc_pfe_LongtermInvestmentsMember_deaa7cdc-b4f8-473a-afd4-fbb195d37b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_27be2e0d-3a10-4628-acdb-8f69fb97b184" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_srt_CounterpartyNameAxis_27be2e0d-3a10-4628-acdb-8f69fb97b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_27be2e0d-3a10-4628-acdb-8f69fb97b184" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PurchaserOfMeridianMember_9c7fc627-1dee-4947-8f81-f93602057a5e" xlink:href="pfe-20211231.xsd#pfe_PurchaserOfMeridianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:to="loc_pfe_PurchaserOfMeridianMember_9c7fc627-1dee-4947-8f81-f93602057a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViatrisMember_ea6a63b3-01e1-464b-a846-1907570420c7" xlink:href="pfe-20211231.xsd#pfe_ViatrisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_694563cd-fb84-49a3-8561-5eb2fdca822b" xlink:to="loc_pfe_ViatrisMember_ea6a63b3-01e1-464b-a846-1907570420c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9fc5fba2-a990-4d5f-b07a-b69b688f6e2b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fac5eeb9-39bc-4582-a8d6-221279864d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_fac5eeb9-39bc-4582-a8d6-221279864d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_7c07d7ef-8546-4f90-97d7-671c93fa069c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2900bbea-2fec-4bf0-9e96-f85043ea22c5" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_7c07d7ef-8546-4f90-97d7-671c93fa069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e845305-7197-4722-8565-dc89bfe8314c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e845305-7197-4722-8565-dc89bfe8314c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3e845305-7197-4722-8565-dc89bfe8314c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_bbcd60d3-957f-4267-b019-696bdfb11707" xlink:href="pfe-20211231.xsd#pfe_MeridianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:to="loc_pfe_MeridianMember_bbcd60d3-957f-4267-b019-696bdfb11707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncMember_cc4aedef-c1fa-4388-90de-c60d5ecedc52" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6395481e-64e3-4596-8d39-2d9ac8888118" xlink:to="loc_pfe_UpjohnIncMember_cc4aedef-c1fa-4388-90de-c60d5ecedc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5d63241a-86a3-44d3-a9cb-111b38c15b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5d63241a-86a3-44d3-a9cb-111b38c15b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5d63241a-86a3-44d3-a9cb-111b38c15b92" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_16e214be-0250-422a-8634-b7091432fed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:to="loc_us-gaap_SeniorNotesMember_16e214be-0250-422a-8634-b7091432fed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_35c7075f-ccd6-47c6-a4e9-a622348787c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_cb18148d-bf32-4a3f-b3be-4981ccb0aeea" xlink:to="loc_us-gaap_UnsecuredDebtMember_35c7075f-ccd6-47c6-a4e9-a622348787c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ba670180-23d2-41ed-88f9-3eb776a60750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_DebtInstrumentAxis_ba670180-23d2-41ed-88f9-3eb776a60750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ba670180-23d2-41ed-88f9-3eb776a60750" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2021Member_974cafd8-d871-4a60-9b48-567c297e21f5" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:to="loc_pfe_SeniorNotesDue2021Member_974cafd8-d871-4a60-9b48-567c297e21f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2023Member_522c2d01-894b-459b-88e2-05e3ccded946" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f6538314-ccae-4cfd-9ef3-8b6e70c8aff9" xlink:to="loc_pfe_SeniorNotesDue2023Member_522c2d01-894b-459b-88e2-05e3ccded946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6bd1278-0f9b-465f-a68e-a9b0334fb554" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_srt_RangeAxis_a6bd1278-0f9b-465f-a68e-a9b0334fb554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a6bd1278-0f9b-465f-a68e-a9b0334fb554" xlink:to="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c20930bf-e5e4-483e-9180-2ae41cd53d54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:to="loc_srt_MinimumMember_c20930bf-e5e4-483e-9180-2ae41cd53d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fe56509f-7e55-4a6b-8b53-b6b0690eb509" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8dd7f9e8-52c3-4e5d-ad2e-e158ebaf6717" xlink:to="loc_srt_MaximumMember_fe56509f-7e55-4a6b-8b53-b6b0690eb509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_CreditFacilityAxis_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_079eabb2-b901-44a0-b9ae-dbfc6a8af967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_0a5c29a0-3e05-437d-8a06-e3a7a9f143eb" xlink:to="loc_us-gaap_CreditFacilityDomain_079eabb2-b901-44a0-b9ae-dbfc6a8af967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_6321992a-1b9a-4e22-b227-faaa72137c00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_079eabb2-b901-44a0-b9ae-dbfc6a8af967" xlink:to="loc_us-gaap_LineOfCreditMember_6321992a-1b9a-4e22-b227-faaa72137c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b3748a90-5d3e-4e92-953c-5c4c94e40928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b3748a90-5d3e-4e92-953c-5c4c94e40928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_a9471b3c-7502-4f5a-8db7-7925d7f3868b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b3748a90-5d3e-4e92-953c-5c4c94e40928" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_a9471b3c-7502-4f5a-8db7-7925d7f3868b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_eb43b204-886a-4bd6-87d7-32c068ef39a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_a9471b3c-7502-4f5a-8db7-7925d7f3868b" xlink:to="loc_us-gaap_CommercialPaperMember_eb43b204-886a-4bd6-87d7-32c068ef39a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementAxis_a25b3288-6cf4-493c-944c-a469f31cd2a9" xlink:href="pfe-20211231.xsd#pfe_AgreementAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_pfe_AgreementAxis_a25b3288-6cf4-493c-944c-a469f31cd2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:href="pfe-20211231.xsd#pfe_AgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AgreementAxis_a25b3288-6cf4-493c-944c-a469f31cd2a9" xlink:to="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TransitionServiceAgreementMember_f632d108-09ee-4c7a-8082-12f7ea5998b6" xlink:href="pfe-20211231.xsd#pfe_TransitionServiceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:to="loc_pfe_TransitionServiceAgreementMember_f632d108-09ee-4c7a-8082-12f7ea5998b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingAndSupplyAgreementMember_5f8cf2ef-edef-468c-b974-370b1a3e8f47" xlink:href="pfe-20211231.xsd#pfe_ManufacturingAndSupplyAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AgreementDomain_dae71eba-d047-488d-888d-396fe9735145" xlink:to="loc_pfe_ManufacturingAndSupplyAgreementMember_5f8cf2ef-edef-468c-b974-370b1a3e8f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e358d314-047f-4734-9de1-14d8f1b2c598" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_da364757-2360-49ba-932f-1e7d4eafb3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_da364757-2360-49ba-932f-1e7d4eafb3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_613affce-145d-4ec2-b2c1-6a6fcdc0480d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_613affce-145d-4ec2-b2c1-6a6fcdc0480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_22e6b9a4-9baf-4cc9-93de-974efedc227f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_22e6b9a4-9baf-4cc9-93de-974efedc227f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod_c8e0c6c0-1d0d-45c0-87b3-ebebbea30c46" xlink:href="pfe-20211231.xsd#pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod_c8e0c6c0-1d0d-45c0-87b3-ebebbea30c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned_2b141f40-dfe8-4af8-90de-0bca72af6292" xlink:href="pfe-20211231.xsd#pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned_2b141f40-dfe8-4af8-90de-0bca72af6292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0efe0ee7-0811-428b-9e25-97110abccdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_0efe0ee7-0811-428b-9e25-97110abccdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4512414d-ae96-4462-8e22-1b2b1094eced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_4512414d-ae96-4462-8e22-1b2b1094eced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0e95f5ec-7b6d-4ded-84a7-9b8a88e9955e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_LongTermDebt_0e95f5ec-7b6d-4ded-84a7-9b8a88e9955e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_be711528-8d7f-4611-9eb4-f6bc901132b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_be711528-8d7f-4611-9eb4-f6bc901132b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2253a330-70b4-41b3-9212-b9ae08ddbd31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2253a330-70b4-41b3-9212-b9ae08ddbd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dc782f-6fb6-44b8-accf-b00dd54541c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e0dc782f-6fb6-44b8-accf-b00dd54541c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_cac889a4-1cfe-4686-8522-72d1121612e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_cac889a4-1cfe-4686-8522-72d1121612e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_651684d5-4c34-433c-a9c2-85bfa50db1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_651684d5-4c34-433c-a9c2-85bfa50db1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ed5a49f-8b1e-4aca-86c6-3a41d6a10dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2ed5a49f-8b1e-4aca-86c6-3a41d6a10dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_bf0244ed-bf53-4b33-abf0-147ad3b0a13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_bf0244ed-bf53-4b33-abf0-147ad3b0a13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax_15cd1374-6e88-4bdc-97a1-07943f891e62" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax_15cd1374-6e88-4bdc-97a1-07943f891e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_e1e35209-8a7b-446f-847e-858fa79b42a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_e1e35209-8a7b-446f-847e-858fa79b42a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_82799e7a-b74d-499e-9125-fc23ff093ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_82799e7a-b74d-499e-9125-fc23ff093ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_a9c5b26c-439f-42ee-9a2e-6e4bc56a3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_a9c5b26c-439f-42ee-9a2e-6e4bc56a3bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontradeReceivablesCurrent_ea2785a3-d8f4-4c7a-849e-0d83b2747415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NontradeReceivablesCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_us-gaap_NontradeReceivablesCurrent_ea2785a3-d8f4-4c7a-849e-0d83b2747415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_1d049de5-eb39-41dc-b984-9e840c51ca82" xlink:href="pfe-20211231.xsd#pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_98fbdbdc-1b8e-40d8-9169-c30cd44cb4bc" xlink:to="loc_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities_1d049de5-eb39-41dc-b984-9e840c51ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_5ea3b347-5831-47b6-b7be-6d42d2369924" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_5ea3b347-5831-47b6-b7be-6d42d2369924" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_90cfeaad-9a90-4dd3-bcf1-96bd96f44cb0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_9da30510-faaa-4eba-91a9-e809a912eb52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_9da30510-faaa-4eba-91a9-e809a912eb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dcf55991-c715-45fb-ba07-f16fbd82db4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cd0b0363-7b41-45fe-b37b-d36ffbb21702" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_dcf55991-c715-45fb-ba07-f16fbd82db4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_466d53ec-1a72-4f7e-ba58-3d2a72c9d1b6" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_92384a7e-6d4f-4443-a2c5-13169bbc710e" xlink:href="pfe-20211231.xsd#pfe_MeridianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:to="loc_pfe_MeridianMember_92384a7e-6d4f-4443-a2c5-13169bbc710e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_ab36b966-4cf0-4061-8bdb-a622a4a02317" xlink:href="pfe-20211231.xsd#pfe_UpjohnIncAndUpjohnFinanceBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:to="loc_pfe_UpjohnIncAndUpjohnFinanceBVMember_ab36b966-4cf0-4061-8bdb-a622a4a02317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UpjohnFinanceBVMember_7924d539-04d5-45a4-bf66-3cd43568688e" xlink:href="pfe-20211231.xsd#pfe_UpjohnFinanceBVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_77d3e2c0-5357-4484-a930-5dea7c80b4bf" xlink:to="loc_pfe_UpjohnFinanceBVMember_7924d539-04d5-45a4-bf66-3cd43568688e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17a083bc-fb50-4240-8973-69cc2326dcca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:to="loc_srt_ProductOrServiceAxis_17a083bc-fb50-4240-8973-69cc2326dcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f38e0356-6aca-4fa9-b16b-eb4390d8984b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_17a083bc-fb50-4240-8973-69cc2326dcca" xlink:to="loc_srt_ProductsAndServicesDomain_f38e0356-6aca-4fa9-b16b-eb4390d8984b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_7ddb9e11-ad18-4aaa-b004-c585b24b6ff4" xlink:href="pfe-20211231.xsd#pfe_EpiPenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f38e0356-6aca-4fa9-b16b-eb4390d8984b" xlink:to="loc_pfe_EpiPenMember_7ddb9e11-ad18-4aaa-b004-c585b24b6ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_5ca802e9-0a90-4da8-b256-cae0f3ea75f1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5be9fece-6e76-44f0-8f15-146a979449b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5be9fece-6e76-44f0-8f15-146a979449b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c7dab54a-9b09-42a4-ae05-8d9485420cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_c7dab54a-9b09-42a4-ae05-8d9485420cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_54809113-0fdd-4ea0-8a7e-d1e2dcad9c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_54809113-0fdd-4ea0-8a7e-d1e2dcad9c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_c7dfc7a6-dffe-4c63-8082-b2b35dff203d" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_c7dfc7a6-dffe-4c63-8082-b2b35dff203d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1543dcaf-bf65-4c5d-aa62-f7bda396b3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1543dcaf-bf65-4c5d-aa62-f7bda396b3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_a2f21607-0c31-4d6b-862e-87e078a55767" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts_a2f21607-0c31-4d6b-862e-87e078a55767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1bbec8d4-94e9-411f-b627-db1401243ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_b3daa75d-2168-43b5-8512-160cee7f86b2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1bbec8d4-94e9-411f-b627-db1401243ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_e2c79570-2647-4b71-a133-1f5297ea608e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_e2c79570-2647-4b71-a133-1f5297ea608e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_f4070731-b09d-405c-8186-53af91a44273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_f4070731-b09d-405c-8186-53af91a44273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_fa4b3526-e4df-4bd0-bc44-74a42c314c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_fa4b3526-e4df-4bd0-bc44-74a42c314c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d7ad4d4e-af26-407c-885c-7001b1d8e974" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_d7ad4d4e-af26-407c-885c-7001b1d8e974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_7605de41-59c3-4d83-b539-19de7c63a1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_7605de41-59c3-4d83-b539-19de7c63a1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e40985fe-a451-4184-a621-794c09503087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_e40985fe-a451-4184-a621-794c09503087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_81564efb-cd91-4647-9c80-cc9965d9630d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_81564efb-cd91-4647-9c80-cc9965d9630d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_7f2a1720-01cb-4c2c-b868-7555edb3b117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_7f2a1720-01cb-4c2c-b868-7555edb3b117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e238460d-ef9e-4a8b-8347-c97d2b99a361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e238460d-ef9e-4a8b-8347-c97d2b99a361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses_373aa0d4-d0f1-4938-a25e-660f1e117f14" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_fc4c3948-8314-4525-8ff3-554ae4ce371b" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses_373aa0d4-d0f1-4938-a25e-660f1e117f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_982f8272-3293-41b7-bf03-c5e223b11b40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_982f8272-3293-41b7-bf03-c5e223b11b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_057971f2-e958-4211-b5e8-cf4f77989481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_057971f2-e958-4211-b5e8-cf4f77989481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_712ea01f-453e-4589-8b4a-e109a68321a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_712ea01f-453e-4589-8b4a-e109a68321a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fdfbc2a0-1058-46e5-933a-e796978b6e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fdfbc2a0-1058-46e5-933a-e796978b6e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc078847-7e20-4ca7-b6fa-2f7869d0bd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_a8eab466-c8cc-4ebc-9bdf-bc5ab8be52e0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_cc078847-7e20-4ca7-b6fa-2f7869d0bd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6b0ca640-020f-4903-9a9f-4def5161747e" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9ee34d53-cfc1-4037-911f-d7c06f72dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9ee34d53-cfc1-4037-911f-d7c06f72dc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_650afc84-438c-4979-8c2b-0bb5d2bfc8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_84b7cef2-9bf5-4014-9bf7-10f33149988b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_650afc84-438c-4979-8c2b-0bb5d2bfc8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_53f0a700-84e8-4e41-a71f-0f9023e10f2c" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract_53f0a700-84e8-4e41-a71f-0f9023e10f2c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_62e8daf6-5625-4796-a027-079f1b92ba2f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_srt_RangeAxis_62e8daf6-5625-4796-a027-079f1b92ba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_62e8daf6-5625-4796-a027-079f1b92ba2f" xlink:to="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2b65d20c-a77e-4d6a-83e7-a84306395206" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:to="loc_srt_MinimumMember_2b65d20c-a77e-4d6a-83e7-a84306395206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89f17041-c6d0-4258-a5c0-1fcd59f06103" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c6fdb1b1-5f65-4ea4-a855-c59dd4c71b2e" xlink:to="loc_srt_MaximumMember_89f17041-c6d0-4258-a5c0-1fcd59f06103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1bdb99a0-377c-4400-80dc-e707bfd3505e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1bdb99a0-377c-4400-80dc-e707bfd3505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fac4ce3c-2f03-4207-a0b8-6bd31377e0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1bdb99a0-377c-4400-80dc-e707bfd3505e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fac4ce3c-2f03-4207-a0b8-6bd31377e0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_2ca2117c-8238-4fc0-a52c-32b08721fdff" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fac4ce3c-2f03-4207-a0b8-6bd31377e0ab" xlink:to="loc_pfe_GSKConsumerHealthcareMember_2ca2117c-8238-4fc0-a52c-32b08721fdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_22309c12-17e5-46d6-ae2c-1ff11801dce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_22309c12-17e5-46d6-ae2c-1ff11801dce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_82676133-1513-4ff1-8148-32bdbf3081aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_22309c12-17e5-46d6-ae2c-1ff11801dce0" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_82676133-1513-4ff1-8148-32bdbf3081aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_024ec797-1419-41e7-980e-ba589e4df13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_82676133-1513-4ff1-8148-32bdbf3081aa" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_024ec797-1419-41e7-980e-ba589e4df13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_31bc7261-7c80-4382-b600-5d5f3bef5aef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_dei_LegalEntityAxis_31bc7261-7c80-4382-b600-5d5f3bef5aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6a8147c4-cdac-433c-ba59-47dd676eaf1a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_31bc7261-7c80-4382-b600-5d5f3bef5aef" xlink:to="loc_dei_EntityDomain_6a8147c4-cdac-433c-ba59-47dd676eaf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKMember_c12e2c62-5282-4c30-8584-04798e1840ff" xlink:href="pfe-20211231.xsd#pfe_GSKMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6a8147c4-cdac-433c-ba59-47dd676eaf1a" xlink:to="loc_pfe_GSKMember_c12e2c62-5282-4c30-8584-04798e1840ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebfa9f4c-496f-4b45-9e17-d1b926677165" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebfa9f4c-496f-4b45-9e17-d1b926677165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ebfa9f4c-496f-4b45-9e17-d1b926677165" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_2953ddb7-63b1-49de-a4e5-1fbc275da373" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:to="loc_pfe_GSKConsumerHealthcareMember_2953ddb7-63b1-49de-a4e5-1fbc275da373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_b80f823f-efc4-4182-aa21-2e7d6a54f2c1" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ec6e01e6-aeb5-45aa-a05f-af5d6595e807" xlink:to="loc_pfe_ViivHealthcareLimitedMember_b80f823f-efc4-4182-aa21-2e7d6a54f2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_a78fda07-d951-4c8a-abb2-150db96c2b8d" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0ee4115a-2ceb-4cc9-a3fb-3aeb1ec630ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0ee4115a-2ceb-4cc9-a3fb-3aeb1ec630ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_8831cd9a-d17c-429d-9dd1-7727766dc7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_8831cd9a-d17c-429d-9dd1-7727766dc7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_f34ba90d-c392-4365-860f-7a1b3305e9f6" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationGainLossAmountNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfTax_f34ba90d-c392-4365-860f-7a1b3305e9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8dcece58-43bd-4a1e-a0c5-04ed03c54654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestments_8dcece58-43bd-4a1e-a0c5-04ed03c54654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_ddd288bb-25d3-42bc-8442-afe2fda7d397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_ddd288bb-25d3-42bc-8442-afe2fda7d397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_2e214581-856e-45b2-bc95-d1089119e2e0" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation_2e214581-856e-45b2-bc95-d1089119e2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3520adf6-41af-42a3-b38e-c1173dfc696e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3520adf6-41af-42a3-b38e-c1173dfc696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c11d77b1-2299-48d4-adbb-6908ebcc235f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_c11d77b1-2299-48d4-adbb-6908ebcc235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_ae8f5a3c-fc0e-452f-8eea-49b7d9d1b92a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_ae8f5a3c-fc0e-452f-8eea-49b7d9d1b92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_0626d2bb-47bc-41da-a47d-94e8fb0fbdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_0626d2bb-47bc-41da-a47d-94e8fb0fbdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_593599fd-ceb8-4113-969d-10d38a40fad8" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_593599fd-ceb8-4113-969d-10d38a40fad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_f96ff80c-71c7-4d00-b912-de3d938a052d" xlink:href="pfe-20211231.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_f96ff80c-71c7-4d00-b912-de3d938a052d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_1576440d-af88-4a8e-aae2-cdabbfddd241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_7fe20f13-3e05-45fa-bfe9-c8d679235213" xlink:to="loc_us-gaap_InvestmentIncomeDividend_1576440d-af88-4a8e-aae2-cdabbfddd241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_fa7a2202-6e43-4b9a-ad25-a9664451acc6" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_fa7a2202-6e43-4b9a-ad25-a9664451acc6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b19208ed-7a47-41f5-939c-91449ef3b315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b19208ed-7a47-41f5-939c-91449ef3b315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_b19208ed-7a47-41f5-939c-91449ef3b315" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_5802688c-5d03-479a-9a66-77c59a7f56b5" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:to="loc_pfe_GSKConsumerHealthcareMember_5802688c-5d03-479a-9a66-77c59a7f56b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_3c4220fa-be5f-4322-b826-f833e5ae836c" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_a88d8973-d797-4006-883b-3278dd13b6e7" xlink:to="loc_pfe_ViivHealthcareLimitedMember_3c4220fa-be5f-4322-b826-f833e5ae836c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5537f9e3-cd38-462b-a5e0-43d6f28f60f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5537f9e3-cd38-462b-a5e0-43d6f28f60f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2adb44bb-f1eb-4526-be88-d293ea03a795" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5537f9e3-cd38-462b-a5e0-43d6f28f60f5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2adb44bb-f1eb-4526-be88-d293ea03a795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_b5017f1f-4f52-41de-87c7-3f5aaaf00e09" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2adb44bb-f1eb-4526-be88-d293ea03a795" xlink:to="loc_pfe_ViivHealthcareLimitedMember_b5017f1f-4f52-41de-87c7-3f5aaaf00e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1282a329-9edd-4c64-98d5-e0119e8e4080" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:href="pfe-20211231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:to="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32765799-ffd9-4b1b-ba1c-3e7eef3cecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_AssetsCurrent_32765799-ffd9-4b1b-ba1c-3e7eef3cecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_cfc256a9-b85c-4caf-ae0d-48cf46c7a8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_AssetsNoncurrent_cfc256a9-b85c-4caf-ae0d-48cf46c7a8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_827c3d7e-f576-43d0-8ad0-a4437c44cb10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_Assets_827c3d7e-f576-43d0-8ad0-a4437c44cb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e11c243-1a1b-426f-85f4-d6de5165ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e11c243-1a1b-426f-85f4-d6de5165ef54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_2d98fc93-8fb8-4ad4-a9d4-1552c9a87d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_2d98fc93-8fb8-4ad4-a9d4-1552c9a87d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ab8e8f5d-7222-40da-b63b-bbb58cad8415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_Liabilities_ab8e8f5d-7222-40da-b63b-bbb58cad8415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e2f548da-c33d-446f-b14d-8a9166c32566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_StockholdersEquity_e2f548da-c33d-446f-b14d-8a9166c32566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_eb207c5e-60b0-427f-9c82-2b2c7999775c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_MinorityInterest_eb207c5e-60b0-427f-9c82-2b2c7999775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6c952427-9692-457a-a9ba-23fe274de20e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_86daad0f-fb74-43c2-bd25-c46669f52b95" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6c952427-9692-457a-a9ba-23fe274de20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a716f967-014f-4737-90e7-00e605a32c4e" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_89ed405c-a83c-4057-8c0d-563b10ea7730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_Revenues_89ed405c-a83c-4057-8c0d-563b10ea7730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_1b7a9b96-70a7-4373-b5f9-e2bb9742a891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_CostOfRevenue_1b7a9b96-70a7-4373-b5f9-e2bb9742a891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_88f1b057-8e3a-4a09-822e-5f23ccb87063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_GrossProfit_88f1b057-8e3a-4a09-822e-5f23ccb87063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b33b61d7-9024-4cc8-91b8-9300a242dc42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b33b61d7-9024-4cc8-91b8-9300a242dc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_221d154e-5a47-4ec8-a6bd-0c73ee1e20c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_ProfitLoss_221d154e-5a47-4ec8-a6bd-0c73ee1e20c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8356d65c-22c7-4492-8214-f761c7ac057d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract_f296b7f6-c448-4c53-b4c8-10186e0335e3" xlink:to="loc_us-gaap_NetIncomeLoss_8356d65c-22c7-4492-8214-f761c7ac057d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_145edf78-eecb-4465-b628-8bef4418dd4e" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_145edf78-eecb-4465-b628-8bef4418dd4e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_50dc1cf0-f414-478e-a443-9a35c6fbdb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_50dc1cf0-f414-478e-a443-9a35c6fbdb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_136a140d-9b44-498d-8e23-638cc1a9943b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_50dc1cf0-f414-478e-a443-9a35c6fbdb1a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_136a140d-9b44-498d-8e23-638cc1a9943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_d09113b6-3aeb-49d6-9bee-342d27f4ec88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_136a140d-9b44-498d-8e23-638cc1a9943b" xlink:to="loc_us-gaap_LicensingAgreementsMember_d09113b6-3aeb-49d6-9bee-342d27f4ec88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_srt_CounterpartyNameAxis_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_53b40a4d-9470-4bf3-b4e6-2dab7b0d512b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ValnevaSEMember_50c049fe-8732-4f29-bf7e-8eb6a5c42ae5" xlink:href="pfe-20211231.xsd#pfe_ValnevaSEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:to="loc_pfe_ValnevaSEMember_50c049fe-8732-4f29-bf7e-8eb6a5c42ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AkceaAndIonisMember_9ec93a87-5b93-4bc9-a809-63c74a65eb44" xlink:href="pfe-20211231.xsd#pfe_AkceaAndIonisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18eb6f52-ef8c-4d10-b10d-f1ca86c9cfe4" xlink:to="loc_pfe_AkceaAndIonisMember_9ec93a87-5b93-4bc9-a809-63c74a65eb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a211dcf9-115b-40dc-ae5d-9427e3097f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a211dcf9-115b-40dc-ae5d-9427e3097f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a0b1a9e8-8157-40c2-a350-8bc3e8f4cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a211dcf9-115b-40dc-ae5d-9427e3097f50" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a0b1a9e8-8157-40c2-a350-8bc3e8f4cadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d817efb1-f284-4f0a-b7fe-aceb1db6e0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a0b1a9e8-8157-40c2-a350-8bc3e8f4cadc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d817efb1-f284-4f0a-b7fe-aceb1db6e0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_75fefbfe-365a-4e9e-a00a-d27358ef6a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_75fefbfe-365a-4e9e-a00a-d27358ef6a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_709c77f4-c1ac-47fc-90df-1913ebec0883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_75fefbfe-365a-4e9e-a00a-d27358ef6a1c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_709c77f4-c1ac-47fc-90df-1913ebec0883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_935daa8a-7238-405d-87b4-6fa7d8ebfa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_709c77f4-c1ac-47fc-90df-1913ebec0883" xlink:to="loc_us-gaap_LicensingAgreementsMember_935daa8a-7238-405d-87b4-6fa7d8ebfa71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_5391539a-6467-4841-895b-36c06a19becb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_13ef532e-486b-43c7-af9a-93ab8c8c5640" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_13ef532e-486b-43c7-af9a-93ab8c8c5640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentForLicensingArrangement_006521f8-f8ae-426b-9819-757e79ca2edb" xlink:href="pfe-20211231.xsd#pfe_PaymentForLicensingArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_PaymentForLicensingArrangement_006521f8-f8ae-426b-9819-757e79ca2edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_ea5cd4cf-0d05-4331-af6b-67e876a0522f" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure_ea5cd4cf-0d05-4331-af6b-67e876a0522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_bd8547ab-ec81-4b66-86c1-329213ab1a75" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure_bd8547ab-ec81-4b66-86c1-329213ab1a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_c4ca6149-c4e1-4926-b795-44f14a560b33" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_06620651-0fc3-4a34-a3a0-8b904ebee0f9" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_c4ca6149-c4e1-4926-b795-44f14a560b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_0978c38f-c5d4-4cc2-b444-ab69d06966aa" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_0978c38f-c5d4-4cc2-b444-ab69d06966aa" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4cbf327-cb32-46bf-bdef-afa4cddbc4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1cc9ee2-f02c-4246-acbd-43ff1070ff7b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4cbf327-cb32-46bf-bdef-afa4cddbc4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_5e3feacc-e7a5-434d-9c70-aa40da3a0af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a4cbf327-cb32-46bf-bdef-afa4cddbc4f2" xlink:to="loc_us-gaap_CollaborativeArrangementMember_5e3feacc-e7a5-434d-9c70-aa40da3a0af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_srt_CounterpartyNameAxis_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ec8e0f5d-4fef-4091-bd3d-2a54ee9572fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeamMember_4ae5448b-de67-47be-9558-da654999fecd" xlink:href="pfe-20211231.xsd#pfe_BeamMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_BeamMember_4ae5448b-de67-47be-9558-da654999fecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember_6d0b63a6-819a-405b-90a0-fcb0f8dd9248" xlink:href="pfe-20211231.xsd#pfe_ArvinasIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_ArvinasIncMember_6d0b63a6-819a-405b-90a0-fcb0f8dd9248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MyovantMember_0d059a4f-8ae4-4605-ada8-91781a1a8bc3" xlink:href="pfe-20211231.xsd#pfe_MyovantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_MyovantMember_0d059a4f-8ae4-4605-ada8-91781a1a8bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_1385e823-c6e6-4106-a0a1-619ad123b858" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b525f953-a420-472e-9035-48595a988c51" xlink:to="loc_pfe_BioNTechMember_1385e823-c6e6-4106-a0a1-619ad123b858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_19fbc3a0-10ea-4e7d-8bfa-5e66344d9b48" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArvinasIncMember_10bcd52e-8b1e-4bce-a86d-57ec0f8f0147" xlink:href="pfe-20211231.xsd#pfe_ArvinasIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:to="loc_pfe_ArvinasIncMember_10bcd52e-8b1e-4bce-a86d-57ec0f8f0147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CStoneMember_70fc3aab-1fd1-44f1-9c5e-5d52eab069b3" xlink:href="pfe-20211231.xsd#pfe_CStoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:to="loc_pfe_CStoneMember_70fc3aab-1fd1-44f1-9c5e-5d52eab069b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_4168c8e3-cf89-4ab6-a01a-a423ce94fd1a" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d4b62ba1-7ffa-4cc1-830a-84abc5054396" xlink:to="loc_pfe_BioNTechMember_4168c8e3-cf89-4ab6-a01a-a423ce94fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a30b15c-172a-4114-87e1-640c82016400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a30b15c-172a-4114-87e1-640c82016400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7073e322-22e2-47c6-87b3-c85779166f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5a30b15c-172a-4114-87e1-640c82016400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7073e322-22e2-47c6-87b3-c85779166f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_27c60cb5-475d-4d35-a4fc-2a8048828c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7073e322-22e2-47c6-87b3-c85779166f28" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_27c60cb5-475d-4d35-a4fc-2a8048828c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d86ea47e-d734-445f-9ccb-106ebb65304a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_dei_LegalEntityAxis_d86ea47e-d734-445f-9ccb-106ebb65304a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_31dc2647-42dd-4a17-b3ff-64f63a69c1d5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d86ea47e-d734-445f-9ccb-106ebb65304a" xlink:to="loc_dei_EntityDomain_31dc2647-42dd-4a17-b3ff-64f63a69c1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeamMember_3a583ced-b22a-4529-9d69-3ba926954cd1" xlink:href="pfe-20211231.xsd#pfe_BeamMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_31dc2647-42dd-4a17-b3ff-64f63a69c1d5" xlink:to="loc_pfe_BeamMember_3a583ced-b22a-4529-9d69-3ba926954cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22a8fcd7-61df-43b6-87af-a6112fe18b31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22a8fcd7-61df-43b6-87af-a6112fe18b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_22a8fcd7-61df-43b6-87af-a6112fe18b31" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShinglesVaccineProgramMRNABasedMember_7ad72f62-4f64-40d8-9465-72ef1848cedc" xlink:href="pfe-20211231.xsd#pfe_ShinglesVaccineProgramMRNABasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:to="loc_pfe_ShinglesVaccineProgramMRNABasedMember_7ad72f62-4f64-40d8-9465-72ef1848cedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CoronavirusVaccineProgramMRNABasedMember_cbfce302-647f-47f1-8069-550216b6c607" xlink:href="pfe-20211231.xsd#pfe_CoronavirusVaccineProgramMRNABasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_40543e56-bb11-4856-86db-578c7e9a8ba4" xlink:to="loc_pfe_CoronavirusVaccineProgramMRNABasedMember_cbfce302-647f-47f1-8069-550216b6c607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9370aa7f-30c2-486e-95ee-1c7f255ed33f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9370aa7f-30c2-486e-95ee-1c7f255ed33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b21a3f8b-6d4b-4b69-a6be-4e1aa5d09629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9370aa7f-30c2-486e-95ee-1c7f255ed33f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b21a3f8b-6d4b-4b69-a6be-4e1aa5d09629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4248a8b0-58be-400d-879e-ed6a9a8557bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b21a3f8b-6d4b-4b69-a6be-4e1aa5d09629" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4248a8b0-58be-400d-879e-ed6a9a8557bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_84aad29f-8b16-469b-b268-4b2a8ea14d1a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_52181d48-2be3-47d5-8a33-b87bd37e38c0" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage_52181d48-2be3-47d5-8a33-b87bd37e38c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsandPaymentstoCollaborators_4b93cb58-fc7c-4bf6-90f1-16903f86cdbe" xlink:href="pfe-20211231.xsd#pfe_PrepaymentsandPaymentstoCollaborators"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_PrepaymentsandPaymentstoCollaborators_4b93cb58-fc7c-4bf6-90f1-16903f86cdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_54fb2b4d-b143-45fe-a59a-0519ea4415fa" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure_54fb2b4d-b143-45fe-a59a-0519ea4415fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_168ddd8a-4fa0-464c-b026-d011d9a4629b" xlink:href="pfe-20211231.xsd#pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1_168ddd8a-4fa0-464c-b026-d011d9a4629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_ad1be270-99a7-47e7-ad61-02304701aef7" xlink:href="pfe-20211231.xsd#pfe_PrepaymentsAndPaymentsToCollaboratorsCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_PrepaymentsAndPaymentsToCollaboratorsCash_ad1be270-99a7-47e7-ad61-02304701aef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_d607a85c-90d2-4e04-a9bd-69db7421b845" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_d607a85c-90d2-4e04-a9bd-69db7421b845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_bf31cf95-50bd-4cb4-8484-396d53fbddcf" xlink:href="pfe-20211231.xsd#pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment_bf31cf95-50bd-4cb4-8484-396d53fbddcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentUponApproval_978983f8-13b8-4fee-955d-94b508535804" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMilestonePaymentUponApproval"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMilestonePaymentUponApproval_978983f8-13b8-4fee-955d-94b508535804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing_0a45b885-3c10-46e7-a4a1-a50189a09ae7" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMilestonePaymentUponCommercializing"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing_0a45b885-3c10-46e7-a4a1-a50189a09ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InvestmentOwnershipPercentage_38118eae-9dee-4e44-895e-033f33f30150" xlink:href="pfe-20211231.xsd#pfe_InvestmentOwnershipPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_InvestmentOwnershipPercentage_38118eae-9dee-4e44-895e-033f33f30150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne_30995ffe-1ddb-4be1-badf-663b65258117" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne_30995ffe-1ddb-4be1-badf-663b65258117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo_377330c4-2706-427f-8e0b-b5c735490cab" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo_377330c4-2706-427f-8e0b-b5c735490cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_658e2a22-cdfc-48d5-99dd-041fb351bc9b" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementContingentPaymentsMaximumExposure"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_658e2a22-cdfc-48d5-99dd-041fb351bc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_041c82cd-ed55-406d-931e-fbce8d7a5777" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementUpfrontAndMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_041c82cd-ed55-406d-931e-fbce8d7a5777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CollaborativeArrangementTieredSalesMilestonePayments_c5d6633b-c5d3-4254-b174-55d1265fa88d" xlink:href="pfe-20211231.xsd#pfe_CollaborativeArrangementTieredSalesMilestonePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_CollaborativeArrangementTieredSalesMilestonePayments_c5d6633b-c5d3-4254-b174-55d1265fa88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7d08628f-8093-486b-b115-509ccb9d8de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7d08628f-8093-486b-b115-509ccb9d8de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_63f904c7-01f9-41c2-a39a-8ea584a196d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_63f904c7-01f9-41c2-a39a-8ea584a196d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_06b28c2b-a16a-4c51-994e-6445cebb3383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_us-gaap_ProceedsFromCollaborators_06b28c2b-a16a-4c51-994e-6445cebb3383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_4e6feca6-611c-4bb3-aa86-f4b3483976f9" xlink:href="pfe-20211231.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f68c68a3-f74b-4b46-8dee-8d584466a2d7" xlink:to="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_4e6feca6-611c-4bb3-aa86-f4b3483976f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f04f2d52-7b1f-4fe3-82f3-dcef7b2cecce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f04f2d52-7b1f-4fe3-82f3-dcef7b2cecce" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21ccf00c-e11c-4909-a811-fff8e49e4f0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:to="loc_srt_ProductOrServiceAxis_21ccf00c-e11c-4909-a811-fff8e49e4f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_21ccf00c-e11c-4909-a811-fff8e49e4f0e" xlink:to="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8f7ad8b0-fe81-4dc6-a609-e36736c2e592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:to="loc_us-gaap_ProductMember_8f7ad8b0-fe81-4dc6-a609-e36736c2e592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CopromotionMember_e030c6d8-347d-4eb7-86fe-f0fa3921d328" xlink:href="pfe-20211231.xsd#pfe_CopromotionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bbc1d848-98c6-4b04-b47b-fdacdf29a09c" xlink:to="loc_pfe_CopromotionMember_e030c6d8-347d-4eb7-86fe-f0fa3921d328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0ee67883-38c6-45a3-a697-2cf9592a112f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0ee67883-38c6-45a3-a697-2cf9592a112f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2980fcf-9710-4863-97d4-7304d344ed9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0ee67883-38c6-45a3-a697-2cf9592a112f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2980fcf-9710-4863-97d4-7304d344ed9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8e4b6efc-10eb-4808-b0a8-4233872b2647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c2980fcf-9710-4863-97d4-7304d344ed9f" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8e4b6efc-10eb-4808-b0a8-4233872b2647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_88a8805b-6dfa-4cc1-be9d-c7c140cac138" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5876546-1725-40d8-bdab-e7e6488f834c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e5876546-1725-40d8-bdab-e7e6488f834c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_961d2ddb-d7f3-4280-96de-9423f532eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_961d2ddb-d7f3-4280-96de-9423f532eb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f77b6008-5fa2-41f9-8e02-8fe205fa1f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f77b6008-5fa2-41f9-8e02-8fe205fa1f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77a302c5-8d87-488d-863d-9eaf65be070e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_77a302c5-8d87-488d-863d-9eaf65be070e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9c7e1a04-1998-47c1-bedc-4eca22d095b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7ceda1c0-e879-4faa-8867-5d2b032b4dd5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9c7e1a04-1998-47c1-bedc-4eca22d095b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3b56b6e1-df7c-4014-9cfb-edd67348e168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f330ba9d-3a5b-4ffb-b108-6fce7dfc18a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3b56b6e1-df7c-4014-9cfb-edd67348e168" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f330ba9d-3a5b-4ffb-b108-6fce7dfc18a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_daa1a3fa-9348-449a-92ef-f16ff85de7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_0f61f7e4-bdb4-4ace-8b9f-d7a724e2bf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_daa1a3fa-9348-449a-92ef-f16ff85de7d8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_0f61f7e4-bdb4-4ace-8b9f-d7a724e2bf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_b12320d5-3dcb-4fdc-9acc-c215a52d1f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_daa1a3fa-9348-449a-92ef-f16ff85de7d8" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_b12320d5-3dcb-4fdc-9acc-c215a52d1f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_563267d1-dbaa-4d92-8902-9d7d55109762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_563267d1-dbaa-4d92-8902-9d7d55109762" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8194aac9-80db-4295-8b94-43fa47c66eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8194aac9-80db-4295-8b94-43fa47c66eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8194aac9-80db-4295-8b94-43fa47c66eb6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_e14be0aa-556b-4c09-839d-15c307f94a81" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:to="loc_pfe_ArrayMember_e14be0aa-556b-4c09-839d-15c307f94a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospiraMember_513953d1-9c30-46ae-8cce-45a06bd4d0d6" xlink:href="pfe-20211231.xsd#pfe_HospiraMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_eeab14c3-4abd-4ed1-9335-1a777799fc76" xlink:to="loc_pfe_HospiraMember_513953d1-9c30-46ae-8cce-45a06bd4d0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_81946f10-df55-4380-8709-88a3e7f438a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_RestructuringPlanAxis_81946f10-df55-4380-8709-88a3e7f438a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_81946f10-df55-4380-8709-88a3e7f438a4" xlink:to="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FocusedCompanyPlanMember_570b549b-e95f-4836-98b2-54e6e397a718" xlink:href="pfe-20211231.xsd#pfe_FocusedCompanyPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:to="loc_pfe_FocusedCompanyPlanMember_570b549b-e95f-4836-98b2-54e6e397a718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_b1aea8b7-bdcb-4a31-83f1-e06a045fc05e" xlink:href="pfe-20211231.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_38a5077b-f7dc-43e2-9876-793815a609b3" xlink:to="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_b1aea8b7-bdcb-4a31-83f1-e06a045fc05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_be4c77a8-4fd4-4ef7-a513-f0ffc726d0d0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CorporateEnablingFunctionsMember_fdb51cd9-8031-4c6d-979b-73f6e1c29257" xlink:href="pfe-20211231.xsd#pfe_CorporateEnablingFunctionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_CorporateEnablingFunctionsMember_fdb51cd9-8031-4c6d-979b-73f6e1c29257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GoToMarketModelMember_e35479f8-6f72-43a6-95de-c832183624c1" xlink:href="pfe-20211231.xsd#pfe_GoToMarketModelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_GoToMarketModelMember_e35479f8-6f72-43a6-95de-c832183624c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ManufacturingOptimizationMember_1e850a1f-2a35-4db2-92e0-fe7b0ab39174" xlink:href="pfe-20211231.xsd#pfe_ManufacturingOptimizationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_ManufacturingOptimizationMember_1e850a1f-2a35-4db2-92e0-fe7b0ab39174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessIntegrationCostsMember_4e5ccd74-864b-49a0-9b6e-eb2c425ddbf8" xlink:href="pfe-20211231.xsd#pfe_BusinessIntegrationCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ea220604-3e28-4314-ac5a-42d3fc6e2934" xlink:to="loc_pfe_BusinessIntegrationCostsMember_4e5ccd74-864b-49a0-9b6e-eb2c425ddbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33d0baf1-5757-4fd6-8947-a43d939454a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e8cc8d52-6eee-4d2c-a8a7-51642ab85a7e" xlink:to="loc_us-gaap_SegmentDomain_33d0baf1-5757-4fd6-8947-a43d939454a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_70d007bd-eb30-480e-be45-9b0a252275a8" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33d0baf1-5757-4fd6-8947-a43d939454a6" xlink:to="loc_pfe_BiopharmaSegmentMember_70d007bd-eb30-480e-be45-9b0a252275a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_378ce883-5a86-4187-b982-bbf1993c5845" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d4aa1a6a-22d2-41f2-918e-32098c7b1388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_d4aa1a6a-22d2-41f2-918e-32098c7b1388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_115c9d75-6c2d-460d-9ec5-9aa1a86d8874" xlink:href="pfe-20211231.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_115c9d75-6c2d-460d-9ec5-9aa1a86d8874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_a530e018-ada6-4ef2-a651-39fba0004e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_a530e018-ada6-4ef2-a651-39fba0004e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4abd28c7-12ea-4fff-9e34-f32f5ad243c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_4abd28c7-12ea-4fff-9e34-f32f5ad243c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_d38c5880-daab-4816-b688-a1846a345217" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_995c0a66-7cf6-47dc-9025-94eefacb3880" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_d38c5880-daab-4816-b688-a1846a345217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3703c3f5-65bb-4df3-a3e8-170ce2ce5291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77d18d77-486e-4717-8744-ed2bb71d51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3703c3f5-65bb-4df3-a3e8-170ce2ce5291" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77d18d77-486e-4717-8744-ed2bb71d51fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f35bd048-70d1-47c8-9d4b-8993716a6357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77d18d77-486e-4717-8744-ed2bb71d51fa" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f35bd048-70d1-47c8-9d4b-8993716a6357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f35bd048-70d1-47c8-9d4b-8993716a6357" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6cff7146-fba8-4eb4-9654-00755c40f18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6cff7146-fba8-4eb4-9654-00755c40f18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8bac1e43-0031-4a54-9283-0d0ff43c23b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_CostOfSalesMember_8bac1e43-0031-4a54-9283-0d0ff43c23b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d43aaf50-15b1-4b81-94b3-7e2e23565613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d43aaf50-15b1-4b81-94b3-7e2e23565613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_629635f0-2659-4590-9744-de896e22c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9abfaecd-20f9-448a-b65a-6e5b9077f6c5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_629635f0-2659-4590-9744-de896e22c1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_77d18d77-486e-4717-8744-ed2bb71d51fa" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_7e175eae-e002-4362-af5b-efde19138cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_us-gaap_SeveranceCosts1_7e175eae-e002-4362-af5b-efde19138cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_3a4d5e7b-3058-44a2-8a1e-3b94d8a31efb" xlink:href="pfe-20211231.xsd#pfe_RestructuringAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_3a4d5e7b-3058-44a2-8a1e-3b94d8a31efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_10f74461-d57c-4892-85fa-efd9e5232352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_us-gaap_BusinessExitCosts1_10f74461-d57c-4892-85fa-efd9e5232352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3e95d91a-7c2c-4aef-9a16-10820ae25f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_57668da5-cd71-4eff-8593-889fdf522055" xlink:to="loc_us-gaap_RestructuringCharges_3e95d91a-7c2c-4aef-9a16-10820ae25f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_422377e2-f201-4c82-8370-457fb958f7b7" xlink:href="pfe-20211231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_422377e2-f201-4c82-8370-457fb958f7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e8e6c49e-e3ba-4a8e-9543-7a9fd32c9ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_e8e6c49e-e3ba-4a8e-9543-7a9fd32c9ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_d9a14d10-ee24-483e-abe3-8c1e53f38184" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_d9a14d10-ee24-483e-abe3-8c1e53f38184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44ce8cab-a66e-48b6-a1c2-c78ab65cceab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_44ce8cab-a66e-48b6-a1c2-c78ab65cceab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8a87242f-d6c0-41d8-8b7d-7cb93cb16f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8a87242f-d6c0-41d8-8b7d-7cb93cb16f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCostAbstract_8c7231c2-e18e-4d5a-a5b4-f161c6493a82" xlink:href="pfe-20211231.xsd#pfe_ImplementationCostAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_ImplementationCostAbstract_8c7231c2-e18e-4d5a-a5b4-f161c6493a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ImplementationCosts_5102ad84-43e6-4068-ada5-9d25a15a3f4b" xlink:href="pfe-20211231.xsd#pfe_ImplementationCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ImplementationCostAbstract_8c7231c2-e18e-4d5a-a5b4-f161c6493a82" xlink:to="loc_pfe_ImplementationCosts_5102ad84-43e6-4068-ada5-9d25a15a3f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e1f6bafd-8c41-463e-87f7-61993a859c0b" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8311fe86-5b2e-4b84-9dad-fd42516b5426" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_e1f6bafd-8c41-463e-87f7-61993a859c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c6ac6ab8-b4e6-4637-aa1e-3233f73455fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c6ac6ab8-b4e6-4637-aa1e-3233f73455fb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_43d4388b-3fd4-4ba5-bf61-05fc9243b43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_43d4388b-3fd4-4ba5-bf61-05fc9243b43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7d385a3a-c242-449a-98ed-852308bf1141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_43d4388b-3fd4-4ba5-bf61-05fc9243b43b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7d385a3a-c242-449a-98ed-852308bf1141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5fd9d22b-8a9c-4378-b0be-cb6c28366ff7" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7d385a3a-c242-449a-98ed-852308bf1141" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5fd9d22b-8a9c-4378-b0be-cb6c28366ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4630c39b-0e37-4d13-b62a-501ea7b56d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4630c39b-0e37-4d13-b62a-501ea7b56d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20795e96-ec1f-4cb7-8d76-65a248559805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4630c39b-0e37-4d13-b62a-501ea7b56d60" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20795e96-ec1f-4cb7-8d76-65a248559805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_a964963e-bdf2-4c4c-ad43-fc0064e5e97c" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_20795e96-ec1f-4cb7-8d76-65a248559805" xlink:to="loc_pfe_ArrayMember_a964963e-bdf2-4c4c-ad43-fc0064e5e97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_41147dab-8b81-494f-8334-46997bd0b283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_41147dab-8b81-494f-8334-46997bd0b283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_41147dab-8b81-494f-8334-46997bd0b283" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionRelatedCostsMember_6ec4ddf8-3f5e-46dc-bee6-f3a5c77906c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:to="loc_us-gaap_AcquisitionRelatedCostsMember_6ec4ddf8-3f5e-46dc-bee6-f3a5c77906c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CostReductionInitiativesMember_f5bb40cd-f928-4d61-8413-e03ee82d77b3" xlink:href="pfe-20211231.xsd#pfe_CostReductionInitiativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_8011d284-45be-4189-897d-b6e8db830345" xlink:to="loc_pfe_CostReductionInitiativesMember_f5bb40cd-f928-4d61-8413-e03ee82d77b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_50397208-2144-4be0-a739-0064ef0abd12" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3a1b2755-ecfe-41de-87d9-897dbadf3606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:to="loc_us-gaap_RestructuringCharges_3a1b2755-ecfe-41de-87d9-897dbadf3606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_f31583ac-ea05-481a-b223-364fca6a19ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_982518f8-8921-4ca3-acee-94bb270a7079" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_f31583ac-ea05-481a-b223-364fca6a19ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d5a559f5-d968-4cdd-9605-49216e9b299f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bf8ebb5f-7e19-408d-bd3b-d8cce1dfcbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d5a559f5-d968-4cdd-9605-49216e9b299f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bf8ebb5f-7e19-408d-bd3b-d8cce1dfcbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d3411f64-f291-4220-9188-c7afd4011f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bf8ebb5f-7e19-408d-bd3b-d8cce1dfcbc8" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d3411f64-f291-4220-9188-c7afd4011f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d3411f64-f291-4220-9188-c7afd4011f76" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_290ee186-8d1c-43e3-a0f2-78aa70e8049c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:to="loc_us-gaap_EmployeeSeveranceMember_290ee186-8d1c-43e3-a0f2-78aa70e8049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AssetImpairmentsMember_cedd91b8-b01f-4ea0-aecc-886a40381f40" xlink:href="pfe-20211231.xsd#pfe_AssetImpairmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:to="loc_pfe_AssetImpairmentsMember_cedd91b8-b01f-4ea0-aecc-886a40381f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_7c3376e7-a031-4ece-9838-d5eeb7336601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_ce3d302a-5984-4fb1-926c-3113b2dadeb9" xlink:to="loc_us-gaap_OtherRestructuringMember_7c3376e7-a031-4ece-9838-d5eeb7336601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_0c062e67-2409-4d6b-a828-570a462f4c46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_bf8ebb5f-7e19-408d-bd3b-d8cce1dfcbc8" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_0c062e67-2409-4d6b-a828-570a462f4c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_0c062e67-2409-4d6b-a828-570a462f4c46" xlink:to="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3914988f-54ed-4508-958d-fc655c45c9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:to="loc_us-gaap_RestructuringReserve_3914988f-54ed-4508-958d-fc655c45c9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_e9e52b2c-cd5d-49a9-a6c2-db88d96c372b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:to="loc_us-gaap_RestructuringCharges_e9e52b2c-cd5d-49a9-a6c2-db88d96c372b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_c46af10f-f1be-497a-92fc-4e42c75095ea" xlink:href="pfe-20211231.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_c46af10f-f1be-497a-92fc-4e42c75095ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6bef1d06-7767-470e-a72d-ff7c9e19f059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_f16170df-4815-4b28-a41c-5d69c9b91866" xlink:to="loc_us-gaap_RestructuringReserve_6bef1d06-7767-470e-a72d-ff7c9e19f059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_87d862aa-9bc2-4607-a5be-387110e7e673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1bf1714b-3acf-4efa-b4ee-9dc9a0ee05f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_87d862aa-9bc2-4607-a5be-387110e7e673" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1bf1714b-3acf-4efa-b4ee-9dc9a0ee05f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1bf1714b-3acf-4efa-b4ee-9dc9a0ee05f9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a2ee7e45-2f06-4df8-9378-f8dd4bc2265b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9056182f-4228-46e2-a09e-8d4622b94be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9056182f-4228-46e2-a09e-8d4622b94be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ebafe373-37ab-4dae-bc47-5511b99dde80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_39401fdf-1fd9-4a3d-89c7-e8cd33bf43cb" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_ebafe373-37ab-4dae-bc47-5511b99dde80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_555b4d7d-6aa6-4ac4-8886-55084108bca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1bf1714b-3acf-4efa-b4ee-9dc9a0ee05f9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_555b4d7d-6aa6-4ac4-8886-55084108bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_f3edede5-3254-48eb-884a-164d3e5986f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_555b4d7d-6aa6-4ac4-8886-55084108bca1" xlink:to="loc_us-gaap_RestructuringReserve_f3edede5-3254-48eb-884a-164d3e5986f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherIncomeDeductionsNet"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6ee175-28b8-4e09-a1ce-62b1911a99cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_e39a0dea-5af8-4d3a-8ee5-99995bf15a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6ee175-28b8-4e09-a1ce-62b1911a99cd" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_e39a0dea-5af8-4d3a-8ee5-99995bf15a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherIncomeDeductionsNetTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_a38c82d6-27bd-43b5-99ff-968fdc0c851a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3ea13f4e-255a-4bae-80f0-9698f8cb8291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_a38c82d6-27bd-43b5-99ff-968fdc0c851a" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_3ea13f4e-255a-4bae-80f0-9698f8cb8291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ada8f3fc-40e2-463f-8d18-cb4db4b71b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ada8f3fc-40e2-463f-8d18-cb4db4b71b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3c60545f-762a-4fff-9306-021d154a3e28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_InterestExpense_3c60545f-762a-4fff-9306-021d154a3e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_c480a3d2-e286-46dc-958a-c417f457db23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_c480a3d2-e286-46dc-958a-c417f457db23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_c9efcd02-5cb1-4583-87d9-968d3f9228e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_c9efcd02-5cb1-4583-87d9-968d3f9228e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_7b4c3c0c-1a0b-431d-9904-4446934650a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_7b4c3c0c-1a0b-431d-9904-4446934650a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_068d3181-f6cc-4c73-a0ce-40241c541679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_068d3181-f6cc-4c73-a0ce-40241c541679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_5862bcf1-2262-4cda-a626-83f324fcb4b4" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_5862bcf1-2262-4cda-a626-83f324fcb4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_a583c760-0083-4d1f-9b5e-d966872c783a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_a583c760-0083-4d1f-9b5e-d966872c783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_360aaecc-6378-44f4-b6d2-80c59ffb98d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_360aaecc-6378-44f4-b6d2-80c59ffb98d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a75f17cc-4f1b-4860-86fa-6e8c47679e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_AssetImpairmentCharges_a75f17cc-4f1b-4860-86fa-6e8c47679e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BusinessAlignmentCosts_bb9fbbc2-b4d2-41ae-898f-4af1526b67b7" xlink:href="pfe-20211231.xsd#pfe_BusinessAlignmentCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_pfe_BusinessAlignmentCosts_bb9fbbc2-b4d2-41ae-898f-4af1526b67b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_4a6304d4-85dd-4c9c-b054-d17b5820209a" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_4a6304d4-85dd-4c9c-b054-d17b5820209a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_72b40c19-0360-4d72-97c0-8c6fc3ce7084" xlink:href="pfe-20211231.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_72b40c19-0360-4d72-97c0-8c6fc3ce7084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13fc9566-305b-45b5-aee4-e1c05b9790db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ba05195f-ce71-4098-bbf0-1c470c1dbf1a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13fc9566-305b-45b5-aee4-e1c05b9790db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_76f2445c-63e9-4c8c-ad73-9c146fee4fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_76f2445c-63e9-4c8c-ad73-9c146fee4fb2" xlink:to="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fa9b8198-b195-44bd-b295-2b17f0d205ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fa9b8198-b195-44bd-b295-2b17f0d205ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa9b8198-b195-44bd-b295-2b17f0d205ac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ArrayMember_3d3838e1-40ad-48a0-a34b-d982982ad344" xlink:href="pfe-20211231.xsd#pfe_ArrayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_ArrayMember_3d3838e1-40ad-48a0-a34b-d982982ad344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AnacorMember_156742a7-e2f8-4b4f-be02-15adee73a20b" xlink:href="pfe-20211231.xsd#pfe_AnacorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_AnacorMember_156742a7-e2f8-4b4f-be02-15adee73a20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospiraMember_f91d8ac0-ecc4-447b-a8d8-77abbdee64bc" xlink:href="pfe-20211231.xsd#pfe_HospiraMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_HospiraMember_f91d8ac0-ecc4-447b-a8d8-77abbdee64bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViiVMember_eac039c2-f43e-490e-92d9-b39707085c7e" xlink:href="pfe-20211231.xsd#pfe_ViiVMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af640136-f90f-47df-81ac-65c49a3d812b" xlink:to="loc_pfe_ViiVMember_eac039c2-f43e-490e-92d9-b39707085c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4dca719-de8f-4a3a-8d11-f58a8a797528" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4dca719-de8f-4a3a-8d11-f58a8a797528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_305603df-9c1f-4902-98f8-7455c672a4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f4dca719-de8f-4a3a-8d11-f58a8a797528" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_305603df-9c1f-4902-98f8-7455c672a4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_daa1fbbe-8193-42c1-b5ee-7807f7a9c2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_305603df-9c1f-4902-98f8-7455c672a4d4" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_daa1fbbe-8193-42c1-b5ee-7807f7a9c2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_036c75d9-b954-4c35-89eb-ca293a6d9bb6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_036c75d9-b954-4c35-89eb-ca293a6d9bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_036c75d9-b954-4c35-89eb-ca293a6d9bb6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_f9a2c65e-b39d-47f9-8f83-eda1ea9faad8" xlink:href="pfe-20211231.xsd#pfe_BioNTechAndCerevelTherapeuticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_BioNTechAndCerevelTherapeuticsLLCMember_f9a2c65e-b39d-47f9-8f83-eda1ea9faad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechAndSpringWorksMember_d1ea5cf5-d8ae-4242-98ef-d65e4e155626" xlink:href="pfe-20211231.xsd#pfe_BioNTechAndSpringWorksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_BioNTechAndSpringWorksMember_d1ea5cf5-d8ae-4242-98ef-d65e4e155626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember_5a77b052-efe4-4252-b689-fa413f026c39" xlink:href="pfe-20211231.xsd#pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember_5a77b052-efe4-4252-b689-fa413f026c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_a6e3d59e-dd8b-44c4-9947-d7942ab1b02d" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_BioNTechMember_a6e3d59e-dd8b-44c4-9947-d7942ab1b02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_d4add2e8-5d45-4bf3-bb68-3dfb12051d8b" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e90e20e7-62e1-448b-b098-f8a840f0f0f5" xlink:to="loc_pfe_ViivHealthcareLimitedMember_d4add2e8-5d45-4bf3-bb68-3dfb12051d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_ac45789f-ad94-46b4-9c73-fa3a8555f352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_ac45789f-ad94-46b4-9c73-fa3a8555f352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_cdf49b8e-9918-4bae-9e4c-a05eb4d7c8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_ac45789f-ad94-46b4-9c73-fa3a8555f352" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_cdf49b8e-9918-4bae-9e4c-a05eb4d7c8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b0f168ef-8471-47bf-a74c-538a7ad39dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_cdf49b8e-9918-4bae-9e4c-a05eb4d7c8ba" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_b0f168ef-8471-47bf-a74c-538a7ad39dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bbe404b2-52b5-483f-b685-5d0e743a9dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4d9c3eb1-af62-4204-bbe7-4ffc46b8248e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bbe404b2-52b5-483f-b685-5d0e743a9dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CK1AssetsSoldToBiogenIncMember_d66da0cd-4165-4d79-bf08-dbafca2e9cac" xlink:href="pfe-20211231.xsd#pfe_CK1AssetsSoldToBiogenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bbe404b2-52b5-483f-b685-5d0e743a9dca" xlink:to="loc_pfe_CK1AssetsSoldToBiogenIncMember_d66da0cd-4165-4d79-bf08-dbafca2e9cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_335029bb-bf08-46a5-a445-e19db2215a73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_srt_CounterpartyNameAxis_335029bb-bf08-46a5-a445-e19db2215a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_335029bb-bf08-46a5-a445-e19db2215a73" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_63652194-99b1-43c0-a5fd-8bd16f0e0d59" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_BioNTechMember_63652194-99b1-43c0-a5fd-8bd16f0e0d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PumaTechnologiesMember_4592a0fb-79c1-4ad5-a11a-c2d5a11fea12" xlink:href="pfe-20211231.xsd#pfe_PumaTechnologiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_PumaTechnologiesMember_4592a0fb-79c1-4ad5-a11a-c2d5a11fea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliLillyCompanyMember_171b1550-f240-41da-ae06-e9779a7fdb56" xlink:href="pfe-20211231.xsd#pfe_EliLillyCompanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_EliLillyCompanyMember_171b1550-f240-41da-ae06-e9779a7fdb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MylanMember_c4824375-856e-4864-aa97-e1f588ff5944" xlink:href="pfe-20211231.xsd#pfe_MylanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18ccb952-c36a-463e-b4e7-f6659db520c2" xlink:to="loc_pfe_MylanMember_c4824375-856e-4864-aa97-e1f588ff5944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8d2d4d32-d2a5-433f-8be7-273dff436733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8d2d4d32-d2a5-433f-8be7-273dff436733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8d2d4d32-d2a5-433f-8be7-273dff436733" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_59ec6199-35da-4993-8e38-8318a6cc20b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:to="loc_us-gaap_CollaborativeArrangementMember_59ec6199-35da-4993-8e38-8318a6cc20b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a8e4889b-7b72-49cb-b8ea-e7cd5506fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44df693f-31d6-4eec-9f56-ad6e4387c405" xlink:to="loc_us-gaap_LicensingAgreementsMember_a8e4889b-7b72-49cb-b8ea-e7cd5506fb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_55428f58-62bd-4886-a3bc-431bc3b21a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_55428f58-62bd-4886-a3bc-431bc3b21a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73386242-75bd-4d64-aa67-a35a0785099e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_55428f58-62bd-4886-a3bc-431bc3b21a0e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73386242-75bd-4d64-aa67-a35a0785099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed89c828-accf-4d68-b765-a49984a41729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73386242-75bd-4d64-aa67-a35a0785099e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed89c828-accf-4d68-b765-a49984a41729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db753c16-2f08-497f-8f3b-87a7e3296d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_5636534f-ecf1-4f32-a0b8-a5bbcc3f356b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db753c16-2f08-497f-8f3b-87a7e3296d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5bd519fa-ff8d-49a3-9643-d4cb24f78038" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_db753c16-2f08-497f-8f3b-87a7e3296d0b" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5bd519fa-ff8d-49a3-9643-d4cb24f78038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2b8fbde9-2744-43b0-8400-6c0753cafa19" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_srt_ProductOrServiceAxis_2b8fbde9-2744-43b0-8400-6c0753cafa19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2b8fbde9-2744-43b0-8400-6c0753cafa19" xlink:to="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_8d71d0da-d66c-408c-b3c9-ebe289cf558c" xlink:href="pfe-20211231.xsd#pfe_EpiPenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:to="loc_pfe_EpiPenMember_8d71d0da-d66c-408c-b3c9-ebe289cf558c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EucrisaMember_a8819fad-b832-44d4-89df-ceae49a418fb" xlink:href="pfe-20211231.xsd#pfe_EucrisaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:to="loc_pfe_EucrisaMember_a8819fad-b832-44d4-89df-ceae49a418fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenericSterileInjectableProductMember_e04b2b85-2cc9-4e10-bb88-2c49a122c6a9" xlink:href="pfe-20211231.xsd#pfe_GenericSterileInjectableProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2dacc2c4-a653-483a-b258-f1c221ecd3f0" xlink:to="loc_pfe_GenericSterileInjectableProductMember_e04b2b85-2cc9-4e10-bb88-2c49a122c6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementAxis_e463c169-284b-40e5-ae8f-a3ea6a48545f" xlink:href="pfe-20211231.xsd#pfe_AgreementAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_pfe_AgreementAxis_e463c169-284b-40e5-ae8f-a3ea6a48545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AgreementDomain_5c64dce7-cab8-4d37-b7f3-a04e2c8baa84" xlink:href="pfe-20211231.xsd#pfe_AgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AgreementAxis_e463c169-284b-40e5-ae8f-a3ea6a48545f" xlink:to="loc_pfe_AgreementDomain_5c64dce7-cab8-4d37-b7f3-a04e2c8baa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TransitionServiceAgreementMember_3e423042-6a3a-4d73-9caf-8798295cc91e" xlink:href="pfe-20211231.xsd#pfe_TransitionServiceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AgreementDomain_5c64dce7-cab8-4d37-b7f3-a04e2c8baa84" xlink:to="loc_pfe_TransitionServiceAgreementMember_3e423042-6a3a-4d73-9caf-8798295cc91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3882ee86-a90d-451e-b3c8-bcd9c2feccb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3882ee86-a90d-451e-b3c8-bcd9c2feccb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a53c3e50-d4b3-43a9-b34f-03cdd176a803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3882ee86-a90d-451e-b3c8-bcd9c2feccb8" xlink:to="loc_us-gaap_SegmentDomain_a53c3e50-d4b3-43a9-b34f-03cdd176a803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_d5b53730-1e60-487a-9cf5-760a384f5836" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a53c3e50-d4b3-43a9-b34f-03cdd176a803" xlink:to="loc_pfe_BiopharmaSegmentMember_d5b53730-1e60-487a-9cf5-760a384f5836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_21b481d8-47ea-4802-9a6b-85a1e439faa3" xlink:to="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_7520e611-9ea4-4f4b-a808-18bc431e489d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_InterestCostsCapitalized_7520e611-9ea4-4f4b-a808-18bc431e489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d203b270-c059-45a2-9d27-e7c3da7ab439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d203b270-c059-45a2-9d27-e7c3da7ab439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_03b8aa63-a2ed-4af1-8268-3d049c065718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_ProceedsFromCollaborators_03b8aa63-a2ed-4af1-8268-3d049c065718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_805cc78e-d43c-4072-aa82-2d6ae84ebf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_805cc78e-d43c-4072-aa82-2d6ae84ebf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58cf3579-9fbe-4429-94aa-34883eae8061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_58cf3579-9fbe-4429-94aa-34883eae8061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_366a85ce-ef67-49a2-9a98-f005c3151201" xlink:href="pfe-20211231.xsd#pfe_OtherNonoperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_366a85ce-ef67-49a2-9a98-f005c3151201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_24f48639-e54b-4de5-acf7-adb363031d88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_InvestmentIncomeDividend_24f48639-e54b-4de5-acf7-adb363031d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_30545c0b-5b14-4ed5-b84c-8a2d8b53913c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_30545c0b-5b14-4ed5-b84c-8a2d8b53913c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_04f1b17b-2223-4392-b2ae-691a85cbdf9f" xlink:href="pfe-20211231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_04f1b17b-2223-4392-b2ae-691a85cbdf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c3474800-9029-4141-a953-0388d7e5b346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b202a40-e853-49a3-9390-01091cd60732" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c3474800-9029-4141-a953-0388d7e5b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMatters"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d87dabd8-8460-46da-9bce-7a207fde6a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4e3bec10-671a-41e9-b74d-b69027af10be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d87dabd8-8460-46da-9bce-7a207fde6a73" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4e3bec10-671a-41e9-b74d-b69027af10be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d1566dfe-3212-456c-9d1d-e848ffac01cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_014a2105-49d3-477d-83bb-fcb481017a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1566dfe-3212-456c-9d1d-e848ffac01cc" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_014a2105-49d3-477d-83bb-fcb481017a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_83d27c2e-2d99-409b-8148-dea265843756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1566dfe-3212-456c-9d1d-e848ffac01cc" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_83d27c2e-2d99-409b-8148-dea265843756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2aa6ec06-3745-437b-aea2-6dc4521f140e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1566dfe-3212-456c-9d1d-e848ffac01cc" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2aa6ec06-3745-437b-aea2-6dc4521f140e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dd70ecef-989f-4dca-82da-a61bd6bf81b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1566dfe-3212-456c-9d1d-e848ffac01cc" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_dd70ecef-989f-4dca-82da-a61bd6bf81b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4cab3960-c070-43b7-83ef-e4c7e043838b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1566dfe-3212-456c-9d1d-e848ffac01cc" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4cab3960-c070-43b7-83ef-e4c7e043838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_c25e72dd-f1c6-4127-b75f-5423bdab7894" xlink:href="pfe-20211231.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d1566dfe-3212-456c-9d1d-e848ffac01cc" xlink:to="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_c25e72dd-f1c6-4127-b75f-5423bdab7894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b5a9d498-7356-4566-ae2c-d941bd0917dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_002b8de5-79f6-4a1f-9da8-91a9da9535c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5a9d498-7356-4566-ae2c-d941bd0917dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_002b8de5-79f6-4a1f-9da8-91a9da9535c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3fbb87d0-5f82-45d0-b09c-4d55389b9b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5a9d498-7356-4566-ae2c-d941bd0917dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3fbb87d0-5f82-45d0-b09c-4d55389b9b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec26c768-d2c5-434b-a5eb-58c69e21572c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5a9d498-7356-4566-ae2c-d941bd0917dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ec26c768-d2c5-434b-a5eb-58c69e21572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersProvisionforTaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f3ea12e5-1a93-483f-882c-41e6426e766d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DomesticIncomeTaxesAbstract_1bf12dfb-a59a-4dbb-a20a-04de7b46a0fd" xlink:href="pfe-20211231.xsd#pfe_DomesticIncomeTaxesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3ea12e5-1a93-483f-882c-41e6426e766d" xlink:to="loc_pfe_DomesticIncomeTaxesAbstract_1bf12dfb-a59a-4dbb-a20a-04de7b46a0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0b1bab35-d437-4e63-b947-7ab0a6ef1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_1bf12dfb-a59a-4dbb-a20a-04de7b46a0fd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0b1bab35-d437-4e63-b947-7ab0a6ef1b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_010cf789-4971-443f-8855-600a1f9d4c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0b1bab35-d437-4e63-b947-7ab0a6ef1b17" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_010cf789-4971-443f-8855-600a1f9d4c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c57453f6-b24f-44c7-9b35-fb2efe359eed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0b1bab35-d437-4e63-b947-7ab0a6ef1b17" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c57453f6-b24f-44c7-9b35-fb2efe359eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_107645be-d0fa-44be-82b9-7e8ba2bb0bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_1bf12dfb-a59a-4dbb-a20a-04de7b46a0fd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_107645be-d0fa-44be-82b9-7e8ba2bb0bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e70de967-8d6c-49d0-ba69-b815877f3da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_107645be-d0fa-44be-82b9-7e8ba2bb0bf1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e70de967-8d6c-49d0-ba69-b815877f3da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9e5821b2-0e65-4394-a508-19b62e2ed1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_107645be-d0fa-44be-82b9-7e8ba2bb0bf1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9e5821b2-0e65-4394-a508-19b62e2ed1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_77ecf425-4126-426d-a8be-293774a375cd" xlink:href="pfe-20211231.xsd#pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_107645be-d0fa-44be-82b9-7e8ba2bb0bf1" xlink:to="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_77ecf425-4126-426d-a8be-293774a375cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectofTaxCutsandJobsActAbstract_0c57bf05-4c21-4c2e-b849-286b24075bb8" xlink:href="pfe-20211231.xsd#pfe_EffectofTaxCutsandJobsActAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_1bf12dfb-a59a-4dbb-a20a-04de7b46a0fd" xlink:to="loc_pfe_EffectofTaxCutsandJobsActAbstract_0c57bf05-4c21-4c2e-b849-286b24075bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_c07ef933-47fe-445b-a28a-65636e446f0f" xlink:href="pfe-20211231.xsd#pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract_0c57bf05-4c21-4c2e-b849-286b24075bb8" xlink:to="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_c07ef933-47fe-445b-a28a-65636e446f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_05795cdf-fa85-48b7-8580-8c5cdf1092e1" xlink:href="pfe-20211231.xsd#pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract_0c57bf05-4c21-4c2e-b849-286b24075bb8" xlink:to="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_05795cdf-fa85-48b7-8580-8c5cdf1092e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_1b1c2450-7585-4596-82c7-d0c76f4c0b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract_0c57bf05-4c21-4c2e-b849-286b24075bb8" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_1b1c2450-7585-4596-82c7-d0c76f4c0b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternationalIncomeTaxesAbstract_f8f468e5-b3e1-4b13-8768-4d00a0b59a51" xlink:href="pfe-20211231.xsd#pfe_InternationalIncomeTaxesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_1bf12dfb-a59a-4dbb-a20a-04de7b46a0fd" xlink:to="loc_pfe_InternationalIncomeTaxesAbstract_f8f468e5-b3e1-4b13-8768-4d00a0b59a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_078f4166-604a-4c3b-810a-4e68a456457c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract_f8f468e5-b3e1-4b13-8768-4d00a0b59a51" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_078f4166-604a-4c3b-810a-4e68a456457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e4495404-5694-488f-bc93-88436fe58a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract_f8f468e5-b3e1-4b13-8768-4d00a0b59a51" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e4495404-5694-488f-bc93-88436fe58a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_a4535593-2d4a-49ff-82e4-651760be8be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract_f8f468e5-b3e1-4b13-8768-4d00a0b59a51" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_a4535593-2d4a-49ff-82e4-651760be8be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c27328d0-395f-488b-8384-db22bae20faa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_1bf12dfb-a59a-4dbb-a20a-04de7b46a0fd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c27328d0-395f-488b-8384-db22bae20faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_734acca4-06a6-41d5-aa20-116e781c66c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_f1545397-f904-4959-937b-69c29c2429a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_734acca4-06a6-41d5-aa20-116e781c66c4" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_f1545397-f904-4959-937b-69c29c2429a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f896705d-a4e0-44eb-b58a-b6ad86484c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f1545397-f904-4959-937b-69c29c2429a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f896705d-a4e0-44eb-b58a-b6ad86484c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f896705d-a4e0-44eb-b58a-b6ad86484c59" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_58ff9da8-7c0c-4854-ad07-6c4da6aff513" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_58ff9da8-7c0c-4854-ad07-6c4da6aff513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxesPayableMember_0ea34cea-617e-4591-8942-d6fef0276a06" xlink:href="pfe-20211231.xsd#pfe_OtherTaxesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:to="loc_pfe_OtherTaxesPayableMember_0ea34cea-617e-4591-8942-d6fef0276a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_42e1d0eb-7230-404d-882e-c8ae056446b5" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxLiabilitiesNetNoncurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e6b4330c-ff51-4199-afbc-cc34a3a2caca" xlink:to="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_42e1d0eb-7230-404d-882e-c8ae056446b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f1545397-f904-4959-937b-69c29c2429a5" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b41259e2-bf30-46cf-85c5-4e4dd89249c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_b41259e2-bf30-46cf-85c5-4e4dd89249c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c6d15d94-d60f-4bf3-a92c-760a4346d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_c6d15d94-d60f-4bf3-a92c-760a4346d44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_68461758-a2a0-4c81-a5cc-7589ef247c09" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_68461758-a2a0-4c81-a5cc-7589ef247c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_abe9ed6e-d476-4b9c-9fda-f74f44a85b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_abe9ed6e-d476-4b9c-9fda-f74f44a85b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_c834882b-7e86-4897-8449-b4d6443422fe" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsExcludingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_c834882b-7e86-4897-8449-b4d6443422fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_85c77ae7-ad73-4330-b9c0-41d33e32b2e7" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_85c77ae7-ad73-4330-b9c0-41d33e32b2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_900818c6-14ab-4c82-9c1f-b9306726ec7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_900818c6-14ab-4c82-9c1f-b9306726ec7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_5c284aa6-4688-4886-9618-8107b275de79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_5c284aa6-4688-4886-9618-8107b275de79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_57144e57-4cb2-4a0c-b10e-7af6f2d0f642" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_57144e57-4cb2-4a0c-b10e-7af6f2d0f642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures_aceca776-75ac-426a-8e1b-6a1784f3960d" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures_aceca776-75ac-426a-8e1b-6a1784f3960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_697c5759-0b33-43dc-b9f3-efc25afb49e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_b909eb1d-259d-42fb-a941-759af4b85fbf" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_697c5759-0b33-43dc-b9f3-efc25afb49e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_31791d00-defc-459d-9fc3-aa3a5cb70d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_31791d00-defc-459d-9fc3-aa3a5cb70d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_a5c0db63-2e4d-410b-ac26-939d8444b3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_a5c0db63-2e4d-410b-ac26-939d8444b3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_bba285f8-0f92-4311-92d8-d050f5cfd1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_bba285f8-0f92-4311-92d8-d050f5cfd1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_d07a9875-26a7-45fb-a791-ab054d42eb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_d07a9875-26a7-45fb-a791-ab054d42eb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_0073f80f-975c-4143-a1e9-47e0559bad85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_0073f80f-975c-4143-a1e9-47e0559bad85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent_9a804a41-8c1f-4175-9fda-5e800f54c15a" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent_9a804a41-8c1f-4175-9fda-5e800f54c15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_136399f0-4bcb-48d1-81a5-60c1bf338154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_136399f0-4bcb-48d1-81a5-60c1bf338154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent_89ef1b55-9f7d-46a7-b710-cd56b5bcb08c" xlink:href="pfe-20211231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent_89ef1b55-9f7d-46a7-b710-cd56b5bcb08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d4d27163-741c-4bd8-9fcb-bba22e9cb714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d4d27163-741c-4bd8-9fcb-bba22e9cb714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_717a4047-0d1e-42f5-af7a-7e354df31f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5f09629f-22a1-4d14-bc04-0e48cfaa7b59" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_717a4047-0d1e-42f5-af7a-7e354df31f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_157452ae-861b-4c74-84d2-af43f3e32ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_157452ae-861b-4c74-84d2-af43f3e32ba7" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_0099a3a7-64b1-4e45-bac1-6f46eea2d33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_0099a3a7-64b1-4e45-bac1-6f46eea2d33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_e0a0b0fe-109e-427a-831e-4914b97c6085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_e0a0b0fe-109e-427a-831e-4914b97c6085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_96cf6766-ee1f-41a7-a7d9-534309fb2adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_96cf6766-ee1f-41a7-a7d9-534309fb2adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_5ac0937e-62f6-4c03-8447-1e37b44aa26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_5ac0937e-62f6-4c03-8447-1e37b44aa26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_b6763a66-aea7-4a37-8cd9-8352a5dd520f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_b6763a66-aea7-4a37-8cd9-8352a5dd520f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_c04bcad1-611d-4800-bb8a-ec53b34160f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_c04bcad1-611d-4800-bb8a-ec53b34160f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_bf3fe3e6-4983-4d43-900b-aee159a74c0c" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_bf3fe3e6-4983-4d43-900b-aee159a74c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_8b388911-a09a-4302-9a44-d710e2c18ead" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_8b388911-a09a-4302-9a44-d710e2c18ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_b67e3bcf-3abc-4a89-b9f0-3dd2888feae4" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_b67e3bcf-3abc-4a89-b9f0-3dd2888feae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_32effa8d-4d9c-4484-b83e-fd4ef70bd654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_32effa8d-4d9c-4484-b83e-fd4ef70bd654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_6f9cc2a6-0e2c-42ff-a0bf-0314874d231f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_6f9cc2a6-0e2c-42ff-a0bf-0314874d231f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ce4849ad-04dd-4b7b-9fb7-f297a3c0e675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ce4849ad-04dd-4b7b-9fb7-f297a3c0e675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0cc61631-f8fb-4088-a13c-f3f3b3844063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0cc61631-f8fb-4088-a13c-f3f3b3844063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_cd560206-061f-4ec9-8597-1f9dd124fdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_4048cd17-96bd-4c25-ba8c-14f3815e7776" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_cd560206-061f-4ec9-8597-1f9dd124fdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_157452ae-861b-4c74-84d2-af43f3e32ba7" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_c417e1d3-dcc1-40fd-a669-fbec6ee6edfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_c417e1d3-dcc1-40fd-a669-fbec6ee6edfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_83f9039a-b21a-400e-9256-9c14268ce0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_83f9039a-b21a-400e-9256-9c14268ce0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_50f8c27c-2796-485e-901d-e8b4ddc2dd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_50f8c27c-2796-485e-901d-e8b4ddc2dd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_df4d7fe6-9bb0-47af-b9d9-a1b66aded7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_df4d7fe6-9bb0-47af-b9d9-a1b66aded7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_3ae38a2d-f4ef-4522-8904-a426af7cdf30" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_3ae38a2d-f4ef-4522-8904-a426af7cdf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_560e61cd-0c77-49df-b64c-49d876772560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_560e61cd-0c77-49df-b64c-49d876772560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_bad2baf3-21bc-4699-9977-611c5a182138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_bad2baf3-21bc-4699-9977-611c5a182138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_a98cf8da-751d-4cc0-bc9d-97c768a13143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_a98cf8da-751d-4cc0-bc9d-97c768a13143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8195259d-8f01-48e8-bfae-8e8448be5b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_48ea6a4a-ddf6-4537-b82a-844d08b868b1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8195259d-8f01-48e8-bfae-8e8448be5b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_16263558-b188-42d4-b025-535b185faee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_157452ae-861b-4c74-84d2-af43f3e32ba7" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_16263558-b188-42d4-b025-535b185faee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_b3ba9d49-b7ed-4929-bd60-d21bf36d30a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_157452ae-861b-4c74-84d2-af43f3e32ba7" xlink:to="loc_us-gaap_DeferredTaxLiabilities_b3ba9d49-b7ed-4929-bd60-d21bf36d30a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersDeferredTaxesFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_24d238ea-8129-463a-a2fa-ff21bb4e7b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_5cebcfcf-2bac-40db-8a53-2258ea9685a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24d238ea-8129-463a-a2fa-ff21bb4e7b90" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_5cebcfcf-2bac-40db-8a53-2258ea9685a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_0e418e42-67da-4ee4-b3cc-10c3c31650d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_5cebcfcf-2bac-40db-8a53-2258ea9685a3" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_0e418e42-67da-4ee4-b3cc-10c3c31650d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_0e418e42-67da-4ee4-b3cc-10c3c31650d0" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_b4877856-c60f-449c-ab38-5aa937798d60" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_b4877856-c60f-449c-ab38-5aa937798d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_01ba9a23-8ac0-4631-add9-7b2bd68e671a" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_617e2d48-113a-48e5-8837-f88e9c4678a9" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_01ba9a23-8ac0-4631-add9-7b2bd68e671a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_5cebcfcf-2bac-40db-8a53-2258ea9685a3" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_8cc445a7-bce5-4c3f-9d62-347fd53e9fe1" xlink:href="pfe-20211231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_8cc445a7-bce5-4c3f-9d62-347fd53e9fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_0971729e-2bbb-41e1-8119-4ecb27279412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7f7ddc7c-4733-43e0-a817-1bcbf2a54c5d" xlink:to="loc_us-gaap_DeferredTaxLiabilities_0971729e-2bbb-41e1-8119-4ecb27279412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cce03b08-8105-45b1-866e-4b654423ca23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cce03b08-8105-45b1-866e-4b654423ca23" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e242cc22-d2c7-4f6a-998e-facc2c6d70a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e242cc22-d2c7-4f6a-998e-facc2c6d70a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition_201a0c42-51d7-4b39-8abc-949339e1357c" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition_201a0c42-51d7-4b39-8abc-949339e1357c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures_0a78db0f-7cff-476b-a632-4a0328d536ff" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures_0a78db0f-7cff-476b-a632-4a0328d536ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7bdc2a3b-b7a5-4af3-8753-dd701fcb1e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7bdc2a3b-b7a5-4af3-8753-dd701fcb1e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_71baf323-4ed4-40ff-9982-d5f26f6cb474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_71baf323-4ed4-40ff-9982-d5f26f6cb474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_38ef0d88-0c2f-4d8c-9046-42cb70b3c884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_38ef0d88-0c2f-4d8c-9046-42cb70b3c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_219d9dc2-b261-481a-89e6-2fbad24a8a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_219d9dc2-b261-481a-89e6-2fbad24a8a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_70312eb9-43e3-4595-a602-008d7ba54a1c" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_70312eb9-43e3-4595-a602-008d7ba54a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_d1274613-f422-4cc0-9e29-8afbda097499" xlink:href="pfe-20211231.xsd#pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_d1274613-f422-4cc0-9e29-8afbda097499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ccf72196-2523-4018-b472-9aa780e76525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_c8fcf36f-0786-4165-948a-783fdf80c83c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ccf72196-2523-4018-b472-9aa780e76525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f566a2ce-9abb-473f-bc6e-c69f44ed5f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_1926cb51-bd56-48c9-b782-8f6e75a0e459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f566a2ce-9abb-473f-bc6e-c69f44ed5f24" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_1926cb51-bd56-48c9-b782-8f6e75a0e459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a00490bc-bf79-4f27-ad15-e2a7e26e08ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1926cb51-bd56-48c9-b782-8f6e75a0e459" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a00490bc-bf79-4f27-ad15-e2a7e26e08ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a00490bc-bf79-4f27-ad15-e2a7e26e08ff" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeTaxesPayableMember_29696350-bc58-4e6e-bc97-833bcc079492" xlink:href="pfe-20211231.xsd#pfe_IncomeTaxesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_IncomeTaxesPayableMember_29696350-bc58-4e6e-bc97-833bcc079492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CurrentTaxAssetsMember_ff2d01be-fdd0-4a7a-a2b7-7a78ffd63867" xlink:href="pfe-20211231.xsd#pfe_CurrentTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_CurrentTaxAssetsMember_ff2d01be-fdd0-4a7a-a2b7-7a78ffd63867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_1ae12ccc-1ef5-424e-b7e1-f59f8de40140" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_1ae12ccc-1ef5-424e-b7e1-f59f8de40140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_dd66f46b-722b-4b53-be9c-a6006ad2149f" xlink:href="pfe-20211231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_dd66f46b-722b-4b53-be9c-a6006ad2149f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherTaxesPayableMember_6bf499e3-3356-4daf-9829-b3807d3bf67b" xlink:href="pfe-20211231.xsd#pfe_OtherTaxesPayableMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f78a993a-e67b-4b6b-bfb1-521cd4ff67af" xlink:to="loc_pfe_OtherTaxesPayableMember_6bf499e3-3356-4daf-9829-b3807d3bf67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_4962c40b-7f65-4720-8f02-e9843b217139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_1926cb51-bd56-48c9-b782-8f6e75a0e459" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_4962c40b-7f65-4720-8f02-e9843b217139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_d21b06e8-386b-42ba-8240-7507315a7aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_4962c40b-7f65-4720-8f02-e9843b217139" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_d21b06e8-386b-42ba-8240-7507315a7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_45c6f2a0-6fbf-42df-aa4e-6150417301ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_45c6f2a0-6fbf-42df-aa4e-6150417301ca" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f2664dee-327c-47eb-a4d8-8fd1b6f13db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f2664dee-327c-47eb-a4d8-8fd1b6f13db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_25a0fd37-9373-4db1-b814-5eebb258de6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_25a0fd37-9373-4db1-b814-5eebb258de6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_966d6330-0af2-4b3d-a9dc-daa118df62d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_966d6330-0af2-4b3d-a9dc-daa118df62d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_b76ad5c0-76db-4a44-9e2d-f17bd9082f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_b76ad5c0-76db-4a44-9e2d-f17bd9082f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_84579367-ba06-4741-b957-a0f31b0ee831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_84579367-ba06-4741-b957-a0f31b0ee831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_92a05e4c-606d-4104-8f4d-c41af87db8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_92a05e4c-606d-4104-8f4d-c41af87db8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_f78095ec-82cf-4ca1-b9ac-9e0093f860c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_f78095ec-82cf-4ca1-b9ac-9e0093f860c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_440b2fbc-3d85-46ef-8a2c-5248f4786ae8" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_440b2fbc-3d85-46ef-8a2c-5248f4786ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_8ff1454b-e8f2-47e6-a152-7bad7907a2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_8ff1454b-e8f2-47e6-a152-7bad7907a2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_02e187ae-291f-40e0-ab24-485b6c18ad5b" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_02e187ae-291f-40e0-ab24-485b6c18ad5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_05c802e6-1c56-4f86-bb27-509d02bccc65" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_05c802e6-1c56-4f86-bb27-509d02bccc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_d6b37a48-2d6b-4a38-8322-8492dd3cb7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_d6b37a48-2d6b-4a38-8322-8492dd3cb7ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3ebc5bf4-019b-4578-a15a-0fdf1db79e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_b9f2ab42-4ebe-4fa9-8eae-dee78556fc7f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_3ebc5bf4-019b-4578-a15a-0fdf1db79e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" xlink:href="pfe-20211231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_badad960-176a-4645-988a-adcfe39cc8de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5656e67b-1bd9-4601-9a64-164ad49f8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_badad960-176a-4645-988a-adcfe39cc8de" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5656e67b-1bd9-4601-9a64-164ad49f8eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_45c24589-a1eb-435a-b3f8-1ef6e9cc991e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5422099c-99d6-473b-bea5-bb6e58cca11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_45c24589-a1eb-435a-b3f8-1ef6e9cc991e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5422099c-99d6-473b-bea5-bb6e58cca11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ca1e7506-5d1b-4388-a2e8-b3ce59c4cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3c0995f-7bad-4a7d-a8d4-9ecf897ae85a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ca1e7506-5d1b-4388-a2e8-b3ce59c4cf9a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3c0995f-7bad-4a7d-a8d4-9ecf897ae85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3c0995f-7bad-4a7d-a8d4-9ecf897ae85a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_739e5cca-b905-413e-9f40-fdbfde73bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f7d6dc0f-be3f-4846-b2ff-3daa81bf5f77" xlink:to="loc_us-gaap_EquityComponentDomain_739e5cca-b905-413e-9f40-fdbfde73bbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_739e5cca-b905-413e-9f40-fdbfde73bbe4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aa1e4844-94e5-479c-8d69-567402e1e4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_aa1e4844-94e5-479c-8d69-567402e1e4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c4142e64-22c6-451d-bcd5-c7c36c8e801f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c4142e64-22c6-451d-bcd5-c7c36c8e801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8522b3f8-c90e-42e4-abf9-1563bb21f18a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_8522b3f8-c90e-42e4-abf9-1563bb21f18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8e66615f-cb8e-485a-bdb0-4203cbb2d422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8325e763-626e-4f74-b741-bba71d215510" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_8e66615f-cb8e-485a-bdb0-4203cbb2d422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33b8301f-8f30-480c-bf14-38a4db79bd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f3c0995f-7bad-4a7d-a8d4-9ecf897ae85a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33b8301f-8f30-480c-bf14-38a4db79bd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_33b8301f-8f30-480c-bf14-38a4db79bd07" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da5f041e-376f-48b3-908d-5fab485dc274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da5f041e-376f-48b3-908d-5fab485dc274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c1d9b868-451c-45c8-afac-9a840f72c15c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c1d9b868-451c-45c8-afac-9a840f72c15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_41b1e25b-dad9-422a-a7d3-72a875903a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_41b1e25b-dad9-422a-a7d3-72a875903a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a85df586-9752-4a12-9c06-3a3b41c0b78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4f8a90bc-7f32-4fde-8a1a-634d96b90b04" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a85df586-9752-4a12-9c06-3a3b41c0b78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_99e9dd13-16bd-4fac-9131-b85cb005cba0" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_450ff7b5-355c-4027-9c3a-ca73daad0277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_99e9dd13-16bd-4fac-9131-b85cb005cba0" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_450ff7b5-355c-4027-9c3a-ca73daad0277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5a738446-eab7-438f-9369-a9404b71c5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5a738446-eab7-438f-9369-a9404b71c5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_a67d1892-d51e-4637-bd55-034ddab66150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_a67d1892-d51e-4637-bd55-034ddab66150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c1139a19-5691-41ff-9404-5cf5759d438f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_c1139a19-5691-41ff-9404-5cf5759d438f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d6b09e57-0323-46d0-bcc5-0a498ff9f741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d6b09e57-0323-46d0-bcc5-0a498ff9f741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_c7581efe-0e96-4578-8a60-558872f3a85e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_c7581efe-0e96-4578-8a60-558872f3a85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_d03b006b-b08d-4692-9606-39710edc7508" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_d03b006b-b08d-4692-9606-39710edc7508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_f9f46996-9abd-4d64-8866-d2a316b3b17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_f9f46996-9abd-4d64-8866-d2a316b3b17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_883dbdfd-9257-4c4e-9b6c-099d9bc574de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_883dbdfd-9257-4c4e-9b6c-099d9bc574de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_38179a19-ac5a-4d2d-a84c-f3ac7f77f7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_38179a19-ac5a-4d2d-a84c-f3ac7f77f7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_0344f391-d22a-4284-85f2-3ab0554be8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_0344f391-d22a-4284-85f2-3ab0554be8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_86988eff-cccd-4366-b2b0-280402012f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_86988eff-cccd-4366-b2b0-280402012f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d292b4d8-40c7-493b-9145-b1c20146b94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_d292b4d8-40c7-493b-9145-b1c20146b94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7cec3737-825a-49de-963d-bc3c1d0648ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_7cec3737-825a-49de-963d-bc3c1d0648ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c2f842ad-4159-47ad-b44a-2a279ab7c40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_04bee422-d980-41b2-aa05-4fd62eeb2bb5" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c2f842ad-4159-47ad-b44a-2a279ab7c40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_334e4ab5-9733-4d21-bade-82495367a27a" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_334e4ab5-9733-4d21-bade-82495367a27a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3f333c70-4ae0-4304-bc63-809e30ef64dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3f333c70-4ae0-4304-bc63-809e30ef64dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3f333c70-4ae0-4304-bc63-809e30ef64dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_c17f3021-6347-4314-b34f-88991920be2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_c17f3021-6347-4314-b34f-88991920be2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f8c87a5d-71cd-4201-83f7-1d5be8e31264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f8c87a5d-71cd-4201-83f7-1d5be8e31264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsMember_8c0e00c3-e3c1-4359-8d35-8fb2ec174a22" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_pfe_LongtermInvestmentsMember_8c0e00c3-e3c1-4359-8d35-8fb2ec174a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_28b94050-10a7-4a3b-bada-8e981fc10fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_28b94050-10a7-4a3b-bada-8e981fc10fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_140225d1-69b2-45b6-8a52-adeaaa46882b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_140225d1-69b2-45b6-8a52-adeaaa46882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c8f2f0d7-7de9-4305-add2-8ebc209903da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_66589d47-3096-4b54-9466-986bd9d78db8" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c8f2f0d7-7de9-4305-add2-8ebc209903da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_576c9473-9064-4611-9d99-a36b82f54438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_576c9473-9064-4611-9d99-a36b82f54438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_576c9473-9064-4611-9d99-a36b82f54438" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3d54b6d8-1306-4355-abc6-f2e1c67aa1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3d54b6d8-1306-4355-abc6-f2e1c67aa1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_efb9dad2-bd8b-4597-9bf7-71cf31d1f47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4789055a-6e66-48d3-8582-4c117081ab3c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_efb9dad2-bd8b-4597-9bf7-71cf31d1f47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1f07c9a9-82c9-4db9-8c79-2c279e0388f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1f07c9a9-82c9-4db9-8c79-2c279e0388f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1f07c9a9-82c9-4db9-8c79-2c279e0388f1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_65034358-478b-48be-912b-c0af695fc2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_65034358-478b-48be-912b-c0af695fc2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4e5b044d-72c6-48e6-9217-b7b958c7975c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4e5b044d-72c6-48e6-9217-b7b958c7975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6ef22e8b-d4db-4a11-927d-b4f3e88e830e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_6ef22e8b-d4db-4a11-927d-b4f3e88e830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8123842d-2af1-440d-b28f-07edb70f927e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f4e292bb-cdd2-401f-8eac-108bd2f8d7f8" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8123842d-2af1-440d-b28f-07edb70f927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1ba6146f-6be5-4d37-9099-ca188626e248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1ba6146f-6be5-4d37-9099-ca188626e248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d253cb1e-d47f-426e-b516-a2a06db2171f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1ba6146f-6be5-4d37-9099-ca188626e248" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d253cb1e-d47f-426e-b516-a2a06db2171f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e909813f-87ed-4a2f-8748-29ad5b41657b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d253cb1e-d47f-426e-b516-a2a06db2171f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e909813f-87ed-4a2f-8748-29ad5b41657b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_53024de0-0d7c-458e-bdc9-f727cd63c74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_53024de0-0d7c-458e-bdc9-f727cd63c74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_53024de0-0d7c-458e-bdc9-f727cd63c74a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_95af2d34-b62d-44b7-93a7-1062aee05db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:to="loc_us-gaap_InterestRateContractMember_95af2d34-b62d-44b7-93a7-1062aee05db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_034f5b97-34db-4c00-8a77-41513dbbfebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a7095725-2e61-4825-9ecf-295db89ef122" xlink:to="loc_us-gaap_ForeignExchangeContractMember_034f5b97-34db-4c00-8a77-41513dbbfebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4db9c9f-6af1-4c37-bbfa-f04a501114c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_95acdaec-b3fe-403e-9029-e1b0e34fb67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_95acdaec-b3fe-403e-9029-e1b0e34fb67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8d4e5d7b-c59c-4ff5-b267-96ed6c01a772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8d4e5d7b-c59c-4ff5-b267-96ed6c01a772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_b32e2c13-3043-4b68-b66e-7902c01ea041" xlink:href="pfe-20211231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_b32e2c13-3043-4b68-b66e-7902c01ea041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_ab914fd2-143d-46d8-ae51-5af7c7d3b096" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_ab914fd2-143d-46d8-ae51-5af7c7d3b096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_47a44055-c6e4-465e-9071-7c7b24c3b297" xlink:href="pfe-20211231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_47a44055-c6e4-465e-9071-7c7b24c3b297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_33d946e6-fe62-4b5a-bf75-c4af4f94b9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_33d946e6-fe62-4b5a-bf75-c4af4f94b9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_d41e937d-c56b-41ee-aa24-35996cf709b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_d41e937d-c56b-41ee-aa24-35996cf709b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_366f7551-48d0-4b7e-b2bb-8bc082400e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_366f7551-48d0-4b7e-b2bb-8bc082400e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0bae91e8-dab2-41a5-8026-e4d14758e4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_Assets_0bae91e8-dab2-41a5-8026-e4d14758e4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_189f7cdb-6c1a-409f-a44f-848a4d7aaa54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_189f7cdb-6c1a-409f-a44f-848a4d7aaa54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_12d1a6a9-f61c-4411-9abe-3a5e04672117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_12d1a6a9-f61c-4411-9abe-3a5e04672117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f828ae38-f283-4df4-b063-3bf342cdac08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_56c1ce0b-4b85-432f-8848-3316c0d9f586" xlink:to="loc_us-gaap_DerivativeLiabilities_f828ae38-f283-4df4-b063-3bf342cdac08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_bddae7ec-ef8b-4b01-a49d-e51a053930bd" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78279083-4f41-4006-a585-61a21624932f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_bddae7ec-ef8b-4b01-a49d-e51a053930bd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78279083-4f41-4006-a585-61a21624932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_243cb21b-1195-4af3-8ebf-4fdd22d8b33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78279083-4f41-4006-a585-61a21624932f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_243cb21b-1195-4af3-8ebf-4fdd22d8b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_25503260-3ed3-4d84-9be8-47316f5951e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_243cb21b-1195-4af3-8ebf-4fdd22d8b33e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_25503260-3ed3-4d84-9be8-47316f5951e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0cff12-8097-4072-bac2-d66953624b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_25503260-3ed3-4d84-9be8-47316f5951e2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4f0cff12-8097-4072-bac2-d66953624b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f510774e-031b-4e23-b970-ccdf23a8c16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_78279083-4f41-4006-a585-61a21624932f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f510774e-031b-4e23-b970-ccdf23a8c16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ea333bf0-9b08-47e4-93e8-f00e7a91349c" xlink:href="pfe-20211231.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f510774e-031b-4e23-b970-ccdf23a8c16c" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_ea333bf0-9b08-47e4-93e8-f00e7a91349c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_6e4eaadc-598b-4925-8200-fa0e101dbf84" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_6e4eaadc-598b-4925-8200-fa0e101dbf84" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2aeaca15-e4bb-470e-ba48-6c4f791282eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2aeaca15-e4bb-470e-ba48-6c4f791282eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13a4f03d-9759-451a-b6db-12e654f66608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2aeaca15-e4bb-470e-ba48-6c4f791282eb" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13a4f03d-9759-451a-b6db-12e654f66608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ea55cf58-6b3e-4cf7-b611-ec4fa54865db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13a4f03d-9759-451a-b6db-12e654f66608" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ea55cf58-6b3e-4cf7-b611-ec4fa54865db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_be452e45-efaf-4b79-ac6b-8f61a503d56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_be452e45-efaf-4b79-ac6b-8f61a503d56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_be452e45-efaf-4b79-ac6b-8f61a503d56c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1e459cd6-9f3a-46fe-be6c-c67fde433b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1e459cd6-9f3a-46fe-be6c-c67fde433b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6be90e8d-fb62-4bbc-aa7a-db8bf8aa0218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c174d172-27ff-4f42-81ce-8135b06b84e4" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_6be90e8d-fb62-4bbc-aa7a-db8bf8aa0218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_653b3634-26b3-4736-af7b-5e9838c96c41" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7b992823-1d8c-45d0-b8af-3a9ec645717e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7b992823-1d8c-45d0-b8af-3a9ec645717e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_466287c4-2143-45a1-a7a1-d4e9258c00f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_837b4f75-6585-4622-97f6-58bee9074967" xlink:to="loc_us-gaap_LongTermDebtFairValue_466287c4-2143-45a1-a7a1-d4e9258c00f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_799eb65d-6d21-4509-bed8-2cd474ccca93" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_3c2936af-cde0-4eda-9421-4e29f20b22e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_799eb65d-6d21-4509-bed8-2cd474ccca93" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_3c2936af-cde0-4eda-9421-4e29f20b22e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c4159ab9-8bb9-4674-b786-12c10a2c6555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_3c2936af-cde0-4eda-9421-4e29f20b22e8" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c4159ab9-8bb9-4674-b786-12c10a2c6555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_24aad07e-8922-4732-8009-40ad3136a0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_3c2936af-cde0-4eda-9421-4e29f20b22e8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_24aad07e-8922-4732-8009-40ad3136a0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_fd861f36-adf2-4ca6-a406-d9e39197b76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_3c2936af-cde0-4eda-9421-4e29f20b22e8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_fd861f36-adf2-4ca6-a406-d9e39197b76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_dbc539a1-c880-4d7f-bf3d-c27cd3a59fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_3c2936af-cde0-4eda-9421-4e29f20b22e8" xlink:to="loc_us-gaap_OtherShortTermInvestments_dbc539a1-c880-4d7f-bf3d-c27cd3a59fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_2033049a-09b6-4b8d-a0c1-28b22e27a569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_799eb65d-6d21-4509-bed8-2cd474ccca93" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_2033049a-09b6-4b8d-a0c1-28b22e27a569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_edfa8cb7-52e0-4509-96b5-8f8c8b33014e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_2033049a-09b6-4b8d-a0c1-28b22e27a569" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_edfa8cb7-52e0-4509-96b5-8f8c8b33014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ab44361e-4fcd-4522-89ef-a776a01164ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_2033049a-09b6-4b8d-a0c1-28b22e27a569" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ab44361e-4fcd-4522-89ef-a776a01164ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_c7c6d1c9-dee9-4461-b9a7-76998c79d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_2033049a-09b6-4b8d-a0c1-28b22e27a569" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_c7c6d1c9-dee9-4461-b9a7-76998c79d6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrivateEquityInvestments_e4765e3b-89b5-4fb6-b1c2-2cf7dacd40a0" xlink:href="pfe-20211231.xsd#pfe_PrivateEquityInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_2033049a-09b6-4b8d-a0c1-28b22e27a569" xlink:to="loc_pfe_PrivateEquityInvestments_e4765e3b-89b5-4fb6-b1c2-2cf7dacd40a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_57539aa2-b983-4e93-b913-107a2656a3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_2033049a-09b6-4b8d-a0c1-28b22e27a569" xlink:to="loc_us-gaap_OtherLongTermInvestments_57539aa2-b983-4e93-b913-107a2656a3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6fd9ffe9-ff7d-4c63-a8b8-2dc36456609e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_799eb65d-6d21-4509-bed8-2cd474ccca93" xlink:to="loc_us-gaap_EquityMethodInvestments_6fd9ffe9-ff7d-4c63-a8b8-2dc36456609e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_1d5bbb7e-607b-415d-9c94-de61e7fa6f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_799eb65d-6d21-4509-bed8-2cd474ccca93" xlink:to="loc_us-gaap_LongTermInvestments_1d5bbb7e-607b-415d-9c94-de61e7fa6f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldToMaturityCashEquivalents_206da784-db83-4cba-a93c-14b240404d0b" xlink:href="pfe-20211231.xsd#pfe_HeldToMaturityCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_799eb65d-6d21-4509-bed8-2cd474ccca93" xlink:to="loc_pfe_HeldToMaturityCashEquivalents_206da784-db83-4cba-a93c-14b240404d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsDebtSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_1bf97be5-3e3d-47fc-8941-af6d502e2cd2" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_bfe78fd8-34c3-494d-a9af-940f55e752f0" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1bf97be5-3e3d-47fc-8941-af6d502e2cd2" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_bfe78fd8-34c3-494d-a9af-940f55e752f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_23a82e94-4a53-4338-8351-0741856301c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_bfe78fd8-34c3-494d-a9af-940f55e752f0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_23a82e94-4a53-4338-8351-0741856301c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_23a82e94-4a53-4338-8351-0741856301c7" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_32512497-f4ee-43af-8689-f8c975c740d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_32512497-f4ee-43af-8689-f8c975c740d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b6cc6d8d-a36a-4c7c-8222-88c150adbf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_b6cc6d8d-a36a-4c7c-8222-88c150adbf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_faeece48-d356-488a-b2a5-21c0713e03cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_faeece48-d356-488a-b2a5-21c0713e03cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_ae4d30f1-9f61-4a46-a5b9-831ffc43a7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb64d9ba-ce10-4956-a28a-077de02f2a63" xlink:to="loc_us-gaap_BankTimeDepositsMember_ae4d30f1-9f61-4a46-a5b9-831ffc43a7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_bfe78fd8-34c3-494d-a9af-940f55e752f0" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd0e7f02-0b63-44d9-83f2-34635193e5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_bd0e7f02-0b63-44d9-83f2-34635193e5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9dc94171-cc53-4464-9c4b-4e008aa1f110" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9dc94171-cc53-4464-9c4b-4e008aa1f110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_504c8c05-eb69-42de-92c5-654a684cac52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_504c8c05-eb69-42de-92c5-654a684cac52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5735063b-2675-4493-8226-21c8d92f9bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_061a8f20-9f27-4e99-a777-73e497f53521" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5735063b-2675-4493-8226-21c8d92f9bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_52e63c8e-d67b-4fc4-bac9-0e04c03562e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_52e63c8e-d67b-4fc4-bac9-0e04c03562e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c78b01bc-d67a-45f8-8e6a-2037b972db48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_c78b01bc-d67a-45f8-8e6a-2037b972db48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_8ce861e3-efd6-4eee-957c-6694b37e9c2d" xlink:href="pfe-20211231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_8ce861e3-efd6-4eee-957c-6694b37e9c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf8506da-4c38-487f-b552-b938a229f532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_60232757-1992-4405-807c-a52f93663fe5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf8506da-4c38-487f-b552-b938a229f532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_17ed03de-2c01-4d52-90c3-dba0ddb0cf25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecurities_17ed03de-2c01-4d52-90c3-dba0ddb0cf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_3cd77058-199a-46c6-81f3-5e20e9451623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_3cd77058-199a-46c6-81f3-5e20e9451623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_423a0380-5cac-47a1-a07e-31ff57f598dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_423a0380-5cac-47a1-a07e-31ff57f598dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_8421a297-d2f7-4715-bb65-53e3e4ab1aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_4695be38-4c3f-4c7e-8021-29b2e406230c" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_8421a297-d2f7-4715-bb65-53e3e4ab1aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_06df3125-486e-4a2a-91c3-f8755019bfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_06df3125-486e-4a2a-91c3-f8755019bfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb1d7bfe-c117-48c5-8696-979497ad3633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_fb1d7bfe-c117-48c5-8696-979497ad3633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_4f132446-5226-4521-9647-c5f3a514d55e" xlink:href="pfe-20211231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_8461c6f4-4919-41ff-83cf-05f637a2b898" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_4f132446-5226-4521-9647-c5f3a514d55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_bbd0ecb1-d0d7-4411-aca3-192d61e276d7" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_bbd0ecb1-d0d7-4411-aca3-192d61e276d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_c152444e-091c-4875-a234-e7c69a3f5803" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_c152444e-091c-4875-a234-e7c69a3f5803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_188b9423-3054-45ff-a749-0b614a99ba87" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_188b9423-3054-45ff-a749-0b614a99ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_db14c376-bdf5-4f77-b6ea-4314d92d50b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_db14c376-bdf5-4f77-b6ea-4314d92d50b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_81495125-339d-4a3a-b409-334f99589797" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_81495125-339d-4a3a-b409-334f99589797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_c0562757-daa6-47c4-a780-f207e8f23783" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_c0562757-daa6-47c4-a780-f207e8f23783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_6e48cd4d-af6e-4756-b259-4a407387b536" xlink:href="pfe-20211231.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_42b3e806-d362-458d-89fc-720603f3e2e2" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_6e48cd4d-af6e-4756-b259-4a407387b536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_af1f4714-25d1-458b-943b-d2645ac42a98" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_69ccc25d-bce4-4fd8-9671-bc95c2ffb93f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_af1f4714-25d1-458b-943b-d2645ac42a98" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_69ccc25d-bce4-4fd8-9671-bc95c2ffb93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_451cf903-0c49-4612-ae76-5bacd0a7514c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_af1f4714-25d1-458b-943b-d2645ac42a98" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_451cf903-0c49-4612-ae76-5bacd0a7514c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1cd396d8-346f-4ad8-a829-764344557815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_af1f4714-25d1-458b-943b-d2645ac42a98" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1cd396d8-346f-4ad8-a829-764344557815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_2ca49d17-50da-4561-b524-6bb12979cf31" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_ce8d2f8a-076e-40ab-b714-8cd04b35fee8" xlink:href="pfe-20211231.xsd#pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2ca49d17-50da-4561-b524-6bb12979cf31" xlink:to="loc_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount_ce8d2f8a-076e-40ab-b714-8cd04b35fee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_5b44fd81-0073-4ae8-bbc5-7538927d0f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2ca49d17-50da-4561-b524-6bb12979cf31" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_5b44fd81-0073-4ae8-bbc5-7538927d0f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_a337ecb4-12cb-485b-b541-6ee191020018" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_a337ecb4-12cb-485b-b541-6ee191020018" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_917dbfa6-5ae5-4327-8ad1-e0ec809569b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:to="loc_us-gaap_DebtInstrumentAxis_917dbfa6-5ae5-4327-8ad1-e0ec809569b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0974612b-de2c-497e-ab3a-82c8561fb727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_917dbfa6-5ae5-4327-8ad1-e0ec809569b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0974612b-de2c-497e-ab3a-82c8561fb727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CreditFacilityExpiring2025Member_8a8685ed-5948-46ce-8f97-f16b91534252" xlink:href="pfe-20211231.xsd#pfe_CreditFacilityExpiring2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0974612b-de2c-497e-ab3a-82c8561fb727" xlink:to="loc_pfe_CreditFacilityExpiring2025Member_8a8685ed-5948-46ce-8f97-f16b91534252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7e7e8d48-9592-4445-9faa-7bad1a35de05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:to="loc_us-gaap_CreditFacilityAxis_7e7e8d48-9592-4445-9faa-7bad1a35de05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_81be2a7c-f363-4a3a-979a-56f51afee3af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7e7e8d48-9592-4445-9faa-7bad1a35de05" xlink:to="loc_us-gaap_CreditFacilityDomain_81be2a7c-f363-4a3a-979a-56f51afee3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e261682f-ee6f-4282-94f2-15217c453e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_81be2a7c-f363-4a3a-979a-56f51afee3af" xlink:to="loc_us-gaap_LineOfCreditMember_e261682f-ee6f-4282-94f2-15217c453e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_655d6008-c6e1-4b92-a51a-82b5e1a599de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_655d6008-c6e1-4b92-a51a-82b5e1a599de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_82fa5b44-0ad0-4e60-9928-752061f7087f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_655d6008-c6e1-4b92-a51a-82b5e1a599de" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_82fa5b44-0ad0-4e60-9928-752061f7087f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_95673560-8cec-4e0d-9a90-ffe587648a99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_82fa5b44-0ad0-4e60-9928-752061f7087f" xlink:to="loc_us-gaap_CommercialPaperMember_95673560-8cec-4e0d-9a90-ffe587648a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1bc3031c-9bb7-40af-bcc5-407979ece968" xlink:to="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaper_24ea1b4e-9ed7-4722-841a-d1da00aa0e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaper"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_CommercialPaper_24ea1b4e-9ed7-4722-841a-d1da00aa0e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_6e4f2128-49d7-40f1-90a4-13a7bc44d3d6" xlink:href="pfe-20211231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_6e4f2128-49d7-40f1-90a4-13a7bc44d3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_484e1693-a1ab-4c48-9c63-d28b0d617c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_OtherShortTermBorrowings_484e1693-a1ab-4c48-9c63-d28b0d617c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShorttermDebtGross_05e024fe-c126-4abd-bef5-9e44e0a32400" xlink:href="pfe-20211231.xsd#pfe_ShorttermDebtGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_pfe_ShorttermDebtGross_05e024fe-c126-4abd-bef5-9e44e0a32400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_337bc63b-b5c6-4360-af7d-2e75b63405dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_337bc63b-b5c6-4360-af7d-2e75b63405dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_0b7987d5-e2ac-4a40-98cf-b637864ca704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_DebtCurrent_0b7987d5-e2ac-4a40-98cf-b637864ca704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_97ade02a-0809-41f1-98b0-db087104ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_97ade02a-0809-41f1-98b0-db087104ac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_66af32d9-5eeb-4747-8c9f-3f8adfb430bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_66af32d9-5eeb-4747-8c9f-3f8adfb430bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_5629fa5b-2efa-4ad7-b4d0-daaaa129ad81" xlink:href="pfe-20211231.xsd#pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_74f1f017-d951-4105-9d76-ff5f63aadcc3" xlink:to="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_5629fa5b-2efa-4ad7-b4d0-daaaa129ad81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_b254c139-f4f5-49c3-9f79-4e68d45baebf" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_b254c139-f4f5-49c3-9f79-4e68d45baebf" xlink:to="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3d3f2eab-e05b-483b-ad97-b396a54fd4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3d3f2eab-e05b-483b-ad97-b396a54fd4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_490d0d58-e32f-4d77-a6e8-eb28b22bf361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d3f2eab-e05b-483b-ad97-b396a54fd4ee" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_490d0d58-e32f-4d77-a6e8-eb28b22bf361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_86058669-0df3-4fd6-88a1-4f6fda121f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_490d0d58-e32f-4d77-a6e8-eb28b22bf361" xlink:to="loc_us-gaap_UnsecuredDebtMember_86058669-0df3-4fd6-88a1-4f6fda121f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_40c51644-396c-467a-96e3-af04f0358f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:to="loc_us-gaap_DebtInstrumentAxis_40c51644-396c-467a-96e3-af04f0358f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_40c51644-396c-467a-96e3-af04f0358f49" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2022Member_58b43fab-45e8-4976-912a-f82b486b22f9" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2022Member_58b43fab-45e8-4976-912a-f82b486b22f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2023Member_9e5da086-5dc4-4595-8903-3ef0cce082bd" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2023Member_9e5da086-5dc4-4595-8903-3ef0cce082bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2024Member_85c4e82e-9ed5-478d-ab7d-31dbffe0fa19" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2024Member_85c4e82e-9ed5-478d-ab7d-31dbffe0fa19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2025Member_3b4beaa6-327b-4772-8059-2f7c6f054cbf" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2025Member_3b4beaa6-327b-4772-8059-2f7c6f054cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2026Member_e1445e27-ed95-464c-8e1d-11b1b9175cf2" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2026Member_e1445e27-ed95-464c-8e1d-11b1b9175cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2027Member_4d1c4e3c-a7e8-480d-a2e5-32f4ac50653c" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2027Member_4d1c4e3c-a7e8-480d-a2e5-32f4ac50653c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20282032Member_3630102d-b55a-415b-a80c-20d29049169f" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20282032Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20282032Member_3630102d-b55a-415b-a80c-20d29049169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20332037Member_e90cf308-a0d1-4758-9228-23c163912194" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20332037Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20332037Member_e90cf308-a0d1-4758-9228-23c163912194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20382042Member_58e88809-7e90-40f0-a0bf-6569ec473452" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20382042Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20382042Member_58e88809-7e90-40f0-a0bf-6569ec473452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20432047Member_3d0df5cd-2e20-4e83-8817-489ebd0ab1df" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20432047Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20432047Member_3d0df5cd-2e20-4e83-8817-489ebd0ab1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20482050Member_cb5f8212-507e-45e8-a289-e5cf49c45519" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtDue20482050Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988cb108-9d70-45b1-85d9-63b01846d57e" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20482050Member_cb5f8212-507e-45e8-a289-e5cf49c45519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2c17e704-47ef-4773-84e9-ed92ae719c81" xlink:to="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_88bca960-ce40-4360-991d-b29773bec4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_88bca960-ce40-4360-991d-b29773bec4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ba760f87-c8b2-481f-9148-b7bfb1bba965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ba760f87-c8b2-481f-9148-b7bfb1bba965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_fbb429dc-03e6-40d8-bc79-a9c43375c217" xlink:href="pfe-20211231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_fbb429dc-03e6-40d8-bc79-a9c43375c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_97d22fd8-6d1b-4b30-9bc6-e20dce22d353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_97d22fd8-6d1b-4b30-9bc6-e20dce22d353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermDebt_f1145d51-8200-42dd-8420-86e2efc54e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_OtherLongTermDebt_f1145d51-8200-42dd-8420-86e2efc54e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_43758325-c4bf-4f93-8e23-128b823cace9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_43758325-c4bf-4f93-8e23-128b823cace9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9653bf51-b242-4c25-b73a-ca6ec15de6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_17f5a1d0-6bf9-4f9a-a8c5-b77f9b4410a6" xlink:to="loc_us-gaap_LongTermDebtCurrent_9653bf51-b242-4c25-b73a-ca6ec15de6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_70a74868-7b38-474f-a524-7ee5173f4115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_70a74868-7b38-474f-a524-7ee5173f4115" xlink:to="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a8dd3ad-6963-4caf-9656-cee8d3268ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a8dd3ad-6963-4caf-9656-cee8d3268ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2380692b-dcd8-46b6-9a6a-51133f229996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a8dd3ad-6963-4caf-9656-cee8d3268ce2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2380692b-dcd8-46b6-9a6a-51133f229996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ebc3a460-bfd7-43fc-88e0-904772fbf24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2380692b-dcd8-46b6-9a6a-51133f229996" xlink:to="loc_us-gaap_SeniorNotesMember_ebc3a460-bfd7-43fc-88e0-904772fbf24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_734309a5-b223-445e-b32e-8674e360e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:to="loc_us-gaap_DebtInstrumentAxis_734309a5-b223-445e-b32e-8674e360e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a15da4f0-88a0-4dec-9efb-08aeb495c57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_734309a5-b223-445e-b32e-8674e360e45a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a15da4f0-88a0-4dec-9efb-08aeb495c57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member_9c8ed546-e2e2-420c-8a18-36ffe477be04" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a15da4f0-88a0-4dec-9efb-08aeb495c57b" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member_9c8ed546-e2e2-420c-8a18-36ffe477be04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7058b71a-50bc-47e5-90c8-78a056db8fc9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a6cf44da-bc62-4acb-902b-cfa970d1672e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a6cf44da-bc62-4acb-902b-cfa970d1672e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b555da87-9b40-42ac-a50a-e3059ee71b64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b555da87-9b40-42ac-a50a-e3059ee71b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1714c1c6-3a46-4d80-9bc7-74316e70525c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b7a8f795-8726-4162-a032-f5231159c36e" xlink:to="loc_us-gaap_LongTermDebt_1714c1c6-3a46-4d80-9bc7-74316e70525c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_115c9115-82d8-427d-90e3-6798b96596ba" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_115c9115-82d8-427d-90e3-6798b96596ba" xlink:to="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fe01e53-7d65-4421-9e7d-f157c165c79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fe01e53-7d65-4421-9e7d-f157c165c79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fe01e53-7d65-4421-9e7d-f157c165c79a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_12a2ad6c-5735-4cb7-8695-a88afd7a477e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:to="loc_us-gaap_SeniorNotesMember_12a2ad6c-5735-4cb7-8695-a88afd7a477e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_53599f5e-86ce-4eef-a1a4-2406a71d33ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_531b20da-d140-4141-83f3-151b6cde3cbf" xlink:to="loc_us-gaap_UnsecuredDebtMember_53599f5e-86ce-4eef-a1a4-2406a71d33ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_365cc1cf-7813-47f3-9e96-a5d201ee65cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:to="loc_us-gaap_DebtInstrumentAxis_365cc1cf-7813-47f3-9e96-a5d201ee65cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_365cc1cf-7813-47f3-9e96-a5d201ee65cc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member_6d745fd0-feec-41f2-93e9-0643a56c51aa" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member_6d745fd0-feec-41f2-93e9-0643a56c51aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member_dacadf2b-0d7f-43d1-a753-267d9db83e8c" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member_dacadf2b-0d7f-43d1-a753-267d9db83e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorNotesDue2047Member_4dfb4380-89bf-4d0e-a483-aef7c38a2b56" xlink:href="pfe-20211231.xsd#pfe_SeniorNotesDue2047Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorNotesDue2047Member_4dfb4380-89bf-4d0e-a483-aef7c38a2b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_393c86f5-7782-4236-aeee-ee926ac1aadf" xlink:href="pfe-20211231.xsd#pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_04c676b2-f88a-4620-b32f-bdf066ea2808" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_393c86f5-7782-4236-aeee-ee926ac1aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_48bfc400-c1bf-4587-8d75-5f0196b7ec22" xlink:to="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_08257128-493a-4fbb-9cfc-ac4f7f048de7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_08257128-493a-4fbb-9cfc-ac4f7f048de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_e578c4bf-280e-4a26-aaa7-fa7576ae141f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_e578c4bf-280e-4a26-aaa7-fa7576ae141f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_783e4281-f1f4-47a8-870c-621168f5d088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_783e4281-f1f4-47a8-870c-621168f5d088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb27e929-e512-4eb6-a11d-ea5e47292627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb27e929-e512-4eb6-a11d-ea5e47292627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cfd0e9e0-cca0-4211-86f5-f12532083a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_cfd0e9e0-cca0-4211-86f5-f12532083a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4330aba6-043a-4008-b45a-ecfbbf5cee04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_541a9b9e-fb82-4831-a355-d6f3c1a633d6" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_4330aba6-043a-4008-b45a-ecfbbf5cee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_5a0b867f-a0ff-463c-b8dd-817a292e8dc9" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_97d417d8-c2c4-4e09-83ef-b7e394e8a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_5a0b867f-a0ff-463c-b8dd-817a292e8dc9" xlink:to="loc_us-gaap_DerivativeTable_97d417d8-c2c4-4e09-83ef-b7e394e8a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_bf8813d3-9720-43a4-8786-52dec893b39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97d417d8-c2c4-4e09-83ef-b7e394e8a7bb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_bf8813d3-9720-43a4-8786-52dec893b39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c8ed9c89-d165-417c-8024-ba94227bc76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_bf8813d3-9720-43a4-8786-52dec893b39b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c8ed9c89-d165-417c-8024-ba94227bc76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_44520fde-7ea2-4b7c-b725-46f0847742e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c8ed9c89-d165-417c-8024-ba94227bc76e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_44520fde-7ea2-4b7c-b725-46f0847742e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_183d1724-4cc8-486c-a84e-5d84b666ed99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_97d417d8-c2c4-4e09-83ef-b7e394e8a7bb" xlink:to="loc_us-gaap_DerivativeLineItems_183d1724-4cc8-486c-a84e-5d84b666ed99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_0b58188b-f5de-42e7-96dc-4dcfe0f2c742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_183d1724-4cc8-486c-a84e-5d84b666ed99" xlink:to="loc_us-gaap_DerivativeTermOfContract_0b58188b-f5de-42e7-96dc-4dcfe0f2c742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_a0972b07-7653-4fe5-b19e-4973a9a7f7eb" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_a0972b07-7653-4fe5-b19e-4973a9a7f7eb" xlink:to="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemAxis_2db1911a-d98b-45e7-865a-61fab769e678" xlink:href="pfe-20211231.xsd#pfe_HedgedItemAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:to="loc_pfe_HedgedItemAxis_2db1911a-d98b-45e7-865a-61fab769e678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HedgedItemDomain_d32308a5-acc1-49f8-8691-6bbe4ea35ce2" xlink:href="pfe-20211231.xsd#pfe_HedgedItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemAxis_2db1911a-d98b-45e7-865a-61fab769e678" xlink:to="loc_pfe_HedgedItemDomain_d32308a5-acc1-49f8-8691-6bbe4ea35ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_ebdce09d-5444-4a08-93dc-8ac220f3462f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemDomain_d32308a5-acc1-49f8-8691-6bbe4ea35ce2" xlink:to="loc_us-gaap_SalesMember_ebdce09d-5444-4a08-93dc-8ac220f3462f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0852316b-1ed5-40c6-b47f-68bec1f513a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0852316b-1ed5-40c6-b47f-68bec1f513a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0852316b-1ed5-40c6-b47f-68bec1f513a8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_c51f0242-1d68-4993-9c4d-f0457fe9e288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:to="loc_us-gaap_ForeignExchangeContractMember_c51f0242-1d68-4993-9c4d-f0457fe9e288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_22e35398-d367-43ed-83ba-cf81e7b3afec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7d5c5ed0-697d-4a99-b2be-15e54e784527" xlink:to="loc_us-gaap_InterestRateContractMember_22e35398-d367-43ed-83ba-cf81e7b3afec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:to="loc_us-gaap_HedgingDesignationAxis_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d3fefaba-ac94-41c0-a554-bd2cc1fbd32c" xlink:to="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_719afe45-cb29-4714-8468-e2006077f874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_719afe45-cb29-4714-8468-e2006077f874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0ece9326-8514-4c65-8413-e00372e0e198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_342b9228-3730-4a6c-921c-95c0752246f4" xlink:to="loc_us-gaap_NondesignatedMember_0ece9326-8514-4c65-8413-e00372e0e198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_368126c5-522e-4ff4-bee5-5a696f118cb1" xlink:to="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_b1dd41c9-d1ad-42d5-b4c0-cce7057c51df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_b1dd41c9-d1ad-42d5-b4c0-cce7057c51df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_62ef5f65-3f8d-482c-90f6-c29572ac6470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:to="loc_us-gaap_DerivativeAssets_62ef5f65-3f8d-482c-90f6-c29572ac6470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_87ee52bb-3ad3-4c51-abc1-91b121a56699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_b7c2729c-2547-449f-96a7-80dff8651fd9" xlink:to="loc_us-gaap_DerivativeLiabilities_87ee52bb-3ad3-4c51-abc1-91b121a56699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_53c720c8-0ed0-494a-924d-4b89ed1efc29" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_53c720c8-0ed0-494a-924d-4b89ed1efc29" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a03456b6-6fed-453a-a038-4f345ab44cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_HedgingDesignationAxis_a03456b6-6fed-453a-a038-4f345ab44cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a03456b6-6fed-453a-a038-4f345ab44cec" xlink:to="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cf25f02d-6706-4aa2-880c-b5f7d2f095e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_cf25f02d-6706-4aa2-880c-b5f7d2f095e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_98ad7dcd-e254-4f1d-a331-ea1d0cf9dec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bfbfc6ff-3f90-4528-8629-fd77f6ebfa4b" xlink:to="loc_us-gaap_NondesignatedMember_98ad7dcd-e254-4f1d-a331-ea1d0cf9dec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_16aa1ff8-ff6b-419c-8932-43d0d7306815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_16aa1ff8-ff6b-419c-8932-43d0d7306815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_16aa1ff8-ff6b-419c-8932-43d0d7306815" xlink:to="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_dc2261af-cf56-4454-ba37-b7320440b43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:to="loc_us-gaap_CashFlowHedgingMember_dc2261af-cf56-4454-ba37-b7320440b43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_e54e92e6-3e1f-4327-827d-642e9983fac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_6174329f-dd1f-40de-a84f-c7e620b1de33" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_e54e92e6-3e1f-4327-827d-642e9983fac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_38d16086-ff01-4a27-a2a1-006b5741869f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_38d16086-ff01-4a27-a2a1-006b5741869f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38d16086-ff01-4a27-a2a1-006b5741869f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e875e81e-5fe1-48fd-9919-429eae2ad34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e875e81e-5fe1-48fd-9919-429eae2ad34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_e3d5102f-2f41-4f5c-9db5-af1bcc230abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_us-gaap_InterestRateContractMember_e3d5102f-2f41-4f5c-9db5-af1bcc230abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_f7353849-b385-47d7-8ef3-bc15a4cf0819" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_f7353849-b385-47d7-8ef3-bc15a4cf0819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_efc9822d-7e36-45fb-b9ff-bbb5095f4236" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyLongTermDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_225ed197-7930-42c6-9a52-5c9f802029b3" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_efc9822d-7e36-45fb-b9ff-bbb5095f4236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_959cbf11-94b0-432b-8d26-91cecca7d999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_959cbf11-94b0-432b-8d26-91cecca7d999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_959cbf11-94b0-432b-8d26-91cecca7d999" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f1c1891-79dc-4b81-b3e2-2bf45bb07609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_1f1c1891-79dc-4b81-b3e2-2bf45bb07609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_91389e2b-ce5b-4a68-91d2-880731dbb283" xlink:href="pfe-20211231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9152cad5-7ec2-48cf-8e3f-e4418a7543c5" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_91389e2b-ce5b-4a68-91d2-880731dbb283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_0ec66ba4-ca04-4afc-b6ad-932822dd0f49" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c371c616-218e-42e2-8c76-004ab3bf6291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_c371c616-218e-42e2-8c76-004ab3bf6291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_00adc950-c2eb-4b19-9617-3c83f4416db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_00adc950-c2eb-4b19-9617-3c83f4416db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_679e639c-7c50-4c05-b2f6-8a8cce28a4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_679e639c-7c50-4c05-b2f6-8a8cce28a4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_049b3751-91fa-43ee-8086-914f2fd570d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_049b3751-91fa-43ee-8086-914f2fd570d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ed734d6c-894b-49f3-9b14-824fa7cd2bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ed734d6c-894b-49f3-9b14-824fa7cd2bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_1fce873b-7f4f-4d92-8711-1236ed49cb46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_1fce873b-7f4f-4d92-8711-1236ed49cb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8983a696-196d-4e1e-893c-6e580daebcb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_8983a696-196d-4e1e-893c-6e580daebcb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_050d3a05-1e6c-4ea8-b8cc-98ba3cc87ff3" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_050d3a05-1e6c-4ea8-b8cc-98ba3cc87ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_989c2a30-bb60-4464-8c01-41ced27bd91f" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_989c2a30-bb60-4464-8c01-41ced27bd91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_77dc8ae8-fa23-4110-8369-b9fc016d4475" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_77dc8ae8-fa23-4110-8369-b9fc016d4475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0590401d-2cef-442f-96d9-3c9900e8bb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_0590401d-2cef-442f-96d9-3c9900e8bb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_c7ff8373-6bd0-404a-b5d2-5dfc676dfc33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_c7ff8373-6bd0-404a-b5d2-5dfc676dfc33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6600bf0d-b2d9-419f-b950-8a3edb9b86dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_6600bf0d-b2d9-419f-b950-8a3edb9b86dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_82c3c10b-1ebf-4a05-b140-606aa78a4508" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_82c3c10b-1ebf-4a05-b140-606aa78a4508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_3b9a057d-e73f-4f23-b4c5-73c048b31d01" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_3b9a057d-e73f-4f23-b4c5-73c048b31d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_142aa153-8f6d-49b3-b9b8-4a9131cc40d3" xlink:href="pfe-20211231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0a4d0a64-c2e8-4c98-bc6a-10eb10cd9c9b" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_142aa153-8f6d-49b3-b9b8-4a9131cc40d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_2ee82899-e548-430f-9204-2db46fba3df5" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2ee82899-e548-430f-9204-2db46fba3df5" xlink:to="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_1018ee81-0c84-4766-b740-a843c53b1680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_HedgingDesignationAxis_1018ee81-0c84-4766-b740-a843c53b1680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7d6aa998-b50d-4f28-bc99-e71e6638c153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_1018ee81-0c84-4766-b740-a843c53b1680" xlink:to="loc_us-gaap_HedgingDesignationDomain_7d6aa998-b50d-4f28-bc99-e71e6638c153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fea99884-3a44-4062-9100-ecfcf74e2c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7d6aa998-b50d-4f28-bc99-e71e6638c153" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_fea99884-3a44-4062-9100-ecfcf74e2c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ac288bfb-dfc9-45ff-b257-42e00da78b06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ac288bfb-dfc9-45ff-b257-42e00da78b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_66df56b9-7f21-4fd3-a352-9544258a5333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ac288bfb-dfc9-45ff-b257-42e00da78b06" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_66df56b9-7f21-4fd3-a352-9544258a5333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_4444543e-0d3d-4ca9-90f3-2c2bf390fef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_66df56b9-7f21-4fd3-a352-9544258a5333" xlink:to="loc_us-gaap_UnsecuredDebtMember_4444543e-0d3d-4ca9-90f3-2c2bf390fef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2d625c38-ad80-4af1-bf13-7ccb9561c8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2d625c38-ad80-4af1-bf13-7ccb9561c8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d625c38-ad80-4af1-bf13-7ccb9561c8a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_4cd76056-c82c-4a10-b9a6-042693246a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:to="loc_us-gaap_ForeignExchangeContractMember_4cd76056-c82c-4a10-b9a6-042693246a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ForeignCurrencyDebtMember_6c7e486b-96ea-48e7-8a7d-e0652bb1fb16" xlink:href="pfe-20211231.xsd#pfe_ForeignCurrencyDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0ccca27a-de97-497d-a14a-c4ccba748621" xlink:to="loc_pfe_ForeignCurrencyDebtMember_6c7e486b-96ea-48e7-8a7d-e0652bb1fb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_34309030-f313-493d-aa4d-22cc36f55ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_34309030-f313-493d-aa4d-22cc36f55ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_1a549d36-6254-4524-b761-0a30973cb5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_34309030-f313-493d-aa4d-22cc36f55ede" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_1a549d36-6254-4524-b761-0a30973cb5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_f83170a5-01ee-4b46-adeb-7f01d6815da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_1a549d36-6254-4524-b761-0a30973cb5dd" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_f83170a5-01ee-4b46-adeb-7f01d6815da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c0848e9d-2fbe-4717-8ba1-fb7e574b9e03" xlink:to="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9a2ab77-a730-474d-9c27-6a421b0d74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d9a2ab77-a730-474d-9c27-6a421b0d74fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_5027f2d8-396b-46a3-a7b4-1355b2820d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_5027f2d8-396b-46a3-a7b4-1355b2820d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_17eb7e0a-7d54-4eee-a8f6-cfc180ad19f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_17eb7e0a-7d54-4eee-a8f6-cfc180ad19f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_31065499-b4d8-48f7-a8e6-9effc226061c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_DebtCurrent_31065499-b4d8-48f7-a8e6-9effc226061c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_306cd422-9ca5-457f-a2b1-81cd2f968989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_2b4d4005-caae-4ca0-ac9e-d04d70bb2ee9" xlink:to="loc_us-gaap_LongTermDebt_306cd422-9ca5-457f-a2b1-81cd2f968989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_fd50e782-0a04-4d12-959b-f30abcbe232d" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_6347fa51-da4c-4f2d-b062-29773cb2400f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_fd50e782-0a04-4d12-959b-f30abcbe232d" xlink:to="loc_us-gaap_DerivativeTable_6347fa51-da4c-4f2d-b062-29773cb2400f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6347fa51-da4c-4f2d-b062-29773cb2400f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cae6f525-a02f-4585-93ed-30680484202c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_71c5bef7-90f8-4b8d-9c6b-c64c7f20e282" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cae6f525-a02f-4585-93ed-30680484202c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_e2388778-caf8-4bf3-a534-cd88bc5c1a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cae6f525-a02f-4585-93ed-30680484202c" xlink:to="loc_us-gaap_LongTermDebtMember_e2388778-caf8-4bf3-a534-cd88bc5c1a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6347fa51-da4c-4f2d-b062-29773cb2400f" xlink:to="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_8aabfcf2-978d-489c-8467-00a502537658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_8aabfcf2-978d-489c-8467-00a502537658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_d8049077-c68b-4544-a5ef-14e6a4ea99ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_d8049077-c68b-4544-a5ef-14e6a4ea99ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_c1776f57-947e-4682-9523-3ec47547072c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_f955afb8-1f1d-46fe-8353-318a78d179b9" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_c1776f57-947e-4682-9523-3ec47547072c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#FinancialInstrumentsCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FinancialInstrumentsAbstract_720e0762-435c-4f0c-a6ed-a00c96df2c79" xlink:href="pfe-20211231.xsd#pfe_FinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_b51849a0-62b8-4ba7-8b2f-d4a1f1d4ab48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_720e0762-435c-4f0c-a6ed-a00c96df2c79" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_b51849a0-62b8-4ba7-8b2f-d4a1f1d4ab48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_77efdfbc-a766-4fcc-999f-0ce80c97fc0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_720e0762-435c-4f0c-a6ed-a00c96df2c79" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_77efdfbc-a766-4fcc-999f-0ce80c97fc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue_79e4f410-cd59-4445-af73-aa017797b101" xlink:href="pfe-20211231.xsd#pfe_DerivativeNetReceivablePositionAggregateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_720e0762-435c-4f0c-a6ed-a00c96df2c79" xlink:to="loc_pfe_DerivativeNetReceivablePositionAggregateFairValue_79e4f410-cd59-4445-af73-aa017797b101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_58663fb6-37fb-4cef-89c1-a47c8a2e0ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_720e0762-435c-4f0c-a6ed-a00c96df2c79" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_58663fb6-37fb-4cef-89c1-a47c8a2e0ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherFinancialInformation"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_6dfbc95a-7ff5-48f6-966b-bc63aa243c74" xlink:href="pfe-20211231.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9edadc5b-1835-4dcb-ab91-4352c69aa728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_6dfbc95a-7ff5-48f6-966b-bc63aa243c74" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_9edadc5b-1835-4dcb-ab91-4352c69aa728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherFinancialInformationTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_f4347653-3086-4fad-88b9-6185cf59c7c2" xlink:href="pfe-20211231.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ddcc4ee8-6c22-4558-8149-2c422e81a4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_f4347653-3086-4fad-88b9-6185cf59c7c2" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ddcc4ee8-6c22-4558-8149-2c422e81a4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8bc2a280-575a-4f2b-afd8-9148729f5d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_f4347653-3086-4fad-88b9-6185cf59c7c2" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8bc2a280-575a-4f2b-afd8-9148729f5d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherFinancialInformationInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_69cebb82-6d87-4049-aae2-b7a479e44b39" xlink:href="pfe-20211231.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_74067f40-0dd8-487d-b1e6-65bfa235cf52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_69cebb82-6d87-4049-aae2-b7a479e44b39" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_74067f40-0dd8-487d-b1e6-65bfa235cf52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_aa6839a3-8215-4246-bbbb-1b315a35ae75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_69cebb82-6d87-4049-aae2-b7a479e44b39" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_aa6839a3-8215-4246-bbbb-1b315a35ae75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_7add67a8-5200-4dd6-9503-8ec6ec032566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_69cebb82-6d87-4049-aae2-b7a479e44b39" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_7add67a8-5200-4dd6-9503-8ec6ec032566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ee1647b5-cea3-46cd-9d44-41764b885285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_69cebb82-6d87-4049-aae2-b7a479e44b39" xlink:to="loc_us-gaap_InventoryNet_ee1647b5-cea3-46cd-9d44-41764b885285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_6972e02c-0952-4502-8f49-e03fd9439807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_69cebb82-6d87-4049-aae2-b7a479e44b39" xlink:to="loc_us-gaap_InventoryNoncurrent_6972e02c-0952-4502-8f49-e03fd9439807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#OtherFinancialInformationOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherFinancialInformationAbstract_d49111b5-93e2-492e-8307-067c6dc4a5b4" xlink:href="pfe-20211231.xsd#pfe_OtherFinancialInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherFinancialInformationAbstract_d49111b5-93e2-492e-8307-067c6dc4a5b4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c6abfdce-8543-4eb3-8a20-4e3ffdffc010" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:to="loc_srt_CounterpartyNameAxis_c6abfdce-8543-4eb3-8a20-4e3ffdffc010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b12bdc1-01f0-44d6-9bf6-422a7d45528d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c6abfdce-8543-4eb3-8a20-4e3ffdffc010" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b12bdc1-01f0-44d6-9bf6-422a7d45528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_df1a402c-1b33-48a7-b759-cd3c0ade83a1" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8b12bdc1-01f0-44d6-9bf6-422a7d45528d" xlink:to="loc_pfe_BioNTechMember_df1a402c-1b33-48a7-b759-cd3c0ade83a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ee34914c-f394-48c4-96c5-0c9b5408c124" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:to="loc_srt_ProductOrServiceAxis_ee34914c-f394-48c4-96c5-0c9b5408c124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a19e851f-4841-49a2-8118-5b0a00a5735a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ee34914c-f394-48c4-96c5-0c9b5408c124" xlink:to="loc_srt_ProductsAndServicesDomain_a19e851f-4841-49a2-8118-5b0a00a5735a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_dd867ca2-cdb6-42cb-9557-475366b41a33" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a19e851f-4841-49a2-8118-5b0a00a5735a" xlink:to="loc_pfe_ComirnatyMember_dd867ca2-cdb6-42cb-9557-475366b41a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c415eb95-4434-473b-a81f-2ebcff19d335" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c415eb95-4434-473b-a81f-2ebcff19d335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e07d1e86-7e86-4482-aafd-655c1dec4fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c415eb95-4434-473b-a81f-2ebcff19d335" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e07d1e86-7e86-4482-aafd-655c1dec4fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_f358489c-62dd-43be-95ea-e9e704b952cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e07d1e86-7e86-4482-aafd-655c1dec4fd8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_f358489c-62dd-43be-95ea-e9e704b952cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f937fe38-6da0-43ef-a2ef-60876da4aa94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c2113312-e016-49bb-9381-9f0756b40fff" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f937fe38-6da0-43ef-a2ef-60876da4aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f542687f-6797-45ba-8591-400c394119ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f937fe38-6da0-43ef-a2ef-60876da4aa94" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f542687f-6797-45ba-8591-400c394119ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPE" xlink:type="simple" xlink:href="pfe-20211231.xsd#PropertyPlantandEquipmentPPE"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PropertyPlantandEquipmentPPE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f9e4b0e6-0d0c-4185-b2c3-71f082de28d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2995c268-2e0c-4ff5-a5b9-0252d600ae83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f9e4b0e6-0d0c-4185-b2c3-71f082de28d6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2995c268-2e0c-4ff5-a5b9-0252d600ae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables" xlink:type="simple" xlink:href="pfe-20211231.xsd#PropertyPlantandEquipmentPPETables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9ad1a28d-143c-4794-99ae-2d309ef938b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_195fbcae-6fe9-4a37-8206-efb09630678b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9ad1a28d-143c-4794-99ae-2d309ef938b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_195fbcae-6fe9-4a37-8206-efb09630678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_8c629b88-1e16-4427-ad64-ab98e6570365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9ad1a28d-143c-4794-99ae-2d309ef938b4" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_8c629b88-1e16-4427-ad64-ab98e6570365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d180c8b9-2fa7-4183-934c-918684152704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d180c8b9-2fa7-4183-934c-918684152704" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5c005f4-5613-4509-aaf7-8607c8f61ae3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:to="loc_srt_RangeAxis_d5c005f4-5613-4509-aaf7-8607c8f61ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d5c005f4-5613-4509-aaf7-8607c8f61ae3" xlink:to="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4223d205-7a99-4e14-a069-746b9fd12c31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:to="loc_srt_MinimumMember_4223d205-7a99-4e14-a069-746b9fd12c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_255684ed-4fb8-4057-b45d-aab4bcf016eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d396eab2-f555-4835-badd-d6cb3abb0525" xlink:to="loc_srt_MaximumMember_255684ed-4fb8-4057-b45d-aab4bcf016eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95e9b0cc-d9ee-46e7-bfe1-69c2fe177a28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_d49f49f8-9a9d-4c43-9389-ed0c4f78934f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_LandMember_d49f49f8-9a9d-4c43-9389-ed0c4f78934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_0a621b5a-089e-4e05-aba3-33bd3e9ed81c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_BuildingMember_0a621b5a-089e-4e05-aba3-33bd3e9ed81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_ccb5baef-8198-4822-b538-7f151787ed24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_ccb5baef-8198-4822-b538-7f151787ed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3657c2a2-da57-4eb8-8fe2-ea0c9ac9d7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3657c2a2-da57-4eb8-8fe2-ea0c9ac9d7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_7a7c95d4-f04f-4b43-bd04-e74bb2de7143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_18b3f395-f9ab-477c-b2fb-7e8ba0a95c7d" xlink:to="loc_us-gaap_ConstructionInProgressMember_7a7c95d4-f04f-4b43-bd04-e74bb2de7143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_08063ff5-5b2c-47f7-b022-0da37289bfb3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48832ab7-d73d-4b8f-8b37-75d59eed3bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_48832ab7-d73d-4b8f-8b37-75d59eed3bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_34c0da34-217a-4d16-ab61-ef9f574afc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_34c0da34-217a-4d16-ab61-ef9f574afc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bff7e489-7fd9-4be6-90fd-f921ae40c1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bff7e489-7fd9-4be6-90fd-f921ae40c1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_db55804b-9e9c-47a9-a981-8e173a256785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d6037c80-60d7-4e7b-af3b-12c93335fb9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_db55804b-9e9c-47a9-a981-8e173a256785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_70d8d4c2-1bcb-4a36-bf04-2f3b957a1344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c71d49b4-c050-448d-904f-3545b907df18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_70d8d4c2-1bcb-4a36-bf04-2f3b957a1344" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c71d49b4-c050-448d-904f-3545b907df18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c71d49b4-c050-448d-904f-3545b907df18" xlink:to="loc_srt_StatementGeographicalAxis_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1ab8f9ab-b810-40c7-bc7a-59c2cff38e54" xlink:to="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a1cf70b4-56a2-4322-9b3d-60b50583c4d2" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_country_US_a1cf70b4-56a2-4322-9b3d-60b50583c4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_05233ffd-8e12-4426-a625-d34bd5d2fe26" xlink:href="pfe-20211231.xsd#pfe_DevelopedEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_pfe_DevelopedEuropeMember_05233ffd-8e12-4426-a625-d34bd5d2fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_cd489704-26f8-45ce-983a-fabd2fd35179" xlink:href="pfe-20211231.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_pfe_DevelopedRestOfWorldMember_cd489704-26f8-45ce-983a-fabd2fd35179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_11fa2dd1-645e-4caa-9284-a16506f6ba21" xlink:href="pfe-20211231.xsd#pfe_EmergingMarketsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f1e968b-b4db-4fb7-b8c3-cf4a7713549a" xlink:to="loc_pfe_EmergingMarketsMember_11fa2dd1-645e-4caa-9284-a16506f6ba21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5508e729-4b68-4104-a62b-aeb7dcf71edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c71d49b4-c050-448d-904f-3545b907df18" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5508e729-4b68-4104-a62b-aeb7dcf71edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_98c89bb5-4053-4833-a49b-202af4900976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5508e729-4b68-4104-a62b-aeb7dcf71edc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_98c89bb5-4053-4833-a49b-202af4900976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d4713c7b-ef3b-40fb-9114-cbf93d5a86b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_85975ddd-76d7-4f6e-951a-b8522615b4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d4713c7b-ef3b-40fb-9114-cbf93d5a86b3" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_85975ddd-76d7-4f6e-951a-b8522615b4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_03b8dc38-c95c-413b-98e8-072aa2a74c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_063de845-fe46-45dc-bc12-8f5a7db15642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_03b8dc38-c95c-413b-98e8-072aa2a74c1a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_063de845-fe46-45dc-bc12-8f5a7db15642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b0d2f2cb-3e51-4bdf-b626-f925940b3457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_03b8dc38-c95c-413b-98e8-072aa2a74c1a" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_b0d2f2cb-3e51-4bdf-b626-f925940b3457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f397be13-e74a-496d-8379-e5695d508b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_03b8dc38-c95c-413b-98e8-072aa2a74c1a" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_f397be13-e74a-496d-8379-e5695d508b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_c29fdbdd-3ea4-4174-8169-0fb6fd3cfd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_03b8dc38-c95c-413b-98e8-072aa2a74c1a" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_c29fdbdd-3ea4-4174-8169-0fb6fd3cfd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d6f7ed36-e4a0-457f-add3-44b945fb00bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d6f7ed36-e4a0-457f-add3-44b945fb00bd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ded74b79-80aa-4699-a293-07acd135dad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ded74b79-80aa-4699-a293-07acd135dad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ded74b79-80aa-4699-a293-07acd135dad3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_5d4efe49-2b66-4079-9edb-e4eff04a9e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_5d4efe49-2b66-4079-9edb-e4eff04a9e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9c9e386d-c993-4eeb-a456-4d46dbfe68ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:to="loc_us-gaap_TradeNamesMember_9c9e386d-c993-4eeb-a456-4d46dbfe68ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_1ad76e58-cdd8-45ac-83ce-e71e251f5986" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a43f42de-8da9-4380-92b5-4b44a7ddb3fd" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_1ad76e58-cdd8-45ac-83ce-e71e251f5986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4d0eac59-2876-4e2f-a330-78f3149fd0cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:to="loc_srt_CounterpartyNameAxis_4d0eac59-2876-4e2f-a330-78f3149fd0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b23f5918-293b-4dac-83a5-2d6bbb6d6258" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4d0eac59-2876-4e2f-a330-78f3149fd0cd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b23f5918-293b-4dac-83a5-2d6bbb6d6258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_6c01ec28-5955-4d7d-a35a-78dd040fe382" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b23f5918-293b-4dac-83a5-2d6bbb6d6258" xlink:to="loc_pfe_BioNTechMember_6c01ec28-5955-4d7d-a35a-78dd040fe382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e2bf569d-d2ef-4141-b97b-3a08e0a905d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:to="loc_srt_ProductOrServiceAxis_e2bf569d-d2ef-4141-b97b-3a08e0a905d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52f1747a-37db-4803-a892-13b8d7abf5c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e2bf569d-d2ef-4141-b97b-3a08e0a905d9" xlink:to="loc_srt_ProductsAndServicesDomain_52f1747a-37db-4803-a892-13b8d7abf5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_ee1fa6c7-db57-4faa-999f-2618cbf1c7ab" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_52f1747a-37db-4803-a892-13b8d7abf5c2" xlink:to="loc_pfe_ComirnatyMember_ee1fa6c7-db57-4faa-999f-2618cbf1c7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b2bdfec6-b332-4898-b71b-a5231e952d3a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62577cd1-4c65-4a3a-92ff-875cf2f09a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62577cd1-4c65-4a3a-92ff-875cf2f09a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41f91f85-4e45-4bd0-ad12-3fdf02da8a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41f91f85-4e45-4bd0-ad12-3fdf02da8a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77f5a103-282c-4a2f-9429-a79d5864b65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_77f5a103-282c-4a2f-9429-a79d5864b65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_0b0f188d-a8a5-4043-a117-b46863dffa0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5d7b8689-2cf3-4967-bbff-90a232fc156f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_0b0f188d-a8a5-4043-a117-b46863dffa0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_46ab79d1-a215-47dd-81b1-58221d526876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d6f7ed36-e4a0-457f-add3-44b945fb00bd" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_46ab79d1-a215-47dd-81b1-58221d526876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_871cc9d3-f954-4553-8502-1c2dc66cc4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_46ab79d1-a215-47dd-81b1-58221d526876" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_871cc9d3-f954-4553-8502-1c2dc66cc4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_871cc9d3-f954-4553-8502-1c2dc66cc4d2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_b6049cdd-5a3a-4591-9a87-2a69a019d853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:to="loc_us-gaap_TradeNamesMember_b6049cdd-5a3a-4591-9a87-2a69a019d853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_059e33c9-6d73-497e-8a37-ae82987fd75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_059e33c9-6d73-497e-8a37-ae82987fd75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_e6254d1e-48f8-47f6-8bc6-d71ed38ed2cf" xlink:href="pfe-20211231.xsd#pfe_LicensingAgreementsAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_05da7f5e-b079-474f-8244-f7a2b3dfd2c5" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_e6254d1e-48f8-47f6-8bc6-d71ed38ed2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5e426ca0-e4ee-462f-b5d6-3d85d746c191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_46ab79d1-a215-47dd-81b1-58221d526876" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5e426ca0-e4ee-462f-b5d6-3d85d746c191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dc405d68-28d6-48e1-9c4f-0a2a40087754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_5e426ca0-e4ee-462f-b5d6-3d85d746c191" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_dc405d68-28d6-48e1-9c4f-0a2a40087754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f2bf1e7b-a372-4493-9f28-57aa8497ef75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d6f7ed36-e4a0-457f-add3-44b945fb00bd" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f2bf1e7b-a372-4493-9f28-57aa8497ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_99cc6ea7-d3d2-4d0e-ac56-bba1c71f09dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d6f7ed36-e4a0-457f-add3-44b945fb00bd" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_99cc6ea7-d3d2-4d0e-ac56-bba1c71f09dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8624264e-a90c-404a-9a0c-ec07f61f2b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6822c8e-ff32-4b9f-8184-b4785a10a00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8624264e-a90c-404a-9a0c-ec07f61f2b62" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6822c8e-ff32-4b9f-8184-b4785a10a00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e528ac1d-300f-4870-823f-18958dc17f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6822c8e-ff32-4b9f-8184-b4785a10a00a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e528ac1d-300f-4870-823f-18958dc17f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_017e036f-5272-4db6-932d-1a5a2a406723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e528ac1d-300f-4870-823f-18958dc17f9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_017e036f-5272-4db6-932d-1a5a2a406723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_f4d77740-8425-421d-a297-c5a3603d4a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_017e036f-5272-4db6-932d-1a5a2a406723" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_f4d77740-8425-421d-a297-c5a3603d4a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c6822c8e-ff32-4b9f-8184-b4785a10a00a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3ad15497-13d7-4ad0-ba29-883a3e882fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3ad15497-13d7-4ad0-ba29-883a3e882fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6dd357f9-95bd-41d7-ade2-b3de5cb793f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ab44f7a3-2ad9-4352-959a-779f6b263189" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6dd357f9-95bd-41d7-ade2-b3de5cb793f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a478012c-7423-4ac4-8b28-6437b85cd643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_250b1ada-eb1d-468b-877e-7eef36647132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a478012c-7423-4ac4-8b28-6437b85cd643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_250b1ada-eb1d-468b-877e-7eef36647132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7bfd3d64-50e1-4f6a-b2e7-a6512d3f4731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a478012c-7423-4ac4-8b28-6437b85cd643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7bfd3d64-50e1-4f6a-b2e7-a6512d3f4731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_080b62fb-b29b-474b-990d-7d08d3126ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a478012c-7423-4ac4-8b28-6437b85cd643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_080b62fb-b29b-474b-990d-7d08d3126ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c1e572cd-f6ed-479f-a17e-4ac5b427460e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a478012c-7423-4ac4-8b28-6437b85cd643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c1e572cd-f6ed-479f-a17e-4ac5b427460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b1b64f02-d688-4e3b-9abc-f06903c2ba87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a478012c-7423-4ac4-8b28-6437b85cd643" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b1b64f02-d688-4e3b-9abc-f06903c2ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#IdentifiableIntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8264b01-2e5e-4c80-89bd-9eff8a6e5b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_854b5deb-e45f-475c-a8e6-5da3c1e11869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8264b01-2e5e-4c80-89bd-9eff8a6e5b8e" xlink:to="loc_us-gaap_GoodwillRollForward_854b5deb-e45f-475c-a8e6-5da3c1e11869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_41492bb0-c6af-4200-a083-5e0c7a73aa96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_854b5deb-e45f-475c-a8e6-5da3c1e11869" xlink:to="loc_us-gaap_Goodwill_41492bb0-c6af-4200-a083-5e0c7a73aa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_f6b7a63e-932d-4622-b772-808364c60b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_854b5deb-e45f-475c-a8e6-5da3c1e11869" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_f6b7a63e-932d-4622-b772-808364c60b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_29025bd4-3a94-4763-9ec4-1a1de5624638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_854b5deb-e45f-475c-a8e6-5da3c1e11869" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_29025bd4-3a94-4763-9ec4-1a1de5624638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5de1e9f6-ef2d-4913-ba01-5cdbb5b02ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_854b5deb-e45f-475c-a8e6-5da3c1e11869" xlink:to="loc_us-gaap_Goodwill_5de1e9f6-ef2d-4913-ba01-5cdbb5b02ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlans"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8e8e9b5f-baa5-495b-9fab-d54f5a704e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d7176322-666d-4fd0-8a5f-5ce33400a28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8e8e9b5f-baa5-495b-9fab-d54f5a704e07" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d7176322-666d-4fd0-8a5f-5ce33400a28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_c967044e-6d7d-401f-aec7-adf01e2ac698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_c967044e-6d7d-401f-aec7-adf01e2ac698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_08f5cd04-8594-43d2-8dca-059b40952d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_08f5cd04-8594-43d2-8dca-059b40952d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_953eac20-2a80-42bd-8295-32440cbbc230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_953eac20-2a80-42bd-8295-32440cbbc230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_db6ea088-75a4-4b27-8326-81bd941f319b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_db6ea088-75a4-4b27-8326-81bd941f319b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_64a11071-f57b-44e6-be6b-b4f12559b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_64a11071-f57b-44e6-be6b-b4f12559b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_b3dfe44b-2b6e-430e-9940-8a32fbf8d6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_b3dfe44b-2b6e-430e-9940-8a32fbf8d6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_b9c960e7-8a6c-42ac-a2cc-8fa90d5a4530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_b9c960e7-8a6c-42ac-a2cc-8fa90d5a4530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_b5455855-31f2-4588-a52f-3787c1976656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_b5455855-31f2-4588-a52f-3787c1976656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_026d35a2-439a-4f73-9e3c-f5f8851ef584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_026d35a2-439a-4f73-9e3c-f5f8851ef584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_3ee39cf8-429e-4457-b57f-8d216efa42ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_3ee39cf8-429e-4457-b57f-8d216efa42ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_2296af07-78d7-4f21-8772-5f9f2b67cbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_38f9c729-d26c-4410-b097-eb1df3944a59" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_2296af07-78d7-4f21-8772-5f9f2b67cbf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e6ede042-facc-4ca2-935e-45a414fbc3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e6ede042-facc-4ca2-935e-45a414fbc3b6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_51ccc823-a21f-4bef-a023-70925cf65e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_51ccc823-a21f-4bef-a023-70925cf65e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_51ccc823-a21f-4bef-a023-70925cf65e1b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_a6a79cb1-db82-4345-92b9-49ec458887e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:to="loc_us-gaap_DomesticPlanMember_a6a79cb1-db82-4345-92b9-49ec458887e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_22e42019-726b-4728-ba0c-5422d39b64b8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_a6a79cb1-db82-4345-92b9-49ec458887e1" xlink:to="loc_country_US_22e42019-726b-4728-ba0c-5422d39b64b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_31c9a64f-ea6a-40a7-9875-416a22021317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_dc287551-a42c-44e0-b8c1-202e87461dce" xlink:to="loc_us-gaap_ForeignPlanMember_31c9a64f-ea6a-40a7-9875-416a22021317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a6eba1dd-5680-49ae-8fe1-2cf869dc13d1" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_722e4a48-5b46-4853-a494-234a1e43ba01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_722e4a48-5b46-4853-a494-234a1e43ba01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_51840cad-6b0c-4fd4-83c9-2fd91bf601c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_272cfdb3-9469-4fef-8746-fdb070f5d367" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_51840cad-6b0c-4fd4-83c9-2fd91bf601c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_36696675-1d89-42ba-9bbd-1164f018966b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_2f5c9681-e5bc-4299-9f48-dae67c093c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_2f5c9681-e5bc-4299-9f48-dae67c093c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_8b2d094b-ca2a-4662-b9a8-2ce10cf277b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_8b2d094b-ca2a-4662-b9a8-2ce10cf277b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f25638fc-8e13-47b3-bcd1-a32929c39127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f25638fc-8e13-47b3-bcd1-a32929c39127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_a16829d5-5403-4641-9431-18cb693acbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_a16829d5-5403-4641-9431-18cb693acbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2ea586b0-b948-4615-b89c-ac1a9691e20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2ea586b0-b948-4615-b89c-ac1a9691e20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_7528e8d1-d8a6-4fd3-93ef-f37c6a9a64d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_7528e8d1-d8a6-4fd3-93ef-f37c6a9a64d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_305fba6c-f0a7-422c-8735-d3bb5a6f02f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_305fba6c-f0a7-422c-8735-d3bb5a6f02f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d20ad997-2fd1-438a-a826-e3b3169caf61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d20ad997-2fd1-438a-a826-e3b3169caf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_cf07ca13-6ed4-4cf3-a039-c5e386b77e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_cf07ca13-6ed4-4cf3-a039-c5e386b77e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_da572958-ecfd-4b5e-b8d4-8b374e4c3190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_dc8614a4-9ca6-48a3-a1ee-1f76e56252f5" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_da572958-ecfd-4b5e-b8d4-8b374e4c3190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d0e8935e-0390-47be-83ac-78351977c0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d0e8935e-0390-47be-83ac-78351977c0e0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e367ceb8-c8e5-4ce8-a743-65288720deef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e367ceb8-c8e5-4ce8-a743-65288720deef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e367ceb8-c8e5-4ce8-a743-65288720deef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_54b6e2f2-f18c-495b-8da7-ffea6fc9e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:to="loc_us-gaap_DomesticPlanMember_54b6e2f2-f18c-495b-8da7-ffea6fc9e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ae2d1d5-191b-4b50-a1d5-a71abd04bbf8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_54b6e2f2-f18c-495b-8da7-ffea6fc9e9a6" xlink:to="loc_country_US_2ae2d1d5-191b-4b50-a1d5-a71abd04bbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_b97b6806-611d-44c7-b742-d0d0ef00d624" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ede207f9-00ce-491b-b913-8587373e78e1" xlink:to="loc_us-gaap_ForeignPlanMember_b97b6806-611d-44c7-b742-d0d0ef00d624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_644540be-a138-4ad8-8c36-3a94d76853a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_644540be-a138-4ad8-8c36-3a94d76853a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_644540be-a138-4ad8-8c36-3a94d76853a6" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_e2ed56b6-2a09-4e11-88fb-fbf63fe1a52f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_e2ed56b6-2a09-4e11-88fb-fbf63fe1a52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_49ff5bf3-3ba6-4d93-b893-aff5d3dee0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_bad03a61-636e-4406-b49c-5e7821c46727" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_49ff5bf3-3ba6-4d93-b893-aff5d3dee0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b17a5413-d285-4473-aa89-6c7d91a5a35b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_37b41cb5-78a6-4e05-839c-c721f0905366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_37b41cb5-78a6-4e05-839c-c721f0905366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_58358e33-d3d5-49bf-8d88-921cf736ef42" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_58358e33-d3d5-49bf-8d88-921cf736ef42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_003be0a5-553d-4775-903c-560283111588" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_003be0a5-553d-4775-903c-560283111588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_6a35b992-6645-41ea-96e0-1dc2517f8e66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_6a35b992-6645-41ea-96e0-1dc2517f8e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_291910ec-43ae-492c-8bf5-75d8c93623c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8082d391-d5ca-402c-a59f-dfb9b855f328" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_291910ec-43ae-492c-8bf5-75d8c93623c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c382acdd-3f40-4231-9734-b25c5f5aec54" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_4fb12d8e-0706-49a3-9cdf-9c5bf8549bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_4fb12d8e-0706-49a3-9cdf-9c5bf8549bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_eb51f1f3-8e87-4589-baf3-269310555f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_e1ad15f5-4d38-4cff-865f-eafb4cdd054d" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_eb51f1f3-8e87-4589-baf3-269310555f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f5bff165-92dc-4728-bee6-865de1e2de07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d17990-2478-4a57-8ed0-a45292a6fb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f5bff165-92dc-4728-bee6-865de1e2de07" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d17990-2478-4a57-8ed0-a45292a6fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_daeb672d-dbff-4bec-b2ae-f81a47510eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d17990-2478-4a57-8ed0-a45292a6fb7b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_daeb672d-dbff-4bec-b2ae-f81a47510eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3298bed3-c55a-476d-9765-c843bf9a8047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_daeb672d-dbff-4bec-b2ae-f81a47510eab" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3298bed3-c55a-476d-9765-c843bf9a8047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_005b9c3f-3647-48bb-92cf-a002bdf320be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3298bed3-c55a-476d-9765-c843bf9a8047" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_005b9c3f-3647-48bb-92cf-a002bdf320be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_54d17990-2478-4a57-8ed0-a45292a6fb7b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ff517208-851e-46f3-8ad7-83eaa6fcc085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ff517208-851e-46f3-8ad7-83eaa6fcc085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e898bcc9-0965-4b69-80e4-8522cc40f994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_c7a834d4-e193-4cca-97cf-80c78a47e388" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_e898bcc9-0965-4b69-80e4-8522cc40f994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d4a5a092-d949-472b-a062-1f94ef92b6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d4a5a092-d949-472b-a062-1f94ef92b6ca" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f5d7f8fe-950d-46a7-9cb9-a5a90cb05d11" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_c8bb2130-5ab8-46ad-a8d9-d81eb0d80427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:to="loc_us-gaap_DomesticPlanMember_c8bb2130-5ab8-46ad-a8d9-d81eb0d80427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4a64386c-b7bb-43d9-ba45-f11574cbb793" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_c8bb2130-5ab8-46ad-a8d9-d81eb0d80427" xlink:to="loc_country_US_4a64386c-b7bb-43d9-ba45-f11574cbb793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_327dd6e9-a6fc-4fdc-ac0b-2177aa20d5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_5e6bbebe-ee3e-444a-9c5d-98a8a748b4ec" xlink:to="loc_us-gaap_ForeignPlanMember_327dd6e9-a6fc-4fdc-ac0b-2177aa20d5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_e90f392f-d917-4a85-91d4-967362289a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_e90f392f-d917-4a85-91d4-967362289a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_e90f392f-d917-4a85-91d4-967362289a7f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_18f9408c-c550-4161-8a47-3357d9e2a592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_18f9408c-c550-4161-8a47-3357d9e2a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aedac4d3-2e96-4e5e-8e1c-6c0351e81344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_22439a16-6ac7-4530-a89e-dda61bfb2c14" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_aedac4d3-2e96-4e5e-8e1c-6c0351e81344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_85e45f34-f67a-4b60-9f98-0c1a71a30875" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_024b4c72-a682-4eec-be50-e4dfdd56bfee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_024b4c72-a682-4eec-be50-e4dfdd56bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_8cb43be3-e331-42f3-881a-7179f8f19bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_8cb43be3-e331-42f3-881a-7179f8f19bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_abd7aea5-aa26-4fc6-a34e-e507e5fd174b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_abd7aea5-aa26-4fc6-a34e-e507e5fd174b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_7e15e44d-a761-4998-86c7-72adb57cadc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_7e15e44d-a761-4998-86c7-72adb57cadc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d11c7faa-751b-4a5f-b4dd-d944cbde184c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_d11c7faa-751b-4a5f-b4dd-d944cbde184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f46aba37-44bc-481b-8264-b566738867f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_f46aba37-44bc-481b-8264-b566738867f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c329bfb4-8a65-4123-b4a5-cc35399997a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_c329bfb4-8a65-4123-b4a5-cc35399997a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_2b3e9745-c08a-46a2-b9b9-2fad4a3c7784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation_2b3e9745-c08a-46a2-b9b9-2fad4a3c7784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_c28928e9-9c3a-4dfe-97f2-2607bf730816" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_c28928e9-9c3a-4dfe-97f2-2607bf730816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits_79ff43ae-8664-49de-b6f4-55b6f5da7353" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits_79ff43ae-8664-49de-b6f4-55b6f5da7353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_856e7694-d040-49e9-b2f0-0717ac7cba44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_856e7694-d040-49e9-b2f0-0717ac7cba44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_ab5ccae4-d8c0-4de9-bcb0-9f191760e516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_ab5ccae4-d8c0-4de9-bcb0-9f191760e516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_4d2a1ea2-b7d6-49a8-a6fb-0dc124b55ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a3ffd851-a690-4488-93ce-187a711703a4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_4d2a1ea2-b7d6-49a8-a6fb-0dc124b55ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2bf518ed-9383-4ce8-8d57-e29b4e6c0aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2bf518ed-9383-4ce8-8d57-e29b4e6c0aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9020d2c9-97b3-4578-9197-a019d5c4b89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_9020d2c9-97b3-4578-9197-a019d5c4b89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_af4610d3-9ecf-4052-a80c-c05ca88d6984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_af4610d3-9ecf-4052-a80c-c05ca88d6984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_53d3d517-4b4b-4528-8ea2-303127efad2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_53d3d517-4b4b-4528-8ea2-303127efad2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_ea71816f-84fc-4c9a-a79b-72a37c1a9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_ea71816f-84fc-4c9a-a79b-72a37c1a9f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_63b96b84-1879-4003-8624-76ee272769d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDivestituresPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanDivestituresPlanAssets_63b96b84-1879-4003-8624-76ee272769d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_c9acff8f-f01f-465c-975d-a8199266709e" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_c9acff8f-f01f-465c-975d-a8199266709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_86a7263b-f820-4c87-a2ba-bc1fbb088649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_86a7263b-f820-4c87-a2ba-bc1fbb088649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6eb811df-92c4-4e3e-bfb6-81fb6f6b4b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_6eb811df-92c4-4e3e-bfb6-81fb6f6b4b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_23b1c2a5-4ac9-457b-b869-5561e7cc16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_dbece049-f5c6-4cb8-a9d2-0b7bbc1d3e4b" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_23b1c2a5-4ac9-457b-b869-5561e7cc16bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_09e337e7-d6d3-4d22-bded-0f2e8752d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_09e337e7-d6d3-4d22-bded-0f2e8752d3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1c1b1314-a17b-47fa-b64d-1b074570c117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1c1b1314-a17b-47fa-b64d-1b074570c117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e7476af-5bb4-40c6-8dcf-25c05530c4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9e7476af-5bb4-40c6-8dcf-25c05530c4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8a59a853-b983-430c-b2aa-4820276d78f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_8a59a853-b983-430c-b2aa-4820276d78f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7cef5b8b-2312-4827-8556-43ec3d647a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_e65b861c-23c3-4591-90e5-61f69988ec24" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_7cef5b8b-2312-4827-8556-43ec3d647a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_c44e75ef-d999-4b65-81b4-6a5b56f1aeab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_c44e75ef-d999-4b65-81b4-6a5b56f1aeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_ee7c0a3e-3838-40ba-a256-125cea2b2025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract_c44e75ef-d999-4b65-81b4-6a5b56f1aeab" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_ee7c0a3e-3838-40ba-a256-125cea2b2025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_090061b9-5f65-4d97-899e-d7007d13ab65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_090061b9-5f65-4d97-899e-d7007d13ab65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_cce63d9b-eb49-4b98-8211-ef9c6ff78f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_513fa089-0abf-4225-930f-95e3c7b29fe7" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_cce63d9b-eb49-4b98-8211-ef9c6ff78f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_c9ccd7f9-b964-4319-9444-b7f640ace5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_c9ccd7f9-b964-4319-9444-b7f640ace5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_c09abdc4-6cab-4304-ae2f-ccc03bbab72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5f395416-f1fb-45ea-a021-15ae867201c2" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_c09abdc4-6cab-4304-ae2f-ccc03bbab72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6d6d16c9-e6ae-46ef-be81-9020d79e930f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_59a0252d-4875-42eb-b113-bca3fdbc1246" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_6d6d16c9-e6ae-46ef-be81-9020d79e930f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_016f00a2-af85-411d-973c-f1614e09fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_016f00a2-af85-411d-973c-f1614e09fcb0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_a2a423db-a35e-4ef2-a066-c9d0a5063a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_a2a423db-a35e-4ef2-a066-c9d0a5063a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_a2a423db-a35e-4ef2-a066-c9d0a5063a6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_006f8825-ede5-4c0a-829c-d97343013e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:to="loc_us-gaap_DomesticPlanMember_006f8825-ede5-4c0a-829c-d97343013e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ddbe79e0-c8d2-4a06-a5e1-4b645b73babe" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_006f8825-ede5-4c0a-829c-d97343013e86" xlink:to="loc_country_US_ddbe79e0-c8d2-4a06-a5e1-4b645b73babe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e01d1201-13bc-44a5-8ec5-02c6aee0741d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c838d3b1-ae77-4e9c-9560-9afc932fec12" xlink:to="loc_us-gaap_ForeignPlanMember_e01d1201-13bc-44a5-8ec5-02c6aee0741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2f9334e1-3588-409e-afe8-7f6f1fb96d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2f9334e1-3588-409e-afe8-7f6f1fb96d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2f9334e1-3588-409e-afe8-7f6f1fb96d54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b482a093-8b85-401f-98b4-b2857201eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b482a093-8b85-401f-98b4-b2857201eeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f1816667-4f6d-468c-8f0a-f9ea10d901ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_efb0746d-6630-4c2c-a227-caba53ced59f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f1816667-4f6d-468c-8f0a-f9ea10d901ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d073975e-a8c3-4eb0-8947-0a709dabc680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d073975e-a8c3-4eb0-8947-0a709dabc680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_d073975e-a8c3-4eb0-8947-0a709dabc680" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_ef7534d9-77b0-42c1-823a-680179fe1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_ef7534d9-77b0-42c1-823a-680179fe1a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember_73536146-1f68-4962-b2ff-fb3b3f67e504" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember_73536146-1f68-4962-b2ff-fb3b3f67e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_b127f305-5fa5-440e-8a29-0e17d925c6c6" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_db286974-be02-4f8c-a6fc-c6b07230554b" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_b127f305-5fa5-440e-8a29-0e17d925c6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDebtSecurityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_81aebb6a-bad9-46fb-a8cc-ac54fc22a0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_81aebb6a-bad9-46fb-a8cc-ac54fc22a0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7e4c9047-5924-4dd4-86a8-3d8ccee460e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7e4c9047-5924-4dd4-86a8-3d8ccee460e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_3e4abe5e-3c36-4b19-8953-4fa04a5ce88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDebtSecurityMember_d15aa075-b16b-41f7-b87a-c2ac83f8272c" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_3e4abe5e-3c36-4b19-8953-4fa04a5ce88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:href="pfe-20211231.xsd#pfe_DefinedBenefitPlanOtherInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_11520dca-12d1-41bd-8434-7a01ae884100" xlink:to="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_PartnershipInterestMember_5af63db8-a2d7-48e7-b900-f5e259497622" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_PartnershipInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_srt_PartnershipInterestMember_5af63db8-a2d7-48e7-b900-f5e259497622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InsuranceContractsMember_33cfffae-42e3-4a06-ae18-422a0831afab" xlink:href="pfe-20211231.xsd#pfe_InsuranceContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_pfe_InsuranceContractsMember_33cfffae-42e3-4a06-ae18-422a0831afab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherCommingledFundsMember_6df01c4b-94a5-476f-85b3-509832051883" xlink:href="pfe-20211231.xsd#pfe_OtherCommingledFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_pfe_OtherCommingledFundsMember_6df01c4b-94a5-476f-85b3-509832051883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_70e76567-ae17-4684-bec9-51a0f28da619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DefinedBenefitPlanOtherInvestmentsMember_7f163505-8a64-4b2e-93be-0b989dfdb875" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_70e76567-ae17-4684-bec9-51a0f28da619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_955323b8-643a-4564-b661-162096281445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_955323b8-643a-4564-b661-162096281445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_955323b8-643a-4564-b661-162096281445" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_86e90bda-641d-4c63-ad0f-f24ac18f9837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_86e90bda-641d-4c63-ad0f-f24ac18f9837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0e0c8df7-37c3-4978-a4d8-af22fb3f1f67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0e0c8df7-37c3-4978-a4d8-af22fb3f1f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_94765807-0bcf-4b16-b499-faa569e47ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_94765807-0bcf-4b16-b499-faa569e47ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_8424e3c6-116c-4d82-99c7-5073e9f000b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7f172ae8-e887-4f62-8e8d-182498ead190" xlink:to="loc_us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember_8424e3c6-116c-4d82-99c7-5073e9f000b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_acf52724-10a9-4bc6-b990-1f4b8dcda7eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_srt_RangeAxis_acf52724-10a9-4bc6-b990-1f4b8dcda7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_acf52724-10a9-4bc6-b990-1f4b8dcda7eb" xlink:to="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_02efb004-9a1c-43d6-97c9-8a8f5a524e2c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:to="loc_srt_MinimumMember_02efb004-9a1c-43d6-97c9-8a8f5a524e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0a9d48c0-130c-43af-9eea-709af911bdc4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_480b6f31-8eea-4fc8-bbc1-485d9e33d2c3" xlink:to="loc_srt_MaximumMember_0a9d48c0-130c-43af-9eea-709af911bdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_290970ed-41bb-407b-afe3-d2ebd15cb35f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ad4c38f-5011-4505-86d8-34ed64142375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ad4c38f-5011-4505-86d8-34ed64142375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6ebdcca4-add6-472f-a94d-580e49c95ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4b0d4b05-9d75-4eb0-bb30-bcdfe08b3b4c" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_6ebdcca4-add6-472f-a94d-580e49c95ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_27826fd5-2a34-4650-be88-3221173b016f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_27826fd5-2a34-4650-be88-3221173b016f" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_912e28f1-1f0c-4088-84e0-43dbcfbf4558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_912e28f1-1f0c-4088-84e0-43dbcfbf4558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ca6a58f0-279f-445e-b3b1-0c4858f4fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_912e28f1-1f0c-4088-84e0-43dbcfbf4558" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ca6a58f0-279f-445e-b3b1-0c4858f4fe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_589e35d8-9364-4042-8e66-e1cedc689885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ca6a58f0-279f-445e-b3b1-0c4858f4fe39" xlink:to="loc_us-gaap_ForeignPlanMember_589e35d8-9364-4042-8e66-e1cedc689885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_66ee3f9d-91c1-4596-85ae-1e75db28a1be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_66ee3f9d-91c1-4596-85ae-1e75db28a1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_73aa9986-0647-42d8-bcdf-84d30b89787b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_66ee3f9d-91c1-4596-85ae-1e75db28a1be" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_73aa9986-0647-42d8-bcdf-84d30b89787b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_24f4d3b5-b40d-4019-a754-1ff6bdc46913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_73aa9986-0647-42d8-bcdf-84d30b89787b" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_24f4d3b5-b40d-4019-a754-1ff6bdc46913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199381bd-142c-460d-aa03-da4166e2059b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199381bd-142c-460d-aa03-da4166e2059b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b46bc37-01b6-45d5-9d0f-77875bc4a601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_199381bd-142c-460d-aa03-da4166e2059b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b46bc37-01b6-45d5-9d0f-77875bc4a601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_62919e71-64e7-4226-80e7-251b6cbbbf44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b46bc37-01b6-45d5-9d0f-77875bc4a601" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_62919e71-64e7-4226-80e7-251b6cbbbf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_149679d9-c0c5-4c7e-98ba-6fb0e8302af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b6282d84-6b00-4f13-b3b9-9f865a177bfb" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_149679d9-c0c5-4c7e-98ba-6fb0e8302af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_149679d9-c0c5-4c7e-98ba-6fb0e8302af0" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_22446737-2ff8-421b-b131-55ff7c892854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_22446737-2ff8-421b-b131-55ff7c892854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_fa44f1bb-79db-4089-8e50-4c6602f3fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_fa44f1bb-79db-4089-8e50-4c6602f3fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f0c4a845-af67-4f2b-911d-d69efae930e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_fa44f1bb-79db-4089-8e50-4c6602f3fabc" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_f0c4a845-af67-4f2b-911d-d69efae930e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_1043be44-6c81-43af-b3cd-7ea11c2c5a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_1043be44-6c81-43af-b3cd-7ea11c2c5a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_6dbe1e10-46a8-4a99-9b9c-dc501cd1fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_6dbe1e10-46a8-4a99-9b9c-dc501cd1fc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_74e84b1a-c603-40ee-9038-62f3ad39e7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_74e84b1a-c603-40ee-9038-62f3ad39e7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9ac1535f-11f6-42fc-861f-877719a304e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_da0a570d-1ffe-4210-ab6e-47107ae7a008" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9ac1535f-11f6-42fc-861f-877719a304e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80eec615-0009-4bdc-b375-efafe8a819dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80eec615-0009-4bdc-b375-efafe8a819dc" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e5306d3b-b5bb-48b6-8904-48c80d0b526a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e5306d3b-b5bb-48b6-8904-48c80d0b526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e5306d3b-b5bb-48b6-8904-48c80d0b526a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_063e5433-8b31-464a-b055-d00724483999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:to="loc_us-gaap_DomesticPlanMember_063e5433-8b31-464a-b055-d00724483999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e1fb8e6f-281b-4bac-808e-33fb7b19b3ab" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_063e5433-8b31-464a-b055-d00724483999" xlink:to="loc_country_US_e1fb8e6f-281b-4bac-808e-33fb7b19b3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_02427980-1398-4ae9-86bd-d9f4fe1c3eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_ac3f52ae-b149-4a3b-818b-ec7f02cc3c5a" xlink:to="loc_us-gaap_ForeignPlanMember_02427980-1398-4ae9-86bd-d9f4fe1c3eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_a820e4e1-5d31-465e-b415-f14bee073be2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_a820e4e1-5d31-465e-b415-f14bee073be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_a820e4e1-5d31-465e-b415-f14bee073be2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_812c143b-7e48-4fa4-a1c6-2934dfab9f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_812c143b-7e48-4fa4-a1c6-2934dfab9f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d35f76b7-a162-40e2-b312-00b3c62fca89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9423daa2-0e55-4c62-8636-dff80a60dfc1" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d35f76b7-a162-40e2-b312-00b3c62fca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_baa3492f-2a01-4c5b-8bcb-da9a3b087536" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_57df5e95-5dbc-4f25-9708-1dd9d830391f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_57df5e95-5dbc-4f25-9708-1dd9d830391f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_eef00c16-f350-4ead-82fe-3aa61ca62516" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_95617858-1b09-4a85-849e-8a048db69f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_95617858-1b09-4a85-849e-8a048db69f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_a24605a0-4113-4515-9469-790df26aa077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_a24605a0-4113-4515-9469-790df26aa077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_80e15b84-4f98-4766-9852-9d5fbe04d8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_80e15b84-4f98-4766-9852-9d5fbe04d8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_086c251a-7d1b-4c12-9c55-6ff69aeb92c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_086c251a-7d1b-4c12-9c55-6ff69aeb92c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_6dd65ce6-d1e2-4b54-b2f7-e54a4fcad7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_6dd65ce6-d1e2-4b54-b2f7-e54a4fcad7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5449a0f0-86d3-43b6-b679-1f0c213e998c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_a3a71917-fd37-47c8-831c-71392e9af3a7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5449a0f0-86d3-43b6-b679-1f0c213e998c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80b0f918-d18e-4d3e-8a7c-fb4fc36f8f54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_4ded4a51-012c-4731-8666-cca18bce3ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_80b0f918-d18e-4d3e-8a7c-fb4fc36f8f54" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_4ded4a51-012c-4731-8666-cca18bce3ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/Equity" xlink:type="simple" xlink:href="pfe-20211231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7651260e-fa9a-4bd1-a66f-d7df9274d3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0446346c-352d-498f-9b2a-074f86225488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7651260e-fa9a-4bd1-a66f-d7df9274d3c3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0446346c-352d-498f-9b2a-074f86225488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a6db5eb8-6aaa-42d4-8920-2d204288d736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_8c49f3f2-5bc8-4bf1-9a73-c086a57a2b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a6db5eb8-6aaa-42d4-8920-2d204288d736" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_8c49f3f2-5bc8-4bf1-9a73-c086a57a2b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_57c1d995-909c-41cd-b27c-79a9aa26d7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_57c1d995-909c-41cd-b27c-79a9aa26d7c3" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_627ecf15-083a-4273-963e-9210882efbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_627ecf15-083a-4273-963e-9210882efbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_627ecf15-083a-4273-963e-9210882efbbc" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_December2017StockPurchasePlanMember_1ac43785-1595-4666-97d6-f1227dcd185d" xlink:href="pfe-20211231.xsd#pfe_December2017StockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:to="loc_pfe_December2017StockPurchasePlanMember_1ac43785-1595-4666-97d6-f1227dcd185d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_December2018StockPurchasePlanMember_2339fa5e-43b4-4587-abdc-2b1b28bf4a51" xlink:href="pfe-20211231.xsd#pfe_December2018StockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:to="loc_pfe_December2018StockPurchasePlanMember_2339fa5e-43b4-4587-abdc-2b1b28bf4a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_b0bc853a-be8d-4d98-ad0d-6e1c749f0369" xlink:href="pfe-20211231.xsd#pfe_ShareRepurchaseAgreementwithGSCoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_715bd9b2-df8b-4d79-b6c5-8391688df699" xlink:to="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_b0bc853a-be8d-4d98-ad0d-6e1c749f0369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_89300d1f-44f2-4269-9ae0-8eda2a694df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_89300d1f-44f2-4269-9ae0-8eda2a694df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_92ba8f2c-d10f-46f3-833f-ef57913e8532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_89300d1f-44f2-4269-9ae0-8eda2a694df1" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_92ba8f2c-d10f-46f3-833f-ef57913e8532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CommonESOPPlanMember_ec00ceec-f460-4ed5-bdde-8c14baf5eaef" xlink:href="pfe-20211231.xsd#pfe_CommonESOPPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_92ba8f2c-d10f-46f3-833f-ef57913e8532" xlink:to="loc_pfe_CommonESOPPlanMember_ec00ceec-f460-4ed5-bdde-8c14baf5eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d1c29a5e-41c3-4861-b473-3c025e8caecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d1c29a5e-41c3-4861-b473-3c025e8caecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e5acbc0-ad53-4578-9227-41735bbe7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d1c29a5e-41c3-4861-b473-3c025e8caecc" xlink:to="loc_us-gaap_EquityComponentDomain_2e5acbc0-ad53-4578-9227-41735bbe7de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_36597a42-3089-4f4d-99e8-b4a92ec5ee2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e5acbc0-ad53-4578-9227-41735bbe7de9" xlink:to="loc_us-gaap_CommonStockMember_36597a42-3089-4f4d-99e8-b4a92ec5ee2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5f0aa123-2b4a-4ec3-85a0-3619cb4ce636" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d14be875-469a-4bf3-95b4-f5e66f3e5e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d14be875-469a-4bf3-95b4-f5e66f3e5e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6a941b8b-10ba-4e90-a057-36f9f6e500de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_6a941b8b-10ba-4e90-a057-36f9f6e500de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_29c09c9b-cf43-47e6-adc1-bc3cdd67a80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_29c09c9b-cf43-47e6-adc1-bc3cdd67a80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_e7068d84-eb9b-4ab0-a0a7-f71135ba03dd" xlink:href="pfe-20211231.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_e7068d84-eb9b-4ab0-a0a7-f71135ba03dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f098b250-f30c-4300-9aa6-a0da6742d9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_f098b250-f30c-4300-9aa6-a0da6742d9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_46a40166-1eea-470f-8d6e-7987dbf5f36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_46a40166-1eea-470f-8d6e-7987dbf5f36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0b532c2d-869c-4d25-ac64-5a02d0b3af51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0b532c2d-869c-4d25-ac64-5a02d0b3af51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e8e8ce53-ba95-4e1b-8f28-b380738df2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e8e8ce53-ba95-4e1b-8f28-b380738df2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NumberofEmployeeStockOwnershipPlans_87dc2ba4-ee3a-47b6-9e5c-a3cfd78e3b45" xlink:href="pfe-20211231.xsd#pfe_NumberofEmployeeStockOwnershipPlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_pfe_NumberofEmployeeStockOwnershipPlans_87dc2ba4-ee3a-47b6-9e5c-a3cfd78e3b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_db7e62bf-1769-40e4-b31c-c8c89dc108f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_bef1b142-8bd7-4ce8-8cf2-8d87ec3b7988" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_db7e62bf-1769-40e4-b31c-c8c89dc108f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#EquitySummaryofCommonStockPurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1b1d7c0d-e465-4bb4-84b9-05edfca22f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_b0adff5a-0b02-44df-b192-04dbe2f15842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1b1d7c0d-e465-4bb4-84b9-05edfca22f23" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_b0adff5a-0b02-44df-b192-04dbe2f15842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_39a912af-4fe0-46fd-882d-938c7b1658ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_b0adff5a-0b02-44df-b192-04dbe2f15842" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_39a912af-4fe0-46fd-882d-938c7b1658ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_e8ad2247-41eb-495a-ad23-f3384efee06d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_39a912af-4fe0-46fd-882d-938c7b1658ea" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_e8ad2247-41eb-495a-ad23-f3384efee06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OpenMarketPurchasesMember_0186400e-71cb-4f87-af9d-bf9a916f98ac" xlink:href="pfe-20211231.xsd#pfe_OpenMarketPurchasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_e8ad2247-41eb-495a-ad23-f3384efee06d" xlink:to="loc_pfe_OpenMarketPurchasesMember_0186400e-71cb-4f87-af9d-bf9a916f98ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_b0adff5a-0b02-44df-b192-04dbe2f15842" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4006f8d6-6358-4ed8-8580-4877187981bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4006f8d6-6358-4ed8-8580-4877187981bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_dafefabd-bf85-4d4f-948c-6495893ce9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_6e6c4466-a986-4ce2-9191-391b47afd6b0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_dafefabd-bf85-4d4f-948c-6495893ce9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d85dd753-2949-4305-b020-827166c5cb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_32163285-557f-43fe-8eeb-8b0bb6fa56b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d85dd753-2949-4305-b020-827166c5cb1a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_32163285-557f-43fe-8eeb-8b0bb6fa56b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1561e0f-fd99-4875-8357-b855f48a28aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_255cfe1b-788b-404b-986f-660ba6cb9845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1561e0f-fd99-4875-8357-b855f48a28aa" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_255cfe1b-788b-404b-986f-660ba6cb9845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f5522ad1-5ae6-43d8-9402-2545a0220711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1561e0f-fd99-4875-8357-b855f48a28aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f5522ad1-5ae6-43d8-9402-2545a0220711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock_c67156b2-f952-4d46-9c31-a9e3d6b6b44e" xlink:href="pfe-20211231.xsd#pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1561e0f-fd99-4875-8357-b855f48a28aa" xlink:to="loc_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock_c67156b2-f952-4d46-9c31-a9e3d6b6b44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d20d1fb2-d424-46e0-9819-94be7c5e19eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e1561e0f-fd99-4875-8357-b855f48a28aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d20d1fb2-d424-46e0-9819-94be7c5e19eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e12b876b-0a7f-491c-b365-efc10f5991de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e12b876b-0a7f-491c-b365-efc10f5991de" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ca22a521-89d7-4ddd-8445-63d86b5ebd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:to="loc_us-gaap_AwardTypeAxis_ca22a521-89d7-4ddd-8445-63d86b5ebd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ca22a521-89d7-4ddd-8445-63d86b5ebd8d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0bf8303a-5222-43e5-b586-0c2326bdf127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0bf8303a-5222-43e5-b586-0c2326bdf127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_dce4d9b3-b66d-41ac-aa53-a5038e98d20f" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_dce4d9b3-b66d-41ac-aa53-a5038e98d20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_24df455e-1d13-47ec-8600-5a88b6cc2b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_us-gaap_PerformanceSharesMember_24df455e-1d13-47ec-8600-5a88b6cc2b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_ea4312f6-4ea6-495b-ab08-295ef46c0946" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_ea4312f6-4ea6-495b-ab08-295ef46c0946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_85251e5d-2091-4316-b809-fd4aec46431e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dedb3a53-3436-45a9-9e90-7f4810b2729f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_85251e5d-2091-4316-b809-fd4aec46431e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_624e673e-161b-46e3-bf52-c035523326fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:to="loc_us-gaap_PlanNameAxis_624e673e-161b-46e3-bf52-c035523326fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_24d8f2a5-71a7-4e9e-b2e5-b51dfa977708" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_624e673e-161b-46e3-bf52-c035523326fd" xlink:to="loc_us-gaap_PlanNameDomain_24d8f2a5-71a7-4e9e-b2e5-b51dfa977708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_A2019StockPlanMember_cae92ec7-74d4-4ca8-9934-d1366f531701" xlink:href="pfe-20211231.xsd#pfe_A2019StockPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_24d8f2a5-71a7-4e9e-b2e5-b51dfa977708" xlink:to="loc_pfe_A2019StockPlanMember_cae92ec7-74d4-4ca8-9934-d1366f531701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_22b79a65-87b2-4e30-881a-8bbf873bb1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_22b79a65-87b2-4e30-881a-8bbf873bb1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_576b7972-7e7f-4f4e-af7b-b47590c36aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_22b79a65-87b2-4e30-881a-8bbf873bb1d3" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_576b7972-7e7f-4f4e-af7b-b47590c36aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_6bbb59fc-e1d0-4b5c-b8e8-6f2da1338749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_576b7972-7e7f-4f4e-af7b-b47590c36aa9" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_6bbb59fc-e1d0-4b5c-b8e8-6f2da1338749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d1fd4879-5887-41fe-b069-ca0022114048" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ce16af83-ccea-42c4-b044-85bc10a7021d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ce16af83-ccea-42c4-b044-85bc10a7021d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c2470d5f-bef2-4e8d-bf4a-13bcc90af718" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_c2470d5f-bef2-4e8d-bf4a-13bcc90af718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_283b3329-9e6b-452b-b7bd-078b9b45b479" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_283b3329-9e6b-452b-b7bd-078b9b45b479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_2f359857-251c-4b39-ae76-22c9adf4ceda" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_2f359857-251c-4b39-ae76-22c9adf4ceda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_886cfe61-68b8-41c8-94ff-22d044bae4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_886cfe61-68b8-41c8-94ff-22d044bae4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_00e5c880-41a8-499f-be17-d6df96907872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_00e5c880-41a8-499f-be17-d6df96907872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_255c4637-c589-42cf-b758-73686668303c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_df63707d-0755-4360-aa99-99b7c9d8ec3e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_255c4637-c589-42cf-b758-73686668303c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4dd848a-261f-4662-ba2b-894a6452196f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4dd848a-261f-4662-ba2b-894a6452196f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:to="loc_us-gaap_AwardTypeAxis_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_aa7dd322-3a0e-4a5c-87c0-eada7d03fbfe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_12e50d89-2443-41f6-ae91-1513568c5e3d" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_12e50d89-2443-41f6-ae91-1513568c5e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_999e8b70-c644-40cd-b896-39e92c818d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_999e8b70-c644-40cd-b896-39e92c818d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_7ab2e160-499b-48d8-b0c9-2595b5a981ba" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_7ab2e160-499b-48d8-b0c9-2595b5a981ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b7e1e625-6eed-4d21-a735-81ab770d4d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_us-gaap_PerformanceSharesMember_b7e1e625-6eed-4d21-a735-81ab770d4d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BreakthroughPerformanceAwardsMember_9bdc0540-8f87-48b4-8e9f-5f65a0da5816" xlink:href="pfe-20211231.xsd#pfe_BreakthroughPerformanceAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_BreakthroughPerformanceAwardsMember_9bdc0540-8f87-48b4-8e9f-5f65a0da5816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b3120630-b60e-4220-a70c-ae9b970f602b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b3120630-b60e-4220-a70c-ae9b970f602b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6c7b996c-5a27-42b6-9c03-b09dc153dd9f" xlink:href="pfe-20211231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ccae20f-c08b-4009-8412-bf8a899a8a57" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6c7b996c-5a27-42b6-9c03-b09dc153dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:to="loc_srt_RangeAxis_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_572c1ea3-7ceb-4e2d-bbb1-a05ba778c134" xlink:to="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_78d1fdf3-b4fa-4ac1-86cc-31df7947dc84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:to="loc_srt_MinimumMember_78d1fdf3-b4fa-4ac1-86cc-31df7947dc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7249ef03-2a67-4010-b3f8-25e7e95ff46c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af24087d-5425-400f-9f41-1af6c20e9813" xlink:to="loc_srt_MaximumMember_7249ef03-2a67-4010-b3f8-25e7e95ff46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_358725b9-2ed1-45e2-9661-38ce05251d81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:to="loc_srt_TitleOfIndividualAxis_358725b9-2ed1-45e2-9661-38ce05251d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_358725b9-2ed1-45e2-9661-38ce05251d81" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_22faa200-7398-49b9-9db2-7db4ca4d606f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:to="loc_srt_ManagementMember_22faa200-7398-49b9-9db2-7db4ca4d606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_6cea97fc-97c4-4cef-9ac5-fada565e40af" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_6cea97fc-97c4-4cef-9ac5-fada565e40af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_0b7096f5-19e1-4af8-8c27-664b368f9496" xlink:href="pfe-20211231.xsd#pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f719a4f3-11b6-43d0-8317-f0d0493e6cf4" xlink:to="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_0b7096f5-19e1-4af8-8c27-664b368f9496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_006100f0-bec2-4938-b63b-7fe65ba6ae6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a27357f4-5fb0-461b-98c8-a09a5c73e3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a27357f4-5fb0-461b-98c8-a09a5c73e3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_84ad37be-ea20-498e-92e2-3c0ea152a77a" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_84ad37be-ea20-498e-92e2-3c0ea152a77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_41092e43-9573-4b6e-9748-97d8ede01277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_41092e43-9573-4b6e-9748-97d8ede01277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_2a7c5307-e685-4550-8a2f-8708012b663a" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_2a7c5307-e685-4550-8a2f-8708012b663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_a3c55636-88e2-4281-a6fe-60e9d0af02de" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_a3c55636-88e2-4281-a6fe-60e9d0af02de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_e2f1e5db-4bd5-4bc7-8789-12445859f519" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_e2f1e5db-4bd5-4bc7-8789-12445859f519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod_2d1cda30-5fe4-485f-898d-2556dc41fd98" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod_2d1cda30-5fe4-485f-898d-2556dc41fd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1fb764f4-c901-41e6-8ac7-f985a972c583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1fb764f4-c901-41e6-8ac7-f985a972c583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0bb6820b-102b-4ebb-b0f1-7e2b7d15eaf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_0bb6820b-102b-4ebb-b0f1-7e2b7d15eaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_2b9a660d-f6af-44eb-83b7-156a19f74a87" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_2b9a660d-f6af-44eb-83b7-156a19f74a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_70f36043-a06b-48a2-bb01-f055d770ffc8" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e15f99dc-b3dc-4224-8831-2f169a9833bb" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_70f36043-a06b-48a2-bb01-f055d770ffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c94ff33-94e4-4bfd-8547-c507326aff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1879acbe-1ca0-4c38-8beb-c017959aa5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c94ff33-94e4-4bfd-8547-c507326aff0c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1879acbe-1ca0-4c38-8beb-c017959aa5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7092fe56-9b12-48c5-bd3b-b4f55690d802" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1879acbe-1ca0-4c38-8beb-c017959aa5a9" xlink:to="loc_us-gaap_AwardTypeAxis_7092fe56-9b12-48c5-bd3b-b4f55690d802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7092fe56-9b12-48c5-bd3b-b4f55690d802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_a76c881f-1979-4be1-9059-14915cd2f2ef" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_a76c881f-1979-4be1-9059-14915cd2f2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_82c01b6a-ab04-45b6-ae23-0888c8bf7416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_82c01b6a-ab04-45b6-ae23-0888c8bf7416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_36301091-2864-42cd-b26c-b8565bbc5474" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_36301091-2864-42cd-b26c-b8565bbc5474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_32d145a8-30cd-4d6a-8363-dad6328dbd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_us-gaap_PerformanceSharesMember_32d145a8-30cd-4d6a-8363-dad6328dbd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3a072d73-38e4-457b-87c9-c24c8e272ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23a29a50-ce72-4bd5-857e-f0249cdb4daa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3a072d73-38e4-457b-87c9-c24c8e272ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1879acbe-1ca0-4c38-8beb-c017959aa5a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcfc3e00-6d8d-4f5a-ab60-5c6e780170b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcfc3e00-6d8d-4f5a-ab60-5c6e780170b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c6efc3de-bf6f-40ff-8a9d-22f62219f24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c6efc3de-bf6f-40ff-8a9d-22f62219f24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6758c89e-4da0-419a-92ac-926c053cfe46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6758c89e-4da0-419a-92ac-926c053cfe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue_74025ea6-50c1-47ec-a659-1f41f1a8d56b" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue_74025ea6-50c1-47ec-a659-1f41f1a8d56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39250ba8-3561-4951-940d-858ea0635a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_39250ba8-3561-4951-940d-858ea0635a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_68251a0a-8947-4f9e-bc9e-29527c42d6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_68251a0a-8947-4f9e-bc9e-29527c42d6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_349785ee-f6d5-45ea-a69c-51f2fa375172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_349785ee-f6d5-45ea-a69c-51f2fa375172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9de59c42-5744-4ba1-a2f3-8a22ec9e3ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9de59c42-5744-4ba1-a2f3-8a22ec9e3ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_93dcfe13-235f-4417-8a9a-4a0615866b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_93dcfe13-235f-4417-8a9a-4a0615866b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_297f087d-d9e2-4a68-865b-2b14a1ad2ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_297f087d-d9e2-4a68-865b-2b14a1ad2ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_957efbc1-5ab9-4618-9b67-4a7328246eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80af0f76-d71d-4d51-8a93-c72bdc2a18f8" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_957efbc1-5ab9-4618-9b67-4a7328246eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsScheduleofValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9996d21-2d9a-4f9d-82d8-8bef360b81af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c105809b-dfda-40bc-b8e8-395a14a67071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b9996d21-2d9a-4f9d-82d8-8bef360b81af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c105809b-dfda-40bc-b8e8-395a14a67071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bebdce60-3463-470c-babe-1588d005a739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c105809b-dfda-40bc-b8e8-395a14a67071" xlink:to="loc_us-gaap_AwardTypeAxis_bebdce60-3463-470c-babe-1588d005a739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bebdce60-3463-470c-babe-1588d005a739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6c05a55f-9053-4eb9-90ff-e20ff8df5509" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6c05a55f-9053-4eb9-90ff-e20ff8df5509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6e4d9b89-8276-49eb-a168-771748172068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a26a3a2-312f-48a7-ba23-dd2314209931" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6e4d9b89-8276-49eb-a168-771748172068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c105809b-dfda-40bc-b8e8-395a14a67071" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bb0a6bdb-2871-4843-89b3-60a7d51823c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_bb0a6bdb-2871-4843-89b3-60a7d51823c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d0c2ddf-ec65-4098-974a-82cd68e3fe38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d0c2ddf-ec65-4098-974a-82cd68e3fe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6906956-937e-4105-886a-ec60cd1ba05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a6906956-937e-4105-886a-ec60cd1ba05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a08cca4c-ab8c-4f94-ab34-d8aced367da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9b980945-e4d5-42ab-857a-f64a78d05dcf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a08cca4c-ab8c-4f94-ab34-d8aced367da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3173c29c-e30f-42dd-a1dc-e8ccf5838b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9cc808-70bf-4f4d-b020-1f3347143456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3173c29c-e30f-42dd-a1dc-e8ccf5838b7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9cc808-70bf-4f4d-b020-1f3347143456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ebf9395b-d56a-4701-9221-f3d846ce459b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9cc808-70bf-4f4d-b020-1f3347143456" xlink:to="loc_us-gaap_AwardTypeAxis_ebf9395b-d56a-4701-9221-f3d846ce459b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ebf9395b-d56a-4701-9221-f3d846ce459b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_aeaccd5d-c93d-4ee5-a394-85399884618f" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_aeaccd5d-c93d-4ee5-a394-85399884618f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_401fb77f-5b94-4129-8a93-c098ffc33ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_401fb77f-5b94-4129-8a93-c098ffc33ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_281597dd-b2fb-4fb9-a386-34690000ee05" xlink:href="pfe-20211231.xsd#pfe_PortfolioPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_281597dd-b2fb-4fb9-a386-34690000ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_cfc40dee-f470-4b3f-acd9-cb0a0fd06dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_us-gaap_PerformanceSharesMember_cfc40dee-f470-4b3f-acd9-cb0a0fd06dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BreakthroughPerformanceAwardsMember_b6dd57fb-a778-478f-97fc-263000da2c70" xlink:href="pfe-20211231.xsd#pfe_BreakthroughPerformanceAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6ba6e0c0-adea-4cfb-a3e9-dc0f5117c77d" xlink:to="loc_pfe_BreakthroughPerformanceAwardsMember_b6dd57fb-a778-478f-97fc-263000da2c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a9cc808-70bf-4f4d-b020-1f3347143456" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c51db7de-2d58-4016-b072-1084ca2bf513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c51db7de-2d58-4016-b072-1084ca2bf513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06175b42-74c5-4998-bbfa-948bcf86bd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_06175b42-74c5-4998-bbfa-948bcf86bd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0aa13d1a-9b06-4382-8391-7a2009981861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0aa13d1a-9b06-4382-8391-7a2009981861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_5796eb1a-e20a-4761-a9fd-67b1678b0bcf" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_5796eb1a-e20a-4761-a9fd-67b1678b0bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f96a70bf-aef6-4bda-a895-cfc325f81a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f96a70bf-aef6-4bda-a895-cfc325f81a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17863249-d0d0-476b-8c91-1887673f5301" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f419fc45-a97f-4d5f-a082-13580cfbc2ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_17863249-d0d0-476b-8c91-1887673f5301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c34a1aa-c4c8-418c-856f-1b89972a61cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7c34a1aa-c4c8-418c-856f-1b89972a61cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ebeb92-08fd-4297-acdc-cf2c93bf005a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_12ebeb92-08fd-4297-acdc-cf2c93bf005a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_03415ffd-e015-4226-9c5e-43bd4095ee51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_03415ffd-e015-4226-9c5e-43bd4095ee51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_4c0aaf5a-3b28-4c5d-8960-bfa8bf98efb2" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_4c0aaf5a-3b28-4c5d-8960-bfa8bf98efb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82154575-e133-4cba-b25a-55eee5089860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82154575-e133-4cba-b25a-55eee5089860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82aeea5e-9240-4393-bb2f-e2cf73f81f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b4cd571b-bd21-4bed-86d3-458a2e1df682" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_82aeea5e-9240-4393-bb2f-e2cf73f81f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_eca6b61b-2d37-4973-ac64-05999598bd55" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_eca6b61b-2d37-4973-ac64-05999598bd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_8305c218-8d6c-4900-9252-546075b8b67d" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_8305c218-8d6c-4900-9252-546075b8b67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_abfbcd74-172c-4c38-b410-65dfcc83664b" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_abfbcd74-172c-4c38-b410-65dfcc83664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_dd15cc15-7d8f-4384-bb16-442335a80bd7" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_dd15cc15-7d8f-4384-bb16-442335a80bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_fc007024-deae-463b-b8ea-437fdc82c3d5" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward_913487d0-528c-4572-b7b2-ab41d8f2835d" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_fc007024-deae-463b-b8ea-437fdc82c3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c63778e4-0b4e-41a5-a3bb-0364869162e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_c63778e4-0b4e-41a5-a3bb-0364869162e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_4019349e-40fa-4230-8bc8-65d4f8420926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_4019349e-40fa-4230-8bc8-65d4f8420926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_18046aa6-8886-45b7-816a-1ead41bcae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_18046aa6-8886-45b7-816a-1ead41bcae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_b6d91d35-11aa-4e27-a6b3-1d8c9f894190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_b6d91d35-11aa-4e27-a6b3-1d8c9f894190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_7a774729-096a-4642-9efa-969b1627fac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward_d02cc605-5f3e-43fb-b44e-ceaa5c202240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_7a774729-096a-4642-9efa-969b1627fac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0a53102e-6620-44dc-b484-bcb3b9c02a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5761cd5a-af3e-4c54-a0e9-b7f77096117a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0a53102e-6620-44dc-b484-bcb3b9c02a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be6370d0-64ee-4c8b-93e9-d022712c2b41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4edd251-291a-4dbb-9581-0358d0412e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_be6370d0-64ee-4c8b-93e9-d022712c2b41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4edd251-291a-4dbb-9581-0358d0412e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ab1e85d8-b667-42fb-a7d2-14d67256d9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4edd251-291a-4dbb-9581-0358d0412e19" xlink:to="loc_us-gaap_AwardTypeAxis_ab1e85d8-b667-42fb-a7d2-14d67256d9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ab1e85d8-b667-42fb-a7d2-14d67256d9a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6bcc2a7a-7ef5-438d-be85-6a374da56690" xlink:href="pfe-20211231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_6bcc2a7a-7ef5-438d-be85-6a374da56690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ProfitUnitsMember_6ea11d86-5894-462b-be32-99a82f90b524" xlink:href="pfe-20211231.xsd#pfe_ProfitUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7cfe38f-61fa-4f12-8ba2-56769ecfe906" xlink:to="loc_pfe_ProfitUnitsMember_6ea11d86-5894-462b-be32-99a82f90b524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4edd251-291a-4dbb-9581-0358d0412e19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b1bd6ecd-3800-4fd8-aa17-b7d9fc7ff2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b1bd6ecd-3800-4fd8-aa17-b7d9fc7ff2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_8b267808-5151-46f9-bcf3-6776dad675bf" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_8b267808-5151-46f9-bcf3-6776dad675bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_a7b9c034-3982-420f-96d6-54a9805ff6a6" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_a7b9c034-3982-420f-96d6-54a9805ff6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber_d39cf70e-baa3-456b-8193-28f1d3c8c4a3" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber_d39cf70e-baa3-456b-8193-28f1d3c8c4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_2f053ce6-01f5-4060-b912-62c824353011" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_2f053ce6-01f5-4060-b912-62c824353011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_6b3db183-0528-4047-b502-3fccf559c06c" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_6b3db183-0528-4047-b502-3fccf559c06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_ccf8d635-229a-4d17-b4a5-6f0a9b9ae082" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_ccf8d635-229a-4d17-b4a5-6f0a9b9ae082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e05dd181-d94e-47c3-9c63-b6d90ffe6243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e05dd181-d94e-47c3-9c63-b6d90ffe6243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_899a6798-4e41-4097-88b5-f30d8bded23d" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_899a6798-4e41-4097-88b5-f30d8bded23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_be3c4dcd-6d5f-41c3-8f42-b0cd84bec354" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_be3c4dcd-6d5f-41c3-8f42-b0cd84bec354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm_9b94fc1c-f9f0-419c-b917-99c0fb2af9c3" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm_9b94fc1c-f9f0-419c-b917-99c0fb2af9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_bc64230d-428d-4d40-9e12-1815fb172a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_bc64230d-428d-4d40-9e12-1815fb172a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_66dd7b59-62ba-48e0-90d4-f62d27ae3e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_66dd7b59-62ba-48e0-90d4-f62d27ae3e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_6eb57497-1e53-46bb-a0e8-ba9615c4a0a9" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_6eb57497-1e53-46bb-a0e8-ba9615c4a0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted_97a61af4-f7c0-4074-9da2-3e8bc02a21d2" xlink:href="pfe-20211231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted_97a61af4-f7c0-4074-9da2-3e8bc02a21d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_6975709c-3b43-4abd-9c8e-b8a7e7f0bbe6" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_6975709c-3b43-4abd-9c8e-b8a7e7f0bbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_5f18cf75-6953-4d8c-a186-ab14c2fc7a70" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_5f18cf75-6953-4d8c-a186-ab14c2fc7a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c8dd4f36-a293-4207-8533-517e7a8d7862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c8dd4f36-a293-4207-8533-517e7a8d7862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_61b7752a-8642-4d1d-8a38-4020aeb8fe41" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_61b7752a-8642-4d1d-8a38-4020aeb8fe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_e08028ff-9934-4f05-9ace-ccffc3ad6448" xlink:href="pfe-20211231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e14abca8-a459-4a3d-a2a5-a85ba5d87f3b" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_e08028ff-9934-4f05-9ace-ccffc3ad6448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51db9d65-0fef-4c42-a6a8-c91ba79047ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51db9d65-0fef-4c42-a6a8-c91ba79047ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c222a98a-cd5f-4e7c-82ac-08c97ca7d926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c222a98a-cd5f-4e7c-82ac-08c97ca7d926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_76b2bb67-64a1-464c-aa84-831ccdb497c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_76b2bb67-64a1-464c-aa84-831ccdb497c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3fb4193b-ebbd-4737-ad2e-5d813ac4fe89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3fb4193b-ebbd-4737-ad2e-5d813ac4fe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a86fdee1-918b-4f66-bf11-b3038fe28041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_a86fdee1-918b-4f66-bf11-b3038fe28041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e29237e-b3d9-4d97-8b08-05e0555aef27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_072c262e-b7fc-47d8-9014-58c0384480e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e29237e-b3d9-4d97-8b08-05e0555aef27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_258322b7-00f3-4047-a34f-0a117e524a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_258322b7-00f3-4047-a34f-0a117e524a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_0e40761f-8d14-4b2d-9b51-4237b0a4e5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_0e40761f-8d14-4b2d-9b51-4237b0a4e5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ed0e080c-d565-46ec-a53d-b461bc060ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ed0e080c-d565-46ec-a53d-b461bc060ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_12be0509-1829-4d71-94a8-a4438fad6d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_12be0509-1829-4d71-94a8-a4438fad6d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7f442481-402c-420f-bc01-9be4f2a86593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7f442481-402c-420f-bc01-9be4f2a86593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_015d133b-f015-4c08-99d2-53e8f2a17ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_015d133b-f015-4c08-99d2-53e8f2a17ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_189eb6bd-ebf0-468f-b5b2-9eb59cc99a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_189eb6bd-ebf0-468f-b5b2-9eb59cc99a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fe738585-e45f-470f-9f81-2c77d031e95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_baedae1e-7dbb-46fd-9190-21330f2dbea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fe738585-e45f-470f-9f81-2c77d031e95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ef2ae74e-1007-4604-b61e-766602c464b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ef2ae74e-1007-4604-b61e-766602c464b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_6d471bfd-d42e-45f7-b5c3-3eb26ca79f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_6d471bfd-d42e-45f7-b5c3-3eb26ca79f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1dbd3472-56b9-42f5-965f-1173bf28fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1dbd3472-56b9-42f5-965f-1173bf28fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_54b6e593-c8c7-404e-a570-4b34afeb43df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_54b6e593-c8c7-404e-a570-4b34afeb43df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5f29ce87-036a-42f1-a419-969526fa3362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_5f29ce87-036a-42f1-a419-969526fa3362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_54f9eab1-6fda-4319-907d-32d9b2551224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_54f9eab1-6fda-4319-907d-32d9b2551224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ebf6b5ac-05cc-43c1-b114-3c711b606221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ebf6b5ac-05cc-43c1-b114-3c711b606221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c7646064-6b5f-4b55-8abc-35b1596c0a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88c291f0-801b-4f66-b936-bc8ca1599a6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c7646064-6b5f-4b55-8abc-35b1596c0a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="simple" xlink:href="pfe-20211231.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bc688b87-a332-48ac-9a9a-8d90c4fd79a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f4d567ee-da2c-492c-9b18-8f8bf561e421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bc688b87-a332-48ac-9a9a-8d90c4fd79a9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f4d567ee-da2c-492c-9b18-8f8bf561e421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e208a83-2574-43d8-b85c-f59cc2b2a7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_705237b5-bbc1-4b3e-acfe-30c687d0ee35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e208a83-2574-43d8-b85c-f59cc2b2a7b0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_705237b5-bbc1-4b3e-acfe-30c687d0ee35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d89e43f1-5331-419c-8279-6cd7699d56cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_7c0a0116-db63-45cb-9e9a-f0030c3a460d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d89e43f1-5331-419c-8279-6cd7699d56cc" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_7c0a0116-db63-45cb-9e9a-f0030c3a460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_ac58527f-26e9-4436-8cc5-9956e21d52bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7c0a0116-db63-45cb-9e9a-f0030c3a460d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_ac58527f-26e9-4436-8cc5-9956e21d52bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_f3822e9e-016e-46bc-a176-f9919496a804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7c0a0116-db63-45cb-9e9a-f0030c3a460d" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_f3822e9e-016e-46bc-a176-f9919496a804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_7ec99c2c-8fdd-4942-b9a1-0c9f0f17573e" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7c0a0116-db63-45cb-9e9a-f0030c3a460d" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_7ec99c2c-8fdd-4942-b9a1-0c9f0f17573e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a8336d73-137d-46a9-803d-5cf54a16cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7c0a0116-db63-45cb-9e9a-f0030c3a460d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a8336d73-137d-46a9-803d-5cf54a16cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6e5581a8-5759-4f0c-9666-a90b8bc209a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_7c0a0116-db63-45cb-9e9a-f0030c3a460d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6e5581a8-5759-4f0c-9666-a90b8bc209a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_85fe0415-abff-46ae-b420-ac7f90e8b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d89e43f1-5331-419c-8279-6cd7699d56cc" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_85fe0415-abff-46ae-b420-ac7f90e8b79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_834770a4-a03a-4790-9a2c-50da84f47861" xlink:href="pfe-20211231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_85fe0415-abff-46ae-b420-ac7f90e8b79e" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_834770a4-a03a-4790-9a2c-50da84f47861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8fa3c1ff-32f9-42a8-a05f-14d5cb434431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_85fe0415-abff-46ae-b420-ac7f90e8b79e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8fa3c1ff-32f9-42a8-a05f-14d5cb434431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ef6dd50a-5d70-4914-90c6-12b102b50494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_85fe0415-abff-46ae-b420-ac7f90e8b79e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ef6dd50a-5d70-4914-90c6-12b102b50494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20c00f15-3b52-4dbd-9330-11c0137dd140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d89e43f1-5331-419c-8279-6cd7699d56cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20c00f15-3b52-4dbd-9330-11c0137dd140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c6a7542d-598f-4bb9-b888-89bd21dad7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20c00f15-3b52-4dbd-9330-11c0137dd140" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c6a7542d-598f-4bb9-b888-89bd21dad7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a0dbda61-a119-47d7-8113-8cb05b33c712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20c00f15-3b52-4dbd-9330-11c0137dd140" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a0dbda61-a119-47d7-8113-8cb05b33c712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6c8bce3-81b5-43ef-a0ee-24aef492a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_20c00f15-3b52-4dbd-9330-11c0137dd140" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b6c8bce3-81b5-43ef-a0ee-24aef492a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_372d9fb6-4d13-4f25-9a13-7503ee0a2211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d89e43f1-5331-419c-8279-6cd7699d56cc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_372d9fb6-4d13-4f25-9a13-7503ee0a2211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/Leases" xlink:type="simple" xlink:href="pfe-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_afabe6d4-f89e-48ac-b924-41146ca86f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9dee054f-77c9-4636-8bf5-1dfc2e06d44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_afabe6d4-f89e-48ac-b924-41146ca86f62" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9dee054f-77c9-4636-8bf5-1dfc2e06d44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a93ad562-e70c-48e6-99ed-500c644469ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock_b98c080c-337d-487e-88ea-5c65b757b184" xlink:href="pfe-20211231.xsd#pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a93ad562-e70c-48e6-99ed-500c644469ec" xlink:to="loc_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock_b98c080c-337d-487e-88ea-5c65b757b184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6d2b3fac-8f11-4a19-875c-6143d0a748d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a93ad562-e70c-48e6-99ed-500c644469ec" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6d2b3fac-8f11-4a19-875c-6143d0a748d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2307f2b9-dc22-4634-aa7e-aabfbc419a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a93ad562-e70c-48e6-99ed-500c644469ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2307f2b9-dc22-4634-aa7e-aabfbc419a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_66ed7255-3887-43e0-93fa-18af21edcc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_44b10b8d-7bff-455f-8558-61a2c70a02cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66ed7255-3887-43e0-93fa-18af21edcc7c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_44b10b8d-7bff-455f-8558-61a2c70a02cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44b10b8d-7bff-455f-8558-61a2c70a02cc" xlink:to="loc_srt_RangeAxis_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c179b8cf-1c44-4bf2-9dbe-834d2a9c3ea3" xlink:to="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41085851-382c-4776-bcd1-57a05fefcac5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:to="loc_srt_MinimumMember_41085851-382c-4776-bcd1-57a05fefcac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6b9b8bda-ef28-493b-a26d-a62f6b954b82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2fa3fac2-dd7f-4247-ad3b-15cc100cf61b" xlink:to="loc_srt_MaximumMember_6b9b8bda-ef28-493b-a26d-a62f6b954b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_44b10b8d-7bff-455f-8558-61a2c70a02cc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_64a7589d-e62b-41f0-befd-4e1097655b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_64a7589d-e62b-41f0-befd-4e1097655b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_a04710da-c238-4324-b65c-1c7e7e25290f" xlink:href="pfe-20211231.xsd#pfe_LesseeOperatingLeaseOptionToExtendTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:to="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_a04710da-c238-4324-b65c-1c7e7e25290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a9ccf320-d7df-4351-8b34-d805da594aed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a178e348-ed35-44cf-8dd9-41d42477afe7" xlink:to="loc_us-gaap_VariableLeaseCost_a9ccf320-d7df-4351-8b34-d805da594aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesScheduleofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_90d4f241-70cc-4d47-ba16-e32993d3ad8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_53ab772e-e935-486b-8d55-c3b67fd5b249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90d4f241-70cc-4d47-ba16-e32993d3ad8e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_53ab772e-e935-486b-8d55-c3b67fd5b249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_43788646-f23b-4f02-951c-84a30ce3ee53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90d4f241-70cc-4d47-ba16-e32993d3ad8e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_43788646-f23b-4f02-951c-84a30ce3ee53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4940a66-2a0f-4feb-9f28-250265687f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90d4f241-70cc-4d47-ba16-e32993d3ad8e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4940a66-2a0f-4feb-9f28-250265687f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_210b70ec-9adf-49b3-9a3e-cd4186fc1907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90d4f241-70cc-4d47-ba16-e32993d3ad8e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_210b70ec-9adf-49b3-9a3e-cd4186fc1907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_eccf169a-7f87-4fec-8213-c4c1aa0b74c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90d4f241-70cc-4d47-ba16-e32993d3ad8e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_eccf169a-7f87-4fec-8213-c4c1aa0b74c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_12861b05-3d36-45ef-816d-a92181099081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90d4f241-70cc-4d47-ba16-e32993d3ad8e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_12861b05-3d36-45ef-816d-a92181099081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b913215b-e8df-4c07-a4cc-d73bc196b958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_OperatingLeaseCost_b913215b-e8df-4c07-a4cc-d73bc196b958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ae713b8b-6008-49d0-8715-c20a8e583e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_VariableLeaseCost_ae713b8b-6008-49d0-8715-c20a8e583e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_0cd54c77-5262-4451-b8f7-efb091bc4364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_SubleaseIncome_0cd54c77-5262-4451-b8f7-efb091bc4364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_40bdc1fe-fdfa-4699-9bdc-382ea7784f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_LeaseCost_40bdc1fe-fdfa-4699-9bdc-382ea7784f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7cbf166b-329c-4a7d-83cc-f27e7e50aa77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7cbf166b-329c-4a7d-83cc-f27e7e50aa77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_18c2cdfa-1fcc-49a4-80aa-b20bd48c248d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_18c2cdfa-1fcc-49a4-80aa-b20bd48c248d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cdcfe583-9dfb-418b-80e3-ab38df45001f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_OperatingLeasePayments_cdcfe583-9dfb-418b-80e3-ab38df45001f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_32967433-967d-44da-bfd3-7fad7ee9840f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_617fcee3-c4e6-47df-890c-c11b787d2fc8" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_32967433-967d-44da-bfd3-7fad7ee9840f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_16cb68f0-e60d-419f-80d3-3223afe9ed3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_16cb68f0-e60d-419f-80d3-3223afe9ed3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_524ed908-953c-4def-aef2-f378fa7c317e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_524ed908-953c-4def-aef2-f378fa7c317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_54ded3a5-f5a5-4eb1-8474-b9a691e28294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_54ded3a5-f5a5-4eb1-8474-b9a691e28294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_c1337d2a-6e1c-404f-9da3-e35b2b0f5f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_c1337d2a-6e1c-404f-9da3-e35b2b0f5f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_9fc79fac-16ff-4468-8c15-c26db66b705d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_9fc79fac-16ff-4468-8c15-c26db66b705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_a5e9d46b-65fb-4f6e-9377-d83416c51145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_a5e9d46b-65fb-4f6e-9377-d83416c51145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3657691c-fba2-402a-b19f-677fc44e730c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3657691c-fba2-402a-b19f-677fc44e730c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8b13e10f-8e1c-441e-a1fd-152aabf8d076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8b13e10f-8e1c-441e-a1fd-152aabf8d076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2104282a-4bea-4635-856b-038c40788959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_OperatingLeaseLiability_2104282a-4bea-4635-856b-038c40788959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_40594424-d71a-4a48-a38b-04f278a1c122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_40594424-d71a-4a48-a38b-04f278a1c122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db2b6fc9-4bff-4410-b60a-98c44047a925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ae085fe-0b82-42c7-90d7-fa31783dcc3f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_db2b6fc9-4bff-4410-b60a-98c44047a925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1" xlink:type="simple" xlink:href="pfe-20211231.xsd#LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="simple" xlink:href="pfe-20211231.xsd#ContingenciesandCertainCommitments"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5ff28bdb-16d6-4af1-98e4-a39dab265ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_06b79d3e-f5b9-48a9-a507-76c5cd0704a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5ff28bdb-16d6-4af1-98e4-a39dab265ec0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_06b79d3e-f5b9-48a9-a507-76c5cd0704a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ContingenciesandCertainCommitmentsPatentLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbd0b4ac-2bb6-4f9d-b3ba-3bf5b18b8048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bbd0b4ac-2bb6-4f9d-b3ba-3bf5b18b8048" xlink:to="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_daa58ed5-973b-4550-b036-bf3560a04843" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_srt_ProductOrServiceAxis_daa58ed5-973b-4550-b036-bf3560a04843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_daa58ed5-973b-4550-b036-bf3560a04843" xlink:to="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_e51f338b-b42a-4a6c-aaac-29bf8c1d5743" xlink:href="pfe-20211231.xsd#pfe_XeljanzMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:to="loc_pfe_XeljanzMember_e51f338b-b42a-4a6c-aaac-29bf8c1d5743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_78e6a299-598f-4744-a9cf-f579fa25b756" xlink:href="pfe-20211231.xsd#pfe_EliquisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e2d9380a-9021-489f-b272-ff7afe58836e" xlink:to="loc_pfe_EliquisMember_78e6a299-598f-4744-a9cf-f579fa25b756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ad27dfab-95cb-470f-8345-968dd0b63d2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_srt_LitigationCaseAxis_ad27dfab-95cb-470f-8345-968dd0b63d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cd108782-91d2-4e7e-9be0-ba9e37b68a89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ad27dfab-95cb-470f-8345-968dd0b63d2a" xlink:to="loc_srt_LitigationCaseTypeDomain_cd108782-91d2-4e7e-9be0-ba9e37b68a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_13701a7e-efd7-400c-9622-9c1b7d8cd28e" xlink:href="pfe-20211231.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_cd108782-91d2-4e7e-9be0-ba9e37b68a89" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_13701a7e-efd7-400c-9622-9c1b7d8cd28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_2fc9970b-0fcb-4b23-929a-2f297a573d51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_2fc9970b-0fcb-4b23-929a-2f297a573d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_2fc9970b-0fcb-4b23-929a-2f297a573d51" xlink:to="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_0cc48a92-acea-4ae4-90f2-235b7c54992d" xlink:href="pfe-20211231.xsd#pfe_PatentInfringementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:to="loc_pfe_PatentInfringementMember_0cc48a92-acea-4ae4-90f2-235b7c54992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PneumococcalVaccinePatentInfringementMember_29ea6d63-265f-4b0c-a86c-cdea92c8d3f0" xlink:href="pfe-20211231.xsd#pfe_PneumococcalVaccinePatentInfringementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:to="loc_pfe_PneumococcalVaccinePatentInfringementMember_29ea6d63-265f-4b0c-a86c-cdea92c8d3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherPatentInfringementMember_978acf1b-2186-4dc9-8ba8-06b1841b95a7" xlink:href="pfe-20211231.xsd#pfe_OtherPatentInfringementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_5b412c77-78c4-4ce5-918d-853bf5cb5b2e" xlink:to="loc_pfe_OtherPatentInfringementMember_978acf1b-2186-4dc9-8ba8-06b1841b95a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_us-gaap_LitigationStatusAxis_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_2cbbb588-3e5c-4c0f-9424-9553cbe50ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_f34576a6-e3c0-4a23-86aa-5a4cd274d3cd" xlink:to="loc_us-gaap_LitigationStatusDomain_2cbbb588-3e5c-4c0f-9424-9553cbe50ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_b171420f-21c2-4653-b338-ef08b6cd0afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_2cbbb588-3e5c-4c0f-9424-9553cbe50ad2" xlink:to="loc_us-gaap_PendingLitigationMember_b171420f-21c2-4653-b338-ef08b6cd0afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa81dc7d-e3e1-461d-9b57-07254ca550b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa81dc7d-e3e1-461d-9b57-07254ca550b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_36223cdb-dbec-4cba-a842-26d7bf7bfb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_aa81dc7d-e3e1-461d-9b57-07254ca550b5" xlink:to="loc_us-gaap_LossContingencyNatureDomain_36223cdb-dbec-4cba-a842-26d7bf7bfb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PatentInfringementMember_3586d350-fabb-4ee2-a523-35315c60676a" xlink:href="pfe-20211231.xsd#pfe_PatentInfringementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_36223cdb-dbec-4cba-a842-26d7bf7bfb1a" xlink:to="loc_pfe_PatentInfringementMember_3586d350-fabb-4ee2-a523-35315c60676a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_c2dfd25e-7777-4316-946b-38f9ed9a0240" xlink:to="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_5e9d747b-048b-4c27-b291-36b6cacd6eb1" xlink:href="pfe-20211231.xsd#pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold_5e9d747b-048b-4c27-b291-36b6cacd6eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_0ff40e33-b7d5-4907-a3cb-a7fb448e8399" xlink:href="pfe-20211231.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_0ff40e33-b7d5-4907-a3cb-a7fb448e8399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1cc2e3c7-6c85-4f1d-a5f5-6d0f97d27889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_1cc2e3c7-6c85-4f1d-a5f5-6d0f97d27889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyNumberofDefendants_1e2aca12-18ea-4450-8191-2f24302bb251" xlink:href="pfe-20211231.xsd#pfe_GainContingencyNumberofDefendants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_GainContingencyNumberofDefendants_1e2aca12-18ea-4450-8191-2f24302bb251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_01efb54d-0d7a-435a-9f5f-4bf271869ffd" xlink:href="pfe-20211231.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_2fd20244-f36b-4b94-83c9-fc5fd3b7458d" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_01efb54d-0d7a-435a-9f5f-4bf271869ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_312f3ae7-8808-4b3d-9e2e-f7b35a9e75cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_312f3ae7-8808-4b3d-9e2e-f7b35a9e75cc" xlink:to="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae6b83f0-8459-4663-9b63-4557878ae2d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_srt_RangeAxis_ae6b83f0-8459-4663-9b63-4557878ae2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_678bdbdf-adfb-4a3e-a0f0-b35d190e2418" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ae6b83f0-8459-4663-9b63-4557878ae2d4" xlink:to="loc_srt_RangeMember_678bdbdf-adfb-4a3e-a0f0-b35d190e2418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_55836d99-0ce6-46de-9571-7ef8e1a907bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_678bdbdf-adfb-4a3e-a0f0-b35d190e2418" xlink:to="loc_srt_MinimumMember_55836d99-0ce6-46de-9571-7ef8e1a907bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_70e001e1-a495-472e-8e22-8b36d7c82be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_483a0abb-c49f-4ae2-8001-43e6ce9e3e4a" xlink:to="loc_us-gaap_LossContingencyNatureDomain_70e001e1-a495-472e-8e22-8b36d7c82be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_e435f730-5b53-4f1b-93ca-92e293f76caf" xlink:href="pfe-20211231.xsd#pfe_EnvironmentalRemediationLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_70e001e1-a495-472e-8e22-8b36d7c82be0" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_e435f730-5b53-4f1b-93ca-92e293f76caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_0edfe132-3d00-4d15-a6bc-047bbb4b530f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_srt_LitigationCaseAxis_0edfe132-3d00-4d15-a6bc-047bbb4b530f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ea8a5ca1-6523-4b11-a2fc-6e6d88a62156" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_0edfe132-3d00-4d15-a6bc-047bbb4b530f" xlink:to="loc_srt_LitigationCaseTypeDomain_ea8a5ca1-6523-4b11-a2fc-6e6d88a62156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_b1270d7d-4f70-48a2-9a12-f58bfb2439a7" xlink:href="pfe-20211231.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ea8a5ca1-6523-4b11-a2fc-6e6d88a62156" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_b1270d7d-4f70-48a2-9a12-f58bfb2439a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2238d8c5-c065-4be1-8c5b-0d915d067663" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_srt_ProductOrServiceAxis_2238d8c5-c065-4be1-8c5b-0d915d067663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2238d8c5-c065-4be1-8c5b-0d915d067663" xlink:to="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EpiPenMember_a07df938-a03b-47f4-82ff-2aa157092057" xlink:href="pfe-20211231.xsd#pfe_EpiPenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:to="loc_pfe_EpiPenMember_a07df938-a03b-47f4-82ff-2aa157092057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DocetaxelMember_d26564cc-5312-4d38-bc95-bfa3b8014042" xlink:href="pfe-20211231.xsd#pfe_DocetaxelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5a53e404-e5e6-4142-b36a-14aa37abdc9d" xlink:to="loc_pfe_DocetaxelMember_d26564cc-5312-4d38-bc95-bfa3b8014042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_LitigationStatusAxis_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_387ef97b-5be1-4d65-a193-f68d6af5496f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_7ea1080f-9bac-448c-aaf6-1b42bca2d0a9" xlink:to="loc_us-gaap_LitigationStatusDomain_387ef97b-5be1-4d65-a193-f68d6af5496f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_24ff41e0-8841-44f4-b8eb-b29ea35c48d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_387ef97b-5be1-4d65-a193-f68d6af5496f" xlink:to="loc_us-gaap_PendingLitigationMember_24ff41e0-8841-44f4-b8eb-b29ea35c48d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_449b35ee-0bd9-4cd6-9afd-872a16dcf03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_449b35ee-0bd9-4cd6-9afd-872a16dcf03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bf2a4da0-ea1b-48bd-bf06-e1cdc91d6910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_449b35ee-0bd9-4cd6-9afd-872a16dcf03b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bf2a4da0-ea1b-48bd-bf06-e1cdc91d6910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0db2feb2-5eb0-40b7-b83b-4ed90ae816b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_bf2a4da0-ea1b-48bd-bf06-e1cdc91d6910" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_0db2feb2-5eb0-40b7-b83b-4ed90ae816b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6eb6424a-1b93-48d9-88a4-18bd0cec36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6eb6424a-1b93-48d9-88a4-18bd0cec36eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a7f530-eb3a-4990-8348-0db852c90f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6eb6424a-1b93-48d9-88a4-18bd0cec36eb" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a7f530-eb3a-4990-8348-0db852c90f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MeridianMember_8662df78-ce9f-4232-ade3-435ca36e43e6" xlink:href="pfe-20211231.xsd#pfe_MeridianMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a9a7f530-eb3a-4990-8348-0db852c90f8e" xlink:to="loc_pfe_MeridianMember_8662df78-ce9f-4232-ade3-435ca36e43e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9c3ee78-328e-47da-af7e-f2825eb334f5" xlink:to="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_7b8ab264-bfce-486a-bc41-1b08cdb85d0f" xlink:href="pfe-20211231.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_7b8ab264-bfce-486a-bc41-1b08cdb85d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_9f9cc89e-0741-4f69-a1d1-b00cc615b4c2" xlink:href="pfe-20211231.xsd#pfe_FeasibilityStudyNumberOfLagoons"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_9f9cc89e-0741-4f69-a1d1-b00cc615b4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f8e44f3a-016a-44fa-bb95-d3664b3d2f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8aa365d4-f38d-4f12-86eb-98bfbb8f7ab8" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f8e44f3a-016a-44fa-bb95-d3664b3d2f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7e9093c-d574-459c-a482-3897a2dd7b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_2cec69ef-1ecc-4403-8049-88d25ff3c79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7e9093c-d574-459c-a482-3897a2dd7b87" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_2cec69ef-1ecc-4403-8049-88d25ff3c79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0bc668bb-3012-4bec-b974-a5540c1ef051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7e9093c-d574-459c-a482-3897a2dd7b87" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0bc668bb-3012-4bec-b974-a5540c1ef051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2ef1ddae-43df-4274-9eae-b79e8c2dc4e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7e9093c-d574-459c-a482-3897a2dd7b87" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2ef1ddae-43df-4274-9eae-b79e8c2dc4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e3420ec5-66e5-4c2e-836c-538a55db8044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e7e9093c-d574-459c-a482-3897a2dd7b87" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_e3420ec5-66e5-4c2e-836c-538a55db8044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformation"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_615fa8c2-3602-4743-9855-fecf2599204e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_a57e8955-3b9b-4fb0-a875-50c23083b270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_615fa8c2-3602-4743-9855-fecf2599204e" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_a57e8955-3b9b-4fb0-a875-50c23083b270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationTables"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_11388ded-8dd0-4100-ba0f-7fb3b54870d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dd905ec9-b87c-4a7f-80b7-91a09140d33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_11388ded-8dd0-4100-ba0f-7fb3b54870d9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_dd905ec9-b87c-4a7f-80b7-91a09140d33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_b395757f-e10e-4a8c-8e9d-e45c33346d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_11388ded-8dd0-4100-ba0f-7fb3b54870d9" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_b395757f-e10e-4a8c-8e9d-e45c33346d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c417fcea-6312-448d-9112-01bbd05e0fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_11388ded-8dd0-4100-ba0f-7fb3b54870d9" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c417fcea-6312-448d-9112-01bbd05e0fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8da79353-cf14-4583-b921-6a150c5dc27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_11388ded-8dd0-4100-ba0f-7fb3b54870d9" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8da79353-cf14-4583-b921-6a150c5dc27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5e65dece-0e52-44e9-8044-ec1ccf73306b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5e65dece-0e52-44e9-8044-ec1ccf73306b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c9cb083b-f84d-425f-acd2-d8eae472ecd1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_52bd81b5-8684-4739-a638-71c8eb4f208d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_52bd81b5-8684-4739-a638-71c8eb4f208d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_00f40ceb-c5ed-4506-9f36-960d9c411f83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_00f40ceb-c5ed-4506-9f36-960d9c411f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_d0a0ebb9-632d-4b6c-8aec-50d13dced1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ac1480f1-6d77-4ca5-94ed-49142e25b4de" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_d0a0ebb9-632d-4b6c-8aec-50d13dced1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b873b3af-8343-460f-b5c0-501f6f12d26c" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8de0bfa5-05bc-401a-a62f-4f47dfc649f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8de0bfa5-05bc-401a-a62f-4f47dfc649f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_ada52ef0-f6dd-4bd8-b4be-790ac4c4590f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0a7007dc-4e59-488a-b24c-5788d8cf8f98" xlink:to="loc_us-gaap_AccountsReceivableMember_ada52ef0-f6dd-4bd8-b4be-790ac4c4590f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_16b0147c-691a-45a8-8ef7-2291075aff0e" xlink:to="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NonUnitedStatesMember_b3dc8374-46fe-44b6-815b-22cd1c87ab8f" xlink:href="pfe-20211231.xsd#pfe_NonUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_pfe_NonUnitedStatesMember_b3dc8374-46fe-44b6-815b-22cd1c87ab8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_51c9d3f1-9b74-4496-aa45-ab6851ce0b80" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_country_US_51c9d3f1-9b74-4496-aa45-ab6851ce0b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_c4630686-323a-47fb-8610-30b161e45ae0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c41d7e8e-116a-432a-a68b-63cbd192f155" xlink:to="loc_country_JP_c4630686-323a-47fb-8610-30b161e45ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_175484a7-5ea7-477f-8eb2-eb3d181dafc1" xlink:to="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ThreeLargestUSWholesaleCustomersMember_bae285a3-0e68-497a-84e3-f810eecae86e" xlink:href="pfe-20211231.xsd#pfe_ThreeLargestUSWholesaleCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:to="loc_pfe_ThreeLargestUSWholesaleCustomersMember_bae285a3-0e68-497a-84e3-f810eecae86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GovernmentAndGovernmentSponsoredMember_ab5898e4-09d6-4abf-9172-2f47eb3264e8" xlink:href="pfe-20211231.xsd#pfe_GovernmentAndGovernmentSponsoredMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_541878b3-f07e-419c-8eff-e25068d6657d" xlink:to="loc_pfe_GovernmentAndGovernmentSponsoredMember_ab5898e4-09d6-4abf-9172-2f47eb3264e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_011f16bb-de30-496c-8c1e-0315eda75cd9" xlink:to="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_4bcaaea3-b2b2-4984-885b-90862dd738d0" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4193f96-78a0-44dc-a6ba-6263d4cf9e78" xlink:to="loc_pfe_ComirnatyMember_4bcaaea3-b2b2-4984-885b-90862dd738d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_379bce3c-bc51-4b15-a5b2-f50b64b87b92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_379bce3c-bc51-4b15-a5b2-f50b64b87b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_7e8273e8-0f8c-4f65-8fe7-af13291a4a1a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_acf48cb9-df8a-4f23-a83e-0ef4693c9dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_NumberOfOperatingSegments_acf48cb9-df8a-4f23-a83e-0ef4693c9dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_efb75b25-94f8-43f8-9ba7-3ee6f976b0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_Assets_efb75b25-94f8-43f8-9ba7-3ee6f976b0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_95252902-342f-4698-a04e-a6ee443568f6" xlink:href="pfe-20211231.xsd#pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_95252902-342f-4698-a04e-a6ee443568f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e2bbfb7f-205e-4d27-b5f2-93856703fb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e2bbfb7f-205e-4d27-b5f2-93856703fb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_ed5a503c-a0cb-4a2a-9473-73fb80eb04ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_ed5a503c-a0cb-4a2a-9473-73fb80eb04ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a7fb9786-0fcd-48d0-9740-fe603d3af17b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_a7fb9786-0fcd-48d0-9740-fe603d3af17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43703ab0-fe9d-4f93-aa85-e19ccee005ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43703ab0-fe9d-4f93-aa85-e19ccee005ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3ab7e9a0-1d1f-4441-a37c-c38f94b2367c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3ab7e9a0-1d1f-4441-a37c-c38f94b2367c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_358ef141-70f7-4a50-8c0f-79844d0e79d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2d2cf64d-265a-4827-ac9c-17e69c3bcdbb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_358ef141-70f7-4a50-8c0f-79844d0e79d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationNarrativeDetail_1"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1a60ffc4-1109-442d-a7e4-b6de92cfa448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1a60ffc4-1109-442d-a7e4-b6de92cfa448" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ea721c1c-4982-4253-87cb-b2f94a1d6633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ea721c1c-4982-4253-87cb-b2f94a1d6633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7acf4f9-f233-436d-ab9e-7018fc31eccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ea721c1c-4982-4253-87cb-b2f94a1d6633" xlink:to="loc_us-gaap_SegmentDomain_c7acf4f9-f233-436d-ab9e-7018fc31eccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_1db10e78-8ba4-44c0-9296-0cba58d4ab65" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7acf4f9-f233-436d-ab9e-7018fc31eccd" xlink:to="loc_pfe_BiopharmaSegmentMember_1db10e78-8ba4-44c0-9296-0cba58d4ab65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e8c04e70-b365-4a3a-a5f0-c29991ccbe60" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_srt_ConsolidationItemsAxis_e8c04e70-b365-4a3a-a5f0-c29991ccbe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e8c04e70-b365-4a3a-a5f0-c29991ccbe60" xlink:to="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c8a8e5f2-99af-4a7b-b995-2d7f88f9d135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:to="loc_us-gaap_OperatingSegmentsMember_c8a8e5f2-99af-4a7b-b995-2d7f88f9d135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_6dfc5756-161a-4e36-b8ad-c5c1d5d6b263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:to="loc_us-gaap_CorporateNonSegmentMember_6dfc5756-161a-4e36-b8ad-c5c1d5d6b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_7cfe56a3-4c9a-442e-aff2-366f82b6a868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_df6b4a1f-64fc-461b-bbfe-3f6819a45d05" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_7cfe56a3-4c9a-442e-aff2-366f82b6a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsAxis_691bf559-956c-40f5-bdd7-8b1bcefc2de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsAxis_691bf559-956c-40f5-bdd7-8b1bcefc2de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsegmentsConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsAxis_691bf559-956c-40f5-bdd7-8b1bcefc2de2" xlink:to="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember_d4dfbb34-89c2-4662-a3f2-1b523495cf68" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:to="loc_pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember_d4dfbb34-89c2-4662-a3f2-1b523495cf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_cda04102-ff7c-4aab-9872-9cc32d9389b7" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsAcquisitionRelatedCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:to="loc_pfe_ReconcilingItemsAcquisitionRelatedCostsMember_cda04102-ff7c-4aab-9872-9cc32d9389b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReconcilingItemsOtherMember_35be61c6-70d7-45d6-a31d-cbdcb16fb317" xlink:href="pfe-20211231.xsd#pfe_ReconcilingItemsOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsConsolidationItemsDomain_cb31295d-7396-47a2-91a3-2e8d82cfa7bc" xlink:to="loc_pfe_ReconcilingItemsOtherMember_35be61c6-70d7-45d6-a31d-cbdcb16fb317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1d48a72-97c6-4252-b48f-af2c96a7a619" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1d48a72-97c6-4252-b48f-af2c96a7a619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a1d48a72-97c6-4252-b48f-af2c96a7a619" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ViivHealthcareLimitedMember_6249ba88-e1e1-4c7e-a9fb-af2fbf3c3c14" xlink:href="pfe-20211231.xsd#pfe_ViivHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:to="loc_pfe_ViivHealthcareLimitedMember_6249ba88-e1e1-4c7e-a9fb-af2fbf3c3c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GSKConsumerHealthcareMember_a28e1187-b042-43af-a6b7-5fe2907a29f7" xlink:href="pfe-20211231.xsd#pfe_GSKConsumerHealthcareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_954c8071-a07b-40a5-a6ad-a7e34c5de1ba" xlink:to="loc_pfe_GSKConsumerHealthcareMember_a28e1187-b042-43af-a6b7-5fe2907a29f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2de41a23-5fa6-452f-af2c-1fc7f15518db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2de41a23-5fa6-452f-af2c-1fc7f15518db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8fcf54fe-f3e5-49b5-96f4-519b082bf2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2de41a23-5fa6-452f-af2c-1fc7f15518db" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8fcf54fe-f3e5-49b5-96f4-519b082bf2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrilliumMember_4fec9b4d-ad12-4cfa-8c2d-311768c6480a" xlink:href="pfe-20211231.xsd#pfe_TrilliumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_8fcf54fe-f3e5-49b5-96f4-519b082bf2fd" xlink:to="loc_pfe_TrilliumMember_4fec9b4d-ad12-4cfa-8c2d-311768c6480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_33003408-7648-4e34-93af-578aca70139f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_33003408-7648-4e34-93af-578aca70139f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_33003408-7648-4e34-93af-578aca70139f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_04b5d3d6-b450-42c2-a8c2-f7404eb4b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_04b5d3d6-b450-42c2-a8c2-f7404eb4b7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b09f1b35-8b9a-45f8-8b89-29a08f922901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_253a2cb0-0500-43e9-96a6-f39bf7f28896" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b09f1b35-8b9a-45f8-8b89-29a08f922901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a79287ec-cc86-4dbb-bdf7-715ae48ee203" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce04e5bf-81ff-4338-b2a8-c501384bd9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce04e5bf-81ff-4338-b2a8-c501384bd9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61bf18a7-f0ef-4143-a549-51ea2e0ed9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_61bf18a7-f0ef-4143-a549-51ea2e0ed9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_238452ec-b5e2-4918-bde1-4c78f363d171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_238452ec-b5e2-4918-bde1-4c78f363d171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeDividend_e96c2a81-38d1-42be-8054-f62405553be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeDividend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_InvestmentIncomeDividend_e96c2a81-38d1-42be-8054-f62405553be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8359e56e-d49f-4c0b-ae3a-eb01b67a002d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_8359e56e-d49f-4c0b-ae3a-eb01b67a002d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_ebb688f8-955a-42d5-ad3d-c2c59f57659f" xlink:href="pfe-20211231.xsd#pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring_ebb688f8-955a-42d5-ad3d-c2c59f57659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaymentForCollaborativeAndLicensingArrangements_e8906e8e-f980-4b2f-b1dc-4d0e1b08f5ad" xlink:href="pfe-20211231.xsd#pfe_PaymentForCollaborativeAndLicensingArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_pfe_PaymentForCollaborativeAndLicensingArrangements_e8906e8e-f980-4b2f-b1dc-4d0e1b08f5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_b3f67ea1-3677-4014-b9e9-3e878fdb48fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit_b3f67ea1-3677-4014-b9e9-3e878fdb48fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7fa08fb9-a2f8-4e6f-bf21-ee92c4e830f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7fa08fb9-a2f8-4e6f-bf21-ee92c4e830f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e80c6d3-70bf-4fb3-9701-5396bd21625c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e80c6d3-70bf-4fb3-9701-5396bd21625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_c5658f09-ef7d-44e2-a25e-f91dbcfbc374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36f4d096-a44c-4e17-8670-4807586aadc5" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_c5658f09-ef7d-44e2-a25e-f91dbcfbc374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_04ce6584-5b1e-4066-9bd7-8a83ab168c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0db4b49a-5f69-48a6-870e-ca267d760f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_04ce6584-5b1e-4066-9bd7-8a83ab168c23" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0db4b49a-5f69-48a6-870e-ca267d760f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ba3f6485-f26c-4b6c-b940-7de4ea26cebc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0db4b49a-5f69-48a6-870e-ca267d760f2f" xlink:to="loc_srt_StatementGeographicalAxis_ba3f6485-f26c-4b6c-b940-7de4ea26cebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ba3f6485-f26c-4b6c-b940-7de4ea26cebc" xlink:to="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fb8d7653-6cc9-4935-bec2-def231242eaa" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_country_US_fb8d7653-6cc9-4935-bec2-def231242eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedEuropeMember_a32a80fc-6c35-4f70-a947-5ca33c76210d" xlink:href="pfe-20211231.xsd#pfe_DevelopedEuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_pfe_DevelopedEuropeMember_a32a80fc-6c35-4f70-a947-5ca33c76210d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_DevelopedRestOfWorldMember_4a91cdb0-ffa9-49f2-939e-1e15dd58e9ef" xlink:href="pfe-20211231.xsd#pfe_DevelopedRestOfWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_pfe_DevelopedRestOfWorldMember_4a91cdb0-ffa9-49f2-939e-1e15dd58e9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EmergingMarketsMember_1cbc17fe-780c-445a-8e19-cb46c10f6cc0" xlink:href="pfe-20211231.xsd#pfe_EmergingMarketsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_27de00a2-c5b2-4fea-8121-8b159de32861" xlink:to="loc_pfe_EmergingMarketsMember_1cbc17fe-780c-445a-8e19-cb46c10f6cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_415ef4a9-253d-4aa7-9512-645f670f6919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_0db4b49a-5f69-48a6-870e-ca267d760f2f" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_415ef4a9-253d-4aa7-9512-645f670f6919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70d4d81a-4b65-4810-bb95-a13f84dfe12a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_415ef4a9-253d-4aa7-9512-645f670f6919" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_70d4d81a-4b65-4810-bb95-a13f84dfe12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_75da2fb0-139e-43d7-8dcd-d736588f0836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_75da2fb0-139e-43d7-8dcd-d736588f0836" xlink:to="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ecd0ea37-b8e4-4254-8095-39921752186f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:to="loc_srt_MajorCustomersAxis_ecd0ea37-b8e4-4254-8095-39921752186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ecd0ea37-b8e4-4254-8095-39921752186f" xlink:to="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_McKessonInc.Member_2e4cd017-c17d-49ad-9b57-8d50a1df09aa" xlink:href="pfe-20211231.xsd#pfe_McKessonInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:to="loc_pfe_McKessonInc.Member_2e4cd017-c17d-49ad-9b57-8d50a1df09aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AmerisourceBergenCorporationMember_21b195cb-5765-4d29-9986-9e0cd13fc1a3" xlink:href="pfe-20211231.xsd#pfe_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:to="loc_pfe_AmerisourceBergenCorporationMember_21b195cb-5765-4d29-9986-9e0cd13fc1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_CardinalHealthInc.Member_5fb63115-c9de-4f88-9506-813d16c76f19" xlink:href="pfe-20211231.xsd#pfe_CardinalHealthInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_dae68ad3-5b5a-4413-9c54-67aaf42a9171" xlink:to="loc_pfe_CardinalHealthInc.Member_5fb63115-c9de-4f88-9506-813d16c76f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d7a703-7f0a-47e6-ab53-650361075b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ae5cf4d9-6579-4f0d-8db2-8c2be3632cc0" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d7a703-7f0a-47e6-ab53-650361075b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_db5adc0a-22a8-4993-94ba-f9719446f75d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_77d7a703-7f0a-47e6-ab53-650361075b8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_db5adc0a-22a8-4993-94ba-f9719446f75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_50f1f097-e089-433b-82c4-1937b4ae6f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_50f1f097-e089-433b-82c4-1937b4ae6f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_53b04c17-e054-4453-971f-e0fd65cacb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50f1f097-e089-433b-82c4-1937b4ae6f1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_53b04c17-e054-4453-971f-e0fd65cacb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_8d388ebf-b9bd-47e6-aafe-370b8dd286bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_53b04c17-e054-4453-971f-e0fd65cacb79" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_8d388ebf-b9bd-47e6-aafe-370b8dd286bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_3c5f4afb-5597-4e08-91b1-6037e28d30e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_b1c47a64-0262-436e-ae57-7e0910b213f4" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_3c5f4afb-5597-4e08-91b1-6037e28d30e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1a1ca68b-b508-48bf-8fcf-16d7fbe70eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_3c5f4afb-5597-4e08-91b1-6037e28d30e9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1a1ca68b-b508-48bf-8fcf-16d7fbe70eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" xlink:href="pfe-20211231.xsd#SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"/>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8c876252-209d-410d-a7c2-d089e3fffe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8c876252-209d-410d-a7c2-d089e3fffe49" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_us-gaap_ReportingUnitAxis_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_2c1cbf48-a3cb-4d5b-872f-b048659fc9f4" xlink:to="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VaccinesMember_2d0078d7-309c-4ca6-a508-d57c2c992c1d" xlink:href="pfe-20211231.xsd#pfe_VaccinesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_VaccinesMember_2d0078d7-309c-4ca6-a508-d57c2c992c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OncologyMember_7ac66340-5c04-4bad-a012-be6513ecbb15" xlink:href="pfe-20211231.xsd#pfe_OncologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_OncologyMember_7ac66340-5c04-4bad-a012-be6513ecbb15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InternalMedicineMember_f7f31805-25b0-4231-8e58-4318fad022cb" xlink:href="pfe-20211231.xsd#pfe_InternalMedicineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_InternalMedicineMember_f7f31805-25b0-4231-8e58-4318fad022cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_HospitalMember_e3f8a582-7517-49b3-98a5-2dfeeeae745b" xlink:href="pfe-20211231.xsd#pfe_HospitalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_HospitalMember_e3f8a582-7517-49b3-98a5-2dfeeeae745b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflammationandImmunologyMember_426b0a70-7a65-49cd-bd9b-94d0a894c776" xlink:href="pfe-20211231.xsd#pfe_InflammationandImmunologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_InflammationandImmunologyMember_426b0a70-7a65-49cd-bd9b-94d0a894c776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RareDiseaseMember_52453523-3900-4534-a896-16b5cec9389e" xlink:href="pfe-20211231.xsd#pfe_RareDiseaseMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_RareDiseaseMember_52453523-3900-4534-a896-16b5cec9389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_faafee14-d57a-4bd2-a1af-435efed2a547" xlink:href="pfe-20211231.xsd#pfe_ConsumerHealthcareReportingUnitMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_933269d2-dba7-4d71-a2ee-38ff5044893d" xlink:to="loc_pfe_ConsumerHealthcareReportingUnitMember_faafee14-d57a-4bd2-a1af-435efed2a547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_srt_ProductOrServiceAxis_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4b9755e5-2595-4e19-8e5e-f1a1bcff2b03" xlink:to="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ComirnatyMember_a4ba74e8-af3a-48e8-9c33-57492e1f59f3" xlink:href="pfe-20211231.xsd#pfe_ComirnatyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ComirnatyMember_a4ba74e8-af3a-48e8-9c33-57492e1f59f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_0b463b37-664a-4c3c-b676-c7947d574c22" xlink:href="pfe-20211231.xsd#pfe_PrevnarPrevenarFamilyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_0b463b37-664a-4c3c-b676-c7947d574c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_NimenrixMember_65a9c1bf-8afe-42e1-9d9f-8dcecfe413cb" xlink:href="pfe-20211231.xsd#pfe_NimenrixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_NimenrixMember_65a9c1bf-8afe-42e1-9d9f-8dcecfe413cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_bb67d37b-2908-4d1e-8fb5-aef3dc4415e6" xlink:href="pfe-20211231.xsd#pfe_FSMEIMMUNTicoVacMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_bb67d37b-2908-4d1e-8fb5-aef3dc4415e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrumenbaMember_9222b5dd-aaa9-4391-9e9f-8c42dd1e3b3c" xlink:href="pfe-20211231.xsd#pfe_TrumenbaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TrumenbaMember_9222b5dd-aaa9-4391-9e9f-8c42dd1e3b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherVaccinesProductsMember_0e6c685f-fc9f-4335-853a-fc38262cf05b" xlink:href="pfe-20211231.xsd#pfe_OtherVaccinesProductsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherVaccinesProductsMember_0e6c685f-fc9f-4335-853a-fc38262cf05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IbranceMember_cfe2a7db-0e96-49ef-ad54-49c0e23d6880" xlink:href="pfe-20211231.xsd#pfe_IbranceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_IbranceMember_cfe2a7db-0e96-49ef-ad54-49c0e23d6880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_6eb6c475-2929-4838-be25-c875087592ce" xlink:href="pfe-20211231.xsd#pfe_XtandiAllianceRevenuesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_6eb6c475-2929-4838-be25-c875087592ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InlytaMember_ac0158be-5098-4399-a74c-3f4efa4be1ee" xlink:href="pfe-20211231.xsd#pfe_InlytaMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_InlytaMember_ac0158be-5098-4399-a74c-3f4efa4be1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SutentMember_b89ffd87-7400-4b58-af12-e994cbe2bba3" xlink:href="pfe-20211231.xsd#pfe_SutentMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_SutentMember_b89ffd87-7400-4b58-af12-e994cbe2bba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BosulifMember_eb2461d7-9ae8-49f3-9d0a-98a45c7a6d61" xlink:href="pfe-20211231.xsd#pfe_BosulifMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BosulifMember_eb2461d7-9ae8-49f3-9d0a-98a45c7a6d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XalkoriMember_8db191c5-bb51-48b6-8206-6ff9ad840493" xlink:href="pfe-20211231.xsd#pfe_XalkoriMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_XalkoriMember_8db191c5-bb51-48b6-8206-6ff9ad840493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RuxienceMember_cdcc19a9-68b7-4c29-9b09-54b4c7ca3731" xlink:href="pfe-20211231.xsd#pfe_RuxienceMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_RuxienceMember_cdcc19a9-68b7-4c29-9b09-54b4c7ca3731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_RetacritMember_2df70e9d-a0bf-482f-9628-2c22d59df067" xlink:href="pfe-20211231.xsd#pfe_RetacritMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_RetacritMember_2df70e9d-a0bf-482f-9628-2c22d59df067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZirabevMember_e3434dbf-8402-4353-9e3a-5bc19d3a1d2b" xlink:href="pfe-20211231.xsd#pfe_ZirabevMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZirabevMember_e3434dbf-8402-4353-9e3a-5bc19d3a1d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_LorbrenaMember_e0da73e7-f1c6-428b-93c6-3d19170131e2" xlink:href="pfe-20211231.xsd#pfe_LorbrenaMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_LorbrenaMember_e0da73e7-f1c6-428b-93c6-3d19170131e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AromasinMember_ab032b99-60ba-4ce7-9809-43a21436706a" xlink:href="pfe-20211231.xsd#pfe_AromasinMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AromasinMember_ab032b99-60ba-4ce7-9809-43a21436706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TrazimeraMember_cd63db85-0cbe-49aa-90e8-29c6fa343f06" xlink:href="pfe-20211231.xsd#pfe_TrazimeraMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TrazimeraMember_cd63db85-0cbe-49aa-90e8-29c6fa343f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BesponsaMember_65225bc8-20b5-4df4-a0b5-e38cfd812ce7" xlink:href="pfe-20211231.xsd#pfe_BesponsaMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BesponsaMember_65225bc8-20b5-4df4-a0b5-e38cfd812ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BraftoviMember_16fae200-9581-450d-9c6a-ac2e6792f9c0" xlink:href="pfe-20211231.xsd#pfe_BraftoviMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BraftoviMember_16fae200-9581-450d-9c6a-ac2e6792f9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BavencioAllianceRevenuesMember_6a81e05a-852a-49df-a31d-caa5e79597de" xlink:href="pfe-20211231.xsd#pfe_BavencioAllianceRevenuesMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BavencioAllianceRevenuesMember_6a81e05a-852a-49df-a31d-caa5e79597de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MektoviMember_9403c952-6c06-4f89-8870-5be2fab45d87" xlink:href="pfe-20211231.xsd#pfe_MektoviMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_MektoviMember_9403c952-6c06-4f89-8870-5be2fab45d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherOncologyProductsMember_d86982f6-cdf5-410b-a645-bc842d470690" xlink:href="pfe-20211231.xsd#pfe_OtherOncologyProductsMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherOncologyProductsMember_d86982f6-cdf5-410b-a645-bc842d470690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EliquisMember_ec9c9d7d-6c3e-46cb-8ec4-db0255ecd20f" xlink:href="pfe-20211231.xsd#pfe_EliquisMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_EliquisMember_ec9c9d7d-6c3e-46cb-8ec4-db0255ecd20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PremarinFamilyMember_b46b7652-8959-4368-a60e-a289b12d89ed" xlink:href="pfe-20211231.xsd#pfe_PremarinFamilyMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PremarinFamilyMember_b46b7652-8959-4368-a60e-a289b12d89ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ChantixChampixMember_d6bfd26e-8f7a-43ff-a629-6fe22c1e6f45" xlink:href="pfe-20211231.xsd#pfe_ChantixChampixMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ChantixChampixMember_d6bfd26e-8f7a-43ff-a629-6fe22c1e6f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BMP2Member_d8d60c93-9515-47d0-aadb-24278986d495" xlink:href="pfe-20211231.xsd#pfe_BMP2Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BMP2Member_d8d60c93-9515-47d0-aadb-24278986d495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ToviazMember_245fa7cc-25ec-4b8e-b432-63a95f627534" xlink:href="pfe-20211231.xsd#pfe_ToviazMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ToviazMember_245fa7cc-25ec-4b8e-b432-63a95f627534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PristiqMember_042119c2-9d6a-4423-8313-4755e5256067" xlink:href="pfe-20211231.xsd#pfe_PristiqMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PristiqMember_042119c2-9d6a-4423-8313-4755e5256067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInternalMedicineMember_975b3c78-9cd4-4e67-8139-41356aa9096c" xlink:href="pfe-20211231.xsd#pfe_AllOtherInternalMedicineMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AllOtherInternalMedicineMember_975b3c78-9cd4-4e67-8139-41356aa9096c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SulperazonMember_bcb68fdc-a3f3-4250-9a5d-0ff6fec5925d" xlink:href="pfe-20211231.xsd#pfe_SulperazonMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_SulperazonMember_bcb68fdc-a3f3-4250-9a5d-0ff6fec5925d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_MedrolMember_898fe160-51a0-4bf3-acde-83064c6eb970" xlink:href="pfe-20211231.xsd#pfe_MedrolMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_MedrolMember_898fe160-51a0-4bf3-acde-83064c6eb970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZaviceftaMember_ebdbaf5f-2553-45ae-bc5f-62bdabdbe217" xlink:href="pfe-20211231.xsd#pfe_ZaviceftaMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZaviceftaMember_ebdbaf5f-2553-45ae-bc5f-62bdabdbe217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_FragminMember_cd25d16d-586b-45fa-9f3a-ec2e77210c9d" xlink:href="pfe-20211231.xsd#pfe_FragminMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_FragminMember_cd25d16d-586b-45fa-9f3a-ec2e77210c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZithromaxZmaxMember_29ed40af-3770-4711-a32b-a0b1ccbe0c86" xlink:href="pfe-20211231.xsd#pfe_ZithromaxZmaxMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZithromaxZmaxMember_29ed40af-3770-4711-a32b-a0b1ccbe0c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VfendMember_225a7966-0606-4019-a410-c919fb590543" xlink:href="pfe-20211231.xsd#pfe_VfendMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_VfendMember_225a7966-0606-4019-a410-c919fb590543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TygacilMember_c3a4a033-6e01-4663-85c6-5bcb3bcf6d64" xlink:href="pfe-20211231.xsd#pfe_TygacilMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TygacilMember_c3a4a033-6e01-4663-85c6-5bcb3bcf6d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PrecedexMember_924afd7a-2b54-45d1-90eb-b37bd52b747d" xlink:href="pfe-20211231.xsd#pfe_PrecedexMember"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PrecedexMember_924afd7a-2b54-45d1-90eb-b37bd52b747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ZyvoxMember_3a5bcceb-c116-4584-aab9-4ee4ad489d14" xlink:href="pfe-20211231.xsd#pfe_ZyvoxMember"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ZyvoxMember_3a5bcceb-c116-4584-aab9-4ee4ad489d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PaxlovidMember_240e5c44-cb65-4562-acdd-b8816e653dc9" xlink:href="pfe-20211231.xsd#pfe_PaxlovidMember"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_PaxlovidMember_240e5c44-cb65-4562-acdd-b8816e653dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_IVIgProductsMember_99c3abc6-f367-4cc7-b29d-1f097156c232" xlink:href="pfe-20211231.xsd#pfe_IVIgProductsMember"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_IVIgProductsMember_99c3abc6-f367-4cc7-b29d-1f097156c232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherAntiinfectivesMember_23bce63d-69ec-4663-9bb3-45a1d7f5f1c4" xlink:href="pfe-20211231.xsd#pfe_OtherAntiinfectivesMember"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherAntiinfectivesMember_23bce63d-69ec-4663-9bb3-45a1d7f5f1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_OtherHospitalProductsMember_9e3bbd5f-946e-4be7-b451-13e1233e6d4b" xlink:href="pfe-20211231.xsd#pfe_OtherHospitalProductsMember"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_OtherHospitalProductsMember_9e3bbd5f-946e-4be7-b451-13e1233e6d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_XeljanzMember_c9f91022-c211-497c-a6c4-ab8d394e6812" xlink:href="pfe-20211231.xsd#pfe_XeljanzMember"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_XeljanzMember_c9f91022-c211-497c-a6c4-ab8d394e6812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_EnbrelMember_1c423c99-3072-453d-b973-3d4638c95e09" xlink:href="pfe-20211231.xsd#pfe_EnbrelMember"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_EnbrelMember_1c423c99-3072-453d-b973-3d4638c95e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_InflectraRemsimaMember_9e090209-2015-4376-9d1e-17c62e58207e" xlink:href="pfe-20211231.xsd#pfe_InflectraRemsimaMember"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_InflectraRemsimaMember_9e090209-2015-4376-9d1e-17c62e58207e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_06c68583-acd5-460f-9e59-f6da70f3a650" xlink:href="pfe-20211231.xsd#pfe_AllOtherInflammationandImmunologyProductsMember"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_06c68583-acd5-460f-9e59-f6da70f3a650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_VyndaqelMember_218ccc51-afe9-482a-a8f3-84571eeb2e7d" xlink:href="pfe-20211231.xsd#pfe_VyndaqelMember"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_VyndaqelMember_218ccc51-afe9-482a-a8f3-84571eeb2e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BeneFIXMember_7cbc3c91-3f13-4457-9253-65558607a402" xlink:href="pfe-20211231.xsd#pfe_BeneFIXMember"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_BeneFIXMember_7cbc3c91-3f13-4457-9253-65558607a402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_GenotropinMember_77acc3b8-9a86-47cc-8797-ea1062a75ee3" xlink:href="pfe-20211231.xsd#pfe_GenotropinMember"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_GenotropinMember_77acc3b8-9a86-47cc-8797-ea1062a75ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_ReFactoAfXynthaMember_eaed3b5a-6787-4b43-8665-1b24a0df1aa5" xlink:href="pfe-20211231.xsd#pfe_ReFactoAfXynthaMember"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_ReFactoAfXynthaMember_eaed3b5a-6787-4b43-8665-1b24a0df1aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_SomavertMember_c1dbcdc7-6f06-4cdb-81e9-887ce02872eb" xlink:href="pfe-20211231.xsd#pfe_SomavertMember"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_SomavertMember_c1dbcdc7-6f06-4cdb-81e9-887ce02872eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_5e9b794a-b7bd-4b3b-a64a-0932a34d1c1b" xlink:href="pfe-20211231.xsd#pfe_AllOtherRareDiseaseProductsMember"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_5e9b794a-b7bd-4b3b-a64a-0932a34d1c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_2b57abcd-dcf8-4e4c-a81e-013d143858a3" xlink:href="pfe-20211231.xsd#pfe_TotalAllianceBiopharmaceuticalsMember"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_2b57abcd-dcf8-4e4c-a81e-013d143858a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalBiosimilarsMember_7a904dec-8d72-47d6-bcd1-d6d6746b948b" xlink:href="pfe-20211231.xsd#pfe_TotalBiosimilarsMember"/>
    <link:presentationArc order="55" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TotalBiosimilarsMember_7a904dec-8d72-47d6-bcd1-d6d6746b948b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_9901766c-74be-4eb4-b22b-f9b6c544ca4f" xlink:href="pfe-20211231.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember"/>
    <link:presentationArc order="56" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_245cdf36-4a30-4c13-8370-3f9602717a00" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_9901766c-74be-4eb4-b22b-f9b6c544ca4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_srt_CounterpartyNameAxis_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da828a59-1631-4bbd-82c1-2b82d5d8f516" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1c5e162f-83b5-4c5d-a20c-57abbc5a3de9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da828a59-1631-4bbd-82c1-2b82d5d8f516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BioNTechMember_ae203fb1-e810-445d-9c56-bb51cdd5466c" xlink:href="pfe-20211231.xsd#pfe_BioNTechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_da828a59-1631-4bbd-82c1-2b82d5d8f516" xlink:to="loc_pfe_BioNTechMember_ae203fb1-e810-445d-9c56-bb51cdd5466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ba054d8-54c0-4500-aad1-1f73e281e3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ba054d8-54c0-4500-aad1-1f73e281e3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ba054d8-54c0-4500-aad1-1f73e281e3b7" xlink:to="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_BiopharmaSegmentMember_b17aa54c-2452-4d79-b438-cab5673b5098" xlink:href="pfe-20211231.xsd#pfe_BiopharmaSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:to="loc_pfe_BiopharmaSegmentMember_b17aa54c-2452-4d79-b438-cab5673b5098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_pfe_PfizerCentreOneMember_bb6947a0-2624-4388-9113-09de6c325225" xlink:href="pfe-20211231.xsd#pfe_PfizerCentreOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_957ed40b-35fd-4195-8e4b-929516ae9dab" xlink:to="loc_pfe_PfizerCentreOneMember_bb6947a0-2624-4388-9113-09de6c325225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_dcafd3fc-a399-43e4-a7f1-b5ffaad7f8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_8c995b65-2f11-413d-9b9c-d5e3e6b5f822" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_dcafd3fc-a399-43e4-a7f1-b5ffaad7f8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20f7ee24-a320-48c8-8778-54546490d112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_dcafd3fc-a399-43e4-a7f1-b5ffaad7f8f2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_20f7ee24-a320-48c8-8778-54546490d112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pfe-20211231_g1.jpg
<TEXT>
begin 644 pfe-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"B17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)O<V5N+"!0
M96YN>2!3+@   >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\%BH?%3?W,Q**FFM;BW8K<021,.H=",5#72FGJCE::T84444Q!1110 4444
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MEC*?/3^:["T445Q'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=-*HW[K/9****^(.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M75VV;JYFG/K)(6_G4%%>C"C2I_!%+T1YLZU6I\<F_5A1116ID%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** .T^%VG&\\7BX(REG$TASZGY1_,_E7M5>?\
MPDTX0:#=7[#Y[F78/]U1_B3^5>@5^?9S6]KC)+I'3^OF?HV24?98*+>\M?Z^
M04445XY[(4444 %%%% !1110 4444 %175K!>V[P7<231.,,CC(-2T4TVG="
M:35F>3^+?AC):A[WP\&EA'+6Q.67_=/?Z=:\Z92C%6!5@<$$=*^G:XWQAX M
M=?1[NP"VVH 9R!A9?9O?WKZC+L[<;4\3MW_S_P SY3,LB4KU<+H^W^7^1XG1
M5B]L;G3KR2UO86AFC.&1A5>OKTU)71\:TXNSW"BBBF(4 LP"C))P!7T=H=B-
M,T&RLU&/)A53]<<_KFO#?!FG?VIXOT^ KN02B1Q_LKR?Y5] U\AQ%6O*%)>O
M^7ZGV7#=&T9UGZ?J_P! HHHKY4^M"BBB@ HHHH X?XQ:\?#_ ,*]7N$;$MQ'
M]ECY[R':?T)/X5\75]$_M/Z[MM=%T*)^79[J50>P^5?YM^5?.U?IW#6']E@>
M=[R;?RV..L[RL%%%%?2F(5[!\.O@2?'/A&/7+G6'L!-*ZQQK;[]RJ<;LY'?/
MY5Y BL[JB LS'  [FONSP7HJ^'?!.D:4@P;:U17_ -\C+?J37S?$&85<%1@J
M+M*3_!;[_(UI04GJ>.?\,MV__0T2?^ 8_P#BJK7G[+<PB)T_Q,CR=EGM2H/X
MAC_*OHBBOC5Q!F2=_:?@O\CH]E#L?%_B[X0>+O!T+7-]8?:K->MS:'S%4>K#
MJOXBN&K]"&574JX#*1@@C(-?./QS^$5OI=O)XJ\,6XBM]V;ZUC'RQY_Y:*.P
MSU';K7TV4\1?6*BH8E)2>S6S\C&=*RNCP6BBBOL# *Z'P1XQU#P/XF@U;37)
M"G;/#GY9H^ZG^A[&N>HJ*E.%6#A-73!.SNC[YT'6K/Q%H5IJVFR>9;748D0]
MQGL?<'BM"OGW]F;Q8[IJ'A:ZDRJ#[5:@GISAQ_(_G7T%7X_F6#>"Q4J/1;>G
M0[X2YHW"O/\ XU^*#X7^&=\\+[;J^_T2'!Y&X'<1]%S^E>@5\O\ [2OB,W_C
M&ST.)OW6FP;Y #_RTDP?T4#\ZZ,EPOUK'0B]EJ_E_P $527+$\6HHHK];.$*
MGLK26_U"WL[==TMQ(L2+ZEC@?SJ"O0_@=H?]M_%?32R[HK'==R9']T?+_P"/
M%:Y\566'H3JO[*;'%7=CZXT33(M%T&QTVW $=I D*@?[( J]117XM*3DW)[L
M]$****D H(!!!&0>H-%% '-ZE\._"&KRF34/#FGRR'JXA",?J5QFGZ9X!\)Z
M-('TWP]I\$@.0_D*S#Z$Y-=#16_UFOR\G.[=KL5D'3I1116 PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X7XM:S_9?A&*U
M0XDU*Z2V'/( !=OT3'XUW5?.O[0/B1%^(WAW3!+B.PC\Z8 \*TK8Y^BJ#]&K
MU\FP_P!8QL(]%K]W_!L<F,O]7FENT_R,NBBBOT(_*PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "E R<"DK7\+:=_:OBBPM,95I@S_[HY/Z"HJ3
M5.#F]DKFE.#J34([MV/<O#&G?V5X8L+,KM:.$%Q_M'D_J36K117Y94FZDW-[
MO4_6*<%3@H1V6@4445!84444 %%%% !1110 4444 %%%% !1110!SOBWPA:>
M)[+Y@(KR,'R9P/T/J*\-U+3;K2=0DL[^(Q31G!![^X]17TA<7,%I TUU-'#$
M@RSR,%4#W)KQ'XJ?$SP+=I';V=TU_J43 +/:+NC5<\AFZ$?3-?49'BL1S^P4
M7*/Y?\ ^=SC*XXB+K4])K\?^"<G138Y%EC62-@R, 5([BG5]B?!;'I'PATWS
M-0OM18<1((5^K<G]!^M>K5R?PVT[[!X-MW*X>Z9IF_'@?H!765^<9I6]MC)O
MHM/N/TS*:/L<'"/5Z_>%%%%>:>F%%%% !115+6M2CT?0K[49B EK;O,2?]E2
M:<8N345U ^1/C?K@USXL:F4;=%9;;1.?[G7_ ,>+5Y]4][=RW]_/>7!W2W$C
M2.?4L<G^=05^UX:BJ%"%)?921YTG=W"BBBMQ'7?"S0O^$A^)NBV13?$+@32C
M_83YC_+%?;=?-G[,6@^?KVK:[(O%K"MM&?\ :<Y/Z+^M?2=?FG$^(]IC?9K:
M*_%Z_P"1V45:-PHHHKY<V"H+ZR@U'3Y[*[C$D%Q&T<B$<%2,&IZ*:;3N@/@K
MQ+HS^'O%&I:1+RUG<O%GU /!_+%9==_\;X5A^,.M[!C>T;GZF-:X"OVG"5'6
MP].H]VD_O1YTE9M!11172([CX-ZJ=(^+.B2AL+-,;=_<."O\R*^T:^$?!;,O
MCW0"GWO[2M\?]_%K[NK\]XK@EB*<^Z_)_P#!.JALQDTR6\$DTK;8XU+,Q[ #
M)KX1\6:U)XB\7:IJTK%C=7+NN>RY^4?@,5]=?&#7O^$?^%FL7"-MEGB^RQ_6
M3Y?Y$G\*^+:[.%,/:%2N^NB_-_H37>J04445]L<X5]$_LOZ(%M=:UR1>6=+2
M,D=@-S?S6OG:OM'X.Z%_8'PKT>!TV33Q?:91C^)SN_D0*^:XFQ'LL#R+>32_
M4VHJ\KG<4445^8G8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5\/?$K7?^$C^).MZDIS&]TT<1
M]43Y%/XA0?QK[!\=ZX?#?@+6=61Q'+;6CF)CVD(VI_X\17PN2222<D]37W/"
M>'UJ5WZ+\W^AS5WLCU7PYJ8U71892V94'ERC_:'^/6M6O+_"^MG1]2_>D_9I
ML+(/3T;\*]>TG1M1UQP-*M)+D'^-!\H^IZ5])B%&BW*3LC\^Q^!G1Q'+!74M
MO\BC17I&E?".YE ?6+Y8!_SS@&YOS/'\Z[#3OA]X=TX*18BXD'\=PV_].GZ5
MX%?.\)2TB^9^7^9T4,BQE76245Y_Y'AD%K/=2;+:&29O2-2Q_2MNU\#>)+O'
MEZ5,@/>7"?SKWJ&V@MD"6\,<2CH$0*/TJ2O)J<15'_#@EZZ_Y'KTN&Z:_B3;
M]-/\SQFW^%&O2X,\EI /0R%C^@K4@^#TI_X^M61?^N<)/\R*]2HKAGG>-EM)
M+T7^9WPR+ QWBWZM_I8\ZC^#]@/];JERW^ZBK_C5I/A+HB_?N;Q_^!*/Z5W=
M%<[S3&O>HSI64X%;4U^)Q2_"KPZ.OVMO^VO_ -:G_P#"K/#G]RZ_[_?_ %J[
M*BL_[1Q?_/Q_>:?V;@_^?:^XXP_"SPX?X;H?]MO_ *U1M\*/#Y^Z]VO_ &U'
M^%=O13_M'&+_ )>/[Q/+<&_^7:^XX)_A'HS?<O+Q/Q4_TJL_P>L3_J]5N%_W
MHU/^%>C45:S7&K_EX_P,WE.!?_+M?B>73?!YQ_Q[ZNI_WX<?R-49OA'K"_ZF
M]M)/J67^E>OT5O'.\;'>5_DC&61X&6T;?-GB$_PQ\20YVV\,P_V)A_7%6O"@
ML? WB;SO&MU;Z0\D#"U^U2A1(<@,0?8?SKV6OD7]H'7!J_Q4N;>-MT>FPI:C
MGC=]YOU;'X5[&78K$9M.6%J646G=K<QADV&PU2-:#=UT?_#'U'9^+/#VH &Q
MUS3[@'IY=RA_K6K'+'*NZ)U=?53D5^? )!R.#5B'4+VW;-O=SQ'U24K_ "-=
M4^$H_8J_>O\ @GK^W\C] :*^$;;QIXGL\?9O$.IICH!=N?ZUJP_%CQW;X$?B
M>_P.S2;OYBN67">(7PU%^/\ P1^W78^V:*^,XOC;\0HNGB.5O]^")OYK5N/X
M]_$!.NK1/_O6L?\ 05B^%<:MI1^]_P"0_;Q/L&BOD5?VA/'PZWMH?K:K2_\
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M'Y5\S>+?'GB#QK?&XUR^>1,YCMD.V*,>@7^IYKG*^GPG"M-1YL3*[[+;[_\
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MAQM%%%??G*=K\']6_L?XL:%.6PDUQ]F;W\P%!^I%?:E?!?A:0Q>,-&D7JE_
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MQP$6]Y7?^7X(QJN\PHHHKWS(*^O_ (%>$!X7^'5O<SQE+[5<74V>H4C]VO\
MWSS]6-?+_@;P_P#\)3XYTG1BK-'=7"B;;U$8^9S_ -\@U]T1QK%$L<:A410J
MJ.@ KXOBK%N,(8:/75^G3\?R.BA'6XZBBBO@#J"BBB@ HHHH **** "BBB@
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M2U7:UO:H)!_MD9;]2:WJ**_$ZDW4FYRW;N>BM$%%%%0,**** "BBB@ HHHH
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M#L4?3Y2?QKU6OR;/<1[?,*CZ+3[O^#<[J2M!!1117BF@4444 %%%% !1110
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MU;3M7@\[2KZVO(_[]O*KC]#5NO'<7%V9H%%%%( HHHH **** "BBB@ HHHH
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MWMY+_-F-6I=V04445]88!1110 ])9(\^7(R9Z[6(IWVJX_Y[R?\ ?9J*BBR
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M %(RAE*GH1@TM% '"M\%OA^[%F\.0EB<DF:7G_QZD_X4I\/?^A;A_P"_TO\
M\57=T5V_VAC/^?LO_ G_ )D\L>QPG_"E/A[_ -"W#_W^E_\ BJ/^%*?#W_H6
MX?\ O]+_ /%5W=%']H8S_G[+_P "?^8<L>QSGASP!X8\(W<MUX=TF.RFF3RW
M=79B5SG'S$]ZZ.BBN:I5G5ES5&V^[U&DEL%%%%9C"BBB@ HHHH **** "BBB
M@#R;]HO7?[+^&HT]&Q)J=PL7']Q?F;^0'XU\GU[/^TMKIO?'%EI$;YCT^V#,
M >CN<G] M>,5^J\/X?V& BWO+7[]OPL<55WF%%%%>\9#HT:618XP6=B%4#N3
M7W;X.T9/#W@O2=*1=IMK5$?W;&6/YDU\@?"G0?\ A(OB=HUFR[HDG$\O^['\
MQ_EC\:^V:^#XLQ%Y4Z"]7^2_4Z:"W84445\0=(55U+3K75],N-/U&+SK6Y0Q
MRQEB-RGJ,CFK5%--Q=T!PG_"E/A[_P!"W#_W^E_^*H_X4I\/?^A;A_[_ $O_
M ,57=T5V?VAC/^?LO_ G_F3RQ['"?\*4^'O_ $+</_?Z7_XJC_A2GP]_Z%N'
M_O\ 2_\ Q5=W11_:&,_Y^R_\"?\ F'+'L9^AZ#IGAK28]-T2T6TLXR66)22
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M+_\ %5W=%']H8S_G[+_P)_YARQ['"?\ "E/A[_T+</\ W^E_^*H_X4I\/?\
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MU&*V04445QE&3XB\+Z/XLT]+'Q!9K>6R2"58V=E 8 @'Y2.Q-<U_PI3X>_\
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ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>%_M.Z[]G\/:3HD3X:ZG,\JC^Z@P/U;]*]TKY"^/NN_VQ\5+N!&S%IL:VJ_
M4?,WZL1^%?0\.X?VV/C)[1N_T7XLRJNT3S.BBBOU(X@JUI=A)JFKV=A "9+J
M=(5QZLP']:JUZ5\!-"&L_%6SED3=#I\;W3<< @87_P >(_*N;%UUA\/.J_LI
ML<5=V/K;3;&/3-*M;& 8BMH4B0#T4 #^56:**_%FVW=GHA1112 **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!&17&'4,/0C-85]X%\*:FS-?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pfe-20211231_g10.jpg
<TEXT>
begin 644 pfe-20211231_g10.jpg
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L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pfe-20211231_g11.jpg
<TEXT>
begin 644 pfe-20211231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!X17AI9@  34T *@    @ !@$Q  (
M   1    5@,!  4    !    : ,#  $    !     %$0  $    ! 0   %$1
M  0    !   .Q%$2  0    !   .Q     !-:6-R;W-O9G0@3V9F:6-E
M 8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,"PL,&1(3#Q0=&A\>'1H<
M'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_; $,!"0D)# L,& T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_  !$( "8 B@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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/NTN4=%8!L,,CBBBD!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pfe-20211231_g12.jpg
<TEXT>
begin 644 pfe-20211231_g12.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !S BD# 2(  A$! Q$!_\0
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MQ#^TS^TQX9_95^".M:Q%K5KJQG\6:AHFK):?:YH;&XN6T<RJZLHBC5+FX.0
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MM[%-!Y,WVK[,C7#2)@8D:8R,_ .YFSS7K]%%;Q22LC-L****8!1110 4444
M%%(6"CD@=J6@ HHHH ^&O^"TG_!3;5?V+O &G>"?AO=V*?%WQA&+FVNKF*.Y
MM_"^G!RK:A/"YP^]T:&)#@,WF,3MA8'Z(_8(^.^J_M-?L8_#7QUKZ64?B+Q%
MH-O-K*V43Q6HOU7R[KR5<EA%YZ2;,DG;MYK\=/A9X+UW_@KC_P % OVF_B#;
MZI'XAT+PSH>M7&AQ),9+218Q/8>&H(FW2!;:7[)=7Q,)VR2-*V-LS*WZ-_\
M!O\ ?$^V^*O_  2H^'%Y D<36<VIVLD<<:1HH_M&YDB("DKAH)(7SU^?G#9
MX:%:4ZSO\-M#:<$HVZGV;1117<8A17S)_P %2_VK/B)^P]\%]!^*WA+PY#XL
M\$>#]<@N/B/IMO8R7FL?\(^^8YKBPC61%,L+NDC&1@BQH[-A58U]&>%O$]AX
MV\,:=K.EW*7FF:O:Q7MG<("%GAD0.CC.#@JP/([TN97L.W4OT444Q!1110 4
M444 %? __!<[]M#X\_LB:#\-(_@QX<U[48?%=_=6=_J.C>'AK=XEZ! +&Q$3
M*Z1K<EYQO9"2T2*&3))^^**BI!RCRIV&G9W/YQ/VR/A=^UMX&\;:9\9/V@=&
M/AWQ!K>HVFD:)KD6IV-MJ$LZ6<UQ#% =+D66SE1/M*_(RR?NI"KM]ZO0_AK^
MRI_P4(_:*\'>'-3\'^)/'T_@SQ1!#J=IX@N_CK?VT$UM,1,I)AN9+M&!)#IL
M!480 X*K^K/_  65_9\;]H__ ()O?$W2K+04\0^(M!TX>)M M0%\YM0T]Q=P
MB)BIP[^4T1 P625TR YKYT_X-E/VG_#OQ"_8]U;X6Z=?6TM[\/=2FU>SC5EW
MSZ7J]Q/?QRD#@[;J2]B(4858XLG+5YWU6,:R3D[/SZG0ZCE"]M4?.Z?\$;_^
M"@VI.ZM\;UTXQH$67_AH+QQ)YAPV2H^SDC+;,YX Z FJ?A7_ ((7?M]>#=>@
MU_0OVAM"\,^*_M$);48?B?XJU.%(+602VT<L%S;F*\3>\RM!.C1;7<G=O9#^
MWU%=JPT$[W?WLP<V%%%%;DA1110 4444 %%%% !7Y-_\').I7/[57Q<_9Z_9
M9\&ZC''\0O&.OMXBAR[QQZ/^YN+.WO)V"D&-87U:<(#N<Z>0!R WZR5^/37&
MK_M/_P#!U-%_96F#4O#_ ,'I&36=0M[AS#!:P>&OW2RC[N]=4U@*J Y)B<[?
MW;&L*][**ZLNGO?L?K/\+?AMI'P:^&7AWPAX?M4L=!\*Z9;:/IMLH 6"VMXE
MBB0  #A$4< #BOS[_P"#7+1X],_X)WZ[*EG/;&\\8-(TDQ+O=[-'TJ)9"^2'
M^6,+N!()0\U]J_MJ_%:7X%?L>?%3QG;RQPW?A;PEJFJ6K/LP9X;25XA\_P I
M)<* #P20*^3O^#:;P-?>$?\ @EWH][=^6L'B'Q!J5U9(B1(J002+IZX6/Y5!
M:R=@O50P':HG_'BET3&O@;/OZBBBNHS"BBB@ HHHH **** "BOE7_@J=_P %
M3] _X)D?#_1;B\\+ZUXN\4>,([T:#86SQVMCOMEB+O>7<AQ!%NGA7Y%DE;>2
ML;!7*XG_  1__;3_ &AOVT?ASKVL_'?X$GX/Q6GV8:%?;YK;_A(23,MPWV"Z
MQ>6JH4B*&5<2+-E20N3'.N;EZCL[7/L6BBBK$%?!?_!3G_@BKI/[3EY<_$OX
M,7T/PI^.EI(;T:KI<TFEV_B67##_ $N:W FAN<,X2]AQ,F_#^:@"#[THJ)TX
MS5I(:;6Q^<G_  3C_P""S&IZK\0H_@C^TQ8O\/\ XO6MZFEVDU_ILFF17\C?
MNX(IQ)(ZF:=E?RKJ$_8[M_EA97:..3]&Z^3O^"L7_!,#1O\ @HS\(+5K,V6E
M_$GPBLT_AO4IR(;>[+QL'TZ^D6.27[#,VQF$8W))%%*H8Q[6\X_X(5_M_:S^
MT;\)]2^%GQ#.LV_Q/^%JBQN%UE,:C>6D+"W87+&1VDO+:=3#<.0-Q:%SN,C&
ML83E"?LY[/9_H6TFKH^^****Z3,**X']IW]IGP?^R#\$];^('CG47T[P_H<8
M:3R86N+FZD8A8X((E!:6:1R%5%&23V )'YQ?\-%_M@?\%H=)\9'X*.G[-'PG
MTV(6NDZKKUC<)KGBRX-U/:7<0OK>1DMDBA4RB2R$C+,(XUN,^8T.<ZJCIN^Q
M2C<_3;XI?&;P?\#O#4FM>-?%?AOPAH\*L[WVM:G#86R!1EB9)65< <GGBO H
M_P#@L5\#/$KW2^"=1\=_%?[&2)9OA]X!UWQ39C#LAQ=V5I);'YE/27I@C@@F
MM\!_^"/7P<^&E]'K?C/PYIWQ?\;*J?\ %2>.(G\0Z@CX!>1)+YYVC9GW',90
M!=JA1@EOJBVMH[.WCAAC2**)0B(BA510,  #H *(N;WT%H?&T'_!8B\U2PN+
MO3?V2?VS-0M()GB#M\/[:PDE5=N)%AN[V&8JQ) ^0-\IR "I)X'_ ."U/AW7
M9[H>)?V?/VP/AY!9EQ+=:]\'M4GMU*G'^LL!= @GHP^4^M?9E?DE_P $Z/\
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M^UJ)5< /L!49A8UZK\"_^"X=]\(OBW;?"/\ ;&^'US\ ?B(\D5G9^*(Q)<^
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M^(?%WQ3T/X?QS2QW2Z+9>/=1\*S6*,JLT)BT:UD5MO*D374QSN^8_*P^QO\
M@@9^T'J_Q]_X)N>%XM>6V.J^ KRY\(&6"82K<6UH5-DY[AOL<ELK9Y9D9@ &
M K[/K>E3]I!3E)O\#*?NMJQ^%'[8/_!#7XF_L_?LK^+OBO\ $+XJZ-\1=:T-
MX=4U6TNK74;]VB,T$<CK?75Q+,#%&TKE_+!<1$L4\QBGZ,?\$5/VEKKXS?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ ID[%('8<$*2*** 'T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pfe-20211231_g13.jpg
<TEXT>
begin 644 pfe-20211231_g13.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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MKF6*19>J@E0I&<$,0:[O]F/XUVOQ\^"/AGQ%'<6<FH:AI-G=:C!;RA_L=Q+
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M5<^)/[$_A?QV\TNGZCXF\)74\(MFDT34Y+51%W4)DHOU !JS\'_V+O WP/\
MAQ:^&=!L[ZWM8=576[FZ-[*UWJ5Z"#YT\I.Z0G !#'& !C H ]9KY _;C^+'
MAOX9_MY_L]W7B37M%T'3M(M]>U6ZN+^Z6%8X5M!'N&X_WG XY[5]?UR'Q%^
M7@GXO:MIM]XI\*:!XAO-'W?8I=0LDN&M@V-P4L#@' R.G% 'YZ?\%$OVK]<_
M;=T7P7X1\/Z#XNTO]EKQEJTFF?$/QQ%I$WVJ\M8\.+:VBQYB6L[+Y;W6W #\
M>M>N?L&?&_XA_!KX=Z[IWC;X9W$/AFXUVX'@*3PKI.V%M$4*EHEPA/F++M7)
M>3);=GI7VQ!80V]BMLL42PHGEK&J (%' 4+TQCC%3* BX P!P .U 'X[?\%
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M  !YK[8*[AT'/'2N4TSX%^#-$U4WEGX4\/6]TTIN/-CT^-6$AY+@XX8^HYH
M^6_@-\=?''@#]H+XM:YKWP[\:76@>/-2LKOPLMK")B(HX!"R2 D&%W(W[6X
MKUCX+?";Q-XG_:5UKXL>);7_ (1>2\TI-#LM!B99'EMTD\P7%U(O#2[B0JCA
M17O &/QZT4 %%%% !114<R-+"ZJQC9E(##JI]: /F7PM=67[77[;4VOQ1->>
M$?@HTVDV<CIN@NM:D \Z://7R4^3<,C+&OIX#%>5_LS?LZ7?[/GAE=,D\0-J
M4*S7,Q2*S6WCG>:4R-+(,EFDYQG(&!TKU2@ HHHH **** /.? _[*7@3X=_&
M[Q5\1M,T.%?&7C-HFU/4Y6,LK".,1JJ;L^6NT $+C.*]&HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pfe-20211231_g2.jpg
<TEXT>
begin 644 pfe-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ A@"&  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MH%%%% !5;4[0W,&5_P!8O3WJS10!SPZ]?_K4M6M8L_L\OF*/ED//'0U5Y!H
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MY/ R:G^*/[7'P[^"_B671O$OB./3=6A@BN3:"TN)YGCD+A618XV+CY&SMSM
MRV 1D[/OMY]?RU'RM-I]/^&_,](HKF_ OQ;\/_$K4]8LM%OVNKO098X;^)[>
M6%H&D021\2*NY60@AERI]:G^'OQ*T7XJZ'+J6@7O]H6$-U-9&<0R1JTL3E)
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MM,\6?L@Q2:/H%KX;TVV\8""&TBF>=S_H3.SR2M\TCEG(R0,*$7^')\-KOO\
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MX_L['?V1BG^[JOW;[1ET^_9^=C\B\4N%?KF%>8X9?O*:U\X_\#\K^1]$^,O
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MO"H^1>Z_=Y[WDH1:N_:;-\SWI-2]VSV#V>'T>FVU_);Z^O\ +KH<+\1OA?\
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MC<MJDAM$6:5X9[J&,PFYC$B7)VX9"Z_1/[.W[!?PC_:/_;,_9?\ %5O\/_\
MA'?@[^T'IWB3S_!$GB>]U"73;W1HKV*3;=A89_)D,=G.N9&;S&G4XC"*?ESX
M(_MK>&?"_P"Q=XA^!OQ ^'5]XR\,ZEXJA\8Z7J.C^)#H>J:/J"VZVTK;WM[F
M&9'@0(%>+"^9*?F8QM%WWPE_X*U'X)_M%_!/7]!^'YA^&WP#T[4K+PWX1EUS
MS;R>74;:6.^N[G43;YDFFN)?.(2!(D6-(XXD^9VVQ5#%R4_9<W-[VO-HTXOE
MLKZ/FMK96LW?76JD:CORWOKU\M+?.QM:MX,^!?[5W[ W[07Q"\%_!?\ X5'K
MWP@U'PY<Z1)9>+M0UC[=;:C<"SEMKH799&VND\HDB6)OF@3@1R&?X@"XKV+X
M*_M:GX/_ +(WQL^%?_"/G4?^%Q?V%_Q-/MWD_P!D?V9>O=?ZGRV\[S=^W[Z;
M,9^;I7C?S>]>EA*,Z;G&5[7]V[;TY8]6V][[F].+BWZZ=>B_6X_&1V/.>>]?
M0G_!,3]NO4?^"?G[5ND^,%>6;POJ@&E^)[-<XN;%V&Y\#J\9 <'K\I QDU\\
M?-[T^/G*MN*L,$#JP],UIB</"K3E3FKIZ!4IJ<7%G]=WAWQ'I_C/PYI^KZ3>
M1ZAI>J6Z75G<Q,&CFB<!E*D=>"*T+:X:TN/,7KGYO]H5^2?_  ;=?\%$/^$A
MT6X_9[\67V=0TF.2^\'S2OQ-;#YI;(,?^>?+JHZ+NSVK]:%W<,/XONY_BK\>
MS+ SPF(E1GTZ^1\Y6I.G*S.@CD$L:LO(;FG5DZ)=?9W\DD['.5SV-:U<!D%%
M%% !1110 5\_?\$M/^3$? O_ '$/_3A<U] UQ_P#^">E?LZ_";2?!NB7&H76
MEZ/YWDRWSH]PWFS23-N**BG#2,!A1P!U/- 'R[^S?^SKX2_:2_9 'Q-\8W'V
M7XA^(/MNK7/C6XOIHI]*NK6>[BM[M2LL:11VZ!#Y:&.(B&/(_=H5SYOA9H/C
M[]IK]EGQMJUC]K\3_$#2I-<U^]\Z2/[?>6>DVLUM+Y:L(X]DBAML:JK8PP(X
MKW#Q9^P'X2\2^*M3OK;Q!\0=!TOQ!=RWVN:#I7B*:#2M=FF<M<-<1'<W[Y3Y
M;B-D&Q0%"XS79>/OV:O#?CS7O >I+_:&@WGPXNQ/HIT><6B10[41[1D *&WD
M2-$9  =B[0RJS!@#YM\;V/AWX_7GBCQ%;_"O4/BAX?U+59[/4?&'BSQ-9:/I
MNC6=E* ITV:'=(-/0^<[2PHK.-^]IF+*NQI>KW6O_%O]C&^OKJXO;Z]\,ZI/
M<7$\ADEGD?1+=F=V;)9F))))R2<UZ!9_\$Z/ .G^,KN\M[KQ1!X9O]1&JW7@
MN/4=OAFYN!L(9[,)AE$D<<@0L4RBKM\L!!L?#7]B;PK\+!\-?[/O_$$W_"K/
M[4.E?:)X6^T?VAN\[S]L0W;=QV[-F.^Z@#V*BBB@ HHHH 9<0K<0LC=&&*PY
MHV@F:-NL?\JWZI:O9>='YB_>3J!W% &96QI7_'A'^/\ ,UC!L]P?<5LZ5_QX
M1_C_ #- %BBBB@#P7]N+4K?1]9^#MU>7$-K:V_CZRDEFF<1QQ*(ILEF/  ]3
M6'^V#\2] ^.,7A/X<>$]9T_Q#KVN>(K&YN8=,NEN?[/L[>19IIYBFX(H 7 8
M@L3QG!KW[QM\._#_ ,2M-CL_$>A:/X@LX9!-'!J5E'=1HX!&X+(I ;!(R.<$
MU'X)^&/AKX:6\L/ASP[H?A^&<[I$TVPBM5D/J1&HS^-%/1Z])<WW<NGWQ^[[
MPGKMUCR_?S:_^3'A?B+3M-UG]L[XFV>L7T>F:3>?#BW@O+MY5B6UA>:X5Y"[
M?*NU23EN!CFI/V??B5K/PE\>>%?A+?:AX:\8:3<:/+)HFMZ1=-]JBM[9%V_;
M(69PH8$!9$?:2N /3WFX\%:-=ZM=ZA+I.F27VH6HL;JY>U1IKFW&2(7?&6CY
M/RDD<GCFJ/@CX1^$_AG-<2>&_#'A[P_)= "=M-TZ&T:8#IN,:C=^-3&-H\K[
M._G=S:^[F_-;,*GO._FOP44_OY?RZH^?OV&_C+X)\#_LQQZ7XH\0>'](UVRU
M34(M<L=1NHH[H7;WDI(>-CN=B"H!P2< <D<7/V9OB7X7^&/Q#^-5KXLUO1=
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MG_:K&]M[^UD<HS1O\I9>,<=#7Q%_P60_;%_X0[PLGPIT"\;^UM<B$FNSQO\
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M-H<1YO[3#K]S27+!]9*^LGJ]WMM[MKJ]P\NCRZ,-1AJ^V/S,/+H\NC#48:@
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M6?&3ZU:W.JIG0[2RDM;2)RXCE2>6;-LRB,;% D#F0[#$_&_#K]O7XH?M]?\
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M  ""S9)R /4?^"M7Q1NOAO\ L>:A:V8N$F\6:A!HC3PW)A:WC8//)G RZO'
MT3)D K,<D@%3H?\ !-[]CRZ_9-^$5X==^S_\)9XHECNM26&0NMG&BD0VQ.XH
M[(7E9G0 %I2N75%8\-_P6P_Y-6\/_P#8UV__ *1WE 'B_P#P1R_9<M?B!XSU
M3XC:Y8V]YIWAF5;/1TF42*=0^61I@-^0T,93;O0@M.&4AHLC]*J^-?\ @B7J
M]K-^S9XFL4NK=KZV\32SS6XD!EBCDM;98W9>H5C'( 2,$QL!]TX^RJ /#O\
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MSY%Q%"%@CW@[%WI-<':1N;RL@@*V=C_@B7I-K#^S9XFODM;=;ZY\32P37 C
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M=DRJ**O([#X$_"2X^,OQ&L],7<EC"?/O90/]7&.H^K?='O7W5?>#=+U/PO\
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MK[+NWY)7;ZV6A]0?\$N_^"7/_"MSIWQ*^)6G?\5)\MSH>AW*?\@?NMS<*?\
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M%KX?AN+[5O#VH0ZU%800B274%1)(I(T&X?,$F:0 !F8Q[%4LXQ\?_P#!+_\
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MM_ST_P#'3_A1_;5M_P ]/_'3_A6/M/K1M/K0!L?VU;?\]/\ QT_X4?VU;?\
M/3_QT_X5C[3ZT;3ZT ;']M6W_/3_ ,=/^%']M6W_ #T_\=/^%8^T^M&T^M &
MQ_;5M_ST_P#'3_A1_;5M_P ]/_'3_A6/M/K1M/K0!L?VU;?\]/\ QT_X4?VU
M;?\ /3_QT_X5C[3ZT;3ZT ; UFV)_P!9_P".G_"L_4+QKVY;R_F6/A1G&XU
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M'PF.Q53&8C&U'.;NWRQ/UW ^+>(PF'AAJ.%@HP5EJS\VX_@7XVV_\B=XJ_\
M!3/_ /$4[_A1GC;_ *$[Q5_X*9__ (BOTBHKC_XEWR[_ *"Y_P#@,3J_XC1C
M?^@:'WL_-W_A1GC;_H3O%7_@IG_^(H_X49XV_P"A.\5?^"F?_P"(K](J*/\
MB7?+O^@N?_@,1_\ $:,;_P! T/O9^;O_  HSQM_T)WBK_P %,_\ \11_PHSQ
MM_T)WBK_ ,%,_P#\17Z144?\2[Y=_P!!<_\ P&(?\1HQO_0-#[V?F[_PHSQM
M_P!"=XJ_\%,__P 11_PHSQM_T)WBK_P4S_\ Q%?I%11_Q+OEW_07/_P&(?\
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M_P"@F?W(/]7Z?\[/S7_X47XX_P"A-\5?^"F?_P"(H_X47XX_Z$WQ5_X*9_\
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M6,M?ZO'MN_ZZK[P?T<\N3L\9/O\ #';:_P!Z:^1^!?\ PQW\7O\ HE?Q(_\
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ML]537WOS_P G]S[,/[4E>UE_5O\ -?>NY_+A_P .[/VA/^B%?&3_ ,(K4O\
MXS1_P[L_:$_Z(5\9/_"*U+_XS7]7=%'^NE?_ )]K[V/^TY?RG\HG_#NS]H3_
M *(5\9/_  BM2_\ C-=)\(O^"5/[0'Q:^*/A_P ,M\(_B5X;AUJ^BMYM6U?P
MO?6=EIJ$_/+)+)$%55&3UYZ5_4O14U.,J\HN*II?-DRS*;5K'E?[.'[.FA_L
MK_ [PWX \*V+6^C>&[9;=6V;7N9<?O)W..7=LL3W)KN!:S'[T<GM\I.*W**^
M/G.4Y.<MV>=*3;NS#^R3?\\I/^^31]DF_P">4G_?)K<HJ1&']DF_YY2?]\FC
M[)-_SRD_[Y-;E% &']DF_P">4G_?)H^R3?\ /*3_ +Y-;E% &']DF_YY2?\
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ML/'>F^&]2A\0:/K%[K^F(_B/5)M-TB^O$N$NY[2P>X-I;&<74YE$,*"1I-[
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M-<RY;+>Z56/,I)=?Q\_*W9.SZ[:^)_''QQXX^+G[9?BKX9Z1\6=6^"NB^"?
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M ["O1*H^&O#6F^"_#MAH^CZ?8Z3I.EV\=I965G L%O9PQJ%2*.-0%1%4 !5
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M\EW&(GB<R^4NUFR?BG^WO\1/!7QJ^"/AVW^ /Q$M[7XEWNHV^JVE[>>'7O\
M3Q;VTTB!'CUDPAAY:SN0TBF E5_??NQ5^$7_  3AU+X-_"#QYX?T32?V2]!U
M+QM#!93OH'P';2M'O;12XFM]1L4UEFOE=)&5 9XECW,2L@8K3? 7_!-?Q'\)
M?!7PEA\+_$+PYI>O?"_Q1JNOJK>$)7\/-:ZDES%-IMCIRWZR6%M%'< 6ZBYE
M6'RP-KJ=HU7+S:^7ITNN^EVV[ZVM%+[6-3FY;1\_7_+5Z)6TNKO>W777_!2+
MPS!X_FM(_!OCZX\"VOBA?!=S\0HH=//ANVU=IEM?LS W8OV47CI:&=+1H%F;
M:9 JNR^>?M&?\%(M4EU/0]/\ ^$_B!9Z+)\5-%\#S>.FT_3KCP_J,G]L06NI
M6<8,\EV@ %U!]HDM8XO-B94FWF+?!X:_X(]^'? /[2%SXRTC0_V=]4TJ^\5S
M>+99O%7P?AUCQA;W%Q=&[G6#7%OH2FV9G,#R6TKP#8N9 BUJ-_P3.\66U_!X
M?L?BU8V/PHTWXC)\2M/\/)X01M46[.KKJTUE/J!NMDEF;AKAHQ':Q3(7AW32
MI&\<RPMN:C*KTE%R[64J;DG;?3GLEHU9.]KSTQ/P5HTNJDH_.-1)^3O[.[]6
MK:6N_P#!2'X_?$KX??%7X&^!_A_I_P 1+>W^(7B6YM]7UCPE%X=EOA!;Z==W
M'V2+^V9?)1F>))7<PL/)AE5'65D5NEO?^"E'AG3_ !H\/_"%?$:X\!6_BE?!
M4_Q#CL[(^'8=7-R++R"OVH7[(+YEM#<)9M;K,2#*$5W7T?XO_ +_ (6M\7/A
M7XJ_M;[!_P *SUJ[UC[+]E\W^TO/TV[L?+W[U\O;]J\S=M?.S;@9W#Q:V_X)
MQ>(K6XU#P<OQ'TM?@;J'C5O'!\++X5*ZY'<-J*ZL]F-5%WY1LWU$-*4-D9O*
MD:+SL8<%.RE&,MKW;]7%-=](W<;*U]7?:2J:IR6]DK?*;;7]Z_+N[6NM-+>B
M_LW?MK6/[4?Q$\8:/X?\!_$&ST7P3K.I^';[Q/JEO96VDSZE879MIK:W'VHW
M4V<>8LJP&';E6D657B7YFL?V]/B;H'B3]J7QQXFM_B%X8\*_"O68] T&PO\
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M<D<\'\0O^">-U\2M:^*VI7WC6WAOOBI+X3N+@P:(5BL)-#F25MBM<$LMP5(
M+ Q ]9<<O7DDNO/I_@Y8;?/FWUV[LS=_:0?V>57[\W-)N_RY=M-[]##\0_\
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M.\<"7&I7-Q+%$&D=O+C94+,6()YI]C^R'\.]-U+[9#X>V7!\82>/M_V^Y/\
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M2^*WPVT_Q(T%W<KI-SXFLH;XQ6OG?:I!"T@?;#]GN/,;&(_(EW8V-CY-\6_
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MZVD-PGV18(%DD54CD6XE4EP)/)8JK_..J_\ !-#Q?X[_ &;_ (OZ)-X6\/\
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MYT@11@'& /6*F=K^Z:1O;4****DH**** "BBB@ HHHH **** "BBB@ HHHH
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MXQFUUNXNI&UEJTW!._::O;<QPLHU/9N6BDX^5E)4Y:O9.TVDNK@_.WZ$:?\
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M@BMNY_:F^&-E\;H?AG-\1O </Q(N$\R+PH^OVBZY*OE&;*V9D\\CRE,F0GW
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MVWNE][35]%MH[I=7LTDVOLVBBBD: 6VC)X ZFO+]._;@^"NK^&_$6LVGQ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K+\1^!]%\8W>DW&KZ/I>JSZ#>C4M,DO+2.=].NA&\8GA+
MF.41RR)O7#;9'&<,02BCS U**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pfe-20211231_g3.jpg
<TEXT>
begin 644 pfe-20211231_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]&EMP;F>9&$R-*ESID\LA(W!+H$G#&@#^B.BOP)_X*H?&;6_%O\ P5=\$?\
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MFHZPGA35(+G6%:QOHU.J;=1FC*%I+_;:1K]H+Y*O)N#%BU?7W_!6'X<^,?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^-/B5_P2/_X6'_P6?^'O_!7C_AH'
M['_P@G@N?P__ ,*]_P"$4\S[=YEGJ=MY_P!O^U#RL?VCNV>0V?)QN^?*_9=%
M 'PE_P %7O\ @B%X=_X*,_&CX:?M6?"']H6Y^#/Q?^&>HQ2Z=X]TSPNNJ/>6
MT4GGP0RP_:;?+0SY='WD!9)49&#@IC?MB_\ !%/XP_%7]KK3/^"C/[%W[=-U
M\$?CL_A2'0_''B#3O!,.HZ5XGCCACBWO8W,S"+*Q1#9(TZA8(.-\?F']!J*
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M$^HZ[X(^*-KX1"12W%WJ4]^R2Z>;I]NUI(0KB<D-;AL$,8Z_4.B@#\TO!_\
MP0>_::U?]O'X/_\ !2']IK_@J/JGQ&^)/PVN735H;[X7VEGIM]IQ1T2QLH;2
MYB6PPL]T6F*S&1YE<HNTJ_MO["?_  2C_P"&*OVY_P!HG]M+_A?7_"2_\+]U
MU-2_X1K_ (1;[%_86VYN9_+^T?:I?M7_ !\;=WEQ?<SCG ^P** /E[_@KY_P
M3;_X>L?L<7?[)?\ PN?_ (0/[5XBL-4_X2#_ (1W^U-OV9F/E^1]HM\[MWWO
M,XQT->!?M?\ _!NW\-_VN?VWO@/^V3KOQ^_LQ?@_HGA[3-?\+CP<)T\61Z3=
MFXC+S_:T^R^8&,3?NYOD"C/%?H]10!\.>$?^"*/A2P_;E_:;_:W\>?':XUG0
M_P!I?X?S>$M9\%6GAS['+I%I-;06TSI??:9/.8I"V/W";3(.NWGYCT+_ (-D
M/VH_^&/];_X)V>*O^"P'B!_@6+JXO/"O@O3/A;91-%>/<_:XWO9S<&:Y@CN/
MWQMEDC1Y,.#&0!7Z_P!% 'YX_$#_ ((0:M\16_8AGUK]KB-)OV-);+8\7P_.
M/%T5K-I;Q)@ZA_H!\O2T0MFXR92V!MVGTW_@K5_P2@3_ (*E6_PEMW^/ \#K
M\+O'T?B4@^%?[4&J!0@^SX^U0>3G9]_Y^OW:^P:* /C+QY_P2,?_ (>U^'_^
M"K_[/G[0O_"!:L^@KHWQ1\&CPG]MM?&MH%$9,DPNX3;2^4D #[)0'M('VG:P
M?Y]\9?\ !N_^T7\+/'?Q0LO^";__  5(\0?!#X9?&?4)KKQO\/!X&@U1;5I]
MPF-A<M/&]ME79%,?ERJ@53*X5<?J?10!\&?M;?\ !"[P3^TM_P $G]#_ ."9
M%M^TEXM2X\-:C:ZMI?Q%\72/K-[<ZE$\S/)<I)*A:)Q<3(L:.HB4H%R$PWT5
M^P#^SW^T#^R]^S-H_P '/VF/VH)_B]XHTV67S/&-QH*Z<S6YP(;81+))D1(
MH<D%NI&<Y]IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO+_ -DK
MXK>+OC#\-;_Q1XTF@>[M_%&HV,9MX!&ODPS%$&!WQU/>O4* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__ "1/5O\ L>]9
M_P#2DU[I7SO^QQ\2_@Y\-?@L;#Q?\6_#NEW^H>)]:O);'5=;M[>6,?VC<1+\
MCN&P1$#G'<UZI_PTE^SM_P!%\\%?^%3:?_'*M4YM729FZM).SDOO.THKB_\
MAI+]G;_HOG@K_P *FT_^.4?\-)?L[?\ 1?/!7_A4VG_QRCV=3LP]M1_F7WG:
M45Q?_#27[.W_ $7SP5_X5-I_\<H_X:2_9V_Z+YX*_P#"IM/_ (Y1[.IV8>VH
M_P R^\[2BN+_ .&DOV=O^B^>"O\ PJ;3_P".4?\ #27[.W_1?/!7_A4VG_QR
MCV=3LP]M1_F7WG:45Q?_  TE^SM_T7SP5_X5-I_\<H_X:2_9V_Z+YX*_\*FT
M_P#CE'LZG9A[:C_,OO.THKB_^&DOV=O^B^>"O_"IM/\ XY1_PTE^SM_T7SP5
M_P"%3:?_ !RCV=3LP]M1_F7WG:45Q?\ PTE^SM_T7SP5_P"%3:?_ !RC_AI+
M]G;_ *+YX*_\*FT_^.4>SJ=F'MJ/\R^\[2BN+_X:2_9V_P"B^>"O_"IM/_CE
M'_#27[.W_1?/!7_A4VG_ ,<H]G4[,/;4?YE]YVE%<7_PTE^SM_T7SP5_X5-I
M_P#'*/\ AI+]G;_HOG@K_P *FT_^.4>SJ=F'MJ/\R^\[2BN+_P"&DOV=O^B^
M>"O_  J;3_XY1_PTE^SM_P!%\\%?^%3:?_'*/9U.S#VU'^9?>=I17%_\-)?L
M[?\ 1?/!7_A4VG_QRC_AI+]G;_HOG@K_ ,*FT_\ CE'LZG9A[:C_ #+[SM**
MXO\ X:2_9V_Z+YX*_P#"IM/_ (Y1_P -)?L[?]%\\%?^%3:?_'*/9U.S#VU'
M^9?>=I17%_\ #27[.W_1?/!7_A4VG_QRC_AI+]G;_HOG@K_PJ;3_ ..4>SJ=
MF'MJ/\R^\[2BN+_X:2_9V_Z+YX*_\*FT_P#CE'_#27[.W_1?/!7_ (5-I_\
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M?^5_<P]O0_F7WHT:*SO^$Q\(_P#0TZ;_ .!T?^-'_"8^$?\ H:=-_P# Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >]_L%_\ (W:__P!@V+_T97T[7S%^P7_R-VO_ /8-
MB_\ 1E?3M?A_&W_)0U/2/_I*/W;@;_DG*7K+_P!*84445\F?7!1110 4444
M%%%% !1110 4444 %%%% !1110!\P_\ !4K_ (*I_ S_ ()6?"'1/'_Q1\+:
M[XJ\0>+]:_LCP/X'\+P+)?ZU>8!*KN.$C7<@9L,V94559F KR#]@_P#X+R>'
M/VH_VNH_V#?VF?V-/B'^S_\ %;4]&?5?"WAWQW'N36;9(WE?RW:*%U?RXIG
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MFFGHTT[II^9V'C3XH6FK>';+P/X(\.'0]%LKIKH0?:S--<7!&WS9),#)"\
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M11_K#FO\Z^Y?Y!_JCD?_ #[?_@3_ ,S\*_\ B$J_:(_Z.W\%_P#@DN_\:/\
MB$J_:(_Z.W\%_P#@DN_\:_=2BC_6'-?YU]R_R#_5'(_^?;_\"?\ F?A7_P 0
ME7[1'_1V_@O_ ,$EW_C1_P 0E7[1'_1V_@O_ ,$EW_C7[J44?ZPYK_.ON7^0
M?ZHY'_S[?_@3_P S\*_^(2K]HC_H[?P7_P""2[_QH_XA*OVB/^CM_!?_ ()+
MO_&OW4HH_P!8<U_G7W+_ "#_ %1R/_GV_P#P)_YGX5_\0E7[1'_1V_@O_P $
MEW_C1_Q"5?M$?]';^"__  27?^-?NI11_K#FO\Z^Y?Y!_JCD?_/M_P#@3_S/
MPK_XA*OVB/\ H[?P7_X)+O\ QH_XA*OVB/\ H[?P7_X)+O\ QK]U**/]8<U_
MG7W+_(/]4<C_ .?;_P# G_F?A7_Q"5?M$?\ 1V_@O_P27?\ C1_Q"5?M$?\
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MP-_SXE_X,G_F?DG_ ,0Y7QJ_Z./\+?\ @JN?\:/^(<KXU?\ 1Q_A;_P57/\
MC7ZV44?\17XV_P"?\?\ P"'^0?\ $).!O^?$O_!D_P#,_)/_ (AROC5_T<?X
M6_\ !5<_XT?\0Y7QJ_Z./\+?^"JY_P :_6RBC_B*_&W_ #_C_P" 0_R#_B$G
M W_/B7_@R?\ F?DG_P 0Y7QJ_P"CC_"W_@JN?\:_1SXU? /5_BEX(T#PI8:_
M;6LFCA1)+-$S+)B()P!TZ9KU"BO&S/CGB/.,11K8JJG*BY./NQ5N9)/9:[=3
MVLKX$X:R;#UZ&%I-1K**G[TG?E;:W>FK>Q\Q?\,%^+O^A^TW_P !I*/^&"_%
MW_0_:;_X#25].T5/^NW$/_/Q?^ Q_P BO]1N'/\ GT__  *7^9\Q?\,%^+O^
MA^TW_P !I*/^&"_%W_0_:;_X#25].T4?Z[<0_P#/Q?\ @,?\@_U&X<_Y]/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )_0_P# E_F?3E%?,?\ P^<_X);?]'L>"_\ P)E_^-T?\/G/^"6W_1['@O\
M\"9?_C='U+&?\^Y?<_\ (/[1R_\ Y_0_\"7^9].45\Q_\/G/^"6W_1['@O\
M\"9?_C='_#YS_@EM_P!'L>"__ F7_P"-T?4L9_S[E]S_ ,@_M'+_ /G]#_P)
M?YGTY17S'_P^<_X);?\ 1['@O_P)E_\ C='_  ^<_P""6W_1['@O_P "9?\
MXW1]2QG_ #[E]S_R#^T<O_Y_0_\  E_F?3E%?,?_  ^<_P""6W_1['@O_P "
M9?\ XW1_P^<_X);?]'L>"_\ P)E_^-T?4L9_S[E]S_R#^T<O_P"?T/\ P)?Y
MGTY17S'_ ,/G/^"6W_1['@O_ ,"9?_C='_#YS_@EM_T>QX+_ / F7_XW1]2Q
MG_/N7W/_ "#^T<O_ .?T/_ E_F?3E%?,?_#YS_@EM_T>QX+_ / F7_XW1_P^
M<_X);?\ 1['@O_P)E_\ C='U+&?\^Y?<_P#(/[1R_P#Y_0_\"7^9].45\Q_\
M/G/^"6W_ $>QX+_\"9?_ (W1_P /G/\ @EM_T>QX+_\  F7_ .-T?4L9_P ^
MY?<_\@_M'+_^?T/_  )?YGTY17S'_P /G/\ @EM_T>QX+_\  F7_ .-T?\/G
M/^"6W_1['@O_ ,"9?_C='U+&?\^Y?<_\@_M'+_\ G]#_ ,"7^9].45\Q_P##
MYS_@EM_T>QX+_P# F7_XW1_P^<_X);?]'L>"_P#P)E_^-T?4L9_S[E]S_P @
M_M'+_P#G]#_P)?YGTY17S'_P^<_X);?]'L>"_P#P)E_^-T?\/G/^"6W_ $>Q
MX+_\"9?_ (W1]2QG_/N7W/\ R#^T<O\ ^?T/_ E_F?3E%?,?_#YS_@EM_P!'
ML>"__ F7_P"-T?\ #YS_ ();?]'L>"__  )E_P#C='U+&?\ /N7W/_(/[1R_
M_G]#_P "7^9].45\Q_\ #YS_ ();?]'L>"__  )E_P#C='_#YS_@EM_T>QX+
M_P# F7_XW1]2QG_/N7W/_(/[1R__ )_0_P# E_F?3E%?,?\ P^<_X);?]'L>
M"_\ P)E_^-T?\/G/^"6W_1['@O\ \"9?_C='U+&?\^Y?<_\ (/[1R_\ Y_0_
M\"7^9].45\Q_\/G/^"6W_1['@O\ \"9?_C='_#YS_@EM_P!'L>"__ F7_P"-
MT?4L9_S[E]S_ ,@_M'+_ /G]#_P)?YGTY17S'_P^<_X);?\ 1['@O_P)E_\
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M_P#(/[1R_P#Y_0_\"7^9].45\Q_\/G/^"6W_ $>QX+_\"9?_ (W1_P /G/\
M@EM_T>QX+_\  F7_ .-T?4L9_P ^Y?<_\@_M'+_^?T/_  )?YGTY17S'_P /
MG/\ @EM_T>QX+_\  F7_ .-T?\/G/^"6W_1['@O_ ,"9?_C='U+&?\^Y?<_\
M@_M'+_\ G]#_ ,"7^9].45\Q_P##YS_@EM_T>QX+_P# F7_XW1_P^<_X);?]
M'L>"_P#P)E_^-T?4L9_S[E]S_P @_M'+_P#G]#_P)?YGTY17S'_P^<_X);?]
M'L>"_P#P)E_^-T?\/G/^"6W_ $>QX+_\"9?_ (W1]2QG_/N7W/\ R#^T<O\
M^?T/_ E_F?3E%?,?_#YS_@EM_P!'L>"__ F7_P"-T?\ #YS_ ();?]'L>"__
M  )E_P#C='U+&?\ /N7W/_(/[1R__G]#_P "7^9].45\Q_\ #YS_ ();?]'L
M>"__  )E_P#C='_#YS_@EM_T>QX+_P# F7_XW1]2QG_/N7W/_(/[1R__ )_0
M_P# E_F?3E%?,?\ P^<_X);?]'L>"_\ P)E_^-T?\/G/^"6W_1['@O\ \"9?
M_C='U+&?\^Y?<_\ (/[1R_\ Y_0_\"7^9].45\Q_\/G/^"6W_1['@O\ \"9?
M_C=>L^#_ -K#]G+Q_P# R7]ICP;\7-)U#P' DS2^*+>1C;*(I#%(22N?E<%3
MQU%)X3%)I.G*[=EH]6]DO-]BXX[ S3<:L797?O+1+=O71+N>AT5X+_P]!_X)
M_P#_ $=1X7_[_P G_P 11_P]!_X)_P#_ $=1X7_[_P G_P 17H?ZO9__ - E
M7_P7/_(X/]8N'_\ H,I?^#(?YGO5%>"_\/0?^"?_ /T=1X7_ ._\G_Q%'_#T
M'_@G_P#]'4>%_P#O_)_\11_J]G__ $"5?_!<_P#(/]8N'_\ H,I?^#(?YGO5
M%>"_\/0?^"?_ /T=1X7_ ._\G_Q%;?PZ_;[_ &-_BWXTL/AU\-OV@] UC6]3
MD9-/TVTE<R3LJ,Y"Y4#A58_A45,BSNE!SGA:B25VW"222W;=MBZ>?Y%5J*$,
M53<F[)*<6VWLDKZMGK]%<WXG^+_PS\&:J=$\4^,K.RNU17,$[$,%/0]*S_\
MAHKX(_\ 12=-_P"^V_PKFAEV85(*4*,FGLU%V_(Z9YEEU*;A.M!-;IR2:_$[
M2BN+_P"&BO@C_P!%)TW_ +[;_"C_ (:*^"/_ $4G3?\ OMO\*O\ LO,_^?$_
M_ 9?Y$?VME?_ #_A_P"!1_S.THKB_P#AHKX(_P#12=-_[[;_  H_X:*^"/\
MT4G3?^^V_P */[+S/_GQ/_P&7^0?VME?_/\ A_X%'_,[2BN+_P"&BO@C_P!%
M)TW_ +[;_"C_ (:*^"/_ $4G3?\ OMO\*/[+S/\ Y\3_ / 9?Y!_:V5_\_X?
M^!1_S.THKB_^&BO@C_T4G3?^^V_PH_X:*^"/_12=-_[[;_"C^R\S_P"?$_\
MP&7^0?VME?\ S_A_X%'_ #.THKB_^&BO@C_T4G3?^^V_PH_X:*^"/_12=-_[
M[;_"C^R\S_Y\3_\  9?Y!_:V5_\ /^'_ (%'_,[2BN+_ .&BO@C_ -%)TW_O
MMO\ "C_AHKX(_P#12=-_[[;_  H_LO,_^?$__ 9?Y!_:V5_\_P"'_@4?\SM*
M*XO_ (:*^"/_ $4G3?\ OMO\*/\ AHKX(_\ 12=-_P"^V_PH_LO,_P#GQ/\
M\!E_D']K97_S_A_X%'_,[2BN+_X:*^"/_12=-_[[;_"C_AHKX(_]%)TW_OMO
M\*/[+S/_ )\3_P# 9?Y!_:V5_P#/^'_@4?\ ,[2BN+_X:*^"/_12=-_[[;_"
MC_AHKX(_]%)TW_OMO\*/[+S/_GQ/_P !E_D']K97_P _X?\ @4?\SM**XO\
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MX%'_ #.THKB_^&BO@C_T4G3?^^V_PH_X:*^"/_12=-_[[;_"C^R\S_Y\3_\
M 9?Y!_:V5_\ /^'_ (%'_,[2BN+_ .&BO@C_ -%)TW_OMO\ "C_AHKX(_P#1
M2=-_[[;_  H_LO,_^?$__ 9?Y!_:V5_\_P"'_@4?\SM**XO_ (:*^"/_ $4G
M3?\ OMO\*/\ AHKX(_\ 12=-_P"^V_PH_LO,_P#GQ/\ \!E_D']K97_S_A_X
M%'_,[2BN+_X:*^"/_12=-_[[;_"C_AHKX(_]%)TW_OMO\*/[+S/_ )\3_P#
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MJ.5_\BZE_A7Y'X?GG_(XK_XW^84445WGEA1110 4444 %%%% !1110 4444
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MX(_D?L'$7_(^Q/\ CE^84445[!XP4444 %%%% !1110 4444 %%%% !1110
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M[.PURTTR>RDAO+4IYUO-;S#=&=LD;J<D,K9XP17=?\$C_P#E(M\,?^PI=_\
MI#<UZF=XFCB^%,94I2;7LJJU33NHR3332::::::5GT/*R/"U\'Q=@J=6*3]M
M2>C35G*+333::::::;NNI^G7[9__ "6^?_L&V_\ Z":\GKUC]L__ )+?/_V#
M;?\ ]!->3U^6</\ _(CPW^"/Y'ZMQ%_R/L3_ (Y?F%%%%>P>,%%%% !1110
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M\-B&G#E3O97OI>UFTWJK6:Z/H@HHHKM.$**** "BBB@ HHHH **** "BBB@
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M'\+OVZOV/KWXAZI\+M&71O!_BKPWX\DT.YGTB-BT.FWJBWF$L<>2J2)L=5X
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M_&G_ ()+3_&C_B$J_9W_ .CM_&G_ ()+3_&OULHH_MO-?^?K^Y?Y!_JSD?\
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M_BG_ ,%5M_C1_P 0Y7P5_P"CC_%/_@JMO\:_1NBC_B(_&W_09+_P&'_R(?\
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M(?\ H(?W1_R#_5'AS_H'7WR_S/!?^&"_"/\ T/VI?^ T='_#!?A'_H?M2_\
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MZ"']T?\ (/\ 5'AS_H'7WR_S/!?^&"_"/_0_:E_X#1T?\,%^$?\ H?M2_P#
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M1/5O^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-?\ PCY/_BZ/[+S'_GU+[F']N9/_ ,_X_>C]!**_/O\ XB:/^"6__0U>-?\
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M_P"+H_LO,?\ GU+[F']N9/\ \_X_>C]!**_/O_B)H_X);_\ 0U>-?_"/D_\
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M_0U>-?\ PCY/_BZ/^(FC_@EO_P!#5XU_\(^3_P"+H_LO,?\ GU+[F']N9/\
M\_X_>C]!**_/O_B)H_X);_\ 0U>-?_"/D_\ BZ/^(FC_ ();_P#0U>-?_"/D
M_P#BZ/[+S'_GU+[F']N9/_S_ (_>C]!**_/O_B)H_P""6_\ T-7C7_PCY/\
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MU>3V2\V=F"XGX>S*I*&%Q4)RBG)J,D[16[?DKGI-%>4?\-G_  1_Y_\ 4O\
MP7M_C1_PV?\ !'_G_P!2_P#!>W^-1_J]GG_0-/\ \!9?^L>0_P#03#_P)'J]
M%>4?\-G_  1_Y_\ 4O\ P7M_C1_PV?\ !'_G_P!2_P#!>W^-'^KV>?\ 0-/_
M ,!8?ZQY#_T$P_\  D>KT5Y1_P -G_!'_G_U+_P7M_C1_P -G_!'_G_U+_P7
MM_C1_J]GG_0-/_P%A_K'D/\ T$P_\"1ZO17E'_#9_P $?^?_ %+_ ,%[?XT?
M\-G_  1_Y_\ 4O\ P7M_C1_J]GG_ $#3_P# 6'^L>0_]!,/_  )'J]%>4?\
M#9_P1_Y_]2_\%[?XT?\ #9_P1_Y_]2_\%[?XT?ZO9Y_T#3_\!8?ZQY#_ -!,
M/_ D>KT5Y1_PV?\ !'_G_P!2_P#!>W^-'_#9_P $?^?_ %+_ ,%[?XT?ZO9Y
M_P! T_\ P%A_K'D/_03#_P "1ZO17E'_  V?\$?^?_4O_!>W^-'_  V?\$?^
M?_4O_!>W^-'^KV>?] T__ 6'^L>0_P#03#_P)'J]%>4?\-G_  1_Y_\ 4O\
MP7M_C1_PV?\ !'_G_P!2_P#!>W^-'^KV>?\ 0-/_ ,!8?ZQY#_T$P_\  D>K
MT5Y1_P -G_!'_G_U+_P7M_C1_P -G_!'_G_U+_P7M_C1_J]GG_0-/_P%A_K'
MD/\ T$P_\"1ZO17E'_#9_P $?^?_ %+_ ,%[?XT?\-G_  1_Y_\ 4O\ P7M_
MC1_J]GG_ $#3_P# 6'^L>0_]!,/_  )'J]%>4?\ #9_P1_Y_]2_\%[?XT?\
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M\-G_  1_Y_\ 4O\ P7M_C1_J]GG_ $#3_P# 6'^L>0_]!,/_  )'J]%>4?\
M#9_P1_Y_]2_\%[?XT?\ #9_P1_Y_]2_\%[?XT?ZO9Y_T#3_\!8?ZQY#_ -!,
M/_ D>KT5B?#[X@^'/B9X<7Q3X6EE>T>5XP9HBC;E//!K;KRJM*I0J.G45I+1
MI[IGK4JM*O252F[Q:NFMF@HHHK,T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /Y:_^"QG_)WTG_8)E_\ 3G?U\IU]
M6?\ !8S_ ).^D_[!,O\ Z<[^OE.OU'*_^1=2_P *_(_#\\_Y'%?_ !O\PHHH
MKO/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /K;_ ((3_P#*63X-?]AJ]_\ 3;=U]F?\%WO^4@&H_P#8KZ9_
MZ+:OC/\ X(3_ /*63X-?]AJ]_P#3;=U]F?\ !=[_ )2 :C_V*^F?^BVKW.!/
M^2[7_7B7_I2.7C#_ )-Y+_L(C_Z0SXUHHHK^@#\%"BBB@ K]GO\ @F5_RA[M
MO]_5_P#TX2U^,-?L]_P3*_Y0]VW^_J__ *<):_-/%+_D3X3_ +":7Y2/T_PI
M_P"1SC/^P:K^<#D:***\H]4**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@S4]"W_$;Q!:GQ)XCO'NI0VE:;<(!8:?Y6[RP[Q@W3EDWJ)HE! W ^I? O\
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MFX_@0[5]"S8[<X?P[T+PK#X)U_XA>*-!_M8:7-:6]KIS74D4;/,SYD=HR&P
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M0GS@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]@_L8?\
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M]M.D_P!EMXN'AK3AX@-EMV^2=4$'VOI_'YGF?[5>3?LW?M8_'[]DKQO=^/\
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M,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^MO\
M@A/_ ,I9/@U_V&KW_P!-MW7V9_P7>_Y2 :C_ -BOIG_HMJ^,_P#@A/\ \I9/
M@U_V&KW_ --MW7V9_P %WO\ E(!J/_8KZ9_Z+:O<X$_Y+M?]>)?^E(Y>,/\
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M31_Q#,?\$M_^A4\:?^%A+_\ $U^@E%5_:F8_\_9?>R/[#R?_ )\1^Y'Y]_\
M$,Q_P2W_ .A4\:?^%A+_ /$T?\0S'_!+?_H5/&G_ (6$O_Q-?H)11_:F8_\
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MR?\ Y\1^Y'Y]_P#$,Q_P2W_Z%3QI_P"%A+_\31_Q#,?\$M_^A4\:?^%A+_\
M$U^@E%']J9C_ ,_9?>P_L/)_^?$?N1^??_$,Q_P2W_Z%3QI_X6$O_P 31_Q#
M,?\ !+?_ *%3QI_X6$O_ ,37Z"44?VIF/_/V7WL/[#R?_GQ'[D?GW_Q#,?\
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M/_/V7WL/[#R?_GQ'[D?GW_Q#,?\ !+?_ *%3QI_X6$O_ ,31_P 0S'_!+?\
MZ%3QI_X6$O\ \37Z"44?VIF/_/V7WL/[#R?_ )\1^Y'QI^S7_P $'_\ @G_^
MRC\;_#_[0GPB\.^*8?$?AJXDFTN6_P#$TD\*N\+PMN0J WR2-^.*] _:6_X)
M:_LG_M8_%"7XO_%[2-<FUF:RAM9'L-:>"/RX@0OR@'G!ZU]%T5IALZS;!XGZ
MQ0KRC4M;F3:=M[7["KY#DN*POU:MAX2IWYN5Q35]KV[V/C7_ (<0?\$__P#H
M7?%/_A32?_$T?\.(/^"?_P#T+OBG_P *:3_XFOLJBO4_UUXM_P"@ZK_X&_\
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M  KU>BH_UASS_H)G_P"!,O\ U=R'_H&A_P" H\H_X8P^"/\ SX:E_P"#!O\
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M:E_X,&_PKU>BC_6'//\ H)G_ .!,/]7<A_Z!H?\ @*/*/^&,/@C_ ,^&I?\
M@P;_  H_X8P^"/\ SX:E_P"#!O\ "O5Z*/\ 6'//^@F?_@3#_5W(?^@:'_@*
M/*/^&,/@C_SX:E_X,&_PH_X8P^"/_/AJ7_@P;_"O5Z*/]8<\_P"@F?\ X$P_
MU=R'_H&A_P" H\H_X8P^"/\ SX:E_P"#!O\ "C_AC#X(_P#/AJ7_ (,&_P *
M]7HH_P!8<\_Z"9_^!,/]7<A_Z!H?^ H\H_X8P^"/_/AJ7_@P;_"C_AC#X(_\
M^&I?^#!O\*]7HH_UASS_ *"9_P#@3#_5W(?^@:'_ ("CRC_AC#X(_P#/AJ7_
M (,&_P */^&,/@C_ ,^&I?\ @P;_  KU>BC_ %ASS_H)G_X$P_U=R'_H&A_X
M"CRC_AC#X(_\^&I?^#!O\*/^&,/@C_SX:E_X,&_PKU>BC_6'//\ H)G_ .!,
M/]7<A_Z!H?\ @*,3X??#[PY\,_#B^%O"T4J6B2O(!-*7;<QYY-;=%%>55JU*
M]1U*CO)ZMO=L]:E2I4*2ITU:*T26R04445F:!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?_  3W_P"2)ZM_V/>L
M_P#I2:]TJ#3]+TS2(#;:5IT%K&TC.T=O"J*6)R6P .2>IJ>@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ(_X.J/BC\3/ /[0/PI
ML_ GQ$UW18;CP=>O/%I.KS6RR,+L ,PC8 G'&37[;U^%?_!VK_R<3\)/^Q*O
M?_2L5[7#Z3S2"?9_DSYOBR4HY'4:?6/YH_,;_AH_]H?_ *+SXT_\*B[_ /CE
M?>G_  ;??&+XN^-?^"FFEZ'XR^*?B/5K)O!VKNUGJ>N7$\181IAMCN1D=CBO
MS8K]!/\ @V8_Y2D:3_V)>L?^BDK[3-*<%EU6R7PO\C\WR2K4>;T$Y/XEU\S^
MCRBBBOS$_; HHHH Q_B'J]]X?\ :YKVERA+FQT>ZN+=RH8+(D3,IP>#R!P:^
M<?\ @BC^U!\8_P!L[_@E_P#"C]IK]H#Q!!JOC#Q5IVH2ZU?VUA%:QS/%J=W;
MH1%$JHF(XD' &<9ZDU](>/=&N_$?@76O#VG[?/O])N;>#<<#>\3*,GZD5\+_
M /!L7XW\-^(?^"-7PO\  MAJ<7]N>"+K6]#\6Z.S@7.DWZ:Q>R&">/K&YCDB
MD /.V130!W_[(_[6_P <OBS_ ,%:_P!KO]E'QOXEM[GP3\);+P')X'TZ/388
MY+-M3T=[J\WS*H>;?* 1O)VCA<"NH_X*[_MQ>*_^"=_[!GB[]IKP!X7T[5?$
M-E<Z?IF@1:Y(R:=;WE]>16L=S>,A!6WB,OF-@C=M"[EW;AX#_P $NM>TCXJ?
M\%G_ /@H)\<? VH0ZAX7DUGP!X<M=8M9 \$^H:;HDT%]"KCY2T,H"L >-P]:
M][_X*>?M5?LC? G]D^#7_P!KCX<-XZ^$OCOQ;IW@_P 626=O;WFG:;;7TK1_
MVA?,\BA+6&1%#21EI$D:/8N[D 'S]\3OA#_P7_\ V>_@]?\ [4G@#_@H]X.^
M.NLZ+IBZO<?!0? NQL=/UN%5\R:TTZ_LY?MCR%-PA+9,K;>%+8K[[^$_C34_
MB1\+/#7Q$UKP5J?AJ\U_P_9ZC=^'-:B,=YI4L\"2O:3J0"LL18QN,##*:_,[
M]H7_ () >!_V#OV</%7[7/\ P3)_X*4?%/X':?X1\,7/B/2?#UYX]_MOP/=1
M0PF>.)[2]WADEP$60R2_ZP$(Y.#]Q_\ !/[]ISQ+^TW^PU\'_P!H[XQZ39>'
M/$?Q!\%:;J-]II?R8Y+N>%6)@20[MDG^LC3+$(ZC)ZD ]NHHHH **** "BBB
M@ HHHH *_!'_ (*5_%KXJZ)^W?\ $_2=%^)OB&SM8/$TBP6UKK4\<<:[$X55
M< #V%?O=7\^'_!3_ /Y/_P#BI_V-,G_H"5^Q^"].G5S[$*<4_P!UU5_MQ/Q?
MQMJU*6089PDU^]Z.WV)'EW_"[_C3_P!%>\4?^#^Y_P#BZ_5;_@WM\8^+O&'P
M<^(=SXN\4ZEJLD/B:U6&34;Z2=HU-N20"Y.!]*_(&OUM_P"#<K_DBOQ'_P"Q
MIM/_ $F-?IGBIA\/3X+KRC!)\T-DOYT?E_A/B,14XWH1E-M<L]V_Y&?HW111
M7\H']<!1110 5\@>-?VM_CEHW_!<GP5^Q)I_B6W3X=ZS^SM?^+-0TDZ;"97U
M2+56MDE$Y7S%41 #8&VGKC->U_M+?MC_  6_9-U_X<>'_C'?7]H_Q3\>VO@[
MPO<V]H'@&J7"2/"D\A8")6$; 'DD\ &OD+XAZII]U_P<]^#FM;M)O^$>_8VU
M*YUH0G>;.-]?(4R!<E<Y7 /)W#U% 'OGQN_X+%?\$OOV<?BE<_!3XT_MN> ]
M#\4V-P+?4M(EU0S/839QY=RT*NMNXSRLA4@<D 5Z?\1?VOOV6?A'X/\ #7Q#
M^)G[0?A'1/#WC$;O"^OZAKL*6.II]F>[WPW&[RW3[/&\V_=MV*6SBOS _9J^
M)'Q^^-7_  3O^(7Q?_8%_9*_9Z^$/[,'BT^*M7U#7?C5XIU?Q!K>OVXGNDU#
M4[NVCPH=WBFQ'<W;>6$51NC"UXQX%T3X1_$7_@EA_P $KO#?[1/V&]\*7OQW
MM[75(-9*M:W 5]42WMY@_P K1-*L,;*WRE25/&: /V"_9<_X*,_L-_MJZ[JG
MA;]EG]ISPKXSU71H!/J.E:7>D744!( G$,@5WARRCS5!3+*-W(SSW[1/_!7'
M_@FI^R=\29/@]^T)^V9X)\-^*( GVW0I]1,UQ9;P"HN%A5_LY(96 EVG:P;H
M0:\"_P""F6E^'-!_X*S?L+:]\*K&TM_B1=^,_$&GWW]GHJW%QX3729&ODG"\
MO;QDJR!\JCLQ3!)KR_\ 9!^*?Q_^.WA3XS?%3_@F+^R7\ /AS\&O$?Q,\13>
M-/B!\>O%FKZM?^*KV.0IJ.ISV,0_=6Y*N1;SW2(J9P%5B* /T3\0?M=_LN^%
MOAKX5^,NO_'[PG;^$?'&IVFG^$?$[:W";#5KFZ5VMXX)U8QN7$;D'.,(>>*X
MK]G+_@J)_P $]?VNOB;>_!K]FO\ :\\%>,/%%A%)++HND:J&FFCC/SR0!@!<
MHO4O$74 @DX(-?C-\)_"OA;XN_\ !O/^Q'\,O&EI;:OX>UO]N/2M'O[%HCY%
MQ87'B+6XY(0C$XC:.1AM/9L5^@__  5(\">"_!W_  4;_8$\6^$?"FG:7J5G
M\5]6T2VO-.LT@>/3I-&E#6@* 8APN GW1DX')H _0RBBB@ HHHH **** "BB
MB@ K/\7.\?A34Y(W*LNGS%6!P0?+;FM"L[QC_P BCJO_ &#9_P#T6U:T/XT?
M5?F95_X,O1_D?!7_  F/B[_H:=2_\#I/\:/^$Q\7?]#3J7_@=)_C6;17])>P
MH_RK[D?S+[>O_,_O9]S_ +/MS<WGP7\.W5W</+*^GJ7DD<LS')Y)/6NQKB_V
M=?\ DB'AO_L&K_Z$:[2OYVS1)9E72_GE_P"E,_I#*FWE=!O^2/\ Z2@HHHKA
M.\*^/_\ @I9^W7\>?@]\4OAG^PK^PWX0T'6OCG\9);V31KWQ69/[(\*Z-9IO
MN]7O5B^>0*"5BB&-[JWWBHCD^P*_-_\ ;7\2Z'^RA_P< ?L^_M;?&[4HM)^'
MOC_X/:M\,;+Q-?N$LM*U\7KW\"3RGY83<(XBC+$;BK=E8@ N?&?X<?\ !>']
MBOX8:C^U)X>_;_\ "G[12^%+"35/%/PB\0?!RP\.IJ-C$IDN$TV]T]S,MPL8
M;RUFWAR!D$XC9?VIO^#@3]GKX7_ S]E[XZ?#?QSX6LM-^/GCG0AKD'BZY99_
M#_A>5YEU6]98V \RVEA^RLY)1)&)PX !^POVS_VI/@[^QK^S#XQ_:,^./B:Q
MT[0/#VAW$[+>SJOV^;RV\JSB!/[R69\1H@R6+5^0?PU_9Z\:?L[?\$G_ /@E
MY\./B_H+V>M2_MA>&M2N;&_@VR6UOJ=WK=_! ZL,H?)N8MR'D,2",C% 'V9X
MA_X+ ?#;X.?\%+?&G@_X^_M1>$?#WP%MOV?_  [XM\):CJ1@B2\O]0O)0LD$
MP7SKDR6ZAEB7=\H+!>":^O\ ]FO]K']FS]L3X;CXN_LP?&G0/&WAP7+6TVIZ
M%?"5;>=5#-#*O#PR!65BCA6VLIQ@@GXI\$?";X<^,/\ @YP\>^-/%'@[3]0U
M#PG^R[H<GAN>\M$D_LZ675)8WFA# ^7)Y8*!UPP5W4'#$'YG_:A_X3+X2>+/
M^"Q>D?LZ:>^D2V_@[X?:BEIHD?E" 7WA^9]6ND5,;'>%KB5W&"3EB<\T ?I'
MX,_X*\?\$Q_B'\<H_P!F[P3^W!\/-2\9SWYL;32+77D*W5T"%^SPS_ZF:4L0
MHC1V8MP 3Q76?M'?\% OV+/V1-1N]&_:7_:3\+>#+ZRT"+6Y[#6K_9<&PDNO
MLD<Z1 %Y%:?,8" G(/& 2/R_^-7[/?[67C;_ ((F:5\.O&OBO]B;P5\ $^'V
MD7F@^-K9/$,<VBAE@:TU.&548"],K(3(H+O)(X.[>P/JV@_!OPQ\9/\ @X!^
M":_M#6>B>/-4\-_L#0:N=3O+#S[6[U;^V_LLE]''<(#\ZW5P5+J& EY - 'Z
M9?#OXA>"?BUX"T;XH_#7Q-::UX>\1:7!J.AZO82;X+VTF02131MW5D8,#Z&M
MFJ^DZ3I6@:5;:%H6F6]E8V5ND%G9VD*QQ01(H5(T10 JJH "@    58H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KYM_;C_X)2_LC?\ !0SQ7H7C/]H_1]=N;[P[I\EEIK:1K;VBK$\GF,&"
M@[CN[U])45I2K5:$^>G)I]T8U\/0Q5-TZL5*+Z/8_/O_ (AF/^"6_P#T*GC3
M_P +"7_XFO4?V/\ _@BQ^P[^PY\9X/CS\!M!\26_B"WT^XLHY-3\0O<Q>5,
M'&PJ!G &#VKZSHKIGF./J0<95)-/S..GD^5T:BG"C%-:II+0****XCT@HHHH
M *^/?V@O^"#7_!+W]I/XM:Q\<O'/[/EUI?B?Q)(TGB?4?!OB_4]$7668DNUS
M#97$<4CL2Q9]@=RQ+,2<U]A44 >=_LV_LF?LX_L@?!JV_9]_9H^$>E>#_"%K
MYA32-*1P)9)  \LLKLTL\K  &61F<A5!;@8P_A+^P+^Q_P#!']DU?V%OA_\
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MTJ<FK-Q;3:WMH>=F6499G%)4L=1C4BG=*232>U]3XU_X<0?\$_\ _H7?%/\
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pfe-20211231_g4.jpg
<TEXT>
begin 644 pfe-20211231_g4.jpg
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-\>Z"&ZUG50)-3@##Y))+,1P[@ =F!7,?&K7?^"T_P"V7^Q=>?\ !.'XA?L
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M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
MZ#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'
M^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** .=O[CQCI]S:VLNKVK&Z
ME\M"MMP#C//-6OL7C?\ Z#=E_P" Q_QH\2_\A?1_^OT_^@FMB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M?!_UQ7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Q_$O_(7T?\ Z_3_ .@FMBL?Q+_R%]'_ .OT_P#H)K8H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q+_ ,A?1_\ K]/_
M *":V*Q_$O\ R%]'_P"OT_\ H)H V**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#'LO^1WO?^O*+^9K8K'LO^1WO?^O*+^9K
M8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L>R
M_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9H V**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#'\#_ /((E_Z_9O\ T*MBL?P/_P @
MB7_K]F_]"K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /"_ /_ "D$\?\ _8B:5_Z,:O=*\+\ _P#*03Q_
M_P!B)I7_ *,:O=* "BBB@ HHHH **** "BBB@ K-\8_\BQ>_]<#6E6;XQ_Y%
MB]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\ KBO\A4U !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!C^)?\ D+Z/_P!?I_\ 036Q
M6/XE_P"0OH__ %^G_P!!-;% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5C^)?^0OH__7Z?_036Q6/XE_Y"^C_]?I_]!- &Q111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8]E_R
M.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHHH Q_ __((E_P"OV;_T*MBL?P/_ ,@B7_K]F_\
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M_99_93\1_&SXK2^&1XDUS0M'UZRTC3_#^DM*88Y[W4+QO+CDD<'RX55G8#.
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M %P-:59OC'_D6+W_ *X&@"YIW_(/@_ZXK_(5-4.G?\@^#_KBO\A4U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^)?^0OH_P#U
M^G_T$UL5C^)?^0OH_P#U^G_T$UL4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_
M -!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 8]E_P CO>_]>47\S6Q6/9?\CO>_]>47\S6Q0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %8]E_R.][_P!>47\S6Q6/9?\
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MR>IKM:Q_ _\ R")?^OV;_P!"K8H **** "BBB@ HHHH **** "BBB@ HHHH
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MY9))+YI)I78EFDD9G8G))KVC]I/_ ()H?&WQW\=O _[;G[-'[7Z^ ?CMX7\
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M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
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MXT67_([WO_7E%_,UL4 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
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MY"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!- &Q1110 4444 %%%% !1110
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M10 4444 %%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/9?\CO
M>_\ 7E%_,UL5CV7_ ".][_UY1?S-;% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5CV7_([WO\ UY1?S-;%8]E_R.][_P!>47\S
M0!L4444 %%%% !1110 4444 %%%% !117G_[0^J?M-:5H'A^7]ESPEX/UC4I
M?&.FQ>)H?&6J7%K%!H338OIK<P1N7N5CYC5L+U)W%0C !IO[1O@;6OVF-7_9
M0A\-^)QX@T?P?:^([O4Y_#-RFCR6MQ<20+%'?%?)DG#1DF('.TG&XI*$M_L_
M_LZ? _\ 96^&EO\ !W]GCX::9X2\,6M[=7=OHVDQ%(4FN9WGF<9)/S22,<9P
MHPJX55 [6B@ HHHH ^8O^"P7_!0KP[_P3*_8(\:?M-WD]N_B".V_LKP'IUQ@
MB^URY5EMDVG[Z1X>XD7O%;R8YQ7\[/\ P;1?\$]?$7_!2O\ X*5R?M$_'&"X
MUOPA\,M17Q;XSU#4\RC6-;EF>2RMI6;.]I+A9+F0-D,ELZM_K!71_P#!U?\
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M10 4444 %8_B7_D+Z/\ ]?I_]!-;%8_B7_D+Z/\ ]?I_]!- &Q1110 4444
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M_K'Q6T/P!HUGXG\06EM:Z]XAM=,BCO=1AMM_V>.>95#RK&)'"!B=H8@8K=H
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M-._Y!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BBB@ HHHH **** "BBB@ HHHH
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M HHHH **** "L>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F: -BBBB@ HHHH
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MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
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M(/I'_/S>_P#@6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
M\(/I'_/S>_\ @6U9FN>%=.M=1TV&.>Y(GN2KEKAB0-O;TKJZQ_$O_(7T?_K]
M/_H)H /^$'TC_GYO?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "
MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
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MYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M_D\9:3XD\4+?>"M$?P[;V0\+:<+:*,V DB.ZZ_>I))YLF#\^,9R3Z!0!C_\
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M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U26?A+3;&Z2[AN+HM&V5#W+$?B*U** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+\ _\I!/'_P#V(FE?^C&K
MW2O"_ /_ "D$\?\ _8B:5_Z,:O=* "BBB@ HHHH **** "BBB@ K-\8_\BQ>
M_P#7 UI5F^,?^18O?^N!H N:=_R#X/\ KBO\A4U0Z=_R#X/^N*_R%34 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XE_Y"^C_]
M?I_]!-;%8_B7_D+Z/_U^G_T$UL4 %%%% !1110 4444 %%%% !1110 4444
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M5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/PW\</V5];LO#G_"5:AHE_X0^+7A6)!J@L+PI'>I;NTBR6\CQK+%(<$[00.
M3Z_!!!:P);6T*1QQH%CCC4!54#   Z #M0 ^BBB@ HHHH **** "OQI_X/ _
M^"F7_"@/V7]*_P""?GPP\0>5XK^+$7VSQ<;>7$EEX<BDQY9QROVJ=/+]#%;W
M"D8<5^NGQ=^*W@/X%?"SQ'\:/BEX@BTKPWX4T6YU;7-1G/RV]K!$TLC^Y"J<
M <DX Y-?R" ?'C_@XD_X+/<_:[.7XF^+>?\ EHOACPQ:C_OG,%E'["68_P!Z
M7D _5/\ X,W?^"9W_"O_ (4^(/\ @IC\4O#^W5O&22Z#\-UN8OF@TJ*7%Y>K
MGH9YXQ"K<$);28RLO/[E5SOPC^%7@/X%_"WP[\&/A=X?ATKPWX4T6VTG0]-@
M'RV]K!$L4:>^%49)Y)R3R:Z*@ HHHH **** "BBB@ HHHH Q_ __ "")?^OV
M;_T*MBL3P%/!/H\S03(X6_G5BC X8.01]0:VZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_P I!/'_
M /V(FE?^C&KW2O"_ /\ RD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB@ HH
MHH *S?&/_(L7O_7 UI5F^,?^18O?^N!H N:=_P @^#_KBO\ (5-4.G?\@^#_
M *XK_(5-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\ 036Q0 4444 %%%%
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MZ]\2&MI?F@TJ*7-G9-CH9IXS,R\$+;1]5EKMO^#/W_@F=_PS_P#LNZK_ ,%
M?B=X?\KQ7\68OLGA);B+$EEX<BDSY@SROVJ=/,/8Q6]NP.'-?C[^S#\*_CA_
MP<*_\%F&N_B++<K_ ,)_XHEU_P =W=JY9="\.VY0-#&Y'RK';K!9PDC[[PYZ
MDU_8-X/\(>&/A_X1TOP%X)T.WTS1M$TZ"PTC3;./9%:6L,:QQ0HO95154#L
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M[J:65CF21E#,$"IN)(49->U5C^!_^01+_P!?LW_H5;% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7X!_Y
M2">/_P#L1-*_]&-7NE>%^ ?^4@GC_P#[$32O_1C5[I0 4444 %%%% !1110
M4444 %9OC'_D6+W_ *X&M*LWQC_R+%[_ -<#0!<T[_D'P?\ 7%?Y"IJAT[_D
M'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ,?Q+_R%]'_Z_3_Z":V*Q_$O_(7T?_K]/_H)K8H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q+_R%]'_ .OT_P#H)K8K
M'\2_\A?1_P#K]/\ Z": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKS_X[_%GXE_"R
M[\%VWPX_9[UOQ\OB7QK9Z-KLFC:C;6X\.6$JR--JL_VAU\R&$)RB?.Q90.2
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MCX8_Z#4'_?5'_"8^&/\ H-0?]]4 :5%9O_"8^&/^@U!_WU1_PF/AC_H-0?\
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M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
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MI92&WM41%)D;)  P,X'Y5[W_ &=I_P#SXP_]^A7B/@'_ )2">/\ _L1-*_\
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M/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@"'^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8?^_0J:B@
M"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[.T__ )\8
M?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@"'^SM/_P"?&'_OT*/[
M.T__ )\8?^_0J:B@"'^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0J:B@#"\1V5FFJZ
M2J6D0#7A# 1CD;36O_9VG_\ /C#_ -^A6;XE_P"0OH__ %^G_P!!-;% $/\
M9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_
M -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A
M1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9V
MG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ%']G:?\ \^,/
M_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-10!#_9VG_\ /C#_ -^A1_9VG_\ /C#_ -^A4U% $/\
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MO_7E%_,UL4 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\
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M:B@"'^SM/_Y\8?\ OT*/[.T__GQA_P"_0J:B@"'^SM/_ .?&'_OT*/[.T_\
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MX _9FT+Q#X?^'VK>([R'Q-XRU+Q+J,GB7Q'<ZE*EW>R"22.)[AV,4"X54B7
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M#_\ ((E_Z_9O_0JV*Q_ _P#R")?^OV;_ -"K8H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_ /_*03Q__
M -B)I7_HQJ]TKPOP#_RD$\?_ /8B:5_Z,:O=* "BBB@ HHHH **** "BBB@
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MO3],S*-8UJ69([VYB5<[VDN%CMXRN0R6T;+_ *PU^ZG_  <2?\%,%_X)L?\
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M1110 5F^,?\ D6+W_K@:TJS?&/\ R+%[_P!<#0!<T[_D'P?]<5_D*FJ'3O\
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M4 %%%% !1110 4444 %%%% !1110!C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\
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M'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z": -BBBB@ HHHH ****
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MC+X6^+_ /AKPO\ ?%/C*V\9>*QI&KZOX>^S_ &?PQ;F"67[?>^;(K" &,+E
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MCP0?%"7.M[C[_P!HS3[OQK[&HH X3X8?LM?LR?!+RQ\&/V<_ GA'R?\ 5?\
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M .01+_U^S?\ H5;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9OC+QCX3^'GA+4_'OCSQ)9:/HFBV$U]J^K:E<K#;V=M$A>2:61B%1%52Q8G
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MR%35A67B/54LXD7PE>,!$H#!EP>.M2_\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2T 'B7_D+Z/\ ]?I_]!-;%<IKFN:C/J.FR2>&
M[F,QW)9$9ES(=O05I_\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L4
M5C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?
M\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C
M_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2T?\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M?!_UQ7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Q_$O_(7T?\ Z_3_ .@FMBL?Q+_R%]'_ .OT_P#H)K8H **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?P/_R")?\
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MV*_^"H'_  5</]M_\%+/BK-\!?@[>_-%^SO\)=;W:MJUN>1'KFLJ/F!'#V\
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M/XX]S0!^K/CG_@Z1_P""(?@K=#!^U]/K<Z9S!H?@/6I?RD>T2,_@]>-^.?\
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M!$BA41%'"JJ@  < "K%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!C^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%6Q0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^ ?^4@GC__ +$32O\ T8U>Z4 %
M%%% !1110 4444 %%%% !6;XQ_Y%B]_ZX&M*LWQC_P BQ>_]<#0!<T[_ )!\
M'_7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,?Q+_ ,A?1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\
MH)K8H **** "BBB@ HHHH **** "BBB@ HK ^*/Q5^&?P1\!:E\4OC%X_P!'
M\+^&]'MS/JFNZ]J,=K:VL8_B>20A5YP!SDD@#)-?A?\ \%5_^#Q/2M+_ +2^
M#'_!+#PVM[<#?!<?%OQ1IQ$,9Z;].L91F0]");D!<@CR&!#4 ?KQ^W?_ ,%*
MOV-/^";GPX/Q'_:R^,ECH7GQ.VC^'[<_:-5U=E_@M;1#YDG.%,A"QH2-[H#F
MOYUO^"H?_!TO^VU^WQJ=U\#?V.]/U3X3> =3G^QP6NA7#2>)-=5SL5)KF+F
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MCU\$M)U#4_"NKVGB30+#7[:"\D\/ZQ'$=DL;J63SHC(X#H2NX!E/"D,_9E^
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MQWD20KG_ *[G\*\";]E/_@XE_P""93F7PM\/?VB_ .GV!S--X'O[^\TE O\
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M(^6VM_L]^(O$S(/O:[\0=43<?4BTF@'X8Q[5[)X&_P""!O\ P1O^'?EC0/\
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M22UF^_"S6,A*-[@G!^E?-_\ P1 \:>$OAO\ \$/?@A\0O'WB*TTC0]"^%O\
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M/:.";EE/2:XSG"LL43"OU#C\":+%&L44UVJJ %5;I@ !V% 'S5_P35_X(O\
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M]ECX+Z'X*\/P8+VFD6N)+J0#'FW$S$RW,N.#)*SN1QFO2*Q_^$'TC_GYO?\
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MW,G_  D?C_7#J6JW33W$D[>=<%5,@5I"JY&5157)QFN]K'_X0?2/^?F]_P#
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M)XINK!I[G9';1LI%PV[))ZF@#JZ*Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJ #P/_ ,@B7_K]F_\ 0JV*Y3PKX5T[4-.DFFGN
M01<R* EPRC :M/\ X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
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MQ%XJ^+'^D?MH?\%:/VG/B9YG_'UHFE^-D\-Z+<>NZQLHSCVQ(, FOL3]HO\
M:A^!W[)WA'2O'?Q]\:-H6E:WXGL/#VFW2Z9<W9EU&]D\JV@V6T<CC>_R[B-J
MYRQ YK:^*'QD^$WP2T>Q\0_&'XDZ)X7L-3U>WTK3[W7M3CM(;B^N&*P6R/(0
M#)(P(5<Y8\"@#Y?^#7_! #_@CS\#[E=2\-_L)^#]:O=^^6^\<_:/$,DTG4NP
MU*2==Q//"@9Z 5]5> OAI\./A7HB^&OAA\/]$\-Z:F-FGZ#I4-G N.F(XE51
M^5:6IZSI&BQQ2ZQJMM:+/.L,+7,ZQB21ONHNXC+'!P!R<59H **** "BBB@
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M .01+_U^S?\ H5;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK2O$G[2?P@_9ATAMRG0_!)3XG>/&7NO^C$:19N5ZQW$T,L;'&<@X_-GXS_\
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ME_R.][_UY1?S-;%8]E_R.][_ ->47\S0!L4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &/X'_P"01+_U^S?^A5L5C^!_^01+
M_P!?LW_H5;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!X7X!_Y2">/_P#L1-*_]&-7NE>%^ ?^4@GC_P#[
M$32O_1C5[I0 4444 %%%% !1110 4444 %9OC'_D6+W_ *X&M*LWQC_R+%[_
M -<#0!<T[_D'P?\ 7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH ****
M "BL#XJ_$WP;\%OAEXA^,/Q%U&:S\/\ A71+K5]<N[>QFN7@M+>)III!%"CR
M2%41CM168XX!-</XW\:_$_\ :/\ V/O^%C?L-_$/1M"\1>,_"UIJ?@+Q'XQT
M&::UM4N%CE62XM,I(&\EF&QAE'(W*VTJ0#T'QEX\\#?#G1U\0_$+QGI.@Z>]
MU%;)?:SJ,5K"T\KA(H@\K*I=W(55SEB0 "37+?'?XB?&_P"']SX+B^"_[/[>
M/(]=\;6>E^+)$\2V^G'PYI$@D:XU;$XQ="((!Y",LCF1=N<$5<^)?P+^&?[0
M7PUM?AM^TE\._#OC+3UN+*]OM,U32UFLI+ZVD29)5AE+8"RH&4,3Q\IW G/D
MO[8W_!6[_@G5^P7'/:?M,_M4^&='UF ?\BKI]R=1UAV_A7[#:B29-QX#.JIG
MJP ) !Z=\4/V>="^*OQ<^'OQBU/XA>,M*N_AQ?WUWIVCZ#XCDM=-U5[JV^SN
MNH6P!2[5$+&/=@QL[$'YB#WSLJ*7=@% R23P!7X'_ME_\'K6EPK=^'/V"?V7
M/,.TBW\6_%&YP#SMRFG64A)[LIDN4X RG.*_)_\ ;'_X+/?\%#/VZ7N]/_:(
M_:5\2ZUHMT94?PM97ATK13&?N9L+$Q)(RC.&F:8G/)/.0#^H[]K#_@O%_P $
MQOV1M4G\&>(_VA(/&OC"+>J>!OA=:MX@U1Y%!+1,ML3% X R5GECK\P/VOO^
M#O?XQZ^MSHG[-'@'P=\*],9?W6L^*;G_ (2GQ'-$>K0:?9,ME9W"G ,-[<>O
MX?E'^RS_ ,$SO^"H?[?=E%I_[-O[+WC'6?#E]*C_ -I)IJ:1H#NHP)#<3>3:
M.X Y(8N?<D9_3/\ 9$_X,GOC-XD^R^(?VX/VKM&\,6[8>;PU\/;%M1NV4]4:
M[N!'%"X]5BG7T)ZT ?G1^T[_ ,%7/B=^TSK9UOXWZ_XO^,>H13%[>Z^+GB24
M:/;R Y6>ST#3'M[2S?/6.22ZC(&"IIGP@^#_ /P5_P#^"G6B1_#3X _"GQ[X
MH\'-<?)H?@_0H]#\(6TV<;FCMTMM,@DXY9MK'').*_IC_9$_X-SO^"1W[')M
M=5\*_LM:?XSUVUP1XC^)DO\ ;=PSCHXAF46L3@\AHH$(/?@8^W-/T^PTFQAT
MO2K&&VMK>)8[>WMX@D<2 8"JHX4 < #@4 ?S<?LB?\&5_P"U=X]^R^(/VSOV
MCO#/P]L7P\N@^%;=M:U+'>-Y"8K>%O\ :1YQ[&OU)_9$_P"#8S_@D/\ LF?9
M=6G_ &?G^)>NVVT_VU\4KP:H&8<_\>85++&>F8"1ZFOT$HH YD^&?#?@V'P]
MX7\(>'['2M,LKCRK/3M-M$@@@0*<*D: *@]@ *Z:L?Q+_P A?1_^OT_^@FMB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$O
M_(7T?_K]/_H)K8K'\2_\A?1_^OT_^@F@#8HHHH **** "BBB@ HHHH ****
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MR)_P1C_X)D?L.?9=0_9\_9"\*VFLVF#%XHURU.JZJKCJZ75X9)(23R1$47T
M  KZ?H _GU_9$_X,E=:NOLNO_MU_M>PVJ':USX8^%VGF5R#SC^T+U JD="!:
MN/1O7]2?V1/^""__  2D_8K^RZG\*/V1?#^J:[:X9?$_C>,ZW?\ F#I*C7>]
M+=_>!(Q[<FOL&B@!$1(D$<:!54855& !Z4M%% !1110 4444 8_B7_D+Z/\
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M?1_^OT_^@FMBL?Q+_P A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Q_$O_(7T?_K]/_H)K8K'\2_\A?1_^OT_
M^@F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** ,>R_Y'>]_P"O*+^9K8K'LO\ D=[W_KRB_F:V* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'LO^1WO?^O*+^9K8K'LO^1W
MO?\ KRB_F: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,>.M>L?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[
MZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!
MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A
M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
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M[ZJIXCLK--5TE4M(@&O"& C'(VFM?^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
MY\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/
M_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]
M]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]5EVGB704\6W
M=Z^J1")[6-4DSP2"<BN@_L[3_P#GQA_[]"LBSLK,^,[V(VD6T6<9"^6, Y-
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M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
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M* "L?Q+_ ,A?1_\ K]/_ *":V*Q_$O\ R%]'_P"OT_\ H)H V**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'LO^1WO?^O*+
M^9K8K'LO^1WO?^O*+^9K8H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9H V**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\#_ /((
ME_Z_9O\ T*MBL?P/_P @B7_K]F_]"K8H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_ /_ "D$\?\ _8B:
M5_Z,:O=*\+\ _P#*03Q__P!B)I7_ *,:O=* "BBB@ HHHH **** "BBB@ K-
M\8_\BQ>_]<#6E6;XQ_Y%B]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\ KBO\
MA4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^
M)?\ D+Z/_P!?I_\ 036Q6/XE_P"0OH__ %^G_P!!-;% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5C^)?^0OH__7Z?_036Q6/X
ME_Y"^C_]?I_]!- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/9?\CO>_]>47
M\S6Q6/9?\CO>_P#7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!C^!_\ D$2_]?LW_H5;%8_@?_D$2_\ 7[-_Z%6Q
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\A?1_P#K]/\ Z":V*Q_$O_(7T?\ Z_3_ .@F@#8HHHH **** "BBB@ HHHH
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M4 %%%% !1110!CV7_([WO_7E%_,UL5CV7_([WO\ UY1?S-;% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CV7_ ".][_UY1?S-
M;%8]E_R.][_UY1?S- &Q1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 8_@?\ Y!$O_7[-_P"A5L5C^!_^01+_ -?LW_H5;% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17S5_P %"O\
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M_P#7E%_,T '_  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7
MO_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\
M]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[
M_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\
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MU2444 %%%% !1110 4444 >%^ ?^4@GC_P#[$32O_1C5[I7A?@'_ )2">/\
M_L1-*_\ 1C5[I0 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS?&/_(L7
MO_7 T 7-._Y!\'_7%?Y"IJAT[_D'P?\ 7%?Y"IJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\ (7T?_K]/_H)K8K'\2_\
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MB7_K]F_]"K8K'\#_ /((E_Z_9O\ T*MB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS?&/_ "+%[_UP- %S3O\
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M -<#6E6;XQ_Y%B]_ZX&@"YIW_(/@_P"N*_R%35#IW_(/@_ZXK_(5-0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B7_D+Z/_U^
MG_T$UL5C^)?^0OH__7Z?_036Q0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %8_B7_D+Z/\ ]?I_]!-;%8_B7_D+Z/\ ]?I_]!-
M&Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8]E_R.][_P!>47\S6Q6/9?\ ([WO_7E%_,UL4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6/9?\CO>_P#7E%_,UL5CV7_([WO_
M %Y1?S- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 8_@?_D$2_P#7[-_Z%6Q6/X'_ .01+_U^S?\ H5;% !1110 4444
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MEO+>ZEM([J,RVMY;75LQBO+69%;;*F.4(*@%"WT10 4444 >%^ ?^4@GC_\
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M%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWKWJB@#P7_ (5]_P %#_\
MHX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%??\%#_P#HX+P)_P"$N]'_
M  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\
MT<%X$_\ "7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWK
MWJB@#P7_ (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%?
M?\%#_P#HX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX
M+P)_X2[T?\*^_P""A_\ T<%X$_\ "7>O>J* /!?^%??\%#_^C@O G_A+O1_P
MK[_@H?\ ]'!>!/\ PEWKWJB@#P7_ (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]
M'!>!/_"7>O>J* /DGXMW_P"WGX"\;^!?#6K?&[PA<3^)M>>RL9;;PWA()!$7
MW2!ADK@8P.:[S_A7W_!0_P#Z."\"?^$N];?[1_@7Q=XL^+'PDUOPYH,]W::'
MXPDNM6GA *VL)@90[<],\5Z_0!X+_P *^_X*'_\ 1P7@3_PEWH_X5]_P4/\
M^C@O G_A+O7O5% '@O\ PK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O G_A+
MO7O5% '@O_"OO^"A_P#T<%X$_P#"7>C_ (5]_P %#_\ HX+P)_X2[U[U10!X
M+_PK[_@H?_T<%X$_\)=Z/^%??\%#_P#HX+P)_P"$N]>]44 >"_\ "OO^"A__
M $<%X$_\)=Z/^%??\%#_ /HX+P)_X2[U[U10!X+_ ,*^_P""A_\ T<%X$_\
M"7>C_A7W_!0__HX+P)_X2[U[U10!X+_PK[_@H?\ ]'!>!/\ PEWH_P"%??\
M!0__ *."\"?^$N]>]44 >"_\*^_X*'_]'!>!/_"7>C_A7W_!0_\ Z."\"?\
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M--MO%,FBW2^&KC6 QM(M0,+"W:<(&;RA+L+[03M!P">* -JBOR(_;*_X)??
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M-U%-"9Y701JJE%48#;6 /V%HK\X?C!\.=*_X*B?\%B_'7[(/[0NM:[<_!SX
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M;M_VW_!WACP7\//#=^]WJ'B6,WES-'KFJ7(VI&I2S!BLE#;!<L9#OC4G];J
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M,L_V>!4\QSU=MH&6/J>:LT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&,27<Q']Z2Y>:0^[FO8Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGXU?%CP3J'AG6/CG\9O$_P 31X<U> Q7>G6NJ72FV29#]QV@ABDV]0)0#@Y
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MY!?M;_\ !0;5O^")W[!G[,G_  3 TOXJ:#X#^*_B3X=6%IXH^(NOZ=/J.G^
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M_P $'O$FDZ/H]C+>ZKJFH_M#>%X;>SMHD+R32.S!4154L6)  !)K T?_ (.
MM:U7_@E_I/\ P4GE_8.\1VJ>)?BA;^#_  GX(NO%T,<NLK.PBBOX;M[<)Y33
MB6$93!,3'?BL;]J/Q3XI_P""X_[6NI?\$[_@EX@O++]FCX4ZW$?VCO'>E7#1
MCQ=JT+B2/PI93(?FC1E5KF13P1C*[8_.N_\ !R5X-3P%_P $T?AWX ^".B:-
MH@T?XW^"K#PEIS6ACT^Q,4[1VT9CBP5@0J@*I@[1@4 =W_P\C_X*Y?\ 2O\
M>,/_  _OAG_&NH_;6_X*A_&C]E'Q1^SY\'_!?[".J>/?B7\?+#5'LO =O\0=
M/TQ]&O-/LK6[NK1[NX4V\I1;B1=^]%)MSMW;U%<O_P (I_P<L?\ 17_V,/\
MPE?%'_Q^O*_^"UC_ +2T'_!3C_@G^_[,UMX&N?B4NI?$+^QH_'=Q>0Z&\_\
M8MCY_GM:(]PJ>5YI3:I._8#QDT =_P#%;_@LK^V!^R9X87XP_MW?\$<?B#\.
MOAI:WL$'B'QOH'Q,T'Q.-&CEE6(7$]K82>:(0SJ"_O@98A3]]:%KFC^)]$L_
M$OA[4H;RPU"UCN;&\MW#1SPR*'212.JLI!!]#7XW_M[_ !0_X*L_'_XP^%O^
M"3O_  4O\8?!7X(?#7X[O'8VOQ-^&.CZIJT?B.6*>*230H+J_FC6QN9OD53/
M H;< C/G8W["> _!7A_X;>!]&^'7A*T-OI6@:3;Z;ID#.6,=O!$L4:DGDX15
M&3UQ0!K4444 %%%% !17'_'[XV>$_P!G'X-^(?CEXZTW6+S2/#6GF\O[70-+
MDO;V2,$#$,$?S2MR/E'-?&/_ !$@?L*?]$>_: _\,EJG_P 30!]_45\ _P#$
M2!^PI_T1[]H#_P ,EJG_ ,31_P 1('["G_1'OV@/_#):I_\ $T ??U%? /\
MQ$@?L*?]$>_: _\ #):I_P#$T?\ $2!^PI_T1[]H#_PR6J?_ !- 'W]17P#_
M ,1('["G_1'OV@/_  R6J?\ Q-'_ !$@?L*?]$>_: _\,EJG_P 30!]_45\
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M",RK%(TV8P&;$>P;G.6(!<_;X_X*"_!?_@GQ\-M)\8?$K1]>\1Z_XKUN/1/
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M=)TV5A:W%]91Z6VHQP,2&$,CHH0Y#;6)X.*^4OA1_P %A/\ @I%\:/A1X?\
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MY1_PX(_X(V_](]OA_P#^ <W_ ,<KZ_HH ^0/^'!'_!&W_I'M\/\ _P  YO\
MXY1_PX(_X(V_](]OA_\ ^ <W_P <KZ_HH ^0/^'!'_!&W_I'M\/_ /P#F_\
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MI7[/7[-'_!;G1?#'A/1O,:STZW_90T25GDD<O)-+-+?M)-*[$EI)&9CP,X
M] _:(_X)/_MG?M=?L2G]F3]I?_@IW!XF\:67Q2TWQ?X>^)D7P1L;%=-BLE0P
MV)TVVO4CF_?!Y?.>3/[S:4(45]XT4 ?"'_#!/_!<;_I/]I__ (B5H'_R;7I'
MC[_@G7\0OB[^T%^RG^TO\6?VGEUGQ/\ LXVFN?\ "072>"8[8>-;S4],ALI;
MD)%<A--P\1F\M5F4[]@V@;C]3T4 >$?\%(OV!?AA_P %)_V3]?\ V8?B3J<N
MD2WKQWWA?Q5:6_FW/AW5X"6MK^%=R$LC$JRAT+QO(FY=^X>D? 'P7\3_ (<?
M!7PQX ^-'Q8B\=^*=&T:&SUKQE%HG]F_VS-&NW[4UMYTPBD< ,X$C N6("@A
M1U]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/7[*7[!W_#,
M7[67[0O[4/\ PM7^W/\ A?'B'1M4_L/^P_LW]A_8+)[;R_.\]_M._?NW;(MN
M,8;K7T+110!^:WP!_P"",W_!3C]D?PSK'PX_98_X+9VGA'PEJ?BO4M>AT*;]
MF;2M1:WGO9VFD'GW.H-(_) Z@<< =*]R\%_L+?MV>)?V<_C/^SW^V7_P4NM_
MBQ#\4/ %[X:\/ZC!\%=/\/\ _",-=6=U;37)CM+HF]R)XF\MFCQY& PWDCZW
MHH _.CX)_P#!*;_@L'^SQ\(/#/P(^$O_  7BL=-\+^#]#MM(\/Z>_P"RKHLY
MMK.WC6.*,R2W[.^$4#<S%CC))-=[^T'_ ,$M_P!J']L+_@G9K_[$W[6__!0J
M'QGXHUGQGI^L6_Q+A^$=II@M+.TNK6YCL?[.M;M4D^>WE_?&4-^_Y4A #]M4
M4 87Q0^&7@/XT_#C7?A%\4?#-MK7AOQ-I-QIFN:3>)NBN[6:,QR1MWP58C(P
M1U!!%>)_\$QOV'O'G_!.[]FQ?V6/$'[2%S\2/#>A:U=-X N=3\/?8KW1='D?
M?%ILTHN)1=^42VV4+%\K;0BJJJOT310!X#_P4#_X)W_"/_@H/X!T+1O&7BC7
M_"/B[P3K2ZU\.?B/X/O!;:OX8U)0/WT$A!#(VU1)$WRN%4_*RHZ_/&O?\$T/
M^"P?Q6\/R_![XV_\%R;Y_ US$;75KGP3\$],T;Q#JEHPVM$;Y9G%HY7(\V)"
M3W')%?H+10!\;_$;_@C;\);WX'?LR?LY_ OXAWG@WPI^S1\8M$\=:3;:A8-J
MT^M"PDN)9+225IXO)>>2X=S, ZH20L6W"K[_ /M?_LJ?"7]MS]FOQ?\ LM?&
M_1_MGASQAI#V=V44>;:R<-#=0D@A9H9525#R T:Y!&17I-% 'R%;?\$G]+^*
M_P#P34\/?\$\/VW/CQJ'Q-N?"L5N/#WQ/TC2#H>L:=/:,?[.O82;BY*7EO&1
M'YV\^:H.]3O?=Y[J_P#P33_X*Y^.?!TGP#^(W_!;F_F^'UQ;FRU'5="^#EA8
M^++ZP(VFW.I"X9892GRFZ2/S&.6(RQK[_HH ^?4_X)B_LA6G_!/:Y_X)C:3X
M ELOA7<^&)-%>QM[G_2OG<RF\\X@YNOM'^D>801YHSMQ\M?-%M_P2G_X*X6'
MPM7]EFR_X+?W:_#!=-_LF.\?X,6#>*$TG9Y?V0:C]HSYGE?)]JQYH^\.1BOT
M9HH ^-OVC/\ @C;\)?B=_P $N="_X):? SX@3^ ?"WARYTB72]:NM(&JS'[%
M?I?2O+&)K</+<2B1G<,H#S,P7&%K[)HHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KX8^,G_  2:_:%\&_M1>,?VN/\ @FA^WE>?!+6/B3<Q
M7GQ)\&ZSX)MO$7A_7;Y%V?;D@FDC:TN&'+R1DESG[H9@?N>B@#Y"_9!_X)B>
M/?AK^T/K/[9_[</[5U[\=/BQJGA-_"^FZA/X5MM&T?P_HKRB66TLM/A9U#2.
M!OF=BSJ,8&Y]WD7A+_@B]^VA\ OAWK7[(G[('_!4_4/ ?P UB_O9+'PI=?#:
MVU+7O#EE>2-)<Z?I^J27"[(V:279(\1DB,A8;FRQ_1JB@#X*_9S_ ."&VE_L
MF?L^_'K]CCX'?M8>*(OA%\8?A]>:)X=\'^)=,BU%O"6JWNGS65[J:3AXGN%D
M#12?9AY2;E?YOF#+]6_L=_L^?\,F_LG_  V_9@_X2[^W_P#A7O@?3/#O]N?8
M/LOV_P"QVT<'G^3YDGE;]F[9O?;G&XXS7I%% !7RO^W!_P $Z/&OQ^^/W@?]
MM3]EK]HN3X4?&?P#I%UHMGXAN/#D>L:;K6C7#>9)IM_9O)$9(Q)ET=)%:-G9
ML,P0I]444 ?*7[(?_!.+QM\,?VBO$O[;7[97[1(^,'Q?\1^%D\+VNIP>%X](
MT?P[H*R^>VG6%D)92!)-\\DLDC,Y'1<ON\2E_P"")?[4/A/X.Z_^PC\$?^"D
MMYX7_9E\27MZLO@=OA]!=>(=(T>\F>6[T2RU=[@!;:0R2J'D@>1$E*_.,Y_1
MJB@#Y7_:Q_X)?>%_C!\._@_:_LQ_$^X^#_CC]GN2/_A37B_3M)348M(M?L:V
M4VGW%K*ZBYM)[9(XY$WJQ\M3NQN5H?V0O^">7Q9^''[4&N?MT_MH_M+P?%;X
ML:EX43PMH-QI/A1=%T?PQH@G^T26UG:B:9FDFF DDG=RQP$ "YS]744 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>pfe-20211231_g5.jpg
<TEXT>
begin 644 pfe-20211231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .,^!GQFTSXY^$+KQ?I.BSV,=KK5WIS
M0W$BLS-!(4+Y7L2,BNSKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^6+_ (>E_P#!1W_H]SXE_P#A6W/_ ,51_P /2_\ @H[_ -'N?$O_ ,*VY_\
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M[_GS/\/\S^IVBOY8O^'I?_!1W_H]SXE_^%;<_P#Q5'_#TO\ X*._]'N?$O\
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M'R[_ )\S_#_,_J=HK^6+_AZ7_P %'?\ H]SXE_\ A6W/_P 51_P]+_X*._\
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M/^?T?N?^0?\ $1\N_P"?,_P_S/ZG:*_EB_X>E_\ !1W_ */<^)?_ (5MS_\
M%4?\/2_^"CO_ $>Y\2__  K;G_XJC_B'F8?\_H_<_P#(/^(CY=_SYG^'^9_4
M[17\L7_#TO\ X*._]'N?$O\ \*VY_P#BJ/\ AZ7_ ,%'?^CW/B7_ .%;<_\
MQ5'_ !#S,/\ G]'[G_D'_$1\N_Y\S_#_ #/ZG:*_EB_X>E_\%'?^CW/B7_X5
MMS_\51_P]+_X*._]'N?$O_PK;G_XJC_B'F8?\_H_<_\ (/\ B(^7?\^9_A_F
M?U.T5_+%_P /2_\ @H[_ -'N?$O_ ,*VY_\ BJ/^'I?_  4=_P"CW/B7_P"%
M;<__ !5'_$/,P_Y_1^Y_Y!_Q$?+O^?,_P_S/ZG:*_EB_X>E_\%'?^CW/B7_X
M5MS_ /%4?\/2_P#@H[_T>Y\2_P#PK;G_ .*H_P"(>9A_S^C]S_R#_B(^7?\
M/F?X?YG]3M%?RQ?\/2_^"CO_ $>Y\2__  K;G_XJC_AZ7_P4=_Z/<^)?_A6W
M/_Q5'_$/,P_Y_1^Y_P"0?\1'R[_GS/\ #_,_J=HK^6+_ (>E_P#!1W_H]SXE
M_P#A6W/_ ,51_P /2_\ @H[_ -'N?$O_ ,*VY_\ BJ/^(>9A_P _H_<_\@_X
MB/EW_/F?X?YG]3M%?RQ?\/2_^"CO_1[GQ+_\*VY_^*H_X>E_\%'?^CW/B7_X
M5MS_ /%4?\0\S#_G]'[G_D'_ !$?+O\ GS/\/\S^IVBOEC_@BE\4_B/\:O\
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MRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /Z4O^" ?_*)'X3?]Q[_T_:C7TM\>_C]\&?V7?A)K
M7QW_ &@?B)IWA7PCX>MA/J^N:I(5B@4L$4 *"SNSLJ*B!G=F55!) KYI_P""
M ?\ RB1^$W_<>_\ 3]J-7_\ @L]^R!\;_P!L/]E30=*_9TTK1]9\7?#WXH:!
MXZTOP?XANQ;V'B@Z9.TC:7/(WR(LJN<%_D+(H8J"67^=\[_Y'6)_Z^3_ /2F
M?T?D?_(DPO\ U[A_Z2AO[%__  6Y_8'_ &Y/C#>_ +X7>/M6TCQ@M]=Q^']"
M\8>&[S2IO$-K;HKO=67VF)!(-C%C"2)U52S1JO->@_M5_P#!3K]@G]B+Q58>
M!?VHOVFO#_A37-2LC>6NB3+/=7GV4$C[0\%M'))%#E6 D<*AV-@G:<? '[!7
M[8/[&WQN_:PD^$7[?W[*OB[X9_&(?M):]XD^$[>-+*3^SK77I+:UCFTVTU:T
MD\BYNE" -#(!')NAP&9D6M&']H7QE^RE_P %I_VJO%G[.O[*GB#]IR?QIX<\
M-R>*7\ QJE]X N[+3S NB75Q>*EM)'<J%G$<$S2J8RKPLR<>6>J?J-\*_BO\
M-/CE\/-)^+7P<\>:5XG\,Z[:"YT?7=$O4N+6[B)(W)(A(.""I'564@@$$5CZ
M;^TG\#-8_:%U+]E+2?B/8W/Q"T?PQ%XAU;PQ;AWFL].EF\F.:5@OEH6?&(RP
M<J0VW:0Q^&/^"$'@.^\8?\$L_B%X=^$'QQM/!WB_QC\1_%]W=:?H&AR,?A'K
M%[)_R!ELKZ*(^;8DHYCDC6-G<[=R%7;C?^"<G['G@/\ 8E_X+X?%/X5>#/&?
MBGQ1=ZE^S+I6M^*?%WC;6GO]5U[5;C7'$]Y<2M@;F$<:A455544 9R2 ?JC7
MS9\3O^"P?_!,GX,_&NY_9Y^)_P"V=X,T?Q987Z6.J6-S=R&#3KIR0(+JZ5#;
MVLF004ED0J1@@5])U^9W_!1GX;>&O^":?_!,GQ_^Q]^R'_P3_P#&?Q.T'Q[X
M=\1W?BSQ5,4U"UTF>_=S/JNK2G?>7DD/FF9?*AD<1VB@NFU6H _2^">&YA2Y
MMIEDCD4-'(C JRD9!!'4&G5X7_P3%B\"6G_!.WX)Z3\,_C/;_$/0]-^&6CV&
MG^-;576/5EM[2.!I0D@$D?S1LOER 2)MV. RFO=* "BBB@ HHHH **** "BB
MB@#X-_X+L>&O^"G7Q<^%?@_]GO\ X)_? ;6_%'ACQ1JLI^,VJ>&/B#I/AW5/
M[&C,0_LNTNM0F4PM=AY0\Z1R;$BVD$2,IG_X)V?$+]M_X1WG@G]DR/\ X(21
M? ;X1Z=#+;2^([#X]>']7BT=%@DD65[2U'VB[DFF5$>3)<M,9')PQK[KHH _
M-'X*>$O^"F/_  2GL_BA^RM^SA^P2WQH\&Z_X\UCQ+\%/%VE^.M-TVUT9-3E
M,[:;J\-W+'+&EM.SMYL0<2HV!M;IR?QH_8B_X*G?L8_\$?\ X9_L#?L ^";W
MQMXZU_5[NY^.7C;PMXSTS1+RTAO+F2\U%-/N-1EB"3327#6\5RL;-'% 6**S
M*1^K5% 'YZ?\$YO%'[<O[,NG>"?V2O!W_! <_![X80WZ0ZSXIB_:(\.:J]BK
MX\[4;F* ?:+^=L N<F1^!G  'J7_  7:_9A^.7[97_!*KXI_LV_LV^!_^$D\
M:^(_[#_L71?[3MK/[1]GUS3[J;]]=21Q)MA@E?YG&=N!EB ?KFB@ HHHH **
M** /Y5?^"D7_ "?'\1_^P\/_ $3'7B-?I)\</^"*W[;/[:'QW\;_ !^^"MAX
M7D\/ZEXGN(+9M4U\6\V^$+$^4V' W*<<\BN9_P"(:O\ X*8_] GP-_X5@_\
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MQ#5_\%,?^@3X&_\ "L'_ ,:H_P!8LC_Z"8?^!(/]6\^_Z!I_^ L^ :*^_O\
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MQ#5_\%,?^@3X&_\ "L'_ ,:H_P!8LC_Z"8?^!(/]6\^_Z!I_^ L^ :*^_O\
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MN1%N 8Q+-<R(A(!**I(!) ^A:** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /"_^">__ "1/5O\ L>]9_P#2DU[I7A?_  3W_P"2)ZM_
MV/>L_P#I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_ ()[
M_P#)$]6_['O6?_2DU[I7A?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /"O^"?+*OP4U8,P'_%=:SU/_3R:]T\R/\
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MJ=LH>\LM-MKEQ+JDUNIPZ1[?G&P9W(6[?XL?\%=OV8O G[$_@']MCX?V&O\
MCO3_ (M:AI^D_"SPCX9LE;5O$6L7A=8M.2-V"Q2H\<RREFQ&87'S-M5O*_\
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M1_PJ63_H/+_X#?\ V5']HX+^?\'_ )!_9&8?R?BO\SCJ*['_ (5+)_T'E_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
M!/?_ )(GJW_8]ZS_ .E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)_\ H#H_^3__ "1^Y/\ P\'_ &*?^CD_"_\ X&G_  H_X>#_ +%/_1R?A?\
M\#3_ (5^&U%'_$O/#7_076_\D_\ D0_XF.XG_P"@.C_Y/_\ )'[D_P##P?\
M8I_Z.3\+_P#@:?\ "C_AX/\ L4_]')^%_P#P-/\ A7X;44?\2\\-?]!=;_R3
M_P"1#_B8[B?_ * Z/_D__P D?N3_ ,/!_P!BG_HY/PO_ .!I_P */^'@_P"Q
M3_T<GX7_ / T_P"%?AM11_Q+SPU_T%UO_)/_ )$/^)CN)_\ H#H_^3__ "1^
MY/\ P\'_ &*?^CD_"_\ X&G_  H_X>#_ +%/_1R?A?\ \#3_ (5^&U%'_$O/
M#7_076_\D_\ D0_XF.XG_P"@.C_Y/_\ )'[D_P##P?\ 8I_Z.3\+_P#@:?\
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MMT:>4G@D1QY!D!'YV_"WPM\3_P#@D]\??#?B?]E#]ICQG>>"/%O[;Q^$FL?
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MWM;D'<MI?ZO>WMJ>0/O6]Q"^>^[/>ON&@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#P#]MS_ ()=?L,_\%&;[PSJ7[9/P7G\7S>#5NAX:*>+M6TT67VD
MQ>>0MA=0!V;R(OF<,0$ ! SGA_V;_P#@A9_P2V_9(^-6A_M#_L_?LV7FA>,/
M#<DSZ-JLOQ%\0WJV[2P202$P7=_+#)F*61?G1L;LC! (^MZ* /EK]HS_ ((Q
M?\$[/VI_BSJWQJ^+7P2O3KGB6.&+QB?#WC#5-(MO$T<0Q&NHV]E<Q17FT<;I
M%+$<$D  ?2?@[P=X4^'GA+3/ 7@3PY9:/HFBV$-CI&DZ;;+#;V=M$@2.&*-0
M%1%50H4#   K2HH X'X8_LP_ WX-_%CX@?''X;^!_P"S?%/Q2O[&]\=ZI_:=
MS-_:<]G;_9K=_+ED:.'9%\N(E0-U8$\UXU^T7_P1H_X)Z?M2_%S5OC=\5O@W
MJ2:_XEMXK?QC+X:\::KHT'B6&)=B)J$%C<Q1W>%^7<ZEBORDD  ?4=% &-\/
M/AYX%^$O@;2?AE\,?".GZ!X>T&PCLM&T72;58+:RMXU"I%'&H 50!T%;-%%
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M_H+>-?\ P=P__(]'_#D?]C?_ *"WC7_P=P__ "/1_P 1WX$[U?\ P#_[8/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'A?_  3W_P"2)ZM_V/>L_P#I2:]TKPO_ ()[_P#)$]6_['O6?_2DU[I0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $&GZ7IFD0&VTK3H+6-I&=
MH[>%44L3DM@ <D]34]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>pfe-20211231_g6.jpg
<TEXT>
begin 644 pfe-20211231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .,^!GQFTSXY^$+KQ?I.BSV,=KK5WIS
M0W$BLS-!(4+Y7L2,BNSKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^6+_ (>E_P#!1W_H]SXE_P#A6W/_ ,51_P /2_\ @H[_ -'N?$O_ ,*VY_\
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M[_GS/\/\S^IVBOY8O^'I?_!1W_H]SXE_^%;<_P#Q5'_#TO\ X*._]'N?$O\
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M'R[_ )\S_#_,_J=HK^6+_AZ7_P %'?\ H]SXE_\ A6W/_P 51_P]+_X*._\
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M/^?T?N?^0?\ $1\N_P"?,_P_S/ZG:*_EB_X>E_\ !1W_ */<^)?_ (5MS_\
M%4?\/2_^"CO_ $>Y\2__  K;G_XJC_B'F8?\_H_<_P#(/^(CY=_SYG^'^9_4
M[17\L7_#TO\ X*._]'N?$O\ \*VY_P#BJ/\ AZ7_ ,%'?^CW/B7_ .%;<_\
MQ5'_ !#S,/\ G]'[G_D'_$1\N_Y\S_#_ #/ZG:*_EB_X>E_\%'?^CW/B7_X5
MMS_\51_P]+_X*._]'N?$O_PK;G_XJC_B'F8?\_H_<_\ (/\ B(^7?\^9_A_F
M?U.T5_+%_P /2_\ @H[_ -'N?$O_ ,*VY_\ BJ/^'I?_  4=_P"CW/B7_P"%
M;<__ !5'_$/,P_Y_1^Y_Y!_Q$?+O^?,_P_S/ZG:*_EB_X>E_\%'?^CW/B7_X
M5MS_ /%4?\/2_P#@H[_T>Y\2_P#PK;G_ .*H_P"(>9A_S^C]S_R#_B(^7?\
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M.S7+JF4X^>%G)-QMJMM4G^I]IE.94\WR^&+IQ:4KZ/?1M?H%%%%><>B%%%%
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M)/JR226TI&Z%C;Q$H<=P3@_2O&*_HG)/^1+AO^O</_24?S?GG_([Q7_7R?\
MZ4PHHHKTSRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /V,_P"#3'_FOW_<J_\ N8K]BI98H(FG
MGD5$12SN[8"@=23V%?CK_P &F/\ S7[_ +E7_P!S%?JW^T1\+;KXX_L_^.?@
MI8^(I-'G\8>#M3T2'5H5)>R>[M)8!.H!!)0R;AR/NU^%<9?\E)7_ .W?_2(G
M[WP5_P DS0_[>_\ 2Y'R4?\ @XO_ ."50^/D7P5_X7W<?V7*K0I\2#X=OAX9
M-\+H6WV7^T##Y1&X_P#'R#]F[>;GBOIS]IS]L3]F']C/X>P_%3]J#XUZ'X-T
M*[NTM;"[U2X)>]G896&WBC#27$A +;(U8X!., FOQJ\!_%GPU^P]XA\.?L/_
M /!9W]A/6]&^'OAG]FN/X?>(?$W@RT.N^&]5TY-;A>+7;B2Q9;BQAD=%+L4\
MX7#9PK, /U7\:?LL?LL:[J7PX_;B\+?#[4_'-[\%_AU>GX0:1X?U07D,]I/9
M(4-E'-)Y4MU-#%%'%.S@G<N7Q\P^8/J3N_V7?VROV7?VU/!=U\0/V6OC9HGC
M/3-/O#::F^ES,)K"X'/E7$$@66W<CD+(BDCD9%>6_$#_ (+2?\$L/A9\7;OX
M&>/OVW/!6G>(].U,:=JD+W,KVMA=DE3!<7B1FVMY%96#+)*I0J0V"#7RU_P3
M2^(5S^T'_P %@OVF/B+\5_ 6K_ 7QUXE^&NBZ=9_!O5HFAUS4M+MV=/^$IEG
M6/[).X>1;>-H))_+P5<\*7[/]L?PW^Q)_P $D?\ @E/<_P#!/KP#X$G\;ZK\
M0='U/PS\-_AK=01:AKOCK7-0W_OIEBC0S;)9D>6Y* 1JB '?Y2D _0VTO+34
M+2*_L+J.>">-9(9H7#)(C#(92.""""".M>2_M7_M\?L=_L.:?I5_^U7\?M#\
M'-KLS1Z)8WK237E^5QO,-K CS2JNY=S*A5=RY(R,T/\ @FU\ _B1^RW^P+\(
M/V=OC!K@U#Q/X.\ :;I>N3)/YJ1W$<"AH$?^-(O]4K=UC!XSBOSQ\%_M'_'G
M6O\ @NC^U;KW[/G[%S_&?XG>#['PWX7\*76O>*8-$TCP/X<33Q-<YO9HY6$M
M[?3.RP11EG$,K%D16+ 'ZA_L[?M+? /]K7X6V7QJ_9L^+&C>,_"U_(\=OK&B
M78EC$J8WQ..&BD7(W1N%=<C(&17<5\2?\$=?B5^S]\0O$?QZ_P"$3_9=U3X)
M_&*W^)$<WQ]^&5]XA.H06FLS6V8;^T="('@NHE+B:*./S2C,0P".WVW0 444
M4 %%%% !1110 4444 ?!O_!=CPU_P4Z^+GPK\'_L]_\ !/[X#:WXH\,>*-5E
M/QFU3PQ\0=)\.ZI_8T9B']EVEUJ$RF%KL/*'G2.38D6T@B1E,_\ P3L^(7[;
M_P ([SP3^R9'_P $)(O@-\(].AEMI?$=A\>O#^KQ:.BP22+*]I:C[1=R33*B
M/)DN6F,CDX8U]UT4 ?FC\%/"7_!3'_@E/9_%#]E;]G#]@EOC1X-U_P >:QXE
M^"GB[2_'6FZ;:Z,FIRF=M-U>&[ECEC2VG9V\V(.)4; VMTY/XT?L1?\ !4[]
MC'_@C_\ #/\ 8&_8!\$WOC;QUK^KW=S\<O&WA;QGIFB7EI#>7,EYJ*:?<:C+
M$$FFDN&MXKE8V:.* L45F4C]6J* /ST_X)S>*/VY?V9=.\$_LE>#O^" Y^#W
MPPAOTAUGQ3%^T1X<U5[%7QYVHW,4 ^T7\[8!<Y,C\#.  /4O^"[7[,/QR_;*
M_P""57Q3_9M_9M\#_P#"2>-?$?\ 8?\ 8NB_VG;6?VC[/KFGW4W[ZZDCB3;#
M!*_S.,[<#+$ _7-% !1110 4444 ?RJ_\%(O^3X_B/\ ]AX?^B8Z\1K])/CA
M_P $5OVV?VT/COXW^/WP5L/"\GA_4O$]Q!;-JFOBWFWPA8GRFPX&Y3CGD5S/
M_$-7_P %,?\ H$^!O_"L'_QJOW/*,]R:CE6'ISQ$5)0@FKK1J*NC\'SC(,ZK
M9MB*D,/-QE.;32>J<G9GP#17W]_Q#5_\%,?^@3X&_P#"L'_QJC_B&K_X*8_]
M GP-_P"%8/\ XU7H?ZQ9'_T$P_\  D>;_JWGW_0-/_P%GP#17W]_Q#5_\%,?
M^@3X&_\ "L'_ ,:H_P"(:O\ X*8_] GP-_X5@_\ C5'^L61_]!,/_ D'^K>?
M?] T_P#P%GP#17W]_P 0U?\ P4Q_Z!/@;_PK!_\ &J/^(:O_ (*8_P#0)\#?
M^%8/_C5'^L61_P#03#_P)!_JWGW_ $#3_P# 6? -%??W_$-7_P %,?\ H$^!
MO_"L'_QJC_B&K_X*8_\ 0)\#?^%8/_C5'^L61_\ 03#_ ,"0?ZMY]_T#3_\
M 6? -%??W_$-7_P4Q_Z!/@;_ ,*P?_&J/^(:O_@IC_T"? W_ (5@_P#C5'^L
M61_]!,/_  )!_JWGW_0-/_P%GP#17W]_Q#5_\%,?^@3X&_\ "L'_ ,:H_P"(
M:O\ X*8_] GP-_X5@_\ C5'^L61_]!,/_ D'^K>??] T_P#P%GP#17W]_P 0
MU?\ P4Q_Z!/@;_PK!_\ &J/^(:O_ (*8_P#0)\#?^%8/_C5'^L61_P#03#_P
M)!_JWGW_ $#3_P# 6? -%??W_$-7_P %,?\ H$^!O_"L'_QJC_B&K_X*8_\
M0)\#?^%8/_C5'^L61_\ 03#_ ,"0?ZMY]_T#3_\  6? -%??W_$-7_P4Q_Z!
M/@;_ ,*P?_&J/^(:O_@IC_T"? W_ (5@_P#C5'^L61_]!,/_  )!_JWGW_0-
M/_P%GP#17W]_Q#5_\%,?^@3X&_\ "L'_ ,:H_P"(:O\ X*8_] GP-_X5@_\
MC5'^L61_]!,/_ D'^K>??] T_P#P%GP#17W]_P 0U?\ P4Q_Z!/@;_PK!_\
M&J/^(:O_ (*8_P#0)\#?^%8/_C5'^L61_P#03#_P)!_JWGW_ $#3_P# 6? -
M%??W_$-7_P %,?\ H$^!O_"L'_QJC_B&K_X*8_\ 0)\#?^%8/_C5'^L61_\
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MO_"L'_QJC_B&K_X*8_\ 0)\#?^%8/_C5'^L61_\ 03#_ ,"0?ZMY]_T#3_\
M 6? -%??W_$-7_P4Q_Z!/@;_ ,*P?_&J/^(:O_@IC_T"? W_ (5@_P#C5'^L
M61_]!,/_  )!_JWGW_0-/_P%GP#17W]_Q#5_\%,?^@3X&_\ "L'_ ,:H_P"(
M:O\ X*8_] GP-_X5@_\ C5'^L61_]!,/_ D'^K>??] T_P#P%GP#17W]_P 0
MU?\ P4Q_Z!/@;_PK!_\ &J/^(:O_ (*8_P#0)\#?^%8/_C5'^L61_P#03#_P
M)!_JWGW_ $#3_P# 6? -%??W_$-7_P %,?\ H$^!O_"L'_QJC_B&K_X*8_\
M0)\#?^%8/_C5'^L61_\ 03#_ ,"0?ZMY]_T#3_\  6? -%??W_$-7_P4Q_Z!
M/@;_ ,*P?_&J/^(:O_@IC_T"? W_ (5@_P#C5'^L61_]!,/_  )!_JWGW_0-
M/_P%GP#17W]_Q#5_\%,?^@3X&_\ "L'_ ,:H_P"(:O\ X*8_] GP-_X5@_\
MC5'^L61_]!,/_ D'^K>??] T_P#P%GP#17W]_P 0U?\ P4Q_Z!/@;_PK!_\
M&J/^(:O_ (*8_P#0)\#?^%8/_C5'^L61_P#03#_P)!_JWGW_ $#3_P# 6? -
M%??W_$-7_P %,?\ H$^!O_"L'_QJC_B&K_X*8_\ 0)\#?^%8/_C5'^L61_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU
M[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH
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M7U3E]Z][].UCT\NS#Z_S>[:UNM][^2[!1117">D%%%% !1110 4444 %%%%
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M?"5XH/B=K^B^*=.TBSTV^>,3'3K0WC;M1O$B^9X8@-K%4)W,!7EGP<NOB/\
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M>PVUK;0M+<W-Q($CBC4$L[,>%4 $DG@ 5^:/[>7[+?[//[+W[<7[$NE?L_\
MP@T3PK'XB_:0UC5O$$VEV@6?5+Z;2KB22XN9FS).Y9VP79MH.T8  J3_ (+6
M_P#!0#]GH?'KPA_P2J^,G[1FG_"[P?XOT9?$?QR\7ZE>26TDWA@3-''H-DZ
ML;C4)(WCE<8\JV27[QD"T ?1?_!-7_@JK\(/^"G^K_%BX^!OA.^M_#GPU\8Q
MZ'IWB*\N05\11/"9%OHHM@,,3XR@8DLC*QVD[1]2U^47_!"G]L+]B'Q'^WK^
MU7\(O@/\7_"\D/C'XCV%]\,="T4&.._T>RT6*)GM4"A1#$(]F.,!< 5]A_\
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M>_9F^%^I:AJ5IH_GW&I:]K$@>]UG4;B9Y[J]N&'WI)9I';_9&U1PHKUVBB@
MHHHH ^7?V9?^210?]A[6?_3I=UWU<O\ L8>%F\8_!NXG6]%O]B\6:S;8,>_?
M_I\TF[J,?ZS&/;WKUG_A4LG_ $'E_P# ;_[*OI:&/PD*$(N6J2Z/MZ'Q^*RO
M'5,3.48:-M[KOZG'45V/_"I9/^@\O_@-_P#94?\ "I9/^@\O_@-_]E6W]HX+
M^?\ !_Y&']D9A_)^*_S..HKL?^%2R?\ 0>7_ ,!O_LJ/^%2R?]!Y?_ ;_P"R
MH_M'!?S_ (/_ "#^R,P_D_%?YG'45V/_  J63_H/+_X#?_94?\*ED_Z#R_\
M@-_]E1_:."_G_!_Y!_9&8?R?BO\ ,XZBNQ_X5+)_T'E_\!O_ +*C_A4LG_0>
M7_P&_P#LJ/[1P7\_X/\ R#^R,P_D_%?YG'45V/\ PJ63_H/+_P" W_V5'_"I
M9/\ H/+_ . W_P!E1_:."_G_  ?^0?V1F'\GXK_,XZBNQ_X5+)_T'E_\!O\
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M^DZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]
MCWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_R1
M/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH ****
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M -')^%__  -/^%?AM17K_P#$O/#7_076_P#)/_D3QO\ B8[B?_H#H_\ D_\
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M_AX/^Q3_ -')^%__  -/^%?AM11_Q+SPU_T%UO\ R3_Y$/\ B8[B?_H#H_\
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M;:Y[I3FHMJ\K72>A^T-%%%?R\?U6%%%% !1110 4444 %%%% !1110 4444
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M2OB7'9QPGQ586'D&&\D$?R&;$Q1F3(;8I+.VYCSO[.?_ "L1?M(_]D(\&?\
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M+2;@#]/Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX2^!M)^&7PQ\(Z?H'A[0;".RT;1=)M5@MK*WC4*D4<:@!5 '05LT44 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH @T_2],TB VVE:=!:QM(SM';PJBEB<EL #DGJ:GHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>pfe-20211231_g7.jpg
<TEXT>
begin 644 pfe-20211231_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .,^!GQFTSXY^$+KQ?I.BSV,=KK5WIS
M0W$BLS-!(4+Y7L2,BNSKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'A?_!/?_DB>K?]CWK/_I2:]TK^:W]LS]NS
M]LOX%_M7_$#X<_!S]IWQMX9T&U\1/);:1HOB":WMXGDC1W941@ 68DGU)KS3
M_AZ7_P %'?\ H]SXE_\ A6W/_P 57W6$X$QV,PE.O&K%*<5*VO57/@L9Q]@,
M'BZF'E1DW"3BWIT=NY_4[17\L7_#TO\ X*._]'N?$O\ \*VY_P#BJ/\ AZ7_
M ,%'?^CW/B7_ .%;<_\ Q5='_$/,P_Y_1^Y_Y'/_ ,1'R[_GS/\ #_,_J=HK
M^6+_ (>E_P#!1W_H]SXE_P#A6W/_ ,51_P /2_\ @H[_ -'N?$O_ ,*VY_\
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M[_GS/\/\S^IVBOY8O^'I?_!1W_H]SXE_^%;<_P#Q5'_#TO\ X*._]'N?$O\
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M'R[_ )\S_#_,_J=HK^6+_AZ7_P %'?\ H]SXE_\ A6W/_P 51_P]+_X*._\
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M/^?T?N?^0?\ $1\N_P"?,_P_S/ZG:*_EB_X>E_\ !1W_ */<^)?_ (5MS_\
M%4?\/2_^"CO_ $>Y\2__  K;G_XJC_B'F8?\_H_<_P#(/^(CY=_SYG^'^9_4
M[17\L7_#TO\ X*._]'N?$O\ \*VY_P#BJ/\ AZ7_ ,%'?^CW/B7_ .%;<_\
MQ5'_ !#S,/\ G]'[G_D'_$1\N_Y\S_#_ #/ZG:*_EB_X>E_\%'?^CW/B7_X5
MMS_\51_P]+_X*._]'N?$O_PK;G_XJC_B'F8?\_H_<_\ (/\ B(^7?\^9_A_F
M?U.T5_+%_P /2_\ @H[_ -'N?$O_ ,*VY_\ BJ/^'I?_  4=_P"CW/B7_P"%
M;<__ !5'_$/,P_Y_1^Y_Y!_Q$?+O^?,_P_S/ZG:*_EB_X>E_\%'?^CW/B7_X
M5MS_ /%4?\/2_P#@H[_T>Y\2_P#PK;G_ .*H_P"(>9A_S^C]S_R#_B(^7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^ L^ :*^_O\ B&K_ ."F/_0)\#?^%8/_ (U1_P 0U?\ P4Q_Z!/@;_PK!_\
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M^ L^ :*^_O\ B&K_ ."F/_0)\#?^%8/_ (U1_P 0U?\ P4Q_Z!/@;_PK!_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[U
MG_TI->Z5X7_P3W_Y(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH
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M_G1YD?\ ST7\Z\<HH_L9?S_A_P $/]87_P ^_P ?^ >Q^9'_ ,]%_.CS(_\
MGHOYUXY11_8R_G_#_@A_K"_^??X_\ ]C\R/_ )Z+^='F1_\ /1?SKQRBC^QE
M_/\ A_P0_P!87_S[_'_@'L?F1_\ /1?SH\R/_GHOYUXY11_8R_G_  _X(?ZP
MO_GW^/\ P#V/S(_^>B_G1YD?_/1?SKQRBC^QE_/^'_!#_6%_\^_Q_P" >QAE
M;[K _0TM<;\)/^8A_P!LO_9Z[*O)Q-'ZO7=.][?Y'N8/$?6L/&K:U[Z?.P44
M45@=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!X+^WG^WQX-_8;\->%+9_AKX@\>^.OB)XD70/AQ\._"@B%]K
MNH%#(PWS,L=O!&@WRSN=L:D$YR!7!?L_?\%//&_B/]JO1?V*OVS_ -C/Q)\#
M?'_C+1+S5?AXE_XGL-=TOQ-#:()+N&"]LFVK<PH3(T+*,(-V[YD#>[_M!ZW^
MS/\ "CPRO[4/[2R^$],L/AM;W.H6GC3Q-90,_A]98_*F>WF=2\+RJ1$1$0\N
MY4 8D*?BW]E/1?C%_P %5?V]O!7_  5-\??#[4O WP4^$6CZO9_L[Z%KUL8-
M7\57&J0"VO/$-U">;>T>W 2WB;YF&V7Y0?G .S^(G_!8+XCW_P 1/B3I/['/
M_!/3QW\;/!OP<UF?1_B1XYT#Q+INGQ1:G;*'O++3;:Y<2ZI-;J<.D>WYQL&=
MR%NW^+'_  5V_9B\"?L3^ ?VV/A_8:_X[T_XM:AI^D_"SPCX9LE;5O$6L7A=
M8M.2-V"Q2H\<RREFQ&87'S-M5O*_^#:M6?\ X)DQ7VIC_B=W7Q6\92^)&?\
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MU\!V^II,;:TO;4O;WD\*J&CE=,/"N$3(1*_3_0_!G[(W_!2KX+_"+]I_QO\
M"#3/%VBRZ?8^-/ -OXJL1,-.FN[17CF>!B8C.B2X^8-L<$J00#7">D97_!,O
M_@H-X._X*:_LS-^U)\/O 5_X=T2X\6:KI.E6FJ72R7$]O:7+11W,@55$32*
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M8+^B- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;T/C\5E>.J8F<HPT;;W7?U..HKL?^%2R?]!Y?_ ;_P"RH_X5+)_T'E_\!O\
M[*MO[1P7\_X/_(P_LC,/Y/Q7^9QU%=C_ ,*ED_Z#R_\ @-_]E1_PJ63_ *#R
M_P#@-_\ 94?VC@OY_P '_D']D9A_)^*_S..HKL?^%2R?]!Y?_ ;_ .RH_P"%
M2R?]!Y?_  &_^RH_M'!?S_@_\@_LC,/Y/Q7^9QU%=C_PJ63_ *#R_P#@-_\
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M/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_P#@GO\
M\D3U;_L>]9_]*37NE>%_\$]_^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /D7]C_]KC]FKX0?#S6O!7Q-^,^AZ)JT7C75I9+"
M^N=LBH]P2K$8Z$<UZO\ \/!_V*?^CD_"_P#X&G_"OQJ_:*_Y+MXM_P"P]<?^
MAFN+K^H>'_ KA_-\APF/J8JJI5J5.;2Y+)SBI-*\;V3>A_*G$7C[Q%DW$&,R
M^GA:3C1JU*:;Y[M0FXINTK7:6I^Y/_#P?]BG_HY/PO\ ^!I_PH_X>#_L4_\
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M[%/_ $<GX7_\#3_A7X;44?\ $O/#7_076_\ )/\ Y$/^)CN)_P#H#H_^3_\
MR1^Y/_#P?]BG_HY/PO\ ^!I_PH_X>#_L4_\ 1R?A?_P-/^%?AM11_P 2\\-?
M]!=;_P D_P#D0_XF.XG_ .@.C_Y/_P#)'[D_\/!_V*?^CD_"_P#X&G_"C_AX
M/^Q3_P!')^%__ T_X5^&U%'_ !+SPU_T%UO_ "3_ .1#_B8[B?\ Z Z/_D__
M ,D?N3_P\'_8I_Z.3\+_ /@:?\*/^'@_[%/_ $<GX7_\#3_A7X;44?\ $O/#
M7_076_\ )/\ Y$/^)CN)_P#H#H_^3_\ R1^Y/_#P?]BG_HY/PO\ ^!I_PH_X
M>#_L4_\ 1R?A?_P-/^%?AM11_P 2\\-?]!=;_P D_P#D0_XF.XG_ .@.C_Y/
M_P#)'[D_\/!_V*?^CD_"_P#X&G_"C_AX/^Q3_P!')^%__ T_X5^&U%'_ !+S
MPU_T%UO_ "3_ .1#_B8[B?\ Z Z/_D__ ,D?N3_P\'_8I_Z.3\+_ /@:?\*/
M^'@_[%/_ $<GX7_\#3_A7X;44?\ $O/#7_076_\ )/\ Y$/^)CN)_P#H#H_^
M3_\ R1^Y/_#P?]BG_HY/PO\ ^!I_PH_X>#_L4_\ 1R?A?_P-/^%?AM11_P 2
M\\-?]!=;_P D_P#D0_XF.XG_ .@.C_Y/_P#)'[D_\/!_V*?^CD_"_P#X&G_"
MC_AX/^Q3_P!')^%__ T_X5^&U%'_ !+SPU_T%UO_ "3_ .1#_B8[B?\ Z Z/
M_D__ ,D?N3_P\'_8I_Z.3\+_ /@:?\*/^'@_[%/_ $<GX7_\#3_A7X;44?\
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MVU3X<Q^(;WQ?J6G%5N[N\>6>/[+:-(P6,0CS-K'(W)EN@_X)C?\ *6'_ (*
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MI=$\4_#/QU#9VD/B&:XDL%EN="GMH&W7<B';Y5RRAI/XV=GPF?\ \%;O#O\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \ _;<_X)=?L,_\
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ML>'_ ,0 X_[4O_!G_P!J?DG17ZV?\.1_V-_^@MXU_P#!W#_\CT?\.1_V-_\
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MC_M2_P#!G_VI^2=%?K9_PY'_ &-_^@MXU_\ !W#_ /(]'_#D?]C?_H+>-?\
MP=P__(]'_$=^!.]7_P  _P#M@_X@!Q_VI?\ @S_[4_).BOUL_P"'(_[&_P#T
M%O&O_@[A_P#D>C_AR/\ L;_]!;QK_P"#N'_Y'H_XCOP)WJ_^ ?\ VP?\0 X_
M[4O_  9_]J?DG17ZV?\ #D?]C?\ Z"WC7_P=P_\ R/1_PY'_ &-_^@MXU_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>pfe-20211231_g8.jpg
<TEXT>
begin 644 pfe-20211231_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .,^!GQFTSXY^$+KQ?I.BSV,=KK5WIS
M0W$BLS-!(4+Y7L2,BNSKPO\ X)[_ /)$]6_['O6?_2DU[I0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^6+_ (>E_P#!1W_H]SXE_P#A6W/_ ,51_P /2_\ @H[_ -'N?$O_ ,*VY_\
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M[_GS/\/\S^IVBOY8O^'I?_!1W_H]SXE_^%;<_P#Q5'_#TO\ X*._]'N?$O\
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M'R[_ )\S_#_,_J=HK^6+_AZ7_P %'?\ H]SXE_\ A6W/_P 51_P]+_X*._\
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M/^?T?N?^0?\ $1\N_P"?,_P_S/ZG:*_EB_X>E_\ !1W_ */<^)?_ (5MS_\
M%4?\/2_^"CO_ $>Y\2__  K;G_XJC_B'F8?\_H_<_P#(/^(CY=_SYG^'^9_4
M[17\L7_#TO\ X*._]'N?$O\ \*VY_P#BJ/\ AZ7_ ,%'?^CW/B7_ .%;<_\
MQ5'_ !#S,/\ G]'[G_D'_$1\N_Y\S_#_ #/ZG:*_EB_X>E_\%'?^CW/B7_X5
MMS_\51_P]+_X*._]'N?$O_PK;G_XJC_B'F8?\_H_<_\ (/\ B(^7?\^9_A_F
M?U.T5_+%_P /2_\ @H[_ -'N?$O_ ,*VY_\ BJ/^'I?_  4=_P"CW/B7_P"%
M;<__ !5'_$/,P_Y_1^Y_Y!_Q$?+O^?,_P_S/ZG:*_EB_X>E_\%'?^CW/B7_X
M5MS_ /%4?\/2_P#@H[_T>Y\2_P#PK;G_ .*H_P"(>9A_S^C]S_R#_B(^7?\
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M?LP:MJFK_&GXJ:9&/LNCI<VC6\7AE+E>)YYG+&6 $B)0V?F655\R_P"#H?\
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MVT?V<_AYJ&HW.F>%OB!X8M(]2U6Z,]Y>S'0Q)/=SR/G?--,\DSGIND. !@4
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ML'_QJC_B&K_X*8_] GP-_P"%8/\ XU1_K%D?_03#_P "0?ZMY]_T#3_\!9\
MT5]_?\0U?_!3'_H$^!O_  K!_P#&J/\ B&K_ ."F/_0)\#?^%8/_ (U1_K%D
M?_03#_P)!_JWGW_0-/\ \!9\ T5]_?\ $-7_ ,%,?^@3X&_\*P?_ !JC_B&K
M_P""F/\ T"? W_A6#_XU1_K%D?\ T$P_\"0?ZMY]_P! T_\ P%GP#17W]_Q#
M5_\ !3'_ *!/@;_PK!_\:H_XAJ_^"F/_ $"? W_A6#_XU1_K%D?_ $$P_P#
MD'^K>??] T__  %GP#17W]_Q#5_\%,?^@3X&_P#"L'_QJC_B&K_X*8_] GP-
M_P"%8/\ XU1_K%D?_03#_P "0?ZMY]_T#3_\!9\ T5]_?\0U?_!3'_H$^!O_
M  K!_P#&J/\ B&K_ ."F/_0)\#?^%8/_ (U1_K%D?_03#_P)!_JWGW_0-/\
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ML'_QJC_B&K_X*8_] GP-_P"%8/\ XU1_K%D?_03#_P "0?ZMY]_T#3_\!9\
MT5]_?\0U?_!3'_H$^!O_  K!_P#&J/\ B&K_ ."F/_0)\#?^%8/_ (U1_K%D
M?_03#_P)!_JWGW_0-/\ \!9\ T5]_?\ $-7_ ,%,?^@3X&_\*P?_ !JC_B&K
M_P""F/\ T"? W_A6#_XU1_K%D?\ T$P_\"0?ZMY]_P! T_\ P%GP#17W]_Q#
M5_\ !3'_ *!/@;_PK!_\:H_XAJ_^"F/_ $"? W_A6#_XU1_K%D?_ $$P_P#
MD'^K>??] T__  %GP#17W]_Q#5_\%,?^@3X&_P#"L'_QJC_B&K_X*8_] GP-
M_P"%8/\ XU1_K%D?_03#_P "0?ZMY]_T#3_\!9\ T5]_?\0U?_!3'_H$^!O_
M  K!_P#&J/\ B&K_ ."F/_0)\#?^%8/_ (U1_K%D?_03#_P)!_JWGW_0-/\
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M[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#PO_@GO_R1/5O^Q[UG_P!*37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=*
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M,"+8J6F'F(5(RP!YH ]K^$O_  5,^)=G^TWX-_93_;H_86\3_ O7OB9%<_\
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M1_:."_G_  ?^0?V1F'\GXK_,XZBNQ_X5+)_T'E_\!O\ [*C_ (5+)_T'E_\
M ;_[*C^T<%_/^#_R#^R,P_D_%?YG'45V/_"I9/\ H/+_ . W_P!E1_PJ63_H
M/+_X#?\ V5']HX+^?\'_ )!_9&8?R?BO\SCJ*['_ (5+)_T'E_\  ;_[*C_A
M4LG_ $'E_P# ;_[*C^T<%_/^#_R#^R,P_D_%?YG'45V/_"I9/^@\O_@-_P#9
M4?\ "I9/^@\O_@-_]E1_:."_G_!_Y!_9&8?R?BO\SCJ]+^'_ /R*-I_VT_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>
ML_\ I2:]TKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!X7_P $]_\ DB>K?]CWK/\ Z4FO=*\+_P"">_\ R1/5
MO^Q[UG_TI->Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\B_L?\
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M_A1_P\'_ &*?^CD_"_\ X&G_  K\-J*/^)>>&O\ H+K?^2?_ "(?\3'<3_\
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M\3'<3_\ 0'1_\G_^2/W)_P"'@_[%/_1R?A?_ ,#3_A1_P\'_ &*?^CD_"_\
MX&G_  K\-J*/^)>>&O\ H+K?^2?_ "(?\3'<3_\ 0'1_\G_^2/W)_P"'@_[%
M/_1R?A?_ ,#3_A1_P\'_ &*?^CD_"_\ X&G_  K\-J*/^)>>&O\ H+K?^2?_
M "(?\3'<3_\ 0'1_\G_^2/W)_P"'@_[%/_1R?A?_ ,#3_A1_P\'_ &*?^CD_
M"_\ X&G_  K\-J*/^)>>&O\ H+K?^2?_ "(?\3'<3_\ 0'1_\G_^2/W)_P"'
M@_[%/_1R?A?_ ,#3_A1_P\'_ &*?^CD_"_\ X&G_  K\-J*/^)>>&O\ H+K?
M^2?_ "(?\3'<3_\ 0'1_\G_^2/W)_P"'@_[%/_1R?A?_ ,#3_A7L=?SIU_19
M7Y'XI^'F6\!?4_JE:=3VWM+\_+IR<EK62WYG?T1^Q>$WB/F?B!]<^N484_8^
MSMR<VO/[2][M[<BM;NPHHHK\C/V(**** "BBB@ HHHH **** "BBB@ HHHH
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M5O@WJ2:_XEMXK?QC+X:\::KHT'B6&)=B)J$%C<Q1W>%^7<ZEBORDD  ?4=%
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M_06\:_\ @[A_^1Z]K_B._ G>K_X!_P#;'A_\0 X_[4O_  9_]J?DG17ZV?\
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M;QK_ .#N'_Y'H_XCOP)WJ_\ @'_VP?\ $ ./^U+_ ,&?_:GY)T5^MG_#D?\
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MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** (-/TO3-(@-MI6G06L;2,[1V\*HI8G);  Y)ZFIZ** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>pfe-20211231_g9.jpg
<TEXT>
begin 644 pfe-20211231_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBOD#_@M+XH^,/A/]FCPC?^ ]:\>:
M5X*E^*VC1?&_6OABER==T[P:5G-[/;-: W,:B9;199+<&58&E*]R #Z]BEBG
MC$L,BNIZ,IR#3J_,W_@B#X1TS4/V:/$?C/\ 8;_X* P>+-.U+P))9P?##Q3K
M4^O1>"_%8N+PP7[R37+W5G;S1F$R6)C7>T;2JX)VC-\+^-?&G[+?_!13X#_L
MD^ O^"B/Q%^*WQCUO4IE_:*\(^-_$#SZ$^E'2'O)[^T@FB2'3YH[A[1K>VLR
M',4I61656- 'ZB45^-GQ'_;R\%_M"^*/CA\5OBE_P4.^.?PSO_"?Q#UKPW\/
M4^$FA:M<^%OA[8Z9<O96NJ>(Q8VDMO,;N[@EGDCO7/\ H[HJ+&A#U^N?PFO]
M9U7X5^&=4\1^,-*\0ZC<^'[*6_U_0HPECJ<S0(7NK=0S;89&)=!N;"L.3UH
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M]K_]O/P!HNN?$O\ :6F\-:%K7@73]<>'1O!]FUW#I>B637T8W.;)[XW5Q=*
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MHNOB?_PB_P#;'V:Z@A^P_;?L^[S'"YW['QC.<;>:^:_^'OO_ %;S_P"7;_\
M<E?39/P=Q'GV%>)P%#G@FXWYH+56;5I23ZKH?+YSQGPUP_BUAL?7Y)M*5N6<
MM'=)WC%KH^I]I5\>_M!?\$/OV%OVBOVC(OV@?%G@K4+)-4NKV[^(/A71O$FI
MV6F>,+F>&*-9KRVMKN.$M^Z!E/EG[2,+-O K/_X>^_\ 5O/_ )=O_P!R4?\
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MO_T"?^5*7_R8?\1/X&_Z"_\ RG5_^0.T?_@CE_P3UD^(3^/6^"M]]FD\2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "OGKXM?\ )1M5_P"O@?\ H"U]"U\]?%K_ )*-JO\
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M*** "BBB@ HHHH **** "BBB@ HHHH _+C]E+7?^"T7_  3^TSQ?^SI\'_\
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M;QC\-5U%;;Q-=VK21ZE/#]N<M):13!8$F4*))(IMNY5#'@OVH_CU^T]\!?\
M@@S)XJ\0KX;TSXI>(/!6C^$_"S^#;^YEM;>YUBXMM+L;B.2XCCD$T<5TD[?+
MA9(V"E@ 3]B_LT? #P%^RK^SYX,_9O\ AA8+;Z#X)\.6FD::JH%,B0QA#*^.
MLDC!I';JS.Q)).: .XHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYZ^+7_)1M5_Z^!_Z M?0M?/7Q:_Y*-JO_ %\#_P! 6OB>.O\
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MQAA#!(Y+,,E<#)(!^I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHKFOBUX@U?PSX+FU;0[OR+A)HU63RU; +8/# BN?%8B&$PTZ\[VBFW;?0Y<
M;BZ>!PE3$5$W&";=M[+73;\SI:*\!_X79\3O^AF_\DH?_B*/^%V?$[_H9O\
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M_':/^&8/^"BO_24;_P PEI'_ ,=H_M'&?] =3[Z/_P M#_57(O\ H?83_P
MQW_S$?2U%?-/_#,'_!17_I*-_P"82TC_ ..T?\,P?\%%?^DHW_F$M(_^.T?V
MCC/^@.I]]'_Y:'^JN1?]#["?^ 8[_P"8CZ6HKYI_X9@_X**_])1O_,):1_\
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MY3?_ +91_JGG_P#SY_\ )H?_ "0?ZD<4?] __D\/_DCRNBO5/^&9_P#J=O\
MRF__ &RC_AF?_J=O_*;_ /;*/]4\_P#^?/\ Y-#_ .2#_4CBC_H'_P#)X?\
MR1Y717JG_#,__4[?^4W_ .V4?\,S_P#4[?\ E-_^V4?ZIY__ ,^?_)H?_)!_
MJ1Q1_P! _P#Y/#_Y(\KHKU3_ (9G_P"IV_\ *;_]LH_X9G_ZG;_RF_\ VRC_
M %3S_P#Y\_\ DT/_ )(/]2.*/^@?_P GA_\ )'9?"7_DG.E?]>Y_]#:NBK.\
M):!_PBWART\/_:_/^RQE?.\O;NY)Z9..OK6C7ZW@*4Z.!I4YJSC&*?JDKG[I
MEM&IA\NHTJBM*,(IKS2284445UG:%%%% !1110 4444 %%%% !1110 4444
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MV#)__1;5^-U?OG@M_ QOK3_*9_/OC?\ Q\#Z5/S@%%%%?N!^$A1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!X'_P4K_Y-1U7_ +"=E_Z.%?FO7Z4?\%*_^34=5_["=E_Z.%?FO7],^$'_
M "2T_P#K[+_TF!_+WC)_R5D/^O4?_2IA1117ZF?E 4444 %%%% !1110 444
M4 %>^?\ !-3_ ).NTK_L&7O_ *)->!U[Y_P34_Y.NTK_ +!E[_Z)-?.<7_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 >!_\%*_^34=5_["=E_Z.%?FO7Z4?\%*_P#DU'5?^PG9?^CA
M7YKU_3/A!_R2T_\ K[+_ -)@?R]XR?\ )60_Z]1_]*F%%%%?J9^4!1110 44
M44 %%%% !1110 5[Y_P34_Y.NTK_ +!E[_Z)->!U[Y_P34_Y.NTK_L&7O_HD
MU\YQ?_R2N-_Z]3_])9])P;_R5F!_Z^P_]*1^E%%%%?QL?VH%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F>-?\ D3=6_P"P
M9/\ ^BVK\;J_9'QK_P B;JW_ &#)_P#T6U?C=7[YX+?P,;ZT_P IG\^^-_\
M'P/I4_. 4445^X'X2%%%% !1110 4444 %%%% !6GX*_Y'+2?^PG!_Z,6LRM
M/P5_R.6D_P#83@_]&+65?^!+T?Y&V'_WB'JOS/V1HHHK^&#^\@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXW_KU/\ ])9])P;_ ,E9@?\ K[#_ -*1^E%%%%?QL?VH%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45XEJG[!'P:U?4[G5KGQ5XW62ZG>:18O%
M]RJAF8L0 #P,G@=J@_X=[_!/_H;?'?\ X65S_C0![I17A?\ P[W^"?\ T-OC
MO_PLKG_&C_AWO\$_^AM\=_\ A97/^- 'NE%>%_\ #O?X)_\ 0V^._P#PLKG_
M !H_X=[_  3_ .AM\=_^%E<_XT >P^-?^1-U;_L&3_\ HMJ_&ZOTP_X=[_!/
M_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&OON"N./]3Z=>/U?VOM'%_'RV
MY;_W97O?R/S[C?@3_7*I0E]8]E[)27P<U^:W]Z-K6\S\SZ*_3#_AWO\ !/\
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M 'NE%>%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C0![I17A?\
MP[W^"?\ T-OCO_PLKG_&C_AWO\$_^AM\=_\ A97/^- 'NE%>%_\ #O?X)_\
M0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XT >Z45X7_P[W^"?_0V^._\
MPLKG_&C_ (=[_!/_ *&WQW_X65S_ (T >Z45X7_P[W^"?_0V^.__  LKG_&C
M_AWO\$_^AM\=_P#A97/^- 'NE%>%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z
M&WQW_P"%E<_XT >Z45\;_L@_LA_#CXK?#'4/$?BGQ5XP%Q!XJU*RC%GXIN(D
M\J&<HF0#RV.I[UZI_P .]_@G_P!#;X[_ /"RN?\ &@#W2BO"_P#AWO\ !/\
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M2BO"_P#AWO\ !/\ Z&WQW_X65S_C1_P[W^"?_0V^._\ PLKG_&@#W2BO"_\
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MY_QKZK_B-?\ U ?^5?\ [F?)_P#$#_\ J8?^4O\ [H?F?17Z8?\ #O?X)_\
M0V^._P#PLKG_ !H_X=[_  3_ .AM\=_^%E<_XT?\1K_Z@/\ RK_]S#_B!_\
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M+_Y"4?@OQA9:HUJ,X!D%M*Y0$]"< Y&,T >BT444 %%%% 'GW[-?P9U/X&>
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M1(#(-[(I 9@O4@%E!/0%AZT 2T44RYN;:RMI+R\N$AAA0O++*X544#)8D\
M<YH ?17&_!3]HGX _M)^';WQ?^SO\;O"7CS2=.U-].O]3\'>(K;4[>WNT5':
M!Y+=W59 LD;%2<[74XP0:[*@ HHHH **** "BBO/_C#^UC^RS^SSJMGH7Q^_
M:6^'_@:^U"W,]A9^,/&5CIDMS$&VF2-+F5"ZAN-P!&>* /0**X;X-_M0?LT_
MM%RZA#^SY^T/X%\=OI"Q-JJ>#?%MGJALA+O\LRBVE?RP_EOMW8W;&QG!KN:
M"BBB@ HK)\#>/? OQ/\ "MIXZ^&OC32?$.B7X<V.LZ'J,5W:W(5V1C'+$S(^
M'5E."<%2.H-:U !117-_%3XR?"'X%>%#X[^-WQ5\-^#=#6X2W;6?%6N6^G6@
ME?.R/SKAT3<V#A<Y.#B@#"\.?!G4]$_:2\2?'&76H'M-<\/6>G16*QL)(FA8
MDN3T(.:]!KR'P?\ \%!/V"OB%XIL/ _@']MWX0ZYK>JW26VEZ/H_Q*TNYNKR
M=SA8HHHYR\CD\!5!)/05Z]0 445D_P#">^!3XZ/PO'C32?\ A)AI/]J'P[_:
M,7VX6/F^3]J^S[O,\GS 8_,V[=WRYSQ0!K4444 %%%% !1110 4444 %%%%
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M,M2N+WX>?$;1+&*\?3_M,8BN[2YM)L1WEG<1J@E@8J6\M"'7!SYIHW_!./\
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M?&V@^ +OP9>V/CKP _B'39]-GNUNO/@CBOK.6UNED!!=9")$(1@ #D _/O\
M:F_;._:1_;F_X)%?&>ROOCIX7OKKX6?M(^$_#4WC;2/AW=6$7C'2Y-8T&:RN
M?L-U<+)82K/>122 %TD2V** LWFCZ+^/?[?WQ$_87^,O[17B7Q_X+\'^-=?^
M%_[/'@:_CU[2O"L>D7WB;6]0U&_L(HKB822O'9FZ,3)"7<0"67:S$Y/3W?\
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MOAOPM'H-[9O)-:+I+WK"YDO'F9KEY?MG(9%(,98NY?@ ^ _VU/\ @KU^TO\
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M_!S7?#FI>!K7PG\%5L)=2;1[N&:#^URVIR"YS'&ZD6PMLS,L[F3:8V /1?\
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MNS4&B=HW8+A6 )!+?8'CS]BC_A-OVB/V>_CW_P +,^S?\*'LM<M_[)_L;?\
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M[7^U?#X2ZL]1TR[L#>,EO=AU$<=S%(5"3K(8BR%#]A?MM?L7:O\ M0:C\/\
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M (CN];UWQ+K:&WMXI9RH%II]EYDBZ?91*BK';J[ $NQ8ES0!ZO1110 4444
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M]U?X4^%+&2S3X<^%?V>(M \R#R)$B6.[75IS"5F9)F8QNTA5@QRY< 'PI?\
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MI:1Q*"Q6*64XR@(!^C%]?66F64VI:E>16]M;Q-+<7$\@1(D499F8\*  22>
M!5/PCXO\)_$#POI_C?P'XHT[6]%U:T2ZTO5](O8[FUO('&Y)8I8R4D1@00RD
M@@Y!KY%N?#O_  5>\ Z9/+^T1\4OAC\1/!?B3X?:Z?'<'AOPE+H5QX-U!=/D
MEM_L+R7<YU*U>3=;L)524827.-R5U_\ P1:_Y1)_LX_]D<T'_P!(HZ /H;QE
MX]\"_#K2X=<^(/C32="LKB_M[&"\UG48K6*2ZGD6*"!7E909))&5$0'<S,%
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M3!EMPDPGZ;4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KXFU#_E8XTC_ +,EU'_U+[&OMFODK]JG_@GS^TQ\
M3_VX-'_;G_96_;4T?X7^(-/^%,O@2]L-;^%"^)(KNSDU-=0:4%M1M1&WF1Q+
MC:W"'GYL  YK_@N#?ZOXH^&'P/\ V7I]:O-.\*?&_P#:-\-^"?B)/8W;V\EU
MH4T=W=7%@)4(:/[4;2. E2,I(Z\[L'3_ ."DO_!//]C;4O\ @G?X_P!.\,?
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MP+\7]3N(O@/-XOO-4;6M-6XO/%^H^(8&6\O9[A9$%N_VAY)L".0$,(QM"AJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'O#NF?#A=)U7Q!=Z:0VFG6;[[;,ERD#JCLD,$ G=%9_2NQ^+'_!+?P-\5?\
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MJ5"G !^@=17M[9Z;:27^HW<5O!"A>:::0(B*.I)/ 'N:_-?X)?\ !6+]K/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM0N4AM[2WC0O)-+(Y"QHJJ69F(  )) %?G=^R5^WA^W)^UW\*OVD?A7^SO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@_I/PY\73>*? 3:OHOBW3-.4?99Y;..]MY;6YBD:9TD2X;Y93&P8#-;WP_\
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M+_#N5Y['0/ _@:3PU<>*[CR&ABEUVX2_G%VB!V<VT4<,,DH5W4[0E 'RK?\
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611154904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Jul. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">235 East 42nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623,346,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.75pt"><tr><td style="width:1.0pt"/><td style="width:397.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.75pt"/><td style="width:1.0pt"/></tr><tr style="height:9pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">DOCUMENTS INCORPORATED BY REFERENCE</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Portions of the Proxy Statement for the 2022 Annual Meeting of Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Part III</span></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member', window );">Notes Due 2022, 0.250% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">Notes Due 2027, 1.000% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615597160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">New York, NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611263112">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 81,288<span></span>
</td>
<td class="nump">$ 41,651<span></span>
</td>
<td class="nump">$ 40,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">30,821<span></span>
</td>
<td class="nump">8,484<span></span>
</td>
<td class="nump">8,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">12,703<span></span>
</td>
<td class="nump">11,597<span></span>
</td>
<td class="nump">12,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">13,829<span></span>
</td>
<td class="nump">9,393<span></span>
</td>
<td class="nump">8,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">(Gain) on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8,107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,878)<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4],[5]</sup></td>
<td class="nump">24,311<span></span>
</td>
<td class="nump">7,036<span></span>
</td>
<td class="nump">11,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,459<span></span>
</td>
<td class="nump">6,666<span></span>
</td>
<td class="nump">10,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,025<span></span>
</td>
<td class="nump">9,195<span></span>
</td>
<td class="nump">16,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,979<span></span>
</td>
<td class="nump">$ 9,159<span></span>
</td>
<td class="nump">$ 16,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.92<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">2.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.93<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
<td class="nump">1.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.45<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares&#8211;&#8211;basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,601<span></span>
</td>
<td class="nump">5,555<span></span>
</td>
<td class="nump">5,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares&#8211;&#8211;diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,708<span></span>
</td>
<td class="nump">5,632<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1M.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609471992">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,025<span></span>
</td>
<td class="nump">$ 9,195<span></span>
</td>
<td class="nump">$ 16,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(682)<span></span>
</td>
<td class="nump">772<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax', window );">Reclassification adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(682)<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">526<span></span>
</td>
<td class="num">(582)<span></span>
</td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">134<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">660<span></span>
</td>
<td class="num">(561)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(355)<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(384)<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Benefit plans: prior service (costs)/credits and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">116<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax', window );">Reclassification adjustments related to curtailments of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(74)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income/(loss), before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(519)<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(589)<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income/(loss) before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,435<span></span>
</td>
<td class="nump">9,666<span></span>
</td>
<td class="nump">15,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income/(loss) attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income/(loss) attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,393<span></span>
</td>
<td class="nump">$ 9,639<span></span>
</td>
<td class="nump">$ 15,908<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116633155&amp;loc=d3e31531-110899<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e709-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633607149960">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 1,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,125<span></span>
</td>
<td class="nump">10,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts: 2021&#8212;$492; 2020&#8212;$508</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,479<span></span>
</td>
<td class="nump">7,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,059<span></span>
</td>
<td class="nump">8,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherTaxAssetsCurrent', window );">Current tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,266<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,820<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,693<span></span>
</td>
<td class="nump">35,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,472<span></span>
</td>
<td class="nump">16,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,054<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,882<span></span>
</td>
<td class="nump">13,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">25,146<span></span>
</td>
<td class="nump">28,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">49,208<span></span>
</td>
<td class="nump">49,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,341<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">181,476<span></span>
</td>
<td class="nump">154,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings, including current portion of long-term debt: 2021&#8212;$1,636; 2020&#8212;$2,002</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,578<span></span>
</td>
<td class="nump">4,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">2,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,332<span></span>
</td>
<td class="nump">3,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,067<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,939<span></span>
</td>
<td class="nump">11,561<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,671<span></span>
</td>
<td class="nump">25,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,195<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent', window );">Postretirement benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">235<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Noncurrent deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">349<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Other taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,331<span></span>
</td>
<td class="nump">11,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,743<span></span>
</td>
<td class="nump">6,669<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">104,013<span></span>
</td>
<td class="nump">90,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021&#8212;9,471; 2020&#8212;9,407</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">473<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,591<span></span>
</td>
<td class="nump">88,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, shares at cost: 2021&#8212;3,851; 2020&#8212;3,840</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(111,361)<span></span>
</td>
<td class="num">(110,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">103,394<span></span>
</td>
<td class="nump">90,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,897)<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Pfizer Inc. shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,201<span></span>
</td>
<td class="nump">63,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">262<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,462<span></span>
</td>
<td class="nump">63,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 181,476<span></span>
</td>
<td class="nump">$ 154,229<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Tax Assets, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611087448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 492<span></span>
</td>
<td class="nump">$ 508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">$ 2,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">12,000,000,000<span></span>
</td>
<td class="nump">12,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">9,471,000,000<span></span>
</td>
<td class="nump">9,407,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">3,851,000,000<span></span>
</td>
<td class="nump">3,840,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633604317288">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Shareholders&#8217; Equity [Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Add&#8217;l Paid-In Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Accum. Other Comp. Loss [Member]</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Non-controlling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,000,000<span></span>
</td>
<td class="nump">9,332,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,615,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 63,758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 63,407<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 86,253<span></span>
</td>
<td class="num">$ (101,610)<span></span>
</td>
<td class="nump">$ 83,527<span></span>
</td>
<td class="num">$ (5,249)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,056<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(130)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,174)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 894<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(213,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (8,865)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(8,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(81)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,000,000<span></span>
</td>
<td class="nump">9,369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63,447<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,143<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">87,428<span></span>
</td>
<td class="num">$ (110,801)<span></span>
</td>
<td class="nump">91,397<span></span>
</td>
<td class="num">(5,367)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,571)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(91)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,261<span></span>
</td>
<td class="num">$ (218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(431,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="num">$ (17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Distribution of Upjohn business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(2,018)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,592)<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,407,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">63,473<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,238<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="nump">88,674<span></span>
</td>
<td class="num">$ (110,988)<span></span>
</td>
<td class="nump">90,392<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,025<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other&#160;comprehensive income/(loss), net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(589)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(587)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,816)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="num">$ (373)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(92)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,471,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,851,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 77,462<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 77,201<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 90,591<span></span>
</td>
<td class="num">$ (111,361)<span></span>
</td>
<td class="nump">$ 103,394<span></span>
</td>
<td class="num">$ (5,897)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 262<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and the impact of our net investment hedging program.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Represents shares purchased pursuant to the ASR with Goldman Sachs &amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615595448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610647528">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,025<span></span>
</td>
<td class="nump">$ 9,195<span></span>
</td>
<td class="nump">$ 16,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income from continuing operations before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,459<span></span>
</td>
<td class="nump">6,666<span></span>
</td>
<td class="nump">10,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,191<span></span>
</td>
<td class="nump">4,681<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetWriteOffsAndAssetImpairmentCharges', window );">Asset write-offs and impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">276<span></span>
</td>
<td class="nump">2,049<span></span>
</td>
<td class="nump">2,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">TCJA impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,293)<span></span>
</td>
<td class="num">(1,575)<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,182<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,123)<span></span>
</td>
<td class="num">(1,242)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(479)<span></span>
</td>
<td class="num">(1,080)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Other changes in assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,811)<span></span>
</td>
<td class="num">(1,275)<span></span>
</td>
<td class="num">(1,124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,125)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
<td class="num">(1,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,057)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="num">(341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,721<span></span>
</td>
<td class="nump">2,768<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Other tax accounts, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,166)<span></span>
</td>
<td class="num">(1,240)<span></span>
</td>
<td class="num">(3,074)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,922<span></span>
</td>
<td class="nump">10,540<span></span>
</td>
<td class="nump">7,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) operating activities from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(343)<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
<td class="nump">5,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,580<span></span>
</td>
<td class="nump">14,403<span></span>
</td>
<td class="nump">12,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,711)<span></span>
</td>
<td class="num">(2,226)<span></span>
</td>
<td class="num">(2,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38,457)<span></span>
</td>
<td class="num">(13,805)<span></span>
</td>
<td class="num">(6,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from redemptions/sales of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,447<span></span>
</td>
<td class="nump">11,087<span></span>
</td>
<td class="nump">9,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess', window );">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,088)<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,068)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments', window );">Proceeds from redemptions/sales of long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">649<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by/(used in) investing activities from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22,534)<span></span>
</td>
<td class="num">(4,162)<span></span>
</td>
<td class="num">(3,825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) investing activities from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22,546)<span></span>
</td>
<td class="num">(4,271)<span></span>
</td>
<td class="num">(3,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,352<span></span>
</td>
<td class="nump">16,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Principal payments on short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,197)<span></span>
</td>
<td class="num">(8,378)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(4,129)<span></span>
</td>
<td class="nump">2,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">997<span></span>
</td>
<td class="nump">5,222<span></span>
</td>
<td class="nump">4,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,004)<span></span>
</td>
<td class="num">(4,003)<span></span>
</td>
<td class="num">(6,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Cash dividends paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,729)<span></span>
</td>
<td class="num">(8,440)<span></span>
</td>
<td class="num">(8,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="num">(444)<span></span>
</td>
<td class="num">(342)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by/(used in) financing activities from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,816)<span></span>
</td>
<td class="num">(21,640)<span></span>
</td>
<td class="num">(8,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash provided by/(used in) financing activities from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by/(used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,816)<span></span>
</td>
<td class="num">(9,649)<span></span>
</td>
<td class="num">(8,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">159<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid/(received) during the period for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,427<span></span>
</td>
<td class="nump">3,153<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InterestReceivedInterestRateHedges', window );">Interest rate hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,943<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">Consumer Healthcare JV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash transactions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment', window );">Equity investment in exchange for Pfizer's assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,711<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The $8.3 billion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> reflects the receipt of a 32% equity-method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other investing activities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetWriteOffsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Write-Offs And Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetWriteOffsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InterestReceivedInterestRateHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Received, Interest Rate Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InterestReceivedInterestRateHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611120616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="nump">$ 8,254<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investments</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationNetAssetsContributed', window );">Deconsolidation net assets contributed</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountCashConveyed', window );">Deconsolidation, cash conveyed</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The $8.3 billion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> reflects the receipt of a 32% equity-method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other investing activities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationNetAssetsContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Net Assets Contributed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationNetAssetsContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125513658&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609320440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP. The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our subsidiaries have been eliminated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">. On December 31, 2021, we completed the sale of our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products. Prior to its sale, Meridian was managed within the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. On December 21, 2020, Pfizer and Viatris completed the termination of a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (the Mylan-Japan collaboration) pursuant to an agreement dated November 13, 2020, and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and the Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. The assets and liabilities associated with Meridian and the Mylan-Japan collaboration are classified as assets and liabilities of discontinued operations as of December 31, 2020. Upon completion of the spin-off of the Upjohn Business on November&#160;16, 2020, the Upjohn assets and liabilities were derecognized from our consolidated balance sheet and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Retained Earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Distribution of Upjohn Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> in the consolidated statement of equity. Prior to the spin-off of the Upjohn Business in November 2020, the Upjohn Business, the Mylan-Japan collaboration and Meridian were managed as part of our former Upjohn operating segment. With the separation of the Upjohn Business, the Mylan-Japan collaboration and Meridian, as well as the formation of the Consumer Healthcare JV in 2019, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines. Certain prior year amounts have been reclassified to conform with the current year presentation. In addition, other acquisitions and business development activities completed in 2021, 2020 and 2019 impacted financial results in the periods presented. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Note 2.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">. </span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New Accounting Standard Adopted in 2021</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.</span></div><div style="margin-top:8pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Change in Accounting Principle</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (MTM Accounting).</span><span style="color:#000000;font-family:'Georgia',serif;font-size:8pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Under the prior policy, we deferred recognition of these gains and losses in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. The accumulated actuarial gains/losses outside of a &#8220;corridor&#8221; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> of $6.0 billion, with a corresponding offset to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.603%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The impacts of the adjustments on our consolidated financial statements are summarized as follows:</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(Gain) on completion of Consumer Healthcare JV transaction</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(8,086)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(8,107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,058</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,420</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,025</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,374</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,026&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.88&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.93</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.85</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="57" style="border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Comprehensive Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Benefit plans: actuarial gains/(losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(826)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(276)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to settlements, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(278)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">545</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(349)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(227)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,575)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,058)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,790)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,242)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(288)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,320</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,679</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,679</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,489</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,489</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103,394</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,313)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,583)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,688)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Estimates and Assumptions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of income. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Acquisitions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Fair Value</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities&#8212;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities with readily determinable fair values&#8212;quoted market prices and observable NAV prices.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Derivative assets and liabilities&#8212;third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Money market funds&#8212;observable NAV prices.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">G. Foreign Currency Translation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and we translate non-monetary items at historical rates.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">H. Revenues and Trade Accounts Receivable</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our Sales Contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to LOE, product recalls or a changing competitive environment.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provisions for pharmaceutical sales returns&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as LOE, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines our common sales arrangements:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#008080;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies, and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period&#8217;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#8220;coverage gap,&#8221; also known as the &#8220;doughnut hole,&#8221; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#8217;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49%</span><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of our revenues in 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17B </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:70.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.185%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,077</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">528</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,850</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,708&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During 2021 and 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">I. Collaborative Arrangements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received for our share of gross profits from our collaboration partners as alliance revenues, a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Royalty payments received from collaboration partners are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reimbursements to or from our collaboration partners for development costs are typically recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets&#8212;Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> over the development period for the products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">J. Cost of Sales and Inventories</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">K. Selling, Informational and Administrative Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.</span></div><div style="margin-top:7pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">L. Research and Development Expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">M. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Long-lived assets include:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, less accumulated depreciation&#8212;These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;These assets are recorded at fair value at acquisition. Intangible assets with finite lives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as these intangible assets benefit multiple business functions. Amortization of intangible assets that are for a single function and depreciation of property, plant and equipment are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as appropriate.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For indefinite-lived intangible assets, such as brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business and platform functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as our corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement).</span></div><div><span><br/></span></div><div style="margin-bottom:7pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">O. Cash Equivalents and Statement of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">P. Investments and Derivative Financial Instruments</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">until realized.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Held-to-maturity debt securities, which are carried at amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#8217;s income and expenses in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative financial instruments are carried at fair value in various balance sheet categories (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> or, for derivative financial instruments in certain qualifying hedging relationships, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Q. Tax Assets and Liabilities and Income Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Assets and Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Current tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Global Intangible Low-Taxed Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as of December 31, 2021 and 2020 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for uncertain tax positions and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Income Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#8220;more likely than not&#8221;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R. Pension and Postretirement Benefit Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">S. Legal and Environmental Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">T. Share-Based Payments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms with the related costs recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633608610136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract', window );"><strong>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock', window );">Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements</a></td>
<td class="text">Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements<div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Acquisitions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Trillium</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno-oncology company developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $18.50 per share in cash, for total consideration of $2.0 billion, net of cash acquired. As a result, Trillium became our wholly owned subsidiary. We previously held a 2% ownership investment in Trillium. Trillium&#8217;s lead program, TTI-622, is an investigational fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">We accounted for the transaction as an asset acquisition since the lead asset, TTI-622, represented substantially all of the fair value of the gross assets acquired, which exclude cash acquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&amp;D asset with no alternative future use in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $81 million.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Array</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On July&#160;30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). We financed the majority of the transaction with debt and the balance with existing cash. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Array&#8217;s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib), a broad pipeline of targeted cancer medicines in different stages of R&amp;D, as well as a portfolio of out-licensed medicines, which may generate milestones and royalties over time.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, consisting of $2.0 billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> with a useful life of 16 years</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $2.8 billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and $1.5 billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Licensing agreements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($1.2 billion for technology in development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">indefinite-lived licensing agreements and $360 million for developed technology</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">finite-lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long-term debt, which was paid in full in 2019.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">In 2020, we recorded measurement period adjustments to the estimated fair values initially recorded in 2019, which resulted in a reduction in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> of approximately $900 million with a corresponding change to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and net deferred tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date and did not have a material impact on our consolidated statement of income for the year ended December 31, 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Therachon</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was $322 million, which consisted of $317 million of cash and our previous $5 million investment in Therachon. In connection with this asset acquisition, we recorded a charge of $337 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Divestitures</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline">Meridian</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On December 31, 2021, we completed the sale of our Meridian subsidiary for approximately $51 million in cash and recognized a loss of approximately $167&#160;million, net of tax, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">. In connection with the sale, Pfizer and the purchaser of Meridian entered into various agreements to provide a framework for our relationship after the sale, including interim TSAs and a manufacturing supply agreement (MSA). The TSAs primarily involve Pfizer providing services related to information technology, among other activities, and are generally expected to be for terms of no more than 12 to 18 months post sale. The MSA is for a term of three years post sale with a two year extension period. No amounts were recorded under the above arrangements in 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Upjohn Separation and Combination with Mylan</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan (the Transactions) to form Viatris. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">The Transactions were structured as an all-stock, Reverse Morris Trust transaction. Specifically, (i) we contributed the Upjohn Business to a wholly owned subsidiary, which was renamed Viatris, so that the Upjohn Business was separated from the remainder of our business (the Separation), (ii) following the Separation, we distributed, on a pro rata basis, all of the shares of Viatris common stock held by Pfizer to Pfizer stockholders as of the November&#160;13, 2020 record date, such that each Pfizer stockholder as of the record date received approximately 0.124079 shares of Viatris common stock per share of Pfizer common stock (the Distribution); and (iii) immediately after the Distribution, the Upjohn Business combined with Mylan in a series of transactions in which Mylan shareholders received one share of Viatris common stock for each Mylan ordinary share held by such shareholder, subject to any applicable withholding taxes (the Combination). Prior to the Distribution, Viatris made a cash payment to Pfizer equal to $12.0 billion as partial consideration for the contribution of the Upjohn Business to Viatris. As of the closing of the Combination, Pfizer stockholders owned approximately 57% of the outstanding shares of Viatris common stock, and Mylan shareholders owned approximately 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis. The Transactions are generally expected to be tax free to Pfizer and Pfizer stockholders for U.S. tax purposes. Beginning November&#160;16, 2020, Viatris operates both the Upjohn Business and Mylan as an independent publicly traded company, which is traded under the symbol &#8220;VTRS&#8221; on the NASDAQ.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with the Transactions, in June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings of $7.45 billion and &#8364;3.60 billion aggregate principal amounts, respectively, (approximately $11.4 billion) of senior unsecured notes and entered into other financing arrangements, including a $600 million delayed draw term loan agreement and a revolving credit facility agreement for up to $4.0 billion. Proceeds from the debt offerings and other financing arrangements were used to fund the $12.0 billion cash distribution Viatris made to Pfizer prior to the Distribution. We used the cash distribution proceeds to pay down commercial paper borrowings and redeem the $1.15 billion aggregate principal amount outstanding of our 1.95% senior unsecured notes that were due in June 2021 and $342 million aggregate principal amount outstanding of our 5.80% senior unsecured notes that were due in August 2023, before the maturity date. Interest expense for the $11.4 billion in debt securities incurred during 2020 is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Following the Separation and Combination of the Upjohn Business with Mylan, we are no longer the obligor or guarantor of any Upjohn debt or Upjohn financing arrangements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As a result of the spin-off of the Upjohn Business, we distributed net assets of $1.6 billion as of November&#160;16, 2020, which was reflected as a reduction to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Retained earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> and reflects the change in accounting principle in the first quarter of 2021 to MTM Accounting. See</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> Note 1C.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Of this amount, $412 million represents cash transferred to the Upjohn Business, with the remainder considered a non-cash activity in the consolidated statement of cash flows for the year ended December 31, 2020. The spin-off also resulted in a net increase to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> of $423 million for the derecognition of net gains on foreign currency translation adjustments of $397 million and prior service net credits associated with benefit plans of $26 million, which were reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Retained earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:115%">. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As a result of the separation of Upjohn, we incurred separation-related costs of $434 million in 2020 and $83 million in 2019, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. These costs primarily relate to professional fees for regulatory filings and separation activities within finance, tax, legal and information system functions as well as investment banking fees.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">In connection with the Transactions, Pfizer and Viatris entered into various agreements to effect the Separation and Combination to provide a framework for our relationship after the Combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. The terms of the MSAs range in initial duration from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcwNjc_b11edfc2-cb4f-4099-b138-98c6766b88f5">four</span> to seven years post-Separation. The TSAs primarily involve Pfizer providing services to Viatris related to finance, information technology and human resource infrastructure and are generally expected to be for terms of no more than three years post-Separation. The amounts recorded under the above agreements were not material to our consolidated results of operations in 2021 and 2020. In addition, Pfizer and Mylan had a pre-existing arms-length commercial agreement, which is continuing with Viatris and is not material to Pfizer&#8217;s consolidated financial statements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net amounts due from Viatris under the above agreements were $53 million as of December 31, 2021 and $401 million as of December 31, 2020. The cash flows associated with the above agreements are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Net cash provided by operating activities from continuing operations, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">except for</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">a $277 million payment to Viatris made in 2021 pursuant to terms of the separation agreement, which is reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Other financing activities, net, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">and was recorded as a payable to Viatris in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> as of December 31, 2020. </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:68.050%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.439%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> Discontinued operations&#8211;&#8211;net of tax: </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,572&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,845&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax income/(loss) from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(375)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,056&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(268)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax loss on sale of discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(211)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit for taxes on income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations&#8212;net of tax, which includes a pre-tax amount for a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345&#160;million; and (ii) the after tax loss of $167&#160;million related to the sale of Meridian recognized in Loss on sale of discontinued operations&#8211;&#8211;net of tax. To a much lesser extent, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-closing adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations&#8212;net of tax. In 2020 and 2019, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">includes pre-tax interest expense of $116 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $223 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of assets and liabilities of discontinued operations and other assets held for sale:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" rowspan="22" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets of discontinued operations and other assets held for sale&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts as of December 31, 2021 represent property, plant and equipment held for sale. Amounts as of December 31, 2020 primarily relate to discontinued operations of our former Meridian subsidiary and the Mylan-Japan collaboration.  </span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Equity-Method Investments</span></div><div style="margin-top:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Formation of Consumer Healthcare JV</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a 32% equity stake in the new company and GSK owns the remaining 68%. Upon closing, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of $8.1 billion ($5.4 billion, net of tax) in the third quarter of 2019 in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the difference in the fair value of our 32% equity stake and the carrying value of our Consumer Healthcare business. Our financial results and our Consumer Healthcare segment&#8217;s operating results for</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The financial results for 2021 and 2020 do not reflect any contribution from the Consumer Healthcare business.</span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In valuing our investment in the Consumer Healthcare JV, we used discounted cash flow techniques. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long term; the discount rate, which seeks to reflect our best estimate of the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. </span></div><div style="margin-top:8pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our investment in the Consumer Healthcare JV is $16.3 billion as of December 31, 2021 and $16.7 billion as of December 31, 2020 and is reported as a private equity investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Equity-method investments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as of December 31, 2021 and 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 to December 31, 2021 is primarily due to dividends totaling $499 million, as well as $384 million in pre-tax foreign currency translation adjustments (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), partially offset by our share of the JV&#8217;s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> commencing from August 1, 2019. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2020 and the first nine months of 2021, which we recorded in our operating results in 2021, was $495 million. Our total share of the JV&#8217;s earnings generated in the fourth quarter of 2019 and the first nine months of 2020, which we recorded in our operating results in 2020, was $417 million. Our total share of two months of the JV&#8217;s earnings generated in the third quarter of 2019, which we recorded in our operating results in the fourth quarter of 2019, was $47 million. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in the Consumer Healthcare JV was $15.7 billion and that 32% of the underlying equity in the carrying value of the net assets of the Consumer Healthcare JV was $11.2 billion, resulting in an initial basis difference of approximately $4.5 billion. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. During the fourth quarter of 2019, the Consumer Healthcare JV revised the initial carrying value of the net assets of the JV and our 32% share of the underlying equity in the carrying value of the net assets of the Consumer Healthcare JV was reduced to $11.0 billion and our initial basis difference was increased to $4.8 billion. The adjustment was allocated to equity method goodwill within the investment account. We began recording the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> commencing August 1, 2019. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and was not material to our results of operations in the periods presented. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of basis differences on inventory and related deferred tax liabilities was completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from 8 to 20 years.</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As a part of Pfizer in 2019, pre-tax income on a management basis for the Consumer Healthcare business was $654 million through July&#160;31, 2019.</span></div><div style="margin-bottom:3pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.776%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, as of September 30, 2021, the most recent period available, and as of September 30, 2020 and for the periods ending September 30, 2021, 2020, and 2019 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,890</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,445</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,975&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,351</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,576&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,705</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net equity</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,400&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Twelve Months Ending</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Two Months Ending</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,836</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,720&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,439)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(803)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,081</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,281&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,547</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Investment in ViiV</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately 11.7% of ViiV, and prior to 2016 we accounted for our investment under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to zero due to the recognition of cumulative equity method losses and dividends. Since 2016, we have recognized dividends from ViiV as income in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when earned, including dividends of $166 million in 2021, $278 million in 2020 and $220 million in 2019 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, ViiV, as of December 31, 2021 and 2020 and for the years ending December 31, 2021, 2020, and 2019 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,608</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,171</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,664&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,536</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,033</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,398&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net equity/(deficit) attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,862)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,734)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:68.050%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,380</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,224&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,139&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(574)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,623&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">      </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-right:9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Licensing Arrangements</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Agreement with Valneva</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">On April&#160;30, 2020, we signed an agreement to co-develop and commercialize Valneva&#8217;s Lyme disease vaccine candidate, VLA15, which covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of up to $308 million in cash payments from us consisting of a $130 million upfront payment, which was paid and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our second quarter of 2020, as well as $35 million in development milestones and $143 million in early commercialization milestones. Under the terms of the agreement, Valneva will fund 30% of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement with Akcea</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On October&#160;4, 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a wholly-owned subsidiary of Ionis. The transaction closed in November 2019 and we made an upfront payment of $250 million to Akcea, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our fourth quarter of 2019. On January 31, 2022, we and Ionis announced the discontinuation of the Pfizer-led clinical development program for the licensed product and that we would be returning the rights to the licensed product to Ionis.</span></div><div style="margin-bottom:8pt;padding-right:9pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Collaborative Arrangements</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration with Beam</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December&#160;24, 2021, we entered into a multi-year research collaboration with Beam to utilize Beam&#8217;s in vivo base editing programs, which use mRNA and lipid nanoparticles, for three targets for rare genetic diseases of the liver, muscle and central nervous system. Under the terms of the agreement, Beam conducts all research activities through development candidate selection for three undisclosed targets, which are not included in Beam&#8217;s existing programs, and we may opt in to obtain exclusive licenses to each development candidate. Beam has a right to opt in, at the end of phase 1/2 studies, upon the payment by Beam of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which we and Beam would share net profits as well as development and commercialization costs in a 65%/35% ratio (Pfizer/Beam). Upon entering into the agreement, we recorded $300 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in the fourth quarter of 2021 for an upfront payment due to Beam, and if we exercise our opt in to licenses for all three targets, Beam would be eligible for up to an additional $1.05 billion in development, regulatory and commercial milestone payments for a potential total deal consideration of up to $1.35 billion. Beam is also eligible to receive royalties on global net sales for each licensed program.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration with Arvinas</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">On July&#160;21, 2021, we entered into a global collaboration with Arvinas to develop and commercialize ARV-471, an investigational oral PROTAC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. In connection with the agreement, we made an upfront cash payment of $650 million to Arvinas and we made a $350 million equity investment in the common stock of Arvinas. We recognized $706 million for the upfront payment and a premium paid on our equity investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">in our third quarter of 2021. Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones. The companies will equally share worldwide development costs, commercialization expenses and profits. As of December 31, 2021, we held a 6.5% equity stake of Arvinas.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Collaboration with Myovant</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On December&#160;26, 2020, we entered into a collaboration with Myovant to jointly develop and commercialize Orgovyx (relugolix) in advanced prostate cancer and Myfembree (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women&#8217;s health in the U.S. and Canada. We also received an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries, which we declined to exercise. Under the terms of the agreement, the companies will equally share profits and allowable expenses for Orgovyx and Myfembree in the U.S. and Canada, with Myovant bearing our share of allowable expenses up to a maximum of $100 million in 2021 and up to a maximum of $50 million in 2022. We record our share of gross profits as Alliance revenue. Myovant remains responsible for regulatory interactions and drug supply and continues to lead clinical development for Myfembree. Myovant is entitled to receive up to $4.35 billion, including an upfront payment of $650 million, which was made in December 2020, $200 million in potential regulatory milestones for FDA approvals for Myfembree in women&#8217;s health, of which $100 million was paid to Myovant in July 2021 and recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets&#8212;Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and tiered sales milestones of up to $3.5 billion in total for prostate cancer and for the combined women&#8217;s health indications. In connection with this transaction, in 2020 we recognized $499 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets&#8211;&#8211;Developed technology</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $151 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">representing the relative fair value of the portion of the upfront payment allocated to the approved indication and unapproved indications of the product, respectively.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Collaboration with CStone</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On September&#160;29, 2020, we entered into a strategic collaboration with CStone to address oncological needs in China. The collaboration encompasses our $200 million upfront equity investment in CStone, the development and commercialization of CStone&#8217;s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between the companies to bring additional oncology assets to the Greater China market. The transaction closed on October&#160;9, 2020. As of December 31, 2021, we held a 9.8% equity stake of CStone.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline">Collaborations with BioNTech</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">On December 30, 2021, we entered into a new research, development and commercialization agreement to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus) based on BioNTech&#8217;s proprietary mRNA technology and our antigen technology. Under the terms of the agreement, we agreed to pay BioNTech $225 million, including an upfront cash payment of $75 million and an equity investment of $150 million. BioNTech is eligible to receive future regulatory and sales milestone payments of up to $200 million. In return, BioNTech agreed to pay us $25 million for our proprietary antigen technology. The net upfront payment to BioNTech was recorded to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">in our fourth quarter of 2021. We and BioNTech will share development costs. We will have commercialization rights to the potential vaccine worldwide, excluding Germany, Turkey and certain developing countries where BioNTech will have commercialization rights. We and BioNTech will share gross profits from commercialization of any product. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On April&#160;9, 2020, we signed a global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program, BNT162b2, aimed at preventing COVID-19 infection. In connection with the April 2020 agreement, we made an upfront cash payment of $72 million and an equity investment in the common stock of BioNTech of $113 million. We recognized $98 million for the upfront payment and a premium paid on the equity investment in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in our second quarter of 2020. BioNTech became eligible to receive potential milestone payments of up to $563 million for a total consideration of $748 million. Under the terms of this agreement, we and BioNTech share gross profits and development costs equally after approval and successful commercialization of the vaccine, and we were responsible for all of </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the development costs until commercialization of the vaccine. Thereafter, BioNTech was to repay us its 50 percent share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. On January 29, 2021, we and BioNTech signed an amended version of the April 2020 agreement. Under the January 2021 agreement, BioNTech paid us their 50 percent share of prior development costs in a lump sum payment during the first quarter of 2021. Further R&amp;D costs are being shared equally. We have commercialization rights to the vaccine worldwide, excluding Germany and Turkey where BioNTech markets and distributes the vaccine under the agreement with us, and excluding China, Hong Kong, Macau and Taiwan, which are subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. We recognize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> on a gross basis in markets where we are commercializing the vaccine and we record our share of gross profits related to sales of the vaccine by BioNTech in Germany and Turkey in Alliance revenues. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We made an additional investment of $50 million in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020. As of December 31, 2021, we held an equity stake of 2.5% of BioNTech.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Summarized Financial Information for Collaborative Arrangements</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.695%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">s&#8212;Alliance revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,652</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from collaborative arrangements</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,703&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16,169)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other income/(deductions)&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">820</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents sales to our partners of products manufactured by us.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2021 reflects increases in alliance revenues from Comirnaty, Eliquis and Xtandi, while the increase in 2020 reflects increases in alliance revenues from Eliquis and Xtandi.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The increase in 2021 is primarily related to Comirnaty.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Primarily relates to royalties from our collaboration partners. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The amounts outlined in the above table do not include transactions with third parties other than our collaboration partners, or other costs for the products under the collaborative arrangements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615605672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, we substantially completed several multi-year initiatives focused on positioning us for future growth and creating a simpler, more efficient operating structure within each business.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Transforming to a More Focused Company Program</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a more focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base and support model align appropriately with our new operating structure. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, to total $1.6 billion, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We expect costs of $1.1&#160;billion, with substantially all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $800 million, with approximately 25% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The program costs discussed above are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">From the start of this program in the fourth quarter of 2019 through December 31, 2021, we incurred costs of $2.2&#160;billion, of which $856 million is associated with Biopharma ($712 million in 2021, $79 million in 2020 and $64 million in 2019).</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Key Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2021 and 2020, we incurred costs of $1.3&#160;billion and $838&#160;million, respectively, composed primarily of the Transforming to a More Focused Company program. In 2019, we incurred costs of $820 million composed of $548 million for the 2017-2019 and Organizing for Growth initiatives, $288 million for the integration of Array, $94 million for the integration of Hospira, and $87 million for the Transforming to a More Focused Company program, partially offset by income of $197 million, primarily due to the reversal of certain accruals upon the effective favorable settlement of an IRS audit for multiple tax years and other acquisition-related initiatives.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.425%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">741</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">802</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">recorded in our consolidated statements of income as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Implementation costs recorded in our consolidated statements of income as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">426</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2021 costs primarily related to our acquisition of Trillium. 2020 costs primarily related to our acquisition of Array. 2019 costs mainly related to our acquisitions of Array, including $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and Hospira.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:52.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.097%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2020 </span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(462)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">741</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes adjustments for foreign currency translation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($628 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($169 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($816 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($255 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615605672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income)/Deductions - Net</a></td>
<td class="text">Other (Income)/Deductions&#8212;Net<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:63.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.860%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(225)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net interest expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,255</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(540)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(454)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(326)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(168)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain legal matters, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business and legal entity alignment costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(298)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(491)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(224)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,878)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Capitalized interest totaled $108 million in 2021, $96 million in 2020 and $88 million in 2019.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine and $97 million of milestone income from multiple licensees. 2020 included, among other things, (i) a $75 million upfront payment received from our sale of our CK1 assets to Biogen, (ii) $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, (iii) $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC and (iv) $108 million in milestone income from multiple licensees. 2019 included, among other things, $78 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, a generic of Advair Diskus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(fluticasone propionate and salmeterol inhalation powder) and $52 million in milestone income from multiple licensees.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2019, other non-service cost components&#8217; activity related to the Consumer Healthcare JV transaction, such as gain on settlements, were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes legal reserves for certain pending legal matters. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">2020 represents intangible asset impairment charges associated with our Biopharma segment: (i) $900 million related to IPR&amp;D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts; (ii) $528 million related to Eucrisa, a finite-lived developed technology right acquired in our Anacor acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures; and (iii) $263&#160;million related to finite-lived developed technology rights for certain generic sterile injectables acquired in our Hospira acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures.</span></div><div style="margin-top:1pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2019 primarily included intangible asset impairment charges of $2.8 billion, mainly composed of $2.6 billion, related to Eucrisa, and reflected updated commercial forecasts mainly reflecting competitive pressures.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Mainly represents incremental costs for the design, planning and implementation of our then new business structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and other advisory services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt">2021 includes, among other things, (i) income net of costs associated with TSAs of $288 million; (ii) dividend income of $166 million from our investment in ViiV and (iii) charges of $142 million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $278 million from our investment in ViiV; (ii) income net of costs associated with TSAs of $114 million and (iii) charges of $105 million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $220&#160;million from our investment in ViiV; (ii) charges of $152 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $138&#160;million.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The asset impairment charges included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are based on estimates of fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609165240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Tax Matters</a></td>
<td class="text">Tax Matters<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Taxes on Income from Continuing Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:67.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.587%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.587%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.886%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,064</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,247</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,321&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:65.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.483%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> based on the location of the taxing authorities include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,342</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,887)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total U.S. tax benefit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(964)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(867)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(543)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">TCJA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total TCJA tax benefit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,769</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(969)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total international tax provision</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,816</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts discussed below are rounded to the nearest hundred million and represent approximations.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date. The fourth annual installment is due April 18, 2022 and is reported in current </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">as of December 31, 2021. The remaining liability is reported in noncurrent </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The changes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> impacting the effective tax rate year-over-year are summarized below:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021 v. 2020</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The higher effective tax rate in 2021 was mainly the result of:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the change in the jurisdictional mix of earnings primarily related to Comirnaty; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower tax benefits related to the impairment of intangible assets,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK based on estimates and assumptions that we believe to be reasonable.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020 v. 2019</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The higher effective tax rate in 2020 was mainly the result of:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the $1.4 billion tax benefits, representing taxes and interest, recorded in 2019 due to the favorable settlement of an IRS audit for multiple tax years; </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the tax benefits related to certain tax initiatives associated with the implementation of our then new business structure; and</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the tax benefits recorded in 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA, as well as:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">lower tax benefits related to the impairment of intangible assets,</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">partially offset by:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the non-recurrence of the tax expense of $2.7 billion recorded in the third quarter of 2019 associated with the gain on the completion of the Consumer Healthcare JV transaction; and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Tax Rate Reconciliation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:65.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.483%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. statutory income tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TCJA impact</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxation of non-U.S. operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax settlements and resolution of certain tax positions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain Consumer Healthcare JV initiatives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. R&amp;D tax credit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate for income from continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions,&#8221; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for the components of pre-tax income and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2029. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2047 on income from manufacturing and other operations.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes changes in interest related to our uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221;.</span></div><div style="margin-bottom:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">All other, net is primarily due to routine business operations.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Deferred Taxes</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:50.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Deferred Tax*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 Deferred Tax*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Liabilities)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid/deferred items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,086</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(456)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,114&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,220)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee benefits</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,594</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructurings and other charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal and product liability reserves</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss/tax credit carryforwards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,431</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unremitted earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local tax adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">197</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(689)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,446</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7,714)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,726)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,462)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,586)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7,714)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,726)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset/(liability)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,123)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net deferred tax assets in 2021 is primarily related to temporary differences associated with Comirnaty royalty accruals and the result of operating lease ROU liabilities recognized during the period.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in the deferred tax assets is primarily due to the acquisition of intangible assets relating to Trillium and the decrease in the 2021 deferred tax liabilities is primarily the result of amortization of intangible assets.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase in net deferred tax liabilities in 2021 is primarily the result of operating lease ROU assets recognized during the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease in net deferred tax assets in 2021 is primarily the result of favorable pension plan asset performance reported in the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 11A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amounts in 2021 and 2020 are reduced for unrecognized tax benefits of $3.0 billion and $3.0 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">The decrease in net deferred tax liabilities in 2021 is primarily due to certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.6 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.3 billion). In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.9 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($4.1 billion).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have carryforwards, primarily related to net operating and capital losses, general business credits, foreign tax credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2022 to 2041. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section&#160;382.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2021, we have not made a U.S. tax provision on $55.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2021 is not practicable. The amount of indefinitely reinvested earnings is based on estimates and assumptions and subject to management evaluation, and is subject to change in the normal course of business based on operational cash flow, completion of local statutory financial statements and the finalization of tax returns and audits, among other things. Accordingly, we regularly update our earnings and profits analysis for such events.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For a description of our accounting policies associated with accounting for income tax contingencies, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Uncertain Tax Positions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2021, we had $4.5 billion and as of December 31, 2020, we had $4.3 billion in net unrecognized tax benefits, excluding associated interest.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Tax assets for uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2021, we had $1.5 billion in assets associated with uncertain tax positions. These amounts were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($1.4 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($105 million). As of December 31, 2020, we had $1.3 billion in assets associated with uncertain tax positions. These amounts were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> ($1.1 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($122 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">($46&#160;million).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. </span></div><div style="margin-top:5pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"/><td style="width:65.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.333%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,595)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,381)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,259)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divestitures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases based on settlements for a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases based on tax positions taken during the current period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6,068)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,595)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,381)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2020, related to the separation of Upjohn. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to cash payments and reductions of tax attributes.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2021, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($19 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($42&#160;million) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($5 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion). In 2020, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($34 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($18 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.5 billion).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. In 2021 and 2020, we recorded net increases in interest of $108 million and $89 million, respectively. In 2019, we recorded a net decrease in interest of $564 million, resulting primarily from a settlement with the IRS. Gross accrued interest totaled $601 million as of December 31, 2021 (reflecting a decrease of $1 million as a result of cash payments) and gross </span></div><div style="margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">accrued interest totaled $493 million as of December 31, 2020 (reflecting a decrease of $5 million as a result of cash payments and a decrease of $75&#160;million relating to the separation of Upjohn). In 2021 and 2020, these amounts were substantially all included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued penalties are not significant. See also </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent&#8217;s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions such as Canada (2013-2021), Europe (2011-2021, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (2011-2021, primarily reflecting China, Japan and Singapore) and Latin America (1998-2021, primarily reflecting Brazil). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $75 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.</span></div><div style="margin-top:1pt"><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:68.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit plans: prior service (costs)/credits and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611075688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</a></td>
<td class="text">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Prior Service (Costs)/ Credits and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,075)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(68)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,249)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(144)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,936)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(35)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,367)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distribution of Upjohn Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(397)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,450)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">547</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(6,172)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">377</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(5,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and the impact of our net investment hedging program.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609296168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Fair Value Measurements</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">709</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">709</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,703</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,278&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Long-term equity securities of $194 million as of December 31, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for U.S. non-qualified employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The carrying value of Long-term debt, excluding the current portion was $36&#160;billion as of December 31, 2021 and $37&#160;billion as of December 31, 2020. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $42&#160;billion as of December 31, 2021 and $46 billion as of December 31, 2020.</span></div>The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2021 and 2020. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Investments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Total Short-Term, Long-Term and Equity-Method Investments</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:73.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,054</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,526</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,262&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">268</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represent investments in the life sciences sector.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Debt Securities</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:21.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.897%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18,032</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,055</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">917</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Any expected credit losses to these portfolios would be immaterial to our financial statements.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Securities</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,344)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(540)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(454)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(515)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(429)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $97 million and upward adjustments of $156 million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Short-Term Borrowings</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:73.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,705&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes cash collateral. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average effective interest rate on commercial paper outstanding was approximately 0.13% as of December 31, 2020.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2021, we had access to a $7 billion committed U.S. revolving credit facility expiring in 2026, which may be used for general corporate purposes including to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have provided us an additional $360 million in lines of credit, of which $322 million expire within one year. Essentially all lines of credit were unused as of December 31, 2021.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Long-Term Debt</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following outlines our senior unsecured long-term debt and the weighted-average stated interest rate by maturity:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2022 (1.0% for 2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2023 (3.2% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,550</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2024 (3.9% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2025 (0.8% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2026 (2.9% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2027 (2.1% for 2021 and 2.0% for 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,051</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2028-2032 (3.1% for 2021 and 3.4% for 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,660</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2033-2037 (5.6% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2038-2042 (5.5% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,079</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,086&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2043-2047 (3.7% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,858</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2048-2050 (3.6% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,774&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(207)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,133&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified to the current portion of long-term debt.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our long-term debt outlined in the above table is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Issuances</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.253%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In August 2021, we issued the following senior unsecured notes at an effective interest rate of 1.79%:</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.750%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August&#160;18, 2031</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In May 2020, we completed a public offering of $4.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.11% and in March 2020, we completed a public offering of $1.25 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.67%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">In March 2019, we completed a public offering of $5.0&#160;billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 3.57%.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Retirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In November 2020, we repurchased all $1.15 billion and $342 million principal amount outstanding of the 1.95% senior unsecured notes due June 2021 and 5.80% senior unsecured notes due August 2023 and recorded a total net loss of $36&#160;million, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In March 2020, we repurchased at par all $1.065 billion principal amount outstanding of our senior unsecured notes due in 2047.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In January 2019, we repurchased all &#8364;1.1 billion ($1.3 billion) principal amount outstanding of the 5.75% euro-denominated debt due June 2021 at a redemption value of &#8364;1.3 billion ($1.5 billion). We recorded a net loss of $138 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, which included the related termination of cross currency swaps</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Derivative Financial Instruments and Hedging Activities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen and Canadian dollar. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We hedge a portion of our forecasted intercompany inventory sales denominated in euro, Japanese yen, Canadian dollar, Chinese renminbi, U.K. pound and Australian dollar for up to two years.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Under certain market conditions, we may seek to protect against possible declines in the reported net investments of our foreign business entities.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Changes in fair value are reported in earnings or in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, depending on the nature and purpose of the financial instrument (hedge or offset relationship). For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an amortization approach in earnings. The hedge relationships are as follows: </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged item. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Generally, we record in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts into earnings in the same period or periods during which the hedged transaction affects earnings. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">We record in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;Foreign currency translation adjustments, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses immediately into earnings along with the earnings impact of the items they generally offset. These contracts take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recognize the change in fair value on interest rate contracts that are designated as fair value hedges in earnings, as well as the offsetting earnings impact of the hedged risk attributable to the hedged item.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.858%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,576</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br/>Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">488</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(649)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(369)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(501)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,077)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions&#8212;net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amounts reclassified from OCI into COS were:</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net loss of $89 million in 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net gain of $172 million in 2020 (including a gain of $22&#160;million reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $362 million within the next 12 months into income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Short-term borrowings and long-term debt include foreign currency borrowings which are used as net investment hedges. The short-term borrowings carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of December 31, 2021 and December 31, 2020 were $844 million and $2.1 billion, respectively.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:24.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.789%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair<br/>Value Hedging Adjustment<br/>Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair <br/>Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active<br/>Hedging<br/>Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,233</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">.</span><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"> Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">On an ongoing basis, we monitor and review the credit risk of our customers, financial institutions and exposures in our investment portfolio.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our trade accounts receivable, we monitor the creditworthiness of our customers to which we grant credit in the normal course of business. In general, there is no requirement for collateral from customers. For additional information on our trade accounts receivable and </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">allowance for credit losses, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1H</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our investments, we monitor concentrations of credit risk associated with government, government agency, and corporate issuers of securities. Investments are placed in instruments that are investment grade and are primarily short in duration. Exposure limits are established to limit a concentration with any single credit counterparty. As of December 31, 2021, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by the U.S., Canada, Japan, U.K., Germany, France, Australia, and Switzerland.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association (ISDA) master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of December 31, 2021, the aggregate fair value of these derivative financial instruments that are in a net payable position was $372 million, for which we have posted collateral of $382 million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. As of December 31, 2021, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $477 million, for which we have received collateral of $581 million with a corresponding amount reported in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Short-term borrowings, including current portion of long-term debt.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609295320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Information</a></td>
<td class="text">Other Financial Information<div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A.</span><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.45pt;text-decoration:underline"> Inventories</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,641</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,867&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,424</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,059</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">939</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></div><div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Other Current Liabilities</span></div>Other current liabilities includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $9.7&#160;billion as of December 31, 2021 and $25&#160;million as of December 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610627832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (PP&amp;E)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment (PP&amp;E)</a></td>
<td class="text">Property, Plant and Equipment (PP&amp;E)<div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:62.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.587%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.886%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Useful Lives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Years)&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33-50</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,998&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-20</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3-12.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,955</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,406&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,074</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,661&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,882</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,745&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.090%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides long-lived assets by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,882</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,745&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609234808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets and Goodwill</a></td>
<td class="text">Identifiable Intangible Assets and Goodwill<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Identifiable Intangible Assets</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.213%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">73,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,532)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55,838)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,714</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,255&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,493)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,762&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55,838)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25,146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,830&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,493)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,337&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Developed Technology Rights</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Developed technology rights represent the cost for developed technology acquired from third parties and can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing our commercialized products. The significant components of developed technology rights are the following: Xtandi, Prevnar 13/Prevenar 13 Infant, Braftovi/Mektovi, Premarin, Prevnar 13/Prevenar 13 Adult, Eucrisa, Orgovyx, Zavicefta, Tygacil, Bavencio, Merrem/Meronem and Comirnaty. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain prescription pharmaceutical products.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Brands</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Brands represent the cost for tradenames and know-how, as the products themselves do not receive patent protection. Indefinite-lived brands include Medrol and Depo-Medrol, while finite-lived brands include Zavedos and Depo-Provera.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D assets represent R&amp;D assets that have not yet received regulatory approval in a major market. The significant components of IPR&amp;D are the following: the program for the oral poly adenosine diphosphate (ADP) ribose polymerase inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part of the Medivation acquisition and assets acquired in connection with the Array acquisition. IPR&amp;D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&amp;D effort. Accordingly, during the development period after the date of acquisition, these assets are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify it out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is abandoned, the related IPR&amp;D assets will likely be written-off, and we will record an impairment charge.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">IPR&amp;D assets are high-risk assets, given the uncertain nature of R&amp;D. Accordingly, we expect that many of these IPR&amp;D assets will become impaired and be written-off at some time in the future.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Licensing Agreements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Licensing agreements for developed technology and for technology in development primarily relate to out-licensing arrangements acquired from third parties, including the Array acquisition. These assets represent the cost for the license, where we acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partner. A significant component of the licensing arrangements are for out-licensing arrangements with a number of partners for oncology technology in varying stages of development that have not yet received regulatory approval in a major market. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will likely be written-off, and we will record an impairment charge.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average life for each of our total finite-lived intangible assets is approximately 8 years, and for the largest component, developed technology rights, is approximately 7 years. Total amortization expense for finite-lived intangible assets was $3.7 billion in 2021, $3.4 billion in 2020 and $4.5 billion in 2019.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:40.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.817%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the expected annual amortization expense:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,686&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Goodwill</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components and changes in the carrying amount of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,181&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,556&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,208</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other represents the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609266024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Postretirement Benefit Plans and Defined Contribution Plans</a></td>
<td class="text">Pension and Postretirement Benefit Plans and Defined Contribution Plans<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of pension and postretirement plans. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.895%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit), including those reported as part of discontinued operations for 2020 and 2019, and the changes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">for our benefit plans:</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,015)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(890)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(170)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,265)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(746)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(372)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(271)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost/(credit) reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost/(credit) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Comprehensive income</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(742)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(168)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(107)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects actuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates, and actuarial remeasurement losses in 2020 and 2019, primarily due to decreases in discount rates partially offset by favorable plan asset performance.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The components of net periodic benefit cost/(credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:3pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Actuarial Assumptions</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(PERCENTAGES)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions used to determine net periodic benefit cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension plans/postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">All of the assumptions are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends as well as market conditions that may have an impact on the cost of providing retirement benefits.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2021 resulted in higher discount rates as compared to the prior year.</span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:75.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year that the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2045</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2037&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Obligations and Funded Status</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures/other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,001&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Amounts recorded in our consolidated balance sheet: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,084)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(645)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Plan Assets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.405%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">The following provides the components of plan assets, including those reported as part of discontinued operations for 2020:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Target Allocation Percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level <br/>2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level<br/>&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. pension plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,326</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20-40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Global equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,233</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,352</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45-75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,566</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,079</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,076</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other commingled funds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,332</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,726</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,103&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">International pension plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,386</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45-70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15-35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,431</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">886</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,672</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,677</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,681&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,707&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. postretirement plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95-100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">669</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">669</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Government and agency obligations are inclusive of repurchase agreements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Mostly includes investments in hedge funds and real estate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.169%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs, including those reported as part of discontinued operations for 2020:</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,362</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held, ending</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases, sales, and settlements, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer into/(out&#160;of) Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange rate changes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, ending</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,677</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans&#8217; assets:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.</span></div><div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Level 3 investments may include securities or insurance contracts that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans&#8217; invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.</span></div><div><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the expected future cash flow information related to our benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected employer contributions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected benefit payments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027&#8211;2031</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,908&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,124&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">F. Defined Contribution Plans</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have defined contribution plans in the U.S. and other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. We also offer a Retirement Savings Contribution (RSC) which is an annual non-contributory employer contribution in the U.S. and Puerto Rico. We recorded charges related to the employer contributions to global defined contribution plans of $732 million in 2021, $685 million in 2020 and $659 million in 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609150456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Common Stock Purchases</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We purchase our common stock through privately negotiated transactions or in the open market as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our BOD, are available for general corporate purposes. In December 2017, the BOD authorized a $10 billion share repurchase program, which was exhausted in the first quarter of 2019. In December 2018, the BOD authorized another $10 billion share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2019, we entered into an ASR with Goldman Sachs &amp; Co. LLC to repurchase $6.8 billion of our common stock pursuant to our previously announced share repurchase authorization. We paid $6.8 billion and received an initial delivery of 130 million shares of common stock, which represented approximately 80% of the notional amount of the ASR. In August 2019, the ASR with Goldman Sachs &amp; Co. LLC was completed resulting in Goldman Sachs &amp; Co. LLC owing us an additional 33.5 million shares of our common stock. The average price paid for all of the shares delivered under the ASR was $41.42 per share. The common stock received is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Treasury stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:46.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.768%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our ASR:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of common stock purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of purchase</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents shares purchased pursuant to the ASR with Goldman Sachs &amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our remaining share-purchase authorization was approximately&#160;$5.3 billion at December 31, 2021.</span></div><div style="margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Preferred Stock and Employee Stock Ownership Plans</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior to May 4, 2020, we had outstanding Series A convertible perpetual preferred stock (the Series A Preferred Stock) that was held by an ESOP trust (the Trust). All outstanding shares of Series A Preferred Stock were converted, at the direction of the independent fiduciary under the Trust and in accordance with the certificate of designations for the Series A Preferred Stock, into shares of our common stock on May 4, 2020. The Trust received an aggregate of 1,070,369 shares of our common stock upon conversion, with zero shares of Series A Preferred Stock remaining outstanding as a result of the conversion. In December 2020, we filed a certificate of elimination and a restated certificate of incorporation with the Delaware Secretary of State, which eliminated the Series A Preferred Stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Since May 4, 2020, we have one ESOP that holds common stock of the Company (Common ESOP). As of December 31, 2021, all shares of common stock held by the Common ESOP have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $19 million in 2021, $19 million in 2020 and $20 million in 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609225096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Our compensation programs can include share-based payment awards with value that is determined by reference to the fair value of our shares and that provide for the grant of shares or options to acquire shares or similar arrangements. Our share-based awards are designed based on competitive survey data or industry peer groups used for compensation purposes, and are allocated between different long-term incentive awards, generally in the form of Total Shareholder Return Units (TSRUs), Restricted Stock Units (RSUs), Portfolio Performance Shares (PPSs), Performance Share Awards (PSAs), Breakthrough Performance Awards (BPAs) and Stock Options, as determined by the Compensation Committee.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The 2019 Stock Plan (2019 Plan) replaced and superseded the 2014 Plan. It provides for 400 million shares, in addition to shares remaining under the 2014 Plan, to be authorized for grants. The 2019 Plan provides that the number of stock options, TSRUs, RSUs, or performance-based awards that may be granted to any one individual during any 36-month period is limited to 20 million shares, and that RSUs count as three shares, PPSs, PSAs and BPAs count as three shares times the maximum potential payout, while TSRUs and stock options count as one share, toward the maximum shares available under the 2019 Plan. As of December 31, 2021, 315 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A summary of the awards and valuation details:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total Shareholder Return Units (TSRUs)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a), (b)</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management and select  employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107">five</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03">seven</span>-year term, if and to the extent the total value is positive.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using a Monte Carlo simulation model</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Units (RSUs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For RSUs granted, in virtually all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portfolio Performance Shares (PPSs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#8217;s long-term product portfolio during a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfMTA5OTUxMTYyODQ4MQ_0da09f05-3e8c-4080-bb4d-fc5dd48fbbca">three</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNDQz_4d00d2e4-77a0-4861-9e03-9cd48bf4e5b8">five</span>-year performance period from the year of the grant date, as applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance Share Awards (PSAs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">Adjusted net income over three <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg5_e6c42dac-714f-4f5e-996c-4d0353676184">one</span>-year periods; and</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNDg1_fcbb828a-fc1b-45e8-92d8-b04179945bfd">three</span>-year performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Breakthrough Performance Awards (BPAs)</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDk_1531252f-ed7d-4bb0-98f0-50eaa78bb5c6">one</span>-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer&#8217;s product pipeline during the performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the probable vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#8217;s assessment of the probability that the specified performance criteria will be achieved and/or management&#8217;s assessment of the probable vesting term.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years. </span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the Black-Scholes-Merton option-pricing model</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#8217; original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (1,444,395 PTSRUs) and 361,099 PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $30.31 and at a GDFV of $5.54 per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.118%"/><td style="width:0.1%"/></tr><tr><td colspan="93" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PPSs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total fair value of shares vested</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$7.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$6.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$8.52</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$304</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$334</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$454</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$181</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$119</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$136</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$33</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$4.86</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$3.56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$5.98</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised or share units converted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$594</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$84</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$175</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$228</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$224</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$245</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$584</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$293</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$261</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash received upon exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$795</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$425</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$394</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax benefits realized from exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$106</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$47</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation cost recognized, pre-tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$259</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$287</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$294</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$281</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$272</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$275</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$535</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$180</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$114</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$76</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total compensation cost related to nonvested awards not yet recognized, pre-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$187</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$224</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$229</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$271</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$228</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$241</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$175</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$32</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$34</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$5</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted-average period over which cost is expected to be recognized (years)</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Weighted-average GDFV per TSRUs and stock options.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">TSRU includes expense for PTSRUs, which is not significant for all years presented.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total share-based payment expense was $1.2 billion, $780 million and $718 million in 2021, 2020 and 2019, respectively, which includes pre-tax share-based payment expense included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of $2 million, $25 million and $32 million in 2021, 2020 and 2019, respectively. Tax benefit for share-based compensation expense was $227 million, $141 million and $137 million in 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all years presented and is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">). Amounts capitalized as part of inventory cost were not significant for any period presented.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.102%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected dividend yield </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(based on a constant dividend yield during the expected term)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.36&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.36&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on interpolated yield on U.S. Treasury zero-coupon issues)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.93</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on implied volatility, after consideration of historical volatility)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26.53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26.54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TSRUs contractual/stock options expected term, years</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on historical exercise and post-vesting termination patterns for stock options) </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5.15</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.13</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6.75</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.75</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.75</span></td></tr></table></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.459%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.757%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of all TSRU, RSU, PPS, PSA and BPA activity during 2021 (with the shares granted representing the maximum award that could be achieved for PPSs, PSAs and BPAs):</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PPSs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BPAs</span></td></tr><tr style="height:5pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">TSRUs&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Per TSRU, Weighted Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;Weighted Avg. GDFV per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">GDFV</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Grant Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nonvested, </span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.90&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32.94&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,692</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35.50&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,077</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36.81&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,264</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36.81&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34,522</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,893</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,632</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,165</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(44,888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7.21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30.54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.88</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.85</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reinvested dividend equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41.33</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6.77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">35.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41.45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">47.47</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nonvested, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">114,599</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">25,540</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">35.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,480</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,154</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">859</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1&#160;million.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.551%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of TSRU and PTU information as of December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TSRUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PTUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average<br/>Grant&#160;Price<br/>Per TSRU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Contractual Term </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206,996</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,969</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92,398</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28.72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,946</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Expected to vest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110,476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34.16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,910</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs exercised and converted to PTUs</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,074</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.8</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, we settled 46,060,346 TSRUs with a weighted-average grant price of $23.04 per unit.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, 7,093,787 TSRUs with a weighted-average grant price of $27.41 per unit were converted into 2,943,737 PTUs.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</span></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.461%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of all stock option activity during 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,402&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.31&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(31,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25.75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34.39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20.27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding, December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,874</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,295</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vested and expected to vest, December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,747</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30.19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable, December 31, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,583</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29.81</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Market price of our underlying common stock less exercise price.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The number of options expected to vest takes into account an estimate of expected forfeitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609260056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</a></td>
<td class="text">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:66.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EPS:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(IN MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,025&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,026&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,708</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,632&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,675&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP was assumed in the diluted EPS calculation until the conversion date, which occurred in May 2020. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609222296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $381 million in 2021, $380 million in 2020 and $326 million in 2019. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.949%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_408086e2-3444-4b88-b89b-d101186f774f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_46ee31d6-1f28-4ba5-b2be-d5c564d17665">Other noncurrent assets</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,839</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liabilities (short-term)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_74739711-6874-4a56-93f6-73a0506beaac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_8b4b2c6e-76ae-4492-a995-73bb701632ff">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">449</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liabilities (long-term)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b27ac467-c383-4750-82e2-f39d2460df2f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b50ecd3f-01e3-4abd-991d-dc5d329b8f81">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:52.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of total lease cost includes:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">888</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.949%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other supplemental information follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Remaining Contractual Lease Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.932%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="21" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains)/losses on sale and leaseback transactions, net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.752%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating Lease Liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Next one year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">520</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-2 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">417</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3-4 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,621</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Imputed interest</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,960</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">449</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)Reflects lease payments due within 12 months subsequent to the balance sheet date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609301512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Certain Commitments</a></td>
<td class="text">Contingencies and Certain Commitments<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5B.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Legal Proceedings</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our legal contingencies include, but are not limited to, the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from that product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A1. Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. For example, some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings with respect to two of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those two patents, and one other patent, were challenged in federal court in Delaware. In September 2021, Pfizer and a challenger entered into a settlement and license agreement, resolving all worldwide legal proceedings involving that challenger, related to our pneumococcal vaccine patents. Other challenges to pneumococcal vaccine patents remain pending at the PTAB and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines into the marketplace. In the event that any of the patents are found valid and infringed, a competitor&#8217;s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Actions In Which We Are The Plaintiff</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EpiPen</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Xeljanz (tofacitinib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the patent covering the active ingredient expiring in December 2025 and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">In February 2022, we brought a separate patent-infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2022, we brought a separate patent-infringement action against Slayback Pharma LLC (Slayback) asserting the infringement and validity of our compound patent covering the active ingredient that was challenged by Slayback in its ANDA seeking approval to market a generic version of tofacitinib oral solution 1 mg/mL.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inlyta (axitinib)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ibrance (palbociclib)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance capsules. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent. We have settled with one of these generic companies on terms not material to the company. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Eucrisa</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Eliquis</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision. </span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Asbestos</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div><span><br/></span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Effexor</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Lipitor</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Court for the District of New Jersey. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EpiPen (Direct Purchaser)</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants&#8217; motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nexium 24HR and Protonix</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Docetaxel</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Personal Injury Actions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.</span></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Mississippi Attorney General Government Action</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Zantac</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. Plaintiffs previously had filed a consolidated third-party payor class action complaint alleging violation of the federal Racketeer Influenced and Corrupt Organizations Act (RICO) statute and seeking reimbursement for payments made for the prescription version of Zantac, but the Multi-District Litigation court dismissed that complaint; Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eleventh Circuit. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#8217; sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state court, alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Chantix</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer&#8217;s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A3. Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Monsanto-Related Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2009, we submitted a revised site-wide feasibility study with regard to the Wyeth Holdings Corporation (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the U.S. Environmental Protection Agency (EPA) with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy. In 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the two adjacent lagoons. In 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. In September 2021, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey, which the court approved in November 2021, that will allow Wyeth Holdings LLC to complete the design and implement the remedy for the two adjacent lagoons. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have accrued for the estimated costs of the site remedies for the Bound Brook facility.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contracts with Iraqi Ministry of Health</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#8217; motions to dismiss and dismissed all of plaintiffs&#8217; claims. In January 2022, the Court of Appeals reversed the District Court&#8217;s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals&#8217; decision.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Allergan Complaint for Indemnity</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Breach of Contract&#8211;&#8211;Xalkori/Lorbrena</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The action was originally filed in 2013. In 2015, the Supreme Court dismissed the action and, in 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2020, NYU filed a separate breach of contract action against Pfizer alleging that it is entitled to royalties on sales of Lorbrena under the terms of the same NYU-Sugen, Inc. Research and Licensing Agreement. In February 2022, the parties reached an agreement to settle both breach of contract actions on terms not material to Pfizer.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Viatris Securities Litigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company&#8217;s current and former officers, directors and employees are named as defendants. The complaint alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Greenstone Investigations</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">U.S. Department of Justice Antitrust Division Investigation</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. </span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">State Attorneys General and Multi-District Generics Antitrust Litigation</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020. The Multi-District Litigation also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Subpoena relating to Manufacturing of Quillivant XR</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2019, we received an informal request from the  U.S. Department of Justice&#8217;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA Unit. We have produced records pursuant to these requests. </span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Mississippi Attorney General Government Investigation</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Product Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Docetaxel</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Attorney General Government Investigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Department of Justice Inquiries relating to India Operations</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#8217;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S. Department of Justice/SEC Inquiry relating to China Operations</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#8217;s FCPA Unit. We are producing records pursuant to these requests.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Zantac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">State of New Mexico and Mayor and City Council of Baltimore Civil Actions</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings&#8211;&#8211;Product Litigation&#8211;&#8211;Zantac</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants&#8217; alleged sale of Zantac in those jurisdictions.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A5. Legal Proceedings&#8211;&#8211;Matters Resolved During 2021</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During 2021, certain matters, including the matter discussed below, were resolved or became the subject of definitive settlement agreements or settlement agreements-in-principle.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">EpiPen</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Beginning in 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its current and former affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan former Chief Executive Officer, Heather Bresch. The plaintiffs in these actions represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal and various state antitrust laws. At least one lawsuit also alleges that Pfizer and/or Mylan violated RICO. Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In 2017, all of these indirect purchase actions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In July 2021, Pfizer and plaintiffs filed a stipulation of settlement to resolve the Multi-District Litigation for $345&#160;million. The District Court approved the settlement in November 2021, and the payment was made in accordance with the terms of the settlement agreement.</span></div><div style="margin-bottom:5pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Guarantees and Indemnifications</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2021, the estimated fair value of these indemnification obligations has been included in our financial statements and is not material to Pfizer. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In addition, in connection with our entry into certain agreements and other transactions, our counterparties may agree to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, Viatris has agreed to assume, and to indemnify Pfizer for, liabilities arising out of certain matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Certain Commitments</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of December 31, 2021, we had commitments totaling $5.2 billion that are legally binding and enforceable. These commitments include payments relating to potential milestone payments deemed reasonably likely to occur, and purchase obligations for goods and services.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for information on the TCJA repatriation tax liability.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">D. Contingent Consideration for Acquisitions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 1E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The estimated fair value of contingent consideration as of December 31, 2021 is $697&#160;million, of which $135&#160;million is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $563&#160;million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and as of December 31, 2020 is $689 million, of which $123 million is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and $566 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The increase in the contingent consideration balance from December 31, 2020 is primarily due to fair value adjustments, partially offset by payments made upon the achievement of certain sales-based milestones.</span></div><div style="margin-bottom:5pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">E. Insurance</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability.</span><span style="color:#1f497d;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance </span></div>coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609290136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, Geographic and Other Revenue Information</a></td>
<td class="text">Segment, Geographic and Other Revenue Information<div style="margin-bottom:8pt"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">A. Segment Information</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources. With the formation of the Consumer Healthcare JV in 2019 and the completion of the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines and beginning in the fourth quarter of 2020 operated as a single operating segment engaged in the discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products worldwide. At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is a science-based medicines business that includes six therapeutic areas &#8211; Oncology, Inflammation &amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital therapeutic area commercializes our global portfolio of sterile injectable and anti-infective medicines. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;D services from GPD and WRDM. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma is the only reportable segment. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Other Costs and Business Activities</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">WRDM&#8211;&#8211;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">GPD&#8211;&#8211;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late-stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Corporate and Other Unallocated&#8211;&#8211;the costs associated with (i) corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others), all strategy, business development, portfolio management and valuation capabilities, patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments; (ii) overhead expenses primarily associated with our manufacturing (which include manufacturing variances associated with production) operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs; and (iii) our share of earnings from the Consumer Healthcare JV.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related items, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as pension and postretirement actuarial remeasurement gains and losses, gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The operating results of PC1, our global contract development and manufacturing organization, and through July 31, 2019 our former Consumer Healthcare business are included in Other business activities.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Segment Assets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $181 billion as of December 31, 2021 and $154 billion as of December 31, 2020.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Selected Income Statement Information</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"/><td style="width:27.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.137%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following table provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">79,557</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">40,226</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">27,089&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,439</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,892&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(10,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12,308)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(11,216)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">598</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3,117)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,584)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">81,288</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,651&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40,905&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,321&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $2.1 billion charge for IPR&amp;D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $1.3&#160;billion ($450 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and (iii) upfront and milestone payments on collaborative and licensing arrangements of $1.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (v) gains on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. For Earnings in 2020, includes, among other items; (i) charges of $1.7 billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) actuarial valuation and other pension and postretirement plan losses of $1.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $791 million ($197 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $8.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $2.8 billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) actuarial valuation and other pension and postretirement plan losses of $750 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 2A, 2C, 3 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">4. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">B. Geographic Information</span></div><div style="margin-bottom:3pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.063%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">29,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,455&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,326&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,336</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,506</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81,288</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,651&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,905&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Revenues exceeded $500 million in each of 21, 8 and 10 countries outside the U.S. in 2021, 2020 and 2019, respectively. The U.S. is the only country to contribute more than 10% of total revenue in 2021, 2020 and 2019. As a percentage of revenues, our largest national market outside the U.S. was Japan, which contributed 9% of total revenue in 2021 and 6% in each of 2020 and 2019.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty with multiple developed and emerging nations around the world and are continuing to deliver doses of Comirnaty under such agreements. We currently sell the Comirnaty vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February and May 2021 with the EC on behalf of the different EU member states and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.</span></div><div><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C. Other Revenue Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Customers</span></div><div><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. </span></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.063%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">McKesson, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Collectively, our three largest U.S. wholesaler customers represented 24%, 30% and 25% of total trade accounts receivable as of December 31, 2021, 2020 and 2019.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Additionally, revenues from the U.S. government represented 13% of total revenues for 2021, and primarily represent sales of Comirnaty. Accounts receivable from the U.S. government represented 12% of total trade accounts receivable as of December 31, 2021, and primarily relate to sales of Comirnaty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Significant Product Revenues</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:20.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,288</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,651&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">79,557</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">40,724&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">38,013&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">42,625</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,575&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,504&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Comirnaty direct sales and alliance revenues</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent COVID-19</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">36,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Prevnar family</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,272</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nimenrix</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Trumenba</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Meningococcal B disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Vaccines</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">12,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,867&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,014&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Ibrance</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,437</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,392&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,961&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inlyta</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sutent</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">673</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bosulif</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">540</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xalkori</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">493</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Ruxience</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retacrit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zirabev</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Trazimera</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%">HER-positive breast cancer and metastatic stomach cancers</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">197</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Braftovi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mektovi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Braftovi for metastatic melanoma in patients  with a BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E/K</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> mutation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Oncology</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">9,329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,003&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,790&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Eliquis alliance revenues and direct sales</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,970</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,949&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,220&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Premarin family</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Chantix/Champix</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">398</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">BMP2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Toviaz</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pristiq</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Depression</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Internal Medicine</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:20.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hospital</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7,301</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,777&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,695&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sulperazon</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">683</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Medrol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fragmin</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vfend</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tygacil</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Precedex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sedation agent in surgery or intensive care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zyvox</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Paxlovid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">COVID-19 Infection (</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">high risk population)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">IVIg Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Anti-infectives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Hospital</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,412</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,431</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,733&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xeljanz</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Enbrel (Outside the U.S. and Canada)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,699&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inflectra/Remsima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other I&amp;I</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">134</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare Disease</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,538</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,278&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Genotropin</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">389</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Refacto AF/Xyntha</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Somavert</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Rare Disease</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CONSUMER HEALTHCARE BUSINESS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,082&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7,652</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">On July&#160;31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare JV. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Remaining Performance Obligations</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totals $34.4 billion as of December 31, 2021, which includes amounts received in advance and deferred and amounts that will be invoiced as we deliver the product to our customers in future periods. Of this amount, we expect to recognize revenue of </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$22.3 billion in 2022, $11.8 billion in 2023 and $265 million in 2024. Remaining performance obligations exclude arrangements with an original expected contract duration of less than one year.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Revenues</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of Comirnaty. The deferred revenues associated with the advance payments related to Comirnaty total $3.3 billion as of December 31, 2021 and $957 million as of December 31, 2020, with $3.0 billion and $249 million recorded in current liabilities and noncurrent liabilities, respectively as of December 31, 2021, and $957 million recorded in current liabilities as of December 31, 2020. The increase in the Comirnaty deferred revenues during 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries less amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> as we delivered doses to our customers. During 2021, we recognized in revenue substantially all of the balance of Comirnaty deferred revenues as of December 31, 2020. The Comirnaty deferred revenues as of December 31, 2021 will be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> in 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of December 31, 2021 or 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633608127880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our subsidiaries have been eliminated.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards Adopted in 2021</a></td>
<td class="text">New Accounting Standard Adopted in 2021On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Estimates and Assumptions</a></td>
<td class="text">Estimates and Assumptions<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of income. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 16D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our fair value methodologies depend on the following types of inputs:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities&#8212;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Equity securities with readily determinable fair values&#8212;quoted market prices and observable NAV prices.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Derivative assets and liabilities&#8212;third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Money market funds&#8212;observable NAV prices.</span></div><div style="margin-bottom:8pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">Foreign Currency Translation<span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, and we translate non-monetary items at historical rates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues and Collaborative Arrangements</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Our Sales Contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to LOE, product recalls or a changing competitive environment.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Deductions from Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span></div><div style="margin-bottom:3pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provisions for pharmaceutical sales returns&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as LOE, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following outlines our common sales arrangements:</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#008080;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8211;&#8211;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies, and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period&#8217;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#8220;coverage gap,&#8221; also known as the &#8220;doughnut hole,&#8221; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#8217;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49%</span><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">of our revenues in 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 17B </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span>Collaborative Arrangements<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received for our share of gross profits from our collaboration partners as alliance revenues, a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Revenues,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Royalty payments received from collaboration partners are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reimbursements to or from our collaboration partners for development costs are typically recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets&#8212;Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> over the development period for the products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Trade Accounts Receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During 2021 and 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Cost of Sales and Inventories</a></td>
<td class="text">Cost of Sales and InventoriesInventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, Informational and Administrative Expenses</a></td>
<td class="text">Selling, Informational and Administrative ExpensesSelling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">Research and Development Expenses<span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, less accumulated depreciation&#8212;These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Identifiable intangible assets, less accumulated amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;These assets are recorded at fair value at acquisition. Intangible assets with finite lives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.</span><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amortization of intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as these intangible assets benefit multiple business functions. Amortization of intangible assets that are for a single function and depreciation of property, plant and equipment are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as appropriate.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Specifically:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For indefinite-lived intangible assets, such as brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Property, Plant and Equipment, Impairment</a></td>
<td class="text">We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our business and platform functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as our corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Short-term investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Statement of Cash Flows</a></td>
<td class="text">Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">Investments and Derivative Financial Instruments<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">until realized.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Held-to-maturity debt securities, which are carried at amortized cost.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#8217;s income and expenses in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative financial instruments are carried at fair value in various balance sheet categories (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 7A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">), with changes in fair value reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> or, for derivative financial instruments in certain qualifying hedging relationships, in </span>Other comprehensive income/(loss)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Tax Assets and Liabilities and Income Tax Contingencies</a></td>
<td class="text">Tax Assets and Liabilities and Income Tax Contingencies<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Assets and Liabilities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Current tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Global Intangible Low-Taxed Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> as of December 31, 2021 and 2020 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5D</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for uncertain tax positions and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 5A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Income Tax Contingencies</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#8220;more likely than not&#8221;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Pension and Postretirement Benefit Plans</a></td>
<td class="text">Pension and Postretirement Benefit Plans<span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Legal and Environmental Contingencies</a></td>
<td class="text">Legal and Environmental ContingenciesWe and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms with the related costs recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales, Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, as appropriate.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $381 million in 2021, $380 million in 2020 and $326 million in 2019. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611066312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Change in Accounting Principle</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.661%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.745%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.603%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The impacts of the adjustments on our consolidated financial statements are summarized as follows:</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(Gain) on completion of Consumer Healthcare JV transaction</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(8,086)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(8,107)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,820)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,058)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,878)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,058</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,584&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(212)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(35)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(82)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income before allocation to noncontrolling interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,420</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">22,025</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20,374</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">21,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(457)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(246)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">16,026&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;basic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.73&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.88&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Earnings per common share&#8211;&#8211;diluted</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.93</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">0.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3.85</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.71&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="57" style="border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Comprehensive Income:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Benefit plans: actuarial gains/(losses), net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(826)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">285</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(276)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(241)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Reclassification adjustments related to settlements, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">209</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(209)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">278&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(278)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(274)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">545</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(349)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(227)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Deferred taxes from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,449)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,575)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Benefit plan contributions in excess of expense/income</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,058)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,790)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,242)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(288)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(55)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous<br/>Accounting<br/>Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Reported</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Previous Accounting Principle</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of Change</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">As Adjusted</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Noncurrent deferred tax assets and other noncurrent tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,320</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,679</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,679</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,879&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Pension benefit obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,489</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,489</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,766&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">101,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103,394</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,378)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,313)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,583)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,688)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,378&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Information About Balance Sheet Classification of Accruals</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:70.392%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.631%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.185%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve against </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,077</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,017&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">528</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued rebates and other sales-related accruals</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,850</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,708&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e725-108305<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615969080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract', window );"><strong>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summarized Financial Information of Discontinued Operations</a></td>
<td class="text"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:68.050%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.439%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"> Discontinued operations&#8211;&#8211;net of tax: </span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,572&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,845&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,624&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax income/(loss) from discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(375)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,879&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,056&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income/(loss) from discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(268)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax loss on sale of discontinued operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(211)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit for taxes on income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on sale of discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations&#8212;net of tax, which includes a pre-tax amount for a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345&#160;million; and (ii) the after tax loss of $167&#160;million related to the sale of Meridian recognized in Loss on sale of discontinued operations&#8211;&#8211;net of tax. To a much lesser extent, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-closing adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations&#8212;net of tax. In 2020 and 2019, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">includes pre-tax interest expense of $116 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $223 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of assets and liabilities of discontinued operations and other assets held for sale:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" rowspan="22" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets of discontinued operations and other assets held for sale&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other current liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities of discontinued operations&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other noncurrent liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)Amounts as of December 31, 2021 represent property, plant and equipment held for sale. Amounts as of December 31, 2020 primarily relate to discontinued operations of our former Meridian subsidiary and the Mylan-Japan collaboration.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Summarized Financial Information of Equity Method Investments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.661%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.776%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, the Consumer Healthcare JV, as of September 30, 2021, the most recent period available, and as of September 30, 2020 and for the periods ending September 30, 2021, 2020, and 2019 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,890</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,614&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,445</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,361&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46,335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,975&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,351</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,576&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,705</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net equity</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,400&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.222%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Twelve Months Ending</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Two Months Ending</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,836</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,720&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,439)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(803)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,081</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,281&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,358&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,547</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:72.968%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.971%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summarized financial information for our equity method investee, ViiV, as of December 31, 2021 and 2020 and for the years ending December 31, 2021, 2020, and 2019 is as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,608</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,283&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,171</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,664&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,028&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,536</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,033</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,398&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total net equity/(deficit) attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,862)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,734)</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:68.050%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,380</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,224&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,139&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(574)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,650&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,623&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income attributable to shareholders</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,040</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.695%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;Revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">590</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">s&#8212;Alliance revenues</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,652</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues from collaborative arrangements</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,703&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16,169)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52)</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(194)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(742)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other income/(deductions)&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">820</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents sales to our partners of products manufactured by us.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2021 reflects increases in alliance revenues from Comirnaty, Eliquis and Xtandi, while the increase in 2020 reflects increases in alliance revenues from Eliquis and Xtandi.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The increase in 2021 is primarily related to Comirnaty.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. </span></div>(f)Primarily relates to royalties from our collaboration partners.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611086072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.425%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges/(credits):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee terminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exit costs/(credits)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges/(credits)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">741</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integration costs and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Restructuring charges and certain acquisition-related costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">802</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">601&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(63)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">recorded in our consolidated statements of income as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">63</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Implementation costs recorded in our consolidated statements of income as follows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Selling, informational and administrative expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">426</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total implementation costs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents external costs for banking, legal, accounting and other similar services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2021 costs primarily related to our acquisition of Trillium. 2020 costs primarily related to our acquisition of Array. 2019 costs mainly related to our acquisitions of Array, including $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and Hospira.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:52.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.795%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.097%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components and changes in restructuring accruals:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Termination<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset<br/>Impairment<br/>Charges</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exit Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrual</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2020 </span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">535&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(462)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">680</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">741</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Utilization and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(468)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,071</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes adjustments for foreign currency translation.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($628 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($169 million).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($816 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($255 million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609191928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense)</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:63.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.860%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.165%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(225)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net interest expense</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,255</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,348&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty-related income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(770)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses on asset disposals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,344)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(540)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(454)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(326)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(168)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit costs/(credits) other than service costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain legal matters, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain asset impairments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,792&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business and legal entity alignment costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consumer Healthcare JV equity method (income)/loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(471)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(298)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(687)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(491)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(224)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income)/deductions&#8211;&#8211;net</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,878)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,497&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Capitalized interest totaled $108 million in 2021, $96 million in 2020 and $88 million in 2019.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine and $97 million of milestone income from multiple licensees. 2020 included, among other things, (i) a $75 million upfront payment received from our sale of our CK1 assets to Biogen, (ii) $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, (iii) $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC and (iv) $108 million in milestone income from multiple licensees. 2019 included, among other things, $78 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, a generic of Advair Diskus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(fluticasone propionate and salmeterol inhalation powder) and $52 million in milestone income from multiple licensees.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2019, other non-service cost components&#8217; activity related to the Consumer Healthcare JV transaction, such as gain on settlements, were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes legal reserves for certain pending legal matters. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">2020 represents intangible asset impairment charges associated with our Biopharma segment: (i) $900 million related to IPR&amp;D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts; (ii) $528 million related to Eucrisa, a finite-lived developed technology right acquired in our Anacor acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures; and (iii) $263&#160;million related to finite-lived developed technology rights for certain generic sterile injectables acquired in our Hospira acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures.</span></div><div style="margin-top:1pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2019 primarily included intangible asset impairment charges of $2.8 billion, mainly composed of $2.6 billion, related to Eucrisa, and reflected updated commercial forecasts mainly reflecting competitive pressures.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Mainly represents incremental costs for the design, planning and implementation of our then new business structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and other advisory services.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(h)</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(i)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt">2021 includes, among other things, (i) income net of costs associated with TSAs of $288 million; (ii) dividend income of $166 million from our investment in ViiV and (iii) charges of $142 million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $278 million from our investment in ViiV; (ii) income net of costs associated with TSAs of $114 million and (iii) charges of $105 million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $220&#160;million from our investment in ViiV; (ii) charges of $152 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $138&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633616306328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:67.305%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.587%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.587%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.886%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,064</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,887)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,332&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,247</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,924&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">a), (b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,321&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Taxes on Income</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:65.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.483%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> based on the location of the taxing authorities include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,342</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,887)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(186)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(491)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(131)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total U.S. tax benefit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(964)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(867)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(543)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">TCJA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred Income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total TCJA tax benefit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,769</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(969)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total international tax provision</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,816</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Provision/(benefit) for taxes on income</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:65.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.483%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income from continuing operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. statutory income tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TCJA impact</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxation of non-U.S. operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax settlements and resolution of certain tax positions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certain Consumer Healthcare JV initiatives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. R&amp;D tax credit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate for income from continuing operations</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions,&#8221; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for the components of pre-tax income and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2029. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2047 on income from manufacturing and other operations.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes changes in interest related to our uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221;.</span></div><div style="margin-bottom:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">All other, net is primarily due to routine business operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:50.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.229%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Deferred Tax*</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 Deferred Tax*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Liabilities)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Liabilities)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid/deferred items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,086</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(456)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,114&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(336)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,778</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,355)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">117</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,220)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee benefits</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,594</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructurings and other charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Legal and product liability reserves</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net operating loss/tax credit carryforwards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,431</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unremitted earnings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State and local tax adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">197</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(689)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,545)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,446</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7,714)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,190&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,726)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,462)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,586)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7,714)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,604&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,726)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset/(liability)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,123)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in net deferred tax assets in 2021 is primarily related to temporary differences associated with Comirnaty royalty accruals and the result of operating lease ROU liabilities recognized during the period.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The increase in the deferred tax assets is primarily due to the acquisition of intangible assets relating to Trillium and the decrease in the 2021 deferred tax liabilities is primarily the result of amortization of intangible assets.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase in net deferred tax liabilities in 2021 is primarily the result of operating lease ROU assets recognized during the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease in net deferred tax assets in 2021 is primarily the result of favorable pension plan asset performance reported in the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 11A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amounts in 2021 and 2020 are reduced for unrecognized tax benefits of $3.0 billion and $3.0 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">The decrease in net deferred tax liabilities in 2021 is primarily due to certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV.</span></div><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.6 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.3 billion). In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.9 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($4.1 billion).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:5pt;padding-left:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"><tr><td style="width:1.0%"/><td style="width:65.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.333%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5,595)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,381)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,259)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Divestitures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(232)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases based on tax positions taken during a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decreases based on settlements for a prior period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increases based on tax positions taken during the current period</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(550)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(411)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(383)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impact of foreign exchange</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b), (e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6,068)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,595)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,381)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2020, related to the separation of Upjohn. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to cash payments and reductions of tax attributes.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2021, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($19 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($42&#160;million) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($5 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion). In 2020, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($34 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($18 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.5 billion).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:68.497%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">include:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(119)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on derivative financial instruments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized holding gains/(losses) on available-for-sale securities, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments for (gains)/losses included in net income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit plans: prior service (costs)/credits and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to amortization of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification adjustments related to curtailments of prior service costs and other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Tax provision/(benefit) on other comprehensive income/(loss)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(227)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609191928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the changes, net of tax, in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net Unrealized Gains/(Losses)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Benefit Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments </span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivative Financial Instruments</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Available-For-Sale Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Prior Service (Costs)/ Credits and Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income/(Loss)</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,075)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(68)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,249)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(144)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,936)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(35)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,367)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(448)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Distribution of Upjohn Business</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(397)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,450)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(428)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(5,310)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income/(loss)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(722)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">547</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(6,172)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">377</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(5,897)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and the impact of our net investment hedging program.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611132392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level 2</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,276&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">709</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">709</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Classified as available-for-sale debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;non-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government and agency&#8212;U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,397</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">242</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">259</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,703</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,278&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,501&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Long-term equity securities of $194 million as of December 31, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for U.S. non-qualified employee benefit plans.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Investments</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:73.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes our investments by classification type:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,365</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,014</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,709&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Total Short-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,437&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Long-term investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,809&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">521</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Private equity securities at cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Total Long-term investments</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,054</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Equity-method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,472</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,856&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term investments and equity-method investments</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,526</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,262&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Held-to-maturity cash equivalents</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">268</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represent investments in the life sciences sector.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale and Held-to-maturity Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:21.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.897%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18,032</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,055</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">917</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:21.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.897%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18,032</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,055</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">917</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Held-to-maturity Securities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:21.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.897%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Maturities (in Years)</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Within 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 1<br/>to 5</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Over 5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Available-for-sale debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18,032</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">17,318</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">465</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,593&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,055</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,050</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Corporate and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">698</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">697</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">647</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline">Held-to-maturity debt securities</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Time deposits and other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">917</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Government and agency</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">non-U.S.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">24,029</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,991&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(5)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,124&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock', window );">Schedule of Gains and Losses on Investment Securities</a></td>
<td class="text"><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.013%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity method investments, held at the reporting date:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains)/losses recognized during the period on equity securities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,344)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(540)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(454)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(515)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(429)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $97 million and upward adjustments of $156 million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Borrowings</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:73.526%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.840%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.842%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term borrowings include:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other short-term borrowings, principal amount</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term borrowings, principal amount</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,705&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Short-term borrowings, including current portion of long-term debt</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">, carried at historical proceeds, as adjusted</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes cash collateral. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following outlines our senior unsecured long-term debt and the weighted-average stated interest rate by maturity:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2022 (1.0% for 2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,728&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2023 (3.2% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,550</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2024 (3.9% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2025 (0.8% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2026 (2.9% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2027 (2.1% for 2021 and 2.0% for 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,051</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2028-2032 (3.1% for 2021 and 3.4% for 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,660</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2033-2037 (5.6% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2038-2042 (5.5% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,079</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,086&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2043-2047 (3.7% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,858</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes due 2048-2050 (3.6% for 2021 and 2020)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,500</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt, principal amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,774&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net fair value adjustments related to hedging and purchase accounting</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unamortized discounts, premiums and debt issuance costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(207)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt, carried at historical proceeds, as adjusted</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,133&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,002&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified to the current portion of long-term debt.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Our long-term debt outlined in the above table is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.</span></div><div style="margin-bottom:3pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline">Issuances</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.368%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.253%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In August 2021, we issued the following senior unsecured notes at an effective interest rate of 1.79%:</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></div></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.750%</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August&#160;18, 2031</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Financial Instruments</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.858%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,576</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Schedule of Derivative Assets at Fair Value</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.858%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,576</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:40.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.858%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,576</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">787</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">808</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">717</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">968</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">881</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><br/>Gains/(Losses)<br/>Recognized in OID</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Recognized in OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">488</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(649)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Hedged item </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(369)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">468</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(501)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount excluded from effectiveness testing and amortized into earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">109</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency short-term borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(183)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">All other net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(192)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,077)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions&#8212;net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The amounts reclassified from OCI into COS were:</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net loss of $89 million in 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net gain of $172 million in 2020 (including a gain of $22&#160;million reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $362 million within the next 12 months into income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The amounts reclassified from OCI were reclassified into OID.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Short-term borrowings and long-term debt include foreign currency borrowings which are used as net investment hedges. The short-term borrowings carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of December 31, 2021 and December 31, 2020 were $844 million and $2.1 billion, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:24.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.789%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair<br/>Value Hedging Adjustment<br/>Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair <br/>Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active<br/>Hedging<br/>Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,233</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:24.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.789%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair<br/>Value Hedging Adjustment<br/>Increase/(Decrease) to <br/>Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair <br/>Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active<br/>Hedging<br/>Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Assets/Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Active Hedging Relationships</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued Hedging Relationships</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,233</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,154</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633863477496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories, Current</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,641</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,867&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,424</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,059</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">939</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Component of Inventories, Noncurrent</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:75.800%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,641</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,867&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,424</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Inventories</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,059</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent inventories not included above</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">939</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633608030712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (PP&amp;E) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property, Plant and Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:62.685%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.587%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.886%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Useful Lives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Years)&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33-50</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,998&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8-20</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,252</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3-12.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29,955</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,406&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,074</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,661&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,882</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,745&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-lived Assets by Geographic Areas</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.090%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.062%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides long-lived assets by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,385</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,666&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,056</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">14,882</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,745&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609388104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.213%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">73,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,532)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55,838)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,714</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,255&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,493)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,762&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55,838)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25,146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,830&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,493)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,337&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.209%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.213%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Identifiable<br/>Intangible<br/>Assets, less<br/>Accumulated<br/>Amortization</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Finite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">73,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(53,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">19,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,532)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,292&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,187)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">76,552</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55,838)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,714</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,255&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,493)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,762&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Indefinite-lived intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,175&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Licensing agreements and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identifiable intangible assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">80,984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(55,838)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25,146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,830&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(52,493)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,337&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.24pt">The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Amortization Expense</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:40.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.817%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the expected annual amortization expense:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,686&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,449&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components and changes in the carrying amount of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,181&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">727&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,556&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">49,208</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other represents the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633607776024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Net Periodic Benefit Costs</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.895%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes the components of net periodic benefit cost/(credit), including those reported as part of discontinued operations for 2020 and 2019, and the changes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income/(loss) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">for our benefit plans:</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,015)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(890)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(170)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains)/losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(165)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Special termination benefits</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit) reported in income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,265)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(746)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(372)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(282)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(271)</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost/(credit) reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other comprehensive income/(loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost/(credit) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Comprehensive income</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,264)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(742)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(168)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(107)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects actuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates, and actuarial remeasurement losses in 2020 and 2019, primarily due to decreases in discount rates partially offset by favorable plan asset performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(PERCENTAGES)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions used to determine net periodic benefit cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension plans/postretirement plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate of compensation increase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Schedule of Health Care Cost Trend Rates</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:75.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.780%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year that the rate reaches the ultimate trend rate</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2045</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2037&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures/other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,001&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Amounts recorded in our consolidated balance sheet: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,084)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(645)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock', window );">Schedule of Amounts Recognized in Balance Sheet</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures/other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,001&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Amounts recorded in our consolidated balance sheet: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,084)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(645)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock', window );">Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures/other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,001&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Amounts recorded in our consolidated balance sheet: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,084)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(645)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures/other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,001&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Amounts recorded in our consolidated balance sheet: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,084)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(645)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. </span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in benefit obligation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, beginning</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,306</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,886&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,059&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in actuarial assumptions and other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,016)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(320)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(218)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures/other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments and special termination benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation, ending</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17,150</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,001&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Change in plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">588</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,405</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,433&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee contributions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(229)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Upjohn spin-off</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(687)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions/divestitures, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(767)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(445)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(372)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets, ending</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Amounts recorded in our consolidated balance sheet: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">447</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,480</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,084)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,681)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(645)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(805)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,211)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(928)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,191)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(651)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax components of cumulative amounts recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (costs)/credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">581</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with an ABO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,674&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ABO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Information related to the funded status of pension plans with a PBO in excess of plan assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,735&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PBO</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,371</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,306&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,447&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.072%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.679%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.405%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.001%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">The following provides the components of plan assets, including those reported as part of discontinued operations for 2020:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Target Allocation Percentage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level <br/>2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level<br/>&#160;2</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Assets Measured at NAV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. pension plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,326</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20-40%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Global equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,233</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,213&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,352</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,152</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45-75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,566</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,476&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,533</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,079</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,076</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other commingled funds</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,009</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">16,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,332</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,726</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,094&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,103&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,684&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">International pension plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10-20%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,386</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">67</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,051&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">45-70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,415</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,334&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fixed income commingled funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,217&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">15-35%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Partnership investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,273</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,431</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">141</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">404</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">886</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,729</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,672</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,677</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,811&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,681&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,707&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline">U.S. postretirement plans</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0-5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95-100%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">669</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">669</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">753</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">750</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Government and agency obligations are inclusive of repurchase agreements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Mostly includes investments in hedge funds and real estate.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock', window );">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.876%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.167%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.169%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs, including those reported as part of discontinued operations for 2020:</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,362</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held, ending</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases, sales, and settlements, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer into/(out&#160;of) Level 3</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exchange rate changes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, ending</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,677</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,362&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Future Cash Flow Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.453%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the expected future cash flow information related to our benefit plans:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postretirement Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected employer contributions:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected benefit payments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,140&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027&#8211;2031</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,908&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,124&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609330024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Summary of Common Stock Purchases</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"/><td style="width:46.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.616%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.768%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our ASR:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2020</span></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of common stock purchased</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of purchase</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents shares purchased pursuant to the ASR with Goldman Sachs &amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633608169672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Share-based Compensation Awards and Valuation Details</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">A summary of the awards and valuation details:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Total Shareholder Return Units (TSRUs)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(a), (b)</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management and select  employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107">five</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03">seven</span>-year term, if and to the extent the total value is positive.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using a Monte Carlo simulation model</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Units (RSUs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For RSUs granted, in virtually all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portfolio Performance Shares (PPSs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#8217;s long-term product portfolio during a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfMTA5OTUxMTYyODQ4MQ_0da09f05-3e8c-4080-bb4d-fc5dd48fbbca">three</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNDQz_4d00d2e4-77a0-4861-9e03-9cd48bf4e5b8">five</span>-year performance period from the year of the grant date, as applicable.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Performance Share Awards (PSAs)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Senior and other key management</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">Adjusted net income over three <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg5_e6c42dac-714f-4f5e-996c-4d0353676184">one</span>-year periods; and</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt">TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNDg1_fcbb828a-fc1b-45e8-92d8-b04179945bfd">three</span>-year performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Breakthrough Performance Awards (BPAs)</span></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDk_1531252f-ed7d-4bb0-98f0-50eaa78bb5c6">one</span>-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer&#8217;s product pipeline during the performance period.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt">The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%">As of the grant date using the intrinsic value method using the closing price of our common stock</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the probable vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#8217;s assessment of the probability that the specified performance criteria will be achieved and/or management&#8217;s assessment of the probable vesting term.</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Awarded to</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Terms</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Valuation</span></td><td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Recognition and Presentation</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock Options</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Select employees</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt">Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years. </span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of the grant date using the Black-Scholes-Merton option-pricing model</span></td><td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortized on a straight-line basis over the vesting term into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, and/or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, as appropriate.</span></div></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#8217; original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (1,444,395 PTSRUs) and 361,099 PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $30.31 and at a GDFV of $5.54 per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-based Payment Arrangement Activity</a></td>
<td class="text"><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.118%"/><td style="width:0.1%"/></tr><tr><td colspan="93" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PPSs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total fair value of shares vested</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$7.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$6.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$8.52</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$304</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$334</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$454</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$181</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$119</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$136</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$33</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$64</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$4.86</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$3.56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$5.98</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total intrinsic value of options exercised or share units converted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$594</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$84</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$175</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$228</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$224</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$245</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$584</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$293</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$261</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash received upon exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$795</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$425</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$394</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Tax benefits realized from exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$106</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$47</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Compensation cost recognized, pre-tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$259</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$287</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$294</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$281</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$272</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$275</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$535</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$180</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$114</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$76</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total compensation cost related to nonvested awards not yet recognized, pre-tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$187</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$224</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$229</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$271</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$228</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$241</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$175</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$87</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$54</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$32</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$34</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$5</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted-average period over which cost is expected to be recognized (years)</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.8</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.6</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.6</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Weighted-average GDFV per TSRUs and stock options.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">TSRU includes expense for PTSRUs, which is not significant for all years presented.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.459%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.757%"/><td style="width:0.1%"/></tr><tr><td colspan="69" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of all TSRU, RSU, PPS, PSA and BPA activity during 2021 (with the shares granted representing the maximum award that could be achieved for PPSs, PSAs and BPAs):</span></div></td></tr><tr style="height:12pt"><td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PPSs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSAs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BPAs</span></td></tr><tr style="height:5pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">TSRUs&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="9" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Per TSRU, Weighted Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;Weighted Avg. GDFV per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shares&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Weighted Avg. Intrinsic Value per share</span></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">GDFV</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Grant Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nonvested, </span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2020</span></div></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129,844</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.90&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32.94&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,692</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35.50&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,077</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36.81&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,264</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36.81&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34,522</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10,893</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,632</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,798</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,165</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">38.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(44,888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7.21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30.54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(8,747)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.66</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(6,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.88</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.85</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Reinvested dividend equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41.33</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(4,879)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6.77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">33.78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,255)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">35.17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(1,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">41.45</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">47.47</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:18pt"><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Nonvested, December 31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">114,599</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">34.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">25,540</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">35.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21,480</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,154</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">859</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59.05</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1&#160;million.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.551%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of TSRU and PTU information as of December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a), (b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TSRUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PTUs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average<br/>Grant&#160;Price<br/>Per TSRU</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Contractual Term </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">206,996</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">31.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,969</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">92,398</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28.72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,946</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs Expected to vest</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">110,476</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34.16</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,910</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs exercised and converted to PTUs</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,074</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.8</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, we settled 46,060,346 TSRUs with a weighted-average grant price of $23.04 per unit.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, 7,093,787 TSRUs with a weighted-average grant price of $27.41 per unit were converted into 2,943,737 PTUs.</span></div><div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.102%"/><td style="width:0.1%"/></tr><tr><td colspan="39" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TSRUs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected dividend yield </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(based on a constant dividend yield during the expected term)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.36&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4.51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.36&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on interpolated yield on U.S. Treasury zero-coupon issues)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">0.93</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1.27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expected stock price volatility</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on implied volatility, after consideration of historical volatility)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26.53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26.54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TSRUs contractual/stock options expected term, years</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> (based on historical exercise and post-vesting termination patterns for stock options) </span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5.15</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.13</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6.75</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.75</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.75</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.461%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Summary of all stock option activity during 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise Price<br/>Per Share</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining Contractual Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Years)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intrinsic Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Millions)</span></div></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75,402&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.31&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33.82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(31,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25.75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34.39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20.27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding, December 31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,874</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,295</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vested and expected to vest, December 31, 2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">44,747</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30.19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,291</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable, December 31, 2021</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41,583</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">29.81</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.3</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Market price of our underlying common stock less exercise price.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The number of options expected to vest takes into account an estimate of expected forfeitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609317512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earning Per Share</a></td>
<td class="text"><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:66.411%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.035%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following presents the detailed calculation of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">EPS:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(IN MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,025&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Numerator&#8211;&#8211;Diluted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">22,414</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,708&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">21,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,159&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,026&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">EPS Denominator</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,555&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,569&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,708</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,632&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,675&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anti-dilutive common stock equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609840120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Assets and Liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.751%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.949%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ROU assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_408086e2-3444-4b88-b89b-d101186f774f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_46ee31d6-1f28-4ba5-b2be-d5c564d17665">Other noncurrent assets</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,839</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liabilities (short-term)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_74739711-6874-4a56-93f6-73a0506beaac"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_8b4b2c6e-76ae-4492-a995-73bb701632ff">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">449</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease liabilities (long-term)</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b27ac467-c383-4750-82e2-f39d2460df2f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b50ecd3f-01e3-4abd-991d-dc5d329b8f81">Other noncurrent liabilities</span></span></span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs and Other Supplemental Information</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:52.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.019%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.023%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Components of total lease cost includes:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">548</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">381</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">888</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.949%"/><td style="width:0.1%"/></tr><tr><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other supplemental information follows:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Remaining Contractual Lease Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-Average Discount Rate</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.932%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="21" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">387</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains)/losses on sale and leaseback transactions, net</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.304%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.752%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2021:</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating Lease Liabilities</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Next one year</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">520</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-2 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">417</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-3 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3-4 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-5 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">217</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,621</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Imputed interest</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,960</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">449</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent portion</span></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,510</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>(a)Reflects lease payments due within 12 months subsequent to the balance sheet date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615636840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information by Segment</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"/><td style="width:27.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.137%"/><td style="width:0.1%"/></tr><tr><td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following table provides selected income statement information by reportable segment:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Earnings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depreciation and Amortization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS OF DOLLARS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reportable Segment:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Biopharma</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">79,557</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">40,226</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">27,089&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,439</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other business activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,892&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(10,396)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12,308)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(11,216)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">598</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reconciling Items:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(3,175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3,117)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">3,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3,047&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acquisition-related costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Certain significant items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,584)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,456&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">81,288</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,651&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40,905&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">24,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,036&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">11,321&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">5,191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4,681&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $2.1 billion charge for IPR&amp;D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $1.3&#160;billion ($450 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and (iii) upfront and milestone payments on collaborative and licensing arrangements of $1.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (v) gains on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. For Earnings in 2020, includes, among other items; (i) charges of $1.7 billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) actuarial valuation and other pension and postretirement plan losses of $1.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $791 million ($197 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $8.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $2.8 billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) actuarial valuation and other pension and postretirement plan losses of $750 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 2A, 2C, 3 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span>4.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.063%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes revenues by geographic area:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">29,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,455&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,326&#160;</span></td><td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18,336</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,788&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,729&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed Rest of World</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,506</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,036&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Markets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20,701</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,372&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Revenues</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81,288</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,651&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,905&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.063%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">McKesson, Inc.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Significant Product Revenues</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The following provides detailed revenue information for several of our major products:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:20.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TOTAL REVENUES</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">81,288</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,651&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a), (b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">79,557</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">40,724&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">38,013&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Vaccines</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">42,625</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,575&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,504&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8pt;padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Comirnaty direct sales and alliance revenues</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Active immunization to prevent COVID-19</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">36,781</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Prevnar family</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pneumococcal disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,272</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nimenrix</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Meningococcal ACWY disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">193</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">FSME-IMMUN/TicoVac</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tick-borne encephalitis disease</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Trumenba</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Meningococcal B disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Vaccines</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">12,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">10,867&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,014&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Ibrance</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">HR-positive/HER2-negative metastatic breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,437</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,392&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,961&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xtandi alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">mCRPC, nmCRPC, mCSPC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">838&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inlyta</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sutent</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">673</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bosulif</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">540</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xalkori</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALK-positive and ROS1-positive advanced NSCLC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">493</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Ruxience</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Non-hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#8217;s Granulomatosis) and microscopic polyangiitis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">491</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Retacrit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Anemia</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zirabev</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Lorbrena</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ALK-positive metastatic NSCLC</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Aromasin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Post-menopausal early and advanced breast cancer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Trazimera</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%">HER-positive breast cancer and metastatic stomach cancers</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">197</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Besponsa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Relapsed or refractory B-cell acute lymphoblastic leukemia </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">192</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Braftovi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Mektovi for metastatic melanoma in patients with a BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E/K </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">mutation and, in combination with Erbitux</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> (cetuximab), for the treatment of BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">-mutant mCRC after prior therapy</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bavencio alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">178</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Mektovi</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">In combination with Braftovi for metastatic melanoma in patients  with a BRAF</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">V600E/K</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"> mutation</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Oncology</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Internal Medicine</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">9,329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">9,003&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">8,790&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Eliquis alliance revenues and direct sales</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,970</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,949&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,220&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Premarin family</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Symptoms of menopause</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">563</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">680&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Chantix/Champix</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">398</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">919&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">BMP2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Development of bone and cartilage</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">266</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Toviaz</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Overactive bladder</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Pristiq</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Depression</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Internal Medicine</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,758&#160;</span></td><td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:20.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.460%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.183%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">(MILLIONS)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PRIMARY INDICATION OR CLASS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Hospital</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7,301</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,777&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">6,695&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sulperazon</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">683</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Medrol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Anti-inflammatory glucocorticoid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">432</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zavicefta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">413</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fragmin</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Treatment/prevention of venous thromboembolism</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">305</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zithromax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">278</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vfend</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Fungal infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Tygacil</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Precedex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Sedation agent in surgery or intensive care</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Zyvox</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Bacterial infections</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Paxlovid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">COVID-19 Infection (</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">high risk population)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">76</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">IVIg Products</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Anti-infectives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,294&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Hospital</span></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,412</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Inflammation &amp; Immunology (I&amp;I)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">4,431</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,567&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,733&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Xeljanz</span></div></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,455</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Enbrel (Outside the U.S. and Canada)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,699&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Inflectra/Remsima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%">Crohn&#8217;s disease, pediatric Crohn&#8217;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other I&amp;I</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">134</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rare Disease</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">3,538</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,278&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Vyndaqel/Vyndamax</span></td><td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">ATTR-cardiomyopathy and polyneuropathy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">BeneFIX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hemophilia B</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Genotropin</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Replacement of human growth hormone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">389</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Refacto AF/Xyntha</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Hemophilia A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Somavert</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Acromegaly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">277</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">All other Rare Disease</span></div></td><td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">115</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">PFIZER CENTREONE</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">1,731</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">CONSUMER HEALTHCARE BUSINESS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(f)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">2,082&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total Alliance revenues</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">7,652</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,418&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">4,648&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Biosimilars</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">2,343</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sterile Injectable Pharmaceuticals</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(g)</span></div></td><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">5,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,315&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%">5,013&#160;</span></td><td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). </span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(f)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">On July&#160;31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare JV. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(g)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610723064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>operatingSegment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | operatingSegment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Decrease to retained earnings</a></td>
<td class="num">$ (103,394)<span></span>
</td>
<td class="num">$ (90,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Increase to AOCI</a></td>
<td class="num">(5,897)<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember', window );">Change in Accounting Principle, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Decrease to retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Increase to AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue [Member] | Top Nine Products [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskAmount', window );">Concentration risk, amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue [Member] | Top Seven Products [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskAmount', window );">Concentration risk, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue [Member] | Top Six Products [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskAmount', window );">Concentration risk, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConcentrationRiskAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConcentrationRiskAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TopNineProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TopNineProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TopSevenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TopSevenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TopSixProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TopSixProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603452408">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfIncomeAbstract', window );"><strong>Consolidated Statements of Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">(Gain) on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (8,107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,878)<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
<td class="nump">24,311<span></span>
</td>
<td class="nump">7,036<span></span>
</td>
<td class="nump">11,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,025<span></span>
</td>
<td class="nump">9,195<span></span>
</td>
<td class="nump">16,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,979<span></span>
</td>
<td class="nump">$ 9,159<span></span>
</td>
<td class="nump">$ 16,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.92<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">2.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.93<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
<td class="nump">1.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.45<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (682)<span></span>
</td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">71<span></span>
</td>
<td class="num">(227)<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Consolidated Statements of Cash Flows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,293)<span></span>
</td>
<td class="num">(1,575)<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,123)<span></span>
</td>
<td class="num">(1,242)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,341<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,489<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">103,394<span></span>
</td>
<td class="nump">90,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,897)<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=pfe_ScenarioPreviousAccountingPrincipleMember', window );">Previous Accounting Principle [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfIncomeAbstract', window );"><strong>Consolidated Statements of Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">(Gain) on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,820)<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="nump">3,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,253<span></span>
</td>
<td class="nump">7,584<span></span>
</td>
<td class="nump">11,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">2,564<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,420<span></span>
</td>
<td class="nump">9,652<span></span>
</td>
<td class="nump">16,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,374<span></span>
</td>
<td class="nump">$ 9,616<span></span>
</td>
<td class="nump">$ 16,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.71<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
<td class="nump">0.97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.63<span></span>
</td>
<td class="nump">1.73<span></span>
</td>
<td class="nump">2.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.65<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="nump">1.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.08)<span></span>
</td>
<td class="nump">0.46<span></span>
</td>
<td class="nump">0.95<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.57<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (731)<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,565<span></span>
</td>
<td class="num">(1,128)<span></span>
</td>
<td class="num">(826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">285<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">209<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">545<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Consolidated Statements of Cash Flows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,746)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,065)<span></span>
</td>
<td class="num">(1,790)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,688)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember', window );">Impact of Change [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfIncomeAbstract', window );"><strong>Consolidated Statements of Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">(Gain) on completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,058)<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,058<span></span>
</td>
<td class="num">(547)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">453<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,605<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,605<span></span>
</td>
<td class="num">$ (457)<span></span>
</td>
<td class="num">$ (246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.29<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.28<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Income:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="num">$ (185)<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial gains/(losses), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,565)<span></span>
</td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(285)<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(475)<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract', window );"><strong>Consolidated Statements of Cash Flows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">453<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,058)<span></span>
</td>
<td class="nump">$ 547<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,378)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,378<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedStatementsOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Cash Flows</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedStatementsOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConsolidatedStatementsOfIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConsolidatedStatementsOfIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=pfe_ScenarioPreviousAccountingPrincipleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=pfe_ScenarioPreviousAccountingPrincipleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611107256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndOtherSalesRelatedAccruals', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">$ 5,850<span></span>
</td>
<td class="nump">$ 4,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Trade accounts receivable, less allowance for doubtful accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndOtherSalesRelatedAccruals', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">3,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndOtherSalesRelatedAccruals', window );">Total accrued rebates and other sales-related accruals</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RebatesAndOtherSalesRelatedAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Certain accrued rebates and accrued sales returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RebatesAndOtherSalesRelatedAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Accrued Liabilities [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603752440">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Acquisitions (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2021</div></th>
<th class="th"><div>Jul. 30, 2019</div></th>
<th class="th"><div>Jul. 01, 2019</div></th>
<th class="th"><div>Nov. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,208<span></span>
</td>
<td class="nump">49,556<span></span>
</td>
<td class="nump">48,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_TrilliumMember', window );">Trillium [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=pfe_TrilliumMember', window );">Trillium [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionSharePrice', window );">Asset acquisition, share price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge to research and development expenses in connection with asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionAssetsAcquired', window );">Asset acquisition, assets acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionLiabilitiesAssumed', window );">Asset acquisition, liabilities assumed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember', window );">Therachon Asset Acquisition [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge to research and development expenses in connection with asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment', window );">Upfront payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum', window );">Maximum potential milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquisition, consideration transferred, equity interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, cash portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Assumed long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member] | Restructuring Charges And Acquisition-Related Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Post closing compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Array [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired intangible assets, useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member] | Array [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Reduction in intangible assets due to measurement period adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | Array [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember', window );">Licensing Agreements, Technology In Development [Member] | Array [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember', window );">Licensing Agreements, Developed Technology [Member] | Array [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Liabilities Assumed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Share Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_TrilliumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_TrilliumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pfe_TrilliumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pfe_TrilliumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633600392232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Divestitures (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 13, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 997,000,000<span></span>
</td>
<td class="nump">$ 5,222,000,000<span></span>
</td>
<td class="nump">$ 4,942,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Reduction in retained earnings</a></td>
<td class="num">$ (103,394,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103,394,000,000)<span></span>
</td>
<td class="num">(90,392,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Notes Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Notes Due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 342,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash received for disposition</a></td>
<td class="nump">51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on sale of discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">167,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember', window );">Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] | Upjohn Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Reduction in retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Cash divested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax', window );">Net increase to accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Derecognition of net gains on foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax', window );">Derecognition of prior service credits associated with benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Separation-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000,000<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_PurchaserOfMeridianMember', window );">Purchaser of Meridian [Member] | Manufacturing and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod', window );">Period of continuing involvement after disposal, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_PurchaserOfMeridianMember', window );">Purchaser of Meridian [Member] | Minimum [Member] | Transition Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_PurchaserOfMeridianMember', window );">Purchaser of Meridian [Member] | Maximum [Member] | Transition Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ViatrisMember', window );">Viatris [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NontradeReceivablesCurrent', window );">Nontrade receivables</a></td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="nump">$ 401,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities', window );">Payment pursuant to terms of the separation agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 277,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ViatrisMember', window );">Viatris [Member] | Minimum [Member] | Manufacturing and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ViatrisMember', window );">Viatris [Member] | Maximum [Member] | Transition Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ViatrisMember', window );">Viatris [Member] | Maximum [Member] | Manufacturing and Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ViatrisMember', window );">Viatris [Member] | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member] | Upjohn Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncAndUpjohnFinanceBVMember', window );">Upjohn Inc and Upjohn Finance B.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncAndUpjohnFinanceBVMember', window );">Upjohn Inc and Upjohn Finance B.V. [Member] | Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnIncMember', window );">Upjohn Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member', window );">Upjohn Finance B.V. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_ViatrisMember', window );">Viatris [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned', window );">Ratio, shares received for each share held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.124079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_ViatrisMember', window );">Viatris [Member] | Mylan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned', window );">Ratio, shares received for each share held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest, ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operation, Period of Continuing Involvement after Disposal, Extension Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operation, Ratio, Shares Received for Each Share Owned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Net Reclassification Adjustment from AOCI, After Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Pursuant to Terms of Separation Agreement, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NontradeReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NontradeReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e709-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116633155&amp;loc=d3e31531-110899<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_UpjohnIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_UpjohnIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_PurchaserOfMeridianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_PurchaserOfMeridianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AgreementAxis=pfe_ManufacturingAndSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AgreementAxis=pfe_ManufacturingAndSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AgreementAxis=pfe_TransitionServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AgreementAxis=pfe_TransitionServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ViatrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ViatrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnIncAndUpjohnFinanceBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnIncAndUpjohnFinanceBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_UpjohnFinanceB.V.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pfe_ViatrisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pfe_ViatrisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_MylanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_MylanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603638488">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Discontinued Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (434)<span></span>
</td>
<td class="nump">$ 2,529<span></span>
</td>
<td class="nump">$ 5,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Income Statement Disclosures</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">7,572<span></span>
</td>
<td class="nump">10,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">2,106<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">1,682<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Amortization of intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax', window );">Pre-tax income/(loss) from discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(375)<span></span>
</td>
<td class="nump">2,879<span></span>
</td>
<td class="nump">6,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod', window );">Provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax', window );">Income/(loss) from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Pre-tax loss on sale of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Benefit for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on sale of discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(434)<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">$ 5,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations and other assets held for sale&#8211;&#8211;Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Identifiable intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent assets of discontinued operations&#8211;&#8211;Other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations&#8211;&#8211;Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Noncurrent liabilities of discontinued operations&#8211;&#8211;Other noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member] | Upjohn Inc and Upjohn Finance B.V. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member] | Upjohn Finance B. V.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses', window );">Pre-tax charges related to remeasurement of Euro debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Loss on sale of discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member] | Epi Pen [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes legal reserves for certain pending legal matters.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations&#8212;net of tax, which includes a pre-tax amount for a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345&#160;million; and (ii) the after tax loss of $167&#160;million related to the sale of Meridian recognized in Loss on sale of discontinued operations&#8211;&#8211;net of tax. To a much lesser extent, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-closing adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations&#8212;net of tax. In 2020 and 2019, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8212;net of tax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">includes pre-tax interest expense of $116 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $223 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Amounts as of December 31, 2021 represent property, plant and equipment held for sale. Amounts as of December 31, 2020 primarily relate to discontinued operations of our former Meridian subsidiary and the Mylan-Japan collaboration.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Costs and Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Foreign Denominated Debt Remeasurement Gains (Losses)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_UpjohnIncAndUpjohnFinanceBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_UpjohnIncAndUpjohnFinanceBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_UpjohnFinanceBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_UpjohnFinanceBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610498056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Equity Method Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">$ 8,107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,472,000,000<span></span>
</td>
<td class="nump">16,856,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfTax', window );">Gain on completion of transaction, after-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300,000,000<span></span>
</td>
<td class="nump">16,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Dividend received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity method investment earnings</a></td>
<td class="nump">$ 47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="nump">417,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investments</a></td>
<td class="nump">15,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Underlying equity in net assets</a></td>
<td class="nump">11,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Difference between carrying amount and underlying equity</a></td>
<td class="nump">$ 4,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000,000<span></span>
</td>
<td class="nump">$ 278,000,000<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_GSKMember', window );">GSK [Member] | Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_GSKConsumerHealthcareMember', window );">Consumer Healthcare JV [Member] | Held-for-sale, Not Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss', window );">Pre-tax income attributable to disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 654,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod', window );">Excess basis amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod', window );">Excess basis amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Excess Basis Amortization, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Increase (Decrease), Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125513658&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610886072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total net equity/(deficit) attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,447<span></span>
</td>
<td class="nump">$ 63,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_GSKConsumerHealthcareMember', window );">Consumer Healthcare JV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total net equity/(deficit) attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="num">(803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV [Member] | ViiV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total net equity/(deficit) attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Income attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611181608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Licensing Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ValnevaSEMember', window );">Valneva [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1', window );">Maximum potential consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure', window );">Potential early commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage', window );">Development cost ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ValnevaSEMember', window );">Valneva [Member] | Research and Development Expense [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Payment for licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | Akcea And Ionis [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Payment for licensing arrangement</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Commercialization Milestones, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contingent Payments, Maximum Exposure1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Development Milestone, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ValnevaSEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ValnevaSEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633599144536">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Collaborative Arrangements (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 30, 2021</div></th>
<th class="th"><div>Dec. 24, 2021</div></th>
<th class="th"><div>Jul. 21, 2021</div></th>
<th class="th"><div>Dec. 26, 2020</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 03, 2021</div></th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 29, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76,552,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,255,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,552,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,552,000,000<span></span>
</td>
<td class="nump">$ 76,255,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,829,000,000<span></span>
</td>
<td class="nump">9,393,000,000<span></span>
</td>
<td class="nump">$ 8,385,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 73,346,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,040,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,346,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,346,000,000<span></span>
</td>
<td class="nump">73,040,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742,000,000<span></span>
</td>
<td class="nump">$ 192,000,000<span></span>
</td>
<td class="num">$ (104,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Arvinas, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | CStone [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount', window );">Committed investment from collaborator</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | BioNTech [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Beam [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage', window );">Development cost ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure', window );">Potential future milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1', window );">Maximum potential consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Beam [Member] | Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrepaymentsandPaymentstoCollaborators', window );">Payment to collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Beam [Member] | Beam [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage', window );">Development cost ownership percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Arvinas, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount', window );">Committed investment from collaborator</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementMilestonePaymentUponApproval', window );">Collaborative arrangement, milestone payment upon approval (up to)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing', window );">Collaborative arrangement, milestone payment upon commercializing</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Arvinas, Inc [Member] | Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrepaymentsAndPaymentsToCollaboratorsCash', window );">Cash payment to collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment', window );">Upfront payment and premium paid in equity investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 706,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Myovant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrepaymentsandPaymentstoCollaborators', window );">Payment to collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne', window );">Maximum reimbursement due from collaborators, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo', window );">Maximum reimbursement due from collaborators, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure', window );">Potential milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementUpfrontAndMilestonePayments', window );">Milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementTieredSalesMilestonePayments', window );">Collaborative Arrangement, tiered sales milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Myovant [Member] | Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | BioNTech [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount', window );">Committed investment from collaborator</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | BioNTech [Member] | Shingles Vaccine Program, mRNA-Based [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrepaymentsandPaymentstoCollaborators', window );">Payment to collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure', window );">Potential future milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount', window );">Committed investment from collaborator</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | BioNTech [Member] | Shingles Vaccine Program, mRNA-Based [Member] | Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrepaymentsAndPaymentsToCollaboratorsCash', window );">Cash payment to collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | BioNTech [Member] | Coronavirus Vaccine Program, mRNA-Based [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure', window );">Potential future milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1', window );">Maximum potential consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 748,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrepaymentsAndPaymentsToCollaboratorsCash', window );">Cash payment to collaborators</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount', window );">Committed investment from collaborator</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed', window );">Percentage of costs to be reimbursed</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | BioNTech [Member] | Coronavirus Vaccine Program, mRNA-Based [Member] | Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment', window );">Upfront payment and premium paid in equity investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="18"></td></tr>
<tr><td colspan="18"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1M.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Investment From Collaborator, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contingent Payments, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementContingentPaymentsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementMilestonePaymentUponApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment Upon Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementMilestonePaymentUponApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementMilestonePaymentUponCommercializing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment Upon Commercializing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementMilestonePaymentUponCommercializing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementTieredSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Tiered Sales Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementTieredSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to our partners for payments made upfront as part of a collaborative arrangement and the payments upon the achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrepaymentsAndPaymentsToCollaboratorsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments and Payments to Collaborators, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrepaymentsAndPaymentsToCollaboratorsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrepaymentsandPaymentstoCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments and Payments to Collaborators</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrepaymentsandPaymentstoCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Contingent Payments, Maximum Exposure1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Future Milestone Payments, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Percentage of Costs to be Reimbursed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ArvinasIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ArvinasIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CStoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CStoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BeamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BeamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_BeamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_BeamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ArvinasIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ArvinasIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MyovantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MyovantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_ShinglesVaccineProgramMRNABasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_ShinglesVaccineProgramMRNABasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_CoronavirusVaccineProgramMRNABasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=pfe_CoronavirusVaccineProgramMRNABasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603138728">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 81,288<span></span>
</td>
<td class="nump">$ 41,651<span></span>
</td>
<td class="nump">$ 40,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(30,821)<span></span>
</td>
<td class="num">(8,484)<span></span>
</td>
<td class="num">(8,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(12,703)<span></span>
</td>
<td class="num">(11,597)<span></span>
</td>
<td class="num">(12,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(13,829)<span></span>
</td>
<td class="num">(9,393)<span></span>
</td>
<td class="num">(8,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income/(deductions)&#8212;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,878<span></span>
</td>
<td class="num">(1,219)<span></span>
</td>
<td class="num">(3,497)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,241<span></span>
</td>
<td class="nump">5,703<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(16,169)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(742)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income/(deductions)&#8212;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">820<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">590<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_CopromotionMember', window );">Co-promotion [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">$ 7,652<span></span>
</td>
<td class="nump">$ 5,418<span></span>
</td>
<td class="nump">$ 4,648<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1M.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The increase in 2021 is primarily related to Comirnaty.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Primarily relates to royalties from our collaboration partners.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Represents sales to our partners of products manufactured by us.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2021 reflects increases in alliance revenues from Comirnaty, Eliquis and Xtandi, while the increase in 2020 reflects increases in alliance revenues from Eliquis and Xtandi.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_CopromotionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_CopromotionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610247464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts', window );">Total costs incurred</a></td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember', window );">Business Integration Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Focused Company Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost incurred to date</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Focused Company Plan [Member] | Biopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost incurred to date</a></td>
<td class="nump">856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs (income)</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Focused Company Plan [Member] | Corporate Enabling Functions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Focused Company Plan [Member] | Go-to Market Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Focused Company Plan [Member] | Manufacturing Optimization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage', window );">Percentage of non-cash restructuring charges expected</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember', window );">2017-2019 and Organizing for Growth [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member] | Business Integration Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Business Integration Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs (income)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Acquisition Related Costs and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Noncash Charges, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringandRelatedCostNoncashChargesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CorporateEnablingFunctionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_CorporateEnablingFunctionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_GoToMarketModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_GoToMarketModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610866712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee terminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 680<span></span>
</td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringAssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit costs/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring charges/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">741<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">20<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">41<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="nump">601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">87<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">472<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts', window );">Total costs associated with acquisitions and cost-reduction/productivity initiatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">63<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, Informational and Administrative Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">426<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents external costs for banking, legal, accounting and other similar services.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2021 costs primarily related to our acquisition of Trillium. 2020 costs primarily related to our acquisition of Array. 2019 costs mainly related to our acquisitions of Array, including $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and Hospira.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation Cost [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Acquisition Related Costs and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633616072136">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 741<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_AcquisitionRelatedCostsMember', window );">Acquisition-related Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CostReductionInitiativesMember', window );">Cost Reduction Initiatives [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember', window );">Restructuring Charges And Acquisition-Related Costs [Member] | Array [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Post closing compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_AcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_AcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_CostReductionInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_CostReductionInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633602859624">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 816<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">741<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(468)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(554)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">770<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">474<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(449)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(462)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,014<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember', window );">Asset Impairment Charges [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(53)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(66)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Exit Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">46<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($628 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($169 million).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes adjustments for foreign currency translation.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($816 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($255 million).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633612446488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 798<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">816<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">628<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($816 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($255 million).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($628 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($169 million).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633607152760">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">$ (73)<span></span>
</td>
<td class="num">$ (225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Net interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,255<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty-related income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(770)<span></span>
</td>
<td class="num">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net (gains)/losses on asset disposals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(99)<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains)/losses recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(1,344)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
<td class="num">(454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights', window );">Income from collaborations, out-licensing arrangements and sales of compound/product rights</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit costs/(credits) other than service costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(2,547)<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">182<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Certain asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">86<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessAlignmentCosts', window );">Business and legal entity alignment costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization', window );">Consumer Healthcare JV equity method (income)/loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="num">(471)<span></span>
</td>
<td class="num">(298)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[10]</sup></td>
<td class="num">(687)<span></span>
</td>
<td class="num">(491)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,878)<span></span>
</td>
<td class="nump">$ 1,219<span></span>
</td>
<td class="nump">$ 3,497<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Capitalized interest totaled $108 million in 2021, $96 million in 2020 and $88 million in 2019.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine and $97 million of milestone income from multiple licensees. 2020 included, among other things, (i) a $75 million upfront payment received from our sale of our CK1 assets to Biogen, (ii) $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, (iii) $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC and (iv) $108 million in milestone income from multiple licensees. 2019 included, among other things, $78 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, a generic of Advair Diskus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(fluticasone propionate and salmeterol inhalation powder) and $52 million in milestone income from multiple licensees.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2019, other non-service cost components&#8217; activity related to the Consumer Healthcare JV transaction, such as gain on settlements, were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Includes legal reserves for certain pending legal matters.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">2020 represents intangible asset impairment charges associated with our Biopharma segment: (i) $900 million related to IPR&amp;D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts; (ii) $528 million related to Eucrisa, a finite-lived developed technology right acquired in our Anacor acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures; and (iii) $263&#160;million related to finite-lived developed technology rights for certain generic sterile injectables acquired in our Hospira acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures.2019 primarily included intangible asset impairment charges of $2.8 billion, mainly composed of $2.6 billion, related to Eucrisa, and reflected updated commercial forecasts mainly reflecting competitive pressures.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Mainly represents incremental costs for the design, planning and implementation of our then new business structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and other advisory services.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">2021 includes, among other things, (i) income net of costs associated with TSAs of $288 million; (ii) dividend income of $166 million from our investment in ViiV and (iii) charges of $142 million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $278 million from our investment in ViiV; (ii) income net of costs associated with TSAs of $114 million and (iii) charges of $105 million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $220&#160;million from our investment in ViiV; (ii) charges of $152 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $138&#160;million.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessAlignmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Alignment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessAlignmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603693192">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,264<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">687<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationExternalIncrementalCostsAmount', window );">External incremental costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Net losses on early retirement of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AgreementAxis=pfe_TransitionServiceAgreementMember', window );">Transition Service Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">288<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">97<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_PumaTechnologiesMember', window );">Puma Technologies [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember', window );">Eli Lilly &amp; Company [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_MylanMember', window );">Mylan [Member] | Collaborative Arrangement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale, Not Discontinued Operations [Member] | CK1 Assets Sold To Biogen, Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash received for disposition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndCerevelTherapeuticsLLCMember', window );">BioNTech and Cerevel Therapeutics, LLC [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndSpringWorksMember', window );">BioNTech and SpringWorks [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember', window );">Cortexyme, Inc. and SpringWorks [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">166<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member] | IPR&amp;D [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember', window );">Anacor [Member] | Developed Technology Rights [Member] | Eucrisa [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember', window );">Anacor [Member] | Developed Technology Rights [Member] | Eucrisa [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Developed Technology Rights [Member] | Generic Sterile Injectable Product [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ViiVMember', window );">ViiV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of fair value contingent consideration liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $97 million and upward adjustments of $156 million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">2021 includes, among other things, (i) income net of costs associated with TSAs of $288 million; (ii) dividend income of $166 million from our investment in ViiV and (iii) charges of $142 million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $278 million from our investment in ViiV; (ii) income net of costs associated with TSAs of $114 million and (iii) charges of $105 million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $220&#160;million from our investment in ViiV; (ii) charges of $152 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $138&#160;million.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationExternalIncrementalCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, External Incremental Costs, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationExternalIncrementalCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AgreementAxis=pfe_TransitionServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AgreementAxis=pfe_TransitionServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_PumaTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_PumaTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MylanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MylanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_CK1AssetsSoldToBiogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_CK1AssetsSoldToBiogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndCerevelTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndCerevelTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndSpringWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_BioNTechAndSpringWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EucrisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EucrisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenericSterileInjectableProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenericSterileInjectableProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ViiVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ViiVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633612924168">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,064<span></span>
</td>
<td class="num">$ (2,887)<span></span>
</td>
<td class="nump">$ 7,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,247<span></span>
</td>
<td class="nump">9,924<span></span>
</td>
<td class="nump">3,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
<td class="nump">$ 24,311<span></span>
</td>
<td class="nump">$ 7,036<span></span>
</td>
<td class="nump">$ 11,321<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633604384376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Provision for Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 3,342<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="num">$ (1,887)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(3,850)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(491)<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations', window );">Total U.S. tax benefit</a></td>
<td class="num">(964)<span></span>
</td>
<td class="num">(867)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectofTaxCutsandJobsActAbstract', window );"><strong>TCJA</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit', window );">Current income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit', window );">Deferred Income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(187)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">Total TCJA tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InternationalIncomeTaxesAbstract', window );"><strong>International</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current income taxes</a></td>
<td class="nump">2,769<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">48<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(969)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Total international tax provision</a></td>
<td class="nump">2,816<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="nump">1,449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="nump">$ 1,852<span></span>
</td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 583<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Domestic Income Tax Expense (Benefit), Continued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectofTaxCutsandJobsActAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of Tax Cuts and Jobs Act [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectofTaxCutsandJobsActAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InternationalIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>International Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InternationalIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633604429016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Tax benefit from IRS settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount', window );">Deconsolidation gain</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Unremitted earnings of international subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsExcludingInterest', window );">Unrecognized tax benefits excluding associated interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits', window );">Deferred tax assets associated with unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Increase (decrease) of interest on income taxes expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="num">$ (564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">601<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual', window );">Unrecognized accrued interest decrease as a result of cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures', window );">Unrecognized tax benefits, interest on income taxes accrued, decrease resulting from divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember', window );">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits', window );">Deferred tax assets associated with unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember', window );">Other Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits', window );">Deferred tax assets associated with unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_DeferredTaxLiabilitiesNetNoncurrentMember', window );">Deferred Tax Liabilities, Net, Noncurrent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits', window );">Deferred tax assets associated with unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Associated With Unrecognized Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsExcludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Excluding Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsExcludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Decrease Resulting From Divestitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28200-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_DeferredTaxLiabilitiesNetNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_DeferredTaxLiabilitiesNetNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603634216">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory income tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">TCJA impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxation of non-U.S. operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax settlements and resolution of certain tax positions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
<td class="num">(14.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Completion of Consumer Healthcare JV transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent', window );">Certain Consumer Healthcare JV initiatives</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">U.S. R&amp;D tax credit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent', window );">Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">All other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate for income from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions,&#8221; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for the components of pre-tax income and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2029. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2047 on income from manufacturing and other operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Includes changes in interest related to our uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221;.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">All other, net is primarily due to routine business operations.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deduction, Interest on Litigation Settlement, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deduction, Joint Venture Initiatives, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633608108792">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Tax Matters - Deferred Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Prepaid/deferred items - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 4,086<span></span>
</td>
<td class="nump">$ 3,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventories - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">408<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">1,778<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant and equipment - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">117<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee benefits - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">1,594<span></span>
</td>
<td class="nump">1,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges', window );">Restructurings and other charges - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">303<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves', window );">Legal and product liability reserves - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">373<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards', window );">Net operating loss/credit carryforwards - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[6]</sup></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments', window );">State and local tax adjustments - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">197<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Investments - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[7]</sup></td>
<td class="nump">70<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">All other - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">89<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,446<span></span>
</td>
<td class="nump">9,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(1,462)<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes - Deferred tax assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,983<span></span>
</td>
<td class="nump">7,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid/deferred items - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">(456)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventories - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(4,577)<span></span>
</td>
<td class="num">(5,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="num">(1,647)<span></span>
</td>
<td class="num">(1,220)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits', window );">Employee benefits - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="num">(178)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Unremitted earnings - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investments - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[7]</sup></td>
<td class="num">(689)<span></span>
</td>
<td class="num">(3,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">All other - Deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities, gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7,714)<span></span>
</td>
<td class="num">(10,726)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[8]</sup></td>
<td class="nump">$ 1,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,123)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The increase in net deferred tax assets in 2021 is primarily related to temporary differences associated with Comirnaty royalty accruals and the result of operating lease ROU liabilities recognized during the period.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The increase in the deferred tax assets is primarily due to the acquisition of intangible assets relating to Trillium and the decrease in the 2021 deferred tax liabilities is primarily the result of amortization of intangible assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase in net deferred tax liabilities in 2021 is primarily the result of operating lease ROU assets recognized during the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 15</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease in net deferred tax assets in 2021 is primarily the result of favorable pension plan asset performance reported in the period. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 11A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">The amounts in 2021 and 2020 are reduced for unrecognized tax benefits of $3.0 billion and $3.0 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">The decrease in net deferred tax liabilities in 2021 is primarily due to certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.6 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.3 billion). In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.9 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($4.1 billion).</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, State and Local Taxes Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610388104">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Deferred Taxes - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward', window );">Reduction for unrecognized tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember', window );">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember', window );">Noncurrent Deferred Tax Liabilities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.6 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.3 billion). In 2020, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.9 billion), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($4.1 billion).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603551944">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (5,595)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (5,381)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition', window );">Acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures', window );">Divestitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">265<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases based on tax positions taken during a prior period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(111)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(232)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases based on tax positions taken during a prior period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[4]</sup></td>
<td class="nump">103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Decreases based on settlements for a prior period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">24<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases based on tax positions taken during the current period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(550)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(411)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation', window );">Impact of foreign exchange</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther', window );">Other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3],[6]</sup></td>
<td class="nump">40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (6,068)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,595)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (5,381)<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2021, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($19 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($42&#160;million) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($5 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion). In 2020, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($34 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($18 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.5 billion).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2020, related to the separation of Upjohn. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Primarily related to cash payments and reductions of tax attributes.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Decrease Resulting from Divestitures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Period Increase (Decrease), Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610232696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 6,068<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">$ 5,381<span></span>
</td>
<td class="nump">$ 6,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember', window );">Income Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">34<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_CurrentTaxAssetsMember', window );">Other Current Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">42<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember', window );">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember', window );">Noncurrent Deferred Tax Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember', window );">Other Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2021, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($19 million),</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($42&#160;million) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($5 million) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion). In 2020, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($34 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($18 million), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.5 billion).</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_CurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_CurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633607104920">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 43<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">84<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Other comprehensive income (loss), available-for-sale securities, tax, total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax', window );">Benefit plans: prior service (costs)/credits and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to curtailments of prior service costs and other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect', window );">Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 71<span></span>
</td>
<td class="num">$ (227)<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603615256">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 63,473<span></span>
</td>
<td class="nump">$ 63,447<span></span>
</td>
<td class="nump">$ 63,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(589)<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Distribution of Upjohn Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">77,462<span></span>
</td>
<td class="nump">63,473<span></span>
</td>
<td class="nump">63,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income/(Loss) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(5,310)<span></span>
</td>
<td class="num">(5,367)<span></span>
</td>
<td class="num">(5,249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(587)<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Distribution of Upjohn Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(5,897)<span></span>
</td>
<td class="num">(5,310)<span></span>
</td>
<td class="num">(5,367)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(5,450)<span></span>
</td>
<td class="num">(5,936)<span></span>
</td>
<td class="num">(6,075)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(722)<span></span>
</td>
<td class="nump">883<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Distribution of Upjohn Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(6,172)<span></span>
</td>
<td class="num">(5,450)<span></span>
</td>
<td class="num">(5,936)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(428)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">547<span></span>
</td>
<td class="num">(448)<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Distribution of Upjohn Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">119<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-For-Sale Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">116<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(336)<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Distribution of Upjohn Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(220)<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">452<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Distribution of Upjohn Business</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 377<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and the impact of our net investment hedging program.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633599230984">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,365<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,679<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">181,476<span></span>
</td>
<td class="nump">154,229<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">881<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,552<span></span>
</td>
<td class="nump">14,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency debt - non-U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,783<span></span>
</td>
<td class="nump">7,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">697<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,849<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,703<span></span>
</td>
<td class="nump">11,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,014<span></span>
</td>
<td class="nump">9,709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,379<span></span>
</td>
<td class="nump">10,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Money market funds [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,365<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,318<span></span>
</td>
<td class="nump">7,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">647<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Money market funds [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,014<span></span>
</td>
<td class="nump">9,709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,379<span></span>
</td>
<td class="nump">10,276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Money market funds [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,365<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,318<span></span>
</td>
<td class="nump">7,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">647<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">709<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">704<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">709<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">704<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">521<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,397<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">465<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,849<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,849<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">27<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">521<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">548<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">465<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">259<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">808<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">242<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">259<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">808<span></span>
</td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">242<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">476<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">476<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">476<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">476<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">881<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 405<span></span>
</td>
<td class="nump">$ 599<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Long-term equity securities of $194 million as of December 31, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for U.S. non-qualified employee benefit plans.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Investments Excluding Held-To-Maturity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of life settlement contracts accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 30<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73718008&amp;loc=d3e42732-111610<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615647688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent', window );">Long-term equity securities held in trust</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restricted, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNIRestrictedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611152584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 36,195<span></span>
</td>
<td class="nump">$ 37,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Estimated Fair Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633600377160">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,365<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,014<span></span>
</td>
<td class="nump">9,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Total Short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,125<span></span>
</td>
<td class="nump">10,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities with readily determinable fair values</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available-for-sale debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">521<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Held-to-maturity debt securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrivateEquityInvestments', window );">Private equity securities at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">623<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Long-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,054<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,472<span></span>
</td>
<td class="nump">16,856<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total long-term investments and equity-method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,526<span></span>
</td>
<td class="nump">20,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldToMaturityCashEquivalents', window );">Held-to-maturity cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represent investments in the life sciences sector.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldToMaturityCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-To-Maturity Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldToMaturityCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633599185496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments - Debt Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 24,835<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss', window );">Debt securities, gross unrealized losses</a></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity', window );">Debt securities, fair value</a></td>
<td class="nump">24,584<span></span>
</td>
<td class="nump">10,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue', window );">Debt securities maturities, within 1 year, fair value</a></td>
<td class="nump">24,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue', window );">Debt securities maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue', window );">Debt securities maturities, over 5 years, fair value</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency debt - non-U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">18,032<span></span>
</td>
<td class="nump">7,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gain</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized loss</a></td>
<td class="num">(263)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">17,783<span></span>
</td>
<td class="nump">7,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">17,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">17,783<span></span>
</td>
<td class="nump">7,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">4,056<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">4,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">4,055<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">947<span></span>
</td>
<td class="nump">$ 283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Next Twelve Months, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Year Two Through Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269825-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269825-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633611072296">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains)/losses recognized during the period on investments in equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (1,344)<span></span>
</td>
<td class="num">$ (540)<span></span>
</td>
<td class="num">$ (454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains)/losses recognized during the period on equity securities sold during the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">$ (1,264)<span></span>
</td>
<td class="num">$ (515)<span></span>
</td>
<td class="num">$ (429)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $97 million and upward adjustments of $156 million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609190488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative impairment losses and downward price adjustments on equity securities</a></td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative upward price adjustments on equity securities</a></td>
<td class="nump">$ 156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633616059624">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Short-Term Borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 556,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting', window );">Current portion of long-term debt, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,636,000,000<span></span>
</td>
<td class="nump">2,004,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">605,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermDebtGross', window );">Total short-term borrowings, principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,241,000,000<span></span>
</td>
<td class="nump">2,705,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,241,000,000<span></span>
</td>
<td class="nump">$ 2,703,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Commercial paper, weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">360,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear', window );">Line of credit facility, due to expire within one year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">322,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Commercial Paper [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_CreditFacilityExpiring2025Member', window );">Credit Facility Expiring 2025 [Member] | Line of Credit [Member] | Commercial Paper [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes cash collateral. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_CreditFacilityExpiring2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_CreditFacilityExpiring2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610753016">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,195<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">$ 2,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,948<span></span>
</td>
<td class="nump">$ 35,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(195)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,195<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">$ 2,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2023 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="nump">$ 2,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2024 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2025 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2026 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2027 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,051<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2028-2032 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,660<span></span>
</td>
<td class="nump">$ 5,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2033-2037 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,250<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2038-2042 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,079<span></span>
</td>
<td class="nump">$ 6,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2043-2047 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,858<span></span>
</td>
<td class="nump">$ 4,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2048-2050 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified to the current portion of long-term debt.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20282032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20282032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20332037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20332037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20382042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20382042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20432047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20432047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20482050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20482050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633608159592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt, New Issuances (Details) - Senior Notes [Member] - Senior Unsecured Debt, One Point Seven Five Zero Percent, Due August 2031<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.79%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633604371160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt, Narrative (Details)<br> $ in Millions, &#8364; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member', window );">Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
<td class="nump">2.67%<span></span>
</td>
<td class="nump">3.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Senior Unsecured Debt, One Point Nine Five Percent, Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt</a></td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Senior Unsecured Debt, Five Point Eight Zero Percent, Due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Notes Due 2047 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609345352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610850248">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">881<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">808<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">717<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">29,576<span></span>
</td>
<td class="nump">24,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">787<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">717<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,419<span></span>
</td>
<td class="nump">15,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">160<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">164<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">1,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HedgedItemAxis=us-gaap_SalesMember', window );">Sales [Member] | Foreign exchange contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HedgedItemAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HedgedItemAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603676296">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 526<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (582)<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(134)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(192)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember', window );">Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(25)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">488<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(649)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">468<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(501)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(89)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="num">(173)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Interest rate contracts [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged Item</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">78<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">86<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(183)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing and amortized into earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign exchange contracts [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign exchange contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing and amortized into earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign exchange contracts [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (192)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions&#8212;net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The amounts reclassified from OCI were reclassified into OID.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">The amounts reclassified from OCI into COS were:<div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net loss of $89 million in 2021; and</span></div><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net gain of $172 million in 2020 (including a gain of $22&#160;million reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#8211;&#8211;net of tax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $362 million within the next 12 months into income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt.</span></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Short-term borrowings and long-term debt include foreign currency borrowings which are used as net investment hedges. The short-term borrowings carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of December 31, 2021 and December 31, 2020 were $844 million and $2.1 billion, respectively.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610833784">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (134)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (21)<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Amount of pre-tax loss to be reclassified</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(362)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Carrying value of short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember', window );">Foreign Currency Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Carrying value of short-term borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (89)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Remaining period of hedging exposure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">21 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Discontinued Operations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Gain (loss) reclassified from OCI into OID and COS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions&#8212;net,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8212;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610986632">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - Long-term debt [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Hedged Assets Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,233<span></span>
</td>
<td class="nump">$ 2,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,154<span></span>
</td>
<td class="nump">$ 1,149<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633604449512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue', window );">Derivatives in a net liability position</a></td>
<td class="nump">$ 372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral posted</a></td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DerivativeNetReceivablePositionAggregateFairValue', window );">Derivatives in a net receivable position</a></td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Cash collateral received</a></td>
<td class="nump">$ 581<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DerivativeNetReceivablePositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Net Receivable Position, Aggregate Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DerivativeNetReceivablePositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetLiabilityPositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesReceivedAsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesReceivedAsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633607767064">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherFinancialInformationAbstract', window );"><strong>Other Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">$ 2,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">4,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">994<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,059<span></span>
</td>
<td class="nump">8,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories not included above</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Financial Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610694632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Information - Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 24,939<span></span>
</td>
<td class="nump">$ 11,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | Comirnaty direct sales and alliance revenues [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603131240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (PP&amp;E) - Components of Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">$ 29,955<span></span>
</td>
<td class="nump">$ 28,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="nump">15,074<span></span>
</td>
<td class="nump">14,661<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="nump">14,882<span></span>
</td>
<td class="nump">13,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">9,001<span></span>
</td>
<td class="nump">8,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">12,252<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">4,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">$ 3,822<span></span>
</td>
<td class="nump">$ 3,481<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">33 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603209176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant, and Equipment (PP&amp;E) - Long-lived Assets by Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 14,882<span></span>
</td>
<td class="nump">$ 13,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">8,385<span></span>
</td>
<td class="nump">7,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5,094<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610722856">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76,552<span></span>
</td>
<td class="nump">$ 76,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(55,838)<span></span>
</td>
<td class="num">(52,493)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,714<span></span>
</td>
<td class="nump">23,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">4,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">80,984<span></span>
</td>
<td class="nump">80,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable Intangible Assets, less Accumulated Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">25,146<span></span>
</td>
<td class="nump">28,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">827<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,092<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">Licensing Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">513<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">73,346<span></span>
</td>
<td class="nump">73,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(53,732)<span></span>
</td>
<td class="num">(50,532)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">19,614<span></span>
</td>
<td class="nump">22,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | BioNTech [Member] | Comirnaty direct sales and alliance revenues [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Finite-lived intangible assets period increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">922<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(807)<span></span>
</td>
<td class="num">(774)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">Licensing Agreements and Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,284<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,299)<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 985<span></span>
</td>
<td class="nump">$ 1,106<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633613027528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for finite-lived intangible assets</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633612426120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">2,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">$ 2,449<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633613300456">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 49,556<span></span>
</td>
<td class="nump">$ 48,181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="num">(348)<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 49,208<span></span>
</td>
<td class="nump">$ 49,556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 17</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Other represents the impact of foreign exchange</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603588024">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(151)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(372)<span></span>
</td>
<td class="num">(282)<span></span>
</td>
<td class="num">(271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Cost/(credit) reported in Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Cost/(credit) recognized in Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(265)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">455<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,052)<span></span>
</td>
<td class="num">(1,015)<span></span>
</td>
<td class="num">(890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(684)<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,265)<span></span>
</td>
<td class="nump">668<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Cost/(credit) reported in Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Cost/(credit) recognized in Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,264)<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">130<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">146<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(327)<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits/(credits)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Actuarial (gains)/losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(690)<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit) reported in income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(746)<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Cost/(credit) reported in Other comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Cost/(credit) recognized in Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (742)<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reflects actuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates, and actuarial remeasurement losses in 2020 and 2019, primarily due to decreases in discount rates partially offset by favorable plan asset performance.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633608104328">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Weighted-average assumptions used to determine net periodic benefit cost:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate: Pension plans/postretirement plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Weighted-average assumptions used to determine net periodic benefit cost:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate: Pension plans/postretirement plans</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Weighted-average assumptions used to determine net periodic benefit cost:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate', window );">Discount rate: Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate', window );">Discount rate: Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Weighted-average assumptions used to determine benefit obligations at fiscal year-end:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633615509672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) - Postretirement Benefits Plan [Member]<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Healthcare cost trend rate assumed for next year</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633600526552">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,238<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Changes in actuarial assumptions and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign exchange impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Upjohn spin-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation', window );">Acquisitions/divestitures/other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits', window );">Curtailments and special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">995<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">588<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">145<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">78<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign exchange impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Upjohn spin-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets', window );">Acquisitions/divestitures, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">753<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status&#8212;Plan assets less than benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recorded in our consolidated balance sheet:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(645)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract', window );"><strong>Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (costs)/credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">581<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">18,306<span></span>
</td>
<td class="nump">17,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">455<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="nump">676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Changes in actuarial assumptions and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(331)<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign exchange impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Upjohn spin-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation', window );">Acquisitions/divestitures/other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits', window );">Curtailments and special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(785)<span></span>
</td>
<td class="num">(767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(512)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,150<span></span>
</td>
<td class="nump">18,306<span></span>
</td>
<td class="nump">17,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,094<span></span>
</td>
<td class="nump">14,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,405<span></span>
</td>
<td class="nump">1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">143<span></span>
</td>
<td class="nump">1,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign exchange impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Upjohn spin-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(785)<span></span>
</td>
<td class="num">(767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(512)<span></span>
</td>
<td class="num">(445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,346<span></span>
</td>
<td class="nump">16,094<span></span>
</td>
<td class="nump">14,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status&#8212;Plan assets less than benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(805)<span></span>
</td>
<td class="num">(2,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recorded in our consolidated balance sheet:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">447<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,113)<span></span>
</td>
<td class="num">(2,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(805)<span></span>
</td>
<td class="num">(2,211)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract', window );"><strong>Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (costs)/credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with an ABO in excess of plan assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">120<span></span>
</td>
<td class="nump">16,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">ABO</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">18,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with a PBO in excess of plan assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">120<span></span>
</td>
<td class="nump">16,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">PBO</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">18,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">753<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,001<span></span>
</td>
<td class="nump">11,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">130<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">146<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Changes in actuarial assumptions and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">89<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign exchange impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(298)<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation', window );">Upjohn spin-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="num">(320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation', window );">Acquisitions/divestitures/other, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits', window );">Curtailments and special termination benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(374)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">11,657<span></span>
</td>
<td class="nump">12,001<span></span>
</td>
<td class="nump">11,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,811<span></span>
</td>
<td class="nump">8,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">451<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign exchange impact</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(229)<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets', window );">Upjohn spin-off</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets', window );">Acquisitions/divestitures, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(374)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,729<span></span>
</td>
<td class="nump">9,811<span></span>
</td>
<td class="nump">$ 8,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status&#8212;Plan assets less than benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(928)<span></span>
</td>
<td class="num">(2,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts recorded in our consolidated balance sheet:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,480<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,376)<span></span>
</td>
<td class="num">(2,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(928)<span></span>
</td>
<td class="num">(2,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract', window );"><strong>Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (costs)/credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with an ABO in excess of plan assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,304<span></span>
</td>
<td class="nump">6,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">ABO</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">3,344<span></span>
</td>
<td class="nump">8,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with a PBO in excess of plan assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,381<span></span>
</td>
<td class="nump">6,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">PBO</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">3,789<span></span>
</td>
<td class="nump">9,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Defined benefit plan, accumulated benefit obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDivestituresBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDivestituresBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDivestituresPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDivestituresPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633594651176">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">$ 519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,346<span></span>
</td>
<td class="nump">16,094<span></span>
</td>
<td class="nump">14,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,332<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,726<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,286<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Cash and cash equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,326<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Equity securities [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Equity securities [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Global Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,273<span></span>
</td>
<td class="nump">3,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,233<span></span>
</td>
<td class="nump">3,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Equity commingled funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,352<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Fixed income securities [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Fixed income securities [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Corporate debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,566<span></span>
</td>
<td class="nump">6,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,548<span></span>
</td>
<td class="nump">6,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Corporate debt [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Government and Agency Obligations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,533<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Other investments [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Other investments [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Partnership Interest [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 2,079<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Partnership Interest [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">2,076<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Insurance Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">158<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">158<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Other Commingled Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 753<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">750<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Cash and cash equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Cash and cash equivalents [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Cash and cash equivalents [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Cash and cash equivalents [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Cash and cash equivalents [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">82<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Cash and cash equivalents [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Cash and cash equivalents [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Insurance Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 669<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,729<span></span>
</td>
<td class="nump">9,811<span></span>
</td>
<td class="nump">8,956<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">191<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,672<span></span>
</td>
<td class="nump">5,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,677<span></span>
</td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">$ 1,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Cash and cash equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 541<span></span>
</td>
<td class="nump">407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">346<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Cash and cash equivalents [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Equity securities [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Equity securities [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Equity commingled funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,453<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Equity commingled funds [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Fixed income securities [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Fixed income securities [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Corporate debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Corporate debt [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Government and Agency Obligations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,266<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,128<span></span>
</td>
<td class="nump">1,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Other investments [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Other investments [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Partnership Interest [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Partnership Interest [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[3]</sup></td>
<td class="nump">106<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Insurance Contracts [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Other [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Other [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">141<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Other [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">404<span></span>
</td>
<td class="nump">393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member] | Other [Member] | Assets Measured at NAV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[4]</sup></td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 1,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Government and agency obligations are inclusive of repurchase agreements</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Mostly includes investments in hedge funds and real estate.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanDebtSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanOtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanOtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_InsuranceContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_InsuranceContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_OtherCommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_OtherCommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAggregatedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAggregatedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633616040888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) - International [Member] - Pension Plan [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, beginning</a></td>
<td class="nump">$ 9,811<span></span>
</td>
<td class="nump">$ 8,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Exchange rate changes</a></td>
<td class="num">(229)<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, ending</a></td>
<td class="nump">10,729<span></span>
</td>
<td class="nump">9,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, beginning</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Actual return on plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Assets held, ending</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases, sales, and settlements, net</a></td>
<td class="nump">52<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfer into/(out&#160;of) Level 3</a></td>
<td class="nump">265<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Exchange rate changes</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value, ending</a></td>
<td class="nump">$ 1,677<span></span>
</td>
<td class="nump">$ 1,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633612498664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions in 2022</a></td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027&#8211;2031</a></td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">US [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions in 2022</a></td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">1,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027&#8211;2031</a></td>
<td class="nump">4,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions in 2022</a></td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027&#8211;2031</a></td>
<td class="nump">$ 2,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633613290216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost recognized</a></td>
<td class="nump">$ 732<span></span>
</td>
<td class="nump">$ 685<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633600288888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 04, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>employeeStockOwnershipPlan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">213,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount of remaining shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NumberofEmployeeStockOwnershipPlans', window );">Number of employee stock ownership plans | employeeStockOwnershipPlan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of convertible preferred stock (in shares) | shares</a></td>
<td class="nump">1,070,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_CommonESOPPlanMember', window );">Common ESOP Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">ESOP compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2017StockPurchasePlanMember', window );">December 2017 Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2018StockPurchasePlanMember', window );">December 2018 Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithGSCoMember', window );">Share Repurchase Agreement with Goldman, Sachs &amp; Co. LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchases, cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,500,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount', window );">Accelerated share repurchase, percentage of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Accelerated share repurchase, final average price paid (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents shares purchased pursuant to the ASR with Goldman Sachs &amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NumberofEmployeeStockOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Employee Stock Ownership Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NumberofEmployeeStockOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_CommonESOPPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_CommonESOPPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2017StockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_December2017StockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2018StockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_December2018StockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithGSCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithGSCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633612901832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Common Stock Purchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares of common stock purchased</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of purchase</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,865<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_OpenMarketPurchasesMember', window );">Open Market Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents shares purchased pursuant to the ASR with Goldman Sachs &amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_OpenMarketPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_OpenMarketPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633614520136">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Narrative (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit for share-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">2019 Stock Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee', window );">Maximum shares available per individual during the plan period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | 2019 Stock Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 535<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member] | 2019 Stock Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Awards [Member] | 2019 Stock Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member] | 2019 Stock Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | 2019 Stock Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">TSRU includes expense for PTSRUs, which is not significant for all years presented</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pfe_A2019StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610523960">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>measure </div>
<div>period </div>
<div>tradingDay </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">779,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage', window );">Trading day average | tradingDay</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout', window );">Number of measures used to determine share payout | measure</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods', window );">Share payout measures, adjusted net income, number of periods | period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod', window );">Share payout measures, adjusted net income, period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Awards [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Awards [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember', window );">Breakthrough Performance Awards (BPAs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember', window );">Breakthrough Performance Awards (BPAs) [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember', window );">Breakthrough Performance Awards (BPAs) [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">600.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember', window );">Performance Total Shareholder Return Unit (PTSRUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice', window );">Grant price (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue', window );">Grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember', window );">Performance Total Shareholder Return Unit (PTSRUs) [Member] | Board of Directors Chairman [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Deferred compensation arrangement, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,444,395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember', window );">Performance Total Shareholder Return Unit (PTSRUs) [Member] | Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Deferred compensation arrangement, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,099<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (1,444,395 PTSRUs) and 361,099 PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $30.31 and at a GDFV of $5.54 per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#8217; original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603212600">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="nump">$ 8.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue', window );">Units converted, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">259<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which cost is expected to be recognized (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">281<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which cost is expected to be recognized (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue', window );">Units converted, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">535<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which cost is expected to be recognized (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which cost is expected to be recognized (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Total fair value of shares vested (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="nump">$ 5.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value on exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received upon exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">795<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefits realized from exercise</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">106<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which cost is expected to be recognized (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Weighted-average GDFV per TSRUs and stock options.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">TSRU includes expense for PTSRUs, which is not significant for all years presented</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633614780808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Valuation Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">4.51%<span></span>
</td>
<td class="nump">4.36%<span></span>
</td>
<td class="nump">3.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.93%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">26.53%<span></span>
</td>
<td class="nump">20.99%<span></span>
</td>
<td class="nump">18.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term/expected term</a></td>
<td class="text">5 years 1 month 24 days<span></span>
</td>
<td class="text">5 years 1 month 13 days<span></span>
</td>
<td class="text">5 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">4.51%<span></span>
</td>
<td class="nump">4.36%<span></span>
</td>
<td class="nump">3.27%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.27%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">26.54%<span></span>
</td>
<td class="nump">20.97%<span></span>
</td>
<td class="nump">18.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term/expected term</a></td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633601485848">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward', window );"><strong>Weighted Avg. Intrinsic Value per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">44,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">129,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(44,888)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114,599<span></span>
</td>
<td class="nump">129,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Avg. GDFV per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">7.26<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
<td class="nump">$ 8.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.90<span></span>
</td>
<td class="nump">6.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward', window );"><strong>Grant Price</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice', window );">Nonvested, beginning of period, grant price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice', window );">Granted, grant price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice', window );">Vested, grant price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">30.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice', window );">Forfeited, grant price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice', window );">Nonvested, end of period, grant price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34.12<span></span>
</td>
<td class="nump">$ 32.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod', window );">Reinvested dividend equivalents, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,540<span></span>
</td>
<td class="nump">23,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Avg. GDFV per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue', window );">Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35.52<span></span>
</td>
<td class="nump">$ 35.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">20,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">8,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(6,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(1,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">21,480<span></span>
</td>
<td class="nump">20,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward', window );"><strong>Weighted Avg. Intrinsic Value per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 36.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">33.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">33.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Forfeited, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">41.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 59.05<span></span>
</td>
<td class="nump">$ 36.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Awards [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,154<span></span>
</td>
<td class="nump">5,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward', window );"><strong>Weighted Avg. Intrinsic Value per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 36.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Forfeited, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 59.05<span></span>
</td>
<td class="nump">$ 36.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember', window );">Breakthrough Performance Awards (BPAs) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">859<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward', window );"><strong>Weighted Avg. Intrinsic Value per share</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Forfeited, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 59.05<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The number of options expected to vest takes into account an estimate of expected forfeitures.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Weighted-average GDFV per TSRUs and stock options.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1&#160;million.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_BreakthroughPerformanceAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603383720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of TSRU and PTU Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Units outstanding, shares</a></td>
<td class="nump">206,996,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares', window );">Units vested, shares</a></td>
<td class="nump">92,398,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber', window );">Units expected to vest, shares</a></td>
<td class="nump">110,476,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice', window );">Units outstanding, weighted average grant price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 31.71<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice', window );">Units vested, weighted average grant price (in dollars per share) | $ / shares</a></td>
<td class="nump">28.72<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice', window );">Units expected to vest, weighted average grant price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 34.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Units outstanding, weighted average remaining contractual term</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms', window );">Units vested, weighted average remaining contractual term</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm', window );">Units expected to vest, weighted average remaining contractual term</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Units outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 5,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Units vested, aggregate intrinsic value | $</a></td>
<td class="nump">2,946<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest', window );">Units expected to vest, aggregate intrinsic value | $</a></td>
<td class="nump">$ 2,910<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2],[3]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares', window );">Units settled, shares</a></td>
<td class="nump">46,060,346<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice', window );">Units settled, weighted average grant price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Units exercised, shares</a></td>
<td class="nump">7,093,787<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice', window );">Units exercised, weighted average grant price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.41<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_ProfitUnitsMember', window );">Profit Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber', window );">Units exercised and converted, shares</a></td>
<td class="nump">3,074,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm', window );">Units exercised and converted, weighted average remaining contractual term</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted', window );">Units exercised and converted, aggregate intrinsic value | $</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion', window );">Units granted upon conversion, shares</a></td>
<td class="nump">2,943,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2021, 7,093,787 TSRUs with a weighted-average grant price of $27.41 per unit were converted into 2,943,737 PTUs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">In 2021, we settled 46,060,346 TSRUs with a weighted-average grant price of $23.04 per unit.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_ProfitUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_ProfitUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610713656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares (Thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period, shares | shares</a></td>
<td class="nump">75,402<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares | shares</a></td>
<td class="nump">779<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares | shares</a></td>
<td class="num">(31,036)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares | shares</a></td>
<td class="num">(89)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, shares | shares</a></td>
<td class="num">(181)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period, shares | shares</a></td>
<td class="nump">44,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period, shares | shares</a></td>
<td class="nump">44,747<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable, end of period, shares | shares</a></td>
<td class="nump">41,583<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">33.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">25.75<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">34.39<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">20.27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">30.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">30.19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 29.81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, end of period, weighted-average remaining contractual term</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, end of period, weighted-average remaining contractual term</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, end of period, weighted-average remaining contractual term</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, end of period, aggregate intrinsic value | $</a></td>
<td class="nump">$ 1,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, end of period, aggregate intrinsic value | $</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable, end of period, aggregate intrinsic value | $</a></td>
<td class="nump">$ 1,216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The number of options expected to vest takes into account an estimate of expected forfeitures.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Market price of our underlying common stock less exercise price.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609954744">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>EPS Numerator-Basic</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations attributable to Pfizer Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,414<span></span>
</td>
<td class="nump">$ 6,630<span></span>
</td>
<td class="nump">$ 10,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: Preferred stock dividends&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,414<span></span>
</td>
<td class="nump">6,630<span></span>
</td>
<td class="nump">10,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,979<span></span>
</td>
<td class="nump">9,159<span></span>
</td>
<td class="nump">16,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Diluted</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,414<span></span>
</td>
<td class="nump">6,630<span></span>
</td>
<td class="nump">10,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(434)<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,979<span></span>
</td>
<td class="nump">$ 9,159<span></span>
</td>
<td class="nump">$ 16,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,601<span></span>
</td>
<td class="nump">5,555<span></span>
</td>
<td class="nump">5,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,708<span></span>
</td>
<td class="nump">5,632<span></span>
</td>
<td class="nump">5,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive common stock equivalents (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633609532328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 381<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LesseeOperatingLeaseOptionToExtendTerm', window );">Operating lease term, option to extend</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LesseeOperatingLeaseOptionToExtendTerm', window );">Operating lease term, option to extend</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LesseeOperatingLeaseOptionToExtendTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Extend, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LesseeOperatingLeaseOptionToExtendTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610331992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">$ 2,839<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities (short-term)</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities (long-term)</a></td>
<td class="nump">$ 2,510<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">ROU assets, statement of financial position</a></td>
<td class="text">Other noncurrent assets<span></span>
</td>
<td class="text">Other noncurrent assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Lease liabilities (short-term), statement of financial position</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Lease liabilities (long-term), statement of financial position</a></td>
<td class="text">Other noncurrent liabilities<span></span>
</td>
<td class="text">Other noncurrent liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633616063608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Costs and Other Supplemental Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
<td class="nump">$ 421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 888<span></span>
</td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-Average Remaining Contractual Lease Term (Years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-Average Discount Rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">$ 333<span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">(Gains)/losses on sale and leaseback transactions, net</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123417830&amp;loc=SL77919786-209982<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610976264">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">Next one year</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">1-2 years</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2-3 years</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">3-4 years</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">4-5 years</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">Thereafter</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">449<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,510<span></span>
</td>
<td class="nump">$ 1,108<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reflects lease payments due within 12 months subsequent to the balance sheet date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633612457768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Patent Litigation) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>patent</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>defendant </div>
<div>patent</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold', window );">Threshold for disclosure of proceedings under environmental laws | $</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber', window );">Number of patents without court proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PneumococcalVaccinePatentInfringementMember', window );">Pneumococcal Vaccine Patent Infringement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_OtherPatentInfringementMember', window );">Other Patent Infringement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_EliquisMember', window );">Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019', window );">Number of patents allegedly infringed upon due to expire in December 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyNumberofDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyNumberofDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Without Court Proceedings, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsWithoutCourtProceedingsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Site Contingency, Regulatory Proceedings, Disclosure Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PneumococcalVaccinePatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PneumococcalVaccinePatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_OtherPatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_OtherPatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610684072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>lagoon </div>
<div>manufacturer</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>lagoon</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss on litigation settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_EpiPenMember', window );">Epi Pen [Member] | Discontinued Operations, Disposed of by Sale [Member] | Meridian [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss on litigation settlement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember', window );">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Docetaxel [Member] | Pending Litigation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant', window );">Number of defendants other than main defendant | manufacturer</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember', window );">Environmental Remediation Litigation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FeasibilityStudyNumberOfLagoons', window );">Feasibility study, number of lagoons | lagoon</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes legal reserves for certain pending legal matters.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FeasibilityStudyNumberOfLagoons">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Feasibility Study, Number Of Lagoons</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FeasibilityStudyNumberOfLagoons</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Defendants Other Than Main Defendant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_MeridianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_DocetaxelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_DocetaxelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603101944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Certain Commitments and Contingent Consideration for Acquisitions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability, current</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, noncurrent</a></td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633610767096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>country </div>
<div>operatingSegment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | operatingSegment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 181,476<span></span>
</td>
<td class="nump">$ 154,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current</a></td>
<td class="nump">3,067<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 22,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period of recognition</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period of recognition</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period of recognition</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember', window );">Government and Government Sponsored [Member] | Comirnaty direct sales and alliance revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">$ 957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, noncurrent</a></td>
<td class="nump">$ 249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue [Member] | Outside United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries', window );">Number of countries with revenue exceeding $500 million | country</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue [Member] | US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue [Member] | Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue [Member] | Government and Government Sponsored [Member] | Comirnaty direct sales and alliance revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest U.S. Wholesaler Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable [Member] | Government and Government Sponsored [Member] | Comirnaty direct sales and alliance revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Revenues, $500,000,000 or More, Number of Countries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_GovernmentAndGovernmentSponsoredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_NonUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_NonUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_ThreeLargestUSWholesaleCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_ThreeLargestUSWholesaleCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603536840">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2021</div></th>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,288<span></span>
</td>
<td class="nump">$ 41,651<span></span>
</td>
<td class="nump">$ 40,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,311<span></span>
</td>
<td class="nump">7,036<span></span>
</td>
<td class="nump">11,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,191<span></span>
</td>
<td class="nump">4,681<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring', window );">Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit', window );">Net periodic benefit, actuarial valuation and other pension and postretirement plan gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains)/losses recognized during the period on equity securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6],[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring', window );">Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForCollaborativeAndLicensingArrangements', window );">Payment for collaborative and licensing arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=pfe_TrilliumMember', window );">Trillium [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge to research and development expenses in connection with asset acquisition</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">Consumer Healthcare JV [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of transaction</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Other Business Activities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="nump">2,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,396)<span></span>
</td>
<td class="num">(12,308)<span></span>
</td>
<td class="num">(11,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5],[8]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Items [Member] | Purchase Accounting Adjustments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,175)<span></span>
</td>
<td class="num">(3,117)<span></span>
</td>
<td class="num">(4,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,067<span></span>
</td>
<td class="nump">3,047<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Items [Member] | Acquisition Related Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Items [Member] | Other Reconciling Items [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,292)<span></span>
</td>
<td class="num">(4,584)<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5],[9]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[10]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,557<span></span>
</td>
<td class="nump">40,724<span></span>
</td>
<td class="nump">38,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member] | Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,557<span></span>
</td>
<td class="nump">40,724<span></span>
</td>
<td class="nump">38,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,226<span></span>
</td>
<td class="nump">27,089<span></span>
</td>
<td class="nump">24,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,439<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 978<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#8217;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8211;&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $2.1 billion charge for IPR&amp;D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $1.3&#160;billion ($450 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and (iii) upfront and milestone payments on collaborative and licensing arrangements of $1.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (v) gains on equity securities of $1.3 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. For Earnings in 2020, includes, among other items; (i) charges of $1.7 billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) actuarial valuation and other pension and postretirement plan losses of $1.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#8212;asset restructuring of $791 million ($197 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $8.1 billion recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $2.8 billion related to certain asset impairments recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) actuarial valuation and other pension and postretirement plan losses of $750 million recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#8211;&#8211;net. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 2A, 2C, 3 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </span>4</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[10]</td>
<td style="vertical-align: top;" valign="top">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForCollaborativeAndLicensingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for Collaborative and Licensing Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForCollaborativeAndLicensingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=pfe_TrilliumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=pfe_TrilliumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsConsolidationItemsAxis=pfe_ReconcilingItemsOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603591784">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 81,288<span></span>
</td>
<td class="nump">$ 41,651<span></span>
</td>
<td class="nump">$ 40,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">US [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,746<span></span>
</td>
<td class="nump">21,455<span></span>
</td>
<td class="nump">20,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,336<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
<td class="nump">7,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,506<span></span>
</td>
<td class="nump">4,036<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 20,701<span></span>
</td>
<td class="nump">$ 8,372<span></span>
</td>
<td class="nump">$ 8,828<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633603193592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details) - Revenue [Member] - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_McKessonInc.Member', window );">McKesson, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_AmerisourceBergenCorporationMember', window );">AmerisourceBergen Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=pfe_CardinalHealthInc.Member', window );">Cardinal Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_McKessonInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_McKessonInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_CardinalHealthInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_CardinalHealthInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139633600095400">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 81,288<span></span>
</td>
<td class="nump">$ 41,651<span></span>
</td>
<td class="nump">$ 40,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">79,557<span></span>
</td>
<td class="nump">40,724<span></span>
</td>
<td class="nump">38,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneMember', window );">Pfizer CentreOne [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BioNTechMember', window );">BioNTech [Member] | Pfizer CentreOne [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">320<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember', window );">Alliance Biopharmaceuticals [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,652<span></span>
</td>
<td class="nump">5,418<span></span>
</td>
<td class="nump">4,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember', window );">Total Biosimilars [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">2,343<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember', window );">Total Sterile Injectable Pharmaceuticals [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">5,746<span></span>
</td>
<td class="nump">5,315<span></span>
</td>
<td class="nump">5,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,625<span></span>
</td>
<td class="nump">6,575<span></span>
</td>
<td class="nump">6,504<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Comirnaty direct sales and alliance revenues [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,781<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Prevenar 13/Prevnar 13 [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">5,272<span></span>
</td>
<td class="nump">5,850<span></span>
</td>
<td class="nump">5,847<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Nimenrix [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">193<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | FSME/IMMUN-TicoVac [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Trumenba [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Other Vaccines Products [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,333<span></span>
</td>
<td class="nump">10,867<span></span>
</td>
<td class="nump">9,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Ibrance [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,437<span></span>
</td>
<td class="nump">5,392<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Xtandi Alliance Revenues [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Inlyta [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Sutent [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">673<span></span>
</td>
<td class="nump">819<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Bosulif [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">540<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Xalkori [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">493<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Ruxience [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">491<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Retacrit [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">444<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Zirabev [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">444<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Lorbrena [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">266<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Aromasin [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">211<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Trazimera [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">197<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Besponsa [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">192<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Braftovi [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Bavencio Alliance Revenues [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">178<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Mektovi [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">155<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Other Oncology Products [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">238<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,329<span></span>
</td>
<td class="nump">9,003<span></span>
</td>
<td class="nump">8,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Eliquis [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,970<span></span>
</td>
<td class="nump">4,949<span></span>
</td>
<td class="nump">4,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Premarin Family [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">563<span></span>
</td>
<td class="nump">680<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Chantix Champix [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">398<span></span>
</td>
<td class="nump">919<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | BMP2 [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">266<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Toviaz [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">238<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Pristiq [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | All Other Internal Medicine [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7,301<span></span>
</td>
<td class="nump">6,777<span></span>
</td>
<td class="nump">6,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Sulperazon [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">683<span></span>
</td>
<td class="nump">618<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Medrol [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">432<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Zavicefta [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">413<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Fragmin [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Zithromax Zmax [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">278<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Vfend [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">267<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Tygacil [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Precedex [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">177<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Zyvox [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">173<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Paxlovid [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | IVIg Products [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">430<span></span>
</td>
<td class="nump">376<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Other Anti-infectives [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,453<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Other Hospital Products [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,412<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
<td class="nump">2,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,431<span></span>
</td>
<td class="nump">4,567<span></span>
</td>
<td class="nump">4,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Xeljanz [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,455<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">2,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Enbrel [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,185<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Inflectra/Remsima [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">657<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | All Other Inflammation and Immunology Products [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">134<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,538<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Vyndaqel/Vyndamax [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,015<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | BeneFIX [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">438<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Genotropin [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">389<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | ReFacto AF Xyntha [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">304<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Somavert [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">277<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | All Other Rare Disease Products [Member] | Biopharma [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember', window );">Consumer Healthcare Reporting Unit [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,082<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">On July&#160;31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare JV. See </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_PfizerCentreOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BioNTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BioNTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ComirnatyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ComirnatyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_NimenrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_NimenrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TrumenbaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TrumenbaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IbranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IbranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InlytaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InlytaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SutentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SutentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XalkoriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XalkoriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RuxienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RuxienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RetacritMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RetacritMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZirabevMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZirabevMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_LorbrenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_LorbrenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AromasinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AromasinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TrazimeraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TrazimeraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BesponsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BesponsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BraftoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BraftoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BavencioAllianceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BavencioAllianceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MektoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MektoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PremarinFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PremarinFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ChantixChampixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ChantixChampixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BMP2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BMP2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ToviazMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ToviazMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PristiqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PristiqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_HospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SulperazonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SulperazonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MedrolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MedrolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZaviceftaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZaviceftaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FragminMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FragminMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VfendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VfendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TygacilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TygacilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrecedexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrecedexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZyvoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZyvoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PaxlovidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PaxlovidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IVIgProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IVIgProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VyndaqelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VyndaqelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BeneFIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BeneFIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenotropinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenotropinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SomavertMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SomavertMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>pfe-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pfe-20211231.xsd" xlink:type="simple"/>
    <context id="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia364c08bab1f4be7a0489033e72f9182_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="i7b0a597b277c43419d1b9be3ccd9b0bd_I20220222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2022-02-22</instant>
        </period>
    </context>
    <context id="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ac39ce3acc7441e86107c1d869cbee9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21a79fdd21944aa89c066de9cbbfee5d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ief8bb2c5291c4b5c9a5015f9815e4ee3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1a2a3761e1b1438383b3a8eb28300997_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i70369ec902474685b7ee35afae6111aa_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1e769fcaccc349d5b816b47154d226a6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7fa41a976be144ff95f4427e340cfcab_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i595cd5191b614c5896a444e2f5f45def_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8f468b487cc540788a176ec913956dca_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8e10b1e1c1f846769573d84f9a61fc72_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i24e366b426034c2d8e2255483179463e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib57063444ae6416ea155fe3b461c2ed1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie6ae9c7231104451b51d26af9103a373_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia99d4818adb64cf09382dd79ab3ff911_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i29a4e3937ea1429897d5a87a331d97a4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf9258b1a52e41f7b182a2eb16acdb9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id51cff7fa3b2450293ac21547637f902_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5931a8435e8847bbb43008b48c1d8f71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd94794713d841c39b811cf2ccdd0e5b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c15300160eb40199b2470fd99513c75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a3ccccf6fbe4566816a85a5ac4c621a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibdc359e016414e0fb3f5cdc5fc783e30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i140dd48fd747453ba5305db06d75f19f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1a777038d48408c84c682c9db5a1598_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e60bc72e4ba4235bf53b47acbec77c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id949a0db74974d919ea4ea4b3db15ae6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6632dff49814e8badeff7ff58c71158_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf786bbc81494d359b7cda3127ee3152_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i07fc9de38c8c4c7e9d03753b2fca1f74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7422d124677a4ff7b2f8d8076c12acca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5835359a69d471cbf36ab74d0cbe6a8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica9a1f0a2c3f454aa866582d5102b28a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8080b824a5384f898232ba254171a741_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibedd8e5bdd3547a59b222ebb89139a56_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4091403708c44027bed1ab29ab967de7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ab09e3a09e941018ddf6f7cc1e0fd05_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib478cdce593043b4a6f3edef11be42c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93c09cc9d0f940729939d72e229af012_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67081b13ebb6408d9bfb81829f457cbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffea6a63f21448c2a42fb089c227bdf1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba64542fbbc240b2b05039d5b8e8bf4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa81ae38e1ae496d93643844df0b8455_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa9bac0ccad24d18a5d2306fb3b1e0f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6af06169f58446f8067cc5be10a39e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d6aaf11901b4bceaf30103029c6a00d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19da914ba5ba4066bf3d29d7d1eeb9c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie607d29116be4fa5babac488462d4080_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic3380b060ff04a11833194263e6f152c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34dd2e3fa1c248e29e1d6758b3059e2d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifcf32e48dba146a8a8302424e15199af_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04819cdee99246d38d6d26c354104c35_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i081d264148eb46f1afc0ba411e33410f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68bc59daf06d4c87a9c731683260774d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioPreviousAccountingPrincipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9edb7a944ede457bb2ca3502417492fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">pfe:ScenarioChangeInAccountingPrincipleAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibfadeff2c1f5480394b1866913a3183a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopNineProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11f0ae3d8acd41fa96131bb2d2405985_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopSevenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if173d80ef8d44c438cb34092fab6cadf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopSixProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f7cb8f0966747fd9a171cc0fd9a0c50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59d45585212a4650a36d5467a52c00b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c659cb958e94f909ae64de8887c53e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe0e5d69b58349a58289b22b8b683cd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0aaf677ffe1c461b92474fb66fe48c68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3eaee674151468f8779787aca2fbdd8_I20211117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TrilliumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TrilliumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-17</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="i40a5967cba7c42799e4a32e326df03fd_D20210101-20211116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:TrilliumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-11-16</endDate>
        </period>
    </context>
    <context id="i863e4743e2d145be857ddf010856d1d2_I20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="i5adbe40672074cb28e27345d594c6111_D20190730-20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="i763f14d53a0f47d2bb88afb5100aeece_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6ef40e33d0e245579352ff0b15309b81_I20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="if00cc3ffe8b74509b0746823ba987ea5_D20190730-20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="iee11b1723a234cdfad038a7b6b8d6698_I20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="i60e43a0fe85848159c571b3aee53daf1_I20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="i8c8f7c06b3f04a218265c1e05e918490_I20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsTechnologyInDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="i1f466f58bbb14f0c960799ddb7db2885_I20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="ibbc5264b1b924484a590099fbbf18894_D20190730-20190730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="i40b3ec61b4cf4015ab587fac323995eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="i314f8d3de1434b56bb2fdf8061d7a953_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b44d95032624046bce69d6abe17288c_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i888e24f18a1748c6b73bcfc6bda4a9b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PurchaserOfMeridianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f02e49d15574798a17efff00d83ccb9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PurchaserOfMeridianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaffca7f3bf5b4256aed31e1ad5ab0cce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PurchaserOfMeridianMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i389169f22b244d9c8c2e87bfedee54c2_D20201113-20201113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-13</startDate>
            <endDate>2020-11-13</endDate>
        </period>
    </context>
    <context id="id93ea4a3a591476aab3a080ee5c9429b_D20201113-20201113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:MylanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-13</startDate>
            <endDate>2020-11-13</endDate>
        </period>
    </context>
    <context id="i10ff88c8caf540d29f9a1a2759e9218f_I20201113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-13</instant>
        </period>
    </context>
    <context id="i18320fc2b9594ddea18b362bf4514a69_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i23323cf2700144a6b84393ffab357354_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:ViatrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:MylanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i031df9beab9042be9970f64529890934_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5bf57b2d36c745beb81e1b7026d3c318_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnFinanceB.V.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0a559b470d334b43b79260c8d2f79c2d_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncAndUpjohnFinanceBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia69d0ecee9684b1386c94a8b435e6cd7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:UpjohnIncAndUpjohnFinanceBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idc5994c3e02a45da952846df4b47bfbc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifc8dbebb0e9d49428a97f4323e05244a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1e71e04bd5f14e7e934d2585e74e3b2b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i146ddcb53ba74d66b6cd862e76bc22d2_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="i4d984e1a55d04f109e2f4777e30a7cef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa8744bbf8a04e279bfe049ce4a864ba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i574afde0d29749d9a45d3066b313f102_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05a3ba48023e426a88cc41e754f240ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:ManufacturingAndSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e17ee2ad705475da2fd98425c5438a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bb26d7550d34c4fa8277bc4dd130b09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83182589a2cf40518e59a55a207f4a48_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74dbcccac2f4425289e1e6696c212de4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ViatrisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i25df7ea17ef54fb9b9166956b884cb0b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ife130b27142a4922bf44614565f191c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnIncAndUpjohnFinanceBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i181dc4bf05244a10b3b37faa99909cbf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:UpjohnFinanceBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee64f2b1f51741cfa08ecb452fe530f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if072dc370d29444380b25f1c9000934b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i252c5ea241a04813985449d2cebbba79_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i7e3dc812e321400f96f18d4c30fd6ac5_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i6e80f25bd480402595d2aea33e91039a_D20190701-20190929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-29</endDate>
        </period>
    </context>
    <context id="icface7a1ee2b4ff28ac480b07f52e93f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8959c4c50fb407583ed92f9c3322282_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i545389717f154954b7abb4cddabeb1cf_D20190930-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i43de6de86aee4f1981210b2cfbd70d8b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7c41e610d4514bd2960d85db52a70189_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21520495e93a4b6f82c194548d489020_D20190101-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="ie644969c98bc4ecd8d8103171f4b1758_I20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-03</instant>
        </period>
    </context>
    <context id="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-27</instant>
        </period>
    </context>
    <context id="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-04</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-09-29</endDate>
        </period>
    </context>
    <context id="i0336041406e84b0dbc587db051c08162_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5259b031a6bd4f3eacca9ff85942926b_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3a3cfa0088ba4234af8b08e75e132786_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dcbf2f54f114c5280a6cb330bf56361_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib9db49261fe34983839218bcd3832009_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id0027658381944a395727958a68002bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i80aa0ad3eddf4f7391796743da2c7d4a_D20200330-20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="ib167df84d3de4e098cfb61db76e453f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ValnevaSEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0fbdbdf768e24f2a8c5d0a5b25a12f65_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:AkceaAndIonisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i5cc0e4c459d54fad8d446a48587269e9_D20211224-20211224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-24</startDate>
            <endDate>2021-12-24</endDate>
        </period>
    </context>
    <context id="ia6b61ff9024b46bb9e45f08915a7f41e_D20211224-20211224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:BeamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-24</startDate>
            <endDate>2021-12-24</endDate>
        </period>
    </context>
    <context id="i69a2ae55438c4493a657b96e948feffb_D20211004-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea2eb9e0f80d46748855049032762b62_I20211224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-24</instant>
        </period>
    </context>
    <context id="if407180f055943a98b83de59f2cd5a1f_D20210721-20210721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-21</endDate>
        </period>
    </context>
    <context id="i812cbbdf3b1245069237af890fdcecae_I20210721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-21</instant>
        </period>
    </context>
    <context id="i6d66cd919bde400083d7783f18057f72_D20210705-20211003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-05</startDate>
            <endDate>2021-10-03</endDate>
        </period>
    </context>
    <context id="i375a1296a03d4608aa7dadc39a4081b0_D20210721-20210721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-21</startDate>
            <endDate>2021-07-21</endDate>
        </period>
    </context>
    <context id="i095915c17bba4c2681c503f9e07eb593_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ArvinasIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5bdb38bc93ee4bdca889f98c7227ecd3_I20201226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-26</instant>
        </period>
    </context>
    <context id="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-26</startDate>
            <endDate>2020-12-26</endDate>
        </period>
    </context>
    <context id="iffe998e9fae8489392c54ceb8b6c3cfc_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie99ef111b6e645c6a56cc65ad07091e8_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="if33e0253955c412683af05e909d4151f_I20201226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MyovantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-26</instant>
        </period>
    </context>
    <context id="i0e5a99e4814b4f128ec2c686a1ec35d1_I20200929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CStoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i2d62ac5456af448bbff21978df756208_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CStoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b21456e1b1e45de977384ffe2104b0d_D20211230-20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:ShinglesVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="i5f00f7ed3e2c4bebad99f1f2c882a39e_D20211230-20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:ShinglesVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="i603a6eec721f4ae6823ed9ad58021e0a_I20211230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:ShinglesVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="i4a30949432804cb2a16f9d87c25227db_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i29f76f6dc48f4d43b42b0c3a2fd099ea_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i1ebf471468de402693afa6538be7c48a_D20200330-20200628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-06-28</endDate>
        </period>
    </context>
    <context id="iaa219a8d864348459268e3b1408b148a_I20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="i6f0797c37dfa45c7a80ce32bac03a312_D20200409-20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">pfe:CoronavirusVaccineProgramMRNABasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-09</endDate>
        </period>
    </context>
    <context id="i0c579c9b9f224be594bcabbfa663f822_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i9ea93613082a4762abffed23b2ec080b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b05b7dcaa61407aba318478b7c59025_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae539c60336f4a0c94b5a022dcf96c0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i16a2adb8ca784b4ea94e14866c48cc70_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib015687530a043e399f09540ca86222d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1967572353a4cf69f29aa1e5a12c183_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i778d084ed9064541a22124cd2f5453c5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3f7200b60394988b20633966561bd86_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8b71faadf0d40afaad23404443a875b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i98027c8fc6b44691900fa8e4048b8871_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CorporateEnablingFunctionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied12c12ed32548d6a549bafb56e60cd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:GoToMarketModelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86b210be8e114d32a572f0bd0df9088a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bc539f8d9004dc099e25a88c5b43895_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i925e41f449714bd2bf405763d6debabb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40868579307a4b29940d0afd5af8d703_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6e76156347742d59ab87928f0b59b21_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i626b2657ceb64b34b2c9c95e2661d1fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee83e2bae3b7490d9df5cb5de4b214ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3b3ff3fbc764236bcf7f1991593041b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f963471072a434bbb65ec9314d42418_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4da04c0815ec4b519aab9003bbf9e69b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i63611b219ac54cf69a70430c5ef474f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia831fe68ea464a7696d368c0b964d933_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i99d15499afc94f0f88944990ff7e08fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5dd3ecfac844087a740d27d7e403e89_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a03d9e689ec4fae8e3c0b59a2584fa3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia2daa7c6ae294186bbe568931b7486c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8edaec2b4f8a4f18b37022f2160559cb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f5a6ab0d6bb475ea4b794272ee41557_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib92e3b0b44374006b6d45a2bf6b453ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3bff8c57bb424ff78fbf4a3f0ebccedf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie05f357a90bb455c808448dd5bdb82b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa0f6d5d21e848678b8da48c334034bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i877d264408a04f79a16737d91ace0ab4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9a1c9f4206be4156af7e5bbf360b0c50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie7ea5bfd40cc43e0b0057cd2055809db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i17a552f33566495aa5aad8a8ce07ffee_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:CostReductionInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia829878673b04d45a644a83794ea47f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id19560e1e9e846f1917dd34fe6665c2f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c9c1d9cd337481ea21924d113ae20f0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc28c341b16f4257858e79aa91bfbb0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8e69ebbcd7843c09dba286f7a84a32e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85ea9a17643b4ba993c0d7767b7df734_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64c5139d761040739c960494538b4e36_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8de8376bf36443928b6f33affb450d42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib978af64a1074124af383834e607186e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia26d7da2bf204ad39d1d01e1c8c71720_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d619ef872034dfea120fc28f055f6a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08555d6e17894c0ebe9ccf5b8c4a0767_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c69c8a8bbc74fa887cd2c9dc0ed4c80_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20f99441233647049f94a89b177f28e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2de81f39d0e4b198f2516dade160b06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if94a5fe65bae431b99f55fff931ebea4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndCerevelTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i421339ba223042529cc05db65a67a1fc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:BioNTechAndSpringWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18931406f81e4214af8bdf650ea9a501_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CortexymeIncAndSpringWorksTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie5017fc8db5942798d4a4ab792e69007_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6feb23a7d7ad4d25b3ff9db357c2d2b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib64fb7f03591425caf0f8ec0bc10107b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:CK1AssetsSoldToBiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cd393823f0a466cb163341642a080ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:PumaTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2547961512514f6a99fc62e7d1581590_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60a8a5bae1304da28157e10b33ab0a5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia825faa5b2044c4d9d91b62b8f59c653_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MylanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd3d48c945234584a9a562a3e928cd52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i56031b6c3a9542fd9a53b737a162f549_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied002bca63d9483da7deb14447eca722_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42d4c757c4044ceab2e6cbc41cab4a64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f422da6aefa4071bc05f672d391dba2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic20790f22ade4cf6b4a0533bf036316c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id442e3abd12b4a22a3b95e39aae09ed2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26ac48141e3840ebb5504bd97d592bec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pfe:AgreementAxis">pfe:TransitionServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77c1de86a8744d5f9ef90c3fe81d1656_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ViiVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iafeac22251414180abb3e88565bac3e0_D20190701-20190929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-29</endDate>
        </period>
    </context>
    <context id="ibb74e76f421148d08f33e3b64b0f55a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i361e612fd47344f486642a0505329347_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15795fd91413493f98813b66ab28bc23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i20860e5e0d834bd0a887924f23c1ddeb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i33ea397ae7d44969805ee21fb8ef3cc5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i841ae3241c284442a2a9ed328bb982f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredTaxLiabilitiesNetNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i21b2ee9ddfcb4ba59cfcd0e1406e7519_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7054cf3b6aaa45ed9aab6e96ec09198c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id25117217bb84d749d33874e62b57092_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b847e7890394d15be5612bf0c10a5ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d1928a49a1c409b9412c1399a30a560_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3cb4c669061b481d96c1121c6720d70d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idcbad3af6ffb42d3a5323f694e0b67e4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0fd2b1aa38ce4c06af821df843b89ce4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2feb25a701eb4da483a23b858699b65e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if58e15d3f4084fffb7602c9eb76f8bc9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7e3cd7c442ae43b9bfd024d7dd0d36b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc4281959bef4c1493773621b7096825_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i40b2c92e98294f13b4dbf574dc8305f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib0393c39513f4c3eac3873a1cd6c7164_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7547ea8333dc473b9f7ac1c8f733c20d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c35fcf0cfc44fd48d3257adee8a9f7c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i24e18b8241eb4dca8f8c5339c218af0e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i11c6dc78bf6441e287c9ac69448c1f36_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ab5367055954f1ab2c49e8bb7ad206d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a66120c91484bf482696981e59cfd8c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53a5e9e7d598442bb2845131112f1a27_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if2dcb1cb0b18446282f631ef686d469e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia43c881a511349ed8186adf0171213b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61f3046c6f3740088aecf1f8ab49180c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if80d286ba9a84220b133795a7fe5879e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic24d6578cd564b11b05d748a5940c8cc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i511ba9110aec4c1ebb32704e802fdfcf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaa1ca16d7938490db0ffebf5bafa0e71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9aa37587879b40bf9f95c485b7bc8caa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13cd8db58f3548899c2ef209a3207f51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e841c53a84a4c519f13fc764830af27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b0f53b05386403bb5d5091940b9f1f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68b19f0bbfb7432a8e12a91e563366db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fa85376258a44a4ae685454ee4b4522_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3418a2b3afcb431cb8d6bb202f7c9e6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64912c49208a4823a52b20d54f71c167_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1832b894d034229bf17f14653fff53a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifbfbfd55f6844d2d82e7590378589389_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ccb03a8326a4f5d815ce199580340b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58d8b7dd831245b68c651101e4deb9ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i145d0984ee1244d0b37449d0c40e9475_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54e2191840f24816b76892c14e08c0a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i786207e27ed54f20957d50f7249fc8f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fb95d9dac1143469cff7c05c1e9b8ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e34c85175c24f12a4b000731b5e3f27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30d4ea08901f40f8ae26a54cf87605c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24d9b25ab1bf48c4a7eb2a2fab5ba59b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08b8d363fe87400582215a448d41b61e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d34428a8a7a4c3a9834e0ab26aac210_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie423b51a2f17446f883f1e3d141a5644_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27e86737f524429b9f6404bf63655dcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2dadd6168e384b76b96623c95ede9e40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0f6509e6a7745c6b86b58623ec0a3da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3db2d0cd435749399fb50288da8b36ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a7b7712fc3d46dc8c9ab62732f132e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54f878726ed649d3b72ab3c31f1e3bbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2890488b7754499db8478c21b1fced49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2cadeec4d4b465ca3663ef815d82155_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5925981dea3b42b6b80c80390ff93ce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1dbee34efeb54f89b1cf37526e026635_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23d63549fe7b43a793936e93998114f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4730f5e3a64488fa803d7863caba436_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83ae4366de7949d1b80d0154a8d14014_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93817b4a8c5f47a784df62085b5ef330_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8ac7b2f72a949818e50952dcb98d810_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i253d96f29fcc4271be1786978a7085bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia483bb7e1f8c43579b9a40f336b26091_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i51bffa6b2c284c08942e4b334c1d5704_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id721d4b7291d43418158c108dc4def27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb1556a00d4f48a98b1c9c8bdeb762d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id530a91ad1454541a5602cb3294a21df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ac39c0dad404d8d8153c80ebdcf66dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0561e1ebce474b1eb9d143fd298c0a82_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8ac2146872344a5aa5941ed2d0c3cd9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic697c580bd3e4b12adcbe2d6812a9bbf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e262b7b10634d05983458087d0d704a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i855416e6b6cc4e2bbbe94916d33fb451_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32bef417f19d46c69b2db7cca231ae59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i348aaa35951d4227a378574421582221_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7724991aa49b4c29813095ac7d7118c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a6657a1ee6049f2939f90c46a8b565e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70512a720d8249c6a447f770e98bf667_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9410a99ac78b49fea836856840cfa817_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16561960de5b416bb80606e87a745433_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifcddc652bbad488ab1ee0afa359aebde_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07737ad4fa9241c6a7af7bedb530cec2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice49e3789be5439c9f19101663f83790_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fb7a0fce89244b7852f6f7fb2718f88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4d8e1febfc94acb9d1eb950557e11ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cf180ee19904407b6436c68eeb033d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a1a4330d80747c7ae68476b979046c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35ef7c64d623476b9744d8d1d932a8ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fae9b56ccbf497790ea241830626958_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica452679157c46e0baa897976e18621f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d5ee66c1ff843b58eb05f3777b56b8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22cbf7ef28864700b19759fa6f01b5b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i699fae78a900497eaac754517d1030c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa71df5a7c754df9b330874d5b7d0aa0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1cd464351ee4fdbb492774c72b7f0ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61199b2ae71d4a119d9701e06a107a16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7c3c53af69848b88bfbc37caf07b4f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i035dd6d3c0a642048d88fe63f7a78ef4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72c04c36693542238bff2f892e06e98f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6c1489c0b2445858572277f4815c6fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i266d5bf8ac8d461eb1d35c89e5cbf036_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib53680812f8648f0b2a86cf92d5a834c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3401d442aa0e49cc9ca695e109e88114_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaacf9e2737204b3fb0fc33abd7e63fa4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e8e9e1c789345cebe1a2feb0a026d46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i044a5eb77497431eb9a60b053d4b39b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fb044a8108646f5b407e315c13bc306_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8394064421940caaa44168cccf97ba7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifef434e9c591416e9cd79efc4e0aa93c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic64f9f7b7805469997412f2d21b49cff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e1030e92ca546ef841323d8c13bf48e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32f41b9fb6664114ba8990752669ce62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4039c10bfb794c72a6cdf0439f64ad94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47b0fd0f68794d0dbf248bb676c8872d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ad0dd09085d4434922268dce88a5be1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e9bf003cb624560a24158c89f5b413c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a5495ffcbab4b708606247546b1099b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id64af4f01f854deba8682c77d92bad2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d5b2cbf5877457a84627eb0b3ef18bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if727b53b9c13428d8682f12d2a2a91a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b344a25e0974083bfd701101c5fa14c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74b605fdab274710a7049bf3271f2010_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4661b56a33040d39e0288c81b250b79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74421933bb0140d9aef90e0ba650d3ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52caa45e571f49c4a4927dc80ab53ddc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i059b59eb77974214a452371c05d01877_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b28fcf96cfe404bad85bce40692dab2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i391f0428ef3846feba697cee554a7311_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i971392f8a1ed4acabefb0363b735d97c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedacf36cb97e40da88831c92a1a13dab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1de3fb51d6144fd87ad3b271bddef08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ea277d746d44a1f85486e2e86259f6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66bc55df7fa54d8eb2c01252174f998d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02ed3353738f4d0bbc5f8a1517448c88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d7f920dd98641c9922cd5f40499d770_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7730012552f84e97b24d81ea22e392e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic33e861c80224332a9e4e4a2669d4e87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b128fac9ff5430ba36b5956d34c25e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib17ddb927ae6489e842698e9bbfc563f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8e722d345f9a4cb1959d4880f98fb229_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b117048a90e4162b3f01f76bd79817e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i660aa25f8def4a02a2ee5ff867c78198_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33a943429e8d4b39919d0b4271200bc6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95769ff280e143bbbf58c6acb40fc937_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5211751f163f4b0f91dd14ccc368ad60_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8c71733d54f40a39764458c5aa47582_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a15e9f4278a4ea88fac685bd5263002_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf5508327199483d8b8486b1d9a35897_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ec3edcb4a104dd28abf353e65230c1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i687b62defe464388a420482db5f02ab4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9963f3c49e9547c8bd245f5a63f96465_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa5eb68768ad4f129e49070a05f2a51d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b38f67d770f409b806366759e0b2089_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfa108cbd7564f07a6abba1a44e49cc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe045779c301429da73c967dc0c4fef3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b8d95576ec143738ffeac1cac97942a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:CreditFacilityExpiring2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib87e561cb5e04d748723b1e3acc726a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5e7c524a0cf45b6a07e42355b143830_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cb403f6b8f742a98ca63fc690188314_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bae6de665ed403789bfbe721f25e08b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3147b1fbc1bd43a2a4e14a4f08917b76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if62b572a74364f54934ae9592882c5ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib981a715bfdd4b488f432d8966a210fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie795359bbbc64f42b3251279ad6b39c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2cf98b9fedf540bc805e6e4573df80ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66c8b6ecab3d40c483eb2e43be3fb7a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie28c7ac7e9a14c6793a223d8dc99e719_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib90c748be7c2480295ad0c48f90c8398_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc5564b52b29440f930fbe373023198e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91d3d8e7604d481c8c76134979113fe2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20282032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i245fc7da45bc4ff69d0b71a3f9034fcd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20282032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15b85141bb6247309c0b1758b23b1d09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20332037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaf8cbda9015c407c87c364cc6e12a77d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20332037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb5bd2da85b845cfa033f3fccf9badef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20382042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9525871ed73f44d6aa391c6a1148f943_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20382042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21459a6d65ad49e68898cea099e9eefe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6fc4b12027964c209dd3f92de86d4757_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if76ee4034a204733a425e8616536a46d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20482050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b3c3f8d66c14cbc8ae2209a47f7b04f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20482050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i002328e67ca24b3c928fb4df0a88e15a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife593b88c8974bd987809c90a29a6b72_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5c6cb1e41494eb09f678d0edb941748_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i9d7b65d44132448f82b9c8c9f19d2196_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7b576060fcf349178ba58a38684ce7d4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i819cd9fe271b4f23b98c4aa8123518f4_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i764ea60e3c5843d187463c0e16bc3a31_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i44be768342d5410a8bc44e78dbfd764a_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ibffce84ee6544fab8b3ff9dad69b30c5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i02409e3cf3f84191a57923a7a02a3573_I20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="i8dd2fabc2dd040398c9f16166684d63e_D20190101-20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="ie2c27ab7b79c44eb8dc5cacfdfc2c180_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibe6795e8aaa24dacb586776b212b0467_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5642d601e9b4575855e7055a2179740_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb5da43009894cfcbe030a782ed8ab5c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f629b69199e405fba72ae99793d09db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib7e05b819b13428c8901fb90ffc12e0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb95eee963804a9da724fc0b9a933126_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80221d1eb71049dd901d6934d2a813dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i50751deda7b94646b1c4601f55800d04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia09f964de2c74f4480c86cb376df89cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i256d1411f2e24c3dbb0fff716df03a28_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i51958a6058fb4561962481a91445c919_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2dfe78c0227242da8d1e000875a849f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b659aec1f844db2a05972343ce9b28e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf57de0273184de19e0ad20b261a65ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23b39b578b49438883023557a0dafa81_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a733f3976f84308acb3ea5484b8f248_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d6c69496dfc4b09a0f1e641b148beb4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i491b1222430d4a789c206cbc43deb5e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07fb7c4b4ddb4737a9d1ce7c1eef3b72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i072201acff8f4a2a8a8840f832ffafad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc6ccc570ab144e78a6500343885c124_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iabe7be2f9ab543b2823384dc71197c46_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6be3ad34af1447dd989b5ed287902d69_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f72bb2019c143ebb3750784176bb259_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73fd8308cd7540aab95e1803c2e1110a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e28876e1ad94a04ba445e3810de2781_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16480fd269184b4aa44edd9f8afb1421_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85a9736e786f4e32b7b3bb0b15bf0fb6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie224dcd349da476b855b2421bb0a0132_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice3bec2ad3a649d58890db5c58d3e893_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib53b2599306346b5a4ab30f2665dab82_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17f9a88a6c804b04a3204e7b05960707_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7df24c7dea094c21834367203566accb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifabc11d015734342b4ec641fcb91a048_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81cf4819818d418f86a5c4e9f3aa0dd2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd276ef364814442a7a5f98817403b1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b05567ffb6747f98016146f80cbafbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9a02ec9594b94a0fa152afb9f34199d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0fe163dc007411b888238de88875679_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7faad75e5b2e4283af9e7fd2a1138431_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6929b7c58269479390aaeda0ef2a64ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib28e1bec91174c29b172af677b8adb54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i862ba5d064f0443ea496670357f0e14d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4c3ddbbd35b4a9c93f095e97b3679ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a96e38f1c5942afbd2a39144f01eea9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id891db98fa4a41bd8a834b3d854a897f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib1196e921cab43bc8fcebc72a5b56c82_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0f9b0f72c81473eaed6b48b9824aa65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5473f4c065384253983909169cb3535b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i533cb430fd184762a6597353269cb90c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id841cfa6c6904f82aef7fd3fa2b9d2f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20c5c5b1d3ad49599584c64b0869f298_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i292ecffd1f5943b892a2111a12ad7ce2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16152f7453824ee58ba88fc30ea238bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i392594e0d42141e994ae16e92832c84a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if38fbf9bf0a244c6846d8ca1b19c3cb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0a6cc9cf7be4281b01b2de3a7c6a65e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i877c3de4913144ab97a4f7a18ca1272e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7dfda91c8274099a7be0f74bfe932e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d01fcc1ead34ff9ad40afc6bbf19695_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3062c07484944e3cba9f2336f472c327_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6ebee0abdc945fb9926a62c16c68fbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c28b6acb28f4060af3af8398ee4be76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5bf1a42539e54965958a728a93c1e756_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icfc5354914a145cc8d158da2eb6e9aed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c7f4f4115a4440391144e3b67630665_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b140461d860414c8311ca9c9a1bcc99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i041d9d29860b421d98fc6a57f3ec5050_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e809c5ad84543eba6828d3d0602e30e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i210ff70401cd4760bb6335c8c08e0015_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45d8008250614fd8b057a37d793a0b06_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d89dabae4f640e895f7324d6d8a39ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab33eff7f5d845e9a17bebbe4e745ebb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i678256d1b0484d0391cb0e64324ad0d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c7941373e994dfa8bce5cfe572bc7e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc33aaaa074a4869814243060c036a4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae113685f9d84078877817f16330ae5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6691b5ea5ce944ac903398a39bf95d3b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i462c90dc9eb3411d9498b4a28515f2ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f2c89e1ddee4381b1db02809acf2a31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib52bc8201e914daf823fa750d650a1f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c471c4205474e1e97c8885b423a5556_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i630b3dfbbd09454388a5a6976f3655c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idec3f3c060644f67803ed29adf181171_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic5710bf2055845c2bb0af48ab186abf3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60429211f00e4543a9d87883c1802d3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60c7b4506a324d4bbcbab70e430c8662_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i283602e4cefb4da5950be8e7d92e7b33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49bdb977a6c048ed8147d55a219d65bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64901c28b3e4435fb58c625d1c7cf873_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i74e82614b28e43cda6969e8c6d06b101_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if89fbc914ea0495c84a57e279acd25e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icba84ca9e34e4da6acddd4a5dca78acb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2eee230e2ad24b56a95a98c396863239_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37b1e9bd443e4b9dacb7b420ea97a93a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89f847d9790b41829a5de2c58516e44b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36aad9909fb14c9e88dc6e895d2ae970_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88fc1d8b0293450faef44d3939baa104_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee309d4671204beb982620ca87935160_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a840d48179840c58c095b54740189e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43adc45933224ebb81d095ee790ac1f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee6805ceeab9416ab34598f009a9a3dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccd31c166a8342b1ab79aa126ec89e2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia386fe05870a4d00bf574703282f8e14_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ecf8cfa85c844e994e95ff8a0b018cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e867961a86c46988276f2a8e0b5563b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1eee291364c41d79df9b38be936c743_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89f82686b88b4e99b6d4c1a1a66cb7e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia951c8cab72446a18ae9742d230213ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83f95cfd93704f94897bc57033b1b31e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6fb94fe8a7447b0b43f4729bc6367ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib998445075734dc0859b69f2f70d7eae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7cdce9769d51453485e9ffd8c6432ac9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5efb9b34ff354aa695d0ce5519469de9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4de93f17bb5246deaf177cd4c179c2d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iedd08d03a6f8444e8e25322e621edaea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2fea9359eb542c88235d0e94cc3e253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7baf2c21a80d4f38986f54d8c0033701_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2702036ed2fc41b8bd3ca11952dd39fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i123f921d862b428288283381a090761f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ccdaa1a811a44b99f3c0c1ca7eb44bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a51613c60584714a3ec9b2ab496acce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09a618c301e845ed90388735dad7841b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e9316f5dab24cc588e8c9e879cd9341_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id568702500f6432588ff76e3c3f36577_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib38fc00053aa4c199b39dece7cad7cd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id20c6d20908b4daaa553daa64deaf5f2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc201aae7f2142fa93d6f1984cee3475_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie08bf866f12c4207b983f1e7a10c0e8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia5407c5de8f4429b9e4f43939bf305b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf1f6db9b9894f909a5796169e3fa818_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57fea877a08c4296bf2ba0c929fae62a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bcc6044a5d34518a267a09836a28a8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i742813cbab044d04a09ecf0ff835c7f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9d5003d9185448588413661fda71f1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6960f5ec76174cb5a4931498467bfc1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c51183fe29945a1bc46769c25b05d2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a2177b163f24101a81bc962d77be4de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9254bb662ee04eb7851f6a0b2686c6a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia249cd5c4d3a4607ad781d7a08f45a32_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id179af66abf14a9fa7b1bba32e3acde8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0614fc26162d4735ab928995a4525919_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57504ba4b31c4e419514d3d822decba5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id76b3e3473a8474aacfe913ead06f99c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecd486b3bd864997bc5dc92f53919f6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f7ba90f110d40e2805438dda627ba7e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73e7d40fad2b40cab376ebfc9484a1fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic97e4ef4dedc4cd4b036e878ea92ff23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if24ee12e5a364e699f1ccff806b6610a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24262e3bc3d74c4f9d4ebcd94821b450_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i91370cf282454c17b017708814f29a5f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i589b9c0f0529485b88483ec95805a113_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id792c4fa30b54b0f86d3a756dec19969_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i557b046786b54cf5a7fd128f940aa558_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d5e155c28ce45949b23ef1c2aa7bdcb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib89426b5421f48bda2e841651169370a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0eeba8032f54437b2332b040493be10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5fa59de110c24310a8a3947fd9bf785c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01e99ad5a3624b79beda47b0277cfc08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9178dd6228bb49e6ac59b6bc450f5f0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idde04c3fab9a4225922b968a4ae389ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i447a8db12c9c4335a9e7ce727e1c6c75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27f1331fac0a44ab8ab767c27460f01c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b8df318e157488ebba552305374f247_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5a6859a81d948b1b05d1524a2329d05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5be279af8994b7baf6fe7f41d4659d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8a28d95791fd48349d327616387cf43e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3fdb174e64745cbb589727b895dff68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe8ad87158d744cb98b1afcde979e2e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3acdd3ac8bd749d6bf766df1d252e13b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c4cadda8ddf40c0865e66aa16db1fb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd30853b5aeb4360a8572bbff63519e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b913c838f444389b2b5e72727c9ead7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfbcbfb8ada844189c00d8838d1d06df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb2a8f3e3f5140a6bbf5b850dd9df831_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61b5f086df574c9692cfb7bc457ede83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id5b1262aee15447893f4283772570e1c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2204111742ee4465b254c1d8def302f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5054f1ba961b478e81844b3970edd709_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i407c2c84a6fa46d19c024b335e5207de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4789a2744a994126861e99bbaa61a091_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib632f9766b1b4f088ee3c17033d9b730_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4b14ebd35ab942468b155850a50635d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89b022b7da864f55abf40a8814adcc45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57736d5c9bd045889e3e70f907687568_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d396dc1a9fc4ebc987eb95b09e2dc46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e2fe0961b7445768068020c53ad927d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie575e7d2482f4c67ae9b25248a9ad0a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6a7d8a3434554d0399db965a1f07c58c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5be90fe1c0944a43b096201649b0b9c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f8da59af46f4f0386aa576b69074f33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22075a2e3ef34cbf995ac7e82012dce0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0863c82bbc51409b8efa496f8db9fdeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib30b271d8b274f408f4ec6c14285b00c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0445954f919744a9887083dd3819fb37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icf9c3b10b55044c49138dc630a759469_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iee038f714c2946bcbbebc2ca551337d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62bb9a408ac64e97878a6c8ad73e05e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iecc0a667f1e24e80a1d4b531f082b57d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b85b80107be4fb8965249fc26340ed0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b0a5ac77175482aad6b61c53e7c43e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b6f712dd8c0447aa8f70d3d13ad1e6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i329e2ccb8f4547afa328cdbd5609b4be_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5836472a076b460991d1eebeaa047f8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d752324547a45d8b253e8c8bcdc884f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if86170cd6f9d428380420d95b35931fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17a849b4291f46ee8770bfb32d9b35e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a9982822ef54206a5a46c76586d2f84_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a347ca6972c4ccf8546cf5025e6876f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd4a43b1598443a7ab6eca61208eba5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c25f3b4c7ec40969b854e0ac925ba55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c46658794be4817aac85595e3b4fbc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c11b3f4356845d6aadac688a6d24730_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i692794301332409594d055d1c7f8e64f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5326e53aef0646728ea9fa61b1a7a0ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b1e59e825ee4981a7d38ce2c03e80f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic93ff27c78464387b5ed9bc21e35646c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb581ffa12d14ff2a9a1844bbaab94cf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61c36130da21474a97558823d72cc9c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82b2e88175ff4f378684f8507ae69794_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i758430987c524ca79a1aaea82cb98356_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84b995529e4646e5b6becab80303e6e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f16642eeded411e90331536700f0546_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i379e7c46cec74ebd955ac7a7e03511cc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2eeca61f3244ee5af945c85a0919a57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c237700488c4cb8b091e549169f189d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03d125dfcb4a417187130ddbb9460600_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53a90980f6dd46818498f9ee7d139756_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifce607f8a3a94cb29fe8250722ea7383_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i632d5976180f4e41b0ae66ce2781ec7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1c72066d02e480a8fcbf60f3979e383_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i671b1638704a44c290bc349298d71e48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i17829ca318b1498cbfae61d52d4675a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a7fdc62e800449d92622b90c9db4ffd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4dfdef0347e94d1498a69a86deaa56d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9b0fa1fef2342d79c4cb9415d79ffd1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f84fb522f6f458e920f395b641bc9ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1120f4dcad384a9abe38b1b29af1c6a6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i015c2dd1d8224aaba8f11e2779372636_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i674db30e4e6e4a1d9f25a2bfb6a2ca07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i732d0c54d73849b69f3d917bd43daa7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if2238ba918384e999cc84aed3dcd385d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i866e56c0277b4bc9a25f19ec84f3fb26_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24949bc17dc543c08cedcde9b2f3d7e8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie133e397deff441e98308ae589756218_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bdc708391174865b782df989e1ce518_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i574f79e048bb417ca2f0db77a714f150_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77d6d46b530f43febb88f895a185afb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifea2ce2cd7f74f449218e9ebc7dcf7c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba350294128c42bc87995ecc8e035456_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i532f4bd22c5c45d4af63afa5a4f2453f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9306a220094a4ee4851877329040ec09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98efc316265f4aeba589a5cdcdb2ba3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i255f65b9224f4081b95ec6f405a1952b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59707801ebc544c4aef8569d05013809_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6f9185b14e74414b6142cd14b78487b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ca53c720af3408083112ad16a8d242f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13d65917ea214718aabb6241059fbb61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab50e3974e214326979f7b8957262eec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6fc429f107fb4881b04687f32fc0685e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f2413d9a6104540883ae20a14dee735_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic18418a4253841c684ea8af6ccec0aa6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3151aa7ee6ab4f8398bd9a46d307ae04_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie891101977024301955e23a929e1b4bf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17489845f01240d096281d798554cdc7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i778bcf63d499487093fcd6b390c2334b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic3987296f1084db39f1525b58cd1a718_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i495275bffa674b0f800ed1decb890131_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i624dc668a9d84bf4918f26033ef6b532_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5289bfcfe10644b0945be402d243ebfe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife9e20479d3c4f3a82eec65d7edb2fec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9af20ea2173648718c35eddadc26f4d7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16cae3cccb9b437482e0606550ca5f7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e4072641bf848fd9a69cde4746de8af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4895c42f91a3449d9e4a69e220f8567d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie49724b7bcd8476597210f4014ed8c5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4e9d20521f84171a18296ea65d842c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaafcfb726811461e84845b5dba189707_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6a77fde9c8d47a0b5a6ce8b6f44b599_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i388802b089ce4803af64b6ab3e8a745d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if48068ea782f42749ec61f3378bf81b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib94cc14b225548bca7b6f25c551f7130_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i60ffdd0bae334efa9bc4cc9090bf826b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2bc6edc92b8c4f049c4a39984706caa1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73f245cfadb84797965a899a8eeb520c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i793b789e8a0242258ea94c9fd8c9f383_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifdf0f90452504d429ae0f90828d23cc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice8be255951e4b8481ed15370c61e701_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib471922b03524068902766bc0fa91108_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa1343d51f60440184a9f78f1c9375fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibcba539f4ba046dd8c2d86a34034ea81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3cacc2f9fbf423f91cee329fa9e42d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb7e4de941cd41a68b47d69317c51b21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iecfedf0b60464ee4ad5a115a4e7bb74a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e1c0d0059f0445cbd0935e842d98ee3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4eecfc1306b84ab281bd797e77e015f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0b8c791011a4a579e971f6153d22ff8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i847e93c8a82e46f1802cb25b6ad0f2a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i622723f52e094267ad1f1a6f20f16021_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i813308e909ae4e17a701ee9b75f8371f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iadc214917ea744b79b2b73e6471dbf01_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebcfd4c10a4142fb88a316179c35e0a0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica401af8d1ff43afb5c3de05ed7396cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanDebtSecurityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27ea04bb8c1e41a9bdd1d1dc8714d350_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51d675d40b3748ea9f8d5ed88c985153_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanOtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1825332913b4ce7b251fe06cd990eb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib14b680e409142e6ac7c80709cd5e4eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13785fc5583c485a8b9868f58464c651_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a668a32aa7b440ba577921b46eb3b30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i367c45882da94e7f95af6582e7a69196_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2017StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ie44e280570da48ac9f0565d31167fa82_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2018StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5cbd61ea7e074c3cb9b549fc73f7ea50_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="if31c50772d7a4726a1a5529a7fef8da5_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i952c34b232a94d2d8ad00e03c4de2d9e_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i81e39a223d384b35843e9b8e7445832b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i56eda332625c487ca483e8359eb0f33a_D20200504-20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-04</startDate>
            <endDate>2020-05-04</endDate>
        </period>
    </context>
    <context id="i152722889eb34e0db6ad2e1dfaeb0eed_I20200504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-05-04</instant>
        </period>
    </context>
    <context id="i7ee44a1fecca4b32be7705bc2cf810b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd44478503164fd8a8e14462b5e7a729_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i917415daad0a4424b8d7a97c2d07bb8f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i805079d974574ff6a2d5f8b886169231_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2151f3e772140029f5252c02f68b75b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic44cb9f5305946c5afb2c81a69675dff_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic17568d2b6964d96a3edee3790b0ffae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idc7be31568a945ebb1201de1758225e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i79ebdb6315104090a143c1f852c2ca78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i867dddfc2367440eab83840a05865495_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7392a7235580422387964189ed5a7ecf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i04e1e8887418409c8efc97bcddd13100_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b45cc72fe144a41a027fcc9d82be277_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6748c5eccf3f46b1be9064d93a0b8af6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a49ac6e8d614f469106f20db9f45fd0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0593f22a56d847448df2ea20affd43af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28be20f732ea48069576d8342f25116e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie383f1f76d1640bb8be8220be13b0054_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd7ecda840fd43338a51a3f00ae86688_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia083e623ee674e548622522766f25245_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9593b3f58b76448e920aee74df7e93c9_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i2f80dcb721524320b19d3c6b3d3391e6_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pfe:GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i443cb80c5f964703aaecddf09596d6a4_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie346598571a44f5e9df70a558c1951da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i79f990b041fd487c830de83552bdbf07_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38803c12b9b3449f99bdef5250359030_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i234cb2011c6d42c5a3f00401f9a682b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i025b64a058c74145a3d20c83e55e303f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2473beb495894534a4c23085d71539f7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32f0385272bd4aac882c487c230d065c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief795c9787db4b308dde841b75ab39f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30bd7895983642db9bf813a473267120_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i220423650ddd4f2190621f8d4fc9821b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if41e5d4716e04e498cba46b05595ab61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fc53e6e2a9e49298a3cfd288203afd2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84a9df877b7a4600aec68656dac6703a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7f0f1f3fa304519914914cfa722b7a5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i97f983501e904503babee369fc4f690c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b9d4654dee8466e88457fed9824652f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibabdd67705e148c3827e146d45375317_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i94325d0fdc4e459f931d66a9b73fffa3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb707d364c664f20a32ea1127fd4286b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5a24c56d22cc4eb1ba8bcbaa319b4761_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if9cb70c93197414db93c20b578e77936_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia38cd1de7c7d4dbd86cd29bd60031120_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:BreakthroughPerformanceAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57785a499e164f5bacbcf350c3fb80f3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i983864cac72f40e9a85d8421bcaebe0f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c06c854564f400a90dbefc01376069e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f1f62383330418da8e053b9b9db9ba8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d1bc977a4bf4a8d8dd29d3800b05abf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bbea5f2ec0948fb967b4a1b64621b58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia34e871fd1d44e8ab3ff53c514b55b51_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="id0ad5620c98c434fba738a4d9c4cf398_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PneumococcalVaccinePatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifdd76542ed8b4ec69bc988447f8ffb86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:OtherPatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib18ea7fb4e2b467092e7d8b1a4245c1c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if309e75442d740928d61d06aba360a99_D20130101-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="ib6e95e1dcabd4e7d8e7e9244ff512b69_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib4cc2245228440d2887171a58dc8189f_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0d7fbd03fa994fe7aec0e5f20e5005af_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:MeridianMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i9655062295ea4eb786880d4953a18367_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic74107e930484043af252b70ef86b1c3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsPurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46149707465a45269f0a4d9663481faf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsPurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4388992791af4d329ee32af6b701ed74_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsPurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea96d19d201f43f78403ae7000de580e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsConsolidationItemsAxis">pfe:ReconcilingItemsOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3331360a352a4974b87a0863eff1cb2b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">pfe:TrilliumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i01706a25eaf44000861f8a5988b1cfd7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80b14f941e6742209cf14aecbed2dcc2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66820026161242ecb7114f5badd98288_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61f3df5393924c84a4d3bd1ee41d293c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie1faeba83c004ae2b29779566eb052c7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee440d1ba7794b8ab3cfc128d24b19b1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib12fb6fa02754813a733da0d0a3c5217_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2bf364c90ee403f905cf44b76b83795_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib5545fe7ef044230b942499024d73124_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i07534c0ef5da443f9d23bb709f1f887a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e4f467b53b54c268aaf5ebd5d255312_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b50c81dd41c4b93866757262314077f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic62778dbebe74ea5854c11429ef857e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99f0e6a9eab54ae4a8ed112ae8d226a7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d0a8aaa82ec487cbe6efb57bd4d09ae_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6b31b69d78a84395930b25d3a0a78c1b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6d67ec1ac5234c0d9f621dcbbb4183bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia9c607e23c364498a9220f891e27bfcb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i76154b8bae914f14a3264e5b5345009a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86eb9d30e32741049330f056b435d474_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie70843c611e141548bd971cd5410e88d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02e740ce254147a096ae80d08c9094f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice936d0c8940458e99b8cd6b72505a29_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1412106f3b64e9190b955c58956f7ea_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9fee695ccc6d4951bceaa4452197ada8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2057fb4eee634619a81384ca8181d059_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b05c103030344159abe87626ef3fc58_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i12c71dca498146b98b69c59745867f99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if47ab8b761c145ba8c1e38b804fff672_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08d75cc0ddf8452ca93b381cb375ed5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec439aa05d4f4752ba182e07bea798ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b1ecddc539948bfb8fb4cf369085020_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9e53394f559452ca83fffb3a7e16401_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibdaa8f31455343a4a4b78e91aea00e81_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67454cc77ab148d1a8042c793aab9a02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ba39cae55e2432688515ca3a47f62e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4ab42ea69a04305a2fa6db983f61342_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1b3fcc1684c04124ad431600c3ae2310_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie683f91cae7e4f439a204f20f28ecdd3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i790164b8b500487995993a2e01eb13c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i010d3fafcc354cc784caf06fb723ade2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff979b3974154ad0803e20ebd7c32f30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if78e81b138394cc1884da57948dee8e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a4239b3555a4e418c8a9a5e9d67c2e6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e5d56e1790d4d3298629659396a640a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4ed595eccea49ffb73f0798a75a1773_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76fcd41f92da44e289e82affd418e306_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i84925602fa144f3ba3a71b13029588f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a69e52cd15347808dffa431d34044db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf42e0f52a3e45b59df985db36745f16_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieff4fe2fbc324b449cb56e68fdcd1a9c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2238b79faba4effaac005b81ff23304_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf497a35e6494fad8698744787351909_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8f72c5f82d75415ba597df7de74760b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0750214c46a64ab6b39e459f0d49daba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i20e64081e3f0434b872e5a4506e536de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacb6a72bdf8141cf863b344e751661ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8eda9019748445348870a74c3bd3ab6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5790195bd954466ba793840f2495ee93_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6a6b539896c45d79c389bacbc2f4743_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie427a740ab1c443d87ea004b5125ac8d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iffa09786cae24e62ad36d600ee535ad2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92db76fc792d40ad86670b655627f383_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i95c0ae9140eb4237841af25b9edac128_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3efd621f0e0d4d2a8760e00099eb67a5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9c93ecc7240f4fa3ad8ec0c4c64303bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d3a6827b38a41d7a516870ab707a086_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55b91f673fc04f73a3ae024b9a41752d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe1f7d47181e475bb3aa38336cc6209a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5858407930714ddc909e6bd243e24efc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifcfc0ac3a4bb41e6b2470eb7d7c0ed54_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic828b8310b6d4b5bb05dea1dfee3affc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i13c1116b8782479b9a95ddf926b9e0b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28052556477d473b8c21d8bafb9cead1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3b1304b5f82e4e58a1c55dc33b956260_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bad590cb383439c9110aca0d945cd2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22e5406f5f364c5eb193983737f6387f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6acf78ac097b422b88e179ee9b747007_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67bcc609ff5d4139b0a6a18177feb882_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibef0fffb95fb47da8f0bdd6c91925689_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7590755364db416f9e17b48ea64413d0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65e7d6b26d7d4a74b5f922d708d9a413_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2460aa2b09c74030b8381ba12fb645fd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RuxienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i81b6c834fb1c4292b59fda40ade5b9d1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6ae2a7d71d9425d8152e464a315bf21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i975049da60424e96b8b532025ae69caa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibb7484561be64aeb9ac7738d08ab387f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4de75bb8b77440d0bf45934e1ba87237_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i83d8b4737c1840a0b89442498290ca65_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZirabevMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida0fb8d22c1645438cba3e8ce25ca48c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67382282eea44a6a957d3764ba308d11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b122ab8ca744c749dc432ff78c16ea0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LorbrenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic36583488c824eb4892877ea211dbad5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifc957ad3d68e45c5ae1a74b135305349_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86b391f47cfe48fe93bdb715d0951829_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AromasinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i23070ab492904e61a59b2297b56b0953_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7733f5b2e9345d9a1e642d4c79139f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1933184cd1e5441e87193869a01461e8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrazimeraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacb7b7f56fda4c10a3da08d150f67fc4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i625be7e17cbc4e3cb80799060c42b8a4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e621ffd98b54fd29f2e02643a70ad30_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f9007e1cc1b42109548c43dc4c66fae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7d9fcaa44eb493cb0d96f6c81f2a2ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28dd61ade4364d5a90e0a17c4f83e822_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i60a9e485dc774f3ba6d70e30217f15f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e987f25dd8b46eca97df2eca4a9c075_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i736cfbcbd4874cd1bb2dfded6deaeeb8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BavencioAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8b56db0f447c437197c532ee8f7047fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf3eeb0ff7cc45b8b0e9b9da65bac12e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id911443b1d0c48de95a2929266a7582c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i25c019e4bb9043ffaab47e93d8c852aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a302d7f90c3424fab750ed285db9b29_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39a027609db240a7866905b49f8d682d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibb26436d0a1448cb81ceb46110a4f3eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie4bfb7acabb24a67a1151e63cc4fce68_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia8c89535e85f4038a7ec373e8a3123cf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea9873a8979b4508be42cfcfe7747f50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iabcd20f9c06a43dabd464c0015ff8930_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cdd55ff3b5d4c52861b121e66ab3ac7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36bb0606d8cc44ddbf05cfe5192a51de_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b4ecb4c49ac45c096a8e6606e325b90_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i33477546f42a4341949e28a3012fca3d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i55ac74fef9494583b8e81681775bc2b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc1f43e55c834e949f22669758cc7ee7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f598e5471364ba699cade3d65d16c2c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b97da5e9af14fe396e47b0d71d869f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7e0cc1b139d40adbb8d7340de280263_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1f3e974364904421b9ba3879babbf5f1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieb84bd57d736452e8091760a4451bf32_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i789c240c68ac4def920f05c29c59b9ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bc19ff52f7843b19250144e07c70512_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia28339e568e9484e962b70b87aa216f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47352f77aa394099a094f2eb6b3aee0e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c315b990d4b4ef4b6f4fe096b1108fe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PristiqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i93eaf75f91e64395917e59ebf57f6d3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icb67eb0248104e43bdd406f377b6ff52_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e5951a6d7c24aabbf638e2cfc5d9fad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1efecefa4ebc419689066fe6e6521f2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie86f9d77d3ac4df098fa6d23ca3fd9c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c0eb57c151e4a51b244e35e9ceb3409_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i864f375b8a0b4cb9ac443ab41aef9bc3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib48b9e43f20748079898c888a0319e4d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23cf6ca73857476c8ff2bdba66164ed9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8fcee28088674808b29e46b75901de61_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia26c6c1402924d3389d90318d7b7a05d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieed935509397465ebdcfc54a917081b4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic429688b0a95432ca599be902169635c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7715e12d4d640cab70794a4955462a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3657cbe2097d49f09bc5c7ace046f357_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZaviceftaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iea0f38aa0b8344479ee03e3bf63754ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i556e45078d274acaae78248df82d7516_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifa5c08d894ca47fcb948a6643738b465_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id11b6e37093449bb86170837f29de961_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cacfa22e3f24fba9a769d3980dee98d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92765a1b79944c1c9064745303c5bb8f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1d9c00b6c0fe43929b5baaef97fd98df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48f1bb2ae72c408dbdd9691315c5ceed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i976152f132e54933961ff0eb781c15eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id5573eebca954b888eb53c05194e1cb1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ec61b9fd42f4e11b22c341a2f524130_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icecd0bd3f5d64be6b655bd11f2dec987_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iac09b89e5bbc4d37ad7c15e4b948b194_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15803142604d40aaba5216963466084d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if479f5e8c2794e9e90a2742677f13fa3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1505f771b019477290eb9cd549444c29_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i64e4fd49f5a94424933d7ef2c6829721_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b70715abc94491a9f13b0b6351cfa47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie735373e16a54b109a6ca3eef912bee6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf401509c5154ce99e7c8858bbbacba4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c1ea9c9b504497db6d2486610d3f9be_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PaxlovidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i08011c6d22d84826921f15b42efbd425_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9e0d8215e037429fa7a23c4023f0d1e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9fb660a81d4c4eab803661bac2510826_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IVIgProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie5eab6ea9c344750a8cbb61f815ce93d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45a69b57be5b4ffb9798f0dd614f0c40_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6571d00942e43b7978e3b7b74f6edd6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8053c4ee14d4eb98043aa3562d93dc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icaa0004eb00541dd973b2f4b93c282c5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i713a733530404ed18373bae05f6b3cb6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d0dfa4a22a74f91abffb964783f5b3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47bcf7ce353c44f5bcfdcdee0877890b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic4f1c35594c544dab5b1dfa223ee4637_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i70c6cef914b94f1d9ad5c0270ad54b42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5563b77001b44cb1904e2c79fdf3e92a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc98ac45c09142c7bd8010806f4ab103_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8922522ea93a4f3daa0785e1fc05776a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05428f6e4c154ff7b4054980d1d8cb46_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i350105d44425447281d31cd6eb39f7c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib47901365d3d4bc0bb6d60c486ef4e67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6baae032a571408ca95cda7430a3f436_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71f59e7bda3142f187e0612cca60056e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i34bb0e10a3254deb9c9b88fa560808c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie013202cd4c84b0ca180ef2bac1c2fd6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49f99cd213cd422f98453a77ea72f411_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11d18c120b6c467ab4451263aebe5da0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62b3761d83784fc7a895b99aab8312b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idfcbdb031a3e4014a0cbb064217500aa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i62bf6fb9bf9145e6badc4cd8e5f71064_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a4105a4588d4e35915a905b52f68c56_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff6d7e329bd24eb4a5a437d5f214dc41_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i03db65ef941c451aa8dda7f330bc59a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d4ea528937245a980a0cd68ff2881a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib70adb8ce46e49d0b66f7c5db2e887d0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0cc90c9a8c6548658c7c62c694f4b1b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idfc908d4ea1448b3be3181f507e32499_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i71abae4333e54c548a4315c66f1b397f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3287158066bd486e8eb1277ac8bd7a2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i378275fdf5c241309e4fc13c042fb25d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i484dba9ec8d0445bb323aed6db364c28_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id0d6d788ad4143ccb88dbf6bae7eeafc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd236c60a6694d4cb50a6a582663bb1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i503af1f1138c4021a803c193d30090a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i623d184c533f47bc94f2a7ad9168813f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27ecd1a0cd424241b3ef5a26c2f58f23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2c4ac602963e4692bf2396276e8987c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i629787cb4c6e49829464bc26f89c64cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iff57629495074f9eba67dffa28d6db32_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9b3c1fffde345738b432a24553ace13_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idc38387d7e3642be97acbeb8bf6bdcb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ef775a73de440e793ff799dbf7b5fa7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e851a6e197444cb8fc69f8308332f99_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i92d39854eb2b4573a531d5ba9f61e8f7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0d7d6064a3a64aa6ad422f45888299a0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39801c36e4b84ce8b6d398e7fc12447b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i82c3b4b2ebc94e5697c6ff08a35994e8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec324211aedf4500bf27dd971b841288_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1e4868147c644c12aa0f667d7f6e8057_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic1631e191e764640a3ad6ad0db704edb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2fae2aac94946139c72a9f5a683a557_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i027e0fdd3ba440ae86709e0f6c28fbf2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8abd4017e8f04c56a2d4cf46f2d31c44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c32373d4dac49c19122e22f70bfe22e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic21b6b2a9bc64c5cb347be77855ca1be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BioNTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i52bc922f23d94809b6348416f7d67f89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1efb123775446d4afb050c15a9de3c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd473cbb8e244c0baf184d66619e9bab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i894356ab8eef44b399b55416273a7ef0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id502e86301f6476e98c1e91bd227d64b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:GovernmentAndGovernmentSponsoredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ComirnatyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="operatingsegment">
        <measure>pfe:operatingSegment</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="employeestockownershipplan">
        <measure>pfe:employeeStockOwnershipPlan</measure>
    </unit>
    <unit id="tradingday">
        <measure>pfe:tradingDay</measure>
    </unit>
    <unit id="measure">
        <measure>pfe:measure</measure>
    </unit>
    <unit id="period">
        <measure>pfe:period</measure>
    </unit>
    <unit id="patent">
        <measure>pfe:patent</measure>
    </unit>
    <unit id="defendant">
        <measure>pfe:defendant</measure>
    </unit>
    <unit id="manufacturer">
        <measure>pfe:manufacturer</measure>
    </unit>
    <unit id="lagoon">
        <measure>pfe:lagoon</measure>
    </unit>
    <unit id="country">
        <measure>pfe:country</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl8yLTEtMS0xLTE1NTYzOA_de7247f2-19f5-4b9c-8988-4ceb434883b4">0000078003</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl80LTEtMS0xLTE1NTYzOA_94f096af-e06a-434b-8735-938d98ddbb89">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl81LTEtMS0xLTE1NTYzOA_1aa8bbba-07a7-4a60-8155-10731f29a432">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl80L2ZyYWc6MGQ3OWNjYWQyNjg4NGI1ZDg1NWNlNjVjNjE3Mjk5MTEvdGFibGU6MDA3MmIzOGJkYmFlNGY5Zjk3YmMyNjc4ZmNmMTU2YWYvdGFibGVyYW5nZTowMDcyYjM4YmRiYWU0ZjlmOTdiYzI2NzhmY2YxNTZhZl82LTEtMS0xLTE1NTYzOA_7f910169-c75c-48bb-b0ac-7cabae2ad569">false</dei:AmendmentFlag>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i574afde0d29749d9a45d3066b313f102_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcwNjc_b11edfc2-cb4f-4099-b138-98c6766b88f5">P4Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ifa1343d51f60440184a9f78f1c9375fa_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yLTItMS0xLTI3MTM3Ng_b4c6f3b9-8438-420f-9ac0-6d540cd6e739"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ibcba539f4ba046dd8c2d86a34034ea81_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yLTMtMS0xLTI3MTM4Mw_2dc430e3-09d0-442a-9b2e-2a095bd3215d"
      unitRef="number">0.10</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="if3cacc2f9fbf423f91cee329fa9e42d5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zLTItMS0xLTI3MTM3Ng_8b03453a-f25c-425d-ab34-d278c1dbbb5c"
      unitRef="number">0.20</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="idb7e4de941cd41a68b47d69317c51b21_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zLTMtMS0xLTI3MTM4Mw_a974c308-9010-4419-8fcc-4c8d44dd24d8"
      unitRef="number">0.40</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iecfedf0b60464ee4ad5a115a4e7bb74a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF82LTItMS0xLTI3MTM3Ng_0dacf702-43b3-4892-bbeb-4577d639a5d6"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i7e1c0d0059f0445cbd0935e842d98ee3_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF82LTMtMS0xLTI3MTM4Mw_c78e26c5-e92b-46a5-b914-ebf670bc636a"
      unitRef="number">0.75</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i4eecfc1306b84ab281bd797e77e015f4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xMC0yLTEtMS0yNzEzNzY_9c0e5109-34cd-4c1d-8c3b-5d1d95a672d4"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ic0b8c791011a4a579e971f6153d22ff8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xMC0zLTEtMS0yNzEzODM_9a8f2202-d8cb-4925-953f-c1ee8f7810d6"
      unitRef="number">0.20</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i847e93c8a82e46f1802cb25b6ad0f2a7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNi0yLTEtMS0yNzEzNzY_8fe86dfd-2890-418d-9c93-99b230adf99e"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i622723f52e094267ad1f1a6f20f16021_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNi0zLTEtMS0yNzEzODM_2b024c0e-04b8-4441-8a70-e307e5d19725"
      unitRef="number">0.10</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i813308e909ae4e17a701ee9b75f8371f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNy0yLTEtMS0yNzEzNzY_80e705ef-7e0c-4b34-99e3-3e4c97467eec"
      unitRef="number">0.10</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iadc214917ea744b79b2b73e6471dbf01_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xNy0zLTEtMS0yNzEzODM_f41bd812-97d6-4986-8a13-757288f6c799"
      unitRef="number">0.20</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iebcfd4c10a4142fb88a316179c35e0a0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xOS0yLTEtMS0yNzEzNzY_8d69df82-7cc2-483a-a9e4-8d2f36fe6a11"
      unitRef="number">0.45</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ica401af8d1ff43afb5c3de05ed7396cc_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8xOS0zLTEtMS0yNzEzODM_e1b8f010-ef94-4e70-9e1a-adb55b5e19e8"
      unitRef="number">0.70</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i27ea04bb8c1e41a9bdd1d1dc8714d350_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yMy0yLTEtMS0yNzEzNzY_3d9592bf-406c-4347-acf9-efdc8ff0c771"
      unitRef="number">0.15</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i51d675d40b3748ea9f8d5ed88c985153_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yMy0zLTEtMS0yNzEzODM_80031335-1fcd-43cc-9f1e-ccf5839be307"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ia1825332913b4ce7b251fe06cd990eb4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yOS0yLTEtMS0yNzEzNzY_90a33cb2-8e6b-4d0e-8a5e-e0d559bebb09"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ib14b680e409142e6ac7c80709cd5e4eb_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8yOS0zLTEtMS0yNzEzODM_05ba382c-8662-400f-b68a-2004b73685b2"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i13785fc5583c485a8b9868f58464c651_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zMC0yLTEtMS0yNzEzNzY_c4ec9488-3601-4581-92d8-c20e3b98a940"
      unitRef="number">0.95</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2a668a32aa7b440ba577921b46eb3b30_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTg1L2ZyYWc6MzU4NjZkMWM2ZWU1NDBmMTg3MjIwODdlYzljOWQ0ZTQvdGFibGU6Y2UyNmU2ZjIxN2ZkNDRlYWE2ZTgzMDJhNjY2N2ZhYTQvdGFibGVyYW5nZTpjZTI2ZTZmMjE3ZmQ0NGVhYTZlODMwMmE2NjY3ZmFhNF8zMC0zLTEtMS0yNzEzODM_f584170c-5e52-4188-85b4-36777c423c7c"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i79ebdb6315104090a143c1f852c2ca78_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i867dddfc2367440eab83840a05865495_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i04e1e8887418409c8efc97bcddd13100_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfMTA5OTUxMTYyODQ4MQ_0da09f05-3e8c-4080-bb4d-fc5dd48fbbca">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i9b45cc72fe144a41a027fcc9d82be277_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNDQz_4d00d2e4-77a0-4861-9e03-9cd48bf4e5b8">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg5_e6c42dac-714f-4f5e-996c-4d0353676184">P1Y</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNDg1_fcbb828a-fc1b-45e8-92d8-b04179945bfd">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDk_1531252f-ed7d-4bb0-98f0-50eaa78bb5c6">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_408086e2-3444-4b88-b89b-d101186f774f">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_46ee31d6-1f28-4ba5-b2be-d5c564d17665">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_74739711-6874-4a56-93f6-73a0506beaac">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_8b4b2c6e-76ae-4492-a995-73bb701632ff">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b27ac467-c383-4750-82e2-f39d2460df2f">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b50ecd3f-01e3-4abd-991d-dc5d329b8f81">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i52bc922f23d94809b6348416f7d67f89_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODk5L2ZyYWc6NGI3YzJkZDVmY2I1NDczZTg4NDcxN2JiOTk4MzEyZTUvdGFibGU6MDE2NGNjODZhYTIzNGJjNThiZGE3YjE1MzBkOTgzMmIvdGFibGVyYW5nZTowMTY0Y2M4NmFhMjM0YmM1OGJkYTdiMTUzMGQ5ODMyYl8yLTEtMS0xLTI1Mzg5NA_17afd8e8-e3ad-4d00-81d9-1d2cad4fb14b">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ic1efb123775446d4afb050c15a9de3c2_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODk5L2ZyYWc6NGI3YzJkZDVmY2I1NDczZTg4NDcxN2JiOTk4MzEyZTUvdGFibGU6MDE2NGNjODZhYTIzNGJjNThiZGE3YjE1MzBkOTgzMmIvdGFibGVyYW5nZTowMTY0Y2M4NmFhMjM0YmM1OGJkYTdiMTUzMGQ5ODMyYl8zLTEtMS0xLTI1Mzg5NA_7e6bcf1a-6bdd-4816-b2af-fe2e5dd891e5">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ifd473cbb8e244c0baf184d66619e9bab_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODk5L2ZyYWc6NGI3YzJkZDVmY2I1NDczZTg4NDcxN2JiOTk4MzEyZTUvdGFibGU6MDE2NGNjODZhYTIzNGJjNThiZGE3YjE1MzBkOTgzMmIvdGFibGVyYW5nZTowMTY0Y2M4NmFhMjM0YmM1OGJkYTdiMTUzMGQ5ODMyYl80LTEtMS0xLTI3MDA4Mg_7343cdd6-da43-43c4-8107-39ad262930d6">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xMg_9e4926d3-49eb-4951-9776-e77ed607ed48">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6NGI4MGE3YTU3MTczNGJlNGI0OTVjYzQ0YjU3YmJjZmEvdGFibGVyYW5nZTo0YjgwYTdhNTcxNzM0YmU0YjQ5NWNjNDRiNTdiYmNmYV8xLTAtMS0xLTE1NTYzOA_c81af558-c45b-4c4f-b052-3f7ad72af68c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF80Ng_fff77130-116a-4a59-9613-20a0ca1f854d">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF80Ng_1c01cf7f-06c2-425d-b5b0-3ef8eb140a74">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6NzA1ZTc0ZDc3YzVlNDA3NTk5Mzg5YWJhYmYwODUyOWQvdGFibGVyYW5nZTo3MDVlNzRkNzdjNWU0MDc1OTkzODlhYmFiZjA4NTI5ZF8wLTAtMS0xLTE1NTYzOA_2aad131e-247f-4907-8d1c-246428f99cd2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xMzI_fc95e0f7-a4a0-4b6d-9cb4-d2e925ab8a6a">1-3619</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xMzg_ba610356-024a-447d-9265-c93db4a82db2">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ODBhYmRjODJhMGRiNGViOGI5MzNmYzNmOWFkYTBiNWMvdGFibGVyYW5nZTo4MGFiZGM4MmEwZGI0ZWI4YjkzM2ZjM2Y5YWRhMGI1Y18wLTAtMS0xLTE1NTYzOA_4500c05c-b4fb-4588-88d3-159ce7970599">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ODBhYmRjODJhMGRiNGViOGI5MzNmYzNmOWFkYTBiNWMvdGFibGVyYW5nZTo4MGFiZGM4MmEwZGI0ZWI4YjkzM2ZjM2Y5YWRhMGI1Y18wLTEtMS0xLTE1NTYzOA_d9cdf8f1-73e4-4732-9cb8-9a050497bfe7">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8xOTk_319083a1-a2ae-4b01-8018-e4b5f296e835">235 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yMDM_05fb14a5-bf92-4cc6-8690-cecebe12804b">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yMDc_7b248e0e-791c-47a9-8145-bda0d5beac87">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yMTE_54911415-02cb-4e63-9c32-0fd411f85a6d">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yNjk_05f64656-d7b1-4032-bb9f-28a4bacc9ce1">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yNzM_102c8447-9047-40f2-8c5c-5b4f47fd0597">733-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8yLTAtMS0xLTE1NTYzOA_62c489d2-7f84-491f-ac5a-dac1adcc877a">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8yLTEtMS0xLTE1NTYzOA_77bf467c-c0e3-493e-981c-328e14c7946c">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ifc6f9e4fa4084e4c92d23ff39e405bbc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8yLTItMS0xLTE1NTYzOA_e6d0a87f-e617-4f01-adf5-7986ae553cf8">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8zLTAtMS0xLTE1NTYzOA_4cadcdb7-246a-4193-be01-c35a6d0a694b">0.250% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8zLTEtMS0xLTE1NTYzOA_4844b559-06da-44bc-a862-d95a149b2aba">PFE22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i68609996e50840cb835df6bf16a3fa70_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV8zLTItMS0xLTE1NTYzOA_e830e780-3da5-4523-9761-667a42b73d2a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV80LTAtMS0xLTE1NTYzOA_a5effaa3-9f9a-4194-bf28-0afe03598372">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV80LTEtMS0xLTE1NTYzOA_ea2f0023-eccf-461e-be57-2b1686773603">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3139581a7daa411ebf66373fe8f82753_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGFibGU6ZGFiZjZkNzk3NmJkNDcxMWFkY2I0OTNmYjkyMjg2ZjkvdGFibGVyYW5nZTpkYWJmNmQ3OTc2YmQ0NzExYWRjYjQ5M2ZiOTIyODZmOV80LTItMS0xLTE1NTYzOA_829b5cf9-262f-4cb4-93e5-51b9ce478a19">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzcy_f8ab659b-8a64-487f-9dfd-b1ea48e29a55">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc3_c4d2360e-77c1-4cfa-a5a9-052da9c337fc">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzcz_93b9698b-d58c-461e-bcf0-4c1b4465e7d5">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc0_40ae870f-35d1-4d03-881d-e735794c2750">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc4_bce0a4f7-e709-4613-b7df-b0af30e43a64">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc5_5902a06c-b215-400d-99e2-b43a5f686057">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzgw_46c88530-7c13-4b30-9a1c-880328b715f6">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc1_c7c24c25-5032-459f-aef9-7935733f77c6">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzc2_9d5675a3-8d60-413b-9d95-84ac47808a94">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ia364c08bab1f4be7a0489033e72f9182_I20210704"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8yODAy_6b285ed0-5473-4d2a-b435-51f508a112b8"
      unitRef="usd">223000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7b0a597b277c43419d1b9be3ccd9b0bd_I20220222"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzI1_994b5511-f18f-4480-9856-dbf86ec73421"
      unitRef="shares">5623346471</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xL2ZyYWc6MjcxMGY1YjZmMWJkNDk5MmExZmI4MDdlZWUxYjUwOGQvdGV4dHJlZ2lvbjoyNzEwZjViNmYxYmQ0OTkyYTFmYjgwN2VlZTFiNTA4ZF8zMzcx_26a6c8e4-6210-4b07-8852-d564b94a5c9d">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:489.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:397.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Portions of the Proxy Statement for the 2022 Annual Meeting of Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Part III&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzItNS0xLTEtMTU1NjM4_483684ae-d3a9-4f4e-a1d4-8e4c43732120"
      unitRef="usd">81288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzItNy0xLTEtMTU1NjM4_a613a535-5035-4806-9718-d8b2254855b9"
      unitRef="usd">41651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzItOS0xLTEtMTU1NjM4_2f539057-26c6-4c9f-a099-8c917a3ed8ee"
      unitRef="usd">40905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNS0xLTEtMTU1NjM4_3a5b51d9-038d-4f73-bddf-66ec154f7f42"
      unitRef="usd">30821000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNy0xLTEtMTU1NjM4_82fdb0a5-c8c5-471d-9db1-f99ad35bface"
      unitRef="usd">8484000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtOS0xLTEtMTU1NjM4_37504520-2fa3-4477-a8d2-80fd135923e2"
      unitRef="usd">8054000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNS0xLTEtMTU1NjM4_7ab61130-3ef5-44a9-b13a-d58d1b2ac9ed"
      unitRef="usd">12703000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNy0xLTEtMTU1NjM4_83da3ba5-9e6d-46f0-bb6d-5f51c1771b0d"
      unitRef="usd">11597000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtOS0xLTEtMTU1NjM4_71b8000c-8a67-476f-86aa-688705b47476"
      unitRef="usd">12726000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNS0xLTEtMTU1NjM4_c68ccd3e-9a44-46de-b86e-808d367c30de"
      unitRef="usd">13829000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNy0xLTEtMTU1NjM4_c50c3076-23b9-4810-8ae0-51e5cafd05d0"
      unitRef="usd">9393000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtOS0xLTEtMTU1NjM4_d0fdaa6b-4fdb-4251-9f23-b2d4a66f8c2a"
      unitRef="usd">8385000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzctNS0xLTEtMTU1NjM4_f806b26c-3f6b-470f-8f1c-2cc99d226980"
      unitRef="usd">3700000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzctNy0xLTEtMTU1NjM4_71b3ebd7-7244-4068-b3f8-37f61e1c0527"
      unitRef="usd">3348000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzctOS0xLTEtMTU1NjM4_ee0cf2dc-65c4-420a-8ebf-412b2c69eb6c"
      unitRef="usd">4429000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzgtNS0xLTEtMTU1NjM4_80ffaa79-fcd8-4a59-89d2-3381af224bd9"
      unitRef="usd">802000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzgtNy0xLTEtMTU1NjM4_e341c4a1-fc93-4aba-a0c6-11313a940986"
      unitRef="usd">579000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzgtOS0xLTEtMTU1NjM4_9b959c76-bddb-4ddf-ac94-be4872444ce6"
      unitRef="usd">601000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzktNS0xLTEtMTU1NjM4_e4c6377a-8a3d-4e68-a21c-68db41c2ed11"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzktNy0xLTEtMTU1NjM4_d97f7061-da2a-4d3d-b3e5-f92bd6bc6e8f"
      unitRef="usd">6000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzktOS0xLTEtMTU1NjM4_5ef1ee20-71b0-4fe9-bba9-a2d5b9f3a3f4"
      unitRef="usd">8107000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEwLTUtMS0xLTE1NTYzOA_b4e851e8-dada-4e99-9f60-7ca607ffbc0e"
      unitRef="usd">4878000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEwLTctMS0xLTE1NTYzOA_c1d512b1-f464-41ab-972b-e99bc10ae4bf"
      unitRef="usd">-1219000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEwLTktMS0xLTE1NTYzOA_00f627ae-495c-440d-90c5-9ea23af6d8f1"
      unitRef="usd">-3497000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3"
      unitRef="usd">24311000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
      unitRef="usd">7036000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
      unitRef="usd">11321000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEyLTUtMS0xLTE1NTYzOA_1ce2ac83-55f8-45b7-a1ca-82e48cb7f220"
      unitRef="usd">1852000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEyLTctMS0xLTE1NTYzOA_46648b7b-1536-456a-a925-29ed449f699a"
      unitRef="usd">370000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEyLTktMS0xLTE1NTYzOA_b679645e-b9b8-4443-9007-e145851af4e6"
      unitRef="usd">583000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEzLTUtMS0xLTE1NTYzOA_04ace51c-d6d2-4d50-a11e-63f47dfac56e"
      unitRef="usd">22459000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEzLTctMS0xLTE1NTYzOA_b0eb3f9a-686b-4197-aae3-802a2a804af6"
      unitRef="usd">6666000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzEzLTktMS0xLTE1NTYzOA_99460422-1d0c-4616-87e0-be7bbedfe2fd"
      unitRef="usd">10738000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE1LTUtMS0xLTE1NTYzOA_e5d7c609-0b4b-4142-9fc2-2a3e85192096"
      unitRef="usd">-434000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE1LTctMS0xLTE1NTYzOA_bb74f6bb-682b-45eb-88da-72fedd1a54bd"
      unitRef="usd">2529000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE1LTktMS0xLTE1NTYzOA_45508b8f-b29f-458b-bd37-34a303e8ea87"
      unitRef="usd">5318000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE4LTUtMS0xLTE1NTYzOA_63381e29-0a2c-496d-b4c6-68a394474885"
      unitRef="usd">22025000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE4LTctMS0xLTE1NTYzOA_af50c122-aeea-46a2-8596-4a51c83c4ee2"
      unitRef="usd">9195000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE4LTktMS0xLTE1NTYzOA_8fa47364-c204-4959-bd6f-cbdf0d676305"
      unitRef="usd">16056000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE5LTUtMS0xLTE1NTYzOA_57edee31-ae84-4725-82df-9433375f7967"
      unitRef="usd">45000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE5LTctMS0xLTE1NTYzOA_37cb86df-be74-46a3-875e-611d5bfbb13b"
      unitRef="usd">36000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzE5LTktMS0xLTE1NTYzOA_16d0978e-95a3-497b-9467-cfe9d8227c44"
      unitRef="usd">29000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIwLTUtMS0xLTE1NTYzOA_77a1a59a-c3ab-4127-9754-8818e2a6c7d5"
      unitRef="usd">21979000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIwLTctMS0xLTE1NTYzOA_0df638b6-48e0-4e58-9cac-8993692d6dda"
      unitRef="usd">9159000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIwLTktMS0xLTE1NTYzOA_1f7da7ae-37c9-4e2a-847b-68e42674ea1a"
      unitRef="usd">16026000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIzLTUtMS0xLTE1NTYzOA_0e545ecc-37de-49d0-9333-adbb95aa1e66"
      unitRef="usdPerShare">4.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIzLTctMS0xLTE1NTYzOA_9266c59a-72d5-4d5f-b9d4-bd97404d6dd3"
      unitRef="usdPerShare">1.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzIzLTktMS0xLTE1NTYzOA_99164c61-c68d-4acd-bb6b-985f75ae5e88"
      unitRef="usdPerShare">1.92</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI0LTUtMS0xLTE1NTYzOA_4f1c724c-81bf-4225-845a-3345c65cdc0b"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI0LTctMS0xLTE1NTYzOA_5e4fb396-35eb-4d8b-822a-67cafb2bad27"
      unitRef="usdPerShare">0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI0LTktMS0xLTE1NTYzOA_65987aba-5b6e-44bd-a2b9-e6ffc251497e"
      unitRef="usdPerShare">0.95</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI1LTUtMS0xLTE1NTYzOA_91dcc62c-eae1-41fe-a34e-d84b4ce79239"
      unitRef="usdPerShare">3.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI1LTctMS0xLTE1NTYzOA_f44cc108-aac9-4178-a98e-881274d828dd"
      unitRef="usdPerShare">1.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI1LTktMS0xLTE1NTYzOA_1fc0bc1d-9832-4e66-80ee-c8b637bc7a9d"
      unitRef="usdPerShare">2.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI3LTUtMS0xLTE1NTYzOA_1e36cbb6-6a9a-4002-9173-dc548d96b324"
      unitRef="usdPerShare">3.93</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI3LTctMS0xLTE1NTYzOA_cc501ebd-4849-406b-adaa-8e1ae22ca36f"
      unitRef="usdPerShare">1.18</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI3LTktMS0xLTE1NTYzOA_5e4c41dd-ce98-4775-bf52-4a90c65db349"
      unitRef="usdPerShare">1.89</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI4LTUtMS0xLTE1NTYzOA_08ad40bd-f385-476d-91e3-a03c3399eb91"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI4LTctMS0xLTE1NTYzOA_9b64b50c-6b5e-4517-985c-3ef44b44465d"
      unitRef="usdPerShare">0.45</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI4LTktMS0xLTE1NTYzOA_6eeb9e52-b337-4eec-9983-dce9a12cb031"
      unitRef="usdPerShare">0.94</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI5LTUtMS0xLTE1NTYzOA_bbc14571-6dc0-4efb-a9e4-087a1b831e5e"
      unitRef="usdPerShare">3.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI5LTctMS0xLTE1NTYzOA_2ab136c1-d27e-40b8-9734-a64365a4aec6"
      unitRef="usdPerShare">1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzI5LTktMS0xLTE1NTYzOA_63fb6b34-d608-4eaf-a67a-5950f882d07c"
      unitRef="usdPerShare">2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMxLTUtMS0xLTE1NTYzOA_b81f7d02-b490-4236-859f-b314719489a3"
      unitRef="shares">5601000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMxLTctMS0xLTE1NTYzOA_800efef4-3464-486b-9d73-1adb195d92a9"
      unitRef="shares">5555000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMxLTktMS0xLTE1NTYzOA_fc5dd36c-dab4-40db-ac14-34cb7e933318"
      unitRef="shares">5569000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMyLTUtMS0xLTE1NTYzOA_2e6162b1-f05d-4337-b157-9aade0cc0169"
      unitRef="shares">5708000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMyLTctMS0xLTE1NTYzOA_152e60bb-7a54-4e8e-b3c3-b5f1610ce051"
      unitRef="shares">5632000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzMyLTktMS0xLTE1NTYzOA_1da896c1-6e2b-4800-8d69-e25b3a2b44cc"
      unitRef="shares">5675000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzItMi0xLTEtMTU1NjM4_63381e29-0a2c-496d-b4c6-68a394474885"
      unitRef="usd">22025000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzItNC0xLTEtMTU1NjM4_af50c122-aeea-46a2-8596-4a51c83c4ee2"
      unitRef="usd">9195000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzItNi0xLTEtMTU1NjM4_8fa47364-c204-4959-bd6f-cbdf0d676305"
      unitRef="usd">16056000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzQtMi0xLTEtMTU1NjM4_e3873478-26ae-4b41-a0b0-65677f23bda8"
      unitRef="usd">-682000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzQtNC0xLTEtMTU1NjM4_b09e94b1-53f8-4315-ae78-7c93bba2b749"
      unitRef="usd">772000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzQtNi0xLTEtMTU1NjM4_fb93be5f-2162-4f8a-aeae-79face3b46e9"
      unitRef="usd">675000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzUtMi0xLTEtMTU1NjM4_32d994d4-b1da-48d7-a29a-37ae415432d1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzUtNC0xLTEtMTU1NjM4_03080745-536e-465c-8c34-e2912b2e41ed"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzUtNi0xLTEtMTU1NjM4_78180590-276f-4e78-8f21-f62bc089dcf6"
      unitRef="usd">288000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzYtMi0xLTEtMTU1NjM4_639072ee-e612-4388-97b5-6d2dcb0b30e1"
      unitRef="usd">-682000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzYtNC0xLTEtMTU1NjM4_6fa117ff-fbaf-44d7-8895-31467355e81b"
      unitRef="usd">755000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzYtNi0xLTEtMTU1NjM4_835c12e1-7986-4142-b02a-eb1350cff8fb"
      unitRef="usd">387000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzctMi0xLTEtMTU1NjM4_24b20650-6c06-4a7d-b3be-84372d41bb0e"
      unitRef="usd">526000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzctNC0xLTEtMTU1NjM4_fddce784-4db8-4693-ba42-78dc07e68a2f"
      unitRef="usd">-582000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzctNi0xLTEtMTU1NjM4_b4af388f-45c1-4b94-a6db-4dcbe2cb5480"
      unitRef="usd">476000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtMi0xLTEtMTU1NjM4_d31e2e96-23db-4582-8a3b-1875408a08a9"
      unitRef="usd">-134000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNC0xLTEtMTU1NjM4_2946e08a-d232-4528-a2f0-63419668fd07"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNi0xLTEtMTU1NjM4_732ab48d-d360-432a-bd11-178fbd622007"
      unitRef="usd">664000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzktMi0xLTEtMTU1NjM4_2870a8c1-6fdc-40e5-8728-d03337339475"
      unitRef="usd">660000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzktNC0xLTEtMTU1NjM4_2fafceaf-d492-4b13-8526-5f6fdfda0f1a"
      unitRef="usd">-561000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzktNi0xLTEtMTU1NjM4_eca88248-5de7-46c4-a411-1590c98179d0"
      unitRef="usd">-188000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEwLTItMS0xLTE1NTYzOA_545d28a7-7a04-487a-bc08-12414c055b27"
      unitRef="usd">-355000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEwLTQtMS0xLTE1NTYzOA_951ac434-5788-49eb-8caf-f3478adbc2dd"
      unitRef="usd">361000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEwLTYtMS0xLTE1NTYzOA_ecb20ed4-3522-4112-ae29-20499f9f7889"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTItMS0xLTE1NTYzOA_061e55c1-6b6a-46e3-b613-1c3fa13abb1e"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTQtMS0xLTE1NTYzOA_b5dd47cb-0404-4dcb-8afb-8ac782a5f655"
      unitRef="usd">188000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTYtMS0xLTE1NTYzOA_154dbc6d-b981-40d8-abc4-8299b6b7a746"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEzLTItMS0xLTE1NTYzOA_3e0ca31a-3b7c-4c27-bed1-2bd4b4ec3be7"
      unitRef="usd">-384000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEzLTQtMS0xLTE1NTYzOA_64f79834-ae5b-42cf-a147-27e3b7444265"
      unitRef="usd">173000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzEzLTYtMS0xLTE1NTYzOA_6ce4d7b7-da63-4460-9dbe-4613f2fe8368"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzE5LTItMS0xLTE1NTYzOA_e8f9ecbb-3333-4fa6-9693-c764f60b8350"
      unitRef="usd">-116000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzE5LTQtMS0xLTE1NTYzOA_9261c8c6-0a01-414c-9b05-deac29a5320a"
      unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzE5LTYtMS0xLTE1NTYzOA_e4b06e5b-75cf-4862-a676-f74cd0083aad"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIwLTItMS0xLTE1NTYzOA_8e9227ee-0951-4b67-b6e2-bf4feb1831f6"
      unitRef="usd">-154000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIwLTQtMS0xLTE1NTYzOA_a93b0275-6ee2-48a8-9009-3b67e669d27f"
      unitRef="usd">-176000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIwLTYtMS0xLTE1NTYzOA_b388c0ba-6113-43ce-93e2-2a8d0c9586b6"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIxLTItMS0xLTE1NTYzOA_f725ba91-6df6-4888-a45c-59fd55ba9f27"
      unitRef="usd">-74000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIxLTQtMS0xLTE1NTYzOA_1fa4e5c7-01ea-43bb-aa99-32bfe3ddb65f"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIxLTYtMS0xLTE1NTYzOA_566f530b-2b6d-4f4f-8a6d-518b5eed83b2"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIyLTItMS0xLTE1NTYzOA_89a12c56-e943-429f-a732-603f68bc9afe"
      unitRef="usd">2000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIyLTQtMS0xLTE1NTYzOA_489504d6-db28-4379-a967-c32868d2b9bf"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIyLTYtMS0xLTE1NTYzOA_708680c8-8be9-4fc9-bcbc-f2f11d236500"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIzLTItMS0xLTE1NTYzOA_ea1d39ee-a810-4964-9e05-d7a36061210b"
      unitRef="usd">113000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIzLTQtMS0xLTE1NTYzOA_3acdc66e-129d-4f97-a5f5-e302e685ede5"
      unitRef="usd">124000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzIzLTYtMS0xLTE1NTYzOA_36b24dae-caf3-4b6c-9b63-83c9e3a6db46"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI0LTItMS0xLTE1NTYzOA_ace33eaa-df32-468a-9f8d-67ea411f67e1"
      unitRef="usd">-519000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI0LTQtMS0xLTE1NTYzOA_da7c2513-eae5-4249-8fd8-2e34cba6916f"
      unitRef="usd">243000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI0LTYtMS0xLTE1NTYzOA_d1708934-cd97-4d54-baeb-dd99c65332d6"
      unitRef="usd">48000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI1LTItMS0xLTE1NTYzOA_7b95a10f-077d-46ac-8b68-58e892e35acd"
      unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI1LTQtMS0xLTE1NTYzOA_3cda1fc7-d2ed-4956-aadb-f3dac3657d13"
      unitRef="usd">-227000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI1LTYtMS0xLTE1NTYzOA_74cc3428-e932-42df-88fb-ec011206b016"
      unitRef="usd">178000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI2LTItMS0xLTE1NTYzOA_eeae9349-18b5-4415-9c52-40956ac3e1fb"
      unitRef="usd">-589000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI2LTQtMS0xLTE1NTYzOA_fded3238-d0bf-49d3-8f94-c817fc303279"
      unitRef="usd">471000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI2LTYtMS0xLTE1NTYzOA_9c7a4c54-7314-4176-8a99-adf87004f203"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI4LTItMS0xLTE1NTYzOA_23c74318-8cf9-4daf-b163-ed9cb7aaa9cc"
      unitRef="usd">21435000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI4LTQtMS0xLTE1NTYzOA_dfae4ae4-8342-4406-9e83-489940f989b3"
      unitRef="usd">9666000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI4LTYtMS0xLTE1NTYzOA_565e670e-39eb-4d87-96ea-3889855ebf27"
      unitRef="usd">15926000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI5LTItMS0xLTE1NTYzOA_b8cc0873-0cf5-46ec-83a7-62955e25549b"
      unitRef="usd">43000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI5LTQtMS0xLTE1NTYzOA_18c5fcd1-3964-4635-8afa-b1e3af7bc5ee"
      unitRef="usd">27000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzI5LTYtMS0xLTE1NTYzOA_b36e0503-01f4-4c7a-a7af-bdb673ec629f"
      unitRef="usd">18000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzMwLTItMS0xLTE1NTYzOA_0a338497-d933-4d75-beea-99aabd0437b2"
      unitRef="usd">21393000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzMwLTQtMS0xLTE1NTYzOA_b2686617-6f3f-4f0a-8bc3-72253dc1b289"
      unitRef="usd">9639000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzMwLTYtMS0xLTE1NTYzOA_21b14619-66b9-4358-98cd-d4afc6bc9625"
      unitRef="usd">15908000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQtMi0xLTEtMTU1NjM4_01af50bf-f259-4642-8f5e-6c51e58dcc9b"
      unitRef="usd">1944000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQtNC0xLTEtMTU1NjM4_6139d87e-823b-43d4-bd4d-3089d8211448"
      unitRef="usd">1786000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUtMi0xLTEtMTU1NjM4_f9e13b2a-f1a7-4f23-95bf-ff6a6e6ab519"
      unitRef="usd">29125000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUtNC0xLTEtMTU1NjM4_46eee88a-511a-4d3d-b0a2-59bde6f3954a"
      unitRef="usd">10437000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246NGQ4YzU0NTA0NGM1NGFlMDg4ZWZmOGUwYWMyMzFiZTdfNzQ_6ed16d0c-890d-4382-87ae-ff285dee1c21"
      unitRef="usd">492000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246NGQ4YzU0NTA0NGM1NGFlMDg4ZWZmOGUwYWMyMzFiZTdfODM_ed4ed753-5a3a-42c5-9913-acb6b71fe85f"
      unitRef="usd">508000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtMi0xLTEtMTU1NjM4_990d4f9e-b815-4a84-9743-4e8154659187"
      unitRef="usd">11479000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzYtNC0xLTEtMTU1NjM4_c841b661-b351-4089-aa18-d63d2791d21c"
      unitRef="usd">7913000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzctMi0xLTEtMTU1NjM4_0bfa1acc-0879-4700-83cd-9ac4d0af7445"
      unitRef="usd">9059000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzctNC0xLTEtMTU1NjM4_dc820441-f2d8-4da4-b1d0-9bbc4f88e000"
      unitRef="usd">8020000000</us-gaap:InventoryNet>
    <pfe:OtherTaxAssetsCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzgtMi0xLTEtMTU1NjM4_88f2d2d1-ab88-45e8-81d4-55aec1626994"
      unitRef="usd">4266000000</pfe:OtherTaxAssetsCurrent>
    <pfe:OtherTaxAssetsCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzgtNC0xLTEtMTU1NjM4_20d3c57b-1bd3-4dcb-a629-d4830681d616"
      unitRef="usd">3264000000</pfe:OtherTaxAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzktMi0xLTEtMTU1NjM4_412efa00-35ce-4d19-8ae0-a4cd22317a92"
      unitRef="usd">3820000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzktNC0xLTEtMTU1NjM4_8e086121-677c-4d60-8137-101e20c4efe1"
      unitRef="usd">3646000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzExLTItMS0xLTE1NTYzOA_4149bdf7-fda3-4719-9396-833b8190899d"
      unitRef="usd">59693000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzExLTQtMS0xLTE1NTYzOA_c37fa48a-6902-4cd9-b82c-be5d3e0d5a40"
      unitRef="usd">35067000000</us-gaap:AssetsCurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEyLTItMS0xLTE1NTYzOA_e92117e2-65e3-4f39-84f8-806cf6c260a2"
      unitRef="usd">16472000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEyLTQtMS0xLTE1NTYzOA_73c0072f-c22c-4afc-abc3-bb67ee46ae41"
      unitRef="usd">16856000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEzLTItMS0xLTE1NTYzOA_fdba4ba5-40ac-4519-ba1f-970d6e1ff1cd"
      unitRef="usd">5054000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzEzLTQtMS0xLTE1NTYzOA_7292e5d4-645a-469a-b3fe-5abd3a51f1fe"
      unitRef="usd">3406000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE0LTItMS0xLTE1NTYzOA_7b1530b8-38b3-4302-8fee-2c3004c7e4cf"
      unitRef="usd">14882000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE0LTQtMS0xLTE1NTYzOA_06f41800-440b-4105-93d3-95f318698cf8"
      unitRef="usd">13745000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE1LTItMS0xLTE1NTYzOA_f9ed2ee3-a376-4f00-b5d7-40e663523c4f"
      unitRef="usd">25146000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE1LTQtMS0xLTE1NTYzOA_bbb5c74b-68ed-4c93-9363-1a4a45c5f213"
      unitRef="usd">28337000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTItMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
      unitRef="usd">49208000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTQtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
      unitRef="usd">49556000000</us-gaap:Goodwill>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE3LTItMS0xLTE1NTYzOA_704923cc-f82f-4f0e-8aea-52fe36121004"
      unitRef="usd">3341000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE3LTQtMS0xLTE1NTYzOA_afdeb93a-ba5b-44e8-af2b-5643be60584c"
      unitRef="usd">2383000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE4LTItMS0xLTE1NTYzOA_7329abef-62ff-4d1f-8727-b0e241585826"
      unitRef="usd">7679000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE4LTQtMS0xLTE1NTYzOA_7818e897-b369-473e-9c31-655472745e0e"
      unitRef="usd">4879000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIwLTItMS0xLTE1NTYzOA_36b993a2-a144-4b31-ab64-0ed8b612253b"
      unitRef="usd">181476000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIwLTQtMS0xLTE1NTYzOA_f58df7bc-f422-4437-8a72-2fec6d2308fd"
      unitRef="usd">154229000000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjkwYTc5MzdhM2RhNDQzYzFhNjQwZDFiMmI4OThiOTljXzc3_b3a5efec-5dfe-4bce-845a-dad8959f75f9"
      unitRef="usd">1636000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjkwYTc5MzdhM2RhNDQzYzFhNjQwZDFiMmI4OThiOTljXzg2_d4ad19c0-0377-4034-9ee6-885cdef9df67"
      unitRef="usd">2002000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTItMS0xLTE1NTYzOA_bdf2a27b-e46c-40e6-b386-bc59126752fe"
      unitRef="usd">2241000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzIzLTQtMS0xLTE1NTYzOA_1db9a4d1-f0c7-414a-a24f-276e6ca72db0"
      unitRef="usd">2703000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI0LTItMS0xLTE1NTYzOA_e47ad4e4-ca8d-4919-b47e-3c782e0dc6d0"
      unitRef="usd">5578000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI0LTQtMS0xLTE1NTYzOA_d77546ba-8ff6-4848-aa5c-2a27c28d1f9c"
      unitRef="usd">4283000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI1LTItMS0xLTE1NTYzOA_a9cbfe93-9fdd-4e6b-abbd-7bdf5b8ca48f"
      unitRef="usd">2249000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI1LTQtMS0xLTE1NTYzOA_8ba94e6e-7841-4588-8519-90d2d8a34846"
      unitRef="usd">2162000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI2LTItMS0xLTE1NTYzOA_4e925446-c952-474f-996f-29b5ff5b644e"
      unitRef="usd">1266000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI2LTQtMS0xLTE1NTYzOA_51dd99de-0d9f-4690-b05a-515c74178ecf"
      unitRef="usd">1049000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI3LTItMS0xLTE1NTYzOA_90a9ad95-3669-4bcf-9b4c-4e35adbede49"
      unitRef="usd">3332000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI3LTQtMS0xLTE1NTYzOA_278e39ea-5305-405f-8481-4821e00a5326"
      unitRef="usd">3049000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI4LTItMS0xLTE1NTYzOA_d82d3488-46f5-451e-9784-d585a0dcb693"
      unitRef="usd">3067000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI4LTQtMS0xLTE1NTYzOA_b460d8a4-ae4b-4195-8f41-b57dbd86f9df"
      unitRef="usd">1113000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI5LTItMS0xLTE1NTYzOA_5c2b3079-cd44-4a9e-bb8d-b35d333c093e"
      unitRef="usd">24939000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzI5LTQtMS0xLTE1NTYzOA_57d11a0f-51c6-473f-bb87-4b00705346e6"
      unitRef="usd">11561000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMxLTItMS0xLTE1NTYzOA_b7304963-b4c1-4633-93c5-0ba5e4814c67"
      unitRef="usd">42671000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMxLTQtMS0xLTE1NTYzOA_6a775158-ef9e-4a77-9c0c-3cb2c4d96e84"
      unitRef="usd">25920000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMzLTItMS0xLTE1NTYzOA_3e03b5b5-e6c2-4a2c-8b2c-000773b8fea4"
      unitRef="usd">36195000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzMzLTQtMS0xLTE1NTYzOA_a7b0e4eb-0911-406e-9147-3725e3385453"
      unitRef="usd">37133000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM0LTItMS0xLTE1NTYzOA_47d27fa0-dfc4-4fe0-82de-e94d1246690c"
      unitRef="usd">3489000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM0LTQtMS0xLTE1NTYzOA_930bb524-2019-472c-8b9a-19deb059cc40"
      unitRef="usd">4766000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM1LTItMS0xLTE1NTYzOA_59e77402-8abb-4ce1-ae86-94e25b8a7554"
      unitRef="usd">235000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM1LTQtMS0xLTE1NTYzOA_418eb048-a467-44e0-9a66-ed0f710e5b5f"
      unitRef="usd">645000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM2LTItMS0xLTE1NTYzOA_927c1b51-2039-4d18-ac37-4b21c088fbea"
      unitRef="usd">349000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM2LTQtMS0xLTE1NTYzOA_218442bd-a092-40ab-b19a-24663d37ba48"
      unitRef="usd">4063000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM3LTItMS0xLTE1NTYzOA_2fdcdbdb-f250-4b0d-9257-4f3fc53778d1"
      unitRef="usd">11331000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM3LTQtMS0xLTE1NTYzOA_3a4d4e4b-c26e-4c9e-90a8-02cdcea3f347"
      unitRef="usd">11560000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM4LTItMS0xLTE1NTYzOA_75d9d52b-c88d-45b1-b4d5-0525c78cc907"
      unitRef="usd">9743000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM4LTQtMS0xLTE1NTYzOA_4bc38830-56fe-4c4b-b738-3e3994992141"
      unitRef="usd">6669000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM5LTItMS0xLTE1NTYzOA_897c04b9-6231-4ed2-9b69-b84af5291d0d"
      unitRef="usd">104013000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzM5LTQtMS0xLTE1NTYzOA_ab1d4bb0-d1d2-4f4d-a596-537aff26be2e"
      unitRef="usd">90756000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQxLTItMS0xLTE1NTYzOA_d5cdced0-71f5-462c-a235-1fff562dfa4d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQxLTQtMS0xLTE1NTYzOA_7d187368-ef70-461f-aa31-ad762496b9e4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzUy_00829a47-59ef-4d65-84eb-0a3f082af5da"
      unitRef="shares">27000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzUy_8409c7b6-6ce1-4f1b-8115-1019bca7a856"
      unitRef="shares">27000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_04bb5f48-f18c-4748-bcf5-86dad6026414"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_15f3478d-2f25-424f-8a19-60f4df32b54f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_5ca81dc3-7bec-4383-8f51-10293e7890e5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjc4MmE4MjJlMDkyNTQ2OTQ5ZThlYWYyNTQ5MDk5ZDgzXzEyNjQ0MzgzNzE5OTgz_f3826e12-4c17-40b5-824b-029962b505a8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTItMS0xLTE1NTYzOA_dcf6230e-9090-4aa4-9af6-77db4147ce06"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQzLTQtMS0xLTE1NTYzOA_59fdc4c5-3e9d-42b2-9c61-f88abf8c4be1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE4_7571583a-fa3f-4fb8-a031-370a0280d97a"
      unitRef="usdPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE4_a9cd47ef-0f4c-43af-8a76-5c702534f396"
      unitRef="usdPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzMy_6a979e66-67b7-4d01-94e5-b7388f3b28c3"
      unitRef="shares">12000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzMy_abd53949-bf1c-4e25-ad4d-3185756cd9ae"
      unitRef="shares">12000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE2NDkyNjc0NDE3Njc_ed78cb9a-16c3-48c5-a6fc-a60384736450"
      unitRef="shares">9471000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI3MzY4NTY0YjdkMjQzYTY5ZTNjNTRkOGQ3MDYwZmE1XzE2NDkyNjc0NDE3NzI_ab6b5fad-b6a2-49be-b222-83d4d0c63e9a"
      unitRef="shares">9407000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTItMS0xLTE1NTYzOA_a284eaea-1d97-4bbe-8bb3-4dc2b020e069"
      unitRef="usd">473000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ0LTQtMS0xLTE1NTYzOA_8865f245-c316-403c-ab90-904758b480e0"
      unitRef="usd">470000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ1LTItMS0xLTE1NTYzOA_7fb6a44f-5ca4-47ae-a2a9-d04571072afa"
      unitRef="usd">90591000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ1LTQtMS0xLTE1NTYzOA_df791389-1768-44c1-a5e5-443791147cab"
      unitRef="usd">88674000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjVkZTYzZmQ5ZDJlNjQ4NWI5ZDU2ODFjZDkxMGE2MGE4XzE2NDkyNjc0NDE3NDE_786842a7-43cc-4e6a-ae85-9551742c7df3"
      unitRef="shares">3851000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjVkZTYzZmQ5ZDJlNjQ4NWI5ZDU2ODFjZDkxMGE2MGE4XzE2NDkyNjc0NDE3NDg_bb7f10f6-6ace-4cb5-a67d-b3915e11921a"
      unitRef="shares">3840000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTItMS0xLTE1NTYzOA_4927892f-96c1-49d6-a6af-9526e643c400"
      unitRef="usd">111361000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ3LTQtMS0xLTE1NTYzOA_e2fb437a-325b-444b-a93f-4cec2020c4de"
      unitRef="usd">110988000000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ4LTItMS0xLTE1NTYzOA_bcdecde8-fd24-493d-85a1-d37f586ed1a5"
      unitRef="usd">103394000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ4LTQtMS0xLTE1NTYzOA_e0b9e02a-3686-4034-8c34-6adf65ce0d34"
      unitRef="usd">90392000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ5LTItMS0xLTE1NTYzOA_fa91a244-e48c-4371-9239-c5ea6ec5caa7"
      unitRef="usd">-5897000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzQ5LTQtMS0xLTE1NTYzOA_2599286e-c17d-4a8c-abff-919150586d2d"
      unitRef="usd">-5310000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUwLTItMS0xLTE1NTYzOA_fd7594a7-207b-4f0f-9471-74b8f7f175eb"
      unitRef="usd">77201000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUwLTQtMS0xLTE1NTYzOA_a19d2f2a-a0ec-4fa0-bfb9-4909ef40a96a"
      unitRef="usd">63238000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUxLTItMS0xLTE1NTYzOA_d7591a0f-ca53-47a4-b8c6-a3a9705d387b"
      unitRef="usd">262000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUxLTQtMS0xLTE1NTYzOA_83e00d46-532f-4d0c-bc6a-9779097d0214"
      unitRef="usd">235000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUyLTItMS0xLTE1NTYzOA_54ce2ca1-d139-4e68-9e5a-bd9c8f0ba003"
      unitRef="usd">77462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUyLTQtMS0xLTE1NTYzOA_67509819-fa05-42c8-a0b5-3071bebf9a68"
      unitRef="usd">63473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUzLTItMS0xLTE1NTYzOA_5d4db4ab-1875-464d-a53d-03c2fb2b7a01"
      unitRef="usd">181476000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzUzLTQtMS0xLTE1NTYzOA_8c4f322b-3cdc-47de-a106-c2a602408cd1"
      unitRef="usd">154229000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i21a79fdd21944aa89c066de9cbbfee5d_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMi0xLTEtMTU1NjM4_35016769-62d4-407f-a841-b834140874c8"
      unitRef="shares">478000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21a79fdd21944aa89c066de9cbbfee5d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtNC0xLTEtMTU1NjM4_789f08e2-5bb2-40bd-a18f-56dc68a22d34"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ief8bb2c5291c4b5c9a5015f9815e4ee3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtNi0xLTEtMTU1NjM4_6b6e7e2c-79fe-4a69-a2b0-c64a88accb59"
      unitRef="shares">9332000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief8bb2c5291c4b5c9a5015f9815e4ee3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtOC0xLTEtMTU1NjM4_9c6bea80-aa46-4393-ab99-1718dd95527a"
      unitRef="usd">467000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a2a3761e1b1438383b3a8eb28300997_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTAtMS0xLTE1NTYzOA_b533bee1-fe7c-4c77-9ce8-eb221e392b93"
      unitRef="usd">86253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i70369ec902474685b7ee35afae6111aa_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTItMS0xLTE1NTYzOA_950199de-3beb-47bc-a97c-864979108920"
      unitRef="shares">3615000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70369ec902474685b7ee35afae6111aa_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTQtMS0xLTE1NTYzOA_908ba995-70b4-42ee-918c-94d2c5b52d46"
      unitRef="usd">-101610000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1e769fcaccc349d5b816b47154d226a6_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTYtMS0xLTE1NTYzOA_91abdcbb-83a1-4642-927b-0142cf3d0171"
      unitRef="usd">83527000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fa41a976be144ff95f4427e340cfcab_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMTgtMS0xLTE1NTYzOA_c71d54e7-945b-47a5-85cc-a86621eaf03b"
      unitRef="usd">-5249000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i595cd5191b614c5896a444e2f5f45def_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMjAtMS0xLTE1NTYzOA_d9ea415e-63c8-413a-adcf-f64cff8236fd"
      unitRef="usd">63407000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f468b487cc540788a176ec913956dca_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMjItMS0xLTE1NTYzOA_2b9db380-e5fe-42fb-b276-7c9e2a6623f2"
      unitRef="usd">351000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e10b1e1c1f846769573d84f9a61fc72_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMtMjQtMS0xLTE1NTYzOA_73c3178c-79df-4b73-ad96-1cec23f0bdae"
      unitRef="usd">63758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMTYtMS0xLTE1NTYzOA_64adc5d5-49d5-41f4-b4c6-bcbc2f473865"
      unitRef="usd">16026000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMjAtMS0xLTE1NTYzOA_7adc3ed5-016c-45d2-8d4b-bfc4b443a1af"
      unitRef="usd">16026000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMjItMS0xLTE1NTYzOA_e71557e0-dbdf-4e95-93c4-25c15c5a733c"
      unitRef="usd">29000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzQtMjQtMS0xLTE1NTYzOA_0b602244-37de-48a8-b73f-cb11d19241fc"
      unitRef="usd">16056000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib57063444ae6416ea155fe3b461c2ed1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMTgtMS0xLTE1NTYzOA_16978a62-b40f-4d30-bc9a-e59aa0a2835b"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMjAtMS0xLTE1NTYzOA_9f35e96d-97ff-447f-b33b-d2df66fdbf0b"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMjItMS0xLTE1NTYzOA_2b646c56-d904-42d6-9a28-e10aa99d7f90"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzUtMjQtMS0xLTE1NTYzOA_ffb8d2ee-b8cd-4187-955c-89e0870cfc1b"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MTM0MTEwNWNhZmUyNDUzMWI0M2Y1NTVlMWE5YTQzZTRfMTY0OTI2NzQ0MTcwNw_b5992faf-1a4e-4553-a0eb-a44348c626c8"
      unitRef="usdPerShare">1.46</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzctMTYtMS0xLTE1NTYzOA_cdac24c3-a52a-46ab-b3c7-2bf7b5a23014"
      unitRef="usd">8174000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzctMjAtMS0xLTE1NTYzOA_90d30b7f-abd0-4ebb-9770-c1d84af0b9bc"
      unitRef="usd">8174000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzctMjQtMS0xLTE1NTYzOA_f764f8bc-4b84-4ab4-aca6-402de5dc3109"
      unitRef="usd">8174000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzgtMTYtMS0xLTE1NTYzOA_a7d8f145-c31a-4406-b440-fd498a2f2fc2"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzgtMjAtMS0xLTE1NTYzOA_e1042e26-41e4-4359-a13e-c30d33bf61da"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzgtMjQtMS0xLTE1NTYzOA_ebdcfc0e-7a76-4602-926f-e7bf9bda4ccd"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzktMjItMS0xLTE1NTYzOA_954413e5-d57a-4f0e-9d9d-cb0c4450a2ce"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzktMjQtMS0xLTE1NTYzOA_6d9d06ea-afb5-4592-bfad-78ce72db38d1"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie6ae9c7231104451b51d26af9103a373_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTYtMS0xLTE1NTYzOA_cdce96a3-dc7a-463b-b085-ffa0c88c0f3f"
      unitRef="shares">37000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie6ae9c7231104451b51d26af9103a373_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTgtMS0xLTE1NTYzOA_bc989c75-a598-4f65-acef-7f5973cea35b"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTEwLTEtMS0xNTU2Mzg_233a12c1-d08e-489f-8843-3c8b3ca7215a"
      unitRef="usd">1219000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTEyLTEtMS0xNTU2Mzg_02d44a33-2a88-4a5d-b2e5-e00c7228416b"
      unitRef="shares">8000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTE0LTEtMS0xNTU2Mzg_65f68417-7444-4eff-adcc-377e10543308"
      unitRef="usd">-326000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTIwLTEtMS0xNTU2Mzg_e1da76bf-b845-44ba-82fe-76f598b111a4"
      unitRef="usd">894000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEwLTI0LTEtMS0xNTU2Mzg_36465679-aee7-460e-b4fe-415df15a5dd4"
      unitRef="usd">894000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTEyLTEtMS0xNTU2Mzg_103671cb-d24d-47ab-b1e4-cca517d108ef"
      unitRef="shares">213000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTE0LTEtMS0xNTU2Mzg_a373a04e-880a-4ff6-ac83-f184cdfa2023"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTIwLTEtMS0xNTU2Mzg_dc98a30d-a5f4-4c1c-87a9-2e8534978fc8"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzExLTI0LTEtMS0xNTU2Mzg_13a064a6-95f2-4cdf-9632-0633a9d8ace0"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="ia99d4818adb64cf09382dd79ab3ff911_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTItMS0xLTE1NTYzOA_5cec47fc-9d60-45a4-8a16-4ec8eba884d1"
      unitRef="shares">47000000</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="ia99d4818adb64cf09382dd79ab3ff911_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTQtMS0xLTE1NTYzOA_b363b7cb-c5b4-4eea-b0ed-6cfff8a8abd4"
      unitRef="usd">2000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTEwLTEtMS0xNTU2Mzg_cf9c2d3c-2acd-4d32-86d3-a3658d75dc6c"
      unitRef="usd">3000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="iaeb3b5ed479c46348771dc62d561aa33_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTE0LTEtMS0xNTU2Mzg_2c24bef5-dede-40ba-89bb-8de0e658b6f2"
      unitRef="usd">-1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTIwLTEtMS0xNTU2Mzg_6aa6a1d8-356a-4b72-86d5-283b2a20a8ba"
      unitRef="usd">4000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEyLTI0LTEtMS0xNTU2Mzg_54d410b6-33a4-45d2-bf2c-3e6359bd38b7"
      unitRef="usd">4000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="i60414e8b83684820b5b67c39dd6eaade_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTEwLTEtMS0xNTU2Mzg_65aa3215-1817-4efd-987e-e06af1a23721"
      unitRef="usd">40000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i519fa0585e4d4603a7dbe32c300964c2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTE2LTEtMS0xNTU2Mzg_86c00528-560a-4601-97b0-87ad26497379"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i98e4422d2d6e470594a19ffb64fe3c74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTIwLTEtMS0xNTU2Mzg_50a119bd-b681-4e27-80e5-6da8f9c8aea2"
      unitRef="usd">21000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i24e366b426034c2d8e2255483179463e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTIyLTEtMS0xNTU2Mzg_e96fdd6f-546e-4ac4-8512-58ef1bcacb6c"
      unitRef="usd">60000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzEzLTI0LTEtMS0xNTU2Mzg_639d3e36-c1ca-44d6-9a24-5a254b80e366"
      unitRef="usd">81000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i29a4e3937ea1429897d5a87a331d97a4_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTItMS0xLTE1NTYzOA_07657776-30a9-4b73-856d-c62a728d48f6"
      unitRef="shares">431000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29a4e3937ea1429897d5a87a331d97a4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTQtMS0xLTE1NTYzOA_fbd20766-9988-4259-a6dc-5fc644155706"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="idf9258b1a52e41f7b182a2eb16acdb9c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTYtMS0xLTE1NTYzOA_22f14ae7-f5b6-47a9-96fe-aea2f91b3a87"
      unitRef="shares">9369000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idf9258b1a52e41f7b182a2eb16acdb9c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTgtMS0xLTE1NTYzOA_953b0dba-6a02-4712-9e28-778aa19cafb7"
      unitRef="usd">468000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id51cff7fa3b2450293ac21547637f902_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTEwLTEtMS0xNTU2Mzg_a6bfd0d9-54bd-48fe-9253-02558a9d0f31"
      unitRef="usd">87428000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i5931a8435e8847bbb43008b48c1d8f71_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTEyLTEtMS0xNTU2Mzg_ce0010ab-96ed-4d96-8001-408a5d7afb11"
      unitRef="shares">3835000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5931a8435e8847bbb43008b48c1d8f71_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTE0LTEtMS0xNTU2Mzg_9bfc3a00-4122-40f1-a727-31447513840d"
      unitRef="usd">-110801000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd94794713d841c39b811cf2ccdd0e5b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTE2LTEtMS0xNTU2Mzg_01a5fd6f-453e-4848-b666-3b6999adb528"
      unitRef="usd">91397000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c15300160eb40199b2470fd99513c75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTE4LTEtMS0xNTU2Mzg_0e0b472e-f98c-4de0-b242-2fdb768b1f9a"
      unitRef="usd">-5367000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a3ccccf6fbe4566816a85a5ac4c621a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTIwLTEtMS0xNTU2Mzg_38653531-2737-425b-bb3a-ecab87de1c5e"
      unitRef="usd">63143000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibdc359e016414e0fb3f5cdc5fc783e30_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTIyLTEtMS0xNTU2Mzg_ff6ecf19-94d3-41e0-9bf3-72314f0fb9bf"
      unitRef="usd">303000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE0LTI0LTEtMS0xNTU2Mzg_7f602d52-c8c1-440e-834a-e3e093c2b0ff"
      unitRef="usd">63447000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTE2LTEtMS0xNTU2Mzg_f532e4c0-3667-4019-89ca-d9a63418e445"
      unitRef="usd">9159000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTIwLTEtMS0xNTU2Mzg_d80d6c24-6e62-410d-b368-6a42ad4d1668"
      unitRef="usd">9159000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTIyLTEtMS0xNTU2Mzg_366ca9d8-193b-4333-b370-97b302f1068f"
      unitRef="usd">36000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE1LTI0LTEtMS0xNTU2Mzg_36b25251-a42e-46f1-bf6d-261e6e3ddde8"
      unitRef="usd">9195000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTE4LTEtMS0xNTU2Mzg_67968595-15dc-4e60-a75c-e6b9500facd3"
      unitRef="usd">480000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTIwLTEtMS0xNTU2Mzg_59d3c311-afd2-4702-93d8-fa0dc91dffbd"
      unitRef="usd">480000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTIyLTEtMS0xNTU2Mzg_67203a57-f04c-4ab2-8b09-8dc1ef8900c3"
      unitRef="usd">-9000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE2LTI0LTEtMS0xNTU2Mzg_74fb7479-20aa-4b3c-894d-0cf548712ac4"
      unitRef="usd">471000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE3LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmNmYzI3NGU5MzZkZTQ0NDNhYzZkZThjMmIxM2Y3ODI4XzE2NDkyNjc0NDE3MDc_cfa62d64-f04b-4442-a2bb-411b7cc3e6f9"
      unitRef="usdPerShare">1.53</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE4LTE2LTEtMS0xNTU2Mzg_226b6c4b-3dcf-45f1-b050-1dd3ac10575b"
      unitRef="usd">8571000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE4LTIwLTEtMS0xNTU2Mzg_d88aff73-e8fe-4027-8149-ab3c66a2ab22"
      unitRef="usd">8571000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzE4LTI0LTEtMS0xNTU2Mzg_c48edd6e-81e9-4504-b0d9-65e63e580af7"
      unitRef="usd">8571000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIwLTIyLTEtMS0xNTU2Mzg_d998ebe1-58cc-4528-a559-8ee48e79c8db"
      unitRef="usd">91000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIwLTI0LTEtMS0xNTU2Mzg_fb8c1718-ddb4-43dd-a4c7-27802c4cf1d3"
      unitRef="usd">91000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="id1a777038d48408c84c682c9db5a1598_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTYtMS0xLTE1NTYzOA_e4223c1f-f97f-46bc-a3d1-729aecc42059"
      unitRef="shares">37000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id1a777038d48408c84c682c9db5a1598_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTgtMS0xLTE1NTYzOA_ef4e76ca-9e65-44d8-857a-f41c1ee7cb2c"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3e60bc72e4ba4235bf53b47acbec77c9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTEwLTEtMS0xNTU2Mzg_d42a99a0-4e68-41df-9744-343191ae74ce"
      unitRef="usd">1261000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTEyLTEtMS0xNTU2Mzg_d05788fd-a03d-41ef-9d48-3d3e546d86ce"
      unitRef="shares">6000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTE0LTEtMS0xNTU2Mzg_f3436f82-7fc8-4d61-b733-1427663776f1"
      unitRef="usd">-218000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTIwLTEtMS0xNTU2Mzg_e493dfba-38c8-4cd7-8b47-4f342db5066d"
      unitRef="usd">1044000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIxLTI0LTEtMS0xNTU2Mzg_8ef9c145-9595-45da-9820-3de2fed4882b"
      unitRef="usd">1044000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="id949a0db74974d919ea4ea4b3db15ae6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTItMS0xLTE1NTYzOA_dba37449-e851-4f87-b74b-3133af112ca0"
      unitRef="shares">431000000</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="id949a0db74974d919ea4ea4b3db15ae6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTQtMS0xLTE1NTYzOA_a7fee7c6-d026-4ef8-b904-5d6d5e67d18a"
      unitRef="usd">17000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i3e60bc72e4ba4235bf53b47acbec77c9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEwLTEtMS0xNTU2Mzg_5dad725e-549b-4223-aac9-3f2d9059f3a0"
      unitRef="usd">15000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEyLTEtMS0xNTU2Mzg_fa9adc0d-8d18-4bf5-b697-f1f1be9f4967"
      unitRef="shares">-1000000</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i8a40083b1c5c48d6825e60e45b8b5670_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTE0LTEtMS0xNTU2Mzg_b372f346-0ed7-48aa-8a70-f15d24733d34"
      unitRef="usd">-31000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTIwLTEtMS0xNTU2Mzg_c1666a68-f1a5-4f68-bec4-836e47f2d352"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTI0LTEtMS0xNTU2Mzg_31952f84-68a5-48a4-a73b-e4df2294aaff"
      unitRef="usd">1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i0d7bae533b4c494c9ac8e779bc2a7f18_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE2LTEtMS0xNjM1MDc_f12fa9f4-f2af-418c-9f50-a45b98820fb3"
      unitRef="usd">-1592000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE4LTEtMS0xNjM1Mzk_47af01b1-de4e-4a07-a969-19224cfd7f0f"
      unitRef="usd">-423000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i0faec8a8c2034b76b5f681268c40c1ab_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIwLTEtMS0xNjM1NzU_7ce6965c-8867-47ca-9836-5f1b997950d3"
      unitRef="usd">-2015000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNjM2MDQ_d0d9da6e-b77b-4841-b3b0-a87f3981f083"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNjM2NDI_cbc5aa61-24ae-48c8-8216-7aefb1f5b7fe"
      unitRef="usd">-2018000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityOther
      contextRef="i7fae88bf74714d8db81772676b07f6aa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNTU2Mzg_9c12f538-bb60-4840-bd14-e468314fc6c3"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNTU2Mzg_6b835bf5-04b6-4105-949c-ed7a550982db"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="ib6632dff49814e8badeff7ff58c71158_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTItMS0xLTE1NTYzOA_c458716e-24f2-4b4c-b8e3-96cbd41d0f7a"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6632dff49814e8badeff7ff58c71158_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTQtMS0xLTE1NTYzOA_562181ba-3b24-4a03-85bf-da89cf6323d8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="icf786bbc81494d359b7cda3127ee3152_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTYtMS0xLTE1NTYzOA_7e7e17db-ac07-4c7d-8539-a191224a114c"
      unitRef="shares">9407000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf786bbc81494d359b7cda3127ee3152_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTgtMS0xLTE1NTYzOA_ee9d7c17-56fd-4693-94ca-322b447c8ab5"
      unitRef="usd">470000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07fc9de38c8c4c7e9d03753b2fca1f74_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTEwLTEtMS0xNTU2Mzg_3ecaacaa-2d13-4cd3-a926-ee536c8e3197"
      unitRef="usd">88674000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i7422d124677a4ff7b2f8d8076c12acca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTEyLTEtMS0xNTU2Mzg_e0d0c644-bfae-4624-9694-b0f76b23a172"
      unitRef="shares">3840000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7422d124677a4ff7b2f8d8076c12acca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTE0LTEtMS0xNTU2Mzg_2c7365e3-b6a9-40f0-b354-f63a40365ded"
      unitRef="usd">-110988000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5835359a69d471cbf36ab74d0cbe6a8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTE2LTEtMS0xNTU2Mzg_34102309-ff8e-4240-a48c-22346d815a00"
      unitRef="usd">90392000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica9a1f0a2c3f454aa866582d5102b28a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTE4LTEtMS0xNTU2Mzg_1c02910e-18ce-440f-a164-73e9b956e2af"
      unitRef="usd">-5310000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8080b824a5384f898232ba254171a741_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTIwLTEtMS0xNTU2Mzg_09c58043-024b-4769-9718-a26a1953c020"
      unitRef="usd">63238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibedd8e5bdd3547a59b222ebb89139a56_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTIyLTEtMS0xNTU2Mzg_2f181023-8b52-4f6d-bd4e-2273b73fd23b"
      unitRef="usd">235000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI1LTI0LTEtMS0xNTU2Mzg_b2c82206-d31b-40ce-8757-8879b771b6cb"
      unitRef="usd">63473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTE2LTEtMS0xNTU2Mzg_5f6b419a-62ec-4d57-b024-6b7bf8ce646f"
      unitRef="usd">21979000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTIwLTEtMS0xNTU2Mzg_f9bfaf8d-58c1-4783-9b14-ae796cb694e0"
      unitRef="usd">21979000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTIyLTEtMS0xNTU2Mzg_79426e0e-63cc-4faf-b627-5355eabc1365"
      unitRef="usd">45000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI2LTI0LTEtMS0xNTU2Mzg_fb4a85d6-04d4-4bf9-a323-bad18b99060b"
      unitRef="usd">22025000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4091403708c44027bed1ab29ab967de7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTE4LTEtMS0xNTU2Mzg_4da9313a-76f9-4326-b48a-2831566916a7"
      unitRef="usd">-587000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTIwLTEtMS0xNTU2Mzg_0def2d48-8182-4096-b2ee-5bb6d2e29f7c"
      unitRef="usd">-587000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTIyLTEtMS0xNTU2Mzg_8215351b-48c5-41ab-8897-70fab98045f7"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI3LTI0LTEtMS0xNTU2Mzg_bfeca38c-4d8a-4261-97a4-77ae1de9c2e2"
      unitRef="usd">-589000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI4LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjg2YzFmZThhYzk1ODRjOWFhZTUxMDk4ZThiZDY2MzNkXzE2NDkyNjc0NDE3MDc_647a2b5a-2335-4e6a-abeb-c029bccd2346"
      unitRef="usdPerShare">1.57</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI5LTE2LTEtMS0xNTU2Mzg_53138950-d3ef-406f-a3b7-4b23ea135449"
      unitRef="usd">8816000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI5LTIwLTEtMS0xNTU2Mzg_1fd0fb00-6894-4f76-8187-516e4d52fc2c"
      unitRef="usd">8816000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI5LTI0LTEtMS0xNTU2Mzg_86ee0243-8789-452b-bff2-e1f1dda76485"
      unitRef="usd">8816000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMxLTIyLTEtMS0xNTU2Mzg_d4ad385d-1153-4986-9fc3-951d77c9a829"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMxLTI0LTEtMS0xNTU2Mzg_ee767e2b-ae39-48ae-b6ee-f4d05410b346"
      unitRef="usd">8000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3ab09e3a09e941018ddf6f7cc1e0fd05_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTYtMS0xLTE1NTYzOA_a4d7ef6a-46c3-4a52-852b-2df253ef5fb3"
      unitRef="shares">64000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3ab09e3a09e941018ddf6f7cc1e0fd05_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTgtMS0xLTE1NTYzOA_114bbef1-d025-410c-809e-b0e79d841297"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib478cdce593043b4a6f3edef11be42c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTEwLTEtMS0xNTU2Mzg_f08c04c1-c59d-4b52-bd0d-f53a90c5328f"
      unitRef="usd">1917000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i93c09cc9d0f940729939d72e229af012_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTEyLTEtMS0xNTU2Mzg_a8ae4a0e-457d-47e4-97d7-310303430799"
      unitRef="shares">11000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i93c09cc9d0f940729939d72e229af012_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTE0LTEtMS0xNTU2Mzg_2984553e-91a3-4f85-a5fb-3056c87e8dc9"
      unitRef="usd">-373000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMzLTE2LTEtMS0xNjM4ODI_f7ef22ac-12b0-44cf-b1bb-3b5e87e66785"
      unitRef="usd">-77000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTIwLTEtMS0xNTU2Mzg_3e4dd48c-7776-4445-b5c4-8f59f06fdf0c"
      unitRef="usd">1470000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzMyLTI0LTEtMS0xNTU2Mzg_5e66a17b-c6f9-48b2-a8cd-f29b1b111580"
      unitRef="usd">1470000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityOther
      contextRef="iabc0d03a0fcd4762bf4ae1968b5aa508_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTE2LTEtMS0xNTU2Mzg_deca069e-998a-40e7-b9ce-9848360056e7"
      unitRef="usd">85000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i91abd22d25184ad3badadf37c842f04a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTIwLTEtMS0xNTU2Mzg_c4a9a7f7-e93c-46bd-8bff-31efbe041d65"
      unitRef="usd">85000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i364b0e9d9753471cb99cde15b45dc7d9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTIyLTEtMS0xNTU2Mzg_e5fd5894-2f21-4fdb-a210-ca140f25194b"
      unitRef="usd">7000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM2LTI0LTEtMS0xNTU2Mzg_fd3ede3a-ccf6-4639-9688-068bf66ef399"
      unitRef="usd">92000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="i67081b13ebb6408d9bfb81829f457cbb_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTItMS0xLTE1NTYzOA_cf3172f0-4874-49c5-aa9c-2db226b78e92"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67081b13ebb6408d9bfb81829f457cbb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTQtMS0xLTE1NTYzOA_ac51f218-6d4a-4b02-9485-3c3d3b57fd1b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iffea6a63f21448c2a42fb089c227bdf1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTYtMS0xLTE1NTYzOA_fd0374ef-8749-412e-a2ee-b1f418bb49a2"
      unitRef="shares">9471000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffea6a63f21448c2a42fb089c227bdf1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTgtMS0xLTE1NTYzOA_ec1c165b-f8a9-4ee7-aba5-420d8a22c7b3"
      unitRef="usd">473000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iba64542fbbc240b2b05039d5b8e8bf4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTEwLTEtMS0xNTU2Mzg_3400f129-9f4c-448e-929a-a749cae28284"
      unitRef="usd">90591000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ifa81ae38e1ae496d93643844df0b8455_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTEyLTEtMS0xNTU2Mzg_9e856544-13c0-4929-b15d-72ef10dd17a6"
      unitRef="shares">3851000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa81ae38e1ae496d93643844df0b8455_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTE0LTEtMS0xNTU2Mzg_df1efb84-adf9-414d-b344-f8426baffdac"
      unitRef="usd">-111361000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa9bac0ccad24d18a5d2306fb3b1e0f8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTE2LTEtMS0xNTU2Mzg_20b522a0-9d79-4d6a-9f8f-2072f20699a4"
      unitRef="usd">103394000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6af06169f58446f8067cc5be10a39e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTE4LTEtMS0xNTU2Mzg_cdf8811f-0b6c-474d-95a4-7fd9e189ea36"
      unitRef="usd">-5897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d6aaf11901b4bceaf30103029c6a00d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTIwLTEtMS0xNTU2Mzg_e8a758fc-e177-4b11-a2e9-dc396d1bfff7"
      unitRef="usd">77201000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19da914ba5ba4066bf3d29d7d1eeb9c2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTIyLTEtMS0xNTU2Mzg_8af85c22-95cf-475f-a4b8-9aeb97e03122"
      unitRef="usd">262000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzM3LTI0LTEtMS0xNTU2Mzg_f4d75ce5-75c0-4373-8906-51544d691ab6"
      unitRef="usd">77462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQtMi0xLTEtMTU1NjM4_63381e29-0a2c-496d-b4c6-68a394474885"
      unitRef="usd">22025000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQtNC0xLTEtMTU1NjM4_af50c122-aeea-46a2-8596-4a51c83c4ee2"
      unitRef="usd">9195000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQtNi0xLTEtMTU1NjM4_8fa47364-c204-4959-bd6f-cbdf0d676305"
      unitRef="usd">16056000000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUtMi0xLTEtMTU1NjM4_b4a57dfd-5d28-4f0a-be43-3d176038a3ed"
      unitRef="usd">-434000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUtNC0xLTEtMTU1NjM4_9f34713f-42c2-490b-b977-8081cdae8bc8"
      unitRef="usd">2529000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUtNi0xLTEtMTU1NjM4_5dd6c81f-5fc6-44a2-8bda-c91dcbbd8708"
      unitRef="usd">5318000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzYtMi0xLTEtMTU1NjM4_023feeab-f978-4d2b-8b6b-e65a7d063c2e"
      unitRef="usd">22459000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzYtNC0xLTEtMTU1NjM4_c7f3cd5e-3a3b-47bd-b448-a54cc44fa663"
      unitRef="usd">6666000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzYtNi0xLTEtMTU1NjM4_a8236d90-802f-4539-b6ff-c72c31264dde"
      unitRef="usd">10738000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzgtMi0xLTEtMTU1NjM4_011359dc-c779-4363-9044-c7654c84e3a8"
      unitRef="usd">5191000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzgtNC0xLTEtMTU1NjM4_5ae7cc81-c073-43c7-9f69-4a606922147f"
      unitRef="usd">4681000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzgtNi0xLTEtMTU1NjM4_1f7a0c8a-60fe-46b4-8b14-6d5012fcca94"
      unitRef="usd">5755000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzktMi0xLTEtMTU1NjM4_1ff380b5-274e-40e9-b0a9-2c324efb369c"
      unitRef="usd">276000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzktNC0xLTEtMTU1NjM4_c51ec24a-138a-4eff-a168-5a9284ce3d9b"
      unitRef="usd">2049000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzktNi0xLTEtMTU1NjM4_d379e196-a5d2-45c0-a707-08a5bf0daf3a"
      unitRef="usd">2889000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEwLTItMS0xLTE1NTYzOA_5bcacf0d-aca6-4138-8524-38db1a498e8a"
      unitRef="usd">0</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEwLTQtMS0xLTE1NTYzOA_3a368134-bf83-458a-9f92-97d2317fe66e"
      unitRef="usd">0</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEwLTYtMS0xLTE1NTYzOA_9e8a9568-334a-4d3a-85fa-3f050fb20354"
      unitRef="usd">-323000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTItMS0xLTE1NTYzOA_61571985-418a-446b-bc96-93bdab6232b4"
      unitRef="usd">0</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTQtMS0xLTE1NTYzOA_36f289d7-f860-4248-ae43-2a845a2fb3a8"
      unitRef="usd">6000000</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTYtMS0xLTE1NTYzOA_460a0367-95db-4b42-8410-22d206dd026d"
      unitRef="usd">8254000000</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEyLTItMS0xLTE1NTYzOA_60a6de51-0c19-4c56-a0c2-1854579e0752"
      unitRef="usd">-4293000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEyLTQtMS0xLTE1NTYzOA_8e51493f-7b20-43d9-8a88-f621958e33b0"
      unitRef="usd">-1575000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzEyLTYtMS0xLTE1NTYzOA_b9380118-4864-4253-bcc2-52db9c11f32b"
      unitRef="usd">561000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE0LTItMS0xLTE1NTYzOA_60035cc9-3106-4d30-ac8c-c91c33f04e7c"
      unitRef="usd">1182000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE0LTQtMS0xLTE1NTYzOA_5dbfee39-9402-4b4d-8070-192b0c1f430f"
      unitRef="usd">755000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE0LTYtMS0xLTE1NTYzOA_37d314b2-e2de-43be-93a9-041cf88cff67"
      unitRef="usd">687000000</us-gaap:ShareBasedCompensation>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE1LTItMS0xLTE1NTYzOA_ef7d36f0-d22f-4e16-9ab0-58f14ff1f26b"
      unitRef="usd">3123000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE1LTQtMS0xLTE1NTYzOA_93afbcb3-1e89-4229-ba7f-625e65d2459d"
      unitRef="usd">1242000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE1LTYtMS0xLTE1NTYzOA_b5837c87-63af-4c6b-9d92-c0edea583f99"
      unitRef="usd">55000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE3LTItMS0xLTE1NTYzOA_7210b006-9b1e-4048-8f1c-f40b87a2de97"
      unitRef="usd">1573000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE3LTQtMS0xLTE1NTYzOA_a3c9d7c8-991c-4cb8-808f-a24808e3cc14"
      unitRef="usd">479000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE3LTYtMS0xLTE1NTYzOA_31acbe9a-e47b-41fa-990a-01b51d57ee4c"
      unitRef="usd">1080000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE5LTItMS0xLTE3MDM1OQ_619d79a0-d818-44e8-9025-b4fe0c59fd08"
      unitRef="usd">3811000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE5LTQtMS0xLTE3MDM2OQ_10882e03-89bf-4ce4-8ddc-8466c2a46265"
      unitRef="usd">1275000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzE5LTYtMS0xLTE3MDM4Mw_dc9f4947-0101-4a0f-9432-01571b73f3ee"
      unitRef="usd">1124000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIwLTItMS0xLTE3MDM1OQ_34b08c68-4bed-4672-9a05-241223a05dd1"
      unitRef="usd">1125000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIwLTQtMS0xLTE3MDM2OQ_7234760c-6bba-4b3d-a2db-0bc30855a9f7"
      unitRef="usd">778000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIwLTYtMS0xLTE3MDM4Mw_f3b978e9-43b9-4f5a-8a17-a77466e87ae7"
      unitRef="usd">1071000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIxLTItMS0xLTE3MDM1OQ_8a81d4d9-3602-4d4c-90d9-62a53e71d590"
      unitRef="usd">1057000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIxLTQtMS0xLTE3MDM2OQ_4a85f0c8-d400-4e3b-94ac-acee360c9a35"
      unitRef="usd">137000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIxLTYtMS0xLTE3MDM4Mw_5dc1be9a-0948-46e3-8203-89decaeaf60f"
      unitRef="usd">-847000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIyLTItMS0xLTE3MDM1OQ_aac66853-7539-464b-ad42-75fe1425d8f5"
      unitRef="usd">1242000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIyLTQtMS0xLTE3MDM2OQ_06962c6d-cc05-40b1-b588-f6e3b6ca8e32"
      unitRef="usd">355000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIyLTYtMS0xLTE3MDM4Mw_02c29a4b-057c-48d1-b6d4-48394dc23e67"
      unitRef="usd">-341000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIzLTItMS0xLTE3MDM1OQ_7319b9f0-6b6c-4ab0-a60e-371d79dcbdc9"
      unitRef="usd">18721000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIzLTQtMS0xLTE3MDM2OQ_87cfb2d9-931e-43bb-a601-864ccdd0de2b"
      unitRef="usd">2768000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzIzLTYtMS0xLTE3MDM4Mw_e7e6cf82-1415-4ed8-8f49-448eaa76ae60"
      unitRef="usd">861000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI0LTItMS0xLTE3MDM1OQ_7bb7cb4c-40c0-45fb-9a34-f878c36845fa"
      unitRef="usd">-1166000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI0LTQtMS0xLTE3MDM2OQ_d3a3ef2b-a78e-4b86-b093-be6594e7a303"
      unitRef="usd">-1240000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI0LTYtMS0xLTE3MDM4Mw_3d72489f-3d63-4e82-b02a-d589d4865e97"
      unitRef="usd">-3074000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI1LTItMS0xLTE1NTYzOA_aef2e792-2124-4082-9ca4-96b3deff3380"
      unitRef="usd">32922000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI1LTQtMS0xLTE1NTYzOA_63e6dc77-b145-4610-b23b-5aeb2175da4e"
      unitRef="usd">10540000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI1LTYtMS0xLTE1NTYzOA_c871ed45-c89e-4ad1-9c24-7a649dd37c20"
      unitRef="usd">7015000000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI2LTItMS0xLTE1NTYzOA_e126175e-c9eb-4989-bc47-de0498352283"
      unitRef="usd">-343000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI2LTQtMS0xLTE1NTYzOA_7bb88fbd-8b4e-4489-9acf-3f29f309cd0f"
      unitRef="usd">3863000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI2LTYtMS0xLTE1NTYzOA_129d737f-a82a-41a3-bb43-4d450e72035a"
      unitRef="usd">5572000000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI3LTItMS0xLTE1NTYzOA_56740753-9d7e-4025-8e7d-4673c84e7c43"
      unitRef="usd">32580000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI3LTQtMS0xLTE1NTYzOA_689df0da-fb90-4af0-83a4-401efb16d17e"
      unitRef="usd">14403000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzI3LTYtMS0xLTE1NTYzOA_8653b656-c5ac-4d4b-9eea-89eeaa09715a"
      unitRef="usd">12588000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMwLTItMS0xLTE1NTYzOA_28842b17-15e7-4597-9bdb-30041d5cdb5c"
      unitRef="usd">2711000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMwLTQtMS0xLTE1NTYzOA_28f480aa-99b3-458f-83f0-dc52c322d262"
      unitRef="usd">2226000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMwLTYtMS0xLTE1NTYzOA_caba672c-6e1d-44bf-9eeb-4bdbaf3e0bf2"
      unitRef="usd">2046000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMxLTItMS0xLTE1NTYzOA_cc4d68ee-b60c-44b6-a122-a04c55a2d909"
      unitRef="usd">38457000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMxLTQtMS0xLTE1NTYzOA_c31f6df8-a569-46e6-8756-07a5e916fa04"
      unitRef="usd">13805000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMxLTYtMS0xLTE1NTYzOA_5f485f61-2688-4163-ab1a-2a5a3b3fcf54"
      unitRef="usd">6835000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMyLTItMS0xLTE1NTYzOA_551b190e-6d38-49a3-b907-e30f980b8422"
      unitRef="usd">27447000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMyLTQtMS0xLTE1NTYzOA_18474f7f-9ad5-49d3-8234-a80baca00f93"
      unitRef="usd">11087000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMyLTYtMS0xLTE1NTYzOA_80dd7182-739c-4dcc-8796-1486c2d05f21"
      unitRef="usd">9183000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMzLTItMS0xLTE1NTYzOA_8d7d984a-c113-47ed-89c6-c7006562dfce"
      unitRef="usd">8088000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMzLTQtMS0xLTE1NTYzOA_d3a0ef05-8252-46c9-9c91-b2232dba2b7f"
      unitRef="usd">-920000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzMzLTYtMS0xLTE1NTYzOA_2c5a4554-190f-4b16-8c53-c397f8bab760"
      unitRef="usd">-6925000000</pfe:PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM0LTItMS0xLTE1NTYzOA_d4b9ca1c-6cc5-438b-b2a0-e4eb2b08e623"
      unitRef="usd">1068000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM0LTQtMS0xLTE1NTYzOA_9fe01b4c-f3b1-4d5b-a6f8-44e8d77bdc6c"
      unitRef="usd">597000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM0LTYtMS0xLTE1NTYzOA_02ed1ab7-e0d9-4f0d-9829-537234e58c42"
      unitRef="usd">201000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM1LTItMS0xLTE1NTYzOA_5588e8ce-53f8-4eec-969a-e1b663feec7a"
      unitRef="usd">649000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM1LTQtMS0xLTE1NTYzOA_e3984a30-560e-4745-8cbb-d68c7c5b3754"
      unitRef="usd">723000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM1LTYtMS0xLTE1NTYzOA_7e35b505-6b56-43f6-9de4-0e1c2cd040c0"
      unitRef="usd">232000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM2LTItMS0xLTE1NTYzOA_d4649de4-a3eb-46a5-88bc-4e04b5f20485"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM2LTQtMS0xLTE1NTYzOA_f2d93f0b-5692-413f-b01a-af207a1b09e3"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM2LTYtMS0xLTE1NTYzOA_749c4286-3a45-4f8a-b603-75f992b323e5"
      unitRef="usd">10861000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTItMS0xLTE1NTYzOA_27302940-e95f-4411-87f2-0004674e6fa8"
      unitRef="usd">305000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTQtMS0xLTE1NTYzOA_06f71829-0412-4c42-b7fe-8a9facdb36c2"
      unitRef="usd">265000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTYtMS0xLTE1NTYzOA_037968a6-be5e-4506-93f4-cb98e0757bd3"
      unitRef="usd">223000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM4LTItMS0xLTE1NTYzOA_9d500b03-1e32-47bd-83a3-e371e795727b"
      unitRef="usd">-22534000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM4LTQtMS0xLTE1NTYzOA_c400c835-bd7e-41c5-80e6-7afd44b888bc"
      unitRef="usd">-4162000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM4LTYtMS0xLTE1NTYzOA_25133874-1cda-4ecf-91e1-eaa401553a7e"
      unitRef="usd">-3825000000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM5LTItMS0xLTE1NTYzOA_9769831c-3cc5-4408-8760-8e4e1731da48"
      unitRef="usd">-12000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM5LTQtMS0xLTE1NTYzOA_7d464530-628a-44a3-ba82-e8fda491d5f3"
      unitRef="usd">-109000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM5LTYtMS0xLTE1NTYzOA_01c480e6-32bd-4177-88d5-1c1dc4c7a6f7"
      unitRef="usd">-120000000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQwLTItMS0xLTE1NTYzOA_b0650607-23df-42f8-a0ef-1ebad1c6fd98"
      unitRef="usd">-22546000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQwLTQtMS0xLTE1NTYzOA_8e5393ad-3ada-447d-9e2f-9566343d0ee3"
      unitRef="usd">-4271000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQwLTYtMS0xLTE1NTYzOA_2d440c40-1cbd-4804-8d68-4997ec152765"
      unitRef="usd">-3945000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQzLTItMS0xLTE1NTYzOA_b66b646e-ff86-4b45-be05-934febe83982"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQzLTQtMS0xLTE1NTYzOA_6d6835cd-202d-4d15-9c3c-e4e6328d2e10"
      unitRef="usd">12352000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQzLTYtMS0xLTE1NTYzOA_92e7485c-f752-42da-88a1-20cd153bcecc"
      unitRef="usd">16455000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ0LTItMS0xLTE1NTYzOA_246a182f-511d-41ad-989b-c1f538f447b5"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ0LTQtMS0xLTE1NTYzOA_cfef50c9-7c08-405e-851d-f56e5b9bd178"
      unitRef="usd">22197000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ0LTYtMS0xLTE1NTYzOA_2376f7c5-2cef-48e7-a15c-6293d31aafc4"
      unitRef="usd">8378000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ1LTItMS0xLTE1NTYzOA_a9b9145a-492b-4d50-9fb6-a0d4d7d53af3"
      unitRef="usd">-96000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ1LTQtMS0xLTE1NTYzOA_816f0bff-6826-4750-930e-f72e6aa0fe1e"
      unitRef="usd">-4129000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ1LTYtMS0xLTE1NTYzOA_200bc92b-b0c6-45ee-b0d1-fbccfb43640a"
      unitRef="usd">2551000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ2LTItMS0xLTE1NTYzOA_b34fb6e6-01c0-4707-8a67-07496c229e78"
      unitRef="usd">997000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ2LTQtMS0xLTE1NTYzOA_072161fc-09fd-42c1-b6ed-8d3b12266886"
      unitRef="usd">5222000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ2LTYtMS0xLTE1NTYzOA_9d40601f-6340-4c2b-8185-9cd2978e7329"
      unitRef="usd">4942000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ3LTItMS0xLTE1NTYzOA_0d5ca583-2728-4738-a32c-7f5912ffb588"
      unitRef="usd">2004000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ3LTQtMS0xLTE1NTYzOA_5619fe7a-b58c-40c7-9eed-d8dcb3479194"
      unitRef="usd">4003000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ3LTYtMS0xLTE1NTYzOA_7fea1396-833f-44a3-8d2c-82edab7c80bc"
      unitRef="usd">6806000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ4LTItMS0xLTE1NTYzOA_5d131b34-0a3b-4778-9e9f-fb03f397947d"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ4LTQtMS0xLTE1NTYzOA_f7b1b341-2876-4b62-9c1a-be0659282006"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ4LTYtMS0xLTE1NTYzOA_4a23e553-d1de-4483-a671-af8655bd90ac"
      unitRef="usd">8865000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ5LTItMS0xLTE1NTYzOA_262de7e1-9bb8-4c10-84a2-2d6e7f4f339d"
      unitRef="usd">8729000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ5LTQtMS0xLTE1NTYzOA_b899cd88-389d-4c1c-8418-373975834c70"
      unitRef="usd">8440000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzQ5LTYtMS0xLTE1NTYzOA_f24ac3bf-1d65-4e73-8341-3595c5feddfe"
      unitRef="usd">8043000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUwLTItMS0xLTE1NTYzOA_db87ea62-b783-48b2-a829-01d7ccf5e691"
      unitRef="usd">16000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUwLTQtMS0xLTE1NTYzOA_3a57de83-20be-41bf-bb10-124b4b008db9"
      unitRef="usd">-444000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUwLTYtMS0xLTE1NTYzOA_93dc82f7-827c-4979-a87f-662ea0608387"
      unitRef="usd">-342000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUxLTItMS0xLTE1NTYzOA_4f2a5708-6d2d-4c87-9d57-6b453d619872"
      unitRef="usd">-9816000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUxLTQtMS0xLTE1NTYzOA_3df325c9-48ab-47e2-aa30-8517aa38b695"
      unitRef="usd">-21640000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUxLTYtMS0xLTE1NTYzOA_72a141e4-518b-41f9-8407-abb348042bf0"
      unitRef="usd">-8485000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUyLTItMS0xLTE1NTYzOA_f2aa6a66-4989-419b-bcf5-b52f43417fea"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUyLTQtMS0xLTE1NTYzOA_72af45d5-ce1f-4c5e-8d17-56f7e0bbe48b"
      unitRef="usd">11991000000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUyLTYtMS0xLTE1NTYzOA_75bd2568-8c7c-46ea-bdc8-b45cdfe9e596"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUzLTItMS0xLTE1NTYzOA_11062f68-e98a-44a2-b2d2-d32e7b955627"
      unitRef="usd">-9816000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUzLTQtMS0xLTE1NTYzOA_92a2ed35-d4c8-4593-855d-4c5bdbfd46fd"
      unitRef="usd">-9649000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzUzLTYtMS0xLTE1NTYzOA_8c4fbcba-4306-4623-8d90-ad8822c05776"
      unitRef="usd">-8485000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU0LTItMS0xLTE1NTYzOA_56f66306-71ef-44ae-a4e9-dd860638916b"
      unitRef="usd">-59000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU0LTQtMS0xLTE1NTYzOA_395cc03b-0653-44f0-96cb-78ad834e448c"
      unitRef="usd">-8000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU0LTYtMS0xLTE1NTYzOA_97b86904-7654-4c78-a692-f0fc87245453"
      unitRef="usd">-32000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU1LTItMS0xLTE1NTYzOA_d747e8d1-6f16-48d6-a9b3-b04f48edba6d"
      unitRef="usd">159000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU1LTQtMS0xLTE1NTYzOA_5f6bafd6-5971-43b7-bc20-7dd4bb1d279c"
      unitRef="usd">475000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU1LTYtMS0xLTE1NTYzOA_e715240e-5cd6-4cb1-95c7-65edd00d4787"
      unitRef="usd">125000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU2LTItMS0xLTE1NTYzOA_9741f2df-f347-412d-a2f7-0b7e2165325c"
      unitRef="usd">1825000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU2LTQtMS0xLTE1NTYzOA_56eacea0-e09f-4f98-b07d-e9ad7f1a555a"
      unitRef="usd">1350000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8e10b1e1c1f846769573d84f9a61fc72_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU2LTYtMS0xLTE1NTYzOA_588143ad-b767-40d1-bcfe-72de3aacf886"
      unitRef="usd">1225000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU3LTItMS0xLTE1NTYzOA_f554d633-5dd1-4eac-8b0e-f4494c906c7e"
      unitRef="usd">1983000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU3LTQtMS0xLTE1NTYzOA_0eb5ae8b-2d8b-4374-9d80-9ae0a7ebe617"
      unitRef="usd">1825000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzU3LTYtMS0xLTE1NTYzOA_a080876f-cadc-408d-a50d-6dfb37ed2265"
      unitRef="usd">1350000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTItMS0xLTE1NTYzOA_43cc687a-b803-4547-80bd-f9aaecabf732"
      unitRef="usd">7427000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTQtMS0xLTE1NTYzOA_4efd385e-9055-4fa2-89fe-c6c912de203a"
      unitRef="usd">3153000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTYtMS0xLTE1NTYzOA_e4a7f37b-8bbe-4694-8acd-b9d0c668bf5b"
      unitRef="usd">3664000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY2LTItMS0xLTE1NTYzOA_c0d4f2b4-73d3-4a92-8baf-8bef55e1a5ec"
      unitRef="usd">1467000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY2LTQtMS0xLTE1NTYzOA_d0382e56-fa25-419f-b08d-d1ce06e3de31"
      unitRef="usd">1641000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY2LTYtMS0xLTE1NTYzOA_f3701413-1731-4e58-9b15-562d5a024e3a"
      unitRef="usd">1587000000</us-gaap:InterestPaidNet>
    <pfe:InterestReceivedInterestRateHedges
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY3LTItMS0xLTE1NTYzOA_b9e60793-e1a2-4356-827f-6914e0286a08"
      unitRef="usd">2000000</pfe:InterestReceivedInterestRateHedges>
    <pfe:InterestReceivedInterestRateHedges
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY3LTQtMS0xLTE1NTYzOA_6635a979-62cc-46b8-a82b-94dfeb4039e1"
      unitRef="usd">20000000</pfe:InterestReceivedInterestRateHedges>
    <pfe:InterestReceivedInterestRateHedges
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY3LTYtMS0xLTE1NTYzOA_84ad179b-f77e-47a2-997c-7c6fccd8a928"
      unitRef="usd">42000000</pfe:InterestReceivedInterestRateHedges>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTItMS0xLTE2NzQ1Nw_35007f70-2d5e-4042-9cc8-e2cc6de505c8"
      unitRef="usd">1943000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTQtMS0xLTE2NzQ2Mw_dc4bdc7f-d2c0-40ad-9fd3-342e96ad0f41"
      unitRef="usd">410000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzY1LTYtMS0xLTE2NzQ3MA_fca6ed56-cc50-4400-9307-eecc0ed00cfa"
      unitRef="usd">314000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie607d29116be4fa5babac488462d4080_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjU1OTRhNTkxNWE1ZDRhNjI5NDYwMWU1N2M3YTNjNDIwXzU_1241243c-7336-42f0-aa02-91ef3754845b"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTItMS0xLTE1NTYzOA_10fe7932-e01c-454e-8302-def516f99899"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="i34dd2e3fa1c248e29e1d6758b3059e2d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTQtMS0xLTE1NTYzOA_19c6fa4b-dbf0-4efd-8ff8-0b7287c1ac97"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTYtMS0xLTE1NTYzOA_2014424e-8adc-4a3b-9815-9c81bcd3344a"
      unitRef="usd">15711000000</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzEy_6b5403a6-b53d-4f87-99ec-d68bedcb184f"
      unitRef="usd">8300000000</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie607d29116be4fa5babac488462d4080_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzEyMA_1241243c-7336-42f0-aa02-91ef3754845b"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="ie607d29116be4fa5babac488462d4080_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzE4Nw_462fe8ce-f277-4f04-ae3f-878ceac3f0a7"
      unitRef="usd">15700000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <pfe:DeconsolidationNetAssetsContributed
      contextRef="ie607d29116be4fa5babac488462d4080_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzIzMg_ccd90f96-1f85-42ec-8718-fa2a86308cd8"
      unitRef="usd">7600000000</pfe:DeconsolidationNetAssetsContributed>
    <pfe:DeconsolidationGainLossAmountCashConveyed
      contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzI4Mw_d14606d4-ad03-456e-a7c2-9f8a701ae6d2"
      unitRef="usd">146000000</pfe:DeconsolidationGainLossAmountCashConveyed>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDM2_c6b3fa4f-ea37-4c83-808b-075e900f600e">Basis of Presentation and Significant Accounting Policies&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP. The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our subsidiaries have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;. On December 31, 2021, we completed the sale of our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products. Prior to its sale, Meridian was managed within the Hospital therapeutic area. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. On December 21, 2020, Pfizer and Viatris completed the termination of a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (the Mylan-Japan collaboration) pursuant to an agreement dated November 13, 2020, and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and the Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. The assets and liabilities associated with Meridian and the Mylan-Japan collaboration are classified as assets and liabilities of discontinued operations as of December 31, 2020. Upon completion of the spin-off of the Upjohn Business on November&#160;16, 2020, the Upjohn assets and liabilities were derecognized from our consolidated balance sheet and are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Retained Earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Distribution of Upjohn Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; in the consolidated statement of equity. Prior to the spin-off of the Upjohn Business in November 2020, the Upjohn Business, the Mylan-Japan collaboration and Meridian were managed as part of our former Upjohn operating segment. With the separation of the Upjohn Business, the Mylan-Japan collaboration and Meridian, as well as the formation of the Consumer Healthcare JV in 2019, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines. Certain prior year amounts have been reclassified to conform with the current year presentation. In addition, other acquisitions and business development activities completed in 2021, 2020 and 2019 impacted financial results in the periods presented. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;. &lt;/span&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;New Accounting Standard Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Change in Accounting Principle&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans (MTM Accounting).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Georgia',serif;font-size:8pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Under the prior policy, we deferred recognition of these gains and losses in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;. The accumulated actuarial gains/losses outside of a &#x201c;corridor&#x201d; were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2019, resulted in a cumulative effect decrease to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; of $6.0 billion, with a corresponding offset to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="57" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The impacts of the adjustments on our consolidated financial statements are summarized as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(MILLIONS, EXCEPT PER COMMON SHARE DATA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous&lt;br/&gt;Accounting&lt;br/&gt;Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Gain) on completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(8,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(8,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,058&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income before allocation to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,374&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="57" style="border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous&lt;br/&gt;Accounting&lt;br/&gt;Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Comprehensive Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plans: actuarial gains/(losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(826)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;545&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Cash Flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred taxes from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plan contributions in excess of expense/income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous&lt;br/&gt;Accounting&lt;br/&gt;Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pension benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103,394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of income. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;F. Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Income approach, which is based on the present value of a future stream of net cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Available-for-sale debt securities&#x2014;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Equity securities with readily determinable fair values&#x2014;quoted market prices and observable NAV prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Derivative assets and liabilities&#x2014;third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Money market funds&#x2014;observable NAV prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;G. Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and we translate non-monetary items at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;H. Revenues and Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our Sales Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to LOE, product recalls or a changing competitive environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deductions from Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provisions for pharmaceutical sales returns&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as LOE, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The following outlines our common sales arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#008080;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies, and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period&#x2019;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#x201c;coverage gap,&#x201d; also known as the &#x201c;doughnut hole,&#x201d; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#x2019;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49%&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;of our revenues in 2019. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,850&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;During 2021 and 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;I. Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received for our share of gross profits from our collaboration partners as alliance revenues, a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Royalty payments received from collaboration partners are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Reimbursements to or from our collaboration partners for development costs are typically recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable intangible assets&#x2014;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; over the development period for the products, when our performance obligations include providing R&amp;amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;J. Cost of Sales and Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Inventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;K. Selling, Informational and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately $2.0 billion in 2021, $1.8 billion in 2020 and $2.3 billion in 2019. Production costs are expensed as incurred and the costs of TV, radio, and other electronic media and publications are expensed when the related advertising occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;L. Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;M. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Long-lived assets include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, less accumulated depreciation&#x2014;These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;These assets are recorded at fair value at acquisition. Intangible assets with finite lives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amortization of finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; as these intangible assets benefit multiple business functions. Amortization of intangible assets that are for a single function and depreciation of property, plant and equipment are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For indefinite-lived intangible assets, such as brands and IPR&amp;amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;N. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our business and platform functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;amp;D, as well as our corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;O. Cash Equivalents and Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;P. Investments and Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;until realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Held-to-maturity debt securities, which are carried at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#x2019;s income and expenses in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;Realized gains or losses on sales of investments are determined by using the specific identification cost method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are carried at fair value in various balance sheet categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;), with changes in fair value reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; or, for derivative financial instruments in certain qualifying hedging relationships, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Q. Tax Assets and Liabilities and Income Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Global Intangible Low-Taxed Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; as of December 31, 2021 and 2020 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; for uncertain tax positions and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#x201c;more likely than not&#x201d;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and are classified on our consolidated balance sheet with the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;R. Pension and Postretirement Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;S. Legal and Environmental Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;T. Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms with the related costs recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDE3_e58a8c78-56a1-45d2-9382-7037054d1506">The consolidated financial statements include the accounts of our parent company and all subsidiaries and are prepared in accordance with U.S. GAAP.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTY1_50da091a-be31-455f-a0ef-48f230491fc8">The decision of whether or not to consolidate an entity for financial reporting purposes requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our subsidiaries have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQxMjMxNjg2MTQxMjU4_07d9dfbb-05f8-4e94-9dc5-8120a487780b">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzEwOTk1MTE3MzEyODI_36183524-29d9-404f-84cc-f1c9c73c36ea"
      unitRef="operatingsegment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDI1_a1d2fa7a-fb5a-41da-aad7-292dd66015af">New Accounting Standard Adopted in 2021On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifcf32e48dba146a8a8302424e15199af_I20200101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzkwOTM_a19d9eea-6aac-4921-ad28-ac24a58efec1"
      unitRef="usd">6000000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifcf32e48dba146a8a8302424e15199af_I20200101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzkwOTM_f8553265-d7fb-423d-a4a8-9705b516cd6a"
      unitRef="usd">-6000000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQzOTgwNDY1NzkwMjk_61d8fda1-1d49-43f3-bf0b-db8556c906da">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="57" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The impacts of the adjustments on our consolidated financial statements are summarized as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(MILLIONS, EXCEPT PER COMMON SHARE DATA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous&lt;br/&gt;Accounting&lt;br/&gt;Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Gain) on completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(8,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(8,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,253&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2,058&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income before allocation to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,420&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;22,025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;20,374&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;21,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(457)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(246)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;16,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;basic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;4.00&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.92&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline"&gt;Earnings per common share&#x2013;&#x2013;diluted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;0.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;0.28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(0.04)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="57" style="border-bottom:0.5pt solid #000;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="51" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous&lt;br/&gt;Accounting&lt;br/&gt;Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Comprehensive Income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plans: actuarial gains/(losses), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(826)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;285&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(278)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(274)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;49&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;545&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Consolidated Statements of Cash Flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Deferred taxes from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(4,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,575)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Benefit plan contributions in excess of expense/income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.786%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous&lt;br/&gt;Accounting&lt;br/&gt;Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Previous Accounting Principle&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Impact of Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;As Adjusted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Balance Sheets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,320&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,341&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,679&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pension benefit obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,489&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;101,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103,394&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,688)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMi0xLTEtMTk1OTA2_bc7c3cf1-825d-47f8-8aa8-0ce61e8ac02d"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNC0xLTEtMTk1OTA2_1806779c-9b0a-40d7-8b88-e326ec7197b2"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTk1ODcy_e4c6377a-8a3d-4e68-a21c-68db41c2ed11"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtOC0xLTEtMTk1OTE2_7d44f143-1322-4aaa-a53c-ed88ed3874c4"
      unitRef="usd">6000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTAtMS0xLTE5NTkxNg_83e058c7-c0c2-4292-9dae-6c3b90836b85"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE5NTg4MA_d97f7061-da2a-4d3d-b3e5-f92bd6bc6e8f"
      unitRef="usd">6000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTQtMS0xLTE5NTkyNQ_0528c310-2d7d-4b18-95b7-1377501a2266"
      unitRef="usd">8086000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTYtMS0xLTE5NTkyNQ_ee649ed2-6db5-4709-a8c9-d075e26ca808"
      unitRef="usd">21000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE5NTg5MQ_5ef1ee20-71b0-4fe9-bba9-a2d5b9f3a3f4"
      unitRef="usd">8107000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMi0xLTEtMTU1NjM4_a8c24596-c4e8-4aaa-a1f8-59635457c3ab"
      unitRef="usd">2820000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtNC0xLTEtMTU1NjM4_eb7b2a56-0ca4-4ca3-950f-58e39c2f471a"
      unitRef="usd">2058000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtNi0xLTEtMTU1NjM4_b4e851e8-dada-4e99-9f60-7ca607ffbc0e"
      unitRef="usd">4878000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtOC0xLTEtMTU1NjM4_60871837-4ddf-4f02-9913-ec586b1f58cd"
      unitRef="usd">-672000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTAtMS0xLTE1NTYzOA_3b558b40-826c-4112-85ef-2541e53fe68d"
      unitRef="usd">-547000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTItMS0xLTE1NTYzOA_c1d512b1-f464-41ab-972b-e99bc10ae4bf"
      unitRef="usd">-1219000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTQtMS0xLTE1NTYzOA_b8d83cf9-64e6-4063-8bc3-a37621e851df"
      unitRef="usd">-3264000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTYtMS0xLTE1NTYzOA_2d4c0b1f-3a03-442f-ab5c-c69db2df5f3c"
      unitRef="usd">-233000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzQtMTgtMS0xLTE1NTYzOA_00f627ae-495c-440d-90c5-9ea23af6d8f1"
      unitRef="usd">-3497000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMi0xLTEtMTU1NjM4_0614c209-9dc5-4b67-9b3c-c6804d6690ac"
      unitRef="usd">22253000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNC0xLTEtMTU1NjM4_d81f917c-575c-4c63-b8bd-93a45c0c27ac"
      unitRef="usd">2058000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
      unitRef="usd">24311000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtOC0xLTEtMTU1NjM4_b90945b7-2595-47c1-8c61-e56abdc77117"
      unitRef="usd">7584000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTAtMS0xLTE1NTYzOA_fac85c0f-cbd0-4c06-ac4a-c35c45377dfe"
      unitRef="usd">-547000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
      unitRef="usd">7036000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTQtMS0xLTE1NTYzOA_d351653b-ba46-4985-ad18-5b8319b71d48"
      unitRef="usd">11533000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTYtMS0xLTE1NTYzOA_55563f9c-9f04-4dd9-9cd6-19dbe4af74d7"
      unitRef="usd">-212000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
      unitRef="usd">11321000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMi0xLTEtMTU1NjM4_d81915bb-b2a3-4b5b-b767-e32b0e45b403"
      unitRef="usd">1399000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtNC0xLTEtMTU1NjM4_fb9f9ae6-a699-4dc6-8f86-53524f5c5d67"
      unitRef="usd">453000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtNi0xLTEtMTU1NjM4_1ce2ac83-55f8-45b7-a1ca-82e48cb7f220"
      unitRef="usd">1852000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtOC0xLTEtMTU1NjM4_a93c4b48-f261-4c9c-a6ab-09fd8aafe16c"
      unitRef="usd">496000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTAtMS0xLTE1NTYzOA_9165618c-02cb-4bfe-9c07-3e0069bd7165"
      unitRef="usd">-125000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTItMS0xLTE1NTYzOA_46648b7b-1536-456a-a925-29ed449f699a"
      unitRef="usd">370000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTQtMS0xLTE1NTYzOA_99de404e-3ecc-4ca4-96e6-8cc2ca69a79a"
      unitRef="usd">631000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTYtMS0xLTE1NTYzOA_2da45aaf-ac09-410a-bc2b-7a9ad56a2df0"
      unitRef="usd">-48000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzYtMTgtMS0xLTE1NTYzOA_b679645e-b9b8-4443-9007-e145851af4e6"
      unitRef="usd">583000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMi0xLTEtMTU1NjM4_d3c4eb6c-0166-4174-bed6-57bfbe0c9cd4"
      unitRef="usd">-434000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctNC0xLTEtMTU1NjM4_f600d9c3-dbca-4042-baed-b00196412af8"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctNi0xLTEtMTU1NjM4_e5d7c609-0b4b-4142-9fc2-2a3e85192096"
      unitRef="usd">-434000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctOC0xLTEtMTU1NjM4_47e1dac8-7637-4978-a66a-5da2859019e8"
      unitRef="usd">2564000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTAtMS0xLTE1NTYzOA_7472d9ad-f441-45e2-bb72-642a4f921538"
      unitRef="usd">-35000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTItMS0xLTE1NTYzOA_4d9fd474-da17-46bd-9955-e2c453350084"
      unitRef="usd">2529000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTQtMS0xLTE1NTYzOA_bbfe93da-6381-4ce2-b8f3-ee5968afe7bd"
      unitRef="usd">5400000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTYtMS0xLTE1NTYzOA_3793095d-3cfe-4f81-8508-ce7f1cc278d3"
      unitRef="usd">-82000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzctMTgtMS0xLTE1NTYzOA_45508b8f-b29f-458b-bd37-34a303e8ea87"
      unitRef="usd">5318000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMi0xLTEtMTU1NjM4_e5a25800-bf7c-4319-8db0-1357be5bdf2e"
      unitRef="usd">20420000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtNC0xLTEtMTU1NjM4_c80bc3b5-a258-4f06-9490-a4ce348c0cad"
      unitRef="usd">1605000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtNi0xLTEtMTU1NjM4_63381e29-0a2c-496d-b4c6-68a394474885"
      unitRef="usd">22025000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtOC0xLTEtMTU1NjM4_a09d3430-2065-430d-8ef0-3854ea32568d"
      unitRef="usd">9652000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTAtMS0xLTE1NTYzOA_26ef6320-debf-42a6-8063-6cb0b37715ff"
      unitRef="usd">-457000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTItMS0xLTE1NTYzOA_af50c122-aeea-46a2-8596-4a51c83c4ee2"
      unitRef="usd">9195000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTQtMS0xLTE1NTYzOA_e5d1f133-628b-42f3-9b7f-7541dfa84356"
      unitRef="usd">16302000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTYtMS0xLTE1NTYzOA_af9c842a-a8f8-4f1c-9522-30f530818287"
      unitRef="usd">-246000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzgtMTgtMS0xLTE1NTYzOA_8fa47364-c204-4959-bd6f-cbdf0d676305"
      unitRef="usd">16056000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMi0xLTEtMTU1NjM4_2fd5a10c-9938-43b0-9077-b9cb03064bca"
      unitRef="usd">20374000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktNC0xLTEtMTU1NjM4_9a66ccb1-e731-49a3-8aa6-b60e0fc2d4d5"
      unitRef="usd">1605000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktNi0xLTEtMTU1NjM4_77a1a59a-c3ab-4127-9754-8818e2a6c7d5"
      unitRef="usd">21979000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktOC0xLTEtMTU1NjM4_d961285d-b46d-4f25-a1a1-bf5ed0efd339"
      unitRef="usd">9616000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTAtMS0xLTE1NTYzOA_ceb9104d-f067-4da6-ba0e-60c1700d7181"
      unitRef="usd">-457000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTItMS0xLTE1NTYzOA_0df638b6-48e0-4e58-9cac-8993692d6dda"
      unitRef="usd">9159000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTQtMS0xLTE1NTYzOA_2c5bc2df-4f05-4b6a-adb0-6812440e17ba"
      unitRef="usd">16273000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTYtMS0xLTE1NTYzOA_41e1db16-ca3d-4d55-aae4-52f4bb00a6e6"
      unitRef="usd">-246000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzktMTgtMS0xLTE1NTYzOA_1f7da7ae-37c9-4e2a-847b-68e42674ea1a"
      unitRef="usd">16026000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTItMS0xLTE1NTYzOA_669465e3-848a-4eca-ab96-61699fba03d7"
      unitRef="usdPerShare">3.71</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTQtMS0xLTE1NTYzOA_9f29c43e-5bdc-4760-a884-080091ee4cf3"
      unitRef="usdPerShare">0.29</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTYtMS0xLTE1NTYzOA_0e545ecc-37de-49d0-9333-adbb95aa1e66"
      unitRef="usdPerShare">4.00</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTgtMS0xLTE1NTYzOA_9898ecf4-a278-4ec3-af59-f98418914f5c"
      unitRef="usdPerShare">1.27</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTEwLTEtMS0xNTU2Mzg_2ba7a659-28d5-4a12-a469-4b3b3c3410fc"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTEyLTEtMS0xNTU2Mzg_9266c59a-72d5-4d5f-b9d4-bd97404d6dd3"
      unitRef="usdPerShare">1.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTE0LTEtMS0xNTU2Mzg_f5870ad3-7f70-4e3e-aa54-830b6d7d2453"
      unitRef="usdPerShare">1.95</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTE2LTEtMS0xNTU2Mzg_38e9e708-3d64-46e7-8c0f-b4df9bd15217"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzExLTE4LTEtMS0xNTU2Mzg_99164c61-c68d-4acd-bb6b-985f75ae5e88"
      unitRef="usdPerShare">1.92</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTItMS0xLTE1NTYzOA_05d09569-4258-4332-a6f2-3cfb1d11e38f"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTQtMS0xLTE1NTYzOA_4be499b4-eb98-41a5-9c13-b98f37bb16c9"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTYtMS0xLTE1NTYzOA_4f1c724c-81bf-4225-845a-3345c65cdc0b"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTgtMS0xLTE1NTYzOA_4c3e707b-525b-454f-a72a-5e82777a7a30"
      unitRef="usdPerShare">0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTEwLTEtMS0xNTU2Mzg_824774bd-9528-44db-81c0-5752510c803c"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTEyLTEtMS0xNTU2Mzg_5e4fb396-35eb-4d8b-822a-67cafb2bad27"
      unitRef="usdPerShare">0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTE0LTEtMS0xNTU2Mzg_4afd8b53-b939-4448-931d-944f770cdff8"
      unitRef="usdPerShare">0.97</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTE2LTEtMS0xNTU2Mzg_222c857a-f5df-4910-b7a6-e5645738f4c4"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEyLTE4LTEtMS0xNTU2Mzg_65987aba-5b6e-44bd-a2b9-e6ffc251497e"
      unitRef="usdPerShare">0.95</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTItMS0xLTE1NTYzOA_79a34e7e-98a1-445b-a6ed-60587e9f3840"
      unitRef="usdPerShare">3.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTQtMS0xLTE1NTYzOA_1495cf92-9a24-45c2-bc8d-d49daf8da1a4"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTYtMS0xLTE1NTYzOA_91dcc62c-eae1-41fe-a34e-d84b4ce79239"
      unitRef="usdPerShare">3.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTgtMS0xLTE1NTYzOA_d7bc6a99-4f19-4e86-b2ec-26d9a83142cb"
      unitRef="usdPerShare">1.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTEwLTEtMS0xNTU2Mzg_ced91ae8-93df-4a06-b881-9b17672874cc"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTEyLTEtMS0xNTU2Mzg_f44cc108-aac9-4178-a98e-881274d828dd"
      unitRef="usdPerShare">1.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTE0LTEtMS0xNTU2Mzg_ee5830e6-e0df-4b2d-a55e-6aae657126e4"
      unitRef="usdPerShare">2.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTE2LTEtMS0xNTU2Mzg_eefba0bb-2ec6-4b41-8707-c8d766e14fa2"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzEzLTE4LTEtMS0xNTU2Mzg_1fc0bc1d-9832-4e66-80ee-c8b637bc7a9d"
      unitRef="usdPerShare">2.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTItMS0xLTE1NTYzOA_9e379d60-0036-4208-9325-63b47a71f655"
      unitRef="usdPerShare">3.65</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTQtMS0xLTE1NTYzOA_aa6ccca0-aaab-4173-ba66-490e0c91074c"
      unitRef="usdPerShare">0.28</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTYtMS0xLTE1NTYzOA_1e36cbb6-6a9a-4002-9173-dc548d96b324"
      unitRef="usdPerShare">3.93</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTgtMS0xLTE1NTYzOA_b93effd7-8060-43c2-92c3-25cc5621bd6b"
      unitRef="usdPerShare">1.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTEwLTEtMS0xNTU2Mzg_06c8dfd8-43f7-46d3-95d2-02a28b5c0d42"
      unitRef="usdPerShare">-0.07</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTEyLTEtMS0xNTU2Mzg_cc501ebd-4849-406b-adaa-8e1ae22ca36f"
      unitRef="usdPerShare">1.18</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTE0LTEtMS0xNTU2Mzg_12480bac-cff2-4468-8158-045c1a7b5741"
      unitRef="usdPerShare">1.92</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTE2LTEtMS0xNTU2Mzg_cd65351a-55cf-4bd4-a7a3-5f4436d1b608"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE1LTE4LTEtMS0xNTU2Mzg_5e4c41dd-ce98-4775-bf52-4a90c65db349"
      unitRef="usdPerShare">1.89</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTItMS0xLTE1NTYzOA_668aca76-5e0f-4746-8643-ab5107a769d4"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTQtMS0xLTE1NTYzOA_7c34ec79-ec72-4e98-850e-9385ccbfe593"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTYtMS0xLTE1NTYzOA_08ad40bd-f385-476d-91e3-a03c3399eb91"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTgtMS0xLTE1NTYzOA_4e3cfee4-80e6-44ee-abd6-2f0348fd876e"
      unitRef="usdPerShare">0.46</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTEwLTEtMS0xNTU2Mzg_815b8af5-39f0-425a-b207-fdd97e397eff"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTEyLTEtMS0xNTU2Mzg_9b64b50c-6b5e-4517-985c-3ef44b44465d"
      unitRef="usdPerShare">0.45</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTE0LTEtMS0xNTU2Mzg_7a9075c6-3725-4293-9cd3-d02a34bdb213"
      unitRef="usdPerShare">0.95</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTE2LTEtMS0xNTU2Mzg_c74ffde6-de29-4247-ac10-bc80aa85afbf"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE2LTE4LTEtMS0xNTU2Mzg_6eeb9e52-b337-4eec-9983-dce9a12cb031"
      unitRef="usdPerShare">0.94</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTItMS0xLTE1NTYzOA_7fc62245-d082-428a-839a-93e43ec0749c"
      unitRef="usdPerShare">3.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTQtMS0xLTE1NTYzOA_5dcab71a-c92c-4a09-95ef-f27c9fb4aa6d"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTYtMS0xLTE1NTYzOA_bbc14571-6dc0-4efb-a9e4-087a1b831e5e"
      unitRef="usdPerShare">3.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTgtMS0xLTE1NTYzOA_a14fa987-48db-406d-9164-d7b77175c723"
      unitRef="usdPerShare">1.71</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTEwLTEtMS0xNTU2Mzg_541db502-a558-45aa-971c-7a200c72a2f6"
      unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTEyLTEtMS0xNTU2Mzg_2ab136c1-d27e-40b8-9734-a64365a4aec6"
      unitRef="usdPerShare">1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTE0LTEtMS0xNTU2Mzg_49ad20b0-9599-4129-a6b3-f43604b8daf9"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTE2LTEtMS0xNTU2Mzg_15f3c967-e339-4649-b312-85bab861cdca"
      unitRef="usdPerShare">-0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzE3LTE4LTEtMS0xNTU2Mzg_63fb6b34-d608-4eaf-a67a-5950f882d07c"
      unitRef="usdPerShare">2.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTItMS0xLTE1NTYzOA_d92b2f2b-910e-4947-8f32-e430b429e941"
      unitRef="usd">-731000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTQtMS0xLTE1NTYzOA_ad5d8dc0-75c3-4070-9fb6-300340269976"
      unitRef="usd">49000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTYtMS0xLTE1NTYzOA_e3873478-26ae-4b41-a0b0-65677f23bda8"
      unitRef="usd">-682000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTgtMS0xLTE1NTYzOA_0e0c880e-a2de-4f67-86a8-06fc51664281"
      unitRef="usd">957000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTEwLTEtMS0xNTU2Mzg_1ee6aa44-67cd-4a90-a376-a71d2391fb43"
      unitRef="usd">-185000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTEyLTEtMS0xNTU2Mzg_fd104b1a-5f82-4cc7-ae89-4540e09f591f"
      unitRef="usd">772000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTE0LTEtMS0xNTU2Mzg_680f150a-a33d-44de-8647-618292e58a2f"
      unitRef="usd">654000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTE2LTEtMS0xNTU2Mzg_dd505de7-56fc-4054-87ab-9446ad581f4b"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI0LTE4LTEtMS0xNTU2Mzg_fb93be5f-2162-4f8a-aeae-79face3b46e9"
      unitRef="usd">675000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTItMS0xLTE1NTYzOA_f22c4d42-3b66-4a76-8a76-e5fb12eb9011"
      unitRef="usd">1565000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTQtMS0xLTE1NTYzOA_0804acee-cc07-4424-879e-b7c8c7cf6c64"
      unitRef="usd">-1565000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTYtMS0xLTE1NTYzOA_c4308bcc-36be-4bba-b75b-548f53e442a0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTgtMS0xLTE1NTYzOA_37f07d74-01fc-48ce-9e66-b5911de86cb0"
      unitRef="usd">-1128000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTEwLTEtMS0xNTU2Mzg_1ba954d4-ff0a-4851-b7b8-2959371b4cf9"
      unitRef="usd">1128000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTEyLTEtMS0xNTU2Mzg_bbb5d531-6310-478c-9f7a-a54effc804f1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTE0LTEtMS0xNTU2Mzg_fd18d875-9ae1-4e6f-9fb7-e0439d3ed105"
      unitRef="usd">-826000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTE2LTEtMS0xNTU2Mzg_3995947b-81c5-493a-98d4-344923e0b894"
      unitRef="usd">826000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI1LTE4LTEtMS0xNTU2Mzg_79029474-2269-44c7-9bb7-98e060af0ab2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTItMS0xLTE1NTYzOA_cd6749a8-5bf0-4d37-aa0e-dff2ca18c982"
      unitRef="usd">-285000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTQtMS0xLTE1NTYzOA_32afd02c-1385-4231-85ef-b73d7f933e9f"
      unitRef="usd">285000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTYtMS0xLTE1NTYzOA_7a700efd-5828-46c1-98c8-dbb598cae622"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTgtMS0xLTE1NTYzOA_fb6a24d4-4361-4e31-830c-ce98c5b08f11"
      unitRef="usd">-276000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTEwLTEtMS0xNTU2Mzg_23249273-a296-4fca-93c7-02bcdd4bb52a"
      unitRef="usd">276000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTEyLTEtMS0xNTU2Mzg_4af11490-885d-43f5-b095-3080b366eda8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTE0LTEtMS0xNTU2Mzg_37ec162b-a3a6-40b7-8514-0b6d284ec4d2"
      unitRef="usd">-241000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTE2LTEtMS0xNTU2Mzg_5e9c4cad-c229-47fc-a22b-61f3f2329212"
      unitRef="usd">241000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI2LTE4LTEtMS0xNTU2Mzg_de3c3234-ec42-4a32-88c4-ccd18aecb840"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTItMS0xLTE1NTYzOA_ddc6cb2d-d0cd-43bd-a298-91c87b0629f9"
      unitRef="usd">-209000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTQtMS0xLTE1NTYzOA_3939d77f-3605-47f9-8614-27ae6d786b16"
      unitRef="usd">209000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTYtMS0xLTE1NTYzOA_12f6fdf0-2f83-485e-8c90-808227e14cea"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTgtMS0xLTE1NTYzOA_c7cbbc4e-7da4-4669-b54a-06c97cec19ef"
      unitRef="usd">-278000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTEwLTEtMS0xNTU2Mzg_29e7d3e7-ee39-479b-84f7-8ad28f3d627f"
      unitRef="usd">278000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTEyLTEtMS0xNTU2Mzg_6502563c-6b0e-4783-b1a2-003b8f9adf57"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTE0LTEtMS0xNTU2Mzg_208f6eab-a973-4847-be10-1ebd3c2ba861"
      unitRef="usd">-274000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTE2LTEtMS0xNTU2Mzg_69a35cf1-e9b0-4751-aafb-3ac28471c4ab"
      unitRef="usd">274000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI3LTE4LTEtMS0xNTU2Mzg_662ea075-be99-4cdc-8af5-96af91817292"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTItMS0xLTE1NTYzOA_fbdd68ae-d90f-4840-8f88-0bf511d93a16"
      unitRef="usd">-49000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTQtMS0xLTE1NTYzOA_fbb6ac25-d422-4dc0-8460-8b937ab3562e"
      unitRef="usd">49000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTYtMS0xLTE1NTYzOA_4b5b063a-5ce8-4da6-b10d-c87a29b6d802"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTgtMS0xLTE1NTYzOA_bd18e024-bf54-4e38-b5ed-c94bf1bcae46"
      unitRef="usd">189000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTEwLTEtMS0xNTU2Mzg_837dc8b2-4098-42d1-8fb7-93c30cfdb916"
      unitRef="usd">-189000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTEyLTEtMS0xNTU2Mzg_b0166fb6-4358-422d-8a17-8c0d733ee543"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTE0LTEtMS0xNTU2Mzg_45cd3e4b-5a1e-4b93-93be-d883e206c20e"
      unitRef="usd">-22000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTE2LTEtMS0xNTU2Mzg_8743df37-d6f5-45b2-bc1e-6cca169594ba"
      unitRef="usd">22000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI4LTE4LTEtMS0xNTU2Mzg_03f92fad-3294-4707-889f-de6c5efaaeab"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTItMS0xLTE1NTYzOA_784dab3c-60e8-4760-aa83-e87bd7eff391"
      unitRef="usd">545000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTQtMS0xLTE1NTYzOA_f27c32ba-9f66-4dde-acd9-4bae8e82c2d5"
      unitRef="usd">-475000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTYtMS0xLTE1NTYzOA_7b95a10f-077d-46ac-8b68-58e892e35acd"
      unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTgtMS0xLTE1NTYzOA_ba27ab4a-6ab2-4cb3-ba40-5f1c249efee5"
      unitRef="usd">-349000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTEwLTEtMS0xNTU2Mzg_42f94024-310b-4b15-9b04-012646fac1c4"
      unitRef="usd">122000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTEyLTEtMS0xNTU2Mzg_681bdf19-13fc-4c95-806f-ff080bde94ae"
      unitRef="usd">-227000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTE0LTEtMS0xNTU2Mzg_e4b8790e-a28f-43c7-805d-942c45c0b920"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTE2LTEtMS0xNTU2Mzg_04a3d318-ba6a-4b28-9596-32c0b45df905"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzI5LTE4LTEtMS0xNTU2Mzg_74cc3428-e932-42df-88fb-ec011206b016"
      unitRef="usd">178000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTItMS0xLTE1NTYzOA_a2dcf71a-e43c-4c3d-b044-07ccca0b39a0"
      unitRef="usd">-4746000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTQtMS0xLTE1NTYzOA_ba5d5374-c355-4171-99ee-925956d5e912"
      unitRef="usd">453000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTYtMS0xLTE1NTYzOA_60a6de51-0c19-4c56-a0c2-1854579e0752"
      unitRef="usd">-4293000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTgtMS0xLTE1NTYzOA_bdb2111d-cbbe-43e9-8673-b2114b3b902a"
      unitRef="usd">-1449000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTEwLTEtMS0xNTU2Mzg_42511a08-e885-46df-8c33-7e5e7524448f"
      unitRef="usd">-125000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTEyLTEtMS0xNTU2Mzg_8e51493f-7b20-43d9-8a88-f621958e33b0"
      unitRef="usd">-1575000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTE0LTEtMS0xNTU2Mzg_77bc4414-871b-45aa-87b9-a56b9fc270fa"
      unitRef="usd">609000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTE2LTEtMS0xNTU2Mzg_11709f31-d336-4b9f-baaa-f1d4a7d3615c"
      unitRef="usd">-48000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMxLTE4LTEtMS0xNTU2Mzg_b9380118-4864-4253-bcc2-52db9c11f32b"
      unitRef="usd">561000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i88fe68c318374ac0a9cc31a38e2beb25_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTItMS0xLTE1NTYzOA_c131e031-435f-4052-9ebc-5835fc582e40"
      unitRef="usd">1065000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i04819cdee99246d38d6d26c354104c35_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTQtMS0xLTE1NTYzOA_9da38216-dd57-456c-aac5-39e7a78bec85"
      unitRef="usd">2058000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTYtMS0xLTE1NTYzOA_ef7d36f0-d22f-4e16-9ab0-58f14ff1f26b"
      unitRef="usd">3123000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="ibcd1ec3d47d74cda976f6013612647dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTgtMS0xLTE1NTYzOA_960f67be-5151-4bd0-b279-62b58dcafdbe"
      unitRef="usd">1790000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="ie336e1fc61da4ae3aaf24f1c62032be6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTEwLTEtMS0xNTU2Mzg_7c4b01ab-2a4e-45c2-a087-99d086c78777"
      unitRef="usd">-547000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTEyLTEtMS0xNTU2Mzg_93afbcb3-1e89-4229-ba7f-625e65d2459d"
      unitRef="usd">1242000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i76a069131cb5414f8c837128ed3faa2d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTE0LTEtMS0xNTU2Mzg_d86245c7-4b06-4b26-8016-8c9cdb099af5"
      unitRef="usd">288000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i5c07cdeb304e47fcb49293f038a4e634_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTE2LTEtMS0xNTU2Mzg_ef33bebc-fd5f-4f04-8313-49c8cdacec03"
      unitRef="usd">-233000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzMyLTE4LTEtMS0xNTU2Mzg_b5837c87-63af-4c6b-9d92-c0edea583f99"
      unitRef="usd">55000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtMi0xLTEtMTU1NjM4_20149a80-2e86-46d9-993e-88a0117bd79d"
      unitRef="usd">3320000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtNC0xLTEtMTU1NjM4_6ae46f50-e4e5-49f4-83e6-5a5543217130"
      unitRef="usd">22000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtNi0xLTEtMTU1NjM4_704923cc-f82f-4f0e-8aea-52fe36121004"
      unitRef="usd">3341000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtOC0xLTEtMTU1NjM4_6f0ed9da-5ab0-4752-8ce0-4c3d2114927c"
      unitRef="usd">2383000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtMTAtMS0xLTE1NTYzOA_108c43df-e1d5-4871-b825-72f8a7f7d4e6"
      unitRef="usd">0</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzMtMTItMS0xLTE1NTYzOA_afdeb93a-ba5b-44e8-af2b-5643be60584c"
      unitRef="usd">2383000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtMi0xLTEtMTU1NjM4_c42f2155-73c4-416b-8073-af3728e869ab"
      unitRef="usd">7679000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtNC0xLTEtMTU1NjM4_875564d9-890e-4072-bb9e-0af590c6603a"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtNi0xLTEtMTU1NjM4_7329abef-62ff-4d1f-8727-b0e241585826"
      unitRef="usd">7679000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtOC0xLTEtMTU1NjM4_1c759361-1112-40a9-af4e-ebcbba821bd0"
      unitRef="usd">4879000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtMTAtMS0xLTE1NTYzOA_12f8c2f7-33a6-479d-9a2f-77719a0be979"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzQtMTItMS0xLTE1NTYzOA_7818e897-b369-473e-9c31-655472745e0e"
      unitRef="usd">4879000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtMi0xLTEtMTU1NjM4_9f403cf9-3dd0-428e-8670-7ce72455095a"
      unitRef="usd">3489000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtNC0xLTEtMTU1NjM4_28c7fe29-6363-47ca-94c3-d8f91f6ea981"
      unitRef="usd">0</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtNi0xLTEtMTU1NjM4_47d27fa0-dfc4-4fe0-82de-e94d1246690c"
      unitRef="usd">3489000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtOC0xLTEtMTU1NjM4_3db7627c-2589-4c9d-a227-0c93b0c53a0c"
      unitRef="usd">4766000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtMTAtMS0xLTE1NTYzOA_eef5fe3a-e0f3-4216-9716-c241223adefc"
      unitRef="usd">0</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzUtMTItMS0xLTE1NTYzOA_930bb524-2019-472c-8b9a-19deb059cc40"
      unitRef="usd">4766000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtMi0xLTEtMTU1NjM4_269ad8e3-de06-4c1f-a32c-08eb6c6b9756"
      unitRef="usd">101789000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtNC0xLTEtMTU1NjM4_81b587bc-9816-42d6-bdbc-d43ed6b71ad9"
      unitRef="usd">1605000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtNi0xLTEtMTU1NjM4_bcdecde8-fd24-493d-85a1-d37f586ed1a5"
      unitRef="usd">103394000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtOC0xLTEtMTU1NjM4_cf62923e-e936-4047-b546-7343725b0536"
      unitRef="usd">96770000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtMTAtMS0xLTE1NTYzOA_88eace87-1817-4150-b031-ec9feeb1ce16"
      unitRef="usd">-6378000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzYtMTItMS0xLTE1NTYzOA_e0b9e02a-3686-4034-8c34-6adf65ce0d34"
      unitRef="usd">90392000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i081d264148eb46f1afc0ba411e33410f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctMi0xLTEtMTU1NjM4_89a2b295-64c7-4661-b88e-7091e2bc045e"
      unitRef="usd">-4313000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1ccaafd7b6f344099e15fe9af9a1f3fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctNC0xLTEtMTU1NjM4_86beeeea-1d1c-4ae6-8491-89b4fa4965a2"
      unitRef="usd">-1583000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctNi0xLTEtMTU1NjM4_fa91a244-e48c-4371-9239-c5ea6ec5caa7"
      unitRef="usd">-5897000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i68bc59daf06d4c87a9c731683260774d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctOC0xLTEtMTU1NjM4_30afaedd-dfd9-473d-9f52-4fbeccbcc1b8"
      unitRef="usd">-11688000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9edb7a944ede457bb2ca3502417492fd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctMTAtMS0xLTE1NTYzOA_64e68ee0-15bb-4b67-a896-76ba901ac39a"
      unitRef="usd">6378000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTowNzQwODcwM2NjOGU0NzkwOTJjNDVmM2M0ODg1N2YzYy90YWJsZXJhbmdlOjA3NDA4NzAzY2M4ZTQ3OTA5MmM0NWYzYzQ4ODU3ZjNjXzctMTItMS0xLTE1NTYzOA_2599286e-c17d-4a8c-abff-919150586d2d"
      unitRef="usd">-5310000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:UseOfEstimates
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1MzY5_c9b4ca6b-9847-4af8-953e-67fe86c3086c">Estimates and Assumptions&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In preparing these financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures. These estimates and assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues, determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, and in determining the reported amounts of liabilities, all of which also impact the consolidated statements of income. Certain estimates of fair value and amounts recorded in connection with acquisitions, revenue deductions, impairment reviews, restructuring-associated charges, investments and financial instruments, valuation allowances, pension and postretirement benefit plans, contingencies, share-based compensation, and other calculations can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted. As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDc0_279471f5-787b-4967-a48a-c61c6c143e28">Acquisitions&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 16D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTU5_8cd544c1-70a4-405f-81f0-d278406bd615">Fair Value&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Income approach, which is based on the present value of a future stream of net cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The following inputs and valuation techniques are used to estimate the fair value of our financial assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Available-for-sale debt securities&#x2014;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted yield curves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Equity securities with readily determinable fair values&#x2014;quoted market prices and observable NAV prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Derivative assets and liabilities&#x2014;third-party matrix-pricing model that uses inputs derived from or corroborated by observable market data. Where applicable, these models use market-based observable inputs, including interest rate yield curves to discount future cash flow amounts, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Money market funds&#x2014;observable NAV prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like benchmark interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTUw_9d805957-c911-4198-82df-78044bc367db">Foreign Currency Translation&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and income and expense amounts at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and we translate non-monetary items at historical rates.&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDk5_d2f8cafc-caa4-4138-8b1e-d4c577da273b">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We typically determine transfer of control based on when the product is shipped or delivered and title passes to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our Sales Contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to LOE, product recalls or a changing competitive environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deductions from Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provisions for pharmaceutical sales returns&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Provisions are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as LOE, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The following outlines our common sales arrangements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#008080;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies, and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. Prescription pharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;In the U.S., we sell our products principally to distributors and hospitals. We also have contracts with managed care programs or PBMs and legislatively mandated contracts with the federal and state governments under which we provide rebates based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior periods. We apply the experience ratio to the respective period&#x2019;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#x201c;coverage gap,&#x201d; also known as the &#x201c;doughnut hole,&#x201d; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#x2019;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices and legislated discounts to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recorded direct product sales and/or Alliance revenues of more than $1 billion for each of nine products in 2021, for each of seven products in 2020 and for each of six products in 2019. In the aggregate, these direct products sales and/or alliance product revenues represented 75% of our revenues in 2021, 54% of our revenues in 2020 and 49%&lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;of our revenues in 2019. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17B &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices and lower volumes due to added generic competition. We generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;Collaborative Arrangements&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received for our share of gross profits from our collaboration partners as alliance revenues, a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion activities for the collaboration and the collaboration partners sell the products to their customers. The related expenses for selling and marketing these products including reimbursements to or from our collaboration partners for these costs are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Royalty payments received from collaboration partners are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Reimbursements to or from our collaboration partners for development costs are typically recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable intangible assets&#x2014;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; over the development period for the products, when our performance obligations include providing R&amp;amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <pfe:ConcentrationRiskAmount
      contextRef="ibfadeff2c1f5480394b1866913a3183a_D20210101-20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNTk3_060498e7-ab9b-4ad9-8c54-9eebe0f5be6c"
      unitRef="usd">1000000000</pfe:ConcentrationRiskAmount>
    <pfe:ConcentrationRiskAmount
      contextRef="i11f0ae3d8acd41fa96131bb2d2405985_D20200101-20201231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNTk3_3f7f24df-4e36-4e56-b0b9-03263c67ee7e"
      unitRef="usd">1000000000</pfe:ConcentrationRiskAmount>
    <pfe:ConcentrationRiskAmount
      contextRef="if173d80ef8d44c438cb34092fab6cadf_D20190101-20191231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNTk3_bbfe0c16-e942-44d2-b038-67e88ab8b2e7"
      unitRef="usd">1000000000</pfe:ConcentrationRiskAmount>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibfadeff2c1f5480394b1866913a3183a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyNzg1_780afbbb-01f2-487b-9f6c-d38459cf9137"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i11f0ae3d8acd41fa96131bb2d2405985_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyODEx_462bb10b-45f0-406e-a363-80bc616c35c0"
      unitRef="number">0.54</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if173d80ef8d44c438cb34092fab6cadf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzIyODQw_03da4573-855b-42ee-9a99-a2bd40e947d9"
      unitRef="number">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDE2_ca6eb23d-3e09-4859-893e-865bb8927024">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reserve against &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,077&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;528&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued rebates and other sales-related accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,850&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pfe:RebatesAndOtherSalesRelatedAccruals
      contextRef="i2f7cb8f0966747fd9a171cc0fd9a0c50_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzMtMi0xLTEtMTU1NjM4_a7fb6a6a-5f5b-4e40-9f98-3e1e4eeb71d3"
      unitRef="usd">1077000000</pfe:RebatesAndOtherSalesRelatedAccruals>
    <pfe:RebatesAndOtherSalesRelatedAccruals
      contextRef="i59d45585212a4650a36d5467a52c00b1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzMtNC0xLTEtMTU1NjM4_3cdb3a7b-06c7-47f7-8b31-8d0b800e68c8"
      unitRef="usd">861000000</pfe:RebatesAndOtherSalesRelatedAccruals>
    <pfe:AccruedRebates
      contextRef="i5c659cb958e94f909ae64de8887c53e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzYtMi0xLTEtMTU1NjM4_060ab353-5dd2-496c-80e0-72f1719b406c"
      unitRef="usd">3811000000</pfe:AccruedRebates>
    <pfe:AccruedRebates
      contextRef="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzYtNC0xLTEtMTU1NjM4_d1cba3d9-1199-4cb6-b3f9-0d0911e8a138"
      unitRef="usd">3017000000</pfe:AccruedRebates>
    <pfe:OtherAccruals
      contextRef="i5c659cb958e94f909ae64de8887c53e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzctMi0xLTEtMTU1NjM4_d17ccc14-d510-4a46-82ce-722b14d1ecae"
      unitRef="usd">528000000</pfe:OtherAccruals>
    <pfe:OtherAccruals
      contextRef="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzctNC0xLTEtMTU1NjM4_dbba5c1e-c509-47a9-9f07-39e59263973a"
      unitRef="usd">432000000</pfe:OtherAccruals>
    <pfe:RebatesAndOtherSalesRelatedAccruals
      contextRef="ibe0e5d69b58349a58289b22b8b683cd0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzktMi0xLTEtMTU1NjM4_a4cb7bf8-4f7b-44af-854d-896a95a6cf52"
      unitRef="usd">433000000</pfe:RebatesAndOtherSalesRelatedAccruals>
    <pfe:RebatesAndOtherSalesRelatedAccruals
      contextRef="i0aaf677ffe1c461b92474fb66fe48c68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzktNC0xLTEtMTU1NjM4_b95d3b18-68a8-4514-a867-9a8fae836bbc"
      unitRef="usd">399000000</pfe:RebatesAndOtherSalesRelatedAccruals>
    <pfe:RebatesAndOtherSalesRelatedAccruals
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzEwLTItMS0xLTE1NTYzOA_56802fc6-4ac1-45ac-b616-ec028c0fbd22"
      unitRef="usd">5850000000</pfe:RebatesAndOtherSalesRelatedAccruals>
    <pfe:RebatesAndOtherSalesRelatedAccruals
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTpkMjI5MzRjYzM2NTI0MDlhOTQ5MGQzYmUyZTUyNTUwYi90YWJsZXJhbmdlOmQyMjkzNGNjMzY1MjQwOWE5NDkwZDNiZTJlNTI1NTBiXzEwLTQtMS0xLTE1NTYzOA_fe23ed8b-49a8-40cd-830c-4f6fbd15ea03"
      unitRef="usd">4708000000</pfe:RebatesAndOtherSalesRelatedAccruals>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTUz_7220f432-1d84-4ed1-825d-6b6024e5d682">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;During 2021 and 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTU0_94c7f175-b960-4594-893f-1dcee6cb6860">Cost of Sales and InventoriesInventories are recorded at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1MzYy_d80d8b25-8111-402c-b2ec-a2f7b350cdf5">Selling, Informational and Administrative ExpensesSelling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzI4OTQz_59f9436c-111b-4bf9-aa4c-8e909ace7854"
      unitRef="usd">2000000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzI4OTUz_afcbea84-5dd7-417a-8412-86d267565200"
      unitRef="usd">1800000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzI4OTY2_9cdd54ad-71b4-46d8-bde1-0c72cdda47e4"
      unitRef="usd">2300000000</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTQx_390b4779-9b0e-4ef8-91cc-58921c0d943d">Research and Development Expenses&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments we make to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and, unless the asset is determined to have an indefinite life, we typically amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTE0_603b5bb0-6002-4a83-b3ca-21bdfca33139">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, less accumulated depreciation&#x2014;These assets are recorded at cost, including any significant improvements after purchase, less accumulated depreciation. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDcw_c046b5a9-6c74-4020-8054-961aab5786de">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;These assets are recorded at fair value at acquisition. Intangible assets with finite lives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives are not amortized until a useful life can be determined.&lt;/span&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amortization of finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; as these intangible assets benefit multiple business functions. Amortization of intangible assets that are for a single function and depreciation of property, plant and equipment are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows for the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For indefinite-lived intangible assets, such as brands and IPR&amp;amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For goodwill, when necessary, we determine the fair value of each reporting unit and record an impairment loss, if any, for the excess of the book value of the reporting unit over the implied fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDYz_74b173ae-def5-4760-815c-00d54aa51fab">We review our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTcy_fc01f6c6-f0d8-490e-94cc-0a793bb8a78e">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges for site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, as appropriate. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our business and platform functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;amp;D, as well as our corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement).&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDEy_42f67dd8-4402-4941-b27b-358a4a1fb58a">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDU1_66cb7d95-25c8-4558-adf5-3065ba63e4cc">Cash flows for financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows for financial instruments designated as net investment hedges are classified according to the nature of the hedging instrument. Cash flows for financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDcy_ec04b923-0b34-4d4b-a97d-28fb7de29504">Investments and Derivative Financial Instruments&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The classification of an investment depends on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence. Our investments are primarily comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Public equity securities with readily determinable fair values, which are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Available-for-sale debt securities, which are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;until realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Held-to-maturity debt securities, which are carried at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#x2019;s income and expenses in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:107%"&gt;Realized gains or losses on sales of investments are determined by using the specific identification cost method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTY4_aa70e101-706f-4308-ae27-367cbdd1ce74">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are carried at fair value in various balance sheet categories (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;), with changes in fair value reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; or, for derivative financial instruments in certain qualifying hedging relationships, in &lt;/span&gt;Other comprehensive income/(loss)</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDU5_c48cb181-c100-41e0-82a0-22896b24f19e">Tax Assets and Liabilities and Income Tax Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; primarily include (i) tax effects for intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party and (ii) income tax receivables that are expected to be recovered either via refunds from taxing authorities or reductions to future tax obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. Amounts recorded for valuation allowances requires judgments about future income which can depend heavily on estimates and assumptions. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Global Intangible Low-Taxed Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Other non-current tax assets primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; as of December 31, 2021 and 2020 include liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability for which we elected payment over eight years through 2026. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; for uncertain tax positions and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; for the repatriation tax liability and other estimates and assumptions in connection with the TCJA.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize all or a portion of the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We regularly monitor our position and subsequently recognize the unrecognized tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#x201c;more likely than not&#x201d;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. Liabilities for uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and are classified on our consolidated balance sheet with the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTQ1_1560cd2e-5e4e-4839-ae96-1ed18d75c366">Pension and Postretirement Benefit Plans&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may be determined using assumptions such as discount rate, expected annual rate of return on plan assets, expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NTYy_9b0c030a-e289-4499-9c28-fad61ac6d835">Legal and Environmental ContingenciesWe and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. In assessing contingencies related to legal and environmental proceedings that are pending against the Company, or unasserted claims that are probable of being asserted, we record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90ZXh0cmVnaW9uOjQ4MjM2YmI4YzQ3NDQ3NzZhZTJkZWNlMTE0ODBhNWJjXzQ1NDM5_9cc713ab-cf44-4ce1-9b72-6093f12beef3">Share-Based Payments&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms with the related costs recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA2_c24d438d-0c84-481a-8755-4d6637273e93">Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Trillium&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;On November 17, 2021, we acquired all of the issued and outstanding common stock not already owned by Pfizer of Trillium, a clinical stage immuno-oncology company developing therapies targeting cancer immune evasion pathways and specific cell targeting approaches, for a price of $18.50 per share in cash, for total consideration of $2.0 billion, net of cash acquired. As a result, Trillium became our wholly owned subsidiary. We previously held a 2% ownership investment in Trillium. Trillium&#x2019;s lead program, TTI-622, is an investigational fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;We accounted for the transaction as an asset acquisition since the lead asset, TTI-622, represented substantially all of the fair value of the gross assets acquired, which exclude cash acquired. At the acquisition date, we recorded a $2.1 billion charge representing an acquired IPR&amp;amp;D asset with no alternative future use in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;, of which the $2.0 billion net cash consideration is presented as a cash outflow from operating activities. In connection with this acquisition, we recorded $256 million of assets acquired primarily consisting of cash and investments. Liabilities assumed were approximately $81 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Array&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On July&#160;30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred was $11.2 billion ($10.9 billion, net of cash acquired). In addition, $157 million in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). We financed the majority of the transaction with debt and the balance with existing cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Array&#x2019;s portfolio includes Braftovi (encorafenib) and Mektovi (binimetinib), a broad pipeline of targeted cancer medicines in different stages of R&amp;amp;D, as well as a portfolio of out-licensed medicines, which may generate milestones and royalties over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in 2020. In connection with this acquisition, we recorded: (i) $6.3 billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, consisting of $2.0 billion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; with a useful life of 16 years&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; $2.8 billion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and $1.5 billion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licensing agreements and other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($1.2 billion for technology in development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;indefinite-lived licensing agreements and $360 million for developed technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;finite-lived licensing agreements with a useful life of 10 years), (ii) $6.1 billion of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, (iii) $1.1 billion of net deferred tax liabilities and (iv) $451 million of assumed long-term debt, which was paid in full in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;In 2020, we recorded measurement period adjustments to the estimated fair values initially recorded in 2019, which resulted in a reduction in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; of approximately $900 million with a corresponding change to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Goodwill &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;and net deferred tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date and did not have a material impact on our consolidated statement of income for the year ended December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Therachon&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million contingent on the achievement of key milestones in the development and commercialization of the lead asset. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was $322 million, which consisted of $317 million of cash and our previous $5 million investment in Therachon. In connection with this asset acquisition, we recorded a charge of $337 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Meridian&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;On December 31, 2021, we completed the sale of our Meridian subsidiary for approximately $51 million in cash and recognized a loss of approximately $167&#160;million, net of tax, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;. In connection with the sale, Pfizer and the purchaser of Meridian entered into various agreements to provide a framework for our relationship after the sale, including interim TSAs and a manufacturing supply agreement (MSA). The TSAs primarily involve Pfizer providing services related to information technology, among other activities, and are generally expected to be for terms of no more than 12 to 18 months post sale. The MSA is for a term of three years post sale with a two year extension period. No amounts were recorded under the above arrangements in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Upjohn Separation and Combination with Mylan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;On November&#160;16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan (the Transactions) to form Viatris. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;The Transactions were structured as an all-stock, Reverse Morris Trust transaction. Specifically, (i) we contributed the Upjohn Business to a wholly owned subsidiary, which was renamed Viatris, so that the Upjohn Business was separated from the remainder of our business (the Separation), (ii) following the Separation, we distributed, on a pro rata basis, all of the shares of Viatris common stock held by Pfizer to Pfizer stockholders as of the November&#160;13, 2020 record date, such that each Pfizer stockholder as of the record date received approximately 0.124079 shares of Viatris common stock per share of Pfizer common stock (the Distribution); and (iii) immediately after the Distribution, the Upjohn Business combined with Mylan in a series of transactions in which Mylan shareholders received one share of Viatris common stock for each Mylan ordinary share held by such shareholder, subject to any applicable withholding taxes (the Combination). Prior to the Distribution, Viatris made a cash payment to Pfizer equal to $12.0 billion as partial consideration for the contribution of the Upjohn Business to Viatris. As of the closing of the Combination, Pfizer stockholders owned approximately 57% of the outstanding shares of Viatris common stock, and Mylan shareholders owned approximately 43% of the outstanding shares of Viatris common stock, in each case on a fully diluted, as-converted and as-exercised basis. The Transactions are generally expected to be tax free to Pfizer and Pfizer stockholders for U.S. tax purposes. Beginning November&#160;16, 2020, Viatris operates both the Upjohn Business and Mylan as an independent publicly traded company, which is traded under the symbol &#x201c;VTRS&#x201d; on the NASDAQ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In connection with the Transactions, in June 2020, Upjohn Inc. and Upjohn Finance B.V. completed privately placed debt offerings of $7.45 billion and &#x20ac;3.60 billion aggregate principal amounts, respectively, (approximately $11.4 billion) of senior unsecured notes and entered into other financing arrangements, including a $600 million delayed draw term loan agreement and a revolving credit facility agreement for up to $4.0 billion. Proceeds from the debt offerings and other financing arrangements were used to fund the $12.0 billion cash distribution Viatris made to Pfizer prior to the Distribution. We used the cash distribution proceeds to pay down commercial paper borrowings and redeem the $1.15 billion aggregate principal amount outstanding of our 1.95% senior unsecured notes that were due in June 2021 and $342 million aggregate principal amount outstanding of our 5.80% senior unsecured notes that were due in August 2023, before the maturity date. Interest expense for the $11.4 billion in debt securities incurred during 2020 is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. Following the Separation and Combination of the Upjohn Business with Mylan, we are no longer the obligor or guarantor of any Upjohn debt or Upjohn financing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;As a result of the spin-off of the Upjohn Business, we distributed net assets of $1.6 billion as of November&#160;16, 2020, which was reflected as a reduction to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; and reflects the change in accounting principle in the first quarter of 2021 to MTM Accounting. See&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; Note 1C.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Of this amount, $412 million represents cash transferred to the Upjohn Business, with the remainder considered a non-cash activity in the consolidated statement of cash flows for the year ended December 31, 2020. The spin-off also resulted in a net increase to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; of $423 million for the derecognition of net gains on foreign currency translation adjustments of $397 million and prior service net credits associated with benefit plans of $26 million, which were reclassified to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Retained earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:115%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;As a result of the separation of Upjohn, we incurred separation-related costs of $434 million in 2020 and $83 million in 2019, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;. These costs primarily relate to professional fees for regulatory filings and separation activities within finance, tax, legal and information system functions as well as investment banking fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;In connection with the Transactions, Pfizer and Viatris entered into various agreements to effect the Separation and Combination to provide a framework for our relationship after the Combination, including a separation and distribution agreement, interim operating models, including agency arrangements, MSAs, TSAs, a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. The terms of the MSAs range in initial duration from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcwNjc_b11edfc2-cb4f-4099-b138-98c6766b88f5"&gt;four&lt;/span&gt; to seven years post-Separation. The TSAs primarily involve Pfizer providing services to Viatris related to finance, information technology and human resource infrastructure and are generally expected to be for terms of no more than three years post-Separation. The amounts recorded under the above agreements were not material to our consolidated results of operations in 2021 and 2020. In addition, Pfizer and Mylan had a pre-existing arms-length commercial agreement, which is continuing with Viatris and is not material to Pfizer&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Net amounts due from Viatris under the above agreements were $53 million as of December 31, 2021 and $401 million as of December 31, 2020. The cash flows associated with the above agreements are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Net cash provided by operating activities from continuing operations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;except for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;a $277 million payment to Viatris made in 2021 pursuant to terms of the separation agreement, which is reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other financing activities, net, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;and was recorded as a payable to Viatris in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt; as of December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt; Discontinued operations&#x2013;&#x2013;net of tax: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax income/(loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income/(loss) from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax loss on sale of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss on sale of discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations&#x2014;net of tax, which includes a pre-tax amount for a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345&#160;million; and (ii) the after tax loss of $167&#160;million related to the sale of Meridian recognized in Loss on sale of discontinued operations&#x2013;&#x2013;net of tax. To a much lesser extent, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-closing adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations&#x2014;net of tax. In 2020 and 2019, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. In 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;includes pre-tax interest expense of $116 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $223 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of assets and liabilities of discontinued operations and other assets held for sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="22" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets of discontinued operations and other assets held for sale&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets of discontinued operations&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities of discontinued operations&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities of discontinued operations&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts as of December 31, 2021 represent property, plant and equipment held for sale. Amounts as of December 31, 2020 primarily relate to discontinued operations of our former Meridian subsidiary and the Mylan-Japan collaboration.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-right:9pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Equity-Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Formation of Consumer Healthcare JV&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On July&#160;31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a 32% equity stake in the new company and GSK owns the remaining 68%. Upon closing, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of $8.1 billion ($5.4 billion, net of tax) in the third quarter of 2019 in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Gain) on completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; for the difference in the fair value of our 32% equity stake and the carrying value of our Consumer Healthcare business. Our financial results and our Consumer Healthcare segment&#x2019;s operating results for&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The financial results for 2021 and 2020 do not reflect any contribution from the Consumer Healthcare business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In valuing our investment in the Consumer Healthcare JV, we used discounted cash flow techniques. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long term; the discount rate, which seeks to reflect our best estimate of the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our investment in the Consumer Healthcare JV is $16.3 billion as of December 31, 2021 and $16.7 billion as of December 31, 2020 and is reported as a private equity investment in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity-method investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;as of December 31, 2021 and 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 to December 31, 2021 is primarily due to dividends totaling $499 million, as well as $384 million in pre-tax foreign currency translation adjustments (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;), partially offset by our share of the JV&#x2019;s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; commencing from August 1, 2019. Our total share of the JV&#x2019;s earnings generated in the fourth quarter of 2020 and the first nine months of 2021, which we recorded in our operating results in 2021, was $495 million. Our total share of the JV&#x2019;s earnings generated in the fourth quarter of 2019 and the first nine months of 2020, which we recorded in our operating results in 2020, was $417 million. Our total share of two months of the JV&#x2019;s earnings generated in the third quarter of 2019, which we recorded in our operating results in the fourth quarter of 2019, was $47 million. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in the Consumer Healthcare JV was $15.7 billion and that 32% of the underlying equity in the carrying value of the net assets of the Consumer Healthcare JV was $11.2 billion, resulting in an initial basis difference of approximately $4.5 billion. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. During the fourth quarter of 2019, the Consumer Healthcare JV revised the initial carrying value of the net assets of the JV and our 32% share of the underlying equity in the carrying value of the net assets of the Consumer Healthcare JV was reduced to $11.0 billion and our initial basis difference was increased to $4.8 billion. The adjustment was allocated to equity method goodwill within the investment account. We began recording the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; commencing August 1, 2019. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and was not material to our results of operations in the periods presented. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amortization of basis differences on inventory and related deferred tax liabilities was completely recognized by the second quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over the lives of the underlying assets, which range from 8 to 20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As a part of Pfizer in 2019, pre-tax income on a management basis for the Consumer Healthcare business was $654 million through July&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-right:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, the Consumer Healthcare JV, as of September 30, 2021, the most recent period available, and as of September 30, 2020 and for the periods ending September 30, 2021, 2020, and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,890&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,705&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total net equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-right:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Twelve Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Two Months Ending&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investment in ViiV&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately 11.7% of ViiV, and prior to 2016 we accounted for our investment under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to zero due to the recognition of cumulative equity method losses and dividends. Since 2016, we have recognized dividends from ViiV as income in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; when earned, including dividends of $166 million in 2021, $278 million in 2020 and $220 million in 2019 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, ViiV, as of December 31, 2021 and 2020 and for the years ending December 31, 2021, 2020, and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total net equity/(deficit) attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;      &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-right:9pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Agreement with Valneva&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;On April&#160;30, 2020, we signed an agreement to co-develop and commercialize Valneva&#x2019;s Lyme disease vaccine candidate, VLA15, which covers six serotypes that are prevalent in North America and Europe. Valneva and Pfizer will work closely together throughout the development of VLA15. Valneva is eligible to receive a total of up to $308 million in cash payments from us consisting of a $130 million upfront payment, which was paid and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;in our second quarter of 2020, as well as $35 million in development milestones and $143 million in early commercialization milestones. Under the terms of the agreement, Valneva will fund 30% of all development costs through completion of the development program, and in return we will pay Valneva tiered royalties. We will lead late-stage development and have sole control over commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Agreement with Akcea&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On October&#160;4, 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a wholly-owned subsidiary of Ionis. The transaction closed in November 2019 and we made an upfront payment of $250 million to Akcea, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in our fourth quarter of 2019. On January 31, 2022, we and Ionis announced the discontinuation of the Pfizer-led clinical development program for the licensed product and that we would be returning the rights to the licensed product to Ionis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-right:9pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaboration with Beam&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On December&#160;24, 2021, we entered into a multi-year research collaboration with Beam to utilize Beam&#x2019;s in vivo base editing programs, which use mRNA and lipid nanoparticles, for three targets for rare genetic diseases of the liver, muscle and central nervous system. Under the terms of the agreement, Beam conducts all research activities through development candidate selection for three undisclosed targets, which are not included in Beam&#x2019;s existing programs, and we may opt in to obtain exclusive licenses to each development candidate. Beam has a right to opt in, at the end of phase 1/2 studies, upon the payment by Beam of an option exercise fee, to a global co-development and co-commercialization agreement with respect to one program licensed under the collaboration pursuant to which we and Beam would share net profits as well as development and commercialization costs in a 65%/35% ratio (Pfizer/Beam). Upon entering into the agreement, we recorded $300 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in the fourth quarter of 2021 for an upfront payment due to Beam, and if we exercise our opt in to licenses for all three targets, Beam would be eligible for up to an additional $1.05 billion in development, regulatory and commercial milestone payments for a potential total deal consideration of up to $1.35 billion. Beam is also eligible to receive royalties on global net sales for each licensed program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaboration with Arvinas&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;On July&#160;21, 2021, we entered into a global collaboration with Arvinas to develop and commercialize ARV-471, an investigational oral PROTAC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. In connection with the agreement, we made an upfront cash payment of $650 million to Arvinas and we made a $350 million equity investment in the common stock of Arvinas. We recognized $706 million for the upfront payment and a premium paid on our equity investment in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;in our third quarter of 2021. Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones. The companies will equally share worldwide development costs, commercialization expenses and profits. As of December 31, 2021, we held a 6.5% equity stake of Arvinas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaboration with Myovant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2020, we entered into a collaboration with Myovant to jointly develop and commercialize Orgovyx (relugolix) in advanced prostate cancer and Myfembree (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in women&#x2019;s health in the U.S. and Canada. We also received an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries, which we declined to exercise. Under the terms of the agreement, the companies will equally share profits and allowable expenses for Orgovyx and Myfembree in the U.S. and Canada, with Myovant bearing our share of allowable expenses up to a maximum of $100 million in 2021 and up to a maximum of $50 million in 2022. We record our share of gross profits as Alliance revenue. Myovant remains responsible for regulatory interactions and drug supply and continues to lead clinical development for Myfembree. Myovant is entitled to receive up to $4.35 billion, including an upfront payment of $650 million, which was made in December 2020, $200 million in potential regulatory milestones for FDA approvals for Myfembree in women&#x2019;s health, of which $100 million was paid to Myovant in July 2021 and recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable intangible assets&#x2014;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, and tiered sales milestones of up to $3.5 billion in total for prostate cancer and for the combined women&#x2019;s health indications. In connection with this transaction, in 2020 we recognized $499 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Identifiable intangible assets&#x2013;&#x2013;Developed technology&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and $151 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;representing the relative fair value of the portion of the upfront payment allocated to the approved indication and unapproved indications of the product, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Collaboration with CStone&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On September&#160;29, 2020, we entered into a strategic collaboration with CStone to address oncological needs in China. The collaboration encompasses our $200 million upfront equity investment in CStone, the development and commercialization of CStone&#x2019;s sugemalimab (CS1001, PD-L1 antibody) in mainland China, and a framework between the companies to bring additional oncology assets to the Greater China market. The transaction closed on October&#160;9, 2020. As of December 31, 2021, we held a 9.8% equity stake of CStone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;Collaborations with BioNTech&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;On December 30, 2021, we entered into a new research, development and commercialization agreement to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus) based on BioNTech&#x2019;s proprietary mRNA technology and our antigen technology. Under the terms of the agreement, we agreed to pay BioNTech $225 million, including an upfront cash payment of $75 million and an equity investment of $150 million. BioNTech is eligible to receive future regulatory and sales milestone payments of up to $200 million. In return, BioNTech agreed to pay us $25 million for our proprietary antigen technology. The net upfront payment to BioNTech was recorded to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:115%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;in our fourth quarter of 2021. We and BioNTech will share development costs. We will have commercialization rights to the potential vaccine worldwide, excluding Germany, Turkey and certain developing countries where BioNTech will have commercialization rights. We and BioNTech will share gross profits from commercialization of any product. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On April&#160;9, 2020, we signed a global agreement with BioNTech to co-develop a mRNA-based coronavirus vaccine program, BNT162b2, aimed at preventing COVID-19 infection. In connection with the April 2020 agreement, we made an upfront cash payment of $72 million and an equity investment in the common stock of BioNTech of $113 million. We recognized $98 million for the upfront payment and a premium paid on the equity investment in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;in our second quarter of 2020. BioNTech became eligible to receive potential milestone payments of up to $563 million for a total consideration of $748 million. Under the terms of this agreement, we and BioNTech share gross profits and development costs equally after approval and successful commercialization of the vaccine, and we were responsible for all of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;the development costs until commercialization of the vaccine. Thereafter, BioNTech was to repay us its 50 percent share of these development costs through reductions in gross profit sharing and milestone payments to BioNTech over time. On January 29, 2021, we and BioNTech signed an amended version of the April 2020 agreement. Under the January 2021 agreement, BioNTech paid us their 50 percent share of prior development costs in a lump sum payment during the first quarter of 2021. Further R&amp;amp;D costs are being shared equally. We have commercialization rights to the vaccine worldwide, excluding Germany and Turkey where BioNTech markets and distributes the vaccine under the agreement with us, and excluding China, Hong Kong, Macau and Taiwan, which are subject to a separate collaboration between BioNTech and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. We recognize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; on a gross basis in markets where we are commercializing the vaccine and we record our share of gross profits related to sales of the vaccine by BioNTech in Germany and Turkey in Alliance revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We made an additional investment of $50 million in common stock of BioNTech as part of an underwritten equity offering by BioNTech, which closed in July 2020. As of December 31, 2021, we held an equity stake of 2.5% of BioNTech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Summarized Financial Information for Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;s&#x2014;Alliance revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from collaborative arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other income/(deductions)&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents sales to our partners of products manufactured by us.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2021 reflects increases in alliance revenues from Comirnaty, Eliquis and Xtandi, while the increase in 2020 reflects increases in alliance revenues from Eliquis and Xtandi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The increase in 2021 is primarily related to Comirnaty.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;Primarily relates to royalties from our collaboration partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The amounts outlined in the above table do not include transactions with third parties other than our collaboration partners, or other costs for the products under the collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock>
    <pfe:AssetAcquisitionSharePrice
      contextRef="id3eaee674151468f8779787aca2fbdd8_I20211117"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2OTE1NjQ_c40d1c9a-a205-4c26-92bf-2207f6cf27ef"
      unitRef="usdPerShare">18.50</pfe:AssetAcquisitionSharePrice>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NDk2_7a98c0df-8f2c-4ed7-a8e8-f5a231260948"
      unitRef="usd">2000000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <pfe:InvestmentOwnershipPercentage
      contextRef="i40a5967cba7c42799e4a32e326df03fd_D20210101-20211116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2OTE1NDA_0455f2bc-ac28-47e4-b799-b7ca05e264b7"
      unitRef="number">0.02</pfe:InvestmentOwnershipPercentage>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NTEz_4a847d13-6615-4db3-85f9-8f9db3283813"
      unitRef="usd">2100000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="ifc5ec4892e0b407285ae1b1055d34c70_D20211117-20211117"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzQ1ODc_7a98c0df-8f2c-4ed7-a8e8-f5a231260948"
      unitRef="usd">2000000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <pfe:AssetAcquisitionAssetsAcquired
      contextRef="id3eaee674151468f8779787aca2fbdd8_I20211117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NTMy_094d8ea3-66d2-4671-bbe1-e0d69c4195fd"
      unitRef="usd">256000000</pfe:AssetAcquisitionAssetsAcquired>
    <pfe:AssetAcquisitionLiabilitiesAssumed
      contextRef="id3eaee674151468f8779787aca2fbdd8_I20211117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA1NTM4_e64b1cfd-de94-4bf3-bee6-67b7836b34ab"
      unitRef="usd">81000000</pfe:AssetAcquisitionLiabilitiesAssumed>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI2Mw_efce6f9b-38e5-428d-81e8-8b5127f7f14e"
      unitRef="usdPerShare">48</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i5adbe40672074cb28e27345d594c6111_D20190730-20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM0Mw_0da11ef9-8cd1-4675-b008-42f1d773ecab"
      unitRef="usd">11200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i5adbe40672074cb28e27345d594c6111_D20190730-20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM0Nw_354decf4-ec43-4e0f-8f72-fd44de2289aa"
      unitRef="usd">10900000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i763f14d53a0f47d2bb88afb5100aeece_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM4Nw_e2482a99-6d2d-463b-8a3f-444be93f641d"
      unitRef="usd">157000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzExNDg_221a3e3c-2b52-49ac-b266-c954bee12fe5"
      unitRef="usd">6300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i6ef40e33d0e245579352ff0b15309b81_I20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyMDA_171f3160-5e44-42ab-aa51-0855f199465e"
      unitRef="usd">2000000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if00cc3ffe8b74509b0746823ba987ea5_D20190730-20190730"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNTY_d05dd152-5932-4d33-8df0-e38ec564b46b">P16Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iee11b1723a234cdfad038a7b6b8d6698_I20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjA_4ce98fe2-d266-4d64-874e-da5c4ce4c75c"
      unitRef="usd">2800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i60e43a0fe85848159c571b3aee53daf1_I20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNzY_b123434c-9d4e-4f7a-bb50-0e2fe8165704"
      unitRef="usd">1500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i8c8f7c06b3f04a218265c1e05e918490_I20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzMDQ_e67fca75-c764-4502-80b7-18cf53f1a718"
      unitRef="usd">1200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1f466f58bbb14f0c960799ddb7db2885_I20190730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzODA_d9e83d6c-b4cc-4e93-a448-abe0842f5517"
      unitRef="usd">360000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibbc5264b1b924484a590099fbbf18894_D20190730-20190730"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE0NjU_7b49a19a-880e-4528-9d01-7a1024e56826">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:Goodwill
      contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE0NzU_93edb67b-0005-41fe-b4f4-6b4097b5004c"
      unitRef="usd">6100000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE0OTc_b452e6ba-acfd-4320-be8f-481618eb46cc"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="i863e4743e2d145be857ddf010856d1d2_I20190730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE1NDE_e97e7925-29cd-445b-b10e-c6ceed71b792"
      unitRef="usd">451000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="i40b3ec61b4cf4015ab587fac323995eb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NTc5NDg_fe4631ab-1ade-4bae-83c8-f278d56bec63"
      unitRef="usd">-900000000</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment
      contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI0NTI_5a0ba9db-4480-43ea-911f-0246cc18e016"
      unitRef="usd">340000000</pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment>
    <pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum
      contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MDc_0333e5e2-6255-4fe0-8270-cafc0fb4e217"
      unitRef="usd">470000000</pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI5MjM_e0ec8ef9-cb85-4a11-8ab5-063497e4b874"
      unitRef="usd">322000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI5NDY_88dc5720-ed17-44ea-92b3-79afb6e40fd7"
      unitRef="usd">317000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI5NzQ_856c2cc9-7647-41f7-965b-67c14463305a"
      unitRef="usd">5000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i3e8dbc4ab9a34438a4a6b9fe5871e0c2_D20190701-20190701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwNjk_20394849-4c99-48fb-bf23-b768fb57692e"
      unitRef="usd">337000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i314f8d3de1434b56bb2fdf8061d7a953_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODA3MDk5_a7497050-1f8d-4595-8a77-0af05c8347f2"
      unitRef="usd">51000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i4b44d95032624046bce69d6abe17288c_D20211231-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3NzM_bb07d65c-b3e8-4106-bd6f-69e86ae5b547"
      unitRef="usd">-167000000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i888e24f18a1748c6b73bcfc6bda4a9b9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MzY4MDg_3d02ea01-f374-45ce-83a1-55042b308237">P12M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i0f02e49d15574798a17efff00d83ccb9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3NzY_6408bced-52d8-40f2-b1fa-c4a90edc76d0">P18M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="iaffca7f3bf5b4256aed31e1ad5ab0cce_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3Nzc_40e9c95c-56ac-4c47-b4f9-2dddf3ece556">P3Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <pfe:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod
      contextRef="iaffca7f3bf5b4256aed31e1ad5ab0cce_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzOTgwNDY2NTE3Nzg_b9eb604b-2205-4771-809c-94387010a809">P2Y</pfe:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod>
    <pfe:DiscontinuedOperationRatioSharesReceivedForEachShareOwned
      contextRef="i389169f22b244d9c8c2e87bfedee54c2_D20201113-20201113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzM4Mzg_6f60f160-6cfd-4f81-9f01-27c7fc48f0ce"
      unitRef="number">0.124079</pfe:DiscontinuedOperationRatioSharesReceivedForEachShareOwned>
    <pfe:DiscontinuedOperationRatioSharesReceivedForEachShareOwned
      contextRef="id93ea4a3a591476aab3a080ee5c9429b_D20201113-20201113"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQwNzY_e1ac9f16-d327-4d2a-96d2-5f86589eba44"
      unitRef="number">1</pfe:DiscontinuedOperationRatioSharesReceivedForEachShareOwned>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i10ff88c8caf540d29f9a1a2759e9218f_I20201113"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQzMDI_66edeab1-5ee1-4a5f-b9d3-d5222a42f158"
      unitRef="usd">12000000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i18320fc2b9594ddea18b362bf4514a69_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQ0NjQ_fa2031d7-f255-4874-96ef-1401be04e719"
      unitRef="number">0.57</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i23323cf2700144a6b84393ffab357354_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzQ1NjE_fdde0048-00b1-45b2-9725-7b497c4284f6"
      unitRef="number">0.43</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:LongTermDebt
      contextRef="i031df9beab9042be9970f64529890934_I20200630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUwOTM_5b98e76c-8f9d-4b6f-a7e5-8b37226e4ffb"
      unitRef="usd">7450000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i5bf57b2d36c745beb81e1b7026d3c318_I20200630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUxMDA_5eb44bd8-cc7b-4fa7-9da2-85adb933a860"
      unitRef="eur">3600000000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0a559b470d334b43b79260c8d2f79c2d_D20200601-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUxNjE_0969cc85-0519-47a1-989b-91cc4c38cc0f"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia69d0ecee9684b1386c94a8b435e6cd7_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUyNTA_ae94d0b2-d74d-4470-a919-8e1c08966eb9"
      unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="idc5994c3e02a45da952846df4b47bfbc_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzUzMzg_7cadaaa2-733f-4e38-80d8-ea932aee9758"
      unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i10ff88c8caf540d29f9a1a2759e9218f_I20201113"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU0MzA_66edeab1-5ee1-4a5f-b9d3-d5222a42f158"
      unitRef="usd">12000000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="ifc8dbebb0e9d49428a97f4323e05244a_I20200630"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU1OTU_02e047f3-983a-4938-8616-909f3fd9b981"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ifc8dbebb0e9d49428a97f4323e05244a_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU2NDQ_78313074-1ea0-47be-8345-c5b1098ba069"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i1e71e04bd5f14e7e934d2585e74e3b2b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU2OTQ_07ead6ce-c690-4d3d-a700-64eb0d860ab4"
      unitRef="usd">342000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1e71e04bd5f14e7e934d2585e74e3b2b_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU3NDM_f250b2f2-669e-414e-a10a-b873d397aa77"
      unitRef="number">0.0580</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0a559b470d334b43b79260c8d2f79c2d_D20200601-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzU4NDE_0969cc85-0519-47a1-989b-91cc4c38cc0f"
      unitRef="usd">11400000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i146ddcb53ba74d66b6cd862e76bc22d2_I20201116"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxOTkwMjMyNjYyMDg4_d184f630-5352-4fa4-ba7b-e04a48b995ab"
      unitRef="usd">-1600000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxOTkwMjMyNjYyMTgx_7ab240db-e30d-4d5c-8062-8c4e15601b3a"
      unitRef="usd">412000000</us-gaap:CashDivestedFromDeconsolidation>
    <pfe:OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax
      contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDkyNjc1ODE3NTU_7c8b000d-5d7d-403d-b1e1-3846edf5282f"
      unitRef="usd">423000000</pfe:OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDkyNjc1ODE3Njk_ed70f013-9d6d-4044-aefe-2ea25deb205f"
      unitRef="usd">397000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="iba452c2e047d48dbb5ae77a58e34b52c_D20201116-20201116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDkyNjc1ODE3NjI_b60ed05f-31aa-4b6c-95df-88bc77263ebb"
      unitRef="usd">-26000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i4d984e1a55d04f109e2f4777e30a7cef_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzYyMTQ_63f8dee6-3375-4179-af7f-c4cebac6d93d"
      unitRef="usd">434000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="iaa8744bbf8a04e279bfe049ce4a864ba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2OTE1NzU_45fd10ea-7e56-4b9b-a6a3-5e4dfa11d452"
      unitRef="usd">83000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i05a3ba48023e426a88cc41e754f240ac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcwNzM_85401c59-cb14-4e7f-b669-af654483778d">P7Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i2e17ee2ad705475da2fd98425c5438a5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcyOTM_6c015bec-67e8-401b-84c8-2dfbc748d3d5">P3Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="i8bb26d7550d34c4fa8277bc4dd130b09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzgwNzk_e7a3ad1b-939b-4a39-be3c-b4ead09e3a3c"
      unitRef="usd">53000000</us-gaap:NontradeReceivablesCurrent>
    <us-gaap:NontradeReceivablesCurrent
      contextRef="i83182589a2cf40518e59a55a207f4a48_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjI4Njc_bef9b23f-9484-433a-80f7-7955ddcf251b"
      unitRef="usd">401000000</us-gaap:NontradeReceivablesCurrent>
    <pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities
      contextRef="i74dbcccac2f4425289e1e6696c212de4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjU2MDc_7b55140f-7590-4245-b02b-11cfb15013e4"
      unitRef="usd">277000000</pfe:PaymentPursuantToTermsOfSeparationAgreementFinancingActivities>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ5_0b3a72ca-0347-47c6-b874-cb50840c59b4">&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt; Discontinued operations&#x2013;&#x2013;net of tax: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;204&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax income/(loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income/(loss) from discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax loss on sale of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss on sale of discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations&#x2014;net of tax, which includes a pre-tax amount for a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345&#160;million; and (ii) the after tax loss of $167&#160;million related to the sale of Meridian recognized in Loss on sale of discontinued operations&#x2013;&#x2013;net of tax. To a much lesser extent, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-closing adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations&#x2014;net of tax. In 2020 and 2019, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. In 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2014;net of tax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;includes pre-tax interest expense of $116 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $223 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of assets and liabilities of discontinued operations and other assets held for sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="22" style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets of discontinued operations and other assets held for sale&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets of discontinued operations&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities of discontinued operations&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities of discontinued operations&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(a)Amounts as of December 31, 2021 represent property, plant and equipment held for sale. Amounts as of December 31, 2020 primarily relate to discontinued operations of our former Meridian subsidiary and the Mylan-Japan collaboration.</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNC0xLTEtMTU1NjM4_12370406-3121-4fd4-9452-791c6fa14d56"
      unitRef="usd">277000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNi0xLTEtMTU1NjM4_9d188531-33a5-407c-acf6-cd88c74e75be"
      unitRef="usd">7572000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtOC0xLTEtMTU1NjM4_3bdde6d7-1ca3-471f-837a-552086df7002"
      unitRef="usd">10845000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNC0xLTEtMTU1NjM4_1ea56822-d50c-454c-ac25-324f18d696a2"
      unitRef="usd">204000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNi0xLTEtMTU1NjM4_74eecd18-698c-4b18-bed9-423ee0f2b18f"
      unitRef="usd">2106000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtOC0xLTEtMTU1NjM4_771a964a-8c6d-4951-9757-362ce504769c"
      unitRef="usd">2173000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNC0xLTEtMTU1NjM4_f5357124-e200-4036-888f-25abdac4d3e3"
      unitRef="usd">26000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNi0xLTEtMTU1NjM4_5f400010-0c6d-4c36-8261-5a6d490d4a94"
      unitRef="usd">1682000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtOC0xLTEtMTU1NjM4_c8a95008-1738-44b6-8266-dfaf053446f7"
      unitRef="usd">1624000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNC0xLTEtMTU1NjM4_a6c1e828-1373-4fbc-98bb-0c166c24987f"
      unitRef="usd">9000000</pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNi0xLTEtMTU1NjM4_5cf15bee-1f6f-4f92-96c0-441dcdc3b93d"
      unitRef="usd">224000000</pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctOC0xLTEtMTU1NjM4_831490eb-418d-4b0f-8395-f8cd4a584883"
      unitRef="usd">265000000</pfe:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNC0xLTEtMTU1NjM4_0c5983f5-742e-4c31-9456-0a86eb67f31b"
      unitRef="usd">45000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNi0xLTEtMTU1NjM4_152f7f45-ad94-4198-8e30-d82dea1a7243"
      unitRef="usd">224000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtOC0xLTEtMTU1NjM4_55c6aa5f-d0e6-4069-a4cc-b50d9f74cfe7"
      unitRef="usd">181000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNC0xLTEtMTU1NjM4_f37f9bc2-c292-4db8-be47-b29936878c30"
      unitRef="usd">2000000</pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNi0xLTEtMTU1NjM4_674641be-b310-442e-9649-04d23ac403da"
      unitRef="usd">29000000</pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktOC0xLTEtMTU1NjM4_19067ebf-2420-4493-9559-b40f806bb59c"
      unitRef="usd">146000000</pfe:DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTQtMS0xLTE1NTYzOA_a7b0aba4-6383-4a13-b9e3-48c7a459c533"
      unitRef="usd">365000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTYtMS0xLTE1NTYzOA_792dcf23-7855-4ba8-be67-f2f2b8a93e38"
      unitRef="usd">428000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTgtMS0xLTE1NTYzOA_8a0c1ae2-b59a-4ab8-a792-11ae10dc864c"
      unitRef="usd">401000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTQtMS0xLTE1NTYzOA_ad3a56fe-b25c-47fa-883e-2628687e528e"
      unitRef="usd">-375000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTYtMS0xLTE1NTYzOA_8f186694-3022-48ef-a96b-b90b416e0172"
      unitRef="usd">2879000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTgtMS0xLTE1NTYzOA_b2209aa3-59c1-4278-bffe-dbda51926033"
      unitRef="usd">6056000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTQtMS0xLTE1NTYzOA_e223faad-d99d-4053-b5f6-cf210bcfee95"
      unitRef="usd">-107000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTYtMS0xLTE1NTYzOA_21f1e072-7210-4f67-920f-95f886cd5e7f"
      unitRef="usd">349000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTgtMS0xLTE1NTYzOA_1f9cb0cd-0fa5-4116-b603-cb6776f180dc"
      unitRef="usd">738000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTIwMTgxNg_bb899a3f-9057-4c42-b88a-a0484d40b99a"
      unitRef="usd">-268000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTIwMTgxNg_4d3d9288-bb84-4f45-bb13-a4f8ec4ec044"
      unitRef="usd">2529000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTIwMTgxNg_245ea242-174d-4d97-8181-86a8c6c5246d"
      unitRef="usd">5318000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTQtMS0xLTIwMTgxOA_5a215c3a-de6d-4316-a287-c5044c461f1d"
      unitRef="usd">-211000000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTYtMS0xLTIwMTgxOA_07f27bea-6a9c-40c6-a2d6-ea80214973a8"
      unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTgtMS0xLTIwMTgxOA_9afe2f6a-295d-4a12-9d6c-1feeef937d00"
      unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTQtMS0xLTIwMTgyNA_79efd58c-9573-475f-92b1-25eb9339724b"
      unitRef="usd">-44000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTYtMS0xLTIwMTgyNA_26d4a734-0b52-4e5d-81b1-025ded81faa6"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTgtMS0xLTIwMTgyNA_d6f5724b-f6f8-41ea-863c-9951d0e46489"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTQtMS0xLTIwMTgyNg_02fe2472-92fb-4536-8323-8b8e4f134181"
      unitRef="usd">-167000000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTYtMS0xLTIwMTgyNg_485a912c-0f9e-4947-8e28-5ea90d0b44d3"
      unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTgtMS0xLTIwMTgyNg_6bd6df99-dd55-4fbf-baa8-aa34cf0a89fc"
      unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTE1NTYzOA_d4777b69-bca4-4da9-8bee-c95607807af1"
      unitRef="usd">-434000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i924f3dd46a44463aa5b3df3267d3f85d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTE1NTYzOA_b8c5bf77-08f1-454f-8409-0583dba8d4d9"
      unitRef="usd">2529000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="if3df9490e9574bb2be687b2b2a722e28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTE1NTYzOA_173beaaa-761b-48ed-9f25-caabbf15d941"
      unitRef="usd">5318000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i25df7ea17ef54fb9b9166956b884cb0b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzM3ODE_c3d1efa0-3bef-4a9d-b708-bb0bf3d2a66f"
      unitRef="usd">-345000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i4b44d95032624046bce69d6abe17288c_D20211231-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MzY4NTM_bb07d65c-b3e8-4106-bd6f-69e86ae5b547"
      unitRef="usd">-167000000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="ife130b27142a4922bf44614565f191c9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjQxMjA_63996794-518d-4eb3-a8bc-468b6a6dd838"
      unitRef="usd">116000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <pfe:DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses
      contextRef="i181dc4bf05244a10b3b37faa99909cbf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjQyOTE_cc6830f9-e003-481d-ac7e-6a3ce3901b88"
      unitRef="usd">-223000000</pfe:DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNC0xLTEtMTU1NjM4_4f4c89e4-6db7-40f7-88d6-39114c8aa258"
      unitRef="usd">25000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if072dc370d29444380b25f1c9000934b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNi0xLTEtMTU1NjM4_9e892a40-9f6c-426f-a55e-95264845f896"
      unitRef="usd">215000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTQtMS0xLTE1NTYzOA_1807f3e3-32c3-4436-8597-9a8d224768f0"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="if072dc370d29444380b25f1c9000934b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTYtMS0xLTE1NTYzOA_a46f22eb-ae36-4c35-a84e-cd3183e01176"
      unitRef="usd">155000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTQtMS0xLTE1NTYzOA_dffafcd0-1e07-4cc5-bef0-d88fb845c696"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="if072dc370d29444380b25f1c9000934b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTYtMS0xLTE1NTYzOA_5890084d-8e26-4833-a562-8c7fbb06d03e"
      unitRef="usd">134000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTQtMS0xLTE1NTYzOA_022b7343-cc02-4d0b-bd17-9219c56120d2"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="if072dc370d29444380b25f1c9000934b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTYtMS0xLTE1NTYzOA_c4a54d97-7d11-4bc4-b781-3dfecf9a8d4a"
      unitRef="usd">29000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTQtMS0xLTE1NTYzOA_f1eb3203-bad7-4a37-b9ba-d995e4c010f3"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="if072dc370d29444380b25f1c9000934b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTYtMS0xLTE1NTYzOA_d083c457-1d57-4eff-b8ba-5cda20c59421"
      unitRef="usd">319000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTQtMS0xLTE1NTYzOA_0ec087d1-5d2f-45e8-af0a-963acbdc9c35"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if072dc370d29444380b25f1c9000934b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTYtMS0xLTE1NTYzOA_e617887c-3da5-43a0-8050-ff8df10abdf9"
      unitRef="usd">74000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="iee64f2b1f51741cfa08ecb452fe530f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTQtMS0xLTE1NTYzOA_709a14a0-1fa2-48ec-9db7-e7fe83b24faf"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="if072dc370d29444380b25f1c9000934b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTYtMS0xLTE1NTYzOA_cea60af2-8c6c-44ce-9379-0c9408a7edd9"
      unitRef="usd">16000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i252c5ea241a04813985449d2cebbba79_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzNzM2_5a137e0d-1c98-4bce-b543-a1926307a9e9"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7e3dc812e321400f96f18d4c30fd6ac5_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzNzk4_9ae1393f-a33a-4cfd-b560-d90a4a274c37"
      unitRef="number">0.68</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i6e80f25bd480402595d2aea33e91039a_D20190701-20190929"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzOTAw_c5e79e30-44f9-4e23-b214-aad73f65c94c"
      unitRef="usd">8100000000</us-gaap:DeconsolidationGainOrLossAmount>
    <pfe:DeconsolidationGainLossAmountNetOfTax
      contextRef="i6e80f25bd480402595d2aea33e91039a_D20190701-20190929"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzOTA0_fd1e7bfd-cb2d-4b61-85d6-59010110dd45"
      unitRef="usd">5400000000</pfe:DeconsolidationGainLossAmountNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i252c5ea241a04813985449d2cebbba79_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEzOTk5_2586f691-8f05-408f-97e8-a3620b31ac6f"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="icface7a1ee2b4ff28ac480b07f52e93f_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE1MDg2_29dbebcc-13d4-403a-978b-e33fd8f0b464"
      unitRef="usd">16300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if8959c4c50fb407583ed92f9c3322282_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE1MTAy_1cf0658b-1581-4e98-9aed-8348aaf907ee"
      unitRef="usd">16700000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MzY5MDI_e7000332-50f7-46ad-988e-0e27bcc76c26"
      unitRef="usd">499000000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation
      contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2Njc2NDQ_629d6562-8733-44b6-8a66-40c3850546ad"
      unitRef="usd">384000000</pfe:EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic3380b060ff04a11833194263e6f152c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NjgwNjc_bcec21a0-261c-4a7d-a5a9-1521d4703917"
      unitRef="usd">495000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i34dd2e3fa1c248e29e1d6758b3059e2d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2MTc0_8201f977-f8c4-4bf6-8041-d40743d6c120"
      unitRef="usd">417000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i545389717f154954b7abb4cddabeb1cf_D20190930-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2MzQ3_4c39b6f2-32a9-4652-88db-06895b8a2201"
      unitRef="usd">47000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="i252c5ea241a04813985449d2cebbba79_I20190731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDc0_05eaf4f5-0f38-4144-86a6-c513217fa80a"
      unitRef="usd">15700000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i252c5ea241a04813985449d2cebbba79_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NDg2_5a137e0d-1c98-4bce-b543-a1926307a9e9"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="i252c5ea241a04813985449d2cebbba79_I20190731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NTg4_a3cba238-4988-4436-8695-44b8609eb96d"
      unitRef="usd">11200000000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="i252c5ea241a04813985449d2cebbba79_I20190731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE2NjUw_e920e2bc-82c2-4b08-a3f0-02b0cb6c52ad"
      unitRef="usd">4500000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i252c5ea241a04813985449d2cebbba79_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE3MjIz_5a137e0d-1c98-4bce-b543-a1926307a9e9"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="ie607d29116be4fa5babac488462d4080_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE3MzQy_b371c4cc-1886-4f1b-9433-83388ff1bd36"
      unitRef="usd">11000000000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="ie607d29116be4fa5babac488462d4080_I20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE3Mzk1_a1483520-a77b-4360-849e-fbdbe6677283"
      unitRef="usd">4800000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod
      contextRef="i43de6de86aee4f1981210b2cfbd70d8b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE4NzE5_be15b83f-a86e-4a91-9b1f-2d4a918a6709">P8Y</pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod>
    <pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod
      contextRef="i7c41e610d4514bd2960d85db52a70189_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzE4NzI1_3430a8b8-d835-4a2f-9711-64d4229ae4a6">P20Y</pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod>
    <pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss
      contextRef="i21520495e93a4b6f82c194548d489020_D20190101-20190731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIwMjE5_27e1edcf-3e78-4ac5-940b-6e5080b3ffbe"
      unitRef="usd">654000000</pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU3_7d7853be-0e60-44d7-ad69-c48aab16b90d">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.661%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, the Consumer Healthcare JV, as of September 30, 2021, the most recent period available, and as of September 30, 2020 and for the periods ending September 30, 2021, 2020, and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,890&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,445&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;46,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,133&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,218&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,351&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,705&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total net equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Twelve Months Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For the Two Months Ending&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,836&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(803)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,081&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.968%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summarized financial information for our equity method investee, ViiV, as of December 31, 2021 and 2020 and for the years ending December 31, 2021, 2020, and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,608&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,171&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,033&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total net equity/(deficit) attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,862)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,734)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.439%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,380&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,040&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzItNC0xLTEtMTU1NjM4_103aaf22-ff1b-4b75-8ebb-1d9247f528d6"
      unitRef="usd">6890000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzItNi0xLTEtMTU1NjM4_e716bdd0-1bb3-4934-8eff-9333a2fc9fb3"
      unitRef="usd">6614000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzMtNC0xLTEtMTU1NjM4_af0c56da-ebec-49cc-8e1b-f782f54489e1"
      unitRef="usd">39445000000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzMtNi0xLTEtMTU1NjM4_5badf77b-22a4-4a2a-8f6b-ab3ea6074f4d"
      unitRef="usd">38361000000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzQtNC0xLTEtMTU1NjM4_17208a61-bf07-4ca4-b184-92287f8db77e"
      unitRef="usd">46335000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzQtNi0xLTEtMTU1NjM4_41dc8449-f5bf-49bb-8116-272d340cb4b4"
      unitRef="usd">44975000000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzYtNC0xLTEtMTU1NjM4_0257cee9-e17e-45f4-bc58-8810d68d3545"
      unitRef="usd">5133000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzYtNi0xLTEtMTU1NjM4_ff01a3ef-a4a2-49ce-829d-2d2ef54d4931"
      unitRef="usd">5246000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzctNC0xLTEtMTU1NjM4_07f2e9c8-d6a7-4dc6-9c30-b466fbd0679e"
      unitRef="usd">5218000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzctNi0xLTEtMTU1NjM4_abec386e-598c-4922-a667-c823fa9b6f34"
      unitRef="usd">5330000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzgtNC0xLTEtMTU1NjM4_8f67bc43-04e9-4c0b-9b85-c10df01ff997"
      unitRef="usd">10351000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzgtNi0xLTEtMTU1NjM4_79112438-e388-4b83-bd39-476c0afdd67b"
      unitRef="usd">10576000000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEwLTQtMS0xLTE1NTYzOA_e7e9be79-1643-44aa-b623-06ae01696b70"
      unitRef="usd">35705000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEwLTYtMS0xLTE1NTYzOA_3502a88d-c22a-420e-88ec-249192f6ebc9"
      unitRef="usd">34154000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzExLTQtMS0xLTE1NTYzOA_8289999d-c811-495a-b530-5c0452531e36"
      unitRef="usd">279000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzExLTYtMS0xLTE1NTYzOA_6efe0fb0-a551-4b3c-aebf-541f7f4a1892"
      unitRef="usd">245000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie644969c98bc4ecd8d8103171f4b1758_I20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEyLTQtMS0xLTE1NTYzOA_30c10d13-342a-4c7d-a1c8-7a37df2637a0"
      unitRef="usd">35984000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie80b0b96288e4dff8133e76d9d32cd0c_I20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYjgyMDAwNjg2YmM0ZjMyYjU1OTgwNzg2Yjg4MjY4ZC90YWJsZXJhbmdlOjBiODIwMDA2ODZiYzRmMzJiNTU5ODA3ODZiODgyNjhkXzEyLTYtMS0xLTE1NTYzOA_67223f82-1456-40d3-b3e3-8c53dd4f21e6"
      unitRef="usd">34400000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:Revenues
      contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzItNC0xLTEtMTYxMzMw_01ae9e51-02bf-4a07-be03-5bfc8ac9c5ef"
      unitRef="usd">12836000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzItNC0xLTEtMTU1NjM4_49c43407-1282-4c33-b18b-29ad92a01087"
      unitRef="usd">12720000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzItNi0xLTEtMTU1NjM4_222ca5e8-0bf5-4d8e-9749-7e69622d73ca"
      unitRef="usd">2161000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzMtNC0xLTEtMTYxMzMw_4e4cae15-d4f6-45e0-a80a-1a9bd01d7c91"
      unitRef="usd">4755000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzMtNC0xLTEtMTU1NjM4_e18a127b-656e-4c90-9f9c-711b6cd6e3e6"
      unitRef="usd">5439000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzMtNi0xLTEtMTU1NjM4_79f9ed61-c286-41dc-aa84-f1eb30ca96f2"
      unitRef="usd">803000000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzQtNC0xLTEtMTYxMzMw_fcb5d0f5-714c-4a21-900b-7dd76ca94d92"
      unitRef="usd">8081000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzQtNC0xLTEtMTU1NjM4_57f14a86-3889-41c5-ab71-3c83d132f527"
      unitRef="usd">7281000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzQtNi0xLTEtMTU1NjM4_69b63ab5-c72d-4de1-83c1-ab04fc6c7d02"
      unitRef="usd">1358000000</us-gaap:GrossProfit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzUtNC0xLTEtMTYxMzMw_fc4f37c0-ab1f-412b-b8b4-5f93eb0f83a3"
      unitRef="usd">1614000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzUtNC0xLTEtMTU1NjM4_f8222a1d-4997-47b0-adce-d8e3922bb477"
      unitRef="usd">1350000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzUtNi0xLTEtMTU1NjM4_9c32c1ad-3cc3-4f20-8736-dab797908ca8"
      unitRef="usd">152000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzYtNC0xLTEtMTYxMzMw_d984decb-ce84-4576-87d7-f7a1c9e4efe1"
      unitRef="usd">1614000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzYtNC0xLTEtMTU1NjM4_d8fff60d-4df9-490c-8f8d-73dd9ba3e447"
      unitRef="usd">1350000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzYtNi0xLTEtMTU1NjM4_62f7f464-18be-496a-9220-78aa928f58f3"
      unitRef="usd">152000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i374b034bc57b49488d0cad4e7e8ccb3e_D20201004-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzctNC0xLTEtMTYxMzMw_abd58b1c-5aa4-40dd-9b41-615a3a4b490e"
      unitRef="usd">1547000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia9dd55b7a96c4c05b583bc64576824e8_D20191001-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzctNC0xLTEtMTU1NjM4_e6bbb99e-586e-430d-b34c-156632dd61ab"
      unitRef="usd">1307000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2852ba11fddf40068d4ed1ba274f18ab_D20190801-20190929"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo2ODdjMDg4OTM3MmY0N2I1YmZjNWI4MmY5OGU5MjExYS90YWJsZXJhbmdlOjY4N2MwODg5MzcyZjQ3YjViZmM1YjgyZjk4ZTkyMTFhXzctNi0xLTEtMTU1NjM4_110cd900-8545-4e4e-a16f-04b7a42f25fc"
      unitRef="usd">148000000</us-gaap:NetIncomeLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0336041406e84b0dbc587db051c08162_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIwNDQy_cc6f2c77-d8b7-42da-8e68-6a3f3420f421"
      unitRef="number">0.117</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i5259b031a6bd4f3eacca9ff85942926b_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIwNzk4_963844c8-7860-45a8-a63d-e996f683a19a"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxMDA1_3fac75bf-2035-498f-8636-6b21f0455bf7"
      unitRef="usd">166000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxMDE1_8fa17084-bdac-4acb-942a-85af47d4e831"
      unitRef="usd">278000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxMDI4_40498035-3118-4ccc-846e-27e398432227"
      unitRef="usd">220000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:AssetsCurrent
      contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzMtNC0xLTEtMTU1NjM4_7a1cf1b9-d392-4552-b9f7-3cb462ef0070"
      unitRef="usd">3608000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzMtNi0xLTEtMTU1NjM4_8ec4d6e6-b312-489a-9038-2512852dc7ed"
      unitRef="usd">3283000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzQtNC0xLTEtMTU1NjM4_c792c5a1-9e50-456e-8a65-514d012c5723"
      unitRef="usd">3563000000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzQtNi0xLTEtMTU1NjM4_8b9ec2ce-cffc-4254-8fc0-a37292d63db8"
      unitRef="usd">3381000000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzUtNC0xLTEtMTU1NjM4_13f8114c-f3bc-4a93-bfd0-d82942e9c5d7"
      unitRef="usd">7171000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzUtNi0xLTEtMTU1NjM4_b27f10d2-4d68-49fa-aa3e-bc63abb8f82d"
      unitRef="usd">6664000000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzctNC0xLTEtMTU1NjM4_fba72730-65b0-4f23-bf5e-0c5e01bb5067"
      unitRef="usd">3497000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzctNi0xLTEtMTU1NjM4_693c80a5-4fb6-4356-a798-2b794e1d4f18"
      unitRef="usd">3028000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzgtNC0xLTEtMTU1NjM4_0b049853-ca23-4cbb-b8c0-387b1d0e7c7d"
      unitRef="usd">6536000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzgtNi0xLTEtMTU1NjM4_037881b4-361f-45d8-a4d3-e326049321a3"
      unitRef="usd">6370000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzktNC0xLTEtMTU1NjM4_988c3585-c5b4-4324-9208-5a0e43f5f65b"
      unitRef="usd">10033000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzktNi0xLTEtMTU1NjM4_1f0535cd-8f66-426b-84be-0db8d8226a91"
      unitRef="usd">9398000000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="i3a3cfa0088ba4234af8b08e75e132786_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzExLTQtMS0xLTE1NTYzOA_d232f8b4-08a4-4c35-a491-602b5c29d045"
      unitRef="usd">-2862000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2dcbf2f54f114c5280a6cb330bf56361_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTo1OGUyZWU3ZTg4ZTQ0YzM1ODg1NzUzMjVjNDZmOTdlMy90YWJsZXJhbmdlOjU4ZTJlZTdlODhlNDRjMzU4ODU3NTMyNWM0NmY5N2UzXzExLTYtMS0xLTE1NTYzOA_79972d57-bd1e-48ab-b6d9-5c8d7fb2c76c"
      unitRef="usd">-2734000000</us-gaap:StockholdersEquity>
    <us-gaap:Revenues
      contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzItNC0xLTEtMTU1NjM4_09d206c2-596e-40ac-9cb1-0c5e2ab833c7"
      unitRef="usd">6380000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0027658381944a395727958a68002bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzItNi0xLTEtMTU1NjM4_0ceda6b5-56e6-4958-af97-c9497ab81343"
      unitRef="usd">6224000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzItOC0xLTEtMTU1NjM4_4f71dde2-626a-498a-9c21-0dd4e7597552"
      unitRef="usd">6139000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzMtNC0xLTEtMTU1NjM4_5f324ea6-dcfd-4b9c-bdc2-a3c8515c46e6"
      unitRef="usd">682000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="id0027658381944a395727958a68002bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzMtNi0xLTEtMTU1NjM4_620834dc-2406-48b6-9412-40f5099cec46"
      unitRef="usd">574000000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzMtOC0xLTEtMTU1NjM4_e49f0962-515e-4a71-92fe-7e3f718d3246"
      unitRef="usd">516000000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzQtNC0xLTEtMTU1NjM4_8172aa8a-1a82-4b81-b4e0-2b13359102ae"
      unitRef="usd">5698000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id0027658381944a395727958a68002bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzQtNi0xLTEtMTU1NjM4_9c5c2fd0-c21c-4df0-a783-103d6d18d14a"
      unitRef="usd">5650000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzQtOC0xLTEtMTU1NjM4_9de0c307-64ff-43fd-80ce-1465e2d005b2"
      unitRef="usd">5623000000</us-gaap:GrossProfit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzUtNC0xLTEtMTU1NjM4_1b55a5d0-af34-40ed-9cab-133f7a8309e9"
      unitRef="usd">2040000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0027658381944a395727958a68002bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzUtNi0xLTEtMTU1NjM4_35e22918-633b-4155-82de-b6d87fae21b3"
      unitRef="usd">2012000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzUtOC0xLTEtMTU1NjM4_bffc17b9-fc13-4e66-bce5-5b176653874f"
      unitRef="usd">3398000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzYtNC0xLTEtMTU1NjM4_4ebe5dd9-cfd9-4e02-9e42-573953d4a14a"
      unitRef="usd">2040000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id0027658381944a395727958a68002bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzYtNi0xLTEtMTU1NjM4_477acfec-5a46-40da-a8fa-766a3802c803"
      unitRef="usd">2012000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzYtOC0xLTEtMTU1NjM4_0cd38e5f-8766-46d6-abcf-3a741537b1be"
      unitRef="usd">3398000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib9db49261fe34983839218bcd3832009_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzctNC0xLTEtMTU1NjM4_389f95ec-6eee-4d11-98b0-815697c19550"
      unitRef="usd">2040000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0027658381944a395727958a68002bb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzctNi0xLTEtMTU1NjM4_9430472d-8989-4a44-aba6-a8353f023150"
      unitRef="usd">2012000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3694dcbe68ff475d91791e4464cc582e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZToyMWE4MmJiM2NlMzM0NTA2YmJkMzZiNGIyYTRkMWVjZS90YWJsZXJhbmdlOjIxYTgyYmIzY2UzMzQ1MDZiYmQzNmI0YjJhNGQxZWNlXzctOC0xLTEtMTU1NjM4_ca44730c-734f-4071-ba75-fbd2fbc6e3aa"
      unitRef="usd">3398000000</us-gaap:NetIncomeLoss>
    <pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
      contextRef="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNDIy_5ddfcf35-a313-4dcb-b8ce-c1ee1d91472f"
      unitRef="usd">308000000</pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1>
    <pfe:PaymentForLicensingArrangement
      contextRef="i80aa0ad3eddf4f7391796743da2c7d4a_D20200330-20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNDY2_019a815f-5b61-4849-9c8b-7a7d045c37fc"
      unitRef="usd">130000000</pfe:PaymentForLicensingArrangement>
    <pfe:ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure
      contextRef="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNTkz_01976b81-bc2e-4bd0-ae7b-c80feb5e45f4"
      unitRef="usd">35000000</pfe:ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure>
    <pfe:ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure
      contextRef="i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNjI2_d10ea93c-7e5c-4745-9663-4a7bdb677e55"
      unitRef="usd">143000000</pfe:ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure>
    <pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage
      contextRef="ib167df84d3de4e098cfb61db76e453f9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIxNzIw_47627210-7c9c-492d-af8d-8d421c76eee6"
      unitRef="number">0.30</pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage>
    <pfe:PaymentForLicensingArrangement
      contextRef="i0fbdbdf768e24f2a8c5d0a5b25a12f65_D20191101-20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzIyODgy_4bbd0427-0ac5-427c-8fb1-41044742dcca"
      unitRef="usd">250000000</pfe:PaymentForLicensingArrangement>
    <pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage
      contextRef="i5cc0e4c459d54fad8d446a48587269e9_D20211224-20211224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExMTI_b0a1e87a-d5cb-4658-8708-88371618467d"
      unitRef="number">0.65</pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage>
    <pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage
      contextRef="ia6b61ff9024b46bb9e45f08915a7f41e_D20211224-20211224"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExMTg_5374638b-1d82-4ff0-b2f0-7e664005c21e"
      unitRef="number">0.35</pfe:ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="i69a2ae55438c4493a657b96e948feffb_D20211004-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExMjQ_93e2da4e-5923-46a4-8ebf-2bfe316a5398"
      unitRef="usd">300000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure
      contextRef="iea2eb9e0f80d46748855049032762b62_I20211224"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExNDI_ee2439cf-c771-4dcf-a7fe-6d60a46224aa"
      unitRef="usd">1050000000.00</pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure>
    <pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
      contextRef="iea2eb9e0f80d46748855049032762b62_I20211224"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDExNjM_b006cb56-cff9-4e4f-a0e3-107433790793"
      unitRef="usd">1350000000</pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1>
    <pfe:PrepaymentsAndPaymentsToCollaboratorsCash
      contextRef="if407180f055943a98b83de59f2cd5a1f_D20210721-20210721"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5MDY_930ea738-ef0e-42ee-9ead-0d1a5aa295b7"
      unitRef="usd">650000000</pfe:PrepaymentsAndPaymentsToCollaboratorsCash>
    <pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
      contextRef="i812cbbdf3b1245069237af890fdcecae_I20210721"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5MjM_9d58d881-a13e-43b7-aa76-6f0700831fe4"
      unitRef="usd">350000000</pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount>
    <pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment
      contextRef="i6d66cd919bde400083d7783f18057f72_D20210705-20211003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcxNDY4MjU3MTcyMzk_9d1bf800-7931-418d-950f-42e2d2db51e1"
      unitRef="usd">706000000</pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment>
    <pfe:CollaborativeArrangementMilestonePaymentUponApproval
      contextRef="i375a1296a03d4608aa7dadc39a4081b0_D20210721-20210721"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NzA1NTk_3290fa32-6636-447d-b7ed-6ccb992c7b01"
      unitRef="usd">400000000</pfe:CollaborativeArrangementMilestonePaymentUponApproval>
    <pfe:CollaborativeArrangementMilestonePaymentUponCommercializing
      contextRef="i375a1296a03d4608aa7dadc39a4081b0_D20210721-20210721"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NzA1OTY_ae83ad9e-ccc5-4cee-bec5-7b4c5788b017"
      unitRef="usd">1000000000</pfe:CollaborativeArrangementMilestonePaymentUponCommercializing>
    <pfe:InvestmentOwnershipPercentage
      contextRef="i095915c17bba4c2681c503f9e07eb593_D20211231-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODI4MDg3_b78c9dd4-aa3e-40bf-96da-91277a41d89f"
      unitRef="number">0.065</pfe:InvestmentOwnershipPercentage>
    <pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne
      contextRef="i5bdb38bc93ee4bdca889f98c7227ecd3_I20201226"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI0Nzc5_0d62720a-2ab6-4eb9-83d8-e93c868a9c04"
      unitRef="usd">100000000</pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne>
    <pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo
      contextRef="i5bdb38bc93ee4bdca889f98c7227ecd3_I20201226"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI0ODEz_e046b2df-cf05-4922-b5b4-8f32c0989470"
      unitRef="usd">50000000</pfe:CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo>
    <pfe:CollaborativeArrangementContingentPaymentsMaximumExposure
      contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MDg2_6f047d1c-d23a-412f-a1c5-632844fdc8b2"
      unitRef="usd">4350000000</pfe:CollaborativeArrangementContingentPaymentsMaximumExposure>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="iffe998e9fae8489392c54ceb8b6c3cfc_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MTIy_917d3adb-f6d8-4814-86f0-fabda95e7ae2"
      unitRef="usd">650000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <pfe:CollaborativeArrangementUpfrontAndMilestonePayments
      contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MTU5_a2c74eb7-0136-4f1b-a5c1-b3c17be85813"
      unitRef="usd">200000000</pfe:CollaborativeArrangementUpfrontAndMilestonePayments>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="ie99ef111b6e645c6a56cc65ad07091e8_D20210701-20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEyNjQ0MzgzODI4MTk1_3d8362e5-4255-4bdf-93ac-624f0b8f48ac"
      unitRef="usd">100000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <pfe:CollaborativeArrangementTieredSalesMilestonePayments
      contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1MzA0_50751ed6-8157-4474-8fa4-0e68aae97c35"
      unitRef="usd">3500000000</pfe:CollaborativeArrangementTieredSalesMilestonePayments>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if33e0253955c412683af05e909d4151f_I20201226"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1NjQ4_ccd100ad-a046-4949-b8b7-5658ab57cac6"
      unitRef="usd">499000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib0a098818299431c93ea556ebc5e58d9_D20201226-20201226"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI1NzE4_20588121-c118-4334-852e-8746312852a4"
      unitRef="usd">151000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
      contextRef="i0e5a99e4814b4f128ec2c686a1ec35d1_I20200929"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE2NzkxMjE_a9885f5d-a901-48f3-8fbc-f2b773414dea"
      unitRef="usd">200000000</pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount>
    <pfe:InvestmentOwnershipPercentage
      contextRef="i2d62ac5456af448bbff21978df756208_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI2NDI0_8b891783-6d05-4a73-a9e6-807fabcf8050"
      unitRef="number">0.098</pfe:InvestmentOwnershipPercentage>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="i4b21456e1b1e45de977384ffe2104b0d_D20211230-20211230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyNDE_aeeee9a8-c840-4dfa-82df-96629e922319"
      unitRef="usd">225000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <pfe:PrepaymentsAndPaymentsToCollaboratorsCash
      contextRef="i5f00f7ed3e2c4bebad99f1f2c882a39e_D20211230-20211230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyNTg_cc24550c-f6fe-48e4-a1fd-8568f39c671f"
      unitRef="usd">75000000</pfe:PrepaymentsAndPaymentsToCollaboratorsCash>
    <pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
      contextRef="i603a6eec721f4ae6823ed9ad58021e0a_I20211230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyNzc_2806ed69-c170-4059-91fb-f4982bd1b4c3"
      unitRef="usd">150000000</pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount>
    <pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure
      contextRef="i603a6eec721f4ae6823ed9ad58021e0a_I20211230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIyOTQ_8bdc85ef-2c1e-400b-b885-5d9e23a6e912"
      unitRef="usd">200000000</pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i5f00f7ed3e2c4bebad99f1f2c882a39e_D20211230-20211230"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3MDIzMTE_b20c3171-445e-433f-b999-eb3b80709625"
      unitRef="usd">25000000</us-gaap:ProceedsFromCollaborators>
    <pfe:PrepaymentsAndPaymentsToCollaboratorsCash
      contextRef="i4a30949432804cb2a16f9d87c25227db_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5NDA_1ff68dc6-ac27-4288-8e91-d2c18e0facd8"
      unitRef="usd">72000000</pfe:PrepaymentsAndPaymentsToCollaboratorsCash>
    <pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
      contextRef="i29f76f6dc48f4d43b42b0c3a2fd099ea_I20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzEwOTk1MTE3NzE5NTY_34735300-eb6a-43e5-bccd-e38adf4044ce"
      unitRef="usd">113000000</pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount>
    <pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment
      contextRef="i1ebf471468de402693afa6538be7c48a_D20200330-20200628"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzcxNDY4MjU3MTcyNjE_7cfee7f2-6712-4b37-b77b-7958117e24a1"
      unitRef="usd">98000000</pfe:PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment>
    <pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure
      contextRef="iaa219a8d864348459268e3b1408b148a_I20200409"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI3NDM2_e3f53f7e-050b-4cbb-8807-5d823b6ba4b9"
      unitRef="usd">563000000</pfe:ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure>
    <pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1
      contextRef="iaa219a8d864348459268e3b1408b148a_I20200409"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI3NDY4_d88f1f2a-150f-43f0-9e87-d480086d3c1a"
      unitRef="usd">748000000</pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1>
    <pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed
      contextRef="i6f0797c37dfa45c7a80ce32bac03a312_D20200409-20200409"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI3Nzc5_4f928860-f0f6-4dc4-8c6a-ade8288b30b3"
      unitRef="number">0.50</pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed>
    <pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed
      contextRef="i6f0797c37dfa45c7a80ce32bac03a312_D20200409-20200409"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI4MDU3_4f928860-f0f6-4dc4-8c6a-ade8288b30b3"
      unitRef="number">0.50</pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed>
    <pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
      contextRef="i0c579c9b9f224be594bcabbfa663f822_I20200731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI4ODA4_2119dd8c-4023-4aa8-8ea8-0e32e04ad557"
      unitRef="usd">50000000</pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount>
    <pfe:InvestmentOwnershipPercentage
      contextRef="i9ea93613082a4762abffed23b2ec080b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzI4OTU5_7cff3189-5bd1-4bdf-b47f-15222b65de77"
      unitRef="number">0.025</pfe:InvestmentOwnershipPercentage>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE5_7c5819b1-c378-4970-a17a-654775287107">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;590&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;s&#x2014;Alliance revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues from collaborative arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other income/(deductions)&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;820&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents sales to our partners of products manufactured by us.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2021 reflects increases in alliance revenues from Comirnaty, Eliquis and Xtandi, while the increase in 2020 reflects increases in alliance revenues from Eliquis and Xtandi.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The increase in 2021 is primarily related to Comirnaty.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. &lt;/span&gt;&lt;/div&gt;(f)Primarily relates to royalties from our collaboration partners.</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b05b7dcaa61407aba318478b7c59025_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtMi0xLTEtMTU1NjM4_4852e44b-060b-4524-8cde-acdd45c8d69f"
      unitRef="usd">590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae539c60336f4a0c94b5a022dcf96c0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNC0xLTEtMTU1NjM4_bd5d325b-76f5-4dd4-a23f-b3930e7dc4ec"
      unitRef="usd">284000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16a2adb8ca784b4ea94e14866c48cc70_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNi0xLTEtMTU1NjM4_812d0cf5-bd12-44dd-a0d9-31b83dc34171"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib015687530a043e399f09540ca86222d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtMi0xLTEtMTU1NjM4_0f5fe7b6-5c36-460b-897e-812a74d93bfa"
      unitRef="usd">7652000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1967572353a4cf69f29aa1e5a12c183_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNC0xLTEtMTU1NjM4_e704333c-12e8-4a4c-b863-0e3dcb069f41"
      unitRef="usd">5418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i778d084ed9064541a22124cd2f5453c5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNi0xLTEtMTU1NjM4_8b8f1901-f635-44ee-9d4a-eb7fdb7e5051"
      unitRef="usd">4648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzUtMi0xLTEtMTU1NjM4_bd5a6e7b-8a2f-40a3-895e-500791e3aa61"
      unitRef="usd">8241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzUtNC0xLTEtMTU1NjM4_6c5f938f-65b0-4221-8fdc-4bee24fcdb95"
      unitRef="usd">5703000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzUtNi0xLTEtMTU1NjM4_50e83aeb-ef19-41e5-a76b-749d819dc3c1"
      unitRef="usd">4953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtMi0xLTEtMTU1NjM4_f570d567-250b-4be3-a646-a17475e0f375"
      unitRef="usd">16169000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNC0xLTEtMTU1NjM4_4735257f-9e5d-4241-a813-229562d69690"
      unitRef="usd">61000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNi0xLTEtMTU1NjM4_5e3e9775-1f4c-4a1a-81a9-ac9d3fc427d8"
      unitRef="usd">52000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctMi0xLTEtMTU1NjM4_4a4349dc-9933-450e-a8f0-cd01ed05abc3"
      unitRef="usd">175000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNC0xLTEtMTU1NjM4_265b3940-4872-4dde-a89e-85ff8265bd36"
      unitRef="usd">194000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNi0xLTEtMTU1NjM4_f03523c1-3500-433c-a25c-7a51aa58bc66"
      unitRef="usd">176000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtMi0xLTEtMTU1NjM4_31b5dfa2-8634-409b-8b1b-5241f26bdbf0"
      unitRef="usd">742000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNC0xLTEtMTU1NjM4_17d32bc8-693e-49b2-9755-f0c64e3067e0"
      unitRef="usd">192000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNi0xLTEtMTU1NjM4_c2a32bf3-b01a-4af5-8c9f-0d092ab35f6c"
      unitRef="usd">-104000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktMi0xLTEtMTU1NjM4_b45deda5-c9eb-4249-973c-69e48319db9e"
      unitRef="usd">820000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id3f7200b60394988b20633966561bd86_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNC0xLTEtMTU1NjM4_29e6b7ac-2fe7-4877-a124-b300cdd5a22f"
      unitRef="usd">567000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if8b71faadf0d40afaad23404443a875b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNi0xLTEtMTU1NjM4_8c950b8b-ad69-4ccf-983e-ea64d5755d84"
      unitRef="usd">362000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NzY_0510ea55-f664-4147-93c1-77e603af957a">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2019, we substantially completed several multi-year initiatives focused on positioning us for future growth and creating a simpler, more efficient operating structure within each business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Transforming to a More Focused Company Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a more focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base and support model align appropriately with our new operating structure. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. This program is primarily composed of the following three initiatives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;We are taking steps to restructure our corporate enabling functions to appropriately support our business, R&amp;amp;D and PGS platform functions. We expect costs, primarily related to restructuring our corporate enabling functions, to total $1.6 billion, with substantially all costs to be cash expenditures. Actions include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;In addition, we are transforming our commercial go-to market model in the way we engage patients and physicians. We expect costs of $1.1&#160;billion, with substantially all costs to be cash expenditures. Actions include, among others, centralization of certain activities and enhanced use of digital technologies. The costs for this effort primarily include severance and associated implementation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;We are also optimizing our manufacturing network under this program and incurring one-time costs for cost-reduction initiatives related to our manufacturing operations. We expect to incur costs of $800 million, with approximately 25% of the costs to be non-cash. The costs for this effort include, among other things, severance costs, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The program costs discussed above are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;From the start of this program in the fourth quarter of 2019 through December 31, 2021, we incurred costs of $2.2&#160;billion, of which $856 million is associated with Biopharma ($712 million in 2021, $79 million in 2020 and $64 million in 2019).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Key Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2021 and 2020, we incurred costs of $1.3&#160;billion and $838&#160;million, respectively, composed primarily of the Transforming to a More Focused Company program. In 2019, we incurred costs of $820 million composed of $548 million for the 2017-2019 and Organizing for Growth initiatives, $288 million for the integration of Array, $94 million for the integration of Hospira, and $87 million for the Transforming to a More Focused Company program, partially offset by income of $197 million, primarily due to the reversal of certain accruals upon the effective favorable settlement of an IRS audit for multiple tax years and other acquisition-related initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee terminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exit costs/(credits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;741&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration costs and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Implementation costs recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2021 costs primarily related to our acquisition of Trillium. 2020 costs primarily related to our acquisition of Array. 2019 costs mainly related to our acquisitions of Array, including $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;), and Hospira.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in restructuring accruals:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Termination&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;br/&gt;Impairment&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2020 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;741&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($628 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($169 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;($816 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;($255 million).&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i98027c8fc6b44691900fa8e4048b8871_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDgyODU_636efc7e-bb41-449e-a85b-9c5c0ef567a5"
      unitRef="usd">1600000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="ied12c12ed32548d6a549bafb56e60cd7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDg4Mjg_ff5a0523-059c-4e8b-a10a-a6b23be7fcdc"
      unitRef="usd">1100000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i86b210be8e114d32a572f0bd0df9088a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDkyNjA_8028a159-da43-4622-8b36-2ad1b5115783"
      unitRef="usd">800000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <pfe:RestructuringandRelatedCostNoncashChargesPercentage
      contextRef="i9bc539f8d9004dc099e25a88c5b43895_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NDkyODQ_979868a7-5fa2-4807-bc50-b3c641e783c2"
      unitRef="number">0.25</pfe:RestructuringandRelatedCostNoncashChargesPercentage>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i925e41f449714bd2bf405763d6debabb_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE3ODc_d523d85d-a476-4ea2-8e05-f6f881d9b8b9"
      unitRef="usd">2200000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i40868579307a4b29940d0afd5af8d703_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU2OTE_4b65f0b6-67b9-4b4e-b1c9-b7633e810ac0"
      unitRef="usd">856000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ic6e76156347742d59ab87928f0b59b21_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU3MDk_ae828c23-0a0a-4936-baa4-410c873432ea"
      unitRef="usd">712000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i626b2657ceb64b34b2c9c95e2661d1fd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU3Mjc_3d39e5b7-f287-4eb5-a67c-7c276865e963"
      unitRef="usd">79000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iee83e2bae3b7490d9df5cb5de4b214ac_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzEwOTk1MTE2NjU3NDQ_bede9eda-7c91-45a8-bed4-8548bfb9f3cb"
      unitRef="usd">64000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NjcxNjM_4a320f49-c6d4-40c4-92bb-f72bdf307ff5"
      unitRef="usd">1300000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NjcxODg_82d2fcd7-d49e-46bf-9325-445898c50dc0"
      unitRef="usd">838000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTYxNjU_556bd094-953e-4dcd-8719-2a4fb43eeef2"
      unitRef="usd">820000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia3b3ff3fbc764236bcf7f1991593041b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE5NTU_dc5bb0fd-a5a4-4e02-8507-23422f77394a"
      unitRef="usd">548000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9f963471072a434bbb65ec9314d42418_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIwMTU_e8000505-abf7-4e7d-9b02-c6506f5a2b19"
      unitRef="usd">288000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4da04c0815ec4b519aab9003bbf9e69b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIwNDg_c313c64e-0cfa-410e-889c-49a26bd093bb"
      unitRef="usd">94000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i63611b219ac54cf69a70430c5ef474f3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIwODc_a97fa5a8-429d-466d-ad58-9e80f23a9d4c"
      unitRef="usd">87000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia831fe68ea464a7696d368c0b964d933_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzIxNzY_bf616fe3-d9fe-4d25-b983-4fee2d0bfaad"
      unitRef="usd">-197000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDY_b7d14ef0-35b5-45ae-ab22-e96635981016">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee terminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exit costs/(credits)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges/(credits)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;741&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transaction costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Integration costs and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;63&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Implementation costs recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;426&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,298&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents external costs for banking, legal, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2021 costs primarily related to our acquisition of Trillium. 2020 costs primarily related to our acquisition of Array. 2019 costs mainly related to our acquisitions of Array, including $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;), and Hospira.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzQtNi0xLTEtMTU1NjM4_99180e59-1d15-4041-99a7-015f26d36da9"
      unitRef="usd">680000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzQtOC0xLTEtMTU1NjM4_ce7d8665-b85b-47da-b064-1af3c169f6c4"
      unitRef="usd">474000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzQtMTAtMS0xLTE1NTYzOA_7fa21ceb-1d4c-420e-9c51-340cd76e362f"
      unitRef="usd">108000000</us-gaap:SeveranceCosts1>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzUtNi0xLTEtMTU1NjM4_2456c9b6-f073-4f1b-915b-be85249099c9"
      unitRef="usd">53000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzUtOC0xLTEtMTU1NjM4_0189d48d-9fb4-42ca-8185-ab2749a77413"
      unitRef="usd">66000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzUtMTAtMS0xLTE1NTYzOA_d09a59e8-5c92-4258-9340-079608315bfd"
      unitRef="usd">69000000</pfe:RestructuringAssetImpairmentCharges>
    <us-gaap:BusinessExitCosts1
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzYtNi0xLTEtMTU1NjM4_d8704cd5-47f0-4efa-818a-6cb50fb0cef3"
      unitRef="usd">8000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzYtOC0xLTEtMTU1NjM4_2236a15c-faac-40cf-9197-9ce7e00954d6"
      unitRef="usd">-6000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzYtMTAtMS0xLTE1NTYzOA_ce5c94bb-6acd-4c56-a524-282f0a987828"
      unitRef="usd">50000000</us-gaap:BusinessExitCosts1>
    <us-gaap:RestructuringCharges
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctNi0xLTEtMTU1NjM4_7593f700-33a1-4b98-91bf-879b34110428"
      unitRef="usd">741000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctOC0xLTEtMTU1NjM4_2d6c1a68-5552-4be1-a010-836b6862e20b"
      unitRef="usd">535000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctMTAtMS0xLTE1NTYzOA_a73c9239-ead4-4169-9fcc-f5c747a69fc4"
      unitRef="usd">227000000</us-gaap:RestructuringCharges>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtNi0xLTEtMTU1NjM4_315394a9-0040-4ea2-bb7c-aa5eb50c4ae2"
      unitRef="usd">20000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtOC0xLTEtMTU1NjM4_6ba80a00-e040-44ed-9659-681083a3a33a"
      unitRef="usd">10000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtMTAtMS0xLTE1NTYzOA_881afe32-f53d-401e-a9d9-f395a68c9bb7"
      unitRef="usd">63000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktNi0xLTEtMTU1NjM4_524c8e42-409b-4ca5-b64b-d98bdfb311bc"
      unitRef="usd">41000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktOC0xLTEtMTU1NjM4_87a0a4bb-c12e-4cc9-a43b-925eafd0e253"
      unitRef="usd">34000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktMTAtMS0xLTE1NTYzOA_1282a7c8-801c-4056-b485-27f13357c051"
      unitRef="usd">311000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEwLTYtMS0xLTE1NTYzOA_31ef0c63-2fc2-4573-8442-55604d8b61ed"
      unitRef="usd">802000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEwLTgtMS0xLTE1NTYzOA_4680639e-1a65-4b0b-a797-21e746cd4611"
      unitRef="usd">579000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEwLTEwLTEtMS0xNTU2Mzg_0168edb4-cb22-47ce-a969-ec69aab7905f"
      unitRef="usd">601000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i99d15499afc94f0f88944990ff7e08fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTYtMS0xLTE1NTYzOA_26b576fd-e42f-47a6-aeab-565869399e1b"
      unitRef="usd">-63000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie5dd3ecfac844087a740d27d7e403e89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTgtMS0xLTE1NTYzOA_c72ce72f-d017-48b5-aa58-e2a94bf428d9"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i4a03d9e689ec4fae8e3c0b59a2584fa3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTEwLTEtMS0xNTU2Mzg_c5e3b7b3-ad7b-4372-8fc9-743761958514"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="ia2daa7c6ae294186bbe568931b7486c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTYtMS0xLTE1NTYzOA_5cd58def-c2a2-44d2-afeb-aba885aa2fc8"
      unitRef="usd">63000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i8edaec2b4f8a4f18b37022f2160559cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTgtMS0xLTE1NTYzOA_dc88088c-58ae-4f64-b4b7-52c9484035eb"
      unitRef="usd">21000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i0f5a6ab0d6bb475ea4b794272ee41557_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTEwLTEtMS0xNTU2Mzg_12244f3f-27df-420a-9f0b-1652ddbc6248"
      unitRef="usd">29000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTYtMS0xLTE1NTYzOA_8d165f23-be85-4dc1-adc5-76c248b7d5f6"
      unitRef="usd">23000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTgtMS0xLTE1NTYzOA_d09cd04e-2282-4eee-b696-e9040247d88d"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="ib92e3b0b44374006b6d45a2bf6b453ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTEwLTEtMS0xNTU2Mzg_daf6262b-ed94-4815-aa85-d2b76b855eae"
      unitRef="usd">3000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTYtMS0xLTE1NTYzOA_a1fe41aa-bf30-4747-9aea-81360d159eb5"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i3bff8c57bb424ff78fbf4a3f0ebccedf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTgtMS0xLTE1NTYzOA_d075da76-8e37-4fb0-92e5-e64957caf8ad"
      unitRef="usd">-3000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="ie05f357a90bb455c808448dd5bdb82b9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTEwLTEtMS0xNTU2Mzg_f22d3ac4-76d9-4abe-b144-2724bdadf6a6"
      unitRef="usd">8000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTYtMS0xLTE1NTYzOA_d40c85f6-ad5d-486b-95fb-11dc5f86ce26"
      unitRef="usd">87000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTgtMS0xLTE1NTYzOA_83acb8fa-0dbe-484f-b7a3-7b391952efb2"
      unitRef="usd">17000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTEwLTEtMS0xNTU2Mzg_1e28e996-4c45-4799-b7ef-7dc4e5449fdd"
      unitRef="usd">40000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <pfe:ImplementationCosts
      contextRef="ia2daa7c6ae294186bbe568931b7486c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTYtMS0xLTE1NTYzOA_14c75760-4acd-4558-9ca3-a81fa2c1c265"
      unitRef="usd">45000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i8edaec2b4f8a4f18b37022f2160559cb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTgtMS0xLTE1NTYzOA_b66de0ca-ed0f-46b4-966e-453127eb66ca"
      unitRef="usd">40000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i0f5a6ab0d6bb475ea4b794272ee41557_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTEwLTEtMS0xNTU2Mzg_9b4bc5aa-1531-4ea6-816c-1d6a55260e53"
      unitRef="usd">61000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTYtMS0xLTE1NTYzOA_098c4e4a-148e-47f7-be0d-6ed93e8aef4e"
      unitRef="usd">426000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTgtMS0xLTE1NTYzOA_2b0e9445-59e0-4280-b6cc-187607b67d79"
      unitRef="usd">197000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="ib92e3b0b44374006b6d45a2bf6b453ae_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTEwLTEtMS0xNTU2Mzg_016183c2-2cbd-4ead-8585-43ac37496738"
      unitRef="usd">73000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTYtMS0xLTE1NTYzOA_33ad584f-aedf-448a-a767-6e77c5498e33"
      unitRef="usd">1000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i3bff8c57bb424ff78fbf4a3f0ebccedf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTgtMS0xLTE1NTYzOA_2dc67f00-13b1-40b3-996a-b5a90fc6ab6f"
      unitRef="usd">1000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="ie05f357a90bb455c808448dd5bdb82b9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTEwLTEtMS0xNTU2Mzg_3eddf7f0-e898-4039-abae-9b3e4026d40d"
      unitRef="usd">22000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTYtMS0xLTE1NTYzOA_facc63c8-eaf3-4e01-9322-54be6880643c"
      unitRef="usd">472000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTgtMS0xLTE1NTYzOA_e0c6ceaf-a4e8-47bf-849b-5a80428433a3"
      unitRef="usd">238000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTEwLTEtMS0xNTU2Mzg_8ab28955-fc79-44d8-8a32-662618a1141b"
      unitRef="usd">156000000</pfe:ImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzI0LTYtMS0xLTE1NTYzOA_6068f09f-bf24-43bc-8c5b-d3756ee9fe37"
      unitRef="usd">1298000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzI0LTgtMS0xLTE1NTYzOA_d6399b89-ee36-432b-b7a2-83fda306bdc1"
      unitRef="usd">838000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzI0LTEwLTEtMS0xNTU2Mzg_556bd094-953e-4dcd-8719-2a4fb43eeef2"
      unitRef="usd">820000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <us-gaap:RestructuringCharges
      contextRef="iaa0f6d5d21e848678b8da48c334034bc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NjYxMzg_d3b181e6-a770-416a-9a24-4c114290e10a"
      unitRef="usd">-9000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i877d264408a04f79a16737d91ace0ab4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI0NDA_1bfcb2e7-86b0-4cc4-b865-2525b13fb5b3"
      unitRef="usd">-192000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9a1c9f4206be4156af7e5bbf360b0c50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI0OTE_fb5fb760-62f4-4c44-983a-f70b58bae0c1"
      unitRef="usd">750000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie7ea5bfd40cc43e0b0057cd2055809db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI1MTA_ee22f552-4598-41d2-82e7-db2a7860e3d2"
      unitRef="usd">535000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i17a552f33566495aa5aad8a8ce07ffee_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTI1MzM_53ba4cbd-d178-41ba-b9ce-be344ba411a5"
      unitRef="usd">418000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="i763f14d53a0f47d2bb88afb5100aeece_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTQ3NTE_e2482a99-6d2d-463b-8a3f-444be93f641d"
      unitRef="usd">157000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDE_a1b3b72c-ce04-43f0-ba32-3e58ee90cbe9">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in restructuring accruals:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Termination&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;br/&gt;Impairment&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exit Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrual&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2020 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;680&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;741&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Utilization and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(468)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($628 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($169 million).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;($816 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;($255 million).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ia829878673b04d45a644a83794ea47f3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItMi0xLTEtMTU1NjM4_ee75f122-6d06-4682-87fa-2483c1e4eebc"
      unitRef="usd">770000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="id19560e1e9e846f1917dd34fe6665c2f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItNC0xLTEtMTU1NjM4_80c7ded3-3904-4420-938e-905ab247cc03"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i4c9c1d9cd337481ea21924d113ae20f0_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItNi0xLTEtMTU1NjM4_e0598e81-8d6f-41f2-bce1-8c89690855df"
      unitRef="usd">46000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzItOC0xLTEtMTU1NjM4_0b7d4ee1-d9ef-46d6-8e2a-dacb8797c6f7"
      unitRef="usd">816000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="icc28c341b16f4257858e79aa91bfbb0f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtMi0xLTEtMTU1NjM4_99b773c7-6f74-4fa8-ad0a-3d9872f2cd47"
      unitRef="usd">474000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ib8e69ebbcd7843c09dba286f7a84a32e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtNC0xLTEtMTU1NjM4_9835c9a3-ad89-4662-9ef7-1d7406b91ed6"
      unitRef="usd">66000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i85ea9a17643b4ba993c0d7767b7df734_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtNi0xLTEtMTU1NjM4_f78a7fc4-2bbd-4c7f-afa7-9759c59b03fa"
      unitRef="usd">-6000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzMtOC0xLTEtMTU1NjM4_3e757d02-5244-4cff-90fc-078785117e84"
      unitRef="usd">535000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="icc28c341b16f4257858e79aa91bfbb0f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtMi0xLTEtMTU1NjM4_37eb2fce-9891-4368-9c58-5e41f032a21d"
      unitRef="usd">462000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="ib8e69ebbcd7843c09dba286f7a84a32e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNC0xLTEtMTU1NjM4_2e4c1c81-5d34-4e61-8316-477276aa7c19"
      unitRef="usd">66000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i85ea9a17643b4ba993c0d7767b7df734_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNi0xLTEtMTU1NjM4_48aa033e-20be-49e8-8390-4b9e5a393d82"
      unitRef="usd">25000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtOC0xLTEtMTU1NjM4_aa6a1288-623f-45a0-aa24-c0b1f7307d3a"
      unitRef="usd">554000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="i64c5139d761040739c960494538b4e36_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtMi0xLTEtMTU1NjM4_2f7f6c8a-d1ea-4776-b3bf-f600ef3cb02e"
      unitRef="usd">782000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i8de8376bf36443928b6f33affb450d42_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNC0xLTEtMTU1NjM4_8725e295-9631-41e9-964a-1c35d13d3069"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib978af64a1074124af383834e607186e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNi0xLTEtMTU1NjM4_9dc8b5f6-80fe-4a13-bf28-33b00373b705"
      unitRef="usd">15000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtOC0xLTEtMTU1NjM4_af969f26-65f5-42e4-84a6-c2edff83475d"
      unitRef="usd">798000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="ia26d7da2bf204ad39d1d01e1c8c71720_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtMi0xLTEtMTU1NjM4_8cef56f3-a45b-4fa7-8917-7a8578627b7d"
      unitRef="usd">680000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7d619ef872034dfea120fc28f055f6a7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtNC0xLTEtMTU1NjM4_8b6df9d6-f083-4f23-b00f-77ee8a297534"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i08555d6e17894c0ebe9ccf5b8c4a0767_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtNi0xLTEtMTU1NjM4_22c9103f-bb44-4ace-a379-561776a03aad"
      unitRef="usd">8000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzYtOC0xLTEtMTU1NjM4_789b435b-1162-4b99-9c0d-e22fc7121bdb"
      unitRef="usd">741000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="ia26d7da2bf204ad39d1d01e1c8c71720_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctMi0xLTEtMTU1NjM4_594ea094-3524-4937-806c-5adc4fdae564"
      unitRef="usd">449000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i7d619ef872034dfea120fc28f055f6a7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNC0xLTEtMTU1NjM4_256f11b6-83b4-4563-84bd-ca2eb2bc8d16"
      unitRef="usd">53000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i08555d6e17894c0ebe9ccf5b8c4a0767_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNi0xLTEtMTU1NjM4_4072a90f-f140-48e6-8f8d-0cfc44b9f2ef"
      unitRef="usd">-34000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctOC0xLTEtMTU1NjM4_7480d3a8-bcd9-4499-9bb2-09960d855b59"
      unitRef="usd">468000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="i4c69c8a8bbc74fa887cd2c9dc0ed4c80_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtMi0xLTEtMTU1NjM4_2a363825-77ea-4727-b774-2d27000e61c9"
      unitRef="usd">1014000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i20f99441233647049f94a89b177f28e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNC0xLTEtMTU1NjM4_bc3cca5e-42f5-463e-8b51-f54d4eb4fc38"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ie2de81f39d0e4b198f2516dade160b06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNi0xLTEtMTU1NjM4_8e7b2b15-4b8a-49c5-90e8-18a0750addb7"
      unitRef="usd">57000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtOC0xLTEtMTU1NjM4_03c5052c-0e84-48f7-9edf-6b33ec73e5b5"
      unitRef="usd">1071000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i2eef90df770b4e9e8f3c74ee49cbd5c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTcyMTc_ef850c66-5871-4846-a83b-04621d330ec1"
      unitRef="usd">628000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i0aaf677ffe1c461b92474fb66fe48c68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTcyNTY_76ae62e6-3cfa-4577-8002-191fc6497ab3"
      unitRef="usd">169000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5c659cb958e94f909ae64de8887c53e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTczMDA_27c269bd-4b3d-430a-bbed-5b85917405cc"
      unitRef="usd">816000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ibe0e5d69b58349a58289b22b8b683cd0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzE2NDkyNjc0NTczMzk_ad8bf4b0-4094-40aa-8710-6bd129cd14a2"
      unitRef="usd">255000000</us-gaap:RestructuringReserve>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTY_3dde7173-1f4e-4acd-a824-38950d000d73">Other (Income)/Deductions&#x2014;Net&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty-related income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certain legal matters, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(h)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Capitalized interest totaled $108 million in 2021, $96 million in 2020 and $88 million in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine and $97 million of milestone income from multiple licensees. 2020 included, among other things, (i) a $75 million upfront payment received from our sale of our CK1 assets to Biogen, (ii) $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, (iii) $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC and (iv) $108 million in milestone income from multiple licensees. 2019 included, among other things, $78 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, a generic of Advair Diskus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(fluticasone propionate and salmeterol inhalation powder) and $52 million in milestone income from multiple licensees.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 1C &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. In 2019, other non-service cost components&#x2019; activity related to the Consumer Healthcare JV transaction, such as gain on settlements, were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Gain) on completion of Consumer Healthcare JV transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes legal reserves for certain pending legal matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;2020 represents intangible asset impairment charges associated with our Biopharma segment: (i) $900 million related to IPR&amp;amp;D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts; (ii) $528 million related to Eucrisa, a finite-lived developed technology right acquired in our Anacor acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures; and (iii) $263&#160;million related to finite-lived developed technology rights for certain generic sterile injectables acquired in our Hospira acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2019 primarily included intangible asset impairment charges of $2.8 billion, mainly composed of $2.6 billion, related to Eucrisa, and reflected updated commercial forecasts mainly reflecting competitive pressures.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Mainly represents incremental costs for the design, planning and implementation of our then new business structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and other advisory services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(h)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;See &lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C&lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt"&gt;2021 includes, among other things, (i) income net of costs associated with TSAs of $288 million; (ii) dividend income of $166 million from our investment in ViiV and (iii) charges of $142 million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $278 million from our investment in ViiV; (ii) income net of costs associated with TSAs of $114 million and (iii) charges of $105 million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $220&#160;million from our investment in ViiV; (ii) charges of $152 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $138&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The asset impairment charges included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; are based on estimates of fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczNjY_cb1c7789-8e79-451e-b039-dc5a8c4b8e88">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty-related income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certain legal matters, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(h)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Capitalized interest totaled $108 million in 2021, $96 million in 2020 and $88 million in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine and $97 million of milestone income from multiple licensees. 2020 included, among other things, (i) a $75 million upfront payment received from our sale of our CK1 assets to Biogen, (ii) $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, (iii) $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC and (iv) $108 million in milestone income from multiple licensees. 2019 included, among other things, $78 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, a generic of Advair Diskus&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;(fluticasone propionate and salmeterol inhalation powder) and $52 million in milestone income from multiple licensees.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 1C &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. In 2019, other non-service cost components&#x2019; activity related to the Consumer Healthcare JV transaction, such as gain on settlements, were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Gain) on completion of Consumer Healthcare JV transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes legal reserves for certain pending legal matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;2020 represents intangible asset impairment charges associated with our Biopharma segment: (i) $900 million related to IPR&amp;amp;D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts; (ii) $528 million related to Eucrisa, a finite-lived developed technology right acquired in our Anacor acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures; and (iii) $263&#160;million related to finite-lived developed technology rights for certain generic sterile injectables acquired in our Hospira acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2019 primarily included intangible asset impairment charges of $2.8 billion, mainly composed of $2.6 billion, related to Eucrisa, and reflected updated commercial forecasts mainly reflecting competitive pressures.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Mainly represents incremental costs for the design, planning and implementation of our then new business structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and other advisory services.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(h)&lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;See &lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C&lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.39pt"&gt;2021 includes, among other things, (i) income net of costs associated with TSAs of $288 million; (ii) dividend income of $166 million from our investment in ViiV and (iii) charges of $142 million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $278 million from our investment in ViiV; (ii) income net of costs associated with TSAs of $114 million and (iii) charges of $105 million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $220&#160;million from our investment in ViiV; (ii) charges of $152 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $138&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzMtMi0xLTEtMTU1NjM4_9101db9c-d02a-45ea-b7ed-ef5493f67d42"
      unitRef="usd">36000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzMtNC0xLTEtMTU1NjM4_d06c1a31-2b50-4f47-a7da-14fdcd72ff7f"
      unitRef="usd">73000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzMtNi0xLTEtMTU1NjM4_653248af-702a-4606-ad44-081c7bf552c2"
      unitRef="usd">225000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtMi0xLTEtMTU1NjM4_fc48ed28-a2ed-4f89-931a-25408f08f1f5"
      unitRef="usd">1291000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNC0xLTEtMTU1NjM4_ffec8e3d-06b3-47b3-8031-20a54e5ae1b2"
      unitRef="usd">1449000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNi0xLTEtMTU1NjM4_69712d4d-8f49-4a68-a2fd-58aefe02d4df"
      unitRef="usd">1573000000</us-gaap:InterestExpense>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzUtMi0xLTEtMTU1NjM4_4e01d22d-76b4-4b9e-962d-b0a6dd19d665"
      unitRef="usd">-1255000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzUtNC0xLTEtMTU1NjM4_b56938a9-cdad-41f3-a291-20bd4169d463"
      unitRef="usd">-1376000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzUtNi0xLTEtMTU1NjM4_343ebccb-dd8c-43fa-bd89-fa9cc80ed529"
      unitRef="usd">-1348000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzYtMi0xLTEtMTU1NjM4_716bd02d-edea-470b-b2ac-099bd2527724"
      unitRef="usd">857000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzYtNC0xLTEtMTU1NjM4_d6fc7258-a493-4d6a-bb34-a04bbea26661"
      unitRef="usd">770000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzYtNi0xLTEtMTU1NjM4_b906d8c2-f73b-4537-ad32-1822c276722e"
      unitRef="usd">646000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzctMi0xLTEtMTU1NjM4_a57bee86-72df-4640-a5df-2661a5548028"
      unitRef="usd">99000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzctNC0xLTEtMTU1NjM4_4196ef42-fba5-4809-9bbc-f01237a735d5"
      unitRef="usd">-237000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzctNi0xLTEtMTU1NjM4_65ffe075-3f5e-4bae-92f7-6fd12f750c3b"
      unitRef="usd">32000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtMi0xLTEtMTU1NjM4_dd00f2ae-15ce-4545-aac3-21a8dfd1b54a"
      unitRef="usd">1344000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNC0xLTEtMTU1NjM4_ed4904c4-f0ad-4598-afb5-a7e4c97cb911"
      unitRef="usd">540000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
      unitRef="usd">454000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTItMS0xLTE1NTYzOA_776c7a5d-e044-4ec7-96e2-4308574f3e72"
      unitRef="usd">396000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTQtMS0xLTE1NTYzOA_ed86179d-92be-4657-b47f-3d6a84617613"
      unitRef="usd">326000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTYtMS0xLTE1NTYzOA_2942a965-a598-4acd-bff1-0c02e059da86"
      unitRef="usd">168000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTItMS0xLTE1NTYzOA_d587cb35-245e-4884-bf51-680732bfade2"
      unitRef="usd">-2547000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTQtMS0xLTE1NTYzOA_46ec01a2-0164-49be-80a9-759dd72302e0"
      unitRef="usd">311000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTYtMS0xLTE1NTYzOA_8cbdacb9-5fe2-4b95-940c-37cd2b822cbf"
      unitRef="usd">305000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTItMS0xLTE1NTYzOA_2c13d92c-9eb8-49ba-a2d9-4ff8ede9d098"
      unitRef="usd">-182000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTQtMS0xLTE1NTYzOA_eff9c8b3-b659-4e27-b655-f84aa2e38f10"
      unitRef="usd">-28000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTYtMS0xLTE1NTYzOA_6d5a2b60-1371-418d-92ac-a68824feb0eb"
      unitRef="usd">-292000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTItMS0xLTE1NTYzOA_20517041-af91-4389-8aae-99fcc9ce939c"
      unitRef="usd">86000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTQtMS0xLTE1NTYzOA_e26ed09a-7f53-4a55-b695-a525fb799f8f"
      unitRef="usd">1691000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTYtMS0xLTE1NTYzOA_00bd7ddf-3c27-4b55-a7de-7a4be52f9b58"
      unitRef="usd">2792000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessAlignmentCosts
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTItMS0xLTE1NTYzOA_1d63a504-43b3-4e6e-b318-390daf304a54"
      unitRef="usd">0</pfe:BusinessAlignmentCosts>
    <pfe:BusinessAlignmentCosts
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTQtMS0xLTE1NTYzOA_23f0c89d-0e2d-4917-8d88-8815bb9cb5cf"
      unitRef="usd">0</pfe:BusinessAlignmentCosts>
    <pfe:BusinessAlignmentCosts
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTYtMS0xLTE1NTYzOA_a23043da-80f6-4944-b8c8-a7314fbae96c"
      unitRef="usd">300000000</pfe:BusinessAlignmentCosts>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTItMS0xLTE1NTYzOA_18721505-f445-4d7f-8156-359aab0e6695"
      unitRef="usd">471000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTQtMS0xLTE1NTYzOA_8855cfec-668e-4aaf-b7b2-4e8a81025858"
      unitRef="usd">298000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTYtMS0xLTE1NTYzOA_c697291f-04b7-45d2-b1f2-649da30c1f4f"
      unitRef="usd">17000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTItMS0xLTE1NTYzOA_ed6860e8-6cef-4092-85bd-14b0db566a9f"
      unitRef="usd">687000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTQtMS0xLTE1NTYzOA_b84fbe8e-6a3f-4099-9eac-641d1f1b18dd"
      unitRef="usd">491000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTYtMS0xLTE1NTYzOA_16ed3388-ebc3-4c1b-af6e-ee2db9e45355"
      unitRef="usd">224000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE3LTItMS0xLTE1NTYzOA_b4e851e8-dada-4e99-9f60-7ca607ffbc0e"
      unitRef="usd">4878000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE3LTQtMS0xLTE1NTYzOA_c1d512b1-f464-41ab-972b-e99bc10ae4bf"
      unitRef="usd">-1219000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE3LTYtMS0xLTE1NTYzOA_00f627ae-495c-440d-90c5-9ea23af6d8f1"
      unitRef="usd">-3497000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestCostsCapitalized
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc1_d83049ac-56fa-4f69-9d8c-4e999f47178d"
      unitRef="usd">108000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzg2_5c8f4106-08e9-4dcd-880d-6f10794a6e4b"
      unitRef="usd">96000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEwMA_9268bd0c-96ec-4b39-ad56-2471a31f8117"
      unitRef="usd">88000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if94a5fe65bae431b99f55fff931ebea4_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTI3MDU4_ae778893-5bfe-4523-aea3-27e170104fd9"
      unitRef="usd">1600000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i421339ba223042529cc05db65a67a1fc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1MzkzMTYyODA0MTEx_22993120-4fd2-4817-a096-aa28c5d70e12"
      unitRef="usd">405000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i18931406f81e4214af8bdf650ea9a501_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzMxOQ_f51cbd57-bc3b-4dad-aad6-d64c6ec3ef06"
      unitRef="usd">295000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ie5017fc8db5942798d4a4ab792e69007_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1MzkzMTYyODA0MDgx_dd19d562-50c7-4c99-a406-c9008c0b198b"
      unitRef="usd">188000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i6feb23a7d7ad4d25b3ff9db357c2d2b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1OTQyOTE4NjI3Njky_eb7cb85f-1d8b-487e-b002-8697130d7291"
      unitRef="usd">97000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="ib64fb7f03591425caf0f8ec0bc10107b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzExMTE_29bacd83-2b03-4393-ae1f-50561affc2d2"
      unitRef="usd">75000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i5cd393823f0a466cb163341642a080ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzExNjI_d751fe12-bc93-4d69-9751-fb8fcbbb6d5b"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i2547961512514f6a99fc62e7d1581590_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyNzQ_172f67ce-2d3a-4f86-912e-7f41589bf4d4"
      unitRef="usd">30000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i60a8a5bae1304da28157e10b33ab0a5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE0MjU_4a31cdb8-d34a-470e-b87f-d98d4bc848b7"
      unitRef="usd">108000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ia825faa5b2044c4d9d91b62b8f59c653_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE1MDY_9b78fa7b-9b61-4f71-a175-6a8c5e9377e3"
      unitRef="usd">78000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ibd3d48c945234584a9a562a3e928cd52_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE3MDk_9b93357a-ae66-465b-89e6-15779e151fb8"
      unitRef="usd">52000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i56031b6c3a9542fd9a53b737a162f549_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzI5Nzk_73f570cc-0ee9-415d-ab9f-7130049e3e19"
      unitRef="usd">900000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ied002bca63d9483da7deb14447eca722_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzMxNjU_72381706-5d93-4e5f-9402-b5212f2efdcf"
      unitRef="usd">528000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i42d4c757c4044ceab2e6cbc41cab4a64_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzMzNTk_8cc5f3bf-cc0f-4766-af1b-fba89c89dc64"
      unitRef="usd">263000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzM2MzU_318fcc9e-ba98-48c8-8eef-d4aec609f6b8"
      unitRef="usd">2800000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i4f422da6aefa4071bc05f672d391dba2_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzM2NTg_471e19d6-f38e-482e-9ada-81f7424426a2"
      unitRef="usd">2600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="ic20790f22ade4cf6b4a0533bf036316c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTMxMDE1_85f2a516-54fd-4d14-9d7a-ee49dd45aaf8"
      unitRef="usd">288000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTI3MDEw_3fac75bf-2035-498f-8636-6b21f0455bf7"
      unitRef="usd">166000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id442e3abd12b4a22a3b95e39aae09ed2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTI2ODU3_5802328e-4c6d-4f99-962e-73a891d0b5af"
      unitRef="usd">142000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE2NDkyNjc0NjEzODI_8fa17084-bdac-4acb-942a-85af47d4e831"
      unitRef="usd">278000000</us-gaap:InvestmentIncomeDividend>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="i26ac48141e3840ebb5504bd97d592bec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzEyMDk0NjI3OTMxMDgw_8e8e8efe-c094-481a-852e-6d238918752d"
      unitRef="usd">114000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i77c1de86a8744d5f9ef90c3fe81d1656_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE2NDkyNjc0NjEzNjI_e89f8473-bea6-4139-b0d0-871a8485b3a0"
      unitRef="usd">105000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzE2NDkyNjc0NjE0MjI_40498035-3118-4ccc-846e-27e398432227"
      unitRef="usd">220000000</us-gaap:InvestmentIncomeDividend>
    <pfe:DeconsolidationExternalIncrementalCostsAmount
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzUxODU_53ab0f3d-2004-44f1-804a-c2e680da980b"
      unitRef="usd">152000000</pfe:DeconsolidationExternalIncrementalCostsAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzU0NDQ_85abf751-9c6b-4ae1-af64-e44ed70cb918"
      unitRef="usd">-138000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg4_554274db-284a-4003-a137-5c07ecb04933">Tax Matters&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Taxes on Income from Continuing Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision/(benefit) for taxes on income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;2021 v. 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;2020 v. 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; based on the location of the taxing authorities include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total U.S. tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TCJA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred Income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total TCJA tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,769&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(969)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total international tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,816&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amounts discussed below are rounded to the nearest hundred million and represent approximations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date. The fourth annual installment is due April 18, 2022 and is reported in current &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;as of December 31, 2021. The remaining liability is reported in noncurrent &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The changes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; impacting the effective tax rate year-over-year are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021 v. 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The higher effective tax rate in 2021 was mainly the result of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;the change in the jurisdictional mix of earnings primarily related to Comirnaty; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;lower tax benefits related to the impairment of intangible assets,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;partially offset by:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV with GSK based on estimates and assumptions that we believe to be reasonable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020 v. 2019&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The higher effective tax rate in 2020 was mainly the result of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;the non-recurrence of the $1.4 billion tax benefits, representing taxes and interest, recorded in 2019 due to the favorable settlement of an IRS audit for multiple tax years; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;the non-recurrence of the tax benefits related to certain tax initiatives associated with the implementation of our then new business structure; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;the non-recurrence of the tax benefits recorded in 2019 as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA, as well as:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;lower tax benefits related to the impairment of intangible assets,&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;partially offset by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;the non-recurrence of the tax expense of $2.7 billion recorded in the third quarter of 2019 associated with the gain on the completion of the Consumer Healthcare JV transaction; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Tax Rate Reconciliation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The reconciliation of the U.S. statutory income tax rate to our effective tax rate for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TCJA impact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxation of non-U.S. operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (b), (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax settlements and resolution of certain tax positions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certain Consumer Healthcare JV initiatives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate for income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions,&#x201d; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;for the components of pre-tax income and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;which is based on the location of the taxing authorities, and for information about settlements and other items impacting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2029. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2047 on income from manufacturing and other operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes changes in interest related to our uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;All other, net is primarily due to routine business operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Deferred Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Deferred Tax*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020 Deferred Tax*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid/deferred items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;117&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructurings and other charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal and product liability reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss/tax credit carryforwards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unremitted earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset/(liability)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt"&gt;The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1Q&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The increase in net deferred tax assets in 2021 is primarily related to temporary differences associated with Comirnaty royalty accruals and the result of operating lease ROU liabilities recognized during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The increase in the deferred tax assets is primarily due to the acquisition of intangible assets relating to Trillium and the decrease in the 2021 deferred tax liabilities is primarily the result of amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The increase in net deferred tax liabilities in 2021 is primarily the result of operating lease ROU assets recognized during the period. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The decrease in net deferred tax assets in 2021 is primarily the result of favorable pension plan asset performance reported in the period. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The amounts in 2021 and 2020 are reduced for unrecognized tax benefits of $3.0 billion and $3.0 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;The decrease in net deferred tax liabilities in 2021 is primarily due to certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($1.6 billion), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($0.3 billion). In 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($0.9 billion), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($4.1 billion).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We have carryforwards, primarily related to net operating and capital losses, general business credits, foreign tax credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2022 to 2041. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section&#160;382.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we have not made a U.S. tax provision on $55.0 billion of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of December 31, 2021 is not practicable. The amount of indefinitely reinvested earnings is based on estimates and assumptions and subject to management evaluation, and is subject to change in the normal course of business based on operational cash flow, completion of local statutory financial statements and the finalization of tax returns and audits, among other things. Accordingly, we regularly update our earnings and profits analysis for such events.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For a description of our accounting policies associated with accounting for income tax contingencies, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1Q.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of December 31, 2021, we had $4.5 billion and as of December 31, 2020, we had $4.3 billion in net unrecognized tax benefits, excluding associated interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Tax assets for uncertain tax positions primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of December 31, 2021, we had $1.5 billion in assets associated with uncertain tax positions. These amounts were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($1.4 billion) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($105 million). As of December 31, 2020, we had $1.3 billion in assets associated with uncertain tax positions. These amounts were included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; ($1.1 billion), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($122 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;($46&#160;million).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Decreases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b), (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Decreases based on settlements for a prior period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases based on tax positions taken during the current period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b), (e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For 2020, related to the separation of Upjohn. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily related to cash payments and reductions of tax attributes.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily related to decreases as a result of a lapse of applicable statutes of limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;In 2021, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($19 million),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($42&#160;million) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($3.0 billion), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($5 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($3.0 billion). In 2020, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($34 million), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($18 million), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($3.0 billion) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($2.5 billion).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. In 2021 and 2020, we recorded net increases in interest of $108 million and $89 million, respectively. In 2019, we recorded a net decrease in interest of $564 million, resulting primarily from a settlement with the IRS. Gross accrued interest totaled $601 million as of December 31, 2021 (reflecting a decrease of $1 million as a result of cash payments) and gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;accrued interest totaled $493 million as of December 31, 2020 (reflecting a decrease of $5 million as a result of cash payments and a decrease of $75&#160;million relating to the separation of Upjohn). In 2021 and 2020, these amounts were substantially all included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Accrued penalties are not significant. See also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent&#x2019;s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open, but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions such as Canada (2013-2021), Europe (2011-2021, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Asia Pacific (2011-2021, primarily reflecting China, Japan and Singapore) and Latin America (1998-2021, primarily reflecting Brazil). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as $75 million, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit plans: prior service (costs)/credits and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to curtailments of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk3_c38bc7b1-54e4-4358-95d6-95773068553e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision/(benefit) for taxes on income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,247&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;2021 v. 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;2020 v. 2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzMtMi0xLTEtMTU1NjM4_15eb2b09-957e-4bf1-84ed-5e5bc5723175"
      unitRef="usd">6064000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzMtNC0xLTEtMTU1NjM4_1c063a9f-5884-46fd-8101-0f7337f27449"
      unitRef="usd">-2887000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzMtNi0xLTEtMTU1NjM4_f278db2c-1a9c-4a6a-a42d-600796fb5ed6"
      unitRef="usd">7332000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzQtMi0xLTEtMTU1NjM4_45709ff4-c072-4116-95c4-ed5f7a61556d"
      unitRef="usd">18247000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzQtNC0xLTEtMTU1NjM4_d14ce17a-f634-4f10-91c7-b27dd1d7c85f"
      unitRef="usd">9924000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzQtNi0xLTEtMTU1NjM4_d458b7ec-898c-4f99-9b22-988f026fa2cc"
      unitRef="usd">3988000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
      unitRef="usd">24311000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663"
      unitRef="usd">7036000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2"
      unitRef="usd">11321000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzY0_eec0a405-fe12-49e8-8c5c-d2d460169f77">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; based on the location of the taxing authorities include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,342&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,887)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3,850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(131)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total U.S. tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(867)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TCJA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred Income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total TCJA tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,769&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(969)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total international tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,816&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzUtMi0xLTEtMTU1NjM4_36782f2e-148e-4134-91d3-35266c79df93"
      unitRef="usd">3342000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzUtNC0xLTEtMTU1NjM4_0b85ee0a-0721-4ac1-a03c-b3aedf7e7bb2"
      unitRef="usd">372000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzUtNi0xLTEtMTU1NjM4_9831361b-d7e2-4bbb-b3fe-baa8fcf14983"
      unitRef="usd">-1887000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzYtMi0xLTEtMTU1NjM4_2f2095a4-5fb3-46e1-ade2-ce0748ccae0a"
      unitRef="usd">34000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzYtNC0xLTEtMTU1NjM4_d3d77bf0-a643-4d0a-a336-e89504edb4ec"
      unitRef="usd">56000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzYtNi0xLTEtMTU1NjM4_c064f5e0-207a-4c65-8204-decc5f4339ed"
      unitRef="usd">-186000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzgtMi0xLTEtMTU1NjM4_3d14877f-2784-4d4e-844d-38f1897ff07d"
      unitRef="usd">-3850000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzgtNC0xLTEtMTU1NjM4_9f0c5455-5f79-42ad-a5ea-9fd596d90af2"
      unitRef="usd">-1164000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzgtNi0xLTEtMTU1NjM4_5c3238d9-4d5a-400e-a3ed-f577c0637b7e"
      unitRef="usd">1254000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzktMi0xLTEtMTU1NjM4_36c5598f-9e64-48c8-a4b7-59d812a42bc5"
      unitRef="usd">-491000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzktNC0xLTEtMTU1NjM4_10ec84ec-3a0d-4be0-b0ea-6d6d0e3d30bd"
      unitRef="usd">-131000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzktNi0xLTEtMTU1NjM4_d358e074-5cc2-48b8-9a53-6ce7400c09cc"
      unitRef="usd">276000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEwLTItMS0xLTE1NTYzOA_1ef3deea-76a6-4bb9-b10b-98f2bdcbfd0a"
      unitRef="usd">-964000000</pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations>
    <pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEwLTQtMS0xLTE1NTYzOA_50708395-8c05-4b15-8dd1-e079c529afee"
      unitRef="usd">-867000000</pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations>
    <pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEwLTYtMS0xLTE1NTYzOA_2956ac84-1b9a-45ab-a472-5703ba602e94"
      unitRef="usd">-543000000</pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations>
    <pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEyLTItMS0xLTE1NTYzOA_30ab224e-84ac-4a51-ba6c-2e02c871374e"
      unitRef="usd">0</pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEyLTQtMS0xLTE1NTYzOA_2868b591-ad86-4112-9cf7-6c742963dec8"
      unitRef="usd">0</pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEyLTYtMS0xLTE1NTYzOA_f58ff270-4309-4b28-a942-61fc814d8aca"
      unitRef="usd">-135000000</pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEzLTItMS0xLTE1NTYzOA_eae7aa55-314d-411f-8c57-52aeda3f9d49"
      unitRef="usd">0</pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEzLTQtMS0xLTE1NTYzOA_6dd9e479-252d-4145-b031-a4b4e4b38956"
      unitRef="usd">0</pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzEzLTYtMS0xLTE1NTYzOA_39da479b-e09a-449c-9a16-adfc3d9657c9"
      unitRef="usd">-187000000</pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE0LTItMS0xLTE1NTYzOA_0c9d4876-1838-4cbf-9faa-b731ac728376"
      unitRef="usd">0</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE0LTQtMS0xLTE1NTYzOA_7580a0db-62a7-4645-8b5b-41ffa1e2ef89"
      unitRef="usd">0</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE0LTYtMS0xLTE1NTYzOA_80115918-d012-4957-9f24-33d28537c64d"
      unitRef="usd">-323000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE2LTItMS0xLTE1NTYzOA_29eb4786-2113-4959-a42b-9d4885bbf7d3"
      unitRef="usd">2769000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE2LTQtMS0xLTE1NTYzOA_c727d74e-0999-495d-ab5d-babd0eb3c518"
      unitRef="usd">1517000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE2LTYtMS0xLTE1NTYzOA_dbc88e5d-f149-4f04-a5c9-83556fae84d8"
      unitRef="usd">2418000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE3LTItMS0xLTE1NTYzOA_c485f665-ce3d-4f85-9bac-085e8ae57194"
      unitRef="usd">48000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE3LTQtMS0xLTE1NTYzOA_a742a737-ca33-414b-99be-902262e1e694"
      unitRef="usd">-279000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE3LTYtMS0xLTE1NTYzOA_c09fcb75-17ed-472b-8b6d-f57df9ebded0"
      unitRef="usd">-969000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE4LTItMS0xLTE1NTYzOA_d2dd06e5-4719-4c90-8965-3b8ce871ae18"
      unitRef="usd">2816000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE4LTQtMS0xLTE1NTYzOA_200303b6-2f58-490f-9f83-7d209226ba35"
      unitRef="usd">1237000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE4LTYtMS0xLTE1NTYzOA_a1b29fdc-46c5-4846-b171-9801eda849f0"
      unitRef="usd">1449000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE5LTItMS0xLTE1NTYzOA_82df1f87-fe7b-4338-809e-5ab383556210"
      unitRef="usd">1852000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE5LTQtMS0xLTE1NTYzOA_75cf28d6-699a-4374-a382-538381e0c8d8"
      unitRef="usd">370000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo0YWFiNjE3ZWI3YTA0Y2ZlYjQ2NmMzZTRhYTBjNDQ0OC90YWJsZXJhbmdlOjRhYWI2MTdlYjdhMDRjZmViNDY2YzNlNGFhMGM0NDQ4XzE5LTYtMS0xLTE1NTYzOA_48d139aa-8c42-4cb1-a4cf-461b0810763b"
      unitRef="usd">583000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE4NDI_e1829130-a225-4b69-a484-d294aa657d0b"
      unitRef="usd">15000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjE0Mzc_96882155-c281-44be-8356-3a23b6ca3bc3"
      unitRef="usd">-1400000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount
      contextRef="iafeac22251414180abb3e88565bac3e0_D20190701-20190929"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjMyMzE_0373aa24-c556-41bd-9892-6d455f69f208"
      unitRef="usd">2700000000</pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDA0_ebd86811-b39b-469a-9dfb-94c18f45f2e1">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The reconciliation of the U.S. statutory income tax rate to our effective tax rate for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. statutory income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TCJA impact&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxation of non-U.S. operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; (b), (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax settlements and resolution of certain tax positions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Certain Consumer Healthcare JV initiatives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate for income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions,&#x201d; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;for the components of pre-tax income and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;which is based on the location of the taxing authorities, and for information about settlements and other items impacting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2029. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2047 on income from manufacturing and other operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes changes in interest related to our uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;All other, net is primarily due to routine business operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzMtMi0xLTEtMTU1NjM4_1f35bad7-de19-4321-90d5-ddc1f225fc3c"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzMtNC0xLTEtMTU1NjM4_8092bc0b-bf1f-424c-aceb-55e38c2fcced"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzMtNi0xLTEtMTU1NjM4_13137ce1-8a91-4963-8287-88f28ff47640"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtMi0xLTEtMTU1NjM4_421fa183-684f-4276-acad-fc30922c2cca"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNC0xLTEtMTU1NjM4_03bc2458-9954-4213-81e3-95026eb68409"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNi0xLTEtMTU1NjM4_9f9d95f4-c3d5-4ad4-b5ad-2f3a60e9eb08"
      unitRef="number">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b"
      unitRef="number">-0.043</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf"
      unitRef="number">-0.099</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b"
      unitRef="number">-0.047</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtMi0xLTEtMTU1NjM4_cb603cf5-b5a6-4654-b0c4-e4fd67fa97ac"
      unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNC0xLTEtMTU1NjM4_f8c79b07-3f6a-4a33-92bb-3a6e9e257dd3"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNi0xLTEtMTU1NjM4_70764fa8-bcdf-4adc-b1d0-98a361ff980a"
      unitRef="number">-0.140</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctMi0xLTEtMTU1NjM4_2adf412a-914a-4578-a230-cd3632fc59e5"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNC0xLTEtMTU1NjM4_748e2b39-345f-44a8-b39b-41e92c60ab82"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNi0xLTEtMTU1NjM4_809ed143-c113-4f6a-81ff-ddef984737d1"
      unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtMi0xLTEtMTU1NjM4_ca2f17af-403d-45d2-a722-b3ea169f5d62"
      unitRef="number">0.060</pfe:EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtNC0xLTEtMTU1NjM4_5b191432-aea1-4255-a33b-3456f30d377f"
      unitRef="number">0</pfe:EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzktMi0xLTEtMTU1NjM4_ee7ff9c9-e32b-43cc-b120-f2be8c0c55a2"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzktNC0xLTEtMTU1NjM4_674b927d-2f8f-469d-bedf-426037e8e0bb"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzktNi0xLTEtMTU1NjM4_b8d1333b-9c0b-494a-a0b5-ca4733c89186"
      unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTItMS0xLTE1NTYzOA_91ad9a52-8b73-4986-a4f4-2d66d93c84da"
      unitRef="number">-0.004</pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTQtMS0xLTE1NTYzOA_ec5b8174-b3c0-42d6-9907-197f66ed9e22"
      unitRef="number">-0.011</pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTYtMS0xLTE1NTYzOA_d35f7b7b-d5e5-4e97-970d-198f3a89ac4c"
      unitRef="number">-0.006</pfe:EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTItMS0xLTE1NTYzOA_1d5c60d8-aa15-4f85-b15a-567ac23fc306"
      unitRef="number">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTQtMS0xLTE1NTYzOA_19a96083-6c93-4b19-9643-21dfc7e6a33e"
      unitRef="number">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTYtMS0xLTE1NTYzOA_fb7a05db-3539-44fd-85eb-fce98e4a8eec"
      unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEzLTItMS0xLTE1NTYzOA_3854ac8e-aa49-4175-9773-79ce7f31ed1c"
      unitRef="number">0.076</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEzLTQtMS0xLTE1NTYzOA_918c7dc0-c7e0-4295-a4a5-2071a35e60b7"
      unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEzLTYtMS0xLTE1NTYzOA_c6e2260a-845c-4d04-8f3a-bd8a469dee4a"
      unitRef="number">0.052</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTE1_fb31486f-539b-43be-be41-3454962025d3">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Deferred Tax*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020 Deferred Tax*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid/deferred items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;408&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,778&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;117&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,220)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee benefits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,594&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructurings and other charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;303&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Legal and product liability reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net operating loss/tax credit carryforwards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unremitted earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State and local tax adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;70&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(689)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,446&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset/(liability)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt"&gt;The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1Q&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The increase in net deferred tax assets in 2021 is primarily related to temporary differences associated with Comirnaty royalty accruals and the result of operating lease ROU liabilities recognized during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The increase in the deferred tax assets is primarily due to the acquisition of intangible assets relating to Trillium and the decrease in the 2021 deferred tax liabilities is primarily the result of amortization of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The increase in net deferred tax liabilities in 2021 is primarily the result of operating lease ROU assets recognized during the period. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The decrease in net deferred tax assets in 2021 is primarily the result of favorable pension plan asset performance reported in the period. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The amounts in 2021 and 2020 are reduced for unrecognized tax benefits of $3.0 billion and $3.0 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;The decrease in net deferred tax liabilities in 2021 is primarily due to certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($1.6 billion), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($0.3 billion). In 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($0.9 billion), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($4.1 billion).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70"
      unitRef="usd">4086000000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54"
      unitRef="usd">456000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f"
      unitRef="usd">3114000000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142"
      unitRef="usd">336000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtMi0xLTEtMTU1NjM4_889185dd-849f-404a-85bb-92422714cc9e"
      unitRef="usd">408000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNC0xLTEtMTU1NjM4_0c488731-aa77-4405-9d8b-f1278437dba0"
      unitRef="usd">56000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNi0xLTEtMTU1NjM4_00ebe2e3-fffa-4d43-8cf2-d10877fccc59"
      unitRef="usd">276000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtOC0xLTEtMTU1NjM4_cffbe9e3-2f79-455d-8521-2b76def7f868"
      unitRef="usd">25000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a"
      unitRef="usd">1778000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45"
      unitRef="usd">4577000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36"
      unitRef="usd">793000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a"
      unitRef="usd">5355000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7"
      unitRef="usd">117000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387"
      unitRef="usd">1647000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5"
      unitRef="usd">211000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92"
      unitRef="usd">1220000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261"
      unitRef="usd">1594000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad"
      unitRef="usd">178000000</pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b"
      unitRef="usd">1981000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae"
      unitRef="usd">124000000</pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtMi0xLTEtMTU1NjM4_3cb674c8-26ff-4296-a3e2-d27455fd0b41"
      unitRef="usd">303000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtNi0xLTEtMTU1NjM4_8da22a9a-074d-4f15-8ef1-49ba93ed5ef6"
      unitRef="usd">291000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktMi0xLTEtMTU1NjM4_b8c25820-33a9-41ca-963b-17e84c50bf38"
      unitRef="usd">373000000</pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves>
    <pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktNi0xLTEtMTU1NjM4_7a8c75d3-6197-43c1-a9e3-3b11f55e48bb"
      unitRef="usd">382000000</pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves>
    <pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1"
      unitRef="usd">1431000000</pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8"
      unitRef="usd">1761000000</pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTQtMS0xLTE1NTYzOA_07797e84-f31d-440f-8696-0e022691ac42"
      unitRef="usd">45000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTgtMS0xLTE1NTYzOA_37f18589-53d6-4dd8-aebf-aa5edae64b03"
      unitRef="usd">46000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTItMS0xLTE1NTYzOA_b19cafe6-5af3-425b-a11f-746e7e40d664"
      unitRef="usd">197000000</pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments>
    <pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTYtMS0xLTE1NTYzOA_9aa0edcb-ec53-4eff-9523-c670836ea3d4"
      unitRef="usd">171000000</pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f"
      unitRef="usd">70000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc"
      unitRef="usd">689000000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3"
      unitRef="usd">130000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2"
      unitRef="usd">3545000000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTItMS0xLTE1NTYzOA_934964c5-66e2-498b-96c7-e1e11097f2bf"
      unitRef="usd">89000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTQtMS0xLTE1NTYzOA_5c85bd6b-451b-400e-81ad-73936f0d12c8"
      unitRef="usd">68000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTYtMS0xLTE1NTYzOA_a9060b32-109c-4e94-9c63-a2e31f16ea3b"
      unitRef="usd">80000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTgtMS0xLTE1NTYzOA_95c4277e-6053-4020-b8f5-b5eb8adf6ae2"
      unitRef="usd">76000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTItMS0xLTE1NTYzOA_dc770b75-d0bb-4cad-9696-a02e91952b4f"
      unitRef="usd">10446000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTQtMS0xLTE1NTYzOA_5f72f016-f854-4d35-b32e-a1523936cf71"
      unitRef="usd">7714000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTYtMS0xLTE1NTYzOA_1be889d8-f1cd-4d88-aae6-0e47f2e407eb"
      unitRef="usd">9190000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTgtMS0xLTE1NTYzOA_2f1f2081-7178-4eff-980a-f932885400d6"
      unitRef="usd">10726000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTItMS0xLTE1NTYzOA_08096b56-06d2-44ca-bf3c-0c1d5ce92617"
      unitRef="usd">1462000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTYtMS0xLTE1NTYzOA_dd1abc95-de40-47a7-8e31-ae4082c6ba2f"
      unitRef="usd">1586000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTItMS0xLTE1NTYzOA_18ea3c1a-9447-45a7-a412-95630ed61f83"
      unitRef="usd">8983000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTQtMS0xLTE1NTYzOA_83cb9115-e0fb-4619-aef9-ab67c7d44420"
      unitRef="usd">7714000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTYtMS0xLTE1NTYzOA_c4fe5a30-44ae-4d42-b16c-dfad5d473ec6"
      unitRef="usd">7604000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTgtMS0xLTE1NTYzOA_a16f7605-4987-4a6a-b6db-1bace5af0ee5"
      unitRef="usd">10726000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d"
      unitRef="usd">1269000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1"
      unitRef="usd">3123000000</us-gaap:DeferredTaxLiabilities>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3Xzk1MjY_9ecce49c-afb8-4d82-8caf-4e5381b98dc1"
      unitRef="usd">3000000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3Xzk1MzM_3c1d1069-fe05-45da-9297-082aaca4fa06"
      unitRef="usd">3000000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ibb74e76f421148d08f33e3b64b0f55a7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3Xzk5ODM_88730be9-f480-411a-b50b-a063444e0aaf"
      unitRef="usd">1600000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i361e612fd47344f486642a0505329347_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwMDI5_2e5faebf-4863-4d8e-a1e5-b25117c53140"
      unitRef="usd">300000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i15795fd91413493f98813b66ab28bc23_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwMTA1_dc55bb08-1755-4bc0-bd09-ced0c215c19a"
      unitRef="usd">900000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i20860e5e0d834bd0a887924f23c1ddeb_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwMTUx_88b71f61-4346-483a-a0e2-2580d4b76168"
      unitRef="usd">4100000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEwNjcz_295c41e0-56ff-40c3-87be-97d9a2666b86"
      unitRef="usd">55000000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <pfe:UnrecognizedTaxBenefitsExcludingInterest
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzExNjUw_cbbfcbfa-4540-4736-bf85-bab66ff8edd8"
      unitRef="usd">4500000000</pfe:UnrecognizedTaxBenefitsExcludingInterest>
    <pfe:UnrecognizedTaxBenefitsExcludingInterest
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzExNjc0_fd6f089c-371c-4505-987a-f20eb746ea71"
      unitRef="usd">4300000000</pfe:UnrecognizedTaxBenefitsExcludingInterest>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNDA5_55aeb3cf-0efd-497f-bfe9-99c4507aaa83"
      unitRef="usd">1500000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="ibb74e76f421148d08f33e3b64b0f55a7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNTU4_785da9aa-932d-4fb4-9f47-5e3b5c56f471"
      unitRef="usd">1400000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="i33ea397ae7d44969805ee21fb8ef3cc5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNjI5_0928d93c-1244-42fc-823d-f2bd05304aeb"
      unitRef="usd">105000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyNjUx_39023125-e48b-4fbd-9ff9-5f736b8be685"
      unitRef="usd">1300000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="i15795fd91413493f98813b66ab28bc23_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyODAw_ea36cd15-5f87-474a-b6e0-550aa184358a"
      unitRef="usd">1100000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="i841ae3241c284442a2a9ed328bb982f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEyODQ1_d84785b2-1bc1-4db3-8cd9-5db7c608356d"
      unitRef="usd">122000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="i21b2ee9ddfcb4ba59cfcd0e1406e7519_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjgxOTI_d18f886c-0a9b-4ca0-8d55-535549dad4d0"
      unitRef="usd">46000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTM1_01f8db05-bf9c-447c-8fd1-bbcd38e7ae33">&lt;div style="margin-top:5pt;padding-left:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.023%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.333%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(5,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Divestitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Decreases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b), (c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Decreases based on settlements for a prior period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increases based on tax positions taken during the current period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(411)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b), (e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;40&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6,068)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For 2020, related to the separation of Upjohn. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision/(benefit) for taxes on income.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily related to cash payments and reductions of tax attributes.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily related to decreases as a result of a lapse of applicable statutes of limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;In 2021, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($19 million),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($42&#160;million) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($3.0 billion), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($5 million) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($3.0 billion). In 2020, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($34 million), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($18 million), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($3.0 billion) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other taxes payable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; ($2.5 billion).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzItMi0xLTEtMTU1NjM4_ae5216be-41d4-496d-bb94-71122bb1d472"
      unitRef="usd">5595000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzItNC0xLTEtMTU1NjM4_cfc69dc9-e217-45e8-bde5-9e8fb3346f9c"
      unitRef="usd">5381000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8e10b1e1c1f846769573d84f9a61fc72_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzItNi0xLTEtMTU1NjM4_97239417-d74f-4d3f-b6c2-658ad6534d9b"
      unitRef="usd">6259000000</us-gaap:UnrecognizedTaxBenefits>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzMtMi0xLTEtMTU1NjM4_69128509-98d6-4882-b9f9-63563ae584e6"
      unitRef="usd">0</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzMtNC0xLTEtMTU1NjM4_e6b51f26-a062-4297-85b5-c9cc367870b3"
      unitRef="usd">-37000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzMtNi0xLTEtMTU1NjM4_d28966a1-8962-44d0-900f-e480feaecefa"
      unitRef="usd">44000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition>
    <pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtMi0xLTEtMTU1NjM4_f68267a4-1cac-41fe-9805-9dee9acc44b0"
      unitRef="usd">0</pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures>
    <pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNC0xLTEtMTU1NjM4_e4128565-3c24-48a5-b18f-612d542f6555"
      unitRef="usd">265000000</pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures>
    <pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNi0xLTEtMTU1NjM4_49615fd2-0a4b-44b8-a14d-ea8b0be890e2"
      unitRef="usd">0</pfe:UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtMi0xLTEtMTU1NjM4_db22426c-6c10-4c2a-a824-e4c66d87abec"
      unitRef="usd">111000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNC0xLTEtMTU1NjM4_c2438de5-3204-47f9-9685-f2d214131cd7"
      unitRef="usd">232000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNi0xLTEtMTU1NjM4_71f74a89-7dbf-4577-a87e-55fadd19a618"
      unitRef="usd">36000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5"
      unitRef="usd">103000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f"
      unitRef="usd">64000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f"
      unitRef="usd">1109000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctMi0xLTEtMTU1NjM4_b93c897e-d113-4fca-af85-ca8fdbfac426"
      unitRef="usd">24000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNC0xLTEtMTU1NjM4_a6ee1f90-c8ba-493a-8df1-90679ee7be35"
      unitRef="usd">15000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNi0xLTEtMTU1NjM4_430e3341-aa36-4836-80f2-03307cb6e72a"
      unitRef="usd">100000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtMi0xLTEtMTU1NjM4_aa2deccf-47ae-41ab-967e-42c0d0e0faea"
      unitRef="usd">550000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNC0xLTEtMTU1NjM4_ed5826a8-7da8-49e4-8756-b5185b33aa9d"
      unitRef="usd">411000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNi0xLTEtMTU1NjM4_b77dc72b-c8f9-4d74-adcf-0cc74961cc96"
      unitRef="usd">383000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzktMi0xLTEtMTU1NjM4_9d3b3b43-5e87-4853-97ed-16b172d898a0"
      unitRef="usd">-22000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzktNC0xLTEtMTU1NjM4_02662971-0841-4247-a175-4363378746e7"
      unitRef="usd">72000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzktNi0xLTEtMTU1NjM4_d62d3510-ec04-4bb0-aa2f-b0f1d16f38fb"
      unitRef="usd">-25000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation>
    <pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba"
      unitRef="usd">-40000000</pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther>
    <pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b"
      unitRef="usd">-120000000</pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther>
    <pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84"
      unitRef="usd">-107000000</pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTItMS0xLTE1NTYzOA_70150eaf-49c1-40c8-a5b3-4c2dc5a3e763"
      unitRef="usd">6068000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTQtMS0xLTE1NTYzOA_4228acb7-0a7e-45cd-bc41-1d26c3fad96a"
      unitRef="usd">5595000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTYtMS0xLTE1NTYzOA_3722d7d6-c8c4-4e6e-8d19-e418b391b627"
      unitRef="usd">5381000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7054cf3b6aaa45ed9aab6e96ec09198c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNTM3_b12714cb-d0ad-4c07-bf8c-49aa445b9161"
      unitRef="usd">19000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id25117217bb84d749d33874e62b57092_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0OTgzMDQ_5f4aa614-d3b5-48fe-ace6-ea176b55a7d5"
      unitRef="usd">42000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibb74e76f421148d08f33e3b64b0f55a7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNjA2_ea37b927-b4f5-42d4-a896-357abf51b73f"
      unitRef="usd">3000000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i361e612fd47344f486642a0505329347_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNjQ4_5cd22f52-ba44-4ccd-9f8b-8f0adc7cee3b"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i33ea397ae7d44969805ee21fb8ef3cc5_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNjc3_b61f248f-66b9-4241-85e2-d1ac43731fb8"
      unitRef="usd">3000000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i7b847e7890394d15be5612bf0c10a5ef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzNzIz_e0ce0f5c-38a3-4d10-8345-3b7f831ae2b9"
      unitRef="usd">34000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i15795fd91413493f98813b66ab28bc23_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzODE3_c39b570c-18ee-4f25-9f8b-dbf91adba6b5"
      unitRef="usd">18000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i20860e5e0d834bd0a887924f23c1ddeb_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzODU5_35c482fe-6c59-41f7-82c9-ea97fddfd6af"
      unitRef="usd">3000000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i21b2ee9ddfcb4ba59cfcd0e1406e7519_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzEzODg4_37973408-f110-4c97-8cb4-62234ab7c6d3"
      unitRef="usd">2500000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0MTI1_dab4ca32-10c7-487d-b20c-038729916daf"
      unitRef="usd">108000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzYwNDczMTQwMjMxNDQ_47183b07-c823-4a52-8406-9de796672333"
      unitRef="usd">89000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0Mjg3_4135d46e-0bca-4a80-823f-2817b4bbbebf"
      unitRef="usd">-564000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0MzIy_a91525f3-3392-441a-a5b6-3151271bd576"
      unitRef="usd">601000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0MzYw_7e40aab7-1787-4c59-802e-cff9bf61b8b7"
      unitRef="usd">-1000000</pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0NDg2_7ee2eb01-dc34-49cf-821d-7caad7c9ee54"
      unitRef="usd">493000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE0NTI0_0dbce7bf-4571-483c-9ebc-f865c5803f78"
      unitRef="usd">-5000000</pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual>
    <pfe:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE2NDkyNjc0NjkxNTc_159259c9-4fbb-4514-a90e-19339f1df035"
      unitRef="usd">75000000</pfe:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE1OTEy_e1b90b0c-637d-475a-9439-33f88cd944aa"
      unitRef="usd">75000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDEw_60b86d5c-4e6e-4fa8-b4a2-075bf4857336">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit plans: prior service (costs)/credits and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments related to curtailments of prior service costs and other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtNi0xLTEtMTU1NjM4_e39da51d-aeec-4e8d-a1e7-561787656116"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtOC0xLTEtMTU1NjM4_eb84dd73-f48f-4386-91cc-70803e7c166b"
      unitRef="usd">-119000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtMTAtMS0xLTE1NTYzOA_69cb70ec-f0d5-43fd-a42b-cdb0a66d8fd3"
      unitRef="usd">260000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzUtNi0xLTEtMTU1NjM4_0296fd60-8941-4c50-a08d-dd1d63fffeed"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzUtOC0xLTEtMTU1NjM4_f8b358aa-1d8d-441a-a3fd-15af3f198180"
      unitRef="usd">-88000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzUtMTAtMS0xLTE1NTYzOA_4a67f947-164f-4e83-baca-f650606bfa29"
      unitRef="usd">83000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzYtNi0xLTEtMTU1NjM4_7f9809ea-6c05-48a9-9dcb-b6f2f14ded7c"
      unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzYtOC0xLTEtMTU1NjM4_70428691-287a-4a41-9905-51d8e2ce48fa"
      unitRef="usd">25000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzYtMTAtMS0xLTE1NTYzOA_8101598c-8aaf-425c-9ab9-4b52fe6dcf3b"
      unitRef="usd">125000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzgtNi0xLTEtMTU1NjM4_9c6ec356-3559-44c2-b74b-0b93a7c5df23"
      unitRef="usd">114000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzgtOC0xLTEtMTU1NjM4_e35dc1e2-ed53-4ac3-adbe-e4efd92f85e0"
      unitRef="usd">-113000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzgtMTAtMS0xLTE1NTYzOA_319a6f0d-a4ae-45f2-a642-cc4807ae3122"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzktNi0xLTEtMTU1NjM4_2d04bfde-09ff-44c4-8128-e03587b248a1"
      unitRef="usd">-44000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzktOC0xLTEtMTU1NjM4_3010c6a2-5d3f-48d2-8b55-760f56f67849"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEwLTYtMS0xLTE1NTYzOA_ea62ddf7-7b7f-4c39-959c-1e309f50bd35"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEwLTgtMS0xLTE1NTYzOA_af5853fa-90f8-4f17-a5d2-a8af2bbc2065"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEwLTEwLTEtMS0xNTU2Mzg_ad6a7f3c-1974-4b23-9940-b0497203f96a"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEyLTYtMS0xLTE1NTYzOA_6be97b48-de09-49dd-bd7d-094cc4126181"
      unitRef="usd">-48000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEyLTgtMS0xLTE1NTYzOA_6831c346-301e-477e-8f2d-6ee7507f9b0a"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzEyLTEwLTEtMS0xNTU2Mzg_1c1c55a7-f647-4b7b-975e-ec7b885240e8"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzE5LTYtMS0xLTE1NTYzOA_16225be0-292b-44e4-9b56-37d3406ea061"
      unitRef="usd">-27000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzE5LTgtMS0xLTE1NTYzOA_b008cd54-cfe3-4f30-8096-1ad84a26704a"
      unitRef="usd">-12000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzE5LTEwLTEtMS0xNTU2Mzg_bcfa992d-9650-4199-8b5a-e6df006a5cf3"
      unitRef="usd">1000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIwLTYtMS0xLTE1NTYzOA_4fb6841d-3613-4b4a-ab6e-d34d5dc48f7e"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIwLTgtMS0xLTE1NTYzOA_fdea3a86-d56d-4d61-8404-a4fde76ca370"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIwLTEwLTEtMS0xNTU2Mzg_c84a52ac-105a-445c-b2b6-f0e350fd575b"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIxLTYtMS0xLTE1NTYzOA_c2297656-4d20-407e-a5b5-273d55b5f009"
      unitRef="usd">-17000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIxLTgtMS0xLTE1NTYzOA_275fbf3f-1f44-4d35-9185-4b35d454f657"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIxLTEwLTEtMS0xNTU2Mzg_2b69f825-363e-40e1-bc58-d97a183b2d4f"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIzLTYtMS0xLTE1NTYzOA_718539f0-d987-4562-a344-ac4ff726b04f"
      unitRef="usd">1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIzLTgtMS0xLTE1NTYzOA_9270c685-977a-4946-936e-538af6cf90fe"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzIzLTEwLTEtMS0xNTU2Mzg_bab09426-91fd-4e7a-9741-38f65fa936da"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI0LTYtMS0xLTE1NTYzOA_7c829053-d934-4703-9ab0-7f9583255f77"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI0LTgtMS0xLTE1NTYzOA_16af20ab-c768-4f03-87de-43df2011c3d3"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI0LTEwLTEtMS0xNTU2Mzg_c1ac2535-e9ac-402e-945c-878768732aeb"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI1LTYtMS0xLTE1NTYzOA_30a8da0c-76ab-4650-8bf5-40d98bcac4b5"
      unitRef="usd">71000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI1LTgtMS0xLTE1NTYzOA_1e175cd3-0e13-477e-bf6e-feca9033b8e9"
      unitRef="usd">-227000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzI1LTEwLTEtMS0xNTU2Mzg_b38a9536-a3ed-4928-8095-ec6afdf7cda3"
      unitRef="usd">178000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0Nzk_0e495520-f857-48ae-a8e4-1d9fbaecc968">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes, net of tax, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Prior Service (Costs)/ Credits and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Distribution of Upjohn Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(6,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(5,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 2C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and the impact of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODE_50e3460c-1015-44b5-aee0-23743fe98e39">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the changes, net of tax, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Net Unrealized Gains/(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Prior Service (Costs)/ Credits and Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(6,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,936)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(448)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Distribution of Upjohn Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(397)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(423)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,450)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(5,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;547&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(6,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;377&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(5,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts include the impact of a change in accounting principle. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; Note 2C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and the impact of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d1928a49a1c409b9412c1399a30a560_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMi0xLTEtMTU1NjM4_e61f106a-42e6-4cf2-bf52-aac6d39c699d"
      unitRef="usd">-6075000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cb4c669061b481d96c1121c6720d70d_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNC0xLTEtMTU1NjM4_df59b808-c19a-458d-9a08-fcc08454107a"
      unitRef="usd">167000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcbad3af6ffb42d3a5323f694e0b67e4_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNi0xLTEtMTU1NjM4_de0b7543-ea69-4805-8352-777920c516c7"
      unitRef="usd">-68000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fd2b1aa38ce4c06af821df843b89ce4_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTAtMS0xLTE1NTYzOA_80cc64e5-d4bf-4658-b77e-6608ae105363"
      unitRef="usd">728000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fa41a976be144ff95f4427e340cfcab_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTItMS0xLTE1NTYzOA_a38ccb42-7b44-4153-978f-eee616f1d02c"
      unitRef="usd">-5249000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2feb25a701eb4da483a23b858699b65e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def"
      unitRef="usd">139000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if58e15d3f4084fffb7602c9eb76f8bc9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b"
      unitRef="usd">-146000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7e3cd7c442ae43b9bfd024d7dd0d36b9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="icc4281959bef4c1493773621b7096825_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib57063444ae6416ea155fe3b461c2ed1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40"
      unitRef="usd">-118000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i40b2c92e98294f13b4dbf574dc8305f3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMi0xLTEtMTU1NjM4_98785a01-befa-4c10-b041-8f84db3b9aa2"
      unitRef="usd">-5936000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib0393c39513f4c3eac3873a1cd6c7164_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNC0xLTEtMTU1NjM4_fd95f5fe-9788-42b7-98a7-2ebcfd5e321f"
      unitRef="usd">20000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7547ea8333dc473b9f7ac1c8f733c20d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNi0xLTEtMTU1NjM4_d8130e94-33e2-41d9-bd5f-dc35bca090cb"
      unitRef="usd">-35000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c35fcf0cfc44fd48d3257adee8a9f7c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTAtMS0xLTE1NTYzOA_123ca141-8291-470b-b0dd-6eda82b33426"
      unitRef="usd">584000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c15300160eb40199b2470fd99513c75_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTItMS0xLTE1NTYzOA_9136e4e7-dd83-4a34-a2bf-5479fca27462"
      unitRef="usd">-5367000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i24e18b8241eb4dca8f8c5339c218af0e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a"
      unitRef="usd">883000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i11c6dc78bf6441e287c9ac69448c1f36_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046"
      unitRef="usd">-448000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ab5367055954f1ab2c49e8bb7ad206d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5"
      unitRef="usd">151000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5a66120c91484bf482696981e59cfd8c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987"
      unitRef="usd">-106000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc"
      unitRef="usd">480000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i24e18b8241eb4dca8f8c5339c218af0e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480"
      unitRef="usd">-397000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i11c6dc78bf6441e287c9ac69448c1f36_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8"
      unitRef="usd">0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i0ab5367055954f1ab2c49e8bb7ad206d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0"
      unitRef="usd">0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i5a66120c91484bf482696981e59cfd8c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc"
      unitRef="usd">-26000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i7b7e6b3783ea4abc9ef384e0022aa3ad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd"
      unitRef="usd">-423000000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53a5e9e7d598442bb2845131112f1a27_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMi0xLTEtMTU1NjM4_0df94e6e-dd72-4a26-9d13-48322b242766"
      unitRef="usd">-5450000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2dcb1cb0b18446282f631ef686d469e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNC0xLTEtMTU1NjM4_3bdff635-14c6-4f72-8238-0b7e0362e571"
      unitRef="usd">-428000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia43c881a511349ed8186adf0171213b4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNi0xLTEtMTU1NjM4_c523199d-997d-4a19-8355-cea3d890630e"
      unitRef="usd">116000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i61f3046c6f3740088aecf1f8ab49180c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTAtMS0xLTE1NTYzOA_4a2275a9-7705-4579-8874-1206874376a9"
      unitRef="usd">452000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica9a1f0a2c3f454aa866582d5102b28a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTItMS0xLTE1NTYzOA_9a80eaa2-1cc5-46e9-84d5-2982df1449c7"
      unitRef="usd">-5310000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if80d286ba9a84220b133795a7fe5879e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582"
      unitRef="usd">-722000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic24d6578cd564b11b05d748a5940c8cc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb"
      unitRef="usd">547000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i511ba9110aec4c1ebb32704e802fdfcf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48"
      unitRef="usd">-336000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaa1ca16d7938490db0ffebf5bafa0e71_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd"
      unitRef="usd">-75000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4091403708c44027bed1ab29ab967de7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c"
      unitRef="usd">-587000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9aa37587879b40bf9f95c485b7bc8caa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTItMS0xLTE1NTYzOA_d0cd48f4-f91e-4631-babd-45ea614f93a3"
      unitRef="usd">-6172000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13cd8db58f3548899c2ef209a3207f51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTQtMS0xLTE1NTYzOA_081dcc47-cdde-4218-b274-fb74672a032a"
      unitRef="usd">119000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0e841c53a84a4c519f13fc764830af27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTYtMS0xLTE1NTYzOA_d3edc723-36cf-4444-b015-fbeec8e2ee52"
      unitRef="usd">-220000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b0f53b05386403bb5d5091940b9f1f0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEwLTEtMS0xNTU2Mzg_9d601fd9-6e60-4673-a18a-9c8efc23f039"
      unitRef="usd">377000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6af06169f58446f8067cc5be10a39e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEyLTEtMS0xNTU2Mzg_5f1e6ae2-9ee1-4d55-bae9-cab3ac64546b"
      unitRef="usd">-5897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyMzY_0f7f58e8-1a6f-4fdd-9529-c22d8401ae15">Financial Instruments&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Long-term equity securities of $194 million as of December 31, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The carrying value of Long-term debt, excluding the current portion was $36&#160;billion as of December 31, 2021 and $37&#160;billion as of December 31, 2020. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $42&#160;billion as of December 31, 2021 and $46 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of December 31, 2021 and 2020. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Total Short-Term, Long-Term and Equity-Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes our investments by classification type:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Private equity securities at cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,054&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represent investments in the life sciences sector.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;697&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;917&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,097&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,029&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Any expected credit losses to these portfolios would be immaterial to our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity method investments, held at the reporting date:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $97 million and upward adjustments of $156 million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes cash collateral. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7F&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The weighted-average effective interest rate on commercial paper outstanding was approximately 0.13% as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we had access to a $7 billion committed U.S. revolving credit facility expiring in 2026, which may be used for general corporate purposes including to support our commercial paper borrowings. In addition to the U.S. revolving credit facility, our lenders have provided us an additional $360 million in lines of credit, of which $322 million expire within one year. Essentially all lines of credit were unused as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following outlines our senior unsecured long-term debt and the weighted-average stated interest rate by maturity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2022 (1.0% for 2020)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2023 (3.2% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,550&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2024 (3.9% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2025 (0.8% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2026 (2.9% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2027 (2.1% for 2021 and 2.0% for 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,051&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2028-2032 (3.1% for 2021 and 3.4% for 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,660&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2033-2037 (5.6% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2038-2042 (5.5% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2043-2047 (3.7% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,858&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2048-2050 (3.6% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,948&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reclassified to the current portion of long-term debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our long-term debt outlined in the above table is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Issuances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In August 2021, we issued the following senior unsecured notes at an effective interest rate of 1.79%:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.750%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;August&#160;18, 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In May 2020, we completed a public offering of $4.0 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.11% and in March 2020, we completed a public offering of $1.25 billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 2.67%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;In March 2019, we completed a public offering of $5.0&#160;billion aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of 3.57%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Retirements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In November 2020, we repurchased all $1.15 billion and $342 million principal amount outstanding of the 1.95% senior unsecured notes due June 2021 and 5.80% senior unsecured notes due August 2023 and recorded a total net loss of $36&#160;million, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In March 2020, we repurchased at par all $1.065 billion principal amount outstanding of our senior unsecured notes due in 2047.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In January 2019, we repurchased all &#x20ac;1.1 billion ($1.3 billion) principal amount outstanding of the 5.75% euro-denominated debt due June 2021 at a redemption value of &#x20ac;1.3 billion ($1.5 billion). We recorded a net loss of $138 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, which included the related termination of cross currency swaps&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Derivative Financial Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. Where foreign exchange risk is not offset by other exposures, we manage our foreign exchange risk principally through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to mitigate the impact on net income as a result of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The derivative financial instruments primarily hedge or offset exposures in the euro, U.K. pound, Japanese yen and Canadian dollar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;We hedge a portion of our forecasted intercompany inventory sales denominated in euro, Japanese yen, Canadian dollar, Chinese renminbi, U.K. pound and Australian dollar for up to two years.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Under certain market conditions, we may seek to protect against possible declines in the reported net investments of our foreign business entities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Changes in fair value are reported in earnings or in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, depending on the nature and purpose of the financial instrument (hedge or offset relationship). For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an amortization approach in earnings. The hedge relationships are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged item. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Generally, we record in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts into earnings in the same period or periods during which the hedged transaction affects earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;We record in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;Foreign currency translation adjustments, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;For foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses immediately into earnings along with the earnings impact of the items they generally offset. These contracts take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our interest-bearing investments and borrowings are subject to interest rate risk. Depending on market conditions, we may change the profile of our outstanding debt or investments by entering into derivative financial instruments like interest rate swaps, either to hedge or offset the exposure to changes in the fair value of hedged items with fixed interest rates, or to convert variable rate debt or investments to fixed rates. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We recognize the change in fair value on interest rate contracts that are designated as fair value hedges in earnings, as well as the offsetting earnings impact of the hedged risk attributable to the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,576&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;488&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(649)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;OID = Other (income)/deductions&#x2014;net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt"&gt;a net loss of $89 million in 2021; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt"&gt;a net gain of $172 million in 2020 (including a gain of $22&#160;million reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $362 million within the next 12 months into income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Short-term borrowings and long-term debt include foreign currency borrowings which are used as net investment hedges. The short-term borrowings carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of December 31, 2021 and December 31, 2020 were $844 million and $2.1 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair&lt;br/&gt;Value Hedging Adjustment&lt;br/&gt;Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair &lt;br/&gt;Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;br/&gt;Hedging&lt;br/&gt;Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;F&lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;.&lt;/span&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt; Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, we monitor and review the credit risk of our customers, financial institutions and exposures in our investment portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;With respect to our trade accounts receivable, we monitor the creditworthiness of our customers to which we grant credit in the normal course of business. In general, there is no requirement for collateral from customers. For additional information on our trade accounts receivable and &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;allowance for credit losses, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1H&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. A significant portion of our trade accounts receivable balances are due from wholesalers and governments. For additional information on our trade accounts receivables with significant customers, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;With respect to our investments, we monitor concentrations of credit risk associated with government, government agency, and corporate issuers of securities. Investments are placed in instruments that are investment grade and are primarily short in duration. Exposure limits are established to limit a concentration with any single credit counterparty. As of December 31, 2021, the largest investment exposures in our portfolio represent primarily sovereign debt instruments issued by the U.S., Canada, Japan, U.K., Germany, France, Australia, and Switzerland.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;With respect to our derivative financial instrument agreements with financial institutions, we do not expect to incur a significant loss from failure of any counterparty. Derivative financial instruments are executed under International Swaps and Derivatives Association (ISDA) master agreements with credit-support annexes that contain zero threshold provisions requiring collateral to be exchanged daily depending on levels of exposure. As a result, there are no significant concentrations of credit risk with any individual financial institution. As of December 31, 2021, the aggregate fair value of these derivative financial instruments that are in a net payable position was $372 million, for which we have posted collateral of $382 million with a corresponding amount reported in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Short-term investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. As of December 31, 2021, the aggregate fair value of our derivative financial instruments that are in a net receivable position was $477 million, for which we have received collateral of $581 million with a corresponding amount reported in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; Short-term borrowings, including current portion of long-term debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyMzM_436c3bc7-5687-45ac-b85e-2bfbdfd3be40">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.099%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.542%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27,379&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;704&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,849&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financial liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Long-term equity securities of $194 million as of December 31, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i68b19f0bbfb7432a8e12a91e563366db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMi0xLTEtMTU1NjM4_444d150b-efaf-41d4-9ef4-da4ef2155309"
      unitRef="usd">5365000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9fa85376258a44a4ae685454ee4b4522_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtNC0xLTEtMTU1NjM4_a68426e3-4d16-44e7-bf87-763cd51f7148"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3418a2b3afcb431cb8d6bb202f7c9e6e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtNi0xLTEtMTU1NjM4_dfbe7e14-7e1c-4351-9680-a0600daaa2bb"
      unitRef="usd">5365000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i64912c49208a4823a52b20d54f71c167_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMTAtMS0xLTE1NTYzOA_578237a9-808b-49b1-bf09-0551f05a71c7"
      unitRef="usd">567000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib1832b894d034229bf17f14653fff53a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMTItMS0xLTE1NTYzOA_777525a4-6b16-4ae6-aed4-2376e409096a"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ifbfbfd55f6844d2d82e7590378589389_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzUtMTQtMS0xLTE1NTYzOA_27078cde-4b6a-49bb-b84a-7a02bd447a1c"
      unitRef="usd">567000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ccb03a8326a4f5d815ce199580340b0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMi0xLTEtMTU1NjM4_3cfd30fa-8ab7-43ad-b45a-7c3e3cca641f"
      unitRef="usd">17318000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58d8b7dd831245b68c651101e4deb9ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtNC0xLTEtMTU1NjM4_6cd40697-7cfb-4fdf-a2aa-740b7207febd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i145d0984ee1244d0b37449d0c40e9475_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtNi0xLTEtMTU1NjM4_5ed0076a-ef3a-40ac-b0d0-41549ef0c829"
      unitRef="usd">17318000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54e2191840f24816b76892c14e08c0a5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMTAtMS0xLTE1NTYzOA_b8ea55b1-008e-42a2-afda-a8a9945b3508"
      unitRef="usd">7719000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i786207e27ed54f20957d50f7249fc8f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMTItMS0xLTE1NTYzOA_f7d038a8-0414-4ef1-b074-abaebb723d79"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8fb95d9dac1143469cff7c05c1e9b8ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzgtMTQtMS0xLTE1NTYzOA_51232922-857f-4487-a225-1db2d6897f51"
      unitRef="usd">7719000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e34c85175c24f12a4b000731b5e3f27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMi0xLTEtMTU1NjM4_8c53015d-26e6-449d-a7ca-f67a8b380479"
      unitRef="usd">4050000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i30d4ea08901f40f8ae26a54cf87605c1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktNC0xLTEtMTU1NjM4_db7d5bc9-1d86-48a8-b528-895c68c383cf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24d9b25ab1bf48c4a7eb2a2fab5ba59b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktNi0xLTEtMTU1NjM4_5882fc88-2785-4566-87e0-c08aec837b9b"
      unitRef="usd">4050000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i08b8d363fe87400582215a448d41b61e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMTAtMS0xLTE1NTYzOA_70825b9f-84c9-4f87-a6b7-7f3fd00e82bc"
      unitRef="usd">982000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d34428a8a7a4c3a9834e0ab26aac210_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMTItMS0xLTE1NTYzOA_b8805c3e-9207-4281-ae12-53aaeda98957"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie423b51a2f17446f883f1e3d141a5644_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzktMTQtMS0xLTE1NTYzOA_29df739a-fabb-410e-8c65-bac54f8ff53c"
      unitRef="usd">982000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27e86737f524429b9f6404bf63655dcb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTItMS0xLTE1NTYzOA_e48d8103-721b-40b3-a6cd-7a304ee7eeb3"
      unitRef="usd">647000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2dadd6168e384b76b96623c95ede9e40_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTQtMS0xLTE1NTYzOA_e3792084-95db-41e5-9b6c-01443caa0a5f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0f6509e6a7745c6b86b58623ec0a3da_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTYtMS0xLTE1NTYzOA_9b63a0de-117c-4649-8226-20db56c54896"
      unitRef="usd">647000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3db2d0cd435749399fb50288da8b36ca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTEwLTEtMS0xNTU2Mzg_39ff8345-8dc9-474f-9939-5168acca3540"
      unitRef="usd">1008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a7b7712fc3d46dc8c9ab62732f132e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTEyLTEtMS0xNTU2Mzg_619978ea-1e5e-4694-bb41-cec85fd6ff96"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54f878726ed649d3b72ab3c31f1e3bbd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEwLTE0LTEtMS0xNTU2Mzg_e419ae1f-892b-4e2a-bdc0-d5474b87ccdf"
      unitRef="usd">1008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2890488b7754499db8478c21b1fced49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTItMS0xLTE1NTYzOA_127e4c85-6eeb-47d6-a6bd-16233fb0f68f"
      unitRef="usd">22014000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2cadeec4d4b465ca3663ef815d82155_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTQtMS0xLTE1NTYzOA_5c270e66-5819-470c-9de3-0421c9c679e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5925981dea3b42b6b80c80390ff93ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTYtMS0xLTE1NTYzOA_0716db17-e10d-4ea1-bf33-842045a93475"
      unitRef="usd">22014000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1dbee34efeb54f89b1cf37526e026635_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTEwLTEtMS0xNTU2Mzg_47958a9c-5440-4c70-bee0-bb2c283fd9c9"
      unitRef="usd">9709000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23d63549fe7b43a793936e93998114f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTEyLTEtMS0xNTU2Mzg_42c8de7e-e485-40d1-9dd0-0ae568e0cc4d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie4730f5e3a64488fa803d7863caba436_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzExLTE0LTEtMS0xNTU2Mzg_c2d109f3-1906-4190-97fa-819c4e38ffc8"
      unitRef="usd">9709000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i2890488b7754499db8478c21b1fced49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTItMS0xLTE1NTYzOA_7f3886d4-329b-4c5d-9766-a0be44c2a0b6"
      unitRef="usd">27379000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="if2cadeec4d4b465ca3663ef815d82155_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTQtMS0xLTE1NTYzOA_9994c6be-156b-40a3-a23e-952cb20e8780"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i5925981dea3b42b6b80c80390ff93ce3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTYtMS0xLTE1NTYzOA_39753e9f-0ec2-4380-9081-492caab90689"
      unitRef="usd">27379000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i1dbee34efeb54f89b1cf37526e026635_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTEwLTEtMS0xNTU2Mzg_3a017a3e-e737-40a0-8a40-9eb6907e0de3"
      unitRef="usd">10276000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="i23d63549fe7b43a793936e93998114f0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTEyLTEtMS0xNTU2Mzg_e45613d3-047f-404f-bda7-f35141c10bce"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="ie4730f5e3a64488fa803d7863caba436_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzEyLTE0LTEtMS0xNTU2Mzg_153614d1-c0e7-40ba-835f-05af6964c28f"
      unitRef="usd">10276000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i83ae4366de7949d1b80d0154a8d14014_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTItMS0xLTE1NTYzOA_cf739142-774c-4492-a8c1-4f64c9804261"
      unitRef="usd">4000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i93817b4a8c5f47a784df62085b5ef330_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTQtMS0xLTE1NTYzOA_e5a51fd5-3a44-4943-b59c-b8c49cb0ea77"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ib8ac7b2f72a949818e50952dcb98d810_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTYtMS0xLTE1NTYzOA_31a9f683-229e-483e-bb55-d18599f9f74c"
      unitRef="usd">4000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i253d96f29fcc4271be1786978a7085bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTEwLTEtMS0xNTU2Mzg_ec76d7ee-b7a5-4b8c-a4dc-1fa1e54199fe"
      unitRef="usd">18000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ia483bb7e1f8c43579b9a40f336b26091_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTEyLTEtMS0xNTU2Mzg_ae5addb7-7fd0-48cc-b4a1-ce80888de3cb"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i51bffa6b2c284c08942e4b334c1d5704_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE1LTE0LTEtMS0xNTU2Mzg_2b79719d-b8ae-4dca-937b-e8a0004353a5"
      unitRef="usd">18000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id721d4b7291d43418158c108dc4def27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTItMS0xLTE1NTYzOA_eff310ac-4a1e-44ec-a515-37f2db39c0b1"
      unitRef="usd">704000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="icb1556a00d4f48a98b1c9c8bdeb762d3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTQtMS0xLTE1NTYzOA_f1f49a35-fb84-4227-acd5-2abdf5d41209"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="id530a91ad1454541a5602cb3294a21df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTYtMS0xLTE1NTYzOA_4c9aadeb-a514-4278-a426-9254fddc6c83"
      unitRef="usd">704000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i8ac39c0dad404d8d8153c80ebdcf66dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTEwLTEtMS0xNTU2Mzg_606277de-d1b8-4c07-afd8-b107b497ce89"
      unitRef="usd">234000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i0561e1ebce474b1eb9d143fd298c0a82_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTEyLTEtMS0xNTU2Mzg_7a862cdf-821f-4039-9a23-5a8be8f22c5f"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie8ac2146872344a5aa5941ed2d0c3cd9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE2LTE0LTEtMS0xNTU2Mzg_522ce0b7-a572-45ec-80ee-015927f2e6f9"
      unitRef="usd">234000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ic697c580bd3e4b12adcbe2d6812a9bbf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTItMS0xLTE1NTYzOA_9ffb740d-9008-4933-b70f-291a17716c7c"
      unitRef="usd">709000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i4e262b7b10634d05983458087d0d704a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTQtMS0xLTE1NTYzOA_45481eeb-9e55-4361-939a-7e996bce9a50"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i855416e6b6cc4e2bbbe94916d33fb451_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTYtMS0xLTE1NTYzOA_c973034c-a5e0-48f9-b135-946ccea26554"
      unitRef="usd">709000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i32bef417f19d46c69b2db7cca231ae59_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTEwLTEtMS0xNTU2Mzg_e4fdbc8c-357c-4950-9b80-5e362e9c5772"
      unitRef="usd">251000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i348aaa35951d4227a378574421582221_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTEyLTEtMS0xNTU2Mzg_d83671f7-db4c-4a40-b2a5-cf41e624b5ba"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i7724991aa49b4c29813095ac7d7118c5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE3LTE0LTEtMS0xNTU2Mzg_6c20ffda-e346-4b4a-bd8f-7e0ecd56cb3c"
      unitRef="usd">251000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTItMS0xLTE1NTYzOA_5fd2c1e6-9de7-40c1-ae80-d3392b8c0703"
      unitRef="usd">3876000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2a6657a1ee6049f2939f90c46a8b565e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTQtMS0xLTE1NTYzOA_37ea546b-438a-45e2-8bf8-c5daef1deea9"
      unitRef="usd">3849000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTYtMS0xLTE1NTYzOA_65c2fd73-d37f-4010-8461-ed242702667b"
      unitRef="usd">27000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i70512a720d8249c6a447f770e98bf667_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEwLTEtMS0xNTU2Mzg_072775e8-2b98-4b98-8a60-50ca224f222b"
      unitRef="usd">2809000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9410a99ac78b49fea836856840cfa817_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEyLTEtMS0xNTU2Mzg_047edc6c-e2d8-4c5f-bb4c-a50070519254"
      unitRef="usd">2776000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i16561960de5b416bb80606e87a745433_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTE0LTEtMS0xNTU2Mzg_c9cf5bc8-d558-48e8-89d0-a7d284348289"
      unitRef="usd">32000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifcddc652bbad488ab1ee0afa359aebde_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTItMS0xLTE1NTYzOA_04252906-382c-4a74-b5ba-eb3c5e6209e1"
      unitRef="usd">465000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07737ad4fa9241c6a7af7bedb530cec2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTQtMS0xLTE1NTYzOA_99d2bfe4-3aae-4db8-ad27-4434b6cd6e6a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice49e3789be5439c9f19101663f83790_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTYtMS0xLTE1NTYzOA_bbe8ad14-b4a5-4804-920f-a7aea1240325"
      unitRef="usd">465000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2fb7a0fce89244b7852f6f7fb2718f88_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTEwLTEtMS0xNTU2Mzg_1c0b36e0-bc23-4f91-b3e9-d60e7e0e5801"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if4d8e1febfc94acb9d1eb950557e11ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTEyLTEtMS0xNTU2Mzg_1c560993-73d5-473f-a2f4-899a56dc89f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0cf180ee19904407b6436c68eeb033d2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIyLTE0LTEtMS0xNTU2Mzg_23a36466-e146-4b91-a3d6-e5e4f480dbbe"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0a1a4330d80747c7ae68476b979046c3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTItMS0xLTE1NTYzOA_8673e3ee-5eb5-4558-bb1b-1d831da901ec"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35ef7c64d623476b9744d8d1d932a8ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTQtMS0xLTE1NTYzOA_8daf23a9-6758-40b3-891f-e62ff19d1fed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fae9b56ccbf497790ea241830626958_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTYtMS0xLTE1NTYzOA_cf5992e0-af1b-41f6-b544-be6f2844d9a3"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica452679157c46e0baa897976e18621f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTEwLTEtMS0xNTU2Mzg_538c1a26-7b61-4f2d-8e6e-dd442952a0b6"
      unitRef="usd">121000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d5ee66c1ff843b58eb05f3777b56b8e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTEyLTEtMS0xNTU2Mzg_a78c8f4a-67ed-4010-94dc-367d5f121ddb"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22cbf7ef28864700b19759fa6f01b5b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzIzLTE0LTEtMS0xNTU2Mzg_1713b036-694c-40eb-87db-dc8b3bace86d"
      unitRef="usd">121000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i699fae78a900497eaac754517d1030c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTItMS0xLTE1NTYzOA_6b1d1459-bb30-4313-8c24-56b090ea6f91"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa71df5a7c754df9b330874d5b7d0aa0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTQtMS0xLTE1NTYzOA_cc35f474-bdad-45ed-8c06-a8899e1fcca9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1cd464351ee4fdbb492774c72b7f0ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTYtMS0xLTE1NTYzOA_6813a88d-71ed-4d8a-893d-a8bb2dc88b03"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i61199b2ae71d4a119d9701e06a107a16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTEwLTEtMS0xNTU2Mzg_e5810af7-c8ee-49f0-b868-529a3c8270ae"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7c3c53af69848b88bfbc37caf07b4f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTEyLTEtMS0xNTU2Mzg_2fa137ad-52c9-460e-ace5-aeccc800b6a2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i035dd6d3c0a642048d88fe63f7a78ef4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI0LTE0LTEtMS0xNTU2Mzg_964bd196-f34b-49d5-ac68-8ff78fb93266"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTItMS0xLTE1NTYzOA_3eeebdb3-28c9-437c-9487-189b801dc027"
      unitRef="usd">521000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a6657a1ee6049f2939f90c46a8b565e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTQtMS0xLTE1NTYzOA_8391baa0-851d-4156-93a6-6a07dcf63a71"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTYtMS0xLTE1NTYzOA_79a22b30-c5db-4ace-a791-254c23986cf7"
      unitRef="usd">521000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i70512a720d8249c6a447f770e98bf667_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTEwLTEtMS0xNTU2Mzg_c65c039e-ed82-4ad8-ad2b-a538862489ec"
      unitRef="usd">128000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9410a99ac78b49fea836856840cfa817_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTEyLTEtMS0xNTU2Mzg_e77c4220-54ec-48d5-accb-70a04f1c2bcd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16561960de5b416bb80606e87a745433_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI1LTE0LTEtMS0xNTU2Mzg_a7e8f666-390b-4219-b2e4-c3896943d5ff"
      unitRef="usd">128000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i2ea81c34e0794e9db360dd2193d3bf2d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTItMS0xLTE1NTYzOA_dc9f0a9f-912d-4c5a-8ff1-3ec399376339"
      unitRef="usd">4397000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i2a6657a1ee6049f2939f90c46a8b565e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTQtMS0xLTE1NTYzOA_a7a326b6-ca83-49f0-b0e7-787733fb192a"
      unitRef="usd">3849000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="ibd6cf7db6d5a49e990c0e899672f1d98_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTYtMS0xLTE1NTYzOA_8b496dc6-d2bf-43b1-a9d0-524264dddaa3"
      unitRef="usd">548000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i70512a720d8249c6a447f770e98bf667_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTEwLTEtMS0xNTU2Mzg_48573c59-50d6-463e-8362-b6183c38d0e1"
      unitRef="usd">2936000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i9410a99ac78b49fea836856840cfa817_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTEyLTEtMS0xNTU2Mzg_d46619fc-9b3d-49c3-bea7-abb41d167ed6"
      unitRef="usd">2776000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="i16561960de5b416bb80606e87a745433_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI2LTE0LTEtMS0xNTU2Mzg_6fade632-3fda-43ac-b7bc-de4fd1758c2c"
      unitRef="usd">160000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i72c04c36693542238bff2f892e06e98f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTItMS0xLTE1NTYzOA_441e2b30-58f9-491f-99ea-27b4d9922a4d"
      unitRef="usd">16000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ia6c1489c0b2445858572277f4815c6fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTQtMS0xLTE1NTYzOA_81a4c8a6-afaf-45dd-a0a1-89eb85b77cfc"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i266d5bf8ac8d461eb1d35c89e5cbf036_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTYtMS0xLTE1NTYzOA_1a6242d5-2cd4-4bc7-a601-64577593b96f"
      unitRef="usd">16000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ib53680812f8648f0b2a86cf92d5a834c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTEwLTEtMS0xNTU2Mzg_01d1e49c-84d0-4d40-b2f2-65afcda248d7"
      unitRef="usd">117000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i3401d442aa0e49cc9ca695e109e88114_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTEyLTEtMS0xNTU2Mzg_c51232b3-737f-4051-b963-59f4d164f8e1"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="iaacf9e2737204b3fb0fc33abd7e63fa4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzI5LTE0LTEtMS0xNTU2Mzg_e4a489a5-c179-48c4-b35c-2e10d318d82c"
      unitRef="usd">117000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7e8e9e1c789345cebe1a2feb0a026d46_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTItMS0xLTE1NTYzOA_3174a526-f3ce-48d9-8d23-910a3d82e2bd"
      unitRef="usd">242000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i044a5eb77497431eb9a60b053d4b39b8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTQtMS0xLTE1NTYzOA_f3033467-bfc8-4721-8edf-4fafd99aedf4"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i2fb044a8108646f5b407e315c13bc306_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTYtMS0xLTE1NTYzOA_10749c1f-f06c-4a75-84fb-d7bcb1beb09c"
      unitRef="usd">242000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="if8394064421940caaa44168cccf97ba7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTEwLTEtMS0xNTU2Mzg_114ef4a0-8a2a-49dd-b7a1-55daf834e7a6"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ifef434e9c591416e9cd79efc4e0aa93c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTEyLTEtMS0xNTU2Mzg_b1beb010-5067-4b38-98cc-ea91d702a7ff"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="ic64f9f7b7805469997412f2d21b49cff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMwLTE0LTEtMS0xNTU2Mzg_bfa7f137-f295-4741-91df-7b83c6fb232b"
      unitRef="usd">5000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i4e1030e92ca546ef841323d8c13bf48e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTItMS0xLTE1NTYzOA_276d609f-a26f-4f6a-a761-6b801694ce9f"
      unitRef="usd">259000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i32f41b9fb6664114ba8990752669ce62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTQtMS0xLTE1NTYzOA_6c7aa4a8-51c6-49be-9045-d038f329d1ea"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i4039c10bfb794c72a6cdf0439f64ad94_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTYtMS0xLTE1NTYzOA_36d8788d-3593-407a-a8b1-fba04ea607ec"
      unitRef="usd">259000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i47b0fd0f68794d0dbf248bb676c8872d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTEwLTEtMS0xNTU2Mzg_80a4479b-dafc-48c5-86ac-dc529bc917f7"
      unitRef="usd">122000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i1ad0dd09085d4434922268dce88a5be1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTEyLTEtMS0xNTU2Mzg_4ba9dd58-8787-43e8-ad95-289b7edd4f92"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="i7e9bf003cb624560a24158c89f5b413c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMxLTE0LTEtMS0xNTU2Mzg_42eea0d2-27ae-4537-a9d5-fd74e87372fc"
      unitRef="usd">122000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i4e1030e92ca546ef841323d8c13bf48e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTItMS0xLTE1NTYzOA_8560e1e6-113f-49a9-a5db-00c29f18a662"
      unitRef="usd">808000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i32f41b9fb6664114ba8990752669ce62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTQtMS0xLTE1NTYzOA_47101ccf-cf07-4de7-bb9b-28d921f5d23a"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i4039c10bfb794c72a6cdf0439f64ad94_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTYtMS0xLTE1NTYzOA_2dad020e-49dc-4f46-9166-52fd70e40e4d"
      unitRef="usd">808000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i47b0fd0f68794d0dbf248bb676c8872d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEwLTEtMS0xNTU2Mzg_b786aead-0eb3-4880-bb46-0174ca150730"
      unitRef="usd">693000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i1ad0dd09085d4434922268dce88a5be1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEyLTEtMS0xNTU2Mzg_d747b835-40c4-4736-9e1a-06a05ad61374"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="i7e9bf003cb624560a24158c89f5b413c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTE0LTEtMS0xNTU2Mzg_820b8eec-4175-4e49-b47a-d53cf5c61a03"
      unitRef="usd">693000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4e1030e92ca546ef841323d8c13bf48e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTItMS0xLTE1NTYzOA_c6841798-ece2-4ad4-a6cf-93c7ecd7d48c"
      unitRef="usd">1067000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i32f41b9fb6664114ba8990752669ce62_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTQtMS0xLTE1NTYzOA_bb2dc4ba-2857-42ff-95f1-94d504ef7eea"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4039c10bfb794c72a6cdf0439f64ad94_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTYtMS0xLTE1NTYzOA_fff3a9a3-c527-4a3e-adf4-fea98c862326"
      unitRef="usd">1067000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i47b0fd0f68794d0dbf248bb676c8872d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTEwLTEtMS0xNTU2Mzg_a3d3653d-45d7-4a38-8a86-d2cf17d4ac05"
      unitRef="usd">814000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1ad0dd09085d4434922268dce88a5be1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTEyLTEtMS0xNTU2Mzg_54d8868e-16c1-46a1-98cd-f73878c8f000"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7e9bf003cb624560a24158c89f5b413c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMzLTE0LTEtMS0xNTU2Mzg_e941cd7a-e34b-4cd2-802e-cf6b23ba0987"
      unitRef="usd">814000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6a5495ffcbab4b708606247546b1099b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTItMS0xLTE1NTYzOA_f8e7fd79-8fb9-4995-b028-0aeaeb946812"
      unitRef="usd">33552000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id64af4f01f854deba8682c77d92bad2c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTQtMS0xLTE1NTYzOA_c74d4d20-eaf7-42ce-a87e-eb619a9c4217"
      unitRef="usd">3849000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8d5b2cbf5877457a84627eb0b3ef18bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTYtMS0xLTE1NTYzOA_d937d1be-923d-48ee-bfd3-95c89588e411"
      unitRef="usd">29703000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if727b53b9c13428d8682f12d2a2a91a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTEwLTEtMS0xNTU2Mzg_e3249881-3bc2-4e9c-8b25-2ab27ad7d312"
      unitRef="usd">14278000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i4b344a25e0974083bfd701101c5fa14c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTEyLTEtMS0xNTU2Mzg_640c62ca-7ee4-4bb3-b86c-cd3383bf8429"
      unitRef="usd">2776000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i74b605fdab274710a7049bf3271f2010_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzM0LTE0LTEtMS0xNTU2Mzg_ef315302-2615-48cc-8265-ed478d78bfd6"
      unitRef="usd">11501000000</us-gaap:Assets>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="if4661b56a33040d39e0288c81b250b79_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTItMS0xLTE1NTYzOA_0659e79d-602f-4b2a-9cf8-a9c7750e7b9b"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i74421933bb0140d9aef90e0ba650d3ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTQtMS0xLTE1NTYzOA_7e03e4e7-5b0f-452e-bb61-6e234788d525"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i52caa45e571f49c4a4927dc80ab53ddc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTYtMS0xLTE1NTYzOA_16432840-1196-44c6-9531-a5143a737d65"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i059b59eb77974214a452371c05d01877_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTEwLTEtMS0xNTU2Mzg_c67a8ec8-a46a-4a96-9f66-65c6d2d2540b"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i1b28fcf96cfe404bad85bce40692dab2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTEyLTEtMS0xNTU2Mzg_484b5897-30b0-4e32-8cef-7e1eb5fc9b1c"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i391f0428ef3846feba697cee554a7311_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQwLTE0LTEtMS0xNTU2Mzg_5aecaa5f-543e-4c51-9eac-7a51b885b83b"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i971392f8a1ed4acabefb0363b735d97c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTItMS0xLTE1NTYzOA_fcfc51e0-f07f-4914-b2cf-38c0cd133d96"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="iedacf36cb97e40da88831c92a1a13dab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTQtMS0xLTE1NTYzOA_fa7c5f99-3819-48bd-a06e-f0ad4639ef53"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="ia1de3fb51d6144fd87ad3b271bddef08_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTYtMS0xLTE1NTYzOA_f6cfa852-ba51-4732-9e79-2c63601230d0"
      unitRef="usd">476000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i8ea277d746d44a1f85486e2e86259f6b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTEwLTEtMS0xNTU2Mzg_228848ec-5cc1-4562-9fdb-9cb211ad7def"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i66bc55df7fa54d8eb2c01252174f998d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTEyLTEtMS0xNTU2Mzg_1dcceb4e-dab2-4e59-8bf5-44de4bb6c795"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="i02ed3353738f4d0bbc5f8a1517448c88_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQxLTE0LTEtMS0xNTU2Mzg_d3b80ed6-fb79-4fc8-aa8f-0ef7f207739d"
      unitRef="usd">501000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8d7f920dd98641c9922cd5f40499d770_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTItMS0xLTE1NTYzOA_bf1a2766-1dfa-4200-8ccf-baa687ddec93"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7730012552f84e97b24d81ea22e392e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTQtMS0xLTE1NTYzOA_20e3e12e-a3a6-4248-a702-91416f894af2"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ic33e861c80224332a9e4e4a2669d4e87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTYtMS0xLTE1NTYzOA_2c0ec8ce-d199-4a19-b840-472f3f49bb93"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i4b128fac9ff5430ba36b5956d34c25e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTEwLTEtMS0xNTU2Mzg_21476965-d560-47d9-9045-4784f7e434db"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ib17ddb927ae6489e842698e9bbfc563f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTEyLTEtMS0xNTU2Mzg_419ca879-0170-40dd-8c23-859e8ce24527"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8e722d345f9a4cb1959d4880f98fb229_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ1LTE0LTEtMS0xNTU2Mzg_8e0c0a02-fdff-4a8f-9fea-7560aa083878"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i6b117048a90e4162b3f01f76bd79817e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTItMS0xLTE1NTYzOA_563dc102-944c-440e-bcc7-6ce36d69ed6c"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i660aa25f8def4a02a2ee5ff867c78198_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTQtMS0xLTE1NTYzOA_568cdd85-cd83-44e9-95fa-2b3c3989753d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i33a943429e8d4b39919d0b4271200bc6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTYtMS0xLTE1NTYzOA_a1aca99a-d2bc-431c-bc31-dbcee9564052"
      unitRef="usd">405000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i95769ff280e143bbbf58c6acb40fc937_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTEwLTEtMS0xNTU2Mzg_ccb189ec-556b-4d31-8956-a247012152bc"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5211751f163f4b0f91dd14ccc368ad60_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTEyLTEtMS0xNTU2Mzg_c6993b13-0097-4c66-85c5-69fe19142cf7"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id8c71733d54f40a39764458c5aa47582_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ2LTE0LTEtMS0xNTU2Mzg_b0a82844-20d3-4b73-813c-24549d4c8ac6"
      unitRef="usd">599000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="i660aa25f8def4a02a2ee5ff867c78198_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTQtMS0xLTE1NTYzOA_07c1b247-14db-41ec-b5c4-efc3e2ccf61c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i33a943429e8d4b39919d0b4271200bc6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTYtMS0xLTE1NTYzOA_6bbeb90b-d7f8-4e33-bae4-28c2d1d4cfac"
      unitRef="usd">881000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i95769ff280e143bbbf58c6acb40fc937_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTEwLTEtMS0xNTU2Mzg_c83af4f1-51e0-4758-85c4-925ffbcf0a76"
      unitRef="usd">1100000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5211751f163f4b0f91dd14ccc368ad60_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTEyLTEtMS0xNTU2Mzg_d38f112d-f669-4a9e-b186-34a683f8fa23"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id8c71733d54f40a39764458c5aa47582_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzQ3LTE0LTEtMS0xNTU2Mzg_e1023e6f-b141-42d5-a6df-c3505ad09b66"
      unitRef="usd">1100000000</us-gaap:DerivativeLiabilities>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="i6a5495ffcbab4b708606247546b1099b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzIyNA_eb1f4a56-45dc-4b66-8ac6-3d0559d8c013"
      unitRef="usd">194000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="if727b53b9c13428d8682f12d2a2a91a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzI0MA_6753646b-f55d-4c61-8d5f-8f88dd758b2f"
      unitRef="usd">190000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDYwNzU_d9f8859f-046b-4f91-95ba-7624fe32206a"
      unitRef="usd">36000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDYwODI_d47be7b7-42b6-4234-81d1-e30f6850f6f5"
      unitRef="usd">37000000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9a15e9f4278a4ea88fac685bd5263002_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDU0OTE_045ad6ab-fed6-4d84-bf53-31076cc669e1"
      unitRef="usd">42000000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="iaf5508327199483d8b8486b1d9a35897_I20201231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzE2NDkyNjc0NDU1MTA_519dae90-50e4-41a8-b160-5154e9ba6c8c"
      unitRef="usd">46000000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg4MQ_083dfa8c-6b68-4606-a849-e8621e31ab17">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes our investments by classification type:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,125&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,876&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;521&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Private equity securities at cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Total Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,054&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,472&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,526&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;268&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represent investments in the life sciences sector.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtMi0xLTEtMTU1NjM4_eac59ed0-b395-4f44-91ec-98b484b8f4b4"
      unitRef="usd">5365000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtNC0xLTEtMTU1NjM4_5e0bc421-d01b-4490-af80-b7bf03c05d79"
      unitRef="usd">567000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzUtMi0xLTEtMTU1NjM4_7f6dfefd-26ed-4f49-99cd-9f093e801983"
      unitRef="usd">22014000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzUtNC0xLTEtMTU1NjM4_c0e6aeb9-aed0-4eed-8a7e-3bbbab139d61"
      unitRef="usd">9709000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzYtMi0xLTEtMTU1NjM4_2ff3046c-f92a-4611-9d05-428d46afe2a3"
      unitRef="usd">1746000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzYtNC0xLTEtMTU1NjM4_bf8899a4-9f22-448d-8d9f-fa752c706ef8"
      unitRef="usd">161000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:OtherShortTermInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzctMi0xLTEtMTU1NjM4_f9e13b2a-f1a7-4f23-95bf-ff6a6e6ab519"
      unitRef="usd">29125000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzctNC0xLTEtMTU1NjM4_086e9ad3-a135-4df0-ad62-f8d2dd91a472"
      unitRef="usd">10437000000</us-gaap:OtherShortTermInvestments>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEwLTItMS0xLTE1NTYzOA_4612ee98-aa8e-47ea-9ed3-88eee03a60be"
      unitRef="usd">3876000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEwLTQtMS0xLTE1NTYzOA_2b2c8cfd-1d35-4b4e-bba8-9e6028719705"
      unitRef="usd">2809000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzExLTItMS0xLTE1NTYzOA_395cea86-d322-4642-922d-7e1756fc2766"
      unitRef="usd">521000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzExLTQtMS0xLTE1NTYzOA_2e611b16-7f64-41a9-bc0c-9e449446af70"
      unitRef="usd">128000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEyLTItMS0xLTE1NTYzOA_9f48646c-4eff-4264-9a89-ab729425a24e"
      unitRef="usd">34000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEyLTQtMS0xLTE1NTYzOA_d9bdd317-656a-455e-bbb7-12902dcad813"
      unitRef="usd">37000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <pfe:PrivateEquityInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTItMS0xLTE1NTYzOA_a7bec050-b698-4726-bd56-085e3fa47cb8"
      unitRef="usd">623000000</pfe:PrivateEquityInvestments>
    <pfe:PrivateEquityInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTQtMS0xLTE1NTYzOA_a037f3fe-76de-4e3a-b45e-df594d2e8044"
      unitRef="usd">432000000</pfe:PrivateEquityInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE0LTItMS0xLTE1NTYzOA_fdba4ba5-40ac-4519-ba1f-970d6e1ff1cd"
      unitRef="usd">5054000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE0LTQtMS0xLTE1NTYzOA_0b1d02ff-b7ae-4a66-a5a4-ba8265fc7555"
      unitRef="usd">3406000000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE1LTItMS0xLTE1NTYzOA_e92117e2-65e3-4f39-84f8-806cf6c260a2"
      unitRef="usd">16472000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE1LTQtMS0xLTE1NTYzOA_ddb656d3-819d-4cb0-909e-51aef1d4e357"
      unitRef="usd">16856000000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE2LTItMS0xLTE1NTYzOA_456f4f6e-57ea-431d-9117-b6b00a8a0624"
      unitRef="usd">21526000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE2LTQtMS0xLTE1NTYzOA_291aa6a5-bb88-4ce4-9c06-ea6e3f71fa23"
      unitRef="usd">20262000000</us-gaap:LongTermInvestments>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE3LTItMS0xLTE1NTYzOA_fa68f9d1-13ce-4b04-80df-60822d32524f"
      unitRef="usd">268000000</pfe:HeldToMaturityCashEquivalents>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzE3LTQtMS0xLTE1NTYzOA_cceb43b9-59c0-4b2a-98cd-c66408afde9b"
      unitRef="usd">89000000</pfe:HeldToMaturityCashEquivalents>
    <us-gaap:HeldToMaturitySecuritiesTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg4Mg_80856edf-9864-486a-ab7f-95514daf2541">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;697&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;917&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,097&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,029&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwNA_2df1a97f-d0a1-4779-b422-6eaee3de855f">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;697&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;917&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,097&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,029&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkxMg_d7989c1a-1d4f-42f9-bb7c-c68d34244514">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, our investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="42" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="18" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Maturities (in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Within 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Over 5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;17,318&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Corporate and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;698&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;697&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;50&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;947&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;917&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Government and agency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,097&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,835&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;14&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;24,029&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMi0xLTEtMTU1NjM4_92b1a056-d0eb-4c53-8113-1a74b68b9504"
      unitRef="usd">18032000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtNC0xLTEtMTU1NjM4_c8ae0638-27f8-4919-a147-4a8e615ba391"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtNi0xLTEtMTU1NjM4_3d671f58-5ed6-4ba3-9f30-30dcbab947df"
      unitRef="usd">263000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtOC0xLTEtMTU1NjM4_f7357671-942d-486d-8c27-75922ab9dc95"
      unitRef="usd">17783000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTAtMS0xLTE1NTYzOA_55ca12fa-66a6-435e-8517-c19a9779bd22"
      unitRef="usd">17318000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTItMS0xLTE1NTYzOA_d5eeb6cc-d833-4772-bc79-3b3ae70a44d7"
      unitRef="usd">465000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTQtMS0xLTE1NTYzOA_349494c0-3977-46d8-8699-5f7708d672cf"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTYtMS0xLTE1NTYzOA_9e98073d-bcee-4468-8901-baeb16ad6ef6"
      unitRef="usd">7593000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMTgtMS0xLTE1NTYzOA_fa32a791-aca2-421c-83ae-9ca8088cfb83"
      unitRef="usd">136000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMjAtMS0xLTE1NTYzOA_f7bd4f3a-8927-4098-8864-c4d01bdd9b36"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzUtMjItMS0xLTE1NTYzOA_a97cd337-3aba-415f-a755-4aed724c6603"
      unitRef="usd">7725000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMi0xLTEtMTU1NjM4_b1c426f2-7069-41fc-b774-335ea603adc8"
      unitRef="usd">4056000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtNC0xLTEtMTU1NjM4_a0350c50-060f-4352-ba6e-0d2752409c46"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtNi0xLTEtMTU1NjM4_d35ecb1d-3b75-4adb-ba87-487b00d06b36"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtOC0xLTEtMTU1NjM4_3c88b5df-508f-479a-b6ed-f8152e9175b4"
      unitRef="usd">4055000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTAtMS0xLTE1NTYzOA_b552cf2d-2d33-4798-883d-c15d460a2e6f"
      unitRef="usd">4050000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTItMS0xLTE1NTYzOA_e3b7c8c0-2f59-47ab-9ee4-5384f6718760"
      unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="i9963f3c49e9547c8bd245f5a63f96465_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTQtMS0xLTE1NTYzOA_15c28168-8f05-4b90-9b30-3cda018fc402"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTYtMS0xLTE1NTYzOA_03784a85-02fe-4a91-bff5-9584f95c28a5"
      unitRef="usd">1104000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMTgtMS0xLTE1NTYzOA_c327c002-e943-40ba-bdd5-90e0a68c8f58"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMjAtMS0xLTE1NTYzOA_7c369d8c-7ce4-4ceb-8c30-4de3d2bf2458"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0b060f3cbd744f2daffdc98afb7b13b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzYtMjItMS0xLTE1NTYzOA_4078a91e-7435-47eb-a9e7-be6c0616ade3"
      unitRef="usd">1103000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMi0xLTEtMTU1NjM4_2c136b2e-c6a9-4d0f-9892-05a26d8d7323"
      unitRef="usd">698000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctNC0xLTEtMTU1NjM4_89ab55aa-e486-4d56-8d2b-66f90620add7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctNi0xLTEtMTU1NjM4_883708d4-b23b-4c93-8dd1-5ebfb9b3a9f4"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctOC0xLTEtMTU1NjM4_af9d1192-2218-46a4-b9b1-8929be91f868"
      unitRef="usd">697000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTAtMS0xLTE1NTYzOA_94284635-8e10-4ee1-bd30-506a0cd57bbd"
      unitRef="usd">647000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTItMS0xLTE1NTYzOA_77bb7a2e-99e3-4716-a836-cb826446dc97"
      unitRef="usd">50000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="ifa5eb68768ad4f129e49070a05f2a51d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTQtMS0xLTE1NTYzOA_fde94977-0e76-43bd-8a70-3e6fd47a60b8"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTYtMS0xLTE1NTYzOA_f3988a45-b3c6-42d1-aca2-c994b47773fc"
      unitRef="usd">1006000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMTgtMS0xLTE1NTYzOA_2e977ddd-1030-41eb-a6e0-42af1ec14082"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMjAtMS0xLTE1NTYzOA_181cb716-b35f-4697-ae35-549df5e0b01d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief5f1d4e79fe42ec8b2db5e63a25f506_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzctMjItMS0xLTE1NTYzOA_b39e99b2-1900-40b4-ad0c-f6fc24dccf05"
      unitRef="usd">1008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i5b38f67d770f409b806366759e0b2089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMi0xLTEtMTU1NjM4_011f2e31-f3eb-4225-b209-ccf9d5bcfda1"
      unitRef="usd">947000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i5b38f67d770f409b806366759e0b2089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktNC0xLTEtMTU1NjM4_0462df6e-55ee-4d95-a507-991c16b0174d"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i5b38f67d770f409b806366759e0b2089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktNi0xLTEtMTU1NjM4_3a31a32e-2054-4cfd-8474-a37ea2377442"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5b38f67d770f409b806366759e0b2089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktOC0xLTEtMTU1NjM4_8afbdaba-ab6e-4af8-a243-a3bcb33a0181"
      unitRef="usd">947000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5b38f67d770f409b806366759e0b2089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTAtMS0xLTE1NTYzOA_636260cb-3d2f-4afe-b41a-edd22352c7bc"
      unitRef="usd">917000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i5b38f67d770f409b806366759e0b2089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTItMS0xLTE1NTYzOA_445c3664-628e-49f3-b01d-5a6170b3849b"
      unitRef="usd">18000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="i5b38f67d770f409b806366759e0b2089_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTQtMS0xLTE1NTYzOA_49f94f4d-925d-42f7-8b8f-e98d42db5cfb"
      unitRef="usd">11000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTYtMS0xLTE1NTYzOA_ea933433-798d-4205-aa6b-a16a8bfbced8"
      unitRef="usd">283000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMTgtMS0xLTE1NTYzOA_5eebab0e-fba3-4159-8f20-7e723fa595e4"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMjAtMS0xLTE1NTYzOA_df503ae1-bd19-4c70-af7d-ea26a188a0fa"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="idfa108cbd7564f07a6abba1a44e49cc4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzktMjItMS0xLTE1NTYzOA_2184c78e-d7c8-41e2-b4dc-30c0ee08f592"
      unitRef="usd">283000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTItMS0xLTE1NTYzOA_9f17995a-3f17-4cbb-8f48-bdcad11b0ee7"
      unitRef="usd">1102000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTQtMS0xLTE1NTYzOA_e95b769f-79c8-4b42-af8d-8c296ace86e4"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTYtMS0xLTE1NTYzOA_fc18df76-fbaa-4fe1-8bd2-8ab7606307c1"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTgtMS0xLTE1NTYzOA_40f80324-9dbb-4f91-8994-044f89aad2b6"
      unitRef="usd">1102000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTEwLTEtMS0xNTU2Mzg_709107bb-3da1-4e5f-aee8-bef0a573f15b"
      unitRef="usd">1097000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTEyLTEtMS0xNTU2Mzg_ab03b990-c916-42c5-8749-793b3cade05a"
      unitRef="usd">4000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="i5ec3edcb4a104dd28abf353e65230c1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTE0LTEtMS0xNTU2Mzg_94ddb736-0a04-4c26-bab6-c686f464a60c"
      unitRef="usd">1000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTE2LTEtMS0xNTU2Mzg_0fcce6d8-139d-48a6-8c53-be2d6d351f1b"
      unitRef="usd">5000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTE4LTEtMS0xNTU2Mzg_24ff06dc-e638-497f-af59-1afaac68cfce"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTIwLTEtMS0xNTU2Mzg_db4000e3-0380-494f-bf46-56ef516f8729"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i687b62defe464388a420482db5f02ab4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzEwLTIyLTEtMS0xNTU2Mzg_240e4817-4c47-4b5d-a209-aaf6bcdd3aa7"
      unitRef="usd">5000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTItMS0xLTE1NTYzOA_7a1fca54-ba83-4296-9aea-ffa8a9e26709"
      unitRef="usd">24835000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTQtMS0xLTE1NTYzOA_e8b4ef09-d971-4165-b9cf-4d84814372f0"
      unitRef="usd">14000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTYtMS0xLTE1NTYzOA_d463bfe2-04b6-4fd5-a49b-8601bb45348c"
      unitRef="usd">265000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTgtMS0xLTE1NTYzOA_975b6273-7178-4f33-99c4-7c286065a5aa"
      unitRef="usd">24584000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTEwLTEtMS0xNTU2Mzg_3aa2716b-b3f5-4492-8f41-7183f953b32d"
      unitRef="usd">24029000000</pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue>
    <pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTEyLTEtMS0xNTU2Mzg_d8f1214e-83f3-47af-b8e9-f998b0b666e9"
      unitRef="usd">543000000</pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue>
    <pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTE0LTEtMS0xNTU2Mzg_962b2150-4e18-4a9a-8e7b-fc33803286bc"
      unitRef="usd">13000000</pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTE2LTEtMS0xNTU2Mzg_f47c9161-fc38-4c21-a3d0-cb618afedee9"
      unitRef="usd">9991000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTE4LTEtMS0xNTU2Mzg_9166548a-e3bd-4d2c-9c9a-e9f3a9580618"
      unitRef="usd">138000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTIwLTEtMS0xNTU2Mzg_25453e19-11c9-45c0-96e4-4774cfd73b8b"
      unitRef="usd">5000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpmYmNjNjIyZGJlZTk0NzRhYmUzZTE2MjAyNzgyOTZjNy90YWJsZXJhbmdlOmZiY2M2MjJkYmVlOTQ3NGFiZTNlMTYyMDI3ODI5NmM3XzExLTIyLTEtMS0xNTU2Mzg_1325d903-7fd7-44db-8dfe-230bcd896d50"
      unitRef="usd">10124000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5MQ_fbd89d64-1b6b-4748-bc95-a2d6a35f3bbc">&lt;div style="margin-top:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.228%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity method investments, held at the reporting date:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains)/losses recognized during the period on equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,344)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(454)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains)/losses recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(515)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;net.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $97 million and upward adjustments of $156 million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtMi0xLTEtMTc3Nzcz_1412e961-c1d0-4724-998b-2b5f26860881"
      unitRef="usd">1344000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNC0xLTEtMTU1NjM4_704706b6-4bd6-4188-ab0c-928c0e14cea6"
      unitRef="usd">540000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
      unitRef="usd">454000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzQtMi0xLTEtMTU1NjM4_6066ba3a-f027-44f7-8111-51321a3c9818"
      unitRef="usd">80000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzQtNC0xLTEtMTU1NjM4_83c96879-57d9-44a7-b57d-eb3c17203450"
      unitRef="usd">24000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzQtNi0xLTEtMTU1NjM4_031a6ec7-2ed6-4b5c-b168-997830e99b30"
      unitRef="usd">25000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtMi0xLTEtMTU1NjM4_5a7da2e0-b310-4992-9ead-53d778086a59"
      unitRef="usd">1264000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNC0xLTEtMTU1NjM4_7610cbaa-8fc4-4815-b1d5-99eac4d0bbb0"
      unitRef="usd">515000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNi0xLTEtMTU1NjM4_3213929f-51ad-4505-8713-b09ae07ab6ff"
      unitRef="usd">429000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzc2Mw_7a40c052-d00a-4d75-af04-723920066f1e"
      unitRef="usd">97000000</pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzc5Mg_010492f4-b192-4078-a78d-44937014c7e0"
      unitRef="usd">156000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzczOQ_6f609302-2dbf-4d59-a452-f36bd5684b06">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.840%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;605&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes cash collateral. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7F&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:CommercialPaper
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzMtMi0xLTEtMTU1NjM4_c68e4e66-9e15-4661-94de-43d3c293c71a"
      unitRef="usd">0</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzMtNC0xLTEtMTU1NjM4_2938a3e4-12c9-4084-9f65-1b8196126544"
      unitRef="usd">556000000</us-gaap:CommercialPaper>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzQtMi0xLTEtMTU1NjM4_ab9592b6-d6eb-4a50-9e4a-8ebf8fd3acc1"
      unitRef="usd">1636000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzQtNC0xLTEtMTU1NjM4_73f21de6-0bcc-4b37-9db5-860429fda96c"
      unitRef="usd">2004000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <us-gaap:OtherShortTermBorrowings
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtMi0xLTEtMTU1NjM4_94dbdfbe-5859-4c23-9d8d-2d3e183bbfd0"
      unitRef="usd">605000000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtNC0xLTEtMTU1NjM4_dd146452-18dc-4d23-a080-83e4f78e3d3b"
      unitRef="usd">145000000</us-gaap:OtherShortTermBorrowings>
    <pfe:ShorttermDebtGross
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzYtMi0xLTEtMTU1NjM4_5234f086-0deb-4eb7-a281-902ab5c2ca19"
      unitRef="usd">2241000000</pfe:ShorttermDebtGross>
    <pfe:ShorttermDebtGross
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzYtNC0xLTEtMTU1NjM4_1333ca5f-ffae-4f64-a68f-0cda7d65b967"
      unitRef="usd">2705000000</pfe:ShorttermDebtGross>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzgtMi0xLTEtMTU1NjM4_09dd6443-07dc-495b-9920-830609a5b819"
      unitRef="usd">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzgtNC0xLTEtMTU1NjM4_4f36ead3-6d2b-4e9b-b17c-c77730a94a81"
      unitRef="usd">2000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzktMi0xLTEtMTU1NjM4_c393ed62-e401-4edc-bed6-b0bfbb1e451e"
      unitRef="usd">2241000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzktNC0xLTEtMTU1NjM4_fd1c67f1-5c2e-4f1a-8e74-7bcd6c050fca"
      unitRef="usd">2703000000</us-gaap:DebtCurrent>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="ibe045779c301429da73c967dc0c4fef3_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzIxOQ_5764537c-d817-4ff5-9567-19d71150477b"
      unitRef="number">0.0013</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7b8d95576ec143738ffeac1cac97942a_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzI3MA_130f3b0c-50f5-4d94-b5af-313ffa7263d2"
      unitRef="usd">7000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib87e561cb5e04d748723b1e3acc726a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzYyMg_c4993439-fcc6-432b-b478-ed83eaf0f15f"
      unitRef="usd">360000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <pfe:LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear
      contextRef="ib87e561cb5e04d748723b1e3acc726a0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzY1NA_486f505c-9288-4eb4-bb3d-3e84cae34aaa"
      unitRef="usd">322000000</pfe:LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mzc_4774dfa0-3621-4bfc-8921-7d595718e039">&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following outlines our senior unsecured long-term debt and the weighted-average stated interest rate by maturity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2022 (1.0% for 2020)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2023 (3.2% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,550&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2024 (3.9% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2025 (0.8% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2026 (2.9% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2027 (2.1% for 2021 and 2.0% for 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,051&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2028-2032 (3.1% for 2021 and 3.4% for 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,660&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2033-2037 (5.6% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2038-2042 (5.5% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2043-2047 (3.7% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,858&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notes due 2048-2050 (3.6% for 2021 and 2020)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,500&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,948&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36,195&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reclassified to the current portion of long-term debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our long-term debt outlined in the above table is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Issuances&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.368%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In August 2021, we issued the following senior unsecured notes at an effective interest rate of 1.79%:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.750%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;August&#160;18, 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ic5e7c524a0cf45b6a07e42355b143830_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246YzM0MDEzMDZlNWU3NDcxNDk3ODlmYTMwYzIxOGFiNzJfMTIwOTQ2Mjc5MDU2Mjc_00de34fa-8fc3-4cfa-92e4-794ddef2a04f"
      unitRef="number">0.010</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2cb403f6b8f742a98ca63fc690188314_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMi0xLTEtMTU1NjM4_d0719a5a-8f70-4d72-8488-4163b8e663c2"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic5e7c524a0cf45b6a07e42355b143830_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtNC0xLTEtMTU1NjM4_fcff6e04-cf91-4aab-a1bf-9b6b771c59d2"
      unitRef="usd">1728000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i3bae6de665ed403789bfbe721f25e08b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MGNlMzFkNjcyYjkwNDI3NThkMjJiMThjMDRhNTRmMTBfMjA_54f192ed-e3a9-45c4-98ec-d9ddcce323c2"
      unitRef="number">0.032</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i3147b1fbc1bd43a2a4e14a4f08917b76_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MGNlMzFkNjcyYjkwNDI3NThkMjJiMThjMDRhNTRmMTBfMjA_669a822a-a73e-46c2-b475-6a586219ece0"
      unitRef="number">0.032</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3bae6de665ed403789bfbe721f25e08b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtMi0xLTEtMTU1NjM4_ff18272b-935a-41cd-a603-1af12a0c59d2"
      unitRef="usd">2550000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3147b1fbc1bd43a2a4e14a4f08917b76_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzUtNC0xLTEtMTU1NjM4_acb69870-5b71-40a7-8bea-98705a18510e"
      unitRef="usd">2550000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="if62b572a74364f54934ae9592882c5ff_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MDM3NTM3NmY3YzBkNGM0MTk5MWU1YmJlNmY5MzQ1NjVfMjA_1d9e0e92-70cd-49ef-82c3-80808fe93f51"
      unitRef="number">0.039</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ib981a715bfdd4b488f432d8966a210fe_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246MDM3NTM3NmY3YzBkNGM0MTk5MWU1YmJlNmY5MzQ1NjVfMjA_e212f962-4fa3-4e88-9cf8-9bced6c2f589"
      unitRef="number">0.039</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib981a715bfdd4b488f432d8966a210fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtMi0xLTEtMTU1NjM4_5cde5dec-f4b6-444a-896f-af8b9c6c7cfa"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if62b572a74364f54934ae9592882c5ff_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzYtNC0xLTEtMTU1NjM4_cb9983e4-0603-4fa3-924a-7ad4a2942264"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ie795359bbbc64f42b3251279ad6b39c1_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctMC0xLTEtMTU1NjM4L3RleHRyZWdpb246YTI1MzUwOTU1OGUxNDViNmIyZjI5OTk1NDg0ZTE3NDNfMjA_60f7b7aa-7295-4294-9218-8d4bcaaec7f6"
      unitRef="number">0.008</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i2cf98b9fedf540bc805e6e4573df80ae_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctMC0xLTEtMTU1NjM4L3RleHRyZWdpb246YTI1MzUwOTU1OGUxNDViNmIyZjI5OTk1NDg0ZTE3NDNfMjA_f46c39b2-87b3-44aa-9877-3335d3946025"
      unitRef="number">0.008</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2cf98b9fedf540bc805e6e4573df80ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctMi0xLTEtMTU1NjM4_433a8eb6-a9bb-4e32-8356-992faf74b447"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie795359bbbc64f42b3251279ad6b39c1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzctNC0xLTEtMTU1NjM4_975c7f47-109c-472b-b265-6cc67ae2e715"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i66c8b6ecab3d40c483eb2e43be3fb7a3_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYxZTVkY2ExNGE2NDM0Zjk3ZjQxYWUwYWE2MDU5MDdfMjA_c19cfd7b-8054-48e0-9c8e-c4c4f27521a7"
      unitRef="number">0.029</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ie28c7ac7e9a14c6793a223d8dc99e719_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtMC0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYxZTVkY2ExNGE2NDM0Zjk3ZjQxYWUwYWE2MDU5MDdfMjA_f8fbe43f-1bc9-4b03-8a5f-76c78ca6e191"
      unitRef="number">0.029</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie28c7ac7e9a14c6793a223d8dc99e719_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtMi0xLTEtMTU1NjM4_16742f28-b3c6-4386-a3a6-f221f6597b7e"
      unitRef="usd">3000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i66c8b6ecab3d40c483eb2e43be3fb7a3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzgtNC0xLTEtMTU1NjM4_9b81b2ac-b807-4b91-8ccb-377b37eeff5f"
      unitRef="usd">3000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ib90c748be7c2480295ad0c48f90c8398_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246ZTM3ZjFkN2I5ZDYzNGEyYzkyNTlmZmE2YTA0OGM0NTRfMjU_5bc5acbb-09c6-413f-b1c6-199a755e003f"
      unitRef="number">0.021</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ifc5564b52b29440f930fbe373023198e_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246ZTM3ZjFkN2I5ZDYzNGEyYzkyNTlmZmE2YTA0OGM0NTRfNDE_e1fb36c8-16b3-485e-b755-3f0c819f05fb"
      unitRef="number">0.020</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib90c748be7c2480295ad0c48f90c8398_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktMi0xLTEtMTU1NjM4_1640f868-7f39-4ca5-9977-4d90b495d986"
      unitRef="usd">1051000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ifc5564b52b29440f930fbe373023198e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzktNC0xLTEtMTU1NjM4_90f3c8fe-4edf-4f31-a50f-bf35b94f4cc2"
      unitRef="usd">1121000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i91d3d8e7604d481c8c76134979113fe2_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNmOGI2YjkxMmJhNjQwOTI4Nzg0OWQzZjAwZWY4NmQ3XzI1_645cd45c-4933-401d-a097-c37b43753d07"
      unitRef="number">0.031</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i245fc7da45bc4ff69d0b71a3f9034fcd_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNmOGI2YjkxMmJhNjQwOTI4Nzg0OWQzZjAwZWY4NmQ3XzE1OTQyOTE4NjAyODI4_d3c3faa4-8b9e-405e-9807-5a2dcc004061"
      unitRef="number">0.034</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i91d3d8e7604d481c8c76134979113fe2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTItMS0xLTE1NTYzOA_6fca44e4-b736-4987-9c3f-e893b305702a"
      unitRef="usd">6660000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i245fc7da45bc4ff69d0b71a3f9034fcd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEwLTQtMS0xLTE1NTYzOA_46b00bbe-4e01-4c87-9349-3a379faccfac"
      unitRef="usd">5660000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i15b85141bb6247309c0b1758b23b1d09_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjFmMjAwN2Q5NWIyNzQzOGU5NjMwNjRhOTQyMzExMTM3XzI1_b6c851e0-7c83-4dde-8b8b-321402a471d4"
      unitRef="number">0.056</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="iaf8cbda9015c407c87c364cc6e12a77d_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjFmMjAwN2Q5NWIyNzQzOGU5NjMwNjRhOTQyMzExMTM3XzI1_e75b8177-077a-4cbe-99bc-0697e91da370"
      unitRef="number">0.056</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaf8cbda9015c407c87c364cc6e12a77d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTItMS0xLTE1NTYzOA_3392dd72-76cf-4346-a4cd-9e251247e3a7"
      unitRef="usd">4250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i15b85141bb6247309c0b1758b23b1d09_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzExLTQtMS0xLTE1NTYzOA_d74a31c6-18cc-4961-a384-eb07aee3deba"
      unitRef="usd">4250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="icb5bd2da85b845cfa033f3fccf9badef_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNkMGMwMjViODQxNjQ1ZWRhZDQ1M2EzZTk5MDE3NjAxXzI1_cff89260-8877-4fbf-a986-a75ad2d0f274"
      unitRef="number">0.055</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i9525871ed73f44d6aa391c6a1148f943_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjNkMGMwMjViODQxNjQ1ZWRhZDQ1M2EzZTk5MDE3NjAxXzI1_de86f4f5-4191-4d96-b380-28c05c008163"
      unitRef="number">0.055</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9525871ed73f44d6aa391c6a1148f943_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTItMS0xLTE1NTYzOA_b25db178-d4c2-4ac8-9cac-d1a55d301b7e"
      unitRef="usd">6079000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icb5bd2da85b845cfa033f3fccf9badef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEyLTQtMS0xLTE1NTYzOA_ff99bbe6-7c9a-4b4c-8bc2-f3728199cded"
      unitRef="usd">6086000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i21459a6d65ad49e68898cea099e9eefe_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmZiZDAyYmU2ZGQ2ODRlNTNiNGZjMTNiM2I5NTkzMWYwXzI1_64ab3ffb-09bb-47ef-bd56-cb7bb5ddda7e"
      unitRef="number">0.037</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i6fc4b12027964c209dd3f92de86d4757_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmZiZDAyYmU2ZGQ2ODRlNTNiNGZjMTNiM2I5NTkzMWYwXzI1_7f2710f4-7f2f-4ebb-a01e-d77504c175c9"
      unitRef="number">0.037</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6fc4b12027964c209dd3f92de86d4757_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTItMS0xLTE1NTYzOA_3d4bdd3c-b945-42b3-b90d-4cfaa664fc6b"
      unitRef="usd">4858000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i21459a6d65ad49e68898cea099e9eefe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTQtMS0xLTE1NTYzOA_d35c410f-2d27-42d9-8423-3b7309cd6101"
      unitRef="usd">4878000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="if76ee4034a204733a425e8616536a46d_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTIzNjk4Mi90ZXh0cmVnaW9uOmYzN2E1ZTViNzFhOTQ0NDBiNTI1OTFmODhjYWVjYjFjXzEyMDk0NjI3OTA1NTY2_6563e6ae-df5b-476c-a07b-cbf636aadca2"
      unitRef="number">0.036</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i4b3c3f8d66c14cbc8ae2209a47f7b04f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTAtMS0xLTIzNjk4Mi90ZXh0cmVnaW9uOmYzN2E1ZTViNzFhOTQ0NDBiNTI1OTFmODhjYWVjYjFjXzEyMDk0NjI3OTA1NTY2_7f8c62fe-5eef-49b6-af2d-eb5f5e15e7a1"
      unitRef="number">0.036</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4b3c3f8d66c14cbc8ae2209a47f7b04f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTItMS0xLTIzNzA5Mw_aa2c053a-6975-4f1b-aaee-fb28d2dd91aa"
      unitRef="usd">3500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if76ee4034a204733a425e8616536a46d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzEzLTQtMS0xLTIzNzYyMw_3eb73003-d726-4ef6-aaae-823e33346740"
      unitRef="usd">3500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE0LTItMS0xLTE1NTYzOA_95383b03-1cc5-4c52-bb0a-4f9bffaa43a6"
      unitRef="usd">34948000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE0LTQtMS0xLTE1NTYzOA_08dd2c52-ee4d-475e-adf4-7017031bf4c5"
      unitRef="usd">35774000000</us-gaap:DebtInstrumentCarryingAmount>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE1LTItMS0xLTE1NTYzOA_2f2e27e2-798f-4868-bb36-1669fbffb815"
      unitRef="usd">1438000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE1LTQtMS0xLTE1NTYzOA_6bc84e75-1548-44ad-b5f9-5671485eb369"
      unitRef="usd">1562000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE2LTItMS0xLTE1NTYzOA_b030497a-0441-45c2-87e7-81e7bfb9d223"
      unitRef="usd">195000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE2LTQtMS0xLTE1NTYzOA_4b5ea304-4217-4cf8-97d9-2df27314d56b"
      unitRef="usd">207000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:OtherLongTermDebt
      contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE3LTItMS0xLTE1NTYzOA_fd341ed1-22de-443d-93ed-eefcd9d3db19"
      unitRef="usd">4000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE3LTQtMS0xLTE1NTYzOA_25cbe2af-6246-4bb8-ab9a-c5459102df1f"
      unitRef="usd">4000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE4LTItMS0xLTE1NTYzOA_ecbf7fd9-65f9-4dac-be8f-c1068ac85142"
      unitRef="usd">36195000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE4LTQtMS0xLTE1NTYzOA_0491606f-db1c-4db1-ae54-c4185dc3bf68"
      unitRef="usd">37133000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmRmMGQyNDkzZGVlZDQ0NzQ4NTc4Y2ExODAyOTQxMTY3XzEwNA_8953588b-5a17-463d-b98a-f6809cf31ea0"
      unitRef="number">0.010</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTAtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOmRmMGQyNDkzZGVlZDQ0NzQ4NTc4Y2ExODAyOTQxMTY3XzExMQ_bac68bde-7d76-4f00-825b-2a8834a35879"
      unitRef="number">0.026</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:LongTermDebtCurrent
      contextRef="i002328e67ca24b3c928fb4df0a88e15a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTItMS0xLTE1NTYzOA_0ead3812-90db-4268-9681-e8d5f95c3317"
      unitRef="usd">1636000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ife593b88c8974bd987809c90a29a6b72_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzE5LTQtMS0xLTE1NTYzOA_5e8d987f-bbf5-4a3b-ab1b-12e28dcc823c"
      unitRef="usd">2002000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzAtMC0xLTEtMTcyNTAyL3RleHRyZWdpb246NmM2MTAyM2E5NzBmNGI5YWI4MTIyZWU0NjlhZGM4NzdfMTE0_f41761c6-511a-489b-a2c4-d80f35398370"
      unitRef="number">0.0179</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246Y2IyMGJkMzcyODA4NGEwMmJmZTljMDUyMTRiMWZjNmNfMTUzOTMxNjI3ODg4ODA_775c18f7-b166-4b7f-9eb2-d8e4c8d70788"
      unitRef="number">0.01750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktNC0xLTEtMTU1NjM4_c41e5f42-b905-4960-9834-889541822283"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie5c6cb1e41494eb09f678d0edb941748_I20200531"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3NDk_27caf779-76c6-46fe-a665-925a0ed3328c"
      unitRef="usd">4000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="ie5c6cb1e41494eb09f678d0edb941748_I20200531"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzY1OTcwNjk3NzAyMTQ_4e569f24-27d0-4ece-a29d-74396502d91a"
      unitRef="number">0.0211</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9d7b65d44132448f82b9c8c9f19d2196_I20200331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3Njc_19936d0f-4749-4490-af2a-4767afae1dec"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i9d7b65d44132448f82b9c8c9f19d2196_I20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3ODY_c3ee08fb-68f2-40a1-9e23-44acb31e56f8"
      unitRef="number">0.0267</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7b576060fcf349178ba58a38684ce7d4_I20190331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU3OTQ_00f77a93-d52b-401a-859c-a7b63e781603"
      unitRef="usd">5000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i7b576060fcf349178ba58a38684ce7d4_I20190331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2NDkyNjc0NDU4MjA_c27881a8-f2b5-4e69-9b30-73d0526701a0"
      unitRef="number">0.0357</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i819cd9fe271b4f23b98c4aa8123518f4_I20201130"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEwMTM_40cf44c3-8912-43d0-bbdd-fba3132755b6"
      unitRef="usd">1150000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i764ea60e3c5843d187463c0e16bc3a31_I20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEwMjA_0cc7260d-112f-4e32-bd31-983315722431"
      unitRef="usd">342000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i819cd9fe271b4f23b98c4aa8123518f4_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEwNTk_7a88895b-f224-4166-8d0d-50de6f3b1af8"
      unitRef="number">0.0195</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i764ea60e3c5843d187463c0e16bc3a31_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzExMDM_17d59131-de28-493e-aa3b-8f9122da050e"
      unitRef="number">0.0580</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i44be768342d5410a8bc44e78dbfd764a_D20201101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzExNzg_a1a0d450-cdde-4a6d-bc7e-b9619bef4c94"
      unitRef="usd">-36000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="ibffce84ee6544fab8b3ff9dad69b30c5_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEyNzE_260c3f8a-941a-466c-8875-53a6f44490c9"
      unitRef="usd">1065000000.000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEzODI_aa7ec76b-a26d-449f-b356-fbf64c0f0c09"
      unitRef="eur">1100000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzEzODY_0d1dbf69-5ae9-4c84-88a4-2ad559fb7514"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE0MjY_948a17f8-66dd-4695-800a-ae02a1c38b04"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE0OTA_89c5cc7b-9878-4ec6-b7d7-3f19caaff171"
      unitRef="eur">1300000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i02409e3cf3f84191a57923a7a02a3573_I20190131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE0OTQ_5d4554ce-3149-4916-b266-33df8d3a5609"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8dd2fabc2dd040398c9f16166684d63e_D20190101-20190131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE1MjU_b28ffa13-43c2-4f0d-8841-fdf54db8cca9"
      unitRef="usd">-138000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DerivativeTermOfContract
      contextRef="ie2c27ab7b79c44eb8dc5cacfdfc2c180_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0Xzc3OA_45b1afc6-ae47-4b74-820e-0e04769a33cb">P2Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MjA_9f2334c4-592e-4835-9602-159897de168a">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,576&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MjE_6ab3c43d-1ddd-41dd-a3c4-df0a5490153a">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,576&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NDA_d23618ef-4e01-4643-a818-5f8150461a1d">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.858%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the fair value of the derivative financial instruments and notional amounts (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,576&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;787&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;808&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,419&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;160&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;164&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;968&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibe6795e8aaa24dacb586776b212b0467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMi0xLTEtMTU1NjM4_8dd5e7fe-af80-4f7e-8aae-6bcbf03bcbba"
      unitRef="usd">29576000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ibe6795e8aaa24dacb586776b212b0467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNC0xLTEtMTU1NjM4_d2ea657c-d7cb-4f42-b560-3a7013368f69"
      unitRef="usd">787000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ibe6795e8aaa24dacb586776b212b0467_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNi0xLTEtMTU1NjM4_23f14970-65b7-4f45-b3d0-015d907672b2"
      unitRef="usd">717000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if5642d601e9b4575855e7055a2179740_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtOC0xLTEtMTU1NjM4_535dfa3d-1e8c-4ba6-b772-d7a9d3638050"
      unitRef="usd">24369000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="if5642d601e9b4575855e7055a2179740_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTAtMS0xLTE1NTYzOA_d6e3fb05-0b79-4e60-b252-30ba3f67fce4"
      unitRef="usd">145000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="if5642d601e9b4575855e7055a2179740_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTItMS0xLTE1NTYzOA_26719813-b100-4a9c-ad1e-f487528d7291"
      unitRef="usd">1005000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibb5da43009894cfcbe030a782ed8ab5c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtMi0xLTEtMTU1NjM4_b4e82fbb-768a-47e6-a64f-4a0681a2ed7a"
      unitRef="usd">2250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ibb5da43009894cfcbe030a782ed8ab5c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtNC0xLTEtMTU1NjM4_d3e4c685-6e04-441c-961b-f6ad46fe72b1"
      unitRef="usd">21000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ibb5da43009894cfcbe030a782ed8ab5c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtNi0xLTEtMTU1NjM4_528119e3-4d66-4c49-845f-71d10c2b7d61"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5f629b69199e405fba72ae99793d09db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtOC0xLTEtMTU1NjM4_dd23ce44-4734-4589-98b9-add943de0a9c"
      unitRef="usd">1950000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5f629b69199e405fba72ae99793d09db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtMTAtMS0xLTE1NTYzOA_cf968d56-aca5-4d93-a025-227011734cb6"
      unitRef="usd">135000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5f629b69199e405fba72ae99793d09db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzYtMTItMS0xLTE1NTYzOA_acb49c74-3641-4d05-b179-7bc720fc8774"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="ib7e05b819b13428c8901fb90ffc12e0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctNC0xLTEtMTU1NjM4_50a8677e-88a4-47e7-95fa-90a3f369d076"
      unitRef="usd">808000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib7e05b819b13428c8901fb90ffc12e0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctNi0xLTEtMTU1NjM4_83c5c93f-ab8a-4dff-8d8b-0ac6796f69fb"
      unitRef="usd">717000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="ieb95eee963804a9da724fc0b9a933126_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctMTAtMS0xLTE1NTYzOA_b2ca0144-80b2-4062-8c6f-26cbc70042f9"
      unitRef="usd">280000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ieb95eee963804a9da724fc0b9a933126_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzctMTItMS0xLTE1NTYzOA_f549fc65-d5df-461a-9222-3b43a3597a60"
      unitRef="usd">1005000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i80221d1eb71049dd901d6934d2a813dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTItMS0xLTE1NTYzOA_79078ed1-0ab7-477c-9e6a-d444434b945a"
      unitRef="usd">21419000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i80221d1eb71049dd901d6934d2a813dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTQtMS0xLTE1NTYzOA_13c92ca5-d2e6-4a5d-af84-f6cb7976526e"
      unitRef="usd">160000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i80221d1eb71049dd901d6934d2a813dc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTYtMS0xLTE1NTYzOA_945f829a-a77a-4f6a-88c9-5305bcfd6d34"
      unitRef="usd">164000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i50751deda7b94646b1c4601f55800d04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTgtMS0xLTE1NTYzOA_03001d41-44e1-4080-a2ab-aa7af1d510e6"
      unitRef="usd">15063000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i50751deda7b94646b1c4601f55800d04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTEwLTEtMS0xNTU2Mzg_0c88de47-271d-4372-9cc0-daa73a34e621"
      unitRef="usd">94000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i50751deda7b94646b1c4601f55800d04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEwLTEyLTEtMS0xNTU2Mzg_d08e1020-d1fd-4502-bdc1-6e3b4d6ce810"
      unitRef="usd">95000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTQtMS0xLTE1NTYzOA_fb0ca067-97ba-45b3-bd82-7730caa86577"
      unitRef="usd">968000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTYtMS0xLTE1NTYzOA_39cf4dbc-e7bd-44e7-a05a-db37521a6298"
      unitRef="usd">881000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTEwLTEtMS0xNTU2Mzg_ba5856d9-d299-45e7-bcfa-75cef78df917"
      unitRef="usd">373000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzEyLTEyLTEtMS0xNTU2Mzg_80fe4a72-b604-41b7-9758-967fbb0467fb"
      unitRef="usd">1100000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia09f964de2c74f4480c86cb376df89cc_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM1MjE_5acd3e1c-f89d-46cd-91e7-ba983acc914e"
      unitRef="usd">4800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i256d1411f2e24c3dbb0fff716df03a28_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM1Mzc_02c1b343-657f-4111-81a7-1d26c914232c"
      unitRef="usd">5000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NDI_988337c8-9372-4570-b0f2-2a453d3cfe1c">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk exposures (including those reported as part of discontinued operations):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;488&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(649)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(369)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amount excluded from effectiveness testing and amortized into earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;109&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;All other net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,210&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;OID = Other (income)/deductions&#x2014;net,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The amounts reclassified from OCI into COS were:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt"&gt;a net loss of $89 million in 2021; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt"&gt;a net gain of $172 million in 2020 (including a gain of $22&#160;million reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $362 million within the next 12 months into income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The amounts reclassified from OCI were reclassified into OID.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Short-term borrowings and long-term debt include foreign currency borrowings which are used as net investment hedges. The short-term borrowings carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of December 31, 2021 and December 31, 2020 were $844 million and $2.1 billion, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94"
      unitRef="usd">488000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0"
      unitRef="usd">-649000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i51958a6058fb4561962481a91445c919_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf"
      unitRef="usd">-173000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i2dfe78c0227242da8d1e000875a849f9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432"
      unitRef="usd">-77000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i6b659aec1f844db2a05972343ce9b28e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="iaf57de0273184de19e0ad20b261a65ce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca"
      unitRef="usd">55000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i23b39b578b49438883023557a0dafa81_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="i0a733f3976f84308acb3ea5484b8f248_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i8d6c69496dfc4b09a0f1e641b148beb4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktMi0xLTEtMTU1NjM4_405037fa-97c4-4b99-97b5-1572a2575232"
      unitRef="usd">-7000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i491b1222430d4a789c206cbc43deb5e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktNC0xLTEtMTU1NjM4_b271c359-33bf-4a28-9b00-fa0f9401e3ab"
      unitRef="usd">369000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i8d6c69496dfc4b09a0f1e641b148beb4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTItMS0xLTE1NTYzOA_28876c1f-28e3-452b-93e2-c007e4934d1f"
      unitRef="usd">7000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i491b1222430d4a789c206cbc43deb5e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTQtMS0xLTE1NTYzOA_aa828aee-7b1e-4248-910d-fe1d51c6c6af"
      unitRef="usd">-369000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTYtMS0xLTE1NTYzOA_c68c8ee5-011e-4dc7-86e5-aad7661b831f"
      unitRef="usd">468000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTgtMS0xLTE1NTYzOA_6e799da1-2a95-45a6-b1fb-6b0cdd11fcd7"
      unitRef="usd">-501000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i51958a6058fb4561962481a91445c919_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTEwLTEtMS0xNTU2Mzg_b9cf7014-7622-4266-bc4f-c827c6e37cb2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i07fb7c4b4ddb4737a9d1ce7c1eef3b72_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774"
      unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i072201acff8f4a2a8a8840f832ffafad_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4"
      unitRef="usd">181000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="ifc6ccc570ab144e78a6500343885c124_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2"
      unitRef="usd">109000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="iabe7be2f9ab543b2823384dc71197c46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49"
      unitRef="usd">154000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i6be3ad34af1447dd989b5ed287902d69_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTYtMS0xLTE1NTYzOA_7c714191-b0a7-4358-88cb-92054d43fc7f"
      unitRef="usd">78000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i0f72bb2019c143ebb3750784176bb259_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTgtMS0xLTE1NTYzOA_ecbe1641-b29d-48d0-9ddf-cbd51d19a42b"
      unitRef="usd">8000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i73fd8308cd7540aab95e1803c2e1110a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTEwLTEtMS0xNTU2Mzg_e1c3d9bb-c8bb-401f-85f1-4325c3b51baa"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i0e28876e1ad94a04ba445e3810de2781_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a"
      unitRef="usd">86000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="i16480fd269184b4aa44edd9f8afb1421_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3"
      unitRef="usd">-183000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i85a9736e786f4e32b7b3bb0b15bf0fb6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ie224dcd349da476b855b2421bb0a0132_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTItMS0xLTE1NTYzOA_d1ade32c-1b05-4905-aa93-36e64fc6a13b"
      unitRef="usd">-192000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ice3bec2ad3a649d58890db5c58d3e893_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTQtMS0xLTE1NTYzOA_28d7ee0d-cb9f-4b69-8080-ff9068ce947e"
      unitRef="usd">178000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df"
      unitRef="usd">1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a"
      unitRef="usd">12000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="ib53b2599306346b5a4ab30f2665dab82_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a"
      unitRef="usd">1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="i17f9a88a6c804b04a3204e7b05960707_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i99d15499afc94f0f88944990ff7e08fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTItMS0xLTE1NTYzOA_19a2a01e-f627-4122-9470-6414cdd9c8c2"
      unitRef="usd">-192000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ie5dd3ecfac844087a740d27d7e403e89_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTQtMS0xLTE1NTYzOA_0211c1c4-f749-4f17-adca-203d6d94039d"
      unitRef="usd">178000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTYtMS0xLTE1NTYzOA_4faca393-6869-4ebe-8b22-d8cb925c1d64"
      unitRef="usd">1210000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTgtMS0xLTE1NTYzOA_3651a24b-22e2-46d0-868b-1ae4481d2de0"
      unitRef="usd">-1077000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="ib53b2599306346b5a4ab30f2665dab82_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEwLTEtMS0xNTU2Mzg_1935d6fe-b15b-4323-8d03-7cb189a21e32"
      unitRef="usd">-25000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="i17f9a88a6c804b04a3204e7b05960707_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEyLTEtMS0xNTU2Mzg_5564e357-a498-4e15-bcdf-ee4d239a8744"
      unitRef="usd">133000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM5NDY_756947b2-ff01-4e85-9822-5130790587b6"
      unitRef="usd">-89000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i31e4a7146bd7442aa289c144cd2bcc60_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQwNTY_791d08fe-20d0-4e18-baa7-0d642f352005"
      unitRef="usd">172000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i7df24c7dea094c21834367203566accb_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQwODQ_57ded72b-dff8-4e3e-8925-3813cf7ba2c5"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQzMTc_a7549a57-e51a-40f0-ba09-da36da4652b3"
      unitRef="usd">362000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="ice70b9e5663e41fa87114fcb417640b2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MzU_39acac43-0466-4c5e-a404-9e8e2fd9381d">P21Y</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DebtCurrent
      contextRef="ifabc11d015734342b4ec641fcb91a048_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MTk_fc1259e5-e547-477d-9b4f-c27a7b71382c"
      unitRef="usd">1100000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="ifabc11d015734342b4ec641fcb91a048_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MDQ_a96e55fe-4b47-4ad9-802b-86197b55d6a2"
      unitRef="usd">844000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i81cf4819818d418f86a5c4e9f3aa0dd2_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzE2NDkyNjc0NDg1MDE_cb9a7a82-c469-4b05-b6b4-06fecb2a0e0d"
      unitRef="usd">2100000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MjY_b59afd0e-06ff-4a1c-9742-a1ed046e86ca">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair&lt;br/&gt;Value Hedging Adjustment&lt;br/&gt;Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair &lt;br/&gt;Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;br/&gt;Hedging&lt;br/&gt;Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTI_f3216551-17ac-4bf2-91dd-54a51e342511">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes cumulative basis adjustments to our long-term debt in fair value hedges:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair&lt;br/&gt;Value Hedging Adjustment&lt;br/&gt;Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cumulative Amount of Fair &lt;br/&gt;Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active&lt;br/&gt;Hedging&lt;br/&gt;Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,154&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="idd276ef364814442a7a5f98817403b1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMi0xLTEtMTU1NjM4_ae4ec295-92df-44ec-931c-f072f3457cad"
      unitRef="usd">2233000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="idd276ef364814442a7a5f98817403b1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtNC0xLTEtMTU1NjM4_4ed5ccb5-f4e6-4137-82de-8a1a4cc601ba"
      unitRef="usd">16000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="idd276ef364814442a7a5f98817403b1b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtNi0xLTEtMTU1NjM4_a949026c-49f6-45ad-8d13-b2af62af1b52"
      unitRef="usd">1154000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="i8b05567ffb6747f98016146f80cbafbe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtOC0xLTEtMTU1NjM4_eebcdce6-a625-447a-a666-c34372d924ab"
      unitRef="usd">2016000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i8b05567ffb6747f98016146f80cbafbe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMTAtMS0xLTE1NTYzOA_949d4adb-f694-4459-b52a-2c9c579fa46e"
      unitRef="usd">117000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i8b05567ffb6747f98016146f80cbafbe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMTItMS0xLTE1NTYzOA_768449e4-bd9e-425d-9688-cd07b05f371d"
      unitRef="usd">1149000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:DerivativeNetLiabilityPositionAggregateFairValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzE4ODI_623323a4-efe9-4798-8b8c-2176d13bf386"
      unitRef="usd">372000000</us-gaap:DerivativeNetLiabilityPositionAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzE5MjU_c2c75dcb-3938-4080-ba32-f79da31092df"
      unitRef="usd">382000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <pfe:DerivativeNetReceivablePositionAggregateFairValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzEyMDk0NjI3OTA4MjM5_25a09e34-c6dc-499d-bef9-3e2fcaa2ae56"
      unitRef="usd">477000000</pfe:DerivativeNetReceivablePositionAggregateFairValue>
    <us-gaap:SecuritiesReceivedAsCollateral
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTkvZnJhZzo4YTU0NjBhZTU3YWM0ZTI0ODVlOTRlYTdmM2ZjMTNkNy90ZXh0cmVnaW9uOjhhNTQ2MGFlNTdhYzRlMjQ4NWU5NGVhN2YzZmMxM2Q3XzIxNjk_d894deff-e3dd-4be5-87d8-598e56336b9d"
      unitRef="usd">581000000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzQzOTgwNDY1MTIzODk_8b96f075-cbf9-4984-9eb3-505b9bf9f625">Other Financial Information&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A.&lt;/span&gt;&lt;span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.45pt;text-decoration:underline"&gt; Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#05497c;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Other Current Liabilities&lt;/span&gt;&lt;/div&gt;Other current liabilities includes, among other things, amounts payable to BioNTech for the gross profit split for Comirnaty, which totaled $9.7&#160;billion as of December 31, 2021 and $25&#160;million as of December 31, 2020.</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzUyNw_954b4c18-b0f4-48eb-a89a-a9491e0ba1cb">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzUyOQ_0c94fd0e-9e34-43dc-82cc-b6cd1d5f0d5f">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,641&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,424&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;994&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,059&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;939&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. There are no recoverability issues for these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzMtMi0xLTEtMTU1NjM4_e3a24aee-d342-475b-89db-f7088898af81"
      unitRef="usd">3641000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzMtNC0xLTEtMTU1NjM4_31cbdca8-81aa-4d6f-a6df-eee6a04cb52e"
      unitRef="usd">2867000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzQtMi0xLTEtMTU1NjM4_7adb8ea4-85a8-4cf9-8a95-1b54be6b3af4"
      unitRef="usd">4424000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzQtNC0xLTEtMTU1NjM4_ec03208b-2247-43af-8db0-0f3a6facffe9"
      unitRef="usd">4436000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzUtMi0xLTEtMTU1NjM4_6abfa5d7-7e42-4630-a0ae-6cc09c80fd5e"
      unitRef="usd">994000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzUtNC0xLTEtMTU1NjM4_0e334bfe-90da-4ff3-9677-800d1fcb2f2f"
      unitRef="usd">716000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtMi0xLTEtMTU1NjM4_54059ecd-aa69-44bb-b887-d96f99d57bae"
      unitRef="usd">9059000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtNC0xLTEtMTU1NjM4_762c2983-3a02-42e0-8d59-df56b7f5c031"
      unitRef="usd">8020000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctMi0xLTEtMTU1NjM4_13d9c7d2-fd2e-4a7e-b9bb-60309e878951"
      unitRef="usd">939000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctNC0xLTEtMTU1NjM4_5e8f8213-8684-4d59-b1e8-3a41c24da7e9"
      unitRef="usd">890000000</us-gaap:InventoryNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i9a02ec9594b94a0fa152afb9f34199d4_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzQ3OQ_9500e936-48c5-4d55-ab71-eb76a1caec69"
      unitRef="usd">9700000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie0fe163dc007411b888238de88875679_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzQ5NQ_9d3cedfb-dcc9-4271-8b9c-f596059a964e"
      unitRef="usd">25000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90ZXh0cmVnaW9uOmZiZGQ3MTlhMGI3YTQwMmVhMTZlY2E1ZGJiYWQ1MWZmXzYz_cea605d3-e890-460b-b635-b9280168fc72">Property, Plant and Equipment (PP&amp;amp;E)&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Years)&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33-50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3-12.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,955&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.090%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides long-lived assets by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90ZXh0cmVnaW9uOmZiZGQ3MTlhMGI3YTQwMmVhMTZlY2E1ZGJiYWQ1MWZmXzQ5_44f829b4-23d8-41da-a31e-64b3c5b636ff">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.685%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Years)&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33-50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,252&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3-12.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,457&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29,955&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7faad75e5b2e4283af9e7fd2a1138431_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzMtNC0xLTEtMTU1NjM4_d25c9bab-13b1-4199-ae43-a0e04c5a0c2d"
      unitRef="usd">423000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6929b7c58269479390aaeda0ef2a64ef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzMtNi0xLTEtMTU1NjM4_b72e6ef0-7e6a-4751-a54f-2d012d4d0cf9"
      unitRef="usd">443000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib28e1bec91174c29b172af677b8adb54_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246ZjdhNGYwNWUxNGY5NGZiZGFkZGVmMTBkZmI0YjRhNmJfNA_8ab1f844-a9df-4bc4-ae7f-04b1ed99748e">P33Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i862ba5d064f0443ea496670357f0e14d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246ZjdhNGYwNWUxNGY5NGZiZGFkZGVmMTBkZmI0YjRhNmJfNw_31ad4268-381c-404d-890e-9b4c949a4a8f">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4c3ddbbd35b4a9c93f095e97b3679ae_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtNC0xLTEtMTU1NjM4_3595c07e-aa09-458f-b37e-6c3ba146d973"
      unitRef="usd">9001000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a96e38f1c5942afbd2a39144f01eea9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzQtNi0xLTEtMTU1NjM4_9a5242d2-12ff-4f9b-afa5-3a2ad38e5c40"
      unitRef="usd">8998000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id891db98fa4a41bd8a834b3d854a897f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246NGRmN2NjMTRkMzBjNDI5Nzk1OTVkNjZiMzUyY2JiM2JfNA_38e19acd-8823-462f-a9bd-f639b48db917">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib1196e921cab43bc8fcebc72a5b56c82_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246NGRmN2NjMTRkMzBjNDI5Nzk1OTVkNjZiMzUyY2JiM2JfNw_78f84baf-4ef1-4758-8d99-997673f62b92">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib0f9b0f72c81473eaed6b48b9824aa65_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtNC0xLTEtMTU1NjM4_70aa99f7-1031-4703-974a-f6bf6d55e9e0"
      unitRef="usd">12252000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5473f4c065384253983909169cb3535b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzUtNi0xLTEtMTU1NjM4_3dcd99d1-b7e6-4a39-b466-c380916a4110"
      unitRef="usd">11000000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i533cb430fd184762a6597353269cb90c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246MDU2YjhiZmQ3Zjg2NDM3MWJiYmMyNThmNzA4ZmM1MTRfNA_035a38f3-7ff0-4e9b-85a0-166d7d4e6412">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id841cfa6c6904f82aef7fd3fa2b9d2f5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtMi0xLTEtMTU1NjM4L3RleHRyZWdpb246MDU2YjhiZmQ3Zjg2NDM3MWJiYmMyNThmNzA4ZmM1MTRfNw_6dc98eaf-fbf1-4330-9a6e-4a55794ca353">P12Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i20c5c5b1d3ad49599584c64b0869f298_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtNC0xLTEtMTU1NjM4_18b58f0e-1e9a-4fa9-8b90-e4cbc81c1c23"
      unitRef="usd">4457000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i292ecffd1f5943b892a2111a12ad7ce2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzYtNi0xLTEtMTU1NjM4_2a4cd8ea-acab-4844-910c-7bf17f1e0d09"
      unitRef="usd">4484000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16152f7453824ee58ba88fc30ea238bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzctNC0xLTEtMTU1NjM4_ac92be53-05b0-4663-b44b-e255b4741b01"
      unitRef="usd">3822000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i392594e0d42141e994ae16e92832c84a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzctNi0xLTEtMTU1NjM4_d0839a16-5b0a-44c8-bede-ca48cea5914b"
      unitRef="usd">3481000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzgtNC0xLTEtMTU1NjM4_58b14bae-89de-4d3e-a9a1-4e3ff029ff48"
      unitRef="usd">29955000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzgtNi0xLTEtMTU1NjM4_b90389a7-db12-4789-a1ee-32b307d5b8d9"
      unitRef="usd">28406000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzktNC0xLTEtMTU1NjM4_051bb250-3e3a-4265-a476-d59fe091df33"
      unitRef="usd">15074000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzktNi0xLTEtMTU1NjM4_628ae782-3728-41ce-9714-30ebafcad0aa"
      unitRef="usd">14661000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzEwLTQtMS0xLTE1NTYzOA_2b7ef0c9-fbbe-4d27-9d06-ae562924003e"
      unitRef="usd">14882000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTplNDE0ZTk1ZTdhZjg0ZWQ4YTExNDE2OWZiMzY1NDk0YS90YWJsZXJhbmdlOmU0MTRlOTVlN2FmODRlZDhhMTE0MTY5ZmIzNjU0OTRhXzEwLTYtMS0xLTE1NTYzOA_a9c2be17-0ca6-4f07-8b96-baf5faa14cc4"
      unitRef="usd">13745000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90ZXh0cmVnaW9uOmZiZGQ3MTlhMGI3YTQwMmVhMTZlY2E1ZGJiYWQ1MWZmXzQ1_fc67596c-7fef-484f-8f74-dbaa4014bf5e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.090%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides long-lived assets by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,385&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,056&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;14,882&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if38fbf9bf0a244c6846d8ca1b19c3cb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzQtMi0xLTEtMTU1NjM4_65603bc6-06ac-4632-9597-884cdda6ebe7"
      unitRef="usd">8385000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie0a6cc9cf7be4281b01b2de3a7c6a65e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzQtNC0xLTEtMTU1NjM4_46a6198d-a4c8-4dd4-a6aa-94c439ced94c"
      unitRef="usd">7666000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i877c3de4913144ab97a4f7a18ca1272e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzUtMi0xLTEtMTU1NjM4_eab4604a-e7e3-429b-816a-7af3b43787da"
      unitRef="usd">5094000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if7dfda91c8274099a7be0f74bfe932e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzUtNC0xLTEtMTU1NjM4_cec3b8ce-de97-424d-a361-03227c9dfa77"
      unitRef="usd">4775000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0d01fcc1ead34ff9ad40afc6bbf19695_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzYtMi0xLTEtMTU1NjM4_6863421b-5e02-41b6-8b36-6e9ad2c062bf"
      unitRef="usd">347000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3062c07484944e3cba9f2336f472c327_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzYtNC0xLTEtMTU1NjM4_b9c9c11e-66df-42e8-881f-65717bdb4509"
      unitRef="usd">413000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic6ebee0abdc945fb9926a62c16c68fbc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzctMi0xLTEtMTU1NjM4_b8eaa808-37bb-45b3-9763-a29e0eef846c"
      unitRef="usd">1056000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2c28b6acb28f4060af3af8398ee4be76_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzctNC0xLTEtMTU1NjM4_9e2ab058-272f-49f2-9e16-56dc13973f53"
      unitRef="usd">890000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzgtMi0xLTEtMTU1NjM4_8a9ff77d-13c7-4144-9849-64dc2589e90e"
      unitRef="usd">14882000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDUvZnJhZzpmYmRkNzE5YTBiN2E0MDJlYTE2ZWNhNWRiYmFkNTFmZi90YWJsZTowYTMyYzI5ZjU2OGI0NTgyOWZhZDE0NGRlMmUxMmU5Ny90YWJsZXJhbmdlOjBhMzJjMjlmNTY4YjQ1ODI5ZmFkMTQ0ZGUyZTEyZTk3XzgtNC0xLTEtMTU1NjM4_22070ac9-09b1-4500-9dd1-64f4dd384446"
      unitRef="usd">13745000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczODQ_dcc640fe-e48f-4a17-9f86-3f9c3d045f9d">Identifiable Intangible Assets and Goodwill&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;73,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;922&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Developed Technology Rights&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Developed technology rights represent the cost for developed technology acquired from third parties and can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing our commercialized products. The significant components of developed technology rights are the following: Xtandi, Prevnar 13/Prevenar 13 Infant, Braftovi/Mektovi, Premarin, Prevnar 13/Prevenar 13 Adult, Eucrisa, Orgovyx, Zavicefta, Tygacil, Bavencio, Merrem/Meronem and Comirnaty. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain prescription pharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Brands represent the cost for tradenames and know-how, as the products themselves do not receive patent protection. Indefinite-lived brands include Medrol and Depo-Medrol, while finite-lived brands include Zavedos and Depo-Provera.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D assets represent R&amp;amp;D assets that have not yet received regulatory approval in a major market. The significant components of IPR&amp;amp;D are the following: the program for the oral poly adenosine diphosphate (ADP) ribose polymerase inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part of the Medivation acquisition and assets acquired in connection with the Array acquisition. IPR&amp;amp;D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&amp;amp;D effort. Accordingly, during the development period after the date of acquisition, these assets are not amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify it out of IPR&amp;amp;D and begin amortization. If the associated R&amp;amp;D effort is abandoned, the related IPR&amp;amp;D assets will likely be written-off, and we will record an impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D assets are high-risk assets, given the uncertain nature of R&amp;amp;D. Accordingly, we expect that many of these IPR&amp;amp;D assets will become impaired and be written-off at some time in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Licensing agreements for developed technology and for technology in development primarily relate to out-licensing arrangements acquired from third parties, including the Array acquisition. These assets represent the cost for the license, where we acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partner. A significant component of the licensing arrangements are for out-licensing arrangements with a number of partners for oncology technology in varying stages of development that have not yet received regulatory approval in a major market. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will likely be written-off, and we will record an impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The weighted-average life for each of our total finite-lived intangible assets is approximately 8 years, and for the largest component, developed technology rights, is approximately 7 years. Total amortization expense for finite-lived intangible assets was $3.7 billion in 2021, $3.4 billion in 2020 and $4.5 billion in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the expected annual amortization expense:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Other represents the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczOTQ_94abbc71-f050-44f0-9e6f-25c4e2bdbec9">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;73,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;922&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1Xzc0MDg_5fff6c83-fcbc-409e-8f3d-dccbb8d3d186">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Identifiable&lt;br/&gt;Intangible&lt;br/&gt;Assets, less&lt;br/&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology rights&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;73,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(53,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;19,614&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;922&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(774)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;76,552&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,714&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,092&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Licensing agreements and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;80,984&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(55,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25,146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(52,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.24pt"&gt;The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5bf1a42539e54965958a728a93c1e756_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMi0xLTEtMTU1NjM4_1db96457-241e-4457-bb5d-70a065db8f45"
      unitRef="usd">73346000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5bf1a42539e54965958a728a93c1e756_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNC0xLTEtMTU1NjM4_006cdb55-7f81-45c9-9480-57256a9c9967"
      unitRef="usd">53732000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5bf1a42539e54965958a728a93c1e756_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNi0xLTEtMTU1NjM4_a4dd9cc9-d0a1-4d4b-87f1-abb2ee502128"
      unitRef="usd">19614000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icfc5354914a145cc8d158da2eb6e9aed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtOC0xLTEtMTU1NjM4_a6383107-a58a-4a33-969c-54b74cd56a82"
      unitRef="usd">73040000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icfc5354914a145cc8d158da2eb6e9aed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTAtMS0xLTE1NTYzOA_86e86249-8876-4e05-ace4-6b91dc0302da"
      unitRef="usd">50532000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icfc5354914a145cc8d158da2eb6e9aed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTItMS0xLTE1NTYzOA_91798efa-c2a4-4afb-b009-5535e620a515"
      unitRef="usd">22508000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtMi0xLTEtMTU1NjM4_cba4d999-d117-4302-a757-1cbefacd97b6"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtNC0xLTEtMTU1NjM4_25821d04-b3f1-4115-92e2-f70b222a579b"
      unitRef="usd">807000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8bc2ec107e9045d48774e8b5afbe2be2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtNi0xLTEtMTU1NjM4_802c0116-0323-4c86-af9c-ac58d6bf7027"
      unitRef="usd">115000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3c7f4f4115a4440391144e3b67630665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtOC0xLTEtMTU1NjM4_0c59fcd5-38ef-4c63-ad0b-6aa15730f405"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3c7f4f4115a4440391144e3b67630665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtMTAtMS0xLTE1NTYzOA_0851137a-80eb-48f0-8453-6f4fa6f672a8"
      unitRef="usd">774000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3c7f4f4115a4440391144e3b67630665_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzUtMTItMS0xLTE1NTYzOA_c4cc2b75-2f1b-4e97-bbe5-68df4a7b2092"
      unitRef="usd">148000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6b140461d860414c8311ca9c9a1bcc99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtMi0xLTEtMTU1NjM4_2327bb71-ae85-4397-bfb5-ec5b5ab439eb"
      unitRef="usd">2284000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6b140461d860414c8311ca9c9a1bcc99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtNC0xLTEtMTU1NjM4_9b9389cf-d3af-4f6c-a7fb-37283347ae79"
      unitRef="usd">1299000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6b140461d860414c8311ca9c9a1bcc99_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtNi0xLTEtMTU1NjM4_a552659d-be55-415b-bc32-2b0fcf8bdf97"
      unitRef="usd">985000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i041d9d29860b421d98fc6a57f3ec5050_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtOC0xLTEtMTU1NjM4_a20b3e89-7cd6-4174-a439-8adf9de1ff41"
      unitRef="usd">2292000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i041d9d29860b421d98fc6a57f3ec5050_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtMTAtMS0xLTE1NTYzOA_a13ded9b-d1ad-4bdf-94b7-9f688b87ed26"
      unitRef="usd">1187000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i041d9d29860b421d98fc6a57f3ec5050_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzYtMTItMS0xLTE1NTYzOA_42f7cae2-7dfe-4a95-96db-54072798a2b5"
      unitRef="usd">1106000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctMi0xLTEtMTU1NjM4_23223cad-a82f-40c2-99a2-229611b54023"
      unitRef="usd">76552000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctNC0xLTEtMTU1NjM4_2d4d2f82-6a72-452c-83e3-ca326c649393"
      unitRef="usd">55838000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctNi0xLTEtMTU1NjM4_5046e14f-be5f-4e0b-b04c-5fe852a2428f"
      unitRef="usd">20714000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctOC0xLTEtMTU1NjM4_0fc05bca-2cc1-4c24-966e-035a22f5a611"
      unitRef="usd">76255000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctMTAtMS0xLTE1NTYzOA_26e955bc-1f0a-46c4-927c-0ffd5698c91f"
      unitRef="usd">52493000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzctMTItMS0xLTE1NTYzOA_2bd00522-0525-4ce0-9012-03374fe9343c"
      unitRef="usd">23762000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5e809c5ad84543eba6828d3d0602e30e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktMi0xLTEtMTU1NjM4_8c73d8c2-50c8-40cf-8eab-6cc1d97d76a8"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5e809c5ad84543eba6828d3d0602e30e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktNi0xLTEtMTU1NjM4_756c4e74-0ba1-4ac2-8cbd-e71d510160fa"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i210ff70401cd4760bb6335c8c08e0015_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktOC0xLTEtMTU1NjM4_33498752-ea9b-447a-902e-58cd7534e49f"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i210ff70401cd4760bb6335c8c08e0015_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzktMTItMS0xLTE1NTYzOA_b1ab9b23-ca05-4540-ba7d-36247a64fd77"
      unitRef="usd">827000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i45d8008250614fd8b057a37d793a0b06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTItMS0xLTE1NTYzOA_64aa0cd8-acfd-4166-88a8-87ef84d54e26"
      unitRef="usd">3092000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i45d8008250614fd8b057a37d793a0b06_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTYtMS0xLTE1NTYzOA_2f13c263-f24e-4f40-ada1-c269e2fa3dc2"
      unitRef="usd">3092000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1d89dabae4f640e895f7324d6d8a39ad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTgtMS0xLTE1NTYzOA_7808cdf0-f184-430d-b09d-447082a6d9c9"
      unitRef="usd">3175000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i1d89dabae4f640e895f7324d6d8a39ad_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEwLTEyLTEtMS0xNTU2Mzg_c6a4693d-9bb1-4812-aa58-a3778fa1e96e"
      unitRef="usd">3175000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iab33eff7f5d845e9a17bebbe4e745ebb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTItMS0xLTE1NTYzOA_38493c6e-bc33-4f8e-b0e4-0b019dfc3d85"
      unitRef="usd">513000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iab33eff7f5d845e9a17bebbe4e745ebb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTYtMS0xLTE1NTYzOA_33b29443-c12b-4544-a4d7-5179cb4ed1d4"
      unitRef="usd">513000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i678256d1b0484d0391cb0e64324ad0d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTgtMS0xLTE1NTYzOA_6d63aab0-3d6b-4b2c-8476-712a80adc931"
      unitRef="usd">573000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i678256d1b0484d0391cb0e64324ad0d4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEyLTEyLTEtMS0xNTU2Mzg_e23cfe04-802a-4723-b855-6152b0dd17da"
      unitRef="usd">573000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTItMS0xLTE1NTYzOA_45cf656c-ce26-4454-9cc9-3304c00081f6"
      unitRef="usd">4432000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTYtMS0xLTE1NTYzOA_1de8e741-dfe2-4a4c-9fdc-a34fbcbf94bb"
      unitRef="usd">4432000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTgtMS0xLTE1NTYzOA_f68df439-8f40-40dd-b7b4-7f26d0287496"
      unitRef="usd">4575000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzEzLTEyLTEtMS0xNTU2Mzg_4a33ea88-7d66-4668-9bfb-aebd231ab821"
      unitRef="usd">4575000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTItMS0xLTE1NTYzOA_ec8ed15c-853f-4f9d-9077-d757457c043f"
      unitRef="usd">80984000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTQtMS0xLTE1NTYzOA_25a2f8eb-5da8-4020-ba2c-8e014a264ad9"
      unitRef="usd">55838000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTYtMS0xLTE1NTYzOA_f9e63e0c-4405-44e8-a587-74d7b2a3a01b"
      unitRef="usd">25146000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTgtMS0xLTE1NTYzOA_fc3931a6-a25a-4777-b4ba-3e187909c117"
      unitRef="usd">80830000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEwLTEtMS0xNTU2Mzg_256ac849-9771-4c25-922b-dee9ffa34d45"
      unitRef="usd">52493000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEyLTEtMS0xNTU2Mzg_501583b2-b019-46e5-97c6-28b9baafb81e"
      unitRef="usd">28337000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="i1c7941373e994dfa8bce5cfe572bc7e4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzE2NDkyNjc0NDk3NDM_f1304669-b13e-43c7-aa20-5536459254a4"
      unitRef="usd">500000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzE2NDkyNjc0NjkwNzQ_c94b14d1-6db0-42ec-bad4-64d1490c1491">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icc33aaaa074a4869814243060c036a4f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczODc_6e6de56f-3d33-4956-b9cb-734aa085825f">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzU3NjY_92638339-9cbc-4c2e-8b5f-e35e374ae20e"
      unitRef="usd">3700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzU3NzY_7bca7a95-0889-430d-a926-2411250fa67e"
      unitRef="usd">3400000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzU3ODk_928d0edc-dec4-4b68-aa48-97b090d267b0"
      unitRef="usd">4500000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczOTg_1ce8d4de-c8c2-4ef6-8848-1e1e55f8f9ab">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.604%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the expected annual amortization expense:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItMi0xLTEtMTU1NjM4_cf34a2db-4816-4a2e-8ea6-214ed9c950ae"
      unitRef="usd">3279000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItNC0xLTEtMTU1NjM4_7899adca-747f-4fea-8d5f-9e772108d762"
      unitRef="usd">2936000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItNi0xLTEtMTU1NjM4_844d3997-ca46-4d29-bec1-9d173b46a055"
      unitRef="usd">2686000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItOC0xLTEtMTU1NjM4_32913ddc-d61c-456b-949d-6725abc73e0e"
      unitRef="usd">2500000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo1YTU3YTRhYTk4M2E0MDVkYjVmZmZhNWU3NWJmMGYwYi90YWJsZXJhbmdlOjVhNTdhNGFhOTgzYTQwNWRiNWZmZmE1ZTc1YmYwZjBiXzItMTAtMS0xLTE1NTYzOA_f69587e0-86f4-4b21-921c-23f82a0452cf"
      unitRef="usd">2449000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzczOTk_d8eccc8d-2423-4762-adaf-3335dfb34eaf">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components and changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;49,208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Other represents the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i140dd48fd747453ba5305db06d75f19f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzItMTAtMS0xLTE1NTYzOA_495466a8-c79e-4cc0-969b-e8a7379b21b8"
      unitRef="usd">48181000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40"
      unitRef="usd">727000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca"
      unitRef="usd">648000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzUtMTAtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
      unitRef="usd">49556000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzYtMTAtMS0xLTE1NTYzOA_2ffcb87d-156e-488c-ab55-3b76d0184eaa"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9"
      unitRef="usd">-348000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzgtMTAtMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
      unitRef="usd">49208000000</us-gaap:Goodwill>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTkz_7f59e0ab-850d-410c-a34d-c0f63374913b">Pension and Postretirement Benefit Plans and Defined Contribution Plans&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of pension and postretirement plans. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of net periodic benefit cost/(credit), including those reported as part of discontinued operations for 2020 and 2019, and the changes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;for our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost/(credit) reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost/(credit) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reflects actuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates, and actuarial remeasurement losses in 2020 and 2019, primarily due to decreases in discount rates partially offset by favorable plan asset performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost/(credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Actuarial Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(PERCENTAGES)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Weighted-average assumptions used to determine net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension plans/postretirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Weighted-average assumptions used to determine benefit obligations at fiscal year-end:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;All of the assumptions are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends as well as market conditions that may have an impact on the cost of providing retirement benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end 2021 resulted in higher discount rates as compared to the prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare cost trend rate assumed for next year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year that the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Obligations and Funded Status&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments and special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Amounts recorded in our consolidated balance sheet: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with an ABO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ABO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with a PBO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PBO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes actuarial gains resulting from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; increases i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;n discount rates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;The following provides the components of plan assets, including those reported as part of discontinued operations for 2020:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Target Allocation Percentage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level &lt;br/&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level&lt;br/&gt;&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;U.S. pension plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0-10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20-40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Global equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45-75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5-20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other commingled funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;International pension plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0-10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10-20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45-70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15-35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;886&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;U.S. postretirement plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0-5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;95-100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Government and agency obligations are inclusive of repurchase agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Mostly includes investments in hedge funds and real estate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs, including those reported as part of discontinued operations for 2020:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases, sales, and settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfer into/(out&#160;of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans&#x2019; assets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments. Level 3 investments may include securities or insurance contracts that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans&#x2019; invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the expected future cash flow information related to our benefit plans:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected employer contributions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected benefit payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&#x2013;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;F. Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We have defined contribution plans in the U.S. and other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. We also offer a Retirement Savings Contribution (RSC) which is an annual non-contributory employer contribution in the U.S. and Puerto Rico. We recorded charges related to the employer contributions to global defined contribution plans of $732 million in 2021, $685 million in 2020 and $659 million in 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY1_9e0160e5-8c62-4dfc-b7a4-c20f49bfaa9d">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="57" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes the components of net periodic benefit cost/(credit), including those reported as part of discontinued operations for 2020 and 2019, and the changes in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;for our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,015)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(890)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(170)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actuarial (gains)/losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(282)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost/(credit) reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost/(credit) recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reflects actuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates, and actuarial remeasurement losses in 2020 and 2019, primarily due to decreases in discount rates partially offset by favorable plan asset performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMi0xLTEtMTU1NjM4_6c1daf5d-8267-4b8a-ab2f-21fff91102fb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtNC0xLTEtMTU1NjM4_65a99a87-bc17-4248-b5fb-3bec3bf5507f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtNi0xLTEtMTU1NjM4_11a98b2f-ec79-4b0d-ab13-fcd4cbe586c3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtOC0xLTEtMTU1NjM4_082bff1b-da17-42d6-b7ae-a559e90c70f1"
      unitRef="usd">130000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTAtMS0xLTE1NTYzOA_34f22271-9dc8-42f9-a874-17200b9a6d16"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTItMS0xLTE1NTYzOA_6f51870c-acd1-4845-b650-29abb524fdbe"
      unitRef="usd">125000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTQtMS0xLTE1NTYzOA_e580cf7a-3e7e-47e5-aa8f-b72f0d07659f"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTYtMS0xLTE1NTYzOA_d0354659-f9ad-4d15-9d77-d2f7f1627ee1"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzYtMTgtMS0xLTE1NTYzOA_1b58234f-453b-422e-9972-e1e39fd81ce0"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMi0xLTEtMTU1NjM4_de3be480-f1a4-48ef-a49e-289a92854f5a"
      unitRef="usd">455000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctNC0xLTEtMTU1NjM4_3bb5a2fe-e5c9-445c-93ee-b377e67f8b16"
      unitRef="usd">533000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctNi0xLTEtMTU1NjM4_88831db4-58fd-44ae-ba7b-56e6288704c7"
      unitRef="usd">676000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctOC0xLTEtMTU1NjM4_affad6ed-70d0-4f10-b4d4-b802df1525ec"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTAtMS0xLTE1NTYzOA_a514ced1-fa9f-4438-9d60-5ccdaccdce2a"
      unitRef="usd">164000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTItMS0xLTE1NTYzOA_cc10349e-09bd-4ba8-8fbd-4d649707f357"
      unitRef="usd">215000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTQtMS0xLTE1NTYzOA_ddd2ec8a-6742-429e-a95e-20b61214e5bf"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTYtMS0xLTE1NTYzOA_936eba50-f2cb-4579-8d56-4edb2b197fd6"
      unitRef="usd">49000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzctMTgtMS0xLTE1NTYzOA_d5a68479-d496-41e9-8902-b795b2e92352"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMi0xLTEtMTU1NjM4_31794087-880d-4187-a73d-33c9a5cb4543"
      unitRef="usd">1052000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtNC0xLTEtMTU1NjM4_2d82003e-f6a5-46c8-80bc-1c4a5c3bebe8"
      unitRef="usd">1015000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtNi0xLTEtMTU1NjM4_00ff6316-7482-4e1e-852c-8b39186d15bc"
      unitRef="usd">890000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtOC0xLTEtMTU1NjM4_79e6a701-7e70-49da-a88e-ef0d5dd8e8f1"
      unitRef="usd">327000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTAtMS0xLTE1NTYzOA_760b7e06-900a-46b3-b26f-2d1a7c61c1e8"
      unitRef="usd">314000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTItMS0xLTE1NTYzOA_1c4970b9-0d1c-41e8-8b44-cc77bcbf59ce"
      unitRef="usd">318000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTQtMS0xLTE1NTYzOA_b7cf010d-3d1e-4219-82be-ce41129669cc"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTYtMS0xLTE1NTYzOA_1b2fd7a2-bcab-43f0-9060-5420993652ff"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzgtMTgtMS0xLTE1NTYzOA_14e37f98-045d-445d-881d-890f4d6dd0e8"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMi0xLTEtMTU1NjM4_a1cd854f-5f4d-4893-988c-8d75b5dc1091"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktNC0xLTEtMTU1NjM4_17d63f6f-920e-418e-9671-3674872cb11a"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktNi0xLTEtMTU1NjM4_f19392f3-4eff-498c-a88d-f9ef89ed8015"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktOC0xLTEtMTU1NjM4_43535e71-a702-4f86-a074-006fb13e9376"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTAtMS0xLTE1NTYzOA_e705ce7c-bf42-4da6-b2f0-8b5f004a8e1d"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTItMS0xLTE1NTYzOA_2d0c3000-7ddb-40f4-924a-f8bd975115c8"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTQtMS0xLTE1NTYzOA_f21a7fa9-7a85-4acf-bf83-db6d673f6bfe"
      unitRef="usd">-151000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTYtMS0xLTE1NTYzOA_f445bd6e-882c-4a73-aac8-862f4fc7d770"
      unitRef="usd">-170000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzktMTgtMS0xLTE1NTYzOA_fc819e50-430d-4b3a-93d6-d580b04a6c83"
      unitRef="usd">-173000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1OTYwNQ_4b55c588-fcbb-46e2-b19a-c1eca06a2fc3"
      unitRef="usd">684000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1OTYwNQ_6cd5bbd6-d390-47be-b4d1-7c6fb8217b14"
      unitRef="usd">-1152000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1OTYwNQ_111bd224-a3dd-4f82-bb71-0880092a2fdc"
      unitRef="usd">-284000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1OTYwNQ_522f8a54-1dd9-44eb-97f7-44c711e37e6b"
      unitRef="usd">690000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTk2MDU_243c4254-90bb-4790-a9b0-be9c0a8e38ad"
      unitRef="usd">-148000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTk2MDU_ca00c7b3-bb10-422e-8c22-eefaeaf2ba59"
      unitRef="usd">-669000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTk2MDU_12f5cf08-b296-4d3d-8e58-d4edd5422f7c"
      unitRef="usd">167000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTk2MDU_f2d9c413-bb86-4b22-92e4-ff5805dbf0ea"
      unitRef="usd">165000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTk2MDU_55f4db3e-a874-4ef3-bfc6-ff9a9d08c0ce"
      unitRef="usd">118000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1NTYzOA_adbf45c2-ad70-4f58-834d-465ae27a2995"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1NTYzOA_afb0f5e0-ba51-4e40-9992-bd5721f4d64e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1NTYzOA_752392a0-57cf-4ba7-83a9-c2d9e7bced5b"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1NTYzOA_249c72c3-28f0-4d20-bdda-64853bc97152"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTU2Mzg_e3f9eae7-fd47-401c-b505-100bb2634a80"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTU2Mzg_20590064-aaf2-4fde-bde5-df117d3fafa6"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTU2Mzg_e877984d-f911-43c8-9f25-79257bbff51c"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTU2Mzg_150066e3-857b-4391-a37e-7541db480583"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTU2Mzg_562c3e5a-70a1-4b1a-aad0-fbc08d34d9e4"
      unitRef="usd">62000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTItMS0xLTE1NTYzOA_c0137553-8fab-4393-ad90-5d81b79957d6"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTQtMS0xLTE1NTYzOA_d9a6316f-8821-4fdd-8761-120424d5f890"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTYtMS0xLTE1NTYzOA_0c92ff0e-b99c-4116-8298-77a730d1c3ee"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTgtMS0xLTE1NTYzOA_a4226001-61d5-4891-b634-eadd543fabe9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTEwLTEtMS0xNTU2Mzg_81f3b49a-75f3-4752-99c8-0b99a77d2dd4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTEyLTEtMS0xNTU2Mzg_a0c41b71-0695-4785-a6b2-75f7bbf9fd83"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTE0LTEtMS0xNTU2Mzg_df2f87b9-0eae-4eb2-bd6c-cd2b9a50b882"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTE2LTEtMS0xNTU2Mzg_84d54169-15ee-41fa-ba9e-d0eba9bb3929"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEyLTE4LTEtMS0xNTU2Mzg_360911dc-736e-4482-897e-295cc721773b"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTItMS0xLTE1NTYzOA_e05ac771-319a-4690-bf31-86c65bf2a238"
      unitRef="usd">-1265000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTQtMS0xLTE1NTYzOA_78be34d1-cf35-4f2a-abdb-bafc33a3920d"
      unitRef="usd">668000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTYtMS0xLTE1NTYzOA_0691ccf6-9103-4489-8ff6-0769b22871ab"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTgtMS0xLTE1NTYzOA_f8d460b7-3066-474c-bc19-2ec3e0d82426"
      unitRef="usd">-746000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTEwLTEtMS0xNTU2Mzg_452d2606-f7df-4676-b742-803ddaa238d8"
      unitRef="usd">141000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTEyLTEtMS0xNTU2Mzg_e55d5c78-5b35-4482-a00e-637953e94731"
      unitRef="usd">686000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTE0LTEtMS0xNTU2Mzg_cf93e3d1-6ec2-4969-bf6d-8593a5dd9c02"
      unitRef="usd">-372000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTE2LTEtMS0xNTU2Mzg_01c47758-eb97-4b0a-b963-d0bd2d47f683"
      unitRef="usd">-282000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEzLTE4LTEtMS0xNTU2Mzg_b6c4b24a-9811-480f-8511-ac57778563f2"
      unitRef="usd">-271000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTItMS0xLTE1NTYzOA_137238f1-c3d9-46cf-8457-ee44e3f68bfe"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTQtMS0xLTE1NTYzOA_b0ea5b7a-04af-4b77-a374-2f988fa5d26b"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTYtMS0xLTE1NTYzOA_d972cdf7-a8e6-4b4e-a3cd-2737a78b4598"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTgtMS0xLTE1NTYzOA_e540e962-0465-46c8-a635-42cfa94a6ae9"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTEwLTEtMS0xNTU2Mzg_4ae9bcb3-9180-4b16-9a99-7cdb6c8cdec3"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTEyLTEtMS0xNTU2Mzg_ea222b8d-fee4-472c-930d-b9935951842f"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTE0LTEtMS0xNTU2Mzg_fd01931a-7fc0-43c5-9eea-f2b66fe9ff17"
      unitRef="usd">107000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTE2LTEtMS0xNTU2Mzg_5a7fd774-44d3-4ed4-a31a-a9a1ce749bbc"
      unitRef="usd">114000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE0LTE4LTEtMS0xNTU2Mzg_d3fdf70e-858b-497d-90fd-82b03a82672e"
      unitRef="usd">164000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTItMS0xLTE1NTYzOA_d819088f-a4d5-4d7f-b430-c950137a0138"
      unitRef="usd">-1264000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTQtMS0xLTE1NTYzOA_1ec0cfda-868a-4777-843b-72e4eb0ad399"
      unitRef="usd">674000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTYtMS0xLTE1NTYzOA_06fd46b2-e2c5-4cc4-a955-afec785876fb"
      unitRef="usd">86000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTgtMS0xLTE1NTYzOA_8aba6b9a-e3d5-44d1-9f1a-3e1be7401d58"
      unitRef="usd">-742000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTEwLTEtMS0xNTU2Mzg_3b0e3274-602a-4a99-8d09-ca3389a41f96"
      unitRef="usd">145000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTEyLTEtMS0xNTU2Mzg_a9af0e71-d07f-442c-8a22-9ef3757b3eb4"
      unitRef="usd">707000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTE0LTEtMS0xNTU2Mzg_1f3c80e2-bfe7-46fa-aece-f43e7bab56e7"
      unitRef="usd">-265000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTE2LTEtMS0xNTU2Mzg_3d665274-c835-4d4d-aa89-466a14968fc6"
      unitRef="usd">-168000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzE1LTE4LTEtMS0xNTU2Mzg_475cdeb1-306a-4665-8736-2d1d2dc76294"
      unitRef="usd">-107000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTQ_1280fd2f-0c78-4c1e-a95e-6e8adfca758a">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="51" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(PERCENTAGES)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Weighted-average assumptions used to determine net periodic benefit cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension plans/postretirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Weighted-average assumptions used to determine benefit obligations at fiscal year-end:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMi0xLTEtMTU1NjM4_00c2e2f7-e0a5-49d1-b5e3-825a3797effb"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtNC0xLTEtMTU1NjM4_78a8a5fa-9f32-415e-803e-198aefa7ec49"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtNi0xLTEtMTU1NjM4_cc6a61eb-03da-42f8-9c00-8923265b5ba0"
      unitRef="number">0.044</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMTQtMS0xLTE1NTYzOA_22decf87-07ee-4106-96f3-5e369bfa1dd6"
      unitRef="number">0.025</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMTYtMS0xLTE1NTYzOA_33924467-58d1-4f11-bd08-5e33128ad4f6"
      unitRef="number">0.032</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzYtMTgtMS0xLTE1NTYzOA_bb5bf43e-3167-4a5f-9c32-3a3719286a47"
      unitRef="number">0.043</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzctOC0xLTEtMTU1NjM4_769ad733-4f06-41c5-8dff-ea939d870880"
      unitRef="number">0.012</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzctMTAtMS0xLTE1NTYzOA_5d69e0cf-2f6d-41d2-a214-ac67b77e0585"
      unitRef="number">0.015</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzctMTItMS0xLTE1NTYzOA_373b6a56-39ed-4d0c-a4ac-5aa11d4ee672"
      unitRef="number">0.022</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzgtOC0xLTEtMTU1NjM4_b72b484a-d731-4064-95f0-1b2775093589"
      unitRef="number">0.014</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzgtMTAtMS0xLTE1NTYzOA_dcb80005-7231-4767-8901-9b6df224c5ed"
      unitRef="number">0.016</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzgtMTItMS0xLTE1NTYzOA_74918878-16d2-4f96-a3eb-631c573d3a4b"
      unitRef="number">0.024</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMi0xLTEtMTU1NjM4_0470de32-2168-4cf1-a233-95ec5bf9baf4"
      unitRef="number">0.068</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktNC0xLTEtMTU1NjM4_a8ec351e-593a-4dc1-96c5-2d8a5812c878"
      unitRef="number">0.070</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ie490efc9eb9c4852baed4c880f4e81af_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktNi0xLTEtMTU1NjM4_f6568181-e8be-49bc-ae58-b2f4ce45ba3a"
      unitRef="number">0.072</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktOC0xLTEtMTU1NjM4_f518e0b7-7c33-4b62-958b-2d4eee8b9d6d"
      unitRef="number">0.034</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTAtMS0xLTE1NTYzOA_a54b2c0f-d454-45c0-9da3-c443a252cc29"
      unitRef="number">0.036</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTItMS0xLTE1NTYzOA_18004f25-4d14-45ac-b664-ab8f9f254998"
      unitRef="number">0.039</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTQtMS0xLTE1NTYzOA_6440d193-2d6a-4a00-8ffa-d5146807963c"
      unitRef="number">0.068</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTYtMS0xLTE1NTYzOA_36f3bd92-a029-4eb4-a2d9-9189d3b12479"
      unitRef="number">0.070</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ieb4fe6627bb7498fa34f6840d0967a5f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzktMTgtMS0xLTE1NTYzOA_e7744716-ba94-4c47-bb5e-e1e1db4940fa"
      unitRef="number">0.073</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEwLTgtMS0xLTE1NTYzOA_dc8c9941-a1bb-4111-a68e-d263dc192856"
      unitRef="number">0.029</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEwLTEwLTEtMS0xNTU2Mzg_90dd473c-0d4d-4f71-bfaf-9af2fb6b0d39"
      unitRef="number">0.029</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i149a74b7a578498b9569af0f1eaadd13_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEwLTEyLTEtMS0xNTU2Mzg_40132255-35fc-4ce9-ac93-160dae4b6398"
      unitRef="number">0.014</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTItMS0xLTE1NTYzOA_413e9c5c-d029-4902-bfb1-8ccbca946baf"
      unitRef="number">0.029</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTQtMS0xLTE1NTYzOA_406c56e0-0068-4b00-992f-b1424d15fa36"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTYtMS0xLTI3MDA2OA_26ce669e-86f8-4b7d-b964-e3d0817a1381"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTgtMS0xLTE1NTYzOA_86ad21cd-ec4e-4193-aa46-8ba3f7c1cc31"
      unitRef="number">0.016</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTEwLTEtMS0xNTU2Mzg_bb9fc44f-289b-448e-a9b5-001821ad3616"
      unitRef="number">0.015</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTEyLTEtMS0yNzAxNDE_010078b2-4248-4de3-b0f1-e9d22cbbd493"
      unitRef="number">0.017</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTE0LTEtMS0xNTU2Mzg_43c138db-aeab-4922-840c-16168b2bf8aa"
      unitRef="number">0.029</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTE2LTEtMS0xNTU2Mzg_312b9688-9498-451f-87e9-30027170fb93"
      unitRef="number">0.025</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="idec3f3c060644f67803ed29adf181171_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzEzLTE4LTEtMS0xNzQwNjM_9170ffee-f6fd-40cd-816a-c234648bf3c0"
      unitRef="number">0.032</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTgtMS0xLTE1NTYzOA_dc3ec28d-15f6-4bc6-ac30-354a3d100de1"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEwLTEtMS0xNTU2Mzg_78ddf880-771b-4688-96e0-3cb5279fd390"
      unitRef="number">0.029</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEyLTEtMS0yNzAxNDE_0357e9db-9c5e-4779-b022-c590a5995791"
      unitRef="number">0.014</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY4_2b783d0c-73fe-4f56-8aab-03843a247e9d">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Healthcare cost trend rate assumed for next year &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year that the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2045&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzQtMi0xLTEtMTU1NjM4_9b9c4bf8-cf6f-401d-8cc5-016fa1fdeffb"
      unitRef="number">0.060</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzQtNC0xLTEtMTU1NjM4_2e45c0fc-7385-4742-875f-1877056e4648"
      unitRef="number">0.056</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzYtMi0xLTEtMTU1NjM4_4849af4c-9663-445a-baa9-b3b6d3261b17"
      unitRef="number">0.040</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTo0NzBkNjRmYzRhNDY0ZWEwODgwNjcyNGE4OWNmYjUzMC90YWJsZXJhbmdlOjQ3MGQ2NGZjNGE0NjRlYTA4ODA2NzI0YTg5Y2ZiNTMwXzYtNC0xLTEtMTU1NjM4_d7019b22-51de-4500-a4be-55e8c25c1d45"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_0cf91b43-af10-412f-8b77-55e04b051558">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments and special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Amounts recorded in our consolidated balance sheet: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with an ABO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ABO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with a PBO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PBO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes actuarial gains resulting from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; increases i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;n discount rates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_189155e9-6bda-4d95-bef9-e5db370d1ea6">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments and special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Amounts recorded in our consolidated balance sheet: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with an ABO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ABO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with a PBO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PBO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes actuarial gains resulting from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; increases i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;n discount rates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_83df9955-6922-4a8c-8222-e9da30791825">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments and special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Amounts recorded in our consolidated balance sheet: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with an ABO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ABO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with a PBO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PBO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes actuarial gains resulting from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; increases i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;n discount rates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_a257b1b4-3a78-4412-bd9c-34a6eb74bc4a">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments and special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Amounts recorded in our consolidated balance sheet: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with an ABO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ABO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with a PBO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PBO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes actuarial gains resulting from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; increases i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;n discount rates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTg2_c8608efd-7ccf-426b-b5db-4b7ddee571ce">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides: (i) an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans, including those reported as part of discontinued operations for 2020, (ii) the funded status recognized in our consolidated balance sheets and (iii) the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,306&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;146&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Curtailments and special termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17,150&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;995&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Change in plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,094&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9,811&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,405&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;143&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;145&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Upjohn spin-off&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(687)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(767)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(445)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(372)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Amounts recorded in our consolidated balance sheet: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;447&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,480&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,084)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(2,376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(645)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Funded status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(651)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;581&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with an ABO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ABO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,344&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Information related to the funded status of pension plans with a PBO in excess of plan assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PBO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,371&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Primarily includes actuarial gains resulting from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; increases i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;n discount rates &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;For more information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMi0xLTEtMTU1NjM4_0da5e0e3-0810-4a16-a80c-2f4b195000fd"
      unitRef="usd">18306000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNC0xLTEtMTU1NjM4_6296c906-9226-4ec4-aca1-227c25bb96ef"
      unitRef="usd">17886000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNi0xLTEtMTU1NjM4_e619fedf-b7de-4035-8db4-50b4796cc9e8"
      unitRef="usd">12001000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctOC0xLTEtMTU1NjM4_cbc1dcb8-9d88-4907-86d3-176196e23a1c"
      unitRef="usd">11059000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTAtMS0xLTE1NTYzOA_874ff190-7970-4199-9c5a-cb06a3757dac"
      unitRef="usd">1238000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idec3f3c060644f67803ed29adf181171_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTItMS0xLTE1NTYzOA_53166da9-0d32-42c1-976b-015a7a580e30"
      unitRef="usd">1667000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtMi0xLTEtMTU1NjM4_5566c3a7-0646-4c2a-b7fd-00e85eb582c2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtNC0xLTEtMTU1NjM4_b3a062d1-de9d-476d-a64c-58ced3850e04"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtNi0xLTEtMTU1NjM4_0027fc31-9d28-4160-9878-8e6d6a95b92d"
      unitRef="usd">130000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtOC0xLTEtMTU1NjM4_1921735d-5f6f-49a8-8b6a-7da084fc456d"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtMTAtMS0xLTE1NTYzOA_bcf4771e-51f6-4e08-b43f-2cf472ce15bc"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzgtMTItMS0xLTE1NTYzOA_c081957a-94a9-4d35-954e-836b35dc006b"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktMi0xLTEtMTU1NjM4_a7bb493d-12f4-4296-8d1c-8ff8f9b70762"
      unitRef="usd">455000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktNC0xLTEtMTU1NjM4_0d94c174-7b85-4652-bfe3-ece730d743bf"
      unitRef="usd">533000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktNi0xLTEtMTU1NjM4_31637ead-c36f-4169-8d1b-ce03d1f46884"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktOC0xLTEtMTU1NjM4_4d51fdf4-bdce-49ae-aeee-55d5f49a1673"
      unitRef="usd">164000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktMTAtMS0xLTE1NTYzOA_2cfaea76-515e-45c1-9ce3-7c651770980a"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzktMTItMS0xLTE1NTYzOA_67284ef6-cbeb-497a-bf17-9abd38971439"
      unitRef="usd">49000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTItMS0xLTE1NTYzOA_9741639d-0337-4afc-9db0-e9f3fcb450cf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTQtMS0xLTE1NTYzOA_fafd7397-89e6-4b33-8f2f-e9a396336003"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTYtMS0xLTE1NTYzOA_cc972c06-9d3d-4748-a4b7-f80d1f86f598"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTgtMS0xLTE1NTYzOA_6cff64c9-ce22-4211-9fc4-8ed827b8d8a7"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTEwLTEtMS0xNTU2Mzg_e6783b35-4312-4dc1-9396-b1efc3a56f4e"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEwLTEyLTEtMS0xNTU2Mzg_b0afe461-9dab-4bec-ab95-81adc32434bf"
      unitRef="usd">88000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTItMS0xLTE1NTYzOA_297b04a5-d3c9-4608-a535-6698ac308af9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTQtMS0xLTE1NTYzOA_e2ee2ea2-7118-40d3-a579-ec962432162f"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTYtMS0xLTE1NTYzOA_0cc671a5-5312-4b4a-a81e-fc5a707f5a20"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTgtMS0xLTE1NTYzOA_dbbac8eb-3e20-498d-a2af-ac22b9e2a947"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTEwLTEtMS0xNTU2Mzg_b337ef38-b1da-4d51-b3c8-c6cc6e6513fa"
      unitRef="usd">-116000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzExLTEyLTEtMS0xNTU2Mzg_c9cea09d-2757-412f-af52-76ce4fc8860b"
      unitRef="usd">-56000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTItMS0xLTE1NTYzOA_11f37d67-9f26-40c9-8a93-23dd3aae225c"
      unitRef="usd">331000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTQtMS0xLTE1NTYzOA_3786047f-58ec-42ac-aabe-4be56f21b571"
      unitRef="usd">-2112000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTYtMS0xLTE1NTYzOA_c47971c5-0f64-4f2e-a645-0124bc609cc0"
      unitRef="usd">-89000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTgtMS0xLTE1NTYzOA_57875fd3-c720-43ff-aa35-5b92292df7bb"
      unitRef="usd">-702000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEwLTEtMS0xNTU2Mzg_6c7828d5-2f33-49d9-99b3-17ae37984b5a"
      unitRef="usd">117000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEyLTEtMS0xNTU2Mzg_6d74d7a6-e6f5-4721-a6da-f3c1fd721422"
      unitRef="usd">132000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTItMS0xLTE1NTYzOA_87485582-96d2-47a5-a9d8-a3c8d85d19e6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTQtMS0xLTE1NTYzOA_f1f2c3bd-d02a-409a-99f5-5bca3b8b67aa"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTYtMS0xLTE1NTYzOA_27519abf-a1a4-4500-bd13-4ddbb5407eeb"
      unitRef="usd">298000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTgtMS0xLTE1NTYzOA_72b50253-2e1b-46f3-87e6-a73cc3bef965"
      unitRef="usd">-646000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTEwLTEtMS0xNTU2Mzg_22f28013-4282-4aea-ad2d-00602d64cc81"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEzLTEyLTEtMS0xNTU2Mzg_d5697fea-c538-42e6-a426-4e32098f17b7"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTItMS0xLTE1NTYzOA_44292426-f74c-4292-8893-599c22df01ba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTQtMS0xLTE1NTYzOA_b0a85b84-e2ba-46b4-9a58-11d5cf85d31b"
      unitRef="usd">1016000000</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTYtMS0xLTE1NTYzOA_6effaeb9-5185-45a2-a184-6f978e917747"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTgtMS0xLTE1NTYzOA_7214571e-28c5-4a59-a95b-1a80823e8a1a"
      unitRef="usd">320000000</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEwLTEtMS0xNTU2Mzg_e06cdaea-af2d-4e26-b6e8-ad3f73f77f00"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanDivestituresBenefitObligation
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEyLTEtMS0xNTU2Mzg_bee459d5-4eee-40cc-a39f-9ff08d6aa4c7"
      unitRef="usd">218000000</us-gaap:DefinedBenefitPlanDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTItMS0xLTE1NTYzOA_175a8beb-69d8-4afb-a85d-4455c3ac7d7a"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTQtMS0xLTE1NTYzOA_4c084078-8f44-414a-84ae-4e3b4e711752"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTYtMS0xLTE1NTYzOA_c6fce690-6c88-422a-98a8-5613176c5d7d"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTgtMS0xLTE1NTYzOA_8615d9ca-ecb2-4c17-acb7-17d29480da05"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE1LTEwLTEtMS0xNTU2Mzg_3895843b-ac78-4fae-9208-f8f9d28f1299"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTItMS0xLTE1NTYzOA_b21735ad-d966-4a81-ac1f-b07afdb44628"
      unitRef="usd">17000000</pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits>
    <pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTQtMS0xLTE1NTYzOA_c9b3b1fb-0e9e-4236-9ab0-f679c542a64d"
      unitRef="usd">1000000</pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits>
    <pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTYtMS0xLTE1NTYzOA_384461e2-bf59-4314-8ada-ff8450eb18d0"
      unitRef="usd">-2000000</pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits>
    <pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTgtMS0xLTE1NTYzOA_2ae40eba-347a-4b87-82b9-1a464945d994"
      unitRef="usd">0</pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits>
    <pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTEwLTEtMS0xNTU2Mzg_69f7b18e-b6fb-4f45-ac3c-04c4d575eb28"
      unitRef="usd">-8000000</pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits>
    <pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE2LTEyLTEtMS0xNTU2Mzg_c86fedec-7c7e-4476-a2e2-8a93aae2edfd"
      unitRef="usd">0</pfe:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTItMS0xLTE1NTYzOA_3e7eb8b4-eb87-4df6-9274-5d002fec072d"
      unitRef="usd">785000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTQtMS0xLTE1NTYzOA_6b113e88-0880-45a7-9906-97894b7739aa"
      unitRef="usd">767000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTYtMS0xLTE1NTYzOA_00c37f90-4aa1-4cf5-a5c7-3d69ef084462"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTgtMS0xLTE1NTYzOA_364fb638-b2dc-4acb-8454-7d84d9d2044c"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTEwLTEtMS0xNTU2Mzg_320097bb-fd8d-4010-bc74-5de663310bc6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE3LTEyLTEtMS0xNTU2Mzg_0eeec7c5-6c87-436f-85fd-61ebd20fa826"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTItMS0xLTE1NTYzOA_9594358b-ab5b-4cc3-b28d-29ff7d1c942d"
      unitRef="usd">512000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTQtMS0xLTE1NTYzOA_85c72d03-e5d1-4f22-a3f4-191098087c72"
      unitRef="usd">445000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTYtMS0xLTE1NTYzOA_813d6cad-544b-4f0b-95a3-51b307f5820a"
      unitRef="usd">374000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTgtMS0xLTE1NTYzOA_2f128b89-b1ed-43e0-bb6b-32a01fb0e9e1"
      unitRef="usd">372000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTEwLTEtMS0xNTU2Mzg_763bca9a-ebd9-4221-bd67-91f38c823c3a"
      unitRef="usd">147000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE5LTEyLTEtMS0xNTU2Mzg_efb0f95b-d2e0-4e1e-8110-55ffadb44345"
      unitRef="usd">201000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTItMS0xLTE1NTYzOA_58c9c685-66d0-4b27-8fd8-86a99f375625"
      unitRef="usd">17150000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTQtMS0xLTE1NTYzOA_f60350e2-50aa-4469-a082-b854a2607d33"
      unitRef="usd">18306000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTYtMS0xLTE1NTYzOA_c1445037-0154-4a97-810f-8753322de790"
      unitRef="usd">11657000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTgtMS0xLTE1NTYzOA_5a142064-c9bd-4118-8f10-6076f944cba2"
      unitRef="usd">12001000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEwLTEtMS0xNTU2Mzg_01d5126a-6e40-4228-a15d-40bed1fa2985"
      unitRef="usd">995000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEyLTEtMS0xNTU2Mzg_28c1b928-0392-404d-b275-6cd17bae9db5"
      unitRef="usd">1238000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTItMS0xLTE1NTYzOA_f1a20b1f-0a25-4629-811f-ad2948ffa27d"
      unitRef="usd">16094000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5fc0f317fd4b45199efc2b3bbd37f980_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTQtMS0xLTE1NTYzOA_030f776d-4afd-44c7-b48b-88dc2d1008fa"
      unitRef="usd">14586000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTYtMS0xLTE1NTYzOA_4900e28a-e7d3-43b4-b380-d69fd97f8dea"
      unitRef="usd">9811000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3c471c4205474e1e97c8885b423a5556_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTgtMS0xLTE1NTYzOA_07658a0f-4f7b-4b83-9d61-fc0ca78de52a"
      unitRef="usd">8956000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTEwLTEtMS0xNTU2Mzg_9b5aaa2c-3311-4eb8-85f2-691955996709"
      unitRef="usd">588000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idec3f3c060644f67803ed29adf181171_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIzLTEyLTEtMS0xNTU2Mzg_e9f59bcf-a07d-4284-bb45-08c5bff14bda"
      unitRef="usd">519000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTItMS0xLTE1NTYzOA_0bfeebf1-2943-4869-8e27-a8ef20bda75f"
      unitRef="usd">1405000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTQtMS0xLTE1NTYzOA_d361d81e-0b62-499d-94cb-4c101159803c"
      unitRef="usd">1974000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTYtMS0xLTE1NTYzOA_f71c30b8-cf78-4e89-8a4d-9c26e068f3c3"
      unitRef="usd">1106000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTgtMS0xLTE1NTYzOA_191ce6ba-fdb3-4ece-b6b9-a7e10cb922bc"
      unitRef="usd">868000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTEwLTEtMS0xNTU2Mzg_cfd1ea74-ecce-4211-93d4-4f90554d2be0"
      unitRef="usd">89000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI0LTEyLTEtMS0xNTU2Mzg_e6c319b1-0bdf-4f93-ae65-4bb5cf83e910"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTItMS0xLTE1NTYzOA_e290273a-ef4b-4349-b8dd-bc9303e88dd3"
      unitRef="usd">143000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTQtMS0xLTE1NTYzOA_832ae95a-e912-4973-a414-c3c7c1a67087"
      unitRef="usd">1433000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTYtMS0xLTE1NTYzOA_698c06e6-0e2c-4515-836f-dc7014d72398"
      unitRef="usd">451000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTgtMS0xLTE1NTYzOA_fd14b0a4-e8cb-4d3e-bf42-1ca82d1e76ac"
      unitRef="usd">197000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTEwLTEtMS0xNTU2Mzg_f16f03c2-7393-41dc-a6de-e7852c5b9673"
      unitRef="usd">145000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI1LTEyLTEtMS0xNTU2Mzg_14db6f02-d11e-43ba-b708-fa6d831190a7"
      unitRef="usd">113000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTItMS0xLTE1NTYzOA_23f33517-32e6-4fae-8333-ad6cae95f348"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTQtMS0xLTE1NTYzOA_9aa94532-f73a-4eba-bc23-674ee4fe8fbb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTYtMS0xLTE1NTYzOA_ed8df1e8-6c59-4b13-bf4c-990db7c31c77"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTgtMS0xLTE1NTYzOA_869cf102-dede-4113-a8dd-7d523e313997"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTEwLTEtMS0xNTU2Mzg_25819382-55fd-4ee9-a3ef-649a4349149a"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI2LTEyLTEtMS0xNTU2Mzg_4787028e-90f0-4130-87f1-0e2e1832b0b9"
      unitRef="usd">88000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTItMS0xLTE1NTYzOA_8b985f30-2e4a-4ed1-90d1-492bdb71b25b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTQtMS0xLTE1NTYzOA_cf0d70ea-3635-4890-9fed-b1a695d7a8c7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTYtMS0xLTE1NTYzOA_92ffeeb8-4670-4f87-bb1a-b18b3dde5cd3"
      unitRef="usd">-229000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTgtMS0xLTE1NTYzOA_766fc894-bc82-4092-a946-8ed1afbe489a"
      unitRef="usd">462000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTEwLTEtMS0xNTU2Mzg_b97f1940-b8a8-4c62-9757-49709df5c675"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI3LTEyLTEtMS0xNTU2Mzg_2c4c337f-fd50-455b-8dd1-00e20852f7d7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTItMS0xLTE1NTYzOA_4fe324c3-d960-439a-ae02-e73b759a4327"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTQtMS0xLTE1NTYzOA_021028ad-3fe7-4eb7-b9b1-d290f1ea062b"
      unitRef="usd">687000000</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTYtMS0xLTE1NTYzOA_5575fd5a-00b6-47b7-89f6-01bc979677c8"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTgtMS0xLTE1NTYzOA_eca4bfad-a0a2-4fa0-b7fe-396339e3ace6"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEwLTEtMS0xNTU2Mzg_5100b054-8edb-48f5-9e21-212ef96b39ab"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanDivestituresPlanAssets
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEyLTEtMS0xNTU2Mzg_ff0dd3dd-2896-4174-8239-5da3b6b44a34"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanDivestituresPlanAssets>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI5LTgtMS0xLTE1NTYzOA_1f68ee4a-7dff-4bce-968f-2422aba1eee6"
      unitRef="usd">-6000000</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI5LTEwLTEtMS0xNTU2Mzg_a7c91c57-338e-4f4b-8410-51a4957d3f90"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI5LTEyLTEtMS0xNTU2Mzg_9368920f-5d70-486a-8a5e-573986bfe1bd"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTItMS0xLTE1NTYzOA_daf77705-c9e2-42c5-8e8e-42367f5d93ce"
      unitRef="usd">785000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTQtMS0xLTE1NTYzOA_e9278fbb-623d-429f-8146-df2274e32897"
      unitRef="usd">767000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTYtMS0xLTE1NTYzOA_30d6a588-af08-4b03-aed9-3036f1ccb79a"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTgtMS0xLTE1NTYzOA_94cd222b-0add-4439-b5f5-7e628e8ac03e"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTEwLTEtMS0xNTU2Mzg_df9f2ed4-aab7-4bc9-873b-f60987f40ae9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMwLTEyLTEtMS0xNTU2Mzg_5148b05b-dc73-4519-8f80-296c0b22f830"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i3575176a5ffe4607a88a7b1f6ceb13ec_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTItMS0xLTE1NTYzOA_de2d91ae-8601-48de-8c38-99daa8352fb3"
      unitRef="usd">512000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="iae113685f9d84078877817f16330ae5a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTQtMS0xLTE1NTYzOA_d0b99f71-7f22-4584-b7f1-e458e06edc63"
      unitRef="usd">445000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i2c4352916baf48a589aebdcb6f5e5186_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTYtMS0xLTE1NTYzOA_73c74d8c-f195-488e-9d4b-eac762ee4b0a"
      unitRef="usd">374000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="if13f2e9bd6154595ab4452db3b51805c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTgtMS0xLTE1NTYzOA_06473701-4c29-478f-8d4d-27901e8c8ba1"
      unitRef="usd">372000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTEwLTEtMS0xNTU2Mzg_6b7a3620-ca69-4496-919d-a2c446687f22"
      unitRef="usd">147000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i8c161701d0a5415e8b619ede58dea2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMyLTEyLTEtMS0xNTU2Mzg_a9895693-8cfd-4e1d-ae35-bdeda7be0ce1"
      unitRef="usd">201000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTItMS0xLTE1NTYzOA_e644bc41-75ce-4ed9-b176-4e53cdc7b10a"
      unitRef="usd">16346000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTQtMS0xLTE1NTYzOA_18268926-acae-4323-ad0a-209890e46d39"
      unitRef="usd">16094000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTYtMS0xLTE1NTYzOA_c9276e20-d089-4adf-890b-f13aba341147"
      unitRef="usd">10729000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTgtMS0xLTE1NTYzOA_91be3edf-d81d-402c-86af-f6e8af129641"
      unitRef="usd">9811000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTEwLTEtMS0xNTU2Mzg_53560837-7125-4f8f-92b5-9aabf9351bfb"
      unitRef="usd">753000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzMzLTEyLTEtMS0xNTU2Mzg_a21109ed-3a27-4704-9788-b86f84b6c533"
      unitRef="usd">588000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTItMS0xLTE1NTYzOA_38ec37f9-9fb6-4d8e-bb50-fd1e881e7fb4"
      unitRef="usd">-805000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTQtMS0xLTE1NTYzOA_eea5a9cc-5be7-46c6-a419-816f223c9540"
      unitRef="usd">-2211000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTYtMS0xLTE1NTYzOA_d0054f61-190a-48df-ad53-571a3578e058"
      unitRef="usd">-928000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTgtMS0xLTE1NTYzOA_b877fcf2-d912-4608-9e2b-9333772cd88b"
      unitRef="usd">-2191000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTEwLTEtMS0xNTU2Mzg_b2b58f3c-b0e0-4067-886b-f3320a9c87fe"
      unitRef="usd">-241000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM0LTEyLTEtMS0xNTU2Mzg_7fb405f2-3171-4721-9787-771885f46e13"
      unitRef="usd">-651000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTItMS0xLTE1NTYzOA_8f14a053-55e7-484d-9d25-e93960c20688"
      unitRef="usd">447000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTQtMS0xLTE1NTYzOA_351fd1df-8e80-47ba-a9ee-219e6be9505d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTYtMS0xLTE1NTYzOA_92b4f368-2e3d-464b-aa06-c4c2372a872e"
      unitRef="usd">1480000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTgtMS0xLTE1NTYzOA_be38023a-71ab-4da7-842f-dd4121ae0da4"
      unitRef="usd">522000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTEwLTEtMS0xNTU2Mzg_54f27304-e29c-4766-9016-22e6fa3b7271"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM4LTEyLTEtMS0xNTU2Mzg_4b9ea827-8840-46fc-b61a-b697820016a2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTItMS0xLTE1NTYzOA_7cefd068-b073-413d-befe-e157755425b4"
      unitRef="usd">138000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTQtMS0xLTE1NTYzOA_39247317-5359-43ae-b18d-0e90b83ee380"
      unitRef="usd">127000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTYtMS0xLTE1NTYzOA_4253484c-9880-47b7-9424-fe55cea7b304"
      unitRef="usd">33000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTgtMS0xLTE1NTYzOA_41b35c9e-a9c8-4d1b-bfbb-8936f3106a6d"
      unitRef="usd">31000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTEwLTEtMS0xNTU2Mzg_76df07bb-034d-4c2d-affb-9f0a8dff5937"
      unitRef="usd">6000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzM5LTEyLTEtMS0xNTU2Mzg_b3871978-c341-4f4b-ac24-10ac664a7b4d"
      unitRef="usd">6000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTItMS0xLTE1NTYzOA_db209ec7-4b72-45f0-b031-2d168860f28b"
      unitRef="usd">1113000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTQtMS0xLTE1NTYzOA_111b48fb-152c-4db4-81ca-befb73834da7"
      unitRef="usd">2084000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTYtMS0xLTE1NTYzOA_b8916270-62cf-4d36-ae18-f747ad175ac7"
      unitRef="usd">2376000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTgtMS0xLTE1NTYzOA_9284fefc-ca64-47bf-9672-2cde1791b0d9"
      unitRef="usd">2681000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTEwLTEtMS0xNTU2Mzg_2f4aa8b2-2a6d-4d6f-911e-ab0196fb4b85"
      unitRef="usd">235000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQwLTEyLTEtMS0xNTU2Mzg_66079cd5-6005-4a84-ae04-ba676a98cdc1"
      unitRef="usd">645000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTItMS0xLTE1NTYzOA_3f733dc7-ec77-42fe-aca9-5e44efa17b16"
      unitRef="usd">-805000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTQtMS0xLTE1NTYzOA_13f750da-25a1-44e5-a6c9-2d4ac778e5c9"
      unitRef="usd">-2211000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTYtMS0xLTE1NTYzOA_8e17a516-a8e0-44d0-8f27-85c5d38d0d17"
      unitRef="usd">-928000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTgtMS0xLTE1NTYzOA_bbefc452-ad22-403b-9340-3e790560dcb3"
      unitRef="usd">-2191000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTEwLTEtMS0xNTU2Mzg_dc9028b8-e92b-4743-bac0-ba7d109d966b"
      unitRef="usd">-241000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzQxLTEyLTEtMS0xNTU2Mzg_efb55c83-466e-4298-9275-14629b542918"
      unitRef="usd">-651000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTItMS0xLTE1NTYzOA_532f9124-3712-47e0-860e-bd6e2b7c2af4"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTQtMS0xLTE1NTYzOA_fea2ee19-ca53-4e0b-b0fb-ad2b6bf94b25"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTYtMS0xLTE1NTYzOA_a640325a-10ae-4f8b-b812-9182606793fb"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTgtMS0xLTE1NTYzOA_1ec6cacf-0d34-4785-9687-09a653a3ef73"
      unitRef="usd">31000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTEwLTEtMS0xNTU2Mzg_2508554a-9534-43cb-9578-9129e92fcbab"
      unitRef="usd">-581000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i630b3dfbbd09454388a5a6976f3655c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzUwLTEyLTEtMS0xNTU2Mzg_6eea9dcc-dfa2-4b17-92ba-93386a04ea33"
      unitRef="usd">-688000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTItMS0xLTE1NTYzOA_e478804d-42ac-4204-89c1-1eb3b3c4d922"
      unitRef="usd">120000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTQtMS0xLTE1NTYzOA_6d723252-e0db-426d-9f98-c3ba2727adce"
      unitRef="usd">16094000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTYtMS0xLTE1NTYzOA_1359244d-9ca7-42ec-af97-2d6bf9cb686b"
      unitRef="usd">1304000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTgtMS0xLTE1NTYzOA_7be9e936-f8d0-4072-9eb0-3e7538b8a30d"
      unitRef="usd">6674000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTItMS0xLTE1NTYzOA_f59a388e-1923-46fe-946e-8ddcbb26213c"
      unitRef="usd">1371000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTQtMS0xLTE1NTYzOA_25fdaedb-fcea-4223-915c-2953a3bd0c5d"
      unitRef="usd">18306000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTYtMS0xLTE1NTYzOA_087da3aa-6d1a-444e-99cb-fb3ba334d61b"
      unitRef="usd">3344000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTgtMS0xLTE1NTYzOA_011302af-b5f5-4dac-8819-02eafbbd14d4"
      unitRef="usd">8961000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTItMS0xLTE1NTYzOA_da4468a1-5047-41ec-9622-d82ce1b6ca86"
      unitRef="usd">120000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTQtMS0xLTE1NTYzOA_ce663fcc-934b-4f97-bc38-6a9f03ef0645"
      unitRef="usd">16094000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTYtMS0xLTE1NTYzOA_63fc9557-bdc2-4b91-a304-6bfa8d2f3a68"
      unitRef="usd">1381000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTgtMS0xLTE1NTYzOA_eef6cb3b-6941-4582-bc48-cf1dc25da512"
      unitRef="usd">6735000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTItMS0xLTE1NTYzOA_1d521dba-67e6-4774-ad3e-263f21d6ba2d"
      unitRef="usd">1371000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTQtMS0xLTE1NTYzOA_8ee7ad89-2b40-4fc9-986d-77b006d108ea"
      unitRef="usd">18306000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTYtMS0xLTE1NTYzOA_52f6660e-780d-4444-9d2b-959ce46860ac"
      unitRef="usd">3789000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTgtMS0xLTE1NTYzOA_dcd76900-b494-4bb3-ae58-5e24f2f31d15"
      unitRef="usd">9447000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM3MDk_2d57a360-3185-454e-bd3f-e7ebbe59ad41"
      unitRef="usd">11200000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM3Mjk_090b58c3-f655-4bc1-b65a-570b111746b0"
      unitRef="usd">11500000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMx_5570607b-7baa-4ce9-b3f0-e8678658df39">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.679%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;The following provides the components of plan assets, including those reported as part of discontinued operations for 2020:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS EXCEPT TARGET ALLOCATION PERCENTAGE)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Target Allocation Percentage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level &lt;br/&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level&lt;br/&gt;&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;U.S. pension plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0-10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,248&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;20-40%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Global equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,352&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,152&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45-75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,566&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;18&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5-20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,079&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,076&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;158&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other commingled funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;16,346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,726&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;International pension plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0-10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;541&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;346&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10-20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Equity commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,386&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;67&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;45-70%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:22.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Government and agency obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,415&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,138&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;15-35%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Partnership investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;106&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,273&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;141&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;404&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;886&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,729&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2,189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;U.S. postretirement plans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0-5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;95-100%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;669&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;753&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Government and agency obligations are inclusive of repurchase agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Mostly includes investments in hedge funds and real estate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic5710bf2055845c2bb0af48ab186abf3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtNC0xLTEtMTU1NjM4_8f8a4545-3ee6-4b76-acc4-eb8102dd23c7"
      unitRef="usd">1326000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60429211f00e4543a9d87883c1802d3a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtNi0xLTEtMTU1NjM4_5d7a8d0c-5e71-4e5a-ae01-b2647c3880e0"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60c7b4506a324d4bbcbab70e430c8662_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtOC0xLTEtMTU1NjM4_7ac08ad7-4819-4499-ab91-2fdd6bbae30d"
      unitRef="usd">1248000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i283602e4cefb4da5950be8e7d92e7b33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTAtMS0xLTE1NTYzOA_08c87c27-3ef7-4d3e-8c58-13979a6ba514"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i49bdb977a6c048ed8147d55a219d65bb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTItMS0xLTE1NTYzOA_9116dce1-29a6-400a-b560-bf236c4d1e10"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i64901c28b3e4435fb58c625d1c7cf873_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTQtMS0xLTE1NTYzOA_49662ad2-7b5e-4f3e-9686-6c17312e512e"
      unitRef="usd">781000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74e82614b28e43cda6969e8c6d06b101_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTYtMS0xLTE1NTYzOA_c0b9ac50-fcc0-40ae-9772-c22055149830"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if89fbc914ea0495c84a57e279acd25e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTgtMS0xLTE1NTYzOA_8a91deca-f4a3-4d27-b2bb-e4cdda935523"
      unitRef="usd">711000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icba84ca9e34e4da6acddd4a5dca78acb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjAtMS0xLTE1NTYzOA_689c1cd2-33c8-4056-9e7c-d7357db82ace"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2eee230e2ad24b56a95a98c396863239_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjItMS0xLTE1NTYzOA_2db1f194-c5bb-4342-8607-e1df12dcbf12"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37b1e9bd443e4b9dacb7b420ea97a93a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctNC0xLTEtMTU1NjM4_8c626707-10cd-4aa6-a6fd-d7fd48b3f542"
      unitRef="usd">2273000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89f847d9790b41829a5de2c58516e44b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctNi0xLTEtMTU1NjM4_44b94996-c908-47d1-b168-24331f7ae8aa"
      unitRef="usd">2233000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i36aad9909fb14c9e88dc6e895d2ae970_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctOC0xLTEtMTU1NjM4_2e58f3e2-e34e-4ea9-928f-3d44e4cd0676"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i88fc1d8b0293450faef44d3939baa104_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTAtMS0xLTE1NTYzOA_6629be45-9242-4a4e-bd24-60453f52de6c"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee309d4671204beb982620ca87935160_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTItMS0xLTE1NTYzOA_242ba833-456a-4cfd-b898-3a48906babf6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a840d48179840c58c095b54740189e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTQtMS0xLTE1NTYzOA_ff76f35c-e32b-4677-81a1-411a85f2ede7"
      unitRef="usd">3241000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i43adc45933224ebb81d095ee790ac1f7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTYtMS0xLTE1NTYzOA_9a827cd6-5f39-4cc1-b4a8-e996cb47d63a"
      unitRef="usd">3213000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee6805ceeab9416ab34598f009a9a3dc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTgtMS0xLTE1NTYzOA_d5be236e-b757-4d5f-8496-f94ced4a9688"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccd31c166a8342b1ab79aa126ec89e2b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjAtMS0xLTE1NTYzOA_c4292b6e-cfd8-4205-aec4-d505cd915fcb"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia386fe05870a4d00bf574703282f8e14_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjItMS0xLTE1NTYzOA_942e2c6f-bd14-48d6-938e-405a246cdb45"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2ecf8cfa85c844e994e95ff8a0b018cb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtNC0xLTEtMTU1NjM4_f3438b85-1ba4-4056-a05d-a9136b6abfc6"
      unitRef="usd">1352000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e867961a86c46988276f2a8e0b5563b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtNi0xLTEtMTU1NjM4_210ffc95-fb23-45a9-81c7-ee2040fb22f9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id1eee291364c41d79df9b38be936c743_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtOC0xLTEtMTU1NjM4_d114910a-6e4d-4687-aa07-dcc368bcd9de"
      unitRef="usd">1152000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89f82686b88b4e99b6d4c1a1a66cb7e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTAtMS0xLTE1NTYzOA_a2ec5dbf-d608-44a3-9b94-a40808eb128f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia951c8cab72446a18ae9742d230213ad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTItMS0xLTE1NTYzOA_285610aa-5b55-40aa-8047-ddd3c15916b4"
      unitRef="usd">200000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i83f95cfd93704f94897bc57033b1b31e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTQtMS0xLTE1NTYzOA_3227f37e-9281-4da3-87a0-f36f2c4c6d5b"
      unitRef="usd">1325000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6fb94fe8a7447b0b43f4729bc6367ef_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTYtMS0xLTE1NTYzOA_2023f9b9-d4cb-4d4d-9441-ff016c24e52d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib998445075734dc0859b69f2f70d7eae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTgtMS0xLTE1NTYzOA_ce9f5431-0b37-480d-997d-1736110b18b1"
      unitRef="usd">1110000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7cdce9769d51453485e9ffd8c6432ac9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjAtMS0xLTE1NTYzOA_765f6c9a-803e-45c0-8160-e5e714fe7690"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5efb9b34ff354aa695d0ce5519469de9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjItMS0xLTE1NTYzOA_fedba956-ea2f-4539-b3f9-abf2ae69c37b"
      unitRef="usd">215000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4de93f17bb5246deaf177cd4c179c2d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTQtMS0xLTE1NTYzOA_399eb3ce-9773-4de8-8d3c-dff2d82b5679"
      unitRef="usd">5566000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iedd08d03a6f8444e8e25322e621edaea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTYtMS0xLTE1NTYzOA_0bc4e969-6ddb-41f5-9c0e-cdbf1f973b76"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2fea9359eb542c88235d0e94cc3e253_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTgtMS0xLTE1NTYzOA_ee1c77d5-8e91-408d-b072-76df6e0532a7"
      unitRef="usd">5548000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7baf2c21a80d4f38986f54d8c0033701_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEwLTEtMS0xNTU2Mzg_f44b1d19-47cb-4e38-9f21-cb3531be557b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2702036ed2fc41b8bd3ca11952dd39fd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEyLTEtMS0xNTU2Mzg_b95480d8-ffdc-448c-bc49-6676b68b2698"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i123f921d862b428288283381a090761f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTE0LTEtMS0xNTU2Mzg_14a4bcc5-3983-476f-9c44-7783117ecdb4"
      unitRef="usd">6499000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5ccdaa1a811a44b99f3c0c1ca7eb44bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTE2LTEtMS0xNTU2Mzg_cc67cbce-9be1-4a26-bd34-7d483f55836d"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a51613c60584714a3ec9b2ab496acce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTE4LTEtMS0xNTU2Mzg_1ac3230b-27aa-463a-b72d-f156f47fb637"
      unitRef="usd">6476000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i09a618c301e845ed90388735dad7841b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTQtMS0xLTE1NTYzOA_3f59ffed-384c-4297-9043-94b52041efad"
      unitRef="usd">2533000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4e9316f5dab24cc588e8c9e879cd9341_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTYtMS0xLTE1NTYzOA_1e4d1b6c-f5a4-40d2-844a-3ab0a45b0bef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id568702500f6432588ff76e3c3f36577_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTgtMS0xLTE1NTYzOA_7e1703d0-e7a0-4115-b0b2-9ff77b3df847"
      unitRef="usd">2533000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib38fc00053aa4c199b39dece7cad7cd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEwLTEtMS0xNTU2Mzg_67b09b8f-e216-4d69-9e74-d98f90ff3ac8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id20c6d20908b4daaa553daa64deaf5f2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icc201aae7f2142fa93d6f1984cee3475_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE0LTEtMS0xNTU2Mzg_2f220032-7e9b-4c18-b46b-94a7e5cade71"
      unitRef="usd">1555000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie08bf866f12c4207b983f1e7a10c0e8e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE2LTEtMS0xNTU2Mzg_26d5df97-f0ad-4152-8dee-55f18443891e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia5407c5de8f4429b9e4f43939bf305b8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE4LTEtMS0xNTU2Mzg_00b437d0-18c0-450b-9dd6-1bfd8657d584"
      unitRef="usd">1555000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf1f6db9b9894f909a5796169e3fa818_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIwLTEtMS0xNTU2Mzg_bfef0997-7812-4779-a11e-800743cd3459"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i57fea877a08c4296bf2ba0c929fae62a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0bcc6044a5d34518a267a09836a28a8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTQtMS0xLTE1NTYzOA_63589cea-c837-4db8-8fca-c1f3063afff9"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i742813cbab044d04a09ecf0ff835c7f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTgtMS0xLTE1NTYzOA_4edec239-3aed-46e7-aa51-3419f0287a1b"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie9d5003d9185448588413661fda71f1d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEwLTEtMS0xNTU2Mzg_15170d7e-8a48-4c9d-903b-1429344b469d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6960f5ec76174cb5a4931498467bfc1a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEyLTEtMS0xNTU2Mzg_891932bd-4a2f-4cb7-9c32-7626400194a1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0c51183fe29945a1bc46769c25b05d2c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTE0LTEtMS0xNTU2Mzg_a891e0f8-83b9-4225-aca1-859e732cd9b8"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7a2177b163f24101a81bc962d77be4de_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTE2LTEtMS0xNTU2Mzg_ea02d588-c380-43a2-b9a8-875f573b1842"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9254bb662ee04eb7851f6a0b2686c6a4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTE4LTEtMS0xNTU2Mzg_a9b53299-52e3-4815-9fe2-10b6ec500b15"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia249cd5c4d3a4607ad781d7a08f45a32_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIwLTEtMS0xNTU2Mzg_740d8a61-f06f-4ce0-aead-2435e33fd773"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id179af66abf14a9fa7b1bba32e3acde8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIyLTEtMS0xNTU2Mzg_91fb8c8a-dfd0-46c4-afe4-83080ad0c295"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0614fc26162d4735ab928995a4525919_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTQtMS0xLTE1NTYzOA_58fd0a00-0fde-4880-a602-5212e1070940"
      unitRef="usd">2079000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i57504ba4b31c4e419514d3d822decba5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTYtMS0xLTE1NTYzOA_504edd22-f235-41c2-beb8-c3f5ea16078f"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id76b3e3473a8474aacfe913ead06f99c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEwLTEtMS0xNTU2Mzg_960e3182-0ff8-451e-94e9-0bad467aa196"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iecd486b3bd864997bc5dc92f53919f6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016"
      unitRef="usd">2076000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0f7ba90f110d40e2805438dda627ba7e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE0LTEtMS0xNTU2Mzg_2f8d3eaa-a853-434b-829f-7ea3e7269a84"
      unitRef="usd">1431000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i73e7d40fad2b40cab376ebfc9484a1fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE2LTEtMS0xNTU2Mzg_a112cd8f-66f3-4c2f-abe3-05cb919427ff"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic97e4ef4dedc4cd4b036e878ea92ff23_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE4LTEtMS0xNTU2Mzg_5bfaf30c-da33-4555-91d7-1f74139286eb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if24ee12e5a364e699f1ccff806b6610a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIwLTEtMS0xNTU2Mzg_dc51b3f5-f461-44e1-a6f5-5f96e785f863"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i24262e3bc3d74c4f9d4ebcd94821b450_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e"
      unitRef="usd">1431000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i91370cf282454c17b017708814f29a5f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTQtMS0xLTE1NTYzOA_362e43a1-d549-4a76-8375-b398929a3029"
      unitRef="usd">158000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i589b9c0f0529485b88483ec95805a113_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTYtMS0xLTE1NTYzOA_906925e8-cc91-4aa1-9fc5-2d02dfbb10f9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id792c4fa30b54b0f86d3a756dec19969_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTgtMS0xLTE1NTYzOA_aa641efa-7340-4b49-8c6d-43b07497c6b0"
      unitRef="usd">158000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i557b046786b54cf5a7fd128f940aa558_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEwLTEtMS0xNTU2Mzg_b5fdbd7b-51af-411e-bff9-b62ade9ac9ec"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6d5e155c28ce45949b23ef1c2aa7bdcb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEyLTEtMS0xNTU2Mzg_7fda2a9e-7697-4cfa-86e9-0fefaeb05694"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib89426b5421f48bda2e841651169370a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTE0LTEtMS0xNTU2Mzg_cf008acb-b18f-4a2c-9774-ee7a24a8d3c6"
      unitRef="usd">190000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0eeba8032f54437b2332b040493be10_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTE2LTEtMS0xNTU2Mzg_9316293d-741f-4994-bf4d-d170c80f50ad"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5fa59de110c24310a8a3947fd9bf785c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTE4LTEtMS0xNTU2Mzg_a3ff76ee-8b86-485b-a961-f3c1964ed3ce"
      unitRef="usd">190000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01e99ad5a3624b79beda47b0277cfc08_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIwLTEtMS0xNTU2Mzg_e11393f9-cc5e-4e3a-a9fc-1fde9d25d812"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9178dd6228bb49e6ac59b6bc450f5f0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIyLTEtMS0xNTU2Mzg_31a8ad27-20a2-4a38-a7b3-82a1801e8339"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idde04c3fab9a4225922b968a4ae389ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTQtMS0xLTE1NTYzOA_253e4e25-a98a-4cf5-8749-395c9dedcd3d"
      unitRef="usd">1019000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i447a8db12c9c4335a9e7ce727e1c6c75_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTYtMS0xLTE1NTYzOA_b93deecb-4ab1-4c04-bb4f-c3884d271f31"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27f1331fac0a44ab8ab767c27460f01c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTgtMS0xLTE1NTYzOA_68e027e6-af0e-4ef0-afae-8b7bf7ff0d27"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6b8df318e157488ebba552305374f247_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEwLTEtMS0xNTU2Mzg_69a9ad1c-52a1-4930-bd2e-8e9bbc9e8e46"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5a6859a81d948b1b05d1524a2329d05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182"
      unitRef="usd">1009000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib5be279af8994b7baf6fe7f41d4659d5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE0LTEtMS0xNTU2Mzg_a07d3655-9ba7-4a78-ac67-692db249b25f"
      unitRef="usd">1049000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8a28d95791fd48349d327616387cf43e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE2LTEtMS0xNTU2Mzg_55d6612b-509e-4e4e-9e3f-38aeafd8d90f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3fdb174e64745cbb589727b895dff68_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE4LTEtMS0xNTU2Mzg_e89a0ca5-4065-4544-9e31-f514a259a70d"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibe8ad87158d744cb98b1afcde979e2e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIwLTEtMS0xNTU2Mzg_aaddd5c9-00c9-410b-ae32-5c465dfd74f4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3acdd3ac8bd749d6bf766df1d252e13b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4"
      unitRef="usd">1038000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTItMS0xLTE3NDk0Mw_cec51836-bac9-4439-822b-4efcaa1e537c"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTQtMS0xLTE1NTYzOA_f0a90553-88b7-426a-8764-8d8fba17b76a"
      unitRef="usd">16346000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c4cadda8ddf40c0865e66aa16db1fb9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTYtMS0xLTE1NTYzOA_0f35b385-52db-4f18-b2b7-ab9f58e646c8"
      unitRef="usd">2332000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibd30853b5aeb4360a8572bbff63519e1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTgtMS0xLTE1NTYzOA_a00b2a6c-ba53-4fd6-86ab-f59d41755b56"
      unitRef="usd">10726000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5b913c838f444389b2b5e72727c9ead7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEwLTEtMS0xNTU2Mzg_56164a78-868b-4aca-9640-d285dd3056dc"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfbcbfb8ada844189c00d8838d1d06df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEyLTEtMS0xNTU2Mzg_b9283d4a-b481-499c-84cc-ab9add6e6bd0"
      unitRef="usd">3286000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i462c90dc9eb3411d9498b4a28515f2ed_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTE0LTEtMS0xNTU2Mzg_732cca42-2573-4efb-98c8-ed72ebc54bb9"
      unitRef="usd">16094000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieb2a8f3e3f5140a6bbf5b850dd9df831_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTE2LTEtMS0xNTU2Mzg_d8802859-0279-4229-a81e-c51cbecda373"
      unitRef="usd">3306000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i61b5f086df574c9692cfb7bc457ede83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTE4LTEtMS0xNTU2Mzg_37fb29e1-e1a2-454c-b2c1-bfc8671a3d1f"
      unitRef="usd">10103000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id5b1262aee15447893f4283772570e1c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIwLTEtMS0xNTU2Mzg_c511edfd-94ac-402e-bc12-0c3d00bf6c04"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2204111742ee4465b254c1d8def302f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIyLTEtMS0xNTU2Mzg_206b5f3d-e5de-48a7-8d90-972f83316239"
      unitRef="usd">2684000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5054f1ba961b478e81844b3970edd709_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTQtMS0xLTE1NTYzOA_7bac0546-8cd1-43dd-a2d3-afa47b156d81"
      unitRef="usd">541000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i407c2c84a6fa46d19c024b335e5207de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTYtMS0xLTE1NTYzOA_210e7d84-f59b-472d-849c-37e41ea5531d"
      unitRef="usd">191000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4789a2744a994126861e99bbaa61a091_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTgtMS0xLTE1NTYzOA_1abc2d0d-a28a-4975-bd50-c6fb79b2c63c"
      unitRef="usd">346000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib632f9766b1b4f088ee3c17033d9b730_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEwLTEtMS0xNTU2Mzg_c29db45a-5c87-4414-9856-cd6a397ed11a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4b14ebd35ab942468b155850a50635d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEyLTEtMS0xNTU2Mzg_2071fbd6-afae-4a6e-950d-29a48f960b3e"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89b022b7da864f55abf40a8814adcc45_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTE0LTEtMS0xNTU2Mzg_02cb0167-3c82-40dd-b2d4-9c5723d31323"
      unitRef="usd">407000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i57736d5c9bd045889e3e70f907687568_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTE2LTEtMS0xNTU2Mzg_867a5ac1-93fd-48c4-a874-1360d2d22595"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3d396dc1a9fc4ebc987eb95b09e2dc46_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTE4LTEtMS0xNTU2Mzg_13640567-b84d-4b81-b176-23241efeed6f"
      unitRef="usd">346000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1e2fe0961b7445768068020c53ad927d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIwLTEtMS0xNTU2Mzg_d4ca7211-fe54-46d0-825b-b7e1a35e1934"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie575e7d2482f4c67ae9b25248a9ad0a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIyLTEtMS0xNTU2Mzg_a214d9db-3c4a-4696-8ebd-fa3ec28ff00e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a7d8a3434554d0399db965a1f07c58c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTQtMS0xLTE1NTYzOA_c3baf82d-f2d0-4984-9470-3b4e9955f8d6"
      unitRef="usd">1453000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5be90fe1c0944a43b096201649b0b9c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTYtMS0xLTE1NTYzOA_a12a2ae1-970f-46ef-8c3c-e8fa2165ed8b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9f8da59af46f4f0386aa576b69074f33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTgtMS0xLTE1NTYzOA_c492aef3-7806-4537-930a-a736903a16f6"
      unitRef="usd">1386000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22075a2e3ef34cbf995ac7e82012dce0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEwLTEtMS0xNTU2Mzg_3608e02b-dc3d-474e-b8c7-7201468f9fd4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0863c82bbc51409b8efa496f8db9fdeb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEyLTEtMS0xNTU2Mzg_b13354c5-fdff-4035-bb77-b00434096449"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib30b271d8b274f408f4ec6c14285b00c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTE0LTEtMS0xNTU2Mzg_a3ef8297-da62-45d2-9e44-fac88b0500bb"
      unitRef="usd">2051000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0445954f919744a9887083dd3819fb37_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTE2LTEtMS0xNTU2Mzg_d2db1ca3-b68f-4161-8687-58c1bfefa9e6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icf9c3b10b55044c49138dc630a759469_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTE4LTEtMS0xNTU2Mzg_cbc65931-edcd-46c2-99c0-ba9ac87ef322"
      unitRef="usd">1681000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee038f714c2946bcbbebc2ca551337d2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIwLTEtMS0xNTU2Mzg_4af73134-292f-4086-b231-63fdf6681b0c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i62bb9a408ac64e97878a6c8ad73e05e5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIyLTEtMS0xNTU2Mzg_12545fb2-9126-41b2-8856-19f2b608c590"
      unitRef="usd">370000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iecc0a667f1e24e80a1d4b531f082b57d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTQtMS0xLTE1NTYzOA_fd059b24-1180-40c7-8648-9f97add7526c"
      unitRef="usd">1187000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0b85b80107be4fb8965249fc26340ed0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTYtMS0xLTE1NTYzOA_97dc468f-aeef-47b0-9e0b-29bea8a23f86"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b0a5ac77175482aad6b61c53e7c43e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTgtMS0xLTE1NTYzOA_cf04dcc9-614e-4ffd-8de2-3df5420a7c04"
      unitRef="usd">1187000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b6f712dd8c0447aa8f70d3d13ad1e6e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEwLTEtMS0xNTU2Mzg_c78878ae-c8a1-41ed-9082-af6e682cfd20"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i329e2ccb8f4547afa328cdbd5609b4be_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEyLTEtMS0xNTU2Mzg_93a56760-b80a-4d6b-8987-359570948f94"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5836472a076b460991d1eebeaa047f8e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTE0LTEtMS0xNTU2Mzg_9ade59bd-0cb5-4fde-a1b1-e2e8b69a9b77"
      unitRef="usd">925000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7d752324547a45d8b253e8c8bcdc884f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTE2LTEtMS0xNTU2Mzg_bb562f69-9d4c-4389-b7f2-ec7b81b19d9e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if86170cd6f9d428380420d95b35931fe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTE4LTEtMS0xNTU2Mzg_cb407699-09c1-41eb-81de-f3cfa01e90cc"
      unitRef="usd">925000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17a849b4291f46ee8770bfb32d9b35e7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIwLTEtMS0xNTU2Mzg_c59c32b5-d2bd-4919-bc5a-4ba6337f0559"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a9982822ef54206a5a46c76586d2f84_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIyLTEtMS0xNTU2Mzg_90374e62-0e6f-46ef-9c7f-4640ff4d6c2e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a347ca6972c4ccf8546cf5025e6876f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTQtMS0xLTE1NTYzOA_59235c5e-1fcd-4074-9c0d-c21db292ee70"
      unitRef="usd">2415000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd4a43b1598443a7ab6eca61208eba5d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTYtMS0xLTE1NTYzOA_9e395521-4d55-4496-bfba-db44fa808527"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c25f3b4c7ec40969b854e0ac925ba55_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTgtMS0xLTE1NTYzOA_d6a323fc-7cb7-4834-ac37-0568992d3f35"
      unitRef="usd">2415000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c46658794be4817aac85595e3b4fbc7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEwLTEtMS0xNTU2Mzg_9c49a9e0-a9b6-45a3-bda0-99fa573d9310"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c11b3f4356845d6aadac688a6d24730_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i692794301332409594d055d1c7f8e64f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE0LTEtMS0xNTU2Mzg_7633de53-4390-47ba-baf3-1655f72106d6"
      unitRef="usd">1334000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5326e53aef0646728ea9fa61b1a7a0ce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE2LTEtMS0xNTU2Mzg_1fc74320-cc41-4d0c-9bc9-8f4d0f01bd77"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b1e59e825ee4981a7d38ce2c03e80f8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE4LTEtMS0xNTU2Mzg_f3c443bf-eba7-44c5-a8dd-89017a09bda3"
      unitRef="usd">1334000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic93ff27c78464387b5ed9bc21e35646c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIwLTEtMS0xNTU2Mzg_eb54842d-f09d-4c97-9447-596ba9c828e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb581ffa12d14ff2a9a1844bbaab94cf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i61c36130da21474a97558823d72cc9c3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTQtMS0xLTE1NTYzOA_0a3ab404-913a-42ec-a9ec-f4f2016f231d"
      unitRef="usd">2266000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i82b2e88175ff4f378684f8507ae69794_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTYtMS0xLTE1NTYzOA_bd7dbf8c-59e4-4953-a0d7-ece7afb92361"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i758430987c524ca79a1aaea82cb98356_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTgtMS0xLTE1NTYzOA_67e5b5cc-f51d-4888-85d9-64f5b5965244"
      unitRef="usd">1138000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i84b995529e4646e5b6becab80303e6e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEwLTEtMS0xNTU2Mzg_4f61b8b4-fdb3-43a3-a595-fe75896e5164"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f16642eeded411e90331536700f0546_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEyLTEtMS0xNTU2Mzg_888ab502-03a6-4cb7-b620-959b81a348e6"
      unitRef="usd">1128000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i379e7c46cec74ebd955ac7a7e03511cc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTE0LTEtMS0xNTU2Mzg_e93e20f7-5972-4da4-b816-d751cab4ae0f"
      unitRef="usd">2484000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib2eeca61f3244ee5af945c85a0919a57_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTE2LTEtMS0xNTU2Mzg_e5f983d9-b615-4e61-9604-d60fc8cfe908"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5c237700488c4cb8b091e549169f189d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTE4LTEtMS0xNTU2Mzg_8d778465-08dd-4dee-ae29-7c1fa5e93d16"
      unitRef="usd">1217000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i03d125dfcb4a417187130ddbb9460600_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIwLTEtMS0xNTU2Mzg_c89926df-0341-4216-9d5a-a829afba5b1b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i53a90980f6dd46818498f9ee7d139756_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIyLTEtMS0xNTU2Mzg_b0a663b2-9770-4574-9771-931cbd79c542"
      unitRef="usd">1267000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifce607f8a3a94cb29fe8250722ea7383_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTQtMS0xLTE1NTYzOA_493e864e-9e6e-490a-a7d1-a8f30874fddb"
      unitRef="usd">107000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i632d5976180f4e41b0ae66ce2781ec7b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTYtMS0xLTE1NTYzOA_db43a12b-305c-43f3-b08d-6ea28ca0bb34"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if1c72066d02e480a8fcbf60f3979e383_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTgtMS0xLTE1NTYzOA_bb9dd044-d788-44d7-96d0-4a99a18f204a"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i671b1638704a44c290bc349298d71e48_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEwLTEtMS0xNTU2Mzg_728ee219-374d-437b-9420-1dcc85581038"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17829ca318b1498cbfae61d52d4675a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6"
      unitRef="usd">106000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a7fdc62e800449d92622b90c9db4ffd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE0LTEtMS0xNTU2Mzg_581ab145-e28c-46d0-ab7b-4a546efa180c"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4dfdef0347e94d1498a69a86deaa56d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE2LTEtMS0xNTU2Mzg_7e00f49e-413c-41cd-ade6-d6f7386418df"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id9b0fa1fef2342d79c4cb9415d79ffd1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE4LTEtMS0xNTU2Mzg_d7965b05-3ae7-452b-aa1c-9dfd16d067a9"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8f84fb522f6f458e920f395b641bc9ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIwLTEtMS0xNTU2Mzg_2dc36c80-8978-4b78-a6b4-e9cf97ed1694"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1120f4dcad384a9abe38b1b29af1c6a6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i015c2dd1d8224aaba8f11e2779372636_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTQtMS0xLTE1NTYzOA_dec758d7-245e-4ce0-bb37-bab214ec28c1"
      unitRef="usd">1329000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i674db30e4e6e4a1d9f25a2bfb6a2ca07_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTYtMS0xLTE1NTYzOA_c1c3936d-0653-46e9-a3e2-14c7d47c719f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i732d0c54d73849b69f3d917bd43daa7f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTgtMS0xLTE1NTYzOA_1efe439c-3d60-43e5-a8ef-ea4151612c7f"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if2238ba918384e999cc84aed3dcd385d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEwLTEtMS0xNTU2Mzg_add6197d-a74d-4d5b-aab2-266dd4844309"
      unitRef="usd">1273000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i866e56c0277b4bc9a25f19ec84f3fb26_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEyLTEtMS0xNTU2Mzg_ea1505b5-7690-4876-bb95-cfe8a69dd83f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i24949bc17dc543c08cedcde9b2f3d7e8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTE0LTEtMS0xNTU2Mzg_adbc75e9-5416-4689-a64f-404a70a92a06"
      unitRef="usd">1027000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie133e397deff441e98308ae589756218_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTE2LTEtMS0xNTU2Mzg_1a6fcd86-b127-438d-a7e1-cafe318a0b30"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6bdc708391174865b782df989e1ce518_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTE4LTEtMS0xNTU2Mzg_c84c7acf-b4f5-4bd0-8aa1-c2ed6bae64c3"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i574f79e048bb417ca2f0db77a714f150_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIwLTEtMS0xNTU2Mzg_e9f0abc8-e514-4b00-8284-bea112d70346"
      unitRef="usd">969000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i77d6d46b530f43febb88f895a185afb9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIyLTEtMS0xNTU2Mzg_8adc4b9f-29fa-4003-9600-58615581fd36"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifea2ce2cd7f74f449218e9ebc7dcf7c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTQtMS0xLTE1NTYzOA_70aac13a-baf8-4171-84d1-f83e89dc4d6f"
      unitRef="usd">1431000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iba350294128c42bc87995ecc8e035456_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTYtMS0xLTE1NTYzOA_d78cb2b6-5dc0-4f55-8ec1-99c8a25c3a7a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i532f4bd22c5c45d4af63afa5a4f2453f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTgtMS0xLTE1NTYzOA_858c9006-32b2-48a8-8d60-39f2cd0e9d08"
      unitRef="usd">141000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9306a220094a4ee4851877329040ec09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEwLTEtMS0xNTU2Mzg_94f58f7c-725d-4068-95d6-a5d42c4fec72"
      unitRef="usd">404000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i98efc316265f4aeba589a5cdcdb2ba3a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61"
      unitRef="usd">886000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i255f65b9224f4081b95ec6f405a1952b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE0LTEtMS0xNTU2Mzg_b7b49a6c-8ac0-40dd-900c-08b8b9b128ff"
      unitRef="usd">1514000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i59707801ebc544c4aef8569d05013809_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE2LTEtMS0xNTU2Mzg_298650ef-6ab3-4cb3-81f1-a735e51a7f90"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if6f9185b14e74414b6142cd14b78487b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE4LTEtMS0xNTU2Mzg_d6752f22-093b-4587-8387-81799384a918"
      unitRef="usd">117000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ca53c720af3408083112ad16a8d242f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIwLTEtMS0xNTU2Mzg_dab840e9-9bf7-41cd-937b-b650f194bbdf"
      unitRef="usd">393000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i13d65917ea214718aabb6241059fbb61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13"
      unitRef="usd">1003000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTItMS0xLTE3NjM2Ng_425f57a6-607d-4ebb-af52-19699ffd0302"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTQtMS0xLTE1NTYzOA_20f456d2-56b6-46eb-a3bf-23473aef2796"
      unitRef="usd">10729000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iab50e3974e214326979f7b8957262eec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTYtMS0xLTE1NTYzOA_8a1d0f7f-bc88-434a-bb61-8529134021dd"
      unitRef="usd">191000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6fc429f107fb4881b04687f32fc0685e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTgtMS0xLTE1NTYzOA_daade72a-2367-4bff-8f44-48258c42c8bd"
      unitRef="usd">6672000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5f2413d9a6104540883ae20a14dee735_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEwLTEtMS0xNTU2Mzg_e75df7df-9d4e-4ccf-9eee-b3c012270a4d"
      unitRef="usd">1677000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic18418a4253841c684ea8af6ccec0aa6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEyLTEtMS0xNTU2Mzg_de7d172e-e54a-4dfb-9374-e22f89b1b318"
      unitRef="usd">2189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib52bc8201e914daf823fa750d650a1f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTE0LTEtMS0xNTU2Mzg_2986f19a-466d-4240-8d5b-922e76669fbc"
      unitRef="usd">9811000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3151aa7ee6ab4f8398bd9a46d307ae04_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTE2LTEtMS0xNTU2Mzg_255763de-a751-4ff6-a8b2-9a9484643116"
      unitRef="usd">61000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie891101977024301955e23a929e1b4bf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTE4LTEtMS0xNTU2Mzg_0c2caa2f-b81f-4fff-bda9-4528a7b0691d"
      unitRef="usd">5681000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17489845f01240d096281d798554cdc7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIwLTEtMS0xNTU2Mzg_5c2089f9-8056-4ba5-92d3-dd8caa08ffa5"
      unitRef="usd">1362000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i778bcf63d499487093fcd6b390c2334b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIyLTEtMS0xNTU2Mzg_49e38d60-4156-420c-b0d3-559b21653490"
      unitRef="usd">2707000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic3987296f1084db39f1525b58cd1a718_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTQtMS0xLTE3NjQyNg_357498f3-eae3-47e6-a717-100ee9859b9a"
      unitRef="usd">85000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i495275bffa674b0f800ed1decb890131_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTYtMS0xLTE3NjQ3MQ_b1de6f06-71ed-4e13-9dcd-7988706f68ea"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i624dc668a9d84bf4918f26033ef6b532_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTgtMS0xLTE3NjUxNg_0a72140e-bfc6-45fc-a6db-b16e3475ccc4"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5289bfcfe10644b0945be402d243ebfe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE0LTEtMS0xNzY2MjE_4082ca8f-abbf-473f-91bd-db8e8256cad1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ife9e20479d3c4f3a82eec65d7edb2fec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE4LTEtMS0xNzY2NDI_66f395c5-8823-4e54-99d7-da791aa1f371"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9af20ea2173648718c35eddadc26f4d7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIwLTEtMS0xNzY2NTE_bbefd3e9-b4f2-4678-9562-3af5bffe61e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i16cae3cccb9b437482e0606550ca5f7c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7e4072641bf848fd9a69cde4746de8af_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE1NTYzOA_79452b9b-8bc1-4b93-b873-62597a118422"
      unitRef="usd">669000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4895c42f91a3449d9e4a69e220f8567d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE1NTYzOA_7b5921d0-3be3-4e5f-a29d-b19cfb7ba075"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie49724b7bcd8476597210f4014ed8c5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE1NTYzOA_d8aeab8c-3274-41ea-b63d-f760575f61ae"
      unitRef="usd">669000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia4e9d20521f84171a18296ea65d842c4_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNTU2Mzg_2bc90cbe-8d40-409b-ba58-60ba596ba1d2"
      unitRef="usd">588000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaafcfb726811461e84845b5dba189707_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNTU2Mzg_602cce56-20e0-4ce1-94c3-e47dc1b24772"
      unitRef="usd">588000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6a77fde9c8d47a0b5a6ce8b6f44b599_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNTU2Mzg_44eb4742-6f2b-478c-8d05-cfec32546ac0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i388802b089ce4803af64b6ab3e8a745d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="if48068ea782f42749ec61f3378bf81b4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTItMS0xLTE3NjM3NQ_d05385c1-a4e4-4f26-9a73-12054be9aa08"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if48068ea782f42749ec61f3378bf81b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE3NjQyNg_1d1a6952-df5d-4cd6-8d55-4c84f4196f29"
      unitRef="usd">753000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib94cc14b225548bca7b6f25c551f7130_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE3NjQ3MQ_64cb9db0-2dcb-4e78-ad63-f53d8e5e81d1"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i60ffdd0bae334efa9bc4cc9090bf826b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE3NjUxNg_e6bd7c83-d3d0-47a5-a1f2-aee47f3caf86"
      unitRef="usd">750000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2bc6edc92b8c4f049c4a39984706caa1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNzY2MjE_c61eac8c-1ade-4f37-90c2-b80ac6d9c38c"
      unitRef="usd">588000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i73f245cfadb84797965a899a8eeb520c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNzY2NDI_59c98ae1-8711-4d60-8f1f-664796bfed11"
      unitRef="usd">588000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i793b789e8a0242258ea94c9fd8c9f383_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNzY2NTE_a5997f8e-98cf-4081-9f7e-e019e7d6edd2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifdf0f90452504d429ae0f90828d23cc3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY0_f5700cd7-79df-42ca-865c-51fd94401e8d">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides an analysis of the changes in our more significant investments valued using significant unobservable inputs, including those reported as part of discontinued operations for 2020:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,362&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases, sales, and settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Transfer into/(out&#160;of) Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;265&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exchange rate changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,677&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17489845f01240d096281d798554cdc7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzUtMTAtMS0xLTE1NTYzOA_20297c66-b2e1-4cf7-aa7c-9781fb7cea49"
      unitRef="usd">1362000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ice8be255951e4b8481ed15370c61e701_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzUtMTItMS0xLTE1NTYzOA_95893552-9d0a-4d85-9e03-81471e7bba62"
      unitRef="usd">1342000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzctMTAtMS0xLTE1NTYzOA_6f054186-1403-4c67-81dd-e739121bab15"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzctMTItMS0xLTE1NTYzOA_e16a6735-310d-43f8-a72d-692effa643cb"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzktMTAtMS0xLTE1NTYzOA_9f6ffc76-4dc0-4763-b147-f95928e5bd7b"
      unitRef="usd">52000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzktMTItMS0xLTE1NTYzOA_6ce47a35-4c66-4993-8ef3-092a5eeb4a8d"
      unitRef="usd">-47000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEwLTEwLTEtMS0xNTU2Mzg_4a44274b-ea82-4bcf-b1dc-16db65f758e8"
      unitRef="usd">265000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEwLTEyLTEtMS0xNTU2Mzg_d0095aad-3663-402d-8825-5de9495e9552"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzExLTEwLTEtMS0xNTU2Mzg_80aad849-fc3a-49bd-9b87-b4d0052dd66e"
      unitRef="usd">-24000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ib471922b03524068902766bc0fa91108_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzExLTEyLTEtMS0xNTU2Mzg_32204547-20af-4e9c-b57c-84955c2c2fe5"
      unitRef="usd">58000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5f2413d9a6104540883ae20a14dee735_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEyLTEwLTEtMS0xNTU2Mzg_d33e8e1f-3097-418c-bc85-5add2283feb3"
      unitRef="usd">1677000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i17489845f01240d096281d798554cdc7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyZTdkN2U2YzlhNmM0NmE5YWVhZGEwOWI2MTExNmQ3Yi90YWJsZXJhbmdlOjJlN2Q3ZTZjOWE2YzQ2YTlhZWFkYTA5YjYxMTE2ZDdiXzEyLTEyLTEtMS0xNTU2Mzg_093525fa-ac94-4c66-89d0-e68473bdb72d"
      unitRef="usd">1362000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDA0_6e5e45c2-ba37-4756-aa27-3a79fe9d9490">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the expected future cash flow information related to our benefit plans:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pension Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Postretirement Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected employer contributions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected benefit payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&#x2013;2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzQtMi0xLTEtMTU1NjM4_6b0a4dc6-8d89-464e-8a14-e691438da250"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzQtNC0xLTEtMTU1NjM4_cb037f61-8e11-4537-822c-8185f636adfd"
      unitRef="usd">177000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzQtNi0xLTEtMTU1NjM4_45b1acc2-0975-41ad-a6b8-6a42a9eb393c"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzYtMi0xLTEtMTU1NjM4_755aa90b-3264-4897-97f3-93e60dce8c29"
      unitRef="usd">1296000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzYtNC0xLTEtMTU1NjM4_ad9342c4-0bb2-43c7-9f12-7d96acd9c64b"
      unitRef="usd">384000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzYtNi0xLTEtMTU1NjM4_614c3340-e33f-42cb-a3e9-5d0ddb12940b"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzctMi0xLTEtMTU1NjM4_d65b5e31-5a65-4c0c-9fd4-fae0610cac2d"
      unitRef="usd">1155000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzctNC0xLTEtMTU1NjM4_6f38ec66-30fe-4ae0-878f-fa54185979dd"
      unitRef="usd">372000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzctNi0xLTEtMTU1NjM4_3552b48e-e9ce-4918-9888-42fb16c5181f"
      unitRef="usd">73000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzgtMi0xLTEtMTU1NjM4_55fda206-8c5d-4898-abae-fbdc73f78571"
      unitRef="usd">1140000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzgtNC0xLTEtMTU1NjM4_0bc7f4f5-dbc2-47e8-9484-03dac5a8ccc6"
      unitRef="usd">383000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzgtNi0xLTEtMTU1NjM4_42783a02-2c1e-4ddb-a6cb-32bebd371e08"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzktMi0xLTEtMTU1NjM4_c03fcaae-b41c-4164-bc50-4613722f9dec"
      unitRef="usd">1089000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzktNC0xLTEtMTU1NjM4_ff8a19a2-73b8-4f62-ab07-5fdbaef467ff"
      unitRef="usd">392000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzktNi0xLTEtMTU1NjM4_0f37266a-1cdd-4d09-a8ad-a3696b819b10"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzEwLTItMS0xLTE1NTYzOA_c3d3574c-9c21-4929-83a4-be44391a42be"
      unitRef="usd">1058000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzEwLTQtMS0xLTE1NTYzOA_1a70d239-9b0c-469b-9174-ade98d0a43e3"
      unitRef="usd">397000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzEwLTYtMS0xLTE1NTYzOA_0a4660bb-0092-4305-8878-b4acb33cbe09"
      unitRef="usd">68000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i6691b5ea5ce944ac903398a39bf95d3b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzExLTItMS0xLTE1NTYzOA_3f043be4-7ede-49b7-9129-87d276026a0a"
      unitRef="usd">4908000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i2f2c89e1ddee4381b1db02809acf2a31_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzExLTQtMS0xLTE1NTYzOA_9e065847-bb07-439a-979d-2fa7e3d77d42"
      unitRef="usd">2124000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToxN2IxYjhjZDU0Yjk0NmVjYjc1YWEwYjYwNWI4MTY1MC90YWJsZXJhbmdlOjE3YjFiOGNkNTRiOTQ2ZWNiNzVhYTBiNjA1YjgxNjUwXzExLTYtMS0xLTE1NTYzOA_4a8dc67d-32b6-4b60-afe7-bf9353c15824"
      unitRef="usd">359000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM2NjU_b30059d9-5f23-4cd4-99d1-78d1d2a22e8a"
      unitRef="usd">732000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM2NTc_bfad13f3-477f-4f37-8d6c-33c23e9059f0"
      unitRef="usd">685000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzE2NDkyNjc0NjM2NDk_01c3bce7-a488-4924-88e2-424b9b2ea2b5"
      unitRef="usd">659000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NzQ_95f6a7ae-7125-46be-a804-7718211c55b1">Equity&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Common Stock Purchases&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We purchase our common stock through privately negotiated transactions or in the open market as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our BOD, are available for general corporate purposes. In December 2017, the BOD authorized a $10 billion share repurchase program, which was exhausted in the first quarter of 2019. In December 2018, the BOD authorized another $10 billion share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2019, we entered into an ASR with Goldman Sachs &amp;amp; Co. LLC to repurchase $6.8 billion of our common stock pursuant to our previously announced share repurchase authorization. We paid $6.8 billion and received an initial delivery of 130 million shares of common stock, which represented approximately 80% of the notional amount of the ASR. In August 2019, the ASR with Goldman Sachs &amp;amp; Co. LLC was completed resulting in Goldman Sachs &amp;amp; Co. LLC owing us an additional 33.5 million shares of our common stock. The average price paid for all of the shares delivered under the ASR was $41.42 per share. The common stock received is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our ASR:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(SHARES IN MILLIONS, DOLLARS IN BILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares of common stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents shares purchased pursuant to the ASR with Goldman Sachs &amp;amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our remaining share-purchase authorization was approximately&#160;$5.3 billion at December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Preferred Stock and Employee Stock Ownership Plans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Prior to May 4, 2020, we had outstanding Series A convertible perpetual preferred stock (the Series A Preferred Stock) that was held by an ESOP trust (the Trust). All outstanding shares of Series A Preferred Stock were converted, at the direction of the independent fiduciary under the Trust and in accordance with the certificate of designations for the Series A Preferred Stock, into shares of our common stock on May 4, 2020. The Trust received an aggregate of 1,070,369 shares of our common stock upon conversion, with zero shares of Series A Preferred Stock remaining outstanding as a result of the conversion. In December 2020, we filed a certificate of elimination and a restated certificate of incorporation with the Delaware Secretary of State, which eliminated the Series A Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Since May 4, 2020, we have one ESOP that holds common stock of the Company (Common ESOP). As of December 31, 2021, all shares of common stock held by the Common ESOP have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was $19 million in 2021, $19 million in 2020 and $20 million in 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i367c45882da94e7f95af6582e7a69196_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzQ4NA_07e01513-c86f-494c-b929-261bdf279581"
      unitRef="usd">10000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="ie44e280570da48ac9f0565d31167fa82_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzYwOA_1aaebf71-cbfd-40e5-878b-c429c5e75d8c"
      unitRef="usd">10000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i5cbd61ea7e074c3cb9b549fc73f7ea50_I20190228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE0MTA_317d33b4-e003-43c8-9056-3380f06a0f0b"
      unitRef="usd">6800000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="i5cbd61ea7e074c3cb9b549fc73f7ea50_I20190228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE1MTA_4c2cf730-c3b8-4a7a-8379-a65270df14fe"
      unitRef="usd">-6800000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if31c50772d7a4726a1a5529a7fef8da5_D20190201-20190228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE1NDk_730424dc-4a09-4a62-9c42-322efcb55740"
      unitRef="shares">130000000</us-gaap:TreasuryStockSharesAcquired>
    <pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount
      contextRef="if31c50772d7a4726a1a5529a7fef8da5_D20190201-20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE2MDg_551a9bec-da3b-41b8-9d4d-afd82aad4f1e"
      unitRef="number">0.80</pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i952c34b232a94d2d8ad00e03c4de2d9e_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE3MjI_6987d4af-9b80-46a6-afbf-d3e8a0b88b1c"
      unitRef="shares">33500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="i952c34b232a94d2d8ad00e03c4de2d9e_D20190801-20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE4MjY_ac88dce9-a341-49c0-9b7f-a34317a68dac"
      unitRef="usdPerShare">41.42</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTU_9a0e5954-b8a7-4665-b660-4b992451c070">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.768%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our ASR:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(SHARES IN MILLIONS, DOLLARS IN BILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;2019&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares of common stock purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of purchase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Represents shares purchased pursuant to the ASR with Goldman Sachs &amp;amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtMi0xLTEtMTU1NjM4_5ddd7032-2734-4e63-b8ef-bd1e472a69bf"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNC0xLTEtMTU1NjM4_bf8d12fe-c187-4087-9b79-67cfe4477e03"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNi0xLTEtMTU1NjM4_f86e5b8a-d846-49f5-82e8-3bfb2f963c41"
      unitRef="shares">213000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtMi0xLTEtMTU1NjM4_d8495ded-2d5d-4a4f-9d8d-7cb3d75f1172"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNC0xLTEtMTU1NjM4_5eaa3323-053f-49a2-8a83-24c5cd9be3ed"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNi0xLTEtMTU1NjM4_e3085a62-dc56-4860-80fe-177014844a33"
      unitRef="usd">8900000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i81e39a223d384b35843e9b8e7445832b_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzIwMjA_4a0adf2e-3681-4e8d-ae9f-190f50e6b017"
      unitRef="usd">2100000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzIyMTU_16baaacd-f520-4c49-a09f-0385a40b08a8"
      unitRef="usd">5300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i56eda332625c487ca483e8359eb0f33a_D20200504-20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzE2NDkyNjc0NDkxOTE_2b4dc8be-8215-45a5-8596-206cc7ce6e13"
      unitRef="shares">1070369</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i152722889eb34e0db6ad2e1dfaeb0eed_I20200504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDgy_b37f7fdd-dad7-4643-af32-c5300f96d1f5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <pfe:NumberofEmployeeStockOwnershipPlans
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzMwODk_7b75b074-dab9-4153-a3de-f5709ebae997"
      unitRef="employeestockownershipplan">1</pfe:NumberofEmployeeStockOwnershipPlans>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i7ee44a1fecca4b32be7705bc2cf810b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDAy_6a889194-0fa7-4cae-b05e-724cedd4fba7"
      unitRef="usd">19000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="ifd44478503164fd8a8e14462b5e7a729_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDA2_2e0363cc-4370-4b71-9da0-b8ce9459f470"
      unitRef="usd">19000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="i917415daad0a4424b8d7a97c2d07bb8f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzEyMDk0NjI3OTEzMDE2_e9779538-8bfd-4118-b8c8-504236152707"
      unitRef="usd">20000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDg_408c783b-271d-45c9-9410-57e7b358c01b">Share-Based Payments&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Our compensation programs can include share-based payment awards with value that is determined by reference to the fair value of our shares and that provide for the grant of shares or options to acquire shares or similar arrangements. Our share-based awards are designed based on competitive survey data or industry peer groups used for compensation purposes, and are allocated between different long-term incentive awards, generally in the form of Total Shareholder Return Units (TSRUs), Restricted Stock Units (RSUs), Portfolio Performance Shares (PPSs), Performance Share Awards (PSAs), Breakthrough Performance Awards (BPAs) and Stock Options, as determined by the Compensation Committee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The 2019 Stock Plan (2019 Plan) replaced and superseded the 2014 Plan. It provides for 400 million shares, in addition to shares remaining under the 2014 Plan, to be authorized for grants. The 2019 Plan provides that the number of stock options, TSRUs, RSUs, or performance-based awards that may be granted to any one individual during any 36-month period is limited to 20 million shares, and that RSUs count as three shares, PPSs, PSAs and BPAs count as three shares times the maximum potential payout, while TSRUs and stock options count as one share, toward the maximum shares available under the 2019 Plan. As of December 31, 2021, 315 million shares were available for award. Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;A summary of the awards and valuation details:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Awarded to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Recognition and Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Total Shareholder Return Units (TSRUs)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Senior and other key management and select  employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107"&gt;five&lt;/span&gt; or &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03"&gt;seven&lt;/span&gt;-year term, if and to the extent the total value is positive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using a Monte Carlo simulation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Select employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;For RSUs granted, in virtually all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the closing price of our common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Portfolio Performance Shares (PPSs)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Select employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#x2019;s long-term product portfolio during a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfMTA5OTUxMTYyODQ4MQ_0da09f05-3e8c-4080-bb4d-fc5dd48fbbca"&gt;three&lt;/span&gt; or &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNDQz_4d00d2e4-77a0-4861-9e03-9cd48bf4e5b8"&gt;five&lt;/span&gt;-year performance period from the year of the grant date, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the intrinsic value method using the closing price of our common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management&#x2019;s assessment of the probability that the specified performance criteria will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Performance Share Awards (PSAs)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Senior and other key management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt"&gt;Adjusted net income over three &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg5_e6c42dac-714f-4f5e-996c-4d0353676184"&gt;one&lt;/span&gt;-year periods; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt"&gt;TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNDg1_fcbb828a-fc1b-45e8-92d8-b04179945bfd"&gt;three&lt;/span&gt;-year performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the intrinsic value method using the closing price of our common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#x2019;s assessment of the probability that the specified performance criteria will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Breakthrough Performance Awards (BPAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt"&gt;Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt"&gt;For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDk_1531252f-ed7d-4bb0-98f0-50eaa78bb5c6"&gt;one&lt;/span&gt;-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer&#x2019;s product pipeline during the performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt"&gt;The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;As of the grant date using the intrinsic value method using the closing price of our common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the probable vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#x2019;s assessment of the probability that the specified performance criteria will be achieved and/or management&#x2019;s assessment of the probable vesting term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Awarded to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Recognition and Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Select employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the Black-Scholes-Merton option-pricing model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#x2019; original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (1,444,395 PTSRUs) and 361,099 PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $30.31 and at a GDFV of $5.54 per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="93" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PPSs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$7.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$6.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$8.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$304&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$4.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$3.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised or share units converted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$594&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$245&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$584&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$261&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash received upon exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$425&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$394&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax benefits realized from exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Compensation cost recognized, pre-tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$259&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$294&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$272&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$535&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$180&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$114&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total compensation cost related to nonvested awards not yet recognized, pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$187&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$241&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted-average period over which cost is expected to be recognized (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Weighted-average GDFV per TSRUs and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;TSRU includes expense for PTSRUs, which is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total share-based payment expense was $1.2 billion, $780 million and $718 million in 2021, 2020 and 2019, respectively, which includes pre-tax share-based payment expense included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; of $2 million, $25 million and $32 million in 2021, 2020 and 2019, respectively. Tax benefit for share-based compensation expense was $227 million, $141 million and $137 million in 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The table above excludes total expense due to the modification for share-based awards in connection with our cost reduction/productivity initiatives, which was not significant for all years presented and is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;). Amounts capitalized as part of inventory cost were not significant for any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expected dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(based on a constant dividend yield during the expected term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; (based on interpolated yield on U.S. Treasury zero-coupon issues)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0.93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; (based on implied volatility, after consideration of historical volatility)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26.53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;TSRUs contractual/stock options expected term, years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; (based on historical exercise and post-vesting termination patterns for stock options) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of all TSRU, RSU, PPS, PSA and BPA activity during 2021 (with the shares granted representing the maximum award that could be achieved for PPSs, PSAs and BPAs):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PPSs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BPAs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;TSRUs&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Per TSRU, Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#160;Weighted Avg. GDFV per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Weighted Avg. Intrinsic Value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Weighted Avg. Intrinsic Value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Weighted Avg. Intrinsic Value per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;GDFV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Grant Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nonvested, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,077&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,632&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,165&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(44,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7.21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reinvested dividend equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6.77&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;35.17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41.45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;47.47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nonvested, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;114,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;25,540&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;35.52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,480&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of TSRU and PTU information as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PTUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Price&lt;br/&gt;Per TSRU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining Contractual Term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206,996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92,398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28.72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,946&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs Expected to vest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,910&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs exercised and converted to PTUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, we settled 46,060,346 TSRUs with a weighted-average grant price of $23.04 per unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, 7,093,787 TSRUs with a weighted-average grant price of $27.41 per unit were converted into 2,943,737 PTUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of all stock option activity during 2021:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(31,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25.75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,874&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest, December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,583&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29.81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Market price of our underlying common stock less exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The number of options expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2Xzc3Nw_dc61253b-ae81-48dc-b975-427d174693c8"
      unitRef="shares">400000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQzOTgwNDY1MTk0NjE_daa779b1-9279-4b8d-b767-c9b98ac45870">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="idf9513f4ba0a486e8f4cf6cdcd953227_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzEwNTE_c4b1eadb-537e-4b1b-b7a7-792047c27c73"
      unitRef="shares">20000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="i805079d974574ff6a2d5f8b886169231_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExMDA_5038a510-9459-4a05-94c6-9a79a5befb66"
      unitRef="shares">3</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="ic2151f3e772140029f5252c02f68b75b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExMDA_8334ada6-4860-429c-bd63-a7715d22a15d"
      unitRef="shares">3</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="ic44cb9f5305946c5afb2c81a69675dff_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExMDA_8bd087c9-5bcf-4311-a7dc-20215c3b0247"
      unitRef="shares">3</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="ic17568d2b6964d96a3edee3790b0ffae_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExNTA_3d1a7d3b-791e-4101-804e-425faac704d1"
      unitRef="shares">1</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="idc7be31568a945ebb1201de1758225e9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzExNTA_a208dd86-148c-4ad0-b03e-b40a26678619"
      unitRef="shares">1</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzEyMjc_5b0cc664-6e5e-4776-aec0-24ed69891e07"
      unitRef="shares">315000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTM_22da06f8-775a-4f70-bdfb-a9a9844e06ff">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;A summary of the awards and valuation details:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Awarded to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Recognition and Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Total Shareholder Return Units (TSRUs)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Senior and other key management and select  employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividend equivalents accumulated during the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107"&gt;five&lt;/span&gt; or &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03"&gt;seven&lt;/span&gt;-year term, if and to the extent the total value is positive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Settlement price is the average closing price of our common stock during the 20 trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using a Monte Carlo simulation model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Select employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive a specified number of shares of our common stock, including dividend equivalents that are reinvested into additional RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;For RSUs granted, in virtually all instances, the units vest on the third anniversary of the grant date assuming continuous service from the grant date.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the closing price of our common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Portfolio Performance Shares (PPSs)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Select employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;For PPSs granted, the awards vest on the third anniversary of the grant assuming continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#x2019;s long-term product portfolio during a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfMTA5OTUxMTYyODQ4MQ_0da09f05-3e8c-4080-bb4d-fc5dd48fbbca"&gt;three&lt;/span&gt; or &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNDQz_4d00d2e4-77a0-4861-9e03-9cd48bf4e5b8"&gt;five&lt;/span&gt;-year performance period from the year of the grant date, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;The number of shares that may be earned ranges from 0% to 200% of the initial award depending on goal achievement over the performance period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the intrinsic value method using the closing price of our common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned, and management&#x2019;s assessment of the probability that the specified performance criteria will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Performance Share Awards (PSAs)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Senior and other key management&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to receive, at the end of the performance period, shares of our common stock (retirees) earned, if any, or an equal value in cash (active colleagues), including dividend equivalents on shares earned, dependent upon the achievement of predetermined goals related to two measures:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt"&gt;Adjusted net income over three &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg5_e6c42dac-714f-4f5e-996c-4d0353676184"&gt;one&lt;/span&gt;-year periods; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:3.17pt"&gt;TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNDg1_fcbb828a-fc1b-45e8-92d8-b04179945bfd"&gt;three&lt;/span&gt;-year performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;PSAs vest on the third anniversary of the grant assuming continuous service from the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;The award that may be earned ranges from 0% to 200% of the target award depending on goal achievement over the performance period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the intrinsic value method using the closing price of our common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#x2019;s assessment of the probability that the specified performance criteria will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Breakthrough Performance Awards (BPAs)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;Select employees identified as instrumental in delivering medicines to patients (excluding executive officers)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt"&gt;Entitle the holder to receive, at the end of the performance period, shares of our common stock, if any, including shares resulting from dividend equivalents earned on such shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt"&gt;For BPAs granted, the awards, if earned/vested, are settled at the end of the performance period, but no earlier than the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDk_1531252f-ed7d-4bb0-98f0-50eaa78bb5c6"&gt;one&lt;/span&gt;-year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goals related to advancing Pfizer&#x2019;s product pipeline during the performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%;padding-left:6.55pt"&gt;The number of shares that may be earned ranges from 0% to 600% of the target award depending on the level and timing of goal achievement over the performance period.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:107%"&gt;As of the grant date using the intrinsic value method using the closing price of our common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the probable vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of our common stock, the number of shares that are probable of being earned and management&#x2019;s assessment of the probability that the specified performance criteria will be achieved and/or management&#x2019;s assessment of the probable vesting term.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Awarded to&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Terms&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Recognition and Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Select employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant, for a period of time when vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Since 2016, only a limited set of non-U.S. employees received stock option grants. No stock options were awarded to senior and other key management in any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:6.55pt"&gt;Stock options vest on the third anniversary of the grant assuming continuous service from the grant date and have a contractual term of 10 years. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;As of the grant date using the Black-Scholes-Merton option-pricing model&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, and/or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#x2019; original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (1,444,395 PTSRUs) and 361,099 PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $30.31 and at a GDFV of $5.54 per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f"
      unitRef="tradingday">20</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="i04e1e8887418409c8efc97bcddd13100_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNTU1_ea826cc7-d654-49ff-822b-867a89ad94f9"
      unitRef="number">0</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="i9b45cc72fe144a41a027fcc9d82be277_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzYtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246ZGM5OGQzMGM4YTExNDgyOGFiY2U2OGZjMTVkMWQ5ODlfNTYx_938610a8-9551-4292-90a7-caf419284548"
      unitRef="number">2</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMjI5_6df88edb-9105-474c-aa2b-f8fc0fafb579"
      unitRef="measure">2</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfMzg2_ff1df9d3-99bf-4f89-858f-7dc326b3ffb5"
      unitRef="period">3</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="i6748c5eccf3f46b1be9064d93a0b8af6_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNjM0_2a3aaf0d-96e4-4459-bd78-231a46d87734"
      unitRef="number">0</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="i0a49ac6e8d614f469106f20db9f45fd0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzgtMS0xLTEtMTU1NjM4L3RleHRyZWdpb246OGYyNWNlMzU3MzEzNDk3Y2I1ZjNmMTJmYWQyMDRjYWJfNjQw_186566ae-e432-4a07-988b-d1d508acd3d6"
      unitRef="number">2</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="i28be20f732ea48069576d8342f25116e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2Mjk0MDE_889cf845-9507-4253-bca6-12ff137683bc"
      unitRef="number">0</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="ie383f1f76d1640bb8be8220be13b0054_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE5NjIyNS90ZXh0cmVnaW9uOmQ5ZWRmZmMyNzdjMTRlNzU5ZWU5OWQ1MTQzMmQzZjE1XzEwOTk1MTE2MjkzOTQ_718ad5ea-cbd9-4669-b3a7-1a334b36a6f9"
      unitRef="number">6</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ifd7ecda840fd43338a51a3f00ae86688_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI1YzI5YzlkZjQ0ZDRlNWU4NmJjODZkNmUwZjNmZTAxXzI3NQ_5288758e-d983-4718-bbb9-309b130eabaa"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzEwLTEtMS0xLTE1NTYzOC90ZXh0cmVnaW9uOjI1YzI5YzlkZjQ0ZDRlNWU4NmJjODZkNmUwZjNmZTAxXzQ2Ng_3f140c97-e4fd-42f5-b17c-b6499c8a16b8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i9593b3f58b76448e920aee74df7e93c9_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIwODg_203953c5-7182-48c9-93e4-7cbfec99bc78"
      unitRef="shares">1444395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i2f80dcb721524320b19d3c6b3d3391e6_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIxMDM_9edc92d1-99bf-44af-beb4-d540d84fc058"
      unitRef="shares">361099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice
      contextRef="i443cb80c5f964703aaecddf09596d6a4_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIyNDg_4a078a9e-685e-4bad-8ada-cad81ce3881a"
      unitRef="usdPerShare">30.31</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue
      contextRef="i443cb80c5f964703aaecddf09596d6a4_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzIyNjg_f0c9ae70-d792-4a54-b349-a9a134fd5b8b"
      unitRef="usdPerShare">5.54</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDk_0012b297-30ea-422c-877a-adca8d8ceef1">&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.361%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.118%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="93" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following provides data related to all TSRU, RSU, PPS, PSA and stock option activity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS, EXCEPT FAIR VALUE OF SHARES VESTED PER TSRU AND STOCK OPTION)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PPSs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$7.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$6.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$8.52&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$304&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$334&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$454&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$119&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$136&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$4.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$3.56&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$5.98&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total intrinsic value of options exercised or share units converted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$594&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$245&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$584&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$293&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$261&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cash received upon exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$795&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$425&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$394&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Tax benefits realized from exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$106&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$55&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Compensation cost recognized, pre-tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$259&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$287&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$294&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$281&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$272&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$275&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$535&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$180&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$114&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total compensation cost related to nonvested awards not yet recognized, pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$187&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$224&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$229&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$228&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$241&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$175&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$104&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$87&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$54&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted-average period over which cost is expected to be recognized (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Weighted-average GDFV per TSRUs and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;TSRU includes expense for PTSRUs, which is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.459%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="69" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of all TSRU, RSU, PPS, PSA and BPA activity during 2021 (with the shares granted representing the maximum award that could be achieved for PPSs, PSAs and BPAs):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="10" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PPSs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;BPAs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;TSRUs&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Per TSRU, Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;&#160;Weighted Avg. GDFV per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Weighted Avg. Intrinsic Value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Weighted Avg. Intrinsic Value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Shares&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Weighted Avg. Intrinsic Value per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;GDFV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;Grant Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Nonvested, &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129,844&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;32.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;35.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20,077&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,264&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34,522&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7.26&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.83&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;10,893&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;8,632&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,798&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1,165&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;38.73&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(44,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;7.21&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;30.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(8,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.66&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(6,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Reinvested dividend equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41.33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(4,879)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6.77&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;33.78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;35.17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(1,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;41.45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.43&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;47.47&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Nonvested, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;114,599&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6.90&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;34.12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;25,540&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;35.52&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;21,480&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5,154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;859&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;59.05&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of TSRU and PTU information as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PTUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Price&lt;br/&gt;Per TSRU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining Contractual Term &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;206,996&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;31.71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;92,398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28.72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,946&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs Expected to vest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;110,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34.16&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,910&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs exercised and converted to PTUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,074&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;182&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, we settled 46,060,346 TSRUs with a weighted-average grant price of $23.04 per unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;In 2021, 7,093,787 TSRUs with a weighted-average grant price of $27.41 per unit were converted into 2,943,737 PTUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMi0xLTEtMTU1NjM4_0030d148-ccdb-493d-9ef6-9c6e5e073b5c"
      unitRef="usdPerShare">7.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNC0xLTEtMTU1NjM4_466fd797-58fa-45d5-848d-734df1c99bde"
      unitRef="usdPerShare">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNi0xLTEtMTU1NjM4_75b7d650-b93e-46a1-87ad-f8b8375f99cd"
      unitRef="usdPerShare">8.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtOC0xLTEtMTU1NjM4_3ddbadfe-2c7e-469b-8b74-ac53c8330c60"
      unitRef="usd">304000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTAtMS0xLTE1NTYzOA_5ce6a7c9-5907-47d5-a423-c9b0057bbc7d"
      unitRef="usd">334000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ie346598571a44f5e9df70a558c1951da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTItMS0xLTE1NTYzOA_9f88f9b8-9153-4eae-9b34-60c2f6485b91"
      unitRef="usd">454000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTQtMS0xLTE1NTYzOA_1e6a6321-5b59-4629-a177-6e2866459aee"
      unitRef="usd">181000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTYtMS0xLTE1NTYzOA_b173fb43-0d28-4160-8fd4-5c4b99367cb5"
      unitRef="usd">119000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTgtMS0xLTE1NTYzOA_72fd28a5-d393-4635-8f84-5f5b000a4bc4"
      unitRef="usd">136000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjAtMS0xLTE1NTYzOA_3a83e750-3f49-46d0-a35a-4b9f84e9a9e4"
      unitRef="usd">33000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjItMS0xLTE1NTYzOA_de7e819a-94c2-4908-b137-6debfd7edbc1"
      unitRef="usd">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjQtMS0xLTE1NTYzOA_dffb3ed7-9572-487e-ad9c-3dc22c16c91a"
      unitRef="usd">64000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjYtMS0xLTE1NTYzOA_e3208f64-720b-4f0f-8801-e090f70792e1"
      unitRef="usdPerShare">4.86</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjgtMS0xLTE1NTYzOA_b49a6e3c-efe7-4be4-92f6-272d3b6a1aa8"
      unitRef="usdPerShare">3.56</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMzAtMS0xLTE1NTYzOA_eaafc4ca-df82-4841-949c-5e448cee1d0c"
      unitRef="usdPerShare">5.98</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMi0xLTEtMTU1NjM4_03dc70e4-91e3-43fc-be3b-f6553da659d7"
      unitRef="usd">594000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtNC0xLTEtMTU1NjM4_422ccd07-400b-458b-80e3-ac06caaaaa98"
      unitRef="usd">84000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtNi0xLTEtMTU1NjM4_eccd41c1-2ce8-47a1-a047-3044812539ef"
      unitRef="usd">175000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMTQtMS0xLTE1NTYzOA_75ccbad2-9a98-4785-b55c-920b87ac2366"
      unitRef="usd">228000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue
      contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMTYtMS0xLTE1NTYzOA_3be03cca-754d-482b-a237-3265c88f9803"
      unitRef="usd">224000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue
      contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMTgtMS0xLTE1NTYzOA_33b8cb4d-733f-4430-8eeb-36c72e21b783"
      unitRef="usd">245000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMjYtMS0xLTE1NTYzOA_bb9c9394-f9a0-412f-be17-717ad59b0770"
      unitRef="usd">584000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMjgtMS0xLTE1NTYzOA_f1937fed-cfe0-41a5-b14d-9e41185ca6e7"
      unitRef="usd">293000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzQtMzAtMS0xLTE1NTYzOA_514b2111-a888-43a6-9ac7-6de6d5366e4b"
      unitRef="usd">261000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzUtMjYtMS0xLTE1NTYzOA_a716dd4e-23c3-4b1c-8e5e-4e71018d62c2"
      unitRef="usd">795000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzUtMjgtMS0xLTE1NTYzOA_05766779-6f44-44c3-b6a4-0f547a0a03c0"
      unitRef="usd">425000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzUtMzAtMS0xLTE1NTYzOA_5dcef52b-0450-49c1-8668-ef8382abe056"
      unitRef="usd">394000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzYtMjYtMS0xLTE1NTYzOA_55485b73-6c6e-4ca1-937b-9aa80922a7fe"
      unitRef="usd">106000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzYtMjgtMS0xLTE1NTYzOA_10d051ca-097e-4661-ac55-1bbb7678bde5"
      unitRef="usd">55000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzYtMzAtMS0xLTE1NTYzOA_f8864890-eb52-47d7-b37e-e8f2b0d5afd1"
      unitRef="usd">47000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMi0xLTEtMTU1NjM4_1a94ef26-c091-4e7d-9c52-3172fbaf29df"
      unitRef="usd">259000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNC0xLTEtMTU1NjM4_992fa98a-bf2f-4f41-a787-082f6d3b2a31"
      unitRef="usd">287000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNi0xLTEtMTU1NjM4_07778de6-12fc-43bd-ade7-053555389107"
      unitRef="usd">294000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctOC0xLTEtMTU1NjM4_87c54e86-a569-4df7-b8e6-04951fcb6787"
      unitRef="usd">281000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTAtMS0xLTE1NTYzOA_5806a747-3c80-4200-947d-3b5d951b4251"
      unitRef="usd">272000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie346598571a44f5e9df70a558c1951da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTItMS0xLTE1NTYzOA_e6579469-97e3-4adb-8f01-c8be1876bf76"
      unitRef="usd">275000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTQtMS0xLTE1NTYzOA_d4d12f82-0c20-47ed-9fbe-8e0227117c6d"
      unitRef="usd">535000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTYtMS0xLTE1NTYzOA_ca3030ec-ef12-4e8d-bc08-dda9ca807e2a"
      unitRef="usd">180000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTgtMS0xLTE1NTYzOA_7bfc61f9-ca76-4c82-a926-959e839402ce"
      unitRef="usd">114000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjAtMS0xLTE1NTYzOA_4b62f3d1-5853-4f73-8a18-d81f343f0906"
      unitRef="usd">76000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjItMS0xLTE1NTYzOA_fa3d1f38-ed77-4ad5-ac7d-a22f0e7a7326"
      unitRef="usd">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjQtMS0xLTE1NTYzOA_fcb4ae62-0c3e-4fac-a30c-235ab34d77a1"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjYtMS0xLTE1NTYzOA_229afef2-6bb7-4825-b021-99094d2266fa"
      unitRef="usd">5000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjgtMS0xLTE1NTYzOA_d579c4af-57c0-45ef-981f-37cabba91840"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMzAtMS0xLTE1NTYzOA_38732335-d53e-4f06-84e2-85dd1154c1a0"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMi0xLTEtMTU1NjM4_6f4a9d0c-9981-4015-8d28-347ef86a4bcd"
      unitRef="usd">187000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtNC0xLTEtMTU1NjM4_917c700f-f374-4d9c-8ada-cbeaacf86df8"
      unitRef="usd">224000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i2473beb495894534a4c23085d71539f7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtNi0xLTEtMTU1NjM4_ee814931-ee55-46db-a91f-95c6e92ba6af"
      unitRef="usd">229000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i32f0385272bd4aac882c487c230d065c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtOC0xLTEtMTU1NjM4_e4b89f4a-6278-43da-8e10-b891c0fdbb32"
      unitRef="usd">271000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ief795c9787db4b308dde841b75ab39f2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTAtMS0xLTE1NTYzOA_8a50fc82-45f4-4066-a171-61d249fb1000"
      unitRef="usd">228000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i30bd7895983642db9bf813a473267120_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTItMS0xLTE1NTYzOA_fcc52ab4-8046-4261-9e29-b80cabd048c6"
      unitRef="usd">241000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTQtMS0xLTE1NTYzOA_60be4c9e-6411-45f0-b9f5-683657d3f996"
      unitRef="usd">175000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if41e5d4716e04e498cba46b05595ab61_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTYtMS0xLTE1NTYzOA_740e5470-772f-4cbb-a59f-34f05f0eef03"
      unitRef="usd">104000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i4fc53e6e2a9e49298a3cfd288203afd2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMTgtMS0xLTE1NTYzOA_6c72f42a-d0b9-4a16-8456-9b688b4a3c8a"
      unitRef="usd">87000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjAtMS0xLTE1NTYzOA_0d9e2f33-02bc-489c-bd68-f2f6b515018f"
      unitRef="usd">54000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i84a9df877b7a4600aec68656dac6703a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjItMS0xLTE1NTYzOA_1a51cd48-1a7f-4437-93ec-4ebeac3d5194"
      unitRef="usd">32000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ic7f0f1f3fa304519914914cfa722b7a5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjQtMS0xLTE1NTYzOA_3bc06075-c243-48a3-9283-026e537ae368"
      unitRef="usd">34000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i97f983501e904503babee369fc4f690c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjYtMS0xLTE1NTYzOA_f9c7003c-50b3-489c-a090-91495fe7e44c"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i1b9d4654dee8466e88457fed9824652f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMjgtMS0xLTE1NTYzOA_76c28f3d-63b8-4e5e-942d-a455f8251902"
      unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibabdd67705e148c3827e146d45375317_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzgtMzAtMS0xLTE1NTYzOA_0988425e-c6db-41bc-aeba-fa82296cc9e7"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMi0xLTEtMTU1NjM4_c8360efa-797b-4b3a-9039-865604d3b4ce">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktNC0xLTEtMTU1NjM4_930117f1-c0e6-46c2-826d-18b8452dfe6b">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktNi0xLTEtMTU1NjM4_f413bcf3-4913-4b10-8b9c-0915588e8ab7">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktOC0xLTEtMTU1NjM4_3c5ac71e-6c33-47ab-8198-b909ebe49cf4">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i210ca1146b4043e9b5e0923ac15bf374_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTAtMS0xLTE1NTYzOA_30334fdd-8da3-44e1-995d-3d2f46d9d1a1">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie346598571a44f5e9df70a558c1951da_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTItMS0xLTE1NTYzOA_c6fb925a-9a8b-4bd9-8f5a-2b998664da9e">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTQtMS0xLTE1NTYzOA_1e4489a1-28c5-4ee7-ad3c-017eaa9f51d8">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1c11dd1c72f74c2fb01a83cf1df9430e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTYtMS0xLTE1NTYzOA_181c257d-d8e6-4fa7-9a65-bf7aeb3e5606">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i463a136a10d340a89aa48e96aab5fb09_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMTgtMS0xLTE1NTYzOA_012b6bc7-d1d3-45ec-88bc-f5298e103a3d">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjAtMS0xLTE1NTYzOA_65aa1b79-61f1-4632-be43-7503d5bd5644">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib1efbd5b127c43f7807db5cd6a044a05_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjItMS0xLTE1NTYzOA_46f5a6ca-ca1a-419a-808e-f53be303b1e6">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3915d49c863444eba8e0a81b4889cb4a_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjQtMS0xLTE1NTYzOA_b82b3c1a-1489-4f42-9af8-ef0f218705d8">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjYtMS0xLTE1NTYzOA_0c850efe-9c3b-48ee-b50a-003d4858dae3">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMjgtMS0xLTE1NTYzOA_ea77eda9-ebde-438b-9c41-0f054211cc69">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzktMzAtMS0xLTE1NTYzOA_26981495-84d9-46ea-8536-41988ec87380">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI2ODk_32511e7b-e063-47a9-a520-d4ea20491a09"
      unitRef="usd">1200000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI2OTM_912dcb5d-c7dc-4a10-80b1-68fa85f384e9"
      unitRef="usd">780000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI3MDA_bc34ce82-9fe4-49e8-999a-de7bfd06cb58"
      unitRef="usd">718000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94325d0fdc4e459f931d66a9b73fffa3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI4NDk_c2e618d0-82be-4df1-8206-2364765da6fc"
      unitRef="usd">2000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb707d364c664f20a32ea1127fd4286b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI4NTM_88bcd10f-ddcd-48de-8332-79fbc0912059"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a24c56d22cc4eb1ba8bcbaa319b4761_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI4NjA_42620df8-d558-47b5-bb4a-a78c2dba3f4b"
      unitRef="usd">32000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI5NDg_db5a9385-4cc9-4b37-9221-e58892125587"
      unitRef="usd">227000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI5NTI_890a2a1a-260f-41e0-93e9-3c9bdd072bda"
      unitRef="usd">141000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzI5NTk_be003806-b1ec-408c-b04d-98a8cdee4c8c"
      unitRef="usd">137000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <pfe:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTQ_6d22720a-4112-4746-a75c-17f520620402">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of the weighted-average assumptions used in the valuation of TSRUs and stock options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;TSRUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expected dividend yield &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(based on a constant dividend yield during the expected term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;4.51&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; (based on interpolated yield on U.S. Treasury zero-coupon issues)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;0.93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;1.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; (based on implied volatility, after consideration of historical volatility)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26.53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;26.54&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;TSRUs contractual/stock options expected term, years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; (based on historical exercise and post-vesting termination patterns for stock options) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;5.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5.13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pfe:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtMi0xLTEtMTU1NjM4_6a08fc3b-40b7-46bb-9dea-d70b7c01263e"
      unitRef="number">0.0451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtNC0xLTEtMTU1NjM4_ed38c7c4-3c4e-44d3-81d3-55a3a1776e32"
      unitRef="number">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtNi0xLTEtMTU1NjM4_30016952-2366-4757-ac9d-bd07b8a49c7b"
      unitRef="number">0.0327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtOC0xLTEtMTU1NjM4_80ee0b2f-9df0-49b2-b7af-a969aebd209a"
      unitRef="number">0.0451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtMTAtMS0xLTE1NTYzOA_27be2afb-dc0e-4547-bfcc-44cf66bcffb8"
      unitRef="number">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzMtMTItMS0xLTE1NTYzOA_0ded1a9b-4392-4de8-846e-0001dd8252e4"
      unitRef="number">0.0327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtMi0xLTEtMTU1NjM4_1fafb186-ce2c-40a4-8e98-5ce1e03cdd64"
      unitRef="number">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtNC0xLTEtMTU1NjM4_9c370a45-6f90-4edb-b52d-ff9d7040d4b4"
      unitRef="number">0.0115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtNi0xLTEtMTU1NjM4_6e210d60-b51f-4021-8d37-f1f179e09b15"
      unitRef="number">0.0255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtOC0xLTEtMTU1NjM4_23ef547e-c772-487b-8097-28f9c35eec22"
      unitRef="number">0.0127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtMTAtMS0xLTE1NTYzOA_651c0767-76b2-498c-8a56-f389a241d29d"
      unitRef="number">0.0125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzQtMTItMS0xLTE1NTYzOA_9da39f07-b2d4-4e40-a8a9-89980eb480d7"
      unitRef="number">0.0266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtMi0xLTEtMTU1NjM4_3f640f34-706a-497b-9630-c8748b0b3cd5"
      unitRef="number">0.2653</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtNC0xLTEtMTU1NjM4_067189c5-a926-4f17-8009-747d41ba888e"
      unitRef="number">0.2099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtNi0xLTEtMTU1NjM4_8764f3a3-e1f3-46ef-a637-f4a019ea838c"
      unitRef="number">0.1834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtOC0xLTEtMTU1NjM4_6e687cac-10c7-4214-ad51-46a99b1b0e71"
      unitRef="number">0.2654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtMTAtMS0xLTE1NTYzOA_ff7b2806-d844-4a79-a4cc-af79a0313c24"
      unitRef="number">0.2097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzUtMTItMS0xLTE1NTYzOA_1980a517-df81-495d-abe6-fa53784c78a7"
      unitRef="number">0.1834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtMi0xLTEtMTU1NjM4_ca3ba93f-485d-4140-b43b-1e1ae783e675">P5Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i81c361b3d3194dc9babbb01f4ef7f209_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtNC0xLTEtMTU1NjM4_4a1bb09a-b387-49d2-8a9e-08d59cba11a6">P5Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i36470cb7a4ad4e90815c77a4c591c76c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtNi0xLTEtMTU1NjM4_b2b51fb3-e1e6-464c-b7b8-eedd3469960a">P5Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia083e623ee674e548622522766f25245_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtOC0xLTEtMTU1NjM4_c20c8475-8fc8-43a2-a7df-a07dc4046ab5">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib3e27fbfd52146b59b2dab935eb911fa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtMTAtMS0xLTE1NTYzOA_b19ee2d4-8e18-4990-a12e-579ca992c092">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i38803c12b9b3449f99bdef5250359030_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphOGIyN2QyZGQxNTI0MTNkYTY2YzQwNzNiZjFiNzExYy90YWJsZXJhbmdlOmE4YjI3ZDJkZDE1MjQxM2RhNjZjNDA3M2JmMWI3MTFjXzYtMTItMS0xLTE1NTYzOA_6c4b5c82-f265-48ed-90aa-44e223222d15">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMi0xLTEtMTU1NjM4_2fdc7757-f649-4996-b091-ba89eab6285a"
      unitRef="shares">129844000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtNC0xLTEtMTU1NjM4_f1b7ff23-d2ed-4b57-aea1-b5d7de3a886f"
      unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice
      contextRef="i025b64a058c74145a3d20c83e55e303f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtNi0xLTEtMTU1NjM4_c8c0ad08-1204-4bc1-9d98-7b1df4d10648"
      unitRef="usdPerShare">32.94</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ief795c9787db4b308dde841b75ab39f2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtOC0xLTEtMTU1NjM4_b6c4fd24-8c3b-4daf-b1f0-5ee9465975c0"
      unitRef="shares">23692000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ief795c9787db4b308dde841b75ab39f2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTAtMS0xLTE1NTYzOA_d49a869a-6853-4802-8229-a4c3736d3500"
      unitRef="usdPerShare">35.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if41e5d4716e04e498cba46b05595ab61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTItMS0xLTE1NTYzOA_cd0713ce-a174-401d-a6cf-b7a389c052b5"
      unitRef="shares">20077000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="if41e5d4716e04e498cba46b05595ab61_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTQtMS0xLTE1NTYzOA_64af5ac8-922a-4e1d-a5a2-766e1fd5157d"
      unitRef="usdPerShare">36.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i84a9df877b7a4600aec68656dac6703a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTYtMS0xLTE1NTYzOA_29872a2d-0656-44d6-ab7a-1ef42e1f6e56"
      unitRef="shares">5264000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="i84a9df877b7a4600aec68656dac6703a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTgtMS0xLTE1NTYzOA_c05aa8ae-781c-4a13-8369-247bf8229f5a"
      unitRef="usdPerShare">36.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if9cb70c93197414db93c20b578e77936_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMjAtMS0xLTE5NjQ0Mw_45930ec5-a1c4-43b4-954c-24ea8a282911"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="if9cb70c93197414db93c20b578e77936_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMjItMS0xLTE5NjQ5NA_20983ce8-7e2b-4b93-8bab-64ca9a9ddc0d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMi0xLTEtMTU1NjM4_265f0150-c839-4fb9-8bc4-7fa060fddd6f"
      unitRef="shares">34522000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtNC0xLTEtMTU1NjM4_752478fa-b051-4b20-9bd6-ec11127faf62"
      unitRef="usdPerShare">7.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtNi0xLTEtMTU1NjM4_3f4f55a2-cc3b-4afa-9bc7-99c1935e660d"
      unitRef="usdPerShare">33.83</pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtOC0xLTEtMTU1NjM4_82e477ba-1cd3-48c1-bfb9-dc1b64547bdc"
      unitRef="shares">10893000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTAtMS0xLTE1NTYzOA_57b94018-d7d4-4ce2-a596-894cd954f6e4"
      unitRef="usdPerShare">34.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTItMS0xLTE1NTYzOA_4211c29b-37c3-4166-8a7b-994500cacb41"
      unitRef="shares">8632000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTQtMS0xLTE1NTYzOA_14faf7c2-7a01-4302-b4ef-c4f8cd899ae8"
      unitRef="usdPerShare">33.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTYtMS0xLTE1NTYzOA_ebbde6c8-9cf9-4c75-a299-9c373c1e2f24"
      unitRef="shares">1798000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTgtMS0xLTE1NTYzOA_c9b81a6f-5cdd-4f35-817f-d753d6aaf746"
      unitRef="usdPerShare">33.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMjAtMS0xLTE5NjQ0Mw_31d8f060-2290-477d-a885-6bbf64728de3"
      unitRef="shares">1165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMjItMS0xLTE5NjQ5NA_219f7804-b5b6-4527-93a0-3338fc9eaab9"
      unitRef="usdPerShare">38.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMi0xLTEtMTU1NjM4_d9b91d49-65bc-4a91-9a09-743e7f544dda"
      unitRef="shares">44888000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctNC0xLTEtMTU1NjM4_42612d0e-2b90-467f-82c3-b67fbf6b6ea1"
      unitRef="usdPerShare">7.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctNi0xLTEtMTU1NjM4_a8f9e630-441f-42a5-b28e-9cd41ba0836d"
      unitRef="usdPerShare">30.54</pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctOC0xLTEtMTU1NjM4_645dd690-6164-4e4f-8079-c01458fc8fbc"
      unitRef="shares">8747000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTAtMS0xLTE1NTYzOA_fe00f3e0-dcd9-4bdb-85dc-aed9ba13cb8c"
      unitRef="usdPerShare">34.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTItMS0xLTE1NTYzOA_2f464006-2cdb-4183-b0fd-f41fe79230da"
      unitRef="shares">6095000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTQtMS0xLTE1NTYzOA_465e3f25-0b56-4f09-812f-8698f3314174"
      unitRef="usdPerShare">33.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTYtMS0xLTE1NTYzOA_b037bb9b-5bfb-49fa-b311-da514d3bc40f"
      unitRef="shares">984000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTgtMS0xLTE1NTYzOA_909f7ac2-138e-457a-9b20-cf9010878726"
      unitRef="usdPerShare">33.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMjAtMS0xLTE5NjQ0Mw_faa430f3-a986-4858-b025-a1d146fde154"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMjItMS0xLTE5NjQ5NA_ce77e5d6-a822-452f-bafc-879fb2707589"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzgtOC0xLTEtMTU1NjM4_07165532-992c-4d21-9566-6438231b115b"
      unitRef="shares">956000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzgtMTAtMS0xLTE1NTYzOA_9eb0160d-40b4-4db0-a925-5dbffeea30d0"
      unitRef="usdPerShare">41.33</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMi0xLTEtMTU1NjM4_e7a7c0cb-9a52-4af6-8ad3-101561a59bdc"
      unitRef="shares">4879000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktNC0xLTEtMTU1NjM4_ee1317c7-af38-4a4b-a928-b24dfb176e6e"
      unitRef="usdPerShare">6.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktNi0xLTEtMTU1NjM4_cd2900aa-4f3c-48ef-b13c-7377166fd875"
      unitRef="usdPerShare">33.78</pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktOC0xLTEtMTU1NjM4_123fef7a-6d37-4e73-8912-0489cfed0e39"
      unitRef="shares">1255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic68f01872ed3485e83b6fc54d0713a4e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTAtMS0xLTE1NTYzOA_ac4627a7-6f1c-41a0-82c2-7de38d4fba79"
      unitRef="usdPerShare">35.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTItMS0xLTE1NTYzOA_532a46be-433a-42ba-8ed4-9fbf1cd26e71"
      unitRef="shares">1133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="i79f990b041fd487c830de83552bdbf07_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTQtMS0xLTE1NTYzOA_3af3c0e7-b52e-4fe4-a24f-8ddc2ed8a412"
      unitRef="usdPerShare">41.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTYtMS0xLTE1NTYzOA_6438e57b-a5f0-412e-b96f-e188eac5534a"
      unitRef="shares">924000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="ief15f6b766db4be488e1617d80f01b37_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTgtMS0xLTE1NTYzOA_e0225c8c-626b-4bf9-b0ad-c2c8d0b97ef3"
      unitRef="usdPerShare">34.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMjAtMS0xLTE5NjQ0Mw_522af3ee-0da4-4d02-8652-7eb79e75703f"
      unitRef="shares">306000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="i0593f22a56d847448df2ea20affd43af_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMjItMS0xLTE5NjQ5NA_e84f71c1-eee3-4e93-ab19-bc2ae28463ff"
      unitRef="usdPerShare">47.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTItMS0xLTE1NTYzOA_ab792de6-3c8c-41e0-b7ee-3e6b6b406a08"
      unitRef="shares">114599000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTQtMS0xLTE1NTYzOA_ca20ae79-66c2-45bf-8702-dd72771b636a"
      unitRef="usdPerShare">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTYtMS0xLTE1NTYzOA_00449635-98f0-41e9-85fe-1dda1c419612"
      unitRef="usdPerShare">34.12</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i32f0385272bd4aac882c487c230d065c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTgtMS0xLTE1NTYzOA_89e88527-d7d5-4755-b238-998ae8db9bdb"
      unitRef="shares">25540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i32f0385272bd4aac882c487c230d065c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEwLTEtMS0xNTU2Mzg_65c775aa-eea8-430b-91ee-c9953c3125fe"
      unitRef="usdPerShare">35.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEyLTEtMS0xNTU2Mzg_30a08688-abc7-4fc1-a6dc-6a6a58197d10"
      unitRef="shares">21480000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE0LTEtMS0xNTU2Mzg_6c6bceb0-130d-49af-862b-de96ffd1fba6"
      unitRef="usdPerShare">59.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE2LTEtMS0xNTU2Mzg_59fb6a1d-60bb-467d-ac41-15e9e31e03bc"
      unitRef="shares">5154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="ic59c885e5ca740d6b87f08fb2af8bc8b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE4LTEtMS0xNTU2Mzg_462f283c-5741-4ea9-b2e5-abf6b80ca956"
      unitRef="usdPerShare">59.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia38cd1de7c7d4dbd86cd29bd60031120_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzEwLTIwLTEtMS0xOTY0NDM_4d24e5c6-ae53-4c07-afa8-43618dde3225"
      unitRef="shares">859000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="ia38cd1de7c7d4dbd86cd29bd60031120_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzEwLTIyLTEtMS0xOTY1MDQ_81e3181b-fd99-46c7-bd65-de89bec6ebab"
      unitRef="usdPerShare">59.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i220423650ddd4f2190621f8d4fc9821b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzM0NTQ_1faff4f5-8a46-4959-a73b-ffa14d778b4c"
      unitRef="shares">34100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca"
      unitRef="shares">206996000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe"
      unitRef="usdPerShare">31.71</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4">P2Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d"
      unitRef="usd">5969000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9"
      unitRef="shares">92398000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945"
      unitRef="usdPerShare">28.72</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617">P0Y9M18D</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc"
      unitRef="usd">2946000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7"
      unitRef="shares">110476000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9"
      unitRef="usdPerShare">34.16</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051">P3Y3M18D</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest
      contextRef="i234cb2011c6d42c5a3f00401f9a682b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182"
      unitRef="usd">2910000000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber
      contextRef="i57785a499e164f5bacbcf350c3fb80f3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44"
      unitRef="shares">3074000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm
      contextRef="i983864cac72f40e9a85d8421bcaebe0f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765">P0Y9M18D</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted
      contextRef="i57785a499e164f5bacbcf350c3fb80f3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981"
      unitRef="usd">182000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQzNjM_bc802032-9dbe-4d6a-973d-8e9b3dc6da76"
      unitRef="shares">46060346</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ0MTE_c8956feb-b099-4545-b7ef-9bdb256e349b"
      unitRef="usdPerShare">23.04</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ0MzE_07d61c9a-af73-4de2-b314-bd591f98bc45"
      unitRef="shares">7093787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice
      contextRef="i7392a7235580422387964189ed5a7ecf_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ0Nzk_004bef92-e359-4e28-96a4-86bbaaebaa3b"
      unitRef="usdPerShare">27.41</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion
      contextRef="i983864cac72f40e9a85d8421bcaebe0f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzQ1MTE_c5948704-62c8-46af-8db8-e423edcbf86c"
      unitRef="shares">2943737</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDY_cd63a67a-281e-4836-a199-ec2bc2789481">&lt;div style="text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Summary of all stock option activity during 2021:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intrinsic Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33.82&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(31,036)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25.75&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(89)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34.39&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20.27&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,874&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30.20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,295&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest, December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;44,747&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;30.19&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41,583&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;29.81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Market price of our underlying common stock less exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;The number of options expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzItMi0xLTEtMTU1NjM4_72d83504-38f4-4131-8ffe-c542310c1690"
      unitRef="shares">75402000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzItNC0xLTEtMTU1NjM4_5a13851f-f257-4ae1-b4ea-074be5a2e77b"
      unitRef="usdPerShare">28.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzMtMi0xLTEtMTU1NjM4_574ae24e-6cb4-4c89-825f-d533213af7a5"
      unitRef="shares">779000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzMtNC0xLTEtMTU1NjM4_aa6913cc-f989-437e-bf6c-9a1b1c3667a8"
      unitRef="usdPerShare">33.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzQtMi0xLTEtMTU1NjM4_928dbe48-61c4-4902-860d-29b325656569"
      unitRef="shares">31036000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzQtNC0xLTEtMTU1NjM4_b34032fe-1e65-46d4-8a46-738c20f2c52e"
      unitRef="usdPerShare">25.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzUtMi0xLTEtMTU1NjM4_3091ff2b-7c39-406f-a9de-f601284bc2b8"
      unitRef="shares">89000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzUtNC0xLTEtMTU1NjM4_988e62ce-f24c-47b7-a195-49e4c1f96100"
      unitRef="usdPerShare">34.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzYtMi0xLTEtMTU1NjM4_1fc5d47f-cbfe-480a-847f-b77096979a46"
      unitRef="shares">181000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzYtNC0xLTEtMTU1NjM4_9c5dfa77-d737-4590-81e0-f4c70bd437ef"
      unitRef="usdPerShare">20.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtMi0xLTEtMTU1NjM4_71f440f8-5ad5-40eb-a48c-cc92cae9946d"
      unitRef="shares">44874000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtNC0xLTEtMTU1NjM4_da9dd5b2-c275-45e2-9660-bb1ac6b49edd"
      unitRef="usdPerShare">30.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtNi0xLTEtMTU1NjM4_44242e42-da66-4011-be23-097e6ede38cd">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtOC0xLTEtMTU1NjM4_a8ea7123-02b9-4280-a4ee-558383a13da3"
      unitRef="usd">1295000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktMi0xLTEtMTU1NjM4_b189be12-71d4-4059-9bf6-009e6706aa64"
      unitRef="shares">44747000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNC0xLTEtMTU1NjM4_e5bdff91-87d3-4fcc-b133-d858a5c2b28b"
      unitRef="usdPerShare">30.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNi0xLTEtMTU1NjM4_0f6f6780-b698-4e7e-9a46-e03c9a909569">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599"
      unitRef="usd">1291000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTItMS0xLTE1NTYzOA_f12e986f-c581-4568-83de-2eaf5cd2d78a"
      unitRef="shares">41583000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTQtMS0xLTE1NTYzOA_2d557ee2-214d-414b-af01-65a333acaae9"
      unitRef="usdPerShare">29.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTYtMS0xLTE1NTYzOA_359659c6-5e7b-440b-8b27-5b2f9441c9f0">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTgtMS0xLTE1NTYzOA_f45c3b5f-a7dd-48d8-9864-4df1b90c966f"
      unitRef="usd">1216000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyOA_50d3e618-606d-4a41-bc43-41946d437c88">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following presents the detailed calculation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;EPS:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP was assumed in the diluted EPS calculation until the conversion date, which occurred in May 2020. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12&lt;/span&gt;.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYzMA_dbfe8d8a-7cc8-4396-85d2-466f51386d44">&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.035%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following presents the detailed calculation of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;EPS:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;22,414&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;21,979&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EPS Denominator&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,601&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,708&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Anti-dilutive common stock equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzQtMi0xLTEtMTU1NjM4_f7d8e03b-88de-4a98-885c-c76d25b1b796"
      unitRef="usd">22414000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzQtNC0xLTEtMTU1NjM4_7623259f-d14e-4443-8f1d-e984fcff2e19"
      unitRef="usd">6630000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzQtNi0xLTEtMTU1NjM4_3773e9d6-2762-46ac-80ae-45a9514ae7d1"
      unitRef="usd">10708000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzUtMi0xLTEtMTU1NjM4_672d96d9-529c-44df-b10a-7744ef3b4c31"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzUtNC0xLTEtMTU1NjM4_32034bac-5078-4403-b938-65108a99cd94"
      unitRef="usd">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzUtNi0xLTEtMTU1NjM4_2a1c7935-7798-4d92-91dd-b8374af47f35"
      unitRef="usd">1000000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzYtMi0xLTEtMTU1NjM4_58371438-6ab1-4623-b71c-d522d4462cba"
      unitRef="usd">22414000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzYtNC0xLTEtMTU1NjM4_ea3e7d80-d8d2-4804-b169-75f386cd2f6a"
      unitRef="usd">6630000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzYtNi0xLTEtMTU1NjM4_d6100fb5-b1d9-40e4-abd9-c5ca08e4336b"
      unitRef="usd">10708000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzktMi0xLTEtMTU1NjM4_d532bc1a-03f4-4c8e-acd6-192c9d6498f8"
      unitRef="usd">-434000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzktNC0xLTEtMTU1NjM4_2bd6d72a-7f4a-4b67-ba5b-c026cfaa9594"
      unitRef="usd">2529000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzktNi0xLTEtMTU1NjM4_7d2be479-0166-4f15-9d90-aceb90724017"
      unitRef="usd">5318000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEwLTItMS0xLTE1NTYzOA_631baeca-5590-49e0-937a-01d7c254387a"
      unitRef="usd">21979000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEwLTQtMS0xLTE1NTYzOA_b85607fe-e9b5-4af0-ae2d-bba75260c851"
      unitRef="usd">9159000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEwLTYtMS0xLTE1NTYzOA_a4602888-f233-4e62-a041-0edbb1028caf"
      unitRef="usd">16025000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEyLTItMS0xLTE1NTYzOA_c95414c0-124b-42e6-b70c-be9bfe803c9f"
      unitRef="usd">22414000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEyLTQtMS0xLTE1NTYzOA_80e1b7f7-e1a3-460a-826c-64e03243a6d7"
      unitRef="usd">6630000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEyLTYtMS0xLTE1NTYzOA_97c65b1c-1dc8-4f9e-8d90-de85810722df"
      unitRef="usd">10708000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEzLTItMS0xLTE1NTYzOA_b9473729-4e52-4c25-90d4-7e5bb7570102"
      unitRef="usd">-434000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEzLTQtMS0xLTE1NTYzOA_0b82e2dc-7840-4407-b44a-ab2955f345d4"
      unitRef="usd">2529000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzEzLTYtMS0xLTE1NTYzOA_2a232e00-7201-4b76-918d-91f12522fe90"
      unitRef="usd">5318000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE0LTItMS0xLTE1NTYzOA_c3e86a89-7d92-459a-ac3d-ee85b68e878a"
      unitRef="usd">21979000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE0LTQtMS0xLTE1NTYzOA_995c75d7-27cb-4d53-b6c3-7fd14e48c7d5"
      unitRef="usd">9159000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE0LTYtMS0xLTE1NTYzOA_aea1c8b7-3be7-4005-a898-84dbb47c6d65"
      unitRef="usd">16026000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE2LTItMS0xLTE1NTYzOA_b81f7d02-b490-4236-859f-b314719489a3"
      unitRef="shares">5601000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE2LTQtMS0xLTE1NTYzOA_2677238c-3cb5-42b0-8e9c-cc9bbf7f8fdb"
      unitRef="shares">5555000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE2LTYtMS0xLTE1NTYzOA_9b6bf15c-0575-44f1-94a4-b25b124acea7"
      unitRef="shares">5569000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE3LTItMS0xLTE1NTYzOA_719a15c0-a8bc-450c-9ada-44a5f94084aa"
      unitRef="shares">107000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE3LTQtMS0xLTE1NTYzOA_3dc1d107-36ca-442a-a012-370aab59a5da"
      unitRef="shares">77000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE3LTYtMS0xLTE1NTYzOA_5a0fbe7b-8a9d-4ad4-b470-5ebbbdd3f69d"
      unitRef="shares">106000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE4LTItMS0xLTE1NTYzOA_2e6162b1-f05d-4337-b157-9aade0cc0169"
      unitRef="shares">5708000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE4LTQtMS0xLTE1NTYzOA_139029e1-6948-4748-8b53-ae3e69a75bd4"
      unitRef="shares">5632000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE4LTYtMS0xLTE1NTYzOA_724575f9-164d-4370-a0da-5643b3f412b0"
      unitRef="shares">5675000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTItMS0xLTE1NTYzOA_1e898dab-8f93-4ef8-94ae-b8e82db17466"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTQtMS0xLTE1NTYzOA_b2fe21d4-54c8-40ac-ab41-f210c214bc66"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTYtMS0xLTE1NTYzOA_f6e6827d-16c5-473d-b9a4-970beab322dd"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjM_668c9f50-c32c-4854-94b9-d020cd84d01a">Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $381 million in 2021, $380 million in 2020 and $326 million in 2019. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_408086e2-3444-4b88-b89b-d101186f774f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_46ee31d6-1f28-4ba5-b2be-d5c564d17665"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,839&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_74739711-6874-4a56-93f6-73a0506beaac"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_8b4b2c6e-76ae-4492-a995-73bb701632ff"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b27ac467-c383-4750-82e2-f39d2460df2f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b50ecd3f-01e3-4abd-991d-dc5d329b8f81"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of total lease cost includes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other supplemental information follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average Remaining Contractual Lease Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on sale and leaseback transactions, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Next one year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;520&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;417&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3-4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,865&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,621&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,960&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(a)Reflects lease payments due within 12 months subsequent to the balance sheet date.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMzA_8a7c3be4-f6ae-4ead-be9e-83c8a7e150ea">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of 1 to 30 years, some of which include options to terminate or extend leases for up to 5 to 10 years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options have not been exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to $381 million in 2021, $380 million in 2020 and $326 million in 2019. We elected the practical expedient to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception of the contract and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i3c06c854564f400a90dbefc01376069e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzEzMw_1a82e224-574f-427c-9beb-33b34d97a4e4">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i3f1f62383330418da8e053b9b9db9ba8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzEzOQ_7f6c76c0-fcd2-4f4d-a447-6db6d8f3b67e">P30Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <pfe:LesseeOperatingLeaseOptionToExtendTerm
      contextRef="i1d1bc977a4bf4a8d8dd29d3800b05abf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIxMw_485e8958-5f15-4781-8291-420f2b9b5beb">P5Y</pfe:LesseeOperatingLeaseOptionToExtendTerm>
    <pfe:LesseeOperatingLeaseOptionToExtendTerm
      contextRef="i0bbea5f2ec0948fb967b4a1b64621b58_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIxOQ_b9c406a8-bbbb-4709-8329-287cd43ac44d">P10Y</pfe:LesseeOperatingLeaseOptionToExtendTerm>
    <us-gaap:VariableLeaseCost
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzkwOQ_09fe62d0-ac6a-4d30-9386-8a96b76843ce"
      unitRef="usd">381000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzkyMg_e8c23781-9d1b-4369-bc5d-2a583198d00c"
      unitRef="usd">380000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzE2NDkyNjc0NDQzNzI_cb95e54a-d72a-4eb1-a91f-695d27b6533d"
      unitRef="usd">326000000</us-gaap:VariableLeaseCost>
    <pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjY_97cc8ba9-96da-4212-a3e6-c66f29811122">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;For operating leases, the ROU assets and liabilities in our consolidated balance sheets follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_408086e2-3444-4b88-b89b-d101186f774f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtMi0xLTEtMTg0MjIw_46ee31d6-1f28-4ba5-b2be-d5c564d17665"&gt;Other noncurrent assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,839&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_74739711-6874-4a56-93f6-73a0506beaac"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtMi0xLTEtMTU1NjM4_8b4b2c6e-76ae-4492-a995-73bb701632ff"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b27ac467-c383-4750-82e2-f39d2460df2f"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtMi0xLTEtMTU1NjM4_b50ecd3f-01e3-4abd-991d-dc5d329b8f81"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtNC0xLTEtMTU1NjM4_590e7fdd-20fd-4dc2-9247-5b1f8277ef78"
      unitRef="usd">2839000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzMtNi0xLTEtMTU1NjM4_66a12a57-eb90-4171-81d6-3104ff730906"
      unitRef="usd">1386000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtNC0xLTEtMTU1NjM4_aed593e7-b95b-4c4d-a7ce-a4a922e75d24"
      unitRef="usd">449000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzQtNi0xLTEtMTU1NjM4_5f9f8bbc-6321-4d37-9592-09c425c56eea"
      unitRef="usd">320000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtNC0xLTEtMTU1NjM4_304141dd-b91b-4b0d-8a2b-6984f3c633e0"
      unitRef="usd">2510000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo5ZGFiMmQ5NzMyNWY0MzE0OWEzMTNmZDg4MWNlMWRkYi90YWJsZXJhbmdlOjlkYWIyZDk3MzI1ZjQzMTQ5YTMxM2ZkODgxY2UxZGRiXzUtNi0xLTEtMTU1NjM4_f4b634b4-9814-4892-8e1e-efe08f17c77b"
      unitRef="usd">1108000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjQ_5be33e70-e3ff-4c1a-a02b-07e75ccc4f81">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.043%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Components of total lease cost includes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;548&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;381&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other supplemental information follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average Remaining Contractual Lease Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.932%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains)/losses on sale and leaseback transactions, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzMtMi0xLTEtMTk0MTIw_25339440-1004-4451-ba4d-d82498093b83"
      unitRef="usd">548000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzMtMi0xLTEtMTU1NjM4_50f49e76-b84a-4968-8dd3-f60a6818f0f1"
      unitRef="usd">432000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzMtNC0xLTEtMTU1NjM4_feabb24a-4a39-4111-a380-7ba1b8dd4d71"
      unitRef="usd">421000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzctMi0xLTEtMTk0MTIw_cf7cbdaa-3d31-4568-9a45-3e04932d8981"
      unitRef="usd">381000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzctMi0xLTEtMTU1NjM4_a63eac93-bf3f-4d99-b625-eb1bc946f2fd"
      unitRef="usd">380000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzctNC0xLTEtMTU1NjM4_ea877075-507f-49fb-96f8-9b09a077f673"
      unitRef="usd">326000000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzgtMi0xLTEtMTk0MTIw_27b01393-0957-4e21-bc0f-c31efd519006"
      unitRef="usd">41000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzgtMi0xLTEtMTU1NjM4_eefc3a91-98dc-4a65-8a52-4777c6fd4259"
      unitRef="usd">40000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzgtNC0xLTEtMTU1NjM4_80f54a9e-1856-44d6-adbe-8f31bdd8443b"
      unitRef="usd">45000000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzktMi0xLTEtMTk0MTIw_cb010f70-0cb4-4214-b780-8637418535b9"
      unitRef="usd">888000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzktMi0xLTEtMTU1NjM4_15c1de8e-0527-4453-88f5-aaa1b8ed97ec"
      unitRef="usd">772000000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTplNTU4OTZjMmE4NzE0ZGFiOTczMWEwNjEyZmYyMWIyZi90YWJsZXJhbmdlOmU1NTg5NmMyYTg3MTRkYWI5NzMxYTA2MTJmZjIxYjJmXzktNC0xLTEtMTU1NjM4_be4c67d1-d541-4400-a383-0739bb0dd7be"
      unitRef="usd">702000000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzQtMi0xLTEtMTU1NjM4_c6a472a5-26f1-440d-9881-6355678fa67d">P12Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzQtNC0xLTEtMTkzOTk0_6762d00c-837b-422e-a11a-b39faf6a7c7b">P6Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzUtMi0xLTEtMTkzOTcw_32db8bf0-0623-4a62-9adc-da572f17867b"
      unitRef="number">0.028</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTpjNzhjOWZlYjk3ZDI0ZmUwYjFiMWE0MWJiYzc1MDg1MC90YWJsZXJhbmdlOmM3OGM5ZmViOTdkMjRmZTBiMWIxYTQxYmJjNzUwODUwXzUtNC0xLTEtMTkzOTk4_d955d51d-6cb4-48e8-be05-f098b3e41e28"
      unitRef="number">0.029</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzktMi0xLTEtMTk0MDYx_53ba338f-8644-4bad-ac1a-c92a9d398549"
      unitRef="usd">387000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzktNC0xLTEtMTk0MDY4_4027d31a-1b49-416a-b661-e360816ed0ee"
      unitRef="usd">333000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzktNi0xLTEtMTU1NjM4_b6adbea7-fdaa-410f-852e-1310098f082f"
      unitRef="usd">338000000</us-gaap:OperatingLeasePayments>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzExLTItMS0xLTE5NDA2NA_d35becf4-6f48-4995-9ed5-ed55b96fa800"
      unitRef="usd">-1000000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzExLTQtMS0xLTE5NDA2OA_d1442bba-041d-4cee-bb86-b2bff8e8a065"
      unitRef="usd">3000000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTozMTcyMGM2MTZlYTM0OTBiOTZhOTFlNGEzNGI2OWZiNC90YWJsZXJhbmdlOjMxNzIwYzYxNmVhMzQ5MGI5NmE5MWU0YTM0YjY5ZmI0XzExLTYtMS0xLTE1NTYzOA_190dd628-45a0-414c-ab1d-bfa9fdb04c57"
      unitRef="usd">29000000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjU_0266b5ba-8f06-4d60-bdca-c5058c7f1d48">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.304%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Next one year&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;520&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;417&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3-4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,865&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,621&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,960&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;449&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Noncurrent portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;(a)Reflects lease payments due within 12 months subsequent to the balance sheet date.</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzMtMi0xLTEtMTU1NjM4_7daeca07-7fb5-4238-8e5a-f50d6b2124ea"
      unitRef="usd">520000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzQtMi0xLTEtMTU1NjM4_7fcc7880-94d2-4739-98b0-8e550b10be77"
      unitRef="usd">417000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzUtMi0xLTEtMTU1NjM4_8ca77d14-64c0-41ff-aa17-59ba42d268e9"
      unitRef="usd">322000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzYtMi0xLTEtMTU1NjM4_5ded3493-c39c-4361-a4f1-196e0a576231"
      unitRef="usd">279000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzctMi0xLTEtMTU1NjM4_bfb29190-b59a-4aaa-853d-ec2cfa071356"
      unitRef="usd">217000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzgtMi0xLTEtMTU1NjM4_3dbbcb76-655c-4017-be11-7df1aa87071f"
      unitRef="usd">1865000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzktMi0xLTEtMTU1NjM4_40765424-75f2-4053-b972-c1fff617e04c"
      unitRef="usd">3621000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzEwLTItMS0xLTE1NTYzOA_0d55ca11-3e2a-4268-9841-37eacddb6cca"
      unitRef="usd">661000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzExLTItMS0xLTE1NTYzOA_2abca1e4-79dc-40b2-b42b-24e08d2caa45"
      unitRef="usd">2960000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzEyLTItMS0xLTE1NTYzOA_c5d6b5f2-b3d9-4545-bd98-e6cf4cda7f74"
      unitRef="usd">449000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzEzLTItMS0xLTE1NTYzOA_108c0775-c6b6-4830-a76b-92ddf979e05c"
      unitRef="usd">2510000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUyNzk3_ef6235eb-91d4-4665-8868-692193cf2a1a">Contingencies and Certain Commitments&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. The following outlines our legal contingencies. For a discussion of our tax contingencies, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5B.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our legal contingencies include, but are not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. An adverse outcome could result in loss of patent protection for a product, a significant loss of revenues from that product or impairment of the value of associated assets. We are the plaintiff in the majority of these actions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Product liability and other product-related litigation related to current or former products, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, and often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Commercial and other asserted or unasserted matters, which can include acquisition-, licensing-, intellectual property-, collaboration- or co-promotion-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain of these contingencies could result in increased expenses and/or losses, including damages, royalty payments, fines and/or civil penalties, which could be substantial, and/or criminal charges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of matters, which could have a material adverse effect on our results of operations and/or our cash flows in the period in which the amounts are accrued or paid. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments, which result from a complex series of judgments about future events and uncertainties, are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For proceedings under environmental laws to which a governmental authority is a party, we have adopted a disclosure threshold of $1 million in potential or actual governmental monetary sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors to assess materiality, such as, among others, the amount of damages and the nature of other relief sought, if specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#x2019;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. Some of the matters discussed below include those which management believes that the likelihood of possible loss in excess of amounts accrued is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A1. Legal Proceedings&#x2013;&#x2013;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We are involved in suits relating to our patents, including but not limited to, those discussed below. Most involve claims by generic drug manufacturers that patents covering our products (or those of our collaboration/licensing partners to which we have licenses or co-promotion rights and to which we may or may not be a party), processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents that are discussed below, patent rights to certain of our products or those of our collaboration/licensing partners are being challenged in various other jurisdictions. For example, some of our collaboration or licensing partners face challenges to the validity of their patent rights in non-U.S. jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In 2017, the Patent Trial and Appeal Board (PTAB) initiated proceedings with respect to two of our pneumococcal vaccine patents. However, the PTAB declined to initiate proceedings as to two other pneumococcal vaccine patents; those two patents, and one other patent, were challenged in federal court in Delaware. In September 2021, Pfizer and a challenger entered into a settlement and license agreement, resolving all worldwide legal proceedings involving that challenger, related to our pneumococcal vaccine patents. Other challenges to pneumococcal vaccine patents remain pending at the PTAB and outside the U.S. The invalidation of any of the patents in our pneumococcal portfolio could potentially allow additional competitor vaccines into the marketplace. In the event that any of the patents are found valid and infringed, a competitor&#x2019;s vaccine might be prohibited from entering the market or a competitor might be required to pay us a royalty.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We are also subject to patent litigation pursuant to which one or more third parties seek damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages or royalty payments, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold if we or one of our subsidiaries is found to have willfully infringed valid patent rights of a third party.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Actions In Which We Are The Plaintiff&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#x2019;s abbreviated new drug application (ANDA) filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Xeljanz (tofacitinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate ANDAs with the FDA seeking approval to market their generic versions of tofacitinib tablets in one or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, we have settled actions with several manufacturers on terms not material to us. The remaining actions continue in the U.S. District Court for the District of Delaware as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In January 2021, we brought a separate patent-infringement action against Aurobindo Pharma Limited (Aurobindo) asserting the infringement and validity of the patent covering the active ingredient expiring in December 2025 and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Aurobindo challenged in its ANDA seeking approval to market a generic version of tofacitinib 5 mg and 10 mg tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In October 2021, we brought a separate patent-infringement action against Sinotherapeutics Inc. (Sinotherapeutics) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Sinotherapeutics in its ANDA seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;In February 2022, we brought a separate patent-infringement action against Teva Pharmaceuticals USA, Inc. (Teva) asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its ANDA seeking approval to market a generic version of tofacitinib 22 mg extended release tablets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2022, we brought a separate patent-infringement action against Slayback Pharma LLC (Slayback) asserting the infringement and validity of our compound patent covering the active ingredient that was challenged by Slayback in its ANDA seeking approval to market a generic version of tofacitinib oral solution 1 mg/mL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inlyta (axitinib)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2019, Glenmark Pharmaceuticals Ltd. (Glenmark) notified us that it had filed an ANDA with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Ibrance (palbociclib)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in September 2020, we received correspondence from several generic companies notifying us that they would seek approval to market generic versions of Ibrance capsules. The generic companies assert the invalidity and non-infringement of our crystalline form patent which expires in 2034. Beginning in October 2020, we brought patent infringement actions against each of these generic companies in various federal courts, asserting the validity and infringement of the crystalline form patent. We have settled with one of these generic companies on terms not material to the company. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in January 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Ibrance tablets. The generic companies are challenging some or all of the following patents: (i) the composition of matter patent expiring in 2027; (ii) the composition of matter patent expiring in 2023; (iii) the method of use patent expiring in 2023; (iv) the crystalline form patent expiring in 2034; and (v) a tablet formulation patent expiring in 2036. We brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Eucrisa&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in September 2021, several generic companies notified us that they had filed ANDAs with the FDA seeking approval to market generic versions of Eucrisa. The companies assert the invalidity and non-infringement of a composition of matter patent expiring in 2026, two method of use patents expiring in 2027, and one other method of use patent expiring in 2030. In September 2021, we brought patent infringement actions against the generic filers in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the patents challenged by the generic companies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Matter Involving Our Collaboration/Licensing Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed ANDAs seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. One of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#x2019; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. In August 2020, the U.S. District Court for the District of Delaware ruled that both the 2026 patent and the 2031 patent are valid and infringed by the proposed generic products. In August and September 2020, the generic filers appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit. Prior to the August 2020 ruling, we and BMS settled with certain of the companies on terms not material to us, and we and BMS may settle with other generic companies in the future. In September 2021, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#x2019;s decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A2. Legal Proceedings&#x2013;&#x2013;Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Asbestos&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Numerous lawsuits against American Optical, Pfizer and certain of its previously owned subsidiaries are pending in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#x2019; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2014, the District Court dismissed the direct purchaser plaintiffs&#x2019; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain Pfizer affiliates, and, in most of the actions, Ranbaxy Laboratories Ltd. (Ranbaxy) and certain Ranbaxy affiliates. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#x2019; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation in the U.S. District&lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In September 2013 and 2014, the District Court dismissed with prejudice the claims of the direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#x2019;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the Court of Appeals. In 2017, the Court of Appeals reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Also, in 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;EpiPen (Direct Purchaser)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2020, a lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, its affiliates King and Meridian, and various Mylan entities, on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants. Plaintiffs in this action generally allege that Pfizer and Mylan conspired to delay market entry of generic EpiPen through the settlement of patent litigation regarding EpiPen, and thereby delayed market entry of generic EpiPen in violation of federal antitrust law. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In July 2021, the District Court granted defendants&#x2019; motion to dismiss the direct purchaser complaint, without prejudice. In September 2021, plaintiffs filed an amended complaint.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Nexium 24HR and Protonix&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the District of New Jersey. As part of our Consumer Healthcare JV transaction with GSK, the JV has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Eastern District of Louisiana.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Mississippi Attorney General Government Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and eight other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Zantac&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;A number of lawsuits have been filed against Pfizer in various federal and state courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and/or sold Zantac. Pfizer has not sold Zantac since 2006, and only sold an OTC version of the product. Plaintiffs seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2020, the federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation in the U.S. District Court for the Southern District of Florida. Plaintiffs in the Multi-District Litigation have filed against Pfizer and many other defendants a master personal injury complaint, a consolidated consumer class action complaint alleging, among other things, claims under consumer protection &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;statutes of all 50 states, and a medical monitoring complaint seeking to certify medical monitoring classes under the laws of 13 states. Plaintiffs previously had filed a consolidated third-party payor class action complaint alleging violation of the federal Racketeer Influenced and Corrupt Organizations Act (RICO) statute and seeking reimbursement for payments made for the prescription version of Zantac, but the Multi-District Litigation court dismissed that complaint; Plaintiffs have appealed the dismissal to the U.S. Court of Appeals for the Eleventh Circuit. In addition, (i) Pfizer has received service of Canadian class action complaints naming Pfizer and other defendants, and seeking compensatory and punitive damages for personal injury and economic loss, allegedly arising from the defendants&#x2019; sale of Zantac in Canada; and (ii) the State of New Mexico and the Mayor and City Council of Baltimore separately filed civil actions against Pfizer and many other defendants in state court, alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in those jurisdictions. In April 2021, a Judicial Council Coordinated Proceeding was created in the Superior Court of California in Alameda County to coordinate personal injury actions against Pfizer and other defendants filed in California state court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Chantix&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in August 2021, a number of putative class actions have been filed against Pfizer in various U.S. federal courts following Pfizer&#x2019;s voluntary recall of Chantix due to the presence of a nitrosamine, N-nitroso-varenicline. Plaintiffs assert that they suffered economic harm purportedly as a result of purchasing Chantix or generic varenicline medicines sold by Pfizer. Plaintiffs seek to represent nationwide and state-specific classes and seek various remedies, including damages and medical monitoring. Similar putative class actions have been filed in Canada and Israel, where the product brand is Champix.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A3. Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Monsanto-Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp;amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#x2019;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#x2019;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#x2019;s indemnification obligations relating to Former Monsanto&#x2019;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#x2019;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#x2019;s and New Monsanto&#x2019;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#x2019;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#x2019;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2009, we submitted a revised site-wide feasibility study with regard to the Wyeth Holdings Corporation (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In 2011, Wyeth Holdings Corporation executed an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the U.S. Environmental Protection Agency (EPA) with regard to the Bound Brook facility. In accordance with the 2011 Administrative Settlement Agreement, we completed construction of an interim remedy. In 2012, the EPA issued a final remediation plan for the Bound Brook facility&#x2019;s main plant area. In 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for two adjacent lagoons. In 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. The consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court in 2015. In 2018, the EPA issued a final remediation plan for the two adjacent lagoons. In 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. In September 2021, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey, which the court approved in November 2021, that will allow Wyeth Holdings LLC to complete the design and implement the remedy for the two adjacent lagoons. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We have accrued for the estimated costs of the site remedies for the Bound Brook facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2017, a number of U.S. service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2020, the District Court granted defendants&#x2019; motions to dismiss and dismissed all of plaintiffs&#x2019; claims. In January 2022, the Court of Appeals reversed the District Court&#x2019;s decision. In February 2022, the defendants filed for en banc review of the Court of Appeals&#x2019; decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Allergan Complaint for Indemnity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In 2019, Pfizer was named as a defendant in a complaint, along with King, filed by Allergan Finance LLC (Allergan) in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. This suit was voluntarily discontinued without prejudice in January 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Breach of Contract&#x2013;&#x2013;Xalkori/Lorbrena&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We are a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#x2019;s sales of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and &lt;/span&gt;&lt;span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The action was originally filed in 2013. In 2015, the Supreme Court dismissed the action and, in 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#x2019; summary judgment motions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In October 2020, NYU filed a separate breach of contract action against Pfizer alleging that it is entitled to royalties on sales of Lorbrena under the terms of the same NYU-Sugen, Inc. Research and Licensing Agreement. In February 2022, the parties reached an agreement to settle both breach of contract actions on terms not material to Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Viatris Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In October 2021, a putative class action was filed in the Court of Common Pleas of Allegheny County, Pennsylvania on behalf of former Mylan N.V. shareholders who received Viatris common stock in exchange for Mylan shares in connection with the spin-off of the Upjohn Business and its combination with Mylan (the Transactions). Viatris, Pfizer, and certain of each company&#x2019;s current and former officers, directors and employees are named as defendants. The complaint alleges that the defendants violated certain provisions of the Securities Act of 1933 in connection with certain disclosures made in or omitted from the registration statement and related prospectus issued in connection with the Transactions. Plaintiff seeks damages, costs and expenses and other equitable and injunctive relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A4. Legal Proceedings&#x2013;&#x2013;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government. Among the investigations by government agencies are the matters discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Greenstone Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;U.S. Department of Justice Antitrust Division Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our former Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. We have produced records relating to this investigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;State Attorneys General and Multi-District Generics Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws. In June 2020, the State Attorneys General filed a new complaint against a large number of companies, including Greenstone and Pfizer, making similar allegations, but concerning a new set of drugs. This complaint was transferred to the Multi-District Litigation in July 2020. The Multi-District Litigation also includes civil complaints filed by private plaintiffs and state counties against Pfizer, Greenstone and a significant number of other defendants asserting allegations that generally overlap with those asserted by the State Attorneys General.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Subpoena relating to Manufacturing of Quillivant XR&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In October 2018, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Government Inquiries relating to Meridian Medical Technologies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In February 2019, we received a civil investigative demand from the U.S. Attorney&#x2019;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at the Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#x2019;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice/SEC Inquiry relating to Russian Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2019, we received an informal request from the  U.S. Department of Justice&#x2019;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#x2019;s FCPA Unit. We have produced records pursuant to these requests. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Docetaxel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; above for information regarding a government investigation related to Docetaxel marketing practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice Inquiries relating to India Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In March 2020, we received an informal request from the U.S. Department of Justice's Consumer Protection Branch seeking documents relating to our manufacturing operations in India, including at our former facility located at Irrungattukottai in India. In April 2020, we received a similar request from the U.S. Attorney&#x2019;s Office for the SDNY regarding a civil investigation concerning operations at our facilities in India. We are producing records pursuant to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;U.S. Department of Justice/SEC Inquiry relating to China Operations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In June 2020, we received an informal request from the U.S. Department of Justice's FCPA Unit seeking documents relating to our operations in China. In August 2020, we received a similar request from the SEC&#x2019;s FCPA Unit. We are producing records pursuant to these requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Zantac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;State of New Mexico and Mayor and City Council of Baltimore Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings&#x2013;&#x2013;Product Litigation&#x2013;&#x2013;Zantac&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; above for information regarding civil actions separately filed by the State of New Mexico and the Mayor and City Council of Baltimore alleging various state statutory and common law claims in connection with the defendants&#x2019; alleged sale of Zantac in those jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A5. Legal Proceedings&#x2013;&#x2013;Matters Resolved During 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;During 2021, certain matters, including the matter discussed below, were resolved or became the subject of definitive settlement agreements or settlement agreements-in-principle.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Beginning in 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its current and former affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan former Chief Executive Officer, Heather Bresch. The plaintiffs in these actions represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#x2019; allegedly unlawful conduct. Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#x2019;s and/or its affiliates&#x2019; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal and various state antitrust laws. At least one lawsuit also alleges that Pfizer and/or Mylan violated RICO. Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2011. In 2017, all of these indirect purchase actions were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In July 2021, Pfizer and plaintiffs filed a stipulation of settlement to resolve the Multi-District Litigation for $345&#160;million. The District Court approved the settlement in November 2021, and the payment was made in accordance with the terms of the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of December 31, 2021, the estimated fair value of these indemnification obligations has been included in our financial statements and is not material to Pfizer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In addition, in connection with our entry into certain agreements and other transactions, our counterparties may agree to indemnify us. For example, in November 2020, we and Mylan completed the transaction to spin-off our Upjohn Business and combine it with Mylan to form Viatris. As part of the transaction and as previously disclosed, Viatris has agreed to assume, and to indemnify Pfizer for, liabilities arising out of certain matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We have also guaranteed the long-term debt of certain companies that we acquired and that now are subsidiaries of Pfizer. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7D&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Certain Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, we had commitments totaling $5.2 billion that are legally binding and enforceable. These commitments include payments relating to potential milestone payments deemed reasonably likely to occur, and purchase obligations for goods and services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 5A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; for information on the TCJA repatriation tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;D. Contingent Consideration for Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We may be required to make payments to sellers for certain prior business combinations that are contingent upon future events or outcomes. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The estimated fair value of contingent consideration as of December 31, 2021 is $697&#160;million, of which $135&#160;million is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and $563&#160;million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and as of December 31, 2020 is $689 million, of which $123 million is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; and $566 million in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The increase in the contingent consideration balance from December 31, 2020 is primarily due to fair value adjustments, partially offset by payments made upon the achievement of certain sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-align:justify"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;E. Insurance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability.&lt;/span&gt;&lt;span style="color:#1f497d;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance &lt;/span&gt;&lt;/div&gt;coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzM1NTA_ed6ceb59-158d-47cf-b572-c74243185747"
      unitRef="usd">1000000</pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold>
    <pfe:GainContingencyPatentsWithoutCourtProceedingsNumber
      contextRef="ia34e871fd1d44e8ab3ff53c514b55b51_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzcwMjk_6551df84-3376-41f5-8fc8-484f8b68fb8a"
      unitRef="patent">2</pfe:GainContingencyPatentsWithoutCourtProceedingsNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="id0ad5620c98c434fba738a4d9c4cf398_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkxNDk1NTA_46e78d3e-ac05-4524-892c-3049acde40f2"
      unitRef="patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ifdd76542ed8b4ec69bc988447f8ffb86_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkxNDk1NTY_cf7c6e5b-48e0-4ed2-9f3f-589495717c72"
      unitRef="patent">1</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyNumberofDefendants
      contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE3NTYz_89d87952-bc6b-4416-a32d-ff12499b6248"
      unitRef="defendant">25</pfe:GainContingencyNumberofDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE3Nzgx_389662c0-c92e-40fa-8b83-8c622f99a316"
      unitRef="patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
      contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE3ODMx_dd21cdde-5ccc-4ae8-923b-33d33384e0ca"
      unitRef="patent">1</pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="ibf79c1b8ff2e4235a814f352810f4f3c_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE4NTE0_d8974931-e936-490b-ae6b-b4de6c0962e8"
      unitRef="patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant
      contextRef="ib18ea7fb4e2b467092e7d8b1a4245c1c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkyMjk2ODk_e6c9d452-88a3-48a2-a561-c89e76b6109c"
      unitRef="manufacturer">8</pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="if309e75442d740928d61d06aba360a99_D20130101-20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzM5NTky_0a4b86c5-9ec0-44de-8d8e-d4aa2a7924cb"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="ib6e95e1dcabd4e7d8e7e9244ff512b69_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzQwMDcz_b78b5806-ec30-4d84-b513-f7caab014b49"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="ib4cc2245228440d2887171a58dc8189f_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkyNzc0MTQ_e4aa2e92-60f7-43a0-a897-66e56338f30b"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i0d7fbd03fa994fe7aec0e5f20e5005af_D20210701-20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzI3NDg3NzkzMDcwMTM_7983850d-9976-49f5-81cb-8976300949a7"
      unitRef="usd">-345000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxMDE1_89d8ebc7-85f4-49b3-86f1-0ddaf29abd19"
      unitRef="usd">5200000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE2NDkyNjc2OTc0MTQ_8a43f9f1-26c8-4a91-82e1-258171c2dce4"
      unitRef="usd">697000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE2NDkyNjc2OTc0MjI_d7d87a46-4fc4-410d-883d-a990fbf42b35"
      unitRef="usd">135000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzE2NDkyNjc2OTc0MzA_dd0d56f7-9794-42c8-9e25-0bbdd460a07f"
      unitRef="usd">563000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxNzEw_e2d678ac-f8d0-4753-a824-16e145bc6ca6"
      unitRef="usd">689000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxNzIz_3340239b-91e6-4a30-b82e-f2693dd2ee2e"
      unitRef="usd">123000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzUvZnJhZzpiNGViYTk4ZmY2ODQ0YzlkOWY4N2RlYzA1ZWQyN2I0Ni90ZXh0cmVnaW9uOmI0ZWJhOThmZjY4NDRjOWQ5Zjg3ZGVjMDVlZDI3YjQ2XzUxNzcx_c67d813e-ef01-4b51-a4de-3450c57994f2"
      unitRef="usd">566000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQyOTY_9cf4dd96-82c3-4e28-9b6a-3867699b6caf">Segment, Geographic and Other Revenue Information&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;A. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We regularly review our operating segments and the approach used by management to evaluate performance and allocate resources. With the formation of the Consumer Healthcare JV in 2019 and the completion of the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer transformed into a more focused, global leader in science-based innovative medicines and vaccines and beginning in the fourth quarter of 2020 operated as a single operating segment engaged in the discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products worldwide. At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1, our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients. Biopharma is a science-based medicines business that includes six therapeutic areas &#x2013; Oncology, Inflammation &amp;amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital therapeutic area commercializes our global portfolio of sterile injectable and anti-infective medicines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Each operating segment has responsibility for its commercial activities. Regional commercial organizations market, distribute and sell our products and are supported by global platform functions that are responsible for the research, development, manufacturing and supply of our products and global corporate enabling functions. Biopharma receives its R&amp;amp;D services from GPD and WRDM. These services include IPR&amp;amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma is the only reportable segment. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Costs and Business Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;WRDM&#x2013;&#x2013;the R&amp;amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#x2013;&#x2013;including patients, healthcare providers, pharmacists, payers and health authorities&#x2013;&#x2013;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#x2019;s medicines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;GPD&#x2013;&#x2013;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late-stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Corporate and Other Unallocated&#x2013;&#x2013;the costs associated with (i) corporate enabling functions (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others), all strategy, business development, portfolio management and valuation capabilities, patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments; (ii) overhead expenses primarily associated with our manufacturing (which include manufacturing variances associated with production) operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs; and (iii) our share of earnings from the Consumer Healthcare JV.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:6.2pt"&gt;Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;amp;E; (ii) acquisition-related items, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as pension and postretirement actuarial remeasurement gains and losses, gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The operating results of PC1, our global contract development and manufacturing organization, and through July 31, 2019 our former Consumer Healthcare business are included in Other business activities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Segment Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were $181 billion as of December 31, 2021 and $154 billion as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Selected Income Statement Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reportable Segment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;79,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;40,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;40,226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;27,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,439&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other business activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(10,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(11,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;598&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reconciling Items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Certain significant items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;81,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;40,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Income from continuing operations before provision/(benefit) for taxes on income.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; Biopharma&#x2019;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $2.1 billion charge for IPR&amp;amp;D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $1.3&#160;billion ($450 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and the remaining amount primarily&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and (iii) upfront and milestone payments on collaborative and licensing arrangements of $1.1 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and (v) gains on equity securities of $1.3 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. For Earnings in 2020, includes, among other items; (i) charges of $1.7 billion related to certain asset impairments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, (ii) actuarial valuation and other pension and postretirement plan losses of $1.1 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $791 million ($197 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and the remaining amount primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $8.1 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Gain) on completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $2.8 billion related to certain asset impairments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and (iii) actuarial valuation and other pension and postretirement plan losses of $750 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 2A, 2C, 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;4. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;B. Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes revenues by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;29,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Revenues exceeded $500 million in each of 21, 8 and 10 countries outside the U.S. in 2021, 2020 and 2019, respectively. The U.S. is the only country to contribute more than 10% of total revenue in 2021, 2020 and 2019. As a percentage of revenues, our largest national market outside the U.S. was Japan, which contributed 9% of total revenue in 2021 and 6% in each of 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of Comirnaty with multiple developed and emerging nations around the world and are continuing to deliver doses of Comirnaty under such agreements. We currently sell the Comirnaty vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February and May 2021 with the EC on behalf of the different EU member states and certain other countries. Each EU member state submits its own Comirnaty vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#00497f;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C. Other Revenue Information&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccine products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;McKesson, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Collectively, our three largest U.S. wholesaler customers represented 24%, 30% and 25% of total trade accounts receivable as of December 31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Additionally, revenues from the U.S. government represented 13% of total revenues for 2021, and primarily represent sales of Comirnaty. Accounts receivable from the U.S. government represented 12% of total trade accounts receivable as of December 31, 2021, and primarily relate to sales of Comirnaty.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Significant Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The following provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;79,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;40,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;38,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;42,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Comirnaty direct sales and alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Active immunization to prevent COVID-19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;36,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Prevnar family&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pneumococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Nimenrix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Meningococcal ACWY disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;FSME-IMMUN/TicoVac&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Trumenba&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Meningococcal B disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;12,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Ibrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;HR-positive/HER2-negative metastatic breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,437&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;mCRPC, nmCRPC, mCSPC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,002&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Ruxience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Non-hodgkin&#x2019;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#x2019;s Granulomatosis) and microscopic polyangiitis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Retacrit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Anemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zirabev&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Lorbrena&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ALK-positive metastatic NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Aromasin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Post-menopausal early and advanced breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Trazimera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%"&gt;HER-positive breast cancer and metastatic stomach cancers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Besponsa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Relapsed or refractory B-cell acute lymphoblastic leukemia &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Braftovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;In combination with Mektovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt; (cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;V600E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;-mutant mCRC after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bavencio alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mektovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;In combination with Braftovi for metastatic melanoma in patients  with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;V600E/K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt; mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Internal Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;9,329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Symptoms of menopause&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Overactive bladder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pristiq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Depression&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Hospital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;7,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;683&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Medrol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zavicefta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zithromax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fungal infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Tygacil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Precedex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Sedation agent in surgery or intensive care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Paxlovid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;COVID-19 Infection (&lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;high risk population)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;IVIg Products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Anti-infectives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,412&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ATTR-cardiomyopathy and polyneuropathy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;BeneFIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Hemophilia B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;389&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Hemophilia A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Acromegaly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PFIZER CENTREONE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTHCARE BUSINESS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total Alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;7,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;On July&#160;31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare JV. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Contracted revenue expected to be recognized from remaining performance obligations for firm orders in long-term contracts to supply Comirnaty to our customers totals $34.4 billion as of December 31, 2021, which includes amounts received in advance and deferred and amounts that will be invoiced as we deliver the product to our customers in future periods. Of this amount, we expect to recognize revenue of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$22.3 billion in 2022, $11.8 billion in 2023 and $265 million in 2024. Remaining performance obligations exclude arrangements with an original expected contract duration of less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Deferred Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of Comirnaty. The deferred revenues associated with the advance payments related to Comirnaty total $3.3 billion as of December 31, 2021 and $957 million as of December 31, 2020, with $3.0 billion and $249 million recorded in current liabilities and noncurrent liabilities, respectively as of December 31, 2021, and $957 million recorded in current liabilities as of December 31, 2020. The increase in the Comirnaty deferred revenues during 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries less amounts recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; as we delivered doses to our customers. During 2021, we recognized in revenue substantially all of the balance of Comirnaty deferred revenues as of December 31, 2020. The Comirnaty deferred revenues as of December 31, 2021 will be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, with the amounts included in current liabilities expected to be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; within the next 12 months, and the amounts included in noncurrent liabilities expected to be recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt; in 2023 and in the first quarter of 2024. Deferred revenues associated with contracts for other products were not significant as of December 31, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzE2NDkyNjc1MzAyNDE_601f28d2-8bd9-4e1f-a3b0-7fef1db7f239"
      unitRef="operatingsegment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Assets
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMzMzI_36b2bd0b-4909-43f8-9ba0-261d5a1b0e9b"
      unitRef="usd">181000000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2ac39ce3acc7441e86107c1d869cbee9_I20201231"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMzMzk_ce8e4830-fad1-4c1b-a88f-af2e1c6cb6d1"
      unitRef="usd">154000000000</us-gaap:Assets>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1MzA1NDY_e6dee14f-5d7f-48bc-87bb-ab4a0494af74">&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="57" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Earnings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-bottom:0.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Depreciation and Amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reportable Segment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Biopharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;79,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;40,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;38,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;40,226&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;27,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;24,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,439&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Other business activities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(10,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(12,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(11,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;598&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Reconciling Items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(3,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(3,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;3,067&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Acquisition-related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Certain significant items&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;(2,292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;(4,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;87&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;81,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;41,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;40,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;24,311&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;11,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;5,191&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;4,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Income from continuing operations before provision/(benefit) for taxes on income.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; Biopharma&#x2019;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $2.1 billion charge for IPR&amp;amp;D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $1.3&#160;billion ($450 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and the remaining amount primarily&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and (iii) upfront and milestone payments on collaborative and licensing arrangements of $1.1 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and (v) gains on equity securities of $1.3 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. For Earnings in 2020, includes, among other items; (i) charges of $1.7 billion related to certain asset impairments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;, (ii) actuarial valuation and other pension and postretirement plan losses of $1.1 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $791 million ($197 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and the remaining amount primarily recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $8.1 billion recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Gain) on completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $2.8 billion related to certain asset impairments recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt; and (iii) actuarial valuation and other pension and postretirement plan losses of $750 million recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income)/deductions&#x2013;&#x2013;net. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes 2A, 2C, 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;4.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9655062295ea4eb786880d4953a18367_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMi0xLTEtMTc3NDQ2_7907a335-b6e5-4e89-9327-3369993fcb70"
      unitRef="usd">79557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtNC0xLTEtMTc3NDQ2_5773ff19-5977-407f-9857-866f5abd9758"
      unitRef="usd">40724000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtNi0xLTEtMTc3NDQ2_822d2be2-4e30-49b1-b0fa-1c5f12d8be68"
      unitRef="usd">38013000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9655062295ea4eb786880d4953a18367_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTQtMS0xLTE3NzQ0Ng_d5714a79-a33f-4049-ad78-b4ab062cf73d"
      unitRef="usd">40226000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTYtMS0xLTE3NzQ0Ng_c78f2480-6e0a-4812-b437-d0f3b88908f9"
      unitRef="usd">27089000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTgtMS0xLTE3NzQ0Ng_3a0c44fa-4538-4105-b1d4-477ae7b6d295"
      unitRef="usd">24419000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9655062295ea4eb786880d4953a18367_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjAtMS0xLTE3NzQ0Ng_ced6d2cc-140c-4c29-904f-0f866c56c86e"
      unitRef="usd">1439000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id15f51192ed542669a27f840b72a1aa4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjItMS0xLTE3NzQ0Ng_7f261ace-5a86-4ffd-a6e4-932d53aefa61"
      unitRef="usd">1013000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3a54d9f827d444568d294ae89ab037c2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjQtMS0xLTE3NzQ0Ng_272ec279-d27e-4efd-83ad-a0d2b248698e"
      unitRef="usd">978000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMi0xLTEtMTc3NDQ2_d98a92f6-45bd-4e4c-a439-374f7de87b82"
      unitRef="usd">1731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNC0xLTEtMTc3NDQ2_48faa6f0-3a30-4022-b30b-caa0a4b7f684"
      unitRef="usd">926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNi0xLTEtMTc3NDQ2_7cda6e54-0181-4805-8205-7bbf2c4abc48"
      unitRef="usd">2892000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd"
      unitRef="usd">-10396000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2"
      unitRef="usd">-12308000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379"
      unitRef="usd">-11216000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i66ba2631f4e34d70b0ce2bcd41925338_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f"
      unitRef="usd">598000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iebe35c7aeffb41ea8b2d3be8ae55cfe3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023"
      unitRef="usd">603000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i859965feedbb4f31b4d70f66a2bfee92_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922"
      unitRef="usd">592000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic74107e930484043af252b70ef86b1c3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTItMS0xLTE3NzQ0Ng_b6b2c880-962a-4299-bed4-13df367d28ad"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46149707465a45269f0a4d9663481faf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTQtMS0xLTE3NzQ0Ng_ca302969-0199-4f74-931f-1860caf7feb8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4388992791af4d329ee32af6b701ed74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTYtMS0xLTE3NzQ0Ng_decaabbb-d51f-4e80-8c6e-a1aa03573408"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic74107e930484043af252b70ef86b1c3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE0LTEtMS0xNzc0NDY_55e56b9a-2c34-47c6-b317-0ec27b23f0d5"
      unitRef="usd">-3175000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i46149707465a45269f0a4d9663481faf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE2LTEtMS0xNzc0NDY_50095a15-4d77-4d87-8ded-edd7b8c37440"
      unitRef="usd">-3117000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4388992791af4d329ee32af6b701ed74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE4LTEtMS0xNzc0NDY_bfcd77b6-37cf-47da-a023-ed1e44db59f5"
      unitRef="usd">-4153000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic74107e930484043af252b70ef86b1c3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIwLTEtMS0xNzc0NDY_8c2ed33c-a0b1-422d-bae1-3dc5d98f8602"
      unitRef="usd">3067000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i46149707465a45269f0a4d9663481faf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIyLTEtMS0xNzc0NDY_8faca64c-3b06-4ec4-b420-0e3155170551"
      unitRef="usd">3047000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4388992791af4d329ee32af6b701ed74_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTI0LTEtMS0xNzc0NDY_0b14d794-f57a-4276-ba3f-c9f69d425ee7"
      unitRef="usd">4145000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea96d19d201f43f78403ae7000de580e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTItMS0xLTE3NzQ0Ng_6f9a1a93-440c-46bb-b62b-5c9257b61c6c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTQtMS0xLTE3NzQ0Ng_c18da5b6-d003-460c-8f9d-6834203d50ff"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTYtMS0xLTE3NzQ0Ng_0ba3cce1-23f3-44da-935b-1582558339db"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iea96d19d201f43f78403ae7000de580e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE0LTEtMS0xNzc0NDY_26e77d3c-7ba5-43c0-9206-33f175077456"
      unitRef="usd">-52000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE2LTEtMS0xNzc0NDY_7c74cf89-4939-4846-a03a-8d93ceceec86"
      unitRef="usd">-44000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE4LTEtMS0xNzc0NDY_4eeae3f4-c6c2-4bd3-b9ec-88e7109b6ce4"
      unitRef="usd">-185000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iea96d19d201f43f78403ae7000de580e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIwLTEtMS0xNzc0NDY_f1fc0f33-3394-49b5-938e-49c96d2b3d65"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icf6c268982d6425eaa574cf3957a686e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIyLTEtMS0xNzc0NDY_54c2cdd6-b12d-4c75-ac60-2812a95fe9c4"
      unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ied51fadb9aa34e08a9232e466bd81ae6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTI0LTEtMS0xNzc0NDY_f6c3282a-ce85-437a-9714-ec11e7f051f1"
      unitRef="usd">3000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTItMS0xLTE3NzQ0Ng_b13619e0-1809-4023-9173-70819e782a56"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTQtMS0xLTE3NzQ0Ng_dfdde423-a842-42c0-bafc-1efbed3dd6e0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTYtMS0xLTE3NzQ0Ng_43752d49-1ae0-4846-8821-0cdf421ce9dc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b"
      unitRef="usd">-2292000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88"
      unitRef="usd">-4584000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4"
      unitRef="usd">2456000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i184c858d30a24dc0898ed4ce683641b8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39"
      unitRef="usd">87000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if939f5d2a8d44446833cb015b10ebd98_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58"
      unitRef="usd">18000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i136ad932178a4ee2834f646202a4aec8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f"
      unitRef="usd">37000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTItMS0xLTE3NzQ0Ng_4e00268c-4a50-41e9-ad17-c1c9904256cf"
      unitRef="usd">81288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTQtMS0xLTE3NzQ0Ng_3d67b997-73af-44b9-9488-9ff83e4d60c5"
      unitRef="usd">41651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTYtMS0xLTE3NzQ0Ng_b3285840-8bf6-415d-a35e-3c1330c64557"
      unitRef="usd">40905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE0LTEtMS0xNzc0NDY_763275c5-6edd-4d3b-af4f-eca2881128a4"
      unitRef="usd">24311000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE2LTEtMS0xNzc0NDY_00320b28-4117-40ba-9719-fa9dddf0ac7e"
      unitRef="usd">7036000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE4LTEtMS0xNzc0NDY_6a4bc1bb-7dd3-49d7-8cc0-6412bf9dbb14"
      unitRef="usd">11321000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIwLTEtMS0xNzc0NDY_67bd40ae-61e5-4b13-b748-ff051595a96f"
      unitRef="usd">5191000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIyLTEtMS0xNzc0NDY_905c3a81-05ac-4ad2-b380-1cf7f60f4219"
      unitRef="usd">4681000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTI0LTEtMS0xNzc0NDY_ed46c745-7e0a-44cb-a4eb-bd65a5789eac"
      unitRef="usd">5755000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i5bd617c93288422a9a85c45194dae5d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMxOTc_f4da4664-1937-473d-b347-80bf213616a9"
      unitRef="usd">166000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i4ed0ce29b52e4e17a63f828a779445a1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMyMjQ_9640921c-dc74-478a-8d0c-a5f56fa9af01"
      unitRef="usd">278000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="i56c2583057f34bbf90d0e45a1b7ce0dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE3MTMyNTA_cefe860a-5ebf-4444-904b-c9998ab596e5"
      unitRef="usd">220000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i3331360a352a4974b87a0863eff1cb2b_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzg3OTYwOTMwMzA3Njg4_35653fa5-9e6f-4380-8436-b5a91e7ecd0a"
      unitRef="usd">2100000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzODA3MjAx_4e91c20c-c4f5-4e3f-8bde-a101d0ab4220"
      unitRef="usd">1300000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="if5e70ab1cd724cf4a24ca46ee341bb9e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg3MTU4_3a534934-86d2-43a2-b077-1a330cb3884a"
      unitRef="usd">450000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <pfe:PaymentForCollaborativeAndLicensingArrangements
      contextRef="iba01b547ea4849269b96e001dc9a1e54_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg3Mzc1_3f20ec19-5c65-47f9-8dc1-dfd9d9404367"
      unitRef="usd">1100000000</pfe:PaymentForCollaborativeAndLicensingArrangements>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMzExOTgw_bfc27195-4b56-424d-93d4-90a6f2aee4db"
      unitRef="usd">1600000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzkyNzI2_d4f2e67b-5f99-4836-9400-d020de949def"
      unitRef="usd">1300000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg3NTMz_619a0d9f-de24-4a50-a1bf-1b9e2c560965"
      unitRef="usd">1700000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4NjMz_762e9298-7632-464f-b720-096026a57a41"
      unitRef="usd">-1100000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4Njk1_a0c02af1-15c6-4e93-b7e2-6f1acc3cb3bc"
      unitRef="usd">791000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring
      contextRef="i86ca67d3478249f6b4140dba487bbcc4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4NzIw_a6fb3d12-ed86-4b59-8f30-4e2b05c508a4"
      unitRef="usd">197000000</pfe:RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i1c1ed45a447e4917aa229618a729bc6a_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzkyNzQ1_b037ea58-3415-47e4-a7ae-a6fe76bf06fb"
      unitRef="usd">8100000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzNzg4ODY5_de43c566-573f-495a-ac60-461ffce8d81d"
      unitRef="usd">2800000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNjQ0MzgzODAyNDA5_58838d8a-0c35-4cff-add4-e21f4e1201c1"
      unitRef="usd">750000000</us-gaap:DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzk_278ae39a-7efe-4dc0-8021-c20bc1f4b079">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes revenues by geographic area:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"&gt;29,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;18,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Emerging Markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20,701&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01706a25eaf44000861f8a5988b1cfd7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzMtOC0xLTEtMTU1NjM4_b74ed92b-ea3c-4ff8-8cc5-1dc89acd1eff"
      unitRef="usd">29746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80b14f941e6742209cf14aecbed2dcc2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzMtMTAtMS0xLTE1NTYzOA_76116342-b96a-4eaf-8c3c-aa68aae9c4de"
      unitRef="usd">21455000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66820026161242ecb7114f5badd98288_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzMtMTItMS0xLTE1NTYzOA_ca61a9da-68a2-4e48-9e38-8f75c12124e4"
      unitRef="usd">20326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61f3df5393924c84a4d3bd1ee41d293c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzQtOC0xLTEtMTU1NjM4_6c740ada-27d2-4228-821d-3828b524878f"
      unitRef="usd">18336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1faeba83c004ae2b29779566eb052c7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzQtMTAtMS0xLTE1NTYzOA_627dc2a3-4131-451f-b8e6-1ff65d9c6305"
      unitRef="usd">7788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee440d1ba7794b8ab3cfc128d24b19b1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzQtMTItMS0xLTE1NTYzOA_43b0a4ee-4f72-49bb-ac06-21e71a347a54"
      unitRef="usd">7729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib12fb6fa02754813a733da0d0a3c5217_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzUtOC0xLTEtMTU1NjM4_1b9c9771-bfa9-40a3-a022-a37b8fb8d764"
      unitRef="usd">12506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2bf364c90ee403f905cf44b76b83795_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzUtMTAtMS0xLTE1NTYzOA_d76e1a76-7229-4b47-8d7d-2c8c52b05da6"
      unitRef="usd">4036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5545fe7ef044230b942499024d73124_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzUtMTItMS0xLTE1NTYzOA_7b358f48-fc22-42b2-8721-7e2793a31f87"
      unitRef="usd">4022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07534c0ef5da443f9d23bb709f1f887a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzYtOC0xLTEtMTU1NjM4_719ae8b3-139d-4e4c-855f-ae75a6cb955e"
      unitRef="usd">20701000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e4f467b53b54c268aaf5ebd5d255312_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzYtMTAtMS0xLTE1NTYzOA_eeeb0bda-8bb9-4163-8e1e-293fc0434de8"
      unitRef="usd">8372000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b50c81dd41c4b93866757262314077f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzYtMTItMS0xLTE1NTYzOA_f3e825c4-b53d-4cab-82f2-ed11745bb984"
      unitRef="usd">8828000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctOC0xLTEtMTU1NjM4_483684ae-d3a9-4f4e-a1d4-8e4c43732120"
      unitRef="usd">81288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTAtMS0xLTE1NTYzOA_a613a535-5035-4806-9718-d8b2254855b9"
      unitRef="usd">41651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTItMS0xLTE1NTYzOA_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
      unitRef="usd">40905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries
      contextRef="ic62778dbebe74ea5854c11429ef857e7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyNQ_f1583119-7954-492a-a5f0-96dbf1567ca2"
      unitRef="country">21</pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries>
    <pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries
      contextRef="i99f0e6a9eab54ae4a8ed112ae8d226a7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEyOQ_7626b3ca-a090-4c2a-9304-855a0db0ddab"
      unitRef="country">8</pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries>
    <pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries
      contextRef="i4d0a8aaa82ec487cbe6efb57bd4d09ae_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEzNg_3a62a8c4-34a8-4252-beec-a2831b29e657"
      unitRef="country">10</pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6b31b69d78a84395930b25d3a0a78c1b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzI1MQ_afa6b299-0744-44f8-85a4-afbbf9e29c4c"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6d67ec1ac5234c0d9f621dcbbb4183bc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzI1MQ_b5cd0b2b-ab79-4843-ac76-485968659045"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia9c607e23c364498a9220f891e27bfcb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzI1MQ_bdcaad2b-2a61-486c-ada3-deffa891a5b7"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i76154b8bae914f14a3264e5b5345009a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQ3Mw_0ca4c54d-6454-4612-8775-4e8bc58cff9a"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i86eb9d30e32741049330f056b435d474_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzUwMw_0876bb99-f9d5-489d-bff9-9833a73cc7d4"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie70843c611e141548bd971cd5410e88d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzUwMw_a1bfab0b-fa9f-45a9-8225-03cf7dcb68d6"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzE_194b6a44-385b-4da7-89ef-8c65dcf1e648">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.185%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The following summarizes revenue, as a percentage of total revenues, for our three largest U.S. wholesaler customers:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;McKesson, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i02e740ce254147a096ae80d08c9094f0_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzMtMi0xLTEtMTU1NjM4_e25dce8d-c420-457d-8a41-df292b741cc6"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ice936d0c8940458e99b8cd6b72505a29_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzMtNC0xLTEtMTU1NjM4_263aaa07-f1f4-4f84-a72a-d1cd3423b5ca"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id1412106f3b64e9190b955c58956f7ea_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzMtNi0xLTEtMTU1NjM4_99dbfb78-e7a1-4c73-bec0-eeac13a35ef5"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9fee695ccc6d4951bceaa4452197ada8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzQtMi0xLTEtMTU1NjM4_c4ee7d65-9e47-47b5-93f7-7e7fd10ae99e"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2057fb4eee634619a81384ca8181d059_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzQtNC0xLTEtMTU1NjM4_760329a0-dd96-4249-abe3-03ed4718eadc"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2b05c103030344159abe87626ef3fc58_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzQtNi0xLTEtMTU1NjM4_f5780f4d-0b08-4db7-97d3-5e75db6da49f"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i12c71dca498146b98b69c59745867f99_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzUtMi0xLTEtMTU1NjM4_07844136-ea7c-4ff2-9c94-49400dff19e8"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if47ab8b761c145ba8c1e38b804fff672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzUtNC0xLTEtMTU1NjM4_249e2ce5-ffb6-405f-9dac-5d20fedbd195"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i08d75cc0ddf8452ca93b381cb375ed5d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTplYzhhNzIxOWY3YjM0ZDNhYjVmZTdlOGM3ZDIxMThiYy90YWJsZXJhbmdlOmVjOGE3MjE5ZjdiMzRkM2FiNWZlN2U4YzdkMjExOGJjXzUtNi0xLTEtMTU1NjM4_6cdad8ad-b347-4e65-bc47-c64821ce4524"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec439aa05d4f4752ba182e07bea798ee_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzc0Mw_43e622da-5bc3-47b9-9ae2-f2d4f7234904"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1b1ecddc539948bfb8fb4cf369085020_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzc0Nw_9c628183-11b7-49c4-ac92-5b51dfa2859a"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia9e53394f559452ca83fffb3a7e16401_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzc1NA_6117e083-b8d8-4ab5-a75a-1bc89819cfaa"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibdaa8f31455343a4a4b78e91aea00e81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzcxNDY4MjU1ODU3Mjg_fd340d49-e315-4bac-960c-af8b9d22da15"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i67454cc77ab148d1a8042c793aab9a02_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzcxNDY4MjU1ODU4ODg_2ead479b-67a5-4ea6-a440-e22e61818b3d"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njg_5ea53535-3f61-4bd7-a999-08818d5ba70b">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The following provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUES&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;81,288&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a), (b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;79,557&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;40,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;38,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;42,625&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Comirnaty direct sales and alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Active immunization to prevent COVID-19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;36,781&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Prevnar family&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pneumococcal disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Nimenrix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Meningococcal ACWY disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;FSME-IMMUN/TicoVac&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Trumenba&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Meningococcal B disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;12,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;10,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Ibrance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;HR-positive/HER2-negative metastatic breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,437&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;mCRPC, nmCRPC, mCSPC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,002&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;673&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;540&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Ruxience&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Non-hodgkin&#x2019;s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener&#x2019;s Granulomatosis) and microscopic polyangiitis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;491&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Retacrit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Anemia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zirabev&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;444&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Lorbrena&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ALK-positive metastatic NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Aromasin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Post-menopausal early and advanced breast cancer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;211&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Trazimera&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%"&gt;HER-positive breast cancer and metastatic stomach cancers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Besponsa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Relapsed or refractory B-cell acute lymphoblastic leukemia &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Braftovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;In combination with Mektovi for metastatic melanoma in patients with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;V600E/K &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;mutation and, in combination with Erbitux&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt; (cetuximab), for the treatment of BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;V600E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;-mutant mCRC after prior therapy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bavencio alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;178&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Mektovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;In combination with Braftovi for metastatic melanoma in patients  with a BRAF&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;V600E/K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt; mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;155&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Internal Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;9,329&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;9,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;8,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Symptoms of menopause&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;398&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;266&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Overactive bladder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;238&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Pristiq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Depression&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;187&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,706&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.460%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;(MILLIONS)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRODUCT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Hospital&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;7,301&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;6,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;683&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Medrol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zavicefta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;413&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zithromax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Fungal infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Tygacil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Precedex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Sedation agent in surgery or intensive care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Bacterial infections&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;173&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Paxlovid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;COVID-19 Infection (&lt;/span&gt;&lt;span style="color:#242424;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;high risk population)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;IVIg Products&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;430&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Anti-infectives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,412&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;4,431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis, ankylosing spondylitis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,455&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:100%;position:relative;top:-2.27pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-bottom:10pt;padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%"&gt;Crohn&#x2019;s disease, pediatric Crohn&#x2019;s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;657&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;134&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;3,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;ATTR-cardiomyopathy and polyneuropathy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,015&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;BeneFIX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Hemophilia B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;438&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;389&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Hemophilia A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Acromegaly&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;277&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;115&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;PFIZER CENTREONE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;1,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTHCARE BUSINESS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;2,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Total Alliance revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;7,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;4,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:0.25pt solid #000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;2,343&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;5,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%"&gt;5,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:0.25pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt"&gt;Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt"&gt;On July&#160;31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare JV. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt"&gt;Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNC0xLTEtMTU1NjM4_e8bbbce6-fc9b-431c-8278-af06ccb82a49"
      unitRef="usd">81288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6500bfc640484536bdc0c9305ac6c78f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNi0xLTEtMTU1NjM4_de2f933a-4fc4-4b54-9f85-3b4de5212a79"
      unitRef="usd">41651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtOC0xLTEtMTU1NjM4_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
      unitRef="usd">40905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ba39cae55e2432688515ca3a47f62e2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae"
      unitRef="usd">79557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4ab42ea69a04305a2fa6db983f61342_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e"
      unitRef="usd">40724000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b3fcc1684c04124ad431600c3ae2310_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c"
      unitRef="usd">38013000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie683f91cae7e4f439a204f20f28ecdd3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTYxODk5_ec2694c1-0583-459e-a31c-55e2675ae948"
      unitRef="usd">42625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i790164b8b500487995993a2e01eb13c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTYxODk5_b98834ea-224d-4322-91b5-25b2baa7ac69"
      unitRef="usd">6575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i010d3fafcc354cc784caf06fb723ade2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTYxODk5_e6fa7690-0e67-4c7e-aec8-da1876f01c9e"
      unitRef="usd">6504000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff979b3974154ad0803e20ebd7c32f30_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxOTE5_a1e7d7a4-34af-4346-8bd3-6ef912f76d62"
      unitRef="usd">36781000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if78e81b138394cc1884da57948dee8e5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxOTE5_51361f70-4b00-4000-a701-186d811cf7d4"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a4239b3555a4e418c8a9a5e9d67c2e6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxOTE5_56260df1-0a6a-415b-a1d8-01d57283b351"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e5d56e1790d4d3298629659396a640a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxODk5_616bc566-ed61-48d2-a689-843292929258"
      unitRef="usd">5272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4ed595eccea49ffb73f0798a75a1773_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxODk5_277205d7-51d1-41dc-9ba5-25bbc37331e1"
      unitRef="usd">5850000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76fcd41f92da44e289e82affd418e306_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxODk5_017fe27d-e80f-421b-8f33-cf6e30a994cf"
      unitRef="usd">5847000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84925602fa144f3ba3a71b13029588f0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNC0xLTEtMTk4MjQ1_9d386c72-04d9-459d-8b6d-3ecb3918d3d7"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a69e52cd15347808dffa431d34044db_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNi0xLTEtMTk4MjQ1_d4de6f1c-922c-4de9-8398-0ebdc1eff27d"
      unitRef="usd">221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf42e0f52a3e45b59df985db36745f16_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtOC0xLTEtMTk4MjQ1_42502b14-4d0a-4568-a60e-ffc8eb925132"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieff4fe2fbc324b449cb56e68fdcd1a9c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNC0xLTEtMTYxOTM3_08b020c0-a780-4fa4-bff5-6c8cb0c51168"
      unitRef="usd">185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2238b79faba4effaac005b81ff23304_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNi0xLTEtMTYxOTM3_fbb0c85f-65ec-452a-b163-34fa49cb20c6"
      unitRef="usd">196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf497a35e6494fad8698744787351909_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctOC0xLTEtMTYxOTM3_b636d60a-56be-4475-b1c8-10003d086c7a"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f72c5f82d75415ba597df7de74760b1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNC0xLTEtMTYxODk5_5a4c69f6-2d75-48e4-9813-1b1ffc534f5e"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0750214c46a64ab6b39e459f0d49daba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctNi0xLTEtMTYxODk5_ac796295-bccb-4581-992a-24bd1e60b4f1"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20e64081e3f0434b872e5a4506e536de_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzctOC0xLTEtMTYxODk5_357edd99-842c-4a85-8d74-5f54cd693b09"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacb6a72bdf8141cf863b344e751661ae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNC0xLTEtMTYxODk5_6386c56d-61f2-4662-8a23-af5d4e4e5578"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8eda9019748445348870a74c3bd3ab6f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNi0xLTEtMTYxODk5_7e90db37-12d7-44c5-92be-8d933e4fd391"
      unitRef="usd">42000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5790195bd954466ba793840f2495ee93_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktOC0xLTEtMTYxODk5_14599c6d-b935-4103-bd53-3661d87bc8c1"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6a6b539896c45d79c389bacbc2f4743_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzExLTQtMS0xLTE2MjAxMA_a9b87b37-3c42-4ab2-b490-e518c5ebc377"
      unitRef="usd">12333000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie427a740ab1c443d87ea004b5125ac8d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzExLTYtMS0xLTE2MjAxMA_b6825040-6ac8-4480-82d0-cbc9e6e5507d"
      unitRef="usd">10867000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffa09786cae24e62ad36d600ee535ad2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzExLTgtMS0xLTE2MjAxMA_5439acc4-bdc3-4693-9f65-55a0a8f0b4ae"
      unitRef="usd">9014000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92db76fc792d40ad86670b655627f383_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEyLTQtMS0xLTE2MjAxMA_d88cd670-836d-472c-9c28-6ab57949f74e"
      unitRef="usd">5437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95c0ae9140eb4237841af25b9edac128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEyLTYtMS0xLTE2MjAxMA_895d22d6-e9e7-47f6-b21e-a760983bb291"
      unitRef="usd">5392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3efd621f0e0d4d2a8760e00099eb67a5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEyLTgtMS0xLTE2MjAxMA_2db541a6-8c64-48af-99ba-eb97e65be903"
      unitRef="usd">4961000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c93ecc7240f4fa3ad8ec0c4c64303bf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEzLTQtMS0xLTE2MjAxMA_3efa1eac-47ce-423c-9ca8-8024c578acb4"
      unitRef="usd">1185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d3a6827b38a41d7a516870ab707a086_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEzLTYtMS0xLTE2MjAxMA_e29a858a-bb4e-4c0b-a494-5743390d8d76"
      unitRef="usd">1024000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55b91f673fc04f73a3ae024b9a41752d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEzLTgtMS0xLTE2MjAxMA_1788c5c7-30b0-403d-8211-0c5dacebfe7d"
      unitRef="usd">838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe1f7d47181e475bb3aa38336cc6209a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTQtMS0xLTE2MjA1NQ_300e637a-1731-476c-b4ca-313514ed544e"
      unitRef="usd">1002000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5858407930714ddc909e6bd243e24efc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTYtMS0xLTE2MjA1NQ_d2fec52b-af5f-46ef-9e71-9f45e6824d5a"
      unitRef="usd">787000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcfc0ac3a4bb41e6b2470eb7d7c0ed54_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTgtMS0xLTE2MjA1NQ_fe8f9412-096c-44bc-97a6-8583eb99db21"
      unitRef="usd">477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic828b8310b6d4b5bb05dea1dfee3affc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTQtMS0xLTE2MjAxMA_8846e87b-14c5-4536-baa5-35496a16d605"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13c1116b8782479b9a95ddf926b9e0b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTYtMS0xLTE2MjAxMA_25534abe-026c-4413-970d-3de1c971e09b"
      unitRef="usd">819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28052556477d473b8c21d8bafb9cead1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE0LTgtMS0xLTE2MjAxMA_0ab32ae5-2a2d-4759-8b49-891d89e29a41"
      unitRef="usd">936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b1304b5f82e4e58a1c55dc33b956260_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE1LTQtMS0xLTE2MjAxMA_764233d1-56f7-4dd0-a5ff-7b9ccd09a31d"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8bad590cb383439c9110aca0d945cd2a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE1LTYtMS0xLTE2MjAxMA_a3198963-77cf-4149-aec0-ead494df16e2"
      unitRef="usd">450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22e5406f5f364c5eb193983737f6387f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE1LTgtMS0xLTE2MjAxMA_a33c1b99-20b1-42f5-8145-698b2582b2c3"
      unitRef="usd">365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6acf78ac097b422b88e179ee9b747007_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE2LTQtMS0xLTE2MjAxMA_1a77ae72-ca64-47ef-8497-29690a87acac"
      unitRef="usd">493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67bcc609ff5d4139b0a6a18177feb882_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE2LTYtMS0xLTE2MjAxMA_16c95711-dd87-44df-b772-6731608386be"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibef0fffb95fb47da8f0bdd6c91925689_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE2LTgtMS0xLTE2MjAxMA_0f0cd947-a91d-4571-b76c-48f88be08f2b"
      unitRef="usd">530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7590755364db416f9e17b48ea64413d0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjA3NA_9fafef35-c537-48a3-9506-c3d44e8130fb"
      unitRef="usd">491000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65e7d6b26d7d4a74b5f922d708d9a413_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjA3NA_898220b7-d9bd-4658-9116-f1f7647bfbf0"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2460aa2b09c74030b8381ba12fb645fd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjA3NA_29abafd8-1987-4b69-8d7b-7b36e729d14d"
      unitRef="usd">-1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81b6c834fb1c4292b59fda40ade5b9d1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjAxMA_b01f1c97-93f1-46a1-99e8-af9042092584"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6ae2a7d71d9425d8152e464a315bf21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjAxMA_6cb5c6c4-f805-4d7c-a4d5-2d9f7e295dd8"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i975049da60424e96b8b532025ae69caa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjAxMA_d5f94ded-8f05-494f-867a-3ada9c6f4618"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb7484561be64aeb9ac7738d08ab387f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTQtMS0xLTE2MjA4NQ_862ece23-b22d-41fb-b445-a8fb8400869e"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4de75bb8b77440d0bf45934e1ba87237_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTYtMS0xLTE2MjA4NQ_0c5c6baa-55e5-4560-8e48-d75e567c277c"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83d8b4737c1840a0b89442498290ca65_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTgtMS0xLTE2MjA4NQ_83c25b6b-7635-4a3f-b803-2b579fac20a1"
      unitRef="usd">1000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida0fb8d22c1645438cba3e8ce25ca48c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTQtMS0xLTE2MjExNQ_77a4e38e-b3a9-4b8e-a365-75748ccd98d8"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67382282eea44a6a957d3764ba308d11_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTYtMS0xLTE2MjExNQ_53885455-62cc-48a7-892f-3515d25275f8"
      unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b122ab8ca744c749dc432ff78c16ea0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTgtMS0xLTE2MjExNQ_5d969c0f-f2c0-4878-9e8d-364bbb1b5b20"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic36583488c824eb4892877ea211dbad5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTQtMS0xLTE2MjA5OA_dd01c4d6-8d66-4e66-9b2a-022ed2b3537e"
      unitRef="usd">211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc957ad3d68e45c5ae1a74b135305349_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTYtMS0xLTE2MjEwMQ_01382730-5417-4952-8642-6037e49b0300"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86b391f47cfe48fe93bdb715d0951829_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIyLTgtMS0xLTE2NDg1Ng_f4c5dd7d-52b0-4e67-8631-60fbbfc7dc9e"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23070ab492904e61a59b2297b56b0953_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTIwNDQ1MQ_9a68c631-ef4a-4008-9ad5-f858dec514b7"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7733f5b2e9345d9a1e642d4c79139f3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTIwNDQ1Ng_873b90bc-fe83-4098-a714-9762073a68b3"
      unitRef="usd">98000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1933184cd1e5441e87193869a01461e8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTIwNDQ1OA_a7dd1abd-ef00-4aab-b4b3-aa247e5e03e9"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacb7b7f56fda4c10a3da08d150f67fc4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIyLTQtMS0xLTE2MjEwOA_cebd0eb5-3fa9-4e90-a1e6-5e066362b78c"
      unitRef="usd">192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i625be7e17cbc4e3cb80799060c42b8a4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIyLTYtMS0xLTE2MjExMQ_1d4df047-23a6-4164-9fc9-845267247d89"
      unitRef="usd">182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e621ffd98b54fd29f2e02643a70ad30_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTgtMS0xLTE2NDg2Mw_a985d820-a747-4d95-8961-ff2f09823906"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f9007e1cc1b42109548c43dc4c66fae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTQtMS0xLTE2MjAxMA_e83125ad-5d69-46da-aaae-9e693bde8351"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7d9fcaa44eb493cb0d96f6c81f2a2ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTYtMS0xLTE2MjAxMA_6353ebf5-6892-4a9e-858b-6c952702ac3e"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28dd61ade4364d5a90e0a17c4f83e822_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIxLTgtMS0xLTE2MjAxMA_12f69580-1319-437d-9110-c6d0b67e635f"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60a9e485dc774f3ba6d70e30217f15f8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE2MjEzMQ_ea4508ec-2a66-4db7-946d-b3e41699159b"
      unitRef="usd">178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e987f25dd8b46eca97df2eca4a9c075_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE2MjEzMw_791c2ff8-36f4-4819-b94b-70ac7502d574"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736cfbcbd4874cd1bb2dfded6deaeeb8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE2NDg2OQ_f30a8c1b-f1ed-46db-aa8d-03a59830e579"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b56db0f447c437197c532ee8f7047fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTQtMS0xLTE2MjAxMA_9935fb69-86dd-4e24-8ff1-880c1943313b"
      unitRef="usd">155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf3eeb0ff7cc45b8b0e9b9da65bac12e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTYtMS0xLTE2MjAxMA_d39b9ae4-f1ab-48aa-826d-9a9208664af3"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id911443b1d0c48de95a2929266a7582c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIzLTgtMS0xLTE2MjAxMA_e505c568-6476-4879-b757-c2f872a81936"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25c019e4bb9043ffaab47e93d8c852aa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTE2MjAzMg_2b9cc75f-c32a-4a16-ba9f-28158fa8bde7"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a302d7f90c3424fab750ed285db9b29_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTE2MjAzMg_04cc689d-6353-4b66-afbc-c479b1895a86"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39a027609db240a7866905b49f8d682d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTE2MjAzMg_9bffbc3d-7d28-4e88-9406-c6f2fbe32483"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb26436d0a1448cb81ceb46110a4f3eb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTU1NjM4_5e625bc4-4ef6-4a37-a7b8-8b366f3dd43d"
      unitRef="usd">9329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4bfb7acabb24a67a1151e63cc4fce68_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTU1NjM4_ec6361fc-0439-4de2-b387-fbda57bb50ee"
      unitRef="usd">9003000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8c89535e85f4038a7ec373e8a3123cf_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTU1NjM4_5006991a-a52b-4b7e-8d89-c8f253f13bf9"
      unitRef="usd">8790000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea9873a8979b4508be42cfcfe7747f50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTU1NjM4_47179b3b-840a-41ed-9ca9-1e2e7a95c19d"
      unitRef="usd">5970000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabcd20f9c06a43dabd464c0015ff8930_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTU1NjM4_c20b2237-6e57-449c-96cc-7564cc651ed6"
      unitRef="usd">4949000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cdd55ff3b5d4c52861b121e66ab3ac7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTU1NjM4_bb4bb18f-271c-48b8-abb0-223e07cb71cf"
      unitRef="usd">4220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36bb0606d8cc44ddbf05cfe5192a51de_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMwLTQtMS0xLTE2NDUzNg_63b52829-faa6-4c88-aa66-621bf0a698de"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b4ecb4c49ac45c096a8e6606e325b90_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMwLTYtMS0xLTE2NDUzNg_6e70f635-5398-4843-96ac-0f02eb479684"
      unitRef="usd">680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33477546f42a4341949e28a3012fca3d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMwLTgtMS0xLTE2NDUzNg_1cdb4772-34c5-417b-a5ee-1765c13b5f66"
      unitRef="usd">734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55ac74fef9494583b8e81681775bc2b7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYtNC0xLTEtMTU1NjM4_2c2fb541-942b-43ce-8d8f-470bcbb41bfe"
      unitRef="usd">398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc1f43e55c834e949f22669758cc7ee7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYtNi0xLTEtMTU1NjM4_cb4fd6ee-a829-4275-9650-3607a3f5c6a4"
      unitRef="usd">919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f598e5471364ba699cade3d65d16c2c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYtOC0xLTEtMTU1NjM4_86e43375-5676-4c87-8de7-d988709eb494"
      unitRef="usd">1107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b97da5e9af14fe396e47b0d71d869f3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNC0xLTEtMTU1NjM4_9711e40a-36ec-454b-bcdc-1d2521466a59"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7e0cc1b139d40adbb8d7340de280263_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtNi0xLTEtMTU1NjM4_955db1cf-7e39-4ef4-bbd3-8f59e52e87e9"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f3e974364904421b9ba3879babbf5f1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzgtOC0xLTEtMTU1NjM4_0cf1ca36-fd87-4df4-800e-b834e7d2a696"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb84bd57d736452e8091760a4451bf32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNC0xLTEtMTU1NjM4_621630f6-c0ed-4aba-afb5-9c95381060a4"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i789c240c68ac4def920f05c29c59b9ba_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktNi0xLTEtMTU1NjM4_25842b9a-729f-4f6e-ad5e-d96226ce0162"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bc19ff52f7843b19250144e07c70512_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzktOC0xLTEtMTU1NjM4_138dc191-39dd-404a-b2ec-1c36a2d8f187"
      unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia28339e568e9484e962b70b87aa216f5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM0LTQtMS0xLTE2NDU0OA_9c21423a-a0f9-4d04-89e6-0f9b2942d1c9"
      unitRef="usd">187000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47352f77aa394099a094f2eb6b3aee0e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM0LTYtMS0xLTE2NDU1MA_9f48fa76-31b9-47a4-a596-628633771442"
      unitRef="usd">171000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c315b990d4b4ef4b6f4fe096b1108fe_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM0LTgtMS0xLTE2NDkxMQ_6fef23f8-2db1-4574-89b3-06b73c5aaa47"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93eaf75f91e64395917e59ebf57f6d3b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEwLTQtMS0xLTE1NTYzOA_8ac9d042-b4aa-439b-972c-a92851b8d83a"
      unitRef="usd">1706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb67eb0248104e43bdd406f377b6ff52_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEwLTYtMS0xLTE1NTYzOA_d535c716-cf3e-48be-b5aa-340a2ce7eb09"
      unitRef="usd">1758000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e5951a6d7c24aabbf638e2cfc5d9fad_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzEwLTgtMS0xLTE1NTYzOA_c4565262-ead6-48e8-b9ae-edf40915855e"
      unitRef="usd">2016000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1efecefa4ebc419689066fe6e6521f2a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE1NTYzOA_84d1e18f-fce3-4724-a67d-9e622d48d437"
      unitRef="usd">7301000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie86f9d77d3ac4df098fa6d23ca3fd9c3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE1NTYzOA_e127b306-d2c4-4e38-b370-f5ab9071a5f2"
      unitRef="usd">6777000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c0eb57c151e4a51b244e35e9ceb3409_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE1NTYzOA_bb7ecbef-0b64-4b85-8cef-019466b07d02"
      unitRef="usd">6695000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i864f375b8a0b4cb9ac443ab41aef9bc3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI2LTQtMS0xLTE1NTYzOA_545eb026-c85a-4bee-ada1-b278ea00b6ab"
      unitRef="usd">683000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib48b9e43f20748079898c888a0319e4d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI2LTYtMS0xLTE1NTYzOA_a01fa71e-8e3c-4ff5-aa15-db1bead5ffd4"
      unitRef="usd">618000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23cf6ca73857476c8ff2bdba66164ed9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI2LTgtMS0xLTE1NTYzOA_fe8eb5cd-5aa9-4e26-b7a8-fdad41de423c"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fcee28088674808b29e46b75901de61_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI3LTQtMS0xLTE1NTYzOA_340c1407-a32d-4b2b-a7d8-b3039b055bb3"
      unitRef="usd">432000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia26c6c1402924d3389d90318d7b7a05d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI3LTYtMS0xLTE1NTYzOA_8b493168-0eb1-464f-b821-dff381d3df7f"
      unitRef="usd">402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieed935509397465ebdcfc54a917081b4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI3LTgtMS0xLTE1NTYzOA_f776c90e-f262-4936-a9c7-07132e8af9aa"
      unitRef="usd">469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic429688b0a95432ca599be902169635c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM5LTQtMS0xLTE2NDU1Ng_03e0dbf8-17ca-4356-9499-58dd82ca25ec"
      unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7715e12d4d640cab70794a4955462a2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM5LTYtMS0xLTE2NDU1Ng_77b7caec-3b75-477f-8ff0-acb13a29e227"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3657cbe2097d49f09bc5c7ace046f357_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM5LTgtMS0xLTE2NDU1Ng_3fc2a782-5aec-4efd-ac6d-30304210824d"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea0f38aa0b8344479ee03e3bf63754ad_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTQtMS0xLTE5ODQ1Ng_52f2b34f-f870-4c68-9a5f-2b3b10a2806b"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i556e45078d274acaae78248df82d7516_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTYtMS0xLTE5ODQ1Ng_9bf9cfef-e516-468d-aa18-d80960960916"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa5c08d894ca47fcb948a6643738b465_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTgtMS0xLTE5ODQ1Ng_c9548c8c-e0fb-4724-8819-de2ecad1e072"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id11b6e37093449bb86170837f29de961_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTQtMS0xLTE2NDU2NQ_12447790-7d7d-4432-9d55-44b84b4a9d5a"
      unitRef="usd">278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cacfa22e3f24fba9a769d3980dee98d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTYtMS0xLTE2NDU2NQ_f02afd30-fc35-470b-9dee-bf1c775e78e9"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92765a1b79944c1c9064745303c5bb8f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQxLTgtMS0xLTE2NDU2NQ_2ee14edc-adf0-4ca6-89eb-c4dc4d362ce7"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d9c00b6c0fe43929b5baaef97fd98df_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQyLTQtMS0xLTE2NDU3Mg_46f02be5-3f8c-4962-a770-84d28163122a"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48f1bb2ae72c408dbdd9691315c5ceed_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQyLTYtMS0xLTE2NDU3Mg_773da79a-1315-43b0-8da8-21f5397798c2"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i976152f132e54933961ff0eb781c15eb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQyLTgtMS0xLTE2NDU3Mg_fae20f86-2c80-4f28-8b57-2c930e344feb"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5573eebca954b888eb53c05194e1cb1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ0LTQtMS0xLTE2NDU4NQ_927339bf-bce9-4c30-86d2-5cd314a5d6c6"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ec61b9fd42f4e11b22c341a2f524130_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ0LTYtMS0xLTE2NDU4Nw_2d147988-0176-4ba9-9d05-6fe202f04276"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icecd0bd3f5d64be6b655bd11f2dec987_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ0LTgtMS0xLTE2NDkzNQ_97e70aca-edf7-4656-91e3-33f196b2ea62"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac09b89e5bbc4d37ad7c15e4b948b194_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTQtMS0xLTE2NDU5MQ_82a1fbf4-be81-4aa2-82bd-4f11f102deeb"
      unitRef="usd">177000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15803142604d40aaba5216963466084d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTYtMS0xLTE2NDU5MQ_3c602997-85d5-4a43-8139-ee491c9e726a"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if479f5e8c2794e9e90a2742677f13fa3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTgtMS0xLTE2NDU5MQ_9afbe674-31cc-488f-be01-d9eb86014efd"
      unitRef="usd">155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1505f771b019477290eb9cd549444c29_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTQtMS0xLTE2NDU5MQ_67d992b5-a7b1-4f03-b6a9-f07c3fdc081d"
      unitRef="usd">173000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64e4fd49f5a94424933d7ef2c6829721_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTYtMS0xLTE2NDU5MQ_7d396500-9546-48db-8ac4-5a888c8e1b26"
      unitRef="usd">222000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b70715abc94491a9f13b0b6351cfa47_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTgtMS0xLTE2NDU5MQ_f9092839-15ea-4e50-8845-358ff10582f2"
      unitRef="usd">251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie735373e16a54b109a6ca3eef912bee6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE5Nzk2Nw_aa0ca3ce-697e-4a68-ae98-277d627422e7"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf401509c5154ce99e7c8858bbbacba4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE5Nzk3MA_035bfa5e-5b80-4006-85bb-06e7eb49148d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c1ea9c9b504497db6d2486610d3f9be_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE5Nzk4NQ_dea0fdf4-fa5a-4a84-b661-c3f92cdd325a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08011c6d22d84826921f15b42efbd425_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE2NDYwMA_8bc8c2da-2d5b-4c39-bae1-d91078e9f19b"
      unitRef="usd">430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e0d8215e037429fa7a23c4023f0d1e4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE2NDYwMg_75ce4bd5-1146-426e-a42c-516b04aa5a41"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb660a81d4c4eab803661bac2510826_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE2NDk3NQ_f1946444-2e33-45ab-9b79-73f3bb433ed8"
      unitRef="usd">275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5eab6ea9c344750a8cbb61f815ce93d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM3LTQtMS0xLTE1NTYzOA_abd7b0b7-dba1-40c5-8cc6-49ddc6c6e7ce"
      unitRef="usd">1453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45a69b57be5b4ffb9798f0dd614f0c40_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM3LTYtMS0xLTE1NTYzOA_bbd3d804-c4df-43c2-8666-37c58169f34b"
      unitRef="usd">1294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6571d00942e43b7978e3b7b74f6edd6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM3LTgtMS0xLTE1NTYzOA_ae04e05b-a4ec-4291-8394-6843d98acc6e"
      unitRef="usd">1396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8053c4ee14d4eb98043aa3562d93dc6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM4LTQtMS0xLTE1NTYzOA_72d209ba-2afc-416c-ae46-5d27be497e91"
      unitRef="usd">2412000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icaa0004eb00541dd973b2f4b93c282c5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM4LTYtMS0xLTE1NTYzOA_0d671c6f-cb59-45de-a261-fcac99b0f072"
      unitRef="usd">2435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i713a733530404ed18373bae05f6b3cb6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzM4LTgtMS0xLTE1NTYzOA_4da9eca7-255d-47ae-b452-4232471717c3"
      unitRef="usd">2225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d0dfa4a22a74f91abffb964783f5b3a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTQtMS0xLTE1NTYzOA_57a9c96b-24da-41a7-9148-0b6057723413"
      unitRef="usd">4431000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47bcf7ce353c44f5bcfdcdee0877890b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTYtMS0xLTE1NTYzOA_a7e89de7-ca32-4095-a0eb-0c4646d670d3"
      unitRef="usd">4567000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4f1c35594c544dab5b1dfa223ee4637_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ1LTgtMS0xLTE1NTYzOA_b803ba39-d9f5-4238-800d-3424cf75acac"
      unitRef="usd">4733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i70c6cef914b94f1d9ad5c0270ad54b42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTQtMS0xLTE1NTYzOA_a4893523-c398-4d64-9e53-1c1600735e5e"
      unitRef="usd">2455000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5563b77001b44cb1904e2c79fdf3e92a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTYtMS0xLTE1NTYzOA_d763b952-6725-4d8c-9103-e92fc8f608cc"
      unitRef="usd">2437000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc98ac45c09142c7bd8010806f4ab103_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ2LTgtMS0xLTE1NTYzOA_26e2c666-8347-4ada-83e7-94b755e7034e"
      unitRef="usd">2242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8922522ea93a4f3daa0785e1fc05776a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE1NTYzOA_4c23db60-a64e-4132-908f-8691821d414b"
      unitRef="usd">1185000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05428f6e4c154ff7b4054980d1d8cb46_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE1NTYzOA_81cabc4e-28a5-4f06-b880-dcd11b948e5b"
      unitRef="usd">1350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i350105d44425447281d31cd6eb39f7c9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE1NTYzOA_46df3ae9-52ed-4b3b-829a-455af7ffc166"
      unitRef="usd">1699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib47901365d3d4bc0bb6d60c486ef4e67_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE1NTYzOA_ef2210fc-2af3-4987-9ee4-e4fabe090c27"
      unitRef="usd">657000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6baae032a571408ca95cda7430a3f436_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE1NTYzOA_b156dc16-529f-44d0-ac01-d31d1d7d5ba1"
      unitRef="usd">659000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71f59e7bda3142f187e0612cca60056e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE1NTYzOA_492c7816-9dbc-458f-9896-5645ccb7be3a"
      unitRef="usd">625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34bb0e10a3254deb9c9b88fa560808c6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ5LTQtMS0xLTE1NTYzOA_aeb05748-49ad-4425-af79-a740b7afbdc0"
      unitRef="usd">134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie013202cd4c84b0ca180ef2bac1c2fd6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ5LTYtMS0xLTE1NTYzOA_fdaa91d6-cdfd-4bdc-a8e9-1fec847da873"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49f99cd213cd422f98453a77ea72f411_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ5LTgtMS0xLTE1NTYzOA_f9d4b1f6-3ab4-4b5f-8a86-e405246a1488"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11d18c120b6c467ab4451263aebe5da0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUwLTQtMS0xLTE1NTYzOA_f74d2f1d-0f76-4973-93d2-e911bb2a499c"
      unitRef="usd">3538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62b3761d83784fc7a895b99aab8312b3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUwLTYtMS0xLTE1NTYzOA_f07ce368-0afb-4c29-a617-b80e2292c6b5"
      unitRef="usd">2936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfcbdb031a3e4014a0cbb064217500aa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUwLTgtMS0xLTE1NTYzOA_07e21691-c471-47cd-83a3-822bdc5d22b0"
      unitRef="usd">2278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62bf6fb9bf9145e6badc4cd8e5f71064_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUxLTQtMS0xLTE1NTYzOA_adc120dc-26c7-49cc-9012-cdefdecbae12"
      unitRef="usd">2015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a4105a4588d4e35915a905b52f68c56_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUxLTYtMS0xLTE1NTYzOA_2d4bd790-b635-4bac-8902-dca5ed1fd229"
      unitRef="usd">1288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff6d7e329bd24eb4a5a437d5f214dc41_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUxLTgtMS0xLTE1NTYzOA_b2e7e1b1-de2c-4f72-88b5-c56e4211fe8b"
      unitRef="usd">473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03db65ef941c451aa8dda7f330bc59a4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUyLTQtMS0xLTE1NTYzOA_c68008b9-ea46-47be-82f6-be98e7030112"
      unitRef="usd">438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d4ea528937245a980a0cd68ff2881a0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUyLTYtMS0xLTE1NTYzOA_66f4625a-058e-471a-96b4-f11f2c27fd50"
      unitRef="usd">454000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib70adb8ce46e49d0b66f7c5db2e887d0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUyLTgtMS0xLTE1NTYzOA_f766ceb0-12b4-4bd1-a37f-5c10adea742e"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cc90c9a8c6548658c7c62c694f4b1b0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUzLTQtMS0xLTE1NTYzOA_29bafd57-3117-4150-9d0a-a25a414d10b9"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idfc908d4ea1448b3be3181f507e32499_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUzLTYtMS0xLTE1NTYzOA_76fc21b3-1ad2-415f-9868-6d7a4c2721e4"
      unitRef="usd">427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71abae4333e54c548a4315c66f1b397f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUzLTgtMS0xLTE1NTYzOA_91df1b65-49ba-4064-956c-b334b4121d25"
      unitRef="usd">498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3287158066bd486e8eb1277ac8bd7a2f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU0LTQtMS0xLTE1NTYzOA_5775949a-a34a-45c3-b1d9-ddc8177cb2dc"
      unitRef="usd">304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i378275fdf5c241309e4fc13c042fb25d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU0LTYtMS0xLTE1NTYzOA_9897d63c-1f13-49ce-8e00-3b7073da917b"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i484dba9ec8d0445bb323aed6db364c28_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU0LTgtMS0xLTE1NTYzOA_0e8cb7b7-0eb1-4cb9-a45b-b3ef71970934"
      unitRef="usd">426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0d6d788ad4143ccb88dbf6bae7eeafc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU1LTQtMS0xLTE1NTYzOA_e19c7858-e5be-4160-b282-c81d0dfa6d76"
      unitRef="usd">277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd236c60a6694d4cb50a6a582663bb1d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU1LTYtMS0xLTE1NTYzOA_00a593f3-0ae3-416b-b2fe-d08ab62bb748"
      unitRef="usd">277000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i503af1f1138c4021a803c193d30090a6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU1LTgtMS0xLTE1NTYzOA_68e8d502-9ae8-4bb2-ac18-e558ad0608b1"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i623d184c533f47bc94f2a7ad9168813f_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU2LTQtMS0xLTE1NTYzOA_923fd574-c718-4857-afab-3e47ea34b4f3"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27ecd1a0cd424241b3ef5a26c2f58f23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU2LTYtMS0xLTE1NTYzOA_141da2c5-f52c-42ee-9321-585b2aa49431"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c4ac602963e4692bf2396276e8987c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU2LTgtMS0xLTE1NTYzOA_7c936533-1664-4f0a-885f-c30bae188022"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i629787cb4c6e49829464bc26f89c64cf_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTQtMS0xLTE5MjY0Mg_973de251-1059-4bc4-8eb8-a7ca4fcc9007"
      unitRef="usd">1731000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff57629495074f9eba67dffa28d6db32_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTYtMS0xLTE5MjY0Mg_df1f1f1e-4008-4cda-ac0a-e639d27cec71"
      unitRef="usd">926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9b3c1fffde345738b432a24553ace13_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTgtMS0xLTE5MjY0Mg_225a7c3f-25ee-4409-844a-ca7bb3aca5e2"
      unitRef="usd">810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc38387d7e3642be97acbeb8bf6bdcb8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTQtMS0xLTE1NTYzOA_e2fa2de8-d998-4b80-bebc-4cd7c402c0c8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ef775a73de440e793ff799dbf7b5fa7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTYtMS0xLTE1NTYzOA_625152f8-e200-4048-8ec7-2928d62faf56"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e851a6e197444cb8fc69f8308332f99_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTgtMS0xLTE1NTYzOA_4a4fd6f2-6e82-4b8a-b870-339dfe8edb35"
      unitRef="usd">2082000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92d39854eb2b4573a531d5ba9f61e8f7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU5LTQtMS0xLTE1NTYzOA_14dfe05a-c342-446a-980a-fc7a95642740"
      unitRef="usd">7652000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d7d6064a3a64aa6ad422f45888299a0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU5LTYtMS0xLTE1NTYzOA_c993556c-1ae4-4f68-a6f2-63cfd83b3cf6"
      unitRef="usd">5418000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39801c36e4b84ce8b6d398e7fc12447b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU5LTgtMS0xLTE1NTYzOA_19d1622f-fff1-4295-944e-e11d0b33158b"
      unitRef="usd">4648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82c3b4b2ebc94e5697c6ff08a35994e8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTQtMS0xLTE1NTYzOA_b5a3ef71-2dba-41da-9044-3e1f336183ad"
      unitRef="usd">2343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec324211aedf4500bf27dd971b841288_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTYtMS0xLTE1NTYzOA_95ca3f57-7179-4721-b012-2d1c1e26855e"
      unitRef="usd">1527000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e4868147c644c12aa0f667d7f6e8057_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTgtMS0xLTE1NTYzOA_22e67cb7-a692-4f22-b211-654b1e63675f"
      unitRef="usd">911000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1631e191e764640a3ad6ad0db704edb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTQtMS0xLTE1NTYzOA_9378fa2a-a4bc-47fc-a652-1bec85705217"
      unitRef="usd">5746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2fae2aac94946139c72a9f5a683a557_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTYtMS0xLTE1NTYzOA_a86bd816-10b9-4f9b-912a-4d22b7e4fec4"
      unitRef="usd">5315000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i027e0fdd3ba440ae86709e0f6c28fbf2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTgtMS0xLTE1NTYzOA_05bf4b6b-a861-4cb5-8cc3-aff476c0dce8"
      unitRef="usd">5013000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8abd4017e8f04c56a2d4cf46f2d31c44_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2NTk1NTE_6816d3be-b6f0-4f15-9d63-bbad2cdc2780"
      unitRef="usd">320000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c32373d4dac49c19122e22f70bfe22e_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2NjIyODA_069baf12-cd25-4337-8195-b90e4497310f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic21b6b2a9bc64c5cb347be77855ca1be_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2NjIyODA_f9e66a03-94c6-4487-b814-c80b3c3d93b3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib1a66c92780d46a0a8f486b6d6a639d7_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMjk0NzYw_89ade013-8341-431c-a287-b73ef10545f9"
      unitRef="usd">34400000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i52bc922f23d94809b6348416f7d67f89_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMjk0Nzcx_67c3db4c-fe82-4af9-85d4-bc6bf56e57b5"
      unitRef="usd">22300000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic1efb123775446d4afb050c15a9de3c2_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzk2NzU3MDIzMjk0Nzgx_cf73cd04-d6b2-4713-b18e-3d58769fa217"
      unitRef="usd">11800000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ifd473cbb8e244c0baf184d66619e9bab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzcxNDY4MjU2NjgwODI_8254e16c-1b01-4dc0-a210-3a63a5e7eb0b"
      unitRef="usd">265000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i894356ab8eef44b399b55416273a7ef0_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzM4Nzg_e951c0b2-adb5-49ac-8ed8-ef864ea198b9"
      unitRef="usd">3300000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id502e86301f6476e98c1e91bd227d64b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkxNzE_f70208cc-065d-4859-83cf-588d41f31536"
      unitRef="usd">957000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i894356ab8eef44b399b55416273a7ef0_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkyMjM_d89f1072-8c10-4ad7-9211-614b08974e12"
      unitRef="usd">3000000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i894356ab8eef44b399b55416273a7ef0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkyMzE_d2008ae4-5fb7-4e36-9643-d3c64d044242"
      unitRef="usd">249000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id502e86301f6476e98c1e91bd227d64b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzEwOTk1MTE2MzkzMjM_7e89508e-aecf-4110-afe0-f4179d0ff357"
      unitRef="usd">957000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <dei:AuditorName
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yNzQvZnJhZzoyYjc3NmE1MTUzYzQ0MTk5OWNjM2FjODRlNWYwYTY2My90ZXh0cmVnaW9uOjJiNzc2YTUxNTNjNDQxOTk5Y2MzYWM4NGU1ZjBhNjYzXzQxMjMxNjg2MDQyNzA5_c4e235c6-6016-4c64-8fdc-ab1e8e8e5700">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yNzQvZnJhZzoyYjc3NmE1MTUzYzQ0MTk5OWNjM2FjODRlNWYwYTY2My90ZXh0cmVnaW9uOjJiNzc2YTUxNTNjNDQxOTk5Y2MzYWM4NGU1ZjBhNjYzXzQxMjMxNjg2MDQyNzEw_50319a69-66db-4685-b90e-9a417b173bc9">New York, NY</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yNzQvZnJhZzoyYjc3NmE1MTUzYzQ0MTk5OWNjM2FjODRlNWYwYTY2My90ZXh0cmVnaW9uOjJiNzc2YTUxNTNjNDQxOTk5Y2MzYWM4NGU1ZjBhNjYzXzQxMjMxNjg2MDQyNzEx_52b5bc54-7c0b-4e22-a7ef-87ca32919cf6">185</dei:AuditorFirmId>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">OID = Other (income)/deductions&#x2014;net,</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> COS = Cost of Sales, included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Short-term borrowings and long-term debt include foreign currency borrowings which are used as net investment hedges. The short-term borrowings carrying value as of December 31, 2021 was $1.1 billion. The long-term debt carrying values as of December 31, 2021 and December 31, 2020 were $844 million and $2.1 billion, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTYtMS0xLTE1NTYzOA_b08b5cd0-8b5b-421e-8e54-6a9b9817562a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTY3NTU5_95143279-7dbd-44ae-a9fb-0d41a68924b0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Other business activities include revenues and costs associated with PC1, as well as costs associated with global WRDM and GPD platform functions, global corporate enabling functions and other corporate items, as noted above, that we do not allocate to our operating segments. In 2019, Other business activities also include revenues and costs associated with our former Consumer Healthcare business through July 31, 2019. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.65pt">Income from continuing operations before provision/(benefit) for taxes on income.</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Biopharma&#x2019;s earnings include dividend income from our investment in ViiV of $166 million in 2021, $278 million in 2020 and $220 million in 2019.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTgtMS0xLTE3NzQ0Ng_41da7346-fb86-40e0-87ef-e2c9da6ee379"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2020 v. 2019</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#x2013;&#x2013;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic loss in 2020 versus domestic income in 2019 was mainly related to the non-recurrence of the gain on the completion of the Consumer Healthcare JV transaction as well as higher asset impairment charges and higher R&amp;D expenses. The increase in the international income was primarily related to the non-recurrence of the write off of assets contributed to the Consumer Healthcare JV as well as lower asset impairment charges and lower amortization of intangible assets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 v. 2020</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#x2013;&#x2013;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&amp;D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtNi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2021, we settled 46,060,346 TSRUs with a weighted-average grant price of $23.04 per unit.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2021, 7,093,787 TSRUs with a weighted-average grant price of $27.41 per unit were converted into 2,943,737 PTUs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtMTAtMS0xLTE1NTYzOA_a67dc6ff-2914-4eaf-9794-57cbb9780981"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts reclassified from OCI were reclassified into OID.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEyLTEtMS0xNTU2Mzg_6ef3711d-0c4d-4bcf-a1c0-e30c21f261ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments include net losses in 2021 and net gains in 2020 and 2019 related to our equity-method investment in the Consumer Healthcare JV (see</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">,</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and the impact of our net investment hedging program.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNC0xLTEtMTU1NjM4_23f7783b-b5a1-45d3-b24a-18b64fff4e3b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:5.89pt">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1Q</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTAw_78fef901-ac4d-4640-a287-c2584eb06359" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTAw_78fef901-ac4d-4640-a287-c2584eb06359" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($1.6 billion), and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.3 billion). In 2020, </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($0.9 billion), and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($4.1 billion).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTgtMS0xLTE1NTYzOA_846d4f2f-bb7b-4494-b721-fc12092a59b1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTAw_78fef901-ac4d-4640-a287-c2584eb06359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts reclassified from OCI into COS were:<xhtml:div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net loss of $89 million in 2021; and</xhtml:span></xhtml:div><xhtml:div style="margin-bottom:1pt;padding-left:18pt;text-indent:-9pt"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#x2022;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:7.18pt">a net gain of $172 million in 2020 (including a gain of $22&#160;million reported in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#x2013;&#x2013;net of tax</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</xhtml:span></xhtml:div><xhtml:div style="padding-left:9pt"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax gain of $362 million within the next 12 months into income</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flows is approximately 21 years and relates to foreign currency debt.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtNi0xLTEtMTU1NjM4_ced07b11-5677-4e28-bf20-b0b820a1db94"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc2_0d9c7877-627d-44ed-bc12-b660cce44b18" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc2_0d9c7877-627d-44ed-bc12-b660cce44b18" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The amounts in 2021 and 2020 are reduced for unrecognized tax benefits of $3.0 billion and $3.0 billion, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc2_0d9c7877-627d-44ed-bc12-b660cce44b18"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTItMS0xLTE1NTYzOA_ebf8a938-d9b7-47bc-8fd4-f42ac32765c1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE1NTYzOA_d5baa1df-918d-4c5c-bd25-928527b07ffc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIyLTEtMS0xNTU2Mzg_1702674b-aeb7-4ba6-8eaa-dc5a72a5489e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTUtMS0xLTE1NTYzOA_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIyLTEtMS0xNTU2Mzg_ed211758-370f-482e-be42-1d06373a82ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The increase in the deferred tax assets is primarily due to the acquisition of intangible assets relating to Trillium and the decrease in the 2021 deferred tax liabilities is primarily the result of amortization of intangible assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtOC0xLTEtMTU1NjM4_1d456ccb-36e1-4146-8976-ae167ebde88a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The decrease in net deferred tax liabilities in 2021 is primarily due to certain initiatives executed in the third quarter of 2021 associated with our investment in the Consumer Healthcare JV.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTQtMS0xLTE1NTYzOA_7b22fac0-5f38-4469-ab87-959a4c7566bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTAw_78fef901-ac4d-4640-a287-c2584eb06359"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE4LTItMS0xLTI2ODA3OQ_02e9996c-f5a9-4d17-b655-d8619a3f911d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">On December 31, 2021, we completed the sale of our Meridian subsidiary. Prior to its sale, Meridian was managed as part of the Hospital therapeutic area. On November&#160;16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. On December 21, 2020, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration. Beginning in the fourth quarter of 2021, the financial results of Meridian are reflected as discontinued operations for all periods presented. Beginning in the fourth quarter of 2020, the financial results of the Upjohn Business and Mylan-Japan collaboration were reflected as discontinued operations for all periods presented. Prior-period financial information has been restated, as appropriate. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1A</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">At the beginning of our fiscal fourth quarter of 2021, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business and PC1. PC1, which previously had been managed within the Hospital therapeutic area, includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($320 million for 2021 and $0 million for 2020 and 2019), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business. We have revised prior period information to conform to the current management structure. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNi0xLTEtMTkyNjMx_64e00b9b-9b74-4038-921d-a455ffb83d9e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The decrease in net deferred tax assets in 2021 is primarily the result of favorable pension plan asset performance reported in the period. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 11A</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctOC0xLTEtMTU1NjM4_d441d64e-e1ef-4264-9df5-10eb7c3ea0ae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the U.S. tax cost on our international operations, changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions,&#x201d; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the U.S. tax implications of our foreign operations is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) the impact of certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as the U.S. tax cost on our international operations, can vary as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">for the components of pre-tax income and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income, </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In all years, the reduction in our effective tax rate is a result of the jurisdictional location of earnings and is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives for our subsidiaries in Singapore and, to a lesser extent, in Puerto Rico. We benefit from Puerto Rican tax incentives pursuant to a grant that expires during 2029. Under such grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2047 on income from manufacturing and other operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNC0xLTEtMTU1NjM4_65625868-f167-475b-90d6-b5c0f4719bcf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtOC0xLTEtMTU1NjM4_bad73568-acef-478c-a286-8c98a3183051"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTEwLTEtMS0xNTU2Mzg_a9a2589a-15c0-4890-afc0-560f9b572194"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTY3NTU5_d3d269ed-7710-4e50-afc8-d93a18282480"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtOC0xLTEtMTkyNjMz_bff34bbf-5322-4962-a890-0802d675813c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTItMS0xLTE1NTYzOA_9f9006d7-6a94-41c8-a636-4229840a8778"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTAtMS0xLTE1NTYzOA_631b5357-4db6-4daf-a261-5aac98787ddd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">The increase in net deferred tax liabilities in 2021 is primarily the result of operating lease ROU assets recognized during the period. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 15</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNi0xLTEtMTU1NjM4_65b6bad9-588b-4dd8-b125-8a18da1d1cb5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTItMS0xLTE1NTYzOA_5e6bffb8-82c6-4b64-974f-f4f4ee358e3f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMTAtMS0xLTE1NTYzOA_5b524d38-629e-4eed-a2cf-eb2c4058e182"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQtNC0xLTEtMTkyNjI5_37fa2af4-b1e2-489e-9434-a2c7f88c0eae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtOC0xLTEtMTU1NjM4_f4e35001-1805-4a67-a5f3-89a2429f2ec0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtNi0xLTEtMTU1NjM4_a8fbc84f-89f0-4b71-a711-3f02348cfb7b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTgtMS0xLTE1NTYzOA_87718221-7ea3-4bea-a863-f222aef991f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Provision/(benefit) for taxes on income.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTQtMS0xLTE1NTYzOA_be2eafcf-6a81-4776-8b57-9c7bbcc5ff4b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in 2021, includes, among other items: (i) a $2.1 billion charge for IPR&amp;D related to our acquisition of Trillium, which was accounted for as an asset acquisition and recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $1.3&#160;billion ($450 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and (iii) upfront and milestone payments on collaborative and licensing arrangements of $1.1 billion recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, partially offset by (iv) actuarial valuation and other pension and postretirement plan gains of $1.6 billion recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (v) gains on equity securities of $1.3 billion recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. For Earnings in 2020, includes, among other items; (i) charges of $1.7 billion related to certain asset impairments recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, (ii) actuarial valuation and other pension and postretirement plan losses of $1.1 billion recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) restructuring charges/(credits) and implementation costs and additional depreciation&#x2014;asset restructuring of $791 million ($197 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Selling, informational and administrative expenses </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and the remaining amount primarily recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Restructuring charges and certain acquisition-related costs</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). For Earnings in 2019, includes, among other items: (i) a pre-tax gain of $8.1 billion recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> associated with the completion of the Consumer Healthcare JV transaction, partially offset by (ii) charges of $2.8 billion related to certain asset impairments recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> and (iii) actuarial valuation and other pension and postretirement plan losses of $750 million recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2013;&#x2013;net. </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">For additional information, see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 2A, 2C, 3 </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </xhtml:span>4</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE2LTEtMS0xNzc0NDY_1a3457d0-7f60-4135-ad5f-33b161dfaf88"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNC0xLTEtMTU1NjM4_7688d74d-40ea-4a6d-9e48-dcec2a124d45"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Government and agency obligations are inclusive of repurchase agreements</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEyLTEtMS0xNTU2Mzg_2d4f8e81-28e7-4c5b-8102-0b41ef0dea79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mostly includes investments in hedge funds and real estate.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIyLTEtMS0xNTU2Mzg_3acad3a7-7085-458f-8cfd-b6ac11a0c8f4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNC0xLTEtMTU1NjM4_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTYtMS0xLTE1NTYzOA_ca877ad8-baf8-4a25-b02c-f5e95682f774"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTYtMS0xLTE1NTYzOA_52b810fb-b4a9-4214-92ec-7bd6e987d2df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjQtMS0xLTE3NzQ0Ng_db22cea1-276c-4a3f-9a1d-fddb1d4de922"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtNC0xLTEtMTU1NjM4_447b81e4-10ba-4a9a-ad7d-08d6c87ff387"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE0LTEtMS0xNzc0NDY_490b1fac-da30-4171-aadc-9e63e2c8411b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtOC0xLTEtMTU1NjM4_fee38e43-6e80-4e61-baf0-da15af7f0765"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMTAtMS0xLTE1NTYzOA_ecd35657-fbd8-497e-80c1-79c03b08ebfc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctMi0xLTEtMTU1NjM4_66a09f3f-9bfc-459c-89d8-a6bd0d5e1261"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNC0xLTEtMTU1NjM4_4272bce6-e887-4059-bcbd-a909c8c692ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The increase in net deferred tax assets in 2021 is primarily related to temporary differences associated with Comirnaty royalty accruals and the result of operating lease ROU liabilities recognized during the period.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtOC0xLTEtMTU1NjM4_da781475-76cd-405c-b400-d0840ca82142"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNC0xLTEtMTU1NjM4_3d512b28-7f57-43b4-a1b9-c9278b731f54"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtOC0xLTEtMTU1NjM4_e87fa1cf-3153-43b6-aa22-74962e2d56ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEyLTEtMS0xNTU2Mzg_160c18bd-5653-4345-a917-b369c92c1208"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtMi0xLTEtMTU1NjM4_9494ac0c-9645-4c5d-826b-a388229ba6c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTY3NTU5_16cd806d-f0ad-4206-a15e-af82d8b310b8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reported in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#x2013;&#x2013;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">net.</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#242424;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(b)</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">2021 gains include, among other things, unrealized gains of $1.6 billion related to investments in BioNTech and Cerevel. 2020 gains included, among other things, unrealized gains of $405&#160;million related to investments in BioNTech and SpringWorks Therapeutics, Inc. (SpringWorks). 2019 gains included, among other things, unrealized gains of $295&#160;million related to investments in Cortexyme, Inc. and SpringWorks.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTQtMS0xLTE3NzQ0Ng_3e256d19-5cdd-4060-98ae-4cb121b626bd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMTItMS0xLTE1NTYzOA_63e192c5-45c4-4c4e-bb0f-e419683a6a8c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNTU2Mzg_3e9e8026-0ef5-451e-9ccf-d52e741ef6d7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTI0LTEtMS0xNzc0NDY_d8409a2b-9ae3-4a7c-b0bf-b7f2741b1c3f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzQ_3dc39e20-b68d-4c8c-9483-64893a13c6ce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIwLTgtMS0xLTE1NTYzOA_f466aefb-213c-421c-b696-d5ff1aaea2d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNi0xLTEtMTU1NjM4_a1920b95-364f-46c0-836c-745ff6c884d5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjItMS0xLTE3NzQ0Ng_5736c62b-6c4d-4a76-ac6a-9418a9fa4023"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtNi0xLTEtMTU1NjM4_babcca13-dff1-4030-b2d7-d8e86c488c36"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIyLTEtMS0xNzY2NjA_51a7a4c0-f695-4a47-a787-ef6435422b9c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEyLTEtMS0xNTU2Mzg_699ffb33-1c80-499e-8415-10e51e84ff49"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEyLTEtMS0xNTU2Mzg_67623cb3-9c92-4b67-bfc7-df993fabe016"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtMi0xLTEtMTU1NjM4_abca9c71-f351-45eb-9661-7f17b48f44e5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTItMS0xLTE1NTYzOA_7dc88e3e-772d-44b2-b9f5-b8439f00ca40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtNi0xLTEtMTU1NjM4_3fa66e02-d8ad-4233-a80d-6f9e631d0945"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTEwLTEtMS0xNTU2Mzg_c5e8b8dc-b7b8-41c7-ac76-e99dc9c1d8c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtMi0xLTEtMTU1NjM4_c4d8ac19-6d15-47e5-9cf1-2175f86c31e9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE2LTgtMS0xLTE1NTYzOA_2878e639-5813-4ed1-a965-544579d3ffd4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTAtMS0xLTE1NTYzOA_cad6fb7f-07f5-4d71-af98-9856b65cedaf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2017, Performance Total Shareholder Return Units (PTSRUs) were awarded to the Former Chairman and Chief Executive Officer (1,444,395 PTSRUs) and 361,099 PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President Pfizer Innovative Health) at a grant price of $30.31 and at a GDFV of $5.54 per PTSRU. In addition to having the same characteristics and valuation methodology of TSRUs, PTSRU grants require special service and performance conditions</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Retirement-eligible holders, as defined in the grant terms, can convert their TSRUs, when vested, into Profit Units (PTUs) with a conversion ratio based on a calculation used to determine the shares at TSRU settlement. The PTUs are entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#x2019; original settlement date and will be subject to the terms and conditions of the original grant including forfeiture provisions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMTk5_059f4014-d5af-4401-971c-3a1fbb494107"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtOC0xLTEtMTU1NjM4_97be52cb-562d-420c-8fef-d70edb636f92"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">As a result of the reorganization of our commercial operations during the fourth quarter of 2021 (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 17</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), we were required to estimate the relative fair values of our PC1 and Hospital organizations to determine any reallocation of goodwill. We completed this analysis and determined that no goodwill was required to be reallocated. As a result, our entire goodwill balance continues to be assigned within the Biopharma reportable segment.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzI_ed1f660f-a339-423e-a681-4ee8c16fd64b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzI_ed1f660f-a339-423e-a681-4ee8c16fd64b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other represents the impact of foreign exchange</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzQtMTAtMS0xLTE1NTYzOA_ed9d4e6b-9c02-4101-85e5-72b4c0f1a7ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzI_ed1f660f-a339-423e-a681-4ee8c16fd64b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNi0xLTEtMTU1NjM4_853baf1c-208b-4716-8ac1-8b0b634be974"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTYtMS0xLTE1NTYzOA_aa30beea-876d-4ee5-a8fd-25a2727c1e84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTA_5fab886f-0468-449d-8ede-04bafcb6d710"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzUtMTItMS0xLTE1NTYzOA_7ed02286-4938-41fc-b60d-1d1f5ed63432"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMTAtMS0xLTE1NTYzOA_6d8e0475-a447-44b3-92fe-bc17d40d5d6d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzUtMi0xLTEtMTU1NjM4_cdc0ce46-3915-4563-8053-d33872376c3a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc1_3a609e92-2fff-4b7f-81e1-3d98ceb53e04"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNi0xLTEtMTU1NjM4_0d89abe3-7bb9-4ed4-b54f-32bb4a1c5c48"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzI_ed1f660f-a339-423e-a681-4ee8c16fd64b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzctMTAtMS0xLTE1NTYzOA_0367c87d-c6e0-40ca-b0ca-007e4c1979a9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNC0xLTEtMTU1NjM4_2f0d1bff-64c1-4bf9-9739-871418d0830f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMzQ2_bb263ea4-272f-4668-b0a5-50838d9c5b4f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAx_c656af31-7092-46b7-b836-46fa5c48849c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzUtMi0xLTEtMTU1NjM4_4ddf13ae-ff29-4f2a-ba96-e13a24e2612b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzMx_b2a4a283-6898-4efa-b10b-f853b1fe8262"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTItMS0xLTE2NzU1OQ_fe41d383-f4aa-4c7b-b07d-7a01a160d0dd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtNi0xLTEtMTU1NjM4_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEyLTEtMS0xNTU2Mzg_1ebf8017-f1d8-463e-8a24-bf1298f6b3b6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIyLTEtMS0xNzc0NDY_6b68cc90-f784-48f0-a0a7-df66f6e4ed58"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMTAtMS0xLTE1NTYzOA_81cd903c-c73d-43d2-bad3-95497575d3f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctNC0xLTEtMTU1NjM4_2722bc9b-bd68-44a1-b6af-f95229efc046"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzYtNi0xLTEtMTU1NjM4_fc66c952-59b2-425b-99e4-a752198a4e1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzc1_6ffd3a77-5ab4-4322-802d-69ced101c507"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzE_c6c9f186-f975-4b2f-9a61-23664fe96dfa" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzE_c6c9f186-f975-4b2f-9a61-23664fe96dfa" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Additions primarily represent the impact of measurement period adjustments related to our Array acquisition (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzE_c6c9f186-f975-4b2f-9a61-23664fe96dfa"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzMtMTAtMS0xLTE1NTYzOA_1a3db85e-749a-4775-89fe-95688fd74a40"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTEwLTEtMS0xNTU2Mzg_62ac1b96-7066-4722-b03e-03f9d64c2e4a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcx_31aa66c3-68fd-44e0-9dc8-2f1a767a099d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzEwLTItMS0xLTE1NTYzOA_efbfda1d-68b0-4c6f-b79f-a35d4c0da4ba"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtNi0xLTEtMTU1NjM4_827f87ce-acbb-4759-8913-1e89d205b375"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEyLTEtMS0xNTU2Mzg_c29666a2-e918-4662-923e-2c5d8567f182"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktNC0xLTEtMTU1NjM4_ed1bf7dd-65f5-4d59-a7f4-fc353e96accb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMy_d0a0311b-66a6-4495-b2d7-1731a83027d9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzYtMi0xLTEtMTU1NjM4_0d5435e9-9eaa-41c2-9ec8-066cd5e167f7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The number of options expected to vest takes into account an estimate of expected forfeitures.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8"
          xlink:type="arc"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Market price of our underlying common stock less exercise price.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktOC0xLTEtMTU1NjM4_b85907d6-a4bd-44cb-84a1-785a32042599"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTE4LTEtMS0xNzc0NDY_3e131332-665e-4af4-a41b-c0251f2a62e4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtNi0xLTEtMTU1NjM4_4f0181ae-1016-4ec6-8d6b-d769c98f120f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTItMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjYvZnJhZzo0ODIzNmJiOGM0NzQ0Nzc2YWUyZGVjZTExNDgwYTViYy90YWJsZTozOWY4ZWMwOTMyOGM0OTAwOGI0MGNjZDgzZDAzZTc2ZC90YWJsZXJhbmdlOjM5ZjhlYzA5MzI4YzQ5MDA4YjQwY2NkODNkMDNlNzZkXzUtMTgtMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc2_0d9c7877-627d-44ed-bc12-b660cce44b18"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEwLTYtMS0xLTE1NTYzOA_4680c1fa-8dc4-4c2b-9365-f63c45eb07e8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItNi0xLTEtMTU1NjM4_cb463ec6-f038-43a0-b879-1a04a0ce48fe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzQxMjMxNjg2MTA4ODMz_ff011e2d-8dfa-495b-9a8a-30da889acb07"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzctNi0xLTEtMTU1NjM4_32e93b2f-c9fb-4880-8b76-8bd95dae9d5b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEyLTEtMS0xNTU2Mzg_0988c6ac-c547-415f-9c49-4b8bc40efc61"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI0LTgtMS0xLTE1NTYzOA_fc6a3fac-7ded-457b-bcd6-8645b773971a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtNi0xLTEtMTU1NjM4_0e16daed-d44e-4824-813a-3fe2e1394058"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzktMi0xLTEtMTU1NjM4_d41f0e47-ec9e-4b2e-b819-22a8e7a30582"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTIwLTEtMS0xNzc0NDY_14a07dc7-01bf-4a13-937f-15a3ff738f39"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NTQw_0264dad2-cde2-4d32-aa7d-8f6b526243e6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEzLTYtMS0xLTE1NTYzOA_bea3111d-7785-4f8c-98c0-e68a197bc2d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMTYtMS0xLTE3NzQ0Ng_1150e5c4-254e-4d39-be30-b86d16540fa2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpjMTk5YTZiYTcwNjU0MTRlYmJkN2ZmZDdhYjdhMGRhMy90YWJsZXJhbmdlOmMxOTlhNmJhNzA2NTQxNGViYmQ3ZmZkN2FiN2EwZGEzXzUtMi0xLTEtMTU1NjM4_82304fd5-0880-42e5-9353-c272309ebef3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTktMS0xLTE1NTYzOA_ba7a7618-147a-498c-aacb-f197a2b4ede2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE1NTYzOA_f7ffee50-164e-4e37-ad92-9d95c64c2987"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIyLTEtMS0xNzY2NjA_fd0de7ba-fe0b-421f-83ed-21209c78941f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMi0xLTEtMTU1NjM4_2016befc-9e0e-4f0b-964b-d2d0f1e3548a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjI_39ddbfd2-a5a1-4b58-9ab2-0b170f1bc418"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTphY2E2Yjk2OTFhNzE0MjJjOGZmODRlOGE2YzBhZWQyYS90YWJsZXJhbmdlOmFjYTZiOTY5MWE3MTQyMmM4ZmY4NGU4YTZjMGFlZDJhXzItMS0xLTEtMTU1NjM4L3RleHRyZWdpb246MWQ4OThmZDM3ODM5NDI0YWEwNzAxYmMxZTFjOTBkZTNfMjA1_7252a616-0d09-4f91-bc3e-9f6a98314b03"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTk_55f278fd-d83c-4ffa-838f-2e2e42432a9d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItOC0xLTEtMTU1NjM4_fc50df49-9cdd-46ce-b836-6b0baba0dda4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzItMi0xLTEtMTU1NjM4_ac405ffe-e8fc-4505-85ca-0dd684cfa0ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDQ1_a1fb8fca-d3d1-4040-8c58-b36f16a16261"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzExLTctMS0xLTE1NTYzOA_f2733c53-9496-4799-a9cb-91b915542663"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDgy_9cc2cdd8-adca-4334-ba5b-e598a9645033"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0ODk_139d647f-4844-444a-a2ba-4a31d5be9a68"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzctMTAtMS0xLTE2NzU1OQ_8cf44f75-1672-4fc0-b33f-780a6ed078bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMjAtMS0xLTE3NzQ0Ng_29c392aa-5027-4193-9e81-72bec764341f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzMtOC0xLTEtMTU1NjM4_6c3151f2-dab8-47e0-959e-e79250145617"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzMtMi0xLTEtMTU1NjM4_b2c5e84f-36dc-480c-ad5a-846dad0d8d70"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDg5_2ccee735-e298-4a86-9a06-68cf1927c690"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTY_fab308c9-4fb5-44c5-841a-a160276b047a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzQtNi0xLTEtMTU1NjM4_08d646d8-0c93-46f9-8a80-6d2085845cd9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzE0OTc_a2f79ae1-4d60-4ec3-aa6e-54c6fc20fb0a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzQtMi0xLTEtMTU1NjM4_00755f99-1d90-4626-9f3a-8a1d80702def"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIyLTEtMS0xNTU2Mzg_cb3f0fe8-527e-4545-b603-17627e19fa6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIyLTEtMS0xNTU2Mzg_cefc3193-24e4-405a-8541-7b7431db7a13"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzYtMTAtMS0xLTE1NTYzOA_2dd12b54-3aae-4f9e-b8b9-6671f200d2d8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4NTE_b95a563e-e147-439b-bd24-4f68cdc10608"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjM_fea39027-5860-4ac7-b00e-bd943049794b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTozOGU0NWZmNDg1ZGI0ODZiODA0YTFmZWU1N2I0ZDE2Mi90YWJsZXJhbmdlOjM4ZTQ1ZmY0ODVkYjQ4NmI4MDRhMWZlZTU3YjRkMTYyXzUtNC0xLTEtMTU1NjM4_3f7b0709-60ae-40f2-ab6d-f2a1cff71d44"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDU_7267f7ba-70fc-4672-9076-7a516293e47a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIyLTEtMS0xNTU2Mzg_18f2b897-6520-40ab-a290-145b6c543c39"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzMtMi0xLTEtMTU1NjM4_7daeca07-7fb5-4238-8e5a-f50d6b2124ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzMtMi0xLTEtMTU1NjM4_7daeca07-7fb5-4238-8e5a-f50d6b2124ea"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjE_cb8ad76c-af7b-4cb3-9b21-56b340a790e5" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjE_cb8ad76c-af7b-4cb3-9b21-56b340a790e5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reflects lease payments due within 12 months subsequent to the balance sheet date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90YWJsZTo0ZWM2YWRmZDA0NTc0NTg3YjAxMWEzZDEyNTU3ZDc4Mi90YWJsZXJhbmdlOjRlYzZhZGZkMDQ1NzQ1ODdiMDExYTNkMTI1NTdkNzgyXzMtMi0xLTEtMTU1NjM4_7daeca07-7fb5-4238-8e5a-f50d6b2124ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjkvZnJhZzozYzQxN2Y0MjljMGU0NWVmYTkzMDllMGZjYzlhOTY2Mi90ZXh0cmVnaW9uOjNjNDE3ZjQyOWMwZTQ1ZWZhOTMwOWUwZmNjOWE5NjYyXzIzMjE_cb8ad76c-af7b-4cb3-9b21-56b340a790e5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTItMS0xLTE1NTYzOA_9a80eaa2-1cc5-46e9-84d5-2982df1449c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTItMS0xLTE1NTYzOA_9a80eaa2-1cc5-46e9-84d5-2982df1449c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEyLTEtMS0xNTU2Mzg_5f1e6ae2-9ee1-4d55-bae9-cab3ac64546b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEyLTEtMS0xNTU2Mzg_5f1e6ae2-9ee1-4d55-bae9-cab3ac64546b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNi0xLTEtMTU1NjM4_de0b7543-ea69-4805-8352-777920c516c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNi0xLTEtMTU1NjM4_de0b7543-ea69-4805-8352-777920c516c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNC0xLTEtMTU1NjM4_3bdff635-14c6-4f72-8238-0b7e0362e571"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNC0xLTEtMTU1NjM4_3bdff635-14c6-4f72-8238-0b7e0362e571"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTAtMS0xLTE1NTYzOA_4a2275a9-7705-4579-8874-1206874376a9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTAtMS0xLTE1NTYzOA_4a2275a9-7705-4579-8874-1206874376a9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTQtMS0xLTE1NTYzOA_081dcc47-cdde-4218-b274-fb74672a032a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTQtMS0xLTE1NTYzOA_081dcc47-cdde-4218-b274-fb74672a032a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTItMS0xLTE1NTYzOA_a38ccb42-7b44-4153-978f-eee616f1d02c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTItMS0xLTE1NTYzOA_a38ccb42-7b44-4153-978f-eee616f1d02c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEwLTEtMS0xNTU2Mzg_9d601fd9-6e60-4673-a18a-9c8efc23f039"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEwLTEtMS0xNTU2Mzg_9d601fd9-6e60-4673-a18a-9c8efc23f039"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTItMS0xLTE1NTYzOA_9136e4e7-dd83-4a34-a2bf-5479fca27462"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTItMS0xLTE1NTYzOA_9136e4e7-dd83-4a34-a2bf-5479fca27462"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTYtMS0xLTE1NTYzOA_d3edc723-36cf-4444-b015-fbeec8e2ee52"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTYtMS0xLTE1NTYzOA_d3edc723-36cf-4444-b015-fbeec8e2ee52"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMi0xLTEtMTU1NjM4_e61f106a-42e6-4cf2-bf52-aac6d39c699d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMi0xLTEtMTU1NjM4_e61f106a-42e6-4cf2-bf52-aac6d39c699d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNi0xLTEtMTU1NjM4_c523199d-997d-4a19-8355-cea3d890630e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNi0xLTEtMTU1NjM4_c523199d-997d-4a19-8355-cea3d890630e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTItMS0xLTE1NTYzOA_d0cd48f4-f91e-4631-babd-45ea614f93a3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTItMS0xLTE1NTYzOA_d0cd48f4-f91e-4631-babd-45ea614f93a3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMi0xLTEtMTU1NjM4_98785a01-befa-4c10-b041-8f84db3b9aa2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMi0xLTEtMTU1NjM4_98785a01-befa-4c10-b041-8f84db3b9aa2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNC0xLTEtMTU1NjM4_fd95f5fe-9788-42b7-98a7-2ebcfd5e321f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNC0xLTEtMTU1NjM4_fd95f5fe-9788-42b7-98a7-2ebcfd5e321f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTAtMS0xLTE1NTYzOA_80cc64e5-d4bf-4658-b77e-6608ae105363"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTAtMS0xLTE1NTYzOA_80cc64e5-d4bf-4658-b77e-6608ae105363"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNi0xLTEtMTU1NjM4_d8130e94-33e2-41d9-bd5f-dc35bca090cb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNi0xLTEtMTU1NjM4_d8130e94-33e2-41d9-bd5f-dc35bca090cb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTAtMS0xLTE1NTYzOA_123ca141-8291-470b-b0dd-6eda82b33426"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTAtMS0xLTE1NTYzOA_123ca141-8291-470b-b0dd-6eda82b33426"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMi0xLTEtMTU1NjM4_0df94e6e-dd72-4a26-9d13-48322b242766"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMi0xLTEtMTU1NjM4_0df94e6e-dd72-4a26-9d13-48322b242766"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNC0xLTEtMTU1NjM4_df59b808-c19a-458d-9a08-fcc08454107a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNC0xLTEtMTU1NjM4_df59b808-c19a-458d-9a08-fcc08454107a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTItMS0xLTE1NTYzOA_9a80eaa2-1cc5-46e9-84d5-2982df1449c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEyLTEtMS0xNTU2Mzg_5f1e6ae2-9ee1-4d55-bae9-cab3ac64546b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNi0xLTEtMTU1NjM4_de0b7543-ea69-4805-8352-777920c516c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNC0xLTEtMTU1NjM4_3bdff635-14c6-4f72-8238-0b7e0362e571"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMTAtMS0xLTE1NTYzOA_4a2275a9-7705-4579-8874-1206874376a9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTQtMS0xLTE1NTYzOA_081dcc47-cdde-4218-b274-fb74672a032a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTItMS0xLTE1NTYzOA_a38ccb42-7b44-4153-978f-eee616f1d02c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTEwLTEtMS0xNTU2Mzg_9d601fd9-6e60-4673-a18a-9c8efc23f039"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTItMS0xLTE1NTYzOA_9136e4e7-dd83-4a34-a2bf-5479fca27462"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTYtMS0xLTE1NTYzOA_d3edc723-36cf-4444-b015-fbeec8e2ee52"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMi0xLTEtMTU1NjM4_e61f106a-42e6-4cf2-bf52-aac6d39c699d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtNi0xLTEtMTU1NjM4_c523199d-997d-4a19-8355-cea3d890630e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzExLTItMS0xLTE1NTYzOA_d0cd48f4-f91e-4631-babd-45ea614f93a3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMi0xLTEtMTU1NjM4_98785a01-befa-4c10-b041-8f84db3b9aa2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNC0xLTEtMTU1NjM4_fd95f5fe-9788-42b7-98a7-2ebcfd5e321f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtMTAtMS0xLTE1NTYzOA_80cc64e5-d4bf-4658-b77e-6608ae105363"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtNi0xLTEtMTU1NjM4_d8130e94-33e2-41d9-bd5f-dc35bca090cb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzYtMTAtMS0xLTE1NTYzOA_123ca141-8291-470b-b0dd-6eda82b33426"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzgtMi0xLTEtMTU1NjM4_0df94e6e-dd72-4a26-9d13-48322b242766"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90YWJsZTowNTk5MDZjYzUzNzM0YzFiYTdmNjAxYzk3Y2E3NmJiOS90YWJsZXJhbmdlOjA1OTkwNmNjNTM3MzRjMWJhN2Y2MDFjOTdjYTc2YmI5XzMtNC0xLTEtMTU1NjM4_df59b808-c19a-458d-9a08-fcc08454107a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODEvZnJhZzoyYjY2ZDAwZDkzZDc0YTc1OTU4MzdmN2NjOTViZjFkMi90ZXh0cmVnaW9uOjJiNjZkMDBkOTNkNzRhNzU5NTgzN2Y3Y2M5NWJmMWQyXzQxMjMxNjg2MDQ3MDgy_efbb8a6e-5761-4a6b-9465-a4c6d0046989"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTQtMS0xLTE1NTYzOA_5f72f016-f854-4d35-b32e-a1523936cf71"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTQtMS0xLTE1NTYzOA_5f72f016-f854-4d35-b32e-a1523936cf71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNi0xLTEtMTU1NjM4_00ebe2e3-fffa-4d43-8cf2-d10877fccc59"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNi0xLTEtMTU1NjM4_00ebe2e3-fffa-4d43-8cf2-d10877fccc59"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTgtMS0xLTE1NTYzOA_2f1f2081-7178-4eff-980a-f932885400d6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTgtMS0xLTE1NTYzOA_2f1f2081-7178-4eff-980a-f932885400d6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtMi0xLTEtMTU1NjM4_889185dd-849f-404a-85bb-92422714cc9e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtMi0xLTEtMTU1NjM4_889185dd-849f-404a-85bb-92422714cc9e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTItMS0xLTE1NTYzOA_934964c5-66e2-498b-96c7-e1e11097f2bf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTItMS0xLTE1NTYzOA_934964c5-66e2-498b-96c7-e1e11097f2bf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTgtMS0xLTE1NTYzOA_95c4277e-6053-4020-b8f5-b5eb8adf6ae2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTgtMS0xLTE1NTYzOA_95c4277e-6053-4020-b8f5-b5eb8adf6ae2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNC0xLTEtMTU1NjM4_0c488731-aa77-4405-9d8b-f1278437dba0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNC0xLTEtMTU1NjM4_0c488731-aa77-4405-9d8b-f1278437dba0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTQtMS0xLTE1NTYzOA_5c85bd6b-451b-400e-81ad-73936f0d12c8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTQtMS0xLTE1NTYzOA_5c85bd6b-451b-400e-81ad-73936f0d12c8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTQtMS0xLTE1NTYzOA_07797e84-f31d-440f-8696-0e022691ac42"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTQtMS0xLTE1NTYzOA_07797e84-f31d-440f-8696-0e022691ac42"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTgtMS0xLTE1NTYzOA_a16f7605-4987-4a6a-b6db-1bace5af0ee5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTgtMS0xLTE1NTYzOA_a16f7605-4987-4a6a-b6db-1bace5af0ee5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTQtMS0xLTE1NTYzOA_83cb9115-e0fb-4619-aef9-ab67c7d44420"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTQtMS0xLTE1NTYzOA_83cb9115-e0fb-4619-aef9-ab67c7d44420"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtNi0xLTEtMTU1NjM4_8da22a9a-074d-4f15-8ef1-49ba93ed5ef6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtNi0xLTEtMTU1NjM4_8da22a9a-074d-4f15-8ef1-49ba93ed5ef6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTItMS0xLTE1NTYzOA_18ea3c1a-9447-45a7-a412-95630ed61f83"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTItMS0xLTE1NTYzOA_18ea3c1a-9447-45a7-a412-95630ed61f83"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTItMS0xLTE1NTYzOA_dc770b75-d0bb-4cad-9696-a02e91952b4f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTItMS0xLTE1NTYzOA_dc770b75-d0bb-4cad-9696-a02e91952b4f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtMi0xLTEtMTU1NjM4_3cb674c8-26ff-4296-a3e2-d27455fd0b41"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtMi0xLTEtMTU1NjM4_3cb674c8-26ff-4296-a3e2-d27455fd0b41"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktNi0xLTEtMTU1NjM4_7a8c75d3-6197-43c1-a9e3-3b11f55e48bb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktNi0xLTEtMTU1NjM4_7a8c75d3-6197-43c1-a9e3-3b11f55e48bb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktMi0xLTEtMTU1NjM4_b8c25820-33a9-41ca-963b-17e84c50bf38"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktMi0xLTEtMTU1NjM4_b8c25820-33a9-41ca-963b-17e84c50bf38"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTItMS0xLTE1NTYzOA_08096b56-06d2-44ca-bf3c-0c1d5ce92617"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTItMS0xLTE1NTYzOA_08096b56-06d2-44ca-bf3c-0c1d5ce92617"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTYtMS0xLTE1NTYzOA_a9060b32-109c-4e94-9c63-a2e31f16ea3b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTYtMS0xLTE1NTYzOA_a9060b32-109c-4e94-9c63-a2e31f16ea3b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTYtMS0xLTE1NTYzOA_c4fe5a30-44ae-4d42-b16c-dfad5d473ec6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTYtMS0xLTE1NTYzOA_c4fe5a30-44ae-4d42-b16c-dfad5d473ec6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTYtMS0xLTE1NTYzOA_dd1abc95-de40-47a7-8e31-ae4082c6ba2f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTYtMS0xLTE1NTYzOA_dd1abc95-de40-47a7-8e31-ae4082c6ba2f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTYtMS0xLTE1NTYzOA_9aa0edcb-ec53-4eff-9523-c670836ea3d4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTYtMS0xLTE1NTYzOA_9aa0edcb-ec53-4eff-9523-c670836ea3d4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTgtMS0xLTE1NTYzOA_37f18589-53d6-4dd8-aebf-aa5edae64b03"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTgtMS0xLTE1NTYzOA_37f18589-53d6-4dd8-aebf-aa5edae64b03"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTItMS0xLTE1NTYzOA_b19cafe6-5af3-425b-a11f-746e7e40d664"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTItMS0xLTE1NTYzOA_b19cafe6-5af3-425b-a11f-746e7e40d664"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtOC0xLTEtMTU1NjM4_cffbe9e3-2f79-455d-8521-2b76def7f868"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtOC0xLTEtMTU1NjM4_cffbe9e3-2f79-455d-8521-2b76def7f868"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTYtMS0xLTE1NTYzOA_1be889d8-f1cd-4d88-aae6-0e47f2e407eb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTYtMS0xLTE1NTYzOA_1be889d8-f1cd-4d88-aae6-0e47f2e407eb"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTQtMS0xLTE1NTYzOA_5f72f016-f854-4d35-b32e-a1523936cf71"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNi0xLTEtMTU1NjM4_00ebe2e3-fffa-4d43-8cf2-d10877fccc59"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTgtMS0xLTE1NTYzOA_2f1f2081-7178-4eff-980a-f932885400d6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtMi0xLTEtMTU1NjM4_889185dd-849f-404a-85bb-92422714cc9e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTItMS0xLTE1NTYzOA_934964c5-66e2-498b-96c7-e1e11097f2bf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTgtMS0xLTE1NTYzOA_95c4277e-6053-4020-b8f5-b5eb8adf6ae2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtNC0xLTEtMTU1NjM4_0c488731-aa77-4405-9d8b-f1278437dba0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTQtMS0xLTE1NTYzOA_5c85bd6b-451b-400e-81ad-73936f0d12c8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTQtMS0xLTE1NTYzOA_07797e84-f31d-440f-8696-0e022691ac42"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTgtMS0xLTE1NTYzOA_a16f7605-4987-4a6a-b6db-1bace5af0ee5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTQtMS0xLTE1NTYzOA_83cb9115-e0fb-4619-aef9-ab67c7d44420"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtNi0xLTEtMTU1NjM4_8da22a9a-074d-4f15-8ef1-49ba93ed5ef6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTItMS0xLTE1NTYzOA_18ea3c1a-9447-45a7-a412-95630ed61f83"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTItMS0xLTE1NTYzOA_dc770b75-d0bb-4cad-9696-a02e91952b4f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzgtMi0xLTEtMTU1NjM4_3cb674c8-26ff-4296-a3e2-d27455fd0b41"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktNi0xLTEtMTU1NjM4_7a8c75d3-6197-43c1-a9e3-3b11f55e48bb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzktMi0xLTEtMTU1NjM4_b8c25820-33a9-41ca-963b-17e84c50bf38"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTItMS0xLTE1NTYzOA_08096b56-06d2-44ca-bf3c-0c1d5ce92617"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE0LTYtMS0xLTE1NTYzOA_a9060b32-109c-4e94-9c63-a2e31f16ea3b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE3LTYtMS0xLTE1NTYzOA_c4fe5a30-44ae-4d42-b16c-dfad5d473ec6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE2LTYtMS0xLTE1NTYzOA_dd1abc95-de40-47a7-8e31-ae4082c6ba2f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTYtMS0xLTE1NTYzOA_9aa0edcb-ec53-4eff-9523-c670836ea3d4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzExLTgtMS0xLTE1NTYzOA_37f18589-53d6-4dd8-aebf-aa5edae64b03"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzEyLTItMS0xLTE1NTYzOA_b19cafe6-5af3-425b-a11f-746e7e40d664"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzQtOC0xLTEtMTU1NjM4_cffbe9e3-2f79-455d-8521-2b76def7f868"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTpkN2QyOGFmNThmZjM0NTU4YTZlMjA2NTI2MzViYzhhNC90YWJsZXJhbmdlOmQ3ZDI4YWY1OGZmMzQ1NThhNmUyMDY1MjYzNWJjOGE0XzE1LTYtMS0xLTE1NTYzOA_1be889d8-f1cd-4d88-aae6-0e47f2e407eb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3Mzcy_9f70d44f-a1ec-49c8-bfb1-2c58cbbe66d0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTYtMS0xLTE1NTYzOA_f6e6827d-16c5-473d-b9a4-970beab322dd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTYtMS0xLTE1NTYzOA_f6e6827d-16c5-473d-b9a4-970beab322dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTItMS0xLTE1NTYzOA_1e898dab-8f93-4ef8-94ae-b8e82db17466"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTItMS0xLTE1NTYzOA_1e898dab-8f93-4ef8-94ae-b8e82db17466"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTQtMS0xLTE1NTYzOA_b2fe21d4-54c8-40ac-ab41-f210c214bc66"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTQtMS0xLTE1NTYzOA_b2fe21d4-54c8-40ac-ab41-f210c214bc66"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyNQ_31721eb0-f80c-45c8-9db8-a5fd7509ba21" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyNQ_31721eb0-f80c-45c8-9db8-a5fd7509ba21" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTYtMS0xLTE1NTYzOA_f6e6827d-16c5-473d-b9a4-970beab322dd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyNQ_31721eb0-f80c-45c8-9db8-a5fd7509ba21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTItMS0xLTE1NTYzOA_1e898dab-8f93-4ef8-94ae-b8e82db17466"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyNQ_31721eb0-f80c-45c8-9db8-a5fd7509ba21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90YWJsZTplMDU2MjE4ODA5Yjg0YWQyOTFmYjc4OWU3OTRhNWMxYi90YWJsZXJhbmdlOmUwNTYyMTg4MDliODRhZDI5MWZiNzg5ZTc5NGE1YzFiXzE5LTQtMS0xLTE1NTYzOA_b2fe21d4-54c8-40ac-ab41-f210c214bc66"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjYvZnJhZzpkYzk0MGRiNzU1ZWE0NTIwYjFhZGE5NTczN2E5OTE0Mi90ZXh0cmVnaW9uOmRjOTQwZGI3NTVlYTQ1MjBiMWFkYTk1NzM3YTk5MTQyXzYyNQ_31721eb0-f80c-45c8-9db8-a5fd7509ba21"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtMi0xLTEtMTU1NjM4_31b5dfa2-8634-409b-8b1b-5241f26bdbf0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtMi0xLTEtMTU1NjM4_31b5dfa2-8634-409b-8b1b-5241f26bdbf0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNi0xLTEtMTU1NjM4_c2a32bf3-b01a-4af5-8c9f-0d092ab35f6c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNi0xLTEtMTU1NjM4_c2a32bf3-b01a-4af5-8c9f-0d092ab35f6c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNC0xLTEtMTU1NjM4_17d32bc8-693e-49b2-9755-f0c64e3067e0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNC0xLTEtMTU1NjM4_17d32bc8-693e-49b2-9755-f0c64e3067e0"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ1_5f3d2047-e309-46f8-a0d2-9b42e2fe3713" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ1_5f3d2047-e309-46f8-a0d2-9b42e2fe3713" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtMi0xLTEtMTU1NjM4_31b5dfa2-8634-409b-8b1b-5241f26bdbf0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ1_5f3d2047-e309-46f8-a0d2-9b42e2fe3713"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNi0xLTEtMTU1NjM4_c2a32bf3-b01a-4af5-8c9f-0d092ab35f6c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ1_5f3d2047-e309-46f8-a0d2-9b42e2fe3713"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzgtNC0xLTEtMTU1NjM4_17d32bc8-693e-49b2-9755-f0c64e3067e0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTQ1_5f3d2047-e309-46f8-a0d2-9b42e2fe3713"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTItMS0xLTE1NTYzOA_70150eaf-49c1-40c8-a5b3-4c2dc5a3e763"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTItMS0xLTE1NTYzOA_70150eaf-49c1-40c8-a5b3-4c2dc5a3e763"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTQtMS0xLTE1NTYzOA_4228acb7-0a7e-45cd-bc41-1d26c3fad96a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTQtMS0xLTE1NTYzOA_4228acb7-0a7e-45cd-bc41-1d26c3fad96a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTYtMS0xLTE1NTYzOA_3722d7d6-c8c4-4e6e-8d19-e418b391b627"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTYtMS0xLTE1NTYzOA_3722d7d6-c8c4-4e6e-8d19-e418b391b627"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk2_8ecaa1ee-28f5-4418-b11d-5f6b7758233b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk2_8ecaa1ee-28f5-4418-b11d-5f6b7758233b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">In 2021, included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($19 million),</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Other current assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($42&#160;million) </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion), </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($5 million) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion). In 2020, included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($34 million), </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($18 million), </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($3.0 billion) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other taxes payable</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($2.5 billion).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTItMS0xLTE1NTYzOA_70150eaf-49c1-40c8-a5b3-4c2dc5a3e763"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk2_8ecaa1ee-28f5-4418-b11d-5f6b7758233b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTQtMS0xLTE1NTYzOA_4228acb7-0a7e-45cd-bc41-1d26c3fad96a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk2_8ecaa1ee-28f5-4418-b11d-5f6b7758233b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzExLTYtMS0xLTE1NTYzOA_3722d7d6-c8c4-4e6e-8d19-e418b391b627"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDk2_8ecaa1ee-28f5-4418-b11d-5f6b7758233b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtMTAtMS0xLTE1NTYzOA_881afe32-f53d-401e-a9d9-f395a68c9bb7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtMTAtMS0xLTE1NTYzOA_881afe32-f53d-401e-a9d9-f395a68c9bb7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtOC0xLTEtMTU1NjM4_6ba80a00-e040-44ed-9659-681083a3a33a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtOC0xLTEtMTU1NjM4_6ba80a00-e040-44ed-9659-681083a3a33a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtNi0xLTEtMTU1NjM4_315394a9-0040-4ea2-bb7c-aa5eb50c4ae2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtNi0xLTEtMTU1NjM4_315394a9-0040-4ea2-bb7c-aa5eb50c4ae2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIz_b47b6a34-d867-43a4-a71a-0856e26745d2" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIz_b47b6a34-d867-43a4-a71a-0856e26745d2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents external costs for banking, legal, accounting and other similar services.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtMTAtMS0xLTE1NTYzOA_881afe32-f53d-401e-a9d9-f395a68c9bb7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIz_b47b6a34-d867-43a4-a71a-0856e26745d2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtOC0xLTEtMTU1NjM4_6ba80a00-e040-44ed-9659-681083a3a33a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIz_b47b6a34-d867-43a4-a71a-0856e26745d2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzgtNi0xLTEtMTU1NjM4_315394a9-0040-4ea2-bb7c-aa5eb50c4ae2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIz_b47b6a34-d867-43a4-a71a-0856e26745d2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1OTYwNQ_522f8a54-1dd9-44eb-97f7-44c711e37e6b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1OTYwNQ_522f8a54-1dd9-44eb-97f7-44c711e37e6b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTk2MDU_12f5cf08-b296-4d3d-8e58-d4edd5422f7c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTk2MDU_12f5cf08-b296-4d3d-8e58-d4edd5422f7c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1OTYwNQ_111bd224-a3dd-4f82-bb71-0880092a2fdc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1OTYwNQ_111bd224-a3dd-4f82-bb71-0880092a2fdc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1OTYwNQ_6cd5bbd6-d390-47be-b4d1-7c6fb8217b14"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1OTYwNQ_6cd5bbd6-d390-47be-b4d1-7c6fb8217b14"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTk2MDU_f2d9c413-bb86-4b22-92e4-ff5805dbf0ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTk2MDU_f2d9c413-bb86-4b22-92e4-ff5805dbf0ea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1OTYwNQ_4b55c588-fcbb-46e2-b19a-c1eca06a2fc3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1OTYwNQ_4b55c588-fcbb-46e2-b19a-c1eca06a2fc3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTk2MDU_55f4db3e-a874-4ef3-bfc6-ff9a9d08c0ce"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTk2MDU_55f4db3e-a874-4ef3-bfc6-ff9a9d08c0ce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTk2MDU_243c4254-90bb-4790-a9b0-be9c0a8e38ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTk2MDU_243c4254-90bb-4790-a9b0-be9c0a8e38ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTk2MDU_ca00c7b3-bb10-422e-8c22-eefaeaf2ba59"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTk2MDU_ca00c7b3-bb10-422e-8c22-eefaeaf2ba59"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reflects actuarial remeasurement gains in 2021, primarily due to favorable plan asset performance and increases in discount rates, and actuarial remeasurement losses in 2020 and 2019, primarily due to decreases in discount rates partially offset by favorable plan asset performance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTgtMS0xLTE1OTYwNQ_522f8a54-1dd9-44eb-97f7-44c711e37e6b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE0LTEtMS0xNTk2MDU_12f5cf08-b296-4d3d-8e58-d4edd5422f7c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTYtMS0xLTE1OTYwNQ_111bd224-a3dd-4f82-bb71-0880092a2fdc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTQtMS0xLTE1OTYwNQ_6cd5bbd6-d390-47be-b4d1-7c6fb8217b14"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE2LTEtMS0xNTk2MDU_f2d9c413-bb86-4b22-92e4-ff5805dbf0ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTItMS0xLTE1OTYwNQ_4b55c588-fcbb-46e2-b19a-c1eca06a2fc3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTE4LTEtMS0xNTk2MDU_55f4db3e-a874-4ef3-bfc6-ff9a9d08c0ce"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEwLTEtMS0xNTk2MDU_243c4254-90bb-4790-a9b0-be9c0a8e38ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyMjdkMjJmZjVlNDM0MzY2YWQxOTdiYWZjMTEyZGY0NS90YWJsZXJhbmdlOjIyN2QyMmZmNWU0MzQzNjZhZDE5N2JhZmMxMTJkZjQ1XzEwLTEyLTEtMS0xNTk2MDU_ca00c7b3-bb10-422e-8c22-eefaeaf2ba59"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxMTU_b9b9481f-edf6-4862-9e2f-e47d47b3b48e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE1NTYzOA_79452b9b-8bc1-4b93-b873-62597a118422"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE1NTYzOA_79452b9b-8bc1-4b93-b873-62597a118422"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNzY2NDI_59c98ae1-8711-4d60-8f1f-664796bfed11"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNzY2NDI_59c98ae1-8711-4d60-8f1f-664796bfed11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNzY2NTE_a5997f8e-98cf-4081-9f7e-e019e7d6edd2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNzY2NTE_a5997f8e-98cf-4081-9f7e-e019e7d6edd2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE3NjQyNg_1d1a6952-df5d-4cd6-8d55-4c84f4196f29"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE3NjQyNg_1d1a6952-df5d-4cd6-8d55-4c84f4196f29"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTgtMS0xLTE3NjUxNg_0a72140e-bfc6-45fc-a6db-b16e3475ccc4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTgtMS0xLTE3NjUxNg_0a72140e-bfc6-45fc-a6db-b16e3475ccc4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNTU2Mzg_602cce56-20e0-4ce1-94c3-e47dc1b24772"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNTU2Mzg_602cce56-20e0-4ce1-94c3-e47dc1b24772"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE3NjQ3MQ_64cb9db0-2dcb-4e78-ad63-f53d8e5e81d1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE3NjQ3MQ_64cb9db0-2dcb-4e78-ad63-f53d8e5e81d1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTQtMS0xLTE3NjQyNg_357498f3-eae3-47e6-a717-100ee9859b9a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTQtMS0xLTE3NjQyNg_357498f3-eae3-47e6-a717-100ee9859b9a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE3NjUxNg_e6bd7c83-d3d0-47a5-a1f2-aee47f3caf86"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE3NjUxNg_e6bd7c83-d3d0-47a5-a1f2-aee47f3caf86"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE4LTEtMS0xNzY2NDI_66f395c5-8823-4e54-99d7-da791aa1f371"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE4LTEtMS0xNzY2NDI_66f395c5-8823-4e54-99d7-da791aa1f371"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTItMS0xLTE3NjM3NQ_d05385c1-a4e4-4f26-9a73-12054be9aa08"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTItMS0xLTE3NjM3NQ_d05385c1-a4e4-4f26-9a73-12054be9aa08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE0LTEtMS0xNzY2MjE_4082ca8f-abbf-473f-91bd-db8e8256cad1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE0LTEtMS0xNzY2MjE_4082ca8f-abbf-473f-91bd-db8e8256cad1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE1NTYzOA_d8aeab8c-3274-41ea-b63d-f760575f61ae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE1NTYzOA_d8aeab8c-3274-41ea-b63d-f760575f61ae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIwLTEtMS0xNzY2NTE_bbefd3e9-b4f2-4678-9562-3af5bffe61e1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIwLTEtMS0xNzY2NTE_bbefd3e9-b4f2-4678-9562-3af5bffe61e1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNzY2MjE_c61eac8c-1ade-4f37-90c2-b80ac6d9c38c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNzY2MjE_c61eac8c-1ade-4f37-90c2-b80ac6d9c38c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNTU2Mzg_44eb4742-6f2b-478c-8d05-cfec32546ac0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNTU2Mzg_44eb4742-6f2b-478c-8d05-cfec32546ac0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE1NTYzOA_7b5921d0-3be3-4e5f-a29d-b19cfb7ba075"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE1NTYzOA_7b5921d0-3be3-4e5f-a29d-b19cfb7ba075"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTYtMS0xLTE3NjQ3MQ_b1de6f06-71ed-4e13-9dcd-7988706f68ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTYtMS0xLTE3NjQ3MQ_b1de6f06-71ed-4e13-9dcd-7988706f68ea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNTU2Mzg_2bc90cbe-8d40-409b-ba58-60ba596ba1d2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNTU2Mzg_2bc90cbe-8d40-409b-ba58-60ba596ba1d2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE1NTYzOA_79452b9b-8bc1-4b93-b873-62597a118422"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNzY2NDI_59c98ae1-8711-4d60-8f1f-664796bfed11"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNzY2NTE_a5997f8e-98cf-4081-9f7e-e019e7d6edd2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTQtMS0xLTE3NjQyNg_1d1a6952-df5d-4cd6-8d55-4c84f4196f29"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTgtMS0xLTE3NjUxNg_0a72140e-bfc6-45fc-a6db-b16e3475ccc4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE4LTEtMS0xNTU2Mzg_602cce56-20e0-4ce1-94c3-e47dc1b24772"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE3NjQ3MQ_64cb9db0-2dcb-4e78-ad63-f53d8e5e81d1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTQtMS0xLTE3NjQyNg_357498f3-eae3-47e6-a717-100ee9859b9a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE3NjUxNg_e6bd7c83-d3d0-47a5-a1f2-aee47f3caf86"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE4LTEtMS0xNzY2NDI_66f395c5-8823-4e54-99d7-da791aa1f371"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTItMS0xLTE3NjM3NQ_d05385c1-a4e4-4f26-9a73-12054be9aa08"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTE0LTEtMS0xNzY2MjE_4082ca8f-abbf-473f-91bd-db8e8256cad1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTgtMS0xLTE1NTYzOA_d8aeab8c-3274-41ea-b63d-f760575f61ae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTIwLTEtMS0xNzY2NTE_bbefd3e9-b4f2-4678-9562-3af5bffe61e1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNzY2MjE_c61eac8c-1ade-4f37-90c2-b80ac6d9c38c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTIwLTEtMS0xNTU2Mzg_44eb4742-6f2b-478c-8d05-cfec32546ac0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTYtMS0xLTE1NTYzOA_7b5921d0-3be3-4e5f-a29d-b19cfb7ba075"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMyLTYtMS0xLTE3NjQ3MQ_b1de6f06-71ed-4e13-9dcd-7988706f68ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzM0LTE0LTEtMS0xNTU2Mzg_2bc90cbe-8d40-409b-ba58-60ba596ba1d2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTky_b6dd9b89-410e-43bf-932a-10020dc488b1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtMi0xLTEtMTU1NjM4_4852e44b-060b-4524-8cde-acdd45c8d69f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtMi0xLTEtMTU1NjM4_4852e44b-060b-4524-8cde-acdd45c8d69f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNC0xLTEtMTU1NjM4_bd5d325b-76f5-4dd4-a23f-b3930e7dc4ec"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNC0xLTEtMTU1NjM4_bd5d325b-76f5-4dd4-a23f-b3930e7dc4ec"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNi0xLTEtMTU1NjM4_812d0cf5-bd12-44dd-a0d9-31b83dc34171"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNi0xLTEtMTU1NjM4_812d0cf5-bd12-44dd-a0d9-31b83dc34171"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA1_58f624c6-ad90-43de-8026-7a18986026d8" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA1_58f624c6-ad90-43de-8026-7a18986026d8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents sales to our partners of products manufactured by us.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtMi0xLTEtMTU1NjM4_4852e44b-060b-4524-8cde-acdd45c8d69f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA1_58f624c6-ad90-43de-8026-7a18986026d8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNC0xLTEtMTU1NjM4_bd5d325b-76f5-4dd4-a23f-b3930e7dc4ec"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA1_58f624c6-ad90-43de-8026-7a18986026d8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzMtNi0xLTEtMTU1NjM4_812d0cf5-bd12-44dd-a0d9-31b83dc34171"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTA1_58f624c6-ad90-43de-8026-7a18986026d8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktMi0xLTEtMTU1NjM4_b45deda5-c9eb-4249-973c-69e48319db9e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktMi0xLTEtMTU1NjM4_b45deda5-c9eb-4249-973c-69e48319db9e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNi0xLTEtMTU1NjM4_8c950b8b-ad69-4ccf-983e-ea64d5755d84"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNi0xLTEtMTU1NjM4_8c950b8b-ad69-4ccf-983e-ea64d5755d84"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNC0xLTEtMTU1NjM4_29e6b7ac-2fe7-4877-a124-b300cdd5a22f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNC0xLTEtMTU1NjM4_29e6b7ac-2fe7-4877-a124-b300cdd5a22f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU2_5902b619-e434-4c25-9870-f93ab88b0fb6" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU2_5902b619-e434-4c25-9870-f93ab88b0fb6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily relates to royalties from our collaboration partners. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktMi0xLTEtMTU1NjM4_b45deda5-c9eb-4249-973c-69e48319db9e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU2_5902b619-e434-4c25-9870-f93ab88b0fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNi0xLTEtMTU1NjM4_8c950b8b-ad69-4ccf-983e-ea64d5755d84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU2_5902b619-e434-4c25-9870-f93ab88b0fb6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzktNC0xLTEtMTU1NjM4_29e6b7ac-2fe7-4877-a124-b300cdd5a22f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDU2_5902b619-e434-4c25-9870-f93ab88b0fb6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtMi0xLTEtMTU1NjM4_eac59ed0-b395-4f44-91ec-98b484b8f4b4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtMi0xLTEtMTU1NjM4_eac59ed0-b395-4f44-91ec-98b484b8f4b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtNC0xLTEtMTU1NjM4_5e0bc421-d01b-4490-af80-b7bf03c05d79"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtNC0xLTEtMTU1NjM4_5e0bc421-d01b-4490-af80-b7bf03c05d79"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwMA_40ce384d-31be-4b40-aaa6-9b94f7f3d188" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwMA_40ce384d-31be-4b40-aaa6-9b94f7f3d188" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of December 31, 2021 and 2020, includes money market funds primarily invested in U.S. Treasury and government debt.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtMi0xLTEtMTU1NjM4_eac59ed0-b395-4f44-91ec-98b484b8f4b4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwMA_40ce384d-31be-4b40-aaa6-9b94f7f3d188"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzQtNC0xLTEtMTU1NjM4_5e0bc421-d01b-4490-af80-b7bf03c05d79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwMA_40ce384d-31be-4b40-aaa6-9b94f7f3d188"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMzAtMS0xLTE1NTYzOA_eaafc4ca-df82-4841-949c-5e448cee1d0c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMzAtMS0xLTE1NTYzOA_eaafc4ca-df82-4841-949c-5e448cee1d0c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTgtMS0xLTE1NTYzOA_72fd28a5-d393-4635-8f84-5f5b000a4bc4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTgtMS0xLTE1NTYzOA_72fd28a5-d393-4635-8f84-5f5b000a4bc4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjYtMS0xLTE1NTYzOA_e3208f64-720b-4f0f-8801-e090f70792e1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjYtMS0xLTE1NTYzOA_e3208f64-720b-4f0f-8801-e090f70792e1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtOC0xLTEtMTU1NjM4_3ddbadfe-2c7e-469b-8b74-ac53c8330c60"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtOC0xLTEtMTU1NjM4_3ddbadfe-2c7e-469b-8b74-ac53c8330c60"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjgtMS0xLTE1NTYzOA_b49a6e3c-efe7-4be4-92f6-272d3b6a1aa8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjgtMS0xLTE1NTYzOA_b49a6e3c-efe7-4be4-92f6-272d3b6a1aa8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMi0xLTEtMTU1NjM4_0030d148-ccdb-493d-9ef6-9c6e5e073b5c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMi0xLTEtMTU1NjM4_0030d148-ccdb-493d-9ef6-9c6e5e073b5c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjAtMS0xLTE1NTYzOA_3a83e750-3f49-46d0-a35a-4b9f84e9a9e4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjAtMS0xLTE1NTYzOA_3a83e750-3f49-46d0-a35a-4b9f84e9a9e4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTQtMS0xLTE1NTYzOA_1e6a6321-5b59-4629-a177-6e2866459aee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTQtMS0xLTE1NTYzOA_1e6a6321-5b59-4629-a177-6e2866459aee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTAtMS0xLTE1NTYzOA_5ce6a7c9-5907-47d5-a423-c9b0057bbc7d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTAtMS0xLTE1NTYzOA_5ce6a7c9-5907-47d5-a423-c9b0057bbc7d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjItMS0xLTE1NTYzOA_de7e819a-94c2-4908-b137-6debfd7edbc1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjItMS0xLTE1NTYzOA_de7e819a-94c2-4908-b137-6debfd7edbc1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNi0xLTEtMTU1NjM4_75b7d650-b93e-46a1-87ad-f8b8375f99cd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNi0xLTEtMTU1NjM4_75b7d650-b93e-46a1-87ad-f8b8375f99cd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTItMS0xLTE1NTYzOA_9f88f9b8-9153-4eae-9b34-60c2f6485b91"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTItMS0xLTE1NTYzOA_9f88f9b8-9153-4eae-9b34-60c2f6485b91"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTYtMS0xLTE1NTYzOA_b173fb43-0d28-4160-8fd4-5c4b99367cb5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTYtMS0xLTE1NTYzOA_b173fb43-0d28-4160-8fd4-5c4b99367cb5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjQtMS0xLTE1NTYzOA_dffb3ed7-9572-487e-ad9c-3dc22c16c91a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjQtMS0xLTE1NTYzOA_dffb3ed7-9572-487e-ad9c-3dc22c16c91a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNC0xLTEtMTU1NjM4_466fd797-58fa-45d5-848d-734df1c99bde"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNC0xLTEtMTU1NjM4_466fd797-58fa-45d5-848d-734df1c99bde"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Weighted-average GDFV per TSRUs and stock options.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMzAtMS0xLTE1NTYzOA_eaafc4ca-df82-4841-949c-5e448cee1d0c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTgtMS0xLTE1NTYzOA_72fd28a5-d393-4635-8f84-5f5b000a4bc4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjYtMS0xLTE1NTYzOA_e3208f64-720b-4f0f-8801-e090f70792e1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtOC0xLTEtMTU1NjM4_3ddbadfe-2c7e-469b-8b74-ac53c8330c60"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjgtMS0xLTE1NTYzOA_b49a6e3c-efe7-4be4-92f6-272d3b6a1aa8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMi0xLTEtMTU1NjM4_0030d148-ccdb-493d-9ef6-9c6e5e073b5c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjAtMS0xLTE1NTYzOA_3a83e750-3f49-46d0-a35a-4b9f84e9a9e4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTQtMS0xLTE1NTYzOA_1e6a6321-5b59-4629-a177-6e2866459aee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTAtMS0xLTE1NTYzOA_5ce6a7c9-5907-47d5-a423-c9b0057bbc7d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjItMS0xLTE1NTYzOA_de7e819a-94c2-4908-b137-6debfd7edbc1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNi0xLTEtMTU1NjM4_75b7d650-b93e-46a1-87ad-f8b8375f99cd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTItMS0xLTE1NTYzOA_9f88f9b8-9153-4eae-9b34-60c2f6485b91"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMTYtMS0xLTE1NTYzOA_b173fb43-0d28-4160-8fd4-5c4b99367cb5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtMjQtMS0xLTE1NTYzOA_dffb3ed7-9572-487e-ad9c-3dc22c16c91a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzMtNC0xLTEtMTU1NjM4_466fd797-58fa-45d5-848d-734df1c99bde"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTA_d973ae38-6ab1-472e-a03f-f34b298bce39"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTQtMS0xLTE1NTYzOA_b84fbe8e-6a3f-4099-9eac-641d1f1b18dd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTQtMS0xLTE1NTYzOA_b84fbe8e-6a3f-4099-9eac-641d1f1b18dd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTItMS0xLTE1NTYzOA_ed6860e8-6cef-4092-85bd-14b0db566a9f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTItMS0xLTE1NTYzOA_ed6860e8-6cef-4092-85bd-14b0db566a9f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTYtMS0xLTE1NTYzOA_16ed3388-ebc3-4c1b-af6e-ee2db9e45355"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTYtMS0xLTE1NTYzOA_16ed3388-ebc3-4c1b-af6e-ee2db9e45355"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTM_1eed2719-76dd-4177-b92f-3f667b7d5c40" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTM_1eed2719-76dd-4177-b92f-3f667b7d5c40" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">2021 includes, among other things, (i) income net of costs associated with TSAs of $288 million; (ii) dividend income of $166 million from our investment in ViiV and (iii) charges of $142 million, reflecting the change in the fair value of contingent consideration. 2020 included, among other things, (i) dividend income of $278 million from our investment in ViiV; (ii) income net of costs associated with TSAs of $114 million and (iii) charges of $105 million, reflecting the change in the fair value of contingent consideration. 2019 included, among other things, (i) dividend income of $220&#160;million from our investment in ViiV; (ii) charges of $152 million for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the Consumer Healthcare JV; and (iii) net losses on early retirement of debt of $138&#160;million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTQtMS0xLTE1NTYzOA_b84fbe8e-6a3f-4099-9eac-641d1f1b18dd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTM_1eed2719-76dd-4177-b92f-3f667b7d5c40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTItMS0xLTE1NTYzOA_ed6860e8-6cef-4092-85bd-14b0db566a9f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTM_1eed2719-76dd-4177-b92f-3f667b7d5c40"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE2LTYtMS0xLTE1NTYzOA_16ed3388-ebc3-4c1b-af6e-ee2db9e45355"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTM_1eed2719-76dd-4177-b92f-3f667b7d5c40"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTItMS0xLTE1NTYzOA_1d5c60d8-aa15-4f85-b15a-567ac23fc306"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTItMS0xLTE1NTYzOA_1d5c60d8-aa15-4f85-b15a-567ac23fc306"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTYtMS0xLTE1NTYzOA_fb7a05db-3539-44fd-85eb-fce98e4a8eec"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTYtMS0xLTE1NTYzOA_fb7a05db-3539-44fd-85eb-fce98e4a8eec"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTQtMS0xLTE1NTYzOA_19a96083-6c93-4b19-9643-21dfc7e6a33e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTQtMS0xLTE1NTYzOA_19a96083-6c93-4b19-9643-21dfc7e6a33e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc0_74c907cb-0fd0-422c-9947-ca1d7ea7c38a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc0_74c907cb-0fd0-422c-9947-ca1d7ea7c38a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">All other, net is primarily due to routine business operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTItMS0xLTE1NTYzOA_1d5c60d8-aa15-4f85-b15a-567ac23fc306"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc0_74c907cb-0fd0-422c-9947-ca1d7ea7c38a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTYtMS0xLTE1NTYzOA_fb7a05db-3539-44fd-85eb-fce98e4a8eec"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc0_74c907cb-0fd0-422c-9947-ca1d7ea7c38a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEyLTQtMS0xLTE1NTYzOA_19a96083-6c93-4b19-9643-21dfc7e6a33e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDc0_74c907cb-0fd0-422c-9947-ca1d7ea7c38a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTgtMS0xLTE1NTYzOA_d6a323fc-7cb7-4834-ac37-0568992d3f35"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTgtMS0xLTE1NTYzOA_d6a323fc-7cb7-4834-ac37-0568992d3f35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE0LTEtMS0xNTU2Mzg_7633de53-4390-47ba-baf3-1655f72106d6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE0LTEtMS0xNTU2Mzg_7633de53-4390-47ba-baf3-1655f72106d6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE4LTEtMS0xNTU2Mzg_00b437d0-18c0-450b-9dd6-1bfd8657d584"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE4LTEtMS0xNTU2Mzg_00b437d0-18c0-450b-9dd6-1bfd8657d584"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEwLTEtMS0xNTU2Mzg_9c49a9e0-a9b6-45a3-bda0-99fa573d9310"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEwLTEtMS0xNTU2Mzg_9c49a9e0-a9b6-45a3-bda0-99fa573d9310"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE4LTEtMS0xNTU2Mzg_f3c443bf-eba7-44c5-a8dd-89017a09bda3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE4LTEtMS0xNTU2Mzg_f3c443bf-eba7-44c5-a8dd-89017a09bda3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTQtMS0xLTE1NTYzOA_3f59ffed-384c-4297-9043-94b52041efad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTQtMS0xLTE1NTYzOA_3f59ffed-384c-4297-9043-94b52041efad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTYtMS0xLTE1NTYzOA_1e4d1b6c-f5a4-40d2-844a-3ab0a45b0bef"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTYtMS0xLTE1NTYzOA_1e4d1b6c-f5a4-40d2-844a-3ab0a45b0bef"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTgtMS0xLTE1NTYzOA_7e1703d0-e7a0-4115-b0b2-9ff77b3df847"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTgtMS0xLTE1NTYzOA_7e1703d0-e7a0-4115-b0b2-9ff77b3df847"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIwLTEtMS0xNTU2Mzg_eb54842d-f09d-4c97-9447-596ba9c828e9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIwLTEtMS0xNTU2Mzg_eb54842d-f09d-4c97-9447-596ba9c828e9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE2LTEtMS0xNTU2Mzg_26d5df97-f0ad-4152-8dee-55f18443891e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE2LTEtMS0xNTU2Mzg_26d5df97-f0ad-4152-8dee-55f18443891e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIwLTEtMS0xNTU2Mzg_bfef0997-7812-4779-a11e-800743cd3459"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIwLTEtMS0xNTU2Mzg_bfef0997-7812-4779-a11e-800743cd3459"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE2LTEtMS0xNTU2Mzg_1fc74320-cc41-4d0c-9bc9-8f4d0f01bd77"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE2LTEtMS0xNTU2Mzg_1fc74320-cc41-4d0c-9bc9-8f4d0f01bd77"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTYtMS0xLTE1NTYzOA_9e395521-4d55-4496-bfba-db44fa808527"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTYtMS0xLTE1NTYzOA_9e395521-4d55-4496-bfba-db44fa808527"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEwLTEtMS0xNTU2Mzg_67b09b8f-e216-4d69-9e74-d98f90ff3ac8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEwLTEtMS0xNTU2Mzg_67b09b8f-e216-4d69-9e74-d98f90ff3ac8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE0LTEtMS0xNTU2Mzg_2f220032-7e9b-4c18-b46b-94a7e5cade71"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE0LTEtMS0xNTU2Mzg_2f220032-7e9b-4c18-b46b-94a7e5cade71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTQtMS0xLTE1NTYzOA_59235c5e-1fcd-4074-9c0d-c21db292ee70"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTQtMS0xLTE1NTYzOA_59235c5e-1fcd-4074-9c0d-c21db292ee70"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTgtMS0xLTE1NTYzOA_d6a323fc-7cb7-4834-ac37-0568992d3f35"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE0LTEtMS0xNTU2Mzg_7633de53-4390-47ba-baf3-1655f72106d6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE4LTEtMS0xNTU2Mzg_00b437d0-18c0-450b-9dd6-1bfd8657d584"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTEwLTEtMS0xNTU2Mzg_9c49a9e0-a9b6-45a3-bda0-99fa573d9310"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE4LTEtMS0xNTU2Mzg_f3c443bf-eba7-44c5-a8dd-89017a09bda3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTQtMS0xLTE1NTYzOA_3f59ffed-384c-4297-9043-94b52041efad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTYtMS0xLTE1NTYzOA_1e4d1b6c-f5a4-40d2-844a-3ab0a45b0bef"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTgtMS0xLTE1NTYzOA_7e1703d0-e7a0-4115-b0b2-9ff77b3df847"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTIwLTEtMS0xNTU2Mzg_eb54842d-f09d-4c97-9447-596ba9c828e9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE2LTEtMS0xNTU2Mzg_26d5df97-f0ad-4152-8dee-55f18443891e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTIwLTEtMS0xNTU2Mzg_bfef0997-7812-4779-a11e-800743cd3459"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTE2LTEtMS0xNTU2Mzg_1fc74320-cc41-4d0c-9bc9-8f4d0f01bd77"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTYtMS0xLTE1NTYzOA_9e395521-4d55-4496-bfba-db44fa808527"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTEwLTEtMS0xNTU2Mzg_67b09b8f-e216-4d69-9e74-d98f90ff3ac8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzExLTE0LTEtMS0xNTU2Mzg_2f220032-7e9b-4c18-b46b-94a7e5cade71"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI1LTQtMS0xLTE1NTYzOA_59235c5e-1fcd-4074-9c0d-c21db292ee70"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTc3_6a57107c-3d74-4afc-8da5-15d0c104e921"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTItMS0xLTE1NTYzOA_4211c29b-37c3-4166-8a7b-994500cacb41"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTItMS0xLTE1NTYzOA_4211c29b-37c3-4166-8a7b-994500cacb41"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTItMS0xLTE1NTYzOA_532a46be-433a-42ba-8ed4-9fbf1cd26e71"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTItMS0xLTE1NTYzOA_532a46be-433a-42ba-8ed4-9fbf1cd26e71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE0LTEtMS0xNTU2Mzg_6c6bceb0-130d-49af-862b-de96ffd1fba6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE0LTEtMS0xNTU2Mzg_6c6bceb0-130d-49af-862b-de96ffd1fba6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTItMS0xLTE1NTYzOA_cd0713ce-a174-401d-a6cf-b7a389c052b5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTItMS0xLTE1NTYzOA_cd0713ce-a174-401d-a6cf-b7a389c052b5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTQtMS0xLTE1NTYzOA_465e3f25-0b56-4f09-812f-8698f3314174"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTQtMS0xLTE1NTYzOA_465e3f25-0b56-4f09-812f-8698f3314174"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEyLTEtMS0xNTU2Mzg_30a08688-abc7-4fc1-a6dc-6a6a58197d10"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEyLTEtMS0xNTU2Mzg_30a08688-abc7-4fc1-a6dc-6a6a58197d10"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTQtMS0xLTE1NTYzOA_3af3c0e7-b52e-4fe4-a24f-8ddc2ed8a412"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTQtMS0xLTE1NTYzOA_3af3c0e7-b52e-4fe4-a24f-8ddc2ed8a412"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTItMS0xLTE1NTYzOA_2f464006-2cdb-4183-b0fd-f41fe79230da"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTItMS0xLTE1NTYzOA_2f464006-2cdb-4183-b0fd-f41fe79230da"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTQtMS0xLTE1NTYzOA_64af5ac8-922a-4e1d-a5a2-766e1fd5157d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTQtMS0xLTE1NTYzOA_64af5ac8-922a-4e1d-a5a2-766e1fd5157d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTQtMS0xLTE1NTYzOA_14faf7c2-7a01-4302-b4ef-c4f8cd899ae8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTQtMS0xLTE1NTYzOA_14faf7c2-7a01-4302-b4ef-c4f8cd899ae8"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Vested and non-vested shares outstanding, but not paid as of December 31, 2021 were 34.1&#160;million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTItMS0xLTE1NTYzOA_4211c29b-37c3-4166-8a7b-994500cacb41"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTItMS0xLTE1NTYzOA_532a46be-433a-42ba-8ed4-9fbf1cd26e71"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTE0LTEtMS0xNTU2Mzg_6c6bceb0-130d-49af-862b-de96ffd1fba6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTItMS0xLTE1NTYzOA_cd0713ce-a174-401d-a6cf-b7a389c052b5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTQtMS0xLTE1NTYzOA_465e3f25-0b56-4f09-812f-8698f3314174"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzExLTEyLTEtMS0xNTU2Mzg_30a08688-abc7-4fc1-a6dc-6a6a58197d10"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzktMTQtMS0xLTE1NTYzOA_3af3c0e7-b52e-4fe4-a24f-8ddc2ed8a412"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzctMTItMS0xLTE1NTYzOA_2f464006-2cdb-4183-b0fd-f41fe79230da"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzUtMTQtMS0xLTE1NTYzOA_64af5ac8-922a-4e1d-a5a2-766e1fd5157d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTowNTQzMTI2MTRhYTU0ZTU1YTM2MmIzYmNkNjczYjVlMi90YWJsZXJhbmdlOjA1NDMxMjYxNGFhNTRlNTVhMzYyYjNiY2Q2NzNiNWUyXzYtMTQtMS0xLTE1NTYzOA_14faf7c2-7a01-4302-b4ef-c4f8cd899ae8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTE_279716d7-7ae4-430a-a79e-e2fe2e69a406"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTItMS0xLTE1NTYzOA_a7bec050-b698-4726-bd56-085e3fa47cb8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTItMS0xLTE1NTYzOA_a7bec050-b698-4726-bd56-085e3fa47cb8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTQtMS0xLTE1NTYzOA_a037f3fe-76de-4e3a-b45e-df594d2e8044"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTQtMS0xLTE1NTYzOA_a037f3fe-76de-4e3a-b45e-df594d2e8044"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Mw_b1b8ff7f-ad8d-468c-af41-2061ee702628" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Mw_b1b8ff7f-ad8d-468c-af41-2061ee702628" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represent investments in the life sciences sector.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTItMS0xLTE1NTYzOA_a7bec050-b698-4726-bd56-085e3fa47cb8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Mw_b1b8ff7f-ad8d-468c-af41-2061ee702628"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTo3ZjhhYzNlZjAzYjM0M2RkOTRkNWNmOWY2Zjk5YTE4MS90YWJsZXJhbmdlOjdmOGFjM2VmMDNiMzQzZGQ5NGQ1Y2Y5ZjZmOTlhMTgxXzEzLTQtMS0xLTE1NTYzOA_a037f3fe-76de-4e3a-b45e-df594d2e8044"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Mw_b1b8ff7f-ad8d-468c-af41-2061ee702628"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNi0xLTEtMTU1NjM4_a4dd9cc9-d0a1-4d4b-87f1-abb2ee502128"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNi0xLTEtMTU1NjM4_a4dd9cc9-d0a1-4d4b-87f1-abb2ee502128"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNC0xLTEtMTU1NjM4_006cdb55-7f81-45c9-9480-57256a9c9967"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNC0xLTEtMTU1NjM4_006cdb55-7f81-45c9-9480-57256a9c9967"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMi0xLTEtMTU1NjM4_1db96457-241e-4457-bb5d-70a065db8f45"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMi0xLTEtMTU1NjM4_1db96457-241e-4457-bb5d-70a065db8f45"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTItMS0xLTE1NTYzOA_91798efa-c2a4-4afb-b009-5535e620a515"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTItMS0xLTE1NTYzOA_91798efa-c2a4-4afb-b009-5535e620a515"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtOC0xLTEtMTU1NjM4_a6383107-a58a-4a33-969c-54b74cd56a82"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtOC0xLTEtMTU1NjM4_a6383107-a58a-4a33-969c-54b74cd56a82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTAtMS0xLTE1NTYzOA_86e86249-8876-4e05-ace4-6b91dc0302da"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTAtMS0xLTE1NTYzOA_86e86249-8876-4e05-ace4-6b91dc0302da"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The increase in the gross carrying amount primarily reflects $500 million of capitalized Comirnaty sales milestones to BioNTech, partially offset by net losses from foreign currency translation adjustments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNi0xLTEtMTU1NjM4_a4dd9cc9-d0a1-4d4b-87f1-abb2ee502128"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtNC0xLTEtMTU1NjM4_006cdb55-7f81-45c9-9480-57256a9c9967"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMi0xLTEtMTU1NjM4_1db96457-241e-4457-bb5d-70a065db8f45"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTItMS0xLTE1NTYzOA_91798efa-c2a4-4afb-b009-5535e620a515"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtOC0xLTEtMTU1NjM4_a6383107-a58a-4a33-969c-54b74cd56a82"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzQtMTAtMS0xLTE1NTYzOA_86e86249-8876-4e05-ace4-6b91dc0302da"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTM_f53cd555-a801-4c12-bbc7-e03296183751"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTgtMS0xLTE1NTYzOA_d09cd04e-2282-4eee-b696-e9040247d88d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTgtMS0xLTE1NTYzOA_d09cd04e-2282-4eee-b696-e9040247d88d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTYtMS0xLTE1NTYzOA_8d165f23-be85-4dc1-adc5-76c248b7d5f6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTYtMS0xLTE1NTYzOA_8d165f23-be85-4dc1-adc5-76c248b7d5f6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTYtMS0xLTE1NTYzOA_5cd58def-c2a2-44d2-afeb-aba885aa2fc8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTYtMS0xLTE1NTYzOA_5cd58def-c2a2-44d2-afeb-aba885aa2fc8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTEwLTEtMS0xNTU2Mzg_daf6262b-ed94-4815-aa85-d2b76b855eae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTEwLTEtMS0xNTU2Mzg_daf6262b-ed94-4815-aa85-d2b76b855eae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTEwLTEtMS0xNTU2Mzg_1e28e996-4c45-4799-b7ef-7dc4e5449fdd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTEwLTEtMS0xNTU2Mzg_1e28e996-4c45-4799-b7ef-7dc4e5449fdd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTgtMS0xLTE1NTYzOA_83acb8fa-0dbe-484f-b7a3-7b391952efb2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTgtMS0xLTE1NTYzOA_83acb8fa-0dbe-484f-b7a3-7b391952efb2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTEwLTEtMS0xNTU2Mzg_12244f3f-27df-420a-9f0b-1652ddbc6248"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTEwLTEtMS0xNTU2Mzg_12244f3f-27df-420a-9f0b-1652ddbc6248"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTYtMS0xLTE1NTYzOA_a1fe41aa-bf30-4747-9aea-81360d159eb5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTYtMS0xLTE1NTYzOA_a1fe41aa-bf30-4747-9aea-81360d159eb5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTYtMS0xLTE1NTYzOA_d40c85f6-ad5d-486b-95fb-11dc5f86ce26"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTYtMS0xLTE1NTYzOA_d40c85f6-ad5d-486b-95fb-11dc5f86ce26"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTgtMS0xLTE1NTYzOA_d075da76-8e37-4fb0-92e5-e64957caf8ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTgtMS0xLTE1NTYzOA_d075da76-8e37-4fb0-92e5-e64957caf8ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTgtMS0xLTE1NTYzOA_dc88088c-58ae-4f64-b4b7-52c9484035eb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTgtMS0xLTE1NTYzOA_dc88088c-58ae-4f64-b4b7-52c9484035eb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTEwLTEtMS0xNTU2Mzg_f22d3ac4-76d9-4abe-b144-2724bdadf6a6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTEwLTEtMS0xNTU2Mzg_f22d3ac4-76d9-4abe-b144-2724bdadf6a6"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTgtMS0xLTE1NTYzOA_d09cd04e-2282-4eee-b696-e9040247d88d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTYtMS0xLTE1NTYzOA_8d165f23-be85-4dc1-adc5-76c248b7d5f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTYtMS0xLTE1NTYzOA_5cd58def-c2a2-44d2-afeb-aba885aa2fc8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE0LTEwLTEtMS0xNTU2Mzg_daf6262b-ed94-4815-aa85-d2b76b855eae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTEwLTEtMS0xNTU2Mzg_1e28e996-4c45-4799-b7ef-7dc4e5449fdd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTgtMS0xLTE1NTYzOA_83acb8fa-0dbe-484f-b7a3-7b391952efb2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTEwLTEtMS0xNTU2Mzg_12244f3f-27df-420a-9f0b-1652ddbc6248"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTYtMS0xLTE1NTYzOA_a1fe41aa-bf30-4747-9aea-81360d159eb5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE2LTYtMS0xLTE1NTYzOA_d40c85f6-ad5d-486b-95fb-11dc5f86ce26"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTgtMS0xLTE1NTYzOA_d075da76-8e37-4fb0-92e5-e64957caf8ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzEzLTgtMS0xLTE1NTYzOA_dc88088c-58ae-4f64-b4b7-52c9484035eb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE1LTEwLTEtMS0xNTU2Mzg_f22d3ac4-76d9-4abe-b144-2724bdadf6a6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE3_29dcb1e1-c1db-44e9-aa1a-49e5debe7928"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNC0xLTEtMTU1NjM4_8725e295-9631-41e9-964a-1c35d13d3069"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNC0xLTEtMTU1NjM4_8725e295-9631-41e9-964a-1c35d13d3069"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNi0xLTEtMTU1NjM4_9dc8b5f6-80fe-4a13-bf28-33b00373b705"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNi0xLTEtMTU1NjM4_9dc8b5f6-80fe-4a13-bf28-33b00373b705"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtOC0xLTEtMTU1NjM4_af969f26-65f5-42e4-84a6-c2edff83475d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtOC0xLTEtMTU1NjM4_af969f26-65f5-42e4-84a6-c2edff83475d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtMi0xLTEtMTU1NjM4_2f7f6c8a-d1ea-4776-b3bf-f600ef3cb02e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtMi0xLTEtMTU1NjM4_2f7f6c8a-d1ea-4776-b3bf-f600ef3cb02e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($628 million) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> ($169 million).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNC0xLTEtMTU1NjM4_8725e295-9631-41e9-964a-1c35d13d3069"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtNi0xLTEtMTU1NjM4_9dc8b5f6-80fe-4a13-bf28-33b00373b705"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtOC0xLTEtMTU1NjM4_af969f26-65f5-42e4-84a6-c2edff83475d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzUtMi0xLTEtMTU1NjM4_2f7f6c8a-d1ea-4776-b3bf-f600ef3cb02e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI2_e9717495-453a-4e4f-b339-765d5416db6f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEwLTEtMS0xNTU2Mzg_78ddf880-771b-4688-96e0-3cb5279fd390"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEwLTEtMS0xNTU2Mzg_78ddf880-771b-4688-96e0-3cb5279fd390"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTgtMS0xLTE1NTYzOA_dc3ec28d-15f6-4bc6-ac30-354a3d100de1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTgtMS0xLTE1NTYzOA_dc3ec28d-15f6-4bc6-ac30-354a3d100de1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEyLTEtMS0yNzAxNDE_0357e9db-9c5e-4779-b022-c590a5995791"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEyLTEtMS0yNzAxNDE_0357e9db-9c5e-4779-b022-c590a5995791"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzU1ODA_bdebfab6-bd01-4f6b-bc21-f6fe009452ff" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzU1ODA_bdebfab6-bd01-4f6b-bc21-f6fe009452ff" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the U.S. pension plans as these plans are frozen.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEwLTEtMS0xNTU2Mzg_78ddf880-771b-4688-96e0-3cb5279fd390"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzU1ODA_bdebfab6-bd01-4f6b-bc21-f6fe009452ff"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTgtMS0xLTE1NTYzOA_dc3ec28d-15f6-4bc6-ac30-354a3d100de1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzU1ODA_bdebfab6-bd01-4f6b-bc21-f6fe009452ff"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozYjViZWE5ZmI5MmQ0MzkwOWI3NDMyZmYxZjI5NmNlZS90YWJsZXJhbmdlOjNiNWJlYTlmYjkyZDQzOTA5Yjc0MzJmZjFmMjk2Y2VlXzE0LTEyLTEtMS0yNzAxNDE_0357e9db-9c5e-4779-b022-c590a5995791"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzU1ODA_bdebfab6-bd01-4f6b-bc21-f6fe009452ff"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTQtMS0xLTE1NTYzOA_b5dd47cb-0404-4dcb-8afb-8ac782a5f655"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTQtMS0xLTE1NTYzOA_b5dd47cb-0404-4dcb-8afb-8ac782a5f655"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTItMS0xLTE1NTYzOA_061e55c1-6b6a-46e3-b613-1c3fa13abb1e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTItMS0xLTE1NTYzOA_061e55c1-6b6a-46e3-b613-1c3fa13abb1e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTYtMS0xLTE1NTYzOA_154dbc6d-b981-40d8-abc4-8299b6b7a746"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTYtMS0xLTE1NTYzOA_154dbc6d-b981-40d8-abc4-8299b6b7a746"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNQ_deb48efb-7fb2-48e3-9a1a-db0fc4767348" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNQ_deb48efb-7fb2-48e3-9a1a-db0fc4767348" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTQtMS0xLTE1NTYzOA_b5dd47cb-0404-4dcb-8afb-8ac782a5f655"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNQ_deb48efb-7fb2-48e3-9a1a-db0fc4767348"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTItMS0xLTE1NTYzOA_061e55c1-6b6a-46e3-b613-1c3fa13abb1e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNQ_deb48efb-7fb2-48e3-9a1a-db0fc4767348"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzExLTYtMS0xLTE1NTYzOA_154dbc6d-b981-40d8-abc4-8299b6b7a746"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNQ_deb48efb-7fb2-48e3-9a1a-db0fc4767348"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNy0xLTEtMTU1NjM4_82fdb0a5-c8c5-471d-9db1-f99ad35bface"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNy0xLTEtMTU1NjM4_82fdb0a5-c8c5-471d-9db1-f99ad35bface"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNS0xLTEtMTU1NjM4_3a5b51d9-038d-4f73-bddf-66ec154f7f42"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNS0xLTEtMTU1NjM4_3a5b51d9-038d-4f73-bddf-66ec154f7f42"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtOS0xLTEtMTU1NjM4_d0fdaa6b-4fdb-4251-9f23-b2d4a66f8c2a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtOS0xLTEtMTU1NjM4_d0fdaa6b-4fdb-4251-9f23-b2d4a66f8c2a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNy0xLTEtMTU1NjM4_83da3ba5-9e6d-46f0-bb6d-5f51c1771b0d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNy0xLTEtMTU1NjM4_83da3ba5-9e6d-46f0-bb6d-5f51c1771b0d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNy0xLTEtMTU1NjM4_c50c3076-23b9-4810-8ae0-51e5cafd05d0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNy0xLTEtMTU1NjM4_c50c3076-23b9-4810-8ae0-51e5cafd05d0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtOS0xLTEtMTU1NjM4_37504520-2fa3-4477-a8d2-80fd135923e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtOS0xLTEtMTU1NjM4_37504520-2fa3-4477-a8d2-80fd135923e2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNS0xLTEtMTU1NjM4_c68ccd3e-9a44-46de-b86e-808d367c30de"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNS0xLTEtMTU1NjM4_c68ccd3e-9a44-46de-b86e-808d367c30de"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNS0xLTEtMTU1NjM4_7ab61130-3ef5-44a9-b13a-d58d1b2ac9ed"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNS0xLTEtMTU1NjM4_7ab61130-3ef5-44a9-b13a-d58d1b2ac9ed"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtOS0xLTEtMTU1NjM4_71b8000c-8a67-476f-86aa-688705b47476"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtOS0xLTEtMTU1NjM4_71b8000c-8a67-476f-86aa-688705b47476"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Exclusive of amortization of intangible assets, except as disclosed in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1M.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNy0xLTEtMTU1NjM4_82fdb0a5-c8c5-471d-9db1-f99ad35bface"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtNS0xLTEtMTU1NjM4_3a5b51d9-038d-4f73-bddf-66ec154f7f42"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtOS0xLTEtMTU1NjM4_d0fdaa6b-4fdb-4251-9f23-b2d4a66f8c2a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNy0xLTEtMTU1NjM4_83da3ba5-9e6d-46f0-bb6d-5f51c1771b0d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNy0xLTEtMTU1NjM4_c50c3076-23b9-4810-8ae0-51e5cafd05d0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzQtOS0xLTEtMTU1NjM4_37504520-2fa3-4477-a8d2-80fd135923e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzYtNS0xLTEtMTU1NjM4_c68ccd3e-9a44-46de-b86e-808d367c30de"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtNS0xLTEtMTU1NjM4_7ab61130-3ef5-44a9-b13a-d58d1b2ac9ed"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90YWJsZTo1NDEyZDgyZmNkZTA0ZTk1OTc2OWVkMThiYmJiNjc2Ni90YWJsZXJhbmdlOjU0MTJkODJmY2RlMDRlOTU5NzY5ZWQxOGJiYmI2NzY2XzUtOS0xLTEtMTU1NjM4_71b8000c-8a67-476f-86aa-688705b47476"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNDgvZnJhZzo0YTAzMWMxMzA1OWY0NTljOTYyZjExZDRiZDliMDNjMy90ZXh0cmVnaW9uOjRhMDMxYzEzMDU5ZjQ1OWM5NjJmMTFkNGJkOWIwM2MzXzExMQ_b48a6b91-dc7e-4b06-ab58-1d80ff43d3e3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMi0xLTEtMTU1NjM4_ae4ec295-92df-44ec-931c-f072f3457cad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMi0xLTEtMTU1NjM4_ae4ec295-92df-44ec-931c-f072f3457cad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtOC0xLTEtMTU1NjM4_eebcdce6-a625-447a-a666-c34372d924ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtOC0xLTEtMTU1NjM4_eebcdce6-a625-447a-a666-c34372d924ab"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4Mjc_73f8b4d4-3c0f-4f3a-a283-8ce485fdaac1" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4Mjc_73f8b4d4-3c0f-4f3a-a283-8ce485fdaac1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtMi0xLTEtMTU1NjM4_ae4ec295-92df-44ec-931c-f072f3457cad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4Mjc_73f8b4d4-3c0f-4f3a-a283-8ce485fdaac1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTpkNTMwZWM4NDgxZjA0MDZhODNhZWMyMGU5Y2E2NDgwYS90YWJsZXJhbmdlOmQ1MzBlYzg0ODFmMDQwNmE4M2FlYzIwZTljYTY0ODBhXzYtOC0xLTEtMTU1NjM4_eebcdce6-a625-447a-a666-c34372d924ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4Mjc_73f8b4d4-3c0f-4f3a-a283-8ce485fdaac1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctNC0xLTEtMTU1NjM4_5e8f8213-8684-4d59-b1e8-3a41c24da7e9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctNC0xLTEtMTU1NjM4_5e8f8213-8684-4d59-b1e8-3a41c24da7e9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctMi0xLTEtMTU1NjM4_13d9c7d2-fd2e-4a7e-b9bb-60309e878951"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctMi0xLTEtMTU1NjM4_13d9c7d2-fd2e-4a7e-b9bb-60309e878951"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU0Mg_c50654f8-e8b0-4416-af9a-f39ecf1625c9" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU0Mg_c50654f8-e8b0-4416-af9a-f39ecf1625c9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent assets</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. There are no recoverability issues for these amounts.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctNC0xLTEtMTU1NjM4_5e8f8213-8684-4d59-b1e8-3a41c24da7e9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU0Mg_c50654f8-e8b0-4416-af9a-f39ecf1625c9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzctMi0xLTEtMTU1NjM4_13d9c7d2-fd2e-4a7e-b9bb-60309e878951"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU0Mg_c50654f8-e8b0-4416-af9a-f39ecf1625c9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTYtMS0xLTE1NTYzOA_a86bd816-10b9-4f9b-912a-4d22b7e4fec4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTYtMS0xLTE1NTYzOA_a86bd816-10b9-4f9b-912a-4d22b7e4fec4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTQtMS0xLTE1NTYzOA_9378fa2a-a4bc-47fc-a652-1bec85705217"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTQtMS0xLTE1NTYzOA_9378fa2a-a4bc-47fc-a652-1bec85705217"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTgtMS0xLTE1NTYzOA_05bf4b6b-a861-4cb5-8cc3-aff476c0dce8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTgtMS0xLTE1NTYzOA_05bf4b6b-a861-4cb5-8cc3-aff476c0dce8"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTM_2e9bea88-c690-449e-914e-399b541e82de" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTM_2e9bea88-c690-449e-914e-399b541e82de" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTYtMS0xLTE1NTYzOA_a86bd816-10b9-4f9b-912a-4d22b7e4fec4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTM_2e9bea88-c690-449e-914e-399b541e82de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTQtMS0xLTE1NTYzOA_9378fa2a-a4bc-47fc-a652-1bec85705217"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTM_2e9bea88-c690-449e-914e-399b541e82de"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYxLTgtMS0xLTE1NTYzOA_05bf4b6b-a861-4cb5-8cc3-aff476c0dce8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTM_2e9bea88-c690-449e-914e-399b541e82de"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNC0xLTEtMTU1NjM4_ffec8e3d-06b3-47b3-8031-20a54e5ae1b2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNC0xLTEtMTU1NjM4_ffec8e3d-06b3-47b3-8031-20a54e5ae1b2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtMi0xLTEtMTU1NjM4_fc48ed28-a2ed-4f89-931a-25408f08f1f5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtMi0xLTEtMTU1NjM4_fc48ed28-a2ed-4f89-931a-25408f08f1f5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNi0xLTEtMTU1NjM4_69712d4d-8f49-4a68-a2fd-58aefe02d4df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNi0xLTEtMTU1NjM4_69712d4d-8f49-4a68-a2fd-58aefe02d4df"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MDU_7baae9c8-1263-4e3d-8ee5-851cb7fc1bec" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MDU_7baae9c8-1263-4e3d-8ee5-851cb7fc1bec" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Capitalized interest totaled $108 million in 2021, $96 million in 2020 and $88 million in 2019.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNC0xLTEtMTU1NjM4_ffec8e3d-06b3-47b3-8031-20a54e5ae1b2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MDU_7baae9c8-1263-4e3d-8ee5-851cb7fc1bec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtMi0xLTEtMTU1NjM4_fc48ed28-a2ed-4f89-931a-25408f08f1f5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MDU_7baae9c8-1263-4e3d-8ee5-851cb7fc1bec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzQtNi0xLTEtMTU1NjM4_69712d4d-8f49-4a68-a2fd-58aefe02d4df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MDU_7baae9c8-1263-4e3d-8ee5-851cb7fc1bec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE4LTEtMS0xNzc0NDY_6a4bc1bb-7dd3-49d7-8cc0-6412bf9dbb14"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE4LTEtMS0xNzc0NDY_6a4bc1bb-7dd3-49d7-8cc0-6412bf9dbb14"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTYtMS0xLTE3NzQ0Ng_c78f2480-6e0a-4812-b437-d0f3b88908f9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTYtMS0xLTE3NzQ0Ng_c78f2480-6e0a-4812-b437-d0f3b88908f9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE0LTEtMS0xNzc0NDY_55e56b9a-2c34-47c6-b317-0ec27b23f0d5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE0LTEtMS0xNzc0NDY_55e56b9a-2c34-47c6-b317-0ec27b23f0d5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTQtMS0xLTE3NzQ0Ng_d5714a79-a33f-4049-ad78-b4ab062cf73d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTQtMS0xLTE3NzQ0Ng_d5714a79-a33f-4049-ad78-b4ab062cf73d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE2LTEtMS0xNzc0NDY_7c74cf89-4939-4846-a03a-8d93ceceec86"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE2LTEtMS0xNzc0NDY_7c74cf89-4939-4846-a03a-8d93ceceec86"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTgtMS0xLTE3NzQ0Ng_3a0c44fa-4538-4105-b1d4-477ae7b6d295"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTgtMS0xLTE3NzQ0Ng_3a0c44fa-4538-4105-b1d4-477ae7b6d295"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE2LTEtMS0xNzc0NDY_50095a15-4d77-4d87-8ded-edd7b8c37440"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE2LTEtMS0xNzc0NDY_50095a15-4d77-4d87-8ded-edd7b8c37440"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE2LTEtMS0xNzc0NDY_00320b28-4117-40ba-9719-fa9dddf0ac7e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE2LTEtMS0xNzc0NDY_00320b28-4117-40ba-9719-fa9dddf0ac7e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE4LTEtMS0xNzc0NDY_4eeae3f4-c6c2-4bd3-b9ec-88e7109b6ce4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE4LTEtMS0xNzc0NDY_4eeae3f4-c6c2-4bd3-b9ec-88e7109b6ce4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE4LTEtMS0xNzc0NDY_bfcd77b6-37cf-47da-a023-ed1e44db59f5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE4LTEtMS0xNzc0NDY_bfcd77b6-37cf-47da-a023-ed1e44db59f5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE0LTEtMS0xNzc0NDY_763275c5-6edd-4d3b-af4f-eca2881128a4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE0LTEtMS0xNzc0NDY_763275c5-6edd-4d3b-af4f-eca2881128a4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE0LTEtMS0xNzc0NDY_26e77d3c-7ba5-43c0-9206-33f175077456"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE0LTEtMS0xNzc0NDY_26e77d3c-7ba5-43c0-9206-33f175077456"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE4LTEtMS0xNzc0NDY_6a4bc1bb-7dd3-49d7-8cc0-6412bf9dbb14"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTYtMS0xLTE3NzQ0Ng_c78f2480-6e0a-4812-b437-d0f3b88908f9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE0LTEtMS0xNzc0NDY_55e56b9a-2c34-47c6-b317-0ec27b23f0d5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTQtMS0xLTE3NzQ0Ng_d5714a79-a33f-4049-ad78-b4ab062cf73d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE2LTEtMS0xNzc0NDY_7c74cf89-4939-4846-a03a-8d93ceceec86"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMTgtMS0xLTE3NzQ0Ng_3a0c44fa-4538-4105-b1d4-477ae7b6d295"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE2LTEtMS0xNzc0NDY_50095a15-4d77-4d87-8ded-edd7b8c37440"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE2LTEtMS0xNzc0NDY_00320b28-4117-40ba-9719-fa9dddf0ac7e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE4LTEtMS0xNzc0NDY_4eeae3f4-c6c2-4bd3-b9ec-88e7109b6ce4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTE4LTEtMS0xNzc0NDY_bfcd77b6-37cf-47da-a023-ed1e44db59f5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTE0LTEtMS0xNzc0NDY_763275c5-6edd-4d3b-af4f-eca2881128a4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTE0LTEtMS0xNzc0NDY_26e77d3c-7ba5-43c0-9206-33f175077456"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAy_5a03806a-0b62-4c9c-92d0-7051d828cb60"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTItMS0xLTE1NTYzOA_27302940-e95f-4411-87f2-0004674e6fa8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTItMS0xLTE1NTYzOA_27302940-e95f-4411-87f2-0004674e6fa8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTQtMS0xLTE1NTYzOA_36f289d7-f860-4248-ae43-2a845a2fb3a8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTQtMS0xLTE1NTYzOA_36f289d7-f860-4248-ae43-2a845a2fb3a8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTYtMS0xLTE1NTYzOA_2014424e-8adc-4a3b-9815-9c81bcd3344a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTYtMS0xLTE1NTYzOA_2014424e-8adc-4a3b-9815-9c81bcd3344a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTQtMS0xLTE1NTYzOA_19c6fa4b-dbf0-4efd-8ff8-0b7287c1ac97"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTQtMS0xLTE1NTYzOA_19c6fa4b-dbf0-4efd-8ff8-0b7287c1ac97"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTItMS0xLTE1NTYzOA_10fe7932-e01c-454e-8302-def516f99899"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTItMS0xLTE1NTYzOA_10fe7932-e01c-454e-8302-def516f99899"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTItMS0xLTE1NTYzOA_61571985-418a-446b-bc96-93bdab6232b4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTItMS0xLTE1NTYzOA_61571985-418a-446b-bc96-93bdab6232b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTYtMS0xLTE1NTYzOA_037968a6-be5e-4506-93f4-cb98e0757bd3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTYtMS0xLTE1NTYzOA_037968a6-be5e-4506-93f4-cb98e0757bd3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTYtMS0xLTE1NTYzOA_460a0367-95db-4b42-8410-22d206dd026d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTYtMS0xLTE1NTYzOA_460a0367-95db-4b42-8410-22d206dd026d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTQtMS0xLTE1NTYzOA_06f71829-0412-4c42-b7fe-8a9facdb36c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTQtMS0xLTE1NTYzOA_06f71829-0412-4c42-b7fe-8a9facdb36c2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">The $8.3 billion </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> reflects the receipt of a 32% equity-method investment in the new company initially valued at $15.7 billion in exchange for net assets contributed of $7.6 billion and is presented in operating activities net of $146 million cash conveyed that is reflected in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other investing activities, net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Note 2C.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTItMS0xLTE1NTYzOA_27302940-e95f-4411-87f2-0004674e6fa8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTQtMS0xLTE1NTYzOA_36f289d7-f860-4248-ae43-2a845a2fb3a8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTYtMS0xLTE1NTYzOA_2014424e-8adc-4a3b-9815-9c81bcd3344a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTQtMS0xLTE1NTYzOA_19c6fa4b-dbf0-4efd-8ff8-0b7287c1ac97"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzcwLTItMS0xLTE1NTYzOA_10fe7932-e01c-454e-8302-def516f99899"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTItMS0xLTE1NTYzOA_61571985-418a-446b-bc96-93bdab6232b4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTYtMS0xLTE1NTYzOA_037968a6-be5e-4506-93f4-cb98e0757bd3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzExLTYtMS0xLTE1NTYzOA_460a0367-95db-4b42-8410-22d206dd026d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90YWJsZTpmZWQzYjk3MjZiZDc0ZDIwYmQxMmZkMDYyOGIzOTZjMS90YWJsZXJhbmdlOmZlZDNiOTcyNmJkNzRkMjBiZDEyZmQwNjI4YjM5NmMxXzM3LTQtMS0xLTE1NTYzOA_06f71829-0412-4c42-b7fe-8a9facdb36c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjAvZnJhZzo4YTM4ZjU3YmIyNjQ0NTJlYTdlNGM0MjY2M2VkMWFiMS90ZXh0cmVnaW9uOjhhMzhmNTdiYjI2NDQ1MmVhN2U0YzQyNjYzZWQxYWIxXzM4OQ_2c934576-d93f-4a86-b14a-f09a6faafdbb"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246Y2IyMGJkMzcyODA4NGEwMmJmZTljMDUyMTRiMWZjNmNfMTUzOTMxNjI3ODg4ODA_775c18f7-b166-4b7f-9eb2-d8e4c8d70788"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246Y2IyMGJkMzcyODA4NGEwMmJmZTljMDUyMTRiMWZjNmNfMTUzOTMxNjI3ODg4ODA_775c18f7-b166-4b7f-9eb2-d8e4c8d70788"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktNC0xLTEtMTU1NjM4_c41e5f42-b905-4960-9834-889541822283"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktNC0xLTEtMTU1NjM4_c41e5f42-b905-4960-9834-889541822283"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjk_7317c2e6-d737-4f5f-88f6-e7ca9d4c840d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjk_7317c2e6-d737-4f5f-88f6-e7ca9d4c840d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The notes may be redeemed by us at any time, in whole, or in part, at a redemption price plus accrued and unpaid interest.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktMC0xLTEtMTU1NjM4L3RleHRyZWdpb246Y2IyMGJkMzcyODA4NGEwMmJmZTljMDUyMTRiMWZjNmNfMTUzOTMxNjI3ODg4ODA_775c18f7-b166-4b7f-9eb2-d8e4c8d70788"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjk_7317c2e6-d737-4f5f-88f6-e7ca9d4c840d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTpmOTM4ODdhYzI1MDk0MmIzOGQ5NDM4NWMxNWJlODIyYS90YWJsZXJhbmdlOmY5Mzg4N2FjMjUwOTQyYjM4ZDk0Mzg1YzE1YmU4MjJhXzktNC0xLTEtMTU1NjM4_c41e5f42-b905-4960-9834-889541822283"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjk_7317c2e6-d737-4f5f-88f6-e7ca9d4c840d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNC0xLTEtMTU1NjM4_a6ee1f90-c8ba-493a-8df1-90679ee7be35"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNC0xLTEtMTU1NjM4_a6ee1f90-c8ba-493a-8df1-90679ee7be35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNi0xLTEtMTU1NjM4_430e3341-aa36-4836-80f2-03307cb6e72a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNi0xLTEtMTU1NjM4_430e3341-aa36-4836-80f2-03307cb6e72a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctMi0xLTEtMTU1NjM4_b93c897e-d113-4fca-af85-ca8fdbfac426"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctMi0xLTEtMTU1NjM4_b93c897e-d113-4fca-af85-ca8fdbfac426"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDY3_1b44c33c-7fa4-431f-b8a2-bc19239b1199" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDY3_1b44c33c-7fa4-431f-b8a2-bc19239b1199" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily related to cash payments and reductions of tax attributes.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNC0xLTEtMTU1NjM4_a6ee1f90-c8ba-493a-8df1-90679ee7be35"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDY3_1b44c33c-7fa4-431f-b8a2-bc19239b1199"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctNi0xLTEtMTU1NjM4_430e3341-aa36-4836-80f2-03307cb6e72a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDY3_1b44c33c-7fa4-431f-b8a2-bc19239b1199"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzctMi0xLTEtMTU1NjM4_b93c897e-d113-4fca-af85-ca8fdbfac426"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDY3_1b44c33c-7fa4-431f-b8a2-bc19239b1199"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNi0xLTEtMTU1NjM4_48aa033e-20be-49e8-8390-4b9e5a393d82"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNi0xLTEtMTU1NjM4_48aa033e-20be-49e8-8390-4b9e5a393d82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctOC0xLTEtMTU1NjM4_7480d3a8-bcd9-4499-9bb2-09960d855b59"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctOC0xLTEtMTU1NjM4_7480d3a8-bcd9-4499-9bb2-09960d855b59"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtOC0xLTEtMTU1NjM4_aa6a1288-623f-45a0-aa24-c0b1f7307d3a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtOC0xLTEtMTU1NjM4_aa6a1288-623f-45a0-aa24-c0b1f7307d3a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtMi0xLTEtMTU1NjM4_37eb2fce-9891-4368-9c58-5e41f032a21d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtMi0xLTEtMTU1NjM4_37eb2fce-9891-4368-9c58-5e41f032a21d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNC0xLTEtMTU1NjM4_256f11b6-83b4-4563-84bd-ca2eb2bc8d16"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNC0xLTEtMTU1NjM4_256f11b6-83b4-4563-84bd-ca2eb2bc8d16"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNi0xLTEtMTU1NjM4_4072a90f-f140-48e6-8f8d-0cfc44b9f2ef"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNi0xLTEtMTU1NjM4_4072a90f-f140-48e6-8f8d-0cfc44b9f2ef"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNC0xLTEtMTU1NjM4_2e4c1c81-5d34-4e61-8316-477276aa7c19"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNC0xLTEtMTU1NjM4_2e4c1c81-5d34-4e61-8316-477276aa7c19"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctMi0xLTEtMTU1NjM4_594ea094-3524-4937-806c-5adc4fdae564"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctMi0xLTEtMTU1NjM4_594ea094-3524-4937-806c-5adc4fdae564"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes adjustments for foreign currency translation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNi0xLTEtMTU1NjM4_48aa033e-20be-49e8-8390-4b9e5a393d82"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctOC0xLTEtMTU1NjM4_7480d3a8-bcd9-4499-9bb2-09960d855b59"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtOC0xLTEtMTU1NjM4_aa6a1288-623f-45a0-aa24-c0b1f7307d3a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtMi0xLTEtMTU1NjM4_37eb2fce-9891-4368-9c58-5e41f032a21d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNC0xLTEtMTU1NjM4_256f11b6-83b4-4563-84bd-ca2eb2bc8d16"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctNi0xLTEtMTU1NjM4_4072a90f-f140-48e6-8f8d-0cfc44b9f2ef"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzQtNC0xLTEtMTU1NjM4_2e4c1c81-5d34-4e61-8316-477276aa7c19"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzctMi0xLTEtMTU1NjM4_594ea094-3524-4937-806c-5adc4fdae564"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI1_e4faf65e-2b72-4952-9768-2bd241c2a67d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNC0xLTEtMTU1NjM4_704706b6-4bd6-4188-ab0c-928c0e14cea6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNC0xLTEtMTU1NjM4_704706b6-4bd6-4188-ab0c-928c0e14cea6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtMi0xLTEtMTc3Nzcz_1412e961-c1d0-4724-998b-2b5f26860881"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtMi0xLTEtMTc3Nzcz_1412e961-c1d0-4724-998b-2b5f26860881"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtNC0xLTEtMTU1NjM4_704706b6-4bd6-4188-ab0c-928c0e14cea6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzMtMi0xLTEtMTc3Nzcz_1412e961-c1d0-4724-998b-2b5f26860881"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzkwOQ_020e6b79-1fa6-4c18-9e6b-9a12e05303f7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTIwMTgxNg_bb899a3f-9057-4c42-b88a-a0484d40b99a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTIwMTgxNg_bb899a3f-9057-4c42-b88a-a0484d40b99a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNi0xLTEtMTU1NjM4_74eecd18-698c-4b18-bed9-423ee0f2b18f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNi0xLTEtMTU1NjM4_74eecd18-698c-4b18-bed9-423ee0f2b18f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtOC0xLTEtMTU1NjM4_771a964a-8c6d-4951-9757-362ce504769c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtOC0xLTEtMTU1NjM4_771a964a-8c6d-4951-9757-362ce504769c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTgtMS0xLTE1NTYzOA_1f9cb0cd-0fa5-4116-b603-cb6776f180dc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTgtMS0xLTE1NTYzOA_1f9cb0cd-0fa5-4116-b603-cb6776f180dc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTE1NTYzOA_b8c5bf77-08f1-454f-8409-0583dba8d4d9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTE1NTYzOA_b8c5bf77-08f1-454f-8409-0583dba8d4d9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTQtMS0xLTIwMTgyNA_79efd58c-9573-475f-92b1-25eb9339724b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTQtMS0xLTIwMTgyNA_79efd58c-9573-475f-92b1-25eb9339724b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTYtMS0xLTE1NTYzOA_8f186694-3022-48ef-a96b-b90b416e0172"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTYtMS0xLTE1NTYzOA_8f186694-3022-48ef-a96b-b90b416e0172"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtOC0xLTEtMTU1NjM4_55c6aa5f-d0e6-4069-a4cc-b50d9f74cfe7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtOC0xLTEtMTU1NjM4_55c6aa5f-d0e6-4069-a4cc-b50d9f74cfe7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTYtMS0xLTIwMTgxOA_07f27bea-6a9c-40c6-a2d6-ea80214973a8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTYtMS0xLTIwMTgxOA_07f27bea-6a9c-40c6-a2d6-ea80214973a8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtOC0xLTEtMTU1NjM4_3bdde6d7-1ca3-471f-837a-552086df7002"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtOC0xLTEtMTU1NjM4_3bdde6d7-1ca3-471f-837a-552086df7002"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTgtMS0xLTE1NTYzOA_b2209aa3-59c1-4278-bffe-dbda51926033"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTgtMS0xLTE1NTYzOA_b2209aa3-59c1-4278-bffe-dbda51926033"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNC0xLTEtMTU1NjM4_f5357124-e200-4036-888f-25abdac4d3e3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNC0xLTEtMTU1NjM4_f5357124-e200-4036-888f-25abdac4d3e3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNi0xLTEtMTU1NjM4_152f7f45-ad94-4198-8e30-d82dea1a7243"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNi0xLTEtMTU1NjM4_152f7f45-ad94-4198-8e30-d82dea1a7243"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTgtMS0xLTIwMTgxOA_9afe2f6a-295d-4a12-9d6c-1feeef937d00"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTgtMS0xLTIwMTgxOA_9afe2f6a-295d-4a12-9d6c-1feeef937d00"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTE1NTYzOA_173beaaa-761b-48ed-9f25-caabbf15d941"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTE1NTYzOA_173beaaa-761b-48ed-9f25-caabbf15d941"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTgtMS0xLTE1NTYzOA_8a0c1ae2-b59a-4ab8-a792-11ae10dc864c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTgtMS0xLTE1NTYzOA_8a0c1ae2-b59a-4ab8-a792-11ae10dc864c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTgtMS0xLTIwMTgyNA_d6f5724b-f6f8-41ea-863c-9951d0e46489"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTgtMS0xLTIwMTgyNA_d6f5724b-f6f8-41ea-863c-9951d0e46489"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTIwMTgxNg_4d3d9288-bb84-4f45-bb13-a4f8ec4ec044"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTIwMTgxNg_4d3d9288-bb84-4f45-bb13-a4f8ec4ec044"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNi0xLTEtMTU1NjM4_674641be-b310-442e-9649-04d23ac403da"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNi0xLTEtMTU1NjM4_674641be-b310-442e-9649-04d23ac403da"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTE1NTYzOA_d4777b69-bca4-4da9-8bee-c95607807af1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTE1NTYzOA_d4777b69-bca4-4da9-8bee-c95607807af1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNi0xLTEtMTU1NjM4_5f400010-0c6d-4c36-8261-5a6d490d4a94"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNi0xLTEtMTU1NjM4_5f400010-0c6d-4c36-8261-5a6d490d4a94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTQtMS0xLTE1NTYzOA_a7b0aba4-6383-4a13-b9e3-48c7a459c533"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTQtMS0xLTE1NTYzOA_a7b0aba4-6383-4a13-b9e3-48c7a459c533"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNi0xLTEtMTU1NjM4_5cf15bee-1f6f-4f92-96c0-441dcdc3b93d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNi0xLTEtMTU1NjM4_5cf15bee-1f6f-4f92-96c0-441dcdc3b93d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNi0xLTEtMTU1NjM4_9d188531-33a5-407c-acf6-cd88c74e75be"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNi0xLTEtMTU1NjM4_9d188531-33a5-407c-acf6-cd88c74e75be"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNC0xLTEtMTU1NjM4_12370406-3121-4fd4-9452-791c6fa14d56"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNC0xLTEtMTU1NjM4_12370406-3121-4fd4-9452-791c6fa14d56"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTQtMS0xLTIwMTgyNg_02fe2472-92fb-4536-8323-8b8e4f134181"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTQtMS0xLTIwMTgyNg_02fe2472-92fb-4536-8323-8b8e4f134181"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTYtMS0xLTIwMTgyNg_485a912c-0f9e-4947-8e28-5ea90d0b44d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTYtMS0xLTIwMTgyNg_485a912c-0f9e-4947-8e28-5ea90d0b44d3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTYtMS0xLTE1NTYzOA_792dcf23-7855-4ba8-be67-f2f2b8a93e38"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTYtMS0xLTE1NTYzOA_792dcf23-7855-4ba8-be67-f2f2b8a93e38"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTQtMS0xLTE1NTYzOA_ad3a56fe-b25c-47fa-883e-2628687e528e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTQtMS0xLTE1NTYzOA_ad3a56fe-b25c-47fa-883e-2628687e528e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTQtMS0xLTIwMTgxOA_5a215c3a-de6d-4316-a287-c5044c461f1d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTQtMS0xLTIwMTgxOA_5a215c3a-de6d-4316-a287-c5044c461f1d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTYtMS0xLTE1NTYzOA_21f1e072-7210-4f67-920f-95f886cd5e7f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTYtMS0xLTE1NTYzOA_21f1e072-7210-4f67-920f-95f886cd5e7f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNC0xLTEtMTU1NjM4_f37f9bc2-c292-4db8-be47-b29936878c30"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNC0xLTEtMTU1NjM4_f37f9bc2-c292-4db8-be47-b29936878c30"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTYtMS0xLTIwMTgyNA_26d4a734-0b52-4e5d-81b1-025ded81faa6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTYtMS0xLTIwMTgyNA_26d4a734-0b52-4e5d-81b1-025ded81faa6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTgtMS0xLTIwMTgyNg_6bd6df99-dd55-4fbf-baa8-aa34cf0a89fc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTgtMS0xLTIwMTgyNg_6bd6df99-dd55-4fbf-baa8-aa34cf0a89fc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktOC0xLTEtMTU1NjM4_19067ebf-2420-4493-9559-b40f806bb59c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktOC0xLTEtMTU1NjM4_19067ebf-2420-4493-9559-b40f806bb59c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTIwMTgxNg_245ea242-174d-4d97-8181-86a8c6c5246d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTIwMTgxNg_245ea242-174d-4d97-8181-86a8c6c5246d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNC0xLTEtMTU1NjM4_1ea56822-d50c-454c-ac25-324f18d696a2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNC0xLTEtMTU1NjM4_1ea56822-d50c-454c-ac25-324f18d696a2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtOC0xLTEtMTU1NjM4_c8a95008-1738-44b6-8266-dfaf053446f7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtOC0xLTEtMTU1NjM4_c8a95008-1738-44b6-8266-dfaf053446f7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNC0xLTEtMTU1NjM4_a6c1e828-1373-4fbc-98bb-0c166c24987f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNC0xLTEtMTU1NjM4_a6c1e828-1373-4fbc-98bb-0c166c24987f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctOC0xLTEtMTU1NjM4_831490eb-418d-4b0f-8395-f8cd4a584883"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctOC0xLTEtMTU1NjM4_831490eb-418d-4b0f-8395-f8cd4a584883"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTQtMS0xLTE1NTYzOA_e223faad-d99d-4053-b5f6-cf210bcfee95"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTQtMS0xLTE1NTYzOA_e223faad-d99d-4053-b5f6-cf210bcfee95"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNC0xLTEtMTU1NjM4_0c5983f5-742e-4c31-9456-0a86eb67f31b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNC0xLTEtMTU1NjM4_0c5983f5-742e-4c31-9456-0a86eb67f31b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">In 2021, </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#x2014;net of tax</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> primarily includes (i) the operations of Meridian prior to its sale on December 31, 2021 recognized in Income/(loss) from discontinued operations&#x2014;net of tax, which includes a pre-tax amount for a Multi-District Litigation relating to EpiPen against the Company in the U.S. District Court for the District of Kansas for $345&#160;million; and (ii) the after tax loss of $167&#160;million related to the sale of Meridian recognized in Loss on sale of discontinued operations&#x2013;&#x2013;net of tax. To a much lesser extent, </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#x2014;net of tax </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021 also includes the operations of the Mylan-Japan collaboration prior to its termination on December 21, 2020 and post-closing adjustments directly related to our former Upjohn and Nutrition discontinued businesses, including adjustments for tax, benefits and legal-related matters recognized in Income/(loss) from discontinued operations&#x2014;net of tax. In 2020 and 2019, </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#x2014;net of tax </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">relates to the operations of the Upjohn Business, Meridian and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2020, </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Discontinued operations&#x2014;net of tax </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">includes pre-tax interest expense of $116 million associated with the U.S. dollar and Euro denominated senior unsecured notes issued by Upjohn Inc. and Upjohn Finance B.V. in the second quarter of 2020 and pre-tax charges of $223 million related to the remeasurement of Euro debt issued by Upjohn Finance B.V. in the second quarter of 2020.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTIwMTgxNg_bb899a3f-9057-4c42-b88a-a0484d40b99a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNi0xLTEtMTU1NjM4_74eecd18-698c-4b18-bed9-423ee0f2b18f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtOC0xLTEtMTU1NjM4_771a964a-8c6d-4951-9757-362ce504769c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTgtMS0xLTE1NTYzOA_1f9cb0cd-0fa5-4116-b603-cb6776f180dc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTE1NTYzOA_b8c5bf77-08f1-454f-8409-0583dba8d4d9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTQtMS0xLTIwMTgyNA_79efd58c-9573-475f-92b1-25eb9339724b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTYtMS0xLTE1NTYzOA_8f186694-3022-48ef-a96b-b90b416e0172"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtOC0xLTEtMTU1NjM4_55c6aa5f-d0e6-4069-a4cc-b50d9f74cfe7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTYtMS0xLTIwMTgxOA_07f27bea-6a9c-40c6-a2d6-ea80214973a8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtOC0xLTEtMTU1NjM4_3bdde6d7-1ca3-471f-837a-552086df7002"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTgtMS0xLTE1NTYzOA_b2209aa3-59c1-4278-bffe-dbda51926033"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNC0xLTEtMTU1NjM4_f5357124-e200-4036-888f-25abdac4d3e3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNi0xLTEtMTU1NjM4_152f7f45-ad94-4198-8e30-d82dea1a7243"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTgtMS0xLTIwMTgxOA_9afe2f6a-295d-4a12-9d6c-1feeef937d00"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTE1NTYzOA_173beaaa-761b-48ed-9f25-caabbf15d941"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTgtMS0xLTE1NTYzOA_8a0c1ae2-b59a-4ab8-a792-11ae10dc864c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTgtMS0xLTIwMTgyNA_d6f5724b-f6f8-41ea-863c-9951d0e46489"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTYtMS0xLTIwMTgxNg_4d3d9288-bb84-4f45-bb13-a4f8ec4ec044"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNi0xLTEtMTU1NjM4_674641be-b310-442e-9649-04d23ac403da"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTQtMS0xLTE1NTYzOA_d4777b69-bca4-4da9-8bee-c95607807af1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtNi0xLTEtMTU1NjM4_5f400010-0c6d-4c36-8261-5a6d490d4a94"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTQtMS0xLTE1NTYzOA_a7b0aba4-6383-4a13-b9e3-48c7a459c533"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNi0xLTEtMTU1NjM4_5cf15bee-1f6f-4f92-96c0-441dcdc3b93d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNi0xLTEtMTU1NjM4_9d188531-33a5-407c-acf6-cd88c74e75be"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzMtNC0xLTEtMTU1NjM4_12370406-3121-4fd4-9452-791c6fa14d56"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTQtMS0xLTIwMTgyNg_02fe2472-92fb-4536-8323-8b8e4f134181"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTYtMS0xLTIwMTgyNg_485a912c-0f9e-4947-8e28-5ea90d0b44d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEwLTYtMS0xLTE1NTYzOA_792dcf23-7855-4ba8-be67-f2f2b8a93e38"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzExLTQtMS0xLTE1NTYzOA_ad3a56fe-b25c-47fa-883e-2628687e528e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE4LTQtMS0xLTIwMTgxOA_5a215c3a-de6d-4316-a287-c5044c461f1d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTYtMS0xLTE1NTYzOA_21f1e072-7210-4f67-920f-95f886cd5e7f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktNC0xLTEtMTU1NjM4_f37f9bc2-c292-4db8-be47-b29936878c30"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE5LTYtMS0xLTIwMTgyNA_26d4a734-0b52-4e5d-81b1-025ded81faa6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzIwLTgtMS0xLTIwMTgyNg_6bd6df99-dd55-4fbf-baa8-aa34cf0a89fc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzktOC0xLTEtMTU1NjM4_19067ebf-2420-4493-9559-b40f806bb59c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzE3LTgtMS0xLTIwMTgxNg_245ea242-174d-4d97-8181-86a8c6c5246d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzUtNC0xLTEtMTU1NjM4_1ea56822-d50c-454c-ac25-324f18d696a2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzYtOC0xLTEtMTU1NjM4_c8a95008-1738-44b6-8266-dfaf053446f7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctNC0xLTEtMTU1NjM4_a6c1e828-1373-4fbc-98bb-0c166c24987f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzctOC0xLTEtMTU1NjM4_831490eb-418d-4b0f-8395-f8cd4a584883"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzEyLTQtMS0xLTE1NTYzOA_e223faad-d99d-4053-b5f6-cf210bcfee95"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTpkYzg3YzAwY2I3ZDU0OTYyYTI0ZTVkNWVlYmNkMmRlNS90YWJsZXJhbmdlOmRjODdjMDBjYjdkNTQ5NjJhMjRlNWQ1ZWViY2QyZGU1XzgtNC0xLTEtMTU1NjM4_0c5983f5-742e-4c31-9456-0a86eb67f31b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY2_5a15cde7-6f38-4bb0-aab8-aa9853766742"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtMi0xLTEtMTU1NjM4_54059ecd-aa69-44bb-b887-d96f99d57bae"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtMi0xLTEtMTU1NjM4_54059ecd-aa69-44bb-b887-d96f99d57bae"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtNC0xLTEtMTU1NjM4_762c2983-3a02-42e0-8d59-df56b7f5c031"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtNC0xLTEtMTU1NjM4_762c2983-3a02-42e0-8d59-df56b7f5c031"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU1NQ_8fe7f8af-5095-4cd6-9f9d-0efa59c2547b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU1NQ_8fe7f8af-5095-4cd6-9f9d-0efa59c2547b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The change from December 31, 2020 reflects increases for certain products, including inventory build for new product launches (primarily Comirnaty), network strategy and supply recovery, partially offset by decreases due to market demand.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtMi0xLTEtMTU1NjM4_54059ecd-aa69-44bb-b887-d96f99d57bae"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU1NQ_8fe7f8af-5095-4cd6-9f9d-0efa59c2547b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90YWJsZTo1MTcwNzIzYzlhNWQ0ODNjOWQ0ZDRjZjI3NDBjMTNiZS90YWJsZXJhbmdlOjUxNzA3MjNjOWE1ZDQ4M2M5ZDRkNGNmMjc0MGMxM2JlXzYtNC0xLTEtMTU1NjM4_762c2983-3a02-42e0-8d59-df56b7f5c031"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDIvZnJhZzo2MGM2OWUyYWU1NWY0ODUwYjA1Y2FkZTAxMzNiZGY1MS90ZXh0cmVnaW9uOjYwYzY5ZTJhZTU1ZjQ4NTBiMDVjYWRlMDEzM2JkZjUxXzU1NQ_8fe7f8af-5095-4cd6-9f9d-0efa59c2547b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtNi0xLTEtMTU1NjM4_e39da51d-aeec-4e8d-a1e7-561787656116"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtNi0xLTEtMTU1NjM4_e39da51d-aeec-4e8d-a1e7-561787656116"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtOC0xLTEtMTU1NjM4_eb84dd73-f48f-4386-91cc-70803e7c166b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtOC0xLTEtMTU1NjM4_eb84dd73-f48f-4386-91cc-70803e7c166b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtMTAtMS0xLTE1NTYzOA_69cb70ec-f0d5-43fd-a42b-cdb0a66d8fd3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtMTAtMS0xLTE1NTYzOA_69cb70ec-f0d5-43fd-a42b-cdb0a66d8fd3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzUw_1275eb2f-488b-4d6e-b5cf-9069ca46c946" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzUw_1275eb2f-488b-4d6e-b5cf-9069ca46c946" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtNi0xLTEtMTU1NjM4_e39da51d-aeec-4e8d-a1e7-561787656116"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzUw_1275eb2f-488b-4d6e-b5cf-9069ca46c946"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtOC0xLTEtMTU1NjM4_eb84dd73-f48f-4386-91cc-70803e7c166b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzUw_1275eb2f-488b-4d6e-b5cf-9069ca46c946"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo4NzI5MThhYjhlODE0OWY0YmUwZWFkYzMxZjRiNmEzNy90YWJsZXJhbmdlOjg3MjkxOGFiOGU4MTQ5ZjRiZTBlYWRjMzFmNGI2YTM3XzMtMTAtMS0xLTE1NTYzOA_69cb70ec-f0d5-43fd-a42b-cdb0a66d8fd3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3MzUw_1275eb2f-488b-4d6e-b5cf-9069ca46c946"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTItMS0xLTE1NTYzOA_d1ade32c-1b05-4905-aa93-36e64fc6a13b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTItMS0xLTE1NTYzOA_d1ade32c-1b05-4905-aa93-36e64fc6a13b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTQtMS0xLTE1NTYzOA_0211c1c4-f749-4f17-adca-203d6d94039d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTQtMS0xLTE1NTYzOA_0211c1c4-f749-4f17-adca-203d6d94039d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTItMS0xLTE1NTYzOA_19a2a01e-f627-4122-9470-6414cdd9c8c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTItMS0xLTE1NTYzOA_19a2a01e-f627-4122-9470-6414cdd9c8c2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktNC0xLTEtMTU1NjM4_b271c359-33bf-4a28-9b00-fa0f9401e3ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktNC0xLTEtMTU1NjM4_b271c359-33bf-4a28-9b00-fa0f9401e3ab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTgtMS0xLTE1NTYzOA_6e799da1-2a95-45a6-b1fb-6b0cdd11fcd7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTgtMS0xLTE1NTYzOA_6e799da1-2a95-45a6-b1fb-6b0cdd11fcd7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTQtMS0xLTE1NTYzOA_28d7ee0d-cb9f-4b69-8080-ff9068ce947e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTQtMS0xLTE1NTYzOA_28d7ee0d-cb9f-4b69-8080-ff9068ce947e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTYtMS0xLTE1NTYzOA_7c714191-b0a7-4358-88cb-92054d43fc7f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTYtMS0xLTE1NTYzOA_7c714191-b0a7-4358-88cb-92054d43fc7f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEyLTEtMS0xNTU2Mzg_5564e357-a498-4e15-bcdf-ee4d239a8744"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEyLTEtMS0xNTU2Mzg_5564e357-a498-4e15-bcdf-ee4d239a8744"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTgtMS0xLTE1NTYzOA_3651a24b-22e2-46d0-868b-1ae4481d2de0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTgtMS0xLTE1NTYzOA_3651a24b-22e2-46d0-868b-1ae4481d2de0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTItMS0xLTE1NTYzOA_28876c1f-28e3-452b-93e2-c007e4934d1f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTItMS0xLTE1NTYzOA_28876c1f-28e3-452b-93e2-c007e4934d1f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTYtMS0xLTE1NTYzOA_c68c8ee5-011e-4dc7-86e5-aad7661b831f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTYtMS0xLTE1NTYzOA_c68c8ee5-011e-4dc7-86e5-aad7661b831f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTEwLTEtMS0xNTU2Mzg_b9cf7014-7622-4266-bc4f-c827c6e37cb2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTEwLTEtMS0xNTU2Mzg_b9cf7014-7622-4266-bc4f-c827c6e37cb2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTYtMS0xLTE1NTYzOA_4faca393-6869-4ebe-8b22-d8cb925c1d64"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTYtMS0xLTE1NTYzOA_4faca393-6869-4ebe-8b22-d8cb925c1d64"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTEwLTEtMS0xNTU2Mzg_e1c3d9bb-c8bb-401f-85f1-4325c3b51baa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTEwLTEtMS0xNTU2Mzg_e1c3d9bb-c8bb-401f-85f1-4325c3b51baa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTgtMS0xLTE1NTYzOA_ecbe1641-b29d-48d0-9ddf-cbd51d19a42b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTgtMS0xLTE1NTYzOA_ecbe1641-b29d-48d0-9ddf-cbd51d19a42b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktMi0xLTEtMTU1NjM4_405037fa-97c4-4b99-97b5-1572a2575232"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktMi0xLTEtMTU1NjM4_405037fa-97c4-4b99-97b5-1572a2575232"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTQtMS0xLTE1NTYzOA_aa828aee-7b1e-4248-910d-fe1d51c6c6af"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTQtMS0xLTE1NTYzOA_aa828aee-7b1e-4248-910d-fe1d51c6c6af"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEwLTEtMS0xNTU2Mzg_1935d6fe-b15b-4323-8d03-7cb189a21e32"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEwLTEtMS0xNTU2Mzg_1935d6fe-b15b-4323-8d03-7cb189a21e32"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM5NDY_756947b2-ff01-4e85-9822-5130790587b6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM5NDY_756947b2-ff01-4e85-9822-5130790587b6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTItMS0xLTE1NTYzOA_d1ade32c-1b05-4905-aa93-36e64fc6a13b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTQtMS0xLTE1NTYzOA_0211c1c4-f749-4f17-adca-203d6d94039d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTItMS0xLTE1NTYzOA_19a2a01e-f627-4122-9470-6414cdd9c8c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktNC0xLTEtMTU1NjM4_b271c359-33bf-4a28-9b00-fa0f9401e3ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTgtMS0xLTE1NTYzOA_6e799da1-2a95-45a6-b1fb-6b0cdd11fcd7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzIzLTQtMS0xLTE1NTYzOA_28d7ee0d-cb9f-4b69-8080-ff9068ce947e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTYtMS0xLTE1NTYzOA_7c714191-b0a7-4358-88cb-92054d43fc7f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEyLTEtMS0xNTU2Mzg_5564e357-a498-4e15-bcdf-ee4d239a8744"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTgtMS0xLTE1NTYzOA_3651a24b-22e2-46d0-868b-1ae4481d2de0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTItMS0xLTE1NTYzOA_28876c1f-28e3-452b-93e2-c007e4934d1f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTYtMS0xLTE1NTYzOA_c68c8ee5-011e-4dc7-86e5-aad7661b831f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE1LTEwLTEtMS0xNTU2Mzg_b9cf7014-7622-4266-bc4f-c827c6e37cb2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTYtMS0xLTE1NTYzOA_4faca393-6869-4ebe-8b22-d8cb925c1d64"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTEwLTEtMS0xNTU2Mzg_e1c3d9bb-c8bb-401f-85f1-4325c3b51baa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzE5LTgtMS0xLTE1NTYzOA_ecbe1641-b29d-48d0-9ddf-cbd51d19a42b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzktMi0xLTEtMTU1NjM4_405037fa-97c4-4b99-97b5-1572a2575232"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzEwLTQtMS0xLTE1NTYzOA_aa828aee-7b1e-4248-910d-fe1d51c6c6af"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTo1MmQ1YmVhNzE5MDQ0ZDU0ODdlMTY1MmZkZGY4MmQ1ZC90YWJsZXJhbmdlOjUyZDViZWE3MTkwNDRkNTQ4N2UxNjUyZmRkZjgyZDVkXzI1LTEwLTEtMS0xNTU2Mzg_1935d6fe-b15b-4323-8d03-7cb189a21e32"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzM5NDY_756947b2-ff01-4e85-9822-5130790587b6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MTQ_424a2b23-4b85-4797-a470-bf1567220185"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEwLTEtMS0xNTU2Mzg_072775e8-2b98-4b98-8a60-50ca224f222b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEwLTEtMS0xNTU2Mzg_072775e8-2b98-4b98-8a60-50ca224f222b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEyLTEtMS0xNTU2Mzg_047edc6c-e2d8-4c5f-bb4c-a50070519254"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEyLTEtMS0xNTU2Mzg_047edc6c-e2d8-4c5f-bb4c-a50070519254"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTItMS0xLTE1NTYzOA_5fd2c1e6-9de7-40c1-ae80-d3392b8c0703"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTItMS0xLTE1NTYzOA_5fd2c1e6-9de7-40c1-ae80-d3392b8c0703"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTYtMS0xLTE1NTYzOA_65c2fd73-d37f-4010-8461-ed242702667b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTYtMS0xLTE1NTYzOA_65c2fd73-d37f-4010-8461-ed242702667b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTE0LTEtMS0xNTU2Mzg_c9cf5bc8-d558-48e8-89d0-a7d284348289"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTE0LTEtMS0xNTU2Mzg_c9cf5bc8-d558-48e8-89d0-a7d284348289"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTQtMS0xLTE1NTYzOA_37ea546b-438a-45e2-8bf8-c5daef1deea9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTQtMS0xLTE1NTYzOA_37ea546b-438a-45e2-8bf8-c5daef1deea9"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Long-term equity securities of $194 million as of December 31, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for U.S. non-qualified employee benefit plans.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEwLTEtMS0xNTU2Mzg_072775e8-2b98-4b98-8a60-50ca224f222b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTEyLTEtMS0xNTU2Mzg_047edc6c-e2d8-4c5f-bb4c-a50070519254"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTItMS0xLTE1NTYzOA_5fd2c1e6-9de7-40c1-ae80-d3392b8c0703"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTYtMS0xLTE1NTYzOA_65c2fd73-d37f-4010-8461-ed242702667b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTE0LTEtMS0xNTU2Mzg_c9cf5bc8-d558-48e8-89d0-a7d284348289"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzE5LTQtMS0xLTE1NTYzOA_37ea546b-438a-45e2-8bf8-c5daef1deea9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDA_2cc23729-8077-4e98-8c0f-0cf6fad94d41"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNC0xLTEtMTU1NjM4_265b3940-4872-4dde-a89e-85ff8265bd36"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNC0xLTEtMTU1NjM4_265b3940-4872-4dde-a89e-85ff8265bd36"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNi0xLTEtMTU1NjM4_f03523c1-3500-433c-a25c-7a51aa58bc66"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNi0xLTEtMTU1NjM4_f03523c1-3500-433c-a25c-7a51aa58bc66"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctMi0xLTEtMTU1NjM4_4a4349dc-9933-450e-a8f0-cd01ed05abc3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctMi0xLTEtMTU1NjM4_4a4349dc-9933-450e-a8f0-cd01ed05abc3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDYw_9c5cb05a-2ebe-49e7-baaa-1924b1949864" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDYw_9c5cb05a-2ebe-49e7-baaa-1924b1949864" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNC0xLTEtMTU1NjM4_265b3940-4872-4dde-a89e-85ff8265bd36"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDYw_9c5cb05a-2ebe-49e7-baaa-1924b1949864"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctNi0xLTEtMTU1NjM4_f03523c1-3500-433c-a25c-7a51aa58bc66"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDYw_9c5cb05a-2ebe-49e7-baaa-1924b1949864"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzctMi0xLTEtMTU1NjM4_4a4349dc-9933-450e-a8f0-cd01ed05abc3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDYw_9c5cb05a-2ebe-49e7-baaa-1924b1949864"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEyLTEtMS0xNTU2Mzg_fa9adc0d-8d18-4bf5-b697-f1f1be9f4967"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEyLTEtMS0xNTU2Mzg_fa9adc0d-8d18-4bf5-b697-f1f1be9f4967"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTI0LTEtMS0xNTU2Mzg_31952f84-68a5-48a4-a73b-e4df2294aaff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTI0LTEtMS0xNTU2Mzg_31952f84-68a5-48a4-a73b-e4df2294aaff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTQtMS0xLTE1NTYzOA_a7fee7c6-d026-4ef8-b904-5d6d5e67d18a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTQtMS0xLTE1NTYzOA_a7fee7c6-d026-4ef8-b904-5d6d5e67d18a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTIwLTEtMS0xNTU2Mzg_c1666a68-f1a5-4f68-bec4-836e47f2d352"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTIwLTEtMS0xNTU2Mzg_c1666a68-f1a5-4f68-bec4-836e47f2d352"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEwLTEtMS0xNTU2Mzg_5dad725e-549b-4223-aac9-3f2d9059f3a0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEwLTEtMS0xNTU2Mzg_5dad725e-549b-4223-aac9-3f2d9059f3a0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTItMS0xLTE1NTYzOA_dba37449-e851-4f87-b74b-3133af112ca0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTItMS0xLTE1NTYzOA_dba37449-e851-4f87-b74b-3133af112ca0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTE0LTEtMS0xNTU2Mzg_b372f346-0ed7-48aa-8a70-f15d24733d34"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTE0LTEtMS0xNTU2Mzg_b372f346-0ed7-48aa-8a70-f15d24733d34"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 12</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEyLTEtMS0xNTU2Mzg_fa9adc0d-8d18-4bf5-b697-f1f1be9f4967"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTI0LTEtMS0xNTU2Mzg_31952f84-68a5-48a4-a73b-e4df2294aaff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTQtMS0xLTE1NTYzOA_a7fee7c6-d026-4ef8-b904-5d6d5e67d18a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTIwLTEtMS0xNTU2Mzg_c1666a68-f1a5-4f68-bec4-836e47f2d352"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTEwLTEtMS0xNTU2Mzg_5dad725e-549b-4223-aac9-3f2d9059f3a0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTItMS0xLTE1NTYzOA_dba37449-e851-4f87-b74b-3133af112ca0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzIzLTE0LTEtMS0xNTU2Mzg_b372f346-0ed7-48aa-8a70-f15d24733d34"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzQzOTgwNDY1MTI4NTk_6c6b7489-2495-4f26-9c47-1ce097ffa87b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNi0xLTEtMTU1NjM4_5e3e9775-1f4c-4a1a-81a9-ac9d3fc427d8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNi0xLTEtMTU1NjM4_5e3e9775-1f4c-4a1a-81a9-ac9d3fc427d8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNC0xLTEtMTU1NjM4_4735257f-9e5d-4241-a813-229562d69690"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNC0xLTEtMTU1NjM4_4735257f-9e5d-4241-a813-229562d69690"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtMi0xLTEtMTU1NjM4_f570d567-250b-4be3-a646-a17475e0f375"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtMi0xLTEtMTU1NjM4_f570d567-250b-4be3-a646-a17475e0f375"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE2_c92105d3-98d3-434a-b36a-0127835a98d8" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE2_c92105d3-98d3-434a-b36a-0127835a98d8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales for inventory purchased from our partners. The increase in 2021 is primarily related to Comirnaty.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNi0xLTEtMTU1NjM4_5e3e9775-1f4c-4a1a-81a9-ac9d3fc427d8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE2_c92105d3-98d3-434a-b36a-0127835a98d8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtNC0xLTEtMTU1NjM4_4735257f-9e5d-4241-a813-229562d69690"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE2_c92105d3-98d3-434a-b36a-0127835a98d8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzYtMi0xLTEtMTU1NjM4_f570d567-250b-4be3-a646-a17475e0f375"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMTE2_c92105d3-98d3-434a-b36a-0127835a98d8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxODk5_277205d7-51d1-41dc-9ba5-25bbc37331e1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxODk5_277205d7-51d1-41dc-9ba5-25bbc37331e1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxODk5_616bc566-ed61-48d2-a689-843292929258"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxODk5_616bc566-ed61-48d2-a689-843292929258"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxODk5_017fe27d-e80f-421b-8f33-cf6e30a994cf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxODk5_017fe27d-e80f-421b-8f33-cf6e30a994cf"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzE_c89bfeea-0241-4819-96f1-38baefbea46b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzE_c89bfeea-0241-4819-96f1-38baefbea46b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult). </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNi0xLTEtMTYxODk5_277205d7-51d1-41dc-9ba5-25bbc37331e1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzE_c89bfeea-0241-4819-96f1-38baefbea46b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtNC0xLTEtMTYxODk5_616bc566-ed61-48d2-a689-843292929258"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzE_c89bfeea-0241-4819-96f1-38baefbea46b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzUtOC0xLTEtMTYxODk5_017fe27d-e80f-421b-8f33-cf6e30a994cf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzE_c89bfeea-0241-4819-96f1-38baefbea46b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTItMS0xLTE1NTYzOA_776c7a5d-e044-4ec7-96e2-4308574f3e72"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTItMS0xLTE1NTYzOA_776c7a5d-e044-4ec7-96e2-4308574f3e72"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTYtMS0xLTE1NTYzOA_2942a965-a598-4acd-bff1-0c02e059da86"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTYtMS0xLTE1NTYzOA_2942a965-a598-4acd-bff1-0c02e059da86"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTQtMS0xLTE1NTYzOA_ed86179d-92be-4657-b47f-3d6a84617613"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTQtMS0xLTE1NTYzOA_ed86179d-92be-4657-b47f-3d6a84617613"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjE_26f1389f-55c0-455d-bee3-4c13d585abc3" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjE_26f1389f-55c0-455d-bee3-4c13d585abc3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">2021 includes, among other things, $188&#160;million of net collaboration income from BioNTech related to the COVID-19 vaccine and $97 million of milestone income from multiple licensees. 2020 included, among other things, (i) a $75 million upfront payment received from our sale of our CK1 assets to Biogen, (ii) $40 million of milestone income from Puma Biotechnology, Inc. related to Neratinib regulatory approvals in the EU, (iii) $30 million of milestone income from Lilly related to the first commercial sale in the U.S. of LOXO-292 for the treatment of RET fusion-positive NSCLC and (iv) $108 million in milestone income from multiple licensees. 2019 included, among other things, $78 million in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#xae;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">, a generic of Advair Diskus</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">&#xae;</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(fluticasone propionate and salmeterol inhalation powder) and $52 million in milestone income from multiple licensees.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTItMS0xLTE1NTYzOA_776c7a5d-e044-4ec7-96e2-4308574f3e72"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjE_26f1389f-55c0-455d-bee3-4c13d585abc3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTYtMS0xLTE1NTYzOA_2942a965-a598-4acd-bff1-0c02e059da86"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjE_26f1389f-55c0-455d-bee3-4c13d585abc3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEwLTQtMS0xLTE1NTYzOA_ed86179d-92be-4657-b47f-3d6a84617613"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjE_26f1389f-55c0-455d-bee3-4c13d585abc3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNi0xLTEtMTc3NDQ2_7cda6e54-0181-4805-8205-7bbf2c4abc48"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNi0xLTEtMTc3NDQ2_7cda6e54-0181-4805-8205-7bbf2c4abc48"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNC0xLTEtMTc3NDQ2_48faa6f0-3a30-4022-b30b-caa0a4b7f684"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNC0xLTEtMTc3NDQ2_48faa6f0-3a30-4022-b30b-caa0a4b7f684"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMi0xLTEtMTc3NDQ2_d98a92f6-45bd-4e4c-a439-374f7de87b82"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMi0xLTEtMTc3NDQ2_d98a92f6-45bd-4e4c-a439-374f7de87b82"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNi0xLTEtMTc3NDQ2_7cda6e54-0181-4805-8205-7bbf2c4abc48"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtNC0xLTEtMTc3NDQ2_48faa6f0-3a30-4022-b30b-caa0a4b7f684"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzgtMi0xLTEtMTc3NDQ2_d98a92f6-45bd-4e4c-a439-374f7de87b82"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA0_29598009-aae4-4d8d-a587-4001a81ea84a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctOC0xLTEtMTU1NjM4_2d6c1a68-5552-4be1-a010-836b6862e20b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctOC0xLTEtMTU1NjM4_2d6c1a68-5552-4be1-a010-836b6862e20b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctNi0xLTEtMTU1NjM4_7593f700-33a1-4b98-91bf-879b34110428"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctNi0xLTEtMTU1NjM4_7593f700-33a1-4b98-91bf-879b34110428"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctMTAtMS0xLTE1NTYzOA_a73c9239-ead4-4169-9fcc-f5c747a69fc4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctMTAtMS0xLTE1NTYzOA_a73c9239-ead4-4169-9fcc-f5c747a69fc4"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI0_d66425c4-36ea-42ca-9afe-89f26f33ded1" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI0_d66425c4-36ea-42ca-9afe-89f26f33ded1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Represents acquisition-related costs ($9&#160;million credit in 2021 and $192 million credit in 2019) and cost reduction initiatives ($750 million charge in 2021, $535 million charge in 2020, and $418 million charge in 2019). 2021 and 2020 charges mainly represent employee termination costs for our Transforming to a More Focused Company cost-reduction program. 2019 restructuring charges mainly represent employee termination costs for cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5B</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">). The employee termination costs for 2019 were primarily for our improvements to operational effectiveness as part of the realignment of our business structure, and also included employee termination costs for the Transforming to a More Focused Company cost-reduction program.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctOC0xLTEtMTU1NjM4_2d6c1a68-5552-4be1-a010-836b6862e20b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI0_d66425c4-36ea-42ca-9afe-89f26f33ded1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctNi0xLTEtMTU1NjM4_7593f700-33a1-4b98-91bf-879b34110428"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI0_d66425c4-36ea-42ca-9afe-89f26f33ded1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzctMTAtMS0xLTE1NTYzOA_a73c9239-ead4-4169-9fcc-f5c747a69fc4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI0_d66425c4-36ea-42ca-9afe-89f26f33ded1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTItMS0xLTE1NTYzOA_1d63a504-43b3-4e6e-b318-390daf304a54"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTItMS0xLTE1NTYzOA_1d63a504-43b3-4e6e-b318-390daf304a54"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTQtMS0xLTE1NTYzOA_23f0c89d-0e2d-4917-8d88-8815bb9cb5cf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTQtMS0xLTE1NTYzOA_23f0c89d-0e2d-4917-8d88-8815bb9cb5cf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTYtMS0xLTE1NTYzOA_a23043da-80f6-4944-b8c8-a7314fbae96c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTYtMS0xLTE1NTYzOA_a23043da-80f6-4944-b8c8-a7314fbae96c"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODY_8f0897b6-0412-434f-8608-7a97cbafee5e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODY_8f0897b6-0412-434f-8608-7a97cbafee5e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Mainly represents incremental costs for the design, planning and implementation of our then new business structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and other advisory services.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTItMS0xLTE1NTYzOA_1d63a504-43b3-4e6e-b318-390daf304a54"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODY_8f0897b6-0412-434f-8608-7a97cbafee5e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTQtMS0xLTE1NTYzOA_23f0c89d-0e2d-4917-8d88-8815bb9cb5cf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODY_8f0897b6-0412-434f-8608-7a97cbafee5e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE0LTYtMS0xLTE1NTYzOA_a23043da-80f6-4944-b8c8-a7314fbae96c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODY_8f0897b6-0412-434f-8608-7a97cbafee5e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTYtMS0xLTE1NTYzOA_c4a54d97-7d11-4bc4-b781-3dfecf9a8d4a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTYtMS0xLTE1NTYzOA_c4a54d97-7d11-4bc4-b781-3dfecf9a8d4a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNC0xLTEtMTU1NjM4_4f4c89e4-6db7-40f7-88d6-39114c8aa258"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNC0xLTEtMTU1NjM4_4f4c89e4-6db7-40f7-88d6-39114c8aa258"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTYtMS0xLTE1NTYzOA_5890084d-8e26-4833-a562-8c7fbb06d03e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTYtMS0xLTE1NTYzOA_5890084d-8e26-4833-a562-8c7fbb06d03e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTQtMS0xLTE1NTYzOA_709a14a0-1fa2-48ec-9db7-e7fe83b24faf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTQtMS0xLTE1NTYzOA_709a14a0-1fa2-48ec-9db7-e7fe83b24faf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTYtMS0xLTE1NTYzOA_a46f22eb-ae36-4c35-a84e-cd3183e01176"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTYtMS0xLTE1NTYzOA_a46f22eb-ae36-4c35-a84e-cd3183e01176"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTYtMS0xLTE1NTYzOA_cea60af2-8c6c-44ce-9379-0c9408a7edd9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTYtMS0xLTE1NTYzOA_cea60af2-8c6c-44ce-9379-0c9408a7edd9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTYtMS0xLTE1NTYzOA_e617887c-3da5-43a0-8050-ff8df10abdf9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTYtMS0xLTE1NTYzOA_e617887c-3da5-43a0-8050-ff8df10abdf9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTYtMS0xLTE1NTYzOA_d083c457-1d57-4eff-b8ba-5cda20c59421"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTYtMS0xLTE1NTYzOA_d083c457-1d57-4eff-b8ba-5cda20c59421"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNi0xLTEtMTU1NjM4_9e892a40-9f6c-426f-a55e-95264845f896"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNi0xLTEtMTU1NjM4_9e892a40-9f6c-426f-a55e-95264845f896"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTQtMS0xLTE1NTYzOA_dffafcd0-1e07-4cc5-bef0-d88fb845c696"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTQtMS0xLTE1NTYzOA_dffafcd0-1e07-4cc5-bef0-d88fb845c696"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTQtMS0xLTE1NTYzOA_0ec087d1-5d2f-45e8-af0a-963acbdc9c35"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTQtMS0xLTE1NTYzOA_0ec087d1-5d2f-45e8-af0a-963acbdc9c35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTQtMS0xLTE1NTYzOA_f1eb3203-bad7-4a37-b9ba-d995e4c010f3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTQtMS0xLTE1NTYzOA_f1eb3203-bad7-4a37-b9ba-d995e4c010f3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTQtMS0xLTE1NTYzOA_022b7343-cc02-4d0b-bd17-9219c56120d2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTQtMS0xLTE1NTYzOA_022b7343-cc02-4d0b-bd17-9219c56120d2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTQtMS0xLTE1NTYzOA_1807f3e3-32c3-4436-8597-9a8d224768f0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTQtMS0xLTE1NTYzOA_1807f3e3-32c3-4436-8597-9a8d224768f0"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Amounts as of December 31, 2021 represent property, plant and equipment held for sale. Amounts as of December 31, 2020 primarily relate to discontinued operations of our former Meridian subsidiary and the Mylan-Japan collaboration. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTYtMS0xLTE1NTYzOA_c4a54d97-7d11-4bc4-b781-3dfecf9a8d4a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNC0xLTEtMTU1NjM4_4f4c89e4-6db7-40f7-88d6-39114c8aa258"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTYtMS0xLTE1NTYzOA_5890084d-8e26-4833-a562-8c7fbb06d03e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTQtMS0xLTE1NTYzOA_709a14a0-1fa2-48ec-9db7-e7fe83b24faf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTYtMS0xLTE1NTYzOA_a46f22eb-ae36-4c35-a84e-cd3183e01176"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzIzLTYtMS0xLTE1NTYzOA_cea60af2-8c6c-44ce-9379-0c9408a7edd9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTYtMS0xLTE1NTYzOA_e617887c-3da5-43a0-8050-ff8df10abdf9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTYtMS0xLTE1NTYzOA_d083c457-1d57-4eff-b8ba-5cda20c59421"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzgtNi0xLTEtMTU1NjM4_9e892a40-9f6c-426f-a55e-95264845f896"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzExLTQtMS0xLTE1NTYzOA_dffafcd0-1e07-4cc5-bef0-d88fb845c696"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE5LTQtMS0xLTE1NTYzOA_0ec087d1-5d2f-45e8-af0a-963acbdc9c35"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzE0LTQtMS0xLTE1NTYzOA_f1eb3203-bad7-4a37-b9ba-d995e4c010f3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEzLTQtMS0xLTE1NTYzOA_022b7343-cc02-4d0b-bd17-9219c56120d2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTowYmYyZDdkZDI2Nzc0NDBmOTFlMjczY2ZlNWRlOTBiOC90YWJsZXJhbmdlOjBiZjJkN2RkMjY3NzQ0MGY5MWUyNzNjZmU1ZGU5MGI4XzEwLTQtMS0xLTE1NTYzOA_1807f3e3-32c3-4436-8597-9a8d224768f0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDk5_2edf7a86-1f6a-4275-a396-c3b1bdae7fa8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtNC0xLTEtMTU1NjM4_fcff6e04-cf91-4aab-a1bf-9b6b771c59d2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtNC0xLTEtMTU1NjM4_fcff6e04-cf91-4aab-a1bf-9b6b771c59d2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMi0xLTEtMTU1NjM4_d0719a5a-8f70-4d72-8488-4163b8e663c2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMi0xLTEtMTU1NjM4_d0719a5a-8f70-4d72-8488-4163b8e663c2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjg_2bdbd7b3-002f-414d-9e23-4b1958cb6998" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjg_2bdbd7b3-002f-414d-9e23-4b1958cb6998" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Reclassified to the current portion of long-term debt.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtNC0xLTEtMTU1NjM4_fcff6e04-cf91-4aab-a1bf-9b6b771c59d2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjg_2bdbd7b3-002f-414d-9e23-4b1958cb6998"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90YWJsZTo1MmMzOTNkY2IzZDI0Mjk2YjdiMDkyYjY3NTZlMmU4MS90YWJsZXJhbmdlOjUyYzM5M2RjYjNkMjQyOTZiN2IwOTJiNjc1NmUyZTgxXzQtMi0xLTEtMTU1NjM4_d0719a5a-8f70-4d72-8488-4163b8e663c2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTMvZnJhZzoxNTY3ZDk2NDI3YmQ0NzM0YjA1ODBlNDI3ZWE0NTdiNi90ZXh0cmVnaW9uOjE1NjdkOTY0MjdiZDQ3MzRiMDU4MGU0MjdlYTQ1N2I2XzE2Mjg_2bdbd7b3-002f-414d-9e23-4b1958cb6998"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNi0xLTEtMTU1NjM4_9f9d95f4-c3d5-4ad4-b5ad-2f3a60e9eb08"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNi0xLTEtMTU1NjM4_9f9d95f4-c3d5-4ad4-b5ad-2f3a60e9eb08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNi0xLTEtMTU1NjM4_809ed143-c113-4f6a-81ff-ddef984737d1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNi0xLTEtMTU1NjM4_809ed143-c113-4f6a-81ff-ddef984737d1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNi0xLTEtMTU1NjM4_70764fa8-bcdf-4adc-b1d0-98a361ff980a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNi0xLTEtMTU1NjM4_70764fa8-bcdf-4adc-b1d0-98a361ff980a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNC0xLTEtMTU1NjM4_f8c79b07-3f6a-4a33-92bb-3a6e9e257dd3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNC0xLTEtMTU1NjM4_f8c79b07-3f6a-4a33-92bb-3a6e9e257dd3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtNC0xLTEtMTU1NjM4_5b191432-aea1-4255-a33b-3456f30d377f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtNC0xLTEtMTU1NjM4_5b191432-aea1-4255-a33b-3456f30d377f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtMi0xLTEtMTU1NjM4_421fa183-684f-4276-acad-fc30922c2cca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtMi0xLTEtMTU1NjM4_421fa183-684f-4276-acad-fc30922c2cca"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNC0xLTEtMTU1NjM4_03bc2458-9954-4213-81e3-95026eb68409"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNC0xLTEtMTU1NjM4_03bc2458-9954-4213-81e3-95026eb68409"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctMi0xLTEtMTU1NjM4_2adf412a-914a-4578-a230-cd3632fc59e5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctMi0xLTEtMTU1NjM4_2adf412a-914a-4578-a230-cd3632fc59e5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtMi0xLTEtMTU1NjM4_ca2f17af-403d-45d2-a722-b3ea169f5d62"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtMi0xLTEtMTU1NjM4_ca2f17af-403d-45d2-a722-b3ea169f5d62"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtMi0xLTEtMTU1NjM4_cb603cf5-b5a6-4654-b0c4-e4fd67fa97ac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtMi0xLTEtMTU1NjM4_cb603cf5-b5a6-4654-b0c4-e4fd67fa97ac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNC0xLTEtMTU1NjM4_748e2b39-345f-44a8-b39b-41e92c60ab82"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNC0xLTEtMTU1NjM4_748e2b39-345f-44a8-b39b-41e92c60ab82"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 5A.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNi0xLTEtMTU1NjM4_9f9d95f4-c3d5-4ad4-b5ad-2f3a60e9eb08"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNi0xLTEtMTU1NjM4_809ed143-c113-4f6a-81ff-ddef984737d1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNi0xLTEtMTU1NjM4_70764fa8-bcdf-4adc-b1d0-98a361ff980a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtNC0xLTEtMTU1NjM4_f8c79b07-3f6a-4a33-92bb-3a6e9e257dd3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtNC0xLTEtMTU1NjM4_5b191432-aea1-4255-a33b-3456f30d377f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtMi0xLTEtMTU1NjM4_421fa183-684f-4276-acad-fc30922c2cca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzQtNC0xLTEtMTU1NjM4_03bc2458-9954-4213-81e3-95026eb68409"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctMi0xLTEtMTU1NjM4_2adf412a-914a-4578-a230-cd3632fc59e5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzgtMi0xLTEtMTU1NjM4_ca2f17af-403d-45d2-a722-b3ea169f5d62"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzYtMi0xLTEtMTU1NjM4_cb603cf5-b5a6-4654-b0c4-e4fd67fa97ac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzctNC0xLTEtMTU1NjM4_748e2b39-345f-44a8-b39b-41e92c60ab82"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDAw_4d335066-0ccd-4851-a085-c041eba7293d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTEwLTEtMS0xNTU2Mzg_c5e3b7b3-ad7b-4372-8fc9-743761958514"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTEwLTEtMS0xNTU2Mzg_c5e3b7b3-ad7b-4372-8fc9-743761958514"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTgtMS0xLTE1NTYzOA_c72ce72f-d017-48b5-aa58-e2a94bf428d9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTgtMS0xLTE1NTYzOA_c72ce72f-d017-48b5-aa58-e2a94bf428d9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTYtMS0xLTE1NTYzOA_26b576fd-e42f-47a6-aeab-565869399e1b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTYtMS0xLTE1NTYzOA_26b576fd-e42f-47a6-aeab-565869399e1b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDk_1533b714-7a5d-4d55-8c40-da98cfed12f5" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDk_1533b714-7a5d-4d55-8c40-da98cfed12f5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(d)</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 1C.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTEwLTEtMS0xNTU2Mzg_c5e3b7b3-ad7b-4372-8fc9-743761958514"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDk_1533b714-7a5d-4d55-8c40-da98cfed12f5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTgtMS0xLTE1NTYzOA_c72ce72f-d017-48b5-aa58-e2a94bf428d9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDk_1533b714-7a5d-4d55-8c40-da98cfed12f5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzExLTYtMS0xLTE1NTYzOA_26b576fd-e42f-47a6-aeab-565869399e1b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQ3NDk_1533b714-7a5d-4d55-8c40-da98cfed12f5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTItMS0xLTE1NTYzOA_44292426-f74c-4292-8893-599c22df01ba"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTItMS0xLTE1NTYzOA_44292426-f74c-4292-8893-599c22df01ba"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTItMS0xLTE1NTYzOA_4fe324c3-d960-439a-ae02-e73b759a4327"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTItMS0xLTE1NTYzOA_4fe324c3-d960-439a-ae02-e73b759a4327"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTYtMS0xLTE1NTYzOA_5575fd5a-00b6-47b7-89f6-01bc979677c8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTYtMS0xLTE1NTYzOA_5575fd5a-00b6-47b7-89f6-01bc979677c8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTQtMS0xLTE1NTYzOA_b0a85b84-e2ba-46b4-9a58-11d5cf85d31b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTQtMS0xLTE1NTYzOA_b0a85b84-e2ba-46b4-9a58-11d5cf85d31b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTYtMS0xLTE1NTYzOA_6effaeb9-5185-45a2-a184-6f978e917747"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTYtMS0xLTE1NTYzOA_6effaeb9-5185-45a2-a184-6f978e917747"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTgtMS0xLTE1NTYzOA_eca4bfad-a0a2-4fa0-b7fe-396339e3ace6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTgtMS0xLTE1NTYzOA_eca4bfad-a0a2-4fa0-b7fe-396339e3ace6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEwLTEtMS0xNTU2Mzg_5100b054-8edb-48f5-9e21-212ef96b39ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEwLTEtMS0xNTU2Mzg_5100b054-8edb-48f5-9e21-212ef96b39ab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEyLTEtMS0xNTU2Mzg_ff0dd3dd-2896-4174-8239-5da3b6b44a34"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEyLTEtMS0xNTU2Mzg_ff0dd3dd-2896-4174-8239-5da3b6b44a34"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEyLTEtMS0xNTU2Mzg_bee459d5-4eee-40cc-a39f-9ff08d6aa4c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEyLTEtMS0xNTU2Mzg_bee459d5-4eee-40cc-a39f-9ff08d6aa4c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTQtMS0xLTE1NTYzOA_021028ad-3fe7-4eb7-b9b1-d290f1ea062b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTQtMS0xLTE1NTYzOA_021028ad-3fe7-4eb7-b9b1-d290f1ea062b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEwLTEtMS0xNTU2Mzg_e06cdaea-af2d-4e26-b6e8-ad3f73f77f00"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEwLTEtMS0xNTU2Mzg_e06cdaea-af2d-4e26-b6e8-ad3f73f77f00"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTgtMS0xLTE1NTYzOA_7214571e-28c5-4a59-a95b-1a80823e8a1a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTgtMS0xLTE1NTYzOA_7214571e-28c5-4a59-a95b-1a80823e8a1a"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">For more information, see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTItMS0xLTE1NTYzOA_44292426-f74c-4292-8893-599c22df01ba"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTItMS0xLTE1NTYzOA_4fe324c3-d960-439a-ae02-e73b759a4327"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTYtMS0xLTE1NTYzOA_5575fd5a-00b6-47b7-89f6-01bc979677c8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTQtMS0xLTE1NTYzOA_b0a85b84-e2ba-46b4-9a58-11d5cf85d31b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTYtMS0xLTE1NTYzOA_6effaeb9-5185-45a2-a184-6f978e917747"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTgtMS0xLTE1NTYzOA_eca4bfad-a0a2-4fa0-b7fe-396339e3ace6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEwLTEtMS0xNTU2Mzg_5100b054-8edb-48f5-9e21-212ef96b39ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTEyLTEtMS0xNTU2Mzg_ff0dd3dd-2896-4174-8239-5da3b6b44a34"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEyLTEtMS0xNTU2Mzg_bee459d5-4eee-40cc-a39f-9ff08d6aa4c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzI4LTQtMS0xLTE1NTYzOA_021028ad-3fe7-4eb7-b9b1-d290f1ea062b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTEwLTEtMS0xNTU2Mzg_e06cdaea-af2d-4e26-b6e8-ad3f73f77f00"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzE0LTgtMS0xLTE1NTYzOA_7214571e-28c5-4a59-a95b-1a80823e8a1a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY2_0da41efa-d940-491f-8732-250abddb346b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE1NTYzOA_84d1e18f-fce3-4724-a67d-9e622d48d437"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE1NTYzOA_84d1e18f-fce3-4724-a67d-9e622d48d437"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtOC0xLTEtMTU1NjM4_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtOC0xLTEtMTU1NjM4_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE1NTYzOA_e127b306-d2c4-4e38-b370-f5ab9071a5f2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE1NTYzOA_e127b306-d2c4-4e38-b370-f5ab9071a5f2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTItMS0xLTE1NTYzOA_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTItMS0xLTE1NTYzOA_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNC0xLTEtMTU1NjM4_e8bbbce6-fc9b-431c-8278-af06ccb82a49"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNC0xLTEtMTU1NjM4_e8bbbce6-fc9b-431c-8278-af06ccb82a49"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNi0xLTEtMTU1NjM4_de2f933a-4fc4-4b54-9f85-3b4de5212a79"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNi0xLTEtMTU1NjM4_de2f933a-4fc4-4b54-9f85-3b4de5212a79"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE1NTYzOA_bb7ecbef-0b64-4b85-8cef-019466b07d02"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE1NTYzOA_bb7ecbef-0b64-4b85-8cef-019466b07d02"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTQtMS0xLTE1NTYzOA_84d1e18f-fce3-4724-a67d-9e622d48d437"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtOC0xLTEtMTU1NjM4_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTYtMS0xLTE1NTYzOA_e127b306-d2c4-4e38-b370-f5ab9071a5f2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3ZjNhNWMyOGQzNDU0ZjQxOGRkODA0OWZmYzYzZmU3MC90YWJsZXJhbmdlOjdmM2E1YzI4ZDM0NTRmNDE4ZGQ4MDQ5ZmZjNjNmZTcwXzctMTItMS0xLTE1NTYzOA_f79fd294-b4a8-4bf1-b851-ba56ed959b3c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNC0xLTEtMTU1NjM4_e8bbbce6-fc9b-431c-8278-af06ccb82a49"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzMtNi0xLTEtMTU1NjM4_de2f933a-4fc4-4b54-9f85-3b4de5212a79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI1LTgtMS0xLTE1NTYzOA_bb7ecbef-0b64-4b85-8cef-019466b07d02"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0Njk_745432d5-41aa-4f6d-ab34-018e28108bee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjYtMS0xLTE1NTYzOA_229afef2-6bb7-4825-b021-99094d2266fa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjYtMS0xLTE1NTYzOA_229afef2-6bb7-4825-b021-99094d2266fa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTgtMS0xLTE1NTYzOA_7bfc61f9-ca76-4c82-a926-959e839402ce"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTgtMS0xLTE1NTYzOA_7bfc61f9-ca76-4c82-a926-959e839402ce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjAtMS0xLTE1NTYzOA_4b62f3d1-5853-4f73-8a18-d81f343f0906"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjAtMS0xLTE1NTYzOA_4b62f3d1-5853-4f73-8a18-d81f343f0906"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjItMS0xLTE1NTYzOA_fa3d1f38-ed77-4ad5-ac7d-a22f0e7a7326"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjItMS0xLTE1NTYzOA_fa3d1f38-ed77-4ad5-ac7d-a22f0e7a7326"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMi0xLTEtMTU1NjM4_1a94ef26-c091-4e7d-9c52-3172fbaf29df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMi0xLTEtMTU1NjM4_1a94ef26-c091-4e7d-9c52-3172fbaf29df"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjgtMS0xLTE1NTYzOA_d579c4af-57c0-45ef-981f-37cabba91840"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjgtMS0xLTE1NTYzOA_d579c4af-57c0-45ef-981f-37cabba91840"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMzAtMS0xLTE1NTYzOA_38732335-d53e-4f06-84e2-85dd1154c1a0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMzAtMS0xLTE1NTYzOA_38732335-d53e-4f06-84e2-85dd1154c1a0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNC0xLTEtMTU1NjM4_992fa98a-bf2f-4f41-a787-082f6d3b2a31"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNC0xLTEtMTU1NjM4_992fa98a-bf2f-4f41-a787-082f6d3b2a31"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjQtMS0xLTE1NTYzOA_fcb4ae62-0c3e-4fac-a30c-235ab34d77a1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjQtMS0xLTE1NTYzOA_fcb4ae62-0c3e-4fac-a30c-235ab34d77a1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctOC0xLTEtMTU1NjM4_87c54e86-a569-4df7-b8e6-04951fcb6787"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctOC0xLTEtMTU1NjM4_87c54e86-a569-4df7-b8e6-04951fcb6787"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNi0xLTEtMTU1NjM4_07778de6-12fc-43bd-ade7-053555389107"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNi0xLTEtMTU1NjM4_07778de6-12fc-43bd-ade7-053555389107"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTQtMS0xLTE1NTYzOA_d4d12f82-0c20-47ed-9fbe-8e0227117c6d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTQtMS0xLTE1NTYzOA_d4d12f82-0c20-47ed-9fbe-8e0227117c6d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTItMS0xLTE1NTYzOA_e6579469-97e3-4adb-8f01-c8be1876bf76"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTItMS0xLTE1NTYzOA_e6579469-97e3-4adb-8f01-c8be1876bf76"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTYtMS0xLTE1NTYzOA_ca3030ec-ef12-4e8d-bc08-dda9ca807e2a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTYtMS0xLTE1NTYzOA_ca3030ec-ef12-4e8d-bc08-dda9ca807e2a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTAtMS0xLTE1NTYzOA_5806a747-3c80-4200-947d-3b5d951b4251"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTAtMS0xLTE1NTYzOA_5806a747-3c80-4200-947d-3b5d951b4251"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">TSRU includes expense for PTSRUs, which is not significant for all years presented</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjYtMS0xLTE1NTYzOA_229afef2-6bb7-4825-b021-99094d2266fa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTgtMS0xLTE1NTYzOA_7bfc61f9-ca76-4c82-a926-959e839402ce"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjAtMS0xLTE1NTYzOA_4b62f3d1-5853-4f73-8a18-d81f343f0906"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjItMS0xLTE1NTYzOA_fa3d1f38-ed77-4ad5-ac7d-a22f0e7a7326"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMi0xLTEtMTU1NjM4_1a94ef26-c091-4e7d-9c52-3172fbaf29df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjgtMS0xLTE1NTYzOA_d579c4af-57c0-45ef-981f-37cabba91840"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMzAtMS0xLTE1NTYzOA_38732335-d53e-4f06-84e2-85dd1154c1a0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNC0xLTEtMTU1NjM4_992fa98a-bf2f-4f41-a787-082f6d3b2a31"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMjQtMS0xLTE1NTYzOA_fcb4ae62-0c3e-4fac-a30c-235ab34d77a1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctOC0xLTEtMTU1NjM4_87c54e86-a569-4df7-b8e6-04951fcb6787"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctNi0xLTEtMTU1NjM4_07778de6-12fc-43bd-ade7-053555389107"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTQtMS0xLTE1NTYzOA_d4d12f82-0c20-47ed-9fbe-8e0227117c6d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTItMS0xLTE1NTYzOA_e6579469-97e3-4adb-8f01-c8be1876bf76"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTYtMS0xLTE1NTYzOA_ca3030ec-ef12-4e8d-bc08-dda9ca807e2a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTpmMWEzNGQ1NDBjOTg0ZTVlOTU5OTcwNDBkNDQyZTQ5Yy90YWJsZXJhbmdlOmYxYTM0ZDU0MGM5ODRlNWU5NTk5NzA0MGQ0NDJlNDljXzctMTAtMS0xLTE1NTYzOA_5806a747-3c80-4200-947d-3b5d951b4251"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMjA_d2b40dff-1d8f-4c7c-bc78-eeec3c58ac81"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTItMS0xLTE1NTYzOA_91ad9a52-8b73-4986-a4f4-2d66d93c84da"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTItMS0xLTE1NTYzOA_91ad9a52-8b73-4986-a4f4-2d66d93c84da"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTYtMS0xLTE1NTYzOA_d35f7b7b-d5e5-4e97-970d-198f3a89ac4c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTYtMS0xLTE1NTYzOA_d35f7b7b-d5e5-4e97-970d-198f3a89ac4c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTQtMS0xLTE1NTYzOA_ec5b8174-b3c0-42d6-9907-197f66ed9e22"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTQtMS0xLTE1NTYzOA_ec5b8174-b3c0-42d6-9907-197f66ed9e22"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcz_15ee60a1-e236-41ba-9ba0-faa094ee830e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcz_15ee60a1-e236-41ba-9ba0-faa094ee830e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes changes in interest related to our uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d;.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTItMS0xLTE1NTYzOA_91ad9a52-8b73-4986-a4f4-2d66d93c84da"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcz_15ee60a1-e236-41ba-9ba0-faa094ee830e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTYtMS0xLTE1NTYzOA_d35f7b7b-d5e5-4e97-970d-198f3a89ac4c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcz_15ee60a1-e236-41ba-9ba0-faa094ee830e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTo5MDM5YWE1MjEwNDE0OTBiOTU2ODhiY2YyMDdlZmJkZS90YWJsZXJhbmdlOjkwMzlhYTUyMTA0MTQ5MGI5NTY4OGJjZjIwN2VmYmRlXzEwLTQtMS0xLTE1NTYzOA_ec5b8174-b3c0-42d6-9907-197f66ed9e22"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDcz_15ee60a1-e236-41ba-9ba0-faa094ee830e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTYtMS0xLTE1NTYzOA_6d5a2b60-1371-418d-92ac-a68824feb0eb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTYtMS0xLTE1NTYzOA_6d5a2b60-1371-418d-92ac-a68824feb0eb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTItMS0xLTE1NTYzOA_2c13d92c-9eb8-49ba-a2d9-4ff8ede9d098"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTItMS0xLTE1NTYzOA_2c13d92c-9eb8-49ba-a2d9-4ff8ede9d098"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTQtMS0xLTE1NTYzOA_eff9c8b3-b659-4e27-b655-f84aa2e38f10"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTQtMS0xLTE1NTYzOA_eff9c8b3-b659-4e27-b655-f84aa2e38f10"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODU_a0039e7b-b917-408b-9d6a-752d7c16fb64" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODU_a0039e7b-b917-408b-9d6a-752d7c16fb64" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes legal reserves for certain pending legal matters.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTYtMS0xLTE1NTYzOA_6d5a2b60-1371-418d-92ac-a68824feb0eb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODU_a0039e7b-b917-408b-9d6a-752d7c16fb64"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTItMS0xLTE1NTYzOA_2c13d92c-9eb8-49ba-a2d9-4ff8ede9d098"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODU_a0039e7b-b917-408b-9d6a-752d7c16fb64"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEyLTQtMS0xLTE1NTYzOA_eff9c8b3-b659-4e27-b655-f84aa2e38f10"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczODU_a0039e7b-b917-408b-9d6a-752d7c16fb64"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTgtMS0xLTE1NTYzOA_57875fd3-c720-43ff-aa35-5b92292df7bb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTgtMS0xLTE1NTYzOA_57875fd3-c720-43ff-aa35-5b92292df7bb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTQtMS0xLTE1NTYzOA_3786047f-58ec-42ac-aabe-4be56f21b571"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTQtMS0xLTE1NTYzOA_3786047f-58ec-42ac-aabe-4be56f21b571"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTYtMS0xLTE1NTYzOA_c47971c5-0f64-4f2e-a645-0124bc609cc0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTYtMS0xLTE1NTYzOA_c47971c5-0f64-4f2e-a645-0124bc609cc0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEyLTEtMS0xNTU2Mzg_6d74d7a6-e6f5-4721-a6da-f3c1fd721422"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEyLTEtMS0xNTU2Mzg_6d74d7a6-e6f5-4721-a6da-f3c1fd721422"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEwLTEtMS0xNTU2Mzg_6c7828d5-2f33-49d9-99b3-17ae37984b5a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEwLTEtMS0xNTU2Mzg_6c7828d5-2f33-49d9-99b3-17ae37984b5a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTItMS0xLTE1NTYzOA_11f37d67-9f26-40c9-8a93-23dd3aae225c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTItMS0xLTE1NTYzOA_11f37d67-9f26-40c9-8a93-23dd3aae225c"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes actuarial gains resulting from</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> increases i</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">n discount rates </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">in 2021, offset by increases in inflation assumptions in 2021 for the international plans, and actuarial losses resulting from decreases in discount rates in</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2020</xhtml:span><xhtml:span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTgtMS0xLTE1NTYzOA_57875fd3-c720-43ff-aa35-5b92292df7bb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTQtMS0xLTE1NTYzOA_3786047f-58ec-42ac-aabe-4be56f21b571"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTYtMS0xLTE1NTYzOA_c47971c5-0f64-4f2e-a645-0124bc609cc0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEyLTEtMS0xNTU2Mzg_6d74d7a6-e6f5-4721-a6da-f3c1fd721422"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTEwLTEtMS0xNTU2Mzg_6c7828d5-2f33-49d9-99b3-17ae37984b5a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzEyLTItMS0xLTE1NTYzOA_11f37d67-9f26-40c9-8a93-23dd3aae225c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAx_25da2742-1855-4001-bde5-4236d7db5a7c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTItMS0xLTE1NTYzOA_242ba833-456a-4cfd-b898-3a48906babf6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTItMS0xLTE1NTYzOA_242ba833-456a-4cfd-b898-3a48906babf6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEyLTEtMS0xNTU2Mzg_de7d172e-e54a-4dfb-9374-e22f89b1b318"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEyLTEtMS0xNTU2Mzg_de7d172e-e54a-4dfb-9374-e22f89b1b318"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEyLTEtMS0xNTU2Mzg_2071fbd6-afae-4a6e-950d-29a48f960b3e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEyLTEtMS0xNTU2Mzg_2071fbd6-afae-4a6e-950d-29a48f960b3e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIyLTEtMS0xNTU2Mzg_49e38d60-4156-420c-b0d3-559b21653490"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIyLTEtMS0xNTU2Mzg_49e38d60-4156-420c-b0d3-559b21653490"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEyLTEtMS0xNTU2Mzg_b9283d4a-b481-499c-84cc-ab9add6e6bd0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEyLTEtMS0xNTU2Mzg_b9283d4a-b481-499c-84cc-ab9add6e6bd0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEyLTEtMS0xNTU2Mzg_93a56760-b80a-4d6b-8987-359570948f94"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEyLTEtMS0xNTU2Mzg_93a56760-b80a-4d6b-8987-359570948f94"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIyLTEtMS0xNTU2Mzg_12545fb2-9126-41b2-8856-19f2b608c590"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIyLTEtMS0xNTU2Mzg_12545fb2-9126-41b2-8856-19f2b608c590"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjItMS0xLTE1NTYzOA_942e2c6f-bd14-48d6-938e-405a246cdb45"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjItMS0xLTE1NTYzOA_942e2c6f-bd14-48d6-938e-405a246cdb45"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIyLTEtMS0xNTU2Mzg_8adc4b9f-29fa-4003-9600-58615581fd36"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIyLTEtMS0xNTU2Mzg_8adc4b9f-29fa-4003-9600-58615581fd36"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIyLTEtMS0xNTU2Mzg_b0a663b2-9770-4574-9771-931cbd79c542"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIyLTEtMS0xNTU2Mzg_b0a663b2-9770-4574-9771-931cbd79c542"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjItMS0xLTE1NTYzOA_fedba956-ea2f-4539-b3f9-abf2ae69c37b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjItMS0xLTE1NTYzOA_fedba956-ea2f-4539-b3f9-abf2ae69c37b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEyLTEtMS0xNTU2Mzg_b13354c5-fdff-4035-bb77-b00434096449"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEyLTEtMS0xNTU2Mzg_b13354c5-fdff-4035-bb77-b00434096449"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEyLTEtMS0xNTU2Mzg_b95480d8-ffdc-448c-bc49-6676b68b2698"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEyLTEtMS0xNTU2Mzg_b95480d8-ffdc-448c-bc49-6676b68b2698"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIyLTEtMS0xNTU2Mzg_31a8ad27-20a2-4a38-a7b3-82a1801e8339"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIyLTEtMS0xNTU2Mzg_31a8ad27-20a2-4a38-a7b3-82a1801e8339"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEyLTEtMS0xNTU2Mzg_7fda2a9e-7697-4cfa-86e9-0fefaeb05694"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEyLTEtMS0xNTU2Mzg_7fda2a9e-7697-4cfa-86e9-0fefaeb05694"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIyLTEtMS0xNTU2Mzg_91fb8c8a-dfd0-46c4-afe4-83080ad0c295"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIyLTEtMS0xNTU2Mzg_91fb8c8a-dfd0-46c4-afe4-83080ad0c295"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIyLTEtMS0xNTU2Mzg_90374e62-0e6f-46ef-9c7f-4640ff4d6c2e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIyLTEtMS0xNTU2Mzg_90374e62-0e6f-46ef-9c7f-4640ff4d6c2e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEyLTEtMS0xNTU2Mzg_888ab502-03a6-4cb7-b620-959b81a348e6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEyLTEtMS0xNTU2Mzg_888ab502-03a6-4cb7-b620-959b81a348e6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIyLTEtMS0xNTU2Mzg_a214d9db-3c4a-4696-8ebd-fa3ec28ff00e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIyLTEtMS0xNTU2Mzg_a214d9db-3c4a-4696-8ebd-fa3ec28ff00e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEyLTEtMS0xNTU2Mzg_ea1505b5-7690-4876-bb95-cfe8a69dd83f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEyLTEtMS0xNTU2Mzg_ea1505b5-7690-4876-bb95-cfe8a69dd83f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIyLTEtMS0xNTU2Mzg_206b5f3d-e5de-48a7-8d90-972f83316239"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIyLTEtMS0xNTU2Mzg_206b5f3d-e5de-48a7-8d90-972f83316239"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTItMS0xLTE1NTYzOA_285610aa-5b55-40aa-8047-ddd3c15916b4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTItMS0xLTE1NTYzOA_285610aa-5b55-40aa-8047-ddd3c15916b4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTItMS0xLTE1NTYzOA_9116dce1-29a6-400a-b560-bf236c4d1e10"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTItMS0xLTE1NTYzOA_9116dce1-29a6-400a-b560-bf236c4d1e10"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEyLTEtMS0xNTU2Mzg_891932bd-4a2f-4cb7-9c32-7626400194a1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEyLTEtMS0xNTU2Mzg_891932bd-4a2f-4cb7-9c32-7626400194a1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjItMS0xLTE1NTYzOA_2db1f194-c5bb-4342-8607-e1df12dcbf12"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjItMS0xLTE1NTYzOA_2db1f194-c5bb-4342-8607-e1df12dcbf12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMTItMS0xLTE1NTYzOA_242ba833-456a-4cfd-b898-3a48906babf6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTEyLTEtMS0xNTU2Mzg_de7d172e-e54a-4dfb-9374-e22f89b1b318"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTEyLTEtMS0xNTU2Mzg_2071fbd6-afae-4a6e-950d-29a48f960b3e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMxLTIyLTEtMS0xNTU2Mzg_49e38d60-4156-420c-b0d3-559b21653490"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTEyLTEtMS0xNTU2Mzg_b9283d4a-b481-499c-84cc-ab9add6e6bd0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTEyLTEtMS0xNTU2Mzg_93a56760-b80a-4d6b-8987-359570948f94"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTIyLTEtMS0xNTU2Mzg_12545fb2-9126-41b2-8856-19f2b608c590"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzctMjItMS0xLTE1NTYzOA_942e2c6f-bd14-48d6-938e-405a246cdb45"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTIyLTEtMS0xNTU2Mzg_8adc4b9f-29fa-4003-9600-58615581fd36"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTIyLTEtMS0xNTU2Mzg_b0a663b2-9770-4574-9771-931cbd79c542"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMjItMS0xLTE1NTYzOA_fedba956-ea2f-4539-b3f9-abf2ae69c37b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzIyLTEyLTEtMS0xNTU2Mzg_b13354c5-fdff-4035-bb77-b00434096449"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEwLTEyLTEtMS0xNTU2Mzg_b95480d8-ffdc-448c-bc49-6676b68b2698"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTIyLTEtMS0xNTU2Mzg_31a8ad27-20a2-4a38-a7b3-82a1801e8339"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE1LTEyLTEtMS0xNTU2Mzg_7fda2a9e-7697-4cfa-86e9-0fefaeb05694"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTIyLTEtMS0xNTU2Mzg_91fb8c8a-dfd0-46c4-afe4-83080ad0c295"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI0LTIyLTEtMS0xNTU2Mzg_90374e62-0e6f-46ef-9c7f-4640ff4d6c2e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI2LTEyLTEtMS0xNTU2Mzg_888ab502-03a6-4cb7-b620-959b81a348e6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE5LTIyLTEtMS0xNTU2Mzg_a214d9db-3c4a-4696-8ebd-fa3ec28ff00e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI5LTEyLTEtMS0xNTU2Mzg_ea1505b5-7690-4876-bb95-cfe8a69dd83f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE3LTIyLTEtMS0xNTU2Mzg_206b5f3d-e5de-48a7-8d90-972f83316239"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzgtMTItMS0xLTE1NTYzOA_285610aa-5b55-40aa-8047-ddd3c15916b4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMTItMS0xLTE1NTYzOA_9116dce1-29a6-400a-b560-bf236c4d1e10"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzEyLTEyLTEtMS0xNTU2Mzg_891932bd-4a2f-4cb7-9c32-7626400194a1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzUtMjItMS0xLTE1NTYzOA_2db1f194-c5bb-4342-8607-e1df12dcbf12"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDMy_dd83851b-7330-45fe-908c-1a14739729ec"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIwLTEtMS0xNTU2Mzg_2dc36c80-8978-4b78-a6b4-e9cf97ed1694"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIwLTEtMS0xNTU2Mzg_2dc36c80-8978-4b78-a6b4-e9cf97ed1694"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEwLTEtMS0xNTU2Mzg_960e3182-0ff8-451e-94e9-0bad467aa196"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEwLTEtMS0xNTU2Mzg_960e3182-0ff8-451e-94e9-0bad467aa196"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEwLTEtMS0xNTU2Mzg_728ee219-374d-437b-9420-1dcc85581038"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEwLTEtMS0xNTU2Mzg_728ee219-374d-437b-9420-1dcc85581038"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIwLTEtMS0xNTU2Mzg_dc51b3f5-f461-44e1-a6f5-5f96e785f863"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIwLTEtMS0xNTU2Mzg_dc51b3f5-f461-44e1-a6f5-5f96e785f863"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTYtMS0xLTE1NTYzOA_db43a12b-305c-43f3-b08d-6ea28ca0bb34"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTYtMS0xLTE1NTYzOA_db43a12b-305c-43f3-b08d-6ea28ca0bb34"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE0LTEtMS0xNTU2Mzg_2f8d3eaa-a853-434b-829f-7ea3e7269a84"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE0LTEtMS0xNTU2Mzg_2f8d3eaa-a853-434b-829f-7ea3e7269a84"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE4LTEtMS0xNTU2Mzg_d7965b05-3ae7-452b-aa1c-9dfd16d067a9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE4LTEtMS0xNTU2Mzg_d7965b05-3ae7-452b-aa1c-9dfd16d067a9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE2LTEtMS0xNTU2Mzg_a112cd8f-66f3-4c2f-abe3-05cb919427ff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE2LTEtMS0xNTU2Mzg_a112cd8f-66f3-4c2f-abe3-05cb919427ff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTYtMS0xLTE1NTYzOA_504edd22-f235-41c2-beb8-c3f5ea16078f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTYtMS0xLTE1NTYzOA_504edd22-f235-41c2-beb8-c3f5ea16078f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTgtMS0xLTE1NTYzOA_bb9dd044-d788-44d7-96d0-4a99a18f204a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTgtMS0xLTE1NTYzOA_bb9dd044-d788-44d7-96d0-4a99a18f204a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTQtMS0xLTE1NTYzOA_493e864e-9e6e-490a-a7d1-a8f30874fddb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTQtMS0xLTE1NTYzOA_493e864e-9e6e-490a-a7d1-a8f30874fddb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE0LTEtMS0xNTU2Mzg_581ab145-e28c-46d0-ab7b-4a546efa180c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE0LTEtMS0xNTU2Mzg_581ab145-e28c-46d0-ab7b-4a546efa180c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE4LTEtMS0xNTU2Mzg_5bfaf30c-da33-4555-91d7-1f74139286eb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE4LTEtMS0xNTU2Mzg_5bfaf30c-da33-4555-91d7-1f74139286eb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTQtMS0xLTE1NTYzOA_58fd0a00-0fde-4880-a602-5212e1070940"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTQtMS0xLTE1NTYzOA_58fd0a00-0fde-4880-a602-5212e1070940"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE2LTEtMS0xNTU2Mzg_7e00f49e-413c-41cd-ade6-d6f7386418df"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE2LTEtMS0xNTU2Mzg_7e00f49e-413c-41cd-ade6-d6f7386418df"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTIwLTEtMS0xNTU2Mzg_2dc36c80-8978-4b78-a6b4-e9cf97ed1694"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTEwLTEtMS0xNTU2Mzg_960e3182-0ff8-451e-94e9-0bad467aa196"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTEwLTEtMS0xNTU2Mzg_728ee219-374d-437b-9420-1dcc85581038"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTIwLTEtMS0xNTU2Mzg_dc51b3f5-f461-44e1-a6f5-5f96e785f863"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTYtMS0xLTE1NTYzOA_db43a12b-305c-43f3-b08d-6ea28ca0bb34"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE0LTEtMS0xNTU2Mzg_2f8d3eaa-a853-434b-829f-7ea3e7269a84"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE4LTEtMS0xNTU2Mzg_d7965b05-3ae7-452b-aa1c-9dfd16d067a9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE2LTEtMS0xNTU2Mzg_a112cd8f-66f3-4c2f-abe3-05cb919427ff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTYtMS0xLTE1NTYzOA_504edd22-f235-41c2-beb8-c3f5ea16078f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTgtMS0xLTE1NTYzOA_bb9dd044-d788-44d7-96d0-4a99a18f204a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTQtMS0xLTE1NTYzOA_493e864e-9e6e-490a-a7d1-a8f30874fddb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE0LTEtMS0xNTU2Mzg_581ab145-e28c-46d0-ab7b-4a546efa180c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTE4LTEtMS0xNTU2Mzg_5bfaf30c-da33-4555-91d7-1f74139286eb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE0LTQtMS0xLTE1NTYzOA_58fd0a00-0fde-4880-a602-5212e1070940"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzI4LTE2LTEtMS0xNTU2Mzg_7e00f49e-413c-41cd-ade6-d6f7386418df"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzEyMDAy_721e229a-6ab6-45bc-b6a4-94f5ff9388ee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTItMS0xLTE1NTYzOA_20517041-af91-4389-8aae-99fcc9ce939c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTItMS0xLTE1NTYzOA_20517041-af91-4389-8aae-99fcc9ce939c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTYtMS0xLTE1NTYzOA_00bd7ddf-3c27-4b55-a7de-7a4be52f9b58"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTYtMS0xLTE1NTYzOA_00bd7ddf-3c27-4b55-a7de-7a4be52f9b58"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTQtMS0xLTE1NTYzOA_e26ed09a-7f53-4a55-b695-a525fb799f8f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTQtMS0xLTE1NTYzOA_e26ed09a-7f53-4a55-b695-a525fb799f8f"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjQ_d2b8d63a-76b5-4c71-adec-7930b09e22e4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjQ_d2b8d63a-76b5-4c71-adec-7930b09e22e4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">2020 represents intangible asset impairment charges associated with our Biopharma segment: (i) $900 million related to IPR&amp;D assets for unapproved indications of certain cancer medicines, acquired in our Array acquisition, and reflected, among other things, updated commercial forecasts; (ii) $528 million related to Eucrisa, a finite-lived developed technology right acquired in our Anacor acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures; and (iii) $263&#160;million related to finite-lived developed technology rights for certain generic sterile injectables acquired in our Hospira acquisition, and reflected updated commercial forecasts mainly reflecting competitive pressures.2019 primarily included intangible asset impairment charges of $2.8 billion, mainly composed of $2.6 billion, related to Eucrisa, and reflected updated commercial forecasts mainly reflecting competitive pressures.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTItMS0xLTE1NTYzOA_20517041-af91-4389-8aae-99fcc9ce939c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjQ_d2b8d63a-76b5-4c71-adec-7930b09e22e4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTYtMS0xLTE1NTYzOA_00bd7ddf-3c27-4b55-a7de-7a4be52f9b58"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjQ_d2b8d63a-76b5-4c71-adec-7930b09e22e4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzEzLTQtMS0xLTE1NTYzOA_e26ed09a-7f53-4a55-b695-a525fb799f8f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjQ_d2b8d63a-76b5-4c71-adec-7930b09e22e4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE2NDYwMA_8bc8c2da-2d5b-4c39-bae1-d91078e9f19b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE2NDYwMA_8bc8c2da-2d5b-4c39-bae1-d91078e9f19b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE2NDk3NQ_f1946444-2e33-45ab-9b79-73f3bb433ed8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE2NDk3NQ_f1946444-2e33-45ab-9b79-73f3bb433ed8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE2NDYwMg_75ce4bd5-1146-426e-a42c-516b04aa5a41"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE2NDYwMg_75ce4bd5-1146-426e-a42c-516b04aa5a41"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTI_8e54b3d4-6b69-441d-8368-d4e6af77c9fd" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTI_8e54b3d4-6b69-441d-8368-d4e6af77c9fd" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTQtMS0xLTE2NDYwMA_8bc8c2da-2d5b-4c39-bae1-d91078e9f19b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTI_8e54b3d4-6b69-441d-8368-d4e6af77c9fd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTgtMS0xLTE2NDk3NQ_f1946444-2e33-45ab-9b79-73f3bb433ed8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTI_8e54b3d4-6b69-441d-8368-d4e6af77c9fd"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ3LTYtMS0xLTE2NDYwMg_75ce4bd5-1146-426e-a42c-516b04aa5a41"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTI_8e54b3d4-6b69-441d-8368-d4e6af77c9fd"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTItMS0xLTE1NTYzOA_8560e1e6-113f-49a9-a5db-00c29f18a662"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTItMS0xLTE1NTYzOA_8560e1e6-113f-49a9-a5db-00c29f18a662"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTQtMS0xLTE1NTYzOA_47101ccf-cf07-4de7-bb9b-28d921f5d23a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTQtMS0xLTE1NTYzOA_47101ccf-cf07-4de7-bb9b-28d921f5d23a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTE0LTEtMS0xNTU2Mzg_820b8eec-4175-4e49-b47a-d53cf5c61a03"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTE0LTEtMS0xNTU2Mzg_820b8eec-4175-4e49-b47a-d53cf5c61a03"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEyLTEtMS0xNTU2Mzg_d747b835-40c4-4736-9e1a-06a05ad61374"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEyLTEtMS0xNTU2Mzg_d747b835-40c4-4736-9e1a-06a05ad61374"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEwLTEtMS0xNTU2Mzg_b786aead-0eb3-4880-bb46-0174ca150730"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEwLTEtMS0xNTU2Mzg_b786aead-0eb3-4880-bb46-0174ca150730"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTYtMS0xLTE1NTYzOA_2dad020e-49dc-4f46-9166-52fd70e40e4d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTYtMS0xLTE1NTYzOA_2dad020e-49dc-4f46-9166-52fd70e40e4d"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 4</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">)</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTItMS0xLTE1NTYzOA_8560e1e6-113f-49a9-a5db-00c29f18a662"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTQtMS0xLTE1NTYzOA_47101ccf-cf07-4de7-bb9b-28d921f5d23a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTE0LTEtMS0xNTU2Mzg_820b8eec-4175-4e49-b47a-d53cf5c61a03"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEyLTEtMS0xNTU2Mzg_d747b835-40c4-4736-9e1a-06a05ad61374"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTEwLTEtMS0xNTU2Mzg_b786aead-0eb3-4880-bb46-0174ca150730"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90YWJsZToyZjBmMzFkMmNjYWY0M2FkOGUxMzkyNGQ3MTVlNTMzYi90YWJsZXJhbmdlOjJmMGYzMWQyY2NhZjQzYWQ4ZTEzOTI0ZDcxNWU1MzNiXzMyLTYtMS0xLTE1NTYzOA_2dad020e-49dc-4f46-9166-52fd70e40e4d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODQvZnJhZzozNWFjMjY0NGVhNTY0OTI2YWVjZGY0ZDQxYjgzMWM2Yy90ZXh0cmVnaW9uOjM1YWMyNjQ0ZWE1NjQ5MjZhZWNkZjRkNDFiODMxYzZjXzEyNDE_6bba6b2c-af7c-453a-ae4f-d38e1c1b429d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtNC0xLTEtMTU1NjM4_dd146452-18dc-4d23-a080-83e4f78e3d3b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtNC0xLTEtMTU1NjM4_dd146452-18dc-4d23-a080-83e4f78e3d3b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtMi0xLTEtMTU1NjM4_94dbdfbe-5859-4c23-9d8d-2d3e183bbfd0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtMi0xLTEtMTU1NjM4_94dbdfbe-5859-4c23-9d8d-2d3e183bbfd0"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzc0NQ_18d5f6d7-e265-405d-b5ef-606a4d9ca43e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzc0NQ_18d5f6d7-e265-405d-b5ef-606a4d9ca43e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Primarily includes cash collateral. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7F</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtNC0xLTEtMTU1NjM4_dd146452-18dc-4d23-a080-83e4f78e3d3b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzc0NQ_18d5f6d7-e265-405d-b5ef-606a4d9ca43e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90YWJsZToxZmZmNDgxNTYyNTk0NmU5OTcxOTY0MWEyNDcwN2ZmNi90YWJsZXJhbmdlOjFmZmY0ODE1NjI1OTQ2ZTk5NzE5NjQxYTI0NzA3ZmY2XzUtMi0xLTEtMTU1NjM4_94dbdfbe-5859-4c23-9d8d-2d3e183bbfd0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTAvZnJhZzo0OWE0OTJiN2NmNzU0NTU1OWU1ZGU4MmZhMWY3YzUxMy90ZXh0cmVnaW9uOjQ5YTQ5MmI3Y2Y3NTQ1NTU5ZTVkZTgyZmExZjdjNTEzXzc0NQ_18d5f6d7-e265-405d-b5ef-606a4d9ca43e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNC0xLTEtMTU1NjM4_e4128565-3c24-48a5-b18f-612d542f6555"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNC0xLTEtMTU1NjM4_e4128565-3c24-48a5-b18f-612d542f6555"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtMi0xLTEtMTU1NjM4_f68267a4-1cac-41fe-9805-9dee9acc44b0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtMi0xLTEtMTU1NjM4_f68267a4-1cac-41fe-9805-9dee9acc44b0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNi0xLTEtMTU1NjM4_49615fd2-0a4b-44b8-a14d-ea8b0be890e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNi0xLTEtMTU1NjM4_49615fd2-0a4b-44b8-a14d-ea8b0be890e2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDIx_9a567361-c846-4e20-a07b-8e6b3bf9e974" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDIx_9a567361-c846-4e20-a07b-8e6b3bf9e974" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">For 2020, related to the separation of Upjohn. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNC0xLTEtMTU1NjM4_e4128565-3c24-48a5-b18f-612d542f6555"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDIx_9a567361-c846-4e20-a07b-8e6b3bf9e974"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtMi0xLTEtMTU1NjM4_f68267a4-1cac-41fe-9805-9dee9acc44b0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDIx_9a567361-c846-4e20-a07b-8e6b3bf9e974"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzQtNi0xLTEtMTU1NjM4_49615fd2-0a4b-44b8-a14d-ea8b0be890e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDIx_9a567361-c846-4e20-a07b-8e6b3bf9e974"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNC0xLTEtMTU1NjM4_2946e08a-d232-4528-a2f0-63419668fd07"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNC0xLTEtMTU1NjM4_2946e08a-d232-4528-a2f0-63419668fd07"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNi0xLTEtMTU1NjM4_732ab48d-d360-432a-bd11-178fbd622007"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNi0xLTEtMTU1NjM4_732ab48d-d360-432a-bd11-178fbd622007"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtMi0xLTEtMTU1NjM4_d31e2e96-23db-4582-8a3b-1875408a08a9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtMi0xLTEtMTU1NjM4_d31e2e96-23db-4582-8a3b-1875408a08a9"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNA_9830691d-ff66-4fc3-a498-0043a67eab32" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNA_9830691d-ff66-4fc3-a498-0043a67eab32" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Reclassified into </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 7E.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNC0xLTEtMTU1NjM4_2946e08a-d232-4528-a2f0-63419668fd07"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNA_9830691d-ff66-4fc3-a498-0043a67eab32"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtNi0xLTEtMTU1NjM4_732ab48d-d360-432a-bd11-178fbd622007"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNA_9830691d-ff66-4fc3-a498-0043a67eab32"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90YWJsZTphNGI2MGE2N2NmNTg0NzYwYjIzMmQwZTcxOWIwNWRlOS90YWJsZXJhbmdlOmE0YjYwYTY3Y2Y1ODQ3NjBiMjMyZDBlNzE5YjA1ZGU5XzgtMi0xLTEtMTU1NjM4_d31e2e96-23db-4582-8a3b-1875408a08a9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTEvZnJhZzozZjY3ZTIxYmY5NzE0NGUwYWJiZjhhYTQ0ZjRjOTFiZi90ZXh0cmVnaW9uOjNmNjdlMjFiZjk3MTQ0ZTBhYmJmOGFhNDRmNGM5MWJmXzIxNA_9830691d-ff66-4fc3-a498-0043a67eab32"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNC0xLTEtMTU1NjM4_e5bdff91-87d3-4fcc-b133-d858a5c2b28b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNC0xLTEtMTU1NjM4_e5bdff91-87d3-4fcc-b133-d858a5c2b28b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktMi0xLTEtMTU1NjM4_b189be12-71d4-4059-9bf6-009e6706aa64"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktMi0xLTEtMTU1NjM4_b189be12-71d4-4059-9bf6-009e6706aa64"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNi0xLTEtMTU1NjM4_0f6f6780-b698-4e7e-9a46-e03c9a909569"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNi0xLTEtMTU1NjM4_0f6f6780-b698-4e7e-9a46-e03c9a909569"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNC0xLTEtMTU1NjM4_e5bdff91-87d3-4fcc-b133-d858a5c2b28b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktMi0xLTEtMTU1NjM4_b189be12-71d4-4059-9bf6-009e6706aa64"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzktNi0xLTEtMTU1NjM4_0f6f6780-b698-4e7e-9a46-e03c9a909569"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMDc_a577d12b-1e9a-4350-88ee-ff8d5ecc33b8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTYtMS0xLTE5MjY0Mg_df1f1f1e-4008-4cda-ac0a-e639d27cec71"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTYtMS0xLTE5MjY0Mg_df1f1f1e-4008-4cda-ac0a-e639d27cec71"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTQtMS0xLTE5MjY0Mg_973de251-1059-4bc4-8eb8-a7ca4fcc9007"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTQtMS0xLTE5MjY0Mg_973de251-1059-4bc4-8eb8-a7ca4fcc9007"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTgtMS0xLTE5MjY0Mg_225a7c3f-25ee-4409-844a-ca7bb3aca5e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTgtMS0xLTE5MjY0Mg_225a7c3f-25ee-4409-844a-ca7bb3aca5e2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTYtMS0xLTE5MjY0Mg_df1f1f1e-4008-4cda-ac0a-e639d27cec71"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTQtMS0xLTE5MjY0Mg_973de251-1059-4bc4-8eb8-a7ca4fcc9007"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzY0LTgtMS0xLTE5MjY0Mg_225a7c3f-25ee-4409-844a-ca7bb3aca5e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzOTgwNDY1NDY0NzA_d0b638c4-8a97-4331-854f-51ce747aa519"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtMi0xLTEtMTU1NjM4_0f5fe7b6-5c36-460b-897e-812a74d93bfa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtMi0xLTEtMTU1NjM4_0f5fe7b6-5c36-460b-897e-812a74d93bfa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNi0xLTEtMTU1NjM4_8b8f1901-f635-44ee-9d4a-eb7fdb7e5051"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNi0xLTEtMTU1NjM4_8b8f1901-f635-44ee-9d4a-eb7fdb7e5051"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNC0xLTEtMTU1NjM4_e704333c-12e8-4a4c-b863-0e3dcb069f41"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNC0xLTEtMTU1NjM4_e704333c-12e8-4a4c-b863-0e3dcb069f41"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY4_42c85971-5021-482d-b383-51e54647f6a4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY4_42c85971-5021-482d-b383-51e54647f6a4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increase in 2021 reflects increases in alliance revenues from Comirnaty, Eliquis and Xtandi, while the increase in 2020 reflects increases in alliance revenues from Eliquis and Xtandi.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtMi0xLTEtMTU1NjM4_0f5fe7b6-5c36-460b-897e-812a74d93bfa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY4_42c85971-5021-482d-b383-51e54647f6a4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNi0xLTEtMTU1NjM4_8b8f1901-f635-44ee-9d4a-eb7fdb7e5051"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY4_42c85971-5021-482d-b383-51e54647f6a4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90YWJsZTozMThiMmJmMDE5MTk0YzkzYjA5OTA2ZDM5MGVhMjc1OC90YWJsZXJhbmdlOjMxOGIyYmYwMTkxOTRjOTNiMDk5MDZkMzkwZWEyNzU4XzQtNC0xLTEtMTU1NjM4_e704333c-12e8-4a4c-b863-0e3dcb069f41"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNjkvZnJhZzoxMDkzNTRkYWM2MWQ0MDgxYTJlYzYxZDZhYTgzZGNmZi90ZXh0cmVnaW9uOjEwOTM1NGRhYzYxZDQwODFhMmVjNjFkNmFhODNkY2ZmXzMwMDY4_42c85971-5021-482d-b383-51e54647f6a4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTItMS0xLTE1NTYzOA_ec8ed15c-853f-4f9d-9077-d757457c043f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTItMS0xLTE1NTYzOA_ec8ed15c-853f-4f9d-9077-d757457c043f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEwLTEtMS0xNTU2Mzg_256ac849-9771-4c25-922b-dee9ffa34d45"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEwLTEtMS0xNTU2Mzg_256ac849-9771-4c25-922b-dee9ffa34d45"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEyLTEtMS0xNTU2Mzg_501583b2-b019-46e5-97c6-28b9baafb81e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEyLTEtMS0xNTU2Mzg_501583b2-b019-46e5-97c6-28b9baafb81e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTQtMS0xLTE1NTYzOA_25a2f8eb-5da8-4020-ba2c-8e014a264ad9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTQtMS0xLTE1NTYzOA_25a2f8eb-5da8-4020-ba2c-8e014a264ad9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTYtMS0xLTE1NTYzOA_f9e63e0c-4405-44e8-a587-74d7b2a3a01b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTYtMS0xLTE1NTYzOA_f9e63e0c-4405-44e8-a587-74d7b2a3a01b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTgtMS0xLTE1NTYzOA_fc3931a6-a25a-4777-b4ba-3e187909c117"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTgtMS0xLTE1NTYzOA_fc3931a6-a25a-4777-b4ba-3e187909c117"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The decrease is primarily due to amortization, partially offset by the capitalization of the Comirnaty milestones described above.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTItMS0xLTE1NTYzOA_ec8ed15c-853f-4f9d-9077-d757457c043f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEwLTEtMS0xNTU2Mzg_256ac849-9771-4c25-922b-dee9ffa34d45"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTEyLTEtMS0xNTU2Mzg_501583b2-b019-46e5-97c6-28b9baafb81e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTQtMS0xLTE1NTYzOA_25a2f8eb-5da8-4020-ba2c-8e014a264ad9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTYtMS0xLTE1NTYzOA_f9e63e0c-4405-44e8-a587-74d7b2a3a01b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZTo5YWFlNzJhMGQyMmQ0YTFlYmVkMmZiZWE2YmRkZjk5YS90YWJsZXJhbmdlOjlhYWU3MmEwZDIyZDRhMWViZWQyZmJlYTZiZGRmOTlhXzE0LTgtMS0xLTE1NTYzOA_fc3931a6-a25a-4777-b4ba-3e187909c117"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1MzA0OTQ_46dca01a-ae9c-433d-b923-0161556c680a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTYtMS0xLTE1NTYzOA_c697291f-04b7-45d2-b1f2-649da30c1f4f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTYtMS0xLTE1NTYzOA_c697291f-04b7-45d2-b1f2-649da30c1f4f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTItMS0xLTE1NTYzOA_18721505-f445-4d7f-8156-359aab0e6695"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTItMS0xLTE1NTYzOA_18721505-f445-4d7f-8156-359aab0e6695"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTQtMS0xLTE1NTYzOA_8855cfec-668e-4aaf-b7b2-4e8a81025858"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTQtMS0xLTE1NTYzOA_8855cfec-668e-4aaf-b7b2-4e8a81025858"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTk_eb112cb9-f220-4b30-8aac-7377f127f4a0" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTk_eb112cb9-f220-4b30-8aac-7377f127f4a0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </xhtml:span><xhtml:span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</xhtml:span><xhtml:span style="color:#242424;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTYtMS0xLTE1NTYzOA_c697291f-04b7-45d2-b1f2-649da30c1f4f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTk_eb112cb9-f220-4b30-8aac-7377f127f4a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTItMS0xLTE1NTYzOA_18721505-f445-4d7f-8156-359aab0e6695"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTk_eb112cb9-f220-4b30-8aac-7377f127f4a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzE1LTQtMS0xLTE1NTYzOA_8855cfec-668e-4aaf-b7b2-4e8a81025858"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4XzczOTk_eb112cb9-f220-4b30-8aac-7377f127f4a0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTgtMS0xLTE1NTYzOA_dcd76900-b494-4bb3-ae58-5e24f2f31d15"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTgtMS0xLTE1NTYzOA_dcd76900-b494-4bb3-ae58-5e24f2f31d15"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTItMS0xLTE1NTYzOA_e478804d-42ac-4204-89c1-1eb3b3c4d922"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTItMS0xLTE1NTYzOA_e478804d-42ac-4204-89c1-1eb3b3c4d922"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTgtMS0xLTE1NTYzOA_7be9e936-f8d0-4072-9eb0-3e7538b8a30d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTgtMS0xLTE1NTYzOA_7be9e936-f8d0-4072-9eb0-3e7538b8a30d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTgtMS0xLTE1NTYzOA_011302af-b5f5-4dac-8819-02eafbbd14d4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTgtMS0xLTE1NTYzOA_011302af-b5f5-4dac-8819-02eafbbd14d4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTItMS0xLTE1NTYzOA_1d521dba-67e6-4774-ad3e-263f21d6ba2d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTItMS0xLTE1NTYzOA_1d521dba-67e6-4774-ad3e-263f21d6ba2d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTYtMS0xLTE1NTYzOA_087da3aa-6d1a-444e-99cb-fb3ba334d61b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTYtMS0xLTE1NTYzOA_087da3aa-6d1a-444e-99cb-fb3ba334d61b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTgtMS0xLTE1NTYzOA_eef6cb3b-6941-4582-bc48-cf1dc25da512"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTgtMS0xLTE1NTYzOA_eef6cb3b-6941-4582-bc48-cf1dc25da512"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTYtMS0xLTE1NTYzOA_63fc9557-bdc2-4b91-a304-6bfa8d2f3a68"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTYtMS0xLTE1NTYzOA_63fc9557-bdc2-4b91-a304-6bfa8d2f3a68"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTQtMS0xLTE1NTYzOA_6d723252-e0db-426d-9f98-c3ba2727adce"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTQtMS0xLTE1NTYzOA_6d723252-e0db-426d-9f98-c3ba2727adce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTQtMS0xLTE1NTYzOA_8ee7ad89-2b40-4fc9-986d-77b006d108ea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTQtMS0xLTE1NTYzOA_8ee7ad89-2b40-4fc9-986d-77b006d108ea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTQtMS0xLTE1NTYzOA_ce663fcc-934b-4f97-bc38-6a9f03ef0645"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTQtMS0xLTE1NTYzOA_ce663fcc-934b-4f97-bc38-6a9f03ef0645"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTItMS0xLTE1NTYzOA_da4468a1-5047-41ec-9622-d82ce1b6ca86"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTItMS0xLTE1NTYzOA_da4468a1-5047-41ec-9622-d82ce1b6ca86"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTQtMS0xLTE1NTYzOA_25fdaedb-fcea-4223-915c-2953a3bd0c5d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTQtMS0xLTE1NTYzOA_25fdaedb-fcea-4223-915c-2953a3bd0c5d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTYtMS0xLTE1NTYzOA_1359244d-9ca7-42ec-af97-2d6bf9cb686b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTYtMS0xLTE1NTYzOA_1359244d-9ca7-42ec-af97-2d6bf9cb686b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTItMS0xLTE1NTYzOA_f59a388e-1923-46fe-946e-8ddcbb26213c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTItMS0xLTE1NTYzOA_f59a388e-1923-46fe-946e-8ddcbb26213c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTYtMS0xLTE1NTYzOA_52f6660e-780d-4444-9d2b-959ce46860ac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTYtMS0xLTE1NTYzOA_52f6660e-780d-4444-9d2b-959ce46860ac"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Our main U.S. qualified plan and many of our international plans were overfunded as of December 31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTgtMS0xLTE1NTYzOA_dcd76900-b494-4bb3-ae58-5e24f2f31d15"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTItMS0xLTE1NTYzOA_e478804d-42ac-4204-89c1-1eb3b3c4d922"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTgtMS0xLTE1NTYzOA_7be9e936-f8d0-4072-9eb0-3e7538b8a30d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTgtMS0xLTE1NTYzOA_011302af-b5f5-4dac-8819-02eafbbd14d4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTItMS0xLTE1NTYzOA_1d521dba-67e6-4774-ad3e-263f21d6ba2d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTYtMS0xLTE1NTYzOA_087da3aa-6d1a-444e-99cb-fb3ba334d61b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTgtMS0xLTE1NTYzOA_eef6cb3b-6941-4582-bc48-cf1dc25da512"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTYtMS0xLTE1NTYzOA_63fc9557-bdc2-4b91-a304-6bfa8d2f3a68"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTQtMS0xLTE1NTYzOA_6d723252-e0db-426d-9f98-c3ba2727adce"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTQtMS0xLTE1NTYzOA_8ee7ad89-2b40-4fc9-986d-77b006d108ea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTQtMS0xLTE1NTYzOA_ce663fcc-934b-4f97-bc38-6a9f03ef0645"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU5LTItMS0xLTE1NTYzOA_da4468a1-5047-41ec-9622-d82ce1b6ca86"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTQtMS0xLTE1NTYzOA_25fdaedb-fcea-4223-915c-2953a3bd0c5d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU0LTYtMS0xLTE1NTYzOA_1359244d-9ca7-42ec-af97-2d6bf9cb686b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzU1LTItMS0xLTE1NTYzOA_f59a388e-1923-46fe-946e-8ddcbb26213c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzYwLTYtMS0xLTE1NTYzOA_52f6660e-780d-4444-9d2b-959ce46860ac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzQzOTgwNDY1MzMxNDY_2a5b58c4-5234-42d8-8832-2b19e9f2ce1c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTgtMS0xLTE1NTYzOA_4a4fd6f2-6e82-4b8a-b870-339dfe8edb35"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTgtMS0xLTE1NTYzOA_4a4fd6f2-6e82-4b8a-b870-339dfe8edb35"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTQtMS0xLTE1NTYzOA_e2fa2de8-d998-4b80-bebc-4cd7c402c0c8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTQtMS0xLTE1NTYzOA_e2fa2de8-d998-4b80-bebc-4cd7c402c0c8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTYtMS0xLTE1NTYzOA_625152f8-e200-4048-8ec7-2928d62faf56"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTYtMS0xLTE1NTYzOA_625152f8-e200-4048-8ec7-2928d62faf56"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzI_70d446fc-6d87-4eaa-9bc7-53cbba59b771" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzI_70d446fc-6d87-4eaa-9bc7-53cbba59b771" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:4.1pt">On July&#160;31, 2019, our Consumer Healthcare business, an OTC medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare JV. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2C</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTgtMS0xLTE1NTYzOA_4a4fd6f2-6e82-4b8a-b870-339dfe8edb35"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzI_70d446fc-6d87-4eaa-9bc7-53cbba59b771"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTQtMS0xLTE1NTYzOA_e2fa2de8-d998-4b80-bebc-4cd7c402c0c8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzI_70d446fc-6d87-4eaa-9bc7-53cbba59b771"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzU3LTYtMS0xLTE1NTYzOA_625152f8-e200-4048-8ec7-2928d62faf56"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzNzI_70d446fc-6d87-4eaa-9bc7-53cbba59b771"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtMi0xLTEtMTU1NjM4_5a7da2e0-b310-4992-9ead-53d778086a59"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtMi0xLTEtMTU1NjM4_5a7da2e0-b310-4992-9ead-53d778086a59"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNC0xLTEtMTU1NjM4_7610cbaa-8fc4-4815-b1d5-99eac4d0bbb0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNC0xLTEtMTU1NjM4_7610cbaa-8fc4-4815-b1d5-99eac4d0bbb0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNi0xLTEtMTU1NjM4_3213929f-51ad-4505-8713-b09ae07ab6ff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNi0xLTEtMTU1NjM4_3213929f-51ad-4505-8713-b09ae07ab6ff"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Nw_399e05ff-d281-48cc-9c48-a9128c75a260" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Nw_399e05ff-d281-48cc-9c48-a9128c75a260" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. As of December 31, 2021, there were cumulative impairments and downward adjustments of $97 million and upward adjustments of $156 million. Impairments, downward and upward adjustments were not significant in 2021, 2020 and 2019</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtMi0xLTEtMTU1NjM4_5a7da2e0-b310-4992-9ead-53d778086a59"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Nw_399e05ff-d281-48cc-9c48-a9128c75a260"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNC0xLTEtMTU1NjM4_7610cbaa-8fc4-4815-b1d5-99eac4d0bbb0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Nw_399e05ff-d281-48cc-9c48-a9128c75a260"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90YWJsZTpkNjlkZTA5N2IzYTc0NmI2OGRhOGIzMTA4Y2Q3ZjkzOC90YWJsZXJhbmdlOmQ2OWRlMDk3YjNhNzQ2YjY4ZGE4YjMxMDhjZDdmOTM4XzUtNi0xLTEtMTU1NjM4_3213929f-51ad-4505-8713-b09ae07ab6ff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xODcvZnJhZzo0ZDk1NzVjMDIxMDY0ODQzOGRhYWZjMGU1OTZlNGJmMC90ZXh0cmVnaW9uOjRkOTU3NWMwMjEwNjQ4NDM4ZGFhZmMwZTU5NmU0YmYwXzg5Nw_399e05ff-d281-48cc-9c48-a9128c75a260"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTgtMS0xLTE1NTYzOA_68e027e6-af0e-4ef0-afae-8b7bf7ff0d27"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTgtMS0xLTE1NTYzOA_68e027e6-af0e-4ef0-afae-8b7bf7ff0d27"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE2LTEtMS0xNTU2Mzg_298650ef-6ab3-4cb3-81f1-a735e51a7f90"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE2LTEtMS0xNTU2Mzg_298650ef-6ab3-4cb3-81f1-a735e51a7f90"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTQtMS0xLTE1NTYzOA_70aac13a-baf8-4171-84d1-f83e89dc4d6f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTQtMS0xLTE1NTYzOA_70aac13a-baf8-4171-84d1-f83e89dc4d6f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTYtMS0xLTE1NTYzOA_b93deecb-4ab1-4c04-bb4f-c3884d271f31"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTYtMS0xLTE1NTYzOA_b93deecb-4ab1-4c04-bb4f-c3884d271f31"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE2LTEtMS0xNTU2Mzg_55d6612b-509e-4e4e-9e3f-38aeafd8d90f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE2LTEtMS0xNTU2Mzg_55d6612b-509e-4e4e-9e3f-38aeafd8d90f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEwLTEtMS0xNTU2Mzg_94f58f7c-725d-4068-95d6-a5d42c4fec72"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEwLTEtMS0xNTU2Mzg_94f58f7c-725d-4068-95d6-a5d42c4fec72"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE4LTEtMS0xNTU2Mzg_d6752f22-093b-4587-8387-81799384a918"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE4LTEtMS0xNTU2Mzg_d6752f22-093b-4587-8387-81799384a918"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE0LTEtMS0xNTU2Mzg_a07d3655-9ba7-4a78-ac67-692db249b25f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE0LTEtMS0xNTU2Mzg_a07d3655-9ba7-4a78-ac67-692db249b25f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTQtMS0xLTE1NTYzOA_253e4e25-a98a-4cf5-8749-395c9dedcd3d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTQtMS0xLTE1NTYzOA_253e4e25-a98a-4cf5-8749-395c9dedcd3d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIwLTEtMS0xNTU2Mzg_aaddd5c9-00c9-410b-ae32-5c465dfd74f4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIwLTEtMS0xNTU2Mzg_aaddd5c9-00c9-410b-ae32-5c465dfd74f4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTYtMS0xLTE1NTYzOA_d78cb2b6-5dc0-4f55-8ec1-99c8a25c3a7a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTYtMS0xLTE1NTYzOA_d78cb2b6-5dc0-4f55-8ec1-99c8a25c3a7a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIwLTEtMS0xNTU2Mzg_dab840e9-9bf7-41cd-937b-b650f194bbdf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIwLTEtMS0xNTU2Mzg_dab840e9-9bf7-41cd-937b-b650f194bbdf"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTgtMS0xLTE1NTYzOA_858c9006-32b2-48a8-8d60-39f2cd0e9d08"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTgtMS0xLTE1NTYzOA_858c9006-32b2-48a8-8d60-39f2cd0e9d08"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEwLTEtMS0xNTU2Mzg_69a9ad1c-52a1-4930-bd2e-8e9bbc9e8e46"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEwLTEtMS0xNTU2Mzg_69a9ad1c-52a1-4930-bd2e-8e9bbc9e8e46"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE4LTEtMS0xNTU2Mzg_e89a0ca5-4065-4544-9e31-f514a259a70d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE4LTEtMS0xNTU2Mzg_e89a0ca5-4065-4544-9e31-f514a259a70d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE0LTEtMS0xNTU2Mzg_b7b49a6c-8ac0-40dd-900c-08b8b9b128ff"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE0LTEtMS0xNTU2Mzg_b7b49a6c-8ac0-40dd-900c-08b8b9b128ff"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTgtMS0xLTE1NTYzOA_68e027e6-af0e-4ef0-afae-8b7bf7ff0d27"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE2LTEtMS0xNTU2Mzg_298650ef-6ab3-4cb3-81f1-a735e51a7f90"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTQtMS0xLTE1NTYzOA_70aac13a-baf8-4171-84d1-f83e89dc4d6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTYtMS0xLTE1NTYzOA_b93deecb-4ab1-4c04-bb4f-c3884d271f31"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE2LTEtMS0xNTU2Mzg_55d6612b-509e-4e4e-9e3f-38aeafd8d90f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTEwLTEtMS0xNTU2Mzg_94f58f7c-725d-4068-95d6-a5d42c4fec72"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE4LTEtMS0xNTU2Mzg_d6752f22-093b-4587-8387-81799384a918"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE0LTEtMS0xNTU2Mzg_a07d3655-9ba7-4a78-ac67-692db249b25f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTQtMS0xLTE1NTYzOA_253e4e25-a98a-4cf5-8749-395c9dedcd3d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTIwLTEtMS0xNTU2Mzg_aaddd5c9-00c9-410b-ae32-5c465dfd74f4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTYtMS0xLTE1NTYzOA_d78cb2b6-5dc0-4f55-8ec1-99c8a25c3a7a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTIwLTEtMS0xNTU2Mzg_dab840e9-9bf7-41cd-937b-b650f194bbdf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTgtMS0xLTE1NTYzOA_858c9006-32b2-48a8-8d60-39f2cd0e9d08"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTEwLTEtMS0xNTU2Mzg_69a9ad1c-52a1-4930-bd2e-8e9bbc9e8e46"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzE2LTE4LTEtMS0xNTU2Mzg_e89a0ca5-4065-4544-9e31-f514a259a70d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZToyOGY0MjA5OTY0ODQ0YmNmYmE2MTg5OTE0Mzg1N2U1ZC90YWJsZXJhbmdlOjI4ZjQyMDk5NjQ4NDRiY2ZiYTYxODk5MTQzODU3ZTVkXzMwLTE0LTEtMS0xNTU2Mzg_b7b49a6c-8ac0-40dd-900c-08b8b9b128ff"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTQ0_59b7935d-6ed5-4f73-a7cc-6ea681b65321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNC0xLTEtMTU1NjM4_ed5826a8-7da8-49e4-8756-b5185b33aa9d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNC0xLTEtMTU1NjM4_ed5826a8-7da8-49e4-8756-b5185b33aa9d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNi0xLTEtMTU1NjM4_b77dc72b-c8f9-4d74-adcf-0cc74961cc96"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNi0xLTEtMTU1NjM4_b77dc72b-c8f9-4d74-adcf-0cc74961cc96"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNi0xLTEtMTU1NjM4_71f74a89-7dbf-4577-a87e-55fadd19a618"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNi0xLTEtMTU1NjM4_71f74a89-7dbf-4577-a87e-55fadd19a618"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNC0xLTEtMTU1NjM4_c2438de5-3204-47f9-9685-f2d214131cd7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNC0xLTEtMTU1NjM4_c2438de5-3204-47f9-9685-f2d214131cd7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtMi0xLTEtMTU1NjM4_aa2deccf-47ae-41ab-967e-42c0d0e0faea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtMi0xLTEtMTU1NjM4_aa2deccf-47ae-41ab-967e-42c0d0e0faea"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtMi0xLTEtMTU1NjM4_db22426c-6c10-4c2a-a824-e4c66d87abec"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtMi0xLTEtMTU1NjM4_db22426c-6c10-4c2a-a824-e4c66d87abec"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNC0xLTEtMTU1NjM4_ed5826a8-7da8-49e4-8756-b5185b33aa9d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtNi0xLTEtMTU1NjM4_b77dc72b-c8f9-4d74-adcf-0cc74961cc96"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNi0xLTEtMTU1NjM4_71f74a89-7dbf-4577-a87e-55fadd19a618"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtNC0xLTEtMTU1NjM4_c2438de5-3204-47f9-9685-f2d214131cd7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzgtMi0xLTEtMTU1NjM4_aa2deccf-47ae-41ab-967e-42c0d0e0faea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90YWJsZTplOTgwYzViZTkwODM0OWViOGRlY2EzM2EzZTU0YWMzOC90YWJsZXJhbmdlOmU5ODBjNWJlOTA4MzQ5ZWI4ZGVjYTMzYTNlNTRhYzM4XzUtMi0xLTEtMTU1NjM4_db22426c-6c10-4c2a-a824-e4c66d87abec"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzgvZnJhZzozMjllMTIzY2UwYzg0ZjM4ODJiOTM5MjIyMDkxZjY4Ny90ZXh0cmVnaW9uOjMyOWUxMjNjZTBjODRmMzg4MmI5MzkyMjIwOTFmNjg3XzE3NDE3_b8f773e0-082a-42ff-b3b6-4142998f58b4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzItMTAtMS0xLTE1NTYzOA_495466a8-c79e-4cc0-969b-e8a7379b21b8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzItMTAtMS0xLTE1NTYzOA_495466a8-c79e-4cc0-969b-e8a7379b21b8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTItMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTItMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzgtMTAtMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzgtMTAtMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzUtMTAtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzUtMTAtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzYtMTAtMS0xLTE1NTYzOA_2ffcb87d-156e-488c-ab55-3b76d0184eaa"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzYtMTAtMS0xLTE1NTYzOA_2ffcb87d-156e-488c-ab55-3b76d0184eaa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTQtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTQtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzItMTAtMS0xLTE1NTYzOA_495466a8-c79e-4cc0-969b-e8a7379b21b8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTItMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzgtMTAtMS0xLTE1NTYzOA_5bc5cc1c-5a9b-442d-a440-bb5d8c6d4da7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzUtMTAtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90YWJsZToxZjk0OGVmNTU1NjQ0ZGNmOWU5MzQwMDBhYjQwODllMi90YWJsZXJhbmdlOjFmOTQ4ZWY1NTU2NDRkY2Y5ZTkzNDAwMGFiNDA4OWUyXzYtMTAtMS0xLTE1NTYzOA_2ffcb87d-156e-488c-ab55-3b76d0184eaa"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTQvZnJhZzphNDQ1OTU4N2RkMzY0YTc4Yjc2NmZmMjdmYzgwOWEzYS90YWJsZTplYjZjYTViOGIxMTY0ZDNkYmMzZThlYTI4MTJkOTE4Zi90YWJsZXJhbmdlOmViNmNhNWI4YjExNjRkM2RiYzNlOGVhMjgxMmQ5MThmXzE2LTQtMS0xLTE1NTYzOA_35c94a76-bf66-4f43-9d63-021c0eb16614"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMDgvZnJhZzo0ZWY1MDNkZjNlZWQ0NTllYTRiNjVkM2I3NmJlMmYwNS90ZXh0cmVnaW9uOjRlZjUwM2RmM2VlZDQ1OWVhNGI2NWQzYjc2YmUyZjA1XzQzOTgwNDY1Mzg3MzA_4178fb35-e733-4579-8db6-f2e91084db70"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIyLTEtMS0xNzc0NDY_54c2cdd6-b12d-4c75-ac60-2812a95fe9c4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIyLTEtMS0xNzc0NDY_54c2cdd6-b12d-4c75-ac60-2812a95fe9c4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTI0LTEtMS0xNzc0NDY_f6c3282a-ce85-437a-9714-ec11e7f051f1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTI0LTEtMS0xNzc0NDY_f6c3282a-ce85-437a-9714-ec11e7f051f1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTI0LTEtMS0xNzc0NDY_ed46c745-7e0a-44cb-a4eb-bd65a5789eac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTI0LTEtMS0xNzc0NDY_ed46c745-7e0a-44cb-a4eb-bd65a5789eac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjItMS0xLTE3NzQ0Ng_7f261ace-5a86-4ffd-a6e4-932d53aefa61"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjItMS0xLTE3NzQ0Ng_7f261ace-5a86-4ffd-a6e4-932d53aefa61"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIwLTEtMS0xNzc0NDY_f1fc0f33-3394-49b5-938e-49c96d2b3d65"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIwLTEtMS0xNzc0NDY_f1fc0f33-3394-49b5-938e-49c96d2b3d65"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjAtMS0xLTE3NzQ0Ng_ced6d2cc-140c-4c29-904f-0f866c56c86e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjAtMS0xLTE3NzQ0Ng_ced6d2cc-140c-4c29-904f-0f866c56c86e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIyLTEtMS0xNzc0NDY_8faca64c-3b06-4ec4-b420-0e3155170551"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIyLTEtMS0xNzc0NDY_8faca64c-3b06-4ec4-b420-0e3155170551"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTI0LTEtMS0xNzc0NDY_0b14d794-f57a-4276-ba3f-c9f69d425ee7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTI0LTEtMS0xNzc0NDY_0b14d794-f57a-4276-ba3f-c9f69d425ee7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIwLTEtMS0xNzc0NDY_8c2ed33c-a0b1-422d-bae1-3dc5d98f8602"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIwLTEtMS0xNzc0NDY_8c2ed33c-a0b1-422d-bae1-3dc5d98f8602"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIwLTEtMS0xNzc0NDY_67bd40ae-61e5-4b13-b748-ff051595a96f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIwLTEtMS0xNzc0NDY_67bd40ae-61e5-4b13-b748-ff051595a96f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjQtMS0xLTE3NzQ0Ng_272ec279-d27e-4efd-83ad-a0d2b248698e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjQtMS0xLTE3NzQ0Ng_272ec279-d27e-4efd-83ad-a0d2b248698e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIyLTEtMS0xNzc0NDY_905c3a81-05ac-4ad2-b380-1cf7f60f4219"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIyLTEtMS0xNzc0NDY_905c3a81-05ac-4ad2-b380-1cf7f60f4219"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIyLTEtMS0xNzc0NDY_54c2cdd6-b12d-4c75-ac60-2812a95fe9c4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTI0LTEtMS0xNzc0NDY_f6c3282a-ce85-437a-9714-ec11e7f051f1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTI0LTEtMS0xNzc0NDY_ed46c745-7e0a-44cb-a4eb-bd65a5789eac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjItMS0xLTE3NzQ0Ng_7f261ace-5a86-4ffd-a6e4-932d53aefa61"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEyLTIwLTEtMS0xNzc0NDY_f1fc0f33-3394-49b5-938e-49c96d2b3d65"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjAtMS0xLTE3NzQ0Ng_ced6d2cc-140c-4c29-904f-0f866c56c86e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIyLTEtMS0xNzc0NDY_8faca64c-3b06-4ec4-b420-0e3155170551"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTI0LTEtMS0xNzc0NDY_0b14d794-f57a-4276-ba3f-c9f69d425ee7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzExLTIwLTEtMS0xNzc0NDY_8c2ed33c-a0b1-422d-bae1-3dc5d98f8602"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIwLTEtMS0xNzc0NDY_67bd40ae-61e5-4b13-b748-ff051595a96f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzUtMjQtMS0xLTE3NzQ0Ng_272ec279-d27e-4efd-83ad-a0d2b248698e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzE0LTIyLTEtMS0xNzc0NDY_905c3a81-05ac-4ad2-b380-1cf7f60f4219"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjAz_9689a1d0-63be-4648-b952-bf64a15acec9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTgtMS0xLTE1NTYzOA_f45c3b5f-a7dd-48d8-9864-4df1b90c966f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTgtMS0xLTE1NTYzOA_f45c3b5f-a7dd-48d8-9864-4df1b90c966f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtOC0xLTEtMTU1NjM4_a8ea7123-02b9-4280-a4ee-558383a13da3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtOC0xLTEtMTU1NjM4_a8ea7123-02b9-4280-a4ee-558383a13da3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzEwLTgtMS0xLTE1NTYzOA_f45c3b5f-a7dd-48d8-9864-4df1b90c966f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90YWJsZTo1YjU1NGZlOTdhMjA0ZWU3ODM0NDJhYWM5ODdiYTA3My90YWJsZXJhbmdlOjViNTU0ZmU5N2EyMDRlZTc4MzQ0MmFhYzk4N2JhMDczXzgtOC0xLTEtMTU1NjM4_a8ea7123-02b9-4280-a4ee-558383a13da3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjMvZnJhZzpjNDY4MTMxZWJjOWI0ODYwYWJkNDkwNzU2MjA0ZDU5Ni90ZXh0cmVnaW9uOmM0NjgxMzFlYmM5YjQ4NjBhYmQ0OTA3NTYyMDRkNTk2XzUxMTc_d4d541a8-7d61-48b9-887e-03ac4ccf3759"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNC0xLTEtMTU1NjM4_bc3cca5e-42f5-463e-8b51-f54d4eb4fc38"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNC0xLTEtMTU1NjM4_bc3cca5e-42f5-463e-8b51-f54d4eb4fc38"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtOC0xLTEtMTU1NjM4_03c5052c-0e84-48f7-9edf-6b33ec73e5b5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtOC0xLTEtMTU1NjM4_03c5052c-0e84-48f7-9edf-6b33ec73e5b5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtMi0xLTEtMTU1NjM4_2a363825-77ea-4727-b774-2d27000e61c9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtMi0xLTEtMTU1NjM4_2a363825-77ea-4727-b774-2d27000e61c9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNi0xLTEtMTU1NjM4_8e7b2b15-4b8a-49c5-90e8-18a0750addb7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNi0xLTEtMTU1NjM4_8e7b2b15-4b8a-49c5-90e8-18a0750addb7"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Included in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($816 million) and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other noncurrent liabilities </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">($255 million).</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNC0xLTEtMTU1NjM4_bc3cca5e-42f5-463e-8b51-f54d4eb4fc38"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtOC0xLTEtMTU1NjM4_03c5052c-0e84-48f7-9edf-6b33ec73e5b5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtMi0xLTEtMTU1NjM4_2a363825-77ea-4727-b774-2d27000e61c9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTozZDFlMWNiYWU2OGQ0NWJiYTk1NDExMGZjYWQ4MDBiMS90YWJsZXJhbmdlOjNkMWUxY2JhZTY4ZDQ1YmJhOTU0MTEwZmNhZDgwMGIxXzgtNi0xLTEtMTU1NjM4_8e7b2b15-4b8a-49c5-90e8-18a0750addb7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDI3_c4e99f37-9067-4de3-ba50-acd9d37b52d4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTgtMS0xLTE1NTYzOA_22e67cb7-a692-4f22-b211-654b1e63675f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTgtMS0xLTE1NTYzOA_22e67cb7-a692-4f22-b211-654b1e63675f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjAxMA_b01f1c97-93f1-46a1-99e8-af9042092584"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjAxMA_b01f1c97-93f1-46a1-99e8-af9042092584"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE1NTYzOA_492c7816-9dbc-458f-9896-5645ccb7be3a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE1NTYzOA_492c7816-9dbc-458f-9896-5645ccb7be3a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTYtMS0xLTE2MjA4NQ_0c5c6baa-55e5-4560-8e48-d75e567c277c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTYtMS0xLTE2MjA4NQ_0c5c6baa-55e5-4560-8e48-d75e567c277c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTQtMS0xLTE2MjA4NQ_862ece23-b22d-41fb-b445-a8fb8400869e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTQtMS0xLTE2MjA4NQ_862ece23-b22d-41fb-b445-a8fb8400869e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTIwNDQ1OA_a7dd1abd-ef00-4aab-b4b3-aa247e5e03e9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTIwNDQ1OA_a7dd1abd-ef00-4aab-b4b3-aa247e5e03e9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE1NTYzOA_b156dc16-529f-44d0-ac01-d31d1d7d5ba1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE1NTYzOA_b156dc16-529f-44d0-ac01-d31d1d7d5ba1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTIwNDQ1MQ_9a68c631-ef4a-4008-9ad5-f858dec514b7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTIwNDQ1MQ_9a68c631-ef4a-4008-9ad5-f858dec514b7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjA3NA_29abafd8-1987-4b69-8d7b-7b36e729d14d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjA3NA_29abafd8-1987-4b69-8d7b-7b36e729d14d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjAxMA_d5f94ded-8f05-494f-867a-3ada9c6f4618"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjAxMA_d5f94ded-8f05-494f-867a-3ada9c6f4618"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTIwNDQ1Ng_873b90bc-fe83-4098-a714-9762073a68b3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTIwNDQ1Ng_873b90bc-fe83-4098-a714-9762073a68b3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjAxMA_6cb5c6c4-f805-4d7c-a4d5-2d9f7e295dd8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjAxMA_6cb5c6c4-f805-4d7c-a4d5-2d9f7e295dd8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTgtMS0xLTE2MjA4NQ_83c25b6b-7635-4a3f-b803-2b579fac20a1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTgtMS0xLTE2MjA4NQ_83c25b6b-7635-4a3f-b803-2b579fac20a1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE1NTYzOA_ef2210fc-2af3-4987-9ee4-e4fabe090c27"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE1NTYzOA_ef2210fc-2af3-4987-9ee4-e4fabe090c27"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjA3NA_9fafef35-c537-48a3-9506-c3d44e8130fb"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjA3NA_9fafef35-c537-48a3-9506-c3d44e8130fb"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjA3NA_898220b7-d9bd-4658-9116-f1f7647bfbf0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjA3NA_898220b7-d9bd-4658-9116-f1f7647bfbf0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTQtMS0xLTE1NTYzOA_b5a3ef71-2dba-41da-9044-3e1f336183ad"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTQtMS0xLTE1NTYzOA_b5a3ef71-2dba-41da-9044-3e1f336183ad"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTYtMS0xLTE1NTYzOA_95ca3f57-7179-4721-b012-2d1c1e26855e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTYtMS0xLTE1NTYzOA_95ca3f57-7179-4721-b012-2d1c1e26855e"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit, Zirabev and Trazimera.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTgtMS0xLTE1NTYzOA_22e67cb7-a692-4f22-b211-654b1e63675f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjAxMA_b01f1c97-93f1-46a1-99e8-af9042092584"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTgtMS0xLTE1NTYzOA_492c7816-9dbc-458f-9896-5645ccb7be3a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTYtMS0xLTE2MjA4NQ_0c5c6baa-55e5-4560-8e48-d75e567c277c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTQtMS0xLTE2MjA4NQ_862ece23-b22d-41fb-b445-a8fb8400869e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTgtMS0xLTIwNDQ1OA_a7dd1abd-ef00-4aab-b4b3-aa247e5e03e9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTYtMS0xLTE1NTYzOA_b156dc16-529f-44d0-ac01-d31d1d7d5ba1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTQtMS0xLTIwNDQ1MQ_9a68c631-ef4a-4008-9ad5-f858dec514b7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjA3NA_29abafd8-1987-4b69-8d7b-7b36e729d14d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTgtMS0xLTE2MjAxMA_d5f94ded-8f05-494f-867a-3ada9c6f4618"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzI0LTYtMS0xLTIwNDQ1Ng_873b90bc-fe83-4098-a714-9762073a68b3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjAxMA_6cb5c6c4-f805-4d7c-a4d5-2d9f7e295dd8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzIwLTgtMS0xLTE2MjA4NQ_83c25b6b-7635-4a3f-b803-2b579fac20a1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzQ4LTQtMS0xLTE1NTYzOA_ef2210fc-2af3-4987-9ee4-e4fabe090c27"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTQtMS0xLTE2MjA3NA_9fafef35-c537-48a3-9506-c3d44e8130fb"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzE4LTYtMS0xLTE2MjA3NA_898220b7-d9bd-4658-9116-f1f7647bfbf0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTQtMS0xLTE1NTYzOA_b5a3ef71-2dba-41da-9044-3e1f336183ad"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZTo3NGE3ODM4Y2RmNGE0N2MzODQ5ZDllNjQyNjgzMzJkMi90YWJsZXJhbmdlOjc0YTc4MzhjZGY0YTQ3YzM4NDlkOWU2NDI2ODMzMmQyXzYwLTYtMS0xLTE1NTYzOA_95ca3f57-7179-4721-b012-2d1c1e26855e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQzMTY_d997c599-57f7-4155-b4d5-24bace85af21"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtMi0xLTEtMTU1NjM4_dd00f2ae-15ce-4545-aac3-21a8dfd1b54a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtMi0xLTEtMTU1NjM4_dd00f2ae-15ce-4545-aac3-21a8dfd1b54a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNC0xLTEtMTU1NjM4_ed4904c4-f0ad-4598-afb5-a7e4c97cb911"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNC0xLTEtMTU1NjM4_ed4904c4-f0ad-4598-afb5-a7e4c97cb911"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtMi0xLTEtMTU1NjM4_dd00f2ae-15ce-4545-aac3-21a8dfd1b54a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzgtNC0xLTEtMTU1NjM4_ed4904c4-f0ad-4598-afb5-a7e4c97cb911"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MjA_b9e36f6f-c3dc-4807-8a2b-0ce64578610a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMi0xLTEtMTU1NjM4_0da5e0e3-0810-4a16-a80c-2f4b195000fd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMi0xLTEtMTU1NjM4_0da5e0e3-0810-4a16-a80c-2f4b195000fd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTQtMS0xLTE1NTYzOA_f60350e2-50aa-4469-a082-b854a2607d33"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTQtMS0xLTE1NTYzOA_f60350e2-50aa-4469-a082-b854a2607d33"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEyLTEtMS0xNTU2Mzg_28c1b928-0392-404d-b275-6cd17bae9db5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEyLTEtMS0xNTU2Mzg_28c1b928-0392-404d-b275-6cd17bae9db5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNC0xLTEtMTU1NjM4_6296c906-9226-4ec4-aca1-227c25bb96ef"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNC0xLTEtMTU1NjM4_6296c906-9226-4ec4-aca1-227c25bb96ef"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEwLTEtMS0xNTU2Mzg_01d5126a-6e40-4228-a15d-40bed1fa2985"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEwLTEtMS0xNTU2Mzg_01d5126a-6e40-4228-a15d-40bed1fa2985"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNi0xLTEtMTU1NjM4_e619fedf-b7de-4035-8db4-50b4796cc9e8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNi0xLTEtMTU1NjM4_e619fedf-b7de-4035-8db4-50b4796cc9e8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTItMS0xLTE1NTYzOA_58c9c685-66d0-4b27-8fd8-86a99f375625"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTItMS0xLTE1NTYzOA_58c9c685-66d0-4b27-8fd8-86a99f375625"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTYtMS0xLTE1NTYzOA_c1445037-0154-4a97-810f-8753322de790"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTYtMS0xLTE1NTYzOA_c1445037-0154-4a97-810f-8753322de790"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctOC0xLTEtMTU1NjM4_cbc1dcb8-9d88-4907-86d3-176196e23a1c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctOC0xLTEtMTU1NjM4_cbc1dcb8-9d88-4907-86d3-176196e23a1c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTItMS0xLTE1NTYzOA_53166da9-0d32-42c1-976b-015a7a580e30"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTItMS0xLTE1NTYzOA_53166da9-0d32-42c1-976b-015a7a580e30"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTgtMS0xLTE1NTYzOA_5a142064-c9bd-4118-8f10-6076f944cba2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTgtMS0xLTE1NTYzOA_5a142064-c9bd-4118-8f10-6076f944cba2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTAtMS0xLTE1NTYzOA_874ff190-7970-4199-9c5a-cb06a3757dac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTAtMS0xLTE1NTYzOA_874ff190-7970-4199-9c5a-cb06a3757dac"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For the U.S. pension plans, the benefit obligation is both the PBO and ABO as these plans are frozen and future benefit accruals no longer increase with future compensation increases. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was $11.2&#160;billion in 2021 and $11.5&#160;billion in 2020. For the postretirement plans, the benefit obligation is the ABO.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMi0xLTEtMTU1NjM4_0da5e0e3-0810-4a16-a80c-2f4b195000fd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTQtMS0xLTE1NTYzOA_f60350e2-50aa-4469-a082-b854a2607d33"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEyLTEtMS0xNTU2Mzg_28c1b928-0392-404d-b275-6cd17bae9db5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNC0xLTEtMTU1NjM4_6296c906-9226-4ec4-aca1-227c25bb96ef"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTEwLTEtMS0xNTU2Mzg_01d5126a-6e40-4228-a15d-40bed1fa2985"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctNi0xLTEtMTU1NjM4_e619fedf-b7de-4035-8db4-50b4796cc9e8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTItMS0xLTE1NTYzOA_58c9c685-66d0-4b27-8fd8-86a99f375625"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTYtMS0xLTE1NTYzOA_c1445037-0154-4a97-810f-8753322de790"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctOC0xLTEtMTU1NjM4_cbc1dcb8-9d88-4907-86d3-176196e23a1c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTItMS0xLTE1NTYzOA_53166da9-0d32-42c1-976b-015a7a580e30"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzIwLTgtMS0xLTE1NTYzOA_5a142064-c9bd-4118-8f10-6076f944cba2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90YWJsZTozNzc1NTk3MTI4ZTQ0NGRmOGE2NjUwOGM5YWMzMWQ2Ni90YWJsZXJhbmdlOjM3NzU1OTcxMjhlNDQ0ZGY4YTY2NTA4YzlhYzMxZDY2XzctMTAtMS0xLTE1NTYzOA_874ff190-7970-4199-9c5a-cb06a3757dac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMTQvZnJhZzoyYzliMjQ3YzA4MjI0NmI3OWFjNDYyZTMyNGNhMzg4OC90ZXh0cmVnaW9uOjJjOWIyNDdjMDgyMjQ2Yjc5YWM0NjJlMzI0Y2EzODg4XzExOTY5_0009c9da-9fcc-4365-a2a7-783a5503c8a8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktMTAtMS0xLTE1NTYzOA_1282a7c8-801c-4056-b485-27f13357c051"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktMTAtMS0xLTE1NTYzOA_1282a7c8-801c-4056-b485-27f13357c051"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktNi0xLTEtMTU1NjM4_524c8e42-409b-4ca5-b64b-d98bdfb311bc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktNi0xLTEtMTU1NjM4_524c8e42-409b-4ca5-b64b-d98bdfb311bc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktOC0xLTEtMTU1NjM4_87a0a4bb-c12e-4cc9-a43b-925eafd0e253"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktOC0xLTEtMTU1NjM4_87a0a4bb-c12e-4cc9-a43b-925eafd0e253"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIw_d222fed4-a927-447d-8d82-a2d2c986c588" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIw_d222fed4-a927-447d-8d82-a2d2c986c588" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.94pt">Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2021 costs primarily related to our acquisition of Trillium. 2020 costs primarily related to our acquisition of Array. 2019 costs mainly related to our acquisitions of Array, including $157 million in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2A</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">), and Hospira.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktMTAtMS0xLTE1NTYzOA_1282a7c8-801c-4056-b485-27f13357c051"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIw_d222fed4-a927-447d-8d82-a2d2c986c588"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktNi0xLTEtMTU1NjM4_524c8e42-409b-4ca5-b64b-d98bdfb311bc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIw_d222fed4-a927-447d-8d82-a2d2c986c588"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzktOC0xLTEtMTU1NjM4_87a0a4bb-c12e-4cc9-a43b-925eafd0e253"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDIw_d222fed4-a927-447d-8d82-a2d2c986c588"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTYtMS0xLTE1NTYzOA_facc63c8-eaf3-4e01-9322-54be6880643c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTYtMS0xLTE1NTYzOA_facc63c8-eaf3-4e01-9322-54be6880643c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTEwLTEtMS0xNTU2Mzg_3eddf7f0-e898-4039-abae-9b3e4026d40d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTEwLTEtMS0xNTU2Mzg_3eddf7f0-e898-4039-abae-9b3e4026d40d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTYtMS0xLTE1NTYzOA_098c4e4a-148e-47f7-be0d-6ed93e8aef4e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTYtMS0xLTE1NTYzOA_098c4e4a-148e-47f7-be0d-6ed93e8aef4e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTgtMS0xLTE1NTYzOA_2b0e9445-59e0-4280-b6cc-187607b67d79"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTgtMS0xLTE1NTYzOA_2b0e9445-59e0-4280-b6cc-187607b67d79"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTgtMS0xLTE1NTYzOA_e0c6ceaf-a4e8-47bf-849b-5a80428433a3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTgtMS0xLTE1NTYzOA_e0c6ceaf-a4e8-47bf-849b-5a80428433a3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTEwLTEtMS0xNTU2Mzg_8ab28955-fc79-44d8-8a32-662618a1141b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTEwLTEtMS0xNTU2Mzg_8ab28955-fc79-44d8-8a32-662618a1141b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTgtMS0xLTE1NTYzOA_b66de0ca-ed0f-46b4-966e-453127eb66ca"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTgtMS0xLTE1NTYzOA_b66de0ca-ed0f-46b4-966e-453127eb66ca"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTYtMS0xLTE1NTYzOA_33ad584f-aedf-448a-a767-6e77c5498e33"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTYtMS0xLTE1NTYzOA_33ad584f-aedf-448a-a767-6e77c5498e33"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTgtMS0xLTE1NTYzOA_2dc67f00-13b1-40b3-996a-b5a90fc6ab6f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTgtMS0xLTE1NTYzOA_2dc67f00-13b1-40b3-996a-b5a90fc6ab6f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTYtMS0xLTE1NTYzOA_14c75760-4acd-4558-9ca3-a81fa2c1c265"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTYtMS0xLTE1NTYzOA_14c75760-4acd-4558-9ca3-a81fa2c1c265"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTEwLTEtMS0xNTU2Mzg_016183c2-2cbd-4ead-8585-43ac37496738"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTEwLTEtMS0xNTU2Mzg_016183c2-2cbd-4ead-8585-43ac37496738"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTEwLTEtMS0xNTU2Mzg_9b4bc5aa-1531-4ea6-816c-1d6a55260e53"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTEwLTEtMS0xNTU2Mzg_9b4bc5aa-1531-4ea6-816c-1d6a55260e53"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTYtMS0xLTE1NTYzOA_facc63c8-eaf3-4e01-9322-54be6880643c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTEwLTEtMS0xNTU2Mzg_3eddf7f0-e898-4039-abae-9b3e4026d40d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTYtMS0xLTE1NTYzOA_098c4e4a-148e-47f7-be0d-6ed93e8aef4e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTgtMS0xLTE1NTYzOA_2b0e9445-59e0-4280-b6cc-187607b67d79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTgtMS0xLTE1NTYzOA_e0c6ceaf-a4e8-47bf-849b-5a80428433a3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIzLTEwLTEtMS0xNTU2Mzg_8ab28955-fc79-44d8-8a32-662618a1141b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTgtMS0xLTE1NTYzOA_b66de0ca-ed0f-46b4-966e-453127eb66ca"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTYtMS0xLTE1NTYzOA_33ad584f-aedf-448a-a767-6e77c5498e33"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIxLTgtMS0xLTE1NTYzOA_2dc67f00-13b1-40b3-996a-b5a90fc6ab6f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTYtMS0xLTE1NTYzOA_14c75760-4acd-4558-9ca3-a81fa2c1c265"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzIwLTEwLTEtMS0xNTU2Mzg_016183c2-2cbd-4ead-8585-43ac37496738"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90YWJsZTo3OTNhODMyZjdhMGI0NjIzOGI4OGM0ODNjY2RhZjZkYi90YWJsZXJhbmdlOjc5M2E4MzJmN2EwYjQ2MjM4Yjg4YzQ4M2NjZGFmNmRiXzE5LTEwLTEtMS0xNTU2Mzg_9b4bc5aa-1531-4ea6-816c-1d6a55260e53"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzIvZnJhZzo3ZjRkNjgzMmQ4NDM0ZDA1OTEyMmJmNTNkMmM1OTA1MC90ZXh0cmVnaW9uOjdmNGQ2ODMyZDg0MzRkMDU5MTIyYmY1M2QyYzU5MDUwXzQxMjMxNjg2MDY2MDE5_10bde7f2-f1af-485a-bb58-5004b443cb0c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNjM2MDQ_d0d9da6e-b77b-4841-b3b0-a87f3981f083"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNjM2MDQ_d0d9da6e-b77b-4841-b3b0-a87f3981f083"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNjM2NDI_cbc5aa61-24ae-48c8-8216-7aefb1f5b7fe"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNjM2NDI_cbc5aa61-24ae-48c8-8216-7aefb1f5b7fe"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIwLTEtMS0xNjM1NzU_7ce6965c-8867-47ca-9836-5f1b997950d3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIwLTEtMS0xNjM1NzU_7ce6965c-8867-47ca-9836-5f1b997950d3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE4LTEtMS0xNjM1Mzk_47af01b1-de4e-4a07-a969-19224cfd7f0f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE4LTEtMS0xNjM1Mzk_47af01b1-de4e-4a07-a969-19224cfd7f0f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE2LTEtMS0xNjM1MDc_f12fa9f4-f2af-418c-9f50-a45b98820fb3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE2LTEtMS0xNjM1MDc_f12fa9f4-f2af-418c-9f50-a45b98820fb3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Note 2B.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIyLTEtMS0xNjM2MDQ_d0d9da6e-b77b-4841-b3b0-a87f3981f083"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTI0LTEtMS0xNjM2NDI_cbc5aa61-24ae-48c8-8216-7aefb1f5b7fe"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTIwLTEtMS0xNjM1NzU_7ce6965c-8867-47ca-9836-5f1b997950d3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE4LTEtMS0xNjM1Mzk_47af01b1-de4e-4a07-a969-19224cfd7f0f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90YWJsZTphMWQ2MzViYWUzNzA0NzQzYmEyNmJmYTM3M2E1MDc1NC90YWJsZXJhbmdlOmExZDYzNWJhZTM3MDQ3NDNiYTI2YmZhMzczYTUwNzU0XzI0LTE2LTEtMS0xNjM1MDc_f12fa9f4-f2af-418c-9f50-a45b98820fb3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNTcvZnJhZzplN2UxNWVlYjRjNGY0NWEyYTJkNjE2YzZhZTFiNGZkMC90ZXh0cmVnaW9uOmU3ZTE1ZWViNGM0ZjQ1YTJhMmQ2MTZjNmFlMWI0ZmQwXzMxNQ_dd240502-c7b9-4961-900f-87005a68b523"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNi0xLTEtMTU1NjM4_e3085a62-dc56-4860-80fe-177014844a33"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNi0xLTEtMTU1NjM4_e3085a62-dc56-4860-80fe-177014844a33"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNi0xLTEtMTU1NjM4_f86e5b8a-d846-49f5-82e8-3bfb2f963c41"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNi0xLTEtMTU1NjM4_f86e5b8a-d846-49f5-82e8-3bfb2f963c41"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTc_c297e4fb-ce0c-4b32-bf03-e6b83d4cb4fc" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTc_c297e4fb-ce0c-4b32-bf03-e6b83d4cb4fc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents shares purchased pursuant to the ASR with Goldman Sachs &amp; Co. LLC entered into in February 2019, as well as open market share repurchases of $2.1 billion</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzQtNi0xLTEtMTU1NjM4_e3085a62-dc56-4860-80fe-177014844a33"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTc_c297e4fb-ce0c-4b32-bf03-e6b83d4cb4fc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90YWJsZTpiNzVkMDQ2ZmQ3MzU0MWRkYWQ4NzhmMTUwMTI4MTQwNS90YWJsZXJhbmdlOmI3NWQwNDZmZDczNTQxZGRhZDg3OGYxNTAxMjgxNDA1XzMtNi0xLTEtMTU1NjM4_f86e5b8a-d846-49f5-82e8-3bfb2f963c41"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMjAvZnJhZzo0NmZkMDk4ZWZmYWY0Yzk5OTQ1NDliZDczNzdmZjdjZS90ZXh0cmVnaW9uOjQ2ZmQwOThlZmZhZjRjOTk5NDU0OWJkNzM3N2ZmN2NlXzM0NTc_c297e4fb-ce0c-4b32-bf03-e6b83d4cb4fc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNi0xLTEtMTU1NjM4_23f14970-65b7-4f45-b3d0-015d907672b2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNi0xLTEtMTU1NjM4_23f14970-65b7-4f45-b3d0-015d907672b2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTItMS0xLTE1NTYzOA_26719813-b100-4a9c-ad1e-f487528d7291"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTItMS0xLTE1NTYzOA_26719813-b100-4a9c-ad1e-f487528d7291"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMi0xLTEtMTU1NjM4_8dd5e7fe-af80-4f7e-8aae-6bcbf03bcbba"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMi0xLTEtMTU1NjM4_8dd5e7fe-af80-4f7e-8aae-6bcbf03bcbba"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNC0xLTEtMTU1NjM4_d2ea657c-d7cb-4f42-b560-3a7013368f69"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNC0xLTEtMTU1NjM4_d2ea657c-d7cb-4f42-b560-3a7013368f69"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtOC0xLTEtMTU1NjM4_535dfa3d-1e8c-4ba6-b772-d7a9d3638050"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtOC0xLTEtMTU1NjM4_535dfa3d-1e8c-4ba6-b772-d7a9d3638050"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTAtMS0xLTE1NTYzOA_d6e3fb05-0b79-4e60-b252-30ba3f67fce4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTAtMS0xLTE1NTYzOA_d6e3fb05-0b79-4e60-b252-30ba3f67fce4"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The notional amount of outstanding foreign exchange contracts hedging our intercompany forecasted inventory sales was $4.8 billion as of December 31, 2021 and $5.0 billion as of December 31, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNi0xLTEtMTU1NjM4_23f14970-65b7-4f45-b3d0-015d907672b2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTItMS0xLTE1NTYzOA_26719813-b100-4a9c-ad1e-f487528d7291"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMi0xLTEtMTU1NjM4_8dd5e7fe-af80-4f7e-8aae-6bcbf03bcbba"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtNC0xLTEtMTU1NjM4_d2ea657c-d7cb-4f42-b560-3a7013368f69"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtOC0xLTEtMTU1NjM4_535dfa3d-1e8c-4ba6-b772-d7a9d3638050"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90YWJsZTowN2U4Y2EyYmEzNTM0ZGFlOTVjNjE4MDA2ZWQyZjk4NS90YWJsZXJhbmdlOjA3ZThjYTJiYTM1MzRkYWU5NWM2MTgwMDZlZDJmOTg1XzUtMTAtMS0xLTE1NTYzOA_d6e3fb05-0b79-4e60-b252-30ba3f67fce4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xOTYvZnJhZzo5ZDVmY2E0NmM5NzY0Y2JjOWU3ZmY3NTVmOWE0NDMwNC90ZXh0cmVnaW9uOjlkNWZjYTQ2Yzk3NjRjYmM5ZTdmZjc1NWY5YTQ0MzA0XzQ4MzI_8bf8fdcb-7637-414d-a8f0-08071c59051d"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTItMS0xLTE1NTYzOA_d587cb35-245e-4884-bf51-680732bfade2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTItMS0xLTE1NTYzOA_d587cb35-245e-4884-bf51-680732bfade2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTQtMS0xLTE1NTYzOA_46ec01a2-0164-49be-80a9-759dd72302e0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTQtMS0xLTE1NTYzOA_46ec01a2-0164-49be-80a9-759dd72302e0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTYtMS0xLTE1NTYzOA_8cbdacb9-5fe2-4b95-940c-37cd2b822cbf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTYtMS0xLTE1NTYzOA_8cbdacb9-5fe2-4b95-940c-37cd2b822cbf"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MzA_1c246f72-a3f7-480c-b93d-85c62a4ffdb7" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MzA_1c246f72-a3f7-480c-b93d-85c62a4ffdb7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:2.65pt">Amounts include the impact of a change in accounting principle. See </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Notes 1C </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">and </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">11</xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">. In 2019, other non-service cost components&#x2019; activity related to the Consumer Healthcare JV transaction, such as gain on settlements, were recorded in </xhtml:span><xhtml:span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(Gain) on completion of Consumer Healthcare JV transaction.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTItMS0xLTE1NTYzOA_d587cb35-245e-4884-bf51-680732bfade2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MzA_1c246f72-a3f7-480c-b93d-85c62a4ffdb7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTQtMS0xLTE1NTYzOA_46ec01a2-0164-49be-80a9-759dd72302e0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MzA_1c246f72-a3f7-480c-b93d-85c62a4ffdb7"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90YWJsZTo1ZjkzOTE4ODZkMjU0OTUzOWVjMzFhNTE2NmZkZGYyMC90YWJsZXJhbmdlOjVmOTM5MTg4NmQyNTQ5NTM5ZWMzMWE1MTY2ZmRkZjIwXzExLTYtMS0xLTE1NTYzOA_8cbdacb9-5fe2-4b95-940c-37cd2b822cbf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8xNzUvZnJhZzphNjYxNjI0OTgzNGM0NjY1YTkxMDQ0YzYzNTQ1ZjMwOC90ZXh0cmVnaW9uOmE2NjE2MjQ5ODM0YzQ2NjVhOTEwNDRjNjM1NDVmMzA4Xzc0MzA_1c246f72-a3f7-480c-b93d-85c62a4ffdb7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTQtMS0xLTE3NzQ0Ng_dfdde423-a842-42c0-bafc-1efbed3dd6e0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTQtMS0xLTE3NzQ0Ng_dfdde423-a842-42c0-bafc-1efbed3dd6e0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTYtMS0xLTE3NzQ0Ng_43752d49-1ae0-4846-8821-0cdf421ce9dc"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTYtMS0xLTE3NzQ0Ng_43752d49-1ae0-4846-8821-0cdf421ce9dc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTItMS0xLTE3NzQ0Ng_b13619e0-1809-4023-9173-70819e782a56"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTItMS0xLTE3NzQ0Ng_b13619e0-1809-4023-9173-70819e782a56"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTQtMS0xLTE3NzQ0Ng_dfdde423-a842-42c0-bafc-1efbed3dd6e0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTYtMS0xLTE3NzQ0Ng_43752d49-1ae0-4846-8821-0cdf421ce9dc"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90YWJsZToxZDFmN2Q0ZDI4MjI0MmY0YjNhYzA5NDM4ZTU2OGNkMC90YWJsZXJhbmdlOjFkMWY3ZDRkMjgyMjQyZjRiM2FjMDk0MzhlNTY4Y2QwXzEzLTItMS0xLTE3NzQ0Ng_b13619e0-1809-4023-9173-70819e782a56"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRiZmY0MDViMjIwNTQ4N2ViODM1ZGQ0Y2Q1ODlmNWM2L3NlYzo0YmZmNDA1YjIyMDU0ODdlYjgzNWRkNGNkNTg5ZjVjNl8yMzgvZnJhZzpiZTliOTNkOTE1Y2U0NGMzODE2ZWVkMzY5YTZhM2ZhMS90ZXh0cmVnaW9uOmJlOWI5M2Q5MTVjZTQ0YzM4MTZlZWQzNjlhNmEzZmExXzQxMjMxNjg2MTI3MjA1_d153f53f-a3bb-4a38-83da-2a0705d00d3f"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>155
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MX/DR2O/_Y+%XUO-:Q,]2+>/2&!C$85+\\J?2$7L&I\X! UH:T%<&[J$16&G
MFAIXI8&7>Z9XE=P/0Z[YY;F2CT29IP'-'.3.S*WA]</$Q'VA%=P-P4Y?#N2#
M4&0&(29M\GDQ)._>OB=O29B0JS"*(#+I>4?#..;ICE]B7A68] "F2\FU3/0Z
M):,D$,%+@ X0W+&D6Y97%$4<"O^8,/>(4(>Z%80&N/E8+(\)I;DYK3 ?XN9_
M9=$Q<;RJT5^\#=OYG.5X[ #>*-&A?B:3I)BV)OV_?X)GR$2+./T;&<';C>#E
M(WB'_"7]#":G)K?/&U$50-S<==H?$1;='8MN,Q;]),EX1.9B(Y6NHH/C:)4)
MA,[)CLY),SHSH4(9F.0D,&<J_5.#5*;C;V_>U*1$;\>MAR(.,J4,M7&8^N"I
M.\$5R@]':[==VF88K],=K].&B:0X:'V>JX?#B&.M>)1B<3S;<3I#<<KI,PXC
M0:99O!2JB@N.X;;9B7N&D'$=*Z!.$SIS<1^F&KRDR93'E4&K 9J-)]]&<S*9
M#C!>>\+N-N$U27RI(&"YSAR1A8:,(E*1@<P2K9[A-Z@FBZ,/1QA):DG2)B1O
M^1.9!)!GX2KT"T4\'-D:2)>UN\SMNCT'8VBUVF5-&/:#0(DT/=H>D%RP;Y)J
MW^&0E'7)B*>:>!2F.-R!XHUQM:KOXKK]FNO G$&L;^5C4LD3AYM"UW8'71O&
MS=8"%Q?QU]QVB3A3\B%,_&I'XIC3.XR:K0LN+N>OJ<UDJD&$OX6;P[,#1W0=
MQ^UAW&Q=<&L*0\X,.OK#5'  ZE*,B"T$+J[>GZ0I3+.U3##5K0'I,=:FC#*,
MD2T#;J,Z\!76#.T?":0X60B> K^ 3-(T.T 0Q[P3*<*-VJ) &Q6%+S("E87U
M5%ZM5&4O78,TE1@A6PUHHVJP[3.*&AXF]_D\S*J)X8@UKK(E@#8J 9-$"U6L
M DW7P[=4*YGAB#7,K/331M*?AXX,0*[NI7JNY(/C?.(*EE=]WX?5+M1AR,\<
M$N-H)9\VDOQ%S*.(7&4IW$ZKHXGCU#5GU H];23THUBH>Y-@?P""7H-\Q1N>
M5+L/!ZRE9H6>XK(\&8SGI)\%H8:ZT]=:@,[GS<8XXO>5S'"\FH4)M2I/<9'>
M1G$-6H9Z"H>I]915>XH+=4EHEBVCT ?W2%XU$8<E2C=',5M,#Y?4J/M#U>!6
MV&DC80<_Q!";A9;^#^@7UARJ,[G)- 0M"2"S*O<!"N23/4+=$\J8=^+UW&I>
MS(HZ:R3J U E!;5PD@3BB7P4E9&J@7+,7^_4<;!2R*RZLYIN?+M,VU\_CN%B
MI134@-7M<EAE9[@.OV95KKL/\\+AQEBWQ_8V7W U[@.EH*!U8-;7 -3-,F;%
MFS7;IDGW5FE0'99F-;D24/VJN^(ZU)O!Y^O1]'9AEI(W\]G-O'\[&I*K.S(?
MC4?ST70P@A97&>%+B5P1O1:F"7]Z+GKRW#4K$$ASW6R8;;=OKF&98@0=3/+)
MN)91 #T-F7&ER60RP5QBJP?#Q7Y_TI/OU\(TFMB.&+/BSTY^T:X;LSK.< &^
M#74DC(-<^F[Y'OI1/U,P:&40:_K^%^+W]MCID@W,Z0<>H26'685GN,+?*A[D
M_=]SO)11)4,<8#;&M@"857N&J_W6263TY*]Y IW2H?V3&J#IW0)CY%F=]^I:
M;N@,R# KTO^(.,>TZ_S>)!L]J]B>^ZOV@*W^>KA@_H=LK$$J/5 X)B@=@W&T
M:NSA8EJ?AC4 D(8XE;T]<UPWFR=B#5!=(EHQ]&KV-_83L7=$W&/H&IHEHI5%
M[U?)HF=ET?MILEB#5'K@12)B&RV>U4/O_^IA#8!)1)2*543O9REB#="A1.SL
M?2\TR[3\NVM*?+,E7'PZW%W=?=OMYU\T._;QXL/P-3>KO)1$8@6FSG$/,EH5
MWUJ+$RTW^=?'I=1:QOGA6G!H',P#<'\E(9;EB1E@]\7[\E]02P,$%     @
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ML/?4 M"^XE"_JQ]Z@OT[@U?_ U!+ P04    "  8<UA45N+B#FX&  "F&P
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M9L#&@),EE42<02!/I?_[@&80J"O439YGYCR_/QW&$!UF>D[69H0.\9D+U]P
MEGJV>6EH4CU[U7'4'N:-:XV[P\EUF:/%&((1]0CD'(!ISM(A&ON^!$"^9:N[
MEA, )N@PINK>UQ0 8HM2]>&)*TBA8#GJV0P (SLN:T=/LHSV@WH--;![]GC
M!VU'/5*?DVPMGRD7_"Y>AQR)R8VB9"72@UQ? B36FG0AZ1\*YG,)E6-FE0MX
MM(KY(;KC''W)2H[P^-#TO&'##>R>_1J0JHUZI%[,"#.49N76FH<LY]$B1?-U
MGO-T_KS)?7&P>2\E_&M=E)M'ZH-RLTT2W,?"!U()S% .95FQG\J7/DBJ+%DS
MEY>JJ57M:LG+BR!*7ZY:U55Y*HIR'E>/_(M^9.L<\:JJ&22\7&:A0#_R31-2
M4(9+OB:P3GB.+GD0E\NY6*[0]$_TKG@)#1FC]^A#I;\=7JD]K2J;K<XE#Q>;
M$&>+/$B,,6VHE-VSQ0(^6S+JD;KEHOXH*E]NUF"TJG-?*+\5ZT"2F:RRZ?/=
M+7J*RB6Z$+5@$HC",)@O"_0V2%8?Y9]PTB&ZOAXC7D52NE%("@>>\_M\'>3/
ME>>%CPKTQ$7Q*#[E^U<H"?+OPD%5^R(NJ]WD^X8<8G2_>>7"Y*:&K-D]3QJ!
M6Y6C'JEF!A)D#%?#=^R>1X' +;Y1C]2V'V1D[,;.H\=FI@-OS(UZI,3\1(F8
MHR*XFU?G1'0^H**G<\.=MW3$5%I4KZL5J%KQ-H]\;J]N7XD;5>\2*=?'^.@4
MNOZ9^4?7S ?NB!7ZZ-JVP#M8W(&TB:DC[A#P#A5W*'B'B3L,O&.+.]4[9,/&
M^,W;@;,@7\A%*N8/PA'6H2N\GV]>N-O\*+-5]0;3?5:665)]7?(@Y+D$B/L/
MF7![_4,VL'WM\>3_4$L#!!0    ( !AS6%3_.9-?9P(  -D%   8    >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&ULC51-;]LP#/TKA#%@+;!%\4?3K7 ,-$F'
M]5 @:+#M,.R@6$PL5)9<24G:?S])=MRT2(I>+(GB>R3U3.8[I1],A6CAJ1;2
MC*/*VN:*$%-66%,S4 U*=[-2NJ;6'?6:F$8C90%4"Y(,AR-24RZC(@^VN2YR
MM;&"2YQK,)NZIOIY@D+MQE$<[0WW?%U9;R!%WM U+M#^:N;:G4C/PGB-TG E
M0>-J'%W'5[/,^P>'WQQWYF /OI*E4@_^<,O&T= GA )+ZQFH6[8X12$\D4OC
ML>.,^I >>+C?L_\(M;M:EM3@5(D_G-EJ''V+@.&*;H2]5[N?V-5SX?E*)4SX
MPJ[U':41E!MC5=V!708UE^U*G[IW. #$HQ. I ,D;P'9"4#: =*/ K(.$)Z:
MM*6$=YA12XM<JQUH[^W8_"8\9D"[\KGTLB^L=K?<X6PQ5=(HP1FUR&!AW>(T
MM0;4"FX>-]P^P]F<:F>JT/*2BG/X"I^ @*F<U>3$NAP\$RF[>),V7G(B7IS
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M6)@L5(=_N3VHU5?C[=<&(7HHY3H"6+PKZ[R*-CFP=3]2JE73=2M$M.G7\1L
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MCF>DA0D* N9TDU1?6(6M_:J^%;NSE<R?Q[']H=KFYIH5^(0.)NPT1\3N.6M
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MT/?+LFSL&RS A[< WH__#5!+ P04    "  8<UA4UEH4-FTI  !#AP  &0
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M\[(++J;'Y;CU"7)3D*CV-()A,_3HED"VIIIG2A^SPSV(]D)YCRE1?%#\'/!
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M #!Q+TJPN#.!.2_X"SZ1%V#;K5,L*Y\C=E?49+\W@CNHOUT!"V!1"1_Q,9N
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M)E/2-8O^C)LF\4P0VLV?XJ0(?W%<>^<0[4&EQO#\0D3HS&%9,S_LM^8_#4>
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MR)2P-84\84KEC!?Y,@BBAO4CGMCO2_XT3_QP[GK4$^'H!9ZX8T9KPJ%*$[=
MOIRGWQ?B?AAH]>W:CWE2/0$UC"BXIAG+C>X/M/ZF*@%@BO']@O9NO_]=<)PO
MW1EL5>J/#S'M_D !WY_Y"*X=X%CIK2,^B5A9[XQQDU #VCD^#JLM#'[)*8"S
MGCO8A2K& F&L#\0^208/G3H.6V>[L';C3K )D# V^F/>YFUS2'[JSX;WY/Z$
M_3TLH-UK*M98.AK,)AW?">L?5A7NI'BEK%69>]P*CCPE GQ?*T!9]8,$-'\=
MG/P?4$L#!!0    ( !AS6%0Y!R0>:AD  ,M1   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;,U<>W/;QK7_*CN^;H?LP!3!-^TD,[*=M&J3QE>VF[ES
MY_ZQ(I?D)B# XB%9_?3]G7-V@04%2G2<]G9&0X'D8O>\W^!7=UG^2[$SIE2?
M]DE:?/UL5Y:'EQ<7Q6IG]KH89 >3XIM-EN]UB;?Y]J(XY$:O^:9]<C$:#F<7
M>VW39]]\Q9^]R[_Y*JO*Q*;F7:Z*:K_7^?UKDV1W7S^+G_D/KNUV5]('%]]\
M==!;\]Z4'P_O<KR[J'=9V[U)"YNE*C>;KY]=QB]?3V@]+_B;-7=%<*T(DYLL
M^X7>7*V_?C8D@$QB5B7MH/'OUKPQ24(; 8R_NSV?U4?2C>&UW_T[QAVXW.C"
MO,F2G^RZW'W];/%,K<U&5TEYG=W]R3A\IK3?*DL*?E5WLG8\?J9655%F>W<S
M(-C;5/[K3XX.P0V+X8D;1NZ&$<,M!S&4;W6IO_DJS^Y43JNQ&UTPJGPW@+,I
M,>5]F>-;B_O*;S[H3^H'798F+[ZZ*+$A?7RQ<C>_EIM')VZ.1^J'+"UWA?HV
M79MU>X,+0%*#,_+@O!X]NN-;LQJH<1RIT7 4/[+?N$9OS/N-3^QWE:ZRO5&$
MY5M;K)*LJ'*C_O?RIBAS",3_/7+$I#YBPD=,?AT%S[Y970X(3E,H"*N#>Y-G
M>_4&)+9I9=.M^O%@<DW27.#3_2%+35IB_::U?M6LSYKU-P8:;-0ASVXM:=1%
M[\:D9F/+OL(7JO0G6]D)_Y)J;5ZJ_S$Z%_8J,,?L;TS.#.K]</7]]U<__O5]
MGWE%+T.\Q$OU,;4E5K\O=8DMGZM9-)Q-\+\WBA:+>1]7\V@\'@%FH)TR>#I1
M\2(:3>9J&2U'$S6.EHO%;X]43^D^(+\A&$:3:!S'#,QP/,/_.([&P*.G'4*W
M \'I]_^U&,7Q*_=/?=@9M<9F16E7#;'<+6!C531?0]P*]^50W>E"D95,[F',
M$DTD*C-BHR4BW+N](MQT!Q+KHH!%MON#MCEL8*E6.YUO31&I%)^# C9;XP2'
MKEKE9FW+XAB2[K59439@Z72M=C!=.)-6;P%A(20W?Z\LX"K,JLIM:>GL@\Y+
MJQ.@D&TV!.#-O;_Y^O=Z?WCU5IE/\!>%*09,*2 %5U$PB4I^'_+<D8\H<\@M
MG()]BCC_ N0?I_> Q847LT! OA\3B!;'C\4AE!;LTRT01*4T2U_D1/;<I"M#
M^DV?$FM(F.D:&QT2PW[-?0LK <<*3/YD=%+N5AIZ\>>_*9BYM-#. Q;J#NZ/
M_CNFG<(ZE(I_!6-/(WD'4:,W&_J P2M8]W-[4P4WG\ VP/!QMH:<WV<0ZG]H
M3TQ@HM.MO4F,.W]P9&O?G6EM*%A8>X8EV4J'[,)BLF6Z*G>9:-=O9W+?,$U+
M#P?#]5)]9]:PFPDLW3@:3T;T?TZOO5C,,M_LZ++"NO%$36?X=C'K XR-P9[K
M$UOVQM%B.NS35O%LTE=Q-)I.'FS8FRQC6C/&ZV@^4Q^R$I]^'+P?T'ZUAO:6
MM$5O,0-,O>EDW%<?WOSYLA,I4<71J_H_-I\&T%X]OI:P%B#XA!"(!XO'(P#2
M]EB=$(VB^6P) DSC.:XG\:*;=FJR@#^<+_N$[M*#T58B@J?V;-AL$<^(LN,Y
M7B>3Y=ER"-<&]@C#AWB=+L;J<I]5),YK!$5507)Z0_&Y(CW*\=4ZT%-((^R7
MVN%30F-ODX2M"1B;&V0"!1%!'P#J)Z@Z.^:!^LDHCKS-.D)$6^YXJXU-V(%#
MN:N<)'<A[/=R1%J=)7;-9B((W:Y-6>5I1! =]#W?;"'Q\$2*+.N>US^/I^K&
MP0:X-$R&:!S1,;$:WY$[XTQ@5>TK,48'^(,7\7(Q(](AA$\5T$T!)2@(^ZTX
MJE?W^+  "B#-=D=Z-Q,K6.YLO@8ETHJY5X")"9L9UG);!.>R+=1V32Z3G-4E
M#".BGJF$NFI=P8L (MEW Q1!LXZ-L2<M=7<O^.X1\P+? &W8,A8UM7+2V=(!
M4$^+82,(6\:%H)##<T->B1C50'^T.6RWW__'DIQ$:_N!^A$<RFX2NW5QVAY<
MNT7.1P=K[%0@9R((8(W3+9L^9FH%1Y"7Y.98]K/"RNU [P*"K6^U36H^PCV4
MSBT4R"E7.]K<,Y'N)Z)D#)T$" I>(K_'BCN=KYT;"P X5YW(F<"?@CPDTF:S
M,9Q8\I$Y63P2EA<D/"_HBE5*4E[[#Z]G+]LA)D'BO&W'?CZL">*%DMGDJ/B2
MK=1H]DHB \;(N^6?$;H5B'^<2=G;3T2X6L0?C[I>,0G]YN(M R-9''OTP,UV
M^='.\+$!WK->-)M(4"#F0(#@9*ZL]>WO%?8!+#B$"8/MLY5E2-C4B'W _:6H
M3/I8R,!W_/']7QIW[4V*! G8O-H?1 [+G2X18! /K2$69;A4% >!NBSXK4#Q
M'+8.SV1K=[3T/!Y,:J,7LB9J3#-+*LLP6PER,<"0%JRR?"VT97#)KCA.;O1M
MEK.E )?*Q'B>:F2FU^\1M9 ZD7+ C)86D2@?SE;RU1E@GQ*B4/M#,3AFL!,V
M@:L.JXCM^ ;6R=RIFZI JHU@'(E^M8+[,&UI/ANX(R(=&3"]7ENG6]L*CHOV
ML9 8PW:>MF,']]:0Z'LJ?B")J?('$3%%(5$0P[[\M^G>X]1PD3]]]'PTF =>
MMB'.">UDBCUDWI>F,@]YV4CL9QG (W:ZT@(T9I.0U#CWY?9*J0R8 . J%VIX
M(1O RRK05C0@4AN)9R((GP^!VZ$=I:9A6&)%R($T+%!.%@BHV&)GR/XPZUC8
M&JG6*R3GXA[9P:19Z?.']><XLUYAC/IK!B!'EZH_4*\'$G 1V-=@;[H">*)A
M$AJT/G+\8A$G5*LRR^^#.%<,'2245+/#!!)$3Q=Y-ED"^2].YT7'R=#CX"#,
M&:K?'?WC!$ \.U> 'L3_HP%%Z?I3C3BI"Y\40-J[H?+2"D']9#"FT)YNPO6<
M;PUL:>&B9T2[E=^P._0A8'K# 65$(]JG%T\&R+3>M)3FC-R_"ZG%8*S>N%-/
M;!%:809E1J<?;\1T\'4"@M\%7 !\2B S^,/!PF50E$WTUGT%M%0\B/%_IBZA
M/1RL28VG9QCA&;\N^!4$_;9;A.R3(C3'";]34^!+KR.\$C+OO>Q/+Z7,\YUH
MR&,\CB2N%P\N\I*;#64ZA:N#M*3-,SIA&C9VQ[:K C#Y0-U0;+'.&BW/JK*P
M:U,K&65 6\,A;6U*Z_R9*ENDV1+]A-8FA#X(>$]%V\>VI P5'W2UI0&=8>Z,
M,\'#5[]2NB.^/7X5UFT" &]U(A:8;&MV1\X5IO;]P:SLQA( \& ]V^^R\V&Y
MI2$Z&?L"Z0'?3L4@7]?QX4.'C3(:F079]8BQ8F($S/>)7K.5)=CA/LB+UE%
MX8!N 5:+5^..W D)HLN$EG!>$WHK.D?GXO<YX.'"@5\!0V4=06JYH$#)>C%S
M>/HT*5"1+R,.0[Z%I\F#$ /!%^F"\Q( NA);=-HA-/N)3V9/3&I])HL9?T>
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M&M0C#A\:#R>Q77>-*71/?C*3Y<AIGP^@8".H8N:2XSHPY*$,86\85[E&0F?
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MBH']HZ%&WSUVORRL5N^T# (_><:;G4UUI/ZL#UHVJB>@Q#I]3WJO+O<(=5=
M(UXN%X]M]SK7_[ )Y;+I?2L,=YV!CH!(*OONNE7^(=1:P\*A/WAD"$J>"_;%
M*"XK24&O?H;NGA87W#.6-IVE@JE[$/E3B?A;[?DG9R(^YXGLS=77"LH9I2'M
M'GX3;&JH;[@.OG>2$=C7Z-@VAY0337SX(+^;O6RHYW/1DX$G/2]+,5!1.)N?
MF[.?1V2UN#&4")&%6 ?/(Q)>33U=5#4L!Q:^C=$=ZG#1N;M22 _TDM+SXX^N
MTB@%.@JUI5"5527%*\[44D%7B,$1@-2M:SB$'W2=.^_#"8D,JW>5X%O-\C9C
MB/YW]!S@(R1WLXNN&R8%0M^6N146R,/QN2F-GT@]/K(9Q1NH[Z05(*+ SJRV
MT_6$2X>HK&02FYRLVD@+0Z^I1,GSOD1/'KOA02RN-YJUC%JS]0EDTU?&::K%
MKDA8*:MK-,U02\Y707).=FD@V.N:GVL\;Y8Q<DT;L-#?* RD,GOH][\5YQ%$
MMJ]]9)OYB(+&"7.SHR$)H"M9QD7O>T#6/QHU)"P^A&VY(% F)9,$K+6===LE
MO-T7_,+&=R[5=<]'WLO#58D;Z6JFRUS%0(8)>4@KCI?\>T.S(<^QD93@V%V6
M<-V 9[T%/AI.S$B+<WLKO&\DGWX"(*^"$Q83U5O0]-F8GM-+8!68Z,?@<+#1
MXT/Z%ZZS&@9U+E>@M&*TE#'&7DRO-/8(T.DIMLFH?Q[D=3_Z!4Y]46A^?+CY
M\2 F#%6X)DT=ZS>"O<?/Q^%EBDM0933"E1,UGKLI7KI"$TTM6B1K/?XAH/Y%
MV',/QF1'<_(TO;C_.(2!NAP//[6/DY\=.CJD1W.=/?HYE![]S,FY)X&B4,ED
MWTSU/WU2/ ^G#/M.]>BJF7_LC>E!.UK),Y5?I&G/U3SFG_P:\0]^Q30"J_MN
M@-B'M;S[VHTK;<Y4L%;&8X.139^)=K;=F_DB>D!C5=:-]IVA&G/0R1YT_23<
M1? #>PBXMOPS@FSTTE)^:Z_^M/ZEPDOY@;YFN?S,X0\ZW]+C'8G9X-;A8#Y]
MIG+YZ4!Y4V8'_KF^FZPLLSU?[HR&5: %^'Z3P26[-W1 _?N-W_P34$L#!!0
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MN1]"[GS@J:!\)W,\/E7<,"Q><9]OI9&7^M-GL>T@\L,T%M#/Y*,*76D*TG[
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M4"HP+67(8;4E\[A'^]M![Q9!1=E#^A#D(,?HGU4--#!/!P_39-_0KMJ-MK+
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M9!G7A]Z \-_ SDF7&TE#?JZ\>$08#$1K::*E/3BWA7)#HC48KDH\UFP)0?$
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M&\#WZPQBI_J $S2_.?OB?P%02P,$%     @ &'-85'OU*$M+ P  $0<  !D
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULK55-;]LX$/TK V$/"2!8LJPX
M<6 ;L),MUD#2!LFV.2SV0$DCB0A%:DDJKOKK=TC)3@*T 5KT((D?,V]F'H=/
MR[W23Z9&M/"U$=*L@MK:]C**3%YCP\Q$M2AIIU2Z89:FNHI,JY$5WJD141+'
M\ZAA7 ;KI5^[T^NEZJS@$N\TF*YIF.ZW*-1^%4R#P\(]KVKK%J+ULF45/J#]
MW-YIFD5'E((W* U7$C26JV SO=RFSMX;?.&X-Z_&X"K)E'IRDUVQ"F*7$ K,
MK4-@]'G&*Q3" 5$:_XV8P3&D<WP]/J!_\+53+1DS>*7$(R]LO0HN BBP9)VP
M]VK_%X[UG#F\7 GCW[ ?;&>+ /+.6-6,SI1!P^7P95]''EXY7,0_<$A&A\3G
M/03R65XSR]9+K?:@G36AN8$OU7M3<ERZ0WFPFG8Y^=GU)UNCA@]<,IES)F G
MAX,FQI:1I0#.+,I'L.T EOP ;)K K9*V-O"G++!X"Q!19L?TDD-ZV^1=Q&O,
M)S";AI#$R?0=O-FQW)G'F_U\N?#/)C-64YO\^TZ@]!@H]8'2W\/K+X/!9D+3
M9Y16:8X&_JX12B7HKG%9C5>-?Z,-@H!<-:V29&M E6_<+F'CUXAO;#(*YC@_
MN=W=W.P^?7PX]?2[5^RRX-1N!51*%0;^@%DX3Z?T3<*+^3D\TAT$+J'5*D=C
M( W3)'7OV1SNV9Y:UZ*F&@PP65!^;2M<_,4BA?/I_$U.)^R48!=A?+:@[T7H
MHG]4,N^T)AL*\F(JE9OGHJ.N Y:I9X23S'O/O.\B]FB.G+QFLB*.M&K>5NNK
M(TEP>F$<&FF<(6RB&G+4E@U5%1UMAV,TQ_$ACQZRCHO"VTM2H]$6!.LD22G5
MTVKN3D/T<*4:KB6S_6E(MM8)%[C>LUCU+\3TE$Y.M>@^A)9I2[31FBI+0V*=
M]20^AQR+#L$J(E<_T59!NBV+B:=@=V"%LA_:2+Y0R PA&9@X8C0"HT>J0U"6
M<<%M#]R8;J2!_ V9-:JC%IK =C)"7HUX-WQPHB/YWA6*7LE4@[KR8FRH*PEN
M4*SCZE'O-X/,O9@//XM;IBLN#0@LR36>G)\%H <!'B96M5[T,F5)0OVPIG\6
M:F= ^Z52]C!Q 8Y_P?7_4$L#!!0    ( !AS6%2"M B(9@,  (8'   9
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M)T6PP=Y-K7DI_H&L3W4D[JS:%-**_J!+MRK< \468!$15"V\V>CN>W5/_[R
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MY:7[8(_?R70I/,<2KNTZ#_3G#:3QN#_O3'_O3TC1B/^Y6H-&8*7_?6  ?QC
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M2?UHJP-_MVA=M6VUY\L=@G-94P,\WU0(4?4/&F#XD-6W_P=02P,$%     @
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M6)77Q$"0R\+_\L?:#AV"P_ %@E%-,'*XO2"'\IQ;?G*DU8)IN@UNM'"J.FJ
MDP4Y96HU3B7H[,G%CTK:Y=' @A?M#**:[M33C5Z@&X[8M2IL:MA%$8MXG<$
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M'J%NF>+5+S1=P/E<*=M\D(#V_P@G_P%02P,$%     @ &'-85.^WS6;'$@
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M2,SLEG)Y)W.N<OL42H5B"C6=^$SA)'W=S<F_1)@U'K!]#[28&\0MW@MI6^8
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M#VP7J JV C]?>]:]P^(G?PWC@_&[5B<##.I1#*I+80;\%^0"]-*#,>RZVC)
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M01*C0:25(XJUBR+X'F0<( +\"-X$[*"MGI'-O,*,D<0B #\=^P&*OY(+E[]
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M?F#SB98#&BAW?&84KFQN.Q1Z ?OP;\0G$7,DD.TD_LLJ2+;U6L0)IN8@D%-
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M*1 >N1;9<;B5\%:,NP24@JB-( )D"]C.*=,KQ+WL,1<:463'P#XRNE1WHT2
M6*"%XC.'7#6\MX(#)0\(L ":L[,R.]/$61TM4Z<&2&(*[8WKAC.L?0AA;)L*
M2BWKV;8>R7N$8L2?;3#GM(P&O0OG&BM:()Y:6YJ@>C IXSI,T&SH+,A*8':
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ME%A(^\S@.?7"B) )I^%SJHO4"R&DW!+8VCNAYU..DLE6PG3KB\U%(O$BC><
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MHH<Y07DQ_UHHJDA23X"ZD%PDA.B2<%U(/XUGHA=G$6]61I3GBWXQ8ST-PV"
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M"XZMJ,34@AC:- !PXN_;A^P(T:T!1?FTOI:Z"9\22ORJI./*WJA.U#)>+/F
M%:*6]4;,^U1AO;N-85>?KA8VPT1,A*#2ZF87T5AG0$;AA_GCVHGLPM/D+IB.
MM&X$QT\->=XS3OL<T 5="!K_(X-H!Q0B/7LV79U<\:6K4^XUZW:DYZS'"40W
M&""C^$4GOX;I[^IV#/LH\-]'BL#-R7N*VT@A&?>0L.< (L3F2&_HQ/DL!C:5
MLM<"E:'HCG+U+]LDX\U^BA1F6\F7VKQWTN:4 X0#T2]31""PJ]U"%Z/+)$S#
M&2R.J/K*A$ST.@E_0]Z^+A!#2X_P&HA!2!T=^.T(C:9FEH>8Q^TB/9$FF;LR
M-ZU+?CJ ,V3B(U8BJB/EX?FM7A6((:2?*,^650@^LR\)J*@[<@-)H;J)OMV.
M#T8P\*[+#"#_A+SFV,J821+&[O!"]1&#]7LC10F^A[NB-96.PNFT@(LM*([_
MM@,J%P2]#M4CVL&(6QPA7 #$IVTZ"W_3R3E_("P9W]_?GD54CLM66Q;CUFQ%
M)EO.NN0283GQE8H<71CM!1*--U>_J+=ZE4$@<-3(I[N8L=M#EHR;?@:@E7B:
M-Z^QO$A;5R7GRQ9Y]@@V+;-\1:ZK,X3;;2,='=%N&A\I5^,WY[]LTW(9^K.,
M@8E(1,A7M_OJ#G@(GX;<%5G-BLX$@%2"'H:?KL>Z&GL<_VA-<"DM1"&F4#.Y
M_'!_>WG]X=(48J0[]R7WYU*9IPEX^G#W\3UN?7LY?G?_=C*^O507'^^N/ES"
M39W,Z2&+1?XG<!"QM32&C_<B&W)A?0 ]M9QV6T-I046 *O=?Q- =!"$4&Y#V
MTFB=+I<=@EZ;JPY(+N3>._/BB:OJQ1,WM;T #+$XE=Y6WC_M!9U6C_]2?8G\
MZ75ZJ-KWZ+;EM>Q3\6M>3.D-T2Y@($RY%8\^Y=L&Q1,9[YG0M@K='53WT5:?
M/7'N=<>5S[U[HT&4N<VC5C\PK33[E-F7]]@V"]\\C[S01S*;;2*OA>$FS4]L
MYD6CQA!;"';O^*$YS)T[9-#FCS<K7>()SGB/L[X1V8!)?<M;?%J!_,:G->7T
MDSMOXI@K[^"8F_Y^/@M:F'W$^@DP[N:#C<AK% KE:L/?2D[S&7+8<^QPF??W
MCO% 3DK\6<)O_!=#5(3YM6,Z9S_5FD^YTO[?S)[\L:>NO0[4UEA)4_3_OY;H
M'WXM44-:INUK"/0#H2^@>AG.1 X6"<@(C;H=18&J<6EGST6898Y8[;R=JCIH
M;C>&79G<M4OMO(JF:GXV+S61=O9J%]IV#*B3EQVOD]YNXDB/_=[U:@?I5'90
MOO8Z);N=8F5?:SUW'-CIZ3WZ6AUO\YD1SS1ITWFZ:&LAK3H==V[Z(XIEO/:/
MRO$6\>[YONI\'/=X?",%%CN]@TH[[U\[ "1'W@>C#KP/YH^^W84W,NI[&WN-
M[ZQO]J96Y_R&?^'/ZJ2*#Z4:"#R4VJM] #IP(I>EN=UW[P3=E.O07K)<0VZ8
MFQ= S 6C['M1S(LK?A<;1&+!FE-_45RU/W=X$7OA<> JUH&K P>NXDM#NN)E
M@].K*[(XD[]*=8O0:)-05R E8Z?5'KXEH?;.(>$E<ATDI(&Z1LRR"%>2;6Q*
MA,7QHL%A%9QP[92 H-)SIPO(OM3U_>3 &\<"#D#<46=6Q)_O_NH"_L@.NSQT
M:,'$!X*]AVZEL^K>&0;R(.##-P=H;I-66K9D@Y:D#Z.GC:6940 N]T//O)>,
M>;S^-A@5ZZR]E>S N\OJZ,1O&;.-JS?>*Y^NIXEY%U9!DF$H]O9O_8,14\T]
MC MQBZP$53.L_QJIS!N3W]$1@_7<CL.+3+)T<4:1EL-^OTFKV@PUP%BU"3!7
M$7EWNHVO';ATOLMYGG#E;Y-+&Z8IR)K6^+GFP\KFL-)&9$E'<V(2(C'W(8LC
MB7+HN(YI["*9&1GNDTS%R W[=Q/W(#0E>(PM01QN")>E5<<PV$F .V#;7E>[
M=-"U _6RU?(Z8^5RQYP3Z_=V#I!U?04X)BS])-9>.UP@567$PWF\X X0IQ/5
MZ>A-[F+FQ+P=D#81-5='Z<R9X:WK'Z#N)\=Q!RR'6A.LC-S!""= WB]Q/0^<
MTJ>I*3^Y4V5&O<P1JUI?VTP<G?/\[.KY0?O:)*\+ Y,]WU1'!,129:WU3(H)
M5*_(\SHL[OF<W"X3#K[$8I\)+GCP#89@XV7'4Y9GSRV/>E5W_)%SRX'0@#&;
MU9BL8=W1P<YFZZF1+D_=\4,I!QWXJ=[Z^GS?2HW<KTYY[!@V\3SF76K>N-EI
MK=R7AJ\DCZ%]^9X]6N;U91_74X&+FNJ1%Z)\"'?./$/B%QW([0YL:@IF)Z'Z
ML^T"%1BB1;/I>3AGH9HK.DZ[/.QR7;"[N 63K=9M,B)_. M.[AB?;+PEB0W^
MD-M80I_C[K-B^N,/MAQ6'UD]I8NT,0")E4;A/"1W+;KRZC3A[QZD<V ,&R_F
M\MJ]PV!JFGNEE&&D&]3>2K-)J_CJJ!X?][_^LKPD+-5/I6JUU8K?Q!VX>LJA
M"0_;Y#?.Z?L;6V^(\Z+<R:>['OH?A;A*_[D/4DY9N/<,:_-B$O\DZ3'YFXRM
M<>AMWN?>V].IF9O?$5](I[&\2-U=5?8U]&-Y^WIUN[S#_GU(O>!D<7,\VFP,
M>B_D;8'V2YFM^5WLTZR$VO#');\QFF[ [_1R4/N%)G OY__IOP!02P,$%
M  @ &'-85+B[0.R],P  (;$  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&ULS7U9D]O6DN9?06AN]T@1K)*J9'F3[8A2R;ZM#B]J2;Y^F)@'D#@D88$
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MDB3<Q]ZV1(#7+WY1D(Z$C"EV_1A6$Q&I2+2#%)">.4]AD_-%XL^3C-]+9@D
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ME&K[B^,J<FF-GR IA,3:"2 3J!@ZA\6_&MJQC,5336R0P7_FC\,LEE(;<=#
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MUUXMLG<-B6'95U\\61"?.\^>+2S]UUSS?Y<U1%&,/],:WF$-2K470NE"NVY
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M$<J=9_^P]MJRGE!<;*>DD/;SMZ=?7W#5+_1:\@V)Z-LGHV^E$]'?GEY^F?[
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MENQN$SYOFUW:(^<R'_ISTCU:67/I&O#]".NRJ]0^T)$UZCZ 8\Q'X5ZY<N?
M9=/+[^ B@MV1[WMYVX,65QRX%_8A1/E<76P!@+BA(J&V2M^S=0,OA4[VV/2
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M.AB/Z!I-V+5:\]2N#[1(N86JE>C69#AN0^ZXC^LH@A8N<9= )-/NI<I01 D
M\&!9(DVA#$\-:TVG,&LPAN;ASC5:Q&J9RS\@*BDUQ0JN90B<5 DQ%+^7TJZ9
M$3'^6HD5K3E4(&4CW(<1*10-HW8=XX56&4/%IGRN*/H(2H<!*0]2&1/.00+7
MFN=+D;EH4DY"5>'B&E.4RSSI%5I12)DFP(',&%(&TQ%=0[H&HXDWQVLJ8S87
MN5A("Q;&FEXKUB*1UK29<JEB5SR'$?H62G@2UDK )^P,(SAV$ 1LT!^RF= 6
M[F&I6/(4$&01+ZA/>=02B.HD9.&$A=.PH?0.EUG!I?8&M19M-J%PCI !86<,
MXM,2=@OCC?6\04I^Y:E<YK2N5FK99BYYP\/F/NCWV0QN+#,8\E$@/58QUX+]
M_5L=G4S8%<+5U /%EK56%)EQ0%9.)^0S&.H*IS)(4BI-**VBJ:,*H_9;*@L%
M$'4FXPF5 A(9!;//!IUH.G85,..%M##O#Y?$5=Y;A4_XL!_T)T#Z-*6F!2]2
MX778_G3TZ&/?>6Q_\H@XF'9=&KIZ=?E<EWF'\4PAQ>JH(]T0OS)'+_>J>&JD
MVG[0';%YQ;6N-JO Z!::^E!"V*E4%U]$O'**(.CB5J1=K]H#P<D;)$?(M.QM
MDF\*JLWO-,:P+Q# "U%:&4,"R@[.V/K?[GKT^M/JA=/7J#=3VHK[=28J%1YI
MV74UZP)4J6!VJ[ ?;$47XBFS'L!'#8$.6!JG;"E&@#6[_'9^=@"K;WD<H]9\
MWB 5MSCC$0:@B3S@F&&TD04ZE\<G(4P5WI<]1]7#V?YXXZJR #\4<L'7KJ"!
MK +#6.+%J%([F"-%Z'GVC\!CAR$38-92Y,05;)$?/U?[JLPX+;-P1JY2M5Q7
M<=ARS(5OOW*.C\L2GY4&XA3 UEOJ#0@BN>[#5R>7! ]>(?@3"-:/W;^0VE#8
M,D!4+ %OSM1*P-?N39?X?;K\Y^4!82?&;/?#(OE<0M'?ZP]?V**D.?@ O4O2
M',LN;F:?9BZ4+7G;?H(:;PDH4N/E@.Z/7\'[\SI%'[E:<<S*L:M <N1COY-M
MOYZ=.*@<'YK&Y1[^>9DC?V'Q=WF/-5B]*N< ^V <'3+HQI ):&HQD9PDM^@K
M[$R:'Z6I:5J+U$DVI!TX%U 9HNM.BF8@-&9LF:]XZBNH4'>)T&U?%,/PS_F0
M^N5)ANYL&U1QEE+OBUT(.8M7U-B)+\J02*G=$RC$Q*W+;@2"BIPU+/!Q1=_M
MP@,N0)TJ(CE28+M5^ZG S7Z52_T^ASK?8QC8W28QYN:&NS[6P=:,,-4XP*,)
M!S5H4S^,=-@=$-[-1#IQ?8NU?@-9F^A(BU38JCA^+JGK1H;S"ORJMH\N",OP
M2C405S,$9L&$'/5@ZNBZ0<(AD18%K?..M_"PQ';ER>1!SM=+L,8/A2(DM]Q)
MNW)P Z0H7-;"W"51OW,(MC_M]W=A_?G5]2\\*P[/:HPB=<O<)[)S#$8N/]RY
ML:TR).8Y'C&.X"\-/,CF&!.*]JXD/4XP^JW]5ZIQB@>E 7:IM(5]MDT5B=-L
M"V"@D$ )6'-8@>8PG.RRY$,9:VDXU=4"4&@%YE"R(*%&C@T*B!H$]=/F4YUS
MCGQX0>D7]6-T:N 0TU%3G"F3D$@.XBBRIL3EL,(Y9TPX&NPRYI46/,RN&DX,
MLDHZ5/XO]' [WB>F?E2FD)K_U;96@ Q@R#AT6C?0_*K\=C-*=U(/;YU:JH,)
M R:>8+0AV)D/?X%5-+U_KHFW:A:;$;( 3/V47S= X +&_PXKT%5RMS."4I)@
MQI'76$.1 7F.V>B.S>N]!#;O&,TAN,/$8B'<R4_=<N=B*3U'+/?82JR?.-Q
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M5A)1@1;@^3)'^6%_$(+V/SGO_Q]02P,$%     @ &'-85-]0EI9_!   S D
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MKZZKH?RU/0@"BU)4 %5QC@@/^WL4-1"]OZ;CLJP1SJ,B+TNV I^A */0B1_
M/^HYU^O6DP+K5<553>BMFHB.B(O[(EQQ88LB18Y@R: &K 0D*FV%JE'SL)00
M6SX]P/ +<?%;!DLI(8NCS!C8'/9/'A;E?%A-P>#K% 1'A3>HR[^$P";H+UC-
M4@V/_ /0"#H$3PPDU?PYI[8^ 95&]T/")3)^DG^LW5D!FOJ:;J%/;* ?/#-=
M"R'?\#3/M\0%A@K.:=^ENE:>Y@14P4)4F-ES*O, H4^BH(TE=/[JS)A3B2.C
M"LH6!MPXNU</2ZSQ.$/@]VJZL-7">(.RE\-@ ^RW]H(/1V'\2YRBN+=Y&4O
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M"B9-@/CUF>Y@5+&K1'XMR"3!5=!);+(YLBH8],=-%&[*#+E-(\IK,BKFHWK
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ME&-<@*+/+>CGESB%5(@8:#T @$^X)FXAZ0:TT&3!)K#"<0O9MT D=- )6!-
MIG4L57D$TWW3;IJK981K8&H8)*BMW^?-TKZXH/)-])52#OJS UT$RSYW[9\
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M(LE7W'?),JL;<&SFM[C/+3%DY8TJH" 1I;JDX>;AOHEVZ/L# ?^-Z3:6=Z6
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M#:68D;L>2?/;>F2G('^#VWVCQ[7%ZD$@;F02;Z<<*]@,DE@A9+1.8%$V)X8
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M:&5E=',O<VAE970T,RYX;6R55FU/XS@0_BNCBI-:J="\M&F*H!)T;V^18$'
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MRH(?X/I#4H0^,WP! 3YNM&<EGGN8C,;8R)3[$V=B<J_AC@NDPYAB5822P\T
M0D'XN7.NM3&7(B"Y1PGI-Y,8:/QO!6V,\\8Z,<6B-&OX@W2E&( FT]G?9+1Y
M]TE4R%VJA-R!.A%XG5+?(L*B$!>NQ0,Q0#L4]*&1Z 5;'=*'9F=B-9B;I#Y'
M%7!1&2 -0] ''TH3)AO&+&)03** (P] -+B;IT"#@J12TIQU6AX@)LBSMI9A
MM DY/-$V7ZH=08'O\_1@:!,F2D>AJ=R?@*'RQ*Z9U'KC]'9(V%S!'!:N%647
M$F$>/2T"\X#"1%:[>DGTC2 K590=L0MF> /B 0;!V^U3'CU?NC:L4N7EBSY7
M,P8<! N+#9P#9J$W6 E&36(X([G5KI\Y%H;0[Y)>:A<&'B5:1&*:RGBERK;,
MGIT._561DJ8'P)TM1EH2]Q%#MH+[-N%) 0Z @?<R+'9@KI5X4R9]]&:#]:4J
M#U(=D (V8[$",RKB^@>)T_#5TLZRW<%;[6$RU@7S77F+E693"R25@\)+@<GY
M%J (<]60]U1+_LF9#EIR]U5+?L>67.F"IL-MT%%;;ZTBK.2P$!FD6H;_)+&E
M/?YK@@J3+%.OJ]%?E53P?X02+J+!J$8)<^C^?T2)0QI(WOXG? D8=8S E<V$
M&3)X0:"M+VC1UC!#(JB<R2'G_\NM #_B3'H'HS=BR_X@].;/!WH)>)Z8DG4R
M^%\QI9W>_MNLR7W!2_T\55H5&K;0T%@#X*>CKDQ8(T1B8P/9&9'U2A&D5Q=!
M>J\60:J:$F<P9X^Y2FGV,9>Z5)J1I!JUJ%&J9':H!O+J)#]3 ]%E2(1LV2Z*
MQ=RK1AT,<[_]\[K#LV+#31R0*LUS3G609 X-U^$:@8G4E--.Y/7(\C]IKXFV
M9T6*.S)6PT8:ZAHN\E5<K6&C#5D^"?];DB+ -"VCU^TC/:6\%5?+$F?@WXJ6
M=B'3.P5]Q31NUQ08U+5P'5B#7;7FE;3X%2'W:R'W?ZK2E966C^@BU]D7O9@%
MV=TAF;X^YI^)S]#Q.;(:FDVNN,R6)SFTJQ*PP4$K1;K(-J#B(8-!+FY.YB>(
M<9%H9C*DU*K2QI?%_T3F%]ZO"-_)=":Q=R*&XC^%V:=+#Y<1A@HR3.NI4XA(
MQ6")SMV((2XU<^ABXC*6J1^016AT*\>C4<PN+ACX%?&XM7C<GR]$-O*HJ4[%
M:RTY)*371]X74EUA]!4@-51^)8F]PB+)),/[%*LNTZ)(_H&7966 ?-#.V%X2
MR'1V]>EF?(W[Y&(T^[N87'Z:C$?7Z"2N9F)\/IK/GPKM^NIZ="YF9[=GES=G
M<R[NO&(6T\^3W\]FXG1R-?TZFEV,QF<WUYCA?"Z^S*YNIJ)5?VG34 ;73UXI
M'MXBE:*DCSY91M\B8.@;/;>\=QUH210 '1&,^G $D MI9QG$ /LES&J'72/>
MWX"_BHJX*H? FVVX02[&5[>33\=8M-T'NIA03*>NH$W1)@97ES*B<(.J(]-8
M%5'B(6>E,"E J)\IT3,L $G/&,#[X.JXXI(V:-+@45PH"BFJ#J/QM[_7O<RA
M+2SBN]T5G^<79\>3BXN;R\YUX"5@@<#][AC)2$SE#D]MUI**2]FN^Z"'(?J"
M2E37*1Q_O)!/ICO=-38'^+.$:??$* Q+QUIS^A:(D129<!VP7+BVN(*C#)/5
MEBI_%K"7ZK1FUQCT26!#B,D1DT7*C/XZ.X93#HC)G:]G,^LX5BL=RD50;BJ9
MPV4LR%WEPJ,>*7CDV"ZN]M "1 _[IO@MA_"" ]*+QK,IO&Q<WJ/Q?#H6IL&+
M![@[8F /  7A-I=BY-]39WB$,;7I=K&4@2L<UQ7S(B=AURW*$DB#0O0QN!1\
M3P;/OU*UI!V.)(7GG<ROH;Q+>.6:I[#"%7PHAR8$< D5'7-@I>9+GB!^)$N.
M@P4FRK842+7+D+<D8X,;.$/S0Z_21,5^XB& 16]H62KZ$,4 NCF$+SM-LB(,
MEF*Z#D+IJQ"N6")L0[204.6FC& J4?"7&.-&6[A)0"N)-U3%G8K0K>=T!27T
M=K\G?I/A79(&8G3^:RU(IG)V-3<;;RJ:+^?C\[%PH+P]QQ$]*.^L> Q(1;D,
M=8GH>IWXJ[L@KJNVX3;:K)-(&C55^HVWI9575!D" 49<A&B88]9,Q[J;)-PB
M\0Y8]UO?%):BTGKD+WL]VF5N[Z5)YB4;C+W7VT&J8KI=T3+;0/)<@M,YTSR*
MF2L.UF,/R*)ZXO<@E0MUSY^O240<;@*%H8CC=Z*(*7KR>&_$$%0_I)BZXI%1
M%M"XRYZ6,?/>-3ZO$*HN0DEN5;Y[HH_O=,0+=XOTB#<C7QH61G7/->/2P&@E
MIF,+4YPG*6POEOOB?4J1L/I8-I#5A%\>0:5DAJ!YBEC[&.M.-K( PE+QG1;9
M5.!]NX8"8EH@#=3U.I4_ (*I9!8"&':S[W=BD>WH84YXZ_)K)BBCI#T=<:JR
M#0)V"=&%<L.5\[1IHJ?''A>;/9AZJ5_,V(:&83! X !_<#RG*<P9;IAJN\@*
M%@@NV#>PUEVH._ZVW.=SA*ECT$<IQ09O./OA#E*<SD:?Q6V_VSWK_"JB(J^S
M&$HCG\]PEBZ"O'B$KS%=YQU\B\(OX,6BK8,QRNCRIN+MQA?'-#S>DBX*#4I(
MBG4GQ.A;K-%%F 4;'XA3"23U@N0 MIX_4=LG2@4\PGAAP&J5PE$\5=$+A7 :
M'XGMC1;L:9.*%$[CMS!(0C6  B%G$*\#K#Y)]]A"JW["U#U =P=B@"4-:^$<
M$EPMU7]9<B8R$A/>$!/N/&;M%RN/:=FD[N V\HQ)7"9M%\H/R+&RK[2MH?:9
M77*B \,==L59&% MXH!,N&C8#&J I\B)[[GN+7/.D9?!@@K094KJ*[41]PKK
MHIV":$% B$2_"".DK[ +1())&&01_.T0X =_BQ4Y!H4-4ZJMP-U4 <X<5@/S
MX^2DLGM$-WU;],%YUT;DM:8]A,<.[M$&X<T(&AYP=2"+DCNNO, CED%6K;U4
M-$!8#8XC#-D"1G@&SD20=80^1:JP\2$\'5Q[%[9Y,;6J#*_2_P55:[F>0S6,
MD'HS:B%FL:#NUQ"Z_"&N*%S6$1^LWZ>A2416S\(?K1A0&GS7FW+:=;.MN.09
M^@U!/Y=E)7$3N6.?KCT,BTBH_S\4A']-LDU 29H.OUW#[IH< ;NNR_?^L(>X
M)J3=JA]8QRF6K5@_D$.H<E>L/X#LP/3^P*&5I EB4 CP&$U"&9';A(:LP@(!
M(^T6>@F$Z=A0>L1.3G\H?I?P*VJ)X.K@\ ["=8O"RNY ?$[E*H*D:V_9*4/L
M,KF]US%(J:2U5MK((+1T;#A=_BH?#\]&N[06I$2E@-LE;?I^+N+5DS:(4"VH
MN>W !6U7M"7[PF#=+D,D^1?8 5!&/8JY\DO87I5ZFQ7(2\$C'=Q1(8IB*RJM
MF1"#10, )W[?WB<O$&VZ%.73^DPQE8\A)7Z[I&-2-10ML0Y6:P']O$/4 O-E
M0MH"ZWVZL3^YG:RJE!0Q$8+*2C<=1&.V2T;1#/,KB2NVBZRAR0Z8CK1N",=/
M!RH:?6KMJX'.<"!H7)%!6 :%2)-*AXA\WC<3$X9^!LC6A%]-VGQ6P+'UF8$>
M)Q".X2*C^$V%?\CXAYB-8!\9+C<4@6O;Y;B-%))QST/J"R!";([T!MEYX ?
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M5BA++<U39N+T>$H54TBLT$*" JYIUCX>HB6+.%NQ@'*-)D$@MEPS'J&%B%G
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M@"9$[Y4Y@$+(QE\JN F>+O;O)2@Q%2BPD4#A$$&)F?F*"0UUEK^$8(@:?0G
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M6,6D&!(%]*8#(%-,@NYD4Y-B%73$[HS,L=6D&'HV4G];YA) (:P_*@B F(7
M8Q7PQ$]_"& O,2E6L4(\$BL<(B;%^^1! !"0!X%0MCQ(K**!>'_9_S E*0;2
M&$!&*S;/3C(36L"]K&F]6/%]_ B^WU]&BA6WQR-)B*/+2#&@F1L+S,18A(18
ML7B\AZJ^GX(4C[[N,'="ABU4)!R[2?B1VE%L\J/12A=DV,K>X3]C_+F':A3#
MA_'HS0,HCQ';BY[([Y_9XV:]IZI&#_<=AIG](Z':ED,X5\LEZVD_]<[&\=U;
MX2\(.M[K?*S8L5/^4^\\+39B?[1.FNUD^'VUFP,2DFV7W%NF=^F2"Z^0]FHO
MMJ7X?L?;*$MZX<]I^EGZX%>(,6_='F8H?Y='"+[Q7HGH2/O5;US-*RP^#"Z@
M>.HZZL3OG;+CNTGQ"[;TLKM8T[:[:=,4;[C;]GY=B0X1O5#5Z:*9<CMC[L3>
M<UNIBUUO=29Y]TGER3-,LV_]B%3,8^F_)B7O=EJ\V<R+7^5&1 Z4_#Q4ZN0O
MXVJ=\(7>/<\R^7>5WLKUTGA'+UUODK1L1FTA1OZ6MRZ_PWS\+EEOOK]\8-)J
MVE@L;"EY4C76U,WWFI=Y,^7$GJFS5%JX*=.UV$CM:^1]F=;RRXW\H>.?';VK
MPA9K>Q:*0&K,P [2V^W(2H4E27Z;RM1"6[][[O7../+=(0M\@-_Y6#&Y6MJY
M)Z:4:^[UIY<LHLV^P=2$Y]Y%L4[E('[K[O5FI!>;+9/,J*3%4M3P0&EB9BS3
MNM); F.+JJX&R[^;=A+=;+U;[\+_V*:B796<,&F=RKHWB1BW),ODP:LWLH'7
MWYYSSIJ=\PS&N_L;G(FSWJ&W8D7<-J<-RT6SS6M)N[U?=T<:GS?G^&J_7\BC
MCH'?Q<1&;R\EO9G7)#_):]#]I%>5UPA\C<IKS6F_,]7L]ESF#\):.?(9OQ$F
M^%.IO97M2<?ME[K8-$?Y7A=U7:R;CRN>+'DI >+Z35'4#U]D!;L#I\_^#U!+
M P04    "  8<UA4UD7#&1<#  !)"@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T-RYX;6R]5DU/XS 0_2M6Q $D(''23]16@E:K15I$19?= ]J#FTQ:"\?N
MV@YE__V.DY"&TG;1'GI)_#%O9MX;9^+!6NEGLP2PY#43T@R]I;6K*]\W\1(R
M9B[5"B3NI$IGS.)4+WRSTL"2 I0)/PR"CI\Q+KW1H%B;ZM% Y59P"5--3)YE
M3/^Y :'60X]Z;PL/?+&T;L$?#59L 3.PCZNIQIE?>TEX!M)P)8F&=.A=TZLQ
MC1R@L/C!86T:8^*HS)5Z=I/;9.@%+B,0$%OG@N'K!<8@A/.$>?RNG'IU3 =L
MCM^\?RG((YDY,S!6XB=/['+H]3R20,IR81_4^BM4A-K.7ZR$*9YD7=D&'HES
M8U56@3&#C,ORS5XK(1H VMH#""M ^%E 5 $*Y?PRLX+6A%DV&FBU)MI9HS<W
M*+0IT,B&2U?&F=6XRQ%G1S?,<$-42J8:#$C+2G%E0F9\(7G*8R8MN8YCE4O+
MY8),E> Q!T,NW*K.(2$/,&<65QSJWBY!ESM,&'(Z <NX,&=H_CB;D-.3,W)"
MN"1W7 B,9 :^118N%S^N,KXI,P[W9#R!^))$])R$04AWP,>?AP?OX3YJ5PL8
MU@*&A;]HC[\9?EA)+H#<I[4@WSB;<\&MD^GI&P+(K87,_#H0+JK#146XUIYP
MWY5E @]_&4@WE%>%\H8),!<:!*XGI1W689?*99QV$<=]["^C=J^-BKPTM?QH
MU.H&O=KH'8563:%UF()F";C4W)$RR"$&_L+F LX)YHYD!/86)F,@V*5(HO*Y
M37.Q 3S=038'?4C-=IU*^QC%Z]3A.D<J7AFGTZ@+#;K=K>)]-.IUZ.[:=6L&
MW8,,RL\[SK7&7D%$4ZI_5Z57!^D=HRK].ES_(*?K]_78)7?_@Y)1C](MN7<8
M!;2[6V\:;/IS\ G%#YV%RD$S<#OL;26WPZ@5A7N2:_P\Z">2DTK^YXF@FRY+
MC])FZ:;/TF,U6KJCB4;1=GT^&D7]_E9]_,9_WEVR[IA><&FP;::("BZ["-?E
MO:6<6+4J?OUS9?$B40R7>-<#[0QP/U7*ODW<;:*^/8[^ E!+ P04    "  8
M<UA4044"1UL(  #:)0  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R]
MFNUOVS83P/\5PNCSH 626-2+[?1) B1Q7SPL79"NVX=B'VB+MKE)HDM2<3+L
MCW^.$BO*D42K:3V@:"Q1QSL>C[\[4CK;<O&77%.JT$.:9/)\L%9J\WHXE(LU
M38D\X1N:0<N2BY0HN!2KH=P(2N)"*$V&ON>-ABEAV>#BK+AW*R[.>*X2EM%;
M@62>ID0\7M&$;\\'>/#UQAU;K96^,;PXVY 5_4C5I\VM@*MAU4O,4II)QC,D
MZ/)\<(E?SZ*)%BB>^(W1K:S]1GHH<\[_TA>S^'S@:8MH0A=*=T'@SSV]IDFB
M>P([OIA.!Y5.+5C__;7WM\7@83!S(NDU3WYGL5J?#R8#%-,ER1-UQ[?OJ1E0
MI/M;\$06_Z.M>=8;H$4N%4^-,%B0LJS\2QZ,(_H(^$; ?R* PPZ!P @$?05"
M(Q#V%8B,0-178&0$1GT%QD9@W%=@8@0F?05.C<!I$0[E_!63/R6*7)P)OD5"
M/PV]Z1]%!!72,.<LT\'^40EH92"G+BX77W(FF0X\>82F$'A2,94+"E=OH$D]
M'M]0M>8QFF6Z#>)<0=//;*$#/ENA2R%(MJ+%?42R&$'8)63.!=%1O-M\C.KJ
MT,LI580E\A4T?/HX12]?O$(OT!#)-0']B&7H4\:TMA?Z]PU+$BUV-E0P;FW]
M<&'&>%V.T>\8XP=^?X+P^ CYGH];Q*=N\9_RY 0%GA;'IRWB;WJ(>[A3_&T?
MXT>=QK]SBT_I HS'G>+O^XM[+>*SWN)/QSZ$0*VBU:^BU2_Z"SKZN\HAYJB4
M]3A"GW^&>VBF:"K_<.@(*AU!H2/LT'%-Y!IMR&,9LI!. ,B5LB.400+B2[30
M3Q4-@L9MTU(JB0HE.N/<7X#_[NN>W_O$K/D$]B8C7#VU,[ZP&E_H'-];!HN*
M'B>P.F-85PJ6)YLG%!$IJ3I"N:3+/$$)6]*V8;G[GJ!'2H1TS$)461DY>WK'
M>;R%%=]BPY5;\C/^H\WPJ.'+\-3W)D_FI'QJM/-4%(V>S$O+4Q,\Z9B7437B
MD=/N7X4&7)ZBSS<TG5/ABN5QU>?X8.ME4NF8..W^99M1(==L@S940%904".U
M8<[=BW_B>?]Q6'-:67/ZP[R(/9LDO8/Y$==2,7;:?JE7X"YMBE2(-@+2+7H)
M23#6R55([>JR[55K.BSUC.O@F)Q$[?&)+7RQ_ZWV+2 ALYCJ9 \>49#KY9**
M=B1>F^[K:Q!J<J_#+,MKO ?8X(<518I#\2T!/XMU48?$]!Y*^8W&.*(/L#F0
M94T!)F>FTMXRM2ZY5Q]5J^E!8\G[V'O"ZW>X">R=IW8':(&-W51M\7MAM'0E
MH&O3Z8[)-9+MVF*QC-UT;;$E863.$K@ _X)=>=IA3Y/ 7<C$EIEX#S37$'N+
M-<QE:=C.^NQ!  M2?#B28HM2[*;@=ZZP-Z;[NH\#W^]PLD4J=C/U7UA@;XP)
M]6@-@G&[Y;[EMN\Y+?^T60H.YIERKDVQZ6%'<=BQ9'V+<M^-\AORP%+(0ANN
M0"\C">S=$M@^<8B7K[5EJS6X65J,NZRI5<UN<-]^K69A"@TRREEI-<%O.@1W
MS82%M.^&]+=$]A&BQ<Y35Z<40J[=S"9K.Q*<;T'K[P$M;%8?^W##M[STHX-Q
MP[<8]-T8K+3L.+@J$HI5J3<LO4N(J5&X4R]/.OQK(>J/OSD.Y\9T?>!0V+CA
MH@,24]/]SH8(^UT)UK?8]=W8_3%;OJG14E\YV#OM-,_RUW?S=_9DD]9&CJG?
M!.@HZ-(=6((&;H(Z]F'3H(G.46>Y$UAV!FYV?@!WQ[1$ 5+DH5Y@M)K19";N
M-L-",]A;[>I2!B4\6QT#AU(P:MZ&HFG0)&88=90V0>T88@\Q=V"$_D%W0$*1
M+U0N]+E;F92!*Y"):VPYOJ,)450?PTF(Y1XL"RP>@_!PIR^6F(&[PKP%P]$B
MX<7IXH*GNK H4X0I,MJ.H8)F<8FCCJ056*P&;JQ.RPH'O/DK7:PSGO#5(RK>
M!_3SK 5C<+CJ,K"8"]R8^[Z3GSV=C_<>_006>($;>'W\#@NB=[H.+>["PVWT
M0TNXT$VX6:R+PB5@+:&-B6AEG.FPW]8YM(P+]S#.9+.F$?O"8;JG9SS:&P^A
M16'H1N'L]NZ_)-W\;_J\V:^=C!X.<*$%7.@&W#-FOTDW?](Y^Q9OH1MO=S3.
MRWT:RYJ&H#@O]GPI)3(7Q1L<73,R'B,2_YF;5T%MKQ3"9NW8606%EI&ANWBL
MO7):"6K>*#TK'BPPP\GAXL'2+OP!Y5W8+.]PU.74R/(N<I=W;4X]JE-WEJ%I
M;9__'']'EHL1/IB_(PN]R(VF7OZ.FC5=]TXCLB2+W"1K]W=KOGN6JRWJHL.A
M+JJ]Q/G1J(N:J M&76ZWI(O<I/NNRF>ZIW/L[7_KI2FW>\="*'(75NWOLZ[V
M2%U*1/1Q79X4>U>UIG#%Q8ID[.^RFH:[/!>ZPDZI6.@C*HC \C!&L[_89&BQ
M)3REUNA+3@3L@K28?I6,7DI*T0>N*,)C].H(;2G\$UJ+*2D@=>AO"5+8C1CU
M2?E)P)(P@>Y)DL/NQ1AQ>XV+(\7W7&Z8TJ;4+"V."V*JMV Z/$GV"'V1).&+
M:B KLTL]0;_38L^04+T'4FNFOTD@R:-DTIQ9FFYT(U$HXY4LVA*Y8_V<6CTT
M/D$UEQX55NO8AA%7'<Q)0K*%-@ :,CV\LA>(,K;2*O5Q**1:[8TKQC>P@TMU
MC_K$HU@ADJXT$4[:(FE8^\8#)FQ5?" D05>>J?+E=G6W^@CIJOA6Y^G]:/SZ
M?31N:8&8@I;B0Y2A55%^]70#NTT&4Y'0):CS3L:P0D7Y(5%YH?BF^,IDSI7B
M:?%S34E,A7X VI<<8L5<: 75YUP7_P=02P,$%     @ &'-85!Q @4)N"0
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MU+0U1B@H"T[31A@L2..L_HN?FXG8$K#,/0)6(V#U%; ; ;NO@-,(.'T%W$;
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M ;Q?4BCTF@?QX[?-;U7/_@102P,$%     @ &'-85,J ?P!E"@  $S   !D
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M#]%T32.T=$P;4G7D;QP#TVRR"Y,,[EB5."73=.QD$&@#@":?SM ^),I[M2$
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MZ1&J=U25Q_J;RIG^CQS$+WJT8)X(TP J0N8Q5%PJ'N!1K3^?SS@ X$"=?]1
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MAK5>LQ!]'@NUKO7QG@7ZPSWC,ZW)A+[HP(2)NH$H/)P)>:A8! ?D=Z')F*M
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M2HV50'=5N4)-DF3%NLD158%4[?/ ).G:W,L PGABCH4M"]4_<RAL%0XBUU3
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MCI,XNG-\Z6?M^RS3=0+Z!^U=^\Y'-0,I^YGJ!JKQ1GN*IMXS4@J0*PR,\;N
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MG5_P),T_BGM..$^B_.>4$J@21 -X/DX@IXH+,4#Y[?')_P%02P,$%     @
M&'-85'\<'>!;"   QR   !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&UL
MS5IM;^,V$OXKA*\X[ *Q+5&2+>>2 ''L0_?0M,&FVSO Z =:HF->)5%+4G%<
MW(^_(:5(MDQ+::XX[)=8TKQPYN%P^(C*U8Z+W^264H5>TB23UX.M4OGE>"RC
M+4V)'/&<9B#9<)$2!;?B:2QS04ELC-)DC!UG,DX)RP8W5^;9@[BYXH5*6$8?
M!))%FA*QG].$[ZX'[N#UP6?VM%7ZP?CF*B=/])&J+_F#@+MQ[25F*<TDXQD2
M=',]N'4OEYZC#8S&+XSNY,$UTJFL.?]-WWR*KP>.CH@F-%+:!8&?9WI'DT1[
M@CB^5DX']9C:\/#ZU?O?3?*0S)I(>L>3?[)8;:\'X0#%=$.*1'WFN^]IE5"@
M_44\D>8OVE6ZS@!%A50\K8PA@I1EY2]YJ8!XBP&N#'#+P)V<,? J Z]MX)\Q
M\"L#_ZT&065@4A^7N1O@%D21FRO!=TAH;?"F+PSZQAKP8IDNE$<E0,K 3MW<
M1E\+)IF>-'F!%C!I4C%5" IW2Q"I_?">JBV/T:=,RZ!&%(A^8)$NENP)W0I!
MLB=JGB.2Q0BF+"%K+HBN@&/Q$#U"H<=%0A'?="EJ/S_R;!B=4T$_PZ4DIM@D
M^K"@BK!$?H01OCPNT(?O/J+O$,O0/4L2K7$U5H"5SG@<5;C<E;C@,[BX&-WS
M3&TE6F8QC8\=C 'D&FG\BO0=[O2XH-$(>>X%P@YV+0$MWF[N6,R7;S9W9QW9
M>'7=>,:?=\;?V<DS<W=X_Y/:4H'4EF2M&5_] #[1)T53^6M'1'X=D6\B\L]$
M])D^TZR@MKF>=UNNW%]M!5(:!<9(]]OGF]#%87@U?CZ<M5,MWYT$[K'6TJ+E
MS)R@UCK*.*@S#CKCON-2Z84D26)/N]M\A:UIET:3@U"'GA/B5D8+BUKHAWXK
M;YN6$_CVO"=UWI/.P!]A6X'6<P$KO-PI88F3Q!0>B:%',JFJ$J,OL*%*.SC=
M8YP!9W*:CXNGCM<"QZ;F!K-I"QV[-SRQPS.MX9GV+ 1)B8BV!I 85D7"<[,2
MN]#H=GD&C:DE?B_$LQ8:%K69-VMAMK1HA5YX9HF$-19A9^!E\V%9Q%,Z_@"-
MO"BWC(]__0N4-/Y;1I4ML? D%C^<ME?^J1+,GMM*?FG1\OR#2CA*:U:G->M9
M^>>Z[^J>IFLJNAJJZS3<P/E&FKQ[P%?<][;YN\KT$.P0^^W.9=$*3I;PTJ+E
MSP+//F\N;L+'_UO/[K%?>=:56%D=%^/$G;27HDUOTMZL;$H!/I-Y0QA<[__0
MM7L&6?EV>#P+/-.@#8Y-:];>TNR^SO1LMV$O;A]]>4?7[O&Y"NQH^*<93'W<
M1L.BY<YP&XU3+=<YL[^[#;%QNZG)^]KVO,?K:F*'XY2DA)IB'Z-QJA1,VONY
M1<F;G%LX#=MQNZG(@^ Z_[JUH_^<?W5Z4_]OB(0[_5;Z?[.AN]T[>A?-[S%=
M3>WS?[I%![.3^3]5PB=LUZ+DG2/Y;K/7NWV;_3 7/.7F8.7/*@+<D #\K9
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MF/7%>=YCM7R)$D#OV2PUDG*AV.]U2;%,0<=E:UB(1$JJ3V/I2T1S]8I=PB4
MQ[(JE_M15R8-)<,]Y,GZXC'OL8*)28E@R1Y@3P!DJ1<:9%3H4]Z<L%C?'Q>$
M;@L9%>5\0STQ@>165S?D#KRO?'-"((.9V^@N [0Y*Q,^=D0.3Y1W6UUGT#6T
M)UVE,.E0)+FIDG+E-B?*%Z9FH\-7-1,-RV#;45SL45X 52<:YPULS::YO,8]
M0C^#-W .W4OJ"[.$$=,%>PR&2?Z.ITQ P]AW3E-#%G'/N97U!6C>8_695HM)
M&H@%9>FZ$++"#J(\3-! (?_PVYR&I! "EFM7H@TWQ3U'4M9WFWF/E;4>BQPF
M$?A+3O;-YP< 9&BZPS.DE3(H <6!Q-0Z5=6M]\?8P!K< 33Z]Q3)SLP;!HQ[
M:*SU-6;>8V7-7/ ]2133Y?U:QO;%V!EYPV1Q-Y.U$_!YC]5!<99+L5V/L$;S
M\AW)\(MB ZNX$.7D%)VA>PT+]IQWT,9YC]4C,"/HU@HV(P!>;UZ6-EA5TDDC
M04464STA!_2?/ E:U9*]S50[J:PE^DJ/#!PATAMM29S+T>K><X&6"=,? DWI
M_PM"CAEPK"V4O>F-K6&</S;,J6_KG(P/OF*F5#R9S\>:7P%*U0EA_;C^1CTW
M7V9;S^_<RZ5K>7Z+\>4"VRR ,X/$LTI\D/A620"2P"J9@&1BE4Q!,K5*0I"$
M5LD,)#.;Q',N%^5'^G&#6/F)_YX((',2)70#Z#FC*6S4HOQJ7MXHGIO/PFNN
M%$_-Y982J#BM /(-!_I0W>@!ZO]=N/DO4$L#!!0    ( !AS6%3W(5V4KP0
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M<D7NI#::W&@M \$,#T$]LR0WP8]4:(&ASHB1[.R9AZD-?_^KDO;G6I@->4R
MD&$^:'*6"SR^YX:)Z 1N_/9R3XZ/3L@1$0EY$E&$0B_[!HQ#%?M!;LA=9@AM
M,<2CY$DF9JG)0Q+R<%= '[Q2NH86KKFCG1+O>7!.?.^4T 'U' K='\X^<+ _
M',SNS3JL\<M ^U:>?U"@@RS0%QV"AZ7@H14\;!'\$*\BN>&<&*X@09EIBU\F
M9F3%8/]:7X^GX)CUMDN;-,/)<)?FH4GC#:8ES8X-H]*&4:<-D-_0DT6\8D)!
M%S1._3,1XZWGCOR:^DV2\;BFO8-DYE9^7"H_[@[ AS DP++J'P>*A\+H$Y?^
MX\:3IS7UFQ1G=?6;)*.!6_U)J?ZD4_UOTK (,,>1GIWVW':+??7^<#EATM!_
M,O1J;FC2C/Q1S0]-&DHG;D=,2T=,NQVA6*)9AI\VG"ZCNT6\4J?1TZ:R]<)K
MDG@UDH<FR=AW6SPK+9YUJON8&+Y0K++88HE$X''9WBWLU7?:/FMHW8AWD\2O
M]QP'B>>YC?<&%?0..C5VMF3K@H K@$<<HTJ</5,\L@#<EAIW^=-V"GQ :[8Z
MB$:36<U:!]%XT&;NUJ3A=3?9,+260+6''*9:'"@P\F>$V?:[TP).R5HHD[(H
MVA#X0^2<O"]%L"1" V$@%6 \#@PX3N"B9A%W%LP>I5Z'SJS)N79\.:F[LDGC
M3>J>;-(,6_JE1RM'TDXH?P3$Y0A3VY6S[129*KB;:!F)T.:,!E++H=%7(@ED
MS,'K9"XCV"ETC@%>-6!X?G<U.]1R1J1;S.O('1&_Z<E)([N;1-2?UF/2)/)&
MXY:@5%.0UST&93"6=[':N,SJXS*204$7X_)J>UP6U;CL],.PJ3V=U9'<035M
M.L)!1-NRLQJEO.Y9*MLW?)$);&:QMT-K>\P2[OCA _:WFI^0UR<>OW'U1U?>
M5>./-_[<R=:K1A.O>XCX FT)K! R% %YXPF?%Z/63KUE)A]G=772#XO ZG_^
M8TH][U_YOX0;9SWL&63&[GIH3B!GX_H\ZB#RZTG@F&1:8-VK)AFO>PXINO(+
M=N6#HEV-#-[L<Z--*SRFW7C\]P#4'J5: (HZ(+H>?0<-K<T^#RZ:EOT(K9">
M>C\/0-$*-RG]%(#:(Z8%H'*N'8 :U2/BH*F/V0Z:<<OL12MLIMV@^L*CR";M
M8Y(=+F9ICEAT$\*N74!F6\PA>8\^J&IIA8YT^,E56^$-W;-W_WNJMENIMJIM
M[OYIHVJ;-(T4:9*TM&Q:H2CM1M'_;\U6"$R[T>_@FMT#HBTUVP2_(1W7 ](D
M\F;U0=]!-&F+206CM!M&H6HX4Y"=6*?W?,TCN4)?%$5Z4(U6R$H_&5G]"EG]
MGQ%9]RC54J-^$Q'KAR4.DK/Z7.6@:3FD]"M<]7\B7/4K7/4_!U?WB&FIT9QK
MY[RW'H^]) \.$DI;XH&HNGNGPCF_>Q?H/G6\W</UC#6A;91:3WS(\=&,Q-GK
M$9(=BV+$\=V$;0]'WHPZU[W92;GG).6><WN;":(GHT'%;"N_$'Y*CD;^R+TX
M.,T>/?2F3@)X]'FE(3*4IUSX#A/J6Q66$^YXC9!;#A.+S6Q[0(KC"_8G(PDC
M3U)Q\HL,4LWQ'52\8LFFMKDFL+E>*!:?6WW<Y\Q_6IO:(]"ZMCW\*5DQ!1?8
MS>1\CMWN;4-@PPA/6W,%S0LKLSKP"Q1T/JSJ+/9@)IJ^E19(_ON&FR5)5W"%
MDOA\SNT+5S)G:ZG86\0)/,AD58D,+"&/SR^$I9@6:$&<1D9 V1+#/L@&4 :R
M0(.]7Z3A9'1+('#?4'*W'ZQ+WSD$8:5$S)0 (XMHB1A<LLZ;#YJ1'0=8$"@5
M3KC&XQ+K(]0S\PN+Q"(I5$=9;ZD6EK0('L\R#SPEL:M%*3; /<JB[+^60EW=
MLII7_3VCH?.,_G8/UU:+X!]@7U(>-J%I;RSY;I$SX@L6G6(:R32Q9R_EB3K1
M FJ4P7^NUB+@NM.<:F[TN]\^N8_=;_=P.<PYQ4"J#$<*VT(!Z&9L99;E((J7
M!F@<E@7$J4P0K#>=XL2$@F%(@GR';"FJ-M&8]KE7,!_$UAL('"4V&N!2%P4=
MY!*WC^0S7_Z (A7SC>TAJ&G>YC*MJUKHKN)O"GMF:EL3ML8_Q7RC%-OD32WC
M+)M8&YLN^4[SHD']C[S1I.S>8."*;<J:M<1E755E-&="D36+4HXB(91K(5,-
M#T\3:'G9X"&#[U#SV7/-DAGRSK)A99&(_P(%5CV661!)G?DQQJ$VBP7/!]RJ
M)]$;<I)%XE>I5T*QSO2M]A?^GHV!<PB\W<.UE;XVBZ!K!+99 : D""@B;\S:
M0#31']!>YFE$(HNWV)!Q[D6ZM8S6V?"V"TW9B\#N(JTV$OZ>]X+.T>IV#]=?
M*=)B)$13, T3F&?:9IL#3L([W5#M</P]KPB=1ZFW>[B.PQ-R$V,_U076U*+.
M\KB3#,&+U@NEG 0(LN?DI4AC[\YI2G_K"YZ8PTR"GTYI8D5E[U/+N^7G6;?V
MHZ3:_3OOXL%SW+_Q_8M[WW>LP' **T/GR@A61LZ5,:R,G2L36)DX5Z:P,G6N
MS&#%?FO6KXS/OE1[@@%-0 >)^!P<,3B? $RJ[..O[,+(E?VZZ4T:(V/[<\E9
MR!42P/I<@MOS"WQ ^0G>]?\ 4$L#!!0    ( !AS6%0I?YFXW 0  )P/   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;+U7W6_B.!#_5T:(AU8J#0D?
M+15%HM#55;K>573W]J':!Q,&L-:)L[8#1;H__L9."(&F+*M;]05B>SY_,Q[/
M]-=2?==+1 .OD8CU;6UI3'+C>3I<8L3TI4PPII.Y5!$SM%0+3R<*V<PQ1<(+
MFLVN%S$>UP9]M_>D!GV9&L%C?%*@TRAB:G.'0JYO:WYMNS'ABZ6Q&]Z@G[ %
M/J/YDCPI6GF%E!F/,-9<QJ!P?EL;^C?W?L<R.(I_.*YUZ1NL*U,IO]O%P^RV
MUK06H<#06!&,_E8X0B&L)++C1RZT5NBTC.7OK?1/SGER9LHTCJ3XRF=F>5N[
MKL$,YRP59B+7?V#ND#,PE$*[7UCGM,T:A*DV,LJ9R8*(Q]D_>\V!.(4AR!F"
M P:_^PY#*V=H'3*TWV%HYPSM4QDZ.8-SW<M\=\"-F6&#OI)K4)::I-D/A[[C
M)KQX;!/EV2@ZY<1G!A/41J6A216/%S!:,K5 #2R>P=]FB0I&4AL-0ZUER)G!
M&9EGEC ,?Z1<<QOJC-B2-28X2UWXO2<EW>>*FPT\Q$3(;#YH:.0"&_!)2A-+
M0WMG8S2,BW/:_/(\AK/Z.=2!Q_#(A; *^IXA1ZVY7I@[-<J<"MYQR@_@4<9F
MJ>$^GN%L7X!'"!4P!5N81L%1B6,,+Z'E7T#0#/P*@\:GLS<KV.]/9O=[1[QI
M%4%O.7FMTX).$7%!I&U4*X27/XD>'@Q&^ML1;>U"6]MI:Y^D+70I!F>APADW
MYQ5@W!T7]^)_J\J(C*GCF&QU7 VNVA2I53E(;VDZK<X^S?U;FB"X*FCV .@4
M '2.6ERZ+0V%PEVC[!J\/&(T174,Y6ZAI/L!,;TJM%W]UIB.,G'=$JR-W@'R
M%21^+ZB&_KJP\_JHG0Z'HB[ME:(3L.\56GH?@+W?W-7LYN]%/Y>W=SLZS8/;
M44'T]GKD1.4HM?WKZB#YI4?(_P6'MJ_0D# LWYU)Y=V!?V&H%-N<$E _V%D4
M?$1(=Q79;QU%X,EJ"(74+J(RHD90,Y>S^&J_L>K5R&66(^9WWBE6OBW7^SN[
M^N4?+V#5)??N)UP3I-958TRQ8A45,'11/*OWJ*UQ#SUD"6R??OO*.KSK5 $J
MS_W>N2.P4JAAW5YP7KK@9W7*\1US=DMRX1=0I]RN/FQ>9*HIKRL)2/7ESD++
MD!]KL)VYV) ]N>> 42+D!A$,*NK>LHAFGE.3#S)5\%FQ6-N.WT;>2&#4NRBD
M_HBZ/Y?L4<+BC6-J[!Q-E%PH%ETZ>TCAVX+PZ]8<J+#>)>5&K@3N!21,T4*0
M?#F?:YIHIAN@CI&TK5!I)F@;0E34V=EI(%0I$QJVL2<WK>NEM+#D7S=(O66:
MT,I*POD<W1@!<[:2BDT% BDR B/K##$PJNB39V"I30OK043C 4^(SK!7V"!3
ME 6:_/V+&DWHW $%[K.5?!P'!^D:*0B)XC0^<7)R&RT>$20K9X%V;B2H'#]Y
M7!@<HZ:<UPXC:V>&"Q-\$6]-M[*F*=UV2[H-'F:91TA) CL4*36O/S/6ROY_
M*515O[S21!$A99,=Y31)2&.3=7[%;C$NWKDAZ6!_9,?(BOVAW[X9^^V*$RHK
M=))--SO5V=SZ2(G-:>00."<SFI=75(%4-@IF"R,3-^M,I:')R7TN:7Q&90GH
M?$Y3QW9A%10#^> _4$L#!!0    ( !AS6%3)=()O[08  *<=   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;+5977.;.!?^*QI/+M*9)D;"8#N39"9V
M/MY<9-].VKZ]R.R%C.58[P+R2L)I]M?O$6"P00AON[UH8]#Y>LXY/$>(RS<A
M_U!KQC3ZGL2INAJLM=Y<#(<J6K.$JG.Q82FLK(1,J(9+^3I4&\GH,E=*XB'Q
MO'"84)X.KB_S>Y_D]:7(=,Q3]DDBE24)E>\S%HNWJP$>[&X\\]>U-C>&UY<;
M^LH^,_UU\TG"U;"RLN0)2Q47*9)L=36XP1</OF<4<HG_<?:F]GXC V4AQ!_F
MXG%Y-?!,1"QFD38F*/S9LCF+8V,)XOBS-#JH?!K%_=\[Z_<Y> "SH(K-1?R-
M+_7Z:C 9H"5;T2S6S^+M/ZP$%!A[D8A5_C]Z*V6] 8HRI452*D,$"4^+O_1[
MF8AC%$BI0!H*..Q0\$L%OZG@=RB,2H514V'4H1"4"L&Q'L)2(3S6P[A4&.?%
M*K*;E^:6:GI]*<4;DD8:K)D?>7US;:@(3TTK?M825CGHZ>MGIK3,(IU)GKZB
M^9K*5Z8039?HOWK-))H+I16Z44I$G&JVA/#T&MU$?V9<<=-,A; 1.WMFRRQO
ML.$G*?*?6Z[?T6,*@M1TG$)GZ-#A313)C,8*G=XR37G\ 22^?KY%IR<?T GB
M*7KB<6R\7 XUH#4Q#Z,2V;Q 1CJ088*>1*K7"MVE2[8\-#"$-%6Y(KM<S8G3
MXBV+SI&//R+B$6P)Z.YX=<^B_G"T.IXZT/A5Y?W<GG]4Y>&*R2U#+\\BCA$\
MY6]4+G]WN!E5;D:YFU&'FQE[Y6EJ7"QH3-.(V2I9F AR$X8\M]?CZ>1RN-V3
MN76[><&_VRK2-CS!867X %!0 0J<GJ"WM]PPL<7?S*WZ0FQ!S@NE<!_]"!^B
MOVO+!'YP*/,0M, 2,K:##2NPH3/BKYK'_"]:3 UXSH4A!1MPMYD7WPH\;($Z
M&X6-NM]9A()@9(<UKF"-G?$ (_1TY+CE%7OC1E%NW4Y>1M:6;%MN]?I]CV%K
MKS^T#7?V^J3*T\2=IV03BW?&T!<F8?@4?5",A)<GEBR8=%'$M/(R_95,A+UZ
MUGD_ST6EC8,"34BC\CV..MC(9GKLV4N$]R8X_F%"FI>Z^R[#B==XQ"Q"HW''
M(X9)'1?Y=[BCQTX'>91:A^PQFC:AV:1"TH&MGIW8_TD"*0T<,@@>-?O([::#
M0BRV6RUZWV?:3B(VTYTM6N\!L'LZP_X1WJH>DPWE$MYC=+71/()%<#V8<?!+
M>:0>BM@]SH[CD?;@\IK5[YF:'2SB,GR(J)Z'V#U2W!S2GBR!WWS.VC)AQ_#!
M]?3![O%S/(.X[70QR,2RM6@!LPAU(JLG'I[^+'],^]O'[:.+/'H-W_<9[J .
ME^'#%ZYZ8A/W(+W[SO7Q&PY2STR"?R55D'H($O?P.HHJ2'M(X<;F_K;'3P=7
M6"R/.IJ7U,./N$>'DRQ(>X T=_06D;.NH.H10]PCYFBNZ+'3P16EUG[,_JB)
MJRUS1H(.8/54(^Z7QGZJ(.T7OV#<;)^>-U,[5U@L-QOSOL^RG2PLECL;T\SE
MPSOU7",_\JHTZ]%Z3*,X6[*E.8 JCL&B3$JS;XDY74"?:0Y[E].3D$Q04AQ0
M?=@[,TM%:I?'X;22/W?12STA2<]DLYXHS'JTGME& N6EP*JT/LD[DRS.C_BB
MG&]/3ZI@4239$H@8TF&.OG*H)WA*K.MX6N3"6$%R=R0(:_4IX.G)./!JY7PO
MN#/^$9T$?F!?]#X6KD=X8A4 U^=UA$:A7%;(G,K'[Q!/B1RQW:NMWGNU+9"O
MA$0BD^B+I*DRI_WF^=,"4?0D)(/Y$&6*F3-/V,^F[[G260UT(\6KI,EY'@\X
MW!\T/QI-PX5!M]D_8MU+[D>TH1(N8K O5BNS[UZ\(^A+\+9E4M$8;J.(20TQ
M0/G+\]==[0&F@;[7%D;\VSO3:Y1MX,I88JL5RS\AH!7="DD7,4/@2,<LW]R#
M DW1X_-G1#/3%@9!DL6:;T!.T^_HG5$)7:  [V]",Q3,$!3NB['LSD.>TC<&
M1=A(GE#) >2N6CR!E&SS"%0.8\-DK@^(JX!3IJ#G59XC$V>1%QKSUW07NK&U
MR!3/17?%8T7G0:8$)+MDAYY@C>V?:R$71=1;3=*S6[,.M%F/5DF!D*SE_S.E
MBZP:5/"/0;9*1HR@M0S$. ?O"MBO]WQ^S^&)=1;->K2.Y>P)#O\19Y,@<'/V
M<._C2\+@\3;?U124-$MU<096W:V^W<WR+U:-^W-\\8!M]\G%K4W^CES<V^[?
MD! 60LL*S#U8&5M7)K RL:Y,865J6_&]B_OB(^2P!EY\PGP"GN.I0C%;01*\
M\S$,>EE\%2PNM-CD'Z460FN1Y#_7C"Z9- *POA) #.6%<5!]F[W^&U!+ P04
M    "  8<UA4](W&@6$#  "M"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6R]5FUOVC 0_BM6U ^MM#5Q@  5(/$RM$KM5K7:]J':!Y,88LVQF>W
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M917@? E#Q&YC'503^N@/4$L#!!0    ( !AS6%0.*B>+30L  -PH   9
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M&[3N$Y';7&<VT."+355H H>2<(/W%N@-''X4Q=L,3( A^E#6244\&TV>1SJ
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M%'#&Q-_O5%V^*"\=_(9[ ^<MTK1!Z\/6Q+V,$4J3R<$5<Z.U(SB0"_D:4,F
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MT'!I7Z6S7[3(S+MB2Z&U2,S'#:-PW%  QE<""D'Q!1?8O=!X]S]02P,$%
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M3J?^YQHXE@":@.-+C1MA^4 *ZL_7Y_\'4$L#!!0    ( !AS6%1V8*_+R@@
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M5MDJ+YL?B)PQF$X9G4+FO&X?/K&RO+\M7[0H[/7A1&@M<OLXIR2ETAA _U3
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M"G)]*0_9^YO,0?EM:_(/4$L#!!0    ( !AS6%0')ES!.@4  $D3   9
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MXJ^)HN/4^273(],;[)V(@#6:T;\>8]AU?F^3OUBU\Q<3*V6MROSC%ACVSPZ
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M)]8W7M8/DB_+*QT/7$J>EC\7E,14: 'U_I&K$&X>= ?5O:.K_P!02P,$%
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MZ).S3JOOM'%N-\7-\6'J<1[PK.0!C_. I^>!(?,6EYZ8YF5S$!(KU22$Q[G
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M+@0@80@XN3($2#0?Q%@83G=(%0(,LA #8^'X!0] F@] [*S0D/X#>/H*;=C
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MK0KB6DD_!(E5$/<$]/-\4SW]R*S4](/4*XA!O6)87I*(3\1Q_Y20S$H]0B*
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M+)8@""Z$M' G5(/@G8%K+!IKI5[!N7 RT!E#VA#C]J=(0BIWP-';FRGL[QW
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M )-& /970NC7A?E ,XC/_@902P,$%     @ &'-85"D6P[]\!@  (RL  !D
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MTBH_3#:^Q0U%'>C&SI/<* J[T0T=,[*N:XX8K"SE$BH803>-#'XT72A]4F7
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M!H99)"N"(3?!GB"YK5I#QV56BQ6_\%,:KCYHVV=A11K\O^BSL.(/?HD^"^N
M(1[U]XJ*P4J6'LM:PXTMO!=LL_!A'CE-=GU0/,(OV&-A0_<$]YUPVNQZH;"$
M3]UA89T[<B%IFZM&AEGZ=:P A5^^P<**2_@5&RRLDTG&U;9L%9GP*_=76&>3
M93\#*S;AU^NN<.ONBB@ZD5-W5T1OFPQ99;"R9Q51R"/0*?^29TN>A8*5;/U3
M+&0T6S"5*(21C@^23L-4HH!$C@?28:82'3/^:+A_SPP[?IYG21'2>-!T AS9
MD$H.]T@&$V3Q0<&(=(;1TY%*#$^:]I%JL+'EOD(2<3^.>H;<UQ\^^8V6I))N
M>D+E6;;?B$(:"5X<J$3!B3POG#H!E1C 1"R='E%H(B= 4Q>>$IU/ME\!5 &*
M/B>@N@&5ZE"RZ55$HFXB'9]4U07<264PLB<55;BC[H[MKR@I*MF2YY'(2Z;R
MMDRE"F$4O^R.*%7LH4=LS1W&)M51,B+:K3'P9FCYI4,;;SL<L2O7?DN4NCA2
MZ6^-&JI00]VH>:XM4:JS1)/O,MF5KUA#C]C6.U!C].;(L&0"_;T?ZY)1C*+#
MU]L3I8H[]#FWZSJ!DNK$&4$+*'V%'-^-G!-OB?J&5LA2N'V%'=^-G=/MB587
M;JY-N+^9,VB\P5B\/GH=9O>R (&8W<E!WED@1V?;-S*W)X(ORY<:IUP(GI2'
M"Q;.6588R._O.!>/)\5[DO5[L9/_ %!+ P04    "  8<UA4X.W%_J0$   A
M#@  &0   'AL+W=O<FMS:&5E=',O<VAE970W."YX;6R=5VUSVC@0_BL[7.<F
MF4GQ"X8 1Y@)D/8RT_8Z27O]D.D'82^@JRU128;D?OVM9.,03J%IOX E[[/:
M??1XM1IMI?JF5X@&[HM<Z(O6RICU, ATNL*"Z;9<HZ W"ZD*9FBHEH%>*V29
M Q5Y$(=A+R@8%ZWQR,U]5..1+$W.!7Y4H,NB8.IA@KG<7K2BUF[BAB]7QDX$
MX]&:+?$6S>?U1T6CH/&2\0*%YE* PL5%ZS(:7D6A!3B+OSEN]=XSV%3F4GZS
M@^OLHA7:B##'U%@7C/XV.,4\MYXHCN^UTU:SI@7N/^^\OW')4S)SIG$J\R\\
M,ZN+5K\%&2Y8F9L;N?T3ZX2ZUE\J<^U^85O;ABU(2VUD48,I@H*+ZI_=UT2\
M!!#7@/@ $/6> 71J0.<0D#P#2&I \E) MP:XU(,J=T?<C!DV'BFY!66MR9M]
M<.P[-/'%A17*K5'TEA/.C-]PP43*60[70AM5D@:,AM<TVJ VN]%G02+,^;^8
MP5L2GP8F,G@GM48--Y@S0R^,A*OO)3</<(MIJ;CA]/)DAH;Q7)]:)[<S.'EU
M"J^ "WC/\YR$HD>!H2QL+$%:1SRM(HZ?B3B*X;T49J7A2F28/7404/H-!_&.
M@VE\U.,,TS9THC.(PSCR!#1[.3STP*]>#(\&1[+I-#O:<?XZ/[6C=Y=S&M!G
M^?7($DFS1.*62)Y9X@,5L).E%<)ID%<J4)C*I7 *R6CSQ1+,"F&-BLL,J"#P
M/3W1]F.E%-THQ</;Y'@0=]'7L[OXJT] %;#K@+92;L:OHTZ2C(+-_JYZK+I)
M^-3HRF.4=!\]/:&OV]#7/1KY.]1Z"+] XO]8 RUSCZV/DRJDWGXB_8-D9QZ;
M^("U*Y]-U\]'K^&C]T,YE8\5YH"4O>P4KJ4R=G24$T.U!59(S#!S@,NH5/FD
M=CS NXY79CV/S.+>H<P\5MVH>\"JQRB)!WY:SUL'$_V&Y_Z/OAA?[L=!-XX[
MVA;Z:O\B,A6<<)'* D\#JKZE.^XU_/Y;/XZB/^H_$&C:= P@?) &(8'VD:(S
M:*(?'(_>^ZU/CH-.YJ>NJH/3%.60YF6&9\ *26J0+A^S(F7HLWT)5M9R :^B
M=@_FU5E%,FI.NH-R-N'RPR=,5^Y<G*+"#>9M=QX\73C[B963L$L'_D^M?+NV
MG\H7VV3")UJ K;$T/*45K@4=,B=[[T_;[KSY]?#BP4O"FUKMW#\46(=P$.4Q
M743A8PL3_L+G.?D!ZKK.V88IGE:@*DNF$.1<H]JP>4ZE5?$4(5TQL:0BXZT\
M6VY6U(R#[=AY_D -JT%%39O#+QA7L&%YB;H-EXY$.OJQF!/3N^;CS)8K6G9K
M?]*R*(E7ZJ.!%VM"5ZQ:"C.Y%5NFJ,!E_Y0[NNVN#,Z;3;%VY=IK%75[.[,V
M7#_Z/MMS[$>[P(0TH#D=5 N>,F$L@57P3O 6^5PK$^PUJ@6JI;LA:$AE*4QU
M7C2SS2UDXGKO@_FIO9UXYB_/A[-SS_RD/YSU??.#X6S@FX_"X:RZ_@2/@5:7
MI_=,+:T^<EQ0T&'[G,JVJNXCU<#(M6NXY])0^^X>5Z0(5-: WB\D5<5Z8!=H
M;H7C_P!02P,$%     @ &'-85%CZN<Y* @  _@0  !D   !X;"]W;W)K<VAE
M971S+W-H965T-SDN>&ULI511;],P$/XKIV@/FP1+FW8;3&FD=64PB4G3JL$#
MXL%-KJV98V?VI=GX]9R=-"JP(A OR9WM[^Z[[\Y.&V,?W!J1X*E4VDVB-5%U
M'L<N7V,IW+&I4//.TMA2$+MV%;O*HB@"J%1Q,AB<QJ60.LK2L'9KL]34I*3&
M6PNN+DMAGZ>H3#.)AM%VX4ZNUN07XBRMQ KG2/?5K64O[J,4LD3MI-%@<3F)
M+H;GT[$_'PY\DMBX'1M\)0MC'KQS74RB@2>$"G/R$03_-GB)2OE 3..QBQGU
M*3UPU]Y&OPJU<RT+X?#2J,^RH/4D>A-!@4M1*[HSS0?LZCGQ\7*C7/A"TYT=
M1)#7CDS9@9E!*77[%T^=#CN 9+@'D'2 )/!N$P66,T$B2ZUIP/K3',T;H=2
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MT/H#O+_D&=PZ_M+T3U[V U!+ P04    "  8<UA4: *5EXD$   >$0  &0
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M!,H*X/Q*(KKRQ2Y0_24R_1=02P,$%     @ &'-85"2=H9.R!@  &2D  !D
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MC5_JQ)H)!AK&A';*_-]2#*PR:@W'9%+=2 8:WH5VXFV@&? />& 15WZ7!2[
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MZ$HX,ZC/R>K34>1.:;(G8JLTT==;V0&-!83QOP;Z1D;?4/2-$OI;%L=(;E-
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M!_G[C,FUTB_) -F=>.]_4$L#!!0    ( !AS6%0A]'Y:,@(   0%   9
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M1L<_:,8W+/ -S^+3A4&G?0;(:[S!;$U S)D2NM+((O3@'] %3:!;IENW8Z+
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M QU_D;6CLA?%M[9!L^!*\=0^;@A>$F$$]/B*<_7^8B8HFH*3?P%02P,$%
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M0U!6 ,]74IK#PAIH9LWI;U!+ P04    "  8<UA4$\@NN(8"  "G!@  &0
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ML(PWYXFL?L%Z8^MWP+R0BJ<;9XT@95G]3UXVC=AR@-$>![1Q0+L.P1X'O''
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MK@]+CIZJ(A)0,I5(F!(Q] YKCK3<,<)KM&+P DW$(Y+S.9@-S1X1+%4(XY6
M;51)!Q^+4=.() *LJV4*#4?$LU")66[?F;SGYUW'Z:9"N7M.CZP]W&@/5PZ^
M:@Y$6NAL799;9E%\GM^@9>@%- <YKK@$7)D D!G@F]9K"SZ8]*EGLYLSA;\8
M= #:N9()FDO%Q2)%X5HIGH9@;^@HLGAC:!;]O<YTD3>MANQOW5,E7"V*^SZ
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M@3@X8(+N54;K"LW+E*6' P3J@G17A>RNRI1X1YRQY26B^!TB(<% 0K/7AX=
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MQ+75>O$E?O$]F:\BD&K:$@S 8DN! =#8X2!)K[_$K[\G=E7M;#ZK#$#,!@I
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M5/3SZD:X&DA6Z"O/%9.29?IQ"S0&7GZ@WJ\9DX=!N4!S+S_Y#U!+ P04
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M&/OEFED<9]:DV"\W$108>0I R+)X<0TI[H#4M- J-^ES08U-@: 4L\WXWK9
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M";7;W0^K_6"2 :QU;,YVH/OO;^R$$ A$_; GW1>([9G'SSQC3R;#G50_]1K
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M@29,D!>V$FS)8HJ(CV(+VEAP3;Y2GB'4JV9B=63T*N1"@]K2!0?TV&1H?/4
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M@XW5B3J=[AL4Z);XW48%/K[%>4(4-4#RY[.'.8?I5H*[#</!B0)UHW8W/"]
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MXA&#TQB78>'0\/_ITV&EO5"IBL-JI;NE(E9%,*JO(>PXCNAX(S+ !AX4#W^
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M^T)H#D%><+8"":SS4V<G!9'"E85R9YZ*,2K%0RUE\)!&15I&_O@]KZ:L7.'
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M55BZ<Z.H"N&Z# &UA  1^,ARN1%@F<<T/G8P4GP<2$'/I%PCK\<%C88 PU.
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M7=XI^&U;3,(>N1@W7D>]D2,C7*L>W$?U>'+Q5[RAZ&BJ)45C^T I&,[,Q.1
MX6$X,9>FC0J'\[;D5 LC[%<!']ID/U!C1Q\ICQ+AW )@^WPH-%] +!P@-,=F
M9 [0I.5< =<2!'><-!&QT0F$)@]JI'?;KG#L\YWIW-2O#E!@U5,'"+>];,"U
MUL$=)T7D467$G*[TMHU3DA99<<59Y@]K:N\GQM8$M$&A%96-"5I4.:[5$O8K
MFV]6"1U^6U1"9744ITF%#;$6H@UI(Z*62]@O:[Z'1)C;I=T,WH:8FS,'I&6S
M'M3Z*/#KH]?6!QW-]W^)U,]1GP/ %^C2,=E:C!W?J>5"X)<+[MIUU6%E#=I/
MBQ__*(IH\4T$('D,1/&:BA5J0PQ]W:]E1O M!S!7'5:Z2ZJ^1>DNIN4DR@4%
M:H<*;HK>GE;3+"E7E4C4I%HE$5':1(-(FA8#(O3Z$C2WMG%E,*/&!UL9Y>OB
M2SE]QK;+9?G)R>'NX6N\J^(;-./^-7R_A([['P+X?A&XGJC14D]<OA0UZDGQ
MX=JH[E3YP>!'PM>JXH.4KE0'Q\.I6M:\_ :OO)!L6WQD=L^D9%GQ<T-)3+D&
MJ.<KQN3SA6[@\"7DY;]02P,$%     @ &'-85(K#+F^X P  % \  !H   !X
M;"]W;W)K<VAE971S+W-H965T,3$Q+GAM;,U7T8[:.!3]E:M(E5JID^ DP% !
MT@!=;:6..H).]Z'J@R$7L":)6=L,P]_7=D)@9H-#VWG8%[ =GV/?XZMCW_Z.
MBP>Y1E3PE*6Y''AKI38?@D NUIA1Z?,-YOK+DHN,*MT5JT!N!-+$@K(T"%NM
M3I!1EGO#OAV[$\,^WZJ4Y7@G0&ZSC(K]"%.^&WC$.PQ,V6JMS$ P[&_H"F>H
M[C=W0O>"BB5A&>:2\1P$+@?>#?DP(;$!V!G?&.[D21M,*'/.'TSG4S+P6F9'
MF.)"&0JJ_QYQC&EJF/0^_BU)O6I- SQM']C_LL'K8.94XIBG_[!$K0?>M0<)
M+NDV55.^^QO+@-J&;\%3:7]A5\SM]CQ8;*7B60G6.\A87OS3IU*($T 8GP&$
M)2"\%!"5@.A20%P"K-1!$8K584(5'?8%WX$PLS6;:5@Q+5J'SW)S[C,E]%>F
M<6HX6U.!5R.M7 )W=*]/5$FX@IG.KV2;(O E?*/IEMI#NI$Z/3:F*>'M!!5E
MZ;M^H/0V#%FP*)<<%4N&9Y8D(=SR7*TE?,P33)X3!'K_51#A(8A1Z&2<X,*'
MB+R'L!62F@V-+X>W:N"3B^&DYX@FJHXDLGSQ&;ZO7-$4[,&L>9J@@"FJK<CA
M/F?Z<-Y^G4WOY3OX?HO9',4/QXIQM6)L5XR<23"W23#FF?8461ZX$#1?H<D*
MF._A=%Z9+'"SHR*![Y\U)7Q2F$G7AMK5AMI."3X^;;0OZ%42]L@2S!/8,TR3
MNEQS$\5^F[RIRX@F6-2I@TW<L,@/NV\<X7>J\#M.GBF3#U=+@0@L5RA0*A!4
M85WX;J*6WXMJPW?#B$_:M>&[8:'??@E[%GZW"K][V>EK]UL\P$:P!<(C3W5.
MIDSMZV1P$X8=OUVO0P-.Z]>K%<*-(]=^%+N4N*Z4N'82C;5/"GTU;K4AZ$3(
M CQ(8WIU0KCYVK!'*B00R(P#0QA#0O>R3IE?(R+1.:+)+Q)U:XB>:=>KM.LY
MF6O-ZNAG[^&+O<DN\5'2.MZFK?^'DY*3"YZ\EI<V,)TUTT;<&3=MP#79*0F/
M&H2O9:@-3.2_>RHU:,356VH#+O0[+[5[KL'Q54'<SXK?<-4&1F.K+VVN%*,!
MJ'VU5L5) [#16,GQR4/B5[;6!L).Z62]PLEJ3?7/*29_1%%H%9R4"QF*E2V[
M)"SX-E?%H[L:K4J[&UO0O!@?F9+/EB%'FJ)>O*5BQ725D.)24[;\KGXXB:($
M*SJ*;VQ1,N=*ESBVN=9E*PHS07]?<JX.';- 50@/?P)02P,$%     @ &'-8
M5/; OM(%"0  \3<  !H   !X;"]W;W)K<VAE971S+W-H965T,3$R+GAM;,U;
M6W/:R!+^*U/LJ5-)51":JX2/[2H#V<M#MEQV+@^I?9!A )6%Q$H")_]^1T+6
M8.:B,8&3?;&1-#W=/9?OZ^Z1+I^R_+%8<EZ";ZLD+:YZR[)<7PP&Q73)5U'A
M96N>BB?S+%]%I;C,%X-BG?-H5@NMD@'R?39817':N[ZL[]WFUY?9IDSBE-_F
MH-BL5E'^?<23[.FJ!WO/-^[BQ;*L;@RN+]?1@M_S\M/Z-A=7@[:76;SB:1%G
M*<CY_*IW R_>AZ@2J%M\COE3L?<;5*X\9-EC=?''[*KG5Q;QA$_+JHM(_-OR
M,4^2JB=AQ]]-I[U69R6X__NY]U]KYX4S#U'!QUGR)9Z5RZM>V ,S/H\V27F7
M/?W.&X=HU=\T2XKZ+WAJVOH],-T49;9JA(4%JSC=_8^^-0/A(H : 70@ )E!
M #<"^%" & 1((T!<!6@C4+L^V/E>#]PD*J/KRSQ[ GG56O16_:A'OY86XQ6G
MU4*Y+W/Q-!9RY?7],LIY?R2&>@9NH^]B"90%Z(-[L2!GFX2#; YV31[VFX";
M/(_2!=_]KN8Z+K^#-Q->1G'R5LC_!PQ 4<D5S__B%'Q<9ILB2F?%Y: 4IE<&
M#*:-F>.=F<A@)D3@0Y:6RP*\3V=\]K*#@?"Y=1P].SY&UAXG?.H!#-\!Y".H
M,6CB+NYKQ-\[B\.AQ1O<3B.N^\.&_K[4&T),T,UVX8$_TC*/Q5Z>@L]1LN%@
MS?/=-%@TD583J341@Z;/O*CTB&D$_-M:;'=Q469@*VZ_ US<%2M&Z(NSV;MF
MZC6C,[+K^ K_TBV1G1"KA2H W%X3$I#@<K#5^$-;?ZA5U\>LC)+=&E]FR4R,
MU!TO-WD*/J6QV IO/M[??2K>@J\?^.J!YW]91I"U&IEUKO[<5#VU.ZNP=!FT
M7096)_[,TFT]+^_  U_$:1JG"Z>)& ?*F$(T# G1#VK8VA-:[?E-H$-MC5EQ
MJ"C&A"*DUSML]0X=%J=-[5!1VR<D#$.]7NA+&/6MF@5KS7G<H;SIXZ7V,!@:
ME.]A.'2=?M<=.&ZZ?#'SD-"A-&8'@[IVEA4"D30:O0*R?IO\^MD)IZ"$1(A_
M:%,\-0;THRW/15 $%M6J!;.HY& >Q3G8O@1/\$9PV"Q+DB@OY-VWVL'=61;L
M#1KS3-,LD1?:8;'=57K+^R>P?-1APE>D1>9&*MSS-_ 0.UQ*1#,J>UM^1YR:
M5J%'#<  )<Q#.\X_0\/YQF[<6' P"M!@N:0+R%RAY9Q+EBG&,R\PD"N4Q 2=
MF>D FL[I2Z#Q10$V>Z.7_DKB@Z$5U>H]"F[S>&H%,4EHT,YH72"V&[1UI>\U
M S14?,?(&QHP'4D61'86;!'J.+.:WE^8A;T0&\R2_(CL_/B\]X^T"JI6^1XU
M#98D0(1<]_61AB'=< 6&6 9)XD3.Q'FP9X^T4V5#3#QX /P373/+HI2TB>R<
M=2=\$197H<9]F4T?F\C>(:)'DET0/55,CR3P(SOP'Q_5-QWO!VT(LZ&!1)%$
M<V1'<X>X'FDR"C\<FO:P!%9D3RFZ0WNDIA3]T)@?(@G!R [!=SQNY@',XFT\
MJ_8$_WL3"WZJJB56D]1T8TB9WB L41:?(-? FEP#(DH-RB66XM/G&EC-(80E
MQ#\  %TS\ZK%$FCQ63(-O%=\^==F&E@#FM0SS;+$3/S34XTQ5I,&00O8$"]C
MB<7XIT?Z6(WTA>G,M+,EXF,[XG="S3E7DIH $.AA W!CR1G8SAG_G_0%J]&\
MV ?0 /Y8T@ZVT\Y/R5\:FPXW]6' 9&AF<%GR';;SW6V6E_,LB3-PR_/Z*"H5
MX=XNKG&)FH@D,N*?*FHBDJ"(,T&]+FH:=73\%>NKTAK6\GU3YDPD:Q%[>M =
M:XTZ>C 9C!2#0X8-+$LD"1(["78&:*..#DSF8C608?[0L,S)WCF&G>)<HJA1
M1Q\FD]63BCZ$)B@EDMF(G=F.B+U&'5V:/*#JHH8D/(S8=,TL:U_R(+$?D9S@
M.$OR$_FQLQ,%Y^/6G./+K!TVF68E4 &?>:$A8B*2Y(CC<<UY?+4K-_D::FM!
M)IB2[$;<CHC.XZI=M\E5335.N&JHXU!)K]0Y3SR+MQWJ#=Y2M<@GXDQBP',J
M>9\>FYB>Q_FC@H5&:G\'TZ'GTP-<U32S;'0J8PIJCPA.<G@_IFH @0GT?8-U
M,H*@]@! "3?!S5.4SYR"3BIYGY)3!9UT[R4"9V9^9:F.JA1*$3,4/:ED4&K/
M)!TJ=50M$L)@:$(=R:?4SEW=A3JJE@C[P]#DLF0Q:B<2I[(8U10)A\BD6[(*
M=3ZF<=]&:G&0PKUCA08*-*V,ZX-);F#VU.O'(RPFD9G]6$9V#GP>LU=!*),0
MRAS3LO-8K3W2,44]3$(K<TO.SF,TUAIM8'0FD9HY9VCGL5M;@"2&-(U),F#'
MIFGG<8,ZQ12:9K8-L?<VFYUI1CF/'LMEGFT6RQ<5HX:\WXQN;QQ?H),<PX)3
M<3B3_,&<2WVOY'"FDHHA&&*249B=41P(G*G4 "$S;+M 4D-@C]N["3Q0SY8,
M_@:2) ([23BQ=Z#6VOK8-Y3= XGI@1W3CV'O0%-%HX?OF&@:F09*0GEP[E=]
M XG @1V!?PIS-S91AT&3D!S8(?F\K!UHCH-"+S 022"A-;!#ZUE9.U##?],P
M[[V&?/Q9STEL5D]Y2."9CO@#"?W!R4YY3N*&>G"C8^RFF<M&J&CEY9O:$N[#
MCC*-]F7[48?4QR4':<O"V;KZZJ=0B@J@C![K;S_$=32=9INT!%$*Q)-X59V3
M"=%69+Y;.QN!MYX%O$+)*&%'"4;[KNJH0^K+X82W[PO47P+4M9.B?HVH<=IJ
MK*2@\)BSFE&'U%X])\W2?G-TW'QQDVW*HA2/!&8+^-Z4HDD)UE$LVA?5R$_X
MM [)VJ]@Q&(7R[AZ->N_OT#F_V\5)XGP4.O@8.^3HQ7/%_6W7@6HIWCW*41[
MM_V>;%1_175P?PPOWD/-_9M@>#$1ZUI](I;FQ40L3]T3*)[H>A,#*9[4^@?2
MW-W'<!^B7%!; 1(^%Z;[7H7F^>[[LMU%F:WK#Z@>LK+,5O7/)8]F/*\:B.?S
M+"N?+RH%[5=^U_\ 4$L#!!0    ( !AS6%2Y[VH"N04  +L9   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$Q,RYX;6S-65MOZC@0_BLC=!YZ) Z)'4I(12NU
M=%=;:2M5O>P^5/O@@H'H)#%KF])*^^-W[(2$0G#"5I7V!1)?9KYO9NP9.Z.U
MD#_5@G,-;VF2J?/.0NOEF>>IR8*G3/7$DF?8,Q,R91I?Y=Q32\G9U$Y*$X_Z
M_L!+69QU+D:V[4Y>C,1*)W'&[R2H59HR^7[%$[$^[Y#.IN$^GB^T:? N1DLV
MYP]</RWO)+YYI91IG/),Q2(#R6?GG4MR-@Y\,\&.^"/F:[7U#(;*BQ _S<O-
M]+SC&T0\X1-M1##\>^5CGB1&$N+XNQ#:*76:B=O/&^F_6O)(YH4I/A;)G_%4
M+\X[PPY,^8RM$GTOUK_Q@M"ID3<1B;*_L"[&^AV8K)06:3$9$:1QEO^SM\(0
M;2;08@+=F4"" Q."8D)@B>;(+*UKIMG%2(HU2#,:I9D':QL[&]G$F7'C@Y;8
M&^,\??&P8)+_N$)#3.&.O:.#M((?\)![%<0,'A_NGX!EV/WX!#=9'CG& R?7
M7+,X4=_A&WB@C" %<09/6:Q5%QOQ^39.$ARK1IY&L$:E-RF 7>7 Z %@A,*M
MR/1"P2_9E$\_"O"094F5;JA>4:?$:S[I04"Z0'U*GAZNX>3;]PIY_NM0$Y06
M#:R:_@$UCT*S!*Q=%R*9<@GW7*]D81<X,?9$FSW?\O2%R[\<&ONEQK[5&#A]
M^&)].!8IKG"5>^A22I;-N7$JO+S#]KC"UW"Y9G(*S[^C2+C1/%4N0*<EH%.G
M"7*FN&DHC8$39_,NU)DW=UHN:F!%F4WG]8+Z@R@:^+X_\EZW1H[=2I_)7]UG
MZH(_*.$/6L!_Y4KSJ0OY8 ]Y1(-HN _<K:X9>%@"#UL YV]+W"/1QUI8$BX*
MX1X%0OQ^6&-\M^:"0_<Y</$8ECR&Q\;/VN['2(J]<HGY!>88VAJ6,IYP.,&=
M9BJ2A$D%2UQPEN]W^&=K8ZHCGX,(M\@'I!>2'>)NJ,W.BTK2T1%1]Q5\<_W#
M[94V[(5TAZ\;93-?XE>IQ_]/X?H5W LH'YS=[Y'!#OD&Q.W"G&PE7_+I0)?<
M5&/8!Q/,AQ+KGA7F%\UE6LO3K9#".S>6HY#FR173[)2]UYELW""J1230R@[T
M,[%_I G<NJ*2^O P=;>(%M2K:H&XRX76B^!(([BU!D4<!&V,X1;5<DU4Q0SI
M'[LFV'PN^9QICB6EEC&>(2;PRI(5-\N^EGVNXG1KM9]&@VAWL;N!M/!R51"1
M-A71)L"/YU-3)$7]O<WKLP42J2HDTJ9$VH_:XYD-]CQ%([);?#2@:1F"51E%
MVM11BFN=N"M LE\_]0?^P ^V?/,10U4"D38U4(GA2W+B?@%$@Y[?/P"]*F1(
MFTJ&OW$YB56# :,] X9^%(3#L!X$K8H+VJZX*$%\A07I?E5!PUZ?' !?U074
MG5OOI)C%NC@QMC@ITBK34OK_."O2*@/2=AFP\)2]:\ 4AUYJ.'\5<K>#)_##
M_O[9I0% \\9(J^Q%VV2O@V0^F=4;E+<I;1I$M+!%E?1HFZ1WT!9'YXI"W7:N
M(,/=XTL#IA;\JB1(VR1!NXT@N]425U%.S]QQ.@-W_^8 TWD0!H=V/9.Y/K94
M>80V'E!K(;AGW63VEJP+81>WXR[NQ_8>4,$ZU@M@91S_J-M,Q0R^V6W0;J4K
MM!*.E[SRO7&X -I%SETD;6X65<_EDBKUT(;CZ:YK"[;N627;-=]D7.@/NIC(
MNYC)CV5N4FC)W$4KJ))9T'#NW"UL<EH-LQX7'+*5R1V;>]S]D@TT^VFO;?&=
M329BA5Q8!M@3IV9IXL1RRDS(&8_U"J.ZEI:W=0V=<CFWM_,*K-#\$JML+;\
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MXT!Z;:]W@$,E+MBN+CN5_?(<^O5YZ+;= ]* *W'"=G4JQ>'R#+SZ+'3:Q#O
MH%(W;)<WF[Q<GI1?GQ8@=8!3I9C8+IGGB-/E.0Z:..+!OK39*=FEC52Z3>P2
M:9.VBZ>BP/:AG@_:AS9(I-)K8M?KL]:P9.:X;J0L@".0A(-Q2B.DF8P;(=LC
M$[1A)@D^BO/S%)RL0KJQ'75(I?>$7&X9GTG3CN0TFOE"/N+JR$*NMB?$OCTY
M:R&?F0Q[Y&TRW#(9_M$YK[8FY(RSZ!XM.I]+-J>:P>%?2YXH'J 5C5)F/KQ&
M(GFLWL[WALF@MU=YCB#Z1:P35FU9B'W+<LYJ/I]I_?0+3/$^4SM"6)HW1]A6
MFQMRTM&Y<7F>SZ[?,(^XO\_.CN@(,[/E^=A3;2&(?0M1^Z0+U':K[PN&DC2>
M@GQ ;D1^*U9;&DC3M^SV"]HT"$2::%A""-[PV&003$N36;ZA3$%]VC:JU3Z"
M'!'=_905Q.Q6SU2^,5UHIJ&62I0F(9/1)J] ,=0-I+++P(@IM2>SC="=G2O+
MF,EY=I.K4):/_#ZG["UOBQ^R.]*]_D=\-\9-_>1NW#3^@7CPPFNT\.&-W_AF
ML+VJ=BJP^44W) =.D@J(SP!X!XX1+23SN^.\H<4RNWZ="JU%G#TN&(7LF0'P
M?B:$WC9,@/(&?_0?4$L#!!0    ( !AS6%1 A [Q/@4   P4   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$Q-2YX;6R]6&UOVS80_BN$5PPID$2B;,MVYAA(
MXA0KL!9&LZX?AGV@I;--5!)=DHK;_?H=*466)5IQMV9!8(G4<T<^]T(>.=T)
M^5EM #3YFB:9NNYMM-Y>>9Z*-I R=2FVD.&7E9 IT]B4:T]M);#8"J6)%_A^
MZ*6,9[W9U/8MY&PJ<IWP#!:2J#Q-F?QV"XG87?=H[ZGC U]OM.GP9M,M6\,#
MZ(_;A<265VF)>0J9XB(C$E;7O1MZ=4\G1L B_N"P4[5W8J@LA?AL&F_CZYYO
M9@0)1-JH8/AXA#M($J,)Y_&E5-JKQC2"]?<G[6\L>22S9 KN1/*)QWISW1OW
M2 PKEB?Z@]C]"B6AH=$7B4397[(KL7Z/1+G2(BV%<08ISXHG^UH:XA2!H!0(
M&@(T/"+0+P7Z38'!$8%!*3 X56!8"ECJ7L'=&F[.-)M-I=@1:="HS;Q8ZUMI
MM!?/3* \:(E?.<KIV3V3&<_6BBQ DCN1INB\APV30&ZTEGR9:[9,@&A!%BO^
M-V+>9M'E 7 CDABD(F=ST(PGZC6Y(!\?YN3LU6NB#$ 1GI%W/$DP,-0Y>55O
M3CV-),Q4O*B<\%TQX>#(A&E WHE,;Q2YSV*(#Q5XR+XR0?!D@KN@4^,<D%&?
MGI/ #ZAC0O/3Q7V'^/W)XG32P:9?.;1O]?6/.73Q0-[G*4BFA;RX98I''5H'
ME=:!U3HXHA6]+E(@*RE2$J'Y>99CU!!<KW <XTC"CH>+R\G%<$,[G%G,'F=!
M,*"#J?=8MWP;%89]_Q!TWP91?^2/*]0!X6%%>-A)^#=0ZHHL<-4"*2$FF(C1
M9Q+S1QY#%JN??QH'E/Y2/C)<T,6*:/;51;48**S-K\%@_BSBOHV@;GYAQ2]\
M.8>BA,U_5<M_%_.P-6N7D]LHAY/;H XGCRHCC#J-,.>JY(X>WE/_'N>.6O.Z
M&/2;#-N@8!A,&@S;H&&?'B$XK@B..PF^Q[GSPM,_P)WC-@TZ&35XS-NH"1TV
MR;9!-/2#H9OMI&([.7WI.W3BG">Y[MPMJ+_?,?W_-W4(RV+"%-9J&(:H\1'[
MCFZ._DDYY8 YDLJ!ZL@J6JLIZ(_,J_,7-1@])4,=*$>*.E#'<Y0&>W,%+Y2E
MWV6(H+WE.M+7 7/DKP-E$C@\8HI]\4*?KU[FD FL=$T2=^7KOG2AW;7+)WM8
M@/B"H7GP\$.R/%VB43'XZB95!,]12J-%,9L/0]51194V';0#(O1ITZ0.%/XU
M3>I"A9,C%MW7,;2[D"E*]0M+D<"7G#^R!#*-Q4U1THBM+NKRHLDQF&SPY5A=
M2P+I-A'? (RE\&RJ;"*3;<)PE2OB37.#WC8*)1N7483G0<Q]TVN'E[#-9;3!
M<QUA:PF0FHF0,_[D@==.&SMJ'W_4-'$;-!HU#>Q2="QB]W44[2ZD_GMT.?>F
MDGN[[!G6U^>2O ,5]H,F?1=J=&3+I?L2BG;74#>XSE_$A@(>^"O*-@AJT?:,
MDV^?&>1/^I?3/(["JFF;-F30-$R7ED.KF+KKL&=?F]#)OZ!P^XS4[QM0'5;=
M 695+;#(2DBB-YB/(+F(E<E+A4B(SPGN*@4^$W:[27(\/INSN,&;],9=QV8W
M1FY<A"0QRW&A4JB]TB5$+,<V"G)9J++W1CN1)S'98"+@#^9_AO_UX(#5"B)]
MZ5K4O=H-!A9P:WMU9):8/-/%*;7JK:ZG;NVE3*/_SEQ;.?IOZ/AJCOYK?T$7
MX!=[T^7MAR[NR=XQN>:XU"6PPFGXER-<0F1Q]50TM-C:NY6ET%JD]G4##%=.
M \#O*R'T4\,,4%T SOX!4$L#!!0    ( !AS6%0F^LYPT0(  (H)   :
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M *(:$+T5$-> V"5:*7-I32G29*3DFB@;;=ALPWGCT"8;)FP59ZC,5V9PF-R
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MDP5A-NCU/>?J>6 (VMYX]1=02P,$%     @ &'-85(JLV#NH P  8@P  !H
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M^@A [3;0\[52]F7B M2?%=-_ %!+ P04    "  8<UA4MM+7\U,$  #;#@
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M>(]<NA>/)J%,A<EJ0C%:O*JNW%OBW?C0/Q_Y)>/7]A56,G[I-\_'?K-D!AV
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MU6^!D,[(*E+7?/T7S0/J&'T!CV3Z'ZSSM5X+!"NI>)P+:P]BEF2?Y"%/1$G
M]VL$4"Z G@B@?HT S@7P4P%8(^#G GZ:F2R4- \3HLAH*/@:"+-::S,7:3)3
M:1T^2TS=ITKH;YF64Z,IG>LJJB/PD?*Y(,L%"P!)0O!%+:@ U_2>)BL*+I(,
M8:92[\%G(@0QY0)O)U01%KT#;P!+P"6+(KU"#MM*>V;TMX/<B_/,"U3C!43@
MDB=J(<&')*3AMH*V#JF("VWB.D=.C1,:' ,,CP#R$+R93L#;-^\"ODJ4>-3O
MC'$_F>>Q5[@[WE^YMZV\0MED;V5P4*EE*P&X*"Q.U6)W874)EUR8:+>*>/M)
M+P<7BL;RN\.87QCS4V-^C;'/J_A.PX7/0)%<(#,')/@/[)'Q\\Q -S5@R.I^
MA(;M^PJ?.H5/':=/7[DB$2!24E6)R$RZ4S((^]#O=0NK&1(JEG5\A ;5SG4+
MY[I.YZZIX623)IV:M"Q)0 &_B]@\+5"5P]V=#&'?][QJ1WJ%(SVG(Q,ZHT+0
M4'-X^JK+(\TZ^D%UD7J[+GC=WI.,[2Z"$.)J-_N%F_V&?*7>'0&;N*M2XKX4
MB3L"'QZ6NJ?HB+ZRV*S3H)SJK^2,!-F"J2)" <V6%-R>/3#Y_<2\Q^B]!_6?
MXV48%+X.7O_-@YXE<.^70RE7648U0K@.2[#43.!/^7)DGC,>FJ((&O!YPFI=
M=%N"X)$2X4H@LDZCWXPMW(@M:&D='H#7H25VZ&;V%Z'+W^5,V*]%ER5TZ&;T
M7XDNMZ5F=%FBATU,_]KH\IO19;L![!T 79;581.MOP!=_5WNZG9JL&4Y&PX.
MABVWI49L(4O]R$W]'_D]%4E:,#.SEVZG2SV'<]/7;R^IF<V^ZS%LS&,F$J(>
M0<AT# I($E&9BA(]N:<1;\: 0L[EJ.T+"+X^K)!E=.1F])VAIJI,N8XRCG"Y
M!>8; ;0SS0PZO6JT(4OB"/_"J2M7MCUV[7J*=^*I]]3R/W+S?X6G"4]<SNZ2
M/_)KIF5DJ1^Y";FT.QUK\]JVR+!SS>2/,L8W.];2HR\K)5E(P8U^974@FD35
MGOBV)(^Z!\"W96GD'MKM=BO;+S(=SYJIQ:9(@#X$E(;&CS<=SP-QMC'7N:C?
MI9ZCW;D=P:<8VUW3WUXRJ5@":SH_LGT"N?O$SY3_9KI7K6VG0 <8[['E>.SF
M>#TLF'C)G)IZJW13ZZ*U!G70._:\/ZI^\GBIX.0%@MNYL&T$NX?^GX'!WV1)
MDGV0@&V;P>@ 2"C]H.-N&L]&@EO=H!8(;KEN+0Z>+;>="-N3L+LGC=.?134!
M/AL$OWE@PK;?X<X!H&7[%W9O4IX-+;<ZB)MJ;5L==K>Z/6M]%J2=3>J$!93=
MD[MHJ^Y?%X)2\(F(.94*W!Q/C\&W!=>UU/74JG,;^]70-BW</T -;5_"[GW%
MLVOH5H?\6GYP"^+Z1M%@L=. &M\V3=_=<\;Z16:J"C.-4/G-%.';9N@?8$_E
MVV;GN_=4SX57@SJ(ZHK=+AUFZ9=RGAX*RFQRS<Y_BJ?%P>-9>MSVY/DY/)ED
MQX=637::>:F)@"421'2F57K'/4W&(CL@S&X47Z9'9G=<:69(+Q>4A%28!?K[
M&>=J<V,,%,>TH_\!4$L#!!0    ( !AS6%3T4 1(PA   *!+   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$R-"YX;6S5'-ERVSCR5U!>UY1=)4OBI2-7E>_)
MU&;&E<SQX)H'B((D[%(DAX<43^W';S< $A0)DHHW<6H?$DM$-]#HNQN@WNRC
MY-_IAK&,?-X&8?KV9)-E\:O1*/4W;$O3812S$$964;*E&7Q-UJ,T3AA="J1M
M,++'X\EH2WEX\NZ->/:0O'L3Y5G 0_:0D#3?;FGR=,6":/_VQ#HI'GSDZTV&
M#T;OWL1TS3ZQ[+?X(8%OHW*6)=^R,.512!*V>GMR:;VZG[B(("!^YVR?5CX3
MW,HBBOZ-7]XOWYZ,D2(6,#_#*2C\V;%K%@0X$]#QEYKTI%P3$:N?B]GOQ.9A
M,PN:LNLH^(,OL\W;D]D)6;(5S8/L8[3_D:D->3B?'P6I^)_L%>SXA/AYFD5;
MA0P4;'DH_]+/BA''(-@*P:XA6&X+@J,0G&,17(7@'HO@*03O6(2)0I@<BS!5
M"%,A+,E=(9H;FM%W;Y)H3Q*$AMGP@Y"OP :)\!!5\5.6P"@'O.S=)[8&Q<H&
MY)Y%ZX3&&^X3&B[)+]F&)>0CV[$P9^1]*)4>E>>"? )[6.8!(]&**'R C*,D
MX^'Z ';Q5 *<W;",\B ]APE^^W1#SD[/R2GA(?G @P!@TS>C#/:#5(U\1?NU
MI-UNH?WG:#<DUG1 [+%M&=!ONM$_L7A([#FB6W,#^FTW^@WSA\2Q6E>_.QY]
M;$"_/QJ]3OP(5*#4 [O4 UO,YW3K08L<'_\)X.1]QK;IGQV+.>5BCEC,;5E,
MJ95)Y%?=F(_6GR9)221/(*'SW;V;6?9L]F:TJPJD">5:$\\ZA+HW0(WG8Z^$
M.MBQ6^[8[:3[?>A'6T962;0E?A0"@W/D,4241' X)0L&[&8D3J(=1S\_.ENP
MD*UX=DY@@&3T,TL)B(*+F4R<ZZ;@T?YS\.C /]?(08D\J>S:=AVKQIN[)M1T
M[$QJ#&P"699C6V8&>B4#O4[R;QA$6I]+=40'=;E%/?U;/#!QHWNZ1\_(!:]!
MNF?-ZTQH KF365V+##--O18EFI0\F/2839HEN9_E">J.OZ')FJ6C,S]A2YZ!
M8T6V\&T<,+1DR2D_2K-4#- E ,$C&D"DUKP<$)JFD/$DU;E-K)DTI>J,QS76
M-(&F\Q;!3\M-3SLW_3,0!U;"HR5$)F42 \Q@<IIPV,R.!KG6BDB$K5BE2O@D
M!@XD+..)X J) QJ2-:1H)N=S.VUN<M+89!/HPK+J4/=-J*DW-K-B5K)BULN*
M,T'[^2B(0&PIB,V/UB'_FRW)4JH%,$#Q"[T%^ROGV1-)F0^C&3>[W.Y5'R?@
M-*9&<YD9=,)U:^QJ GENG5E-&-=SS<R:E\R:]WC<C(9KOH T16HX6 ;E"2J!
MB0EW\^9>I@VA-H'LV;A%JM98IV#C3E+O0:1$&"L:K]!ER*RRA(8I]5O\VZV:
MLTI+75$-('5?;0"96>-IRXXJ2:75N:-/4%J ,F)6&4*$"Z3'7D+^RL$:*58?
MY/8SFBGH\.,'MEVPI"NQL'0:8[U 'F/I1,;JRV2^HTM6M!V:34,)FD#6O$W
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M%;;)G&^P^6Y^=ZJAK@*]GDZM,9^]ZL&Z9DF&W@<BR#*7SF1%L2<H+@F@\:5
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M(G\.2G[)HEC\&M$BRK)H*SYN&%VR! %@?!5!V%!?<('R1[G>_1=02P,$%
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M;,,:3)?&JK0 $X-4R/R7_RX"<0P@*@#1%H"U]P :!:"Q#6CN 30+0/-80*L
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M7?'F1JR ]^*4_"K25<:WZVA.>+(@[XNUR,@'<2>2G2"7254F);4O#E=S<OY
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M$-V$&M4,03$C)@M#P4"XB32M7>@(V<1(>Y?QU6; .@>J15U2>Q3%10NOI/8
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M-^((I@ T8$@8FO?@SOLH6+^G@LTOG:,_4$L#!!0    ( !AS6%27BKL<P
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MJG<!Z%U4[P+0NZK>%:!W5;TK0.^J>E> WE7UK@"]J^I= 7I7U;L"]*[N9A.
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M    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( !AS6%20S_:=[@   "L"   1              "  :\   !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( !AS6%297)PC$ 8  )PG   3
M      "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ &'-8
M5#6F\OS1!@  _1X  !@              ("!#0@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( !AS6%3$\<--% (  %L%   8
M      " @10/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  8<UA4DO!I'^L)   _*   &               @(%>$0  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ &'-85%;BX@YN!@  IAL  !@
M             ("!?QL  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( !AS6%1V/.S)#@H  #8G   8              " @2,B  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  8<UA4:%K$#S #   A
M"@  &               @(%G+   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ &'-85+CI0809"P   CD  !@              ("!S2\
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !AS6%3_.9-?
M9P(  -D%   8              " @1P[  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  8<UA4<R#.8!8,   ;.P  &
M@(&Y/0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ &'-8
M5$S.>GBF P  B0H  !D              ("!!4H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  8<UA4*6I^LN<J   $AP  &0
M        @('B30  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( !AS6%366A0V;2D  $.'   9              " @0!Y  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ &'-85'HVX) 5#   ."(
M !D              ("!I*(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  8<UA4>KD)'!0)  !&&   &0              @('PK@
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !AS6%0Y!R0>
M:AD  ,M1   9              " @3NX  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ &'-85&9XAMIK!   #0H  !D
M ("!W-$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  8
M<UA48+7^O]09  !_5@  &0              @(%^U@  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !AS6%1[]2A+2P,  !$'   9
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M970R,BYX;6Q02P$"% ,4    "  8<UA4[[?-9L<2  #$.P  &0
M    @($A(@$ >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M !AS6%2=<4JMH@0  ( ,   9              " @1\U 0!X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ &'-85/M,YQP_!P  ?1$  !D
M             ("!^#D! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  8<UA4!$YC6HTF  !FA0  &0              @(%N00$ >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !AS6%0H2<'L?2$
M *A?   9              " @3)H 0!X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ &'-85+B[0.R],P  (;$  !D              ("!
MYHD! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  8<UA4
MVYE-]%((  "X%0  &0              @(':O0$ >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !AS6%3.'24*)PL  ),@   9
M      " @6/& 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ &'-85&?](EG=!P  #A4  !D              ("!P=$! 'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  8<UA4.$VT @X)  #!%P
M&0              @('5V0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( !AS6%2O<\B 51   )\S   9              " @1KC 0!X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ &'-85-]0EI9_
M!   S D  !D              ("!IO,! 'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  8<UA4VTH&94\2  #"3P  &0
M@(%<^ $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !AS
M6%1LZ:JH< ,  /4)   9              " @>(* @!X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ &'-85 %"G7:3 P  ) @  !D
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M=#0Q+GAM;%!+ 0(4 Q0    ( !AS6%0.49ES. 0  .@*   9
M  " @9 ] @!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M&'-85#OG8]SH!   [ L  !D              ("!_T$" 'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  8<UA4T97)U.P5  "[-@  &0
M            @($>1P( >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( !AS6%1"KXB^)P0  %@1   9              " @4%= @!X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ &'-85-XSGC'B#@
M?%H  !D              ("!GV$" 'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    "  8<UA4UD7#&1<#  !)"@  &0              @(&X
M< ( >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !AS6%1!
M10)'6P@  -HE   9              " @09T @!X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ &'-85!Q @4)N"0  MSH  !D
M     ("!F'P" 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !AS6%27^T??T@D  (<\   9              "
M@6NB @!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ &'-8
M5'\<'>!;"   QR   !D              ("!=*P" 'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    "  8<UA4]R%=E*\$  #-%   &0
M        @($&M0( >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( !AS6%3\EU>21PD  (XG   9              " @>RY @!X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ &'-85"E_F;C<!   G \
M !D              ("!:L," 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    "  8<UA4R72";^T&  "G'0  &0              @(%]R (
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !AS6%3TC<:!
M80,  *T+   9              " @:'/ @!X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ &'-85 XJ)XM-"P  W"@  !D
M ("!.=," 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  8
M<UA4^@7'/>\(  #X)P  &0              @(&]W@( >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( !AS6%3ZK5SYVP0  -X.   9
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M970V-RYX;6Q02P$"% ,4    "  8<UA4K):"',L#  !5#   &0
M    @(&!!P, >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (
M !AS6%1NM8"P#@8  %$7   9              " @8,+ P!X;"]W;W)K<VAE
M971S+W-H965T-CDN>&UL4$L! A0#%     @ &'-85,KQ&_.-!   YQ(  !D
M             ("!R!$# 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"
M% ,4    "  8<UA4!R9<P3H%  !)$P  &0              @(&,%@, >&PO
M=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( !AS6%3HV(AE1 <
M (,D   9              " @?T; P!X;"]W;W)K<VAE971S+W-H965T-S(N
M>&UL4$L! A0#%     @ &'-85.;@'73\#P  !Y,  !D              ("!
M>",# 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    "  8<UA4
M4[@(;EL"  !G!0  &0              @(&K,P, >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;%!+ 0(4 Q0    ( !AS6%2=-)GAF0(  +<&   9
M      " @3TV P!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%
M  @ &'-85"(QY710!   E \  !D              ("!#3D# 'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    "  8<UA4*1;#OWP&   C*P
M&0              @(&4/0, >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+
M 0(4 Q0    ( !AS6%3@[<7^I 0  "$.   9              " @4=$ P!X
M;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ &'-85%CZN<Y*
M @  _@0  !D              ("!(DD# 'AL+W=O<FMS:&5E=',O<VAE970W
M.2YX;6Q02P$"% ,4    "  8<UA4: *5EXD$   >$0  &0
M@(&C2P, >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( !AS
M6%0DG:&3L@8  !DI   9              " @6-0 P!X;"]W;W)K<VAE971S
M+W-H965T.#$N>&UL4$L! A0#%     @ &'-85$^(E=,! P  = <  !D
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M=#@V+GAM;%!+ 0(4 Q0    ( !AS6%17'X-DP 0   81   9
M  " @5)P P!X;"]W;W)K<VAE971S+W-H965T.#<N>&UL4$L! A0#%     @
M&'-85!X6A)L3 P  D@@  !D              ("!274# 'AL+W=O<FMS:&5E
M=',O<VAE970X."YX;6Q02P$"% ,4    "  8<UA4>7WY'$,"  !V!0  &0
M            @(&3> , >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4
M Q0    ( !AS6%3(XXH LP,  '<*   9              " @0U[ P!X;"]W
M;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ &'-85!/(+KB& @
MIP8  !D              ("!]WX# 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX
M;6Q02P$"% ,4    "  8<UA4O[GTZ( $  #*%P  &0              @(&T
M@0, >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( !AS6%0J
MX9F]]0(  *4*   9              " @6N& P!X;"]W;W)K<VAE971S+W-H
M965T.3,N>&UL4$L! A0#%     @ &'-85'N9+]LG!@  PQT  !D
M     ("!EXD# 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !AS6%1ZL@^;JP0  *,7   9              "
M@3"A P!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%     @ &'-8
M5(62#[UC @  !P8  !H              ("!$J8# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,# N>&UL4$L! A0#%     @ &'-85#KD+C'^#@  H5H  !H
M         ("!K:@# 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&UL4$L! A0#
M%     @ &'-85/N1Q'_L&   C?P  !H              ("!X[<# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ &'-85'8F"=_\ P
M^PP  !H              ("!!]$# 'AL+W=O<FMS:&5E=',O<VAE970Q,#,N
M>&UL4$L! A0#%     @ &'-85.V:[UV[ P  8A   !H              ("!
M.]4# 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L! A0#%     @ &'-8
M5%]OLR9P @  \04  !H              ("!+MD# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#4N>&UL4$L! A0#%     @ &'-85*!=?*9V!0  AA8  !H
M         ("!UML# 'AL+W=O<FMS:&5E=',O<VAE970Q,#8N>&UL4$L! A0#
M%     @ &'-85"OHZM18 P  _@D  !H              ("!A.$# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%     @ &'-85/KM%<83!@
M82   !H              ("!%.4# 'AL+W=O<FMS:&5E=',O<VAE970Q,#@N
M>&UL4$L! A0#%     @ &'-85']=5M53"   O"H  !H              ("!
M7^L# 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL4$L! A0#%     @ &'-8
M5+1J:.!T!P  %2D  !H              ("!ZO,# 'AL+W=O<FMS:&5E=',O
M<VAE970Q,3 N>&UL4$L! A0#%     @ &'-85(K#+F^X P  % \  !H
M         ("!EOL# 'AL+W=O<FMS:&5E=',O<VAE970Q,3$N>&UL4$L! A0#
M%     @ &'-85/; OM(%"0  \3<  !H              ("!AO\# 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3(N>&UL4$L! A0#%     @ &'-85+GO:@*Y!0
MNQD  !H              ("!PP@$ 'AL+W=O<FMS:&5E=',O<VAE970Q,3,N
M>&UL4$L! A0#%     @ &'-85#=EYE5$!0  S1<  !H              ("!
MM X$ 'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&UL4$L! A0#%     @ &'-8
M5$"$#O$^!0  #!0  !H              ("!,!0$ 'AL+W=O<FMS:&5E=',O
M<VAE970Q,34N>&UL4$L! A0#%     @ &'-85";ZSG#1 @  B@D  !H
M         ("!IAD$ 'AL+W=O<FMS:&5E=',O<VAE970Q,38N>&UL4$L! A0#
M%     @ &'-85%!*,R.O @  \P@  !H              ("!KQP$ 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3<N>&UL4$L! A0#%     @ &'-85/'YK0FF P
MDPL  !H              ("!EA\$ 'AL+W=O<FMS:&5E=',O<VAE970Q,3@N
M>&UL4$L! A0#%     @ &'-85(5*]I6% P  )PL  !H              ("!
M=",$ 'AL+W=O<FMS:&5E=',O<VAE970Q,3DN>&UL4$L! A0#%     @ &'-8
M5(JLV#NH P  8@P  !H              ("!,2<$ 'AL+W=O<FMS:&5E=',O
M<VAE970Q,C N>&UL4$L! A0#%     @ &'-85+;2U_-3!   VPX  !H
M         ("!$2L$ 'AL+W=O<FMS:&5E=',O<VAE970Q,C$N>&UL4$L! A0#
M%     @ &'-85(VNV#G# @  : <  !H              ("!G"\$ 'AL+W=O
M<FMS:&5E=',O<VAE970Q,C(N>&UL4$L! A0#%     @ &'-85%2[.Z?$!0
MLAT  !H              ("!ES($ 'AL+W=O<FMS:&5E=',O<VAE970Q,C,N
M>&UL4$L! A0#%     @ &'-85/10!$C"$   H$L  !H              ("!
MDS@$ 'AL+W=O<FMS:&5E=',O<VAE970Q,C0N>&UL4$L! A0#%     @ &'-8
M5-0=]%;Q!   RA   !H              ("!C4D$ 'AL+W=O<FMS:&5E=',O
M<VAE970Q,C4N>&UL4$L! A0#%     @ &'-85.#P^BSW @  /PH  !H
M         ("!MDX$ 'AL+W=O<FMS:&5E=',O<VAE970Q,C8N>&UL4$L! A0#
M%     @ &'-85)6+$%_N%   EX<  !H              ("!Y5$$ 'AL+W=O
M<FMS:&5E=',O<VAE970Q,C<N>&UL4$L! A0#%     @ &'-85)9$ 3-5 P
M]A0   T              ( !"V<$ 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M"  8<UA4EXJ[',     3 @  "P              @ &+:@0 7W)E;',O+G)E
M;'-02P$"% ,4    "  8<UA46+@65_X'  #<4P  #P              @ %T
M:P0 >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ &'-85(7GKL!V P  ?DH
M !H              ( !GW,$ 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ &'-85(6C?WBN @  44<  !,              ( !37<$
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     (< AP!$)0  +'H$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1133</ContextCount>
  <ElementCount>913</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>303</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100010003 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100020004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100030005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100040006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100050007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100060008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100070009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100080010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210071002 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210171003 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210241004 - Disclosure - Other (Income)/Deductions - Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNet</Role>
      <ShortName>Other (Income)/Deductions - Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210281005 - Disclosure - Tax Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMatters</Role>
      <ShortName>Tax Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210391006 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210421007 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210611008 - Disclosure - Other Financial Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformation</Role>
      <ShortName>Other Financial Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210651009 - Disclosure - Property, Plant and Equipment (PP&amp;E)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PropertyPlantandEquipmentPPE</Role>
      <ShortName>Property, Plant and Equipment (PP&amp;E)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210691010 - Disclosure - Identifiable Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwill</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210751011 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210851012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210891013 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>210981014 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>211011015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>211071016 - Disclosure - Contingencies and Certain Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitments</Role>
      <ShortName>Contingencies and Certain Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>211111017 - Disclosure - Segment, Geographic and Other Revenue Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation</Role>
      <ShortName>Segment, Geographic and Other Revenue Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>220022001 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>230033001 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>230083002 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>230183003 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230253004 - Disclosure - Other (Income)/Deductions - Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</Role>
      <ShortName>Other (Income)/Deductions - Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230293005 - Disclosure - Tax Matters (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTables</Role>
      <ShortName>Tax Matters (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMatters</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230403006 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230433007 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230623008 - Disclosure - Other Financial Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationTables</Role>
      <ShortName>Other Financial Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherFinancialInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230663009 - Disclosure - Property, Plant and Equipment (PP&amp;E) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables</Role>
      <ShortName>Property, Plant and Equipment (PP&amp;E) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PropertyPlantandEquipmentPPE</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230703010 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwill</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230763011 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230863012 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/Equity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230903013 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ShareBasedPayments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230993014 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>231023015 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>231123016 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>240044001 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>240054002 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>240064003 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>240094004 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>240104005 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240114006 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240124007 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240134008 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240144009 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Licensing Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Licensing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240154010 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Collaborative Arrangements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Collaborative Arrangements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240164011 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240194012 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240204013 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240214014 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240224015 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240234016 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240264017 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240274018 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240304019 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails</Role>
      <ShortName>Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240314020 - Disclosure - Tax Matters - Provision for Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails</Role>
      <ShortName>Tax Matters - Provision for Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240324021 - Disclosure - Tax Matters - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersNarrativeDetails</Role>
      <ShortName>Tax Matters - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240334022 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails</Role>
      <ShortName>Tax Matters - Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240344023 - Disclosure - Tax Matters - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails</Role>
      <ShortName>Tax Matters - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240354024 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails</Role>
      <ShortName>Tax Matters - Deferred Taxes - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240364025 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240374026 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails</Role>
      <ShortName>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240384027 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240414028 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240444029 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240454030 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240464031 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240474032 - Disclosure - Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240484033 - Disclosure - Financial Instruments - Investments - Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Investments - Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240494034 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240504035 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240514036 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails</Role>
      <ShortName>Financial Instruments - Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240524037 - Disclosure - Financial Instruments - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240534038 - Disclosure - Financial Instruments - Long-Term Debt, New Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt, New Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240544039 - Disclosure - Financial Instruments - Long-Term Debt, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240554040 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240564041 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240574042 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240584043 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240594044 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails</Role>
      <ShortName>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240604045 - Disclosure - Financial Instruments - Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails</Role>
      <ShortName>Financial Instruments - Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240634046 - Disclosure - Other Financial Information - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails</Role>
      <ShortName>Other Financial Information - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240644047 - Disclosure - Other Financial Information - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Financial Information - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240674048 - Disclosure - Property, Plant and Equipment (PP&amp;E) - Components of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (PP&amp;E) - Components of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240684049 - Disclosure - Property, Plant, and Equipment (PP&amp;E) - Long-lived Assets by Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails</Role>
      <ShortName>Property, Plant, and Equipment (PP&amp;E) - Long-lived Assets by Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240714050 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240724051 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240734052 - Disclosure - Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240744053 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240774054 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240784055 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240794056 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240804057 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240814058 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240824059 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240834060 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240844061 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240874062 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240884063 - Disclosure - Equity - Summary of Common Stock Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails</Role>
      <ShortName>Equity - Summary of Common Stock Purchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240914064 - Disclosure - Share-Based Payments - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail</Role>
      <ShortName>Share-Based Payments - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240924065 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240934066 - Disclosure - Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails</Role>
      <ShortName>Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240944067 - Disclosure - Share-Based Payments - Schedule of Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail</Role>
      <ShortName>Share-Based Payments - Schedule of Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>240954068 - Disclosure - Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail</Role>
      <ShortName>Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>240964069 - Disclosure - Share-Based Payments - Summary of TSRU and PTU Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails</Role>
      <ShortName>Share-Based Payments - Summary of TSRU and PTU Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>240974070 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail</Role>
      <ShortName>Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>241004071 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>241034072 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>241044073 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>241054074 - Disclosure - Leases - Schedule of Lease Costs and Other Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails</Role>
      <ShortName>Leases - Schedule of Lease Costs and Other Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>241064075 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail</Role>
      <ShortName>Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>241084076 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Patent Litigation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesandCertainCommitments</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>241094077 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesandCertainCommitments</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>241104078 - Disclosure - Contingencies and Certain Commitments (Certain Commitments and Contingent Consideration for Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Certain Commitments and Contingent Consideration for Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesandCertainCommitments</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>241134079 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>241144080 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>241154081 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>241164082 - Disclosure - Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="pfe-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>241174083 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pfe-20211231.htm">pfe-20211231.htm</File>
    <File>pfe-20211231.xsd</File>
    <File>pfe-20211231_cal.xml</File>
    <File>pfe-20211231_def.xml</File>
    <File>pfe-20211231_lab.xml</File>
    <File>pfe-20211231_pre.xml</File>
    <File>pfe-exh21x12312021x10k.htm</File>
    <File>pfe-exh23x12312021x10k.htm</File>
    <File>pfe-exh311x12312021x10k.htm</File>
    <File>pfe-exh312x12312021x10k.htm</File>
    <File>pfe-exh321x12312021x10k.htm</File>
    <File>pfe-exh322x12312021x10k.htm</File>
    <File>pfe-exh424x12312021x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pfe-20211231_g1.jpg</File>
    <File>pfe-20211231_g10.jpg</File>
    <File>pfe-20211231_g11.jpg</File>
    <File>pfe-20211231_g12.jpg</File>
    <File>pfe-20211231_g13.jpg</File>
    <File>pfe-20211231_g2.jpg</File>
    <File>pfe-20211231_g3.jpg</File>
    <File>pfe-20211231_g4.jpg</File>
    <File>pfe-20211231_g5.jpg</File>
    <File>pfe-20211231_g6.jpg</File>
    <File>pfe-20211231_g7.jpg</File>
    <File>pfe-20211231_g8.jpg</File>
    <File>pfe-20211231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3014">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>161
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pfe-20211231.htm": {
   "axisCustom": 2,
   "axisStandard": 56,
   "contextCount": 1133,
   "dts": {
    "calculationLink": {
     "local": [
      "pfe-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pfe-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pfe-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pfe-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 1379,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 36,
    "http://www.pfizer.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 41
   },
   "keyCustom": 171,
   "keyStandard": 742,
   "memberCustom": 188,
   "memberStandard": 95,
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Cover Page",
     "role": "http://www.pfizer.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DeconsolidationGainLossAmountNetOfCashConveyed",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080010 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie607d29116be4fa5babac488462d4080_I20191231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "pfe:DeconsolidationNetAssetsContributed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794056 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i630b3dfbbd09454388a5a6976f3655c2_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804057 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814058 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i6691b5ea5ce944ac903398a39bf95d3b_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib52bc8201e914daf823fa750d650a1f1_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824059 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i387b7e6d1316444fafcb33e016ac9694_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834060 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ia1bf2ef00fca4b9f9b184b631accbeb0_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240844061 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874062 - Disclosure - Equity - Narrative (Details)",
     "role": "http://www.pfizer.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884063 - Disclosure - Equity - Summary of Common Stock Purchases (Details)",
     "role": "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails",
     "shortName": "Equity - Summary of Common Stock Purchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i81e39a223d384b35843e9b8e7445832b_D20190101-20191231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240914064 - Disclosure - Share-Based Payments - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
     "shortName": "Share-Based Payments - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240924065 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
     "shortName": "Share-Based Payments - Schedule of Share-based Compensation Awards and Valuation Details (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ifd7ecda840fd43338a51a3f00ae86688_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240934066 - Disclosure - Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails",
     "shortName": "Share-Based Payments - Summary of Data Related to Share-based Payment Arrangement Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i7392a7235580422387964189ed5a7ecf_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "pfe:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i7392a7235580422387964189ed5a7ecf_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240944067 - Disclosure - Share-Based Payments - Schedule of Valuation Assumptions (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail",
     "shortName": "Share-Based Payments - Schedule of Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "pfe:ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i7392a7235580422387964189ed5a7ecf_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954068 - Disclosure - Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
     "shortName": "Share-Based Payments - Schedule of Share-based Payment Arrangement Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i7392a7235580422387964189ed5a7ecf_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i234cb2011c6d42c5a3f00401f9a682b1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240964069 - Disclosure - Share-Based Payments - Summary of TSRU and PTU Information (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails",
     "shortName": "Share-Based Payments - Summary of TSRU and PTU Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i234cb2011c6d42c5a3f00401f9a682b1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2ac39ce3acc7441e86107c1d869cbee9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240974070 - Disclosure - Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail",
     "shortName": "Share-Based Payments - Schedule of Share-based Compensation, Stock Options, Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2ac39ce3acc7441e86107c1d869cbee9_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241004071 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034072 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.pfizer.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3c06c854564f400a90dbefc01376069e_I20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044073 - Disclosure - Leases - Schedule of Lease Assets and Liabilities (Details)",
     "role": "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails",
     "shortName": "Leases - Schedule of Lease Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241054074 - Disclosure - Leases - Schedule of Lease Costs and Other Supplemental Information (Details)",
     "role": "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails",
     "shortName": "Leases - Schedule of Lease Costs and Other Supplemental Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241064075 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)",
     "role": "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail",
     "shortName": "Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210071002 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084076 - Disclosure - Contingencies and Certain Commitments (Patent Litigation) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
     "shortName": "Contingencies and Certain Commitments (Patent Litigation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:SiteContingencyRegulatoryProceedingsDisclosureThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241094077 - Disclosure - Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
     "shortName": "Contingencies and Certain Commitments (Product Litigation, Commercial and Other Matters, Resolved Matters) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib18ea7fb4e2b467092e7d8b1a4245c1c_D20180101-20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "manufacturer",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241104078 - Disclosure - Contingencies and Certain Commitments (Certain Commitments and Contingent Consideration for Acquisitions) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails",
     "shortName": "Contingencies and Certain Commitments (Certain Commitments and Contingent Consideration for Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "operatingsegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241134079 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241144080 - Disclosure - Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "shortName": "Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241154081 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i01706a25eaf44000861f8a5988b1cfd7_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i02e740ce254147a096ae80d08c9094f0_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241164082 - Disclosure - Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails",
     "shortName": "Segment, Geographic and Other Revenue Information - Schedules of Concentration of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i02e740ce254147a096ae80d08c9094f0_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241174083 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i629787cb4c6e49829464bc26f89c64cf_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210171003 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210241004 - Disclosure - Other (Income)/Deductions - Net",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNet",
     "shortName": "Other (Income)/Deductions - Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210281005 - Disclosure - Tax Matters",
     "role": "http://www.pfizer.com/role/TaxMatters",
     "shortName": "Tax Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210391006 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210421007 - Disclosure - Financial Instruments",
     "role": "http://www.pfizer.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210611008 - Disclosure - Other Financial Information",
     "role": "http://www.pfizer.com/role/OtherFinancialInformation",
     "shortName": "Other Financial Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210651009 - Disclosure - Property, Plant and Equipment (PP&E)",
     "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentPPE",
     "shortName": "Property, Plant and Equipment (PP&E)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "000020002 - Document - Audit Information",
     "role": "http://www.pfizer.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210691010 - Disclosure - Identifiable Intangible Assets and Goodwill",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwill",
     "shortName": "Identifiable Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210751011 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210851012 - Disclosure - Equity",
     "role": "http://www.pfizer.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210891013 - Disclosure - Share-Based Payments",
     "role": "http://www.pfizer.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210981014 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211011015 - Disclosure - Leases",
     "role": "http://www.pfizer.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211071016 - Disclosure - Contingencies and Certain Commitments",
     "role": "http://www.pfizer.com/role/ContingenciesandCertainCommitments",
     "shortName": "Contingencies and Certain Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211111017 - Disclosure - Segment, Geographic and Other Revenue Information",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation",
     "shortName": "Segment, Geographic and Other Revenue Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220022001 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230033001 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010003 - Statement - Consolidated Statements of Income",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230083002 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements (Tables)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230183003 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230253004 - Disclosure - Other (Income)/Deductions - Net (Tables)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables",
     "shortName": "Other (Income)/Deductions - Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230293005 - Disclosure - Tax Matters (Tables)",
     "role": "http://www.pfizer.com/role/TaxMattersTables",
     "shortName": "Tax Matters (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230403006 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230433007 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230623008 - Disclosure - Other Financial Information (Tables)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationTables",
     "shortName": "Other Financial Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230663009 - Disclosure - Property, Plant and Equipment (PP&E) (Tables)",
     "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables",
     "shortName": "Property, Plant and Equipment (PP&E) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230703010 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables",
     "shortName": "Identifiable Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230763011 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020004 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230863012 - Disclosure - Equity (Tables)",
     "role": "http://www.pfizer.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230903013 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230993014 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231023015 - Disclosure - Leases (Tables)",
     "role": "http://www.pfizer.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:LeaseAssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231123016 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)",
     "role": "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables",
     "shortName": "Segment, Geographic and Other Revenue Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "operatingsegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240044001 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240054002 - Disclosure - Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Summary of Change in Accounting Principle (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:RebatesAndOtherSalesRelatedAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064003 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)",
     "role": "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:RebatesAndOtherSalesRelatedAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094004 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Acquisitions (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i40a5967cba7c42799e4a32e326df03fd_D20210101-20211116",
      "decimals": "2",
      "lang": "en-US",
      "name": "pfe:InvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104005 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Divestitures (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Divestitures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ifc8dbebb0e9d49428a97f4323e05244a_I20200630",
      "decimals": "-7",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030005 - Statement - Consolidated Balance Sheets",
     "role": "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240114006 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Discontinued Operations (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie9db97c5ee74476aa163cd45bfdb62a0_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124007 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Equity Method Investment (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Equity Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i252c5ea241a04813985449d2cebbba79_I20190731",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134008 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie644969c98bc4ecd8d8103171f4b1758_I20211003",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144009 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Licensing Arrangements (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Licensing Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i1f749c2a6a064f97a0319fbdfb3d1fb1_I20200430",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154010 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Collaborative Arrangements (Detail)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Collaborative Arrangements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i095915c17bba4c2681c503f9e07eb593_D20211231-20211231",
      "decimals": "3",
      "lang": "en-US",
      "name": "pfe:InvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164011 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements - Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i88c2ce9f81c3403c8e13781878abdf31_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240194012 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ia831fe68ea464a7696d368c0b964d933_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240204013 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214014 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "iaa0f6d5d21e848678b8da48c334034bc_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2ac39ce3acc7441e86107c1d869cbee9_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224015 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234016 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i5c659cb958e94f909ae64de8887c53e5_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240264017 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails",
     "shortName": "Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240274018 - Disclosure - Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
     "shortName": "Other (Income)/Deductions - Net - Schedule of Other Nonoperating Income (Expense) - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304019 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails",
     "shortName": "Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314020 - Disclosure - Tax Matters - Provision for Taxes on Income (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails",
     "shortName": "Tax Matters - Provision for Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324021 - Disclosure - Tax Matters - Narrative (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
     "shortName": "Tax Matters - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334022 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails",
     "shortName": "Tax Matters - Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344023 - Disclosure - Tax Matters - Deferred Taxes (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails",
     "shortName": "Tax Matters - Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354024 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
     "shortName": "Tax Matters - Deferred Taxes - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2ac39ce3acc7441e86107c1d869cbee9_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364025 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i21a79fdd21944aa89c066de9cbbfee5d_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050007 - Statement - Consolidated Statements of Equity",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i21a79fdd21944aa89c066de9cbbfee5d_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240374026 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails",
     "shortName": "Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i7054cf3b6aaa45ed9aab6e96ec09198c_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384027 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails",
     "shortName": "Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2ac39ce3acc7441e86107c1d869cbee9_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240414028 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i0d1928a49a1c409b9412c1399a30a560_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240444029 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i6a5495ffcbab4b708606247546b1099b_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i6a5495ffcbab4b708606247546b1099b_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesFVNIRestrictedNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454030 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i6a5495ffcbab4b708606247546b1099b_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesFVNIRestrictedNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464031 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i9a15e9f4278a4ea88fac685bd5263002_I20211231",
      "decimals": "-9",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240474032 - Disclosure - Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails",
     "shortName": "Financial Instruments - Investments - Short-term, Long-term and Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240484033 - Disclosure - Financial Instruments - Investments - Debt Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails",
     "shortName": "Financial Instruments - Investments - Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494034 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504035 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514036 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails",
     "shortName": "Financial Instruments - Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524037 - Disclosure - Financial Instruments - Long-Term Debt (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
     "shortName": "Financial Instruments - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i002328e67ca24b3c928fb4df0a88e15a_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240534038 - Disclosure - Financial Instruments - Long-Term Debt, New Issuances (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
     "shortName": "Financial Instruments - Long-Term Debt, New Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i550844e4b39d4ea2aa63d7dcbcf20d49_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2bb2fed9bbcf481c83c1388ac08d9ee5_D20190101-20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240544039 - Disclosure - Financial Instruments - Long-Term Debt, Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
     "shortName": "Financial Instruments - Long-Term Debt, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i8dd2fabc2dd040398c9f16166684d63e_D20190101-20190131",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie2c27ab7b79c44eb8dc5cacfdfc2c180_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240554040 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities- Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie2c27ab7b79c44eb8dc5cacfdfc2c180_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240564041 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240574042 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584043 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "idd276ef364814442a7a5f98817403b1b_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594044 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
     "shortName": "Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "idd276ef364814442a7a5f98817403b1b_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HedgedLiabilityFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604045 - Disclosure - Financial Instruments - Credit Risk (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails",
     "shortName": "Financial Instruments - Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070009 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634046 - Disclosure - Other Financial Information - Inventories (Details)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails",
     "shortName": "Other Financial Information - Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644047 - Disclosure - Other Financial Information - Other Current Liabilities (Details)",
     "role": "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
     "shortName": "Other Financial Information - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i9a02ec9594b94a0fa152afb9f34199d4_I20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240674048 - Disclosure - Property, Plant and Equipment (PP&E) - Components of Property, Plant and Equipment (Details)",
     "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (PP&E) - Components of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684049 - Disclosure - Property, Plant, and Equipment (PP&E) - Long-lived Assets by Geographic Areas (Details)",
     "role": "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails",
     "shortName": "Property, Plant, and Equipment (PP&E) - Long-lived Assets by Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "if38fbf9bf0a244c6846d8ca1b19c3cb9_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714050 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724051 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734052 - Disclosure - Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ib1a66c92780d46a0a8f486b6d6a639d7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i2ac39ce3acc7441e86107c1d869cbee9_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744053 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "i3dbeac67c2d5435389ad54d499ececf5_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240774054 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Schedule of Net Periodic Benefit Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240784055 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)",
     "role": "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "pfe-20211231.htm",
      "contextRef": "ie79d91e814fd4eeb9a27c97315e7f463_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 303,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan [Member]"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "US [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r1092",
      "r1093",
      "r1094"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r1092",
      "r1093",
      "r1094"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r1092",
      "r1093",
      "r1094"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r1092",
      "r1093",
      "r1094"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r1095"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1090"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r1103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1089"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r1104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r1092",
      "r1093",
      "r1094"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1088"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1091"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pfe_A2019StockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Stock Plan [Member]",
        "label": "2019 Stock Plan [Member]",
        "terseLabel": "2019 Stock Plan [Member]"
       }
      }
     },
     "localname": "A2019StockPlanMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount",
        "label": "Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount",
        "terseLabel": "Accelerated share repurchase, percentage of agreement"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_AccruedRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement",
        "label": "Agreement [Axis]",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement",
        "label": "Agreement [Domain]",
        "terseLabel": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AkceaAndIonisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Akcea And Ionis [Member]",
        "label": "Akcea And Ionis [Member]",
        "terseLabel": "Akcea And Ionis [Member]"
       }
      }
     },
     "localname": "AkceaAndIonisMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherInflammationandImmunologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Inflammation and Immunology Products [Member]",
        "label": "All Other Inflammation and Immunology Products [Member]",
        "terseLabel": "All Other Inflammation and Immunology Products [Member]"
       }
      }
     },
     "localname": "AllOtherInflammationandImmunologyProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherInternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Internal Medicine [Member]",
        "label": "All Other Internal Medicine [Member]",
        "terseLabel": "All Other Internal Medicine [Member]"
       }
      }
     },
     "localname": "AllOtherInternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherRareDiseaseProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Rare Disease Products [Member]",
        "label": "All Other Rare Disease Products [Member]",
        "terseLabel": "All Other Rare Disease Products [Member]"
       }
      }
     },
     "localname": "AllOtherRareDiseaseProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Corporation [Member]",
        "label": "AmerisourceBergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation [Member]"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.",
        "label": "Amortization Of Intangible Assets Not Associated With Single Function",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AnacorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anacor [Member]",
        "label": "Anacor [Member]",
        "terseLabel": "Anacor [Member]"
       }
      }
     },
     "localname": "AnacorMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AromasinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aromasin",
        "label": "Aromasin [Member]",
        "terseLabel": "Aromasin [Member]"
       }
      }
     },
     "localname": "AromasinMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ArrayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Array [Member]",
        "label": "Array [Member]",
        "terseLabel": "Array [Member]"
       }
      }
     },
     "localname": "ArrayMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ArvinasIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arvinas, Inc",
        "label": "Arvinas, Inc [Member]",
        "terseLabel": "Arvinas, Inc [Member]"
       }
      }
     },
     "localname": "ArvinasIncMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetAcquisitionAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Assets Acquired",
        "label": "Asset Acquisition, Assets Acquired",
        "terseLabel": "Asset acquisition, assets acquired"
       }
      }
     },
     "localname": "AssetAcquisitionAssetsAcquired",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum",
        "label": "Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum",
        "terseLabel": "Maximum potential milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Upfront Payment",
        "label": "Asset Acquisition, Consideration Transferred, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredUpfrontPayment",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetAcquisitionLiabilitiesAssumed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Liabilities Assumed",
        "label": "Asset Acquisition, Liabilities Assumed",
        "terseLabel": "Asset acquisition, liabilities assumed"
       }
      }
     },
     "localname": "AssetAcquisitionLiabilitiesAssumed",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Share Price",
        "label": "Asset Acquisition, Share Price",
        "terseLabel": "Asset acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionSharePrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_AssetImpairmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset impairments [Member]",
        "label": "Asset Impairments [Member]",
        "terseLabel": "Asset Impairment Charges [Member]"
       }
      }
     },
     "localname": "AssetImpairmentsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetWriteOffsAndAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-Offs And Asset Impairment Charges",
        "label": "Asset Write-Offs And Asset Impairment Charges",
        "terseLabel": "Asset write-offs and impairments"
       }
      }
     },
     "localname": "AssetWriteOffsAndAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Available-for-sale securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BMP2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BMP2 [Member]",
        "label": "BMP2 [Member]",
        "terseLabel": "BMP2 [Member]"
       }
      }
     },
     "localname": "BMP2Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BavencioAllianceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bavencio Alliance Revenues",
        "label": "Bavencio Alliance Revenues [Member]",
        "terseLabel": "Bavencio Alliance Revenues [Member]"
       }
      }
     },
     "localname": "BavencioAllianceRevenuesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BeamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beam",
        "label": "Beam [Member]",
        "terseLabel": "Beam [Member]"
       }
      }
     },
     "localname": "BeamMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BeneFIXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bene F I X [Member]",
        "label": "Bene F I X [Member]",
        "terseLabel": "BeneFIX [Member]"
       }
      }
     },
     "localname": "BeneFIXMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BesponsaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Besponsa [Member]",
        "label": "Besponsa [Member]",
        "terseLabel": "Besponsa [Member]"
       }
      }
     },
     "localname": "BesponsaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechAndCerevelTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioNTech and Cerevel Therapeutics, LLC",
        "label": "BioNTech and Cerevel Therapeutics, LLC [Member]",
        "terseLabel": "BioNTech and Cerevel Therapeutics, LLC [Member]"
       }
      }
     },
     "localname": "BioNTechAndCerevelTherapeuticsLLCMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechAndSpringWorksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioNTech and SpringWorks",
        "label": "BioNTech and SpringWorks [Member]",
        "terseLabel": "BioNTech and SpringWorks [Member]"
       }
      }
     },
     "localname": "BioNTechAndSpringWorksMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BioNTechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BionTech [Member]",
        "label": "BioNTech [Member]",
        "terseLabel": "BioNTech [Member]"
       }
      }
     },
     "localname": "BioNTechMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiopharmaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biopharma Segment [Member]",
        "label": "Biopharma Segment [Member]",
        "terseLabel": "Biopharma [Member]"
       }
      }
     },
     "localname": "BiopharmaSegmentMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BosulifMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bosulif [Member]",
        "label": "Bosulif [Member]",
        "terseLabel": "Bosulif [Member]"
       }
      }
     },
     "localname": "BosulifMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BraftoviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Braftovi [Member]",
        "label": "Braftovi [Member]",
        "terseLabel": "Braftovi [Member]"
       }
      }
     },
     "localname": "BraftoviMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BreakthroughPerformanceAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Breakthrough Performance Awards",
        "label": "Breakthrough Performance Awards [Member]",
        "terseLabel": "Breakthrough Performance Awards (BPAs) [Member]"
       }
      }
     },
     "localname": "BreakthroughPerformanceAwardsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessAlignmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Alignment Costs",
        "label": "Business Alignment Costs",
        "terseLabel": "Business and legal entity alignment costs"
       }
      }
     },
     "localname": "BusinessAlignmentCosts",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.",
        "label": "Business Combination, Acquisition Related Costs, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCostsTransactionCosts",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "label": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "terseLabel": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]",
        "terseLabel": "Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangements and Collaborative Arrangements"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsEquityMethodInvestmentsAndResearchAndDevelopmentArrangementAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Integration Costs [Member]",
        "label": "Business Integration Costs [Member]",
        "terseLabel": "Business Integration Costs [Member]"
       }
      }
     },
     "localname": "BusinessIntegrationCostsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CK1AssetsSoldToBiogenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CK1 Assets Sold To Biogen, Inc [Member]",
        "label": "CK1 Assets Sold To Biogen, Inc [Member]",
        "terseLabel": "CK1 Assets Sold To Biogen, Inc [Member]"
       }
      }
     },
     "localname": "CK1AssetsSoldToBiogenIncMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CStoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CStone",
        "label": "CStone [Member]",
        "terseLabel": "CStone [Member]"
       }
      }
     },
     "localname": "CStoneMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CardinalHealthInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health, Inc. [Member]",
        "label": "Cardinal Health, Inc. [Member]",
        "terseLabel": "Cardinal Health, Inc. [Member]"
       }
      }
     },
     "localname": "CardinalHealthInc.Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ChantixChampixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chantix / Champix [Member]",
        "label": "Chantix Champix [Member]",
        "terseLabel": "Chantix Champix [Member]"
       }
      }
     },
     "localname": "ChantixChampixMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Investment From Collaborator, Amount",
        "label": "Collaborative Arrangement, Committed Investment From Collaborator, Amount",
        "terseLabel": "Committed investment from collaborator"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementContingentPaymentsMaximumExposure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Contingent Payments, Maximum Exposure",
        "label": "Collaborative Arrangement, Contingent Payments, Maximum Exposure",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementContingentPaymentsMaximumExposure",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year One",
        "label": "Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year One",
        "terseLabel": "Maximum reimbursement due from collaborators, 2021"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearOne",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year Two",
        "label": "Collaborative Arrangement, Maximum Reimbursement Due from Collaborators, Year Two",
        "terseLabel": "Maximum reimbursement due from collaborators, 2022"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumReimbursementDueFromCollaboratorsYearTwo",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementMilestonePaymentUponApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment Upon Approval",
        "label": "Collaborative Arrangement, Milestone Payment Upon Approval",
        "terseLabel": "Collaborative arrangement, milestone payment upon approval (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentUponApproval",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementMilestonePaymentUponCommercializing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment Upon Commercializing",
        "label": "Collaborative Arrangement, Milestone Payment Upon Commercializing",
        "terseLabel": "Collaborative arrangement, milestone payment upon commercializing"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentUponCommercializing",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementTieredSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Tiered Sales Milestone Payments",
        "label": "Collaborative Arrangement, Tiered Sales Milestone Payments",
        "terseLabel": "Collaborative Arrangement, tiered sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementTieredSalesMilestonePayments",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to our partners for payments made upfront as part of a collaborative arrangement and the payments upon the achievement of milestones.",
        "label": "Collaborative Arrangement Upfront And Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontAndMilestonePayments",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ComirnatyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comirnaty",
        "label": "Comirnaty [Member]",
        "terseLabel": "Comirnaty direct sales and alliance revenues [Member]"
       }
      }
     },
     "localname": "ComirnatyMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CommonESOPPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common ESOP Plan [Member]",
        "label": "Common ESOP Plan [Member]",
        "terseLabel": "Common ESOP Plan [Member]"
       }
      }
     },
     "localname": "CommonESOPPlanMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConcentrationRiskAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Amount",
        "label": "Concentration Risk, Amount",
        "terseLabel": "Concentration risk, amount"
       }
      }
     },
     "localname": "ConcentrationRiskAmount",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Revenues, $500,000,000 or More, Number of Countries",
        "label": "Concentration Risk, Revenues, $500,000,000 or More, Number of Countries",
        "terseLabel": "Number of countries with revenue exceeding $500 million"
       }
      }
     },
     "localname": "ConcentrationRiskRevenues500000000orMoreNumberofCountries",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets:"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsolidatedStatementsOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Cash Flows",
        "label": "Consolidated Statements of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows:"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfCashFlowsAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsolidatedStatementsOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Comprehensive Income",
        "label": "Consolidated Statements of Comprehensive Income [Abstract]",
        "terseLabel": "Consolidated Statements of Comprehensive Income:"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfComprehensiveIncomeAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsolidatedStatementsOfIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Income",
        "label": "Consolidated Statements of Income [Abstract]",
        "terseLabel": "Consolidated Statements of Income:"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfIncomeAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ConsumerHealthcareReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Healthcare Reporting Unit [Member]",
        "label": "Consumer Healthcare Reporting Unit [Member]",
        "terseLabel": "Consumer Healthcare Reporting Unit [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareReportingUnitMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CopromotionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-promotion [Member]",
        "label": "Co-promotion [Member]",
        "terseLabel": "Co-promotion [Member]"
       }
      }
     },
     "localname": "CopromotionMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CoronavirusVaccineProgramMRNABasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus Vaccine Program, mRNA-Based",
        "label": "Coronavirus Vaccine Program, mRNA-Based [Member]",
        "terseLabel": "Coronavirus Vaccine Program, mRNA-Based [Member]"
       }
      }
     },
     "localname": "CoronavirusVaccineProgramMRNABasedMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CorporateEnablingFunctionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Enabling Functions",
        "label": "Corporate Enabling Functions [Member]",
        "terseLabel": "Corporate Enabling Functions [Member]"
       }
      }
     },
     "localname": "CorporateEnablingFunctionsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CortexymeIncAndSpringWorksTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cortexyme, Inc. and SpringWorks Therapeutics, Inc",
        "label": "Cortexyme, Inc. and SpringWorks Therapeutics, Inc [Member]",
        "terseLabel": "Cortexyme, Inc. and SpringWorks [Member]"
       }
      }
     },
     "localname": "CortexymeIncAndSpringWorksTherapeuticsIncMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CostReductionInitiativesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Reduction Initiatives",
        "label": "Cost Reduction Initiatives [Member]",
        "terseLabel": "Cost Reduction Initiatives [Member]"
       }
      }
     },
     "localname": "CostReductionInitiativesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CreditFacilityExpiring2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility Expiring 2024 [Member]",
        "label": "Credit Facility Expiring 2025 [Member]",
        "terseLabel": "Credit Facility Expiring 2025 [Member]"
       }
      }
     },
     "localname": "CreditFacilityExpiring2025Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CurrentTaxAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Tax Assets [Member]",
        "label": "Current Tax Assets [Member]",
        "terseLabel": "Other Current Tax Assets [Member]"
       }
      }
     },
     "localname": "CurrentTaxAssetsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "label": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "terseLabel": "Net fair value adjustments related to hedging and purchase accounting"
       }
      }
     },
     "localname": "DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Gain",
        "label": "Debt Securities, Accumulated Gross Unrealized Gain",
        "terseLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Loss",
        "label": "Debt Securities, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Amortized Cost Basis",
        "label": "Debt Securities, Amortized Cost Basis",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, After Year Five, Fair Value",
        "label": "Debt Securities Maturities, After Year Five, Fair Value",
        "terseLabel": "Debt securities maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "label": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "terseLabel": "Debt securities maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "label": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "terseLabel": "Debt securities maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "label": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "terseLabel": "Schedule of Gains and Losses on Investment Securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_December2017StockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2017 Stock Purchase Plan [Member]",
        "label": "December 2017 Stock Purchase Plan [Member]",
        "terseLabel": "December 2017 Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "December2017StockPurchasePlanMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_December2018StockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2018 Stock Purchase Plan [Member]",
        "label": "December 2018 Stock Purchase Plan [Member]",
        "terseLabel": "December 2018 Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "December2018StockPurchasePlanMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DeconsolidationExternalIncrementalCostsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation, External Incremental Costs, Amount",
        "label": "Deconsolidation, External Incremental Costs, Amount",
        "terseLabel": "External incremental costs"
       }
      }
     },
     "localname": "DeconsolidationExternalIncrementalCostsAmount",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationGainLossAmountCashConveyed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Cash Conveyed",
        "label": "Deconsolidation, Gain (Loss), Amount, Cash Conveyed",
        "terseLabel": "Deconsolidation, cash conveyed"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountCashConveyed",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationGainLossAmountNetOfCashConveyed": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "label": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "negatedTerseLabel": "Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed",
        "terseLabel": "Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountNetOfCashConveyed",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationGainLossAmountNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Net Of Tax",
        "label": "Deconsolidation, Gain (Loss), Amount, Net Of Tax",
        "terseLabel": "Gain on completion of transaction, after-tax"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountNetOfTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationNetAssetsContributed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation, Net Assets Contributed",
        "label": "Deconsolidation, Net Assets Contributed",
        "terseLabel": "Deconsolidation net assets contributed"
       }
      }
     },
     "localname": "DeconsolidationNetAssetsContributed",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Associated With Unrecognized Tax Benefits",
        "label": "Deferred Tax Assets Associated With Unrecognized Tax Benefits",
        "terseLabel": "Deferred tax assets associated with unrecognized tax benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward",
        "label": "Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward",
        "terseLabel": "Reduction for unrecognized tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "label": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards",
        "terseLabel": "Net operating loss/credit carryforwards - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, State and Local Taxes Adjustments",
        "label": "Deferred Tax Assets, State and Local Taxes Adjustments",
        "terseLabel": "State and local tax adjustments - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsStateandLocalTaxesAdjustments",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves",
        "terseLabel": "Legal and product liability reserves - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxLiabilitiesNetNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Net, Noncurrent [Member]",
        "label": "Deferred Tax Liabilities, Net, Noncurrent [Member]",
        "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent [Member]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetNoncurrentMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "label": "Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "negatedLabel": "Employee benefits - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax",
        "negatedLabel": "Benefit plans: prior service (costs)/credits and other, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate",
        "terseLabel": "Discount rate: Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate",
        "terseLabel": "Discount rate: Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Curtailments and Special Termination Benefits",
        "terseLabel": "Curtailments and special termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForCurtailmentsAndSpecialTerminationBenefits",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation",
        "label": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation",
        "negatedTerseLabel": "Acquisitions/divestitures/other, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets",
        "label": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets",
        "terseLabel": "Acquisitions/divestitures, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]",
        "label": "Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]",
        "terseLabel": "Equity commingled funds [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Equity Securities, Global Equity Securities",
        "label": "Defined Benefit Plan, Equity Securities, Global Equity Securities [Member]",
        "terseLabel": "Global Equity Securities [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesGlobalEquitySecuritiesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DefinedBenefitPlanOtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Other Investments",
        "label": "Defined Benefit Plan, Other Investments [Member]",
        "terseLabel": "Other investments [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherInvestmentsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.",
        "label": "Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DerivativeNetReceivablePositionAggregateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Net Receivable Position, Aggregate Fair Value",
        "label": "Derivative, Net Receivable Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net receivable position"
       }
      }
     },
     "localname": "DerivativeNetReceivablePositionAggregateFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DevelopedEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed Europe [Member]",
        "label": "Developed Europe [Member]",
        "terseLabel": "Developed Europe [Member]"
       }
      }
     },
     "localname": "DevelopedEuropeMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DevelopedRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed Rest Of World [Member]",
        "label": "Developed Rest Of World [Member]",
        "terseLabel": "Developed Rest Of World [Member]"
       }
      }
     },
     "localname": "DevelopedRestOfWorldMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Operation, Period of Continuing Involvement after Disposal, Extension Period",
        "label": "Discontinued Operation, Period of Continuing Involvement after Disposal, Extension Period",
        "terseLabel": "Period of continuing involvement after disposal, extension period"
       }
      }
     },
     "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposalExtensionPeriod",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_DiscontinuedOperationRatioSharesReceivedForEachShareOwned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Operation, Ratio, Shares Received for Each Share Owned",
        "label": "Discontinued Operation, Ratio, Shares Received for Each Share Owned",
        "terseLabel": "Ratio, shares received for each share held"
       }
      }
     },
     "localname": "DiscontinuedOperationRatioSharesReceivedForEachShareOwned",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Costs and Expenses",
        "label": "Disposal Group, Including Discontinued Operation, Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Foreign Denominated Debt Remeasurement Gains (Losses)",
        "label": "Disposal Group, Including Discontinued Operation, Foreign Denominated Debt Remeasurement Gains (Losses)",
        "negatedTerseLabel": "Pre-tax charges related to remeasurement of Euro debt"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationForeignDenominatedDebtRemeasurementGainsLosses",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Research and Development Expense",
        "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs",
        "label": "Disposal Group, Including Discontinued Operation, Restructuring Charges and Acquisition-Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)",
        "label": "Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)",
        "verboseLabel": "Pre-tax income attributable to disposal group"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DocetaxelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Docetaxel [Member]",
        "label": "Docetaxel [Member]",
        "terseLabel": "Docetaxel [Member]"
       }
      }
     },
     "localname": "DocetaxelMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Income Tax Expense (Benefit), Continued Operations",
        "label": "Domestic Income Tax Expense (Benefit), Continued Operations",
        "totalLabel": "Total U.S. tax benefit"
       }
      }
     },
     "localname": "DomesticIncomeTaxExpenseBenefitContinuedOperations",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DomesticIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domestic Income Taxes [Abstract]",
        "label": "Domestic Income Taxes [Abstract]",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "DomesticIncomeTaxesAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount",
        "label": "Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Interest on Litigation Settlement, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Interest on Litigation Settlement, Percent",
        "negatedTerseLabel": "Interest"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionInterestOnLitigationSettlementPercent",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Joint Venture Initiatives, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Joint Venture Initiatives, Percent",
        "negatedTerseLabel": "Certain Consumer Healthcare JV initiatives"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionJointVentureInitiativesPercent",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_EffectofTaxCutsandJobsActAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of Tax Cuts and Jobs Act [Abstract]",
        "label": "Effect of Tax Cuts and Jobs Act [Abstract]",
        "terseLabel": "TCJA"
       }
      }
     },
     "localname": "EffectofTaxCutsandJobsActAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_EliLillyCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eli Lilly &amp; Company [Member]",
        "label": "Eli Lilly &amp; Company [Member]",
        "terseLabel": "Eli Lilly &amp; Company [Member]"
       }
      }
     },
     "localname": "EliLillyCompanyMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliquisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliquis [Member]",
        "label": "Eliquis [Member]",
        "terseLabel": "Eliquis [Member]"
       }
      }
     },
     "localname": "EliquisMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging Markets [Member]",
        "label": "Emerging Markets [Member]",
        "terseLabel": "Emerging Markets [Member]"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enbrel [Member]",
        "label": "Enbrel [Member]",
        "terseLabel": "Enbrel [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnvironmentalRemediationLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Environmental Remediation Litigation [Member]",
        "label": "Environmental Remediation Litigation [Member]",
        "terseLabel": "Environmental Remediation Litigation [Member]"
       }
      }
     },
     "localname": "EnvironmentalRemediationLitigationMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EpiPenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EpiPen [Member]",
        "label": "Epi Pen [Member]",
        "terseLabel": "Epi Pen [Member]"
       }
      }
     },
     "localname": "EpiPenMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Excess Basis Amortization, Period",
        "label": "Equity Method Investment, Excess Basis Amortization, Period",
        "terseLabel": "Excess basis amortization period"
       }
      }
     },
     "localname": "EquityMethodInvestmentExcessBasisAmortizationPeriod",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "label": "Equity Method Investment, Increase (Decrease), Foreign Currency Translation",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "EquityMethodInvestmentIncreaseDecreaseForeignCurrencyTranslation",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]",
        "label": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]",
        "terseLabel": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_EquitySecuritiesFVNIRestrictedNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "label": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "terseLabel": "Long-term equity securities held in trust"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictedNoncurrent",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "label": "Equity Securities Without Readily Determinable Fair Value, Impairment Loss And Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative impairment losses and downward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAndDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EucrisaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eucrisa [Member]",
        "label": "Eucrisa [Member]",
        "terseLabel": "Eucrisa [Member]"
       }
      }
     },
     "localname": "EucrisaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FSMEIMMUNTicoVacMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FSME/IMMUN-TicoVac [Member]",
        "label": "FSME/IMMUN-TicoVac [Member]",
        "terseLabel": "FSME/IMMUN-TicoVac [Member]"
       }
      }
     },
     "localname": "FSMEIMMUNTicoVacMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FeasibilityStudyNumberOfLagoons": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Feasibility Study, Number Of Lagoons",
        "label": "Feasibility Study, Number Of Lagoons",
        "terseLabel": "Feasibility study, number of lagoons"
       }
      }
     },
     "localname": "FeasibilityStudyNumberOfLagoons",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]",
        "terseLabel": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pfe_FocusedCompanyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Focused Company Plan [Member]",
        "label": "Focused Company Plan [Member]",
        "terseLabel": "Focused Company Plan [Member]"
       }
      }
     },
     "localname": "FocusedCompanyPlanMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency long - term debt [Member]",
        "label": "Foreign Currency Debt [Member]",
        "terseLabel": "Foreign Currency Debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyDebtMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency long - term debt [Member]",
        "label": "Foreign Currency Long Term Debt [Member]",
        "terseLabel": "Foreign currency long-term debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyLongTermDebtMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyShortTermBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency short - term borrowings [Member]",
        "label": "Foreign Currency Short Term Borrowings [Member]",
        "terseLabel": "Foreign currency short-term borrowings [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyShortTermBorrowingsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FragminMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fragmin [Member]",
        "label": "Fragmin [Member]",
        "terseLabel": "Fragmin [Member]"
       }
      }
     },
     "localname": "FragminMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK Consumer Healthcare [Member]",
        "label": "GSK Consumer Healthcare [Member]",
        "terseLabel": "Consumer Healthcare JV [Member]"
       }
      }
     },
     "localname": "GSKConsumerHealthcareMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GSK [Member]",
        "label": "GSK [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GainContingencyNumberofDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number of Defendants",
        "label": "Gain Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberofDefendants",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "label": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "terseLabel": "Number of patents allegedly infringed upon due to expire in December 2019"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsWithoutCourtProceedingsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Patents Without Court Proceedings, Number",
        "label": "Gain Contingency, Patents Without Court Proceedings, Number",
        "terseLabel": "Number of patents without court proceedings"
       }
      }
     },
     "localname": "GainContingencyPatentsWithoutCourtProceedingsNumber",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GenericSterileInjectableProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generic Sterile Injectable Product [Member]",
        "label": "Generic Sterile Injectable Product [Member]",
        "terseLabel": "Generic Sterile Injectable Product [Member]"
       }
      }
     },
     "localname": "GenericSterileInjectableProductMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GenotropinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genotropin [Member]",
        "label": "Genotropin [Member]",
        "terseLabel": "Genotropin [Member]"
       }
      }
     },
     "localname": "GenotropinMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GoToMarketModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Go-to Market Model",
        "label": "Go-to Market Model [Member]",
        "terseLabel": "Go-to Market Model [Member]"
       }
      }
     },
     "localname": "GoToMarketModelMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GovernmentAndGovernmentSponsoredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Government Sponsored",
        "label": "Government and Government Sponsored [Member]",
        "terseLabel": "Government and Government Sponsored [Member]"
       }
      }
     },
     "localname": "GovernmentAndGovernmentSponsoredMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]",
        "label": "Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]",
        "terseLabel": "Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]"
       }
      }
     },
     "localname": "GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HedgedItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedged Item [Axis]",
        "label": "Hedged Item [Axis]",
        "terseLabel": "Hedged Item [Axis]"
       }
      }
     },
     "localname": "HedgedItemAxis",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_HedgedItemDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Hedged Item [Axis]",
        "label": "Hedged Item [Domain]",
        "terseLabel": "Hedged Item [Domain]"
       }
      }
     },
     "localname": "HedgedItemDomain",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HeldToMaturityCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held-To-Maturity Cash Equivalents",
        "label": "Held-To-Maturity Cash Equivalents",
        "terseLabel": "Held-to-maturity cash equivalents"
       }
      }
     },
     "localname": "HeldToMaturityCashEquivalents",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HospiraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospira [Member]",
        "label": "Hospira [Member]",
        "terseLabel": "Hospira [Member]"
       }
      }
     },
     "localname": "HospiraMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospital [Member]",
        "label": "Hospital [Member]",
        "terseLabel": "Hospital [Member]"
       }
      }
     },
     "localname": "HospitalMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IVIgProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IVIg Products",
        "label": "IVIg Products [Member]",
        "terseLabel": "IVIg Products [Member]"
       }
      }
     },
     "localname": "IVIgProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IbranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ibrance [Member]",
        "label": "Ibrance [Member]",
        "terseLabel": "Ibrance [Member]"
       }
      }
     },
     "localname": "IbranceMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ImplementationCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implementation Cost [Abstract]",
        "label": "Implementation Cost [Abstract]",
        "terseLabel": "Implementation costs recorded in our consolidated statements of income as follows:"
       }
      }
     },
     "localname": "ImplementationCostAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.",
        "label": "Implementation Costs",
        "terseLabel": "Implementation costs"
       }
      }
     },
     "localname": "ImplementationCosts",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "label": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "negatedTerseLabel": "Income from collaborations, out-licensing arrangements and sales of compound/product rights"
       }
      }
     },
     "localname": "IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders Basic",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders diluted",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "label": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "negatedTerseLabel": "Consumer Healthcare JV equity method (income)/loss"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Payable [Member]",
        "label": "Income Taxes Payable [Member]",
        "terseLabel": "Income Taxes Payable [Member]"
       }
      }
     },
     "localname": "IncomeTaxesPayableMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflammationandImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inflammation and Immunology [Member]",
        "label": "Inflammation and Immunology [Member]",
        "terseLabel": "Inflammation and Immunology [Member]"
       }
      }
     },
     "localname": "InflammationandImmunologyMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflectraRemsimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inflectra/Remsima [Member]",
        "label": "Inflectra/Remsima [Member]",
        "terseLabel": "Inflectra/Remsima [Member]"
       }
      }
     },
     "localname": "InflectraRemsimaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InlytaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inlyta [Member]",
        "label": "Inlyta [Member]",
        "terseLabel": "Inlyta [Member]"
       }
      }
     },
     "localname": "InlytaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InsuranceContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Contracts [Member]",
        "label": "Insurance Contracts [Member]",
        "terseLabel": "Insurance Contracts [Member]"
       }
      }
     },
     "localname": "InsuranceContractsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InterestReceivedInterestRateHedges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Received, Interest Rate Hedges",
        "label": "Interest Received, Interest Rate Hedges",
        "negatedTerseLabel": "Interest rate hedges"
       }
      }
     },
     "localname": "InterestReceivedInterestRateHedges",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Medicine [Member]",
        "label": "Internal Medicine [Member]",
        "terseLabel": "Internal Medicine [Member]"
       }
      }
     },
     "localname": "InternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InternationalIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Income Taxes [Abstract]",
        "label": "International Income Taxes [Abstract]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "InternationalIncomeTaxesAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_InvestmentOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment, Ownership Percentage",
        "label": "Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "InvestmentOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_LeaseAssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Assets and Liabilities, Lessee",
        "label": "Lease, Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Lease Assets and Liabilities"
       }
      }
     },
     "localname": "LeaseAssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_LesseeOperatingLeaseOptionToExtendTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Extend, Term",
        "label": "Lessee, Operating Lease, Option To Extend, Term",
        "terseLabel": "Operating lease term, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtendTerm",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_LicensingAgreementsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements And Other [Member]",
        "label": "Licensing Agreements And Other [Member]",
        "terseLabel": "Licensing Agreements and Other [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsAndOtherMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingAgreementsDevelopedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements, Developed Technology [Member]",
        "label": "Licensing Agreements, Developed Technology [Member]",
        "terseLabel": "Licensing Agreements, Developed Technology [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsDevelopedTechnologyMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingAgreementsTechnologyInDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements, Technology In Development [Member]",
        "label": "Licensing Agreements, Technology In Development [Member]",
        "terseLabel": "Licensing Agreements, Technology In Development [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsTechnologyInDevelopmentMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year",
        "terseLabel": "Line of credit facility, due to expire within one year"
       }
      }
     },
     "localname": "LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "label": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "verboseLabel": "Current portion of long-term debt, principal amount"
       }
      }
     },
     "localname": "LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "label": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "totalLabel": "Total long-term investments"
       }
      }
     },
     "localname": "LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term Investments [Member]",
        "label": "Long-term Investments [Member]",
        "terseLabel": "Long-term Investments [Member]"
       }
      }
     },
     "localname": "LongtermInvestmentsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LorbrenaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lorbrena",
        "label": "Lorbrena [Member]",
        "terseLabel": "Lorbrena [Member]"
       }
      }
     },
     "localname": "LorbrenaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "label": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "terseLabel": "Number of defendants other than main defendant"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendantsOtherThanMainDefendant",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_ManufacturingAndSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Supply Agreement",
        "label": "Manufacturing and Supply Agreement [Member]",
        "terseLabel": "Manufacturing and Supply Agreement [Member]"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ManufacturingOptimizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Optimization [Member]",
        "label": "Manufacturing Optimization [Member]",
        "terseLabel": "Manufacturing Optimization [Member]"
       }
      }
     },
     "localname": "ManufacturingOptimizationMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_McKessonInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson, Inc. [Member]",
        "label": "McKesson, Inc. [Member]",
        "terseLabel": "McKesson, Inc. [Member]"
       }
      }
     },
     "localname": "McKessonInc.Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MedrolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medrol [Member]",
        "label": "Medrol [Member]",
        "terseLabel": "Medrol [Member]"
       }
      }
     },
     "localname": "MedrolMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MektoviMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mektovi [Member]",
        "label": "Mektovi [Member]",
        "terseLabel": "Mektovi [Member]"
       }
      }
     },
     "localname": "MektoviMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MeridianMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Meridian",
        "label": "Meridian [Member]",
        "terseLabel": "Meridian [Member]"
       }
      }
     },
     "localname": "MeridianMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MylanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mylan [Member]",
        "label": "Mylan [Member]",
        "terseLabel": "Mylan [Member]"
       }
      }
     },
     "localname": "MylanMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MyovantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Myovant",
        "label": "Myovant [Member]",
        "terseLabel": "Myovant [Member]"
       }
      }
     },
     "localname": "MyovantMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NimenrixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nimenrix [Member]",
        "label": "Nimenrix [Member]",
        "terseLabel": "Nimenrix [Member]"
       }
      }
     },
     "localname": "NimenrixMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NonUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-United States [Member]",
        "label": "Non-United States [Member]",
        "terseLabel": "Outside United States [Member]"
       }
      }
     },
     "localname": "NonUnitedStatesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment",
        "label": "Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment",
        "terseLabel": "Equity investment in exchange for Pfizer's assets"
       }
      }
     },
     "localname": "NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]",
        "label": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]",
        "terseLabel": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NoncurrentDeferredTaxLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent Deferred Tax Liabilities [Member]",
        "label": "Noncurrent Deferred Tax Liabilities [Member]",
        "terseLabel": "Noncurrent Deferred Tax Liabilities [Member]"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxLiabilitiesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20220.250Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Due 2022, 0.250% [Member]",
        "label": "Notes Due 2022, 0.250% [Member]",
        "terseLabel": "Notes Due 2022, 0.250% [Member]"
       }
      }
     },
     "localname": "NotesDue20220.250Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20271.000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "terseLabel": "Notes Due 2027, 1.000% [Member]"
       }
      }
     },
     "localname": "NotesDue20271.000Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NumberofEmployeeStockOwnershipPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Employee Stock Ownership Plans",
        "label": "Number of Employee Stock Ownership Plans",
        "terseLabel": "Number of employee stock ownership plans"
       }
      }
     },
     "localname": "NumberofEmployeeStockOwnershipPlans",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology [Member]"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OpenMarketPurchasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Purchases [Member]",
        "label": "Open Market Purchases [Member]",
        "terseLabel": "Open Market Purchases [Member]"
       }
      }
     },
     "localname": "OpenMarketPurchasesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accruals",
        "label": "Other Accruals",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "OtherAccruals",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherAntiinfectivesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Anti-infectives [Member]",
        "label": "Other Anti-infectives [Member]",
        "terseLabel": "Other Anti-infectives [Member]"
       }
      }
     },
     "localname": "OtherAntiinfectivesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherCommingledFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Commingled Funds [Member]",
        "label": "Other Commingled Funds [Member]",
        "terseLabel": "Other Commingled Funds [Member]"
       }
      }
     },
     "localname": "OtherCommingledFundsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax",
        "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Net Reclassification Adjustment from AOCI, After Tax",
        "label": "Other Comprehensive Income (Loss), Net Reclassification Adjustment from AOCI, After Tax",
        "terseLabel": "Net increase to accumulated other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetReclassificationAdjustmentFromAOCIAfterTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gain/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Financial Information",
        "label": "Other Financial Information [Abstract]"
       }
      }
     },
     "localname": "OtherFinancialInformationAbstract",
     "nsuri": "http://www.pfizer.com/20211231",
     "xbrltype": "stringItemType"
    },
    "pfe_OtherHospitalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Hospital Products [Member]",
        "label": "Other Hospital Products [Member]",
        "terseLabel": "Other Hospital Products [Member]"
       }
      }
     },
     "localname": "OtherHospitalProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherIncomeDeductionsAndCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other (Income) Deductions And Cost Of Sales [Member]",
        "label": "Other (Income) Deductions And Cost Of Sales [Member]",
        "terseLabel": "Other (Income) Deductions And Cost Of Sales [Member]"
       }
      }
     },
     "localname": "OtherIncomeDeductionsAndCostOfSalesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherNonoperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Net",
        "label": "Other Nonoperating Income (Expense), Net",
        "negatedTerseLabel": "Other, net",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseNet",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology Products [Member]",
        "label": "Other Oncology Products [Member]",
        "terseLabel": "Other Oncology Products [Member]"
       }
      }
     },
     "localname": "OtherOncologyProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherPatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Patent Infringement",
        "label": "Other Patent Infringement [Member]",
        "terseLabel": "Other Patent Infringement [Member]"
       }
      }
     },
     "localname": "OtherPatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherTaxAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Tax Assets, Current",
        "label": "Other Tax Assets, Current",
        "terseLabel": "Current tax assets"
       }
      }
     },
     "localname": "OtherTaxAssetsCurrent",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Taxes Payable [Member]",
        "label": "Other Taxes Payable [Member]",
        "terseLabel": "Other Taxes Payable [Member]"
       }
      }
     },
     "localname": "OtherTaxesPayableMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Vaccines Products [Member]",
        "label": "Other Vaccines Products [Member]",
        "terseLabel": "Other Vaccines Products [Member]"
       }
      }
     },
     "localname": "OtherVaccinesProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent Infringement [Member]",
        "label": "Patent Infringement [Member]",
        "terseLabel": "Patent Infringement [Member]"
       }
      }
     },
     "localname": "PatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaxlovidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paxlovid",
        "label": "Paxlovid [Member]",
        "terseLabel": "Paxlovid [Member]"
       }
      }
     },
     "localname": "PaxlovidMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaymentForCollaborativeAndLicensingArrangements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Collaborative and Licensing Arrangements",
        "label": "Payment for Collaborative and Licensing Arrangements",
        "terseLabel": "Payment for collaborative and licensing arrangements"
       }
      }
     },
     "localname": "PaymentForCollaborativeAndLicensingArrangements",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentForLicensingArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Licensing Arrangement",
        "label": "Payment For Licensing Arrangement",
        "terseLabel": "Payment for licensing arrangement"
       }
      }
     },
     "localname": "PaymentForLicensingArrangement",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentPursuantToTermsOfSeparationAgreementFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Pursuant to Terms of Separation Agreement, Financing Activities",
        "label": "Payment Pursuant to Terms of Separation Agreement, Financing Activities",
        "terseLabel": "Payment pursuant to terms of the separation agreement"
       }
      }
     },
     "localname": "PaymentPursuantToTermsOfSeparationAgreementFinancingActivities",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "label": "Payments For (Proceeds From) Short Term Investments With Original Maturities Of Three Months Or Less",
        "negatedLabel": "Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestmentsWithOriginalMaturitiesOfThreeMonthsOrLess",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment",
        "label": "Payments to Collaborators, Upfront Payment and Premium Paid in Equity Investment",
        "terseLabel": "Upfront payment and premium paid in equity investment"
       }
      }
     },
     "localname": "PaymentsToCollaboratorsUpfrontPaymentAndPremiumPaidInEquityInvestment",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "label": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "negatedLabel": "Utilization and other"
       }
      }
     },
     "localname": "PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).",
        "label": "Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)",
        "negatedTerseLabel": "Benefit plan contributions in excess of expense/income"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Total Shareholder Return Unit (PTSRUs) [Member]",
        "label": "Performance Total Shareholder Return Unit (PTSRUs) [Member]",
        "terseLabel": "Performance Total Shareholder Return Unit (PTSRUs) [Member]"
       }
      }
     },
     "localname": "PerformanceTotalShareholderReturnUnitPTSRUsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "label": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "terseLabel": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]"
       }
      }
     },
     "localname": "PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerCentreOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer CentreOne [Member]",
        "label": "Pfizer CentreOne [Member]",
        "terseLabel": "Pfizer CentreOne [Member]"
       }
      }
     },
     "localname": "PfizerCentreOneMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerandBMSVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "label": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer and BMS Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerandBMSVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PneumococcalVaccinePatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumococcal Vaccine Patent Infringement",
        "label": "Pneumococcal Vaccine Patent Infringement [Member]",
        "terseLabel": "Pneumococcal Vaccine Patent Infringement [Member]"
       }
      }
     },
     "localname": "PneumococcalVaccinePatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PortfolioPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portfolio Performance Shares [Member]",
        "label": "Portfolio Performance Shares [Member]",
        "terseLabel": "Portfolio Performance Shares [Member]"
       }
      }
     },
     "localname": "PortfolioPerformanceSharesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrecedexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Precedex [Member]",
        "label": "Precedex [Member]",
        "terseLabel": "Precedex [Member]"
       }
      }
     },
     "localname": "PrecedexMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PremarinFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premarin family [Member]",
        "label": "Premarin Family [Member]",
        "terseLabel": "Premarin Family [Member]"
       }
      }
     },
     "localname": "PremarinFamilyMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrepaymentsAndPaymentsToCollaboratorsCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments and Payments to Collaborators, Cash",
        "label": "Prepayments and Payments to Collaborators, Cash",
        "terseLabel": "Cash payment to collaborators"
       }
      }
     },
     "localname": "PrepaymentsAndPaymentsToCollaboratorsCash",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PrepaymentsandPaymentstoCollaborators": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments and Payments to Collaborators",
        "label": "Prepayments and Payments to Collaborators",
        "verboseLabel": "Payment to collaborators"
       }
      }
     },
     "localname": "PrepaymentsandPaymentstoCollaborators",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PrevnarPrevenarFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevnar/Prevenar Family 13 [Member]",
        "label": "Prevnar Prevenar Family [Member]",
        "terseLabel": "Prevenar 13/Prevnar 13 [Member]"
       }
      }
     },
     "localname": "PrevnarPrevenarFamilyMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PristiqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pristiq",
        "label": "Pristiq [Member]",
        "terseLabel": "Pristiq [Member]"
       }
      }
     },
     "localname": "PristiqMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Equity Investments",
        "label": "Private Equity Investments",
        "terseLabel": "Private equity securities at cost"
       }
      }
     },
     "localname": "PrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ProfitUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Units [Member]",
        "label": "Profit Units [Member]",
        "terseLabel": "Profit Units [Member]"
       }
      }
     },
     "localname": "ProfitUnitsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PumaTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Puma Technologies [Member]",
        "label": "Puma Technologies [Member]",
        "terseLabel": "Puma Technologies [Member]"
       }
      }
     },
     "localname": "PumaTechnologiesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PurchaserOfMeridianMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchaser of Meridian",
        "label": "Purchaser of Meridian [Member]",
        "terseLabel": "Purchaser of Meridian [Member]"
       }
      }
     },
     "localname": "PurchaserOfMeridianMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RareDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rare Disease [Member]",
        "label": "Rare Disease [Member]",
        "terseLabel": "Rare Disease [Member]"
       }
      }
     },
     "localname": "RareDiseaseMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReFactoAfXynthaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Re Facto AF Xyntha [Member]",
        "label": "Re Facto AF Xyntha [Member]",
        "terseLabel": "ReFacto AF Xyntha [Member]"
       }
      }
     },
     "localname": "ReFactoAfXynthaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RebatesAndOtherSalesRelatedAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain accrued rebates and accrued sales returns",
        "label": "Rebates And Other Sales-Related Accruals",
        "terseLabel": "Total accrued rebates and other sales-related accruals"
       }
      }
     },
     "localname": "RebatesAndOtherSalesRelatedAccruals",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ReconcilingItemsAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciling Items, Acquisition Related Costs",
        "label": "Reconciling Items, Acquisition Related Costs [Member]",
        "terseLabel": "Acquisition Related Costs [Member]"
       }
      }
     },
     "localname": "ReconcilingItemsAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReconcilingItemsOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciling Items, Other",
        "label": "Reconciling Items, Other [Member]",
        "terseLabel": "Other Reconciling Items [Member]"
       }
      }
     },
     "localname": "ReconcilingItemsOtherMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReconcilingItemsPurchaseAccountingAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Accounting Adjustments [Member]",
        "label": "Reconciling Items, Purchase Accounting Adjustments [Member]",
        "terseLabel": "Purchase Accounting Adjustments [Member]"
       }
      }
     },
     "localname": "ReconcilingItemsPurchaseAccountingAdjustmentsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage",
        "label": "Research And Development Arrangement, Collaborator's Development Cost Ownership Percentage",
        "terseLabel": "Development cost ownership percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementCollaboratorsDevelopmentCostOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Commercialization Milestones, Maximum Exposure",
        "label": "Research And Development Arrangement, Commercialization Milestones, Maximum Exposure",
        "terseLabel": "Potential early commercialization milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementCommercializationMilestonesMaximumExposure",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Contingent Payments, Maximum Exposure1",
        "label": "Research And Development Arrangement, Contingent Payments, Maximum Exposure1",
        "terseLabel": "Maximum potential consideration"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContingentPaymentsMaximumExposure1",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Development Milestone, Maximum Exposure",
        "label": "Research And Development Arrangement, Development Milestone, Maximum Exposure",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementDevelopmentMilestoneMaximumExposure",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Future Milestone Payments, Maximum Exposure",
        "label": "Research And Development Arrangement, Future Milestone Payments, Maximum Exposure",
        "terseLabel": "Potential future milestone payments"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementFutureMilestonePaymentsMaximumExposure",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Percentage of Costs to be Reimbursed",
        "label": "Research and Development Arrangement, Percentage of Costs to be Reimbursed",
        "terseLabel": "Percentage of costs to be reimbursed"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RestructuringAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring, Asset Impairment Charges",
        "label": "Restructuring, Asset Impairment Charges",
        "terseLabel": "Asset impairments"
       }
      }
     },
     "localname": "RestructuringAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "label": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "terseLabel": "Total costs incurred",
        "totalLabel": "Total costs associated with acquisitions and cost-reduction/productivity initiatives"
       }
      }
     },
     "localname": "RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.",
        "label": "Restructuring Charges And Acquisition Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs",
        "totalLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Acquisition-Related Costs [Member]",
        "label": "Restructuring Charges And Acquisition-Related Costs [Member]",
        "terseLabel": "Restructuring Charges And Acquisition-Related Costs [Member]"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring",
        "label": "Restructuring Charges (Credits), Implementation Costs and Additional Depreciation, Asset Restructuring",
        "terseLabel": "Restructuring charges/(credits) and implementation costs and additional depreciation, asset restructuring"
       }
      }
     },
     "localname": "RestructuringChargesCreditsImplementationCostsAndAdditionalDepreciationAssetRestructuring",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringandRelatedCostNoncashChargesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "label": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "terseLabel": "Percentage of non-cash restructuring charges expected"
       }
      }
     },
     "localname": "RestructuringandRelatedCostNoncashChargesPercentage",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RetacritMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retacrit [Member]",
        "label": "Retacrit [Member]",
        "terseLabel": "Retacrit [Member]"
       }
      }
     },
     "localname": "RetacritMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RuxienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ruxience",
        "label": "Ruxience [Member]",
        "terseLabel": "Ruxience [Member]"
       }
      }
     },
     "localname": "RuxienceMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScenarioChangeInAccountingPrincipleAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario, Change in Accounting Principle, Adjustment",
        "label": "Scenario, Change in Accounting Principle, Adjustment [Member]",
        "terseLabel": "Impact of Change [Member]"
       }
      }
     },
     "localname": "ScenarioChangeInAccountingPrincipleAdjustmentMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScenarioPreviousAccountingPrincipleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario, Previous Accounting Principle",
        "label": "Scenario, Previous Accounting Principle [Member]",
        "terseLabel": "Previous Accounting Principle [Member]"
       }
      }
     },
     "localname": "ScenarioPreviousAccountingPrincipleMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Line Items]",
        "terseLabel": "Schedule Of Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesLineItems",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Table]",
        "terseLabel": "Schedule Of Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTable",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]",
        "terseLabel": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Table]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]",
        "terseLabel": "Schedule of Available for sale Securities and Held to maturity Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Valuation Assumptions",
        "label": "Schedule of Share-based Payment Award, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_SeniorNotesDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2021",
        "label": "Senior Notes Due 2021 [Member]",
        "terseLabel": "Senior Notes Due 2021 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2021Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2023",
        "label": "Senior Notes Due 2023 [Member]",
        "terseLabel": "Senior Notes Due 2023 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2023Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorNotesDue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Due 2047 [Member]",
        "label": "Senior Notes Due 2047 [Member]",
        "terseLabel": "Senior Notes Due 2047 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2047Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2022 [Member]",
        "label": "Senior Unsecured Debt, Due 2022 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2022 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2022Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2023 [Member]",
        "label": "Senior Unsecured Debt, Due 2023 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2023 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2023Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2024 [Member]",
        "label": "Senior Unsecured Debt, Due 2024 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2024 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2024Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2025",
        "label": "Senior Unsecured Debt, Due 2025 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2025 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2025Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2026",
        "label": "Senior Unsecured Debt, Due 2026 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2026 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2026Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2027",
        "label": "Senior Unsecured Debt, Due 2027 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2027 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2027Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20282032Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2028-2032",
        "label": "Senior Unsecured Debt, Due 2028-2032 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2028-2032 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20282032Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20332037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2033-2037",
        "label": "Senior Unsecured Debt, Due 2033-2037 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2033-2037 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20332037Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20382042Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2038-2042",
        "label": "Senior Unsecured Debt, Due 2038-2042 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2038-2042 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20382042Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20432047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2043-2047",
        "label": "Senior Unsecured Debt, Due 2043-2047 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2043-2047 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20432047Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20482050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2048-2050",
        "label": "Senior Unsecured Debt, Due 2048-2050 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2048-2050 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20482050Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, Five Point Eight Zero Percent, Due 2023",
        "label": "Senior Unsecured Debt, Five Point Eight Zero Percent, Due 2023 [Member]",
        "terseLabel": "Senior Unsecured Debt, Five Point Eight Zero Percent, Due 2023 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtFivePointEightZeroPercentDue2023Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point Nine Five Percent, Due 2021",
        "label": "Senior Unsecured Debt, One Point Nine Five Percent, Due 2021 [Member]",
        "terseLabel": "Senior Unsecured Debt, One Point Nine Five Percent, Due 2021 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointNineFivePercentDue2021Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Debt, One Point Seven Five Zero Percent, Due August 2031",
        "label": "Senior Unsecured Debt, One Point Seven Five Zero Percent, Due August 2031 [Member]",
        "terseLabel": "Senior Unsecured Debt, One Point Seven Five Zero Percent, Due August 2031"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtOnePointSevenFiveZeroPercentDueAugust2031Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]",
        "label": "Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]",
        "terseLabel": "Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercised and Converted",
        "terseLabel": "Units exercised and converted, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisedAndConverted",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Number",
        "terseLabel": "Units exercised and converted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedNumber",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised and Converted, Weighted Average Remaining Contractual Term",
        "terseLabel": "Units exercised and converted, weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedAndConvertedWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Roll Forward]",
        "terseLabel": "Grant Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageGrantPriceRollForward",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Units Converted, Intrinsic Value",
        "terseLabel": "Units converted, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnitsConvertedIntrinsicValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Intrinsic Value [Roll Forward]",
        "terseLabel": "Weighted Avg. Intrinsic Value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageIntrinsicValueRollForward",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee",
        "terseLabel": "Maximum shares available per individual during the plan period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Period",
        "terseLabel": "Share payout measures, adjusted net income, period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomePeriod",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee",
        "terseLabel": "Number of shares counted toward maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_ShareRepurchaseAgreementwithGSCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Agreement with GS&amp;Co [Member]",
        "label": "Share Repurchase Agreement with GS&amp;Co [Member]",
        "terseLabel": "Share Repurchase Agreement with Goldman, Sachs &amp; Co. LLC [Member]"
       }
      }
     },
     "localname": "ShareRepurchaseAgreementwithGSCoMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price",
        "terseLabel": "Units settled, weighted average grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price",
        "terseLabel": "Units vested, weighted average grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest",
        "terseLabel": "Units expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price",
        "terseLabel": "Units exercised, weighted average grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number",
        "terseLabel": "Units expected to vest, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price",
        "terseLabel": "Units expected to vest, weighted average grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term",
        "terseLabel": "Units expected to vest, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price",
        "periodEndLabel": "Nonvested, end of period, grant price (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning of period, grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award",
        "terseLabel": "Number of shares earned as a percentage of initial award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price",
        "terseLabel": "Units outstanding, weighted average grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period",
        "terseLabel": "Reinvested dividend equivalents, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares",
        "terseLabel": "Units settled, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares",
        "terseLabel": "Units vested, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Units vested, weighted average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion",
        "terseLabel": "Units granted upon conversion, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price",
        "terseLabel": "Grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout",
        "terseLabel": "Number of measures used to determine share payout"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average",
        "terseLabel": "Trading day average"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods",
        "terseLabel": "Share payout measures, adjusted net income, number of periods"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price",
        "terseLabel": "Forfeited, grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price",
        "terseLabel": "Granted, grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price",
        "terseLabel": "Vested, grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_ShinglesVaccineProgramMRNABasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shingles Vaccine Program, mRNA-Based",
        "label": "Shingles Vaccine Program, mRNA-Based [Member]",
        "terseLabel": "Shingles Vaccine Program, mRNA-Based [Member]"
       }
      }
     },
     "localname": "ShinglesVaccineProgramMRNABasedMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShorttermDebtGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term Debt, Gross",
        "label": "Short-term Debt, Gross",
        "totalLabel": "Total short-term borrowings, principal amount"
       }
      }
     },
     "localname": "ShorttermDebtGross",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term Investments Excluding Held-To-Maturity Securities",
        "label": "Short-term Investments Excluding Held-To-Maturity Securities",
        "totalLabel": "Total short-term investments"
       }
      }
     },
     "localname": "ShorttermInvestmentsExcludingHeldToMaturitySecurities",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SiteContingencyRegulatoryProceedingsDisclosureThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Site Contingency, Regulatory Proceedings, Disclosure Threshold",
        "label": "Site Contingency, Regulatory Proceedings, Disclosure Threshold",
        "terseLabel": "Threshold for disclosure of proceedings under environmental laws"
       }
      }
     },
     "localname": "SiteContingencyRegulatoryProceedingsDisclosureThreshold",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SomavertMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Somavert [Member]",
        "label": "Somavert [Member]",
        "terseLabel": "Somavert [Member]"
       }
      }
     },
     "localname": "SomavertMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions (in shares)"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SulperazonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sulperazon [Member]",
        "label": "Sulperazon [Member]",
        "terseLabel": "Sulperazon [Member]"
       }
      }
     },
     "localname": "SulperazonMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SutentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sutent [Member]",
        "label": "Sutent [Member]",
        "terseLabel": "Sutent [Member]"
       }
      }
     },
     "localname": "SutentMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)",
        "terseLabel": "Current income taxes"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Income taxes"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TherachonAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Therachon Asset Acquisition [Member]",
        "label": "Therachon Asset Acquisition [Member]",
        "terseLabel": "Therachon Asset Acquisition [Member]"
       }
      }
     },
     "localname": "TherachonAssetAcquisitionMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ThreeLargestUSWholesaleCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Largest US Wholesale Customers [Member]",
        "label": "Three Largest US Wholesale Customers [Member]",
        "terseLabel": "Three Largest U.S. Wholesaler Customers [Member]"
       }
      }
     },
     "localname": "ThreeLargestUSWholesaleCustomersMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TopNineProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Top Nine Products",
        "label": "Top Nine Products [Member]",
        "terseLabel": "Top Nine Products [Member]"
       }
      }
     },
     "localname": "TopNineProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TopSevenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Top Seven Products",
        "label": "Top Seven Products [Member]",
        "terseLabel": "Top Seven Products [Member]"
       }
      }
     },
     "localname": "TopSevenProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TopSixProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Top Six Products",
        "label": "Top Six Products [Member]",
        "terseLabel": "Top Six Products [Member]"
       }
      }
     },
     "localname": "TopSixProductsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalAllianceBiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Alliance Biopharmaceuticals [Member]",
        "label": "Total Alliance Biopharmaceuticals [Member]",
        "terseLabel": "Alliance Biopharmaceuticals [Member]"
       }
      }
     },
     "localname": "TotalAllianceBiopharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalBiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Biosimilars [Member]",
        "label": "Total Biosimilars [Member]",
        "terseLabel": "Total Biosimilars [Member]"
       }
      }
     },
     "localname": "TotalBiosimilarsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalShareholderReturnUnitsTSRUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Shareholder Return Units (TSRUs) [Member]",
        "label": "Total Shareholder Return Units (TSRUs) [Member]",
        "terseLabel": "Total Shareholder Return Units (TSRUs) [Member]"
       }
      }
     },
     "localname": "TotalShareholderReturnUnitsTSRUsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalSterileInjectablePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Sterile Injectable Pharmaceuticals [Member]",
        "label": "Total Sterile Injectable Pharmaceuticals [Member]",
        "terseLabel": "Total Sterile Injectable Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "TotalSterileInjectablePharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ToviazMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Toviaz [Member]",
        "label": "Toviaz [Member]",
        "terseLabel": "Toviaz [Member]"
       }
      }
     },
     "localname": "ToviazMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TransitionServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition Service Agreement",
        "label": "Transition Service Agreement [Member]",
        "terseLabel": "Transition Service Agreement [Member]"
       }
      }
     },
     "localname": "TransitionServiceAgreementMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TrazimeraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trazimera",
        "label": "Trazimera [Member]",
        "terseLabel": "Trazimera [Member]"
       }
      }
     },
     "localname": "TrazimeraMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TrilliumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trillium",
        "label": "Trillium [Member]",
        "terseLabel": "Trillium [Member]"
       }
      }
     },
     "localname": "TrilliumMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TrumenbaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trumenba",
        "label": "Trumenba [Member]",
        "terseLabel": "Trumenba [Member]"
       }
      }
     },
     "localname": "TrumenbaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]",
        "label": "Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]",
        "terseLabel": "2017-2019 and Organizing for Growth [Member]"
       }
      }
     },
     "localname": "TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TygacilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tygacil",
        "label": "Tygacil [Member]",
        "terseLabel": "Tygacil [Member]"
       }
      }
     },
     "localname": "TygacilMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Decrease Resulting from Divestitures",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Divestitures",
        "terseLabel": "Divestitures"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromDivestitures",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsExcludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Excluding Interest",
        "label": "Unrecognized Tax Benefits, Excluding Interest",
        "terseLabel": "Unrecognized tax benefits excluding associated interest"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsExcludingInterest",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Acquisition",
        "negatedTerseLabel": "Acquisitions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromAcquisition",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation",
        "negatedLabel": "Impact of foreign exchange"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Decrease Resulting From Divestitures",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Decrease Resulting From Divestitures",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued, decrease resulting from divestiture"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccruedDecreaseResultingFromDivestitures",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual",
        "negatedTerseLabel": "Unrecognized accrued interest decrease as a result of cash payments"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Period Increase (Decrease), Other",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease), Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UpjohnFinanceB.V.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upjohn Finance B.V. [Member]",
        "label": "Upjohn Finance B.V. [Member]",
        "terseLabel": "Upjohn Finance B.V. [Member]"
       }
      }
     },
     "localname": "UpjohnFinanceB.V.Member",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnFinanceBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upjohn Finance B. V.",
        "label": "Upjohn Finance B. V. [Member]",
        "terseLabel": "Upjohn Finance B. V."
       }
      }
     },
     "localname": "UpjohnFinanceBVMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnIncAndUpjohnFinanceBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upjohn Inc and Upjohn Finance B.V.",
        "label": "Upjohn Inc and Upjohn Finance B.V. [Member]",
        "terseLabel": "Upjohn Inc and Upjohn Finance B.V. [Member]"
       }
      }
     },
     "localname": "UpjohnIncAndUpjohnFinanceBVMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upjohn Inc [Member]",
        "label": "Upjohn Inc [Member]",
        "terseLabel": "Upjohn Inc [Member]"
       }
      }
     },
     "localname": "UpjohnIncMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccines [Member]",
        "label": "Vaccines [Member]",
        "terseLabel": "Vaccines [Member]"
       }
      }
     },
     "localname": "VaccinesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ValnevaSEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valneva SE [Member]",
        "label": "Valneva SE [Member]",
        "terseLabel": "Valneva [Member]"
       }
      }
     },
     "localname": "ValnevaSEMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VfendMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vfend [Member]",
        "label": "Vfend [Member]",
        "terseLabel": "Vfend [Member]"
       }
      }
     },
     "localname": "VfendMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViatrisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viatris",
        "label": "Viatris [Member]",
        "terseLabel": "Viatris [Member]"
       }
      }
     },
     "localname": "ViatrisMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViiVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV [Member]",
        "label": "ViiV [Member]",
        "terseLabel": "ViiV [Member]"
       }
      }
     },
     "localname": "ViiVMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViivHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ViiV Healthcare Limited [Member]",
        "label": "ViiV Healthcare Limited [Member]",
        "terseLabel": "ViiV [Member]"
       }
      }
     },
     "localname": "ViivHealthcareLimitedMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VyndaqelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vyndaqel [Member]",
        "label": "Vyndaqel [Member]",
        "terseLabel": "Vyndaqel/Vyndamax [Member]"
       }
      }
     },
     "localname": "VyndaqelMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalkoriMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xalkori [Member]",
        "label": "Xalkori [Member]",
        "terseLabel": "Xalkori [Member]"
       }
      }
     },
     "localname": "XalkoriMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XeljanzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xeljanz [Member]",
        "label": "Xeljanz [Member]",
        "terseLabel": "Xeljanz [Member]"
       }
      }
     },
     "localname": "XeljanzMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XtandiAllianceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xtandi Alliance Revenues [Member]",
        "label": "Xtandi Alliance Revenues [Member]",
        "terseLabel": "Xtandi Alliance Revenues [Member]"
       }
      }
     },
     "localname": "XtandiAllianceRevenuesMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZaviceftaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zavicefta",
        "label": "Zavicefta [Member]",
        "terseLabel": "Zavicefta [Member]"
       }
      }
     },
     "localname": "ZaviceftaMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZirabevMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zirabev",
        "label": "Zirabev [Member]",
        "terseLabel": "Zirabev [Member]"
       }
      }
     },
     "localname": "ZirabevMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZithromaxZmaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zithromax / Zmax [Member]",
        "label": "Zithromax Zmax [Member]",
        "terseLabel": "Zithromax Zmax [Member]"
       }
      }
     },
     "localname": "ZithromaxZmaxMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZyvoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zyvox [Member]",
        "label": "Zyvox [Member]",
        "terseLabel": "Zyvox [Member]"
       }
      }
     },
     "localname": "ZyvoxMember",
     "nsuri": "http://www.pfizer.com/20211231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r211",
      "r280",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r306",
      "r310",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r481",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r211",
      "r280",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r306",
      "r310",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r481",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r117",
      "r119",
      "r208",
      "r209",
      "r490",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r319",
      "r556",
      "r560",
      "r1046"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r321",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management [Member]"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r489",
      "r516",
      "r656",
      "r661",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r973",
      "r1043",
      "r1047",
      "r1086",
      "r1087"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/LeasesNarrativeDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r489",
      "r516",
      "r656",
      "r661",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r973",
      "r1043",
      "r1047",
      "r1086",
      "r1087"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/LeasesNarrativeDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r319",
      "r556",
      "r560",
      "r1046"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PartnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Partnership Interest [Member]",
        "terseLabel": "Partnership Interest [Member]"
       }
      }
     },
     "localname": "PartnershipInterestMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r313",
      "r556",
      "r558",
      "r975",
      "r1042",
      "r1044"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r313",
      "r556",
      "r558",
      "r975",
      "r1042",
      "r1044"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r489",
      "r516",
      "r592",
      "r656",
      "r661",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r973",
      "r1043",
      "r1047",
      "r1086",
      "r1087"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/LeasesNarrativeDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r489",
      "r516",
      "r592",
      "r656",
      "r661",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r973",
      "r1043",
      "r1047",
      "r1086",
      "r1087"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/LeasesNarrativeDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r208",
      "r209",
      "r490",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r251",
      "r376",
      "r377",
      "r706",
      "r753",
      "r863",
      "r867",
      "r868",
      "r869",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1108",
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r251",
      "r376",
      "r377",
      "r706",
      "r753",
      "r863",
      "r867",
      "r868",
      "r869",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1108",
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember": {
     "auth_ref": [
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Change in Accounting Principle, Adjustment [Member]",
        "terseLabel": "Change in Accounting Principle, Adjustment [Member]"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodChangeInAccountingPrincipleAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r314",
      "r315",
      "r556",
      "r559",
      "r1045",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r314",
      "r315",
      "r556",
      "r559",
      "r1045",
      "r1070",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r321",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.",
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "terseLabel": "Accelerated share repurchase, final average price paid (in dollars per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "negatedTerseLabel": "Accelerated share repurchases, cash paid"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r94",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts [Member]",
        "verboseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r41",
      "r71",
      "r322",
      "r323"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts: 2021\u2014$492; 2020\u2014$508"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": {
     "auth_ref": [
      "r129",
      "r134",
      "r145",
      "r146",
      "r147",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]",
        "terseLabel": "Prior Service (Costs)/Credits and Other [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r91",
      "r425"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r134",
      "r145",
      "r146",
      "r147",
      "r148",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r134",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Available-For-Sale Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r74",
      "r131",
      "r133",
      "r134",
      "r1021",
      "r1055",
      "r1059"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "verboseLabel": "Increase to AOCI"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r145",
      "r146",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r130",
      "r134",
      "r145",
      "r146",
      "r147",
      "r213",
      "r214",
      "r215",
      "r806",
      "r1050",
      "r1051",
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accum. Other Comp. Loss [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Income/(Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r121",
      "r134",
      "r145",
      "r146",
      "r147",
      "r806",
      "r902",
      "r903",
      "r904",
      "r905",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired intangible assets, useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of acquisition-related costs allocated to (included in) reported pro forma earnings (supplemental pro forma information).",
        "label": "Acquisition-related Costs [Member]",
        "terseLabel": "Acquisition-related Costs [Member]"
       }
      }
     },
     "localname": "AcquisitionRelatedCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other Financial Information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r72",
      "r706",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r703",
      "r704",
      "r705",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Add\u2019l Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r714"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r664",
      "r695",
      "r708"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation cost recognized, pre-tax"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r78",
      "r325",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r189",
      "r402",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.",
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax",
        "totalLabel": "Cost/(credit) recognized in Comprehensive income"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive common stock equivalents (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition, consideration transferred"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r788",
      "r789",
      "r790"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Asset acquisition, consideration transferred, equity interest"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r189",
      "r421"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Certain asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r202",
      "r288",
      "r301",
      "r308",
      "r369",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r799",
      "r808",
      "r886",
      "r939",
      "r941",
      "r984",
      "r1019"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r42",
      "r43",
      "r114",
      "r202",
      "r369",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r799",
      "r808",
      "r886",
      "r939",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r202",
      "r369",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r799",
      "r808",
      "r886",
      "r939"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r33",
      "r37",
      "r423",
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations and other assets held for sale\u2013\u2013Other current assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r338"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale debt securities, gross unrealized gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale debt securities, gross unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r336",
      "r384"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r340",
      "r342",
      "r1011"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Available-for-sale securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r340",
      "r341",
      "r1010"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Available-for-sale securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r333",
      "r337",
      "r384",
      "r991"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale securities, debt securities",
        "totalLabel": "Available-for-sale securities, debt maturities",
        "verboseLabel": "Available-for-sale securities, debt maturities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r335",
      "r384"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r335",
      "r384"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r666",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r822",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r1005"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits and other [Member]"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r651",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r651",
      "r657",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, per share in cash (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r188",
      "r786"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of fair value contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r781",
      "r782",
      "r785"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "verboseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r781",
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r781",
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration liability, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Integration costs and other"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r777"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "negatedTerseLabel": "Reduction in intangible assets due to measurement period adjustments"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r776"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r775",
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r776"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Assumed long-term debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r772"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Post closing compensation expense"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Exit costs/(credits)"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r87",
      "r191"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r184",
      "r191",
      "r195"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r184",
      "r898"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "terseLabel": "Cash divested"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash transactions:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by/(used in) financing activities from discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r30",
      "r184"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by/(used in) investing activities from discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r30",
      "r184"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by/(used in) operating activities from discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r855"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r855"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Hedged Item"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r199",
      "r202",
      "r236",
      "r237",
      "r242",
      "r245",
      "r247",
      "r258",
      "r259",
      "r260",
      "r369",
      "r471",
      "r476",
      "r477",
      "r478",
      "r484",
      "r485",
      "r514",
      "r515",
      "r519",
      "r523",
      "r886",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails",
      "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r849"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral posted"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r60",
      "r985",
      "r1020"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r105",
      "r456",
      "r992",
      "r1026"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r464",
      "r1072"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Certain Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r467",
      "r1073"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Legal and Environmental Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r213",
      "r214",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity",
      "http://www.pfizer.com/role/CoverPage",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r70",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.05 par value; 12,000 shares authorized; issued: 2021\u20149,471; 2020\u20149,407"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r159",
      "r1002",
      "r1036"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income/(loss) attributable to Pfizer Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r140",
      "r142",
      "r158",
      "r797",
      "r798",
      "r812",
      "r1001",
      "r1035"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income/(loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r140",
      "r142",
      "r157",
      "r796",
      "r812",
      "r1000",
      "r1034"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income/(loss) before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r156",
      "r170",
      "r999",
      "r1033"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r269",
      "r270",
      "r319",
      "r883",
      "r884",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r319",
      "r883",
      "r884",
      "r1062",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r319",
      "r883",
      "r884",
      "r1062",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r269",
      "r270",
      "r319",
      "r883",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of total revenues",
        "verboseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r265",
      "r269",
      "r270",
      "r271",
      "r883",
      "r885",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r269",
      "r270",
      "r319",
      "r883",
      "r884",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r196",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r543",
      "r544",
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r543",
      "r544",
      "r557"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues",
        "verboseLabel": "Deferred revenues, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r543",
      "r544",
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r593",
      "r642",
      "r1061"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt [Member]",
        "verboseLabel": "Corporate and Other [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Other Business Activities [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r163",
      "r975"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r164",
      "r202",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r886"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedTerseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r443",
      "r444",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r203",
      "r746",
      "r756"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r203",
      "r746"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Current income taxes"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income taxes:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r203",
      "r746",
      "r756"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r266",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Carrying value of short-term borrowings",
        "totalLabel": "Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted",
        "verboseLabel": "Short-term borrowings, including current portion of long-term debt: 2021\u2014$1,636; 2020\u2014$2,002"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r201",
      "r211",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r508",
      "r509",
      "r510",
      "r511",
      "r915",
      "r986",
      "r988",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r63",
      "r504",
      "r988",
      "r1017"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Total principal amount of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r486",
      "r508",
      "r509",
      "r913",
      "r915",
      "r916"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r102",
      "r507",
      "r913",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r102",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r103",
      "r201",
      "r211",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r508",
      "r509",
      "r510",
      "r511",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchased debt"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Redemption value"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r103",
      "r201",
      "r211",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r508",
      "r509",
      "r510",
      "r511",
      "r531",
      "r532",
      "r533",
      "r534",
      "r912",
      "r913",
      "r915",
      "r916",
      "r1014"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r493",
      "r505",
      "r508",
      "r509",
      "r914"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Net unamortized discounts, premiums and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity": {
     "auth_ref": [
      "r991"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss",
        "terseLabel": "Debt securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate",
        "verboseLabel": "Interest rate, percentage"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r807"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "(Gain) on completion of Consumer Healthcare JV transaction",
        "terseLabel": "Gain on completion of transaction"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r729"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "verboseLabel": "Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r203",
      "r747",
      "r756"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r203",
      "r747",
      "r756"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r189",
      "r203",
      "r747",
      "r756",
      "r757",
      "r758"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred taxes from continuing operations",
        "verboseLabel": "Deferred taxes from continuing operations"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred income taxes:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r66",
      "r67",
      "r738",
      "r987",
      "r1016"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities, gross"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r723",
      "r724"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Noncurrent deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r203",
      "r747",
      "r756"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 4.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Investments - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r739"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventories - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r741"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred taxes - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "All other - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "terseLabel": "Prepaid/deferred items - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Employee benefits - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges",
        "terseLabel": "Restructurings and other charges - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r740"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r724",
      "r741"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability",
        "terseLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails",
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "negatedLabel": "Inventories - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "negatedTerseLabel": "Investments - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "All other - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid/deferred items - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r744",
      "r745"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, plant and equipment - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r744"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedLabel": "Unremitted earnings - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r65",
      "r565",
      "r566",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Pension benefit obligations"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r601"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Defined benefit plan, accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r134",
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Prior service (costs)/credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r582",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]",
        "terseLabel": "Actual return on plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": {
     "auth_ref": [
      "r597",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held",
        "terseLabel": "Assets held, ending"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Changes in actuarial assumptions and other"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit": {
     "auth_ref": [
      "r567",
      "r608",
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss), recognized immediately as component of net periodic benefit (cost) credit, for change in value of benefit obligation or plan assets from experience different from that assumed, change in actuarial assumption, or consequence of temporarily deviating from substantive plan. Includes, but is not limited to, amount in excess of ten percent of greater of fair value of plan assets or benefit obligation.",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Immediate Recognition as Component in Net Periodic Benefit (Cost) Credit",
        "terseLabel": "Net periodic benefit, actuarial valuation and other pension and postretirement plan gains"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossImmediateRecognitionAsComponentInNetPeriodicBenefitCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r567",
      "r608",
      "r636",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Actuarial (gains)/losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r567",
      "r609",
      "r637",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credits/(credits)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r565",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts recorded in our consolidated balance sheet:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r129",
      "r131",
      "r612"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax",
        "negatedTotalLabel": "Other comprehensive income (loss), benefit plans, prior service (costs)/credits, before tax, total"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax [Abstract]",
        "terseLabel": "Pre-tax components of cumulative amounts recognized in Accumulated other comprehensive loss:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r59",
      "r565",
      "r566",
      "r590",
      "r642",
      "r983",
      "r1018"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate: Pension plans/postretirement plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r617",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation, ending",
        "periodStartLabel": "Benefit obligation, beginning"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r576",
      "r648"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "auth_ref": [
      "r573"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "terseLabel": "Employee contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r620",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r584",
      "r593",
      "r595",
      "r640",
      "r642",
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "terseLabel": "Special termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDebtSecurityMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporation, government and governmental agency, municipality, and other institution; in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Debt Security [Member]",
        "terseLabel": "Fixed income securities [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDebtSecurityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanDivestituresBenefitObligation": {
     "auth_ref": [
      "r579"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale.",
        "label": "Defined Benefit Plan, Benefit Obligation, Divestiture",
        "negatedTerseLabel": "Upjohn spin-off"
       }
      }
     },
     "localname": "DefinedBenefitPlanDivestituresBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDivestituresPlanAssets": {
     "auth_ref": [
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale.",
        "label": "Defined Benefit Plan, Plan Assets, Divestiture",
        "negatedTerseLabel": "Upjohn spin-off"
       }
      }
     },
     "localname": "DefinedBenefitPlanDivestituresPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r593",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Equity securities [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Employer Contributions [Abstract]",
        "terseLabel": "Expected benefit payments:"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2027\u20132031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r603",
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected contributions in 2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r567",
      "r607",
      "r635",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r581",
      "r593",
      "r595",
      "r596",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value, ending",
        "periodStartLabel": "Fair value, beginning",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r565",
      "r590",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "terseLabel": "Funded status\u2014Plan assets less than benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Healthcare cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r567",
      "r572",
      "r606",
      "r634",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r604",
      "r632",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 4.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit costs recorded in Other (income)/deductions\u2013\u2013net",
        "totalLabel": "Net periodic benefit cost/(credit) reported in income"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "auth_ref": [
      "r628",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": {
     "auth_ref": [
      "r628",
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "PBO"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Pension plans with an ABO in excess of plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r628",
      "r629",
      "r642"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "ABO"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r628",
      "r629",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Plan amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r586",
      "r648"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Employee contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Exchange rate changes",
        "verboseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r592",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Equity and debt securities, target allocation percentage"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Pension plans with a PBO in excess of plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": {
     "auth_ref": [
      "r598",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement",
        "terseLabel": "Purchases, sales, and settlements, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r568",
      "r611",
      "r639"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r570",
      "r605",
      "r633",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r589"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": {
     "auth_ref": [
      "r599",
      "r642"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3",
        "terseLabel": "Transfer into/(out\u00a0of) Level 3"
       }
      }
     },
     "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Weighted-average assumptions used to determine benefit obligations at fiscal year-end:"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit cost:"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r649"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, cost recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r189",
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r115",
      "r116",
      "r119",
      "r882"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "verboseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Current derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Noncurrent derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r824"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r119",
      "r823",
      "r826",
      "r835",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r820",
      "r823",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r820",
      "r823",
      "r835",
      "r843",
      "r844",
      "r853",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r834",
      "r836"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r115",
      "r116",
      "r119",
      "r882"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total liabilities",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Current derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Noncurrent derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": {
     "auth_ref": [
      "r848"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.",
        "label": "Derivative, Net Liability Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net liability position"
       }
      }
     },
     "localname": "DerivativeNetLiabilityPositionAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r815",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "terseLabel": "Remaining period of hedging exposure"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r814",
      "r816",
      "r817",
      "r820",
      "r821",
      "r828",
      "r835",
      "r850",
      "r852",
      "r856",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r814",
      "r816",
      "r820",
      "r821",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativesReportingOfDerivativeActivity": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.",
        "label": "Derivatives, Reporting of Derivative Activity [Policy Text Block]",
        "terseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "DerivativesReportingOfDerivativeActivity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "EPS Numerator\u2013\u2013Diluted"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r666",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation Awards and Valuation Details"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r13",
      "r15",
      "r19"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax",
        "terseLabel": "Pre-tax loss on sale of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r13",
      "r15",
      "r19",
      "r34"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "negatedTerseLabel": "Loss on sale of discontinued operations\u2013\u2013net of tax",
        "totalLabel": "Loss on sale of discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": {
     "auth_ref": [
      "r13",
      "r14",
      "r28"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax",
        "totalLabel": "Pre-tax income/(loss) from discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": {
     "auth_ref": [
      "r13",
      "r14",
      "r34"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax",
        "totalLabel": "Income/(loss) from discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Discontinued Operation, Period of Continuing Involvement after Disposal",
        "terseLabel": "Period of continuing involvement after disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": {
     "auth_ref": [
      "r14",
      "r34",
      "r764"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period",
        "terseLabel": "Provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "auth_ref": [
      "r15",
      "r19",
      "r34",
      "r764"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "terseLabel": "Benefit for taxes on income"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of in a spinoff and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale [Member]"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r422",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale, Not Discontinued Operations [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r33",
      "r420",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Held-for-sale, Not Discontinued Operations [Member]"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r33",
      "r37",
      "r419",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "totalLabel": "Noncurrent assets of discontinued operations\u2013\u2013Other noncurrent assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Cash received for disposition"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r29",
      "r37"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r419",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r17",
      "r18",
      "r29",
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Other (income)/deductions\u2013\u2013net",
        "verboseLabel": "Separation-related costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r419",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r419",
      "r429"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r29",
      "r37"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Income Statement Disclosures"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r651",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]",
        "verboseLabel": "Disposal Groups, Including Discontinued Operations, Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends [Abstract]",
        "terseLabel": "Cash dividends declared:"
       }
      }
     },
     "localname": "DividendsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r46",
      "r100"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r535",
      "r1013"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedLabel": "Preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r650",
      "r654",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r160",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r233",
      "r236",
      "r245",
      "r246",
      "r247",
      "r251",
      "r252",
      "r868",
      "r869",
      "r1003",
      "r1037"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013basic:",
        "verboseLabel": "EPS Numerator-Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r160",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r236",
      "r245",
      "r246",
      "r247",
      "r251",
      "r252",
      "r868",
      "r869",
      "r1003",
      "r1037"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013diluted:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r898"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r726"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate for income from continuing operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r205",
      "r726",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r726",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "terseLabel": "Completion of Consumer Healthcare JV transaction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r726",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Taxation of non-U.S. operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r726",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "All other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r726",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "U.S. R&amp;D tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r726"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "terseLabel": "TCJA impact"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r726",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Tax settlements and resolution of certain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related items"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost related to nonvested awards not yet recognized, pre-tax"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period over which cost is expected to be recognized (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost related to nonvested awards not yet recognized, pre-tax"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r695"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit for share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r698"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefits realized from exercise"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Termination Costs [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "auth_ref": [
      "r710"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of plan compensation cost recognized during the period.",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "terseLabel": "ESOP compensation expense"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails",
      "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r145",
      "r146",
      "r147",
      "r213",
      "r214",
      "r215",
      "r218",
      "r228",
      "r231",
      "r257",
      "r375",
      "r530",
      "r535",
      "r703",
      "r704",
      "r705",
      "r752",
      "r753",
      "r867",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r908",
      "r1050",
      "r1051",
      "r1052",
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Difference between carrying amount and underlying equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r153",
      "r183",
      "r189",
      "r1029"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Dividend received"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r37",
      "r202",
      "r369",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r37",
      "r202",
      "r369",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Summarized Financial Information [Abstract]",
        "terseLabel": "Equity Method Investment, Summarized Financial Information [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Underlying equity in net assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r88",
      "r289",
      "r363"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity-method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Summarized Financial Information of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r880"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r880"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities with readily determinable fair values",
        "verboseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Net (gains)/losses recognized during the period on equity securities",
        "negatedTotalLabel": "Net (gains)/losses recognized during the period on investments in equity securities",
        "terseLabel": "Net (gains)/losses recognized during the period on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r361",
      "r1039"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Less: Net (gains)/losses recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r361",
      "r1039"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date",
        "terseLabel": "Unrealized gain on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative upward price adjustments on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsandLossesRelatedtoEquitySecuritiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r495",
      "r508",
      "r509",
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r871",
      "r872",
      "r873",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r495",
      "r508",
      "r509",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r642",
      "r872",
      "r945",
      "r946",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Defined Benefit Plan, Fair Value of Plan Assets by Measurement [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r495",
      "r508",
      "r509",
      "r871",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r871",
      "r872",
      "r874",
      "r875",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r495",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r495",
      "r593",
      "r595",
      "r600",
      "r642",
      "r872",
      "r945"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r495",
      "r508",
      "r509",
      "r593",
      "r595",
      "r600",
      "r642",
      "r872",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r495",
      "r508",
      "r509",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r642",
      "r872",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": {
     "auth_ref": [
      "r595",
      "r870",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Measured at Net Asset Value Per Share [Member]",
        "terseLabel": "Assets Measured at NAV [Member]"
       }
      }
     },
     "localname": "FairValueMeasuredAtNetAssetValuePerShareMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r495",
      "r508",
      "r509",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r642",
      "r945",
      "r946",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value Plan Asset Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r876",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r349",
      "r353",
      "r358",
      "r359",
      "r360",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r385",
      "r386",
      "r387",
      "r388",
      "r503",
      "r528",
      "r858",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r403",
      "r407",
      "r411",
      "r415",
      "r976",
      "r980"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r411",
      "r980"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r403",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r411",
      "r976"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-lived intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Finite-lived intangible assets period increase (decrease)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeSecuritiesMember": {
     "auth_ref": [
      "r593",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.",
        "label": "Fixed Income Securities [Member]",
        "terseLabel": "Fixed Income Commingled Funds [Member]"
       }
      }
     },
     "localname": "FixedIncomeSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r857"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "negatedTerseLabel": "Amount of pre-tax loss to be reclassified"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r909"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r119",
      "r593",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contracts [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r593",
      "r1061"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Government and agency debt - non-U.S. [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total international tax provision"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r650",
      "r654",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures and other [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Net (gains)/losses on asset disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r456"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Loss on litigation settlement",
        "negatedTerseLabel": "Certain legal matters, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r189",
      "r512",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early retirement of debt",
        "terseLabel": "Net losses on early retirement of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r268",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk [Member]"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r393",
      "r394",
      "r941",
      "r982"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r397",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r161",
      "r202",
      "r288",
      "r300",
      "r304",
      "r307",
      "r310",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r886"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r847"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r845"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Hedged Assets Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r846"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r820",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r326",
      "r343",
      "r378",
      "r381"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Held-to-maturity securities, amortized cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r345",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity securities, gross unrealized gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r346",
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedTerseLabel": "Held-to-maturity securities, gross unrealized losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r335",
      "r343",
      "r378"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r348",
      "r355",
      "r1009",
      "r1011"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r347",
      "r354",
      "r1008",
      "r1010"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Held-to-maturity securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r344",
      "r350",
      "r991"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Held-to-maturity securities, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r335",
      "r343",
      "r378"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r349",
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity [Table Text Block]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r189",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairments"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r162",
      "r190",
      "r222",
      "r223",
      "r225",
      "r226",
      "r243",
      "r247",
      "r795"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r204",
      "r759"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r152",
      "r288",
      "r300",
      "r304",
      "r307",
      "r310",
      "r981",
      "r996",
      "r1006",
      "r1040"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income from continuing operations before provision/(benefit) for taxes on income",
        "totalLabel": "Income from continuing operations before provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails",
      "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r204",
      "r759"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersIncomefromContinuingOperationsBeforeProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r202",
      "r217",
      "r288",
      "r300",
      "r304",
      "r307",
      "r310",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r796",
      "r869",
      "r886"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations",
        "verboseLabel": "Net income from continuing operations before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r149",
      "r160",
      "r217",
      "r222",
      "r223",
      "r225",
      "r226",
      "r236",
      "r245",
      "r246",
      "r869",
      "r994",
      "r997",
      "r1003",
      "r1030"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r149",
      "r160",
      "r217",
      "r222",
      "r223",
      "r225",
      "r226",
      "r236",
      "r245",
      "r246",
      "r247",
      "r869",
      "r1003",
      "r1030",
      "r1033",
      "r1037"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r16",
      "r19",
      "r34",
      "r37",
      "r766",
      "r1031"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax",
        "totalLabel": "Discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r16",
      "r19",
      "r28",
      "r34",
      "r796"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r154",
      "r160",
      "r237",
      "r245",
      "r246",
      "r1003",
      "r1031",
      "r1033",
      "r1037"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r237",
      "r245",
      "r246",
      "r813"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r153",
      "r189",
      "r285",
      "r363",
      "r995",
      "r1029"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Equity method investment earnings"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r651",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r6",
      "r21",
      "r22",
      "r23",
      "r24",
      "r26",
      "r27",
      "r32",
      "r35",
      "r36",
      "r37",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r428",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r730",
      "r735",
      "r737",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r727",
      "r736",
      "r743",
      "r754",
      "r761",
      "r767",
      "r768",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Tax Matters"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "verboseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r206",
      "r230",
      "r231",
      "r286",
      "r725",
      "r755",
      "r763",
      "r1041"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision/(benefit) for taxes on income",
        "totalLabel": "Provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r721",
      "r722",
      "r736",
      "r737",
      "r742",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Tax Assets and Liabilities and Income Tax Contingencies"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "auth_ref": [
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "negatedTerseLabel": "Tax benefit from IRS settlement"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "terseLabel": "Other tax accounts, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r405",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Total indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r405",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r401",
      "r409"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable Intangible Assets, less Accumulated Amortization",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r911"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest costs capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r150",
      "r282",
      "r910",
      "r914",
      "r1004"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r181",
      "r186",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r119",
      "r593",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate contracts [Member]"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).",
        "label": "Interest Revenue (Expense), Net",
        "negatedTotalLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestRevenueExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r79",
      "r391"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r40",
      "r110",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Noncurrent inventories not included above"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r111",
      "r197",
      "r256",
      "r389",
      "r390",
      "r392",
      "r974"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Cost of Sales and Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r81",
      "r82",
      "r391"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r80",
      "r391"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r167",
      "r281"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r366",
      "r1038"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale and Held-to-maturity Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r932",
      "r934"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs and Other Supplemental Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "4-5 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "3-4 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2-3 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "1-2 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "Next one year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r933"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r99",
      "r202",
      "r302",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r800",
      "r808",
      "r809",
      "r886",
      "r939",
      "r940"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r77",
      "r202",
      "r369",
      "r886",
      "r941",
      "r990",
      "r1024"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r101",
      "r202",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r800",
      "r808",
      "r809",
      "r886",
      "r939",
      "r940",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r63",
      "r64",
      "r202",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r800",
      "r808",
      "r809",
      "r886",
      "r939",
      "r940"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r33",
      "r37",
      "r423",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations\u2013\u2013Other current liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r31",
      "r33",
      "r37",
      "r419",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities of discontinued operations\u2013\u2013Other noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method.",
        "label": "Life Settlement Contracts, Fair Value",
        "terseLabel": "Insurance contracts"
       }
      }
     },
     "localname": "LifeSettlementContractsFairValueMethodCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Long-lived Assets by Geographic Areas"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r63",
      "r494",
      "r506",
      "r508",
      "r509",
      "r988",
      "r1020"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Current portion of long-term debt, carried at historical proceeds, as adjusted (not included above (1.0% for 2021 and 2.6% for 2020))"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "verboseLabel": "Long-term debt, excluding the current portion"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsforFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt, carried at historical proceeds, as adjusted"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "totalLabel": "Total long-term investments and equity-method investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Investments [Abstract]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Amount",
        "terseLabel": "Long-term purchase commitment, amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsCertainCommitmentsandContingentConsiderationforAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r103",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Reconciling Items [Member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r109",
      "r202",
      "r369",
      "r471",
      "r476",
      "r477",
      "r478",
      "r484",
      "r485",
      "r886",
      "r989",
      "r1023"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Equity attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by/(used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by/(used in) financing activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash provided by/(used in) investing activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r184",
      "r187",
      "r190"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r184",
      "r187",
      "r190"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r37",
      "r138",
      "r141",
      "r147",
      "r155",
      "r190",
      "r202",
      "r217",
      "r222",
      "r223",
      "r225",
      "r226",
      "r230",
      "r231",
      "r243",
      "r288",
      "r300",
      "r304",
      "r307",
      "r310",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r869",
      "r886",
      "r998",
      "r1032"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Income attributable to shareholders",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders",
        "verboseLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r138",
      "r141",
      "r147",
      "r230",
      "r231",
      "r803",
      "r811"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r222",
      "r223",
      "r225",
      "r226",
      "r233",
      "r234",
      "r244",
      "r247",
      "r288",
      "r300",
      "r304",
      "r307",
      "r310"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r235",
      "r238",
      "r239",
      "r240",
      "r241",
      "r244",
      "r247"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic benefit costs/(credits) other than service costs"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r225",
      "r232",
      "r251",
      "r331",
      "r332",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r470",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r750",
      "r751",
      "r752",
      "r753",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r937",
      "r977",
      "r978",
      "r979",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standards Adopted in 2021"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r535",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NontradeReceivablesCurrent": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of amounts currently receivable other than from customers. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Nontrade Receivables, Current",
        "terseLabel": "Nontrade receivables"
       }
      }
     },
     "localname": "NontradeReceivablesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r924",
      "r934"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r918"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r918"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities (short-term)",
        "verboseLabel": "Less: Current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail",
      "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Lease liabilities (short-term), statement of financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r918"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities (long-term)",
        "verboseLabel": "Noncurrent portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofFutureMinimumRentalPaymentsforOperatingLeasesDetail",
      "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Lease liabilities (long-term), statement of financial position"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r920",
      "r928"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r917"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "ROU assets, statement of financial position"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r931",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-Average Discount Rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r930",
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-Average Remaining Contractual Lease Term (Years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAggregatedInvestmentsMember": {
     "auth_ref": [
      "r1063",
      "r1064",
      "r1065"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.",
        "label": "Other Security Investments [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherAggregatedInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r113",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets",
        "totalLabel": "Total other noncurrent assets",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r129",
      "r131",
      "r612"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedLabel": "Benefit plans: prior service (costs)/credits and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r120",
      "r131",
      "r895",
      "r896",
      "r900"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r137",
      "r612"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r137",
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax",
        "negatedTerseLabel": "Derecognition of prior service credits associated with benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax",
        "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r124",
      "r125",
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r124",
      "r125",
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r145",
      "r146",
      "r156",
      "r364",
      "r901",
      "r906",
      "r908",
      "r999",
      "r1033"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income/(loss), before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r122",
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r122",
      "r131",
      "r825",
      "r830",
      "r854"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net",
        "verboseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r832"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Reclassification adjustments for (gains)/losses included in net income",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS",
        "verboseLabel": "Gain (loss) reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "negatedLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": {
     "auth_ref": [
      "r123",
      "r131",
      "r135",
      "r833"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax",
        "terseLabel": "Amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r123",
      "r131",
      "r831",
      "r839",
      "r854"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Amount excluded from effectiveness testing and amortized into earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r120",
      "r131"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r136",
      "r137",
      "r899"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax",
        "negatedTerseLabel": "Reclassification adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r136",
      "r137",
      "r899"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax",
        "terseLabel": "Derecognition of net gains on foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r120",
      "r132",
      "r897",
      "r907"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r837"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r838"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r139",
      "r142",
      "r145",
      "r146",
      "r148",
      "r156",
      "r530",
      "r901",
      "r906",
      "r908",
      "r999",
      "r1033"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other\u00a0comprehensive income/(loss), net of tax",
        "totalLabel": "Other\u00a0comprehensive income/(loss), net of tax",
        "verboseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r128",
      "r131",
      "r612",
      "r642"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "terseLabel": "Cost/(credit) reported in Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": {
     "auth_ref": [
      "r132",
      "r796"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax",
        "negatedTotalLabel": "Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r127",
      "r131",
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Benefit plans: actuarial gains/(losses), net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r137",
      "r357"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r132",
      "r357"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r131",
      "r135",
      "r137",
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r132",
      "r145",
      "r156",
      "r725",
      "r762",
      "r765",
      "r901",
      "r904",
      "r908",
      "r999",
      "r1033"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision/(benefit) on other comprehensive income/(loss)",
        "totalLabel": "Tax provision/(benefit) on other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r124",
      "r131",
      "r357"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r125",
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesonItemsofOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r822",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities [Member]",
        "verboseLabel": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r562",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r45",
      "r100",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r63",
      "r988",
      "r1020"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-term Debt",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r88",
      "r1027"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term investments"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities [Member]",
        "verboseLabel": "Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesAccruedRebatesandOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r169"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/deductions\u2013\u2013net",
        "negatedTotalLabel": "Other (income)/deductions\u2013\u2013net",
        "terseLabel": "Other income/(deductions)\u2014net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r564",
      "r565",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r617",
      "r618",
      "r620",
      "r623",
      "r627",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefits Plan [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r65",
      "r565",
      "r566",
      "r590"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent",
        "terseLabel": "Postretirement benefit obligations"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r436",
      "r437",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Exit Costs [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-term Borrowings",
        "terseLabel": "Other short-term borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r113",
      "r993",
      "r1028"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Total Short-term investments"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Shareholders\u2019 Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r171",
      "r174"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r172",
      "r784"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Payments to acquire businesses, cash portion"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisitions of businesses, net of cash acquired",
        "terseLabel": "Cash payments for acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r173",
      "r788",
      "r789",
      "r790"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire asset"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsPatentLitigationDetails",
      "http://www.pfizer.com/role/ContingenciesandCertainCommitmentsProductLitigationCommercialandOtherMattersResolvedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r592",
      "r594",
      "r600",
      "r619",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r642",
      "r644",
      "r647",
      "r649",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans and Defined Contribution Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r62",
      "r565",
      "r566",
      "r590",
      "r642"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r65",
      "r565",
      "r566",
      "r590",
      "r642"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r626",
      "r645",
      "r646",
      "r649",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r563",
      "r565",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r617",
      "r618",
      "r620",
      "r623",
      "r627",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r649",
      "r650",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Awards [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r620",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r666",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsandLiabilitiesNotMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Less: Preferred stock dividends\u2013\u2013net of tax"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "verboseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r69",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r69",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds received from upfront payments and milestone payments"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r177",
      "r180"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "auth_ref": [
      "r176",
      "r179",
      "r192"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.",
        "label": "Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less",
        "terseLabel": "Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale, Maturity and Collection of Long-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of long-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r175",
      "r698"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received upon exercise"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r37",
      "r138",
      "r141",
      "r147",
      "r182",
      "r202",
      "r217",
      "r230",
      "r231",
      "r288",
      "r300",
      "r304",
      "r307",
      "r310",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r796",
      "r802",
      "r804",
      "r811",
      "r812",
      "r869",
      "r886",
      "r1006"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income before allocation to noncontrolling interests",
        "totalLabel": "Net income before allocation to noncontrolling interests",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r91",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment by Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r433",
      "r1074",
      "r1075",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Plant and Equipment (PP&amp;E)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r90",
      "r424"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment before accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment, Impairment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r55",
      "r56",
      "r426",
      "r941",
      "r1012",
      "r1025"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment",
        "totalLabel": "Property, plant and equipment",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r426",
      "r1074",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r55",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r55",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives (years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r324",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Principal payments on short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Charge to research and development expenses in connection with asset acquisition"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r716"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "negatedTerseLabel": "Research and development expenses",
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r435",
      "r437",
      "r440",
      "r450",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r436",
      "r439",
      "r447",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring cost incurred to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r436",
      "r439",
      "r447",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r436",
      "r439",
      "r447",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring costs (income)"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r189",
      "r434",
      "r443",
      "r447"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charge (credit)",
        "totalLabel": "Total restructuring charges/(credits)",
        "verboseLabel": "Provision"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring charges:"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r436",
      "r437",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r437",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r73",
      "r535",
      "r706",
      "r941",
      "r1022",
      "r1054",
      "r1059"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Decrease to retained earnings",
        "negatedTerseLabel": "Reduction in retained earnings",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails",
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesSummaryofChangeinAccountingPrincipleDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r213",
      "r214",
      "r215",
      "r218",
      "r228",
      "r231",
      "r375",
      "r703",
      "r704",
      "r705",
      "r752",
      "r753",
      "r867",
      "r1050",
      "r1052"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r623",
      "r628",
      "r629",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r650",
      "r654",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r620",
      "r623",
      "r628",
      "r629",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r650",
      "r654",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r617",
      "r618",
      "r620",
      "r623",
      "r627",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r615",
      "r617",
      "r618",
      "r620",
      "r623",
      "r627",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r658",
      "r659",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r279",
      "r280",
      "r299",
      "r305",
      "r306",
      "r313",
      "r314",
      "r319",
      "r555",
      "r556",
      "r975"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r269",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationSchedulesofConcentrationofRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues and Collaborative Arrangements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, period of recognition"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r151",
      "r202",
      "r279",
      "r280",
      "r299",
      "r305",
      "r306",
      "r313",
      "r314",
      "r319",
      "r369",
      "r471",
      "r472",
      "r473",
      "r476",
      "r477",
      "r478",
      "r480",
      "r482",
      "r484",
      "r485",
      "r886",
      "r1006"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r929",
      "r934"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "negatedLabel": "Royalty-related income"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "auth_ref": [
      "r927",
      "r934",
      "r936"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "negatedTerseLabel": "(Gains)/losses on sale and leaseback transactions, net"
       }
      }
     },
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales [Member]"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueofDerivativeFinancialInstrumentsandRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue [Member]"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Information About Balance Sheet Classification of Accruals"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r628",
      "r629",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r134",
      "r906",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.",
        "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r628",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Taxes on Income"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r103",
      "r211",
      "r508",
      "r510",
      "r531",
      "r532",
      "r533",
      "r534",
      "r912",
      "r913",
      "r916",
      "r1014"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r626",
      "r627",
      "r630",
      "r631",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansAnalysisofChangesinSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansObligationsandFundedStatusDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansScheduleofNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative assets at fair value.",
        "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Assets at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r823",
      "r835",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r814",
      "r816",
      "r817",
      "r820",
      "r821",
      "r828",
      "r835",
      "r850",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r6",
      "r21",
      "r22",
      "r23",
      "r24",
      "r26",
      "r27",
      "r32",
      "r35",
      "r36",
      "r37",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summarized Financial Information of Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.",
        "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Significant Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r37",
      "r202",
      "r368",
      "r369",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsEquityMethodInvestmentDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Expected Future Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r871",
      "r872"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r403",
      "r410",
      "r976"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r403",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r397",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Schedule of Health Care Cost Trend Rates"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r47",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [
      "r47",
      "r83",
      "r84",
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Component of Inventories, Noncurrent"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherFinancialInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.",
        "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r221",
      "r225",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]",
        "terseLabel": "Summary of Change in Accounting Principle"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r91",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPEComponentsofPropertyPlantandEquipmentDetails",
      "http://www.pfizer.com/role/PropertyPlantandEquipmentPPELonglivedAssetsbyGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r436",
      "r437",
      "r438",
      "r439",
      "r447",
      "r448",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r441",
      "r442",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r437",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r151",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r288",
      "r291",
      "r303",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r288",
      "r291",
      "r303",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r679",
      "r684",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Arrangement Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r666",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r671",
      "r684",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Borrowings"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Summary of Common Stock Purchases"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r735",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Expected Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r265",
      "r269",
      "r270",
      "r271",
      "r883",
      "r885"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedules of Concentration of Risk"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesReceivedAsCollateral": {
     "auth_ref": [
      "r956"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.",
        "label": "Securities Received as Collateral",
        "terseLabel": "Cash collateral received"
       }
      }
     },
     "localname": "SecuritiesReceivedAsCollateral",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations [Member]"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofDiscontinuedOperationsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r275",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r319",
      "r439",
      "r449",
      "r1042"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r277",
      "r278",
      "r288",
      "r292",
      "r304",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, Geographic and Other Revenue Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "Selling, informational and administrative expenses",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, Informational and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, Informational and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee terminations"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r188"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period",
        "verboseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "terseLabel": "Forfeited, weighted-average intrinsic value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Granted, weighted-average intrinsic value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, weighted-average grant-date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "periodEndLabel": "Nonvested, end of period, weighted-average intrinsic value per share (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning of period, weighted-average intrinsic value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, end of period, shares",
        "periodStartLabel": "Nonvested, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Avg. GDFV per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Units outstanding, weighted average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Vested, weighted-average intrinsic value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested, weighted-average grant-date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "terseLabel": "Units exercised, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Deferred compensation arrangement, shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r672",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Units outstanding, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value on exercise"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r673",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period, shares",
        "periodStartLabel": "Outstanding, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares (Thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r689"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Exercisable, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable, end of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, end of period, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, end of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r663",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedPaymentArrangementActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r666",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails",
      "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails",
      "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Units outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Units vested, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofTSRUandPTUInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationAwardsandValuationDetailsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r690",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual term/expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Total fair value of shares vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsSummaryofDataRelatedtoSharebasedPaymentArrangementActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Commercial paper, weighted average interest rate"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Investments [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsShorttermLongtermandEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r20",
      "r275",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r319",
      "r397",
      "r430",
      "r439",
      "r449",
      "r1042"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationRevenuesByProductsDetail",
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r199",
      "r202",
      "r236",
      "r237",
      "r242",
      "r245",
      "r247",
      "r258",
      "r259",
      "r260",
      "r369",
      "r471",
      "r476",
      "r477",
      "r478",
      "r484",
      "r485",
      "r514",
      "r515",
      "r519",
      "r523",
      "r530",
      "r886",
      "r1096"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r108",
      "r145",
      "r146",
      "r147",
      "r213",
      "r214",
      "r215",
      "r218",
      "r228",
      "r231",
      "r257",
      "r375",
      "r530",
      "r535",
      "r703",
      "r704",
      "r705",
      "r752",
      "r753",
      "r867",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r908",
      "r1050",
      "r1051",
      "r1052",
      "r1109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r257",
      "r975"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r107",
      "r497",
      "r530",
      "r531",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Shares issued upon conversion of convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r69",
      "r70",
      "r530",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r70",
      "r530",
      "r535",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsScheduleofSharebasedCompensationStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r69",
      "r70",
      "r535",
      "r665",
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Amount of shares authorized in stock purchase plan, value"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount of remaining shares authorized in stock purchase plan, value"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r70",
      "r75",
      "r76",
      "r202",
      "r327",
      "r369",
      "r886",
      "r941"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "terseLabel": "Total net equity/(deficit) attributable to shareholders",
        "totalLabel": "Total Pfizer Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r146",
      "r202",
      "r213",
      "r214",
      "r215",
      "r218",
      "r228",
      "r369",
      "r375",
      "r535",
      "r703",
      "r704",
      "r705",
      "r752",
      "r753",
      "r793",
      "r794",
      "r810",
      "r867",
      "r886",
      "r901",
      "r902",
      "r908",
      "r1051",
      "r1052",
      "r1109"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsSummarizedFinancialInformationofEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r529",
      "r535",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "terseLabel": "Distribution of Upjohn business",
        "verboseLabel": "Distribution of Upjohn Business"
       }
      }
     },
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r926",
      "r934"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Axis]",
        "terseLabel": "Subsegments Consolidation Items [Axis]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsegments, eliminations and reconciling items used in consolidating a reportable segment and its subsegments.",
        "label": "Subsegments Consolidation Items [Domain]",
        "terseLabel": "Subsegments Consolidation Items [Domain]"
       }
      }
     },
     "localname": "SubsegmentsConsolidationItemsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicandOtherRevenueInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid/(received) during the period for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r748"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit)",
        "terseLabel": "TCJA impact",
        "totalLabel": "Total TCJA tax benefit"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.pfizer.com/role/TaxMattersProvisionforTaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r770"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Repatriation tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Brands [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsandGoodwillFinitelivedandIndefinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r349",
      "r353",
      "r358",
      "r359",
      "r360",
      "r503",
      "r528",
      "r858",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r106",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r106",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r70",
      "r530",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of common stock (in shares)",
        "terseLabel": "Shares repurchased",
        "verboseLabel": "Shares of common stock purchased"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity",
      "http://www.pfizer.com/role/EquityNarrativeDetails",
      "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r106",
      "r537",
      "r540"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, shares at cost: 2021\u20143,851; 2020\u20143,840"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r530",
      "r535",
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Purchases of common stock",
        "terseLabel": "Cost of purchase"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofEquity",
      "http://www.pfizer.com/role/EquitySummaryofCommonStockPurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsScheduleofCollaborativeArrangementsandNoncollaborativeArrangementTransactionsDetails",
      "http://www.pfizer.com/role/OtherFinancialInformationOtherCurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetScheduleofOtherNonoperatingIncomeExpenseFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r436",
      "r437",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesandOtherCostsAssociatedwithAcquisitionsandCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r207",
      "r593",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government and agency - U.S. [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r207",
      "r593",
      "r642",
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "Government and Agency Obligations [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionandPostretirementBenefitPlansandDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r719",
      "r769",
      "r1015",
      "r1060"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Unremitted earnings of international subsidiaries"
       }
      }
     },
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r720",
      "r731"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "negatedPeriodEndLabel": "Balance, ending",
        "negatedPeriodStartLabel": "Balance, beginning",
        "verboseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r732"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Decreases based on tax positions taken during a prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r734"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Decreases based on settlements for a prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r733"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "negatedLabel": "Increases based on tax positions taken during the current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r732"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "negatedLabel": "Increases based on tax positions taken during a prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r728"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r728"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Increase (decrease) of interest on income taxes expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsLicensingArrangementsandCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsandHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r925",
      "r934"
     ],
     "calculation": {
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/LeasesNarrativeDetails",
      "http://www.pfizer.com/role/LeasesScheduleofLeaseCostsandOtherSupplementalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r247"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common-share equivalents: stock options, stock issuable under employee compensation plans convertible preferred stock and accelerated share repurchase agreements (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r235",
      "r247"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares\u2013\u2013diluted",
        "totalLabel": "Weighted-average number of common shares outstanding\u2013\u2013Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "EPS Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r233",
      "r247"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares outstanding\u2013\u2013Basic",
        "verboseLabel": "Weighted-average shares\u2013\u2013basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsofIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributabletoPfizerIncCommonShareholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r1074": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r1075": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r1076": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r1077": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1078": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1079": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1080": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1081": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1082": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1083": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1084": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1085": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r1086": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r1087": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r1088": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1089": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1090": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1091": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1092": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r1093": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r1094": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r1095": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1096": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r1097": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r1098": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r1099": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r1100": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r1101": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r1102": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r1103": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r1104": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r1105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r1106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r1107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r1108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r1109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e709-108580"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3098-108585"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e725-108305"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e765-108305"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269825-111563"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269825-111563"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269825-111563"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "325",
   "URI": "http://asc.fasb.org/extlink&oid=73718008&loc=d3e42732-111610"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "60",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28200-109314"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=122636397&loc=SL7495116-110257"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=116633155&loc=d3e31531-110899"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123417830&loc=SL77919786-209982"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>162
<FILENAME>0000078003-22-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-22-000027-xbrl.zip
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M:LMA^^;0/6N6#QH;@@/P!:@F<;FR=A0+VVS6A%@.0IQ]@1"!?<I54\^G(H1
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M-,GQ.+^]_WXPO??SY2$/QX>'X]'LC?/S_//'+Y[^PZ/[<!>= -.C5S%&ST[
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M03#D[$ >&9(.7JQ26U7U):^.%6J9'_+%)^/A<#8'[9@E?NT,2JQ5$H>N-3P
M+Z;)!5L0:B2O:P[F[E!:F/;0L;:2?(DN"GAE*93$UN3FTGK(9@'K1YVWS M9
MW;J":D06LVV**9XA*!>!!.>:/%2V.<#JH7I;QF'Q6!I@Z\5)-B*=T ;7L3'.
M 5H=(GC+JX?E79F4Q6.;7%"^53M)< K:,VGG1$(3>)T-%[UZV"[$[UX\T.R)
MHS@45NLVW4DGIXO$NVWLK24;[.H!?6?9+HL!U"O0P)C0>@0T*KGD0[:QB,4E
M*BNHE>]L57#QX%+KB>>X0(@96DYZ"+ID;XKSFLBNH+3>\EKB$D :8P'42$6<
MX%Q5M&A*"9&2K:*%5]#2WO;VU^(Q-9'$-XXVB-\$)F(,Q1$&$5!=8J!9/^4U
ME-^VLA#GMK)0:C0.DR9G&'0-2:,APTE[RB7%O#+HW-5.YARA<3K7&BK99, I
M$RUEHQT$;T.-RJP,-(O8R9P?3"Y:30AM"BQ"2"F!5:HM*K=\E1KTRL!T=SN9
M\P.GEBCN(03=%HRU>/X)M4B5R;D4Q2ZM##AWNI,Y/WP@:R?BHGV;K" GCJ+J
M@A+4HM,V![<R^"QZ)W-^D%FR6?Y7?4T,SGL45P$=.<H@P9>FE8'L#G8RYX=*
M*MFZR"));<5#50F87"[9U1S0\GGG^)5 90$[F?-#28.:M;<M 0(XFTB4GRM)
M^1)<U;'>'4J+>@*JA$3L;)NM Q%RI(P<0DS94*@:%U!!T'G+O/CZ!E6)VV#J
M;)2%%'QR5>R"\9A!94UI]5"]BYW,Q6 I :=$,JF*BM)0L(C''(+Q JH*U1.M
M'I:+V,E<$+:I]7^PS24@H)0C5XOB+BACB"R5U<-VX3N9BP&Z: HA*(OB;8#"
MC.*;H\FQ)$?:Q14TLW=7M[\00"U[E7(P#(G 6)>JN(\0*"?.(>2X>H N9"=S
M,> B@5)HD\XN Q:15"=P2W2=,#E_T91AI<"]PYW,!2G@")%420%B@!)U%(,K
M?Y(M23MBOWJ0WN5.YF(P3=Y;4VJ%B+.L$BK<]F>JPQRT=GAW5:D=A_)6*F9S
M#>A3RH)-;,._8PJYD-6F599I9U8&G3O:R9PC-!(XYM8:4/S0##EP+,H&\5],
MS:0ET%P9:!:PDSE'F$)+1M<&? @$HMD$'RRH@L_:4#ZOAED)F.YL)W..X)!#
MZT2KD8\%@LZI6D_B7A0E(8"GU3$^=[F3.4_S0U%TF2*3;0776C9X[] 4IY5)
M!E='>!:\DSE'R%"A2FB G$6H&-%8D\@XT$%3 +TRD-W^3N8<44E<"K)+17PX
M""1^G#&&4\)6E4G.KPPJ=[^3.4]SE+(2+XY4S6*.O$D5B'7TF!R14U\<2-UM
MN.YX'V\A_0>CIE1:1:+3"%2LA+A4J@T9P50%M'JHWLD^WF):@WI(2D*M*)'6
MS&&,,1?6+H$K.92X>E@N9!]O(=B"BAHDAE823X,R06RF2*Z)E*(/A;\X%;3;
MV"Y^'V\Q0DQ)118S&SF"P(FE5%]#SII5+6H1/<MO&>@5[[^=(& NF5VT"FP"
M\M5RX:IU8C"YD_VWEV1-;/'@1IM5; /G58V@@HFQM>LT;$0S5PE95@_<N]S'
M6TR_?+&Q.FDK :B'UJTWU80:3:S@0D[I[GJQWK8C?'=[/O/K$ULK4VN*6XT&
MP&Q(PI2D,&8C/E&I>F70N:L]G_E!D\B#:W"D;$ ETT9$V5DO0<94@5<&FD7L
M^<Q1@@@UL466OR'Z$B5LM A0JDH(SJT,3'>WYS,_<(ABHJQRIF*@:"17C%6^
M)IN:_X\K \Z=[OG,4<=Y<>N\]K$Z$1E?4?G623"Q5F0CQY7!9]%[/O.#S!9/
M)-%65#I!RDS5BC]NE8G9DU)E92"[@SV?^:&B8Z&HVR#X1*"\3]46(Z%3T<PI
M7IDHV6U4%K#G,S^4V*L@L&CM4QL')UB)=0)$\*9(;+3$-8;3R?%/K^2*Y63(
M6_4<HCX?[X_%7WLG 'P$[M-7F3?ID#^.H'KRZG\?CD?3-C'DWTS#X_TL,K:\
ME8<?)JF,3MJ]_,DDH"/Y\?($UYX#E*U%E917M>T*:8W6Z@C&6_95.].%D8"=
MHL3BUT$LE&+85M(2SB&;R+KXX#!9Y2*;+E0.=1?QA60[ZZRY@". ()&A#D3&
M1"]!2# QB;/4@5Y<G47\[J=MC8_:&*P6>YW?\A^L17L2'PYZ=7[0-]N-FJLU
M#%@2:?"$A.)Y@P'63L=(]3RWIW%J&:GT4LAQX>6=L^/\Q7>#=LA6?2X/>O)\
M]K@?[M-H3P(CB9O&)Z/VQ.3-41X<#?E^.3@Y9]XM9_I<(=!-LN2PLL=LQ<@'
MH*PH9OF%K!B!Q,ET80ORB^ U0K_*/")Y$L\G@N+X9/H%O%;1F"M W9)!.$8#
MOE@LOAB?K0.M0/Y9!4@7)(*+!S=EB9JS+1!*@%S:F)CJE;9>&R^OY8YX:DLJ
MKPMQQ=A:S[IFKPL!L26J!JK.WB@K2K@+Q82=D-?%]&3PI'S45N<D^A<J9C&T
MVB 7B;;H/++J@)^]G/*ZF):W+JL@YE5B8V (-2>()MJJ+!*PMUT8[-$%>5T,
MN K;4 "15.0$OFJJ624"K45+B_]4EW>M>KG$]'8V$G(6XUA"\M4"J!@ELJPL
MD64KSK)UB;,.EE7@;@4FCRF[6-KN:8&,06+*8+5':[P* <IR[R0LHPS-L45?
MY)($$0 N#"ZT0<=DG3*@@]BQVF5P%BY#\^SX66?])TS6U0$J&R%I],V3I+96
MTZ5:G8?CD0!TW-86QZ.7@^G;!Z</>)3W#VGR]NK^Z2L:\O0EO^/1"3^?C,M)
M/GXV&'U-LFYR(]NG1_QYIN3LNG\X]J8WT=A[<>ZMR2N>O!OD3U:AM\='F_)-
M+PY8R>HSW>JGV1:D7$!7BEZB(E$_Q8!R$5U'PMR_Q/!5X^XU05S+3^>#^ZK;
MJ%+%%0M !HLY67%+3:7D,Y7:@4AP:4CV==D:O+\#R5H60B]HFD\-.6%5T?L
MH1:)JX($7:UE/ZGLU/(&6)=H/: A"5"O]IF/GXWS#*T_9#LV[U HG'GPCE)G
MHE\)J< Y=$8; N\465\<^$#.9*52!QI:+!TX\^N8X+)W,:?HD"/4J&*;)EH8
M$4-VECN0:?]U<,Z3@T\F+?7TV8#28#@X'G!7TKD-L^!2:@@J 4?&VJ8P,X/
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M\BZ(\[=D@-Y?0P8Z24FJ-5.H-E67P#A/7*QF344"4)7/DPK6E+P6)?LT.I&
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MUQH79X!HR;N0HN<(6+G6BZJFCQFA2^S@+;MA_"X8_ V)KO/J$D.&19>JBJJ
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MI.U)87'^?5N3 ;#18/(2]U&M"9PJ8%8 HKOV->>(3HH!J7H@K0)H U0MRG_
M7@6-GE< G<7XFG/$B(POH;0, :. BJ@[791FG3$''<Q*+7(NRM=<R IG*%Y'
MKB@86BB524MXEUOS!^>JI[!*P"[ UUP(I@J=<\6S#A@A*TX<<ZXN8092XG*N
M$J8+\S47@BQD'S,22FP8H!)BVXS(L0C(!3*JCO7N61Y?<W[==$1]Q@CBQUAQ
M-H,$ C4"84PZA&J05Z4CYYWZFG-LB6DD%-!5_!?%D'3$:ISVA0KKMEWK5P"=
M!?F:\\.H"8RK[%TB!JM3C%5\D5JCU6+*J L9B_,=VB4(/^1)2X7:%DCIB$^.
M!WGZ[-G#E31Q1EL;$QEC%1AGQ'51KB3OR ?2-7=@H6SNZ+\Z:N+[9CQYNY)K
MH[H5[X'R%35#:_)4,97JG6I+ID[I#NS$SP?RA^.)/)730WXZRE=A_U3PY<U5
MW+-G03K4C"6Y5B\6L0 !I1 -^RA0=43M?X>30Q=O-'SE9"R%$JA ,:[U_HHE
M61>R*29U:7GJ*Z@^&^3VB='>_;T)\W5<[VM?>>G+S1?#K>2AIE"5=5&+0Y*I
M-0;AK%)NA II^9>G/P/V 0U;//UJG_EX5@I59GFZ--P83/-P/#V9\/3!J?QR
M-)[2\,ED?'+4;,[PI C<[1AY.H/1"9>M<PZ,1Y_T%GSXOWH6&DY?C8=E>RPZ
M;Z^UH/N:Q;KV=[ER6P^'-)W*P_D24:\<>/Z+W'%]<-I*=3?'QU_^(AU9CG>Y
MV&C1V*H(O,])>VM!>S"D4%$7>JW^M:U\?G)(S5:.QL/QWN"K28H=MYD+\;J-
M@Q"]=MHX#=63A-G9&PY%.]0NJLYSZ-%P\&PP')Y>-"1;4VC^J0^*D-HRC998
MO9 1W@36*EE+29'KPNCDM=NUI-PB-*Z2L,LH@ PEEJB3-PFKB]F[+O1Q^FOU
MU#^=8]?GI51*"RIX+[8 Y@C.6' (;0W)&[(<#>;B3 >(LU9*2\HMYY45+90M
M10>F%J&63<$&TKZ-S.U2^\ ;=W3^!BX5KH/1X)B?B?8I3T<2]>P-TI#/ \4'
MIWTZ&$]FL=Q5?CT=/9^,L]SCERO"YW5_2]<Q?T%M!HI2)F7RMD1 6R@43AH
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MX]?Y 1=F8X316ELR!#&P-5#6&6NP-IN+A8<5 VZ1\>O\D,-L7<U5Y2K>42V
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M[AD,Q5?KL\=*HD>@H$Y'(HSM?EQ(=ITDBL$()9?.FPT9R*M;^'Y(M!?17?)
M,!G66D, -&611#6W)AYM]>K>#V1V)5[V@E],11R2#2/9;HYI\SX2%AD-M<NZ
M*OQ(\7N4/M5(ED9/H_'$;T_=1D8V:]2<F=Z-R%RZ=P_XW8O* YTXZ4D2UXY8
M4'+.C;L'LU:+-<]Z/Y YHY1]RIURL3$1Y=8RUI:V#H.5G67;-X%5+WNL^#U*
MA^0VS;74,=S4T"AQ2Q/(-!VW01)9US1V*+/Z= ,#1X+!%7M,E]LX.U&7;-KS
MZ@Y\GDGK= #B7FUK[5:9""LI8\L4EJS$ +8%H//,&B?<W:9,5HN)0\',?0M
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MR4H?4QHFV2XY,&O5)M1&:;7Z 1J2'6?53M@P/+R,XJFEACC:?$]+]"S:!S
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MB-.L.R4N D#(K1IQ[D-8 CSJ(L[C(,ZCL>@GO&-+.$@B(9LAD&L>J1N1$N"
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MEEI(WNL!KO.B5<O8O356Z3S-(@KPR"V5$F.[U9X7K1:M?H_O?*2TJIG%AH^
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M6[?!U"6KDN%T&UJ))(-A"RNV.E,>EPDK)WP:$THCQ\J<NPH&#:DZ6N4<I$U
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MH"U"QRM'][!F5PR546OP!.KV2+MCE8S%K!U5&Z!?A[M:8Z[$U[(%[U)T02-
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MX>*?#\KI#.6KB4B,<K?#G@3K%KQ.&+6-D.5+U$6Y$9$,E&] A&)(N:R5;?\
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MR^O_;+P??IX]V)G-GLSW%GDI4!TQ:(\BGXVQD4*J2 B"6<2LE*.H:S76*NA
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M>Q4Q:S;[9SONUYM\-5_<4N)*Z":0>.(.D]-@34A3*"1V!.0)4Z5)%=#H8S)
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M<MT(N87GV6^8<$E+4XBT$EBWE)!&\;,FD6!)A>R\ME<4-L!<?T7O;;OKP(%
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M[],!/F,ANM.-A,]"^1TQ7W_ $\.7?MF\P,]NT;[SSVVU+_-IAZ(O:KX\2_S
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M\S0;GM+&@"/)HB:%"@MQWU,2K'&$>2H]!0=G2QX;*BY4+[7:&(Y%E\$30PN
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M'U/"1N2DW26%D4=BUD'+:D@J"51 -1I[2,"6X&R XP7A! 4W'F6NG<#?-NM
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M'XM9!\Y&91JBY(PDB@KO$JO"BP4KFU"HB%0EXT;G;'YT-;YV-K@"*P'/\-2
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MX'"2N*BS&8-9WPB-7.G"6 #/+0+ 0VE!K P)G V'M#%$'+18S?JMW3KPX<*
M]4K,0)$< Z^C+8H%6Z*R9(4*[CFK@PJ^:=;A;@42PZ)E1"6L;LB:P;YE&NM&
MN-'>&W#JU:S?<@(#WVJDI> ^+01%'$<GG2,N &FD#EA^LDH%5<WZ[=TZR(^M
M]Y +9\(I3OQTV?Y?]MZUI[$DZ1;^12%E1MX_TH\I1$E[6T:F:/L+RBM@8\U\
M>"7 O_Z-<#]=%[;GP*D^8L\6UDQW%\7%9F7NB!69$6O1;N4AQ12JB2JH,J*E
M^T1@/59V"*HK@FC0I!:L+DO)J_D"(K>L"=N&==21MFG .DA9)N@:1="@#-$J
M*I(=57,V@XDEZU9B-59/L.P8W:U$WE;=8K.&XD!R2,@:A."($6 JR((HT;K/
M=(PTG^7O0F;K&>WL_;<-X?1,>-'W+?949-^O;J@HO+BF]5@_]A=?=S^>D'_3
M&CZR&HCID4K(969W N3OX?N@C@IN>G_J,!@Z*,QI#0]J(%O%38/]GMT)Z$FY
M..?[('K]^\UZ5@Y'P7_NNY^>D*SZ?=[?2BVQ!GLP9V/;.WI,0O")UM$TM-X*
M[\?S*ID,K -2YX1VPB8^K2Z6.\=8TEYP#Z#/HDJ=:YS>><?OKL8KM;XMA6]%
M[^&IVYP_]9M#X")DO]RO=]W3FC41=]?TOE84>+9/\\6M0%%M<@%DBVSA+CUK
M(":67\<JC!*JN4\4:OK-]OO% >W/?;^\VJ[H9W4W"WK-N^<57WON5\_KV?I^
MM;S;KR_ZW4]^!-O5_HY-4)Y6>*G6_%K+U<MJ>2G6RV_;_N;;XVK':>/JL1_<
M"EUMY@<3E#\VJTW9'N;+-U_ONPU][<U"KF^^/=#O]K*FU3\(@P[FRXTR3E*
MJ80P:,%'J]XW0!-3B5FSZN*8-_M3@)7;N <W^Q51M1@+E! * 6L4'"S:<D,I
M4FZUCCAY,!5@C[5,1)=$3%&#55[]K]E=J/0GGUW4)F2C3COV#6"/W+HWY5I(
M&2%C(.Y8$A7I53M(&(*RWOFLQO0*F 2L/#+W=^_4Y5.WO'OF-DK7T*4:P<:0
M*1"P\1P2_ZC1"Y0ZN)$[JJ< [/:(WHS35LM4>>J(Y9BPLI4H-ZL65)2XA"JC
MMJ1- =:[(:S2L*.P-A +5>A:!@^^*@&%Y:VBC%2+G*+K6V' _!"Y.X2!E_[L
MMMAF"+S$'G,\B<@NYE91\1$,%7F5-K,?M>EW$L >:_KU37IK^3B)K1'9#@IB
MX'F@()*6M@KI1FU3GP2PQYI^7<"2V2G$>6.H9N9C^VH=-&R8? Q4&9P2UUO
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M/QUKOWGZ.N0#F7(3'P?(9MD+.% Y:_/!JK/DDE4*(RKQ3P36;IBV5"JEVN)
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MOJ&'XH9*W24G8>[#O'SZ#[/;SMGL(A''*K0&7;.CE>3^826\<;JI.JI/]F2
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M'F5R"GR4'HJ736G51! G8-\![/ 8+1*JC6KF2LF?=ZR!F!T%6L0FJHM$Q$[
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M3O>!D'78O%+2HCKMV;?VK#B&;!#*Z4/;,E$[T):OT+/C/VG1FBXVXYC]BM-
M]N48LA*--BTA!(F'RP*6>#,6)%&]9(7/)DRW@/X@9(_VU06-%3/MUE2DIF#
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M!A:1W8]4 S04<;06 ;S6$7)T*:F8HZD3E+D9I:?J[HF2AJ1_^ KBMHADE><
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M_" J?/?<[;@G]'[W'^Y$E<E!1T>D^"_#(,W.LBP1C#*+FJ2U<D3K]>D .YA
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M5! ]']AEF7%$G=F) ,NQ8  L9:=BO*;LQ;=.6OL(T;%3=74N&QU\'?',;BK
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MFCDS:NRRSXS&"^<ENSQAP]]Z17T^T^7__C>C63WL'@WQ&J-3JZ_JMKM6&#<
M@=07PX@E8\%<+X:#8#/!(R8"1SB[4"*OX,FATPN<8TY.U#F-OW;@D_($WCG&
MV\H.GY5Q;641/$MB?[36B<XFUW5;+:-6+1M&DY?KO-$I=YI&#4#+JS8WW#:
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M+H>GL\OCCY/+]^W9FN!/T[3K[8YCEEMN&]OE&&Z9XXQHA]L&=VRPQ%M<9O$
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MYJGC)6I=%?*&U3J'/WABSK[$ZWZ@M#NUW:B+H VC[AS!3GP^TL)N26DS/MD
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MJ)%N2Z2[&!I-TS+_H5%O<T%;SC6[H\OWI\=EH\/><]N&JTNRTO\F".\"K#\
MK/2B@"<:+[?%R\MCC9$;,<.01U3F=>Q% DNZ=,+AMJC6/]+JWF:XUA<\3MA1
M-[ %-MJ);3%-/,OSO63&1B+0>=Q;HM[1\9'&O(UK_XZH25A,K0F.O1CK4T'
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MU*T_B2DL$GD)&"AXC?ITGJ"E6W5L@\]O=8["1C@[E<T19LP2@7"]A,E2.\U
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M!F13+'^,QX.J,EC\2]]@_NEDW>=?IJ!?+G\*N/EYS<<R#W+E8I\'RY]9PO<
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MNB87N^A0W_^\5PZ5RB]W/4$U\H'<H;LP\AW *$%[AK]N&(X0GS=JEE.$YX,
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M0>>[N%#YSCBU/F,"7I*+$QF PTY:293&R;RP3?7[HN:NN.YLINR\TKZ"12
M63>-Y'QC+X;+XT):=^Z;S03H6O:\T X,]4]XVD\W30[>L,M;3"E'U<4E1_>5
MB"AK&2BTQ"YE,2( I#<OV2ZQ07''EVGBA^'-#PDE/+CT6&4&JIC-^3$-B9$T
MO0>0O0 T9Z8VZ*1!!Y19I9.1+.Y[A@P!?XRR )X<9;=V$%*%#4E5E!WVB,<L
M#%J:YQ](QJ.>D]U.;)@4Z FV\XPQP@WOQ)E<*)FE*KE8HTM.G.)@:_>!Z3>Z
MU%27FNI24UUJJDM-U\*D]DQ+37^"=-UPCII29.<CG1?*TY1&N@^*TU-II&02
MFH<Y)*Z49-\O375/@'X*ABDSNA6&I<?L!%2K,(KO@^#. <@R")+5!_9@SBT?
M75=CMK]=5[,CD:BH^/R\US\Z[9ZQRZM>OSL\O;P8[*$N?P+JGYR!GKD1XRFL
M)'3=S#%HJ59>N6MJ^CD<!^QM9A6_D%8]9LG.<ZF+_GUX5EG55F:3MO'1:L;V
MW!O_4KJ#SF<^^1W)QL@GSJLAV)S&)2O_YOH\[Q)[#X9YY*F^WKDS<%ZLK39R
ME'4T_6V>R?G[>[F(=X,_Y!*,#ED.,;]3683^I "/I>RN)(OW<X7=Y.V9A)'(
M EAYFKHOR/,)[U )(#*-O>C/69__*7=E"<"70#J U.[0H8&1J"B1@0@%/J',
M,00>^E/1'^)G'U+ZHQB1>2-32?/F/]_.4R<CZ>DRU;O2JIOO3/EC7%@(3KM9
MW&#N6LM;P(MY(IYTSR[;H?!D'L@459Q?^<#56;QH =OF9?P4L)#!)D2ENW 5
MFEF/>%]:HCG8Y:NCU^ACEC IJ5X"^;$OXL,J[ HQ&]C4U9$ROW.?OTR>78PE
M4.RL<&X+K>2EHD$823M0\Y#(4S@5")MDIC*.ETG.PT9+CDQUW$/FANI&#NBY
M'T_%46)%.!D#E%Y3VIH*,"-@;L0L1]?5U,AG9%P;[4JK_?3&=;U3Z9A/_UBS
M5>ETGJ1 KVA=52MFHV!"M:MVQWVP4O2'%KT]0KFCHQ\6$+4+B+JEB;D1$!C]
M6WT&T#@6L1UYTV*ZS5\3$'\ I[I2G&JU0/(! N'VS8@JH,IJQ;8MA/M ??5C
M' \2//=6)3<76U8T5SI4/-"/@LJ]GQ"\ZUT8[Y4"ML:3\5A4^[$ 7F[YL2/)
M:S0H1*!$;$&QF5<PR5I$CI55(Y&9I5[@<E*<N(,3@NV\B($[&";(KV+30*23
MT YM6_:8QG@E**("E<:5CP%"-X!C48!!6%N *H#9+/+!F2$LVW&""I0G&Y&V
M+@<:4#-/C/;F\6&ZN)C&D083H>;:4G18.)5G@R2K[89^$MH0C1V%$P^;D<Y>
MO;T8&DW3,O\AXS!7D;@-. Z"QU?!AQ<>''CD?2FQD\%Y[]7I^?GU17GHV2&0
M*1WN, +;+K#X?8Y'S0^_DQ]>JBP2C>J/0O5U'#)/S"$_2:QL9_C$LS'+8((<
M<P+,T4Y]6="*^1OS9 \R<KTP]F"-/)KS688&-J,JRWFZSDJQHSZY34_.HH[Z
MP(3^)P&0>_#+:>#/$@Z_#-*$O"1]D0#T/?CM+(PL2IK!TWD;<3<);SW-E'X0
M4SK-)@.>*^?9L\'Q?>-%B@6!OF7SR/'@XYAFX6!)-K=P5A5A]%T(4C9W@&8E
M]87"^4B,9'Q*/E!K1H\[HI[O82+=/_(@$VA$Z%\/E$JD.<H/XBB_J=8-__B'
MQMSO,P4+7NIY@0 ZF8%E>SZF@&*:IRRV">2@U+*ROXK1D*4AKQMVZ-/'M2&C
M&:0^!C.^8A8!"-$H]$OL(\<NQ6["X5</@R,3#H;7>U<$3@FCR%]G(ZG?7/$O
M/C9IT=SHA^DW*E<;XS:4=L!.R0K0EMB3^JJ4]K-L4='L/L#_ "=((]Q%UN9[
M70;]LSF/G\EO_D?XGX&#@.WT_[/WMMUM&\FZZ%_!FCW[+/LL2K%D.XZ3>V<M
M698=[;$M74E)]KY?S@*))HD8!#@ (9GSZT\]]=+= "G93FR)BGGV61-9(H%^
MJ:ZNEZ>>.BK)42J2!U8*X^M@.%:7EFF6/F1?BWE9:E)&1RWY6$WZW?DBA7$D
M'\R'>?FOZLMKH""MM/PM;BE;D:V*BC?T##B*EW((/O<$?'2-MRKK8P[;F,M;
MRI8+D 3ITLMJ<_R:2Y\B;K3 5SU;%E6>5<P^/G6S:C[-BURN=[KO*SIQ9?CF
M9UM9VQW^M!W^=5EFZ;]<\1W_0/86:;X7KG2OCO^;M^*U*ZM%C1JP3T/67J?M
M]Q[O/EVA>>#?W290XW]_00CBLT]X8X_#X='N8][>(T!V .O2;,/>X^].N;Z#
M?Z:K1R)_=/&(-SY(]/;B+='[JT8+F(QY+]$[VU>R:YOO@X).$\J6/4D=ZD !
M$5M,:>Y_WR.#@SY2&01N;Q 7V^P]WTULE*O)$OZ0Q"*_^##">R7JR>]:D=(O
M_EHK,GJTNV:^?B/X4SHN1?>L>95@TWA8P*HUN[VTDO^J_P9S8*Z7AN3!G#Q2
M  U'(4OY4+P@_0+MV@/Y]?7@J$T\C/];"*-7__>63^G?_G%:YRA@K:Z'.-+Q
M.#W<2Z8I\'VN5(!=%C,_6@1GY2K<)1EI*M 6A)+=QW+>!%L(1&DA=:H QBKO
M*>(8;VDZM/LEBE,;_%1[MI*KB!WAQM<#(BNS _$)GKZ;G+LO"A]_]E$;[H9B
MQ[V#KS*4&U\\OK:F8?4(?:3J[18AU->-V?A(5^&A,=>L%A!O0-6 ;/NSVZ^H
MX#+1&Y<1)PE03(_29;YN5M/*!^'YI0- =H.J8 YHP,R0$8'/JR+/&)C-U-$B
M%_1G,NZKV>T3 B;7E+58Q7RW4MY:*S5@CJE&.<^#/0ML0>;07HD)4NGC([*\
MT]P7V,_2WZNZ)_P;LDLWELU4I1! W FQUU<HF7F\MVDE,V_>'+PXD5J9Y.#=
MR^3P9.?T[.3M"?]B _'EOSFF'EDAEH&E.ZIVT FNDM_%'-<1XYF<E:BZXHS/
MW$LIIC"+M5M-8:?I^JH*3[2QCB]HT$6]__BIZ[K:06S3VX7]P:Z?-\CHVG9A
MJV[)[2L']H"8 D?+1L@)HROR,J_;YJ.]KB)>%NFY]7N5<RN+;K.(#N]1YIF2
MWJ%IJ?%<"\A%?PG>.R:$8[H8Y49LY(Z+JU.,H\8OI/'[K'/YR-)OQ-*WIGEI
MX$B2]GM)VBZF56W5+3D[!2 [:DE[,TZJU^Z!V3FKN6^)?DG6/-9A:%_2WB$@
M+I.Y3!A812\=PW2W>;*W&"^3KQ.[QE7'H\#+'R]Z9UTQ,F%80R4.A_G0AS2G
M:\E8#CML5,**)]OM2ZN2!^Z#1?<.Z69/!^23T,__K%"U]38=I:T@)M/\*BT?
M]@AW0L>X>%6EZ:$N>Z-58%@P^4ELAMAB*->Z[QMT]7\S9<J?5*CU=*OPKU7X
M%G.Z]0U]D,[S#^F0SBAT=1QC "%<D9P "7%0DC%0I3BVI%OU8#)2BQ3G9VCV
MM^>*KT@+AM2)\@DT8M(*F53$55J/&8B4JR*>U_ &HAX(OZ'/ A=@+JZ@N9\^
M^D]^[_?T7Y#J%$7G/I!+0EP(I1#E\,NBS98#<YQ9\4HW(-!9LBIEW9QY=4Q:
MS\VY.:693.$*\-2Q7?T9AQ/G*>HVZ>##ZD\%.ELZ#1UBXK1$S/UF3V=\KJM]
M,R4C'!JW1;'F6E!&0;XQ:;&U[+(Q^C2.FH(5KTE269-D7N ?O2$)C6TT+(<$
M)C.@ >2[J8?],[7S!AU_#3/?_NEWY;_3HEW0 S/W4$T^&DJ?-+.<YD,8"$*7
M.BRJ$3GI,[2BGG.AJILW5N.]^FV4M:3<5X:.[_0J7?I :CN#4^.*0GE8O;5X
MHR[A0[?*0MJ@=6NJC8/8HK)#JR/K&EC1.8_ZNS(V((B^YY;M/A#:1;=L]0R*
MJDD7XF Q]$R#S?QP.<D=@\@.NR@7813L\#]>V8SLD_U";.4H[*R*^S '$:FR
M$^:E:ER.<H49<K7[R$$1U]62]#+4A=C[VCF:22:#?OCZI__+G[F-.NLO0 ,[
MRJN[N.M):MI9.I23GDSIYU(PD>H=S9!DH^MXFA3YA 1K9R]Y</IRY\W>0_[8
ML,J6?_ZDOJ5/O$_^^3H]X+-J]L/8_">.Y8$'N^?3]5_0.6[@F*:[;K'B0$6'
M.TB]L69K VCI;JWT$6 [H#/&N 5=KT\C?MX*_?5"?U)/JLOEASN0>=K_=E(5
M^0>[WAC;.R$UF"G888<^XE+F="5G=%:1G_O@=7GV\\-PA:50?569-^LHF&%N
M(B,;VF1)Z:?P/[)EV7 ?1RF2^IP#I.0UY!"#G.MB:G2]N5JGRGONCQA;MK>\
MWW_[!XUP[&;#VMU!@B'L;_+DT98Q<\N8N67,W#)F;ADSUTO(DWO,F+G.NKK-
M8.%L,N!V$FF65T5"&BG!;W!GEU6-UCKP>X'='SF^[!_M/J5//+2&PY=+L$F
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MB#,&*NT_X5C7]3&$Q]?&$!ZOBR'L[S_]HS&$YS?'$'0^MVVF=CEL>T9KW&"
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MW0SBFU473:@.^;G"O1U'GKD94^'9@CM<9> RD4P4HO03QX:;7W>4_^#KDFO
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M#1,P+LVQ.W2<MG:(XBH B6C),C>J':G<CBQY^$X^FZ>LB\(.5F.:"W13FM!
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MTWV9%FT_),/;D":C.I>(FO#Q\&G3PJ!-M&-^LYUU$GF5!&^H;9*ZMQ!&#-'
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ME^8-:'!45L9YW;"6V9;L;TOVMR7[VY+];<G^VC7YX9Z6[-_!52O>C5D=9&.
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MJ9HYK EY,Z^(.J\6^H5-#="=.MYC>PH?)):AZHHE0:? MBBNE#IM%H/H(*'
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MAL$LD A>6GA$UER""!P4P(ZIGRF<AMHP9]H=RZ!# *#L/@S.T0$J/_F( QT
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MD]&99]ZA7C6D&)Y([J@T+H==;U5"#0DQ&[4\KCSE'CH+4/?S!T<U ZP+Y1Q
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MX*Q"TR#FW<B=)B+U3)F#ES;&DRHNX'39L/O96:_HZ=8N4ED'DDPND5%WV?G
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M> ] ?6/!M]))VP O\2Y1SM*;=Z&(SAZG#Z?VZ=A9RB+*$%^ZJ"#[*PY]4^I
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M9M@7.8P@"Y=PZ> @L=*++1!.HY\ZKF<;P^**.A1@,_$*IFNJ+!'XL(\4HE8
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MMQHE02I#")D>$Z*HL[YHHP V;(#)+>&D(P'NJ@RWEU#]D%U^IP+B\$NOA=J
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MVS[F%P(D*KGS67%Q05V:9N38KZ*IC QQ19Z+>V$7"R98NBTS!("D];+P@>9
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M& ,S 82#T4)T"5#1>TY04" E@QP1!D3*?FSNY@90@B)XM?Q&LPTJ$Y,A9L3
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M0YD)3W>P<L/4?6GT&)".E"A'G1'"00Q0KD?R=JF?2*+<*W4H".F4/(T3@R!
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MT/[PJ/X) XCD9^CW5\5TC&Z?$M!>.QSOD ^RHA[:QN:/*4Y%.2BS^&3>\$A
MP*TU+>H"CN&L$,:]&;C8U22=,4[>%N$P59T-; <C?-1*D1=&Q5L=IL?LT5QA
M8 %#\QQZE^$C3799<KK>]9NR]5C#NI3**>J\[J<!!5SH1^%CCU^)U$] M2U
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MV1YW5,D8444LJP3?@W_]]J%BER7I%]:LQJ3@;+[!9*G]V48_8?)_E,L2$<#
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MKA1:>(*/2 ,7C^.,WLY68=7>HC'PW=2&E-!@^S/H<-)3U++3<G<TH@HQ#.0
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M:[@W(;"VD:*?TOO%6DX3[/&@+'K"3LJE)[,FAQ\#$T1A>RXA<?-[47XT"(+
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M+.I1(#<;)-4X&F7%E;8T9D9=VR*)[3;OU3K1'T;&*WF#MK=J=)=+P"Q,/CK
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M7P+?USG+7P+34@Z >X%3"B[H0TUVA(>8)5SY!EW-SF R&!/VMIJ#8WHQ#W^
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MK^<&&?>QVL9[O#)$REE>6;C=R9LSA*O-T/VPP@BS?MXLL2! ]'M15[YXHDG
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M6BY\##+0J;/H95&767*_!P+CH!<47=J05P KQ8Q&=\?F/O"<[#YY,,GP;7>
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M\:K86QWX<2Q,L/1/6B<<&/QT5J;]6I=A^<)%5T69#<&P,2"-9GSP[5OI2L!
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M43AH?.-*A&J"XJZ _3=-I]3*A$FL2[PBRS84"@^[#U7^J"8)<E$65[-QQTH
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M2F-HS;D#.>=-,9& 6SK!J8$5IT?$V+L3QL6FS0Q]E(%T0_="\YYUZDD$FUA
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MZ:&$@Q@#+"RR"S! 6,.0&*K+!HT#F\JHC#9H6^E/I$AA3$Q37/)9$=K9EE?
M-$Z+E A*HRH9&5@6^/$(WBWF7\-:2YD D4I8F#)E]?0*859"QB8'KLSF5'"%
M2'X:OCYRAMLR6"_L&8=VI Q 3&*X>#"G&B]AO2,4++-T2\HRT3>5FF,8%!5X
M9!IQVJ"IEC>2P@I_:KEDV2N.;C#E41C:/<8Q6]HYP5O6LW%1$A*;X/%)G?__
M[+T+<]NVMC;\5SA]VS/)'ED1=5<R9\^X3M*Z.Q>?.&W/>;_YY@Q%0A(;BE1Y
ML>/]ZU^L!8 $)5*F9$H"9<QTFL0F06!A86%=GV4O /(9@7NS/%]Z^;LQV 0
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M!!,HY4?X(+!9\8QCY[]-9I+7R  EV-_8SH4$NQ* ,DWF;N3QV\@.0;5&(@(
MQ ;< ,#GT*\Q/9"1R4[@6P!4)[P74VAOU^++E+'/&-X//^+T^Z#->H&=U?ZB
M'I/"3>#RF%.2Z70M X'$.F_  (*"**9'A:*)GU@=/F6^,5ZX;=)N<8X%]K49
M;D>Z0"I!OPGO #<FI+UD"XR8-R!@M6$<(P/?IT?X9<OXKZMW E6([_X?/]^@
MZRK']UGW%[CQLZ9'V),,N.(J\.>AW$?I9\H8OG$I)=4P/9%/5-Y-)J+IK#R'
MNU6!5].=O2/<U9->?:(/'_@@YSZ'$I&YA^DXY+L%O:Y$RPTWRJ!))+;!DT+9
M;0;H4^"8H O&J5A0 &5\Q%LBQ /HDWD0,VV=T1:.469WX7%B76FX/)6<RLSE
M(LXE_12KE9[RVO?IP]J=1O5A([1<NF^(3R\^2$U M-?013L3GL9+*EE:Z4RD
M-H5LM2"8(4_EXRT05H;DZ0AG$5NFBV=D'EI+)'FOW_DY^SP_BO#;]%I=P@?H
MD2.NARYR, 0XV\$Z\=W\NL#L9@EYK*R$9,4=$;T=Y8 H/X)(?3H Q\]J<4[)
M:AZQ=QF?/CN_1C#UN(XJ9!-_.&U.AX(6.3LF+$: JT6<8[#91;\?=\;:3\X#
M=JLQUP E>68)I4TT&2EQG)2,(>]RPQ"].(@-/R0NJ@5QPB0ME7?4\F8W!?VZ
M[:[8_<^@D40+'%;>:+A2&Y -4S9=;;9M7+U+Q3&W DIJU-6PPE I/"F2<U<@
M.:>:M (4$<I^JK.S^Q^U/<>X H[[+/6(.VYP&&<(\U&.;(HF%^#<LM*[37/]
MS"U:4?AXFZQ6GHJ1ZS])FGV.>BQ5U>#R ),.IPS@M]8#Z/]N%":KU,T;+<!*
MG.?@J(734\32'M(H2TA@]"@-$3&_,_ID>"4Y?V2S:C+U4A<\S30G-_J6:W G
M/KK6C54-J5^>Y;+F@..+^)A?Q&T*1O QC2O!($JYX!0$+@'+\1<&\/V.ZA+!
MTK4KI-;5)84.0?\"H*3-%#OA(>#>4 B\"ZRDLGP^ 4Z+J/:4SS@L.BJ2Z$R1
M$7H0*_L[4\-!>Q2DM1]L3XXHI9X*9GB),<7C)-N)+#PO@BN0+,*>E\J,BC(%
M@0U]L$L8_IO]8,P\Z%;'7FD)Q&'>&%,T/6>&5=3:F%2&K)AS',V$.9Y&L.]D
M]Y8(C;=2O1ES'PMB@BW>>Y/^.Q;W([,$P6H ZM+[VDG#[FQ0R'M.,2&EWZ0.
M .*D.I,(TELL:QH<J!PPKZ5[=>GR;%V>K<NS=7EV27GVN"GEV4KH(ESCQFN1
M.V5:'(I?**G!K)5A,N)%R5(Q'>X^%F'S#.Y$\BXR50!UDU7@\6:5X)RDBHAG
M)#Y<Q9@E"TXT*\U/DTT3#*#Q'O/T9I]111WR<^-[2%+\ I%BEG+W^S?$H6T!
MI'48A!"A$"C^+?JEB%U.Z^$L=I/S#A0MO._#B^PA^CNXKA)TO;/$->'^"Y(8
M.07RBE:N0ZCF@2$V7_S5MZCNSP9 [RA:7[(Q)ED^MH?1#*YZR)$*R4<&+DI$
M4F4N7XX,ON9* ZU%]$$0>3KWZ&>6E\Y"<CZC$&$=.ER6TB0\X*@ELAV&-J.0
MB 0+8 K;DE@LQQX#=5P5JXS)?P@[X>KS']=O+\R)<<-W0&D4LW2V@E\P[S9-
M0<SW;I"T9VQ<Y/K03,/RI)@.4RHA1+%K@J*B[A?(R__"$U2!WP7!=FBSE =T
M.Z94Y6H*;"FD56%<QW)R!A0F<_'X$$,.C@O9(M<\Q3)X227K7<5M1LS]R@<5
M6;+7DG=FEV*Y&? PZ[(D]T226RSQ:>8<,56K[D[1XFI'-\X!.R?M=@**>BFE
MN)2O?O[TU1QVI\='L-V[/9TY/GE/K,FH<YC^ECOLHSF"5?_)L<VSLTDE@>@3
M\.DKL1<@ /Z"XA0O;?QA;&X_= M9?OETR=-VJ;@,?.O.#>D-SU,BT@1.CLV?
M"A*6>0'%!B",TI*.#/I43KY #VS^?>8#H?OO.@F48)A#EH:+[J0YDQ68.\22
M#.+[X,()H@PC#XA)-9<7O8[Q'__'')MOYM@@!)YYV9:G$4FM-M*/2ZN;0E<E
M*L' $<9](2)\+$HI%A;K3>"R]%M6Q"(7FZ"S<[,@)D<#T<;#>/?[)96<( ]S
M<6E&4#$Q =&>^XQ,KP'\P!P(HGE._@-B2=)*!,C,"W.39"RN3V6[0[5A&)M+
M;M/,[\J+SW8<B(X7+UG(O&2TW.9VRS;WQ4?K@0WV<HVC</59=1#6I2U).$<O
M7A(1!K9C<=!UA^=[;/*XG%[.>M= ,GA(GXNP_8-,TC(.1!0=^K6"T9$[IT&
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M2-SP T%0-5@N74QW+7,*:9_047Q"UW]LZ(5T1CN X>M3O,5?DQ[A]/QBS;E
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M":9@SQ)T4^5 TT6:*.*R<:T<B0H&?:I53&4-#!YW 2<-TY1 M1&8?)8+00<
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M]PK_LK2^Y_IV. (]$9H>K *?"*N6>+QE'W9K90%/L!PEL J1_,B%0;9()N<
M#"1*IH!_FB;!;LK1#/!*+#?$C/%"Y#CZV"LH6YC)F>,1;AU^![(=D; LMKO
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M& \\VMJSMD!B'1K^CT_II+Y#(\]CKVLT:0T&HWVJM.O0_IO2I+[@N*O$LB6
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M?KNP9G2/7UO>O?40_? J?Q-20<4_VN\R:5M=4.I[M?Y[]8F^AM;>>NDQ-Z+
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M_23Z_L!&ME 1>?_VDH-,9B\G\2)@1>H"!>G=[_C0;Q8E3WO_7C+')C#+FV?
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ML<*RD++UMLE\C;+U3?R0W\"%.!-,E=/?_"9F41#;FTQM.E8];(I,%)#BK_C
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ML1JR>F2ZFO ,K(7=D>?O FAEQ'6J@IRHCO=3FJGJ5?8I#I&2PIU/2E<3W$L
MBCL1 F>T)"9>I%)ZYR#!N>DY:DP\$4OHP+'_\Q>G-1@.6[7VH-&HM5O=,S'H
M-MNVW;+L=K<W;%N=_U=OM'Y93SW=U=2S86\"G?'ZYOKT2[]_RSY?7?>OSZ_Z
M7]FWR_[][W>7'UC_XA^_WW^_Q%FQYS??+E>H"2M]I3N[I[Z-K(_4 M*X,!R
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M!ZZ%+D*X*N+^3@3(%^IB'+C>IX0W7E )_!VL%&D%15T*>;.]!. [(.@1$I<
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M$T(V)&,//L8[92-8":Q4#JG^G!)HW)-;)F+0335G,GB=R5A07:JU>9<1:DH
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M'[V#DSU^B!G#R2_>"&-N0Y7G_6<,'#.28]\L/D6LP5; \*6E6OGC[R12 SF
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M UOVHK-B"L&I!P'&^H'"<?9M4-)]B7JUUQN[3Z<;4KY+F@>FHM6$+;E&><E
M$BV.[41!I7 _]CE,AIA0VKAL^$P9/RZ*/,^/*=9/:Y_J'[.IR[$M,I"/&]N:
MNV#[.5?((/R\'I#I[UQE_6@QT4S2D>0D4L'-O9#'T=@/E"I,<V>H/>)/!T @
M8*>_MM,)M$_R?W3K;*PU^8L%Z7!XFNO:0"-JO9%N@GWN)WVD98#_AC3YF[21
M='$Q]['8P;>!JU<2-X%M.1[R)0NN.<^U*J3B/F+R$S(GD&P^)IN=JA:3@ D(
M')X!CN3PV#$1\#UV(Y6@]43;[42W79'.1?7O:#51]_*<NJQ3MVA->(T7<DMU
M!G_$9R+AD?4U <DQ4]07XVEHB! ^/4(!"=(4K&]L\>@Z,L$F::)J&G^;QM_/
MC.:;QM^F\?=6 5*FQM^=PV[\O5\9C)*2!XX:?K=$]&5$&J.J '1)DOZ6Y$M+
M^T<FB";^(IF*//%E7FA6'QV!Q0 6E%"24PM'Q](3-<HT;ZG>V?W I;T:4/GN
MTUHI20R'4]"L)[[&!@ D9L]G-'@V0J-0MG[&[_R <GU1V?&D:Q!0!U]'F:6>
M&,%:Z,H$#*FH7/W0GZ"!'LKD4]7X6EH@>CMI[VE 6;E?3-"?VYWR;\NWX<)3
M8<E.[*2"4;-JPG.5,4O3:/('AO5P5"EB<QS@<HC0E?R L(HZJO3*J[=J+VM.
M-T5B(_@0P<';IH!B'HZ2Q-&, NPQ3R03,:OL5D^$E(>'=>= +0"DU)1]@)$(
MP>Q85ANDC@-*K54VX)R76)\TX^[%W.%1#'3M!S-=89 FTFD+*]EJ,D8(SR41
M%-:"':FZ(7+I)#_P\#OF6U8<;"1-=\==V6_FQBH5,"K(WEXLFU*3!##9>?BA
M^&'SM9$[: )[*/6A7^=&!J>>!^U213=?Z2;YG>U^D%_:T)_<J0 S= 1KAO/1
MX.*K<?$RC,CMI-J2)C-],]H2LN+OY__HT\A?$$*2J8KDP8C_3'P LW*A;'OW
M*%ME*4B5H[XX4/.@E+Y_=&:3$&*D[R_ASY&/@9)?NZG7L(*,7$HRGKVJ7\_:
MR5!EC-+*B 7-C%;!"@\C%=&C<!^2X>AJ=G-VE<PHZX55I@ WWR;%":P4W+*A
MT]?3Z;E2?E"[<500G.X=Q<:O[6KCR:NO5]OY"?0%[U\Z;']M5L_2.U]VR^RD
M!%2/S$>90>>[IWV#Z*]']-OL('JP9@#1</*3RU6D&1MGRU2/4N%;;Q^21D[\
M;9#C'HN\I4488M[4?$BIF0H'=&EHP%:609;J-%>BLD'<Y8C[60K[B>,YDWC"
M EGVGN77TBKV?._4PF"0G!J6CH)S96UQJ12H^CXTJ"VGQ.TF)/K%+<$=^FOW
ML!M #( *+BW?\R>.A8%@Y?W:I\L072/_%)[X*P8B)-[7#T;HU_)X=@#Z,/8L
M/6YP/$.-QQO*V7(8_!7R3.@XQJP49S+EDO^J")#*NB7GB4U5\\B+<>_KFE[H
M_(>1ZR/@A :<R*;QE:A[S54D)JS>K[([)_S!/@,(_"!4@W/4'U_D46X2P.XO
MNVYA@-AQ\)IO<BX#7D$YTP553YQ,^CCFHCDC&HA)K1S0P_RCDOIXJ(6#_$SK
M)J@&!HXE/Y9$E\PL3WI$)7YV_!%VM>'2EXT:SRC@$V7UD)3&R;%12KJ8G[>P
M*]R&#/ID-S;Q'W17)MD)1'!*,%;M?VP[P RV, 8C#/0R&F.7F4>+2L$ -JH3
M/A.6@VYUP55Z1W9<91@%L?*QKPI2C?U'.7H33RQA,7^8Q7,@D,H5OPI9_<ON
M^0-"I@0 .+O<^=$KZ/7'P;_X9^EE2F-1F.P^8W&E,*$N=#_$3+GQ::HTM?5"
M9\RC5O6%3%@.,0!'L6>,7&$+.&GR$M,@NB26B7,PXQ"3'0?"]1^?-X]V5^;0
MFJ:]GQ43NM1,*"ND=EUR0-G#W D8IFAG&@LNX;14#"4;=5"J-5S07X*RE3%4
M>(H6-H@16V 8!UZ'I./D+W6ID$.FFXRIOE((Q%4'P(I^*5;5J/@<#\-X,I68
MCJIDI*UU^D*VF,,$![4J=:;R="*YE6E<1.Q>Y=EI!_3OU?LJLS$TC$/+L08+
M-5;9P<J;9;I5<4_N9NFRX;IU0:3+9E/Z-2!]\&?HGA 61=)U/F%ZZ S]#&9
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MWI.*@*IHD2VKI!31:N)*H8 +J'=GJCW!Z G\B:PI1@D#?]*F*31*Q<O2TEH
M_("J1!0-).#2'AF=O9=F_,A$# 'W,'$B70F2M3E1<7OI_;Z"Y>6O8RG;6U0G
MD05NBS7LU=OQ]>K3S=T!EDU_7JQT6K3&B<[HA,;-MT$W'[IE;)]P6P?*=*JP
MHWLAP"ZY2Q/Y2)>E*X&/54-7[;R=(Q_7 =JTB??EO$^Z,_EJL6J*84PQC"F&
M,<4P;[P8YBS/EXH4PR O=.S__,5I#8;#5JT]:#1J[5;W3 RZS;9MMRR[W>T-
MVU;G_]6;G5_*6$*SQHC:,)"E8_WR7ZQ_?G[S^S4U3[W_WK^^Z-]=W+_>Y-N%
MQK?."+S3_;C[MC]%[.];5"J!ROL]F/<V#Q8S6=YJ=?^G0L7D^^@F_@K5H-T%
MU:"WE:;7Q43X,YM>-UNM0]IL,>UHJ1I3;V]L3-Z.7%#+1%0A[G,5AO%RY@-&
M.!!?PIY6./%6R<#-=_->K@MM;<;C<J&O@?/^0H16X)!']F#;*.\8=I<4E$$#
M]0(L4@.UYT!-)U=]3NST=+[6AMI1/P&,4G,[4A7NQ% $Y(!6(4-T6.W>E:.:
MAX4,KF<*K#>8,7^J<F30@V,[20FW^&D)%=11\<=1[-C4;F5(]:"R[A$C0L(>
MR4$R,HTO'#M35=^PV Y%!E:#!!SDE*-A/BH8&N0AE?A995$%!NY]V1C,5I4[
M9/\-A,5CV30F6 ;JHG&8'5>3?J?:D,<4M.D%H0>?II21QWSQDCZL;@A3\K*(
M=#S/7A++&Z!_X8'OG<G4Q68\/-4ODI0156>N"D<I\OZEW[_-H3Z;^';:K^ 9
M&%:NZVB4[#JH1AT;*H6Z1!T9C)[R!2(ZZ2N)75(?E[,?X U#H;L4+N4(%#%3
MK&3UW97JIIKEN*D^@9VB[:<4/12NBA!@F8SJ>DP\?XBM#;%%9":L9[DXHX?:
M+X#:/A8NL785[9_-BP>N<D6?NLWJ$EU_CT,/]C[Q'70S=2DA-;D<8/ZL-)9
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MT-J&PFVBU'\_N[UUKOT12Y8G,S38+"RF--R? -85P\_):W(O?JX*3$[^6E/
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MRVPMT/0?8-$(T+E0DY.)[@AD%>4YF1>7(G"%7C5+*17,61',J:?*$9$(M1.
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M329?SY,MG.)!=3S<);,HK*(9_HEJ50K&S EC/M=I!<,D1(,04.Y"PABL09F
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MRW<O_%%ZG_Q=+@XO?CO:.W[]]</6;YW=DQVV?W#4V3_H'O]UX>A'2PT/B1,
M]S$D;>0"J'S+V1NO--=1\J@33V@+6E=&2V_^7+;;2FVW3^2C9\9C[1 @*O,=
M$LI AR! *>Y\B-I'(7,T%:'[+[0^N@7T3\<#5]0QUQP5VAC/6T&,N2%&S?UF
M?22&2 N!"5?=&P-+5?K#<8V)D#FQ*ML\*0E54V-9XR!K.O=9<Y"I,?ZQ@DQS
M0Z::DPQ[JPWS&")RB8U@9L 0%H%($80SDGB+,C))5'*[I@^V#HP/+7/9,+[U
MQ9SG>_8EM6O9U&?S<D5>C1>D8,WLL692+9_ I/$L,'!&>6 Z%Q!D,@!U4I&
MO!,>Y0*"7);+;B6W:SZAMV+Y"[#\&LOP4G(FK $5HP"FF )CN(,LBAQ1'D?M
MJJ:X)8-\>I:QU?F[XT//%X+1&()QO20%9^:&,Y,J]9AT&L20RW)$GQA&$!:,
MM1ZD]9%;Y0Q3<>QG*=GCA6',QWE13'\1IE^C&,H:G0P^@%0, ^-*@<HERC7R
MQ"M#$^D0V?2QJ(=5"L7X49G GNN?A'Q?/A26T1B6<9"7H\#,W&!F4L4>%C3A
MC EPFA-@DD706D0@VO*8.(9@+.1D 2)6-HVZ,(QF,XQB]G,W^QJ[X-A[K7T
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M8KBSI:T_C>%/#:HG+_N]4/UD$+DQ'+\@\F(1N>[?="Q20BQ0YW//2A_ 8"3
M$2,084@YGQ&9LS8A^E'T?:DX6/'[9Y5 O+HMGOZX&N&-]W(AZ\5%\O&W(;0V
M74XQ-[WS'![=ZX_"</WVU?8;@[U\,<?K,NN++_UA5=;G^2!TS:CS=_CU:\>/
MCJY,^<8++Q< ?7N)L6FF3T?UEXR__L9_V\&SC=I TMI6@=W;RYOFJ&N^#,/S
MJQ]^O:K)TNE57[IZT:\G9O"IT[O:#/D+W%FW:BW&#W\;UCH:#^U2H5U^\N7#
MZ]5#=S;=^#&JUSFC]SZ,UO&]CWWO;;%<9T+._&W3:(6^_^&;;_LPO9HM"E?V
M-LJ7&=(&UM37#.J'IG32\;X;[K,)IF5\N$WH!VF"&SF3#Y>DF31,^KJ/GHPQ
M%BQR-B:?QU4WPM_2^=?""/YWB1,RB99=3\?]=9'FL4,XG5#[8P+*W_PS8V'%
M#YB-D2%N"4&<*1FLHMQ[YCQ7.G(G/F(NUZY>=33XYNW]%, .@OD,)J:=\=QT
MOYKSX=JS6S![DN#M<JA"5BZ@*=%U!B</1C^:Q,ON4[WJJ*VN.E6->D[2EA^V
M^K&U?=L?--/1/>Q<O)DWG3U4;T_ML.,[9G#>>E$=EHDKWGM(WCYF\G2LW3_K
M][TZ&PBO7KDR!Q[AZUJH1YU,WW^,H\>]\KOGW;I"JS-63E9GK*LTKX0]CDDM
M?JQL'2F],F.E8G7&JNG#:&\3QBKXZHQUE>9U=?8K7R?XL>-9PKRJA[WKI:2\
MXV; 8P?P'9TQZ'_]3GX#_I$+9Y&N7O$3'OY9?.5[4T.2Q/C9N9LL4!<_>Z]^
MV_FP_::UL_=BO?7V/YMOMO^S_W)K^\W;ATO51\ZA_F=LQ0>;IGY,NE%3-]55
MM^]6%0Z8;B]][SM_;S<]F=F[;"R]J*F;^IU6R?S*;OO1I%U7*2_[K;'[K4Q9
MF;)'WJEH[K5443G8'U#Y9G?GY<N=_;VW[?%,;/_U8OO50>O5F^W?MM^\V=X:
MT]:WM;HFC\GYGL6NF7LFR,.VS;B>_HI86E/F;%2%4ZH*S&4[E>WTLS+(#.:Q
MEYK_Q3>]ORR1U*UB=KEK%>STJI]?S*ZAX!/:*L6\'J.3AZ-_FF5=%U??GF%Q
M]56:@*H4X7J%)%4IPC&F]$^^K+=>SJBXZRI-1X4;+:AFX79QNNJ?MF=V'WN5
M)F6OWX.;16MV9EFT9I4FHKHO=M]&>'@>XD,S>R??FJM^[_1\Z(V> UN?D$:S
M^(GYM^F:G@OMUA^F=VH&YV-EB=LM@K"><?F"IE\>?MB,3=DA#ANIH_<$:\:,
M4=HA(7S0SMH8 O?Y;@%6=^\6H-KUX>J]=X;#T^ ;=%/ 7=T4Z.Z1=V=[[_],
MSWUSO/?[(=I[OWU^>/#'Y[WC;7)X\>'HP\%OG;W?/WS>?7%]4^!H]_UKLGOQ
M9^?P_;N+O8M-M'?Q^N+P9/M\[^2/D\.#7;I+MO'NEL-[+^[>%-@^^[!UF,:4
M/CL_;^LUW=O:ZQP>[) T_J/="W=Q>/#NZ][%._37Q>YHMU/=$ACM'KS#>\>[
M["/E" LI- CB&3 D(QC%,%A%&69(2>94;IS>O-IJ,Z7",[++9C@'?W#/J7G7
MF'X2;29<8WH4U,RO5$%!J:E0:N_%'9222D>D @%N+4DH93T8K")PX9U0AI"J
M009^W$6FE0&I0B3&UAVB2MO <:*Q8Y8[;=(AQJ-6F <6 GVP==]B$JMQ(7%%
M#/@NS1!6!!F(@P3+ 9A)A,,0B\ )9I0RSEFNUS9TF](I&]RLF@T7HO&DB,;,
MH*@0C67@U/Y=HJ&=L,$H!,8P 8QJ"L9J#5ABY;WFG$B3Y)"H=[HI*%50JJDH
MA0TQ5 H<L,6,JO1?2XT*EBB*D-9RT2A5J-8,/3H'F[6VHIQ2&P*&&*0#YJ0$
M[8*"M. $!ZJ)U71M0XDVX<VKW%84TT^V_IHHF22B0@>G$6&2"<6M3.2$FVB"
MP!@;4R33\NVX5E5+)RZIM0^0K-D"D]:!T<FBE6!::HR4)FAM@[8%KE>IOK?Q
MWHI9<&$BS6<BT[0A?#P0W=.&L'"2)F)9K1Z51LH:K3E(9!DP$@)HK!QHYI-\
MMIQX)G*K<YS0[.']"0N:%31;IJX*4NCHC'..,NVY55A8)C%/FYH((XJN6F4,
M.ZQA&#;6.VM!48-SE5,"FD@+"#/B(O4(2YQT%6US4OQ#!<=6B95%PW#2%L(&
MS%B,FD?&B R4(9?PS196]B00[=-=1',2>\Z"3#2,9X5I."CNDLQ40A <3$34
MYI[1A-5#ZX63%2QK("?CFCO/L<968.:XTL(PQ@*)"=*X#[%PLA5&L..:K]OK
MD(XN'D!0IX!A:L!X%R$*YF)4A(KHQUU*4.%D!<=6!\=49$)9IJ1S/.U=I0R6
M(CB-J<Y9;P_WV)?,@N5 5<V=3ZSVEBH$@><<*!(M6"(%2*<#,8EPT4C6-BC'
M!:<*3JT.3@6,+ [8X:A8ODG )?6*Y?9@.#I)"M]:91"K^?$E=11+E1,Y?01F
M)4U\2PO +K@$8,AZ$RJ^)7GSKHPTN.[)P^XPAE&KD[;]R9R*!Y2GEJ?.XJE-
MZNH^>P<#UKDCIN*!>280-=+;0(G+J71)=)*/6_F^*,((0_[AQR??JT$_=D;Y
MHGHYO?X_>^^ZW,:1;(V^"H)GGQ.>"*1<EZR;Y@M&R)*]M_9G2K(MCT?ZHZA+
ME@69)#@ 9%V>_E0!%$6I08D00:!!EL.F2:+9:'3U6KGR4IGKLUZ_+,O@:/0I
MJJ2@9NL >48(&#6$&*+(:*35:F^?ZR$3W3%UUS[XO6%X4QAVEA"%2")I0L.4
M0U]0G8/&3#(:;!CN"X:[$3]3("RIP)=Q'0%5$F 3%E\Z1PR(TG.?=P[#-QIM
M DEJ'5 4:UD,9+(DA%)HBR/A4$NZ$MH:H%8$5"<N188K98A!"M6E(Z? R8@@
M5.0J*F^DC'O[JTX);&"Z)C"%(#(E%T+,:'FT,G)9MU RFQR1:J:K-TCK!$]8
MT$P(1)!U'B=:;R$8F2$&SA-WH@C2N#!=:@NFZYJB(^?F<)V>8C'(#C\V!OJD
M$= F<3?O%K:XL75@YX1>TO%T]#>=1EF^_^ZPP.(?P\$QS>H0M9E_NV1*7:]D
M>SNT'=H<PM4KX((R3$M$]*21:_)%$Q5?,*#F45#BES"K%Y3"S3GF_GEV>3@G
MEVIQ']'L<7[JWS;CNI)Q_7U9+1O7SEBO!01D1<8FR2!$YX&4\YYY8:4*Q;CR
M;EKBHDJV)F&O"6QK"+\TL&T0;-T@C,M2D=,)G,D%;&@R!"D#E"7-6N<4,FM@
MZP?8UA!]:6#;)-B6% YIU%%I2([5O7-)@ROV#(@S[YU+)CM6P=:PMG6L73TX
MT["V2:QU0C1%A=A4=Z<&&Q,@MP:<4A&L(V9-W0W#JV&3E]^CVD(SW];(WT]?
M#LH%CLK[IVD%R:&?4!H.3F@RF/>XN#OXKR]!\PE-YMTJU@M1\3DP%X/YYM5K
M#SY<[8>W?G!ZT6? 9 V8EP#FL]G!9WVY?I:_'M+__/KN^1_I) C4!T\/V,'3
M']\\^N/1R^='O[][].#W]P=_/&0'XED!\K\.#_[X43U[^LO[YT]_S0=/G[''
MY7W*M9:_B6\>O7D1E',B^PS<(P$J)<$S"N 1)=JHA:Y-C_D=[$9A6_RO'=H.
M;8<N.70;1GJC%GDQ@G9:3=V@\6 [M.^'WFQ?<^UUJ&?R]9RDK2J\E06L3]K&
M956I,?DH,!81JH0'U#Y D-& "-D$Y85D'/?V[9 ;W(403P/S5C(B#<Q; /.2
MS A+DH4Z1B<D!D@A@#.&0>3)HL\LN! ;F&\TF-=>HM? O!DP=Z/!IA"P#1$P
M6 3T <%'KP&92*12E)RY;8#YIKN:3R:4:3*AM/ VF[/9#NW[H3?;I%V?LWD&
M]7-6K1FN%0S7G\M<RK(^-G-44$Q4<2F1:0CE*^2$SGJ118YB;W\G*@8:7/OD
M3C:X7AVN7:>1.$-!H@A+3D5G2N7 <TD%O<6;E"%KGGR#ZXV%Z_4YC VN:X!K
MQRVDD&*.C,!X4S"K66T$K3.0"=F%Y#'&M&FXWG27\--^3X/1:<.G:?,-VZ'M
MT-ML:?^__\<*+O[9=J/OZ.Z"3Z7+P>AX/)EW_UL0_ .*$_)3^FDR/GHPFBY:
M ):+FE[4 O!_%CT$F\Y92>?\M6SC@5.(Q0U1D)3Q@+DH'I=<@AA81%3,BUB;
M_>V"6W+#4;AN!Z*A<&LH['@;ND".:?+@<U" R@D(V2<P-I(1M:5PXIM&X6K>
MQOPMU,=-!>?\CNXF@^TC;UZ[#Z$\[FEPXM\=E6L;S";E?(L;.[UMS3=WCSM7
M&XY*VI.+II B9\6L\:!X$MIGQYGTTLB5V7,>;%D,27WP>E)NV)/R*<9I,3QU
M_O6'^G#5[5Q4GJIZB8TH5R+*']_\O*R.+I+37D**5:YH&2 PJR!GSZ*UD669
M]_;EBG,@FFBYGD96FT+=O_SA:VJ@6Q/H.FTW0G2V+*,"KYPM/H(NWT7*8+)R
M1D;R\[8;HF&N#YC3##F2#59JBU:PH((V4;J4BK[T:75O_5LPUVK6U@G(^7]S
M4#YZ^GMYSS]?""D]%Y%#8K9VF7,9K$4),MH@HS>"JYI,' K>6CINPWU?JD$]
M!1D4)30N%N6"UAB>HA9):>Z];!JTI^A[]SGZF$B(9<% >%OLH5<)@B %Q%@1
M.\(BU\4>MKXX6X^9K0%Q7QI^VH3H-2./?8X\K7)1-=R 041 RKF. HP@C2'.
M%$K);''_EG0%[R'V=NG0W>.);9;2-7;8 #L\[*ABXLD;'3($BPH0@P<K,H'1
MQ5&U@7/NZR9+U]W(T5=-W,"\_>;I#<R; '/'U$N-6FGCP!.96H!'$+ .U>0J
MY>+>JI2V!>9;V*KKR>M)?%F>\VGMD1[/=0EIM7FW\]#=LR';CM8\K=45KR?O
MYO9D$:.Y%__S>G2^>5PS&)<R&&^7164XD]KP6!L48P(TM<5&W6H1HU?<),XL
MY;U]P>4N^(8W"5[7$I?Y K;FRNP#M.Z/I[,#FKT<IY:56#,".Y*MIG0]0P)K
M6:TES!I\T=^0N<68LA=,R+J5WFJU"QC<I4-O-E^L/4#3^&+S?-&-UZ3HK)<L
M@5<9 2./8(UW(,@JB<[87'NTWG*^N-G(7GNTIB%["\CN* %>=(!&K\&I+* :
M?W!:"F!:2N]265]BVT#V;8S<?-IGI\*O?(QI+7(>^.,T**_0T<FG1<]7CN7<
M)-):'AUP+A6^LCX5$1(S<]**E(SS0>;L^-=FB;$/M'62Z7R ^=YQ^K6L!QTM
MJ^BX?[9RIX<MEFV<YR=HO+4:;[TKO/5YH:.*%-'D""YI!J@\@O5< U*T%+RU
M6+=A8+>ZN(=JY"9!<$D$X6KX^Z@;+@? N9!H^%LS_CK;H(+4,I@8(*I0RSO(
M0V"40,><L_76AYKSZ18:]Q!^NW3HS::*M15$-ZK8'E5T2Z!C=E$D&4'X.L4I
M%>_"ZB3!2ZUL,BI%'??V6["_]6/8A1NZU:+61FQ;)+9.[$1$@8&R@E1N+R"K
M56PN!+")&!5N"SHO[>O85S#NTJ&[1QQ;2:,TPMABT**CA+3WVO-D02KM 8.9
M*R$%PLH@O&#>!K^WWT81W%!4KRV%TE"]151W9(#"A)P%#5)Z!%2IMH01$21I
MJ5Q(T@:S:51?4_ID8[":3UB^;:U==NG0F\W4U[,U_^6B#=>/_WD]FKV;/^&-
M?U?CW_?+XDM:%6=:< 7<<E.W&B9PUA 0TSYS+Z01-1>TV2'AMP96+<#4;FB_
M;^AF)ZM\:1MZ,P#K, #B<P-@=61,"0M*UVIF75;'F<!JB6(2&IV1QNWM[U"#
ME2;9>E!YW!"[+L1V V&*><Z+:PQ!6UXDFS!@&2G0R=OLHO7D1=T!U"3;MF&U
M]I;B#59K@U5G8QTYG8N+FD&A)D ?$:SB I2ES$/T,=1,NVZ>T/9A=2V]#QJL
MU@&K;B\CZ9(L- B1QSJ_+VEP7B H+Q2&8K@*0^[MVSZ/&-JQIM\_^$-_'&DX
M>$"1C@)-%DI=\N&@PF$=@>&/_!+&DX(:F(U/[K+Z\0?3\>$H#3Y\M%VAG]7*
MXH7SQ;([:<AS%,XZDY0O#I.4/#GC\<7#+U;#G]'._-R+-%3CFM6XABVI:V=&
M*V.,!LF\JQEB62RX3A"U\$;8A#87JD&Y8E')"H_X>LW\)=^XH7291O@FB%Y&
M&CP\CH>OZ^UZ,I[4J[@W6\P0\>&0+IHATM"],KJ[$^Q#$@7A13ZXVHY4U,FB
M.D50.6I$KI1A!=U\Q9[X#=R]!_=2$YRR$\H&[I4@Y-D$;H47%+CV,047+XWO
M3VQPVS"[3@AWQEH(D3EZ,I!5T+5WC8/B=!/4B%5V/,C"T'O[;BCUBN'FAN+>
MH[AKHM<&X6:BMX/OS@0-IV1@*7C0GHF";R[ D;!@C/6>N^CSO)A+=WN&-W3?
M.'0K'G,VV<L@4#'AI(^"*S1:FNR8V#2ZFVE?)_2[A41>AYQ8<J P)"BN-D&A
M=PE,*&6]2RR7E=ZW9HBBP7]'X;]B]PCE)/<6I2)KT8004#)F ]K(D\V&-XW>
M R!W\F"1&./,AR+-J>XX=1IL^0T@LUXE4VPX+T"60RLOW]2F0;C_$%Y2T/7-
M^+UT'5>SY3V@@$[.SH4<I6<,D(NBXUGFX(TP(#FB45Q:9&EOGW,VM.SRB;M&
M GTA@14X(">'IOS+9;+(HW3!\B+L18PI,5*AR?B=AGZG')1QKW*M@D$EZ\@]
MM!"TUB"#=L[Y%)2P>_N.#Z5KD?8=A?\J&@ C5\7JEW6E@ 7IKGCSAA56<,4.
M1*.:!K@91( =(B 6T B"[&PL;@ Q*$LO0.04C+:!9^?W]M50ZLOWB6L4T!<*
M6($!I)>Q_)-U#H1*:\NUM\HK'S%JP7U3 +L,_&YYN;1:224Y""--S;,'"$%Z
MH.B#-8EX5+2WK^608[?M5%, -PW^(46I'!4%4'?ULAQD5C%%E:.QDB1K6;J^
M([P3X<M94\S<@<,DBX]?3'OQ^"68LHB8RQ*7G_;V)6OPOOGPYLA2+8Q,!DUQ
M^8(O:E^EP'0RJCPBN5GWG<9^)[1GLF8B*0'11@Z(C,!*+-9=$G,RBL!RGEMW
M7-+_>=OPW_7&+(]H-AB5Y_Z(6G>6=FA_#]V][6,K6#R63/"DI P8T6%T/EHR
MQH4HO,G<UMUC@IWN'BO&[ZNF[\EDG$>SG\?3:3-?:S1??%EX.BLI"",#J75Q
M3HLT >NBA^2\ELCK-G95*TBY:@T+;C*&LZ=HO8V"20Q&!Y6UY4+;B"QR'QJ&
M>X/A)?/0+$LZ"@1-6A3WDR4(4EO0'H5/F+C6=M<P?*/19@K:K VYN(@<DTW!
M<F.$+K!CQ9WP_DIH:X!:%5"=>$ZQA;&.&P/N9 "44A9 &5;[^$@F,F?:UGB.
M;FCJ YJT8BS4/6L,+2JI0XHL.LF4CSH:FYOMZ@_4.N&3LEQ""<6AV"H"U)E#
MR#J!T)PTR902+6R7ZQ9'7CO:;N'8OWF?CL6-C>.CDPF]I./IZ&\Z#;-\_]UA
M@<4_AH-CF@W&>3#S;]<W_:\=V@[=I4-OM%4UP9 NJL=*\NA#=)2E16),".^E
M3RM;U3FSW#_/*0_GE%+M[".:/<Y/_=MF4E<SJ6)9H9$V3EOE%'"5(B!I!MZH
M"&4Y79%*V<<D]_;1=AMO-?EZ$T(O#6C7 K0E?2-=DE'RHEUSJKMSF0 GB]>8
M/4O1\91S2 UH_2F]74/8Y8(:W :YZX%<)S*C36%)KPQDAL6V^2# !N; IL@I
M6\=8++:M&^9L+25W/";3$'8]".O6LV .A2!=61=?IX+)"-9A A:S0FNX\!'K
M+/,M#!*\A>&8^W[Z<E N<%3>/TTK0@[]A-)P<$*3P7R/^-W!?WT)ET]H,M_M
MO5Y\BL_A69!Y-#Z>UZP]^'"U'][ZP>E%G\&3-7A>!I[RYZ?W/FT(4\[W_-\O
M63SZU['_P[U^?/3HZ-G[A_+1?_^N#MX__^OYTU]8.=_+9_/O7[XZ.'KX]D \
MDX\?/,0*]T</_GKWZ%4LQ_Q8WCN^B-EKD3168QH $05X$<IWG <3HR2=ZZ2"
M.ZI;M]J"?NW0=F@[=,FAV[#2&S7)<U-7WJK8ND'CP79HWP_=/4=SE:#.VJM/
MS_3K.4U;97BK!5BCML5EM:A"Z*!CD:(RQ=HOH=8",,6 IR1]Y$P9%?;V[5 M
M<3Y[&.!I:/X&-*\[&=+0O!DT+ZM*M3YG(X%JZT)D=:H61P<^R*BU%SX(T=!\
MH]&\]BAP0_.&T-P)"T>T5.=-%PR3*[:98;'-R8%6I"4IRWPVVT#S3?<VGTPH
MTV1":>%P-G^S'=KW0W?/IO5\R'5;IK9,;9ENG>G_M*/'8'3:TF/:-$ [M!W:
M&+:WAG#W;NB&JT@_#6H<C(['DWE_IP7!/Z X(3^EGR;CHP>CZ:+)4[FHZ45-
MGOYGT26JQ3E6BG/4B&6WP#0Y9RD0!V5C!%3"@E?*@25"2\;%LN"U7?,NA"QO
M-@[7'EQL.-P>#COQQAQLY(9;2"D@H$P)/$8#PE@F(L;,ZR:F#>/P%A:@SBLX
M(108I,&)?W=4KF(PFY3S+6[W+75&=H]95QP&R[TQALDZXAN9C1:CMB*Z%)3G
MRJU>5#'/U"P&3CUX/2DW[$GY%..T&$0U__I#?<1J@3^59ZM>8J/1U6CT[9+Y
ML(1"R,@S9&<RH X1O$P<C'">8D3!E-O;ERLVIFR2YIHF/&X(=?_RAZ^I@6Y-
MH.L,;:6,9'3TX$@KP.(C@E7&0T8>.9&)0<2]?=$PUP?,2=(L1",(@T<A5<A*
M!C0^!HK&1+<1S+7BA74"LCM*-:'PSGE6FR%80)XR.(,($B5WW)/!2'O[?"CT
M%G:UW1I4KCCLU/IR&BL#CRJB3<42JH)50A5L4-JPID'[B;YN2(TI8VTN#CR3
MJ4Y'*.@K"@=DDJ10)ZLK^KK-]%I$;<,1M34@[DLSRIH0O6;D=8-HQ<#I; 68
M'(O=2YI#,%("1V&TEL;HS(L2Y=WYX3W$WBX=NGL\L<T:_2:9MTT=W>I]0B=3
M#AZDK=01DP%;_"+ PBDB!<6TKA.+APQQ9R1SP_KV^[@TK&\=ZQV98"F[R%&!
MJUT#424/S@I6!#J)3$6J6Q&VAO6OY-S2:'IRZ-_5:Z(O [D=V8YL1][$(V]A
M6OZS;4'5:)>/,:T9^8$_3H/R"AV=?)*A7\.UR3ON$E?WSY/Q=%3?^NZ$#HL)
M_YO^66?8@;A3[_[G=[N8^WJ"O?WO_#_65TRP>Z)LQ>AH<N@\2\&@,Y@<=^2Q
M_!MD"EQYTE\19NR#+CO)=%Z3W3M.OY9'AXZ6Q4COGSUDIX<MGK!QGI^@2;'5
MI-C[(L4^3QVFX*5!=$!6\>)K60-EA0-(+J7/G(OHV=X^RE9^N/5@Z14!^-$S
MNAP"YPY2 ^": ?C+YP#T)M<,O8;$A :D;"$XAJ"23HJT2=SZX@IU"V9ZB+]=
M.O1F<\7:B@P:5VR/*[IE!2KY9(0B4.@"U%([\#XZD%DDQY3+LEIKWAU<U$.R
MV#T ;KR:X+/<9E/.VP1CI\H@>^=39 ELL=& A6(A:&<@\\P#N8Q.FP+&G4E6
MW"! ;J+2H%G&+8*QDU$(TH@L40.C9 "M]V"]806,*@DT4B:)>_M+W-B^HG&7
M#MT]YMA*A\#&&%L,?'6T=.1::Z]MH0BO ,N:0G&.$*S4A*8(:JG$,O/=0RG=
M4+W%S;P-U5M$=7>Z+W=*9(N@;45UD7W@C0Q F+(0#KW/>=.HOKYLX0:Q=7X_
M>IW#^_O)J_'+X\$/KZ?ET.GNY/S"&G-^[=!V:+.]6^F@_Z6R_Y>+KA@__N?U
M:/;NT7A&OYV,BI'-3S]V$6@E?FLTQ.R3UOJO#NHY7V0NLG<9(0N? ;F-X+)B
MX%$%9ZU@.<A:XJ=<=U]J#R7VS0;D&D9O7QF0#7.K8@X_P=S[OUZ@\9GQP N1
M(0%Z9L [[8 [(3#F9#(KXA=%=[I:0]SN!96:">P5',]%F H<R^]?F$C::17!
M6FT 36W08*4&E7EPSCC%:D<I,60M8;M]0%[?J.YF J\/<^_.84Z4XU\DEESR
MFB 8$P M<@@R%-EI39;.\LQLP5PS@%O'VQKBK\T ]@N,[#P8'SUX^"*&J+S7
M9071%SU:]W5:P3483SGPK(+)M#" F]T/?DT!V8WA;#Z:_O/[TY_@53MT]ZB[
M-?B^73>T/?=MF=HRW5YZVNK\@:Y"GRN:IKFOX@"?%D"XR$56TD((FE4'F$%(
M'(%06\FQ>%Q1[DA9T\U&U?4T.FFH6J\G>XHJ'>Q\$Q4P#!J0,P4.701*QBO%
MG!5U2$>?RXKF;Z$^-A(XY\]V&PML'TD_^$-_'&DX>$"1C@)-%J9?\N&@HF$=
MSN]'>@GC20$-U/HA5C_^8#H^'*7!AX^V*^RSVOZDH+44*6=TEB/9X!/E;')6
M-AK.E7WQ\(O;^,]89W[N1>WCIQ&U/'I+"=[39'Q&0:Q1T&4HB"_9J!]16<,U
M@< L  -&")8D.!U#0IY8-OY,)Z^VRV&%QW^]"N"2;]P0O$0^?!M\+Z,:'A['
MP]?U=CT93^I5W)LM"C]].*2+!A%]%?E-?%P6^9T. 4H+;GEMC!@$UJH.";9H
M$4C>NIC+4R"3;<B_J<A?:KMC-E:'$ OT'2:I7# Q><F%(9)<B4N#_T+CW=)A
M5\5Q9S2.(4/<I  ^,@,832HXE@X\=UP(])QCW-MW0V0K3L=I*.X]BKOV>VT0
M7I/];OA>$=_=*3SDDHG<@-(Y 6I7Q#G&8K:%"(@F6A_4WCX:UM!]X]'-3(XN
M46UE'0O3ER>#2:.*@,O1\VQPF^J\F?:K0K_;F$=2]+[\"R)Q69N72_!.:"!2
M4L?BIW-G]O:M'6JS8D?C!O^^P'_%?ID&17D8!&IC/!;7O&#?)LN,CESX&'W3
MZ#T <B=]1BRQJ!$AY%JRIHO'[;0K/[)L=!#2<R/V]N708M>,7Q3L;Q#N/X27
M9+V_&;^7KDMMMKP'%-#)]8EHI%8D(6CO %EF$*1"R%IZ9.6E1'40"6=#9R]?
MM]I(H"\DL ('>&6E*KZYURZAX3%DJ7TP6&Q$(.VW&F1OT+\R]$5'QB-G0C('
M.=MB_076_<HV@A"RC@WDRC.VM^_84"[9M=QD_$[ ?Q4-$+TK[CKS(LJ,"KVW
M6BLKDBJ/21"V:8 ;0@3X.1'PR(3CC(#;6(B@B #P7",822XXI4GXO+>OAI(W
M-V#W*&"5OJ',LF %>B4M9NNLD")XH9 ;[@WRI@!V&?C=KH#,16492F " Z#1
M#ISA%KS0GCLE"R\4!:#E4,BN]F\*X*;!/U!*EE1(J7B QBL7A! 4@G5<.J]T
MR]+U'>&=")_(W%:5#S8H4?M^)@@)J6A\(X.1.0D9]O:%[/9D:/"^:? 6/DH7
M2?H8#2(GJSDSD2>K77'PR37KOM/8[W8)%]$*P30DR8MU9T7;6Z,,6&M<,(8'
M'</<NJ/IMHC8-OQW9]>Z68K+1S0;C,IS?T3KW;H>?/SKS\GX]7&"T^N/D2CG
MKU-?.T<[1SO'9L\A+G^._@B-Y82V2B(A1):8]"S'5)Q*$3)ZXDX7#>J]8HN.
MI_S#9C_^=<7Q9#+.H]G/X^FTJ88UJ@:Q+"N@L@[(G0<M* *F(A@"$P@ZF)!M
M)(TZ%X^!#YUQ'=6PQL;8E]TJ_R69<AG,K=D_:92UDY3EN ])B"04M^B3##[Y
ME*6)%D5FZ!ME]8:RNF',[$+VV290-G) 8R6XP!$\F;IA4#LDUBBK4<5ZJ$)J
M#(Q<<D;)>9F$<S$15P%5BB:Y*U%%8X-5V: 3\C0.A29&H&4L J8P P0M#"BI
M%!5IRJ6N.Q.Z$<_&!(T)5F."%,A';:)("J62UOGR34+G*%+,JHF&_M!$)SJ:
M WJKD@965JP.-'7@I9!0E!^WA=.99C4S(H9,W&JJN+YY3I^= NKQ=_%CTY9/
MFK1LD@+FG806=SR.CTXF])*.IZ._Z32@^_UWAP6A_Q@.CFE6AT/-_-OKF+*T
M^ZYD.T<[1SM'"]]\(PVO4KN*S'%DTC ;$9DP@1+W03@?G#:)S"6DV 5%K'-C
M</^\&7@XMP)5I3VBV>/\U+]M@FPU02:75:%B\DYRZ<'HHL50"@T!K0=A)5=:
M.ZZ]V=M7MMLOXL(:U.9"]1ZX:PB\-N!N$KA+JD@399'0@N560&'B EQ!!"H$
MG00)ETULP+UIP%U#&+0!=Z/ [41*K>!*JEH;9J,"+$P,UCH#AN6BFRQ#E<TJ
MXX,:;'< ME>/63;8;A2VW;K.3-%+6XLSBCQ&H3DXXQ&,\<03N5AL;K6WW5SG
M5H!["P.(]_WTY:!<X*B\?YI6^!SZ":7AX(0F@WG_E+N#__H2:)_09-X)9;W@
M%9]#MJ#U:'P\K^=^\.%J/[SU@].+;NV,5X-L\6OO?=HLK9SO^;]?LGCTKV/_
MAWO]^-6?Y1I_.GK^].7+9^__*O?DUU>/__BIG/OWMP</_L+R^U%YOW*MC_[Z
M]_L?Q:,'?[U[]"JR1P]^E'76M$;C15#%,9:R6&W2'GR@ '439X@QU=W;>_O\
MCNKJ[1:F;N=HYVCG:.=HYUCO.;8A\C:JZ.9*J;Q5D4J#9D;;.=HY;O,Y;FGP
M:.T;>\Z\SG.>:'6>6_G;&CU2M72;C^32.L4@2<J 3&?P,AC ("1Y+A6BV]NW
M0\MU/\)(?:2!1B7;S/LV*MD&E73SOSPGE@-CH*U#P&QTS00;4%P3)B5R%+%1
M2:.2'J>T&I5LA4HZJ2VKB9A "=98!ZA$@)"S .*9I^2-1JMZ124W/>[Q9$*9
M)A-*B]!'BWRT<[1SM'.T<]Q S74V5//6[&WKXP/5'LI;_E#>=$GY:3O(P>BT
M'^2T:<MVCG:.=HYVCF;&;X 9;P]#7[89?1K</1@=CR?SGM4+W?& XH3\E'Z:
MC(\>C*:+QM7EHJ87-:[^GT7GZQ;O72G>>_!VV0ZD5%-_5B7@7$E 9S6X'"4X
MQ9,QT7DK:A:Z'['>ANA^IFL:HK>'Z$X&A\AH0R* )^D K2<(F@@R)J:0LS#?
MG= 31-_"K4GSO3T0"CS2X,2_.RI7,9A-ROD6Z]"\\*;FK] C;^EL<.D#<R1]
M^>(* W";4M;9Q,B)Y<(**Q/^/"&_F!'^X/6DW+ GY5.,TV)V^/SK#_7YKGM1
MJ3S8]1(;MZ_&[46I/?MT%]N]%QZ3H:P]H"X2#;T28&N&7J0LE*2L<I![^QIO
M<[>\1AIK::RY(<;XES]\38TPUD08?WY.&)QC")0Y)"9J?PD6P98EA>+0&Y<L
M<N&6]I=H?-'X8B6^"&AL3)&4DPQE0*^SI%2>/!X(160;X8M6&[A.,OFQV^6?
MV<@P<HC*)< ZSS DEB KZ1V+2@J;]_;YT/&+-[XW1KG-C')QE&JIW^)D9"Y&
MEUAVR(QP3KID! GA?&9<-+^EG\S1B3)[ZPD](T!E"G,80G F&9"<2291,N-<
M80[>CZ!4 _!Z-AA=';T7-+IJSL0F4-R)+ MG42E)X+B7@-DJ\"H'D$SI: W9
M% N*Y9)9I@W&NPOC-6PY;C#>$HS??[+Q^-4!/G[P\$4VE(7P$;@(#!!CAL!#
M@7%05%"LM:E;?,P-;1;;EW/<(#;9YJ;C%B?8MD[H;D>6A"FAC6",T85@4$%0
M$<%FY3+3.646:YP #6MQ@GZQ4F.VWHPB:\RV=6;K>$"JJ"//38 XGY!A@P!O
M8X(L7)%0G'-E66.VKU7UI-'TY-"_JW>'ODQ"[<AV9#OR)A[9**(=V8YL1WX[
M17QK;?#&G(?Y.([/Y5>KXVWG: YWVZ78LE3M86@/0WL8VL.P _GK)8'9EXL=
MBS_^Y_5H]FZN]%J =;4 JUC6%+O<=\^T(W"N3E9C9""X6'ZT:*5F3&DR>_M6
MM=QT$Y3][XC=F&)=3-%-,D?TSIML@)R,@#HDL"%GD)QR((8\:75SF>*6(G3M
MO4@:0M>&T$[1-ZF<5&U(+[+@@#D%\&5Q('J.+!>2=1CV]F]HF=EM!>BU5$$T
M@*X#H)UJAISJ'CWI(<:LBPF5#HI;9($5WRAK35G671E.] .A7TD'A/&D/".P
M^)N[LKQ)&K\.AS3X@(IEUZ ^]@,YESGH]@?9/@A_\(?^.-)P\*  Z2C09!&7
MD'PXJ$"Z1)KATC?H*ISVU3<Y/6 V/KG+ZIT=3,>'H[1TD?K,B:OM8].&61ZX
MI! T,IM<R,%R*UQ&96((+QXN(T/6X<+YN1<E89_6>N716TKPGB;CO38L>B5B
MK//=/]\U'[/DIGA\@-8@H(L*O'<11 I"Z& L.7$N(+F;=5[K1.J&1->Z+OES
M@MLZJ?4C7_U?VWR$5GATMD_R7=W[;0Q_&;G[\#@>OJZWZ<EX4J_BWFS13L^7
M&WU1.[VO&H>FFB]K''[I]&"*BA=_UH).Z $#$^#0*I!1)AF4R8F'9AQNCG%H
MZO>JZC=G\MIK65"#:*/P*')@UD4A3$B97YH;+Y2_;:O#56FNTVHN)R8-4H8B
M@1T@%P1>$$'@&;D- 9TO&M@-T72;-C22VS62VSJQ-06\ZPIX;2R_)@7<3,"*
M)J#3/) BCURK -GZ8@*(#/C@%:!@R7HAHJG=1G%)NX]F )H!: ;@EAF X#6J
M2OHA"F1!!*:8=$D%2S9DI&V&0)J#<%7KT.T&*0L59RX<N(P1BLTG<,)Y\,5A
MB)Z$%1:+A\"&RC478?<M1(N#7+F=9?:6>Y*6RE=T.CFI45K$E%FHG=5:(*0'
M/-<I8W)DE5:(P&5D@(7C('"5P C*G*7$C==[^W)HU1K:5S;":9*T2=*UE:-]
M.^-^J65A$Z=](^U.:5O*M0S<(OA4&_5P3!!DX?!L4>C@<TZ^MB#C?"AUH^U&
MVXVV>Q1)\-Z5V\1B]$E@XM:K)"33.<A0Q\_8%DG8:;+N;/H3+"@A/ .73"'K
MI#VX;#,(9D063#OGL9 UDT/I=G:V53,1S40T$[$V91^TSTQS[;(J>EYGR[2)
M407BS$M'KBG[FV$LL+/O,V5K.<_ @HZ IBA[ISR"R<D1MXZ\U'O[:FC=&G:6
M-=)NI-U(>WTMDK7WF7/'>, 0R6?)Z@ @X:+VC*6FZW>9JKM;],EZHVR.0-P8
MP,!YK2%TD*)T.O&0<S9UT,10L)8A;!:B68A;;R&X2]YQ#%X%CTSKD&42+IG$
MB8*+HA41]MT(=-*GUF>KHA!%I<=<]+K*X#%8<+ZLJ"$FN1![^T)W=YDW"] L
M0+, M\P"!.ZUCDX8RQ(6K\#;C%8'G6IM>;$$S4?8:?/0[4&"R:A("LI7!BB-
M!.N8!L458M*U)9N>^PC8+,25NZ=\/W_8R__3Z._]_U.^?-:"'"I_WG4GG[5
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M\&!DED3SXG'1^PWZ/1;M#X__IN/9>%*<NR;3^RW3SRU5(Y_UD<_#-TOTN<3
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MMKXG#=8H#<QX18[K7(!:I]\,+6L#X'L P^L7[PV&UP_#CFY793%5UF71M+6
M7$OP@7L07GD99"X"J,!0#ZW<+ IO@&Z?C(LV2*>[L":4Z.AD7FS\_;0\M$W-
M[T;YY8=5_*DLXF]EW0[\[/5D-'MW[SC='Q\>TOR*'N<Y=\T:=UT;=[U;5H^I
M>"@FAT G6;C+U:)RQPR09-E9%BR*&G,P0UPRTVMGZC&;IMF9NLI&%KTABXZ_
MP2T:S"9#M0B%+%*=_B<1?"$*'STKE%'[\O$ALUL8 -@ NAF?HP&T+P#M5E"R
ME RW HQTM8(R1K#&:>!H=9%S3&7!]_;=D-LM;.+\ABUBZLZR[MOSGT?'J3Q2
M=P'GAVP7D^+#MK'O3LXE&O[Q_<FWNB^#-Z/9R\&XW-31L3\<'"T@-EK\R>SE
MA&AP5"[H9?EY,BAG:OY.+[(7)YG.0C(_C2>?,.62P,P?99$?GZ[QP=D2/\Y/
MZP(?S-?W\>3GLKJ--]?(F^^7>$$VF>0L>HB<2T!#":R+&F)YN+32(N5(>_NV
MZ)INX7G+<_1&ZZR_+_CU(;J!=D70=KR1)#VCS%3Q090 U-&!BXY#$$**%+P(
M)A>Q(U;LF=?@V6-79&/P; 9WG=CM."HB*H]*(93USH"!:[!128C2F6R##Z:.
M"=)#)[8PO/<&Y$W.USL=CH__; F27CH,%^9Q#_SD+YK5Z0:_43SEJ49*:R0E
MML0+2!A<]#R"CE$!2AN*EO ,""F(P"QI,1\[PI:,"VQ>0'_*+*Z_VFDY/!L"
M5T1@1]*[3(S7 5U9!@Z85!W8F2T@4G'135E('??VE;M\M6&#V0Y7,S68K05F
M'?7-!"5>-#802PXPLP3."@=*&B&1E(U8D_[L\KORFNR^9+E2$^,WI%KIY[*0
MG?1FHZ95J&G9Y!VEK"4;J7!1M?M$$9QV'H@'K64N/QN_MZ_1M6*D6R))=J 8
MJ7'!.KB@XPV0K#DYR4!I1H &%=@8 B1MHXDJ2%/KJHMD:0'^?N!O6[5&#7_K
MP%_'33 D55!,@0Y* \JLP25"8,2CB(G5*=K%39"];S?=1U]A[N).1W/WH#H&
MX?6T'#.=TG0X.*99_=6\";5?N,*I^0A]\A$^CU3\<+9ZCVCV.->.DJ>OI$_#
M]GGTEA*\I\FX,=1J#+5LT$S".C^K4)*7M4^"]D4AV!"+W\ PJ"R*#E15IEO!
MQ3^;Q] 4R^93!8T9-L$,'=\AB^1D9J'X#DX <IDA,.[!%U(PG@?F2%[,#,U_
MN*DIA4O#L>77KXK)KC^!+J*P&J2O<VZS];6QB 2CLG,B2"%)S>?<6MVKS$,:
M34\._;MZ.?1E -^.(Z_)^4JCOS=*3(]G+VERFH;Y=+#/W -;HSK$.]9<II_S
MR7CA$-Z=T*$O%T/_K,VL0=S18LD>%S^E1:_G[_Q'<,QO8O,1^U34]5EAZORQ
M.VO/?7Z\0+,PJUB89=.%A)%,.&1 3F5 Y!RLR0+*PX7:(.GL[=Z^7*$;3O/)
M;E#]5D/B=2&QXW\QG>M&5 <,>?&_BNZ#8#*!]2[[F(+4L9:8Z-:7J@> NS:W
MJP'NN@#7K>F2QFGK-012!*B8!B<S0@S.$C/*A"0+X)8D2_M3T[5S8T&__^[U
MM'PS.O['4C]B40=V.BNWOC0^FY;;9H?V5\9_MLGL*Y/"EO#9_;,5;^.1KX4
M<8GV=ZG*1B:!DRR*P]11YM)+(&DX&:>,,*$2X%!)O+K\;Y,!>Z=BUK_[NR&_
MC\COML$MST[1K K"?*8PCPHL(PW&YX08;$T)[^WCD.MNI<J%P&_X[AN^U[]]
MO.&[C_CN;A977$IK$'A,'K"H.'"<.)#WR+A2TM?YOG)HEVP6WQ:^F^-S-$BC
MZ:GO4P[=N.O31Q+LLWMS209\<&Y1SW-@H[E5:$XM<V",=E;R"'*^_1R9!6LT
M TM(W$B>/-HZ_KCE+GHL4J[/"6GXW"P^.VZ&J=6F2C+0PA89@K55MK<"R.8"
M3<>3RK4]!.MN36LIC1OD+#0<;A:'W4P'CSCW[Z4(J;C[QH"U217O@*>(T7B=
M3;63W;YO_<ETK%(4]=DIH!Y_E]LYKOOM!FRT*FG7 B)]]@4N'Q!IP8_UL=TO
MRV9H!U8DI68&A$P94-1I7XPR< H^\:AS<G:1UEAA*FA+:^R.DNE#6J.A?+TH
M[_@6EI1TTB<H_U7?PB1P)#(XI;5$F1C5[2HX%.;RE?$-R[W#<A]2& W+Z\5R
M-UV1$%E$5AR2ZI]8AF"3KL.UG*'(E3!:U72%P]ZE*SZ\W>D#+N<(_D:<?].A
M5Q(F:[Z4_K_CKG=!6%Q1H9[Q(CQRMZP[31:;6GX:'?OC6/W)>UU_\GJ?M2_<
MM][XB<MWJ*X'I_WXW*MLH+\&?MIU;'W>C?#<H*'",Y/QFW+U+17;JZ8BRZ87
M/* P:WT"UB/6EDW^"5H'C9H@9ZL! RH(Q!0XB9D"6>FL:!U$;ENFJ3<]!R^F
M@>:X794+.D$87;PTJ6*J"U4<M\0+#409:_]_+85-@CBKB:6A5%MH>=;@M_F6
M@PU^UP>_3MS$"3)H581LZCPOD3R4A:SK%@L492BJ*A;XZ2&J-A3HF_R!47&H
M3_SAX.1T>^:@8*OY!7WW"WZE#^MU.E6Y^07K):-ELX $:L^MR* XKT4FOHY(
M< $BSV5),Z()K;/@K1,F6^UB<4D>:,KDJF30W6"6*:NR>&"*K 1DBL"J0@M9
M:5+!A<3-H@:#M\E$?8#>VIV"!KT-0:^;3)5&9Q,5B$@9T)(!SXN/H(6327+O
M<\0ZF5N:R\_D:^[ AWK.[\YY O_X_N3K"8/!F]'LY6!\.D-W<'0V1+?V*Y_5
M,;J#HW&=HUN.&1S2M'D2_2SP/!_EN)#<%M,6CO]\>-SFEU^1VI:-.O(N.([*
M SH1ZK!#!BX'#9XE3"8IZ>M^$K>&JLXF-?JL\J\-HDV:K!._W9I-KG-9^PS:
M"@UH*GXE(\A&D/:>9>(T;SLAVHZP&YXH:/C</CZ[KD-AYEA-:V"QX%,1E>\2
MAQQBS %EX6Q?O/:A4MV:ZI9.6+&\:#2=OO;'D3Z=<9H*!)H'T*-<PGG2>GBZ
M9(OY:1\C&HUY5F&>96.)@L0BY$D#XY$59< ,6*\-,(-.1R$<U7BA6Q(L;(F#
M6R]4KK6@Z"+,-RFR3D+H=L,V@FN>(S"7$Z"(' H_)+!)!BZ$UM;JO7TU%*(5
M%O4$AM?J+S08;@*&W0JCA$PS7CQVB<4NQ^(;6&YKE5\2SE@R4KCJL3ML(TW7
M5F#4O($^Y0,NSFLV)KHF)EHVJ(8E%;VR$H01MG@(TH*7(H+)JIB2G(.RM:)@
MR-@:>E4WD=#G\']#Y#80V9'H2G.7R7@HT(N +!HH,B]!LBD6?]XX[K!J \8V
M.T&C 6_S)3X->-<'O.Y4T$R>2Z?!2ID7;15M*J;0"DH^F&A9[=ZNAY9=/A/>
M]/A<C[^>Q)=^NBC.B>.CHUKN/QO'OYH([U-(_N.LK,)!ITOV.-^?K]=O=;E:
MG?]ZV&?9U!B5N.3%O@/S,A0A;FPQ^RY##DQFZ8Q#DUJ=_VU3(CT95MGXX+KY
MH.,&9!,J'93%LJ;V ] "7.2^-@70R@E;EE)?S <M5G]#O(%50=C\@JLBL>,7
MH!>2E)*0>*+B%U@)7AL./ENM5$B.^5@K_^V&9\CNOE]0&P4.TJ@V"CQ.T\&)
M'Z7F$?0I+/_D+!+Q>%+NEY^\>_!AM1KMK)%VEDUA$5HD,L2A&!,+&#D#6Z@(
M1-)D,F8I7:JT8U:HZFVR_ 9$YALH-P;*CBH/UKF8K(7"K:F",A90\O*C*2ZZ
MLA*C8164B)L=^M"PMUDYWK!W[=CKZ/ LT$<9,O"D%2 9";8ZR%(Y%559YI2I
M8H]AGT?+KV7@RN(DH^/RX,WNPN9'L#R>O:3)()]UQOTX:64X.*:/M36;&+?2
M1^;J87#_7-'?N9C"?"'/.AR?[\W>^&H%OOI]V<"4%*PAKP4$8R6@#0*\%0X8
M3R:6-23M>&TCUH+Y3;EL:3MO8X+K8(*.UR"],HEJD1T+=2Y\T3 A%'^>"PP8
M6!&CH9;[XN5+[!KR^NPS-.1M"7G=0GN9HA79@!4F CKCB@TV&;06Y)EF5EJS
MMR^7E-GWQV/8Y9GLRUR$Q3[=TYFD]:6-3V3?M7E/O<@,K#;O:0F?W3];\?-C
M:%O09&T$^':)$X)9%/'!+.A46XE':\ E94"'HBJ3YLX:L;?OAG:)']*&-FX;
M^'WV(QKP^P3\KL^1LA0J.D#K:STA"?!>LMHOU)1O;-!.[>T+/M0KI"H:P'L'
M\(U/<FP WPK N]L5A.?("4%Q6P#.LP.+S( /0=99CR+D12K2]FZZXZUV?-)H
M>NK[E$,W[OKTD03[ERVY).\].+>4%S%?JXK^5M)[M\2=*=Z,UUYK0&>+M.$N
M0+%["H(2&27RNH>K[9*X;>'=;59CK9$JFDBZ*E]TO* BDC*JI" 2SX"Q#DQ(
MW(#2V1 +@="&O7W.A\YMH?=B@^A&BK::->\'.KLNC I)*&W!QIJ=T>2A\+&%
M@"JF3(Z4V^8>I]OMK;1<S W.Q33AL49J6S;.F7.F12[41L[ZVDQ"0!!)0)*"
M3'!*:6%:WJ6O(+\9>9<&\O6"O.-=..$%):D@85$MJ)P$JU1-LQ9A$W)"G5,%
MN<85MF@U+/<-RWU(L30LKQ?+'5_$1LPAAF*K)=/%%Q&U^Y-CX).U0D2FC-&[
MG4ZY$3M/?LR9XJSVD:*W\:4__I.@..HT6'P_[_,Z]W/\<5I\0_]Y/?J[@*,V
M@:V_G-!T-AG%&:6+#]SH_I5=X],^.T"+I^-Q_O'TV?BU/!J/CRO%UO]^_+C"
MOYX]!?6%>\?ITU^<.[)QZVK<NFR&M=)9ZTJKAM.\LQZ!1W*0DM5,E_7G.NSM
MJS7L8V_JJ7?JZ?H\H8;V/J"]6WGF5(Q,!F!:R8+VS,#I&,#8HJ4D$J*M_7)Z
MHZ(:IGOD$35,]P'3W7TT)ECM&(+1"@$+;X/73D!F.5HC4!5FW]N7E]]&<P-=
MH\UG=$;'<4)^2M]_5[ U_^X?Y7<WR 'J*X/VLV+MFQGR2?G X_3P]&EZ</HL
ME9\/7]=;?YZ+%_S<*'4U2ETV=3L9-&03!YVY!K1)@W=!0F!8;"JEX'7:V^=+
MO**=*6-; =E]%&]]99]^%L$U]NDQ^W2GC&0=?"Z<HYSA@#(8"%$P,"EA"#P)
MXXJ3AJ8;[/XR%33$]Q+QUU)3UQ#?8\1W7#@R7 ED!"H6V&,,')R*!K2BE!A+
M:&HK!"[ZA_@;TNCX2A[9<.!G@T!_CHZ/YRT3\N!D#J*V;>@*I.BC=)&DC]$@
M<K*:,Q-YLMK%0.1>/-R ^FF)_37RWK(9Z,X@SR)ER!(-(!<)?.T(PX(AP;6J
MNZ0+[PWM$N;;&4^K%\*JCR1Q9>7$D15);'-UUXNO%+PJ?E(*3">C,G>YDL2U
M"Z9&$NLEB25#%\E'\@R(N0R8G87 3 )R/IG,O5+*5Y*0JMLLH6T3V@HP+7$6
M./'(LT5MM%-&)EN6SM<!]T;,@6D;,'<*F!VO15G+4?H$P>ABO5GB=<,O@1&I
M"#<?L[6Z E.LZK<TQV2-C@F5%];ADEPRH+RX4W=E6;;_G[UW76[C2+9&7P7!
M,^><F0@F7?>+/,$(69)G:SZ3E&UY//(?15TER"3!#8#6Y>F_K ; 6X,20 )$
M0ZK8>VA2:* ;5;569E:NRHR#<W^<)GG#>^7A'WY&YL<O?[OC)OM]QV3;@SE/
MG5+!,FU(%,H19[(PRJNHG.(VZB:86W<BK9J#%9J#>>WJLY0B*LY!1K0$ ITV
M,)XDR$)8$2Q10:=B#JQI]P#8FF!N-8A^&&_S^B[@UT',\^?R5F+^*OCW_AF&
MNIGV]?%O*TXFR4N7C <62]$QK@78: A8EXC3R2=%]6V;:8ND$2KG5<[;'LZK
M>X-?(>>UMB <,<1HE2&X&$ 0$\%)$D'%[+E.D3$E[[0WN%G.FVY>S!YFB@'>
M,-VU;43Z>4*<NPDRYTUS:"[@^DW#=8+>+ 1YZ#VYJ,@(UR:K^7+?C1W.RDP-
M>T4"//T02?=TX9:SP:A?9OW1,!V[<?^O]/W[?AR_G?'*E3=.IYQ<OL5YG-[S
M<?LMDV'8_Z<??K=_79;;_&@>[<:"PK$Z=F>C]&CVR_>Q/SH[=A\?]4^;+]^\
MZ?L3-WS3/YTMO_(%;DQ$,U.3ER\?:X],'FTZX],[3U_>:UZZL<PGKW&[)P6_
M]66R1V]][7,?2_6>4'KE'XM/J^SM+U_]V"]L EZ!,6T0/B[;:;B0+8\M('\1
MPB?]&(_3;=@05N?%L6$7VH)YD?':8>_Y:=A;8&-O^FTGFOCVU[WS8,QGBG6.
MQGRF*'M(O1_1WO8H@?^SP0&9YR%>#,<%;3S("I%RSG&!.<1Y]>?;X:5Y>)/
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M&7\-FK?TIP6O1KL]-^J]3[@0\;\IYU0V-U.O[) /3G -X2T'S<,U^9W!<6^
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M'(XOE6I3'">O/7-2 0E.@ B.@Y4D@S2)V\"RT-05'!-I*HZ_*ARO7&I5<?R
M.+YICSV:84G1%$<7'0@D9[!98?P0G"(Z9Q](VMD7NT9W&L=+P+6+J+RW>F %
M,J);NMU\"9T5@$L!\.BF(57$Z!+:@(@Q8\1.&%A+.:0@C?(T2Q/BSK[2K.LZ
M@6\%:BL0ZE2H/4CL>2G,H8<O7WTZ>OR:>RF-%P0,1AX@T#D!(U,&AD%(DKQL
M-"#8I&AOCE6P;01L*Y"YW!%LU>M<)1*?WT1BH%%2YBEDH3!^I,Z#U<P#.J ^
M4.*2\'EGG^ZR4N.O8K$+6%R!S*1BL0-8_/DF%KV)AH=L08FD0!#%P?C P7&M
M&"WQ840L\ET,)2H6NX'%%:@XJA/Z,'![=1-N+(I ,+(#[@@'(5@&YV6 H&ST
M+&:9>=C99YQ7L'4#;"M0253#UP$DOKF)1$*R8MHE$!;Q)P2)8$F08)-CW&45
M3:;%\ F[@8#PFZL"-5G[O3P<G,R:;97JE%-LE+:J/N5)0]G!7_W2J/B[O_MT
MFG)__(^"E-[8?4A-NX:))*.J+CI456DRN44)]B/.[Y.+Z3VZF-T?FLF=7/>R
MS.2S#^.A&PQQ<-WPX_-Q.ADA4Y:G' Z.CQNNG'3GK32YGK),TPUJHJ@(C%BP
M$:E1>*7!>E[<%4-$5,H25]P5MLMDVV.IY_%KBGGS]8PJ^6P)^;1D)M'0;*D.
M('7QT(+BX(U'-XT[(<OI6MV0SUR92>6>RCV;+R14N6=;N.>FXV,8)R)'"<08
M H(E# QQ10"2#KYB$T8C'+E'['+:/GE3R>>;WS9:>6F?2B5;0B4MD8^WQ(IR
M@I=)6P[P!0HF* I)*N=CT)I2O;.O=Z6I&9:NG(U;G\YGK3BN4+UK]9[9KG!V
MP6!LD2'XB'8_$ 4N" <8>08AN=8QI_DBH>X<M]UJE&ZR#$ZUL5L#W):F*#/-
M>4 /W0JKT,I:"\X&#Y9Z2Z443"E>K"SA[;(9U<INJZ:HXG=+\=O2(44NJ9+<
M@W<"\6N-!!>I >D-I]9K&H79V:=T5U9M1&?<Y/4ID:J;W"6TMF1,4DK%<^E5
MD(DHIU<LV! 54!M]$BYK$74I2M,^N%+=Y"U4,%4SNZ7 ;:F>O--.*[2K5&A7
MS&P Y]!-SM1JQ[Q(,;'&S/(Y%:6J[&G5LJ<75<VTI6HFI+6I4O.'R<15ZEH=
M=;UJ*Y&B0=,D/<8'S'$07N)O6NG2'<F3)*07A)<S0]RVSPS5?%P5 W1%B#2'
M-RHU+$4-+9U0]C9;EQ0X92T&(T&!R4:!Y)*)+(.,"H,1416*E1@ZK!*J#L5Z
M6>.F0T%#8@Z#89 R&V@2](X&!X8E88+7F3%2' HCVYL8E3>^^5V5-0E\JGMP
M7Z"W]#?.\B"\,)"9HB""#>@H. _$YFB<RXFJ@.Z!K7G!KJ05UJV^J2"[=WC>
M5LY8JJ2B)@!AP6. GA/80#3P1(BR/FI\'>TIDS4EL''CM2;E3,75_7'5$K8(
MI83QV@/%B4(_53EPEDE@-D4A;,:8U^WL<]TNF5S-U]<D:ZG@NC^X6JH3:V-"
M$DQHI4(Y8N8$6)44F!!8<,HZ7<"E^ 9R8=\0N+HD.:DPNS_,YE2]<4*B%P\N
M$ N"$@<^, _:E;TSA:28"89@BU<9K@#;,K5(A=7]8=46<RAME9 )O/4&A! <
M+,&0*U$AC:0N(R/N[$NS <'D-Z?D>-H?3>O6I'BE;$VK'5!OD(NZHRHZ-ML5
M:"'9Z=4YO12W':;Q448^JPRV%(.%.9H.'D3R*@"A"D-;J@7X%!5([;-/)-@0
M!;H%O'TNLD/=!VH"M2/*BD51>S6KFOL?4H1/:3BH:%X2S6T9AB(DVL A^N
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M%/+M\<4=Z.*>VO/J6CP\2XA6%&*I$D%1",I$$"Y$\%YYL$9F+5V2R9C&M=A
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M*F73JCCT.E#[T>ITW6!LQT82S0W)X*$('(6MW/><+W4&!-76\A'X P;#X,O
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MJHN)5J<F4.& TDR?NP7.N%CI=!M"(YK:GG5H/I1TAE1F_83ITFNR=Q&.'_2
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M!);&>O=4A6VM(0>]9>L);=M_[;H99T:^X.\"Z[+IF\[,@@, 9B-\1,+(X+?
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M'[7A!9%KO9:+'3ZW56%V[(L\X]@; Q2R!17V'9L-&[UCYKMF9F>)W9H;:3Q
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M/8.7?ES69:-*V36Q&7Q5.\+*Q'@M@*F-^E:FNWI&>4=7ZF/$5T\D#7SN&Z6
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M]2.W)7VXAYG*4S#MR3/ F2?]G/"N4>GH^*_+DUSXTH]\[NDPRST&F^OE,LR
M(U02P.ZK+(I7[4B=!HD*0OC8AR^$0":_$+D625)$29AGJW;D[SADB(3%J]EY
M65=.#-U56]*]^>1!N+7A\]H]H5J%W@Q':YST:YR-4#?UU2CU9[@5%!$<%#/
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M!=P7)^O<-[7<U\/Y=(*_/[ZT+5IN72*J/6ECIL/F,2KXQ*I+:N;# ,QG*DN
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M>;E"..LBY9X0L>^!T0QD#I(X]1EHE+WXL1^C#EZ!G]:Z!ZY@B@'O/S-\JY"
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M(*$TLQE/^2,XCLX>O==X,CT9+8:K3 K3Z7R-J"3LC%80TIP/&O%1ZV*"LV]
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M6X5BS'AG<W@?7\@]OH@#:@YLGO>0WOTD9JZK;):G=][F59GI]*ZW:[!\F2\
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M/%&,M&(2!>N44;#"WFK03$'7KE3QVE.=?&:M48A]Q6F^:TY3>FPRME5FQ/+
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MRLM5"Y>%;R*_T04X:8#4V4(?4_,2I _>/+6]?/53^Q4$[FO_(K=YG(-!P<M
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MEW_OGN#]JW>?X;QB_Z@(HI%]^N?EQROX>_?#Q7^N_F0'5Q^/L2 XVIPY+"4
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MNE?*..Z\L!81T*$\BEPB3:1')$@K!)4XYHE:<NUG_+PTYM"483;TXM'*,!O
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M*0?[G!'(<.P14SY0E\]$N 0JB<<+BZQ85:1GHC-O812VWJPUXK%MU, +[(*
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M W 5RYA$41N!>0R.1[^V*>8L_E%IV:IZ_96^+5;?1NVKQY(G$3$L3ZX3X:5
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M>:O31<1HF5<DKU4M]A>KU@+,JA527KN$/W9 J$&CCT] E*G<J!V B'=/ZNT
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M,U9#?I;6C\M0X&\R[\^^Y'RB^(-]-5=HQJ9&CW U8_/-V%"2[GSP/N<++P?
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M.<A0[;U.O\E,<;Z_STPFEN!?%6Y2;=FL/BL9+?59P>D\<'HXSD&\DYC!JN5
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MY*IMW'"++'8"><L58UX;HF4V>_J%)+X\H2KMY*+BL;,ZU8U"%:!=AA25D<3
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MJWRO]S_S%"Z@*^3TAZQ<ZZ3EV)N:!3O?7HO'_K5T5(@Y)V)>3: 23 MNO8Y
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MV?LX;]=!QNLW_@?8.^!"<2@$/)LYZV\5[^6RWW5_U_%#;E1ZP)[L7$2JU,$
M$%*._74O>Q:EK+_=J&W'%-LYAGF0783;+W+K/1:0B7H[U>&3/P&/LA'WTV ,
M,(2M'(3I;#7#^[IU@'B9S1[D'>4#>/1OX#Q^7=%DAQ]2AH-WY"@Y1KB6"8FB
M409S$;G(2:Y2RXV$21:!K0U2NV/8RI6"G<=::9^BI)PK;74TW@:JM>,2,^'6
M:K'C[3DL2K?=BX.3LL4._D@J XALPYYWXNO!#V\&YW?KS4+BBHO>C!N)$9PM
MA+'\^,U%/71/7ANSH07)B3?]K/W^@\M/R4:1DS.27U%^)O"&)&SJQWB#// S
MP<6#KKQKL 1O4"JKP5:#I=3,=-N))UFHFI*01^Y+(GK(29:^.F>WB3Q]&\&;
MN'%VF,/ 4&4GMHC5]\/R-X9BO=8Y:5TT@=7F/;71R .8^1S:7 >'(>]@OIYP
MX&6VPT/]Z9@RW5-3*1=U'S/??28L?Z;YL?W\:?39,[CE@/R_V7-:?Z+)FZPA
M.:7]CLE;WB+GLNA2.L,!T]V=]^]W]O<^C1T7?,@!VXD"-$/NY3(N?>DDSZ<K
M=[WJ3S%IOPPQBDJB*HEZ3(F:W8^8\]67J,S17^UX;NOAU;5?5FPAKTRYHP4T
M,YOQ-.2##\0\=;>1R4[:OQYX"'2FUU["LYU3S__T.F'D\(\C5DIOJ-(X<&FQ
MU8EKZ6205C(3U-'.I%/82(Y&PL;B7_##X&_ORARFV^V?FKTS%%I%5"_?]/HH
MD%S1X%AY$NC\ZQ[]<+G_Q^]G>P<G9_!]O'?PF1\>?&GLGF[1O8,=NGOU=_WP
MZN1D[^W(2:"S#^S+]@X__.>0[/_QY6SWZ@.!>YSLG7V&YQR2W=-#&.^?I_M_
MO,/_N=H=;Q[BJ!=1\X28#!YQC3VR0>1C03+8@(,."J]M\G6L5_UL]B,=.;K+
MT-]7[JK"U9\!5Z?7"WH28!WRU?J>2Q]9.Q5ZSHF>8RU?6!"$.JJ12D+EK0F.
M+'$&%2OH%"-)<$!/L8 2><^&8O>!U8IATF3+,A635@5ZYCS2/8X\U'IF?&36
M>\4YB5H2K#P)6AKO8C0%\HR5DJA<NN<'I5&7CB=,-+$1$4PDXM%+I(-T*"A8
M2J,3H3BM;;)U0L:[.\QRN+N"H J"%E$M\4DPJ/)^%@8T^Z/>3[!*$ZX$4C*?
M>L?"(P="@ +6''NK*>$4@(;-X?T\/L(L[_;0K+VYOL5FMY53MZN^MTL7OQJL
MSF6%+G.ARX?QR)3.'?Q$"$ASDP!=N$5:.(<,Y90JPKTW$;@5'J]RO")QJ24*
M/+U$.%B>L,L(_7EKSXL,UJL8KN'B;:O3K3R2>3%C+!Z#\]DOQ0BR5BG$P25!
M)FB'@/,HS9D*SN*US46$8ZJ*Z2L6AJ@L\X.U;-0R8QQ=I)&AE))%/'"&M$\4
M!8*U4LE[+\S:)E7/T';JIU&IY:'5E75[)+T;X]L^)1<-Z!U-RB N1.X[0 FB
M3LD0DTI::M [L4QM!U8CI6>GV;7-XWH^_6%O)80M?3:/JYJ7+6LLX(]6*US4
M&XVM9KB1K_*C:@=D<4#Y>3QTX',]],@E8B9W+A,2'!0L& J,:469DI[9M4VR
MKE05/*B"!\L=/+@#12I4>4Q4&0LN**EU4#SO=$2@/58&9"+7*/CHJ244B)#(
MJ7)"J2J^\-/%%^ZT]I7JS:=Z8UFJUGEO"5CPE CH'\/(T:!0T+" .>;GF5S;
M5&;.CAF5DJUDQ*$RB<^DEV,1"0(F3WKO$),1])* RZV-DLA&(E5T(6J=NTBL
M,U$%)1YPSJBL:+9>.V_8?M77^-]>_3P7.UJ9 (6O A3+&J 8"-A?6;P 3-\-
MA*L"QKF \7 \ H&+XD#1 $.PP!6(I_"3UPC#2@:1T3&IM4U"QIE"%7^HX@_+
M%'^X R0JUVIQ"#(6;>!<.4TB1P2['&TP%MF@ L(Z2*]52DQG!%F7O(HV_'S1
MALIT+TSQ1DVW%$XZ&PP26CO$0]#($2J0MD0'2P+Q3JQM J!6L8:?(-90F;\G
MT<*QR()1+@KJ'1*2!L0I]DBGF%!0. 8GF4R&9O-'*:XB"_.JU[NS\T;K,EY7
M05^==(=011.6-9HP?LXSES*$?XOBNP"=O_6%;2!]@]\K)%T<DOKQ4(2$13:)
M)61<\H@+ TAJP*FQT@6<8Q%4DHRDPHP?!ZV"$54PXFF#$><I3O'$[L87>Q>^
M5! R%X2,QR*HHLY'B:+6*A_T-,AY%Y UV'CMI:$V (1,R*:J(A$O/1)1F?WE
MT-E1L\]H-,S1A+Q)#G&M,=).2?A/,"+8:()PV>P;704R7D8@HS*=SZ^&XS42
M8"6#Y!%%$A/B5')D0A*(X.B49Q$\)."UA([[WBL8Q7@RM?HXW,AVN)MGOZ=M
M51EA!<(#L(BQ_2WFGC=;WK=[<*=;Z_JV7,L*@^;"H./Q" #S3BKN-:(R90PR
M$ED6*0I4<2%2P(Z3M4V&Q[,G*_Y?\?^\*)H2^N:G%X87Z)\N)X.L+,/C6(8Q
MDJB#I32GEN#B7$LB NF8,^R-LX;%(&*2:YO45!3Q,5&N0-='G]!5]_G?QV/;
M*%S]\W8K-^2^;H!UF9N^%H!1^?W/Y?>/!!_N0W9[@^S%NL+O?Y6K.@A;7 Z^
M6J'\7"C_=4*-?^VIT!0CQJS)R<@6&<D<(BIJ[@5VB6GP_U7E_U?^?^7__U3.
MQ_.%IRL+\7P68HP'**N]$H$A24SN8^ )LKG0$'.$)"$BU\Z!A="TX@$5#UB&
M#,:]V!TTI6\>UQJM3N=5[H[K 4?JW9JW[?9E:K4O;#NL3FYCK'(;EY'$[ _$
M[#U(V=MAR=IJYF^]+63NU@=5:L/BK-6[B_<'.]W=3X7%@N\=7NUO'467M#5,
MHV <V"OE<G9XX"CQ[*50)84O<AHY&X]<_?1N;,5I*D[SDAVIY^8TE<%X=H-Q
M.&HPN-38DV21#IXC[JE#ADF!DF2>B^BPBKJH""BKK8Z*XCSW/'UNMN-9O=N-
MH19MNYESG*J=C<I\5[[<\Y]/N?NT\.=FJ'>Z[;KK@>[^WFK#*)OO^AI<F?'Y
MS#B8[P^C9APK9?*F%4J,A-S?(R%PU23"$5,J#;$^=QSCLQ<;JSSN5;+K/\V$
M+D_]@PK1%HIHQZ.(QE0B6FB#! NRK#9BHTO(6A&#C9([S #19N]85/G/:YN?
MNK8;BU2A1@O&4<M; S:<]CK=7+FC\J67*\!>K!8LUON\5O#7V-FZ6:L*8^;#
MF,L)T7)'C+<I2B1L8HA3X9 E)"'%9521XR E7]LDIBI&6/&KBFS_5([F<\?*
M*^Q?+/:/!;Z-M3@&[U#T K ?% 0901GR4F'-9+0L9.Q75=A[]>GQB\CLR4T#
M1_STI<_<257FSK(>.\[U&KN7N[%[T@I#HE69EOE,R]4$6B&B="DYC33U$G&7
M2QLHGE#BB<?(A(XLK6VJ\?J,/[TC6;&*I=JUN<&%G>9>JYF?W&XU&C%LI01?
M 0^UPHOY\6)L\T8Y2I/U&(G$-.)<&F2=5N"/&LN]$E(ZO[8IM:EV;UXJ!ZS,
M]*.KW1@#=,#Q""$!*:4%XDE[9#1H893:$J.<IX$! V3C=KIB@"]O/V\F6U<E
M(RY2(\?V_+121%-*D +5!,<Y6F2U9"A12FU,QI!$US;9NI@CD6&)XP=/IF5;
MC499!JS:X%LZ'K[__]E[UZ8VDBU=^*\H./.>Z#Y!RGF_N'<00=OM'O:TH&WC
M]L9?B+R"L) 878SAU[\KJR002 ()"Y!PS>RV,255966NYUF77+E67I>*/!8C
M#SS%ZS:,&\F]0%)&BKC1#AGI5:XO2 @V*E$'7O<4([KRNBNO>Y6\[HH1'L8(
M$WZU\%JX(!WB@L ?&$>DB05[GQDF$PZ$>IW]ZLJM_NG<Z@IC#\/8A!-M#9;8
M,8I Q7K$H^'(>##9+8V,))+W41UHW<J'_AE\Z I5#T/5A"-LA.=4J8@DSLD)
ML"3(Z220$]%I&Y*T$1QAM9+)KS.1M5P?TW6Z(791WH;&=0&OU.NTFJ$VPMCJ
M@7=U7= _NYU>%=Q:)J;)%/\T>*6P4P(%[, :]6"(FGQ$QV(:#3&".@[^*<&;
M?$I2^YKXJ N <HU<V!="-<_IX>ZT?><TWK06*L99+N-,^K])T82)1$D+CGA@
M8$ P&I$E@F87V"=%P(K85&3^)ANK!_U%$+YN0%Y=![JR&1X!P1/>-7%1%STI
M$_$!$*PULC;F8[U<)1HY5A&\:[-)S((.=H76G\(]K]3NXX-VPGFGB22*-4&*
M*#T\6:"Q1<DPJD$38QQD8>@K.K\#_P2 7?==[G]L:U#T;:O95JMS;MN^JGN_
M0B[ E>EPM4[;HV6J*&F)E$2GQ!ZPQD8Z 8:##!1Q[BURB7F$0;<('PV51!5E
M(>5D(>,5V@RK-JJK0Z?53LXC>W85/3\V/4^X>2$0Z[P1,*<<(ZZL0CHR@BS\
M,Y\A<I;FT/"FT$^[X_/3 &_-#Z(^V3SM=_JV!7124D8N'_-#)O9C!]Z?>M*F
M*^S_>L10Z@("^%-M:>[&?J6UEJBUV!2G@NAHF2<6&<X5X@*TEN6$(B,DPS%(
MDC3;V-*;1J]M_ZSUV<^LJ/0E4FFU9?NR.75BRU8S[PPA D6<'.*2&)0//B'K
MI/(J<,XI?KE;MDO:^%D-6WDF5ZT+):WNYG-EW2V=B29B$IZG*"S#B',;$0^<
M(D>D1R'9( )7+'J9F4CB229:KZWGBG56GW6J3?2733\3F^B6R*0D%OD@)SB7
M5EH$IJQ#!*P9X*6$8Q1KN(D^'$'YG=<,'A(Z ]>*L\:P2"VZ6SR'\N=?\_R>
M3XG4W(!R/$!8LUEEO_KEJB?]KTOT_1^W>MW1_-7KYE[7!_KMLV^\;FIKN8[]
M<N9E!3W_50BBCNF[RN)>KLKCU_'4';KW=IOMO3_,YT", 1,["6O XB8*5)X0
M" P78BQ+AI"0=P&I7-L:!LM$[1,%7!_,[$M]R)SS,L\8EOD^:S#L)0]U9?3H
M@]R_%Z N5\\_K#S#QU23DT7"N P\T82<4PYQ;CARBA*4/*'84"N,([E(&"S@
MHH[AL^JEPG-\U;?PV)'#,<NI,R/J:;9#;/=?(_-D/A[-:/M_HVF$Z4V=3K_=
MZ<?UE.<O_SG&_O2?MOUL!GLGC8N]SY^^-TYV3[[L_WZR]_8#R.<1;YSNB,;E
MUXL\[KU]D/F3(Y:C%HU+?W%HD@*KFR=D2?2(&Z^12XX@ZH7VSD4I \Z44$[2
MATY>F^-^_^SUJU?GY^?U[Z[;JG>Z1Z\HQNQ5%RZ_&GUV.0NJYEC0WVX(EZCK
M0ISVC^,41[Y7=H^ZYKO\ZX[/]1%#[;S9/ZX=M3K.MFK-=M^VCYH91*W..<JI
M0@%^F4-I-=N-^<?6(!2_J_7A4>":QV^VW:]YN-51IPNWKM<^QEA;HFE[-1G%
M;5XW^X!#/X>\[V;Y)N\?8R1W/K=^]?*OQI V#SN,?E'PSB/RQ1P!&/KP (Q=
M9JQH<230NBR#9S\US>V^/1*'-#LJB@D4J=&(6RV1L5@BJ7TBABHOS8-I+A,-
ML$$WPL)G-FA/C2#V\J4<R*@U>[6S+EA375CR6B%0^7.=6C^>GG6ZMGM1"\T$
M7X_Y - $/;WIG#:[;=N'KW8N; O^!CNP.P ;KV"VDHIZ@U:_UDFUSJAC?:U5
MC.[#WJ<;W->-OG/4!ND*M3#HYL_E[\.7FIU0OPW:\5#BR\>NJ["["MCUY)!9
MB4TT%-&4$N).):1))(@%HWUT@D7,EX7=_@RCX09FPR 6>(7/6O^_@V8I7QEO
M8T;#\(NET&5@=6K[\.U6<W!Z!53PJFX\N:"'&X\?!^N-,=S$N3WM@!Q?VIGC
MN!/,0R]C=W *8NO+?V>/L]DN#U+<@/M08@6I*Y'!/H&N\V;H'X^BP&-?'#HG
M^/HKUH$7,NA/?J7$W-:_7/?5).^ WY-]C%NN#P"S9<]Z\?7HA]]"LW?6LA>O
MF^T":<67?H/9.VJV1XZ2F&2 @JK*R]?#JN-R:,-]L>&3AY?KQ:5;#EEYC9FZ
MX&SF95PG,Z_==5NBZERJI=\61@M:<*[;SK=+F'F6%+YH/ZLO8$W#PIU;A%/=
MS--F"*V9[@0W*LU/Q&:NS8N_$WRV6]MI^_H<IP.&;UO0]I37??!D>%"7L?N4
MLS$]-E6PTKM.][1&,/J?9YR0:2'*J^F8W<SL,21$\2E;JU,B(.-_'G>O3::C
MB!Q0_U=D$ZSQ:]LZMQ>]C5<W"/,4B&KX4*ERT&8FM8[-4>ZQV$P7&_=0Z!)L
M&D+NFZDKW[.7M=^;3KL(.A6F[+MFV[;!K&W5BD:1-[LWW[8P;Y(V>]I8T1@7
M%'K[X\#UFJ&9S70PQ6$4S3A[Y!-HWE@G[47KE"U?>SWF;?DBVNN615/*U3BC
MF45+N=S8NYG)!K>LJ]*JI\XG'A/'\!+<6:*#<-0Z)Q2GT3E2[@' =V+8SK%Y
M%Z6@D<1$.>$Q&LNHE J^%*VS+J<V3G^.\U@K<'JCI)PK;74TW@:JM>,2,^'N
M2,5Y.;Z=_[4* %^^A\\UOL//M+&_#?=O7!P&;#$CQ"$IK<Q;$P(Y&A0BBA&K
M&:8JF/4*!M.ZX:-@\)TQFAN.UK1 S?V!E2N/[XZ8RFI%A,731X1_[H!PJ(AG
M"O%<'J:$"8DT(!V21< [#AFK+6(X6*V-]0ZK=2.>,GZW?RO,LU!P^";G)/NM
MTRV,Q[/8[F6-#A9BN[Q!YI=BW[[M\U?..MW^]=;42G(/V:[(YVG))U81[>>F
MOB*B30]Q,%YII9 $BPKLK!B0\X0B)R7V/H(#0/2/1+3M:6?0'B.5[+?FG*!B
MXQJ(9^"!'( N:H/VF+62V<C%=DQ-^"KPS7\MD)/$ C@>7BI/@^!,,.!L^"%P
M8Z*//HG#MWD@&/X?34WFU:/DI+,4)Q-YMZ_VP#XW^\>?Q@8-'_E]..2]D4GV
M5Z?7>V.[W0MXPW/;#=OM\ ;NUNR/_W*^-">SIFE.#Y?0KSF%Z1!6#<30>&1S
M&W >-$7:VX1XA*4ESNC@<XY2?;)J:\WE/8Y<PQ!D;A$)D@)CE[SDF&LNF'3!
M8V\8%B!6 )942! >2=!D>ELE0:LC09>-0^9)(%@:E&(^!"6"188:A;"FUGK+
MD\7R;@G:S*;/6?19P;4N-FOGQQ'8ZSS6CNVW6-A18TX8+%C-CRU.;[/6:X(6
ML]W2NX/K$7X'0OFJ4_[*%PMZ\TM@+=E^09+VFX4O@ZVU"3(;8K>PHXH[V?/,
MC<7>W]D9&#R%078"CEXO-(L7V,S!3I"Y?MY\:U_4L@[,OR]RBHKTH:+L4/FL
M\\Z@%48V7NIV3LM]P6;OJ@1HL;U7/'JD]G_RC?GTO&8,KY/*BH%W.#_$5/)@
M T4^Y(:5@5%D+=@S.DDGJ*2<1?DC5LR=;M.]\9KA)KT'.;+P@29HGF8A9;U:
M_![]8,P_ZA\WNZ'VOP,+3E,WXZTTFFXEWG0&7?C"J,GRZ+MY5R/OF]?^.]I6
M_]AG\OCW/S\Y1(^J,$>)DNWS0S!=8C)@M5C/P=8'^P99JA7R5&@>'99,K%U,
MM73D=DK8;:Y&3*'M!T .[>G1E6R,%@VD:^WK#UY??_)(1.V714QCYQ2/2B8.
MCA/7 >O$6&1.<H>3$';6 4F]S ,?/Z$=*V#LAUHKAET$.Y9KC#@A%CF!'0+S
ME7'PW+&UN;1I??(0_\B._;4P.U<9)&.Z=,61P"2)DM"4Z[=PGH\)2TXM%E@P
M:ABOD/ XFNR\\79''-(HDHTN(9AVEH,"N1-3S%N$@A#E!2,<;VSA^N2QI2LH
MU&NETL"5TGALJ!"AC$C!$$X8-RP9K0GH#&D=U<Y3-N.48 65'X7*_C8Y#%X(
MY[!&1 F!N/,8N8 -\C%@3XGPQ-@,E<F#\)766#X4*-821Q%QT(S#.EA0ZH;R
M1'.0*D170>&QH/#I.QA03I$D">*,2U =S(+M%"D"]P<'[I0D4F]L\3JY0VO<
MM6\W-5G]\;,?YTL>_#R,5MX*34X]_G,SHIG![^U91NE5]/(HMN%RJ^8&/7A2
MCG@6,4RX K>&Q[;' INE^O+'\)@RX3#/4;?I!GF.>CF:VO3'-T.=>1#EYE M
M#?H#N/2I_K%>2S$43QW&3GLY7Q/(J5<[CZU6_KN9$QO;MHQQ;MX,<I[9B^+6
M100E-@MM:G,T!J@DAV0BT$B*-;AO_'[6++)E;+_V#4;=&?1J_>8IW*,(BP)"
M:1X@Q9S4:V^&49V<B3/HEN.<C C'<A)F35OQ]KV!.XF^GV_=:I["7!7S,PSZ
M[GQX4_L8"VDLZX4P3>LSY.GYA6V[V+5[&WT\=3!X!IYYZ9]?Q<P[_=JI#;#D
MY8P50>5NYUNS2": _RWDE#ZL:L\$J7YJAV:OE,P8_K#=-JQ>;R^]*R7Z*MNV
M(MH[B';WQ%\>TMQTG42,A,S'I+!G2"L7D5'!6"JE=%IN; EQUZ8=R$_>$@8<
M9%**P]48P>P&T#-RKI:F7MO.&QJQ%Z^_5!Z2[L=V*/G-Q3'8%]171E/A:N=;
M[/:B!5HJ3T7!8TZ;[:O33+9V?'&6+?$BW'ASTWJJ27*1:6D:%G*(.*/@K'CS
M8N^F7KO>,2^/3DT?X]5[P2URJ#-DP, E$+[^D&C +QB<GI4$DO\]QBVGMFV/
MBC3W6OPV:E!3FGAPO[$/ F.WCZX.A+6SP+< > .8GSRZ*PZ[&L*0\HHE\;9W
M7$NMSODF?.7TK!5',]CJY(G+U#WH=[H7M725?M^[2K^_.I66+[;&#I/EF>U&
M4 C#U[*#4NG G '1EAY2_SC/#8B!]YUN#A46.W8YV>!HT+)=F,K!6<[\+^3H
M6D3@;D! J517MG71@\G(>0F] 2BG^"T/:SE\N]@9$/T@4[D,U0,?=<H%>5TH
MD3(D_A;$#*;Q36&H@$+RTTX-K(HB >X%S(78\]WFV4@*\L)96-U!\0:ULPY,
MR;3R"6.?R2MY;0T,$]B'+[]9ZRTW&^UA:W95&V%5U?I=0O6I/=K=RK+U]W"O
M9G7E*NN(X18ZX+QDJ.]EF"6!GABGP6P!%AMTH K.@'SLT&QM]O-7!U<O?@Y*
M(?-/+PO94$K']\K!2@75EG5/;]#+WX";#LYR>DHFL4)MW6$S+9;!\J,644Y<
MF9&9\L?W7&P$P+.3)P2T3F4+S;"%ON^>?#H_],XE[W(JL2@:DC&)7-(".>LD
M6$<ZAE XG>+N_*7I5@1^D'0\L&I7)1U+E@Z/#U.0"6OC$5/$@XA@@8Q6%B6*
MHU-<1JM(EH[9@>Q12L+,_,E-\&>'BS*N(9O#!9K4-K?..N9M=C:6#[ 29;-R
MESDJG[1SY\3FL\R)"QM;^]=A^C*/=:00;I+_>* %U$@OV]^%!3JTVT>I7.!=
MP*5L#]](@LT1AG9IO(QG>)6I6WYJZM:9O2BL_,*3& N$-#.C#&WE6[<K/)#>
M^""N!C ,713COWZ.[PR-?O#I8X+WS^9S88S#K0N)&_2/.]TB.EE$:KKQ?P?-
M["2YB^+I_6ZT1>9,]DS USF%M1A5C(/K0^<$1@\W+9X]\K$Z^6[Y-;/RCGFX
M5\^ZR):\!]>D=*@R+L"K&_ECY3SW1N4H1O$GX%$76TVP](<>XBFX_>#&?8W%
MZ0>0+YBSS:SR0SR+A=27ZKNLO=$?P&2-S?C55$]=-6#T')TJ;05PE>+0WP1G
M(X\[#>!>X#$5G\U"-7R%B[O7;M4LB(>EOE8:8X;&N("QB4,A;'3,)X1C"B@[
MDV!/1(.,\: ^E+4VMXHC=]D3S?;5ON(MCVD&>8UH893,?QYO59U;">=I1790
MYU-@3YMV4Z'Q$="X_XD?*BV"-=8BPRB@,3F.3.(*"5@=X06L6+;?2'VRL<_5
MEM*R-U<?"J"]D5:YWBM9<50 !BPSRL;<S<U(H[&(D9+D=$S,>W%?M?['1L6Z
M5B;^(52<[(A#;*@.AGE$*.>(T^21IBR 5^,"%@QS4&&YX\P4'75ZE9XSW9IY
M/H^WXL]E2\JG[X?,8)AT*E#DVF7^#,"?R2"1%)-.NRAU[DUTC_];63-K9<W\
M:#Y8A<;EHW'O[?;Y(:A3Z0,1 +_<*4SQW"DL;^,*;"W1G EM,QKO2)!9:C;E
MLM$S?E+GR3&R$$0T)S8RRHFG.G>JM=2:&!C@PQE-$[ZOL4)EVCP&1-Z3PZ Y
MV/R.(N(\03PXAK0/H+""4UYBS83,G84HG6W:K+#!O^*HH,11L-9"2-YQ9X7Q
MR0<<"<<R*D'N;3=2H6+IJ*"[;[]>Y*T,^/?WO?V=PT!TTEIZA*T!B\Y;C'00
MH%*8$-P$&WC &UM\\I!*F=9V.I%H66U+/&A;(J>K]6T1Q&]=U."/Z\#W'5M%
MS316-&QS>":\>7H&:U3N5J14'H,?SZ;H GC&^BN,*@M>UW%>0H&.FYEZ'_UQ
M#(-6W$LS\/JATVJ]*Y-<]S.Q[</3?V]U_->?#Z%L=[]!#C%).C@LD$O&(\X5
MN.0I$.2<#TQ'!=8&VZA%(+*S7"RT.X@;LU GIJ#NR8N)&E4'S_$AM42EJ#,R
MN[#G744_[[XFI%QZ*5%39]148WV,L<Y9^'5J?7%*)EJAKVP?N]$6:-N#ZW.=
M27F<]SL!=>U1BG]LERD"PZ@(?.:HFVN9S"[,E#JY,DCO]8TZW(O58[^_]Y<J
MB_O?GM8;6K[HS/R8,RV+!]P_U[\T=O[Z:V=O]^-$=[2'3L7\_1SGFM(5;,^;
M=7PU6_.B.3LXU6S-/UO$/)"=YNA-N'I<_[MMY4)-F]?4/H>L_& _];5I\[K<
M=NFKW]YU^OL^1WO7GS*H,NSOVMK;/X+/_M/\LO_U',:$]S[#V/[\T#J@?UPV
MX+\O^Y_@LXW+O8G^KI_$WMO?3W8__QONL<T;E^_%E\\[_,N?_YP<[#<N#_9W
M6[O['XX/+AO\/Y<[_4:SZ.W:;^Q_(KLPKD,;!2721<1)X(@;&<#;,QPI<*FI
M<_!+13>VQ*8PD_NP,[N[+@$5R^TV/E^SZK4AJ0?UHEY]+OKQ5M.$XQ"X3D%Q
MQ05S5C L@L,R*)&(29F+B*FX:"6X:/?-+2[RR4L3O$&1$H6XB!JY$ 4R42?'
M&)?)^,Q%3$_N+=[3:;JBG(IR'H=R="38D4@\29I+)8U0+&B>C)4D>44+RM$5
MY:P&Y=PV?XRBS'!@&] 8*=<$3<A)3Y$4V@8I& _&;6S)32HF2]\\(^7<XZ&N
MO NZ?=V&M/<#SN=UJ'7C7MOS7D9=$=?K"8O8RSG.ZNT,FQ"]'1:W_5"<ZX&)
M?-?MG(XMXTV>2LWO,:#+V.U4%+40134F/30)]JH6V""C0RY(I"ER)ADDF9 ,
MW#?-HRPWE0G];8*DGG*7&9>[VWF'?E'/\.GML"G<L7H4,7V*G[!+ :"V!R\)
M/RV5*RI.6(@3)CRE*)T@B<I<UI4BGAL5:.$$\L9[)I56V+&-+:9FY,_,0&<%
MPD?R$:AS-$4P)7/33$V\9IXPK:W'.I@8"T5-S!"%=\4G*O ] _AN*^1 M9'2
M$@1_ ?AXP,A@G/+I!)RB!=LKV8TM/GF::Y;#L,(>P9,57"DP]3:W.^@W<RV_
M91Y/F*-Y 'YX\P#[Z\VDMLJ/644_9BHMCLM;Y< LA2_?3SHP26HJE>6(>.L1
M)RFB? H3F9#[0'O/N<.5 _,SV4Y/Z\ L@QLJ#EB( R8=%IZ#&%(@YBE'7%N!
M'-$)29(YGR8IA-C8HG)RD[GR6)X!=4_AL%0:^<G0>%LC<R.)2($B;+D##\9I
M9 D/*%KML(O:X$AG:^1'1^2+\&5&_OA8Z=N;M;[Z]FMLU\*@+"*>2W]UNL/6
MUVOC^[C*]_G1V-#2G)][-I*OY/$&W_Z=I>[O0NC@LU<E62N*78AB/TTZ/<%1
MRJGT2'J"$??4(JO!](G<2QFTLB[ZC2U"%LADJ5R/)P[;+LWWJ*#YC-"<3#.C
MG.F<5\8H!E]$)8.,U (E&FBN-D)\4."+L,G3^8\9P*T0^)A^2(7 YT3@;>6H
M2%+<:H-4R.WYA%*@'%5$0B008I)3Y_3&%IL\_E_MH-RW@Q)_"J]CL_:+KUR/
M5=EVN8=<KV2R(M>ED^O!E!,]SEOC%4&)"9*SZ!V8-Y(@E8AR7"?.8ZZ6AR>K
MY55;+2_/VEI!=Z?B@\?D@PEWAR8<B$L)29Z+D;GL[BAFD%;@[.0RT0RGC2TY
MF:Y2[;RL\\[+<D%8'4)9(D(G$B1\[J(@*!+&Y6Q. 1K;1(ZL$I08;7DD@%"R
M2?#D(91J,^:!;E$O]ONM82?!5#206TM?*%1NT%J[01^OQ3!7EMPO&N)L7_?#
MJ=AU(7;UD_Z0,\QKHR(*A##$D[?(YMYJWNH47+*>4[FQ12?MG\H=^JDML>=U
MARI>6#(O3/A%5D:PJPQ&7CN+N&$6Z9 (,E@JL+25BRS'2:J,M)5 X_/Z114:
MEXW&B90TAB-CG"!K63[E"G]HG"C"C&'EG8R*YJX">+(9?.4!+3\=K6B9.&R.
ML&8.4962MN8I:6]*N:M"P3](LD=3MH8LA67R"7%E<\4WF[>&P#/BU.. (TXV
M LD*,4FR55+:JJ3$/&]26@7.98%S\HA,$)I*JY$*\ ?/ 6"MA$1.$"T<8]::
ML+'%%\@8K3#X(M/2*@PN#8,3L4*E@E?4(:^303PHCFS(;91S;5LCB?=&;FPQ
M/9D[L8:9:4_G>PQ;PZ2\T0(7VK7XW1_;]E&\/6D_N9'^M#;Z$@K[)*"C=^6:
MEJSD+_:[\/XM6Y4:69B/ODX:["8PQQQG2,3<:U$+AHR* 1'IB*)!&VWQQM:4
M/G+5WL7/;:$\Q;'YBA6>AA4F/ 5,I:1&$80U)^"\<X4L40)Q)AE36G$9U<:6
MJLZOO(!-BTI)KQP<)XYZ2AJ8(!A%G\^3.8>1M30AAQ,)1":FDP,E_0P;B2]B
MYZ+H0+M9:\?^&NU!;-9^B=5&Q#KY.&4XY3:)%L)74>1"%/G'^5_[._W&QX(F
MR>[^P>7>]F%,+@5+ I+:Y?/P$OA1F80L$X%['"QWN6CBY,Y#Y<G\U";4DQ8P
MKCA@F1SP_C8'N$BC33XA:37X+4I)I)U0R'@%%K(7*7$PE A]AAR/"GK/[+U4
MT%LF] YN0\]:AEV,%FDE ^*P>BBG/R,J+%54>1(US^E5SU Q?+YNF\.VWPP>
M$CJ#W$3\1_MM/JT7<]5TL^R@O#:N3)K?BYE[I1[80W3VC=>MF=9RFXPN9UY6
MT%5<).#MB,V'Z*C2.'!I,; ;U]+)(*UD)JBB"^G#4]6J$Y!+5%#?I_B'"A.!
MP3I$W.13RMAK9(5CN7):\,*RJ"3+C;BPU$OK0[H4X"S7XOQA#GUI5/F@OH,O
M@!&7D*14]65>)T:<\)8YI>!K.86PS2FZP@?D/">(!"H]2S88:1?NS%P17T5\
M+YWXJB;0:T5\$[$*IB@-*DCDM>>(1QF1#L2@R(EVS! GJ7I@&^AG);XBT/&J
M;^&Q(V\:_K@52D&99UX3/2*?9CO$=O\U,@7I/4VX@"ZC&1(L3.IT^NU./ZXG
M$K[\YQC[TW_:]K,9[)TT+O8^?_K>.-D]^;+_^\G>VP^GC<LCWCC=$8W+KQ=Y
MW'O[[TYW3XX82#7;?;OS_=!8(163!.282Y!CBI'%RB$=I6,NF6@4SV123M*'
M3E[4XW[_[/6K5^?GY_7OKMNJ=[I'KRC&[%47+K\:?78YDJ#FDH-QL:1U*;(<
MONMT:]EXW*P5TA%#K=\IS@SVXIGM%FDE.=OWT]E)Y[A=KWV,L;;$@-?5N(O;
MO&[V00K]O6^RL;6;19'^_A@CN?.Y]2M.&L/$BV4 5S% R0!_L$.GDU(L8H0U
MM8C3E! @'[B <&J,3D*[-66 O[M@[73A ;5FV[<& 2B@V5X%D/_=[7QK]D!L
M7_WB2H/MUZ*\4]]^C[U\ZAG&VSF-/Q<F?87)C,G&I2>',J7 K%)(6 ?6):,4
M:4P#DL;'0##Q JMUPZ3A-S$YII5C2M%G28%?%R7/\O%^#Y)B :_-7F\ J#AO
M]H\+]?VI_K%>L^UP=4XGEPBPUV4N5DN5B^V?"\77I=Z>E?I_;@[9?7O #HGC
MW#/FD4HV<P@!O:XM1<X30YEQA!CS4 Z9BF)O>\>U,WM1EBO,".W&,/!EY0ZP
MM N<]OO=IAOT ::W\3"^@?OB8!$K6*P"+/SW0T9LWH1E2.;4$L[!\#7!:T03
ML4HJBXT)2X5%N"KK:>%_<"6?>,AXL+66/>O%XL>S,] I.>@"HF'[&1_YUZWF
M*6B; D _%UQ290N6 ON5'NKHK24Q(@J^& @LT0BX.R"1I%-*:,J86R];D->+
MW9&==H[/D,U5\\YV"N=KZ(R!/LNP?/)X3.V7_UI@-T%AP7T"K]U:RT4,QEHG
MHY'18T.,]E5BR>,@]')WO\$.':&*<.]0P!94BL<*N:0]XK ,G MGB"0;6V2R
M+G8-I*4%/_RZN0)B7ROR6*\JJMD>>&*]%9?[0 4ABA+EG,Z%,$Q@3"L>)75"
M84,KN7\<N:>@F2YV3SS>VS^Z;+Q]?R@2![.*<!28 R6E4T361XFB)4HZ(:P*
M8F.+3Y[V+3-W1SA8!?K?[;1'& @Q1?@IE*Y+ 8C"K^D42&E??_#Z^HH#QCE
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M0#P"J(WB!#&=I$@6L!WL,P:DUMWIJ8J2O-SS=RM;_'+N)(VQGW?@3IUOQ2>
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M(4LE0<):G\M&@Q$0P"Y?H"QE!=PU "['AG#,%-:><TR5 XO/.@HD;J0*457
M73'@3D0R)8O$T!S$!.6*N.?@4 /]HLB)D9I9:77NQ:H7*%7WF,B])X(YC*&6
MWWG-X"&A,W"M.#77Z'G3&:>#;V8Z(YDCG7&^MY_567O6LMU]U_5KR#U]XF<V
MY'[\:5E[+6"L94ID+6\<QRZ99+*E+IQR7GM;[H(M0O[5+MBJZ8X_0&=,%GG
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M?1!1?^^K;6SE&ELU\J9^Q2AC\OM2P>HJL()6PGO[_M#2I(PM%%#V0:(''Z2
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MJE[[UPVC\5:207#1>JD\#6#_"*:-A1\"-R;ZZ).8>H#NYO;3%=1WVKU^=U!
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M+#$.UL*RNLJH6X$PQQ37?R78</I*S6+#U2&]Z>->Q)/EAE#/#<5@W6G*K*!
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M)H*.+@:9@C0HJT%JTALG0V<]HT6?011!>N5R5%ZPDKG:.-1&JA@C F@)EM"
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M$M2FQ5H-VD'.F5H?)PM#$[#C3P_QC,H%==,03R=0HX>O88@(@O4F61169B?
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M1IVHX@V7 ,IHDT,SM N$A8?6=+Q9%=[\.<=-K[W+3F(1I%WSN3D2Y)T2KDW
M<@B)L2IR;7LKLU$YYKX\.#&Z@(I8HG,.JJD7*2!*;[5SF-CI[N0?$<P,G/PN
M>2*@(*Q*KMKFD05*L")+$XK1F!73UCOY.]3<#:@!:3 I&4OT50%Z32[E(L%@
M<4 9H3.7#4#*($1@7 X^A"R,12- ^LI<0E2B1)+ Y*1O<V8Z<]FZ",+6 <Z-
M73/@HRQ9%A<JX&298]$08G3>I1#\FR;WW36S7L 9!AB";-TI,8I,I<W'258$
M1TGD9#7&A,JWR7I*#X.2F^Z%U!N:+=_0C*H@9HDRV Q@ +76+N3$(9"-K'J
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M2R)E8]KN!=!8Z=J>]ZX#30>:\0"-A^BD+;EIQ-;'A+P$C,5HKTH%&-F!9J-
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M96<LHPXDS4.AK0*;&_ME I/V/GMP&8!F[2>#8\W!:8O%Q>Z7V0C8#",W6H<
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M&5UHQRBT.22OO#'90@%)!KT#J K5$H&WX6;-A[LVO8EP#B(A45+0 4!HF8V
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MVB=/?YC\,0/*LP^0LH/ADF XZ("<+7-T*8D<C&DM@[2(R:,PT1![20#9[QZ
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M)(F58+3FX0FR5#%GC*82#%@XX:$#Q=T%BA'@1$]&6 ].#%S,A#YE8[PP%$F
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MZ]'VW?_>D665^<:;AI;NA[@1A%PF)B&8U@H,1-2F#7Y"4R$D*U$WN42,AK!
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M$@?W*;]'!Y0.*%L&*-UKLU) &?;:2BKDXEUSI)* PDJTT>RB[K)WTAGID^J
MT@%EBP#EBNZ=W;BY*7@,HC @2Y!&@\!<[1HHV,80( @)4 (291U=-VXZ=&P-
M="R6H=U1996H,OO_#%GN/WBH#U\_^<U+5-+'EK]-2@#;(H@YB,A%DO6F*!MG
MW97ZD),.*]L'*SV#^Q9 Y-5E$*$H3424(J%J3823%<$#"H\FFD29I:7= ^@
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M>&U#XM&J!B6S*IG5 CQ#I6HO2+5':$\(A,N<!D1T -H30+4MUAAI%GE2.K+
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MCNI 0S#$VEQ02Y3E]$IS:A$DK]3_93"GLO[O78+^LYCM)LQ04%0B'A/LL0
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MWF5E:^$/_QQ"<8?2C^C.2T8X-KL%?YAD;KSJV+:BCYF^5!A0IDQ)YMZ$QCN
M9LRU6U)N^1+<3TS/_?[JY?(V)?&;E_B=W"%^WT@-OC=,_/8H/.OGWT^J5_YR
M=VN3USYO7U1/?S_=KS>/80XNJ_6OC>KW_>/::0V(W[<K&/>/HM#TUB&,?_-
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MQ(E@.</8:,-]\BYBAJW2- 9MG?!E@&MY0&EO-,#E>-0T.8>4U!9Q%26RDB<
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MX0'V6H?(%:**!,29HLAXCU$ ?6*6\2@I6=LPHUM^J4IO0I5*"OTD?;H<UJ>
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M=.\N2$;_X]MAK>/^T 9!ZL&=!Q^O%Q\-\:?^9\RL"\XF?HS7R<3/'KHL4>O
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M:PR72/%"2'$XC!0R*F."A=6T1B NK$2.)(>DPSX$0I(/:FU#8%)&1Y=U3U]
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MI.6I$I4YBXJ__+3M#V64(0J9$ NYL9H1$CGC'5*,PUIHH:D  %:3Q6.CME=
MQFAD7V1?6]T271[ DG,[6WGFH^!DI#Q3WY:840#_E&Y7:$Y7BVE^.<GYQG9/
M]@\-E4PS9A"(B\_GBB+23B04F8@,E#A2G-O%;HQ7T]?<H/ZRWJKE=5J?20BD
MP-@E+WGNL"(8^ X>>\.P ,GP2I= @8=",'X^HQ*">0G!Y?ZA<MXJ:P3"6INR
M*;@%P4"4@_8)G*Q4A1",DXS=$@)<6)I9Y( Z1U,,QCF?N"9>,T^8UM9C'4R,
M!1@0,Y #8BHY>"XY^+1]"F"@ X[!YPGAB#NID04SCHQRV&#P\.'OM4V^,4[$
M>E,.B)EJ/TT,BW>?T?'\ZH]CZ#=B.]U3Q/^^V)T9E9QWI?G;R\'/'HSG3:/M
M3W\YJ?"YN/B0^ @A78C(:T\1CTDBK4$J2"11B*23L6ZM%D%WSG+&H-./"T\2
M&+,A!'M,CH#C#8FGB[IG^TSP^2>XS88FCQU/-=9JK"\QUNFN.GD_9H7:O>^-
MEN+E*KP?]1#+:M&RD*6H2&GU[XBS7M_8E9AM=^K><ZB+G"E9Y/BGX+38^?C7
M7Q\_[7X=XR5X[,/.UJ=AIDE;DA/OX-_0:K9FF"U6S=8,L\6KV9IAMD0U6S/,
MEGR$;9L7#<-#Y@\NL\C9V)I@^J>7I8H-IV+#61(6V_LHPL;3*+MP_[WS?$YJ
M!P9S/&46;E7I$08\.61_[QN#[QSO[YWR'?HNC_-T_^0?&,'!\>[W;VSW^Y_-
MG0_[Y_OUVSPY_QSO[H7CW0_OCS_M'5WN[WT^A_'5=[_#+YOOR,&>)_MPKX.3
M-_7_7'[L[=0+$L7>SMXWLGNRPP]]8MS2X!#71")X&9&.5B)*> S&&X%M3N>N
M4V56CR.G0L@*(7\^A-R/MK-WWJZ <9[ N/OV%C J;8P-WB+%5>ZG$RW2021D
MHE*48!V4I."RKALVSOI= 6,%C!4PO@PP'G?B3TZIM7!HO.TS:LX#,T8A;SGX
MC($:Y*(GR 2BF,OK+42&1JDK:*R@L8+&)8'&]^U^IT+&>2+CI]M.(Z.&L)"+
M8B3QB OID.$F(*FHL,XK%G.%'%V?Q%%8(6.%C!4RO@PRPG<K9)QKGG%O:ZQA
MBS1"JXB1EBD7#%)P&"F@)&5)4XNYH#YE;.1\!3.--\\_W>:6O*>N\9X#?HLX
MT50^9LBGY0NE>%WPSY64K6\V:D.R^IL5FHNIPOR4AG?_M8LJ3P^#CMY['1#E
ME"&N)$4VV(088R(DQWBT::RH<K7( S3?X%(\0ZD:,U-?=8)S,YP9$/=8?7/&
M;TZ]^(1N*/X$+@;SY-*_A9W/G%#_U^TW,U?1Y: "<(3#KR"U/<[T*]TA ]5M
M]OMVJCU'B\GI;4CQ0+?-Q,)F\O5=Q 150>1<"XN6$E]6^)O/(H23J1@*YW6A
MU<WY@.@<D6"*M@1X'IUE'@4A<R@K>R$C],8V,L?J>NU/V^IG@@^R7IS*FS =
MDV>A@H^%NE'W"-U/D@-[^-%6.[]%. Z!ZQ045UPP9P7#(C@L@Q*)F)3S6Q-.
MK8[EMWZI#G+_'IR<XD\?_FGN%CGVS_C@PV[ST_=O8N?R\_G.]IOC_9//YS"^
MQLY8QNI]\Q,\2[YG[@BWN_WE=)_NBX.]TTL8^_G.A_=U^)O#M2[NR%AQ([B4
M5B.O3$3<>XR,- Y%;153QE'B]-HFU^M$DT>EK!Z4^">EH^XV8*MAH;;"@/-Y
M99P)-\F9J*SG4GR33I3^B=9R]4S+4QDR[K0Q6P.&XNV"-;=L8%>9EIE,R\XD
MTT(L"TZ+B!0W1?=Z@;1)$1DA=>$A6([7-A6=L3%I93L&NO,IMQ=8&;OA*[NQ
MM-^L[,9C[,;[LAGFVT$OS+WK5I@?;+WU5[O;K:S(3%;D\R0K$H,)/.8B(X\I
MXGF9P*8(I*CC'B=BE;=KFY+KRHH\+4>V'7TL.AJP*DNVY-^\QNNG%HZM'IQ3
MZYGQD5GO%><D:DFP\B1H:;R+T1055#.@>)5AFA^ ?YL$X$QXPZV2R"4I$4^<
M(1,D0Y@2CZ,C4A*^MLG-NA"/*Z5_]IJG^4/\,RC69%K[L?Q2!>/+\\T1&+?^
M]*B3N^6B@3AX'V-*2PC@D^5L@72W,^9Q1M$]U?^- 5W&3KL"]IF ?7\2L-.4
MO-,J(")D1%QKCZP3 C&G9,!$\VC!,_\__Y^FA/XQANP+KZ.YWY1,HX!+9D2>
M*TZ8K.%5MFG9S<FJ?/,G,GN_+=;NY8:&\*I*2"W([/E)9@\S6,-L]KR,&''L
M+7+Y#XQ5Y)X89:Q9VV03$E)CU8Q+8'RF/MJVW-;ISBP6F=H.//J0WY+ ZD_S
MS8>TXJ<[33E9I.^L)%O(O"RAL7V!8Y95DG#^1O5HDE$5S@OOB4?"&H<XIP%9
MSC%R3@3M9>#!JB))2/&X75V14'+YSG#>/K,YN$/9Z-,,03&W>F[U7B,SKSZ-
M4X1^=![5[B FJ=WNM=J]N)J*^?A#E9]SIXKSW6VXU^41V[G<.N1$Z>280%'E
MEEA"&:2#DRC1: C6/#B%,\R5\_6EG=?WN-<[>_WJU?GY^<:_KM/8:'>.7E&,
MV:L.?/QJ^-WY"(6:2B1&!91NR*)CRE:W9G-C[W[CJKE[)\)0;6O(+#OH!'C=
M/;[6/HOE8>#N:+/T!-_J'=?^MV\[O;*U>]$J][=NC/,\@G;UJ-,?0;OJO%HC
MZCE&<N]]?U\O>H['3I[8,L>:^[_&;J]H@7?=S#RW54^VWJG]L(U^V>4^S_O?
M;TEQSN__MKMG^6%KHXM3M)*][N9N6Q=P+=MHM/W5VAT-K/!&[7MY=K 1<_N
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MF2>>)T4N5_E9K$FCX'^Y((/%B@Q^0LU\;@$\Q]^++OX,'SD9^M-&3V@^;E/
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M)]"XYM$+-%%*-G[57/NDN780B%$E90=1&7,$2L4"3]*!)@XEI:<.==A((/M
M3.0BVB1V]M3U)66/@S*N*H=A+Q?#L-V6POCU!-'AC@:S-#D>CN9=0_P<#=-:
M8Z+WD1VE0$\IV3/^>UAF;[&:KR;/<!QEA*?NZ/7GE5U\\3/%/3^=X+=^PHD8
MQTIIJU':V9(PCT HUU*B3I&;SF*6@XN6@(R&>FVMU+'8XNVXZAKA<?\4FWY%
M>%2FV"13M,(]HG6*4Y5+*3Y:O'81C%84*"."B2BSL629UZ[:'=M9$:/"L\_P
M; 6#D&!9SB2!M[;TRJ8*#+,&M'::E_[9/*6=/=9.V.\_/A^2!MY!1,A:@5O=
M?6L"="N<Q G&%&I0H&B4I;T?!:^X@.1*QB-'=3W9&H!=Y?^F0EDJC?211MKQ
M+H9F[H5UH&5ICJ8E ]00#!!4%)S6D<4HZJE!K]#;0;A+16\OT=N*E7$D"-J4
MP%,6M0!M)#CE60%S.9JW.6[WF=]#TNT[B)JI1OE&X=L*K8F99:.]!9)< I%\
M28]2 4)DN/R2>&/8LA[=57U_T I !_$\50'H)8.T@GZ,0&N?*@NX#4I'\>S
M.YL@DH3_]YY;]A4W0/\5@'N(W@YB?JJ<WRA*6X%!7!%+:0R@N4*4"L/ 6)V
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MK&(.K'$&I*(<-<(@HXY5_%?Q?[>'"Y4W>LX;K3,)@TL>;7"0@F<@ M7@@M=
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MSA81Z!P%$3*:TC)HX%'9E$EQ?+.=/5%;P_57&'900:6B<*TH;/FEN1+9*V[
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M@S$QL(C;P^0FUO.1-"L>;?8"@0])3-_=$4.%9@?0;!U3"DM(8L9!TI&#X%Z
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M: /4,8>O&FY-##7+6%N+%/+AT7*XQ_20:_&0N\HL3X/<AT$N4LH2,#O*:$H
M9Z -55#IG-59+BE!)ZU0MS'(F4?^U<:2F4I^R*GD7X#-%"K>!2;]QW?7I)JK
M>$M:L@')8U!]LT9L<,97EQ"3;7ZT"G&/G)N1]'IYPKZ2S=-F[\%FEU.WG!/
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MGUK.OCKM5U$_.?W#5?N^OXSN?1-@MP/8[Z^;SM1R"+5DHR5G [YUPE.83%0
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MG\.?X+%E3J1NFMFZ2 @0.+,D[5CBO$45CG>K=IZ,\1:XL10L:J 8O3-08S0
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M0UQ%B6"E%(*UC]%H,!^-77NAQ5.-J'I"$:DUP*T\P'$CJ!(N)2L5=SAIX))
M ,J<-IC<0[I^#7!+ MS^),"QK?<'#I9')BR1(C'75R$,F> #4D9KA662.@+
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M?P($VFOTCVR_8;NQ<1)M;]"-H0'_WM[\5^,T=AN]HWSFMTZWT81+XW\&S:\
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M=?J/LV;H'V5/\0:NO,7#6D;#-P]/;Y134V[ ZIR2&UK)*T_C#?*/Z[<O1M\
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M(C8L2!2Y,&R[DY_3:A:UWK;KW98?\VV\/BM^C<J_(;;AN[9WIWL OA>?/WV
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MX3Z47!L1M''Z$;D^MVQ6>C)F@./WC?WC,H[E878K'4\5* 12]L*QVW]R8;K
MQ:Z@F^/A6?=Y.'CNQ"]]38/0&Z9F)L)1?SB"O]-PU+0SQ6OM'8Y/"8_<"'_%
M;](,'#O_W?[1F?J@<+I-,4U'X!N:=,R^[59$N%\W>VJNP\0)1LC?;(3\+$9H
M%[<)O3#?$+]\>!J/!V6;5TLTA27::Q\B!L>]LSR#,&B"!!4$O. >:*(NZ1)?
MT7)C2YXKL3G9-%M3J+O% 7%M\':M)IR(M[F.Q2K>U@-OK>,PX2C>7>O ([&B
M[HL,C+,)B(G2!N\H=:K!&ZMX6P[>YCIJJGA;$[Q=MF^>E1(Q7XZ8T+L22@3P
MVAM(*48NE+6*N 9O_%[Q]AB%YES'-Q6(ZP'$UK%-8"08H268' P([A@X'3,X
MHF,01"CG46BJKJY"<TF&;ZZ#B(JW]<#;A ,(3VU*I5K )(J(LY: HRR!U#8X
M:UD@EE7$+55JSA/<KXA;%\2U@OHJ""^#89"9DB!,BF")<R!$8HPSQB*=QL8U
MP? GS83PK?83Q]%/_&O9:KW#\<C9ZR?-C]_;#YYL78RAGGO-R9Z6%"\.]_U1
M?]@K[_MTD,K1S]_IQ_3Q_[H8(S\!+OGQ$N>'_?WC4?LEUU[(UOK,4>>V*P5?
M^%1FJKM"Z86_+5ZMLE<_?/.TYZLFVT9<SM3T?+0\+IJJA=5Y>JJV4SDCOV5\
M[J#SZC!TI[=PS=G/A*\[]V+,,^KW=JMQY7!%VGF))J!#"?SO/2[(I*.XL^4X
MHXT[V2&63CADNDC'X[^?^_?CX,=QX8<$?I#<9V@JX)ZZ_2_NVW#CR45V1J(Z
M^5"EFS/%JZCUW!I].AZ.>OG;]5R^$-5#Z4TKQ<IU[O1':=@9]3O_1%U1>K\V
M33M?]@[=8< W[[P=X1^*&!E>:7(NDC9?U$GJC4/>V24N:$XDWQ[[82_VRMSW
M(K3<82]=?>4M-&^LD_5B7<87;[V6^;9B%NMU2=&,]]5Y1K/3= &_THNYD@TN
M*;*QB':41'2TD\O9BV"YD<K$1!7G-'&O_,85K]/HG1'F"(M)"FJB99ERE0)1
M0G(JU<95@N_DZZ[+9J2RRYB::]=<_Q@WB]^+JBO,=$+J_J]5X!UA:W.MS,[W
MKG4//)QK54S6:WW4>T!VA;1K<JWKM:Y:3A=7F!@ 4';6/$QZJZ'Q4_A^"_8(
M&NWR]OC@H,C_?NZX_?U.2;7<[/S^%O_Y[;>W^,_;9XVC\,MO^-\PZOW=&WT[
M'<C>N-(_?>F-/C:SV8<E(#OL?!BXP^(4#=(1_IH.1Z>SVP_<U][!\4''E3@M
M_L6-<+&/]V/')WSKC[WT-[ZJ)$#B!P^;3QZ>?O3P'T^O\E!;RI>REO1%9W[0
M_S+^65P5UYEPYZZ+XY^](253!O5O\7E47O$9K2DD-W_(@F(SM]N+U^3Y3A^2
MF6<E)WI!Z[=2"-"[6Z@;V&^V%;R)^JX+-MS9\A8&6F ".7I[4W#QA-.'LK3
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M-:>B//KD@M*!12FXY,8Z_"&68X6 %E].T[8Z?$SQ>#^]SI.UY=M1/WP^/19
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MF+Z'8\6.5**/2I/'TZY\:/_G7F=-K]6>]NN-FUYX[1TT,C;(NT0F\[PXM/S
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M@>3$VH!F=;,Z-"QA7^B(@#_*L!YQ$;&J8J(4)#*>0>6F-9M"L>X:UJ!N+N_
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M5I\\4\DZ*:?:MU,>19T#4C9#2[@Q8<#"K]BTB!^3+)0,]8K'E?_I5F43W?N
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M9EN)GJ:FY81AY%E.@*TCP-YS/05/9;$_8%$)E"@:_CCXA"S$3@HV.=7?_JU
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M&.[3O,GRJ"8E=U:7NE)J['6)98%(Q0,,<K/W4LYZ%S%+1_^RK+2.TQV#3[N
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M)6(L$26P4ES(K1TQ761:9?ZL3\[ $LS_2GPW07RGDGN4SPNM#>*&P0_-);(
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M)AEY#$+G7.$-5+P_I*0MW7*N).UI)&TJ !4TQ\92AXR-++<R]<AAT+1.):K
M-"*>I:T=M@)NKGNRCQPX2;&+RN_\RN FH3-PK5@;R<,B;=<>>JW[=/N]%QY^
M("?ZX"R6M5ZGU0S%V_=;XL]/=S3;$/^O14V>Y4W+ICLF++AHO52>!L&98-I8
M^"5P8Z*//HGGSSNJ0@F/ ED\(_F(1XPI&#0 KR)' :-!-A"%//'&8$Z%]("Q
MFM2IWN ^\4L3ZN6:9H_&]A\,PF<O^9T0_J,@]:--7"DPV$5>\DQ:+9ATP6-O
M&!8 WU[I%?2=JY#ZL4@]E07&@E3.&(44LPEQ[@PR7&MD4M(L\B"QSP3SI"X%
M6<PBKM"Q0L<?&!VI<S3%8)SSB6OB-?.$:6T]UL'$*)X_$Z]"Q\>BXU0ZGF-4
M"\TQTBY)L&-%0):)B/):,PRJ48A,((SK!B_((/RCH>.:9-NMY)-53*2*B:Q7
M3*1*P]@8G3.=(:DDHTIX@60, ?' '+*))Q2]I5K#ZFN;TS!XG9%ID[P*GE3N
M0>4>K-X]6'KPI(+TS8'TJ:Q8C!G%CFIP(8A"'+N"\,# YC0AA(2M5V!0JCIF
M"V;652A:H>@/C*)+#[)4*+HY*#J5GRPM=YXXAU0(#'$3%-+>8R0YH2Z9X!S)
M?(JDSF@5JZXB$E5$8HTB$E5#O!6D94SEEDOE L<V(DFB0-P1AISB&J7,N26,
ML$:FK1U1!U5:11;6#<Q_,,RN;.(UB2Q4T+P":)XJ #!8>&8U07DA$;>!(L<T
M1L2G7$J;V3],+IR5NK)M*SBLX/#)0@05'*X #J<.P6+@H,VX0"IBBSCW#ED>
M'7)!"BN4-N">9$M5B4U+O"BJ/'[I6[CGB+_T+GY8<Q.4/@]Z_6:Z+%]JMD-L
M]W]%9ED$LF*;WB>;]'N<K?J[E*UV3.X BY4ZG7Z[TX^;*1Z?_G.&_?G?;?O!
M#([._]TZ^G @&O2-:!S__?G3,8SKJL$;QY]:GSZ\N3K\W#H[/-^_^G2^_^T_
M5V^^-3XWOAU^/J6-XP/6^+Q[>2(L!BTO+<).4L2]\<C03)\!#EG05'LG<4:;
M<L+>=O("G_7[%[_^\LO7KU^WO[EN:[O3/?T%+#[V2Q?>_F7TV24A]FA/%)?Y
MM=F'E?5S[)+);4RW94%S7 95:ZG;.2\PO R]UCKCV&O-%<'7VD6W\T^S!Z_\
M\L+%=DS-_LL,N+5^CL?60!\TBRMM+],EG6/O;^W4?F]V+LXL0']!P:9^Z]6B
M[;;A*7IY3*U!B#40YB:(9A@.LGS<SJ +?_\G]OKG,1,NMVM_-YM_USJI]E\+
MZ#H!Z$<4&/M4:TZI-58+SP4Q/-@H@GI GLAH2.7:O!J._<?6;P\7X/VO1\=?
M2.-XGS6.&]^.COU)@JGG4G)$#%.(*Q; ;.<*:?#1:*;@E1;,=B*GS_5JL"E;
MS6(SU_)JU1?:"CP&[",U3M#((U%6L@1P894RG M+'G"^7&V%!V^%;.*<&'#)
M#24>!3!<8"OHW(\->V1%$C*!L"9,MG:HFJYXNK45<,T"?"P$#-)3H1D6*C'N
M7#(XX)BW@5,^XA ><$Y6[8:'[X;#X]T3'U/4$FQ7$3.-!_R##.8.>6.,MDX8
M&07L!HKOV0W$C-7<+Q.FT]RFXX;9B>[E,ROUV:9*9:5.6*E7 &W:6 )FJ60N
M(BZY1LX(BER2W!)A??3FH5;JJ"$%&'UA4")=LK[9@MT#QIX%<[ '%E<,V[5)
MS[S6A/=:K8ZW_1AJ>0.%;!@": $2];.5F&H79Y>]O,LF+KU= S=^T.[W:F<1
MKESLS9@]O-BZK/4[M?X9&'"3M\E(;"<\_YKM]3KY3;C?UV;_;+8ANWU;5B>[
M5?QH(NLKUVZ&T. 3:H31&!MD;01[(.@ IH#.Z5^86$VBU=RNA6NW #H:GO?D
M$8A)M^8&/?AT#^001.N?4EQ'3E"W+&;J%?+C.ST0N-N"\WH/3%[;JWV-K5;^
M<_:G3EL=!Q+\X>VK1G&M/U^_JEW [LQF2"T-VH54]^JCS_E.]Z+3S3(=V];E
M])SK#Q7?[Q1#O_Y8T?JF&$>>6)!UU_DGU@$';!]&5@N=_/H8:3)$9%=N*.EP
M]5X\S592;[MV4&KK>NWNV0%CJ[/(%.5;Y0>%R^W! PSR+_^*MM4_\QD7Q[?H
MGW4[@].SVK\'@&(,IK4P&VKO8JP]A39=*!2PM7.8X8#N?=>,&=I A_D1FWYA
MC(1O#W%XJ!PR^ B=J/7)"F<)5Q%K+X,4G$BCP?P*<6N$W3'L9H,V);#-O*56
M$,:3959(!_\3 FY6((9N A:'"HMG8#$Y"42P!/\ARYQ#W#*-- L648L5%@'C
MP-+M_:"3DTEQ'B08[I8G[96.R<I\JN \EIN&W:5E>V?_K]+4&KA>'UZ"#9=Q
MZ9=.%]S.06]@6_4"I_(7<U#+PY;K 83Y0;<+MZ@/+_'B)HZ^+'"T7HO- A+A
M30O?Z0U:_6R>P6O-+OB=_0'<&&Z4'ZQ>^]H9M$(!N@Y _-M%]/ER&7<]W"Q?
MX\)VB^]G=&QG;[1UC8390(-;G Y:MINMPB8 \Q]P[?WK*-TPV#*$X8S]YYUL
MO!5#+![CU]J+YDNXSB(>.&.,,'#WF*"6&\6=5A9KR6)*Q#OJ[@O-Z>ERX%ZT
M77^VVPZO0%.T.A=9S^3BW_ZN_W^#)EC$A:(Y/K/MXQ+_?Q_.PE[GW#7;!1)^
MZ#;[_=@^2FD^S]W\=)[[*3LZ_@C>>^-KXVJ7 6CP$R8D0(45F9,>7/=\"J\Y
MD\@):TA4T0=LP77?GCZ(K[FAZ^[!93F-1=#ZX/7;_['G%[^]&GH;861$V+R,
M)<KG[7S<S=\=G(,(G#7]6>UK%A?OL[<"W\E7RB\4#DCLW_AR%DP0Q7QN54CH
M&NC\T>XMQA:N]V\AT6W CF</W==!J$&J<Z9V%WS!08:MX3+U?GGA09R:_=[+
M$N3.+UHQC[8T)H:V678$ 4_S2X XDT[BL!U+N3 W;[!@@/^Q:9=C%+E(,2/(
M]4CVRB?=*Y_SX,83[N4'S"?<X\>;]+0+R+EQK0I*[@@"7AY^?H/AOG#MW6QW
M?#OAT1!/L4>>)X%X! M$NQ"1A24$%'&<4KRU0[;OZG4ZPI,7B^RB)**":Q,?
M%.4^<0L_+9<Q,DZ<,_.WK%^#7?03AI+'N^@0E%/C^#TH)"L8-XPC+0,%A60I
M<E@I1&QFH7!,YTC"#A??B26OF7YX%XO:F6R&E;N@1-429,^;[29LE,+M&2N,
M)QGU=\>8!Y/C@=UX#@9S1G-;Q YK%UW8HJ"M+]=@(I]_6M9L)[V=I=#+F,K0
MTYDPE=#(!"MT^K-/W9.<;:S]ALEK ;87&%^#B]2%CQ>K U>'E>NT(_ASET4(
MK5;86JT6N(Y#V<^?@Z<"^2^DK]NU[=,X_.QBAI6SF#C!5;1<<T.E<49&##K8
M&TNBX L95J_+ 8-?N3<Y7-!]?XT&NSLQULI<FDO177ERPA+%T1.#A)=@+JED
MD Z>H)"""89C\,)4-I>^XWFM'SRMG2.4 RAPE=8E2%'*/HN[! ']YV4.50]L
MOD'M']L:7!^ E;&1/-[1*Q> G]W8;W:++9XC\NW:*8#MPH*Y-(_G.GTWP2.'
MW\N\L=<PL-W14_T) \REOP?GYV"_@AYX"WOEM-TL[=.]SOD%P%'.>#B,_=<P
MMYW0],/K9..VM'HK:9XMS5_HX=5[UGAU<-6XVO]V='SZ]<0E3Q4QN=!,2,0I
M#\BPD/,@K$S4QLB#R](\(S=J3:6Y/-IY46;VO?P%!E8>*_>*$ #Y;?A'._:?
M/S6Q4+,@Q$,Q;-<BF#W]RUHO!VG+\Z=5R^9^,:)WXP']\<]A<R24E5S=KR6_
M7!Y>'="3P!.-4CDDDC&(:R81Z$:, J8X1,--B&EV4*&2JX7E:N;Y ?[N^<%O
MQ?G!R!594.@>6]XW)70'YQ>VV<UJ^B@=M/M@EC9=*Q;QF-Z85/3/3B=\A;U1
M2>$\MNKA<>/J1!)C<3 )9H?RDNC>YHY=Q)E(O9#82)&E<+J1R(04C@\$QLYJ
M$41NCM>L5XGJHB'^QUFQK4[FUUV!U-[1#;>R9]= XOGA9Y!X)6DTU&B4&1IS
M%F1N&D0Q DG'5%JA+">;Y9VNL3#7KL-&ZWUFM[1Z_.JT90W$_ LYL=AC:A-!
M1'AP6Z/))"F1(IF(]9YYQYS?VE$S*%+&IRT+'==IZ:U4@7&E*3=).DXX#LYR
MK9SSGE<;:(,VT-7!UQ,KDV.!4!2#ECGX89!.#,-6H@X++W!!X$O,#,NP.JY[
MPN.Z=9O5C3JZFN4'YVSG.?+H %90WWXK(E.+:E?B20Q<6,Y5Y(8H:RDUDFBK
MJ'%>VOLJVV;$A^'Z14E_L8NS#7W4S59T61A2F</SA:'>D!.'F8I6:,0XR8<U
MD2.K;$0 ?U%)ES# X-:.WB!S^$7>#2_+<\CS(?-'WK"SDN___7<-,*_=*Q]I
M!>;QK5J!#'TW1YU?N7_D=QT'/3R"]5A&EBJ"]?1VRM&KC^(D1,Z\D!()Q1+B
M1E@$/@O8*9*DY*,.FH2<YSJC8+F*8#VUT[N**-83<"FM0_#J9W9*CE[M7L(X
MQ8G0FH%$6X0] VWM4T(V!(XB)8E'V'Y@:8%7NT$YA//+\?;S>R/96)X(/4WX
M3?5:;WWJ\GHUNENOT;UZC:W&8[NC*/!60=]*YVEV=>$<U8(SOW=O5=D.GW[\
M[>F7KF?N=E'Y-&/8L.9LY_^Z[B_3Q>AW3"XW*LT_N?IA/%'%6$/&E>*I?AVT
M0^R6M8R_;]?^C)W3KKTX:_K:P;4 W?G@X.6?-ML3U&Z_#5_)I9-L5"AZ76:Z
MA&R'.ULX[G_KQRY(_JA]8^_WR^NGV>U&VSO.#'#'</O?6QW_Y:=346^R(WE"
ME;:1&8M43!'QX#'2,+G(4^P\*":'%9CJ$13Y1=[9W4&NGRRX\V[Q^16)HQ>]
M^.OHE]]&S?J:[6+7%5_Z[>86$=.UM,6&+-_^[6LS],\R(^4V+EDI,W/?-9/@
M\.WMXJU;+(/E>Y)M$RWN?!MODP>^)SB?]YN;TD3Q"1LSWK]0!)98WOWVLRS4
M#SQ8-M=E"V+,H8B-UYB2.QB#R0UF3CQ-SOF<=+[Z/GNGP(_CLUP1VFIUOA;,
M$8/S'):^*NJHAU00[K)V>JWS+*B)7V_0F,Z<HBE.Y:SN-G!Z9M.V/O0QG[5!
M+1&/7@,?<Q^AU:_"QVB[M?UV=O->@>%S[L#'8J2^R#9<X4Z3<Q),OV@<_/77
MP='ANY=S[+>JY_%<G_P.<?(]>__)><=O;_W9_7&R6;\8_'SO.>?8+1LT8[/%
M*.<C5#.VV(P1\T"5/L<#%X3D:EN)==3O[]O-?%3PKI_Y^2K8?<I6\_-LES7I
M>['<UFUS/?BF-V?#1&%IJ8@V<1 UK"5)V@JCM2,^/8 &?")NE5MBYB%\:/;/
M1K&K\1EK/G*%_\*Q_?9CG[P,.V"P3Y\/S^#>ET=_OKDZA'M]^OSFV]&?;[\<
MO=K%1Q]@Y%<?KSZ=OV?3'3#">8/"?:X.^*=7#7QX_!;&O,_AF7CCU1OQZ1RN
M_/GP_-.Q__J?JT;_: ]_*SI@'+\GAY\;_,0I'H.A#D7+/.(IZ=SJ4B 2O#;6
M!P)['I2)J2L^73VW:9W:%E%NRVD^-%]OH;5%T?GT[3V]@]8/*N=[K$4R:[$C
M/!E.HE29:<?X1+B-WL5 @_=T89+\"BA7#)2-X]VB31" )3D\_GAUM'NB)"&2
M<8J<D19Q4(H E0":UDIM;32>!["@**GS![8*JN"I@J<G@2<I-: /E402RBG
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M)@W6 @RZRKY;UK(>?CTQ7E)--$.$.$!<XSFRWE!894%"LE2+S$''IJVS_WX
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MNXCQZRPSWD8A(N6,2@VP)KQEEJLD:;PO)Z]27FNFO";9:+[ -0_$"5/)4IM
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MCZSMG3S.E:$./UWJE#%PN?C3PF$U'Y+$E+SPSLV.1GCZLF='^%F3H;YUE+F
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M3/(OI2IS?;'G "3X'K$&9G!+&;><75W_VQR./IRDO$[,,/0MQT3%X-X!*D9
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M7*LP8:NPK]LFK&)R:SB"]?+[?2:ZP/(]Q^--V.\=D-6+L6MZ_";V\>BKB02
MF;LF*/'\FWCG!4S2=N"2R4Y+!JSS4.LS03%<'*M%:8?=#A,Y'=\.)_>4B]>5
M3RLP^Y:,,#:Z3]AKA^\E/.>5M*^ZC/JPB"/V!Q0RV%I0TD"KP%,YJ0G[3[+P
M"PC?M!")@;_<,5_S,!ZF7T]0&Q[$WC/T8]PFAN:8>#YH_+<!9?$.MC7@WL%/
M 87?QK#K+:"A8__?&T?K]?N:I/<41=*U1IWV&JINVYIEZPVCKUNUOQ2M_B9W
M%QB9++ R;6<R;AR%]'WZX0/PW,@UQ^\=CQ&.W?1A>KGT>8%GR,0O?[AW[&B
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MSP#'4]H+8LRI17_FE,+Y8H#$E=I_S^1+2"U04J#DE@WP3$FLE0H;U]5&['D
MJ;P (!<:XUM2'O?<E%Z-[-5W"[A50*: S/4KEG4I52P5^<%0ZBAALO1W"IUU
M 9V9#*LO@$ZX)4I"YFM7+B=IH_.JY6_9.=8CH(%O$RPLLG/#4>I[C*JKK8A
M58&JFT=5&3^JC0Q5&XFIKDCY)*.&P-5,BK47X&K'_YG JKY^FUV17IO-OAJI
M!6 *P-R"Y:[*=:D.EKM:4Z4Z&.YJ8KBKAYN*B1THKRFK_+!)"P?3Y[GO2;GQ
M)-E]-B%32V%P?<;WW,.KPI4G &%SJ=IU_*C7CV$:JOQ7;WSDFO<A6*5U.<6%
MLB0A[@07/G&"5% #,H?<GIN(*+,N93#J3%9EM@X 8"W)LC<H,G^#  $! IL
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M33ZV=:TNR88-ZIJ2 EI9BNJV#F@W R=8 <^8I,JJP+.G\4Q6!9X)/-L@GFG
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M@RB: Z9O%LT!"Q8PBN: HCG@JVL.J*_>'/"XY]MC^&<0#=V/_Q]02P,$%
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M_'V9R:/.49.2CDOL4;E?=F%SNT4?QBM9LK[]T&'!#4A=,9.85%OFE5Z:U3[
MG^QJ2Q!6"L86+?H%]WSN,@<O;D.8A%3Q?3Z^@1O?K#*GE\(H(4@O8O]#H,*B
MI^3_!&+RA6_QL:6 [B@TON SF-B4>CY[IFV0*P^@AG:XF8ZJTRXSPG93\IRX
M>!4:3BD-_/ITRW;74.D0?H[+J!1!LQ2X'44"_Y$(F-64!@SP7),\65@:6AW!
MSZ?JM+)^RD#_^Y;2+BW&KOX,6?"ZGBB,8&AH=0P_)]6EGP*ZHU"TNFMN,1U
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MV7958)HS_:R74TDQ#=M*@*?CS&/X._(MKWB=$[X>R/+#_F3_<#U2;N-Y7Y$
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M:UA:1O]WQ]+QM/ N$TW,8IZ5PCR34D--SI*SRS1*S\]2$]QMD?I<%MO K\,
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M<UV\:\:M7YZ$RS[/98I=1/'G=TXH(B.)'P)H%LB,+5\$#^<_OU/-64!G[ZQ
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M9'!#U84[Z@BN<39EVQC +D7!J4>G!_O'&EM M;X&3/*"SP6?<82J<ZFM-#0
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M2 A(2SDEK7I/Y;E/B]MO.& !M%/X2)#XD<. SJ/]Z,?WS?@#)QUZEWX<O7A
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M]BQ^4UF]@G!>-P-X=PCM\-FA9OLMM3( \1I5F.(J$-%AK"T,W KH#<?19.8
M<C/_I8N #?"2W.RKE;RJ#LU4Q]^5]\P$]Z3T<;$:EZ.>DMZ"[)U4V-C5^QNP
M4>0=,#9,PUUP7MODJ^]LP#3UQ@IY$>S,%%()NJ'G6W<OVZ]>, >!+U=M\<!=
MF:<W\,Z^%)O-YE+&JQ2U83E G/ALIDW1E]_:@'V8)*.KX]W5]3)@8BH7 1^O
M7/UUZD2%CAM6%BX6[SRH<ZX$SG!*,;&>9FH5.FYX:JV&/7V%6<MD]W KBU_#
M;#P[:6VD##V$0(_T[HCX3H/8+JNK%%;<P0!QL?(H,]*3O8GTH1$A7H$B>&SA
M_0%E@]1X,U]4?_'9"+B91H06*MIW&-S6:%!#=USFM;7DH^1U9_3XNMI+[:*^
MALX;[C'W(RIS9UU0+._KIM\SW-Y>:$RI5;L;((4JI F+0LB#2)->S@[66R<%
MF1ZVH?ZVK_-_\:EWS3QY[_U6SA %C0T@_Y?A/U%%@]N04-YL&VXCY9,I[6+
ME!X%G4?<A$71HE]'/%/YY8+XT^(\/]4A&&O RBW*- QG,R)0$52\R(B;>N*7
MUL^U5Y;6X&]8_3\/01&F,F;I"7"65H!<XZ4,6D];.?VBM*[^(IYU>7VTUZ5-
M86/"':P/<V1>E,ZO2@W@_ X&2" )"H2(SQRI[# ZC@G[, ;MCPHNKF%74)%M
MJ2(K;CR/*U52B5>--.YD+ ,6,76#2?G50;L&;=N.JF7JGF16!6# =&.=L9IF
M:1#BRX[W:GE1\MH;,)EST#I=-M80(=O( +13I^W"M*T[:LK[F' @/, %NWJ-
MD](N!M#H7%#R/9@"P,DTE3!&^B5TCT>J=#5@BC7<XOE7P\A)7LW+O-8 AAH>
M&K_XJ%(1(W[TH>R]'=0F;83$IE^;9^Q4!)VRB_R!J"C +2^R5B7O8ZK9O*K"
M,N%U36&R,DT)0'T_ \12AU4=9<$BW\B"DY51,Z+:Y(I6V*NI1?9,8CCHGLJ\
M,: 3#-3D M42FV()T(F\U;O2QCF:@IS$;''%7-(4GJ&VT_R*ME%NR0L>BB U
M,4TL2"-8FSYS1H+\Q>!*K@GB6&EF F]W]B:U/YD(.@'Z9<M;H,IF!UA/X%M9
M\KJ-XV6FKS2V!?5=-O&4RZ4LYKJHN:'J<F']][B2341H+(W=G\\%?RZI,]4,
MF+$KD\3=R,S&BK7'Z+6X=OF/6H$[&@";KF 8NGCI^TL7D[O:S@!Q>L'%'%F.
M7F$694S.$GJR5HW&)*#O9\#DKEQV"UB\HD0FGN:I6$%C Z8!6P%O49%=@?G?
MM>7^"MJ;ZBR\'MY=W=S=?;T?,9M_(YJDCT6M#:#4E^$_M;YK@]!M7F^)1\K)
MBO*2O?7)ORY!2BR>.7=0^VD-7(RX>@X (SO@_?'OKQZH?9H"1_F-#6"FXB*C
MFAB;!F5+M1!-U8J&J,=I3M9,&P,(FWWW>4>"Z+?_H42,?O"1\@M< XWTN[P1
M+#-O-O4JP>AV=1-8!O!&E(Q\$>6K8>V"U@9,I.7K>^I)SS==H?FW,2C4P:CM
MAT9-3L6B^Y_RXC2]/2[WWO#5<<EX&/NFDA3)5<V.>3TW;60L],V<'NP?-O7K
M9/H:(#=B#63,14:(RSV7#4'WG,S?(]APOJLV]2+WCZ[T8WOCF'H7[,Z.FC68
M;EP@-\',!,%<D &X]93"_[YI@Q]A/M2A+[JTW=E6!@BSFV\WDVK!3GDM#9C
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MUV(49+(YTEA@,65$:V.P?<*WUT",R0]KK00.G.INR3478+S5*5<_P,G$0&%
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M03)1($:17*<VE7N ? ;W \9@,!XJUG:][#Z%)?Y R')M94_+8+O;LYPE*E]
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M<U9$=&"D)R(XVI4=D1&",C(I-,9TJF?:=!BCNEEY IKOY+@-PI%AE,4.J'_
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MJ!@Z@B=\+:UA($CN(&L6E18B,-\GS>4I9&/6U@VXM(>^WE]0I]/85NM"^X@
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M $J@[WVC!RU?!K2D$+X)>YZW8L,$,YDI>W;&OU/L=M-K$_.;?VM3JUW?X%C
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MT-AJLUP&6;,4DS(D.&F(=*568#029Q)+6MF(JVJE@,WV8(_;VJG-7H]5G!^
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MYFPNF_:' \FIR#%0@C9BVQ17$V=P=96!&JLXBD34":1N!._YJ5-GDNKTJXX
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M HIQNDP#:C_UH^E>*W]O!N40-;]W$-*M:M^E,QXD@3J!6PU+V6=FJ R)*95
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M:.L0GH]@=JWJQW7GRJ3$LS8X'@.,2%=RE5-V1"7'*5HMT<8Z_DFU(1VWDA^
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M_P"P_9M>58F]TW6\/U8J./LK;(-Y^$P&9J16),JVC@S:USXP1JSV%@U A];
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MMW$D::.O,JOO8R;/AW_MN;!ER:W]VY*6I>Y9^PHK#Y$2>BA  X"R-4^_(T&
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M<OZ!9QZ"XQQ**0Z51U6ZG>^=FCP\A."<[D5W(<2T1\7TW!=DA>>VM[1.A>L
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M&&P4)28>M;<QQ3+:\KE]9$;2Q[]8-JOYB)/TC1:,KVF7F(^B9QXCSR!TG:!
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M(X2+6HOP>E(;5=?78+V*M6RT$%$6!\DSDHU !2$6#UP;VK0%+[Q1F&-7I,^
M8/UKK$%X[1;>7ZH2,*^*7-Y=T*9[L]W28M[-QM/9:DC]B^E\<=7R9KT,-,9P
M\C]3=%@[ 9+MD".C!3&9:MLJ)=JTE>EI <^ CX/I=XATEE?C29BD<;AX/9DO
M9I?+:9'7/[O*J N3_%V259A?THK"XE48S_X9+BYQ.@E_8,W,&D\^_ASFXP-2
M7)K".3CM93AAW4V%D9;^8:PDK^HX#^^U*M(8D3PFJ=RH*;+#=L;KS[].W7P
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M,%Y"8;9IWKG3PU\CHZ;15 =7_D>:GW[!-KWZ6G8WQ4,GF*(TM2B01A<PK@1
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M1*P0C:C6DK>JBBTX-0:6WOV&CX)?DROM:+H+/^P0<=TQ4F-0%-D+P598J76
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M-Y)D)$5,39960189#!39KKJESQ $;[4)HU'*I^R[]>&;FB1/AH(/P9$A\N_
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M+5[/,4^7/V&9S?$C_/U=J$EK= 8+RR&$VH#8,"_H6+!@HK%%0*M6JR,Q> P
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MOX!Q8*6.4IGS.-G3KSBQ.5N3T+(L4#(=C:ZS6!U#HT&7!-E!FYOG'0E^P>+
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M92Q,.!MJB%_7$']BR2<?R(_EOK0IH.U-ZM,!TSC:N@^OL"^\-HGB*CG&% Y
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M/AIHX/C<(6TUI_"&LM>SQ?)W7'Z>Y4F&0I94S"P6;YC.NK"@?6)6!T,.?\(
M;69&=J'NB<-E")VT,'BV.H&10R[% ..12Z9U+BR*(!G7.:(LPGC=)I9V$EEJ
M^^!B&)F?0)::"A"$A$)F'?(:6<K,>TD&GO+)16&-QT:E1">4I=9+Y]VSU/K(
M?NS4HRZTO62I[:3)/CE(NZAA;*B@ARREKMXE1D9G(I#;*14K2GF-!9';_$0@
MLGN66C.$])'^P!<T;[_@Q>\P_Q<NO[N1-VU"A;=D;2-S(A%1I:;4E% -J"H&
M6X*'M2C^QEN:K0\XLAR57CJ8#2W ,4(N*_9_JL7[WV<_WFW@M$.DY?'OW#O
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M5*C V>K+)K28DU'<,;2U6ZDQY+6#+.3$<T_L1VM5TRU_4&Z>S:HX'I'W M"
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M[?HXEI<VP;VTVK]-<!^5#-P-Z=U\5J;+%44WQ" (D;UEQM?^LE9&(D9)<J[
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M]A;N@%5'#S?8ZD+4LVOIV$M3G?KZ[2+FT5HZ&C#D#W/-T-2PJ]"2D;<$3&@
MY2#F%#K5'AZC[ONV=!Q>]7VD.W3(X,OT'=XXKL!=+D%Y!KPVJW1%,R]+81)
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M<<QPPK,T:.U<R]UZ^T;4V\TV=-1[T&D_?6VVV[A0QC+>_0.>?X*B%9:<A<B
M4,$4)&]43*W>6 ;7R.J4;EYGS5<L&MS?<J2-4/]V7:X.0JI5JZ-CU'RR+E<>
M-SV1G2;&>A1.IEBZ1GJBN19)QNS M'JG?XS8']KEJC[TAVBW.M?*U6@V\8NO
MZ[-(AN@]H <2./JOTEE)K%6!.&HU3\D(FVB+\WUGV,?2/>D@14_K:*F')^_.
M1>KO%GZV^-XO5@8MC L11"0A*E9Z>BKB52B--&G0,E@37#_M->JNXZE[#8\
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MQ^EH_=S%R77!Z?ET?CT>Y<T#;.!2LV2(\U#*=K/ 2PKUY146UVF\3KN,_8U
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MN7<+O><[7/]U^27@]?#__<?_!U!+ P04    "  9<UA4ZR;A^(II   7EP
M$P   '!F92TR,#(Q,3(S,5]G,2YJ<&?LNP=85,^R+[H0$<& "",21P$%&8*
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MA+7GR&5>O9V9YRXP=9%%,M"&LF=:,X L13 =I"#JI>5GL+":,K%="FJY0P9
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M!UU(-_<AF155N:,S[1CTL![!>9MW/!CS\LF D!D[NVPE)Y+MT(D@UU<C:T=
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M<_!0AD 2ZY2T2-DJGGB1@TMAVI-QSX@4NPRBN+4-R*PX<HY=YOQUXE#BJ2,
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M#3*7,)X$=HX/G403&X=^0G@5?RKF(13R'WK1)V).-R#PAC'/ W2HH)!HK$T
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M!1\:&'^5#R<#[(1UY'5-'"QZ>(WU/'C$$KLEY$_$G.&0,%YLJ)V:UFC.VL-
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M];T5%N'@;.,8WW]?PWF?S2$!33YC;PXC [A,6).UC.$LY@8+4#AR3BQWF==
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M[D8U:7]$-9]ZZ*BSG7&]=K>).W=^9B1^M+,=*=G;X7C\57S;_=\[M,DK@2S
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MSC,91G;2*C9V"CCFYY"IS(LT&H1^[\E1*+D?4.TM*#4$2\8W28<5>9RLGQV
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M$8$(L:"5!CMM_YD_9N:^\WWWGGOO>>]]WGL;LHT)L,6#R6(""(+ <=4 &Y.
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M;F%9&*S,D6][7HSS@^HZR!F4<O3&Z"]02P,$%     @ &7-85,R S(_".
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MZ$2HXG*X]#T>NK<%!O(N+ XL>UZV%XQ8=8M]@.:5+A'V5*WW(,\57R Y4#*
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M"WUKZC-WDKGSZO3MF=+4DF2'A*07&:]&Y6S^7,'8]+,SD9AP>I7Q,&Y,!CL
M&4 (]DY4_.R$J?,]YKOVL/%V];/L4=&@)VIYS37F]N]2FLY *AUE(@F6. ?"
M-,5F1C!WRM'7'J8$Y%::0(8N_9FX-6D^)XT[B*]7W(-)U=I_55+XCNI+B9_-
MZ3NOP2Z'R#RO\5(JB;\<=T 2HL(?$;)P?Q$)N(9^8=""MNO\#>>&!))4'9!.
MMF-N\VR?Q;ZVYZ7*?9:[R>CFNG3XFWPX*]J6_DU]2$"_K.D]315DO/AK5G_0
MMK'C^[ME>4-5I/GHA3/0>;BW2'*OPLPNW#NE..7I]<EDA?C&2F]A,:,_:7R;
MLLY7C4PUJ=MF5%4D_<?$M=_/E+]BD?0-XSI8@^^F$-4?\=.OWP(2B+H1 S<]
M"IQG6TVB#&X"&I6.5]-*DW\>>R[8>O-9#(MZQAJXNMMFB6@1S,C,%+Q/.V,&
MR([T"PD(\0^JD]F I+6"*B686NTR%._L\- I)=@CJ *&;G:4?"0X&A(:@<G>
M^DUJPZ&_H\FL@T P+GA(4R.%+!^1;05T8",Y\E2\VZW#VE:YV[NHC#\C'BJI
MPR]U3Q1[Y]\^?OZ*-*COJ%.IIN$5<M(S<;WVB75^V5H&(,&^5[ V^5V0,+K0
M*I*D"4]L$=(8[)2=\C_8U[X>EM<I^&IMSD]X<[',H:*MB/_83@S6,]3EJK\G
M?II!? SO&T"8>S=!1:CE_6]>*0_74<6SY6TL&K!(.^R&61CFL>I@N4.7 _7K
MXIDT?]A,B^#N!0#B+OU(0%9C2$%IY&EZ [8A855C=G?C0\>\MFPGS.)7HT;V
M1AVNH[5@\O=M!S?1&KG/.T:.=".G6<BU9V@:B(=2\E.-M!\]E$)O$,X+^!_L
MH=0.4D)S$$**?N5,7#,SX$B;4,FF[FG#GTMVMN?7+P4.S,<2'B,*3[(O#9N]
M+J/,PQ@,-0C"^S3/0#Y*<<7<H<6,OYYZUM8\J8.>!*1J[TF+G%]R[@L.N!+5
MB,V<O[7 I*6LG^DHAK@L34M^3KI!B9>J;O:WWH&3%21!_""_()>1.UZ]IQQJ
M#WMD7"7N$YG2+JJL?:P;\Y5I*#H;]N"TJ)N.J NU#A.&X,Q>= >X58Y*SL^C
MR)D!5;HTH]S]NU4J*K'31N+"UVQ<(]0VBBCY)-8T>EP8](UU/YNH Q-L[S[,
MC]B$,WX?)]0N2MYR5K_\SNA8 E46^.G';&5<C;%VSE9E/D\EW_[TL:X/,9("
M=&[ UZITA#\V P&8O0!CW.:[M0H*UR%/NF4J:N7)EF"?SIQXNTRJ%>3=)77=
MR\Q=>D^4/@7$B%!6=F<'9#>+<43"Q&SE3$@#XXT%9?M%Y_H2#,O?+!F^O*>)
MWH.ST!E?A!H=!Q-"[6.BF"MR>@5V3 R%]RE'<\'[;K4(NN._IES/2PH9NC_3
M;5-JB'A*R*'A6Q3JTV?GE,RF'964+!Q6^<1IV:\!==X+7]IGG#/>05VA&43B
M;%P6==?0S^Q"BM-$F$,C_9A'LR9OXJ([O&I67ZUE_&AO;VX.?]#_0H^97\LF
MF31[6@59*X-<1*XUN7#4Z?"0*% 0JP#NTRS\HAVFXS1NJ;2_<2FX88?#<#YL
M_H']-9W1))/+%N\V4@UU/N @)$$EW/,;>-9RU-%@0RKY\K3\/F+M9]["B5-A
M!3;6+$\5$79YF<-H5-F$4_LP5B]JB'B-/ YA1[K#X_$1!IB&%R$N#!%/KYF.
MH;9QOAJ6N58^23^N93U9-*<Q!:NF-88K?ZJ4"ZW6,JT0'JO22/Y.@BQ$4Y,7
M*55<<89 0PI,HL1@G9T-2/\JJQ1Z!F(#'AX.:@KM*ON_?C#7 D@[?)>,Z?Z6
MOL9YWN&U^N=S#0*1>?'(M4UT$I+UA8#9$/MB@6/*H U>3QJ!,*GZ&?2+<7?Z
MM$3^+XN2\H-#];11^4]4,E*Y]Y$/JU6;XI0D/]J6\G.5#O^.HUJQ:KPO4P5J
MYM#RUWF7/V L8)&;M\H6/F](>H_+(UV<Q$XF.0OZ'#"2!XM;,E(U[M3PH(3S
M3])21CI@LX1$L<!-<97"&,/E6XA[NC93.B(4/T60I\Y 7'E]&F3NT_AH>7@_
M!"MEI.90S!O1KHO;(*07/,M$?+%;]0*_B7OET!73GTQ\E/SSA7NO3)!3)QV/
MN?4_3[K2_!!)%,$Y32X^QTQFP$PQD4B1'0W4T8N#>M4QHM^5_I.Z/W!HC"14
MW"2Q+I]!;EK;/>FRI%/Y<^=@O""9S0R@6EO1OQKBQ(TM3BN!ON!RW+;GX0N\
M'=@E^4B#K_X+E84Q.&I-,Y:AD61"85@A>JR8GP3'LG,#*6OH>#56KZ'PK$>:
MW44>XY=W^"V4G_A+QE^SEI!/-=':7=Y"2'[;8R S8H@R0,BFR.+8VM" '[,]
ML=_:IO;&[9O9JOY&@SZ3CHCK3DE;.3[7O+_UL'+'M1H,"4M3HJV!Q,W6-)\/
M&6!(_10;F8-G3PLY5<>>?S*VV^Y0DIESU=,\=O EOPS7 9G-"2C IU@Z7<&X
M[*YCM8A_EV<86])\!F>>//AL=UL][.6F.N<=7H2^M>A+=)<'I!K)C/0J!L&8
MIK/OXB QW2)K*SJJRA7U"64.T*GJ[*P2,3T0]U?E^4Z,0!(%L.R"%-(-+WPZ
M-=NR>/^-:$GBJ)#MR<T8$:&!]^DBU][!6^H[^ HQ&3$HEP2%AX/-CP0R!GY-
MGJ/FX?CL8#?7/ J*N<CU^),_YA5D"(V[.PE<$MF[XB>%3B8K1L#[QZH,LQSM
M;N)EK&=8D?M?>#F\">;#EN<^C1!B:P>"N>-&=OUX5B\8K5K HY#B5G6-Q^8X
M$S)KX@=$OR Z!2U("L8Z>?Y@0+;CEM5/HFK4T4IC#BFO]I68$[^!0A'7:.A=
MQW[3GC*>OH(_/ /%(1LKXXJ- .A:&DU_YO(03_A"6-NG'8%V!*-!5Z?O9-!Z
M\(-W81*2U R\VW^L/Y0QPF0O%OS3VYZZZ2@RHK3HA<G8NUZYB((9 :%K 8GJ
MJ.#7"N)XZ><^U0IEG+'32=,$KJM?UA:>Z(%@P7AN,B,O49:D'V]8#CCPQ='6
M26;P)[36Z>JGO9[F@+4U#ZO+B=Y/C-Z["9&Y<P\_21*<)4H!AQ9S7GF8G,X[
M F4.K4/I&5A6 ],FX3M^YVTQ\:&&]^?J_R:*AB5KB';N-[1ZUY[F:(FM%"/@
MN'N3@(:N/MX_H]0Y>BQ?(T;GHH]IE?,DED7(S:(WP61.HL,P4/7!PP[O5;[G
M3+0F/'K^GI+QP]$3%&^.HN3Z:V01>)].[SGOI_P)(2(L$UA ]7-M]TTLT8F>
MA=5R\/"2XJ'CYZZ*Q^Z><DTFTE,WE@.S#_Y8I D$YJG>?[6\9/U C\>ZO(CN
M#$1G@W/:&C0#I,WVZ$JATT[++CL0MK_?ZTI:];-\DG3ZE&VG;1"*-YS*$"OI
M?X$^#!R094O"99,9![ BL4^%*DA/%]):TXR)@_;-J.,/TBG!JI8KU"S*D06)
MJR:WT]7$S(6^SEMQG8%T_5/D>%TOV+K&JC V/"=Q4^#S&GE<AQ,8@&,+&MA]
MBB1F_$/#YQ6TA6K0!AIQ?SK.[W/HN6>*1KK[YK075J0%/RNY08/HN31:R>!F
M'YQLG=6!I* HAM/BT(QG9R#<71%VYXCLN]E&>/9!4^/#8?ZP[!MB18S^C@8/
MFU)I-J-B!:_W/?.X9D%E3S3.Y-"/L:*[?QYT#G3)IY3#/#GYIY=,>!CLG_[J
M-,"$3Z&4),E^VE*X2/U&O,*WK>26F@S.GS.KNAZ!5=#'IEL/F=Z!!;K# Q?'
MOXQW8>.M5@Y]H[W(C/\\1GX\3]E,S9X)M*=$2T:8W9GJ!4<0_E86! \%5T$U
M;Y7?6C)#N)NW'!C)1.0N,[S92+K'?R @%Y6_M;7#']98@$72>Y.U9B6:%E0+
M->R:D[&"@[$GWQ3%C3"9'LGWZAG9LN0ZV^][T'+<4*O0XWT;FRS[EO% 'C/G
M)]7^,?G:6N&Y( /Q>".>5%Y1W,V+'#X#H6A :F1W#)OF_.O>W!G(RR7&/KXD
M2L(T.#1X34'.KC+LFE>X-\L5[E')S1Y4LO4-V$;POYX*R]D_X'H"\6*/59(,
M>E)33 \E!O]^5@&KY:&ZP:@_=15$[;- YH%1X60^15Y0@+&O-3 !FBCODEC#
MENOB:#,CB;BPVZGB>E]*2=7L*Q?/V3CI,5_R?0;^D;&T0&9LQKD0"-\\\&P5
M#R+7S!*Y/(J'BGA-?$R-C]OTDY5H!O&KLH:9#&]2OSRK5O'L;2_-*2VODPI\
M-S^R+I*"7%M$IYR!6*1,'3 )PY1BYU'GKH9/H. J:A70=+WUEJN@1],(KZ@+
M&Z7>DI")93<G:L+[VLCR^(S4="3Q)LPX?L^_0>=;#32:?^Y 31#)>3D4MN+#
M'S@4V+(G>U^,BS:S?[RN->_O3/+F21H+.@?V>S^B,AFR]D:$B@0E7MXNIE<S
M>T%F[ 9<2CW^H-EU\F.7[N8<ORZBOHQWY%8=_)HJY:;ZHE%Q$#@'Q_D'['9
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M=T@T[")'.27:&*;_E[^L_%\GJK/%_P%02P,$%     @ &7-85# QTIWG#0
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MY;3Q'%Q3M//X<+O14.\Z_*6/=SNC7$^" PIM<&2]4@="@*4,<L6%3J6V;GJ
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M.C%_1'$3/,;OV>K:7S9Q&X2_4ON-;.BX A=:F01"=#I,LQ>>'ROV^RHNT2#
MN.P S8#\OMP-;JYJ_09NN3*>O/".R_(6YT$8?:P)6;^05UWW[BL[0L"K..9]
M2+9#JGE@#@U:_<0\,"KP_:4 OG6O"W(7 #K[D-S)&Y,WJ.2'FI)?9[_^]G]Q
MH3; 2E[_V1"]./Z0N9>E[,&&Z^]?JXK[/'EWVCGUTS/%FC=^G $6XJMB9XDS
MAWZ$=F#'P$=7!]I$63&#PX '@%]."2S9ITD\D$Z! KQWN(H 'G8&L"#8%KW=
M-7\PAFFJB+NT7%86^""^^<WG^ZKGZ9HT3M/(=ZN;(6$_YW6$SP"6:"I(P2-0
MG5Z/Z!@KZ('CMK8SGW;-J.48IK(\;F/E:A7VHK32G?[[FT&=HD@,>%Q-$&]X
MF,=RU_T4*RXR-V.[%I!'S<9D(S!<7)+DV$.*:45-IQWZCH&L!Z*F.X-E@7<?
MET/46I8_B/G:_3EV82WH& YX,?$UDE/VY QP!J %G7[F/DPF\)_D)4-6?%J;
M?Q^]NFJP6O^)-XG)TZG@MX#W#>IBV/VZTE?.(48"/X+=?R@(;R@.Y&/ LR2V
MMM*^74)7_<O0.',2&?YU (-FKY& @M*T$C@+1KV#MJJ7CV$/N?3FL'G;[1)R
M$7)!8.NL5Z8N,)?K)_+#6QQ.'("T-;3V3_V?S\Y!L@,DFM6;[S$T1>W7T_+1
M OYO+LEPFB- ;"?80>[",ZE[5383K8@PO\X64-AEO7 9OM"JL0KEA+HJA=E:
M>A$](OUGC488!M9W!A"L0$S;+HR'+S$+)+ODLIZ\H"IS%K6X%G:$*9_@Y9$E
M:,1E+P_P1QJ.HG#:DC.,9%[4$B]NN])SF?"PX_DU@R10W<^Z#J$T)%73IJ#'
M+DYL#\ZN8+UB!"S6!S?DE#1,O-R= Y83%#L9K_<VY4; :W\,0XZMRY+SU6%?
MH _&H:SX,O!%TBT\#6/!S"87JVV!<0^+Y5<!V&M5,ZL[^U<$QTCC9#2\-*.2
M2 <;O7P&:#W5OY[:,0VNM/..9##7T'.'%E)["R=X3+@#'<A9IJU)-TOD"@_%
M/$<;?D:Y"M/I?(QT.>(Y^H6,IHS6:B!.C^.T%F[=5:E*1P,)0[&^,M=X?*,F
M[N3BMSX;/8,:0,_$RC.I+F2+@O==GZ<:Y06G4_9G !KR<O-;11&7U;W\P8.Y
MG8@'^S]R>9.>_(EX)"*HR.W8L13Z2B#L2J#JX^NS$QOXN+BZF<Q]H?]1U_W7
M+B7Q&,GV*/\%C38L?4<&=X,SJ$V0MUZ;*/:^=D;HCHAI^4U>\_R@#,?TR9MZ
MG-(Q*F; 9VXKKVP/[A-981,PX&DMR@;,3'HTJ#LV=G6W4DQU)F<$\IE*MO9$
MSG>M^S[GIJ47S$6O1(H,;T%E0 A7P22.>[!V5$4WP;#-.T.O%1'.WFD+VR;$
M:#42?\ZYN];^UE AU2S)GC+?F9[=G<\G-+(N@S^O^EHV+YH9MAS$'$-CTMOU
MWZWPMO/F6+[7VY5)(]K.-WA\^2]!SR;B:>09X#S$#/\@G97<"!#GH, @@$.?
MX@/05]^0?T;UF*]@CH(;_SR<>@.0%7$#4!PE1E81)L%3?OA-#J.66D"=QZF
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M#<(90-KHH#07WAD,C]F3H7H;<>/;N?]"F$X=>OQ\>XZ2=_PC^IK%CF)$U<X
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MU+D#'N>#S1T6HUQ4T!]SK?57&.S2>=S3:-'7=)?%BVL":Q0ZLQU1/Y,_"E$
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M4I1:'T1&@ ZO@B)H>NW8+T9[O8[]'9:9:"1 #!=A$YB8_;5B,2'FDQ[P*#O
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MS6N8B!?),]^F_>FF\B'Q6A24\7#NM$I6<GKI<&JB2=9>R?GH?:7Y\R6]AK+
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MC6M<M[8@I[UI3&5(O67J+946=KZMR<B53MH"83PRS.Q+9JA"\<JNQ7K*IL+
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MF=-_W:O$-@%OHY_2,[50U/$<^\/J5/A:VK%P6E;$T0#!6R\*M783 R8Q(,X
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M0]HPLO#-5N@G:#^!/;MSJ;H^U,GY+G^BB:XOK67RC'S\XQO/UH2BZ!MD>#W
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MN&B[AGJQ+87C?(:.XFM)-\E8]8,SNU-,2_910YVM!Y+(,L&NLA ^-1E;X_W
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M!L9M2E;0<<QV(&?16MLM7:]M"PE5B+Z]24 KL\0486D)KI4;)8B2P !RH^@
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MS!BEJ[NT/E:!2KO7GR!= C-8RW: E<&;(M69Q+NWC2C, !Q9P^R?JTTCS3$
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MYMN"CEZL>*D2E!>+*M03'>>;:$]J?S/]"]9!.\>LIL[D"3X]5,Y-W,XT.S0
MUV778GLDV2CM06GM #)@A8_C_87K&MRUORXE\;XW:I1ZL^;B(2)FYIEM>[%S
MU>PA4=DT^.UD_P::JN(W&-AQ/27?T!<6&IC0="OB%?5N:,[*L%*U;6'NA*Y3
MB$,0FX:7B^HS8YV<N.?V?H]-4YY??'FB*QBSQDWA"7Q%.J#E^W*$TX'?Z5WT
M_FT9/VG3=9&J5UIE40'Z7I<_,0#^\J=^(J5*+_E.?X?-0*VKF+(',66_BRFG
M!N"!YZ#\@PJ2R!NT6]O-$8W8NN')-_#<MD7K1^TH]SX[RIV/7PXEG-AW1Y*#
M\M?,&8"C\^10!N $_)6JZ<RXFXJT"D7OM/@/4EPAW%4G<?^J2 W:_,6F",]2
MV$;^.0&M?F4S]J"K7H)!_21?9T/L>F74WL;Z0N*'TG*OBL?[T7""%W!=+I_Z
M&\6\R:^:W JG7.ABY/=>QR-R6^Q\OTWH'^X2&"E:K;-7;)T48CW)<G2R.5ZQ
MPP!^LT9R&C23!2(\V!2 -VBK*^O.(KEU:8AL%[J]D!!AM[957^WD6*3HPS>J
M[0C7]XY7^;1, 2(N EYDH8[=ZP*5%E)7\T%1-1C;:5%R!DZB^N&^+:[L ^_A
MC+(4+4GLDA_[:52U/0F/V4)6@F;",83[B[1*C*OR[CJL:X[L0YC509W6S3CF
MQU^;^G+0_LD+AZE1/.O+XSCP1:@2.:#X=^(C.]"PR=_85?TB470B.#2L[/"O
MK:H?R@+K1DG-OH!T.@+^&#FZ>(?V&NX(Y("J]1G9IW>#*E;VOO.C)!<!G9)G
MESRS:2G<6U3=][72'$X&E'XJKT^,H.4=U4*?,<6OLAV%?(^/:9XW!3R66&]#
MZ;L\&S&70SH^2E+A,"R^8YYO6WMH%5M900&5-M#'O1>G,-=Z"3*;WGX/HKD\
M60#&?9H7?^=^U/V8>O]$/39<KT[O-.>I!X;/4LP(I,_L*.[79Z)$![G/,6?<
M<=SVT?<Y@...<FNF4G@@D#ES9!D CTE>DN/W8:@D7C(F!GQRU9A6CR4IG^K,
MMSF*I?3+7R_KB#HWYS':)]L9$0 >_+IO3BIB]F4<J$V*(G[LB:H(M<(WI)-R
MKW9^.>_.L])!_$:9O[9QI_RFA.40Z6/.6YFUG4,[(V&UUKF!BQKH(7D#0\-A
M^9KB*8/YN,9'UEVHZ,J1.P]Q*6]G"!J"FM ,IB%+TC"J2H1M7&45@0%H0O/!
M(ZD&LRKZ'R6-SOXABNY[XDGX0U0"CL=O?FUY\R"NYSFWR#X#0!= $$WHX1P1
M3.L79-K$3]0*\#!\)FJ8SW0^]3.1DQG_8#/!/8J)V:U]UC52G[ZB.F>UX[*/
M7B_R^BZ[]7T\%8#_O6,TJ/QX80%4)WDVO#!WW^IXAHM:7HR/? +_A.W-LZJ)
M%V=U^H55GW5M;2:S525&AX91@J"L&%H6QF'S;"!$JVQ@TX^T!9%O\#?U[^+Z
MLCY?<TI;N%DT5NXJ*/CN]0([VT3F#>'H,01D0SH\HE8MWWK92C'E3/CP\!G_
MUBJ1I/OZ-\Y9OH]R=)32%4DNO0U,1A#T$K!P/5IF_4U7/GB4@N$:YC2YND]:
MY#W>L+PI,.D(1*0?F*[<6+MD(?BI(_>'Z12B,/@^T@VY;(8>5C+;JU0J%2'M
MG=$1B0Z<.&ZN]2C<[.@9C086A2WD>AC3_K\0IM=9D*ZV$H3NSTP@0,;(;LL3
MW[U:KHX=?Y3F^T#HBHAWQOR=IGE'.95RN7W,OZFXXM $O,$,!.'@(.,;$(1B
M5<ZOUJL/IO1/#Z,+QCH%2 9\9T7\^[Z?$D1'SCG%/3>4-I&RTC1\P)P]NK .
M;Z@ 65,I#E7HYC=2ZW7*Q/),NZ2U2]B]Q-,-WG%7('*#*H<+C]^I_G:! 2CG
MI9[=;&029@6+W00@V)J,W7_Z4L=W'AWH2U$)NS0GO;TP[WWX^4JD.8P\[LE*
M,@5P&6D"M -\*]_<0'N\&OXV-C;MX]TO@' M+9@*+<&[,@!?[ZOG%;HW?#I6
M'/?W/&OP:#\&WPAJV__;4ZE_>7"?WNTM1SNI!7/XW.;:K9G@#@O96NPO;\0G
MKJ:;><_'0%OVU7?C\)L"EM";!-CG8O#/4NPR<?,BXOTX^0&'3UNQSVSIPV^#
M#K;E%4]+II,4LK7\OEY].#0WF5:HBB#UDZ>9XR#.]*XX_H&\\4(W9^C8(08@
M(1 4B;@#6T(F]%U[-^<4C24NQB+KA0,Q#X91QQD O4&1B<Z/G4Q'=I+CL7)1
M:D( >@ %/T(.:QD*C%!,O6JXY[7WN$:$ 5"JV0>.U/(V>;:7+>%&VF2##7NH
MJ=.$F>R%?.-C+=+0F[N=C[.B)0!_?9R?>7!(8]DH=:_KI(71^"\9A?B%'<"+
M9'H(B>HV#7K*\=*N!28,YUZ1N^%R<#>EX@YH>,*WA\JB%NIE>Y<P_4,)P4EU
ML<L:E0P:B>>>YG\MEU!WB70$%!>**&%Z;T+/ 3RL5B6+[+CY<&!!TL/^1>6[
MPXG?=_8_S'WK9A%(I[4UP$[$NR30!UJU]Q[:#)&\E^JM$4GDSRU@XT95-/NZ
M<=9(=0(5N*U"&></U3QJSD.8:'LS>_/,-:G\BS/$ACGSSFFT;.O\( 2.8QM@
M\GYMU&6#!P7[-@<Y(,T5;>3QNFQ2%'D$0@#C!@]>EM47!I\R.RO@$:0S_Y,!
ML/?6OB\'9IFRZ?PRI>OEN2Z_Q]ZO*RS8O79?5WQD"O.4:!(C>!(T%ABPV3.[
MI9_?<S!!U^LN'4XHC;#Y^;P-NHU8UO_>JVZ6.PWN$0KM24EXHL2GQ&>S _GT
MU$/>0[YF:?HVZ_>^[_V;V:$ ,;P67K\^;@>0$<<?)W.@U'OX[T4$#:FR< %X
M[_PLDLIOR "T#!]'(Z<#TTR2*,9UU8.R8FWOO7PD]:7>'=*RC!(''.IY?+7D
M0&G$X)G'Y8H@UVYCFPS(MHRIN+3(Z-^:'I$#L%Y^SG:6MD8<#T )ZU;PM*YY
M:T.#&8#=0C@.T=39$YVI^*VWZ&%%FF'47*NQ1)O4V,Z1W1\EL=*L(X5\\D,3
M'],*3YCXI%V=K!$>Q3S!O'2;!9U1BE4X\4<JG_6[G1VF2[(!$6\*1:H$?XA/
MV35M^< 7>UJ T.3'B>OXF9'R\]G<XG?AF^N/9*-5M:8/522<7K+BC1 ?+LII
MJ;_X!IE4&%LZ,Y\ALDT>^?UJD0GH&9+L!'PEW(25;DAHM;T6EO7B%6SO?J4R
MQY4CS[7\8X7RA961:YL<@6(/)?H[KGW=%7<27ZR!1<&T^QPM\_@O=>3'E?0_
M,(=!<F!./X$$4\3X,1@(:@,^L12@!6$EJYN]5OU#<47I^9,Y_-=/'05+09?K
M[\LT>"7'O_MT+-+=YI?*8M4JHB0H;P.YH9I\)3MU!A?VJ6ZT,+@>N= SHR[2
M0[S0_<3D6K.:XZ9'9Y9MY T$@>N&CP:TK_;DSI[JV;^/^-$)MSYF[+")Q<_R
MKJ%HQ4QS!T:"OF'04 0:_FG<)HAN^'Z> 2B)(^&[X#6Q&XO*Y[<_[D"*Y)2M
ME*,]XB^?] HI$!FHK,[/._AH(>4OSF+YU#-%]+Y772X/7M3/R3'==;F"^C$A
M&XY;GZX0IW%Q4#^[8*@)VE2U&M)K!B#K!0/P5EJ) 4A<793>@2 E:9;M#,#2
MN30Z6\2^T-X!L1F^<PW) +QRA6]I]V$(I$TL)SV:A?Z@8IJN7>(S.TWE,L2+
MMX$CJB/"H*9XCG4#EH=;]"$W6K(=2\;\SZ3\'H&K>/;HP"<?'A,3;27KXW9S
M900["KH>YH?EY7P<>!#M4ISNWU>R8$IN A7??^AF5ZAWW4!^I2LO,TY^WC&]
M+_][1IP_YC#(&7,!]HLN\WVD]FP1_.G*B+_[$RFF';Y<A)Y:6LMPU#9*C6._
MW2/H>3^PCGD7]^M.FA94FV;E\E:[R--,^C+%>+G!I\T4" .>'_R,8USR)Q6^
M[@O%46[31X!G,*[@-0394%6#5D,+6PR-H!W'COS<KL7<H/WA4J-N'+J&AYQO
M[_GPI]&9A#?V-0T\]"0\B![3%$G9[9-6&BSR4.&,+2(J5R<5W+3:2O9.+BNK
M<4?;)]GJ-?[-5*T_?.*7]VB;U^/W.QFTF"LH<[BT\57/)_PFD/YML1_#C'QG
MXD!E1YQOB2"X=SM-*8X%_..!L M:JE]N1,D$+?7$?2+<9BDW;\.4BJ^5^U$L
MJ?[?" =1V7W/B '%$U^3OED57-!8Z;[]0%E9*L1\C2.!ZB+>\%&EJ=HQ"A<2
M=[_Q3JI7FWN*M40OH/;QW'H[8'=\T!Q??\7K[F=MRM57>[G$()F8Q?U@1!_L
M.$'5RR)A_=?#T [XL8/.PAWKX -!5.M']@*.L87PF_AD#[O$(U<VV&_9\U'/
M_OF2'[Q!"X[[6@_B"+?EK-^&'B%,!>C.A[6E%;H^/[-E[]G7?#U:^VA2<#3M
M]XLI"\S2$6NFE!O 4V0/8C8YAGAY2M_@6J%[LDZ%,N<D0@L[;OXF0%'+?V2[
M"W-D05IL04:?MF W6+JA.W>03IT.\XYW"?5 &O#N(\8L3LH88N5T)X)?96*L
MW"JO0"=V]Q.\M:T,;R@<\)J,_C>0OIYPGG )Z*M_SNF5[94[K74 ,&B-:TT+
MY5\Z] \3_.LB*C<_'?>0W[%97>X!;P(-(<42K;=5RMH AP:#$_)S0Q:IG"8D
MOD'0S"<XRC9FYEV2,U3%%38]&S)X++6_4?$"8&?RRJ&' D[2KQ(?D6/O20SX
M.57XB9ERV?WJZ0.3%<?IK#/8XZ_\*!J!)<VAA:;:I01?I9/\G>CN,>0M3\OP
M9N6)PVAE5YJS&6WT_'A;_M601303![Z0S1NQ 2^H<GE+5FH?K&")V>/:3D[N
M9["5Q,MA#X^,'NHQL3(S8P">?<=F"\P7$G]U"JK:7AI&=%(3THN-N@W*AN.<
M%M ?IGT]LX'%KL:73_1>);#H6<U>_Q\7D7\?^47@T/33A7O3"9\*C3N^:?V:
MN!J;WI0^7U)B=?^0\(OX04##7OW'*\XM7(!_+$X/JSW[_6(/$$_M J@OD%34
MZNW<)P=>NLJN%T+VEQF > 3ABQ\.(4ZDIV14'/0>;R,-H:D[#$";(=F(AG)G
M -1 Q $Z=T+%0=__UY=_#+M',0"6?\I<1+M#1'I8=^ZGJG,Y\<?=/G)D.#';
MW)B?',[:#;("\.Z]?G;I;28'FHF:5O4:-!1,D0%H=,$?(TPA%-?%[SUUM(>D
MAL3']63Y'HQ\APT!^3 X8_*AI*$(TD)Q-;\F Y!Y%RC_??W%P%2]4&+&K\F]
M3*V)7Q,;XB5N^\@V=>6Y?-J+URDY:PLC'HG[&W3M]2E. K*B@%8<926Y!<:8
M;XW!?P#/8^7:A%YQK3R#!U3MR:_0K4&?S!J8?/7:_\3F\C"3^0^F_9]?$MY[
MJT);_VJ!E +,A82Z_+!#;/K.UIF3],@B,$GJ'8K#COU2,+]4LL>R_/-Y8>J^
M^)(D]J>WWGZE>B8XPOP#=J1LA:ZS=:.H/][F=:9BS=X3_H/ZF*'R"0; #OSR
M-&&Q 3ANWEL4W/T]8T1\H3+BB\">FLX>]YKYK0^W'!$*D\TQQU"U,/NDTK:W
MG^PK0P[%9NZV!V8\)+Z$&O>O[=0I=H-/5MR>LM'=>C=J7Y8\> S@_N.F./<<
M$.W4)EMJA3BVG 3/>>2.>.BW+J1A@1%B/;#[C-S0U3_6J I:6\YUE@SJ,(!L
M3]"OS_YQD"=[ENF>,<&&&S9G\< *V5;=>D7JG>^#H,!JA\K5D!./:*,OYDO'
MWFWID$K.Q^[>5*^[P@WSD%MMRW>UJ4+.?V@2M.:-3A4_LY^K-FVWA1T2-\NO
M>&,G%BO-?U]B[%&(L].9QKZP; =^"8EK%4^<Q[0Z /^+LXM<%\">+KS[V74M
M:L$Z<M&Y9R]HQDF( 8C(KPM]3^&#,N$WS'U&:QCR>6L7>>9R_3!0H0C8B"#(
MUGJM+]OR4H2IG" >*#0-_68_72C:S*6!@CZWJX,I.."P.LAN"<;$7B9G9(VY
MW/+[0!=, NV,1[&?%(*9Q+_C]P0LUL$6<2"VO"E(E+FUACJ-&=@=_)%PQ'\5
MDUA -)R-3V-RXJGBV6(/7+%O%\]8B:/PIJ+RB?J2MI-J/W>13=-887QW*46/
M"AZ&VA6IT+*-DNW/<&Z-CB?L>B*_ 0L4=A:I/"RD!G TX@P<9TV&K56^PKV_
MEYZ3J-09$JQ\1&U85J-U83$1S%N^< V ;5+> >PB=_B;9'A364[3LB/ITIJY
M!]KH7W1K8F%\JDM\D-E9^D)R>65_TB1&M/<Q(/H/:?Y !F"UUQCST'\2^#J<
MASDD$F,Z1]BT>'XO2?]OS\=.\.<O+ALW.>^5-QV5&'C4O7K*2*)39\T3(+@5
MXM^E">SH'$ &4\#T$Q3*160S Q"9!-4;D;8UY" _-935C=:<0*/KYH2R0+89
M\2KFR0@GKK*B4T247V5GC5._9QJ[><\-O2"_TW.[H6EF/67PF4QXV3-P6<0/
M%6O]GXFUIK.GT0>#G4-@H,B%U4J%'VTEAL&[''' \U00194J1@3&U9I T^$1
MU!NN>WOE24?TSGCQ;7_\-6IJNS9DTGJK)_8)^7W6V-*!>_%PF \# $R[KK3)
M^T$ @?O1RG)S#]D&_//;"-<Q%^K%VPA*C4HK4^<)[FU8J*ZJX=;*K<@9C<2A
M2RP(,V^.2>3\52/DAP5VE%. N#\54WR6'NE)TK][Z'5N&L[.V407;HLTP2'&
M]4F51);U!HH..686%&F)3S9/ZQPHZO9?KKRJ\Q+ D?4!07I?V#&)SH1SN/*G
MNXD9P)!:L<X##[.*4MO&6T_*5?B?DCYOI6A45G'^B7-C7UG<6\#_^NPRFK>6
M7_1LM TC_IRE&"!EMFVC+Z!(U%5H:3J!BSJ3EC(:]D!NI?E4 '*9DWX"SP <
MW8L@':6]+9;VL[; $QF V).N4\)OOTQ[K%7%#ZC=:<Y/6:XMW01G,.-2CVDJ
MYP]H*+E=MA7,9;%!@#]W8LO65+7/*_C*?A=?Z\F1,=G-H4<;AMD_HZTEA7S(
MK$)VDY&*?N*[5H;WZ_,3WCV5H7WPYQ^E?@V:T%$)8D[4X;P/O9;C+QTBY1%R
M^V$.*52*_8,S[$U;R)@!NTY47 ^Z@>F./C, ]2U R"MZR%T&(#2ZI8TBJ04:
MLP)@*5#@-A9(63,BD4&+%:"]T:)'\+(*.UK*I]/(_W-KFH3-B=.MVI@73S8Q
M+QHX[X6JR=WF187TJ&OP77.PM1;L,C[" (S<B37N_3/1\D];/>V6YL+;7L,3
MMN4/L9=SZL^OFSUS4KZP\Q5DGT$/TF4 H.D36<^OT=N5J%O)]'WYT"3(_KPX
M;<O-.QK01!&9WNXPI,SUD70QBV\1>^W%'1)'.-:2X3U70)O)VF-B3/=K#)\6
M0TM\.@4J,V  5'.8MV( _%\T/1A@I.ON+A('D8_A2Y,H374"^ *\=7>X>XU,
M1":L[O]R'1DD<^ #(NB7J/;DB(#"]AD&@">W!%JHDZ'WG38H_*FU^\9PE1:9
M&Q\ZQ@"\5FH!DZ]\9P!FW78RHZF\<@0@:WS+P]:G<BB!A8UI*<,13W7IV6OO
M I]\P3W./N90"%+$DWGQ[I@M\<!"!N#8#0: R+5)-LIDLI#/*K_;0C 1"ME_
M53*!+CHMPP!\JF*&'W*W,+/R=O E/F (2 F.TPH<I[_>Y(;/Y,'IEQ/^HK($
M Q 5T(E9DH&33S'#E[/9_ S [5[*V'X- W#R1NOTSC]U#F^,):)IK%-7F4'[
M[ZTA-&&)1MI4_7H;!D"#B4@_G@*)?'*8G=,<=8@,#"'[]SX2=P*B,003$+-A
M;:I$#S^\]^,LDLK5PP TFR]S<\&;:^:G=WA!U..7_O^N_Z+K8?*%__OX<Q_H
M:@*),OL!M&/,U@Y%PIN=6QF 7GEU$LR#R</+F;16@?]G\4BCK=CKGHM@11L9
M7XLMKR0] HL)& *]2#8"-AI&D&Y)5YSJO_-\HK-B(8A#IHTX$W+(-DHS=/$P
M&?P<E[[=W)=1<%/25M>Y&CO9DS#;K=KJ]!:GE?-0F#=$;!<6L.8)YX1JP&?@
M1U9NI80G%[AB7WNM5Z)0E4%3NOR?KW[ZP$YOFJKG'U8_2[U#9"_W^S(5:-B2
M;#OUQ\@Y':Q!FPQ\1A#T"=E_4G)PMH0U/,CX7*'M@P=C(L4K&S#W=PY,J@W;
M2=\!*3  .,W &?BOC[,8*I<A4W5&3/W(M@%WQ,C_T(:1)C2!JO&!?V3U!B5Q
MD0$H9!+_CXAT)KAG4;V8XP#YIW' ",![,_Y[');RTO"AO(^(BH598ZX'-@OE
MGT]8&W][N2Q2/=#<8<4I_W@CX9?ITYKG$UR)'\P^*W.#B,<]P3N<LE4LI&.@
M1:<%S+\T^%?2'2)DX!->UJLM\5JA7T"?X.!\+OY*WBY[O.GLA<=S(1 ?(;8?
MFVS7BV*JO%]O\(=K*PR:,(U2CAF,?XJB_01]N\( J/R7(LAX^NOI?U@Q3)EI
MQ4K_L.)HB;_7>\^L-W0 [^[I@O]KL6PZ%S@>M&1 -*>?=&*BD.1.5CDJX;R+
MNM#03C'HP9#\*C_-/Z!RP+U$QO@*BM58/ 4?=OZ5L)173<H#G8>.JH>=_[F3
M_Q+N%NC_-=FB0;.G'F.6Q.#>'+LPQ';Y-OA?RC#;#>/%)QQP0G]_ON0] T".
MIDED)9!?G9<]8$5,O**!\ZEKU)%_+_4O,F/T)++I%UO9Z"^=]BXR .;+_ZWU
MP+^78O**R +I>@!Y@;Z@#,)Q$*_N]U_U2-/_:.3MJ:L2>*3@P'Q9E L_,\PJ
M3R^55DV; *[05/)_]=PDJQ"B0:\8 (ZU'6N+L;FP@(D.SHRHG_LY/> G2X 2
M3M(BN0#/\1IS&)+P BH]:W@NL-P"^+3,1E(W<WM-)9QOUE#ZOF+\^X;N6]O@
MVWW@<OL*PKY/[@D3XS 5*Q5Q#Y+*]JFCI>>O/+EB,%#MHNN!'*2>09!NDQM4
MDW3%?W]$.[GKQC[S9_BFY<=N?3EUL+?/[A<,+IXN"^^3)"<R?5+7)@/ CQR%
M\S+!31_C!(R8DAFL!2%AO<"C%6HAVM5)3'@Q&%3UR1VWM9C0:A&Z\#2H*2?Z
M1X$9X.4)885UKY]EK47,O^LG;AXU7S,BAEPX+_-(WKURC<J7WS<NZ[-'3+E9
MB^='O, 0VN"\F*44J@XSA';<8P#B?C_0'$ ,H4>!FQ.H8A X>1*VYWHKKCXA
MOR<@0%6QLK*T8L#@QNMX+J-41[L?#PZ)9 *X>5XA+<B%=\N&Y&LZ#?0-!C_I
M%^K76*8ZRWSV.Y6DM:)7=OW-W<,:1YG6KB7E1#O2MAD*QR$F#*GZ>=9,L$YF
M@K4=S4][!DV5FV[9/!"%GP/]8\,6JNV?&[8(_VW#%G#]6Z9)GXVYP$1G(F44
MWES%Q.P+3,P6GP'_1]53FCHI>H$\ RWJ\GT;5(-\%S2"'5?^G<@/3F5&.-DU
M6B'^0?-L9]F_M%U=]+@V*G(8WORT%=ZK"B,Q ?X]A':<B7F'HL@1_Z8FX+^I
M<F0SE^N?:P<%_+TV[W]2>[VM+0$+9I*]<H?45[(QLGXZ"T2M'/FXRYWZ?1!4
M\5WCZJV<#VVGB]_>N$]Y&FYYX27WO;CWD4<4IB0]'H0&S3U-(,=:=()7B.LU
M]&ID+;"O1^9^SP5U9L_^6 8@V&T.=HP!^#<%:?^K$OTHRTS7=KX4L<,!K(N@
MZF?:_&W(GOZG]=T)XZ1L<@@1TC3%.R0OR^-R8YR,=>L,/:SR_G1*=ZEH]L\T
MR:.<KU/OGHV^T_  ]Q ]V5!R\%OXG@.6A*DFNNB -!.EVG^3*-!AIOW_JYED
MT\]OSN[1SF&B@.0_II@(7TW;*=H\&8C1)4Y%"!5\7DGW+\_[M:4M.!G7\>CV
MND"<0+0@J['9/=_''*>*V$]<_A^Z8@']6T_Y'*.KLR3X7 J52<D:7?\<I8V%
M%/PZVR.B1_$GBU4K@X6Z3SGG7(.?\2:V!^1+X=)YTB_JMXJ<:&$[]/V*L+)"
M!A&$EPVGG];^A(E2D%T;(JJCW'"3UVB9EO4#<.^6QQ%[KN,!9[06&MG7?N-S
M2VPUV#R^6+1P"&U?9]TG@[S-! _?3F-WO'B6.Z6T3]1_.LD*(VW(C(G#I[^!
M6A"1F:K]OC>I1_#N)\>-JW3$!R$[_%^DU[+%%Q(_9A\!.-7!?D&%R7?SJ.?(
M+MED\[NESKZ3/&/2??X^5^A*(GY2WKH;!L''N(FUYJT61;MW%)Y^/K]CL$(I
MW[E_C#!RI$E]V-=QY7ZPCZY(_UH1%,/TJ(KD;28*CVV2S(<]U,^3)5O5;Q#I
MW]G?YVA\7D);)0YD:H17I[5KC986=*2V6L0Z'37?'F&&9$</:%G(S1*9$A@K
MU+6ZIC9E\?OWM(;T9%TOR8]=PD#Q33D1A$\ZO5B219]<@ N%S/(4X/AESSDK
M94KVKN-J!RLL%$[D#,J3Q7I2I'J/;PMK8\<MWQYO:%!&*EWM$3HN<R8O(WER
M,XL!>#YV\%' O"PN"92JQ70T_K!>Z^]D3B)S I_H8IK:.M_?_@O?N5-_'8[C
M+8 3T^DE7Y#6-%^D6XC"7GD^Q=@??86:!6^J 3D;'EP"7P 1H@<QY"X@8:,'
MRTF/-&\UI%Y&R=)O@ <V7E&,J&K$DRMQO#'R&:9]U =0;N^1+?YCMWK'8L[_
MPAWM1[][<2_D57*8E$9;Z!V\7O=5O?1R%"K4V&W30&%N8"R&8FSN55:-F<'"
M?0Q \B-W]^\Q !%,\1#_)1[W;_% N$E$A3CM##(60=9T!5,=,5^1/&2,+H$C
M0F8W+N#A0(6-L*'A]94#^KQT<7':18\@@3"CI..Z@J[B1%(8;[P=H<;-2H^<
M[L8SB.\WF'NZO\ZCP?_HA$]MLXC#'3+VPO/N^\RY9R,Y-=45NCFR-0A"B=:E
M[>8OP"7!_WK+VE25\C\7N;C_U&BQ_N]]Z'8#-(&KN?!]4CT)M'X3_I_I;F@R
M"/P<XPX)!YV3\3,=@-[_AEV^Q63UE_,?#*[)5-0I&0U!]]WC/L9-_C(:G]83
M#[>(QK;+")[\(' 2-**W/F9BOAO:3\7:%LMD!>4D+;A8TX_ DR!]ZFW;<@P
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MF=A.P[APB6?SN5MZUT/YX#Z&Q-%<L6QE).J"]F:,+C7#< ZJK@#BPR1@7+N
M!L0L<@#.Z8?-935@8SV@GRJ;+1;_)+DQ=4],,EFT*$FMUEN'3^*I\TOJZJ5T
M,8OL+016F[1%1#?TC.*;@M.:)B&M![!20MO,9D2M4]'R%'>OJJ0#KE/8SV/A
MT%=! _P;;+>[?;1**)]\ZIFD4+S("4QN(0'3=$4I,D=(L/=UYK4VTC;;";1;
M8)A[&S9^FDE3+#!!-7,/,+Z''J7%@^Q^)XXY/7QU:W4)^3ADI".A.],W3LC
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MT[FVP1&U8/7^."MP=[JM^?82NKJRI'NE2^%5<O95X]02:44* V CN(8R"S"
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M]R59;6KRW0]D4S/ Q20#ZG6]'IML-]_-D9$0V7J]@Y8:9#3F"03[BO2.O!A
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M:%C'!N^ 3IM"6#%8JT:6!#G1K>TFSR+E^W] J*SG9!)8H9H:PU5H]:TS$GI
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M_YA=X%YTMS8N)CS2N9KP;=C4LC- %4TTU>1*V;,F&/;=A%UF2Z2)DY3ID<Q
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M"^K%GO L@J(N' S]I^#EBC^9=8N<8&X$S(6HQY$TWP>TBGP"8L#/4^.T<6+
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MRNJBQ3-3J@D==X/T#ZX*NXY?4/XKWB FK=,CDXLP6*UGBPLZ\\X-"Z208N.
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MJ:WP6?&;#$6ET/UNWT+)'[=>UI/%;)H6HE="1#3("'>!DG35JM:JDO'EX5V
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MKGIR:]^F__W4JDQA%B&)^?S8F\RD#=I4-$&%EXKXC_B!_9 :I?1GXI%&CFU
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M6'=,4V_NF\\[XA4KKN7?9CTYT31^Y[>M"Q?>IG" 4EOJ*WH0XQ+40;M*\6L
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M1Z(*H'4[!6!,*V?<%?B_M4#=H[8L432\#<7:!E+F61)CL#3O+$B[[Z\!"G.
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M\+03+4B*+(% 6(#(-,)](]+NN7>\+(RAF]9EUH.>)?2"EY926J<U* >Z5LT
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M@+KXJZ,Q>I(2'JJ:IMB%8[F1C>>MK!-74[!M>=DKCE/OI]'O.YK!,'P1H:5
M<PS?*,S=-JI'RY>4#GMTYW;1[,*,F9@,OX:?R+/='Q<F+I6KC_,T;^]S81["
M]<,BWPQUZ1X4--6.0A"!BA "*)7SOL?0,A<*LHT<O%#Z/7]NO.(^0RG]T.['
M11:W/LB_^:'XZ=(YE\D*Y=RC:28_*@9I?IC85Z<D["-/:AKC\%_SY\GFPA?9
MQ1S ;=""E#>ZC(]B&8RTT"8?L0Y1S#7KX2W?7M<PS_4&GDF[4<J8T1D\=VJO
M@.,SE9CVW[9OJ(J-5)FJUWGY2O9)FGU1@64[U@9QK]VS?].[<Y.S2"91:9O!
M+(\AV62*=)(E3QCJZ!>$SZ?V$F=:, @G*T[\[,!>3SB8*7#*E("$4.55XJP<
MX2?.L]-8@GT&U))K81K@NH8!R(<VTXCAQAT*EK20AO0:_4I78//7;^^PCYVN
M>:A5T%1=&[.6*>$Z<$)>]M"/#I(!(ZO+2 U2:@ WPF+!^Z+J4,)52FHKTM?O
MZ^I5?ZRL3I7SI XUJ 1TO>,R$=]X\2W="6T<@.^'A O9V,1%<NIHLJ9N>4"Y
M9FM;:S85K$[/;/?FO;>6H_6S3+-![J;3S9NV!MX'%SU:@S"=<HFTE3%<!*V5
M =+Q#1Q R+7/;)0H\\.AW]U^1BN<NG2P(TTQ_X+!@P[]I@FQEF0^)S_=P+ Z
M[& 8!7/?4)5&/@_%T.(N]!HZT[RI5VO+DJ1_W+K@I%94W:@*RASO$MG8I;TW
M(CF0XK#]!\XY(U,BWAGJ_WP^*KAKPO- VH\ N=R"'8<'/;&'3]6[E,<*6-[)
M2E8+L+IM;F>1YMIM:UU,J&85J\U(ES"J\X8\4K*&G=NHK1VW]^RO,+WR%10U
MM\F(7+:RM#&-'TRH_#O@TA?#?PV7>EG_NW") VP(-N\N%A9R@GB;C22EF\-"
MO,K0+J<R-Y:N"!R(N'IK"[\3G_QCH_*?ROFWMP=>2 E.W)9RF.168&UNE_,+
M&];86]\S^7KY^XT4MU_=9Z9R)GSE=*!7;GG^OJVU,!^-\FW)0?5UQ=:0_#;=
MICJ9X &%VL^"M0# -=^\$_*C'[.BR66'O#$76AE=//'Q@TC)E(7:EX^+VH_:
M#Q_L>%-H']GD#%GD56S1BZJ>&[RY5CHT1TYK2[\<[9^(2>FR*8DW<S@>7Q*_
M\%[-REAWU"SWE*I)E_#A;^-?)N.U>\9Z*]'0Q3@W^O6^T4UIF5R7<TS4U71R
M$KC4CIM+)GZ\HR@58<CZ:J';T&EO4W^V$13!F**>EK'*M%]%$1[!,J5O,0>I
M*YBK^71\K*%>$$55$X!0IM4EW>J$\9H4<Y/Q:REN0^?1]\[QG#O+Z]W3IV0L
M<4[9NJ'[9UCJ]Z'29<]2$WD1:S'K])#X3CN%8C,%9*[>N/+?Z";FWRHX;=PW
M%.VWCB@B[6R'Y#&F*:0WMO*(9>!\QT>0I]OGL-:HW?F7WPE/2W\>K.N0J <;
M%3'%IFQ9XGT.0#/S@W77D-FW<2W)SHAO.D(ANAZ]8T;E[HM0E/O5>[^TS%CF
M06F!2]Y?FT.5NQ\FQG_HE-LD_T@K^'R 3>ZF<26_O"%61ST1>IC'".< F64T
M#,ROL?Y4X \U1!_E G3OCK[5OA_$3RULRT\<8'*0 ]3B5_&A()W?EBK" 4RQ
M(T26J./Z4XD_U."F+4W7&E(X@#XS>95W+?,)!^@HXP#WT(MH 03(B!)(\G L
MN0Z$%"HY@#3Z]Q7LGHRXY3!=V&=%<T%XV52> ^"QR"0")W 2'.!W!M'Y@X68
MN<:HF2T>K)DYS$_4=*PI!S BPQLYP%>6*D+@3A)=X]8,0"0=C\3/LUS_4..Q
M8A7Y+ZJCO^^(@T.(+'X.\!RRY0!;$W&=J"5?>'UGB")Y_8')[VKZYK+%P?Q#
MA$5".?@8?'L(Q6*"D!@'T*81X%TJ[ ST+RIKG62?(M(S?U]!&#JIS $N>&,F
M,5X<8"<'..>%7D6P#DT)=J%@6$?/,X^#G8.0)N+_Y/5G.[^KP%0\M83?31#;
M:\;A(_";G^ B%='(XN_W>";[<AN8%M+*>O"GP_]T^'^HP]E"[!?@R',C?6A]
M/UO.^L[$0'>B6'$J]?H"V2HFV!CKHD+*+:_R"%44[EAX1 J9F8U444R?L,H]
M<_,D+3Z^$RMK62(G]47Y:-9E7K>FNFE8RK47X1&K2HA#QH/=$<7B:&6P0"&(
M:!JF.F;+W@&&$FGGO9%\.6 < K*,<0A+P"/4HW87;/H%;%1 \CA=DR6%B*N
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M'6C<Y\K+:1V1LR0'5\(KD2&[MATQXKW=+Z_SJUEE9@)V9A?SM!*O3ONL&G"
M3>X=A6U(<DCX/O:== PKV7S8^4[U:NV#67MOV9IAMU1Z&^[]/]V%7$"2$$\T
M!TBH28#KM) 9U@[76!/RT"/O\0M^76#_'@S[$+GOB\]:+)+N=T]C*)@G$"Z
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MYTP.9[^P<M\7[AMEE^:WW3OAXQL5_K&)3RU2^2>7-*58J.]7I-NS@\8</#B
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MP2F/HD(ENN_&UQ@*D<%-@$(\2@G3-[MDGUL8KDVR$5DJZSH'/2?O2D)_Y&F
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MK!;?_/]_+/>[_*\N@NS!_P-02P,$%     @ &7-85/O=H$(\X@  ='D! !,
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MPJ>PSX8LZ7:EEW^CHB9Q.^5[TWYIV<\U+/S_J67_V;!?VX4#!#DYV(/'*09
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MR"^H509TE:_T'T_S_ZYTGU)&5\(UV@,G!_]@.VV;E?-V8Z&7,X.>Q)73S5G
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M_OS?#IR0=NR25"\+^/R%/08[JE5_$_^I2GX)):@-;+I@)NRAZV<!6>DCO_T
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M0898]NX@/[S5[CQN7!U0-+Q75ZWWR;F$]I$D,P4)CDE,C4FG[$DF?RZJA,W
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M"[X]SJ!ML^Z*E;'(MJ;4K+^;G)*AX$[M>3\29L22R4>C6%*?D;4C'PWYE_&
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MWJGVEN\@&%(87W?6I6 I?K/VLUO-#V^K-F,)8;"EJ,71S\R77R"K^QU75^,
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M/F;3K:G0F<^>\,0^N(?;F[WX=_[D7Q>[B( ]'#P0L*SY))0PV\,0:F1Q/6G
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M1%WA;J[WI&C;%Q1@M;JID4:3OZNE(@#7OHDMB(3,.LFWEA1X5(OL$**"P56
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M<VJ;,Y<$":,0 $\_3YTDAW2@X!/F.)VYB9%Y<V+FJ(:I_&V!=C8<YAZML#4
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MR$WI'>MO Q^E=7]V,OR<G)K[_MX4^WZ]4S"YX>N("6?4A*\%50PWN\K=!63
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M4(F/EY,?[]9<P[SO*L_FY$WQNW.7,)+UQY,8_@^)^5<DQFE:E1I_LP4.7MB
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M%XR"D1(,8^8CQF6%NCGX#O1NZG$WY"ZW(\>>XY?=QW:VS4>A1FL\P?ANMQU
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M$0Q9B-]SI('%'R?0-O@9@0ZKC-8<I!!X8MI%"5NU-UNAHY)>?2FBB/W'\5L
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M\H+PD%!^X":GQU]0R"$\=*N -D1+/CN.T_V I<9.P2 >^M8^/D=')%(-)KG
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M@0+RK24C<S-6?AO<6J-O*QWKRCW/R(7M!"&GNWH1-ZK*$43X0JPT Y'T# K
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M@I@S-[JP<(U]"U^31>=DJYU@5ZN=G\MH?M3=DVKIJ"5C$E07MSL_W8:P:[6
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MFX=QQ'G8\*/(5S"6Q6?F<5Q_,@;!!5KCF"PU+A SA?-!+>]8C(9BL:-(7"2
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MHCZU':E)FN[\--EF:;13+3#EP&Q)_OHP$:P^9XH+B"-(Q0@X9SOHS!$TA 1
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M%%F[09KMQ)*G[$*6C_;%H!,.V?P/KQH9#>D[[8-BBER2STP=4RQ8L+8@W@)
M#\)8J:"P-Q30H7:R0#M@+336\MHO<9>V EYQ# [HG4WG<KNOQWK:A=Q]WY \
M;]8C-=P R0CF14]G@0O89&)M&N\\@A.S0TU*0,MS,'0Z?F<CVAE**+G8PW6H
MN/0\N"35XM)M]+DFF\V>6EDW43Q=!H[!3G17A]7"G$4/*']>$RI1#H@>[62M
MPB8W&:L)6"H[38(G7=3Q3,RT6J2%JZGQHR"4GW8@+RUM?1AO$@GCS?I P C
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MD![U[Y?'[0/+OH,3'O9A$HDG4UT4"GKGDR77//VJE8CJK4S&X8%F%[&YNWA
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MV"F.HUWRT,28MZTBV*=*W%WWQN7>-#USL=V9Q9ARL,:,N3C_H?X.$^LM"0V
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M-_[]J>!+5:+UR#/(B1XAH32629S-$N+@"%$J3H8ZI&.8Q%%OQ\8-9QO$(0K
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MI#!/EZKJ32<@N^:$K,AI8L1U^&:M>Y-#K4"S^(#MA07V5H!S[H+HE>"#SDC
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M8B6JUV3BQA.M45_[S4-@%64HZ'XZ-/5>5!,(VW6XZ7K6E<4U.M3PM)+))K.
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MS-_D$G>XLNA-=3ST\S+-+N]RP[X\RWCNY505VS<I[8Q4D)T(3=#& :C+"6?
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M?C36GLY'E]($:GC-=:UFPMLB<?H^\#O5NK=QM2XR80D,.$7D 5LPH% /4<&
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MN>9SQG7.[_IMU_?Z_JZY1#TB!K!PUP[['8#8/#'@&/H'B+X!"VR\B![>@#>
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M/ZC"56;?;@&.MLK_W9L8$^3BP=EE%\J$E MMR*U[,[L0?_!46W\1OQE2$[C
M6Z! ;B _C5<6?5Z3H&B9W+<C@263QV&%Z=H%[]\!J'K8_UA1T8%HIX@ 22T1
MD#$ H7=1 6TB0(40=(6Q.]A$9F^%7_VJ^EU]/URLY=0;>^2UC1YK[_<:T&,-
MIFF]IG[BJ, %8.U'U($9M.EPZB(1P,TK%P&L)R(@)DL$5-N!8S/6RT4 TRU0
M!-2[V,';6FH1T.X;^ 7]7F?73!MM$0&8*5Q.G\&LQR_?<43['43 Y201T/Z-
MA-[5E(Z*@/@,1&?DN C 9<S@OF.@V-D0>);*1'Q^;+8%#0G<:1JT<E*H/5I'
M@PU.@]!3'',<Y#K2YZS:XD#HX( (X.T'ZRQ;<*/3Y%'$1@0H8HU$ -4$QK4@
MV2?SAQ-^Z1([V,H8D=TL NS*><8B0+:?BJRF0#%W8V"$@HI\BV/I#M.G1L"8
MV7^K7U ;%TZM135H%U!GI>'MI-<(J8TK DSFTM)IR<;0!0*L'()0 ED$1*4,
M!Q_ _MY EO8)[-0<#I6V5 3$4E+ MKL(=@1T+G;Y7O\O>?#71OY3A+ \Q>^3
MLU.X6KCM:W \<HCV"R?^VL38L#M@VYBP#8Y$EEF[BP!K'PB\*]S;3FA6^Z4/
M?V<?#V."F15B47'7P#^RY(\L^2-+_LB2_Y>SI!D+;8CA/Q9FT'R)D#N!^P&G
M6;%GR)A-@':(@$(<<UEGYBL!-DV8,S(;WM1/>T?9.%$08?##HG*S6?-3[XVS
M3!^]@8"G_?NI7R,>.]]U;OT.>8S79QF,S;27S$DJ.QX].Q:E[+A%\E]H2PB-
M(J#/F.'"SN/6"(9P''6>VW8N,:J8E1N4Y]^=*Z'3P]0],J67&'KHDZIGE=1+
M?.\V1-9>H$ ><&W(8>;W>O*O?2 =SCU9.G$V9^Q%7![QX:7X2^M*RY,V[3[L
MK7W,Z:ZW>I-*./^6,-9:%NG"*5>JD!RAMWUYXY -*P[>QFS#9-79[:[X='2@
M5GGFFKV2^CWYNSJKWSHV;5K*JMP$JD)NB*P"FE]?(%\>D6_7<;R2F\VN9;8M
M\@75*E>//[&NS_MJ<?MA62EWP%RN?LBUW#\%*-SN'GW@[8#8M C@**+O^J 1
M/4MN$@&JTE7T/C5^.3<[FG3P>NWRD>M!AH5O+CN4-?N716D9UDH=E K>G6L0
M\5'A JV.WJ?$\*FF1G83BM7J\0D/M#^0,#['M=B#!I^"#MVH97\/^)YYN*BD
M+O7#BH\.*?O*#<6@0$1A%@(9( 7+Q=-B<9ID PB/[PXB4'"JL'<.:9M%WM-6
M8;;ZI^>&R5T!5=\NZ23XU9$/+.@1/]LF(P(DPH0WK#60SP2N0]L5JCSHJ^#C
MWG4>[)T8:BA$%G=8]VJZ?J7W:J0-!"^D-QJ>-@I@)45<QMWR,%6OJ@<BL@4&
M:#H[XHYA^ST;U$ ,[@2V#ZP=7,F3O'VG(G6K[8.//_)>"N$S[G9+;M29&WG9
M>FNFZ'FYI)/;:<74JK9>70:2QYOD)T$43R9^_EB"^J>2M"V;#4_8JVYL=S+S
MU0L./K#?]H0>5X&D(]@&%=70RB9AU6R&RV6:5]X&+2=B;^3!3C/P*D[%]&UC
M[_GSY<7^H17K4PSJIEJ&$U_,V[Y+$[?^7>X(@7L>Q]8E#F%[*$-JG-<\PM!H
MHN5VR^68Z YF2&U^R9K'D<S#)SJ+FPV:VU88:DZ4)[M=6W&'NL9(785\X)C8
MW+BM\CXQ6R]HHLXB.\I2%V19*=6471C^G"FUTS15U=&LPXL4ZY8HC#!X"S*?
M66\ VRG0I B8ET>#G@+(.9"12?A. M&<8%OBIG<'L<S8*-SLZR]'GPG 8.D#
M/4W^>G.%]LN+,T]'7:W8_JCQS%[,QPH/6OHY_.PB)FUB #=]"S0?I7[?7 ]V
MHPDUOGME>OQTFR'Z"?QG-&&B"(C<#8[0P(%<$5 >+XQ//O0P+ON![79;PV^<
MBP^#]/@JT(0(D+HC EK)Z!,N(B!09:Y,L)VTYA4T),!!HXPL2FQF^R@O)K+$
M:I&6J\IR]H-O'P])?!63N+7^]!+*:T+4V13XUFUTZM"%R_0G22HB0*\5(P@7
M 0[7OZ/X&)F 0O7M;4-?")(@,V( ]'Z7)TO:::U5J:UN7C/F%I$BV%([K/A2
M!#2^Q9W@C(S&SP7R[PL+T'3L:6.R<2HX/\S5"]C(\P:OBTM>O.XTD@GO[?$^
M7A:_]N.1G5O6%)IY7MR[5B:_(5\,/LSM9ENQL O(M6B0#M-[\&[ME=J0#]^?
MPIR))>UA-&][#A$/=-QTBV)UG]8K\'Y9$&UG:U1OR3S36U,$X [ O@)#<K/&
MMRSN$)_%+:OEX!O-:9*(UE'J%0V[F!\V8?+\F[TZV[R7? QS^KQ'WM%.F<U(
M:TYI;+$^-G?SM3 %/)7?&\+_Q'7OKL/T^@^=B!NR,L%7;+B7.AZX]EX-(W#X
MB,W2PP$#25O?QN_\XN62#&]!<>8C6&UHK4IR?PVI#TWV!U:[AL1.<W;[]F4:
M!QKT];C?V%]]-O1ZJG^8RNU(PQLY6S,WS#?[W@TK.;!4VCC2*%9=%CZV7@:[
M<%7SN6J-1Y=#_NGC7:#4CY/WM *=/G)Z.Y!%=WT.(4V;8ZX'#)W4HS97NUBN
M(K?Q&[ETMCT*(==1%9S1):?:ND*<80\3G\(V[3]P\K YY!\DX1K]>B@O<!]=
M,)Z\\D-KX>'KP^4K)?QBQ>C#JP"A0G%%\:<URV@O7B6%ZE_UBCYY9/W.Q/7J
M.QF7YR]-*OE"*P$Y/($64GN/?!L4'(#)'^ E?>Q6[3C/"Q_WA)%=-%LVO-!M
M7?U\>.!=E,NY+XF)'U!- DCBT'7!&J2*-A_G0TS48'RRQ#,F =]71\O7XT<R
M0Q2K'CVT0TP3A$YE08G:)O$PCTO@8'FCKNB[8TCGJQGVK$ -UP#&#6(*N/0H
M>%50?NAC!:6=7%R,$E[IR C_Y/#Q-9SI]\T2CLEGY9\=5CST0OHKELT1.)#$
MA7EDU5Z2GS#5VO#DH FW!*9H51:DN\=Y+GIL7C<4'6_[]K-F5-#;M^HJ RYU
M5*X=(8Y0-%-GK A?$ %7\'SW3FL9V*,,NKZ$CB6K$T*O?%WHZF_B=D)38+=U
M::A1NA/K9 :E=67+-B")'O!![$^P],]-NIK&=:<H@-5[*XU(!ER0/8/&!H$4
M\J",6NV5G=XX]1*\/,GF(VGS4]!SAP>V-SC%]<J[X_XOOL>DZ=[TL"V^K.=M
M@D9QL[4.N5\$S)^T5!*LL$-EZ"4PS&NL+-0#LGA:,8WYF*^\DV,O[)>]XR=G
M<-3.[5F?;GG7R-53]V:TV8R[LMAL!M>YAL!UQD++K:CUF%XW_AGA9;<AN\@@
M$:#MK[T<6L7B&#>ZGD[USUB1O2JM^/-1S7+/9-/2M+2*GL@XQQ<;RO;BA^S8
MMFA>[A4F@@R*") 7 <>(/=+5YI4;>%VTW,\#\#E>652%S^.3*<G7!H\TA3UY
M3#W[I'FA_>,;S#Q6^:'>C/AY]2IW=PI=TR_BK'",^X,KA>7@"??-U;A"ET@:
MX^(H8Z9V/O&CED_].G*[]I+.H_4$[>",0&5QCMI4J5C@35VNR47@AS%DU,VN
MY37SWZ&I<8#D+$P%3]#%47YF/T1 X1PE9QYCM+[@+O"DP+H\^_,>P42.;MR&
M6HG\J8WO!^0+ &&@+:#L^%L#5].X3L:SUKA8$<#7QLZML.!I"/4@)NK>@\)2
M, "3A)A#0N[!VIKOH: 3SZI.M?6I/VLP@!L5]SUU@=3PQM'K1]K@;2BT2JX3
M 0_QEVC<9UC8CQ;XSF3@7M*!F&S+[?MO+;WWJOU);@:7-+3T?>Z)GOAKM:T-
MSJE[])^>"_:I,G6ATWD**%MM1"Y92Z%6O !Y*/?6H$&K*,)Y))3O1!T3 4,'
MQL!GA[%""13_YMFE(GFC]&D%'"Q)!=H)(%AG!J*!G9. -%'^6RT"&GX29C\4
MFQ_CIF6XYHA*I BXZH@4>('32AA81GJNC I^,$615)4D;ALA1$N%3C3!=H-C
M2@PB;(!"CP;*<M%%Y3*Z='S0KZ)#!S&(F=U</8HH'W;CN'K8KX,1(F!+APBH
M.LQ54)F9^;T'*%!T/B+KB3Y%%0>9AW!0)W9"%<U:&[0FJ;H&YH;-",7Q(D#L
M'W; _G^VW^8/\_\P_P_S_S#_#_/_*\V?#H$U4"O-!,@P0=CB,J'6B)> &EDN
MU00UDB44Q%LP66.]M-O2+.+XH]"GU>)[,@8=Q#/-8S'R[3N;EVKQ695+T''D
MP6HST)<"Z5/@-43H9.Z>!<:0@PAX02L0 05!Q!(?-K5/^[0(N!V,5A$MAR8>
M1!A,;Z!IL9[9RA^-<,U37V7[O3>O^(K+"+F])O34#J68L8]Y:NI&_MD9+O>I
M7\C+H>[#Z"AU)#M>UR,!AH071N7]F$S4F&1G1'#I!WF<F;HU%GO$][V@[G/S
MM70Q2)YZN^X&YY3'U#W/&6"S7<]1?4@-#:\&*H,$.?.#L04#2K /5[J&'L5'
MYD.IW*MF#FM63QU:Z[9MB<7PE9E0_":-#5*?A_=Y]L7*G/ 6O&8?!$\A'P1Z
MA)/?*VBX9DV^S^:0H(:P>GN"983B+(<;PACEM/%F^' 7&K1<W!+0:XK+(XES
M/=!LP,VO7/@YM+1FPHVG-5!8TC] .%*M4U+D<FQITHIK'.,W[R275YX1)L"Z
MJ(8/( 5>?IT(*'7A;$+)B\TG:V,XA.?>TF[/$]\GS( -?(@/?6U3FSZ>3]AP
MX_CQ4[%G^MT?.+6X)[%=V/7*8@Q72B.UOY 00Y<FX3/(U1]JGX>^KB\-!M4L
MUX7Q]/<&<Q?<U'WQLM+MRC*K/>G[\H9MD@-ZQ"./BO'D&(V<!,$\L-K.>A72
MCRNDLXO,&_(!F-QN:C/4)@N%UR5;G"YA"HGVEQT.&3UT&]>-'ND[Z37;>62G
MWO)861J.?FN?=".!ZT#O#>=3N)0& H5:5L8)803@JA]8"A]6V&?L07-;!.SI
MTOUD%V,:H%W7Z\O%!ZI]>_S**TS#67%5VLM-RUW8KBL?SHO_UQM&#@TE6L V
M*772V.%=X'1F]RN7*'0.6(F +W%?Z7RK"=R<D__G__+?+/^AWS5_\9/E[=__
M&OB?LAWQ?]NX^9!^\VI8N3-R+9;G[F^%%UK>F\&OQ\V.T=)(;P3KT9 MBT1J
M^]J0-*.)ROP3R4Y/G1)G9^PY]!&2\!2O/6\U^3T_@-@[I]TX@H*ME=I41@L%
MN6 \>G23K:\PD4;EHH'W1E[09F<@%+VL*+_UVMW%PM.$]Q7GXG$%*5,(EKM-
M>!R<FN2)@(OAV-_Z*+\I$3JL#'H:C\(X1LP<ZO=1^I ( /BXWSJUO<"I=M""
M]VXETD!H@\!JS \TJ=IHC8@8F_Q;G^5;]*5T)&CHEN-?U,%.H-E(!2FP> _\
M6^_Y,!1IVVSAB<:5&0)U$/>S$,%UH1!D+0*PD'3![&_=8U/HG'^0,-N=Y&C'
M7X^ M<A\\)DQ$H'@N!C//_>U_]D-^4O2*6QO6 3$P M%P"$"+(!!QB^<A.UI
MGA4!&$CG/\I':T(_AR\_XWF&L']X)C]\FN/9T5R$R9\*+RUY10^?-:JV57:1
M&?^7-J?_/9JVG" ,H6LK"*-A,Z:##^3/PFA#$RS].+4MT%GN9,UEG8CG7R7E
M$\U;FK4J%!_2#;\%-V0JW;]T1(V-KI22ECP:6B7ZO5'CKQ86B0!/W"*2 NJ#
MQ&*'5A<FBP ]J'7_".]12)<Q8E[F-Y7FM:S<?55N98U"?Z67PC<14*Q=)C"!
M5W+?(9]PQ840?O<+*( 8^,0UM*.N:Y\)%.%->7>7,Q)D+/<N<_OV[9:O;P,>
M6ZD)H+>5VI :K.+"YW-=8!7S1CJFQ%B<I S99GSE@T654?ENB\U E2-^U^3\
MVQ9^WAI65AQ^9M'@BMD[ 2G#TJ, &UD&5A^KU*7#VZ&;F4@CCHO':\&GN,3J
MUA,16)9=TGG,HO%7)$>_X'?:WYOWE):?-<HQ>W7?PJYL5%,J1.<TG=4(J_3S
M/;CZ;#P#V^_)%$;3AM[@6%V/LL=Q<I:ZS-3E 6YUKO7,H(2].S]?KE]M&6B8
ME:IXYPBIM<0-+= 9?24_M]R]ZB-R*%#:9])!WJU*/?0_A[H;W<H7>$V^/D;)
MWUA_ELJU204O/L#^K.CUZXD4#3!*AQM32TFH-.NRU&<9J[CVIX(8UVVYGQ7#
MB*95"1Y9C[4]5'0-Q48N6N4SC6$5$Y8[E6/.H/?B^6/"J H\U_@H=%>E#38(
M.#I9/T>,-4T[\770>(._VJN"4ZZ?)9H.#1SG;BW=%9W/"T1D2WAFB%7H#(/
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M%.E\[42V7_6)B8\2>AK;DPVROQ;;;S%IHM1<_0SR.@F:X$@S$H4!%[R8B"<
MK0=YNTQG[4$<% )MPMQ*&[Z& ((-POMG,* \/GURXLC!LHQS/GH9O;NL?VD:
MT-DY^$Q?^FO 6F+K>GTD\1CS^P1A;BN8,\V87<JACWW&@&]YRNX.9X*NX9_
M?^90$1E"M0 &?%D,RM G-F! _K@C/;L7O4)GG8>F$@F_,F>T,:!-<)<HQU%
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M9$0957C^FB<-2M<LV4RY-&9OF"Q(X T]%*R"I\LT?[M-"*;??"IWXSKAP@U
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M_WW!\&]:5/S)>N'5OUZ* PQRD_[;#QX-UF]9A2AWQ*XA\/W#-KB)[+)GW,S
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MNO#]!INH;.?HY;Q!SF1J9+H,G-SH53[$K.^\-#JS)<#OW1J=[H*0^-\N.K<
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M7='25(+LV+<;/DE(($43"T(:O28F^%]N@<6]%BFJ:^=/6Q6]ZK]^-!:52<4
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M<)7<7ML8?2_YJPB,_$PQCBU/_PP=EL8K&($/K,. ,E-$'0-ZJ1D1WF-!/PO
M7VO6$,7:\1WB*:#=( <XCH>3"..YHNQOAL;(/T?&4^@/7/R!B_\"7-!&BFO
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M(.ST 0,$A\$Z\Q;B\#?:,+H3 Y0)ZS& 88006]#LT\S/L3]5B36RW1"5-\,
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M>,8$JL2#S:LDAIA*FMW/?@F-H=:!Q+$^#&A[<&F=8&)PNIK1$\1=72S@"*_
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M'^[8A.KIJ:S<3-_66R5APK;)4 V&ELVJ4[YYF1<.V<B_ECLEMX)@]>]Q>%'
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MXSZ''Y=&J12]T2V0N_%<7DT/D%AYGRT&%OM:F[2=KCS(]CS3Z=(QO<4^?VK
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M6H74"F*(MG.6"5/?@C<=[[4V(O1OG!Q3Y+@(3%5/NBQ-,IH\(R@TLF]>(C*
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M+3^_Z:!TU2E:S*J6-;,TS=Z,-(=^#X+CI:!7TVZK+T2UGDU4C-GO[$2]\F;
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MEQ93A+)H>LA4*S+&UQ F-OGA!,H18L#6U)L *4V!MTNQ(HY.[B3NI&\&&='
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M'F$R?/]'R?\O<7>9T"0&^C#LINLT Z(9[W,,AZJA!2J%/G<TM?\8^I1CI[A
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M0.H8[PBC+,YJNW79D)EJ +U(+R2MM HT+M+,_T[Q'%A9W:^[5\E"XJ#=)F!
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M^Z[H<5(2\]4B])H"AY_@S<3W4+ZKZK>O44I<1 LF,X9/@RF10#Y#A+?LL40
M"Q)YY@;*@F'7^W^EOS_QF%='<\-QO4IT)0_/BN)SQV2^D.50['>(U3UF89"9
M,X9,V;T/DMY\$Q"Z^;AVO\L) -$:@-@XYK8M[$T8M=]PR7[VO]KP &+F5*3A
MJX?R"AWO]HC;EA'ERR+EM(Z[T[Q28%K@R9?A1;'3TJZ8M\M:G=$H=6M!R9HA
MY*[B4$Y5U(#:UH3)3(MW>GU'7EU@>ME)WZQ<?UBP MM(;-81*7M"X5?6AV(_
MDYB#K6\PQ:2MN79@[*N9I.N17F^LWU:7^$1O-M1IUM1(,YXT:F[9KR.S,Y0H
M3?-",%/AJ9+M8*O0C<!*X(K-FW.<QHJ3V ND\8U9+?_"RT-"MB50EAY*6*'&
MA9>DZ1OD6Y5(WYRZ8/@W0@W)&+%*AMX=@ZI$S+4*35Q%YB 6$B>)FLI\3&*#
M&U<?):7OYZ'>:UKJ7GKHAY]CUV9L2(@EW\BU9:>BK=-(O 8_0K)I=71TASB;
M("_Y$8Y0,H.3)+OY67/+4>QMEHIO?XWOR.SH=K_O6OO0SA2PLRQ6TXEW?!\[
M<N/)D0M?J$[8%%8%Y1Z$GL^(FU9@WB@Y!,.S?5R.[].*PY\O_+4"HQXB V0A
MIO66&V94]B.U-,K!OCCC<+!]R<A/UUL5(Y61Z9G-+>+'J.O$!"+@2"31JE?W
M-5R!^1(5_-5EZ(AMH)ZE"3^JC0S70$M&U97"AU7-5:[8-\CMB,F6>R[]\>NI
MJPWOMWV0Z6O<#$Y"%9$6Y]&PK ?D2B+/BQ_%64@3H?CTUG&=VBKT1IQ*M IZ
MD_]=AT^?F">5,CRN:C!=4L.336-UQM1K.C-*\E=@]TE>&? 1>\ZI'M%1[+:C
MA/[QM5Y QK8U0Y\':LL1OEZD@\2WXAEYT0K,1/8QQ@[O*\Y <;"$X?\Q[]"?
M!<F?$190<IU_@'@-4C^1+"BW&0)'QG3WHLN<Q.4I;=Z.%HX\>Y-#;+9%W2"J
M2,8PZRW-@84FE 8;C"Z#:.0<:<)*M2W"0UG]FUU$\54U3@K/H:LVS+@&U?"K
MMKD+%HF>FWC[6WVZ8P6V98;1+=IZ8((3N/Z_SX2=[HAU=;YEZ96%/\KKHY*S
MG!QO7&BJM839L@E&4'Z<1&&)\:BJ\3=02:OZ&TPXGTYR66EX-/8=7@5,./1,
MU:8&,+WGAZ6$R5[?[V<<N*ZH3?-"A6Q6IHR3TQ9X#1XISJ&QWQ]530MUP')U
M1<K&39*=@#B?$H2L?\$@=*5?[GSC6OBVWVWWYZ'"0SR=ZX_LRP4J<E7E]UO
M1<F&5IFV23ZM@Z).Z,LZ0.@A[ 1)/ES:>GQ@!? Z$;TNQ;+"K\XI+\G]<!!2
M/U(WWE<=^Q^MZNR?K=_J80:_,1HT[ *#+B@ VP&4X 0XS,:0\C5!5:/L5U<#
M"'J 0<[8<)+ER9 2:^(^VW=AP9G.YPN!TV?]_U12DPO7R7KHOS\.!<9F\!WT
M]P'@3B)54=:*=,#';PCMX7UXFX%@*HF_NSA]%RX'<\@0N29D[;<^=&6 O=9E
M+NO1O"K*&L<2K!&_%>GR61TLJLQ<D-#K%P)>A4XZ&IY#4_R/%\6)''I?-!C(
M4^DU2SF XFVX\O7.VEW/B@(>DCM/C.RS#R9\6X$!#M$H@:^X &_,GW  %RA@
M#DI.)$7B5#)QQ>;U V%ZJLY!9QR<HZ:?94;N&#F[:^<[\M-[,3%2;7A#J-3R
MXK(RVG6*.NXQG:PHV02>I!/ED*C?F,T-(7R7CHS&/$YG@(9^3$4 U VW2\TZ
M6W6.&UBWD+*_:_C^P*7=0P'.Y!271H/5[9U*3HE+&A3Y=9U-K$KG O[!)LC
MA*))+D<WV40'!FM%J;V(+(P7;)V1?F>Z>;U:3X9-Y^\5F#R1G:*I-425.^D,
M$H7V(Y?!1J;@]4"C.>[,\E5@)ZVO-'B> Q&HMX>K1I5YR*N#O%H[K?3+\4X7
M]F.O$IOU"):B4V O7U] $K]8@07E&F\%L[@1<XOO\/JT#WU(#3F4?:_A?-'B
MM=KRAZQ.H\^NTSZ)?EZ1.8%_>_>]A<&1@ T/\ACK#H)A',H(5O &%//-.<4?
MV2P&HATR_E-50/\)P%00H;E=?>S!8X9[ZYNJB=SL M_^[Z?CM)&>[Z_!2B_.
MDJL1(J7Z"7H3+151XS+WB:_!J2&)X$"K&_]<+CN-Y+$3N+0\K*E7W9.#,UHP
MJE)N2&8XF XM/M.V==VJ<\)=^"SMA64$E#[SD#,9%D2+GR.AG&]A"\U%!Q>2
M15H4" "@SRB:,$JXJ;=41-;G2<TU$GC,9?O)"0U,*2%",C2N6P%>YY 940('
M<)WP@N@2&#Y^B*^:N(XV-Q$"''"PO\+7I+PNN&]."O-U[3/4O9#=ENT[]M*U
MN+DZ.$:SBG]1(GMR@IFV5:0&*K^6](UO DVBN:@15BM+OG&GR'I(@A@/X%D)
MBA0>AG8A6S;*[^K46;0S>-_LV/'0/-AL"2%2<!'\X>OR1@"7]KJTU&!JM/U5
M0"8-:VD2QJ7(^9D['_5)X$TDJO&JW *B7O4QWY>?>\GQCLYHW[G9)2A$4V95
M\DMZ6'!3]'V,)LH'P9 ] V+YV!84[#]CDH=E.5_W 8VSLT=TW,M+.C"]2]HE
MO,+&4G7/G1UM%V^7.<9?Q%@3Z)#<7VY;&)GE=!04X/W$17AKODM[S@KLX?S2
MIXBV.H9&%*[H^6N5G.BL[%TS@O/[]M&#RYH4YBYGF:[Y_=__RXKF2#HO0+@?
MA LZQ>2&XT(S_/EALT[$%MS+H%=#S-::V: [=X*4OUW\5)Z>3G^\/^G+TY"L
M1#M5[7";-@*B7P(714*5*\ =G# 6*0YS]MPOQBD*?(&T1%-R F:KI6ZAM6<1
M+E/PN_TZ%2A]QWQ;"E"?JLQ?J'\5VV>ZN:P-409QX M:I7D[EJDAL.=C((<>
M)4BM!2^^ :L9%OHT-5=?A]?H=>GI#M_D.VH.39[MC7]0^TC93F/[(YL<0CNY
M7)77+MP[CCO9='>8]P58=@$O<NS5#/HYW7%$GX=4^ 'XKE,)GO7N5^YL=,W>
MXVU2;^MT?_O'6VN (@C<%TA'S44:Z[R$@5? .V=0JD&A;M@D$Y%]P+856#4\
MD7G9?NJ3.6[Q;/*W:RCS?P63XG'].0ICL07S 3X75PHN"%CB(H(FJ@VU0^1=
MT6^)XD":*N"N4W75:_^^9K^?3##J9*6O_=NS\WUGR0<B,QHJE!U-OC.A&VL@
M]>C .$N@4RO^4%HHSN3AK]4-8#;3.&O/EYG=\T<Q]#A3@Y)AZDS+SRV$;[K[
M8^'9-5/O:*I$=B:M.BN)B%T]$WX<\LY0Z[U"0@!JS].4TVC.0242I(P^01J8
M\"P]UO!3<I\_\)#!/?''85\'12OHXX9#/>O(([J2C33^$ K4&6[!_K@_0::S
ME'&;A YVWGQQ2<S2)>'5NK.+X]\;U5/%K5^PF_7N! 7V,].U4C\7WM[WI8Y*
M8X_7VT?!0>VT9GU96X'U^O0W=(6;>6_-HGK6HZW615L LBU$=4LX4' 6H/-D
M^*1S_.6DTAPB#ZT\XZ&DKJ/ZLB3\H6'&Z#FM$44;-?%L\%Y,"M-&=764?%43
M/%B!>2ZLDWQ% !]0'#T(,4XP?B-X*[ YR@<QY7M#_C32)M<X*\T"RPKD=:LU
MP017_O_<#N,K@$[%J_'U6X;R#X.1W$\65WNKI'T^#%)SVVJK/SK=*"I(W^BB
M\23YGHWR(E:DXL/M3D&J2IHUM7J0ZK/],Q[:8!)7#MYT%%D:*/3Z$(2]6-U?
M7)M"TM,)7_S^J_5IV$E&PQV!!$JH>[]8'Q;HZ#@R<,[X/D+5<@=@?RJ-\R[@
M;EHJWH;-_!1NI6M#S38P,(7@:J3'\@_UMK==;F>B?OA.BXI$F'C3*YJY1)K8
M;(<*A(14A. "2'\CZ?H'71@?P4>P=9/FIFJ&#2V-(XI]:8HB9-#07/MF<_24
M7TW&":.=@9;I]#O!M<BK9'V1-D0?F6 17U%@MKJH;)T/0(SA/6;[Q%M:YA";
MNS?\=N9:8=K^??V>V<_R^%K6,L3D]145ANPU<-;S.OQU[9I_)M'17L6N#F_\
M7=+=F&YM?:-7T3M/)2AY93\#7L#L=&/67032DB"-(-7RCY@BDN&F6+CUA@6<
MJNM;BMXEL,AU^[P]V.Y&YH$+IZX=WUQX;\MQ2GHPW@(JB >P)=N21K5I-XY'
MR5NJ<M$DQ@Q_5%,#>%*G3+\?MJ[_9R9KSGCWZ/2%JDASMP]/+YQ_D'5X]"DD
M.)M5:),*Q,HT<7H7A,NV!2_@+QN\)EAK14?[.,/(G6"_7<_[,F/>W+6&H;!M
MI3<R?D>J[-WI\O2)FD[Z4_DUH]^:C^G$7AE<5!4I/^;.%P%N@A" EDBEK =]
MKF8L3J#OA193^1XDS9=!ZNZS0X],9[8_-^"3C)4*GOUTNOZ9DB?91_B! B[!
MU6<ASS^=B%PG<@/].&A9R;><R8$ZY<P:MEJ5!47)0'U==?&_T#])GYW[3#[2
M\Q/_F'R$26^5 %+_92:*ED!WH1]4E>/4M 1R!:L#G:IY$(R*7IWU4%"GD@*P
MC@// 7?0=/37Q=]#AIJOE\]B1PTTKTZR$S:&_QF0*[Q-D!.70]A1BCPL3B7H
M$9M/4,D/(3BYWH-4 LD=-F?!H!!VY(C([=6OHWES+G+(%T:MKE>?!14F:FT_
M5\]V>7SKR?MKB.(!E^EIGCO4&RK\%K"U174<(6Y PB7=X])\;*O#P;9&Y:SV
MHS"^<:+(/NQNFFZ6YI,L1ZK*!_KD9,OG_SE;A:X/V$LVM0M=)0.82O.Y138Y
MKARG>P9LY].Y\$212<2$[ +< YE2] ,7MB GH*CDZ?1^[[>3:UBO[WKS6,7W
MDX_>5,>@SAAC _]CVADO:=2^N*=D;-IOJRQO<\&.#;]S87B2*%(>;B4"%\3Z
MDHW=?/,F&E6F RV%F3EJW-8-L^<0'ZHC[J=\HB>\+\-;EW0(:IP1@=<]S8IF
MW;Y,%=1=;2NV2E?Q0;S2- .3H!3"5$Q5\>],^#SL;\OR6 ,8#E5R2UWL^^(2
M?SMX>2^.VBM_S#B^?@6F]Y4^A1R-K9TP7?-+N3T 1<V:XW-8*>HN<QR**!R(
MSFHS#!^<#\5(N>,RAZQN_%.R22],['KNL$LZT7GT[>D?S_]SIK=<F>85K<ZU
M .'"'3ASR:9W_'XZ62X,0_HG]#U:DRS9[#N^.7]\NE6B.61D^#*.9^9=[UW7
M6.WV^N;3F[$WLI;?YAYZ>8C&)F-D""9PT-"&=Y^OR(6WI\G.%IP:%.D%W5+E
M]!V/,HC0U+0SR)"M#.7Y?SBIE6CM=/U6>R'2F?<$2M[_A5O K/=)%@6P622D
MZB<^O<U8929G2U)QB_= 6(JWQ,+-[3)]W<],YTO6/V^W;0EX!"H*W21?655*
M$7V2+B*U)*9QI]S^V#?$%E7NK-59QLU'EKU!VL^:FYL#?:H#?BXP[S1+$.(W
M1'8Y H:ZB4YE.#52@.Z3H!_7^*%-RY7G-]Q1;4>7JKJ*GK[^&%>1M7;((L'G
MU+5+!S..4R+YY#FX< ^<X<.A\UQ?_LH<7\NGW_=N^-"'Q6L+W UP\8S?(WT.
M1G^E,3,]L.*;2?$IW/$'URO6+%QRF?J>) PB-CLTFA':-?4A<*6*MO&[6]TM
M.((DE1H*[B*[N)0],O5Q2&16A+Z=\6GH0XW_T/"R_)5.@QN'U;=]2;B,G-8N
MZ%^!!<*9]8(A\8<P2BRYG-;>O0YO =B(]E)D1,?[\0[<M+7(JM>M>\J,U0S:
MULYO^/JYO*-+6\7DX::W)EFW8838(33),HJ-V>9_MS&!8ZSN=[1H@;30GDKS
M*_$W01OEAGK:G5+=D'SV0.1M[;E;&@%O.C:8_4T 6B6;[*#PLN"KSD4 =R2;
M//E2[439P 8$E_R0@7B /P]DV0+1G5UW@NZ4IFR9OIAV*6,A]&)NWF)[L)9)
MH;7R^.G-;CX3))&2C" 95'LEZ<O?+<XG[!!9WF]'(L2E(FUVWC8'3F^09J5*
M4="K@L8" QW+17*5Z0WV9)_9L34_UL$(S\]CR(0#((1$Z[P!%YXG0!&L3Q,\
M ]U>XTAT!%R$YB(4\+;$N$H;E2RYI[Q[QP3_;M':^N)J?<,;OI*Z%#X@G>D1
ML2LP+)%I;R?.(B!]4?(-4<!M.(1E4HW&[>Q.2B+2R*>GX0#C:L_,LGZI.].J
M6<\T?+DTUW9ZK=UY9<S43ZG_-KVB?JH<V"ETB!N]2/_T^%O\L<Z/E]]M3N7$
M2H?O3!0-BS-H[ +,#H(YX<?=DCE7-H99SUEN%UNT(]978>1Q&&YQ+) QX8"&
M!ZAD':J67#P1W%7])K S=+=X].UO1^W#TB:+W>!N-$].>([P&0.<0_W(ZF@\
M#))>0@RP4:*%*Y#(HQ1;+/<'!8NL5$JVI_M^"\8O*\0-O/*=S'XJ92@**,=_
M^K;F'\<:OR1$2/I8BD0_"@,Q,=AW*)^V&8G ,5C-R(T9&B=JS!FE3RL::T)T
MXE+!OM^A5<=>P(8>W\RXU6B]ZN/%E<A](E7QJYV@&XHW"P2PX7',EI[Q7\.:
MNWJ(G#U\FX0E-9UL=ZV^S-\J\=]WGQ*S[31=O)WTJ6RI^7WZ?Y:;,( 3BYDU
MP9JK$IK@<CD;P&BOB>XDFCK^),0[;8RR-YQ.UAS%&)WF?/Q-N^^B38A:^Y.(
M/2-CKL],=Q?(?;R+W49LME^!!6!^G.X6Y(%10J=9I I86BI2!V1(EDYL8WE?
M3?5H*:%?U;O<I&T&V*"XMEG5K"BE@*G3HK8YV\U0P-S'W:<WK@?RRPO B'8/
MT[[0KI-MYFE^+R[_5D]V['HS:N"@?S(XM;GXT>G424<%9;7R&(< ERDTG;5V
ME2SQ&L)(0KLJJJJ[ Q+JX*S] -+ __'9<47@+$/_UY5RH..U0Z'U_+30JT K
M*S!5^^E9M:"6L[HS5?_;M]_\7_.ZS./+-NE-_ 0OC!_NI2?>[&4ZH^5VG#/F
MK>\?<HHK:V]<V-^TVRNYL^9:N.SSYX[KVY5&BA/']^1'.LDK5=97KXW]HI-_
MKZ$2 LH1H0+^!IABW P)='(UO&4%IH0K4^"BY7!1]+IH'JB7-_$YWONVBTRX
M3&=JR+'M&)&RF\"/3^==%&[!U7,66BX7$#5F%/TD>X%=9YHVAN7M$>PX/;0Y
M7^FLH&4M/6:/;E5(OAFXD4MDHMQ!5RAZS<6)A".45N.' >R-IB6:^D"4_Y!Z
M61*.?_5+H7\X,IK::X^-4#E)-\ JO=M7\>&PYE_^?4&E^.D*S"?/H_\8*!;:
MBU" F5A<7EM>P2<ESX5^*;N^^=(7]:M?DV=KY6O7'C"Q XB":O%3E*^[]VPK
M&4;SHY#&#P\$!A'ZHZZS5V!J/W[?<6NM-<Z9"=*OV#,E6QMSX-C",002]TZR
M\9W05N0BSL4[ <83&)$2JHTQN0)KAZL?)_+M7:MZ;E;7/&YMOG!$=.0E0[:O
M;G=#[\Z4:;D0[01=GRU]:Q_])@.GB??16'X!>_@!WAO"?HL)XH,7U&&"_"_&
MKG:5!$I+@L)LCM?G+*]WIH[,;,-O6RAF#;>S$ ?,1RXYRGSV4!/'0!S2K8&K
M/S&("J" >W?A.NT ']*2!7SS#%(!D/TE=:F^H3S*F+?#-^GOD,26FWGZLO9E
MK45T=LW.->.2;\0*F0[4")9CW(2(D6P2%[.S6C ;1)K_5%.H7RSA6XGJ#S[8
M1QW)\*[UZ1-E/_KNM'G\&M;PV9JZQICWY.VXY2;6Y@:3D EL M*T#V]5<,72
M/N+=;$ZR<^8':H;!>1)$ZQ?ZCNZZ%^GCI*:S";:(8#X60,P3WPW:O1(9K,#B
M8E</-A78M*&VX H@JS>""5PD5E0=-I9T578E87-_1A*\)RK#>924DI1^%#L/
M^D:CBO@-W@P2K/>)(M/J(F+$].H3I#30!MG_@CFC$2)(^Z^KT2;O>6L><[])
M@]C0PXFO+9@3)R"WX*V3./!V&E.&0XP3N5B\HG,H6\%E="5M=X=CI,*W"KD1
MC=O(P&3O&$O!"DRRD2E8V"CIU(3L:5QSC42MX'S_?,,*#+19A* ;,1*JD:(=
MS*(27\XOBN:F H-&[N=-3&!_6 C@XG*4'^+'-->FV8W%5$&OQVN#"7P2O;IQ
M/X!G;7E0-W<EM'%G8^+4L,- _J0"0_;S;=>BJKPG7=JG?]Q27;JK]JHVP>>>
M4VC8YM241TU_-FB_+G&4Z?B7)E(\.1'1@F74MV.HI#F4T!Z\V'0HWPH(C^70
MMOYJU >OA?T-?1>T:XQ7BCGS',.,)B\;O'R9[?VP[F_<95%5IPBR3O<,0!)[
M>@Y2_Q@IT4%(=&QHU!;M =]Q$6JB0V#>.]P)_01YLP0CARGR&X9LG/VOJ<3?
MER<S=*L-FG>H&-:CQY4<9=K(2BCV$];VU;5*(XO<A?LT/SCS[K0+>)]_8:*U
MTC7@G_&#G.%6B:+Z;M'1N.1#1RUK,N;E0N3]?F:PO^R_9K[36GD)209:K_!+
MYB0$.4G?T?E<KK#+IZ7/5V)&ZZ?&]Y>&88]*R77NIN7I'\O01WV9,G$D+(4_
M39@P3L!L(>S W7'DD]H0B%\Y*NF%#7YO?^=\?R=76O78]KRG0J?^OH[+7[8Y
MMMW\7"MLW8E0GF$!MMT,1!MJ@TA+J"RZ):XOX&/FEMAY-O89W2WG11;VZ*VS
M=\.S+>_,_#M7]#:)GNCFFR-[:T&N\,"W#S&N=CIB5>#@:LC&&0N=\;?%)2C.
M-:(?L65Z &\5)DX0/_VY O-<@7G-F,P(\0MFC;U3<XL'*ZRRF?$=OP5G_L]5
MX15XN563>0ZHHJ02U"&7R=^2$$V;N])!>MT>$1!2SC ?,3C[6>BNMF5CJY[,
MHX K_TN>6"")XMH5V'4_6H"<?=/JL*&J*&! L@U_&<2\<?? H\"XHID03))9
MW<.3D3YA/B:7&JBU*8Z6UNF5Z@?J'MUI$EFNSI^2]-*VKL#\X.L(?2S D<)8
M=@!S4:UJTPU@&)N\ 2>-(Y[JKSIRPU?#Z:--75WFGYD;WO+S8;;VY=9?NJ*C
MK6%XC:@5F'2<^*4IZKZ'GIA$D)>,]8(!@CO\:$EQ<(/V"FP3S\C2IM#O2O(?
M='3!9?\.P'H'-3XJSB6SS_5&ZH67N;"T2%!-N D,8*ORO+@TAD4SP<"6&AW%
M(<5;*A>"AZP,WLX<8ASTB#QG=/:;UY:L,[F;_5V^?I\>HS<,J_&3!,GB?(@*
MHC1VH 4QX *[>RW3_W;#E2!Z,OZ\7_%NYHMU0WL^IDO''9>.^P)+7GH!SZ&B
M0)T2@;E(,0+2/6@RZ L_*-F:ICF3OQNBO'J)_-GHFKE\'0E3B!HA#. _K<!^
MF_\MK1%[]R_K(7<1FW5H'&06]R89Z$'<7!V>%I[&>7*+41REQ=7AWO*.[!68
M @O\IXG-$^=):#]'IHEOH\GF?0@9J)E9(Q1!7%2M9 VAIW$]O_7RWH!)@)@4
MN'0P>&/3@>@<FQ\;E]HC3-=,>.Q??6"F+VZPE!<&0OC7)$2)M&A;PFB;H \'
MQ4]I/#)#U=D%X2>TR;&D&<]%X6F&-9'9H_6W\(H3)2+YN@GN(*FMR]Y:7*#=
M;[:PC=##T&UGR8YZ@";&@:%Y-F<KJ%6)'8+!^6,#I<_=#M9TK?F6%/OL#^N6
MLRU_(1:=FM;"GW#0 ;-#T]^:DXC4&\);Y0>>60^/+$?FHY]M)GB/U<=>G4Z$
M_25R,"+%"<&C-,$40.,M"FTE/ZZ@$T7'7X*RSL!3^@-+<^#GS%&#</,[;N?B
M>ZS$;<#7BJ8.UST9Q"-7S)QB;!;QTT(;25>=L4B1+MG0RL6 NE@Z*E6]I.WC
M4KW%)T5!: 50TAKPS"Q^8&+7@DWEG:#=;;='VPGE9XS</KN_R2OPHPSLVRL%
M:3XVF5AIQIJ[+]P.PME[/KXV%'PJ^K4"\^<37F] ,=1YHVD1;]QOABT:Z]:&
MS#6%4PQ6)QTIS@I2>XA!9$W)CQ58A0_/A9,FXRYR @1IA6!?9P=J\Q::U<-^
MSXR]/GW3;D),9:8=TM?+[M4!^/YWT8Q_)!NHK? GN7F>3?]D4DQS>=A6EH^$
MU3NWM*VHKM_ROP/'!0^?)K5.[33*;1I_D9Y^NG2")>6KN:_/4K8, HF*(=&Q
M&KD7OX;O)I\?^WUB3'GZ$% I\^ST^_?"-3^VJ33MBD&:KX8V.V69N$9D GBV
M7)0,9#5JD]@LJ+[RHF-4VJ#EOJ3(]_2WK:]U?\SKV#]*.G#HQ?SPWMC_N>J&
M)X$RO-F L%W21U-I/(P;Y@ZGE<V;PE-H&__#K,/X'E+'W9NP#3K*%7 -3V@4
M:,L\L0_3>/4LYG3-!?OX?<@2"&(,>Z'[Y[*J?5)IOL;W6!I$?TB"(+,G]+&Q
MC3L_TGI"'>"<,S,H9F-X]IT;R^H/2AQSS9_E7;93*#RCXJCUC5D@//._^!R'
M_UTO2D(5_._E"=L56.7N >*2<3FE.N GA5$BV;@H/(M'BVM-B4RRP%E<94J,
MD^SLERAULNV9<EC."3!#O_Z(F=F NJ/;^2KYFNSM]BFE+9J$0-B6  FD<=Z!
M!1P2!-\C=Z/]%\\!)5#7,LQ;"1O!!*L4)O-+V$N''6.#[3%/-_A*!H*T8YYJ
MZVE3+#Z$0MU22 /0J!_,"ZM'-8$KL', O6EA [AG@<.*J=H1Q5E.:#!^R9RI
MR5<:")UU-2HU-C3:>2E#:ON'ET'OS8TF ^/-^G!DR48AWU/P5)QE>5)X5,)B
M59U"; V3Y84/.P-9*0T;V4Y WG(<Q?#*D2"CTA-C8U-3&@\652X<TTH\H*QK
M*9.&8N>P:N@\$S8%],$R+22; K!<[(-EY%6D7A]>$2A&P&<)1A7.FP,7JM8U
M9&LE.KST$AJ8J%VJF)22/X;08>&#P3@^3?!3G(E$@A,"U=R)A01+'Z'T\?>S
MC9MB0W&BI'>E-@[Y0:>,2@T<]Y%NO]!;A'W<IA'A^9^J0+Z.[,*7>5@E=U&R
MT45W;C8$ZR,=_N]IMT@[^5^?Q4><$S5R\IKVWN13]<?'ZV\?I^L)[8C-YD@+
ML%Y !2)X?D)UPO!1F6;QR1;$QBE 6MWH)9!M>=S_7V#6AS&XX;F7_EJ,((ZU
M8VD,*?^6%4*  ?6%T:+#_*6IC\)+A#&"*DCFS(1&[JSL,47?ZP5ONT7U&YS-
MVC,9IO_J=_G[+Y.!:@?B1P]=CSF" O5J>$?XQH*07I%"HZJX&*D N>*I3V_=
MV[G="2C%L>#B<MN7\'75V<55;0CLQYP3)Q5^GE0_N&WT _//CAJ1BJ<@#\K"
M&S1&"5U3 8QE+R0TZH"R7.S&XVR*Y@BX;^$$E6^56FF5U6D5UY9\(UVZ1GYC
M>D.-YM7$#9.-[>)*U'5,(G$[T0\51ZM&S"WR6X\!:6E(5;]_C=F>V F,=,U#
MTR2FE>VQ/7LVS/-VU]1>7*N<HW=\YY-KE_@3XUI0=.F)3D-@&4/SY<EPR3R:
M\4.S!<91B(?44VLH7<"?PZHV];VZ*8)F[(Y?<D$ZCJW2(0=EXCQ'_XR:[(DY
M9$#T,V;2!6?$U1(UD9JX$FDB0O&G'S0:@R?;CV8CMP+;_YDV*M!Z@W9^RMB;
M;]]Y/]H?^/I+_5A&9HK;Y)>+?[)XPWQ/R29SH0>Q6<-H!1;4O0T*=LY222LE
M09T4O^0$VOEP-F8*3_9X\97O_SB74UZ/\FM88S@>ZJNRJ^+K5CWKL7\.?*;@
M:"4X*;P,E:!X":%A$X %<OK;519!?_?MY^H8 8?V,_8?5+MT3%M>1;OS\;>Q
MFI\=Z$ZD.53Y?9(^PBYQ5K=(<;$5 3B"U+18=8_2@#".PQ9BO'Y$&6.$Z2\_
MSO0S/YI ._6Q,F["L>A:X@T%,[]-!?HQT2'"2)$;G]QD_"-B D%'D?8O\&7N
M$U1F_XW'6WY@NS-F^KLW[B, 6Q)MY]?A( L0(=FX(-0863V7H1$Q(]$#U3@(
M]3'1*4 SCR(ZSM=-#+6(/K?0?B6SP&_'X-CD6-OOA2,9=L_+IBPNO2V#*2]-
MU;_\-:[;:VQIQC4TDN6ASE,S&)*OO_?SKY[<]00WAM[\OO >W#& 2Y8B-A]"
M8;$C)<TE@DAQ$@0GQ<[CJB Z^":IA8%*(2BU<W=@6PZ=M9>UV'&<<MWU55K(
M9>N! \\>[9LZ]L)1IG-UH8._,:-;<%J<M\0:L1"<&*2Z7P;M!6(RNZ8UEZ*Y
M<:'4=$%NE*%16[H[+-W[T>6&^@.(B*<;4L+Y:2_QT9#O7R<N@AP?2@D?#=0(
M1OE9I,:],W=]FJQ\N,1[#1<Y9-E#L1%W]CPUN#7N.ZP"N9':-*-@PWRU@3(I
MV[)M,0'QXD84FSQ$KK292Q.:2J 2572G6IXO^<T"AALU!JL0":K.LV_]^P-4
M40R%T=D:YI/=K=1YS6,<3_V'$J<FS867Q&;C!AM^4H>'%5CP/V;#S)2(T,.B
M(*!BD?.IM"3.<A?>JN@784<]\0 _B!WU[J/#Z!^#<\MP/?W)TZ_?OOLL\Q6U
MCL:N02GS+ , 8KO'(7%IHSK^+"9AW*@O%*TAT@&(+9_<SM8"-_S/:MOG6IWQ
MN^I16DA1_[[G^%2Q(.TZS*6.\(U([18IE0A(8#V_GQM-26U4=\6;@89\3 <!
MWB=2C'KQ16XY4;UE++_/;NDTN;/_5:I=D'SAGYNC*IQG:SYLZ>;HSLD(P\!@
M*"?HK0M)*.#";)</A]+".],WZ]!OJ<>.Z*E:@2E:^\89&BSEG;'XJS U=NRX
M08A;FU&U9%'-K,>7#)R-7HL:R14\$C\3.?$)DMESXE>6(=PNPO+%OO^:?4)>
MV92VI&N$?JO8^,WBX-2.>V?9'05'8']U.<LBY>Z)-%(C$K^U9PG.7&23.TK
M;+Z^ Y#6!B>MP#8W2-W.]%#)E.C99M*O)O[!E2&[CQI$>?\M.>WM=!7?&!TP
M@6*8"VZ+GZ'8+U'J>,\)VEK1\:I>HB_(TP%H"8UJ=,.G\X4K,"!9ZU/Z[KJG
M5W979Q[N&WW#U-'?^UAGE]AI!;;EE;C,,KH(+P=TTQ',UI9%7R*DPM-,X5M!
MFU:)#'C --?=16B\[,GC+!U)>,IC7.YA/KN14.1CXA#G1)Y0%<E/<XW;Q C!
M8]"M4#*LDH.)0?EB%5UQ153[-%++U/*QX1NY9_R*W5Y&;?MXSY;ZX9Y"^I.#
MZ\>9&QY)>:S )LB\2>$-PB!YFV2KY#-JV^KDF1:4M)G%CK5!GFV$=8\Q]7PD
MS>R!2__I64%]&+4BSFAGTEYUE]MS:L?6-B2=AA#FE6243'U+^$:6(ZSW&Y<"
MS%.1^F 27:($DI$UA:/^=83[;W"!@;7UE2G>\78]S[QQK_S6G^TU2'MP&THC
M+F).3FB/LQ"D0QC-4Q3*$H;OFK=F@54[GI"WXJVX"R04\(BQX_302-"NP<!#
M'HS< ')EH>^,;JY2O)GWU=0 O#)4AC,X;38BD>9C%=%$4UVR>-@HU05Y]O-5
MI6;!QI:8UV#\>K?.D7F54RH+ E)&X(:?TON3@S:IQQQ&D5C5-;PN-F*+9)"X
MME$7U\JQ26S<A8<=W4&/)V@%\&OB0F6%.SS:W&V0;S2NGJEF><F:/.Y\>NJ=
M^NN]78VUM!%MR2827[>-##BBXC$5<Y@:5&L: ]'"4OS/(9JR1%DG,JOM&6[-
M2<WUK_'[Z9Z4S5MX\=1R0*_VB]JI&S^PN4,H?PRH/4X6GO.0].:D+-/_4A,(
M%N[@GA48^A10=]7FA3L8J!?3O?WQW,"+G%.G,U0NQUPMLVM-DNQ8U4V$0:2)
M^ -ABV2$167Q7G+$$9? XRI5?D6@<3---M>VUXLZ0)VJ?$;)?3UZKF;W P6U
M*S9I@<@KQW)S3JR!BS265V![D\#_H[WO#&MRZ]H,HB+-(%T0 M*E62@*2$!$
MX"!RQ(+4B @("!Q$>DB.(KW$"@=1H@(B B(U"I$(H:@(H0A(4-)$I 2>QQ(>
M36$>SC<SW_?]FG*],^]\,_-C71=_LMG9>Z^][GOG7FNY_YA817Q?13R:F+3D
MP)22 7\K56^>,U"\6+>*D!87R1,AYPX&[(;+:UJ'&JY-QL#L+X)50"ENN&FY
M-2&:LU>S_[^[5<I_TW 7X/AQGNS.9$BL":D;PK)%6M@-XR*#<.5I:[!XRDZ6
M19-VJ0N<#R+OV_&H\,T!Y1C3W#<7<"=RB(\GOHPE$;GPEN&[?@H?VXOC1M%
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M!=]0]'(5H6"O*AK7-!8^7T6$$PKLU<#$;KQ"DME$5W;9!D!%H-,6\*14=C1
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MYYH6KL]K3<UC0K]92Q\K?_8..7!9)_:J6!^=T8PI$*0!3;QD$-^-S%(N0W6
MFEFLTIH7>MB 6K/2RI:W?S093_O?,5%F%HQ8J_[^H;"<%3,YRE+I(L)#BZ0)
M',\I K/V%W>"RL@2;6EJ&0]]=]&V5%W6B6U8N'PXF3L^KQM> ?L%Z=8[)5F[
MO6><T_+X*;A7OY!<%E\+6N:Y@N;Y]=C]X9P [:C-I*J7C:_#MGML UV#SZRO
M_GRPE*TK*==X-OH5 HK[F]#6"'SP4\',^LZ-P@Z<O&C(QJ GS?OH,-DO$OC&
MZAF\&\-*?7]Q*N]]9>.[\?DD,_9NAZ&_9H*-/*<W\R\LKR6X0,:;J_E;!#[P
M6 7GT$KV2J>2XIB, K)W9 RPM/!21:&?/6#N.FYF^BDR#TS)[/7<OD=MT]\U
MK0FEC>A[WB+)!KZ?P!WB .X<"A?%CX;.B&(N=1C DT-"[B\IFR@-W_,6PB_^
M7*Q2T+U]\VO=J&ZVU_%8&>VSCM&BT)D/K6LEQ]*(:ZG#82+)'[!#3:"!YGAS
ME8!51!=LF_H$Z6B2I73I "6$[[E,)C2?I]TN"QUX?YB)"(I@-%.X1'Z@Z+V]
MM?#N*B(X)D>T&0J_A]4'$K/B/14B.TP _]L_QEMJ%JQ&IOU.Z;HGGG_JVW,^
M>^2-ZAN:X7&ZF"5*(">&#:4 GCG>;"MB6#A["YC55Q[8/%H11LI<$<FGN=!<
M2SI"\]V>&=E=W1A9"5($"E.<B71[VX^B84J#"]>O$FL/2N22E2J@2+9S<8X(
MA8\)IP^-'F4WOF/EQ$25T7FJE46[2G1SANXEO?;HH\!?.![7JT)YZK)(DUC\
M\4@0_ +D=N.,QG]4"XY6SX6'QR7\*JR,Q4Y'Z+25* Z>N)N0I?7TH,1IQ,IO
M_SM3DO\O-+LSGI#ALD!A4"/@NR0E!I4NB2O>*-$8DVOC6A(BV]Q[C*N>+M[[
M(<S.N\$G<'+^9&R$3?P';^65+297/64NC1P,NA42U+E>SG&;7"3H)Y*,!U-Y
MX2/HTX_L)#@P]];Q[*85V(Q"[;V[_)-*#T);'\ZW);1\3LKS,I)[%UWY^YO<
M?NDFYJ'@D"\/7C0QX9/.7:NC"R/-RV>PXI "&,G+AMP!HR7S'_708:PWZ'3*
M(Q C^?YU?&QRU;F4D.KG5R**W;8-^S5)^FB[HB)<VS<AA <>X[3!S9=8&NOX
M/3CC"9/O ^:'FXJ6O=ZU2-_,G!Z9MC#7'7GUR>3<X\J2O_Y$Z%[=@$O$O<:0
MLKBO^0&"'<(*G))H<!6QE2S.H67C)2P]-&,R1>CBE]Z^5J4<]<A^[123I44S
M_8_1G_KV/WU>T!V&]7JT8[,(UR^24@?S1%)9?%G<**H9]:= &YG>L2DICI<&
M:EZQN'MF\NQX?(P*/JC?_H',)5"V\NJMJ*S7)3,,K=.YBG_B2KZD?,YA%\C3
MNCO4QDWC-:R/MA3.>KXSB58^9W;ZFE.?R07M'5_>.&U<?WF3%G/LL>"SL!0.
M)TCZ+"="L%V83CF+RIY6@9+#F<3)Q,XR8QA:$ 2.+*L)L\!(ON.&PM*P<]%:
M!8>F?"J+PK="AKGW9JHMX/W9@>*&,,V1G=78N%&RKBYDR3],Q^X2WH^753A<
M9*O.53E&RK!@;/'-T4MLD+84E8T>&-#?LU.VH%GLER2'J FIL @93\BQH''O
M;<^L9G<-8M2XY< A8W>_M*6&AS]#0@Y^6,K>?<CGSVW7?,=^KO4(D!2^L-\5
MB-TOK(M?WIADVVFS0D5?1@'92;Y=?3UEJH3CS>/D$['5/OX1H2=NM=HE%*T4
M'<WF"9J*L#.(^F,OH)]\+&YLC<SW8C)AJ##;@\P2K0=(+^N.4 ^(]W3($$\5
M]ZH)QN7F%:@6.8EB3QL+S+32L>ZZE;==7DL]<K G ]8$K"R([H*9#Q3)\3#H
MMM&_5SNN-KB6&1!^06E2M<_B\"OF[L8["I<KXC>VU' PD/7(_@,H2&>B\UQ+
MI&?3QR<ECZ7_$H_^^DFMAS=#PV[+YWM/'O]GDY'_^';<[@2;(@VI4&VR"K Q
M;'=9]4,CYRO(8_%1)T%3[ODZCM=7#Y-&N6N]CZ7W[$(@W+2\;W[! T<)D $E
MYT=>##(IDL>%+!\QIG_;WMS0 !$K!BR^:J[;KM<9&OQ>[#8B720YR]? 4S?B
MWOQR61R 8ZJ*2)ZR6)?H_P[?NM8M@_H9]J?YB11"\:>?(]ROHK&9I>G$Y-2G
M[:V%:Z OH\-H[9%,I(Q[CVIB] K%N^SM()_@VG!Z&J7 3IXNNI8:5FVR#MNI
M\;'VJ;_1):D!Q3>N)OE29?:W'_QIKSR*9U['-&?<(G(W/*+!?J#2L8JX4LJ[
MBD>:YPN\PX#/MI%U.Z9[):/,F*/K$Z>BBB*M"Z=58G6+'NR>>:)[>H%D(-C2
M_Y*X.10BL)"3>]@A%*IG%EX))TEC>JI@;4E YXM&ZX6J#F)PO0,C(IL:K]2^
M:=9+->"Q=H*;1"DF[*@#2GWMA^I74#]0W%,F!@WS-7!C-I@K=JDL?/HO3RI1
MQ8--%+.J?P"1#H_>3"M*/L]Y02H:_VRD%N8FS^KP.7Q>569\A;HF5,!?LJ"]
MGX71\N)KD,".6BFT7"9XW^ZH IWZBMO\$T8"YTGC<^L^^/F6*[7D3FJ3Y YH
MD"G:1]ANEC].*(J!E^#;_4"/N4"^W0_^ZP)#-.SM/:T%AM;2&?D=)A&:ZO+^
M"[[=;1]26L:^MQ+#418$U$V505LY U.2Q#VH@"^&&];4%)8+4L%EGK&P?M%>
MS1%,,-:';CR(Q",G C D^I2TZX^ 71T3T29+ XTNZI(GDP+*W=1V.\K^6'L1
M1 .>^,DM^-.,]PN=Z$8O["%B3S]SROV11/;2Q>7&URGZY++9N)[/;BU9=YOO
MSL8&? @3GZQN<M<@>]@-*FUQM]5\><$C+,F\MTP.W@M3ZSX&4G"T:B%%LRE8
MX_.UVG#OG-BHU)CMF86G*@Z<&+YY655^DX58U3\PN?__19,8Q "GS'\ZH[AZ
MJXBSUCWH7Q'/Z@>6\U81S1BJ\!AO Z"R6,VIA[1_3-^J%00 2EGI FG.,JJ3
M56!+_;9@;7.F+RI1OU*CFQ"E?9XF]=0]9^NZ7KM!8AVJ%;FXIMZ1Q? -!6["
MO_ LT[6'KHP,9M0Q*F6*>)KOS<-/F9XE?1,0=Z.MPTK:0[]_S(_>.G"!H80/
M0EY916A23M=#IS$%T?'UR'ZF.QKI^=CEO':)?@NI<*_EIN--/X^YF+C97)CR
M<=#+O" &DOJ6IXK9WFOI-5N719+);!2]J:MC$ZA9 MCW'X<*P)H>W)87(.+:
M^2(-F[TFY]EG=W_P_^#\Q^?(3*EK!]R0.I>.D]>:BMR"?E:+!G"[H3Z)'#MC
MCBR:J=)+0)X2>(*#Z2SC?G6D,H3\_>MXP,F1\9FW18E%T\G)-[#7JAM*PW=P
M8MH_X#LM\1&F2)$2NL]<'/>!Y\*9H'J*^2<9^T%9]=A]UC:8PHO[]-V*&%ZC
MF??TW+Q<@V[Z.U]4[?_<X*7[OJ,4B.,9@C=1XAUZ6+.UXB;GN)&<S??!V/I@
M\.)$45U0Q?M)?WK:U3GZR3NA)2:F12;@BVDWC4^)H7:(I$0NO&T;_$#&XD=0
MG9<#I;,"Q(^,B]1$@WA)BY+X/(Q)+9U2T)*7D2JM]WS]%5+N&-<WX/$I]4_H
M+O%D[\4%^,/IT+5POCMV.Q3+04VIL&B]"^:YTUH!XCWV*,"\J\[;\1EP\KZ=
MO%M,7%1LG$E>ZFE]QRB#._)'/SL;VC4BTX3$M0<Y&9PZS*FM_NZE] V: N.\
MH3]7$5L>=CP')[IUSK2EB>XGFQ<5D=RV7@]2+!J:.E61'+:>;KPET] &>872
M0.$N4A2Q2'C_LD12^PUR!>; DG=9GP. OE0!C/7E+MEE9AK%3UVAW EX(!%F
M->PBL_LWI8]'AFZ*?:V#<2ZXUN[OW7_NOP0<'9!F5W75H#9CMX&DW+HHD<;'
MI'7L9*Q/Y9S:0 ^Y(!9G_OO[_D^'@IUS5?H=7[S_V1[\:Q7!1'-C0!4V2:#H
MPH87)E4I'X<$9KO0$A#1,2<J-J'8IJ(M^XZ;_J(-MS5+7%PBT<!RT&\M PE+
M@/27>_"009_ W!_FE+1W6+_X581DHD ']55&-/4N.B9!6,Q%=WS%#3?91R27
M6@?M:;9>.[547NX(.OP1.@+]?A7!HXR0Q>LB8.^QH*V'/O=W$S<?:H]\-'7*
MS:*(Q'MC'D6GSZ.;#S\++=*7:;_*M?W3/@*FBLHTCLH52JAYEE<2L4]3!B#D
M=Q@)+H"T*RQPJ9U54S-@3%733*\./+A2%QS!]FLGZAN?*B>DZ/1;K>QX[#@$
M><(KER5\\ ,O)1I"R8@VSY>AA!5V < LZTP2C56<9Z?#-'4Z1/ SW3-%>S@]
MM[1(BX\R*-[I%X8ZE^E\0E(_\IU@"[SE/F,X1=P@?C-Y ]#.:Q\S$1D(MD,E
M;)0J),%^4LYRC3[5VA"7L%)DDT$HJTZ4&0I0#=GU6MQV^ZLR[P]/^+\)T]&1
MYII):';&!%<#GI$JB)W>!9_EJ2@=ZEJA;=-H.\L*2,/T8V4AYT@C/X2ZO_^M
MXVVVCWN_6C;.]>LF"1B^=^["QV"RT<VS??O(6\/A0<0@1["&VM?5%+#0MI]X
M^0E9 XZR,O/7^N6S!V_%6M3OO^9]S>?3)G!O?O0?'U90@,>+! Z+QG7D'\-U
M)W@0D8*]T*TJ**\3*%2F>H)F96T514?K#^;:PN=MH_.V'6\0+Q$26'TXZJ9B
M4Y\+GPBV\L-%=$8S#$5@Q(7*M%<;LZC?1-R -==4^];S_6A/;&+UX94)SPO3
MQ\_J&LTXJ=ON]2\S66OB)D#6)O7UHK:A8QA;PDG*>*!#I$5-9!E'_G78"R4U
M9Q4[E^)!U4$<_U"Q)]#0[F=B["?QVXA?@_]L5=G_M__PAER=_$]02P,$%
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MH*QD!@.AP:^]V!8H8210.Y^SECHV* E<DT;-[I&O%9.\YJMUW?^FX1;H^5T
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M.''?D3GY&2L"OBC8X 1=?56N<GD!_[Y^(_7^;>E'"$=^&D*2*6,Y0"G$?A1
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M<&5;:.&IE/)GJ88DS+[1W!>\YN\:1ETBS+TDBT-(PR2%*(UCF/E9 GT6!)'
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M5J$Q3W6V_)RA\G#=.><QY@O.F[S\])53=7CT^DYZ8S=_*ZO?^L\F2Y,T0YF
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M]BW3)$$!9RF,J8@@\D4(248(I%DHA/ I]IAA,]+)9)W;.M$K!G&KF7)9>]7
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M(XHF$%F-(VH-[#1Z: +%TYBAT;VC2XLU!TJD+?HQQR1?Y>N<U[L Y8=BD#+
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M4AA&42@-JRR"A$8^C##S$A&@.&!&]0)T!IT;375%S =";W<D.[E_,/R C:;
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MZ9<<$>=N<,\9/RW55R>J]3?!1',4H/Z9K(4>3U3S+(O#B,4J5Y2Q]A4)@GG
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M6+]3NO]SSG(2,EU=1V6$58Q+(WUB(H(\"X,X2C'/LZ3?B7I+":86U7Y9WZE
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ML5>7XVC*_(=&)T"V2KFLS5YD1YO%\+&L,[@+I6NPTV3O_%1+FQGX6\LV&XW
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MO"WHHJEN_+Q:JW^L6*%+;C2OT7?EM!;BX^.2F?>(\CB,1"9@3CB%*$49S&F
M828)XPR%*2=6Y<H72S(U)]561J?OQ58=I\+FRRUTWMN-AOO 'G(/\B\2[#1I
M^$2!T@7LE#$$;:!6!VST&<LL]NYX-/.,Y,)O[M0GL#WX2MI&6]^1-2@JL%1V
M(CL[:?)*0$!56THVJOT%U,=GJ_:EQ?+EA8"4ID7<XI'75Q@J)S6V/J2O*V6%
MZ2,U4W^2J_*^%D6WNR#\OE@6*EJK*^Y%3=M3F;_I'3GE9^_,#UP\B<7JP;3>
MV%SU%S_3DQ?K=TQIESU_M&G0"PSMJ=// WLS9!^T<->,4$P-]?%1=W'?_*$I
M(=4L@A_5YS>/LY"Q($0PE7FDMP,"F >$0(%Y(O,44\0#-U+]GI*X>)5Q2/?5
M>YTXLVGW,H+=6L (P X\FQXPYIG5@AG8: %J-79_K169&:93H%7QRMI]"9:^
M:;U[R3(V[_<E@!TA!K_H<1?1DOR\4@YDJ1^\SXW29+6("I:3-(!IBLSQJ!CF
M*,]A&B%).8VI3)R*4JQ&G5JNL9.V#EMN#6V%88R"NOLM_.TOW__BN'C@9@8[
MI^@=W,%=X([CZ7D&=G+/=)-:=8G'I8A>& W!WG%FY-<@Y[ #XP3WAN7-_9R4
MX=BCY]N1T<-V9$W3L18[W]^5L'?*IUXI<=47_$WH16'-+ZT[W1*V?B2+&U'>
M1_-,I"P,PE %@"F!2.8AS$VKV"#B(4$95?9U<7FOH,/4'&A+!=,&RS RF4J+
M&?BCT0F26BE0;K0";*<64&+>NWG6UWAW[/STQ-^(@;V^A[Z;V\Z:>R_6!@O0
M@ &V:( 6'."FZTURGD]>T99>9Z?7T&/4N>X5#74X<[ZF*)>RJ>PZ?'XKJG^:
M"D">A'G$]!&K&"&(<D0A$7$(LR FF,=,\,RJK;K-8%.;V5J$(3MAG6HJK2"V
M713Q ]S@87\/S"[@63D-QD!D*T<&?"7&E=.JGZ9=Z;C'???S.Q-+H@*]ZSOM
MV\S!3[VGH"LSRF+)BH>%N.+_]5BM]7A-LDLH53XC9! 3EBM_DE*8ZRU0F6=Q
MRGG*<,YM]SQ[C#\U%_/I7OW![*?42O2H4NACA?/[F@-C.W08VD@_V\!:F-/J
MC09@J\(,[)08"7K[O<N!33#2CF4?4_C9_;L OZYV]CV>.E[O^?XJ[S6*O^ Q
M?8MRUT5IPF.]1/[]007"J_(7;5X=/.LH"0L1J<DAA$@&F9HX.(<Y$Q@RG@9)
M$#":!E:G ZQ'G-I4L1.X+CYM1 8;F7L%IN=QMXM.O:(Y\.1P*9 ]BGHMP?%<
MWGMNU)$+?2U!>%GR:WMC/]?3'#Y<WOZBZ4M^*0@UK0KG6420Q'$, Y)AB+AN
M\Y3(5,',98"0("Q.7'INGQC'R<V,T'3[JR9P4)_&$UD\FB:>NHQ']^Q<& 8@
M-VJN<QC;.1</R WL4K82 B/B#&R%].=%SJ#@U7><&FM4CW%&X4,_<>[RGK0/
M-4/I1Z%N(8L;\J/I/]?LV\]IP)(X( ED- P@"E$,<TXH%$F21"*@ZK[(K:SH
MS(C3*Q]J)'5D73B#JYUG\(C5P!YBP]'<B&HHV+9M-!MQWWJD1; #QB_QP9DQ
MQZ4VL /@!7F!Y6WN1,7OFW3[IB3+JM"QRS?QL"K7<X(EB=,$0:E>(H@2?>XP
M1(:S..8QXQB%H2U)\:E!II;+;.0$.T%!+:D],_%)0+M=AR^8AEY'=T?(B8KX
M' 2]:8A//G@T"N)SJK7IA\]>VR]JJ&D2=8.:CTJTZYKG1(4F+>*@1.2$$\X@
MST4$$9(2XB#*(>=21#A@),ISE_6,\T-.S0DT7*.&R8EMY6WQ. &R7I<%?5SK
M)F^Z6]176?Q+E)J.]/0!@;[VL LX_*(\L ]I &ZZ;1F<=Q*WV)AF0#-PJ51/
MS7<S<'4(.O';(\$>0J_1B<6PHP8H]C <QB@.=_;,>79]<'_7JP#SB*4\CJ,(
M*F@91!$+8)X&*4RR*(S3*&.$.?FJPP&FYIF:SLQ5W9GY?P9_"1+P0,IZ3>2O
M((QF01" JN[83![7=ZM2,^;^%115]2CXOP/]#O[;_\!1&/TUGZ$L_*O^3;#[
M39 Y9DN'%K%,CR[ >>A\:*_YM9%N!CX9^#QF02?T]YOV' XR;IYS0L47B<VI
MZ_JYB%]6RUM=>_15O0]WI!+Z\879#JK/%<X%IQ&3(E,^0N_94)%#&DL.0\*3
MC-. 4D%<7,:Y :?F0K2\4->U@H=&8A7C;$2>-6<XW9S 6<SMG()/) =V$CL0
M-\*"ZQ:(5]T@.KL+6V2\NH^S@X[J3FPA.'0OUO>Y5QDU-9+JR=4C49G:2H]3
M?9'?A9J2ZTV@VU*8#:(C-)-SDL8LS*,4\I00B#)!($TXAZGZD:2$LC2WZ@%U
MN2A3<U&;NNN'1AT=[.N/K=*IP/I.@&JK%B ;O>R+8RZT6[<S&]<: [NYC2&^
MM@QQLS'$3ANP56=VE&UW--/8ES"-9Z*1JIF&-I53@9,?=#MJG2X<8+2R)S]
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M-Z\%!T]:<@?ZB]=Y.;J][Y_#Y$/OO6KM(-7J@38$>ZS"]!FTKVMP  :(UFK
M%HLV#7$#QPS4[]7U[KW:8@)^_U.\30Y,+)-_J\:B<9G^V^5&"?.JANWBDWD=
MP<8CHWE5X/>8;%Y7DG[9X(?[A\7J60BSNU(/UU06D2C.3 L6EB+-UQ93B",>
MP3B("8YSC%G@M"U[<J2IA3E'74Z;.:,6OF=YUVG [3)"+S".&#I<A*!S-G@6
M':\YX.G11LW\SBI]F.^=O\$]R^MJ:7W]6*Y)L3 .;WM 6>YWM"9G.UK+CH[6
M>ITXC%F0I11#1K),-Y[+(0VELAOF(LU0+@6R[AGUZMI,S2E^T_OL557(@C6\
M(5O5*[#IUK9> ;8#Q]!,/V@%055KJ')'W<YM2SGBV'_VU8UBD3:^NHP3F@;J
M:'P/#/"FAN,MT(#,0 N2%KU%O0VB4=$%.@87\]+4#]R'!K0[JJHG:J8-O=AH
M  (-0N;D,7A3@_1VUKEM,L'7SCZ_?'59)YAJ_CE?0Z?L<S)F[TA$7U_&T7+2
MUU?U2'HZ':%Z\,4]WI,;P>Z6J\7JMM@>?LGB,,,$)3!/>0A12@*(,_4?@D1$
M4A:S,+5*44\/,;4P3$L)VF+V.&AZ LSSL<WE$ T<< R(C@.KV<4HC45.YHZ6
M&[U8)Q!=+&'';QR/[*M3\#W.KNXKW1Q=5:Y;;6.4Z4TSK^84C@SB%,N P3P(
M8X@"DD 2"O6OC$941C0D@57WA*Y!IN;L]N2LF\XY'F;JA+3;X?D":F"7UPLC
MZ\_8!H2N%35U?VLU3?UTN)+6.< H'[R-BIM/WNK:?NOP'TE1FO7\=\_;?_ZM
M$*7FZGW^13/U-GV#"0ORE, DI2E$,DH@3B,):1#GFFF>14GHLBAO-^S4'(,6
MM=Z\ UMA36;V^>KW7BV"+=%/DR1@4OG?.&,"HH3',!=9 #-)$$$9YIQ1-\H"
M__B/PU7P7@7]2\'WLMX9:-EE)<WO&HHEO9/[JR":-=HDRP/:R&X7Q3_N _OY
M2UYYYUT4-W2\;JE8#CWJ_HH;'(>;+8YW]]S&-5O(V]:6$1(T#4D.)=9]GYEN
M2A(C!HD((A$G-&8R=]J[W7O\U*:#IA#$M57H">PLMV%[(S*PH[ 'PWUS]:C.
M?G=4]X<8=QOUJ'HO]DZ/7]7OLU73J#GQ=$-^U!/EUW+U(,KULYX[UU=+4QIB
M.C3,)>)<DB2%J40)1)$0D'*&89H($6,:8!DG+I^T_=!3^]PW@L[ @Q;5S()B
M(RR 8*,96),?-5&F8_F^@U7LG,4P6 _L2+8PZA[PM=@SL,/^ZQ;[K?#^/(T[
M8%Z]D,/PHWHH=U@.O5>/)_0,2*04AKISVZG^&UF+;T)K6BR*^L@G^5%O#E1S
M'-$X2V(,)<\#B&*90XPC C.2,I'B$,N4;QJXW#C$+4Y26'U\^XU:;L8HN__+
M][^ ;_]&[A_^^M[X-&;$=0QRW.QA&03YAW>D(&DC^*;-O/9Q6G:P+[S9H@6U
M_%N><H\!52_\_ 9<;B*,&Y#U@N=%P-;O*1>VS6AXTC6CV>[ >XM.?;N%B?)0
M"HDAPTD,44@3W9X]AQQE.6(T)019A75]!9A:<+??/*!1PO3%::D!VPT%^FSR
M]3+5^0W2H0TPL%><,/8]>V@,8(-7::+AR1;]NV@X FG;1L/VL:_31\-1Z9.-
M-%R?T[_X^EZ-MA#\X^.2;[Z<%&=2)GD*LR#69)>(0LIX!IF:9A#+XQQ%5CM&
MW<-,;1K9UOPUH@(C:P]OU8'L^?G #UX#>_TQH'(O8+T,LK$K2QVAZU7;>1H1
MBZ++(S>/7@UY6H%C98H=5_=;D>BJ?_PLUIH#H:Y[_)O@M^)G4BSU7]X)N2K%
MX>D'Y<IU77;$HIQ&"8<II@@B1A*(]<XPXP&/)4<TB@.7-5G_(D[-+U_=KQZ7
MA@E$2U_]]$8K(*JW)N^^71;_4A]1L01?KC^Y+6\,8%R[)9#7-=E84T.K<KY9
M,#&&>UOSNNR4!$;+F3'N]A)JE 4O3Q M/?-7#6<+KTLN X@YZK+,<# ?+MT,
M.%+?#B>W>KAOXF%5KM4$];ZHV,(T0[\1/];O%$K_G.-44IS3!(8R5)-"G(?0
MM,^@$8\HRM6<$3I1P%J,.34OWXBLVS:L;DOR<%>PUL&9#===J\V):X>,\U:P
M\]Z>L1W8'3?2@JVX8"<O^(>6&!B1O7; L ;(<]^+\^..W.W"&HB7/2[L;W5/
M_:_*IV))*N48FUPK"0,<T!1#@;(0(IY)B&F<PY3G>1I'*0L3ZU9VAP^?FJ-I
MY-.<+JQ'QOH"N_,I_26(#.P>?(-AG[1? LI(J7H;'#]Y^2FE.[+Q%[>,EH.?
M$K:=>9^\IF>LQ.X$?UR(+_)DC<%-S9F?!4B%2@)R3AA$.,\@E53 -,:$AI&0
M,;9R6*X#3\V9;>0VM=-==39JKM?RN_85L[6'9>@T ,H#.\C+0'6/G1P1\AM
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MT&NZN>FP(S6I70X3(AB-PCQ+F'4ER?ZCI_:I;Z3KL;1X@-GY:+,_$@-_Q/Y
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MHY"G(DBH=?=FCW)-[7.OQ=5YY$.M%2 ;M4"QT0L\*L4 ?S1SF#!:Z;J<C5Y
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M3$,12)[#, T$1%E.8$Y9 %$8D33*TU1PZT7Y_4=/S:-MI/O)_..>_.A1_W4
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MDF[+PJ #J,9()="3$'I8J#'KGIH3&JK)RGY*4. CCP9VB?47XCI-3OU99!>
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M?A 1R$),(:()@22(*62IAWE PU@@JW$X+\;)W'R,=D!B_^"72;;Z<Y?7'0R
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MTPVY?K_WQK[=O;$N)D/]J[RQY@&E>3(PP[C6_Y(WV"KD-N^7XT3D;Z:$3Q:
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M'(TLV)<WHA2#0'$(-(L+H)C<_I4H3L%35K=REMQ.8W9=((;)S+,A-,[&C+L
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MY@X$F]K7?<$8K82U*2B6):A/\=U927KOAA$+0I\B=+^N\\DK[+7/[UGV>_,
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MZFNN+ I19JO:^MC15;0^?WK2G=&K*W1+9RD%*^>A)Y&?,"4Y1A.(<,H@C:,
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MN<YV*&[EM\=\5>HDA?>"EK\JO:D#XCXM[Y7\Q*_YLGPL;E>?%8%*J7'!$D]
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M"XGNSA,FD$@_@4P0P10MA<*LCZ?!6'-CJ):XH-#R+L"ZE%A7J%E5,IM_J[>
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MUW8=ZCM=RUT:9]*U6X>BIVNUKDO[YK/3[2'F\C7)\Q_9^N'N23?Q7@8!\;R
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MUT4[>,D3*/$(2F$841^B-)8P33T*0Q9ZOD^Q%S'+'*)Q!9Z;WW*LK^:BML9
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M,DKL$KI->)W7]=M+:M>^7?.OVPW[9WVN784T+&,N8Y'@1*VS(MWGDA!(9!!
M27@21@'%90=@G45CMA=T:T KNML/.Z+'4"8(K5HUJ[7K4$6+V>V[W(3:;-_$
M)8 C4^*'$]3>=J-FO3MA"H73W86;@TZZ.V *P>GJWOB^?K3R5DK!MMDWL7?"
MOI"M.-E2T,T?[O@_=D75WGR9R#05%'$8H2C1 >>Z9BP5BFI"@<.(<"*,DH>&
M"#$W;^MNM0(;+>,"K(5E%F(O(YB1T-C0CDQ,>_';"SVM 3A685&WXVEI448;
M,2<1E2[ =$IMO029E.Z&0'5*@8.>9;]XO+)_JMZF;*/7JKDNOOM&5/\MQUV&
MTH^0Q!PF*=(%&8((DA1AF$@_H(F,0K7 7*[+ACG\]N+27@"C+S:MOMBV&.-]
MN)\LJ; G\+<7HR.!.0W]=9P^50J 1@/P4Z/#SS47CHJ[^6)W7/PG6@J/8@>K
MY7)_&#L6TST>.ME2N[_"[87X@*?83QS_EWS+F)!;TO2/\3#V4RRASV0(4<0#
MB&,40"$]1# )61 :YVV=/'MNWN]>O!Z[::>PW>;T 6",3-@N<3#GV %X3$2@
M>PG=L.$5A3NH[O2.R7CLBJAMDKIVB8O4HXNEKXN/8OM)*CX\S54)0U&VO()2
MJ.4\BDD,4X\)F!!*.0^B@)AEFCJ096X,=U10_I"$]#__!U9OVO^N_Z/<77U&
MN54>@OMD(SM3FFT/3&2@D5GW0@+2Y?K_U>[FOFN ,M65ZQ;@8V5*I?>$:4N]
M##!B I.=/"^8RM0+N.ZDIGZ/[-F;2WN>U?!W:]Y4O[^CQ38G;+M,1)20.,)0
MI/IH)XH5+4=>"&.*) ZQYY,HMNK1U3G<W)BWVMFKO_'R=*(6&/S1B&P96'L#
M;C/J= ?BR.PX"#_[!EY&L+AMY-4]Y+0-O8S4/VOL9797/W+1V9GZ,?^5;1]?
M[XJM&B1O3I5^O*YK,7@B1H2DD:XARR'B@8"I+SCT(N;[*(F8\@QM*,9DT+D1
MS3ZH+!??A*)]R_8C1C@3'U$:^@C&R$.*RI,(8D%]2$7J(>PE$<78KHRG:Z2G
M*>=YAO4"6!4:L0+=C-!= SDRK3?B@C^5O* 1>+'OVOUC 5Z[*BG2!R*G%&\T
M\*1$;P/%*=U;W=NWEK#4 ?WUAN=G]>:\+;;9DS[Y>;?;[G+Q]NEYM?DA\E(6
M745#>[=[%RA(6,1T<3GL>U+1% H@B1F#F(0X3GB2DL@H5M*-.'.;*/0$K<O%
M %KIHY/:RU/'_["M/CS(2&:T-AWT(Q->K4AS]@*T*@NPMT6E#&BT 4?JC.+J
MND'6<57D02)-7#?9!7SGE96=/'7 .EYG(^?B4;GP^Y %O:=P]XUD*UVJZ-TF
M_TI6XE"#ZA"V\$K(3:X#')8T"N.();Y:\M-4^>.,0IHF'$H_#!.?8L;2V"::
MTYED5EP\0=AGM;IE;<U 5N\'KO1^X *01C^H=("%TK!=/9#L=5PH/M=:ZOW;
M!2B%[[&OX,3\%EL04QMU[-V*U^\798GZHY)Y=T<FU/HLP"\D6]=[OLK&<GL4
M_K6WI=+.\>:&2\#=[X,XD6[Z+1.7H%[<77$Z0+_9H=PI?M51L*)X]>-P3;MB
MQ:?G<I9Z^UWD+"M$\7Y=13#\E\@>'M7,=J<6[>1!-+__G&=,+'D2TR3"ZI/1
M#8*0#M6EDGLP12Q*@E 2+S9JB?8RXL_/YZ^$XPOP9RTV))7<0-2_T^U)F#@<
M]SDY!)SXK3&;>>;[+HP\/9D4/BIN5#ZJ(=!KEQH$7;VX@F$!&B! C<3^*E!B
MX6XR>QD;.IWQ)E9ATFGQ9<QS.G>^D!2N-KWT_^^*0B@QF] _DO%EPAGSL(=A
M@F0 $48AQ(SKXDEA&@D_204-FGCM^R&[7)?'-^*SXW#M^PFFN$9$\*QD'+J3
M=07YOGM6 X!\R=TI_2>HY%[L@X;!YRY\'6Q#=8,U\H;3E<%?>&NI&Y+;FT@W
M[N_'5[]]_66C6'!=<N:#6#.U[-!+W\,BI(DDIEXBI9 P\A"'B.$4T@ ',$I1
MBK%0GGYL%9=G.O#<G/"#U&4@ ]&B_P 0_/:WKW^SC+BUMH$9<XV![,C,]=M7
MT,*U$?IT#\9A^G]?K)P2E_'@DQ*7+22GQ&5]?\]B!$)1H?A0)4\4+,]*7^]>
M[Z,L.:4AB4@"PY0RB)#T((F8<K P]SCU?!E*JYJ4'6/-C9XJ41>@%%;O8N[%
M!7^4 EMR4Q?,9G3D"+R1&6@ ;O:E"&XCXK8*0<=XTQ8@N*WX6>T!@UOLTZ3^
M4_ 'P=]OQ=.;S1/)UDM.$K4:$PF,A>()Y/L1Q$' ()-Q*F4L"1'&Q?=/'SXW
MBJCD UI \$<EHD6*T!ETW2PP%)"1/WO'6)CG2PW!9**$J08/(#<Y. +*47^_
M+APZ\JC.;IDLD>J:L.U,JJO7]"R.4H4*B*\BUQE:E_?"#FFE.FN@V<[Z),M2
M+?4FV#*.L)>$FM@D5A0G"=?'^0+RR/<3A% 2(V95,<659'/C1YU<39M]DER0
M59ER7:;T-*<LEK55G-G0S.-Z$<M,>.BQ/\LX; $?#C)TQE0E_J*=)N^P HMK
M=-V697$FW;2U6ER#>E; Q?D O3,A=$&@*I7K2U;\\T.V%GJV*)8HPERYGP+&
M2:((&C$*4^$E4'@DX,@3 0JL2EI='VINC'LD*="B@C^TL*6[8=M@N0-A,_IT
M@]O(?-@7LC[Q]C?0<!UE?VVXJ6/K;ZA](:+^UAW.CA356_2HR*O0X4)E33ZQ
MW:ZJL]"E#+B/D>*-E$H?(LI]F'H^@IR)@*)$LH#Q87'S7<//C5KVLBZ CKI4
M_]&[]L5!X!ZU\BP-TON\T1',+WWJ"#Z(;PK%\*Q>WH6"1>5:LU%\ :HH2VVQ
M@^ZCGEH:0#[VV667""]]@FD C\$YILE3^E)EGGTCND[?8=*GDA 6QC%4$*00
M>3R$B@:16OQ21C&)/!8B.SX\&V-NI'<0<8 ?=0E+4RH;A-#H?&4'3@]:N:J^
M8^XX'V=B@KBJZ#D+7+^T;V.[8IOOV':79^L']0^UKA-?6HW%0H9#XLL$4D("
MB*2,RC[FD(F41X+@,*2A75^ZSO'F1@%'XH):WH&MX+H!-^,&AS".S!.#$.S1
M/,T(%\>]S[K'G+AUF1$ YYW'S&X;4LA,]XXIR_"4L3YUB('$%'DX@1(Q!%&*
M/9ARX2O7@A&?<>EYJ=5FS=61YD8LK2+8+5'[!1=<A]>,3)R -C*-],2K9Q6O
M#BQ&J-%U:;07J,#5H?3E^EI=-_3-J]KDVWN1/^E(IWOUC/I ./8)PKX70Z*6
M(1!%$5;^"$:0)"SDB0PP%E:';E?&F1M)E&)"W<RXC.%; "VJY0'[+6C-*,(!
M8*.?;/7"JD>N32<2CI-B+H\U<?9*I\+G:2;=E_<HQIQM'Y54Y/O_5?]OPJC#
M0":22QASX2F_05!(];Y$0CAG092$OGF@T87GSXT(]B("+6.?BL07,.S^\AT@
M,_(7/PHH%J6:AX$S5;GF/4A_-X3)KGSS=1"Z2CA?N&NZ,L[713XJY=QQF3V'
MO7W./HMU_8[1,"")KQP9/Q*Z(DCJPS3P&.1IBA!&^N]&%?I.'SPWUE*R 25<
MCR_S"*[;/-47A)$)RI'^YI34%X>)N*@2SS$#7=*Y@WJ.+I^,<RX)V2:;B[_O
M&>E(<MT)7C?&**-S[L7W[2LEQS^7"?<HB<, )DE$E<_D<XACWX<RB9$G4X]'
MV*HPZ-619L=#M:!E]>_7FZ>GS;I*Z@=WVZIPE%ZZ@NT&?);9OZH*NW\[NK#N
MTV<9KWC5$F9K+B?XCDUQ;6@K3/_0<H)24(?+KIM@N W_NSK:M.%\MY0^"\^[
M>4,_4KG7806[_$<9P?<[6>W$'?OO79;KN+]B^ZO8/F[X,@F#",?$@]P+.$0T
M2F&:2@1]3J6O*">A(C1KG68SK-'',&G#M/W!O(ZA916+%%H#._HPPEQXB?#"
M $.*XA"B&*60T,2'F)" \5AZ)+6*4G*&^*1ACT79X.&YQGT$F,T(VS5X(W-W
M(RXHY5V 4N(%:&1>@!+82FQW1&X#DE-.-QIX4GJW@>*4Z:WN[>E)EEV)JT>]
M7W\350FU3W^NU3?]F#W7/5G)@U@*%J92=T:COF8A$C%(4$H@1S$G,0ZPB.P\
M2].1YT9%E>#@J90<9'O1%V#3"*^KA]726[J3QN8P="_' 'EL=[/"MQ(:O&_A
MNY<;?+Z-K[WW:8N56V_4>/1IO5-;4,Z\5>L']".R=YM<9 ]EX9=Z2T52&F)-
M4SCB*421%T :$H5](E :1BP.J-5YXMD(<R.F]VLURKK<WR&KGO55SF$T(YI!
MX(Q,*+5L59RU^[HH5U5WR@_GHTS* U>5//W>KU_HK#-"74*^J@_>_*(NZ?__
M"I+?_[E9!I3X:8@HC'RF/_Y 0")%"@.!F AQ&B$OMFO<TD\0F\]@FE8NZOT*
M!_<],#&!&7&,#^O([&+6YV#_VTJ/!="* *7)J/T-+) <NZ^!B2@OW<_  BZ#
M/@8V3[/CQB+?+G_-UMG3[JF>I(GT>.JKU5A(?:(69[Y:G!$101I$7LH)ICPU
M:CEX]N2Y^3BU<);>S3E@W>0T"(:1^<88 6,"N:IM%R>HFUI\H/YUR@7G3YWD
M\[ZJ3//%7K_ _L2_3-HK]V2*3+O=Y7Y\59@[#7@4HYC#0(H (J0^QE0*!F4H
MT@ SR1@VVK3M'F9NGV<I*2 '41=U:?6JU/J0 NLW\.[^H-VA./+770%XUP:P
M.G'KKB9N@Y1YJ($;Q"8*/.B)G%4<PFU .J(2.FZ>+$;AM@+MB 6#J^TYLWP(
M[2I13G\<KFF7**^VDMZO=19+>6'9*63[2-9UO9'?1:$<KNQRY?)?U #;Z@N(
M?>D3#U.()?<ATOO9:<HD#'2.J_*@(L2,TESGH<[<YH!*[ 5XT!(Z(OZ71]E@
M@GEY(6<TD;GHO%&?!+1P 57_,(W,H2]'!4YG4XX2(MLY].7M:3%7O[RP,_0)
M_GHOH94[,A^;=[@],Q!R,O=J!KI><.-F))6]N_A1H4Z*QTW^F>3;^A]O,GV.
MF.E]M79;T+N'7)3Z-&(WIXW+&"4R2@6"'O$3?1J ($X0A02%S L"P1 SSB1R
M(=#<7+::XPZQ#)K'Q'?VJ-^0JLY0&33[OPI RCI%YI.H$_O=]KVFMLK(WE.M
M =#(*X5 \^^62HNCELE@KU5KQFH4F]A:YD[+U%:;R.V8R'I6OH)+J#MF>R?#
M3#9?NP2E/>,Z?:[]G'FO>R&_RC9%]I3I)7=]YL'"!.& !M!3_X$HC2A,_11!
M%B,4X)"DR"P@YOH0<YO72BE!2\P>:5I7P+P])0V':.1)9D1TS*> X2A-1.H]
MT+(BZ&X@.BCWRHV3D6BWX&U:O'&E/=&]$5+DN>#WY/N'C-!L5?9,4O]J?J$/
MX=>%:*][R+HYI2^:0M?-OY<L\$.1>"F4).8089'"-! ^]+E',(K2F+# ++ME
M!.F,OHE)DV :"0\M "!H= -;\AVL#FJ;4XIKH]YFZI<PU&3!294U=$VEEFY5
MO?_];VO]%L>;9+J6;*.3\DL;8S<_>CF+FL\N+VC9B::E%[&PU<0VD@TZ9D37
M(TXVE8X$57L.'FN(?M&]O^2;HOB<;]2CEE[LAR&3,12IWJ0CD8 D]CGD!&&6
M(C\-:;K<:A>B>^J]\&RK=<E^A/$^VE(T\%S*9A>+VP:L>V(;",/($U.%P.=N
M!*Q#8"_HZC2NM?W\28-5+RAV&H%ZZ9(^6P?/7[/OZC%\Q[;-:B[Q1!P@%$)&
M9 A1&G*8QC&#$0^#*$&Q\IF-HDNO#3"_;8-GH(0$C92]UL47<#39,QB&SN@[
M!N, 8[-=, R@R38+CH%RM45P7?G.#8(+MTVX/7!=Z./-@8[K>B8W2RG8]I-\
M6Y]D?5%KXD_KUZ1XU/_7&Z[?R$H?:Y:5D3,=K:]_<;?FQS]H7;GDA L<1Q3Z
M,8\APCZ!E$08<DE\IMP4PN+$*@W:O8QSH]-*15V]H3E2A+G2$E1_+X!:B)3'
M(WHU4OY%''0I?YCO-;U^H66>]0AOAID[]L+V'GF".)BZT0]H!;6)M="+\D_0
MDGT!#FI5O]3&/?W96P,[V^=[CV<)MYGA(\@Y;0[Y>$"?99N/.%3/:M?L4?#=
M2GR27\0WL=Z)HNJ76*9JKU[OBNWF27&PDN##9OWP(?LF>-4*JBKNGJ3,1S2,
M(4X#H5QOSX.I\ 64<8)E(@*!?*O6',/$F=O,TFBC":?1I^H^VV@$]BJ5Q**5
M@J563<.M7L7X!QK5;*:8SE0C3PH36,F^PK<3<-T6 A\FTK3UPIW =U96W,U3
M^Q&U?J0N:7Z(P"CNJ)H3"-LN?1$DS/<0C+#D$/'0UZT)(BAP0$D88_5[JU(B
M'6/-C6++;[&LN'^(#K1TMKN0-:-"1WB-S','J%IR@C\:21VREP$>3JFI:[Q)
M><= \5-2,;FEIVLG5NJW#[^(M<C)2K'2'7_*UEE1]K7])NJ#E"4C>FL@E%!&
M*8;(0Q*FR)?0\]2//10%.+'K:V(T[-QXI)9ZH6A$;O*GIDJ1GN[)D?Q 5 I8
MDHRA,;@7>WZ*! P8EQ E'H$D%CY,"66)LH_T0F97O]2A.28-WIB)00Q]8>?O
M_-@^;X-N+7*)Z['0S9F\0Z?6"B6WSJO9T-,ZJ59PG#FC=G?W;9K'=>&8;"M*
M;_;]>JM>HDPYLY5?^^K'K^0?F_SUBA3%W?>L6!(42Q(H"_" 4HAPXD$<:S8+
M4:)^D81,&B6R]!Q_;I/*07RX*I>+!P7V*T<MMW6O/3NKF''8B%B/3&;#8>[1
MHJ\76(X;]]G),'$[OUX G3?YZ_<8^\B"+X(JKT8OWLLDPK*A^1>QTI[.'6/Y
MCJR*I10H" E5/AD2 J)(K;/3A!/(0NPS$G@AQ\(TT,!@O+G1615B3K1T0I]Z
ME0J4GL.FS#@NM XPKY2HKE-:F)^]FYC@=HR"8V!'YJY:6J#$K?.V2X%A+3&X
M&P5%\X &QVA.%-_P6N1;DJTOOJO-S\JW5?UFN\O7C@(@+,#JB(<P><IDX1$6
M*K6C)6QNZ^>:?L[K@-"R^GR9'U[<[;:/FSS[E^#+$ 78BQ"'$:$11*$@$(<1
M@S[V(X:#2)+8J(:.V7!S8^J]M%73C[K*F7K_]Q+;>9PWP#9S,-U!.#(G']"K
MNU)4LH*[V^A9.Y)FH#CU&V\,.:F;:*;^J5=H>)>]$_B?F^(YRTD=]A=[5 ;,
M"Z! *8-(_PU'7@@]YE.!,>,!QZ;NWM&3YT87M7 ]PB6/ ;OMG/6&8>1/WA4"
MYHY5;R0F<J&,$;'RD"YJW>$+'5\_F==S4<RV?W/Y@D$9HM6*5OVY89GVD_XK
MVS[^MLX%VSRL-:VI2_899G%(N)\&! 91J+R;V!>0QD+")*8DP&$2!=0HRK._
M"'.CL*.\SJH(C/Y/K0CX4VD"=BU5RNOHD%1!&WO=)L;QK3 R@QXE^M6[;@<=
M@%8"M+4HKQN4JVEC@%XIF2,9XB4R+YT9I&]J90\LS3(H;1[\$HF2/12_D@_9
MYTD]ZM^*=;;)/V[4ZOW-3@0>2FK7!@4D]4(I8<!T#7\_#2$AE$.)(^3'4<*2
MV+@\R[5!YC:K5'*"4E"@) 5:U!Y.XE50;T\,+J :_3!Y9)0LRHPZ0&NJXI_]
M4+.KP'D#CJZZF-=NG:Y:Y0WACVI(WKJVEVM^TC*EW,ILQ6G5;V<4A&$:*!><
M)Z%.N6(28I\QB"B*"><8,6SCC!L-.C>BK(XNLG9<H?7G;PRXD3?M',;Q_><+
M?9HJ7-]/@ZN5D^P<W^G<8A.<G3G 5CAUN[QFCYK2R;52[L2MM;O7GK\_Y^*Y
M;F=UMV[*!A?WF]>ZSC_=Y-ILA4ZF6K*0)G$B).2ACQ5M^Q+2@,>0,X^D"!,6
MAY$I@1N/.C<&+Q,9:]'!=@-86V!SLC%'_3:+CX+E^&='C<SE:7,CM8;T2.XJ
MUW0,8,UI?!2 )^)Q5T!;\;DU8!V$;OZLR1C=6KTVI=O?W//@?__DNMO\JUVA
MYI*B$,5'L?TDRX39N@_],N L$A[U82R\$**0"4A(F$"U0(B)'R5^'.\K)MY;
M1 -8R&#T[1R'UM]/P/>MODF%SGRD>PT68"W*'/FJF$&MAF7 @(V1L!=1F28"
MEH4KD/ 8I"$/(!9)( *?)LRLW]%HUGFA:;@H2]L?=:N;V#+=<_38>(\]5;=F
MC%H\\*KU%7RLL"XM<G<+:_O CQZ@N0T#L1%@VJ"0'M"<A8CT>4;?W?+?UH5@
M._6D-X)NR_VG$ <>"NIUM61",DRYFGKT^D)X E(?!S!&/@\%2W'L$[N=\^X!
MY\9I]4[G7FB@I5[4>YXAAEKRWMO%-[ WW6!WA^@TF^TO J;M/KP[4*?=D^\$
MU^7.O!E -W?I;SQFXAU[,Z7.=^\-[^NW:KACZ@7:E0'(]SE9%ZNJR13_QZ[:
M;ZK?<)\S]6:0",:<$(@2Y86F7/-UC -"(D;CT"H9VFS8N1'VNTTNLH<U>+W+
M<[%F/T!+=G 0WG8SVM(69LZG>X1')O"6P. ,Z(/<X&Y;-6'1M4.TB_J9Y/K'
M[@X(^R'HU <U''I2[],.CE._T_+N?F1VOGM^][39E67#FF"0]^M71/V<B:^/
M0FSW]4RB &&/AA%,(YE 1*E::A/$("=^R@65),%&KNA@2>9&>;780(?3*$N4
MG3+5PX%Z:8K-*N/EYTHK14"A-?D/.]+K;S,S'IS$$B]R!MJ81F^&5%W4?VI*
MP__X&1S4TR;[JCS$LEV57KF_R]9*VXRLP.=-M8$R2K6;P<@[I=3^TDS*LH-!
M.R7>X0\<6D!1MR38K+5?]$F^7[/-D[@GW^LZ#+5892&P>_%]^TIA\<]E0BB*
MA&!0N984(B]((9'"@UA((A .!8IDO^J)UK+,C8_;1?D^YYMO6:$_7TT!2I&J
M*&^E5]_*B/;6,N/AB6PP]BY#"_Z#'OI?E29EL'"M"_BIUN;GN@XBT!J!4J51
M2B+V!G:D>HCV\KQ0,<3>P%VOA-C_D?WHM@P3*8OA[MAVEV?KAWJUF,:<>T$@
M(8D1@@A%'!),*(S],*$)]1 /J V77AMH;D3Y]KMRE%YOBMZK\:N(FO&="YQ&
M)K,JN.M(QA&6T;> <$H^5P>;E%ENJ7Q*&S>O[[T</LZ1^&6SX7]F*UT5Z[1B
MS)*FB#&./.@S'$,4)#'$$E/E>!'/1YZ?A)1;KH"-!Y\;=[3J)-4I<R<-$FVZ
MJ?>RAO':=A2,QU_.GF9@+4 C>AFT=%:HRNFJU!HSUPM1<P&F7GM:0W-AN6G_
MC)Z5G]6Z5CE::K"LV1H724A"#ZGE8D#*L"8"4Y]I9P=Y!/,D"K!5G;WS(>9&
M55K"<C%2RMC3U;F I!D!#<-G9)JQA<:^G/-5[=U6<3X?9MKBS5?5/*O9?/W*
MGAY,5K#5IMCE]8JJZ6Q9ETPJW?NRS,DK4HA#;.5A(XDRBE..H(PX@2B*&*14
M)## 2<@QDM@/V?*;R.G&V*T9)I'-Y]&6:\0=#2TL+*7=QPI;.C8#C63HZTP'
M_-A[2"7BM(TXN,MSW?>F_/L?HVP3.<+/K2LT4*9IO2,W )XY3(X>VR-&;[]9
M=?;\NS])SG\GJUUU2EL4NZ?G,B+Z9.LW%C(.J4[LE$Q )'T,J?1B* CV/$H3
M/_*,"W\.%V=NOEE[LW@O/6B);Q&&-MQ6W30[O04FW*F_R+A:H\5EN]CLUX]A
M*HMXPDE--E6TX0#3.8I"= 9K5XSB\$&FBV!T!LA1?*.[I_9M!;,OC] $.GI!
MDD0^@7X<AU!7YX=IE$K(U5]E2A.9)$8SVM419C=)M<MM]-L^.$?1\$AX"#9C
M3Q]6L/1H^7%%=<?=/4Y'F;B1QQ4ESWMV7+NPWV?]CF2YY@[Q?OV\VQ8?Q#>Q
M"IM8?1GR--*?M1?'$$4!@@0G L9QG(:!1W%(K#IS=HPUMT^]E V$/;_R+E#-
MOG='4(W\Y6LI2]]"+$ EZ (8(V=-! :8.*6$KO$F)0<#Q4]IPN26GD<).@%.
M?!#* 2D^;U89^W%PQB,_) &B&$9^$D$D0@IQY'LP\5@:<R$DM6OEVS'6_ B#
M6/</ZX+2\%#!#4!CGRZ44FIJT'*"/RI)QPGQ,D#$[8E#QWC3'CW<5OSL#,+@
MEGXDH9N+;W_\*K:/&WXHR/,FDU+H)!7Q2FS_%&+]FN3YCVS]4(79WJWY;VLU
MQDK_J'J"<D&20"+F04F20.>]^KHP6@ #$L=>BE+ECUB%9+D2;&[T<]  T$H%
MP&H= "F5*(,%=GLU@"CUL",L9V8U8[>7,-;(5%@)!"J=6L7"%J!EP5HOT"A6
MIR^4%CSH!MYV6]":.EW#[91GG0DW*2F[AO24P9T_OT^-RT-^4[99_T*R]8=-
M451#E742[LGWI<=3082/H.\C#A'Q0XA1(&#@1Z$(4Y+&S+A^@=&(<R-H+:7.
M.&";I^>5*+=B-Q)L=7X?855A%B*5('!+OMO4930!__9QAG-(1Z;1$WD7H(3W
M)RWSSTVV5U5]Y9/4H7.N$;4I<^D8V<EJ7#I"V++8I05:G94N39XS89E+"[6.
M:US:W.@H]%G]I?E9G87Q110B_U;V8FM:KQV%8+]^)/F#*)8^P7XJO12*&*<0
MH43 -.(>9 03M?Q'GD?308'1O46;VW1P)&.[ 2:KY!TEBKJ_8<W\]9<QU^A3
MS84(;/WW_2]JU1:@4:[JA%ZKMSC)&JDU'#%*>S#JX\9P]Q?O92.\!\-Z,_Y[
M^ CV[OO=FK!-7I]-T$#2A,D TB"2$"5!!%/EN,,H8"+@'A=I:K1_>_K@N;%O
M)5N/$E=':-UVJ_MB,#*EN5'?W ?N"\-$KJXI'%:>["6=.QS6H\LG\TLO"=EV
M/R_^?FB-@[?K;;;]\5\9%^_7<I,_U2&<W\1Z)]XI\=Y^5Q2P)JO7NV*[>5)L
M\.K'YWS#%>5I&ORJ^#!CHA4336C ?:E 34)$(<(RA,2+ ^@AA@F*?10PJT26
MT22=&PL>Q8YE#^M,9HRLMZ#6 =2:6GJ=XQG:S F=A?E&)O!:":"_9M"H ?9Z
M /JC,6+EBS:Z3%1<823@1RJ]X%K:%RK,,!+HU\LVC#5@O_EEGSM9%^1]4_K'
MGT6>;?B2<B:Y1S&D7LPA\CT*T]"7,!'83S&5?D2M2C)V#38WEK_C/+.(H#?"
MTXR)7:$T,IDV8B[V%;I!)2FH1/W_V'O7YL9Q9&WPKR!B(_;MCA"F>0%OLY]<
MMS[>M[I<4>7N$R?Z@P)7FS,RZ2$E=WE^_0*\2)0L40 %4IPW=F*ZVZXBB<P'
MY(/,1"+3'D/J &*5Y'H'G)2G=%0_I!JM>X:QQ3M<IN6=D#ZU"J2JIU;I#X=)
M.#P(*:?4A]R)(XBP+SUCUY7F.V88,<=U$#?*<-8;=FX,4DE=%]'B9>N.F;&)
M)MYZO&(?Q9$99@O@3N0%:)*@1DV&,D/**O5H#CTI"9G!<4A'AG</[$S#B\J6
MJBH,XJ)SUH+%R&,,4JJJ-;B(PR3A/F38BW'D1*'+C)CHQ#ASHYZ.F/7QIOI
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M61<+D]B_;$\T)U<J_7(X,?NE2;H*62I+8@].J\EF%X@S:;+9Y; =)IM9>.*
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M@ G0H]W101V99FOY8:4 V&E01Z\752EOJMBUJ\P"*#V 5,1J'Y+A.-KN4C)
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M^=_X^C%GN]*\NP(PCO (#02&(4.JL0SV(7:\&(:!B)R("21B[1;OUU%A;LM
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M]"^Y>CA>U6VXEX(@P3VNNLZH4PTA=6"U)\K<V!,$$^0+8D+HIP::&T'OY%R
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M&S&&K -VTZ<H+G&H#L!;?4H@\@+\](#3K/SYEY74O4H]5J^1Y*<T RI$FE;
M#-AZL?TJ&.S;7&-FI]STV=.OC;76:4VJWN3!A._4!(JH@%*TFGFE:M4YLW/,
M_+XG'#YL^VBDR;"_]V1;T.DWKD:"^NBNUUAC#5M\.GMP2^JX/N$N@B*FTHW
M(8&8J2,J2819PAT?>62YSM=XI;=8=)YMY -L1QB/#N[5&,.WR+NHZ='K0"Q&
M9L7/&@ 8D]<15:UR3O?YDU+%$<4.O_!CEYA7F:]/(^ ?O/R*7U7YE[:A;<1P
MC*6+CSE)((H# 8GOJ4\5N6Y H\A'VF7B3XPQ-V>]7K<K.4$CJ&%+VSY ^[]=
M2S!-8MF,A9!^"7,+2$U4@WP08D:5P\]@T5/Z^]2=D]7N/B-ZM_CVN4O-B>]]
MGI7Y*F75CI$JT4WY]T?.U^4-*=>%R@N) R])2.C#F'N!M$P<#!/?8Q!31A,1
MR[_42YK4&FUN9-@5&#02@UKDO^M_ZN=!/D^+5J$;F2![4 -_MO(:4.5Y_/1)
MTRJ.$]%G#YYVV%,;E!X>/?^,R1A56YTNM^K?-,SO^Y1FZ9I_EBXHN]T62JGW
M+[NU$YH>"E_XC_7]7WSUPG_+L_5CN4RH'X8\P=!GA$E+E$4P=N0\R#^DTD(-
MW=#WS+*L+Q/(Y#.9)AE;OI&>F5-YX93H^:'3P3PRJ]>*P$H3L%.EWH-?5%UD
MJ"*HKE8+\#\<%^ N.QV6-?9V[0!JU4&^4*1)?6H[\!VZX9:>.E(-RO)4/;*Z
M&%E=?*R\S;[R(LW9?_/TX5&^R3>2M_ #__B#%S0M^=<BI7SIN#P0+B/0CQ&%
MB 8"8A]A&#A!XOG$%1$Q2F*?4/:Y&==-R;<%^*L1&N)::L ;L<&SDAL\2^>Q
MJE<)?DHSP/+5"A?E[D]/'Y"^^MNBMT3,]!T8>3W1*7!9GJEPV>C?U+*LJA'5
M&"Q BP)H8  M#J "8L*JE_9G;]HRF!;EGU==3/L38UPH<P01)J[CW AZMUF7
MJA%QFCW<J@2^K$SI'ZIZ^C(*HAB%D0H;!0E$7NC".(I"**CO!YX?4X:,>JJ-
M)NG<UL>.H O ,U95&FC8#3\\%%5FAJJZ6>M0%ZN?J)3SV5FWM/)-,9<S6.=T
ME[F]5V*K,?BC=^:GJ^.L.ROS*.-\5MIYK5:7@FZMB+/V@-=9B?[@I5HB,]9&
M).YS]4?-8JEV37I-=NR1P$E(#$7H(HB<F$"<!!$,B<^$QQR.@F#*Y>HR=>:V
MIG7$?K.FS<P-'/<UFV9]G.[E^0]:1&M0ZM3U-FBYSJL_7H"]%W0^/N0D\SRK
M9?E"E?ZCUFX[TV=[@;<DU76L "ES6I\GV'K/2R\A 7<9AR$-?(@8HY $!$//
M#9U !%'D1JY9!;L1I-0BW4E+W55"JCAMW3-HVF7VV#Q.LW8.G9O_O 6QH^DN
M@CJ?Q:UG(F:U8AV3\S]J&>H!VO;:TC>4V8)1%NM.[H9\X.V:/Y4W/])RF: 8
MQ=B)H1/A2+IRDNHQC4)('8?&Q&6">%I[=:>'F)M[M2<EJ,0$?RI!-;.M>L#L
M)UT[$$V6EZ:-CC;9G0>@CZODW1V>DK\=<E3/XR>AF//JM0RA<:5YFNKQ@Z(5
M;=R)]_7?5'&HEWSU4O'/C9#?6WOJ]../M3K]T]ZRY&[LAQ0QZ%%?&H(1$3")
M@P0R:1TZ$:'<H=HYK79%FQNAU%*I* W=JB)MA*TN "ME &NT60#>ZM.$=?2S
M/"W/<3]?77?F1N:YDX?WMY.YTP[<OIG,#]O)W*IXSB8<>S+U\WNO-ZD3)0-/
M/[E&J<3CX-^3=VQYP,F2E,<!JIO1/-((P^(YTDUXRK.J1F/E&)2W5>?A9>"@
M4(01A3%SY5*LFFX22B*(B>.'?B"\.(A,MEM.C#.W=;46LR[[V@96%H.Z,9\"
M5B](8@&NT8WV"JGO-5+?&Z1N^Y$RCE&<P<%JG.'46)/&"LXH?.COG[O<1OGH
MO=<W80&COB P#'$,41QC&"=>")GC)QPG$:/<J 7OZ:'F1@T'1:$O:M7> [ >
M/]B!;62*.*CNW+*$=9(X#\:(=9NO1Q7GU>ZOR6R!,"ISAM/JM*OGN''UW+8%
MCRH4U1R>#KTH3A#BT,?*F@BD-8%9$$$2NRRFQ(TX8=J._?GQYD8=K<A R=R4
M.F^EK@MFFI]3UX%=P]>V"^;8#O25<#1P<^WB.97O>CFN9LZH/DI]'J;&4Z9S
M&_55VO,%#6ZS7U3O:^U(WF1UV]>O>;DN^#HMZIVB7>W7<E>#Z1T7><%5-37"
MD8,=+X()%A0BEU&8^(X/8^2ZP@W\T NT:K",+>C<%H/W4OA??J)R%4[7/X."
M/^?%NBZ6U[0MVBO-5A?/^^6G56_'R6EG7L]$G<-\CKP>':NE]U.MY<] Z;D
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M.'(CZ?#X1H6(SXXX-\M";5@WO9,EN7!<K%[!+C%+15^8E-HLXG(>=D*I+XW
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M!EH]7K 'V.AQ0K(&.TD78"<KJ(6UF/JB!8K=#);^(:=-1-%2_TT^B=Y=EWJ
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M$HBY2*#/')>AV$/$,PJ"'3Q_;EQ]:Z6#? N>GA%X 20C,^P6C8]GT!A<*/-
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M$+F^!TE(L#I)P0(?)2+4:[G4/\S<6&Y/RCKZ7T=<#"V@$Z#J63^70S4RX0U
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M39)W%'.?8Y]!E[($HM"73G08^#"1+AJ/$QP&/-#==CPSUMQHIRMNE?"]$WA
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MRRN8ZR1QZ$/FQPE$% >JR$\(F1MX*)&SRXC6R:=!H\^-7SL*@+IV5D<%4.L
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MD-QZ/<,]7^?]ZMD<0>95=I$FT)HXZZ7AN^,LH3G+4BQ(',!$<091%J>04IY
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MT/<Q^BI*":*)7G'$D5Z'9RJ%5"$.0XH(B8(XI#*IT?^0BQMBWXP^+O(R%X/
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M]YH(OI9!YOO2&2C/H>_6ZI*0+ Y$"&D:!F97-(.4A"E42299Q"7G6<^02_?
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M$#%[,#)..6:9"#*G]JP]!9D:LX4P M^U:([9A[WM8+>&&P/=@=FR4F$&MDJ
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M#C'O'L/%YWY![WL!VACO@81%K$'L26/$W(X+R8U8 W58><3^4=TXLEP%VK,
M_EN^5&%C]A\I?EK,=5VWAJIO\HW(]M4R*]2O/JA_YK//I29;)?=Z1[]-"8\P
M"PB#?N )B*($P42D'$HOP,(3(A"AE=IJ;Y:.C6\W#H'[RB,P4RX5/[R9*Z]D
M\5;'^O299G/](D#E!2RH8H%B[6V'U?'^W@,SRAY%[_9,[#?OKR?EX6MPV^JJ
MJZV>O%4].0&M5Z!V>SNFK06XK\2_GJIC<J6JA_+6'?WWWB%.!XG^K!UT*.D=
M]-T!I_\&'5:B#.N\S1C'J<0L@IZNC8RBE$)&M8XW\P3RI"Z$9I0:8M+8V :'
MXY7_0I>5%$/C7&&7(/8=7 ^/GX-*E!UP'(.XB F>;BI1AL89RB<?<7%AD5UG
MC"I1[M[3;390D;_F>;U9K ^0+?)5EC])4><++O*B7*51#-^N[WRW^"(?==WG
M?/91W;!ZF;*$)23F"$8X4AP=ARKZ3\(0^A2)F/J)D*'1H0SGEHV-T-NN@,7:
ME[_^)5$O[C_J/^IU^I6NM$)WZFI_3M4PO=2Y:7_3.P#EH7U](%G/';1@G(X,
M::&W D2UQK\L= -VTP-W+X;9=. BW=WST+-5,;W*NMGJ_(UGU6*UZO"RM,YN
M(?7/JG./9 181_K.L78:V;NS;M!(WCFHNY&[^P8Z1.I/*_4F-O7A0^(Q'@8P
M$CZ!B*4^)%+X$!&.0Y*PP$?F@H"M!X^-L"O;N@2*;;0,@NJ.&/0=0#MQWR(F
M[@C#4/&O(1QV8>X>GX^%M.W+APM?]QBY%:KN^WW7LR,+_N>UBF%4Q-M:;"AU
M5XKRES>/)>%]_":7/"NDF 8L\@C!$G(1)A#I#!]"(P%]GWF"22*8\)OD'L.=
M/&LC.N3W],Q=:],F58QHNV-GWP^&&W;]8#L0(VHK(:.%KH"R>'B4>5&2SI:&
M-GL![>OJ/%QP]94NA3Z=5\=]C7]%66KL>)6;#F=,NJ+L^)B)M1D#GS3I"M/K
MPR:=G]21*/63RS>L_2*VWL-W+YM+ZG>P? 5U;9;52ZO(0;DP?'=/\]K"J]EL
M65+4=:YBR;S(>*E^];LL%&M-$XS3Q,<15/-\Q;8>\V""L(K]$I^)-$5(V.5T
M7\B/L86:O^79J@#/I6UJXM^8KK/&*]LK33Y+$K_0.V(X$HR_Y\<_G%18;)6@
MJ0[TK!0<F\%FC0A80U+)$$Y A8K#H>>RW>IV_+J0+\,.@I?ML%<CZ87-.?_X
MI][8_X6N]-;I2WGF=#Z791;V37I[OUBNU'CRL)&]+::,I#1(D@@*$@9Z.45"
M-6FAD. HP@'SN,>ME$+.L&5LP^+VR<6E%/*AZLL?=!Y,H1=."^T&U'ZHP7+M
M2/<#H[:]9S;8#=0G/0]8V]U1); TGI2[#QM?=-?<;KKFVJ!KSCI6VA'4WHZ8
MVMISL>.F'8$[=O2TZR/=YC7J!?-F67S*$HZC6,8PH*F6^>8$)GY*=(HB(XF,
MDEC@Z6JQHG,SCC5IU(I,UTWWF)2F;?[K7WSL_8-OB5UDI>E5TN';]5&AU9$<
ML^X=@;$7!6D40T\0 A&//4@81Y!+[!.FOJLHCESDBG;NB*'$#B[=$=RGGN<)
M"8,@P;HC(L@$(C#&TI.$)B'V\/19+MGB4EW1;KSGS@!'^J$'[,UB!M=X]AP<
M5$#NE=%IDEDW>]W]9Z_N0VF01-2MAD>14[H/"M/TT+WW=M2+H-FRG''](JG6
MJBX'_R\ZO4DOF#9[RY'@F*K93Q+Y:C*D"QM1*@+H>RC"41+1E%OIWILT.K;Q
M86V>Y=ZK%=!F'.0:OIXY2)O;+&Q9H&BO"F$!BUME").&AU6'L(#BE4*$S;UG
M[).\.[V<]&YW.:G\SQ?Y[Z>LR%;R5BZ?,RZK71U_RI#$ 6,(XC20E2(!2Q5?
M>2C$R"<RP+%5U:!>K!P;K96V@F5C+"@J:W5MH6.;GP-VJT>2.,:1A&I"Z$,4
MQ6H80B&"1 T[.!4DYJ%O%Q-?O&.'":+'W[46>U*7[*[Q[SA57;UV%=2^ND]A
MZ+,KW.\2.;=T^#V@OL#>N\/36V,=BW)EQ>.BH/,?EXNG1S7SF3_IHW![<VVK
MH]F_*F!5F*),F_IA2@C%:HX2<SUJ< FI5'^3-$JY1REE,;%96SS#EK$M.6XL
MJT7O]/1?F)R#J%83\MW[+:M\G=&K9@/&0'W5\[#0> %*-R9@[<B!8PN3M=K>
MQAV'E<+.Q]1M_; S[!FVJMCYP+VJ->;@D?:G#3[G\NEAP1><T_GOE/,LEY^I
MSC&^SE,],RQ'B:8F4,02BGT"!=?B$R*D4)$Q@9Z')*<RC=2/3 \C6+0[MLE5
MVW10VPXJXT';^@[I_#:]<9PU>\2X[YWO<<!K?IBB)Y@'.FMA"K>;0Q@=L#IR
M1L/F:8,=X>C@8ON$1Y?;[6G_XSS3L7W]KN,$$\E"#!/&"$32#R 5G@=#C)&4
M<<@3:DSL6T\>&W77QG6@CFW 3G-O9QAZ9E=7")C38V<D!B) 8T2LB&ZOUT>H
M;/OZP<AJKYEM.MI_P1DGSNH3]%4*Z:^+E=Q4U-TH$@KII23@ GJ<Z(IN00(3
MKA,H$/8CR7$@ JNM2>.61T=8I;$=#I09P6RX4ML'>'VOOK9L_C]-ZKXV>ZOZ
M=C\2C[9PN3\'9M3Z\,>_;$#9>^K+Z@'GRMMNS<>+XQ/RHLK@6-=!>D?5V\CE
M[;V4JZM<7 F1Z<OH?&-PL?D,$TI0H#<VI1>66YP8$L0)E(%B.TX9D51VD\<=
MS(>Q\>;MT\,#799:?W4U%C6[41'T8OE FYSI SHA7?5VAWM?#&E[W&_!H.NL
MQ>F%UJ%T?P?OC)YT@X?SXT*ZPX-WU&'=XN%-.3/M\-U+*\WH'2VRXNI;5DQC
MCS).? %%7)8?90B2E/@P3J7Z%14RMJO$=Z*]L0U*+1M!:23X0YO9->7P ,AF
MHX-#Z'IF<FO4NJ<8'L>BG^S" VU>)K'P.  '<PI/W-:-3*XX?WIXFFL!ET8G
M]U>YTI4L/LT77W^28B8KT;8FG=E'@O  P3A)]7$73B'C(8(^"TC(2!B)T$HN
MP;+]L9'-![G,GM6(\"RW(N#-X?5N"<^VO6+&1CUBW3,[M2S?5A-7]D^JNCC:
M!5#Z,*EE!GM(D^Z(H%-.L[5A4([K"- NYW5]C/.ZGU</6F_P/V7,]_&;SNV2
MNJ;\)W7M5,@ ,TI"B/T 0\0P@U12!N.0LC@4U&.2V"77=C/$YCL=)GM6O;G8
M6=G/8UU@&(7U#FO/]'>TE(Y6WGJ47%-CVYL)T(X [<D@Q4,-D!RJI.@Q4\92
M:-0 +HORHR9/L^-&(;/IE9K_JO?A4[9\N!;3(&;<YR*"B8<\B$0<0)8B#.,(
M$>GQ( Z9T1&15T\>6TQ7&P>T=>#Z@QF1O<;K.#>=A4+?T98A ,;T<=#9/8Q0
M2/ZWV>+Y!W5/20;_1OJOL/IKR0"OGS;(1WW0B>8[/7Q!A\R1<O/E%[FZ7XB-
MLL1FO7T]V6BMMF^M03$U!:%\-<6^'_EI+*'49U 1QP(F(4^@GR#$!&98)K%Q
MTHDCH\;VP=<;EY5C+667"3BUP3$!M7^@=!#\T;AHD_'AJJN/$\ZE.K!GKOK_
MI.\L$GTNT(=#Y0@-V9=V>4:.03^6HN2JJ>&RFQR#LY48Y?K9W58(ZL6'S\O%
M<R:D>/?R6Z&#\,JB+)]=\57V7!86FPI?Q@%*U("+DA@B$B%(0LEABD3 TR".
M EU+P/SPE'G35L/J$&>EU(=8EF=_K&T'[.6'-T_Z"&:6OZW%[?16,5V[8+=H
M8-$K9@L%_6#=\PBH82Y70#]O8 9O?FM@7AL/KD[#;+T@8(^8TT4 B^8'G?C;
MP[([V>_PA(X'166:Y:H!F:N_K#ZK5^O]O3ZW>IW7/[IA\VQ6$NN7Q7S^:;'4
MAU:G:>R))"$2\ICX$,G4ATF"$RA2R@,62<)BJQ*YW<P8VTRBLED+X+/*:K!8
MFVUYTK-;MYCQ7/]@]\QYM0.@-A=H%R9@@W[S\XT?X _M":A=<;@E=!Z6;L]U
M=C-EV".=9\'UZC3G>4_K*(VLUUH7^=5JO3.__LLFVZ?>F$UXZK%$8!B((("(
MJWYC*?<@1PE'(<-$ID;++QW:'ALWUJ8#N@(;52O0SCOIME=NTQUF]-@3R#US
MH@-\[06+[9%R*U!LT?ZP@L3VP+P2(.[PB,ZE4Y?J-9$?9/7G=5[G.>:S]_0Q
M4S/%]3H5B8B?IHF @GHA1#BFD'A8P##F4<HPBY'G6=9&-6QZ;'16RZR6PTU9
M\JC6 ]&JX?.,LFQ>1N=KT5O**YF7,@E:7R2R,I1?Z=30OUN7-#7M,#/&ZZ<;
M>B:\QFCPIC%;+RJ M>6@-MWI:F!WQ%R7%C5M?NC:H9:P["D.:ON$;JRW?VGQ
MMUP]8?ZB2XS6Y3?43+S:9)]RSP_"-/"@%^HRH2J&@RP2!!(:I@GR(I'BU(;\
MK"T8&P=N3 6R6KM7WY_FNR[:1O;]8<9MO:)\L=VM%O0?U]#KI<"KX]!;$UUG
M^)SRG;T5@])>9Y!VV:_[@[J1X$]R+NX636V+6ZU46RV81P+3.%&!GB2QXKI(
M<IC$40@9X3Q,$D1B)&VV,0XU-+9-"VTG7"W@0U,%IEB;.@&T2K,JJ]$7A[5:
M[) V8S$7^/6^*,=6X+8%5X-E8_6D25 LQ3H+Q6),IHNE!%?S^>)KN7VK_@G>
M+Z7(5D G_;JCL5/X.66K@XT-2DJG7-[EGI/7#RQ8?;+^657H[#JO%#/_*;/9
MO?KWU;,*%V?R1_7\U0>ZVLR:I](+14A2I.*WQ(,H02EDGJ*XR/=D*CE+*6(#
MJ2&[]LV&!H;) ?^]+OWYM38=TLIV,-/&0Z%K-Z9ZG:JL ZJ%E:NZSN"-"F3$
M8CZGRV+S4\NB):/IE[YEFB_Y'O4\G Q73+3":%.V>@(:G$ -%"B1 AJJUN+J
M"+2A^^K_<>A)._?N^]"@[JM3G>E6]V:@ ZWK7Q>KO2?V=P[LM\[EK]=*(Y%$
M:F+CP43@"")$$&2!AR%*_50DTD?43B'&D5UC6_6I:V"M36Z)/9TC9WU&QQEF
M/0S?'7W/N*QEKH_U72_KY(Y![T\'^PS;+J>)?3Z@1_6Q'3R^&Z._G].BN$E+
M.;(/BP>:Y5/!&.9"*DKV_!0BXE%((N;!"'LT#;T(L]2JJ/3K)L;&LZ6%9=EA
M;2/XH[+2,CMB#Y)F;'D>/CT3GRTTUK1UV'NG#+2GF4')Y+";N[QPY$K[TVVW
M,L\6R]_R<FU5"KUP^.%)ZE/C=9Y.2&/!(HFACX6*ORB2,,&4PH"GOB^X[PEN
M5%37I+&Q??:5O6!M,- 63X"R&6BC.V@*GX3[.".X!K'O=8/A\3,_O>42QX%.
M99W T\T!*U-<CAR<.OF(P0Y$F3K3/NAD?$_'G-5J]E[<+:YT'I*:TS\562Z+
M0A8JTBN*:8P"[(?8ARA)U=PWQBK08AZ")&9I$(0)H=*S6QL_U>3XEJP;B\%J
M4:5K+25@:Z,G]6&F*BW/,D?U%/QF,9E+2'MFX3:6M;'@70O+TEZ'B:B&R+C-
M/CW5Z+ IIX80O,HS-;VO&_-\D7J5D.M-Q7RF_B&7S_**<SG7<TE-=(]+R;-J
MY,0XC4C(8\AEI!?@:*I(B$60!\P+>8"HQZVJT%JT/;8H<*,@"D3+3 "KW"JP
M;+LV <_9<O5$Y_,7H/ZC)T9?[S-^#[)"7<AU=Y7;&WK37?]2S>]ME^ILNM&,
MS'KJG)YY;<OJ,H_WBZQTZ:J,AI8'H.V".ZKK@)M3UK-I?U "[ #,+A=V>40W
M6BQW3/2VRU+>R[S(GF6UJ*:S7K9T[AK]NR^2ZREXEF:\;/^.?IMZ5/ TT14[
MXL"#B"N^)'&*(1-1PH4?$>XETUS.M.UFC.G"+*.OE51?:]NX/C_:;2,!%?]Z
MJE+KBC+EZ,U,N5.\_6&^T,.>HDJ]CEYQIDYGS4H,[ C320>;,>E@G38,Q59;
M]%O^-/L6C>SG*\7/+5'07?<F0#GHCH!=PNV4F9T8-BAENX1RE\N=/KL;R?^L
MXNB;M,IG_$2Y/A+T\@O]ECT\/;Q;+)>+K]6A!O6;U<LTB)#T L1A3)-03<,C
M IE,!$S\5& <!20DV";XM6E\;-&OMET'JKQ*!4UK\R?@H7( L,8#-2FO7+!C
M9ZN>,6/AOO#NF6T;J.NLVT]KJ&O;P=IX\/X4U-94V@4SIY1I9<"@U-@%FET*
M[/2,;E3WXV(AOF;E$7N9S?+W9<ED_G*WI'DQ+^FTH=EI*GQ!B I311JIJ%6?
MH$IBX4.*.(F\D$8,696=,V]Z;#17#E%VQ&6!LQEM]8->SZ35&#T!M=F@L1NT
M#&]'A>XXRQXPIXQET?R@?&4/RRY;=7A"QQ,)<J:G?E]DN9:?SUK:<9HQKU?R
M0;&43UB"/16.!5)"Q#C7<^L >A&*8^;'04"-MJ!M&AT;/]4V@[716\7=_BA#
MA])PRZ04HPXPHR_7L/:^.7TVHO;)Y180N<W[-FEXV)1L"RA>94O;W&M'3,5R
M-;WYFJLO^CY[K+.TO$!X) JX"HN\"**4A) )1*'D<2P0\JB:)IKPSYYGCXUF
MUN99YKCM@^TX:YP)1M\+7^8X&)/ $8^/?>OJMM9WKOZU^XWO>^X@G_(1AYHO
M]M@E]LEJ6WL"[^_I<B8+7>)OH^=2[P#I#:!B2E(624H#2!(<0H2"2,4-,8*<
M4^D''HFE;U1]S[[IL7W6VUMEO#*_W#+C<KG2H7E+$P<NZVTT?;+:<&^R0^]$
MBE-QB#!D-$A55,<$)&K>"04*8BY]P3PL3(ZU]]P[ QQT'V/O'"?O?C$?=-^X
MMAPHTT'+]JV]Y/Y@-D]7[ _N@9(7[^ZS LAY==9EJ;=OBW+3[TWV=CN%HOD"
M)G7FA#Z)3!\63_KBZE<"T'*7< 4D7>;JEE+U:W5?GEW.%J+<2,QRKJ>MHOR0
MM+S7P^:ST9D;"[U[K'[P-5O= _E-KVVKD4V-14 T9WD6Z3KIK*6,K2_9,K@
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M9P6+ T3;!#3>3M-L3D9N)9350<'+V?ET.?_^<I9Q) W9-U:C>AM=13J'P'0
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M,2Q@'2?74%DRLBP),K=<IX+")/U8LYH#IM)L1=_ 4P3Z@%@/BFD ;A](,T3
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M!\?'0Y%;C/KB)28#J7:Q4R&0]YE,A.)CEI)< 7.4Q/(.) ][@>I8$.U+APV
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M5%ZB2IILLD(!J@0#*OH"+A*T1-;::64D5_U<8]V&ND,MTGKFZR6O/!JF3=#
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M<[!BXB8'V0H=C*8U*W5MV,0UA-6(>1Y*1!E39CV>_NR.D]Z.M[OV0O87<P-
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M]3Z?3ZFD?D;I[4;GP!>8CI0J[4US#>#RGLZ9=SL#WL\I<:GJ.%B0N=Y59_7
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MV:+&\$)6+D2O*(1,+-%:B+03NUKXJG0NR?(L>>[I=NVV) Y[]M[=YM6+2AK
MVOU%-1M>LLG"<E[ :,Y!R1# *4=[-&9BQZ>8>BK<>XRJ89WI[F/TSC30 )HN
M$U[OR J_I6\7(Z%U,10O0K 40RK,9'L9K3I:B*AX"%&K?O(Z=VEIY"9VAVGD
M_<3< %#(9%;7#E_A^M^WT[N'-1]H1;R9S?\,\SQRLF!,7$*Q%%XJ;2TM,*?
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MRZP4*?>3+]J>QF&/-)LUNSNIK@$3^P!GZW8#]PNRH',Z90E)N3KUK&0(7D=
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M>YY'O]U L&/-[8Y%O\;B%#_79W:"QFL\K K7:VWE'$]K-?M77/=9>#=;+/[
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MK+Y]2V[8-%S\E-+\JLX/.5L5Y'^]P"7^E/]YM4X^NQVYVIQ%,9;8M\AKE;P
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M#<O%=-NQUUMKHLT**'S)M2U^/9'6"J+VV@4M931=NB;?>6@#RMU'+?,^9-3
M:<)S[<5=B9()FR#F1#NV4?5@A%@QCH?,0M*J#%-R<6C;_P'GKK:[W?2MT7;!
MN5FO*1B71$V+Q(2@=*2E2G88#*8L/2^,RV'.4D]T6L!.RM]I6L NFF@ 5JLJ
MB3_GL_EZU6WN7W%3C[2QXQB=US+29J^RKW:<@S<Y0\JL1"4LL39,_-F%NB9!
MM@\8Y@-K9D2T99Q.WN%9N/B5C/SR^VH)9JF5TBR!P)) E90@"(E09"I6FB!=
M9,^ ZA+3W\[FW_Z#'KW"TW^K^A'6'U<@>N2E8X^3;G?'/%1#(X-K3?5FU:%
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M4O 1TG*BD9PEJ2QH)SDH&PT%%)$\J:Q$%M)X+U0'\ST.]>UW25FWU=!D'9E
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M&C<P.Q6$#Z?J'[.P[<D?K*NM&JQM>XGB$RAOVTGHIUOAQKQU2;H"2>=5?;N
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MS4<R]OO+;V37\:79#0^_1;QVE+@OA&&R9+41/BBTF3SO$D"C,5*I[./]S>$
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MF^M6=+]@(0GEGW%&'Y:U,]J?N/R B^D\3]/FVW4.LDKH4H@03#W$<]% X$E
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M[%68LH^"D;<+#57*=+9PVP#':J/AFH/%Y@RQB/XH"^CMHGTO)8 ./,-H*]/
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M5P^[T_7ZW+4_N^5ENU @"<:)8*#*8%>Q7H[C,'#69:. 1!M%^\SM?NI[&H#
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MD>:^&Q9]JZE%Y14,_X,]; 6IA>1909EUCFP%#;9(,'N&A'-I4ZKC./0B;]P
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M]WR/ *_CU= BF'Z;HU<P"0E/@76Q;%5#P7CMP6:O(3.K'0\D*7VA%YT5/?W
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MIC R2-8([AG5E%\N6_.VL7[Q00/MX?30 *@.9=S+,#RBD@%TW_"L,>_ ,$%
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M5LX*ZFEBTD,IZ4-7FSE )XJ#9LYH:0EWBE_(CNZG<.1LP&B6<@!]-8K$D^X
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MG[^X9=HY/X%2;ATM]4:6HA0SGA\\.2!#EA@]QW*BJD#N'*K'R8!41>3%E-@
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M#:+\OL?SD,^)CR3I3!@0K]",X#V'=U!F:%44E]3R)%.=L.I82L=- EP41D]
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M[[CY(1M9NB1 !&Y F#*N1<K2P\>-8\QB-#'N'+!60[6+F] 3E=9 DOA0>'!
MA$)9Z5-A+/!<BHL2BA QQ*QG21#%.*FSU.<X.L?KRVPB*JNHU ;LYR'N)E2G
M2'C$6S@@@$3$4V=)X!"](S%Z$C*KDS0X1-&X<51-%/0$W%$J:=@:WLD=E[1Q
MZ+[,2OKO;]U5G,Z^E">3"0]1:R)-N5S*XIB@P-#,029&DA62H@ O"KZG:1XW
M FH G@.KM6';^#BGY0$$+QSN"#<$9' !1)DV[\I4TU(Y)W66UL3+7NU/TSQN
M>-0\@(]6:SO/68<8OA/T"48=LQHBRQKYHA*\5Q(D3SP)YZESE[WLCPO:JT5%
M#:#R-"4U;#WOR^YV=\A6B$8H&E06("RU(/!D@>$A Y%9<>V8-[9.,O1$@L<;
M/O*,PJ/SU/QLT'S@88.HF#EE$H11"81C#BQ%QST;+26AUN?=$6X7A72+[U87
M@=5)4!Y Q\\&ST^_861/H_8Y0: 4+R43)!AE%5AMA=4.#0J_;*3VK!ZNVD7Y
ML)H?^?6JL+SLOO5A^>&#B,B4,R$4R%(5)"2BT2JA(<C,G:0B2OG4U*%S:7@.
MH=DP(+VHMD9&Y=,E\J5&/G@*D40\88)BM!D<!VI95#0QK:+N@;Q!FA:J3$H;
MU8$=7 4CC]P[IB9]$JC$4R(2$'12RL.:!,>X@*2#LHYG:4B?M7/'?&<OF*G_
M!I@-IYJV+-BC->$3:HRW@G'@1(I2[5*&O0M;^G^H<-9Z9TZP9H]^9R_(Z?]J
MR!VMFG;2FCLL[LCY@70GT5,1N%;@8R[CO[4&KY(#P=$M0'LN2:6=24<2V@NU
MYB^'VDNHM2E[>>O+ODM_+C__.UW]2+]WL^77NSE?*JPL607.;03AN ,OB,5?
MBFRM-!AL'6\T>WQQ+PS:OQP&ZRNI40260.KSO[L[T?Z=,E4BU:K2*SJ'(559
MI.VT(9 9T<EDQK4YWE?L]=7]4I#DOPJ&0VFJ42 >".M5$B;$,CXDE^RJEFCN
MF;1E* W1W&@ON3H#@V>D7>A?;RQ%9?T\RP'D]X.TA9NM/.>T^)A67O6RV]W"
M5FU&^<F4U!]C/HR0:D\Z=YEFH:D )F,9P6\\6,$]1*:$=$$PM_O ?+%)YUL?
M>-^B[B+25;2F; CA_V/O39?;.I9TT2?*<VH>?LJRO=L1VI+#LD]'WS^,&K(D
M=%. &B!MJY_^9H&D")$@N1:P"JN@W3NZ98U #E]E96;E0+1#3$C16AVOY(WE
M]$NODR@E>MEFC-]S5'4ZSWR,KH=L2S]("4>'S!.O OJ6I=]VCNQ-D9/FJ7@F
M@255%\)S 0$IOM(QI,R"U11OG0Q?#ZGK="WLU#@[2BG]I&CVL?;M)7&3?TI9
M>K,=$V<*^0STL^"$!VN45$IKZWB;\K-A]'6ZF&IJS!VIF*E1U[5W]_-J=;5<
M7?7DYCTBJ4-_[WFQM7;\1 K*9VY!L]I2INLV4"T4F!BY\-:G(OE,CE_]W(?"
MJH5&J^LKN@KRXO(+20S7G^BK:RAX%W?]\NDS_;124 5/ >&/J[^6?X5U_G6]
M2/@J_^?UC:9>WV3_*61[]6EU71>CHLNB;,?#UGB-A0BQFA(*XIB*4A?$(3[P
M"4GNU,$<@ZG=^+I797=0FG: :/[X/$0..JKJJ),CP*RDVPP=Q)@T6"V=%S:S
M(M1)W(RI..K4&3[D3'2E_//)4+W_N%I?U3V1/ZS6Z]5?B^6'B3V29[Z@D7\Q
ME*7F:2(I+::H@(L403E-5E,K#@:1>\Y(Z7SN--%]EOBKT&K>]F;V-H]),LD3
M^!AMM?H%8B+ *V;I#&)";]KT43Q'5:>W^!A=/[18DRFA@ZNW$OY@IY7G-L<2
M#.B 1+<4%ER@>!,9)L>\-CZVF;KUF)9Y.Q*FT_.>@H<CA-X=;-Z&3WB[E()Y
M6U-5$3**!,I;A!!E ">2([>@1"M. 9Y[BN:%T+&:?A8X!XI]YG?@U_1UBZN?
M0UI<DM_WT]^?%VNZ\4FK^G8)B0O..(T9M%>N]HPCN%(WAW$3/==2B8?S@_=>
MPR]]3T_ .%23JT9B[<#"?,O/]N18M!37$O%>;P<0*0V^A  VTOD)4F=D;9+&
MCVF9MXFHV<5TI-"[@\WMF7(\H@@V09%U\T MUR)1!-"F:!X*H@R-UJ#MH69>
MNW.LAI\%S 'B[@ R%+[22;KAY-96HC#<.%$ L;Z"""? JR* :\%M4EKBP^F%
M$P'F,2T]P>40_:XF%78'</G6Y-(_VAXBHW4VC#E(!CFH2"<ID##HVHX:>=#>
M9VR"F+WDS-L^V.QZ.E[T/>+G[E2)$FK*$EC(#!0:!MX+!U8+1GZ?9<ZVN:2>
M(&CFV/MX5;\$G@/DW@%\7J\^?<)U36O]&C[C^M:&4MAHI2;27<)4U\MD\,$S
M* 6ULT:YX-NLI=A+3F?0.431CW:U'BOU#J#SC6#>?"T8MJKPPKB%[#4=*L[(
M_\O6$!>U;3N$G%*;+JG]],P[_^DT=]=APN\ 0@_.P850&'A4"!YKM[2MB[(5
M&>3,<V L!(8/6SS;V)V.+,Z!NGW>X(P2],P)OC>KY8>K6V&\OEY7 =YW$_ST
M=[J\KM/UWN+5_0")KX^X=X5$OZ_^#?,'^FNOEOG7ZW7Z&#;X*J7ZKDN_69L/
MBN!DNY6OTMAN+&9! 9?!QJ14EGE(<TA[2F?.$TV'RPX5V\5JIG=7'W&]YP'[
M0CF%W'@)@8<(*M7\2J)P.0L76384V>HVM^I3%,T<$TYO(B<1_=Q;S"OY=V=J
MVZA_P30RH;93ENH\FQ S1"PD%U3D808I%&,#;-OC3Y[9L9K6%ATIN Z&97_[
M O3',MS-HOEQL=G:PU_7^&EQ_:F6_=6_NME<AV7".JEF0S;V0DJRB'6+7=2)
MV)44AH1B,PBT.AJIF,YM<I1'$C[/\*&&=NB4BNRGT6/'";A@T7IGLP84=4AR
M4!19NT3!D9'6&96"96W*+'>(F&?84&-8'2+@#DS;-]+X=UQ\^$C0>T5N5_B
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MMTA>(YE6+/2#E> 4>L#L14#+?7IH;YI$CSVW"(S1[/,QX7B1]^!1[61[OS[
MRRR+P! !F:YM$Q2UANS)'$IO@E8E*VQ3YK*/FIXJ> ]0\4/WZ%AY=XB9VY=W
MY5EF63M *4@LV5H(!NF74;@H1"S2M#$V^^F9%S?'Z_D%X!P@] Z@\\=R4UM
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M:7MH\G^,Z#N T)!,<RI"%R8R&,L,';0@P#E&ITT7FT5A7F.K,/A<D_^C4'!
M\G^,2CI V;Y,M'<AVYPR((6#=.9XAB E!PP\LU1\QM2FH.M\DO_'H.A8D7>
MFO&^Q-:L<Q,"+\5!*2:"XCZ!(Y^@#L=FV4IF'&\S$NHP>GO)[77MKYT "AT
M?@\;MY; <*ND\ 5RY@44RUB[(PLDBT:PR#-*V=*A>TS2N849X_&PW^,[4CD=
MH.QUV'S\^7+UURU#=XL$DA"&!Z*Z:/(H5"V""=)"M%(PI5A4LLT;V5YRNG#K
MCE7U:FJY=P">MWCUR_)/W%S5$_<M)[58TPLT(+'*1@H+KNX\-4J@]TZ6D-K<
MNT_3U(5?-S&,)M) !UAZMG]!NLP-<X9,-6E<!>(EB$#J9R9JJ[@SOO6;_8%]
M0R=X4SL[7^T@M78%T3UUZT)HS-Q;L+[69HEDP <M0"=?'"-X^=C&*3O3EJ11
MNA_3DC1&$1V ZOD^&'16H^,(NB!)R14Z=9Y[8LMC0!&R5&TV9)]K2](H[8]J
M21JCBB[J4I[IAD&9-6>B@"B*>"DZ@<]10R@\IB3J0-TV]^E9MB0=@ZF)E##S
M/(?;D_'ZFKYWF;Z\_[A:7]7I2C^LUNO57^1GW#6K%RNU=,I#E$Z#LIF<3BP2
M8N(ZJ%28XX-J'@9^7R\NV$2@:2;JON!3%TK_?KM0^NXLE.2K+PD6)06^ND2(
MOA2(,6KF=:EKQ,;CYO$7]5*BW0XP1PJW X_HB2AEZS5Z[5,LG(-7L4XX%1%<
M%B0IGC"E8+-O5%7Y#%&]8*KK.' JI?:+S]MC[+D6*60-=?\=N8FID%F6!5!1
M3!.L5K)1XNM9LN;UV"=3_C!0':")#F#U[NHCKM^NEJO/6)<4U'?^RMU/?W_&
MY09O33DO/''G.5T2=7)E=)RN?Q0@8E$Z1F8-:V/_AE#7)<@. <.JL69F=L>V
M_-SP\"/FZ[2]&%XM\^O5YNI=V9T]Y;ET'NE()M2Q-APZ.I=Y6UYB)<\Q"B<'
MN&6#OW#>('!Z!+63=@<&ZUG/X\W71@\65&;!D-<@T($B5Y1"%!. ,XR<I>S3
M"9=!/*9O[LU<9^&]-5!U!P!^O4WS_;+\8[G&<+GX'\QW++U;?IT2_*CH;L,O
MDK0\&6Y <+>=)$UG-%D#C*D092Q&^#:#;0^EN)>$[73H>?B<?@I5=@[9^PF4
MOWS+,_(+QD).7K,J6[I:(O?@#;<@DY.%+C"38YOZR@,)[B4;/ M@IU)D!WC=
M*\FWJZMGRYJ_BOHM7ET8Z]%(G\ FXEHEIB&*8L %EQ(*%Q2>L(!S#.F])*>;
M8?BTRNT*S?>'=6?> 3'$E(_2ZMIT7$(=,X?@ZB.WYZJ(DK5EN?5NCR=(ZSA+
M.34:IU!.!VC;!HZO5Y_H^S_B<K.57?7\*VN[Y8-?^?T!RVJ-OV&Z#)O-HBQN
MLVS+_'OX^P*SE2J;6N.J8AU'+<''.B9*J!)LRB+&-N.5)F6CXVAM&A3/I_0N
M:A:>8_]>^C_]G2ZO,^;Z%U=+K&O.$[E1&_P1;_Y[(Y17^3^O;RHC-[?RX"6A
MLS*"+:J RIZ\?<LY<"$-9N535.;DA^!XON9>_#SKJ3@Q+#J_&!X5! \S%,X[
M6>>" ?<F@T*.M1<B@4'M6 X84Z/JQ>EY&708['=Z&$Z@_AX>+Y[B?O6MQ_>$
M*.)>480;43#-L@P4B'"D>U-A(,U0, +>Q2!3<K:4P4\>[<@<!')WAB#O3<7G
M@O9ZE>W\:OOO!@G#.Y]$D QB-!2"*U*72[4BFR?,PL9,P=*4>#^4T$&(]]\[
MXD^BYC/%_" Y6)N3"Z2<$H0D[CD#)XVO!7$D#I.5LKHAW"=#.F?_8E"?7+N=
M._)[@_V';-\X=3=WFF>*\0PB(84P2M1QBMF#3-XSABY&WJ919#H>AN'^G%\I
M9])WYT@?$<#OA.[WHDCDKSEI)9A8Y]LQ%2#J+$#GDHPU]&.C<0@-F1IV%L[Y
M ;071'1^.)X.<9ZV#<8P%@O+$ 59!,5]H0M0TU48).;HHS,YG_Q ',#(L$-P
MSB^H<VK^7+S\0^3@1)*)L[KO,):Z,[6NUE8,##,A6!>49D.62K>D<1BXS_%!
MMBOMG@O*GPOLGY:$C)ZXMQG02I)$H: GJJ3!RL24BY)GQAM&L\.H'(;T<WRT
M[4S#9XKUEX7 E0B!:PFNU.<)'TD(=)G5[9!<\I04RY/FY,<2. SAY_@ VX]>
M)P-WA_L:?EZMKI:KJ_D7-SPBI)L-#L^+J/4J!X'HA/,>4"N"IV0%O& *1([*
ME!AD+D.RQJ=9Y7#3[I&84PY]!E$BUHV %EP,'$JTJ*V*'EGK>40]+T48H]&G
M*PW'B[J#=,,3 ] YXXZ$0BI-3A$7QD"TY%4'5SO;9.3&M1GLW??F@@-4/&R]
MP!AY=XF:KPN[*>KRU9G0+%</M;H5]6!9CL9(E^B"/Q%N>NAUGT+;0]<+C!%]
M!Q :,LN^8&6(1"2#(CDQ(\!SQ@!32<4J%,FVZA8]U_4"HU!PP'J!,2KI &5U
M ,[5[0"<.E[G9KM'$L[%$B&7Y.L(G )1:%L;_AC+P;K(VA3^[J.FE^:VXZ^V
MHV7=(5[NIO(:\@!-]&"+J-/9LH0@-4%?*R6T"UHV>E7<3\^\MN=X/;\ G .$
MW@%T_EAN,%W3]^X,VU*JCNV6""Q+LL8I^+J^5()((A9)/\72I@-L#S%]@>80
M':^F%7@'F'EV**[(1N@D'83LZH+WPB$6+L&F%+TV/+G0YIHZASG7QU]7D\F^
M*QSMF27(4DI!V  9/1ED;S,$K@(D1<P$JYP1;094G.DPZE&Z'S.,>HPB.@#5
M\Q.05<K6,&T@U:7<*G &T0<#3 GCI5 F>&R"JG,=1CU*^Z.&48]115_#7W=N
M;I,LD@PB>(,!R*J3*0_UJ9.9NL>;E\@/&/HZTOV99Z3T(<B83I@=6)JOXZO>
MW0W5NW_K>8\?ZI_<K E0DGDF&11)]EAY<O%"4'3[BY2D*5IC;F-S!A+8RUB%
MXYVC%AKI 6@WI.]AZO8H\J"5S]* V>Y!U$)!M(8@$8A/*U/4C:HE7Z)LWHNM
M"1P>0FY*W?2#M1\7FT0F?[&\QGS+VVKY=6R[D]RRH D02$<T*D-.)];6<\9S
M73F7&X5X XB;&7&3HF$_U"9330=HNS?^;[[6^(BHLF),0PH!:S*$04@>(3.5
M+8M1(+:9#[R'F%YFM4R9-SA,TAV 9<+6H^R#"-%:"+8N*K!D['T2%DQ0@D>6
MK2IMGNA.W6K6'IH'PJE=6]D8W78Q,.A!0+27W=]7/^PTC&+^\7I-U\M;_/N*
MBW_2;?!Q<Z&9L$5D!]+77; F2)) 5,"EUE$XP7*CO1+3T-]+I#L-GF?0Z7@L
M^QLL+_%#?3W_O<&M_AM6KZ<N] Q7Q-W5%W[!+=)UQ0+87#T@Q+HJM!A()7''
M0N:^J,;7^V.J>GD?F 9\D\F_@TN_IH=N3M'5A>3,D/OL@63CZOHZLO$.#7@L
MI6X=9H:G1M#Y2D0OR9*ID'*8=#L QNZ2J O)3,I*"+KI*?91VA8((G)P/&51
MO''>M;G[=JGH)5B8!AH'R_=\NAQ>7W^ZOMR*[(>P66QV^K#)E_QV:O7$;0V'
M?'.C/H:CA="Z<:%DS= Z 6R[]"'S6F?A(Y2Z73)%%%+D%U1PZL8%(Y4M07/(
M0:5:SI@AUII#X6W-\0@ZDZUW???<N#!&HR\U+HP1=0>WU@_ADN2"[S\B?KM#
MS/*D(]*=ZUEQ=?=2C5K)YT]&)0H!&)*WWP0R3U'42W[A #6O&LB\4^S<II53
M0%.TT!#J,EZEG08O,0/=VXXIITCW;3SCIVF:%S_3Z'P D Y00 =0VK=A54CG
MK'7D*VX%4R0$+16D[%Q,.O'P<(AB Q>ZAS><J;3\C#]]@,@[ ,V^"*-XK4.)
M#GCA&90AS\M)+4G'+EB7N?6QK\>:D_4D''-C'2OI#L!RLP#HS2+$Q>7BZLNW
M@<2%"R&65,CO(])!.9_ *6.!L:"9T-(:W6:3P[-D]>+R'*CT/2UWTVB@=SC=
MA[ /1ZM=9+++GEE+][N+9+&5(A.+!;A"$U3M"L,V,R4/)+@7&W8""$ZDM?[
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MXF+0!+-!!F0?!?,VB75T:1VMGC[@M4W!W7!P-R<X<(].\T+T*TX2"10:<^Y
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MYBV];XVEJ;31 ;!^OEXO%U?7:R16?E[\77]V5X$KC;9UT"7D4/M0D,(,5U
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MA!B$MY!TD(;)K,A5;@+&[VK\QRA0C!S_,49#'0!N4'%=B$H5&R2(4/>?2RW
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M=&#ESSX"/1BGG_)B.D]O5[A8-4+KJ[BZQJLW>76]F/UQI^3NZ_-W04576PA
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M+JJ':>X3]VX]<_BS;]<Z2HFZADH/NM3$RNS2 CL1A6D9LZ%@I2;16!TD[+D
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M#N6$[W2^G4#ES@!4#<0QM-/>-#GYR_7J>I&W325OUJFY&\TJ\\6#82R;3-T
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M*0F4R8))CG98R+ ,NF@PF15OLZ@5^,_Q"MN#UBF%R8]&Y#.);%HJ;[N!KOQ
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M^_FT.?T&HU%"D2<=R5 A8\*3H1$4<!($2Y@D_851,/P\^VL\07WX:WV"L)C
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M/8/@Y+8F&UHD)Z^O-H]7A\20GOZ-Y]5=]VUL; W&N217&#.XG!DHSNKD=%;
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M@:@3H_WP8@H769BQ1O$]3EGC-X_VIOWA<IHD[O:[V9U0%BQC-A.?L([P<BY
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M",D^"I0#V#P!F^1.;ME.;R87'&X>V'TH=1H5;<-[#2+;XESQF<M>:'FR=?(
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M=;]]"HO?/BV[BX^?]@T,7G7GD91ZY>D?R]EZC8NWI9PYJ3UJ@Y"5)RV>6(2
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MZ0PJ.H3@>>1@F+0H:)\,GTE9O7E25LMHG9^>X]X[C/U3!-([7-;?"!^1G_'
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M:RM+7PT<A,(#CZD4$5FO9G^]JF7NHV J!?>M0U"#2&@:"+O.D'WW#*53+M*
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M:L5^@CZ1Z-R!C&H=F2-#-/QK_QZD= DV)1!T^X"*#B$J29:I#%X7(ZR6JH>
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M0QQB//0?EQH#I?0-K_97:?,=$W>H0]>+(H<N9OYD"4""GDY95\'_6NT,N"D
MAP/HCN%#@#7K\4Q:1X-+E53' Y2G 4T'JKJ,GI)1#P<V.NHO=PZWL6P$VBQX
MB01M(@$H"59K>.!0@"R#F@'?G&U0&)&3F8A,!NL3=]DX,$$"9"#Z;@-+^%$"
M%ASD0S[UYX/:2*_9-;(+0-&NL2Y\)L+,N#80$THFP''@5*@%,OB"Y][O:XQ
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M025 >>Z-IDB'FLE208ZY17;F(,>=YP<J*G+KKO8XT(631 T4"8;"]<6Y>>,
M:YD?6)Y [HM6J"/-\O &_8A?R]QZ$2(T*9*FY[C0KZ0JYNSH>PMJ[-=:-!W#
MIZR?2L,MI,CXRV2 8@+\*C NIKF,)#<+-DA\@+/,RSQ&'Q@CM<)A0M-[6"9<
MQ6Y2C'T&<__.P6_!3L4[E=>+"G^KWM]=[^224X4Q2.Q7=2F) A00\XPB(Z-3
M79<:_E&WD:)B_DF(A?^>U^,S\()I/OUKP32;4QTMW)_8ILF7_P%02P,$%
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M52A+E*FT3M"49GRI(KOA.43R!%U5TY(EC(@5U-]%07)&2_1R0^J5ZL4K 2.
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MG<S69%Z+S+9L5Y42U"TT=^L=P+D'SP^\SG[W<U#-JU(BO2G![=EF.P[VX2U
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M@(O4P)<GT6\KF&>> :]+A7I3H-0R;UF$HSI6I*@8 >7*RM5LIK)*Y,W8HM=
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M85!MH?*99*08O#3^%VTB"72E8(HF)I84RP]5DM!M+6<QZ]_P0DDVD8SA1GU
MVDG;AG/B* =3M/(JFF,0J1!?(U!;-6=FN@:&J3&^5"AV/A*+9X@@F$F98\;
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M@^LLK$ FQ$>.BX&;/+0(4YY^\%)(13/BQMOXK_=K4]EL8.U?-?.U56O&M,D
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MV*=IV^\$AP:_==]Y!.3Y)(R$#JR_CO3&E]H_MEBCMX1T?81T=NEIAF>XS8F
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M7B:FIH0NZK:25G\>P IO]E1;08JO275-;="Y;]Y.UY7]73PAE)QFUF:(2RJ
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M[L=TM)F8(Y./I,TO6_GHVXKO'AU^6H#WSK1,-_"?1;/,__Z_4$L! A0#%
M  @ &7-85%FD6Z#"60D !"IP !               ( !     '!F92TR,#(Q
M,3(S,2YH=&U02P$"% ,4    "  9<UA4]1A%?XDV  "OH0( $
M    @ 'P60D <&9E+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( !ES6%1XKP?E
M(%,  !AZ P 4              "  :>0"0!P9F4M,C R,3$R,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( !ES6%3EE5Z'BUX! &PV$  4              "  ?GC
M"0!P9F4M,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( !ES6%3K)N'XBFD
M !>7   3              "  ;9""P!P9F4M,C R,3$R,S%?9S$N:G!G4$L!
M A0#%     @ &7-85)GNDXN:!P  ;P@  !0              ( !<:P+ '!F
M92TR,#(Q,3(S,5]G,3 N:G!G4$L! A0#%     @ &7-85#+JG[GA!@  G@<
M !0              ( !/;0+ '!F92TR,#(Q,3(S,5]G,3$N:G!G4$L! A0#
M%     @ &7-85,R S(_".   VSL  !0              ( !4+L+ '!F92TR
M,#(Q,3(S,5]G,3(N:G!G4$L! A0#%     @ &7-85# QTIWG#0  $@\  !0
M             ( !1/0+ '!F92TR,#(Q,3(S,5]G,3,N:G!G4$L! A0#%
M  @ &7-85(;Q_'CI*0$ R#@! !,              ( !70(, '!F92TR,#(Q
M,3(S,5]G,BYJ<&=02P$"% ,4    "  9<UA4E8-R9K9X   ZS   $P
M        @ %W+ T <&9E+3(P,C$Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( !ES
M6%3[W:!"/.(  '1Y 0 3              "  5ZE#0!P9F4M,C R,3$R,S%?
M9S0N:G!G4$L! A0#%     @ &7-85'<-P+H6+0  9TH  !,
M ( !RX<. '!F92TR,#(Q,3(S,5]G-2YJ<&=02P$"% ,4    "  9<UA4[GE"
M:H\L  "#1P  $P              @ $2M0X <&9E+3(P,C$Q,C,Q7V<V+FIP
M9U!+ 0(4 Q0    ( !ES6%2I?$LB*"T  %-+   3              "  =+A
M#@!P9F4M,C R,3$R,S%?9S<N:G!G4$L! A0#%     @ &7-85(=JWB-R+0
MMDL  !,              ( !*P\/ '!F92TR,#(Q,3(S,5]G."YJ<&=02P$"
M% ,4    "  9<UA42\TWVIRG  ")U0  $P              @ './ \ <&9E
M+3(P,C$Q,C,Q7V<Y+FIP9U!+ 0(4 Q0    ( !ES6%02BBS74L$" &U@'0 4
M              "  9OD#P!P9F4M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( !ES6%3M4I:81[T!  ,5%0 4              "  1^F$@!P9F4M,C R
M,3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( !ES6%0( _1?K!,  .15 @ :
M          "  9AC% !P9F4M97AH,C%X,3(S,3(P,C%X,3!K+FAT;5!+ 0(4
M Q0    ( !ES6%1=9UV&/@4  !LA   :              "  7QW% !P9F4M
M97AH,C-X,3(S,3(P,C%X,3!K+FAT;5!+ 0(4 Q0    ( !ES6%1HSK0:T <
M %4B   ;              "  ?)\% !P9F4M97AH,S$Q>#$R,S$R,#(Q>#$P
M:RYH=&U02P$"% ,4    "  9<UA4_>!@6M8'  !3(@  &P
M@ '[A!0 <&9E+65X:#,Q,G@Q,C,Q,C R,7@Q,&LN:'1M4$L! A0#%     @
M&7-85%$$ I_@!   '1$  !L              ( !"HT4 '!F92UE>&@S,C%X
M,3(S,3(P,C%X,3!K+FAT;5!+ 0(4 Q0    ( !ES6%3IA+/'[ 0   L1   ;
M              "  2.2% !P9F4M97AH,S(R>#$R,S$R,#(Q>#$P:RYH=&U0
M2P$"% ,4    "  9<UA4W$&J+8 Z  #,.@$ &P              @ %(EQ0
M<&9E+65X:#0R-'@Q,C,Q,C R,7@Q,&LN:'1M4$L%!@     : !H T@8   '2
$%     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
